Phase	
I	O
study	O
of	O
escalating	O
doses	O
of	O
edatrexate	B-DRUG
in	O
combination	O
with	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
Motivated	O
by	O
the	O
observation	O
of	O
preclinical	O
synergy	O
","	O
a	O
Phase	O
I	O
dose	O
escalation	O
study	O
of	O
edatrexate	B-DRUG
in	O
combination	O
with	O
a	O
3-h	O
paclitaxel	B-DRUG
infusion	O
was	O
performed	O
in	O
patients	O
with	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
edatrexate	B-DRUG
and	O
the	O
toxicities	O
associated	O
with	O
this	O
combination	O
and	O
to	O
report	O
preliminary	O
observations	O
of	O
efficacy	O
with	O
this	O
novel	O
combination	O
.	O
	
Thirty-six	O
patients	O
were	O
enrolled	O
in	O
this	O
Phase	O
I	O
trial	O
.	O
	
Thirty-five	O
eligible	O
patients	O
were	O
treated	O
every	O
21	O
days	O
in	O
cohorts	O
of	O
at	O
least	O
three	O
patients	O
and	O
were	O
assessable	O
for	O
toxicity	O
.	O
	
One	O
patient	O
was	O
ineligible	O
due	O
to	O
hyperbilirubinemia	B-TOXI
.	O
	
Stepwise	O
dose	O
escalations	O
of	O
edatrexate	B-DRUG
were	O
administered	O
until	O
grade	O
&	O
gt	O
;	O
3	O
nonhematological	O
dose-limiting	O
toxicities	O
were	O
reported	O
.	O
	
The	O
initial	O
dose	O
level	O
of	O
edatrexate	B-DRUG
was	O
180	O
mg	O
/	O
m2	O
;	O
subsequent	O
cohorts	O
were	O
treated	O
with	O
escalating	O
doses	O
of	O
edatrexate	B-DRUG
(	O
210	O
","	O
240	O
","	O
270	O
","	O
300	O
","	O
350	O
","	O
and	O
400	O
mg	O
/	O
m2	O
)	O
.	O
	
Edatrexate	B-DRUG
was	O
administered	O
by	O
i.v.	O
infusion	O
over	O
1	O
h.	O
Paclitaxel	B-DRUG
was	O
administered	O
24	O
h	O
later	O
at	O
a	O
fixed	O
dose	O
of	O
175	O
mg	O
/	O
m2	O
as	O
a	O
3-h	O
infusion	O
with	O
standard	O
dexamethasone	B-DRUG
","	O
diphenhydramine	B-DRUG
","	O
and	O
cimetidine	B-DRUG
premedication	O
.	O
	
The	O
MTD	O
of	O
edatrexate	B-DRUG
was	O
reached	O
at	O
the	O
350	O
mg	O
/	O
m2	O
level	O
in	O
this	O
study	O
.	O
	
Grade	O
3	O
diarrhea	B-TOXI
was	O
seen	O
in	O
one	O
patient	O
at	O
the	O
300	O
and	O
400	O
mg	O
/	O
m2	O
dose	O
levels	O
","	O
requiring	O
dose	O
reductions	O
.	O
	
Two	O
patients	O
experienced	O
grade	O
4	O
stomatitis	B-TOXI
at	O
the	O
400	O
mg	O
/	O
m2	O
dose	O
level	O
and	O
also	O
required	O
dose	O
reduction	O
","	O
establishing	O
the	O
MTD	O
as	O
350	O
mg	O
/	O
m2	O
.	O
	
Grade	O
3	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
were	O
noted	O
in	O
two	O
of	O
three	O
patients	O
at	O
the	O
highest	O
dose	O
level	O
.	O
	
Of	O
35	O
patients	O
","	O
4	O
patients	O
reported	O
grade	O
3	O
myalgias	B-TOXI
and	O
1	O
patient	O
reported	O
grade	O
3	O
neurosensory	B-TOXI
complaints	I-TOXI
","	O
which	O
were	O
seen	O
mostly	O
at	O
the	O
350	O
and	O
400	O
mg	O
/	O
m2	O
dose	O
levels	O
;	O
however	O
","	O
1	O
patient	O
reported	O
grade	O
3	O
myalgias	B-TOXI
at	O
180	O
mg	O
/	O
m2	O
.	O
	
No	O
cumulative	O
neurotoxicity	B-TOXI
was	O
observed	O
","	O
and	O
no	O
patient	O
experienced	O
an	O
allergic	B-TOXI
reaction	I-TOXI
to	O
paclitaxel	B-DRUG
.	O
	
In	O
23	O
patients	O
with	O
bidimensionally	O
measurable	O
disease	O
","	O
there	O
were	O
four	O
complete	O
(	O
17	O
%	O
)	O
and	O
seven	O
partial	O
responses	O
","	O
with	O
an	O
overall	O
response	O
rate	O
of	O
48	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
27-69	O
%	O
)	O
.	O
	
All	O
of	O
the	O
responses	O
were	O
seen	O
in	O
patients	O
who	O
had	O
not	O
received	O
prior	O
chemotherapy	O
for	O
stage	O
IV	O
disease	O
.	O
	
The	O
median	O
duration	O
of	O
response	O
was	O
not	O
assessable	O
because	O
many	O
responding	O
patients	O
went	O
on	O
to	O
receive	O
high-dose	O
chemotherapy	O
treatment	O
with	O
stem	O
cell	O
support	O
.	O
	
The	O
combination	O
of	O
edatrexate	B-DRUG
and	O
paclitaxel	B-DRUG
for	O
treatment	O
of	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
is	O
a	O
feasible	O
and	O
safe	O
regimen	O
.	O
	
The	O
MTD	O
of	O
edatrexate	B-DRUG
was	O
350	O
mg	O
/	O
m2	O
when	O
combined	O
with	O
a	O
3-h	O
infusion	O
of	O
paclitaxel	B-DRUG
(	O
175	O
mg	O
/	O
m2	O
)	O
given	O
24	O
h	O
later	O
.	O
	
Activity	O
was	O
noted	O
even	O
among	O
patients	O
who	O
had	O
relapsed	O
shortly	O
after	O
receiving	O
methotrexate-	B-DRUG
and	O
/	O
or	O
doxorubicin-containing	B-DRUG
adjuvant	O
regimens	O
.	O
	
Additional	O
studies	O
evaluating	O
the	O
sequences	O
and	O
dosing	O
schema	O
for	O
this	O
combination	O
are	O
warranted	O
to	O
improve	O
the	O
response	O
proportion	O
and	O
define	O
the	O
duration	O
of	O
the	O
response	O
.	O
	
Phase	O
I	O
study	O
of	O
a	O
weekly	O
schedule	O
of	O
irinotecan	B-DRUG
","	O
high-dose	O
leucovorin	B-DRUG
","	O
and	O
infusional	B-DRUG
fluorouracil	I-DRUG
as	O
first-line	O
chemotherapy	O
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
determine	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
a	O
weekly	O
schedule	O
of	O
irinotecan	B-DRUG
(	O
CPT-11	B-DRUG
)	O
","	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
","	O
and	O
a	O
24-hour	O
infusion	O
of	O
fluorouracil	B-DRUG
(	O
5-FU24h	B-DRUG
)	O
as	O
first-line	O
chemotherapy	O
in	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
and	O
to	O
assess	O
preliminary	O
data	O
on	O
the	O
antitumor	O
activity	O
.	O
	
Twenty-six	O
patients	O
with	O
measurable	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
were	O
entered	O
onto	O
this	O
phase	O
I	O
study	O
.	O
	
In	O
the	O
first	O
six	O
dose	O
levels	O
","	O
fixed	O
doses	O
of	O
CPT-11	B-DRUG
(	O
80	O
mg	O
/	O
m2	O
)	O
and	O
LV	B-DRUG
(	O
500	O
mg	O
/	O
m2	O
)	O
in	O
combination	O
with	O
escalated	O
doses	O
of	O
5-FU24h	B-DRUG
ranging	O
from	O
1.8	O
to	O
2.6	O
g	O
/	O
m2	O
were	O
administered	O
on	O
a	O
weekly-times-four	O
(	O
dose	O
levels	O
1	O
to	O
4	O
)	O
or	O
weekly-times-six	O
(	O
dose	O
levels	O
5	O
to	O
6	O
)	O
schedule	O
.	O
	
The	O
dose	O
of	O
CPT-11	B-DRUG
was	O
then	O
increased	O
to	O
100	O
mg	O
/	O
m2	O
(	O
dose	O
level	O
7	O
)	O
.	O
	
Seventy-nine	O
cycles	O
of	O
5-FU24h	B-DRUG
/	O
LV	B-DRUG
with	O
CPT-11	B-DRUG
were	O
administered	O
in	O
an	O
outpatient	O
setting	O
.	O
	
No	O
dose-limiting	O
toxicities	O
were	O
observed	O
during	O
the	O
first	O
cycle	O
at	O
dose	O
levels	O
1	O
to	O
6	O
","	O
but	O
diarrhea	B-TOXI
of	O
grade	O
4	O
(	O
National	O
Cancer	O
Institute	O
common	O
toxicity	O
criteria	O
)	O
was	O
observed	O
in	O
three	O
patients	O
after	O
multiple	O
treatment	O
cycles	O
.	O
	
Other	O
nonhematologic	B-TOXI
and	I-TOXI
hematologic	I-TOXI
side	I-TOXI
effects	I-TOXI
","	O
specifically	O
alopecia	B-TOXI
and	O
neutropenia	B-TOXI
","	O
did	O
not	O
exceed	O
grade	O
2	O
With	O
the	O
escalation	O
of	O
CPT-11	B-DRUG
to	O
100	O
mg	O
/	O
m2	O
(	O
dose	O
level	O
7	O
)	O
","	O
diarrhea	B-TOXI
of	O
grade	O
3	O
or	O
higher	O
was	O
observed	O
in	O
four	O
of	O
six	O
patients	O
during	O
the	O
first	O
cycle	O
;	O
thus	O
","	O
the	O
MTD	O
was	O
achieved	O
.	O
	
Sixteen	O
of	O
25	O
response-assessable	O
patients	O
(	O
64	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
","	O
45	O
%	O
to	O
83	O
%	O
)	O
achieved	O
an	O
objective	O
response	O
.	O
	
The	O
recommended	O
doses	O
for	O
further	O
studies	O
are	O
CPT-11	B-DRUG
80	O
mg	O
/	O
m2	O
","	O
LV	B-DRUG
500	O
mg	O
/	O
m2	O
","	O
and	O
5-FU24h	B-DRUG
2.6	O
g	O
/	O
m2	O
given	O
on	O
a	O
weekly-times-six	O
schedule	O
followed	O
by	O
a	O
1-week	O
rest	O
period	O
.	O
	
The	O
addition	O
of	O
CPT-11	B-DRUG
to	O
5-FU24h	B-DRUG
/	O
LV	B-DRUG
seems	O
to	O
improve	O
the	O
therapeutic	O
efficacy	O
in	O
terms	O
of	O
tumor	O
response	O
with	O
manageable	O
toxicity	O
.	O
	
Phase	O
I-II	O
study	O
of	O
gemcitabine	B-DRUG
and	O
carboplatin	B-DRUG
in	O
stage	O
IIIB-IV	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
Platinum-based	B-DRUG
chemotherapy	I-DRUG
currently	O
represents	O
standard	O
treatment	O
for	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
Gemcitabine	B-DRUG
is	O
one	O
of	O
the	O
most	O
interesting	O
agents	O
currently	O
in	O
use	O
in	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
","	O
and	O
high	O
response	O
rates	O
have	O
been	O
reported	O
when	O
it	O
is	O
administered	O
in	O
combination	O
with	O
cisplatin	B-DRUG
.	O
	
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
combination	O
of	O
gemcitabine	B-DRUG
and	O
carboplatin	B-DRUG
in	O
a	O
phase	O
I-II	O
study	O
.	O
	
Chemotherapy-naive	O
patients	O
with	O
stage	O
IIIB-IV	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
received	O
carboplatin	B-DRUG
at	O
area	O
under	O
the	O
concentration-time	O
curve	O
(	O
AUC	O
)	O
5	O
mg	O
/	O
mL	O
/	O
min	O
and	O
gemcitabine	B-DRUG
at	O
an	O
initial	O
dose	O
of	O
800	O
mg	O
/	O
m2	O
","	O
subsequently	O
escalated	O
by	O
100	O
mg	O
/	O
m2	O
per	O
step	O
.	O
	
Gemcitabine	B-DRUG
was	O
administered	O
on	O
days	O
1	O
and	O
8	O
and	O
carboplatin	B-DRUG
on	O
day	O
8	O
of	O
the	O
28-day	O
cycle	O
.	O
	
Dose	O
escalation	O
proceeded	O
up	O
to	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
","	O
which	O
was	O
defined	O
as	O
grade	O
4	O
neutropenia	B-TOXI
or	O
thrombocytopenia	B-TOXI
or	O
grade	O
3	O
nonhematologic	B-TOXI
toxicity	I-TOXI
.	O
	
Neutropenia	B-TOXI
was	O
DLT	O
","	O
inasmuch	O
as	O
it	O
occurred	O
in	O
three	O
of	O
five	O
patients	O
receiving	O
gemcitabine	B-DRUG
"1,200"	O
mg	O
/	O
m2	O
.	O
	
Nonhematologic	B-TOXI
toxicities	I-TOXI
were	O
mild	O
.	O
	
Gemcitabine	B-DRUG
"1,100"	O
mg	O
/	O
m2	O
plus	O
carboplatin	B-DRUG
AUC	I-DRUG
5	I-DRUG
was	O
recommended	O
for	O
phase	O
II	O
studies	O
.	O
	
An	O
objective	O
response	O
was	O
observed	O
in	O
13	O
(	O
50	O
%	O
)	O
of	O
26	O
patients	O
","	O
including	O
four	O
complete	O
responses	O
(	O
15	O
%	O
)	O
and	O
nine	O
partial	O
responses	O
(	O
35	O
%	O
)	O
.	O
	
Median	O
duration	O
of	O
response	O
was	O
13	O
months	O
(	O
range	O
","	O
3	O
to	O
23	O
months	O
)	O
.	O
	
Median	O
overall	O
survival	O
was	O
16	O
months	O
(	O
range	O
","	O
3	O
to	O
26	O
months	O
)	O
.	O
	
The	O
combination	O
of	O
gemcitabine	B-DRUG
and	O
carboplatin	B-DRUG
is	O
well	O
tolerated	O
and	O
active	O
.	O
	
Neutropenia	B-TOXI
was	O
DLT	O
.	O
	
The	O
observed	O
activity	O
matches	O
that	O
observable	O
in	O
cisplatin-gemcitabine	B-DRUG
studies	O
","	O
whereas	O
duration	O
of	O
response	O
and	O
survival	O
are	O
even	O
higher	O
.	O
	
A	O
phase	O
II	O
trial	O
is	O
under	O
way	O
.	O
	
Paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
in	O
the	O
treatment	O
of	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
patients	O
resistant	O
to	O
cyclophosphamide	B-DRUG
","	O
doxorubicin	B-DRUG
","	O
and	O
etoposide	B-DRUG
:	O
a	O
non-cross-resistant	O
schedule	O
.	O
	
	
To	O
evaluate	O
the	O
efficacy	O
of	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
(	O
PC	B-DRUG
)	O
in	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
SCLC	B-CANCER
)	O
patients	O
resistant	O
to	O
cyclophosphamide	B-DRUG
","	O
doxorubicin	B-DRUG
","	O
and	O
etoposide	B-DRUG
(	O
CDE	B-DRUG
)	O
.	O
	
We	O
performed	O
a	O
phase	O
II	O
study	O
with	O
PC	B-DRUG
in	O
SCLC	B-CANCER
patients	O
who	O
relapsed	O
within	O
3	O
months	O
after	O
first-line	O
treatment	O
with	O
CDE	B-DRUG
.	O
	
Paclitaxel	B-DRUG
administration	O
(	O
175	O
mg	O
/	O
m2	O
by	O
a	O
3-hour	O
intravenous	O
infusion	O
)	O
was	O
followed	O
by	O
a	O
30-minute	O
infusion	O
of	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
7	O
;	O
Chatelut	O
formula	O
)	O
once	O
every	O
3	O
weeks	O
for	O
five	O
cycles	O
.	O
	
Dexamethasone	B-DRUG
","	O
clemastine	B-DRUG
","	O
and	O
ranitidine	B-DRUG
were	O
standard	O
premedication	O
before	O
every	O
cycle	O
.	O
	
Included	O
were	O
35	O
patients	O
(	O
median	O
age	O
","	O
59	O
years	O
;	O
16	O
with	O
limited	O
disease	O
and	O
19	O
with	O
extensive	B-TOXI
disease	I-TOXI
;	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
&	O
lt	O
;	O
or	O
=	O
1	O
;	O
median	O
time	O
off	O
treatment	O
6	O
weeks	O
)	O
who	O
were	O
previously	O
treated	O
with	O
CDE	B-DRUG
(	O
n	O
=	O
33	O
)	O
","	O
oral	B-DRUG
etoposide	I-DRUG
(	O
n	O
=	O
2	O
)	O
","	O
and	O
reinduction	B-DRUG
CDE	I-DRUG
(	O
n	O
=	O
15	O
)	O
;	O
only	O
one	O
patient	O
had	O
received	O
three	O
CDE	B-DRUG
treatments	O
of	O
five	O
cycles	O
.	O
	
The	O
CDE	B-DRUG
regimen	O
was	O
followed	O
by	O
local	O
thoracic	O
radiotherapy	O
in	O
seven	O
patients	O
.	O
	
Hematologic	B-TOXI
toxicity	I-TOXI
of	O
grade	O
3	O
or	O
4	O
","	O
for	O
leukopenia	B-TOXI
was	O
27	O
%	O
and	O
6	O
%	O
","	O
for	O
thrombocytopenia	B-TOXI
21	O
%	O
and	O
13	O
%	O
","	O
and	O
for	O
anemia	B-TOXI
17	O
%	O
and	O
0	O
%	O
","	O
respectively	O
","	O
for	O
a	O
total	O
of	O
132	O
cycles	O
.	O
	
Two	O
patients	O
had	O
neutropenic	B-TOXI
fever	I-TOXI
;	O
no	O
toxic	B-TOXI
death	I-TOXI
occurred	O
.	O
	
Nonhematologic	B-TOXI
toxicity	I-TOXI
was	O
paresthesia	B-TOXI
CTC	O
grade	O
3	O
","	O
diarrhea	B-TOXI
grade	O
4	O
","	O
and	O
myalgia	B-TOXI
grade	O
3	O
in	O
one	O
patient	O
each	O
.	O
	
Reversible	B-TOXI
paresthesia	I-TOXI
(	O
CTC	O
grade	O
1	O
and	O
2	O
)	O
in	O
toes	O
and	O
fingers	O
was	O
reported	O
in	O
69	O
%	O
of	O
patients	O
.	O
	
Thirty-four	O
patients	O
were	O
assessable	O
for	O
response	O
:	O
complete	O
response	O
in	O
two	O
patients	O
","	O
partial	O
response	O
in	O
23	O
patients	O
","	O
stable	O
disease	O
in	O
eight	O
patients	O
","	O
and	O
progressive	O
disease	O
in	O
one	O
patient	O
(	O
response	O
rate	O
","	O
73.5	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
","	O
59	O
%	O
to	O
88	O
%	O
)	O
.	O
	
One	O
patient	O
was	O
found	O
to	O
have	O
atypical	B-TOXI
carcinoid	I-TOXI
at	O
pathologic	O
review	O
and	O
was	O
excluded	O
.	O
	
Median	O
time	O
to	O
progression	O
was	O
21	O
weeks	O
(	O
range	O
","	O
3	O
to	O
40	O
weeks	O
)	O
.	O
	
Median	O
survival	O
was	O
31	O
weeks	O
(	O
range	O
","	O
6	O
to	O
112	O
weeks	O
)	O
.	O
	
One-year	O
survival	O
was	O
9	O
%	O
.	O
	
Second-line	O
PC	B-DRUG
in	O
CDE-resistant	B-DRUG
SCLC	B-CANCER
patients	O
yields	O
a	O
high	O
response	O
rate	O
and	O
seems	O
non-cross-resistant	O
to	O
CDE	B-DRUG
.	O
	
Toxicity	O
was	O
mild	O
in	O
these	O
poor-prognosis	O
patients	O
.	O
	
Phase	O
I-II	O
study	O
of	O
gemcitabine	B-DRUG
and	O
fluorouracil	B-DRUG
as	O
a	O
continuous	O
infusion	O
in	O
patients	O
with	O
pancreatic	B-CANCER
cancer	I-CANCER
.	O
	
	
To	O
determine	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
dose-limiting	O
toxicities	O
","	O
and	O
efficacy	O
of	O
gemcitabine	B-DRUG
combined	O
with	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
in	O
patients	O
with	O
pancreatic	B-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
measurable	O
","	O
locally	O
advanced	O
","	O
nonresectable	O
or	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
were	O
candidates	O
for	O
the	O
study	O
.	O
	
5-FU	B-DRUG
was	O
given	O
via	O
protracted	O
venous	O
infusion	O
(	O
PVI	O
)	O
at	O
a	O
fixed	O
dosage	O
of	O
200	O
mg	O
/	O
m2	O
/	O
d	O
","	O
and	O
gemcitabine	B-DRUG
was	O
administered	O
weekly	O
for	O
3	O
consecutive	O
weeks	O
every	O
4	O
weeks	O
.	O
	
The	O
initial	O
dose	O
of	O
gemcitabine	B-DRUG
was	O
700	O
mg	O
/	O
m2	O
and	O
was	O
escalated	O
in	O
increments	O
of	O
100	O
mg	O
/	O
m2	O
/	O
wk	O
until	O
the	O
appearance	O
of	O
severe	B-TOXI
toxicity	I-TOXI
.	O
	
Measurements	O
of	O
efficacy	O
included	O
the	O
following	O
:	O
response	O
rate	O
;	O
clinical	O
benefit	O
response	O
","	O
which	O
is	O
a	O
composite	O
measurement	O
of	O
pain	B-TOXI
","	O
performance	O
status	O
","	O
and	O
weight	B-TOXI
loss	I-TOXI
;	O
time	O
to	O
disease	O
progression	O
;	O
and	O
survival	O
.	O
	
Twenty-six	O
patients	O
received	O
a	O
total	O
of	O
109	O
courses	O
.	O
	
Dose-limiting	O
toxicity	O
","	O
which	O
consisted	O
of	O
grade	O
4	O
neutropenia	B-TOXI
with	O
fever	B-TOXI
(	O
one	O
patient	O
)	O
and	O
grade	O
4	O
thrombocytopenia	B-TOXI
(	O
one	O
patient	O
)	O
","	O
was	O
observed	O
in	O
two	O
of	O
three	O
patients	O
treated	O
with	O
"1,100"	O
mg	O
/	O
m2	O
/	O
wk	O
of	O
gemcitabine	B-DRUG
.	O
	
On	O
the	O
basis	O
of	O
these	O
results	O
","	O
the	O
MTD	O
of	O
gemcitabine	B-DRUG
with	O
5-FU	B-DRUG
via	O
PVI	O
on	O
this	O
schedule	O
was	O
"1,000"	O
mg	O
/	O
m2	O
.	O
	
Sixteen	O
patients	O
developed	O
grade	O
3月4日	O
neutropenia	B-TOXI
","	O
and	O
three	O
patients	O
developed	O
grade	O
3月4日	O
thrombocytopenia	B-TOXI
.	O
	
Grade	O
3月4日	O
nonhematologic	B-TOXI
toxicity	I-TOXI
consisted	O
of	O
diarrhea	B-TOXI
(	O
two	O
patients	O
)	O
and	O
cutaneous	B-TOXI
toxicity	I-TOXI
","	O
asthenia	B-TOXI
","	O
edema	B-TOXI
","	O
mucositis	B-TOXI
","	O
and	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
(	O
one	O
patient	O
each	O
)	O
.	O
	
The	O
delivered	O
dose-intensity	O
of	O
gemcitabine	B-DRUG
was	O
similar	O
at	O
the	O
"1,000"	O
mg	O
/	O
m2	O
dose	O
level	O
(	O
599	O
mg	O
/	O
m2	O
/	O
wk	O
)	O
as	O
at	O
the	O
900	O
mg	O
/	O
m2	O
(	O
601	O
mg	O
/	O
m2	O
/	O
wk	O
)	O
dose	O
level	O
.	O
	
For	O
this	O
reason	O
","	O
the	O
recommended	O
dose	O
of	O
gemcitabine	B-DRUG
for	O
phase	O
II	O
evaluation	O
on	O
this	O
schedule	O
was	O
900	O
mg	O
/	O
m2	O
.	O
	
Five	O
patients	O
had	O
objective	O
responses	O
(	O
one	O
complete	O
response	O
and	O
four	O
partial	O
responses	O
;	O
response	O
rate	O
","	O
19.2	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
6.5	O
to	O
39.3	O
)	O
","	O
and	O
10	O
patients	O
had	O
improvement	O
of	O
disease-related	O
symptoms	O
(	O
45	O
%	O
;	O
95	O
%	O
CI	O
","	O
24	O
to	O
67	O
)	O
.	O
	
After	O
a	O
median	O
follow-up	O
of	O
17.7	O
months	O
(	O
range	O
","	O
7.8	O
to	O
24.8	O
months	O
)	O
","	O
the	O
median	O
progression-free	O
survival	O
and	O
overall	O
survival	O
times	O
were	O
7.4	O
months	O
(	O
95	O
%	O
CI	O
","	O
3.3	O
to	O
11.4	O
)	O
and	O
10.3	O
months	O
(	O
95	O
%	O
CI	O
","	O
8.1	O
to	O
12.5	O
)	O
","	O
respectively	O
.	O
	
The	O
MTD	O
of	O
gemcitabine	O
when	O
combined	O
with	O
5-FU	B-DRUG
via	O
PVI	O
on	O
this	O
schedule	O
was	O
"1,000"	O
mg	O
/	O
m2	O
/	O
wk	O
;	O
however	O
","	O
on	O
the	O
basis	O
of	O
administered	O
dose-intensity	O
","	O
the	O
recommended	O
dose	O
for	O
additional	O
investigation	O
is	O
900	O
mg	O
/	O
m2	O
.	O
	
This	O
combination	O
chemotherapy	O
regimen	O
was	O
well	O
tolerated	O
and	O
showed	O
promising	O
antitumor	O
activity	O
in	O
the	O
treatment	O
of	O
pancreatic	B-CANCER
cancer	I-CANCER
.	O
	
First-line	O
chemotherapy	O
with	O
epirubicin	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
and	O
carboplatin	B-DRUG
for	O
advanced	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
:	O
a	O
phase	O
I	O
/	O
II	O
study	O
of	O
the	O
Arbeitsgemeinschaft	O
Gyn盲kologische	O
Onkologie	O
Ovarian	B-CANCER
Cancer	I-CANCER
Study	O
Group	O
.	O
	
	
Despite	O
the	O
progress	O
that	O
has	O
been	O
achieved	O
over	O
the	O
years	O
","	O
survival	O
rates	O
in	O
patients	O
with	O
advanced	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
are	O
still	O
disappointing	O
.	O
	
New	O
methods	O
to	O
improve	O
the	O
efficiency	O
of	O
first-line	O
chemotherapy	O
are	O
warranted	O
.	O
	
One	O
method	O
to	O
improve	O
results	O
is	O
to	O
add	O
more	O
non-cross-resistant	O
drugs	O
to	O
platinum-paclitaxel	B-DRUG
combination	O
regimens	O
.	O
	
Anthracyclines	B-DRUG
are	O
among	O
the	O
candidates	O
for	O
incorporation	O
as	O
the	O
	O
into	O
first-line	O
regimens	O
for	O
advanced	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
We	O
performed	O
a	O
phase	O
I	O
/	O
II	O
trial	O
with	O
escalating	O
doses	O
of	O
epirubicin	B-DRUG
(	O
60	O
","	O
75	O
","	O
and	O
90	O
mg	O
/	O
m2	O
)	O
combined	O
with	O
fixed	O
doses	O
of	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
in	O
27	O
previously	O
untreated	O
patients	O
with	O
advanced	B-CANCER
gynecologic	I-CANCER
malignancies	I-CANCER
.	O
	
Dose-limiting	O
toxicity	O
occurred	O
at	O
dose	O
level	O
2	O
(	O
75	O
mg	O
/	O
m2	O
epirubicin	O
)	O
and	O
consisted	O
of	O
myelosuppression	B-TOXI
(	O
neutropenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
)	O
.	O
	
No	O
dose-limiting	O
","	O
nonhematologic	B-TOXI
toxicities	I-TOXI
were	O
observed	O
.	O
	
The	O
maximum	O
tolerable	O
dose	O
was	O
epirubicin	B-DRUG
60	O
mg	O
/	O
m2	O
(	O
E	O
)	O
combined	O
with	O
a	O
3-hour	O
infusion	O
of	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m2	O
(	O
T	O
)	O
and	O
carboplatin	B-DRUG
AUC	O
5	O
(	O
Carbo	B-DRUG
)	O
.	O
	
Preliminary	O
analysis	O
indicated	O
promising	O
activity	O
against	O
ovarian	B-CANCER
cancer	I-CANCER
.	O
	
The	O
three-drug	O
combination	O
ET-Carbo	B-DRUG
","	O
given	O
according	O
to	O
the	O
outlined	O
dose	O
and	O
schedule	O
","	O
should	O
be	O
considered	O
for	O
further	O
phase	O
III	O
evaluation	O
.	O
	
A	O
randomized	O
German-French	O
intergroup	O
trial	O
comparing	O
ET-Carbo	B-DRUG
with	O
carboplatin-paclitaxel	B-DRUG
has	O
already	O
been	O
initiated	O
.	O
	
Sequential	O
dose-dense	O
doxorubicin	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
and	O
cyclophosphamide	B-DRUG
for	O
resectable	B-CANCER
high-risk	I-CANCER
breast	I-CANCER
cancer	I-CANCER
:	O
feasibility	O
and	O
efficacy	O
.	O
	
	
Dose-dense	O
chemotherapy	O
is	O
predicted	O
to	O
be	O
a	O
superior	O
treatment	O
plan	O
.	O
	
Therefore	O
","	O
we	O
studied	O
dose-dense	O
doxorubicin	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
and	O
cyclophosphamide	B-DRUG
(	O
A	O
=--	O
&	O
gt	O
;	O
T	O
=--	O
&	O
gt	O
;	O
C	O
)	O
as	O
adjuvant	O
therapy	O
.	O
	
Patients	O
with	O
resected	B-CANCER
breast	I-CANCER
cancer	I-CANCER
involving	O
four	O
or	O
more	O
ipsilateral	O
axillary	O
lymph	O
nodes	O
were	O
treated	O
with	O
nine	O
cycles	O
of	O
chemotherapy	O
","	O
using	O
14-day	O
intertreatment	O
intervals	O
.	O
	
Doses	O
were	O
as	O
follows	O
:	O
doxorubicin	B-DRUG
90	O
mg	O
/	O
m2	O
x	O
3	O
","	O
then	O
paclitaxel	B-DRUG
250	O
mg	O
/	O
m2	O
/	O
24	O
hours	O
x	O
3	O
","	O
and	O
then	O
cyclophosphamide	B-DRUG
3	O
g	O
/	O
m2	O
x	O
3	O
;	O
all	O
doses	O
were	O
given	O
with	O
subcutaneous	O
injections	O
of	O
5	O
microg	O
/	O
kg	O
granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
on	O
days	O
3	O
through	O
10	O
.	O
	
Amenorrheic	O
patients	O
with	O
hormone	B-CANCER
receptor-positive	I-CANCER
tumors	I-CANCER
received	O
tamoxifen	B-DRUG
20	O
mg	O
/	O
day	O
for	O
5	O
years	O
.	O
	
Patients	O
treated	O
with	O
breast	O
conservation	O
","	O
those	O
with	O
10	O
or	O
more	O
positive	B-TOXI
nodes	I-TOXI
","	O
and	O
those	O
with	O
tumors	O
larger	O
than	O
5	O
cm	O
received	O
radiotherapy	O
.	O
	
Between	O
March	O
1993	O
and	O
June	O
1994	O
","	O
we	O
enrolled	O
42	O
patients	O
.	O
	
The	O
median	O
age	O
was	O
46	O
years	O
(	O
range	O
","	O
29	O
to	O
63	O
years	O
)	O
","	O
the	O
median	O
number	O
of	O
positive	B-TOXI
lymph	I-TOXI
nodes	I-TOXI
was	O
eight	O
(	O
range	O
","	O
four	O
to	O
25	O
)	O
","	O
and	O
the	O
median	O
tumor	O
size	O
was	O
3	O
cm	O
(	O
range	O
","	O
0	O
to	O
11	O
cm	O
)	O
.	O
	
The	O
median	O
intertreatment	O
interval	O
was	O
14	O
days	O
(	O
range	O
","	O
13	O
to	O
36	O
days	O
)	O
","	O
and	O
the	O
median	O
delivered	O
dose-intensity	O
exceeded	O
92	O
%	O
of	O
the	O
planned	O
dose-intensity	O
for	O
all	O
three	O
drugs	O
.	O
	
Hospital	O
admission	O
was	O
required	O
for	O
29	O
patients	O
(	O
69	O
%	O
)	O
","	O
and	O
28	O
patients	O
(	O
67	O
%	O
)	O
required	O
blood	O
product	O
transfusion	O
.	O
	
No	O
treatment-related	O
deaths	B-TOXI
or	O
cardiac	B-TOXI
toxicities	I-TOXI
occurred	O
.	O
	
Doxorubicin	B-DRUG
was	O
dose-reduced	O
in	O
four	O
patients	O
(	O
10	O
%	O
)	O
and	O
paclitaxel	B-DRUG
was	O
reduced	O
in	O
eight	O
(	O
20	O
%	O
)	O
.	O
	
At	O
a	O
median	O
follow-up	O
from	O
surgery	O
of	O
48	O
months	O
(	O
range	O
","	O
3	O
to	O
57	O
months	O
)	O
","	O
nine	O
patients	O
(	O
19	O
%	O
)	O
had	O
relapsed	B-TOXI
","	O
the	O
actuarial	O
disease-free	O
survival	O
rate	O
was	O
78	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
66	O
%	O
to	O
92	O
%	O
)	O
","	O
and	O
four	O
patients	O
(	O
10	O
%	O
)	O
had	O
died	B-TOXI
of	O
metastatic	O
disease	O
.	O
	
Dose-dense	O
sequential	O
adjuvant	O
chemotherapy	O
with	O
doxorubicin	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
and	O
cyclophosphamide	B-DRUG
(	O
A	O
=--	O
&	O
gt	O
;	O
T	O
=--	O
&	O
gt	O
;	O
C	O
)	O
is	O
feasible	O
and	O
promising	O
.	O
	
Several	O
ongoing	O
phase	O
III	O
trials	O
are	O
evaluating	O
this	O
approach	O
.	O
	
Induction	O
with	O
mitomycin	B-DRUG
C	I-DRUG
","	O
doxorubicin	B-DRUG
","	O
cisplatin	B-DRUG
and	O
maintenance	O
with	O
weekly	O
5-fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
for	O
treatment	O
of	O
metastatic	B-CANCER
nasopharyngeal	I-CANCER
carcinoma	I-CANCER
:	O
a	O
phase	O
II	O
study	O
.	O
	
	
The	O
combination	O
of	O
cisplatin	B-DRUG
and	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
(	O
PF	B-DRUG
)	O
is	O
the	O
most	O
popular	O
regimen	O
for	O
treating	O
metastatic	B-CANCER
nasopharyngeal	I-CANCER
carcinoma	I-CANCER
(	O
NPC	B-CANCER
)	O
but	O
it	O
is	O
limited	O
by	O
severe	B-TOXI
stomatitis	I-TOXI
and	O
chronic	B-TOXI
cisplatin-related	I-TOXI
toxicity	I-TOXI
.	O
	
A	O
novel	O
approach	O
including	O
induction	O
with	O
mitomycin	B-DRUG
C	I-DRUG
","	O
doxorubicin	B-DRUG
and	O
cisplatin	B-DRUG
(	O
MAP	B-DRUG
)	O
and	O
subsequent	O
maintenance	O
with	O
weekly	O
5-FU	B-DRUG
and	O
leucovorin	B-DRUG
(	O
FL	B-DRUG
)	O
were	O
designed	O
with	O
an	O
aim	O
to	O
reduce	O
acute	B-TOXI
and	I-TOXI
chronic	I-TOXI
toxicity	I-TOXI
of	O
PF	B-DRUG
.	O
	
Thirty-two	O
patients	O
of	O
NPC	B-CANCER
with	O
measurable	O
metastatic	B-TOXI
lesions	I-TOXI
in	O
the	O
liver	O
or	O
lung	O
were	O
entered	O
into	O
this	O
phase	O
II	O
trial	O
.	O
	
Mitomycin	B-DRUG
C	I-DRUG
8	O
mg	O
m	O
(	O
-2	O
)	O
","	O
doxorubicin	B-DRUG
40	O
mg	O
m	O
(	O
-2	O
)	O
and	O
cisplatin	B-DRUG
60	O
mg	O
m	O
(	O
-2	O
)	O
were	O
given	O
on	O
day	O
1	O
every	O
3	O
weeks	O
as	O
initial	O
induction	O
.	O
	
After	O
either	O
four	O
courses	O
or	O
remission	O
was	O
achieved	O
","	O
patients	O
received	O
weekly	O
dose	O
of	O
5-FU	B-DRUG
450	O
mg	O
m	O
(	O
-2	O
)	O
and	O
leucovorin	B-DRUG
30	O
mg	O
m	O
(	O
-2	O
)	O
for	O
maintenance	O
until	O
disease	O
progression	O
.	O
	
With	O
105	O
courses	O
of	O
MAP	B-DRUG
given	O
","	O
5	O
%	O
were	O
accompanied	O
by	O
grade	O
3	O
and	O
0	O
%	O
were	O
accompanied	O
by	O
grade	O
4	O
stomatitis	B-TOXI
.	O
	
The	O
dose-limiting	O
toxicity	O
of	O
MAP	B-DRUG
was	O
myelosuppression	B-TOXI
.	O
	
Forty	O
per	O
cent	O
of	O
courses	O
had	O
grade	O
3	O
and	O
13	O
%	O
of	O
courses	O
had	O
grade	O
4	O
leukopenia	B-TOXI
.	O
	
No	O
grade	O
3	O
or	O
4	O
cisplatin-related	B-TOXI
toxicity	I-TOXI
was	O
observed	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
94	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
84.9-100	O
%	O
)	O
with	O
a	O
complete	O
response	O
rate	O
(	O
CR	O
)	O
of	O
6	O
%	O
(	O
95	O
%	O
CI	O
:	O
0-15.2	O
%	O
)	O
and	O
a	O
good	O
partial	O
response	O
(	O
PR	O
)	O
rate	O
of	O
28	O
%	O
(	O
95	O
%	O
CI	O
11.7-44.6	O
%	O
)	O
","	O
which	O
was	O
optionally	O
defined	O
as	O
observance	O
of	O
only	O
equivocal	B-TOXI
lesion	I-TOXI
identifiable	O
under	O
imaging	O
study	O
.	O
	
Twenty-seven	O
cases	O
entered	O
weekly	O
FL	B-DRUG
maintenance	O
phase	O
.	O
	
The	O
median	O
duration	O
of	O
maintenance	O
with	O
weekly	O
FL	B-DRUG
was	O
38	O
weeks	O
(	O
8-91	O
weeks	O
)	O
.	O
	
There	O
was	O
no	O
grade	O
3	O
or	O
4	O
toxicity	O
noted	O
during	O
weekly	O
FL	B-DRUG
.	O
	
The	O
median	O
progression-free	O
survival	O
and	O
overall	O
survival	O
were	O
11.6+	O
/	O
-0.4	O
and	O
18.1+	O
/	O
-3.6	O
months	O
respectively	O
.	O
	
Six	O
patients	O
with	O
a	O
median	O
follow-up	O
of	O
19.8	O
months	O
(	O
9.6-41.0	O
months	O
)	O
were	O
still	O
alive	O
and	O
five	O
of	O
them	O
had	O
disease	O
under	O
control	O
with	O
FL	B-DRUG
.	O
	
Good	O
responders	O
(	O
CR	O
and	O
good	O
PR	O
)	O
had	O
better	O
survival	O
than	O
less	O
satisfactory	O
responders	O
(	O
PR	O
and	O
stable	O
disease	O
)	O
(	O
P	O
=	O
0.05	O
)	O
.	O
	
From	O
Cox	O
's	O
multivariate	O
regression	O
analysis	O
","	O
the	O
only	O
significant	O
prognostic	O
factor	O
for	O
survival	O
was	O
good	O
response	O
to	O
MAP	B-DRUG
(	O
P	O
=	O
0.042	O
)	O
.	O
	
Liver	B-TOXI
metastasis	I-TOXI
was	O
the	O
only	O
significant	O
variable	O
in	O
the	O
best	O
subset	O
regression	O
model	O
that	O
predicted	O
good	O
response	O
to	O
MAP	B-DRUG
(	O
CR	O
and	O
good	O
PR	O
)	O
(	O
P	O
=	O
0.027	O
)	O
.	O
	
MAP	B-DRUG
was	O
an	O
effective	O
combination	O
for	O
metastatic	B-CANCER
NPC	I-CANCER
with	O
minimal	B-TOXI
stomatitis	I-TOXI
and	O
cisplatin-related	B-TOXI
toxicity	I-TOXI
but	O
had	O
significant	O
myelosuppression	B-TOXI
.	O
	
Weekly	O
FL	B-DRUG
was	O
a	O
maintenance	O
therapy	O
with	O
minimal	B-TOXI
side-effects	I-TOXI
.	O
	
The	O
response	O
rate	O
and	O
overall	O
survival	O
of	O
MAP-FL	B-DRUG
were	O
better	O
than	O
series	O
previously	O
reported	O
even	O
when	O
a	O
subset	O
of	O
patients	O
with	O
poor	B-TOXI
prognosis	I-TOXI
was	O
selected	O
.	O
	
MAP-FL	B-DRUG
's	I-DRUG
role	O
as	O
neoadjuvant	O
or	O
adjuvant	O
therapy	O
is	O
worthy	O
of	O
further	O
study	O
.	O
	
Phase	O
II	O
study	O
of	O
area	O
under	O
the	O
plasma-concentration-versus-time	O
curve-based	O
carboplatin	B-DRUG
plus	O
standard-dose	O
intravenous	O
etoposide	B-DRUG
in	O
elderly	O
patients	O
with	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
target	O
area	O
under	O
the	O
plasma-concentration-versus-time	O
curve	O
(	O
AUC	O
)	O
#NAME?	O
dosing	O
of	O
carboplatin	B-DRUG
using	O
Calvert	O
's	O
formula	O
is	O
expected	O
to	O
result	O
in	O
more	O
acceptable	O
toxicity	O
and	O
greater	O
efficacy	O
in	O
elderly	O
patients	O
with	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
SCLC	B-CANCER
)	O
than	O
the	O
body	O
surface	O
area-based	O
dosing	O
strategy	O
.	O
	
This	O
phase	O
II	O
study	O
was	O
designed	O
to	O
determine	O
the	O
toxicity	O
and	O
efficacy	O
of	O
carboplatin	B-DRUG
based	O
on	O
Calvert	O
's	O
formula	O
plus	O
the	O
standard	O
dose	O
of	O
intravenous	O
etoposide	B-DRUG
for	O
elderly	O
patients	O
with	O
SCLC	B-CANCER
.	O
	
Carboplatin	B-DRUG
","	O
dosed	O
to	O
a	O
target	O
AUC	O
of	O
5	O
x	O
(	O
24-hour	O
creatinine	O
clearance	O
=+	O
25	O
)	O
","	O
was	O
given	O
intravenously	O
on	O
day	O
1	O
and	O
etoposide	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
was	O
given	O
intravenously	O
on	O
days	O
1	O
","	O
2	O
","	O
and	O
3	O
Patients	O
aged	O
&	O
gt	O
;	O
/	O
=	O
70	O
years	O
old	O
with	O
a	O
performance	O
status	O
of	O
0	O
to	O
2	O
were	O
eligible	O
.	O
	
Thirty-six	O
patients	O
were	O
enrolled	O
onto	O
the	O
study	O
.	O
	
The	O
patient	O
characteristics	O
were	O
as	O
follows	O
:	O
median	O
age	O
","	O
73	O
years	O
;	O
limited	O
disease	O
(	O
LD	O
)	O
","	O
16	O
patients	O
;	O
and	O
extensive	O
disease	O
(	O
ED	O
)	O
","	O
20	O
patients	O
.	O
	
Grades	O
3	O
and	O
4	O
leukopenia	B-TOXI
occurred	O
in	O
57	O
%	O
and	O
3	O
%	O
of	O
patients	O
","	O
and	O
grades	O
3	O
and	O
4	O
thrombocytopenia	B-TOXI
occurred	O
in	O
40	O
%	O
and	O
11	O
%	O
of	O
patients	O
","	O
respectively	O
.	O
	
There	O
was	O
one	O
treatment-related	O
death	B-TOXI
due	O
to	O
hemoptysis	B-TOXI
.	O
	
Other	O
toxicities	B-TOXI
were	O
relatively	O
mild	O
.	O
	
There	O
were	O
two	O
complete	O
responses	O
and	O
25	O
partial	O
responses	O
","	O
for	O
a	O
response	O
rate	O
of	O
75	O
%	O
.	O
	
The	O
median	O
survival	O
time	O
was	O
10.8	O
months	O
(	O
LD	O
","	O
11.6	O
months	O
;	O
ED	O
","	O
10.1	O
months	O
)	O
","	O
and	O
the	O
1-year	O
survival	O
rate	O
was	O
47	O
%	O
.	O
	
This	O
carboplatin	B-DRUG
/	O
etoposide	B-DRUG
combination	O
chemotherapy	O
is	O
an	O
active	O
and	O
relatively	O
nontoxic	O
regimen	O
in	O
elderly	O
patients	O
with	O
SCLC	B-CANCER
","	O
which	O
suggests	O
that	O
the	O
combination	O
may	O
be	O
suitable	O
for	O
randomized	O
controlled	O
trials	O
.	O
	
Multicenter	O
phase	O
II	O
study	O
of	O
bimonthly	O
high-dose	O
leucovorin	B-DRUG
","	O
fluorouracil	B-DRUG
infusion	I-DRUG
","	O
and	O
oxaliplatin	B-DRUG
for	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
resistant	O
to	O
the	O
same	O
leucovorin	B-DRUG
and	O
fluorouracil	B-DRUG
regimen	O
.	O
	
	
To	O
evaluate	O
the	O
objective	O
tumor	O
response	O
rates	O
and	O
toxicities	O
of	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
plus	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
cancer	O
regimen	O
combined	O
with	O
oxaliplatin	B-DRUG
(	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
every	O
2	O
weeks	O
on	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
patients	O
with	O
documented	O
proof	O
of	O
progression	O
while	O
on	O
bimonthly	O
LV	B-DRUG
and	O
5-FU	B-DRUG
alone	O
.	O
	
One	O
hundred	O
patients	O
were	O
enrolled	O
onto	O
this	O
study	O
and	O
97	O
received	O
the	O
study	O
drugs	O
between	O
October	O
1995	O
and	O
December	O
1996	O
.	O
	
Eighty-nine	O
patients	O
were	O
eligible	O
for	O
per-protocol	O
efficacy	O
analysis	O
with	O
documented	O
proof	O
of	O
progression	O
on	O
one	O
of	O
the	O
following	O
two	O
treatments	O
:	O
LV	B-DRUG
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
continuous	O
5-FU	B-DRUG
infusion	O
1.5	O
to	O
2	O
g	O
/	O
m	O
(	O
2	O
)	O
/	O
22	O
hours	O
","	O
days	O
1	O
through	O
2	O
every	O
2	O
weeks	O
(	O
FOLFUHD	B-DRUG
)	O
;	O
or	O
LV	B-DRUG
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
bolus	O
5-FU	B-DRUG
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
and	O
continuous	O
5-FU	B-DRUG
infusion	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
22	O
hours	O
","	O
days	O
1	O
through	O
2	O
every	O
2	O
weeks	O
(	O
LV5FU2	B-DRUG
)	O
.	O
	
In	O
our	O
study	O
","	O
40	O
patients	O
received	O
FOLFUHD	B-DRUG
=+	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
oxaliplatin	B-DRUG
day	O
1	O
(	O
FOLFOX3	B-DRUG
)	O
and	O
57	O
patients	O
received	O
LV5FU2	B-DRUG
=+	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
oxaliplatin	B-DRUG
day	O
1	O
(	O
FOLFOX4	B-DRUG
)	O
.	O
	
Of	O
the	O
97	O
patients	O
treated	O
","	O
20	O
partial	O
responses	O
were	O
observed	O
(	O
FOLFOX3	B-DRUG
/	I-DRUG
4	I-DRUG
:	O
response	O
rate	O
","	O
20.6	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
","	O
13	O
%	O
to	O
31.1	O
%	O
;	O
FOLFOX3	B-DRUG
:	O
response	O
"rate,18.4"	O
%	O
;	O
FOLFOX4	B-DRUG
:	O
response	O
rate	O
","	O
23.5	O
%	O
)	O
.	O
	
For	O
patients	O
treated	O
with	O
FOLFOX3	B-DRUG
/	I-DRUG
4	I-DRUG
","	O
the	O
median	O
response	O
duration	O
for	O
was	O
7.5	O
months	O
","	O
and	O
the	O
major	O
toxicities	O
were	O
peripheral	B-TOXI
neuropathy	I-TOXI
and	O
neutropenia	B-TOXI
.	O
	
The	O
incidence	O
of	O
grade	O
3	O
(	O
National	O
Cancer	O
Institute	O
common	O
toxicity	O
criteria	O
)	O
peripheral	B-TOXI
neuropathy	I-TOXI
was	O
20.6	O
%	O
;	O
whereas	O
the	O
overall	O
incidence	O
of	O
grade	O
3	O
to	O
4	O
neutropenia	B-TOXI
was	O
27.8	O
%	O
","	O
15	O
%	O
","	O
and	O
36.9	O
%	O
for	O
FOLFOX3	B-DRUG
/	I-DRUG
4	I-DRUG
","	O
FOLFOX3	B-DRUG
","	O
and	O
FOLFOX4	B-DRUG
","	O
respectively	O
(	O
P	O
0.02	O
)	O
.	O
	
From	O
the	O
start	O
of	O
treatment	O
","	O
median	O
progression-free	O
survival	O
was	O
4	O
7	O
","	O
4.6	O
","	O
and	O
5.1	O
months	O
for	O
FOLFOX3	B-DRUG
/	I-DRUG
4	I-DRUG
","	O
FOLFOX3	B-DRUG
","	O
FOLFOX4	B-DRUG
","	O
respectively	O
","	O
and	O
median	O
overall	O
survival	O
was	O
10.8	O
","	O
10.6	O
","	O
and	O
11.1	O
months	O
","	O
respectively	O
.	O
	
This	O
phase	O
II	O
study	O
of	O
oxaliplatin	B-DRUG
at	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
combination	O
with	O
bimonthly	O
LV	B-DRUG
plus	O
5-FU	B-DRUG
in	O
patients	O
with	O
colorectal	B-CANCER
cancer	I-CANCER
resistant	O
to	O
LV	B-DRUG
plus	O
5-FU	B-DRUG
alone	O
confirms	O
the	O
enhanced	O
antitumor	O
activity	O
of	O
oxaliplatin	B-DRUG
in	O
combination	O
with	O
5-FU	B-DRUG
.	O
	
Paclitaxel	B-DRUG
and	O
cisplatin	B-DRUG
as	O
first-line	O
therapy	O
in	O
recurrent	B-CANCER
or	I-CANCER
advanced	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
cervix	I-CANCER
:	O
a	O
gynecologic	O
oncology	O
group	O
study	O
.	O
	
	
On	O
the	O
basis	O
of	O
the	O
activity	O
of	O
paclitaxel	B-DRUG
as	O
a	O
single	O
agent	O
in	O
chemotherapy-naive	B-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
cervix	I-CANCER
in	O
a	O
prior	O
Gynecologic	O
Oncology	O
Group	O
(	O
GOG	O
)	O
trial	O
","	O
a	O
phase	O
II	O
study	O
of	O
paclitaxel	B-DRUG
and	O
cisplatin	B-DRUG
as	O
first-line	O
therapy	O
was	O
conducted	O
by	O
the	O
GOG	O
.	O
	
Eligibility	O
included	O
squamous	B-CANCER
cell	I-CANCER
cancer	I-CANCER
of	I-CANCER
the	I-CANCER
cervix	I-CANCER
not	O
curable	O
by	O
surgery	O
or	O
radiation	O
","	O
measurable	O
disease	O
","	O
WBC	O
count	O
&	O
gt	O
;	O
or	O
=	O
"3,000"	O
/	O
microL	O
","	O
platelet	O
count	O
&	O
gt	O
;	O
or	O
=	O
100	O
","	O
0	O
/	O
microL	O
","	O
serum	O
creatinine	O
&	O
gt	O
;	O
or	O
=	O
2	O
mg	O
/	O
100	O
mL	O
","	O
and	O
adequate	O
hepatic	O
function	O
.	O
	
The	O
starting	O
dose	O
was	O
paclitaxel	B-DRUG
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
infused	O
over	O
24	O
hours	O
followed	O
by	O
cisplatin	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
every	O
21	O
days	O
.	O
	
On	O
the	O
basis	O
of	O
toxicity	O
","	O
a	O
dose	O
escalation	O
of	O
paclitaxel	B-DRUG
to	O
a	O
maximum	O
dose	O
of	O
170	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d	O
was	O
prescribed	O
.	O
	
Forty-seven	O
patients	O
were	O
enrolled	O
onto	O
this	O
study	O
;	O
44	O
patients	O
were	O
assessable	O
for	O
toxicity	O
and	O
41	O
for	O
response	O
.	O
	
Forty	O
(	O
90.9	O
%	O
)	O
had	O
received	O
prior	O
radiation	O
therapy	O
.	O
	
A	O
median	O
of	O
six	O
courses	O
of	O
chemotherapy	O
was	O
given	O
(	O
range	O
","	O
one	O
to	O
10	O
courses	O
)	O
.	O
	
Neutropenia	B-TOXI
grade	O
3	O
(	O
15.9	O
%	O
)	O
and	O
4	O
(	O
61.4	O
%	O
)	O
was	O
the	O
most	O
frequent	O
severe	B-TOXI
adverse	I-TOXI
effect	I-TOXI
and	O
was	O
associated	O
with	O
fever	B-TOXI
in	O
13	O
patients	O
(	O
27.7	O
%	O
)	O
.	O
	
Two	O
patients	O
(	O
4.5	O
%	O
)	O
died	B-TOXI
from	O
neutropenic	B-TOXI
sepsis	I-TOXI
.	O
	
Grade	O
4	O
thrombocytopenia	B-TOXI
occurred	O
in	O
6.8	O
%	O
of	O
patients	O
.	O
	
Of	O
41	O
assessable	O
patients	O
","	O
five	O
(	O
12.2	O
%	O
)	O
had	O
complete	O
responses	O
and	O
14	O
(	O
34.1	O
%	O
)	O
had	O
partial	O
responses	O
for	O
an	O
overall	O
response	O
rate	O
of	O
46.3	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
30.7	O
%	O
to	O
62.6	O
%	O
)	O
.	O
	
The	O
median	O
progression-free	O
interval	O
","	O
was	O
5.4+	O
months	O
(	O
range	O
","	O
0.3	O
to	O
22+	O
months	O
)	O
with	O
a	O
median	O
survival	O
of	O
10.0+	O
months	O
(	O
range	O
","	O
0.9	O
to	O
22	O
.	O
	
2	O
months	O
)	O
.	O
	
Response	O
was	O
more	O
frequent	O
in	O
patients	O
with	O
disease	B-TOXI
in	I-TOXI
nonirradiated	I-TOXI
sites	I-TOXI
(	O
70	O
%	O
v	O
23	O
%	O
","	O
P	O
0.008	O
)	O
.	O
	
This	O
regimen	O
seems	O
highly	O
active	O
in	O
advanced	B-CANCER
and	I-CANCER
recurrent	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
cervix	I-CANCER
and	O
is	O
currently	O
being	O
evaluated	O
by	O
the	O
GOG	O
in	O
a	O
phase	O
III	O
randomized	O
study	O
comparing	O
the	O
combination	O
of	O
paclitaxel	B-DRUG
and	O
cisplatin	B-DRUG
with	O
cisplatin	B-DRUG
alone	O
.	O
	
Irinotecan	B-DRUG
combined	O
with	O
bolus	B-DRUG
fluorouracil	I-DRUG
","	O
continuous	O
infusion	O
fluorouracil	B-DRUG
","	O
and	O
high-dose	O
leucovorin	B-DRUG
every	O
two	O
weeks	O
(	O
LV5FU2	B-DRUG
regimen	O
)	O
:	O
a	O
clinical	O
dose-finding	O
and	O
pharmacokinetic	O
study	O
in	O
patients	O
with	O
pretreated	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
determine	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
recommended	O
dose	O
of	O
irinotecan	B-DRUG
(	O
CPT-11	B-DRUG
)	O
in	O
combination	O
with	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
and	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
","	O
using	O
a	O
biweekly	O
LV5FU2	B-DRUG
regimen	O
and	O
increasing	O
doses	O
of	O
CPT-11	B-DRUG
","	O
and	O
to	O
assess	O
the	O
efficacy	O
of	O
this	O
combination	O
in	O
pretreated	O
patients	O
with	O
colorectal	B-CANCER
cancer	I-CANCER
(	O
CRC	B-CANCER
)	O
.	O
	
All	O
patients	O
had	O
metastatic	B-CANCER
CRC	I-CANCER
and	O
a	O
World	O
Health	O
Organization	O
performance	O
status	O
of	O
0	O
or	O
1	O
CPT-11	B-DRUG
was	O
administered	O
over	O
a	O
90-minute	O
infusion	O
every	O
2	O
weeks	O
at	O
a	O
range	O
of	O
dose	O
levels	O
(	O
100	O
","	O
120	O
","	O
150	O
","	O
180	O
","	O
200	O
","	O
220	O
","	O
and	O
260	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O
	
LV5FU2	B-DRUG
was	O
started	O
1	O
hour	O
after	O
the	O
end	O
of	O
the	O
biweekly	O
CPT-11	B-DRUG
infusion	O
and	O
was	O
also	O
administered	O
on	O
day	O
2	O
Fifty-five	O
patients	O
were	O
entered	O
onto	O
this	O
trial	O
;	O
549	O
cycles	O
were	O
administered	O
.	O
	
The	O
MTD	O
was	O
not	O
reached	O
at	O
260	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
and	O
a	O
dose	O
level	O
of	O
300	O
mg	O
/	O
m	O
(	O
2	O
)	O
was	O
added	O
.	O
	
The	O
MTD	O
as	O
defined	O
in	O
the	O
protocol	O
was	O
not	O
reached	O
at	O
this	O
dose	O
level	O
either	O
","	O
but	O
all	O
patients	O
had	O
cycles	O
delayed	O
and	O
/	O
or	O
required	O
a	O
dose	O
reduction	O
.	O
	
This	O
dose	O
was	O
deemed	O
to	O
be	O
the	O
MTD	O
.	O
	
To	O
take	O
into	O
account	O
both	O
the	O
toxicity	O
of	O
and	O
compliance	O
with	O
the	O
biweekly	O
schedule	O
","	O
the	O
recommended	O
CPT-11	B-DRUG
dose	O
was	O
established	O
at	O
180	O
to	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Antitumor	O
activity	O
was	O
observed	O
at	O
almost	O
all	O
dose	O
levels	O
","	O
with	O
an	O
objective	O
response	O
rate	O
of	O
22	O
%	O
.	O
	
Median	O
time	O
to	O
progression	O
was	O
6.3	O
months	O
and	O
overall	O
survival	O
was	O
15	O
months	O
.	O
	
The	O
biweekly	O
CPT-11	B-DRUG
/	O
LV5FU2	B-DRUG
combination	O
is	O
feasible	O
and	O
safe	O
","	O
without	O
overlapping	O
toxicity	O
.	O
	
CPT-11	B-DRUG
at	O
180	O
to	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
combination	O
with	O
LV5FU2	B-DRUG
has	O
been	O
selected	O
as	O
the	O
recommended	O
dose	O
for	O
further	O
studies	O
.	O
	
Ifosfamide	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
etoposide	B-DRUG
:	O
a	O
highly	O
effective	O
cytoreduction	B-TOXI
and	O
peripheral-blood	B-TOXI
progenitor-cell	I-TOXI
mobilization	I-TOXI
regimen	O
for	O
transplant-eligible	O
patients	O
with	O
non-Hodgkin	B-CANCER
's	I-CANCER
lymphoma	I-CANCER
.	O
	
	
To	O
evaluate	O
a	O
chemotherapy	O
regimen	O
that	O
consisted	O
of	O
ifosfamide	B-DRUG
administered	O
as	O
an	O
infusion	O
with	O
bolus	B-DRUG
carboplatin	I-DRUG
","	O
and	O
etoposide	B-DRUG
(	O
ICE	B-DRUG
)	O
supported	O
by	O
granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
(	O
G-CSF	B-DRUG
)	O
for	O
cytoreduction	B-TOXI
and	O
stem-cell	B-TOXI
mobilization	I-TOXI
in	O
transplant-eligible	O
patients	O
with	O
primary	O
refractory	O
or	O
relapsed	O
non-Hodgkin	B-CANCER
's	I-CANCER
lymphoma	I-CANCER
(	O
NHL	B-CANCER
)	O
.	O
	
One	O
hundred	O
sixty-three	O
transplant-eligible	O
patients	O
with	O
relapsed	O
or	O
primary	O
refractory	O
NHL	B-CANCER
were	O
treated	O
from	O
October	O
1993	O
to	O
December	O
1997	O
with	O
ICE	B-DRUG
chemotherapy	O
at	O
Memorial	O
Sloan-Kettering	O
Cancer	O
Center	O
.	O
	
Administration	O
of	O
three	O
cycles	O
of	O
ICE	B-DRUG
chemotherapy	O
was	O
planned	O
at	O
2-week	O
intervals	O
.	O
	
Peripheral-blood	O
progenitor	O
cells	O
were	O
collected	O
after	O
cycle	O
3	O
","	O
and	O
all	O
patients	O
who	O
achieved	O
a	O
partial	O
response	O
(	O
PR	O
)	O
or	O
complete	O
response	O
(	O
CR	O
)	O
to	O
ICE	B-DRUG
chemotherapy	O
were	O
eligible	O
to	O
proceed	O
to	O
transplantation	O
.	O
	
Event-free	O
and	O
overall	O
survival	O
","	O
ICE-related	B-TOXI
toxicity	I-TOXI
","	O
and	O
the	O
number	O
of	O
CD34	O
(	O
=+	O
)	O
cells	O
collected	O
after	O
treatment	O
with	O
ICE	B-DRUG
and	O
G-CSF	B-DRUG
were	O
evaluated	O
.	O
	
All	O
163	O
patients	O
were	O
assessable	O
for	O
response	O
","	O
and	O
there	O
was	O
no	O
treatment-related	O
mortality	O
.	O
	
A	O
major	O
response	O
(	O
CR	O
/	O
PR	O
)	O
was	O
evident	O
in	O
108	O
patients	O
(	O
66.3	O
%	O
)	O
;	O
89	O
%	O
of	O
the	O
responding	O
patients	O
underwent	O
successful	O
transplantation	O
.	O
	
Patient	O
who	O
underwent	O
transplantation	O
and	O
achieved	O
a	O
CR	O
to	O
ICE	B-DRUG
had	O
a	O
superior	O
overall	O
survival	O
to	O
that	O
of	O
patients	O
who	O
achieved	O
a	O
PR	O
(	O
65	O
%	O
v	O
30	O
%	O
;	O
P	O
0.003	O
)	O
.	O
	
The	O
median	O
number	O
of	O
CD34	O
(	O
=+	O
)	O
cells	O
/	O
kg	O
collected	O
was	O
8.4	O
x	O
10	O
(	O
6	O
)	O
.	O
	
The	O
dose-limiting	O
toxicity	O
of	O
ICE	B-DRUG
was	O
hematologic	O
","	O
with	O
29.4	O
%	O
of	O
patients	O
developing	O
grade	O
3	O
/	O
4	O
thrombocytopenia	B-TOXI
.	O
	
There	O
were	O
minimal	B-TOXI
nonhematologic	I-TOXI
side	I-TOXI
effects	I-TOXI
.	O
	
ICE	B-DRUG
chemotherapy	O
","	O
with	O
ifosfamide	B-DRUG
administered	O
as	O
a	O
24-hour	O
infusion	O
to	O
decrease	O
CNS	B-TOXI
side	I-TOXI
effects	I-TOXI
","	O
and	O
the	O
substitution	O
of	O
carboplatin	B-DRUG
for	O
cisplatin	B-DRUG
to	O
minimize	O
nephrotoxicity	B-TOXI
","	O
is	O
a	O
very	O
effective	O
cytoreduction	B-TOXI
and	O
mobilization	B-TOXI
regimen	O
in	O
patients	O
with	O
NHL	B-CANCER
.	O
	
Furthermore	O
","	O
the	O
quality	O
of	O
the	O
clinical	O
response	O
to	O
ICE	B-DRUG
predicts	O
for	O
posttransplant	O
outcome	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
gemcitabine	B-DRUG
and	O
docetaxel	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
A	O
Phase	O
I	O
study	O
was	O
initiated	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
of	O
weekly	O
gemcitabine	B-DRUG
combined	O
with	O
monthly	O
","	O
fixed-dose	O
docetaxel	B-DRUG
.	O
	
Patients	O
with	O
metastatic	B-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
treated	O
with	O
docetaxel	B-DRUG
","	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
on	O
Day	O
1	O
every	O
28	O
days	O
.	O
	
Gemcitabine	B-DRUG
was	O
administered	O
on	O
Days	O
1	O
","	O
8	O
","	O
and	O
15	O
and	O
underwent	O
dose	O
adjustment	O
in	O
cohorts	O
of	O
3月6日	O
patients	O
.	O
	
At	O
the	O
maximum	O
tolerated	O
dose	O
","	O
11	O
additional	O
patients	O
were	O
enrolled	O
.	O
	
Twenty-six	O
patients	O
received	O
85	O
cycles	O
of	O
therapy	O
.	O
	
At	O
the	O
first	O
dose	O
level	O
","	O
the	O
planned	O
gemcitabine	B-DRUG
dose	O
on	O
Days	O
1	O
","	O
8	O
","	O
and	O
15	O
was	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Two	O
of	O
the	O
6	O
patients	O
treated	O
at	O
this	O
dose	O
level	O
experienced	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
requiring	O
the	O
reduction	O
of	O
gemcitabine	B-DRUG
to	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
dose	O
and	O
the	O
administration	O
of	O
ciprofloxacin	B-DRUG
","	O
500	O
mg	O
orally	O
twice	O
daily	O
","	O
on	O
Days	O
8月18日	O
.	O
	
At	O
the	O
second	O
dose	O
level	O
the	O
first	O
3	O
patients	O
experienced	O
no	O
DLTs	O
and	O
the	O
dose	O
of	O
gemcitabine	B-DRUG
was	O
increased	O
to	O
700	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Two	O
of	O
the	O
6	O
patients	O
treated	O
at	O
the	O
700	O
mg	O
/	O
m	O
(	O
2	O
)	O
dose	O
level	O
experienced	O
DLTs	O
.	O
	
Eleven	O
additional	O
patients	O
were	O
enrolled	O
at	O
the	O
recommended	O
Phase	O
II	O
dose	O
of	O
gemcitabine	B-DRUG
(	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O
	
At	O
this	O
dose	O
level	O
","	O
Grade	O
3	O
/	O
4	O
(	O
according	O
the	O
National	O
Cancer	O
Institute	O
's	O
common	O
toxicity	O
criteria	O
)	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
occurred	O
in	O
12.5	O
%	O
and	O
2.1	O
%	O
of	O
cycles	O
","	O
respectively	O
.	O
	
Grade	O
3	O
and	O
4	O
nonhematologic	B-TOXI
toxicities	I-TOXI
were	O
uncommon	O
.	O
	
Three	O
of	O
seven	O
evaluable	O
patients	O
with	O
pancreatic	B-CANCER
carcinoma	I-CANCER
had	O
evidence	O
of	O
significant	O
antineoplastic	O
activity	O
(	O
three	O
partial	O
responses	O
)	O
.	O
	
In	O
addition	O
","	O
two	O
complete	O
responses	O
(	O
one	O
patient	O
with	O
gastric	B-CANCER
carcinoma	I-CANCER
and	O
one	O
patient	O
with	O
ovarian	B-CANCER
carcinoma	I-CANCER
)	O
and	O
one	O
partial	O
response	O
(	O
patient	O
with	O
hepatocellular	B-CANCER
carcinoma	I-CANCER
)	O
were	O
noted	O
in	O
patients	O
with	O
other	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
The	O
regimen	O
comprised	O
of	O
docetaxel	B-DRUG
","	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
on	O
Day	O
1	O
and	O
gemcitabine	B-DRUG
","	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
on	O
Days	O
1	O
","	O
8	O
","	O
and	O
15	O
with	O
ciprofloxacin	B-DRUG
on	O
Days	O
8月18日	O
every	O
28	O
days	O
is	O
safe	O
","	O
well	O
tolerated	O
","	O
and	O
active	O
.	O
	
Phase	O
I	O
study	O
of	O
3-week	O
schedule	O
of	O
irinotecan	B-DRUG
combined	O
with	O
cisplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
To	O
assess	O
the	O
feasibility	O
","	O
pharmacokinetic	O
interaction	O
","	O
and	O
possible	O
sequence-dependent	O
effects	O
of	O
the	O
irinotecan	B-DRUG
/	O
cisplatin	B-DRUG
combination	O
given	O
every	O
3	O
weeks	O
","	O
and	O
to	O
assess	O
the	O
influence	O
of	O
additional	O
granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
(	O
G-CSF	B-DRUG
)	O
on	O
the	O
hematologic	B-TOXI
toxicity	I-TOXI
.	O
	
Patients	O
who	O
had	O
received	O
no	O
more	O
than	O
one	O
prior	O
combination	O
chemotherapy	O
regimen	O
or	O
two	O
single-agent	O
regimens	O
were	O
entered	O
.	O
	
Treatment	O
consisted	O
of	O
a	O
90-minute	O
irinotecan	B-DRUG
infusion	O
followed	O
by	O
a	O
3-hour	O
cisplatin	B-DRUG
infusion	O
on	O
day	O
1	O
","	O
with	O
cycles	O
repeated	O
once	O
every	O
3	O
weeks	O
.	O
	
After	O
the	O
maximum-tolerated	O
dose	O
was	O
determined	O
","	O
the	O
sequence	O
of	O
administration	O
was	O
reversed	O
.	O
	
In	O
a	O
separate	O
cohort	O
of	O
six	O
patients	O
","	O
we	O
assessed	O
the	O
effect	O
of	O
G-CSF	B-DRUG
on	O
the	O
experienced	O
hematologic	B-TOXI
toxicity	I-TOXI
and	O
dose-intensity	O
.	O
	
Irinotecan	B-DRUG
doses	O
ranged	O
from	O
175	O
to	O
300	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
cisplatin	B-DRUG
doses	O
ranged	O
from	O
60	O
to	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Fifty-two	O
patients	O
entered	O
the	O
study	O
;	O
one	O
was	O
not	O
eligible	O
","	O
and	O
two	O
were	O
not	O
assessable	O
for	O
response	O
.	O
	
Twenty-five	O
patients	O
were	O
pretreated	O
","	O
and	O
26	O
were	O
not	O
.	O
	
Fifty-one	O
patients	O
received	O
a	O
total	O
of	O
223	O
courses	O
.	O
	
The	O
dose-limiting	O
toxicity	O
was	O
a	O
combination	O
of	O
neutropenic	B-TOXI
fever	I-TOXI
","	O
diarrhea	B-TOXI
","	O
and	O
fatigue	B-TOXI
at	O
a	O
dose	O
level	O
combining	O
irinotecan	B-DRUG
300	O
mg	O
/	O
m	O
(	O
2	O
)	O
with	O
cisplatin	B-DRUG
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Neutropenia	B-TOXI
was	O
common	O
(	O
grades	O
3	O
to	O
4	O
","	O
68	O
%	O
)	O
.	O
	
Irinotecan	B-DRUG
pharmacokinetics	O
were	O
linear	O
over	O
the	O
dose	O
range	O
studied	O
.	O
	
No	O
sequence-dependent	O
side	O
effects	O
were	O
observed	O
.	O
	
Tumor	O
responses	O
included	O
three	O
complete	O
responses	O
and	O
eight	O
partial	O
responses	O
.	O
	
For	O
phase	O
II	O
studies	O
","	O
we	O
recommend	O
irinotecan	B-DRUG
260	O
mg	O
/	O
m	O
(	O
2	O
)	O
combined	O
with	O
cisplatin	B-DRUG
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
once	O
every	O
3	O
weeks	O
for	O
chemotherapy-naive	O
patients	O
in	O
good	O
physical	O
condition	O
","	O
and	O
irinotecan	B-DRUG
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
combined	O
with	O
cisplatin	B-DRUG
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
other	O
patients	O
.	O
	
Phase	O
I	O
and	O
pharmacokinetic	O
study	O
of	O
tomudex	B-DRUG
combined	O
with	O
5-fluorouracil	B-DRUG
plus	O
levofolinic	B-DRUG
acid	I-DRUG
in	O
advanced	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
and	O
colorectal	B-CANCER
cancer	I-CANCER
.	O
	
	
In	O
vitro	O
studies	O
have	O
shown	O
a	O
schedule-dependent	O
synergism	O
between	O
Tomudex	B-DRUG
and	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
.	O
	
Incubation	O
of	O
different	O
types	O
of	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
and	I-CANCER
colorectal	I-CANCER
cancer	I-CANCER
cells	O
with	O
levofolinic	B-DRUG
acid	I-DRUG
(	O
LFA	B-DRUG
)	O
plus	O
5-FU	B-DRUG
for	O
4	O
or	O
24	O
h	O
","	O
after	O
24-h	O
incubation	O
with	O
Tomudex	B-DRUG
","	O
produces	O
a	O
clear	O
synergism	O
.	O
	
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
tolerability	O
and	O
activity	O
of	O
a	O
combination	O
of	O
Tomudex	B-DRUG
","	O
LFA	B-DRUG
","	O
and	O
5-FU	B-DRUG
in	O
advanced	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
and	I-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Furthermore	O
","	O
the	O
potential	O
for	O
5-FU	B-DRUG
pharmacomodulation	O
by	O
Tomudex	B-DRUG
was	O
also	O
evaluated	O
through	O
an	O
intrapatient	O
assessment	O
of	O
dihydropyrimidine	B-DRUG
dehydrogenase	I-DRUG
(	O
DPD	B-DRUG
)	O
activity	O
and	O
5-FU	B-DRUG
AUC	O
with	O
and	O
without	O
pretreatment	O
with	O
Tomudex	B-DRUG
.	O
	
Eligible	O
patients	O
were	O
treated	O
with	O
Tomudex	B-DRUG
at	O
the	O
starting	O
dose	O
of	O
1.5	O
mg	O
/	O
m2	O
on	O
day	O
1	O
","	O
LFA	B-DRUG
at	O
a	O
fixed	O
dose	O
of	O
250	O
mg	O
/	O
m2	O
on	O
day	O
2	O
","	O
immediately	O
followed	O
by	O
bolus	O
5-FU	B-DRUG
at	O
the	O
starting	O
dose	O
of	O
600	O
mg	O
/	O
m2	O
.	O
	
Tomudex	B-DRUG
and	O
5-FU	B-DRUG
doses	O
were	O
alternately	O
escalated	O
.	O
	
Courses	O
were	O
repeated	O
every	O
2	O
weeks	O
.	O
	
In	O
the	O
second	O
course	O
","	O
LFA	B-DRUG
and	O
5-FU	B-DRUG
were	O
administered	O
on	O
day	O
1	O
and	O
Tomudex	B-DRUG
on	O
day	O
2	O
;	O
further	O
treatment	O
was	O
given	O
according	O
to	O
the	O
sequence	O
used	O
in	O
the	O
first	O
course	O
.	O
	
Plasma	O
5-FU	B-DRUG
concentrations	O
were	O
analyzed	O
on	O
courses	O
1	O
and	O
2	O
using	O
a	O
high-performance	O
liquid	O
chromatography	O
assay	O
with	O
UV	O
detection	O
.	O
	
DPD	B-DRUG
activity	O
was	O
measured	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
on	O
courses	O
1	O
and	O
2	O
using	O
incubation	O
of	O
cytosol	O
with	O
[	O
14C	O
]	O
FU	B-DRUG
and	O
quantitation	O
of	O
metabolite	O
formation	O
.	O
	
Fifty-eight	O
patients	O
were	O
enrolled	O
in	O
the	O
study	O
.	O
	
Dose	O
escalation	O
was	O
stopped	O
at	O
step	O
8	O
","	O
because	O
of	O
the	O
occurrence	O
of	O
dose-limiting	O
toxicity	O
in	O
two	O
of	O
three	O
patients	O
.	O
	
The	O
dose	O
level	O
immediately	O
before	O
(	O
3	O
mg	O
/	O
m2	O
Tomudex	B-DRUG
","	O
1050	O
mg	O
/	O
m2	O
5-FU	B-DRUG
)	O
was	O
selected	O
for	O
further	O
evaluation	O
.	O
	
Tomudex	B-DRUG
and	O
5-FU	B-DRUG
mean	O
dose	O
intensities	O
actually	O
delivered	O
at	O
the	O
seventh	O
step	O
were	O
1.32	O
and	O
462	O
mg	O
/	O
m2	O
/	O
week	O
","	O
respectively	O
.	O
	
Six	O
of	O
40	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
obtained	O
an	O
objective	O
response	O
(	O
15	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
","	O
6月30日	O
%	O
)	O
.	O
	
In	O
particular	O
","	O
three	O
complete	O
responses	O
and	O
three	O
partial	O
responses	O
were	O
observed	O
.	O
	
Six	O
of	O
17	O
patients	O
with	O
locally	O
advanced	O
or	O
metastatic	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
obtained	O
an	O
objective	O
response	O
(	O
1	O
complete	O
response	O
=+	O
5	O
partial	O
responses	O
;	O
35	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
","	O
14-62	O
%	O
)	O
.	O
	
Median	O
duration	O
of	O
response	O
in	O
colorectal	B-CANCER
cancer	I-CANCER
patients	O
was	O
12	O
months	O
.	O
	
5-FU	B-DRUG
AUC	O
was	O
not	O
significantly	O
different	O
between	O
the	O
two	O
courses	O
(	O
median	O
intrapatient	O
difference	O
","	O
9.3	O
%	O
;	O
P	O
=	O
0.28	O
)	O
.	O
	
DPD	B-DRUG
activity	O
in	O
course	O
1	O
was	O
significantly	O
higher	O
than	O
course	O
2	O
(	O
P	O
=	O
0.041	O
)	O
in	O
the	O
16	O
patients	O
in	O
which	O
values	O
were	O
evaluable	O
.	O
	
The	O
combination	O
of	O
Tomudex	B-DRUG
","	O
LFA	B-DRUG
","	O
and	O
5-FU	B-DRUG
is	O
well	O
tolerated	O
and	O
active	O
in	O
colorectal	B-CANCER
and	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
.	O
	
The	O
Tomudex	B-DRUG
mean	O
dose	O
intensity	O
actually	O
delivered	O
is	O
higher	O
than	O
usually	O
achieved	O
in	O
monotherapy	O
.	O
	
The	O
absence	O
of	O
a	O
clear	O
pharmacokinetic	O
interaction	O
suggests	O
that	O
the	O
synergism	O
of	O
Tomudex	B-DRUG
and	O
5-FU	B-DRUG
might	O
occur	O
at	O
the	O
cellular	O
level	O
.	O
	
Phase	O
I	O
study	O
of	O
dose-escalated	O
paclitaxel	B-DRUG
","	O
ifosfamide	B-DRUG
","	O
and	O
cisplatin	B-DRUG
(	O
PIC	B-DRUG
)	O
combination	O
chemotherapy	O
in	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
	
Based	O
on	O
the	O
already	O
known	O
in	O
vitro	O
synergy	O
between	O
paclitaxel	B-DRUG
(	O
taxol	B-DRUG
)	O
","	O
cisplatin	B-DRUG
and	O
oxazophosphorine	O
cytostatics	O
and	O
the	O
broad	O
spectrum	O
of	O
activity	O
of	O
the	O
above	O
drugs	O
we	O
sought	O
to	O
evaluate	O
the	O
paclitaxel	B-DRUG
(	O
taxol	B-DRUG
)	O
#NAME?	B-DRUG
(	O
PIC	B-DRUG
)	O
combination	O
in	O
the	O
outpatient	O
setting	O
in	O
individuals	O
with	O
a	O
variety	O
of	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
Cohorts	O
of	O
patients	O
were	O
entered	O
into	O
six	O
successive	O
dose	O
levels	O
(	O
DLs	O
)	O
with	O
drug	O
doses	O
ranging	O
as	O
follows	O
:	O
paclitaxel	B-DRUG
135-215	O
mg	O
m	O
(	O
-2	O
)	O
day	O
1	O
=-	O
(	O
1	O
h	O
infusion	O
)	O
","	O
ifosfamide	B-DRUG
4.5-6.0	O
g	O
m	O
(	O
-2	O
)	O
(	O
total	O
dose	O
)	O
=-	O
divided	O
over	O
days	O
1	O
and	O
2	O
","	O
and	O
cisplatin	B-DRUG
80-100	O
mg	O
m	O
(	O
-2	O
)	O
(	O
total	O
)	O
=-	O
divided	O
over	O
days	O
1	O
and	O
2	O
Granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
was	O
given	O
from	O
day	O
5	O
to	O
14	O
.	O
	
Forty-two	O
patients	O
were	O
entered	O
.	O
	
Eighteen	O
patients	O
had	O
2月8日	O
cycles	O
of	O
prior	O
chemotherapy	O
with	O
no	O
taxanes	B-DRUG
or	O
ifosfamide	B-DRUG
(	O
cisplatin	B-DRUG
was	O
allowed	O
)	O
.	O
	
The	O
regimen	O
was	O
tolerated	O
with	O
outpatient	O
administration	O
in	O
36	O
/	O
42	O
patients	O
.	O
	
Toxicities	O
included	O
:	O
grade	O
4	O
neutropenia	B-TOXI
for	O
&	O
lt	O
;	O
or	O
=	O
5	O
days	O
in	O
27	O
%	O
of	O
cycles	O
;	O
5	O
episodes	O
of	O
febrile	B-TOXI
neutropenia	I-TOXI
in	O
three	O
patients	O
at	O
DL-III	O
","	O
#NAME?	O
and	O
#NAME?	O
.	O
	
Grade	O
3	O
/	O
4	O
thrombocytopenia	B-TOXI
and	O
cumulative	O
grade	O
3	O
anaemia	B-TOXI
were	O
seen	O
in	O
7	O
%	O
and	O
13	O
%	O
of	O
cycles	O
respectively	O
.	O
	
Three	O
cases	O
of	O
severe	O
grade	O
3	O
neuromotor	B-TOXI
/	O
sensory	B-TOXI
neuropathy	I-TOXI
were	O
recorded	O
at	O
DL-II	O
","	O
#NAME?	O
","	O
and	O
#NAME?	O
","	O
all	O
after	O
cycle	O
3	O
The	O
maximum	O
tolerated	O
dose	O
was	O
not	O
formally	O
reached	O
at	O
DL-V	O
","	O
but	O
because	O
of	O
progressive	O
anaemia	B-TOXI
and	O
asthenia	B-TOXI
/	O
fatigue	B-TOXI
","	O
it	O
was	O
decided	O
to	O
test	O
a	O
new	O
DL-VI	O
with	O
doses	O
of	O
paclitaxel	B-DRUG
200	O
mg	O
m	O
(	O
-2	O
)	O
","	O
ifosfamide	B-DRUG
5	O
g	O
m	O
(	O
-2	O
)	O
and	O
cisplatin	B-DRUG
100	O
mg	O
m	O
(	O
-2	O
)	O
;	O
this	O
appeared	O
to	O
be	O
tolerable	O
and	O
is	O
recommended	O
for	O
further	O
phase	O
II	O
testing	O
.	O
	
The	O
response	O
rate	O
was	O
47.5	O
%	O
(	O
complete	O
response	O
=+	O
partial	O
response	O
:	O
20	O
/	O
42	O
)	O
.	O
	
The	O
PIC	B-DRUG
regimen	O
appears	O
to	O
be	O
feasible	O
and	O
safe	O
in	O
the	O
outpatient	O
setting	O
.	O
	
Care	O
should	O
be	O
paid	O
to	O
neurotoxicity	B-TOXI
.	O
	
Phase	O
II	O
studies	O
are	O
starting	O
in	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
","	O
ovarian	B-CANCER
cancer	I-CANCER
and	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
at	O
DL-VI	O
.	O
	
Multi-institutional	O
phase	O
I	O
/	O
II	O
trial	O
of	O
paclitaxel	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
etoposide	B-DRUG
with	O
concurrent	O
radiation	O
for	O
limited-stage	O
small-cell	B-CANCER
lung	I-CANCER
carcinoma	I-CANCER
.	O
	
	
To	O
determine	O
the	O
feasibility	O
of	O
adding	O
paclitaxel	B-DRUG
to	O
standard	O
cisplatin	B-DRUG
/	O
etoposide	B-DRUG
(	O
EP	B-DRUG
)	O
and	O
thoracic	O
radiotherapy	O
.	O
	
Thirty-one	O
patients	O
were	O
enrolled	O
onto	O
this	O
study	O
.	O
	
During	O
the	O
phase	O
I	O
section	O
of	O
this	O
study	O
","	O
the	O
dose	O
of	O
paclitaxel	B-DRUG
was	O
escalated	O
in	O
groups	O
of	O
three	O
or	O
more	O
patients	O
.	O
	
Cycles	O
were	O
repeated	O
every	O
21	O
days	O
.	O
	
For	O
cycles	O
1	O
and	O
2	O
","	O
paclitaxel	B-DRUG
was	O
administered	O
according	O
to	O
the	O
dose-escalation	O
schema	O
at	O
doses	O
of	O
100	O
","	O
135	O
","	O
or	O
170	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
over	O
3	O
hours	O
on	O
day	O
1	O
Once	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
paclitaxel	B-DRUG
(	O
for	O
cycles	O
1	O
and	O
2	O
","	O
concurrent	O
with	O
radiation	O
)	O
was	O
determined	O
","	O
that	O
dose	O
was	O
used	O
in	O
all	O
subsequent	O
patients	O
entered	O
onto	O
the	O
phase	O
II	O
section	O
of	O
this	O
study	O
.	O
	
For	O
cycles	O
3	O
and	O
4	O
","	O
the	O
paclitaxel	B-DRUG
dose	O
was	O
fixed	O
at	O
170	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
all	O
patients	O
.	O
	
On	O
day	O
2	O
","	O
cisplatin	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
was	O
administered	O
for	O
all	O
cycles	O
.	O
	
On	O
days	O
1	O
","	O
2	O
","	O
and	O
3	O
","	O
etoposide	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d	O
(	O
cycles	O
1	O
and	O
2	O
)	O
or	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d	O
(	O
cycles	O
3	O
and	O
4	O
)	O
was	O
administered	O
.	O
	
Chest	O
radiation	O
was	O
given	O
at	O
9	O
Gy	O
/	O
wk	O
in	O
five	O
fractions	O
for	O
5	O
weeks	O
beginning	O
on	O
day	O
1	O
of	O
cycle	O
1	O
Granulocyte	B-DRUG
colony-stimulating	I-DRUG
factors	I-DRUG
were	O
used	O
during	O
cycles	O
3	O
and	O
4	O
only	O
.	O
	
Twenty-eight	O
patients	O
were	O
assessable	O
.	O
	
The	O
MTD	O
of	O
paclitaxel	B-DRUG
was	O
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
with	O
the	O
dose-limiting	O
toxicity	O
being	O
grade	O
4	O
neutropenia	B-TOXI
.	O
	
Cycles	O
1	O
and	O
2	O
were	O
associated	O
with	O
grade	O
4	O
neutropenia	B-TOXI
in	O
32	O
%	O
of	O
courses	O
","	O
with	O
fever	B-TOXI
occurring	O
in	O
7	O
%	O
of	O
courses	O
and	O
grade	O
2	O
/	O
3	O
esophagitis	B-TOXI
in	O
13	O
%	O
.	O
	
Cycles	O
3	O
and	O
4	O
were	O
complicated	O
by	O
grade	O
4	O
neutropenia	B-TOXI
in	O
20	O
%	O
of	O
courses	O
","	O
with	O
fever	B-TOXI
occurring	O
in	O
6	O
%	O
of	O
courses	O
and	O
grade	O
2	O
/	O
3	O
esophagitis	B-TOXI
in	O
16	O
%	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
96	O
%	O
(	O
complete	O
responses	O
","	O
39	O
%	O
;	O
partial	O
responses	O
","	O
57	O
%	O
)	O
.	O
	
After	O
a	O
median	O
follow-up	O
period	O
of	O
23	O
months	O
(	O
range	O
","	O
9	O
to	O
40	O
months	O
)	O
","	O
the	O
median	O
survival	O
time	O
was	O
22.3	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
15.1	O
to	O
34.3	O
months	O
)	O
The	O
MTD	O
of	O
paclitaxel	B-DRUG
with	O
radiation	O
and	O
EP	B-DRUG
treatment	O
is	O
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
over	O
3	O
hours	O
.	O
	
In	O
this	O
schedule	O
of	O
administration	O
","	O
a	O
high	O
response	O
rate	O
and	O
acceptable	O
toxicity	O
can	O
be	O
anticipated	O
.	O
	
Sequential	O
dose-intensive	O
paclitaxel	B-DRUG
","	O
ifosfamide	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
etoposide	B-DRUG
salvage	O
therapy	O
for	O
germ	B-CANCER
cell	I-CANCER
tumor	I-CANCER
patients	O
.	O
	
	
To	O
evaluate	O
the	O
efficacy	O
and	O
toxicity	O
of	O
sequential	O
","	O
dose-intensified	O
chemotherapy	O
with	O
paclitaxel	B-DRUG
/	O
ifosfamide	B-DRUG
and	O
carboplatin	B-DRUG
/	O
etoposide	B-DRUG
administered	O
plus	O
peripheral	B-DRUG
blood-derived	I-DRUG
stem-cell	I-DRUG
(	O
PBSC	B-DRUG
)	O
support	O
for	O
patients	O
with	O
germ	B-CANCER
cell	I-CANCER
tumors	I-CANCER
(	O
GCT	B-CANCER
)	O
who	O
have	O
unfavorable	O
prognostic	O
features	O
in	O
response	O
to	O
conventional-dose	O
salvage	O
programs	O
.	O
	
Carboplatin	B-DRUG
was	O
dose	O
escalated	O
by	O
target	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
;	O
in	O
[	O
milligrams	O
per	O
milliliter	O
]	O
x	O
minutes	O
)	O
among	O
patient	O
cohorts	O
","	O
and	O
pharmacokinetic	O
studies	O
were	O
performed	O
for	O
comparison	O
.	O
	
Thirty-seven	O
previously	O
treated	O
patients	O
who	O
had	O
cisplatin-resistant	B-DRUG
GCT	B-CANCER
and	O
unfavorable	O
prognostic	O
features	O
for	O
response	O
to	O
conventional-dose	O
salvage	O
therapy	O
were	O
treated	O
.	O
	
Two	O
cycles	O
of	O
paclitaxel	B-DRUG
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
plus	O
ifosfamide	B-DRUG
6	O
g	O
/	O
m	O
(	O
2	O
)	O
were	O
given	O
2	O
weeks	O
apart	O
with	O
leukapheresis	B-DRUG
","	O
followed	O
by	O
three	O
cycles	O
of	O
carboplatin	B-DRUG
plus	O
etoposide	B-DRUG
given	O
14	O
to	O
21	O
days	O
apart	O
with	O
reinfusion	O
of	O
PBSCs	B-DRUG
.	O
	
The	O
dose	O
of	O
etoposide	B-DRUG
was	O
1	O
","	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
and	O
the	O
carboplatin	B-DRUG
target	O
AUC	O
ranged	O
among	O
cohorts	O
from	O
12	O
to	O
32	O
(	O
mg	O
/	O
mL	O
)	O
x	O
min	O
.	O
	
Pharmacokinetic	O
studies	O
of	O
carboplatin	B-DRUG
were	O
performed	O
for	O
comparison	O
of	O
target	O
to	O
measured	O
AUC	O
.	O
	
Twenty-one	O
patients	O
(	O
57	O
%	O
)	O
achieved	O
a	O
complete	O
response	O
and	O
an	O
additional	O
two	O
patients	O
(	O
5	O
%	O
)	O
achieved	O
a	O
partial	O
response	O
with	O
normal	O
tumor	O
markers	O
;	O
therefore	O
","	O
23	O
(	O
62	O
%	O
)	O
achieved	O
a	O
favorable	O
response	O
.	O
	
Eight	O
patients	O
relapsed	O
","	O
and	O
15	O
(	O
41	O
%	O
)	O
of	O
the	O
favorable	O
responses	O
remained	O
durable	O
at	O
a	O
median	O
follow-up	O
of	O
30	O
months	O
.	O
	
Myelosuppression	B-TOXI
was	O
the	O
major	O
toxicity	O
;	O
58	O
%	O
of	O
carboplatin	B-DRUG
/	O
etoposide	B-DRUG
cycles	O
were	O
associated	O
with	O
hospitalization	O
for	O
nadir	B-TOXI
fever	I-TOXI
.	O
	
The	O
AUC	O
of	O
carboplatin	B-DRUG
measured	O
in	O
serum	O
was	O
lower	O
than	O
the	O
target	O
AUC	O
;	O
this	O
may	O
be	O
related	O
to	O
underestimation	O
of	O
the	O
glomerular	O
filtration	O
rate	O
used	O
in	O
the	O
dosing	O
formula	O
.	O
	
Dose-intense	O
therapy	O
with	O
sequential	O
","	O
accelerated	O
chemotherapy	O
of	O
paclitaxel	B-DRUG
/	O
ifosfamide	B-DRUG
and	O
carboplatin	B-DRUG
/	O
etoposide	B-DRUG
administered	O
with	O
PBSC	B-DRUG
support	O
was	O
relatively	O
well	O
tolerated	O
.	O
	
The	O
durable	O
complete	O
response	O
proportion	O
was	O
substantial	O
in	O
patients	O
with	O
unfavorable	O
prognostic	O
features	O
for	O
achieving	O
durable	O
complete	O
response	O
to	O
conventional-dose	O
salvage	O
programs	O
.	O
	
Optimal	O
dosing	O
of	O
carboplatin	B-DRUG
in	O
the	O
high-dose	O
setting	O
warrants	O
further	O
investigation	O
.	O
	
Phase	O
II	O
trial	O
of	O
up-front	O
accelerated	O
thoracic	O
radiotherapy	O
combined	O
with	O
chemotherapy	O
and	O
optional	O
up-front	O
prophylactic	O
cranial	O
irradiation	O
in	O
limited	O
small-cell	B-CANCER
lung	I-CANCER
cancer.	I-CANCER
Groupe	O
d'Oncologie	O
Thoracique	O
des	O
R茅gions	O
Alpines	O
.	O
	
	
To	O
investigate	O
the	O
feasibility	O
and	O
outcome	O
of	O
bifractionated	O
","	O
up-front	O
thoracic	O
radiotherapy	O
(	O
TR	O
)	O
(	O
45	O
Gy	O
in	O
30	O
fractions	O
of	O
1.5	O
Gy	O
twice	O
daily	O
over	O
3	O
weeks	O
)	O
combined	O
with	O
chemotherapy	O
(	O
CT	O
)	O
(	O
six	O
cycles	O
of	O
cisplatin	O
and	O
etoposide	O
)	O
and	O
optional	O
low-dose	O
","	O
up-front	O
prophylactic	O
cranial	O
irradiation	O
(	O
18	O
Gy	O
in	O
10	O
fractions	O
of	O
1.8	O
Gy	O
twice	O
daily	O
over	O
5	O
days	O
)	O
in	O
limited	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
CT	B-DRUG
(	O
etoposide	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
3	O
days	O
and	O
cisplatin	B-DRUG
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
3	O
days	O
)	O
was	O
started	O
on	O
day	O
8	O
or	O
15	O
after	O
the	O
first	O
TR	O
treatment	O
.	O
	
In	O
the	O
five	O
subsequent	O
cycles	O
","	O
cisplatin	B-DRUG
was	O
given	O
as	O
a	O
single	O
100-mg	O
/	O
m	O
(	O
2	O
)	O
dose	O
on	O
day	O
1	O
every	O
4	O
weeks	O
.	O
	
A	O
total	O
of	O
52	O
patients	O
were	O
entered	O
(	O
41	O
men	O
and	O
11	O
women	O
)	O
;	O
the	O
median	O
age	O
was	O
55	O
years	O
(	O
range	O
","	O
33	O
to	O
67	O
years	O
)	O
.	O
	
World	O
Health	O
Organization	O
performance	O
status	O
was	O
0	O
in	O
34	O
patients	O
","	O
1	O
in	O
16	O
patients	O
","	O
and	O
2	O
in	O
two	O
patients	O
.	O
	
Thirty-six	O
patients	O
(	O
69	O
%	O
)	O
received	O
the	O
full	O
planned	O
six	O
cycles	O
of	O
CT.	B-DRUG
All	O
treated	O
patients	O
were	O
assessable	O
for	O
response	O
.	O
	
Thirty-one	O
patients	O
(	O
60	O
%	O
)	O
achieved	O
a	O
complete	O
response	O
","	O
and	O
16	O
(	O
30	O
%	O
)	O
had	O
a	O
partial	O
response	O
.	O
	
One-	O
","	O
-3	O
","	O
and	O
4-year	O
survival	O
rates	O
were	O
74	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
60	O
%	O
to	O
84	O
%	O
)	O
","	O
34	O
%	O
(	O
95	O
%	O
CI	O
","	O
21	O
%	O
to	O
49	O
%	O
)	O
","	O
and	O
32	O
%	O
(	O
95	O
CI	O
","	O
16	O
%	O
to	O
46	O
%	O
)	O
","	O
respectively	O
.	O
	
The	O
median	O
survival	O
time	O
was	O
18	O
months	O
.	O
	
Event-free	O
survival	O
at	O
1	O
year	O
was	O
45	O
%	O
(	O
95	O
%	O
CI	O
","	O
32	O
%	O
to	O
58	O
%	O
)	O
and	O
at	O
3	O
years	O
","	O
30	O
%	O
(	O
95	O
%	O
CI	O
","	O
18	O
%	O
to	O
44	O
%	O
)	O
.	O
	
The	O
main	O
radiation-related	O
acute	B-TOXI
toxicity	I-TOXI
was	O
esophageal	O
:	O
38	O
%	O
of	O
the	O
patients	O
experienced	O
grade	O
3	O
or	O
4	O
acute	B-TOXI
toxicity	I-TOXI
.	O
	
CT	B-DRUG
was	O
well	O
tolerated	O
.	O
	
Although	O
grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
was	O
observed	O
in	O
86	O
%	O
of	O
the	O
patients	O
","	O
only	O
4	O
%	O
presented	O
with	O
associated	B-TOXI
fever	I-TOXI
.	O
	
Grade	O
3	O
/	O
4	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
was	O
seen	O
in	O
35	O
%	O
of	O
patients	O
.	O
	
This	O
trial	O
demonstrates	O
that	O
up-front	O
accelerated	O
TR	O
associated	O
with	O
CT	O
is	O
feasible	O
","	O
has	O
acceptable	O
toxicity	O
","	O
and	O
shows	O
considerable	O
long-term	O
survival	O
potential	O
.	O
	
Phase	O
II	O
trial	O
of	O
gemcitabine	B-DRUG
plus	O
cisplatin	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
urothelial	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
assess	O
the	O
activity	O
and	O
toxicity	O
of	O
the	O
combination	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
in	O
the	O
treatment	O
of	O
chemotherapy-naive	O
patients	O
with	O
metastatic	B-CANCER
urothelial	I-CANCER
cancer	I-CANCER
.	O
	
Forty-six	O
patients	O
with	O
measurable	O
stage	O
IV	O
carcinoma	B-CANCER
of	I-CANCER
the	I-CANCER
urothelium	I-CANCER
were	O
enrolled	O
onto	O
this	O
trial	O
.	O
	
Gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
was	O
administered	O
intravenously	O
for	O
30	O
to	O
60	O
minutes	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
of	O
each	O
28-day	O
cycle	O
.	O
	
Cisplatin	B-DRUG
was	O
administered	O
after	O
gemcitabine	B-DRUG
on	O
day	O
1	O
of	O
each	O
cycle	O
.	O
	
The	O
first	O
11	O
patients	O
received	O
an	O
initial	O
cisplatin	B-DRUG
dose	O
of	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Due	O
to	O
the	O
hematologic	B-TOXI
toxicity	I-TOXI
observed	O
in	O
several	O
of	O
these	O
patients	O
","	O
the	O
dose	O
was	O
reduced	O
to	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
the	O
remaining	O
35	O
patients	O
.	O
	
Patients	O
were	O
treated	O
with	O
six	O
cycles	O
","	O
unless	O
disease	O
progression	O
or	O
severe	B-TOXI
toxicity	I-TOXI
necessitated	O
earlier	O
discontinuation	O
.	O
	
Ten	O
of	O
the	O
46	O
patients	O
achieved	O
a	O
complete	O
response	O
and	O
nine	O
showed	O
a	O
partial	O
response	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
41	O
%	O
.	O
	
The	O
median	O
time	O
to	O
treatment	O
failure	O
was	O
5.5	O
months	O
.	O
	
The	O
median	O
survival	O
was	O
14.3	O
months	O
","	O
and	O
the	O
1-year	O
survival	O
probability	O
was	O
54	O
%	O
.	O
	
Most	O
of	O
the	O
toxicities	O
were	O
hematologic	O
and	O
","	O
in	O
general	O
","	O
easily	O
manageable	O
.	O
	
Gemcitabine	B-DRUG
plus	O
cisplatin	B-DRUG
is	O
active	O
in	O
the	O
treatment	O
of	O
metastatic	B-CANCER
urothelial	I-CANCER
cancer	I-CANCER
in	O
chemotherapy-naive	O
patients	O
and	O
has	O
an	O
acceptable	O
clinical	O
safety	O
profile	O
.	O
	
Studies	O
are	O
under	O
way	O
to	O
further	O
define	O
the	O
place	O
of	O
gemcitabine	B-DRUG
in	O
combination	O
with	O
other	O
chemotherapeutic	O
agents	O
in	O
the	O
treatment	O
of	O
metastatic	B-CANCER
urothelial	I-CANCER
cancer	I-CANCER
.	O
	
Chemo-biotherapy	O
with	O
5-fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
alpha	B-DRUG
interferon	I-DRUG
in	O
metastatic	B-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
colon	I-CANCER
=--	O
a	O
Cancer	O
Biotherapy	O
Research	O
Group	O
[	O
CBRG	O
]	O
phase	O
II	O
study	O
.	O
	
	
Biochemical	O
modulation	O
of	O
5-Fluorouracil	B-DRUG
activity	O
with	O
Leucovorin	B-DRUG
has	O
been	O
well	O
documented	O
in	O
colorectal	B-CANCER
cancer	I-CANCER
.	O
	
Several	O
studies	O
have	O
shown	O
increased	O
efficacy	O
of	O
5-fluorouracil	B-DRUG
in	O
combination	O
with	O
alpha	B-DRUG
interferon	I-DRUG
.	O
	
We	O
therefore	O
initiated	O
a	O
phase	O
II	O
trial	O
of	O
dual	O
modulation	O
of	O
5-fluorouracil	B-DRUG
with	O
leucovorin	B-DRUG
and	O
alpha	B-DRUG
interferon	I-DRUG
to	O
evaluate	O
outcomes	O
in	O
patients	O
with	O
metastatic	B-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
colon	I-CANCER
.	O
	
Patients	O
with	O
metastatic	B-CANCER
colon	I-CANCER
carcinoma	I-CANCER
with	O
expected	O
survival	O
&	O
gt	O
;	O
4	O
months	O
and	O
performance	O
status	O
of	O
ECOG	O
&	O
lt	O
;	O
or	O
=	O
2	O
were	O
treated	O
weekly	O
with	O
Leucovorin	B-DRUG
400	O
mg	O
i.v.	O
followed	O
by	O
5-FU	B-DRUG
600	O
mg	O
/	O
m2	O
i.v.	O
bolus	O
.	O
	
Alpha	B-DRUG
interferon	I-DRUG
3月9日	O
million	O
units	O
was	O
administered	O
subcutaneously	O
every	O
Monday	O
","	O
Wednesday	O
and	O
Friday	O
.	O
	
Patients	O
were	O
analyzed	O
for	O
toxicity	O
","	O
tumor	O
response	O
and	O
survival	O
.	O
	
Sixteen	O
patients	O
with	O
a	O
median	O
age	O
of	O
66	O
years	O
were	O
treated	O
.	O
	
Three	O
patients	O
were	O
not	O
evaluable	O
for	O
response	O
but	O
were	O
evaluable	O
for	O
toxicity	O
.	O
	
Grades	O
3	O
and	O
4	O
toxicities	O
were	O
neutropenia	B-TOXI
","	O
diarrhea	B-TOXI
","	O
mucositis	B-TOXI
","	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
","	O
fatigue	B-TOXI
","	O
fever	B-TOXI
","	O
asthenia	B-TOXI
and	O
elevated	B-TOXI
hepatic	I-TOXI
enzymes	I-TOXI
.	O
	
One	O
patient	O
died	B-TOXI
from	O
complications	O
associated	O
with	O
diverticulitis	B-TOXI
and	O
neutropenia	B-TOXI
.	O
	
Objective	O
response	O
rate	O
was	O
23	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
4-46	O
%	O
)	O
and	O
median	O
survival	O
was	O
11.5	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
6.3-19	O
months	O
)	O
.	O
	
Thirty-eight	O
percent	O
of	O
the	O
patients	O
were	O
alive	O
at	O
one	O
year	O
and	O
19	O
%	O
at	O
two	O
years	O
.	O
	
The	O
combination	O
of	O
5-fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
and	O
alpha	B-DRUG
interferon	I-DRUG
as	O
administered	O
in	O
this	O
phase	O
II	O
study	O
did	O
not	O
result	O
in	O
enhanced	O
response	O
rate	O
or	O
survival	O
.	O
	
However	O
this	O
regimen	O
was	O
associated	O
with	O
considerable	O
toxicity	O
.	O
	
Weekly	O
docetaxel	B-DRUG
plus	O
gemcitabine	B-DRUG
or	O
vinorelbine	B-DRUG
in	O
refractory	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
patients	O
:	O
a	O
parallel	O
dose-finding	O
study.	O
Southern	O
Italy	O
Cooperative	O
Oncology	O
Group	O
(	O
SICOG	O
)	O
.	O
	
	
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
docetaxel	B-DRUG
MTD	O
when	O
combined	O
with	O
gemcitabine	B-DRUG
or	O
vinorelbine	B-DRUG
in	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
patients	O
who	O
had	O
received	O
previous	O
anthracycline-based	B-DRUG
chemotherapy	O
for	O
advanced	O
disease	O
.	O
	
Advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
patients	O
aged	O
between	O
18	O
and	O
70	O
with	O
ECOG	O
PS	O
0-2	O
who	O
had	O
not	O
responded	O
to	O
","	O
or	O
had	O
relapsed	O
after	O
","	O
first-line	O
anthracycline-based	B-DRUG
chemotherapy	O
","	O
were	O
randomized	O
to	O
receive	O
either	O
gemcitabine	B-DRUG
1000	O
mg	O
/	O
m2	O
or	O
vinorelbine	B-DRUG
25	O
mg	O
/	O
m2	O
in	O
combination	O
with	O
escalating	O
doses	O
of	O
docetaxel	B-DRUG
(	O
starting	O
from	O
30	O
mg	O
/	O
m2	O
)	O
","	O
all	O
on	O
days	O
1	O
and	O
8	O
every	O
three	O
weeks	O
.	O
	
Escalation	O
was	O
stopped	O
if	O
&	O
gt	O
;	O
33	O
%	O
of	O
patients	O
treated	O
at	O
a	O
given	O
dose	O
level	O
showed	O
DLT	O
at	O
the	O
first	O
cycle	O
.	O
	
A	O
total	O
of	O
34	O
patients	O
with	O
locally	O
advanced	O
(	O
8	O
)	O
or	O
metastatic	O
disease	O
(	O
26	O
)	O
were	O
treated	O
","	O
for	O
a	O
total	O
of	O
94	O
cycles	O
delivered	O
.	O
	
Nineteen	O
patients	O
received	O
docetaxel	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
and	O
15	O
with	O
vinorelbine	B-DRUG
.	O
	
All	O
patients	O
had	O
been	O
pretreated	O
with	O
anthracyclines	B-DRUG
","	O
and	O
24	O
of	O
34	O
had	O
also	O
received	O
weekly	O
dose-dense	O
paclitaxel	B-DRUG
.	O
	
A	O
docetaxel	B-DRUG
dose	O
of	O
40	O
/	O
m2	O
proved	O
to	O
be	O
safe	O
when	O
combined	O
on	O
days	O
1	O
and	O
8	O
with	O
gemcitabine	B-DRUG
","	O
while	O
a	O
dose	O
of	O
35	O
mg	O
/	O
m2	O
was	O
tolerated	O
in	O
combination	O
with	O
vinorelbine	B-DRUG
.	O
	
Overall	O
","	O
nine	O
episodes	O
of	O
DLT	O
","	O
all	O
of	O
them	O
neutropenia	B-TOXI
","	O
occurred	O
at	O
the	O
first	O
cycle	O
.	O
	
Considering	O
all	O
94	O
cycles	O
","	O
grades	O
3	O
or	O
4	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
occurred	O
in	O
15	O
(	O
44	O
%	O
)	O
","	O
and	O
7	O
(	O
20	O
%	O
)	O
patients	O
.	O
	
Non-hematologic	B-TOXI
toxicity	I-TOXI
was	O
mild	O
","	O
except	O
for	O
three	O
cases	O
of	O
grade	O
2	O
peripheral	B-TOXI
neuropathy	I-TOXI
.	O
	
All	O
patients	O
were	O
assessed	O
for	O
response	O
on	O
an	O
'intent-to-treat	O
'	O
basis	O
.	O
	
Overall	O
","	O
five	O
partial	O
responses	O
were	O
recorded	O
(	O
docetaxel	B-DRUG
=+	O
gemcitabine	B-DRUG
=	O
3	O
and	O
docetaxel	B-DRUG
=+	O
vinorelbine	B-DRUG
=	O
2	O
)	O
","	O
for	O
a	O
15	O
%	O
(	O
95	O
%	O
CI	O
:	O
5	O
%	O
-31	O
%	O
)	O
overall	O
response	O
rate	O
.	O
	
Only	O
1	O
of	O
24	O
(	O
4	O
%	O
)	O
patients	O
who	O
had	O
received	O
weekly	O
dose-dense	O
paclitaxel	B-DRUG
responded	O
to	O
treatment	O
.	O
	
The	O
weekly	O
docetaxel	B-DRUG
administration	O
in	O
combination	O
with	O
either	O
gemcitabine	B-DRUG
or	O
vinorelbine	B-DRUG
is	O
a	O
well-tolerated	O
treatment	O
for	O
heavily	O
pretreated	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
patients	O
.	O
	
This	O
approach	O
","	O
although	O
sometimes	O
capable	O
of	O
achieving	O
a	O
major	O
response	O
","	O
does	O
not	O
seem	O
advisable	O
in	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
patients	O
refractory	O
to	O
both	O
anthracyclines	B-DRUG
and	O
paclitaxel	B-DRUG
.	O
	
Gemcitabine	B-DRUG
combined	O
with	O
continuous	O
infusion	O
5-fluorouracil	B-DRUG
in	O
advanced	B-CANCER
and	I-CANCER
symptomatic	I-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
:	O
a	O
clinical	O
benefit-oriented	O
phase	O
II	O
study	O
.	O
	
	
Gemcitabine	B-DRUG
and	O
5-fluorouracil	B-DRUG
are	O
the	O
only	O
two	O
compounds	O
with	O
reproducible	O
activity	O
against	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
(	O
APC	B-CANCER
)	O
.	O
	
We	O
have	O
evaluated	O
a	O
novel	O
combination	O
of	O
gemcitabine	B-DRUG
and	O
5-fluorouracil	B-DRUG
on	O
the	O
clinical	O
benefit	O
response	O
(	O
CBR	O
)	O
end	O
point	O
.	O
	
Eleven	O
consecutive	O
patients	O
with	O
symptomatic	B-CANCER
APC	I-CANCER
were	O
entered	O
in	O
a	O
two-stage	O
phase	O
II	O
trial	O
.	O
	
Gemcitabine	B-DRUG
was	O
administered	O
by	O
intravenous	O
(	O
i.v.	O
)	O
bolus	O
injection	O
at	O
the	O
dose	O
of	O
"1,000"	O
mg	O
m	O
(	O
-2	O
)	O
on	O
days	O
1	O
","	O
8	O
","	O
15	O
and	O
5-fluorouracil	B-DRUG
500	O
mg	O
m	O
(	O
-2	O
)	O
was	O
given	O
by	O
continuous	O
i.v.	O
infusion	O
on	O
days	O
1月5日	O
.	O
	
Treatment	O
was	O
repeated	O
every	O
28	O
days	O
.	O
	
A	O
CBR	O
was	O
achieved	O
in	O
7	O
/	O
11	O
patients	O
.	O
	
The	O
mean	O
time	O
to	O
loss	O
of	O
CBR	O
was	O
26.5	O
weeks	O
(	O
range	O
14-18	O
","	O
median	O
22	O
)	O
.	O
	
Toxicity	O
was	O
mild	O
and	O
no	O
APC	B-CANCER
patient	O
experienced	O
WHO	O
grade	O
3	O
toxicity	O
.	O
	
The	O
gemcitabine	B-DRUG
/	O
5-fluorouracil	B-DRUG
combination	O
is	O
well	O
tolerated	O
and	O
produces	O
a	O
symptomatic	O
relief	O
in	O
the	O
majority	O
of	O
APC	B-CANCER
patients	O
.	O
	
Phase	O
II	O
trial	O
of	O
weekly	O
intravenous	O
gemcitabine	B-DRUG
with	O
continuous	O
infusion	O
fluorouracil	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
renal	I-CANCER
cell	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
determine	O
the	O
clinical	O
response	O
rate	O
of	O
the	O
combination	O
of	O
weekly	O
intravenous	O
(	O
IV	O
)	O
gemcitabine	B-DRUG
with	O
continuous	O
infusion	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
in	O
patients	O
with	O
metastatic	B-CANCER
renal	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
RCC	B-CANCER
)	O
.	O
	
Between	O
June	O
1998	O
and	O
February	O
1999	O
","	O
41	O
patients	O
with	O
metastatic	B-CANCER
RCC	I-CANCER
were	O
enrolled	O
onto	O
this	O
multi-institutional	O
phase	O
II	O
study	O
of	O
gemcitabine	B-DRUG
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
over	O
30	O
minutes	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
and	O
5-FU	B-DRUG
150	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d	O
via	O
continuous	O
IV	O
infusion	O
through	O
a	O
permanent	O
catheter	O
on	O
days	O
1	O
to	O
21	O
of	O
a	O
28-day	O
cycle	O
.	O
	
Patients	O
had	O
a	O
Cancer	O
and	O
Leukemia	O
Group	O
B	O
performance	O
status	O
of	O
0	O
or	O
1	O
","	O
with	O
a	O
median	O
time	O
since	O
diagnosis	O
of	O
metastatic	O
disease	O
of	O
10	O
months	O
(	O
range	O
","	O
0	O
to	O
129	O
months	O
)	O
.	O
	
Thirty-three	O
patients	O
(	O
80	O
%	O
)	O
had	O
multiple	O
metastatic	O
sites	O
","	O
and	O
34	O
patients	O
(	O
83	O
%	O
)	O
had	O
prior	O
chemotherapy	O
or	O
immunotherapy	O
.	O
	
Of	O
the	O
39	O
assessable	O
patients	O
","	O
there	O
were	O
no	O
complete	O
responses	O
but	O
seven	O
partial	O
responses	O
(	O
objective	O
response	O
rate	O
=	O
17	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
","	O
8	O
%	O
to	O
34	O
%	O
)	O
.	O
	
Five	O
minor	O
responses	O
(	O
25	O
%	O
to	O
50	O
%	O
decreased	O
tumor	O
size	O
)	O
were	O
also	O
observed	O
.	O
	
The	O
duration	O
of	O
response	O
for	O
the	O
seven	O
partial	O
responders	O
was	O
2	O
","	O
3	O
","	O
7	O
","	O
8	O
","	O
10	O
","	O
11	O
","	O
and	O
14	O
months	O
.	O
	
Median	O
progression-free	O
survival	O
for	O
the	O
gemcitabine	B-DRUG
/	I-DRUG
5-FU	I-DRUG
group	O
was	O
28.7	O
weeks	O
versus	O
8	O
weeks	O
for	O
a	O
similar	O
cohort	O
of	O
patients	O
treated	O
on	O
previous	O
phase	O
II	O
studies	O
at	O
the	O
University	O
of	O
Chicago	O
(	O
P	O
0.008	O
)	O
.	O
	
The	O
regimen	O
was	O
well	O
tolerated	O
","	O
with	O
fatigue	B-TOXI
","	O
mucositis	B-TOXI
","	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
","	O
and	O
grade	O
2	O
hematologic	B-TOXI
toxicities	I-TOXI
being	O
most	O
common	O
.	O
	
Weekly	O
gemcitabine	B-DRUG
with	O
continuous	O
infusion	O
5-FU	B-DRUG
is	O
an	O
active	O
combination	O
in	O
patients	O
with	O
metastatic	B-CANCER
RCC	I-CANCER
.	O
	
Therapy	O
was	O
well	O
tolerated	O
and	O
produced	O
an	O
improvement	O
in	O
progression-free	O
survival	O
over	O
historical	O
controls	O
.	O
	
A	O
dose-finding	O
study	O
of	O
raltitrexed	B-DRUG
(	O
tomudex	B-DRUG
)	O
with	O
cisplatin	B-DRUG
and	O
epirubicin	B-DRUG
in	O
advanced	B-CANCER
gastro-oesophageal	I-CANCER
adenocarcinoma	I-CANCER
.	O
	
	
The	O
standard	O
treatment	O
for	O
advanced	B-CANCER
gastro-oesophageal	I-CANCER
cancer	I-CANCER
in	O
the	O
UK	O
is	O
epirubicin	B-DRUG
","	O
cisplatin	B-DRUG
and	O
continuous	O
infusion	O
5-fluoruracil	B-DRUG
by	O
an	O
indwelling	O
central	O
venous	O
catheter	O
(	O
ECF	O
)	O
","	O
which	O
has	O
significant	O
morbidity	O
.	O
	
Raltitrexed	B-DRUG
(	O
tomudex	B-DRUG
)	O
","	O
a	O
specific	O
inhibitor	O
of	O
thymidylate	O
synthase	O
with	O
a	O
long	O
plasma	O
terminal	O
half-life	O
(	O
50-100	O
h	O
)	O
has	O
activity	O
in	O
gastro-intestinal	B-CANCER
tract	I-CANCER
malignancy	I-CANCER
.	O
	
To	O
reduce	O
the	O
Hickman	O
line-associated	O
morbidity	O
of	O
ECF	O
;	O
we	O
have	O
conducted	O
a	O
dose-finding	O
study	O
of	O
tomudex	B-DRUG
combined	O
with	O
epirubicin	B-DRUG
and	O
cisplatin	B-DRUG
.	O
	
Twenty-four	O
patients	O
(	O
22	O
males	O
","	O
two	O
female	O
)	O
","	O
median	O
age	O
63	O
years	O
(	O
range	O
21-75	O
)	O
","	O
ECOG	O
performance	O
status	O
&	O
lt	O
;	O
or	O
2	O
with	O
histologically	O
proven	O
","	O
unresectable	O
or	O
metastatic	O
gastric	O
(	O
14	O
patients	O
)	O
","	O
gastro-oesophageal	O
junction	O
(	O
nine	O
patients	O
)	O
or	O
oesophageal	O
(	O
one	O
patient	O
)	O
adenocarcinoma	B-CANCER
received	O
treatment	O
with	O
3-weekly	O
cisplatin	B-DRUG
60	O
mg	O
m	O
(	O
-2	O
)	O
","	O
epirubicin	B-DRUG
50	O
mg	O
m	O
(	O
-2	O
)	O
and	O
tomudex	B-DRUG
at	O
doses	O
of	O
2	O
mg	O
m	O
(	O
-2	O
)	O
","	O
2.5	O
mg	O
m	O
(	O
-2	O
)	O
or	O
3	O
mg	O
m	O
(	O
-2	O
)	O
in	O
successive	O
cohorts	O
.	O
	
Six	O
patients	O
were	O
treated	O
per	O
dose	O
level	O
with	O
no	O
intra-patient	O
dose	O
escalation	O
.	O
	
Dose	O
escalation	O
occurred	O
after	O
six	O
patients	O
had	O
completed	O
at	O
least	O
one	O
cycle	O
of	O
chemotherapy	O
at	O
the	O
previous	O
dose	O
level	O
.	O
	
After	O
defining	O
the	O
maximum	O
tolerated	O
dose	O
a	O
further	O
six	O
patients	O
were	O
treated	O
at	O
the	O
preceding	O
dose	O
level	O
to	O
assess	O
toxicity	O
at	O
the	O
proposed	O
phase	O
II	O
dose	O
.	O
	
A	O
total	O
of	O
102	O
cycles	O
(	O
50	O
%	O
completed	O
6	O
cycles	O
)	O
were	O
administered	O
.	O
	
The	O
dose-limiting	O
toxicities	O
are	O
neutropenia	B-TOXI
and	O
diarrhoea	B-TOXI
occurring	O
in	O
2	O
/	O
6	O
patients	O
at	O
the	O
3	O
mg	O
m	O
(	O
-2	O
)	O
dose	O
level	O
.	O
	
Of	O
those	O
patients	O
evaluable	O
for	O
response	O
","	O
there	O
were	O
eight	O
partial	O
and	O
one	O
complete	O
response	O
(	O
overall	O
response	O
rate	O
38	O
%	O
)	O
.	O
	
The	O
median	O
survival	O
was	O
9.9	O
months	O
.	O
	
ECT	O
is	O
an	O
active	O
regimen	O
in	O
oesophagogastric	B-CANCER
adenocarcinoma	I-CANCER
.	O
	
The	O
recommended	O
dose	O
of	O
tomudex	B-DRUG
for	O
further	O
study	O
in	O
combination	O
with	O
epirubicin	B-DRUG
and	O
cisplatin	B-DRUG
is	O
2.5	O
mg	O
m	O
(	O
-2	O
)	O
.	O
	
The	O
effect	O
of	O
tamoxifen	B-DRUG
and	O
cisplatin	B-DRUG
on	O
the	O
disease-free	O
and	O
overall	O
survival	O
of	O
patients	O
with	O
high	O
risk	O
malignant	B-CANCER
melanoma	I-CANCER
.	O
	
	
The	O
adjuvant	O
treatment	O
of	O
high-risk	O
malignant	B-CANCER
melanoma	I-CANCER
remains	O
problematic	O
.	O
	
Previously	O
we	O
reported	O
moderate	O
success	O
in	O
the	O
treatment	O
of	O
metastatic	O
disease	O
using	O
tamoxifen	B-DRUG
","	O
cisplatin	B-DRUG
","	O
dacarbazine	B-DRUG
and	O
carmustine	B-DRUG
.	O
	
Based	O
upon	O
data	O
that	O
suggested	O
tamoxifen	B-DRUG
and	O
cisplatin	B-DRUG
were	O
the	O
active	O
agents	O
in	O
this	O
regimen	O
","	O
we	O
initiated	O
a	O
phase	O
II	O
trial	O
of	O
this	O
combination	O
in	O
the	O
adjuvant	O
setting	O
.	O
	
We	O
treated	O
153	O
patients	O
with	O
4	O
cycles	O
of	O
tamoxifen	B-DRUG
(	O
160	O
mg	O
day	O
(	O
-1	O
)	O
","	O
days	O
1月7日	O
)	O
and	O
cisplatin	B-DRUG
(	O
100	O
mg	O
m	O
(	O
-2	O
)	O
","	O
day	O
2	O
)	O
for	O
28-day	O
intervals	O
.	O
	
Patients	O
received	O
an	O
anti-nausea	O
regimen	O
of	O
dexamethasone	B-DRUG
with	O
ondansetron	B-DRUG
or	O
granisetron	B-DRUG
.	O
	
During	O
the	O
first	O
2	O
years	O
of	O
follow-up	O
","	O
patients	O
were	O
evaluated	O
every	O
2	O
months	O
with	O
a	O
history	O
","	O
physical	O
exam	O
","	O
laboratory	O
work	O
and	O
computed	O
tomography	O
scans	O
of	O
the	O
chest	O
","	O
abdomen	O
and	O
pelvis	O
every	O
4	O
months	O
.	O
	
Thereafter	O
","	O
patients	O
were	O
evaluated	O
every	O
3	O
months	O
and	O
radiographic	O
studies	O
were	O
performed	O
if	O
necessary	O
.	O
	
Currently	O
","	O
with	O
a	O
median	O
follow-up	O
of	O
36	O
months	O
","	O
the	O
disease-free	O
survival	O
(	O
DFS	O
)	O
is	O
68.4	O
%	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
is	O
84.5	O
%	O
.	O
	
Kaplan-Meier	O
analysis	O
predicts	O
a	O
5-year	O
DFS	O
of	O
62	O
%	O
with	O
an	O
OS	O
of	O
79	O
%	O
.	O
	
Relapses	O
after	O
20	O
months	O
have	O
been	O
rare	O
.	O
	
No	O
effect	O
of	O
gender	O
or	O
number	O
of	O
positive	B-TOXI
lymph	I-TOXI
nodes	I-TOXI
was	O
noted	O
","	O
however	O
","	O
stage	O
of	O
disease	O
prior	O
treatment	O
was	O
a	O
factor	O
.	O
	
The	O
major	O
toxicity	O
proved	O
to	O
be	O
gastrointestinal	O
in	O
nature	O
with	O
nausea	B-TOXI
the	O
most	O
prevalent	O
symptom	O
.	O
	
Minimal	B-TOXI
renal	I-TOXI
","	O
haematologic	B-TOXI
and	I-TOXI
neurologic	I-TOXI
toxicity	I-TOXI
occurred	O
.	O
	
These	O
preliminary	O
results	O
suggest	O
that	O
there	O
is	O
a	O
positive	O
impact	O
of	O
tamoxifen	B-DRUG
and	O
cisplatin	B-DRUG
on	O
both	O
the	O
DFS	O
and	O
OS	O
of	O
high-risk	O
malignant	B-CANCER
melanoma	I-CANCER
patients	O
.	O
	
The	O
5-year	O
projected	O
DFS	O
and	O
OS	O
compare	O
favourably	O
with	O
those	O
reported	O
for	O
the	O
ECOG	O
1684	O
trial	O
and	O
warrant	O
confirmation	O
in	O
a	O
prospective	O
randomized	O
trial	O
.	O
	
Southwest	O
Oncology	O
Group	O
Study	O
of	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
for	O
advanced	B-CANCER
transitional-cell	I-CANCER
carcinoma	I-CANCER
:	O
the	O
importance	O
of	O
survival	O
as	O
a	O
clinical	O
trial	O
end	O
point	O
.	O
	
	
The	O
combination	O
of	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
for	O
the	O
treatment	O
of	O
advanced	B-CANCER
transitional-cell	I-CANCER
carcinoma	I-CANCER
(	O
TCC	B-CANCER
)	O
of	O
the	O
urothelium	O
has	O
promising	O
activity	O
and	O
acceptable	O
toxicity	O
.	O
	
The	O
purpose	O
of	O
this	O
trial	O
was	O
to	O
evaluate	O
the	O
efficacy	O
of	O
this	O
regimen	O
in	O
a	O
cooperative	O
group	O
setting	O
.	O
	
Twenty-nine	O
patients	O
with	O
advanced	B-CANCER
TCC	I-CANCER
were	O
treated	O
every	O
21	O
days	O
with	O
paclitaxel	B-DRUG
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
administered	O
as	O
a	O
3-hour	O
infusion	O
","	O
followed	O
by	O
carboplatin	B-DRUG
dosed	O
to	O
an	O
area	O
under	O
the	O
curve	O
of	O
5	O
Prior	O
systemic	O
adjuvant	O
or	O
neoadjuvant	O
platinum-based	B-DRUG
therapy	O
was	O
not	O
permitted	O
unless	O
completed	O
at	O
least	O
1	O
year	O
before	O
enrollment	O
.	O
	
Patients	O
were	O
evaluated	O
for	O
response	O
every	O
three	O
cycles	O
","	O
and	O
follow-up	O
was	O
conducted	O
to	O
determine	O
survival	O
.	O
	
Twenty-nine	O
patients	O
were	O
enrolled	O
and	O
were	O
assessable	O
.	O
	
Four	O
(	O
14	O
%	O
)	O
had	O
received	O
prior	O
adjuvant	O
or	O
neoadjuvant	O
therapy	O
.	O
	
Node-only	O
disease	O
was	O
present	O
in	O
24	O
%	O
","	O
and	O
76	O
%	O
of	O
patients	O
had	O
extranodal	O
disease	O
.	O
	
The	O
median	O
number	O
of	O
cycles	O
received	O
was	O
five	O
.	O
	
Grade	O
4	O
toxicity	O
consisted	O
primarily	O
of	O
neutropenia	B-TOXI
(	O
38	O
%	O
of	O
patients	O
)	O
.	O
	
Neurologic	B-TOXI
toxicity	I-TOXI
was	O
noted	O
in	O
16	O
patients	O
(	O
grade	O
1	O
in	O
four	O
patients	O
","	O
grade	O
2	O
in	O
five	O
patients	O
","	O
grade	O
3	O
in	O
six	O
patients	O
","	O
and	O
grade	O
4	O
in	O
one	O
patient	O
)	O
.	O
	
Six	O
partial	O
responses	O
and	O
no	O
complete	O
responses	O
were	O
noted	O
","	O
for	O
a	O
response	O
proportion	O
of	O
20.7	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
8	O
%	O
to	O
40	O
%	O
)	O
.	O
	
Median	O
progression-free	O
survival	O
time	O
was	O
4	O
months	O
","	O
and	O
overall	O
survival	O
time	O
was	O
9	O
months	O
.	O
	
The	O
combination	O
of	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
for	O
the	O
treatment	O
of	O
advanced	B-CANCER
TCC	I-CANCER
is	O
reasonably	O
well	O
tolerated	O
.	O
	
However	O
","	O
a	O
response	O
proportion	O
considerably	O
lower	O
than	O
that	O
previously	O
reported	O
was	O
noted	O
.	O
	
In	O
addition	O
","	O
the	O
median	O
survival	O
time	O
of	O
9	O
months	O
was	O
less	O
than	O
the	O
survival	O
time	O
previously	O
reported	O
for	O
patients	O
treated	O
with	O
the	O
combination	O
of	O
methotrexate	B-DRUG
","	O
vinblastine	B-DRUG
","	O
doxorubicin	B-DRUG
","	O
and	O
cisplatin	B-DRUG
.	O
	
Although	O
our	O
results	O
may	O
reflect	O
enrollment	O
of	O
patients	O
with	O
poor	B-TOXI
prognostic	I-TOXI
features	I-TOXI
","	O
they	O
also	O
call	O
into	O
question	O
the	O
utility	O
of	O
this	O
regimen	O
.	O
	
Cyclophosphamide	B-DRUG
","	O
methotrexate	B-DRUG
","	O
and	O
fluorouracil	B-DRUG
versus	O
tamoxifen	B-DRUG
plus	O
ovarian	B-DRUG
suppression	I-DRUG
as	O
adjuvant	O
treatment	O
of	O
estrogen	O
receptor-positive	O
pre-	O
/	O
perimenopausal	O
breast	B-CANCER
cancer	I-CANCER
patients	O
:	O
results	O
of	O
the	O
Italian	O
Breast	O
Cancer	O
Adjuvant	O
Study	O
Group	O
2	O
randomized	O
trial.	O
boccardo	O
@	O
hp380.ist.unige.it	O
.	O
	
	
To	O
compare	O
the	O
efficacy	O
of	O
chemotherapy	O
versus	O
that	O
of	O
tamoxifen	B-DRUG
plus	O
ovarian	B-DRUG
suppression	I-DRUG
in	O
pre-	O
/	O
perimenopausal	O
estrogen	O
receptor-positive	O
patients	O
with	O
early	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
six	O
cycles	O
of	O
a	O
standard	O
regimen	O
of	O
cyclophosphamide	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
orally	O
days	O
1	O
to	O
14	O
","	O
methotrexate	B-DRUG
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
(	O
IV	O
)	O
days	O
1	O
and	O
8	O
","	O
and	O
fluorouracil	B-DRUG
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
days	O
1	O
and	O
8	O
(	O
CMF	B-DRUG
)	O
","	O
with	O
all	O
drugs	O
restarted	O
on	O
day	O
29	O
","	O
or	O
5	O
years	O
of	O
tamoxifen	B-DRUG
","	O
30	O
mg	O
/	O
d	O
","	O
plus	O
ovarian	B-DRUG
suppression	I-DRUG
with	O
surgical	O
oophorectomy	O
","	O
ovarian	O
irradiation	O
","	O
or	O
monthly	O
goserelin	B-DRUG
3.6-mg	O
injections	O
.	O
	
Disease-free	O
survival	O
was	O
the	O
main	O
study	O
end	O
point	O
.	O
	
Overall	O
survival	O
and	O
toxicity	O
were	O
additional	O
end	O
points	O
.	O
	
Between	O
1989	O
and	O
1997	O
","	O
120	O
patients	O
were	O
assigned	O
to	O
CMF	B-DRUG
and	O
124	O
to	O
tamoxifen	B-DRUG
and	O
ovarian	B-DRUG
suppression	I-DRUG
(	O
oophorectomy	O
","	O
n	O
=	O
6	O
;	O
ovarian	O
irradiation	O
","	O
n	O
=	O
31	O
;	O
and	O
goserelin	B-DRUG
injections	O
","	O
n	O
=	O
87	O
)	O
.	O
	
At	O
the	O
time	O
of	O
analysis	O
(	O
median	O
follow-up	O
time	O
","	O
76	O
months	O
;	O
range	O
","	O
9	O
to	O
121	O
months	O
)	O
","	O
82	O
patients	O
had	O
relapsed	O
and	O
39	O
had	O
died	O
.	O
	
No	O
difference	O
between	O
groups	O
had	O
emerged	O
with	O
respect	O
to	O
either	O
disease-free	O
or	O
overall	O
survival	O
.	O
	
Treatments	O
were	O
comparable	O
even	O
in	O
respect	O
to	O
age	O
","	O
tumor	O
size	O
","	O
and	O
nodal	O
status	O
","	O
although	O
a	O
nonsignificant	O
trend	O
favored	O
patients	O
with	O
poorly	O
differentiated	O
tumors	O
treated	O
with	O
CMF	B-DRUG
.	O
	
Leukopenia	B-TOXI
","	O
nausea	B-TOXI
","	O
vomiting	B-TOXI
","	O
stomatitis	B-TOXI
","	O
and	O
alopecia	B-TOXI
were	O
significantly	O
more	O
common	O
in	O
patients	O
treated	O
with	O
CMF	B-DRUG
.	O
	
There	O
were	O
few	O
patients	O
who	O
developed	O
benign	B-CANCER
gynecologic	I-CANCER
changes	O
in	O
either	O
group	O
","	O
and	O
numbers	O
were	O
comparable	O
.	O
	
The	O
combination	O
of	O
tamoxifen	B-DRUG
with	O
ovarian	B-DRUG
suppression	I-DRUG
seems	O
to	O
be	O
safe	O
and	O
to	O
yield	O
comparable	O
results	O
relative	O
to	O
standard	O
CMF	B-DRUG
.	O
	
Cisplatin	B-DRUG
","	O
raltitrexed	B-DRUG
","	O
levofolinic	B-DRUG
acid	I-DRUG
and	O
5-fluorouracil	B-DRUG
in	O
locally	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
:	O
a	O
phase	O
I-II	O
trial	O
of	O
the	O
Southern	O
Italy	O
Cooperative	O
Oncology	O
Group	O
(	O
SICOG	O
)	O
.	O
	
	
The	O
combination	O
of	O
cisplatin	B-DRUG
(	O
CDDP	B-DRUG
)	O
and	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
can	O
be	O
regarded	O
as	O
a	O
reference	O
regimen	O
in	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	O
SCCHN	B-CANCER
)	O
.	O
	
Raltitrexed	B-DRUG
(	O
Tomudex	B-DRUG
)	O
is	O
a	O
direct	O
and	O
specific	O
thymidilate	O
synthase	O
(	O
TS	O
)	O
inhibitor	O
","	O
which	O
has	O
shown	O
clinical	O
activity	O
against	O
SCCHN	B-CANCER
in	O
a	O
previous	O
phase	O
I	O
study	O
","	O
when	O
combined	O
with	O
5-FU	B-DRUG
and	O
levo-folinic	B-DRUG
acid	I-DRUG
(	O
LFA	B-DRUG
)	O
.	O
	
Preclinical	O
data	O
support	O
the	O
combination	O
of	O
CDDP	B-DRUG
and	O
raltitrexed	B-DRUG
.	O
	
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
combination	O
of	O
cisplatin	B-DRUG
","	O
raltitrexed	B-DRUG
.	O
	
LFA	B-DRUG
and	O
5-FU	B-DRUG
in	O
a	O
phase	O
I-II	O
study	O
.	O
	
Patients	O
with	O
locally	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
SCCHN	I-CANCER
were	O
treated	O
with	O
a	O
combination	O
of	O
cisplatin	B-DRUG
at	O
the	O
starting	O
dose	O
of	O
40	O
mg	O
/	O
m2	O
.	O
	
followed	O
by	O
raltitrexed	B-DRUG
at	O
the	O
starting	O
dose	O
of	O
2.5	O
mg	O
/	O
m2	O
on	O
day	O
1	O
;	O
levo-folinic	B-DRUG
acid	I-DRUG
at	O
fixed	O
dose	O
of	O
250	O
mg	O
/	O
m2	O
","	O
followed	O
by	O
5-fluorouracil	B-DRUG
at	O
the	O
starting	O
dose	O
of	O
750	O
mg	O
/	O
m2	O
on	O
day	O
2	O
Doses	O
of	O
the	O
three	O
cytotoxic	B-DRUG
agents	I-DRUG
were	O
alternately	O
escalated	O
up	O
to	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
.	O
	
Treatment	O
was	O
recycled	O
every	O
two	O
weeks	O
and	O
given	O
up	O
to	O
a	O
maximum	O
of	O
eight	O
courses	O
;	O
after	O
chemotherapy	O
","	O
patients	O
with	O
locally	O
advanced	O
disease	O
received	O
a	O
locoregional	O
treatment	O
.	O
	
Forty-five	O
patients	O
were	O
entered	O
into	O
the	O
study	O
.	O
	
Six	O
dose	O
levels	O
were	O
tested	O
.	O
	
At	O
CDDP	B-DRUG
50	O
mg	O
/	O
m2	O
","	O
raltitrexed	B-DRUG
3	O
mg	O
/	O
m2	O
","	O
5-FU	B-DRUG
900	O
mg	O
/	O
m2	O
","	O
four	O
out	O
of	O
six	O
patients	O
showed	O
DLT	O
","	O
which	O
was	O
in	O
all	O
cases	O
grade	O
4	O
neutropenia	B-TOXI
.	O
	
Therefore	O
","	O
this	O
dose	O
level	O
was	O
defined	O
as	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
.	O
	
CDDP	B-DRUG
60	O
mg	O
/	O
m2	O
","	O
raltitrexed	B-DRUG
2.5	O
mg	O
/	O
m2	O
","	O
LFA	B-DRUG
250	O
mg	O
/	O
m2	O
","	O
5-FU	B-DRUG
900	O
mg	O
/	O
m2	O
was	O
the	O
dose	O
level	O
recommended	O
for	O
phase	O
II	O
.	O
	
CDDP	B-DRUG
","	O
Raltitrexed	B-DRUG
and	O
5-FU	B-DRUG
mean	O
actually	O
delivered	O
dose	O
intensities	O
at	O
the	O
selected	O
dose	O
level	O
were	O
26	O
","	O
1.05	O
","	O
and	O
378	O
mg	O
/	O
m2	O
/	O
week	O
","	O
respectively	O
.	O
	
Neutropenia	B-TOXI
was	O
the	O
main	O
side	O
effect	O
and	O
was	O
observed	O
even	O
at	O
the	O
lowest	O
dose	O
levels	O
.	O
	
Nonhematologic	B-TOXI
side	I-TOXI
effects	I-TOXI
were	O
mild	O
.	O
	
Nine	O
complete	O
responses	O
(	O
20	O
%	O
)	O
and	O
twenty-one	O
partial	O
responses	O
(	O
47	O
%	O
)	O
were	O
observed	O
","	O
for	O
an	O
overall	O
response	O
rate	O
of	O
67	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
CI	O
)	O
:	O
51	O
%	O
-80	O
%	O
)	O
","	O
according	O
to	O
intention	O
to	O
treat	O
analysis	O
.	O
	
Fifteen	O
of	O
fifteen	O
patients	O
(	O
100	O
%	O
)	O
treated	O
at	O
the	O
dose	O
level	O
selected	O
for	O
phase	O
II	O
had	O
an	O
objective	O
response	O
(	O
5	O
complete	O
responses	O
","	O
10	O
partial	O
responses	O
)	O
.	O
	
The	O
results	O
of	O
our	O
dose	O
escalation	O
clearly	O
demonstrate	O
that	O
it	O
is	O
possible	O
to	O
combine	O
CDDP	B-DRUG
","	O
raltitrexed	B-DRUG
","	O
and	O
modulated	O
5-FU	B-DRUG
at	O
effective	O
doses	O
","	O
without	O
unexpected	O
toxicities	O
.	O
	
The	O
response	O
data	O
point	O
to	O
an	O
impressive	O
clinical	O
activity	O
","	O
which	O
will	O
be	O
better	O
defined	O
by	O
an	O
ongoing	O
large	O
phase	O
II	O
study	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
gemcitabine	B-DRUG
and	O
epirubicin	B-DRUG
for	O
the	O
treatment	O
of	O
platinum-resistant	O
or	O
refractory	O
advanced	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
	
Gemcitabine	B-DRUG
is	O
active	O
in	O
patients	O
with	O
otherwise	O
resistant	O
or	O
refractory	O
ovarian	B-CANCER
cancer	I-CANCER
.	O
	
As	O
the	O
drug	O
is	O
well	O
tolerated	O
","	O
studies	O
using	O
gemcitabine	B-DRUG
combined	O
with	O
other	O
antineoplastic	B-DRUG
agents	I-DRUG
are	O
needed	O
.	O
	
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
epirubicin	B-DRUG
combined	O
with	O
gemcitabine	B-DRUG
","	O
with	O
and	O
without	O
support	O
of	O
G-CSF	B-DRUG
.	O
	
Patients	O
with	O
platinum-resistant	O
or	O
refractory	O
ovarian	B-CANCER
cancer	I-CANCER
were	O
eligible	O
.	O
	
Gemcitabine	B-DRUG
(	O
G	O
)	O
(	O
starting	O
dose	O
800	O
mg	O
/	O
m2	O
day	O
1	O
and	O
8	O
;	O
200	O
mg	O
/	O
m2	O
escalation	O
per	O
level	O
)	O
and	O
epirubicin	B-DRUG
(	O
E	O
)	O
(	O
starting	O
dose	O
60	O
mg	O
/	O
m2	O
day	O
1	O
;	O
15	O
mg	O
/	O
m2	O
escalation	O
per	O
level	O
)	O
were	O
given	O
every	O
21	O
days	O
for	O
four	O
to	O
six	O
cycles	O
.	O
	
G-CSF	B-DRUG
(	O
filgrastim	B-DRUG
5	O
microg	O
/	O
kg	O
/	O
die	O
)	O
was	O
given	O
in	O
case	O
of	O
grade	O
4	O
neutropenia	B-TOXI
(	O
levels	O
without	O
support	O
)	O
or	O
from	O
day	O
9	O
up	O
to	O
leukocyte	O
count	O
&	O
gt	O
;	O
10	O
/	O
mm3	O
after	O
nadir	O
(	O
levels	O
with	O
support	O
)	O
.	O
	
Cohorts	O
of	O
three	O
patients	O
were	O
enrolled	O
at	O
each	O
level	O
","	O
and	O
another	O
three	O
patients	O
were	O
planned	O
","	O
if	O
one	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
was	O
registered	O
.	O
	
MTD	O
was	O
determined	O
first	O
without	O
and	O
then	O
with	O
G-CSF	B-DRUG
.	O
	
Four	O
levels	O
were	O
studied	O
(	O
G	O
800	O
=+	O
E	O
60	O
;	O
G	O
1000	O
=+	O
E	O
60	O
;	O
G	O
1000	O
=+	O
E	O
75	O
;	O
G	O
1000	O
=+	O
E	O
75	O
=+	O
G-CSF	O
)	O
with	O
four	O
","	O
four	O
","	O
three	O
and	O
three	O
patients	O
enrolled	O
","	O
respectively	O
.	O
	
DLT	O
(	O
grade	O
4	O
febrile	B-TOXI
neutropenia	I-TOXI
)	O
was	O
observed	O
in	O
two	O
patients	O
at	O
level	O
3	O
Thus	O
","	O
G1000	O
=+	O
E	O
60	O
mg	O
/	O
m2	O
was	O
the	O
MTD	O
without	O
G-CSF	B-DRUG
.	O
	
The	O
addition	O
of	O
prophylactic	O
G-CSF	B-DRUG
did	O
not	O
allow	O
a	O
further	O
increase	O
of	O
the	O
dose	O
and	O
grade	O
4	O
thrombocytopenia	B-TOXI
was	O
the	O
DLT	O
at	O
level	O
4	O
Non-hematological	B-TOXI
toxicity	I-TOXI
was	O
mild	O
.	O
	
Grade	O
2	O
mucositis	B-TOXI
was	O
reported	O
in	O
four	O
patients	O
.	O
	
Among	O
the	O
13	O
patients	O
with	O
measurable	O
or	O
evaluable	O
disease	O
","	O
3	O
partial	O
responses	O
were	O
observed	O
for	O
an	O
overall	O
response	O
rate	O
of	O
23.1	O
%	O
.	O
	
The	O
combination	O
of	O
gemcitabine	B-DRUG
1000	O
mg	O
/	O
m2	O
(	O
day	O
1	O
","	O
8	O
)	O
and	O
epirubicin	B-DRUG
at	O
60	O
mg	O
/	O
m2	O
(	O
day	O
1	O
)	O
is	O
a	O
feasible	O
therapy	O
.	O
	
Grade	O
4	O
neutropenia	B-TOXI
is	O
frequent	O
and	O
G-CSF	B-DRUG
support	O
is	O
often	O
required	O
.	O
	
With	O
prophylactic	O
support	O
of	O
G-CSF	B-DRUG
","	O
the	O
DLT	O
is	O
thrombocytopenia	B-TOXI
.	O
	
Cisplatin	B-DRUG
","	O
ifosfamide	B-DRUG
","	O
oral	B-DRUG
etoposide	I-DRUG
","	O
and	O
concurrent	O
accelerated	O
hyperfractionated	O
thoracic	O
radiation	O
for	O
patients	O
with	O
limited	O
small-cell	B-CANCER
lung	I-CANCER
carcinoma	I-CANCER
:	O
results	O
of	O
radiation	O
therapy	O
oncology	O
group	O
trial	O
Dec-93	O
.	O
	
	
The	O
combination	O
of	O
cisplatin	B-DRUG
","	O
ifosfamide	B-DRUG
","	O
and	O
oral	B-DRUG
etoposide	I-DRUG
(	O
PIEo	O
)	O
given	O
concurrently	O
with	O
accelerated	O
hyperfractionated	O
thoracic	O
radiation	O
was	O
studied	O
in	O
patients	O
with	O
limited	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
in	O
a	O
phase	O
II	O
trial	O
to	O
assess	O
response	O
","	O
survival	O
","	O
and	O
toxicity	O
.	O
	
Sixty-seven	O
patients	O
were	O
accrued	O
between	O
March	O
1994	O
and	O
April	O
1996	O
.	O
	
Chemotherapy	O
doses	O
were	O
cisplatin	B-DRUG
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
ifosfamide	B-DRUG
"1,200"	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
to	O
3	O
and	O
etoposide	B-DRUG
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
administered	O
orally	O
days	O
1	O
through	O
14	O
.	O
	
Radiation	O
consisted	O
of	O
accelerated	O
hyperfractionated	O
thoracic	O
radiation	O
(	O
AHTRT	O
)	O
1.5	O
Gy	O
bid	O
x	O
30	O
fractions	O
(	O
total	O
45	O
Gy	O
)	O
days	O
1	O
through	O
19	O
","	O
concurrent	O
with	O
cycle	O
1	O
of	O
chemotherapy	O
.	O
	
Three	O
additional	O
cycles	O
of	O
chemotherapy	O
were	O
given	O
every	O
4	O
weeks	O
after	O
completion	O
of	O
chemoradiation	O
.	O
	
Prophylactic	O
cranial	O
radiation	O
(	O
25	O
Gy	O
in	O
10	O
fractions	O
)	O
was	O
offered	O
to	O
patients	O
for	O
whom	O
complete	O
response	O
(	O
CR	O
)	O
after	O
completion	O
of	O
chemotherapy	O
was	O
achieved	O
.	O
	
An	O
overall	O
objective	O
response	O
rate	O
of	O
78	O
%	O
(	O
41	O
CRs	O
[	O
67	O
%	O
]	O
and	O
seven	O
partial	O
responses	O
[	O
11	O
%	O
]	O
)	O
was	O
seen	O
in	O
61	O
patients	O
whose	O
disease	O
response	O
could	O
be	O
evaluated	O
.	O
	
Median	O
progression-free	O
and	O
overall	O
survival	O
estimates	O
were	O
12.7	O
and	O
23.7	O
months	O
","	O
respectively	O
.	O
	
Two-	O
and	O
3-year	O
survival	O
rates	O
were	O
estimated	O
at	O
50	O
%	O
and	O
39	O
%	O
","	O
respectively	O
.	O
	
Major	O
toxic	O
effects	O
included	O
grade	O
4	O
granulocytopenia	B-TOXI
in	O
34	O
(	O
55	O
%	O
)	O
","	O
grade	O
4	O
thrombocytopenia	B-TOXI
in	O
16	O
(	O
26	O
%	O
)	O
","	O
grade	O
3	O
to	O
5	O
fever	B-TOXI
/	O
infection	B-TOXI
in	O
six	O
(	O
10	O
%	O
;	O
with	O
one	O
death	B-TOXI
resulting	O
from	O
sepsis	O
)	O
","	O
and	O
grade	O
3	O
/	O
4	O
esophagitis	B-TOXI
in	O
27	O
patients	O
(	O
43	O
%	O
)	O
.	O
	
Other	O
nonhematologic	B-TOXI
toxic	I-TOXI
greater	O
than	O
grade	O
2	O
occurred	O
in	O
11	O
patients	O
(	O
18	O
%	O
)	O
.	O
	
Relative	O
to	O
conventional	O
etoposide	B-DRUG
/	O
cisplatin	B-DRUG
and	O
concurrent	O
AHTRT	O
","	O
chemoradiation	O
with	O
PIEo	B-DRUG
produced	O
similar	O
median	O
and	O
2-year	O
survival	O
rates	O
and	O
a	O
higher	O
rate	O
of	O
acute	B-TOXI
esophageal	I-TOXI
toxicity	I-TOXI
.	O
	
However	O
","	O
the	O
locoregional	O
control	O
rate	O
with	O
a	O
minimum	O
follow-up	O
of	O
2	O
years	O
is	O
excellent	O
at	O
80	O
%	O
.	O
	
It	O
is	O
conceivable	O
that	O
longer	O
follow-up	O
will	O
prove	O
this	O
regimen	O
more	O
promising	O
.	O
	
Research	O
efforts	O
should	O
focus	O
on	O
other	O
methods	O
to	O
improve	O
disease	O
control	O
in	O
all	O
potential	O
sites	O
of	O
recurrence	O
.	O
	
Gemcitabine	B-DRUG
plus	O
vinorelbine	B-DRUG
in	O
elderly	O
or	O
unfit	O
patients	O
with	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
Cisplatin-based	B-DRUG
combinations	O
are	O
efficacious	O
in	O
increasing	O
the	O
overall	O
survival	O
of	O
patients	O
with	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
","	O
but	O
their	O
toxicity	O
makes	O
them	O
unsuitable	O
for	O
elderly	O
and	O
unfit	O
patients	O
.	O
	
The	O
primary	O
objective	O
of	O
this	O
non-randomized	O
phase	O
II	O
study	O
was	O
to	O
evaluate	O
the	O
feasibility	O
and	O
activity	O
of	O
the	O
gemcitabine	B-DRUG
plus	O
vinorelbine	B-DRUG
combination	O
in	O
previously	O
untreated	O
elderly	O
and	O
/	O
or	O
unfit	O
patients	O
with	O
measurable	O
stage	O
III	O
or	O
IV	O
NSCLC	B-CANCER
.	O
	
Forty-three	O
patients	O
aged	O
&	O
gt	O
;	O
/	O
=	O
65	O
years	O
or	O
with	O
contraindications	O
against	O
cisplatin	B-DRUG
treatment	O
(	O
36	O
males	O
and	O
seven	O
females	O
:	O
median	O
age	O
66	O
years	O
;	O
range	O
48-75	O
:	O
PS	O
0	O
=	O
11	O
","	O
PS	O
1	O
=	O
19	O
","	O
PS	O
2	O
=	O
13	O
)	O
received	O
intravenous	O
(	O
i.v.	O
)	O
gemcitabine	B-DRUG
1000	O
mg	O
m	O
(	O
-2	O
)	O
","	O
followed	O
by	O
vinorelbine	B-DRUG
25	O
mg	O
m	O
(	O
-2	O
)	O
i.v.	O
on	O
day	O
1	O
and	O
8	O
every	O
21	O
days	O
.	O
	
Fifteen	O
patients	O
(	O
34.9	O
%	O
)	O
achieved	O
partial	O
remission	O
(	O
confidence	O
interval	O
:	O
27	O
.	O
	
6-42.2	O
%	O
)	O
for	O
a	O
median	O
duration	O
of	O
6	O
months	O
;	O
the	O
median	O
survival	O
of	O
these	O
patients	O
has	O
not	O
yet	O
been	O
reached	O
.	O
	
A	O
further	O
15	O
had	O
stable	O
disease	O
for	O
a	O
median	O
of	O
4	O
months	O
and	O
a	O
median	O
survival	O
of	O
7	O
months	O
.	O
	
The	O
10	O
patients	O
(	O
23.2	O
%	O
)	O
who	O
experienced	O
disease	O
progression	O
had	O
a	O
median	O
survival	O
of	O
4	O
months	O
.	O
	
Three	O
patients	O
are	O
not	O
evaluable	O
.	O
	
The	O
1-year	O
actuarial	O
survival	O
rate	O
is	O
31.1	O
%	O
.	O
	
The	O
treatment	O
was	O
well	O
tolerated	O
:	O
only	O
35	O
%	O
of	O
the	O
patients	O
had	O
grade	O
3	O
or	O
4	O
granulocytopenia	B-TOXI
on	O
day	O
14	O
","	O
none	O
experienced	O
episodes	O
of	O
neutropenic	B-TOXI
fever	I-TOXI
","	O
and	O
there	O
was	O
no	O
evidence	O
of	O
severe	O
haematological	B-TOXI
toxicity	I-TOXI
upon	O
recycling	O
.	O
	
Only	O
9	O
%	O
of	O
the	O
patients	O
suffered	O
from	O
gastrointestinal	B-TOXI
toxicity	I-TOXI
(	O
grade	O
3	O
)	O
;	O
increased	O
but	O
reversible	O
transaminase	O
levels	O
were	O
observed	O
in	O
11.6	O
%	O
.	O
	
In	O
conclusion	O
","	O
the	O
results	O
of	O
this	O
phase	O
II	O
study	O
show	O
that	O
the	O
combination	O
of	O
gemcitabine	B-DRUG
and	O
vinorelbine	B-DRUG
is	O
active	O
and	O
well	O
tolerated	O
in	O
NSCLC	B-CANCER
","	O
and	O
thus	O
encourage	O
its	O
use	O
in	O
elderly	O
or	O
unfit	O
patients	O
.	O
	
A	O
phase	O
II	O
trial	O
of	O
paclitaxel	B-DRUG
and	O
epirubicin	B-DRUG
in	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
Initial	O
trials	O
of	O
paclitaxel	B-DRUG
and	O
doxorubicin	B-DRUG
in	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
yielded	O
high	O
response	O
rates	O
but	O
significant	O
cardiac	B-TOXI
toxicity	I-TOXI
was	O
observed	O
.	O
	
In	O
this	O
phase	O
II	O
trial	O
we	O
investigated	O
the	O
efficacy	O
and	O
safety	O
of	O
paclitaxel	B-DRUG
combined	O
with	O
epirubicin	B-DRUG
.	O
	
Patients	O
with	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
","	O
performance	O
status	O
0-2	O
","	O
measurable	O
disease	O
","	O
and	O
a	O
normal	O
left	O
ventricular	O
ejection	O
fraction	O
","	O
who	O
may	O
have	O
received	O
adjuvant	O
chemotherapy	O
were	O
treated	O
with	O
epirubicin	B-DRUG
75	O
mg	O
m	O
(	O
-2	O
)	O
followed	O
by	O
a	O
3-h	O
infusion	O
of	O
paclitaxel	B-DRUG
175	O
mg	O
m	O
(	O
-2	O
)	O
repeated	O
every	O
3	O
weeks	O
.	O
	
Forty-three	O
eligible	O
patients	O
were	O
treated	O
at	O
six	O
centres	O
.	O
	
67	O
%	O
patients	O
received	O
the	O
maximum	O
of	O
six	O
cycles	O
.	O
	
The	O
response	O
rate	O
was	O
54	O
%	O
(	O
95	O
%	O
CI	O
38-69	O
%	O
)	O
","	O
12	O
%	O
CR	O
and	O
42	O
%	O
PR	O
.	O
	
Estimated	O
median	O
progression-free	O
survival	O
was	O
6.9	O
months	O
(	O
95	O
%	O
CI	O
5.4-10.0	O
)	O
and	O
estimated	O
median	O
overall	O
survival	O
was	O
17.9	O
months	O
(	O
95	O
%	O
CI	O
14.2-25.7	O
)	O
.	O
	
Four	O
patients	O
had	O
a	O
decrease	O
in	O
the	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
of	O
&	O
gt	O
;	O
or	O
20	O
%	O
of	O
baseline	O
value	O
","	O
and	O
in	O
two	O
patients	O
the	O
LVEF	O
decreased	O
to	O
below	O
the	O
lower	O
limit	O
of	O
normal	O
","	O
but	O
no	O
patient	O
developed	O
clinical	O
evidence	O
of	O
cardiac	O
failure	O
.	O
	
Grade	O
4	O
neutropenia	B-TOXI
occurred	O
in	O
56	O
%	O
cycles	O
","	O
but	O
only	O
4	O
%	O
of	O
cycles	O
were	O
complicated	O
by	O
febrile	B-TOXI
neutropenia	I-TOXI
.	O
	
Grade	O
3	O
or	O
4	O
non-haematologic	B-TOXI
toxicity	I-TOXI
was	O
uncommon	O
.	O
	
In	O
conclusion	O
","	O
paclitaxel	B-DRUG
175	O
mg	O
m	O
(	O
-2	O
)	O
and	O
epirubicin	B-DRUG
75	O
mg	O
m	O
(	O
-2	O
)	O
is	O
a	O
well	O
tolerated	O
","	O
promising	O
regimen	O
for	O
the	O
treatment	O
of	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Gemcitabine	B-DRUG
plus	O
vinorelbine	B-DRUG
in	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
a	O
phase	O
II	O
study	O
of	O
three	O
different	O
doses.	O
Gem	B-DRUG
Vin	I-DRUG
Investigators	O
.	O
	
	
Our	O
aim	O
was	O
to	O
study	O
the	O
activity	O
and	O
toxicity	O
of	O
the	O
gemcitabine	B-DRUG
plus	O
vinorelbine	B-DRUG
(	O
Gem	B-DRUG
Vin	I-DRUG
)	O
combination	O
and	O
to	O
identify	O
the	O
optimal	O
dose	O
.	O
	
Previously	O
untreated	O
patients	O
aged	O
&	O
lt	O
;	O
70	O
years	O
","	O
with	O
stage	O
IV	O
or	O
IIIb	O
(	O
not	O
candidates	O
for	O
radiotherapy	O
)	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
were	O
eligible	O
.	O
	
Studied	O
dose-levels	O
of	O
Gem	B-DRUG
Vin	I-DRUG
","	O
administered	O
on	O
days	O
1	O
and	O
8	O
every	O
3	O
weeks	O
","	O
were	O
(	O
mg	O
m	O
(	O
-2	O
)	O
)	O
:	O
level	O
I	O
=	O
1000	O
/	O
25	O
;	O
level	O
II	O
=	O
1200	O
/	O
25	O
;	O
level	O
III	O
=	O
1000	O
/	O
30	O
;	O
level	O
IV	O
=	O
1200	O
/	O
30	O
.	O
	
A	O
feasibility	O
study	O
was	O
performed	O
at	O
each	O
dose-level	O
","	O
followed	O
by	O
a	O
single-stage	O
phase	O
II	O
study	O
.	O
	
Dose-level	O
IV	O
was	O
unfeasible	O
because	O
of	O
grade	O
4	O
neutropenia	B-TOXI
.	O
	
Overall	O
","	O
out	O
of	O
126	O
patients	O
enrolled	O
in	O
phase	O
II	O
studies	O
","	O
there	O
were	O
one	O
complete	O
and	O
32	O
partial	O
responses	O
(	O
response	O
rate	O
26	O
%	O
:	O
95	O
%	O
CI	O
18-34	O
%	O
)	O
.	O
	
Response	O
rates	O
were	O
27.9	O
%	O
","	O
21.4	O
%	O
and	O
29.3	O
%	O
at	O
levels	O
I	O
","	O
II	O
and	O
III	O
","	O
respectively	O
.	O
	
The	O
treatment	O
was	O
well	O
tolerated	O
.	O
	
Toxicity	O
was	O
less	O
frequent	O
and	O
severe	O
at	O
level	O
I.	O
Overall	O
median	O
survival	O
was	O
33	O
weeks	O
(	O
95	O
%	O
CI	O
28-40	O
)	O
.	O
	
Descriptive	O
quality	O
of	O
life	O
analysis	O
showed	O
that	O
patients	O
with	O
a	O
worse	O
baseline	O
global	O
health	O
status	O
score	O
tended	O
to	O
drop	O
out	O
of	O
the	O
study	O
earlier	O
than	O
those	O
with	O
a	O
better	O
score	O
.	O
	
Gem	B-DRUG
Vin	I-DRUG
is	O
feasible	O
at	O
different	O
doses	O
.	O
	
It	O
is	O
sufficiently	O
active	O
and	O
well	O
tolerated	O
.	O
	
A	O
phase	O
III	O
study	O
to	O
compare	O
the	O
effect	O
on	O
quality	O
of	O
life	O
of	O
Gem	B-DRUG
Vin	I-DRUG
(	O
level	O
I	O
)	O
vs	O
cisplatin-based	B-DRUG
chemotherapy	O
is	O
ongoing	O
.	O
	
Phase	O
I	O
dose	O
escalation	O
study	O
of	O
gemcitabine	B-DRUG
and	O
paclitaxel	B-DRUG
plus	O
colony-stimulating	B-DRUG
factors	I-DRUG
in	O
previously	O
treated	O
patients	O
with	O
advanced	B-CANCER
breast	I-CANCER
and	I-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
	
Gemcitabine	B-DRUG
and	O
paclitaxel	B-DRUG
(	O
PTX	B-DRUG
)	O
are	O
among	O
the	O
most	O
active	O
new	O
drugs	O
in	O
advanced	B-CANCER
breast	I-CANCER
and	I-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
In	O
this	O
Phase	O
I	O
study	O
","	O
we	O
used	O
fixed	O
doses	O
of	O
gemcitabine	B-DRUG
administered	O
on	O
days	O
1	O
and	O
8	O
and	O
escalating	O
doses	O
of	O
paclitaxel	B-DRUG
on	O
day	O
1	O
of	O
a	O
21-day	O
cycle	O
in	O
patients	O
with	O
pretreated	O
metastatic	B-CANCER
breast	I-CANCER
or	I-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
The	O
dose	O
of	O
gemcitabine	B-DRUG
was	O
fixed	O
at	O
"1,000"	O
mg	O
/	O
m2	O
;	O
PTX	B-DRUG
was	O
commenced	O
in	O
the	O
first	O
small	O
patient	O
group	O
at	O
a	O
dose	O
of	O
90	O
mg	O
/	O
m2	O
","	O
which	O
was	O
then	O
escalated	O
in	O
subsequent	O
groups	O
by	O
30	O
mg	O
/	O
m2	O
per	O
step	O
.	O
	
From	O
the	O
third	O
dose	O
level	O
onwards	O
","	O
all	O
patients	O
received	O
granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
300	O
microg	O
by	O
subcutaneous	O
injection	O
on	O
days	O
5	O
and	O
6	O
","	O
and	O
granulocyte	B-DRUG
macrophage	I-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
on	O
days	O
15-18	O
.	O
	
Cohorts	O
of	O
at	O
least	O
3	O
patients	O
were	O
treated	O
at	O
each	O
dose	O
level	O
.	O
	
Dose	O
escalation	O
was	O
stopped	O
if	O
at	O
least	O
a	O
third	O
of	O
the	O
patients	O
in	O
a	O
given	O
cohort	O
had	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
","	O
which	O
was	O
defined	O
as	O
grade	O
4	O
neutropenia	B-TOXI
or	O
thrombocytopenia	B-TOXI
","	O
or	O
grade	O
3月4日	O
non-haematological	B-TOXI
toxicity	I-TOXI
.	O
	
The	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
was	O
defined	O
as	O
the	O
dose	O
level	O
immediately	O
below	O
that	O
causing	O
DLT	O
in	O
one-third	O
of	O
the	O
patients	O
or	O
more	O
.	O
	
Evaluation	O
of	O
the	O
tumour	O
response	O
was	O
performed	O
every	O
three	O
cycles	O
.	O
	
Forty-five	O
patients	O
(	O
31	O
with	O
breast	B-CANCER
cancer	I-CANCER
","	O
14	O
with	O
ovarian	B-CANCER
cancer	I-CANCER
)	O
were	O
treated	O
at	O
seven	O
different	O
dose	O
levels	O
.	O
	
Only	O
at	O
the	O
seventh	O
PTX	B-DRUG
dose	O
level	O
was	O
DLT	O
observed	O
after	O
the	O
first	O
course	O
of	O
therapy	O
:	O
three	O
grade	O
4	O
neutropenia	B-TOXI
","	O
one	O
grade	O
4	O
thrombocytopenia	B-TOXI
","	O
and	O
one	O
grade	O
4	O
anaemia	B-TOXI
.	O
	
DLT	O
occurred	O
in	O
5	O
/	O
6	O
patients	O
at	O
at	O
PTX	B-DRUG
dose	O
of	O
270	O
mg	O
/	O
m2	O
;	O
therefore	O
dose	O
escalation	O
was	O
stopped	O
at	O
that	O
level	O
and	O
the	O
dose	O
immediately	O
before	O
it	O
(	O
PTX	B-DRUG
240	O
mg	O
/	O
m2	O
)	O
was	O
considered	O
as	O
the	O
MTD	O
and	O
recommended	O
for	O
further	O
studies	O
.	O
	
No	O
toxic	B-TOXI
deaths	I-TOXI
occurred	O
.	O
	
Grade	O
3月4日	O
uncomplicated	B-TOXI
neutropenia	I-TOXI
was	O
observed	O
in	O
four	O
patients	O
.	O
	
Three	O
had	O
uncomplicated	O
grade	O
3月4日	O
thrombocytopenia	B-TOXI
.	O
	
One	O
patient	O
had	O
grade	O
3	O
and	O
one	O
grade	O
4	O
anaemia	B-TOXI
.	O
	
Nonhaematological	B-TOXI
side	I-TOXI
effects	I-TOXI
were	O
generally	O
mild	O
.	O
	
Among	O
30	O
evaluable	O
patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
","	O
four	O
complete	O
responses	O
(	O
CR	O
)	O
(	O
13	O
%	O
)	O
and	O
12	O
partial	O
responses	O
(	O
PR	O
)	O
(	O
40	O
%	O
)	O
were	O
observed	O
","	O
for	O
an	O
overall	O
response	O
rate	O
of	O
53	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
34-72	O
)	O
.	O
	
The	O
median	O
duration	O
of	O
response	O
was	O
31	O
weeks	O
.	O
	
Among	O
13	O
evaluable	O
patients	O
with	O
advanced	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
","	O
one	O
CR	O
(	O
8	O
%	O
)	O
and	O
five	O
PRs	O
(	O
38	O
%	O
)	O
were	O
observed	O
","	O
for	O
an	O
overall	O
response	O
rate	O
of	O
46	O
%	O
(	O
95	O
%	O
CI	O
19-78	O
)	O
.	O
	
The	O
median	O
duration	O
of	O
response	O
was	O
32	O
weeks	O
.	O
	
Our	O
study	O
shows	O
that	O
gemcitabine	B-DRUG
and	O
PTX	B-DRUG
can	O
be	O
administered	O
in	O
combination	O
in	O
patients	O
with	O
breast	B-CANCER
and	I-CANCER
ovarian	I-CANCER
cancer	I-CANCER
without	O
unexpected	O
toxicities	O
and	O
with	O
encouraging	O
therapeutic	O
results	O
.	O
	
Eastern	O
Cooperative	O
Oncology	O
Group	O
Phase	O
I	O
trial	O
of	O
protracted	O
venous	O
infusion	O
fluorouracil	B-DRUG
plus	O
weekly	O
gemcitabine	B-DRUG
with	O
concurrent	O
radiation	O
therapy	O
in	O
patients	O
with	O
locally	O
advanced	B-DRUG
pancreas	I-DRUG
cancer	I-DRUG
:	O
a	O
regimen	O
with	O
unexpected	O
early	O
toxicity	O
.	O
	
	
We	O
performed	O
a	O
phase	O
I	O
trial	O
of	O
protracted	O
venous	O
infusion	O
(	O
PVI	O
)	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
plus	O
weekly	O
gemcitabine	B-DRUG
with	O
concurrent	O
radiation	O
therapy	O
in	O
patients	O
with	O
locally	O
advanced	B-CANCER
pancreas	I-CANCER
cancer	I-CANCER
to	O
determine	O
the	O
maximum-tolerated	O
dose	O
of	O
gemcitabine	B-DRUG
that	O
could	O
be	O
safely	O
administered	O
.	O
	
We	O
also	O
sought	O
to	O
identify	O
the	O
toxicities	O
associated	O
with	O
this	O
treatment	O
protocol	O
.	O
	
Seven	O
patients	O
with	O
locally	B-CANCER
advanced	I-CANCER
pancreas	I-CANCER
cancer	I-CANCER
were	O
treated	O
with	O
planned	O
doses	O
of	O
radiation	O
(	O
59.4	O
Gy	O
)	O
and	O
PVI	O
of	O
5-FU	B-DRUG
(	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d	O
)	O
with	O
gemcitabine	B-DRUG
doses	O
of	O
50	O
to	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
wk	O
.	O
	
Two	O
of	O
three	O
patients	O
at	O
the	O
100-mg	O
/	O
m	O
(	O
2	O
)	O
/	O
wk	O
dose	O
level	O
experienced	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
","	O
as	O
did	O
three	O
of	O
four	O
at	O
the	O
50-mg	O
/	O
m	O
(	O
2	O
)	O
/	O
wk	O
dose	O
level	O
.	O
	
One	O
patient	O
experienced	O
a	O
mucocutaneous	O
reaction	O
described	O
as	O
a	O
Stevens-Johnson	O
syndrome	O
that	O
was	O
attributed	O
to	O
chemotherapy	O
.	O
	
Three	O
patients	O
developed	O
gastric	B-TOXI
or	O
duodenal	B-TOXI
ulcers	I-TOXI
with	O
severe	B-TOXI
bleeding	I-TOXI
requiring	O
transfusion	O
.	O
	
One	O
patient	O
developed	O
severe	O
thrombocytopenia	B-TOXI
lasting	O
longer	O
than	O
4	O
weeks	O
.	O
	
Three	O
of	O
the	O
five	O
episodes	O
of	O
DLT	O
developed	O
at	O
radiation	O
doses	O
&	O
lt	O
;	O
or	O
=	O
36	O
Gy	O
.	O
	
Based	O
on	O
this	O
experience	O
","	O
we	O
can	O
not	O
recommend	O
further	O
investigation	O
of	O
regimens	O
incorporating	O
gemcitabine	B-DRUG
into	O
regimens	O
of	O
radiation	O
with	O
PVI	O
5-FU	B-DRUG
.	O
	
The	O
mechanism	O
of	O
this	O
synergistic	O
toxicity	O
remains	O
to	O
be	O
determined	O
.	O
	
Phase	O
I	O
chemotherapy	O
study	O
of	O
biochemical	O
modulation	O
of	O
folinic	B-DRUG
acid	I-DRUG
and	O
fluorouracil	B-DRUG
by	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
solid	B-CANCER
tumor	I-CANCER
malignancies	I-CANCER
.	O
	
	
This	O
phase	O
I	O
biochemical	O
modulation	O
study	O
evaluated	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
toxicity	O
","	O
and	O
effectiveness	O
of	O
the	O
combination	O
of	O
folinic	B-DRUG
acid	I-DRUG
(	O
FA	B-DRUG
)	O
/	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
followed	O
by	O
escalated	O
dose	O
levels	O
of	O
gemcitabine	B-DRUG
(	O
FFG	B-DRUG
)	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Patients	O
were	O
refractory	O
to	O
primary	O
treatment	O
and	O
/	O
or	O
without	O
effective	O
treatment	O
options	O
.	O
	
Twenty-eight	O
patients	O
received	O
an	O
intravenous	O
(	O
IV	O
)	O
infusion	O
of	O
FA	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
over	O
1	O
hour	O
and	O
a	O
5-FU	B-DRUG
450	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
bolus	O
in	O
the	O
middle	O
of	O
the	O
FA	B-DRUG
infusion	O
.	O
	
After	O
the	O
FA	B-DRUG
infusion	O
","	O
gemcitabine	B-DRUG
was	O
administered	O
at	O
a	O
steady	O
rate	O
of	O
infusion	O
of	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
min	O
over	O
initially	O
30	O
minutes	O
and	O
with	O
increases	O
of	O
an	O
additional	O
15	O
minutes	O
at	O
each	O
given	O
level	O
.	O
	
One	O
cycle	O
consisted	O
of	O
six	O
weekly	O
treatments	O
followed	O
by	O
a	O
2-week	O
rest	O
.	O
	
The	O
MTD	O
of	O
gemcitabine	B-DRUG
was	O
established	O
at	O
900	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
over	O
90	O
minutes	O
.	O
	
Eight	O
patients	O
of	O
21	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
achieved	O
responses	O
(	O
one	O
complete	O
response	O
;	O
seven	O
partial	O
responses	O
)	O
","	O
for	O
a	O
response	O
rate	O
of	O
38	O
%	O
.	O
	
Responses	O
were	O
seen	O
across	O
the	O
gemcitabine	B-DRUG
doses	O
of	O
300	O
to	O
900	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
One	O
patient	O
had	O
prior	O
treatment	O
with	O
FA	B-DRUG
/	O
5-FU	B-DRUG
for	O
advanced	O
disease	O
.	O
	
Patients	O
with	O
colorectal	B-CANCER
carcinoma	I-CANCER
had	O
a	O
median	O
survival	O
of	O
18	O
months	O
","	O
and	O
the	O
patient	O
with	O
lung	B-CANCER
carcinoma	I-CANCER
has	O
been	O
alive	O
for	O
24+	O
months	O
.	O
	
The	O
combination	O
chemotherapy	O
of	O
FFG	B-DRUG
was	O
well	O
tolerated	O
and	O
may	O
benefit	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
.	O
	
A	O
phase	O
II	O
evaluation	O
in	O
this	O
patient	O
population	O
is	O
in	O
progress	O
.	O
	
Phase	O
I	O
dose-finding	O
and	O
pharmacokinetic	O
study	O
of	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
with	O
oral	O
valspodar	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
To	O
evaluate	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
","	O
and	O
pharmacokinetic	O
(	O
PK	O
)	O
profile	O
of	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
when	O
administered	O
every	O
3	O
weeks	O
with	O
the	O
oral	O
semisynthetic	O
cyclosporine	B-DRUG
analog	O
valspodar	O
(	O
PSC	B-DRUG
833	I-DRUG
)	O
","	O
an	O
inhibitor	O
of	O
P-glycoprotein	O
function	O
.	O
	
Fifty-eight	O
patients	O
were	O
treated	O
with	O
escalating	O
doses	O
of	O
paclitaxel	B-DRUG
ranging	O
from	O
54	O
to	O
94.5	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
carboplatin	B-DRUG
area	O
under	O
the	O
plasma	O
concentration	O
versus	O
time	O
curve	O
(	O
AUC	O
)	O
ranging	O
from	O
6	O
to	O
9	O
mg.min	O
/	O
mL	O
","	O
every	O
21	O
days	O
.	O
	
The	O
dose	O
of	O
valspodar	B-DRUG
was	O
fixed	O
at	O
5	O
mg	O
/	O
kg	O
every	O
6	O
hours	O
for	O
a	O
total	O
of	O
12	O
doses	O
from	O
day	O
0	O
to	O
day	O
3	O
The	O
MTD	O
was	O
determined	O
for	O
the	O
following	O
two	O
groups	O
:	O
(	O
1	O
)	O
previously	O
treated	O
patients	O
","	O
where	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
doses	O
were	O
escalated	O
;	O
and	O
(	O
2	O
)	O
chemotherapy-na茂ve	O
patients	O
","	O
where	O
paclitaxel	B-DRUG
dose	O
was	O
escalated	O
and	O
carboplatin	B-DRUG
AUC	O
was	O
fixed	O
at	O
6	O
mg.min	O
/	O
mL	O
.	O
	
PK	O
studies	O
of	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
were	O
performed	O
on	O
day	O
1	O
of	O
course	O
1	O
Fifty-eight	O
patients	O
were	O
treated	O
with	O
186	O
courses	O
of	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
valspodar	B-DRUG
.	O
	
Neutropenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
and	O
hepatic	B-TOXI
transaminase	I-TOXI
elevations	I-TOXI
were	O
DLTs	O
.	O
	
In	O
previously	O
treated	O
patients	O
","	O
no	O
DLTs	O
occurred	O
at	O
the	O
first	O
dose	O
level	O
(	O
paclitaxel	B-DRUG
54	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
carboplatin	B-DRUG
AUC	O
6	O
mg.min	O
/	O
mL	O
)	O
.	O
	
However	O
","	O
one	O
of	O
12	O
","	O
two	O
of	O
six	O
","	O
two	O
of	O
four	O
","	O
four	O
of	O
11	O
","	O
and	O
two	O
of	O
five	O
patients	O
experienced	O
DLTs	O
at	O
doses	O
of	O
paclitaxel	B-DRUG
(	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
/	O
carboplatin	B-DRUG
AUC	O
(	O
mg.min	O
/	O
mL	O
)	O
of	O
67.5	O
/	O
6	O
","	O
81	O
/	O
6	O
","	O
94.5	O
/	O
6	O
","	O
67	O
.	O
	
5	O
/	O
7.5	O
","	O
and	O
67.5	O
/	O
9	O
","	O
respectively	O
.	O
	
In	O
chemotherapy-na茂ve	O
patients	O
","	O
one	O
of	O
17	O
developed	O
DLT	O
at	O
paclitaxel	B-DRUG
81	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
carboplatin	B-DRUG
AUC	O
6	O
mg	O
/	O
mL.min	O
.	O
	
There	O
was	O
prolongation	O
of	O
the	O
terminal	O
phase	O
of	O
paclitaxel	B-DRUG
elimination	O
as	O
evidenced	O
by	O
an	O
increased	O
time	O
that	O
plasma	O
paclitaxel	B-DRUG
concentration	O
was	O
&	O
gt	O
;	O
/	O
=	O
0.05	O
micromol	O
/	O
L	O
","	O
ranging	O
from	O
16.6	O
=+	O
/	O
=-	O
6.7	O
hours	O
to	O
41.5	O
=+	O
/	O
=-	O
9.8	O
hours	O
for	O
paclitaxel	B-DRUG
doses	O
of	O
54.5	O
mg	O
/	O
m	O
(	O
2	O
)	O
to	O
94.5	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
respectively	O
.	O
	
The	O
recommended	O
phase	O
II	O
dose	O
in	O
chemotherapy-na茂ve	O
patients	O
is	O
paclitaxel	B-DRUG
81	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
carboplatin	B-DRUG
AUC	O
6	O
mg.min	O
/	O
mL	O
","	O
and	O
valspodar	B-DRUG
5	O
mg	O
/	O
kg	O
every	O
6	O
hours	O
.	O
	
In	O
previously	O
treated	O
patients	O
","	O
the	O
recommended	O
phase	O
II	O
dose	O
is	O
paclitaxel	B-DRUG
67.5	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
carboplatin	B-DRUG
AUC	O
6	O
mg.min	O
/	O
mL	O
","	O
and	O
valspodar	B-DRUG
5	O
mg	O
/	O
kg	O
every	O
6	O
hours	O
.	O
	
The	O
acceptable	O
toxicity	O
profile	O
supports	O
the	O
rationale	O
for	O
performing	O
disease-directed	O
evaluations	O
of	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
and	O
valspodar	B-DRUG
on	O
the	O
schedule	O
evaluated	O
in	O
this	O
study	O
.	O
	
Phase	O
I	O
and	O
pharmacokinetic	O
trial	O
of	O
weekly	O
oral	O
fluorouracil	B-DRUG
given	O
with	O
eniluracil	B-DRUG
and	O
low-dose	O
leucovorin	B-DRUG
to	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
Fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
given	O
as	O
a	O
weekly	O
","	O
high-dose	O
24-hour	O
infusion	O
is	O
active	O
and	O
tolerable	O
.	O
	
We	O
evaluated	O
an	O
oral	O
regimen	O
of	O
eniluracil	B-DRUG
(	O
which	O
inactivates	B-DRUG
dihydropyrimidine	I-DRUG
dehydrogenase	I-DRUG
[	O
DPD	B-DRUG
]	O
)	O
","	O
5-FU	B-DRUG
","	O
and	O
leucovorin	B-DRUG
to	O
simulate	O
this	O
schedule	O
.	O
	
Patients	O
received	O
a	O
single	O
24-hour	O
infusion	O
of	O
5-FU	B-DRUG
(	O
"2,300"	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
2	O
)	O
with	O
leucovorin	B-DRUG
(	O
15	O
mg	O
orally	O
[	O
PO	O
]	O
bid	O
on	O
days	O
1	O
through	O
3	O
)	O
to	O
provide	O
reference	O
pharmacokinetic	O
data	O
.	O
	
Two	O
weeks	O
later	O
","	O
patients	O
began	O
treatment	O
with	O
eniluracil	B-DRUG
(	O
20	O
mg	O
)	O
and	O
leucovorin	B-DRUG
(	O
15	O
mg	O
)	O
(	O
PO	O
bid	O
on	O
days	O
1	O
through	O
3	O
)	O
and	O
5-FU	B-DRUG
(	O
10	O
to	O
15	O
mg	O
/	O
m	O
(	O
2	O
)	O
PO	O
bid	O
on	O
day	O
2	O
)	O
.	O
	
Dose-limiting	O
toxicity	O
(	O
diarrhea	B-TOXI
","	O
neutropenia	B-TOXI
","	O
and	O
fatigue	B-TOXI
)	O
was	O
seen	O
with	O
5-FU	B-DRUG
15	O
mg	O
/	O
m	O
(	O
2	O
)	O
PO	O
bid	O
on	O
day	O
2	O
given	O
weekly	O
for	O
either	O
6	O
of	O
8	O
weeks	O
or	O
3	O
of	O
4	O
weeks	O
","	O
whereas	O
five	O
of	O
seven	O
patients	O
tolerated	O
5-FU	B-DRUG
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
PO	O
bid	O
given	O
weekly	O
for	O
3	O
of	O
4	O
weeks	O
.	O
	
Eniluracil	B-DRUG
led	O
to	O
a	O
35-fold	O
reduction	O
in	O
5-FU	B-DRUG
clearance	O
.	O
	
Fluoro-beta-alanine	B-DRUG
","	O
a	O
5-FU	B-DRUG
catabolite	I-DRUG
","	O
was	O
not	O
detected	O
in	O
plasma	O
during	O
oral	O
5-FU-eniluracil	B-DRUG
therapy	O
.	O
	
DPD	B-DRUG
activity	O
was	O
markedly	O
suppressed	O
in	O
all	O
patients	O
during	O
eniluracil	B-DRUG
therapy	O
;	O
the	O
inactivation	O
persisted	O
after	O
the	O
last	O
eniluracil	B-DRUG
dose	O
;	O
percentages	O
of	O
baseline	O
values	O
were	O
1.8	O
%	O
on	O
day	O
5	O
","	O
4.5	O
%	O
on	O
day	O
12	O
","	O
and	O
23.6	O
%	O
on	O
day	O
19	O
.	O
	
The	O
recommended	O
oral	O
dosage	O
of	O
5-FU	B-DRUG
(	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
PO	O
bid	O
)	O
given	O
with	O
eniluracil	B-DRUG
and	O
leucovorin	B-DRUG
is	O
approximately	O
115-fold	O
lower	O
than	O
the	O
reference	O
dosage	O
for	O
24-hour	O
infusional	B-DRUG
5-FU	I-DRUG
.	O
	
This	O
difference	O
is	O
greater	O
than	O
expected	O
given	O
the	O
reduction	O
in	O
5-FU	B-DRUG
clearance	O
.	O
	
DPD	B-DRUG
inactivation	O
persisted	O
for	O
several	O
weeks	O
after	O
completion	O
of	O
eniluracil	B-DRUG
therapy	O
.	O
	
A	O
medical	O
research	O
council	O
randomized	O
trial	O
of	O
single	O
agent	O
carboplatin	B-DRUG
versus	O
etoposide	B-DRUG
and	O
cisplatin	B-DRUG
for	O
advanced	B-CANCER
metastatic	I-CANCER
seminoma.	I-CANCER
MRC	O
Testicular	O
Tumour	O
Working	O
Party	O
.	O
	
	
The	O
UK	O
Medical	O
Research	O
Council	O
conducted	O
this	O
trial	O
of	O
carboplatin	B-DRUG
chemotherapy	O
in	O
advanced	B-CANCER
seminoma	I-CANCER
to	O
compare	O
single	O
agent	O
carboplatin	B-DRUG
with	O
a	O
standard	O
combination	O
of	O
etoposide	B-DRUG
with	O
cisplatin	B-DRUG
.	O
	
The	O
use	O
of	O
single	O
agent	O
carboplatin	B-DRUG
was	O
expected	O
to	O
be	O
associated	O
with	O
reduced	O
toxicity	O
.	O
	
A	O
total	O
of	O
130	O
patients	O
with	O
advanced	B-CANCER
seminoma	I-CANCER
were	O
randomly	O
assigned	O
to	O
treatment	O
with	O
either	O
single	O
agent	O
carboplatin	B-CANCER
(	O
C	O
)	O
at	O
a	O
dose	O
of	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
to	O
be	O
corrected	O
for	O
glomerular	O
filtration	O
rate	O
outside	O
the	O
range	O
81-120	O
ml	O
min	O
(	O
-1	O
)	O
and	O
to	O
be	O
administered	O
on	O
day	O
1	O
of	O
a	O
21	O
day	O
cycle	O
to	O
a	O
total	O
of	O
4	O
cycles	O
or	O
to	O
etoposide	B-DRUG
=+	O
platinum	B-DRUG
(	O
EP	B-DRUG
)	O
.	O
	
The	O
trial	O
was	O
designed	O
as	O
an	O
equivalence	O
study	O
aiming	O
to	O
exclude	O
a	O
reduction	O
in	O
the	O
3-year	O
progression-free	O
survival	O
in	O
patients	O
allocated	O
to	O
carboplatin	B-DRUG
of	O
between	O
10	O
and	O
15	O
%	O
","	O
requiring	O
initially	O
a	O
target	O
accrual	O
of	O
250	O
patients	O
(	O
90	O
%	O
power	O
significance	O
level	O
5	O
%	O
(	O
one-sided	O
)	O
)	O
.	O
	
The	O
trial	O
closed	O
after	O
130	O
patients	O
had	O
been	O
randomized	O
following	O
recommendation	O
by	O
an	O
independent	O
data	O
monitoring	O
committee	O
.	O
	
At	O
a	O
median	O
follow-up	O
time	O
of	O
4.5	O
years	O
","	O
81	O
%	O
of	O
patients	O
had	O
been	O
followed	O
up	O
for	O
at	O
least	O
3	O
years	O
and	O
19	O
patients	O
have	O
died	O
.	O
	
The	O
estimated	O
PFS	O
rate	O
(	O
95	O
%	O
Confidence	O
Intervals	O
(	O
CI	O
)	O
)	O
at	O
3	O
years	O
was	O
71	O
%	O
(	O
60-82	O
%	O
)	O
in	O
patients	O
allocated	O
C	O
and	O
81	O
%	O
(	O
71-90	O
%	O
)	O
in	O
those	O
allocated	O
EP	B-DRUG
;	O
the	O
95	O
%	O
CI	O
for	O
the	O
difference	O
in	O
3	O
year	O
PFS	O
was	O
=-	O
6	O
%	O
to	O
19	O
%	O
.	O
	
The	O
hazard	O
ratio	O
of	O
0.64	O
(	O
95	O
%	O
CI	O
0.32-1.28	O
)	O
favoured	O
EP	B-DRUG
but	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
log	O
rank	O
chi-squared	O
=	O
1.59	O
P	O
=	O
0.21	O
)	O
.	O
	
The	O
3-year	O
survival	O
rate	O
was	O
84	O
%	O
(	O
75-92	O
%	O
)	O
in	O
those	O
allocated	O
C	O
","	O
and	O
89	O
%	O
(	O
81-96	O
%	O
)	O
in	O
those	O
allocated	O
EP	B-DRUG
.	O
	
The	O
hazard	O
ratio	O
for	O
survival	O
was	O
0.85	O
with	O
95	O
%	O
CI	O
","	O
0.35-2.10	O
","	O
log	O
rank	O
chi-squared	O
=	O
0.12	O
","	O
P	O
=	O
0.73	O
.	O
	
The	O
trial	O
has	O
not	O
demonstrated	O
statistically	O
significant	O
differences	O
in	O
the	O
major	O
survival	O
endpoints	O
comparing	O
single	O
agent	O
carboplatin	B-DRUG
with	O
a	O
combination	O
of	O
etoposide	B-DRUG
=+	O
cisplatin	B-DRUG
.	O
	
This	O
can	O
not	O
be	O
taken	O
as	O
an	O
indication	O
of	O
equivalence	O
since	O
the	O
limited	O
size	O
of	O
this	O
trial	O
rendered	O
it	O
unable	O
to	O
exclude	O
a	O
19	O
%	O
lower	O
progression-free	O
survival	O
and	O
survival	O
in	O
those	O
treated	O
with	O
single	O
agent	O
carboplatin	B-DRUG
which	O
would	O
be	O
important	O
clinically	O
.	O
	
Standard	O
initial	O
chemotherapy	O
for	O
advanced	B-CANCER
seminoma	I-CANCER
should	O
be	O
based	O
on	O
cisplatin	B-DRUG
combinations	O
and	O
the	O
role	O
of	O
carboplatin	B-DRUG
awaits	O
the	O
outcome	O
of	O
further	O
studies	O
.	O
	
Neoadjuvant	O
therapy	O
for	O
organ	O
preservation	O
in	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
.	O
	
	
We	O
designed	O
two	O
sequential	O
trials	O
of	O
induction	O
chemotherapy	O
followed	O
by	O
definitive	O
radiation	O
in	O
patients	O
with	O
potentially	O
resectable	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
to	O
determine	O
whether	O
organ	O
preservation	O
is	O
feasible	O
without	O
apparent	O
compromise	O
of	O
survival	O
Study	O
Design	O
Both	O
trials	O
were	O
Phase	O
II	O
studies	O
.	O
	
Two	O
clinical	O
trials	O
were	O
conducted	O
sequentially	O
at	O
the	O
University	O
of	O
Michigan	O
.	O
	
Fifty-two	O
patients	O
enrolled	O
in	O
the	O
first	O
study	O
and	O
were	O
treated	O
with	O
a	O
planned	O
three	O
cycles	O
of	O
carboplatin	B-DRUG
and	O
5-fluorouracil	B-DRUG
.	O
	
Patients	O
who	O
achieved	O
at	O
least	O
50	O
%	O
reduction	O
in	O
the	O
size	O
of	O
the	O
primary	O
tumor	O
received	O
definitive	O
radiation	O
therapy	O
","	O
to	O
a	O
dose	O
of	O
6600	O
to	O
7380	O
cGy	O
.	O
	
Patients	O
with	O
minimal	O
response	O
or	O
progression	O
had	O
immediate	O
salvage	O
surgery	O
.	O
	
Thirty-seven	O
patients	O
enrolled	O
in	O
the	O
second	O
trial	O
","	O
in	O
which	O
the	O
chemotherapy	O
consisted	O
of	O
carboplatin	B-DRUG
","	O
5-fluororuracil	B-DRUG
","	O
and	O
leukovorin	B-DRUG
.	O
	
Responders	O
were	O
treated	O
with	O
accelerated	O
radiation	O
therapy	O
","	O
to	O
a	O
total	O
dose	O
of	O
7120	O
cGy	O
delivered	O
in	O
41	O
fractions	O
over	O
5.5	O
weeks	O
.	O
	
Toxicity	O
and	O
response	O
were	O
similar	O
in	O
both	O
trials	O
;	O
therefore	O
","	O
the	O
results	O
are	O
reported	O
first	O
separately	O
and	O
then	O
combined	O
for	O
all	O
89	O
patients	O
.	O
	
Tumor	O
sites	O
included	O
:	O
oropharynx	O
","	O
55	O
patients	O
;	O
hypopharynx	O
","	O
34	O
patients	O
.	O
	
Eighty-three	O
percent	O
of	O
patients	O
tolerated	O
all	O
three	O
cycles	O
of	O
chemotherapy	O
and	O
toxicity	O
was	O
mild	O
.	O
	
Response	O
to	O
chemotherapy	O
was	O
:	O
48	O
%	O
complete	O
response	O
at	O
the	O
primary	O
tumor	O
site	O
","	O
and	O
34	O
%	O
partial	O
response	O
at	O
the	O
primary	O
tumor	O
site	O
.	O
	
Initial	O
organ	O
preservation	O
at	O
individual	O
tumor	O
sites	O
was	O
:	O
oropharynx	O
","	O
58	O
%	O
;	O
hypopharynx	O
","	O
59	O
%	O
.	O
	
Median	O
survival	O
was	O
28	O
months	O
","	O
and	O
survival	O
at	O
3	O
and	O
5	O
years	O
was	O
40	O
%	O
and	O
24	O
%	O
","	O
respectively	O
.	O
	
These	O
two	O
regimens	O
were	O
well	O
tolerated	O
","	O
and	O
survival	O
did	O
not	O
appear	O
to	O
be	O
compromised	O
by	O
organ	O
preservation	O
treatment	O
compared	O
with	O
historical	O
controls	O
.	O
	
This	O
approach	O
warrants	O
further	O
investigation	O
","	O
particularly	O
in	O
those	O
patients	O
for	O
whom	O
surgery	O
could	O
be	O
functionally	O
debilitating	O
.	O
	
Paclitaxel	B-DRUG
","	O
estramustine	B-DRUG
phosphate	I-DRUG
","	O
and	O
carboplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
prostate	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
determine	O
the	O
safety	O
and	O
activity	O
of	O
weekly	O
paclitaxel	B-DRUG
in	O
combination	O
with	O
estramustine	B-DRUG
and	O
carboplatin	B-DRUG
(	O
TEC	B-DRUG
)	O
in	O
patients	O
with	O
advanced	B-CANCER
prostate	I-CANCER
cancer	I-CANCER
.	O
	
In	O
a	O
dose-escalation	O
study	O
","	O
patients	O
with	O
advanced	B-CANCER
prostate	I-CANCER
cancer	I-CANCER
were	O
administered	O
paclitaxel	B-DRUG
(	O
weekly	O
1-hour	O
infusions	O
of	O
60	O
to	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
oral	O
estramustine	B-DRUG
(	O
10	O
mg	O
/	O
kg	O
)	O
","	O
and	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
","	O
6	O
mg	O
/	O
mL-min	O
every	O
4	O
weeks	O
)	O
.	O
	
Paclitaxel	B-DRUG
levels	O
were	O
determined	O
0	O
","	O
30	O
","	O
60	O
","	O
90	O
","	O
and	O
120	O
minutes	O
and	O
18	O
hours	O
after	O
infusion	O
","	O
and	O
a	O
concentration-time	O
curve	O
was	O
estimated	O
.	O
	
Once	O
a	O
safe	O
dose	O
was	O
established	O
","	O
a	O
multi-institutional	O
phase	O
II	O
trial	O
was	O
conducted	O
in	O
patients	O
with	O
progressive	O
androgen-independent	O
disease	O
.	O
	
Fifty-six	O
patients	O
with	O
progressive	O
androgen-independent	O
disease	O
were	O
treated	O
for	O
a	O
median	O
of	O
four	O
cycles	O
.	O
	
The	O
dose	O
of	O
paclitaxel	B-DRUG
was	O
escalated	O
from	O
60	O
to	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
without	O
the	O
occurrence	O
of	O
DLT	O
.	O
	
Posttherapy	O
decreases	O
in	O
serum	O
prostate-specific	O
antigen	O
levels	O
of	O
50	O
%	O
","	O
80	O
%	O
","	O
and	O
90	O
%	O
were	O
seen	O
in	O
67	O
%	O
","	O
48	O
%	O
","	O
and	O
39	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
55	O
%	O
to	O
79	O
%	O
","	O
35	O
%	O
to	O
61	O
%	O
","	O
26	O
%	O
to	O
52	O
%	O
)	O
of	O
the	O
patients	O
","	O
respectively	O
.	O
	
Of	O
the	O
33	O
patients	O
with	O
measurable	O
disease	O
","	O
two	O
(	O
6	O
%	O
)	O
had	O
a	O
complete	O
response	O
and	O
13	O
(	O
39	O
%	O
)	O
had	O
a	O
partial	O
response	O
.	O
	
The	O
overall	O
median	O
time	O
to	O
progression	O
was	O
21	O
weeks	O
","	O
and	O
the	O
median	O
survival	O
time	O
for	O
all	O
patients	O
was	O
19.9	O
months	O
.	O
	
Major	O
grade	O
3	O
or	O
4	O
adverse	O
effects	O
were	O
thromboembolic	B-TOXI
disease	I-TOXI
(	O
in	O
25	O
%	O
of	O
patients	O
)	O
","	O
hyperglycemia	B-TOXI
(	O
in	O
38	O
%	O
)	O
","	O
and	O
hypophosphatemia	B-TOXI
(	O
in	O
42	O
%	O
)	O
.	O
	
Significant	O
leukopenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
and	O
peripheral	B-TOXI
neuropathy	I-TOXI
were	O
not	O
observed	O
.	O
	
TEC	O
has	O
significant	O
antitumor	O
activity	O
and	O
is	O
well	O
tolerated	O
in	O
patients	O
with	O
progressive	O
androgen-independent	O
prostate	B-CANCER
cancer	I-CANCER
.	O
	
Salvage	O
treatment	O
with	O
paclitaxel	B-DRUG
","	O
ifosfamide	B-DRUG
","	O
and	O
cisplatin	B-DRUG
plus	O
high-dose	O
carboplatin	B-DRUG
","	O
etoposide	B-DRUG
","	O
and	O
thiotepa	B-DRUG
followed	O
by	O
autologous	O
stem-cell	O
rescue	O
in	O
patients	O
with	O
relapsed	O
or	O
refractory	O
germ	B-CANCER
cell	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
study	O
feasibility	O
and	O
efficacy	O
of	O
a	O
new	O
salvage	O
regimen	O
in	O
patients	O
with	O
relapsed	O
and	O
/	O
or	O
refractory	O
germ	B-CANCER
cell	I-CANCER
tumors	I-CANCER
.	O
	
Between	O
May	O
1995	O
and	O
February	O
1997	O
","	O
80	O
patients	O
were	O
entered	O
onto	O
a	O
phase	O
II	O
study	O
.	O
	
Conventional-dose	O
salvage	O
treatment	O
with	O
three	O
cycles	O
of	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
ifosfamide	B-DRUG
5	O
x	O
1.2	O
g	O
/	O
m	O
(	O
2	O
)	O
","	O
and	O
cisplatin	B-DRUG
5	O
x	O
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
TIP	B-DRUG
)	O
was	O
followed	O
by	O
one	O
cycle	O
of	O
high-dose	O
chemotherapy	O
(	O
HDCT	O
)	O
with	O
carboplatin	B-DRUG
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
x	O
3	O
","	O
etoposide	B-DRUG
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
x	O
4	O
","	O
and	O
thiotepa	B-DRUG
150	O
to	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
x	O
3	O
(	O
CET	B-DRUG
)	O
.	O
	
In	O
23	O
patients	O
","	O
one	O
additional	O
cycle	O
of	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
ifosfamide	B-DRUG
5	O
g	O
/	O
m	O
(	O
2	O
)	O
(	O
TI	O
)	O
was	O
given	O
immediately	O
before	O
TIP	B-DRUG
to	O
improve	O
stem-cell	O
mobilization	O
.	O
	
Fifty-five	O
(	O
69	O
%	O
)	O
of	O
80	O
patients	O
responded	O
to	O
TIP	B-DRUG
","	O
24	O
(	O
30	O
%	O
)	O
of	O
80	O
patients	O
had	O
stable	O
disease	O
(	O
n	O
=	O
5	O
)	O
or	O
tumor	O
progression	O
(	O
n	O
=	O
19	O
)	O
","	O
and	O
one	O
patient	O
died	B-TOXI
.	O
	
Only	O
62	O
(	O
78	O
%	O
)	O
of	O
80	O
patients	O
received	O
subsequent	O
HDCT	O
.	O
	
Among	O
those	O
","	O
41	O
(	O
66	O
%	O
)	O
of	O
62	O
patients	O
responded	O
and	O
20	O
(	O
32	O
%	O
)	O
of	O
62	O
patients	O
had	O
stable	O
disease	O
(	O
n	O
=	O
3	O
)	O
or	O
tumor	O
progression	O
(	O
n	O
=	O
17	O
)	O
.	O
	
One	O
patient	O
died	B-TOXI
after	O
HDCT	O
from	O
multiorgan	O
failure	O
.	O
	
Survival	O
probabilities	O
at	O
3	O
years	O
were	O
30	O
%	O
for	O
overall	O
and	O
25	O
%	O
for	O
event-free	O
survival	O
.	O
	
Peripheral	B-TOXI
neurotoxicity	I-TOXI
with	O
sensorimotor	B-TOXI
impairment	I-TOXI
grade	O
2	O
through	O
4	O
in	O
29	O
%	O
","	O
paresthesias	B-TOXI
grade	O
2	O
through	O
4	O
in	O
24	O
%	O
","	O
and	O
skin	B-TOXI
toxicity	I-TOXI
grade	O
2	O
through	O
3	O
in	O
15	O
%	O
of	O
patients	O
were	O
the	O
most	O
relevant	O
side	O
effects	O
.	O
	
Treatment	O
with	O
TIP	B-DRUG
followed	O
by	O
high-dose	O
CET	B-DRUG
is	O
feasible	O
and	O
can	O
induce	O
long-term	O
remissions	O
in	O
25	O
%	O
of	O
patients	O
with	O
relapsed	O
or	O
refractory	O
germ	B-CANCER
cell	I-CANCER
tumors	I-CANCER
.	O
	
Peripheral	B-TOXI
nervous	I-TOXI
toxicity	I-TOXI
in	O
approximately	O
one	O
third	O
of	O
patients	O
is	O
a	O
disadvantage	O
of	O
this	O
salvage	O
strategy	O
.	O
	
Phase	O
Ib	O
trial	O
of	O
intravenous	O
recombinant	B-DRUG
humanized	I-DRUG
monoclonal	I-DRUG
antibody	I-DRUG
to	O
vascular	O
endothelial	O
growth	O
factor	O
in	O
combination	O
with	O
chemotherapy	O
in	O
patients	O
with	O
advanced	B-CANCER
cancer	I-CANCER
:	O
pharmacologic	O
and	O
long-term	O
safety	O
data	O
.	O
	
	
Tumor	O
angiogenesis	O
mediated	O
by	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
inhibited	O
by	O
the	O
recombinant	O
humanized	O
(	O
rhu	O
)	O
monoclonal	O
antibody	O
(	O
MAb	O
)	O
rhuMAbVEGF	B-DRUG
","	O
which	O
has	O
synergy	O
with	O
chemotherapy	O
in	O
animal	O
models	O
.	O
	
The	O
present	O
study	O
was	O
designed	O
to	O
assess	O
the	O
safety	O
and	O
pharmacokinetics	O
of	O
weekly	O
intravenous	O
(	O
IV	O
)	O
rhuMAbVEGF	B-DRUG
with	O
one	O
of	O
three	O
standard	O
chemotherapy	O
regimens	O
.	O
	
Twelve	O
adult	O
patients	O
were	O
enrolled	O
four	O
on	O
each	O
combination	O
.	O
	
rhuMAbVEGF	B-DRUG
","	O
3	O
mg	O
/	O
kg	O
IV	O
","	O
was	O
administered	O
weekly	O
for	O
8	O
weeks	O
with	O
(	O
1	O
)	O
doxorubicin	B-DRUG
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
every	O
4	O
weeks	O
;	O
(	O
2	O
)	O
carboplatin	B-DRUG
at	O
area	O
under	O
the	O
curve	O
of	O
6	O
plus	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
every	O
4	O
weeks	O
;	O
and	O
(	O
3	O
)	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
with	O
leucovorin	B-DRUG
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
","	O
weeks	O
1	O
to	O
6	O
every	O
8	O
weeks	O
.	O
	
The	O
median	O
number	O
of	O
rhuMAbVEGF	B-DRUG
doses	O
delivered	O
was	O
eight	O
(	O
range	O
","	O
four	O
to	O
eight	O
doses	O
)	O
.	O
	
Grade	O
3	O
toxicities	O
were	O
diarrhea	B-TOXI
(	O
one	O
5-FU	B-DRUG
patient	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
two	O
patients	O
on	O
carboplatin	B-DRUG
plus	O
paclitaxel	B-DRUG
)	O
","	O
and	O
leukopenia	B-TOXI
(	O
one	O
patient	O
on	O
carboplatin	B-DRUG
plus	O
paclitaxel	B-DRUG
)	O
.	O
	
These	O
toxicities	O
were	O
likely	O
attributable	O
to	O
the	O
chemotherapy	O
component	O
of	O
the	O
regimen	O
.	O
	
The	O
mean	O
(	O
=+	O
/	O
=-	O
SD	O
)	O
peak	O
serum	O
level	O
of	O
rhuMAbVEGF	B-DRUG
was	O
167	O
=+	O
/	O
=-	O
46	O
microg	O
/	O
mL	O
","	O
and	O
the	O
mean	O
terminal	O
half-life	O
was	O
13	O
days	O
.	O
	
Total	O
(	O
free	O
plus	O
bound	O
)	O
serum	O
VEGF	O
levels	O
increased	O
from	O
51	O
=+	O
/	O
=-	O
39	O
pg	O
/	O
mL	O
(	O
day	O
0	O
)	O
to	O
211	O
=+	O
/	O
=-	O
112	O
(	O
day	O
49	O
)	O
pg	O
/	O
mL	O
.	O
	
Three	O
responding	O
patients	O
continued	O
treatment	O
with	O
rhuMAbVEGF	B-DRUG
and	O
chemotherapy	O
","	O
receiving	O
the	O
equivalent	O
of	O
36	O
","	O
20	O
","	O
and	O
40	O
total	O
rhuMAbVEGF	B-DRUG
doses	O
with	O
no	O
cumulative	O
or	O
late	O
toxicities	O
.	O
	
rhuMAbVEGF	B-DRUG
can	O
be	O
safely	O
combined	O
with	O
chemotherapy	O
at	O
doses	O
associated	O
with	O
VEGF	B-DRUG
blockade	O
and	O
without	O
apparent	O
synergistic	O
toxicity	O
.	O
	
Its	O
contribution	O
to	O
the	O
treatment	O
of	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
should	O
be	O
evaluated	O
in	O
randomized	O
treatment	O
trials	O
.	O
	
Phase	O
I	O
trial	O
of	O
escalating	O
doses	O
of	O
paclitaxel	B-DRUG
combined	O
with	O
fixed	O
doses	O
of	O
cisplatin	B-DRUG
and	O
doxorubicin	B-DRUG
in	O
advanced	B-CANCER
endometrial	I-CANCER
cancer	I-CANCER
and	O
other	O
gynecologic	B-CANCER
malignancies	I-CANCER
:	O
a	O
Gynecologic	O
Oncology	O
Group	O
study	O
.	O
	
	
The	O
primary	O
objective	O
of	O
this	O
phase	O
I	O
trial	O
was	O
to	O
determine	O
the	O
feasibility	O
of	O
administering	O
a	O
combination	O
of	O
paclitaxel	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
doxorubicin	B-DRUG
with	O
or	O
without	O
granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
(	O
G-CSF	B-DRUG
)	O
in	O
patients	O
with	O
advanced	O
endometrial	B-CANCER
and	I-CANCER
other	I-CANCER
gynecologic	I-CANCER
cancers	I-CANCER
.	O
	
Patients	O
were	O
chemotherapy-naive	O
.	O
	
Doxorubicin	B-DRUG
was	O
administered	O
as	O
a	O
brief	O
infusion	O
","	O
paclitaxel	B-DRUG
for	O
3	O
hours	O
","	O
and	O
cisplatin	B-DRUG
for	O
60	O
minutes	O
.	O
	
Treatments	O
were	O
repeated	O
every	O
3	O
weeks	O
.	O
	
For	O
most	O
dose	O
levels	O
","	O
the	O
cisplatin	B-DRUG
and	O
doxorubicin	B-DRUG
were	O
fixed	O
at	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
45	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
whereas	O
the	O
paclitaxel	B-DRUG
was	O
escalated	O
in	O
successive	O
cohorts	O
from	O
90	O
to	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Patients	O
who	O
had	O
received	O
previous	O
radiotherapy	O
to	O
the	O
whole	O
pelvis	O
were	O
escalated	O
separately	O
from	O
those	O
who	O
had	O
not	O
.	O
	
Eighty	O
patients	O
received	O
320	O
cycles	O
of	O
therapy	O
.	O
	
When	O
G-CSF	B-DRUG
was	O
not	O
used	O
","	O
myelosuppression	O
prevented	O
escalation	O
beyond	O
the	O
starting	O
dose	O
for	O
patients	O
with	O
or	O
without	O
previous	O
pelvic	O
radiotherapy	O
.	O
	
When	O
G-CSF	B-DRUG
was	O
added	O
","	O
neurotoxicity	B-TOXI
became	O
dose-limiting	O
for	O
both	O
groups	O
.	O
	
Ten	O
patients	O
were	O
removed	O
from	O
the	O
study	O
for	O
asymptomatic	O
declines	O
in	O
ejection	O
fraction	O
","	O
but	O
no	O
symptomatic	O
congestive	B-TOXI
heart	I-TOXI
failure	I-TOXI
was	O
observed	O
.	O
	
Major	O
antitumor	O
responses	O
occurred	O
in	O
46	O
%	O
of	O
patients	O
(	O
six	O
of	O
13	O
)	O
with	O
measurable	O
endometrial	B-CANCER
carcinoma	I-CANCER
and	O
50	O
%	O
of	O
patients	O
(	O
eight	O
of	O
16	O
)	O
with	O
measurable	O
cervical	B-CANCER
carcinoma	I-CANCER
.	O
	
The	O
combination	O
of	O
paclitaxel	B-DRUG
","	O
doxorubicin	B-DRUG
","	O
and	O
cisplatin	B-DRUG
at	O
relevant	O
single-agent	O
doses	O
is	O
active	O
and	O
feasible	O
with	O
the	O
addition	O
of	O
G-CSF	B-DRUG
.	O
	
A	O
regimen	O
of	O
cisplatin	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
doxorubicin	B-DRUG
45	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
and	O
paclitaxel	B-DRUG
160	O
mg	O
/	O
m	O
(	O
2	O
)	O
with	O
G-CSF	B-DRUG
support	O
is	O
recommended	O
for	O
further	O
testing	O
.	O
	
Phase	O
I	O
trial	O
of	O
the	O
combination	O
of	O
irinotecan	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
and	O
carboplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
determine	O
the	O
maximum-tolerated	O
dose	O
","	O
toxicities	O
","	O
and	O
dose	O
suitable	O
for	O
phase	O
II	O
/	O
III	O
trials	O
of	O
irinotecan	B-DRUG
(	O
CPT-11	B-DRUG
)	O
combined	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Patients	O
with	O
stage	O
IIIB	O
/	O
IV	O
NSCLC	B-CANCER
were	O
enrolled	O
to	O
this	O
multicenter	O
","	O
phase	O
I	O
study	O
.	O
	
The	O
initial	O
regimen	O
was	O
paclitaxel	B-DRUG
225	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
3	O
h	O
","	O
followed	O
by	O
carboplatin	B-DRUG
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
6	O
over	O
30	O
minutes	O
on	O
day	O
1	O
","	O
and	O
CPT-11	B-DRUG
starting	O
at	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
over	O
90	O
minutes	O
","	O
days	O
1	O
and	O
8	O
","	O
every	O
3	O
weeks	O
.	O
	
Dose-limiting	O
toxicity	O
occurred	O
in	O
three	O
of	O
seven	O
patients	O
.	O
	
The	O
regimen	O
was	O
amended	O
","	O
with	O
doses	O
reduced	O
to	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
3	O
h	O
","	O
carboplatin	B-DRUG
AUC	O
5	O
and	O
CPT-11	B-DRUG
at	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
all	O
on	O
day	O
1	O
every	O
3	O
weeks	O
.	O
	
Dose	O
escalation	O
of	O
CPT-11	B-DRUG
proceeded	O
to	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
then	O
125	O
mg	O
/	O
m	O
(	O
2	O
)	O
before	O
dose-limiting	O
toxicities	O
were	O
experienced	O
.	O
	
Subsequent	O
patients	O
received	O
an	O
intermediate	O
CPT-11	B-DRUG
dose	O
of	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Thirty-three	O
patients	O
were	O
enrolled	O
;	O
32	O
patients	O
were	O
assessable	O
for	O
safety	O
","	O
and	O
31	O
were	O
assessable	O
for	O
tumor	O
response	O
.	O
	
The	O
primary	O
first-cycle	O
dose-limiting	O
toxicities	O
were	O
neutropenia	B-TOXI
and	O
diarrhea	B-TOXI
.	O
	
The	O
most	O
common	O
grade	O
3	O
/	O
4	O
toxicity	O
observed	O
during	O
all	O
cycles	O
was	O
neutropenia	B-TOXI
(	O
16	O
patients	O
[	O
50	O
%	O
]	O
","	O
with	O
six	O
[	O
19	O
%	O
]	O
developing	O
neutropenic	B-TOXI
fever	I-TOXI
)	O
.	O
	
Objective	O
tumor	O
response	O
was	O
observed	O
in	O
39	O
%	O
(	O
12	O
/	O
31	O
","	O
95	O
%	O
confidence	O
interval	O
","	O
22	O
%	O
to	O
58	O
%	O
)	O
.	O
	
The	O
median	O
time	O
to	O
tumor	O
progression	O
was	O
6.8	O
months	O
","	O
median	O
survival	O
11	O
months	O
","	O
and	O
1-year	O
survival	O
probability	O
0.46	O
.	O
	
CPT-11	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
and	O
carboplatin	B-DRUG
AUC	O
5	O
given	O
every	O
3	O
weeks	O
can	O
be	O
safely	O
administered	O
in	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
Neutropenia	B-TOXI
and	O
diarrhea	B-TOXI
are	O
the	O
dose-limiting	O
toxicities	O
.	O
	
The	O
combination	O
shows	O
appreciable	O
activity	O
","	O
and	O
survival	O
data	O
are	O
favorable	O
.	O
	
A	O
phase	O
II	O
study	O
of	O
sequential	O
chemotherapy	O
with	O
docetaxel	B-DRUG
after	O
the	O
weekly	O
PELF	B-DRUG
regimen	O
in	O
advanced	B-CANCER
gastric	I-CANCER
cancer.	I-CANCER
A	O
report	O
from	O
the	O
Italian	O
group	O
for	O
the	O
study	O
of	O
digestive	B-CANCER
tract	I-CANCER
cancer	I-CANCER
.	O
	
	
In	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
","	O
we	O
investigated	O
feasibility	O
and	O
activity	O
of	O
sequential	O
chemotherapy	O
with	O
docetaxel	B-DRUG
after	O
an	O
intensive	O
weekly	O
regimen	O
consisting	O
of	O
cisplatin	B-DRUG
","	O
epidoxorubicin	B-DRUG
","	O
fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
(	O
PELF	B-DRUG
)	O
plus	O
filgrastim	B-DRUG
.	O
	
Chemotherapy-naive	O
patients	O
with	O
relapsed	B-CANCER
or	I-CANCER
metastatic	I-CANCER
gastric	I-CANCER
cancer	I-CANCER
received	O
8	O
weekly	O
administrations	O
of	O
chemotherapy	O
with	O
cisplatin	B-DRUG
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
fluorouracil	B-DRUG
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
epidoxorubicin	B-DRUG
35	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
6S-stereoisomer	O
of	O
leucovorin	B-DRUG
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
glutathione	B-DRUG
1.5	O
g	O
/	O
m	O
(	O
2	O
)	O
.	O
	
On	O
the	O
other	O
days	O
filgrastim	B-DRUG
5	O
microg	O
kg	O
(	O
-1	O
)	O
was	O
administered	O
by	O
subcutaneous	O
injection	O
.	O
	
Subsequently	O
","	O
patients	O
with	O
partial	O
response	O
or	O
stable	O
disease	O
received	O
3	O
cycles	O
of	O
docetaxel	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
every	O
3	O
weeks	O
.	O
	
40	O
patients	O
have	O
been	O
enrolled	O
and	O
they	O
are	O
evaluable	O
for	O
response	O
and	O
toxicity	O
.	O
	
After	O
the	O
PELF	B-DRUG
regimen	O
","	O
3	O
patients	O
achieved	O
complete	O
response	O
","	O
13	O
patients	O
showed	O
partial	O
response	O
","	O
21	O
patients	O
had	O
stable	O
disease	O
and	O
3	O
patients	O
progressed	O
(	O
40	O
%	O
response	O
rate	O
;	O
95	O
%	O
CI	O
25	O
%	O
to	O
55	O
%	O
)	O
.	O
	
After	O
docetaxel	B-DRUG
","	O
9	O
out	O
34	O
patients	O
improved	O
the	O
outcome	O
(	O
26.5	O
%	O
)	O
;	O
7	O
patients	O
with	O
stable	O
disease	O
achieved	O
partial	O
response	O
and	O
2	O
patients	O
with	O
partial	O
response	O
achieved	O
complete	O
response	O
.	O
	
The	O
overall	O
response	O
rate	O
in	O
the	O
40	O
patients	O
was	O
57.5	O
%	O
(	O
95	O
%	O
CI	O
","	O
42.5	O
%	O
to	O
72.5	O
%	O
)	O
.	O
	
The	O
PELF	B-DRUG
regimen	O
did	O
not	O
cause	O
any	O
grade	O
IV	O
toxicity	O
","	O
the	O
most	O
frequent	O
grade	O
III	O
acute	O
side-effects	O
were	O
thrombocytopenia	B-TOXI
and	O
vomiting	B-TOXI
which	O
occurred	O
in	O
the	O
10	O
%	O
of	O
320	O
PELF	B-DRUG
cycles	O
.	O
	
Docetaxel	B-DRUG
caused	O
grade	O
III-IV	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
in	O
the	O
10	O
%	O
and	O
the	O
19	O
%	O
of	O
cycles	O
respectively	O
.	O
	
Fatigue	O
was	O
a	O
frequent	O
side-effect	O
during	O
both	O
PELF	B-DRUG
and	O
docetaxel	B-DRUG
chemotherapy	O
.	O
	
The	O
sequential	O
application	O
of	O
docetaxel	B-DRUG
after	O
PELF	B-DRUG
chemotherapy	O
gained	O
major	O
objective	O
responses	O
with	O
manageable	O
toxicity	O
.	O
	
This	O
strategy	O
is	O
worth	O
of	O
further	O
investigation	O
in	O
the	O
setting	O
of	O
palliative	O
or	O
neoadjuvant	O
chemotherapy	O
.	O
	
Doxorubicin	B-DRUG
and	O
paclitaxel	B-DRUG
versus	O
fluorouracil	B-DRUG
","	O
doxorubicin	B-DRUG
","	O
and	O
cyclophosphamide	B-DRUG
as	O
first-line	O
therapy	O
for	O
women	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
:	O
final	O
results	O
of	O
a	O
randomized	O
phase	O
III	O
multicenter	O
trial	O
.	O
	
	
This	O
phase	O
III	O
trial	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
doxorubicin	B-DRUG
and	O
paclitaxel	B-DRUG
(	O
AT	B-DRUG
)	O
to	O
5-fluorouracil	B-DRUG
","	O
doxorubicin	B-DRUG
","	O
and	O
cyclophosphamide	B-DRUG
(	O
FAC	B-DRUG
)	O
as	O
first-line	O
therapy	O
for	O
women	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
A	O
total	O
of	O
267	O
women	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
were	O
randomized	O
to	O
receive	O
either	O
AT	B-DRUG
(	O
doxorubicin	B-DRUG
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
followed	O
24	O
hours	O
later	O
by	O
paclitaxel	B-DRUG
220	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
or	O
FAC	B-DRUG
(	O
5-fluorouracil	B-DRUG
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
doxorubicin	B-DRUG
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
cyclophosphamide	B-DRUG
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
each	O
administered	O
every	O
3	O
weeks	O
for	O
up	O
to	O
eight	O
cycles	O
.	O
	
Patients	O
had	O
to	O
have	O
measurable	O
disease	O
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
to	O
2	O
Only	O
one	O
prior	O
non-anthracycline	O
","	O
nontaxane-containing	O
adjuvant	O
chemotherapy	O
regimen	O
was	O
allowed	O
.	O
	
Overall	O
response	O
rates	O
for	O
patients	O
randomized	O
to	O
AT	B-DRUG
and	O
FAC	B-DRUG
were	O
68	O
%	O
and	O
55	O
%	O
","	O
respectively	O
(	O
P	O
0.032	O
)	O
.	O
	
Median	O
time	O
to	O
progression	O
and	O
overall	O
survival	O
were	O
significantly	O
longer	O
for	O
AT	B-DRUG
compared	O
with	O
FAC	B-DRUG
(	O
time	O
to	O
progression	O
8.3	O
months	O
v	O
6.2	O
months	O
[	O
P	O
0.034	O
]	O
;	O
overall	O
survival	O
23.3	O
months	O
v	O
18.3	O
months	O
[	O
P	O
0.013	O
]	O
)	O
.	O
	
Therapy	O
was	O
generally	O
well-tolerated	O
(	O
median	O
of	O
eight	O
cycles	O
delivered	O
in	O
each	O
arm	O
)	O
.	O
	
Grade	O
3	O
or	O
4	O
neutropenia	B-TOXI
was	O
more	O
common	O
with	O
AT	B-DRUG
than	O
with	O
FAC	B-DRUG
(	O
89	O
%	O
v	O
65	O
%	O
;	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
;	O
however	O
","	O
the	O
incidence	O
of	O
fever	B-TOXI
and	O
infection	B-TOXI
was	O
low	O
.	O
	
Grade	O
3	O
or	O
4	O
arthralgia	B-TOXI
and	O
myalgia	B-TOXI
","	O
peripheral	B-TOXI
neuropathy	I-TOXI
","	O
and	O
diarrhea	B-TOXI
were	O
more	O
common	O
with	O
AT	B-DRUG
","	O
whereas	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
were	O
more	O
common	O
with	O
FAC	B-DRUG
.	O
	
The	O
incidence	O
of	O
cardiotoxicity	B-TOXI
was	O
low	O
in	O
both	O
arms	O
.	O
	
AT	O
conferred	O
a	O
significant	O
advantage	O
in	O
response	O
rate	O
","	O
time	O
to	O
progression	O
","	O
and	O
overall	O
survival	O
compared	O
with	O
FAC	B-DRUG
.	O
	
Treatment	O
was	O
well-tolerated	O
with	O
no	O
unexpected	O
toxicities	O
.	O
	
Concomitant	O
infusional	O
paclitaxel	B-DRUG
and	O
fluorouracil	B-DRUG
","	O
oral	O
hydroxyurea	B-DRUG
","	O
and	O
hyperfractionated	O
radiation	O
for	O
locally	O
advanced	B-CANCER
squamous	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
improve	O
local	O
disease	O
control	O
and	O
survival	O
with	O
organ	O
preservation	O
","	O
we	O
conducted	O
a	O
phase	O
II	O
multi-institutional	O
trial	O
with	O
a	O
concomitant	O
taxane-based	B-DRUG
chemotherapy	O
and	O
hyperfractionated	O
radiation	O
regimen	O
.	O
	
Sixty-four	O
patients	O
with	O
locally	B-CANCER
advanced	I-CANCER
squamous	I-CANCER
cancers	I-CANCER
(	O
stage	O
IV	O
","	O
98	O
%	O
;	O
N2	O
/	O
3	O
","	O
81	O
%	O
)	O
were	O
treated	O
on	O
an	O
intensive	O
regimen	O
consisting	O
of	O
5-day	O
(	O
120-hour	O
)	O
infusions	O
of	O
paclitaxel	B-DRUG
(	O
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d	O
)	O
and	O
fluorouracil	B-DRUG
(	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d	O
)	O
","	O
oral	B-DRUG
hydroxyurea	I-DRUG
500	O
mg	O
every	O
12	O
hours	O
for	O
11	O
doses	O
","	O
and	O
radiation	O
1.5	O
Gy	O
bid	O
(	O
T-FH2X	O
)	O
.	O
	
Chemoradiation	O
was	O
administered	O
concomitantly	O
on	O
days	O
1	O
to	O
5	O
of	O
each	O
14-day	O
cycle	O
.	O
	
A	O
full	O
treatment	O
course	O
consisted	O
of	O
five	O
cycles	O
during	O
a	O
10-week	O
period	O
to	O
a	O
total	O
radiation	O
dose	O
of	O
72	O
to	O
75	O
Gy	O
.	O
	
The	O
median	O
follow-up	O
for	O
the	O
group	O
is	O
34	O
months	O
.	O
	
At	O
3	O
years	O
","	O
progression-free	O
survival	O
is	O
63	O
%	O
","	O
locoregional	O
control	O
is	O
86	O
%	O
","	O
and	O
systemic	O
control	O
is	O
79	O
%	O
;	O
overall	O
survival	O
is	O
60	O
%	O
.	O
	
Seventeen	O
patients	O
died	B-TOXI
of	O
recurrent	B-CANCER
cancer	I-CANCER
","	O
two	O
died	B-TOXI
of	O
second	B-CANCER
primary	I-CANCER
cancers	I-CANCER
","	O
and	O
four	O
died	B-TOXI
of	O
other	O
causes	O
.	O
	
Side	O
effects	O
observed	O
include	O
anemia	B-TOXI
(	O
22	O
%	O
required	O
transfusion	O
)	O
","	O
leucopenia	B-TOXI
(	O
34	O
%	O
","	O
grade	O
3	O
to	O
4	O
)	O
","	O
and	O
mucositis	B-TOXI
(	O
84	O
%	O
","	O
grade	O
3	O
to	O
4	O
)	O
.	O
	
Organ	O
preservation	O
principles	O
were	O
maintained	O
.	O
	
At	O
1	O
year	O
posttreatment	O
","	O
61	O
%	O
of	O
patients	O
had	O
severe	B-TOXI
xerostomia	I-TOXI
and	O
47	O
%	O
had	O
compromised	B-TOXI
swallowing	I-TOXI
.	O
	
There	O
was	O
little	O
disturbance	O
of	O
speech	O
quality	O
in	O
97	O
%	O
of	O
patients	O
at	O
the	O
same	O
follow-up	O
point	O
.	O
	
T-FH2X	O
is	O
a	O
highly	O
active	O
and	O
tolerable	O
concomitant	O
chemotherapy	O
and	O
hyperfractionated	O
radiation	O
regimen	O
that	O
induces	O
sustained	O
local	O
tumor	O
control	O
and	O
holds	O
promise	O
for	O
improved	O
survival	O
with	O
organ	O
preservation	O
in	O
high-risk	O
patients	O
.	O
	
Identification	O
of	O
less	O
toxic	O
therapy	O
and	O
improved	O
distant	O
disease	O
control	O
are	O
needed	O
.	O
	
T-FH2X	O
should	O
be	O
tested	O
in	O
a	O
randomized	O
trial	O
and	O
compared	O
with	O
a	O
less	O
intensive	O
concomitant	O
regimen	O
that	O
uses	O
once-daily	O
radiation	O
fractionation	O
.	O
	
Oxaliplatin	B-DRUG
plus	O
raltitrexed	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
:	O
results	O
of	O
a	O
Phase	O
I-II	O
trial	O
.	O
	
	
Oxaliplatin	B-DRUG
and	O
raltitrexed	B-DRUG
both	O
are	O
active	O
anticancer	O
agents	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
:	O
They	O
have	O
different	O
mechanisms	O
of	O
action	O
and	O
toxicity	O
profiles	O
and	O
have	O
shown	O
at	O
least	O
additive	O
effects	O
in	O
experimental	O
and	O
preliminary	O
clinical	O
studies	O
.	O
	
The	O
aim	O
of	O
this	O
disease	O
oriented	O
Phase	O
I-II	O
study	O
was	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
the	O
dose-limiting	O
toxicities	O
(	O
DLT	O
)	O
","	O
and	O
the	O
objective	O
response	O
rate	O
of	O
this	O
combination	O
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
.	O
	
Between	O
April	O
1998	O
and	O
March	O
1999	O
","	O
69	O
patients	O
with	O
measurable	O
metastatic	B-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
who	O
previously	O
were	O
unexposed	O
to	O
palliative	O
chemotherapy	O
were	O
enrolled	O
.	O
	
In	O
the	O
Phase	O
I	O
part	O
of	O
the	O
study	O
","	O
27	O
patients	O
were	O
treated	O
with	O
3-weekly	O
courses	O
of	O
a	O
fixed	O
dose	O
of	O
raltitrexed	B-DRUG
(	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
as	O
a	O
15-minute	O
intravenous	O
infusion	O
)	O
followed	O
by	O
a	O
2-hour	O
infusion	O
of	O
oxaliplatin	B-DRUG
","	O
which	O
was	O
escalated	O
in	O
consecutive	O
cohorts	O
of	O
three	O
to	O
six	O
patients	O
from	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
to	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
130	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
and	O
140	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
After	O
having	O
defined	O
the	O
toxic	O
dose	O
","	O
42	O
additional	O
patients	O
were	O
entered	O
at	O
one	O
dose	O
level	O
below	O
to	O
define	O
the	O
therapeutic	O
index	O
of	O
this	O
combination	O
more	O
precisely	O
.	O
	
In	O
the	O
Phase	O
I	O
part	O
of	O
the	O
study	O
","	O
during	O
the	O
first	O
three	O
dose	O
levels	O
","	O
only	O
one	O
patient	O
each	O
experienced	O
DLT	O
(	O
Grade	O
3	O
increase	B-TOXI
in	I-TOXI
transaminases	I-TOXI
","	O
diarrhea	B-TOXI
","	O
and	O
stomatitis	B-TOXI
)	O
;	O
at	O
level	O
4	O
","	O
two	O
of	O
the	O
first	O
six	O
patients	O
entered	O
had	O
Grade	O
3	O
neutropenic	B-TOXI
infection	I-TOXI
or	O
peripheral	B-TOXI
neurotoxicity	I-TOXI
","	O
whereas	O
dose	O
level	O
5	O
(	O
oxaliplatin	B-DRUG
140	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
constituted	O
the	O
toxic	O
dose	O
with	O
three	O
of	O
three	O
patients	O
experiencing	O
DLT	O
(	O
Grade	O
3	O
asthenia	B-TOXI
","	O
transient	B-TOXI
amaurosis	I-TOXI
","	O
and	O
diarrhea	B-TOXI
with	O
Grade	O
4	O
neutropenia	B-TOXI
)	O
.	O
	
Externally	O
reviewed	O
objective	O
responses	O
were	O
noted	O
in	O
9	O
of	O
these	O
27	O
patients	O
(	O
33	O
%	O
)	O
","	O
and	O
stable	O
disease	O
occurred	O
in	O
12	O
patients	O
(	O
44.4	O
%	O
)	O
.	O
	
Among	O
the	O
42	O
patients	O
who	O
were	O
treated	O
subsequently	O
at	O
the	O
MTD	O
level	O
(	O
Phase	O
II	O
portion	O
)	O
","	O
20	O
patients	O
(	O
47.6	O
%	O
)	O
responded	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
32-62.6	O
%	O
)	O
","	O
and	O
21	O
patients	O
(	O
50	O
%	O
)	O
had	O
stable	O
disease	O
.	O
	
Their	O
median	O
progression	O
free	O
survival	O
was	O
9	O
months	O
","	O
and	O
the	O
median	O
overall	O
survival	O
","	O
with	O
42	O
patients	O
(	O
67	O
%	O
)	O
currently	O
alive	O
","	O
is	O
&	O
gt	O
;	O
14.5	O
months	O
.	O
	
Treatment	O
tolerance	O
at	O
the	O
MTD	O
was	O
acceptable	O
","	O
with	O
only	O
9	O
of	O
42	O
patients	O
(	O
21	O
%	O
)	O
experiencing	O
Grade	O
3月4日	O
neutropenia	B-TOXI
;	O
Grade	O
3	O
nonhematologic	B-TOXI
adverse	I-TOXI
reactions	I-TOXI
included	O
increase	B-TOXI
in	I-TOXI
serum	I-TOXI
transaminases	I-TOXI
in	O
6	O
patients	O
","	O
peripheral	B-TOXI
neuropathy	I-TOXI
in	O
3	O
patients	O
","	O
diarrhea	B-TOXI
in	O
3	O
patients	O
","	O
and	O
both	O
stomatitis	B-TOXI
and	O
emesis	B-TOXI
in	O
only	O
1	O
patient	O
each	O
.	O
	
The	O
described	O
objective	O
response	O
and	O
toxicity	O
data	O
","	O
which	O
are	O
in	O
agreement	O
with	O
preliminary	O
results	O
of	O
other	O
Phase	O
I-II	O
studies	O
","	O
support	O
the	O
promising	O
therapeutic	O
potential	O
of	O
this	O
combination	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
.	O
	
Due	O
to	O
its	O
substantial	O
antitumor	O
activity	O
","	O
tolerance	O
(	O
at	O
the	O
recommended	O
MTD	O
level	O
)	O
","	O
and	O
convenient	O
3-weekly	O
outpatient	O
administration	O
schedule	O
","	O
further	O
evaluation	O
of	O
this	O
regimen	O
seems	O
warranted	O
.	O
	
Effect	O
of	O
food	O
on	O
the	O
oral	O
bioavailability	O
of	O
UFT	B-DRUG
and	O
leucovorin	B-DRUG
in	O
cancer	O
patients	O
.	O
	
	
UFT	B-DRUG
is	O
composed	O
of	O
tegafur	B-DRUG
(	O
FT	B-DRUG
)	O
","	O
a	O
prodrug	O
of	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
and	O
uracil	B-DRUG
in	O
a	O
fixed	O
combination	O
(	O
01:04	O
)	O
.	O
	
In	O
conjunction	O
with	O
leucovorin	B-DRUG
","	O
UFT	B-DRUG
is	O
being	O
developed	O
for	O
the	O
first-line	O
oral	O
treatment	O
of	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
The	O
effect	O
of	O
food	O
on	O
the	O
oral	O
bioavailability	O
of	O
UFT	B-DRUG
(	O
2	O
x	O
100	O
mg	O
capsules	O
;	O
dose	O
in	O
terms	O
of	O
FT	B-DRUG
)	O
and	O
leucovorin	B-DRUG
(	O
2	O
x	O
15	O
mg	O
tablets	O
)	O
was	O
evaluated	O
in	O
a	O
single-dose	O
","	O
randomized	O
","	O
two-way	O
crossover	O
study	O
.	O
	
Patients	O
(	O
n	O
=	O
25	O
)	O
were	O
assigned	O
to	O
receive	O
both	O
drugs	O
after	O
an	O
overnight	O
fast	O
or	O
5	O
min	O
after	O
completion	O
of	O
a	O
high-fat	O
meal	O
(	O
721	O
calories	O
)	O
with	O
a	O
3-day	O
washout	O
period	O
between	O
treatments	O
;	O
then	O
they	O
were	O
permitted	O
to	O
continue	O
on	O
oral	O
UFT	B-DRUG
/	O
leucovorin	B-DRUG
therapy	O
for	O
safety	O
assessment	O
.	O
	
UFT	B-DRUG
(	O
300	O
mg	O
/	O
m2	O
/	O
day	O
as	O
three	O
divided	O
doses	O
)	O
and	O
leucovorin	B-DRUG
(	O
90	O
mg	O
/	O
day	O
as	O
three	O
divided	O
doses	O
)	O
were	O
given	O
for	O
28	O
days	O
.	O
	
After	O
a	O
7-day	O
rest	O
","	O
the	O
28-day	O
cycle	O
was	O
repeated	O
.	O
	
Pharmacokinetics	O
(	O
n	O
=	O
22	O
patients	O
)	O
were	O
determined	O
for	O
FT	B-DRUG
","	O
5-FU	B-DRUG
","	O
uracil	B-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
5-methyltetrahydrofolate	B-DRUG
(	O
an	O
active	O
metabolite	O
of	O
leucovorin	B-DRUG
)	O
.	O
	
The	O
absence	O
of	O
food-effect	O
on	O
peak	O
plasma	O
concentration	O
(	O
CMAX	O
)	O
and	O
the	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
was	O
concluded	O
if	O
the	O
90	O
%	O
confidence	O
interval	O
for	O
the	O
ratio	O
of	O
the	O
treatment	O
means	O
was	O
entirely	O
contained	O
in	O
0.75-1.33	O
.	O
	
Administration	O
of	O
UFT	B-DRUG
with	O
food	O
resulted	O
in	O
a	O
34	O
%	O
decrease	O
in	O
CMAX	O
of	O
FT	B-DRUG
","	O
whereas	O
the	O
AUC	O
of	O
FT	B-DRUG
remained	O
unchanged	O
.	O
	
Food	O
decreased	O
the	O
CMAX	O
and	O
AUC	O
values	O
of	O
uracil	O
and	O
5-FU	B-DRUG
by	O
37-76	O
%	O
.	O
	
On	O
the	O
contrary	O
","	O
the	O
CMAX	O
and	O
AUC	O
values	O
of	O
leucovorin	B-DRUG
and	O
5-methyltetrahydrofolate	B-DRUG
were	O
increased	O
by	O
14-60	O
%	O
with	O
food	O
.	O
	
Time	O
to	O
reach	O
CMAX	O
for	O
all	O
analytes	O
was	O
significantly	O
(	O
P	O
&	O
lt	O
;	O
or	O
=	O
0.001	O
)	O
delayed	O
by	O
food	O
.	O
	
Except	O
for	O
the	O
AUCs	O
of	O
FT	B-DRUG
","	O
the	O
statistical	O
criterion	O
for	O
concluding	O
a	O
lack	O
of	O
food-effect	O
was	O
not	O
met	O
.	O
	
These	O
data	O
suggest	O
that	O
UFT	B-DRUG
/	O
leucovorin	B-DRUG
should	O
not	O
be	O
dosed	O
simultaneously	O
with	O
food	O
.	O
	
It	O
is	O
recommended	O
that	O
food	O
should	O
not	O
be	O
consumed	O
for	O
1	O
h	O
before	O
and	O
after	O
an	O
oral	O
dose	O
of	O
UFT	B-DRUG
and	O
leucovorin	B-DRUG
in	O
a	O
manner	O
similar	O
to	O
pivotal	O
Phase	O
III	O
trials	O
.	O
	
The	O
28-day	O
oral	O
regimen	O
of	O
UFT	B-DRUG
and	O
leucovorin	B-DRUG
was	O
generally	O
well	O
tolerated	O
in	O
the	O
population	O
studied	O
.	O
	
5-fluorouracil	B-DRUG
modulated	O
by	O
leucovorin	B-DRUG
","	O
methotrexate	B-DRUG
and	O
mitomycin	B-DRUG
:	O
highly	O
effective	O
","	O
low-cost	O
chemotherapy	O
for	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
We	O
have	O
reported	O
that	O
an	O
alternating	O
regimen	O
of	O
bolus	O
and	O
continuous	O
infusion	O
5-fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
was	O
superior	O
to	O
bolus	O
FU	B-DRUG
in	O
terms	O
of	O
response	O
rate	O
and	O
progression-free	O
survival	O
in	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Biochemical	O
modulation	O
was	O
an	O
essential	O
part	O
of	O
this	O
regimen	O
and	O
it	O
was	O
selective	O
for	O
the	O
schedule	O
of	O
FU	B-DRUG
administration	O
:	O
bolus	O
FU	B-DRUG
was	O
in	O
fact	O
modulated	O
by	O
methotrexate	B-DRUG
(	O
MTX	B-DRUG
)	O
while	O
continuous	O
infusion	O
FU	B-DRUG
was	O
potentiated	O
by	O
6-s-leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
.	O
	
Considering	O
the	O
low	O
cost	O
and	O
the	O
favourable	O
report	O
on	O
the	O
activity	O
of	O
mitomycin	B-DRUG
C	I-DRUG
(	O
mito	O
)	O
added	O
to	O
CI	O
FU	B-DRUG
","	O
we	O
have	O
incorporated	O
this	O
agent	O
in	O
the	O
infusional	O
part	O
of	O
our	O
treatment	O
programme	O
.	O
	
105	O
patients	O
with	O
untreated	O
","	O
advanced	O
","	O
measurable	O
colorectal	B-CANCER
cancer	I-CANCER
were	O
accrued	O
from	O
13	O
Italian	O
centres	O
and	O
treated	O
with	O
the	O
following	O
regimen	O
.	O
	
2	O
biweekly	O
cycles	O
of	O
FU	B-DRUG
bolus	O
(	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
modulated	O
by	O
MTX	B-DRUG
(	O
24	O
h	O
earlier	O
","	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
were	O
alternated	O
with	O
a	O
3-week	O
continuous	O
infusion	O
of	O
FU	B-DRUG
(	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
daily	O
)	O
","	O
modulated	O
by	O
LV	B-DRUG
(	O
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
bolus	O
)	O
.	O
	
Mito	B-DRUG
","	O
7	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
was	O
given	O
on	O
the	O
first	O
day	O
of	O
the	O
infusional	O
period	O
.	O
	
After	O
a	O
1	O
week	O
rest	O
","	O
the	O
whole	O
cycle	O
(	O
8	O
weeks	O
)	O
was	O
repeated	O
","	O
if	O
indicated	O
.	O
	
5	O
complete	O
and	O
34	O
partial	O
responses	O
were	O
obtained	O
(	O
response	O
rate	O
","	O
37	O
%	O
on	O
the	O
intention	O
to	O
treat	O
basis	O
;	O
95	O
%	O
confidence	O
limits	O
","	O
28-46	O
%	O
)	O
.	O
	
After	O
a	O
median	O
follow-up	O
time	O
of	O
26	O
months	O
","	O
37	O
patients	O
are	O
still	O
alive	O
.	O
	
The	O
median	O
progression-free	O
survival	O
is	O
7.7	O
months	O
with	O
an	O
overall	O
survival	O
of	O
18.8	O
months	O
and	O
a	O
2-year	O
survival	O
rate	O
of	O
30	O
%	O
.	O
	
The	O
regimen	O
was	O
very	O
well	O
tolerated	O
with	O
fewer	O
than	O
13	O
%	O
of	O
patients	O
experiencing	O
WHO	O
grade	O
III-IV	O
toxicity	O
.	O
	
These	O
results	O
are	O
consistent	O
with	O
those	O
obtained	O
by	O
our	O
group	O
in	O
3	O
previous	O
trials	O
of	O
schedule	O
specific	O
biochemical	O
modulation	O
of	O
FU	B-DRUG
.	O
	
They	O
also	O
indicate	O
a	O
highly	O
active	O
","	O
little	O
toxic	O
","	O
inexpensive	O
regimen	O
of	O
old	O
drugs	O
to	O
be	O
used	O
(	O
a	O
)	O
as	O
an	O
alternative	O
to	O
the	O
more	O
expensive	O
combinations	O
including	O
CPT-11	B-DRUG
or	O
oxaliplatin	B-DRUG
or	O
(	O
b	O
)	O
as	O
the	O
basis	O
for	O
combination	O
programmes	O
with	O
these	O
agents	O
.	O
	
Phase	O
I	O
study	O
of	O
gemcitabine	B-DRUG
and	O
carboplatin	B-DRUG
in	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
carcinoma	I-CANCER
.	O
	
	
This	O
phase	O
I	O
study	O
was	O
designed	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
of	O
carboplatin	B-DRUG
with	O
a	O
fixed	O
dose	O
of	O
gemcitabine	B-DRUG
without	O
growth	B-DRUG
factor	I-DRUG
or	O
hematopoietic	B-DRUG
precursor	I-DRUG
support	O
.	O
	
Nineteen	O
patients	O
with	O
previously	O
untreated	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
were	O
treated	O
at	O
three	O
dose	O
levels	O
.	O
	
Initially	O
","	O
the	O
gemcitabine	B-DRUG
dose	O
was	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
on	O
days	O
1	O
and	O
8	O
Of	O
the	O
first	O
five	O
patients	O
treated	O
with	O
carboplatin	B-DRUG
AUC	O
4	O
","	O
three	O
experienced	O
dose	O
limiting	O
toxicity	O
(	O
DLT	O
)	O
.	O
	
The	O
study	O
was	O
","	O
therefore	O
","	O
amended	O
to	O
decrease	O
the	O
dose	O
of	O
gemcitabine	B-DRUG
to	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
on	O
days	O
1	O
and	O
8	O
in	O
a	O
21-day	O
cycle	O
.	O
	
Dose	O
limiting	O
toxicity	O
(	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
)	O
were	O
seen	O
at	O
dose	O
level	O
2A	O
(	O
carboplatin	B-DRUG
AUC=5	O
)	O
.	O
	
Thus	O
","	O
no	O
further	O
dose	O
escalation	O
was	O
performed	O
.	O
	
Grade	O
3	O
and	O
4	O
toxicities	O
were	O
seen	O
as	O
follows	O
:	O
leukopenia	B-TOXI
in	O
five	O
of	O
18	O
(	O
28	O
%	O
)	O
;	O
neutropenia	B-TOXI
","	O
four	O
of	O
18	O
(	O
22	O
%	O
)	O
;	O
and	O
thrombocytopenia	B-TOXI
","	O
four	O
of	O
18	O
(	O
22	O
%	O
)	O
evaluable	O
patients	O
.	O
	
Grade	O
3	O
or	O
4	O
anemia	B-TOXI
occurred	O
in	O
one	O
of	O
18	O
(	O
6	O
%	O
)	O
patients	O
and	O
no	O
neutropenic	B-TOXI
fever	I-TOXI
or	O
treatment	O
related	O
mortality	O
was	O
observed	O
.	O
	
Partial	O
responses	O
were	O
seen	O
in	O
six	O
patients	O
and	O
one	O
patient	O
with	O
evaluable	O
disease	O
had	O
an	O
objective	O
response	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
37	O
%	O
(	O
seven	O
of	O
19	O
)	O
.	O
	
Six	O
other	O
patients	O
had	O
stable	O
disease	O
.	O
	
A	O
total	O
of	O
89	O
courses	O
were	O
administered	O
with	O
a	O
median	O
of	O
five	O
courses	O
per	O
patient	O
(	O
range	O
:	O
two	O
to	O
six	O
courses	O
)	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
for	O
all	O
patients	O
was	O
3.7	O
months	O
.	O
	
The	O
median	O
overall	O
survival	O
was	O
7.4	O
months	O
with	O
four	O
patients	O
still	O
alive	O
(	O
median	O
follow	O
up	O
13.5	O
months	O
)	O
.	O
	
The	O
survival	O
at	O
6	O
months	O
and	O
1	O
year	O
is	O
64	O
and	O
23	O
%	O
","	O
respectively	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
in	O
this	O
group	O
of	O
patients	O
was	O
defined	O
as	O
carboplatin	B-DRUG
AUC	O
4	O
when	O
administered	O
with	O
gemcitabine	B-DRUG
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
and	O
8	O
of	O
a	O
21-day	O
schedule	O
.	O
	
Addition	O
of	O
oxaliplatin	B-DRUG
to	O
continuous	O
fluorouracil	B-DRUG
","	O
l-folinic	B-DRUG
acid	I-DRUG
","	O
and	O
concomitant	O
radiotherapy	O
in	O
rectal	B-CANCER
cancer	I-CANCER
:	O
the	O
Lyon	O
R	O
Mar-97	O
phase	O
I	O
trial	O
.	O
	
	
Oxaliplatin	B-DRUG
could	O
increase	O
the	O
efficacy	O
of	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
/	O
folinic	B-DRUG
acid	I-DRUG
chemoradiotherapy	O
in	O
rectal	B-CANCER
cancer	I-CANCER
.	O
	
We	O
tested	O
three	O
dose	O
levels	O
to	O
identify	O
a	O
feasible	O
oxaliplatin	B-DRUG
dose	O
for	O
combination	O
therapy	O
.	O
	
Between	O
February	O
1998	O
and	O
April	O
2000	O
","	O
we	O
included	O
17	O
rectal	B-CANCER
adenocarcinoma	I-CANCER
patients	O
in	O
a	O
single-center	O
phase	O
I	O
study	O
.	O
	
Patients	O
had	O
T4	O
rectal	B-CANCER
carcinoma	I-CANCER
","	O
T1-T3	O
disease	O
with	O
colostomy	O
refusal	O
","	O
or	O
potentially	O
operable	O
T2	O
/	O
T3	O
M1	O
requiring	O
local	O
treatment	O
.	O
	
Pelvic	O
radiotherapy	O
was	O
45	O
Gy	O
over	O
5	O
weeks	O
","	O
1.8	O
Gy	O
/	O
fraction	O
","	O
with	O
concomitant	O
chemotherapy	O
weeks	O
1	O
and	O
5	O
Chemotherapy	O
was	O
oxaliplatin	B-DRUG
80	O
","	O
100	O
","	O
or	O
130	O
mg	O
/	O
m2	O
2-hour	O
infusion	O
on	O
day	O
1	O
followed	O
by	O
L-folinic	B-DRUG
acid	I-DRUG
100	O
mg	O
/	O
m2	O
/	O
d	O
intravenous	O
bolus	O
","	O
and	O
5-FU	B-DRUG
350	O
mg	O
/	O
m2	O
/	O
d	O
continuous	O
infusion	O
on	O
days	O
1	O
to	O
5	O
(	O
FolfoR1	O
)	O
.	O
	
Six	O
patients	O
refusing	O
surgery	O
received	O
additional	O
contact	O
radiotherapy	O
=+	O
/	O
=-	O
brachytherapy	O
.	O
	
Dose	O
escalation	O
proceeded	O
if	O
less	O
than	O
two	O
of	O
six	O
patients	O
had	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
at	O
a	O
given	O
dose-level	O
.	O
	
All	O
except	O
two	O
patients	O
completed	O
treatment	O
;	O
patients	O
at	O
level	O
1	O
(	O
prolonged	O
grade	O
1	O
thrombocytopenia	B-TOXI
)	O
and	O
level	O
3	O
(	O
prolonged	O
cold-related	B-TOXI
dysesthesia	I-TOXI
)	O
had	O
no	O
second	O
chemotherapy	O
course	O
.	O
	
Median	O
follow-up	O
is	O
14	O
months	O
(	O
range	O
","	O
2	O
to	O
28	O
months	O
)	O
.	O
	
One	O
elderly	O
patient	O
at	O
dose	O
level	O
1	O
had	O
DLT	O
asthenia	B-TOXI
","	O
severe	B-TOXI
diarrhea	I-TOXI
and	O
vomiting	B-TOXI
","	O
and	O
more	O
than	O
10	O
%	O
weight	B-TOXI
loss	I-TOXI
.	O
	
There	O
were	O
no	O
other	O
DLTs	O
and	O
no	O
severe	O
rectitis	B-TOXI
or	O
gastrointestinal	B-TOXI
toxicity	I-TOXI
.	O
	
There	O
were	O
objective	O
responses	O
at	O
all	O
doses	O
and	O
no	O
progressions	O
.	O
	
Eight	O
patients	O
underwent	O
radical	O
surgery	O
after	O
chemoradiotherapy	O
.	O
	
Two	O
had	O
complete	O
pathologic	O
responses	O
.	O
	
FolfoR1	O
seems	O
feasible	O
and	O
effective	O
.	O
	
Dose	O
escalation	O
did	O
not	O
increase	O
toxicity	O
.	O
	
Although	O
the	O
MTD	O
was	O
not	O
reached	O
in	O
this	O
study	O
","	O
we	O
recommend	O
oxaliplatin	B-DRUG
130	O
mg	O
/	O
m2	O
for	O
phase	O
II	O
studies	O
because	O
it	O
is	O
the	O
dose	O
determined	O
from	O
studies	O
in	O
metastatic	O
patients	O
with	O
no	O
toxicity	O
when	O
given	O
concurrently	O
with	O
radiation	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
a	O
fixed	O
dose	O
of	O
cisplatin	B-DRUG
with	O
increasing	O
doses	O
of	O
raltitrexed	B-DRUG
(	O
Tomudex	B-DRUG
)	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
locally	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
	
A	O
phase	O
I	O
trial	O
of	O
raltitrexed	B-DRUG
in	O
combination	O
with	O
cisplatin	B-DRUG
in	O
patients	O
with	O
locally	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	O
SCCHN	B-CANCER
)	O
.	O
	
Eligible	O
patients	O
had	O
locally	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
SCCHN	I-CANCER
.	O
	
Cohorts	O
of	O
patients	O
were	O
treated	O
with	O
escalating	O
doses	O
of	O
raltitrexed	B-DRUG
(	O
2	O
mg	O
/	O
m2	O
to	O
3.5	O
mg	O
/	O
m2	O
)	O
as	O
a	O
15-minute	O
intravenous	O
infusion	O
immediately	O
followed	O
by	O
cisplatin	B-DRUG
(	O
80	O
mg	O
/	O
m2	O
)	O
administered	O
over	O
four	O
hours	O
every	O
three	O
weeks	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
.	O
	
A	O
total	O
of	O
17	O
patients	O
was	O
administered	O
60	O
courses	O
of	O
an	O
escalating	O
dose	O
of	O
raltitrexed	B-DRUG
.	O
	
Starting	O
dose	O
of	O
cisplatin	B-DRUG
was	O
initially	O
100	O
mg	O
/	O
m2	O
in	O
the	O
first	O
three	O
patients	O
treated	O
at	O
the	O
first	O
dose	O
level	O
.	O
	
Due	O
to	O
cisplatin-induced	B-DRUG
nephrotoxicity	B-TOXI
expressed	O
as	O
a	O
creatinine	B-DRUG
clearance	O
decrease	O
by	O
more	O
than	O
50	O
%	O
","	O
the	O
cisplatin	B-DRUG
dose	O
was	O
reduced	O
to	O
80	O
mg	O
/	O
m2	O
for	O
all	O
subsequent	O
treatment	O
cycles	O
.	O
	
Dose-limiting	O
toxicity	O
was	O
observed	O
at	O
raltitrexed	B-DRUG
dose	O
of	O
3.5	O
mg	O
/	O
m2	O
in	O
two	O
out	O
of	O
five	O
patients	O
.	O
	
Dose-limiting	O
grade	O
4	O
(	O
CTC	O
)	O
neutropenia	B-TOXI
","	O
grade	O
4	O
diarrhoea	B-TOXI
","	O
grade	O
3	O
lethargy	B-TOXI
and	O
elevation	O
of	O
transaminases	B-TOXI
and	I-TOXI
bilirubine	I-TOXI
was	O
seen	O
in	O
these	O
two	O
patients	O
.	O
	
One	O
patient	O
treated	O
at	O
the	O
level	O
of	O
the	O
MTD	O
","	O
died	B-TOXI
23	O
days	O
after	O
the	O
first	O
cycle	O
with	O
unresolved	O
gastro-intestinal	B-TOXI
toxicity	I-TOXI
.	O
	
In	O
all	O
other	O
dose	O
levels	O
toxicity	O
was	O
very	O
limited	O
.	O
	
The	O
recommended	O
dose	O
for	O
further	O
study	O
was	O
raltitrexed	B-DRUG
3	O
mg	O
/	O
m2	O
in	O
combination	O
with	O
cisplatin	B-DRUG
80	O
mg	O
/	O
m2	O
.	O
	
In	O
15	O
evaluable	O
patients	O
","	O
we	O
observed	O
9	O
WHO	O
objective	O
responses	O
(	O
1	O
complete	O
and	O
8	O
partial	O
)	O
.	O
	
At	O
the	O
recommended	O
dose	O
level	O
3	O
partial	O
responses	O
were	O
observed	O
in	O
five	O
evaluable	O
patients	O
.	O
	
The	O
regimen	O
of	O
raltitrexed	B-DRUG
3	O
mg	O
/	O
m2	O
followed	O
by	O
cisplatin	B-DRUG
80	O
mg	O
/	O
m2	O
on	O
day	O
1	O
","	O
every	O
three	O
weeks	O
has	O
manageable	O
toxicity	O
and	O
these	O
doses	O
are	O
recommended	O
for	O
phase	O
II	O
evaluation	O
.	O
	
Results	O
indicate	O
that	O
this	O
combination	O
is	O
active	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
locally	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
SCCHN	I-CANCER
.	O
	
Recently	O
","	O
a	O
phase	O
II	O
study	O
has	O
been	O
started	O
.	O
	
Randomized	O
phase	O
III	O
trial	O
of	O
high-dose-intensity	O
methotrexate	B-DRUG
","	O
vinblastine	B-DRUG
","	O
doxorubicin	B-DRUG
","	O
and	O
cisplatin	B-DRUG
(	O
MVAC	B-DRUG
)	O
chemotherapy	O
and	O
recombinant	O
human	O
granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
versus	O
classic	O
MVAC	B-DRUG
in	O
advanced	B-CANCER
urothelial	I-CANCER
tract	I-CANCER
tumors	I-CANCER
:	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Protocol	O
no.	O
30924	O
.	O
	
	
This	O
randomized	O
trial	O
evaluated	O
antitumor	O
activity	O
of	O
and	O
survival	O
asociated	O
with	O
high-dose-intensity	O
chemotherapy	O
with	O
methotrexate	B-DRUG
","	O
vinblastine	B-DRUG
","	O
doxorubicin	B-DRUG
","	O
and	O
cisplatin	B-DRUG
(	O
MVAC	B-DRUG
)	O
plus	O
granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
(	O
HD-MVAC	O
)	O
versus	O
MVAC	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
transitional-cell	I-CANCER
carcinoma	I-CANCER
(	O
TCC	B-CANCER
)	O
.	O
	
A	O
total	O
of	O
263	O
patients	O
with	O
metastatic	B-CANCER
or	I-CANCER
advanced	I-CANCER
TCC	I-CANCER
who	O
had	O
no	O
prior	O
chemotherapy	O
were	O
randomized	O
to	O
HD-MVAC	B-DRUG
(	O
2-week	O
cycles	O
)	O
or	O
MVAC	B-DRUG
(	O
4-week	O
cycles	O
)	O
.	O
	
Using	O
an	O
intent-to-treat	O
analysis	O
","	O
at	O
a	O
median	O
follow-up	O
of	O
38	O
months	O
","	O
on	O
the	O
HD-MVAC	B-DRUG
arm	O
there	O
were	O
28	O
complete	O
responses	O
(	O
CRs	O
)	O
(	O
21	O
%	O
)	O
and	O
55	O
partial	O
responses	O
(	O
PRs	O
)	O
(	O
41	O
%	O
)	O
","	O
for	O
an	O
overall	O
response	O
of	O
62	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
54	O
%	O
to	O
70	O
%	O
)	O
.	O
	
On	O
the	O
MVAC	B-DRUG
arm	O
","	O
there	O
were	O
12	O
CRs	O
(	O
9	O
%	O
)	O
and	O
53	O
PRs	O
(	O
41	O
%	O
)	O
","	O
for	O
an	O
overall	O
response	O
of	O
50	O
%	O
(	O
95	O
%	O
CI	O
","	O
42	O
%	O
to	O
59	O
%	O
)	O
.	O
	
The	O
P	O
value	O
for	O
the	O
difference	O
in	O
CR	O
rate	O
was.009	O
;	O
and	O
for	O
the	O
overall	O
response	O
","	O
it	O
was.06	O
.	O
	
There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
survival	O
(	O
P	O
0.122	O
)	O
or	O
time	O
to	O
progression	O
(	O
P	O
0.114	O
)	O
.	O
	
Progression-free	O
survival	O
was	O
significantly	O
better	O
with	O
HD-MVAC	B-DRUG
(	O
P=.037	O
;	O
hazard	O
ratio.75	O
;	O
95	O
%	O
CI.58	O
to.98	O
)	O
.	O
	
The	O
median	O
progression-free	O
survival	O
time	O
was	O
9.1	O
months	O
on	O
the	O
HD-MVAC	B-DRUG
arm	O
versus	O
8.2	O
months	O
on	O
the	O
MVAC	B-DRUG
arm	O
.	O
	
The	O
2-year	O
progression-free	O
survival	O
rate	O
was	O
24.7	O
%	O
for	O
HD-MVAC	B-DRUG
(	O
95	O
%	O
CI	O
","	O
17.1	O
%	O
to	O
32.3	O
%	O
)	O
versus	O
11.6	O
%	O
for	O
MVAC	B-DRUG
(	O
95	O
%	O
CI	O
","	O
5.9	O
%	O
to	O
17.4	O
%	O
)	O
.	O
	
With	O
HD-MVAC	B-DRUG
","	O
it	O
was	O
possible	O
to	O
deliver	O
twice	O
the	O
doses	O
of	O
cisplatin	B-DRUG
and	O
doxorubicin	B-DRUG
in	O
half	O
the	O
time	O
","	O
with	O
fewer	O
dose	O
delays	O
and	O
less	O
toxicity	O
.	O
	
Although	O
a	O
50	O
%	O
difference	O
in	O
median	O
overall	O
survival	O
was	O
not	O
detected	O
","	O
a	O
benefit	O
was	O
observed	O
in	O
progression-free	O
survival	O
","	O
CR	O
rates	O
","	O
and	O
overall	O
response	O
rates	O
with	O
HD-MVAC	B-DRUG
.	O
	
A	O
phase	O
II	O
study	O
of	O
sequential	O
5-fluorouracil	B-DRUG
","	O
epirubicin	B-DRUG
and	O
cyclophosphamide	B-DRUG
(	O
FEC	B-DRUG
)	O
and	O
paclitaxel	B-DRUG
in	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
Protocol	O
PV	O
BC	O
97	O
/	O
1	O
)	O
.	O
	
	
Sequential	O
administration	O
of	O
the	O
association	O
of	O
5-fluorouracil	B-DRUG
","	O
epirubicin	B-DRUG
and	O
cyclophosphamide	B-DRUG
(	O
FEC	B-DRUG
)	O
and	O
paclitaxel	B-DRUG
could	O
be	O
better	O
tolerated	O
than	O
the	O
association	O
of	O
an	O
anthracycline	B-DRUG
and	O
paclitaxel	B-DRUG
while	O
having	O
a	O
similar	O
antitumour	O
effect	O
.	O
	
69	O
patients	O
with	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
previously	O
untreated	O
with	O
anthracyclines	B-DRUG
or	O
paclitaxel	B-DRUG
entered	O
a	O
phase	O
II	O
multicentre	O
study	O
in	O
which	O
FEC	B-DRUG
was	O
followed	O
by	O
paclitaxel	B-DRUG
.	O
	
Both	O
regimens	O
were	O
administered	O
4	O
times	O
every	O
21	O
days	O
.	O
	
The	O
median	O
follow-up	O
is	O
20	O
months	O
and	O
38	O
/	O
69	O
patients	O
have	O
died	B-TOXI
.	O
	
Grade	O
III-IV	O
toxicity	O
was	O
acceptable	O
.	O
	
Leukopenia	B-TOXI
occurred	O
in	O
26	O
%	O
of	O
patients	O
","	O
thrombocytopenia	B-TOXI
in	O
2	O
%	O
and	O
anaemia	B-TOXI
in	O
4	O
%	O
.	O
	
One	O
patient	O
had	O
reversible	B-TOXI
heart	I-TOXI
failure	I-TOXI
during	O
FEC	B-DRUG
therapy	O
.	O
	
Peripheral	B-TOXI
neuropathy	I-TOXI
and	O
arthralgia-myalgia	B-TOXI
occurred	O
in	O
9	O
%	O
and	O
4	O
%	O
of	O
patients	O
","	O
respectively	O
and	O
one	O
patient	O
had	O
respiratory	B-TOXI
hypersensitivity	I-TOXI
during	O
paclitaxel	B-DRUG
treatment	O
.	O
	
9	O
patients	O
did	O
not	O
complete	O
therapy	O
because	O
of	O
:	O
treatment	O
refusal	O
(	O
n	O
=	O
1	O
)	O
","	O
cardiac	B-TOXI
toxicity	I-TOXI
(	O
n	O
=	O
1	O
)	O
","	O
early	B-TOXI
death	I-TOXI
during	O
FEC	B-DRUG
chemotherapy	O
(	O
n	O
=	O
1	O
)	O
","	O
major	O
protocol	O
violations	O
(	O
n	O
=	O
4	O
)	O
","	O
hypersensitivity	B-TOXI
reaction	I-TOXI
(	O
n	O
=	O
1	O
)	O
and	O
early	B-TOXI
death	I-TOXI
during	O
paclitaxel	B-DRUG
chemotherapy	O
(	O
n	O
=	O
1	O
)	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
65	O
%	O
(	O
95	O
%	O
CI	O
=	O
53-76	O
)	O
","	O
and	O
7	O
%	O
of	O
patients	O
had	O
stable	O
disease	O
.	O
	
Therapy	O
was	O
defined	O
as	O
having	O
failed	O
in	O
28	O
%	O
of	O
patients	O
because	O
they	O
were	O
not	O
evaluable	O
(	O
13	O
%	O
)	O
or	O
had	O
progressive	O
disease	O
(	O
15	O
%	O
)	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
and	O
survival	O
are	O
13.2	O
and	O
23.5	O
months	O
","	O
respectively	O
.	O
	
Sequential	O
FEC-paclitaxel	B-DRUG
is	O
a	O
suitable	O
strategy	O
for	O
patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
who	O
have	O
not	O
been	O
previously	O
treated	O
with	O
anthracyclines	B-DRUG
and	O
/	O
or	O
taxanes	B-DRUG
.	O
	
In	O
fact	O
","	O
it	O
avoids	O
major	O
haematologic	B-TOXI
toxicity	I-TOXI
and	O
has	O
a	O
good	O
antitumour	O
effect	O
.	O
	
Multicenter	O
phase	O
II	O
trial	O
of	O
paclitaxel	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
etoposide	B-DRUG
with	O
concurrent	O
radiation	O
for	O
limited-stage	B-CANCER
small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
investigate	O
the	O
feasibility	O
","	O
efficacy	O
","	O
and	O
safety	O
of	O
adding	O
paclitaxel	B-DRUG
to	O
cisplatin	B-DRUG
/	O
etoposide	B-DRUG
chemotherapy	O
and	O
concurrent	O
thoracic	O
radiotherapy	O
(	O
TRT	O
)	O
in	O
treatment	O
of	O
limited-stage	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
LD-SCLC	O
)	O
.	O
	
Patients	O
received	O
five	O
courses	O
of	O
chemotherapy	O
(	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m2	O
1-hour	O
intravenous	O
[	O
IV	O
]	O
infusion	O
day	O
1	O
;	O
cisplatin	B-DRUG
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
day	O
1	O
;	O
etoposide	B-DRUG
100	O
mg	O
/	O
m2	O
IV	O
day	O
1	O
;	O
oral	B-DRUG
etoposide	I-DRUG
100	O
mg	O
bid	O
days	O
2	O
to	O
5	O
)	O
at	O
3-week	O
intervals	O
.	O
	
TRT	O
(	O
42	O
Gy	O
administered	O
in	O
15	O
fractions	O
)	O
was	O
administered	O
concurrent	O
with	O
chemotherapy	O
cycle	O
3	O
All	O
patients	O
were	O
evaluated	O
before	O
starting	O
TRT	O
and	O
4	O
weeks	O
after	O
termination	O
of	O
chemotherapy	O
.	O
	
Patients	O
achieving	O
complete	O
remission	O
(	O
CR	O
)	O
were	O
administered	O
prophylactic	O
cranial	O
irradiation	O
.	O
	
Thirty-nine	O
patients	O
were	O
included	O
","	O
and	O
the	O
median	O
age	O
was	O
63	O
years	O
.	O
	
The	O
median	O
follow-up	O
was	O
36	O
months	O
(	O
range	O
","	O
19	O
to	O
57	O
months	O
)	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
92	O
%	O
(	O
CR	O
","	O
81	O
%	O
;	O
partial	O
response	O
","	O
11	O
%	O
)	O
","	O
and	O
the	O
median	O
survival	O
was	O
21	O
months	O
.	O
	
The	O
-1	O
and	O
2-year	O
disease-specific	O
survival	O
rates	O
were	O
69	O
%	O
and	O
37	O
%	O
","	O
respectively	O
.	O
	
Of	O
29	O
CR	O
patients	O
","	O
83	O
%	O
have	O
relapsed	O
.	O
	
Brain	B-CANCER
metastasis	I-CANCER
was	O
as	O
frequent	O
as	O
local	O
recurrences	O
(	O
42	O
%	O
)	O
.	O
	
Hematologic	B-TOXI
toxicity	I-TOXI
included	O
grade	O
3	O
to	O
4	O
leukopenia	B-TOXI
in	O
74	O
%	O
of	O
patients	O
and	O
grade	O
3	O
thrombocytopenia	B-TOXI
in	O
10	O
%	O
.	O
	
One	O
treatment-related	O
death	B-TOXI
occurred	O
as	O
a	O
result	O
of	O
severe	B-TOXI
neutropenia	I-TOXI
and	O
septicemia	B-TOXI
.	O
	
Hematotoxicity	B-TOXI
caused	O
dose	O
reductions	O
in	O
31	O
%	O
of	O
courses	O
.	O
	
One	O
patient	O
had	O
an	O
anaphylactic	B-TOXI
reaction	I-TOXI
during	O
the	O
first	O
paclitaxel	B-DRUG
infusion	O
.	O
	
Paclitaxel-related	B-DRUG
neuropathy	B-TOXI
and	O
myalgia	B-TOXI
were	O
reversible	O
.	O
	
Grade	O
3	O
esophagitis	B-TOXI
was	O
seen	O
in	O
five	O
patients	O
during	O
and	O
shortly	O
after	O
TRT	O
.	O
	
This	O
novel	O
multimodal	O
regimen	O
is	O
effective	O
and	O
well	O
tolerated	O
in	O
patients	O
with	O
LD-SCLC	O
.	O
	
It	O
compares	O
favorably	O
with	O
previously	O
published	O
phase	O
II	O
studies	O
.	O
	
Dexamethasone	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
etoposide	B-DRUG
","	O
cyclophosphamide	B-DRUG
(	O
d-TEC	B-DRUG
)	O
and	O
G-CSF	B-DRUG
for	O
stem	B-CANCER
cell	I-CANCER
mobilisation	I-CANCER
in	I-CANCER
multiple	I-CANCER
myeloma	I-CANCER
.	O
	
	
Forty-one	O
patients	O
with	O
multiple	O
myeloma	B-CANCER
were	O
treated	O
with	O
a	O
novel	O
stem	O
cell	O
mobilisation	O
regimen	O
.	O
	
The	O
primary	O
end	O
points	O
were	O
adequate	O
stem	O
cell	O
mobilising	O
ability	O
(	O
&	O
gt	O
;	O
1	O
%	O
circulating	O
CD34-positive	O
cells	O
)	O
and	O
collection	O
(	O
&	O
gt	O
;	O
or	O
=	O
4	O
x	O
10	O
(	O
6	O
)	O
CD34-positive	O
cells	O
/	O
kg	O
)	O
","	O
and	O
safety	O
.	O
	
The	O
secondary	O
end	O
point	O
was	O
activity	O
against	O
myeloma	B-CANCER
.	O
	
The	O
regimen	O
(	O
d-TEC	B-DRUG
)	O
consisted	O
of	O
dexamethasone	B-DRUG
","	O
paclitaxel	B-DRUG
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
i.v.	O
","	O
etoposide	B-DRUG
60	O
mg	O
/	O
kg	O
i.v.	O
","	O
cyclophosphamide	B-DRUG
3	O
g	O
/	O
m	O
(	O
2	O
)	O
i.v.	O
","	O
and	O
G-CSF	B-DRUG
5月10日	O
microg	O
/	O
kg	O
/	O
day	O
i.v.	O
A	O
total	O
of	O
84	O
cycles	O
were	O
administered	O
to	O
these	O
41	O
individuals	O
.	O
	
Patient	O
characteristics	O
included	O
a	O
median	O
age	O
of	O
53	O
years	O
","	O
a	O
median	O
of	O
five	O
prior	O
chemotherapy	O
cycles	O
","	O
and	O
a	O
median	O
interval	O
of	O
10	O
months	O
from	O
diagnosis	O
of	O
myeloma	B-CANCER
to	O
first	O
cycle	O
of	O
d-TEC	B-DRUG
.	O
	
Seventy-five	O
percent	O
of	O
the	O
patients	O
had	O
stage	O
II	O
or	O
III	O
disease	O
","	O
50	O
%	O
had	O
received	O
carmustine	B-DRUG
and	O
/	O
or	O
melphalan	B-DRUG
previously	O
","	O
and	O
25	O
%	O
had	O
received	O
prior	O
radiation	O
therapy	O
.	O
	
Eighty-eight	O
percent	O
of	O
patients	O
mobilised	O
adequately	O
after	O
the	O
first	O
cycle	O
of	O
d-TEC	B-DRUG
and	O
91	O
%	O
mobilized	O
adequately	O
after	O
the	O
second	O
cycle	O
.	O
	
An	O
adequate	O
number	O
of	O
stem	O
cells	O
were	O
collected	O
in	O
32	O
patients	O
.	O
	
Of	O
the	O
remaining	O
nine	O
patients	O
","	O
three	O
mobilised	O
","	O
but	O
stem	O
cells	O
were	O
not	O
collected	O
","	O
two	O
mobilised	O
but	O
stem	O
cell	O
collection	O
was	O
&	O
lt	O
;	O
4	O
x	O
10	O
(	O
6	O
)	O
CD34-positive	O
cells	O
/	O
kg	O
","	O
three	O
did	O
not	O
mobilise	O
","	O
and	O
one	O
died	B-TOXI
of	O
disease	O
progression	O
.	O
	
Major	O
toxicities	O
included	O
pancytopenia	B-TOXI
","	O
alopecia	B-TOXI
","	O
fever	B-TOXI
and	O
stomatitis	B-TOXI
.	O
	
One	O
patient	O
died	B-TOXI
from	O
multi-organ	B-TOXI
failure	I-TOXI
and	O
progressive	O
disease	O
.	O
	
Fifty	O
percent	O
of	O
evaluable	O
patients	O
demonstrated	O
a	O
partial	O
response	O
and	O
28.6	O
%	O
of	O
patients	O
had	O
a	O
minor	O
response	O
.	O
	
This	O
novel	O
dose-intense	O
regimen	O
was	O
safe	O
","	O
capable	O
of	O
stem	O
cell	O
mobilisation	O
and	O
collection	O
","	O
even	O
in	O
heavily	O
pre-treated	O
patients	O
","	O
and	O
active	O
against	O
the	O
underlying	O
myeloma	B-CANCER
.	O
	
Multiple	O
cycles	O
of	O
dose-intensive	O
chemotherapy	O
with	O
repeated	O
stem	O
cell	O
support	O
as	O
induction	O
treatment	O
in	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
:	O
a	O
feasibility	O
study	O
.	O
	
	
The	O
purpose	O
of	O
this	O
trial	O
was	O
to	O
study	O
feasibility	O
and	O
tolerance	O
of	O
a	O
dose-intensive	O
multicyclic	O
alternating	O
induction	O
chemotherapy	O
with	O
repeated	O
stem	O
cell	O
support	O
in	O
a	O
series	O
of	O
43	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
patients	O
.	O
	
Anthracycline-naive	O
patients	O
(	O
n	O
=	O
21	O
)	O
received	O
cyclophosphamide	B-DRUG
2.5	O
g	O
/	O
m	O
(	O
2	O
)	O
plus	O
doxorubicin	B-DRUG
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
alternating	O
every	O
14	O
days	O
with	O
paclitaxel	B-DRUG
200-350	O
mg	O
/	O
m	O
(	O
2	O
)	O
plus	O
cisplatin	B-DRUG
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Patients	O
who	O
had	O
previously	O
received	O
anthracyclines	B-DRUG
(	O
n	O
=	O
22	O
)	O
received	O
cisplatin	B-DRUG
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
plus	O
etoposide	B-DRUG
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
alternating	O
with	O
paclitaxel	B-DRUG
200-350	O
mg	O
/	O
m	O
(	O
2	O
)	O
plus	O
ifosfamide	B-DRUG
8	O
g	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Peripheral	O
blood	O
stem	O
cells	O
were	O
infused	O
after	O
every	O
course	O
except	O
the	O
first	O
","	O
with	O
a	O
median	O
CD34	O
(	O
=+	O
)	O
dose	O
of	O
2.1	O
x	O
10	O
(	O
6	O
)	O
/	O
kg	O
per	O
cycle	O
.	O
	
Positive	O
selection	O
of	O
CD34	O
(	O
=+	O
)	O
cells	O
was	O
performed	O
in	O
good	O
mobilizers	O
.	O
	
The	O
median	O
number	O
of	O
cycles	O
administered	O
was	O
six	O
(	O
4月8日	O
)	O
","	O
and	O
the	O
time	O
interval	O
between	O
them	O
was	O
17	O
days	O
.	O
	
Median	O
summation	O
dose	O
intensities	O
(	O
SDI	O
)	O
actually	O
administered	O
for	O
the	O
CA-TP	B-DRUG
and	O
PE-TI	B-DRUG
protocol	O
were	O
4.95	O
and	O
4.69	O
","	O
respectively	O
(	O
87	O
%	O
of	O
scheduled	O
SDI	O
)	O
.	O
	
There	O
were	O
15	O
complete	O
(	O
35	O
%	O
)	O
and	O
21	O
partial	O
responses	O
(	O
49	O
%	O
)	O
","	O
for	O
an	O
overall	O
response	O
rate	O
of	O
84	O
%	O
(	O
95	O
%	O
CI	O
","	O
73	O
%	O
-95	O
%	O
)	O
.	O
	
Infection	B-TOXI
or	O
neutropenic	B-TOXI
fever	I-TOXI
occurred	O
in	O
50	O
%	O
of	O
the	O
cycles	O
.	O
	
There	O
was	O
one	O
treatment-related	O
death	B-TOXI
.	O
	
After	O
a	O
median	O
follow-up	O
of	O
26	O
months	O
","	O
the	O
median	O
event-free-survival	O
was	O
12	O
months	O
(	O
95	O
%	O
CI	O
:	O
10月14日	O
)	O
and	O
overall	O
survival	O
was	O
31	O
months	O
.	O
	
These	O
high	O
dose-intensity	O
induction	O
treatments	O
seem	O
to	O
be	O
feasible	O
with	O
sequential	O
stem	O
cell	O
support	O
.	O
	
Dose-finding	O
","	O
pharmacokinetic	O
and	O
phase	O
II	O
study	O
of	O
docetaxel	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
inoperable	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
good	O
efficacy-toxicity	O
ratio	O
of	O
both	O
docetaxel	B-DRUG
and	O
gemcitabine	B-DRUG
in	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
stimulates	O
the	O
investigation	O
of	O
the	O
combination	O
of	O
these	O
drugs	O
as	O
a	O
first	O
line	O
chemotherapy	O
.	O
	
This	O
two-step	O
study	O
firstly	O
aimed	O
at	O
determining	O
the	O
maximum	O
tolerated	O
and	O
recommended	O
doses	O
of	O
docetaxel	B-DRUG
given	O
every	O
3	O
weeks	O
in	O
combination	O
with	O
a	O
fixed	O
dose	O
of	O
gemcitabine	B-DRUG
;	O
the	O
phase	O
I	O
study	O
paid	O
particular	O
attention	O
to	O
pharmacokinetics	O
.	O
	
Afterwards	O
","	O
the	O
safety	O
and	O
efficacy	O
of	O
the	O
recommended	O
dose	O
was	O
carefully	O
assessed	O
in	O
the	O
phase	O
II-step	O
.	O
	
The	O
following	O
range	O
of	O
docetaxel	B-DRUG
dosages	O
were	O
tested	O
in	O
the	O
phase	O
I	O
study	O
;	O
60	O
","	O
75	O
","	O
85	O
","	O
and	O
100	O
mg	O
m	O
(	O
-2	O
)	O
given	O
on	O
day	O
8	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
1000	O
mg	O
m	O
(	O
-2	O
)	O
delivered	O
on	O
days	O
1	O
and	O
8	O
of	O
a	O
3-week	O
cycle	O
.	O
	
Haematopoietic	B-DRUG
growth	I-DRUG
factors	I-DRUG
were	O
not	O
allowed	O
.	O
	
The	O
treatment	O
was	O
delivered	O
on	O
an	O
outpatient	O
basis	O
.	O
	
Main	O
eligibility	O
criteria	O
consisted	O
of	O
stage	O
III	O
b	O
or	O
IV	O
histologically	O
proven	O
NSCLC	B-CANCER
","	O
Eastern	O
Co-operative	O
Oncology	O
Group	O
(	O
ECOG	O
)	O
performance	O
status	O
PS	O
&	O
lt	O
;	O
or	O
2	O
","	O
age	O
&	O
lt	O
;	O
or	O
70	O
years	O
","	O
measurable	O
disease	O
","	O
adequate	O
blood	O
counts	O
","	O
chemistry	O
","	O
and	O
no	O
symptomatic	O
brain	O
metastasis	O
.	O
	
Four	O
centres	O
enrolled	O
49	O
patients	O
(	O
eight	O
having	O
been	O
pre-treated	O
)	O
;	O
16	O
in	O
phase	O
I	O
and	O
33	O
in	O
phase	O
II	O
.	O
	
The	O
maximal	O
tolerated	O
dose	O
was	O
almost	O
reached	O
at	O
the	O
last	O
dose	O
level	O
(	O
i.e.	O
docetaxel	O
","	O
100	O
mg	O
m	O
(	O
-2	O
)	O
)	O
.	O
	
Consequently	O
","	O
we	O
considered	O
the	O
85	O
mg	O
m	O
(	O
-2	O
)	O
level	O
as	O
the	O
recommended	O
dose	O
.	O
	
There	O
was	O
a	O
positive	O
relationship	O
of	O
the	O
docetaxel	B-DRUG
dose	O
to	O
the	O
area	O
under	O
the	O
curve	O
of	O
this	O
drug	O
.	O
	
Toxicity	O
was	O
assessable	O
in	O
all	O
patients	O
.	O
	
Among	O
the	O
200	O
cycles	O
delivered	O
","	O
192	O
were	O
assessable	O
for	O
this	O
feature	O
.	O
	
Main	O
toxicity	O
was	O
grade	O
3月4日	O
neutropenia	B-TOXI
affecting	O
23	O
patients	O
(	O
47	O
%	O
of	O
the	O
population	O
;	O
23	O
%	O
of	O
the	O
cycles	O
)	O
.	O
	
Six	O
febrile	B-TOXI
episodes	I-TOXI
were	O
recorded	O
leading	O
to	O
two	O
treatment-related	O
deaths	B-TOXI
.	O
	
Another	O
patient	O
died	B-TOXI
from	O
congestive	B-TOXI
cardiac	I-TOXI
failure	I-TOXI
.	O
	
In	O
addition	O
","	O
six	O
patients	O
experienced	O
interstitial	B-TOXI
pneumonitis	I-TOXI
","	O
(	O
one	O
half	O
considered	O
as	O
severe	O
)	O
","	O
two	O
of	O
them	O
having	O
received	O
the	O
recommended	O
dose	O
.	O
	
All	O
patients	O
recovered	O
from	O
this	O
toxicity	O
after	O
corticosteroids	B-DRUG
.	O
	
Fourteen	O
patients	O
out	O
of	O
the	O
whole	O
population	O
(	O
29	O
%	O
;	O
95	O
%	O
CI	O
[	O
17-43	O
]	O
","	O
including	O
ten	O
patients	O
receiving	O
the	O
recommended	O
dose	O
)	O
","	O
achieved	O
an	O
objective	O
response	O
.	O
	
Median	O
follow-up	O
was	O
14	O
months	O
(	O
range	O
","	O
0.3-29.4	O
)	O
.	O
	
Median	O
survival	O
was	O
11.2	O
months	O
(	O
95	O
%	O
CI	O
[	O
8.3-13.2	O
]	O
)	O
","	O
and	O
the	O
1-year	O
survival	O
rate	O
was	O
45	O
%	O
.	O
	
Gemcitabine	B-DRUG
","	O
1000	O
mg	O
m	O
(	O
-2	O
)	O
days	O
1	O
and	O
8	O
in	O
combination	O
with	O
docetaxel	B-DRUG
","	O
85	O
mg	O
m	O
(	O
-2	O
)	O
","	O
day	O
8	O
","	O
given	O
every	O
3	O
weeks	O
could	O
be	O
considered	O
as	O
an	O
active	O
regimen	O
with	O
manageable	O
toxicities	O
in	O
locally	O
advanced	O
or	O
metastatic	B-CANCER
NSCLC	I-CANCER
.	O
	
This	O
study	O
deserves	O
further	O
comparisons	O
with	O
classical	O
platinum-based	B-DRUG
regimens	O
.	O
	
Phase	O
I	O
and	O
pharmacokinetic	O
study	O
of	O
two	O
sequences	O
of	O
gemcitabine	B-DRUG
and	O
docetaxel	B-DRUG
administered	O
weekly	O
to	O
patients	O
with	O
advanced	B-CANCER
cancer	I-CANCER
.	O
	
	
To	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
","	O
and	O
effect	O
of	O
drug	O
sequence	O
on	O
toxicities	O
and	O
pharmacokinetics	O
of	O
the	O
combination	O
of	O
gemcitabine	B-DRUG
and	O
docetaxel	B-DRUG
.	O
	
A	O
total	O
of	O
34	O
patients	O
with	O
advanced	B-CANCER
cancers	I-CANCER
were	O
treated	O
with	O
gemcitabine	B-DRUG
and	O
docetaxel	B-DRUG
on	O
days	O
1	O
and	O
8	O
of	O
each	O
21-day	O
cycle	O
according	O
to	O
the	O
following	O
dose	O
escalation	O
schedule	O
:	O
level	O
1	O
","	O
800	O
and	O
30	O
mg	O
/	O
m2	O
","	O
respectively	O
;	O
level	O
2	O
","	O
800	O
and	O
40	O
mg	O
/	O
m2	O
;	O
level	O
3	O
","	O
"1,000"	O
and	O
40	O
mg	O
/	O
m2	O
;	O
and	O
level	O
4	O
","	O
"1,250"	O
and	O
40	O
mg	O
/	O
m2	O
.	O
	
At	O
each	O
dose	O
level	O
","	O
at	O
least	O
three	O
patients	O
were	O
assigned	O
to	O
one	O
of	O
the	O
two	O
sequences	O
of	O
drug	O
administration	O
:	O
gemcitabine	B-DRUG
=--	O
&	O
gt	O
;	O
docetaxel	B-DRUG
or	O
docetaxel	B-DRUG
=--	O
&	O
gt	O
;	O
gemcitabine	B-DRUG
.	O
	
Once	O
the	O
MTD	O
had	O
been	O
reached	O
","	O
six	O
additional	O
patients	O
","	O
who	O
had	O
received	O
no	O
more	O
than	O
one	O
chemotherapy	O
regimen	O
","	O
were	O
enrolled	O
to	O
dose	O
levels	O
3	O
and	O
4	O
(	O
gemcitabine	B-DRUG
=--	O
&	O
gt	O
;	O
docetaxel	B-DRUG
)	O
to	O
determine	O
the	O
MTD	O
in	O
minimally	O
pretreated	O
patients	O
.	O
	
Neutropenia	B-TOXI
was	O
the	O
most	O
frequent	O
DLT	O
with	O
an	O
overall	O
incidence	O
of	O
23.5	O
%	O
.	O
	
Grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
occurred	O
in	O
62	O
%	O
of	O
patients	O
(	O
8	O
/	O
13	O
)	O
who	O
had	O
received	O
two	O
or	O
more	O
prior	O
chemotherapy	O
regimens	O
","	O
but	O
not	O
at	O
all	O
(	O
0	O
/	O
15	O
)	O
in	O
patients	O
who	O
had	O
received	O
no	O
more	O
than	O
one	O
prior	O
chemotherapy	O
regimens	O
(	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
.	O
	
Additional	O
DLTs	O
included	O
grade	O
4	O
diarrhea	B-TOXI
and	O
grade	O
4	O
stomatitis	B-TOXI
in	O
one	O
patient	O
each	O
.	O
	
The	O
MTD	O
was	O
determined	O
to	O
be	O
gemcitabine	B-DRUG
800	O
mg	O
/	O
m2	O
and	O
docetaxel	B-DRUG
40	O
mg	O
/	O
m2	O
in	O
patients	O
who	O
had	O
received	O
two	O
or	O
more	O
prior	O
chemotherapy	O
regimens	O
.	O
	
However	O
","	O
minimally	O
pretreated	O
patients	O
(	O
no	O
more	O
than	O
one	O
prior	O
chemotherapy	O
regimen	O
)	O
were	O
able	O
to	O
tolerate	O
higher	O
doses	O
with	O
an	O
MTD	O
of	O
gemcitabine	B-DRUG
"1,250"	O
mg	O
/	O
m2	O
and	O
docetaxel	B-DRUG
40	O
mg	O
/	O
m2	O
.	O
	
There	O
were	O
no	O
significant	O
differences	O
in	O
toxicities	O
or	O
pharmacokinetics	O
between	O
the	O
two	O
sequences	O
of	O
administration	O
.	O
	
Partial	O
and	O
minor	O
responses	O
were	O
observed	O
in	O
23.5	O
%	O
of	O
patients	O
:	O
non-small-cell	B-CANCER
lung	I-CANCER
(	O
two	O
of	O
eight	O
)	O
","	O
gastric	O
(	O
two	O
of	O
three	O
)	O
","	O
head	O
and	O
neck	O
(	O
one	O
of	O
two	O
)	O
","	O
bladder	O
(	O
two	O
of	O
four	O
)	O
and	O
hepatocellular	B-CANCER
cancer	I-CANCER
(	O
one	O
of	O
one	O
)	O
.	O
	
The	O
combination	O
of	O
gemcitabine	B-DRUG
and	O
docetaxel	B-DRUG
administered	O
on	O
days	O
1	O
and	O
8	O
every	O
21	O
days	O
was	O
feasible	O
and	O
well	O
tolerated	O
in	O
patients	O
with	O
advanced	B-CANCER
malignancies	I-CANCER
.	O
	
The	O
sequence	O
of	O
administration	O
had	O
no	O
significant	O
effect	O
on	O
the	O
toxicity	O
or	O
pharmacokinetics	O
of	O
either	O
drug	O
.	O
	
Minimally	O
pretreated	O
patients	O
tolerated	O
higher	O
doses	O
of	O
this	O
combination	O
without	O
significant	O
toxicities	O
.	O
	
This	O
schedule	O
and	O
combination	O
demonstrated	O
activity	O
in	O
a	O
variety	O
of	O
solid	B-CANCER
tumors	I-CANCER
","	O
and	O
merits	O
further	O
evaluation	O
.	O
	
Dose	O
and	O
schedule-finding	O
study	O
of	O
oral	O
topotecan	B-DRUG
and	O
weekly	O
cisplatin	B-DRUG
in	O
patients	O
with	O
recurrent	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
	
Both	O
weekly	O
cisplatin	B-DRUG
chemotherapy	O
and	O
single	O
agent	O
topotecan	B-DRUG
have	O
proven	O
to	O
be	O
effective	O
in	O
recurrent	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
Preclinical	O
data	O
show	O
synergism	O
between	O
cisplatin	B-DRUG
and	O
topotecan	B-DRUG
.	O
	
Side	O
effects	O
for	O
this	O
combination	O
are	O
drug	O
sequence	O
dependent	O
and	O
predominantly	O
haematologic	O
.	O
	
Since	O
preclinical	O
data	O
suggest	O
that	O
Cremophor	B-DRUG
EL	I-DRUG
(	O
CrEL	B-DRUG
)	O
","	O
the	O
formulation	O
vehicle	O
of	O
paclitaxel	B-DRUG
","	O
has	O
a	O
protective	O
effect	O
on	O
haematological	B-TOXI
toxicity	I-TOXI
of	O
cisplatin	B-DRUG
","	O
CrEL	B-DRUG
was	O
added	O
to	O
the	O
combination	O
cisplatin	B-DRUG
and	O
topotecan	B-DRUG
.	O
	
In	O
this	O
phase	O
I	O
study	O
","	O
escalating	O
doses	O
of	O
oral	O
topotecan	B-DRUG
administered	O
on	O
day	O
1	O
","	O
2	O
","	O
8	O
","	O
9	O
","	O
15	O
","	O
16	O
","	O
29	O
","	O
30	O
","	O
36	O
","	O
37	O
","	O
43	O
","	O
44	O
were	O
combined	O
with	O
weekly	O
cisplatin	B-DRUG
70	O
mg	O
m	O
(	O
-2	O
)	O
d	O
(	O
-1	O
)	O
on	O
day	O
1	O
","	O
8	O
","	O
15	O
","	O
29	O
","	O
36	O
","	O
43	O
(	O
scheme	O
A	O
)	O
or	O
with	O
the	O
presumably	O
less	O
myelotoxic	O
sequence	O
weekly	O
cisplatin	B-DRUG
day	O
2	O
","	O
9	O
","	O
16	O
","	O
30	O
","	O
37	O
","	O
44	O
(	O
scheme	O
B	O
)	O
.	O
	
In	O
scheme	O
C	O
","	O
CrEL	B-DRUG
12	O
ml	O
was	O
administered	O
prior	O
to	O
cisplatin	B-DRUG
in	O
the	O
sequence	O
of	O
Scheme	O
A.	O
18	O
patients	O
have	O
received	O
a	O
total	O
of	O
85	O
courses	O
.	O
	
In	O
scheme	O
A	O
4	O
/	O
10	O
patients	O
","	O
all	O
treated	O
with	O
topotecan	B-DRUG
0.45	O
mg	O
m	O
(	O
-2	O
)	O
d	O
(	O
-1	O
)	O
","	O
experienced	O
DLT	O
:	O
1	O
patient	O
had	O
vomiting	B-TOXI
grade	O
4	O
","	O
1	O
patient	O
had	O
grade	O
4	O
neutropenia	B-TOXI
&	O
gt	O
;	O
5	O
days	O
","	O
1	O
patient	O
had	O
&	O
gt	O
;	O
2	O
weeks	O
delay	O
due	O
to	O
thrombocytopenia	B-TOXI
and	O
1	O
patient	O
due	O
to	O
neutropenia	B-TOXI
.	O
	
Both	O
patients	O
in	O
scheme	O
B	O
(	O
topotecan	B-DRUG
0.45	O
mg	O
m	O
(	O
-2	O
)	O
d	O
(	O
-1	O
)	O
)	O
had	O
DLT	O
due	O
to	O
a	O
delay	O
&	O
gt	O
;	O
2	O
weeks	O
because	O
of	O
prolonged	O
haematological	B-TOXI
toxicity	I-TOXI
.	O
	
No	O
DLT	O
was	O
observed	O
in	O
the	O
first	O
3	O
patients	O
in	O
scheme	O
C	O
(	O
topotecan	B-DRUG
0.45	O
mg	O
m	O
(	O
-2	O
)	O
d	O
(	O
-1	O
)	O
)	O
.	O
	
However	O
","	O
2	O
out	O
of	O
3	O
patients	O
treated	O
at	O
dose	O
level	O
topotecan	B-DRUG
0.6	O
mg	O
m	O
(	O
-2	O
)	O
d	O
(	O
-1	O
)	O
in	O
scheme	O
C	O
experienced	O
DLT	O
due	O
to	O
&	O
gt	O
;	O
2	O
weeks	O
delay	O
because	O
of	O
persistent	O
thrombocytopenia	B-TOXI
or	O
neutropenia	B-TOXI
.	O
	
We	O
conclude	O
that	O
there	O
is	O
a	O
modest	O
clinical	O
effect	O
of	O
CrEL	B-DRUG
on	O
haematological	B-TOXI
toxicity	I-TOXI
for	O
this	O
cisplatin-based	B-DRUG
combination	O
regimen	O
","	O
which	O
seems	O
to	O
reduce	O
these	O
side	O
effects	O
but	O
does	O
not	O
really	O
enable	O
an	O
increase	O
of	O
the	O
oral	O
topotecan	B-DRUG
dose	O
.	O
	
Phase	O
I	O
study	O
to	O
evaluate	O
multiple	O
regimens	O
of	O
intravenous	O
5-fluorouracil	B-DRUG
administered	O
in	O
combination	O
with	O
weekly	O
gemcitabine	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
:	O
a	O
potential	O
broadly	O
active	O
regimen	O
for	O
advanced	B-CANCER
solid	I-CANCER
tumor	I-CANCER
malignancies	I-CANCER
.	O
	
	
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
and	O
toxicity	O
profile	O
of	O
gemcitabine	B-DRUG
given	O
on	O
a	O
weekly	O
schedule	O
with	O
continuous	O
infusion	O
5-fluorouracil	B-DRUG
.	O
	
Eligible	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
received	O
escalating	O
doses	O
of	O
gemcitabine	B-DRUG
200	O
and	O
300	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
as	O
a	O
30-minute	O
infusion	O
on	O
Days	O
1	O
","	O
8	O
","	O
and	O
15	O
every	O
4	O
weeks	O
(	O
schedule	O
1	O
)	O
or	O
450	O
","	O
600	O
","	O
800	O
","	O
1000	O
","	O
1250	O
","	O
1500	O
","	O
1800	O
","	O
and	O
2200	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
Days	O
1	O
and	O
8	O
(	O
schedule	O
2	O
)	O
every	O
3	O
weeks	O
","	O
respectively	O
.	O
	
At	O
the	O
completion	O
of	O
gemcitabine	B-DRUG
infusion	O
(	O
Day	O
1	O
)	O
","	O
patients	O
received	O
fixed	O
dose	O
continuous	O
infusion	O
of	O
5-fluorouracil	B-DRUG
at	O
either	O
300	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
Days	O
1月21日	O
)	O
or	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
Days	O
1月21日	O
;	O
schedule	O
1	O
)	O
every	O
4	O
weeks	O
or	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
Days	O
1月14日	O
;	O
schedule	O
2	O
]	O
every	O
3	O
weeks	O
","	O
respectively	O
.	O
	
Toxicity	O
assessments	O
were	O
performed	O
weekly	O
on	O
study	O
","	O
and	O
efficacy	O
measurements	O
were	O
performed	O
every	O
6月8日	O
weeks	O
.	O
	
Seventy	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
malignancies	I-CANCER
received	O
a	O
total	O
of	O
220	O
cycles	O
of	O
combination	O
chemotherapy	O
.	O
	
Eleven	O
(	O
14.3	O
%	O
)	O
patients	O
received	O
no	O
more	O
than	O
1	O
treatment	O
cycle	O
of	O
combination	O
therapy	O
.	O
	
Schedule	O
1	O
maximum	O
tolerated	O
dose	O
of	O
gemcitabine	B-DRUG
was	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
week	O
when	O
combined	O
with	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
at	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
(	O
Days	O
1月21日	O
)	O
repeated	O
every	O
4	O
weeks	O
.	O
	
The	O
schedule	O
2	O
maximum	O
tolerated	O
dose	O
of	O
gemcitabine	B-DRUG
was	O
2200	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
week	O
when	O
combined	O
with	O
5-FU	B-DRUG
dosed	O
at	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
(	O
Days	O
1月14日	O
)	O
repeated	O
every	O
3	O
weeks	O
.	O
	
In	O
schedule	O
1	O
","	O
the	O
limiting	O
factor	O
for	O
gemcitabine	B-DRUG
delivery	O
was	O
the	O
Day	O
15	O
dose	O
that	O
often	O
was	O
omitted	O
because	O
of	O
myelosuppression	B-TOXI
and	O
/	O
or	O
mucositis	B-TOXI
.	O
	
In	O
schedule	O
1	O
cycle	O
1	O
","	O
nonhematologic	B-TOXI
toxicity	I-TOXI
was	O
common	O
and	O
included	O
Grade	O
3月4日	O
toxicities	O
:	O
mucositis	B-TOXI
(	O
8	O
patients	O
)	O
","	O
fatigue	B-TOXI
(	O
2	O
patients	O
)	O
","	O
and	O
anorexia	B-TOXI
(	O
1	O
patient	O
)	O
.	O
	
One	O
patient	O
had	O
Grade	O
3月4日	O
neutropenia	B-TOXI
at	O
dose	O
level	O
5	O
(	O
maximum	O
tolerated	O
dose	O
)	O
.	O
	
In	O
schedule	O
2	O
cycle	O
1	O
","	O
hematologic	B-TOXI
toxicities	I-TOXI
were	O
more	O
common	O
than	O
nonhematologic	B-TOXI
toxicity	I-TOXI
and	O
included	O
Grade	O
3	O
anemia	B-TOXI
(	O
3	O
patients	O
)	O
","	O
Grade	O
3	O
neutropenia	B-TOXI
(	O
4	O
patients	O
)	O
","	O
and	O
Grade	O
3	O
thrombocytopenia	B-TOXI
(	O
2	O
patients	O
)	O
.	O
	
The	O
nonhematologic	B-TOXI
toxicities	I-TOXI
included	O
Grade	O
3	O
mucositis	B-TOXI
(	O
3	O
patients	O
)	O
","	O
Grade	O
3	O
fatigue	B-TOXI
(	O
2	O
patients	O
)	O
","	O
and	O
Grade	O
3	O
dehydration	B-TOXI
(	O
1	O
patient	O
)	O
.	O
	
Overall	O
","	O
antitumor	O
activity	O
was	O
observed	O
in	O
seven	O
patients	O
.	O
	
Three	O
of	O
30	O
patients	O
with	O
cytokine	O
refractory	O
renal	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
RCC	B-CANCER
;	O
relative	O
risk	O
[	O
RR	O
]	O
10	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
0.82-22	O
%	O
)	O
had	O
a	O
partial	O
response	O
.	O
	
Of	O
the	O
remaining	O
27	O
patients	O
with	O
RCC	B-CANCER
","	O
4	O
patients	O
had	O
a	O
minor	O
response	O
","	O
and	O
10	O
patients	O
had	O
stable	O
disease	O
lasting	O
a	O
median	O
of	O
6.4	O
(	O
range	O
","	O
4月12日	O
)	O
months	O
.	O
	
The	O
remaining	O
5	O
responses	O
occurred	O
in	O
40	O
patients	O
(	O
RR	O
","	O
12.5	O
%	O
;	O
95	O
%	O
CI	O
","	O
4.2-26.8	O
%	O
)	O
:	O
2	O
patients	O
with	O
5-FU	B-DRUG
refractory	O
colon	B-CANCER
carcinoma	I-CANCER
","	O
1	O
patient	O
with	O
hepatoma	B-CANCER
","	O
1	O
patient	O
with	O
paclitaxel-cisplatin-resistant	B-DRUG
ovarian	B-CANCER
carcinoma	I-CANCER
","	O
and	O
1	O
patient	O
with	O
cisplatin-resistant	B-DRUG
head	B-CANCER
and	I-CANCER
neck	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
had	O
a	O
partial	O
response	O
.	O
	
For	O
Phase	O
II	O
development	O
","	O
gemcitabine	B-DRUG
450-600	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
Days	O
1	O
","	O
8	O
","	O
and	O
15	O
can	O
be	O
safely	O
combined	O
with	O
5-FU	B-DRUG
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
as	O
a	O
continuous	O
infusion	O
(	O
Days	O
1月21日	O
)	O
of	O
a	O
28-day	O
cycle	O
or	O
gemcitabine	B-DRUG
1800	O
mg	O
/	O
m	O
(	O
2	O
)	O
Days	O
1	O
and	O
8	O
given	O
with	O
5-FU	B-DRUG
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
continuous	O
infusion	O
(	O
Days	O
1月14日	O
)	O
of	O
a	O
21-day	O
cycle	O
.	O
	
The	O
observed	O
antitumor	O
activity	O
in	O
several	O
solid	B-CANCER
tumors	I-CANCER
","	O
especially	O
in	O
renal	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
","	O
warrants	O
broad	O
Phase	O
II	O
evaluation	O
.	O
	
Phase	O
I	O
study	O
of	O
combination	O
topotecan	B-DRUG
and	O
carboplatin	B-DRUG
in	O
pediatric	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
We	O
conducted	O
a	O
phase	O
I	O
trial	O
of	O
escalating	O
doses	O
of	O
topotecan	B-DRUG
(	O
TOPO	B-DRUG
)	O
in	O
association	O
with	O
a	O
fixed	O
systemic	O
exposure	O
of	O
carboplatin	B-DRUG
(	O
CARBO	B-DRUG
)	O
with	O
or	O
without	O
granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
(	O
G-CSF	O
)	O
in	O
children	O
.	O
	
Two	O
separate	O
cohorts	O
of	O
patients	O
(	O
pts	O
)	O
with	O
solid	B-CANCER
tumors	I-CANCER
were	O
studied	O
:	O
(	O
A	O
)	O
pts	O
with	O
refractory	O
or	O
recurrent	O
disease	O
and	O
(	O
B	O
)	O
pts	O
with	O
no	O
prior	O
myelosuppressive	O
therapy	O
or	O
newly	O
diagnosed	O
tumors	O
for	O
which	O
there	O
was	O
no	O
standard	O
chemotherapy	O
.	O
	
CARBO	B-DRUG
was	O
given	O
on	O
day	O
1	O
at	O
an	O
area	O
under	O
the	O
curve	O
of	O
6.5	O
","	O
followed	O
by	O
TOPO	B-DRUG
as	O
a	O
continuous	O
infusion	O
for	O
3	O
days	O
;	O
the	O
starting	O
dose	O
of	O
TOPO	B-DRUG
was	O
0.5	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d.	O
Cycles	O
were	O
repeated	O
every	O
21	O
days	O
.	O
	
G-CSF	B-DRUG
was	O
given	O
at	O
a	O
dose	O
of	O
5	O
microg	O
/	O
kg	O
/	O
d	O
starting	O
on	O
day	O
4	O
Forty-eight	O
of	O
51	O
pts	O
were	O
assessable	O
for	O
toxicity	O
.	O
	
In	O
group	O
A	O
","	O
dose-limiting	O
myelosuppression	B-TOXI
persisted	O
despite	O
de-escalation	O
of	O
TOPO	B-DRUG
to	O
0.3	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d	O
and	O
use	O
of	O
G-CSF	B-DRUG
.	O
	
In	O
group	O
B	O
","	O
the	O
maximum-tolerated	O
dose	O
of	O
TOPO	B-DRUG
was	O
0.5	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d	O
for	O
3	O
days	O
","	O
and	O
0.6	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d	O
for	O
3	O
days	O
with	O
G-CSF	B-DRUG
.	O
	
No	O
significant	O
nonhematologic	B-TOXI
toxicities	I-TOXI
were	O
observed	O
.	O
	
Among	O
46	O
pts	O
assessable	O
for	O
response	O
","	O
one	O
had	O
complete	O
response	O
","	O
five	O
had	O
partial	O
response	O
","	O
and	O
18	O
had	O
stable	O
disease	O
.	O
	
Although	O
this	O
combination	O
possesses	O
antineoplastic	O
activity	O
in	O
pediatric	B-CANCER
solid	I-CANCER
tumors	I-CANCER
","	O
hematologic	B-TOXI
toxicity	I-TOXI
precluded	O
any	O
meaningful	O
TOPO	B-DRUG
dose	O
escalation	O
.	O
	
The	O
addition	O
of	O
G-CSF	B-DRUG
did	O
not	O
alter	O
this	O
.	O
	
The	O
potential	O
for	O
preservation	O
of	O
activity	O
and	O
diminution	O
of	O
toxicity	O
with	O
alternative	O
sequences	O
and	O
schedules	O
of	O
administration	O
(	O
topoisomerase	B-DRUG
followed	O
by	O
alkylating	B-DRUG
or	I-DRUG
platinating	I-DRUG
agents	I-DRUG
)	O
should	O
be	O
evaluated	O
.	O
	
A	O
phase	O
I-II	O
study	O
on	O
a	O
gemcitabine-cyclophosphamide-fluorouracil	B-DRUG
/	O
folinic	B-DRUG
acid	I-DRUG
triplet	O
combination	O
in	O
anthracycline-	B-DRUG
and	O
taxane-refractory	B-DRUG
breast	B-CANCER
cancer	I-CANCER
patients	O
.	O
	
	
To	O
define	O
the	O
cyclophosphamide	B-DRUG
(	O
CTX	B-DRUG
)	O
maximal	O
tolerated	O
dose	O
when	O
combined	O
with	O
fixed	O
doses	O
of	O
gemcitabine	B-DRUG
","	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
and	O
folinic	B-DRUG
acid	I-DRUG
(	O
leucovorin	B-DRUG
","	O
LFA	B-DRUG
)	O
in	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
patients	O
pretreated	O
with	O
anthracyclines	B-DRUG
and	O
taxanes	B-DRUG
.	O
	
Metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
patients	O
aged	O
&	O
lt	O
;	O
or	O
=	O
75	O
years	O
","	O
with	O
ECOG	O
performance	O
status	O
0-2	O
","	O
were	O
eligible	O
","	O
provided	O
that	O
they	O
had	O
received	O
previous	O
anthracycline-	B-DRUG
and	O
taxane-based	B-DRUG
chemotherapy	O
for	O
the	O
advanced	O
disease	O
.	O
	
Chemotherapy	O
consisted	O
of	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
5-FU	O
425	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
LFA	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
escalating	O
doses	O
of	O
CTX	B-DRUG
","	O
starting	O
from	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
on	O
days	O
1	O
and	O
8	O
every	O
3	O
weeks	O
.	O
	
The	O
dose	O
escalation	O
was	O
stopped	O
if	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
occurred	O
in	O
&	O
gt	O
;	O
33	O
%	O
of	O
patients	O
of	O
a	O
given	O
cohort	O
.	O
	
After	O
the	O
definition	O
of	O
DLT	O
","	O
a	O
further	O
escalation	O
with	O
the	O
addition	O
of	O
granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
(	O
G-CSF	B-DRUG
;	O
on	O
days	O
3月5日	O
and	O
10月12日	O
)	O
was	O
planned	O
.	O
	
Since	O
March	O
1999	O
","	O
69	O
patients	O
have	O
entered	O
this	O
trial	O
through	O
seven	O
different	O
cohorts	O
.	O
	
The	O
dose	O
escalation	O
was	O
stopped	O
at	O
the	O
CTX	B-DRUG
dose	O
of	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
since	O
3	O
/	O
6	O
patients	O
showed	O
DLT	O
.	O
	
A	O
further	O
dose	O
escalation	O
was	O
attempted	O
in	O
the	O
presence	O
of	O
G-CSF	B-DRUG
support	O
.	O
	
A	O
CTX	B-DRUG
dose	O
of	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
proved	O
to	O
be	O
safe	O
and	O
was	O
chosen	O
for	O
the	O
phase	O
II	O
.	O
	
A	O
total	O
of	O
33	O
patients	O
were	O
treated	O
at	O
this	O
dose	O
level	O
.	O
	
The	O
treatment	O
was	O
fairly	O
well	O
tolerated	O
","	O
grade	O
3月4日	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
occurring	O
in	O
38	O
and	O
16	O
%	O
of	O
patients	O
","	O
respectively	O
.	O
	
No	O
cases	O
of	O
sepsis	B-TOXI
or	O
bleeding	B-TOXI
were	O
registered	O
.	O
	
Four	O
patients	O
required	O
a	O
packed	O
red	O
blood	O
cell	O
transfusion	O
.	O
	
Severe	O
nonhematologic	B-TOXI
toxicity	I-TOXI
was	O
also	O
uncommon	O
","	O
occurring	O
in	O
10	O
patients	O
.	O
	
Three	O
complete	O
and	O
24	O
partial	O
responses	O
were	O
recorded	O
for	O
an	O
overall	O
response	O
rate	O
of	O
38	O
%	O
(	O
95	O
%	O
CI	O
=	O
26-50	O
)	O
.	O
	
Two	O
complete	O
and	O
12	O
partial	O
responses	O
were	O
recorded	O
in	O
the	O
33	O
patients	O
treated	O
in	O
the	O
phase	O
II	O
for	O
an	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
of	O
42	O
%	O
(	O
95	O
%	O
CI	O
=	O
25-61	O
)	O
.	O
	
The	O
gemcitabine-CTX-5-FU	B-DRUG
/	O
LFA	B-DRUG
combination	O
is	O
a	O
well-tolerated	O
treatment	O
for	O
poor-prognosis	B-CANCER
breast	I-CANCER
cancer	I-CANCER
patients	O
with	O
previous	O
exposure	O
to	O
anthracyclines	B-DRUG
and	O
taxanes	B-DRUG
.	O
	
With	O
the	O
addition	O
of	O
G-CSF	B-DRUG
","	O
a	O
cumulative	O
CTX	B-DRUG
dose	O
of	O
"1,600"	O
mg	O
/	O
m	O
(	O
2	O
)	O
can	O
be	O
safely	O
delivered	O
every	O
3	O
weeks	O
.	O
	
The	O
evidence	O
of	O
an	O
ORR	O
approaching	O
40	O
%	O
is	O
very	O
promising	O
and	O
justifies	O
further	O
evaluations	O
in	O
this	O
subset	O
of	O
patients	O
.	O
	
Weekly	O
administration	O
of	O
gemcitabine	B-DRUG
plus	O
docetaxel	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
:	O
a	O
phase	O
1	O
study	O
.	O
	
	
This	O
study	O
was	O
designed	O
to	O
determine	O
the	O
maximum	O
tolerable	O
dose	O
(	O
MTD	O
)	O
of	O
gemcitabine	B-DRUG
plus	O
docetaxel	B-DRUG
","	O
both	O
given	O
on	O
a	O
weekly	O
schedule	O
","	O
in	O
patients	O
with	O
pretreated	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
MBC	B-CANCER
)	O
.	O
	
Heavily	O
pretreated	O
patients	O
with	O
MBC	O
","	O
aged	O
18-75	O
years	O
with	O
World	O
Health	O
Organization	O
performance	O
status	O
of	O
0-2	O
were	O
enrolled	O
.	O
	
Three	O
escalating	O
weekly	O
doses	O
of	O
docetaxel	B-DRUG
(	O
30	O
","	O
35	O
and	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
followed	O
by	O
a	O
weekly	O
fixed	O
dose	O
of	O
gemcitabine	B-DRUG
","	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
were	O
administered	O
on	O
days	O
1	O
","	O
8	O
and	O
15	O
of	O
a	O
28-day	O
cycle	O
.	O
	
Dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
included	O
grade	O
&	O
gt	O
;	O
3	O
hematologic	B-TOXI
toxicity	I-TOXI
and	O
grade	O
&	O
gt	O
;	O
2	O
stomatitis	B-TOXI
","	O
asthenia	B-TOXI
","	O
diarrhea	B-TOXI
or	O
organ-specific	B-TOXI
toxicity	I-TOXI
(	O
except	O
alopecia	B-TOXI
)	O
.	O
	
Dose	O
escalation	O
was	O
stopped	O
if	O
&	O
gt	O
;	O
or	O
=	O
3	O
of	O
5	O
patients	O
at	O
any	O
dose	O
level	O
experienced	O
DLT	O
.	O
	
Eighteen	O
patients	O
(	O
median	O
age	O
56	O
years	O
)	O
received	O
a	O
mean	O
of	O
4.1	O
(	O
range	O
1月6日	O
)	O
cycles	O
.	O
	
Asthenia	B-TOXI
","	O
stomatitis	B-TOXI
and	O
leukopenia	B-TOXI
were	O
the	O
main	O
DLTs	O
.	O
	
One	O
of	O
5	O
patients	O
had	O
DLT	O
at	O
dose	O
level	O
1	O
and	O
2	O
of	O
5	O
patients	O
at	O
dose	O
level	O
2	O
At	O
dose	O
level	O
3	O
","	O
3	O
of	O
5	O
patients	O
had	O
DLTs	O
.	O
	
Three	O
additional	O
patients	O
treated	O
at	O
dose	O
level	O
3	O
confirmed	O
that	O
the	O
MTD	O
had	O
been	O
reached	O
.	O
	
Therefore	O
","	O
the	O
recommended	O
docetaxel	B-DRUG
dose	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
phase	O
II	O
studies	O
was	O
established	O
at	O
the	O
next	O
lower	O
dose	O
","	O
35	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Of	O
12	O
evaluable	O
patients	O
","	O
7	O
(	O
58	O
%	O
)	O
achieved	O
an	O
objective	O
response	O
.	O
	
Gemcitabine	B-DRUG
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
plus	O
docetaxel	B-DRUG
35	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
","	O
8	O
and	O
15	O
of	O
a	O
28-day	O
cycle	O
is	O
a	O
safe	O
regimen	O
which	O
shows	O
activity	O
in	O
heavily	O
pretreated	O
patients	O
with	O
MBC	O
.	O
	
Further	O
phase	O
II	O
investigations	O
with	O
this	O
combination	O
are	O
now	O
warranted	O
.	O
	
Infusional	B-DRUG
5-fluorouracil	I-DRUG
","	O
cisplatin	B-DRUG
and	O
mitomycin	B-DRUG
C	I-DRUG
in	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
:	O
a	O
low	O
cost	O
effective	O
regimen	O
.	O
	
	
Recently	O
","	O
we	O
reported	O
a	O
highly	O
active	O
regimen	O
in	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
including	O
a	O
weekly	O
administration	O
of	O
cisplatin	B-DRUG
","	O
epidoxorubicin	B-DRUG
","	O
leucovorin	B-DRUG
","	O
5-fluorouracil	B-DRUG
with	O
the	O
support	O
of	O
filgrastim	B-DRUG
.	O
	
In	O
order	O
to	O
simplify	O
the	O
administration	O
and	O
to	O
decrease	O
the	O
toxicity	O
of	O
these	O
drugs	O
","	O
mainly	O
epidoxorubicin-induced	B-DRUG
alopecia	B-TOXI
","	O
we	O
designed	O
a	O
regimen	O
including	O
an	O
infusional	B-DRUG
5-fluorouracil	I-DRUG
schedule	O
according	O
to	O
the	O
de	O
Gramont	O
regimen	O
","	O
cisplatin	B-DRUG
and	O
mitomycin	B-DRUG
C	I-DRUG
replacing	O
epidoxorubicin	B-DRUG
.	O
	
Forty-five	O
patients	O
with	O
advanced	O
or	O
metastatic	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
were	O
treated	O
with	O
cisplatin	B-DRUG
50	O
mg	O
m	O
(	O
-2	O
)	O
i.v.	O
on	O
day	O
1	O
","	O
every	O
2	O
weeks	O
","	O
6S-stereoisomer-leucovorin	B-DRUG
100	O
mg	O
m	O
(	O
-2	O
)	O
i.v.	O
followed	O
by	O
5-fluorouracil	B-DRUG
400	O
mg	O
m	O
(	O
-2	O
)	O
i.v.	O
bolus	O
and	O
600	O
mg	O
m	O
(	O
-2	O
)	O
i.v.	O
in	O
a	O
22-h	O
infusion	O
","	O
on	O
days	O
1	O
and	O
2	O
","	O
every	O
2	O
weeks	O
","	O
and	O
mitomycin	B-DRUG
C	I-DRUG
7	O
mg	O
m	O
(	O
-2	O
)	O
i.v.	O
bolus	O
on	O
day	O
2	O
","	O
every	O
6	O
weeks	O
.	O
	
Grades	O
3月4日	O
toxicities	O
(	O
National	O
Cancer	O
Institute-Common	O
Toxicity	O
Criteria	O
)	O
consisted	O
mainly	O
of	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
.	O
	
Five	O
patients	O
had	O
a	O
complete	O
response	O
and	O
16	O
had	O
a	O
partial	O
response	O
for	O
an	O
overall	O
response	O
rate	O
of	O
46.7	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
32.1-61.2	O
%	O
)	O
.	O
	
The	O
median	O
survival	O
was	O
11	O
months	O
.	O
	
The	O
combination	O
of	O
cisplatin	B-DRUG
","	O
5-fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
according	O
to	O
de	O
Gramont	O
","	O
and	O
mitomycin	B-DRUG
C	I-DRUG
seems	O
to	O
be	O
an	O
active	O
and	O
safe	O
regimen	O
in	O
the	O
treatment	O
of	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Because	O
of	O
its	O
low	O
cost	O
it	O
may	O
be	O
suggested	O
for	O
patients	O
not	O
enrolled	O
into	O
clinical	O
trials	O
.	O
	
Multicentre	O
phase	O
II	O
study	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
in	O
malignant	B-CANCER
pleural	I-CANCER
mesothelioma	I-CANCER
.	O
	
	
Malignant	B-CANCER
pleural	I-CANCER
mesothelioma	I-CANCER
is	O
a	O
notoriously	O
chemoresistant	O
tumour	O
.	O
	
However	O
","	O
a	O
recent	O
single	O
institution	O
study	O
showed	O
an	O
impressive	O
activity	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
.	O
	
Our	O
aim	O
is	O
to	O
investigate	O
the	O
efficacy	O
and	O
toxicity	O
of	O
a	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
combination	O
in	O
selected	O
and	O
chemo-naive	O
patients	O
with	O
histologically	O
proven	O
malignant	B-CANCER
pleural	I-CANCER
mesothelioma	I-CANCER
.	O
	
Gemcitabine	B-DRUG
1250	O
mg	O
m	O
(	O
-2	O
)	O
was	O
administered	O
on	O
day	O
1	O
and	O
day	O
8	O
and	O
cisplatin	B-DRUG
80	O
mg	O
m	O
(	O
-2	O
)	O
was	O
administered	O
on	O
day	O
1	O
in	O
a	O
3-week	O
cycle	O
with	O
a	O
maximum	O
of	O
six	O
cycles	O
.	O
	
Response	O
and	O
toxicity	O
evaluations	O
were	O
performed	O
according	O
to	O
WHO	O
and	O
NCIC-CTC	O
criteria	O
.	O
	
Pathology	O
and	O
radiology	O
were	O
centrally	O
reviewed	O
.	O
	
Results	O
show	O
that	O
in	O
25	O
evaluable	O
patients	O
","	O
four	O
PR	O
were	O
observed	O
(	O
ORR	O
16	O
%	O
","	O
95	O
%	O
CI	O
1月31日	O
%	O
)	O
.	O
	
Responses	O
of	O
seven	O
patients	O
were	O
unevaluable	O
.	O
	
No	O
unexpected	O
toxicity	O
occurred	O
.	O
	
Time	O
to	O
progression	O
was	O
6	O
months	O
(	O
5月7日	O
months	O
)	O
with	O
a	O
median	O
survival	O
from	O
registration	O
of	O
9.6	O
months	O
(	O
95	O
%	O
CI	O
8月12日	O
months	O
)	O
.	O
	
In	O
conclusion	O
this	O
trial	O
excludes	O
with	O
90	O
%	O
power	O
a	O
response	O
rate	O
of	O
greater	O
than	O
30	O
%	O
in	O
patients	O
with	O
malignant	B-CANCER
pleural	I-CANCER
mesothelioma	I-CANCER
using	O
a	O
combination	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
at	O
the	O
proposed	O
dose	O
and	O
schedule	O
.	O
	
Phase	O
II	O
study	O
of	O
paclitaxel	B-DRUG
plus	O
gemcitabine	B-DRUG
in	O
refractory	O
germ	B-CANCER
cell	I-CANCER
tumors	I-CANCER
(	O
E9897	O
)	O
:	O
a	O
trial	O
of	O
the	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
.	O
	
	
Despite	O
great	O
success	O
in	O
the	O
treatment	O
of	O
disseminated	O
germ	B-CANCER
cell	I-CANCER
tumors	I-CANCER
","	O
20	O
%	O
of	O
patients	O
are	O
incurable	O
and	O
become	O
candidates	O
for	O
investigational	O
therapy	O
.	O
	
Paclitaxel	B-DRUG
and	O
gemcitabine	B-DRUG
have	O
shown	O
activity	O
as	O
single	O
agents	O
in	O
refractory	O
germ	B-CANCER
cell	I-CANCER
tumors	I-CANCER
and	O
can	O
be	O
combined	O
with	O
manageable	O
toxicity	O
.	O
	
Patients	O
with	O
germ	B-CANCER
cell	I-CANCER
tumors	I-CANCER
believed	O
to	O
be	O
incurable	O
with	O
chemotherapy	O
or	O
surgery	O
were	O
treated	O
with	O
paclitaxel	B-DRUG
110	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
of	O
a	O
4-week	O
cycle	O
for	O
a	O
maximum	O
of	O
six	O
cycles	O
.	O
	
Patients	O
were	O
evaluated	O
for	O
response	O
and	O
toxicity	O
.	O
	
Twenty-eight	O
of	O
30	O
enrolled	O
patients	O
were	O
assessable	O
.	O
	
Toxicity	O
was	O
primarily	O
hematologic	O
but	O
was	O
manageable	O
with	O
only	O
a	O
single	O
case	O
of	O
neutropenic	B-TOXI
fever	I-TOXI
.	O
	
Six	O
(	O
21.4	O
%	O
)	O
of	O
28	O
patients	O
responded	O
","	O
including	O
three	O
complete	O
responses	O
.	O
	
Two	O
of	O
the	O
complete	O
responders	O
were	O
continuously	O
disease-free	O
at	O
15+	O
and	O
25+	O
months	O
.	O
	
Paclitaxel	B-DRUG
plus	O
gemcitabine	B-DRUG
is	O
an	O
active	O
regimen	O
in	O
refractory	O
germ	B-CANCER
cell	I-CANCER
tumors	I-CANCER
","	O
with	O
an	O
acceptable	O
toxicity	O
profile	O
.	O
	
This	O
regimen	O
has	O
the	O
possibility	O
for	O
long-term	O
disease-free	O
survival	O
in	O
this	O
refractory	O
patient	O
population	O
.	O
	
A	O
dose-finding	O
study	O
of	O
carboplatin-epirubicin-docetaxel	B-DRUG
in	O
advanced	B-CANCER
epithelial	I-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
docetaxel-carboplatin	B-DRUG
combination	O
is	O
active	O
and	O
well	O
tolerated	O
in	O
patients	O
with	O
epithelial	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
We	O
added	O
epirubicin	B-DRUG
to	O
this	O
combination	O
to	O
investigate	O
additional	O
benefits	O
of	O
anthracyclines	B-DRUG
in	O
epithelial	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
Twenty-one	O
patients	O
","	O
FIGO	B-DRUG
Ic-IV	I-DRUG
","	O
performance	O
status	O
0-1	O
","	O
were	O
treated	O
in	O
four	O
dose	O
cohorts	O
.	O
	
Docetaxel	B-DRUG
was	O
fixed	O
at	O
75	O
mg	O
m	O
(	O
-2	O
)	O
","	O
carboplatin	B-DRUG
doses	O
were	O
AUC	O
4月5日	O
and	O
epirubicin	B-DRUG
doses	O
were	O
50-60	O
mg	O
m	O
(	O
-2	O
)	O
.	O
	
Drugs	O
were	O
given	O
on	O
day	O
1	O
","	O
every	O
3	O
weeks	O
","	O
except	O
in	O
cohort	O
3	O
","	O
where	O
epirubicin	B-DRUG
was	O
given	O
on	O
day	O
8	O
Dexamethasone	B-DRUG
was	O
given	O
prophylactically	O
.	O
	
One	O
dose-limiting	O
toxicity	O
occurred	O
in	O
cohorts	O
1	O
","	O
2	O
and	O
4	O
","	O
two	O
occurred	O
in	O
cohort	O
3	O
Complicated	O
neutropenia	B-TOXI
occurred	O
in	O
two	O
patients	O
in	O
cohorts	O
1	O
and	O
2	O
and	O
one	O
patient	O
in	O
cohorts	O
3	O
and	O
4	O
Two	O
patients	O
experienced	O
grade	O
III	O
diarrhoea	B-TOXI
or	O
stomatitis	B-TOXI
in	O
cohort	O
1	O
and	O
two	O
in	O
cohort	O
3	O
There	O
were	O
no	O
treatment-related	O
deaths	B-TOXI
.	O
	
Grade	O
II	O
sensory	B-TOXI
neuropathy	I-TOXI
occurred	O
in	O
one	O
patient	O
.	O
	
No	O
cardiac	O
toxicity	O
or	O
significant	O
oedema	B-TOXI
was	O
observed	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
36	O
%	O
","	O
and	O
62	O
%	O
were	O
CA125	O
responders	O
.	O
	
The	O
predefined	O
maximum	O
tolerated	O
dose	O
was	O
exceeded	O
in	O
cohort	O
3	O
The	O
cohort	O
4	O
dose	O
level	O
(	O
epirubicin	B-DRUG
50	O
mg	O
m	O
(	O
-2	O
)	O
","	O
carboplatin	B-DRUG
AUC	O
4	O
","	O
docetaxel	B-DRUG
75	O
mg	O
m	O
(	O
-2	O
)	O
)	O
","	O
warrants	O
further	O
study	O
.	O
	
Schedule-selective	O
biochemical	O
modulation	O
of	O
5-fluorouracil	B-DRUG
in	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
=--	O
a	O
phase	O
II	O
study	O
.	O
	
	
5-fluorouracil	B-DRUG
remains	O
the	O
standard	O
therapy	O
for	O
patients	O
with	O
advanced	B-CANCER
/	I-CANCER
metastatic	I-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Pre-clinical	O
studies	O
have	O
demonstrated	O
the	O
biological	O
modulation	O
of	O
5-fluorouracil	B-DRUG
by	O
methotrexate	B-DRUG
and	O
leucovorin	B-DRUG
.	O
	
This	O
phase	O
II	O
study	O
was	O
initiated	O
to	O
determine	O
the	O
activity	O
and	O
toxicity	O
of	O
sequential	O
methotrexate	B-DRUG
=--	I-DRUG
leucovorin	I-DRUG
and	O
5-fluorouracil	B-DRUG
chemotherapy	O
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Ninety-seven	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
were	O
enrolled	O
onto	O
the	O
study	O
.	O
	
Methotrexate	B-DRUG
=--	O
30	O
mg	O
/	O
m2	O
was	O
administered	O
every	O
6	O
hours	O
for	O
6	O
doses	O
followed	O
by	O
a	O
2	O
hour	O
infusion	O
of	O
LV	B-DRUG
=--	O
500	O
mg	O
/	O
m2	O
.	O
	
Midway	O
through	O
the	O
leucovorin	B-DRUG
infusion	O
","	O
patients	O
received	O
5-fluorouracil	B-DRUG
=--	O
600	O
mg	O
/	O
m2	O
.	O
	
This	O
constituted	O
a	O
cycle	O
of	O
therapy	O
and	O
was	O
repeated	O
every	O
2	O
weeks	O
until	O
progression	O
.	O
	
The	O
median	O
age	O
was	O
64	O
yrs	O
(	O
34-84	O
)	O
and	O
the	O
Eastern	O
Cooperative	O
Group	O
Oncology	O
performance	O
score	O
was	O
0	O
in	O
37	O
%	O
","	O
1	O
in	O
55	O
%	O
and	O
2	O
in	O
8	O
%	O
of	O
patients	O
.	O
	
Partial	O
and	O
complete	O
responses	O
were	O
seen	O
in	O
31	O
%	O
of	O
patients	O
with	O
a	O
median	O
duration	O
of	O
response	O
of	O
6.4	O
months	O
.	O
	
The	O
overall	O
median	O
survival	O
was	O
13	O
months	O
.	O
	
The	O
estimated	O
1-year	O
survival	O
was	O
53.7	O
%	O
.	O
	
Grade	O
III	O
and	O
IV	O
toxic	O
effects	O
were	O
modest	O
and	O
included	O
mucositis	B-TOXI
","	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
.	O
	
This	O
phase	O
II	O
study	O
supports	O
previously	O
reported	O
data	O
demonstrating	O
the	O
modest	O
clinical	O
benefit	O
of	O
5-FU	B-DRUG
modulation	O
utilizing	O
methotrexate	B-DRUG
and	O
leucovorin	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Ongoing	O
studies	O
evaluating	O
5-fluorouracil	B-DRUG
modulation	O
with	O
more	O
novel	O
agents	O
(	O
Irinotecan	B-DRUG
and	O
/	O
or	O
oxaliplatin	B-DRUG
)	O
are	O
in	O
progress	O
and	O
may	O
prove	O
encouraging	O
.	O
	
Triplet	O
combination	O
with	O
irinotecan	B-DRUG
plus	O
oxaliplatin	B-DRUG
plus	O
continuous-infusion	O
fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
as	O
first-line	O
treatment	O
in	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
:	O
a	O
multicenter	O
phase	O
II	O
trial	O
.	O
	
	
To	O
evaluate	O
the	O
efficacy	O
and	O
tolerance	O
of	O
irinotecan	B-DRUG
(	O
CPT-11	B-DRUG
)	O
in	O
combination	O
with	O
oxaliplatin	B-DRUG
(	O
L-OHP	B-DRUG
)	O
plus	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
/	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
(	O
de	O
Gramont	O
regimen	O
)	O
as	O
first-line	O
treatment	O
of	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
MCC	B-CANCER
)	O
.	O
	
Thirty-one	O
patients	O
with	O
MCC	B-CANCER
who	O
had	O
not	O
received	O
prior	O
therapy	O
for	O
metastatic	O
disease	O
were	O
enrolled	O
.	O
	
Their	O
median	O
age	O
was	O
60	O
years	O
;	O
performance	O
status	O
(	O
World	O
Health	O
Organization	O
)	O
was	O
0	O
in	O
12	O
","	O
1	O
in	O
14	O
","	O
and	O
2	O
in	O
five	O
patients	O
;	O
19	O
patients	O
(	O
61	O
%	O
)	O
had	O
prior	O
surgery	O
","	O
and	O
14	O
(	O
45	O
%	O
)	O
had	O
adjuvant	O
chemotherapy	O
.	O
	
CPT-11	B-DRUG
was	O
administered	O
on	O
day	O
1	O
at	O
150	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
90-minute	O
intravenous	O
(	O
IV	O
)	O
infusion	O
;	O
L-OHP	B-DRUG
was	O
administered	O
on	O
day	O
2	O
at	O
65	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
2-hour	O
IV	O
infusion	O
;	O
and	O
on	O
days	O
2	O
and	O
3	O
","	O
LV	B-DRUG
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
preceded	O
5-FU	B-DRUG
administration	O
of	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d	O
initial	O
IV	O
bolus	O
dose	O
followed	O
by	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d	O
22-hour	O
IV	O
continuous	O
infusion	O
.	O
	
The	O
regimen	O
was	O
repeated	O
every	O
2	O
weeks	O
.	O
	
All	O
patients	O
were	O
assessable	O
for	O
toxicity	O
and	O
30	O
for	O
response	O
to	O
treatment	O
.	O
	
Complete	O
response	O
was	O
achieved	O
in	O
two	O
patients	O
(	O
6.5	O
%	O
)	O
and	O
partial	O
response	O
in	O
16	O
(	O
51.6	O
%	O
)	O
(	O
overall	O
response	O
rate	O
","	O
58.1	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
","	O
40.7	O
%	O
to	O
75.4	O
%	O
)	O
;	O
eight	O
patients	O
(	O
25.8	O
%	O
)	O
had	O
stable	O
disease	O
","	O
and	O
five	O
(	O
16.1	O
%	O
)	O
had	O
disease	O
progression	O
.	O
	
The	O
median	O
duration	O
of	O
response	O
was	O
9	O
months	O
","	O
and	O
the	O
median	O
time	O
to	O
disease	O
progression	O
was	O
13	O
months	O
.	O
	
Neutropenia	B-TOXI
grade	O
3	O
to	O
4	O
occurred	O
in	O
14	O
patients	O
(	O
45	O
%	O
)	O
and	O
febrile	B-TOXI
neutropenia	I-TOXI
in	O
two	O
(	O
6	O
%	O
)	O
.	O
	
Diarrhea	B-TOXI
grade	O
3	O
to	O
4	O
was	O
observed	O
in	O
10	O
patients	O
(	O
32	O
%	O
)	O
","	O
neurotoxicity	B-TOXI
grade	O
3	O
to	O
4	O
in	O
three	O
(	O
9	O
%	O
)	O
","	O
and	O
asthenia	B-TOXI
grade	O
3	O
in	O
two	O
(	O
10	O
%	O
)	O
.	O
	
No	O
treatment-related	O
death	B-TOXI
has	O
occurred	O
.	O
	
The	O
triplet	O
combination	O
of	O
5-FU	B-DRUG
/	O
LV	B-DRUG
=+	O
CPT-11	B-DRUG
=+	O
L-OHP	B-DRUG
is	O
a	O
highly	O
active	O
regimen	O
with	O
manageable	O
toxicity	O
as	O
front-line	O
treatment	O
in	O
MCC	B-CANCER
.	O
	
Phase	O
I	O
clinical	O
and	O
pharmacokinetic	O
study	O
of	O
combination	O
chemotherapy	O
with	O
topotecan	B-DRUG
and	O
ifosfamide	B-DRUG
in	O
patients	O
with	O
progressive	O
or	O
relapsed	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
Topotecan	B-DRUG
and	O
ifosfamide	B-DRUG
are	O
effective	O
in	O
the	O
treatment	O
of	O
various	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
Up	O
to	O
the	O
time	O
of	O
this	O
study	O
","	O
the	O
two	O
drugs	O
have	O
been	O
combined	O
just	O
once	O
(	O
Smith	O
et	O
al.	O
1998	O
)	O
.	O
	
Due	O
to	O
its	O
hematotoxicity	B-TOXI
","	O
topotecan	B-DRUG
has	O
been	O
used	O
predominantly	O
within	O
monochemotherapy	O
protocols	O
.	O
	
However	O
","	O
the	O
combination	O
of	O
topotecan	B-DRUG
and	O
alkylating	B-DRUG
agents	I-DRUG
is	O
supra-additive	O
in	O
many	O
preclinical	O
models	O
.	O
	
This	O
phase-I	O
trial	O
was	O
primarily	O
performed	O
to	O
evaluate	O
the	O
maximum	O
tolerable	O
dose	O
(	O
MTD	O
)	O
and	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
of	O
a	O
combination	O
chemotherapy	O
with	O
topotecan	B-DRUG
and	O
ifosfamide	B-DRUG
using	O
a	O
5-day	O
schedule	O
.	O
	
A	O
secondary	O
goal	O
was	O
to	O
estimate	O
the	O
response	O
rate	O
in	O
a	O
group	O
of	O
heavily	O
pretreated	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
The	O
pharmacokinetics	O
of	O
topotecan	B-DRUG
were	O
preliminarily	O
determined	O
in	O
some	O
of	O
the	O
patients	O
.	O
	
A	O
total	O
of	O
12	O
patients	O
(	O
three	O
female	O
/	O
nine	O
male	O
)	O
","	O
median	O
age	O
49	O
years	O
(	O
range	O
19-69	O
)	O
","	O
11	O
with	O
prior	O
chemotherapy	O
","	O
received	O
a	O
total	O
of	O
24	O
courses	O
of	O
chemotherapy	O
at	O
three	O
dose-levels	O
of	O
topotecan	B-DRUG
.	O
	
Ifosfamide	B-DRUG
was	O
administered	O
by	O
intravenous	O
infusion	O
over	O
3	O
h	O
immediately	O
followed	O
by	O
a	O
30-min	O
infusion	O
of	O
topotecan	B-DRUG
.	O
	
Mesna	B-DRUG
(	O
3	O
x	O
300	O
mg	O
x	O
m	O
(	O
2	O
)	O
x	O
day	O
)	O
was	O
given	O
routinely	O
during	O
chemotherapy	O
as	O
a	O
uroprotector	O
.	O
	
G-CSF	B-DRUG
(	O
filgrastim	B-DRUG
)	O
was	O
permitted	O
only	O
in	O
cases	O
of	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
FN	B-TOXI
)	O
.	O
	
The	O
major	O
toxicity	O
was	O
non-hematologic	O
;	O
severe	B-TOXI
liver	I-TOXI
and	I-TOXI
renal	I-TOXI
toxicity	I-TOXI
were	O
observed	O
in	O
three	O
out	O
of	O
11	O
patients	O
.	O
	
Two	O
treatment-related	O
deaths	B-TOXI
occurred	O
.	O
	
No	O
clinical	O
remissions	O
occurred	O
in	O
11	O
evaluable	O
patients	O
.	O
	
The	O
pharmacokinetics	O
of	O
topotecan	B-DRUG
were	O
relatively	O
similar	O
in	O
our	O
patients	O
and	O
supported	O
findings	O
in	O
recent	O
literature	O
.	O
	
The	O
MTD	O
of	O
this	O
combination	O
was	O
defined	O
at	O
dose-level	O
2	O
(	O
1	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
topotecan	B-DRUG
and	O
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
ifosfamide	B-DRUG
)	O
.	O
	
Further	O
trials	O
should	O
not	O
exceed	O
this	O
dose	O
.	O
	
The	O
pharmacological	O
causes	O
for	O
the	O
pronounced	O
toxicity	O
have	O
to	O
be	O
clarified	O
.	O
	
Cisplatin	B-DRUG
","	O
gemcitabine	B-DRUG
","	O
and	O
ifosfamide	B-DRUG
as	O
weekly	O
therapy	O
:	O
a	O
feasibility	O
and	O
phase	O
II	O
study	O
of	O
salvage	O
treatment	O
for	O
advanced	B-CANCER
transitional-cell	I-CANCER
carcinoma	I-CANCER
.	O
	
	
We	O
investigated	O
the	O
feasibility	O
","	O
safety	O
","	O
and	O
antitumor	O
activity	O
of	O
weekly	O
gemcitabine	B-DRUG
given	O
in	O
combination	O
with	O
low	O
doses	O
of	O
cisplatin	B-DRUG
and	O
ifosfamide	B-DRUG
in	O
previously	O
treated	O
patients	O
with	O
advanced	B-CANCER
transitional-cell	I-CANCER
carcinoma	I-CANCER
(	O
TCC	B-CANCER
)	O
of	O
the	O
urothelium	O
.	O
	
Patients	O
with	O
measurable	O
","	O
metastatic	B-CANCER
or	I-CANCER
unresectable	I-CANCER
TCC	I-CANCER
who	O
had	O
received	O
one	O
or	O
two	O
prior	O
chemotherapy	O
regimens	O
were	O
eligible	O
.	O
	
On	O
a	O
28-day	O
course	O
","	O
doses	O
of	O
cisplatin	B-DRUG
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
gemcitabine	B-DRUG
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
and	O
ifosfamide	B-DRUG
1	O
g	O
/	O
m	O
(	O
2	O
)	O
were	O
given	O
on	O
day	O
1	O
and	O
then	O
repeated	O
on	O
day	O
8	O
and	O
day	O
15	O
unless	O
there	O
was	O
dose-limiting	O
hematologic	B-TOXI
toxicity	I-TOXI
.	O
	
Fifty-one	O
patients	O
were	O
registered	O
;	O
10	O
patients	O
participated	O
in	O
a	O
pilot	O
study	O
","	O
after	O
which	O
41	O
patients	O
were	O
registered	O
onto	O
the	O
phase	O
II	O
protocol	O
.	O
	
Forty-eight	O
patients	O
(	O
94.1	O
%	O
)	O
had	O
dose-limiting	O
hematologic	B-TOXI
toxicity	I-TOXI
on	O
day	O
8	O
or	O
day	O
15	O
.	O
	
Nonhematologic	B-TOXI
toxicity	I-TOXI
of	O
grade	O
3	O
or	O
greater	O
consisted	O
mainly	O
of	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
(	O
seven	O
patients	O
","	O
13.7	O
%	O
)	O
and	O
infection	B-TOXI
(	O
seven	O
patients	O
","	O
13.7	O
%	O
)	O
.	O
	
Responses	O
could	O
be	O
assessed	O
in	O
49	O
of	O
51	O
eligible	O
patients	O
;	O
two	O
complete	O
responses	O
(	O
4.1	O
%	O
)	O
and	O
18	O
partial	O
responses	O
(	O
36.7	O
%	O
)	O
were	O
observed	O
for	O
an	O
overall	O
response	O
rate	O
of	O
40.8	O
%	O
(	O
exact	O
95	O
%	O
confidence	O
interval	O
","	O
27	O
%	O
to	O
56	O
%	O
)	O
.	O
	
This	O
regimen	O
of	O
cisplatin	B-DRUG
","	O
gemcitabine	B-DRUG
","	O
and	O
ifosfamide	B-DRUG
is	O
not	O
feasible	O
for	O
weekly	O
administration	O
because	O
of	O
hematologic	B-TOXI
toxicity	I-TOXI
.	O
	
Nevertheless	O
","	O
there	O
was	O
promising	O
activity	O
with	O
only	O
two	O
doses	O
per	O
28-day	O
cycle	O
.	O
	
On	O
the	O
basis	O
of	O
these	O
results	O
","	O
we	O
have	O
initiated	O
a	O
phase	O
II	O
trial	O
of	O
this	O
combination	O
given	O
as	O
a	O
single	O
dose	O
every	O
14	O
days	O
in	O
patients	O
with	O
untreated	O
","	O
metastatic	B-CANCER
urothelial	I-CANCER
carcinoma	I-CANCER
.	O
	
Pilot	O
study	O
of	O
gemcitabine	B-DRUG
(	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
min	O
)	O
and	O
cisplatin	B-DRUG
.	O
	
	
Gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
are	O
routinely	O
used	O
in	O
combination	O
.	O
	
In	O
this	O
combination	O
","	O
gemcitabine	B-DRUG
at	O
conventional	O
doses	O
of	O
1000-1500	O
mg	O
/	O
m	O
(	O
2	O
)	O
is	O
delivered	O
weekly	O
as	O
a	O
30-minute	O
bolus	O
.	O
	
Laboratory	O
data	O
suggest	O
that	O
the	O
synthesis	O
of	O
gemcitabine	B-DRUG
triphosphate	I-DRUG
is	O
saturable	O
","	O
and	O
that	O
gemcitabine	B-DRUG
infused	O
at	O
a	O
rate	O
of	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
min	O
optimizes	O
accumulation	O
of	O
the	O
triphosphate	B-DRUG
.	O
	
Early	O
clinical	O
experience	O
suggests	O
that	O
gemcitabine	B-DRUG
delivered	O
by	O
a	O
more	O
prolonged	O
infusion	O
is	O
more	O
myelosuppressive	O
.	O
	
In	O
this	O
pilot	O
study	O
","	O
we	O
wished	O
to	O
assess	O
if	O
full-dose	O
gemcitabine	B-DRUG
when	O
given	O
with	O
cisplatin	B-DRUG
could	O
be	O
delivered	O
by	O
this	O
more	O
prolonged	O
infusion	O
.	O
	
In	O
this	O
study	O
","	O
all	O
patients	O
received	O
cisplatin	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
All	O
gemcitabine	B-DRUG
doses	O
were	O
delivered	O
at	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
min	O
.	O
	
For	O
the	O
initial	O
cohort	O
(	O
level	O
1	O
)	O
the	O
gemcitabine	B-DRUG
dose	O
was	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
min	O
.	O
	
Subsequent	O
escalations	O
were	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
min	O
(	O
level	O
2	O
)	O
","	O
and	O
1250	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
min	O
(	O
levels	O
3	O
and	O
4	O
)	O
.	O
	
For	O
the	O
first	O
three	O
cohorts	O
","	O
patients	O
received	O
gemcitabine	B-DRUG
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
and	O
cisplatin	B-DRUG
on	O
day	O
15	O
on	O
a	O
28-day	O
cycle	O
.	O
	
Patients	O
on	O
level	O
4	O
received	O
gemcitabine	B-DRUG
on	O
days	O
1	O
and	O
8	O
and	O
cisplatin	B-DRUG
on	O
day	O
8	O
on	O
a	O
21-day	O
cycle	O
.	O
	
Dose	O
omissions	O
or	O
delays	O
(	O
holds	O
)	O
were	O
mandated	O
for	O
NCI	O
CTC	O
grade	O
3	O
or	O
4	O
granulocytopenia	B-TOXI
or	O
grade	O
2月4日	O
thrombocytopenia	B-TOXI
.	O
	
Entered	O
onto	O
this	O
dose-finding	O
study	O
were	O
23	O
patients	O
(	O
12	O
male	O
","	O
11	O
female	O
)	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Seven	O
patients	O
were	O
treatment-naive	O
.	O
	
Six	O
patients	O
were	O
treated	O
on	O
level	O
1	O
","	O
five	O
each	O
on	O
levels	O
2	O
and	O
3	O
and	O
seven	O
on	O
level	O
4	O
Patients	O
received	O
one	O
to	O
seven	O
cycles	O
of	O
treatment	O
.	O
	
Myelosuppression-related	B-TOXI
dose	O
holds	O
occurred	O
at	O
all	O
levels	O
.	O
	
First-cycle	O
dose	O
holds	O
occurred	O
in	O
three	O
of	O
six	O
","	O
four	O
of	O
five	O
","	O
three	O
of	O
five	O
and	O
two	O
of	O
seven	O
patients	O
on	O
successive	O
levels	O
.	O
	
First-cycle	O
grade	O
3	O
or	O
4	O
granulocytopenia	B-TOXI
/	O
thrombocytopenia	B-TOXI
occurred	O
in	O
three	O
patients	O
on	O
level	O
1	O
","	O
one	O
patient	O
on	O
level	O
2	O
","	O
two	O
patients	O
on	O
level	O
3	O
and	O
three	O
patients	O
on	O
level	O
4	O
There	O
were	O
no	O
partial	O
or	O
complete	O
responses	O
.	O
	
Four	O
patients	O
were	O
removed	O
for	O
toxicity	O
(	O
three	O
myelosuppression	B-TOXI
","	O
one	O
nephrotoxicity	B-TOXI
)	O
","	O
one	O
at	O
physician	O
discretion	O
","	O
and	O
15	O
with	O
disease	O
progression	O
.	O
	
Three	O
patients	O
stopped	O
therapy	O
with	O
stable	O
disease	O
after	O
5月6日	O
months	O
.	O
	
On	O
level	O
3	O
","	O
three	O
of	O
five	O
patients	O
remained	O
on	O
therapy	O
for	O
4	O
months	O
or	O
more	O
","	O
compared	O
to	O
only	O
one	O
patient	O
on	O
each	O
of	O
the	O
other	O
three	O
levels	O
.	O
	
CONCLUSIONS	O
Weekly	O
gemcitabine	B-DRUG
1250	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
utilizing	O
a	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
min	O
infusion	O
rate	O
","	O
can	O
be	O
delivered	O
with	O
cisplatin	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
with	O
tolerable	O
toxicity	O
.	O
	
When	O
used	O
in	O
combination	O
with	O
cisplatin	B-DRUG
","	O
however	O
","	O
the	O
benefit	O
of	O
this	O
fixed	O
dose	O
rate	O
infusion	O
gemcitabine	B-DRUG
compared	O
to	O
standard	O
bolus	O
gemcitabine	B-DRUG
remains	O
to	O
be	O
determined	O
.	O
	
Phase	O
I	O
study	O
of	O
weekly	O
CPT-11	B-DRUG
(	O
irinotecan	B-DRUG
)	O
/	O
docetaxel	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Based	O
on	O
the	O
synergistic	O
cytotoxicity	O
demonstrated	O
in	O
vitro	O
by	O
topoisomerase	B-DRUG
I	I-DRUG
inhibitors	I-DRUG
followed	O
by	O
docetaxel	B-DRUG
and	O
the	O
feasibility	O
of	O
giving	O
both	O
drugs	O
on	O
a	O
weekly	O
schedule	O
avoiding	O
overlapping	O
toxicities	O
","	O
we	O
designed	O
a	O
phase	O
I	O
trial	O
of	O
weekly	O
CPT-11	B-DRUG
(	O
irinotecan	B-DRUG
)	O
/	O
docetaxel	B-DRUG
to	O
determine	O
the	O
dose-limiting	O
toxicities	O
(	O
DLT	O
)	O
and	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
this	O
combination	O
.	O
	
Eighteen	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
treated	O
with	O
at	O
least	O
one	O
prior	O
chemotherapy	O
regimen	O
were	O
included	O
in	O
this	O
trial	O
.	O
	
CPT-11	B-DRUG
was	O
administered	O
as	O
a	O
90-min	O
(	O
intravenous	O
)	O
IV	O
infusion	O
followed	O
immediately	O
by	O
docetaxel	B-DRUG
as	O
a	O
30-min	O
IV	O
infusion	O
.	O
	
Both	O
drugs	O
were	O
given	O
on	O
days	O
1	O
","	O
8	O
and	O
15	O
in	O
4-week	O
cycles	O
.	O
	
Four	O
escalating	O
dose	O
levels	O
of	O
CPT-11	B-DRUG
/	I-DRUG
docetaxel	I-DRUG
(	O
level	O
I	O
:	O
60	O
/	O
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
level	O
II	O
:	O
60	O
/	O
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
level	O
III	O
:	O
70	O
/	O
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
and	O
level	O
IV	O
:	O
70	O
/	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
were	O
studied	O
.	O
	
Forty-seven	O
cycles	O
were	O
administered	O
(	O
range	O
","	O
1月5日	O
courses	O
)	O
with	O
a	O
median	O
number	O
of	O
2.6	O
cycles	O
per	O
patient	O
.	O
	
Grade	O
4	O
leukopenia	B-TOXI
was	O
the	O
DLT	O
reached	O
at	O
dose-level	O
IV	O
(	O
CPT-11	B-DRUG
/	O
docetaxel	B-DRUG
70	O
/	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O
	
Four	O
patients	O
had	O
grade	O
3	O
anemia	B-TOXI
at	O
dose	O
levels	O
III	O
(	O
two	O
patients	O
)	O
and	O
IV	O
(	O
two	O
patients	O
)	O
","	O
while	O
grade	O
3	O
/	O
4	O
thrombocytopenia	B-TOXI
was	O
not	O
seen	O
.	O
	
Grade	O
3	O
/	O
4	O
non-hematologic	B-TOXI
toxicities	I-TOXI
included	O
grade	O
3	O
diarrhea	B-TOXI
in	O
two	O
patients	O
(	O
dose	O
levels	O
II	O
and	O
IV	O
)	O
","	O
grade	O
3	O
asthenia	B-TOXI
in	O
one	O
patient	O
(	O
dose	O
level	O
II	O
)	O
and	O
grade	O
3	O
stomatitis	B-TOXI
in	O
one	O
patient	O
(	O
dose	O
level	O
I	O
)	O
.	O
	
The	O
recommended	O
dose	O
of	O
this	O
weekly	O
schedule	O
is	O
CPT-11	B-DRUG
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
docetaxel	B-DRUG
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
DLT	O
of	O
this	O
regimen	O
is	O
leukopenia	B-TOXI
","	O
although	O
toxicity	O
is	O
manageable	O
at	O
the	O
recommended	O
dose	O
level	O
.	O
	
The	O
activity	O
of	O
this	O
regimen	O
is	O
being	O
evaluated	O
in	O
a	O
phase	O
II	O
study	O
in	O
previously	O
treated	O
patients	O
with	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
A	O
dose-escalation	O
study	O
of	O
irinotecan	B-DRUG
(	O
CPT-11	B-DRUG
)	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
previously	O
treated	O
with	O
a	O
cisplatin-based	B-DRUG
front	O
line	O
chemotherapy	O
.	O
	
	
CPT-11	B-DRUG
and	O
gemcitabine	B-DRUG
are	O
both	O
active	O
agents	O
against	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
study	O
to	O
determine	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
the	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
of	O
their	O
combination	O
in	O
patients	O
with	O
previously	O
treated	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
Twenty-seven	O
patients	O
with	O
histologically	O
confirmed	O
NSCLC	B-CANCER
","	O
who	O
had	O
failed	O
cisplatin-based	B-DRUG
front-line	O
chemotherapy	O
","	O
were	O
enrolled	O
.	O
	
The	O
patients	O
'	O
median	O
age	O
was	O
56	O
years	O
","	O
24	O
were	O
male	O
and	O
22	O
had	O
a	O
performance	O
status	O
(	O
WHO	O
)	O
0-1	O
.	O
	
Gemcitabine	B-DRUG
was	O
administered	O
on	O
days	O
1	O
and	O
8	O
","	O
as	O
a	O
30-minute	O
i.v.	O
infusion	O
","	O
at	O
escalated	O
doses	O
ranging	O
from	O
900	O
to	O
1200	O
mg	O
/	O
m2	O
.	O
	
CPT-11	B-DRUG
was	O
given	O
over	O
a	O
60-minute	O
i.v.	O
infusion	O
on	O
day	O
8	O
at	O
escalated	O
doses	O
ranging	O
from	O
200	O
to	O
350	O
mg	O
/	O
m2	O
","	O
following	O
gemcitabine	B-DRUG
administration	O
.	O
	
The	O
treatment	O
was	O
repeated	O
every	O
three	O
weeks	O
.	O
	
The	O
MTD	O
was	O
exceeded	O
at	O
dose-level	O
7	O
with	O
CPT-11	B-DRUG
350	O
mg	O
/	O
m2	O
and	O
gemcitabine	B-DRUG
1200	O
mg	O
/	O
m2	O
","	O
where	O
all	O
three	O
enrolled	O
patients	O
presented	O
DLTs	O
(	O
one	O
patient	O
grade	O
4	O
thrombocytopenia	B-TOXI
","	O
one	O
grade	O
3	O
diarrhea	B-TOXI
and	O
one	O
grade	O
3	O
asthenia	B-TOXI
)	O
.	O
	
The	O
recommended	O
doses	O
for	O
future	O
phase	O
II	O
studies	O
are	O
CPT-11	B-DRUG
300	O
mg	O
/	O
m2	O
on	O
day	O
8	O
and	O
gemcitabine	B-DRUG
1200	O
mg	O
/	O
m2	O
on	O
days	O
1	O
and	O
8	O
A	O
total	O
of	O
107	O
treatment	O
cycles	O
were	O
administered	O
.	O
	
Grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
was	O
observed	O
in	O
13	O
(	O
13	O
%	O
)	O
cycles	O
","	O
febrile	B-TOXI
neutropenia	I-TOXI
in	O
3	O
(	O
3	O
%	O
)	O
and	O
grade	O
3	O
/	O
4	O
thrombocytopenia	B-TOXI
in	O
2	O
(	O
2	O
%	O
)	O
.	O
	
Grade	O
2	O
/	O
3	O
diarrhea	B-TOXI
was	O
seen	O
in	O
6	O
(	O
6	O
%	O
)	O
cycles	O
","	O
grade	O
2	O
/	O
3	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
in	O
13	O
(	O
13	O
%	O
)	O
and	O
grade	O
2	O
/	O
3	O
asthenia	B-TOXI
in	O
8	O
(	O
8	O
%	O
)	O
.	O
	
Other	O
toxicities	O
were	O
mild	O
.	O
	
Among	O
23	O
patients	O
evaluable	O
for	O
response	O
","	O
PR	O
was	O
achieved	O
in	O
one	O
(	O
4.5	O
%	O
)	O
","	O
SD	O
in	O
12	O
(	O
52.5	O
%	O
)	O
and	O
PD	O
in	O
10	O
(	O
43	O
%	O
)	O
.	O
	
The	O
results	O
of	O
this	O
phase	O
I	O
study	O
clearly	O
demonstrate	O
that	O
gemcitabine	B-DRUG
and	O
CPT-11	B-DRUG
can	O
be	O
efficiently	O
combined	O
in	O
a	O
low-toxicity	O
regimen	O
with	O
doses	O
equal	O
or	O
near	O
monotherapy	O
levels	O
.	O
	
Further	O
studies	O
are	O
needed	O
to	O
evaluate	O
the	O
efficacy	O
of	O
this	O
combination	O
in	O
both	O
chemotherapy-naive	O
and	O
pre-treated	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
Modulation	O
of	O
the	O
Fas	O
signaling	O
pathway	O
by	O
IFN-gamma	B-DRUG
in	O
therapy	O
of	O
colon	B-CANCER
cancer	I-CANCER
:	O
phase	O
I	O
trial	O
and	O
correlative	O
studies	O
of	O
IFN-gamma	B-DRUG
","	O
5-fluorouracil	B-DRUG
","	O
and	O
leucovorin	B-DRUG
.	O
	
	
Potentiation	O
of	O
5-fluorouracil	B-DRUG
/	O
leucovorin	B-DRUG
(	O
FUra	B-DRUG
/	O
LV	B-DRUG
)	O
cytotoxicity	O
by	O
IFN-gamma	B-DRUG
in	O
colon	B-CANCER
carcinoma	I-CANCER
cells	O
is	O
dependent	O
on	O
FUra-induced	B-DRUG
DNA	O
damage	O
","	O
the	O
Fas	O
death	O
receptor	O
","	O
and	O
independent	O
of	O
p53	O
and	O
RNA-mediated	O
FUra	B-DRUG
toxicity	O
","	O
which	O
occurs	O
in	O
normal	O
gastrointestinal	O
tissues	O
.	O
	
This	O
provides	O
a	O
rationale	O
for	O
enhancing	O
the	O
selective	O
action	O
of	O
FUra	B-DRUG
/	O
LV	B-DRUG
by	O
IFN-gamma	B-DRUG
in	O
the	O
treatment	O
of	O
colorectal	B-CANCER
carcinoma	I-CANCER
.	O
	
Based	O
on	O
results	O
from	O
our	O
preclinical	O
studies	O
we	O
designed	O
a	O
Phase	O
I	O
trial	O
combining	O
FUra	B-DRUG
(	O
370	O
mg	O
/	O
m2	O
)	O
and	O
LV	B-DRUG
(	O
200	O
mg	O
/	O
m2	O
)	O
","	O
i.v.	O
bolus	O
daily	O
x	O
5	O
days	O
","	O
with	O
escalating	O
doses	O
of	O
IFN-gamma	B-DRUG
(	O
10-100	O
micro	O
g	O
/	O
m2	O
)	O
s.c.	O
on	O
days	O
1	O
","	O
3	O
","	O
and	O
5	O
","	O
every	O
28	O
days	O
.	O
	
Twenty-five	O
patients	O
with	O
carcinomas	B-CANCER
were	O
enrolled	O
;	O
6	O
patients	O
received	O
IFN-gamma	B-DRUG
on	O
days	O
1	O
and	O
3	O
only	O
.	O
	
The	O
dose-limiting	O
toxicity	O
","	O
stomatitis	B-TOXI
","	O
occurred	O
most	O
frequently	O
at	O
100	O
micro	O
g	O
/	O
m2	O
IFN-gamma	B-DRUG
.	O
	
Minor	O
response	O
or	O
SD	O
was	O
observed	O
in	O
2	O
of	O
9	O
patients	O
and	O
in	O
4	O
of	O
12	O
patients	O
at	O
dose	O
levels	O
of	O
&	O
lt	O
;	O
or	O
50	O
micro	O
g	O
/	O
m2	O
and	O
&	O
gt	O
;	O
or	O
75	O
micro	O
g	O
/	O
m2	O
IFN-gamma	B-DRUG
","	O
respectively	O
.	O
	
Three	O
evaluable	O
chemonaive	O
patients	O
demonstrated	O
partial	O
response	O
(	O
2	O
)	O
or	O
complete	O
response	O
(	O
1	O
)	O
.	O
	
Serial	O
plasma	O
samples	O
revealed	O
peak	O
FUra	B-DRUG
concentrations	O
of	O
&	O
gt	O
;	O
100	O
micro	O
M	O
;	O
at	O
100	O
micro	O
g	O
/	O
m2	O
IFN-gamma	B-DRUG
plasma	O
concentrations	O
&	O
gt	O
;	O
5	O
units	O
/	O
ml	O
persisted	O
for	O
6.5	O
h	O
and	O
&	O
gt	O
;	O
1	O
unit	O
/	O
ml	O
for	O
28.5	O
h.	O
The	O
pharmacokinetic	O
parameters	O
of	O
IFN-gamma	B-DRUG
correlated	O
with	O
a	O
2-3-fold	O
up-regulation	O
of	O
Fas	O
expression	O
at	O
24	O
h	O
in	O
CD15+	O
cells	O
in	O
peripheral	O
blood	O
samples	O
.	O
	
Furthermore	O
","	O
clinically	O
relevant	O
IFN-gamma	B-DRUG
concentrations	O
up-regulated	O
Fas	O
expression	O
and	O
sensitized	O
HT29	O
colon	B-CANCER
carcinoma	I-CANCER
cells	O
in	O
vitro	O
to	O
FUra	B-DRUG
/	O
LV	B-DRUG
cytotoxicity	O
.	O
	
On	O
the	O
basis	O
of	O
the	O
modulation	O
of	O
Fas	O
signaling	O
","	O
FUra	B-DRUG
/	O
LV	B-DRUG
combined	O
with	O
IFN-gamma	B-DRUG
has	O
shown	O
activity	O
in	O
a	O
Phase	O
I	O
trial	O
in	O
colorectal	B-CANCER
carcinoma	I-CANCER
and	O
warrants	O
additional	O
evaluation	O
in	O
Phase	O
II	O
.	O
	
A	O
'modified	O
de	O
Gramont	O
'	O
regimen	O
of	O
fluorouracil	B-DRUG
","	O
alone	O
and	O
with	O
oxaliplatin	B-DRUG
","	O
for	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
standard	O
de	O
Gramont	O
(	O
dG	O
)	O
regimen	O
of	O
fortnightly	O
leucovorin	B-DRUG
","	O
bolus	O
fluorouracil	B-DRUG
and	O
22-h	O
infusion	O
of	O
fluorouracil	B-DRUG
","	O
d1+2	O
","	O
and	O
the	O
same	O
regimen	O
plus	O
oxaliplatin	B-DRUG
","	O
are	O
effective	O
but	O
also	O
cumbersome	O
.	O
	
We	O
therefore	O
present	O
simplified	O
'Modified	O
de	O
Gramont	O
'	O
(	O
MdG	O
)	O
regimens	O
.	O
	
Forty-six	O
advanced	B-CANCER
gastrointestinal	I-CANCER
cancer	I-CANCER
patients	O
entered	O
a	O
dose-exploring	O
study	O
of	O
MdG	O
","	O
including	O
an	O
expanded	O
cohort	O
of	O
colorectal	B-CANCER
cancer	I-CANCER
patients	O
at	O
optimum	O
dose	O
.	O
	
Treatment	O
(	O
fortnightly	O
)	O
comprised	O
:	O
2-h	O
i.v.i.	O
leucovorin	B-DRUG
(	O
350	O
mg	O
d	O
","	O
l-LV	O
or	O
175	O
mg	O
l-LV	O
","	O
not	O
adjusted	O
for	O
patient	O
surface	O
area	O
)	O
;	O
bolus	O
fluorouracil	B-DRUG
(	O
400	O
mg	O
m	O
(	O
-2	O
)	O
)	O
","	O
then	O
ambulatory	O
46-h	O
fluorouracil	B-DRUG
infusion	O
(	O
2000-3600	O
mg	O
m	O
(	O
-2	O
)	O
","	O
cohort	O
escalation	O
)	O
.	O
	
Subsequently	O
","	O
62	O
colorectal	O
patients	O
(	O
25	O
unpretreated	O
;	O
37	O
fluorouracil-resistant	B-DRUG
)	O
received	O
MdG	O
plus	O
oxaliplatin	B-DRUG
(	O
OxMdG	O
)	O
85	O
mg	O
m	O
(	O
-2	O
)	O
.	O
	
Fluorouracil	B-DRUG
pharmacokinetics	O
during	O
MdG	O
were	O
compared	O
with	O
dG	O
.	O
	
The	O
optimum	O
fluorouracil	B-DRUG
doses	O
for	O
MdG	O
alone	O
were	O
determined	O
as	O
400	O
mg	O
m	O
(	O
-2	O
)	O
bolus	O
=+	O
2800	O
mg	O
m	O
(	O
-2	O
)	O
46-h	O
infusion	O
.	O
	
A	O
lower	O
dose	O
of	O
400	O
mg	O
m	O
(	O
-2	O
)	O
bolus	O
=+	O
2400	O
mg	O
m	O
(	O
-2	O
)	O
infusion	O
which	O
","	O
like	O
dG	O
produces	O
minimal	O
toxicity	O
","	O
was	O
chosen	O
for	O
the	O
OxMdG	O
combination	O
.	O
	
Fluorouracil	B-DRUG
exposure	O
(	O
AUC	O
(	O
0-48	O
h	O
)	O
)	O
at	O
this	O
lower	O
dose	O
is	O
equivalent	O
to	O
dG	O
.	O
	
With	O
OxMdG	O
","	O
grade	O
3月4日	O
toxicity	O
was	O
rare	O
(	O
neutropenia	B-TOXI
2.8	O
%	O
cycles	O
;	O
vomiting	B-TOXI
or	O
diarrhoea	B-TOXI
&	O
lt	O
;	O
1	O
%	O
cycles	O
)	O
","	O
but	O
despite	O
this	O
there	O
were	O
two	O
infection-associated	B-TOXI
deaths	I-TOXI
.	O
	
Oxaliplatin	B-DRUG
was	O
omitted	O
for	O
cumulative	O
neurotoxicity	B-TOXI
in	O
17	O
out	O
of	O
62	O
patients	O
.	O
	
Objective	O
responses	O
in	O
colorectal	B-CANCER
cancer	I-CANCER
patients	O
were	O
:	O
1st-line	O
MdG	O
(	O
22	O
assessable	O
)	O
:	O
PR=36	O
%	O
","	O
NC=32	O
%	O
","	O
PD=32	O
%	O
.	O
	
1st-line	O
OxMdG	O
(	O
24	O
assessable	O
)	O
:	O
CR	O
/	O
PR=72	O
%	O
;	O
NC=20	O
%	O
;	O
PD=8	O
%	O
;	O
2nd	O
line	O
OxMdG	O
(	O
34	O
assessable	O
)	O
:	O
PR=12	O
%	O
;	O
NC=38	O
%	O
;	O
PD=50	O
%	O
.	O
	
MdG	O
and	O
OxMdG	O
are	O
convenient	O
and	O
well-tolerated	O
.	O
	
OxMdG	O
was	O
particularly	O
active	O
as	O
1st-line	O
treatment	O
of	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Both	O
regimens	O
are	O
being	O
further	O
evaluated	O
in	O
the	O
current	O
UK	O
MRC	B-CANCER
phase	O
III	O
trial	O
.	O
	
A	O
multicentre	O
phase	O
II	O
study	O
of	O
cisplatin	B-DRUG
and	O
gemcitabine	B-DRUG
for	O
malignant	B-CANCER
mesothelioma	I-CANCER
.	O
	
	
Our	O
previous	O
phase	O
II	O
study	O
of	O
cisplatin	B-DRUG
and	O
gemcitabine	B-DRUG
in	O
malignant	B-CANCER
mesothelioma	I-CANCER
showed	O
a	O
47.6	O
%	O
(	O
95	O
%	O
CI	O
26.2-69.0	O
%	O
)	O
response	O
rate	O
with	O
symptom	O
improvement	O
in	O
responding	O
patients	O
.	O
	
Here	O
we	O
confirm	O
these	O
findings	O
in	O
a	O
multicentre	O
setting	O
","	O
and	O
assess	O
the	O
effect	O
of	O
this	O
treatment	O
on	O
quality	O
of	O
life	O
and	O
pulmonary	O
function	O
.	O
	
Fifty-three	O
patients	O
with	O
pleural	B-CANCER
malignant	I-CANCER
mesothelioma	I-CANCER
received	O
cisplatin	B-DRUG
100	O
mg	O
m	O
(	O
-2	O
)	O
i.v.	O
day	O
1	O
and	O
gemcitabine	B-DRUG
1000	O
mg	O
m	O
(	O
-2	O
)	O
i.v.	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
of	O
a	O
28	O
day	O
cycle	O
for	O
a	O
maximum	O
of	O
six	O
cycles	O
.	O
	
Quality	O
of	O
life	O
and	O
pulmonary	O
function	O
were	O
assessed	O
at	O
each	O
cycle	O
.	O
	
The	O
best	O
response	O
achieved	O
in	O
52	O
assessable	O
patients	O
was	O
:	O
partial	O
response	O
","	O
17	O
(	O
33	O
%	O
","	O
95	O
%	O
CI	O
20-46	O
%	O
)	O
;	O
stable	O
disease	O
","	O
31	O
(	O
60	O
%	O
)	O
;	O
and	O
progressive	O
disease	O
","	O
four	O
(	O
8	O
%	O
)	O
.	O
	
The	O
median	O
time	O
to	O
disease	O
progression	O
was	O
6.4	O
months	O
","	O
median	O
survival	O
from	O
start	O
of	O
treatment	O
11.2	O
months	O
","	O
and	O
median	O
survival	O
from	O
diagnosis	O
17.3	O
months	O
.	O
	
Vital	O
capacity	O
and	O
global	O
quality	O
of	O
life	O
remained	O
stable	O
in	O
all	O
patients	O
and	O
improved	O
significantly	O
in	O
responding	O
patients	O
.	O
	
Major	O
toxicities	O
were	O
haematological	B-TOXI
","	O
limiting	O
the	O
mean	O
relative	O
dose	O
intensity	O
of	O
gemcitabine	B-DRUG
to	O
75	O
%	O
.	O
	
This	O
schedule	O
of	O
cisplatin	B-DRUG
and	O
gemcitabine	B-DRUG
is	O
active	O
in	O
malignant	B-CANCER
mesothelioma	I-CANCER
in	O
a	O
multicentre	O
setting	O
.	O
	
Investigation	O
of	O
alternative	O
scheduling	O
is	O
needed	O
to	O
decrease	O
haematological	B-TOXI
toxicity	I-TOXI
and	O
increase	O
the	O
relative	O
dose	O
intensity	O
of	O
gemcitabine	B-DRUG
whilst	O
maintaining	O
response	O
rate	O
and	O
quality	O
of	O
life	O
.	O
	
A	O
phase	O
I	O
and	O
pharmacokinetic	O
study	O
of	O
capecitabine	B-DRUG
in	O
combination	O
with	O
epirubicin	B-DRUG
and	O
cisplatin	B-DRUG
in	O
patients	O
with	O
inoperable	O
oesophago-gastric	B-CANCER
adenocarcinoma	I-CANCER
.	O
	
	
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
and	O
maximum	O
tolerated	O
dose	O
of	O
capecitabine	O
when	O
used	O
in	O
combination	O
with	O
epirubicin	B-DRUG
and	O
cisplatin	B-DRUG
(	O
ECC	B-DRUG
)	O
in	O
patients	O
with	O
oesophageal	B-CANCER
or	I-CANCER
gastric	I-CANCER
adenocarcinoma	I-CANCER
.	O
	
Response	O
rate	O
","	O
progression-free	O
survival	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
were	O
also	O
determined	O
","	O
and	O
the	O
effect	O
of	O
previous	O
oesophago-gastric	O
surgery	O
or	O
concurrent	O
oesophago-gastric	B-CANCER
cancer	I-CANCER
on	O
the	O
absorption	O
and	O
metabolism	O
of	O
capecitabine	B-DRUG
was	O
evaluated	O
.	O
	
Patients	O
with	O
inoperable	O
oesophago-gastric	B-CANCER
adenocarcinoma	I-CANCER
received	O
up	O
to	O
six	O
cycles	O
of	O
epirubicin	B-DRUG
(	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
i.v.	O
","	O
3-weekly	O
)	O
","	O
cisplatin	B-DRUG
(	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
i.v.	O
","	O
3-weekly	O
)	O
and	O
capecitabine	B-DRUG
","	O
the	O
latter	O
administered	O
orally	O
in	O
an	O
intermittent	O
schedule	O
(	O
14	O
days	O
treatment	O
;	O
7-day	O
rest	O
period	O
)	O
at	O
3-weekly	O
intervals	O
.	O
	
Patients	O
were	O
recruited	O
into	O
one	O
of	O
four	O
escalating	O
dose	O
cohorts	O
(	O
500	O
","	O
825	O
","	O
1000	O
and	O
1250	O
mg	O
/	O
m	O
(	O
2	O
)	O
bd	O
)	O
.	O
	
Dose	O
escalation	O
occurred	O
after	O
six	O
patients	O
had	O
completed	O
at	O
least	O
one	O
cycle	O
of	O
chemotherapy	O
at	O
the	O
previous	O
dose	O
level	O
","	O
with	O
DLT	O
assessed	O
on	O
the	O
toxicity	O
of	O
the	O
first	O
cycle	O
only	O
.	O
	
Blood	O
sampling	O
for	O
pharmacokinetic	O
analyses	O
was	O
performed	O
over	O
the	O
first	O
10	O
h	O
of	O
day	O
1	O
of	O
cycle	O
1	O
Thirty-two	O
patients	O
","	O
median	O
age	O
63	O
years	O
(	O
range	O
32-76	O
years	O
)	O
","	O
ECOG	O
performance	O
status	O
&	O
lt	O
;	O
or	O
2	O
with	O
locally	O
advanced	O
(	O
10	O
)	O
or	O
metastatic	O
(	O
22	O
)	O
disease	O
were	O
recruited	O
and	O
were	O
evaluable	O
for	O
toxicity	O
.	O
	
Two	O
of	O
five	O
patients	O
experienced	O
DLT	O
at	O
1250	O
mg	O
/	O
m	O
(	O
2	O
)	O
bd	O
with	O
grade	O
II	O
stomatitis	B-TOXI
(	O
one	O
patient	O
)	O
and	O
grade	O
III	O
diarrhoea	B-TOXI
with	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
one	O
patient	O
)	O
.	O
	
Cumulative	O
toxicity	O
for	O
all	O
cycles	O
(	O
n	O
=	O
140	O
)	O
(	O
worst	O
grade	O
per	O
patient	O
)	O
includes	O
grade	O
IV	O
oesophagitis	B-TOXI
(	O
one	O
patient	O
)	O
","	O
grade	O
III	O
diarrhoea	B-TOXI
(	O
five	O
)	O
","	O
grade	O
IV	O
neutropenia	B-TOXI
with	I-TOXI
infection	I-TOXI
(	O
seven	O
)	O
","	O
grade	O
II	O
stomatitis	B-TOXI
(	O
four	O
)	O
and	O
grade	O
IV	O
thrombocytopenia	B-TOXI
(	O
one	O
)	O
.	O
	
Of	O
29	O
patients	O
with	O
evaluable	O
disease	O
","	O
there	O
was	O
one	O
complete	O
response	O
and	O
six	O
partial	O
responses	O
[	O
24	O
%	O
response	O
rate	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
10	O
%	O
to	O
44	O
%	O
]	O
]	O
","	O
a	O
median	O
PFS	O
of	O
22	O
weeks	O
(	O
95	O
%	O
CI	O
17-27	O
weeks	O
)	O
and	O
median	O
overall	O
survival	O
of	O
34	O
weeks	O
(	O
95	O
%	O
CI	O
19-49	O
weeks	O
)	O
.	O
	
Capecitabine	B-DRUG
was	O
rapidly	O
absorbed	O
after	O
oral	O
administration	O
","	O
with	O
a	O
t	O
(	O
max	O
)	O
of	O
1月2日	O
h	O
for	O
capecitabine	B-DRUG
","	O
DFCR	B-DRUG
(	O
5'-deoxy-5-fluorocytidine	B-DRUG
)	O
and	O
DFUR	B-DRUG
(	O
5'-deoxy-5-fluorouridine	B-DRUG
)	O
.	O
	
The	O
C	O
(	O
max	O
)	O
and	O
AUC	O
(	O
0	O
)	O
(	O
infinity	O
)	O
for	O
capecitabine	B-DRUG
","	O
DFCR	B-DRUG
and	O
DFUR	B-DRUG
were	O
similar	O
to	O
those	O
observed	O
in	O
previous	O
monotherapy	O
studies	O
of	O
capecitabine	B-DRUG
taken	O
after	O
food	O
.	O
	
A	O
dose	O
of	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
bd	O
of	O
capecitabine	B-DRUG
is	O
recommended	O
for	O
use	O
on	O
an	O
intermittent	O
schedule	O
in	O
combination	O
with	O
these	O
doses	O
and	O
schedule	O
of	O
epirubicin	B-DRUG
and	O
cisplatin	B-DRUG
.	O
	
This	O
regimen	O
is	O
tolerable	O
and	O
active	O
in	O
oesophago-gastric	B-CANCER
adenocarcinoma	I-CANCER
.	O
	
A	O
randomised	O
phase	O
III	O
comparison	O
with	O
ECF	O
is	O
justified	O
.	O
	
Phase	O
I-II	O
and	O
pharmacokinetic	O
study	O
of	O
gemcitabine	B-DRUG
combined	O
with	O
oxaliplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
and	O
ovarian	B-CANCER
carcinoma	I-CANCER
.	O
	
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
toxicity	O
profile	O
","	O
the	O
recommended	O
dose	O
(	O
RD	O
)	O
and	O
the	O
pharmacokinetic	O
parameters	O
","	O
and	O
to	O
evaluate	O
the	O
antitumor	O
activity	O
of	O
gemcitabine	B-DRUG
combined	O
with	O
oxaliplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
and	O
ovarian	B-CANCER
carcinoma	I-CANCER
(	O
OC	B-CANCER
)	O
.	O
	
Gemcitabine	B-DRUG
was	O
administered	O
as	O
a	O
30-min	O
infusion	O
followed	O
by	O
a	O
2-h	O
infusion	O
of	O
oxaliplatin	B-DRUG
","	O
repeated	O
every	O
2	O
weeks	O
.	O
	
Doses	O
of	O
gemcitabine	B-DRUG
and	O
oxaliplatin	B-DRUG
ranged	O
from	O
800	O
to	O
1500	O
and	O
70	O
to	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
respectively	O
.	O
	
Forty-four	O
patients	O
(	O
26	O
males	O
","	O
18	O
females	O
;	O
median	O
age	O
55	O
years	O
)	O
including	O
35	O
NSCLC	B-CANCER
(	O
five	O
platinum	O
pretreated	O
)	O
and	O
nine	O
OC	B-CANCER
patients	O
(	O
all	O
platinum	O
pretreated	O
)	O
received	O
a	O
total	O
of	O
355	O
cycles	O
.	O
	
All	O
patients	O
were	O
evaluable	O
for	O
toxicity	O
.	O
	
No	O
dose-limiting	O
toxicity	O
at	O
any	O
dose	O
level	O
occurred	O
during	O
the	O
first	O
two	O
cycles	O
;	O
therefore	O
","	O
the	O
highest	O
dose-level	O
of	O
gemcitabine	B-DRUG
(	O
1500	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
oxaliplatin	B-DRUG
(	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
was	O
considered	O
as	O
the	O
RD.	O
Hematological	B-TOXI
toxicity	I-TOXI
was	O
moderate	O
amongst	O
the	O
22	O
patients	O
treated	O
(	O
167	O
cycles	O
)	O
at	O
that	O
dose	O
level	O
.	O
	
Thirteen	O
cycles	O
were	O
associated	O
with	O
grade	O
3月4日	O
non-febrile	B-TOXI
neutropenia	I-TOXI
in	O
six	O
patients	O
","	O
and	O
eight	O
cycles	O
with	O
grade	O
3月4日	O
thrombocytopenia	B-TOXI
in	O
two	O
patients	O
.	O
	
Other	O
toxicities	O
were	O
mild	O
to	O
moderate	O
","	O
consisting	O
of	O
asthenia	B-TOXI
and	O
peripheral	B-TOXI
neurotoxicity	I-TOXI
.	O
	
Four	O
of	O
the	O
35	O
patients	O
treated	O
with	O
oxaliplatin	B-DRUG
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
experienced	O
grade	O
3	O
neurotoxicity	B-TOXI
requiring	O
treatment	O
discontinuation	O
at	O
cycle	O
10	O
.	O
	
In	O
the	O
range	O
of	O
the	O
doses	O
used	O
","	O
gemcitabine	B-DRUG
and	O
its	O
main	O
metabolite	O
"2',2'-difluorodeoxyuridine"	B-DRUG
appeared	O
not	O
to	O
be	O
affected	O
by	O
oxaliplatin	B-DRUG
70-100	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Of	O
the	O
44	O
patients	O
evaluable	O
for	O
activity	O
","	O
12	O
NSCLC	B-CANCER
patients	O
experienced	O
objective	O
responses	O
(	O
one	O
complete	O
and	O
11	O
partial	O
responses	O
)	O
and	O
three	O
OC	B-CANCER
patients	O
showed	O
tumor	O
stabilization	O
lasting	O
for	O
6	O
months	O
with	O
a	O
50	O
%	O
decrease	O
of	O
CA	O
125	O
level	O
.	O
	
Two	O
partial	O
responses	O
(	O
NSCLC	B-CANCER
)	O
and	O
one	O
tumor	O
stabilization	O
(	O
OC	B-CANCER
)	O
occurred	O
in	O
platinum-resistant	B-DRUG
patients	O
.	O
	
The	O
combination	O
of	O
gemcitabine	B-DRUG
and	O
oxaliplatin	B-DRUG
could	O
be	O
safely	O
administered	O
on	O
an	O
out-patient	O
schedule	O
in	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
and	O
OC	B-CANCER
.	O
	
The	O
RD	O
was	O
gemcitabine	B-DRUG
1500	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
oxaliplatin	B-DRUG
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
every	O
2	O
weeks	O
.	O
	
Promising	O
antitumor	O
activity	O
was	O
reported	O
in	O
patients	O
with	O
NSCLC	B-CANCER
and	O
platinum-pretreated	O
OC	B-CANCER
","	O
and	O
thus	O
","	O
deserves	O
further	O
evaluation	O
.	O
	
Paclitaxel	B-DRUG
plus	O
carboplatin	B-DRUG
versus	O
gemcitabine	B-DRUG
plus	O
paclitaxel	B-DRUG
in	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
a	O
phase	O
III	O
randomized	O
trial	O
.	O
	
	
We	O
conducted	O
this	O
randomized	O
study	O
comparing	O
the	O
activity	O
and	O
toxicity	O
of	O
paclitaxel	B-DRUG
and	O
gemcitabine	B-DRUG
(	O
PG	B-DRUG
)	O
and	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
(	O
PC	B-DRUG
)	O
combinations	O
for	O
the	O
treatment	O
of	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Chemotherapy-naive	O
patients	O
were	O
randomized	O
to	O
paclitaxel	B-DRUG
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
plus	O
either	O
carboplatin	B-DRUG
at	O
an	O
area	O
under	O
the	O
concentration-time	O
curve	O
of	O
6	O
on	O
day	O
1	O
(	O
group	O
A	O
)	O
or	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
and	O
8	O
(	O
group	O
B	O
)	O
every	O
3	O
weeks	O
.	O
	
A	O
retrospective	O
cost	O
analysis	O
was	O
conducted	O
using	O
Student	O
's	O
t	O
test	O
to	O
compare	O
independent	O
samples	O
between	O
groups	O
.	O
	
A	O
total	O
of	O
509	O
patients	O
(	O
group	O
A	O
","	O
252	O
patients	O
;	O
group	O
B	O
","	O
257	O
patients	O
)	O
were	O
enrolled	O
;	O
all	O
characteristics	O
were	O
well	O
balanced	O
.	O
	
The	O
median	O
survival	O
time	O
was	O
10.4	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
8.8	O
to	O
12	O
months	O
)	O
for	O
group	O
A	O
and	O
9.8	O
months	O
(	O
95	O
%	O
CI	O
","	O
8	O
to	O
11.7	O
months	O
)	O
for	O
group	O
B	O
(	O
P	O
0.32	O
)	O
.	O
	
Respective	O
1-year	O
survival	O
rates	O
were	O
41.7	O
%	O
and	O
41.4	O
%	O
.	O
	
The	O
response	O
rate	O
for	O
group	O
A	O
was	O
28	O
%	O
(	O
2	O
%	O
complete	O
response	O
[	O
CR	O
]	O
","	O
26	O
%	O
partial	O
response	O
[	O
PR	O
]	O
[	O
95	O
%	O
CI	O
","	O
22	O
%	O
to	O
34	O
%	O
]	O
)	O
","	O
and	O
the	O
response	O
rate	O
for	O
group	O
B	O
was	O
35	O
%	O
(	O
5	O
%	O
CR	O
","	O
30	O
%	O
PR	O
)	O
[	O
95	O
%	O
CI	O
","	O
29	O
%	O
to	O
41	O
%	O
]	O
)	O
(	O
P	O
0.12	O
)	O
.	O
	
Toxicity	O
was	O
mild	O
.	O
	
Grades	O
3	O
/	O
4	O
neutropenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
and	O
anemia	B-TOXI
for	O
groups	O
A	O
and	O
B	O
were	O
seen	O
in	O
15	O
%	O
and	O
15	O
%	O
","	O
2	O
%	O
and	O
1	O
%	O
","	O
and	O
5	O
%	O
and	O
2	O
%	O
","	O
respectively	O
.	O
	
The	O
mean	O
total	O
cost	O
(	O
outpatient	O
clinic	O
visits	O
plus	O
chemotherapy	O
drug	O
fee	O
)	O
for	O
group	O
A	O
(	O
euro	O
;	O
"7,612.64"	O
)	O
versus	O
group	O
B	O
(	O
euro	O
;	O
"7,484.77"	O
)	O
was	O
not	O
statistically	O
significant	O
(	O
P	O
&	O
lt	O
;	O
0.66	O
)	O
.	O
	
The	O
PG	B-DRUG
combination	O
is	O
as	O
equally	O
active	O
and	O
well	O
tolerated	O
as	O
the	O
PC	B-DRUG
combination	O
in	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
Phase	O
II	O
multicenter	O
trial	O
of	O
a	O
weekly	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
regimen	O
in	O
patients	O
with	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
determine	O
the	O
activity	O
of	O
weekly	O
paclitaxel	B-DRUG
plus	O
carboplatin	B-DRUG
as	O
first-line	O
therapy	O
in	O
patients	O
with	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
ABC	B-CANCER
)	O
by	O
assessing	O
response	O
rate	O
","	O
survival	O
","	O
and	O
safety	O
.	O
	
One	O
hundred	O
patients	O
with	O
ABC	B-CANCER
received	O
paclitaxel	B-DRUG
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
group	O
1	O
","	O
n	O
=	O
20	O
)	O
and	O
carboplatin	B-DRUG
area	O
under	O
the	O
concentration-time	O
curve	O
(	O
AUC	O
)	O
of	O
2	O
Paclitaxel	B-DRUG
was	O
subsequently	O
reduced	O
to	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
group	O
2	O
","	O
n	O
=	O
80	O
)	O
because	O
of	O
toxicity	O
.	O
	
The	O
median	O
age	O
was	O
58.5	O
years	O
","	O
and	O
most	O
patients	O
had	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
&	O
lt	O
;	O
or=	O
2	O
Estrogen	O
and	O
progesterone	O
receptor	O
status	O
were	O
evenly	O
distributed	O
among	O
both	O
groups	O
.	O
	
Sixty-one	O
patients	O
received	O
prior	O
chemotherapy	O
","	O
37	O
(	O
61	O
%	O
)	O
of	O
whom	O
received	O
prior	O
doxorubicin	B-DRUG
.	O
	
Among	O
47	O
patients	O
who	O
received	O
prior	O
hormonal	O
therapy	O
","	O
43	O
received	O
tamoxifen	B-DRUG
.	O
	
The	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
among	O
95	O
assessable	O
patients	O
was	O
62	O
%	O
","	O
including	O
8	O
%	O
complete	O
responses	O
and	O
54	O
%	O
partial	O
responses	O
.	O
	
The	O
median	O
time	O
to	O
response	O
was	O
1.8	O
months	O
","	O
and	O
the	O
median	O
duration	O
of	O
response	O
was	O
13.3	O
months	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
was	O
4.8	O
months	O
.	O
	
The	O
median	O
survival	O
was	O
16	O
months	O
.	O
	
Neutropenia	B-TOXI
and	O
leukopenia	B-TOXI
were	O
the	O
most	O
common	O
grade	O
3	O
and	O
4	O
toxicities	O
.	O
	
In	O
group	O
1	O
","	O
neutropenia	B-TOXI
(	O
50	O
%	O
)	O
and	O
leukopenia	B-TOXI
(	O
35	O
%	O
)	O
necessitated	O
dose	O
reductions	O
for	O
50	O
%	O
of	O
patients	O
during	O
the	O
first	O
three	O
cycles	O
","	O
prompting	O
the	O
reduction	O
in	O
paclitaxel	B-DRUG
dose	O
to	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Grade	O
3	O
and	O
4	O
nonhematologic	B-TOXI
toxicities	I-TOXI
for	O
all	O
patients	O
included	O
peripheral	B-TOXI
neuropathy	I-TOXI
(	O
11	O
%	O
)	O
","	O
infection	B-TOXI
(	O
6	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
5	O
%	O
)	O
","	O
weakness	B-TOXI
(	O
6	O
%	O
)	O
","	O
and	O
paresthesia	B-TOXI
(	O
3	O
%	O
)	O
.	O
	
The	O
62	O
%	O
ORR	O
achieved	O
with	O
weekly	O
paclitaxel	B-DRUG
plus	O
carboplatin	B-DRUG
is	O
among	O
the	O
highest	O
achieved	O
with	O
chemotherapy	O
for	O
ABC	B-CANCER
.	O
	
This	O
high	O
response	O
rate	O
and	O
the	O
lack	O
of	O
cardiotoxicity	B-TOXI
suggest	O
that	O
the	O
regimen	O
should	O
be	O
considered	O
as	O
a	O
nonanthracycline	O
regimen	O
for	O
future	O
adjuvant	O
therapy	O
.	O
	
Phase	O
II	O
study	O
to	O
evaluate	O
combining	O
gemcitabine	B-DRUG
with	O
flutamide	B-DRUG
in	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
patients	O
.	O
	
	
A	O
phase	O
II	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
safety	O
of	O
combining	O
flutamide	B-DRUG
with	O
gemcitabine	B-DRUG
","	O
with	O
response	O
rate	O
being	O
the	O
primary	O
end	O
point	O
.	O
	
Twenty-seven	O
patients	O
with	O
histologically	O
proven	O
","	O
previously	O
untreated	O
","	O
unresectable	O
pancreatic	B-CANCER
adenocarcinoma	I-CANCER
received	O
gemcitabine	B-DRUG
","	O
1	O
g	O
m	O
(	O
-2	O
)	O
intravenously	O
on	O
days	O
1	O
","	O
8	O
and	O
15	O
of	O
a	O
28	O
day	O
cycle	O
","	O
and	O
flutamide	B-DRUG
250	O
mg	O
given	O
orally	O
three	O
times	O
daily	O
.	O
	
Treatment	O
was	O
halted	O
if	O
there	O
was	O
unacceptable	O
toxicity	O
","	O
or	O
evidence	O
of	O
disease	O
progression	O
.	O
	
Toxicity	O
was	O
documented	O
every	O
cycle	O
.	O
	
Tumour	O
assessment	O
was	O
undertaken	O
after	O
cycles	O
2	O
and	O
4	O
","	O
and	O
thereafter	O
at	O
least	O
every	O
additional	O
four	O
cycles	O
.	O
	
One	O
hundred	O
and	O
seventeen	O
cycles	O
of	O
treatment	O
were	O
administered	O
","	O
median	O
four	O
cycles	O
per	O
patient	O
(	O
range	O
1月18日	O
)	O
.	O
	
Gemcitabine	B-DRUG
combined	O
with	O
flutamide	B-DRUG
was	O
well	O
tolerated	O
","	O
with	O
most	O
toxicities	O
being	O
recorded	O
as	O
grade	O
1	O
or	O
2	O
and	O
only	O
nine	O
treatment	O
cycles	O
associated	O
with	O
grade	O
3	O
toxicity	O
.	O
	
The	O
most	O
frequent	O
toxicity	O
was	O
myelosuppression	B-TOXI
.	O
	
One	O
case	O
of	O
transient	B-TOXI
jaundice	I-TOXI
was	O
recorded	O
.	O
	
The	O
commonest	O
symptomatic	O
toxicity	O
was	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
.	O
	
The	O
response	O
rate	O
was	O
15	O
%	O
(	O
four	O
partial	O
responses	O
)	O
","	O
median	O
survival	O
6	O
months	O
and	O
22	O
%	O
of	O
patients	O
were	O
alive	O
at	O
1	O
year	O
.	O
	
These	O
results	O
suggest	O
antitumour	O
activity	O
of	O
the	O
combination	O
therapy	O
to	O
be	O
equivalent	O
to	O
single	O
agent	O
gemcitabine	B-DRUG
.	O
	
Combination	O
chemotherapy	O
comprising	O
5-fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
","	O
etoposide	B-DRUG
","	O
and	O
cis-diamminedichloroplatinum	B-DRUG
for	O
the	O
treatment	O
of	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
FLEP	B-DRUG
regimen	O
(	O
5-FU	B-DRUG
","	O
LV	B-DRUG
","	O
ETP	B-DRUG
","	O
and	O
CDDP	B-DRUG
)	O
has	O
been	O
recommended	O
as	O
a	O
combination	O
chemotherapy	O
to	O
control	O
advanced	B-CANCER
and	I-CANCER
recurrent	I-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
We	O
performed	O
a	O
phase	O
II	O
study	O
of	O
this	O
regimen	O
in	O
49	O
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
The	O
treatment	O
regimen	O
consisted	O
of	O
:	O
5-FU	B-DRUG
at	O
370	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
days	O
1月5日	O
","	O
i.v.	O
24	O
h	O
)	O
;	O
LV	B-DRUG
at	O
a	O
dose	O
of	O
30	O
mg	O
(	O
days	O
1月5日	O
","	O
i.v.	O
bolus	O
)	O
;	O
and	O
ETP	B-DRUG
and	O
CDDP	B-DRUG
each	O
at	O
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
days	O
7	O
and	O
21	O
","	O
i.a.	O
2	O
h	O
)	O
","	O
which	O
was	O
repeated	O
every	O
five	O
weeks	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
40.8	O
%	O
(	O
20	O
/	O
49	O
patients	O
)	O
and	O
the	O
median	O
survival	O
time	O
was	O
12.6	O
months	O
(	O
range	O
1.1-41.8	O
)	O
.	O
	
The	O
adverse	O
events	O
were	O
Grade	O
3	O
/	O
4	O
leukocytopenia	B-TOXI
(	O
16.3	O
%	O
)	O
","	O
Grade	O
3	O
/	O
4	O
thrombocytopenia	B-TOXI
(	O
8.2	O
%	O
)	O
","	O
Grade	O
3	O
nausea	B-TOXI
and	O
/	O
or	O
vomiting	B-TOXI
(	O
4.1	O
%	O
)	O
","	O
and	O
Grade	O
3	O
stomatitis	B-TOXI
(	O
2	O
%	O
)	O
.	O
	
Based	O
on	O
the	O
encouraging	O
response	O
rate	O
and	O
prognosis	O
","	O
we	O
recommend	O
applying	O
the	O
FLEP	B-DRUG
regimen	O
to	O
patients	O
with	O
primary	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Chronomodulated	O
chemotherapy	O
in	O
metastatic	B-CANCER
gastrointestinal	I-CANCER
cancer	I-CANCER
combining	O
5-FU	B-DRUG
and	O
sodium	B-DRUG
folinate	I-DRUG
with	O
oxaliplatin	B-DRUG
","	O
irinotecan	B-DRUG
or	O
gemcitabine	B-DRUG
:	O
the	O
Jena	O
experience	O
in	O
79	O
patients	O
.	O
	
	
To	O
study	O
efficacy	O
and	O
tolerability	O
of	O
chronomodulated	O
(	O
CM	O
)	O
#NAME?	O
in	O
patients	O
with	O
metastatic	O
or	O
locally	O
advanced	B-CANCER
tumors	I-CANCER
of	I-CANCER
the	I-CANCER
GI	I-CANCER
tract	I-CANCER
.	O
	
Furthermore	O
","	O
calcium	B-DRUG
folinate	I-DRUG
was	O
replaced	O
by	O
sodium	B-DRUG
folinate	I-DRUG
due	O
to	O
better	O
feasibility	O
.	O
	
We	O
treated	O
79	O
patients	O
with	O
metastatic	B-CANCER
or	I-CANCER
locally	I-CANCER
advanced	I-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
n=52	O
)	O
","	O
cancer	B-CANCER
of	I-CANCER
the	I-CANCER
pancreas	I-CANCER
/	I-CANCER
biliary	I-CANCER
tract	I-CANCER
(	O
n=14	O
)	O
","	O
and	O
other	O
malignancies	O
(	O
n=14	O
)	O
with	O
a	O
total	O
of	O
592	O
courses	O
of	O
CM-therapy	O
.	O
	
Out	O
of	O
the	O
total	O
study	O
population	O
53	O
/	O
79	O
","	O
i.e.	O
","	O
67.1	O
%	O
had	O
received	O
prior	O
chemotherapy	O
.	O
	
Most	O
of	O
the	O
patients	O
(	O
77.2	O
%	O
)	O
received	O
sodium-folinate-5-FU-oxaliplatin-CM	B-DRUG
(	O
SOFOX-CM	B-DRUG
)	O
as	O
first-line	O
chronomodulated	O
therapy	O
","	O
20.3	O
%	O
received	O
sodium-folinate-5-FU-irinotecan-CM	B-DRUG
(	O
SOFIRI-CM	B-DRUG
)	O
","	O
and	O
2.5	O
%	O
(	O
n=1	O
)	O
received	O
sodium-folinate-5-FU-gemcitabine-CM	B-DRUG
(	O
SOFGEM-CM	B-DRUG
)	O
.	O
	
We	O
found	O
a	O
moderate	O
overall	O
toxicity	O
with	O
grade	O
3月4日	O
neuropathy	B-TOXI
in	O
7.46	O
%	O
of	O
patients	O
during	O
a	O
total	O
of	O
433	O
courses	O
of	O
SOFOX-CM	B-DRUG
and	O
grade	O
3月4日	O
diarrhea	B-TOXI
in	O
10.26	O
%	O
of	O
patients	O
after	O
154	O
courses	O
of	O
SOFIRI-CM	B-DRUG
.	O
	
SOFOX-CM	B-DRUG
had	O
to	O
be	O
stopped	O
only	O
in	O
one	O
patient	O
due	O
to	O
grade	O
3月4日	O
sensory	B-TOXI
neuropathy	I-TOXI
.	O
	
CM-therapy	O
led	O
to	O
complete	O
response	O
(	O
CR	O
)	O
in	O
1.3	O
%	O
","	O
partial	O
response	O
(	O
PR	O
)	O
in	O
15.2	O
%	O
","	O
stable	O
disease	O
(	O
SD	O
)	O
in	O
32.9	O
%	O
","	O
and	O
progressive	O
disease	O
(	O
PD	O
)	O
in	O
44.3	O
%	O
of	O
all	O
patients	O
.	O
	
For	O
the	O
26	O
chemonaive	O
patients	O
remission	O
data	O
were	O
as	O
follows	O
:	O
CR	O
one	O
patient	O
(	O
3.8	O
%	O
)	O
","	O
PR	O
four	O
patients	O
(	O
15.4	O
%	O
)	O
","	O
SD	O
seven	O
patients	O
(	O
26.9	O
%	O
)	O
","	O
PD	O
12	O
patients	O
(	O
46.3	O
%	O
)	O
","	O
lost	O
to	O
follow-up	O
one	O
patient	O
(	O
3.8	O
%	O
)	O
","	O
and	O
too-early-for-analysis	O
one	O
patient	O
(	O
3.8	O
%	O
)	O
.	O
	
The	O
median	O
progression-free-survival	O
(	O
PFS	O
)	O
was	O
4	O
months	O
(	O
range	O
","	O
0-24	O
months	O
)	O
.	O
	
The	O
median	O
PFS	O
was	O
also	O
4	O
months	O
(	O
range	O
","	O
0-21	O
months	O
)	O
for	O
those	O
patients	O
receiving	O
SOFOX-CM	B-DRUG
as	O
first	O
CM-therapy	O
(	O
n=61	O
)	O
","	O
while	O
it	O
was	O
found	O
to	O
be	O
0	O
months	O
(	O
range	O
","	O
0-10	O
months	O
)	O
for	O
patients	O
(	O
n=16	O
)	O
receiving	O
SOFIRI-CM	B-DRUG
as	O
first	O
chronomodulated	O
therapy	O
.	O
	
We	O
found	O
CM-therapy	O
to	O
be	O
effective	O
and	O
safe	O
in	O
the	O
treatment	O
of	O
advanced	B-CANCER
malignancies	I-CANCER
of	I-CANCER
the	I-CANCER
GI	I-CANCER
tract	I-CANCER
.	O
	
Sodium	B-DRUG
folinate	I-DRUG
offers	O
superior	O
feasibility	O
and	O
compatibility	O
with	O
cytostatic	B-DRUG
drugs	I-DRUG
without	O
drawbacks	O
.	O
	
Folinic	B-DRUG
acid	I-DRUG
","	O
5-fluorouracil	B-DRUG
and	O
mitomycin	B-DRUG
C	I-DRUG
in	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
patients	O
previously	O
treated	O
with	O
at	O
least	O
two	O
chemotherapy	O
regimens	O
.	O
	
	
To	O
assess	O
the	O
activity	O
and	O
safety	O
of	O
combined	O
folinic	B-DRUG
acid	I-DRUG
(	O
FA	B-DRUG
)	O
","	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
and	O
mitomycin	B-DRUG
C	I-DRUG
(	O
MMC	B-DRUG
)	O
in	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
patients	O
previously	O
treated	O
with	O
at	O
least	O
two	O
chemotherapy	O
regimens	O
.	O
	
A	O
total	O
of	O
104	O
consecutive	O
patients	O
were	O
enrolled	O
for	O
treatment	O
with	O
FA	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
plus	O
5-FU	B-DRUG
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
i.v.	O
on	O
days	O
1月5日	O
","	O
and	O
MMC	B-DRUG
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
3月5日	O
(	O
FFM	O
)	O
.	O
	
The	O
cycles	O
were	O
repeated	O
every	O
21	O
days	O
until	O
progression	O
","	O
severe	B-TOXI
toxicity	I-TOXI
or	O
patient	O
refusal	O
.	O
	
Of	O
the	O
104	O
patients	O
","	O
96	O
were	O
evaluable	O
for	O
response	O
and	O
toxicity	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
43	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
32.8-53.2	O
%	O
)	O
;	O
40	O
patients	O
achieved	O
stable	O
disease	O
(	O
42	O
%	O
)	O
and	O
15	O
progressed	O
(	O
15	O
%	O
)	O
.	O
	
In	O
a	O
retrospectively	O
defined	O
subgroup	O
of	O
patients	O
with	O
clinical	O
resistance	O
to	O
taxanes	B-DRUG
(	O
12	O
patients	O
)	O
or	O
anthracyclines	B-DRUG
(	O
14	O
patients	O
)	O
","	O
the	O
response	O
rate	O
was	O
42	O
%	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
was	O
8	O
months	O
(	O
3月18日	O
months	O
)	O
","	O
and	O
the	O
median	O
overall	O
survival	O
was	O
10.5+	O
months	O
(	O
2-36	O
months	O
)	O
.	O
	
The	O
most	O
common	O
treatment-related	O
adverse	O
events	O
were	O
stomatitis	B-TOXI
","	O
neutropenia	B-TOXI
","	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
and	O
diarrhea	B-TOXI
.	O
	
Stomatitis	B-TOXI
","	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
were	O
the	O
only	O
grade	O
4	O
treatment-related	O
adverse	O
events	O
","	O
and	O
occurred	O
in	O
no	O
more	O
than	O
3	O
%	O
of	O
patients	O
.	O
	
The	O
tested	O
FFM	O
regimen	O
seems	O
to	O
offer	O
a	O
valid	O
option	O
for	O
patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
who	O
have	O
been	O
pretreated	O
with	O
two	O
or	O
more	O
chemotherapeutic	O
lines	O
or	O
who	O
have	O
failed	O
on	O
regimens	O
containing	O
anthracyclines	B-DRUG
or	O
taxanes	B-DRUG
.	O
	
Intermittent	O
weekly	O
high-dose	O
capecitabine	B-DRUG
in	O
combination	O
with	O
oxaliplatin	B-DRUG
:	O
a	O
phase	O
I	O
/	O
II	O
study	O
in	O
first-line	O
treatment	O
of	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
aim	O
of	O
this	O
phase	O
I	O
study	O
was	O
to	O
determine	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
the	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
of	O
an	O
intermittent	O
weekly	O
capecitabine	B-DRUG
regimen	O
in	O
combination	O
with	O
oxaliplatin	B-DRUG
.	O
	
Furthermore	O
","	O
we	O
intended	O
to	O
explore	O
its	O
safety	O
at	O
the	O
recommended	O
dose	O
","	O
and	O
to	O
assess	O
its	O
principal	O
antitumor	O
activity	O
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Thirty	O
patients	O
with	O
measurable	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
who	O
previously	O
were	O
unexposed	O
to	O
palliative	O
chemotherapy	O
were	O
enrolled	O
on	O
to	O
this	O
disease-oriented	O
phase	O
I	O
trial	O
.	O
	
They	O
were	O
treated	O
with	O
a	O
fixed	O
dose	O
of	O
oxaliplatin	B-DRUG
(	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
administered	O
as	O
a	O
2-h	O
intravenous	O
infusion	O
on	O
day	O
1	O
)	O
plus	O
escalating	O
doses	O
of	O
capecitabine	B-DRUG
(	O
given	O
at	O
two	O
divided	O
daily	O
doses	O
from	O
days	O
1	O
to	O
7	O
)	O
","	O
repeated	O
every	O
2	O
weeks	O
.	O
	
The	O
dose	O
of	O
oral	O
fluoropyrimidine	B-DRUG
was	O
escalated	O
in	O
consecutive	O
cohorts	O
of	O
three	O
to	O
six	O
patients	O
from	O
2500	O
to	O
4000	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
.	O
	
After	O
having	O
defined	O
the	O
toxic	O
dose	O
","	O
nine	O
additional	O
patients	O
were	O
entered	O
at	O
the	O
MTD	O
/	O
recommended	O
dose	O
to	O
confirm	O
its	O
safety	O
profile	O
","	O
and	O
assure	O
suitability	O
for	O
future	O
phase	O
II	O
/	O
III	O
studies	O
.	O
	
In	O
the	O
phase	O
I	O
part	O
of	O
the	O
study	O
","	O
21	O
patients	O
were	O
enrolled	O
","	O
and	O
a	O
total	O
of	O
222	O
courses	O
were	O
administered	O
through	O
four	O
dose	O
levels	O
of	O
capecitabine	B-DRUG
combined	O
with	O
oxaliplatin	B-DRUG
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Gastrointestinal	B-TOXI
toxicities	I-TOXI
","	O
predominantly	O
diarrhea	B-TOXI
","	O
were	O
the	O
principal	O
DLTs	O
.	O
	
Other	O
severe	O
adverse	O
events	O
included	O
grade	O
3	O
asthenia	B-TOXI
","	O
acute	B-TOXI
neurological	I-TOXI
symptoms	I-TOXI
and	O
skin	B-TOXI
toxicity	I-TOXI
.	O
	
The	O
combination	O
was	O
not	O
myelosuppressive	O
","	O
eliciting	O
only	O
sporadically	O
grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
and	O
/	O
or	O
thrombocytopenia	B-TOXI
.	O
	
There	O
was	O
no	O
alopecia	B-TOXI
","	O
and	O
only	O
a	O
few	O
patients	O
experienced	O
mild	O
symptoms	O
of	O
hand-foot	B-TOXI
syndrome	I-TOXI
.	O
	
Externally	O
reviewed	O
objective	O
responses	O
were	O
noted	O
in	O
15	O
of	O
all	O
30	O
evaluable	O
patients	O
(	O
overall	O
response	O
rate	O
","	O
50	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
31	O
%	O
to	O
69	O
%	O
)	O
including	O
three	O
complete	O
remissions	O
and	O
median	O
progression-free	O
survival	O
was	O
8.8	O
months	O
(	O
range	O
7-14+	O
months	O
)	O
.	O
	
Overall	O
results	O
of	O
this	O
study	O
indicate	O
that	O
the	O
administration	O
of	O
clinically	O
relevant	O
single-agent	O
doses	O
of	O
both	O
capecitabine	B-DRUG
and	O
oxaliplatin	B-DRUG
is	O
feasible	O
and	O
seems	O
to	O
result	O
in	O
promising	O
therapeutic	O
activity	O
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
On	O
the	O
basis	O
of	O
the	O
toxicological	O
profile	O
of	O
the	O
combination	O
regimen	O
shown	O
in	O
the	O
present	O
study	O
","	O
oxaliplatin	B-DRUG
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
2-h	O
intravenous	O
infusion	O
every	O
2	O
weeks	O
administered	O
in	O
combination	O
with	O
capecitabine	B-DRUG
3500	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
x7	O
in	O
two	O
divided	O
doses	O
is	O
recommended	O
for	O
further	O
evaluations	O
.	O
	
Phase	O
I	O
trial	O
of	O
gemcitabine	B-DRUG
","	O
administered	O
as	O
a	O
standard	O
and	O
constant	O
dose-rate	O
infusion	O
","	O
in	O
combination	O
with	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
(	O
LOA-2	O
)	O
.	O
	
	
The	O
major	O
purposes	O
of	O
this	O
study	O
were	O
to	O
determine	O
the	O
maximally	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
","	O
toxicity	O
profile	O
","	O
and	O
antitumor	O
activity	O
of	O
gemcitabine	B-DRUG
and	O
paclitaxel	B-DRUG
combination	O
therapy	O
when	O
administered	O
to	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
","	O
using	O
two	O
infusion	O
schedules	O
of	O
each	O
agent	O
.	O
	
Paclitaxel	B-DRUG
was	O
administered	O
on	O
day	O
1	O
","	O
followed	O
by	O
gemcitabine	B-DRUG
","	O
and	O
gemcitabine	B-DRUG
alone	O
was	O
administered	O
on	O
day	O
8	O
","	O
of	O
each	O
21-day	O
treatment	O
course	O
.	O
	
In	O
the	O
initial	O
phase	O
of	O
the	O
trial	O
","	O
paclitaxel	B-DRUG
was	O
administered	O
during	O
3	O
hours	O
and	O
gemcitabine	B-DRUG
during	O
30	O
minutes	O
(	O
schedule	O
A	O
)	O
.	O
	
After	O
the	O
MTD	O
was	O
determined	O
on	O
this	O
schedule	O
","	O
patients	O
were	O
then	O
treated	O
with	O
paclitaxel	B-DRUG
during	O
1	O
hour	O
and	O
gemcitabine	B-DRUG
at	O
a	O
fixed	O
dose-rate	O
of	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
min	O
(	O
schedule	O
B	O
)	O
.	O
	
Forty-six	O
patients	O
were	O
treated	O
with	O
176	O
courses	O
at	O
7	O
dose	O
levels	O
.	O
	
The	O
MTD	O
for	O
schedule	O
A	O
was	O
"1,300"	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
for	O
schedule	O
B	O
was	O
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
gemcitabine	B-DRUG
and	O
paclitaxel	B-DRUG
","	O
respectively	O
.	O
	
The	O
DLT	O
for	O
schedule	O
A	O
was	O
neutropenia	B-TOXI
and	O
for	O
schedule	O
B	O
was	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
.	O
	
Nonhematologic	B-TOXI
toxicity	I-TOXI
was	O
relatively	O
mild	O
.	O
	
Gemcitabine	B-DRUG
and	O
paclitaxel	B-DRUG
","	O
using	O
both	O
schedules	O
of	O
administration	O
in	O
the	O
current	O
trial	O
","	O
is	O
a	O
promising	O
chemotherapeutic	O
regimen	O
.	O
	
Gemcitabine	B-DRUG
and	O
interferon-alpha	B-DRUG
2b	I-DRUG
in	O
solid	B-CANCER
tumors	I-CANCER
:	O
a	O
phase	O
I	O
study	O
in	O
patients	O
with	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
","	O
ovarian	B-CANCER
","	O
pancreatic	B-CANCER
or	O
renal	B-CANCER
cancer	I-CANCER
.	O
	
	
We	O
performed	O
a	O
phase	O
I	O
study	O
combining	O
gemcitabine	B-DRUG
and	O
interferon	B-DRUG
(	I-DRUG
IFN	I-DRUG
)	I-DRUG
=-	I-DRUG
2b	I-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
recommended	O
doses	O
for	O
phase	O
II	O
trials	O
.	O
	
Five	O
dose	O
levels	O
of	O
gemcitabine	B-DRUG
(	O
mg	O
/	O
m	O
)	O
/	O
IFN-	B-DRUG
(	O
x10	O
IU	O
)	O
were	O
planned	O
:	O
500	O
/	O
5	O
","	O
1000	O
/	O
5	O
","	O
1000	O
/	O
7	O
","	O
1000	O
/	O
10	O
and	O
1200	O
/	O
10	O
.	O
	
Gemcitabine	B-DRUG
was	O
given	O
once	O
weekly	O
and	O
IFN	B-DRUG
3	O
x	O
weekly	O
for	O
3	O
consecutive	O
weeks	O
followed	O
by	O
1	O
week	O
of	O
rest	O
(	O
28-day	O
cycles	O
)	O
.	O
	
Between	O
February	O
1997	O
and	O
June	O
1999	O
","	O
21	O
patients	O
with	O
advanced	B-CANCER
pancreatic	I-CANCER
(	O
3	O
)	O
","	O
ovarian	O
(	O
1	O
)	O
","	O
renal	O
(	O
10	O
)	O
and	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
;	O
7	O
)	O
were	O
enrolled	O
.	O
	
The	O
MTD	O
was	O
reached	O
at	O
gemcitabine	B-DRUG
1000	O
mg	O
/	O
m	O
and	O
IFN-	B-DRUG
7	O
x	O
10	O
IU	O
","	O
with	O
two	O
of	O
three	O
patients	O
having	O
dose-limiting	O
toxicity	O
(	O
thrombocytopenia	B-TOXI
)	O
.	O
	
The	O
predominant	O
hematologic	B-TOXI
toxicities	I-TOXI
(	O
grade	O
3	O
/	O
4	O
)	O
were	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
(	O
13	O
and	O
five	O
patients	O
","	O
respectively	O
)	O
.	O
	
Three	O
patients	O
had	O
moderate	O
neutropenic	B-TOXI
fever	I-TOXI
and	O
one	O
had	O
grade	O
4	O
AST	O
/	O
ALT	O
;	O
none	O
required	O
hospitalization	O
.	O
	
Of	O
the	O
18	O
evaluable	O
patients	O
","	O
responses	O
included	O
one	O
partial	O
response	O
(	O
NSCLC	B-CANCER
)	O
and	O
10	O
stable	O
diseases	O
(	O
eight	O
renal	B-CANCER
cancer	I-CANCER
)	O
.	O
	
We	O
conclude	O
that	O
the	O
recommended	O
phase	O
II	O
study	O
regimen	O
is	O
gemcitabine	B-DRUG
1000	O
mg	O
/	O
m	O
and	O
IFN-	B-DRUG
5	O
x	O
10	O
IU	O
","	O
every	O
28	O
days	O
.	O
	
The	O
results	O
","	O
particularly	O
those	O
in	O
metastatic	B-CANCER
renal	I-CANCER
carcinoma	I-CANCER
","	O
are	O
encouraging	O
and	O
worthy	O
of	O
further	O
evaluation	O
in	O
phase	O
II	O
trials	O
.	O
	
Phase	O
I	O
study	O
of	O
pegylated	B-DRUG
liposomal	I-DRUG
doxorubicin	I-DRUG
and	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
malignancies	I-CANCER
.	O
	
	
Pegylated	B-DRUG
liposomal	I-DRUG
doxorubicin	I-DRUG
(	O
PEG-LD	B-DRUG
)	O
and	O
gemcitabine	B-DRUG
have	O
single-agent	O
activity	O
in	O
breast	B-CANCER
and	I-CANCER
ovarian	I-CANCER
carcinoma	I-CANCER
patients	O
.	O
	
We	O
conducted	O
a	O
Phase	O
I	O
trial	O
to	O
evaluate	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
toxicities	O
of	O
this	O
combination	O
in	O
patients	O
with	O
advanced	B-CANCER
malignancies	I-CANCER
.	O
	
Twenty-six	O
patients	O
with	O
refractory	O
or	O
recurrent	B-CANCER
malignancies	I-CANCER
were	O
enrolled	O
in	O
this	O
dose	O
escalation	O
trial	O
.	O
	
Dose	O
escalation	O
proceeded	O
from	O
a	O
starting	O
level	O
of	O
PEG-LD	B-DRUG
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
gemcitabine	B-DRUG
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
administered	O
on	O
Days	O
1	O
and	O
15	O
of	O
a	O
28-day	O
cycle	O
.	O
	
The	O
MTD	O
was	O
PEG-LD	B-DRUG
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
gemcitabine	B-DRUG
2000	O
mg	O
/	O
m	O
(	O
2	O
)	O
administered	O
on	O
Days	O
1	O
and	O
15	O
of	O
a	O
28-day	O
cycle	O
.	O
	
Dose-limiting	O
toxicity	O
","	O
a	O
Grade	O
3	O
rash	B-TOXI
","	O
was	O
observed	O
in	O
one	O
patient	O
during	O
Cycle	O
1	O
and	O
Grade	O
3	O
stomatitis	B-TOXI
and	O
a	O
rash	B-TOXI
were	O
observed	O
in	O
a	O
second	O
patient	O
during	O
Cycle	O
2	O
after	O
administration	O
of	O
PEG-LD	B-DRUG
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
gemcitabine	B-DRUG
2000	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Other	O
side	O
effects	O
included	O
palmar-plantar	B-TOXI
erythrodysesthesia	I-TOXI
","	O
nausea	B-TOXI
","	O
and	O
fatigue	B-TOXI
.	O
	
One	O
complete	O
and	O
two	O
partial	O
responses	O
were	O
observed	O
.	O
	
The	O
recommended	O
Phase	O
II	O
dose	O
is	O
PEG-LD	B-DRUG
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
with	O
gemcitabine	B-DRUG
2000	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
Days	O
1	O
and	O
15	O
of	O
a	O
28-day	O
cycle	O
.	O
	
A	O
trial	O
with	O
this	O
combination	O
is	O
currently	O
ongoing	O
at	O
this	O
institution	O
comprising	O
patients	O
with	O
refractory	O
ovarian	B-CANCER
carcinoma	I-CANCER
.	O
	
Phase	O
I	O
study	O
of	O
rubitecan	B-DRUG
and	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
malignancies	I-CANCER
.	O
	
	
Rubitecan	B-DRUG
(	O
9-nitrocamptothecin	B-DRUG
","	O
9-NC	B-DRUG
","	O
Orathecin	B-DRUG
)	O
and	O
gemcitabine	B-DRUG
have	O
single-agent	O
activity	O
in	O
pancreatic	B-CANCER
and	I-CANCER
ovarian	I-CANCER
carcinoma	I-CANCER
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
trial	O
to	O
evaluate	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
toxicities	O
of	O
this	O
combination	O
in	O
advanced	B-CANCER
malignancies	I-CANCER
.	O
	
Twenty-one	O
patients	O
with	O
refractory	O
or	O
recurrent	B-CANCER
malignancies	I-CANCER
were	O
enrolled	O
in	O
this	O
dose	O
escalation	O
trial	O
.	O
	
Dose	O
escalation	O
proceeded	O
from	O
a	O
starting	O
level	O
of	O
rubitecan	B-DRUG
at	O
0.75	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
administered	O
orally	O
on	O
days	O
1月5日	O
and	O
8月12日	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
administered	O
intravenously	O
on	O
days	O
1	O
and	O
8	O
of	O
a	O
21-day	O
cycle	O
.	O
	
The	O
MTD	O
was	O
defined	O
as	O
rubitecan	B-DRUG
1	O
mg	O
/	O
m	O
(	O
2	O
)	O
administered	O
orally	O
days	O
1月5日	O
and	O
8月12日	O
","	O
and	O
gemcitabine	B-DRUG
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
administered	O
intravenously	O
over	O
30	O
min	O
days	O
1	O
and	O
8	O
","	O
given	O
every	O
21	O
days	O
.	O
	
Dose-limiting	O
toxicity	O
was	O
myelosuppression	B-TOXI
including	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
.	O
	
Other	O
side	O
effects	O
included	O
diarrhea	B-TOXI
","	O
nausea	B-TOXI
","	O
vomiting	B-TOXI
and	O
fatigue	B-TOXI
.	O
	
Five	O
patients	O
with	O
stable	O
disease	O
were	O
observed	O
among	O
18	O
evaluable	O
patients	O
.	O
	
The	O
recommended	O
phase	O
II	O
dose	O
is	O
rubitecan	B-DRUG
1	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
orally	O
on	O
days	O
1月5日	O
and	O
8月12日	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
30-min	O
intravenous	O
infusion	O
on	O
days	O
1	O
and	O
8	O
of	O
a	O
21-day	O
cycle	O
.	O
	
A	O
phase	O
I	O
trial	O
of	O
weekly	O
docetaxel	B-DRUG
and	O
cisplatinum	B-DRUG
combined	O
to	O
concurrent	O
hyperfractionated	O
radiotherapy	O
for	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
and	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
	
We	O
conducted	O
a	O
phase	O
I	O
study	O
to	O
evaluate	O
the	O
activity	O
and	O
tolerability	O
of	O
concurrent	O
docetaxel	B-DRUG
and	O
cisplatinum	B-DRUG
radiosensitization	O
with	O
hyperfractionated	O
irradiation	O
","	O
in	O
patients	O
with	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
and	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	O
SCCHN	B-CANCER
)	O
.	O
	
Nine	O
patients	O
(	O
5	O
stage	O
III	O
(	O
A	O
)	O
and	O
4	O
III	O
(	O
B	O
)	O
)	O
with	O
NSCLC	B-CANCER
","	O
and	O
15	O
with	O
SCCHN	B-CANCER
(	O
10	O
stage	O
III	O
and	O
5	O
IV	O
)	O
were	O
treated	O
with	O
a	O
b.i.d.	O
hyperfractionated	O
(	O
HF	O
)	O
radiotherapy	O
schedule	O
.	O
	
The	O
normalized	O
total	O
dose	O
for	O
alpha	O
/	O
beta	O
ratio	O
=	O
10	O
Gy	O
was	O
69.6	O
Gy	O
for	O
NSCLC	B-CANCER
and	O
80.5	O
Gy	O
for	O
SCCHN	B-CANCER
patients	O
.	O
	
The	O
standard	O
dose	O
of	O
cisplatin	B-DRUG
(	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
was	O
given	O
combined	O
to	O
docetaxel	B-DRUG
on	O
a	O
weekly	O
basis	O
.	O
	
The	O
docetaxel	B-DRUG
starting	O
dose	O
level	O
was	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
week	O
and	O
was	O
escalated	O
by	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
increments	O
in	O
cohorts	O
of	O
8	O
patients	O
(	O
5	O
SCCHN	B-CANCER
and	O
3	O
NSCLC	B-CANCER
)	O
.	O
	
DLT	O
(	O
grade	O
3	O
malaise	B-TOXI
)	O
was	O
observed	O
in	O
4	O
out	O
of	O
8	O
patients	O
treated	O
at	O
the	O
16	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
week	O
docetaxel	B-DRUG
dose	O
level	O
.	O
	
The	O
13	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
week	O
docetaxel	B-DRUG
dose	O
level	O
was	O
defined	O
as	O
the	O
MTD	O
causing	O
grade	O
3	O
mucositis	B-TOXI
in	O
4	O
out	O
of	O
8	O
patients	O
.	O
	
In	O
total	O
4	O
(	O
17	O
%	O
)	O
patients	O
developed	O
grade	O
3	O
neutropenia	B-TOXI
.	O
	
G-CSF	B-DRUG
support	O
was	O
given	O
in	O
1	O
/	O
8	O
","	O
4	O
/	O
8	O
","	O
and	O
5	O
/	O
8	O
patients	O
treated	O
at	O
the	O
10	O
","	O
13	O
and	O
16	O
mg	O
/	O
m	O
(	O
2	O
)	O
docetaxel	B-DRUG
dose	O
levels	O
respectively	O
.	O
	
Fatigue	B-TOXI
was	O
the	O
most	O
common	O
adverse	O
event	O
(	O
5	O
/	O
24	O
:	O
21	O
%	O
)	O
and	O
was	O
responsible	O
for	O
more	O
than	O
1	O
week	O
treatment	O
delay	O
in	O
4	O
out	O
of	O
8	O
patients	O
treated	O
at	O
the	O
16	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
week	O
docetaxel	B-DRUG
dose	O
level	O
.	O
	
Nine	O
(	O
3	O
NSCLC	B-CANCER
and	O
6	O
SCCHN	B-CANCER
patients	O
:	O
37.5	O
%	O
)	O
had	O
treatment	O
delay	O
of	O
1	O
week	O
","	O
while	O
7	O
(	O
3	O
NSCLC	B-CANCER
and	O
4	O
SCCHN	B-CANCER
:	O
29	O
%	O
)	O
had	O
delays	O
of	O
2	O
weeks	O
for	O
combined	O
chemoradiation	B-TOXI
sequelae	I-TOXI
.	O
	
Acute	B-TOXI
hypersensitivity	I-TOXI
reactions	I-TOXI
occurred	O
in	O
3	O
(	O
12.5	O
%	O
)	O
patients	O
","	O
and	O
grade	O
3	O
mucositis	B-TOXI
in	O
2	O
/	O
8	O
","	O
5	O
/	O
8	O
and	O
6	O
/	O
8	O
patients	O
","	O
treated	O
at	O
10	O
","	O
13	O
and	O
16	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
week	O
docetaxel	B-DRUG
dose	O
levels	O
respectively	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
79	O
%	O
(	O
CI	O
=	O
63-96	O
%	O
)	O
with	O
33	O
%	O
and	O
53	O
%	O
CRs	O
for	O
NSCLC	B-CANCER
and	O
SCCHN	B-CANCER
patients	O
respectively	O
.	O
	
There	O
were	O
3	O
deaths	B-TOXI
among	O
9	O
NSCLC	B-CANCER
and	O
4	O
among	O
15	O
SCCHN	B-CANCER
patients	O
.	O
	
Local	O
and	O
/	O
or	O
distant	B-TOXI
disease	I-TOXI
recurrences	I-TOXI
were	O
shown	O
in	O
4	O
NSCLC	B-CANCER
and	O
in	O
6	O
SCCHN	B-CANCER
patients	O
;	O
5	O
NSCLC	B-CANCER
and	O
9	O
SCCHN	B-CANCER
patients	O
are	O
alive	O
with	O
no	O
evidence	O
of	O
tumor	O
progression	O
at	O
8.5	O
months	O
mean	O
follow-up	O
time	O
.	O
	
Radiosensitization	O
with	O
docetaxel	B-DRUG
and	O
cisplatin	B-DRUG
given	O
concurrently	O
with	O
HF	O
(	O
b.i.d.	O
)	O
radiotherapy	O
on	O
a	O
weekly	O
basis	O
is	O
a	O
promising	O
approach	O
and	O
the	O
recommended	O
dose	O
for	O
further	O
phase	O
II	O
studies	O
is	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
week	O
for	O
both	O
drugs	O
.	O
	
The	O
antitumor	O
activity	O
shown	O
was	O
significant	O
in	O
both	O
types	O
of	O
tumors	O
.	O
	
The	O
incorporation	O
of	O
docetaxel	B-DRUG
in	O
chemoradiotherapy	O
regimens	O
for	O
future	O
treatment	O
of	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
lung	I-CANCER
and	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
","	O
merits	O
evaluation	O
in	O
phase	O
II	O
and	O
III	O
trials	O
.	O
	
Temozolomide	B-DRUG
in	O
combination	O
with	O
interferon	B-DRUG
alpha-2b	I-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
melanoma	I-CANCER
:	O
a	O
phase	O
I	O
dose-escalation	O
study	O
.	O
	
	
Metastatic	B-CANCER
melanoma	I-CANCER
(	O
MM	B-CANCER
)	O
is	O
associated	O
with	O
a	O
high	O
risk	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
metastases	O
","	O
and	O
current	O
chemotherapy	O
does	O
not	O
adequately	O
treat	O
or	O
protect	O
patients	O
with	O
MM	O
against	O
CNS	O
metastases	O
.	O
	
Therefore	O
","	O
the	O
authors	O
initiated	O
a	O
Phase	O
I	O
study	O
to	O
determine	O
the	O
pharmacokinetics	O
and	O
safety	O
profile	O
of	O
temozolomide	B-DRUG
(	O
TMZ	O
)	O
","	O
a	O
novel	O
oral	O
alkylating	B-DRUG
agent	I-DRUG
known	O
to	O
cross	O
the	O
blood-brain	O
barrier	O
","	O
in	O
combination	O
with	O
interferon	B-DRUG
alpha-2b	I-DRUG
(	O
IFN-alpha2b	B-DRUG
)	O
.	O
	
Twenty-three	O
patients	O
with	O
MM	B-CANCER
were	O
enrolled	O
in	O
this	O
single-center	O
","	O
open-label	O
study	O
.	O
	
Patients	O
with	O
CNS	O
metastasis	O
were	O
excluded	O
.	O
	
One	O
cohort	O
(	O
n	O
=	O
6	O
patients	O
)	O
received	O
oral	O
TMZ	B-DRUG
(	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
day	O
)	O
for	O
5	O
days	O
every	O
28-day	O
cycle	O
plus	O
subcutaneous	O
IFN-alpha2b	B-DRUG
(	O
5	O
million	O
International	O
Units	O
[	O
MIU	O
]	O
/	O
m	O
(	O
2	O
)	O
per	O
day	O
","	O
3	O
times	O
per	O
week	O
)	O
.	O
	
A	O
second	O
cohort	O
(	O
n	O
=	O
17	O
patients	O
)	O
received	O
TMZ	B-DRUG
150	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
day	O
on	O
the	O
same	O
schedule	O
plus	O
escalating	O
doses	O
of	O
IFN-alpha2b	B-DRUG
(	O
5	O
MIU	O
/	O
m	O
(	O
2	O
)	O
per	O
day	O
","	O
7.5	O
MIU	O
/	O
m	O
(	O
2	O
)	O
per	O
day	O
","	O
and	O
10	O
MIU	O
/	O
m	O
(	O
2	O
)	O
per	O
day	O
3	O
times	O
per	O
week	O
)	O
.	O
	
The	O
most	O
common	O
adverse	O
events	O
were	O
fatigue	B-TOXI
","	O
fever	B-TOXI
","	O
nausea	B-TOXI
/	O
emesis	B-TOXI
","	O
anxiety	B-TOXI
","	O
and	O
diarrhea	B-TOXI
.	O
	
Most	O
toxicity	O
was	O
mild	O
to	O
moderate	O
in	O
severity	O
.	O
	
The	O
primary	O
dose-limiting	O
toxicity	O
was	O
thrombocytopenia	B-TOXI
.	O
	
The	O
maximum	O
tolerated	O
dose	O
was	O
either	O
TMZ	B-DRUG
150	O
mg	O
/	O
m	O
(	O
2	O
)	O
plus	O
IFN-alpha2b	B-DRUG
7.5	O
MIU	O
/	O
m	O
(	O
2	O
)	O
or	O
TMZ	B-DRUG
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
plus	O
IFN-alpha2b	B-DRUG
5	O
MIU	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Four	O
patients	O
(	O
17	O
%	O
)	O
had	O
objective	O
responses	O
(	O
one	O
complete	O
response	O
and	O
three	O
partial	O
responses	O
)	O
","	O
and	O
four	O
patients	O
had	O
stable	O
disease	O
.	O
	
The	O
median	O
survival	O
was	O
9	O
months	O
.	O
	
The	O
pharmacokinetics	O
of	O
TMZ	B-DRUG
were	O
not	O
affected	O
by	O
coadministration	O
of	O
IFN-alpha2b	B-DRUG
.	O
	
TMZ	B-DRUG
can	O
be	O
combined	O
safely	O
with	O
IFN-alpha2b	B-DRUG
.	O
	
This	O
regimen	O
demonstrated	O
clinical	O
activity	O
in	O
patients	O
with	O
MM	B-DRUG
and	O
merits	O
further	O
investigation	O
to	O
define	O
its	O
effect	O
on	O
the	O
incidence	O
of	O
brain	O
metastases	O
.	O
	
Phase	O
I	O
trial	O
of	O
weekly	O
docetaxel	B-DRUG
and	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
refractory	O
malignancies	B-CANCER
.	O
	
	
A	O
Phase	O
I	O
study	O
using	O
weekly	O
docetaxel	B-DRUG
and	O
gemcitabine	B-DRUG
was	O
conducted	O
to	O
investigate	O
toxicity	O
;	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
each	O
agent	O
;	O
and	O
","	O
in	O
a	O
preliminary	O
fashion	O
","	O
to	O
determine	O
the	O
antitumor	O
activity	O
of	O
the	O
combination	O
.	O
	
Docetaxel	B-DRUG
and	O
gemcitabine	B-DRUG
were	O
administered	O
intravenously	O
on	O
Days	O
1	O
","	O
8	O
","	O
and	O
15	O
every	O
28	O
days	O
.	O
	
The	O
dose	O
levels	O
of	O
docetaxel	B-DRUG
and	O
gemcitabine	B-DRUG
were	O
as	O
follows	O
:	O
Level	O
I	O
","	O
docetaxel	B-DRUG
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
gemcitabine	B-DRUG
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
;	O
Level	O
II	O
","	O
docetaxel	B-DRUG
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
gemcitabine	B-DRUG
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
;	O
Level	O
III	O
","	O
docetaxel	B-DRUG
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
gemcitabine	B-DRUG
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
;	O
Level	O
IV	O
","	O
docetaxel	B-DRUG
36	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
gemcitabine	B-DRUG
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
;	O
and	O
Level	O
V	O
","	O
docetaxel	B-DRUG
36	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
gemcitabine	B-DRUG
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Thirty-three	O
eligible	O
patients	O
were	O
entered	O
.	O
	
The	O
diagnoses	O
were	O
as	O
follows	O
:	O
Eleven	O
patients	O
had	O
nonsmall	B-CANCER
cell	I-CANCER
lung	I-CANCER
carcinoma	I-CANCER
","	O
3	O
patients	O
had	O
carcinoma	B-CANCER
of	I-CANCER
the	I-CANCER
bladder	I-CANCER
","	O
3	O
patients	O
had	O
renal	B-CANCER
carcinoma	I-CANCER
","	O
2	O
patients	O
had	O
adrenal	B-CANCER
carcinoma	I-CANCER
","	O
5	O
patients	O
had	O
unknown	B-CANCER
primary	I-CANCER
tumors	I-CANCER
","	O
and	O
9	O
patients	O
had	O
miscellaneous	B-CANCER
malignancies	I-CANCER
.	O
	
Fifty-nine	O
percent	O
of	O
patients	O
had	O
received	O
prior	O
chemotherapy	O
.	O
	
The	O
median	O
age	O
was	O
62	O
years	O
(	O
range	O
","	O
27-77	O
years	O
)	O
","	O
and	O
the	O
median	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
was	O
1	O
(	O
range	O
","	O
0-1	O
)	O
.	O
	
Five	O
patients	O
were	O
treated	O
at	O
Dose	O
Levels	O
I	O
and	O
II	O
","	O
6	O
patients	O
were	O
treated	O
at	O
Dose	O
Levels	O
III	O
and	O
V	O
","	O
and	O
11	O
patients	O
were	O
treated	O
at	O
Dose	O
Level	O
IV	O
.	O
	
Grade	O
3月4日	O
toxicities	O
during	O
Cycle	O
I	O
included	O
neutropenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
mucositis	B-TOXI
","	O
and	O
diarrhea	B-TOXI
.	O
	
Dose-limiting	O
toxicity	O
","	O
consisting	O
of	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
","	O
occurred	O
in	O
three	O
of	O
six	O
patients	O
at	O
Dose	O
Level	O
V.	O
The	O
combination	O
of	O
docetaxel	B-DRUG
36	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
gemcitabine	B-DRUG
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
Dose	O
Level	O
IV	O
)	O
was	O
determined	O
as	O
the	O
MTD	O
and	O
was	O
the	O
recommended	O
Phase	O
II	O
dose	O
.	O
	
Two	O
patients	O
had	O
a	O
partial	O
response	O
:	O
one	O
patient	O
with	O
bladder	B-CANCER
carcinoma	I-CANCER
(	O
Dose	O
Level	O
II	O
)	O
and	O
one	O
patient	O
with	O
nonsmall	B-CANCER
cell	I-CANCER
lung	I-CANCER
carcinoma	I-CANCER
(	O
Dose	O
Level	O
III	O
)	O
.	O
	
Overall	O
","	O
weekly	O
docetaxel	B-DRUG
and	O
gemcitabine	B-DRUG
were	O
well	O
tolerated	O
.	O
	
Further	O
studies	O
using	O
this	O
combination	O
are	O
planned	O
","	O
including	O
a	O
Phase	O
II	O
trial	O
in	O
patients	O
with	O
advanced	B-CANCER
nonsmall	I-CANCER
cell	I-CANCER
lung	I-CANCER
carcinoma	I-CANCER
.	O
	
A	O
dose-escalation	O
and	O
pharmacokinetic	O
study	O
of	O
gemcitabine	B-DRUG
and	O
oxaliplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Gemcitabine	B-DRUG
and	O
oxaliplatin	B-DRUG
have	O
broad	O
antineoplastic	O
activity	O
and	O
favorable	O
toxicity	O
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
study	O
to	O
determine	O
the	O
maximum	O
tolerated	O
doses	O
(	O
MTDs	O
)	O
and	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
of	O
the	O
combination	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Sixty-eight	O
patients	O
with	O
advanced	B-CANCER
stage	I-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
enrolled	O
.	O
	
Treatment	O
was	O
first-line	O
for	O
35	O
%	O
of	O
patients	O
","	O
second-line	O
for	O
27	O
%	O
","	O
and	O
third-line	O
for	O
38	O
%	O
.	O
	
Gemcitabine	B-DRUG
was	O
administered	O
at	O
escalating	O
doses	O
of	O
1000-2000	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
30-min	O
intravenous	O
(	O
i.v.	O
)	O
infusion	O
on	O
days	O
1	O
and	O
8	O
and	O
oxaliplatin	B-DRUG
at	O
60-130	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
4-h	O
i.v.	O
infusion	O
on	O
day	O
8	O
every	O
21	O
days	O
without	O
growth	O
factor	O
support	O
.	O
	
The	O
MTD	O
was	O
defined	O
at	O
gemcitabine	B-DRUG
1800	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
and	O
8	O
and	O
oxaliplatin	B-DRUG
130	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
8	O
Twelve	O
dose	O
levels	O
were	O
evaluated	O
and	O
DLTs	O
occurring	O
during	O
the	O
first	O
cycle	O
consisted	O
of	O
grade	O
4	O
neutropenia	B-TOXI
","	O
grade	O
3	O
asthenia	B-TOXI
or	O
mucositis	B-TOXI
and	O
grade	O
1月3日	O
neutropenia	B-TOXI
or	O
thrombocytopenia	B-TOXI
resulting	O
in	O
treatment	O
delays	O
.	O
	
A	O
total	O
of	O
266	O
cycles	O
were	O
administered	O
with	O
only	O
one	O
episode	O
of	O
febrile	B-TOXI
neutropenia	I-TOXI
and	O
no	O
toxic	B-TOXI
deaths	I-TOXI
.	O
	
Seven	O
(	O
3	O
%	O
)	O
and	O
26	O
(	O
10	O
%	O
)	O
cycles	O
were	O
complicated	O
by	O
grade	O
4	O
and	O
3	O
neutropenia	B-TOXI
","	O
respectively	O
","	O
three	O
(	O
1	O
%	O
)	O
and	O
13	O
(	O
5	O
%	O
)	O
by	O
grade	O
4	O
and	O
3	O
thrombocytopenia	B-TOXI
","	O
and	O
eight	O
(	O
3	O
%	O
)	O
by	O
grade	O
3	O
anemia	B-TOXI
.	O
	
The	O
most	O
common	O
non-hematological	B-TOXI
toxicity	I-TOXI
was	O
grade	O
2	O
/	O
3	O
asthenia	B-TOXI
observed	O
in	O
23	O
%	O
of	O
cycles	O
.	O
	
Responses	O
were	O
observed	O
in	O
patients	O
with	O
a	O
variety	O
of	O
epithelial	B-CANCER
neoplasms	I-CANCER
.	O
	
The	O
pharmacokinetic	O
study	O
revealed	O
no	O
significant	O
interaction	O
between	O
the	O
two	O
drugs	O
.	O
	
The	O
combination	O
of	O
gemcitabine	B-DRUG
and	O
oxaliplatin	B-DRUG
has	O
excellent	O
tolerability	O
and	O
promising	O
activity	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
As	O
the	O
MTD	O
exceeds	O
the	O
recommended	O
single-agent	O
dose	O
for	O
gemcitabine	B-DRUG
","	O
and	O
a	O
dose-response	O
effect	O
has	O
not	O
been	O
established	O
","	O
we	O
recommend	O
using	O
both	O
drugs	O
at	O
full	O
doses	O
","	O
e.g.	O
gemcitabine	B-DRUG
1200-1400	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
and	O
8	O
and	O
oxaliplatin	B-DRUG
130	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
8	O
for	O
further	O
phase	O
II	O
studies	O
.	O
	
Gemcitabine	B-DRUG
and	O
vinorelbine	B-DRUG
followed	O
by	O
docetaxel	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
a	O
multi-institutional	O
phase	O
II	O
trial	O
of	O
nonplatinum	O
sequential	O
triplet	O
combination	O
chemotherapy	O
(	O
JMTO	O
LC00-02	O
)	O
.	O
	
	
To	O
evaluate	O
the	O
efficacy	O
and	O
toxicity	O
of	O
the	O
sequential	O
nonplatinum	O
combination	O
chemotherapy	O
consisting	O
of	O
gemcitabine	B-DRUG
(	O
GEM	B-DRUG
)	O
and	O
vinorelbine	B-DRUG
(	O
VNR	B-DRUG
)	O
followed	O
by	O
docetaxel	B-DRUG
(	O
DOC	B-DRUG
)	O
in	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
","	O
we	O
conducted	O
the	O
multiinstitutional	O
phase	O
II	O
study	O
.	O
	
A	O
total	O
of	O
44	O
chemotherapy-naive	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
were	O
treated	O
with	O
GEM	B-DRUG
1000	O
mg	O
m	O
(	O
-2	O
)	O
and	O
VNR	B-DRUG
25	O
mg	O
m	O
(	O
-2	O
)	O
intravenously	O
on	O
days	O
1	O
and	O
8	O
every	O
3	O
weeks	O
for	O
three	O
cycles	O
.	O
	
DOC	B-DRUG
60	O
mg	O
m	O
(	O
-2	O
)	O
was	O
then	O
administrated	O
intravenously	O
at	O
3-week	O
intervals	O
for	O
three	O
cycles	O
.	O
	
Patients	O
were	O
evaluated	O
for	O
response	O
and	O
toxicity	O
with	O
each	O
cycle	O
of	O
the	O
treatment	O
.	O
	
The	O
major	O
objective	O
response	O
rate	O
was	O
47.7	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
","	O
33.8-62.1	O
%	O
)	O
.	O
	
Median	O
survival	O
time	O
(	O
MST	O
)	O
was	O
15.7	O
months	O
and	O
1-year	O
survival	O
rate	O
was	O
59	O
%	O
.	O
	
In	O
the	O
GEM	B-DRUG
/	I-DRUG
VNR	I-DRUG
cycle	O
","	O
grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
occurred	O
in	O
36.3	O
%	O
","	O
grade	O
3	O
/	O
4	O
anaemia	B-TOXI
in	O
two	O
patients	O
(	O
4.5	O
%	O
)	O
and	O
grade	O
3	O
thrombocytopenia	B-TOXI
in	O
one	O
patient	O
(	O
2.3	O
%	O
)	O
.	O
	
Grade	O
3	O
pneumonitis	B-TOXI
occurred	O
in	O
two	O
patients	O
(	O
4.5	O
%	O
)	O
in	O
GEM	B-DRUG
/	I-DRUG
VNR	I-DRUG
cycles	O
.	O
	
In	O
the	O
DOC	B-DRUG
cycles	O
","	O
grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
occurred	O
in	O
39.4	O
%	O
but	O
no	O
patient	O
experienced	O
grade	O
3	O
/	O
4	O
anaemia	B-TOXI
or	O
thrombocytopenia	B-TOXI
.	O
	
Of	O
the	O
44	O
eligible	O
patients	O
","	O
33	O
patients	O
completed	O
three	O
cycles	O
of	O
GEM	B-DRUG
/	I-DRUG
VNR	I-DRUG
and	O
22	O
patients	O
completed	O
six	O
cycles	O
of	O
planned	O
chemotherapy	O
(	O
three	O
cycles	O
of	O
GEM	B-DRUG
/	I-DRUG
VNR	I-DRUG
followed	O
by	O
three	O
cycles	O
of	O
DOC	B-DRUG
)	O
.	O
	
The	O
sequential	O
triplet	O
nonplatinum	O
chemotherapy	O
consisted	O
of	O
GEM	B-DRUG
/	I-DRUG
VNR	I-DRUG
followed	O
by	O
DOC	B-DRUG
","	O
and	O
was	O
very	O
active	O
and	O
well	O
tolerated	O
.	O
	
This	O
study	O
forms	O
the	O
basis	O
for	O
an	O
ongoing	O
phase	O
III	O
trial	O
that	O
compares	O
this	O
nonplatinum	O
triplet	O
and	O
standard	O
platinum	O
doublet	O
combination	O
(	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
)	O
.	O
	
Final	O
results	O
of	O
a	O
randomized	O
phase	O
III	O
trial	O
comparing	O
cyclophosphamide	B-DRUG
","	O
epirubicin	B-DRUG
","	O
and	O
fluorouracil	B-DRUG
with	O
a	O
dose-intensified	O
epirubicin	B-DRUG
and	O
cyclophosphamide	B-DRUG
=+	I-DRUG
filgrastim	I-DRUG
as	O
neoadjuvant	O
treatment	O
in	O
locally	B-CANCER
advanced	I-CANCER
breast	I-CANCER
cancer	I-CANCER
:	O
an	O
EORTC-NCIC-SAKK	O
multicenter	O
study	O
.	O
	
	
To	O
compare	O
the	O
efficacy	O
of	O
a	O
standard	O
anthracycline-based	B-DRUG
regimen	O
to	O
a	O
dose-intensified	O
anthracycline	B-DRUG
regimen	O
in	O
locally	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Locally	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
patients	O
were	O
randomly	O
assigned	O
onto	O
a	O
study	O
comparing	O
cyclophosphamide	B-DRUG
(	O
C	O
;	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
orally	O
days	O
1	O
to	O
14	O
)	O
","	O
epirubicin	B-DRUG
(	O
E	O
;	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
[	O
IV	O
]	O
days	O
1	O
","	O
8	O
)	O
","	O
and	O
fluorouracil	B-DRUG
(	O
F	O
;	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
days	O
1	O
","	O
8	O
)	O
six	O
cycles	O
every	O
28	O
days	O
versus	O
E	O
(	O
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
day	O
1	O
)	O
","	O
C	O
(	O
830	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
day	O
1	O
)	O
","	O
and	O
granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
(	O
filgrastim	B-DRUG
;	O
5	O
micro	O
g	O
/	O
kg	O
/	O
d	O
subcutaneously	O
days	O
2	O
to	O
13	O
)	O
six	O
cycles	O
every	O
14	O
days	O
.	O
	
The	O
study	O
was	O
designed	O
to	O
detect	O
a	O
15	O
%	O
improvement	O
;	O
that	O
is	O
","	O
from	O
50	O
%	O
to	O
65	O
%	O
in	O
median	O
progression-free	O
survival	O
(	O
PFS	O
)	O
in	O
favor	O
of	O
the	O
dose-intensified	O
regimen	O
.	O
	
A	O
total	O
of	O
448	O
patients	O
were	O
enrolled	O
over	O
a	O
period	O
of	O
3	O
years	O
.	O
	
The	O
median	O
dose	O
intensity	O
delivered	O
for	O
C	O
and	O
E	O
reached	O
","	O
respectively	O
","	O
85	O
%	O
and	O
87	O
%	O
of	O
that	O
planned	O
in	O
the	O
CEF	O
arm	O
and	O
96	O
%	O
and	O
95	O
%	O
of	O
that	O
planned	O
in	O
the	O
EC	O
arm	O
.	O
	
The	O
dose-intensified	O
arm	O
was	O
slightly	O
more	O
emetogenic	B-TOXI
and	O
generated	O
more	O
grade	O
3	O
to	O
4	O
anemia	B-TOXI
but	O
less	O
febrile	B-TOXI
neutropenia	I-TOXI
episodes	O
.	O
	
After	O
a	O
median	O
follow-up	O
of	O
5.5	O
years	O
","	O
277	O
events	O
have	O
been	O
reported	O
.	O
	
The	O
median	O
PFS	O
was	O
34	O
and	O
33.7	O
months	O
for	O
CEF	O
and	O
EC	O
","	O
respectively	O
(	O
P	O
0.68	O
)	O
","	O
and	O
the	O
5-year	O
survival	O
rate	O
was	O
53	O
%	O
and	O
51	O
%	O
for	O
CEF	O
and	O
EC	O
","	O
respectively	O
(	O
P	O
0.94	O
)	O
.	O
	
Dose-intensified	O
EC	O
does	O
not	O
provide	O
a	O
measurable	O
therapeutic	O
benefit	O
over	O
CEF	O
as	O
neoadjuvant	O
chemotherapy	O
for	O
unselected	O
locally	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
patients	O
.	O
	
High-dose	O
consolidation	O
chemotherapy	O
with	O
Idarubicin	B-DRUG
and	O
alkylating	B-DRUG
agents	I-DRUG
following	O
induction	O
with	O
gemcitabine-epirubicin-paclitaxel	B-DRUG
in	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
:	O
a	O
dose	O
finding	O
study	O
.	O
	
	
Preliminary	O
randomized	O
studies	O
have	O
failed	O
to	O
show	O
a	O
survival	O
benefit	O
of	O
high-dose	O
chemotherapy	O
with	O
alkylators	B-DRUG
in	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Idarubicin	B-DRUG
is	O
an	O
active	O
agent	O
in	O
breast	B-CANCER
cancer	I-CANCER
and	O
is	O
suitable	O
for	O
dose	O
escalation	O
.	O
	
We	O
designed	O
a	O
dose	O
finding	O
study	O
with	O
escalating	O
high-dose	O
idarubicin	B-DRUG
(	O
HD-Ida	B-DRUG
)	O
followed	O
by	O
fixed	O
high-dose	O
thiotepa+melphalan	B-DRUG
(	O
HD-TM	B-DRUG
)	O
with	O
peripheral	B-DRUG
blood	I-DRUG
progenitor	I-DRUG
cells	I-DRUG
(	O
PBPC	O
)	O
in	O
MBC	O
patients	O
with	O
stable	O
disease	O
or	O
in	O
partial	O
response	O
after	O
six	O
courses	O
of	O
induction	O
chemotherapy	O
with	O
gemcitabine	B-DRUG
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
days	O
1	O
and	O
4	O
","	O
epirubicin	B-DRUG
90	O
mg	O
/	O
m	O
(	O
2	O
)	O
day	O
1	O
","	O
taxol	O
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
day	O
1	O
(	O
GET	B-DRUG
)	O
.	O
	
Aims	O
of	O
the	O
study	O
were	O
to	O
identify	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
idarubicin	O
","	O
to	O
evaluate	O
the	O
cardiac	O
safety	O
and	O
activity	O
of	O
HD-Ida	B-DRUG
and	O
HD-TM	B-DRUG
after	O
GET	B-DRUG
and	O
to	O
study	O
the	O
pharmacokinetic	O
profile	O
of	O
idarubicin	B-DRUG
and	O
idarubicinol	B-DRUG
.	O
	
A	O
total	O
of	O
14	O
patients	O
were	O
treated	O
.	O
	
Idarubicin	B-DRUG
was	O
administered	O
as	O
a	O
48	O
h	O
continuous	O
i.v.	O
infusion	O
at	O
the	O
following	O
dose	O
levels	O
:	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
three	O
patients	O
)	O
","	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
three	O
patients	O
)	O
","	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
five	O
patients	O
)	O
and	O
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
three	O
patients	O
)	O
.	O
	
Mucositis	B-TOXI
was	O
the	O
dose-limiting	O
toxicity	O
and	O
the	O
MTD	O
was	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
C	O
(	O
max	O
)	O
of	O
Idarubicin	B-DRUG
and	O
idarubicinol	B-DRUG
were	O
7.7+	O
/	O
-2	O
and	O
26.3+	O
/	O
-9.7	O
ng	O
/	O
ml	O
at	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
increased	O
to	O
14.8+3.0	O
and	O
47.4+12.6	O
ng	O
/	O
ml	O
at	O
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
AUCt	O
(	O
0-264	O
)	O
of	O
idarubicin	B-DRUG
and	O
idarubicinol	B-DRUG
increased	O
from	O
423.2+	O
/	O
-111.6	O
and	O
2581+	O
/	O
-606	O
hng	O
/	O
ml	O
at	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
to	O
732.8+	O
/	O
-140.2	O
and	O
4590+	O
/	O
-1258	O
hng	O
/	O
ml	O
at	O
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Conversion	O
rates	O
after	O
HD-Ida	B-DRUG
and	O
HD-TM	B-DRUG
were	O
28.6	O
and	O
38.5	O
%	O
","	O
respectively	O
.	O
	
No	O
episodes	O
of	O
cardiac	B-TOXI
toxicity	I-TOXI
were	O
observed	O
.	O
	
We	O
conclude	O
that	O
HD-Ida	B-DRUG
followed	O
by	O
HD-TM	B-DRUG
is	O
feasible	O
and	O
devoid	O
of	O
cardiac	B-TOXI
toxicity	I-TOXI
.	O
	
Moreover	O
","	O
the	O
activity	O
of	O
HD-Ida	B-DRUG
after	O
a	O
epirubicin-containing	B-DRUG
regimen	O
suggests	O
incomplete	O
cross-resistance	O
between	O
the	O
two	O
drugs	O
.	O
	
Preoperative	O
concurrent	O
chemoradiotherapy	O
in	O
locally	O
advanced	B-CANCER
rectal	I-CANCER
cancer	I-CANCER
with	O
high-dose	O
radiation	O
and	O
oxaliplatin-containing	B-DRUG
regimen	O
:	O
the	O
Lyon	O
R0-04	O
phase	O
II	O
trial	O
.	O
	
	
The	O
combination	O
of	O
radiation	O
","	O
fluorouracil	B-DRUG
","	O
and	O
oxaliplatin	B-DRUG
in	O
locally	O
advanced	B-CANCER
rectal	I-CANCER
cancer	I-CANCER
has	O
been	O
shown	O
to	O
be	O
feasible	O
in	O
a	O
phase	O
I	O
trial	O
.	O
	
The	O
purpose	O
of	O
this	O
phase	O
II	O
trial	O
was	O
to	O
assess	O
tolerance	O
and	O
efficacy	O
of	O
this	O
regimen	O
in	O
a	O
preoperative	O
setting	O
.	O
	
Between	O
May	O
2000	O
and	O
October	O
2001	O
","	O
40	O
operable	O
patients	O
were	O
entered	O
onto	O
the	O
study	O
.	O
	
Radiotherapy	O
was	O
delivered	O
with	O
a	O
three-field	O
technique	O
to	O
a	O
dose	O
of	O
50	O
Gy	O
over	O
5	O
weeks	O
with	O
a	O
concomitant	O
boost	O
approach	O
.	O
	
Two	O
cycles	O
of	O
chemotherapy	O
were	O
given	O
synchronously	O
on	O
weeks	O
1	O
and	O
5	O
","	O
with	O
oxaliplatin	B-DRUG
130	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
followed	O
by	O
5-day	O
continuous	O
infusion	O
of	O
fluorouracil	B-DRUG
350	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
L-folinic	B-DRUG
acid	I-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Surgery	O
was	O
planned	O
5	O
weeks	O
later	O
.	O
	
All	O
patients	O
completed	O
treatment	O
without	O
modification	O
except	O
one	O
who	O
experienced	O
grade	O
3	O
/	O
4	O
toxicity	O
.	O
	
Grade	O
3	O
toxicity	O
was	O
seen	O
in	O
seven	O
patients	O
.	O
	
Surgery	O
was	O
performed	O
in	O
all	O
patients	O
after	O
a	O
mean	O
interval	O
time	O
of	O
5	O
weeks	O
.	O
	
An	O
objective	O
clinical	O
response	O
was	O
seen	O
in	O
30	O
patients	O
(	O
75	O
%	O
)	O
.	O
	
Sphincter-saving	O
surgery	O
was	O
possible	O
in	O
26	O
patients	O
.	O
	
No	O
postoperative	O
deaths	B-TOXI
occurred	O
.	O
	
In	O
four	O
patients	O
(	O
10	O
%	O
)	O
","	O
a	O
reoperation	O
was	O
necessary	O
(	O
anastomotic	B-TOXI
fistula	I-TOXI
","	O
n	O
=	O
2	O
;	O
pelvic	B-TOXI
abscess	I-TOXI
","	O
n	O
=	O
2	O
)	O
.	O
	
In	O
six	O
cases	O
the	O
operative	O
specimen	O
was	O
sterilized	O
(	O
15	O
%	O
)	O
","	O
and	O
in	O
12	O
cases	O
(	O
30	O
%	O
)	O
","	O
only	O
few	O
residual	O
cells	O
were	O
detected	O
.	O
	
Such	O
a	O
combined	O
preoperative	O
chemoradiotherapy	O
and	O
oxaliplatin-containing	B-DRUG
regimen	O
is	O
well	O
tolerated	O
with	O
no	O
increase	O
in	O
surgical	O
toxicity	O
.	O
	
The	O
good	O
response	O
rate	O
observed	O
warrants	O
its	O
use	O
in	O
further	O
clinical	O
trials	O
.	O
	
Phase	O
I	O
trial	O
of	O
gemcitabine	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Gemcitabine	B-DRUG
and	O
paclitaxel	B-DRUG
are	O
chemotherapeutic	O
agents	O
with	O
clinical	O
antitumor	O
activity	O
in	O
a	O
broad	O
range	O
of	O
malignant	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Because	O
of	O
preclinical	O
synergy	O
","	O
unique	O
mechanisms	O
of	O
action	O
and	O
resistance	O
","	O
and	O
nonoverlapping	O
toxicities	O
","	O
gemcitabine	B-DRUG
and	O
paclitaxel	B-DRUG
combinations	O
are	O
attractive	O
for	O
testing	O
in	O
clinical	O
trials	O
.	O
	
Prior	O
weekly	O
gemcitabine	B-DRUG
and	O
paclitaxel	B-DRUG
regimens	O
administered	O
on	O
a	O
28-day	O
cycle	O
have	O
been	O
limited	O
by	O
cumulative	O
hematological	B-TOXI
toxicity	I-TOXI
on	O
day	O
15	O
","	O
thus	O
reducing	O
the	O
planned	O
gemcitabine	B-DRUG
dose	O
intensity	O
.	O
	
We	O
therefore	O
conducted	O
a	O
phase	O
I	O
trial	O
of	O
a	O
21-day	O
schedule	O
of	O
weekly	O
gemcitabine	B-DRUG
and	O
paclitaxel	B-DRUG
to	O
determine	O
the	O
tolerability	O
","	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
and	O
preliminary	O
estimates	O
of	O
efficacy	O
of	O
this	O
regimen	O
.	O
	
Forty-one	O
patients	O
with	O
advanced	B-CANCER
malignant	I-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
accrued	O
.	O
	
Gemcitabine	B-DRUG
was	O
given	O
at	O
a	O
fixed	O
dose	O
of	O
1000	O
mg	O
/	O
m2	O
while	O
paclitaxel	B-DRUG
was	O
administered	O
at	O
an	O
initial	O
dose	O
of	O
60	O
mg	O
/	O
m2	O
","	O
then	O
escalated	O
by	O
15	O
mg	O
/	O
m2	O
increments	O
over	O
seven	O
dose	O
levels	O
to	O
a	O
prospectively	O
planned	O
maximum	O
dose	O
of	O
150	O
mg	O
/	O
m2	O
.	O
	
Both	O
agents	O
were	O
infused	O
intravenously	O
on	O
days	O
one	O
and	O
eight	O
every	O
21	O
days	O
.	O
	
At	O
least	O
three	O
patients	O
were	O
enrolled	O
per	O
dose	O
level	O
.	O
	
No	O
intrapatient	O
dose	O
escalation	O
was	O
allowed	O
.	O
	
All	O
patients	O
were	O
assessable	O
for	O
toxicity	O
and	O
31	O
were	O
assessable	O
for	O
response	O
.	O
	
The	O
regimen	O
was	O
generally	O
well-tolerated	O
.	O
	
Dose-limiting	O
thrombocytopenia	B-DRUG
was	O
observed	O
in	O
one	O
patient	O
at	O
a	O
paclitaxel	B-DRUG
dose	O
of	O
135	O
mg	O
/	O
m2	O
/	O
week	O
(	O
dose	O
level	O
6	O
)	O
.	O
	
After	O
expansion	O
of	O
this	O
dose	O
level	O
by	O
14	O
additional	O
patients	O
","	O
no	O
further	O
dose-limiting	O
toxicities	O
were	O
observed	O
although	O
one	O
patient	O
at	O
dose	O
level	O
seven	O
died	B-TOXI
of	O
neutropenic	B-TOXI
sepsis	I-TOXI
after	O
completing	O
three	O
cycles	O
.	O
	
There	O
were	O
eight	O
partial	O
responders	O
for	O
an	O
overall	O
response	O
proportion	O
of	O
26	O
%	O
(	O
95	O
%	O
CI	O
:	O
11	O
","	O
41	O
)	O
.	O
	
Twelve	O
patients	O
(	O
39	O
%	O
)	O
had	O
stable	O
disease	O
.	O
	
This	O
21-day	O
schedule	O
of	O
gemcitabine	B-DRUG
and	O
paclitaxel	B-DRUG
is	O
safe	O
","	O
well-tolerated	O
","	O
and	O
active	O
.	O
	
The	O
recommended	O
phase	O
II	O
dose	O
is	O
gemcitabine	B-DRUG
1000	O
mg	O
/	O
m2	O
and	O
paclitaxel	B-DRUG
150	O
mg	O
/	O
m2	O
on	O
days	O
one	O
and	O
eight	O
every	O
21	O
days	O
.	O
	
The	O
antitumor	O
activity	O
observed	O
with	O
this	O
regimen	O
warrants	O
further	O
investigation	O
.	O
	
Phase	O
I	O
/	O
II	O
trial	O
of	O
weekly	O
cisplatin	B-DRUG
","	O
etoposide	B-DRUG
","	O
and	O
irinotecan	B-DRUG
chemotherapy	O
for	O
metastatic	B-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
JCOG	O
9507	O
.	O
	
	
Combinations	O
of	O
cisplatin-irinotecan	B-DRUG
and	O
cisplatin-etoposide	B-DRUG
are	O
active	O
and	O
well	O
tolerated	O
in	O
patients	O
with	O
both	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
SCLC	B-CANCER
)	O
and	O
nonsmall-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
To	O
define	O
the	O
recommended	O
dose	O
for	O
phase	O
II	O
trials	O
of	O
irinotecan	B-DRUG
combined	O
with	O
cisplatin	B-DRUG
and	O
etoposide	B-DRUG
in	O
chemonaive	O
patients	O
with	O
stage	O
IV	O
disease	O
","	O
56	O
patients	O
(	O
11	O
having	O
SCLC	B-CANCER
and	O
45	O
NSCLC	B-CANCER
)	O
received	O
cisplatin	B-DRUG
25	O
mg	O
m	O
(	O
-2	O
)	O
weekly	O
for	O
9	O
weeks	O
","	O
etoposide	B-DRUG
60	O
mg	O
m	O
(	O
-2	O
)	O
for	O
3	O
days	O
on	O
weeks	O
1	O
","	O
3	O
","	O
5	O
","	O
7	O
and	O
9	O
","	O
and	O
irinotecan	B-DRUG
20-100	O
mg	O
m	O
(	O
-2	O
)	O
(	O
levels	O
1月8日	O
)	O
on	O
weeks	O
2	O
","	O
4	O
","	O
6	O
and	O
8	O
","	O
together	O
with	O
a	O
prophylactical	O
granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
support	O
(	O
50	O
microg	O
m	O
(	O
-2	O
)	O
on	O
days	O
4月7日	O
on	O
weeks	O
1	O
","	O
3	O
","	O
5	O
","	O
7	O
and	O
9	O
","	O
and	O
on	O
days	O
2月7日	O
on	O
weeks	O
2	O
","	O
4	O
","	O
6	O
and	O
8	O
)	O
.	O
	
Grade	O
3月4日	O
leukocytopenia	B-TOXI
","	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
were	O
noted	O
in	O
20	O
(	O
36	O
%	O
)	O
","	O
28	O
(	O
50	O
%	O
)	O
and	O
nine	O
(	O
16	O
%	O
)	O
patients	O
","	O
respectively	O
.	O
	
Grade	O
3	O
diarrhoea	B-TOXI
","	O
grade	O
3	O
cardiac	B-TOXI
toxicity	I-TOXI
","	O
and	O
grade	O
4	O
transaminase	B-TOXI
elevation	I-TOXI
developed	O
in	O
one	O
(	O
1.8	O
%	O
)	O
patient	O
each	O
.	O
	
Totally	O
","	O
four	O
of	O
56	O
patients	O
were	O
removed	O
from	O
the	O
study	O
because	O
of	O
toxicity	O
and	O
recovered	O
","	O
and	O
two	O
other	O
patients	O
died	B-TOXI
in	O
situations	O
where	O
drug	O
toxicity	O
might	O
contribute	O
to	O
their	O
death	B-TOXI
.	O
	
Dose-limiting	O
toxicity	O
was	O
noted	O
in	O
less	O
than	O
one-third	O
of	O
patients	O
at	O
dose	O
levels	O
1月7日	O
","	O
but	O
in	O
all	O
patients	O
at	O
dose	O
level	O
8	O
Thus	O
","	O
the	O
recommended	O
dose	O
was	O
determined	O
to	O
be	O
level	O
7	O
(	O
irinotecan	O
90	O
mg	O
m	O
(	O
-2	O
)	O
)	O
.	O
	
The	O
response	O
rates	O
for	O
SCLC	B-CANCER
and	O
NSCLC	B-CANCER
were	O
91	O
%	O
(	O
10	O
/	O
11	O
)	O
and	O
38	O
%	O
(	O
17	O
/	O
45	O
)	O
","	O
respectively	O
.	O
	
The	O
median	O
survival	O
time	O
and	O
1-year	O
survival	O
rate	O
were	O
11.9	O
months	O
and	O
46	O
%	O
for	O
SCLC	B-CANCER
and	O
10.1	O
months	O
and	O
40	O
%	O
for	O
NSCLC	B-CANCER
","	O
respectively	O
.	O
	
This	O
regimen	O
was	O
considered	O
to	O
be	O
feasible	O
and	O
promising	O
for	O
the	O
treatment	O
of	O
stage	O
IV	O
SCLC	B-CANCER
and	O
NSCLC	B-CANCER
.	O
	
Adjuvant	O
treatment	O
of	O
high-risk	O
stage	O
II	O
breast	B-CANCER
cancer	I-CANCER
with	O
doxorubicin	B-DRUG
followed	O
by	O
high-dose	O
chemotherapy	O
and	O
autologous	O
stem-cell	O
transplantation	O
:	O
a	O
single-institution	O
experience	O
with	O
132	O
consecutive	O
patients	O
.	O
	
	
Several	O
studies	O
have	O
shown	O
conflicting	O
results	O
with	O
the	O
use	O
of	O
intensive	O
consolidation	O
chemotherapy	O
for	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
efficacy	O
","	O
feasibility	O
and	O
toxicity	O
of	O
high-dose	O
chemotherapy	O
with	O
stem	O
cell	O
support	O
in	O
patients	O
with	O
high-risk	O
stage	O
II	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
From	O
February	O
1994	O
to	O
November	O
1998	O
","	O
132	O
consecutive	O
patients	O
with	O
multinode	O
positive	O
breast	B-CANCER
cancer	I-CANCER
were	O
entered	O
to	O
the	O
study	O
.	O
	
In	O
total	O
","	O
86	O
patients	O
had	O
&	O
gt	O
;	O
or=10	O
positive	B-TOXI
axillary	I-TOXI
lymph	I-TOXI
nodes	I-TOXI
","	O
and	O
46	O
had	O
4月9日	O
positive	B-TOXI
axillary	I-TOXI
lymph	I-TOXI
nodes	I-TOXI
with	I-TOXI
at	I-TOXI
least	I-TOXI
two	I-TOXI
additional	I-TOXI
predetermined	I-TOXI
risk	I-TOXI
factors	I-TOXI
at	O
diagnosis	O
.	O
	
All	O
patients	O
were	O
offered	O
adjuvant	O
chemotherapy	O
(	O
doxorubicin	B-DRUG
","	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
x	O
4	O
)	O
followed	O
by	O
high-dose	O
chemotherapy	O
(	O
cyclophosphamide	B-DRUG
6000	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
carboplatin	B-DRUG
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
thio-tepa	B-DRUG
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
autologous	O
stem	O
cell	O
support	O
with	O
growth	O
factor	O
.	O
	
In	O
all	O
","	O
131	O
patients	O
also	O
received	O
local	O
radiation	O
therapy	O
and	O
tamoxifen	B-DRUG
based	O
on	O
receptor	O
status	O
.	O
	
After	O
a	O
median	O
follow-up	O
of	O
51	O
months	O
(	O
range	O
27-87	O
)	O
","	O
the	O
disease-free	O
and	O
overall	O
survival	O
rates	O
were	O
72	O
and	O
81	O
%	O
","	O
respectively	O
.	O
	
There	O
was	O
no	O
difference	O
in	O
the	O
outcome	O
for	O
high-risk	O
patients	O
with	O
&	O
gt	O
;	O
or	O
&	O
lt	O
;	O
than	O
10	O
positive	B-TOXI
axillary	I-TOXI
lymph	I-TOXI
nodes	I-TOXI
.	O
	
On	O
Cox	O
regression	O
analysis	O
only	O
progesterone	B-DRUG
receptor	O
status	O
was	O
predictive	O
of	O
disease-free	O
","	O
but	O
not	O
overall	O
survival	O
.	O
	
There	O
were	O
no	O
treatment-related	O
deaths	B-TOXI
;	O
grades	O
III-IV	O
toxicity	O
was	O
relatively	O
low	O
.	O
	
This	O
combined	O
approach	O
of	O
doxorubicin	B-DRUG
followed	O
by	O
high-dose	O
chemotherapy	O
and	O
stem-cell	O
support	O
","	O
followed	O
by	O
locoregional	O
radiotherapy	O
","	O
was	O
safe	O
and	O
seems	O
to	O
be	O
effective	O
in	O
patients	O
with	O
multinode	O
positive	O
stage	O
II	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
In	O
previous	O
trials	O
of	O
adjuvant	O
high-dose	O
therapy	O
in	O
this	O
patient	O
population	O
","	O
treatment-related	O
morbidity	O
and	O
mortality	O
markedly	O
influenced	O
the	O
outcome	O
.	O
	
For	O
this	O
high-risk	O
patient	O
population	O
","	O
further	O
testing	O
of	O
intensive	O
chemotherapy	O
regimens	O
with	O
a	O
lower	O
toxicity	O
profile	O
is	O
warranted	O
.	O
	
Randomized	O
phase	O
I	O
trial	O
of	O
recombinant	B-DRUG
human	I-DRUG
keratinocyte	I-DRUG
growth	I-DRUG
factor	I-DRUG
plus	O
chemotherapy	O
:	O
potential	O
role	O
as	O
mucosal	O
protectant	O
.	O
	
	
To	O
evaluate	O
the	O
safety	O
of	O
recombinant	B-DRUG
human	I-DRUG
keratinocyte	I-DRUG
growth	I-DRUG
factor	I-DRUG
(	O
KGF	B-DRUG
)	O
when	O
administered	O
with	O
fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
in	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
(	O
N	O
=	O
81	O
)	O
received	O
KGF	B-DRUG
by	O
intravenous	O
(	O
IV	O
)	O
bolus	O
on	O
days	O
1	O
to	O
3	O
","	O
followed	O
by	O
FU	B-DRUG
425	O
mg	O
/	O
m2	O
/	O
d	O
IV	O
bolus	O
plus	O
leucovorin	B-DRUG
20	O
mg	O
/	O
m2	O
/	O
d	O
IV	O
on	O
days	O
4	O
to	O
8	O
KGF	B-DRUG
dose	O
levels	O
were	O
1	O
","	O
10	O
","	O
20	O
","	O
40	O
","	O
60	O
","	O
and	O
80	O
microg	O
/	O
kg	O
/	O
d.	O
A	O
randomized	O
","	O
placebo-controlled	B-DRUG
design	O
was	O
employed	O
(	O
02:01	O
randomization	O
of	O
KGF	B-DRUG
to	O
placebo	B-DRUG
)	O
.	O
	
Oral	B-TOXI
mucositis	I-TOXI
was	O
assessed	O
by	O
examination	O
on	O
days	O
1	O
","	O
4	O
","	O
8	O
","	O
15	O
","	O
and	O
28	O
.	O
	
In	O
addition	O
","	O
patients	O
provided	O
daily	O
assessments	O
of	O
oral	B-TOXI
symptoms	I-TOXI
using	O
a	O
self-administered	O
questionnaire	O
.	O
	
Skin	B-TOXI
and	I-TOXI
oral	I-TOXI
events	I-TOXI
occurred	O
in	O
13	O
of	O
18	O
patients	O
(	O
eight	O
patients	O
","	O
grade	O
1	O
;	O
four	O
patients	O
","	O
grade	O
2	O
;	O
and	O
one	O
patient	O
","	O
grade	O
3	O
)	O
treated	O
with	O
60	O
and	O
80	O
microg	O
/	O
kg	O
of	O
KGF	B-DRUG
and	O
three	O
of	O
11	O
patients	O
treated	O
with	O
40	O
microg	O
/	O
kg	O
(	O
grade	O
1	O
)	O
.	O
	
These	O
symptoms	O
were	O
dose	O
limiting	O
in	O
three	O
cases	O
(	O
ie	O
","	O
in	O
two	O
of	O
10	O
patients	O
treated	O
with	O
80	O
microg	O
/	O
kg	O
and	O
in	O
one	O
of	O
eight	O
patients	O
treated	O
with	O
60	O
microg	O
/	O
kg	O
)	O
.	O
	
The	O
frequency	O
of	O
grade	O
2	O
to	O
4	O
mucositis	B-TOXI
was	O
43	O
%	O
in	O
patients	O
treated	O
with	O
KGF	B-DRUG
","	O
compared	O
with	O
67	O
%	O
in	O
patients	O
treated	O
with	O
placebo	B-DRUG
(	O
P	O
0.06	O
)	O
.	O
	
Patient	O
self-assessments	O
of	O
oral	O
pain	O
and	O
clinical	O
assessments	O
of	O
mucositis	B-TOXI
showed	O
good	O
correlation	O
(	O
Kendall	O
's	O
tau	O
=	O
0.75	O
)	O
.	O
	
KGF	B-DRUG
is	O
generally	O
well	O
tolerated	O
when	O
administered	O
IV	O
at	O
doses	O
up	O
to	O
40	O
microg	O
/	O
kg	O
/	O
d	O
for	O
3	O
days	O
before	O
a	O
5-day	O
course	O
of	O
FU	B-DRUG
plus	O
leucovorin	B-DRUG
.	O
	
A	O
clinically	O
meaningful	O
biologic	O
effect	O
was	O
also	O
suggested	O
in	O
that	O
patients	O
treated	O
with	O
the	O
epithelial	B-DRUG
growth	I-DRUG
factor	I-DRUG
KGF	B-DRUG
had	O
a	O
lower	O
rate	O
of	O
grade	O
2	O
to	O
4	O
mucositis	B-TOXI
than	O
did	O
patients	O
treated	O
with	O
placebo	B-DRUG
.	O
	
Phase	O
I-II	O
study	O
of	O
docetaxel	B-DRUG
and	O
ifosfamide	B-DRUG
combination	O
in	O
patients	O
with	O
anthracycline	B-DRUG
pretreated	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
Given	O
the	O
established	O
individual	O
activity	O
of	O
docetaxel	B-DRUG
and	O
ifosfamide	B-DRUG
in	O
anthracycline	B-DRUG
pretreated	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
","	O
the	O
present	O
phase	O
I-II	O
study	O
aimed	O
to	O
define	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
the	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
","	O
and	O
activity	O
of	O
the	O
docetaxel-ifosfamide	B-DRUG
combination	O
in	O
this	O
setting	O
.	O
	
Cohorts	O
of	O
three	O
to	O
six	O
patients	O
with	O
histologically	O
confirmed	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
after	O
prior	O
anthracycline-based	B-DRUG
chemotherapy	O
were	O
treated	O
at	O
successive	O
dose	O
levels	O
(	O
DLs	O
)	O
with	O
escalated	O
doses	O
of	O
docetaxel	B-DRUG
70-100	O
mg	O
x	O
m	O
(	O
-2	O
)	O
over	O
1	O
h	O
on	O
day	O
1	O
followed	O
by	O
ifosfamide	B-DRUG
5月6日	O
g	O
x	O
m	O
(	O
-2	O
)	O
divided	O
over	O
days	O
1	O
and	O
2	O
(	O
2.5-3.0	O
g	O
x	O
m	O
(	O
-2	O
)	O
day	O
(	O
-1	O
)	O
over	O
1	O
h	O
)	O
","	O
and	O
recycled	O
every	O
21	O
days	O
.	O
	
G-CSF	B-DRUG
was	O
added	O
once	O
dose-limiting	O
neutropenia	B-TOXI
was	O
encountered	O
at	O
a	O
certain	O
DL	O
and	O
planned	O
to	O
be	O
incorporated	O
prophylactically	O
in	O
subsequent	O
higher	O
DLs	O
.	O
	
In	O
total	O
","	O
56	O
patients	O
with	O
a	O
median	O
age	O
of	O
54.5	O
(	O
range	O
","	O
32-72	O
)	O
years	O
and	O
performance	O
status	O
(	O
WHO	O
)	O
of	O
1	O
(	O
range	O
","	O
0-2	O
)	O
were	O
treated	O
at	O
five	O
DLs	O
as	O
follows	O
:	O
21	O
in	O
phase	O
I	O
DLs	O
(	O
DL1	O
:	O
3	O
","	O
DL2	O
:	O
6	O
","	O
DL3	O
:	O
3	O
","	O
DL4	O
:	O
6	O
","	O
and	O
DL5	O
:	O
3	O
)	O
and	O
the	O
remaining	O
35	O
were	O
treated	O
at	O
DL4	O
(	O
total	O
of	O
41	O
patients	O
at	O
DL4	O
)	O
","	O
which	O
was	O
defined	O
as	O
the	O
level	O
for	O
phase	O
II	O
testing	O
.	O
	
All	O
patients	O
were	O
assessable	O
for	O
toxicity	O
and	O
53	O
for	O
response	O
.	O
	
Dose-limiting	O
toxicity	O
(	O
with	O
the	O
addition	O
of	O
G-CSF	B-DRUG
after	O
DL2	O
)	O
was	O
reached	O
at	O
DL5	O
with	O
two	O
out	O
of	O
three	O
initial	O
patients	O
developing	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
FN	B-TOXI
)	O
.	O
	
Clinical	O
response	O
rates	O
","	O
on	O
an	O
intention-to-treat	O
basis	O
","	O
in	O
phase	O
II	O
were	O
:	O
53.6	O
%	O
(	O
95	O
%	O
CI	O
","	O
38.3-68.9	O
%	O
)	O
;	O
three	O
complete	O
remissions	O
","	O
19	O
partial	O
remissions	O
","	O
seven	O
stable	O
disease	O
","	O
and	O
12	O
progressive	O
disease	O
.	O
	
The	O
median	O
response	O
duration	O
was	O
7	O
months	O
(	O
3月24日	O
months	O
)	O
","	O
median	O
time	O
to	O
progression	O
6.5	O
month	O
(	O
0.1-26	O
month	O
)	O
","	O
and	O
median	O
overall	O
survival	O
13	O
months	O
(	O
0.1-33	O
months	O
)	O
.	O
	
Grade	O
3	O
/	O
4	O
toxicities	O
included	O
time	O
to	O
progression	O
neutropenia	B-TOXI
in	O
78	O
%	O
of	O
patients-with	O
63	O
%	O
developing	O
grade	O
4	O
neutropenia	B-TOXI
(	O
&	O
lt	O
;	O
or=7	O
days	O
)	O
and	O
in	O
12	O
%	O
of	O
these	O
FN	B-TOXI
","	O
while	O
no	O
grade	O
3	O
/	O
4	O
thrombocytopenia	B-TOXI
was	O
observed	O
.	O
	
Other	O
toxicities	O
included	O
peripheral	B-TOXI
neuropathy	I-TOXI
grade	O
2	O
only	O
in	O
12	O
%	O
","	O
grade	O
1	O
/	O
2	O
reversible	B-TOXI
CNS	I-TOXI
toxicity	I-TOXI
in	O
17	O
%	O
","	O
no	O
renal	O
toxicity	O
","	O
grade	O
2	O
myalgias	B-TOXI
in	O
10	O
%	O
","	O
grade	O
3	O
diarrhoea	B-TOXI
in	O
10	O
%	O
","	O
skin	B-TOXI
/	I-TOXI
nail	I-TOXI
toxicity	I-TOXI
in	O
17	O
%	O
","	O
and	O
grade	O
2	O
fluid	B-TOXI
retention	I-TOXI
in	O
2	O
%	O
of	O
patients	O
.	O
	
One	O
patient	O
in	O
the	O
study	O
treated	O
at	O
phase	O
II	O
died	O
as	O
a	O
result	O
of	O
acute	B-TOXI
liver	I-TOXI
failure	I-TOXI
after	O
the	O
first	O
cycle	O
.	O
	
In	O
conclusion	O
","	O
the	O
present	O
phase	O
I-II	O
study	O
determined	O
the	O
feasibility	O
of	O
the	O
docetaxel-ifosfamide	B-DRUG
combination	O
","	O
defined	O
the	O
MTD	O
and	O
demonstrated	O
the	O
encouraging	O
activity	O
of	O
the	O
regimen	O
in	O
phase	O
II	O
","	O
thus	O
warranting	O
further	O
randomised	O
phase	O
III	O
comparisons	O
to	O
single-agent	O
docetaxel	B-DRUG
or	O
combinations	O
of	O
the	O
latter	O
with	O
other	O
active	O
agents	O
.	O
	
Combination	O
second-line	O
chemotherapy	O
with	O
gemcitabine	B-DRUG
and	O
docetaxel	B-DRUG
for	O
recurrent	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
after	O
platinum-containing	B-DRUG
chemotherapy	O
:	O
a	O
phase	O
I	O
/	O
II	O
trial	O
.	O
	
	
In	O
a	O
randomized	O
trial	O
","	O
docetaxel	B-DRUG
monotherapy	O
yielded	O
longer	O
survival	O
than	O
the	O
best	O
supportive	O
care	O
in	O
patients	O
with	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
previously	O
treated	O
with	O
platinum-based	B-DRUG
chemotherapy	O
","	O
and	O
combination	O
chemotherapy	O
regimens	O
containing	O
docetaxel	B-DRUG
have	O
been	O
assessed	O
to	O
enhance	O
the	O
efficacy	O
of	O
second-line	O
chemotherapy	O
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
/	O
II	O
trial	O
of	O
gemcitabine	B-DRUG
and	O
docetaxel	B-DRUG
in	O
patients	O
with	O
recurrent	B-CANCER
NSCLC	I-CANCER
after	O
platinum-based	B-DRUG
chemotherapy	O
and	O
with	O
an	O
ECOG	O
performance	O
status	O
(	O
PS	O
)	O
of	O
0	O
or	O
1	O
Docetaxel	B-DRUG
administration	O
was	O
fixed	O
at	O
a	O
dosage	O
of	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
8	O
","	O
and	O
gemcitabine	B-DRUG
was	O
administered	O
on	O
days	O
1	O
and	O
8	O
The	O
starting	O
dose	O
level	O
of	O
gemcitabine	B-DRUG
was	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
level	O
0	O
)	O
","	O
and	O
the	O
subsequent	O
dose	O
level	O
of	O
gemcitabine	B-DRUG
was	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
level	O
1	O
)	O
.	O
	
Treatment	O
was	O
repeated	O
every	O
3	O
weeks	O
.	O
	
In	O
the	O
phase	O
I	O
study	O
","	O
13	O
patients	O
were	O
enrolled	O
","	O
and	O
in	O
the	O
phase	O
II	O
study	O
","	O
29	O
patients	O
were	O
enrolled	O
.	O
	
Neutropenic	B-TOXI
fever	I-TOXI
and	O
omission	O
of	O
treatment	O
on	O
day	O
8	O
due	O
to	O
leukopenia	B-TOXI
(	O
leukocyte	O
count	O
less	O
than	O
3000	O
/	O
mm	O
(	O
3	O
)	O
)	O
were	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
.	O
	
Three	O
of	O
six	O
patients	O
experienced	O
DLTs	O
at	O
level	O
1	O
","	O
which	O
was	O
the	O
maximum	O
tolerated	O
dose	O
.	O
	
Gemcitabine	B-DRUG
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
and	O
8	O
plus	O
docetaxel	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
8	O
(	O
level	O
0	O
)	O
was	O
recommended	O
for	O
the	O
phase	O
II	O
study	O
.	O
	
An	O
objective	O
response	O
was	O
observed	O
in	O
8	O
(	O
28	O
%	O
)	O
of	O
the	O
29	O
patients	O
.	O
	
The	O
median	O
time	O
to	O
disease	O
progression	O
was	O
4.2	O
months	O
(	O
95	O
%	O
CI	O
0.9-7.7	O
months	O
)	O
.	O
	
The	O
median	O
survival	O
time	O
was	O
11.1	O
months	O
(	O
95	O
%	O
CI	O
9.9-12.4	O
months	O
)	O
","	O
and	O
the	O
1-year	O
survival	O
rate	O
was	O
41	O
%	O
.	O
	
The	O
most	O
common	O
toxicity	O
","	O
though	O
mild	O
","	O
was	O
hematologic	O
","	O
and	O
consisted	O
of	O
grade	O
4	O
neutropenia	B-TOXI
(	O
18	O
%	O
)	O
","	O
grade	O
3	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
11	O
%	O
)	O
","	O
and	O
grade	O
3	O
thrombocytopenia	B-TOXI
(	O
11	O
%	O
)	O
.	O
	
There	O
were	O
no	O
toxic	B-TOXI
deaths	I-TOXI
.	O
	
Grade	O
3	O
non-hematologic	B-TOXI
toxicities	I-TOXI
included	O
nausea	B-TOXI
(	O
4	O
%	O
)	O
and	O
rash	B-TOXI
(	O
4	O
%	O
)	O
.	O
	
The	O
combination	O
chemotherapy	O
of	O
gemcitabine	B-DRUG
and	O
docetaxel	B-DRUG
is	O
active	O
and	O
well	O
tolerated	O
in	O
patients	O
with	O
recurrent	B-CANCER
NSCLC	I-CANCER
after	O
platinum-based	B-DRUG
chemotherapy	O
and	O
with	O
a	O
good	O
PS	O
.	O
	
Phase	O
I	O
and	O
pharmacokinetic	O
study	O
of	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
with	O
a	O
biweekly	O
schedule	O
in	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
A	O
phase	O
I	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
of	O
carboplatin	B-DRUG
in	O
combination	O
with	O
paclitaxel	B-DRUG
using	O
a	O
biweekly	O
schedule	O
in	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
The	O
pharmacokinetics	O
of	O
paclitaxel	B-DRUG
were	O
determined	O
preliminarily	O
in	O
some	O
patients	O
.	O
	
The	O
criteria	O
for	O
eligibility	O
for	O
study	O
entry	O
included	O
histologically	O
and	O
/	O
or	O
cytologically	O
confirmed	O
NSCLC	B-CANCER
(	O
stage	O
IIIb	O
or	O
IV	O
)	O
","	O
no	O
prior	O
treatment	O
","	O
and	O
measurable	O
disease	O
.	O
	
Paclitaxel	B-DRUG
was	O
given	O
in	O
combination	O
with	O
a	O
fixed	O
dose	O
of	O
carboplatin	B-DRUG
at	O
an	O
area	O
under	O
the	O
concentration-time	O
curve	O
(	O
AUC	O
)	O
of	O
3	O
mg	O
/	O
ml	O
x	O
min	O
","	O
every	O
2	O
weeks	O
.	O
	
The	O
starting	O
dose	O
of	O
paclitaxel	B-DRUG
was	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
and	O
the	O
dose	O
was	O
increased	O
in	O
increments	O
of	O
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Three	O
to	O
six	O
patients	O
were	O
allocated	O
to	O
each	O
dose	O
level	O
.	O
	
A	O
total	O
of	O
19	O
patients	O
(	O
11	O
male	O
and	O
8	O
female	O
)	O
with	O
a	O
median	O
age	O
of	O
61	O
years	O
(	O
range	O
43-74	O
years	O
)	O
and	O
a	O
median	O
ECOG	O
performance	O
status	O
of	O
0	O
(	O
range	O
0-1	O
)	O
were	O
enrolled	O
.	O
	
The	O
MTD	O
of	O
paclitaxel	B-DRUG
proved	O
to	O
be	O
160	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
and	O
the	O
DLT	O
was	O
neutropenia	B-TOXI
","	O
which	O
improved	O
well	O
following	O
treatment	O
with	O
G-CSF	B-DRUG
.	O
	
Gastrointestinal	B-TOXI
toxicity	I-TOXI
was	O
well	O
tolerated	O
.	O
	
Of	O
17	O
patients	O
who	O
received	O
four	O
cycles	O
or	O
more	O
","	O
7	O
(	O
41	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
18.4-67.1	O
%	O
)	O
responded	O
to	O
this	O
combination	O
therapy	O
.	O
	
The	O
pharmacokinetics	O
of	O
paclitaxel	B-DRUG
did	O
not	O
differ	O
from	O
published	O
data	O
.	O
	
The	O
recommended	O
dose	O
for	O
phase	O
II	O
study	O
is	O
paclitaxel	B-DRUG
140	O
mg	O
/	O
m	O
(	O
2	O
)	O
with	O
a	O
carboplatin	B-DRUG
AUC	O
of	O
3	O
mg	O
/	O
ml.min	O
.	O
	
This	O
biweekly	O
regimen	O
is	O
highly	O
effective	O
and	O
acceptable	O
","	O
and	O
the	O
present	O
data	O
indicate	O
that	O
the	O
regimen	O
may	O
be	O
suitable	O
for	O
use	O
on	O
an	O
outpatient	O
basis	O
.	O
	
Pilot	O
trial	O
of	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
tyrosine	O
kinase	O
inhibitor	O
gefitinib	B-DRUG
plus	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
stage	O
IIIB	O
or	O
IV	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
Gefitinib	B-DRUG
is	O
an	O
oral	O
agent	O
that	O
inhibits	O
the	O
tyrosine	B-DRUG
kinase	I-DRUG
of	I-DRUG
the	I-DRUG
epidermal	I-DRUG
growth	I-DRUG
factor	I-DRUG
receptor	I-DRUG
.	O
	
In	O
phase	O
I	O
trials	O
gefitinib	B-DRUG
was	O
well	O
tolerated	O
and	O
antitumor	O
activity	O
was	O
seen	O
in	O
pretreated	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
patients	O
.	O
	
Preclinical	O
studies	O
indicated	O
enhanced	O
effects	O
when	O
gefitnib	B-DRUG
was	O
added	O
to	O
carboplatin	B-DRUG
or	O
paclitaxel	B-DRUG
.	O
	
This	O
pilot	O
trial	O
combined	O
gefitinib	B-DRUG
with	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
to	O
define	O
the	O
toxicities	O
of	O
the	O
combination	O
and	O
assess	O
drug-drug	O
interactions	O
in	O
untreated	O
advanced	B-CANCER
NSCLC	I-CANCER
patients	O
.	O
	
Initially	O
(	O
part	O
1	O
)	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
intermittent	O
gefitinib	B-DRUG
with	O
cycle	O
1	O
or	O
2	O
of	O
chemotherapy	O
.	O
	
Thereafter	O
(	O
part	O
2	O
)	O
","	O
the	O
highest	O
dose	O
of	O
gefitinib	B-DRUG
that	O
was	O
given	O
without	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
from	O
part	O
1	O
was	O
administered	O
continuously	O
beginning	O
with	O
the	O
first	O
cycle	O
of	O
chemotherapy	O
.	O
	
Three	O
sequentially	O
enrolled	O
cohorts	O
received	O
gefitinib	B-DRUG
250	O
and	O
500	O
mg	O
(	O
intermittently	O
)	O
and	O
500	O
mg	O
(	O
continuously	O
)	O
.	O
	
We	O
treated	O
24	O
patients	O
;	O
nine	O
patients	O
with	O
250	O
mg	O
and	O
15	O
patients	O
with	O
500	O
mg	O
(	O
nine	O
patients	O
continuous	O
)	O
.	O
	
Two	O
occurrences	O
of	O
DLT	O
were	O
observed	O
.	O
	
One	O
patient	O
(	O
500	O
mg	O
","	O
part	O
1	O
)	O
developed	O
grade	O
3	O
rash	B-TOXI
and	O
another	O
patient	O
(	O
part	O
2	O
)	O
developed	O
prolonged	B-TOXI
neutropenia	I-TOXI
.	O
	
Steady-state	O
gefitinib	B-DRUG
levels	O
did	O
not	O
affect	O
exposure	O
to	O
chemotherapy	O
.	O
	
In	O
a	O
limited	O
sample	O
","	O
chemotherapy	O
modestly	O
increased	O
the	O
gefitinib	B-DRUG
area	O
under	O
concentration-time	O
curve	O
at	O
steady-state	O
and	O
minimum	O
steady-state	O
trough	O
concentration	O
.	O
	
Partial	O
responses	O
were	O
observed	O
in	O
five	O
of	O
24	O
patients	O
.	O
	
The	O
median	O
survival	O
was	O
8	O
months	O
.	O
	
The	O
gefitinib	B-DRUG
with	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
regimen	O
was	O
generally	O
well	O
tolerated	O
and	O
no	O
unanticipated	O
toxicities	O
or	O
clinically	O
relevant	O
pharmacokinetic	O
interactions	O
were	O
observed	O
.	O
	
Both	O
doses	O
of	O
gefitinib	B-DRUG
were	O
believed	O
to	O
be	O
safe	O
for	O
further	O
study	O
with	O
chemotherapy	O
.	O
	
This	O
regimen	O
was	O
thus	O
tested	O
in	O
a	O
completed	O
randomized	O
phase	O
III	O
trial	O
.	O
	
Combination	O
of	O
low-dose	O
cisplatin	B-DRUG
and	O
gemcitabine	B-DRUG
for	O
treatment	O
of	O
elderly	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
evaluate	O
the	O
feasibility	O
","	O
toxicity	O
and	O
efficacy	O
of	O
the	O
combination	O
of	O
low-dose	O
cisplatin	B-DRUG
(	O
CDDP	B-DRUG
)	O
and	O
gemcitabine	B-DRUG
(	O
GEM	B-DRUG
)	O
in	O
elderly	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
This	O
phase	O
II	O
trial	O
included	O
46	O
patients	O
aged	O
70	O
years	O
or	O
older	O
with	O
previously	O
untreated	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
All	O
patients	O
were	O
evaluable	O
for	O
response	O
and	O
toxicity	O
.	O
	
Treatment	O
consisted	O
of	O
CDDP	B-DRUG
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
plus	O
GEM	B-DRUG
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
and	O
8	O
The	O
regimen	O
was	O
repeated	O
every	O
21	O
days	O
.	O
	
Patients	O
received	O
a	O
minimum	O
of	O
three	O
courses	O
unless	O
progressive	O
disease	O
was	O
detected	O
.	O
	
A	O
total	O
of	O
190	O
GEM-CDDP	B-DRUG
courses	O
were	O
administered	O
(	O
median	O
4.1	O
courses	O
per	O
patient	O
)	O
.	O
	
The	O
chemotherapy	O
regimen	O
was	O
well	O
tolerated	O
.	O
	
No	O
patients	O
developed	O
grade	O
4	O
toxicity	O
.	O
	
Grade	O
3	O
toxicities	O
were	O
as	O
follows	O
:	O
neutropenia	B-TOXI
in	O
six	O
patients	O
(	O
13	O
%	O
)	O
","	O
and	O
anemia	B-TOXI
","	O
thrombopenia	B-TOXI
and	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
in	O
one	O
(	O
2	O
%	O
)	O
each	O
.	O
	
Two	O
patients	O
(	O
4	O
%	O
)	O
had	O
mild	O
nephrotoxicity	B-TOXI
.	O
	
Of	O
the	O
46	O
patients	O
","	O
16	O
had	O
a	O
partial	O
response	O
(	O
35	O
%	O
","	O
95	O
%	O
confidence	O
interval	O
","	O
CI	O
","	O
28-52	O
%	O
)	O
","	O
17	O
(	O
37	O
%	O
)	O
remained	O
stable	O
and	O
13	O
(	O
28	O
%	O
)	O
had	O
disease	O
progression	O
.	O
	
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
improved	O
in	O
17	O
patients	O
(	O
37	O
%	O
)	O
","	O
whereas	O
25	O
(	O
54	O
%	O
","	O
95	O
%	O
CI	O
44-74	O
%	O
)	O
showed	O
a	O
clinical	O
benefit	O
.	O
	
Median	O
time	O
to	O
progression	O
was	O
20	O
weeks	O
.	O
	
Overall	O
median	O
survival	O
was	O
44	O
weeks	O
","	O
with	O
a	O
1-year	O
actuarial	O
survival	O
rate	O
of	O
35	O
%	O
.	O
	
The	O
combination	O
of	O
low-dose	O
CDDP	B-DRUG
and	O
GEM	B-DRUG
for	O
elderly	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
is	O
an	O
effective	O
and	O
well-tolerated	O
chemotherapeutic	O
approach	O
.	O
	
A	O
Phase	O
I	O
trial	O
of	O
the	O
farnesyl	O
protein	O
transferase	O
inhibitor	O
R115777	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
cancer	I-CANCER
.	O
	
	
This	O
Phase	O
I	O
study	O
was	O
undertaken	O
to	O
define	O
the	O
toxicity	O
","	O
pharmacodynamics	O
","	O
and	O
maximum	O
tolerated	O
dose	O
of	O
the	O
combination	O
of	O
R115777	B-DRUG
","	O
a	O
farnesyl	O
transferase	O
inhibitor	O
","	O
with	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Thirty	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
received	O
a	O
median	O
of	O
2.5	O
cycles	O
(	O
range	O
1-30+	O
)	O
through	O
five	O
dose	O
levels	O
.	O
	
R115777	B-DRUG
was	O
administered	O
p.o.	O
twice	O
daily	O
for	O
14	O
days	O
.	O
	
Gemcitabine	B-DRUG
was	O
infused	O
15	O
min	O
after	O
the	O
ingestion	O
of	O
R115777	B-DRUG
on	O
days	O
1	O
and	O
8	O
Cisplatin	B-DRUG
was	O
administered	O
starting	O
30	O
min	O
after	O
completion	O
of	O
the	O
gemcitabine	B-DRUG
infusion	O
on	O
day	O
1	O
Cycles	O
were	O
repeated	O
every	O
21	O
days	O
.	O
	
Toxicities	O
were	O
graded	O
by	O
the	O
National	O
Cancer	O
Institute	O
Common	O
Toxicity	O
Criteria	O
and	O
recorded	O
as	O
maximum	O
grade	O
per	O
patient	O
for	O
each	O
treatment	O
cycle	O
.	O
	
At	O
the	O
maximum	O
tolerated	O
dose	O
","	O
accumulation	O
of	O
prelamin	O
A	O
in	O
buccal	O
mucosa	O
cells	O
of	O
patients	O
was	O
evaluated	O
as	O
a	O
marker	O
of	O
farnesyl	O
transferase	O
inhibition	O
by	O
R115777	B-DRUG
.	O
	
Neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
were	O
the	O
most	O
common	O
toxicities	O
.	O
	
Dose-limiting	O
toxicity	O
in	O
cycle	O
1	O
was	O
myelosuppression	B-TOXI
with	O
thrombocytopenia	B-TOXI
alone	O
(	O
4	O
patients	O
)	O
","	O
neutropenia	B-TOXI
alone	O
(	O
1	O
patient	O
)	O
","	O
or	O
a	O
combination	O
of	O
both	O
(	O
3	O
patients	O
)	O
.	O
	
Common	O
nonhematologic	B-TOXI
toxicities	I-TOXI
were	O
anorexia	B-TOXI
","	O
rash	B-TOXI
","	O
nausea	B-TOXI
","	O
vomiting	B-TOXI
","	O
and	O
fatigue	B-TOXI
","	O
none	O
of	O
which	O
was	O
dose	O
limiting	O
in	O
the	O
first	O
cycle	O
.	O
	
At	O
the	O
maximum	O
tolerated	O
dose	O
","	O
defined	O
as	O
R115777	B-DRUG
300	O
mg	O
twice	O
daily	O
p.o.	O
","	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
gemcitabine	B-DRUG
","	O
and	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
cisplatin	B-DRUG
","	O
inhibition	O
of	O
prelamin	O
A	O
farnesylation	O
in	O
buccal	O
mucosa	O
cells	O
of	O
patients	O
was	O
demonstrated	O
","	O
confirming	O
that	O
R115777	B-DRUG
inhibits	O
protein	O
farnesylation	O
in	O
vivo	O
.	O
	
Nine	O
objective	O
responses	O
(	O
one	O
complete	O
response	O
and	O
eight	O
partial	O
responses	O
)	O
were	O
documented	O
in	O
27	O
evaluable	O
patients	O
.	O
	
The	O
combination	O
of	O
R115777	B-DRUG
with	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
was	O
well	O
tolerated	O
and	O
showed	O
evidence	O
of	O
antitumor	O
activity	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
of	O
R115777	B-DRUG
successfully	O
inhibits	O
farnesyltransferase	O
in	O
patients	O
in	O
vivo	O
.	O
	
This	O
combination	O
warrants	O
further	O
evaluation	O
in	O
a	O
number	O
of	O
tumor	O
types	O
.	O
	
Oxaliplatin	B-DRUG
with	O
weekly	O
bolus	O
fluorouracil	B-DRUG
and	O
low-dose	O
leucovorin	B-DRUG
as	O
first-line	O
therapy	O
for	O
patients	O
with	O
colorectal	B-CANCER
cancer	I-CANCER
.	O
	
	
To	O
determine	O
the	O
activity	O
of	O
biweekly	O
oxaliplatin	B-DRUG
","	O
combined	O
with	O
weekly	O
bolus	O
fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
and	O
low-dose	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
chemotherapy	O
(	O
bFOL	O
)	O
","	O
as	O
first-line	O
therapy	O
for	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
measurable	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
;	O
no	O
previous	O
therapy	O
for	O
advanced	O
disease	O
(	O
adjuvant	O
therapy	O
allowed	O
if	O
&	O
gt	O
;	O
6	O
months	O
since	O
completion	O
)	O
;	O
and	O
performance	O
status	O
0	O
","	O
1	O
","	O
or	O
2	O
were	O
eligible	O
and	O
were	O
treated	O
with	O
oxaliplatin	B-DRUG
85	O
mg	O
/	O
m2	O
days	O
1	O
and	O
15	O
plus	O
LV	B-DRUG
20	O
mg	O
/	O
m2	O
over	O
10	O
to	O
20	O
minutes	O
","	O
followed	O
by	O
a	O
500	O
mg	O
/	O
m2	O
bolus	O
dose	O
of	O
FU	B-DRUG
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
every	O
28	O
days	O
.	O
	
Patients	O
underwent	O
response	O
evaluation	O
by	O
computed	O
tomographic	O
scan	O
every	O
2	O
months	O
.	O
	
Forty-two	O
patients	O
were	O
entered	O
","	O
and	O
41	O
patients	O
were	O
treated	O
","	O
including	O
20	O
men	O
and	O
22	O
women	O
","	O
nine	O
with	O
previous	O
adjuvant	O
chemotherapy	O
and	O
four	O
with	O
radiation	O
therapy	O
.	O
	
Three	O
patients	O
achieved	O
complete	O
response	O
","	O
and	O
23	O
patients	O
achieved	O
partial	O
response	O
","	O
for	O
a	O
response	O
rate	O
of	O
63	O
%	O
(	O
95	O
%	O
CI	O
","	O
49	O
%	O
to	O
78	O
%	O
)	O
.	O
	
Major	O
toxicities	O
included	O
cumulative	O
neuropathy	B-TOXI
grade	O
2	O
(	O
24	O
%	O
)	O
and	O
grade	O
3	O
(	O
12	O
%	O
;	O
requiring	O
discontinuation	O
of	O
oxaliplatin	B-DRUG
)	O
","	O
diarrhea	B-TOXI
grade	O
3	O
to	O
4	O
(	O
29	O
%	O
)	O
and	O
grade	O
3	O
to	O
4	O
hematologic	B-TOXI
toxicity	I-TOXI
(	O
10	O
%	O
)	O
.	O
	
Median	O
time	O
to	O
progression	O
was	O
9	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
7.1	O
to	O
10.8	O
months	O
)	O
with	O
median	O
survival	O
of	O
15.9	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
11.4	O
to	O
19.7	O
months	O
)	O
.	O
	
The	O
bFOL	O
regimen	O
seems	O
to	O
have	O
activity	O
comparable	O
to	O
be	O
infusional	O
programs	O
of	O
FU	B-DRUG
combined	O
with	O
oxaliplatin	B-DRUG
.	O
	
Prospective	O
trials	O
are	O
warranted	O
to	O
determine	O
the	O
relative	O
merits	O
of	O
this	O
schedule	O
compared	O
with	O
the	O
currently	O
indicated	O
schedules	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
capecitabine	B-DRUG
in	O
combination	O
with	O
vinorelbine	B-DRUG
in	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
A	O
phase	O
I	O
study	O
was	O
conducted	O
in	O
order	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
of	O
the	O
combination	O
of	O
vinorelbine	B-DRUG
and	O
capecitabine	B-DRUG
in	O
patients	O
affected	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Eighteen	O
patients	O
with	O
histologically	O
confirmed	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
","	O
who	O
had	O
failed	O
1	O
prior	O
chemotherapy	O
regimen	O
","	O
were	O
enrolled	O
.	O
	
The	O
median	O
age	O
was	O
56	O
years	O
(	O
range	O
","	O
39-70	O
years	O
)	O
.	O
	
All	O
but	O
1	O
had	O
previously	O
received	O
a	O
combination	O
of	O
anthracyclines	B-DRUG
and	O
taxanes	B-DRUG
;	O
performance	O
status	O
(	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
)	O
was	O
0	O
/	O
1	O
or	O
2	O
in	O
13	O
and	O
5	O
patients	O
","	O
respectively	O
.	O
	
Vinorelbine	B-DRUG
was	O
administered	O
at	O
a	O
fixed	O
dosage	O
of	O
25	O
mg	O
/	O
m2	O
on	O
days	O
1	O
and	O
8	O
every	O
3	O
weeks	O
.	O
	
Capecitabine	B-DRUG
was	O
administered	O
orally	O
","	O
at	O
an	O
escalated	O
dose	O
ranging	O
from	O
1400	O
mg	O
/	O
m2	O
to	O
2250	O
mg	O
/	O
m2	O
for	O
14	O
consecutive	O
days	O
starting	O
on	O
day	O
1	O
of	O
the	O
cycle	O
","	O
divided	O
into	O
2	O
daily	O
doses	O
delivered	O
half	O
an	O
hour	O
after	O
eating	O
at	O
12-hour	O
intervals	O
.	O
	
Three	O
patients	O
were	O
treated	O
at	O
each	O
dose	O
level	O
:	O
if	O
1	O
patient	O
developed	O
a	O
DLT	O
","	O
an	O
additional	O
3	O
patients	O
were	O
treated	O
at	O
the	O
same	O
dose	O
level	O
.	O
	
If	O
2	O
additional	O
patients	O
experienced	O
DLT	O
","	O
no	O
further	O
escalation	O
was	O
allowed	O
and	O
the	O
previous	O
dose	O
level	O
was	O
declared	O
MTD	O
.	O
	
Dose-limiting	O
toxicity	O
was	O
reached	O
at	O
2250	O
mg	O
/	O
m2	O
of	O
capecitabine	B-DRUG
with	O
3	O
out	O
of	O
3	O
patients	O
experiencing	O
grade	O
4	O
neutropenia	B-TOXI
plus	O
grade	O
3	O
diarrhea	B-TOXI
and	O
grade	O
3	O
oral	B-TOXI
mucositis	I-TOXI
in	O
1	O
patient	O
)	O
.	O
	
Thus	O
","	O
MTD	O
was	O
defined	O
at	O
2000	O
mg	O
/	O
m2	O
capecitabine	O
.	O
	
Other	O
observed	O
grade	O
2	O
side	O
effects	O
were	O
:	O
1	O
patient	O
with	O
neutropenia	B-TOXI
","	O
1	O
with	O
hand-foot	B-TOXI
syndrome	I-TOXI
","	O
2	O
with	O
mucositis	B-TOXI
","	O
1	O
with	O
cutaneous	B-TOXI
rash	I-TOXI
","	O
and	O
1	O
with	O
thrombocytopenia	B-TOXI
.	O
	
With	O
regard	O
to	O
response	O
rate	O
","	O
we	O
observed	O
1	O
complete	O
response	O
(	O
5.5	O
%	O
)	O
","	O
6	O
partial	O
responses	O
(	O
33	O
%	O
)	O
","	O
and	O
4	O
disease	O
stabilizations	O
(	O
22	O
%	O
)	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
was	O
12	O
weeks	O
and	O
the	O
median	O
survival	O
41	O
weeks	O
.	O
	
The	O
MTD	O
of	O
capecitabine	B-DRUG
in	O
combination	O
with	O
vinorelbine	B-DRUG
at	O
25	O
mg	O
/	O
m2	O
dosage	O
on	O
days	O
1	O
and	O
8	O
of	O
a	O
3-week	O
schedule	O
is	O
2000	O
mg	O
/	O
m2	O
/	O
day	O
for	O
14	O
consecutive	O
days	O
.	O
	
Moreover	O
","	O
this	O
regimen	O
showed	O
interesting	O
activity	O
with	O
61	O
%	O
overall	O
disease	O
control	O
(	O
complete	O
plus	O
partial	O
response	O
plus	O
disease	O
stabilization	O
)	O
in	O
patients	O
pretreated	O
with	O
anthracyclines	B-DRUG
and	O
taxanes	B-DRUG
warranting	O
further	O
investigations	O
in	O
a	O
large	O
","	O
multicenter	O
phase	O
II	O
study	O
.	O
	
Safety	O
and	O
toxicity	O
analysis	O
of	O
oxaliplatin	B-DRUG
combined	O
with	O
fluorouracil	B-DRUG
or	O
as	O
a	O
single	O
agent	O
in	O
patients	O
with	O
previously	O
treated	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
Two	O
consecutive	O
compassionate	O
use	O
studies	O
of	O
oxaliplatin	B-DRUG
were	O
conducted	O
in	O
the	O
United	O
States	O
and	O
Canada	O
in	O
more	O
than	O
5000	O
patients	O
with	O
locally	B-CANCER
advanced	I-CANCER
or	I-CANCER
metastatic	I-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
who	O
had	O
experienced	O
treatment	O
failure	O
after	O
at	O
least	O
one	O
prior	O
chemotherapy	O
regimen	O
.	O
	
The	O
main	O
focus	O
was	O
safety	O
.	O
	
Patients	O
were	O
assigned	O
to	O
treatment	O
with	O
either	O
single-agent	O
oxaliplatin	B-DRUG
or	O
oxaliplatin	B-DRUG
in	O
combination	O
with	O
fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
and	O
with	O
or	O
without	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
in	O
various	O
regimens	O
.	O
	
Response	O
data	O
collection	O
was	O
not	O
a	O
trial	O
objective	O
","	O
but	O
time	O
to	O
treatment	O
failure	O
(	O
TTF	O
)	O
was	O
recorded	O
in	O
the	O
first	O
cohort	O
(	O
1370	O
patients	O
)	O
.	O
	
All	O
treatment	O
regimens	O
were	O
well	O
tolerated	O
","	O
with	O
an	O
overall	O
incidence	O
of	O
grade	O
3	O
or	O
4	O
hematologic	B-TOXI
toxicity	I-TOXI
of	O
23.2	O
%	O
","	O
grade	O
3	O
or	O
4	O
treatment-related	O
gastrointestinal	B-TOXI
toxicity	I-TOXI
of	O
26.4	O
%	O
(	O
including	O
diarrhea	B-TOXI
","	O
vomiting	B-TOXI
","	O
and	O
mucositis	B-TOXI
)	O
","	O
and	O
grade	O
3	O
neurosensory	B-TOXI
toxicity	I-TOXI
3.9	O
%	O
.	O
	
Similar	O
results	O
were	O
reported	O
in	O
the	O
second	O
cohort	O
(	O
3806	O
patients	O
)	O
","	O
in	O
which	O
the	O
eligibility	O
criteria	O
were	O
much	O
less	O
restrictive	O
.	O
	
In	O
the	O
first	O
cohort	O
(	O
in	O
which	O
83	O
%	O
received	O
prior	O
irinotecan	B-DRUG
)	O
","	O
median	O
TTF	O
was	O
14	O
weeks	O
","	O
and	O
was	O
similar	O
for	O
the	O
five	O
regimens	O
combining	O
oxaliplatin	B-DRUG
and	O
FU	B-DRUG
with	O
or	O
without	O
LV	B-DRUG
","	O
but	O
significantly	O
shorter	O
for	O
the	O
single-agent	O
oxaliplatin	B-DRUG
arm	O
.	O
	
The	O
overall	O
dose-intensity	O
of	O
oxaliplatin	B-DRUG
was	O
maintained	O
at	O
85.5	O
%	O
(	O
range	O
","	O
80.6	O
%	O
to	O
94.3	O
%	O
)	O
of	O
that	O
prescribed	O
by	O
protocol	O
(	O
average	O
36.7	O
mg	O
/	O
m2	O
/	O
wk	O
)	O
.	O
	
These	O
data	O
in	O
a	O
heavily	O
pretreated	O
patient	O
population	O
confirm	O
that	O
oxaliplatin	B-DRUG
is	O
safe	O
when	O
used	O
as	O
a	O
single	O
agent	O
or	O
with	O
a	O
variety	O
of	O
FU-based	B-DRUG
regimens	O
as	O
salvage	O
therapy	O
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
A	O
phase	O
I	O
and	O
pharmacologic	O
study	O
of	O
weekly	O
gemcitabine	B-DRUG
in	O
combination	O
with	O
infusional	B-DRUG
5-fluorodeoxyuridine	I-DRUG
and	O
oral	O
calcium	B-DRUG
leucovorin	I-DRUG
.	O
	
	
Since	O
preclinical	O
studies	O
have	O
shown	O
more	O
than	O
additive	O
cytotoxicity	O
and	O
DNA	O
damage	O
with	O
the	O
combination	O
of	O
gemcitabine	B-DRUG
and	O
5-fluoro-2'-deoxyuridine	B-DRUG
(	O
FUDR	B-DRUG
)	O
","	O
we	O
studied	O
this	O
combination	O
in	O
a	O
phase	O
I	O
trial	O
.	O
	
Gemcitabine	B-DRUG
alone	O
was	O
given	O
in	O
cycle	O
1	O
as	O
a	O
24-h	O
","	O
2-h	O
or	O
1-h	O
i.v.	O
infusion	O
weekly	O
for	O
3	O
of	O
4	O
weeks	O
;	O
if	O
tolerated	O
","	O
a	O
24-h	O
i.v.	O
infusion	O
of	O
FUDR	B-DRUG
was	O
added	O
with	O
oral	O
leucovorin	B-DRUG
.	O
	
The	O
cycle	O
was	O
aborted	O
for	O
grade	O
3	O
thrombocytopenia	B-TOXI
","	O
grade	O
4	O
neutropenia	B-TOXI
","	O
and	O
grade	O
2	O
or	O
worse	O
nonhematologic	B-TOXI
toxicity	I-TOXI
.	O
	
During	O
cycle	O
1	O
","	O
six	O
of	O
eight	O
patients	O
who	O
received	O
150	O
or	O
100	O
mg	O
/	O
m2	O
over	O
24	O
h	O
had	O
dose-limiting	O
neutropenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
fatigue	B-TOXI
or	O
mucositis	B-TOXI
.	O
	
Six	O
of	O
seven	O
patients	O
treated	O
with	O
1000	O
mg	O
/	O
m2	O
over	O
2	O
h	O
required	O
a	O
gemcitabine	B-DRUG
dose	O
reduction	O
for	O
cycle	O
2	O
(	O
thrombocytopenia	B-TOXI
","	O
neutropenia	B-TOXI
","	O
fatigue	B-TOXI
)	O
.	O
	
Of	O
25	O
assessable	O
patients	O
who	O
received	O
gemcitabine	B-DRUG
1000	O
mg	O
/	O
m2	O
over	O
1	O
h	O
","	O
7	O
did	O
not	O
complete	O
cycle	O
1	O
due	O
to	O
thrombocytopenia	B-TOXI
(	O
n=6	O
)	O
or	O
diarrhea	B-TOXI
(	O
n=1	O
)	O
.	O
	
Of	O
42	O
patients	O
entered	O
","	O
27	O
received	O
at	O
least	O
one	O
course	O
of	O
gemcitabine	B-DRUG
/	I-DRUG
FUDR	I-DRUG
(	O
5-19.5	O
mg	O
/	O
m2	O
over	O
24	O
h	O
)	O
without	O
appreciable	O
toxicity	O
.	O
	
Due	O
to	O
a	O
shortage	O
of	O
FUDR	B-DRUG
","	O
the	O
protocol	O
was	O
closed	O
early	O
.	O
	
Gemcitabine	B-DRUG
plasma	O
concentrations	O
averaged	O
0.061	O
micro	O
M	O
(	O
24	O
h	O
)	O
","	O
16.3	O
micro	O
M	O
(	O
2	O
h	O
)	O
","	O
and	O
31.9	O
micro	O
M	O
(	O
1	O
h	O
)	O
.	O
	
In	O
21	O
paired	O
bone	O
marrow	O
mononuclear	O
cell	O
samples	O
obtained	O
before	O
treatment	O
and	O
during	O
FUDR	B-DRUG
infusion	O
","	O
thymidylate	O
synthase	O
ternary	O
complex	O
was	O
only	O
seen	O
during	O
FUDR	B-DRUG
infusion	O
.	O
	
Gemcitabine	B-DRUG
100-150	O
mg	O
/	O
m2	O
over	O
24	O
h	O
was	O
poorly	O
tolerated	O
","	O
whereas	O
toxicity	O
was	O
acceptable	O
with	O
800-1000	O
mg	O
/	O
m2	O
over	O
1	O
h.	O
Inhibition	O
of	O
the	O
target	O
enzyme	O
was	O
demonstrated	O
at	O
all	O
FUDR	B-DRUG
doses	O
.	O
	
Phase	O
I	O
and	O
pharmacokinetic	O
study	O
of	O
two	O
different	O
schedules	O
of	O
oxaliplatin	B-DRUG
","	O
irinotecan	B-DRUG
","	O
Fluorouracil	B-DRUG
","	O
and	O
leucovorin	B-DRUG
in	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
We	O
sought	O
to	O
determine	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
evaluate	O
the	O
toxicities	O
and	O
clinical	O
activity	O
of	O
two	O
irinotecan	B-DRUG
(	O
CPT-11	B-DRUG
)	O
","	O
fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
","	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
","	O
and	O
oxaliplatin	B-DRUG
schedules	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Additionally	O
","	O
we	O
investigated	O
the	O
effect	O
of	O
CPT-11	B-DRUG
on	O
oxaliplatin	B-DRUG
pharmacokinetics	O
.	O
	
Thirteen	O
patients	O
(	O
cohort	O
1	O
)	O
received	O
intravenous	O
CPT-11	B-DRUG
(	O
infusion	O
)	O
and	O
FU	B-DRUG
/	O
LV	B-DRUG
(	O
bolus	O
)	O
on	O
days	O
1	O
","	O
8	O
","	O
15	O
","	O
and	O
22	O
and	O
oxaliplatin	B-DRUG
(	O
infusion	O
)	O
on	O
days	O
1	O
and	O
15	O
every	O
6	O
weeks	O
for	O
a	O
total	O
37	O
courses	O
(	O
median	O
","	O
three	O
courses	O
)	O
at	O
three	O
dose	O
levels	O
.	O
	
Twenty-two	O
cohort	O
2	O
patients	O
received	O
intravenous	O
CPT-11	B-DRUG
/	O
oxaliplatin	B-DRUG
(	O
infusion	O
","	O
day	O
1	O
)	O
and	O
FU	B-DRUG
/	O
LV	B-DRUG
(	O
90-minute	O
bolus	O
infusion	O
","	O
days	O
2	O
to	O
5	O
)	O
every	O
3	O
weeks	O
for	O
a	O
total	O
of	O
122	O
courses	O
(	O
median	O
","	O
four	O
courses	O
)	O
at	O
three	O
dose	O
levels	O
.	O
	
Pharmacokinetic	O
and	O
neurotoxicity	B-TOXI
assessments	O
were	O
performed	O
at	O
the	O
cohort	O
2	O
MTD	O
.	O
	
Dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
seen	O
in	O
both	O
cohorts	O
at	O
the	O
starting	O
dose	O
required	O
dose	O
de-escalation	O
.	O
	
Cohort	O
1	O
DLT	O
included	O
diarrhea	B-TOXI
and	O
neutropenia	B-TOXI
.	O
	
In	O
cohort	O
2	O
","	O
diarrhea	B-TOXI
","	O
vomiting	B-TOXI
","	O
dehydration	B-TOXI
","	O
neutropenia	B-TOXI
","	O
febrile	B-TOXI
neutropenia	I-TOXI
","	O
and	O
paresthesias	B-TOXI
were	O
DLTs	O
.	O
	
Antitumor	O
activity	O
was	O
seen	O
in	O
both	O
cohorts	O
.	O
	
In	O
cohort	O
2	O
","	O
the	O
total	O
platinum	B-DRUG
area	O
under	O
the	O
curve	O
of	O
patients	O
increased	O
17	O
%	O
in	O
cycle	O
2	O
(	O
P	O
0.048	O
)	O
","	O
but	O
objective	O
neurotoxicity	B-TOXI
was	O
not	O
seen	O
.	O
	
The	O
toxicities	O
resulting	O
from	O
the	O
addition	O
of	O
oxaliplatin	B-DRUG
to	O
CPT-11	B-DRUG
/	O
FU	B-DRUG
/	O
LV	B-DRUG
are	O
significant	O
but	O
manageable	O
.	O
	
The	O
MTDs	O
for	O
the	O
weekly	O
schedule	O
are	O
CPT-11	B-DRUG
(	O
75	O
mg	O
/	O
m2	O
)	O
","	O
oxaliplatin	B-DRUG
(	O
50	O
mg	O
/	O
m2	O
)	O
","	O
FU	O
(	O
320	O
mg	O
/	O
m2	O
)	O
","	O
and	O
LV	B-DRUG
(	O
20	O
mg	O
/	O
m2	O
)	O
;	O
and	O
","	O
for	O
the	O
3-weekly	O
schedule	O
","	O
the	O
MTDs	O
are	O
CPT-11	B-DRUG
(	O
175	O
mg	O
/	O
m2	O
)	O
","	O
oxaliplatin	B-DRUG
(	O
85	O
mg	O
/	O
m2	O
)	O
","	O
FU	B-DRUG
(	O
240	O
mg	O
/	O
m2	O
)	O
","	O
and	O
LV	B-DRUG
(	O
20	O
mg	O
/	O
m2	O
)	O
.	O
	
Second-cycle	O
platinum	B-DRUG
accumulation	O
raises	O
the	O
possibility	O
for	O
enhanced	O
cumulative	O
neurotoxicity	B-TOXI
with	O
CPT-11	B-DRUG
/	I-DRUG
oxaliplatin	I-DRUG
combinations	O
.	O
	
High-dose	O
tamoxifen	B-DRUG
as	O
an	O
enhancer	O
of	O
etoposide	B-TOXI
cytotoxicity.	I-TOXI
Clinical	O
effects	O
and	O
in	O
vitro	O
assessment	O
in	O
p-glycoprotein	O
expressing	O
cell	O
lines	O
.	O
	
	
Twenty-six	O
patients	O
with	O
relapsed	B-CANCER
or	I-CANCER
drug-resistant	I-CANCER
cancer	I-CANCER
were	O
treated	O
with	O
a	O
combination	O
of	O
oral	O
etoposide	B-DRUG
(	O
300	O
mg	O
day-1	O
for	O
3	O
days	O
)	O
and	O
high-dose	O
oral	O
tamoxifen	B-DRUG
as	O
a	O
potential	O
modulator	O
of	O
drug	O
resistance	O
(	O
480	O
or	O
720	O
mg	O
day-1	O
for	O
6	O
days	O
beginning	O
3	O
days	O
before	O
etoposide	B-DRUG
)	O
.	O
	
One	O
patient	O
with	O
relapsed	O
high-grade	O
lymphoma	B-TOXI
and	O
one	O
with	O
adenocarcinoma	B-TOXI
of	O
unknown	O
primary	O
site	O
has	O
a	O
partial	O
response	O
.	O
	
Toxicity	O
consisting	O
of	O
nausea	B-TOXI
","	O
vomiting	B-TOXI
and	O
subjective	B-TOXI
dizziness	I-TOXI
","	O
unsteadiness	B-TOXI
of	I-TOXI
gait	I-TOXI
and	O
malaise	B-TOXI
occurred	O
during	O
tamoxifen	B-DRUG
treatment	O
.	O
	
Serum	O
levels	O
of	O
tamoxifen	B-DRUG
averaged	O
3-3.5	O
microM	O
on	O
day	O
4	O
of	O
all	O
courses	O
of	O
treatment	O
at	O
both	O
480	O
and	O
720	O
mg	O
day-1	O
.	O
	
N-desmethyltamoxifen	B-DRUG
levels	O
were	O
lower	O
than	O
tamoxifen	B-DRUG
during	O
the	O
first	O
course	O
(	O
2	O
microM	O
)	O
but	O
increased	O
to	O
equal	O
tamoxifen	B-DRUG
levels	O
during	O
the	O
second	O
course	O
.	O
	
Didesmethyltamoxifen	B-DRUG
levels	O
remained	O
below	O
1	O
microM	O
.	O
	
In	O
vitro	O
","	O
both	O
tamoxifen	B-DRUG
and	O
the	O
standard	O
modulator	O
of	O
multidrug	O
resistance	O
","	O
verapamil	B-DRUG
","	O
produced	O
minor	O
enhancement	O
of	O
etoposide	B-TOXI
cytotoxicity	I-TOXI
in	O
the	O
MCF-7	O
wt	O
cell	O
line	O
but	O
produced	O
no	O
enhancement	O
with	O
any	O
other	O
cell	O
line	O
.	O
	
High	O
","	O
intermittent	O
doses	O
of	O
tamoxifen	B-DRUG
can	O
be	O
given	O
with	O
acceptable	O
toxicity	O
and	O
produce	O
serum	O
levels	O
that	O
have	O
been	O
shown	O
to	O
modulate	O
drug	O
resistance	O
in	O
vitro	O
.	O
	
In	O
vitro	O
","	O
however	O
","	O
such	O
levels	O
have	O
no	O
significant	O
effect	O
on	O
etoposide	B-TOXI
cytotoxicity	I-TOXI
towards	O
a	O
range	O
of	O
wild-type	O
and	O
MDR	O
cell	O
lines	O
.	O
	
Induction	O
chemotherapy	O
in	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
:	O
results	O
of	O
a	O
phase	O
III	O
trial	O
.	O
	
	
Between	O
December	O
1982	O
and	O
October	O
1986	O
","	O
131	O
patients	O
with	O
stage	O
II-III-IV	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	O
the	O
oropharynx	O
or	O
oral	O
cavity	O
were	O
randomized	O
to	O
induction	O
chemotherapy	O
","	O
consisting	O
of	O
bleomycin	B-DRUG
(	O
10	O
mg	O
/	O
m2	O
/	O
day	O
in	O
continuous	O
infusion	O
from	O
day	O
1	O
to	O
day	O
5	O
)	O
","	O
methotrexate	B-DRUG
(	O
120	O
mg	O
/	O
m2	O
on	O
day	O
2	O
)	O
followed	O
by	O
folinic	B-DRUG
acid	I-DRUG
","	O
5-fluorouracil	B-DRUG
(	O
5	B-DRUG
FU	I-DRUG
)	O
(	O
600	O
mg	O
/	O
m2	O
on	O
day	O
2	O
)	O
","	O
and	O
cisplatin	B-DRUG
(	O
120	O
mg	O
/	O
m2	O
on	O
day	O
4	O
)	O
every	O
4	O
weeks	O
for	O
a	O
total	O
of	O
three	O
cycles	O
followed	O
by	O
definitive	O
locoregional	O
treatment	O
versus	O
locoregional	O
treatment	O
alone	O
.	O
	
The	O
modalities	O
of	O
definitive	O
treatment	O
(	O
radiotherapy	O
=+	O
/	O
=-	O
surgery	O
)	O
were	O
chosen	O
prior	O
to	O
randomization	O
.	O
	
A	O
total	O
of	O
116	O
patients	O
were	O
evaluable	O
.	O
	
Of	O
55	O
patients	O
in	O
the	O
chemotherapy	O
arm	O
","	O
four	O
(	O
7	O
%	O
)	O
had	O
a	O
complete	O
response	O
(	O
CR	O
)	O
and	O
23	O
(	O
42	O
%	O
)	O
a	O
partial	O
response	O
(	O
PR	O
)	O
following	O
the	O
induction	O
regimen	O
.	O
	
At	O
the	O
completion	O
of	O
locoregional	O
treatment	O
","	O
76	O
%	O
(	O
42	O
of	O
55	O
)	O
of	O
patients	O
in	O
the	O
experimental	O
group	O
were	O
in	O
CR	O
compared	O
to	O
89	O
%	O
(	O
54	O
of	O
61	O
)	O
in	O
the	O
control	O
group	O
.	O
	
There	O
was	O
no	O
difference	O
in	O
survival	O
","	O
cause-specific	O
survival	O
","	O
and	O
pattern	O
of	O
relapse	O
between	O
both	O
groups	O
.	O
	
The	O
median	O
survival	O
was	O
22	O
months	O
in	O
the	O
chemotherapy	O
group	O
and	O
29	O
months	O
in	O
the	O
control	O
group	O
.	O
	
Responders	O
to	O
chemotherapy	O
did	O
not	O
fare	O
better	O
than	O
nonresponders	O
.	O
	
Chemotherapy-related	O
toxicities	O
were	O
few	O
and	O
most	O
of	O
them	O
related	O
to	O
cisplatin	B-DRUG
which	O
was	O
reduced	O
to	O
100	O
mg	O
/	O
m2	O
for	O
35	O
patients	O
.	O
	
There	O
were	O
no	O
treatment-related	O
deaths	B-TOXI
and	O
","	O
in	O
the	O
experimental	O
arm	O
of	O
the	O
trial	O
","	O
no	O
increased	O
morbidity	O
from	O
locoregional	O
treatment	O
.	O
	
This	O
induction	O
regimen	O
does	O
not	O
offer	O
any	O
advantages	O
over	O
standard	O
treatment	O
.	O
	
Etoposide	B-DRUG
and	O
carboplatin	B-DRUG
in	O
neuroblastoma	B-TOXI
:	O
a	O
French	O
Society	O
of	O
Pediatric	O
Oncology	O
phase	O
II	O
study	O
.	O
	
	
A	O
phase	O
II	O
study	O
of	O
etoposide	B-DRUG
(	O
VP	B-DRUG
16	I-DRUG
)	O
and	O
carboplatin	B-DRUG
(	O
CBDCA	B-DRUG
)	O
was	O
performed	O
in	O
patients	O
with	O
metastatic	B-CANCER
neuroblastoma	I-CANCER
(	O
NB	B-CANCER
)	O
.	O
	
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
find	O
an	O
alternative	O
treatment	O
for	O
induction	O
with	O
different	O
toxicities	O
than	O
the	O
VP	B-DRUG
16	I-DRUG
/	I-DRUG
cisplatin	I-DRUG
(	O
CDDP	B-DRUG
)	O
combination	O
.	O
	
Forty-seven	O
patients	O
who	O
were	O
from	O
6	O
months	O
to	O
16	O
years	O
of	O
age	O
","	O
with	O
either	O
relapsed	O
(	O
29	O
)	O
or	O
primary	O
resistant	O
(	O
18	O
)	O
NB	B-DRUG
","	O
were	O
included	O
in	O
a	O
cooperative	O
multicenter	O
phase	O
II	O
study	O
of	O
the	O
French	O
Society	O
of	O
Pediatric	O
Oncology	O
(	O
SFOP	O
)	O
.	O
	
The	O
schedule	O
consisted	O
of	O
5	O
consecutive	O
days	O
of	O
VP	B-DRUG
16	I-DRUG
100	O
mg	O
/	O
m2	O
/	O
d	O
and	O
CBDCA	B-DRUG
160	O
mg	O
/	O
m2	O
/	O
d.	O
The	O
response	O
rate	O
for	O
the	O
39	O
assessable	O
patients	O
was	O
43	O
%	O
;	O
there	O
were	O
four	O
complete	O
remissions	O
and	O
13	O
partial	O
remissions	O
.	O
	
Neither	O
the	O
status	O
of	O
the	O
patients	O
nor	O
the	O
total	O
dose	O
of	O
CDDP	B-DRUG
that	O
was	O
received	O
previously	O
influenced	O
response	O
.	O
	
Hematologic	B-TOXI
toxicity	I-TOXI
was	O
marked	O
and	O
caused	O
considerable	O
delay	O
between	O
courses	O
(	O
median	O
interval	O
","	O
39	O
days	O
)	O
.	O
	
In	O
these	O
heavily	O
pretreated	O
patients	O
","	O
16	O
%	O
had	O
a	O
more	O
than	O
50	O
%	O
decrease	O
in	O
creatinine	O
clearance	O
and	O
a	O
22	O
%	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
grade	O
2	O
ototoxicity	B-TOXI
.	O
	
This	O
VP	B-DRUG
16	I-DRUG
/	I-DRUG
CBDCA	I-DRUG
combination	O
deserves	O
further	O
evaluation	O
for	O
efficacy	O
and	O
toxicity	O
in	O
newly	O
diagnosed	O
patients	O
","	O
and	O
the	O
combination	O
of	O
both	O
drugs	O
should	O
be	O
considered	O
for	O
high-dose	O
therapy	O
with	O
bone	O
marrow	O
transplantation	O
.	O
	
Phase	O
I	O
and	O
II	O
study	O
of	O
high-dose	O
ifosfamide	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
etoposide	B-DRUG
with	O
autologous	O
bone	O
marrow	O
rescue	O
in	O
lymphomas	B-CANCER
and	I-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
High-dose	O
chemotherapy	O
produces	O
durable	O
disease-free	O
remissions	O
in	O
a	O
minority	O
of	O
patients	O
with	O
resistant	O
lymphomas	B-CANCER
and	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
In	O
an	O
attempt	O
to	O
improve	O
on	O
the	O
available	O
regimens	O
","	O
ifosfamide	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
etoposide	B-DRUG
(	O
ICE	B-DRUG
)	O
were	O
selected	O
for	O
a	O
new	O
high-dose	O
regimen	O
because	O
of	O
their	O
favorable	O
spectrum	O
of	O
nonhematopoietic	B-TOXI
toxicity	I-TOXI
and	O
evidence	O
of	O
synergy	O
in	O
in	O
vitro	O
systems	O
.	O
	
Forty-one	O
patients	O
with	O
drug-resistant	O
Hodgkin	O
's	O
and	O
non-Hodgkin	B-CANCER
's	I-CANCER
lymphomas	I-CANCER
","	O
and	O
breast	B-CANCER
and	I-CANCER
testicular	I-CANCER
cancers	I-CANCER
were	O
entered	O
onto	O
a	O
phase	O
I	O
and	O
II	O
trial	O
of	O
a	O
single	O
course	O
of	O
ICE	B-DRUG
with	O
autologous	O
bone	O
marrow	O
rescue	O
.	O
	
Before	O
transplantation	O
","	O
all	O
patients	O
received	O
combination	O
chemotherapy	O
until	O
maximal	O
tumor	O
response	O
was	O
achieved	O
.	O
	
Patients	O
received	O
total	O
doses	O
of	O
ifosfamide	B-DRUG
from	O
10	O
to	O
18	O
g	O
/	O
m2	O
","	O
carboplatin	B-DRUG
from	O
0.9	O
to	O
1.98	O
g	O
/	O
m2	O
","	O
and	O
etoposide	B-DRUG
from	O
0.6	O
to	O
1.5	O
g	O
/	O
m2	O
administered	O
during	O
a	O
4-day	O
period	O
","	O
with	O
a	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
ifosfamide	B-DRUG
16	O
g	O
/	O
m2	O
","	O
carboplatin	B-DRUG
1.8	O
g	O
/	O
m2	O
","	O
and	O
etoposide	B-DRUG
1.5	O
g	O
/	O
m2	O
.	O
	
The	O
dose-limiting	O
toxicities	O
included	O
irreversible	B-TOXI
renal	I-TOXI
","	O
cardiac	B-TOXI
","	O
and	O
CNS	B-TOXI
dysfunction	I-TOXI
.	O
	
There	O
were	O
three	O
toxic	B-TOXI
deaths	I-TOXI
(	O
7	O
%	O
)	O
","	O
and	O
all	O
occurred	O
above	O
the	O
MTD	O
.	O
	
Thirteen	O
patients	O
who	O
were	O
treated	O
at	O
the	O
MTD	O
tolerated	O
the	O
regimen	O
well	O
;	O
reversible	O
renal	B-TOXI
dysfunction	I-TOXI
and	O
grade	O
2	O
mucositis	B-TOXI
commonly	O
were	O
observed	O
.	O
	
Of	O
23	O
heavily	O
pretreated	O
patients	O
with	O
persistent	O
disease	O
at	O
the	O
time	O
of	O
transplant	O
","	O
10	O
(	O
43	O
%	O
)	O
achieved	O
complete	O
remissions	O
(	O
CRs	O
)	O
and	O
11	O
(	O
48	O
%	O
)	O
achieved	O
partial	O
remissions	O
(	O
PRs	O
)	O
.	O
	
Hodgkin	B-CANCER
's	I-CANCER
and	I-CANCER
non-Hodgkin	I-CANCER
's	I-CANCER
lymphoma	I-CANCER
patients	O
who	O
were	O
treated	O
at	O
or	O
below	O
the	O
MTD	O
had	O
a	O
median	O
potential	O
follow-up	O
of	O
11.9	O
months	O
","	O
and	O
12-month	O
progression-free	O
survivals	O
of	O
62	O
%	O
and	O
48	O
%	O
","	O
respectively	O
.	O
	
High-dose	O
ICE	B-DRUG
with	O
bone	O
marrow	O
rescue	O
was	O
well	O
tolerated	O
with	O
a	O
high	O
response	O
rate	O
","	O
and	O
should	O
be	O
considered	O
for	O
further	O
testing	O
.	O
	
Neoadjuvant	O
chemotherapy	O
with	O
cisplatin	B-DRUG
","	O
5-FU	B-DRUG
","	O
and	O
leucovorin	B-DRUG
(	O
PLF	B-DRUG
)	O
in	O
locally	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
:	O
a	O
prospective	O
phase	O
II	O
study	O
.	O
	
	
Patients	O
with	O
locally	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
(	O
cT3	O
","	O
cT4	O
","	O
N+	O
","	O
M0	O
)	O
have	O
a	O
dismal	O
prognosis	O
","	O
despite	O
complete	O
resection	O
.	O
	
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
toxicity	O
and	O
efficacy	O
of	O
neoadjuvant	O
chemotherapy	O
using	O
the	O
PLF	B-DRUG
(	O
cisplatin	B-DRUG
/	I-DRUG
leucovorin	I-DRUG
[	O
folinic	B-DRUG
acid	I-DRUG
]	O
/	O
5-fluorouracil	B-DRUG
[	O
FU	B-DRUG
]	O
)	O
regimen	O
in	O
these	O
patients	O
.	O
	
Primary	O
endpoints	O
of	O
the	O
study	O
were	O
the	O
toxicity	O
and	O
the	O
response	O
to	O
chemotherapy	O
.	O
	
Secondary	O
endpoints	O
were	O
the	O
rate	O
of	O
complete	O
resection	O
","	O
survival	O
","	O
and	O
first	O
site	O
of	O
failure	O
.	O
	
Forty-nine	O
patients	O
with	O
adenocarcinoma	B-CANCER
of	I-CANCER
the	I-CANCER
stomach	I-CANCER
were	O
enrolled	O
.	O
	
Staging	O
was	O
based	O
on	O
abdominal	O
computed	O
tomography	O
(	O
CT	O
)	O
scans	O
","	O
endosonography	O
","	O
and	O
laparoscopy	O
.	O
	
The	O
intention	O
was	O
to	O
administer	O
two	O
cycles	O
(	O
each	O
containing	O
six	O
courses	O
)	O
of	O
preoperative	O
chemotherapy	O
","	O
consisting	O
of	O
cisplatin	B-DRUG
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
high-dose	O
folinic	B-DRUG
acid	I-DRUG
(	O
HD-FA	O
)	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
and	O
HD	O
5-FU	B-DRUG
(	O
HD-5-FU	O
)	O
2000	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
PLF	O
)	O
.	O
	
Following	O
chemotherapy	O
all	O
patients	O
were	O
referred	O
to	O
surgery	O
.	O
	
To	O
be	O
evaluable	O
for	O
response	O
","	O
survival	O
","	O
and	O
first	O
site	O
of	O
failure	O
","	O
the	O
patient	O
had	O
to	O
receive	O
at	O
least	O
one	O
cycle	O
of	O
chemotherapy	O
.	O
	
Toxicity	O
observed	O
was	O
low	O
","	O
with	O
grade	O
3	O
toxicity	O
in	O
fewer	O
than	O
5	O
%	O
of	O
the	O
patients	O
and	O
two	O
events	O
of	O
grade	O
4	O
toxicity	O
(	O
diarrhea	B-TOXI
and	O
pulmonary	B-TOXI
embolism	I-TOXI
)	O
.	O
	
Forty-two	O
of	O
the	O
patients	O
(	O
86	O
%	O
)	O
received	O
at	O
least	O
one	O
cycle	O
of	O
chemotherapy	O
.	O
	
The	O
clinical	O
response	O
rate	O
in	O
these	O
patients	O
was	O
26	O
%	O
(	O
11	O
/	O
42	O
patients	O
)	O
.	O
	
In	O
76	O
%	O
of	O
the	O
patients	O
(	O
32	O
/	O
42	O
)	O
","	O
a	O
complete	O
resection	O
was	O
possible	O
.	O
	
The	O
median	O
duration	O
of	O
follow-up	O
for	O
the	O
surviving	O
patients	O
was	O
58	O
months	O
(	O
range	O
","	O
38	O
to	O
80+	O
months	O
)	O
.	O
	
The	O
median	O
survival	O
time	O
for	O
the	O
42	O
patients	O
assessable	O
for	O
response	O
was	O
25.4	O
months	O
(	O
range	O
","	O
6	O
to	O
80+	O
months	O
)	O
.	O
	
After	O
complete	O
resection	O
","	O
median	O
survival	O
time	O
was	O
32	O
months	O
(	O
range	O
","	O
7.6	O
to	O
80+	O
months	O
)	O
.	O
	
The	O
median	O
survival	O
time	O
for	O
clinically	O
responding	O
patients	O
has	O
not	O
yet	O
been	O
determined	O
","	O
but	O
5-year	O
survival	O
is	O
90	O
%	O
.	O
	
Twenty	O
of	O
the	O
32	O
completely	O
resected	O
patients	O
(	O
62.5	O
%	O
)	O
had	O
recurrences	O
.	O
	
First	O
site	O
of	O
failure	O
was	O
peritoneal	B-TOXI
dissemination	I-TOXI
in	O
10	O
patients	O
;	O
locoregional	B-TOXI
and	I-TOXI
distant	I-TOXI
recurrences	I-TOXI
were	O
rare	O
.	O
	
Neoadjuvant	O
chemotherapy	O
with	O
PLF	B-DRUG
in	O
patients	O
with	O
locally	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
has	O
low	O
toxicity	O
and	O
reasonable	O
efficacy	O
","	O
allowing	O
administration	O
on	O
an	O
outpatient	O
basis	O
.	O
	
Clinically	O
responding	O
patients	O
have	O
an	O
excellent	O
outcome	O
after	O
complete	O
resection	O
.	O
	
The	O
development	O
of	O
peritoneal	O
dissemination	O
even	O
after	O
neoadjuvant	O
chemotherapy	O
and	O
complete	O
resection	O
remains	O
an	O
unsolved	O
problem	O
in	O
patients	O
with	O
nonintestinal	O
type	O
tumors	O
.	O
	
A	O
phase	O
II	O
study	O
of	O
weekly	O
cisplatin	B-DRUG
","	O
6S-stereoisomer	B-DRUG
leucovorin	I-DRUG
and	O
fluorouracil	B-DRUG
as	O
first-line	O
chemotherapy	O
for	O
elderly	O
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
incidence	O
of	O
gastric	B-CANCER
cancer	I-CANCER
(	O
GC	B-CANCER
)	O
increases	O
significantly	O
after	O
the	O
fifth	O
decade	O
and	O
palliative	O
chemotherapy	O
is	O
the	O
ultimate	O
treatment	O
in	O
the	O
majority	O
of	O
patients	O
.	O
	
We	O
investigated	O
safety	O
and	O
efficacy	O
of	O
a	O
weekly	O
regimen	O
with	O
cisplatin	B-DRUG
","	O
fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
as	O
first-line	O
chemotherapy	O
for	O
elderly	O
patients	O
with	O
advanced	B-CANCER
GC	I-CANCER
.	O
	
Chemotherapy-naive	O
patients	O
older	O
than	O
65	O
years	O
were	O
considered	O
eligible	O
for	O
study	O
entry	O
.	O
	
Frail	O
elderly	O
patients	O
were	O
identified	O
and	O
excluded	O
according	O
to	O
the	O
following	O
criteria	O
:	O
age	O
&	O
gt	O
;	O
85	O
years	O
","	O
dependence	O
in	O
one	O
or	O
more	O
activities	O
of	O
daily	O
living	O
(	O
activities	O
of	O
daily	O
living	O
and	O
instrumental	O
activities	O
of	O
daily	O
living	O
scales	O
)	O
","	O
three	O
or	O
more	O
comorbid	O
conditions	O
","	O
one	O
or	O
more	O
geriatric	B-CANCER
syndromes	I-CANCER
.	O
	
Chemotherapy	O
consisted	O
of	O
1-day	O
per	O
week	O
administration	O
of	O
intravenous	O
cisplatin	B-DRUG
35	O
mg	O
m	O
(	O
-2	O
)	O
","	O
6S-stereoisomer	B-DRUG
leucovorin	I-DRUG
250	O
mg	O
m	O
(	O
-2	O
)	O
and	O
fluorouracil	B-DRUG
500	O
mg	O
m	O
(	O
-2	O
)	O
(	O
PLF	O
)	O
.	O
	
Patients	O
were	O
re-evaluated	O
after	O
eight	O
weekly	O
cycles	O
and	O
six	O
additional	O
weekly	O
administrations	O
were	O
planned	O
for	O
patients	O
without	O
disease	O
progression	O
.	O
	
A	O
5-day	O
subcutaneous	O
filgrastim	B-DRUG
(	O
5	O
mug	O
Kg	O
(	O
-1	O
)	O
day	O
(	O
-1	O
)	O
","	O
days	O
-4	O
)	O
was	O
used	O
after	O
the	O
first	O
treatment	O
delay	O
for	O
neutropenia	B-TOXI
and	O
maintained	O
thereafter	O
.	O
	
In	O
the	O
whole	O
group	O
","	O
the	O
best	O
intention-to-treat	O
overall	O
response	O
rate	O
was	O
43	O
%	O
(	O
95	O
%	O
CI	O
:	O
30-56	O
%	O
)	O
.	O
	
The	O
time	O
to	O
disease	O
progression	O
and	O
the	O
median	O
survival	O
time	O
were	O
5.3	O
and	O
8.6	O
months	O
","	O
respectively	O
.	O
	
Fatigue	B-TOXI
was	O
the	O
commonest	O
nonhaematologic	B-TOXI
toxicity	I-TOXI
(	O
71	O
%	O
of	O
the	O
patients	O
)	O
.	O
	
Filgrastim	B-DRUG
was	O
used	O
in	O
30	O
patients	O
who	O
showed	O
grade	O
II	O
(	O
20	O
patients	O
)	O
or	O
grade	O
III	O
(	O
10	O
patients	O
)	O
neutropenia	B-TOXI
.	O
	
Neither	O
grade	O
IV	O
toxicity	O
nor	O
toxic	B-TOXI
deaths	I-TOXI
were	O
observed	O
.	O
	
The	O
weekly	O
PLF	B-DRUG
regimen	O
resulted	O
safe	O
and	O
effective	O
in	O
elderly	O
patients	O
with	O
advanced	B-CANCER
GC	I-CANCER
.	O
	
This	O
outpatient	O
regimen	O
is	O
based	O
on	O
old	O
and	O
low-cost	O
drugs	O
and	O
it	O
may	O
represent	O
an	O
alternative	O
to	O
new	O
and	O
more	O
expensive	O
combinations	O
.	O
	
Aggressive	O
simultaneous	O
radiochemotherapy	O
with	O
cisplatin	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
combination	O
with	O
accelerated	O
hyperfractionated	O
radiotherapy	O
in	O
locally	O
advanced	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
tumors.	I-CANCER
Results	O
of	O
a	O
phase	O
I-II	O
trial	O
.	O
	
	
Simultaneous	O
radiochemotherapy	O
(	O
sRCT	O
)	O
is	O
the	O
treatment	O
of	O
first	O
choice	O
in	O
locally	O
advanced	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancers	I-CANCER
.	O
	
We	O
have	O
tested	O
a	O
very	O
aggressive	O
combination	O
protocol	O
with	O
cisplatin	B-DRUG
and	O
escalated	O
paclitaxel	B-DRUG
in	O
combination	O
with	O
accelerated	O
hyperfractionated	O
radiotherapy	O
to	O
assess	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
","	O
overall	O
toxicity	O
","	O
and	O
response	O
rate	O
.	O
	
The	O
trial	O
recruited	O
24	O
patients	O
(	O
21	O
males	O
","	O
three	O
females	O
","	O
mean	O
age	O
57	O
years	O
)	O
treated	O
at	O
our	O
department	O
from	O
1998	O
through	O
2001	O
.	O
	
Irradiation	O
was	O
administered	O
in	O
daily	O
doses	O
of	O
2	O
Gy	O
up	O
to	O
30	O
Gy	O
followed	O
by	O
1.4	O
Gy	O
twice	O
daily	O
up	O
to	O
70.6	O
Gy	O
to	O
the	O
primary	O
tumor	O
and	O
involved	O
nodes	O
and	O
51	O
Gy	O
to	O
the	O
clinically	O
negative	O
regional	O
nodes	O
.	O
	
The	O
chemotherapy	O
schedule	O
included	O
cisplatin	B-DRUG
in	O
a	O
fixed	O
dose	O
of	O
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1月5日	O
and	O
29-33	O
and	O
paclitaxel	B-DRUG
at	O
increasing	O
dose	O
levels	O
of	O
20	O
","	O
25	O
","	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
weekly	O
over	O
the	O
whole	O
treatment	O
time	O
.	O
	
Patients	O
were	O
recruited	O
in	O
cohorts	O
of	O
three	O
to	O
six	O
","	O
and	O
the	O
MTD	O
was	O
reached	O
if	O
two	O
out	O
of	O
six	O
patients	O
in	O
one	O
cohort	O
developed	O
DLT	O
.	O
	
DLT	O
was	O
defined	O
as	O
any	O
grade	O
4	O
toxicity	O
or	O
any	O
grade	O
3	O
toxicity	O
requiring	O
treatment	O
interruption	O
or	O
unplanned	O
hospitalization	O
or	O
any	O
grade	O
3	O
neurotoxicity	B-TOXI
.	O
	
We	O
recruited	O
mainly	O
patients	O
with	O
large	O
tumors	O
for	O
this	O
protocol	O
;	O
all	O
patients	O
were	O
stage	O
IV	O
","	O
and	O
the	O
mean	O
tumor	O
volume	O
(	O
primary	O
=+	O
metastases	O
)	O
amounted	O
to	O
72	O
=+	O
/	O
=-	O
61	O
cm	O
(	O
3	O
)	O
.	O
	
The	O
mean	O
follow-up	O
was	O
30	O
months	O
(	O
range	O
4-39	O
months	O
)	O
.	O
	
One	O
early	O
death	B-TOXI
(	O
peritonitis	B-TOXI
and	O
sepsis	B-TOXI
at	O
day	O
10	O
)	O
occurred	O
","	O
and	O
23	O
patients	O
were	O
evaluable	O
for	O
acute	B-TOXI
toxicity	I-TOXI
and	I-TOXI
response	I-TOXI
.	O
	
The	O
MTD	O
of	O
paclitaxel	B-DRUG
was	O
reached	O
at	O
the	O
third	O
dose	O
level	O
(	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
paclitaxel	B-DRUG
twice	O
weekly	O
)	O
.	O
	
The	O
DLT	O
was	O
severe	B-TOXI
mucositis	I-TOXI
grade	O
3	O
(	O
n	O
=	O
1	O
)	O
and	O
skin	B-TOXI
erythema	I-TOXI
grade	O
4	O
(	O
n	O
=	O
2	O
)	O
.	O
	
After	O
determining	O
the	O
MTD	O
","	O
another	O
14	O
patients	O
were	O
treated	O
at	O
the	O
recommended	O
dose	O
level	O
of	O
paclitaxel	B-DRUG
with	O
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
weekly	O
.	O
	
In	O
summary	O
","	O
13	O
/	O
23	O
patients	O
(	O
57	O
%	O
)	O
developed	O
grade	O
3	O
and	O
10	O
/	O
23	O
(	O
43	O
%	O
)	O
grade	O
2	O
mucositis	B-TOXI
.	O
	
Two	O
patients	O
(	O
9	O
%	O
)	O
had	O
grade	O
4	O
","	O
five	O
(	O
22	O
%	O
)	O
grade	O
3	O
","	O
and	O
16	O
(	O
69	O
%	O
)	O
grade	O
2	O
dermatitis	B-TOXI
.	O
	
One	O
patient	O
died	B-TOXI
at	O
day	O
30	O
of	O
neutropenic	B-TOXI
infection	I-TOXI
.	O
	
In	O
one	O
patient	O
","	O
a	O
grade	O
2	O
nephrotoxicity	B-TOXI
appeared	O
requiring	O
cessation	O
of	O
cisplatin	B-DRUG
chemotherapy	O
.	O
	
18	O
/	O
23	O
patients	O
(	O
78	O
%	O
)	O
required	O
blood	O
transfusion	O
(	O
1月3日	O
units	O
)	O
and	O
16	O
/	O
23	O
(	O
70	O
%	O
)	O
i.v.	O
antibiotics	O
.	O
	
14	O
patients	O
(	O
61	O
%	O
)	O
achieved	O
a	O
complete	O
and	O
nine	O
(	O
39	O
%	O
)	O
a	O
partial	O
remission	O
","	O
yielding	O
an	O
overall	O
response	O
rate	O
of	O
100	O
%	O
.	O
	
In	O
summary	O
","	O
six	O
patients	O
died	B-TOXI
of	O
local	O
tumor	O
progression	O
(	O
n	O
=	O
2	O
)	O
","	O
distant	B-TOXI
metastases	I-TOXI
(	O
n	O
=	O
2	O
)	O
","	O
or	O
therapy-related	O
complications	B-TOXI
(	O
n	O
=	O
2	O
)	O
during	O
follow-up	O
.	O
	
The	O
3-year	O
overall	O
survival	O
was	O
71	O
%	O
.	O
	
Tumor	O
volume	O
was	O
not	O
a	O
risk	O
factor	O
for	O
failure	O
in	O
this	O
protocol	O
(	O
mean	O
tumor	O
volume	O
in	O
relapse-free	O
vs.	O
progressive	O
patients	O
71	O
=+	O
/	O
=-	O
65	O
cm	O
(	O
3	O
)	O
vs.	O
64	O
=+	O
/	O
=-	O
38	O
cm	O
(	O
3	O
)	O
)	O
.	O
	
All	O
patients	O
have	O
","	O
so	O
far	O
","	O
developed	O
only	O
slight	O
late	O
effects	O
(	O
fibrosis	B-TOXI
","	O
lymphedema	B-TOXI
)	O
with	O
no	O
grade	O
3月4日	O
late	B-TOXI
sequelae	I-TOXI
.	O
	
This	O
very	O
aggressive	O
sRCT	O
protocol	O
yielded	O
excellent	O
response	O
and	O
survival	O
figures	O
but	O
was	O
associated	O
with	O
a	O
very	O
high	O
rate	O
of	O
acute	B-TOXI
toxicity	I-TOXI
(	O
8	O
%	O
therapy-related	O
deaths	B-TOXI
)	O
.	O
	
A	O
maximal	O
supportive	O
treatment	O
is	O
therefore	O
required	O
.	O
	
Phase	O
I	O
clinical	O
study	O
of	O
infusional	B-DRUG
5-fluorouracil	I-DRUG
with	O
oxaliplatin	B-DRUG
and	O
gemcitabine	B-DRUG
(	O
FOG	B-DRUG
regimen	O
)	O
in	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
","	O
recommended	O
phase	O
II	O
dose	O
(	O
RPTD	O
)	O
and	O
toxicities	O
of	O
the	O
FOG	B-DRUG
regimen	O
(	O
infusional	B-DRUG
5-fluorouracil	I-DRUG
","	O
oxaliplatin	B-DRUG
","	O
gemcitabine	B-DRUG
)	O
.	O
	
Patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
treated	O
in	O
an	O
accelerated	O
titration	O
scheme	O
.	O
	
5-Fluorouracil	B-DRUG
was	O
administered	O
intravenously	O
at	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
for	O
14	O
days	O
and	O
repeated	O
every	O
21	O
days	O
(	O
one	O
cycle	O
)	O
.	O
	
Gemcitabine	B-DRUG
was	O
administered	O
on	O
days	O
1	O
and	O
8	O
over	O
30	O
min	O
at	O
450-650	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Oxaliplatin	B-DRUG
was	O
administered	O
on	O
day	O
1	O
over	O
2	O
h	O
at	O
85-130	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
For	O
cycles	O
1	O
","	O
3	O
and	O
beyond	O
","	O
gemcitabine	B-DRUG
followed	O
oxaliplatin	B-DRUG
;	O
for	O
cycle	O
2	O
","	O
gemcitabine	B-DRUG
preceded	O
oxaliplatin	B-DRUG
.	O
	
Forty-five	O
and	O
39	O
patients	O
were	O
assessable	O
for	O
toxicity	O
and	O
response	O
","	O
respectively	O
.	O
	
Cycle	O
1	O
dose-limiting	O
toxicities	O
(	O
DLT	O
)	O
included	O
neutropenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
and	O
diarrhea	B-TOXI
.	O
	
No	O
DLT	O
was	O
observed	O
in	O
cycle	O
1	O
at	O
the	O
first	O
four	O
dose	O
levels	O
(	O
DL	O
)	O
.	O
	
At	O
DL-5	O
","	O
two	O
of	O
four	O
(	O
50	O
%	O
)	O
patients	O
experienced	O
DLT	O
in	O
cycle	O
1	O
Expanding	O
DL-4	O
","	O
nine	O
of	O
26	O
(	O
35	O
%	O
)	O
patients	O
experienced	O
DLT	O
in	O
cycle	O
1	O
Because	O
recurrent	O
grade	O
3	O
toxicities	O
were	O
observed	O
in	O
three	O
of	O
six	O
(	O
50	O
%	O
)	O
patients	O
at	O
DL-3	O
","	O
DL-2	O
was	O
considered	O
the	O
RPTD	O
.	O
	
At	O
the	O
RPTD	O
","	O
three	O
patients	O
had	O
a	O
partial	O
response	O
(	O
response	O
rate	O
23	O
%	O
)	O
.	O
	
The	O
RPTD	O
for	O
the	O
5-fluorouracil-oxaliplatin-gemcitabine	B-DRUG
combination	O
is	O
200	O
/	O
100	O
/	O
450	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
This	O
novel	O
regimen	O
has	O
demonstrated	O
activity	O
in	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
and	O
merits	O
further	O
investigation	O
.	O
	
A	O
phase	O
II	O
study	O
of	O
irinotecan	B-DRUG
plus	O
chronomodulated	O
oxaliplatin	B-DRUG
","	O
5-fluorouracil	B-DRUG
and	O
folinic	B-DRUG
acid	I-DRUG
in	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
patients	O
.	O
	
	
The	O
combination	O
of	O
irinotecan	B-DRUG
(	O
CPT-11	B-DRUG
)	O
","	O
oxaliplatin	B-DRUG
(	O
L-OHP	B-DRUG
)	O
","	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
and	O
folinic	B-DRUG
acid	I-DRUG
(	O
FA	B-DRUG
)	O
is	O
one	O
of	O
the	O
possibilities	O
to	O
overcome	O
chemoresistance	O
in	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
ACRC	B-CANCER
)	O
patients	O
.	O
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
tolerability	O
and	O
activity	O
of	O
CPT-11	B-DRUG
plus	O
chronomodulated	O
infusion	O
of	O
L-OHP	B-DRUG
","	O
5-FU	B-DRUG
and	O
FA	B-DRUG
in	O
ACRC	B-CANCER
patients	O
.	O
	
A	O
total	O
of	O
35	O
patients	O
(	O
91	O
%	O
pretreated	O
","	O
77	O
%	O
with	O
CPT-11	B-DRUG
","	O
54	O
%	O
with	O
L-OHP	B-DRUG
","	O
42	O
%	O
with	O
both	O
)	O
were	O
treated	O
every	O
3	O
weeks	O
with	O
CPT-11	B-DRUG
","	O
180	O
mg	O
m	O
(	O
-2	O
)	O
day	O
1	O
i.v.	O
","	O
plus	O
L-OHP	B-DRUG
","	O
20	O
mg	O
m	O
(	O
-2	O
)	O
day	O
(	O
-1	O
)	O
","	O
5-FU	B-DRUG
","	O
700	O
mg	O
m	O
(	O
-2	O
)	O
day	O
(	O
-1	O
)	O
and	O
FA	B-DRUG
","	O
150	O
mg	O
m	O
(	O
-2	O
)	O
day	O
(	O
-1	O
)	O
","	O
all	O
three	O
drugs	O
from	O
day	O
2	O
to	O
day	O
5	O
by	O
chronomodulated	O
infusion	O
.	O
	
The	O
patients	O
'	O
(	O
pt	O
)	O
data	O
were	O
as	O
follows	O
:	O
male	O
/	O
female	O
21	O
/	O
14	O
;	O
median	O
age	O
58	O
years	O
(	O
range	O
:	O
38-70	O
)	O
;	O
PS	O
0	O
:	O
26	O
pts	O
(	O
74	O
%	O
)	O
","	O
PS	O
1	O
:	O
8	O
pts	O
(	O
23	O
%	O
)	O
","	O
PS	O
2	O
:	O
1	O
pt	O
(	O
3	O
%	O
)	O
;	O
primary	O
tumour	B-CANCER
colon	I-CANCER
/	I-CANCER
rectum	I-CANCER
26	O
/	O
9	O
;	O
involved	O
organs	O
:	O
1	O
","	O
14	O
pts	O
(	O
40	O
%	O
)	O
;	O
2	O
","	O
17	O
pts	O
(	O
48	O
%	O
)	O
;	O
&	O
gt	O
;	O
or=3	O
:	O
4	O
pts	O
(	O
11	O
%	O
)	O
;	O
previous	O
chemotherapy	O
lines	O
1	O
:	O
12	O
pts	O
(	O
34	O
%	O
)	O
","	O
2	O
:	O
10	O
pts	O
(	O
28	O
%	O
)	O
","	O
&	O
gt	O
;	O
or=3	O
:	O
10	O
pts	O
(	O
28	O
%	O
)	O
.	O
	
A	O
total	O
of	O
221	O
courses	O
(	O
c	O
)	O
were	O
performed	O
;	O
no	O
grade	O
4	O
toxicity	O
was	O
observed	O
with	O
only	O
one	O
grade	O
3	O
(	O
G3	O
)	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
(	O
3	O
%	O
)	O
in	O
one	O
out	O
of	O
221	O
courses	O
(	O
&	O
lt	O
;	O
1	O
%	O
)	O
.	O
	
Maximal	O
toxicity	O
(	O
G3	O
)	O
was	O
nausea	B-TOXI
and	O
diarrhoea	B-TOXI
in	O
10	O
pts	O
(	O
28	O
%	O
)	O
","	O
occurring	O
in	O
14	O
out	O
of	O
221	O
c	O
(	O
6	O
%	O
)	O
and	O
12	O
out	O
of	O
221	O
c	O
(	O
5	O
%	O
)	O
respectively	O
.	O
	
Seven	O
patients	O
achieved	O
a	O
partial	O
response	O
(	O
20	O
%	O
","	O
confidence	O
interval	O
(	O
c.i.	O
)	O
6.8-33.3	O
)	O
and	O
one	O
patient	O
a	O
complete	O
response	O
(	O
2.9	O
%	O
","	O
c.i.	O
0-8.4	O
)	O
","	O
for	O
a	O
total	O
overall	O
response	O
rate	O
of	O
22.9	O
%	O
(	O
c.i.	O
9-36.8	O
)	O
;	O
15	O
out	O
of	O
35	O
(	O
42.9	O
%	O
","	O
c.i.	O
26.5-59.3	O
)	O
had	O
stable	O
disease	O
and	O
12	O
out	O
of	O
35	O
(	O
34.3	O
%	O
","	O
c.i.	O
18.6-50	O
)	O
patients	O
underwent	O
a	O
progression	O
.	O
	
In	O
conclusion	O
","	O
this	O
four-drug	O
regimen	O
is	O
feasible	O
in	O
advanced	B-CANCER
pretreated	I-CANCER
ACRC	I-CANCER
patients	O
with	O
no	O
significant	O
haematological	B-TOXI
toxicity	I-TOXI
and	O
acceptable	O
diarrhoea	B-TOXI
.	O
	
The	O
activity	O
of	O
this	O
combination	O
is	O
currently	O
studied	O
in	O
EORTC	O
5011	O
study	O
.	O
	
FOLFIRI	B-DRUG
followed	O
by	O
FOLFOX6	B-DRUG
or	O
the	O
reverse	O
sequence	O
in	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
:	O
a	O
randomized	O
GERCOR	O
study	O
.	O
	
	
In	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
","	O
phase	O
III	O
studies	O
have	O
demonstrated	O
the	O
superiority	O
of	O
fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
with	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
in	O
combination	O
with	O
irinotecan	B-DRUG
or	O
oxaliplatin	B-DRUG
over	O
FU	B-DRUG
=+	O
LV	B-DRUG
alone	O
.	O
	
This	O
phase	O
III	O
study	O
investigated	O
two	O
sequences	O
:	O
folinic	B-DRUG
acid	I-DRUG
","	O
FU	B-DRUG
","	O
and	O
irinotecan	B-DRUG
(	O
FOLFIRI	B-DRUG
)	O
followed	O
by	O
folinic	B-DRUG
acid	I-DRUG
","	O
FU	B-DRUG
","	O
and	O
oxaliplatin	B-DRUG
(	O
FOLFOX6	B-DRUG
;	O
arm	O
A	O
)	O
","	O
and	O
FOLFOX6	B-DRUG
followed	O
by	O
FOLFIRI	B-DRUG
(	O
arm	O
B	O
)	O
.	O
	
Previously	O
untreated	O
patients	O
with	O
assessable	O
disease	O
were	O
randomly	O
assigned	O
to	O
receive	O
a	O
2-hour	O
infusion	O
of	O
l-LV	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
or	O
dl-LV	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
followed	O
by	O
a	O
FU	B-DRUG
bolus	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
46-hour	O
infusion	O
"2,400"	O
to	O
"3,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
every	O
46	O
hours	O
every	O
2	O
weeks	O
","	O
either	O
with	O
irinotecan	B-DRUG
180	O
mg	O
/	O
m	O
(	O
2	O
)	O
or	O
with	O
oxaliplatin	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
2-hour	O
infusion	O
on	O
day	O
1	O
At	O
progression	O
","	O
irinotecan	B-DRUG
was	O
replaced	O
by	O
oxaliplatin	B-DRUG
(	O
arm	O
A	O
)	O
","	O
or	O
oxaliplatin	B-DRUG
by	O
irinotecan	B-DRUG
(	O
arm	O
B	O
)	O
.	O
	
Median	O
survival	O
was	O
21.5	O
months	O
in	O
109	O
patients	O
allocated	O
to	O
FOLFIRI	B-DRUG
then	O
FOLFOX6	B-DRUG
versus	O
20.6	O
months	O
in	O
111	O
patients	O
allocated	O
to	O
FOLFOX6	B-DRUG
then	O
FOLFIRI	B-DRUG
(	O
P	O
0.99	O
)	O
.	O
	
Median	O
second	O
progression-free	O
survival	O
(	O
PFS	O
)	O
was	O
14.2	O
months	O
in	O
arm	O
A	O
versus	O
10.9	O
in	O
arm	O
B	O
(	O
P	O
0.64	O
)	O
.	O
	
In	O
first-line	O
therapy	O
","	O
FOLFIRI	B-DRUG
achieved	O
56	O
%	O
response	O
rate	O
(	O
RR	O
)	O
and	O
8.5	O
months	O
median	O
PFS	O
","	O
versus	O
FOLFOX6	B-DRUG
which	O
achieved	O
54	O
%	O
RR	O
and	O
8	O
months	O
median	O
PFS	O
(	O
P	O
0.26	O
)	O
.	O
	
Second-line	O
FOLFIRI	B-DRUG
achieved	O
4	O
%	O
RR	O
and	O
2.5	O
months	O
median	O
PFS	O
","	O
versus	O
FOLFOX6	B-DRUG
which	O
achieved	O
15	O
%	O
RR	O
and	O
4.2	O
months	O
PFS	O
.	O
	
In	O
first-line	O
therapy	O
","	O
National	O
Cancer	O
Institute	O
Common	O
Toxicity	O
Criteria	O
grade	O
3	O
/	O
4	O
mucositis	B-TOXI
","	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
","	O
and	O
grade	O
2	O
alopecia	B-TOXI
were	O
more	O
frequent	O
with	O
FOLFIRI	B-DRUG
","	O
and	O
grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
and	O
neurosensory	B-TOXI
toxicity	I-TOXI
were	O
more	O
frequent	O
with	O
FOLFOX6	B-DRUG
.	O
	
Both	O
sequences	O
achieved	O
a	O
prolonged	O
survival	O
and	O
similar	O
efficacy	O
.	O
	
The	O
toxicity	O
profiles	O
were	O
different	O
.	O
	
Multicenter	O
phase	O
II	O
study	O
of	O
Nordic	O
fluorouracil	B-DRUG
and	O
folinic	B-DRUG
acid	I-DRUG
bolus	O
schedule	O
combined	O
with	O
oxaliplatin	B-DRUG
as	O
first-line	O
treatment	O
of	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
This	O
Nordic	O
multicenter	O
phase	O
II	O
study	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
oxaliplatin	B-DRUG
combined	O
with	O
the	O
Nordic	O
bolus	O
schedule	O
of	O
fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
and	O
folinic	B-DRUG
acid	I-DRUG
(	O
FA	B-DRUG
)	O
as	O
first-line	O
treatment	O
in	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Eighty-five	O
patients	O
were	O
treated	O
with	O
oxaliplatin	B-DRUG
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
2-hour	O
infusion	O
on	O
day	O
1	O
","	O
followed	O
by	O
a	O
3-minute	O
bolus	O
injection	O
with	O
FU	B-DRUG
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
","	O
30	O
minutes	O
later	O
","	O
by	O
a	O
bolus	O
injection	O
with	O
FA	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
every	O
second	O
week	O
.	O
	
The	O
same	O
doses	O
of	O
FU	B-DRUG
and	O
FA	B-DRUG
were	O
also	O
given	O
on	O
day	O
2	O
Fifty-one	O
of	O
82	O
assessable	O
patients	O
achieved	O
a	O
complete	O
(	O
n	O
=	O
4	O
)	O
or	O
partial	O
(	O
n	O
=	O
47	O
)	O
response	O
","	O
leading	O
to	O
a	O
response	O
rate	O
of	O
62	O
%	O
(	O
95	O
%	O
CI	O
","	O
52	O
%	O
to	O
72	O
%	O
)	O
.	O
	
Nineteen	O
patients	O
showed	O
stable	O
disease	O
","	O
and	O
12	O
patients	O
had	O
progressive	O
disease	O
.	O
	
Thirty-eight	O
of	O
the	O
51	O
responses	O
were	O
radiologically	O
confirmed	O
8	O
weeks	O
later	O
(	O
confirmed	O
response	O
rate	O
","	O
46	O
%	O
;	O
95	O
%	O
CI	O
","	O
36	O
%	O
to	O
58	O
%	O
)	O
.	O
	
The	O
estimated	O
median	O
time	O
to	O
progression	O
was	O
7	O
months	O
(	O
95	O
%	O
CI	O
","	O
6.3	O
to	O
7.7	O
months	O
)	O
","	O
and	O
the	O
median	O
overall	O
survival	O
was	O
16.1	O
months	O
(	O
95	O
%	O
CI	O
","	O
12.7	O
to	O
19.6	O
months	O
)	O
in	O
the	O
intent-to-treat	O
population	O
.	O
	
Neutropenia	B-TOXI
was	O
the	O
main	O
adverse	O
event	O
","	O
with	O
grade	O
3	O
to	O
4	O
toxicity	O
in	O
58	O
%	O
of	O
patients	O
.	O
	
Febrile	B-TOXI
neutropenia	I-TOXI
developed	O
in	O
seven	O
patients	O
.	O
	
Nonhematologic	B-TOXI
toxicity	I-TOXI
consisted	O
mainly	O
of	O
neuropathy	B-TOXI
(	O
grade	O
3	O
in	O
11	O
patients	O
and	O
grade	O
2	O
in	O
another	O
27	O
patients	O
)	O
.	O
	
Oxaliplatin	B-DRUG
combined	O
with	O
the	O
bolus	O
Nordic	O
schedule	O
of	O
FU+FA	B-DRUG
(	O
Nordic	O
FLOX	B-DRUG
)	O
is	O
a	O
well-tolerated	O
","	O
effective	O
","	O
and	O
feasible	O
bolus	O
schedule	O
as	O
first-line	O
treatment	O
of	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
that	O
yields	O
comparable	O
results	O
compared	O
with	O
more	O
complex	O
schedules	O
.	O
	
Phase	O
II	O
trial	O
of	O
cisplatin	B-DRUG
/	O
etoposide	B-DRUG
and	O
concurrent	O
radiotherapy	O
followed	O
by	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
consolidation	O
for	O
limited	B-CANCER
small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
Southwest	O
Oncology	O
Group	O
9713	O
.	O
	
	
Limited	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
LSCLC	O
)	O
is	O
characterized	O
by	O
a	O
high	O
initial	O
response	O
rate	O
to	O
chemoradiotherapy	O
","	O
but	O
local	O
or	O
systemic	O
relapse	O
occurs	O
in	O
the	O
majority	O
of	O
patients	O
.	O
	
Previous	O
Southwest	O
Oncology	O
Group	O
trials	O
in	O
LSCLC	O
have	O
utilized	O
cisplatin	B-DRUG
and	O
etoposide	B-DRUG
(	O
PE	B-DRUG
)	O
delivered	O
concurrently	O
with	O
thoracic	O
radiotherapy	O
followed	O
by	O
two	O
consolidation	O
cycles	O
.	O
	
Newer	O
chemotherapy	O
regimens	O
such	O
as	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
are	O
active	O
in	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
and	O
hold	O
the	O
promise	O
of	O
improving	O
both	O
local	O
and	O
systemic	O
control	O
.	O
	
S9713	O
evaluated	O
the	O
substitution	O
of	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
for	O
PE	B-DRUG
consolidation	O
in	O
LSCLC	O
.	O
	
Between	O
July	O
1998	O
and	O
August	O
1999	O
","	O
96	O
patients	O
were	O
accrued	O
from	O
43	O
institutions	O
.	O
	
Eighty-nine	O
patients	O
were	O
eligible	O
;	O
87	O
were	O
assessable	O
for	O
survival	O
and	O
response	O
.	O
	
Treatment	O
consisted	O
of	O
cisplatin	B-DRUG
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
","	O
8	O
","	O
29	O
","	O
and	O
36	O
","	O
and	O
etoposide	B-DRUG
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
to	O
5	O
and	O
days	O
29	O
to	O
33	O
","	O
with	O
concurrent	O
radiotherapy	O
of	O
61	O
Gy	O
beginning	O
on	O
day	O
1	O
Consolidation	O
therapy	O
was	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
=	O
6	O
)	O
and	O
paclitaxel	B-DRUG
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
both	O
drugs	O
administered	O
on	O
day	O
1	O
of	O
a	O
21	O
day	O
cycle	O
for	O
three	O
cycles	O
.	O
	
The	O
response	O
rate	O
was	O
86	O
%	O
(	O
complete	O
response	O
","	O
33	O
%	O
;	O
partial	O
response	O
","	O
53	O
%	O
)	O
.	O
	
Median	O
overall	O
survival	O
was	O
17	O
months	O
(	O
95	O
%	O
CI	O
","	O
12.7	O
to	O
19	O
)	O
.	O
	
One-	O
and	O
2-year	O
overall	O
survivals	O
were	O
61	O
%	O
and	O
33	O
%	O
","	O
respectively	O
.	O
	
Median	O
progression-free	O
survival	O
(	O
PFS	O
)	O
was	O
9	O
months	O
","	O
1-year	O
PFS	O
was	O
40	O
%	O
","	O
and	O
2-year	O
PFS	O
was	O
21	O
%	O
.	O
	
Consolidation	O
therapy	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
in	O
LSCLC	O
resulted	O
in	O
an	O
outcome	O
similar	O
to	O
that	O
seen	O
in	O
prior	O
Southwest	O
Oncology	O
Group	O
trials	O
.	O
	
This	O
study	O
and	O
others	O
which	O
have	O
tested	O
paclitaxel	B-DRUG
in	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
dampens	O
enthusiasm	O
for	O
this	O
agent	O
in	O
the	O
primary	O
management	O
of	O
LSCLC	O
.	O
	
Multicentric	O
phase	O
II	O
trial	O
of	O
gemcitabine	B-DRUG
plus	O
epirubicin	B-DRUG
plus	O
paclitaxel	B-DRUG
as	O
first-line	O
chemotherapy	O
in	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
In	O
this	O
phase	O
II	O
","	O
multicentre	O
trial	O
","	O
patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
MBC	B-CANCER
)	O
were	O
treated	O
with	O
a	O
combination	O
of	O
gemcitabine	B-DRUG
","	O
epirubicin	B-DRUG
and	O
paclitaxel	B-DRUG
(	O
GET	B-DRUG
)	O
.	O
	
The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
tolerability	O
and	O
activity	O
in	O
terms	O
of	O
complete	O
responce	O
(	O
CR	O
)	O
and	O
overall	O
response	O
rate	O
of	O
the	O
GET	B-DRUG
combination	O
in	O
this	O
patient	O
population	O
.	O
	
Patients	O
with	O
no	O
prior	O
treatment	O
for	O
MBC	O
","	O
and	O
at	O
least	O
one	O
bidimensionally	O
measurable	O
lesion	O
received	O
gemcitabine	B-DRUG
1000	O
mg	O
m	O
(	O
-2	O
)	O
intravenously	O
(	O
i.v.	O
)	O
over	O
30	O
min	O
on	O
days	O
1	O
and	O
4	O
","	O
followed	O
by	O
epirubicin	B-DRUG
i.v.	O
at	O
90	O
mg	O
m	O
(	O
-2	O
)	O
on	O
day	O
1	O
","	O
and	O
paclitaxel	B-DRUG
175	O
mg	O
m	O
(	O
-2	O
)	O
over	O
3	O
h	O
on	O
day	O
1	O
","	O
every	O
21	O
days	O
","	O
up	O
to	O
eight	O
courses	O
.	O
	
From	O
May	O
1999	O
to	O
June	O
2000	O
","	O
48	O
patients	O
were	O
enrolled	O
from	O
seven	O
Italian	O
institutions	O
.	O
	
A	O
total	O
of	O
297	O
chemotherapy	O
courses	O
were	O
administered	O
with	O
a	O
median	O
of	O
six	O
cycles	O
patient	O
(	O
-1	O
)	O
(	O
range	O
1月8日	O
)	O
.	O
	
Seven	O
patients	O
(	O
15	O
%	O
)	O
obtained	O
CR	O
and	O
27	O
patients	O
(	O
56	O
%	O
)	O
had	O
partial	O
responce	O
","	O
for	O
an	O
overall	O
response	O
rate	O
of	O
71	O
%	O
(	O
95	O
%	O
CI	O
:	O
58.3-83.7	O
)	O
.	O
	
After	O
a	O
median	O
follow-up	O
of	O
23.7	O
months	O
(	O
range	O
7.0-34.4	O
)	O
","	O
median	O
progression-free	O
survival	O
was	O
10.5	O
months	O
(	O
95	O
%	O
CI	O
:	O
9.2-11.7	O
)	O
","	O
and	O
median	O
overall	O
survival	O
25.9	O
months	O
.	O
	
The	O
main	O
haematological	B-TOXI
toxicity	I-TOXI
consisted	O
of	O
grade	O
3	O
or	O
4	O
neutropenia	B-TOXI
that	O
occurred	O
in	O
62	O
%	O
of	O
cycles	O
(	O
22	O
%	O
grade	O
4	O
and	O
40	O
%	O
grade	O
3	O
)	O
.	O
	
The	O
GET	B-DRUG
combination	O
is	O
active	O
and	O
well	O
tolerated	O
as	O
first-line	O
chemotherapy	O
for	O
MBC	O
.	O
	
A	O
randomised	O
phase	O
II	O
study	O
of	O
weekly	O
paclitaxel	B-DRUG
or	O
vinorelbine	B-DRUG
in	O
combination	O
with	O
cisplatin	B-DRUG
against	O
inoperable	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
previously	O
untreated	O
.	O
	
	
Phase	O
II	O
studies	O
have	O
suggested	O
that	O
weekly	O
paclitaxel	B-DRUG
has	O
a	O
higher	O
response	O
rate	O
and	O
better	O
toxicity	O
profile	O
than	O
the	O
conventional	O
schedule	O
of	O
once	O
every	O
3	O
or	O
4	O
weeks	O
.	O
	
Our	O
aim	O
was	O
to	O
evaluate	O
the	O
efficacy	O
of	O
weekly	O
paclitaxel	B-DRUG
plus	O
cisplatin	B-DRUG
(	O
PC	B-DRUG
)	O
vs	O
vinorelbine	B-DRUG
plus	O
cisplatin	B-DRUG
(	O
VC	B-DRUG
)	O
in	O
chemona茂ve	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
patients	O
.	O
	
From	O
October	O
2000	O
to	O
May	O
2002	O
","	O
140	O
patients	O
were	O
enrolled	O
.	O
	
The	O
treatment	O
dose	O
was	O
P	O
66	O
mg	O
m	O
(	O
-2	O
)	O
intravenous	O
infusion	O
(	O
i.v.	O
)	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
","	O
and	O
C	O
60	O
mg	O
m	O
(	O
-2	O
)	O
i.v.	O
on	O
day	O
15	O
","	O
or	O
V	O
23	O
mg	O
m	O
(	O
-2	O
)	O
i.v.	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
","	O
and	O
C	O
60	O
mg	O
m	O
(	O
-2	O
)	O
i.v.	O
on	O
day	O
15	O
","	O
every	O
4	O
weeks	O
.	O
	
In	O
all	O
","	O
281	O
cycles	O
of	O
PC	B-DRUG
and	O
307	O
cycles	O
of	O
VC	B-DRUG
were	O
given	O
to	O
the	O
patients	O
in	O
the	O
PC	B-DRUG
and	O
VC	B-DRUG
arms	O
","	O
respectively	O
.	O
	
There	O
were	O
26	O
partial	O
responses	O
and	O
one	O
complete	O
response	O
(	O
overall	O
38.6	O
%	O
)	O
in	O
the	O
PC	O
arm	O
","	O
and	O
no	O
complete	O
responses	O
","	O
but	O
27	O
partial	O
responses	O
(	O
overall	O
38.6	O
%	O
)	O
in	O
the	O
VC	B-DRUG
arm	O
.	O
	
Myelosuppression	B-TOXI
was	O
more	O
common	O
in	O
the	O
VC	B-DRUG
arm	O
(	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
.	O
	
Peripheral	B-TOXI
neuropathy	I-TOXI
and	O
myalgia	B-TOXI
were	O
significantly	O
more	O
common	O
in	O
the	O
PC	B-DRUG
arm	O
(	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
.	O
	
The	O
median	O
time	O
to	O
disease	O
progression	O
was	O
6	O
months	O
in	O
the	O
PC	B-DRUG
arm	O
and	O
8.4	O
months	O
in	O
the	O
VC	B-DRUG
arm	O
(	O
P=0.0344	O
)	O
.	O
	
The	O
median	O
survival	O
time	O
was	O
11.7	O
months	O
in	O
the	O
PC	B-DRUG
arm	O
and	O
15.4	O
months	O
in	O
the	O
VC	B-DRUG
arm	O
(	O
P=0.297	O
)	O
.	O
	
We	O
concluded	O
that	O
weekly	O
PC	B-DRUG
is	O
not	O
suggested	O
for	O
NSCLC	B-CANCER
patients	O
due	O
to	O
the	O
relatively	O
shorter	O
progression-free	O
survival	O
and	O
more	O
common	O
nonhaematological	B-TOXI
toxicities	I-TOXI
.	O
	
British	O
Journal	O
of	O
Cancer	O
(	O
2004	O
)	O
90	O
","	O
359-365	O
.	O
	
doi:10.1038	O
/	O
sj.bjc.6601526	O
www.bjcancer.com	O
	
Phase	O
II	O
trial	O
of	O
biweekly	O
infusional	B-DRUG
fluorouracil	I-DRUG
","	O
folinic	B-DRUG
acid	I-DRUG
","	O
and	O
oxaliplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
evaluate	O
the	O
toxicity	O
and	O
activity	O
of	O
infusional	B-DRUG
fluorouracil	I-DRUG
(	O
FU	B-DRUG
)	O
","	O
folinic	B-DRUG
acid	I-DRUG
(	O
FA	B-DRUG
)	O
","	O
and	O
oxaliplatin	B-DRUG
","	O
administered	O
every	O
2	O
weeks	O
in	O
patients	O
with	O
metastatic	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Forty-one	O
previously	O
untreated	O
patients	O
with	O
measurable	O
adenocarcinoma	B-TOXI
of	I-TOXI
the	I-TOXI
stomach	I-TOXI
were	O
eligible	O
for	O
the	O
study	O
.	O
	
Patients	O
received	O
FU	B-DRUG
2.6	O
g	O
/	O
m	O
(	O
2	O
)	O
(	O
24-hour	O
continuous	O
infusion	O
)	O
","	O
FA	B-DRUG
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
2-hour	O
intravenous	O
infusion	O
)	O
","	O
and	O
oxaliplatin	B-DRUG
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
2-hour	O
intravenous	O
infusion	O
)	O
every	O
2	O
weeks	O
for	O
6	O
weeks	O
.	O
	
Treatment	O
was	O
continued	O
until	O
progression	B-TOXI
of	I-TOXI
disease	I-TOXI
was	O
observed	O
.	O
	
All	O
patients	O
were	O
assessable	O
for	O
toxicity	O
and	O
37	O
of	O
41	O
patients	O
were	O
assessable	O
for	O
response	O
.	O
	
Patient	O
characteristics	O
were	O
:	O
sex	O
(	O
male	O
","	O
28	O
;	O
"female,13"	O
)	O
","	O
median	O
age	O
60	O
years	O
(	O
range	O
","	O
20	O
to	O
77	O
years	O
)	O
","	O
and	O
median	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
1	O
Response	O
was	O
evaluated	O
every	O
6	O
weeks	O
.	O
	
Of	O
37	O
assessable	O
patients	O
","	O
one	O
complete	O
and	O
15	O
partial	O
remissions	O
were	O
observed	O
(	O
overall	O
response	O
rate	O
","	O
43	O
%	O
)	O
.	O
	
Stable	O
disease	O
was	O
observed	O
in	O
12	O
patients	O
(	O
32	O
%	O
)	O
and	O
progressive	O
disease	O
in	O
nine	O
patients	O
(	O
24	O
%	O
)	O
.	O
	
The	O
median	O
overall	O
survival	O
was	O
9.6	O
months	O
.	O
	
WHO	O
grade	O
3	O
or	O
4	O
hematologic	B-TOXI
toxicities	I-TOXI
included	O
neutropenia	B-TOXI
in	O
two	O
patients	O
(	O
4.9	O
%	O
)	O
and	O
thrombocytopenia	B-TOXI
in	O
one	O
patient	O
(	O
2.4	O
%	O
)	O
.	O
	
Other	O
WHO	O
grade	O
3	O
or	O
4	O
toxicities	O
included	O
diarrhea	B-TOXI
in	O
three	O
patients	O
(	O
7.3	O
%	O
)	O
and	O
vomiting	B-TOXI
in	O
two	O
patients	O
(	O
4.9	O
%	O
)	O
.	O
	
There	O
were	O
no	O
cases	O
of	O
grade	O
3	O
peripheral	B-TOXI
neuropathy	I-TOXI
and	O
no	O
treatment-related	O
deaths	B-TOXI
.	O
	
Biweekly	O
fluorouracil	B-DRUG
","	O
folinic	B-DRUG
acid	I-DRUG
","	O
and	O
oxaliplatin	B-DRUG
is	O
active	O
and	O
well-tolerated	O
in	O
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Response	O
rates	O
","	O
time	O
to	O
progression	O
","	O
and	O
overall	O
survival	O
were	O
comparable	O
to	O
those	O
achieved	O
with	O
other	O
combination	O
chemotherapy	O
regimens	O
","	O
including	O
FOLFOX6	B-DRUG
","	O
with	O
significantly	O
less	O
toxicity	O
.	O
	
Gefitinib	B-DRUG
in	O
combination	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
in	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
a	O
phase	O
III	O
trial	O
=--	O
INTACT	O
2	O
.	O
	
	
Preclinical	O
studies	O
indicate	O
that	O
gefitinib	B-DRUG
(	O
Iressa	O
","	O
ZD1839	O
;	O
AstraZeneca	O
","	O
Wilmington	O
","	O
DE	O
)	O
","	O
an	O
orally	O
active	O
epidermal	O
growth	O
factor	O
receptor	O
tyrosine	O
kinase	O
inhibitor	O
","	O
may	O
enhance	O
antitumor	O
efficacy	O
of	O
cytotoxics	O
","	O
and	O
combination	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
had	O
acceptable	O
tolerability	O
in	O
a	O
phase	O
I	O
trial	O
.	O
	
Gefitinib	B-DRUG
monotherapy	O
demonstrated	O
unparalleled	O
antitumor	O
activity	O
for	O
a	O
biologic	O
agent	O
","	O
with	O
less	O
toxicity	O
than	O
docetaxel	B-DRUG
","	O
in	O
phase	O
II	O
trials	O
in	O
refractory	O
","	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
This	O
phase	O
III	O
","	O
randomized	O
","	O
placebo-controlled	O
","	O
double-blind	O
trial	O
evaluated	O
gefitinib	B-DRUG
plus	O
paclitaxel	B-DRUG
and	O
carboplatin	O
in	O
chemotherapy-naive	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
Patients	O
received	O
paclitaxel	B-DRUG
225	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
carboplatin	B-DRUG
area	O
under	O
concentration	O
/	O
time	O
curve	O
of	O
6	O
mg	O
/	O
min	O
/	O
mL	O
(	O
day	O
1	O
every	O
3	O
weeks	O
)	O
plus	O
gefitinib	B-DRUG
500	O
mg	O
/	O
d	O
","	O
gefitinib	B-DRUG
250	O
mg	O
/	O
d	O
","	O
or	O
placebo	B-DRUG
.	O
	
After	O
a	O
maximum	O
of	O
six	O
cycles	O
","	O
daily	O
gefitinib	B-DRUG
or	O
placebo	O
continued	O
until	O
disease	O
progression	O
.	O
	
End	O
points	O
included	O
overall	O
survival	O
","	O
time	O
to	O
progression	O
(	O
TTP	O
)	O
","	O
response	O
rate	O
(	O
RR	O
)	O
","	O
and	O
safety	O
evaluation	O
.	O
	
Results	O
A	O
total	O
of	O
"1,037"	O
patients	O
were	O
recruited	O
.	O
	
Baseline	O
demographic	O
characteristics	O
were	O
well	O
balanced	O
.	O
	
There	O
was	O
no	O
difference	O
in	O
overall	O
survival	O
(	O
median	O
","	O
8.7	O
","	O
9.8	O
","	O
and	O
9.9	O
months	O
for	O
gefitinib	B-DRUG
500	O
mg	O
/	O
d	O
","	O
250	O
mg	O
/	O
d	O
","	O
and	O
placebo	B-DRUG
","	O
respectively	O
;	O
P	O
0.64	O
)	O
","	O
TTP	O
","	O
or	O
RR	O
between	O
arms	O
.	O
	
Expected	O
dose-related	O
diarrhea	B-TOXI
and	O
skin	B-TOXI
toxicity	I-TOXI
were	O
observed	O
in	O
gefitinib-treated	B-DRUG
patients	O
","	O
with	O
no	O
new	O
significant	O
/	O
unexpected	O
safety	O
findings	O
from	O
combination	O
with	O
chemotherapy	O
.	O
	
Subset	O
analysis	O
of	O
patients	O
with	O
adenocarcinoma	B-TOXI
who	O
received	O
&	O
gt	O
;	O
or	O
=	O
90	O
days	O
'	O
chemotherapy	O
demonstrated	O
statistically	O
significant	O
prolonged	O
survival	O
","	O
suggesting	O
a	O
gefitinib	B-DRUG
maintenance	O
effect	O
.	O
	
Gefitinib	B-DRUG
showed	O
no	O
added	O
benefit	O
in	O
survival	O
","	O
TTP	O
","	O
or	O
RR	O
compared	O
with	O
standard	O
chemotherapy	O
alone	O
.	O
	
This	O
large	O
","	O
placebo-controlled	B-DRUG
trial	O
confirmed	O
the	O
favorable	O
gefitinib	B-DRUG
safety	O
profile	O
observed	O
in	O
phase	O
I	O
and	O
II	O
monotherapy	O
trials	O
.	O
	
Phase	O
I	O
dose-finding	O
study	O
of	O
biweekly	O
irinotecan	B-DRUG
in	O
combination	O
with	O
fixed	O
doses	O
of	O
5-fluorouracil	B-DRUG
/	O
leucovorin	B-DRUG
","	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
(	O
G-FLIP	B-DRUG
)	O
in	O
patients	O
with	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
or	O
other	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
This	O
phase	O
I	O
trial	O
was	O
initiated	O
based	O
on	O
encouraging	O
clinical	O
data	O
with	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
/	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
","	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
(	O
G-FLIP	B-DRUG
)	O
in	O
the	O
therapy	O
of	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
In	O
this	O
trial	O
","	O
G-FLIP	B-DRUG
has	O
been	O
modified	O
to	O
facilitate	O
outpatient	O
administration	O
and	O
to	O
optimize	O
sequence-dependent	O
synergistic	O
activity	O
.	O
	
Treatment	O
consisted	O
of	O
biweekly	O
(	O
once	O
every	O
14	O
days	O
)	O
cycles	O
of	O
sequential	O
gemcitabine	B-DRUG
500	O
mg	O
/	O
m	O
","	O
irinotecan	B-DRUG
per	O
dose	O
escalation	O
schedule	O
","	O
bolus	O
5-FU	B-DRUG
400	O
mg	O
/	O
m	O
and	O
LV	B-DRUG
300	O
mg	O
on	O
day	O
1	O
followed	O
by	O
a	O
24-h	O
5-FU	B-DRUG
infusion	O
1500	O
mg	O
/	O
m	O
","	O
followed	O
by	O
cisplatin	B-DRUG
35	O
mg	O
/	O
m	O
on	O
day	O
2	O
The	O
irinotecan	B-DRUG
starting	O
dose	O
was	O
80	O
mg	O
/	O
m	O
and	O
escalated	O
by	O
20	O
mg	O
/	O
m	O
in	O
cohorts	O
of	O
three	O
patients	O
until	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
was	O
defined	O
.	O
	
Twenty-three	O
patients	O
were	O
enrolled	O
(	O
13	O
men	O
/	O
10	O
women	O
)	O
with	O
the	O
following	O
cancers	O
:	O
11	O
pancreatic	O
","	O
five	O
gallbladder	O
","	O
three	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
","	O
one	O
hepatocellular	B-CANCER
carcinoma	I-CANCER
","	O
one	O
melanoma	B-CANCER
","	O
one	O
gastric	O
","	O
and	O
one	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
Median	O
patient	O
age	O
was	O
63	O
years	O
(	O
range	O
44-78	O
)	O
and	O
median	O
Karnofsky	O
performance	O
status	O
(	O
KPS	O
)	O
was	O
80	O
.	O
	
Patients	O
received	O
a	O
median	O
of	O
8	O
cycles	O
(	O
range	O
1月16日	O
)	O
over	O
five	O
irinotecan	B-DRUG
dose	O
levels	O
(	O
80	O
","	O
100	O
","	O
120	O
","	O
140	O
and	O
160	O
mg	O
/	O
m	O
)	O
.	O
	
Dose-limiting	O
toxicity	O
consisting	O
of	O
grade	O
3	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
despite	O
aggressive	O
anti-emetic	O
therapy	O
occurred	O
in	O
one	O
patient	O
at	O
dose	O
level	O
1	O
and	O
three	O
patients	O
at	O
dose	O
level	O
3	O
Grade	O
3月4日	O
hematological	B-TOXI
toxicities	I-TOXI
per	O
patient	O
consisted	O
of	O
thrombocytopenia	B-TOXI
(	O
3	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
6	O
%	O
)	O
","	O
thrombosis	B-TOXI
(	O
23	O
%	O
)	O
","	O
neutropenia	B-TOXI
(	O
16	O
%	O
)	O
and	O
neutropenic	B-TOXI
fever	I-TOXI
(	O
10	O
%	O
)	O
.	O
	
Of	O
18	O
patients	O
evaluable	O
for	O
response	O
","	O
one	O
complete	O
response	O
(	O
pancreatic	O
)	O
and	O
eight	O
partial	O
responses	O
(	O
three	O
gallbladder	O
","	O
two	O
pancreatic	O
","	O
two	O
head	O
and	O
neck	O
","	O
and	O
one	O
breast	O
)	O
were	O
attained	O
.	O
	
Seven	O
patients	O
had	O
disease	O
stabilization	O
(	O
five	O
pancreatic	O
","	O
one	O
hepatocellular	O
and	O
one	O
gastric	O
)	O
for	O
a	O
median	O
of	O
16	O
weeks	O
(	O
range	O
10月22日	O
)	O
.	O
	
Median	O
time	O
to	O
disease	O
progression	O
among	O
all	O
23	O
patients	O
enrolled	O
to	O
the	O
phase	O
I	O
portion	O
of	O
the	O
trial	O
was	O
20.5	O
weeks	O
(	O
range	O
4-37	O
)	O
.	O
	
We	O
conclude	O
that	O
G-FLIP	B-DRUG
is	O
a	O
novel	O
outpatient	O
chemotherapy	O
regimen	O
with	O
acceptable	O
toxicity	O
at	O
the	O
maximum	O
tolerated	O
irinotecan	B-DRUG
dose	O
of	O
120	O
mg	O
/	O
m.	O
The	O
phase	O
II	O
trial	O
of	O
G-FLIP	B-DRUG
using	O
an	O
irinotecan	B-DRUG
dose	O
of	O
120	O
mg	O
/	O
m	O
for	O
patients	O
with	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
is	O
ongoing	O
.	O
	
Phase	O
I	O
and	O
pharmacokinetic	O
study	O
of	O
the	O
polyamine	O
synthesis	O
inhibitor	O
SAM486A	B-DRUG
in	O
combination	O
with	O
5-fluorouracil	B-DRUG
/	O
leucovorin	B-DRUG
in	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
determine	O
the	O
maximum-tolerated	O
dose	O
","	O
dose-limiting	O
toxicity	O
","	O
safety	O
profile	O
","	O
and	O
pharmacokinetics	O
of	O
the	O
polyamine	O
synthesis	O
inhibitor	O
SAM486A	B-DRUG
given	O
in	O
combination	O
with	O
5-fluorouracil	B-DRUG
/	O
leucovorin	B-DRUG
(	O
5-FU	B-DRUG
/	O
LV	B-DRUG
)	O
in	O
cancer	O
patients	O
.	O
	
Patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
were	O
treated	O
with	O
5-FU	B-DRUG
[	O
bolus	O
(	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
followed	O
by	O
a	O
22-h	O
infusion	O
(	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
]	O
and	O
LV	B-DRUG
(	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
escalating	O
doses	O
of	O
SAM486A	B-DRUG
","	O
1-3-h	O
infusion	O
daily	O
for	O
3	O
days	O
.	O
	
Plasma	O
sampling	O
was	O
performed	O
to	O
characterize	O
the	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
the	O
combination	O
Twenty-seven	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
and	O
1	O
with	O
pseudomyxoma	B-CANCER
peritonei	I-CANCER
were	O
treated	O
.	O
	
Twenty-six	O
patients	O
received	O
SAM486A	B-DRUG
in	O
the	O
combination	O
at	O
doses	O
ranging	O
from	O
25	O
to	O
150	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
.	O
	
Dose-limiting	O
toxicity	O
consisting	O
of	O
fatigue	B-TOXI
grade	O
3	O
was	O
seen	O
at	O
150	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
.	O
	
Other	O
adverse	O
events	O
included	O
neutropenia	B-TOXI
","	O
hand	B-TOXI
and	I-TOXI
foot	I-TOXI
syndrome	I-TOXI
","	O
nausea	B-TOXI
","	O
vomiting	B-TOXI
","	O
diarrhea	B-TOXI
","	O
and	O
constipation	B-TOXI
.	O
	
Fifteen	O
of	O
26	O
patients	O
evaluable	O
for	O
best	O
response	O
according	O
to	O
the	O
Southwest	O
Oncology	O
Group	O
criteria	O
achieved	O
a	O
partial	O
response	O
[	O
8	O
(	O
30	O
%	O
)	O
of	O
26	O
]	O
or	O
stable	O
disease	O
[	O
9	O
(	O
35	O
%	O
)	O
of	O
26	O
]	O
.	O
	
SAM486A	B-DRUG
did	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
5-FU	B-DRUG
","	O
and	O
SAM486A	B-DRUG
clearance	O
was	O
similar	O
to	O
that	O
when	O
used	O
as	O
a	O
single	O
agent	O
.	O
	
The	O
novel	O
molecular	O
agent	O
SAM486A	B-DRUG
is	O
tolerable	O
and	O
safe	O
in	O
combination	O
with	O
a	O
standard	O
5-FU	B-DRUG
regimen	O
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
The	O
dose	O
of	O
SAM486A	B-DRUG
recommended	O
for	O
additional	O
studies	O
with	O
this	O
combination	O
is	O
125	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
.	O
	
A	O
disease-directed	O
evaluation	O
of	O
SAM486A	B-DRUG
using	O
this	O
regimen	O
is	O
warranted	O
.	O
	
[	O
A	O
phase	O
I	O
study	O
of	O
combination	O
chemotherapy	O
using	O
TS-1	B-DRUG
and	O
pirarubicin	B-DRUG
(	O
THP	B-DRUG
)	O
for	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
]	O
.	O
	
	
The	O
safety	O
of	O
chemotherapy	O
combining	O
TS-1	B-DRUG
and	O
pirarubicin	B-DRUG
(	O
THP	B-DRUG
)	O
for	O
treatment	O
of	O
recurrent	O
or	O
locally	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
was	O
evaluated	O
.	O
	
THP	B-DRUG
was	O
administered	O
by	O
intravenous	O
drip	O
infusion	O
at	O
a	O
dose	O
of	O
14	O
mg	O
/	O
m2	O
every	O
other	O
week	O
.	O
	
TS-1	B-DRUG
was	O
administered	O
orally	O
at	O
a	O
dose	O
of	O
40	O
mg	O
/	O
m2	O
twice	O
a	O
day	O
for	O
2	O
weeks	O
followed	O
by	O
2	O
weeks	O
of	O
rest	O
(	O
level	O
1	O
)	O
","	O
for	O
3	O
weeks	O
followed	O
by	O
2	O
weeks	O
of	O
rest	O
(	O
level	O
2	O
)	O
","	O
and	O
for	O
4	O
weeks	O
followed	O
by	O
2	O
weeks	O
of	O
rest	O
(	O
level	O
3	O
)	O
.	O
	
Three	O
patients	O
were	O
treated	O
with	O
the	O
level	O
1	O
schedule	O
.	O
	
One	O
patient	O
with	O
peritoneal	B-DRUG
dissemination	O
received	O
22	O
courses	O
of	O
the	O
treatment	O
","	O
and	O
benefited	O
from	O
a	O
long-term	B-CANCER
NC	I-CANCER
.	O
	
However	O
the	O
remaining	O
2	O
cases	O
were	O
diagnosed	O
as	O
PD	O
after	O
4	O
courses	O
and	O
were	O
withdrawn	O
from	O
further	O
treatment	O
.	O
	
Two	O
patients	O
in	O
this	O
group	O
suffered	O
from	O
grade	O
2	O
adverse	O
events	O
according	O
to	O
the	O
NCI-CTC	O
.	O
	
Only	O
1	O
patient	O
who	O
had	O
liver	B-CANCER
metastasis	I-CANCER
was	O
treated	O
at	O
level	O
2	O
Fourteen	O
courses	O
were	O
administered	O
","	O
and	O
a	O
PR	O
was	O
achieved	O
while	O
grade	O
2	O
adverse	O
events	O
were	O
observed	O
.	O
	
One	O
of	O
3	O
patients	O
who	O
were	O
treated	O
with	O
level	O
3	O
had	O
grade	O
3	O
adverse	O
events	O
.	O
	
Consequently	O
","	O
3	O
more	O
cases	O
were	O
added	O
to	O
this	O
dose	O
level	O
","	O
and	O
no	O
additional	O
grade	O
3	O
adverse	O
events	O
were	O
observed	O
","	O
while	O
grade	O
2	O
adverse	O
events	O
were	O
seen	O
in	O
4	O
cases	O
.	O
	
Urinary	B-TOXI
urgency	I-TOXI
had	O
completely	O
disappeared	O
in	O
1	O
patient	O
with	O
peritoneal	B-TOXI
recurrence	I-TOXI
.	O
	
Myelosuppression	B-TOXI
","	O
which	O
was	O
the	O
main	O
observed	O
adverse	O
event	O
","	O
was	O
well	O
controlled	O
and	O
of	O
brief	O
duration	O
.	O
	
The	O
response	O
","	O
including	O
alleviation	O
of	O
clinical	O
symptoms	O
","	O
was	O
confirmed	O
in	O
3	O
of	O
5	O
chemo-naive	O
patients	O
.	O
	
A	O
phase	O
II	O
study	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
in	O
chemotherapy-naive	O
","	O
unresectable	B-CANCER
gall	I-CANCER
bladder	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
response	O
rates	O
of	O
the	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
combination	O
in	O
unresectable	B-CANCER
gall	I-CANCER
bladder	I-CANCER
cancer	I-CANCER
patients	O
.	O
	
The	O
secondary	O
objectives	O
were	O
to	O
evaluate	O
the	O
toxicity	O
","	O
time	O
to	O
progressive	O
disease	O
","	O
and	O
overall	O
survival	O
.	O
	
Chemona茂ve	O
patients	O
with	O
histologically	O
proven	O
","	O
unresectable	O
bidimensionally	O
measurable	O
gall	B-CANCER
bladder	I-CANCER
cancer	I-CANCER
were	O
enrolled	O
into	O
this	O
study	O
.	O
	
All	O
patients	O
were	O
required	O
to	O
have	O
a	O
Zubrod	O
's	O
performance	O
status	O
&	O
lt	O
;	O
or=2	O
","	O
no	O
prior	O
radiotherapy	O
","	O
and	O
adequate	O
major	O
organ	O
function	O
.	O
	
Patients	O
received	O
gemcitabine	B-DRUG
(	O
1000	O
mg	O
x	O
m	O
(	O
-2	O
)	O
intravenously	O
over	O
30-60	O
min	O
)	O
on	O
days	O
1	O
and	O
8	O
","	O
and	O
cisplatin	B-DRUG
(	O
70	O
mg	O
x	O
m	O
(	O
-2	O
)	O
intravenously	O
over	O
2	O
h	O
)	O
on	O
day	O
1	O
","	O
every	O
21	O
days	O
.	O
	
Response	O
assessment	O
was	O
done	O
by	O
a	O
CT	O
scan	O
after	O
every	O
other	O
cycle	O
of	O
chemotherapy	O
.	O
	
In	O
all	O
","	O
30	O
patients	O
were	O
eligible	O
for	O
efficacy	O
and	O
toxicity	O
analysis	O
.	O
	
There	O
were	O
four	O
(	O
13.3	O
%	O
)	O
complete	O
responders	O
","	O
seven	O
(	O
23.3	O
%	O
)	O
partial	O
responders	O
","	O
and	O
seven	O
(	O
23.3	O
%	O
)	O
with	O
stable	O
disease	O
","	O
with	O
four	O
(	O
13.2	O
%	O
)	O
patients	O
showing	O
disease	O
progression	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
was	O
18	O
weeks	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
14-24	O
weeks	O
)	O
","	O
and	O
the	O
median	O
duration	O
of	O
response	O
was	O
13.5	O
weeks	O
(	O
range	O
5.5-104	O
weeks	O
)	O
.	O
	
The	O
median	O
overall	O
survival	O
was	O
20	O
weeks	O
(	O
95	O
%	O
CI	O
14-31	O
weeks	O
)	O
","	O
with	O
1-year	O
survival	O
rate	O
of	O
18.6	O
%	O
.	O
	
WHO	O
grade	O
3	O
or	O
4	O
anaemia	B-TOXI
was	O
seen	O
in	O
seven	O
(	O
23.3	O
%	O
)	O
and	O
four	O
(	O
13.3	O
%	O
)	O
patients	O
","	O
respectively	O
.	O
	
Five	O
(	O
16.6	O
%	O
)	O
patients	O
each	O
experienced	O
grade	O
3	O
or	O
4	O
neutropenia	B-TOXI
","	O
and	O
grade	O
3	O
or	O
4	O
thrombocytopenia	B-TOXI
was	O
seen	O
in	O
three	O
(	O
10	O
%	O
)	O
and	O
two	O
(	O
6.6	O
%	O
)	O
patients	O
","	O
respectively	O
.	O
	
The	O
present	O
study	O
shows	O
that	O
gemcitabine	B-DRUG
/	O
cisplatin	B-DRUG
combination	O
is	O
well	O
tolerated	O
and	O
active	O
in	O
advanced	B-CANCER
unresectable	I-CANCER
gall	I-CANCER
bladder	I-CANCER
cancer	I-CANCER
.	O
	
Pegylated	B-DRUG
liposomal	I-DRUG
doxorubicin	I-DRUG
in	O
combination	O
with	O
mitomycin	B-DRUG
C	I-DRUG
","	O
infusional	B-DRUG
5-fluorouracil	I-DRUG
and	O
sodium	B-DRUG
folinic	I-DRUG
acid.	I-DRUG
A	O
phase-I-study	O
in	O
patients	O
with	O
upper	O
gastrointestinal	B-CANCER
cancer	I-CANCER
.	O
	
	
Mitomycin	B-DRUG
C	I-DRUG
(	O
MMC	B-DRUG
)	O
in	O
combination	O
with	O
infusional	B-DRUG
5-fluorouracil	I-DRUG
(	O
FU	B-DRUG
)	O
plus	O
folinic	B-DRUG
acid	I-DRUG
(	O
FA	B-DRUG
)	O
is	O
an	O
effective	O
treatment	O
for	O
metastatic	B-CANCER
gastrointestinal	I-CANCER
cancer	I-CANCER
.	O
	
Anthracyclines	B-DRUG
are	O
commonly	O
used	O
in	O
the	O
treatment	O
of	O
upper	O
gastrointestinal	B-CANCER
cancer	I-CANCER
.	O
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
of	O
liposomal	B-DRUG
","	O
pegylated	B-DRUG
doxorubicin	I-DRUG
(	O
Caelyx	B-DRUG
)	O
in	O
combination	O
with	O
infusional	B-DRUG
5-FU	I-DRUG
/	O
sodium	B-DRUG
FA	I-DRUG
and	O
MMC	B-DRUG
.	O
	
Escalating	O
doses	O
of	O
Caelyx	B-DRUG
(	O
15-25-30-35	O
mg	O
m	O
(	O
-2	O
)	O
corresponding	O
to	O
dose	O
levels	O
I-IV	O
)	O
were	O
applied	O
on	O
days	O
1	O
and	O
29	O
","	O
given	O
to	O
fixed	O
doses	O
of	O
24-h	O
5-FU	B-DRUG
(	O
2000	O
mg	O
m	O
(	O
-2	O
)	O
)	O
and	O
sodium	B-DRUG
FA	I-DRUG
(	O
500	O
mg	O
m	O
(	O
-2	O
)	O
","	O
mixed	O
with	O
5-FU	B-DRUG
in	O
one	O
pump	O
)	O
weekly	O
for	O
6	O
weeks	O
","	O
and	O
MMC	B-DRUG
7	O
mg	O
m	O
(	O
-2	O
)	O
on	O
days	O
8	O
and	O
36	O
.	O
	
At	O
least	O
three	O
patients	O
were	O
treated	O
at	O
each	O
dose	O
level	O
.	O
	
A	O
total	O
of	O
25	O
patients	O
are	O
evaluable	O
.	O
	
No	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
was	O
observed	O
on	O
level	O
I	O
(	O
n=3	O
)	O
.	O
	
On	O
level	O
II	O
","	O
DLT	O
occurred	O
in	O
three	O
out	O
of	O
five	O
patients	O
(	O
mucositis	B-TOXI
and	O
leucopenia	B-TOXI
)	O
.	O
	
Owing	O
to	O
the	O
early	O
DLTs	O
at	O
this	O
dose	O
","	O
we	O
added	O
a	O
20	O
mg	O
m	O
(	O
-2	O
)	O
Caelyx	B-DRUG
dose	O
level	O
(	O
Ia	O
)	O
.	O
	
In	O
total	O
","	O
17	O
patients	O
were	O
treated	O
at	O
this	O
dose	O
level	O
.	O
	
Among	O
these	O
","	O
only	O
two	O
patients	O
experienced	O
DLT	O
in	O
cycle	O
one	O
and	O
37	O
complete	O
cycles	O
have	O
been	O
administered	O
in	O
association	O
with	O
a	O
low	O
toxicity	O
profile	O
.	O
	
The	O
median	O
dose	O
intensity	O
was	O
100	O
%	O
for	O
each	O
drug	O
during	O
the	O
first	O
course	O
and	O
no	O
treatment	O
delay	O
exceeding	O
7	O
days	O
was	O
required	O
.	O
	
The	O
recommended	O
dose	O
of	O
4-weekly	O
Caelyx	B-DRUG
in	O
combination	O
with	O
weekly	O
24-h	O
5-FU	B-DRUG
/	O
sodium	B-DRUG
FA	I-DRUG
and	O
4-weekly	O
MMC	B-DRUG
is	O
20	O
mg	O
m	O
(	O
-2	O
)	O
.	O
	
Preliminary	O
antitumour	O
activity	O
has	O
been	O
observed	O
in	O
patients	O
with	O
pretreated	O
pancreatic	B-CANCER
cancer	I-CANCER
and	O
in	O
untreated	O
gastric	B-CANCER
cancer	I-CANCER
.	O
	
A	O
novel	O
biweekly	O
multidrug	O
regimen	O
of	O
gemcitabine	B-DRUG
","	O
oxaliplatin	B-DRUG
","	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
and	O
folinic	B-DRUG
acid	I-DRUG
(	O
FA	B-DRUG
)	O
in	O
pretreated	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
.	O
	
	
Previous	O
results	O
suggest	O
that	O
GEM	O
affects	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
metabolism	O
and	O
pharmacokinetics	O
in	O
cancer	O
patients	O
","	O
while	O
combined	O
with	O
oxaliplatin	B-DRUG
","	O
levo-folinic	B-DRUG
acid	I-DRUG
","	O
and	O
5-FU	B-DRUG
(	O
GOLF	B-DRUG
regimen	O
)	O
","	O
at	O
doses	O
achievable	O
in	O
cancer	O
patients	O
","	O
determines	O
high	O
cytotoxic	O
and	O
proapoptotic	O
antitumour	O
activity	O
in	O
colon	B-CANCER
cancer	I-CANCER
cells	O
in	O
vitro	O
.	O
	
On	O
these	O
bases	O
we	O
designed	O
a	O
phase	O
I-II	O
clinical	O
trial	O
testing	O
the	O
GOLF	B-DRUG
regimen	O
in	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
","	O
who	O
had	O
received	O
at	O
least	O
a	O
prior	O
line	O
of	O
chemotherapy	O
.	O
	
In	O
total	O
","	O
29	O
patients	O
(	O
20	O
males	O
and	O
nine	O
females	O
)	O
enrolled	O
in	O
the	O
study	O
received	O
every	O
2	O
weeks	O
","	O
gemcitabine	B-DRUG
(	O
patients	O
#	O
1月3日	O
received	O
600	O
mg	O
m	O
(	O
-2	O
)	O
;	O
patients	O
#	O
4月6日	O
received	O
850	O
mg	O
m	O
(	O
-2	O
)	O
;	O
while	O
patients	O
#	O
7月29日	O
received	O
1000	O
mg	O
m	O
(	O
-2	O
)	O
)	O
on	O
the	O
day	O
1	O
","	O
levo-folinic	B-DRUG
acid	I-DRUG
(	O
100	O
mg	O
m	O
(	O
-2	O
)	O
)	O
on	O
the	O
days	O
1	O
and	O
2	O
;	O
5-fluorouracil	B-DRUG
(	O
400	O
mg	O
m	O
(	O
-2	O
)	O
)	O
in	O
bolus	O
injection	O
","	O
followed	O
by	O
a	O
22-h	O
continuous	O
infusion	O
(	O
800	O
mg	O
m	O
(	O
-2	O
)	O
)	O
on	O
the	O
days	O
1	O
and	O
2	O
","	O
and	O
oxaliplatin	B-DRUG
(	O
85	O
mg	O
m	O
(	O
-2	O
)	O
)	O
","	O
6	O
h	O
after	O
the	O
5-FU	B-DRUG
bolus	O
on	O
day	O
2	O
The	O
most	O
frequent	O
side	O
effect	O
was	O
grade	O
I-II	O
haematological	B-TOXI
toxicity	I-TOXI
.	O
	
In	O
total	O
","	O
28	O
patients	O
were	O
evaluable	O
for	O
response	O
:	O
three	O
achieved	O
a	O
complete	O
response	O
","	O
nine	O
a	O
partial	O
response	O
","	O
10	O
had	O
a	O
stable	O
disease	O
","	O
and	O
six	O
progressed	O
.	O
	
The	O
average	O
time	O
to	O
progression	O
and	O
overall	O
survival	O
of	O
the	O
patients	O
was	O
","	O
respectively	O
","	O
7.26	O
and	O
22	O
months	O
.	O
	
Our	O
GOLF	B-DRUG
combination	O
is	O
well	O
tolerated	O
and	O
seems	O
promising	O
for	O
the	O
treatment	O
of	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
XELOX	B-DRUG
(	O
capecitabine	B-DRUG
plus	O
oxaliplatin	B-DRUG
)	O
:	O
active	O
first-line	O
therapy	O
for	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
Capecitabine	B-DRUG
has	O
demonstrated	O
high	O
efficacy	O
as	O
first-line	O
treatment	O
for	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
MCRC	B-CANCER
)	O
.	O
	
Oxaliplatin	B-DRUG
shows	O
synergy	O
with	O
fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
","	O
with	O
little	O
toxicity	O
overlap	O
.	O
	
The	O
XELOX	B-DRUG
regimen	O
(	O
capecitabine	B-DRUG
plus	O
oxaliplatin	B-DRUG
)	O
","	O
established	O
in	O
a	O
previous	O
dose-finding	O
study	O
","	O
should	O
improve	O
on	O
infused	O
oxaliplatin	B-DRUG
with	O
FU	B-DRUG
and	O
leucovorin	B-DRUG
(	O
FOLFOX	B-DRUG
)	O
regimens	O
.	O
	
The	O
present	O
studies	O
further	O
characterize	O
efficacy	O
and	O
safety	O
of	O
the	O
XELOX	B-DRUG
regimen	O
.	O
	
The	O
antitumor	O
activity	O
of	O
XELOX	B-DRUG
was	O
investigated	O
in	O
a	O
colon	B-CANCER
cancer	I-CANCER
xenograft	O
model	O
.	O
	
Patients	O
with	O
MCRC	B-CANCER
received	O
first-line	O
XELOX	B-DRUG
in	O
3-week	O
treatment	O
cycles	O
:	O
intravenous	O
oxaliplatin	B-DRUG
130	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
day	O
1	O
)	O
followed	O
by	O
oral	O
capecitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
daily	O
(	O
day	O
1	O
","	O
evening	O
","	O
to	O
day	O
15	O
","	O
morning	O
)	O
.	O
	
A	O
preclinical	O
study	O
confirmed	O
that	O
capecitabine	B-DRUG
has	O
supra-additive	O
activity	O
with	O
oxaliplatin	B-DRUG
.	O
	
In	O
the	O
clinical	O
study	O
","	O
53	O
of	O
96	O
patients	O
(	O
55	O
%	O
)	O
achieved	O
an	O
objective	O
response	O
","	O
and	O
30	O
(	O
31	O
%	O
)	O
experienced	O
disease	O
stabilization	O
for	O
&	O
gt	O
;	O
/	O
=	O
3	O
months	O
following	O
treatment	O
.	O
	
After	O
24	O
months	O
'	O
minimum	O
follow-up	O
","	O
median	O
time	O
to	O
disease	O
progression	O
(	O
TTP	O
)	O
and	O
median	O
overall	O
survival	O
were	O
7.7	O
and	O
19.5	O
months	O
","	O
respectively	O
.	O
	
XELOX	B-DRUG
safety	O
was	O
predictable	O
and	O
similar	O
to	O
the	O
FOLFOX4	B-DRUG
regimen	O
","	O
except	O
that	O
myelosuppression	B-TOXI
was	O
uncommon	O
with	O
XELOX	B-DRUG
(	O
grade	O
3	O
or	O
4	O
neutropenia	B-TOXI
","	O
7	O
%	O
)	O
.	O
	
Most	O
adverse	O
events	O
were	O
mild	O
to	O
moderate	O
","	O
the	O
most	O
common	O
being	O
acute	B-TOXI
sensory	I-TOXI
neuropathy	I-TOXI
(	O
85	O
%	O
)	O
.	O
	
Sixty-day	O
","	O
all-cause	O
mortality	O
was	O
2	O
%	O
.	O
	
XELOX	B-DRUG
is	O
a	O
highly	O
effective	O
first-line	O
treatment	O
for	O
MCRC	B-CANCER
.	O
	
Response	O
rates	O
","	O
TTP	O
","	O
and	O
overall	O
survival	O
are	O
similar	O
to	O
those	O
observed	O
with	O
FU	B-DRUG
/	O
leucovorin	B-DRUG
/	O
oxaliplatin	B-DRUG
combinations	O
.	O
	
XELOX	B-DRUG
provides	O
a	O
more	O
convenient	O
regimen	O
","	O
likely	O
to	O
be	O
preferred	O
by	O
both	O
patients	O
and	O
healthcare	O
providers	O
.	O
	
Capecitabine	B-DRUG
has	O
the	O
potential	O
to	O
replace	O
FU	B-DRUG
/	O
LV	B-DRUG
in	O
combination	O
with	O
oxaliplatin	B-DRUG
for	O
MCRC	B-CANCER
.	O
	
Phase	O
III	O
trial	O
of	O
doxorubicin	B-DRUG
plus	O
cisplatin	B-DRUG
with	O
or	O
without	O
paclitaxel	B-DRUG
plus	O
filgrastim	B-DRUG
in	O
advanced	B-CANCER
endometrial	I-CANCER
carcinoma	I-CANCER
:	O
a	O
Gynecologic	O
Oncology	O
Group	O
Study	O
.	O
	
	
To	O
determine	O
whether	O
the	O
addition	O
of	O
paclitaxel	B-DRUG
to	O
doxorubicin	B-DRUG
plus	O
cisplatin	B-DRUG
improves	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
women	O
with	O
advanced	B-CANCER
or	I-CANCER
recurrent	I-CANCER
endometrial	I-CANCER
carcinoma	I-CANCER
.	O
	
Secondary	O
comparisons	O
included	O
progression-free	O
survival	O
(	O
PFS	O
)	O
","	O
response	O
rate	O
(	O
RR	O
)	O
","	O
and	O
toxicities	O
.	O
	
Eligible	O
","	O
consenting	O
patients	O
received	O
doxorubicin	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
cisplatin	B-DRUG
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
AP	O
)	O
","	O
or	O
doxorubicin	B-DRUG
45	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
cisplatin	B-DRUG
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
day	O
1	O
)	O
","	O
followed	O
by	O
paclitaxel	B-DRUG
160	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
day	O
2	O
)	O
with	O
filgrastim	B-DRUG
support	O
(	O
TAP	B-DRUG
)	O
.	O
	
The	O
initial	O
doxorubicin	B-DRUG
dose	O
in	O
the	O
AP	O
arm	O
was	O
reduced	O
to	O
45	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
patients	O
with	O
prior	O
pelvic	O
radiotherapy	O
and	O
those	O
older	O
than	O
65	O
years	O
.	O
	
Both	O
regimens	O
were	O
repeated	O
every	O
3	O
weeks	O
to	O
a	O
maximum	O
of	O
seven	O
cycles	O
.	O
	
Patients	O
completed	O
a	O
neurotoxicity	B-TOXI
questionnaire	O
before	O
each	O
cycle	O
.	O
	
Two	O
hundred	O
seventy-three	O
women	O
(	O
10	O
ineligible	O
)	O
were	O
registered	O
.	O
	
Objective	O
response	O
(	O
57	O
%	O
v	O
34	O
%	O
;	O
P	O
&	O
lt	O
;	O
0.01	O
)	O
","	O
PFS	O
(	O
median	O
","	O
8.3	O
v	O
5.3	O
months	O
;	O
P	O
&	O
lt	O
;	O
0.01	O
)	O
","	O
and	O
OS	O
(	O
median	O
","	O
15.3	O
v	O
12.3	O
months	O
;	O
P	O
0.037	O
)	O
were	O
improved	O
with	O
TAP	B-DRUG
.	O
	
Treatment	O
was	O
hematologically	O
well	O
tolerated	O
","	O
with	O
only	O
2	O
%	O
of	O
patients	O
receiving	O
AP	O
","	O
and	O
3	O
%	O
of	O
patients	O
receiving	O
TAP	B-DRUG
experiencing	O
neutropenic	B-TOXI
fever	I-TOXI
.	O
	
Neurologic	B-TOXI
toxicity	I-TOXI
was	O
worse	O
for	O
those	O
receiving	O
TAP	B-DRUG
","	O
with	O
12	O
%	O
grade	O
3	O
","	O
and	O
27	O
%	O
grade	O
2	O
peripheral	B-TOXI
neuropathy	I-TOXI
","	O
compared	O
with	O
1	O
%	O
and	O
4	O
%	O
","	O
respectively	O
","	O
in	O
those	O
receiving	O
AP	O
.	O
	
Patient-reported	O
neurotoxicity	B-TOXI
was	O
significantly	O
higher	O
in	O
the	O
TAP	B-DRUG
arm	O
following	O
two	O
cycles	O
of	O
therapy	O
.	O
	
TAP	B-DRUG
significantly	O
improves	O
RR	O
","	O
PFS	O
","	O
and	O
OS	O
compared	O
with	O
AP	O
.	O
	
Evaluation	O
of	O
this	O
regimen	O
in	O
the	O
high-risk	O
adjuvant	O
setting	O
is	O
warranted	O
","	O
but	O
close	O
attention	O
should	O
be	O
paid	O
to	O
the	O
increased	O
risk	O
of	O
peripheral	B-TOXI
neuropathy	I-TOXI
.	O
	
Randomized	O
phase	O
II	O
trial	O
comparing	O
bevacizumab	B-DRUG
plus	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
with	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
alone	O
in	O
previously	O
untreated	O
locally	B-CANCER
advanced	I-CANCER
or	I-CANCER
metastatic	I-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
investigate	O
the	O
efficacy	O
and	O
safety	O
of	O
bevacizumab	B-DRUG
plus	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
or	I-CANCER
recurrent	I-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
In	O
a	O
phase	O
II	O
trial	O
","	O
99	O
patients	O
were	O
randomly	O
assigned	O
to	O
bevacizumab	B-DRUG
7.5	O
(	O
n	O
=	O
32	O
)	O
or	O
15	O
mg	O
/	O
kg	O
(	O
n	O
=	O
35	O
)	O
plus	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
=	O
6	O
)	O
and	O
paclitaxel	B-DRUG
(	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
every	O
3	O
weeks	O
or	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
alone	O
(	O
n	O
=	O
32	O
)	O
.	O
	
Primary	O
efficacy	O
end	O
points	O
were	O
time	O
to	O
disease	O
progression	O
and	O
best	O
confirmed	O
response	O
rate	O
.	O
	
On	O
disease	O
progression	O
","	O
patients	O
in	O
the	O
control	O
arm	O
had	O
the	O
option	O
to	O
receive	O
single-agent	O
bevacizumab	B-DRUG
15	O
mg	O
/	O
kg	O
every	O
3	O
weeks	O
.	O
	
Compared	O
with	O
the	O
control	O
arm	O
","	O
treatment	O
with	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
plus	O
bevacizumab	B-DRUG
(	O
15	O
mg	O
/	O
kg	O
)	O
resulted	O
in	O
a	O
higher	O
response	O
rate	O
(	O
31.5	O
%	O
v	O
18.8	O
%	O
)	O
","	O
longer	O
median	O
time	O
to	O
progression	O
(	O
7.4	O
v	O
4.2	O
months	O
)	O
and	O
a	O
modest	O
increase	O
in	O
survival	O
(	O
17.7	O
v	O
14.9	O
months	O
)	O
.	O
	
Of	O
the	O
19	O
control	O
patients	O
that	O
crossed	O
over	O
to	O
single-agent	O
bevacizumab	B-DRUG
","	O
five	O
experienced	O
stable	O
disease	O
","	O
and	O
1-year	O
survival	O
was	O
47	O
%	O
.	O
	
Bleeding	B-TOXI
was	O
the	O
most	O
prominent	O
adverse	O
event	O
and	O
was	O
manifested	O
in	O
two	O
distinct	O
clinical	O
patterns	O
;	O
minor	B-TOXI
mucocutaneous	I-TOXI
hemorrhage	I-TOXI
and	O
major	B-TOXI
hemoptysis	I-TOXI
.	O
	
Major	B-TOXI
hemoptysis	I-TOXI
was	O
associated	O
with	O
squamous	O
cell	O
histology	O
","	O
tumor	B-TOXI
necrosis	I-TOXI
and	O
cavitation	B-TOXI
","	O
and	O
disease	O
location	O
close	O
to	O
major	O
blood	O
vessels	O
.	O
	
Bevacizumab	B-DRUG
in	O
combination	O
with	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
improved	O
overall	O
response	O
and	O
time	O
to	O
progression	O
in	O
patients	O
with	O
advanced	B-CANCER
or	I-CANCER
recurrent	I-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
nonsquamous	O
cell	O
histology	O
appear	O
to	O
be	O
a	O
subpopulation	O
with	O
improved	O
outcome	O
and	O
acceptable	O
safety	O
risks	O
.	O
	
Topotecan	B-DRUG
compared	O
with	O
no	O
therapy	O
after	O
response	O
to	O
surgery	O
and	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
ovarian	B-CANCER
cancer	I-CANCER
:	O
Multicenter	O
Italian	O
Trials	O
in	O
Ovarian	B-CANCER
Cancer	I-CANCER
(	O
MITO-1	O
)	O
randomized	O
study	O
.	O
	
	
Topotecan	B-DRUG
is	O
an	O
active	O
second-line	O
treatment	O
for	O
advanced	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
Its	O
efficacy	O
as	O
consolidation	O
treatment	O
after	O
first-line	O
standard	O
chemotherapy	O
is	O
unknown	O
.	O
	
To	O
investigate	O
whether	O
topotecan	B-DRUG
(	O
1.5	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
through	O
5	O
","	O
four	O
cycles	O
","	O
every	O
3	O
weeks	O
)	O
prolonged	O
progression-free	O
survival	O
(	O
PFS	O
)	O
for	O
patients	O
responding	O
to	O
standard	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
5	O
)	O
and	O
paclitaxel	B-DRUG
(	O
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
administered	O
as	O
a	O
3-hour	O
infusion	O
in	O
six	O
cycles	O
;	O
CP	B-DRUG
)	O
","	O
a	O
multicenter	O
phase	O
III	O
study	O
was	O
performed	O
with	O
an	O
80	O
%	O
power	O
to	O
detect	O
a	O
50	O
%	O
prolongation	O
of	O
median	O
PFS	O
.	O
	
Patients	O
were	O
registered	O
at	O
diagnosis	O
and	O
randomized	O
after	O
the	O
end	O
of	O
CP	B-DRUG
.	O
	
Two	O
hundred	O
seventy-three	O
patients	O
were	O
randomly	O
assigned	O
(	O
topotecan	B-DRUG
","	O
n	O
=	O
137	O
;	O
observation	O
","	O
n	O
=	O
136	O
)	O
","	O
with	O
a	O
median	O
age	O
of	O
56	O
years	O
.	O
	
Stage	O
at	O
diagnosis	O
was	O
advanced	O
in	O
three	O
fourths	O
of	O
patients	O
(	O
stage	O
III	O
in	O
65	O
%	O
of	O
patients	O
;	O
stage	O
IV	O
in	O
10	O
%	O
)	O
;	O
after	O
primary	O
surgery	O
","	O
46	O
%	O
had	O
no	O
residual	O
disease	O
and	O
20	O
%	O
were	O
optimally	O
debulked	O
.	O
	
After	O
CP	B-DRUG
","	O
87	O
%	O
reached	O
a	O
clinical	O
complete	O
response	O
","	O
and	O
13	O
%	O
achieved	O
a	O
partial	O
response	O
.	O
	
Neutropenia	B-TOXI
(	O
grade	O
3	O
/	O
4	O
in	O
58	O
%	O
of	O
the	O
patients	O
)	O
and	O
thrombocytopenia	B-TOXI
(	O
grade	O
3	O
in	O
21	O
%	O
;	O
grade	O
4	O
in	O
3	O
%	O
)	O
were	O
the	O
most	O
frequent	O
toxicities	O
attributed	O
to	O
topotecan	B-DRUG
.	O
	
There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
PFS	O
between	O
the	O
arms	O
(	O
P	O
0.83	O
;	O
log-rank	O
test	O
)	O
:	O
median	O
PFS	O
was	O
18.2	O
months	O
in	O
the	O
topotecan	B-DRUG
arm	O
and	O
28.4	O
in	O
the	O
control	O
arm	O
.	O
	
Hazard	O
ratio	O
of	O
progression	O
for	O
patients	O
receiving	O
topotecan	B-DRUG
was	O
1.18	O
(	O
95	O
%	O
CI	O
","	O
0.86	O
to	O
1.63	O
)	O
after	O
adjustment	O
for	O
residual	O
disease	O
","	O
interval	O
debulking	O
surgery	O
","	O
and	O
response	O
to	O
CP	B-DRUG
.	O
	
The	O
present	O
analysis	O
indicates	O
that	O
consolidation	O
with	O
topotecan	B-DRUG
does	O
not	O
improve	O
PFS	O
for	O
patients	O
with	O
advanced	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
who	O
respond	O
to	O
initial	O
chemotherapy	O
with	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
.	O
	
Phase	O
I	O
/	O
II	O
study	O
of	O
first-line	O
irinotecan	B-DRUG
combined	O
with	O
5-fluorouracil	B-DRUG
and	O
folinic	B-DRUG
acid	I-DRUG
Mayo	O
Clinic	O
schedule	O
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
This	O
multicentre	O
phase	O
I	O
/	O
II	O
study	O
was	O
designed	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
of	O
irinotecan	B-DRUG
when	O
combined	O
with	O
5-fluorouracil	B-DRUG
and	O
folinic	B-DRUG
acid	I-DRUG
according	O
to	O
the	O
Mayo	O
Clinic	O
schedule	O
and	O
to	O
evaluate	O
the	O
activity	O
of	O
this	O
combination	O
as	O
first-line	O
therapy	O
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Sixty-three	O
patients	O
received	O
irinotecan	B-DRUG
(	O
250	O
or	O
300	O
mg	O
/	O
m2	O
","	O
-30	O
to	O
90-minute	O
intravenous	O
infusion	O
on	O
day	O
1	O
)	O
","	O
immediately	O
followed	O
by	O
folinic	B-DRUG
acid	I-DRUG
(	O
20	O
mg	O
/	O
m2	O
/	O
day	O
)	O
and	O
5-fluorouracil	B-DRUG
(	O
425	O
mg	O
/	O
m2	O
","	O
15-minute	O
bolus	O
infusion	O
)	O
days	O
1	O
to	O
5	O
","	O
every	O
four	O
weeks	O
.	O
	
Diarrhoea	B-TOXI
was	O
dose	O
limiting	O
at	O
300	O
mg	O
/	O
m2	O
irinotecan	B-DRUG
in	O
combination	O
with	O
5-fluorouracil	B-DRUG
and	O
folinic	B-DRUG
acid	I-DRUG
","	O
and	O
this	O
was	O
determined	O
to	O
be	O
the	O
maximum	O
tolerated	O
dose	O
.	O
	
Grade	O
3月4日	O
neutropenia	B-TOXI
was	O
the	O
most	O
frequently	O
reported	O
toxicity	O
.	O
	
The	O
recommended	O
dose	O
of	O
irinotecan	B-DRUG
for	O
the	O
phase	O
II	O
part	O
of	O
the	O
study	O
was	O
250	O
mg	O
/	O
m2	O
.	O
	
The	O
response	O
rate	O
for	O
the	O
evaluable	O
patient	O
population	O
was	O
36	O
%	O
(	O
13	O
/	O
36	O
)	O
","	O
and	O
44	O
%	O
(	O
16	O
patients	O
)	O
had	O
stable	O
disease	O
(	O
including	O
19	O
%	O
of	O
minor	O
response	O
)	O
.	O
	
For	O
the	O
intention-to-treat	O
population	O
","	O
the	O
response	O
rate	O
was	O
29	O
%	O
(	O
14	O
/	O
49	O
)	O
and	O
35	O
%	O
(	O
17	O
patients	O
)	O
stable	O
disease	O
(	O
including	O
14	O
%	O
of	O
minor	O
response	O
)	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
was	O
7	O
months	O
and	O
the	O
median	O
survival	O
was	O
12	O
months	O
.	O
	
Grade	O
3月4日	O
non-haematological	B-TOXI
drug-related	O
toxicities	O
included	O
delayed	B-TOXI
diarrhoea	I-TOXI
","	O
stomatitis	B-TOXI
","	O
fatigue	B-TOXI
","	O
and	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
.	O
	
There	O
were	O
three	O
deaths	B-TOXI
due	O
to	O
septic	B-TOXI
shock	I-TOXI
that	O
were	O
possibly	O
or	O
probably	O
treatment-related	O
.	O
	
This	O
regimen	O
of	O
irinotecan	B-DRUG
in	O
combination	O
with	O
the	O
Mayo	O
Clinic	O
schedule	O
of	O
bolus	O
5-fluorouracil	B-DRUG
/	O
folinic	B-DRUG
acid	I-DRUG
every	O
four	O
weeks	O
showed	O
activity	O
as	O
first-line	O
therapy	O
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
In	O
keeping	O
with	O
other	O
published	O
results	O
of	O
studies	O
using	O
bolus	O
5-fluorouracil	B-DRUG
combined	O
with	O
irinotecan	B-DRUG
","	O
the	O
use	O
of	O
this	O
regimen	O
is	O
limited	O
by	O
a	O
relatively	O
high	O
rate	O
of	O
grade	O
3月4日	O
neutropenia	B-TOXI
","	O
and	O
the	O
combination	O
of	O
irinotecan	B-DRUG
and	O
infusional	B-DRUG
5-fluorouracil	I-DRUG
/	O
folinic	B-DRUG
acid	I-DRUG
should	O
remain	O
the	O
regimen	O
of	O
first	O
choice	O
.	O
	
Multi-institutional	O
phase	O
II	O
trial	O
of	O
irinotecan	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
etoposide	B-DRUG
for	O
sensitive	O
relapsed	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
Irinotecan	B-DRUG
(	O
CPT-11	B-DRUG
)	O
has	O
been	O
shown	O
to	O
exhibit	O
excellent	O
antitumour	O
activity	O
against	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
SCLC	B-CANCER
)	O
.	O
	
A	O
multi-institutional	O
phase	O
II	O
study	O
was	O
therefore	O
conducted	O
to	O
evaluate	O
the	O
efficacy	O
and	O
toxicity	O
of	O
CPT-11	B-DRUG
combined	O
with	O
cisplatin	B-DRUG
(	O
CDDP	B-DRUG
)	O
and	O
etoposide	B-DRUG
(	O
ETOP	B-DRUG
)	O
(	O
PEI	B-DRUG
regimen	O
)	O
for	O
the	O
treatment	O
of	O
sensitive	O
relapsed	O
SCLC	B-CANCER
.	O
	
Patients	O
who	O
responded	O
to	O
first-line	O
chemotherapy	O
but	O
relapsed	O
more	O
than	O
8	O
weeks	O
after	O
the	O
completion	O
of	O
first-line	O
therapy	O
(	O
n=40	O
)	O
were	O
treated	O
using	O
the	O
PEI	B-DRUG
regimen	O
","	O
which	O
consisted	O
of	O
CDDP	B-DRUG
(	O
25	O
mg	O
m	O
(	O
-2	O
)	O
)	O
weekly	O
for	O
9	O
weeks	O
","	O
ETOP	B-DRUG
(	O
60	O
mg	O
m	O
(	O
-2	O
)	O
)	O
for	O
3	O
days	O
on	O
weeks	O
1	O
","	O
3	O
","	O
5	O
","	O
7	O
","	O
and	O
9	O
","	O
and	O
CPT-11	B-DRUG
(	O
90	O
mg	O
m	O
(	O
-2	O
)	O
)	O
on	O
weeks	O
2	O
","	O
4	O
","	O
6	O
","	O
and	O
8	O
with	O
granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
support	O
.	O
	
Five	O
complete	O
responses	O
and	O
26	O
partial	O
responses	O
were	O
observed	O
","	O
and	O
the	O
overall	O
response	O
rate	O
was	O
78	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
61.5-89.2	O
%	O
)	O
.	O
	
The	O
median	O
survival	O
time	O
was	O
11.8	O
months	O
","	O
and	O
the	O
estimated	O
1-year	O
survival	O
rate	O
was	O
49	O
%	O
.	O
	
Grade	O
3	O
/	O
4	O
leucocytopenia	B-TOXI
","	O
neutropenia	B-TOXI
","	O
and	O
thrombocytopenia	B-TOXI
were	O
observed	O
in	O
55	O
","	O
73	O
","	O
and	O
33	O
%	O
of	O
the	O
patients	O
","	O
respectively	O
.	O
	
Nonhaematological	B-TOXI
toxicities	I-TOXI
were	O
mild	O
and	O
transient	O
in	O
all	O
patients	O
.	O
	
In	O
conclusion	O
","	O
the	O
PEI	B-DRUG
regimen	O
is	O
considered	O
to	O
be	O
highly	O
active	O
and	O
well	O
tolerated	O
for	O
the	O
treatment	O
of	O
sensitive	O
relapsed	O
SCLC	B-CANCER
.	O
	
Cisplatin	B-DRUG
","	O
fluorouracil	B-DRUG
","	O
and	O
leucovorin	B-DRUG
induction	O
chemotherapy	O
followed	O
by	O
concurrent	O
cisplatin	B-DRUG
chemoradiotherapy	O
for	O
organ	O
preservation	O
and	O
cure	O
in	O
patients	O
with	O
advanced	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
:	O
long-term	O
follow-up	O
.	O
	
	
The	O
poor	O
functional	O
outcome	O
in	O
patients	O
with	O
advanced	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
HNSCC	B-CANCER
)	O
with	O
surgery	O
and	O
radiation	O
has	O
led	O
to	O
alternative	O
approaches	O
to	O
advanced	O
disease	O
.	O
	
We	O
conducted	O
a	O
phase	O
II	O
study	O
of	O
induction	O
chemotherapy	O
followed	O
by	O
concurrent	O
chemoradiotherapy	O
for	O
organ	O
preservation	O
in	O
patients	O
with	O
advanced	O
resectable	O
and	O
unresectable	O
(	O
nasopharyngeal	B-CANCER
)	I-CANCER
tumors	I-CANCER
.	O
	
Forty-two	O
patients	O
with	O
stage	O
III	O
to	O
IV	O
resectable	O
HNSCC	B-CANCER
and	O
nasopharyngeal	B-CANCER
tumors	I-CANCER
received	O
induction	O
chemotherapy	O
with	O
two	O
courses	O
of	O
cisplatin	B-DRUG
(	O
20	O
mg	O
/	O
m2	O
/	O
d	O
continuous	O
infusion	O
[	O
CI	O
]	O
)	O
","	O
fluorouracil	B-DRUG
(	O
800	O
mg	O
/	O
m2	O
/	O
d	O
CI	O
)	O
","	O
and	O
leucovorin	B-DRUG
(	O
500	O
mg	O
/	O
m2	O
/	O
d	O
CI	O
;	O
PFL	B-DRUG
)	O
for	O
4	O
days	O
followed	O
by	O
concurrent	O
therapy	O
with	O
cisplatin	B-DRUG
(	O
100	O
mg	O
/	O
m2	O
/	O
d	O
on	O
days	O
1	O
and	O
22	O
)	O
and	O
approximately	O
70	O
Gy	O
of	O
external-beam	O
radiotherapy	O
.	O
	
Response	O
to	O
induction	O
chemotherapy	O
included	O
partial	O
response	O
rate	O
of	O
52	O
%	O
and	O
complete	O
response	O
rate	O
of	O
24	O
%	O
.	O
	
The	O
most	O
common	O
grade	O
3	O
or	O
4	O
toxicity	O
was	O
neutropenia	B-TOXI
(	O
59	O
%	O
)	O
.	O
	
After	O
cisplatin	B-DRUG
chemoradiotherapy	O
the	O
complete	O
response	O
rate	O
was	O
67	O
%	O
.	O
	
Toxicities	O
of	O
cisplatin	B-DRUG
chemoradiotherapy	O
consisted	O
of	O
grade	O
3	O
or	O
4	O
mucositis	B-TOXI
(	O
79	O
%	O
)	O
and	O
neutropenia	B-TOXI
(	O
51	O
%	O
)	O
.	O
	
At	O
a	O
median	O
follow-up	O
of	O
71.5	O
months	O
","	O
43	O
%	O
of	O
the	O
patients	O
are	O
still	O
alive	O
and	O
disease-free	O
.	O
	
The	O
5-year	O
progression-free	O
survival	O
(	O
PFS	O
)	O
rate	O
was	O
60	O
%	O
","	O
and	O
the	O
-2	O
and	O
5-year	O
overall	O
survival	O
(	O
OS	O
)	O
rates	O
were	O
67	O
%	O
and	O
52	O
%	O
","	O
respectively	O
.	O
	
Three	O
patients	O
died	B-TOXI
of	O
second	O
primaries	O
.	O
	
Late	O
complications	O
of	O
treatment	O
included	O
xerostomia	B-TOXI
and	O
hoarseness	B-TOXI
.	O
	
One	O
patient	O
had	O
persistent	O
dysphagia	B-TOXI
and	O
required	O
laser	O
epiglotectomy	O
108	O
months	O
after	O
treatment	O
.	O
	
Induction	O
chemotherapy	O
with	O
PFL	B-DRUG
followed	O
by	O
concurrent	O
cisplatin	B-DRUG
chemoradiotherapy	O
is	O
well	O
tolerated	O
and	O
results	O
in	O
a	O
good	O
likelihood	O
of	O
organ	O
preservation	O
and	O
excellent	O
PFS	O
and	O
OS	O
.	O
	
Phase	O
II	O
trial	O
of	O
carboplatin	B-DRUG
and	O
etoposide	B-DRUG
for	O
patients	O
with	O
recurrent	B-CANCER
high-grade	I-CANCER
glioma	I-CANCER
.	O
	
	
We	O
present	O
the	O
results	O
of	O
a	O
phase	O
II	O
trial	O
of	O
carboplatin	B-DRUG
and	O
etoposide	B-DRUG
(	O
CE	B-DRUG
)	O
combination	O
as	O
first-line	O
chemotherapy	O
in	O
patients	O
with	O
recurrent	B-CANCER
glioblastoma	I-CANCER
multiforme	I-CANCER
(	O
GBM	B-CANCER
)	O
and	O
anaplastic	B-CANCER
astrocytoma	I-CANCER
(	O
AA	B-CANCER
)	O
after	O
surgery	O
and	O
radiotherapy	O
.	O
	
We	O
assess	O
the	O
activity	O
and	O
the	O
tolerability	O
of	O
this	O
combination	O
.	O
	
30	O
patients	O
with	O
GBM	B-CANCER
(	O
25	O
)	O
and	O
AA	B-CANCER
(	O
5	O
)	O
were	O
treated	O
with	O
VP-16	B-DRUG
(	O
etoposide	B-DRUG
)	O
120	O
mg	O
m	O
(	O
-2	O
)	O
and	O
CBCDA	B-DRUG
(	O
carboplatin	B-DRUG
)	O
100	O
mg	O
m	O
(	O
-2	O
)	O
for	O
3	O
days	O
every	O
4	O
weeks	O
.	O
	
Moreover	O
","	O
we	O
performed	O
a	O
retrospective	O
analysis	O
of	O
topoisomerase	B-DRUG
IIalpha	I-DRUG
gene	O
status	O
using	O
chromogenic	O
in	O
situ	O
hybridisation	O
.	O
	
The	O
median	O
age	O
was	O
54	O
years	O
(	O
21-73	O
years	O
)	O
;	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
score	O
was	O
0-1	O
in	O
25	O
patients	O
and	O
2	O
in	O
five	O
patients	O
.	O
	
All	O
patients	O
had	O
been	O
previously	O
treated	O
with	O
surgical	O
resection	O
(	O
21	O
radical	O
resections	O
)	O
followed	O
by	O
radiation	O
therapy	O
(	O
40-60	O
Gy	O
)	O
.	O
	
We	O
observed	O
six	O
(	O
20	O
%	O
)	O
complete	O
responses	O
","	O
three	O
(	O
10	O
%	O
)	O
partial	O
responses	O
and	O
12	O
(	O
40	O
%	O
)	O
stable	O
diseases	O
","	O
with	O
a	O
response	O
rate	O
of	O
30	O
%	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
was	O
4	O
months	O
","	O
while	O
progression-free	O
survival	O
at	O
6	O
months	O
was	O
33.3	O
%	O
.	O
	
The	O
median	O
survival	O
time	O
was	O
10	O
months	O
.	O
	
Neutropenia	B-TOXI
occurred	O
in	O
9	O
patients	O
:	O
four	O
patients	O
had	O
grade	O
4	O
","	O
two	O
patients	O
grade	O
3	O
and	O
three	O
patients	O
grade	O
2	O
In	O
the	O
conclusion	O
of	O
this	O
clinical	O
trial	O
","	O
the	O
CE	B-DRUG
combination	O
has	O
shown	O
activity	O
in	O
recurrent	O
GBM	B-CANCER
and	O
AA	B-CANCER
","	O
with	O
a	O
good	O
toxicity	O
profile	O
.	O
	
Alterations	O
in	O
the	O
copy	O
number	O
of	O
topoisomerase	B-DRUG
IIalpha	I-DRUG
gene	I-DRUG
seem	O
to	O
be	O
a	O
rare	O
event	O
and	O
in	O
our	O
series	O
do	O
not	O
influence	O
response	O
to	O
the	O
CE	B-DRUG
combination	O
.	O
	
A	O
phase	O
I	O
trial	O
of	O
gemcitabine	B-DRUG
plus	O
cladribine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
hematologic	I-CANCER
malignant	I-CANCER
diseases	I-CANCER
.	O
	
	
Gemcitabine	B-DRUG
and	O
cladribine	B-DRUG
(	O
2CdA	B-DRUG
)	O
are	O
nucleoside	O
analogues	O
that	O
decrease	O
DNA	O
synthesis	O
via	O
inhibition	O
of	O
ribonucleotide	O
reductase	O
;	O
the	O
combination	O
could	O
be	O
additive	O
or	O
synergistic	O
.	O
	
We	O
conducted	O
a	O
dose	O
escalation	O
study	O
to	O
establish	O
the	O
maximum	O
tolerable	O
doses	O
(	O
MTD	O
)	O
of	O
gemcitabine	B-DRUG
and	O
2CdA	B-DRUG
when	O
given	O
in	O
combination	O
in	O
patients	O
with	O
advanced	B-CANCER
hematologic	I-CANCER
malignancies	I-CANCER
and	O
to	O
describe	O
the	O
toxicity	O
profile	O
of	O
this	O
combination	O
.	O
	
A	O
total	O
of	O
45	O
patients	O
with	O
advanced	B-CANCER
hematologic	I-CANCER
diseases	I-CANCER
were	O
enrolled	O
into	O
two	O
groups	O
.	O
	
Group	O
A	O
had	O
adequate	O
baseline	O
hematopoiesis	O
","	O
defined	O
as	O
absolute	O
neutrophil	O
count	O
(	O
ANC	O
)	O
&	O
gt	O
;	O
1	O
x	O
10	O
(	O
9	O
)	O
/	O
l	O
and	O
platelet	O
count	O
&	O
gt	O
;	O
50	O
x	O
10	O
(	O
9	O
)	O
/	O
l.	O
Group	O
B	O
did	O
not	O
meet	O
these	O
criteria	O
.	O
	
Hematologic	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
for	O
group	O
A	O
was	O
defined	O
as	O
grade	O
4	O
neutropenia	B-TOXI
or	O
thrombocytopenia	B-TOXI
lasting	O
&	O
gt	O
;	O
28	O
days	O
;	O
group	O
B	O
was	O
not	O
evaluated	O
for	O
hematologic	B-TOXI
toxicity	I-TOXI
.	O
	
Nonhematologic	O
DLT	O
was	O
defined	O
similarly	O
for	O
both	O
groups	O
.	O
	
Death	B-TOXI
occurring	O
during	O
the	O
first	O
cycle	O
of	O
treatment	O
was	O
considered	O
a	O
DLT	O
event	O
only	O
if	O
it	O
was	O
related	O
to	O
drug	O
toxicity	O
.	O
	
Gemcitabine	B-DRUG
was	O
administered	O
as	O
a	O
4-h	O
intravenous	O
infusion	O
once	O
every	O
28	O
days	O
.	O
	
2CdA	B-DRUG
was	O
administered	O
over	O
1	O
h	O
daily	O
for	O
the	O
first	O
3	O
days	O
of	O
each	O
28-day	O
cycle	O
.	O
	
The	O
MTD	O
was	O
not	O
reached	O
in	O
either	O
group	O
.	O
	
Myelosuppression	B-TOXI
was	O
common	O
","	O
but	O
not	O
dose-limiting	O
.	O
	
Febrile	B-TOXI
neutropenia	I-TOXI
and	O
infections	O
were	O
also	O
common	O
","	O
particularly	O
in	O
group	O
B	O
","	O
and	O
judged	O
in	O
most	O
cases	O
to	O
be	O
due	O
to	O
bone	O
marrow	O
failure	O
at	O
baseline	O
.	O
	
Nonhematologic	B-TOXI
toxicities	I-TOXI
were	O
generally	O
mild	O
","	O
and	O
skin	B-TOXI
rash	I-TOXI
","	O
the	O
most	O
frequently	O
observed	O
","	O
was	O
dose-limiting	O
in	O
one	O
patient	O
enrolled	O
in	O
each	O
group	O
.	O
	
Four	O
deaths	B-TOXI
(	O
three	O
during	O
the	O
first	O
cycle	O
of	O
treatment	O
)	O
occurred	O
at	O
the	O
highest	O
dose	O
level	O
tested	O
in	O
group	O
B	O
(	O
gemcitabine	B-DRUG
5000	O
mg	O
/	O
m2	O
and	O
2CdA	B-DRUG
16	O
mg	O
/	O
m2	O
)	O
.	O
	
Although	O
only	O
one	O
of	O
these	O
deaths	B-TOXI
was	O
dose-limiting	O
by	O
stated	O
criteria	O
","	O
this	O
dose	O
level	O
did	O
not	O
appear	O
to	O
be	O
safely	O
tolerated	O
in	O
this	O
patient	O
population	O
.	O
	
Several	O
responses	O
were	O
observed	O
in	O
patients	O
with	O
Hodgkin	B-CANCER
's	I-CANCER
disease	I-CANCER
.	O
	
The	O
combination	O
of	O
gemcitabine	B-DRUG
and	O
2CdA	B-DRUG
is	O
feasible	O
in	O
patients	O
with	O
hematologic	B-CANCER
malignancies	I-CANCER
.	O
	
Phase	O
II	O
studies	O
of	O
this	O
combination	O
should	O
be	O
considered	O
","	O
particularly	O
in	O
patients	O
with	O
Hodgkin	B-CANCER
's	I-CANCER
disease	I-CANCER
.	O
	
Phase	O
I	O
trial	O
of	O
topotecan	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
refractory	O
solid	B-CANCER
tumor	I-CANCER
patients	O
.	O
	
	
To	O
determine	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
evidence	O
of	O
antitumor	O
activity	O
of	O
topotecan	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
refractory	O
cancer	O
patients	O
.	O
	
To	O
determine	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
evidence	O
of	O
antitumor	O
activity	O
of	O
topotecan	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
refractory	B-CANCER
cancer	I-CANCER
patients	O
.	O
	
This	O
was	O
a	O
Phase	O
I	O
","	O
prospective	O
","	O
dose-escalation	O
trial	O
that	O
employed	O
a	O
novel-dosing	O
schema	O
to	O
investigate	O
clinical	O
safety	O
.	O
	
Patients	O
were	O
treated	O
in	O
six	O
cohorts	O
with	O
topotecan	B-DRUG
(	O
T	O
)	O
#NAME?	B-DRUG
(	O
G	O
)	O
.	O
	
The	O
doses	O
of	O
T	O
and	O
G	O
were	O
administered	O
by	O
30-minute	O
IV	O
infusion	O
","	O
T	O
on	O
days	O
one	O
through	O
five	O
(	O
0.3	O
mg	O
/	O
m2	O
to	O
1	O
mg	O
/	O
m2	O
)	O
and	O
G	O
on	O
days	O
one	O
and	O
15	O
of	O
a	O
28-day	O
cycle	O
(	O
1000	O
mg	O
/	O
m2	O
to	O
1500	O
mg	O
/	O
m2	O
)	O
.	O
	
Toxicity	O
was	O
monitored	O
.	O
	
Twenty-three	O
cancer	O
patients	O
were	O
enrolled	O
(	O
colorectal	B-CANCER
","	O
n=5	O
;	O
lung	B-CANCER
","	O
n=4	O
;	O
gastric	B-CANCER
","	O
n=4	O
;	O
esophageal	B-CANCER
","	O
n=2	O
;	O
other	O
","	O
n=8	O
)	O
.	O
	
Two	O
of	O
three	O
patients	O
developed	O
grade	O
3	O
nonhematologic	B-TOXI
toxicity	I-TOXI
attributed	O
to	O
study	O
regimen	O
","	O
thereby	O
fulfilling	O
dose	O
limiting	O
toxicity	O
requirements	O
at	O
cohort	O
6	O
(	O
T	O
","	O
1	O
mg	O
/	O
m2	O
","	O
G	O
","	O
1500	O
mg	O
/	O
m2	O
)	O
.	O
	
Maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
was	O
established	O
at	O
cohort	O
5	O
(	O
T	O
","	O
1	O
mg	O
/	O
m2	O
","	O
G	O
","	O
1250	O
mg	O
/	O
m2	O
)	O
.	O
	
Ten	O
patients	O
were	O
treated	O
at	O
cohort	O
5	O
Nonhematologic	B-TOXI
adverse	I-TOXI
effects	I-TOXI
(	O
AEs	O
)	O
&	O
gt	O
;	O
grade	O
3	O
attributed	O
to	O
the	O
study	O
regimen	O
were	O
not	O
observed	O
.	O
	
Hematologic	B-TOXI
toxicity	I-TOXI
was	O
frequent	O
.	O
	
Twenty-five	O
percent	O
of	O
patients	O
in	O
cohort	O
2	O
and	O
50	O
%	O
of	O
patients	O
in	O
cohorts	O
4	O
","	O
5	O
","	O
and	O
6	O
had	O
a	O
reduction	O
of	O
ANC	O
to	O
&	O
lt	O
;	O
500	O
mm3	O
.	O
	
All	O
neutropenic	B-TOXI
episodes	O
were	O
less	O
than	O
one	O
week	O
in	O
duration	O
.	O
	
Five	O
of	O
the	O
patients	O
in	O
the	O
last	O
three	O
cohorts	O
required	O
delay	O
and	O
/	O
or	O
dose-reduction	O
of	O
G.	O
Nineteen	O
of	O
23	O
enrolled	O
patients	O
were	O
evaluable	O
for	O
response	O
.	O
	
Two	O
patients	O
achieved	O
a	O
minimal	O
response	O
.	O
	
The	O
MTD	O
was	O
observed	O
at	O
a	O
T	O
dose	O
of	O
1	O
mg	O
/	O
m2	O
administered	O
on	O
days	O
1	O
through	O
15	O
","	O
and	O
a	O
G	O
dose	O
of	O
1250	O
mg	O
/	O
m2	O
administered	O
on	O
days	O
1	O
and	O
15	O
via	O
30	O
minute	O
intravenous	O
(	O
IV	O
)	O
infusion	O
.	O
	
Phase	O
I	O
/	O
II	O
study	O
of	O
DHA-paclitaxel	B-DRUG
in	O
combination	O
with	O
carboplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
malignant	I-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
	
DHA-paclitaxel	B-DRUG
is	O
a	O
conjugate	O
of	O
paclitaxel	B-DRUG
and	O
the	O
fatty	B-DRUG
acid	I-DRUG
","	O
docosahexaenoic	B-DRUG
acid	I-DRUG
.	O
	
Preclinical	O
studies	O
have	O
demonstrated	O
increased	O
activity	O
","	O
relative	O
to	O
paclitaxel	B-DRUG
","	O
with	O
the	O
potential	O
for	O
an	O
improved	O
therapeutic	O
ratio	O
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
study	O
to	O
determine	O
the	O
maximum	O
tolerated	O
doses	O
of	O
DHA-paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
when	O
administered	O
in	O
combination	O
.	O
	
Two	O
cohorts	O
of	O
patients	O
were	O
treated	O
:	O
carboplatin	B-DRUG
AUC	O
5	O
with	O
DHA-paclitaxel	B-DRUG
660	O
mg	O
m	O
(	O
-2	O
)	O
and	O
carboplatin	B-DRUG
AUC	O
5	O
with	O
DHA-paclitaxel	B-DRUG
880	O
mg	O
m	O
(	O
-2	O
)	O
.	O
	
Both	O
drugs	O
were	O
given	O
on	O
day	O
1	O
every	O
21	O
days	O
.	O
	
A	O
total	O
of	O
15	O
patients	O
were	O
enrolled	O
with	O
a	O
median	O
age	O
of	O
59	O
years	O
(	O
range	O
33-71	O
)	O
.	O
	
All	O
patients	O
had	O
advanced	B-CANCER
cancer	I-CANCER
refractory	O
to	O
standard	O
treatment	O
","	O
performance	O
status	O
0-2	O
and	O
were	O
without	O
major	O
organ	B-TOXI
dysfunction	I-TOXI
.	O
	
A	O
total	O
of	O
54	O
cycles	O
of	O
treatment	O
were	O
delivered	O
.	O
	
No	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
was	O
seen	O
in	O
the	O
first	O
cohort	O
of	O
three	O
patients	O
.	O
	
In	O
an	O
expanded	O
second	O
cohort	O
","	O
neutropenia	B-TOXI
was	O
the	O
main	O
DLT	O
","	O
occurring	O
in	O
the	O
first	O
cycle	O
of	O
treatment	O
in	O
five	O
of	O
12	O
patients	O
:	O
three	O
of	O
these	O
patients	O
and	O
one	O
additional	O
patient	O
also	O
experienced	O
dose-limiting	O
grade	O
3	O
transient	B-TOXI
rises	I-TOXI
in	I-TOXI
liver	I-TOXI
transaminases	I-TOXI
.	O
	
No	O
alopecia	B-TOXI
was	O
seen	O
and	O
one	O
patient	O
developed	O
clinically	O
significant	O
neuropathy	B-TOXI
.	O
	
One	O
partial	O
response	O
was	O
seen	O
in	O
a	O
patient	O
with	O
advanced	B-CANCER
adenocarcinoma	I-CANCER
of	O
the	O
oesophago-gastric	O
junction	O
and	O
12	O
patients	O
had	O
stable	O
disease	O
with	O
a	O
median	O
time	O
to	O
progression	O
of	O
184	O
days	O
(	O
range	O
60-506	O
days	O
)	O
.	O
	
The	O
recommended	O
phase	O
II	O
dose	O
in	O
pretreated	O
patients	O
is	O
Carboplatin	B-DRUG
AUC	O
5	O
and	O
DHA-paclitaxel	B-DRUG
660	O
mg	O
m	O
(	O
-2	O
)	O
given	O
every	O
21	O
days	O
.	O
	
Further	O
studies	O
with	O
Carboplatin	B-DRUG
AUC	O
5	O
and	O
DHA-paclitaxel	B-DRUG
880	O
mg	O
m	O
(	O
-2	O
)	O
","	O
given	O
every	O
28	O
days	O
","	O
are	O
warranted	O
in	O
chemo-naive	O
patients	O
.	O
	
Randomised	O
phase	O
2	O
trial	O
of	O
SIR-Spheres	O
plus	O
fluorouracil	B-DRUG
/	O
leucovorin	B-DRUG
chemotherapy	O
versus	O
fluorouracil	B-DRUG
/	O
leucovorin	B-DRUG
chemotherapy	O
alone	O
in	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
Selective	O
internal	O
radiation	O
therapy	O
(	O
SIRT	O
)	O
with	O
SIR-Spheres	O
(	O
R	O
)	O
is	O
a	O
new	O
technique	O
for	O
selectively	O
targeting	O
high	O
doses	O
of	O
radiation	O
to	O
tumours	O
within	O
the	O
liver	O
.	O
	
The	O
primary	O
objectives	O
of	O
this	O
randomised	O
trial	O
were	O
to	O
compare	O
the	O
response	O
rate	O
","	O
time	O
to	O
progressive	O
disease	O
(	O
PD	O
)	O
","	O
and	O
toxicity	O
of	O
a	O
regimen	O
of	O
systemic	O
fluorouracil	B-DRUG
/	O
leucovorin	B-DRUG
chemotherapy	O
versus	O
the	O
same	O
chemotherapy	O
plus	O
a	O
single	O
administration	O
of	O
SIR-Spheres	O
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
liver	I-CANCER
metastases	I-CANCER
.	O
	
The	O
trial	O
was	O
designed	O
to	O
presage	O
a	O
larger	O
trial	O
that	O
would	O
have	O
survival	O
as	O
the	O
primary	O
outcome	O
.	O
	
Twenty-one	O
patients	O
with	O
previously	O
untreated	O
advanced	B-CANCER
colorectal	I-CANCER
liver	I-CANCER
metastases	I-CANCER
","	O
with	O
or	O
without	O
extrahepatic	O
metastases	O
","	O
were	O
randomised	O
into	O
the	O
study	O
.	O
	
Using	O
RECIST	O
criteria	O
","	O
the	O
response	O
rate	O
for	O
11	O
patients	O
receiving	O
the	O
combination	O
treatment	O
was	O
significantly	O
greater	O
than	O
for	O
10	O
patients	O
receiving	O
chemotherapy	O
alone	O
(	O
First	O
Integrated	O
Response	O
;	O
10	O
PR	O
","	O
1	O
SD	O
vs.	O
0	O
PR	O
","	O
6	O
SD	O
","	O
4	O
PD	O
","	O
P	O
&	O
lt	O
;	O
0.001	O
and	O
Best	O
Confirmed	O
Response	O
;	O
8	O
PR	O
","	O
3	O
SD	O
vs.	O
0	O
PR	O
","	O
6	O
SD	O
","	O
4	O
PD	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
.	O
	
The	O
time	O
to	O
PD	O
was	O
greater	O
for	O
patients	O
receiving	O
the	O
combination	O
treatment	O
(	O
18.6	O
months	O
vs.	O
3.6	O
months	O
","	O
P	O
&	O
lt	O
;	O
0.0005	O
)	O
.	O
	
Median	O
survival	O
was	O
significantly	O
longer	O
for	O
patients	O
receiving	O
the	O
combination	O
treatment	O
(	O
29.4	O
months	O
vs.	O
12.8	O
months	O
","	O
P	O
=	O
0.02	O
)	O
.	O
	
One	O
patient	O
in	O
the	O
combination	O
arm	O
died	B-TOXI
from	O
chemotherapy	O
induced	O
neutropenic	B-TOXI
sepsis	I-TOXI
after	O
the	O
fourth	O
chemotherapy	O
cycle	O
.	O
	
There	O
were	O
more	O
Grade	O
3	O
and	O
4	O
toxicity	O
events	O
in	O
patients	O
receiving	O
the	O
combination	O
treatment	O
.	O
	
There	O
was	O
no	O
difference	O
in	O
quality-of-life	O
over	O
a	O
3	O
month	O
period	O
between	O
the	O
two	O
treatments	O
when	O
rated	O
by	O
patients	O
(	O
P	O
=	O
0.96	O
)	O
or	O
physicians	O
(	O
P	O
=	O
0.98	O
)	O
.	O
	
This	O
small	O
phase	O
2	O
randomised	O
trial	O
demonstrated	O
that	O
the	O
addition	O
of	O
a	O
single	O
administration	O
of	O
SIR-Spheres	O
to	O
a	O
regimen	O
of	O
systemic	O
fluorouracil	B-DRUG
/	O
leucovorin	B-DRUG
chemotherapy	O
significantly	O
increased	O
both	O
treatment	O
related	O
response	O
","	O
time	O
to	O
PD	O
","	O
and	O
survival	O
with	O
acceptable	O
toxicity	O
.	O
	
The	O
combination	O
of	O
SIR-Spheres	O
plus	O
systemic	O
chemotherapy	O
is	O
now	O
the	O
subject	O
of	O
ongoing	O
trials	O
to	O
further	O
define	O
patient	O
benefit	O
.	O
	
Randomized	O
multicenter	O
phase	O
II	O
trial	O
of	O
a	O
biweekly	O
regimen	O
of	O
fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
(	O
LV5FU2	B-DRUG
)	O
","	O
LV5FU2	B-DRUG
plus	O
cisplatin	B-DRUG
","	O
or	O
LV5FU2	B-DRUG
plus	O
irinotecan	B-DRUG
in	O
patients	O
with	O
previously	O
untreated	O
metastatic	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
:	O
a	O
Federation	O
Francophone	O
de	O
Cancerologie	O
Digestive	O
Group	O
Study	O
=--	O
FFCD	O
9803	O
.	O
	
	
To	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
a	O
biweekly	O
regimen	O
of	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
plus	O
fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
alone	O
or	O
in	O
combination	O
with	O
cisplatin	B-DRUG
or	O
irinotecan	B-DRUG
in	O
patients	O
with	O
previously	O
untreated	O
metastatic	B-CANCER
gastric	I-CANCER
adenocarcinoma	I-CANCER
and	O
to	O
select	O
the	O
best	O
arm	O
for	O
a	O
phase	O
III	O
study	O
.	O
	
One	O
hundred	O
thirty-six	O
patients	O
(	O
two	O
were	O
ineligible	O
)	O
were	O
enrolled	O
onto	O
the	O
randomized	O
multicenter	O
phase	O
II	O
trial	O
.	O
	
Patients	O
received	O
LV	B-DRUG
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
2-hour	O
infusion	O
)	O
followed	O
by	O
FU	B-DRUG
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
bolus	O
)	O
and	O
FU	B-DRUG
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
22-hour	O
continuous	O
infusion	O
)	O
on	O
days	O
1	O
and	O
2	O
every	O
14	O
days	O
(	O
LV5FU2	B-DRUG
;	O
arm	O
A	O
)	O
","	O
LV5FU2	B-DRUG
plus	O
cisplatin	B-DRUG
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
1-hour	O
infusion	O
)	O
on	O
day	O
1	O
or	O
2	O
(	O
arm	O
B	O
)	O
","	O
or	O
LV5FU2	B-DRUG
plus	O
irinotecan	B-DRUG
180	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
2-hour	O
infusion	O
)	O
on	O
day	O
1	O
(	O
arm	O
C	O
)	O
.	O
	
The	O
overall	O
response	O
rates	O
","	O
which	O
were	O
confirmed	O
by	O
an	O
independent	O
expert	O
panel	O
","	O
were	O
13	O
%	O
(	O
95	O
%	O
CI	O
","	O
3.4	O
%	O
to	O
23.3	O
%	O
)	O
","	O
27	O
%	O
(	O
95	O
%	O
CI	O
","	O
14.1	O
%	O
to	O
40.4	O
%	O
)	O
","	O
and	O
40	O
%	O
(	O
95	O
%	O
CI	O
","	O
25.7	O
%	O
to	O
54.3	O
%	O
)	O
for	O
arms	O
A	O
","	O
B	O
","	O
and	O
C	O
","	O
respectively	O
.	O
	
Median	O
progression-free	O
survival	O
and	O
overall	O
survival	O
times	O
were	O
3.2	O
months	O
(	O
95	O
%	O
CI	O
","	O
1.8	O
to	O
4.6	O
months	O
)	O
and	O
6.8	O
months	O
(	O
95	O
%	O
CI	O
","	O
2.6	O
to	O
11.1	O
months	O
)	O
with	O
LV5FU2	B-DRUG
","	O
respectively	O
;	O
4.9	O
months	O
(	O
95	O
%	O
CI	O
","	O
3.5	O
to	O
6.3	O
months	O
)	O
and	O
9.5	O
months	O
(	O
95	O
%	O
CI	O
","	O
6.9	O
to	O
12.2	O
months	O
)	O
with	O
LV5FU2-cisplatin	B-DRUG
","	O
respectively	O
;	O
and	O
6.9	O
months	O
(	O
95	O
%	O
CI	O
","	O
5.5	O
to	O
8.3	O
months	O
)	O
and	O
11.3	O
months	O
(	O
95	O
%	O
CI	O
","	O
9.3	O
to	O
13.3	O
months	O
)	O
with	O
LV5FU2-irinotecan	B-DRUG
","	O
respectively	O
.	O
	
Of	O
the	O
three	O
regimens	O
tested	O
","	O
the	O
combination	O
of	O
LV5FU2-irinotecan	B-DRUG
is	O
the	O
most	O
promising	O
and	O
will	O
be	O
assessed	O
in	O
a	O
phase	O
III	O
trial	O
.	O
	
Carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
or	O
carboplatin	B-DRUG
/	O
vinorelbine	B-DRUG
followed	O
by	O
accelerated	O
hyperfractionated	O
conformal	O
radiation	O
therapy	O
:	O
report	O
of	O
a	O
prospective	O
phase	O
I	O
dose	O
escalation	O
trial	O
from	O
the	O
Carolina	O
Conformal	O
Therapy	O
Consortium	O
.	O
	
	
To	O
prospectively	O
determine	O
the	O
maximum-tolerated	O
dose	O
of	O
accelerated	O
hyperfractionated	O
conformal	O
radiotherapy	O
(	O
RT	O
;	O
1.6	O
Gy	O
bid	O
)	O
for	O
unresectable	O
locally	B-CANCER
advanced	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
IIB	O
to	O
IIIA	O
/	O
B	O
)	O
following	O
induction	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
(	O
C	O
/	O
T	O
)	O
or	O
carboplatin	B-DRUG
/	O
vinorelbine	B-DRUG
(	O
C	O
/	O
N	O
)	O
.	O
	
Induction	O
chemotherapy	O
","	O
C	O
/	O
T	O
or	O
C	O
/	O
N	O
","	O
was	O
followed	O
by	O
escalating	O
doses	O
of	O
conformally-planned	O
RT	O
(	O
73.6	O
to	O
86.4	O
Gy	O
in	O
6.4-Gy	O
increments	O
)	O
.	O
	
Concurrent	O
boost	O
methods	O
delivered	O
1.6	O
and	O
1.25	O
Gy	O
bid	O
to	O
the	O
gross	O
and	O
clinical	O
target	O
volumes	O
","	O
respectively	O
.	O
	
Between	O
November	O
1997	O
and	O
February	O
2002	O
","	O
44	O
patients	O
were	O
enrolled	O
(	O
median	O
age	O
","	O
59	O
years	O
;	O
59	O
%	O
male	O
;	O
stage	O
III	O
","	O
98	O
%	O
;	O
median	O
tumor	O
size	O
","	O
4	O
cm	O
)	O
.	O
	
Thirty-nine	O
patients	O
completed	O
induction	O
chemotherapy	O
:	O
19	O
had	O
a	O
partial	O
response	O
","	O
seven	O
progressed	O
","	O
15	O
had	O
no	O
response	O
","	O
and	O
three	O
were	O
not	O
assessable	O
.	O
	
Chemotherapy-associated	B-TOXI
toxicities	I-TOXI
were	O
similar	O
in	O
the	O
two	O
chemotherapy	O
groups	O
.	O
	
The	O
incidence	O
of	O
grade	O
&	O
gt	O
;	O
or	O
=	O
3	O
RT-induced	O
toxicity	O
was	O
1	O
/	O
13	O
","	O
2	O
/	O
14	O
","	O
and	O
4	O
/	O
12	O
at	O
73.6	O
","	O
80	O
","	O
and	O
86.4	O
Gy	O
","	O
respectively	O
","	O
thus	O
defining	O
the	O
maximum	O
tolerated	O
dose	O
at	O
approximately	O
80	O
Gy	O
.	O
	
Toxicities	O
were	O
in	O
both	O
lung	O
and	O
esophagus	O
and	O
were	O
similar	O
in	O
the	O
two	O
chemotherapy	O
arms	O
.	O
	
With	O
a	O
median	O
followup	O
of	O
34	O
months	O
in	O
the	O
survivors	O
","	O
the	O
actuarial	O
2-year	O
survival	O
was	O
47	O
%	O
","	O
the	O
median	O
survival	O
was	O
18	O
months	O
.	O
	
Fifteen	O
patients	O
had	O
tumor	B-TOXI
relapse	I-TOXI
:	O
5	O
local	O
failures	O
in	O
the	O
high-dose	O
volume	O
","	O
2	O
regional	O
failures	O
outside	O
of	O
the	O
high-dose	O
volume	O
","	O
and	O
8	O
distant	B-TOXI
metastases	I-TOXI
.	O
	
High-dose	O
conformal	O
twice-daily	O
radiation	O
therapy	O
to	O
approximately	O
80	O
Gy	O
appears	O
tolerable	O
in	O
well-selected	O
patients	O
with	O
unresectable	B-CANCER
lung	I-CANCER
cancer	I-CANCER
following	O
either	O
C	O
/	O
T	O
or	O
C	O
/	O
N.	O
Dose-limiting	O
toxicities	O
are	O
mainly	O
pulmonary	O
and	O
esophageal	O
.	O
	
Results	O
of	O
a	O
planned	O
interim	O
toxicity	O
analysis	O
with	O
trimodality	O
therapy	O
","	O
including	O
carboplatin	B-DRUG
AUC	O
=	O
4	O
","	O
paclitaxel	B-DRUG
","	O
5-fluorouracil	B-DRUG
","	O
amifostine	B-DRUG
","	O
and	O
radiation	O
for	O
locally	B-CANCER
advanced	I-CANCER
esophageal	I-CANCER
cancer	I-CANCER
:	O
preliminary	O
analyses	O
and	O
treatment	O
recommendations	O
from	O
the	O
North	O
Central	O
Cancer	O
Treatment	O
Group	O
.	O
	
	
PURPOSE	O
:	O
An	O
aggressive	O
trimodality	O
approach	O
from	O
the	O
Minnie	O
Pearl	O
Cancer	O
Research	O
Network	O
[	O
carboplatin	B-DRUG
AUC	O
=	O
6	O
","	O
days	O
1	O
and	O
22	O
;	O
5-fluorouracil	B-DRUG
225	O
mg	O
/	O
m2	O
continuous	O
infusion	O
","	O
days	O
1-42	O
","	O
paclitaxel	B-DRUG
200	O
mg	O
/	O
m2	O
","	O
days	O
1	O
and	O
22	O
;	O
45	O
Gy	O
]	O
has	O
resulted	O
in	O
remarkable	O
pathologic	O
response	O
rates	O
but	O
notable	O
toxicity	O
.	O
	
This	O
trial	O
was	O
designed	O
to	O
mitigate	O
this	O
toxicity	O
by	O
starting	O
with	O
a	O
lower	O
carboplatin	B-DRUG
dose	O
","	O
AUC	O
=	O
4	O
","	O
and	O
by	O
adding	O
subcutaneous	O
amifostine	B-DRUG
.	O
	
METHODS	O
:	O
This	O
phase	O
II	O
trial	O
included	O
patients	O
with	O
locally	O
advanced	O
","	O
potentially	O
resectable	O
esophageal	B-CANCER
cancer	I-CANCER
.	O
	
All	O
were	O
to	O
receive	O
the	O
above	O
regimen	O
with	O
modifications	O
of	O
carboplatin	B-DRUG
AUC	O
=	O
4	O
and	O
amifostine	B-DRUG
500	O
mg	O
subcutaneously	O
before	O
radiation	O
.	O
	
All	O
were	O
then	O
to	O
undergo	O
an	O
esophagectomy	O
.	O
	
A	O
planned	O
interim	O
toxicity	O
analysis	O
after	O
the	O
first	O
10	O
patients	O
was	O
to	O
determine	O
whether	O
the	O
carboplatin	B-DRUG
dose	O
should	O
escalate	O
to	O
AUC	O
=	O
6	O
RESULTS	O
:	O
Ten	O
patients	O
were	O
enrolled	O
","	O
and	O
all	O
required	O
dose	O
reductions	O
/	O
omissions	O
during	O
neoadjuvant	O
therapy	O
.	O
	
One	O
patient	O
died	B-TOXI
from	O
paclitaxel	B-DRUG
anaphylaxis	B-TOXI
.	O
	
Six	O
patients	O
manifested	O
a	O
complete	O
pathologic	O
response	O
.	O
	
CONCLUSION	O
:	O
With	O
this	O
regimen	O
","	O
carboplatin	B-DRUG
AUC	O
=	O
4	O
for	O
patients	O
with	O
locally	B-CANCER
advanced	I-CANCER
esophageal	I-CANCER
cancer	I-CANCER
is	O
appropriate	O
.	O
	
A	O
phase	O
IB	O
clinical	O
and	O
pharmacokinetic	O
study	O
of	O
the	O
angiogenesis	O
inhibitor	O
SU5416	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
recurrent	B-CANCER
or	I-CANCER
metastatic	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
	
SU5416	B-DRUG
is	O
a	O
novel	O
small	O
organic	O
molecule	O
that	O
non-competitively	O
inhibits	O
the	O
phosphorylation	O
of	O
the	O
VEGF	O
tyrosine	O
kinase	O
receptor	O
","	O
Flk-1	O
.	O
	
This	O
phase	O
IB	O
study	O
was	O
performed	O
to	O
determine	O
the	O
safety	O
","	O
pharmacokinetics	O
","	O
and	O
preliminary	O
efficacy	O
of	O
the	O
combination	O
of	O
SU5416	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
recurrent	B-CANCER
or	I-CANCER
metastatic	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
Enrolled	O
in	O
the	O
study	O
were	O
12	O
patients	O
with	O
biopsy-proven	O
recurrent	B-CANCER
or	I-CANCER
metastatic	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
Six	O
patients	O
received	O
intravenous	O
SU5416	B-DRUG
110	O
mg	O
/	O
m2	O
on	O
days	O
1	O
","	O
15	O
","	O
18	O
","	O
22	O
and	O
25	O
","	O
and	O
paclitaxel	B-DRUG
70	O
mg	O
/	O
m2	O
on	O
days	O
8	O
","	O
15	O
and	O
22	O
.	O
	
Since	O
two	O
patients	O
experienced	O
a	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
in	O
cohort	O
1	O
","	O
the	O
next	O
six	O
patients	O
received	O
identical	O
treatment	O
as	O
above	O
except	O
the	O
paclitaxel	B-DRUG
dose	O
was	O
reduced	O
to	O
55	O
mg	O
/	O
m2	O
per	O
week	O
.	O
	
A	O
total	O
of	O
42	O
cycles	O
at	O
two	O
different	O
dose	O
levels	O
were	O
given	O
.	O
	
In	O
cohort	O
1	O
there	O
were	O
two	O
deep	O
venous	B-TOXI
thromboses	I-TOXI
that	O
were	O
DLTs	O
.	O
	
In	O
the	O
second	O
cohort	O
there	O
was	O
a	O
DLT	O
consisting	O
of	O
a	O
transient	B-TOXI
ischemic	I-TOXI
attack	O
after	O
receiving	O
SU5416	B-DRUG
.	O
	
Most	O
of	O
the	O
other	O
toxicities	O
seen	O
were	O
grade	O
1	O
or	O
2	O
in	O
nature	O
and	O
consisted	O
of	O
headache	B-TOXI
","	O
facial	B-TOXI
flushing	I-TOXI
","	O
and	O
fatigue	B-TOXI
.	O
	
Two	O
patients	O
developed	O
extensive	O
ulcerative	B-TOXI
cavities	I-TOXI
at	O
sites	O
of	O
prior	O
radiation	O
.	O
	
There	O
were	O
no	O
significant	O
changes	O
in	O
the	O
pharmacokinetic	O
parameters	O
of	O
SU5416	B-DRUG
given	O
with	O
paclitaxel	B-DRUG
.	O
	
Four	O
patients	O
had	O
prolonged	O
freedom	O
from	O
progression	O
of	O
18	O
","	O
28	O
","	O
42	O
","	O
and	O
60	O
weeks	O
duration	O
.	O
	
The	O
combination	O
of	O
SU5416	B-DRUG
with	O
paclitaxel	B-DRUG
had	O
a	O
higher	O
than	O
expected	O
incidence	O
of	O
thromboembolic	B-TOXI
events	I-TOXI
and	O
prophylactic	B-TOXI
anticoagulation	I-TOXI
should	O
be	O
considered	O
for	O
future	O
trials	O
that	O
combine	O
an	O
angiogenesis	O
inhibitor	O
with	O
cytotoxic	O
chemotherapy	O
.	O
	
Although	O
the	O
future	O
development	O
of	O
SU5416	B-DRUG
as	O
a	O
chemotherapeutic	O
agent	O
is	O
unclear	O
","	O
there	O
was	O
a	O
clinical	O
benefit	O
seen	O
with	O
this	O
combination	O
in	O
36	O
%	O
of	O
the	O
patients	O
.	O
	
This	O
trial	O
supports	O
the	O
use	O
of	O
developing	O
antiangiogenic	O
combinations	O
","	O
using	O
molecular	O
targeted	O
agents	O
","	O
in	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
carcinoma	I-CANCER
.	O
	
Results	O
of	O
paclitaxel	B-DRUG
(	O
day	O
1	O
and	O
8	O
)	O
and	O
carboplatin	B-DRUG
given	O
on	O
every	O
three	O
weeks	O
in	O
advanced	O
(	O
stage	O
III-IV	O
)	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
Both	O
paclitaxel	B-DRUG
(	O
P	O
)	O
and	O
carboplatin	B-DRUG
(	O
C	O
)	O
have	O
significant	O
activity	O
in	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
The	O
weekly	O
administration	O
of	O
P	O
is	O
active	O
","	O
dose	O
intense	O
","	O
and	O
has	O
a	O
favorable	O
toxicity	O
profile	O
.	O
	
We	O
retrospectively	O
reviewed	O
the	O
data	O
of	O
51	O
consecutive	O
patients	O
receiving	O
C	O
and	O
day	O
1	O
and	O
8	O
P	O
chemotherapy	O
(	O
CT	O
)	O
regimen	O
in	O
advanced	B-CANCER
stage	I-CANCER
NSCLC	I-CANCER
to	O
evaluate	O
the	O
efficacy	O
and	O
toxicity	O
.	O
	
Patients	O
treated	O
in	O
our	O
institutions	O
having	O
pathologically	O
proven	O
NSCLC	B-CANCER
","	O
no	O
CNS	O
metastases	O
","	O
adequate	O
organ	O
function	O
and	O
performance	O
status	O
(	O
PS	O
)	O
ECOG	O
0-2	O
were	O
given	O
P	O
112.5	O
mg	O
/	O
m2	O
intravenously	O
(	O
IV	O
)	O
over	O
1	O
hour	O
on	O
day	O
1	O
and	O
8	O
","	O
followed	O
by	O
C	O
AUC	O
5	O
IV	O
over	O
1	O
hour	O
","	O
repeated	O
in	O
every	O
three	O
weeks	O
.	O
	
PC	O
was	O
given	O
for	O
maximum	O
of	O
6	O
cycles	O
.	O
	
Median	O
age	O
was	O
58	O
(	O
age	O
range	O
39-77	O
)	O
and	O
41	O
patients	O
(	O
80	O
%	O
)	O
were	O
male	O
.	O
	
PS	O
was	O
0	O
/	O
1	O
/	O
2	O
in	O
29	O
/	O
17	O
/	O
5	O
patients	O
and	O
stage	O
was	O
IIIA	O
/	O
IIIB	O
/	O
IV	O
in	O
3	O
/	O
14	O
/	O
34	O
patients	O
respectively	O
.	O
	
The	O
median	O
number	O
of	O
cycles	O
administered	O
was	O
3	O
(	O
1月6日	O
)	O
.	O
	
Seven	O
patients	O
(	O
14	O
%	O
)	O
did	O
not	O
complete	O
the	O
first	O
3	O
cycles	O
either	O
due	O
to	O
death	B-TOXI
","	O
progression	O
","	O
grade	O
3	O
hypersensitivity	B-TOXI
reactions	I-TOXI
to	O
P	O
or	O
lost	O
to	O
follow	O
up	O
.	O
	
Best	O
evaluable	O
response	O
was	O
partial	O
response	O
(	O
PR	O
)	O
in	O
45	O
%	O
and	O
stable	O
disease	O
(	O
SD	O
)	O
in	O
18	O
%	O
.	O
	
Twelve	O
patients	O
(	O
24	O
%	O
)	O
received	O
local	O
RT.	O
Thirteen	O
patients	O
(	O
25	O
%	O
)	O
received	O
2nd	O
line	O
CT	O
at	O
progression	O
.	O
	
At	O
a	O
median	O
follow-up	O
of	O
7	O
months	O
(	O
range	O
","	O
1月20日	O
)	O
","	O
25	O
(	O
49	O
%	O
)	O
patients	O
died	B-TOXI
and	O
35	O
patients	O
(	O
69	O
%	O
)	O
progressed	O
.	O
	
Median	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
11	O
=+	O
/	O
=-	O
2	O
months	O
(	O
95	O
%	O
CI	O
;	O
6	O
to	O
16	O
)	O
","	O
1-year	O
OS	O
ratio	O
was	O
44	O
%	O
.	O
	
Median	O
time	O
to	O
progression	O
(	O
TTP	O
)	O
was	O
6	O
=+	O
/	O
=-	O
1	O
months	O
(	O
95	O
%	O
CI	O
;	O
4	O
to	O
8	O
)	O
","	O
1-year	O
progression	O
free	O
survival	O
(	O
PFS	O
)	O
ratio	O
was	O
20	O
%	O
.	O
	
We	O
observed	O
following	O
grade	O
3	O
toxicities	O
:	O
asthenia	B-TOXI
(	O
10	O
%	O
)	O
","	O
neuropathy	B-TOXI
(	O
4	O
%	O
)	O
","	O
anorexia	B-TOXI
(	O
4	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
4	O
%	O
)	O
","	O
hypersensitivity	B-TOXI
to	O
P	O
(	O
2	O
%	O
)	O
","	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
(	O
2	O
%	O
)	O
","	O
diarrhea	B-TOXI
(	O
2	O
%	O
)	O
and	O
neutropenia	B-TOXI
(	O
2	O
%	O
)	O
.	O
	
Two	O
patients	O
(	O
4	O
%	O
)	O
died	B-TOXI
of	O
febrile	B-TOXI
neutropenia	I-TOXI
.	O
	
Doses	O
of	O
CT	O
were	O
reduced	O
or	O
delayed	O
in	O
12	O
patients	O
(	O
24	O
%	O
)	O
.	O
	
P	O
on	O
day	O
1	O
and	O
8	O
and	O
C	O
every	O
three	O
weeks	O
is	O
practical	O
and	O
fairly	O
well	O
tolerated	O
outpatient	O
regimen	O
.	O
	
This	O
regimen	O
seems	O
to	O
be	O
comparably	O
active	O
to	O
regimens	O
given	O
once	O
in	O
every	O
three	O
weeks	O
.	O
	
Rituximab	B-DRUG
in	O
combination	O
with	O
fludarabine	B-DRUG
chemotherapy	O
in	O
low-grade	O
or	O
follicular	B-CANCER
lymphoma	I-CANCER
.	O
	
	
To	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
fludarabine	B-DRUG
plus	O
rituximab	B-DRUG
in	O
treatment-naive	O
or	O
relapsed	O
patients	O
with	O
low-grade	O
and	O
/	O
or	O
follicular	O
non-Hodgkin	B-CANCER
's	I-CANCER
lymphoma	I-CANCER
.	O
	
This	O
was	O
an	O
open-label	O
","	O
single-arm	O
","	O
single-center	O
phase	O
II	O
study	O
enrolling	O
40	O
patients	O
.	O
	
During	O
the	O
first	O
week	O
of	O
the	O
study	O
","	O
patients	O
received	O
two	O
infusions	O
of	O
rituximab	B-DRUG
375	O
mg	O
/	O
m2	O
administered	O
4	O
days	O
apart	O
.	O
	
Seventy-two	O
hours	O
after	O
the	O
second	O
infusion	O
of	O
rituximab	B-DRUG
","	O
patients	O
received	O
the	O
first	O
of	O
six	O
cycles	O
of	O
fludarabine	B-DRUG
chemotherapy	O
(	O
25	O
mg	O
/	O
m2	O
/	O
d	O
for	O
5	O
days	O
on	O
a	O
28-day	O
cycle	O
)	O
.	O
	
Single	O
infusions	O
of	O
rituximab	B-DRUG
were	O
administered	O
72	O
hours	O
before	O
the	O
second	O
","	O
fourth	O
","	O
and	O
sixth	O
cycles	O
of	O
fludarabine	B-DRUG
","	O
and	O
two	O
infusions	O
of	O
rituximab	B-DRUG
were	O
given	O
4	O
weeks	O
after	O
the	O
last	O
cycle	O
of	O
fludarabine	B-DRUG
.	O
	
Treatment	O
duration	O
was	O
26	O
weeks	O
.	O
	
An	O
overall	O
response	O
rate	O
of	O
90	O
%	O
(	O
80	O
%	O
complete	O
response	O
rate	O
)	O
was	O
achieved	O
in	O
the	O
intent-to-treat	O
population	O
.	O
	
Similar	O
response	O
rates	O
were	O
seen	O
in	O
treatment-naive	O
and	O
previously	O
treated	O
patients	O
.	O
	
The	O
median	O
duration	O
of	O
response	O
has	O
not	O
been	O
reached	O
at	O
40+	O
months	O
.	O
	
The	O
median	O
follow-up	O
time	O
in	O
this	O
study	O
is	O
44	O
months	O
(	O
range	O
","	O
15	O
to	O
66	O
months	O
)	O
.	O
	
In	O
patients	O
positive	O
for	O
the	O
14	O
;	O
18	O
translocation	B-TOXI
in	I-TOXI
blood	I-TOXI
and	O
/	O
or	O
marrow	O
at	O
enrollment	O
","	O
molecular	O
remission	O
was	O
achieved	O
in	O
88	O
%	O
of	O
cases	O
","	O
with	O
patients	O
remaining	O
negative	O
for	O
up	O
to	O
4	O
years	O
to	O
date	O
.	O
	
Hematologic	B-TOXI
toxicity	I-TOXI
was	O
manageable	O
","	O
and	O
except	O
for	O
a	O
15	O
%	O
incidence	O
of	O
herpes	B-TOXI
simplex	I-TOXI
/	O
zoster	B-TOXI
infections	I-TOXI
","	O
infectious	B-TOXI
complications	I-TOXI
were	O
rare	O
.	O
	
Nonhematologic	B-TOXI
toxicities	I-TOXI
were	O
minimal	O
.	O
	
Rituximab	B-DRUG
plus	O
fludarabine	B-DRUG
was	O
well	O
tolerated	O
and	O
associated	O
with	O
an	O
excellent	O
complete	O
response	O
rate	O
","	O
including	O
molecular	O
remissions	O
","	O
in	O
patients	O
with	O
low-grade	O
or	O
follicular	B-CANCER
lymphoma	I-CANCER
.	O
	
Phase	O
III	O
study	O
of	O
matrix	O
metalloproteinase	O
inhibitor	O
prinomastat	B-DRUG
in	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
Matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
degrade	O
extracellular	O
proteins	O
and	O
facilitate	O
tumor	O
growth	O
","	O
invasion	O
","	O
metastasis	O
","	O
and	O
angiogenesis	O
.	O
	
This	O
trial	O
was	O
undertaken	O
to	O
determine	O
the	O
effect	O
of	O
prinomastat	B-DRUG
","	O
an	O
inhibitor	O
of	O
selected	O
MMPs	O
","	O
on	O
the	O
survival	O
of	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
","	O
when	O
given	O
in	O
combination	O
with	O
gemcitabine-cisplatin	B-DRUG
chemotherapy	O
.	O
	
Chemotherapy-naive	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
prinomastat	B-DRUG
15	O
mg	O
or	O
placebo	B-DRUG
twice	O
daily	O
orally	O
continuously	O
","	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
"1,250"	O
mg	O
/	O
m2	O
days	O
1	O
and	O
8	O
plus	O
cisplatin	B-DRUG
75	O
mg	O
/	O
m2	O
day	O
1	O
","	O
every	O
21	O
days	O
for	O
up	O
to	O
six	O
cycles	O
.	O
	
The	O
planned	O
sample	O
size	O
was	O
420	O
patients	O
.	O
	
Study	O
results	O
at	O
an	O
interim	O
analysis	O
and	O
lack	O
of	O
efficacy	O
in	O
another	O
phase	O
III	O
trial	O
prompted	O
early	O
closure	O
of	O
this	O
study	O
.	O
	
There	O
were	O
362	O
patients	O
randomized	O
(	O
181	O
on	O
prinomastat	B-DRUG
and	O
181	O
on	O
placebo	B-DRUG
)	O
.	O
	
One	O
hundred	O
thirty-four	O
patients	O
had	O
stage	O
IIIB	O
disease	O
with	O
T4	O
primary	O
tumor	O
","	O
193	O
had	O
stage	O
IV	O
disease	O
","	O
and	O
34	O
had	O
recurrent	O
disease	O
(	O
one	O
enrolled	O
patient	O
was	O
ineligible	O
with	O
stage	O
IIIA	O
disease	O
)	O
.	O
	
Overall	O
response	O
rates	O
for	O
the	O
two	O
treatment	O
arms	O
were	O
similar	O
(	O
27	O
%	O
for	O
prinomastat	B-DRUG
v	O
26	O
%	O
for	O
placebo	B-DRUG
;	O
P	O
=	O
0.81	O
)	O
.	O
	
There	O
was	O
no	O
difference	O
in	O
overall	O
survival	O
or	O
time	O
to	O
progression	O
;	O
for	O
prinomastat	B-DRUG
versus	O
placebo	B-DRUG
patients	O
","	O
the	O
median	O
overall	O
survival	O
times	O
were	O
11.5	O
versus	O
10.8	O
months	O
(	O
P	O
=	O
0.82	O
)	O
","	O
1-year	O
survival	O
rates	O
were	O
43	O
%	O
v	O
38	O
%	O
(	O
P	O
=	O
0.45	O
)	O
","	O
and	O
progression-free	O
survival	O
times	O
were	O
6.1	O
v	O
5.5	O
months	O
(	O
P	O
=	O
0.11	O
)	O
","	O
respectively	O
.	O
	
The	O
toxicities	O
of	O
prinomastat	B-DRUG
were	O
arthralgia	B-TOXI
","	O
stiffness	B-TOXI
","	O
and	O
joint	B-TOXI
swelling	I-TOXI
.	O
	
Treatment	O
interruption	O
was	O
required	O
in	O
38	O
%	O
of	O
prinomastat	B-DRUG
patients	O
and	O
12	O
%	O
of	O
placebo	B-DRUG
patients	O
.	O
	
Prinomastat	B-DRUG
does	O
not	O
improve	O
the	O
outcome	O
of	O
chemotherapy	O
in	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
Weekly	O
paclitaxel	B-DRUG
and	O
gemcitabine	B-DRUG
in	O
advanced	B-CANCER
transitional-cell	I-CANCER
carcinoma	I-CANCER
of	O
the	O
urothelium	O
:	O
a	O
phase	O
II	O
Hoosier	O
Oncology	O
Group	O
study	O
.	O
	
	
To	O
evaluate	O
the	O
efficacy	O
and	O
toxicity	O
of	O
weekly	O
paclitaxel	B-DRUG
and	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
transitional-cell	I-CANCER
carcinoma	I-CANCER
(	O
TCC	B-CANCER
)	O
of	O
the	O
urothelial	O
tract	O
.	O
	
Patients	O
with	O
advanced	O
unresectable	O
TCC	B-CANCER
were	O
enrolled	O
onto	O
this	O
multicenter	O
","	O
community-based	O
","	O
phase	O
II	O
trial	O
.	O
	
Initially	O
","	O
patients	O
were	O
treated	O
with	O
paclitaxel	B-DRUG
110	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
by	O
intravenous	O
infusion	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
every	O
28	O
days	O
.	O
	
Patients	O
who	O
had	O
an	O
objective	O
response	O
or	O
stable	O
disease	O
continued	O
treatment	O
for	O
a	O
maximum	O
of	O
six	O
courses	O
.	O
	
Paclitaxel	B-DRUG
was	O
decreased	O
to	O
90	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
gemcitabine	B-DRUG
was	O
decreased	O
to	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
the	O
last	O
12	O
patients	O
because	O
of	O
a	O
concerning	O
incidence	O
of	O
pulmonary	B-TOXI
toxicity	I-TOXI
in	O
the	O
first	O
24	O
patients	O
.	O
	
Thirty-six	O
patients	O
were	O
enrolled	O
between	O
September	O
1998	O
and	O
March	O
2003	O
.	O
	
Twenty-four	O
patients	O
received	O
the	O
higher	O
doses	O
of	O
paclitaxel	B-DRUG
and	O
gemcitabine	B-DRUG
","	O
and	O
12	O
patients	O
received	O
the	O
lower	O
doses	O
.	O
	
Twenty-five	O
(	O
69.4	O
%	O
)	O
of	O
36	O
patients	O
had	O
major	O
responses	O
to	O
treatment	O
","	O
including	O
15	O
patients	O
(	O
41.7	O
%	O
)	O
with	O
complete	O
responses	O
.	O
	
With	O
a	O
median	O
follow-up	O
time	O
of	O
38.7	O
months	O
","	O
the	O
median	O
survival	O
time	O
was	O
15.8	O
months	O
.	O
	
Grade	O
3	O
and	O
4	O
toxicities	O
included	O
granulocytopenia	B-TOXI
(	O
36.1	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
8.3	O
%	O
)	O
","	O
and	O
neuropathy	B-TOXI
(	O
16.7	O
%	O
)	O
.	O
	
Five	O
patients	O
(	O
13.9	O
%	O
)	O
had	O
grades	O
3	O
to	O
5	O
pulmonary	B-TOXI
toxicity	I-TOXI
","	O
and	O
one	O
patient	O
had	O
grade	O
2	O
pulmonary	B-TOXI
toxicity	I-TOXI
.	O
	
Weekly	O
paclitaxel	B-DRUG
and	O
gemcitabine	B-DRUG
is	O
an	O
active	O
regimen	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
advanced	B-CANCER
TCC	I-CANCER
.	O
	
However	O
","	O
because	O
of	O
the	O
high	O
incidence	O
of	O
pulmonary	B-TOXI
toxicity	I-TOXI
associated	O
with	O
this	O
schedule	O
of	O
paclitaxel	B-DRUG
and	O
gemcitabine	B-DRUG
","	O
we	O
recommend	O
against	O
the	O
use	O
of	O
this	O
regimen	O
in	O
this	O
patient	O
population	O
.	O
	
Irinotecan	B-DRUG
plus	O
oxaliplatin	B-DRUG
and	O
leucovorin-modulated	B-DRUG
fluorouracil	I-DRUG
in	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
=--	O
a	O
Groupe	O
Tumeurs	O
Digestives	O
of	O
the	O
Federation	O
Nationale	O
des	O
Centres	O
de	O
Lutte	O
Contre	O
le	O
Cancer	O
study	O
.	O
	
	
To	O
evaluate	O
response	O
rate	O
and	O
toxicity	O
of	O
irinotecan	B-DRUG
and	O
oxaliplatin	B-DRUG
plus	O
fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
and	O
leucovorin	B-DRUG
(	O
Folfirinox	B-DRUG
)	O
in	O
advanced	B-CANCER
pancreatic	I-CANCER
adenocarcinoma	I-CANCER
(	O
APA	B-CANCER
)	O
.	O
	
Chemotherapy-naive	O
patients	O
with	O
histologically	O
proven	O
APA	B-CANCER
and	O
bidimensionally	O
measurable	O
disease	O
were	O
treated	O
with	O
Folfirinox	B-DRUG
therapy	O
every	O
2	O
weeks	O
","	O
which	O
comprised	O
oxaliplatin	B-DRUG
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
irinotecan	B-DRUG
180	O
mg	O
/	O
m	O
(	O
2	O
)	O
plus	O
leucovorin	B-DRUG
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
followed	O
by	O
bolus	O
FU	B-DRUG
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
","	O
then	O
FU	B-DRUG
"2,400"	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
46-hour	O
continuous	O
infusion	O
.	O
	
Quality	O
of	O
life	O
(	O
QOL	O
)	O
was	O
assessed	O
using	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
C30	O
(	O
EORTC	O
QLQ-C30	O
)	O
.	O
	
Forty-seven	O
patients	O
were	O
entered	O
","	O
and	O
46	O
received	O
treatment	O
.	O
	
Thirty-five	O
patients	O
(	O
76	O
%	O
)	O
had	O
metastatic	O
disease	O
.	O
	
A	O
total	O
of	O
356	O
cycles	O
were	O
delivered	O
","	O
with	O
a	O
median	O
of	O
eight	O
cycles	O
per	O
patient	O
(	O
range	O
","	O
one	O
to	O
24	O
cycles	O
)	O
.	O
	
All	O
patients	O
were	O
assessable	O
for	O
safety	O
.	O
	
No	O
toxic	B-TOXI
death	I-TOXI
occurred	O
.	O
	
Grade	O
3	O
to	O
4	O
neutropenia	B-TOXI
occurred	O
in	O
52	O
%	O
of	O
patients	O
","	O
including	O
two	O
patients	O
with	O
febrile	B-TOXI
neutropenia	I-TOXI
.	O
	
Other	O
relevant	O
toxicities	O
included	O
grade	O
3	O
to	O
4	O
nausea	B-TOXI
(	O
20	O
%	O
)	O
","	O
vomiting	B-TOXI
(	O
17	O
%	O
)	O
","	O
and	O
diarrhea	B-TOXI
(	O
17	O
%	O
)	O
and	O
grade	O
3	O
neuropathy	B-TOXI
(	O
15	O
%	O
;	O
Levi	O
's	O
scale	O
)	O
.	O
	
The	O
confirmed	O
response	O
rate	O
was	O
26	O
%	O
(	O
95	O
%	O
CI	O
","	O
13	O
%	O
to	O
39	O
%	O
)	O
","	O
including	O
4	O
%	O
complete	O
responses	O
.	O
	
Median	O
time	O
to	O
progression	O
was	O
8.2	O
months	O
(	O
95	O
%	O
CI	O
","	O
5.3	O
to	O
11.6	O
months	O
)	O
","	O
and	O
median	O
overall	O
survival	O
was	O
10.2	O
months	O
(	O
95	O
%	O
CI	O
","	O
8.1	O
to	O
14.4	O
months	O
)	O
.	O
	
Between	O
baseline	O
and	O
end	O
of	O
treatment	O
","	O
patients	O
had	O
improvement	O
in	O
all	O
functional	O
scales	O
of	O
the	O
EORTC	O
QLQ-C30	O
","	O
except	O
cognitive	O
functioning	O
.	O
	
Responders	O
had	O
major	O
improvement	O
in	O
global	O
QOL	O
.	O
	
With	O
a	O
good	O
safety	O
profile	O
","	O
a	O
promising	O
response	O
rate	O
","	O
and	O
an	O
improvement	O
in	O
QOL	O
","	O
Folfirinox	B-DRUG
will	O
be	O
further	O
assessed	O
in	O
a	O
phase	O
III	O
trial	O
.	O
	
Docetaxel	B-DRUG
(	O
Taxotere	B-DRUG
)	O
","	O
cisplatin	B-DRUG
","	O
UFT	B-DRUG
","	O
and	O
leucovorin	B-DRUG
combination	O
chemotherapy	O
in	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
	
We	O
conducted	O
this	O
study	O
to	O
ascertain	O
the	O
efficacy	O
and	O
toxicity	O
of	O
docetaxel	B-DRUG
and	O
cisplatin	B-DRUG
combined	O
with	O
oral	O
UFT	B-DRUG
and	O
leucovorin	B-DRUG
as	O
a	O
first-line	O
treatment	O
for	O
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
In	O
all	O
","	O
52	O
patients	O
received	O
courses	O
of	O
docetaxel	B-DRUG
60	O
mg	O
m	O
(	O
-2	O
)	O
intravenously	O
(	O
i.v.	O
)	O
for	O
1	O
h	O
and	O
then	O
cisplatin	B-DRUG
75	O
mg	O
m	O
(	O
-2	O
)	O
i.v.	O
for	O
2	O
h	O
on	O
day	O
1	O
Oral	O
UFT	B-DRUG
at	O
400-600	O
mg	O
day	O
(	O
-1	O
)	O
","	O
as	O
determined	O
by	O
body	O
surface	O
area	O
","	O
and	O
leucovorin	B-DRUG
at	O
75	O
mg	O
day	O
(	O
-1	O
)	O
were	O
administered	O
for	O
21	O
consecutive	O
days	O
from	O
day	O
1	O
","	O
and	O
this	O
was	O
followed	O
by	O
a	O
7-day	O
drug-free	O
interval	O
.	O
	
A	O
total	O
of	O
225	O
courses	O
were	O
administered	O
","	O
and	O
the	O
median	O
number	O
of	O
courses	O
per	O
patient	O
was	O
four	O
.	O
	
Four	O
complete	O
responses	O
(	O
7.7	O
%	O
)	O
and	O
22	O
partial	O
responses	O
(	O
42.3	O
%	O
)	O
were	O
achieved	O
","	O
giving	O
an	O
overall	O
response	O
rate	O
of	O
50	O
%	O
(	O
95	O
%	O
Confidence	O
Interval	O
:	O
36.4-63.6	O
%	O
)	O
.	O
	
The	O
major	O
toxicity	O
was	O
neutropenia	B-TOXI
","	O
which	O
reached	O
grade	O
3	O
/	O
4	O
in	O
36	O
patients	O
(	O
69.3	O
%	O
)	O
.	O
	
Grade	O
3	O
/	O
4	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
was	O
observed	O
in	O
12	O
patients	O
(	O
23.1	O
%	O
)	O
.	O
	
Median	O
time	O
to	O
progression	O
was	O
22	O
weeks	O
(	O
4	O
to	O
156+	O
weeks	O
)	O
","	O
median	O
survival	O
duration	O
was	O
48	O
weeks	O
(	O
4	O
to	O
156+	O
weeks	O
)	O
","	O
and	O
median	O
response	O
duration	O
was	O
24	O
weeks	O
(	O
6-152	O
weeks	O
)	O
.	O
	
We	O
conclude	O
that	O
docetaxel	B-DRUG
","	O
cisplatin	B-DRUG
","	O
oral	O
UFT	B-DRUG
","	O
and	O
leucovorin	B-DRUG
combination	O
chemotherapy	O
is	O
effective	O
and	O
tolerable	O
for	O
the	O
treatment	O
of	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
The	O
evaluation	O
of	O
amifostine	B-DRUG
for	O
mucosal	O
protection	O
in	O
patients	O
with	O
advanced	B-CANCER
loco-regional	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinomas	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	O
SCCHN	B-CANCER
)	O
treated	O
with	O
concurrent	O
weekly	O
carboplatin	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
and	O
daily	O
radiotherapy	O
(	O
RT	O
)	O
.	O
	
	
Concurrent	O
chemotherapy	O
and	O
radiation	O
has	O
improved	O
the	O
outcome	O
for	O
patients	O
presenting	O
with	O
locally	O
advanced	B-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinomas	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	O
SCCHN	B-CANCER
)	O
.	O
	
These	O
improvements	O
have	O
come	O
at	O
a	O
cost	O
of	O
increased	O
treatment-related	O
toxicities	O
.	O
	
We	O
previously	O
reported	O
the	O
results	O
of	O
a	O
phase	O
II	O
trial	O
examining	O
the	O
role	O
of	O
concurrent	O
carboplatin	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
and	O
daily	O
radiotherapy	O
(	O
RT	O
)	O
in	O
SCCHN	B-CANCER
.	O
	
In	O
an	O
attempt	O
to	O
decrease	O
these	O
side	O
effects	O
","	O
we	O
conducted	O
a	O
prospective	O
phase	O
II	O
trial	O
evaluating	O
the	O
role	O
of	O
amifostine	B-DRUG
(	O
Ethyol	O
","	O
MedImmune	O
Oncology	O
","	O
Inc	O
","	O
Gaithersburg	O
","	O
MD	O
)	O
in	O
patients	O
treated	O
with	O
this	O
concurrent	O
chemoRT	O
scheme	O
.	O
	
From	O
April	O
2002	O
to	O
September	O
2004	O
","	O
19	O
patients	O
with	O
stage	O
III-IV	O
SCCHN	B-CANCER
were	O
enrolled	O
on	O
a	O
prospective	O
phase	O
II	O
trial	O
.	O
	
Treatment	O
consisted	O
of	O
daily	O
RT	O
delivered	O
to	O
70.2	O
Gy	O
(	O
1.8	O
Gy	O
/	O
fx	O
)	O
with	O
amifostine	B-DRUG
500	O
mg	O
IV	O
(	O
&	O
lt	O
;	O
1	O
hour	O
before	O
RT	O
)	O
","	O
and	O
concurrent	O
weekly	O
carboplatin	B-DRUG
(	O
100	O
mg	O
/	O
m2	O
)	O
and	O
paclitaxel	B-DRUG
(	O
40	O
mg	O
/	O
m2	O
)	O
.	O
	
Median	O
age	O
was	O
58.5	O
years	O
(	O
range	O
","	O
48	O
to	O
70	O
years	O
)	O
;	O
male	O
to	O
female	O
ratio	O
was	O
","	O
83	O
%	O
:17	O
%	O
;	O
Caucasian	O
versus	O
other	O
was	O
","	O
61	O
%	O
/	O
39	O
%	O
.	O
	
Tumor	O
characteristics	O
based	O
on	O
histology	O
were	O
:	O
primary	O
cancers	B-CANCER
of	I-CANCER
the	I-CANCER
oropharynx	I-CANCER
(	O
55.6	O
%	O
)	O
;	O
supraglottic	B-CANCER
larynx	I-CANCER
(	O
16.7	O
%	O
)	O
;	O
hypopharynx	O
(	O
16.7	O
%	O
)	O
;	O
oral	B-TOXI
cavity	I-TOXI
(	O
5.6	O
%	O
)	O
;	O
and	O
unknown	O
primaries	O
(	O
5.6	O
%	O
)	O
.	O
	
All	O
patients	O
presented	O
with	O
locally	O
advanced	O
","	O
unresectable	O
disease	O
T4	O
(	O
50	O
%	O
)	O
","	O
T3	O
(	O
27.8	O
%	O
)	O
","	O
and	O
advanced	B-CANCER
nodal	I-CANCER
disease	I-CANCER
(	O
N2b-N3	O
)	O
(	O
78	O
%	O
)	O
.	O
	
Toxicities	O
were	O
measured	O
weekly	O
during	O
treatment	O
and	O
at	O
each	O
follow-up	O
visit	O
.	O
	
Disease	O
response	O
to	O
therapy	O
was	O
determined	O
2	O
months	O
after	O
completion	O
of	O
therapy	O
.	O
	
Seventeen	O
patients	O
are	O
evaluable	O
for	O
response	O
and	O
survival	O
at	O
2	O
months	O
following	O
completion	O
of	O
RT.	O
Eighty-four	O
percent	O
completed	O
the	O
prescribed	O
radiation	O
treatment	O
","	O
and	O
84	O
%	O
of	O
patients	O
received	O
more	O
than	O
six	O
cycles	O
of	O
chemotherapy	O
.	O
	
The	O
median	O
number	O
of	O
missed	O
chemotherapy	O
cycles	O
was	O
1.5	O
(	O
range	O
","	O
0	O
to	O
5	O
cycles	O
)	O
.	O
	
Fifty-six	O
percent	O
of	O
patients	O
received	O
more	O
than	O
90	O
%	O
of	O
prescribed	O
amifostine	B-DRUG
doses	O
","	O
with	O
chemoRT-related	O
toxicity	O
being	O
the	O
most	O
common	O
reason	O
for	O
withholding	O
the	O
dose	O
(	O
77	O
%	O
)	O
.	O
	
Median	O
doses	O
of	O
missed	O
amifostine	B-DRUG
were	O
three	O
(	O
range	O
","	O
0	O
to	O
30	O
doses	O
)	O
.	O
	
Grade	O
3	O
toxicities	O
associated	O
with	O
therapy	O
were	O
:	O
mucositis	B-TOXI
and	O
dysphagia	B-TOXI
(	O
40	O
%	O
of	O
patients	O
each	O
)	O
","	O
dehydration	B-TOXI
(	O
27	O
%	O
)	O
","	O
xerostomia	B-TOXI
(	O
20	O
%	O
)	O
","	O
and	O
dermatitis	B-TOXI
(	O
20	O
%	O
)	O
;	O
53	O
%	O
of	O
patients	O
experienced	O
grade	O
3	O
leukopenia	B-TOXI
","	O
while	O
grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
developed	O
in	O
20	O
%	O
/	O
13	O
%	O
.	O
	
No	O
grade	O
4	O
/	O
5	O
nonhematologic	B-TOXI
toxicities	I-TOXI
were	O
encountered	O
.	O
	
Forty	O
percent	O
of	O
patients	O
completed	O
RT	O
without	O
unscheduled	O
treatment	O
breaks	O
secondary	O
to	O
treatment-related	O
toxicity	O
.	O
	
Median	O
treatment-break	O
time	O
was	O
5	O
days	O
(	O
range	O
","	O
0	O
to	O
20	O
days	O
)	O
.	O
	
Clinical	O
complete	O
response	O
at	O
both	O
the	O
primary	O
site	O
of	O
disease	O
and	O
neck	O
was	O
achieved	O
in	O
75	O
%	O
of	O
patients	O
2	O
months	O
following	O
completion	O
of	O
RT.	O
Weekly	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
administered	O
concurrently	O
with	O
definitive	O
RT	O
and	O
daily	O
amifostine	O
is	O
well	O
tolerated	O
","	O
with	O
over	O
85	O
%	O
of	O
patients	O
completing	O
therapy	O
with	O
acceptable	O
toxicity	O
.	O
	
The	O
addition	O
of	O
amifostine	B-DRUG
appears	O
to	O
decrease	O
treatment-related	O
toxicity	O
without	O
impacting	O
efficacy	O
.	O
	
Initial	O
experience	O
from	O
a	O
combination	O
of	O
systemic	O
and	O
regional	O
chemotherapy	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
nonresectable	O
cholangiocellular	B-CANCER
carcinoma	I-CANCER
in	O
the	O
liver	O
.	O
	
	
In	O
nonresectable	O
cholangiocellular	B-CANCER
carcinoma	I-CANCER
(	O
CCC	O
)	O
therapeutic	O
options	O
are	O
limited	O
.	O
	
Recently	O
","	O
systemic	O
chemotherapy	O
has	O
shown	O
response	O
rates	O
of	O
up	O
to	O
30	O
%	O
.	O
	
Additional	O
regional	O
therapy	O
of	O
the	O
arterially	O
hyper	O
vascularized	O
hepatic	B-CANCER
tumors	I-CANCER
might	O
represent	O
a	O
rational	O
approach	O
in	O
an	O
attempt	O
to	O
further	O
improve	O
response	O
and	O
palliation	O
.	O
	
Hence	O
","	O
a	O
protocol	O
combining	O
transarterial	O
chemoembolization	O
and	O
systemic	O
chemotherapy	O
was	O
applied	O
in	O
patients	O
with	O
CCC	O
limited	O
to	O
the	O
liver	O
.	O
	
Eight	O
patients	O
(	O
6	O
women	O
","	O
2	O
men	O
","	O
mean	O
age	O
62	O
years	O
)	O
with	O
nonresectable	O
CCC	O
received	O
systemic	O
chemotherapy	O
(	O
gemcitabine	B-DRUG
1	O
0	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
additional	O
transarterial	O
chemoembolization	O
procedures	O
(	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
cisplatin	B-DRUG
","	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
doxorubicin	B-DRUG
","	O
up	O
to	O
600	O
mg	O
degradable	O
starch	O
microspheres	O
)	O
.	O
	
Clinical	O
follow-up	O
of	O
patients	O
","	O
tumor	O
markers	O
","	O
CT	O
and	O
ultrasound	O
were	O
performed	O
to	O
evaluate	O
maximum	O
response	O
and	O
toxicity	O
.	O
	
Both	O
systemic	O
and	O
regional	O
therapies	O
were	O
tolerated	O
well	O
;	O
no	O
severe	B-TOXI
toxicity	I-TOXI
(	O
WHO	O
III	O
/	O
IV	O
)	O
was	O
encountered	O
.	O
	
Nausea	B-TOXI
and	O
fever	B-TOXI
were	O
the	O
most	O
commonly	O
observed	O
side	O
effects	O
.	O
	
A	O
progressive	O
rarefication	O
of	O
the	O
intrahepatic	O
arteries	O
limited	O
the	O
maximum	O
number	O
of	O
chemoembolization	O
procedures	O
in	O
4	O
patients	O
.	O
	
A	O
median	O
of	O
2	O
chemoembolization	O
cycles	O
(	O
range	O
","	O
1月3日	O
)	O
and	O
a	O
median	O
of	O
6.5	O
gemcitabine	B-DRUG
cycles	O
(	O
range	O
","	O
4月11日	O
)	O
were	O
administered	O
.	O
	
Complete	O
responses	O
were	O
not	O
achieved	O
.	O
	
As	O
maximum	O
response	O
","	O
partial	O
responses	O
were	O
achieved	O
in	O
3	O
cases	O
","	O
stable	O
diseases	O
in	O
5	O
cases	O
.	O
	
Two	O
patients	O
died	B-TOXI
from	O
progressive	O
disease	O
after	O
9	O
and	O
10	O
mo.	O
Six	O
patients	O
are	O
still	O
alive	O
.	O
	
The	O
current	O
median	O
survival	O
is	O
12	O
mo	O
(	O
range	O
","	O
9月18日	O
)	O
;	O
the	O
median	O
time	O
to	O
tumor	O
progression	O
is	O
7	O
mo	O
(	O
range	O
","	O
3月18日	O
)	O
.	O
	
Seven	O
patients	O
suffered	O
from	O
tumor-related	O
symptoms	O
prior	O
to	O
therapy	O
","	O
3	O
of	O
these	O
experienced	O
a	O
treatment-related	O
clinical	O
relief	O
.	O
	
In	O
one	O
patient	O
the	O
tumor	O
became	O
resectable	O
under	O
therapy	O
and	O
was	O
successfully	O
removed	O
after	O
10	O
mo.	O
The	O
present	O
results	O
indicate	O
that	O
a	O
combination	O
of	O
systemic	O
gemcitabine	B-DRUG
therapy	O
and	O
repeated	O
regional	O
chemoembolizations	O
is	O
well	O
tolerated	O
and	O
may	O
enhance	O
the	O
effect	O
of	O
palliation	O
in	O
a	O
selected	O
group	O
of	O
patients	O
with	O
intrahepatic	O
nonresectable	O
CCC	O
.	O
	
Australian	O
experience	O
of	O
a	O
modified	O
schedule	O
of	O
FOLFOX	B-DRUG
with	O
high	O
activity	O
and	O
tolerability	O
and	O
improved	O
convenience	O
in	O
untreated	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
patients	O
.	O
	
	
This	O
study	O
determined	O
the	O
efficacy	O
and	O
safety	O
of	O
a	O
modified	O
FOLFOX	B-DRUG
regimen	O
that	O
improved	O
patient	O
convenience	O
without	O
compromising	O
oxaliplatin	B-DRUG
dose	O
intensity	O
.	O
	
A	O
total	O
of	O
62	O
patients	O
with	O
previously	O
untreated	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
were	O
enrolled	O
to	O
receive	O
","	O
entirely	O
as	O
outpatients	O
","	O
2-weekly	O
cycles	O
of	O
oxaliplatin	B-DRUG
100	O
mg	O
m	O
(	O
-2	O
)	O
i.v.	O
over	O
2	O
h	O
","	O
together	O
with	O
leucovorin	B-DRUG
400	O
mg	O
m	O
(	O
-2	O
)	O
over	O
2	O
h	O
","	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
400	O
mg	O
m	O
(	O
-2	O
)	O
","	O
bolus	O
","	O
followed	O
by	O
a	O
46-h	O
infusion	O
of	O
5-FU	B-DRUG
at	O
2.4	O
g	O
m	O
(	O
-2	O
)	O
.	O
	
Treatment	O
was	O
given	O
until	O
progression	O
or	O
unmanageable	O
toxicity	O
.	O
	
In	O
all	O
","	O
61	O
patients	O
received	O
&	O
gt	O
;	O
or	O
#NAME?	O
oxaliplatin	B-DRUG
dose	O
and	O
a	O
median	O
of	O
11	O
treatment	O
cycles	O
(	O
range	O
1月20日	O
cycles	O
)	O
;	O
22	O
(	O
36	O
%	O
)	O
reported	O
grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
and	O
13	O
patients	O
(	O
21	O
%	O
)	O
experienced	O
grade	O
3	O
neurotoxicity	B-TOXI
;	O
16	O
patients	O
(	O
26	O
%	O
)	O
discontinued	O
treatment	O
due	O
to	O
disease	O
progression	O
or	O
death	B-TOXI
","	O
15	O
(	O
25	O
%	O
)	O
due	O
to	O
neurotoxicity	B-TOXI
and	O
six	O
(	O
10	O
%	O
)	O
due	O
to	O
haematological	B-TOXI
toxicity	I-TOXI
.	O
	
Of	O
the	O
56	O
eligible	O
patients	O
","	O
complete	O
or	O
partial	O
responses	O
were	O
observed	O
in	O
29	O
or	O
52	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
38-65	O
%	O
)	O
.	O
	
Median	O
progression-free	O
survival	O
was	O
8.2	O
months	O
(	O
7.1-9.9	O
)	O
and	O
median	O
overall	O
survival	O
was	O
18.7	O
months	O
(	O
14.0-23.4	O
)	O
.	O
	
In	O
our	O
experience	O
","	O
a	O
modified	O
schedule	O
of	O
FOLFOX	B-DRUG
improves	O
convenience	O
without	O
compromising	O
efficacy	O
or	O
toxicity	O
.	O
	
Chemoimmunotherapy	O
with	O
fludarabine	B-DRUG
","	O
cyclophosphamide	B-DRUG
","	O
and	O
rituximab	B-DRUG
for	O
relapsed	O
and	O
refractory	O
chronic	B-CANCER
lymphocytic	I-CANCER
leukemia	I-CANCER
.	O
	
	
The	O
efficacy	O
","	O
toxicity	O
","	O
and	O
tolerability	O
of	O
chemoimmunotherapy	O
with	O
the	O
combination	O
of	O
fludarabine	B-DRUG
","	O
cyclophosphamide	B-DRUG
","	O
and	O
rituximab	B-DRUG
(	O
FCR	B-DRUG
)	O
were	O
evaluated	O
in	O
previously	O
treated	O
patients	O
with	O
chronic	B-CANCER
lymphocytic	I-CANCER
leukemia	I-CANCER
(	O
CLL	B-CANCER
)	O
.	O
	
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
improve	O
the	O
complete	O
remission	O
(	O
CR	O
)	O
rate	O
for	O
previously	O
treated	O
patients	O
and	O
evaluate	O
the	O
quality	O
of	O
bone	O
marrow	O
response	O
.	O
	
One	O
hundred	O
seventy-seven	O
previously	O
treated	O
patients	O
with	O
CLL	B-CANCER
were	O
evaluated	O
.	O
	
Treatment	O
consisted	O
of	O
rituximab	B-DRUG
375	O
mg	O
/	O
m	O
(	O
2	O
)	O
day	O
1	O
of	O
course	O
1	O
and	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
day	O
1	O
of	O
courses	O
2	O
to	O
6	O
;	O
fludarabine	B-DRUG
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d	O
days	O
2	O
to	O
4	O
of	O
course	O
1	O
and	O
days	O
1	O
to	O
3	O
of	O
courses	O
2	O
to	O
6	O
;	O
and	O
cyclophosphamide	B-DRUG
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d	O
days	O
2	O
to	O
4	O
of	O
course	O
1	O
and	O
days	O
1	O
to	O
3	O
of	O
courses	O
2	O
to	O
6	O
Courses	O
were	O
repeated	O
every	O
4	O
weeks	O
.	O
	
CR	O
was	O
achieved	O
in	O
25	O
%	O
of	O
177	O
patients	O
","	O
and	O
nodular	O
partial	O
remission	O
and	O
partial	O
remission	O
were	O
achieved	O
in	O
16	O
%	O
and	O
32	O
%	O
of	O
patients	O
","	O
respectively	O
;	O
the	O
overall	O
response	O
rate	O
was	O
73	O
%	O
.	O
	
Twelve	O
(	O
32	O
%	O
)	O
of	O
37	O
complete	O
responders	O
tested	O
achieved	O
molecular	O
remission	O
in	O
bone	O
marrow	O
.	O
	
Univariate	O
and	O
multivariate	O
analyses	O
were	O
used	O
to	O
identify	O
pretreatment	O
patient	O
characteristics	O
associated	O
with	O
CR	O
and	O
overall	O
remission	O
","	O
longer	O
time	O
to	O
progression	O
","	O
and	O
overall	O
survival	O
.	O
	
The	O
FCR	B-DRUG
regimen	O
was	O
an	O
active	O
and	O
well-tolerated	O
treatment	O
for	O
previously	O
treated	O
patients	O
with	O
CLL	B-CANCER
.	O
	
Myelosuppression	B-TOXI
was	O
the	O
most	O
common	O
toxicity	O
.	O
	
FCR	B-DRUG
induced	O
the	O
highest	O
CR	O
rate	O
reported	O
in	O
a	O
clinical	O
trial	O
of	O
previously	O
treated	O
patients	O
with	O
CLL	B-CANCER
.	O
	
Furthermore	O
","	O
molecular	O
remissions	O
were	O
achieved	O
in	O
a	O
third	O
of	O
patients	O
achieving	O
CR	O
.	O
	
Mitomycin-C	B-DRUG
and	O
capecitabine	B-DRUG
as	O
third-line	O
chemotherapy	O
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
:	O
a	O
phase	O
II	O
study	O
.	O
	
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
therapeutic	O
value	O
and	O
safety	O
of	O
third-line	O
treatment	O
with	O
mitomycin-C	B-DRUG
(	O
MMC	B-DRUG
)	O
and	O
capecitabine	B-DRUG
(	O
Xeloda	B-DRUG
)	O
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
pretreated	O
with	O
combination	O
regimens	O
including	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
folinic	B-DRUG
acid	I-DRUG
(	O
FA	B-DRUG
)	O
and	O
irinotecan	B-DRUG
(	O
CPT-11	B-DRUG
)	O
or	O
5-FU	B-DRUG
","	O
FA	B-DRUG
and	O
oxaliplatin	B-DRUG
(	O
L-OHP	B-DRUG
)	O
.	O
	
A	O
total	O
of	O
21	O
patients	O
(	O
M	O
/	O
F	O
16	O
/	O
5	O
","	O
median	O
age	O
60	O
years	O
)	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
","	O
all	O
of	O
whom	O
had	O
developed	O
progressive	O
disease	O
while	O
receiving	O
or	O
within	O
6	O
months	O
of	O
discontinuing	O
two	O
sequential	O
chemotherapy	O
lines	O
with	O
5-FU	B-DRUG
","	O
FA	B-DRUG
and	O
CPT-11	B-DRUG
or	O
5-FU	B-DRUG
","	O
FA	B-DRUG
and	O
L-OHP	B-DRUG
","	O
were	O
accrued	O
to	O
this	O
study	O
.	O
	
At	O
the	O
time	O
of	O
their	O
relapse	O
or	O
progression	O
","	O
cytotoxic	O
chemotherapy	O
","	O
consisting	O
of	O
intravenous	O
MMC	B-DRUG
7	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
therapeutic	O
day	O
1	O
plus	O
oral	O
capecitabine	B-DRUG
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
daily	O
on	O
days	O
1月14日	O
","	O
was	O
initiated	O
.	O
	
After	O
rest	O
for	O
7	O
days	O
","	O
capecitabine	B-DRUG
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
daily	O
was	O
administered	O
on	O
days	O
22-35	O
followed	O
by	O
7	O
days	O
rest	O
.	O
	
Treatment	O
courses	O
were	O
repeated	O
every	O
6	O
weeks	O
unless	O
there	O
was	O
evidence	O
of	O
progressive	O
disease	O
","	O
unacceptable	O
toxicity	O
or	O
patient	O
refusal	O
of	O
treatment	O
.	O
	
All	O
the	O
patients	O
were	O
assessable	O
for	O
toxicity	O
and	O
19	O
for	O
response	O
.	O
	
The	O
median	O
number	O
cycles	O
of	O
chemotherapy	O
was	O
two	O
(	O
range	O
one	O
to	O
four	O
)	O
.	O
	
Only	O
1	O
patient	O
(	O
4.8	O
%	O
)	O
had	O
a	O
partial	O
response	O
","	O
4	O
patients	O
(	O
19	O
%	O
)	O
had	O
stable	O
disease	O
","	O
and	O
14	O
patients	O
(	O
66.7	O
%	O
)	O
progressed	O
.	O
	
The	O
median	O
follow-up	O
period	O
was	O
7.3	O
months	O
and	O
median	O
time	O
to	O
progression	O
was	O
2.6	O
months	O
.	O
	
The	O
median	O
overall	O
survival	O
was	O
6.8	O
months	O
.	O
	
No	O
toxic	B-TOXI
deaths	I-TOXI
occurred	O
.	O
	
Toxicities	O
of	O
third-line	O
treatment	O
were	O
mild	O
and	O
manageable	O
.	O
	
As	O
NCI	O
/	O
NIH	O
common	O
toxicity	O
criteria	O
","	O
grade	O
3	O
/	O
4	O
anemia	B-TOXI
","	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
occurred	O
in	O
two	O
","	O
one	O
and	O
one	O
patients	O
","	O
respectively	O
.	O
	
Our	O
findings	O
suggest	O
that	O
the	O
combination	O
of	O
MMC	B-DRUG
and	O
capecitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
pretreated	O
with	O
combination	O
regimens	O
including	O
5-FU	B-DRUG
","	O
FA	B-DRUG
and	O
CPT-11	B-DRUG
or	O
5-FU	B-DRUG
","	O
FA	B-DRUG
and	O
L-OHP	B-DRUG
is	O
safe	O
.	O
	
However	O
","	O
this	O
regimen	O
had	O
a	O
poor	O
response	O
rate	O
and	O
no	O
definitive	O
contribution	O
to	O
increasing	O
patients	O
'	O
overall	O
survival	O
time	O
.	O
	
Further	O
evaluation	O
of	O
other	O
salvage	O
regimens	O
seems	O
to	O
be	O
warranted	O
.	O
	
Effects	O
of	O
Onyx-015	B-DRUG
among	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
patients	O
that	O
have	O
failed	O
prior	O
treatment	O
with	O
5-FU	B-DRUG
/	O
leucovorin	B-DRUG
.	O
	
	
Despite	O
recent	O
improvements	O
in	O
the	O
treatment	O
of	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
","	O
few	O
patients	O
are	O
cured	O
and	O
the	O
response	O
rates	O
to	O
second-line	O
treatments	O
are	O
poor	O
.	O
	
Onyx-015	B-DRUG
","	O
an	O
oncolytic	O
virus	O
","	O
was	O
administered	O
to	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
by	O
hepatic	O
artery	O
infusion	O
.	O
	
No	O
dose-limiting	O
toxicities	O
were	O
observed	O
in	O
the	O
phase	O
I	O
/	O
II	O
studies	O
.	O
	
Onyx-015	B-DRUG
can	O
kill	O
tumor	O
cells	O
by	O
mechanisms	O
that	O
are	O
distinct	O
from	O
chemotherapeutic	O
agents	O
and	O
may	O
therefore	O
have	O
activity	O
among	O
patients	O
who	O
have	O
failed	O
first-line	O
chemotherapy	O
.	O
	
The	O
24	O
patients	O
included	O
in	O
this	O
analysis	O
had	O
failed	O
first-line	O
therapy	O
with	O
5-FU	B-DRUG
/	O
leucovorin	B-DRUG
","	O
79	O
%	O
of	O
the	O
patients	O
failed	O
two	O
or	O
more	O
regimens	O
and	O
58	O
%	O
had	O
failed	O
treatment	O
with	O
Irinotecan	B-DRUG
.	O
	
Despite	O
the	O
extensive	O
prior	O
therapy	O
","	O
the	O
median	O
survival	O
of	O
these	O
patients	O
was	O
10.7	O
months	O
","	O
46	O
%	O
were	O
alive	O
at	O
1	O
year	O
and	O
two	O
patients	O
(	O
8	O
%	O
)	O
had	O
partial	O
responses	O
.	O
	
In	O
all	O
","	O
11	O
patients	O
(	O
46	O
%	O
)	O
had	O
stable	O
disease	O
at	O
the	O
completion	O
of	O
the	O
four	O
planned	O
viral	O
treatments	O
(	O
3	O
months	O
)	O
.	O
	
The	O
median	O
survival	O
of	O
this	O
group	O
of	O
patients	O
was	O
19	O
months	O
","	O
suggesting	O
that	O
stable	O
disease	O
may	O
be	O
an	O
important	O
predictor	O
of	O
benefit	O
with	O
oncolytic	O
viruses	O
.	O
	
Eight	O
of	O
the	O
11	O
patients	O
with	O
stable	O
disease	O
at	O
3	O
months	O
demonstrated	O
a	O
unique	O
radiographic	O
pattern	O
of	O
transient	O
enlargement	O
of	O
tumor	O
masses	O
(	O
10-48	O
%	O
)	O
after	O
the	O
initial	O
infusions	O
of	O
Onyx-015	B-DRUG
","	O
followed	O
by	O
radiographic	O
evidence	O
of	O
extensive	O
tumor	O
necrosis	O
and	O
regression	O
.	O
	
The	O
initial	O
enlargement	O
and	O
subsequent	O
tumor	B-TOXI
necrosis	I-TOXI
resulted	O
in	O
a	O
prolonged	O
time	O
to	O
achieve	O
objective	O
tumor	O
regression	O
.	O
	
In	O
addition	O
","	O
the	O
transient	O
enlargement	O
of	O
the	O
tumor	O
masses	O
may	O
have	O
resulted	O
in	O
premature	O
removal	O
of	O
responding	O
patients	O
.	O
	
Treatment	O
of	O
eight	O
patients	O
was	O
stopped	O
prior	O
to	O
completion	O
of	O
the	O
planned	O
four	O
treatments	O
due	O
to	O
presumed	O
progression	O
as	O
defined	O
by	O
standard	O
radiographic	O
criteria	O
(	O
&	O
gt	O
;	O
25	O
%	O
increase	O
in	O
tumor	O
size	O
)	O
.	O
	
Functional	O
imaging	O
","	O
such	O
as	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
scans	O
","	O
may	O
help	O
distinguish	O
clinical	O
responses	O
from	O
progressive	O
disease	O
following	O
treatment	O
with	O
oncolytic	O
viruses	O
.	O
	
Onyx-015	B-DRUG
may	O
benefit	O
patients	O
with	O
refractory	O
colorectal	B-CANCER
cancer	I-CANCER
and	O
additional	O
studies	O
that	O
include	O
PET	O
scans	O
to	O
assess	O
clinical	O
response	O
are	O
warranted	O
.	O
	
Phase	O
I	O
and	O
initial	O
phase	O
II	O
results	O
from	O
a	O
trial	O
investigating	O
weekly	O
docetaxel	B-DRUG
and	O
carboplatin	B-DRUG
given	O
neoadjuvantly	O
and	O
then	O
concurrently	O
with	O
concomitant	O
boost	O
radiotherapy	O
for	O
locally	O
advanced	B-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
	
The	O
current	O
Phase	O
I	O
/	O
II	O
study	O
assessed	O
induction	O
docetaxel	B-DRUG
/	O
carboplatin	B-DRUG
given	O
weekly	O
for	O
4	O
weeks	O
","	O
followed	O
by	O
weekly	O
docetaxel	B-DRUG
/	O
carboplatin	B-DRUG
and	O
concomitant	O
boost	O
radiotherapy	O
(	O
CB-XRT	O
)	O
for	O
locally	O
advanced	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
Twenty	O
patients	O
with	O
Stage	O
III	O
or	O
IV	O
(	O
M0	O
)	O
disease	O
of	O
the	O
oropharynx	O
","	O
supraglottic	B-CANCER
larynx	I-CANCER
","	O
or	O
hypopharynx	O
were	O
enrolled	O
.	O
	
Patients	O
initially	O
received	O
docetaxel	B-DRUG
20	O
mg	O
/	O
m2	O
and	O
carboplatin	B-DRUG
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
2	O
weekly	O
x	O
4	O
Patients	O
with	O
stable	O
(	O
SD	O
)	O
or	O
responding	O
disease	O
subsequently	O
received	O
dose-escalated	O
docetaxel	B-DRUG
(	O
10月20日	O
mg	O
/	O
m2	O
in	O
sequential	O
patient	O
cohorts	O
)	O
and	O
carboplatin	B-DRUG
AUC	O
1	O
weekly	O
x	O
5	O
with	O
CB-XRT	O
(	O
1.8	O
gray	O
[	O
Gy	O
]	O
every	O
day	O
x	O
15	O
days	O
","	O
followed	O
by	O
1.8	O
/	O
1.5	O
Gy	O
twice	O
per	O
day	O
x	O
13	O
days	O
)	O
.	O
	
All	O
patients	O
were	O
evaluable	O
","	O
and	O
15	O
patients	O
(	O
5	O
patients	O
with	O
Stage	O
III	O
disease	O
","	O
10	O
patients	O
with	O
Stage	O
IV	O
disease	O
)	O
completed	O
all	O
planned	O
therapy	O
.	O
	
The	O
target	O
docetaxel	B-DRUG
dose	O
level	O
of	O
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
with	O
radiotherapy	O
was	O
achieved	O
with	O
no	O
dose-limiting	O
toxicities	O
.	O
	
The	O
most	O
frequent	O
maximum	O
toxicities	O
during	O
chemoradiotherapy	O
were	O
Grade	O
3	O
mucositis	B-TOXI
","	O
dysphagia	B-TOXI
","	O
and	O
/	O
or	O
pain	B-TOXI
.	O
	
Primary	O
site	O
responses	O
after	O
induction	O
included	O
4	O
patients	O
with	O
partial	O
responses	O
","	O
11	O
patients	O
with	O
SD	O
","	O
and	O
5	O
patients	O
with	O
disease	O
progression	O
.	O
	
Fifteen	O
patients	O
(	O
75	O
%	O
)	O
continued	O
to	O
receive	O
chemoradiotherapy	O
","	O
with	O
14	O
patients	O
attaining	O
a	O
complete	O
response	O
(	O
CR	O
)	O
.	O
	
Overall	O
","	O
a	O
clinicopathologic	O
neck	O
CR	O
after	O
chemoradiotherapy	O
was	O
achieved	O
in	O
9	O
of	O
10	O
patients	O
.	O
	
One	O
patient	O
had	O
persistent	B-TOXI
primary	I-TOXI
disease	I-TOXI
and	O
underwent	B-TOXI
salvage	I-TOXI
surgery	I-TOXI
","	O
whereas	O
another	O
died	B-TOXI
of	O
unrelated	O
causes	O
before	O
neck	O
assessment	O
.	O
	
Thirteen	O
patients	O
remain	O
free	O
of	O
any	O
disease	O
event	O
","	O
with	O
a	O
median	O
follow-up	O
of	O
15	O
months	O
(	O
range	O
","	O
3月29日	O
months	O
)	O
.	O
	
This	O
regimen	O
was	O
feasible	O
","	O
safe	O
","	O
and	O
particularly	O
well	O
tolerated	O
.	O
	
Early	O
Phase	O
II	O
outcomes	O
revealed	O
promising	O
activity	O
in	O
patients	O
completing	O
all	O
treatment	O
.	O
	
Initial	O
induction	O
response	O
results	O
suggested	O
that	O
further	O
investigation	O
of	O
this	O
regimen	O
with	O
more	O
aggressive	O
induction	O
therapy	O
is	O
warranted	O
.	O
	
Salvage	O
chemotherapy	O
with	O
irinotecan	B-DRUG
","	O
5-fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
for	O
taxane-	B-DRUG
and	O
cisplatin-refractory	B-DRUG
","	O
metastatic	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
	
We	O
performed	O
a	O
phase	O
II	O
study	O
of	O
combination	O
chemotherapy	O
with	O
irinotecan	B-DRUG
","	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
and	O
leucovorin	B-DRUG
in	O
metastatic	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
patients	O
who	O
were	O
previously	O
treated	O
with	O
taxane	B-DRUG
and	O
cisplatin	B-DRUG
","	O
to	O
evaluate	O
the	O
antitumour	O
activity	O
and	O
toxicity	O
of	O
the	O
combination	O
chemotherapy	O
.	O
	
The	O
metastatic	B-CANCER
gastric	I-CANCER
adenocarcinoma	I-CANCER
patients	O
who	O
were	O
previously	O
treated	O
with	O
taxane	B-DRUG
and	O
cisplatin	B-DRUG
combination	O
as	O
first	O
line	O
","	O
and	O
had	O
at	O
least	O
one	O
measurable	O
lesion	O
","	O
0-2	O
ECOG	O
performance	O
status	O
and	O
adequate	O
organ	O
functions	O
","	O
were	O
considered	O
eligible	O
.	O
	
They	O
received	O
irinotecan	B-DRUG
(	O
150	O
mg	O
m	O
(	O
-2	O
)	O
","	O
day	O
1	O
)	O
and	O
leucovorin	B-DRUG
(	O
100	O
mg	O
m	O
(	O
-2	O
)	O
","	O
day	O
1	O
)	O
","	O
followed	O
by	O
continuous	O
infusion	O
of	O
5-FU	B-DRUG
(	O
1000	O
mg	O
m	O
(	O
-2	O
)	O
day	O
(	O
-1	O
)	O
","	O
days	O
1	O
and	O
2	O
)	O
every	O
2	O
weeks	O
.	O
	
Treatment	O
was	O
continued	O
until	O
progression	B-TOXI
of	I-TOXI
disease	I-TOXI
was	O
observed	O
.	O
	
In	O
all	O
","	O
64	O
patients	O
were	O
treated	O
with	O
this	O
combination	O
chemotherapy	O
.	O
	
The	O
median	O
age	O
of	O
the	O
patients	O
was	O
55	O
years	O
(	O
range	O
","	O
33-74	O
years	O
)	O
","	O
and	O
the	O
median	O
ECOG	O
performance	O
status	O
was	O
1	O
(	O
0-1	O
","	O
61	O
(	O
95	O
%	O
)	O
)	O
.	O
	
Out	O
of	O
64	O
patients	O
","	O
57	O
were	O
assessable	O
for	O
response	O
.	O
	
Among	O
57	O
assessable	O
patients	O
","	O
no	O
complete	O
response	O
and	O
12	O
partial	O
responses	O
were	O
observed	O
(	O
overall	O
response	O
rate	O
","	O
21	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
","	O
10-32	O
%	O
)	O
.	O
	
Stable	O
disease	O
was	O
observed	O
in	O
14	O
patients	O
(	O
25	O
%	O
)	O
and	O
progressive	O
disease	O
in	O
31	O
patients	O
(	O
54	O
%	O
)	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
was	O
2.5	O
months	O
(	O
95	O
%	O
CI	O
","	O
1.6-3.4	O
)	O
and	O
the	O
median	O
overall	O
survival	O
since	O
the	O
start	O
of	O
the	O
second-line	O
modified	O
FOLFIRI	B-DRUG
was	O
7.6	O
months	O
(	O
95	O
%	O
CI	O
","	O
6.5-8.7	O
)	O
.	O
	
Grade	O
3月4日	O
haematologic	B-TOXI
toxicities	I-TOXI
included	O
neutropenia	B-TOXI
in	O
seven	O
patients	O
(	O
11	O
%	O
)	O
and	O
thrombocytopenia	B-TOXI
in	O
five	O
patients	O
(	O
8	O
%	O
)	O
.	O
	
Grade	O
3月4日	O
nonhaematologic	B-TOXI
toxicities	I-TOXI
included	O
diarrhoea	B-TOXI
in	O
two	O
patients	O
(	O
3	O
%	O
)	O
and	O
vomiting	B-TOXI
in	O
two	O
patients	O
(	O
3	O
%	O
)	O
.	O
	
There	O
were	O
no	O
treatment-related	O
deaths	B-TOXI
.	O
	
The	O
combination	O
of	O
irinotecan	B-DRUG
","	O
5-FU	B-DRUG
and	O
leucovorin	B-DRUG
showed	O
moderate	O
activity	O
and	O
favourable	O
toxicity	O
profile	O
as	O
a	O
second-line	O
treatment	O
in	O
metastatic	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
patients	O
","	O
who	O
were	O
previously	O
treated	O
with	O
taxane	B-DRUG
and	O
cisplatin	B-DRUG
.	O
	
A	O
phase	O
II	O
trial	O
of	O
gefitinib	B-DRUG
with	O
5-fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
irinotecan	B-DRUG
in	O
patients	O
with	O
colorectal	B-CANCER
cancer	I-CANCER
.	O
	
	
Inhibition	O
of	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
signalling	O
contributes	O
to	O
the	O
therapy	O
of	O
colorectal	B-CANCER
cancer	I-CANCER
.	O
	
Gefitinib	B-DRUG
","	O
an	O
oral	O
EGFR	O
tyrosine	O
kinase	O
inhibitor	O
","	O
shows	O
supra-additive	O
growth	O
inhibition	O
with	O
irinotecan	B-DRUG
and	O
fluoropyrimidines	B-DRUG
in	O
xenograft	O
models	O
.	O
	
We	O
designed	O
a	O
study	O
to	O
determine	O
the	O
tolerability	O
and	O
efficacy	O
of	O
gefitinib	B-DRUG
in	O
combination	O
with	O
irinotecan	B-DRUG
","	O
infusional	B-DRUG
5-fluorouracil	I-DRUG
(	O
5-FU	B-DRUG
)	O
and	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
","	O
on	O
a	O
2-week	O
schedule	O
.	O
	
Among	O
13	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
","	O
10	O
required	O
dose	O
reductions	O
of	O
irinotecan	B-DRUG
and	O
5-FU	B-DRUG
because	O
of	O
dehydration	B-TOXI
","	O
diarrhoea	B-TOXI
","	O
and	O
neutropenia	B-TOXI
","	O
seven	O
of	O
whom	O
required	O
hospitalisation	O
","	O
three	O
with	O
neutropenic	B-TOXI
fever	I-TOXI
.	O
	
One	O
patient	O
achieved	O
partial	O
response	O
and	O
seven	O
had	O
disease	O
stabilisation	O
.	O
	
The	O
combination	O
of	O
this	O
standard	O
chemotherapy	O
regimen	O
with	O
gefitinib	B-DRUG
is	O
associated	O
with	O
excessive	O
toxicity	O
","	O
suggesting	O
an	O
interaction	O
at	O
a	O
pharmacokinetic	O
or	O
pharmacodynamic	O
level	O
.	O
	
Bevacizumab	B-DRUG
in	O
combination	O
with	O
fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
:	O
an	O
active	O
regimen	O
for	O
first-line	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
In	O
a	O
phase	O
III	O
trial	O
","	O
combining	O
bevacizumab	B-DRUG
(	O
BV	B-DRUG
)	O
=--	O
a	O
recombinant	O
","	O
humanized	O
","	O
monoclonal	O
antibody	O
targeting	O
vascular	O
endothelial	O
growth	O
factor	O
=--	O
with	O
irinotecan	B-DRUG
","	O
bolus	O
fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
","	O
and	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
;	O
IFL	B-DRUG
)	O
increased	O
survival	O
compared	O
with	O
IFL	B-DRUG
alone	O
in	O
first-line	O
treatment	O
of	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
CRC	B-CANCER
)	O
.	O
	
Results	O
for	O
the	O
parent	O
study	O
of	O
IFL	B-DRUG
/	O
BV	B-DRUG
versus	O
IFL	B-DRUG
/	O
placebo	B-DRUG
are	O
reported	O
elsewhere	O
.	O
	
Here	O
","	O
we	O
describe	O
efficacy	O
and	O
safety	O
results	O
for	O
the	O
third	O
patient	O
cohort	O
in	O
this	O
trial	O
","	O
who	O
received	O
BV	B-DRUG
combined	O
with	O
FU	B-DRUG
/	O
LV	B-DRUG
","	O
and	O
compare	O
them	O
with	O
results	O
for	O
concurrently	O
enrolled	O
patients	O
who	O
received	O
IFL	B-DRUG
.	O
	
Patients	O
(	O
N	O
=	O
923	O
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
IFL	B-DRUG
/	O
placebo	B-DRUG
(	O
control	O
)	O
","	O
IFL	B-DRUG
/	O
BV	B-DRUG
","	O
or	O
FU	B-DRUG
/	O
LV	B-DRUG
/	O
BV	B-DRUG
.	O
	
Bevacizumab	B-DRUG
(	O
Avastin	O
;	O
Genentech	O
Inc	O
","	O
South	O
San	O
Francisco	O
","	O
CA	O
)	O
5	O
mg	O
/	O
kg	O
was	O
administered	O
intravenously	O
every	O
2	O
weeks	O
.	O
	
Before	O
an	O
interim	O
analysis	O
confirmed	O
acceptable	O
safety	O
for	O
IFL	B-DRUG
/	O
BV	B-DRUG
","	O
313	O
patients	O
were	O
concurrently	O
randomly	O
assigned	O
to	O
these	O
three	O
arms	O
;	O
after	O
this	O
analysis	O
","	O
the	O
FU	B-DRUG
/	O
LV	B-DRUG
/	O
BV	B-DRUG
arm	O
was	O
discontinued	O
.	O
	
Median	O
overall	O
survivals	O
were	O
18.3	O
and	O
15.1	O
months	O
with	O
FU	B-DRUG
/	O
LV	B-DRUG
/	O
BV	B-DRUG
(	O
n	O
=	O
110	O
)	O
and	O
IFL	B-DRUG
/	O
placebo	B-DRUG
(	O
n	O
=	O
100	O
)	O
","	O
respectively	O
.	O
	
Median	O
progression-free	O
survivals	O
were	O
8.8	O
and	O
6.8	O
months	O
","	O
respectively	O
.	O
	
Overall	O
response	O
rates	O
were	O
40	O
%	O
and	O
37	O
%	O
","	O
and	O
median	O
response	O
durations	O
were	O
8.5	O
and	O
7.2	O
months	O
","	O
respectively	O
.	O
	
Adverse	O
events	O
consistent	O
with	O
those	O
expected	O
from	O
FU	B-DRUG
/	O
leucovorin-	B-DRUG
or	O
IFL-based	B-DRUG
regimens	O
were	O
seen	O
","	O
as	O
were	O
modest	O
increases	O
in	O
hypertension	B-TOXI
and	O
bleeding	B-TOXI
in	O
the	O
bevacizumab	B-DRUG
arm	O
","	O
which	O
were	O
generally	O
easily	O
managed	O
.	O
	
The	O
FU	B-DRUG
/	O
LV	B-DRUG
/	O
BV	B-DRUG
regimen	O
seems	O
as	O
effective	O
as	O
IFL	B-DRUG
and	O
has	O
an	O
acceptable	O
safety	O
profile	O
.	O
	
FU	B-DRUG
/	O
LV	B-DRUG
/	O
BV	B-DRUG
is	O
an	O
active	O
alternative	O
treatment	O
regimen	O
for	O
patients	O
with	O
previously	O
untreated	O
metastatic	B-CANCER
CRC	I-CANCER
.	O
	
Randomized	O
phase	O
III	O
trial	O
of	O
cisplatin	B-DRUG
with	O
or	O
without	O
topotecan	B-DRUG
in	O
carcinoma	B-CANCER
of	I-CANCER
the	I-CANCER
uterine	I-CANCER
cervix	I-CANCER
:	O
a	O
Gynecologic	O
Oncology	O
Group	O
Study	O
.	O
	
	
On	O
the	O
basis	O
of	O
reported	O
activity	O
of	O
methotrexate	B-DRUG
","	O
vinblastine	B-DRUG
","	O
doxorubicin	B-DRUG
","	O
and	O
cisplatin	B-DRUG
(	O
MVAC	B-DRUG
)	O
or	O
topotecan	B-DRUG
plus	O
cisplatin	B-DRUG
in	O
advanced	B-CANCER
cervix	I-CANCER
cancer	I-CANCER
","	O
we	O
undertook	O
a	O
randomized	O
trial	O
comparing	O
these	O
combinations	O
versus	O
cisplatin	B-DRUG
alone	O
","	O
to	O
determine	O
whether	O
survival	O
is	O
improved	O
with	O
either	O
combination	O
compared	O
with	O
cisplatin	B-DRUG
alone	O
","	O
and	O
to	O
compare	O
toxicities	O
and	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
among	O
the	O
regimens	O
.	O
	
Eligible	O
patients	O
were	O
randomly	O
allocated	O
to	O
receive	O
cisplatin	B-DRUG
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
every	O
3	O
weeks	O
(	O
CPT	O
)	O
;	O
cisplatin	B-DRUG
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
day	O
1	O
plus	O
topotecan	B-DRUG
0.75	O
mg	O
/	O
m	O
(	O
2	O
)	O
days	O
1	O
to	O
3	O
every	O
3	O
weeks	O
(	O
CT	O
)	O
;	O
or	O
methotrexate	B-DRUG
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
days	O
1	O
","	O
15	O
","	O
and	O
22	O
","	O
vinblastine	B-DRUG
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
days	O
2	O
","	O
15	O
","	O
and	O
22	O
","	O
doxorubicin	B-DRUG
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
day	O
2	O
","	O
and	O
cisplatin	B-DRUG
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
day	O
2	O
every	O
4	O
weeks	O
(	O
MVAC	O
)	O
.	O
	
Survival	O
was	O
the	O
primary	O
end	O
point	O
;	O
response	O
rate	O
and	O
progression-free	O
survival	O
(	O
PFS	O
)	O
were	O
secondary	O
end	O
points	O
.	O
	
QOL	O
data	O
are	O
reported	O
separately	O
.	O
	
The	O
MVAC	B-DRUG
arm	O
was	O
closed	O
by	O
the	O
Data	O
Safety	O
Monitoring	O
Board	O
after	O
four	O
treatment-related	O
deaths	B-TOXI
occurred	O
among	O
63	O
patients	O
","	O
and	O
is	O
not	O
included	O
in	O
this	O
analysis	O
.	O
	
Two	O
hundred	O
ninety-four	O
patients	O
enrolled	O
onto	O
the	O
remaining	O
regimens	O
:	O
146	O
to	O
CPT	B-DRUG
and	O
147	O
to	O
CT.	B-DRUG
Grade	O
3	O
to	O
4	O
hematologic	B-TOXI
toxicity	I-TOXI
was	O
more	O
common	O
with	O
CT.	B-DRUG
Patients	O
receiving	O
CT	B-DRUG
had	O
statistically	O
superior	O
outcomes	O
to	O
those	O
receiving	O
CPT	B-DRUG
","	O
with	O
median	O
overall	O
survival	O
of	O
9.4	O
and	O
6.5	O
months	O
(	O
P	O
=	O
0.017	O
)	O
","	O
median	O
PFS	O
of	O
4.6	O
and	O
2.9	O
months	O
(	O
P	O
=	O
0.014	O
)	O
","	O
and	O
response	O
rates	O
of	O
27	O
%	O
and	O
13	O
%	O
","	O
respectively	O
.	O
	
This	O
is	O
the	O
first	O
randomized	O
phase	O
III	O
trial	O
to	O
demonstrate	O
a	O
survival	O
advantage	O
for	O
combination	O
chemotherapy	O
over	O
cisplatin	B-DRUG
alone	O
in	O
advanced	B-CANCER
cervix	I-CANCER
cancer	I-CANCER
.	O
	
Paclitaxel	B-DRUG
and	O
gemcitabine	B-DRUG
combination	O
in	O
a	O
biweekly	O
schedule	O
in	O
patients	O
with	O
advanced	B-CANCER
non	I-CANCER
small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
a	O
phase	O
I	O
study	O
.	O
	
	
This	O
phase	O
I	O
study	O
was	O
designed	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
dose	O
limiting	O
toxicities	O
(	O
DLTs	O
)	O
of	O
the	O
paclitaxel-gemcitabine	B-DRUG
combination	O
in	O
a	O
biweekly	O
schedule	O
in	O
chemotherapy-naive	O
patients	O
with	O
advanced	B-CANCER
non	I-CANCER
small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Treatment	O
was	O
administered	O
on	O
an	O
outpatient	O
basis	O
every	O
2	O
weeks	O
:	O
paclitaxel	B-DRUG
over	O
a	O
1-h	O
IV	O
infusion	O
and	O
gemcitabine	B-DRUG
as	O
a	O
30-min	O
IV	O
infusion	O
immediately	O
following	O
paclitaxel	B-DRUG
.	O
	
Twenty-nine	O
patients	O
were	O
treated	O
at	O
six	O
different	O
dose	O
levels	O
","	O
ranging	O
from	O
paclitaxel	B-DRUG
135-175	O
mg	O
/	O
m2	O
and	O
gemcitabine	B-DRUG
"1,500-3,000"	O
mg	O
/	O
m2	O
.	O
	
A	O
total	O
of	O
198	O
cycles	O
were	O
administered	O
(	O
median	O
7	O
","	O
range	O
1月13日	O
)	O
.	O
	
DLTs	O
in	O
the	O
first	O
two	O
cycles	O
were	O
grade	O
4	O
neutropenia	B-TOXI
and	O
myocardial	B-TOXI
ischemia	I-TOXI
at	O
the	O
dose	O
level	O
paclitaxel	B-DRUG
/	O
gemcitabine	B-DRUG
150	O
/	O
"2,000"	O
mg	O
/	O
m2	O
","	O
febrile	B-TOXI
neutropenia	I-TOXI
and	O
grade	O
4	O
neutropenia	B-TOXI
at	O
the	O
dose	O
level	O
paclitaxel	B-DRUG
/	O
gemcitabine	B-DRUG
175	O
/	O
"2,500"	O
mg	O
/	O
m2	O
","	O
fatal	B-TOXI
pneumonitis	I-TOXI
","	O
sudden	B-TOXI
death	I-TOXI
and	O
grade	O
3	O
neutropenia	B-TOXI
at	O
the	O
dose	O
level	O
paclitaxel	B-DRUG
/	O
gemcitabine	B-DRUG
175	O
/	O
"3,000"	O
mg	O
/	O
m2	O
.	O
	
The	O
MTD	O
was	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m2	O
and	O
gemcitabine	B-DRUG
"2,500"	O
mg	O
/	O
m2	O
.	O
	
The	O
average	O
dose	O
intensity	O
at	O
this	O
dose	O
level	O
was	O
98	O
%	O
.	O
	
The	O
overall	O
intent-to-treat	O
response	O
rate	O
was	O
35.7	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
17.97	O
%	O
-53.47	O
%	O
)	O
.	O
	
Overall	O
median	O
survival	O
was	O
36	O
weeks	O
(	O
95	O
%	O
CI	O
","	O
24-48	O
)	O
.	O
	
Paclitaxel	B-DRUG
and	O
gemcitabine	B-DRUG
can	O
be	O
safely	O
administered	O
at	O
a	O
high	O
dose	O
intensity	O
on	O
an	O
every-other-week	O
schedule	O
.	O
	
The	O
recommended	O
phase	O
II	O
dose	O
is	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m2	O
and	O
gemcitabine	B-DRUG
"2,500"	O
mg	O
/	O
m2	O
.	O
	
Study	O
of	O
paclitaxel	B-DRUG
","	O
etoposide	B-DRUG
","	O
and	O
cisplatin	B-DRUG
chemotherapy	O
combined	O
with	O
twice-daily	O
thoracic	O
radiotherapy	O
for	O
patients	O
with	O
limited-stage	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
a	O
Radiation	O
Therapy	O
Oncology	O
Group	O
9609	O
phase	O
II	O
study	O
.	O
	
	
To	O
determine	O
the	O
response	O
rate	O
","	O
progression-free	O
survival	O
and	O
overall	O
survival	O
","	O
and	O
toxicity	O
of	O
paclitaxel	B-DRUG
","	O
etoposide	B-DRUG
","	O
and	O
cisplatin	B-DRUG
combined	O
with	O
accelerated	O
hyperfractionated	O
thoracic	O
radiotherapy	O
in	O
patients	O
with	O
limited-disease	O
(	O
LD	O
)	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
SCLC	B-CANCER
)	O
.	O
	
LD-SCLC	O
patients	O
with	O
measurable	O
disease	O
","	O
Karnofsky	O
performance	O
score	O
of	O
&	O
gt	O
;	O
or	O
=	O
70	O
","	O
and	O
adequate	O
organ	O
function	O
who	O
were	O
previously	O
untreated	O
were	O
eligible	O
for	O
the	O
study	O
.	O
	
Treatment	O
was	O
as	O
follows	O
.	O
	
In	O
cycle	O
1	O
of	O
chemotherapy	O
","	O
concurrent	O
thoracic	O
radiation	O
therapy	O
was	O
administered	O
.	O
	
In	O
cycles	O
2	O
to	O
4	O
","	O
chemotherapy	O
was	O
administered	O
alone	O
.	O
	
In	O
cycle	O
1	O
","	O
chemotherapy	O
consisted	O
of	O
paclitaxel	B-DRUG
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenous	O
over	O
3	O
hours	O
on	O
day	O
1	O
","	O
etoposide	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenous	O
on	O
day	O
1	O
and	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
orally	O
on	O
days	O
2	O
and	O
3	O
","	O
and	O
cisplatin	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenous	O
on	O
day	O
1	O
In	O
cycles	O
2	O
to	O
4	O
","	O
the	O
paclitaxel	B-DRUG
dose	O
was	O
increased	O
to	O
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
with	O
the	O
etoposide	B-DRUG
and	O
cisplatin	B-DRUG
doses	O
remaining	O
the	O
same	O
as	O
in	O
cycle	O
1	O
The	O
thoracic	O
radiation	O
therapy	O
consisted	O
of	O
1.5	O
Gy	O
in	O
30	O
fractions	O
(	O
total	O
dose	O
","	O
45	O
Gy	O
)	O
administered	O
5	O
days	O
a	O
week	O
for	O
3	O
weeks	O
.	O
	
Fifty-five	O
patients	O
were	O
enrolled	O
onto	O
the	O
study	O
","	O
and	O
53	O
were	O
assessable	O
.	O
	
The	O
major	O
toxicities	O
included	O
grade	O
3	O
and	O
4	O
acute	B-TOXI
neutropenia	I-TOXI
(	O
32	O
%	O
and	O
43	O
%	O
","	O
respectively	O
)	O
and	O
grade	O
3	O
and	O
4	O
esophagitis	B-TOXI
(	O
32	O
%	O
and	O
4	O
%	O
","	O
respectively	O
)	O
.	O
	
Two	O
patients	O
died	O
as	O
a	O
result	O
of	O
therapy	O
(	O
one	O
died	B-TOXI
of	I-TOXI
acute	I-TOXI
respiratory	I-TOXI
distress	I-TOXI
syndrome	I-TOXI
","	O
and	O
one	O
died	B-TOXI
of	I-TOXI
sepsis	I-TOXI
)	O
.	O
	
There	O
was	O
one	O
late	O
fatal	B-TOXI
pulmonary	I-TOXI
toxicity	I-TOXI
.	O
	
The	O
median	O
survival	O
time	O
was	O
24.7	O
months	O
.	O
	
The	O
2-year	O
survival	O
rate	O
was	O
54.7	O
%	O
.	O
	
The	O
median	O
progression-free	O
survival	O
time	O
was	O
13	O
months	O
","	O
with	O
a	O
2-year	O
progression-free	O
survival	O
rate	O
of	O
26.4	O
%	O
.	O
	
Although	O
this	O
therapeutic	O
regimen	O
is	O
effective	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
LD-SCLC	O
","	O
it	O
is	O
unlikely	O
that	O
the	O
three-drug	O
combination	O
with	O
thoracic	O
radiation	O
therapy	O
will	O
improve	O
the	O
survival	O
times	O
compared	O
with	O
the	O
etoposide	B-DRUG
plus	O
cisplatin	B-DRUG
chemotherapy	O
regimen	O
with	O
thoracic	O
radiation	O
therapy	O
in	O
LD-SCLC	O
patients	O
.	O
	
Randomised	O
phase	O
II	O
evaluation	O
of	O
irinotecan	B-DRUG
plus	O
high-dose	O
5-fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
(	O
ILF	B-DRUG
)	O
vs	O
5-fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
etoposide	B-DRUG
(	O
ELF	B-DRUG
)	O
in	O
untreated	O
metastatic	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
	
An	O
open-label	O
randomised	O
comparison	O
of	O
efficacy	O
and	O
tolerability	O
of	O
irinotecan	B-DRUG
plus	O
high-dose	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
and	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
(	O
ILF	B-DRUG
)	O
with	O
etoposide	B-DRUG
plus	O
5-FU	B-DRUG
/	O
LV	B-DRUG
(	O
ELF	B-DRUG
)	O
in	O
patients	O
with	O
untreated	O
metastatic	B-CANCER
or	I-CANCER
locally	I-CANCER
advanced	I-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
One	O
cycle	O
of	O
ILF	B-DRUG
comprised	O
six	O
once-weekly	O
infusions	O
of	O
irinotecan	B-DRUG
80	O
mg	O
m	O
(	O
-2	O
)	O
","	O
LV	B-DRUG
500	O
mg	O
m	O
(	O
-2	O
)	O
","	O
24-h	O
5-FU	B-DRUG
2000	O
mg	O
m	O
(	O
-2	O
)	O
","	O
and	O
ELF	B-DRUG
comprised	O
three	O
once-daily	O
doses	O
of	O
etoposide	B-DRUG
120	O
mg	O
m	O
(	O
-2	O
)	O
","	O
LV	B-DRUG
300	O
mg	O
m	O
(	O
-2	O
)	O
","	O
5-FU	B-DRUG
500	O
mg	O
m	O
(	O
-2	O
)	O
.	O
	
In	O
all	O
","	O
56	O
patients	O
received	O
ILF	B-DRUG
and	O
58	O
ELF	B-DRUG
.	O
	
Median	O
age	O
was	O
62	O
years	O
","	O
Karnofsky	O
performance	O
90	O
%	O
","	O
and	O
disease	O
status	O
was	O
comparable	O
for	O
both	O
arms	O
.	O
	
The	O
objective	O
clinical	O
response	O
rates	O
after	O
14	O
weeks	O
treatment	O
(	O
primary	O
end	O
point	O
)	O
were	O
30	O
%	O
for	O
ILF	B-DRUG
and	O
17	O
%	O
for	O
ELF	B-DRUG
(	O
risk	O
ratio	O
(	O
RR	O
)	O
0.57	O
","	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0.29-1.13	O
","	O
P	O
=	O
0.0766	O
)	O
.	O
	
Overall	O
response	O
rates	O
over	O
the	O
entire	O
treatment	O
period	O
for	O
ILF	B-DRUG
and	O
ELF	B-DRUG
were	O
43	O
and	O
24	O
%	O
","	O
respectively	O
(	O
RR	O
0.56	O
","	O
95	O
%	O
CI	O
0.33-0.97	O
;	O
P	O
=	O
0.0467	O
)	O
.	O
	
For	O
ILF	B-DRUG
and	O
ELF	B-DRUG
","	O
respectively	O
","	O
median	O
progression-free	O
survival	O
was	O
4.5	O
vs	O
2.3	O
months	O
","	O
time	O
to	O
treatment	O
failure	O
was	O
3.6	O
vs	O
2.2	O
months	O
(	O
P	O
=	O
0.4542	O
)	O
","	O
and	O
overall	O
survival	O
was	O
10.8	O
vs	O
8.3	O
months	O
(	O
P	O
=	O
0.2818	O
)	O
.	O
	
Both	O
regimens	O
were	O
well	O
tolerated	O
","	O
the	O
main	O
grade	O
3	O
/	O
4	O
toxicities	O
being	O
diarrhoea	B-TOXI
(	O
18	O
%	O
","	O
ILF	B-DRUG
)	O
and	O
neutropenia	B-TOXI
(	O
57	O
%	O
","	O
ELF	B-DRUG
)	O
.	O
	
The	O
data	O
from	O
this	O
randomised	O
phase	O
II	O
study	O
indicate	O
that	O
ILF	B-DRUG
provides	O
a	O
better	O
response	O
rate	O
than	O
ELF	B-DRUG
","	O
and	O
that	O
ILF	B-DRUG
should	O
be	O
investigated	O
further	O
for	O
the	O
treatment	O
of	O
metastatic	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Phase	O
I	O
trial	O
of	O
oral	O
S-1	B-DRUG
combined	O
with	O
gemcitabine	B-DRUG
in	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
of	O
S-1	B-DRUG
","	O
an	O
oral	O
fluorouracil	B-DRUG
derivative	I-DRUG
","	O
combined	O
with	O
gemcitabine	B-DRUG
","	O
the	O
current	O
standard	O
treatment	O
for	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
(	O
APC	B-CANCER
)	O
.	O
	
The	O
subjects	O
were	O
histopathologically	O
proven	O
APC	B-CANCER
patients	O
with	O
distant	B-CANCER
metastasis	I-CANCER
.	O
	
S-1	B-DRUG
was	O
administered	O
orally	O
twice	O
daily	O
each	O
day	O
for	O
14	O
days	O
and	O
gemcitabine	B-DRUG
on	O
days	O
8	O
and	O
15	O
of	O
each	O
cycle	O
","	O
and	O
this	O
was	O
repeated	O
every	O
21	O
days	O
.	O
	
Doses	O
of	O
each	O
drug	O
were	O
planned	O
as	O
follows	O
:	O
level	O
1	O
:	O
800	O
/	O
60	O
","	O
level	O
2a	O
:	O
800	O
/	O
80	O
","	O
level	O
2b	O
:	O
1000	O
/	O
60	O
","	O
level	O
3	O
:	O
1000	O
/	O
80	O
(	O
gemcitabine	B-DRUG
(	O
mg	O
m	O
(	O
-2	O
)	O
)	O
/	O
S-1	B-DRUG
(	O
mg	O
m	O
(	O
-2	O
)	O
day	O
(	O
-1	O
)	O
)	O
)	O
.	O
	
In	O
all	O
","	O
21	O
patients	O
with	O
APC	B-CANCER
were	O
enrolled	O
.	O
	
The	O
main	O
grade	O
3月4日	O
toxicities	O
observed	O
during	O
first	O
cycle	O
were	O
neutropenia	B-TOXI
(	O
33	O
%	O
)	O
","	O
anaemia	B-TOXI
(	O
10	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
14	O
%	O
)	O
and	O
anorexia	B-TOXI
(	O
10	O
%	O
)	O
.	O
	
There	O
were	O
no	O
DLT	O
observed	O
in	O
level	O
1	O
Three	O
of	O
six	O
patients	O
in	O
level	O
2a	O
had	O
DLT	O
and	O
this	O
level	O
was	O
considered	O
the	O
MTD	O
.	O
	
In	O
all	O
","	O
12	O
patients	O
in	O
level	O
2b	O
had	O
no	O
DLT	O
and	O
this	O
level	O
was	O
selected	O
as	O
the	O
recommended	O
dose	O
.	O
	
Applicable	O
responses	O
were	O
one	O
complete	O
response	O
and	O
nine	O
partial	O
responses	O
(	O
48	O
%	O
)	O
.	O
	
As	O
toxicities	O
were	O
well	O
tolerated	O
and	O
antitumour	O
activities	O
seem	O
to	O
be	O
promising	O
","	O
this	O
combination	O
can	O
be	O
recommended	O
for	O
further	O
phase	O
II	O
studies	O
with	O
APC	B-CANCER
.	O
	
Capecitabine	B-DRUG
plus	O
oxaliplatin	B-DRUG
for	O
the	O
first-line	O
treatment	O
of	O
elderly	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
:	O
final	O
results	O
of	O
the	O
Southern	O
Italy	O
Cooperative	O
Oncology	O
Group	O
Trial	O
108	O
.	O
	
	
In	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
(	O
MCC	B-CANCER
)	O
","	O
capecitabine	O
has	O
demonstrated	O
a	O
superior	O
response	O
rate	O
(	O
RR	O
)	O
","	O
equivalent	O
disease	O
progression-free	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
","	O
and	O
an	O
improved	O
overall	O
tolerability	O
profile	O
compared	O
with	O
bolus	O
5-fluorouracil	B-DRUG
/	O
leucovorin	B-DRUG
(	O
5-FU	B-DRUG
/	O
LV	B-DRUG
)	O
.	O
	
The	O
FOLFOX4	B-DRUG
regimen	O
","	O
combining	O
oxaliplatin	B-DRUG
with	O
LV	B-DRUG
and	O
bolus	O
plus	O
infusional	B-DRUG
5-FU	I-DRUG
(	O
LV5FU2	B-DRUG
)	O
","	O
has	O
been	O
shown	O
to	O
improve	O
RR	O
and	O
PFS	O
versus	O
LV5FU2	B-DRUG
","	O
and	O
it	O
was	O
more	O
effective	O
and	O
less	O
toxic	O
than	O
irinotecan	B-DRUG
plus	O
bolus	O
5-FU	B-DRUG
/	O
LV	B-DRUG
.	O
	
Capecitabine	B-DRUG
(	O
an	O
oral	O
fluoropyrimidine	B-DRUG
)	O
may	O
be	O
an	O
effective	O
","	O
well	O
tolerated	O
","	O
and	O
more	O
convenient	O
alternative	O
to	O
5-FU	B-DRUG
/	O
LV	B-DRUG
in	O
combination	O
with	O
oxaliplatin	B-DRUG
","	O
especially	O
in	O
older	O
patients	O
.	O
	
Elderly	O
(	O
&	O
gt	O
;	O
or	O
=	O
70	O
years	O
)	O
patients	O
with	O
MCC	B-CANCER
were	O
treated	O
with	O
a	O
3-weekly	O
regimen	O
of	O
oxaliplatin	B-DRUG
at	O
an	O
initial	O
dose	O
of	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
on	O
Day	O
1	O
plus	O
capecitabine	B-DRUG
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
orally	O
twice	O
daily	O
from	O
Days	O
2	O
to	O
15	O
(	O
XELOX	B-DRUG
regimen	O
)	O
.	O
	
In	O
the	O
absence	O
of	O
Grade	O
&	O
gt	O
;	O
or	O
=	O
2	O
hematologic	B-TOXI
toxicity	I-TOXI
","	O
oxaliplatin	B-DRUG
was	O
increased	O
to	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
the	O
second	O
cycle	O
","	O
and	O
in	O
the	O
absence	O
of	O
Grade	O
&	O
gt	O
;	O
or	O
=	O
2	O
nonhematologic	B-TOXI
adverse	I-TOXI
events	I-TOXI
during	O
Cycle	O
2	O
","	O
capecitabine	B-DRUG
was	O
increased	O
to	O
1250	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
daily	O
in	O
the	O
third	O
and	O
subsequent	O
cycles	O
.	O
	
After	O
the	O
first	O
35	O
patients	O
(	O
first	O
series	O
)	O
","	O
the	O
treatment	O
protocol	O
was	O
amended	O
so	O
that	O
only	O
an	O
oxaliplatin	B-DRUG
increase	O
to	O
110	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
130	O
mg	O
/	O
m	O
(	O
2	O
)	O
during	O
Cycles	O
2	O
and	O
3	O
","	O
respectively	O
","	O
was	O
planned	O
in	O
the	O
remaining	O
41	O
patients	O
(	O
second	O
series	O
)	O
.	O
	
Seventy-six	O
patients	O
with	O
a	O
median	O
age	O
of	O
75	O
years	O
(	O
range	O
","	O
70-82	O
years	O
)	O
entered	O
the	O
current	O
study	O
.	O
	
In	O
the	O
first	O
series	O
","	O
the	O
oxaliplatin	B-DRUG
dose	O
was	O
increased	O
in	O
18	O
(	O
51	O
%	O
)	O
patients	O
","	O
and	O
the	O
capecitabine	B-DRUG
dose	O
was	O
increased	O
in	O
4	O
(	O
11	O
%	O
)	O
patients	O
.	O
	
In	O
the	O
second	O
series	O
","	O
the	O
oxaliplatin	B-DRUG
dose	O
was	O
increased	O
to	O
110	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
26	O
(	O
63	O
%	O
)	O
patients	O
","	O
and	O
to	O
130	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
19	O
(	O
46	O
%	O
)	O
patients	O
.	O
	
In	O
all	O
","	O
2	O
complete	O
and	O
29	O
partial	O
responses	O
were	O
observed	O
","	O
for	O
an	O
overall	O
RR	O
of	O
41	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
30-53	O
%	O
)	O
.	O
	
The	O
median	O
PFS	O
was	O
8.5	O
months	O
(	O
95	O
%	O
CI	O
","	O
6.7-10.3	O
months	O
)	O
","	O
and	O
the	O
median	O
OS	O
was	O
14.4	O
months	O
(	O
95	O
%	O
CI	O
","	O
11.9-16.9	O
months	O
)	O
.	O
	
In	O
a	O
multivariate	O
analysis	O
","	O
the	O
presence	O
of	O
disease	O
symptoms	O
affected	O
both	O
PFS	O
and	O
OS	O
","	O
whereas	O
OS	O
also	O
was	O
independently	O
affected	O
by	O
male	O
gender	O
and	O
disease	O
spread	O
.	O
	
Age	O
had	O
no	O
independent	O
effect	O
on	O
PFS	O
or	O
OS	O
.	O
	
Five	O
percent	O
of	O
patients	O
developed	O
Grade	O
&	O
gt	O
;	O
or	O
=	O
3	O
hematologic	B-TOXI
toxicity	I-TOXI
during	O
treatment	O
","	O
Grade	O
3	O
peripheral	B-TOXI
neuropathy	I-TOXI
occurred	O
in	O
8	O
%	O
of	O
patients	O
","	O
and	O
severe	B-TOXI
hand-foot	I-TOXI
syndrome	I-TOXI
in	O
13	O
%	O
of	O
patients	O
.	O
	
Fit	O
elderly	O
patients	O
with	O
MCC	B-CANCER
showed	O
a	O
good	O
RR	O
to	O
XELOX	B-DRUG
with	O
only	O
mild	O
toxicity	O
observed	O
in	O
most	O
patients	O
.	O
	
XELOX	B-DRUG
","	O
should	O
","	O
therefore	O
be	O
considered	O
as	O
an	O
important	O
therapeutic	O
option	O
for	O
elderly	O
patients	O
with	O
MCC	B-CANCER
.	O
	
Pharmacokinetically	O
guided	O
phase	O
I	O
trial	O
of	O
topotecan	B-DRUG
and	O
etoposide	B-DRUG
phosphate	I-DRUG
in	O
recurrent	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
	
A	O
pharmacokinetically	O
guided	O
phase	O
I	O
study	O
of	O
topotecan	B-DRUG
and	O
etoposide	B-DRUG
phosphate	I-DRUG
was	O
conducted	O
in	O
recurrent	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
The	O
scheduling	O
of	O
the	O
topoisomerase	B-DRUG
I	I-DRUG
and	I-DRUG
II	I-DRUG
inhibitors	I-DRUG
was	O
determined	O
using	O
in	O
vitro	O
activity	O
data	O
.	O
	
All	O
patients	O
had	O
recurrent	O
disease	O
following	O
prior	O
platinum-containing	B-DRUG
chemotherapy	O
.	O
	
Patients	O
had	O
a	O
World	O
Health	O
Organisation	O
performance	O
status	O
of	O
0-2	O
and	O
adequate	O
bone	O
marrow	O
","	O
renal	O
and	O
hepatic	O
function	O
.	O
	
Treatment	O
was	O
with	O
topotecan	B-DRUG
intravenously	O
for	O
5	O
days	O
followed	O
immediately	O
by	O
a	O
5-day	O
intravenous	O
infusion	O
of	O
etoposide	B-DRUG
phosphate	I-DRUG
(	O
EP	B-DRUG
)	O
","	O
with	O
pharmacokinetically	O
guided	O
dose	O
adjustment	O
.	O
	
Plasma	O
etoposide	B-DRUG
levels	O
were	O
measured	O
on	O
days	O
2	O
and	O
4	O
of	O
the	O
infusion	O
.	O
	
A	O
total	O
of	O
21	O
patients	O
entered	O
the	O
study	O
.	O
	
In	O
all	O
","	O
48	O
%	O
were	O
platinum	B-DRUG
resistant	O
and	O
71	O
%	O
had	O
received	O
prior	O
paclitaxel	B-DRUG
.	O
	
The	O
main	O
toxicities	O
were	O
haematological	O
","	O
short	O
lived	O
and	O
reversible	O
.	O
	
A	O
total	O
of	O
29	O
%	O
of	O
patients	O
experienced	O
grade	O
4	O
thrombocytopenia	B-TOXI
and	O
66	O
%	O
grade	O
4	O
neutropenia	B-TOXI
after	O
the	O
first	O
cycle	O
.	O
	
Neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
was	O
dose	O
limiting	O
.	O
	
The	O
maximum-tolerated	O
dose	O
was	O
topotecan	B-DRUG
0.85	O
mg	O
m	O
(	O
-2	O
)	O
day	O
(	O
-1	O
)	O
days	O
1月5日	O
followed	O
immediately	O
by	O
a	O
5-day	O
infusion	O
of	O
EP	B-DRUG
at	O
a	O
plasma	O
concentration	O
of	O
1	O
mug	O
ml	O
(	O
-1	O
)	O
.	O
	
The	O
response	O
rate	O
(	O
RR	O
)	O
was	O
28	O
%	O
in	O
18	O
evaluable	O
patients	O
.	O
	
There	O
was	O
marked	O
interpatient	O
variability	O
in	O
topoisomerase	B-DRUG
IIalpha	I-DRUG
levels	O
measured	O
from	O
peripheral	O
lymphocytes	O
","	O
with	O
no	O
observed	O
increase	O
following	O
topotecan	B-DRUG
.	O
	
This	O
regimen	O
of	O
topotecan	B-DRUG
followed	O
by	O
EP	B-DRUG
demonstrated	O
good	O
activity	O
in	O
recurrent	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
and	O
was	O
noncrossresistant	O
with	O
paclitaxel	B-DRUG
.	O
	
Both	O
the	O
toxicity	O
and	O
RR	O
was	O
higher	O
than	O
would	O
be	O
expected	O
from	O
the	O
single	O
agent	O
data	O
","	O
in	O
keeping	O
with	O
synergy	O
of	O
action	O
.	O
	
Phase	O
I	O
study	O
of	O
etoposide	B-DRUG
","	O
cisplatin	B-DRUG
and	O
irinotecan	B-DRUG
triplet	O
in	O
patients	O
with	O
advanced-stage	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
irinotecan-cisplatin	B-DRUG
combination	O
has	O
emerged	O
as	O
a	O
new	O
standard	O
for	O
the	O
treatment	O
of	O
advanced-stage	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
AS-SCLC	O
)	O
.	O
	
To	O
move	O
forward	O
we	O
developed	O
a	O
3-day	O
regimen	O
of	O
cisplatin	B-DRUG
","	O
etoposide	B-DRUG
and	O
irinotecan	B-DRUG
.	O
	
Successive	O
cohorts	O
of	O
AS-SCLC	O
patients	O
were	O
treated	O
with	O
irinotecan	B-DRUG
administered	O
as	O
a	O
single	O
1-h	O
infusion	O
in	O
combination	O
with	O
fixed	O
doses	O
of	O
cisplatin	B-DRUG
(	O
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
etoposide	B-DRUG
(	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
both	O
given	O
for	O
three	O
consecutive	O
days	O
(	O
ECI	B-DRUG
regimen	O
)	O
.	O
	
Irinotecan	B-DRUG
dose	O
was	O
escalated	O
from	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
by	O
40-mg	O
/	O
m	O
(	O
2	O
)	O
increments	O
.	O
	
At	O
mid-step	O
between	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
the	O
previous	O
dose	O
level	O
","	O
patients	O
were	O
randomized	O
for	O
the	O
day	O
of	O
administration	O
of	O
irinotecan	B-DRUG
(	O
day	O
1	O
vs	O
day	O
3	O
)	O
.	O
	
A	O
total	O
of	O
36	O
AS-SCLC	O
patients	O
received	O
166	O
courses	O
of	O
treatment	O
at	O
four	O
dose	O
levels	O
.	O
	
The	O
MTD	O
of	O
irinotecan	B-DRUG
was	O
140	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
three	O
dose-limiting	O
toxicities	O
","	O
DLTs	O
)	O
","	O
and	O
the	O
recommended	O
optimal	O
dose	O
(	O
ROD	O
)	O
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
two	O
DLTs	O
)	O
.	O
	
DLTs	O
were	O
febrile	B-TOXI
neutropenia	I-TOXI
and	O
grade	O
3	O
diarrhea	B-TOXI
.	O
	
Other	O
toxicities	O
were	O
mild	O
.	O
	
No	O
difference	O
in	O
toxicity	O
was	O
seen	O
between	O
the	O
two	O
time	O
schedules	O
.	O
	
A	O
77	O
%	O
(	O
95	O
%	O
CI	O
63.25-90.75	O
%	O
)	O
response	O
rate	O
was	O
recorded	O
among	O
31	O
evaluable	O
patients	O
and	O
the	O
median	O
survival	O
was	O
12	O
months	O
.	O
	
The	O
ECI	B-DRUG
regimen	O
was	O
well	O
tolerated	O
and	O
showed	O
considerable	O
activity	O
in	O
patients	O
with	O
AS-SCLC	O
.	O
	
Phase	O
II	O
/	O
III	O
evaluation	O
is	O
ongoing	O
.	O
	
Carboplatin	B-DRUG
plus	O
paclitaxel	B-DRUG
in	O
the	O
treatment	O
of	O
advanced	B-CANCER
or	I-CANCER
recurrent	I-CANCER
endometrial	I-CANCER
carcinoma	I-CANCER
.	O
	
	
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
the	O
combination	O
of	O
carboplatin	B-DRUG
plus	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
advanced	O
","	O
metastatic	B-CANCER
and	I-CANCER
recurrent	I-CANCER
endometrial	I-CANCER
cancer	I-CANCER
.	O
	
Medical	O
records	O
were	O
retrospectively	O
reviewed	O
to	O
identify	O
endometrial	B-CANCER
cancer	I-CANCER
patients	O
treated	O
in	O
the	O
Gynecologic	B-CANCER
Cancer	I-CANCER
Program	O
of	O
the	O
Cleveland	O
Clinic	O
with	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
who	O
had	O
both	O
a	O
histologic	O
diagnosis	O
of	O
endometrial	B-CANCER
adenocarcinoma	I-CANCER
and	O
either	O
measurable	O
(	O
CT	O
scan	O
","	O
physical	O
examination	O
)	O
or	O
evaluable	O
(	O
CA-125	O
criteria	O
)	O
disease	O
.	O
	
From	O
1994	O
to	O
2003	O
","	O
22	O
individuals	O
(	O
median	O
age	O
65	O
years	O
)	O
meeting	O
the	O
above	O
noted	O
criteria	O
received	O
a	O
total	O
of	O
23	O
courses	O
of	O
carboplatin	B-DRUG
(	O
AUC	O
4月6日	O
)	O
/	O
paclitaxel	B-DRUG
(	O
135-175	O
mg	O
/	O
m2	O
)	O
administered	O
on	O
a	O
21-day	O
schedule	O
(	O
median	O
six	O
cycles	O
/	O
patient	O
)	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
87	O
%	O
(	O
20	O
/	O
23	O
)	O
.	O
	
The	O
most	O
common	O
toxicity	O
was	O
hematologic	O
.	O
	
Five	O
patients	O
required	O
dose	O
reductions	O
due	O
to	O
excessive	O
toxicity	O
(	O
three	O
hematologic	B-TOXI
","	O
one	O
gastrointestinal	B-TOXI
","	O
one	O
fatigue	B-TOXI
)	O
.	O
	
There	O
were	O
no	O
treatment	B-TOXI
related	I-TOXI
deaths	I-TOXI
.	O
	
With	O
a	O
median	O
follow-up	O
of	O
42	O
months	O
","	O
13	O
patients	O
have	O
died	B-TOXI
of	O
progressive	B-TOXI
cancer	I-TOXI
","	O
while	O
four	O
currently	O
have	O
no	O
evidence	O
of	O
disease	O
at	O
the	O
time	O
of	O
last	O
follow-up	O
.	O
	
The	O
combination	O
of	O
carboplatin	B-DRUG
plus	O
paclitaxel	B-DRUG
demonstrates	O
substantial	O
biological	O
activity	O
in	O
endometrial	B-CANCER
adenocarcinoma	I-CANCER
.	O
	
The	O
safety	O
and	O
efficacy	O
of	O
this	O
regimen	O
makes	O
it	O
an	O
attractive	O
option	O
for	O
first-line	O
chemotherapy	O
in	O
patients	O
with	O
advanced	B-CANCER
or	I-CANCER
recurrent	I-CANCER
endometrial	I-CANCER
carcinoma	I-CANCER
.	O
	
Gemcitabine	B-DRUG
with	O
or	O
without	O
continuous	O
infusion	O
5-FU	B-DRUG
in	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
:	O
a	O
randomised	O
phase	O
II	O
trial	O
of	O
the	O
Italian	O
oncology	O
group	O
for	O
clinical	O
research	O
(	O
GOIRC	O
)	O
.	O
	
	
This	O
study	O
was	O
performed	O
to	O
determine	O
the	O
activity	O
of	O
adding	O
continuous	O
infusion	O
(	O
CI	O
)	O
of	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
to	O
gemcitabine	B-DRUG
(	O
GEM	B-DRUG
)	O
vs	O
GEM	B-DRUG
alone	O
in	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
(	O
APC	B-CANCER
)	O
.	O
	
In	O
all	O
","	O
94	O
chemo-na茂ve	O
patients	O
with	O
APC	B-CANCER
were	O
randomised	O
to	O
receive	O
GEM	B-DRUG
alone	O
(	O
arm	O
A	O
:	O
1000	O
mg	O
m	O
(	O
-2	O
)	O
per	O
week	O
for	O
7	O
weeks	O
followed	O
by	O
a	O
2	O
week	O
rest	O
period	O
","	O
then	O
weekly	O
for	O
3	O
consecutive	O
weeks	O
out	O
of	O
every	O
4	O
weeks	O
)	O
or	O
in	O
combination	O
with	O
CI	O
5-FU	B-DRUG
(	O
arm	O
B	O
:	O
CI	O
5-FU	B-DRUG
200	O
mg	O
m	O
(	O
-2	O
)	O
day	O
(	O
-1	O
)	O
for	O
6	O
weeks	O
followed	O
by	O
a	O
2	O
week	O
rest	O
period	O
","	O
then	O
for	O
3	O
weeks	O
every	O
4	O
weeks	O
)	O
.	O
	
Overall	O
response	O
rate	O
(	O
RR	O
)	O
was	O
the	O
primary	O
end	O
point	O
and	O
criteria	O
for	O
decision	O
were	O
planned	O
according	O
to	O
the	O
Simon	O
's	O
optimal	O
two-stage	O
design	O
.	O
	
The	O
overall	O
RR	O
was	O
8	O
%	O
(	O
arm	O
A	O
)	O
and	O
11	O
%	O
(	O
arm	O
B	O
)	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
0.5-16	O
%	O
and	O
2月22日	O
%	O
)	O
","	O
respectively	O
","	O
and	O
stable	O
disease	O
was	O
29	O
and	O
28	O
%	O
.	O
	
The	O
median	O
duration	O
of	O
RR	O
was	O
34	O
weeks	O
(	O
range	O
25-101	O
weeks	O
)	O
for	O
GEM	B-DRUG
and	O
26	O
weeks	O
(	O
range	O
16-46	O
weeks	O
)	O
for	O
the	O
combination	O
.	O
	
The	O
median	O
progression-free	O
survival	O
(	O
PFS	O
)	O
was	O
14	O
weeks	O
(	O
range	O
2-65	O
weeks	O
)	O
and	O
18	O
weeks	O
(	O
range	O
4-51	O
weeks	O
)	O
","	O
respectively	O
.	O
	
The	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
31	O
weeks	O
(	O
range	O
1-101	O
weeks	O
)	O
and	O
30	O
weeks	O
(	O
1-101	O
weeks	O
)	O
.	O
	
Toxicity	O
was	O
mild	O
in	O
both	O
arms	O
.	O
	
This	O
study	O
does	O
not	O
show	O
promising	O
activity	O
in	O
terms	O
of	O
RR	O
","	O
PFS	O
and	O
OS	O
for	O
the	O
double	O
combination	O
arm	O
in	O
APC	B-CANCER
.	O
	
Hepatic	O
arterial	O
oxaliplatin	B-DRUG
infusion	O
plus	O
intravenous	O
chemotherapy	O
in	O
colorectal	B-CANCER
cancer	I-CANCER
with	O
inoperable	O
hepatic	O
metastases	O
:	O
a	O
trial	O
of	O
the	O
gastrointestinal	O
group	O
of	O
the	O
Federation	O
Nationale	O
des	O
Centres	O
de	O
Lutte	O
Contre	O
le	O
Cancer	O
.	O
	
	
Isolated	O
hepatic	O
metastases	O
of	O
colorectal	B-CANCER
cancer	I-CANCER
constitute	O
a	O
frequent	O
and	O
serious	O
therapeutic	O
problem	O
that	O
has	O
led	O
to	O
the	O
evaluation	O
of	O
hepatic	O
arterial	O
infusion	O
(	O
HAI	O
)	O
of	O
different	O
drugs	O
.	O
	
Oxaliplatin	B-DRUG
combined	O
with	O
fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
and	O
leucovorin	B-DRUG
is	O
effective	O
in	O
the	O
treatment	O
of	O
colorectal	B-CANCER
cancer	I-CANCER
.	O
	
In	O
this	O
context	O
","	O
a	O
phase	O
II	O
study	O
was	O
conducted	O
to	O
evaluate	O
concomitant	O
administration	O
of	O
oxaliplatin	B-DRUG
by	O
HAI	O
and	O
intravenous	O
(	O
IV	O
)	O
FU	B-DRUG
plus	O
leucovorin	B-DRUG
according	O
to	O
the	O
LV5FU2	B-DRUG
protocol	O
(	O
leucovorin	B-DRUG
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
FU	B-DRUG
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
bolus	O
","	O
FU	B-DRUG
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
22-hour	O
continuous	O
infusion	O
on	O
days	O
1	O
and	O
2	O
every	O
2	O
weeks	O
)	O
.	O
	
Patients	O
had	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
that	O
was	O
restricted	O
to	O
the	O
liver	O
and	O
inoperable	O
.	O
	
The	O
patients	O
were	O
not	O
to	O
have	O
previously	O
received	O
oxaliplatin	B-DRUG
.	O
	
After	O
surgical	O
insertion	O
of	O
a	O
catheter	O
in	O
the	O
hepatic	O
artery	O
","	O
patients	O
were	O
treated	O
with	O
oxaliplatin	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
HAI	O
combined	O
with	O
FU	B-DRUG
=+	O
leucovorin	B-DRUG
IV	O
according	O
to	O
the	O
LV5FU2	B-DRUG
protocol	O
.	O
	
Treatment	O
was	O
continued	O
until	O
disease	O
progression	O
or	O
toxicity	O
.	O
	
Response	O
was	O
evaluated	O
every	O
2	O
months	O
.	O
	
Twenty-eight	O
patients	O
were	O
included	O
","	O
and	O
26	O
patients	O
were	O
treated	O
.	O
	
Two	O
hundred	O
courses	O
of	O
therapy	O
were	O
administered	O
","	O
and	O
the	O
median	O
number	O
of	O
courses	O
received	O
was	O
eight	O
courses	O
(	O
range	O
","	O
zero	O
to	O
20	O
courses	O
)	O
.	O
	
The	O
most	O
frequent	O
toxicity	O
consisted	O
of	O
neutropenia	B-TOXI
.	O
	
The	O
main	O
toxicity	O
related	O
to	O
HAI	O
was	O
pain	B-TOXI
.	O
	
The	O
intent-to-treat	O
objective	O
response	O
rate	O
was	O
64	O
%	O
(	O
95	O
%	O
CI	O
","	O
44	O
%	O
to	O
81	O
%	O
;	O
18	O
of	O
28	O
patients	O
)	O
.	O
	
With	O
a	O
median	O
follow-up	O
of	O
23	O
months	O
","	O
the	O
median	O
overall	O
and	O
disease-free	O
survival	O
times	O
were	O
27	O
and	O
27	O
months	O
","	O
respectively	O
.	O
	
The	O
combination	O
of	O
oxaliplatin	B-DRUG
HAI	O
and	O
FU	B-DRUG
=+	O
leucovorin	B-DRUG
according	O
to	O
the	O
LV5FU2	B-DRUG
protocol	O
is	O
feasible	O
and	O
effective	O
in	O
patients	O
presenting	O
with	O
isolated	O
hepatic	O
metastases	O
of	O
colorectal	B-CANCER
cancer	I-CANCER
.	O
	
Phase	O
II	O
study	O
of	O
weekly	O
oxaliplatin	B-DRUG
plus	O
infusional	B-DRUG
fluorouracil	I-DRUG
and	O
folinic	B-DRUG
acid	I-DRUG
(	O
FUFOX	B-DRUG
regimen	O
)	O
as	O
first-line	O
treatment	O
in	O
metastatic	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
	
Oxaliplatin	B-DRUG
plus	O
fluorouracil	B-DRUG
/	O
folinic	B-DRUG
acid	I-DRUG
(	O
5-FU	B-DRUG
/	O
FA	B-DRUG
)	O
every	O
2	O
weeks	O
has	O
shown	O
promising	O
activity	O
in	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
This	O
study	O
assessed	O
the	O
efficacy	O
and	O
safety	O
of	O
weekly	O
oxaliplatin	B-DRUG
plus	O
5-FU	B-DRUG
/	O
FA	B-DRUG
(	O
FUFOX	B-DRUG
regimen	O
)	O
in	O
the	O
metastatic	O
setting	O
.	O
	
Patients	O
with	O
previously	O
untreated	O
metastatic	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
received	O
oxaliplatin	B-DRUG
(	O
50	O
mg	O
m	O
(	O
-2	O
)	O
)	O
plus	O
FA	B-DRUG
(	O
500	O
mg	O
m	O
(	O
-2	O
)	O
","	O
2-h	O
infusion	O
)	O
followed	O
by	O
5-FU	B-DRUG
(	O
2000	O
mg	O
m	O
(	O
-2	O
)	O
","	O
24-h	O
infusion	O
)	O
given	O
on	O
days	O
1	O
","	O
8	O
","	O
15	O
and	O
22	O
of	O
a	O
5-week	O
cycle	O
.	O
	
The	O
primary	O
end	O
point	O
of	O
this	O
multicentre	O
phase	O
II	O
study	O
was	O
the	O
response	O
rate	O
according	O
to	O
RECIST	O
criteria	O
.	O
	
A	O
total	O
of	O
48	O
patients	O
were	O
enrolled	O
.	O
	
Median	O
age	O
was	O
62	O
years	O
and	O
all	O
patients	O
had	O
metastatic	O
disease	O
","	O
with	O
a	O
median	O
number	O
of	O
three	O
involved	O
organs	O
.	O
	
The	O
most	O
common	O
treatment-related	O
grade	O
3	O
/	O
4	O
adverse	O
events	O
were	O
diarrhoea	B-TOXI
(	O
17	O
%	O
)	O
","	O
deep	B-TOXI
vein	I-TOXI
thrombosis	I-TOXI
(	O
15	O
%	O
)	O
","	O
neutropenia	B-TOXI
(	O
8	O
%	O
)	O
","	O
nausea	B-TOXI
(	O
6	O
%	O
)	O
","	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
4	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
4	O
%	O
)	O
","	O
anaemia	B-TOXI
(	O
4	O
%	O
)	O
","	O
tumour	B-TOXI
bleeding	I-TOXI
(	O
4	O
%	O
)	O
","	O
emesis	B-TOXI
(	O
2	O
%	O
)	O
","	O
cardiac	B-TOXI
ischaemia	I-TOXI
(	O
2	O
%	O
)	O
and	O
pneumonia	B-TOXI
(	O
2	O
%	O
)	O
.	O
	
Grade	O
1	O
/	O
2	O
sensory	B-TOXI
neuropathy	I-TOXI
occurred	O
in	O
67	O
%	O
of	O
patients	O
but	O
there	O
were	O
no	O
episodes	O
of	O
grade	O
3	O
neuropathy	B-TOXI
.	O
	
Intent-to-treat	O
analysis	O
showed	O
a	O
response	O
rate	O
of	O
54	O
%	O
(	O
95	O
%	O
CI	O
","	O
39-69	O
%	O
)	O
","	O
including	O
two	O
complete	O
responses	O
.	O
	
At	O
a	O
median	O
follow-up	O
of	O
18.1	O
months	O
(	O
range	O
11.2-26.2	O
months	O
)	O
","	O
median	O
survival	O
is	O
11.4	O
months	O
(	O
95	O
%	O
CI	O
","	O
8.0-14.9	O
months	O
)	O
and	O
the	O
median	O
time	O
to	O
progression	O
is	O
6.5	O
months	O
(	O
95	O
%	O
CI	O
","	O
3.9-9.2	O
months	O
)	O
.	O
	
The	O
weekly	O
FUFOX	B-DRUG
regimen	O
is	O
well	O
tolerated	O
and	O
shows	O
notable	O
activity	O
as	O
first-line	O
treatment	O
in	O
metastatic	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Gemcitabine	B-DRUG
(	O
GEM	B-DRUG
)	O
plus	O
oxaliplatin	B-DRUG
","	O
folinic	B-DRUG
acid	I-DRUG
","	O
and	O
5-fluorouracil	B-DRUG
(	O
FOLFOX-4	B-DRUG
)	O
in	O
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
	
oxaliplatin	B-DRUG
in	O
combination	O
with	O
folinic	B-DRUG
acid	I-DRUG
(	O
FA	B-DRUG
)	O
and	O
infusional	B-DRUG
5-fluorouracil	I-DRUG
(	O
5-FU	B-DRUG
)	O
has	O
shown	O
significant	O
anti-tumor	O
activity	O
in	O
gastric	B-CANCER
cancer	I-CANCER
patients	O
(	O
FOLFOX	B-DRUG
)	O
.	O
	
Previous	O
studies	O
have	O
shown	O
that	O
gemcitabine	B-DRUG
(	O
GEM	B-DRUG
)	O
","	O
a	O
new	O
fluorinated	O
anti-metabolite	O
","	O
enhances	O
the	O
individual	O
anti-tumor	O
activity	O
of	O
either	O
5-FU	B-DRUG
or	O
oxaliplatin	B-DRUG
.	O
	
We	O
have	O
therefore	O
designed	O
a	O
multi-center	O
phase	O
II	O
trial	O
in	O
order	O
to	O
test	O
a	O
novel	O
GEM+FOLFOX-4	B-DRUG
regimen	O
in	O
patients	O
with	O
metastatic	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
we	O
enrolled	O
36	O
patients	O
","	O
28	O
males	O
and	O
8	O
females	O
","	O
with	O
an	O
average	O
age	O
of	O
64.4	O
years	O
(	O
range	O
37-78	O
)	O
","	O
who	O
received	O
bi-weekly	O
treatment	O
with	O
GEM	B-DRUG
(	O
"1,000"	O
mg	O
/	O
m2	O
on	O
day	O
1	O
)	O
","	O
levo-FA	B-DRUG
(	O
100	O
mg	O
/	O
m2	O
on	O
days	O
1	O
and	O
2	O
)	O
","	O
a	O
5-FU	B-DRUG
(	O
400	O
mg	O
/	O
m2	O
)	O
bolus	O
injection	O
followed	O
by	O
22-h	O
continuous	O
infusion	O
(	O
800	O
mg	O
/	O
m2	O
)	O
on	O
days	O
1	O
and	O
2	O
","	O
and	O
oxaliplatin	B-DRUG
85	O
mg	O
/	O
m2	O
in	O
a	O
4月6日	O
h	O
intravenous	O
(	O
i.v.	O
)	O
infusion	O
before	O
the	O
second	O
FUFA	B-DRUG
administration	O
on	O
day	O
2	O
the	O
most	O
frequent	O
side	O
effect	O
was	O
grade	O
1月2日	O
hematological	B-TOXI
toxicity	I-TOXI
and	O
late	O
sensorial	B-TOXI
neurotoxicity	I-TOXI
.	O
	
Two	O
patients	O
developed	O
hypersensitivity	B-TOXI
to	O
oxaliplatin	B-DRUG
while	O
another	O
developed	O
an	O
aseptic	B-TOXI
eosinophilic	I-TOXI
pneumonitis	I-TOXI
.	O
	
Two	O
patients	O
refused	O
to	O
continue	O
the	O
treatment	O
after	O
two	O
cycles	O
of	O
chemotherapy	O
and	O
were	O
lost	O
at	O
the	O
follow-up	O
.	O
	
Among	O
the	O
remaining	O
34	O
patients	O
four	O
achieved	O
a	O
complete	O
response	O
","	O
15	O
a	O
partial	O
response	O
","	O
12	O
had	O
a	O
stable	O
disease	O
and	O
three	O
progressed	O
.	O
	
these	O
results	O
may	O
grant	O
the	O
rationale	O
to	O
evaluate	O
this	O
multi-drug	O
combination	O
in	O
randomized	O
phase	O
III	O
trials	O
in	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
A	O
phase	O
I	O
study	O
to	O
determine	O
the	O
effect	O
of	O
tamoxifen	B-DRUG
on	O
the	O
pharmacokinetics	O
of	O
a	O
single	O
250	O
mg	O
oral	O
dose	O
of	O
gefitinib	B-DRUG
(	O
IRESSA	O
)	O
in	O
healthy	O
male	O
volunteers	O
.	O
	
	
To	O
determine	O
the	O
effect	O
of	O
tamoxifen	B-DRUG
on	O
the	O
pharmacokinetics	O
of	O
a	O
single	O
250	O
mg	O
oral	O
dose	O
of	O
gefitinib	B-DRUG
(	O
IRESSA	O
)	O
in	O
healthy	O
volunteers	O
.	O
	
An	O
open-label	O
","	O
single-center	O
","	O
phase	O
I	O
study	O
in	O
healthy	O
male	O
volunteers	O
.	O
	
Each	O
volunteer	O
received	O
a	O
single	O
250	O
mg	O
oral	O
dose	O
of	O
gefitinib	B-DRUG
on	O
day	O
1	O
On	O
days	O
11月14日	O
","	O
oral	O
loading	O
doses	O
of	O
60	O
mg	O
tamoxifen	B-DRUG
were	O
administered	O
","	O
followed	O
by	O
20	O
mg	O
tamoxifen	B-DRUG
for	O
a	O
further	O
16	O
days	O
to	O
maintain	O
steady-state	O
exposure	O
.	O
	
On	O
day	O
24	O
","	O
volunteers	O
received	O
a	O
second	O
single	O
250	O
mg	O
oral	O
dose	O
of	O
gefitinib	B-DRUG
.	O
	
The	O
last	O
dose	O
of	O
tamoxifen	B-DRUG
was	O
given	O
on	O
day	O
30	O
.	O
	
Pharmacokinetic	O
and	O
safety	O
assessments	O
were	O
conducted	O
throughout	O
the	O
trial	O
.	O
	
A	O
total	O
of	O
18	O
volunteers	O
were	O
recruited	O
.	O
	
The	O
presence	O
of	O
tamoxifen	B-DRUG
did	O
not	O
have	O
a	O
clinically	O
significant	O
effect	O
on	O
the	O
primary	O
variables	O
AUC	O
and	O
Cmax	O
of	O
gefitinib	B-DRUG
","	O
nor	O
on	O
the	O
secondary	O
variables	O
AUC	O
(	O
0-t	O
)	O
","	O
tmax	O
","	O
t1	O
/	O
2	O
","	O
and	O
lambdaz	O
.	O
	
The	O
geometric	O
least	O
square	O
mean	O
values	O
for	O
AUC	O
were	O
"3,407.60"	O
versus	O
"3,397.90"	O
ng.h	O
/	O
ml	O
in	O
the	O
absence	O
and	O
presence	O
of	O
tamoxifen	B-DRUG
","	O
respectively	O
(	O
90	O
%	O
CL	O
0.894	O
","	O
1.112	O
)	O
and	O
for	O
Cmax	O
were	O
110.8	O
versus	O
103.6	O
ng	O
/	O
ml	O
","	O
respectively	O
(	O
90	O
%	O
CL	O
0.786	O
","	O
1.111	O
)	O
.	O
	
The	O
combination	O
of	O
gefitinib	B-DRUG
with	O
tamoxifen	B-DRUG
was	O
generally	O
well	O
tolerated	O
by	O
the	O
volunteers	O
.	O
	
There	O
were	O
no	O
serious	O
adverse	O
events	O
and	O
no	O
volunteer	O
discontinued	O
the	O
study	O
due	O
to	O
an	O
adverse	O
event	O
.	O
	
NCI-CTC	O
grade	O
1	O
/	O
2	O
drug-related	O
adverse	O
events	O
were	O
observed	O
in	O
seven	O
volunteers	O
","	O
including	O
loose	B-TOXI
stools	I-TOXI
and	O
skin	B-TOXI
events	I-TOXI
associated	O
with	O
gefitinib	B-DRUG
","	O
and	O
lethargy	B-TOXI
and	O
headache	B-TOXI
","	O
flushing	B-TOXI
","	O
and	O
dizziness	B-TOXI
associated	O
with	O
tamoxifen	B-DRUG
.	O
	
This	O
study	O
suggests	O
that	O
tamoxifen	B-DRUG
has	O
no	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
","	O
tolerability	O
","	O
or	O
safety	O
of	O
a	O
single	O
250	O
mg	O
oral	O
dose	O
of	O
gefitinib	B-DRUG
.	O
	
Therefore	O
","	O
in	O
clinical	O
investigations	O
of	O
this	O
combination	O
","	O
no	O
dose	O
adjustment	O
of	O
gefitinib	B-DRUG
is	O
indicated	O
.	O
	
Fluoropyrimidine	B-DRUG
therapy	O
:	O
hyperbilirubinemia	B-TOXI
as	O
a	O
consequence	O
of	O
hemolysis	B-TOXI
.	O
	
	
Hemolytic	B-TOXI
anemia	I-TOXI
has	O
been	O
noted	O
during	O
treatment	O
with	O
a	O
variety	O
of	O
chemotherapeutic	O
agents	O
.	O
	
We	O
observed	O
mild	O
compensated	O
hemolytic	B-TOXI
anemia	I-TOXI
in	O
a	O
patient	O
receiving	O
capecitabine	B-DRUG
during	O
a	O
randomized	O
","	O
controlled	O
trial	O
of	O
adjuvant	O
therapy	O
.	O
	
In	O
order	O
to	O
investigate	O
the	O
hypothesis	O
that	O
hemolysis	B-TOXI
is	O
the	O
underlying	O
cause	O
of	O
the	O
hyperbilirubinemia	B-TOXI
sometimes	O
observed	O
during	O
capecitabine	B-DRUG
treatment	O
","	O
we	O
evaluated	O
factors	O
associated	O
with	O
hemolysis	B-TOXI
in	O
ten	O
patients	O
.	O
	
Factors	O
were	O
also	O
analyzed	O
in	O
ten	O
patients	O
receiving	O
5-fluorourocil	B-DRUG
/	O
leucovorin	B-DRUG
(	O
5-FU	B-DRUG
/	O
LV	B-DRUG
)	O
.	O
	
Twenty	O
chemotherapy-na茂ve	O
patients	O
undergoing	O
surgery	O
for	O
Dukes	O
'	O
C	O
colon	B-CANCER
cancer	I-CANCER
were	O
included	O
in	O
the	O
phase	O
III	O
","	O
'X-ACT	O
'	O
trial	O
","	O
and	O
randomized	O
to	O
receive	O
24-week	O
adjuvant	O
treatment	O
with	O
either	O
oral	O
capecitabine	B-DRUG
(	O
eight	O
cycles	O
of	O
"1,250"	O
mg	O
/	O
m2	O
twice	O
daily	O
for	O
14	O
days	O
","	O
followed	O
by	O
a	O
7-day	O
rest	O
period	O
)	O
(	O
n=10	O
)	O
or	O
5-FU	B-DRUG
/	O
LV	B-DRUG
administered	O
according	O
to	O
the	O
Mayo	O
Clinic	O
regimen	O
(	O
six	O
cycles	O
of	O
LV	B-DRUG
20	O
mg	O
/	O
m2	O
followed	O
by	O
5-FU	B-DRUG
425	O
mg	O
/	O
m2	O
","	O
administered	O
as	O
an	O
i.v.	O
bolus	O
on	O
days	O
1月5日	O
every	O
28	O
days	O
)	O
(	O
n=10	O
)	O
.	O
	
Ten	O
patients	O
randomized	O
in	O
each	O
treatment	O
arm	O
were	O
evaluated	O
.	O
	
Hemolytic	O
parameters	O
evaluated	O
included	O
bilirubin	O
","	O
lactate	O
dehydrogenase	O
","	O
haptoglobin	O
","	O
and	O
reticulocytes	O
.	O
	
Seven	O
patients	O
receiving	O
capecitabine	B-DRUG
and	O
three	O
patients	O
receiving	O
5-FU	B-DRUG
/	O
LV	B-DRUG
experienced	O
grade	O
1	O
/	O
2	O
elevations	O
of	O
bilirubin	B-TOXI
during	O
the	O
24-week	O
treatment	O
period	O
.	O
	
In	O
most	O
cases	O
","	O
hyperbilirubinemia	B-TOXI
was	O
associated	O
with	O
concomitant	O
alterations	O
in	O
other	O
hemolytic	O
parameters	O
.	O
	
Five	O
episodes	O
of	O
grade	O
1	O
compensated	O
hemolytic	B-TOXI
anemia	I-TOXI
were	O
reported	O
in	O
four	O
capecitabine-treated	B-DRUG
patients	O
","	O
all	O
of	O
which	O
were	O
associated	O
with	O
hyperbilirubinemia	B-TOXI
.	O
	
Adjuvant	O
treatment	O
with	O
capecitabine	B-DRUG
or	O
5-FU	B-DRUG
/	O
LV	B-DRUG
in	O
a	O
small	O
sample	O
of	O
patients	O
with	O
Dukes	O
'	O
C	O
colon	B-CANCER
cancer	I-CANCER
was	O
associated	O
with	O
alterations	O
in	O
hemolytic	O
parameters	O
.	O
	
These	O
alterations	O
","	O
in	O
particular	O
hyperbilirubinemia	B-TOXI
","	O
were	O
associated	O
in	O
some	O
patients	O
with	O
low-grade	O
compensated	O
hemolytic	B-TOXI
anemia	I-TOXI
.	O
	
All	O
changes	O
were	O
clinically	O
insignificant	O
","	O
fully	O
reversible	O
","	O
and	O
may	O
represent	O
a	O
fluoropyrimidine	B-DRUG
class	O
effect	O
.	O
	
Further	O
studies	O
are	O
indicated	O
to	O
evaluate	O
the	O
incidence	O
and	O
implications	O
of	O
this	O
effect	O
.	O
	
Phase	O
II	O
study	O
with	O
a	O
combination	O
of	O
epirubicin	B-DRUG
","	O
cisplatin	B-DRUG
","	O
UFT	B-DRUG
","	O
and	O
leucovorin	B-DRUG
in	O
advanced	B-CANCER
hepatocellular	I-CANCER
carcinoma	I-CANCER
.	O
	
	
Hepatocellular	B-CANCER
carcinoma	I-CANCER
(	O
HCC	B-CANCER
)	O
is	O
one	O
of	O
the	O
most	O
common	O
malignancies	O
worldwide	O
.	O
	
Because	O
HCC	B-CANCER
usually	O
presents	O
as	O
an	O
advanced	O
disease	O
and	O
occurs	O
in	O
the	O
background	O
of	O
liver	O
cirrhosis	O
","	O
most	O
patients	O
are	O
not	O
suitable	O
for	O
treatment	O
with	O
curative	O
intent	O
","	O
thus	O
effective	O
systemic	O
chemotherapy	O
is	O
required	O
.	O
	
However	O
","	O
the	O
outcome	O
of	O
systemic	O
chemotherapy	O
has	O
been	O
disappointing	O
in	O
advanced	B-CANCER
HCC	I-CANCER
.	O
	
This	O
study	O
was	O
conducted	O
to	O
test	O
the	O
efficacy	O
and	O
toxicity	O
of	O
the	O
combined	O
regimen	O
of	O
epirubicin	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
UFT	B-DRUG
moderated	O
by	O
leucovorin	B-DRUG
in	O
advanced	B-CANCER
or	I-CANCER
recurrent	I-CANCER
HCC	I-CANCER
.	O
	
All	O
53	O
patients	O
received	O
epirubicin	B-DRUG
(	O
50	O
mg	O
/	O
m2	O
i.v.	O
)	O
on	O
day	O
1	O
and	O
cisplatin	B-DRUG
(	O
60	O
mg	O
/	O
m2	O
i.v.	O
)	O
after	O
epirubicin	B-DRUG
administration	O
.	O
	
Oral	O
UFT	B-DRUG
400-600	O
mg	O
/	O
day	O
","	O
determined	O
by	O
body	O
surface	O
area	O
","	O
and	O
leucovorin	B-DRUG
75	O
mg	O
/	O
day	O
were	O
administered	O
for	O
21	O
consecutive	O
days	O
","	O
followed	O
by	O
a	O
7-day	O
drug	O
free	O
interval	O
.	O
	
Nine	O
had	O
a	O
partial	O
response	O
","	O
representing	O
16.9	O
%	O
of	O
response	O
rate	O
(	O
95	O
%	O
confidence	O
interval	O
rate	O
;	O
7.0-26.8	O
%	O
)	O
with	O
median	O
response	O
duration	O
of	O
17.1	O
weeks	O
(	O
95	O
%	O
CI	O
;	O
5.0-29.3	O
weeks	O
","	O
range	O
;	O
7.1-51.7	O
weeks	O
)	O
.	O
	
Fifteen	O
patients	O
had	O
stable	O
disease	O
and	O
the	O
disease	B-TOXI
progressed	I-TOXI
in	O
26	O
patients	O
.	O
	
The	O
median	O
overall	O
survival	O
for	O
the	O
patients	O
was	O
24.6	O
weeks	O
(	O
95	O
%	O
CI	O
;	O
17.3-31.9	O
weeks	O
","	O
range	O
;	O
3.0-131.3	O
weeks	O
)	O
.	O
	
The	O
main	O
toxicities	O
were	O
hematologic	B-TOXI
toxicities	I-TOXI
including	O
neutropenia	B-TOXI
","	O
which	O
reached	O
grade	O
3	O
/	O
4	O
in	O
17	O
patients	O
(	O
38.5	O
%	O
)	O
","	O
and	O
grade	O
3	O
or	O
4	O
thrombocytopenia	B-TOXI
in	O
five	O
patients	O
(	O
9.4	O
%	O
)	O
.	O
	
The	O
combination	O
of	O
epirubicin	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
UFT	B-DRUG
moderated	O
by	O
leucovorin	B-DRUG
showed	O
modest	O
anti-tumor	O
activity	O
with	O
relatively	O
tolerable	O
toxicities	O
.	O
	
However	O
","	O
a	O
randomized	O
phase	O
III	O
trial	O
based	O
on	O
this	O
regimen	O
is	O
warranted	O
to	O
clarify	O
its	O
survival	O
benefit	O
in	O
patients	O
with	O
advanced	B-CANCER
HCC	I-CANCER
.	O
	
Bi-weekly	O
chemotherapy	O
of	O
paclitaxel	B-DRUG
and	O
cisplatin	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
or	I-CANCER
recurrent	I-CANCER
esophageal	I-CANCER
cancer	I-CANCER
.	O
	
	
Although	O
various	O
combinations	O
of	O
chemotherapy	O
regimens	O
have	O
been	O
tried	O
for	O
patients	O
with	O
esophageal	B-CANCER
cancer	I-CANCER
","	O
their	O
duration	O
of	O
survival	O
is	O
extremely	O
poor	O
.	O
	
In	O
this	O
study	O
","	O
we	O
investigated	O
the	O
safety	O
and	O
clinical	O
efficacy	O
of	O
paclitaxel	B-DRUG
and	O
cisplatin	B-DRUG
chemotherapy	O
in	O
metastatic	B-CANCER
or	I-CANCER
recurrent	I-CANCER
esophageal	I-CANCER
cancer	I-CANCER
.	O
	
32	O
patients	O
enrolled	O
in	O
this	O
study	O
and	O
the	O
median	O
age	O
was	O
60	O
yr	O
.	O
	
Of	O
all	O
the	O
32	O
","	O
28	O
patients	O
(	O
88	O
%	O
)	O
had	O
been	O
treated	O
previously	O
","	O
22	O
of	O
them	O
with	O
chemotherapy	O
or	O
radiation	O
therapy	O
.	O
	
All	O
patients	O
in	O
the	O
study	O
received	O
biweekly	O
paclitaxel	B-DRUG
(	O
90	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
followed	O
by	O
cisplatin	B-DRUG
(	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O
	
One	O
patient	O
(	O
3	O
%	O
)	O
responded	O
completely	O
","	O
and	O
12	O
patients	O
(	O
38	O
%	O
)	O
showed	O
a	O
partial	O
response	O
;	O
in	O
9	O
patients	O
(	O
28	O
%	O
)	O
the	O
disease	O
remained	O
stable	O
","	O
and	O
in	O
10	O
patients	O
(	O
31	O
%	O
)	O
it	O
progressed	O
.	O
	
The	O
objective	O
response	O
rate	O
was	O
41	O
%	O
.	O
	
The	O
median	O
duration	O
of	O
response	O
was	O
4.8	O
months	O
","	O
and	O
the	O
median	O
overall	O
survival	O
in	O
all	O
patients	O
was	O
7	O
months	O
.	O
	
The	O
1-yr	O
and	O
2-yr	O
survival	O
rates	O
were	O
28.1	O
%	O
and	O
7.1	O
%	O
","	O
respectively	O
.	O
	
Grade	O
3	O
or	O
4	O
of	O
neutropenia	B-TOXI
and	O
anemia	B-TOXI
were	O
observed	O
in	O
6	O
(	O
19	O
%	O
)	O
and	O
5	O
(	O
16	O
%	O
)	O
patients	O
","	O
respectively	O
.	O
	
The	O
major	O
non-hematologic	B-TOXI
toxicity	I-TOXI
was	O
fatigue	B-TOXI
","	O
but	O
most	O
of	O
them	O
could	O
manageable	O
.	O
	
In	O
conclusion	O
","	O
biweekly	O
paclitaxel	B-DRUG
and	O
cisplatin	B-DRUG
is	O
effective	O
in	O
patients	O
with	O
metastatic	B-CANCER
or	I-CANCER
recurrent	I-CANCER
esophageal	I-CANCER
cancer	I-CANCER
.	O
	
Phase	O
II	O
trial	O
of	O
the	O
novel	O
retinoid	B-DRUG
","	O
bexarotene	B-DRUG
","	O
and	O
gemcitabine	B-DRUG
plus	O
carboplatin	B-DRUG
in	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
Platinum-based	B-DRUG
chemotherapy	O
is	O
the	O
standard	O
treatment	O
for	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Unfortunately	O
","	O
a	O
plateau	O
in	O
efficacy	O
with	O
currently	O
available	O
agents	O
has	O
been	O
reached	O
.	O
	
Previous	O
studies	O
of	O
the	O
retinoid	B-DRUG
","	O
bexarotene	B-DRUG
","	O
a	O
retinoid	O
X	O
receptor-specific	O
ligand	O
","	O
have	O
indicated	O
that	O
it	O
may	O
improve	O
outcome	O
in	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
Patients	O
with	O
previously	O
untreated	O
stage	O
IIIB	O
or	O
stage	O
IV	O
disease	O
","	O
a	O
performance	O
status	O
of	O
0	O
to	O
2	O
","	O
and	O
adequate	O
organ	O
status	O
were	O
entered	O
.	O
	
Treatment	O
consisted	O
of	O
up	O
to	O
six	O
cycles	O
of	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
=	O
5	O
on	O
day	O
1	O
)	O
and	O
gemcitabine	B-DRUG
(	O
"1,000"	O
mg	O
/	O
m2	O
on	O
days	O
1	O
and	O
8	O
)	O
administered	O
every	O
21	O
days	O
.	O
	
Bexarotene	B-DRUG
400	O
mg	O
/	O
m2	O
orally	O
was	O
to	O
be	O
administered	O
continuously	O
beginning	O
on	O
day	O
1	O
and	O
until	O
progression	B-TOXI
of	I-TOXI
disease	I-TOXI
.	O
	
All	O
patients	O
received	O
atorvastatin	B-DRUG
10	O
mg	O
orally	O
beginning	O
before	O
bexarotene	B-DRUG
.	O
	
The	O
objective	O
was	O
to	O
demonstrate	O
a	O
1-year	O
survival	O
rate	O
of	O
more	O
than	O
50	O
%	O
.	O
	
Forty-eight	O
patients	O
were	O
entered	O
;	O
all	O
were	O
assessable	O
for	O
survival	O
","	O
and	O
47	O
were	O
assessable	O
for	O
toxicity	O
and	O
response	O
.	O
	
The	O
therapeutic	O
regimen	O
was	O
well	O
tolerated	O
except	O
for	O
hypertriglyceridemia	B-TOXI
.	O
	
The	O
median	O
time	O
to	O
progression	O
was	O
6.7	O
months	O
","	O
and	O
overall	O
median	O
survival	O
was	O
12.7	O
months	O
.	O
	
There	O
was	O
a	O
25	O
%	O
response	O
rate	O
and	O
a	O
1-year	O
survival	O
rate	O
of	O
53	O
%	O
.	O
	
These	O
results	O
were	O
compared	O
with	O
the	O
outcome	O
of	O
33	O
patients	O
treated	O
at	O
our	O
institution	O
with	O
two-drug	O
","	O
platinum-based	B-DRUG
chemotherapy	O
on	O
controlled	O
trials	O
with	O
similar	O
entry	O
criteria	O
in	O
the	O
previous	O
5	O
years	O
.	O
	
Bexarotene	B-DRUG
can	O
be	O
safely	O
added	O
to	O
platinum-based	B-DRUG
chemotherapy	O
provided	O
that	O
there	O
is	O
aggressive	O
prophylaxis	O
of	O
hypertriglyceridemia	B-TOXI
.	O
	
The	O
median	O
time	O
to	O
progression	O
and	O
overall	O
survival	O
are	O
promising	O
and	O
warrant	O
further	O
evaluation	O
of	O
bexarotene	B-DRUG
in	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
High	O
efficacy	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
in	O
patients	O
with	O
predominantly	O
anthracycline-	B-DRUG
and	O
taxane-pretreated	B-DRUG
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
Effective	O
and	O
tolerable	O
regimens	O
are	O
sought	O
specifically	O
in	O
patients	O
who	O
have	O
been	O
pretreated	O
with	O
anthracyclines	B-DRUG
and	O
taxanes	B-DRUG
.	O
	
Gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
demonstrated	O
synergistic	O
activity	O
in	O
vitro	O
and	O
provides	O
a	O
new	O
mechanism	O
of	O
drug	O
interaction	O
.	O
	
Previously	O
treated	O
patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
MBC	B-CANCER
)	O
were	O
enrolled	O
in	O
a	O
multicentre	O
phase	O
II	O
study	O
.	O
	
Treatment	O
consisted	O
of	O
gemcitabine	B-DRUG
(	O
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
cisplatin	B-DRUG
(	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
given	O
on	O
day	O
1	O
and	O
8	O
every	O
3	O
weeks	O
.	O
	
Thirty-eight	O
patients	O
were	O
recruited	O
","	O
all	O
of	O
whom	O
had	O
previously	O
received	O
chemotherapy	O
(	O
35	O
pretreated	O
with	O
taxanes	B-DRUG
","	O
33	O
pretreated	O
with	O
anthracyclines	B-DRUG
)	O
.	O
	
A	O
median	O
of	O
5	O
cycles	O
of	O
the	O
study	O
treatment	O
was	O
delivered	O
.	O
	
There	O
were	O
2	O
complete	O
and	O
13	O
partial	O
responses	O
","	O
for	O
an	O
overall	O
response	O
rate	O
of	O
40	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
23-56	O
%	O
)	O
.	O
	
Thirteen	O
patients	O
(	O
35	O
%	O
)	O
had	O
stable	O
disease	O
.	O
	
Tumour	O
response	O
appeared	O
independent	O
of	O
previously	O
applied	O
chemotherapy	O
.	O
	
Median	O
time-to-progression	O
was	O
6	O
months	O
and	O
median	O
overall	O
survival	O
was	O
13.5	O
months	O
.	O
	
Main	O
toxicities	O
were	O
leucopenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
(	O
grade	O
3	O
/	O
4	O
in	O
26	O
and	O
16	O
%	O
of	O
cycles	O
","	O
respectively	O
)	O
.	O
	
Non-haematological	B-TOXI
toxicity	I-TOXI
was	O
rarely	O
severe	O
.	O
	
Combination	O
chemotherapy	O
with	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
given	O
on	O
2	O
out	O
of	O
3	O
weeks	O
is	O
well	O
tolerated	O
and	O
active	O
in	O
heavily	O
pretreated	O
patients	O
with	O
MBC	O
","	O
even	O
after	O
prior	O
exposure	O
to	O
anthracyclines	B-DRUG
and	O
taxanes	B-DRUG
.	O
	
Second-line	O
treatment	O
with	O
irinotecan	B-DRUG
plus	O
cisplatin	B-DRUG
vs	O
cisplatin	B-DRUG
of	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
pretreated	O
with	O
taxanes	B-DRUG
and	O
gemcitabine	B-DRUG
:	O
a	O
multicenter	O
randomised	O
phase	O
II	O
study	O
.	O
	
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
irinotecan	B-DRUG
/	O
cisplatin	B-DRUG
regimen	O
with	O
cisplatin	B-DRUG
as	O
second-line	O
chemotherapy	O
in	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
pretreated	O
with	O
a	O
taxane	B-DRUG
/	O
gemcitabine	B-DRUG
regimen	O
.	O
	
Patients	O
(	O
n	O
=	O
147	O
)	O
with	O
stage	O
IV	O
NSCLC	B-CANCER
pretreated	O
with	O
a	O
taxane	B-DRUG
/	O
gemcitabine	B-DRUG
regimen	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
irinotecan	B-DRUG
(	O
110	O
mg	O
m	O
(	O
-2	O
)	O
","	O
day	O
1	O
and	O
100	O
mg	O
m	O
(	O
-2	O
)	O
","	O
day	O
8	O
)	O
and	O
cisplatin	B-DRUG
(	O
80	O
mg	O
m	O
(	O
-2	O
)	O
","	O
day	O
8	O
)	O
(	O
IC	O
;	O
n	O
=	O
74	O
)	O
or	O
CDDP	B-DRUG
(	O
80	O
mg	O
m	O
(	O
-2	O
)	O
","	O
day	O
1	O
)	O
(	O
C	O
;	O
n	O
=	O
73	O
)	O
every	O
3	O
weeks	O
.	O
	
Patients	O
treated	O
with	O
IC	O
and	O
C	O
had	O
a	O
median	O
survival	O
of	O
7.8	O
and	O
8.8	O
months	O
","	O
respectively	O
(	O
P	O
=	O
0.933	O
)	O
.	O
	
The	O
1-year	O
survival	O
rate	O
was	O
34.3	O
%	O
for	O
IC-treated	O
patients	O
and	O
31.7	O
%	O
for	O
C-treated	O
patients	O
.	O
	
Cox	O
's	O
regression	O
analysis	O
revealed	O
that	O
response	O
to	O
treatment	O
(	O
hazard	O
ratio	O
(	O
HR	O
)	O
=	O
2.787	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
1.1578-4.922	O
)	O
and	O
performance	O
status	O
(	O
HR	O
=	O
1.865	O
;	O
95	O
%	O
CI	O
:	O
1.199-2.872	O
)	O
was	O
independent	O
prognostic	O
factors	O
for	O
survival	O
.	O
	
Overall	O
response	O
rate	O
was	O
22.5	O
%	O
(	O
95	O
%	O
CI	O
:	O
12.8-32.2	O
%	O
)	O
for	O
IC-treated	O
patients	O
and	O
7	O
%	O
(	O
95	O
%	O
CI	O
:	O
1.15-13.6	O
%	O
)	O
for	O
C-treated	O
patients	O
(	O
P	O
=	O
0.012	O
)	O
;	O
tumour	O
growth	O
control	O
(	O
partial	O
remission	O
(	O
PR	O
)	O
=+	O
stable	O
disease	O
(	O
SD	O
)	O
)	O
was	O
observed	O
in	O
26	O
(	O
38	O
%	O
)	O
IC	O
and	O
25	O
(	O
36	O
%	O
)	O
C	O
patients	O
(	O
P	O
=	O
0.878	O
)	O
.	O
	
There	O
was	O
no	O
difference	O
in	O
terms	O
of	O
quality	O
of	O
life	O
between	O
the	O
two	O
chemotherapy	O
arms	O
.	O
	
The	O
incidence	O
of	O
febrile	B-TOXI
neutropenia	I-TOXI
","	O
grade	O
3	O
and	O
4	O
neutropenia	B-TOXI
and	O
grade	O
3	O
and	O
4	O
diarrhoea	B-TOXI
was	O
significantly	O
higher	O
in	O
the	O
IC-	O
than	O
the	O
C-treated	O
patients	O
.	O
	
Other	O
toxicities	O
were	O
mild	O
.	O
	
There	O
were	O
no	O
treatment-related	O
deaths	B-TOXI
in	O
either	O
arm	O
.	O
	
The	O
IC	O
regimen	O
did	O
not	O
confer	O
a	O
survival	O
benefit	O
compared	O
with	O
C	O
as	O
second-line	O
treatment	O
of	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
pretreated	O
with	O
a	O
taxane	B-DRUG
/	O
gemcitabine	B-DRUG
regimen	O
","	O
despite	O
its	O
better	O
efficacy	O
in	O
terms	O
of	O
response	O
rate	O
.	O
	
Concurrent	O
hyperfractionated	O
radiotherapy	O
and	O
low-dose	O
daily	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
early-stage	O
(	O
I	O
/	O
II	O
)	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
long-term	O
results	O
of	O
a	O
phase	O
II	O
study	O
.	O
	
	
Feasibility	O
and	O
activity	O
of	O
concurrent	O
hyperfractionated	O
radiotherapy	O
(	O
Hfx	O
RT	O
)	O
and	O
low-dose	O
","	O
daily	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
were	O
investigated	O
in	O
patients	O
with	O
early-stage	O
(	O
I	O
/	O
II	O
)	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
in	O
a	O
phase	O
II	O
study	O
.	O
	
Fifty-six	O
patients	O
started	O
their	O
treatment	O
on	O
day	O
1	O
with	O
30	O
mg	O
/	O
m2	O
of	O
paclitaxel	B-DRUG
.	O
	
Hfx	O
RT	O
using	O
1.3	O
Gy	O
bid	O
to	O
a	O
total	O
dose	O
of	O
67.6	O
Gy	O
and	O
concurrent	O
low-dose	O
daily	O
carboplatin	B-DRUG
25	O
mg	O
/	O
m2	O
and	O
paclitaxel	B-DRUG
10	O
mg	O
/	O
m2	O
","	O
both	O
given	O
Mondays	O
through	O
Fridays	O
during	O
the	O
RT	O
course	O
","	O
started	O
from	O
the	O
second	O
day	O
.	O
	
There	O
were	O
29	O
complete	O
responses	O
(	O
52	O
%	O
)	O
and	O
15	O
partial	O
responses	O
(	O
27	O
%	O
)	O
","	O
and	O
12	O
patients	O
(	O
21	O
%	O
)	O
","	O
experienced	O
stable	O
disease	O
.	O
	
The	O
median	O
survival	O
time	O
was	O
35	O
months	O
","	O
and	O
-3	O
and	O
5-year	O
survival	O
rates	O
were	O
50	O
%	O
and	O
36	O
%	O
","	O
respectively	O
.	O
	
The	O
median	O
time	O
to	O
local	O
progression	O
has	O
not	O
been	O
achieved	O
","	O
but	O
-3	O
and	O
5-year	O
local	O
progression-free	O
survival	O
rates	O
were	O
56	O
%	O
and	O
54	O
%	O
","	O
respectively	O
.	O
	
The	O
median	O
time	O
to	O
distant	O
metastasis	O
has	O
not	O
been	O
achieved	O
","	O
but	O
-3	O
and	O
-5	O
year	O
distant	O
metastasis-free	O
survival	O
rates	O
were	O
61	O
%	O
and	O
61	O
%	O
","	O
respectively	O
.	O
	
The	O
median	O
and	O
5-year	O
cause-specific	O
survivals	O
were	O
39	O
months	O
and	O
43	O
%	O
","	O
respectively	O
.	O
	
Acute	O
high-grade	O
(	O
&	O
gt	O
;	O
3	O
)	O
toxicity	O
was	O
hematologic	O
(	O
22	O
%	O
)	O
","	O
esophageal	O
(	O
7	O
%	O
)	O
","	O
or	O
bronchopulmonary	O
(	O
7	O
%	O
)	O
.	O
	
No	O
grade	O
5	O
toxicity	O
was	O
observed	O
.	O
	
Late	O
high-grade	O
toxicity	O
was	O
rarely	O
observed	O
(	O
total	O
","	O
10	O
%	O
)	O
.	O
	
Hfx	O
RT	O
and	O
concurrent	O
low-dose	O
daily	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
was	O
feasible	O
with	O
low	O
toxicity	O
and	O
effective	O
in	O
patients	O
with	O
stage	O
I	O
/	O
II	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
It	O
should	O
continue	O
to	O
be	O
investigated	O
for	O
this	O
disease	O
.	O
	
Phase	O
II	O
trial	O
of	O
tamoxifen	B-DRUG
and	O
goserelin	B-DRUG
in	O
recurrent	B-CANCER
epithelial	I-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
	
Endocrine	O
therapy	O
is	O
a	O
recognised	O
option	O
in	O
the	O
treatment	O
of	O
chemo-resistant	O
ovarian	B-CANCER
cancer	I-CANCER
.	O
	
We	O
conducted	O
a	O
nonrandomised	O
phase	O
II	O
evaluation	O
of	O
combination	O
endocrine	O
therapy	O
with	O
tamoxifen	B-DRUG
and	O
goserelin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
that	O
had	O
recurred	O
following	O
chemotherapy	O
.	O
	
In	O
total	O
","	O
26	O
patients	O
entered	O
the	O
study	O
","	O
of	O
which	O
17	O
had	O
platinum-resistant	B-DRUG
disease	O
.	O
	
The	O
median	O
age	O
was	O
63	O
years	O
and	O
enrolled	O
patients	O
had	O
received	O
a	O
median	O
of	O
three	O
chemotherapy	O
regimens	O
prior	O
to	O
trial	O
entry	O
.	O
	
Patients	O
were	O
given	O
oral	O
tamoxifen	B-DRUG
20	O
mg	O
twice	O
daily	O
on	O
a	O
continuous	O
basis	O
and	O
subcutaneous	O
goserelin	B-DRUG
3.6	O
mg	O
once	O
a	O
month	O
until	O
disease	O
progression	O
.	O
	
Using	O
the	O
definition	O
of	O
endocrine	O
response	O
that	O
included	O
patients	O
with	O
stable	O
disease	O
(	O
SD	O
)	O
of	O
6	O
months	O
or	O
greater	O
","	O
the	O
overall	O
response	O
rate	O
(	O
clinical	O
benefit	O
rate	O
)	O
was	O
50	O
%	O
.	O
	
This	O
included	O
one	O
complete	O
response	O
(	O
CR	O
)	O
(	O
3.8	O
%	O
)	O
","	O
two	O
partial	O
responses	O
(	O
PR	O
)	O
(	O
7.7	O
%	O
)	O
and	O
10	O
patients	O
with	O
SD	O
(	O
38.5	O
%	O
)	O
.	O
	
The	O
median	O
progression-free	O
interval	O
(	O
PFI	O
)	O
was	O
4	O
months	O
(	O
95	O
%	O
CI	O
2.4-9.6	O
)	O
while	O
the	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
13.6	O
months	O
(	O
95	O
%	O
CI	O
5.5-30.6	O
)	O
.	O
	
Four	O
patients	O
received	O
treatment	O
for	O
more	O
than	O
2	O
years	O
(	O
range	O
1月31日	O
)	O
and	O
one	O
of	O
them	O
is	O
still	O
on	O
treatment	O
.	O
	
In	O
none	O
of	O
the	O
four	O
patients	O
was	O
there	O
any	O
evidence	O
of	O
recurrent	O
or	O
cumulative	O
treatment	O
related	O
toxicity	O
.	O
	
Treatment-limiting	O
toxicity	O
was	O
not	O
seen	O
in	O
any	O
of	O
the	O
study	O
population	O
.	O
	
Endocrine	O
data	O
demonstrated	O
a	O
marked	O
suppression	O
of	O
luteinising	O
hormone	O
(	O
LH	O
)	O
and	O
follicle-stimulating	O
hormone	O
(	O
FSH	O
)	O
to	O
less	O
than	O
4	O
%	O
of	O
baseline	O
values	O
.	O
	
No	O
consistent	O
correlation	O
could	O
be	O
established	O
between	O
LH	O
/	O
FSH	O
suppression	O
and	O
tumour	O
response	O
.	O
	
Likewise	O
no	O
relationship	O
was	O
observed	O
between	O
Inhibin	O
A	O
/	O
B	O
and	O
pro-alpha	O
C	O
levels	O
and	O
tumour	O
response	O
.	O
	
Inhibin	O
is	O
unlikely	O
to	O
be	O
a	O
useful	O
surrogate	O
marker	O
for	O
response	O
in	O
locally	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
Combination	O
endocrine	B-DRUG
therapy	O
with	O
tamoxifen	B-DRUG
and	O
goserelin	B-DRUG
is	O
an	O
active	O
regimen	O
in	O
platinum-resistant	B-DRUG
ovarian	B-CANCER
cancer	I-CANCER
patients	O
.	O
	
Hormonal	O
therapy	O
is	O
advantageous	O
in	O
its	O
relative	O
lack	O
of	O
toxicity	O
","	O
ease	O
of	O
administration	O
and	O
tolerability	O
","	O
thus	O
making	O
it	O
suitable	O
for	O
patients	O
with	O
heavily	O
pretreated	O
disease	O
","	O
compromised	O
bone	O
marrow	O
function	O
and	O
other	O
comorbid	O
conditions	O
that	O
contraindicate	O
cytotoxic	O
therapy	O
as	O
well	O
as	O
in	O
patients	O
with	O
indolent	O
disease	O
.	O
	
Multicenter	O
phase	O
I	O
/	O
II	O
study	O
of	O
cetuximab	B-DRUG
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
in	O
untreated	O
patients	O
with	O
stage	O
IV	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
Epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
tyrosine	O
kinase	O
inhibitors	O
have	O
demonstrated	O
antitumor	O
activity	O
in	O
patients	O
with	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
This	O
study	O
examined	O
the	O
safety	O
profile	O
of	O
the	O
monoclonal	O
antibody	O
EGFR	O
inhibitor	O
","	O
cetuximab	B-DRUG
","	O
when	O
added	O
to	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
in	O
untreated	O
patients	O
with	O
stage	O
IV	O
NSCLC	B-CANCER
.	O
	
Secondary	O
objectives	O
included	O
efficacy	O
and	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
pharmacokinetics	O
during	O
cetuximab	B-DRUG
treatment	O
.	O
	
Patients	O
with	O
tumor	O
evidence	O
of	O
EGFR	O
by	O
immunohistochemistry	O
","	O
performance	O
status	O
of	O
0	O
to	O
2	O
","	O
and	O
measurable	O
disease	O
received	O
paclitaxel	B-DRUG
225	O
mg	O
/	O
m2	O
with	O
carboplatin	B-DRUG
area	O
under	O
the	O
curve	O
=	O
6	O
on	O
day	O
1	O
every	O
3	O
weeks	O
.	O
	
Cetuximab	B-DRUG
was	O
administered	O
at	O
400	O
mg	O
/	O
m2	O
","	O
1	O
week	O
before	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
","	O
then	O
weekly	O
at	O
250	O
mg	O
/	O
m2	O
.	O
	
The	O
regimen	O
continued	O
until	O
disease	O
progression	O
or	O
intolerable	O
toxicity	O
.	O
	
Thirty-one	O
of	O
32	O
enrolled	O
patients	O
were	O
treated	O
.	O
	
The	O
most	O
common	O
cetuximab	B-TOXI
toxicity	I-TOXI
was	O
rash	O
in	O
84	O
%	O
of	O
patients	O
(	O
grade	O
3	O
in	O
13	O
%	O
)	O
.	O
	
Pharmacokinetic	O
sampling	O
did	O
not	O
reveal	O
an	O
interaction	O
between	O
carboplatin	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
and	O
cetuximab	B-DRUG
.	O
	
An	O
objective	O
response	O
was	O
observed	O
in	O
eight	O
patients	O
(	O
26	O
%	O
)	O
.	O
	
With	O
a	O
median	O
follow-up	O
of	O
19	O
months	O
","	O
the	O
median	O
time	O
to	O
progression	O
was	O
5	O
months	O
","	O
median	O
survival	O
was	O
11	O
months	O
","	O
and	O
the	O
-1	O
and	O
2-year	O
survival	O
rates	O
were	O
40	O
%	O
and	O
16	O
%	O
","	O
respectively	O
.	O
	
The	O
combination	O
of	O
cetuximab	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
and	O
carboplatin	B-DRUG
was	O
safe	O
and	O
well	O
tolerated	O
in	O
this	O
population	O
of	O
stage	O
IV	O
patients	O
.	O
	
The	O
response	O
rate	O
","	O
time	O
to	O
progression	O
","	O
and	O
median	O
survival	O
were	O
slightly	O
superior	O
to	O
historical	O
controls	O
treated	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
alone	O
.	O
	
A	O
randomized	O
phase	O
II	O
trial	O
has	O
completed	O
accrual	O
.	O
	
Neoadjuvant	O
chemotherapy	O
with	O
high-dose	O
Ifosfamide	B-DRUG
","	O
high-dose	O
methotrexate	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
doxorubicin	B-DRUG
for	O
patients	O
with	O
localized	O
osteosarcoma	B-CANCER
of	I-CANCER
the	I-CANCER
extremity	I-CANCER
:	O
a	O
joint	O
study	O
by	O
the	O
Italian	O
and	O
Scandinavian	O
Sarcoma	O
Groups	O
.	O
	
	
To	O
explore	O
the	O
effect	O
of	O
high-dose	O
ifosfamide	B-DRUG
in	O
first-line	O
treatment	O
for	O
patients	O
&	O
lt	O
;	O
or	O
=	O
40	O
years	O
of	O
age	O
with	O
nonmetastatic	B-CANCER
osteosarcoma	I-CANCER
of	I-CANCER
the	I-CANCER
extremity	I-CANCER
.	O
	
From	O
March	O
1997	O
to	O
September	O
2000	O
","	O
182	O
patients	O
were	O
evaluated	O
.	O
	
Primary	O
treatment	O
consisted	O
of	O
two	O
blocks	O
of	O
high-dose	O
ifosfamide	B-DRUG
(	O
15	O
g	O
/	O
m2	O
)	O
","	O
methotrexate	B-DRUG
(	O
12	O
g	O
/	O
m2	O
)	O
","	O
cisplatin	B-DRUG
(	O
120	O
mg	O
/	O
m2	O
)	O
","	O
and	O
doxorubicin	B-DRUG
(	O
75	O
mg	O
/	O
m2	O
)	O
.	O
	
Postoperatively	O
","	O
patients	O
received	O
two	O
cycles	O
of	O
doxorubicin	B-DRUG
(	O
90	O
mg	O
/	O
m2	O
)	O
","	O
and	O
three	O
cycles	O
each	O
of	O
high-dose	O
ifosfamide	B-DRUG
","	O
methotrexate	B-DRUG
","	O
and	O
cisplatin	B-DRUG
(	O
120	O
to	O
150	O
mg	O
/	O
m2	O
)	O
.	O
	
Granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
support	O
was	O
mandatory	O
after	O
the	O
high-dose	O
ifosfamide	B-DRUG
/	O
cisplatin	B-DRUG
/	O
doxorubicin	B-DRUG
combination	O
.	O
	
No	O
disease	O
progression	O
was	O
recorded	O
during	O
primary	O
chemotherapy	O
","	O
164	O
patients	O
(	O
92	O
%	O
)	O
underwent	O
limb-salvage	B-TOXI
surgery	I-TOXI
","	O
four	O
patients	O
(	O
2	O
%	O
)	O
underwent	O
rotation	B-TOXI
plasty	I-TOXI
","	O
and	O
11	O
patients	O
(	O
6	O
%	O
)	O
had	O
limbs	B-TOXI
amputated	I-TOXI
.	O
	
Three	O
(	O
1.6	O
%	O
)	O
patients	O
died	B-TOXI
as	O
a	O
result	O
of	O
treatment-related	B-TOXI
toxicity	I-TOXI
","	O
and	O
one	O
died	B-TOXI
as	O
a	O
result	O
of	O
pulmonary	B-TOXI
embolism	I-TOXI
after	O
pathologic	B-TOXI
fracture	I-TOXI
.	O
	
Grade	O
4	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
followed	O
52	O
%	O
and	O
31	O
%	O
of	O
all	O
courses	O
","	O
respectively	O
","	O
and	O
mild	O
to	O
severe	B-TOXI
nephrotoxicity	I-TOXI
was	O
recorded	O
in	O
19	O
patients	O
(	O
10	O
%	O
)	O
.	O
	
The	O
median	O
received	O
dose-intensity	O
compared	O
with	O
protocol	O
was	O
0.82	O
.	O
	
With	O
a	O
median	O
follow-up	O
of	O
55	O
months	O
","	O
the	O
5-year	O
probability	O
of	O
event-free	O
survival	O
was	O
64	O
%	O
(	O
95	O
%	O
CI	O
","	O
57	O
%	O
to	O
71	O
%	O
)	O
and	O
overall	O
survival	O
was	O
77	O
%	O
(	O
95	O
%	O
CI	O
","	O
67	O
%	O
to	O
81	O
%	O
)	O
","	O
whereas	O
seven	O
patients	O
(	O
4	O
%	O
)	O
experienced	O
local	O
recurrence	O
.	O
	
The	O
addition	O
of	O
high-dose	O
ifosfamide	B-DRUG
to	O
methotrexate	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
doxorubicin	B-DRUG
in	O
the	O
preoperative	O
phase	O
is	O
feasible	O
","	O
but	O
with	O
major	O
renal	O
and	O
hematologic	B-TOXI
toxicities	I-TOXI
","	O
and	O
survival	O
rates	O
similar	O
to	O
those	O
obtained	O
with	O
four-drug	O
regimens	O
using	O
standard-dose	O
ifosfamide	B-DRUG
.	O
	
Italian	O
Sarcoma	O
Group	O
/	O
Scandinavian	O
Sarcoma	O
Group	O
study	O
I	O
showed	O
that	O
in	O
a	O
multicenter	O
setting	O
","	O
more	O
than	O
90	O
%	O
of	O
patients	O
with	O
osteosarcoma	B-CANCER
of	I-CANCER
the	I-CANCER
extremity	I-CANCER
can	O
undergo	O
conservative	O
surgery	O
.	O
	
Phase	O
I	O
and	O
pharmacological	O
study	O
of	O
the	O
farnesyltransferase	O
inhibitor	O
tipifarnib	B-DRUG
(	O
Zarnestra	O
","	O
R115777	O
)	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
	
This	O
phase	O
I	O
trial	O
was	O
designed	O
to	O
determine	O
the	O
safety	O
and	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
tipifarnib	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
Furthermore	O
","	O
the	O
pharmacokinetics	O
of	O
each	O
of	O
these	O
agents	O
was	O
evaluated	O
.	O
	
Patients	O
were	O
treated	O
with	O
tipifarnib	B-DRUG
b.i.d.	O
on	O
days	O
1月7日	O
of	O
each	O
21-day	O
cycle	O
.	O
	
In	O
addition	O
","	O
gemcitabine	B-DRUG
was	O
given	O
as	O
a	O
30-min	O
i.v.	O
infusion	O
on	O
days	O
1	O
and	O
8	O
and	O
cisplatin	B-DRUG
as	O
a	O
3-h	O
i.v.	O
infusion	O
on	O
day	O
1	O
An	O
interpatient	O
dose-escalation	O
scheme	O
was	O
used	O
.	O
	
Pharmacokinetics	O
was	O
determined	O
in	O
plasma	O
and	O
white	O
blood	O
cells	O
.	O
	
In	O
total	O
","	O
31	O
patients	O
were	O
included	O
at	O
five	O
dose	O
levels	O
.	O
	
Dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
consisted	O
of	O
thrombocytopenia	B-TOXI
grade	O
4	O
","	O
neutropenia	B-TOXI
grade	O
4	O
","	O
febrile	B-TOXI
neutropenia	I-TOXI
grade	O
4	O
","	O
electrolyte	B-TOXI
imbalance	I-TOXI
grade	O
3	O
","	O
fatigue	B-TOXI
grade	O
3	O
and	O
decreased	B-TOXI
hearing	I-TOXI
grade	O
2	O
The	O
MTD	O
was	O
tipifarnib	B-DRUG
200	O
mg	O
b.i.d.	O
","	O
gemcitabine	B-DRUG
1000	O
mg	O
m	O
(	O
-2	O
)	O
and	O
cisplatin	B-DRUG
75	O
mg	O
m	O
(	O
-2	O
)	O
.	O
	
Eight	O
patients	O
had	O
a	O
confirmed	O
partial	O
response	O
and	O
12	O
patients	O
stable	O
disease	O
.	O
	
No	O
clinically	O
relevant	O
pharmacokinetic	O
interactions	O
were	O
observed	O
.	O
	
Tipifarnib	B-DRUG
can	O
be	O
administered	O
safely	O
at	O
200	O
mg	O
b.i.d.	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
1000	O
mg	O
m	O
(	O
-2	O
)	O
and	O
cisplatin	B-DRUG
75	O
mg	O
m	O
(	O
-2	O
)	O
.	O
	
This	O
combination	O
showed	O
evidence	O
of	O
antitumour	O
activity	O
and	O
warrants	O
further	O
evaluation	O
in	O
a	O
phase	O
II	O
setting	O
.	O
	
Phase	O
III	O
study	O
comparing	O
cisplatin	B-DRUG
plus	O
fluorouracil	B-DRUG
to	O
paclitaxel	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
fluorouracil	B-DRUG
induction	O
chemotherapy	O
followed	O
by	O
chemoradiotherapy	O
in	O
locally	O
advanced	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
compare	O
the	O
antitumor	O
activity	O
and	O
toxicity	O
of	O
the	O
two	O
induction	O
chemotherapy	O
treatments	O
of	O
paclitaxel	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
fluorouracil	B-DRUG
(	O
FU	B-DRUG
;	O
PCF	B-DRUG
)	O
versus	O
standard	O
cisplatin	B-DRUG
and	O
FU	B-DRUG
(	O
CF	B-DRUG
)	O
","	O
both	O
followed	O
by	O
chemoradiotherapy	O
(	O
CRT	O
)	O
","	O
in	O
locally	O
advanced	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
(	O
HNC	B-CANCER
)	O
.	O
	
Eligibility	O
criteria	O
included	O
biopsy-proven	O
","	O
previously	O
untreated	O
","	O
stage	O
III	O
or	O
IV	O
locally	O
advanced	B-CANCER
HNC	I-CANCER
.	O
	
Patients	O
received	O
either	O
CF	B-DRUG
(	O
cisplatin	B-DRUG
100	O
mg	O
/	O
m2	O
on	O
day	O
1	O
plus	O
FU	B-DRUG
1000	O
[	O
corrected	O
]	O
mg	O
/	O
m2	O
continuous	O
infusion	O
on	O
days	O
1	O
through	O
5	O
)	O
or	O
PCF	B-DRUG
(	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m2	O
on	O
day	O
1	O
","	O
cisplatin	B-DRUG
100	O
mg	O
/	O
m2	O
on	O
day	O
2	O
","	O
and	O
FU	B-DRUG
500	O
mg	O
/	O
m2	O
continuous	O
infusion	O
on	O
days	O
2	O
through	O
6	O
)	O
;	O
both	O
regimens	O
were	O
administered	O
for	O
three	O
cycles	O
every	O
21	O
days	O
.	O
	
Patients	O
with	O
complete	O
response	O
(	O
CR	O
)	O
or	O
partial	O
response	O
of	O
greater	O
than	O
80	O
%	O
in	O
primary	O
tumor	O
received	O
additional	O
CRT	O
(	O
cisplatin	B-DRUG
100	O
mg	O
/	O
m2	O
on	O
days	O
1	O
","	O
22	O
","	O
and	O
43	O
plus	O
70	O
Gy	O
)	O
.	O
	
A	O
total	O
of	O
382	O
eligible	O
patients	O
were	O
randomly	O
assigned	O
to	O
CF	B-DRUG
(	O
n	O
=	O
193	O
)	O
or	O
PCF	B-DRUG
(	O
n	O
=	O
189	O
)	O
.	O
	
The	O
CR	O
rate	O
was	O
14	O
%	O
in	O
the	O
CF	B-DRUG
arm	O
v	O
33	O
%	O
in	O
the	O
PCF	B-DRUG
arm	O
(	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
.	O
	
Median	O
time	O
to	O
treatment	O
failure	O
was	O
12	O
months	O
in	O
the	O
CF	B-DRUG
arm	O
compared	O
with	O
20	O
months	O
in	O
the	O
PCF	B-DRUG
arm	O
(	O
log-rank	O
test	O
","	O
P	O
=	O
0.006	O
;	O
Tarone-Ware	O
","	O
P	O
=	O
0.003	O
)	O
.	O
	
PCF	B-DRUG
patients	O
had	O
a	O
trend	O
to	O
longer	O
overall	O
survival	O
(	O
OS	O
;	O
37	O
months	O
in	O
CF	B-DRUG
arm	O
v	O
43	O
months	O
in	O
PCF	B-DRUG
arm	O
;	O
log-rank	O
test	O
","	O
P	O
=	O
0.06	O
;	O
Tarone-Ware	O
","	O
P	O
=	O
0.03	O
)	O
.	O
	
This	O
difference	O
was	O
more	O
evident	O
in	O
patients	O
with	O
unresectable	O
disease	O
(	O
OS	O
:	O
26	O
months	O
in	O
CF	B-DRUG
arm	O
v	O
36	O
months	O
in	O
PCF	B-DRUG
arm	O
;	O
log-rank	O
test	O
","	O
P	O
=	O
0.04	O
;	O
Tarone-Ware	O
","	O
P	O
=	O
0.03	O
)	O
.	O
	
CF	B-DRUG
patients	O
had	O
a	O
higher	O
occurrence	O
of	O
grade	O
2	O
to	O
4	O
mucositis	B-TOXI
than	O
PCF	B-DRUG
patients	O
(	O
53	O
%	O
v	O
16	O
%	O
","	O
respectively	O
;	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
.	O
	
Induction	O
chemotherapy	O
with	O
PCF	B-DRUG
was	O
better	O
tolerated	O
and	O
resulted	O
in	O
a	O
higher	O
CR	O
rate	O
than	O
CF	B-DRUG
.	O
	
However	O
","	O
new	O
trials	O
that	O
compare	O
induction	O
chemotherapy	O
plus	O
CRT	O
versus	O
CRT	O
alone	O
are	O
needed	O
to	O
better	O
define	O
the	O
role	O
of	O
neoadjuvant	O
treatment	O
.	O
	
Phase	O
II	O
study	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
in	O
locally	O
advanced	B-CANCER
/	I-CANCER
metastatic	I-CANCER
oesophageal	I-CANCER
cancer	I-CANCER
.	O
	
	
Palliative	O
chemotherapy	O
for	O
inoperable	B-CANCER
/	I-CANCER
metastatic	I-CANCER
oesophageal	I-CANCER
cancer	I-CANCER
has	O
limited	O
activity	O
.	O
	
This	O
study	O
assesses	O
the	O
feasibility	O
and	O
activity	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
in	O
this	O
group	O
of	O
patients	O
.	O
	
In	O
total	O
","	O
42	O
patients	O
with	O
locally	O
advanced	O
/	O
metastatic	B-CANCER
squamous	I-CANCER
or	I-CANCER
adenocarcinoma	I-CANCER
of	O
the	O
oesophagus	O
were	O
treated	O
with	O
gemcitabine	B-DRUG
1250	O
mg	O
m	O
(	O
-2	O
)	O
days	O
1	O
and	O
8	O
and	O
cisplatin	B-DRUG
75	O
mg	O
m	O
(	O
-2	O
)	O
day	O
1	O
in	O
a	O
21-day	O
cycle	O
.	O
	
Interim	O
safety	O
analysis	O
was	O
carried	O
out	O
after	O
the	O
first	O
19	O
patients	O
suggested	O
significant	O
toxicity	O
.	O
	
The	O
dose	O
of	O
gemcitabine	B-DRUG
was	O
subsequently	O
reduced	O
to	O
1000	O
mg	O
m	O
(	O
-2	O
)	O
.	O
	
Patients	O
were	O
assessed	O
for	O
toxicity	O
and	O
response	O
.	O
	
The	O
median	O
number	O
of	O
treatment	O
cycles	O
per	O
patient	O
was	O
4	O
(	O
range	O
1月6日	O
)	O
.	O
	
Grade	O
3月4日	O
neutropenia	B-TOXI
occurred	O
in	O
37	O
%	O
of	O
cycles	O
;	O
however	O
","	O
there	O
was	O
only	O
one	O
episode	O
of	O
neutropenic	B-TOXI
fever	I-TOXI
.	O
	
Nonhaematological	B-TOXI
toxicities	I-TOXI
included	O
fatigue	B-TOXI
","	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
.	O
	
Among	O
32	O
patients	O
eligible	O
for	O
response	O
","	O
there	O
were	O
three	O
complete	O
responses	O
and	O
16	O
partial	O
responses	O
(	O
overall	O
response	O
rate	O
of	O
45	O
%	O
)	O
;	O
nine	O
patients	O
had	O
stable	O
disease	O
.	O
	
Median	O
survival	O
was	O
11	O
months	O
.	O
	
The	O
response	O
rate	O
appears	O
to	O
be	O
greatest	O
in	O
those	O
with	O
squamous	B-CANCER
carcinoma	I-CANCER
compared	O
to	O
adenocarcinoma	B-CANCER
(	O
71	O
vs	O
33	O
%	O
","	O
P=0.036	O
)	O
.	O
	
The	O
combination	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
in	O
this	O
schedule	O
has	O
manageable	O
toxicity	O
and	O
significant	O
activity	O
in	O
patients	O
with	O
locally	O
advanced	B-CANCER
/	I-CANCER
metastatic	I-CANCER
oesophageal	I-CANCER
cancer	I-CANCER
and	O
is	O
worthy	O
of	O
further	O
study	O
.	O
	
Phase	O
I	O
trial	O
of	O
UCN-01	B-DRUG
in	O
combination	O
with	O
topotecan	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
cancers	I-CANCER
:	O
a	O
Princess	O
Margaret	O
Hospital	O
Phase	O
II	O
Consortium	O
study	O
.	O
	
	
7-Hydroxystaurosporine	B-DRUG
(	O
UCN-01	B-DRUG
)	O
inhibits	O
serine-threonine	O
kinases	O
including	O
the	O
Ca2+	O
and	O
phospholipid-dependent	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
","	O
CDKs	O
2	O
","	O
4	O
","	O
6	O
","	O
Chk-1	O
and	O
PDK1	O
.	O
	
UCN-01	B-DRUG
mediates	O
distinct	O
effects	O
in	O
vitro	O
/	O
in	O
vivo	O
:	O
cell	O
cycle	O
arrest	O
in	O
G1	O
","	O
abrogation	O
of	O
G2	O
arrest	O
by	O
inhibiting	O
chk1	O
","	O
induction	O
of	O
apoptosis	O
and	O
potentiation	O
of	O
cytotoxicity	O
of	O
S-phase-active	O
chemotherapeutics	O
including	O
the	O
topoisomerase	B-DRUG
1	I-DRUG
inhibitor	I-DRUG
topotecan	B-DRUG
(	O
T	O
)	O
.	O
	
This	O
phase	O
I	O
study	O
was	O
designed	O
to	O
determine	O
the	O
maximal	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
recommended	O
phase	O
2	O
dose	O
(	O
RPTD	O
)	O
","	O
toxicity	O
profile	O
","	O
pharmacokinetics	O
and	O
antitumor	O
activity	O
of	O
T	O
and	O
UCN-01	B-DRUG
in	O
patients	O
with	O
refractory	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
Both	O
agents	O
were	O
administered	O
every	O
21	O
days	O
intravenously	O
through	O
central	O
venous	O
access	O
in	O
escalating	O
doses	O
to	O
eligible	O
patients	O
.	O
	
On	O
day	O
1	O
","	O
following	O
antiemetic	O
prophylaxis	O
with	O
dexamethasone	B-DRUG
and	O
a	O
serotonin	B-DRUG
type	O
3	O
(	O
A	O
)	O
receptor	O
(	O
5HT3	O
)	O
inhibitor	O
","	O
UCN-01	B-DRUG
was	O
infused	O
over	O
3	O
h	O
","	O
followed	O
by	O
T	O
infused	O
over	O
30	O
min	O
.	O
	
On	O
days	O
2月5日	O
","	O
patients	O
received	O
T	O
only	O
.	O
	
UCN-01	B-DRUG
doses	O
were	O
reduced	O
by	O
50	O
%	O
in	O
cycles	O
2	O
and	O
beyond	O
because	O
of	O
its	O
prolonged	O
half-life	O
.	O
	
Thirty-three	O
patients	O
were	O
entered	O
in	O
three	O
cohorts	O
:	O
Dose	O
Level	O
(	O
DL	O
)	O
1	O
(	O
UCN-01	B-DRUG
70	O
mg	O
/	O
m2	O
","	O
T	O
0.75	O
mg	O
/	O
m2	O
)	O
","	O
three	O
patients	O
;	O
DL	O
2	O
(	O
UCN-01	O
70	O
mg	O
/	O
m2	O
","	O
T	O
1	O
mg	O
/	O
m2	O
)	O
","	O
24	O
patients	O
;	O
DL	O
3	O
(	O
UCN-01	B-DRUG
90	O
mg	O
/	O
m2	O
","	O
T	O
1	O
mg	O
/	O
m2	O
)	O
","	O
six	O
patients	O
.	O
	
All	O
but	O
three	O
patients	O
were	O
PS	O
0	O
or	O
1	O
","	O
median	O
age	O
was	O
54	O
years	O
(	O
range	O
","	O
29-72	O
)	O
","	O
91	O
%	O
were	O
female	O
.	O
	
Primary	O
tumor	O
types	O
:	O
ovary	B-CANCER
/	O
peritoneal	B-CANCER
(	O
23	O
patients	O
)	O
","	O
colon	B-CANCER
(	O
three	O
patients	O
)	O
","	O
salivary	B-CANCER
gland	I-CANCER
(	O
two	O
patients	O
)	O
","	O
others	O
(	O
five	O
patients	O
)	O
.	O
	
All	O
patients	O
were	O
eligible	O
for	O
adverse	O
event	O
(	O
AE	O
)	O
analysis	O
and	O
22	O
patients	O
were	O
eligible	O
for	O
survival	O
and	O
tumor	O
response	O
analysis	O
.	O
	
Two	O
of	O
six	O
patients	O
had	O
dose	O
limiting	O
toxicity	O
(	O
DLT	O
)	O
at	O
DL	O
3	O
(	O
grade	O
3	O
N	O
/	O
V	O
;	O
grade	O
4	O
neutropenia	B-TOXI
with	I-TOXI
infection	I-TOXI
)	O
.	O
	
One	O
DLT	O
was	O
seen	O
in	O
one	O
patient	O
at	O
DL	O
2	O
","	O
consisting	O
of	O
grade	O
4	O
leukopenia	B-TOXI
.	O
	
This	O
cohort	O
was	O
expanded	O
and	O
no	O
further	O
DLTs	O
were	O
observed	O
.	O
	
Most	O
common	O
drug-related	O
AEs	O
were	O
mild	O
(	O
grade	O
1月2日	O
)	O
.	O
	
Non-hematological	O
grade	O
3月4日	O
AEs	O
consisted	O
of	O
transient	B-TOXI
hyperglycemia	I-TOXI
(	O
4	O
)	O
","	O
infection	B-TOXI
(	O
3	O
)	O
","	O
coagulation	B-TOXI
","	O
fatigue	B-TOXI
","	O
hypotension	B-TOXI
","	O
nausea	B-TOXI
(	O
2	O
)	O
","	O
hypomagnesemia	B-TOXI
","	O
vomiting	B-TOXI
","	O
headache	B-TOXI
(	O
1	O
)	O
.	O
	
Hematologic	B-TOXI
toxicities	I-TOXI
occurred	O
in	O
100	O
%	O
of	O
patients	O
.	O
	
Grade	O
3月4日	O
hematologic	B-TOXI
abnormalities	I-TOXI
included	O
neutropenia	B-TOXI
(	O
16	O
","	O
including	O
three	O
with	O
infection	B-TOXI
)	O
","	O
leukopenia	B-TOXI
(	O
11	O
)	O
","	O
lymphopenia	B-TOXI
(	O
7	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
5	O
)	O
.	O
	
Best	O
response	O
for	O
22	O
evaluable	O
patients	O
was	O
PD	O
(	O
8	O
)	O
","	O
SD	O
for	O
at	O
least	O
six	O
cycles	O
(	O
12	O
)	O
","	O
PR	O
(	O
1	O
:	O
carcinoma	B-CANCER
of	I-CANCER
ovary	I-CANCER
","	O
dose	O
level	O
2	O
)	O
and	O
one	O
not	O
assessable	O
.	O
	
Pharmacokinetic	O
analysis	O
confirmed	O
the	O
prolonged	O
half-life	O
of	O
UCN-01	B-DRUG
of	O
approximately	O
15	O
days	O
.	O
	
DLT	O
was	O
observed	O
at	O
DL	O
3	O
and	O
RPTD	O
was	O
determined	O
to	O
be	O
DL	O
2	O
To	O
date	O
","	O
this	O
combination	O
has	O
been	O
relatively	O
well	O
tolerated	O
with	O
some	O
preliminary	O
evidence	O
of	O
efficacy	O
.	O
	
A	O
phase	O
II	O
study	O
of	O
this	O
combination	O
in	O
patients	O
with	O
ovarian	B-CANCER
cancer	I-CANCER
is	O
underway	O
.	O
	
Phase	O
I	O
/	O
IIa	O
study	O
of	O
cetuximab	B-DRUG
with	O
gemcitabine	B-DRUG
plus	O
carboplatin	B-DRUG
in	O
patients	O
with	O
chemotherapy-naive	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
This	O
multicenter	O
","	O
open-label	O
","	O
phase	O
I	O
/	O
IIa	O
study	O
was	O
undertaken	O
to	O
establish	O
the	O
safety	O
/	O
toxicity	O
profile	O
of	O
cetuximab	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
and	O
carboplatin	B-DRUG
in	O
patients	O
with	O
chemotherapy-na茂ve	O
","	O
epidermal	B-DRUG
growth	I-DRUG
factor	I-DRUG
receptor-positive	I-DRUG
","	O
stage	O
IV	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
Secondary	O
objectives	O
were	O
to	O
gather	O
preliminary	O
evidence	O
of	O
efficacy	O
including	O
tumor	O
response	O
rate	O
","	O
time	O
to	O
progression	O
","	O
and	O
overall	O
survival	O
.	O
	
Thirty-five	O
patients	O
received	O
a	O
total	O
of	O
264	O
3-week	O
cycles	O
of	O
treatment	O
with	O
cetuximab	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
gemcitabine	B-DRUG
.	O
	
An	O
initial	O
dose	O
of	O
cetuximab	B-DRUG
400	O
mg	O
/	O
m2	O
intravenously	O
was	O
administered	O
the	O
first	O
week	O
","	O
followed	O
by	O
weekly	O
doses	O
of	O
250	O
mg	O
/	O
m2	O
.	O
	
Carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
=	O
5	O
","	O
day	O
1	O
)	O
and	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m2	O
on	O
days	O
1	O
and	O
8	O
were	O
administered	O
every	O
3	O
weeks	O
.	O
	
Patients	O
were	O
evaluated	O
for	O
tumor	O
response	O
after	O
every	O
two	O
cycles	O
of	O
therapy	O
.	O
	
The	O
most	O
frequently	O
reported	O
adverse	O
events	O
related	O
to	O
cetuximab	B-DRUG
included	O
an	O
acne-like	B-TOXI
rash	I-TOXI
(	O
88.6	O
%	O
)	O
","	O
dry	B-TOXI
skin	I-TOXI
(	O
34.3	O
%	O
)	O
","	O
asthenia	B-TOXI
and	O
skin	B-TOXI
disorders	I-TOXI
(	O
31.4	O
%	O
)	O
","	O
mucositis	B-TOXI
/	O
stomatitis	B-TOXI
(	O
25.7	O
%	O
)	O
","	O
fever	B-TOXI
/	O
chills	B-TOXI
(	O
20	O
%	O
)	O
","	O
and	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
(	O
17.1	O
%	O
)	O
.	O
	
The	O
majority	O
of	O
these	O
toxicities	O
were	O
mild	O
to	O
moderate	O
.	O
	
One	O
patient	O
withdrew	O
from	O
the	O
study	O
because	O
of	O
a	O
grade	O
3	O
allergic	B-TOXI
reaction	I-TOXI
.	O
	
Myelosuppression	B-TOXI
was	O
the	O
most	O
frequently	O
observed	O
toxicity	O
related	O
to	O
chemotherapy	O
.	O
	
Responses	O
among	O
35	O
assessable	O
patients	O
included	O
10	O
partial	O
responses	O
(	O
28.6	O
%	O
)	O
.	O
	
Twenty-one	O
patients	O
had	O
stable	O
disease	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
was	O
165	O
days	O
","	O
and	O
the	O
median	O
overall	O
survival	O
was	O
310	O
days	O
.	O
	
The	O
combination	O
of	O
cetuximab	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
gemcitabine	B-DRUG
was	O
well	O
tolerated	O
with	O
an	O
acceptable	O
toxicity	O
profile	O
.	O
	
Most	O
grade	O
3	O
adverse	O
events	O
were	O
attributable	O
to	O
chemotherapy	O
.	O
	
The	O
response	O
rate	O
and	O
median	O
survival	O
are	O
encouraging	O
and	O
warrant	O
additional	O
investigation	O
.	O
	
Biweekly	O
regimen	O
of	O
cisplatin	B-DRUG
","	O
gemcitabine	B-DRUG
and	O
vinorelbine	B-DRUG
for	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
Improving	O
chemotherapeutic	O
efficacy	O
in	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
will	O
require	O
the	O
development	O
of	O
new	O
strategies	O
to	O
better	O
use	O
currently	O
available	O
agents	O
.	O
	
To	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
a	O
biweekly	O
regimen	O
of	O
cisplatin	B-DRUG
","	O
gemcitabine	B-DRUG
and	O
vinorelbine	B-DRUG
for	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
selected	O
stage	O
IIIb	O
(	O
pleural	O
effusion	O
)	O
/	O
stage	O
IV	O
NSCLC	B-CANCER
","	O
performance	O
status	O
of	O
0-2	O
and	O
normal	O
organ	O
function	O
were	O
eligible	O
.	O
	
Treatment	O
consisted	O
of	O
cisplatin	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
plus	O
gemcitabine	B-DRUG
","	O
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
vinorelbine	B-DRUG
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
and	O
15	O
every	O
28	O
days	O
.	O
	
Of	O
the	O
40	O
patients	O
enrolled	O
and	O
assessable	O
for	O
response	O
","	O
there	O
were	O
five	O
(	O
12.5	O
%	O
)	O
with	O
confirmed	O
complete	O
response	O
and	O
14	O
(	O
35	O
%	O
)	O
with	O
a	O
confirmed	O
partial	O
response	O
for	O
an	O
overall	O
response	O
rate	O
of	O
47.5	O
%	O
.	O
	
Nine	O
patients	O
had	O
stable	O
disease	O
while	O
12	O
(	O
30	O
%	O
)	O
progressed	O
.	O
	
Median	O
progression-free	O
survival	O
and	O
overall	O
survival	O
for	O
all	O
patients	O
were	O
6.3	O
and	O
11.1	O
months	O
","	O
respectively	O
.	O
	
Toxicity	O
was	O
principally	O
hematologic	O
","	O
with	O
grade	O
3月4日	O
neutropenia	B-TOXI
in	O
30	O
%	O
","	O
and	O
grade	O
3月4日	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
in	O
22.5	O
%	O
.	O
	
There	O
were	O
no	O
treatment-related	O
deaths	B-TOXI
.	O
	
The	O
biweekly	O
regimen	O
of	O
cisplatin	B-DRUG
","	O
gemcitabine	B-DRUG
and	O
vinorelbine	B-DRUG
is	O
associated	O
with	O
a	O
high	O
rate	O
of	O
response	O
","	O
lesser	O
toxicity	O
than	O
other	O
three-drug	O
regimens	O
and	O
no	O
benefit	O
of	O
survival	O
.	O
	
Therefore	O
","	O
the	O
regimen	O
under	O
study	O
may	O
be	O
an	O
appealing	O
alternative	O
when	O
considering	O
other	O
treatment	O
modalities	O
for	O
advanced	B-CANCER
lung	I-CANCER
cancer	I-CANCER
","	O
such	O
as	O
neoadjuvant	O
therapy	O
.	O
	
First-line	O
therapy	O
with	O
gemcitabine	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
locally	O
","	O
recurrent	B-CANCER
or	I-CANCER
metastatic	I-CANCER
breast	I-CANCER
cancer	I-CANCER
:	O
a	O
phase	O
II	O
study	O
.	O
	
	
This	O
phase	O
II	O
study	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
gemcitabine	B-DRUG
(	O
G	O
)	O
plus	O
paclitaxel	B-DRUG
(	O
T	O
)	O
as	O
first-line	O
therapy	O
in	O
recurrent	B-CANCER
or	I-CANCER
metastatic	I-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
locally	O
","	O
recurrent	B-CANCER
or	I-CANCER
metastatic	I-CANCER
breast	I-CANCER
cancer	I-CANCER
and	O
no	O
prior	O
chemotherapy	O
for	O
metastatic	O
disease	O
received	O
G	O
1200	O
mg	O
/	O
m2	O
on	O
days	O
1	O
and	O
8	O
","	O
and	O
T	O
175	O
mg	O
/	O
m2	O
on	O
day	O
1	O
(	O
before	O
G	O
)	O
every	O
21	O
days	O
for	O
a	O
maximum	O
of	O
10	O
cycles	O
.	O
	
Forty	O
patients	O
","	O
39	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
and	O
1	O
locally-advanced	O
disease	O
","	O
were	O
enrolled	O
.	O
	
Their	O
median	O
age	O
was	O
61.5	O
years	O
","	O
and	O
85	O
%	O
had	O
a	O
World	O
Health	O
Organization	O
performance	O
status	O
(	O
PS	O
)	O
of	O
0	O
or	O
1	O
Poor	O
prognostic	O
factors	O
at	O
baseline	O
included	O
visceral	O
involvement	O
(	O
87.5	O
%	O
)	O
and	O
&	O
gt	O
;	O
or	O
2	O
metastatic	O
sites	O
(	O
70	O
%	O
)	O
.	O
	
Also	O
","	O
27	O
(	O
67.5	O
%	O
)	O
patients	O
had	O
prior	O
adjuvant	O
chemotherapy	O
","	O
25	O
of	O
which	O
had	O
prior	O
anthracyclines	B-DRUG
.	O
	
A	O
total	O
of	O
220	O
cycles	O
(	O
median	O
6	O
;	O
range	O
","	O
1月10日	O
)	O
were	O
administered	O
.	O
	
Of	O
the	O
40	O
enrolled	O
patients	O
","	O
2	O
had	O
complete	O
response	O
and	O
12	O
partial	O
response	O
","	O
for	O
an	O
overall	O
response	O
rate	O
of	O
35	O
%	O
for	O
intent-to-treat	O
population	O
.	O
	
Among	O
35	O
patients	O
evaluable	O
for	O
efficacy	O
the	O
response	O
rate	O
was	O
40	O
%	O
.	O
	
Additional	O
14	O
patients	O
had	O
stable	O
disease	O
","	O
and	O
7	O
had	O
progressive	O
disease	O
.	O
	
The	O
median	O
duration	O
of	O
response	O
was	O
12	O
months	O
;	O
median	O
time	O
to	O
progression	O
","	O
7.2	O
months	O
;	O
median	O
survival	O
","	O
25.7	O
months	O
.	O
	
Common	O
grade	O
3	O
/	O
4	O
toxicities	O
were	O
neutropenia	B-TOXI
in	O
17	O
(	O
42.5	O
%	O
)	O
patients	O
each	O
","	O
grade	O
3	O
leukopenia	B-TOXI
in	O
19	O
(	O
47.5	O
%	O
)	O
","	O
and	O
grade	O
3	O
alopecia	B-TOXI
in	O
30	O
(	O
75	O
%	O
)	O
patients	O
;	O
1	O
(	O
2.5	O
%	O
)	O
patient	O
had	O
grade	O
4	O
thrombocytopenia	B-TOXI
.	O
	
GT	O
exhibited	O
encouraging	O
activity	O
and	O
tolerable	O
toxicity	O
as	O
first-line	O
therapy	O
in	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Phase	O
III	O
trials	O
for	O
further	O
evaluation	O
are	O
ongoing	O
.	O
	
Second-line	O
chemotherapy	O
with	O
weekly	O
paclitaxel	B-DRUG
and	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
pretreated	O
with	O
platinum	B-DRUG
and	O
etoposide	B-DRUG
:	O
a	O
single	O
institution	O
phase	O
II	O
trial	O
.	O
	
	
The	O
safety	O
and	O
efficacy	O
of	O
a	O
combined	O
regimen	O
of	O
weekly	O
paclitaxel	B-DRUG
and	O
gemcitabine	B-DRUG
was	O
tested	O
in	O
patients	O
with	O
refractory	O
and	O
sensitive	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
SCLC	B-CANCER
)	O
.	O
	
Treatment	O
consisted	O
of	O
paclitaxel	B-DRUG
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
","	O
8	O
","	O
15	O
and	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
and	O
8	O
every	O
3	O
weeks	O
.	O
	
Of	O
the	O
31	O
patients	O
enrolled	O
","	O
10	O
had	O
refractory	O
and	O
21	O
had	O
sensitive	O
disease	O
.	O
	
Objective	O
responses	O
occurred	O
in	O
8	O
patients	O
(	O
26	O
%	O
)	O
","	O
including	O
2	O
out	O
of	O
10	O
patients	O
with	O
refractory-	O
and	O
6	O
out	O
of	O
21	O
patients	O
with	O
sensitive	O
SCLC	B-CANCER
.	O
	
Median	O
time	O
to	O
progression	O
and	O
median	O
survival	O
were	O
9.4	O
and	O
32	O
weeks	O
","	O
respectively	O
.	O
	
The	O
schedule	O
was	O
very	O
well	O
tolerated	O
","	O
with	O
grade	O
3月4日	O
thrombocytopenia	B-TOXI
in	O
26	O
%	O
of	O
the	O
patients	O
","	O
grade	O
3	O
neutropenia	B-TOXI
in	O
26	O
%	O
","	O
grade	O
3月4日	O
asthenia	B-TOXI
in	O
13	O
%	O
and	O
grade	O
1月2日	O
sensory	B-TOXI
neuropathy	I-TOXI
in	O
32	O
%	O
.	O
	
To	O
conclude	O
","	O
this	O
weekly	O
schedule	O
of	O
paclitaxel	B-DRUG
and	O
gemcitabine	B-DRUG
was	O
found	O
to	O
have	O
moderate	O
activity	O
in	O
platinum-etoposide	B-DRUG
pretreated	O
SCLC	B-CANCER
patients	O
and	O
a	O
favorable	O
toxicity	O
profile	O
.	O
	
Phase	O
II	O
study	O
of	O
fixed	O
dose	O
rate	O
gemcitabine	B-DRUG
with	O
cisplatin	B-DRUG
for	O
metastatic	B-CANCER
adenocarcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
pancreas	I-CANCER
.	O
	
	
Although	O
gemcitabine	B-DRUG
remains	O
the	O
standard	O
of	O
care	O
for	O
patients	O
with	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
","	O
additional	O
improvements	O
may	O
be	O
realized	O
by	O
combining	O
therapeutic	O
agents	O
with	O
synergistic	O
activity	O
","	O
and	O
optimizing	O
drug	O
delivery	O
using	O
pharmacokinetic	O
principles	O
such	O
as	O
fixed	O
dose	O
rate	O
(	O
FDR	O
)	O
infusion	O
.	O
	
The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
determine	O
safety	O
and	O
efficacy	O
in	O
patients	O
with	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
treated	O
with	O
FDR	O
gemcitabine	B-DRUG
in	O
combination	O
with	O
low-dose	O
cisplatin	B-DRUG
.	O
	
Chemotherapy-naive	O
patients	O
with	O
metastatic	B-CANCER
pancreatic	I-CANCER
adenocarcinoma	I-CANCER
were	O
treated	O
with	O
a	O
combination	O
of	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m2	O
at	O
10	O
mg	O
/	O
m2	O
/	O
min	O
together	O
with	O
cisplatin	B-DRUG
20	O
mg	O
/	O
m2	O
on	O
days	O
1	O
and	O
8	O
of	O
a	O
21-day	O
cycle	O
.	O
	
Patient	O
follow-up	O
was	O
performed	O
using	O
computerized	O
tomographic	O
scans	O
and	O
serial	O
CA	O
9月19日	O
measurements	O
.	O
	
A	O
total	O
of	O
51	O
patients	O
were	O
enrolled	O
onto	O
the	O
study	O
","	O
with	O
a	O
median	O
follow-up	O
time	O
of	O
215	O
days	O
.	O
	
Twenty-two	O
of	O
40	O
patients	O
(	O
55	O
%	O
)	O
with	O
a	O
baseline	O
serum	O
CA	O
9月19日	O
level	O
&	O
gt	O
;	O
or	O
=	O
2x	O
the	O
upper	O
limit	O
of	O
normal	O
demonstrated	O
a	O
&	O
gt	O
;	O
or	O
=	O
50	O
%	O
biomarker	O
decline	O
during	O
treatment	O
.	O
	
Nine	O
of	O
47	O
patients	O
(	O
19.1	O
%	O
)	O
with	O
measurable	O
disease	O
achieved	O
a	O
partial	O
response	O
","	O
and	O
28	O
patients	O
(	O
59.6	O
%	O
)	O
had	O
disease	O
stabilization	O
for	O
at	O
least	O
two	O
treatment	O
cycles	O
.	O
	
Median	O
time	O
to	O
progression	O
was	O
3.9	O
months	O
and	O
median	O
survival	O
was	O
7.1	O
months	O
","	O
with	O
an	O
estimated	O
1-year	O
survival	O
rate	O
of	O
29	O
%	O
.	O
	
The	O
most	O
frequently	O
reported	O
grade	O
3	O
or	O
4	O
adverse	O
events	O
were	O
neutropenia	B-TOXI
(	O
52.9	O
%	O
)	O
and	O
thrombocytopenia	B-TOXI
(	O
15.7	O
%	O
)	O
.	O
	
Most	O
patients	O
were	O
switched	O
to	O
an	O
every-other-week	O
dosing	O
schedule	O
.	O
	
The	O
combination	O
of	O
FDR	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
is	O
well	O
tolerated	O
and	O
appears	O
to	O
be	O
an	O
acceptable	O
","	O
albeit	O
not	O
clearly	O
superior	O
","	O
alternative	O
to	O
other	O
gemcitabine	B-DRUG
/	O
platinum	B-DRUG
regimens	O
for	O
the	O
treatment	O
of	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
Clindamycin-paclitaxel	B-DRUG
pharmacokinetic	O
interaction	O
in	O
ovarian	B-CANCER
cancer	I-CANCER
patients	O
.	O
	
	
Plasma	O
protein	O
binding	O
is	O
an	O
important	O
factor	O
for	O
many	O
drugs	O
that	O
can	O
influence	O
the	O
tissue	O
distribution	O
and	O
pharmacokinetics	O
.	O
	
alpha	B-DRUG
(	I-DRUG
1	I-DRUG
)	I-DRUG
#NAME?	I-DRUG
glycoprotein	I-DRUG
(	O
AGP	B-DRUG
)	O
is	O
an	O
acute-phase	O
protein	O
that	O
can	O
increase	O
in	O
plasma	O
of	O
patients	O
with	O
several	O
pathological	O
conditions	O
including	O
cancer	O
.	O
	
Studies	O
performed	O
in	O
cultured	O
cells	O
indicate	O
that	O
paclitaxel	B-DRUG
cytotoxicity	O
is	O
reduced	O
by	O
adding	O
AGP	B-DRUG
and	O
the	O
sensitivity	O
to	O
paclitaxel	B-DRUG
is	O
restored	O
by	O
displacing	O
its	O
binding	O
to	O
AGP	B-DRUG
with	O
clindamycin	B-DRUG
","	O
resulting	O
in	O
an	O
increased	O
paclitaxel	B-DRUG
cell	O
uptake	O
.	O
	
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
whether	O
clindamycin	B-DRUG
modifies	O
paclitaxel	B-DRUG
pharmacokinetics	O
also	O
in	O
cancer	O
patients	O
.	O
	
Sixteen	O
patients	O
with	O
advanced	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
","	O
previously	O
treated	O
with	O
surgery	O
and	O
chemotherapy	O
were	O
enrolled	O
in	O
this	O
study	O
.	O
	
A	O
pharmacokinetic	O
study	O
of	O
paclitaxel	B-DRUG
was	O
performed	O
in	O
the	O
first	O
three	O
cycles	O
of	O
the	O
consolidation	O
therapy	O
(	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
)	O
in	O
each	O
patient	O
.	O
	
In	O
these	O
cycles	O
paclitaxel	B-DRUG
was	O
administered	O
alone	O
and	O
with	O
two	O
different	O
doses	O
(	O
600	O
and	O
"1,200"	O
mg	O
)	O
of	O
concurrent	O
clindamycin	B-DRUG
.	O
	
The	O
sequence	O
of	O
the	O
three	O
treatments	O
was	O
randomly	O
assigned	O
in	O
each	O
patient	O
in	O
order	O
to	O
avoid	O
the	O
same	O
order	O
of	O
treatments	O
.	O
	
Paclitaxel	B-DRUG
pharmacokinetics	O
were	O
partly	O
modified	O
by	O
the	O
concurrent	O
administration	O
of	O
clindamycin	B-DRUG
.	O
	
C	O
(	O
max	O
)	O
and	O
AUC	O
(	O
0-last	O
)	O
of	O
paclitaxel	B-DRUG
were	O
significantly	O
higher	O
when	O
the	O
drug	O
was	O
given	O
alone	O
than	O
when	O
it	O
was	O
coadministered	O
with	O
"1,200"	O
mg	O
clindamycin	B-DRUG
.	O
	
Moreover	O
","	O
AGP	B-DRUG
concentrations	O
seem	O
to	O
have	O
a	O
small	O
but	O
statistically	O
significant	O
influence	O
on	O
paclitaxel	B-DRUG
pharmacokinetic	O
","	O
since	O
AUC	O
(	O
0-last	O
)	O
showed	O
a	O
positive	O
significant	O
correlation	O
with	O
AGP	B-DRUG
plasma	O
concentration	O
when	O
paclitaxel	B-DRUG
was	O
given	O
alone	O
.	O
	
The	O
linear	O
relation	O
was	O
lost	O
when	O
paclitaxel	B-DRUG
was	O
coadministered	O
with	O
"1,200"	O
mg	O
clindamycin	B-DRUG
.	O
	
Toxicity	O
was	O
not	O
influenced	O
by	O
the	O
coadministration	O
of	O
clindamycin	B-DRUG
.	O
	
The	O
hypothesis	O
that	O
clindamycin	B-DRUG
could	O
affect	O
paclitaxel	B-DRUG
pharmacokinetics	O
seems	O
to	O
be	O
verified	O
with	O
this	O
study	O
.	O
	
Nevertheless	O
","	O
changes	O
induced	O
by	O
giving	O
the	O
combination	O
of	O
the	O
two	O
drugs	O
are	O
minimal	O
and	O
thus	O
of	O
questionable	O
clinical	O
relevance	O
.	O
	
A	O
dose	O
escalation	O
study	O
of	O
pegylated	B-DRUG
liposomal	I-DRUG
Doxorubicin	I-DRUG
(	O
caelyx	O
)	O
in	O
combination	O
with	O
capecitabine	B-DRUG
(	O
xeloda	O
)	O
in	O
patients	O
with	O
refractory	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
Pegylated	B-DRUG
liposomal	I-DRUG
doxorubicin	I-DRUG
(	O
PLD	B-DRUG
)	O
and	O
capecitabine	B-DRUG
(	O
CAP	B-DRUG
)	O
have	O
separately	O
shown	O
significant	O
antitumor	O
activity	O
in	O
a	O
wide	O
range	O
of	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
A	O
phase	O
I	O
study	O
was	O
conducted	O
in	O
order	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
of	O
their	O
combination	O
in	O
patients	O
with	O
refractory	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
Fifteen	O
patients	O
with	O
histologically	O
confirmed	O
inoperable	O
solid	B-CANCER
neoplasms	I-CANCER
were	O
enrolled	O
.	O
	
The	O
patients	O
'	O
median	O
age	O
was	O
65	O
years	O
","	O
10	O
were	O
male	O
","	O
and	O
12	O
had	O
a	O
performance	O
status	O
score	O
(	O
WHO	O
)	O
of	O
0-1	O
.	O
	
PLD	B-DRUG
was	O
administered	O
on	O
day	O
1	O
as	O
a	O
1-hour	O
intravenous	O
infusion	O
at	O
escalated	O
doses	O
ranging	O
from	O
35	O
to	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
CAP	B-DRUG
was	O
administered	O
on	O
days	O
1月14日	O
per	O
os	O
","	O
at	O
escalated	O
doses	O
ranging	O
from	O
"1,600"	O
to	O
"1,800"	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
given	O
as	O
two	O
daily	O
divided	O
doses	O
.	O
	
Treatment	O
was	O
repeated	O
every	O
3	O
weeks	O
.	O
	
At	O
the	O
dose	O
of	O
PLD	B-DRUG
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
CAP	B-DRUG
"1,800"	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
all	O
3	O
enrolled	O
patients	O
presented	O
DLTs	O
[	O
2	O
patients	O
grade	O
3	O
palmar-plantar	B-TOXI
erythrodysesthesia	I-TOXI
(	O
PPE	B-TOXI
)	O
and	O
1	O
patient	O
grade	O
3	O
asthenia	B-TOXI
]	O
and	O
thus	O
","	O
the	O
recommended	O
MTD	O
for	O
future	O
phase	O
II	O
studies	O
is	O
PLD	B-DRUG
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
CAP	B-DRUG
"1,700"	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
A	O
total	O
of	O
57	O
treatment	O
cycles	O
were	O
administered	O
.	O
	
Grade	O
2	O
/	O
3	O
neutropenia	B-TOXI
complicated	O
9	O
(	O
17	O
%	O
)	O
cycles	O
and	O
1	O
patient	O
was	O
hospitalized	O
for	O
febrile	B-TOXI
neutropenia	I-TOXI
.	O
	
There	O
was	O
no	O
septic	B-TOXI
death	I-TOXI
.	O
	
The	O
main	O
nonhematologic	B-TOXI
toxicity	I-TOXI
was	O
PPE	O
grade	O
2	O
in	O
3	O
(	O
19	O
%	O
)	O
patients	O
and	O
grade	O
3	O
in	O
4	O
(	O
27	O
%	O
)	O
.	O
	
PPE	B-TOXI
was	O
the	O
reason	O
of	O
treatment	O
interruption	O
for	O
3	O
patients	O
.	O
	
Other	O
toxicities	O
were	O
mild	O
and	O
easily	O
manageable	O
.	O
	
Two	O
patients	O
(	O
16	O
%	O
)	O
with	O
partial	O
response	O
suffering	O
from	O
gastric	B-CANCER
cancer	I-CANCER
and	O
5	O
patients	O
with	O
(	O
42	O
%	O
)	O
stable	O
disease	O
were	O
observed	O
among	O
12	O
evaluable	O
patients	O
.	O
	
The	O
results	O
of	O
this	O
phase	O
I	O
study	O
demonstrate	O
that	O
PLD	B-DRUG
and	O
CAP	B-DRUG
can	O
be	O
combined	O
at	O
clinically	O
effective	O
and	O
relevant	O
doses	O
.	O
	
However	O
","	O
PPE	B-TOXI
is	O
a	O
common	O
side	O
effect	O
and	O
further	O
investigation	O
is	O
warranted	O
to	O
define	O
its	O
precise	O
role	O
in	O
the	O
treatment	O
of	O
solid	B-CANCER
malignancies	I-CANCER
.	O
	
Phase	O
I	O
trial	O
of	O
sorafenib	B-DRUG
and	O
gemcitabine	B-DRUG
in	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
with	O
an	O
expanded	O
cohort	O
in	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
	
With	O
its	O
potent	O
inhibitory	O
effects	O
against	O
Raf-1	O
kinase	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
receptor-2	O
","	O
sorafenib	B-DRUG
is	O
a	O
novel	O
oral	O
anticancer	O
agent	O
targeting	O
signal	O
transduction	O
and	O
angiogenic	O
pathways	O
.	O
	
This	O
study	O
is	O
designed	O
to	O
combine	O
sorafenib	B-DRUG
and	O
gemcitabine	B-DRUG
due	O
to	O
their	O
compatibility	O
in	O
preclinical	O
models	O
and	O
nonoverlapping	O
clinical	O
toxicities	O
.	O
	
An	O
initial	O
dose-escalation	O
part	O
of	O
the	O
study	O
enrolled	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
","	O
followed	O
by	O
an	O
expanded	O
cohort	O
at	O
the	O
recommended	O
dose	O
for	O
patients	O
with	O
advanced	O
unresectable	O
or	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
Sorafenib	B-DRUG
is	O
administered	O
continuously	O
","	O
whereas	O
gemcitabine	B-DRUG
is	O
given	O
at	O
"1,000"	O
mg	O
/	O
m2	O
weekly	O
x	O
7	O
followed	O
by	O
1	O
rest	O
week	O
","	O
then	O
weekly	O
x	O
3	O
every	O
4	O
weeks	O
.	O
	
Forty-two	O
patients	O
have	O
been	O
enrolled	O
overall	O
","	O
including	O
19	O
in	O
the	O
dose-escalation	O
part	O
and	O
23	O
in	O
the	O
extended	O
pancreatic	B-CANCER
cancer	I-CANCER
cohort	O
.	O
	
Demographics	O
were	O
as	O
follows	O
:	O
male-to-female	O
ratio	O
=	O
26:16:00	O
;	O
median	O
age	O
=	O
61	O
years	O
(	O
range	O
39-83	O
years	O
)	O
;	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
00:01:02	O
ratio	O
=	O
16:21:05	O
The	O
recommended	O
dose	O
of	O
this	O
combination	O
is	O
sorafenib	B-DRUG
400	O
mg	O
twice	O
daily	O
and	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m2	O
.	O
	
The	O
most	O
frequent	O
grade	O
3	O
or	O
4	O
adverse	O
events	O
of	O
all	O
causalities	O
were	O
thrombocytopenia	B-TOXI
(	O
28.6	O
%	O
)	O
","	O
lymphopenia	B-TOXI
(	O
21.4	O
%	O
)	O
","	O
lipase	B-TOXI
elevation	I-TOXI
(	O
19	O
%	O
)	O
","	O
neutropenia	B-TOXI
(	O
16.7	O
%	O
)	O
","	O
and	O
fatigue	B-TOXI
(	O
14.3	O
%	O
)	O
.	O
	
Antitumor	O
activity	O
was	O
observed	O
in	O
both	O
groups	O
","	O
with	O
2	O
(	O
10.5	O
%	O
)	O
confirmed	O
partial	O
responses	O
in	O
ovarian	B-CANCER
cancer	I-CANCER
and	O
12	O
patients	O
(	O
63.2	O
%	O
)	O
with	O
disease	O
stabilization	O
in	O
the	O
dose-escalation	O
part	O
;	O
13	O
patients	O
(	O
56.5	O
%	O
)	O
achieved	O
disease	O
stabilization	O
in	O
the	O
pancreatic	O
cohort	O
.	O
	
There	O
was	O
no	O
consistent	O
pharmacokinetic	O
drug-to-drug	O
interaction	O
between	O
sorafenib	B-DRUG
and	O
gemcitabine	B-DRUG
.	O
	
Sorafenib	B-DRUG
and	O
gemcitabine	B-DRUG
are	O
well	O
tolerated	O
in	O
combination	O
;	O
further	O
evaluations	O
in	O
pancreatic	O
and	O
ovarian	B-CANCER
cancers	I-CANCER
are	O
warranted	O
.	O
	
Fixed	O
dose-rate	O
infusion	O
of	O
gemcitabine	B-DRUG
in	O
combination	O
with	O
cisplatin	B-DRUG
and	O
UFT	B-DRUG
in	O
advanced	B-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
pancreas	I-CANCER
.	O
	
	
Gemcitabine	B-DRUG
is	O
currently	O
considered	O
the	O
standard	O
treatment	O
for	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
(	O
APC	B-CANCER
)	O
.	O
	
Cisplatin	B-DRUG
and	O
a	O
fluoropyrimidine	B-DRUG
have	O
some	O
activity	O
in	O
the	O
treatment	O
of	O
this	O
cancer	O
.	O
	
The	O
aim	O
of	O
this	O
trial	O
is	O
to	O
evaluate	O
the	O
efficacy	O
and	O
toxicity	O
of	O
a	O
fixed	O
dose-rate	O
infusion	O
of	O
gemcitabine	O
associated	O
with	O
cisplatin	B-DRUG
and	O
UFT	B-DRUG
in	O
patients	O
with	O
APC	B-CANCER
.	O
	
Forty-six	O
chemotherapy-na茂ve	O
patients	O
with	O
APC	B-CANCER
that	O
was	O
either	O
unresectable	O
or	O
metastatic	O
were	O
included	O
in	O
this	O
phase	O
II	O
study	O
.	O
	
All	O
of	O
them	O
had	O
Karnofsky	O
performance	O
status	O
&	O
gt	O
;	O
or	O
50	O
and	O
unidimensionally	O
measurable	O
disease	O
.	O
	
Treatment	O
consisted	O
of	O
gemcitabine	B-DRUG
"1,200"	O
mg	O
/	O
m2	O
given	O
as	O
a	O
120-min	O
infusion	O
weekly	O
for	O
three	O
consecutive	O
weeks	O
","	O
cisplatin	B-DRUG
50	O
mg	O
/	O
m2	O
on	O
day	O
1	O
and	O
oral	O
UFT	B-DRUG
400	O
mg	O
/	O
m2	O
/	O
day	O
(	O
in	O
two	O
to	O
three	O
daily	O
doses	O
)	O
on	O
days	O
1	O
to	O
21	O
;	O
cycles	O
of	O
treatment	O
were	O
given	O
every	O
28	O
days	O
.	O
	
A	O
total	O
of	O
208	O
cycles	O
of	O
chemotherapy	O
were	O
given	O
with	O
a	O
median	O
of	O
4	O
per	O
patient	O
.	O
	
Fourteen	O
patients	O
(	O
30	O
%	O
)	O
achieved	O
partial	O
responses	O
(	O
95	O
%	O
CI	O
19-48	O
%	O
)	O
and	O
17	O
(	O
37	O
%	O
)	O
had	O
stable	O
disease	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
was	O
5	O
months	O
","	O
and	O
the	O
median	O
overall	O
survival	O
9	O
months	O
.	O
	
Nineteen	O
patients	O
(	O
49	O
%	O
;	O
95	O
%	O
CI	O
32-64	O
%	O
)	O
had	O
a	O
clinical	O
benefit	O
response	O
.	O
	
Grade	O
3月4日	O
WHO	O
toxicities	O
were	O
as	O
follows	O
:	O
neutropaenia	B-TOXI
in	O
26	O
patients	O
(	O
57	O
%	O
)	O
","	O
with	O
5	O
cases	O
of	O
febrile	B-TOXI
neutropaenia	I-TOXI
(	O
11	O
%	O
)	O
","	O
thrombocytopaenia	B-TOXI
in	O
15	O
(	O
33	O
%	O
)	O
","	O
anaemia	B-TOXI
in	O
six	O
(	O
13	O
%	O
)	O
","	O
diarrhoea	B-TOXI
in	O
5	O
(	O
11	O
%	O
)	O
","	O
asthenia	B-TOXI
in	O
2	O
(	O
4	O
%	O
)	O
and	O
mucositis	B-TOXI
in	O
1	O
(	O
2	O
%	O
)	O
.	O
	
Seven	O
patients	O
required	O
hospitalisation	O
for	O
treatment-related	O
complications	B-TOXI
.	O
	
A	O
fixed	O
dose-rate	O
infusion	O
of	O
gemcitabine	B-DRUG
associated	O
with	O
cisplatin	B-DRUG
and	O
UFT	B-DRUG
is	O
active	O
in	O
patients	O
with	O
APC	B-CANCER
","	O
though	O
at	O
the	O
cost	O
of	O
considerable	O
toxicity	O
.	O
	
Phase	O
I	O
dose	O
escalation	O
of	O
iodine-131-metaiodobenzylguanidine	B-DRUG
with	O
myeloablative	O
chemotherapy	O
and	O
autologous	O
stem-cell	O
transplantation	O
in	O
refractory	O
neuroblastoma	B-CANCER
:	O
a	O
new	O
approaches	O
to	O
Neuroblastoma	B-CANCER
Therapy	O
Consortium	O
Study	O
.	O
	
	
To	O
determine	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
toxicity	O
of	O
iodine-131-metaiodobenzylguanidine	B-DRUG
(	B-DRUG
(	I-DRUG
131	I-DRUG
)	I-DRUG
I-MIBG	I-DRUG
)	O
with	O
carboplatin	B-DRUG
","	O
etoposide	B-DRUG
","	O
melphalan	B-DRUG
(	O
CEM	B-DRUG
)	O
and	O
autologous	O
stem-cell	O
transplantation	O
(	O
ASCT	O
)	O
in	O
refractory	O
neuroblastoma	B-CANCER
.	O
	
Twenty-four	O
children	O
with	O
primary	O
refractory	O
neuroblastoma	B-CANCER
and	O
no	O
prior	O
ASCT	O
were	O
entered	O
;	O
22	O
were	O
assessable	O
for	O
toxicity	O
and	O
response	O
.	O
	
(	B-DRUG
131	I-DRUG
)	I-DRUG
I-MIBG	I-DRUG
was	O
administered	O
on	O
day	O
-21	O
","	O
CEM	B-DRUG
was	O
administered	O
on	O
days	O
-7	O
to	O
-4	O
","	O
and	O
ASCT	O
was	O
performed	O
on	O
day	O
0	O
","	O
followed	O
by	O
13-cis-retinoic	B-DRUG
acid	I-DRUG
.	O
	
(	B-DRUG
131	I-DRUG
)	I-DRUG
I-MIBG	I-DRUG
was	O
escalated	O
in	O
groups	O
of	O
three	O
to	O
six	O
patients	O
","	O
stratified	O
by	O
corrected	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
.	O
	
The	O
MTD	O
for	O
patients	O
with	O
normal	O
GFR	O
(	O
&	O
gt	O
;	O
or	O
=	O
100	O
mL	O
/	O
min	O
/	O
1.73	O
m2	O
)	O
was	O
131I-MIBG	B-DRUG
12	O
mCi	O
/	O
kg	O
","	O
carboplatin	B-DRUG
"1,500"	O
mg	O
/	O
m2	O
","	O
etoposide	B-DRUG
"1,200"	O
mg	O
/	O
m2	O
","	O
and	O
melphalan	B-DRUG
210	O
mg	O
/	O
m2	O
.	O
	
In	O
the	O
low-GFR	O
cohort	O
","	O
at	O
the	O
initial	O
dose	O
level	O
using	O
12	O
mCi	O
/	O
kg	O
of	O
131I-MIBG	B-DRUG
and	O
reduced	O
chemotherapy	O
","	O
one	O
in	O
six	O
patients	O
had	O
dose	O
limiting	O
toxicity	O
(	O
DLT	O
)	O
","	O
including	O
veno-occlusive	B-TOXI
disease	I-TOXI
(	O
VOD	B-TOXI
)	O
.	O
	
Three	O
more	O
patients	O
in	O
this	O
group	O
had	O
grade	O
3	O
or	O
4	O
hepatotoxicity	B-TOXI
","	O
and	O
two	O
had	O
VOD	B-TOXI
","	O
without	O
meeting	O
DLT	O
criteria	O
.	O
	
There	O
was	O
only	O
one	O
death	B-TOXI
as	O
a	O
result	O
of	O
toxicity	O
among	O
all	O
24	O
patients	O
.	O
	
All	O
assessable	O
patients	O
engrafted	O
","	O
with	O
median	O
time	O
for	O
neutrophils	O
&	O
gt	O
;	O
or	O
=	O
500	O
/	O
microL	O
of	O
10	O
days	O
and	O
median	O
time	O
for	O
platelets	O
&	O
gt	O
;	O
or	O
=	O
"20,000"	O
/	O
microL	O
of	O
26	O
days	O
.	O
	
Six	O
of	O
22	O
assessable	O
patients	O
had	O
complete	O
or	O
partial	O
response	O
","	O
and	O
15	O
patients	O
had	O
mixed	O
response	O
or	O
stable	O
disease	O
.	O
	
The	O
estimated	O
probability	O
of	O
event-free	O
survival	O
and	O
survival	O
from	O
the	O
day	O
of	O
MIBG	B-DRUG
infusion	O
for	O
all	O
patients	O
at	O
3	O
years	O
was	O
0.31	O
=+	O
/	O
=-	O
0.1	O
and	O
0.58	O
=+	O
/	O
=-	O
0.1	O
","	O
respectively	O
.	O
	
131I-MIBG	B-DRUG
with	O
myeloablative	O
chemotherapy	O
is	O
feasible	O
and	O
effective	O
for	O
patients	O
with	O
neuroblastoma	B-CANCER
exhibiting	O
de	O
novo	O
resistance	O
to	O
chemotherapy	O
.	O
	
Adding	O
gemcitabine	B-DRUG
to	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
combination	O
increases	O
survival	O
in	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
results	O
of	O
a	O
phase	O
II-III	O
study	O
.	O
	
	
Paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
(	O
PC	B-DRUG
)	O
is	O
one	O
of	O
the	O
reference	O
combinations	O
in	O
the	O
treatment	O
of	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
No	O
triplet	O
novel	O
agent	O
combination	O
has	O
until	O
now	O
shown	O
superiority	O
over	O
a	O
two-drug	O
combination	O
for	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
We	O
therefore	O
conducted	O
a	O
clinical	O
trial	O
to	O
test	O
if	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
/	O
gemcitabine	B-DRUG
(	O
PCG	B-DRUG
)	O
increases	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
response	O
rate	O
(	O
RR	O
)	O
over	O
PC	B-DRUG
.	O
	
Stage	O
IIIB	O
patients	O
not	O
suitable	O
for	O
radical	O
radiation	O
treatment	O
and	O
stage	O
IV	O
chemotherapy-naive	O
patients	O
with	O
measurable	O
disease	O
and	O
performance	O
status	O
of	O
0	O
to	O
2	O
were	O
randomly	O
assigned	O
to	O
PC	B-DRUG
arm	O
(	O
paclitaxel	B-DRUG
200	O
mg	O
/	O
m2	O
and	O
carboplatin	B-DRUG
area	O
under	O
the	O
concentration-time	O
curve	O
6	O
day	O
1	O
/	O
q21	O
days	O
)	O
or	O
the	O
PCG	B-DRUG
arm	O
(	O
paclitaxel	B-DRUG
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
carboplatin	B-DRUG
area	O
under	O
the	O
concentration-time	O
curve	O
6	O
day	O
1	O
","	O
and	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m2	O
days	O
1	O
and	O
8	O
every	O
21	O
days	O
)	O
.	O
	
A	O
total	O
of	O
324	O
patients	O
were	O
randomly	O
assigned	O
to	O
the	O
two	O
arms	O
.	O
	
The	O
RR	O
for	O
PC	B-DRUG
arm	O
and	O
PCG	B-DRUG
arm	O
were	O
20.2	O
%	O
and	O
43.6	O
%	O
[	O
corrected	O
]	O
(	O
P	O
&	O
lt	O
;	O
0.0001	O
)	O
.	O
	
The	O
median	O
time	O
to	O
the	O
progression	O
was	O
5.1	O
months	O
in	O
the	O
PC	B-DRUG
group	O
and	O
7.6	O
months	O
in	O
the	O
PCG	B-DRUG
group	O
(	O
P	O
=	O
0.012	O
;	O
hazard	O
ratio	O
[	O
HR	O
]	O
1.34	O
;	O
95	O
%	O
CI	O
:	O
1.06	O
to	O
1.72	O
)	O
.	O
	
Median	O
OS	O
was	O
8.3	O
months	O
and	O
10.8	O
months	O
(	O
P	O
=	O
0.032	O
;	O
HR	O
1.309	O
;	O
95	O
%	O
CI	O
:	O
1.03	O
to	O
1.67	O
)	O
in	O
favor	O
of	O
the	O
PCG	B-DRUG
arm	O
.	O
	
One-year	O
survival	O
was	O
34	O
%	O
(	O
PC	B-DRUG
arm	O
)	O
and	O
45	O
%	O
(	O
PCG	B-DRUG
arm	O
;	O
P	O
=	O
0.032	O
)	O
.	O
	
Only	O
hematologic	B-TOXI
toxicity	I-TOXI
(	O
neutropenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
and	O
anemia	B-TOXI
)	O
was	O
significantly	O
increased	O
in	O
the	O
PCG	B-DRUG
arm	O
and	O
the	O
experimental	O
arm	O
required	O
more	O
platelet	O
and	O
red	O
blood	O
cell	O
transfusions	O
","	O
and	O
more	O
granulocyte	O
colony-stimulating	O
factor	O
usage	O
.	O
	
No	O
toxic	O
/	O
early	O
deaths	B-TOXI
were	O
observed	O
.	O
	
The	O
PCG	B-DRUG
regimen	O
offers	O
a	O
significant	O
survival	O
advantage	O
over	O
PC	B-DRUG
in	O
advanced	B-CANCER
NSCLC	I-CANCER
","	O
making	O
PCG	B-DRUG
a	O
treatment	O
option	O
for	O
advanced	B-CANCER
NSCLC	I-CANCER
patients	O
.	O
	
Pilot	O
phase	O
II	O
study	O
of	O
weekly	O
chemotherapy	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
for	O
refractory	O
or	O
relapsed	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
safety	O
and	O
efficacy	O
of	O
weekly	O
chemotherapy	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
for	O
the	O
treatment	O
of	O
patients	O
with	O
refractory	O
or	O
relapsed	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
SCLC	B-CANCER
)	O
were	O
evaluated	O
.	O
	
Paclitaxel	B-DRUG
(	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
carboplatin	B-DRUG
(	O
with	O
a	O
target	O
area	O
under	O
the	O
concentration	O
versus	O
time	O
curve	O
of	O
2	O
mg	O
min	O
/	O
ml	O
using	O
the	O
Calvert	O
formula	O
)	O
were	O
administered	O
to	O
patients	O
with	O
previously-	O
treated	O
SCLC	B-CANCER
on	O
days	O
1	O
and	O
8	O
at	O
every	O
3月4日	O
weeks	O
.	O
	
A	O
total	O
of	O
29	O
patients	O
(	O
pts	O
)	O
[	O
male	O
/	O
female	O
","	O
26	O
/	O
3	O
pts	O
;	O
median	O
age	O
62.7	O
years	O
(	O
43-74	O
)	O
;	O
performance	O
status	O
0	O
/	O
1	O
/	O
2	O
","	O
9	O
/	O
10	O
/	O
10	O
pts	O
]	O
were	O
enrolled	O
between	O
March	O
2000	O
and	O
June	O
2002	O
.	O
	
The	O
mean	O
number	O
of	O
cycles	O
administered	O
per	O
pt	O
was	O
3	O
(	O
1月7日	O
)	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
69	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
52-86	O
%	O
)	O
","	O
and	O
83	O
%	O
(	O
15	O
/	O
18	O
)	O
in	O
sensitive	O
pts	O
and	O
45	O
%	O
(	O
5	O
/	O
11	O
)	O
in	O
refractory	O
pts	O
(	O
P	O
&	O
lt	O
;	O
0.01	O
)	O
.	O
	
The	O
overall	O
median	O
survival	O
time	O
was	O
29.6	O
weeks	O
with	O
a	O
1-year	O
survival	O
rate	O
of	O
37	O
%	O
[	O
34.1	O
weeks	O
in	O
sensitive	O
pts	O
and	O
23.1	O
weeks	O
in	O
refractory	O
pts	O
(	O
P=0.085	O
)	O
","	O
46.9	O
weeks	O
in	O
PS	O
0-1	O
and	O
16.3	O
weeks	O
in	O
PS	O
2	O
(	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
]	O
.	O
	
The	O
median	O
time	O
to	O
progressive	O
disease	O
was	O
16.4	O
weeks	O
[	O
21.7	O
weeks	O
in	O
sensitive	O
pts	O
and	O
15.3	O
weeks	O
in	O
refractory	O
pts	O
(	O
P=0.32	O
)	O
]	O
.	O
	
Hematologic	B-TOXI
toxicities	I-TOXI
observed	O
included	O
grade	O
&	O
gt	O
;	O
or=3	O
neutropenia	B-TOXI
in	O
55	O
%	O
","	O
grade	O
&	O
gt	O
;	O
or=3	O
anemia	B-TOXI
in	O
36	O
%	O
","	O
and	O
grade	O
&	O
gt	O
;	O
or=3	O
thrombocytopenia	B-TOXI
in	O
3	O
%	O
.	O
	
Non-hematologic	B-TOXI
toxicities	I-TOXI
were	O
mild	O
except	O
for	O
grade	O
3	O
diarrhea	B-TOXI
in	O
three	O
pts	O
and	O
grade	O
3	O
pneumonitis	B-TOXI
in	O
one	O
pt	O
.	O
	
Weekly	O
chemotherapy	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
was	O
well-	O
tolerated	O
and	O
gave	O
a	O
high-response	O
rate	O
in	O
pts	O
with	O
refractory	O
or	O
relapsed	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
A	O
Phase	O
I	O
study	O
of	O
escalating	O
doses	O
of	O
the	O
tyrosine	O
kinase	O
inhibitor	O
semaxanib	B-DRUG
(	O
SU5416	B-DRUG
)	O
in	O
combination	O
with	O
irinotecan	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
.	O
	
	
One	O
of	O
the	O
most	O
studied	O
pro-angiogenic	O
factors	O
involved	O
in	O
the	O
development	O
of	O
colorectal	B-CANCER
cancer	I-CANCER
is	O
the	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
.	O
	
The	O
small	O
molecule	O
tyrosine	O
kinase	O
inhibitor	O
semaxanib	B-DRUG
(	O
SU5416	B-DRUG
)	O
is	O
one	O
of	O
the	O
several	O
agents	O
targeting	O
the	O
VEGF	O
signaling	O
pathway	O
","	O
and	O
its	O
development	O
centered	O
mostly	O
in	O
the	O
treatment	O
of	O
colorectal	B-CANCER
cancer	I-CANCER
.	O
	
We	O
designed	O
and	O
conducted	O
an	O
NCI-sponsored	O
trial	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
of	O
semaxanib	B-DRUG
given	O
twice	O
weekly	O
in	O
combination	O
with	O
weekly	O
irinotecan	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
who	O
had	O
failed	O
at	O
least	O
one	O
prior	O
treatment	O
.	O
	
The	O
irinotecan	B-DRUG
dose	O
was	O
fixed	O
at	O
125	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
weekly	O
for	O
4	O
weeks	O
followed	O
by	O
2	O
weeks	O
of	O
rest	O
.	O
	
Patients	O
with	O
prior	O
pelvic	O
irradiation	O
received	O
a	O
reduced	O
dose	O
of	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
The	O
semaxanib	B-DRUG
dose	O
was	O
escalated	O
","	O
going	O
from	O
85	O
to	O
110	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
finally	O
to	O
145	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Ten	O
patients	O
were	O
treated	O
in	O
our	O
study	O
and	O
all	O
were	O
evaluable	O
for	O
toxicity	O
.	O
	
There	O
were	O
no	O
drug-related	O
Grade	O
4	O
toxicities	O
.	O
	
There	O
was	O
one	O
episode	O
of	O
Grade	O
3	O
headache	B-TOXI
and	O
one	O
episode	O
of	O
Grade	O
3	O
vomiting	B-TOXI
.	O
	
The	O
most	O
common	O
Grades	O
1	O
and	O
2	O
toxicities	O
included	O
diarrhea	B-TOXI
","	O
abdominal	B-TOXI
cramping	I-TOXI
","	O
anemia	B-TOXI
and	O
nausea	B-TOXI
.	O
	
Nine	O
patients	O
completed	O
at	O
least	O
one	O
6	O
week	O
cycle	O
of	O
treatment	O
and	O
were	O
considered	O
evaluable	O
for	O
response	O
.	O
	
Among	O
those	O
nine	O
","	O
two	O
had	O
a	O
partial	O
response	O
","	O
three	O
had	O
stable	O
disease	O
and	O
four	O
had	O
progressive	O
disease	O
after	O
the	O
first	O
cycle	O
.	O
	
Both	O
irinotecan	B-DRUG
and	O
semaxanib	B-DRUG
could	O
be	O
given	O
at	O
their	O
full	O
single-agent	O
recommended	O
doses	O
without	O
significant	O
toxicity	O
","	O
and	O
the	O
combination	O
showed	O
signs	O
of	O
clinical	O
activity	O
.	O
	
However	O
","	O
owing	O
to	O
discouraging	O
results	O
from	O
Phase	O
III	O
trials	O
","	O
it	O
is	O
unlikely	O
that	O
this	O
combination	O
will	O
be	O
further	O
explored	O
.	O
	
A	O
phase	O
I	O
trial	O
of	O
carboplatin	B-DRUG
and	O
etoposide	B-DRUG
for	O
elderly	O
(	O
&	O
gt	O
;	O
or=75	O
year-old	O
)	O
patients	O
with	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
combination	O
of	O
carboplatin	B-DRUG
and	O
etoposide	B-DRUG
is	O
currently	O
considered	O
the	O
most	O
appropriate	O
regimen	O
for	O
treating	O
elderly	O
patients	O
with	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
SCLC	B-CANCER
)	O
.	O
	
Previous	O
reports	O
on	O
elderly	O
patients	O
","	O
70	O
years	O
or	O
older	O
","	O
found	O
that	O
the	O
recommended	O
dose	O
was	O
close	O
to	O
that	O
of	O
younger	O
patients	O
.	O
	
Then	O
","	O
we	O
conducted	O
a	O
phase	O
I	O
study	O
of	O
carboplatin	B-DRUG
and	O
etoposide	B-DRUG
in	O
elderly	O
patients	O
","	O
75	O
years	O
or	O
older	O
","	O
with	O
SCLC	B-CANCER
.	O
	
This	O
study	O
aimed	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
.	O
	
Twenty-six	O
patients	O
fulfilling	O
the	O
eligibility	O
criteria	O
","	O
chemotherapy-naive	O
","	O
performance	O
status	O
(	O
PS	O
)	O
of	O
0-2	O
","	O
age	O
&	O
gt	O
;	O
or=75	O
","	O
and	O
adequate	O
organ	O
functions	O
were	O
enrolled	O
.	O
	
Patients	O
'	O
characteristics	O
were	O
:	O
male	O
/	O
female=21	O
/	O
5	O
;	O
PS	O
0	O
/	O
1	O
/	O
2=9	O
/	O
11	O
/	O
6	O
;	O
median	O
age	O
(	O
range	O
)	O
78	O
(	O
75-82	O
)	O
;	O
and	O
limited	O
/	O
extensive	O
stage=16	O
/	O
10	O
.	O
	
The	O
patients	O
intravenously	O
received	O
carboplatin	B-DRUG
with	O
a	O
target	O
AUC	O
of	O
4	O
or	O
5	O
mg	O
min	O
/	O
ml	O
(	O
Chatelut	O
formula	O
)	O
on	O
day	O
1	O
and	O
etoposide	B-DRUG
at	O
80-120	O
mg	O
/	O
m2	O
on	O
days	O
1	O
","	O
2	O
and	O
3	O
Therapy	O
was	O
repeated	O
four	O
times	O
in	O
every	O
4	O
weeks	O
.	O
	
The	O
MTD	O
of	O
carboplatin	B-DRUG
/	O
etoposide	B-DRUG
was	O
AUC=5	O
/	O
80	O
","	O
4	O
/	O
110	O
","	O
and	O
4	O
/	O
120	O
.	O
	
The	O
DLTs	O
were	O
thrombocytopenia	B-TOXI
","	O
neutropenia	B-TOXI
","	O
leukopenia	B-TOXI
","	O
and	O
febrile	B-TOXI
neutropenia	I-TOXI
.	O
	
Overall	O
","	O
grade	O
4	O
thrombocytopenia	B-TOXI
","	O
neutropenia	B-TOXI
(	O
&	O
gt	O
;	O
or=4	O
days	O
)	O
","	O
leukopenia	B-TOXI
(	O
&	O
gt	O
;	O
or=4	O
days	O
)	O
","	O
and	O
febrile	B-TOXI
neutropenia	I-TOXI
occurred	O
in	O
27	O
","	O
20	O
","	O
7	O
","	O
and	O
13	O
%	O
of	O
cases	O
at	O
MTD	O
levels	O
","	O
respectively	O
","	O
and	O
0	O
%	O
at	O
other	O
levels	O
.	O
	
Twenty	O
of	O
26	O
patients	O
showed	O
objective	O
responses	O
(	O
2CR	O
","	O
18PR	O
;	O
RR=77	O
%	O
)	O
.	O
	
A	O
dose	O
of	O
carboplatin	B-DRUG
of	O
AUC=4	O
and	O
etoposide	B-DRUG
of	O
100	O
mg	O
/	O
m2	O
was	O
recommended	O
in	O
this	O
regimen	O
.	O
	
Concurrent	O
chemotherapy	O
(	O
carboplatin	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
etoposide	B-DRUG
)	O
and	O
involved-field	O
radiotherapy	O
in	O
limited	O
stage	O
small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
a	O
Dutch	O
multicenter	O
phase	O
II	O
study	O
.	O
	
	
To	O
improve	O
the	O
prognosis	O
of	O
limited	O
stage	O
small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
LS-SCLC	O
)	O
the	O
addition	O
of	O
concurrent	O
thoracic	O
radiotherapy	O
to	O
a	O
platinum-containing	B-DRUG
regimen	O
is	O
important	O
.	O
	
In	O
the	O
Netherlands	O
","	O
we	O
initiated	O
a	O
multicenter	O
","	O
phase	O
II	O
study	O
","	O
of	O
the	O
combination	O
of	O
four	O
cycles	O
of	O
carboplatin	B-DRUG
(	O
AUC	O
5	O
)	O
","	O
paclitaxel	B-DRUG
(	O
200	O
mg	O
m	O
(	O
-2	O
)	O
)	O
and	O
etoposide	B-DRUG
(	O
2	O
x	O
50	O
mg	O
orally	O
for	O
5	O
days	O
)	O
combined	O
with	O
45	O
Gy	O
(	O
daily	O
fractions	O
of	O
1.8	O
Gy	O
)	O
.	O
	
The	O
radiation	O
was	O
given	O
to	O
the	O
involved	O
field	O
and	O
concurrently	O
with	O
the	O
second	O
and	O
third	O
chemotherapy	O
cycle	O
.	O
	
Patients	O
with	O
a	O
partial	O
or	O
complete	O
response	O
received	O
prophylactic	O
cranial	O
irradiation	O
to	O
a	O
dose	O
of	O
30	O
Gy	O
.	O
	
From	O
January	O
1999	O
to	O
December	O
2001	O
","	O
37	O
of	O
the	O
38	O
patients	O
with	O
LS-SCLC	O
entered	O
were	O
eligible	O
for	O
toxicity	O
analysis	O
and	O
response	O
.	O
	
Grade	O
3	O
and	O
4	O
haematological	B-TOXI
toxicity	I-TOXI
occurred	O
in	O
57	O
%	O
(	O
21	O
/	O
37	O
)	O
with	O
febrile	B-TOXI
neutropenia	I-TOXI
in	O
24	O
%	O
(	O
9	O
/	O
37	O
)	O
.	O
	
There	O
were	O
no	O
treatment-related	O
deaths	B-TOXI
or	O
other	O
grade	O
4	O
toxicity	O
.	O
	
Grade	O
3	O
toxicities	O
were	O
oesophagitis	B-TOXI
(	O
27	O
%	O
)	O
","	O
radiation	B-TOXI
pneumonitis	I-TOXI
(	O
6	O
%	O
)	O
","	O
anorexia	B-TOXI
(	O
14	O
%	O
)	O
","	O
nausea	B-TOXI
(	O
16	O
%	O
)	O
","	O
dyspnea	B-TOXI
(	O
19	O
%	O
)	O
and	O
lethargy	B-TOXI
(	O
22	O
%	O
)	O
.	O
	
The	O
objective	O
response	O
rate	O
was	O
92	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
80-98	O
%	O
)	O
with	O
a	O
median	O
survival	O
time	O
of	O
19.5	O
months	O
(	O
95	O
%	O
CI	O
12.8-29.2	O
)	O
.	O
	
The	O
-1	O
","	O
-2	O
and	O
5-year	O
survival	O
rate	O
was	O
70	O
","	O
47	O
and	O
27	O
%	O
","	O
respectively	O
.	O
	
In	O
field	O
local	O
recurrences	O
occurred	O
in	O
six	O
patients	O
.	O
	
Distant	B-TOXI
metastases	I-TOXI
were	O
observed	O
in	O
19	O
patients	O
of	O
which	O
13	O
in	O
the	O
brain	O
.	O
	
This	O
study	O
indicates	O
that	O
combination	O
chemotherapy	O
with	O
concurrent	O
involved-field	O
radiation	O
therapy	O
is	O
an	O
effective	O
treatment	O
for	O
LS-SCLC	O
.	O
	
Despite	O
PCI	O
","	O
the	O
brain	O
remained	O
the	O
most	O
important	O
site	O
of	O
recurrence	O
.	O
	
Comparison	O
of	O
the	O
efficacy	O
of	O
oral	O
capecitabine	B-DRUG
versus	O
bolus	O
5-FU	B-DRUG
in	O
preoperative	O
radiotherapy	O
of	O
locally	O
advanced	B-CANCER
rectal	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
effects	O
of	O
treatment	O
with	O
oral	O
capecitabine	B-DRUG
vs.	O
bolus	O
5-FU	B-DRUG
","	O
administered	O
concurrently	O
with	O
preoperative	O
radiotherapy	O
","	O
were	O
compared	O
in	O
the	O
treatment	O
of	O
locally	O
advanced	B-CANCER
rectal	I-CANCER
cancer	I-CANCER
(	O
LARC	B-CANCER
)	O
.	O
	
One	O
hundred	O
and	O
twenty-seven	O
patients	O
with	O
LARC	B-CANCER
received	O
concurrent	O
preoperative	O
chemoradiation	O
using	O
two	O
cycles	O
bolus	O
5-FU	B-DRUG
(	O
500	O
mg	O
/	O
m2	O
/	O
day	O
)	O
plus	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
","	O
20	O
mg	O
/	O
m2	O
/	O
day	O
)	O
(	O
Group	O
I	O
)	O
.	O
	
Another	O
LARC	B-CANCER
group	O
received	O
concurrent	O
chemoradiation	O
using	O
two	O
cycles	O
"1,650"	O
mg	O
/	O
m2	O
/	O
day	O
of	O
oral	O
capecitabine	B-DRUG
and	O
20	O
mg	O
/	O
m2	O
/	O
day	O
of	O
LV	B-DRUG
(	O
Group	O
II	O
","	O
97	O
patients	O
)	O
.	O
	
Radiation	O
was	O
delivered	O
to	O
the	O
primary	O
tumor	O
at	O
50.4	O
Gy	O
in	O
both	O
groups	O
.	O
	
Definitive	O
surgery	O
was	O
performed	O
6	O
weeks	O
after	O
the	O
completion	O
of	O
chemoradiation	O
.	O
	
A	O
pathologic	O
complete	O
remission	O
was	O
achieved	O
in	O
11.4	O
%	O
of	O
patients	O
in	O
Group	O
I	O
and	O
in	O
22.2	O
%	O
of	O
patients	O
in	O
Group	O
II	O
(	O
p=	O
0.042	O
)	O
.	O
	
The	O
down-staging	O
rates	O
of	O
the	O
primary	O
tumor	O
and	O
lymph	O
nodes	O
were	O
39	O
/	O
68.7	O
%	O
in	O
Group	O
I	O
and	O
61.1	O
/	O
87.5	O
%	O
in	O
Group	O
II	O
(	O
p=0.002	O
/	O
0.005	O
)	O
.	O
	
Sphincter-preserving	O
surgery	O
was	O
possible	O
in	O
42.1	O
%	O
of	O
patients	O
in	O
Group	O
I	O
and	O
66.7	O
%	O
of	O
those	O
in	O
Group	O
II	O
(	O
p=0.021	O
)	O
.	O
	
Grade	O
3	O
or	O
4	O
leucopenia	B-TOXI
","	O
diarrhea	B-TOXI
","	O
and	O
radiation	B-TOXI
dermatitis	I-TOXI
were	O
statistically	O
more	O
prevalent	O
in	O
Group	O
I	O
than	O
in	O
Group	O
II	O
","	O
while	O
the	O
opposite	O
was	O
TRUE	O
for	O
grade	O
3	O
hand-foot	B-TOXI
syndrome	I-TOXI
.	O
	
Preoperative	O
chemoradiation	O
using	O
oral	O
capecitabine	B-DRUG
was	O
better	O
tolerated	O
than	O
bolus	O
5-FU	B-DRUG
and	O
was	O
more	O
effective	O
in	O
the	O
promotion	O
of	O
both	O
down-staging	O
and	O
sphincter	O
preservation	O
in	O
patients	O
with	O
LARC	B-CANCER
.	O
	
A	O
randomized	O
trial	O
of	O
alternating	O
chemotherapy	O
versus	O
best	O
supportive	O
care	O
in	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
From	O
April	O
1985	O
to	O
September	O
1988	O
","	O
128	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
were	O
enrolled	O
in	O
a	O
prospective	O
randomized	O
trial	O
evaluating	O
chemotherapy	O
(	O
arm	O
A	O
)	O
versus	O
best	O
supportive	O
care	O
(	O
arm	O
B	O
)	O
.	O
	
Chemotherapy	O
consisted	O
of	O
cyclophosphamide	B-DRUG
500	O
mg	O
/	O
m2	O
intravenously	O
(	O
IV	O
)	O
day	O
1	O
","	O
epirubicin	B-DRUG
50	O
mg	O
/	O
m2	O
IV	O
day	O
1	O
","	O
and	O
cisplatin	B-DRUG
80	O
mg	O
/	O
m2	O
IV	O
day	O
1	O
(	O
CE'P	O
regimen	O
)	O
alternating	O
every	O
4	O
weeks	O
with	O
methotrexate	B-DRUG
30	O
mg	O
/	O
m2	O
IV	O
day	O
1	O
","	O
etoposide	B-DRUG
200	O
mg	O
/	O
m2	O
IV	O
day	O
1	O
","	O
and	O
lomustine	B-DRUG
(	O
CCNU	O
)	O
70	O
mg	O
/	O
m2	O
orally	O
day	O
1	O
(	O
MEC	O
'	O
regimen	O
)	O
until	O
progression	O
.	O
	
Of	O
the	O
123	O
patients	O
(	O
62	O
treated	O
and	O
61	O
controls	O
)	O
eligible	O
for	O
survival	O
","	O
115	O
were	O
fully	O
evaluable	O
for	O
response	O
(	O
58	O
treated	O
and	O
57	O
controls	O
)	O
.	O
	
Response	O
rates	O
were	O
21	O
%	O
partial	O
response	O
","	O
53	O
%	O
stable	O
disease	O
","	O
and	O
26	O
%	O
progressive	O
disease	O
in	O
arm	O
A	O
","	O
and	O
47	O
%	O
stable	O
disease	O
and	O
53	O
%	O
progressive	O
disease	O
in	O
arm	O
B.	O
Median	O
survival	O
was	O
34.3	O
weeks	O
(	O
range	O
","	O
4.3	O
to	O
218.6+	O
weeks	O
)	O
in	O
arm	O
A	O
versus	O
21.1	O
weeks	O
(	O
range	O
","	O
4.3	O
to	O
188.6	O
weeks	O
)	O
in	O
arm	O
B	O
;	O
the	O
difference	O
was	O
not	O
significant	O
at	O
P	O
=	O
0.153	O
(	O
Mantel-Cox	O
)	O
.	O
	
Subgroups	O
of	O
patients	O
retrospectively	O
analyzed	O
by	O
age	O
","	O
performance	O
status	O
","	O
stage	O
M0	O
/	O
M1	O
","	O
and	O
weight	B-TOXI
loss	I-TOXI
or	O
not	O
showed	O
no	O
significant	O
difference	O
in	O
survival	O
.	O
	
Poor-risk	O
patients	O
(	O
at	O
least	O
two	O
of	O
the	O
following	O
:	O
poor	O
performance	O
status	O
","	O
stage	O
M1	O
","	O
weight	B-TOXI
loss	I-TOXI
)	O
of	O
arm	O
A	O
survived	O
significantly	O
longer	O
than	O
poor-risk	O
patients	O
of	O
arm	O
B	O
(	O
23.6	O
weeks	O
v	O
12.4	O
weeks	O
","	O
Mantel-Cox	O
P	O
=	O
0.008	O
)	O
;	O
a	O
significant	O
difference	O
in	O
survival	O
was	O
also	O
observed	O
between	O
nonsquamous	O
cell	O
patients	O
of	O
arm	O
A	O
and	O
those	O
of	O
arm	O
B	O
(	O
median	O
survival	O
","	O
38.6	O
weeks	O
v	O
16.7	O
weeks	O
;	O
Mantel-Cox	O
P	O
=	O
0.041	O
)	O
.	O
	
Toxicity	O
on	O
the	O
chemotherapy	O
arm	O
was	O
hematologic	O
(	O
World	O
Health	O
Organization	O
[	O
WHO	O
]	O
grade	O
greater	O
than	O
3	O
)	O
in	O
12	O
%	O
of	O
CE'P	O
and	O
in	O
13	O
%	O
of	O
MEC	O
'	O
courses	O
and	O
gastroenteric	O
(	O
WHO	O
grade	O
greater	O
than	O
3	O
)	O
in	O
24	O
%	O
of	O
CE'P	O
courses	O
and	O
in	O
8	O
%	O
of	O
MEC	O
'	O
courses	O
.	O
	
Our	O
alternating	O
treatment	O
was	O
not	O
significantly	O
superior	O
to	O
supportive	O
care	O
.	O
	
It	O
is	O
likely	O
that	O
certain	O
subgroups	O
of	O
the	O
NSCLC	B-CANCER
category	O
may	O
have	O
an	O
advantage	O
with	O
chemotherapy	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
the	O
humanized	O
monoclonal	O
anti-epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
antibody	O
EMD	O
72000	O
(	O
matuzumab	B-DRUG
)	O
in	O
combination	O
with	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
EGFR-positive	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
	
Epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
is	O
overexpressed	O
in	O
80	O
%	O
-90	O
%	O
of	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Matuzumab	B-DRUG
","	O
a	O
humanized	O
immunoglobulin	O
G	O
(	O
1	O
)	O
(	O
IgG	O
(	O
1	O
)	O
)	O
anti-EGFR	O
monoclonal	O
antibody	O
","	O
blocks	O
activation	O
of	O
EGFR	O
.	O
	
Paclitaxel	B-DRUG
and	O
EGFR	O
inhibitors	O
have	O
additive	O
antitumour	O
effects	O
in	O
vitro	O
.	O
	
This	O
phase	O
I	O
study	O
assessed	O
the	O
tolerability	O
","	O
pharmacokinetics	O
and	O
efficacy	O
of	O
the	O
combination	O
of	O
matuzumab	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
Eighteen	O
chemotherapy-na茂ve	O
(	O
n	O
=	O
9	O
)	O
or	O
pretreated	O
(	O
n	O
=	O
9	O
)	O
patients	O
with	O
stage	O
IIIB	O
or	O
IV	O
EGFR-positive	O
NSCLC	B-CANCER
received	O
weekly	O
doses	O
of	O
matuzumab	B-DRUG
(	O
100	O
","	O
200	O
","	O
400	O
or	O
800	O
mg	O
)	O
followed	O
by	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
every	O
3	O
weeks	O
.	O
	
Toxicity	O
was	O
evaluated	O
weekly	O
and	O
pharmacokinetics	O
were	O
measured	O
during	O
cycles	O
1	O
and	O
2	O
The	O
maximum	O
planned	O
matuzumab	B-DRUG
dose	O
of	O
800	O
mg	O
was	O
achieved	O
without	O
reaching	O
the	O
maximum	O
tolerated	O
dose	O
.	O
	
Grade	O
4	O
neutropenia	B-TOXI
occurred	O
in	O
one	O
of	O
three	O
patients	O
at	O
800	O
mg	O
but	O
resolved	O
within	O
1	O
week	O
;	O
five	O
additional	O
patients	O
treated	O
with	O
800	O
mg	O
had	O
no	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
.	O
	
Grade	O
1	O
/	O
2	O
acneiform	B-TOXI
skin	I-TOXI
rash	I-TOXI
in	O
14	O
patients	O
was	O
the	O
most	O
frequent	O
matuzumab-related	B-DRUG
side-effect	O
.	O
	
There	O
were	O
no	O
higher-grade	O
adverse	O
events	O
.	O
	
Grade	O
2	O
toxicities	O
included	O
pruritus	B-TOXI
(	O
n	O
=	O
2	O
)	O
","	O
bronchospasm	B-TOXI
(	O
n	O
=	O
1	O
)	O
","	O
fissures	B-TOXI
(	O
n	O
=	O
1	O
)	O
","	O
abdominal	B-TOXI
pain	I-TOXI
(	O
n	O
=	O
1	O
)	O
and	O
hot	B-TOXI
flushes	I-TOXI
(	O
n	O
=	O
1	O
)	O
.	O
	
Paclitaxel	B-DRUG
was	O
discontinued	O
in	O
four	O
patients	O
due	O
to	O
allergic	B-TOXI
reactions	I-TOXI
.	O
	
Coadministration	O
of	O
paclitaxel	B-DRUG
did	O
not	O
alter	O
matuzumab	B-DRUG
pharmacokinetics	O
.	O
	
Responses	O
occurred	O
in	O
four	O
of	O
18	O
patients	O
and	O
included	O
one	O
complete	O
response	O
.	O
	
Matuzumab	B-DRUG
doses	O
up	O
to	O
800	O
mg	O
weekly	O
with	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
every	O
3	O
weeks	O
are	O
well	O
tolerated	O
","	O
with	O
no	O
apparent	O
drug	O
interactions	O
and	O
with	O
evidence	O
of	O
antitumor	O
activity	O
.	O
	
Randomized	O
trial	O
of	O
tamoxifen	B-DRUG
alone	O
or	O
combined	O
with	O
fluoxymesterone	B-DRUG
as	O
adjuvant	O
therapy	O
in	O
postmenopausal	O
women	O
with	O
resected	O
estrogen	O
receptor	O
positive	O
breast	B-CANCER
cancer.	I-CANCER
North	O
Central	O
Cancer	O
Treatment	O
Group	O
Trial	O
89-30-52	O
.	O
	
	
This	O
clinical	O
trial	O
evaluated	O
the	O
addition	O
of	O
fluoxymesterone	B-DRUG
(	O
Flu	B-DRUG
)	O
to	O
tamoxifen	B-DRUG
(	O
Tam	B-DRUG
)	O
in	O
women	O
with	O
resected	O
early	O
stage	O
breast	B-CANCER
cancer	I-CANCER
and	O
attempted	O
to	O
corroborate	O
the	O
findings	O
of	O
superiority	O
for	O
the	O
combination	O
over	O
Tam	B-DRUG
alone	O
seen	O
in	O
a	O
previous	O
randomized	O
trial	O
in	O
metastatic	O
disease	O
.	O
	
Postmenopausal	O
women	O
with	O
early	O
stage	O
breast	B-CANCER
cancer	I-CANCER
that	O
was	O
known	O
to	O
be	O
estrogen	O
receptor	O
(	O
ER	O
)	O
positive	O
were	O
randomized	O
to	O
treatment	O
with	O
Tam	B-DRUG
(	O
20	O
mg	O
per	O
day	O
orally	O
for	O
5	O
years	O
)	O
alone	O
or	O
combined	O
with	O
Flu	B-DRUG
(	O
10	O
mg	O
orally	O
twice	O
per	O
day	O
for	O
1	O
year	O
)	O
.	O
	
The	O
primary	O
endpoint	O
was	O
relapse-free	O
survival	O
(	O
RFS	O
)	O
defined	O
as	O
local-regional	O
or	O
distant	O
recurrence	O
including	O
ductal	B-CANCER
carcinoma	I-CANCER
in	O
situ	O
of	O
the	O
ipsilateral	O
","	O
but	O
not	O
contralateral	O
breast	O
","	O
and	O
death	O
from	O
any	O
cause	O
.	O
	
There	O
were	O
541	O
eligible	O
patients	O
entered	O
between	O
1991	O
and	O
1995	O
and	O
the	O
treatment	O
arms	O
were	O
balanced	O
with	O
respect	O
to	O
patient	O
characteristics	O
.	O
	
The	O
median	O
follow	O
up	O
of	O
patients	O
still	O
alive	O
was	O
11.4	O
years	O
.	O
	
No	O
significant	O
difference	O
was	O
found	O
between	O
Tam	B-DRUG
plus	O
Flu	B-DRUG
and	O
Tam	B-DRUG
alone	O
in	O
terms	O
of	O
RFS	O
or	O
overall	O
survival	O
.	O
	
The	O
adjusted	O
hazard	O
ratio	O
(	O
Tam+Flu	B-DRUG
/	O
Tam	B-DRUG
)	O
for	O
relapse	O
or	O
death	O
without	O
relapse	O
was	O
estimated	O
to	O
be	O
0.84	O
(	O
95	O
%	O
CI	O
:	O
0.64-1.10	O
)	O
and	O
that	O
for	O
death	B-TOXI
was	O
0.89	O
(	O
95	O
%	O
CI	O
:	O
0.67-1.18	O
)	O
.	O
	
As	O
expected	O
there	O
was	O
more	O
virilization	B-TOXI
in	O
women	O
who	O
received	O
Flu	B-DRUG
.	O
	
This	O
clinical	O
trial	O
did	O
not	O
demonstrate	O
superiority	O
of	O
Tam	B-DRUG
plus	O
Flu	B-DRUG
over	O
Tam	B-DRUG
alone	O
as	O
adjuvant	O
therapy	O
for	O
postmenopausal	O
women	O
with	O
resected	O
early	O
breast	B-CANCER
cancer	I-CANCER
known	O
to	O
be	O
ER	O
positive	O
.	O
	
Phase	O
III	O
study	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
with	O
or	O
without	O
aprinocarsen	B-DRUG
","	O
a	O
protein	O
kinase	O
C-alpha	O
antisense	O
oligonucleotide	O
","	O
in	O
patients	O
with	O
advanced-stage	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
determine	O
whether	O
aprinocarsen	B-DRUG
","	O
an	O
antisense	O
oligonucleotide	O
directed	O
against	O
protein	O
kinase	O
C-alpha	O
","	O
when	O
added	O
to	O
the	O
chemotherapy	O
regimen	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
improved	O
survival	O
in	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Patients	O
with	O
previously	O
untreated	O
stage	O
IIIB	O
/	O
IV	O
NSCLC	B-CANCER
and	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
or	O
1	O
","	O
were	O
randomly	O
assigned	O
to	O
either	O
a	O
control	O
arm	O
of	O
gemcitabine	B-DRUG
"1,250"	O
mg	O
/	O
m2	O
on	O
days	O
1	O
and	O
8	O
and	O
cisplatin	B-DRUG
80	O
mg	O
/	O
m2	O
on	O
day	O
1	O
","	O
or	O
experimental	O
arms	O
consisting	O
of	O
the	O
identical	O
chemotherapy	O
plus	O
aprinocarsen	B-DRUG
2	O
mg	O
/	O
kg	O
/	O
d	O
as	O
continuous	O
infusion	O
for	O
14	O
days	O
","	O
starting	O
on	O
either	O
day	O
1	O
or	O
3	O
days	O
before	O
chemotherapy	O
.	O
	
Cycles	O
were	O
repeated	O
every	O
21	O
days	O
.	O
	
A	O
total	O
of	O
670	O
patients	O
were	O
randomly	O
assigned	O
between	O
the	O
control	O
(	O
n	O
=	O
328	O
)	O
and	O
experimental	O
arms	O
(	O
n	O
=	O
342	O
)	O
.	O
	
Due	O
to	O
the	O
results	O
from	O
another	O
phase	O
III	O
study	O
of	O
aprinocarsen	B-DRUG
in	O
NSCLC	B-CANCER
","	O
further	O
enrollment	O
was	O
stopped	O
","	O
and	O
the	O
study	O
was	O
terminated	O
early	O
.	O
	
The	O
median	O
number	O
of	O
cycles	O
was	O
four	O
on	O
the	O
control	O
arm	O
and	O
three	O
on	O
the	O
combined	O
experimental	O
arms	O
.	O
	
Median	O
overall	O
survival	O
was	O
not	O
different	O
between	O
the	O
two	O
groups	O
(	O
control	O
","	O
10.4	O
months	O
[	O
95	O
%	O
CI	O
","	O
8.6	O
to	O
12.2	O
]	O
;	O
experimental	O
","	O
10	O
months	O
[	O
95	O
%	O
CI	O
","	O
8.4	O
to	O
10.8	O
]	O
;	O
P	O
=	O
0.613	O
;	O
hazard	O
ratio	O
=	O
1.05	O
[	O
95	O
%	O
CI	O
","	O
0.88	O
to	O
1.25	O
]	O
)	O
.	O
	
Response	O
rates	O
(	O
control	O
arm	O
","	O
35	O
%	O
;	O
experimental	O
arms	O
","	O
28.9	O
%	O
;	O
P	O
=	O
0.124	O
)	O
and	O
other	O
time-to-event	O
measures	O
were	O
not	O
significantly	O
different	O
.	O
	
Grade	O
3	O
and	O
4	O
toxicities	O
were	O
significantly	O
increased	O
for	O
thrombocytopenia	B-TOXI
(	O
P	O
&	O
lt	O
;	O
0.0001	O
)	O
","	O
epistaxis	B-TOXI
","	O
and	O
thrombosis	B-TOXI
/	O
embolism	B-TOXI
in	O
the	O
experimental	O
arms	O
.	O
	
Adding	O
aprinocarsen	B-DRUG
to	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
regimen	O
did	O
not	O
enhance	O
survival	O
and	O
other	O
efficacy	O
measures	O
in	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
Phase	O
II	O
study	O
of	O
gemcitabine	B-DRUG
","	O
doxorubicin	B-DRUG
and	O
paclitaxel	B-DRUG
(	O
GAT	O
)	O
as	O
first-line	O
chemotherapy	O
for	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
:	O
a	O
translational	O
research	O
experience	O
.	O
	
	
Patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
are	O
frequently	O
treated	O
with	O
anthracyclines	B-DRUG
and	O
taxanes	B-DRUG
","	O
which	O
are	O
among	O
the	O
most	O
active	O
agents	O
in	O
this	O
disease	O
.	O
	
Gemcitabine	B-DRUG
is	O
an	O
interesting	O
candidate	O
for	O
a	O
three-drug	O
combination	O
because	O
of	O
its	O
different	O
mechanism	O
of	O
action	O
and	O
non-overlapping	O
toxicity	O
with	O
respect	O
to	O
the	O
other	O
two	O
drugs	O
.	O
	
We	O
aimed	O
to	O
evaluate	O
the	O
activity	O
and	O
toxicity	O
of	O
the	O
GAT	O
(	O
gemcitabine	B-DRUG
","	O
doxorubicin	B-DRUG
and	O
paclitaxel	B-DRUG
)	O
regimen	O
","	O
derived	O
from	O
experimental	O
preclinical	O
studies	O
","	O
as	O
first-line	O
chemotherapy	O
in	O
patients	O
with	O
stage	O
IIIB-IV	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
locally	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
breast	I-CANCER
cancer	I-CANCER
and	O
at	O
least	O
one	O
bidimensionally	O
measurable	O
lesion	O
were	O
included	O
in	O
the	O
present	O
study	O
.	O
	
Adequate	O
bone	O
marrow	O
reserve	O
","	O
normal	O
cardiac	O
","	O
hepatic	O
and	O
renal	O
function	O
","	O
and	O
an	O
ECOG	O
performance	O
status	O
of	O
0	O
to	O
2	O
were	O
required	O
.	O
	
Only	O
prior	O
adjuvant	O
non	O
anthracycline-based	B-DRUG
chemotherapy	O
was	O
permitted	O
.	O
	
Treatment	O
consisted	O
of	O
doxorubicin	B-DRUG
50	O
mg	O
/	O
m2	O
on	O
day	O
1	O
","	O
paclitaxel	B-DRUG
160	O
mg	O
/	O
m2	O
on	O
day	O
2	O
and	O
gemcitabine	B-DRUG
800	O
mg	O
/	O
m2	O
on	O
day	O
6	O
","	O
repeated	O
every	O
21-28	O
days	O
.	O
	
Thirty-three	O
consecutive	O
breast	B-CANCER
cancer	I-CANCER
patients	O
were	O
enrolled	O
onto	O
the	O
trial	O
(	O
7	O
stage	O
IIIB	O
and	O
26	O
stage	O
IV	O
)	O
.	O
	
All	O
patients	O
were	O
evaluable	O
for	O
toxicity	O
and	O
29	O
were	O
assessable	O
for	O
response	O
.	O
	
A	O
total	O
of	O
169	O
cycles	O
were	O
administered	O
","	O
with	O
a	O
median	O
of	O
6	O
cycles	O
per	O
patient	O
(	O
range	O
1月8日	O
cycles	O
)	O
.	O
	
Complete	O
and	O
partial	O
responses	O
were	O
observed	O
in	O
6.9	O
%	O
and	O
48.3	O
%	O
of	O
patients	O
","	O
respectively	O
","	O
for	O
an	O
overall	O
response	O
rate	O
of	O
55.2	O
%	O
.	O
	
A	O
response	O
was	O
reported	O
in	O
all	O
metastatic	O
sites	O
","	O
with	O
a	O
median	O
duration	O
of	O
16.4	O
months	O
.	O
	
Median	O
time	O
to	O
progression	O
and	O
overall	O
survival	O
were	O
10.2	O
and	O
36.4	O
months	O
","	O
respectively	O
.	O
	
The	O
most	O
important	O
toxicity	O
was	O
hematological	O
","	O
with	O
grade	O
III-IV	O
neutropenia	B-TOXI
observed	O
in	O
69	O
%	O
of	O
patients	O
","	O
sometimes	O
requiring	O
the	O
use	O
of	O
granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
(	O
27	O
%	O
)	O
.	O
	
Non	B-TOXI
hematological	I-TOXI
toxicity	I-TOXI
was	O
rare	O
and	O
mild	O
.	O
	
One	O
patient	O
died	B-TOXI
from	O
sepsis	B-TOXI
during	O
the	O
first	O
treatment	O
cycle	O
before	O
the	O
administration	O
of	O
gemcitabine	B-DRUG
.	O
	
The	O
strong	O
synergism	O
among	O
the	O
three	O
drugs	O
found	O
in	O
the	O
preclinical	O
setting	O
was	O
confirmed	O
in	O
terms	O
of	O
both	O
clinical	O
activity	O
and	O
hematological	B-TOXI
toxicity	I-TOXI
.	O
	
Our	O
results	O
seem	O
to	O
indicate	O
that	O
the	O
GAT	B-DRUG
regimen	O
is	O
effective	O
in	O
anthracycline-na茂ve	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
and	O
provides	O
a	O
feasible	O
chemotherapeutic	O
option	O
in	O
this	O
clinical	O
setting	O
.	O
	
Phase	O
I	O
trial	O
of	O
concomitant	O
hyperfractionated	O
radiotherapy	O
with	O
docetaxel	B-DRUG
and	O
cisplatin	B-DRUG
for	O
locally	O
advanced	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
.	O
	
	
This	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
of	O
docetaxel	B-DRUG
when	O
administered	O
concomitantly	O
with	O
radical	O
hyperfractionated	O
radiotherapy	O
and	O
cisplatin	B-DRUG
in	O
patients	O
with	O
locally	O
advanced	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
stage	O
III-IV	O
tumors	O
received	O
radical	O
radiotherapy	O
of	O
74.4	O
Gy	O
given	O
in	O
two	O
daily	O
fractions	O
of	O
1.2	O
Gy	O
for	O
6	O
weeks	O
.	O
	
Cisplatin	B-DRUG
was	O
given	O
once	O
weekly	O
on	O
day	O
1	O
at	O
a	O
constant	O
dose	O
of	O
15	O
mg	O
/	O
m2	O
.	O
	
The	O
starting	O
dose	O
of	O
docetaxel	B-DRUG
was	O
10	O
mg	O
/	O
m2	O
once	O
weekly	O
on	O
day	O
3	O
","	O
with	O
planned	O
escalation	B-DRUG
steps	O
of	O
5	O
mg	O
/	O
m2	O
.	O
	
Main	O
endpoints	O
of	O
the	O
study	O
were	O
the	O
maximum	O
tolerated	O
dose	O
of	O
docetaxel	B-DRUG
","	O
acute	B-TOXI
toxicities	I-TOXI
","	O
and	O
the	O
preliminary	O
efficacy	O
results	O
.	O
	
Twenty-five	O
patients	O
were	O
enrolled	O
.	O
	
Median	O
follow-up	O
was	O
15	O
months	O
(	O
range	O
:	O
4-40	O
months	O
)	O
.	O
	
Two	O
of	O
three	O
patients	O
presented	O
with	O
dose-limiting	O
toxicities	O
at	O
the	O
15-mg	O
/	O
m2	O
dose	O
of	O
docetaxel	B-DRUG
(	O
one	O
patient	O
presented	O
with	O
multiple	O
grade	O
3月4日	O
toxicities	O
requiring	O
hospitalization	O
for	O
management	O
and	O
another	O
presented	O
with	O
multiple	O
toxicities	O
including	O
life-threatening	O
bronchoaspiration	B-TOXI
)	O
.	O
	
Thus	O
","	O
the	O
weekly	O
docetaxel	B-DRUG
dose	O
of	O
10	O
mg	O
/	O
m2	O
was	O
considered	O
the	O
maximum	O
tolerated	O
dose	O
.	O
	
Nineteen	O
patients	O
were	O
then	O
treated	O
with	O
the	O
maximum	O
tolerated	O
dose	O
and	O
no	O
dose-limiting	O
toxicities	O
were	O
observed	O
.	O
	
Radiotherapy	O
was	O
completed	O
in	O
all	O
patients	O
except	O
one	O
(	O
median	O
dose	O
:	O
74.4	O
;	O
range	O
:	O
73.2-74.4	O
)	O
","	O
and	O
at	O
least	O
80	O
%	O
of	O
the	O
scheduled	O
cisplatin	B-DRUG
and	O
docetaxel	B-DRUG
doses	O
were	O
given	O
in	O
92	O
%	O
of	O
the	O
patients	O
.	O
	
Acute	B-TOXI
toxicities	I-TOXI
were	O
dominated	O
by	O
grade	O
3	O
mucositis	B-TOXI
(	O
92	O
%	O
)	O
and	O
grade	O
3月4日	O
dysphagia	B-TOXI
(	O
68	O
%	O
)	O
.	O
	
The	O
2.5	O
year	O
actuarial	O
local	O
control	O
rate	O
was	O
87.5	O
%	O
","	O
and	O
the	O
disease-free	O
survival	O
rate	O
was	O
75	O
%	O
.	O
	
At	O
the	O
time	O
of	O
last	O
follow-up	O
","	O
23	O
patients	O
were	O
alive	O
and	O
two	O
had	O
died	B-TOXI
from	O
cancer	O
.	O
	
No	O
distant	B-TOXI
metastases	I-TOXI
were	O
observed	O
.	O
	
In	O
patients	O
with	O
locally	O
advanced	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
","	O
this	O
study	O
determined	O
the	O
maximum	O
tolerated	O
dose	O
of	O
docetaxel	B-DRUG
to	O
be	O
10	O
mg	O
/	O
m2	O
administered	O
once	O
weekly	O
when	O
given	O
concurrently	O
with	O
74.4	O
Gy	O
hyperfractionated	O
radiotherapy	O
and	O
a	O
weekly	O
15-mg	O
/	O
m2	O
dose	O
of	O
cisplatin	B-DRUG
.	O
	
The	O
toxicity	O
profile	O
and	O
the	O
encouraging	O
results	O
suggest	O
that	O
this	O
new	O
combination	O
merits	O
further	O
investigation	O
in	O
a	O
multi-institutional	O
phase	O
II	O
trial	O
.	O
	
A	O
phase	O
I-II	O
study	O
of	O
bi-weekly	O
gemcitabine	B-DRUG
and	O
irinotecan	B-DRUG
as	O
second-line	O
chemotherapy	O
in	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
after	O
prior	O
taxane	B-DRUG
=+	O
platinum-based	B-DRUG
regimens	O
.	O
	
	
Treatment	O
options	O
in	O
patients	O
with	O
recurrent	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
remain	O
limited	O
as	O
a	O
result	O
of	O
poor	O
activity	O
of	O
most	O
agents	O
after	O
failure	O
of	O
platinum-based	B-DRUG
therapy	O
.	O
	
In	O
the	O
present	O
phase	O
I-II	O
study	O
","	O
we	O
evaluated	O
the	O
feasibility	O
and	O
efficacy	O
of	O
bi-weekly	O
gemcitabine	B-DRUG
(	O
GEM	B-DRUG
)	O
=+	O
irinotecan	B-DRUG
(	O
CPT-11	B-DRUG
)	O
in	O
patients	O
with	O
relapsed	O
NSCLC	B-CANCER
.	O
	
Patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
","	O
WHO-performance	O
status	O
(	O
PS	O
)	O
&	O
lt	O
;	O
/	O
=	O
2	O
","	O
prior	O
taxane	B-DRUG
/	O
platinum-based	B-DRUG
chemotherapy	O
were	O
eligible	O
.	O
	
Chemotherapy	O
was	O
administered	O
in	O
a	O
dose-escalated	O
fashion	O
in	O
subgroups	O
of	O
3月6日	O
patients	O
until	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
was	O
encountered	O
as	O
follows	O
:	O
CPT-11	B-DRUG
150	O
or	O
180	O
mg	O
/	O
m	O
(	O
2	O
)	O
followed	O
by	O
GEM	B-DRUG
"1,200-1,800"	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
both	O
on	O
days	O
1	O
=+	O
15	O
","	O
recycled	O
every	O
28	O
days	O
in	O
four	O
dose	O
levels	O
(	O
DLs	O
)	O
.	O
	
Forty-nine	O
patients	O
entered	O
the	O
phase	O
I	O
and	O
II	O
part	O
of	O
the	O
study	O
(	O
phase	O
I	O
:	O
12-phase	O
II	O
:	O
37	O
=+	O
3	O
at	O
DL-3	O
)	O
","	O
and	O
40	O
patients	O
were	O
evaluable	O
for	O
a	O
response	O
in	O
phase	O
II	O
and	O
all	O
for	O
toxicity	O
:	O
median	O
age	O
","	O
61	O
years	O
(	O
range	O
36-74	O
)	O
;	O
PS	O
","	O
1	O
(	O
0-2	O
)	O
;	O
gender	O
","	O
43	O
males	O
/	O
6	O
females-histologies	O
;	O
adenocarcinoma	B-CANCER
","	O
25	O
;	O
squamous	O
","	O
20	O
;	O
large	O
cell	O
","	O
4	O
Metastatic	O
sites	O
included	O
lymph	O
nodes	O
","	O
38	O
;	O
bone	O
","	O
5	O
;	O
liver	O
","	O
4	O
;	O
brain	O
","	O
3	O
;	O
lung	O
nodules	O
","	O
14	O
;	O
adrenals	O
","	O
13	O
;	O
other	O
","	O
3	O
All	O
patients	O
had	O
prior	O
taxane	B-DRUG
=+	O
platinum-based	B-DRUG
treatment	O
","	O
and	O
42	O
patients	O
had	O
prior	O
docetaxel-ifosfamide-cisplatin	B-DRUG
/	O
or-carboplatin	B-DRUG
regimens	O
.	O
	
DLT	O
was	O
observed	O
at	O
DL-4	O
and	O
included	O
2	O
/	O
3	O
cases	O
with	O
grade	O
3	O
diarrhea-1	B-TOXI
/	O
3	O
of	O
these	O
with	O
febrile	B-TOXI
neutropenia	I-TOXI
.	O
	
The	O
recommended	O
DL	O
for	O
phase	O
II	O
evaluation	O
was	O
DL3	O
:	O
GEM	B-DRUG
","	O
"1,500"	O
=+	O
CPT-11-180	B-DRUG
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Objective	O
responses	O
in	O
phase	O
II	O
were	O
PR	O
","	O
6	O
/	O
40	O
[	O
15	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
","	O
5月31日	O
%	O
]	O
;	O
stable	O
disease	O
","	O
16	O
/	O
40	O
(	O
40	O
%	O
;	O
95	O
%	O
CI	O
","	O
21-53	O
%	O
)	O
;	O
and	O
progressive	O
disease	O
","	O
18	O
/	O
40	O
(	O
45	O
%	O
;	O
95	O
%	O
CI	O
","	O
28.5-62.5	O
%	O
)	O
.	O
	
The	O
median	O
time-to-progression	O
was	O
4	O
months	O
(	O
range	O
1月12日	O
)	O
and	O
median	O
survival	O
7	O
months	O
(	O
range	O
1.5-42	O
=+	O
)	O
","	O
while	O
1-year	O
survival	O
was	O
20	O
%	O
.	O
	
Grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
was	O
seen	O
in	O
18	O
%	O
of	O
patients	O
(	O
6	O
%	O
grade	O
4	O
)	O
and	O
6	O
%	O
incidence	O
of	O
febrile	B-TOXI
neutropenia	I-TOXI
.	O
	
No	O
Grade	O
3	O
/	O
4	O
thrombocytopenia	B-TOXI
were	O
seen	O
","	O
grade	O
3	O
diarrhea	B-TOXI
in	O
6	O
%	O
of	O
patients	O
and	O
grade	O
2	O
in	O
15	O
%	O
of	O
patients	O
","	O
while	O
other	O
grade	O
3	O
non-hematologic	B-TOXI
toxicities	I-TOXI
were	O
never	O
encountered	O
.	O
	
Bi-weekly	O
GEM	B-DRUG
=+	O
CPT-11	B-DRUG
is	O
active	O
and	O
well	O
tolerated	O
in	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
failing	O
prior	O
taxane	B-DRUG
=+	O
platinum	B-DRUG
regimens	O
","	O
and	O
represents	O
an	O
effective	O
and	O
convenient	O
combination	O
to	O
apply	O
in	O
the	O
palliative	O
treatment	O
of	O
relapsed	O
NSCLC	B-CANCER
particularly	O
after	O
failure	O
of	O
first-line	O
docetaxel	B-DRUG
=+	O
platinum-based	B-DRUG
regimens	O
.	O
	
Phase	O
I-II	O
trial	O
of	O
weekly	O
gemcitabine	B-DRUG
plus	O
high-dose	O
5-fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
in	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
	
Pancreatic	B-CANCER
cancer	I-CANCER
is	O
a	O
dismal	O
disease	O
.	O
	
Few	O
drugs	O
","	O
including	O
gemcitabine	B-DRUG
and	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
have	O
notable	O
antitumor	O
effects	O
against	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
5-FU	B-DRUG
and	O
the	O
efficacy	O
and	O
toxicity	O
profile	O
of	O
weekly	O
gemcitabine	B-DRUG
plus	O
infusional	B-DRUG
5-FU	I-DRUG
/	O
leucovorin	B-DRUG
in	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
histo-	O
/	O
cytologically	O
confirmed	O
","	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
were	O
eligible	O
.	O
	
Treatment	O
consisted	O
of	O
a	O
30-min	O
infusion	O
of	O
gemcitabine	B-DRUG
(	O
800	O
mg	O
/	O
m2	O
)	O
","	O
followed	O
by	O
a	O
24-h	O
infusion	O
of	O
5-FU	B-DRUG
and	O
leucovorin	B-DRUG
(	O
300	O
mg	O
/	O
m2	O
)	O
at	O
day	O
1	O
","	O
day	O
8	O
and	O
day	O
15	O
every	O
28	O
days	O
","	O
and	O
was	O
termed	O
the	O
GemFL24	O
regimen	O
.	O
	
The	O
dose	O
of	O
5-FU	B-DRUG
was	O
escalated	O
from	O
1600	O
","	O
2000	O
","	O
to	O
2600	O
mg	O
/	O
m2	O
in	O
the	O
phase	O
I	O
study	O
","	O
and	O
fixed	O
MTD	O
for	O
subsequent	O
enrolled	O
patients	O
.	O
	
Eighteen	O
patients	O
were	O
enrolled	O
in	O
the	O
phase	O
I	O
study	O
","	O
and	O
24	O
in	O
phase	O
II	O
.	O
	
The	O
MTD	O
of	O
5-FU	B-DRUG
was	O
2000	O
mg	O
/	O
m2	O
","	O
with	O
major	O
dose-limiting	O
toxicities	O
being	O
febrile	B-TOXI
neutropenia	I-TOXI
and	O
delayed	O
recovery	O
from	O
neutropenia	B-TOXI
.	O
	
The	O
dose	O
intensity	O
of	O
gemcitabine	B-DRUG
of	O
the	O
35	O
patients	O
with	O
5-FU	B-DRUG
dosage	O
set	O
at	O
MTD	O
was	O
593	O
mg	O
/	O
m2	O
per	O
week	O
.	O
	
In	O
the	O
entire	O
series	O
of	O
42	O
patients	O
","	O
myelosuppression	B-TOXI
was	O
the	O
main	O
toxicity	O
","	O
with	O
grade	O
3	O
neutropenia	B-TOXI
in	O
eight	O
patients	O
","	O
and	O
grade	O
3	O
/	O
4	O
thrombocytopenia	B-TOXI
in	O
six	O
.	O
	
On	O
an	O
intention-to-treat	O
analysis	O
","	O
the	O
overall	O
and	O
clinical	O
benefit	O
response	O
rates	O
were	O
22	O
%	O
and	O
46	O
%	O
","	O
respectively	O
;	O
with	O
median	O
progression-free	O
and	O
overall	O
survival	O
of	O
4.1	O
and	O
6.9	O
months	O
","	O
respectively	O
.	O
	
The	O
GemFL24	O
regimen	O
is	O
a	O
feasible	O
and	O
moderately	O
active	O
treatment	O
with	O
manageable	O
toxicities	O
for	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
","	O
and	O
could	O
be	O
a	O
basis	O
for	O
further	O
combination	O
with	O
other	O
anticancer	O
drugs	O
.	O
	
A	O
phase	O
I	O
clinical	O
and	O
pharmacokinetic	O
study	O
of	O
the	O
multi-drug	O
resistance	O
protein-1	O
(	O
MRP-1	O
)	O
inhibitor	O
sulindac	B-DRUG
","	O
in	O
combination	O
with	O
epirubicin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
cancer	I-CANCER
.	O
	
	
Multi-drug	O
resistance	O
mediated	O
by	O
ATP-binding	O
cassette	O
trans-membrane	O
protein	O
pumps	O
is	O
an	O
important	O
cause	O
of	O
cancer	O
treatment	O
failure	O
.	O
	
Sulindac	B-DRUG
has	O
been	O
shown	O
to	O
be	O
a	O
competitive	O
substrate	O
for	O
the	O
clinically	O
important	O
resistance	O
protein	O
","	O
multi-drug	O
resistance	O
protein-1	O
(	O
MRP-1	O
)	O
","	O
and	O
thus	O
might	O
enhance	O
the	O
anti-cancer	O
activity	O
of	O
substrate	O
chemotherapeutic	O
agents	O
","	O
e.g.	O
anthracyclines	B-DRUG
.	O
	
We	O
conducted	O
a	O
dose-escalating	O
","	O
single	O
arm	O
","	O
prospective	O
","	O
open	O
label	O
","	O
non-randomised	O
phase	O
I	O
trial	O
of	O
epirubicin	B-DRUG
(	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
in	O
combination	O
with	O
escalating	O
oral	O
doses	O
of	O
sulindac	B-DRUG
(	O
0-800	O
mg	O
)	O
in	O
patients	O
with	O
advanced	B-CANCER
cancer	I-CANCER
to	O
identify	O
an	O
appropriate	O
dose	O
of	O
sulindac	B-DRUG
to	O
use	O
in	O
future	O
resistance	O
studies	O
.	O
	
Anthracycline	B-DRUG
and	O
sulindac	B-DRUG
pharmacokinetics	O
were	O
studied	O
in	O
cycles	O
1	O
and	O
3	O
Seventeen	O
patients	O
(	O
8	O
breast	O
","	O
3	O
lung	O
","	O
2	O
bowel	O
","	O
1	O
melanoma	O
","	O
1	O
renal	O
","	O
1	O
ovarian	O
and	O
1	O
of	O
unknown	O
primary	O
origin	O
","	O
16	O
/	O
17	O
having	O
had	O
prior	O
chemotherapy	O
)	O
were	O
enrolled	O
.	O
	
Eight	O
patients	O
received	O
a	O
full	O
six	O
cycles	O
of	O
treatment	O
;	O
14	O
patients	O
received	O
three	O
or	O
more	O
cycles	O
.	O
	
Dose-limiting	O
toxicity	O
was	O
observed	O
in	O
two	O
patients	O
at	O
800	O
mg	O
sulindac	B-DRUG
(	O
1	O
renal	B-TOXI
impairment	I-TOXI
","	O
1	O
fatal	B-TOXI
haemoptysis	I-TOXI
in	O
a	O
patient	O
with	O
advanced	B-CANCER
lung	I-CANCER
cancer	I-CANCER
)	O
","	O
and	O
sulindac	B-DRUG
600	O
mg	O
was	O
deemed	O
to	O
be	O
the	O
maximum	O
tolerated	O
dose	O
.	O
	
Sulindac	B-DRUG
had	O
no	O
effect	O
on	O
epirubicin	B-DRUG
pharmacokinetics	O
.	O
	
Among	O
15	O
patients	O
with	O
evaluable	O
tumour	O
","	O
two	O
partial	O
responses	O
were	O
seen	O
(	O
malignant	B-CANCER
melanoma	I-CANCER
and	O
breast	B-CANCER
cancer	I-CANCER
)	O
.	O
	
Four	O
others	O
had	O
prolonged	O
stable	O
disease	O
.	O
	
Epirubicin	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
sulindac	B-DRUG
600	O
mg	O
are	O
the	O
recommended	O
doses	O
for	O
phase	O
II	O
studies	O
for	O
these	O
agents	O
in	O
combination	O
.	O
	
Neoadjuvant	O
concurrent	O
chemoradiation	O
with	O
weekly	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
for	O
patients	O
with	O
oesophageal	B-CANCER
cancer	I-CANCER
:	O
a	O
phase	O
II	O
study	O
.	O
	
	
This	O
study	O
was	O
performed	O
to	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
preoperative	O
chemoradiation	O
consisting	O
of	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
and	O
concurrent	O
radiotherapy	O
for	O
patients	O
with	O
resectable	O
(	O
T2-3N0-1M0	O
)	O
oesophageal	O
cancer	O
.	O
	
Treatment	O
consisted	O
of	O
paclitaxel	B-DRUG
50	O
mg	O
m	O
(	O
-2	O
)	O
and	O
carboplatin	B-DRUG
AUC=2	O
on	O
days	O
1	O
","	O
8	O
","	O
15	O
","	O
22	O
and	O
29	O
and	O
concurrent	O
radiotherapy	O
(	O
41.4	O
Gy	O
in	O
23	O
fractions	O
","	O
5	O
days	O
per	O
week	O
)	O
","	O
followed	O
by	O
oesophagectomy	O
.	O
	
All	O
54	O
entered	O
patients	O
completed	O
the	O
chemoradiation	O
without	O
delay	O
or	O
dose-reduction	O
.	O
	
Grade	O
3月4日	O
toxicities	O
were	O
:	O
neutropaenia	B-TOXI
15	O
%	O
","	O
thrombocytopaenia	B-TOXI
2	O
%	O
","	O
and	O
oesophagitis	B-TOXI
7.5	O
%	O
.	O
	
After	O
completion	O
of	O
the	O
chemoradiotherapy	O
63	O
%	O
had	O
a	O
major	O
endoscopical	O
response	O
.	O
	
Fifty-two	O
patients	O
(	O
96	O
%	O
)	O
underwent	O
a	O
resection	O
.	O
	
The	O
postoperative	O
mortality	O
rate	O
was	O
7.7	O
%	O
.	O
	
All	O
patients	O
had	O
an	O
R0-resection	O
.	O
	
The	O
pathological	O
complete	O
response	O
rate	O
was	O
25	O
%	O
","	O
and	O
an	O
additional	O
36.5	O
%	O
had	O
less	O
than	O
10	O
%	O
vital	O
residual	O
tumour	O
cells	O
.	O
	
At	O
a	O
median	O
follow-up	O
of	O
23.2	O
months	O
","	O
the	O
median	O
survival	O
time	O
has	O
not	O
yet	O
been	O
reached	O
.	O
	
The	O
probability	O
of	O
disease-free	O
survival	O
after	O
30	O
months	O
was	O
60	O
%	O
.	O
	
In	O
conclusion	O
","	O
weekly	O
neoadjuvant	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
with	O
concurrent	O
radiotherapy	O
is	O
a	O
very	O
tolerable	O
regimen	O
and	O
can	O
be	O
given	O
on	O
an	O
outpatient	O
basis	O
.	O
	
It	O
achieves	O
considerable	O
down	O
staging	O
and	O
a	O
subsequent	O
100	O
%	O
radical	O
resection	O
rate	O
in	O
this	O
series	O
.	O
	
A	O
phase	O
III	O
trial	O
with	O
this	O
regimen	O
is	O
now	O
ongoing	O
.	O
	
Phase	O
II	O
trial	O
of	O
oral	O
S-1	B-DRUG
combined	O
with	O
gemcitabine	B-DRUG
in	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
	
We	O
conducted	O
a	O
phase	O
II	O
trial	O
of	O
gemcitabine	B-DRUG
with	O
S-1	B-DRUG
","	O
oral	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
prodrug	O
tegafur	B-DRUG
combined	O
with	O
two	O
modulators	O
","	O
5-chloro-2	B-DRUG
","	O
4-dihydroxypyridine	B-DRUG
and	O
potassium	B-DRUG
oxonate	I-DRUG
","	O
to	O
evaluate	O
the	O
activity	O
and	O
toxicity	O
of	O
such	O
a	O
combination	O
in	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
(	O
MPC	B-CANCER
)	O
patients	O
.	O
	
Patients	O
who	O
had	O
pathologically	O
proven	O
pancreatic	B-CANCER
cancer	I-CANCER
with	O
metastatic	O
lesions	O
were	O
eligible	O
candidates	O
for	O
entry	O
into	O
the	O
study	O
.	O
	
S-1	B-DRUG
was	O
given	O
orally	O
(	O
30	O
mg	O
m	O
(	O
-2	O
)	O
)	O
b.i.d.	O
for	O
14	O
consecutive	O
days	O
and	O
gemcitabine	B-DRUG
(	O
1000	O
mg	O
m	O
(	O
-2	O
)	O
)	O
was	O
given	O
on	O
days	O
8	O
and	O
15	O
.	O
	
The	O
cycle	O
was	O
repeated	O
every	O
21	O
days	O
.	O
	
We	O
enrolled	O
33	O
MPC	O
patients	O
.	O
	
The	O
median	O
number	O
of	O
cycles	O
was	O
eight	O
(	O
range	O
1月20日	O
)	O
.	O
	
Grade	O
3月4日	O
toxicities	O
were	O
leucopenia	B-TOXI
(	O
33	O
%	O
)	O
","	O
neutropenia	B-TOXI
(	O
55	O
%	O
)	O
","	O
anaemia	B-TOXI
(	O
9	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
15	O
%	O
)	O
","	O
anorexia	B-TOXI
(	O
6	O
%	O
)	O
","	O
fever	O
(	O
9	O
%	O
)	O
","	O
and	O
interstitial	B-TOXI
pneumonia	I-TOXI
(	O
6	O
%	O
)	O
.	O
	
Objective	O
responses	O
were	O
obtained	O
in	O
16	O
patients	O
(	O
one	O
complete	O
response	O
and	O
15	O
partial	O
responses	O
;	O
response	O
rate	O
","	O
48	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
","	O
33-65	O
)	O
.	O
	
Median	O
survival	O
and	O
1-year	O
survival	O
rate	O
were	O
12.5	O
months	O
(	O
95	O
%	O
CI	O
","	O
5.9-19.1	O
)	O
and	O
54	O
%	O
(	O
95	O
%	O
CI	O
","	O
36-72	O
)	O
","	O
respectively	O
.	O
	
Combination	O
chemotherapy	O
with	O
GEM	B-DRUG
and	O
S-1	B-DRUG
was	O
well	O
tolerated	O
and	O
yielded	O
a	O
significantly	O
high	O
response	O
rate	O
.	O
	
Biweekly	O
oxaliplatin	B-DRUG
","	O
raltitrexed	B-DRUG
","	O
5-fluorouracil	B-DRUG
and	O
folinic	B-DRUG
acid	I-DRUG
combination	O
chemotherapy	O
during	O
preoperative	O
radiation	O
therapy	O
for	O
locally	O
advanced	B-CANCER
rectal	I-CANCER
cancer	I-CANCER
:	O
a	O
phase	O
I-II	O
study	O
.	O
	
	
Oxaliplatin	B-DRUG
(	O
OXA	B-DRUG
)	O
","	O
raltitrexed	B-DRUG
(	O
RTX	B-DRUG
)	O
","	O
5-fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
and	O
folinic	B-DRUG
acid	I-DRUG
(	O
FA	B-DRUG
)	O
have	O
shown	O
activity	O
in	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
","	O
radioenhancing	O
effect	O
and	O
synergism	O
when	O
combined	O
.	O
	
We	O
evaluated	O
a	O
chemotherapy	O
(	O
CT	O
)	O
combination	O
of	O
OXA	B-DRUG
","	O
RTX	B-DRUG
and	O
FU	B-DRUG
/	O
FA	B-DRUG
during	O
preoperative	O
radiotherapy	O
(	O
RT	O
)	O
in	O
locally	O
advanced	B-CANCER
rectal	I-CANCER
cancer	I-CANCER
(	O
LARC	O
)	O
patients	O
.	O
	
Fifty-one	O
patients	O
with	O
LARC	O
at	O
high	O
risk	O
of	O
recurrence	O
(	O
T4	O
","	O
N+	O
or	O
T3N0	O
&	O
lt	O
;	O
or	O
5	O
cm	O
from	O
anal	O
verge	O
and	O
/	O
or	O
circumferential	O
resection	O
margin	O
&	O
lt	O
;	O
or	O
5	O
mm	O
)	O
received	O
three	O
biweekly	O
courses	O
of	O
CT	O
during	O
pelvic	O
RT	O
(	O
45	O
Gy	O
)	O
.	O
	
Surgery	O
was	O
planned	O
8	O
weeks	O
after	O
CT-RT.	O
Recommended	O
doses	O
(	O
RDs	O
)	O
determined	O
during	O
phase	O
I	O
were	O
utilised	O
in	O
the	O
subsequent	O
phase	O
II	O
trial	O
","	O
where	O
the	O
rate	O
of	O
tumour	O
regression	O
grade	O
(	O
TRG	O
)	O
1	O
or	O
2	O
was	O
the	O
main	O
end	O
point	O
.	O
	
No	O
toxic	B-TOXI
deaths	I-TOXI
occurred	O
","	O
and	O
severe	B-TOXI
toxicity	I-TOXI
was	O
easily	O
managed	O
.	O
	
In	O
phase	O
II	O
","	O
RDs	O
delivered	O
in	O
31	O
patients	O
were	O
OXA	B-DRUG
100	O
mg	O
m	O
(	O
-2	O
)	O
and	O
RTX	B-DRUG
2.5	O
mg	O
m	O
(	O
-2	O
)	O
on	O
day	O
1	O
","	O
and	O
FU	B-DRUG
900	O
mg	O
m	O
(	O
-2	O
)	O
and	O
LFA	B-DRUG
250	O
mg	O
m	O
(	O
-2	O
)	O
on	O
day	O
2	O
Main	O
severe	O
toxicities	O
by	O
patients	O
were	O
grade	O
4	O
neutropenia	B-TOXI
(	O
23	O
%	O
)	O
and	O
grade	O
3	O
diarrhoea	B-TOXI
(	O
19	O
%	O
)	O
.	O
	
In	O
71	O
%	O
(	O
95	O
%	O
confidence	O
limits	O
","	O
52-86	O
%	O
)	O
of	O
patients	O
","	O
TRG1	O
(	O
13	O
)	O
or	O
TRG2	O
(	O
9	O
)	O
was	O
obtained	O
.	O
	
All	O
patients	O
are	O
alive	O
and	O
recurrence-free	O
after	O
a	O
median	O
follow-up	O
of	O
29	O
months	O
.	O
	
Combination	O
of	O
OXA	B-DRUG
","	O
RTX	B-DRUG
and	O
FU	B-DRUG
/	O
FA	B-DRUG
with	O
pelvic	O
RT	O
has	O
an	O
acceptable	O
toxicity	O
and	O
a	O
high	O
clinical	O
activity	O
in	O
LARC	O
and	O
should	O
be	O
studied	O
further	O
in	O
patients	O
at	O
high	O
risk	O
of	O
recurrence	O
.	O
	
A	O
phase	O
I	O
trial	O
to	O
determine	O
the	O
optimal	O
biological	O
dose	O
of	O
celecoxib	O
when	O
combined	O
with	O
erlotinib	B-DRUG
in	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
Overexpression	O
of	O
cyclooxygenase-2	O
(	O
COX-2	O
)	O
activates	O
extracellular	O
signal-regulated	O
kinase	O
/	O
mitogen-activated	O
protein	O
kinase	O
signaling	O
in	O
an	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
tyrosine	O
kinase	O
inhibition	O
(	O
TKI	O
)	O
#NAME?	O
manner	O
.	O
	
Because	O
preclinical	O
data	O
indicated	O
that	O
tumor	O
COX-2	O
expression	O
caused	O
resistance	O
to	O
EGFR	O
TKI	O
","	O
a	O
phase	O
I	O
trial	O
to	O
establish	O
the	O
optimal	O
biological	O
dose	O
(	O
OBD	O
)	O
","	O
defined	O
as	O
the	O
maximal	O
decrease	O
in	O
urinary	O
prostaglandin	B-DRUG
E-M	I-DRUG
(	O
PGE-M	B-DRUG
)	O
","	O
and	O
toxicity	O
profile	O
of	O
the	O
combination	O
of	O
celecoxib	B-DRUG
and	O
erlotinib	B-DRUG
in	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
was	O
done	O
.	O
	
Twenty-two	O
subjects	O
with	O
stage	O
IIIB	O
and	O
/	O
or	O
IV	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
received	O
increasing	O
doses	O
of	O
celecoxib	B-DRUG
from	O
200	O
to	O
800	O
mg	O
twice	O
daily	O
(	O
bid	O
)	O
and	O
a	O
fixed	O
dose	O
of	O
erlotinib	B-DRUG
.	O
	
Primary	O
end	O
points	O
included	O
evaluation	O
of	O
toxicity	O
and	O
determination	O
of	O
the	O
OBD	O
of	O
celecoxib	B-DRUG
when	O
combined	O
with	O
erlotinib	B-DRUG
.	O
	
Secondary	O
end	O
points	O
investigate	O
exploratory	O
biological	O
markers	O
and	O
clinical	O
response	O
.	O
	
Twenty-two	O
subjects	O
were	O
enrolled	O
","	O
and	O
21	O
were	O
evaluable	O
for	O
the	O
determination	O
of	O
the	O
OBD	O
","	O
toxicity	O
","	O
and	O
response	O
.	O
	
Rash	B-TOXI
and	O
skin-related	B-TOXI
effects	I-TOXI
were	O
the	O
most	O
commonly	O
reported	O
toxicities	O
and	O
occurred	O
in	O
86	O
%	O
.	O
	
There	O
were	O
no	O
dose-limiting	O
toxicities	O
and	O
no	O
cardiovascular	B-TOXI
toxicities	I-TOXI
related	O
to	O
study	O
treatment	O
.	O
	
All	O
subjects	O
were	O
evaluated	O
on	O
intent	O
to	O
treat	O
.	O
	
Seven	O
patients	O
showed	O
partial	O
responses	O
(	O
33	O
%	O
)	O
","	O
and	O
five	O
patients	O
developed	O
stable	O
disease	O
(	O
24	O
%	O
)	O
.	O
	
Responses	O
were	O
seen	O
in	O
patients	O
both	O
with	O
and	O
without	O
EGFR-activating	O
mutations	O
.	O
	
A	O
significant	O
decline	O
in	O
urinary	O
PGE-M	B-DRUG
was	O
shown	O
after	O
8	O
weeks	O
of	O
treatment	O
","	O
with	O
an	O
OBD	O
of	O
celecoxib	B-DRUG
of	O
600	O
mg	O
bid	O
.	O
	
This	O
study	O
defines	O
the	O
OBD	O
of	O
celecoxib	B-DRUG
when	O
combined	O
with	O
a	O
fixed	O
dose	O
of	O
EGFR	O
TKI	O
.	O
	
These	O
results	O
show	O
objective	O
responses	O
with	O
an	O
acceptable	O
toxicity	O
profile	O
.	O
	
Future	O
trials	O
using	O
COX-2	B-DRUG
inhibition	O
strategies	O
should	O
use	O
the	O
OBD	O
of	O
celecoxib	B-DRUG
at	O
600	O
mg	O
bid	O
.	O
	
Targeted	O
inhibition	O
of	O
farnesyltransferase	B-DRUG
in	O
locally	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
:	O
a	O
phase	O
I	O
and	O
II	O
trial	O
of	O
tipifarnib	B-DRUG
plus	O
dose-dense	O
doxorubicin	B-DRUG
and	O
cyclophosphamide	B-DRUG
.	O
	
	
To	O
determine	O
the	O
recommended	O
phase	O
II	O
dose	O
(	O
RPTD	O
)	O
of	O
the	O
farnesyltransferase	O
(	O
FTase	O
)	O
inhibitor	O
tipifarnib	B-DRUG
when	O
combined	O
with	O
doxorubicin	B-DRUG
and	O
cyclophosphamide	B-DRUG
(	O
AC	O
)	O
in	O
patients	O
with	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
","	O
the	O
pathologic	O
complete	O
response	O
(	O
pCR	O
)	O
rate	O
after	O
preoperative	O
treatment	O
with	O
four	O
cycles	O
of	O
the	O
combination	O
in	O
locally	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
LABC	O
)	O
","	O
and	O
the	O
effect	O
of	O
tipifarnib	B-DRUG
on	O
primary	O
tumor	O
FTase	O
enzyme	O
activity	O
in	O
vivo	O
.	O
	
Thirty-two	O
patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
n	O
=	O
11	O
)	O
or	O
LABC	O
(	O
n	O
=	O
21	O
)	O
received	O
AC	O
(	O
doxorubicin	B-DRUG
60	O
mg	O
/	O
m2	O
and	O
cyclophosphamide	B-DRUG
600	O
mg	O
/	O
m2	O
)	O
administered	O
intravenously	O
on	O
day	O
1	O
plus	O
tipifarnib	B-DRUG
(	O
100	O
","	O
200	O
","	O
or	O
300	O
mg	O
bid	O
for	O
6	O
to	O
14	O
days	O
)	O
without	O
(	O
n	O
=	O
2	O
)	O
or	O
with	O
(	O
n	O
=	O
30	O
)	O
granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
(	O
G-CSF	B-DRUG
)	O
for	O
up	O
to	O
four	O
cycles	O
.	O
	
Patients	O
with	O
LABC	O
underwent	O
surgery	O
after	O
up	O
to	O
four	O
cycles	O
of	O
the	O
combination	O
.	O
	
When	O
combined	O
with	O
AC	O
every	O
2	O
weeks	O
plus	O
G-CSF	B-DRUG
","	O
the	O
RPTD	O
of	O
tipifarnib	B-DRUG
was	O
200	O
mg	O
bid	O
administered	O
on	O
days	O
2	O
to	O
7	O
Seven	O
(	O
33	O
%	O
)	O
of	O
21	O
patients	O
(	O
95	O
%	O
CI	O
","	O
15	O
%	O
to	O
55	O
%	O
)	O
with	O
LABC	O
treated	O
with	O
up	O
to	O
four	O
cycles	O
of	O
the	O
combination	O
at	O
the	O
RPTD	O
had	O
a	O
pCR	O
in	O
the	O
breast	O
at	O
surgery	O
.	O
	
The	O
five	O
patients	O
had	O
serial	O
biopsies	O
that	O
demonstrated	O
at	O
least	O
50	O
%	O
FTase	O
enzyme	O
inhibition	O
in	O
the	O
primary	O
tumor	O
(	O
median	O
","	O
100	O
%	O
;	O
range	O
","	O
55	O
%	O
to	O
100	O
%	O
)	O
after	O
tipifarnib	B-DRUG
.	O
	
Tipifarnib	B-DRUG
may	O
be	O
safely	O
combined	O
with	O
dose-dense	O
AC	O
using	O
a	O
dose	O
and	O
schedule	O
that	O
significantly	O
inhibits	O
FTase	B-DRUG
enzyme	O
activity	O
in	O
human	O
breast	B-CANCER
cancer	I-CANCER
in	O
vivo	O
and	O
may	O
enhance	O
the	O
pCR	O
rate	O
after	O
four	O
cycles	O
of	O
preoperative	O
dose-dense	O
AC	O
.	O
	
Randomized	O
phase	O
III	O
study	O
of	O
trastuzumab	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
and	O
carboplatin	B-DRUG
compared	O
with	O
trastuzumab	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
women	O
with	O
HER-2-overexpressing	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
This	O
randomized	O
","	O
multicenter	O
","	O
phase	O
III	O
trial	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
trastuzumab	B-DRUG
and	O
paclitaxel	B-DRUG
with	O
or	O
without	O
carboplatin	B-DRUG
as	O
first-line	O
therapy	O
for	O
women	O
with	O
HER-2-overexpressing	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
MBC	B-CANCER
)	O
.	O
	
HER-2	O
overexpression	O
was	O
defined	O
as	O
immunohistochemical	O
staining	O
scores	O
of	O
2+	O
or	O
3+	O
.	O
	
Between	O
November	O
1998	O
and	O
May	O
2002	O
","	O
196	O
women	O
with	O
HER-2-overexpressing	O
MBC	O
were	O
randomly	O
assigned	O
to	O
six	O
cycles	O
of	O
either	O
trastuzumab	B-DRUG
4	O
mg	O
/	O
kg	O
loading	O
dose	O
plus	O
2	O
mg	O
/	O
kg	O
weekly	O
thereafter	O
with	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m2	O
every	O
3	O
weeks	O
(	O
TP	O
)	O
","	O
or	O
trastuzumab	B-DRUG
4	O
mg	O
/	O
kg	O
loading	O
dose	O
plus	O
2	O
mg	O
/	O
kg	O
weekly	O
thereafter	O
with	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m2	O
and	O
carboplatin	B-DRUG
area	O
under	O
the	O
time-concentration	O
curve	O
=	O
6	O
every	O
3	O
weeks	O
(	O
TPC	O
)	O
followed	O
by	O
weekly	O
trastuzumab	B-DRUG
alone	O
.	O
	
Baseline	O
characteristics	O
of	O
the	O
196	O
patients	O
were	O
well	O
balanced	O
between	O
study	O
arms	O
.	O
	
Objective	O
response	O
rate	O
(	O
ORR	O
)	O
was	O
52	O
%	O
(	O
95	O
%	O
CI	O
","	O
42	O
%	O
to	O
62	O
%	O
)	O
for	O
TPC	O
versus	O
36	O
%	O
(	O
95	O
%	O
CI	O
","	O
26	O
%	O
to	O
46	O
%	O
)	O
for	O
TP	O
(	O
P	O
=	O
0.04	O
)	O
.	O
	
Median	O
progression-free	O
survival	O
(	O
PFS	O
)	O
was	O
10.7	O
months	O
for	O
TPC	O
and	O
7.1	O
months	O
for	O
TP	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
","	O
0.66	O
;	O
95	O
%	O
CI	O
","	O
0.59	O
to	O
0.73	O
;	O
P	O
=	O
0.03	O
)	O
.	O
	
Improved	O
clinical	O
outcomes	O
with	O
TPC	O
were	O
most	O
evident	O
in	O
HER-2	O
3+	O
patients	O
","	O
with	O
an	O
ORR	O
of	O
57	O
%	O
(	O
95	O
%	O
CI	O
","	O
45	O
%	O
to	O
70	O
%	O
)	O
v	O
36	O
%	O
(	O
95	O
%	O
CI	O
","	O
25	O
%	O
to	O
48	O
%	O
;	O
P	O
=	O
0.03	O
)	O
and	O
median	O
PFS	O
of	O
13.8	O
v	O
7.6	O
months	O
(	O
P	O
=	O
0.005	O
)	O
for	O
TPC	O
and	O
TP	O
","	O
respectively	O
(	O
HR	O
","	O
0.55	O
;	O
95	O
%	O
CI	O
","	O
0.46	O
to	O
0.64	O
)	O
.	O
	
Both	O
regimens	O
were	O
well	O
tolerated	O
","	O
and	O
febrile	B-TOXI
neutropenia	I-TOXI
and	O
neurotoxicity	B-TOXI
occurred	O
infrequently	O
;	O
grade	O
4	O
neutropenia	B-TOXI
occurred	O
more	O
frequently	O
with	O
TPC	O
(	O
P	O
&	O
lt	O
;	O
0.01	O
)	O
.	O
	
The	O
addition	O
of	O
carboplatin	B-DRUG
to	O
paclitaxel	B-DRUG
and	O
trastuzumab	B-DRUG
improved	O
ORR	O
and	O
PFS	O
in	O
women	O
with	O
HER-2-overexpressing	O
MBC	O
.	O
	
This	O
well-tolerated	O
regimen	O
represents	O
a	O
new	O
therapeutic	O
option	O
.	O
	
Dose-intense	O
PEFG	B-DRUG
(	O
cisplatin	B-DRUG
","	O
epirubicin	B-DRUG
","	O
5-fluorouracil	B-DRUG
","	O
gemcitabine	B-DRUG
)	O
in	O
advanced	B-CANCER
pancreatic	I-CANCER
adenocarcinoma	I-CANCER
.	O
	
	
PEFG	B-DRUG
regimen	O
(	O
cisplatin	B-DRUG
and	O
epirubicin	B-DRUG
40	O
mg	O
/	O
m2	O
day	O
1	O
","	O
gemcitabine	B-DRUG
600	O
mg	O
/	O
m2	O
days	O
1	O
and	O
8	O
","	O
5-fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
200	O
mg	O
/	O
m2	O
/	O
day	O
continuous	O
infusion	O
)	O
significantly	O
improved	O
the	O
outcome	O
of	O
patients	O
with	O
advanced	B-CANCER
pancreatic	I-CANCER
adenocarcinoma	I-CANCER
(	O
PA	O
)	O
with	O
respect	O
to	O
standard	O
gemcitabine	B-DRUG
in	O
a	O
previous	O
phase	O
III	O
trial	O
.	O
	
This	O
regimen	O
was	O
subsequently	O
modified	O
in	O
a	O
dose-finding	O
study	O
by	O
increasing	O
dose	O
intensity	O
of	O
cisplatin	B-DRUG
and	O
epirubicin	B-DRUG
(	O
both	O
at	O
30	O
mg	O
/	O
m2	O
every	O
14	O
days	O
)	O
and	O
of	O
gemcitabine	B-DRUG
(	O
at	O
800	O
mg	O
/	O
m2	O
every	O
14	O
days	O
)	O
.	O
	
Results	O
of	O
a	O
consecutive	O
series	O
treated	O
by	O
dose-intense	O
PEFG	B-DRUG
regimen	O
are	O
herewith	O
reported	O
.	O
	
Dose-intense	O
PEFG	B-DRUG
was	O
administered	O
to	O
chemotherapy-naive	O
patients	O
with	O
stages	O
III-IV	O
PA	O
","	O
&	O
lt	O
;	O
75	O
years	O
","	O
performance	O
status	O
(	O
PS	O
)	O
&	O
gt	O
;	O
50	O
","	O
till	O
progressive	O
disease	O
or	O
for	O
a	O
maximum	O
of	O
6	O
months	O
.	O
	
Between	O
January	O
2004	O
and	O
June	O
2005	O
","	O
49	O
(	O
31	O
or	O
63	O
%	O
metastatic	O
)	O
patients	O
","	O
median	O
age	O
62	O
years	O
","	O
median	O
PS	O
80	O
","	O
were	O
treated	O
with	O
dose-intense	O
PEFG	B-DRUG
.	O
	
Partial	O
response	O
and	O
stable	O
disease	O
was	O
observed	O
in	O
24	O
(	O
49	O
%	O
)	O
and	O
16	O
(	O
33	O
%	O
)	O
patients	O
","	O
respectively	O
;	O
31	O
patients	O
were	O
progression-free	O
at	O
6	O
months	O
(	O
PFS-6	O
=	O
63	O
%	O
)	O
.	O
	
Median	O
survival	O
was	O
10.5	O
months	O
and	O
1-year	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
48	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
33-61	O
%	O
)	O
.	O
	
Main	O
grade	O
3月4日	O
toxicity	O
was	O
:	O
neutropenia	B-TOXI
in	O
26	O
%	O
of	O
patients	O
","	O
stomatitis	B-TOXI
and	O
fatigue	B-TOXI
in	O
8	O
%	O
","	O
anaemia	B-TOXI
","	O
diarrhoea	B-TOXI
","	O
nausea	B-TOXI
/	O
vomit	B-TOXI
in	O
6	O
%	O
","	O
febrile	B-TOXI
neutropenia	I-TOXI
and	O
thrombocytopaenia	B-TOXI
in	O
4	O
%	O
","	O
hand-foot	B-TOXI
syndrome	I-TOXI
in	O
2	O
%	O
.	O
	
When	O
compared	O
with	O
84	O
patients	O
treated	O
by	O
classical	O
PEFG	B-DRUG
at	O
the	O
same	O
institution	O
","	O
dose-intense	O
PEFG	B-DRUG
was	O
not	O
inferior	O
in	O
terms	O
of	O
PFS-6	O
(	O
63	O
versus	O
57	O
%	O
)	O
","	O
1-year	O
OS	O
(	O
48	O
versus	O
42	O
%	O
)	O
and	O
response	O
rate	O
(	O
49	O
versus	O
49	O
%	O
)	O
;	O
it	O
allowed	O
to	O
increase	O
dose	O
intensity	O
for	O
gemcitabine	B-DRUG
by	O
32	O
%	O
","	O
for	O
cisplatin	B-DRUG
and	O
epirubicin	B-DRUG
by	O
36	O
%	O
(	O
FU	B-DRUG
reduced	O
by	O
3	O
%	O
)	O
","	O
to	O
significantly	O
reduce	O
grade	O
3月4日	O
hematological	B-TOXI
toxicity	I-TOXI
(	O
neutropenia	B-TOXI
:	O
26	O
versus	O
86	O
%	O
;	O
P	O
&	O
lt	O
;	O
0.00001	O
;	O
thrombocytopaenia	B-TOXI
:	O
4	O
versus	O
58	O
%	O
;	O
P	O
&	O
lt	O
;	O
0.00001	O
)	O
and	O
to	O
reduce	O
by	O
one-third	O
the	O
number	O
of	O
outpatient	O
accesses	O
.	O
	
The	O
new	O
PEFG	B-DRUG
schedule	O
appears	O
more	O
suitable	O
for	O
clinical	O
use	O
and	O
should	O
be	O
preferred	O
as	O
a	O
basis	O
for	O
further	O
development	O
of	O
therapeutic	O
strategies	O
against	O
pancreatic	B-CANCER
cancer	I-CANCER
.	O
	
Dose-finding	O
study	O
of	O
docetaxel	B-DRUG
added	O
to	O
ifosfamide	B-DRUG
and	O
cisplatin	B-DRUG
followed	O
by	O
concomitant	O
capecitabine	B-DRUG
and	O
radiotherapy	O
in	O
the	O
treatment	O
of	O
locally	O
advanced	B-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
	
Docetaxel	B-DRUG
(	O
DOC	B-DRUG
)	O
is	O
a	O
promising	O
new	O
drug	O
in	O
the	O
management	O
of	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
The	O
aim	O
of	O
this	O
phase	O
I	O
study	O
was	O
to	O
determine	O
the	O
toxicity	O
and	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
as	O
well	O
as	O
to	O
obtain	O
preliminary	O
data	O
on	O
the	O
activity	O
of	O
DOC	B-DRUG
combined	O
with	O
fixed	O
doses	O
of	O
ifosfamide	B-DRUG
(	O
IFO	B-DRUG
)	O
and	O
cisplatin	B-DRUG
(	O
CDDP	B-DRUG
)	O
","	O
followed	O
by	O
concomitant	O
capecitabine	B-DRUG
(	O
C	O
)	O
and	O
radiation	O
therapy	O
in	O
the	O
organ-sparing	O
treatment	O
of	O
patients	O
with	O
locally	O
advanced	O
","	O
inoperable	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	O
A-SCCHN	B-CANCER
)	O
.	O
	
Chemotherapy	O
and	O
radiotherapy-naive	O
patients	O
with	O
A-SCCHN	B-CANCER
were	O
treated	O
in	O
cohorts	O
of	O
three	O
with	O
escalating	O
doses	O
of	O
DOC	B-DRUG
administered	O
on	O
day	O
1	O
The	O
doses	O
of	O
DOC	B-DRUG
ranged	O
from	O
40	O
mg	O
/	O
m2	O
up	O
to	O
the	O
dose-limiting	O
toxicity	O
(	O
DTL	O
)	O
.	O
	
Fixed	O
doses	O
of	O
IFO	B-DRUG
(	O
1200	O
mg	O
/	O
m2	O
)	O
with	O
mesna	O
and	O
CDDP	B-DRUG
(	O
20	O
mg	O
/	O
m2	O
)	O
were	O
administered	O
on	O
days	O
1	O
to	O
4	O
","	O
every	O
4	O
weeks	O
.	O
	
Patients	O
who	O
had	O
achieved	O
a	O
response	O
received	O
definitive	O
radiation	O
therapy	O
(	O
6000	O
cGy	O
)	O
concomitantly	O
with	O
C	O
(	O
1000	O
mg	O
/	O
m2	O
/	O
day	O
)	O
.	O
	
Twenty-four	O
patients	O
were	O
entered	O
into	O
the	O
study	O
.	O
	
The	O
MTD	O
of	O
DOC	B-DRUG
was	O
70	O
mg	O
/	O
m2	O
.	O
	
A	O
total	O
of	O
99	O
courses	O
of	O
chemotherapy	O
were	O
given	O
.	O
	
Grade	O
3	O
and	O
4	O
hematological	B-TOXI
toxicities	I-TOXI
were	O
observed	O
in	O
twelve	O
and	O
nine	O
patients	O
","	O
respectively	O
","	O
while	O
grade	O
3	O
gastrointestinal	B-TOXI
toxicity	I-TOXI
occurred	O
in	O
four	O
patients	O
.	O
	
Concomitant	O
C	O
and	O
radiation	O
therapy	O
demonstrated	O
a	O
tolerable	O
toxicity	O
profile	O
.	O
	
An	O
overall	O
response	O
rate	O
of	O
83.3	O
%	O
(	O
95	O
%	O
CI	O
:	O
65.6	O
%	O
to	O
95.2	O
%	O
)	O
was	O
obtained	O
","	O
with	O
a	O
median	O
time	O
to	O
progression	O
and	O
overall	O
survival	O
of	O
15.6	O
and	O
22.3	O
months	O
","	O
respectively	O
.	O
	
Out-patient	O
administration	O
of	O
DOC	B-DRUG
","	O
IFO	B-DRUG
and	O
CDDP	B-DRUG
for	O
A-SCCHN	O
was	O
safe	O
and	O
did	O
not	O
affect	O
the	O
ability	O
to	O
administer	O
chemoradiotherapy	O
on	O
schedule	O
.	O
	
Myelosuppression	B-TOXI
was	O
the	O
DLT	O
.	O
	
A	O
phase	O
II	O
trial	O
of	O
irinotecan	B-DRUG
and	O
cisplatin	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
neuroendocrine	I-CANCER
tumors	I-CANCER
.	O
	
	
The	O
role	O
of	O
systemic	O
chemotherapy	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
metastatic	B-CANCER
neuroendocrine	I-CANCER
tumors	I-CANCER
is	O
controversial	O
.	O
	
While	O
combination	O
regimens	O
containing	O
cisplatin	B-DRUG
and	O
etoposide	B-DRUG
have	O
activity	O
against	O
more	O
aggressive	O
neuroendocrine	B-CANCER
tumor	I-CANCER
variants	O
","	O
such	O
regimens	O
appear	O
to	O
have	O
little	O
efficacy	O
in	O
patients	O
with	O
well-differentiated	O
neuroendocrine	B-CANCER
tumor	I-CANCER
subtypes	O
.	O
	
The	O
combination	O
of	O
irinotecan	B-DRUG
and	O
cisplatin	B-DRUG
is	O
active	O
both	O
against	O
small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
and	O
in	O
upper	O
gastrointestinal	B-CANCER
malignancies	I-CANCER
but	O
has	O
not	O
been	O
prospectively	O
evaluated	O
in	O
patients	O
with	O
metastatic	B-CANCER
neuroendocrine	I-CANCER
tumors	I-CANCER
.	O
	
We	O
therefore	O
assessed	O
the	O
efficacy	O
of	O
an	O
irinotecan	B-DRUG
/	O
cisplatin	B-DRUG
combination	O
in	O
patients	O
with	O
this	O
disease	O
.	O
	
Eighteen	O
patients	O
with	O
metastatic	B-CANCER
neuroendocrine	I-CANCER
tumors	I-CANCER
(	O
excluding	O
small	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
)	O
were	O
treated	O
with	O
irinotecan	B-DRUG
","	O
65	O
mg	O
/	O
m2	O
","	O
and	O
cisplatin	B-DRUG
","	O
30	O
mg	O
/	O
m2	O
","	O
administered	O
weekly	O
for	O
2	O
of	O
every	O
3	O
weeks	O
.	O
	
Patients	O
were	O
followed	O
for	O
evidence	O
of	O
toxicity	O
","	O
response	O
","	O
and	O
survival	O
.	O
	
The	O
toxicities	O
associated	O
with	O
this	O
regimen	O
were	O
mild	O
and	O
included	O
myelosuppression	B-TOXI
","	O
nausea	B-TOXI
","	O
and	O
diarrhea	B-TOXI
.	O
	
Only	O
one	O
radiologic	O
response	O
was	O
observed	O
among	O
four	O
patients	O
with	O
poorly	O
differentiated	O
neuroendocrine	B-CANCER
tumors	I-CANCER
.	O
	
No	O
radiologic	O
responses	O
were	O
observed	O
in	O
14	O
patients	O
with	O
well-differentiated	O
tumors	O
.	O
	
The	O
median	O
overall	O
survival	O
duration	O
of	O
patients	O
treated	O
with	O
this	O
regimen	O
was	O
11.4	O
months	O
.	O
	
We	O
conclude	O
that	O
while	O
the	O
combination	O
of	O
irinotecan	B-DRUG
and	O
cisplatin	B-DRUG
may	O
have	O
activity	O
in	O
aggressive	O
neuroendocrine	B-CANCER
tumor	I-CANCER
subtypes	O
","	O
this	O
combination	O
is	O
inactive	O
in	O
patients	O
with	O
well-differentiated	O
neuroendocrine	B-CANCER
tumors	I-CANCER
.	O
	
Multicenter	O
phase	O
II	O
trial	O
of	O
accelerated	O
cisplatin	B-DRUG
and	O
high-dose	O
epirubicin	B-DRUG
followed	O
by	O
surgery	O
or	O
radiotherapy	O
in	O
patients	O
with	O
stage	O
IIIa	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
with	O
mediastinal	O
lymph	O
node	O
involvement	O
(	O
N2-disease	O
)	O
.	O
	
	
To	O
assess	O
the	O
therapeutic	O
activity	O
of	O
accelerated	O
cisplatin	B-DRUG
and	O
high-dose	O
epirubicin	B-DRUG
with	O
erythropoietin	B-DRUG
and	O
G-CSF	B-DRUG
support	O
as	O
induction	O
therapy	O
for	O
patients	O
with	O
stage	O
IIIa-N2	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Patients	O
with	O
stage	O
IIIa-N2	O
NSCLC	B-CANCER
were	O
enrolled	O
in	O
a	O
phase	O
II	O
trial	O
.	O
	
They	O
received	O
cisplatin	B-DRUG
60	O
mg	O
m	O
(	O
-2	O
)	O
and	O
epirubicin	B-DRUG
135	O
mg	O
m	O
(	O
-2	O
)	O
every	O
2	O
weeks	O
for	O
three	O
courses	O
combined	O
with	O
erythropoietin	B-DRUG
and	O
G-CSF	B-DRUG
.	O
	
Depending	O
on	O
results	O
of	O
clinical	O
response	O
to	O
induction	O
therapy	O
and	O
restaging	O
","	O
patients	O
were	O
treated	O
with	O
surgery	O
or	O
radiotherapy	O
.	O
	
In	O
total	O
","	O
61	O
patients	O
entered	O
from	O
March	O
2001	O
to	O
April	O
2004	O
.	O
	
During	O
169	O
courses	O
of	O
induction	O
chemotherapy	O
","	O
National	O
Cancer	O
Institute	O
of	O
Canada	O
(	O
NCI-C	O
)	O
grade	O
III	O
/	O
IV	O
leucocytopenia	B-TOXI
was	O
reported	O
in	O
35	O
courses	O
(	O
20.7	O
%	O
)	O
","	O
NCI-C	O
grade	O
III	O
/	O
IV	O
thrombocytopenia	B-TOXI
in	O
26	O
courses	O
(	O
15.4	O
%	O
)	O
and	O
NCI-C	O
grade	O
III	O
/	O
IV	O
anaemia	B-TOXI
in	O
six	O
courses	O
(	O
3.6	O
%	O
)	O
.	O
	
Main	O
cause	O
of	O
cisplatin	B-DRUG
dose	O
reduction	O
was	O
nephrotoxicity	B-TOXI
(	O
12	O
courses	O
)	O
.	O
	
Most	O
patients	O
received	O
three	O
courses	O
.	O
	
There	O
were	O
no	O
chemotherapy-related	O
deaths	B-TOXI
.	O
	
Three	O
patients	O
were	O
not	O
evaluable	O
for	O
clinical	O
response	O
.	O
	
Twenty-eight	O
patients	O
had	O
a	O
partial	O
response	O
(	O
48.3	O
%	O
","	O
95	O
%	O
CI	O
:	O
36-61.1	O
%	O
)	O
","	O
24	O
stable	O
disease	O
and	O
six	O
progressive	O
disease	O
.	O
	
After	O
induction	O
therapy	O
","	O
30	O
patients	O
underwent	O
surgery	O
;	O
complete	O
resection	O
was	O
achieved	O
in	O
19	O
procedures	O
(	O
31.1	O
%	O
)	O
.	O
	
Radical	O
radiotherapy	O
was	O
delivered	O
to	O
25	O
patients	O
(	O
41	O
%	O
)	O
.	O
	
Six	O
patients	O
were	O
considered	O
unfit	O
for	O
further	O
treatment	O
.	O
	
Median	O
survival	O
for	O
all	O
patients	O
was	O
18	O
months	O
.	O
	
Response	O
rate	O
of	O
accelerated	O
cisplatin	B-DRUG
and	O
high-dose	O
epirubicin	B-DRUG
as	O
induction	O
chemotherapy	O
for	O
stage	O
IIIa-N2	O
NSCLC	B-CANCER
patients	O
is	O
not	O
different	O
from	O
more	O
commonly	O
used	O
cisplatin-based	B-DRUG
regimen	O
.	O
	
Randomized	O
phase	O
III	O
trial	O
of	O
gemcitabine	B-DRUG
plus	O
cisplatin	B-DRUG
compared	O
with	O
gemcitabine	B-DRUG
alone	O
in	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
compare	O
the	O
effectiveness	O
and	O
tolerability	O
of	O
gemcitabine	B-DRUG
plus	O
cisplatin	B-DRUG
with	O
single-agent	O
gemcitabine	B-DRUG
as	O
first-line	O
chemotherapy	O
for	O
locally	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
advanced	B-CANCER
adenocarcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
pancreas	I-CANCER
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m2	O
and	O
cisplatin	B-DRUG
50	O
mg	O
/	O
m2	O
given	O
on	O
days	O
1	O
and	O
15	O
of	O
a	O
4-week	O
cycle	O
(	O
GemCis	O
arm	O
)	O
or	O
gemcitabine	B-DRUG
alone	O
at	O
a	O
dose	O
of	O
"1,000"	O
mg	O
/	O
m2	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
of	O
a	O
4-week	O
regimen	O
(	O
Gem	O
arm	O
)	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
overall	O
survival	O
;	O
secondary	O
end	O
points	O
were	O
progression-free	O
survival	O
","	O
response	O
rate	O
","	O
safety	O
","	O
and	O
quality	O
of	O
life	O
.	O
	
One	O
hundred	O
ninety-five	O
patients	O
were	O
enrolled	O
and	O
showed	O
baseline	O
characteristics	O
well	O
balanced	O
between	O
treatment	O
arms	O
.	O
	
Combination	O
treatment	O
in	O
the	O
GemCis	O
arm	O
was	O
associated	O
with	O
a	O
prolonged	O
median	O
progression-free	O
survival	O
(	O
5.3	O
months	O
v	O
3.1	O
months	O
;	O
hazard	O
ratio	O
[	O
HR	O
]	O
=	O
0.75	O
;	O
P	O
=	O
0.053	O
)	O
.	O
	
Also	O
","	O
median	O
overall	O
survival	O
was	O
superior	O
for	O
patients	O
treated	O
in	O
the	O
GemCis	O
arm	O
as	O
compared	O
with	O
the	O
Gem	O
arm	O
(	O
7.5	O
v	O
6	O
months	O
)	O
","	O
an	O
advantage	O
which	O
did	O
not	O
","	O
however	O
","	O
reach	O
statistical	O
significance	O
(	O
HR	O
=	O
0.8	O
;	O
P	O
=	O
0.15	O
)	O
.	O
	
Tumor	O
response	O
rates	O
were	O
comparable	O
between	O
treatment	O
arms	O
(	O
10.2	O
%	O
v	O
8.2	O
%	O
)	O
.	O
	
The	O
rate	O
of	O
stable	O
disease	O
was	O
","	O
however	O
","	O
greater	O
in	O
the	O
combination	O
arm	O
(	O
60.2	O
%	O
v	O
40.2	O
%	O
;	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
.	O
	
Grade	O
3	O
to	O
4	O
hematologic	B-TOXI
toxicity	I-TOXI
did	O
not	O
exceed	O
15	O
%	O
in	O
both	O
treatment	O
arms	O
.	O
	
These	O
results	O
support	O
the	O
efficacy	O
and	O
safety	O
of	O
an	O
every-2-weeks	O
treatment	O
with	O
gemcitabine	B-DRUG
plus	O
cisplatin	B-DRUG
.	O
	
Median	O
overall	O
survival	O
and	O
progression-free	O
survival	O
were	O
more	O
favorable	O
in	O
the	O
combination	O
arm	O
as	O
compared	O
with	O
gemcitabine	B-DRUG
alone	O
","	O
although	O
the	O
difference	O
did	O
not	O
attain	O
statistical	O
significance	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
cetuximab	B-DRUG
/	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
advanced-stage	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
	
The	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
is	O
part	O
of	O
the	O
ErbB	O
family	O
of	O
receptor	O
tyrosine	O
kinases	O
and	O
is	O
known	O
to	O
be	O
variably	O
expressed	O
in	O
breast	B-CANCER
cancers	I-CANCER
.	O
	
Cetuximab	B-DRUG
is	O
a	O
humanized	O
monoclonal	O
antibody	O
directed	O
against	O
the	O
EGFR	O
that	O
works	O
by	O
blocking	O
the	O
downstream	O
signaling	O
function	O
of	O
this	O
protein	O
and	O
thereby	O
interfering	O
with	O
cancer	O
cell	O
proliferation	O
.	O
	
Preclinical	O
studies	O
have	O
indicated	O
a	O
synergistic	O
effect	O
for	O
the	O
combination	O
of	O
anti-EGFR	O
therapy	O
plus	O
paclitaxel	B-DRUG
in	O
breast	B-CANCER
cancer	I-CANCER
models	O
.	O
	
Hence	O
","	O
we	O
conducted	O
a	O
dose-escalation	O
phase	O
I	O
trial	O
using	O
cetuximab	B-DRUG
/	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
to	O
evaluate	O
the	O
feasibility	O
of	O
this	O
combination	O
.	O
	
Patients	O
with	O
EGFR-positive	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
treated	O
with	O
&	O
lt	O
;	O
or=	O
1	O
previous	O
therapy	O
","	O
excluding	O
taxanes	B-DRUG
","	O
were	O
eligible	O
.	O
	
Treatment	O
consisted	O
of	O
weekly	O
cetuximab	B-DRUG
therapy	O
and	O
every-3-week	O
paclitaxel	B-DRUG
","	O
with	O
dose	O
escalation	O
of	O
cetuximab	B-DRUG
until	O
the	O
maximum	O
tolerated	O
dose	O
was	O
reached	O
.	O
	
Twelve	O
patients	O
were	O
enrolled	O
to	O
3	O
treatment	O
cohorts	O
.	O
	
Two	O
of	O
6	O
patients	O
on	O
the	O
second	O
cohort	O
(	O
cetuximab	B-DRUG
100	O
mg	O
/	O
m2	O
)	O
developed	O
dose-limiting	O
toxicities	O
","	O
presenting	O
as	O
grade	O
3	O
rash	B-TOXI
.	O
	
The	O
third	O
cohort	O
was	O
amended	O
to	O
allow	O
the	O
same	O
cetuximab	B-DRUG
dose	O
but	O
to	O
modify	O
the	O
paclitaxel	B-DRUG
to	O
a	O
weekly	O
schedule	O
.	O
	
Despite	O
this	O
","	O
1	O
of	O
3	O
patients	O
in	O
this	O
group	O
also	O
developed	O
grade	O
3	O
skin	B-TOXI
toxicity	I-TOXI
as	O
a	O
dose-limiting	O
toxicity	O
;	O
thus	O
","	O
the	O
trial	O
was	O
stopped	O
.	O
	
Ten	O
of	O
the	O
12	O
patients	O
were	O
evaluable	O
for	O
response	O
","	O
and	O
of	O
these	O
","	O
2	O
patients	O
experienced	O
stable	O
disease	O
","	O
and	O
8	O
patients	O
experienced	O
disease	O
progression	O
.	O
	
Because	O
of	O
prohibitive	O
dermatologic	B-TOXI
toxicity	I-TOXI
and	O
disappointing	O
preliminary	O
efficacy	O
","	O
the	O
combination	O
of	O
paclitaxel	B-DRUG
/	O
cetuximab	B-DRUG
was	O
not	O
considered	O
promising	O
in	O
this	O
population	O
","	O
although	O
further	O
study	O
of	O
this	O
regimen	O
might	O
be	O
warranted	O
.	O
	
A	O
randomized	O
trial	O
of	O
cisplatin	B-DRUG
","	O
vinblastine	B-DRUG
","	O
and	O
bleomycin	B-DRUG
versus	O
vinblastine	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
etoposide	B-DRUG
in	O
the	O
treatment	O
of	O
advanced	B-CANCER
germ	I-CANCER
cell	I-CANCER
tumors	I-CANCER
of	O
the	O
testis	O
:	O
a	O
Southwest	O
Oncology	O
Group	O
study	O
.	O
	
	
This	O
is	O
a	O
Southwest	O
Oncology	O
Group	O
(	O
SWOG	O
)	O
prospective	O
randomized	O
trial	O
of	O
cisplatin	B-DRUG
","	O
vinblastine	B-DRUG
","	O
and	O
bleomycin	B-DRUG
(	O
PVB	O
)	O
versus	O
vinblastine	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
etoposide	B-DRUG
(	O
VP-16	B-DRUG
)	O
(	O
VPV	O
)	O
in	O
the	O
treatment	O
of	O
advanced	B-CANCER
germ	I-CANCER
cell	I-CANCER
tumors	I-CANCER
of	O
the	O
testis	O
.	O
	
The	O
study	O
objective	O
was	O
to	O
determine	O
what	O
effect	O
the	O
replacement	O
of	O
bleomycin	B-DRUG
with	O
VP-16	B-DRUG
has	O
on	O
complete	O
response	O
(	O
CR	O
)	O
","	O
survival	O
","	O
and	O
drug	O
toxicity	O
.	O
	
One	O
hundred	O
sixty-nine	O
patients	O
were	O
registered	O
and	O
randomized	O
.	O
	
Of	O
these	O
patients	O
","	O
160	O
were	O
assessable	O
for	O
response	O
.	O
	
All	O
had	O
histologically	O
confirmed	O
disseminated	O
germ	B-CANCER
cell	I-CANCER
neoplasms	I-CANCER
of	I-CANCER
testicular	I-CANCER
origin	I-CANCER
.	O
	
Forty-six	O
had	O
minimal	O
metastatic	O
disease	O
","	O
and	O
114	O
had	O
maximal	O
disease	O
.	O
	
Seventy-seven	O
were	O
randomized	O
to	O
PVB	O
and	O
83	O
to	O
VPV	O
chemotherapy	O
.	O
	
There	O
was	O
no	O
significant	O
difference	O
in	O
pretreatment	O
characteristics	O
between	O
the	O
two	O
arms	O
with	O
regard	O
to	O
tumor	O
burden	O
","	O
histologic	O
type	O
","	O
and	O
overall	O
performance	O
status	O
.	O
	
Patients	O
received	O
four	O
courses	O
of	O
induction	O
chemotherapy	O
","	O
either	O
PVB	O
(	O
cisplatin	B-DRUG
120	O
mg	O
/	O
m2	O
day	O
3	O
","	O
vinblastine	B-DRUG
12	O
mg	O
/	O
m2	O
day	O
1	O
","	O
bleomycin	B-DRUG
15	O
U	O
/	O
m2	O
twice	O
per	O
week	O
)	O
or	O
VPV	O
(	O
vinblastine	B-DRUG
8	O
mg	O
/	O
m2	O
day	O
1	O
","	O
cisplatin	B-DRUG
120	O
mg	O
/	O
m2	O
day	O
3	O
","	O
VP-16	B-DRUG
50	O
mg	O
/	O
m2	O
days	O
2	O
to	O
5	O
)	O
.	O
	
Chemotherapy	O
was	O
given	O
every	O
3	O
weeks	O
.	O
	
Cytoreductive	O
surgery	O
was	O
done	O
postinduction	O
if	O
a	O
chemotherapy	O
CR	O
was	O
not	O
achieved	O
.	O
	
There	O
was	O
no	O
difference	O
in	O
the	O
percentage	O
of	O
patients	O
achieving	O
a	O
disease-free	O
status	O
between	O
PVB	O
(	O
77	O
%	O
)	O
and	O
VPV	O
(	O
73	O
%	O
)	O
.	O
	
The	O
mean	O
leukocyte	O
nadir	O
was	O
similar	O
for	O
both	O
treatments	O
","	O
but	O
the	O
mean	O
platelet	O
nadir	O
was	O
significantly	O
lower	O
(	O
P	O
=	O
0.003	O
)	O
in	O
the	O
VPV	O
arm	O
.	O
	
All	O
bleomycin-related	B-DRUG
toxicities	O
(	O
pulmonary	O
","	O
mucositis	O
","	O
skin	O
)	O
were	O
avoided	O
in	O
the	O
VPV	O
arm	O
.	O
	
We	O
conclude	O
that	O
bleomycin	B-DRUG
can	O
be	O
replaced	O
in	O
first-line	O
therapy	O
for	O
advanced	B-CANCER
germ	I-CANCER
cell	I-CANCER
tumors	I-CANCER
without	O
sacrificing	O
efficacy	O
and	O
with	O
the	O
advantage	O
of	O
avoiding	O
unnecessary	O
drug	O
toxicity	O
.	O
	
Phase	O
I	O
clinical	O
trial	O
of	O
bortezomib	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Bortezomib	B-DRUG
is	O
the	O
first	O
proteasome	O
inhibitor	O
to	O
show	O
preliminary	O
evidence	O
of	O
activity	O
against	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
Findings	O
from	O
preclinical	O
studies	O
prompted	O
a	O
Phase	O
I	O
trial	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
of	O
bortezomib	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
recurring	O
/	O
refractory	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
The	O
effect	O
of	O
gemcitabine	B-DRUG
on	O
proteasome	O
inhibition	O
by	O
bortezomib	B-DRUG
in	O
whole	O
blood	O
was	O
also	O
investigated	O
.	O
	
Bortezomib	B-DRUG
was	O
administered	O
as	O
an	O
intravenous	O
bolus	O
injection	O
on	O
Days	O
1	O
","	O
4	O
","	O
8	O
","	O
and	O
11	O
","	O
with	O
gemcitabine	B-DRUG
(	O
30-minute	O
infusion	O
)	O
on	O
Days	O
1	O
and	O
8	O
of	O
a	O
21-day	O
cycle	O
.	O
	
Groups	O
of	O
&	O
gt	O
;	O
or	O
3	O
patients	O
were	O
evaluated	O
at	O
each	O
dose	O
level	O
.	O
	
Escalating	O
doses	O
of	O
gemcitabine	B-DRUG
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
to	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
with	O
bortezomib	B-DRUG
1	O
mg	O
/	O
m	O
(	O
2	O
)	O
to	O
1.5	O
mg	O
/	O
m	O
(	O
2	O
)	O
were	O
planned	O
.	O
	
There	O
were	O
no	O
DLTs	O
in	O
patients	O
receiving	O
bortezomib	B-DRUG
1	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
gemcitabine	B-DRUG
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
to	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
the	O
first	O
3	O
dose	O
levels	O
.	O
	
Dose-limiting	O
nausea	B-TOXI
","	O
vomiting	B-TOXI
","	O
gastrointestinal	B-TOXI
obstruction	I-TOXI
","	O
and	O
thrombocytopenia	B-TOXI
occurred	O
in	O
4	O
of	O
5	O
evaluable	O
patients	O
in	O
dose	O
level	O
4	O
(	O
bortezomib	B-DRUG
1.3	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
gemcitabine	B-DRUG
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
establishing	O
bortezomib	B-DRUG
1	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
gemcitabine	B-DRUG
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
the	O
MTD	O
.	O
	
Most	O
common	O
Grade	O
&	O
gt	O
;	O
or	O
3	O
toxicities	O
were	O
neutropenia	B-TOXI
(	O
6	O
patients	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
5	O
patients	O
)	O
","	O
gastrointestinal	B-TOXI
disorders	I-TOXI
(	O
6	O
patients	O
)	O
","	O
and	O
general	B-TOXI
disorders	I-TOXI
(	O
4	O
patients	O
)	O
such	O
as	O
fatigue	B-TOXI
.	O
	
One	O
patient	O
with	O
nonsmall	B-CANCER
cell	I-CANCER
lung	I-CANCER
carcinoma	I-CANCER
achieved	O
a	O
partial	O
response	O
and	O
7	O
achieved	O
stable	O
disease	O
.	O
	
Inhibition	O
of	O
20S	O
proteasome	O
activity	O
by	O
bortezomib	B-DRUG
was	O
unaffected	O
by	O
gemcitabine	B-DRUG
coadministration	O
.	O
	
Dosages	O
of	O
bortezomib	B-DRUG
and	O
gemcitabine	B-DRUG
suitable	O
for	O
further	O
evaluation	O
of	O
antitumor	O
activity	O
have	O
been	O
established	O
.	O
	
Analysis	O
of	O
efficacy	O
and	O
toxicity	O
of	O
chemotherapy	O
with	O
cisplatin	B-DRUG
","	O
5-fluorouracil	B-DRUG
","	O
methotrexate	B-DRUG
and	O
leucovorin	B-DRUG
(	O
PFML	B-DRUG
)	O
and	O
radiotherapy	O
in	O
the	O
treatment	O
of	O
locally	O
advanced	B-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
toxicity	O
of	O
concurrent	O
chemoradiotherapy	O
using	O
cisplatin	B-DRUG
(	O
CDDP	B-DRUG
)	O
","	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
methotrexate	B-DRUG
(	O
MTX	B-DRUG
)	O
and	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
(	O
PFML	B-DRUG
)	O
in	O
patients	O
with	O
locally	O
advanced	B-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	O
SCCHN	B-CANCER
)	O
.	O
	
Seventy-seven	O
patients	O
with	O
previously	O
untreated	O
stages	O
III-IV	O
SCCHN	B-CANCER
were	O
included	O
in	O
this	O
trial	O
.	O
	
Patients	O
received	O
two	O
cycles	O
of	O
chemotherapy	O
repeated	O
every	O
4	O
weeks	O
.	O
	
The	O
chemotherapy	O
regimen	O
consisted	O
CDDP	B-DRUG
(	O
60	O
mg	O
/	O
m2	O
","	O
day	O
4	O
)	O
","	O
5-FU	B-DRUG
(	O
600	O
mg	O
/	O
m2	O
given	O
over	O
24	O
h	O
for	O
5	O
days	O
","	O
days	O
1月5日	O
)	O
","	O
MTX	B-DRUG
(	O
30	O
mg	O
/	O
m2	O
","	O
day	O
1	O
)	O
and	O
LV	B-DRUG
(	O
20	O
mg	O
/	O
m2	O
","	O
days	O
1月5日	O
)	O
.	O
	
Radiation	O
was	O
targeted	O
to	O
begin	O
on	O
the	O
starting	O
day	O
of	O
chemotherapy	O
","	O
day	O
1	O
The	O
total	O
radiation	O
dose	O
to	O
the	O
primary	O
site	O
and	O
neck	O
lymph	O
nodes	O
was	O
70	O
Gy	O
.	O
	
When	O
grade	O
&	O
gt	O
;	O
or=3	O
toxicities	O
were	O
observed	O
frequently	O
","	O
radiotherapy	O
and	O
/	O
or	O
chemotherapy	O
were	O
delayed	O
or	O
reduced	O
.	O
	
The	O
main	O
toxicities	O
were	O
mucositis	B-TOXI
(	O
grade	O
&	O
gt	O
;	O
or=3	O
","	O
39	O
%	O
)	O
","	O
leukocytopenia	B-TOXI
(	O
grade	O
&	O
gt	O
;	O
or=3	O
","	O
34	O
%	O
)	O
and	O
neutropenia	B-TOXI
(	O
grade	O
&	O
gt	O
;	O
or=3	O
","	O
30	O
%	O
)	O
.	O
	
The	O
overall	O
clinical	O
response	O
rate	O
and	O
the	O
pathological	O
complete	O
response	O
(	O
CR	O
)	O
were	O
94	O
%	O
(	O
72	O
/	O
77	O
)	O
and	O
71	O
%	O
(	O
55	O
/	O
77	O
)	O
.	O
	
The	O
primary	O
site	O
CR	O
and	O
neck	O
lymph	O
node	O
CR	O
were	O
79	O
%	O
(	O
61	O
/	O
77	O
)	O
and	O
85	O
%	O
(	O
44	O
/	O
52	O
)	O
","	O
and	O
3-year	O
survival	O
rate	O
was	O
73	O
%	O
.	O
	
This	O
concurrent	O
chemoradiotherapy	O
with	O
PFML	B-DRUG
was	O
safe	O
and	O
well	O
tolerated	O
.	O
	
The	O
high	O
CR	O
rate	O
justifies	O
further	O
evaluation	O
of	O
this	O
chemoradiotherapy	O
modality	O
in	O
locally	O
advanced	B-CANCER
SCCHN	I-CANCER
patients	O
.	O
	
Gemcitabine	B-DRUG
and	O
carboplatin	B-DRUG
in	O
carcinoma	B-CANCER
of	O
unknown	O
primary	O
site	O
:	O
a	O
phase	O
2	O
Adelaide	O
Cancer	O
Trials	O
and	O
Education	O
Collaborative	O
study	O
.	O
	
	
Cancer	O
of	O
unknown	O
primary	O
site	O
(	O
CUP	O
)	O
represents	O
up	O
to	O
5	O
%	O
of	O
all	O
cancer	O
diagnoses	O
and	O
is	O
associated	O
with	O
poor	O
survival	O
.	O
	
We	O
have	O
performed	O
a	O
prospective	O
multicentre	O
phase	O
2	O
trial	O
to	O
evaluate	O
efficacy	O
and	O
toxicity	O
of	O
the	O
combination	O
of	O
gemcitabine	B-DRUG
(	O
G	O
)	O
and	O
carboplatin	B-DRUG
(	O
C	O
)	O
for	O
patients	O
with	O
CUP	O
.	O
	
Patients	O
with	O
histologically	O
confirmed	O
metastatic	B-CANCER
carcinoma	I-CANCER
in	O
which	O
the	O
primary	O
site	O
of	O
cancer	O
was	O
not	O
evident	O
after	O
prospectively	O
designated	O
investigation	O
and	O
who	O
had	O
ECOG	O
performance	O
status	O
0-2	O
were	O
treated	O
with	O
G	O
1000	O
mg	O
m	O
(	O
-2	O
)	O
intravenously	O
(	O
i.v.	O
)	O
days	O
1	O
and	O
8	O
","	O
and	O
C	O
AUC	O
5	O
i.v.	O
on	O
day	O
8	O
every	O
3	O
weeks	O
to	O
a	O
maximum	O
of	O
nine	O
cycles	O
.	O
	
The	O
primary	O
end	O
points	O
were	O
response	O
rate	O
","	O
and	O
toxicity	O
","	O
with	O
secondary	O
end	O
points	O
of	O
progression-free	O
survival	O
and	O
overall	O
survival	O
.	O
	
Fifty-one	O
(	O
23	O
male	O
","	O
27	O
female	O
)	O
patients	O
were	O
enrolled	O
(	O
one	O
patient	O
ineligible	O
)	O
","	O
with	O
a	O
median	O
age	O
of	O
69	O
years	O
(	O
range	O
41-83	O
years	O
)	O
.	O
	
Fifty	O
patients	O
were	O
evaluable	O
for	O
toxicity	O
and	O
46	O
patients	O
were	O
evaluable	O
for	O
efficacy	O
.	O
	
The	O
overall	O
response	O
rate	O
to	O
the	O
GC	O
regimen	O
was	O
30.5	O
%	O
.	O
	
With	O
a	O
median	O
follow-up	O
of	O
24	O
months	O
","	O
the	O
median	O
progression-free	O
survival	O
was	O
18	O
weeks	O
(	O
4.2	O
months	O
)	O
and	O
the	O
median	O
overall	O
survival	O
was	O
34	O
weeks	O
(	O
7.8	O
months	O
)	O
.	O
	
The	O
frequency	O
of	O
grade	O
3	O
or	O
4	O
toxicity	O
was	O
low	O
.	O
	
Nausea	B-TOXI
/	O
vomiting	B-TOXI
was	O
the	O
most	O
common	O
side	O
effect	O
","	O
but	O
was	O
usually	O
only	O
mild	O
in	O
severity	O
.	O
	
Uncomplicated	O
neutropenia	B-TOXI
(	O
14	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
10	O
%	O
)	O
and	O
anaemia	B-TOXI
(	O
8	O
%	O
)	O
were	O
the	O
most	O
common	O
causes	O
of	O
grade	O
3月4日	O
toxicity	O
.	O
	
The	O
regimen	O
was	O
very	O
well	O
tolerated	O
","	O
particularly	O
in	O
the	O
elderly	O
.	O
	
The	O
GC	O
regimen	O
is	O
an	O
active	O
regimen	O
in	O
CUP	O
with	O
excellent	O
tolerability	O
and	O
should	O
be	O
considered	O
particularly	O
for	O
elderly	O
patients	O
with	O
CUP	O
.	O
	
Weekly	O
administration	O
of	O
topotecan-paclitaxel	B-DRUG
as	O
second-line	O
treatment	O
in	O
ovarian	B-CANCER
cancer	I-CANCER
.	O
	
	
To	O
investigate	O
the	O
weekly	O
administration	O
of	O
topotecan	B-DRUG
combined	O
with	O
paclitaxel	B-DRUG
in	O
pretreated	O
advanced	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
patients	O
;	O
our	O
objectives	O
were	O
to	O
determine	O
efficacy	O
","	O
toxicity	O
and	O
survival	O
.	O
	
The	O
chemotherapy	O
agents	O
","	O
topotecan	B-DRUG
and	O
paclitaxel	B-DRUG
were	O
administered	O
on	O
a	O
weekly	O
basis	O
for	O
3	O
consecutive	O
weeks	O
","	O
every	O
28	O
days	O
.	O
	
The	O
plan	O
was	O
to	O
give	O
three	O
courses	O
(	O
each	O
course	O
included	O
three	O
once-weekly	O
infusions	O
)	O
.	O
	
The	O
dose	O
of	O
topotecan	B-DRUG
was	O
1.75	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
of	O
paclitaxel	B-DRUG
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
From	O
January	O
2004	O
until	O
January	O
2006	O
","	O
45	O
patients	O
were	O
enrolled	O
in	O
this	O
multicenter	O
trial	O
;	O
44	O
patients	O
were	O
evaluable	O
for	O
response	O
and	O
toxicity	O
.	O
	
The	O
median	O
age	O
was	O
60	O
years	O
old	O
(	O
range	O
39-82	O
years	O
)	O
and	O
performance	O
status	O
was	O
0-2	O
.	O
	
Thirty-nine	O
patients	O
were	O
in	O
stage	O
III	O
and	O
5	O
in	O
stage	O
IV	O
.	O
	
All	O
patients	O
had	O
been	O
pretreated	O
with	O
carboplatin	B-DRUG
or	O
cisplatin	B-DRUG
in	O
combination	O
with	O
paclitaxel	B-DRUG
.	O
	
Complete	O
and	O
partial	O
responses	O
were	O
seen	O
in	O
39	O
%	O
of	O
the	O
patients	O
","	O
stable	O
disease	O
in	O
43	O
%	O
and	O
progressive	O
disease	O
in	O
18	O
%	O
;	O
median	O
survival	O
time	O
was	O
9	O
months	O
","	O
range	O
2-24+	O
months	O
","	O
(	O
95	O
%	O
CI	O
:	O
7.9-10.2	O
)	O
.	O
	
There	O
was	O
a	O
notable	O
absence	O
of	O
grade	O
3	O
toxicity	O
except	O
for	O
neutropenia	B-TOXI
in	O
11	O
%	O
of	O
the	O
patients	O
.	O
	
The	O
combination	O
of	O
topotecan	B-DRUG
and	O
paclitaxel	B-DRUG
administered	O
on	O
a	O
weekly	O
basis	O
is	O
a	O
well-tolerated	O
chemotherapy	O
schedule	O
.	O
	
The	O
response	O
rate	O
of	O
39	O
%	O
is	O
quite	O
high	O
for	O
patients	O
with	O
pretreated	O
ovarian	B-CANCER
cancer	I-CANCER
.	O
	
Biweekly	O
oxaliplatin	B-DRUG
plus	O
1-day	O
infusional	B-DRUG
fluorouracil	I-DRUG
/	O
leucovorin	B-DRUG
followed	O
by	O
metronomic	O
chemotherapy	O
with	O
tegafur	B-DRUG
/	O
uracil	B-DRUG
in	O
pretreated	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
Metronomic	O
chemotherapy	O
","	O
at	O
a	O
minimally	O
toxic	O
dose	O
and	O
with	O
a	O
frequent	O
schedule	O
","	O
is	O
a	O
potentially	O
novel	O
approach	O
to	O
the	O
control	O
of	O
advanced	B-CANCER
cancer	I-CANCER
disease	O
via	O
a	O
different	O
mechanism	O
from	O
maximum	O
tolerable	O
doses	O
chemotherapy	O
.	O
	
Taking	O
advantage	O
of	O
the	O
potential	O
effectiveness	O
of	O
metronomic	O
therapy	O
","	O
tegafur	B-DRUG
/	O
uracil	B-DRUG
(	O
UFT	O
)	O
was	O
incorporated	O
into	O
an	O
oxaliplation	B-DRUG
/	O
infusioanl	O
fluouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
/	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
protocol	O
in	O
this	O
study	O
.	O
	
The	O
primary	O
endpoints	O
were	O
response	O
rate	O
","	O
time	O
to	O
progression	O
(	O
TTP	O
)	O
and	O
safety	O
profile	O
in	O
5-FU-pretreated	B-DRUG
metastatic	B-CANCER
colorectal	I-CANCER
cancers	I-CANCER
(	O
CRCs	B-CANCER
)	O
.	O
	
Twenty-eight	O
patients	O
with	O
metastatic	B-CANCER
CRCs	I-CANCER
resistant	O
or	O
refractory	O
to	O
5-FU	B-DRUG
/	O
LV	B-DRUG
were	O
enrolled	O
.	O
	
Chemotherapy	O
was	O
administrated	O
every	O
2	O
weeks	O
sequentially	O
with	O
2-h	O
infusion	O
of	O
oxaliplatin	B-DRUG
(	O
85	O
mg	O
/	O
m2	O
)	O
and	O
LV	B-DRUG
(	O
200	O
mg	O
/	O
m2	O
)	O
","	O
intravenous	O
bolus	O
5-FU	B-DRUG
(	O
400	O
mg	O
/	O
m2	O
)	O
","	O
22-h	O
infusion	O
of	O
5-FU	B-DRUG
(	O
600	O
mg	O
/	O
m2	O
)	O
on	O
day	O
1	O
and	O
then	O
followed	O
by	O
10-day	O
daily	O
oral	O
UFT	B-DRUG
(	O
200	O
mg	O
/	O
m2	O
)	O
/	O
LV	B-DRUG
(	O
30	O
mg	O
/	O
m2	O
)	O
.	O
	
Partial	O
response	O
was	O
seen	O
in	O
ten	O
(	O
35.7	O
%	O
)	O
patients	O
.	O
	
The	O
median	O
TTP	O
was	O
5.2	O
(	O
95	O
%	O
CI	O
:	O
4.16-6.31	O
)	O
months	O
and	O
the	O
median	O
overall	O
survival	O
was	O
13.4	O
(	O
95	O
%	O
CI	O
:	O
6.39-20.5	O
)	O
months	O
.	O
	
No	O
grade	O
3	O
toxicities	O
above	O
5	O
%	O
according	O
to	O
National	O
Cancer	O
Institute-Common	O
Toxicity	O
Criteria	O
(	O
NCI-CTC	O
)	O
occurred	O
except	O
sensory	B-TOXI
neuropathy	I-TOXI
(	O
10.7	O
%	O
)	O
.	O
	
No	O
grade	O
4	O
toxicity	O
","	O
treatment-related	O
mortality	O
or	O
hand-foot	B-TOXI
syndrome	I-TOXI
was	O
found	O
.	O
	
This	O
study	O
protocol	O
with	O
favorable	O
toxicity	O
profile	O
is	O
thus	O
promisingly	O
effective	O
against	O
5-FU-pretreated	B-DRUG
metastatic	B-CANCER
CRCs	I-CANCER
.	O
	
Given	O
the	O
present	O
experience	O
","	O
an	O
evaluation	O
of	O
the	O
regimen	O
as	O
front-line	O
treatment	O
of	O
metastatic	B-CANCER
CRC	I-CANCER
is	O
planned	O
.	O
	
Phase	O
II	O
study	O
of	O
consolidation	O
paclitaxel	B-DRUG
after	O
concurrent	O
chemoradiation	O
in	O
poor-risk	O
stage	O
III	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
SWOG	O
S9712	O
.	O
	
	
A	O
previous	O
Southwest	O
Oncology	O
Group	O
(	O
SWOG	O
)	O
study	O
(	O
S9429	O
)	O
demonstrated	O
efficacy	O
and	O
tolerability	O
of	O
concurrent	O
chemoradiotherapy	O
in	O
poor-risk	O
stage	O
III	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
This	O
study	O
evaluated	O
adding	O
consolidation	O
paclitaxel	B-DRUG
after	O
chemoradiotherapy	O
for	O
a	O
similar	O
patient	O
cohort	O
.	O
	
Patients	O
with	O
histologically	O
/	O
cytologically	O
determined	O
stage	O
III	O
NSCLC	B-CANCER
were	O
eligible	O
based	O
on	O
performance	O
status	O
(	O
PS	O
)	O
2	O
and	O
either	O
low	B-TOXI
albumin	I-TOXI
or	O
weight	B-TOXI
loss	I-TOXI
more	O
than	O
10	O
%	O
","	O
poor	B-TOXI
pulmonary	I-TOXI
function	I-TOXI
","	O
or	O
comorbidities	B-TOXI
precluding	O
cisplatin	B-DRUG
use	O
.	O
	
Treatment	O
was	O
carboplatin	B-DRUG
200	O
mg	O
/	O
m2	O
days	O
1	O
","	O
3	O
","	O
29	O
","	O
and	O
31	O
","	O
and	O
etoposide	B-DRUG
50	O
mg	O
/	O
m2	O
days	O
1	O
through	O
4	O
","	O
and	O
29	O
to	O
32	O
.	O
	
Beginning	O
day	O
1	O
","	O
thoracic	O
radiation	O
was	O
delivered	O
at	O
1.8	O
Gy	O
in	O
25	O
fractions	O
plus	O
16-Gy	O
boost	O
(	O
total	O
dose	O
","	O
61	O
Gy	O
)	O
.	O
	
Patients	O
without	O
disease	O
progression	O
received	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m2	O
every	O
21	O
days	O
for	O
three	O
cycles	O
.	O
	
Characteristics	O
of	O
87	O
eligible	O
patients	O
were	O
age	O
51	O
to	O
82	O
years	O
;	O
57	O
%	O
PS	O
0	O
to	O
1	O
","	O
43	O
%	O
PS	O
2	O
;	O
and	O
51	O
%	O
stage	O
IIIA	O
","	O
49	O
%	O
stage	O
IIIB	O
.	O
	
Toxicities	O
of	O
concurrent	O
chemoradiotherapy	O
included	O
grade	O
3	O
esophagitis	B-TOXI
(	O
7	O
%	O
)	O
and	O
grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
(	O
43	O
%	O
)	O
.	O
	
Fifty-four	O
assessable	O
patients	O
received	O
paclitaxel	B-DRUG
consolidation	O
.	O
	
Four	O
treatment-related	O
deaths	B-TOXI
occurred	O
during	O
chemoradiotherapy	O
and	O
four	O
occurred	O
during	O
consolidation	O
.	O
	
Overall	O
response	O
rate	O
was	O
53	O
%	O
.	O
	
Median	O
progression	O
free-	O
and	O
overall	O
survival	O
were	O
6.1	O
and	O
10.2	O
months	O
","	O
respectively	O
.	O
	
One-	O
and	O
2-year	O
survival	O
rates	O
were	O
43	O
%	O
and	O
25	O
%	O
.	O
	
Compared	O
with	O
a	O
previous	O
SWOG	O
trial	O
in	O
a	O
similar	O
patient	O
population	O
","	O
the	O
addition	O
of	O
consolidation	O
paclitaxel	B-DRUG
after	O
chemoradiotherapy	O
resulted	O
in	O
increased	O
toxicity	O
without	O
a	O
survival	O
advantage	O
.	O
	
More	O
PS	O
2	O
patients	O
(	O
43	O
%	O
v	O
18	O
%	O
)	O
enrolled	O
onto	O
S9712	O
","	O
which	O
may	O
explain	O
increased	O
toxicity	O
and	O
lack	O
of	O
benefit	O
.	O
	
The	O
optimal	O
chemoradiotherapy	O
approach	O
for	O
poor-risk	O
patients	O
remains	O
to	O
be	O
defined	O
.	O
	
Phase	O
I	O
study	O
of	O
bryostatin	B-DRUG
1	O
and	O
gemcitabine	B-DRUG
.	O
	
	
Bryostatin	B-DRUG
1	O
is	O
a	O
macrocyclic	O
lactone	O
with	O
protein	O
kinase	O
C	O
inhibitory	O
activity	O
.	O
	
Gemcitabine	B-DRUG
is	O
a	O
nucleotide	O
analogue	O
with	O
a	O
broad	O
spectrum	O
of	O
anticancer	O
activity	O
.	O
	
Bryostatin	B-DRUG
1	O
enhanced	O
the	O
activity	O
of	O
antitumor	O
agents	O
including	O
gemcitabine	B-DRUG
in	O
preclinical	O
models	O
.	O
	
The	O
primary	O
objective	O
of	O
this	O
phase	O
I	O
study	O
was	O
to	O
determine	O
the	O
recommended	O
doses	O
for	O
phase	O
II	O
trials	O
of	O
bryostatin	B-DRUG
1	O
and	O
gemcitabine	B-DRUG
.	O
	
Eligible	O
patients	O
had	O
histologic	O
or	O
cytologic	O
diagnosis	O
of	O
nonhematologic	O
cancer	O
refractory	O
to	O
conventional	O
treatment	O
;	O
life	O
expectancy	O
of	O
&	O
gt	O
;	O
3	O
months	O
;	O
normal	O
renal	O
","	O
hepatic	O
","	O
and	O
bone	O
marrow	O
function	O
;	O
and	O
a	O
Southwest	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
to	O
2	O
Gemcitabine	B-CANCER
was	O
administered	O
i.v.	O
over	O
30	O
minutes	O
and	O
was	O
followed	O
by	O
bryostatin	B-DRUG
1	O
by	O
i.v.	O
infusion	O
over	O
24	O
hours	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
of	O
a	O
28-day	O
cycle	O
.	O
	
Bryostatin	B-DRUG
1	O
(	O
microg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
gemcitabine	B-DRUG
(	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
doses	O
were	O
escalated	O
as	O
follows	O
:	O
25	O
/	O
600	O
","	O
25	O
/	O
800	O
","	O
25	O
/	O
"1,000"	O
","	O
30	O
/	O
"1,000"	O
","	O
35	O
/	O
"1,000"	O
","	O
and	O
45	O
/	O
"1,000"	O
","	O
respectively	O
.	O
	
Thirty-six	O
patients	O
(	O
mean	O
age	O
","	O
57	O
years	O
;	O
male	O
/	O
female	O
15:21	O
)	O
were	O
treated	O
.	O
	
The	O
median	O
number	O
of	O
treatment	O
cycles	O
per	O
patient	O
was	O
3	O
(	O
range	O
","	O
0-24	O
)	O
.	O
	
Four	O
patients	O
developed	O
dose	O
limiting	O
toxicities	O
:	O
myalgia	B-TOXI
","	O
2	O
;	O
myelosuppression	B-TOXI
","	O
1	O
;	O
and	O
elevation	B-TOXI
of	I-TOXI
serum	I-TOXI
alanine	I-TOXI
aminotransferase	I-TOXI
levels	I-TOXI
","	O
1	O
Ten	O
grade	O
3	O
toxicities	O
were	O
observed	O
(	O
anemia	B-TOXI
","	O
2	O
;	O
neutropenia	B-TOXI
","	O
5	O
;	O
thrombocytopenia	B-TOXI
","	O
3	O
)	O
.	O
	
No	O
treatment-related	O
death	B-TOXI
was	O
seen	O
.	O
	
The	O
recommended	O
doses	O
for	O
phase	O
II	O
trials	O
for	O
bryostatin	B-DRUG
1	O
and	O
gemcitabine	B-DRUG
were	O
35	O
microg	O
/	O
m	O
(	O
2	O
)	O
and	O
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
respectively	O
.	O
	
Two	O
heavily	O
pretreated	O
patients	O
with	O
breast	O
and	O
colon	B-CANCER
cancer	I-CANCER
experienced	O
partial	O
responses	O
lasting	O
22	O
and	O
8	O
months	O
","	O
respectively	O
.	O
	
Eight	O
patients	O
had	O
stable	O
disease	O
.	O
	
The	O
combination	O
of	O
bryostatin	B-DRUG
1	O
and	O
gemcitabine	B-DRUG
seemed	O
to	O
be	O
well	O
tolerated	O
with	O
limited	O
grade	O
3	O
toxicity	O
.	O
	
The	O
recommended	O
dose	O
of	O
bryostatin	B-DRUG
1	O
in	O
combination	O
with	O
full	O
doses	O
of	O
gemcitabine	B-DRUG
was	O
35	O
microg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
pemetrexed	B-DRUG
(	O
ALIMTA	O
)	O
and	O
cyclophosphamide	B-DRUG
in	O
patients	O
with	O
locally	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
Determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
pemetrexed	B-DRUG
and	O
cyclophosphamide	B-DRUG
combination	O
therapy	O
for	O
patients	O
with	O
locally	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
locally	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
breast	I-CANCER
cancer	I-CANCER
and	O
WHO	O
performance	O
status	O
0	O
to	O
2	O
were	O
eligible	O
.	O
	
Pemetrexed	B-DRUG
(	O
range	O
","	O
"400-2,400"	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
was	O
administered	O
on	O
day	O
1	O
of	O
a	O
21-day	O
schedule	O
followed	O
by	O
cyclophosphamide	B-DRUG
(	O
range	O
","	O
400-800	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O
	
Folic	B-DRUG
acid	I-DRUG
and	O
vitamin	B-DRUG
B	I-DRUG
(	O
12	O
)	O
supplementation	O
began	O
1	O
to	O
2	O
weeks	O
before	O
the	O
first	O
pemetrexed	B-DRUG
dose	O
.	O
	
Fifty-seven	O
pretreated	O
patients	O
were	O
enrolled	O
and	O
received	O
342	O
cycles	O
(	O
median	O
","	O
4	O
cycles	O
;	O
range	O
","	O
1月26日	O
)	O
through	O
14	O
dose	O
levels	O
.	O
	
The	O
MTD	O
of	O
pemetrexed	B-DRUG
was	O
"2,400"	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
combined	O
with	O
cyclophosphamide	B-DRUG
","	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
with	O
dose-limiting	O
toxicities	O
of	O
grade	O
4	O
neutropenia	B-TOXI
with	O
grade	O
4	O
infection	B-TOXI
and	O
grade	O
3	O
diarrhea	B-TOXI
.	O
	
Other	O
grade	O
3	O
or	O
4	O
toxicities	O
included	O
(	O
febrile	B-TOXI
)	O
neutropenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
anemia	B-TOXI
","	O
elevated	B-TOXI
alanine	I-TOXI
aminotransferase	I-TOXI
/	O
aspartate	B-TOXI
aminotransferase	I-TOXI
","	O
and	O
diarrhea	B-TOXI
.	O
	
Pharmacokinetic	O
analysis	O
indicated	O
that	O
pemetrexed	B-DRUG
clearance	O
and	O
central	O
volume	O
of	O
distribution	O
were	O
40	O
%	O
lower	O
than	O
single-agent	O
reference	O
data	O
","	O
yielding	O
a	O
68	O
%	O
increase	O
in	O
total	O
systemic	O
exposure	O
and	O
a	O
56	O
%	O
increase	O
in	O
maximal	O
plasma	O
concentration	O
.	O
	
Among	O
the	O
50	O
patients	O
evaluable	O
for	O
efficacy	O
","	O
13	O
(	O
26	O
%	O
)	O
patients	O
had	O
a	O
partial	O
response	O
and	O
17	O
(	O
34	O
%	O
)	O
patients	O
had	O
stable	O
disease	O
.	O
	
Pemetrexed	B-DRUG
was	O
generally	O
well	O
tolerated	O
.	O
	
The	O
observed	O
toxicities	O
were	O
consistent	O
with	O
the	O
known	O
toxicity	O
profiles	O
of	O
pemetrexed	B-DRUG
and	O
cyclophosphamide	B-DRUG
.	O
	
Considering	O
the	O
MTD	O
and	O
the	O
toxicity	O
and	O
efficacy	O
results	O
in	O
this	O
and	O
prior	O
studies	O
","	O
a	O
low	O
(	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
a	O
high	O
(	O
"1,800"	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
dose	O
of	O
pemetrexed	B-DRUG
with	O
cyclophosphamide	B-DRUG
(	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
will	O
be	O
evaluated	O
in	O
the	O
consecutive	O
prospective	O
randomized	O
phase	O
II	O
study	O
.	O
	
Erlotinib	B-DRUG
plus	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
unresectable	O
pancreatic	B-CANCER
cancer	I-CANCER
and	O
other	O
solid	B-CANCER
tumors	I-CANCER
:	O
phase	O
IB	O
trial	O
.	O
	
	
The	O
purpose	O
of	O
this	O
phase	O
IB	O
trial	O
was	O
to	O
evaluate	O
the	O
tolerability	O
","	O
pharmacokinetics	O
and	O
preliminary	O
evidence	O
of	O
antitumor	O
activity	O
of	O
erlotinib	B-DRUG
plus	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
pancreatic	B-CANCER
cancer	I-CANCER
and	O
other	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
Patients	O
included	O
those	O
with	O
advanced	B-CANCER
pancreatic	I-CANCER
adenocarcinoma	I-CANCER
or	O
other	O
malignancies	O
potentially	O
responsive	O
to	O
gemcitabine	B-DRUG
.	O
	
In	O
the	O
escalating	O
phase	O
of	O
the	O
trial	O
","	O
patients	O
were	O
enrolled	O
in	O
sequential	O
cohorts	O
using	O
100	O
or	O
150	O
mg	O
oral	O
daily	O
dosing	O
of	O
erlotinib	B-DRUG
.	O
	
Gemcitabine	B-DRUG
dose	O
was	O
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
x	O
7	O
(	O
first	O
cycle	O
)	O
","	O
then	O
weekly	O
x	O
3	O
","	O
every	O
4	O
weeks	O
.	O
	
Twenty-six	O
patients	O
completed	O
at	O
least	O
one	O
course	O
on	O
study	O
.	O
	
In	O
Cohort	O
IA	O
","	O
at	O
the	O
100	O
mg	O
/	O
day	O
dose	O
of	O
erlotinib	B-DRUG
","	O
three	O
patients	O
have	O
developed	O
grade	O
3	O
transaminase	O
elevations	O
.	O
	
After	O
stricter	O
inclusion	O
criteria	O
were	O
adopted	O
(	O
Cohort	O
IB	O
)	O
","	O
no	O
additional	O
events	O
of	O
grade	O
3	O
transaminase	O
elevations	O
were	O
observed	O
and	O
the	O
dose	O
of	O
erlotinib	B-DRUG
was	O
escalated	O
to	O
150	O
mg	O
/	O
day	O
(	O
Cohorts	O
IB	O
and	O
IIB	O
)	O
without	O
reaching	O
dose-limiting	O
toxicities	O
.	O
	
The	O
most	O
common	O
toxicities	O
included	O
diarrhea	B-TOXI
","	O
skin	B-TOXI
rash	I-TOXI
","	O
fatigue	B-TOXI
and	O
neutropenia	B-TOXI
.	O
	
The	O
pharmacokinetic	O
analyses	O
did	O
not	O
reveal	O
any	O
significant	O
interactions	O
between	O
erlotinib	B-DRUG
and	O
gemcitabine	B-DRUG
.	O
	
Objective	O
responses	O
were	O
seen	O
in	O
two	O
patients	O
:	O
cholangiocarcinoma	B-CANCER
and	O
pancreatic	B-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
unresectable	O
or	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
(	O
n	O
=	O
15	O
)	O
had	O
a	O
median	O
progression-free	O
survival	O
of	O
289	O
days	O
","	O
the	O
estimated	O
overall	O
survival	O
of	O
389	O
days	O
(	O
12.5	O
months	O
)	O
","	O
and	O
a	O
1-year	O
survival	O
rate	O
of	O
51	O
%	O
.	O
	
The	O
150	O
mg	O
/	O
day	O
dose	O
of	O
erlotinib	B-DRUG
can	O
be	O
safely	O
administered	O
in	O
combination	O
with	O
standard	O
dose	O
gemcitabine	B-DRUG
in	O
selected	O
patients	O
with	O
pancreatic	B-CANCER
cancer	I-CANCER
and	O
other	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Promising	O
antitumor	O
activity	O
has	O
been	O
observed	O
in	O
patients	O
with	O
pancreatic	B-CANCER
cancer	I-CANCER
.	O
	
A	O
phase	O
I	O
trial	O
of	O
fixed	O
dose	O
rate	O
gemcitabine	B-DRUG
plus	O
capecitabine	B-DRUG
in	O
metastatic	B-CANCER
cancer	I-CANCER
patients	O
.	O
	
	
Capecitabine	B-DRUG
and	O
gemcitabine	B-DRUG
given	O
as	O
fixed	O
dose	O
rate	O
(	O
FDR	O
)	O
has	O
not	O
been	O
demonstrated	O
to	O
be	O
well	O
tolerated	O
in	O
phase	O
I	O
previous	O
studies	O
.	O
	
The	O
goals	O
of	O
this	O
phase	O
I	O
study	O
were	O
to	O
determine	O
the	O
maximum-tolerated	O
dose	O
of	O
this	O
combination	O
and	O
to	O
describe	O
the	O
dose-limiting	O
toxic	O
effects	O
(	O
DLT	O
)	O
and	O
the	O
safety	O
profile	O
of	O
this	O
way	O
of	O
administration	O
.	O
	
Patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
eligible	O
for	O
this	O
study	O
.	O
	
Capecitabine	B-DRUG
was	O
administered	O
orally	O
at	O
a	O
dose	O
of	O
650	O
mg	O
/	O
m	O
(	O
2	O
)	O
bis	O
in	O
die	O
(	O
b.i.d.	O
)	O
for	O
14	O
consecutive	O
days	O
.	O
	
Gemcitabine	B-DRUG
was	O
administered	O
at	O
FDR	O
of	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
min	O
in	O
escalating	O
durations	O
of	O
infusion	O
on	O
days	O
1	O
and	O
8	O
The	O
cycles	O
were	O
repeated	O
every	O
21	O
days	O
.	O
	
All	O
20	O
patients	O
enrolled	O
into	O
the	O
study	O
were	O
assessable	O
for	O
toxicity	O
.	O
	
Only	O
one	O
out	O
of	O
the	O
first	O
six	O
patients	O
treated	O
at	O
FDR	O
gemcitabine	B-DRUG
dose	O
of	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
met	O
protocol-specified	O
DLT	O
criteria	O
(	O
grade	O
4	O
neutropenia	B-TOXI
lasting	O
&	O
gt	O
;	O
or=7	O
days	O
)	O
during	O
the	O
first	O
two	O
cycles	O
.	O
	
At	O
these	O
doses	O
the	O
majority	O
of	O
cycles	O
of	O
therapy	O
were	O
","	O
however	O
","	O
delivered	O
without	O
dose	O
reduction	O
or	O
delay	O
.	O
	
Another	O
similar	O
episode	O
of	O
DLT	O
was	O
observed	O
at	O
the	O
same	O
dose	O
step	O
among	O
the	O
following	O
eight	O
included	O
patients	O
.	O
	
The	O
dose	O
of	O
FDR	O
gemcitabine	B-DRUG
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
80	O
min	O
on	O
days	O
1	O
and	O
8	O
plus	O
capecitabine	B-DRUG
650	O
mg	O
/	O
m	O
(	O
2	O
)	O
b.i.d.	O
","	O
for	O
14	O
consecutive	O
days	O
followed	O
by	O
1	O
week	O
of	O
rest	O
is	O
recommended	O
for	O
further	O
study	O
.	O
	
The	O
combination	O
of	O
FDR	O
gemcitabine	B-DRUG
plus	O
capecitabine	B-DRUG
can	O
be	O
administered	O
with	O
acceptable	O
toxicity	O
.	O
	
The	O
evidence	O
of	O
antitumor	O
activity	O
deserves	O
further	O
investigation	O
in	O
phase	O
II	O
combination	O
chemotherapy	O
studies	O
.	O
	
Phase	O
III	O
trial	O
of	O
capecitabine	B-DRUG
plus	O
oxaliplatin	B-DRUG
as	O
adjuvant	O
therapy	O
for	O
stage	O
III	O
colon	B-CANCER
cancer	I-CANCER
:	O
a	O
planned	O
safety	O
analysis	O
in	O
"1,864"	O
patients	O
.	O
	
	
To	O
report	O
the	O
results	O
of	O
a	O
planned	O
safety	O
analysis	O
from	O
a	O
phase	O
III	O
trial	O
comparing	O
capecitabine	B-DRUG
plus	O
oxaliplatin	B-DRUG
(	O
XELOX	B-DRUG
)	O
with	O
bolus	O
fluorouracil	B-DRUG
/	O
leucovorin	B-DRUG
(	O
FU	B-DRUG
/	O
LV	B-DRUG
)	O
as	O
adjuvant	O
therapy	O
for	O
stage	O
III	O
colon	B-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
stage	O
III	O
colon	B-CANCER
carcinoma	I-CANCER
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
XELOX	B-DRUG
(	O
intravenous	O
oxaliplatin	B-DRUG
plus	O
oral	O
capecitabine	B-DRUG
;	O
3-week	O
cycle	O
for	O
eight	O
cycles	O
)	O
or	O
standard	O
intravenous	O
bolus	O
FU	B-DRUG
/	O
LV	B-DRUG
administered	O
as	O
the	O
Mayo	O
Clinic	O
(	O
Mayo	O
;	O
Rochester	O
","	O
MN	O
)	O
or	O
Roswell	O
Park	O
(	O
RP	O
;	O
Buffalo	O
","	O
NY	O
)	O
regimen	O
for	O
a	O
similar	O
length	O
of	O
time	O
.	O
	
A	O
total	O
of	O
"1,886"	O
patients	O
were	O
randomly	O
assigned	O
.	O
	
The	O
safety	O
population	O
comprised	O
"1,864"	O
patients	O
","	O
of	O
whom	O
938	O
received	O
XELOX	B-DRUG
and	O
926	O
received	O
FU	B-DRUG
/	O
LV	B-DRUG
.	O
	
Most	O
treatment-related	O
adverse	O
events	O
(	O
AEs	O
)	O
occurred	O
at	O
similar	O
rates	O
in	O
both	O
treatment	O
arms	O
.	O
	
However	O
","	O
patients	O
receiving	O
XELOX	B-DRUG
experienced	O
less	O
all-grade	O
diarrhea	B-TOXI
","	O
alopecia	B-TOXI
","	O
and	O
more	O
neurosensory	B-TOXI
toxicity	I-TOXI
","	O
vomiting	B-TOXI
","	O
and	O
hand-foot	B-TOXI
syndrome	I-TOXI
than	O
those	O
patients	O
receiving	O
FU	B-DRUG
/	O
LV	B-DRUG
.	O
	
Compared	O
with	O
Mayo	O
","	O
XELOX	B-DRUG
showed	O
fewer	O
grade	O
3	O
/	O
4	O
hematologic	B-TOXI
AE	I-TOXI
and	O
more	O
grade	O
3	O
/	O
4	O
gastrointestinal	B-TOXI
AE	I-TOXI
.	O
	
Compared	O
with	O
RP	O
","	O
XELOX	B-DRUG
showed	O
less	O
grade	O
3	O
/	O
4	O
gastrointestinal	B-TOXI
AE	I-TOXI
and	O
more	O
grade	O
3	O
/	O
4	O
hematologic	B-TOXI
AE	I-TOXI
.	O
	
As	O
expected	O
grade	O
3	O
/	O
4	O
neurosensory	B-TOXI
toxicity	I-TOXI
and	O
grade	O
3	O
hand-foot	B-TOXI
syndrome	I-TOXI
were	O
higher	O
with	O
XELOX	B-DRUG
.	O
	
Treatment-related	O
mortality	O
within	O
28	O
days	O
from	O
the	O
last	O
study	O
dose	O
was	O
0.6	O
%	O
in	O
the	O
XELOX	B-DRUG
group	O
and	O
0.6	O
%	O
in	O
the	O
FU	B-DRUG
/	O
LV	B-DRUG
group	O
.	O
	
XELOX	B-DRUG
has	O
a	O
manageable	O
tolerability	O
profile	O
in	O
the	O
adjuvant	O
setting	O
.	O
	
Efficacy	O
data	O
will	O
be	O
available	O
within	O
the	O
next	O
24	O
months	O
.	O
	
Phase	O
I	O
study	O
of	O
gefitinib	B-DRUG
","	O
irinotecan	B-DRUG
","	O
5-fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
determine	O
the	O
maximum	O
tolerated	O
doses	O
(	O
MTD	O
)	O
","	O
toxicities	O
","	O
efficacy	O
","	O
and	O
pharmacokinetics	O
(	O
PK	O
)	O
of	O
gefitinib	B-DRUG
combined	O
with	O
irinotecan	B-DRUG
","	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
and	O
leucovorin	B-DRUG
(	O
IFL	B-DRUG
)	O
in	O
patients	O
with	O
previously	O
untreated	O
advanced	O
colorectal	B-CANCER
cancer	I-CANCER
.	O
	
Starting	O
doses	O
were	O
gefitinib	B-DRUG
250	O
mg	O
/	O
day	O
orally	O
without	O
interruption	O
","	O
irinotecan	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
90	O
min	O
intravenous	O
(	O
i.v.	O
)	O
infusion	O
","	O
5-FU	B-DRUG
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
bolus	O
i.v.	O
and	O
leucovorin	B-DRUG
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
i.v.	O
on	O
days	O
1	O
and	O
8	O
of	O
a	O
21-day	O
cycle	O
.	O
	
Dose	O
escalations	O
involved	O
increasing	O
gefitinib	B-DRUG
to	O
500	O
mg	O
then	O
increasing	O
irinotecan	B-DRUG
to	O
125	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
5-FU	B-DRUG
to	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Twenty-four	O
patients	O
received	O
therapy	O
.	O
	
The	O
starting	O
doses	O
proved	O
to	O
be	O
the	O
MTD	O
","	O
as	O
attempts	O
to	O
increase	O
the	O
dose	O
of	O
either	O
gefitinib	B-DRUG
or	O
the	O
chemotherapeutic	O
agents	O
resulted	O
in	O
dose-limiting	O
toxicities	O
.	O
	
Gastrointestinal	B-TOXI
effects	I-TOXI
and	O
bone	B-TOXI
marrow	I-TOXI
suppression	I-TOXI
were	O
the	O
principal	O
toxicities	O
;	O
however	O
","	O
only	O
1	O
/	O
17	O
(	O
6	O
%	O
)	O
patients	O
treated	O
with	O
the	O
MTD	O
had	O
severe	O
(	O
grades	O
3月4日	O
)	O
diarrhea	B-TOXI
and	O
severe	O
neutropenia	B-TOXI
occurred	O
in	O
only	O
two	O
(	O
12	O
%	O
)	O
patients	O
.	O
	
Partial	O
responses	O
occurred	O
in	O
10	O
/	O
17	O
patients	O
receiving	O
the	O
MTD	O
and	O
another	O
five	O
had	O
stable	O
disease	O
.	O
	
Median	O
progression-free	O
and	O
overall	O
survivals	O
were	O
12.2	O
and	O
26.6	O
months	O
","	O
respectively	O
.	O
	
In	O
ten	O
patients	O
treated	O
with	O
the	O
MTD	O
","	O
the	O
steady-state	O
PK	O
of	O
gefitinib	B-DRUG
was	O
not	O
affected	O
by	O
IFL	B-DRUG
nor	O
did	O
gefitinib	B-DRUG
appear	O
to	O
influence	O
the	O
PK	O
of	O
either	O
irinotecan	B-DRUG
or	O
5-FU	B-DRUG
.	O
	
Gefitinib	B-DRUG
can	O
be	O
safely	O
combined	O
with	O
an	O
intermittent	O
weekly	O
schedule	O
of	O
IFL	B-DRUG
.	O
	
Evidence	O
of	O
promising	O
activity	O
should	O
encourage	O
further	O
clinical	O
evaluation	O
of	O
epidermal	O
growth	O
factor	O
receptor	O
tyrosine	O
kinase	O
inhibitors	O
","	O
such	O
as	O
gefitinib	B-DRUG
","	O
combined	O
with	O
multiagent	O
chemotherapy	O
for	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Phase	O
1b	O
dose	O
escalation	O
study	O
of	O
erlotinib	B-DRUG
in	O
combination	O
with	O
infusional	B-DRUG
5-Fluorouracil	I-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
oxaliplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Erlotinib	B-DRUG
(	O
Tarceva	O
)	O
is	O
a	O
potent	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
HER1	O
)	O
inhibitor	O
.	O
	
Infusional	B-DRUG
5-fluorouracil	I-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
leucovorin	B-DRUG
","	O
and	O
oxaliplatin	B-DRUG
(	O
FOLFOX	B-DRUG
)	O
is	O
a	O
standard	O
therapy	O
for	O
colorectal	B-CANCER
cancer	I-CANCER
.	O
	
This	O
trial	O
assessed	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
safety	O
","	O
preliminary	O
efficacy	O
","	O
and	O
pharmacokinetics	O
of	O
erlotinib	B-DRUG
combined	O
with	O
FOLFOX	B-DRUG
.	O
	
Patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
sequentially	O
enrolled	O
into	O
three	O
cohorts	O
(	O
cohort	O
1	O
:	O
100	O
mg	O
/	O
d	O
erlotinib	B-DRUG
","	O
65	O
mg	O
/	O
m	O
(	O
2	O
)	O
oxaliplatin	B-DRUG
","	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
leucovorin	B-DRUG
","	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
bolus	O
5-FU	B-DRUG
","	O
and	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
continuous	O
infusion	O
5-FU	B-DRUG
;	O
cohort	O
2	O
:	O
oxaliplatin	B-DRUG
increased	O
to	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
5-FU	B-DRUG
infusion	O
increased	O
to	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
;	O
and	O
cohort	O
3	O
:	O
erlotinib	B-DRUG
increased	O
to	O
150	O
mg	O
/	O
d	O
)	O
.	O
	
Thirty-two	O
patients	O
were	O
enrolled	O
(	O
23	O
with	O
colorectal	B-CANCER
cancer	I-CANCER
)	O
:	O
no	O
dose-limiting	O
toxicities	O
(	O
DLT	O
)	O
were	O
observed	O
in	O
cohort	O
1	O
In	O
cohort	O
2	O
","	O
two	O
of	O
nine	O
patients	O
experienced	O
a	O
DLT	O
(	O
both	O
diarrhea	B-TOXI
)	O
.	O
	
In	O
cohort	O
3	O
","	O
two	O
of	O
nine	O
patients	O
had	O
a	O
DLT	O
(	O
diarrhea	B-TOXI
and	O
staphylococcal	B-TOXI
septicemia	I-TOXI
)	O
.	O
	
Cohort	O
3	O
determined	O
the	O
MTD	O
cohort	O
and	O
expanded	O
to	O
17	O
patients	O
in	O
total	O
.	O
	
The	O
most	O
common	O
adverse	O
events	O
were	O
diarrhea	B-TOXI
","	O
nausea	B-TOXI
","	O
stomatitis	B-TOXI
","	O
and	O
rash	B-TOXI
(	O
primarily	O
mild	O
/	O
moderate	O
)	O
.	O
	
No	O
pharmacokinetics	O
interactions	O
were	O
observed	O
.	O
	
One	O
patient	O
(	O
colorectal	B-CANCER
cancer	I-CANCER
)	O
had	O
a	O
complete	O
response	O
","	O
seven	O
patients	O
had	O
a	O
partial	O
response	O
","	O
and	O
nine	O
had	O
stable	O
disease	O
.	O
	
The	O
MTD	O
was	O
defined	O
as	O
follows	O
:	O
150	O
mg	O
/	O
d	O
erlotinib	B-DRUG
","	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
oxaliplatin	B-DRUG
;	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
leucovorin	B-DRUG
","	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
bolus	O
5-FU	B-DRUG
","	O
and	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
infusion	O
5-FU	B-DRUG
.	O
	
At	O
the	O
MTD	O
","	O
the	O
combination	O
was	O
well	O
tolerated	O
and	O
showed	O
antitumor	O
activity	O
","	O
warranting	O
further	O
investigation	O
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
and	O
other	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
A	O
phase	O
I	O
/	O
II	O
study	O
of	O
irinotecan	B-DRUG
when	O
added	O
to	O
5-fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
and	O
pelvic	O
radiation	O
in	O
locally	O
advanced	B-CANCER
rectal	I-CANCER
cancer	I-CANCER
:	O
a	O
Colorectal	O
Clinical	O
Oncology	O
Group	O
Study	O
.	O
	
	
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
recommended	O
dose	O
of	O
irinotecan	B-DRUG
administered	O
as	O
a	O
5-day	O
schedule	O
synchronously	O
with	O
5-fluorouracil	B-DRUG
(	O
5FU	B-DRUG
)	O
","	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
and	O
preoperative	O
pelvic	O
radiation	O
(	O
45	O
Gy	O
)	O
for	O
primary	O
borderline	O
/	O
unresectable	O
","	O
locally	O
advanced	B-CANCER
rectal	I-CANCER
cancer	I-CANCER
.	O
	
The	O
study	O
used	O
escalating	O
doses	O
of	O
intravenous	O
irinotecan	B-DRUG
(	O
6	O
","	O
8	O
","	O
10	O
","	O
12	O
","	O
14	O
","	O
16	O
","	O
18	O
","	O
and	O
20	O
mg	O
m	O
(	O
-2	O
)	O
)	O
administered	O
on	O
days	O
1月5日	O
and	O
29-33	O
followed	O
by	O
low	O
dose	O
LV	B-DRUG
(	O
20	O
mg	O
m	O
(	O
-2	O
)	O
)	O
and	O
5FU	B-DRUG
(	O
350	O
mg	O
m	O
(	O
-2	O
)	O
over	O
1	O
h	O
)	O
in	O
sequential	O
cohorts	O
.	O
	
Preoperative	O
pelvic	O
radiotherapy	O
using	O
a	O
three-	O
or	O
four-field	O
technique	O
and	O
megavoltage	O
photons	O
comprised	O
45	O
Gy	O
given	O
in	O
25	O
fractions	O
","	O
1.8	O
Gy	O
per	O
fraction	O
.	O
	
Surgery	O
in	O
the	O
form	O
of	O
mesorectal	O
excision	O
was	O
performed	O
6月10日	O
weeks	O
later	O
.	O
	
Histopathological	O
examination	O
of	O
the	O
resected	O
specimen	O
was	O
performed	O
according	O
to	O
techniques	O
of	O
Quirke	O
","	O
and	O
compared	O
with	O
clinical	O
staging	O
.	O
	
A	O
distance	O
of	O
1	O
mm	O
or	O
less	O
between	O
the	O
peripheral	O
extent	O
of	O
the	O
tumour	O
and	O
the	O
radial	O
resection	O
margin	O
defined	O
an	O
involved	O
circumferential	O
resection	O
margin	O
(	O
CRM	O
)	O
.	O
	
The	O
MTD	O
was	O
determined	O
as	O
the	O
dose	O
causing	O
more	O
than	O
a	O
third	O
of	O
patients	O
to	O
have	O
a	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
defined	O
as	O
specific	O
grade	O
3	O
or	O
4	O
toxicities	O
.	O
	
Once	O
the	O
MTD	O
was	O
reached	O
","	O
a	O
further	O
14	O
patients	O
were	O
treated	O
at	O
the	O
dose	O
level	O
below	O
the	O
MTD	O
.	O
	
In	O
total	O
","	O
57	O
patients	O
received	O
irinotecan	B-DRUG
at	O
the	O
eight	O
dose	O
levels	O
.	O
	
The	O
final	O
cohort	O
reached	O
DLT	O
after	O
only	O
four	O
patients	O
had	O
been	O
enrolled	O
.	O
	
The	O
median	O
age	O
was	O
62	O
years	O
(	O
range	O
26-75	O
)	O
","	O
37	O
male	O
and	O
20	O
female	O
subjects	O
.	O
	
The	O
MTD	O
of	O
irinotecan	B-DRUG
in	O
this	O
schedule	O
was	O
20	O
mg	O
m	O
(	O
-2	O
)	O
when	O
three	O
out	O
of	O
four	O
patients	O
experienced	O
DLT	O
.	O
	
Dose	O
limiting	O
grade	O
3	O
or	O
4	O
diarrhoea	B-TOXI
was	O
reported	O
in	O
seven	O
out	O
of	O
57	O
patients	O
","	O
three	O
at	O
the	O
20	O
mg	O
m	O
(	O
-2	O
)	O
dose	O
level	O
.	O
	
Serious	O
haematological	B-TOXI
toxicity	I-TOXI
(	O
grade	O
3	O
)	O
was	O
minimal	O
and	O
reported	O
in	O
only	O
three	O
patients	O
;	O
one	O
grade	O
3	O
neutropaenia	B-TOXI
","	O
one	O
grade	O
4	O
neutropaenia	B-TOXI
and	O
one	O
grade	O
3	O
febrile	B-TOXI
neutropaenia	I-TOXI
and	O
anaemia	B-TOXI
.	O
	
Compliance	O
was	O
good	O
with	O
93	O
and	O
89	O
%	O
of	O
patients	O
completing	O
radiotherapy	O
and	O
chemotherapy	O
","	O
respectively	O
.	O
	
The	O
remaining	O
patients	O
had	O
only	O
minor	O
deviations	O
from	O
protocol	O
therapy	O
.	O
	
Eight	O
patients	O
did	O
not	O
proceed	O
to	O
surgery	O
","	O
in	O
six	O
cases	O
because	O
they	O
remained	O
unresectable	O
or	O
had	O
developed	O
metastatic	O
disease	O
","	O
one	O
patient	O
was	O
unfit	O
for	O
surgery	O
and	O
one	O
died	B-TOXI
as	O
a	O
result	O
of	O
complications	O
from	O
radiotherapy	O
.	O
	
Forty-nine	O
patients	O
underwent	O
a	O
potentially	O
curative	O
surgical	O
resection	O
.	O
	
Histopathological	O
examination	O
of	O
the	O
resected	O
specimen	O
demonstrated	O
pCR	O
12	O
out	O
of	O
49	O
(	O
24	O
%	O
)	O
and	O
12	O
out	O
of	O
57	O
(	O
21	O
%	O
)	O
overall	O
.	O
	
A	O
histologically	O
confirmed	O
clear	O
circumferential	O
resection	O
margin	O
(	O
CRM	O
)	O
was	O
achieved	O
in	O
39	O
out	O
of	O
49	O
(	O
80	O
%	O
)	O
of	O
those	O
resected	O
","	O
and	O
39	O
out	O
of	O
57	O
(	O
68	O
%	O
)	O
overall	O
.	O
	
In	O
conclusion	O
","	O
MTD	O
with	O
this	O
scheduled	O
regimen	O
of	O
irinotecan	B-DRUG
is	O
20	O
mg	O
m	O
(	O
-2	O
)	O
(	O
days	O
1月5日	O
and	O
29-33	O
)	O
.	O
	
The	O
acceptable	O
toxicity	O
and	O
compliance	O
at	O
18	O
mg	O
m	O
(	O
-2	O
)	O
recommend	O
testing	O
this	O
dose	O
in	O
future	O
phase	O
III	O
studies	O
.	O
	
The	O
tumour	O
downstaging	O
and	O
complete	O
resection	O
rates	O
(	O
negative	O
CRM	O
)	O
are	O
encouragingly	O
high	O
for	O
this	O
very	O
locally	O
advanced	O
group	O
.	O
	
Randomized	O
phase	O
II	O
trial	O
of	O
paclitaxel	B-DRUG
plus	O
carboplatin	B-DRUG
or	O
gemcitabine	B-DRUG
plus	O
cisplatin	B-DRUG
in	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
2	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
patients	O
:	O
ECOG	O
1599	O
.	O
	
	
Appropriate	O
therapy	O
for	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
(	O
ECOG	O
)	O
performance	O
status	O
(	O
PS	O
)	O
-2	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
remains	O
challenging	O
.	O
	
PS-2	O
patients	O
on	O
ECOG	O
1594	O
had	O
a	O
median	O
survival	O
(	O
MS	O
)	O
of	O
only	O
4.1	O
months	O
and	O
1-year	O
overall	O
survival	O
(	O
OS	O
)	O
of	O
19	O
%	O
.	O
	
Three	O
percent	O
had	O
grade	O
5	O
toxicity	O
.	O
	
ECOG	O
1599	O
","	O
the	O
first	O
PS	O
2-specific	O
","	O
US	O
cooperative	O
group	O
trial	O
for	O
treatment-na茂ve	O
advanced	B-CANCER
NSCLC	I-CANCER
","	O
randomly	O
assigned	O
patients	O
to	O
dose-attenuated	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
(	O
the	O
least	O
toxic	O
regimen	O
in	O
ECOG	O
1594	O
)	O
or	O
gemcitabine	B-DRUG
/	O
cisplatin	B-DRUG
(	O
which	O
yielded	O
an	O
MS	O
of	O
7.9	O
months	O
in	O
PS-2	O
patients	O
)	O
.	O
	
Patients	O
received	O
either	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
concentration-time	O
curve	O
","	O
6	O
)	O
and	O
paclitaxel	B-DRUG
200	O
mg	O
/	O
m2	O
every	O
3	O
weeks	O
(	O
CbP	O
)	O
or	O
gemcitabine	B-DRUG
1	O
g	O
/	O
m2	O
days	O
1	O
and	O
8	O
and	O
cisplatin	B-DRUG
60	O
mg	O
/	O
m2	O
day	O
1	O
every	O
3	O
weeks	O
(	O
CG	O
)	O
.	O
	
One	O
hundred	O
three	O
patients	O
were	O
enrolled	O
;	O
100	O
proved	O
eligible	O
.	O
	
Median	O
age	O
was	O
66	O
years	O
;	O
46	O
%	O
had	O
at	O
least	O
5	O
%	O
weight	B-TOXI
loss	I-TOXI
;	O
88	O
%	O
had	O
stage	O
IV	O
or	O
recurrent	B-TOXI
disease	I-TOXI
.	O
	
Median	O
number	O
of	O
cycles	O
administered	O
was	O
three	O
per	O
arm	O
.	O
	
CbP	O
featured	O
more	O
grade	O
3	O
neutropathy	B-TOXI
(	O
10	O
%	O
v	O
0	O
%	O
)	O
and	O
more	O
grade	O
&	O
gt	O
;	O
or	O
=	O
3	O
neutropenia	B-TOXI
(	O
59	O
%	O
v	O
33	O
%	O
)	O
","	O
whereas	O
CG	O
yielded	O
more	O
grade	O
3	O
thrombocytopenia	B-TOXI
(	O
33	O
%	O
v	O
14	O
%	O
)	O
","	O
more	O
grade	O
3	O
fatigue	B-TOXI
(	O
22	O
%	O
v	O
14	O
%	O
)	O
","	O
and	O
more	O
grade	O
&	O
gt	O
;	O
or	O
=	O
1	O
creatinine	O
elevations	O
(	O
43	O
%	O
v	O
6	O
%	O
)	O
.	O
	
One	O
grade	O
5	O
toxicity	O
","	O
confined	O
to	O
the	O
CbP	O
arm	O
","	O
occurred	O
.	O
	
Response	O
rate	O
","	O
time	O
to	O
progression	O
","	O
MS	O
","	O
and	O
1-year	O
OS	O
rates	O
for	O
CG	O
and	O
CbP	O
","	O
were	O
23	O
%	O
","	O
4.8	O
months	O
","	O
6.9	O
months	O
","	O
and	O
25	O
%	O
","	O
and	O
14	O
%	O
","	O
4.2	O
months	O
","	O
6.2	O
months	O
","	O
and	O
19	O
%	O
","	O
respectively	O
.	O
	
Platinum-based	B-DRUG
combination	O
chemotherapy	O
for	O
PS-2	O
patients	O
with	O
NSCLC	B-CANCER
is	O
feasible	O
with	O
acceptable	O
toxicity	O
","	O
but	O
survival	O
in	O
these	O
patients	O
remains	O
inferior	O
to	O
that	O
of	O
PS-0	O
to	O
-1	O
patients	O
.	O
	
Phase	O
II	O
study	O
of	O
paclitaxel	B-DRUG
plus	O
gemcitabine	B-DRUG
salvage	O
chemotherapy	O
for	O
germ	B-CANCER
cell	I-CANCER
tumors	I-CANCER
after	O
progression	O
following	O
high-dose	O
chemotherapy	O
with	O
tandem	O
transplant	O
.	O
	
	
To	O
determine	O
long-term	O
survival	O
and	O
potential	O
cure	O
with	O
salvage	O
chemotherapy	O
with	O
paclitaxel	B-DRUG
plus	O
gemcitabine	B-DRUG
after	O
progression	O
after	O
both	O
cisplatin	B-DRUG
combination	O
chemotherapy	O
and	O
subsequent	O
high-dose	O
chemotherapy	O
with	O
tandem	O
transplantation	O
.	O
	
One	O
hundred	O
eighty-four	O
patients	O
received	O
salvage	O
high-dose	O
chemotherapy	O
at	O
Indiana	O
University	O
(	O
Indianapolis	O
","	O
IN	O
)	O
from	O
February	O
1996	O
to	O
December	O
2004	O
.	O
	
After	O
further	O
evidence	O
of	O
progressive	O
disease	O
","	O
32	O
patients	O
were	O
subsequently	O
treated	O
with	O
paclitaxel	B-DRUG
100	O
mg	O
/	O
n2	O
over	O
1	O
hour	O
plus	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m2	O
over	O
30	O
minutes	O
","	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
every	O
4	O
weeks	O
for	O
a	O
maximum	O
of	O
six	O
courses	O
.	O
	
This	O
is	O
a	O
retrospective	O
review	O
of	O
this	O
patient	O
population	O
.	O
	
Patients	O
were	O
evaluated	O
for	O
response	O
","	O
duration	O
of	O
response	O
","	O
and	O
survival	O
.	O
	
Patients	O
were	O
ineligible	O
if	O
they	O
received	O
prior	O
paclitaxel	B-DRUG
or	O
gemcitabine	B-DRUG
.	O
	
Ten	O
(	O
31	O
%	O
)	O
of	O
32	O
patients	O
achieved	O
objective	O
response	O
","	O
including	O
four	O
partial	O
remissions	O
(	O
-2	O
to	O
6-month	O
duration	O
)	O
and	O
six	O
complete	O
responses	O
(	O
CRs	O
)	O
.	O
	
Four	O
of	O
these	O
six	O
CRs	O
(	O
12.5	O
%	O
of	O
total	O
patient	O
population	O
)	O
are	O
continuously	O
disease	O
free	O
(	O
NED	O
)	O
with	O
paclitaxel	B-DRUG
plus	O
gemcitabine	B-DRUG
alone	O
(	O
no	O
postchemotherapy	O
surgery	O
)	O
at	O
more	O
than	O
20	O
","	O
40	O
","	O
44	O
","	O
and	O
57	O
months	O
from	O
start	O
of	O
paclitaxel	B-DRUG
plus	O
gemcitabine	B-DRUG
","	O
respectively	O
.	O
	
One	O
additional	O
CR	O
is	O
currently	O
NED	O
more	O
than	O
63	O
months	O
after	O
paclitaxel	B-DRUG
plus	O
gemcitabine	B-DRUG
with	O
two	O
subsequent	O
resections	O
of	O
carcinoma	B-CANCER
.	O
	
Long-term	O
disease-free	O
survival	O
is	O
possible	O
with	O
paclitaxel	B-DRUG
plus	O
gemcitabine	B-DRUG
in	O
this	O
patient	O
population	O
that	O
progressed	O
after	O
high-dose	O
chemotherapy	O
","	O
and	O
had	O
not	O
received	O
prior	O
paclitaxel	B-DRUG
or	O
gemcitabine	B-DRUG
.	O
	
A	O
phase	O
I	O
study	O
of	O
bi-weekly	O
administration	O
of	O
24-h	O
gemcitabine	B-DRUG
followed	O
by	O
24-h	O
irinotecan	B-DRUG
in	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
To	O
determine	O
the	O
maximal	O
tolerated	O
doses	O
(	O
MTD	O
)	O
and	O
dose-limiting	O
toxicities	O
(	O
DLT	O
)	O
of	O
combination	O
of	O
24-h	O
infusions	O
of	O
gemcitabine	B-DRUG
and	O
irinotecan	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Twenty-four	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
received	O
gemcitabine	B-DRUG
as	O
a	O
24-h	O
IV	O
infusion	O
followed	O
by	O
a	O
24-h	O
infusion	O
of	O
irinotecan	B-DRUG
every	O
2	O
weeks	O
.	O
	
Pharmacokinetic	O
parameters	O
of	O
both	O
drugs	O
and	O
their	O
metabolites	O
were	O
estimated	O
by	O
using	O
non-compartmental	O
methods	O
.	O
	
Twenty-four	O
patients	O
were	O
fully	O
evaluable	O
for	O
toxicity	O
.	O
	
DLT	O
was	O
observed	O
in	O
two	O
of	O
six	O
patients	O
at	O
irinotecan	B-DRUG
/	O
gemcitabine	B-DRUG
110	O
/	O
150	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
grade	O
3	O
diarrhea	B-TOXI
and	O
grade	O
3	O
GI	O
bleeding	B-TOXI
)	O
.	O
	
No	O
patient	O
developed	O
acute	B-TOXI
cholinergic	I-TOXI
symptoms	I-TOXI
at	O
any	O
dose	O
.	O
	
Other	O
toxicities	O
were	O
&	O
lt	O
;	O
or	O
#NAME?	O
2	O
nausea	B-TOXI
","	O
vomiting	B-TOXI
","	O
and	O
fatigue	B-TOXI
.	O
	
Tumor	O
responses	O
were	O
observed	O
in	O
three	O
patients	O
(	O
one	O
CR	O
:	O
cholangiocarcinoma	B-CANCER
;	O
two	O
PR	O
:	O
SCLC	B-CANCER
","	O
gastric	B-CANCER
neuroendocrine	I-CANCER
tumor	I-CANCER
)	O
.	O
	
Stable	O
disease	O
&	O
gt	O
;	O
3	O
months	O
was	O
found	O
in	O
six	O
patients	O
including	O
five	O
patients	O
who	O
had	O
failed	O
short	O
infusions	O
of	O
either	O
drug	O
.	O
	
Pharmacokinetic	O
analysis	O
showed	O
that	O
C	O
(	O
max	O
)	O
of	O
each	O
drug	O
and	O
active	O
metabolites	O
were	O
dose-dependent	O
.	O
	
High	O
dose	O
of	O
gemcitabine	B-DRUG
increased	O
C	O
(	O
max	O
)	O
","	O
AUC	O
","	O
and	O
T	O
(	O
1	O
/	O
2	O
)	O
of	O
irinotecan	B-DRUG
.	O
	
However	O
","	O
gemcitabine	B-DRUG
had	O
minimal	O
effects	O
on	O
SN-38	O
.	O
	
The	O
recommended	O
dose	O
for	O
Phase	O
II	O
studies	O
is	O
gemcitabine	B-DRUG
125	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
as	O
a	O
24-h	O
IV	O
infusion	O
on	O
D1	O
and	O
D15	O
","	O
followed	O
by	O
a	O
24-h	O
IV	O
infusion	O
of	O
irinotecan	B-DRUG
110	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
D2	O
and	O
D16	O
.	O
	
Both	O
pretreated	O
patients	O
and	O
chemo-naive	O
patients	O
seem	O
to	O
tolerate	O
higher	O
doses	O
of	O
this	O
combination	O
without	O
significant	O
toxicities	O
.	O
	
Objective	O
responses	O
among	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
","	O
in	O
particular	O
cholangiocarcinoma	B-CANCER
and	O
small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
merits	O
further	O
investigation	O
.	O
	
Dose	O
escalation	O
of	O
docetaxel	B-DRUG
and	O
ifosfamide	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
failing	O
prior	O
anthracyclines	B-DRUG
:	O
mature	O
results	O
of	O
a	O
phase	O
I-II	O
study	O
.	O
	
	
Single-agent	O
docetaxel	B-DRUG
and	O
ifosfamide	B-DRUG
are	O
clinically	O
active	O
in	O
anthracycline-pretreated	B-DRUG
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
We	O
conducted	O
a	O
phase	O
I-II	O
study	O
aiming	O
to	O
define	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
the	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
","	O
and	O
the	O
activity	O
of	O
the	O
docetaxel-ifosfamide	B-DRUG
combination	O
in	O
this	O
setting	O
.	O
	
Cohorts	O
of	O
3月6日	O
patients	O
with	O
histologically	O
confirmed	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
after	O
prior	O
anthracycline-based	B-DRUG
chemotherapy	O
were	O
treated	O
at	O
successive	O
dose	O
levels	O
(	O
DLs	O
)	O
with	O
escalated	O
doses	O
of	O
docetaxel	B-DRUG
(	O
70-100	O
mg	O
/	O
m	O
(	O
2	O
)	O
over	O
1	O
h	O
on	O
day	O
1	O
)	O
","	O
followed	O
by	O
ifosfamide	B-DRUG
5月6日	O
g	O
/	O
m	O
(	O
2	O
)	O
divided	O
over	O
days	O
1	O
and	O
2	O
(	O
2.5-3.0	O
g	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
over	O
1	O
h	O
)	O
","	O
and	O
recycled	O
every	O
21	O
days	O
.	O
	
G-CSF	B-DRUG
was	O
added	O
once	O
dose-limiting	O
neutropenia	B-TOXI
was	O
encountered	O
at	O
a	O
certain	O
DL	O
and	O
planned	O
to	O
be	O
incorporated	O
prophylactically	O
in	O
subsequent	O
higher	O
DLs	O
.	O
	
Sixty-five	O
patients	O
(	O
median	O
age	O
57	O
years	O
","	O
range	O
32-72	O
)	O
and	O
performance	O
status	O
(	O
PS	O
)	O
(	O
World	O
Health	O
Organization-WHO	O
)	O
of	O
1	O
(	O
range	O
0-2	O
)	O
were	O
treated	O
at	O
5	O
DLs	O
as	O
follows	O
:	O
21	O
in	O
phase	O
I	O
DLs	O
(	O
DL1	O
:	O
3	O
","	O
DL2	O
:	O
6	O
","	O
DL3	O
:	O
3	O
","	O
DL4	O
:	O
6	O
","	O
and	O
DL5	O
:	O
3	O
)	O
and	O
the	O
remaining	O
44	O
were	O
treated	O
at	O
DL4	O
(	O
total	O
of	O
50	O
patients	O
at	O
DL4	O
)	O
","	O
which	O
was	O
defined	O
as	O
the	O
level	O
for	O
phase	O
II	O
testing	O
.	O
	
All	O
patients	O
were	O
evaluable	O
for	O
toxicity	O
and	O
62	O
for	O
response	O
.	O
	
DLT	O
(	O
with	O
the	O
addition	O
of	O
G-CSF	B-DRUG
after	O
DL2	O
)	O
was	O
reached	O
at	O
DL5	O
with	O
2	O
/	O
3	O
initial	O
patients	O
developing	O
febrile	B-TOXI
neutropenia	I-TOXI
.	O
	
Clinical	O
response	O
rates	O
(	O
RRs	O
)	O
","	O
on	O
an	O
intention-to-treat	O
basis	O
","	O
in	O
phase	O
II	O
were	O
56	O
%	O
(	O
95	O
%	O
CI	O
42.2-69.7	O
)	O
:	O
complete	O
remission	O
(	O
CR	O
)	O
4	O
","	O
partial	O
remission	O
(	O
PR	O
)	O
24	O
","	O
stable	O
disease	O
(	O
SD	O
)	O
10	O
and	O
progressive	O
disease	O
(	O
PD	O
)	O
12	O
.	O
	
The	O
median	O
response	O
duration	O
was	O
7	O
months	O
(	O
range	O
3月24日	O
)	O
","	O
the	O
median	O
time	O
to	O
progression	O
(	O
TTP	O
)	O
6.5	O
months	O
(	O
range	O
0.1-26	O
)	O
","	O
and	O
the	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
13	O
months	O
(	O
range	O
0.1-33	O
)	O
.	O
	
Grade	O
3	O
/	O
4	O
toxicities	O
included	O
neutropenia	B-TOXI
in	O
72	O
%	O
of	O
patients-with	O
60	O
%	O
developing	O
grade	O
4	O
neutropenia	B-TOXI
(	O
&	O
lt	O
;	O
/	O
=	O
7	O
days	O
)	O
and	O
10	O
%	O
of	O
these	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
FN	O
)	O
","	O
while	O
no	O
grade	O
3	O
/	O
4	O
thrombocytopenia	B-TOXI
was	O
observed	O
.	O
	
Other	O
toxicities	O
included	O
grade	O
2	O
peripheral	B-TOXI
neuropathy	I-TOXI
only	O
in	O
10	O
%	O
of	O
the	O
patients	O
","	O
grade	O
1	O
/	O
2	O
reversible	O
CNS	B-TOXI
toxicity	I-TOXI
in	O
16	O
%	O
","	O
no	O
renal	B-TOXI
toxicity	I-TOXI
","	O
grade	O
2	O
myalgias	B-TOXI
in	O
8	O
%	O
","	O
grade	O
3	O
diarrhea	B-TOXI
in	O
8	O
%	O
","	O
skin	B-TOXI
/	I-TOXI
nail	I-TOXI
toxicity	I-TOXI
in	O
14	O
%	O
","	O
and	O
grade	O
2	O
fluid	B-TOXI
retention	I-TOXI
in	O
2	O
%	O
.	O
	
One	O
patient	O
treated	O
at	O
the	O
phase	O
II	O
part	O
of	O
the	O
study	O
died	B-TOXI
of	O
acute	B-TOXI
liver	I-TOXI
failure	I-TOXI
after	O
the	O
first	O
cycle	O
.	O
	
The	O
present	O
phase	O
I-II	O
study	O
determined	O
the	O
feasibility	O
","	O
defined	O
the	O
MTD	O
and	O
demonstrated	O
the	O
encouraging	O
activity	O
of	O
the	O
docetaxel-ifosfamide	B-DRUG
combination	O
in	O
the	O
phase	O
II	O
part	O
of	O
the	O
study	O
.	O
	
Therefore	O
","	O
future	O
randomized	O
phase	O
III	O
studies	O
versus	O
single-agent	O
docetaxel	B-DRUG
or	O
combinations	O
of	O
the	O
latter	O
with	O
other	O
active	O
agents	O
are	O
warranted	O
.	O
	
A	O
phase	O
I	O
trial	O
of	O
BMS-247550	B-DRUG
(	O
NSC	O
#	O
710428	O
)	O
and	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
establish	O
the	O
maximum	O
tolerated	O
dose	O
and	O
define	O
the	O
dose-limiting	O
toxicity	O
of	O
the	O
investigational	O
epothilone	B-DRUG
BMS-247550	B-DRUG
in	O
combination	O
with	O
fixed	O
dose-rate	O
gemcitabine	B-DRUG
.	O
	
Patients	O
with	O
advanced	O
","	O
recurrent	B-CANCER
solid	I-CANCER
tumors	I-CANCER
who	O
had	O
received	O
&	O
lt	O
;	O
or=2	O
prior	O
cytotoxic	O
regimens	O
for	O
recurrent	O
disease	O
were	O
treated	O
with	O
gemcitabine	B-DRUG
over	O
90	O
min	O
on	O
days	O
1	O
and	O
8	O
plus	O
BMS-247550	B-DRUG
over	O
3	O
h	O
on	O
day	O
8	O
","	O
every	O
21	O
days	O
in	O
a	O
phase	O
I	O
study	O
.	O
	
Dose-limiting	O
toxicity	O
definitions	O
were	O
based	O
on	O
severe	O
myelosuppression	B-TOXI
","	O
or	O
grade	O
3	O
or	O
4	O
treatment-related	O
non-hematologic	B-TOXI
toxicity	I-TOXI
","	O
or	O
dose	O
delay	O
of	O
greater	O
than	O
2	O
weeks	O
due	O
to	O
treatment	O
toxicity	O
observed	O
in	O
the	O
first	O
treatment	O
cycle	O
.	O
	
Dose	O
cohort	O
1	O
received	O
gemcitabine	B-DRUG
900	O
mg	O
/	O
m2	O
and	O
BMS-247550	B-DRUG
20	O
mg	O
/	O
m2	O
.	O
	
Grade	O
4	O
neutropenia	B-TOXI
lasting	I-TOXI
&	O
gt	O
;	O
or=7	O
days	O
occurred	O
in	O
one	O
of	O
six	O
patients	O
.	O
	
Two	O
of	O
three	O
patients	O
in	O
cohort	O
2	O
(	O
gemcitabine	B-DRUG
900	O
mg	O
/	O
m2	O
plus	O
BMS-247550	B-DRUG
30	O
mg	O
/	O
m2	O
)	O
had	O
dose-limiting	O
toxicities	O
of	O
grade	O
4	O
neutropenia	B-TOXI
.	O
	
An	O
additional	O
three	O
patients	O
were	O
treated	O
at	O
dose	O
level	O
1	O
with	O
no	O
additional	O
dose-limiting	O
toxicities	O
observed	O
.	O
	
At	O
an	O
intermediate	O
dose	O
level	O
(	O
gemcitabine	B-DRUG
750	O
mg	O
/	O
m2	O
plus	O
BMS-247550	B-DRUG
30	O
mg	O
/	O
m2	O
)	O
","	O
two	O
of	O
six	O
patients	O
experienced	O
a	O
dose-limiting	O
toxicity	O
(	O
febrile	B-TOXI
neutropenia	I-TOXI
and	O
grade	O
3	O
hypophosphatemia	B-TOXI
in	O
1	O
","	O
grade	O
3	O
hypophosphatemia	B-TOXI
and	O
grade	O
3	O
hyponatremia	B-TOXI
in	O
(	O
1	O
)	O
","	O
and	O
five	O
of	O
six	O
patients	O
experienced	O
dose	O
delays	O
.	O
	
In	O
the	O
final	O
cohort	O
(	O
gemcitabine	B-DRUG
750	O
mg	O
/	O
m2	O
plus	O
BMS-247550	B-DRUG
25	O
mg	O
/	O
m2	O
)	O
","	O
two	O
of	O
two	O
patients	O
experienced	O
a	O
dose-limiting	O
toxicity	O
.	O
	
Treatment-related	O
toxicities	O
included	O
neutropenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
neutropenic	B-TOXI
fever	I-TOXI
","	O
hypophosphatemia	B-TOXI
","	O
and	O
hyponatremia	B-TOXI
.	O
	
Nine	O
of	O
14	O
patients	O
evaluable	O
for	O
response	O
had	O
stable	O
disease	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
for	O
this	O
schedule	O
is	O
gemcitabine	B-DRUG
900	O
mg	O
/	O
m2	O
over	O
90	O
min	O
days	O
1	O
and	O
8	O
plus	O
BMS-247550	B-DRUG
20	O
mg	O
/	O
m2	O
on	O
day	O
8	O
Attempts	O
to	O
increase	O
the	O
dose	O
of	O
BMS-247550	B-DRUG
by	O
decreasing	O
the	O
gemcitabine	B-DRUG
dose	O
did	O
not	O
sufficiently	O
ameliorate	O
myelosuppression	B-TOXI
.	O
	
Stable	O
disease	O
was	O
observed	O
in	O
some	O
patients	O
with	O
prior	O
taxane	B-DRUG
exposure	O
.	O
	
Radioembolization	O
of	O
liver	O
metastases	O
from	O
colorectal	B-CANCER
cancer	I-CANCER
using	O
yttrium-90	O
microspheres	O
with	O
concomitant	O
systemic	O
oxaliplatin	B-DRUG
","	O
fluorouracil	B-DRUG
","	O
and	O
leucovorin	B-DRUG
chemotherapy	O
.	O
	
	
Liver	O
metastases	O
represent	O
the	O
principal	O
cause	O
of	O
death	B-TOXI
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
CRC	B-CANCER
)	O
.	O
	
Injection	O
of	O
resin	O
microspheres	O
(	O
SIR	O
Spheres	O
)	O
=--	O
containing	O
the	O
beta-emitter	O
","	O
yttrium-90	O
=--	O
into	O
the	O
arterial	O
supply	O
of	O
the	O
liver	O
can	O
cause	O
radioembolization	O
of	O
metastases	O
.	O
	
This	O
treatment	O
has	O
not	O
been	O
tested	O
with	O
the	O
radiosensitizing	O
chemotherapy	O
","	O
oxaliplatin	B-DRUG
","	O
which	O
appears	O
synergistic	O
in	O
the	O
treatment	O
of	O
CRC	B-CANCER
when	O
combined	O
with	O
fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
(	O
FOLFOX	B-DRUG
)	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
SIR-Spheres	O
therapy	O
with	O
modified	O
FOLFOX4	B-DRUG
systemic	O
chemotherapy	O
was	O
conducted	O
in	O
patients	O
with	O
inoperable	O
liver	O
metastases	O
from	O
CRC	B-CANCER
who	O
had	O
not	O
previously	O
received	O
chemotherapy	O
for	O
metastatic	O
disease	O
.	O
	
Oxaliplatin	B-DRUG
(	O
30	O
to	O
85	O
mg	O
/	O
m2	O
)	O
was	O
administered	O
for	O
the	O
first	O
three	O
cycles	O
with	O
full	O
FOLFOX4	B-DRUG
doses	O
from	O
cycle	O
4	O
until	O
cycle	O
12	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
toxicity	O
.	O
	
Twenty	O
patients	O
were	O
enrolled	O
onto	O
the	O
study	O
.	O
	
Five	O
patients	O
experienced	O
National	O
Cancer	O
Institute	O
(	O
NCI	O
;	O
Bethesda	O
","	O
MD	O
)	O
grade	O
3	O
abdominal	B-TOXI
pain	I-TOXI
","	O
two	O
of	O
whom	O
had	O
microsphere-induced	O
gastric	B-TOXI
ulcers	I-TOXI
.	O
	
The	O
dose-limiting	O
toxicity	O
was	O
grade	O
3	O
or	O
4	O
neutropenia	B-TOXI
","	O
which	O
was	O
recorded	O
in	O
12	O
patients	O
.	O
	
One	O
episode	O
of	O
transient	O
grade	O
3	O
hepatotoxicity	B-TOXI
was	O
recorded	O
.	O
	
Mean	O
splenic	O
volume	O
increased	O
by	O
92	O
%	O
following	O
6	O
months	O
of	O
protocol	O
therapy	O
.	O
	
Partial	O
responses	O
were	O
demonstrated	O
in	O
18	O
patients	O
and	O
stable	O
disease	O
in	O
two	O
patients	O
.	O
	
Two	O
patients	O
underwent	O
partial	O
hepatic	O
resection	O
following	O
protocol	O
therapy	O
.	O
	
Median	O
progression-free	O
survival	O
was	O
9.3	O
months	O
","	O
and	O
median	O
time	O
to	O
progression	O
in	O
the	O
liver	O
was	O
12.3	O
months	O
.	O
	
The	O
maximum-tolerated	O
dose	O
was	O
60	O
mg	O
/	O
m2	O
of	O
oxaliplatin	B-DRUG
for	O
the	O
first	O
three	O
cycles	O
","	O
with	O
full	O
FOLFOX4	B-DRUG
doses	O
thereafter	O
.	O
	
This	O
chemoradiation	O
regime	O
merits	O
evaluation	O
in	O
phase	O
II-III	O
trials	O
.	O
	
Imatinib	B-DRUG
mesylate	I-DRUG
for	O
targeting	O
the	O
platelet-derived	O
growth	O
factor	O
beta	O
receptor	O
in	O
combination	O
with	O
fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
in	O
patients	O
with	O
refractory	O
pancreatic	O
","	O
bile	O
duct	O
","	O
colorectal	O
","	O
or	O
gastric	B-CANCER
cancer	I-CANCER
=--	O
a	O
dose-escalation	O
Phase	O
I	O
trial	O
.	O
	
	
In	O
previous	O
experimental	O
models	O
","	O
because	O
of	O
its	O
ability	O
to	O
inhibit	O
the	O
activity	O
of	O
platelet-derived	O
growth	O
factor	O
beta	O
receptor	O
","	O
imatinib	B-DRUG
decreased	O
the	O
interstitial	O
fluid	O
pressure	O
and	O
improved	O
the	O
delivery	O
and	O
efficacy	O
of	O
anticancer	O
drugs	O
","	O
including	O
fluorouracil	B-DRUG
.	O
	
The	O
objective	O
of	O
this	O
Phase	O
I	O
study	O
was	O
to	O
define	O
the	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
and	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
imatinib	B-DRUG
in	O
combination	O
with	O
fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
in	O
patients	O
with	O
chemotherapy-refractory	O
gastrointestinal	B-CANCER
cancer	I-CANCER
.	O
	
A	O
3-patient	O
cohort	O
dose-escalating	O
study	O
design	O
was	O
used	O
.	O
	
Patients	O
received	O
leucovorin	B-DRUG
200	O
mg	O
/	O
m2	O
followed	O
by	O
fluorouracil	B-DRUG
2000	O
mg	O
/	O
m2	O
as	O
a	O
24-hour	O
infusion	O
on	O
Days	O
1	O
and	O
2	O
combined	O
with	O
imatinib	B-DRUG
on	O
Days	O
-4	O
","	O
-3	O
","	O
-2	O
","	O
-1	O
","	O
1	O
","	O
2	O
","	O
3	O
","	O
and	O
4	O
Cycles	O
were	O
repeated	O
every	O
2	O
weeks	O
","	O
and	O
the	O
imatinib	B-DRUG
dose	O
was	O
escalated	O
from	O
300	O
mg	O
daily	O
to	O
700	O
mg	O
daily	O
in	O
100-mg	O
steps	O
.	O
	
Thirty	O
patients	O
were	O
enrolled	O
at	O
5	O
dose	O
levels	O
.	O
	
Frequent	O
and	O
dose-dependant	O
National	O
Cancer	O
Institute	O
Common	O
Toxicity	O
Criteria	O
grade	O
1月4日	O
adverse	O
events	O
with	O
suspected	O
relation	O
to	O
the	O
treatment	O
were	O
anemia	B-TOXI
(	O
43	O
%	O
)	O
","	O
nausea	B-TOXI
(	O
33	O
%	O
)	O
","	O
fluid	B-TOXI
retention	I-TOXI
(	O
27	O
%	O
)	O
","	O
elevated	B-TOXI
serum	I-TOXI
gamma-glutamyl-transpeptidase	I-TOXI
(	O
20	O
%	O
)	O
","	O
and	O
diarrhea	B-TOXI
.	O
	
DLTs	O
were	O
severe	O
neutropenia	B-TOXI
","	O
central	B-TOXI
fluid	I-TOXI
retention	I-TOXI
","	O
and	O
severe	O
nausea	B-TOXI
observed	O
in	O
1	O
patient	O
each	O
","	O
resulting	O
in	O
an	O
MTD	O
for	O
imatinib	B-DRUG
of	O
600	O
mg	O
per	O
day	O
.	O
	
There	O
were	O
no	O
differences	O
in	O
imatinib	B-DRUG
pharmacokinetics	O
before	O
or	O
during	O
chemotherapy	O
.	O
	
A	O
minor	O
response	O
was	O
observed	O
;	O
and	O
signs	O
of	O
clinical	O
activity	O
","	O
including	O
the	O
resolution	O
of	O
ascites	B-TOXI
and	O
improvement	O
in	O
performance	O
status	O
","	O
were	O
noted	O
in	O
some	O
patients	O
.	O
	
The	O
combination	O
of	O
biweekly	O
fluorouracil	B-DRUG
/	O
leucovorin	B-DRUG
and	O
imatinib	B-DRUG
600	O
mg	O
daily	O
given	O
in	O
a	O
week-on	O
/	O
week-off	O
schedule	O
was	O
feasible	O
and	O
safe	O
.	O
	
Nausea	B-TOXI
and	O
fluid	B-TOXI
retention	I-TOXI
represented	O
the	O
DLTs	O
.	O
	
Weekly	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
(	O
PC-W	O
)	O
for	O
patients	O
with	O
primary	O
advanced	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
:	O
results	O
of	O
a	O
multicenter	O
phase-II	O
study	O
of	O
the	O
NOGGO	O
.	O
	
	
To	O
study	O
the	O
toxicity	O
and	O
efficacy	O
of	O
weekly	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
(	O
PC-W	O
)	O
in	O
women	O
with	O
primary	O
ovarian	B-CANCER
cancer	I-CANCER
This	O
investigation	O
extended	O
a	O
phase-I	O
dose	O
finding	O
study	O
and	O
was	O
approved	O
by	O
the	O
institutional	O
review	O
boards	O
of	O
all	O
participating	O
institutions	O
.	O
	
Between	O
1999	O
and	O
2003	O
","	O
women	O
with	O
radically	O
resected	O
ovarian	B-CANCER
cancer	I-CANCER
of	O
FIGO	O
stages	O
II	O
B	O
to	O
IV	O
were	O
enrolled	O
at	O
17	O
German	O
centres	O
.	O
	
Patients	O
received	O
weekly	O
paclitaxel	B-DRUG
at	O
a	O
dose	O
of	O
100	O
mg	O
/	O
m2	O
","	O
followed	O
by	O
carboplatin	B-DRUG
AUC	O
2	O
After	O
a	O
first	O
treatment	O
block	O
consisting	O
of	O
six	O
cycles	O
of	O
chemotherapy	O
","	O
patients	O
had	O
a	O
treatment-free	O
interval	O
of	O
14	O
days	O
","	O
followed	O
by	O
a	O
second	O
block	O
of	O
six	O
cycles	O
.	O
	
Treatment	O
was	O
completed	O
by	O
a	O
28-days	O
break	O
and	O
a	O
final	O
block	O
of	O
six	O
cycles	O
.	O
	
Altogether	O
","	O
129	O
women	O
with	O
a	O
mean	O
age	O
of	O
59	O
=+	O
/	O
=-	O
standard	O
deviation	O
11	O
years	O
entered	O
the	O
study	O
.	O
	
Most	O
patients	O
(	O
82.9	O
%	O
)	O
had	O
serous	O
papillary	B-TOXI
carcinoma	I-TOXI
of	O
FIGO	O
stage	O
III	O
(	O
72.9	O
%	O
)	O
and	O
IV	O
(	O
20.9	O
%	O
)	O
.	O
	
Participants	O
received	O
"1,851"	O
cycles	O
of	O
chemotherapy	O
;	O
averaging	O
14.3	O
=+	O
/	O
=-	O
4.3	O
cycles	O
each	O
patient	O
.	O
	
PC-W	O
produced	O
low	O
rates	O
of	O
peripheral	B-TOXI
neuropathy	I-TOXI
(	O
grade	O
3	O
:	O
2.3	O
%	O
","	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
0.5-6.6	O
%	O
)	O
","	O
with	O
rapid	O
recovery	O
after	O
3	O
months	O
.	O
	
However	O
","	O
72	O
patients	O
had	O
grade	O
III	O
/	O
IV	O
anaemia	B-TOXI
(	O
55.8	O
%	O
","	O
95	O
%	O
CI	O
46.8-64.5	O
%	O
)	O
.	O
	
There	O
were	O
36	O
events	O
of	O
grade	O
III	O
/	O
IV	O
leukopenia	B-TOXI
(	O
27.9	O
%	O
","	O
95	O
%	O
CI	O
20.4-36.5	O
%	O
)	O
.	O
	
One	O
patient	O
sustained	O
neutropenic	B-TOXI
fever	I-TOXI
.	O
	
CA-125-	O
and	O
objective	O
response	O
was	O
noted	O
in	O
73.9	O
%	O
(	O
95	O
%	O
CI	O
64.7-81.8	O
%	O
)	O
and	O
55.6	O
%	O
(	O
95	O
%	O
CI	O
41.4-69.1	O
%	O
)	O
of	O
patients	O
.	O
	
Median	O
progression	O
free	O
and	O
overall	O
survival	O
was	O
21	O
and	O
43	O
months	O
","	O
respectively	O
.	O
	
PC-W	O
is	O
feasible	O
;	O
a	O
randomized	O
study	O
is	O
warranted	O
to	O
compare	O
this	O
new	O
regimen	O
with	O
conventional	O
3-weekly	O
treatment	O
.	O
	
Early	O
recovery	O
of	O
aggressive	O
cytotoxic	O
cells	O
and	O
improved	O
immune	O
resurgence	O
with	O
post-transplant	O
immunotherapy	O
for	O
multiple	O
myeloma	B-CANCER
.	O
	
	
A	O
phase	O
I	O
/	O
II	O
trial	O
evaluated	O
early	O
administration	O
and	O
dose	O
escalation	O
of	O
interleukin	B-DRUG
(	O
IL	O
)	O
-2	O
with	O
granulocyte	B-DRUG
macrophage	I-DRUG
colony	I-DRUG
stimulating	I-DRUG
factor	I-DRUG
(	O
GM-CSF	B-DRUG
)	O
post-transplant	O
.	O
	
Following	O
melphalan	B-DRUG
(	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
an	O
autologous	O
transplant	O
","	O
IL-2	B-DRUG
was	O
initiated	O
(	O
day	O
0	O
)	O
and	O
continued	O
for	O
4	O
weeks	O
.	O
	
GM-CSF	B-DRUG
(	O
250	O
mcg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
)	O
began	O
on	O
day	O
5	O
Fifteen	O
of	O
19	O
patients	O
completed	O
therapy	O
.	O
	
No	O
treatment-related	O
deaths	B-TOXI
occurred	O
.	O
	
IL-2	B-DRUG
(	O
1	O
x	O
10	O
(	O
6	O
)	O
IU	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
)	O
was	O
not	O
tolerated	O
in	O
two	O
of	O
six	O
patients	O
due	O
to	O
&	O
gt	O
;	O
or	O
#NAME?	O
3	O
fatigue	B-TOXI
/	O
diarrhea	B-TOXI
(	O
n=1	O
)	O
or	O
supraventricular	B-TOXI
tachycardia	I-TOXI
(	O
n=1	O
)	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
of	O
IL-2	B-DRUG
was	O
6	O
x	O
10	O
(	O
5	O
)	O
IU	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
;	O
this	O
dose	O
was	O
well	O
tolerated	O
by	O
11	O
of	O
13	O
patients	O
.	O
	
Neutrophil	O
and	O
platelet	O
engraftment	O
occurred	O
on	O
day	O
13	O
(	O
median	O
;	O
range	O
10月17日	O
days	O
)	O
and	O
day	O
13	O
(	O
median	O
;	O
range	O
0-74	O
days	O
)	O
","	O
respectively	O
.	O
	
When	O
compared	O
to	O
control	O
patients	O
","	O
there	O
was	O
a	O
marked	O
increase	O
in	O
the	O
number	O
of	O
CD3+	O
T	O
cells	O
(	O
P=0.005	O
)	O
","	O
CD4+	O
T	O
cells	O
(	O
P=0.01	O
)	O
","	O
CD8+	O
T	O
cells	O
(	O
P=0.001	O
)	O
and	O
CD4+CD25+Treg	O
cells	O
(	O
P=0.015	O
)	O
post-transplant	O
.	O
	
Cytotoxicity	O
directed	O
against	O
myeloma	B-CANCER
cells	O
was	O
markedly	O
increased	O
when	O
compared	O
to	O
control	O
patients	O
(	O
P=0.017	O
)	O
.	O
	
This	O
unique	O
trial	O
design	O
using	O
early	O
administration	O
of	O
IL-2	B-DRUG
with	O
GM-CSF	B-DRUG
during	O
the	O
period	O
of	O
lymphodepletion	O
","	O
demonstrated	O
a	O
marked	O
increase	O
in	O
the	O
number	O
and	O
function	O
of	O
early	O
cytotoxic	O
effector	O
T	O
cells	O
","	O
without	O
suppression	O
of	O
engraftment	O
.	O
	
Chemo-hormone	O
therapy	O
of	O
non-well-differentiated	O
endocrine	B-CANCER
tumours	I-CANCER
from	O
different	O
anatomic	O
sites	O
with	O
cisplatinum	B-DRUG
","	O
etoposide	B-DRUG
and	O
slow	O
release	O
lanreotide	B-DRUG
formulation	O
.	O
	
	
We	O
report	O
the	O
results	O
of	O
a	O
phase	O
II	O
trial	O
in	O
patients	O
with	O
metastatic	B-CANCER
endocrine	I-CANCER
tumours	I-CANCER
from	O
different	O
sites	O
","	O
which	O
aimed	O
to	O
evaluate	O
the	O
anti-tumour	O
activity	O
and	O
toxicity	O
of	O
a	O
cisplatinum	B-DRUG
and	O
etoposide	B-DRUG
regimen	O
administered	O
in	O
combination	O
with	O
the	O
somatostatin	B-DRUG
agonist	O
lanreotide	B-DRUG
given	O
in	O
slow	O
release	O
formulation	O
.	O
	
Between	O
January	O
1999	O
and	O
November	O
2003	O
","	O
27	O
patients	O
with	O
histological	O
diagnoses	O
of	O
endocrine	B-CANCER
tumours	I-CANCER
with	O
different	O
degrees	O
of	O
differentiation	O
","	O
excluding	O
well	O
differentiated	O
carcinoid	B-CANCER
neoplasms	I-CANCER
","	O
received	O
intravenous	O
(	O
i.v.	O
)	O
administration	O
of	O
cisplatinum	B-DRUG
(	O
30	O
mg	O
m	O
(	O
-2	O
)	O
)	O
and	O
etoposide	B-DRUG
(	O
100	O
mg	O
m	O
(	O
-2	O
)	O
)	O
on	O
days	O
1月3日	O
and	O
intramuscular	O
administration	O
of	O
60	O
mg	O
lanreotide	B-DRUG
on	O
day	O
1	O
","	O
in	O
a	O
21-day	O
cycle	O
.	O
	
All	O
of	O
the	O
patients	O
were	O
evaluable	O
for	O
toxicity	O
and	O
response	O
.	O
	
The	O
treatment	O
was	O
very	O
well	O
tolerated	O
as	O
no	O
grade	O
4	O
toxicity	O
was	O
observed	O
.	O
	
Four	O
patients	O
achieved	O
a	O
complete	O
response	O
","	O
six	O
a	O
partial	O
response	O
","	O
12	O
experienced	O
disease	O
stabilisation	O
and	O
five	O
disease	O
progression	O
.	O
	
The	O
average	O
time	O
to	O
progression	O
and	O
to	O
survival	O
were	O
9	O
and	O
24	O
months	O
respectively	O
.	O
	
These	O
results	O
suggest	O
that	O
this	O
chemo-hormone	O
therapy	O
regimen	O
is	O
well	O
tolerated	O
and	O
active	O
in	O
patients	O
with	O
non-well	O
differentiated	O
endocrine	B-CANCER
tumours	I-CANCER
.	O
	
Phase	O
II	O
trial	O
of	O
infusional	B-DRUG
fluorouracil	I-DRUG
","	O
leucovorin	B-DRUG
","	O
mitomycin	B-DRUG
","	O
and	O
dipyridamole	B-DRUG
in	O
locally	O
advanced	O
unresectable	O
pancreatic	B-CANCER
adenocarcinoma	I-CANCER
:	O
SWOG	O
S9700	O
.	O
	
	
To	O
test	O
the	O
hypothesis	O
that	O
dual	O
biochemical	O
modulation	O
of	O
fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
in	O
combination	O
with	O
mitomycin	B-DRUG
improves	O
the	O
survival	O
of	O
patients	O
with	O
pancreas	B-CANCER
cancer	I-CANCER
.	O
	
Eligibility	O
included	O
stage	O
II	O
or	O
III	O
unresectable	O
adenocarcinoma	B-CANCER
of	I-CANCER
the	I-CANCER
pancreas	I-CANCER
","	O
performance	O
status	O
of	O
0	O
to	O
2	O
","	O
and	O
adequate	O
organ	O
function	O
.	O
	
Treatment	O
included	O
FU	B-DRUG
200	O
mg	O
/	O
m2	O
/	O
d	O
via	O
continuous	O
intravenous	O
infusion	O
for	O
4	O
weeks	O
followed	O
by	O
1	O
week	O
of	O
rest	O
;	O
leucovorin	B-DRUG
30	O
mg	O
/	O
m2	O
administered	O
via	O
intravenous	O
bolus	O
infusion	O
on	O
days	O
1	O
","	O
8	O
","	O
15	O
","	O
and	O
22	O
","	O
followed	O
by	O
1	O
week	O
rest	O
;	O
mitomycin	B-DRUG
10	O
mg	O
/	O
m2	O
intravenous	O
bolus	O
infusion	O
every	O
6	O
weeks	O
for	O
a	O
total	O
of	O
four	O
doses	O
.	O
	
Dipyridamole	B-DRUG
75	O
mg	O
was	O
administered	O
orally	O
three	O
times	O
daily	O
during	O
the	O
FU	B-DRUG
administration	O
.	O
	
Fifty	O
patients	O
(	O
median	O
age	O
","	O
61	O
years	O
;	O
23	O
males	O
","	O
27	O
females	O
)	O
with	O
localized	O
unresectable	O
pancreatic	B-CANCER
cancer	I-CANCER
were	O
eligible	O
for	O
this	O
trial	O
.	O
	
Twenty-seven	O
patients	O
survived	O
past	O
1	O
year	O
for	O
a	O
1-year	O
survival	O
probability	O
of	O
54	O
%	O
(	O
95	O
%	O
CI	O
","	O
40	O
%	O
to	O
68	O
%	O
)	O
.	O
	
Overall	O
","	O
the	O
objective	O
response	O
rate	O
was	O
26	O
%	O
(	O
confirmed	O
and	O
unconfirmed	O
)	O
in	O
the	O
47	O
patients	O
with	O
measurable	O
disease	O
","	O
with	O
two	O
complete	O
responders	O
.	O
	
Six	O
of	O
the	O
responding	O
patients	O
underwent	O
curative	O
successful	O
resection	O
of	O
the	O
tumor	O
.	O
	
The	O
most	O
common	O
toxicity	O
to	O
treatment	O
was	O
stomatitis	B-TOXI
.	O
	
Three	O
patients	O
had	O
reversible	O
hemolytic	B-TOXI
uremic	I-TOXI
syndrome	I-TOXI
.	O
	
Five	O
patients	O
experienced	O
grade	O
4	O
toxicity	O
.	O
	
There	O
were	O
no	O
treatment-related	O
deaths	B-TOXI
.	O
	
Potential	O
improvement	O
in	O
survival	O
and	O
resectability	O
of	O
localized	O
unresectable	O
pancreatic	B-CANCER
cancer	I-CANCER
may	O
be	O
attained	O
without	O
radiation	O
.	O
	
The	O
strategy	O
of	O
dual	O
biochemical	O
modulation	O
of	O
FU	B-DRUG
warrants	O
additional	O
investigation	O
in	O
a	O
randomized	O
fashion	O
.	O
	
Phase	O
III	O
trial	O
of	O
infusional	B-DRUG
fluorouracil	I-DRUG
","	O
leucovorin	B-DRUG
","	O
oxaliplatin	B-DRUG
","	O
and	O
irinotecan	B-DRUG
(	O
FOLFOXIRI	B-DRUG
)	O
compared	O
with	O
infusional	B-DRUG
fluorouracil	I-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
irinotecan	B-DRUG
(	O
FOLFIRI	B-DRUG
)	O
as	O
first-line	O
treatment	O
for	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
:	O
the	O
Gruppo	O
Oncologico	O
Nord	O
Ovest	O
.	O
	
	
The	O
Gruppo	O
Oncologico	O
Nord	O
Ovest	O
(	O
GONO	O
)	O
conducted	O
a	O
phase	O
III	O
study	O
comparing	O
fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
","	O
oxaliplatin	B-DRUG
","	O
and	O
irinotecan	B-DRUG
(	O
FOLFOXIRI	B-DRUG
[	O
irinotecan	B-DRUG
165	O
mg	O
/	O
m2	O
day	O
1	O
","	O
oxaliplatin	B-DRUG
85	O
mg	O
/	O
m2	O
day	O
1	O
","	O
leucovorin	B-DRUG
200	O
mg	O
/	O
m2	O
day	O
1	O
","	O
fluorouracil	B-DRUG
"3,200"	O
mg	O
/	O
m2	O
48-hour	O
continuous	O
infusion	O
starting	O
on	O
day	O
1	O
","	O
every	O
2	O
weeks	O
]	O
)	O
with	O
infusional	B-DRUG
fluorouracil	I-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
irinotecan	B-DRUG
(	O
FOLFIRI	B-DRUG
)	O
.	O
	
Selection	O
criteria	O
included	O
unresectable	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
","	O
age	O
18	O
to	O
75	O
years	O
","	O
and	O
no	O
prior	O
chemotherapy	O
for	O
advanced	O
disease	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
response	O
rate	O
(	O
RR	O
)	O
.	O
	
A	O
total	O
of	O
244	O
patients	O
were	O
randomly	O
assigned	O
.	O
	
An	O
increase	O
of	O
grade	O
2	O
to	O
3	O
peripheral	B-TOXI
neurotoxicity	I-TOXI
(	O
0	O
%	O
v	O
19	O
%	O
;	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
","	O
and	O
grade	O
3	O
to	O
4	O
neutropenia	B-TOXI
(	O
28	O
%	O
v	O
50	O
%	O
;	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
were	O
observed	O
in	O
the	O
FOLFOXIRI	B-DRUG
arm	O
.	O
	
The	O
incidence	O
of	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
3	O
%	O
v	O
5	O
%	O
)	O
and	O
grade	O
3	O
to	O
4	O
diarrhea	B-TOXI
(	O
12	O
%	O
v	O
20	O
%	O
)	O
were	O
not	O
significantly	O
different	O
.	O
	
Responses	O
","	O
as	O
assessed	O
by	O
investigators	O
","	O
were	O
","	O
for	O
FOLFIRI	B-DRUG
and	O
FOLFOXIRI	B-DRUG
","	O
respectively	O
","	O
complete	O
","	O
6	O
%	O
and	O
8	O
%	O
;	O
and	O
partial	O
","	O
35	O
%	O
and	O
58	O
%	O
","	O
(	O
RR	O
","	O
41	O
%	O
v	O
66	O
%	O
;	O
P	O
=	O
0.0002	O
)	O
.	O
	
RR	O
confirmed	O
by	O
an	O
external	O
panel	O
was	O
34	O
%	O
versus	O
60	O
%	O
(	O
P	O
&	O
lt	O
;	O
0.0001	O
)	O
.	O
	
The	O
R0	O
secondary	O
resection	O
rate	O
of	O
metastases	O
was	O
greater	O
in	O
the	O
FOLFOXIRI	B-DRUG
arm	O
(	O
6	O
%	O
v	O
15	O
%	O
;	O
P	O
=	O
0.033	O
","	O
among	O
all	O
244	O
patients	O
;	O
and	O
12	O
%	O
v	O
36	O
%	O
;	O
P	O
=	O
0.017	O
among	O
patients	O
with	O
liver	O
metastases	O
only	O
)	O
.	O
	
Progression-free	O
survival	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
were	O
both	O
significantly	O
improved	O
in	O
the	O
FOLFOXIRI	B-DRUG
arm	O
(	O
median	O
PFS	O
","	O
6.9	O
v	O
9.8	O
months	O
;	O
hazard	O
ratio	O
[	O
HR	O
]	O
","	O
0.63	O
;	O
P	O
=	O
0.0006	O
;	O
median	O
OS	O
","	O
16.7	O
v	O
22.6	O
months	O
;	O
HR	O
","	O
0.7	O
;	O
P	O
=	O
0.032	O
)	O
.	O
	
The	O
FOLFOXIRI	B-DRUG
regimen	O
improves	O
RR	O
","	O
PFS	O
","	O
and	O
OS	O
compared	O
with	O
FOLFIRI	B-DRUG
","	O
with	O
an	O
increased	O
","	O
but	O
manageable	O
","	O
toxicity	O
in	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
with	O
favorable	O
prognostic	O
characteristics	O
.	O
	
Further	O
studies	O
of	O
FOLFOXIRI	B-DRUG
in	O
combination	O
with	O
targeted	O
agents	O
and	O
in	O
the	O
neoadjuvant	O
setting	O
are	O
warranted	O
.	O
	
A	O
dose	O
escalation	O
study	O
of	O
docetaxel	B-DRUG
plus	O
capecitabine	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Capecitabine	B-DRUG
(	O
CAP	B-DRUG
)	O
","	O
gemcitabine	B-DRUG
(	O
GEM	B-DRUG
)	O
","	O
and	O
docetaxel	B-DRUG
(	O
DOC	B-DRUG
)	O
have	O
shown	O
interesting	O
activity	O
in	O
a	O
wide	O
range	O
of	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
A	O
phase	O
I	O
study	O
was	O
conducted	O
in	O
order	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
of	O
their	O
combination	O
in	O
patients	O
with	O
refractory	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
Eighteen	O
patients	O
were	O
enrolled	O
.	O
	
The	O
patients	O
'	O
median	O
age	O
was	O
60	O
years	O
","	O
15	O
were	O
male	O
","	O
and	O
11	O
were	O
chemo-naive	O
.	O
	
DOC	B-DRUG
was	O
administered	O
on	O
day	O
1	O
as	O
an	O
1-h	O
(	O
IV	O
)	O
infusion	O
at	O
escalating	O
doses	O
ranging	O
from	O
40	O
to	O
50	O
mg	O
/	O
m2	O
.	O
	
GEM	B-DRUG
was	O
administered	O
on	O
day	O
1	O
as	O
a	O
30-min	O
(	O
IV	O
)	O
infusion	O
at	O
a	O
standard	O
dose	O
of	O
1500	O
mg	O
/	O
m2	O
.	O
	
CAP	B-DRUG
was	O
administered	O
orally	O
on	O
days	O
1	O
to	O
7	O
at	O
escalating	O
doses	O
ranging	O
from	O
1750	O
to	O
2500	O
mg	O
/	O
m2	O
given	O
as	O
two	O
daily	O
divided	O
doses	O
.	O
	
Treatment	O
was	O
repeated	O
every	O
2	O
weeks	O
.	O
	
Five	O
different	O
dose	O
levels	O
were	O
examined	O
.	O
	
At	O
dose	O
level	O
V	O
two	O
out	O
of	O
three	O
enrolled	O
patients	O
presented	O
DLTs	O
(	O
one	O
patient	O
grade	O
4	O
neutropenia	B-TOXI
and	O
grade	O
3	O
stomatitis	B-TOXI
and	O
another	O
grade	O
3	O
diarrhea	B-TOXI
)	O
","	O
and	O
thus	O
the	O
recommended	O
MTD	O
for	O
future	O
phase	O
II	O
studies	O
are	O
CAP	B-DRUG
2250	O
mg	O
/	O
m2	O
","	O
DOC	O
50	O
mg	O
/	O
m2	O
","	O
and	O
GEM	B-DRUG
1500	O
mg	O
/	O
m2	O
.	O
	
A	O
total	O
of	O
124	O
treatment	O
cycles	O
were	O
administered	O
.	O
	
Toxicity	O
was	O
generally	O
mild	O
.	O
	
Grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
was	O
observed	O
in	O
eight	O
(	O
7	O
%	O
)	O
treatment	O
cycles	O
and	O
grade	O
3	O
thrombocytopenia	B-TOXI
in	O
one	O
(	O
1	O
%	O
)	O
.	O
	
There	O
was	O
no	O
febrile	B-TOXI
episode	O
.	O
	
Grade	O
2	O
/	O
3	O
asthenia	B-TOXI
was	O
observed	O
in	O
six	O
(	O
33	O
%	O
)	O
patients	O
","	O
grade	O
2	O
/	O
3	O
diarrhea	B-TOXI
in	O
four	O
(	O
22	O
%	O
)	O
","	O
and	O
grade	O
2	O
/	O
3	O
hand-foot	B-TOXI
syndrome	I-TOXI
in	O
three	O
(	O
17	O
%	O
)	O
.	O
	
Other	O
toxicities	O
were	O
uncommon	O
.	O
	
There	O
was	O
no	O
treatment-related	O
death	B-TOXI
.	O
	
One	O
(	O
6	O
%	O
)	O
CR	O
","	O
four	O
(	O
25	O
%	O
)	O
PRs	O
","	O
and	O
six	O
(	O
38	O
%	O
)	O
SD	O
were	O
observed	O
among	O
16	O
evaluable	O
patients	O
.	O
	
Responses	O
were	O
seen	O
in	O
patients	O
with	O
breast	O
(	O
one	O
CR	O
)	O
","	O
gastric	O
(	O
three	O
PRs	O
)	O
","	O
and	O
pancreatic	O
(	O
one	O
PR	O
)	O
cancer	O
.	O
	
These	O
results	O
demonstrate	O
that	O
CAP	B-DRUG
","	O
DOC	B-DRUG
","	O
and	O
GEM	B-DRUG
can	O
be	O
safely	O
combined	O
at	O
clinically	O
relevant	O
doses	O
and	O
this	O
regimen	O
merits	O
further	O
evaluation	O
.	O
	
Front-line	O
bevacizumab	B-DRUG
in	O
combination	O
with	O
oxaliplatin	B-DRUG
","	O
leucovorin	B-DRUG
and	O
5-fluorouracil	B-DRUG
(	O
FOLFOX	B-DRUG
)	O
in	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
:	O
a	O
multicenter	O
phase	O
II	O
study	O
.	O
	
	
To	O
evaluate	O
the	O
efficacy	O
and	O
the	O
toxicity	O
of	O
front	O
line	O
FOLFOX4	B-DRUG
combined	O
with	O
bevacizumab	B-DRUG
in	O
patients	O
with	O
metastatsic	O
CRC	B-CANCER
(	O
mCRC	B-CANCER
)	O
.	O
	
Chemotherapy-na茂ve	O
patients	O
with	O
mCRC	B-CANCER
","	O
received	O
bevacizumab	B-DRUG
(	O
5	O
mg	O
/	O
kg	O
every	O
2	O
weeks	O
d1	O
)	O
","	O
oxaliplatin	B-DRUG
(	O
85	O
mg	O
/	O
m2	O
on	O
d1	O
)	O
","	O
leucovorin	B-DRUG
(	O
200	O
mg	O
/	O
m2	O
)	O
on	O
days	O
1	O
and	O
2	O
and	O
5-Fluorouracil	B-DRUG
(	O
400	O
mg	O
/	O
m2	O
as	O
i.v.	O
bolus	O
and	O
600	O
mg	O
/	O
m2	O
as	O
22	O
h	O
i.v.	O
continuous	O
infusion	O
on	O
days	O
1	O
and	O
2	O
)	O
every	O
2	O
weeks	O
.	O
	
Fifty	O
three	O
patients	O
(	O
46	O
with	O
a	O
PS	O
0-1	O
)	O
were	O
enrolled	O
.	O
	
Complete	O
and	O
partial	O
response	O
was	O
achieved	O
in	O
eight	O
(	O
15.1	O
%	O
)	O
and	O
28	O
(	O
52.8	O
%	O
)	O
patients	O
","	O
respectively	O
(	O
ORR	O
:	O
67.9	O
%	O
;	O
95	O
%	O
C.I.	O
:	O
53.8	O
%	O
-92	O
%	O
)	O
;	O
11	O
(	O
20.7	O
%	O
)	O
patients	O
had	O
stable	O
disease	O
and	O
six	O
(	O
11.3	O
%	O
)	O
progressive	O
disease	O
.	O
	
With	O
a	O
median	O
follow	O
up	O
period	O
of	O
13.5	O
months	O
","	O
time	O
to	O
tumor	O
progression	O
was	O
11	O
months	O
while	O
the	O
median	O
survival	O
has	O
not	O
yet	O
been	O
reached	O
;	O
the	O
probability	O
of	O
-1	O
","	O
-2	O
and	O
-3	O
year	O
survival	O
was	O
79.8	O
%	O
","	O
63.8	O
%	O
and	O
58.3	O
%	O
","	O
respectively	O
;	O
Two	O
patients	O
relapsed	O
during	O
the	O
follow	O
up	O
period	O
.	O
	
Eight	O
(	O
15	O
%	O
)	O
patients	O
underwent	O
metastasectomy	O
with	O
R0	O
resections	O
.	O
	
Grade	O
3月4日	O
neutropenia	B-TOXI
occurred	O
in	O
15.1	O
%	O
of	O
patients	O
and	O
one	O
(	O
1.9	O
%	O
)	O
of	O
them	O
presented	O
febrile	B-TOXI
neutropenia	I-TOXI
.	O
	
Non-hematologic	B-TOXI
toxicity	I-TOXI
included	O
grade	O
3	O
diarrhea	B-TOXI
(	O
7.6	O
%	O
)	O
and	O
grade	O
2	O
and	O
3	O
neurotoxicity	B-TOXI
in	O
16.9	O
and	O
15.1	O
%	O
of	O
patients	O
","	O
respectively	O
.	O
	
One	O
(	O
1.9	O
%	O
)	O
patient	O
presented	O
pulmonary	B-TOXI
embolism	I-TOXI
and	O
one	O
(	O
1.9	O
%	O
)	O
cardiac	B-TOXI
ischaemia	I-TOXI
.	O
	
There	O
was	O
one	O
(	O
1.9	O
%	O
)	O
sudden	O
death	B-TOXI
after	O
the	O
first	O
cycle	O
.	O
	
The	O
combination	O
of	O
FOLFOX4	B-DRUG
/	O
bevacizumab	B-DRUG
appears	O
to	O
be	O
highly	O
effective	O
","	O
well	O
tolerated	O
and	O
merits	O
further	O
evaluation	O
in	O
patients	O
with	O
mCRC	B-CANCER
.	O
	
Trastuzumab	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
gemcitabine	B-DRUG
in	O
advanced	O
human	O
epidermal	B-DRUG
growth	I-DRUG
factor	I-DRUG
receptor-2	I-DRUG
/	O
neu-positive	O
urothelial	B-CANCER
carcinoma	I-CANCER
:	O
results	O
of	O
a	O
multicenter	O
phase	O
II	O
National	O
Cancer	O
Institute	O
trial	O
.	O
	
	
We	O
investigated	O
the	O
safety	O
and	O
efficacy	O
(	O
response	O
rates	O
","	O
time	O
to	O
disease	O
progression	O
","	O
survival	O
)	O
of	O
trastuzumab	B-DRUG
","	O
carboplatin	B-DRUG
","	O
gemcitabine	B-DRUG
","	O
and	O
paclitaxel	B-DRUG
in	O
advanced	B-CANCER
urothelial	I-CANCER
carcinoma	I-CANCER
patients	O
and	O
prospectively	O
evaluated	O
human	O
epidermal	B-DRUG
growth	I-DRUG
factor	I-DRUG
receptor-2	I-DRUG
(	O
Her-2	O
/	O
neu	O
)	O
overexpression	O
rates	O
.	O
	
Advanced	B-CANCER
urothelial	I-CANCER
carcinoma	I-CANCER
patients	O
were	O
screened	O
for	O
Her-2	O
/	O
neu	O
overexpression	O
.	O
	
Eligibility	O
for	O
therapy	O
required	O
human	O
epidermal	B-DRUG
growth	I-DRUG
factor	I-DRUG
receptor-2	I-DRUG
(	O
Her-2	O
/	O
neu	O
)	O
overexpression	O
by	O
immunohistochemistry	O
(	O
IHC	O
)	O
","	O
gene	O
amplification	O
and	O
/	O
or	O
elevated	O
serum	O
Her-2	O
/	O
neu	O
","	O
no	O
prior	O
chemotherapy	O
for	O
metastasis	O
","	O
and	O
adequate	O
organ	O
function	O
including	O
a	O
normal	O
cardiac	O
function	O
.	O
	
Treatment	O
consisted	O
of	O
trastuzumab	B-DRUG
(	O
T	O
)	O
4	O
mg	O
/	O
kg	O
loading	O
dose	O
followed	O
by	O
2	O
mg	O
/	O
kg	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
;	O
paclitaxel	B-DRUG
(	O
P	O
)	O
200	O
mg	O
/	O
m2	O
on	O
day	O
1	O
;	O
carboplatin	B-DRUG
(	O
C	O
;	O
area	O
under	O
the	O
curve	O
","	O
5	O
)	O
on	O
day	O
1	O
;	O
and	O
gemcitabine	B-DRUG
(	O
G	O
)	O
800	O
mg	O
/	O
m2	O
on	O
days	O
1	O
and	O
8	O
The	O
primary	O
end	O
point	O
was	O
cardiac	B-TOXI
toxicity	I-TOXI
.	O
	
Fifty-seven	O
(	O
52.3	O
%	O
)	O
of	O
109	O
registered	O
patients	O
were	O
Her-2	O
/	O
neu	O
positive	O
","	O
and	O
48.6	O
%	O
were	O
positive	O
by	O
IHC	O
.	O
	
Her-2	O
/	O
neu-positive	O
patients	O
had	O
more	O
metastatic	O
sites	O
and	O
visceral	O
metastasis	O
than	O
did	O
Her-2	O
/	O
neu	O
negative	O
patients	O
.	O
	
Forty-four	O
of	O
57	O
Her-2	O
/	O
neu-positive	O
patients	O
were	O
treated	O
with	O
TPCG	O
.	O
	
The	O
median	O
number	O
of	O
cycles	O
was	O
six	O
(	O
range	O
","	O
1	O
to	O
12	O
cycles	O
)	O
.	O
	
The	O
most	O
common	O
grade	O
3	O
/	O
4	O
toxicity	O
was	O
myelosuppression	B-TOXI
.	O
	
Grade	O
3	O
sensory	B-TOXI
neuropathy	I-TOXI
occurred	O
in	O
14	O
%	O
of	O
patients	O
","	O
and	O
22.7	O
%	O
experienced	O
grade	O
1	O
to	O
3	O
cardiac	B-TOXI
toxicity	I-TOXI
(	O
grade	O
3	O
","	O
n	O
=	O
2	O
:	O
one	O
left	O
ventricular	B-TOXI
dysfunction	I-TOXI
","	O
one	O
tachycardia	B-TOXI
)	O
.	O
	
There	O
were	O
three	O
[	O
corrected	O
]	O
therapy-related	O
deaths	B-TOXI
.	O
	
Thirty-one	O
(	O
70	O
%	O
)	O
of	O
44	O
patients	O
responded	O
(	O
five	O
complete	O
and	O
26	O
partial	O
)	O
","	O
and	O
25	O
(	O
57	O
%	O
)	O
of	O
44	O
were	O
confirmed	O
responses	O
.	O
	
Median	O
time	O
to	O
progression	O
and	O
survival	O
were	O
9.3	O
and	O
14.1	O
months	O
","	O
respectively	O
.	O
	
We	O
prospectively	O
characterized	O
Her-2	O
/	O
neu	O
status	O
in	O
advanced	B-CANCER
urothelial	I-CANCER
carcinoma	I-CANCER
patients	O
.	O
	
TPCG	O
is	O
feasible	O
;	O
cardiac	B-TOXI
toxicity	I-TOXI
rates	O
were	O
higher	O
than	O
projected	O
","	O
but	O
the	O
majority	O
were	O
grade	O
two	O
or	O
lower	O
.	O
	
Determining	O
the	O
TRUE	O
contribution	O
of	O
trastuzumab	B-DRUG
requires	O
a	O
randomized	O
trial	O
.	O
	
A	O
dose	O
escalation	O
and	O
pharmacokinetic	O
study	O
of	O
biweekly	O
pegylated	B-DRUG
liposomal	I-DRUG
doxorubicin	I-DRUG
","	O
paclitaxel	B-DRUG
and	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
	
To	O
determine	O
the	O
maximum	O
tolerated	O
doses	O
(	O
MTDs	O
)	O
and	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
of	O
pegylated	B-DRUG
liposomal	I-DRUG
doxorubicin	I-DRUG
(	O
PLD	B-DRUG
)	O
","	O
paclitaxel	B-DRUG
(	O
PCX	B-DRUG
)	O
and	O
gemcitabine	B-DRUG
(	O
GEM	B-DRUG
)	O
combination	O
administered	O
biweekly	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
Twenty-two	O
patients	O
with	O
advanced-stage	O
solid	B-CANCER
tumours	I-CANCER
were	O
treated	O
with	O
escalated	O
doses	O
of	O
PLD	B-DRUG
on	O
day	O
1	O
and	O
PCX	B-DRUG
plus	O
GEM	B-DRUG
on	O
day	O
2	O
(	O
starting	O
doses	O
:	O
10	O
","	O
100	O
and	O
800	O
mg	O
m	O
(	O
-2	O
)	O
","	O
respectively	O
)	O
every	O
2	O
weeks	O
.	O
	
DLTs	O
and	O
pharmacokinetic	O
(	O
PK	O
)	O
parameters	O
of	O
all	O
drugs	O
were	O
determined	O
during	O
the	O
first	O
cycle	O
of	O
treatment	O
.	O
	
All	O
but	O
six	O
(	O
73	O
%	O
)	O
patients	O
had	O
previously	O
received	O
at	O
least	O
one	O
chemotherapy	O
regimen	O
.	O
	
The	O
DLT	O
dose	O
level	O
was	O
reached	O
at	O
PLD	B-DRUG
12	O
mg	O
m	O
(	O
-2	O
)	O
","	O
PCX	B-DRUG
110	O
mg	O
m	O
(	O
-2	O
)	O
and	O
GEM	B-DRUG
1000	O
mg	O
m	O
(	O
-2	O
)	O
with	O
neutropaenia	B-TOXI
being	O
the	O
dose-limiting	O
event	O
.	O
	
Of	O
the	O
86	O
chemotherapy	O
cycles	O
delivered	O
","	O
grade	O
3	O
and	O
4	O
neutropaenia	B-TOXI
occurred	O
in	O
20	O
%	O
with	O
no	O
cases	O
of	O
febrile	B-TOXI
neutropaenia	I-TOXI
.	O
	
Non-haematological	B-TOXI
toxicities	I-TOXI
were	O
mild	O
.	O
	
The	O
recommended	O
MTDs	O
are	O
PLD	B-DRUG
12	O
mg	O
m	O
(	O
-2	O
)	O
","	O
PCX	B-DRUG
100	O
mg	O
m	O
(	O
-2	O
)	O
and	O
GEM	B-DRUG
1000	O
mg	O
m	O
(	O
-2	O
)	O
administered	O
every	O
2	O
weeks	O
.	O
	
The	O
PK	O
data	O
revealed	O
no	O
obvious	O
drug	O
interactions	O
.	O
	
Biweekly	O
administration	O
of	O
PLD	B-DRUG
","	O
PCX	B-DRUG
and	O
GEM	B-DRUG
is	O
a	O
well-tolerated	O
chemotherapy	O
regimen	O
","	O
which	O
merits	O
further	O
evaluation	O
in	O
various	O
types	O
of	O
solid	B-CANCER
tumours	I-CANCER
.	O
	
A	O
phase	O
II	O
trial	O
of	O
gemcitabine	B-DRUG
plus	O
carboplatin	B-DRUG
in	O
advanced	B-CANCER
transitional	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
urothelium	I-CANCER
.	O
	
	
Recent	O
studies	O
have	O
demonstrated	O
the	O
effectiveness	O
of	O
cisplatin-based	B-DRUG
combinations	O
in	O
patients	O
with	O
advanced	B-CANCER
transitional	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
TCC	B-CANCER
)	O
of	O
the	O
urothelium	O
.	O
	
Concern	O
over	O
cisplatin	B-TOXI
toxicity	I-TOXI
instigated	O
a	O
search	O
for	O
alternative	O
regimens	O
.	O
	
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
activity	O
and	O
tolerability	O
of	O
gemcitabine	B-DRUG
plus	O
carboplatin	B-DRUG
combination	O
as	O
first-line	O
treatment	O
in	O
patients	O
with	O
advanced	B-CANCER
transitional	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
urothelium	I-CANCER
.	O
	
Patients	O
with	O
advanced	B-CANCER
TCC	I-CANCER
were	O
treated	O
with	O
gemcitabine	B-DRUG
1200	O
mg	O
/	O
m2	O
on	O
days	O
1	O
and	O
8	O
and	O
carboplatin	B-DRUG
area	O
under	O
the	O
concentration-time	O
curve	O
(	O
AUC	O
)	O
5	O
on	O
day	O
1	O
every	O
21	O
days	O
.	O
	
Out	O
of	O
41	O
patients	O
","	O
thirty-nine	O
were	O
evaluable	O
for	O
efficacy	O
and	O
41	O
for	O
toxicity	O
.	O
	
A	O
median	O
of	O
5	O
cycles	O
(	O
range	O
1月6日	O
)	O
was	O
administered	O
.	O
	
Overall	O
response	O
rate	O
was	O
46.2	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
32-65	O
%	O
)	O
including	O
10.3	O
%	O
complete	O
responses	O
and	O
35.9	O
%	O
partial	O
responses	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
and	O
median	O
overall	O
survival	O
were	O
7.5	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
6.6-8.4	O
months	O
)	O
and	O
13.6	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
10.2-17.0	O
months	O
)	O
","	O
respectively	O
.	O
	
Grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
","	O
anemia	B-TOXI
and	O
thrombocytopenia	B-TOXI
were	O
observed	O
in	O
36.6	O
%	O
","	O
26.8	O
","	O
and	O
24.4	O
%	O
of	O
patients	O
","	O
respectively	O
.	O
	
Non-hematological	B-TOXI
toxicity	I-TOXI
was	O
generally	O
mild	O
.	O
	
Grade	O
3	O
vomiting	B-TOXI
occurred	O
in	O
1	O
(	O
2.4	O
%	O
)	O
patients	O
.	O
	
The	O
gemcitabine	B-DRUG
plus	O
carboplatin	B-DRUG
combination	O
is	O
active	O
in	O
advanced	B-CANCER
TCC	I-CANCER
with	O
acceptable	O
toxicity	O
and	O
needs	O
to	O
be	O
evaluated	O
further	O
and	O
compared	O
with	O
other	O
non-cisplatin-containing	B-DRUG
regimens	O
.	O
	
ISRCTN88259320	O
.	O
	
Experience	O
with	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
in	O
the	O
therapy	O
of	O
inoperable	O
and	O
metastatic	B-CANCER
cholangiocarcinoma	I-CANCER
.	O
	
	
To	O
study	O
the	O
activity	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
in	O
a	O
cohort	O
of	O
patients	O
with	O
inoperable	O
or	O
metastatic	B-CANCER
cholangiocarcinoma	I-CANCER
.	O
	
Chemotherapy-naive	O
patients	O
with	O
pathologically	O
proven	O
cholangiocarcinoma	B-CANCER
","	O
receiving	O
treatment	O
that	O
consisted	O
of	O
gemcitabine	B-DRUG
at	O
1250	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
a	O
30-min	O
infusion	O
on	O
d	O
1	O
and	O
8	O
","	O
and	O
cisplatin	B-DRUG
at	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
at	O
every	O
21-d	O
cycle	O
","	O
were	O
retrospectively	O
analyzed	O
.	O
	
From	O
June	O
2003	O
to	O
December	O
2005	O
","	O
42	O
patients	O
were	O
evaluated	O
.	O
	
Twelve	O
patients	O
(	O
28	O
%	O
)	O
had	O
unresectable	O
disease	O
and	O
30	O
(	O
72	O
%	O
)	O
had	O
metastatic	O
disease	O
.	O
	
There	O
were	O
28	O
males	O
and	O
14	O
females	O
with	O
a	O
median	O
age	O
of	O
51	O
years	O
(	O
range	O
33-67	O
)	O
and	O
median	O
ECOG	O
PS	O
of	O
1	O
(	O
range	O
0-2	O
)	O
.	O
	
A	O
total	O
of	O
171	O
cycles	O
were	O
given	O
with	O
a	O
median	O
number	O
of	O
cycles	O
of	O
4	O
(	O
range	O
1月6日	O
)	O
.	O
	
There	O
were	O
0	O
CR	O
","	O
9	O
PR	O
","	O
11	O
SD	O
and	O
13	O
PD	O
(	O
response	O
rate	O
21	O
%	O
)	O
.	O
	
Grade	O
3月4日	O
hematologic	B-TOXI
toxicities	I-TOXI
were	O
:	O
anemia	B-TOXI
in	O
33	O
%	O
","	O
neutropenia	B-TOXI
in	O
22	O
%	O
and	O
thrombocytopenia	B-TOXI
in	O
5	O
%	O
.	O
	
Non-hematologic	B-TOXI
toxicity	I-TOXI
was	O
generally	O
mild	O
.	O
	
No	O
cases	O
of	O
febrile	B-TOXI
neutropenia	I-TOXI
or	O
treatment-related	O
death	B-TOXI
were	O
noted	O
.	O
	
The	O
median	O
survival	O
was	O
10.8	O
mo	O
(	O
range	O
8.4-13	O
mo	O
)	O
and	O
progression	O
free	O
survival	O
was	O
8.5	O
mo.	O
One-year	O
survival	O
rate	O
was	O
40	O
%	O
.	O
	
Our	O
results	O
indicate	O
that	O
the	O
combination	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
had	O
consistent	O
efficacy	O
in	O
patients	O
with	O
unresectable	O
or	O
metastatic	B-CANCER
cholangiocarcinoma	I-CANCER
.	O
	
Leuprorelin	B-DRUG
acetate	I-DRUG
every-3-months	O
depot	O
versus	O
cyclophosphamide	B-DRUG
","	O
methotrexate	B-DRUG
","	O
and	O
fluorouracil	B-DRUG
as	O
adjuvant	O
treatment	O
in	O
premenopausal	O
patients	O
with	O
node-positive	O
breast	B-CANCER
cancer	I-CANCER
:	O
the	O
TABLE	O
study	O
.	O
	
	
Ovarian	O
suppression	O
with	O
luteinizing	B-DRUG
hormone-releasing	I-DRUG
hormone	I-DRUG
(	O
LHRH	B-DRUG
)	O
agonists	O
is	O
an	O
effective	O
adjuvant	O
treatment	O
for	O
premenopausal	O
women	O
with	O
estrogen	O
receptor	O
(	O
ER	O
)	O
#NAME?	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
Whereas	O
monthly	O
LHRH	B-DRUG
agonist	O
therapy	O
has	O
been	O
well	O
established	O
","	O
the	O
value	O
of	O
every-3-months	O
(	O
3-monthly	O
)	O
formulations	O
is	O
unclear	O
.	O
	
This	O
randomized	O
phase	O
III	O
trial	O
was	O
performed	O
to	O
compare	O
the	O
3-monthly	O
depot	O
LHRH	B-DRUG
agonist	O
leuprorelin	B-DRUG
acetate	I-DRUG
(	O
LAD-3M	O
;	O
n	O
=	O
299	O
)	O
and	O
chemotherapy	O
with	O
cyclophosphamide	B-DRUG
","	O
methotrexate	B-DRUG
","	O
and	O
fluorouracil	B-DRUG
(	O
CMF	B-DRUG
;	O
n	O
=	O
300	O
)	O
in	O
pre-	O
or	O
perimenopausal	O
patients	O
with	O
ER-positive	O
","	O
node-positive	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
With	O
a	O
median	O
follow-up	O
of	O
5.8	O
years	O
","	O
recurrence-free	O
survival	O
was	O
similar	O
for	O
patients	O
treated	O
with	O
LAD-3M	O
or	O
CMF	B-DRUG
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
","	O
1.19	O
;	O
95	O
%	O
CI	O
","	O
0.94	O
to	O
1.51	O
;	O
P	O
=	O
0.15	O
)	O
.	O
	
There	O
was	O
no	O
substantial	O
heterogeneity	O
in	O
the	O
relative	O
treatment	O
effect	O
among	O
subgroups	O
defined	O
by	O
age	O
","	O
progesterone	O
receptor	O
(	O
PR	O
)	O
status	O
","	O
nodal	O
status	O
","	O
hormone	O
levels	O
","	O
or	O
menstrual	O
recovery	O
after	O
treatment	O
.	O
	
Exploratory	O
overall	O
survival	O
analysis	O
favored	O
LAD-3M	O
(	O
HR	O
","	O
1.5	O
;	O
95	O
%	O
CI	O
","	O
1.13	O
to	O
1.99	O
;	O
P	O
=	O
0.005	O
)	O
.	O
	
Chemotherapy-related	O
adverse	O
effects	O
such	O
as	O
nausea	B-TOXI
","	O
vomiting	B-TOXI
","	O
and	O
alopecia	B-TOXI
were	O
more	O
common	O
with	O
CMF	B-DRUG
","	O
whereas	O
symptoms	O
of	O
estrogen	B-TOXI
suppression	I-TOXI
such	O
as	O
hot	B-TOXI
flushes	I-TOXI
and	O
sweating	B-TOXI
were	O
initially	O
more	O
pronounced	O
with	O
LAD-3M	O
.	O
	
The	O
3-monthly	O
depot	O
LHRH-agonist	O
leuprorelin	B-DRUG
acetate	I-DRUG
is	O
an	O
effective	O
adjuvant	O
treatment	O
in	O
premenopausal	O
patients	O
with	O
hormone	O
receptor-positive	O
","	O
node-positive	O
breast	B-CANCER
cancer	I-CANCER
that	O
is	O
not	O
inferior	O
to	O
CMF	B-DRUG
.	O
	
Gemcitabine	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
radiotherapy	O
for	O
patients	O
with	O
locally	O
advanced	B-CANCER
pancreatic	I-CANCER
adenocarcinoma	I-CANCER
:	O
results	O
of	O
the	O
North	O
Central	O
Cancer	O
Treatment	O
Group	O
Phase	O
II	O
Study	O
N9942	O
.	O
	
	
A	O
phase	O
II	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
efficacy	O
and	O
toxicity	O
of	O
radiotherapy	O
with	O
concomitant	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
for	O
patients	O
with	O
locally	O
advanced	B-CANCER
pancreatic	I-CANCER
adenocarcinoma	I-CANCER
.	O
	
Forty-eight	O
patients	O
with	O
locally	O
advanced	B-CANCER
pancreatic	I-CANCER
adenocarcinoma	I-CANCER
received	O
gemcitabine	B-DRUG
(	O
30	O
mg	O
/	O
m2	O
)	O
and	O
cisplatin	B-DRUG
(	O
10	O
mg	O
/	O
m2	O
)	O
twice	O
weekly	O
during	O
the	O
first	O
3	O
weeks	O
of	O
radiotherapy	O
.	O
	
The	O
radiation	O
dose	O
to	O
the	O
primary	O
tumor	O
and	O
regional	O
nodes	O
was	O
45	O
Gy	O
in	O
25	O
fractions	O
","	O
and	O
the	O
gross	O
tumor	O
volume	O
received	O
an	O
additional	O
5.4	O
Gy	O
in	O
three	O
fractions	O
.	O
	
Four	O
weeks	O
after	O
radiotherapy	O
","	O
patients	O
received	O
gemcitabine	B-DRUG
(	O
"1,000"	O
mg	O
/	O
m2	O
)	O
once	O
weekly	O
every	O
3	O
of	O
4	O
weeks	O
for	O
a	O
12-week	O
period	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
survival	O
at	O
12	O
months	O
.	O
	
Secondary	O
end	O
points	O
were	O
time	O
to	O
progression	O
","	O
toxicity	O
","	O
and	O
quality	O
of	O
life	O
.	O
	
Survival	O
at	O
1	O
year	O
was	O
40	O
%	O
for	O
47	O
eligible	O
patients	O
.	O
	
The	O
median	O
survival	O
was	O
10.2	O
months	O
.	O
	
Confirmed	O
responses	O
were	O
observed	O
for	O
8.5	O
%	O
(	O
two	O
partial	O
","	O
two	O
complete	O
)	O
","	O
and	O
median	O
time	O
to	O
progression	O
was	O
7.3	O
months	O
.	O
	
Grade	O
4	O
or	O
higher	O
toxicity	O
was	O
observed	O
for	O
31	O
%	O
and	O
consisted	O
primarily	O
of	O
hematologic	O
and	O
GI	O
toxicity	O
.	O
	
There	O
was	O
a	O
trend	O
toward	O
improved	O
overall	O
quality	O
of	O
life	O
","	O
measured	O
by	O
the	O
Symptom	O
Distress	O
Scale	O
(	O
P	O
=	O
0.06	O
)	O
","	O
with	O
significant	O
improvements	O
in	O
domains	O
of	O
insomnia	B-TOXI
","	O
pain	B-TOXI
","	O
and	O
outlook	O
.	O
	
The	O
combination	O
of	O
radiotherapy	O
","	O
gemcitabine	B-DRUG
","	O
and	O
cisplatin	B-DRUG
was	O
well	O
tolerated	O
.	O
	
Survival	O
results	O
were	O
similar	O
to	O
those	O
achieved	O
with	O
other	O
treatment	O
regimens	O
for	O
patients	O
with	O
locally	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
but	O
did	O
not	O
meet	O
our	O
predefined	O
criteria	O
for	O
additional	O
evaluation	O
of	O
this	O
regimen	O
.	O
	
Weekly	O
infusional	O
high-dose	O
fluorouracil	B-DRUG
(	O
HD-FU	B-DRUG
)	O
","	O
HD-FU	B-DRUG
plus	O
folinic	B-DRUG
acid	I-DRUG
(	O
HD-FU	B-DRUG
/	O
FA	B-DRUG
)	O
","	O
or	O
HD-FU	B-DRUG
/	O
FA	B-DRUG
plus	O
biweekly	O
cisplatin	B-DRUG
in	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
:	O
randomized	O
phase	O
II	O
trial	O
40953	O
of	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Gastrointestinal	O
Group	O
and	O
the	O
Arbeitsgemeinschaft	O
Internistische	O
Onkologie	O
.	O
	
	
This	O
multicentric	O
","	O
randomized	O
","	O
two-stage	O
phase	O
II	O
trial	O
evaluated	O
three	O
simplified	O
weekly	O
infusional	O
regimens	O
of	O
fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
or	O
FU	B-DRUG
plus	O
folinic	B-DRUG
acid	I-DRUG
(	O
FA	B-DRUG
)	O
and	O
cisplatin	B-DRUG
(	O
Cis	B-DRUG
)	O
with	O
the	O
aim	O
to	O
select	O
a	O
regimen	O
for	O
future	O
phase	O
III	O
trials	O
.	O
	
A	O
total	O
of	O
145	O
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
where	O
randomly	O
assigned	O
to	O
weekly	O
FU	B-DRUG
"3,000"	O
mg	O
/	O
m2	O
/	O
24	O
hours	O
(	O
HD-FU	B-DRUG
)	O
","	O
FU	B-DRUG
"2,600"	O
mg	O
/	O
m2	O
/	O
24	O
hours	O
plus	O
dl-FA	B-DRUG
500	O
mg	O
/	O
m2	O
or	O
l-FA	B-DRUG
250	O
mg	O
/	O
m2	O
(	O
HD-FU	B-DRUG
/	O
FA	B-DRUG
)	O
","	O
or	O
FU	B-DRUG
2000	O
mg	O
/	O
m2	O
/	O
24	O
hours	O
plus	O
FA	B-DRUG
plus	O
biweekly	O
Cis	B-DRUG
50	O
mg	O
/	O
m2	O
","	O
each	O
administered	O
for	O
6	O
weeks	O
with	O
a	O
1-week	O
rest	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
the	O
response	O
rate	O
.	O
	
Confirmed	O
responses	O
were	O
observed	O
in	O
6.1	O
%	O
(	O
two	O
of	O
33	O
)	O
of	O
the	O
eligible	O
patients	O
treated	O
with	O
HD-FU	B-DRUG
","	O
in	O
25	O
%	O
(	O
12	O
of	O
48	O
","	O
including	O
one	O
complete	O
remission	O
[	O
CR	O
]	O
)	O
with	O
HD-FU	B-DRUG
/	O
FA	B-DRUG
","	O
and	O
in	O
45.7	O
%	O
(	O
21	O
of	O
46	O
","	O
including	O
four	O
CRs	O
)	O
with	O
HD-FU	B-DRUG
/	O
FA	B-DRUG
/	O
Cis	B-DRUG
.	O
	
The	O
HD-FU	B-DRUG
arm	O
was	O
closed	O
after	O
stage	O
1	O
because	O
the	O
required	O
minimum	O
number	O
of	O
responses	O
was	O
not	O
met	O
.	O
	
The	O
median	O
progression-free	O
survival	O
of	O
all	O
patients	O
in	O
the	O
HD-FU	B-DRUG
","	O
HD-FU	B-DRUG
/	O
FA	B-DRUG
","	O
and	O
HD-FU	B-DRUG
/	O
FA	B-DRUG
/	O
Cis	B-DRUG
arm	O
was	O
1.9	O
","	O
4	O
","	O
and	O
6.1	O
months	O
","	O
respectively	O
.	O
	
The	O
median	O
overall	O
survival	O
was	O
7.1	O
","	O
8.9	O
","	O
and	O
9.7	O
months	O
","	O
and	O
the	O
survival	O
rate	O
at	O
1	O
year	O
was	O
24.3	O
%	O
","	O
30.3	O
%	O
","	O
and	O
45.3	O
%	O
","	O
respectively	O
.	O
	
Grade	O
4	O
toxicities	O
were	O
rare	O
.	O
	
The	O
most	O
relevant	O
grade	O
3	O
/	O
4	O
toxicities	O
were	O
neutropenia	B-TOXI
in	O
1.9	O
%	O
","	O
5.4	O
%	O
","	O
and	O
19.6	O
%	O
","	O
and	O
diarrhea	B-TOXI
in	O
2.7	O
%	O
","	O
1.9	O
%	O
","	O
and	O
3.9	O
%	O
of	O
the	O
cycles	O
in	O
the	O
HD-FU	B-DRUG
","	O
HD-FU	B-DRUG
/	O
FA	O
","	O
and	O
HD-	O
/	O
FU	B-DRUG
/	O
Cis	B-DRUG
arms	O
","	O
respectively	O
.	O
	
Weekly	O
infusional	B-DRUG
FU	I-DRUG
/	O
FA	B-DRUG
plus	O
biweekly	O
Cis	B-DRUG
is	O
effective	O
and	O
safe	O
in	O
patients	O
with	O
gastric	B-CANCER
cancer	I-CANCER
.	O
	
Randomised	O
phase	O
III	O
trial	O
of	O
carboplatin	B-DRUG
plus	O
etoposide	B-DRUG
vs	O
split	O
doses	O
of	O
cisplatin	B-DRUG
plus	O
etoposide	B-DRUG
in	O
elderly	O
or	O
poor-risk	O
patients	O
with	O
extensive	O
disease	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
JCOG	O
9702	O
.	O
	
	
We	O
compared	O
the	O
efficacy	O
and	O
the	O
safety	O
of	O
a	O
carboplatin	B-DRUG
plus	O
etoposide	B-DRUG
regimen	O
(	O
CE	O
)	O
vs	O
split	O
doses	O
of	O
cisplatin	B-DRUG
plus	O
etoposide	B-DRUG
(	O
SPE	O
)	O
in	O
elderly	O
or	O
poor-risk	O
patients	O
with	O
extensive	O
disease	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
ED-SCLC	O
)	O
.	O
	
Eligibility	O
criteria	O
included	O
:	O
untreated	O
ED-SCLC	O
;	O
age	O
&	O
gt	O
;	O
/	O
70	O
and	O
performance	O
status	O
0-2	O
","	O
or	O
age	O
&	O
lt	O
;	O
70	O
and	O
PS	O
3	O
The	O
CE	O
arm	O
received	O
carboplatin	B-DRUG
area	O
under	O
the	O
curve	O
of	O
five	O
intravenously	O
(	O
IV	O
)	O
on	O
day	O
1	O
and	O
etoposide	B-DRUG
80	O
mg	O
m	O
(	O
-2	O
)	O
IV	O
on	O
days	O
1月3日	O
.	O
	
The	O
SPE	O
arm	O
received	O
cisplatin	B-DRUG
25	O
mg	O
m	O
(	O
-2	O
)	O
IV	O
on	O
days	O
1月3日	O
and	O
etoposide	B-DRUG
80	O
mg	O
m	O
(	O
-2	O
)	O
IV	O
on	O
days	O
1月3日	O
.	O
	
Both	O
regimens	O
were	O
given	O
with	O
granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
support	O
in	O
a	O
21-28	O
day	O
cycle	O
for	O
four	O
courses	O
.	O
	
A	O
total	O
of	O
220	O
patients	O
were	O
randomised	O
.	O
	
Median	O
age	O
was	O
74	O
years	O
and	O
74	O
%	O
had	O
a	O
PS	O
of	O
0	O
or	O
1	O
Major	O
grade	O
3月4日	O
toxicities	O
were	O
(	O
%	O
CE	O
/	O
%	O
SPE	O
)	O
:	O
leucopenia	B-TOXI
54	O
/	O
51	O
","	O
neutropenia	B-TOXI
95	O
/	O
90	O
","	O
thrombocytopenia	B-TOXI
56	O
/	O
16	O
","	O
infection	B-TOXI
7	O
/	O
6	O
There	O
was	O
no	O
significant	O
difference	O
(	O
CE	O
/	O
SPE	O
)	O
in	O
the	O
response	O
rate	O
(	O
73	O
/	O
73	O
%	O
)	O
and	O
overall	O
survival	O
(	O
median	O
10.6	O
/	O
9.9	O
mo	O
;	O
P=0.54	O
)	O
.	O
	
Palliation	O
scores	O
were	O
very	O
similar	O
between	O
the	O
arms	O
.	O
	
Although	O
the	O
SPE	O
regimen	O
is	O
still	O
considered	O
to	O
be	O
the	O
standard	O
treatment	O
in	O
elderly	O
or	O
poor-risk	O
patients	O
with	O
ED-SCLC	O
","	O
the	O
CE	O
regimen	O
can	O
be	O
an	O
alternative	O
for	O
this	O
population	O
considering	O
the	O
risk-benefit	O
balance	O
.	O
	
First	O
clinical	O
experience	O
of	O
orally	O
active	O
epidermal	O
growth	O
factor	O
receptor	O
inhibitor	O
combined	O
with	O
simplified	O
FOLFOX6	B-DRUG
as	O
first-line	O
treatment	O
for	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
Gefitinib	B-DRUG
","	O
an	O
orally	O
active	O
inhibitor	O
of	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
tyrosine	O
kinase	O
","	O
combined	O
with	O
chemotherapy	O
","	O
has	O
shown	O
efficacy	O
as	O
second-line	O
treatment	O
for	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
CRC	B-CANCER
)	O
.	O
	
Gefitinib	B-DRUG
combined	O
with	O
FOLFOX6	B-DRUG
(	O
oxaliplatin	B-DRUG
plus	O
folinic	B-DRUG
acid	I-DRUG
and	O
5-fluorouracil	B-DRUG
)	O
was	O
tested	O
as	O
a	O
first-line	O
therapy	O
.	O
	
Patients	O
with	O
metastatic	O
EGFR-positive	O
CRC	B-CANCER
received	O
gefitinib	B-DRUG
at	O
a	O
dose	O
of	O
250	O
mg	O
/	O
day	O
combined	O
with	O
simplified	O
FOLFOX6	B-DRUG
.	O
	
Gefitinib	B-DRUG
was	O
continued	O
as	O
maintenance	O
treatment	O
in	O
nonprogressing	O
patients	O
.	O
	
Responses	O
were	O
assessed	O
by	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	B-CANCER
Tumors	I-CANCER
(	O
RECIST	O
)	O
criteria	O
and	O
adverse	O
events	O
were	O
assessed	O
with	O
the	O
National	O
Cancer	O
Institute	O
Common	O
Toxicity	O
Criteria	O
(	O
NCI-CTC	O
)	O
scale	O
.	O
	
A	O
total	O
of	O
56	O
patients	O
were	O
recruited	O
.	O
	
There	O
were	O
26	O
men	O
and	O
30	O
women	O
","	O
with	O
a	O
median	O
age	O
of	O
57.5	O
years	O
.	O
	
The	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
(	O
ECOG	O
)	O
performance	O
status	O
was	O
as	O
follows	O
:	O
0	O
in	O
39	O
patients	O
","	O
1	O
in	O
12	O
patients	O
","	O
and	O
2	O
in	O
5	O
patients	O
.	O
	
Thirty-nine	O
patients	O
(	O
69.6	O
%	O
)	O
had	O
stage	O
IV	O
disease	O
at	O
diagnosis	O
","	O
92.9	O
%	O
had	O
liver	O
involvement	O
","	O
and	O
46.4	O
%	O
had	O
&	O
gt	O
;	O
or	O
2	O
metastatic	O
sites	O
.	O
	
All	O
patients	O
were	O
evaluated	O
for	O
safety	O
","	O
and	O
53	O
were	O
evaluated	O
for	O
response	O
:	O
40	O
patients	O
(	O
71.4	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
95	O
%	O
CI	O
]	O
","	O
57.8	O
%	O
-82.6	O
%	O
)	O
had	O
complete	O
or	O
partial	O
responses	O
","	O
and	O
11	O
patients	O
(	O
19.6	O
%	O
)	O
had	O
stable	O
disease	O
.	O
	
Median	O
time	O
to	O
progression	O
was	O
7	O
months	O
(	O
range	O
","	O
2.1-33.0	O
months	O
;	O
95	O
%	O
CI	O
","	O
6.2-9.0	O
months	O
)	O
.	O
	
Radical	O
surgery	O
or	O
thermoablation	O
of	O
metastatic	O
sites	O
was	O
performed	O
in	O
14	O
patients	O
(	O
25	O
%	O
)	O
.	O
	
NCI-CTC	O
grade	O
3月4日	O
events	O
occurred	O
in	O
36	O
patients	O
(	O
64.3	O
%	O
)	O
:	O
diarrhea	B-TOXI
in	O
9	O
patients	O
(	O
16.1	O
%	O
)	O
","	O
and	O
hematologic	B-TOXI
toxicity	I-TOXI
in	O
13	O
patients	O
(	O
23.2	O
%	O
)	O
.	O
	
Four	O
patients	O
(	O
7.1	O
%	O
)	O
were	O
withdrawn	O
for	O
drug-related	O
adverse	O
events	O
.	O
	
The	O
regimen	O
has	O
shown	O
promising	O
efficacy	O
with	O
manageable	O
toxicity	O
as	O
a	O
first-line	O
treatment	O
for	O
patients	O
with	O
advanced	B-CANCER
CRC	I-CANCER
.	O
	
Docetaxel-ifosfamide	B-DRUG
combination	O
in	O
patients	O
with	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
failing	O
prior	O
anthracycline-based	B-DRUG
regimens	O
:	O
results	O
of	O
a	O
phase	O
I-II	O
study	O
.	O
	
	
The	O
established	O
clinical	O
activity	O
of	O
docetaxel	B-DRUG
and	O
ifosfamide	B-DRUG
as	O
single	O
agents	O
in	O
anthracycline	B-DRUG
pre-treated	O
breast	B-CANCER
cancer	I-CANCER
","	O
led	O
us	O
to	O
conduct	O
a	O
phase	O
I-II	O
study	O
to	O
define	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
","	O
and	O
clinical	O
activity	O
of	O
the	O
docetaxel+ifosfamide	B-DRUG
combination	O
in	O
this	O
setting	O
.	O
	
Patients	O
with	O
histologically	O
confirmed	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
","	O
after	O
failure	O
on	O
prior	O
anthracycline-based	B-DRUG
chemotherapy	O
","	O
were	O
treated	O
at	O
successive	O
dose	O
levels	O
(	O
DLs	O
)	O
in	O
cohorts	O
of	O
3月6日	O
with	O
escalated	O
doses	O
of	O
docetaxel	B-DRUG
70-100	O
mg	O
/	O
m	O
(	O
2	O
)	O
over	O
1	O
h	O
on	O
day	O
1	O
followed	O
by	O
ifosfamide	B-DRUG
5月6日	O
g	O
/	O
m	O
(	O
2	O
)	O
divided	O
over	O
days	O
1+2	O
(	O
2.5-3.0	O
g	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
over	O
1	O
h	O
)	O
","	O
every	O
21	O
days	O
.	O
	
G-CSF	B-DRUG
was	O
added	O
once	O
dose-limiting	O
neutropenia	B-TOXI
was	O
encountered	O
at	O
a	O
certain	O
DL	O
and	O
planned	O
to	O
be	O
incorporated	O
prophylactically	O
in	O
subsequent	O
higher	O
DLs	O
.	O
	
Between	O
March	O
1997	O
and	O
December	O
2002	O
","	O
65	O
patients	O
with	O
a	O
median	O
age	O
of	O
57	O
years	O
(	O
range	O
","	O
32-72	O
)	O
and	O
performance	O
status	O
(	O
WHO	O
)	O
of	O
1	O
(	O
range	O
","	O
0-2	O
)	O
were	O
treated	O
at	O
5	O
DLs	O
as	O
follows	O
;	O
21	O
in	O
phase	O
I	O
DLs	O
(	O
DL1	O
:	O
3	O
","	O
DL2	O
:	O
6	O
","	O
DL3	O
:	O
3	O
","	O
DL4	O
:	O
6	O
","	O
and	O
DL5	O
:	O
3	O
)	O
and	O
the	O
remaining	O
44	O
were	O
treated	O
at	O
DL4	O
(	O
total	O
of	O
50	O
patients	O
at	O
DL4	O
)	O
","	O
which	O
was	O
defined	O
as	O
the	O
level	O
for	O
phase	O
II	O
testing	O
.	O
	
All	O
patients	O
were	O
assessable	O
for	O
toxicity	O
and	O
62	O
for	O
response	O
.	O
	
DLT	O
(	O
with	O
the	O
addition	O
of	O
G-CSF	B-DRUG
after	O
DL2	O
)	O
was	O
reached	O
at	O
DL5	O
with	O
2	O
/	O
3	O
initial	O
patients	O
developing	O
febrile	B-TOXI
neutropenia	I-TOXI
.	O
	
Clinical	O
response	O
rates	O
(	O
RRs	O
)	O
","	O
on	O
an	O
intention-to-treat	O
basis	O
","	O
in	O
phase	O
II	O
were	O
:	O
56	O
%	O
;	O
(	O
95	O
%	O
CI	O
","	O
42.2-69.7	O
%	O
)	O
;	O
4	O
CRs	O
","	O
24	O
PRs	O
","	O
10	O
SD	O
and	O
12	O
PD.	O
The	O
median	O
response	O
duration	O
was	O
7	O
mo	O
(	O
3月24日	O
mo	O
)	O
","	O
median	O
TTP	O
6.5	O
mo	O
(	O
0.1-26	O
mo	O
)	O
","	O
and	O
median	O
OS	O
13	O
mo	O
(	O
0.1-33	O
mo	O
)	O
.	O
	
Grade	O
3	O
/	O
4	O
toxicities	O
included	O
:	O
neutropenia	B-TOXI
in	O
72	O
%	O
of	O
patients	O
","	O
with	O
60	O
%	O
developing	O
grade	O
4	O
neutropenia	B-TOXI
(	O
&	O
lt	O
;	O
or=7	O
days	O
)	O
and	O
in	O
10	O
%	O
of	O
these	O
febrile	B-TOXI
neutropenia	I-TOXI
","	O
while	O
no	O
grade	O
3	O
/	O
4	O
thrombocytopenia	B-TOXI
was	O
observed	O
.	O
	
Other	O
toxicities	O
included	O
peripheral	B-TOXI
neuropathy	I-TOXI
grade	O
2	O
only	O
in	O
10	O
%	O
","	O
grade	O
1	O
/	O
2	O
reversible	O
CNS	B-TOXI
toxicity	I-TOXI
in	O
16	O
%	O
","	O
no	O
renal	B-TOXI
toxicity	I-TOXI
","	O
grade	O
2	O
myalgias	B-TOXI
in	O
8	O
%	O
","	O
grade	O
3	O
diarrhea	B-TOXI
in	O
8	O
%	O
","	O
skin	B-TOXI
/	I-TOXI
nail	I-TOXI
toxicity	I-TOXI
in	O
14	O
%	O
","	O
and	O
grade	O
2	O
fluid	B-TOXI
retention	I-TOXI
in	O
2	O
%	O
of	O
patients	O
.	O
	
One	O
patient	O
in	O
the	O
study	O
treated	O
at	O
phase	O
II	O
died	B-TOXI
as	I-TOXI
a	I-TOXI
result	I-TOXI
of	I-TOXI
acute	I-TOXI
liver	I-TOXI
failure	I-TOXI
after	O
the	O
first	O
cycle	O
.	O
	
The	O
present	O
phase	O
I-II	O
study	O
has	O
determined	O
the	O
feasibility	O
","	O
defined	O
the	O
MTD	O
and	O
demonstrated	O
the	O
encouraging	O
activity	O
of	O
the	O
docetaxel-ifosfamide	B-DRUG
combination	O
in	O
the	O
phase	O
II	O
part	O
of	O
the	O
study	O
.	O
	
Therefore	O
","	O
future	O
randomized	O
phase	O
III	O
studies	O
versus	O
single-agent	O
docetaxel	B-DRUG
or	O
combinations	O
of	O
the	O
latter	O
with	O
other	O
active	O
agents	O
are	O
warranted	O
.	O
	
Phase-II	O
study	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
in	O
patients	O
with	O
metastatic	O
biliary	O
and	O
gallbladder	B-CANCER
cancer	I-CANCER
.	O
	
	
There	O
is	O
no	O
standard	O
chemotherapy	O
option	O
for	O
patients	O
with	O
biliary	B-CANCER
tract	I-CANCER
cancers	I-CANCER
.	O
	
These	O
patients	O
present	O
fairly	O
ill	O
and	O
can	O
have	O
a	O
rapid	O
progression	B-TOXI
of	I-TOXI
disease	I-TOXI
.	O
	
We	O
conducted	O
a	O
multi-center	O
","	O
phase-II	O
trial	O
for	O
patients	O
with	O
locally	O
unresectable	O
or	O
metastatic	O
bile	O
duct	O
or	O
gallbladder	B-CANCER
adenocarcinomas	I-CANCER
using	O
a	O
modified	O
regimen	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
to	O
potentially	O
improve	O
tolerability	O
.	O
	
Patients	O
received	O
a	O
21-day	O
treatment	O
cycle	O
of	O
gemcitabine	B-DRUG
at	O
"1,000"	O
mg	O
/	O
m2	O
and	O
cisplatin	B-DRUG
at	O
30	O
mg	O
/	O
m2	O
on	O
days	O
1	O
and	O
8	O
To	O
participate	O
","	O
33	O
patients	O
signed	O
informed	O
consent	O
","	O
and	O
30	O
patients	O
received	O
at	O
least	O
one	O
dose	O
of	O
chemotherapy	O
.	O
	
By	O
intention-to-treat	O
analyses	O
","	O
7	O
patients	O
(	O
21	O
%	O
)	O
experienced	O
a	O
partial	O
response	O
and	O
another	O
12	O
(	O
36	O
%	O
)	O
had	O
stable	O
disease	O
for	O
at	O
least	O
12	O
weeks	O
.	O
	
The	O
median	O
progression-free	O
survival	O
was	O
6.3	O
months	O
and	O
median	O
overall	O
survival	O
was	O
9.7	O
months	O
.	O
	
After	O
1	O
year	O
","	O
39	O
%	O
of	O
patients	O
were	O
alive	O
.	O
	
Most	O
common	O
grade	O
3月4日	O
toxicities	O
included	O
neutropenia	B-TOXI
(	O
33	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
23	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
20	O
%	O
)	O
","	O
nausea	B-TOXI
(	O
20	O
%	O
)	O
","	O
emesis	B-TOXI
(	O
13	O
%	O
)	O
and	O
fatigue	B-TOXI
(	O
10	O
%	O
)	O
.	O
	
Of	O
note	O
","	O
52	O
%	O
of	O
patients	O
withdrew	O
from	O
study	O
treatment	O
","	O
principally	O
due	O
to	O
treatment-related	O
adverse	O
events	O
.	O
	
We	O
concluded	O
that	O
this	O
modified	O
regimen	O
appeared	O
to	O
have	O
comparable	O
activity	O
to	O
other	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
regimens	O
against	O
advanced	O
bile	O
duct	O
and	O
gallbladder	B-CANCER
cancers	I-CANCER
","	O
but	O
there	O
was	O
still	O
moderate	O
toxicity	O
in	O
this	O
patient	O
population	O
.	O
	
Phase	O
1	O
study	O
of	O
lonafarnib	B-DRUG
(	O
SCH	O
66336	O
)	O
and	O
imatinib	B-DRUG
mesylate	I-DRUG
in	O
patients	O
with	O
chronic	B-CANCER
myeloid	I-CANCER
leukemia	I-CANCER
who	O
have	O
failed	O
prior	O
single-agent	O
therapy	O
with	O
imatinib	B-DRUG
.	O
	
	
Lonafarnib	B-DRUG
is	O
an	O
orally	O
bioavailable	O
nonpetidomimetic	O
farnesyl	O
transferase	O
inhibitor	O
with	O
significant	O
activity	O
against	O
BCR-ABL-positive	O
cell	O
lines	O
and	O
primary	O
human	O
chronic	B-CANCER
myeloid	I-CANCER
leukemia	I-CANCER
(	O
CML	O
)	O
cells	O
.	O
	
Lonafarnib	B-DRUG
can	O
inhibit	O
the	O
proliferation	O
of	O
imatinib-resistant	B-DRUG
cells	O
and	O
increases	O
imatinib-induced	B-DRUG
apoptosis	O
in	O
vitro	O
in	O
cells	O
from	O
imatinib-resistant	B-DRUG
patients	O
.	O
	
The	O
authors	O
conducted	O
a	O
phase	O
1	O
study	O
of	O
lonafarnib	B-DRUG
in	O
combination	O
with	O
imatinib	B-DRUG
in	O
patients	O
with	O
CML	O
who	O
failed	O
imatinib	B-DRUG
therapy	O
.	O
	
The	O
starting	O
dose	O
level	O
for	O
patients	O
with	O
chronic	O
phase	O
(	O
CP	O
)	O
disease	O
was	O
imatinib	B-DRUG
","	O
400	O
mg	O
/	O
day	O
","	O
plus	O
lonafarnib	B-DRUG
at	O
a	O
dose	O
of	O
100	O
mg	O
twice	O
daily	O
.	O
	
The	O
starting	O
dose	O
levels	O
for	O
accelerated	O
phase	O
(	O
AP	O
)	O
and	O
blast	O
phase	O
(	O
BP	O
)	O
disease	O
were	O
600	O
mg	O
/	O
day	O
and	O
100	O
mg	O
twice	O
daily	O
","	O
respectively	O
.	O
	
A	O
total	O
of	O
23	O
patients	O
were	O
treated	O
(	O
9	O
with	O
CP	O
","	O
11	O
with	O
AP	O
","	O
and	O
3	O
with	O
BP	O
)	O
for	O
a	O
median	O
of	O
25	O
weeks	O
(	O
range	O
","	O
4-102	O
weeks	O
)	O
.	O
	
Of	O
those	O
with	O
CP	O
disease	O
","	O
2	O
patients	O
had	O
grade	O
3	O
(	O
according	O
to	O
the	O
National	O
Cancer	O
Institute	O
Common	O
Toxicity	O
Criteria	O
[	O
version	O
2	O
]	O
)	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
at	O
the	O
400	O
=+	O
125-mg	O
dose	O
","	O
including	O
diarrhea	B-TOXI
(	O
2	O
patients	O
)	O
","	O
vomiting	B-TOXI
(	O
1	O
patient	O
)	O
","	O
and	O
fatigue	B-TOXI
(	O
1	O
patient	O
)	O
.	O
	
In	O
patients	O
with	O
AP	O
/	O
BP	O
disease	O
","	O
DLTs	O
were	O
observed	O
at	O
the	O
600	O
=+	O
125-mg	O
dose	O
and	O
was	O
comprised	O
of	O
diarrhea	B-TOXI
(	O
1	O
patient	O
)	O
and	O
hypokalemia	B-TOXI
(	O
1	O
patient	O
)	O
.	O
	
Eight	O
patients	O
(	O
35	O
%	O
)	O
responded	O
;	O
3	O
with	O
CP	O
disease	O
achieved	O
a	O
complete	O
hematologic	O
response	O
(	O
CHR	O
)	O
(	O
2	O
patients	O
)	O
and	O
a	O
complete	O
cytogenetic	O
response	O
(	O
1	O
patient	O
)	O
.	O
	
Three	O
patients	O
with	O
AP	O
disease	O
responded	O
(	O
2	O
CHR	O
","	O
1	O
partial	O
cytogenetic	O
response	O
)	O
","	O
and	O
2	O
patients	O
with	O
BP	O
disease	O
demonstrated	O
hematologic	O
improvement	O
.	O
	
Pharmacokinetics	O
data	O
suggest	O
no	O
apparent	O
increase	O
in	O
exposure	O
or	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
lonafarnib	B-DRUG
or	O
imatinib	B-DRUG
when	O
they	O
are	O
coadministered	O
.	O
	
The	O
results	O
of	O
the	O
current	O
study	O
indicate	O
that	O
the	O
combination	O
of	O
lonafarnib	B-DRUG
and	O
imatinib	B-DRUG
is	O
well	O
tolerated	O
and	O
the	O
maximum	O
tolerated	O
dose	O
of	O
lonafarnib	B-DRUG
is	O
100	O
mg	O
twice	O
daily	O
when	O
combined	O
with	O
imatinib	B-DRUG
at	O
a	O
dose	O
of	O
either	O
400	O
mg	O
or	O
600	O
mg	O
daily	O
.	O
	
Gemcitabine	B-DRUG
","	O
ifosfamide	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
advanced	B-CANCER
/	I-CANCER
metastatic	I-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
patients	O
:	O
a	O
phase	O
II	O
study	O
.	O
	
	
Although	O
platinum-based	O
two-drug	O
combinations	O
represent	O
the	O
elective	O
therapeutic	O
approach	O
for	O
advanced	B-CANCER
/	I-CANCER
metastatic	I-CANCER
NSCLC	I-CANCER
","	O
there	O
is	O
still	O
interest	O
in	O
exploring	O
the	O
efficacy	O
and	O
tolerability	O
of	O
platinum-free	B-DRUG
combinations	O
including	O
third	O
generation	O
agents	O
in	O
selected	O
NSCLC	B-CANCER
population	O
.	O
	
Based	O
on	O
the	O
satisfying	O
activity	O
of	O
gemcitabine	B-DRUG
(	O
G	O
)	O
","	O
ifosfamide	B-DRUG
(	O
I	O
)	O
and	O
paclitaxel	B-DRUG
(	O
T	O
)	O
as	O
single	O
agents	O
in	O
NSCLC	B-CANCER
","	O
we	O
have	O
designed	O
a	O
phase	O
II	O
study	O
to	O
explore	O
an	O
alternative	O
approach	O
to	O
platinum-containing	B-DRUG
regimens	O
using	O
a	O
combination	O
of	O
these	O
three	O
drugs	O
.	O
	
To	O
investigate	O
the	O
activity	O
/	O
toxicity	O
of	O
T	O
175	O
mg	O
/	O
m2	O
on	O
day	O
1	O
","	O
I	O
3	O
g	O
/	O
m2	O
on	O
day	O
1	O
(	O
with	O
Mesna	O
uroprotection	O
)	O
and	O
G	O
"1,000"	O
mg	O
/	O
m2	O
on	O
day	O
1月8日	O
","	O
every	O
3	O
weeks	O
in	O
the	O
treatment	O
of	O
advanced	B-CANCER
/	I-CANCER
metastatic	I-CANCER
NSCLC	I-CANCER
","	O
46	O
patients	O
(	O
38	O
male	O
","	O
8	O
female	O
)	O
with	O
NSCLC	B-CANCER
were	O
enrolled	O
:	O
mean	O
age	O
58	O
(	O
range	O
33-70	O
)	O
;	O
Stage	O
IIIB	O
/	O
IV=15	O
/	O
31	O
;	O
ECOG	O
PS	O
0-1	O
/	O
2=31	O
/	O
15	O
;	O
adenocarcinoma=20	B-CANCER
","	O
squamous=14	O
","	O
large	O
cell=3	O
","	O
NSCLC=8	B-CANCER
","	O
adenosquamous=1.	B-CANCER
A	O
total	O
of	O
221	O
cycles	O
have	O
been	O
administered	O
(	O
median	O
number	O
4.8	O
for	O
patients	O
)	O
.	O
	
In	O
intent-to-treat	O
analysis	O
","	O
partial	O
response	O
was	O
achieved	O
in	O
17	O
patients	O
(	O
36.95	O
%	O
)	O
","	O
stable	O
disease	O
and	O
progressive	O
disease	O
was	O
detected	O
in	O
16	O
(	O
34.78	O
%	O
)	O
and	O
10	O
(	O
21.73	O
%	O
)	O
patients	O
","	O
respectively	O
.	O
	
Time	O
to	O
progression	O
was	O
30.9	O
weeks	O
;	O
median	O
survival	O
time	O
was	O
42.7	O
weeks	O
;	O
the	O
survival	O
rates	O
at	O
12	O
and	O
18	O
months	O
were	O
34.79	O
and	O
15.21	O
%	O
","	O
respectively	O
.	O
	
No	O
toxic	B-TOXI
deaths	I-TOXI
occurred	O
.	O
	
No	O
patients	O
experienced	O
grade	O
4	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
.	O
	
Neutropenia	B-TOXI
grade	O
3	O
occurred	O
in	O
10	O
patients	O
(	O
21.7	O
%	O
)	O
;	O
Anemia	B-TOXI
grade	O
3	O
in	O
1	O
(	O
2.1	O
%	O
)	O
;	O
Thrombocytopenia	B-TOXI
grade	O
2	O
in	O
two	O
patients	O
(	O
4.3	O
%	O
)	O
and	O
grade	O
3	O
in	O
one	O
(	O
2.1	O
%	O
)	O
.	O
	
Peripheral	B-TOXI
neuropathy	I-TOXI
grade	O
1	O
occurred	O
in	O
ten	O
(	O
21.7	O
%	O
)	O
and	O
grade	O
2	O
in	O
two	O
patients	O
(	O
4.3	O
%	O
)	O
.	O
	
Additional	O
non-haematological	B-TOXI
toxicities	I-TOXI
were	O
mild	O
nausea	B-TOXI
","	O
emesis	B-TOXI
and	O
fatigue	B-TOXI
.	O
	
GIT	O
is	O
well	O
tolerated	O
and	O
active	O
regimen	O
in	O
both	O
advanced	B-CANCER
and	I-CANCER
metastatic	I-CANCER
NSCLC	I-CANCER
.	O
	
These	O
data	O
suggest	O
future	O
investigations	O
for	O
GIT	O
schedule	O
as	O
a	O
possible	O
alternative	O
to	O
platinum-based	B-DRUG
regimens	O
in	O
selected	O
advanced	O
/	O
metastatic	B-CANCER
NSCLC	I-CANCER
patients	O
where	O
survival	O
","	O
tolerability	O
and	O
quality	O
of	O
life	O
are	O
the	O
primary	O
goals	O
.	O
	
A	O
dose	O
escalation	O
study	O
of	O
gemcitabine	B-DRUG
plus	O
pemetrexed	B-DRUG
administered	O
biweekly	O
in	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
The	O
study	O
aimed	O
to	O
determine	O
the	O
maximum	O
tolerated	O
doses	O
(	O
MTDs	O
)	O
and	O
identify	O
the	O
dose-limiting	O
toxicities	O
of	O
the	O
biweekly	O
administration	O
of	O
pemetrexed	B-DRUG
plus	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
Patients	O
with	O
advanced	B-CANCER
malignancies	I-CANCER
were	O
treated	O
with	O
escalated	O
doses	O
of	O
gemcitabine	B-DRUG
and	O
pemetrexed	B-DRUG
(	O
starting	O
doses	O
"1,250"	O
and	O
300	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
respectively	O
)	O
both	O
given	O
on	O
days	O
1	O
and	O
15	O
in	O
cycles	O
of	O
4	O
weeks	O
.	O
	
Forty-one	O
patients	O
were	O
treated	O
at	O
7	O
dose	O
levels	O
.	O
	
The	O
MTD	O
was	O
reached	O
at	O
the	O
dose	O
of	O
"1,750"	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
gemcitabine	B-DRUG
and	O
450	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
pemetrexed	O
.	O
	
Dose-limiting	O
events	O
were	O
grade	O
IV	O
neutropenia	B-TOXI
","	O
febrile	B-TOXI
neutropenia	I-TOXI
and	O
treatment	O
delay	O
due	O
to	O
grade	O
III	O
hematological	B-TOXI
toxicities	I-TOXI
.	O
	
One	O
partial	O
response	O
in	O
a	O
pretreated	O
patient	O
with	O
ovarian	B-CANCER
cancer	I-CANCER
was	O
observed	O
","	O
while	O
4	O
other	O
patients	O
experienced	O
stable	O
disease	O
.	O
	
The	O
biweekly	O
administration	O
of	O
gemcitabine	B-DRUG
plus	O
pemetrexed	B-DRUG
at	O
the	O
recommended	O
MTDs	O
is	O
safe	O
","	O
well	O
tolerated	O
and	O
demonstrates	O
antitumor	O
activity	O
which	O
merits	O
further	O
evaluation	O
in	O
phase	O
II	O
studies	O
.	O
	
Gemcitabine	B-DRUG
with	O
a	O
specific	O
conformal	O
3D	O
5FU	B-DRUG
radiochemotherapy	O
technique	O
is	O
safe	O
and	O
effective	O
in	O
the	O
definitive	O
management	O
of	O
locally	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
aim	O
of	O
this	O
phase	O
II	O
study	O
was	O
to	O
assess	O
the	O
feasibility	O
and	O
efficacy	O
of	O
a	O
specific	O
three-dimensional	O
conformal	O
radiotherapy	O
technique	O
with	O
concurrent	O
continuous	O
infusion	O
of	O
5-fluorouracil	B-DRUG
(	O
CI	O
5FU	B-DRUG
)	O
sandwiched	O
between	O
gemcitabine	B-DRUG
chemotherapy	O
in	O
patients	O
with	O
locally	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
inoperable	O
cancer	O
in	O
the	O
pancreatic	O
head	O
or	O
body	O
without	O
metastases	O
were	O
given	O
gemcitabine	B-DRUG
at	O
1000	O
mg	O
m	O
(	O
-2	O
)	O
weekly	O
for	O
3	O
weeks	O
followed	O
by	O
a	O
1-week	O
rest	O
and	O
a	O
6-week	O
period	O
of	O
radiotherapy	O
and	O
concurrent	O
CI	O
5FU	B-DRUG
(	O
200	O
mg	O
m	O
(	O
-2	O
)	O
day	O
(	O
-1	O
)	O
)	O
.	O
	
The	O
defined	O
target	O
volume	O
was	O
treated	O
to	O
54	O
Gy	O
in	O
30	O
daily	O
fractions	O
of	O
1.8	O
Gy	O
.	O
	
After	O
4	O
weeks	O
'	O
rest	O
","	O
gemcitabine	B-DRUG
treatment	O
was	O
re-initiated	O
for	O
three	O
cycles	O
(	O
days	O
1	O
","	O
8	O
","	O
15	O
","	O
q28	O
)	O
.	O
	
Forty-one	O
patients	O
were	O
enrolled	O
.	O
	
At	O
the	O
end	O
of	O
radiotherapy	O
","	O
one	O
patient	O
(	O
2.4	O
%	O
)	O
had	O
a	O
complete	O
response	O
and	O
four	O
patients	O
(	O
9.6	O
%	O
)	O
had	O
a	O
partial	O
response	O
;	O
at	O
the	O
end	O
of	O
treatment	O
","	O
three	O
patients	O
(	O
7.3	O
%	O
)	O
had	O
a	O
complete	O
response	O
and	O
two	O
patients	O
(	O
4.9	O
%	O
)	O
had	O
a	O
partial	O
response	O
.	O
	
Median	O
survival	O
time	O
was	O
11.7	O
months	O
","	O
median	O
time	O
to	O
progression	O
was	O
7.1	O
months	O
","	O
and	O
median	O
time	O
to	O
failure	O
of	O
local	O
control	O
was	O
11.9	O
months	O
.	O
	
The	O
-1	O
and	O
2-year	O
survival	O
rates	O
were	O
46.3	O
and	O
9.8	O
%	O
","	O
respectively	O
.	O
	
Treatment-related	O
grade	O
3	O
and	O
4	O
toxicities	O
were	O
reported	O
by	O
16	O
(	O
39	O
%	O
)	O
and	O
four	O
(	O
9.8	O
%	O
)	O
patients	O
","	O
respectively	O
.	O
	
Sixteen	O
out	O
of	O
41	O
patients	O
did	O
not	O
complete	O
the	O
planned	O
treatment	O
and	O
nine	O
due	O
to	O
disease	O
progression	O
.	O
	
This	O
approach	O
to	O
treatment	O
of	O
locally	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
is	O
safe	O
and	O
promising	O
","	O
with	O
good	O
local	O
control	O
for	O
a	O
substantial	O
proportion	O
of	O
patients	O
","	O
and	O
merits	O
testing	O
in	O
a	O
randomised	O
trial	O
.	O
	
Phase	O
II	O
trial	O
of	O
sorafenib	B-DRUG
plus	O
interferon	B-DRUG
alfa-2b	O
as	O
first-	O
or	O
second-line	O
therapy	O
in	O
patients	O
with	O
metastatic	B-CANCER
renal	I-CANCER
cell	I-CANCER
cancer	I-CANCER
.	O
	
	
We	O
undertook	O
this	O
study	O
to	O
determine	O
the	O
activity	O
and	O
tolerability	O
of	O
sorafenib	O
administered	O
with	O
interferon	B-DRUG
alfa-2b	I-DRUG
(	O
IFN-alpha-2b	B-DRUG
)	O
as	O
first-	O
or	O
second-line	O
therapy	O
in	O
metastatic	B-CANCER
renal	I-CANCER
cell	I-CANCER
cancer	I-CANCER
(	O
RCC	B-CANCER
)	O
.	O
	
Between	O
November	O
2004	O
and	O
October	O
2006	O
","	O
40	O
patients	O
at	O
two	O
sites	O
were	O
enrolled	O
onto	O
a	O
phase	O
II	O
trial	O
of	O
sorafenib	B-DRUG
plus	O
IFN-alpha-2b	B-DRUG
.	O
	
Treatment	O
consisted	O
of	O
8-week	O
cycles	O
of	O
sorafenib	B-DRUG
400	O
mg	O
orally	O
bid	O
plus	O
IFN-alpha-2b	B-DRUG
10	O
million	O
U	O
subcutaneously	O
three	O
times	O
a	O
week	O
followed	O
by	O
a	O
2-week	O
break	O
.	O
	
Patients	O
were	O
eligible	O
to	O
receive	O
additional	O
cycles	O
of	O
therapy	O
until	O
disease	O
progression	O
.	O
	
Dose	O
reduction	O
of	O
both	O
drugs	O
by	O
50	O
%	O
was	O
permitted	O
once	O
for	O
toxicity	O
.	O
	
The	O
response	O
rate	O
was	O
33	O
%	O
(	O
95	O
%	O
CI	O
","	O
19	O
%	O
to	O
49	O
%	O
;	O
13	O
of	O
40	O
patients	O
)	O
","	O
including	O
28	O
%	O
partial	O
responses	O
(	O
n	O
=	O
11	O
)	O
and	O
5	O
%	O
complete	O
responses	O
(	O
n	O
=	O
2	O
)	O
.	O
	
Responses	O
were	O
seen	O
in	O
treatment-na茂ve	O
and	O
interleukin-2	B-DRUG
(	O
IL-2	B-DRUG
)	O
#NAME?	O
patients	O
within	O
the	O
first	O
two	O
cycles	O
.	O
	
The	O
median	O
duration	O
of	O
response	O
was	O
12	O
months	O
.	O
	
With	O
a	O
median	O
follow-up	O
time	O
of	O
14	O
months	O
","	O
median	O
progression-free	O
survival	O
time	O
was	O
10	O
months	O
(	O
95	O
%	O
CI	O
","	O
8	O
to	O
18	O
months	O
)	O
","	O
and	O
median	O
overall	O
survival	O
time	O
has	O
not	O
yet	O
been	O
reached	O
.	O
	
Fatigue	B-TOXI
","	O
anorexia	B-TOXI
","	O
anemia	B-TOXI
","	O
diarrhea	B-TOXI
","	O
hypophosphatemia	B-TOXI
","	O
rash	B-TOXI
","	O
nausea	B-TOXI
","	O
and	O
weight	B-TOXI
loss	I-TOXI
were	O
the	O
most	O
common	O
toxicities	O
.	O
	
Grade	O
3	O
toxicities	O
were	O
uncommon	O
but	O
included	O
hypophosphatemia	B-TOXI
","	O
neutropenia	B-TOXI
","	O
rash	B-TOXI
","	O
fatigue	B-TOXI
","	O
and	O
anemia	B-TOXI
.	O
	
Dose	O
reductions	O
were	O
required	O
in	O
65	O
%	O
of	O
patients	O
.	O
	
The	O
combination	O
of	O
sorafenib	B-DRUG
and	O
IFN-alpha-2b	B-DRUG
has	O
substantial	O
activity	O
in	O
treatment-na茂ve	O
and	O
IL-2-treated	B-DRUG
patients	O
with	O
RCC	B-CANCER
.	O
	
The	O
toxicity	O
exceeded	O
that	O
of	O
either	O
drug	O
alone	O
","	O
but	O
dose	O
reductions	O
and	O
breaks	O
between	O
cycles	O
allowed	O
for	O
chronic	O
therapy	O
.	O
	
A	O
larger	O
","	O
randomized	O
trial	O
would	O
determine	O
whether	O
there	O
is	O
any	O
advantage	O
to	O
this	O
regimen	O
compared	O
with	O
sorafenib	B-DRUG
alone	O
.	O
	
Phase	O
I	O
pharmacokinetic	O
and	O
pharmacodynamic	O
study	O
of	O
the	O
oral	O
protein	O
kinase	O
C	O
beta-inhibitor	O
enzastaurin	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
cancer	I-CANCER
.	O
	
	
Enzastaurin	B-DRUG
targets	O
the	O
protein	O
kinase	O
C	O
and	O
phosphatidylinositol	O
3-kinase	O
/	O
AKT	O
pathways	O
to	O
reduce	O
tumor	O
angiogenesis	O
and	O
cell	O
proliferation	O
and	O
to	O
induce	O
cell	O
death	O
.	O
	
A	O
phase	O
I	O
trial	O
was	O
conducted	O
to	O
evaluate	O
the	O
feasibility	O
of	O
combining	O
enzastaurin	B-DRUG
with	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
.	O
	
Patients	O
with	O
advanced	B-DRUG
cancer	I-DRUG
received	O
a	O
14-day	O
lead-in	O
treatment	O
with	O
oral	O
enzastaurin	B-DRUG
followed	O
by	O
subsequent	O
21-day	O
cycles	O
of	O
daily	O
enzastaurin	B-DRUG
","	O
gemcitabine	B-DRUG
on	O
days	O
1	O
and	O
8	O
","	O
and	O
cisplatin	B-DRUG
on	O
day	O
1	O
Enzastaurin	B-DRUG
doses	O
were	O
escalated	O
between	O
350	O
mg	O
once	O
daily	O
to	O
500	O
mg	O
twice	O
daily	O
","	O
whereas	O
gemcitabine	B-DRUG
doses	O
were	O
either	O
"1,000"	O
or	O
"1,250"	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
cisplatin	B-DRUG
doses	O
were	O
either	O
60	O
or	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Circulating	O
endothelial	O
cell	O
numbers	O
and	O
CD146	O
and	O
CD133	O
mRNA	O
expression	O
were	O
evaluated	O
as	O
pharmacodynamic	O
markers	O
.	O
	
Thirty-three	O
patients	O
(	O
median	O
age	O
","	O
58	O
years	O
)	O
were	O
enrolled	O
in	O
seven	O
dose	O
levels	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
was	O
not	O
identified	O
.	O
	
Two	O
dose-limiting	O
toxicities	O
(	O
grade	O
2	O
QT	O
interval	O
corrected	O
for	O
heart	B-TOXI
rate	I-TOXI
prolongation	I-TOXI
and	O
grade	O
3	O
fatigue	B-TOXI
)	O
were	O
reported	O
.	O
	
Other	O
toxicities	O
included	O
grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
(	O
3	O
of	O
6	O
patients	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
1	O
of	O
6	O
patients	O
)	O
","	O
grade	O
3	O
leukopenia	B-TOXI
(	O
2	O
patients	O
)	O
","	O
and	O
fatigue	B-TOXI
(	O
5	O
patients	O
)	O
.	O
	
Enzastaurin	B-DRUG
twice	O
daily	O
(	O
&	O
gt	O
;	O
or	O
250	O
mg	O
)	O
resulted	O
in	O
more	O
discontinuations	O
and	O
low-grade	O
toxicities	O
.	O
	
In	O
the	O
combination	O
","	O
enzastaurin	B-DRUG
exposures	O
decreased	O
slightly	O
but	O
remained	O
above	O
the	O
target	O
of	O
"1,400"	O
nmol	O
/	O
L	O
","	O
whereas	O
gemcitabine	B-DRUG
/	O
cisplatin	B-DRUG
exposures	O
were	O
unaltered	O
.	O
	
Three	O
patients	O
(	O
9.1	O
%	O
)	O
had	O
partial	O
responses	O
and	O
13	O
(	O
39.4	O
%	O
)	O
had	O
stable	O
disease	O
.	O
	
Measurement	O
of	O
circulating	O
endothelial	O
cell	O
numbers	O
and	O
CD146	O
and	O
CD133	O
mRNA	O
expression	O
did	O
not	O
contribute	O
to	O
decision-making	O
on	O
dose	O
escalation	O
.	O
	
Recommended	O
phase	O
II	O
dose	O
is	O
500	O
mg	O
enzastaurin	B-DRUG
once	O
daily	O
","	O
"1,250"	O
mg	O
/	O
m	O
(	O
2	O
)	O
gemcitabine	B-DRUG
","	O
and	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
cisplatin	B-DRUG
.	O
	
This	O
regimen	O
is	O
well	O
tolerated	O
with	O
no	O
significant	O
alterations	O
in	O
the	O
pharmacokinetic	O
variables	O
of	O
any	O
drug	O
.	O
	
Phase	O
I	O
/	O
II	O
trial	O
of	O
temsirolimus	B-DRUG
combined	O
with	O
interferon	B-DRUG
alfa	I-DRUG
for	O
advanced	B-CANCER
renal	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
	
Temsirolimus	B-DRUG
","	O
an	O
inhibitor	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	B-DRUG
","	O
has	O
single-agent	O
activity	O
against	O
advanced	B-CANCER
renal	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
RCC	B-CANCER
)	O
.	O
	
A	O
recommended	O
dose	O
and	O
safety	O
profile	O
for	O
the	O
combination	O
of	O
temsirolimus	B-DRUG
and	O
interferon	B-DRUG
alfa	I-DRUG
(	O
IFN	B-DRUG
)	O
were	O
determined	O
in	O
patients	O
with	O
advanced	B-CANCER
RCC	I-CANCER
.	O
	
Patients	O
were	O
enrolled	O
onto	O
a	O
multicenter	O
","	O
ascending-dose	O
study	O
of	O
temsirolimus	B-DRUG
(	O
5	O
","	O
10	O
","	O
15	O
","	O
20	O
","	O
or	O
25	O
mg	O
)	O
administered	O
intravenously	O
once	O
a	O
week	O
combined	O
with	O
IFN	B-DRUG
(	O
6	O
or	O
9	O
million	O
units	O
[	O
MU	O
]	O
)	O
administered	O
subcutaneously	O
three	O
times	O
per	O
week	O
.	O
	
An	O
expanded	O
cohort	O
was	O
treated	O
at	O
the	O
recommended	O
dose	O
to	O
obtain	O
additional	O
safety	O
and	O
efficacy	O
information	O
.	O
	
Seventy-one	O
patients	O
were	O
entered	O
to	O
receive	O
one	O
of	O
six	O
dose	O
levels	O
.	O
	
The	O
recommended	O
dose	O
was	O
temsirolimus	B-DRUG
15	O
mg	O
/	O
IFN	B-DRUG
6	O
MU	O
based	O
on	O
dose-limiting	O
toxicities	O
of	O
stomatitis	B-TOXI
","	O
fatigue	B-TOXI
","	O
and	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
","	O
which	O
were	O
observed	O
at	O
higher	O
doses	O
of	O
temsirolimus	B-DRUG
and	O
IFN	B-DRUG
.	O
	
The	O
most	O
frequent	O
grade	O
3	O
or	O
4	O
toxicities	O
occurring	O
in	O
any	O
cycle	O
included	O
leukopenia	B-TOXI
","	O
hypophosphatemia	B-TOXI
","	O
asthenia	B-TOXI
","	O
anemia	B-TOXI
","	O
and	O
hypertriglyceridemia	B-TOXI
for	O
all	O
patients	O
and	O
those	O
who	O
received	O
the	O
recommended	O
dose	O
.	O
	
Among	O
patients	O
who	O
received	O
the	O
recommended	O
dose	O
(	O
n	O
=	O
39	O
)	O
","	O
8	O
%	O
achieved	O
partial	O
response	O
and	O
36	O
%	O
had	O
stable	O
disease	O
for	O
at	O
least	O
24	O
weeks	O
.	O
	
Median	O
progression-free	O
survival	O
for	O
all	O
patients	O
in	O
the	O
study	O
was	O
9.1	O
months	O
.	O
	
The	O
combination	O
of	O
temsirolimus	B-DRUG
and	O
IFN	B-DRUG
has	O
an	O
acceptable	O
safety	O
profile	O
and	O
displays	O
antitumor	O
activity	O
in	O
patients	O
with	O
advanced	B-CANCER
RCC	I-CANCER
.	O
	
Temsirolimus	B-DRUG
15	O
mg	O
plus	O
IFN	B-DRUG
6	O
MU	O
is	O
the	O
recommended	O
dose	O
for	O
evaluation	O
in	O
a	O
randomized	O
phase	O
III	O
study	O
.	O
	
A	O
phase	O
II	O
study	O
of	O
capecitabine	B-DRUG
and	O
cisplatin	B-DRUG
(	O
XP	O
)	O
as	O
first-line	O
chemotherapy	O
in	O
patients	O
with	O
advanced	B-CANCER
esophageal	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
	
The	O
combination	O
of	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
and	O
cisplatin	B-DRUG
(	O
FP	B-DRUG
)	O
remains	O
the	O
mostly	O
used	O
regimen	O
for	O
metastatic	B-CANCER
esophageal	I-CANCER
squamous	I-CANCER
carcinoma	I-CANCER
.	O
	
This	O
phase	O
II	O
study	O
assessed	O
the	O
efficacy	O
and	O
safety	O
of	O
capecitabine	B-DRUG
/	O
cisplatin	B-DRUG
(	O
XP	O
)	O
as	O
a	O
first-line	O
chemotherapy	O
in	O
a	O
homogenous	O
cohort	O
of	O
patients	O
with	O
metastatic	B-CANCER
or	I-CANCER
recurrent	I-CANCER
esophageal	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
Patients	O
received	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
cisplatin	B-DRUG
intravenously	O
(	O
IV	O
)	O
on	O
day	O
1	O
and	O
capecitabine	B-DRUG
"1,250"	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
dose	O
orally	O
twice	O
a	O
day	O
on	O
days	O
1月14日	O
.	O
	
Treatment	O
cycles	O
were	O
repeated	O
every	O
3	O
weeks	O
until	O
the	O
documented	O
disease	O
progression	O
","	O
unacceptable	O
toxicity	O
","	O
or	O
patient	O
's	O
refusal	O
.	O
	
Immunohistochemical	O
studies	O
against	O
thymidylate	O
synthase	O
(	O
TS	O
)	O
and	O
thymidine	O
phosphorylase	O
(	O
TP	O
)	O
were	O
performed	O
to	O
seek	O
predictive	O
markers	O
for	O
treatment	O
response	O
.	O
	
Between	O
December	O
2003	O
and	O
March	O
2006	O
","	O
45	O
patients	O
entered	O
the	O
study	O
.	O
	
All	O
patients	O
had	O
histologically	O
proven	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
esophagus	I-CANCER
.	O
	
The	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
was	O
57.8	O
%	O
(	O
95	O
%	O
CI	O
","	O
43.3-72.2	O
)	O
with	O
0	O
CR	O
and	O
26	O
PRs	O
.	O
	
The	O
median	O
duration	O
of	O
response	O
in	O
responders	O
was	O
4.6	O
months	O
(	O
1.0-15.6	O
months	O
)	O
.	O
	
With	O
a	O
median	O
follow-up	O
duration	O
of	O
25.7	O
months	O
(	O
10.8-42.6	O
months	O
)	O
","	O
the	O
median	O
time	O
to	O
progression	O
was	O
4.7	O
months	O
(	O
95	O
%	O
CI	O
","	O
2.5-7.0	O
)	O
and	O
the	O
median	O
survival	O
time	O
was	O
11.2	O
months	O
(	O
95	O
%	O
CI	O
","	O
8.5-13.9	O
)	O
.	O
	
Common	O
grade	O
3	O
or	O
4	O
non-hematological	B-TOXI
adverse	I-TOXI
events	I-TOXI
were	O
anorexia	B-TOXI
(	O
18	O
/	O
191	O
","	O
9.4	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
9	O
/	O
191	O
","	O
4.7	O
%	O
)	O
","	O
constipation	B-TOXI
(	O
6	O
/	O
191	O
","	O
3.1	O
%	O
)	O
","	O
hand-foot	B-TOXI
syndrome	I-TOXI
(	O
6	O
/	O
191	O
","	O
3.1	O
%	O
)	O
and	O
diarrhea	B-TOXI
(	O
4	O
/	O
191	O
","	O
2.1	O
%	O
)	O
.	O
	
The	O
most	O
common	O
grade	O
3	O
or	O
4	O
hematological	B-TOXI
adverse	I-TOXI
events	I-TOXI
were	O
neutropenia	B-TOXI
(	O
33	O
/	O
191	O
","	O
17.3	O
%	O
)	O
","	O
followed	O
by	O
leucopenia	B-TOXI
(	O
11	O
/	O
191	O
","	O
5.8	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
2	O
/	O
191	O
","	O
1	O
%	O
)	O
and	O
thrombocytopenia	B-TOXI
(	O
1	O
/	O
191	O
","	O
0.5	O
%	O
)	O
.	O
	
There	O
was	O
no	O
treatment-related	O
death	B-TOXI
.	O
	
Neither	O
TS	O
nor	O
TP	O
showed	O
predictive	O
value	O
for	O
treatment	O
response	O
.	O
	
The	O
XP	O
regimen	O
demonstrated	O
a	O
promising	O
antitumor	O
activity	O
in	O
metastatic	B-CANCER
esophageal	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
","	O
which	O
may	O
potentially	O
replace	O
the	O
FP	O
regimen	O
.	O
	
Phase	O
1	O
study	O
of	O
tipifarnib	B-DRUG
in	O
combination	O
with	O
imatinib	B-DRUG
for	O
patients	O
with	O
chronic	B-CANCER
myelogenous	I-CANCER
leukemia	I-CANCER
in	O
chronic	O
phase	O
after	O
imatinib	B-DRUG
failure	O
.	O
	
	
The	O
tolerability	O
and	O
efficacy	O
of	O
the	O
combination	O
of	O
tipifarnib	B-DRUG
","	O
an	O
orally	O
bioavailable	O
nonpeptidomimetic	O
farnesyl	O
transferase	O
inhibitor	O
","	O
and	O
imatinib	B-DRUG
was	O
investigated	O
in	O
patients	O
with	O
chronic	B-CANCER
myelogenous	I-CANCER
leukemia	I-CANCER
in	O
chronic	O
phase	O
who	O
had	O
failed	O
imatinib	B-DRUG
.	O
	
Twenty-six	O
patients	O
(	O
13	O
[	O
50	O
%	O
]	O
with	O
Abl	O
kinase	O
domain	O
mutations	O
)	O
were	O
treated	O
.	O
	
The	O
initial	O
dose	O
level	O
was	O
tipifarnib	B-DRUG
at	O
a	O
dose	O
of	O
300	O
mg	O
twice	O
daily	O
and	O
imatinib	B-DRUG
at	O
a	O
dose	O
of	O
300	O
mg	O
daily	O
.	O
	
Therapy	O
was	O
escalated	O
following	O
a	O
'3	O
=+	O
3	O
'	O
phase	O
1	O
design	O
and	O
the	O
maximum	O
tolerated	O
dose	O
was	O
defined	O
as	O
tipifarnib	B-DRUG
at	O
a	O
dose	O
of	O
400	O
mg	O
twice	O
daily	O
and	O
imatinib	B-DRUG
at	O
a	O
dose	O
of	O
400	O
mg	O
daily	O
.	O
	
Therapy	O
was	O
administered	O
for	O
a	O
median	O
of	O
26	O
weeks	O
(	O
range	O
","	O
3-150	O
weeks	O
)	O
.	O
	
Adverse	O
events	O
included	O
diarrhea	B-TOXI
in	O
21	O
patients	O
(	O
81	O
%	O
)	O
and	O
nausea	B-TOXI
in	O
18	O
patients	O
(	O
69	O
%	O
)	O
","	O
but	O
were	O
generally	O
grade	O
2	O
or	O
less	O
(	O
using	O
the	O
revised	O
National	O
Cancer	O
Institute	O
Common	O
Toxicity	O
Criteria	O
)	O
.	O
	
Grade	O
3月4日	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
occurred	O
in	O
11	O
patients	O
(	O
42	O
%	O
)	O
and	O
8	O
patients	O
(	O
31	O
%	O
)	O
","	O
respectively	O
.	O
	
Sixteen	O
patients	O
discontinued	O
therapy	O
(	O
5	O
due	O
to	O
toxicity	O
and	O
11	O
due	O
to	O
lack	O
of	O
response	O
or	O
disease	O
progression	O
)	O
.	O
	
Hematologic	O
responses	O
were	O
attained	O
by	O
17	O
(	O
68	O
%	O
)	O
of	O
25	O
assessable	O
patients	O
.	O
	
Nine	O
patients	O
(	O
36	O
%	O
)	O
also	O
achieved	O
a	O
cytogenetic	O
response	O
(	O
3	O
complete	O
responses	O
","	O
4	O
partial	O
responses	O
","	O
and	O
2	O
minimal	O
responses	O
)	O
","	O
including	O
4	O
patients	O
harboring	O
mutant	O
Bcr-Abl	O
tyrosine	O
kinases	O
.	O
	
One	O
patient	O
bearing	O
the	O
highly	O
imatinib-resistant	B-DRUG
T315I	O
mutant	O
achieved	O
a	O
partial	O
cytogenetic	O
response	O
.	O
	
The	O
median	O
response	O
duration	O
was	O
3	O
months	O
(	O
range	O
","	O
2-30+	O
months	O
)	O
.	O
	
The	O
combination	O
of	O
tipifarnib	B-DRUG
and	O
imatinib	B-DRUG
is	O
well	O
tolerated	O
and	O
has	O
activity	O
against	O
several	O
Abl	O
kinase	O
domain	O
mutants	O
.	O
	
Combinations	O
of	O
tipifarnib	B-DRUG
with	O
more	O
potent	O
tyrosine	O
kinase	O
inhibitors	O
warrant	O
further	O
investigation	O
.	O
	
A	O
highly	O
active	O
and	O
tolerable	O
neoadjuvant	O
regimen	O
combining	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
","	O
5-FU	B-DRUG
","	O
and	O
radiation	O
therapy	O
in	O
patients	O
with	O
stage	O
II	O
and	O
III	O
esophageal	B-CANCER
cancer	I-CANCER
.	O
	
	
The	O
present	O
phase	O
II	O
study	O
aimed	O
to	O
assess	O
the	O
feasibility	O
and	O
efficacy	O
of	O
a	O
new	O
paclitaxel-based	B-DRUG
neoadjuvant	O
chemoradiation	O
regimen	O
followed	O
by	O
surgery	O
in	O
patients	O
with	O
stage	O
II-III	O
esophageal	B-CANCER
cancer	I-CANCER
.	O
	
From	O
January	O
2002	O
to	O
November	O
2004	O
","	O
50	O
patients	O
with	O
a	O
potentially	O
resectable	O
stage	O
II-III	O
esophageal	B-CANCER
cancer	I-CANCER
received	O
chemotherapy	O
with	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
5-FU	B-DRUG
in	O
combination	O
with	O
radiotherapy	O
45	O
Gy	O
in	O
25	O
fractions	O
.	O
	
Surgery	O
followed	O
6月8日	O
weeks	O
after	O
completion	O
of	O
neoadjuvant	O
treatment	O
.	O
	
male	O
/	O
female	O
:	O
44	O
/	O
6	O
","	O
median	O
age	O
60	O
years	O
(	O
34-75	O
)	O
","	O
median	O
WHO	O
1	O
(	O
0-2	O
)	O
","	O
adenocarcinoma	B-CANCER
(	O
n	O
=	O
42	O
)	O
","	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
n	O
=	O
8	O
)	O
.	O
	
Toxicity	O
was	O
mild	O
","	O
and	O
84	O
%	O
of	O
the	O
patients	O
completed	O
the	O
whole	O
regimen	O
.	O
	
Forty-seven	O
patients	O
underwent	O
surgery	O
with	O
a	O
curative	O
intention	O
(	O
transhiatal	O
n	O
=	O
44	O
","	O
transthoracic	O
n	O
=	O
3	O
)	O
.	O
	
Pathologic	O
complete	O
tumor	O
regression	O
was	O
achieved	O
in	O
18	O
of	O
47	O
operated	O
patients	O
(	O
38	O
%	O
)	O
.	O
	
R0	O
resection	O
was	O
achieved	O
in	O
45	O
of	O
47	O
operated	O
patients	O
(	O
96	O
%	O
)	O
.	O
	
There	O
were	O
four	O
postoperative	O
deaths	B-TOXI
(	O
8.5	O
)	O
.	O
	
Postoperative	O
complications	O
were	O
comparable	O
with	O
other	O
studies	O
.	O
	
After	O
a	O
median	O
follow-up	O
of	O
41.5	O
months	O
(	O
21-59	O
)	O
estimated	O
-3	O
and	O
5-year	O
survival	O
on	O
an	O
intention-to-treat	O
basis	O
was	O
56	O
and	O
48	O
%	O
.	O
	
Estimated	O
3-year	O
survival	O
in	O
responders	O
was	O
61	O
%	O
","	O
in	O
nonresponders	O
33	O
%	O
.	O
	
This	O
novel	O
neoadjuvant	O
chemoradiation	O
regimen	O
for	O
treatment	O
of	O
patients	O
with	O
stage	O
II-III	O
esophageal	B-CANCER
cancer	I-CANCER
is	O
feasible	O
.	O
	
Results	O
are	O
encouraging	O
with	O
a	O
high	O
pathologic	O
complete	O
tumor	O
regression	O
and	O
R0	O
resection	O
rate	O
and	O
an	O
acceptable	O
morbidity	O
and	O
mortality	O
.	O
	
Preliminary	O
survival	O
data	O
are	O
very	O
promising	O
.	O
	
Randomized	O
phase	O
II	O
study	O
of	O
cisplatin	B-DRUG
and	O
5-FU	B-DRUG
continuous	O
infusion	O
(	O
PF	B-DRUG
)	O
versus	O
cisplatin	B-DRUG
","	O
UFT	B-DRUG
and	O
vinorelbine	B-DRUG
(	O
UFTVP	B-DRUG
)	O
as	O
induction	O
chemotherapy	O
in	O
locally	O
advanced	B-CANCER
squamous	I-CANCER
cell	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
(	O
LA-SCHNC	O
)	O
.	O
	
	
We	O
conducted	O
a	O
multicentric	O
randomized	O
phase	O
II	O
trial	O
comparing	O
5-FU	B-DRUG
continuous	O
infusion	O
(	O
PF	B-DRUG
)	O
and	O
cisplatin	B-DRUG
","	O
UFT	B-DRUG
and	O
vinorelbine	B-DRUG
(	O
UFTVP	B-DRUG
)	O
as	O
induction	O
chemotherapy	O
(	O
IC	O
)	O
in	O
locally	O
advanced	B-CANCER
squamous	I-CANCER
cell	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
(	O
LA-SCHNC	O
)	O
.	O
	
Primary	O
objective	O
was	O
complete	O
response	O
(	O
CR	O
)	O
to	O
IC	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
a	O
secondary	O
objective	O
.	O
	
PF	B-DRUG
:	O
cisplatin	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
i.v.	O
Day	O
1	O
(	O
D1	O
)	O
and	O
5-FU	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
day	O
i.v.	O
continous	O
infusion	O
D1-D5	O
","	O
every	O
21	O
days	O
.	O
	
UFTVP	B-DRUG
:	O
cisplatin	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
i.v.	O
D1	O
;	O
UFT	B-DRUG
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
day	O
p.o.	O
D1-D21	O
and	O
vinorelbine	B-DRUG
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
i.v.	O
D1	O
and	O
D8	O
","	O
every	O
21	O
days	O
.	O
	
Four	O
IC	O
courses	O
were	O
planned	O
in	O
both	O
arms	O
.	O
	
A	O
total	O
of	O
206	O
patients	O
(	O
pts	O
)	O
were	O
included	O
(	O
PF	B-DRUG
/	O
UFTVP	B-DRUG
:	O
99	O
/	O
107	O
)	O
:	O
oral	O
cavity	O
:	O
8	O
%	O
/	O
10	O
%	O
","	O
oropharynx	O
:	O
20	O
%	O
/	O
25	O
%	O
","	O
hypopharynx	O
:	O
17	O
%	O
/	O
14	O
%	O
","	O
larynx	O
:	O
54	O
%	O
/	O
50	O
%	O
.	O
	
Stage	O
(	O
TNM	O
","	O
2002	O
)	O
:	O
III	O
:	O
41	O
%	O
/	O
35	O
%	O
","	O
IVA	O
:	O
23	O
%	O
/	O
27	O
%	O
","	O
IVB	O
:	O
35	O
%	O
/	O
38	O
%	O
.	O
	
Complete	O
response	O
to	O
IC	O
:	O
PF:36	B-DRUG
%	O
/	O
UFTVP:31	B-DRUG
%	O
(	O
P	O
:	O
no	O
significative	O
(	O
NS	O
)	O
)	O
.	O
	
G	O
3月4日	O
toxicity	O
(	O
PF	B-DRUG
/	O
UFTVP	B-DRUG
)	O
:	O
neutropenia	B-TOXI
:	O
52	O
%	O
/	O
72	O
%	O
;	O
febrile	B-TOXI
neutropenia	I-TOXI
:	O
3	O
%	O
/	O
20	O
%	O
(	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
;	O
anaemia:1	B-TOXI
%	O
/	O
14	O
%	O
(	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
;	O
trombocytopenia	B-TOXI
:	O
5	O
%	O
/	O
0	O
%	O
(	O
P	O
=	O
0.02	O
)	O
;	O
mucositis	B-TOXI
:	O
15	O
%	O
/	O
7	O
%	O
(	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
.	O
	
Deaths	B-TOXI
during	O
IC	O
:	O
2	O
(	O
2	O
%	O
)	O
/	O
3	O
(	O
3	O
%	O
)	O
.	O
	
IC	O
with	O
UFTVP	B-DRUG
was	O
associated	O
with	O
a	O
favourable	O
OS	O
in	O
the	O
Cox	O
analysis	O
(	O
actuarial	O
5	O
year	O
OS	O
:	O
49	O
%	O
vs.	O
34	O
%	O
;	O
HR	O
:	O
0.67	O
","	O
95	O
%	O
CI	O
:	O
0.47-0.95	O
","	O
P	O
:	O
0.03	O
)	O
.	O
	
Although	O
clinical	O
response	O
is	O
equal	O
in	O
both	O
arms	O
","	O
overall	O
survival	O
(	O
Cox	O
)	O
is	O
better	O
in	O
the	O
UFTVP	B-DRUG
arm	O
.	O
	
Febrile	B-TOXI
neutropenia	I-TOXI
and	O
anaemia	B-TOXI
were	O
more	O
frequent	O
with	O
UFTVP	B-DRUG
while	O
mucositis	B-TOXI
and	O
trombocytopenia	B-TOXI
were	O
more	O
severe	O
with	O
PF	B-DRUG
.	O
	
Tritherapy	O
with	O
fluorouracil	B-DRUG
/	O
leucovorin	B-DRUG
","	O
irinotecan	B-DRUG
and	O
oxaliplatin	B-DRUG
(	O
FOLFIRINOX	B-DRUG
)	O
:	O
a	O
phase	O
II	O
study	O
in	O
colorectal	B-CANCER
cancer	I-CANCER
patients	O
with	O
non-resectable	O
liver	O
metastases	O
.	O
	
	
To	O
assess	O
the	O
rate	O
of	O
R	O
(	O
0	O
)	O
resection	O
of	O
liver	O
metastases	O
achieved	O
after	O
chemotherapy	O
with	O
FOLFIRINOX	B-DRUG
.	O
	
Patients	O
with	O
histologically	O
proven	O
primary	O
colorectal	B-CANCER
cancer	I-CANCER
and	O
bidimensionally	O
measurable	O
liver	O
metastasis	O
","	O
not	O
fully	O
resectable	O
based	O
on	O
technical	O
inability	O
to	O
achieve	O
R	O
(	O
0	O
)	O
resection	O
","	O
but	O
potentially	O
resectable	O
after	O
tumor	O
reduction	O
","	O
were	O
given	O
FOLFIRINOX	B-DRUG
:	O
oxaliplatin	B-DRUG
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
irinotecan	B-DRUG
180	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
leucovorin	B-DRUG
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
bolus	O
fluorouracil	B-DRUG
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
fluorouracil	B-DRUG
46-h	O
continuous	O
IV	O
infusion	O
"2,400"	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
every	O
2	O
weeks	O
for	O
a	O
maximum	O
of	O
12	O
cycles	O
.	O
	
Thirty-four	O
patients	O
were	O
enrolled	O
.	O
	
Response	O
rate	O
before	O
surgery	O
was	O
70.6	O
%	O
(	O
95	O
%	O
CI	O
:	O
52.5-84.9	O
)	O
.	O
	
Twenty-eight	O
patients	O
(	O
82.4	O
%	O
)	O
underwent	O
hepatic	O
resection	O
and	O
nine	O
achieved	O
R	O
(	O
0	O
)	O
resection	O
[	O
26.5	O
%	O
(	O
95	O
%	O
CI	O
:	O
12.9-44.4	O
%	O
)	O
]	O
.	O
	
The	O
rate	O
of	O
clinical	O
complete	O
remission	O
after	O
surgery	O
was	O
79.4	O
%	O
.	O
	
Two-year	O
overall	O
survival	O
was	O
83	O
%	O
.	O
	
The	O
most	O
frequent	O
grade	O
3	O
or	O
4	O
toxicities	O
were	O
neutropenia	B-TOXI
(	O
64.8	O
%	O
)	O
","	O
diarrhea	B-TOXI
(	O
29.4	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
23.5	O
%	O
)	O
","	O
abdominal	B-TOXI
cramps	I-TOXI
(	O
14.7	O
%	O
)	O
","	O
neuropathy	B-TOXI
and	O
nausea	B-TOXI
(	O
11.8	O
%	O
each	O
)	O
","	O
and	O
AST	B-TOXI
/	I-TOXI
ALT	I-TOXI
elevation	I-TOXI
(	O
14.7	O
/	O
11.8	O
%	O
)	O
.	O
	
Only	O
one	O
patient	O
experienced	O
febrile	B-TOXI
neutropenia	I-TOXI
","	O
four	O
patients	O
withdrew	O
due	O
to	O
toxicity	O
and	O
no	O
toxic	B-TOXI
death	I-TOXI
was	O
observed	O
.	O
	
FOLFIRINOX	B-DRUG
","	O
with	O
an	O
acceptable	O
toxicity	O
profile	O
","	O
shows	O
a	O
high	O
response	O
rate	O
in	O
liver	O
metastases	O
from	O
colorectal	B-CANCER
cancer	I-CANCER
.	O
	
The	O
rate	O
of	O
hepatic	O
resection	O
in	O
patients	O
initially	O
not	O
resectable	O
","	O
is	O
attractive	O
and	O
warrants	O
further	O
assessment	O
of	O
this	O
regimen	O
in	O
randomized	O
studies	O
compared	O
to	O
standard	O
regimens	O
.	O
	
Phase	O
I	O
and	O
pharmacokinetic	O
study	O
of	O
imatinib	B-DRUG
mesylate	I-DRUG
(	O
Gleevec	B-DRUG
)	O
and	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
refractory	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
Preclinical	O
data	O
shows	O
improvements	O
in	O
response	O
for	O
the	O
combination	O
of	O
imatinib	B-DRUG
mesylate	I-DRUG
(	O
IM	O
","	O
Gleevec	B-DRUG
)	O
and	O
gemcitabine	B-DRUG
(	O
GEM	B-DRUG
)	O
therapy	O
compared	O
with	O
GEM	B-DRUG
alone	O
.	O
	
Our	O
goals	O
were	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
of	O
GEM	B-DRUG
and	O
IM	O
in	O
combination	O
","	O
the	O
pharmacokinetics	O
of	O
GEM	B-DRUG
in	O
the	O
absence	O
and	O
in	O
the	O
presence	O
of	O
IM	O
","	O
and	O
IM	O
pharmacokinetics	O
in	O
this	O
combination	O
.	O
	
Patients	O
with	O
refractory	O
malignancy	O
","	O
intact	O
intestinal	O
absorption	O
","	O
measurable	O
/	O
evaluable	O
disease	O
","	O
adequate	O
organ	O
function	O
","	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
PS	O
0-2	O
","	O
and	O
signed	O
informed	O
consent	O
were	O
eligible	O
.	O
	
Initially	O
","	O
treatment	O
consisted	O
of	O
600	O
mg	O
/	O
m2	O
of	O
GEM	B-DRUG
(	O
10	O
mg	O
/	O
m2	O
/	O
min	O
)	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
","	O
and	O
300	O
mg	O
of	O
IM	B-DRUG
daily	O
every	O
28	O
days	O
.	O
	
Due	O
to	O
excessive	O
toxicity	O
","	O
the	O
schedule	O
was	O
altered	O
to	O
IM	B-DRUG
on	O
days	O
1	O
to	O
5	O
and	O
8	O
to	O
12	O
","	O
and	O
GEM	B-DRUG
on	O
days	O
3	O
and	O
10	O
every	O
21	O
days	O
.	O
	
Two	O
final	O
cohorts	O
received	O
IM	B-DRUG
on	O
days	O
1	O
to	O
5	O
","	O
8	O
to	O
12	O
","	O
and	O
15	O
to	O
19	O
.	O
	
Fifty-four	O
patients	O
were	O
treated	O
.	O
	
IM	B-DRUG
and	O
GEM	B-DRUG
given	O
daily	O
at	O
500	O
to	O
600	O
mg	O
/	O
m2	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
produced	O
frequent	O
dose-limiting	O
toxicities	O
.	O
	
With	O
the	O
modified	O
scheduling	O
","	O
GEM	B-DRUG
given	O
at	O
"1,500"	O
mg	O
/	O
m2	O
/	O
150	O
min	O
was	O
deliverable	O
","	O
along	O
with	O
400	O
mg	O
of	O
IM	B-DRUG
","	O
without	O
dose-limiting	O
toxicities	O
.	O
	
Three	O
partial	O
(	O
laryngeal	O
","	O
renal	O
","	O
and	O
mesothelioma	O
)	O
and	O
two	O
minor	O
(	O
renal	O
and	O
pancreatic	O
)	O
responses	O
were	O
noted	O
at	O
GEM	B-DRUG
doses	O
of	O
450	O
to	O
"1,500"	O
mg	O
/	O
m2	O
.	O
	
Stable	O
disease	O
&	O
gt	O
;	O
24	O
weeks	O
was	O
seen	O
in	O
17	O
patients	O
.	O
	
CA19-9	O
in	O
7	O
of	O
10	O
patients	O
with	O
pancreatic	B-CANCER
cancer	I-CANCER
was	O
reduced	O
by	O
approximately	O
90	O
%	O
.	O
	
IM	B-DRUG
did	O
not	O
significantly	O
alter	O
GEM	B-DRUG
pharmacokinetics	O
.	O
	
The	O
addition	O
of	O
intermittently	O
dosed	O
IM	B-DRUG
to	O
GEM	B-DRUG
at	O
low	O
to	O
full	O
dose	O
was	O
associated	O
with	O
broad	O
antitumor	O
activity	O
and	O
little	O
increase	O
in	O
toxicity	O
.	O
	
Topotecan	B-DRUG
and	O
carboplatin	B-DRUG
in	O
patients	O
with	O
platinum-sensitive	B-DRUG
recurrent	B-CANCER
ovarian	I-CANCER
cancer.	I-CANCER
Results	O
of	O
a	O
multicenter	O
NOGGO	O
:	O
phase	O
I	O
/	O
II	O
study	O
.	O
	
	
Second-line	O
treatment	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
enhances	O
survival	O
of	O
women	O
with	O
platinum-sensitive	B-DRUG
recurrent	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
(	O
ROC	B-CANCER
)	O
.	O
	
However	O
","	O
because	O
of	O
its	O
cumulative	O
neurotoxicity	B-TOXI
","	O
there	O
is	O
a	O
strong	O
demand	O
for	O
platinum-combinations	B-DRUG
with	O
better	O
therapeutic	O
index	O
.	O
	
Because	O
of	O
its	O
pharmacological	O
properties	O
","	O
topotecan	B-DRUG
is	O
a	O
good	O
adjunct	O
to	O
carboplatin	B-DRUG
in	O
this	O
setting	O
","	O
but	O
its	O
safety	O
and	O
efficacy	O
remains	O
to	O
be	O
defined	O
.	O
	
Patients	O
with	O
platinum-sensitive	B-DRUG
ROC	B-CANCER
were	O
eligible	O
in	O
this	O
multicenter	O
phase	O
I	O
/	O
II	O
study	O
","	O
stratified	O
according	O
to	O
treatment-free	O
interval	O
(	O
TFI	O
)	O
.	O
	
Dose	O
level	O
0	O
consisted	O
of	O
topotecan	B-DRUG
1	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d1-3	O
/	O
q21d	O
plus	O
carboplatin	B-DRUG
AUC5	O
/	O
d3	O
/	O
q21d	O
.	O
	
DLT	O
was	O
defined	O
as	O
grade	O
&	O
gt	O
;	O
or	O
3	O
neutropenia	B-TOXI
or	O
thrombocytopenia	B-TOXI
or	O
grade	O
&	O
gt	O
;	O
or	O
3	O
non-hematological	B-TOXI
toxicity	I-TOXI
excluding	O
alopecia	B-TOXI
","	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
","	O
accompanied	O
by	O
a	O
treatment	O
delay	O
&	O
gt	O
;	O
1	O
week	O
.	O
	
From	O
June	O
2004	O
to	O
August	O
2005	O
","	O
26	O
patients	O
were	O
enrolled	O
","	O
receiving	O
a	O
total	O
of	O
145	O
cycles	O
of	O
chemotherapy	O
.	O
	
MTD	O
was	O
reached	O
at	O
topotecan	B-DRUG
0.75	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
carboplatin	B-DRUG
AUC5	O
.	O
	
We	O
observed	O
a	O
single	O
grade	O
4	O
leucopenia	B-TOXI
.	O
	
There	O
were	O
3	O
(	O
12	O
%	O
)	O
","	O
15	O
(	O
58	O
%	O
)	O
and	O
8	O
(	O
31	O
%	O
)	O
events	O
of	O
grade	O
3	O
/	O
4	O
hematological	B-TOXI
anaemia	I-TOXI
","	O
leucopenia	B-TOXI
","	O
and	O
thrombocytopenia	B-TOXI
.	O
	
Response	O
rate	O
was	O
67	O
%	O
(	O
95	O
%	O
CI	O
43-85	O
)	O
","	O
median	O
progression-free	O
survival	O
9.5	O
months	O
(	O
95	O
%	O
CI	O
7.3-12.0	O
)	O
","	O
median	O
overall	O
survival	O
19.4	O
months	O
(	O
95	O
%	O
CI	O
12.3-26.9	O
)	O
.	O
	
None	O
of	O
the	O
toxicity	O
or	O
efficacy	O
endpoints	O
were	O
associated	O
with	O
TFI	O
.	O
	
Topotecan	B-DRUG
and	O
carboplatin	B-DRUG
is	O
a	O
well	O
tolerated	O
novel	O
doublet	O
option	O
for	O
women	O
with	O
platinum	B-DRUG
sensitive	O
ROC	B-CANCER
.	O
	
We	O
encourage	O
further	O
studies	O
on	O
this	O
approach	O
","	O
but	O
to	O
limit	O
the	O
doses	O
of	O
topotecan	B-DRUG
to	O
0.75	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d1-3	O
and	O
carboplatin	B-DRUG
AUC	O
5	O
/	O
d3	O
.	O
	
Irinotecan	B-DRUG
plus	O
cisplatin	B-DRUG
and	O
dexamethasone	B-DRUG
(	O
ICD	B-DRUG
)	O
combination	O
chemotherapy	O
for	O
patients	O
with	O
diffuse	B-CANCER
large	I-CANCER
B-cell	I-CANCER
lymphoma	I-CANCER
previously	O
treated	O
with	O
Rituximab	B-DRUG
plus	O
CHOP	B-DRUG
.	O
	
	
The	O
therapeutic	O
strategy	O
for	O
relapsed	O
or	O
refractory	O
patients	O
with	O
diffuse	B-CANCER
large	I-CANCER
B-cell	I-CANCER
lymphoma	I-CANCER
(	O
DLBL	B-CANCER
)	O
remains	O
challenging	O
yet	O
.	O
	
Salvage	O
therapy	O
has	O
been	O
tried	O
for	O
these	O
patients	O
according	O
to	O
their	O
clinical	O
status	O
.	O
	
We	O
studied	O
ICD	B-DRUG
(	O
irinotecan	B-DRUG
","	O
cisplatin	B-DRUG
and	O
dexamethasone	B-DRUG
)	O
regimen	O
as	O
salvage	O
chemotherapy	O
for	O
DLBL	B-CANCER
patients	O
previously	O
treated	O
with	O
RCHOP	B-DRUG
.	O
	
Between	O
February	O
2005	O
and	O
May	O
2006	O
","	O
15	O
patients	O
were	O
treated	O
prospectively	O
with	O
ICD	B-DRUG
chemotherapy	O
;	O
irinotecan	B-DRUG
65	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
on	O
days	O
1	O
and	O
8	O
","	O
cisplatin	B-DRUG
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
on	O
days	O
1	O
and	O
8	O
","	O
and	O
dexamethasone	B-DRUG
40	O
mg	O
/	O
day	O
on	O
days	O
1月2日	O
and	O
8月9日	O
.	O
	
This	O
schedule	O
was	O
planned	O
to	O
repeat	O
every	O
3	O
weeks	O
until	O
disease	O
progression	O
","	O
severe	B-TOXI
toxicity	I-TOXI
or	O
stem	B-TOXI
cell	I-TOXI
transplantation	I-TOXI
.	O
	
Of	O
the	O
14	O
patients	O
evaluable	O
for	O
response	O
","	O
3	O
patients	O
achieved	O
CR	O
","	O
7	O
patients	O
PR	O
","	O
with	O
1	O
SD	O
and	O
3	O
PD	O
;	O
overall	O
response	O
rate	O
71	O
%	O
(	O
10	O
/	O
14	O
;	O
95	O
%	O
confidence	O
interval	O
","	O
47-95	O
%	O
)	O
.	O
	
The	O
median	O
progression	O
free	O
survival	O
(	O
PFS	O
)	O
and	O
event	O
free	O
survival	O
(	O
EFS	O
)	O
were	O
113	O
(	O
range	O
21-493+	O
)	O
and	O
77	O
(	O
range	O
21-324+	O
)	O
days	O
","	O
respectively	O
.	O
	
The	O
median	O
overall	O
survival	O
was	O
267	O
(	O
range	O
31-493+	O
)	O
days	O
.	O
	
Grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
and	O
grade	O
3	O
neutropenic	B-TOXI
fever	I-TOXI
were	O
observed	O
in	O
67	O
%	O
(	O
22	O
/	O
33	O
)	O
and	O
18	O
%	O
(	O
6	O
/	O
33	O
)	O
of	O
cycles	O
","	O
respectively	O
.	O
	
There	O
were	O
20	O
%	O
of	O
grade	O
3	O
/	O
4	O
nausea	B-TOXI
and	O
diarrhea	B-TOXI
observed	O
.	O
	
The	O
ICD	B-DRUG
regimen	O
with	O
current	O
schedule	O
showed	O
high	O
response	O
rate	O
for	O
DLBL	B-CANCER
patients	O
previously	O
treated	O
with	O
RCHOP	B-DRUG
.	O
	
But	O
the	O
high	O
incidence	O
of	O
neutropenia	B-TOXI
led	O
to	O
delay	O
of	O
subsequent	O
cycles	O
causing	O
dose	O
intensity	O
reduced	O
","	O
which	O
seems	O
to	O
be	O
related	O
with	O
short	O
PFS	O
and	O
EFS	O
.	O
	
Phase	O
II	O
study	O
of	O
low-dose	O
paclitaxel	B-DRUG
and	O
cisplatin	B-DRUG
as	O
a	O
second-line	O
therapy	O
after	O
5-fluorouracil	B-DRUG
/	O
platinum	B-DRUG
chemotherapy	O
in	O
gastric	B-CANCER
cancer	I-CANCER
.	O
	
	
This	O
study	O
was	O
performed	O
to	O
evaluate	O
the	O
efficacy	O
and	O
toxicity	O
of	O
low-dose	O
paclitaxel	B-DRUG
/	O
cisplatin	B-DRUG
chemotherapy	O
in	O
patients	O
with	O
metastatic	B-CANCER
or	I-CANCER
recurrent	I-CANCER
gastric	I-CANCER
cancer	I-CANCER
that	O
had	O
failed	O
5-fluorouracil	B-DRUG
/	O
platinum-based	B-DRUG
chemotherapy	O
.	O
	
Thirty-two	O
patients	O
with	O
documented	O
progression	O
on	O
or	O
within	O
6	O
months	O
after	O
discontinuing	O
5-fluorouracil	B-DRUG
/	O
platinum-based	B-DRUG
chemotherapy	O
were	O
enrolled	O
.	O
	
As	O
a	O
second-line	O
treatment	O
","	O
paclitaxel	B-DRUG
(	O
145	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
cisplatin	B-DRUG
(	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
was	O
administered	O
on	O
day	O
1	O
every	O
3	O
weeks	O
.	O
	
Among	O
32	O
patients	O
enrolled	O
","	O
8	O
(	O
25	O
%	O
)	O
responded	O
partially	O
to	O
paclitaxel	B-DRUG
/	O
cisplatin	B-DRUG
","	O
8	O
(	O
25	O
%	O
)	O
had	O
stable	O
disease	O
","	O
and	O
14	O
(	O
44	O
%	O
)	O
had	O
progressive	O
disease	O
.	O
	
Two	O
patients	O
(	O
6	O
%	O
)	O
were	O
not	O
evaluable	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
(	O
TTP	O
)	O
and	O
overall	O
survival	O
for	O
all	O
patients	O
were	O
2.9	O
months	O
and	O
9.1	O
months	O
","	O
respectively	O
.	O
	
The	O
most	O
common	O
hematologic	B-TOXI
toxicity	I-TOXI
was	O
anemia	B-TOXI
(	O
47	O
%	O
)	O
.	O
	
Grade	O
3	O
neutropenia	B-TOXI
developed	O
in	O
three	O
patients	O
(	O
9	O
%	O
)	O
","	O
but	O
no	O
other	O
grade	O
3	O
/	O
4	O
hematologic	B-TOXI
toxicity	I-TOXI
occurred	O
.	O
	
The	O
most	O
common	O
non-hematologic	B-TOXI
toxicities	I-TOXI
were	O
emesis	O
(	O
31	O
%	O
)	O
and	O
peripheral	B-TOXI
neuropathy	I-TOXI
(	O
38	O
%	O
)	O
.	O
	
Three	O
cases	O
(	O
9	O
%	O
)	O
of	O
grade	O
3	O
/	O
4	O
emesis	B-TOXI
and	O
2	O
cases	O
(	O
6	O
%	O
)	O
of	O
grade	O
3	O
peripheral	B-TOXI
neuropathy	I-TOXI
developed	O
.	O
	
In	O
conclusion	O
","	O
low-dose	O
paclitaxel	B-DRUG
and	O
cisplatin	B-DRUG
chemotherapy	O
showed	O
moderate	O
activity	O
with	O
favorable	O
toxicity	O
profiles	O
.	O
	
However	O
","	O
relatively	O
short	O
TTP	O
of	O
this	O
regimen	O
warrants	O
the	O
development	O
of	O
more	O
effective	O
paclitaxel-based	B-DRUG
regimens	O
other	O
than	O
combination	O
with	O
cisplatin	B-DRUG
in	O
these	O
patients	O
as	O
second-line	O
therapies	O
.	O
	
Cisplatin	B-DRUG
plus	O
gemcitabine	B-DRUG
or	O
vinorelbine	B-DRUG
for	O
elderly	O
patients	O
with	O
advanced	B-CANCER
non	I-CANCER
small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
the	O
MILES-2P	O
studies	O
.	O
	
	
Two	O
phase	O
I	O
/	O
II	O
trials	O
were	O
done	O
to	O
evaluate	O
the	O
feasibility	O
of	O
cisplatin	B-DRUG
combined	O
with	O
gemcitabine	B-DRUG
or	O
vinorelbine	B-DRUG
in	O
elderly	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
who	O
were	O
older	O
than	O
70	O
years	O
of	O
age	O
and	O
who	O
had	O
a	O
performance	O
status	O
of	O
0	O
to	O
1	O
were	O
eligible	O
.	O
	
Cisplatin	B-DRUG
was	O
given	O
on	O
day	O
1	O
(	O
a	O
starting	O
dose	O
of	O
50	O
mg	O
/	O
m2	O
with	O
increasing	O
increments	O
of	O
10	O
mg	O
/	O
m2	O
at	O
each	O
level	O
)	O
and	O
gemcitabine	B-DRUG
(	O
"1,000"	O
mg	O
/	O
m2	O
)	O
or	O
vinorelbine	B-DRUG
(	O
25	O
mg	O
/	O
m2	O
)	O
on	O
days	O
1	O
and	O
8	O
Cycles	O
were	O
repeated	O
every	O
21	O
days	O
.	O
	
A	O
two-stage	O
flexible	O
optimal	O
design	O
was	O
applied	O
in	O
the	O
phase	O
II	O
study	O
","	O
and	O
unacceptable	O
toxicity	O
was	O
the	O
primary	O
end	O
point	O
.	O
	
Overall	O
","	O
159	O
patients	O
were	O
enrolled	O
:	O
38	O
in	O
phase	O
I	O
and	O
121	O
in	O
phase	O
II	O
studies	O
.	O
	
Cisplatin	B-DRUG
was	O
feasible	O
at	O
60	O
mg	O
/	O
m2	O
with	O
gemcitabine	B-DRUG
and	O
at	O
40	O
mg	O
/	O
m2	O
with	O
vinorelbine	B-DRUG
.	O
	
With	O
the	O
former	O
combination	O
","	O
50	O
of	O
60	O
(	O
83.3	O
%	O
)	O
patients	O
were	O
treated	O
without	O
unacceptable	O
toxicity	O
;	O
objective	O
responses	O
were	O
reported	O
in	O
26	O
of	O
60	O
patients	O
(	O
43.5	O
%	O
;	O
95	O
%	O
CI	O
","	O
30.6	O
to	O
56.8	O
)	O
;	O
median	O
progression-free	O
and	O
overall	O
survivals	O
were	O
25.3	O
and	O
43.6	O
weeks	O
","	O
respectively	O
.	O
	
With	O
the	O
latter	O
combination	O
","	O
50	O
(	O
82	O
%	O
)	O
of	O
61	O
patients	O
were	O
treated	O
without	O
unacceptable	O
toxicity	O
;	O
objective	O
responses	O
were	O
reported	O
in	O
22	O
of	O
61	O
patients	O
(	O
36.1	O
%	O
;	O
95	O
%	O
CI	O
","	O
24.2	O
to	O
49.4	O
)	O
;	O
median	O
progression-free	O
and	O
overall	O
survivals	O
were	O
21.1	O
and	O
33.1	O
weeks	O
","	O
respectively	O
.	O
	
Both	O
cisplatin	B-DRUG
(	O
60	O
mg	O
/	O
m2	O
)	O
plus	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
(	O
40	O
mg	O
/	O
m2	O
)	O
plus	O
vinorelbine	B-DRUG
are	O
feasible	O
and	O
active	O
in	O
the	O
treatment	O
of	O
elderly	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
The	O
former	O
combination	O
","	O
which	O
provides	O
a	O
higher	O
dose	O
of	O
cisplatin	B-DRUG
","	O
deserves	O
comparison	O
versus	O
single-agent	O
chemotherapy	O
in	O
this	O
setting	O
of	O
patients	O
.	O
	
A	O
phase	O
1	O
study	O
of	O
fixed	O
dose	O
rate	O
gemcitabine	B-DRUG
and	O
irinotecan	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
pancreatic	I-CANCER
and	O
biliary	B-CANCER
cancer	I-CANCER
.	O
	
	
The	O
combination	O
of	O
a	O
fixed	O
dose	O
rate	O
(	O
FDR	O
)	O
infusion	O
of	O
gemcitabine	B-DRUG
and	O
irinotecan	B-DRUG
may	O
have	O
a	O
synergistic	O
effect	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
advanced	O
and	O
metastatic	O
pancreatic	O
and	O
biliary	B-CANCER
cancer	I-CANCER
.	O
	
The	O
current	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
and	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
the	O
combination	O
.	O
	
There	O
were	O
32	O
patients	O
with	O
metastatic	B-CANCER
pancreatic	I-CANCER
and	I-CANCER
advanced	I-CANCER
unresectable	I-CANCER
/	I-CANCER
metastatic	I-CANCER
biliary	I-CANCER
adenocarcinoma	I-CANCER
who	O
were	O
entered	O
into	O
this	O
open-label	O
","	O
phase	O
1	O
dose	O
escalation	O
trial	O
.	O
	
Gemcitabine	B-DRUG
was	O
administered	O
at	O
an	O
FDR	O
of	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
minute	O
intravenously	O
(	O
iv	O
)	O
.	O
	
Irinotecan	B-DRUG
was	O
administered	O
iv	O
over	O
60	O
minutes	O
after	O
gemcitabine	B-DRUG
.	O
	
Both	O
gemcitabine	B-DRUG
and	O
irinotecan	B-DRUG
were	O
given	O
on	O
Days	O
1	O
and	O
8	O
of	O
a	O
21-day	O
cycle	O
.	O
	
The	O
MTD	O
of	O
the	O
combination	O
was	O
gemcitabine	B-DRUG
at	O
an	O
FDR	O
of	O
1200	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
irinotecan	B-DRUG
at	O
a	O
dose	O
of	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
The	O
DLTs	O
were	O
neutropenia	B-TOXI
and	O
neutropenic	B-TOXI
fever	I-TOXI
.	O
	
Other	O
DLTs	O
included	O
diarrhea	B-TOXI
","	O
dehydration	B-TOXI
","	O
and	O
fatigue	B-TOXI
.	O
	
Two	O
patients	O
developed	O
deep	B-TOXI
venous	I-TOXI
thrombosis	I-TOXI
during	O
the	O
treatment	O
.	O
	
The	O
efficacy	O
of	O
the	O
combination	O
was	O
encouraging	O
","	O
even	O
at	O
the	O
lower	O
dose	O
levels	O
.	O
	
Of	O
30	O
assessable	O
patients	O
","	O
there	O
was	O
1	O
complete	O
response	O
","	O
6	O
partial	O
responses	O
","	O
and	O
16	O
patients	O
with	O
stable	O
disease	O
","	O
with	O
a	O
response	O
rate	O
of	O
23	O
%	O
","	O
a	O
disease	O
control	O
rate	O
of	O
76	O
%	O
","	O
a	O
median	O
progression-free	O
survival	O
of	O
4.7	O
months	O
","	O
and	O
a	O
median	O
overall	O
survival	O
of	O
7	O
months	O
.	O
	
The	O
average	O
number	O
of	O
treatment	O
cycles	O
received	O
was	O
11	O
.	O
	
The	O
recommended	O
doses	O
of	O
the	O
combination	O
for	O
future	O
study	O
are	O
gemcitabine	B-DRUG
at	O
an	O
FDR	O
of	O
1200	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
irinotecan	B-DRUG
at	O
a	O
dose	O
of	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
The	O
efficacy	O
of	O
the	O
combination	O
is	O
encouraging	O
.	O
	
Further	O
assessment	O
of	O
the	O
combination	O
with	O
or	O
without	O
biologic	O
agents	O
is	O
suggested	O
.	O
	
Gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
in	O
unresectable	O
malignant	O
mesothelioma	B-CANCER
of	I-CANCER
the	I-CANCER
pleura	I-CANCER
:	O
a	O
phase	O
II	O
study	O
of	O
the	O
Southwest	O
Oncology	O
Group	O
(	O
SWOG	O
9810	O
)	O
.	O
	
	
The	O
purpose	O
of	O
this	O
open-label	O
phase	O
II	O
SWOG	O
study	O
was	O
to	O
evaluate	O
the	O
activity	O
of	O
gemcitabine	B-DRUG
(	O
Gemzar	O
;	O
Eli	O
Lilly	O
","	O
Indiana	O
","	O
USA	O
)	O
and	O
cisplatin	B-DRUG
combination	O
therapy	O
","	O
in	O
patients	O
with	O
unresectable	O
malignant	O
mesothelioma	B-CANCER
of	I-CANCER
the	I-CANCER
pleura	I-CANCER
.	O
	
Fifty	O
eligible	O
chemotherapy	O
na茂ve	O
patients	O
with	O
histologically	O
proven	O
malignant	O
mesothelioma	B-CANCER
of	I-CANCER
the	I-CANCER
pleura	I-CANCER
","	O
and	O
a	O
SWOG	O
performance	O
status	O
0-2	O
were	O
enrolled	O
between	O
February	O
1999	O
and	O
August	O
2000	O
.	O
	
Treatment	O
consisted	O
of	O
gemcitabine	B-DRUG
1000mg	O
/	O
m	O
(	O
2	O
)	O
and	O
cisplatin	B-DRUG
30mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
","	O
8	O
and	O
15	O
of	O
a	O
28-day	O
cycle	O
","	O
until	O
progression	B-TOXI
of	I-TOXI
disease	I-TOXI
or	O
two	O
cycles	O
beyond	O
complete	O
response	O
.	O
	
Using	O
SWOG	O
response	O
criteria	O
","	O
one	O
patient	O
had	O
a	O
confirmed	O
complete	O
response	O
and	O
five	O
patients	O
had	O
a	O
confirmed	O
partial	O
response	O
","	O
for	O
a	O
total	O
response	O
rate	O
of	O
12	O
%	O
(	O
95	O
%	O
CI	O
5月24日	O
%	O
)	O
.	O
	
All	O
the	O
responses	O
were	O
seen	O
in	O
patients	O
with	O
epithelioid	O
or	O
unspecified	O
histology	O
.	O
	
Stable	O
disease	O
was	O
seen	O
in	O
25	O
patients	O
(	O
50	O
%	O
)	O
.	O
	
The	O
median	O
overall	O
survival	O
was	O
10	O
months	O
(	O
95	O
%	O
CI	O
7月15日	O
months	O
)	O
","	O
with	O
a	O
median	O
progression-free	O
survival	O
of	O
6	O
months	O
.	O
	
Sixteen	O
patients	O
experienced	O
Grade	O
4	O
toxicity	O
.	O
	
Twelve	O
of	O
these	O
Grade	O
4	O
toxicities	O
were	O
hematologic	O
.	O
	
There	O
were	O
no	O
treatment-related	O
deaths	B-TOXI
.	O
	
Cisplatin-gemcitabine	B-DRUG
combination	O
chemotherapy	O
has	O
modest	O
activity	O
with	O
an	O
acceptable	O
toxicity	O
profile	O
","	O
as	O
first	O
line	O
treatment	O
for	O
patients	O
with	O
malignant	O
mesothelioma	B-CANCER
.	O
	
A	O
phase	O
II	O
study	O
of	O
paclitaxel	B-DRUG
combined	O
with	O
infusional	B-DRUG
5-fluorouracil	I-DRUG
and	O
low-dose	O
leucovorin	B-DRUG
for	O
advanced	O
gastric	B-CANCER
cancer	I-CANCER
.	O
	
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
efficacy	O
and	O
safety	O
of	O
the	O
combination	O
chemotherapy	O
of	O
paclitaxel	B-DRUG
","	O
infusional	B-DRUG
5-fluorouracil	I-DRUG
(	O
5-FU	B-DRUG
)	O
and	O
leucovorin	B-DRUG
(	O
FLT	B-DRUG
regimen	O
)	O
in	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
The	O
primary	O
end	O
point	O
was	O
the	O
time	O
to	O
progression	O
(	O
TTP	O
)	O
.	O
	
Patients	O
with	O
evaluable	O
disease	O
with	O
or	O
without	O
measurable	O
lesions	O
received	O
175	O
mg	O
/	O
m2	O
paclitaxel	B-DRUG
on	O
day	O
1	O
followed	O
by	O
20	O
mg	O
/	O
m2	O
leucovorin	B-DRUG
and	O
24-h	O
infusion	O
of	O
5-FU	B-DRUG
"1,000"	O
mg	O
/	O
m2	O
(	O
day	O
1月3日	O
)	O
repeated	O
every	O
3	O
weeks	O
.	O
	
Sixty	O
patients	O
were	O
enrolled	O
.	O
	
The	O
median	O
TTP	O
and	O
overall	O
survival	O
duration	O
were	O
13	O
and	O
60	O
weeks	O
","	O
respectively	O
.	O
	
One-year	O
survival	O
rate	O
was	O
53.3	O
%	O
.	O
	
Of	O
the	O
50	O
patients	O
with	O
measurable	O
lesion	O
","	O
the	O
overall	O
response	O
rate	O
was	O
31.7	O
%	O
.	O
	
The	O
most	O
common	O
grade	O
3月4日	O
adverse	O
event	O
was	O
neutropenia	B-TOXI
(	O
61.7	O
%	O
)	O
.	O
	
The	O
FLT	B-DRUG
regimen	O
showed	O
an	O
efficacy	O
comparable	O
to	O
other	O
regimens	O
of	O
cisplatin	B-DRUG
or	O
anthracycline	B-DRUG
combinations	O
with	O
the	O
advantage	O
of	O
remarkably	O
low	O
non-hematological	B-TOXI
toxicity	I-TOXI
.	O
	
These	O
data	O
about	O
the	O
efficacy	O
of	O
this	O
regimen	O
need	O
confirmation	O
in	O
a	O
phase	O
III	O
trial	O
.	O
	
A	O
phase	O
I	O
safety	O
","	O
pharmacological	O
","	O
and	O
biological	O
study	O
of	O
the	O
farnesyl	O
protein	O
transferase	O
inhibitor	O
","	O
lonafarnib	B-DRUG
(	O
SCH	O
663366	O
)	O
","	O
in	O
combination	O
with	O
cisplatin	B-DRUG
and	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
This	O
phase	O
I	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
safety	O
","	O
tolerability	O
","	O
pharmacological	O
properties	O
and	O
biological	O
activity	O
of	O
the	O
combination	O
of	O
the	O
lonafarnib	B-DRUG
","	O
a	O
farnesylproteintransferase	O
(	O
FTPase	O
)	O
inhibitor	O
","	O
with	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
malignancies	I-CANCER
.	O
	
This	O
was	O
a	O
single	O
institution	O
study	O
to	O
determine	O
the	O
maximal	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
escalating	O
lonafarnib	B-DRUG
(	O
75-125	O
mg	O
po	O
BID	O
)	O
with	O
gemcitabine	B-DRUG
(	O
"750-1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
","	O
8	O
","	O
15	O
)	O
and	O
fixed	O
cisplatin	B-DRUG
(	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
day	O
1	O
)	O
every	O
28	O
days	O
.	O
	
Due	O
to	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
of	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
in	O
initial	O
patients	O
","	O
these	O
patients	O
were	O
considered	O
	O
and	O
the	O
protocol	O
was	O
amended	O
to	O
limit	O
prior	O
therapy	O
and	O
re-escalate	O
lonafarnib	B-DRUG
in	O
	O
on	O
28-day	O
and	O
21-day	O
schedules	O
.	O
	
Cycle	O
1	O
and	O
2	O
pharmacokinetics	O
(	O
PK	O
)	O
","	O
and	O
farnesylation	O
of	O
the	O
HDJ2	O
chaperone	O
protein	O
and	O
FPTase	O
activity	O
were	O
analyzed	O
.	O
	
Twenty-two	O
patients	O
received	O
53	O
courses	O
of	O
therapy	O
.	O
	
Nausea	B-TOXI
","	O
vomiting	B-TOXI
","	O
and	O
fatigue	B-TOXI
were	O
frequent	O
in	O
all	O
patients	O
.	O
	
Severe	B-TOXI
toxicities	I-TOXI
were	O
observed	O
in	O
91	O
%	O
of	O
patients	O
:	O
neutropenia	B-TOXI
(	O
41	O
%	O
)	O
","	O
nausea	B-TOXI
(	O
36	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
32	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
23	O
%	O
)	O
and	O
vomiting	B-TOXI
(	O
23	O
%	O
)	O
.	O
	
Nine	O
patients	O
withdrew	O
from	O
the	O
study	O
due	O
to	O
toxicity	O
.	O
	
DLTs	O
of	O
neutropenia	B-TOXI
","	O
febrile	B-TOXI
neutropenia	I-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
and	O
fatigue	B-TOXI
limited	O
dose-escalation	O
on	O
the	O
28-day	O
schedule	O
.	O
	
The	O
MTD	O
was	O
established	O
as	O
lonafarnib	B-DRUG
75	O
mg	O
BID	O
","	O
gemcitabine	B-DRUG
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
days	O
1	O
","	O
8	O
","	O
15	O
","	O
and	O
cisplatin	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
heavily	O
pre-treated	O
patients	O
.	O
	
The	O
MTD	O
in	O
the	O
less	O
heavily	O
pre-treated	O
patients	O
could	O
not	O
be	O
established	O
on	O
the	O
28-day	O
schedule	O
as	O
DLTs	O
were	O
observed	O
at	O
the	O
lowest	O
dose	O
level	O
","	O
and	O
dose	O
escalation	O
was	O
not	O
completed	O
on	O
the	O
21-day	O
schedule	O
due	O
to	O
early	O
study	O
termination	O
by	O
the	O
Sponsor	O
.	O
	
No	O
PK	O
interactions	O
were	O
observed	O
.	O
	
FTPase	O
inhibition	O
was	O
not	O
observed	O
at	O
the	O
MTD	O
","	O
however	O
HDJ-2	O
gel	O
shift	O
was	O
observed	O
in	O
one	O
patient	O
at	O
the	O
100	O
mg	O
BID	O
lonafarnib	B-DRUG
dose	O
.	O
	
Anti-cancer	O
activity	O
was	O
observed	O
:	O
four	O
patients	O
had	O
stable	O
disease	O
lasting	O
&	O
gt	O
;	O
2	O
cycles	O
","	O
one	O
subject	O
had	O
a	O
complete	O
response	O
","	O
and	O
another	O
had	O
a	O
partial	O
response	O
","	O
both	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Lonafarnib	B-DRUG
75	O
mg	O
BID	O
","	O
gemcitabine	B-DRUG
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
days	O
1	O
","	O
8	O
","	O
15	O
","	O
and	O
cisplatin	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
day	O
1	O
on	O
a	O
28-day	O
schedule	O
was	O
established	O
as	O
the	O
MTD	O
.	O
	
Lonafarnib	B-DRUG
did	O
not	O
demonstrate	O
FTPase	O
inhibition	O
at	O
these	O
doses	O
.	O
	
Despite	O
the	O
observed	O
efficacy	O
","	O
substantial	O
toxicity	O
and	O
questionable	O
contribution	O
of	O
anti-tumor	O
activity	O
of	O
lonafarnib	B-DRUG
to	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
limits	O
further	O
exploration	O
of	O
this	O
combination	O
.	O
	
Bevacizumab	B-DRUG
plus	O
infusional	B-DRUG
5-fluorouracil	I-DRUG
","	O
leucovorin	B-DRUG
and	O
irinotecan	B-DRUG
for	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
that	O
progressed	O
after	O
oxaliplatin	B-DRUG
and	O
irinotecan	B-DRUG
chemotherapy	O
:	O
a	O
pilot	O
study	O
.	O
	
	
To	O
evaluate	O
the	O
combination	O
of	O
bevacizumab	B-DRUG
with	O
infusional	B-DRUG
5-fluorouracil	I-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
and	O
irinotecan	B-DRUG
(	O
FOLFIRI	B-DRUG
)	O
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
CRC	B-CANCER
)	O
pretreated	O
with	O
combination	O
regimens	O
including	O
irinotecan	B-DRUG
and	O
oxaliplatin	B-DRUG
.	O
	
Fourteen	O
patients	O
(	O
median	O
age	O
56	O
years	O
)	O
with	O
advanced	B-CANCER
CRC	I-CANCER
","	O
all	O
having	O
progressed	O
after	O
oxaliplatin-	B-DRUG
and	O
irinotecan-based	B-DRUG
combination	O
chemotherapy	O
","	O
were	O
enrolled	O
in	O
this	O
study	O
.	O
	
Patients	O
were	O
treated	O
with	O
2	O
h	O
infusion	O
of	O
irinotecan	B-DRUG
150	O
mg	O
/	O
m2	O
on	O
d	O
1	O
","	O
plus	O
bevacizumab	B-DRUG
5	O
mg	O
/	O
kg	O
iv	O
infusion	O
for	O
90	O
min	O
on	O
d	O
2	O
","	O
and	O
iv	O
injection	O
of	O
LV	B-DRUG
20	O
mg	O
/	O
m2	O
followed	O
by	O
a	O
bolus	O
of	O
5-FU	B-DRUG
400	O
mg	O
/	O
m2	O
and	O
then	O
22	O
h	O
continuous	O
infusion	O
of	O
600	O
mg	O
/	O
m2	O
given	O
on	O
two	O
consecutive	O
days	O
every	O
14	O
d.	O
The	O
median	O
number	O
of	O
cycles	O
of	O
chemotherapy	O
was	O
six	O
(	O
range	O
3月12日	O
)	O
.	O
	
The	O
response	O
rate	O
was	O
28.5	O
%	O
","	O
one	O
patient	O
had	O
a	O
complete	O
response	O
","	O
and	O
three	O
patients	O
had	O
a	O
partial	O
response	O
.	O
	
Eight	O
patients	O
had	O
stable	O
disease	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
was	O
3.9	O
mo	O
(	O
95	O
%	O
CI	O
2.0-8.7	O
)	O
","	O
and	O
the	O
median	O
overall	O
survival	O
was	O
10.9	O
mo	O
(	O
95	O
%	O
CI	O
9.6-12.1	O
)	O
.	O
	
Grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
occurred	O
in	O
five	O
patients	O
","	O
and	O
two	O
of	O
these	O
developed	O
neutropenic	B-TOXI
fever	I-TOXI
.	O
	
Grade	O
3	O
hematuria	B-TOXI
and	O
hematochezia	B-TOXI
occurred	O
in	O
one	O
.	O
	
Grade	O
2	O
proteinuria	B-TOXI
occurred	O
in	O
two	O
patients	O
.	O
	
However	O
","	O
hypertension	B-TOXI
","	O
bowel	B-TOXI
perforation	I-TOXI
or	O
thromboembolic	B-TOXI
events	I-TOXI
did	O
not	O
occur	O
in	O
a	O
total	O
of	O
90	O
cycles	O
.	O
	
Bevacizumab	B-DRUG
with	O
FOLFIRI	B-DRUG
is	O
well	O
tolerated	O
and	O
a	O
feasible	O
treatment	O
in	O
patients	O
with	O
heavily	O
treated	O
advanced	B-CANCER
CRC	I-CANCER
.	O
	
Cisplatin	B-DRUG
","	O
gemcitabine	B-DRUG
and	O
treosulfan	B-DRUG
is	O
effective	O
in	O
chemotherapy-pretreated	O
relapsed	O
stage	O
IV	O
uveal	B-CANCER
melanoma	I-CANCER
patients	O
.	O
	
	
The	O
efficacy	O
of	O
cisplatin	B-DRUG
","	O
gemcitabine	B-DRUG
","	O
and	O
treosulfan	B-DRUG
(	O
CGT	B-DRUG
)	O
was	O
evaluated	O
in	O
patients	O
with	O
chemotherapy	O
pretreated	O
relapsed	O
AJCC	O
stage	O
IV	O
uveal	B-CANCER
malignant	I-CANCER
melanoma	I-CANCER
.	O
	
Patients	O
received	O
i.v.	O
/	O
intrahepatic	O
cisplatin	B-DRUG
","	O
i.v.	O
gemcitabine	B-DRUG
","	O
and	O
i.v.	O
treosulfan	B-DRUG
(	O
CGT	B-DRUG
)	O
on	O
day	O
1	O
and	O
8	O
as	O
first-line	O
(	O
n	O
=	O
1	O
)	O
","	O
second-line	O
(	O
n	O
=	O
9	O
)	O
","	O
third-line	O
(	O
n	O
=	O
1	O
)	O
or	O
fourth-line	O
(	O
n	O
=	O
1	O
)	O
therapy	O
.	O
	
Cisplatin	B-DRUG
","	O
gemcitabine	B-DRUG
","	O
and	O
treosulfan	B-DRUG
(	O
CGT	B-DRUG
)	O
#NAME?	O
was	O
repeated	O
every	O
5	O
weeks	O
until	O
progression	B-TOXI
of	I-TOXI
disease	I-TOXI
occurred	O
.	O
	
A	O
maximum	O
of	O
six	O
CGT-cycles	B-DRUG
(	O
mean	O
","	O
2	O
cycles	O
)	O
was	O
administered	O
per	O
patient	O
.	O
	
No	O
objective	O
response	O
was	O
observed	O
","	O
six	O
patients	O
(	O
50	O
%	O
)	O
had	O
stable	O
disease	O
and	O
six	O
(	O
50	O
%	O
)	O
patients	O
progressed	O
upon	O
first	O
reevaluation	O
.	O
	
Overall	O
survival	O
of	O
all	O
the	O
12	O
patients	O
was	O
6	O
months	O
.	O
	
Patients	O
with	O
stable	O
disease	O
reached	O
a	O
median	O
overall	O
survival	O
of	O
12	O
months	O
","	O
while	O
patients	O
with	O
disease	O
progression	O
upon	O
first	O
reevaluation	O
had	O
a	O
median	O
overall	O
survival	O
of	O
4	O
months	O
","	O
only	O
.	O
	
Grade	O
III	O
/	O
IV	O
related	O
hematotological	B-TOXI
side	I-TOXI
effects	I-TOXI
were	O
experienced	O
in	O
six	O
(	O
leukopenia	B-TOXI
)	O
and	O
four	O
(	O
thrombocytopenia	B-TOXI
)	O
patients	O
.	O
	
Treatment	O
with	O
CGT	B-DRUG
may	O
lead	O
to	O
disease	O
stabilization	O
and	O
prolonged	O
survival	O
in	O
a	O
substantial	O
proportion	O
of	O
progressive	O
stage	O
IV	O
uveal	B-CANCER
melanoma	I-CANCER
patients	O
","	O
even	O
following	O
heavy	O
chemotherapy	O
treatment	O
.	O
	
Methotrexate	B-DRUG
","	O
vinblastine	B-DRUG
","	O
doxorubicin	B-DRUG
and	O
cisplatin	B-DRUG
combination	O
regimen	O
as	O
salvage	O
chemotherapy	O
for	O
patients	O
with	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
transitional	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
after	O
failure	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
chemotherapy	O
.	O
	
	
We	O
investigated	O
the	O
safety	O
and	O
efficacy	O
of	O
a	O
methotrexate	B-DRUG
","	O
vinblastine	B-DRUG
","	O
doxorubicin	B-DRUG
and	O
cisplatin	B-DRUG
(	O
M-VAC	B-DRUG
)	O
combination	O
regimen	O
as	O
second-line	O
chemotherapy	O
for	O
patients	O
with	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
transitional	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
who	O
failed	O
first-line	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
(	O
GC	B-DRUG
)	O
chemotherapy	O
.	O
	
Thirty	O
patients	O
who	O
had	O
progressed	O
or	O
relapsed	O
after	O
GC	B-DRUG
chemotherapy	O
as	O
first-line	O
treatment	O
were	O
enrolled	O
in	O
this	O
study	O
.	O
	
The	O
major	O
toxicities	O
were	O
neutropaenia	B-TOXI
and	O
thrombocytopaenia	B-TOXI
.	O
	
A	O
grade	O
3	O
or	O
4	O
neutropaenia	B-TOXI
occurred	O
in	O
19	O
(	O
63.3	O
%	O
)	O
and	O
a	O
grade	O
3	O
or	O
4	O
thrombocytopaenia	B-TOXI
developed	O
in	O
nine	O
patients	O
(	O
30	O
%	O
)	O
.	O
	
There	O
were	O
no	O
life-threatening	O
complications	O
during	O
the	O
study	O
.	O
	
The	O
overall	O
response	O
was	O
30	O
%	O
.	O
	
A	O
complete	O
response	O
was	O
achieved	O
in	O
two	O
patients	O
(	O
6.7	O
%	O
)	O
and	O
a	O
partial	O
response	O
in	O
seven	O
(	O
23.3	O
%	O
)	O
.	O
	
The	O
overall	O
disease	O
control	O
rate	O
was	O
50	O
%	O
.	O
	
Seven	O
out	O
of	O
16	O
patients	O
who	O
had	O
responded	O
previously	O
to	O
GC	B-DRUG
responded	O
to	O
M-VAC	B-DRUG
","	O
while	O
2	O
out	O
of	O
14	O
who	O
had	O
not	O
responded	O
to	O
GC	B-DRUG
responded	O
to	O
M-VAC	B-DRUG
.	O
	
The	O
median	O
response	O
duration	O
was	O
3.9	O
months	O
and	O
the	O
median	O
progression-free	O
survival	O
was	O
5.3	O
months	O
.	O
	
The	O
median	O
overall	O
survival	O
was	O
10.9	O
months	O
.	O
	
M-VAC	B-DRUG
showed	O
encouraging	O
efficacy	O
and	O
reversible	O
toxicities	O
in	O
patients	O
who	O
had	O
progressed	O
after	O
GC	B-DRUG
chemotherapy	O
and	O
","	O
especially	O
","	O
M-VAC	B-DRUG
appears	O
to	O
be	O
a	O
reasonable	O
option	O
as	O
a	O
sequential	O
treatment	O
regimen	O
in	O
patients	O
who	O
responded	O
previously	O
to	O
GC	B-DRUG
chemotherapy	O
.	O
	
Phase	O
I	O
/	O
II	O
study	O
of	O
sequential	O
dose-intensified	O
ifosfamide	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
etoposide	B-DRUG
plus	O
paclitaxel	B-DRUG
as	O
induction	O
chemotherapy	O
for	O
poor	O
prognosis	O
germ	B-CANCER
cell	I-CANCER
tumors	I-CANCER
by	O
the	O
German	O
Testicular	O
Cancer	O
Study	O
Group	O
.	O
	
	
To	O
evaluate	O
the	O
feasibility	O
and	O
the	O
toxicity	O
of	O
sequential	O
","	O
dose-intensified	O
chemotherapy	O
combined	O
with	O
paclitaxel	B-DRUG
plus	O
peripheral	O
blood-derived	O
hematopoietic	O
stem-cell	O
support	O
(	O
PBSC	O
)	O
for	O
patients	O
with	O
untreated	O
metastatic	B-CANCER
germ	I-CANCER
cell	I-CANCER
tumors	I-CANCER
(	O
GCTs	B-CANCER
)	O
who	O
have	O
poor	O
International	O
Germ	O
Cell	O
Consensus	O
Cancer	O
Group	O
prognostic	O
features	O
.	O
	
Paclitaxel	B-DRUG
was	O
added	O
to	O
high-dose	O
(	O
HD	O
)	O
etoposide	B-DRUG
","	O
ifosfamide	B-DRUG
","	O
and	O
cisplatin	B-DRUG
(	O
VIP	O
;	O
etoposide	B-DRUG
"1,500"	O
mg	O
/	O
m2	O
","	O
ifosfamide	B-DRUG
"10,000"	O
mg	O
/	O
m2	O
","	O
and	O
cisplatin	B-DRUG
100	O
mg	O
/	O
m2	O
;	O
cumulative	O
dose	O
;	O
days	O
-6	O
through	O
-2	O
per	O
cycle	O
)	O
at	O
three	O
dose	O
levels	O
(	O
135	O
","	O
175	O
","	O
and	O
225	O
mg	O
/	O
m2	O
)	O
applied	O
on	O
day	O
-6	O
.	O
	
Cycles	O
were	O
supported	O
by	O
PBSC	O
and	O
granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
.	O
	
One	O
cycle	O
of	O
standard	O
VIP	O
was	O
administered	O
before	O
start	O
of	O
HD-VIP	O
plus	O
paclitaxel	B-DRUG
cycles	O
to	O
collect	O
autologous	O
PBSC	O
.	O
	
Fifty-two	O
of	O
53	O
patients	O
receiving	O
152	O
cycles	O
were	O
assessable	O
.	O
	
As	O
expected	O
","	O
myelosuppression	B-TOXI
was	O
the	O
major	O
adverse	O
effect	O
.	O
	
Median	O
durations	O
of	O
leukocytes	O
less	O
than	O
"1,000"	O
/	O
microL	O
and	O
thrombocytes	O
less	O
than	O
"25,000"	O
/	O
microL	O
were	O
6	O
and	O
4	O
days	O
","	O
respectively	O
","	O
independently	O
of	O
the	O
dose	O
of	O
paclitaxel	B-DRUG
applied	O
.	O
	
WHO	O
grade	O
2	O
neurotoxicity	B-TOXI
and	O
grade	O
3	O
encephalopathy	B-TOXI
were	O
observed	O
in	O
5	O
%	O
of	O
patients	O
each	O
.	O
	
Other	O
main	O
adverse	O
effects	O
observed	O
were	O
stomatitis	B-TOXI
","	O
diarrhea	B-TOXI
","	O
and	O
obstipation	B-TOXI
.	O
	
Seventy-nine	O
percent	O
of	O
patients	O
achieved	O
a	O
favorable	O
response	O
to	O
chemotherapy	O
plus	O
secondary	O
surgery	O
.	O
	
After	O
a	O
median	O
follow-up	O
time	O
of	O
41	O
months	O
in	O
surviving	O
patients	O
","	O
the	O
calculated	O
-2	O
and	O
5-year	O
survival	O
rates	O
were	O
77.6	O
%	O
(	O
95	O
%	O
CI	O
","	O
65.4	O
%	O
to	O
89.9	O
%	O
)	O
and	O
75.2	O
%	O
(	O
95	O
%	O
CI	O
","	O
62.5	O
%	O
to	O
87.8	O
%	O
)	O
","	O
respectively	O
.	O
	
Dose-intensive	O
","	O
sequential	O
HD-VIP	O
plus	O
paclitaxel	B-DRUG
up	O
to	O
a	O
dose	O
of	O
225	O
mg	O
/	O
m2	O
in	O
patients	O
with	O
poor	O
prognosis	O
GCT	B-CANCER
is	O
a	O
feasible	O
approach	O
.	O
	
The	O
regimen	O
warrants	O
investigation	O
for	O
its	O
therapeutic	O
potential	O
in	O
an	O
expanded	O
cohort	O
of	O
poor	O
prognosis	O
GCT	B-CANCER
patients	O
.	O
	
The	O
predictive	O
value	O
of	O
18F-FDG-PET	O
early	O
evaluation	O
in	O
patients	O
with	O
metastatic	B-CANCER
gastric	I-CANCER
adenocarcinoma	I-CANCER
treated	O
with	O
chemotherapy	O
plus	O
cetuximab	B-DRUG
.	O
	
	
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
whether	O
the	O
therapy-induced	O
reduction	O
of	O
the	O
(	B-DRUG
18	I-DRUG
)	I-DRUG
F-fluorodeoxyglucose	I-DRUG
positron	I-DRUG
emission	I-DRUG
tomography	I-DRUG
(	O
18F-FDG-PET	B-DRUG
)	O
maximum	O
standardized	O
uptake	O
value	O
in	O
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
adenocarcinoma	I-CANCER
treated	O
with	O
chemotherapy	O
plus	O
cetuximab	B-DRUG
could	O
predict	O
the	O
objective	O
response	O
and	O
outcome	O
early	O
during	O
the	O
treatment	O
.	O
	
The	O
study	O
was	O
performed	O
as	O
a	O
part	O
of	O
a	O
phase	O
II	O
trial	O
evaluating	O
cetuximab	B-DRUG
plus	O
the	O
leucovorin	B-DRUG
/	O
5-fluorouracil	B-DRUG
/	O
irinotecan	B-DRUG
(	O
FOLFIRI	B-DRUG
)	O
regimen	O
.	O
	
The	O
objective	O
response	O
was	O
evaluated	O
according	O
to	O
the	O
response	O
evaluation	O
criteria	O
in	O
solid	B-CANCER
tumors	I-CANCER
(	O
RECIST	O
)	O
every	O
6	O
weeks	O
.	O
	
The	O
early	O
metabolic	O
response	O
evaluated	O
by	O
18F-FDG-PET	B-DRUG
was	O
assessed	O
according	O
to	O
our	O
own	O
evaluated	O
cutoff	O
value	O
(	O
&	O
lt	O
;	O
35	O
%	O
)	O
after	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
analysis	O
.	O
	
Twenty	O
of	O
22	O
patients	O
had	O
positive	O
baseline	O
18F-FDG-PET	B-DRUG
.	O
	
The	O
best	O
RECIST	O
response	O
was	O
:	O
complete	O
response	O
(	O
CR	O
)	O
","	O
3	O
;	O
partial	O
response	O
(	O
PR	O
)	O
","	O
9	O
;	O
stable	O
disease	O
(	O
SD	O
)	O
","	O
8	O
Twelve	O
patients	O
(	O
60	O
%	O
)	O
were	O
classified	O
as	O
metabolic	O
responders	O
and	O
8	O
(	O
40	O
%	O
)	O
as	O
nonresponders	O
.	O
	
At	O
the	O
median	O
follow-up	O
time	O
of	O
11	O
months	O
","	O
median	O
time	O
to	O
disease	O
progression	O
(	O
TTP	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
for	O
early	O
metabolic	O
responders	O
versus	O
nonresponders	O
were	O
11	O
versus	O
5	O
months	O
(	O
P	O
=	O
0.0016	O
)	O
and	O
16	O
versus	O
6	O
months	O
(	O
P	O
=	O
0.1493	O
)	O
","	O
respectively	O
.	O
	
The	O
early	O
metabolic	O
response	O
evaluated	O
by	O
18F-FDG-PET	B-DRUG
predicted	O
the	O
clinical	O
outcome	O
in	O
this	O
series	O
of	O
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
treated	O
with	O
chemotherapy	O
plus	O
cetuximab	B-DRUG
.	O
	
Phase	O
I	O
study	O
of	O
induction	O
chemotherapy	O
and	O
concomitant	O
chemoradiotherapy	O
with	O
irinotecan	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
paclitaxel	B-DRUG
for	O
stage	O
III	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
dose	O
limiting	O
toxicities	O
(	O
DLTs	O
)	O
","	O
and	O
determine	O
the	O
phase	O
II	O
dose	O
for	O
the	O
combination	O
of	O
irinotecan-carboplatin-paclitaxel	B-DRUG
given	O
as	O
induction	O
chemotherapy	O
and	O
with	O
concomitant	O
chest	O
radiotherapy	O
for	O
patients	O
with	O
Stage	O
III	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
Cancer	O
and	O
Leukemia	B-CANCER
Group	O
B	O
performance	O
status	O
of	O
0	O
to	O
2	O
","	O
stage	O
IIIA	O
and	O
IIIB	O
NSCLC	B-CANCER
patients	O
with	O
resectable	O
or	O
unresectable	O
disease	O
were	O
treated	O
with	O
induction	O
chemotherapy	O
(	O
irinotecan	B-DRUG
100	O
mg	O
/	O
m2	O
","	O
carboplatin	B-DRUG
AUC	O
5	O
","	O
and	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m2	O
days	O
1	O
and	O
22	O
)	O
followed	O
by	O
concomitant	O
chemotherapy	O
(	O
irinotecan	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
paclitaxel	B-DRUG
)	O
and	O
chest	O
radiotherapy	O
(	O
66	O
Gy	O
for	O
unresectable	O
and	O
50	O
Gy	O
for	O
resectable	O
disease	O
)	O
beginning	O
on	O
week	O
7	O
The	O
primary	O
objective	O
was	O
to	O
escalate	O
the	O
dose	O
of	O
irinotecan	B-DRUG
during	O
chemoradiation	O
in	O
sequential	O
cohorts	O
to	O
determine	O
the	O
DLT	O
and	O
MTD	O
of	O
the	O
regimen	O
.	O
	
Thirty-eight	O
patients	O
were	O
enrolled	O
(	O
median	O
age	O
63	O
years	O
","	O
57	O
%	O
male	O
","	O
41	O
%	O
performance	O
status	O
0	O
","	O
30	O
%	O
resectable	O
)	O
.	O
	
Induction	O
chemotherapy	O
was	O
tolerable	O
and	O
active	O
(	O
response	O
rate	O
26	O
%	O
;	O
stable	O
disease	O
60	O
%	O
)	O
.	O
	
Eight	O
patients	O
did	O
not	O
receive	O
concurrent	O
chemoradiotherapy	O
because	O
of	O
progressive	O
disease	O
(	O
5	O
)	O
","	O
death	B-TOXI
(	O
1	O
)	O
","	O
hypersensitivity	B-TOXI
reaction	O
to	O
paclitaxel	B-DRUG
(	O
1	O
)	O
","	O
and	O
withdrawal	O
of	O
consent	O
(	O
1	O
)	O
.	O
	
Twenty-nine	O
patients	O
received	O
concurrent	O
chemoradiotherapy	O
.	O
	
The	O
concomitant	O
administration	O
of	O
chest	O
radiotherapy	O
with	O
weekly	O
irinotecan	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
paclitaxel	B-DRUG
was	O
not	O
feasible	O
at	O
the	O
first	O
","	O
second	O
","	O
and	O
third	O
dose	O
levels	O
.	O
	
DLT	O
was	O
failure	O
to	O
achieve	O
recovery	O
to	O
&	O
lt	O
;	O
or=	O
grade	O
1	O
absolute	O
neutrophil	O
count	O
by	O
the	O
day	O
of	O
scheduled	O
chemotherapy	O
administration	O
.	O
	
Dose	O
de-escalation	O
to	O
irinotecan	B-DRUG
30	O
mg	O
/	O
m2	O
","	O
paclitaxel	B-DRUG
40	O
mg	O
/	O
m2	O
(	O
with	O
omission	O
of	O
carboplatin	B-DRUG
)	O
delivered	O
on	O
weeks	O
2	O
","	O
3	O
","	O
5	O
","	O
and	O
6	O
of	O
radiotherapy	O
was	O
the	O
MTD	O
.	O
	
After	O
induction	O
chemotherapy	O
","	O
partial	O
responses	O
","	O
stable	O
disease	O
","	O
and	O
progressive	O
disease	O
was	O
observed	O
in	O
26	O
%	O
","	O
60	O
%	O
","	O
and	O
14	O
%	O
of	O
patients	O
","	O
respectively	O
.	O
	
After	O
chemoradiotherapy	O
","	O
partial	O
responses	O
were	O
attained	O
in	O
16	O
(	O
55	O
%	O
)	O
patients	O
","	O
whereas	O
12	O
patients	O
(	O
41	O
%	O
)	O
attained	O
disease	O
stabilization	O
.	O
	
Median	O
overall	O
survival	O
was	O
21	O
months	O
for	O
the	O
entire	O
cohort	O
.	O
	
Resectable	O
patients	O
had	O
a	O
median	O
survival	O
of	O
24	O
months	O
","	O
whereas	O
unresectable	O
patients	O
had	O
a	O
median	O
survival	O
of	O
19	O
months	O
.	O
	
Differences	O
in	O
overall	O
and	O
progression-free	O
survival	O
rates	O
between	O
resectable	O
and	O
unresectable	O
patients	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0.52	O
and	O
p	O
=	O
0.9	O
","	O
respectively	O
)	O
.	O
	
Carboplatin	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
and	O
irinotecan	B-DRUG
with	O
concurrent	O
chemoradiotherapy	O
was	O
poorly	O
tolerated	O
as	O
a	O
result	O
of	O
neutropenia	B-TOXI
.	O
	
Although	O
dose	O
de-escalation	O
was	O
required	O
for	O
delivery	O
of	O
the	O
regimen	O
","	O
the	O
response	O
rates	O
and	O
survival	O
outcomes	O
were	O
comparable	O
to	O
other	O
similar	O
regimens	O
.	O
	
A	O
phase	O
I	O
trial	O
of	O
gemcitabine	B-DRUG
in	O
combination	O
with	O
patupilone	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Chemotherapy	O
regimens	O
including	O
gemcitabine	B-DRUG
in	O
combination	O
with	O
microtubule	O
inhibitors	O
such	O
as	O
docetaxel	B-DRUG
and	O
paclitaxel	B-DRUG
have	O
wide	O
clinical	O
application	O
.	O
	
Patupilone	B-DRUG
is	O
a	O
novel	O
tubulin-polymerizing	O
agent	O
with	O
activity	O
against	O
paclitaxel-resistant	B-DRUG
cell	O
lines	O
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
trial	O
to	O
assess	O
the	O
maximum	O
tolerated	O
dose	O
","	O
dose	O
limiting	O
toxicity	O
(	O
DLT	O
)	O
and	O
antitumor	O
activity	O
of	O
gemcitabine	B-DRUG
and	O
patupilone	B-DRUG
.	O
	
Patients	O
with	O
refractory	O
solid	B-CANCER
tumors	I-CANCER
enrolled	O
in	O
cohorts	O
of	O
three	O
.	O
	
Cohorts	O
received	O
fixed	O
doses	O
of	O
gemcitabine	B-DRUG
(	O
"1,000"	O
or	O
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
along	O
with	O
escalating	O
doses	O
of	O
patupilone	B-DRUG
(	O
1.5-3	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
on	O
days	O
1	O
and	O
8	O
of	O
a	O
21-day	O
cycle	O
.	O
	
Twenty-seven	O
patients	O
received	O
a	O
total	O
of	O
99	O
courses	O
of	O
treatment	O
on	O
study	O
.	O
	
Hematologic	B-TOXI
toxicity	I-TOXI
in	O
the	O
first	O
cohort	O
required	O
a	O
modification	O
of	O
the	O
protocol	O
to	O
decrease	O
the	O
gemcitabine	B-DRUG
dose	O
.	O
	
Subsequent	O
patients	O
received	O
gemcitabine	B-DRUG
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
escalating	O
doses	O
of	O
patupilone	B-DRUG
from	O
1.5	O
to	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
DLTs	O
were	O
grade	O
3	O
asthenia	B-TOXI
and	O
grade	O
3	O
dehydration	B-TOXI
.	O
	
There	O
was	O
also	O
one	O
treatment-related	O
death	B-TOXI
due	O
to	O
neutropenic	B-TOXI
infection	I-TOXI
.	O
	
Other	O
clinically	O
significant	O
toxicities	O
were	O
persistent	O
asthenia	B-TOXI
and	O
persistent	O
nausea	B-TOXI
.	O
	
Four	O
patients	O
","	O
one	O
each	O
with	O
pancreatic	B-CANCER
cancer	I-CANCER
","	O
esophageal	B-CANCER
carcinoma	I-CANCER
","	O
cholangiocarcinoma	B-CANCER
and	O
gallbladder	B-CANCER
carcinoma	I-CANCER
","	O
experienced	O
a	O
partial	O
response	O
.	O
	
The	O
dose-limiting	O
toxicities	O
of	O
gemcitabine	B-DRUG
and	O
patupilone	B-DRUG
were	O
asthenia	B-TOXI
and	O
dehydration	B-TOXI
.	O
	
Dose	O
reductions	O
also	O
occurred	O
due	O
to	O
persistent	O
fatigue	B-TOXI
that	O
was	O
not	O
dose-limiting	O
.	O
	
However	O
","	O
patients	O
with	O
advanced	B-CANCER
malignancies	I-CANCER
were	O
able	O
to	O
tolerate	O
gemcitabine	B-DRUG
and	O
patupilone	B-DRUG
at	O
doses	O
that	O
resulted	O
in	O
clinical	O
benefit	O
.	O
	
The	O
recommended	O
phase	O
II	O
dose	O
for	O
this	O
schedule	O
is	O
gemcitabine	B-DRUG
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
patupilone	B-DRUG
1.5	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
and	O
8	O
of	O
a	O
21-day	O
cycle	O
.	O
	
A	O
phase	O
II	O
study	O
of	O
cisplatin	B-DRUG
preceded	O
by	O
a	O
12-h	O
continuous	O
infusion	O
of	O
concurrent	O
hydroxyurea	B-DRUG
and	O
cytosine	B-DRUG
arabinoside	I-DRUG
(	O
Ara-C	B-DRUG
)	O
for	O
adult	O
patients	O
with	O
malignant	B-CANCER
gliomas	I-CANCER
(	O
Southwest	O
Oncology	O
Group	O
S9149	O
)	O
.	O
	
	
Inhibition	O
of	O
DNA	O
excision	O
repair	O
can	O
modulate	O
resistance	O
to	O
cisplatin	B-DRUG
.	O
	
Cytosine	B-DRUG
arabinoside	I-DRUG
(	O
Ara-C	B-DRUG
)	O
and	O
hydroxyurea	B-DRUG
(	O
HU	B-DRUG
)	O
","	O
in	O
combination	O
","	O
inhibit	O
the	O
excision-repair	O
system	O
and	O
removal	O
of	O
platinum-DNA	B-DRUG
adducts	O
.	O
	
Marked	O
cytotoxic	O
synergy	O
had	O
been	O
demonstrated	O
in	O
vitro	O
at	O
clinically	O
achievable	O
levels	O
.	O
	
The	O
three-drug	O
regimen	O
was	O
found	O
to	O
be	O
feasible	O
in	O
clinical	O
pilot	O
studies	O
.	O
	
A	O
Phase	O
II	O
study	O
in	O
patients	O
with	O
relapsed	O
or	O
progressive	O
anaplastic	B-CANCER
astrocytoma	I-CANCER
(	O
AA	O
)	O
or	O
glioblastoma	B-CANCER
multiforme	I-CANCER
(	O
GBM	B-CANCER
)	O
was	O
performed	O
in	O
the	O
Southwest	O
Oncology	O
Group	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
6	O
month	O
survival	O
","	O
historically	O
about	O
42	O
%	O
.	O
	
A	O
loading	O
dose	O
of	O
HU	B-DRUG
"1,260"	O
mg	O
/	O
m2	O
IV	O
over	O
1	O
h	O
was	O
followed	O
by	O
Ara-C	B-DRUG
"1,200"	O
mg	O
/	O
m2	O
plus	O
HU	B-DRUG
"5,040"	O
mg	O
/	O
m2	O
IV	O
over	O
12	O
h	O
","	O
followed	O
by	O
cisplatin	B-DRUG
100	O
mg	O
/	O
m2	O
IV	O
over	O
1	O
h.	O
A	O
total	O
of	O
76	O
patients	O
were	O
registered	O
.	O
	
The	O
GBM	B-CANCER
stratum	O
registered	O
56	O
patients	O
in	O
a	O
two-stage	O
accrual	O
.	O
	
Among	O
51	O
eligible	O
GBM	B-CANCER
patients	O
","	O
the	O
6-month	O
survival	O
probability	O
was	O
41	O
%	O
(	O
95	O
%	O
CI	O
28-55	O
%	O
)	O
","	O
and	O
median	O
overall	O
survival	O
was	O
5	O
months	O
(	O
95	O
%	O
CI	O
4月6日	O
months	O
)	O
.	O
	
The	O
6-month	O
progression-free	O
survival	O
probability	O
was	O
25	O
%	O
(	O
95	O
%	O
CI	O
14-37	O
%	O
)	O
","	O
and	O
median	O
progression-free	O
survival	O
was	O
2	O
months	O
(	O
95	O
%	O
CI	O
2月4日	O
months	O
)	O
.	O
	
One	O
patient	O
achieved	O
a	O
partial	O
response	O
(	O
2	O
%	O
","	O
95	O
%	O
CI	O
0-10	O
%	O
)	O
","	O
13	O
patients	O
had	O
stable	O
disease	O
(	O
25	O
%	O
","	O
95	O
%	O
CI	O
14-39	O
%	O
)	O
.	O
	
Twenty-two	O
patients	O
progressed	O
","	O
and	O
14	O
were	O
not	O
assessable	O
for	O
response	O
.	O
	
The	O
AA	O
stratum	O
was	O
closed	O
early	O
after	O
20	O
patients	O
due	O
to	O
slow	O
accrual	O
.	O
	
Among	O
19	O
eligible	O
patients	O
","	O
the	O
6-month	O
survival	O
probability	O
was	O
58	O
%	O
(	O
95	O
%	O
CI	O
36-80	O
%	O
)	O
","	O
and	O
median	O
overall	O
survival	O
was	O
7	O
months	O
(	O
95	O
%	O
CI	O
7月14日	O
months	O
)	O
.	O
	
The	O
6-month	O
progression-free	O
survival	O
probability	O
was	O
26	O
%	O
(	O
95	O
%	O
CI	O
6-46	O
%	O
)	O
","	O
and	O
median	O
progression-free	O
survival	O
was	O
3	O
months	O
(	O
95	O
%	O
CI	O
2月5日	O
months	O
)	O
.	O
	
No	O
responses	O
were	O
seen	O
.	O
	
Six	O
patients	O
(	O
32	O
%	O
)	O
had	O
stable	O
disease	O
(	O
95	O
%	O
CI	O
13-57	O
%	O
)	O
","	O
11	O
progressed	O
","	O
and	O
2	O
were	O
not	O
assessable	O
for	O
response	O
.	O
	
Of	O
the	O
70	O
patients	O
evaluable	O
for	O
toxicity	O
","	O
two	O
died	B-TOXI
of	O
infection	B-TOXI
.	O
	
Twenty-three	O
patients	O
(	O
33	O
%	O
)	O
experienced	O
Grade	O
4	O
toxicities	O
","	O
primarily	O
hematological	O
.	O
	
Cisplatin	B-DRUG
combined	O
with	O
HU	B-DRUG
and	O
Ara-C	B-DRUG
did	O
not	O
improve	O
the	O
6	O
month	O
survival	O
rate	O
in	O
patients	O
with	O
relapsed	O
or	O
progressive	O
AA	O
or	O
GBM	B-CANCER
.	O
	
Significantly	O
more	O
hematological	B-TOXI
toxicity	I-TOXI
was	O
seen	O
than	O
expected	O
from	O
cisplatin	B-DRUG
alone	O
.	O
	
Although	O
benefit	O
might	O
be	O
possible	O
in	O
a	O
more	O
platinum-sensitive	B-DRUG
tumor	O
type	O
","	O
further	O
clinical	O
trials	O
with	O
this	O
regimen	O
for	O
patients	O
with	O
glioblastoma	B-CANCER
multiforme	I-CANCER
or	O
anaplastic	B-CANCER
astrocytoma	I-CANCER
are	O
not	O
justified	O
.	O
	
Phase	O
I	O
study	O
of	O
a	O
3-drug	O
regimen	O
of	O
gemcitabine	B-DRUG
/	O
cisplatin	B-DRUG
/	O
pemetrexed	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
transitional	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
urothelium	I-CANCER
.	O
	
	
Gemcitabine	B-DRUG
(	O
G	O
)	O
plus	O
cisplatin	B-DRUG
(	O
C	O
)	O
is	O
standard	O
care	O
for	O
metastatic	B-CANCER
transitional	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
TCC	B-CANCER
)	O
of	O
the	O
urothelium	O
.	O
	
Pemetrexed	B-DRUG
(	O
P	O
)	O
","	O
alone	O
or	O
in	O
combination	O
with	O
G	O
","	O
is	O
active	O
in	O
metastatic	B-CANCER
TCC	I-CANCER
.	O
	
However	O
","	O
the	O
safety	O
and	O
efficacy	O
of	O
P	O
combined	O
with	O
GC	O
therapy	O
is	O
unknown	O
.	O
	
This	O
phase	O
I	O
trial	O
was	O
designed	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
GC	O
followed	O
by	O
P+G	O
in	O
patients	O
with	O
metastatic	B-CANCER
TCC	I-CANCER
.	O
	
Cohorts	O
of	O
3	O
to	O
6	O
patients	O
received	O
escalating	O
doses	O
28-day	O
cycles	O
(	O
maximum	O
6	O
cycles	O
)	O
:	O
G	O
"800-1,000"	O
mg	O
/	O
m2	O
on	O
days	O
1	O
and	O
15	O
;	O
P	O
400-500	O
mg	O
/	O
m2	O
on	O
day	O
15	O
;	O
and	O
C	O
50-70	O
mg	O
/	O
m2	O
on	O
day	O
1	O
All	O
patients	O
received	O
folic	B-DRUG
acid	I-DRUG
","	O
vitamin	B-DRUG
B12	I-DRUG
","	O
and	O
full	O
supportive	O
care	O
.	O
	
The	O
3+3	O
standard	O
phase	O
I	O
escalation	O
rule	O
was	O
used	O
to	O
determine	O
MTD	O
.	O
	
Fifteen	O
patients	O
registered	O
:	O
13	O
/	O
15	O
white	O
males	O
;	O
median	O
age	O
70	O
years	O
(	O
range	O
","	O
53-82	O
)	O
;	O
11	O
/	O
15	O
had	O
KPS	O
&	O
gt	O
;	O
or=90	O
.	O
	
At	O
dose	O
level	O
0	O
","	O
2	O
/	O
4	O
patients	O
experienced	O
unrelated	O
DLTs	O
","	O
and	O
1	O
patient	O
was	O
replaced	O
(	O
completed	O
&	O
lt	O
;	O
1	O
cycle	O
)	O
.	O
	
Dose	O
escalation	O
proceeded	O
to	O
dose	O
level	O
1	O
At	O
level	O
1	O
","	O
4	O
/	O
6	O
patients	O
experienced	O
DLTs	O
;	O
dosing	O
decreased	O
to	O
level	O
0	O
and	O
4	O
/	O
5	O
patients	O
experienced	O
DLTs	O
.	O
	
The	O
MTD	O
was	O
not	O
determined	O
.	O
	
The	O
2	O
patients	O
that	O
completed	O
6	O
cycles	O
both	O
had	O
partial	O
responses	O
.	O
	
Grades	O
3月4日	O
hematologic	B-TOXI
toxicities	I-TOXI
included	O
neutropenia	B-TOXI
(	O
60	O
%	O
)	O
","	O
leukopenia	B-TOXI
(	O
20	O
%	O
)	O
","	O
and	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
13	O
%	O
)	O
.	O
	
Adding	O
P	O
to	O
the	O
standard	O
GC	O
regimen	O
as	O
first-line	O
therapy	O
for	O
metastatic	B-CANCER
TCC	I-CANCER
produced	O
no	O
benefit	O
.	O
	
The	O
MTD	O
exceeded	O
therapeutic	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
doses	O
for	O
urothelial	B-CANCER
cancer	I-CANCER
and	O
thus	O
the	O
study	O
was	O
aborted	O
.	O
	
A	O
phase	O
II	O
study	O
to	O
determine	O
the	O
ability	O
of	O
gefitinib	B-DRUG
to	O
reverse	O
fluoropyrimidine	B-DRUG
resistance	O
in	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
the	O
INFORM	O
study	O
)	O
.	O
	
	
There	O
are	O
data	O
suggesting	O
that	O
inhibition	O
of	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
tyrosine	O
kinase	O
signalling	O
may	O
reverse	O
resistance	O
to	O
fluoropyrimidine	B-DRUG
treatment	O
.	O
	
To	O
investigate	O
this	O
further	O
","	O
the	O
INFORM	O
study	O
was	O
an	O
open-label	O
","	O
non-comparative	O
phase	O
II	O
study	O
of	O
gefitinib	B-DRUG
(	O
Iressa	O
","	O
ZD1839	O
;	O
AstraZeneca	O
","	O
Wilmington	O
","	O
DE	O
","	O
USA	O
)	O
250	O
mg	O
daily	O
in	O
combination	O
with	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
administered	O
as	O
an	O
intravenous	O
400	O
mg	O
m	O
(	O
-2	O
)	O
bolus	O
injection	O
followed	O
by	O
2800	O
mg	O
m	O
(	O
-2	O
)	O
infusion	O
over	O
46	O
h	O
and	O
folinic	B-DRUG
acid	I-DRUG
administered	O
as	O
a	O
350	O
mg	O
infusion	O
over	O
2	O
h	O
)	O
every	O
2	O
weeks	O
for	O
up	O
to	O
12	O
cycles	O
in	O
24	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
refractory	O
to	O
previous	O
fluoropyrimidine	B-DRUG
treatment	O
.	O
	
There	O
were	O
no	O
objective	O
responses	O
.	O
	
The	O
stable	O
disease	O
rate	O
was	O
37.5	O
%	O
(	O
95	O
%	O
CI	O
:	O
18.8	O
","	O
59.41	O
)	O
","	O
median	O
progression-free	O
survival	O
measured	O
116	O
days	O
and	O
overall	O
survival	O
was	O
226	O
days	O
.	O
	
Quality	O
of	O
life	O
was	O
unchanged	O
compared	O
to	O
baseline	O
values	O
","	O
and	O
the	O
commonest	O
toxicities	O
were	O
diarrhoea	B-TOXI
","	O
rash	B-TOXI
and	O
fatigue	B-TOXI
with	O
7	O
out	O
of	O
24	O
(	O
29	O
%	O
)	O
patients	O
having	O
a	O
grade	O
3	O
or	O
4	O
toxicity	O
.	O
	
Gefitinib	B-DRUG
does	O
not	O
sensitise	O
patients	O
with	O
fluoropyrimidine	B-DRUG
refractory	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
to	O
5-FU	B-DRUG
chemotherapy	O
.	O
	
Concomitant	O
administration	O
of	O
weekly	O
oxaliplatin	B-DRUG
","	O
fluorouracil	B-DRUG
continuous	O
infusion	O
","	O
and	O
radiotherapy	O
after	O
2	O
months	O
of	O
gemcitabine	B-DRUG
and	O
oxaliplatin	B-DRUG
induction	O
in	O
patients	O
with	O
locally	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
:	O
a	O
Groupe	O
Coordinateur	O
Multidisciplinaire	O
en	O
Oncologie	O
phase	O
II	O
study	O
.	O
	
	
According	O
to	O
previously	O
reported	O
Groupe	O
Coordinateur	O
Multidisciplinaire	O
en	O
Oncologie	O
(	O
GERCOR	O
)	O
studies	O
in	O
locally	O
advanced	B-DRUG
pancreatic	I-DRUG
cancer	I-DRUG
(	O
LAPC	B-CANCER
)	O
","	O
concomitant	O
chemoradiotherapy	O
(	O
CCRT	O
)	O
may	O
be	O
recommended	O
for	O
patients	O
who	O
do	O
not	O
experience	O
disease	O
progression	O
after	O
systemic	O
induction	O
chemotherapy	O
(	O
CT	O
)	O
.	O
	
To	O
further	O
improve	O
patient	O
outcome	O
with	O
classical	O
fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
#NAME?	O
CCRT	O
","	O
this	O
study	O
was	O
designed	O
to	O
prospectively	O
investigate	O
a	O
CCRT	O
with	O
FU	B-DRUG
infusion	O
and	O
weekly	O
oxaliplatin	B-DRUG
after	O
2	O
months	O
of	O
gemcitabine	B-DRUG
and	O
oxaliplatin	B-DRUG
(	O
GEMOX	B-DRUG
)	O
induction	O
chemotherapy	O
.	O
	
Nonpretreated	O
patients	O
with	O
LAPC	O
having	O
WHO	O
performance	O
status	O
(	O
PS	O
)	O
of	O
0	O
to	O
2	O
received	O
four	O
induction	O
cycles	O
of	O
GEMOX	B-DRUG
(	O
gemcitabine	B-DRUG
1	O
g	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
and	O
oxaliplatin	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
2	O
;	O
day	O
1	O
of	O
a	O
15-day	O
cycle	O
)	O
.	O
	
One	O
month	O
after	O
cycle	O
4	O
","	O
patients	O
who	O
did	O
not	O
experience	O
disease	O
progression	O
with	O
PS	O
0	O
to	O
2	O
received	O
45	O
Gy	O
over	O
5	O
weeks	O
=+	O
10	O
Gy	O
(	O
as	O
a	O
concomitant	O
boost	O
during	O
the	O
last	O
2	O
weeks	O
)	O
of	O
radiotherapy	O
(	O
RT	O
)	O
","	O
with	O
daily	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
FU	B-DRUG
as	O
a	O
continuous	O
infusion	O
and	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
oxaliplatin	B-DRUG
weekly	O
.	O
	
Of	O
59	O
patients	O
","	O
50	O
patients	O
(	O
84.7	O
%	O
)	O
received	O
CCRT	O
","	O
whereas	O
nine	O
patients	O
did	O
not	O
because	O
of	O
disease	O
progression	O
(	O
seven	O
patients	O
)	O
","	O
CT	O
toxicity	O
(	O
one	O
patient	O
)	O
","	O
or	O
personal	O
decision	O
(	O
one	O
patient	O
)	O
.	O
	
Forty-four	O
patients	O
(	O
74.5	O
%	O
)	O
completed	O
the	O
fully	O
planned	O
CCRT	O
.	O
	
Median	O
progression-free	O
survival	O
and	O
overall	O
survival	O
durations	O
were	O
7.6	O
and	O
12.2	O
months	O
","	O
respectively	O
","	O
for	O
the	O
whole	O
population	O
and	O
9.4	O
and	O
12.6	O
months	O
","	O
respectively	O
","	O
for	O
patients	O
who	O
completed	O
CCRT	O
.	O
	
CCRT	O
grade	O
3	O
to	O
4	O
toxicities	O
(	O
National	O
Cancer	O
Institute	O
Common	O
Toxicity	O
Criteria	O
)	O
were	O
neutropenia	B-TOXI
(	O
10.4	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
8.4	O
%	O
)	O
","	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
(	O
16.7	O
%	O
)	O
","	O
and	O
diarrhea	B-TOXI
(	O
12.5	O
%	O
)	O
.	O
	
Concomitant	O
administration	O
of	O
weekly	O
oxaliplatin	B-DRUG
","	O
continuous-infusion	O
FU	B-DRUG
","	O
and	O
RT	O
in	O
patients	O
with	O
LAPC	O
is	O
feasible	O
","	O
with	O
an	O
acceptable	O
acute	O
and	O
late	O
safety	O
profile	O
.	O
	
The	O
encouraging	O
results	O
observed	O
despite	O
a	O
nonoptimal	O
patient	O
selection	O
(	O
owing	O
to	O
the	O
short	O
induction	O
time	O
)	O
indicates	O
that	O
further	O
randomized	O
evaluation	O
to	O
better	O
define	O
the	O
specific	O
role	O
of	O
oxaliplatin	B-DRUG
in	O
CCRT	O
is	O
deserved	O
.	O
	
Dual	O
inhibition	O
of	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
with	O
cetuximab	B-DRUG
","	O
an	O
IgG1	O
monoclonal	O
antibody	O
","	O
and	O
gefitinib	B-DRUG
","	O
a	O
tyrosine	O
kinase	O
inhibitor	O
","	O
in	O
patients	O
with	O
refractory	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
:	O
a	O
phase	O
I	O
study	O
.	O
	
	
To	O
determine	O
the	O
optimal	O
doses	O
of	O
the	O
antiepidermal	O
growth	O
factor	O
receptor	O
(	O
anti-EGFR	O
)	O
monoclonal	O
antibody	O
cetuximab	B-DRUG
and	O
the	O
EGFR	O
tyrosine	O
kinase	O
inhibitor	O
gefitinib	B-DRUG
when	O
administered	O
as	O
a	O
combination	O
for	O
patients	O
with	O
advanced	O
/	O
metastatic	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
previously	O
treated	O
with	O
platinum-based	B-DRUG
chemotherapy	O
.	O
	
Patients	O
with	O
advanced	O
/	O
metastatic	B-CANCER
NSCLC	I-CANCER
treated	O
with	O
prior	O
platinum-based	B-DRUG
chemotherapy	O
received	O
escalating	O
doses	O
of	O
weekly	O
cetuximab	B-DRUG
(	O
100	O
","	O
200	O
","	O
and	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
IV	O
)	O
and	O
fixed	O
doses	O
of	O
gefitinib	B-DRUG
(	O
250	O
mg	O
/	O
d	O
","	O
PO	O
)	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
.	O
	
Available	O
tumor	O
samples	O
were	O
analyzed	O
for	O
EGFR	O
expression	O
","	O
EGFR	O
gene	O
copy	O
number	O
and	O
mutations	O
","	O
and	O
K-RAS	O
mutations	O
.	O
	
Thirteen	O
patients	O
were	O
enrolled	O
in	O
three	O
cohorts	O
.	O
	
Treatment	O
was	O
generally	O
well-tolerated	O
at	O
all	O
doses	O
.	O
	
One	O
grade	O
3	O
headache	B-TOXI
","	O
observed	O
on	O
the	O
first	O
treatment	O
cycle	O
was	O
initially	O
considered	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
;	O
this	O
event	O
was	O
eventually	O
determined	O
to	O
be	O
caused	O
by	O
a	O
brain	O
metastasis	O
","	O
not	O
toxicity	O
.	O
	
Three	O
cases	O
of	O
grade	O
3	O
/	O
4	O
hypomagnesemia	B-TOXI
and	O
1	O
case	O
of	O
grade	O
3	O
skin	B-TOXI
rash	I-TOXI
occurred	O
in	O
the	O
highest-dose	O
cohort	O
.	O
	
Grade	O
1	O
/	O
2	O
infusion	O
reactions	O
occurred	O
in	O
three	O
patients	O
without	O
requiring	O
treatment	O
discontinuation	O
.	O
	
Four	O
patients	O
(	O
31	O
%	O
)	O
achieved	O
stable	O
disease	O
","	O
no	O
responses	O
were	O
observed	O
.	O
	
None	O
of	O
the	O
patients	O
had	O
EGFR	O
mutations	O
or	O
gene	O
amplification	O
in	O
their	O
tumor	O
samples	O
.	O
	
Dual	O
EGFR	O
inhibition	O
with	O
cetuximab	B-DRUG
and	O
gefitinib	B-DRUG
is	O
feasible	O
;	O
the	O
combination	O
can	O
be	O
safely	O
administered	O
and	O
may	O
have	O
modest	O
activity	O
in	O
advanced	O
/	O
metastatic	B-CANCER
NSCLC	I-CANCER
.	O
	
Cetuximab	B-DRUG
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
IV	O
and	O
gefitinib	B-DRUG
250	O
mg	O
/	O
d	O
PO	O
is	O
the	O
recommended	O
phase	O
II	O
dose	O
","	O
although	O
the	O
potential	O
for	O
late-onset	O
hypomagnesemia	B-TOXI
warrants	O
close	O
monitoring	O
of	O
patients	O
receiving	O
this	O
combined	O
dosage	O
.	O
	
Safety	O
and	O
pharmacokinetics	O
of	O
dose-intensive	O
imatinib	B-DRUG
mesylate	I-DRUG
plus	O
temozolomide	B-DRUG
:	O
phase	O
1	O
trial	O
in	O
adults	O
with	O
malignant	B-CANCER
glioma	I-CANCER
.	O
	
	
We	O
determined	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
of	O
imatinib	B-DRUG
mesylate	I-DRUG
","	O
an	O
inhibitor	O
of	O
the	O
receptor	O
tyrosine	O
kinases	O
platelet-derived	O
growth	O
factor	O
receptor	O
(	O
PDGFR	O
)	O
","	O
the	O
proto-oncogene	O
product	O
c-kit	O
","	O
and	O
the	O
fusion	O
protein	O
Bcr-Abl	O
","	O
when	O
administered	O
for	O
8	O
days	O
in	O
combination	O
with	O
temozolomide	B-DRUG
(	O
TMZ	B-DRUG
)	O
to	O
malignant	B-CANCER
glioma	I-CANCER
(	O
MG	O
)	O
patients	O
.	O
	
MG	O
patients	O
who	O
had	O
not	O
failed	O
prior	O
TMZ	B-DRUG
were	O
eligible	O
to	O
receive	O
TMZ	B-DRUG
at	O
a	O
dose	O
of	O
150-200	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
day	O
on	O
days	O
4月8日	O
plus	O
imatinib	B-DRUG
mesylate	I-DRUG
administered	O
orally	O
on	O
days	O
1月8日	O
of	O
each	O
4-week	O
cycle	O
.	O
	
Patients	O
were	O
stratified	O
based	O
on	O
concurrent	O
administration	O
of	O
CYP3A4-inducing	O
antiepileptic	O
drugs	O
(	O
EIAEDs	O
)	O
.	O
	
The	O
imatinib	B-DRUG
dose	O
was	O
escalated	O
in	O
successive	O
cohorts	O
of	O
patients	O
independently	O
for	O
each	O
stratum	O
.	O
	
Imatinib	B-DRUG
","	O
at	O
doses	O
ranging	O
from	O
400	O
mg	O
to	O
"1,200"	O
mg	O
","	O
was	O
administered	O
with	O
TMZ	B-DRUG
to	O
65	O
patients	O
:	O
52	O
(	O
80	O
%	O
)	O
with	O
glioblastoma	B-CANCER
multiforme	I-CANCER
(	O
GBM	B-CANCER
)	O
and	O
13	O
(	O
20	O
%	O
)	O
with	O
grade	O
III	O
MG	O
.	O
	
At	O
enrollment	O
","	O
34	O
patients	O
(	O
52	O
%	O
)	O
had	O
stable	O
disease	O
","	O
and	O
33	O
(	O
48	O
%	O
)	O
had	O
progressive	O
disease	O
;	O
30	O
patients	O
(	O
46	O
%	O
)	O
were	O
on	O
EIAEDs	O
.	O
	
The	O
MTD	O
of	O
imatinib	B-DRUG
for	O
patients	O
concurrently	O
receiving	O
or	O
not	O
receiving	O
EIAEDs	O
was	O
"1,000"	O
mg	O
.	O
	
DLTs	O
were	O
hematologic	O
","	O
gastrointestinal	O
","	O
renal	O
","	O
and	O
hepatic	O
.	O
	
Pharmacokinetic	O
analyses	O
revealed	O
lowered	O
exposures	O
and	O
enhanced	O
clearance	O
among	O
patients	O
on	O
EIAEDs	O
.	O
	
Among	O
GBM	B-CANCER
patients	O
with	O
stable	O
disease	O
at	O
enrollment	O
(	O
n=28	O
)	O
","	O
the	O
median	O
progression-free	O
and	O
overall	O
survival	O
times	O
were	O
41.7	O
and	O
56.1	O
weeks	O
","	O
respectively	O
.	O
	
Imatinib	B-DRUG
doses	O
up	O
to	O
"1,000"	O
mg	O
/	O
day	O
for	O
8	O
consecutive	O
days	O
are	O
well	O
tolerated	O
when	O
combined	O
with	O
standard	O
TMZ	B-DRUG
dosing	O
for	O
MG	O
patients	O
.	O
	
A	O
subsequent	O
phase	O
2	O
study	O
is	O
required	O
to	O
further	O
evaluate	O
the	O
efficacy	O
of	O
this	O
regimen	O
for	O
this	O
patient	O
population	O
.	O
	
Phase-II	O
study	O
of	O
weekly	O
schedule	O
of	O
trastuzumab	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
and	O
carboplatin	B-DRUG
followed	O
by	O
a	O
week	O
off	O
every	O
28	O
days	O
for	O
HER2+	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
Addition	O
of	O
carboplatin	B-DRUG
(	O
C	O
)	O
to	O
trastuzumab	B-DRUG
(	O
T	O
)	O
and	O
paclitaxel	B-DRUG
(	O
P	O
)	O
improves	O
the	O
efficacy	O
in	O
HER2+	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
MBC	B-CANCER
)	O
.	O
	
The	O
aim	O
of	O
this	O
phase-II	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
this	O
combination	O
given	O
weekly	O
(	O
3x	O
)	O
followed	O
by	O
a	O
week	O
off	O
.	O
	
The	O
primary	O
endpoint	O
was	O
:	O
objective	O
response	O
rate	O
(	O
ORR	O
)	O
","	O
and	O
secondary	O
endpoints	O
were	O
:	O
time	O
to	O
progression	O
(	O
TTP	O
)	O
","	O
overall	O
survival	O
(	O
OS	O
)	O
","	O
and	O
toxicity	O
profile	O
.	O
	
HER2+	O
MBC	O
patients	O
were	O
included	O
in	O
the	O
study	O
.	O
	
Treatment	O
was	O
as	O
follows	O
:	O
T	O
(	O
loading	O
dose:4	O
mg	O
/	O
kg	O
per	O
week	O
and	O
2	O
mg	O
/	O
kg	O
per	O
day	O
thereafter	O
)	O
","	O
P	O
(	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
C	O
(	O
AUC	O
2	O
)	O
given	O
weekly	O
3x	O
","	O
followed	O
by	O
1	O
week	O
off	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
.	O
	
Forty-one	O
patients	O
(	O
pts	O
)	O
were	O
enrolled-median	O
age	O
:	O
54.5	O
years	O
(	O
range	O
29-75	O
)	O
;	O
87.8	O
%	O
PS	O
0	O
or	O
1	O
;	O
39	O
(	O
97.5	O
%	O
)	O
had	O
received	O
prior	O
adjuvant	O
or	O
neoadjuvant	O
treatment	O
;	O
11	O
(	O
27	O
%	O
)	O
had	O
received	O
one	O
prior	O
CT	O
line	O
for	O
metastatic	O
disease	O
;	O
disease	O
sites	O
:	O
liver	O
(	O
40	O
%	O
)	O
","	O
bone	O
(	O
32.5	O
%	O
)	O
","	O
lymph	O
nodes	O
(	O
32.5	O
%	O
)	O
and	O
lung	O
(	O
20	O
%	O
)	O
;	O
19	O
(	O
47.5	O
%	O
)	O
had	O
&	O
gt	O
;	O
or	O
2	O
lesions	O
and	O
97.5	O
%	O
had	O
measurable	O
disease	O
.	O
	
A	O
total	O
of	O
37	O
pts	O
were	O
evaluated	O
for	O
response	O
:	O
11	O
(	O
26.8	O
%	O
)	O
CR	O
;	O
12	O
(	O
29.3	O
%	O
)	O
PR	O
;	O
9	O
(	O
22	O
%	O
)	O
SD	O
;	O
5	O
(	O
12.2	O
%	O
)	O
PD	O
and	O
4	O
NE	O
","	O
resulting	O
in	O
an	O
ORR	O
of	O
56.1	O
%	O
(	O
95	O
%	O
CI	O
39.7-71.5	O
%	O
)	O
and	O
tumor	O
growth	O
control	O
rate	O
(	O
RR	O
=+	O
SD	O
)	O
of	O
78	O
%	O
(	O
95	O
%	O
CI	O
62.4-89.4	O
%	O
)	O
.	O
	
With	O
a	O
median	O
follow	O
up	O
of	O
39.4	O
months	O
","	O
26	O
(	O
70.3	O
%	O
)	O
patients	O
have	O
progressed	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
was	O
12.3	O
months	O
(	O
95	O
%	O
CI	O
8.2-15.5	O
)	O
.	O
	
At	O
the	O
time	O
of	O
this	O
report	O
","	O
ten	O
patients	O
have	O
died	B-TOXI
.	O
	
Forty	O
patients	O
received	O
202	O
cycles	O
(	O
median	O
five	O
cycles	O
)	O
.	O
	
Grades	O
3月4日	O
toxicities	O
/	O
pts	O
:	O
3	O
(	O
7.5	O
%	O
)	O
anemia	B-TOXI
","	O
2	O
(	O
5	O
%	O
)	O
leucopenia	B-TOXI
","	O
10	O
(	O
25	O
%	O
)	O
neutropenia	B-TOXI
","	O
1	O
(	O
2.5	O
%	O
)	O
febrile	B-TOXI
"neutropenia,1"	I-TOXI
(	O
2.5	O
%	O
)	O
thrombopenia	B-TOXI
","	O
2	O
(	O
5	O
%	O
)	O
asthenia	B-TOXI
","	O
2	O
(	O
5	O
%	O
)	O
diarrhea	B-TOXI
","	O
3	O
(	O
7.5	O
%	O
)	O
nausea	B-TOXI
","	O
2	O
(	O
5	O
%	O
)	O
vomiting	B-TOXI
","	O
and	O
3	O
(	O
7.5	O
%	O
)	O
mucositis	B-TOXI
.	O
	
The	O
schedule	O
showed	O
an	O
interesting	O
activity	O
","	O
taking	O
into	O
account	O
that	O
27	O
%	O
of	O
patients	O
had	O
received	O
previous	O
treatment	O
for	O
MBC	O
.	O
	
One	O
week	O
of	O
rest	O
may	O
benefit	O
not	O
only	O
the	O
patient	O
but	O
may	O
also	O
improve	O
tolerability	O
and	O
efficacy	O
of	O
the	O
combination	O
.	O
	
Phase	O
III	O
trial	O
comparing	O
carboplatin	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
and	O
bexarotene	B-DRUG
with	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
chemotherapy-naive	O
patients	O
with	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
SPIRIT	O
II	O
.	O
	
	
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
addition	O
of	O
the	O
synthetic	O
rexinoid	B-DRUG
bexarotene	I-DRUG
(	O
Targretin	O
;	O
Eisai	O
Inc	O
","	O
Woodcliff	O
Lake	O
","	O
NJ	O
)	O
to	O
standard	O
first-line	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
therapy	O
provides	O
additional	O
survival	O
benefit	O
in	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Patients	O
with	O
stage	O
IIIB	O
disease	O
with	O
pleural	B-TOXI
effusion	I-TOXI
","	O
or	O
stage	O
IV	O
NSCLC	B-CANCER
and	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
0	O
to	O
1	O
","	O
were	O
randomly	O
assigned	O
to	O
bexarotene	B-DRUG
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d	O
combined	O
with	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
","	O
or	O
assigned	O
to	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
alone	O
.	O
	
Bexarotene	B-DRUG
patients	O
also	O
received	O
lipid-lowering	O
agents	O
on	O
or	O
before	O
day	O
1	O
The	O
primary	O
efficacy	O
end	O
point	O
was	O
overall	O
survival	O
;	O
secondary	O
efficacy	O
and	O
supportive	O
analyses	O
were	O
also	O
conducted	O
.	O
	
A	O
total	O
of	O
612	O
patients	O
(	O
306	O
per	O
arm	O
)	O
were	O
enrolled	O
onto	O
the	O
study	O
.	O
	
In	O
the	O
intent-to-treat	O
population	O
","	O
no	O
significant	O
difference	O
in	O
survival	O
occurred	O
between	O
the	O
two	O
arms	O
.	O
	
However	O
","	O
a	O
subpopulation	O
(	O
approximately	O
40	O
%	O
)	O
of	O
bexarotene-treated	B-DRUG
patients	O
who	O
experienced	O
National	O
Cancer	O
Institute	O
grade	O
3	O
/	O
4	O
hypertriglyceridemia	B-TOXI
had	O
significantly	O
longer	O
median	O
survival	O
than	O
control	O
patients	O
(	O
12.4	O
v	O
9.2	O
months	O
;	O
log-rank	O
","	O
P	O
=	O
0.014	O
)	O
.	O
	
Bexarotene-treated	B-DRUG
patients	O
with	O
grade	O
3	O
/	O
4	O
hypertriglyceridemia	B-TOXI
who	O
received	O
the	O
most	O
benefit	O
included	O
those	O
who	O
were	O
male	O
","	O
were	O
smokers	O
","	O
experienced	O
6-month	O
prior	O
weight	B-TOXI
loss	I-TOXI
&	O
gt	O
;	O
or=	O
5	O
%	O
","	O
and	O
had	O
stage	O
IV	O
disease	O
.	O
	
The	O
incidence	O
and	O
severity	O
of	O
most	O
adverse	O
events	O
were	O
similar	O
between	O
arms	O
","	O
although	O
hyperlipidemia	B-TOXI
","	O
neutropenia	B-TOXI
","	O
fatigue	B-TOXI
","	O
leukopenia	B-TOXI
","	O
arthralgia	B-TOXI
","	O
and	O
diarrhea	B-TOXI
were	O
more	O
frequent	O
in	O
the	O
bexarotene	B-DRUG
arm	O
.	O
	
Although	O
the	O
addition	O
of	O
bexarotene	B-DRUG
to	O
chemotherapy	O
did	O
not	O
improve	O
survival	O
in	O
the	O
overall	O
study	O
population	O
","	O
occurrence	O
of	O
high-grade	O
hypertriglyceridemia	B-TOXI
in	O
bexarotene-treated	B-DRUG
patients	O
strongly	O
correlated	O
with	O
increased	O
survival	O
","	O
suggesting	O
that	O
bexarotene	B-DRUG
may	O
benefit	O
a	O
segment	O
of	O
first-line	O
NSCLC	B-CANCER
patients	O
.	O
	
Phase	O
I	O
trial	O
of	O
pemetrexed	B-DRUG
plus	O
oxaliplatin	B-DRUG
administered	O
every	O
other	O
week	O
in	O
patients	O
with	O
metastatic	B-CANCER
cancer	I-CANCER
.	O
	
	
To	O
identify	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
describe	O
dose-limiting	O
toxicities	O
(	O
DLT	O
)	O
of	O
pemetrexed	B-DRUG
and	O
oxaliplatin	B-DRUG
given	O
on	O
a	O
once-every-2-week	O
schedule	O
in	O
patients	O
with	O
metastatic	B-CANCER
cancer	I-CANCER
.	O
	
Twenty-five	O
patients	O
were	O
enrolled	O
.	O
	
Due	O
to	O
toxicities	O
observed	O
at	O
the	O
first	O
dose	O
level	O
in	O
unselected	O
patients	O
","	O
a	O
second	O
MTD	O
was	O
determined	O
in	O
patients	O
who	O
had	O
received	O
zero	O
to	O
two	O
prior	O
chemotherapy	O
regimens	O
.	O
	
DLT	O
was	O
observed	O
at	O
dose	O
level	O
1-pemetrexed	B-DRUG
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
oxaliplatin	B-DRUG
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
#NAME?	O
the	O
form	O
of	O
grade	O
3	O
fatigue	B-TOXI
in	O
two	O
of	O
six	O
patients	O
.	O
	
Enrollment	O
was	O
then	O
limited	O
to	O
lightly	O
pretreated	O
patients	O
and	O
DLT	O
was	O
observed	O
at	O
dose	O
level	O
2-pemetrexed	B-DRUG
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
oxaliplatin	B-DRUG
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
#NAME?	O
the	O
form	O
of	O
neutropenic	B-TOXI
fever	I-TOXI
in	O
one	O
of	O
five	O
patients	O
.	O
	
Complete	O
response	O
was	O
confirmed	O
in	O
one	O
patient	O
(	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
)	O
and	O
partial	O
response	O
was	O
confirmed	O
in	O
three	O
patients	O
.	O
	
The	O
combination	O
of	O
pemetrexed	B-DRUG
and	O
oxaliplatin	B-DRUG
can	O
be	O
safely	O
administered	O
at	O
doses	O
of	O
400	O
to	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
pemetrexed	B-DRUG
and	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
patients	O
without	O
extensive	O
prior	O
therapy	O
and	O
300	O
and	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
respectively	O
","	O
every	O
2	O
weeks	O
in	O
patients	O
with	O
more	O
extensive	O
prior	O
therapy	O
.	O
	
Based	O
on	O
promising	O
results	O
observed	O
in	O
this	O
study	O
","	O
a	O
phase	O
II	O
trial	O
in	O
patients	O
with	O
recurrent	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
has	O
been	O
initiated	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
high-dose	O
ifosfamide	B-DRUG
and	O
escalating	O
doses	O
of	O
carboplatin	B-DRUG
with	O
autologous	O
bone	O
marrow	O
support	O
.	O
	
	
The	O
dose-limiting	O
toxicity	O
in	O
two	O
separate	O
phase	O
I	O
trials	O
of	O
the	O
high-dose	O
single	O
agents	O
ifosfamide	B-DRUG
and	O
carboplatin	B-DRUG
was	O
renal	B-TOXI
insufficiency	I-TOXI
at	O
18	O
g	O
/	O
m2	O
and	O
hepatic	O
and	O
ototoxicity	B-TOXI
at	O
"2,400"	O
mg	O
/	O
m2	O
","	O
respectively	O
.	O
	
In	O
this	O
phase	O
I	O
study	O
","	O
16	O
adults	O
were	O
treated	O
with	O
ifosfamide	B-DRUG
at	O
75	O
%	O
of	O
the	O
single-agent	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
(	O
12	O
g	O
/	O
m2	O
)	O
and	O
escalating	O
doses	O
of	O
carboplatin	B-DRUG
(	O
400	O
to	O
"1,600"	O
mg	O
/	O
m2	O
)	O
to	O
determine	O
the	O
nonhematologic	O
dose-limiting	O
toxicity	O
and	O
the	O
maximum-tolerated	O
dose	O
of	O
the	O
combination	O
.	O
	
Both	O
drugs	O
as	O
well	O
as	O
mesna	B-DRUG
for	O
uroprotection	O
were	O
given	O
by	O
continuous	O
infusion	O
over	O
4	O
days	O
with	O
an	O
additional	O
day	O
of	O
mesna	B-DRUG
(	O
total	O
dose	O
per	O
course	O
","	O
15	O
g	O
/	O
m2	O
)	O
.	O
	
Autologous	O
bone	O
marrow	O
support	O
was	O
stipulated	O
for	O
subsequent	O
dose	O
levels	O
once	O
granulocytes	O
remained	O
less	O
than	O
500	O
/	O
microL	O
for	O
more	O
than	O
14	O
days	O
in	O
two	O
of	O
three	O
to	O
five	O
patients	O
entered	O
at	O
a	O
given	O
dose	O
level	O
.	O
	
Autologous	O
bone	O
marrow	O
support	O
was	O
used	O
at	O
doses	O
above	O
the	O
400	O
mg	O
/	O
m2	O
carboplatin	B-DRUG
dose	O
level	O
.	O
	
At	O
the	O
maximum-tolerated	O
dose	O
level	O
of	O
"1,600"	O
mg	O
/	O
m2	O
of	O
carboplatin	B-DRUG
","	O
renal	B-TOXI
toxicity	I-TOXI
precluded	O
further	O
dose	O
escalation	O
.	O
	
Of	O
the	O
five	O
patients	O
entered	O
at	O
this	O
dose	O
level	O
","	O
reversible	O
creatinine	O
elevation	O
greater	O
than	O
2	O
mg	O
/	O
dL	O
(	O
median	O
peak	O
","	O
2.6	O
mg	O
/	O
dL	O
)	O
was	O
observed	O
in	O
three	O
patients	O
","	O
and	O
irreversible	O
renal	B-TOXI
failure	I-TOXI
occurred	O
in	O
an	O
additional	O
patient	O
(	O
peak	O
creatinine	O
","	O
6.9	O
mg	O
/	O
dL	O
.	O
	
Transient	O
gross	B-TOXI
hematuria	I-TOXI
appeared	O
more	O
common	O
with	O
the	O
combination	O
than	O
with	O
ifosfamide	B-DRUG
alone	O
.	O
	
Two	O
patients	O
developed	O
severe	O
somnolence	B-TOXI
and	O
confusion	B-TOXI
associated	O
with	O
a	O
rising	O
creatinine	O
.	O
	
There	O
were	O
two	O
complete	O
(	O
CRs	O
)	O
and	O
four	O
partial	O
responses	O
(	O
PRs	O
)	O
in	O
14	O
heavily	O
pretreated	O
assessable	O
patients	O
(	O
including	O
four	O
partial	O
or	O
complete	O
responses	O
in	O
eight	O
assessable	O
patients	O
with	O
advanced	O
refractory	O
sarcoma	B-CANCER
","	O
and	O
one	O
CR	O
in	O
two	O
patients	O
with	O
germ	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
)	O
.	O
	
Carboplatin	B-DRUG
and	O
ifosfamide	B-DRUG
appear	O
to	O
have	O
overlapping	O
renal	B-TOXI
toxicity	I-TOXI
.	O
	
Nevertheless	O
","	O
carboplatin	B-DRUG
and	O
ifosfamide	B-DRUG
can	O
be	O
combined	O
at	O
80	O
%	O
and	O
75	O
%	O
of	O
the	O
single-agent	O
maximum-tolerated	O
doses	O
","	O
respectively	O
","	O
with	O
acceptable	O
nonhematologic	B-TOXI
toxicity	I-TOXI
.	O
	
Ifosfamide	B-DRUG
and	O
carboplatin	B-DRUG
are	O
an	O
attractive	O
core	O
combination	O
for	O
further	O
studies	O
in	O
the	O
treatment	O
of	O
sarcoma	B-CANCER
","	O
germ	O
cell	O
","	O
ovarian	O
","	O
and	O
lung	B-CANCER
carcinomas	I-CANCER
.	O
	
Phase	O
I	O
dose	O
escalation	O
and	O
pharmacokinetic	O
study	O
of	O
lapatinib	B-DRUG
in	O
combination	O
with	O
trastuzumab	B-DRUG
in	O
patients	O
with	O
advanced	O
ErbB2-positive	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
	
The	O
combination	O
of	O
lapatinib	B-DRUG
and	O
trastuzumab	B-DRUG
has	O
been	O
observed	O
to	O
have	O
a	O
synergistic	O
","	O
antiproliferative	O
effect	O
against	O
ErbB2-positive	O
breast	B-CANCER
cancer	I-CANCER
cells	O
in	O
vitro	O
.	O
	
This	O
phase	O
I	O
study	O
assessed	O
the	O
safety	O
","	O
clinical	O
feasibility	O
","	O
optimally	O
tolerated	O
regimen	O
(	O
OTR	O
)	O
","	O
pharmacokinetics	O
(	O
PK	O
)	O
","	O
and	O
preliminary	O
clinical	O
activity	O
of	O
this	O
combination	O
in	O
patients	O
with	O
ErbB2-positive	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Cohorts	O
of	O
three	O
patients	O
with	O
ErbB2-positive	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
were	O
treated	O
with	O
escalating	O
doses	O
of	O
lapatinib	B-DRUG
(	O
750	O
to	O
"1,500"	O
mg	O
)	O
administered	O
once	O
daily	O
(	O
continuous	O
)	O
in	O
combination	O
with	O
trastuzumab	B-DRUG
(	O
4	O
mg	O
/	O
kg	O
loading	O
dose	O
then	O
2	O
mg	O
/	O
kg	O
weekly	O
)	O
to	O
determine	O
the	O
OTR	O
.	O
	
Once	O
the	O
OTR	O
was	O
determined	O
","	O
additional	O
patients	O
were	O
enrolled	O
to	O
provide	O
the	O
PK	O
profile	O
of	O
both	O
agents	O
alone	O
and	O
in	O
combination	O
.	O
	
A	O
total	O
of	O
54	O
patients	O
were	O
treated	O
:	O
27	O
in	O
the	O
dose-escalation	O
group	O
and	O
27	O
in	O
the	O
PK	O
group	O
.	O
	
Overall	O
","	O
adverse	O
events	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
","	O
with	O
no	O
drug-related	O
grade	O
4	O
events	O
.	O
	
The	O
most	O
frequent	O
drug-related	O
grade	O
3	O
events	O
included	O
diarrhea	B-TOXI
(	O
17	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
11	O
%	O
)	O
","	O
and	O
rash	B-TOXI
(	O
6	O
%	O
)	O
.	O
	
The	O
OTR	O
was	O
"1,000"	O
mg	O
lapatinib	B-DRUG
with	O
standard	O
weekly	O
trastuzumab	B-DRUG
.	O
	
One	O
patient	O
had	O
a	O
complete	O
response	O
and	O
seven	O
patients	O
had	O
partial	O
responses	O
.	O
	
The	O
PK	O
parameters	O
(	O
maximum	O
concentration	O
in	O
plasma	O
and	O
area	O
under	O
the	O
curve	O
)	O
of	O
lapatinib	B-DRUG
and	O
trastuzumab	B-DRUG
in	O
combination	O
were	O
not	O
significantly	O
different	O
than	O
when	O
either	O
was	O
administered	O
alone	O
.	O
	
The	O
OTR	O
of	O
the	O
lapatinib	B-DRUG
/	O
trastuzumab	B-DRUG
combination	O
was	O
lapatinib	B-DRUG
"1,000"	O
mg	O
per	O
day	O
with	O
standard	O
weekly	O
trastuzumab	B-DRUG
.	O
	
At	O
these	O
doses	O
","	O
the	O
regimen	O
was	O
well	O
tolerated	O
and	O
clinically	O
active	O
in	O
this	O
heavily	O
pretreated	O
ErbB2-positive	O
breast	B-CANCER
cancer	I-CANCER
population	O
.	O
	
Phase	O
III	O
study	O
comparing	O
cisplatin	B-DRUG
plus	O
gemcitabine	B-DRUG
with	O
cisplatin	B-DRUG
plus	O
pemetrexed	B-DRUG
in	O
chemotherapy-naive	O
patients	O
with	O
advanced-stage	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
Cisplatin	B-DRUG
plus	O
gemcitabine	B-DRUG
is	O
a	O
standard	O
regimen	O
for	O
first-line	O
treatment	O
of	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Phase	O
II	O
studies	O
of	O
pemetrexed	B-DRUG
plus	O
platinum	B-DRUG
compounds	O
have	O
also	O
shown	O
activity	O
in	O
this	O
setting	O
.	O
	
This	O
noninferiority	O
","	O
phase	O
III	O
","	O
randomized	O
study	O
compared	O
the	O
overall	O
survival	O
between	O
treatment	O
arms	O
using	O
a	O
fixed	O
margin	O
method	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
&	O
lt	O
;	O
1.176	O
)	O
in	O
"1,725"	O
chemotherapy-naive	O
patients	O
with	O
stage	O
IIIB	O
or	O
IV	O
NSCLC	B-CANCER
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
to	O
1	O
Patients	O
received	O
cisplatin	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
and	O
gemcitabine	B-DRUG
"1,250"	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
and	O
8	O
(	O
n	O
=	O
863	O
)	O
or	O
cisplatin	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
pemetrexed	B-DRUG
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
(	O
n	O
=	O
862	O
)	O
every	O
3	O
weeks	O
for	O
up	O
to	O
six	O
cycles	O
.	O
	
Overall	O
survival	O
for	O
cisplatin	B-DRUG
/	O
pemetrexed	B-DRUG
was	O
noninferior	O
to	O
cisplatin	B-DRUG
/	O
gemcitabine	B-DRUG
(	O
median	O
survival	O
","	O
10.3	O
v	O
10.3	O
months	O
","	O
respectively	O
;	O
HR	O
=	O
0.94	O
;	O
95	O
%	O
CI	O
","	O
0.84	O
to	O
1.05	O
)	O
.	O
	
Overall	O
survival	O
was	O
statistically	O
superior	O
for	O
cisplatin	B-DRUG
/	O
pemetrexed	B-DRUG
versus	O
cisplatin	B-DRUG
/	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
adenocarcinoma	B-CANCER
(	O
n	O
=	O
847	O
;	O
12.6	O
v	O
10.9	O
months	O
","	O
respectively	O
)	O
and	O
large-cell	B-CANCER
carcinoma	I-CANCER
histology	O
(	O
n	O
=	O
153	O
;	O
10.4	O
v	O
6.7	O
months	O
","	O
respectively	O
)	O
.	O
	
In	O
contrast	O
","	O
in	O
patients	O
with	O
squamous	O
cell	O
histology	O
","	O
there	O
was	O
a	O
significant	O
improvement	O
in	O
survival	O
with	O
cisplatin	B-DRUG
/	O
gemcitabine	B-DRUG
versus	O
cisplatin	B-DRUG
/	O
pemetrexed	B-DRUG
(	O
n	O
=	O
473	O
;	O
10.8	O
v	O
9.4	O
months	O
","	O
respectively	O
)	O
.	O
	
For	O
cisplatin	B-DRUG
/	O
pemetrexed	B-DRUG
","	O
rates	O
of	O
grade	O
3	O
or	O
4	O
neutropenia	B-TOXI
","	O
anemia	B-TOXI
","	O
and	O
thrombocytopenia	B-TOXI
(	O
P	O
&	O
lt	O
;	O
or=	O
0.001	O
)	O
;	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
P	O
=	O
0.002	O
)	O
;	O
and	O
alopecia	B-TOXI
(	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
were	O
significantly	O
lower	O
","	O
whereas	O
grade	O
3	O
or	O
4	O
nausea	B-TOXI
(	O
P	O
=	O
0.004	O
)	O
was	O
more	O
common	O
.	O
	
In	O
advanced	B-CANCER
NSCLC	I-CANCER
","	O
cisplatin	B-DRUG
/	O
pemetrexed	B-DRUG
provides	O
similar	O
efficacy	O
with	O
better	O
tolerability	O
and	O
more	O
convenient	O
administration	O
than	O
cisplatin	B-DRUG
/	O
gemcitabine	B-DRUG
.	O
	
This	O
is	O
the	O
first	O
prospective	O
phase	O
III	O
study	O
in	O
NSCLC	B-CANCER
to	O
show	O
survival	O
differences	O
based	O
on	O
histologic	O
type	O
.	O
	
Sequential	O
induction	O
chemotherapy	O
followed	O
by	O
radical	O
chemo-radiation	O
in	O
the	O
treatment	O
of	O
locoregionally	O
advanced	B-CANCER
head-and-neck	I-CANCER
cancer	I-CANCER
.	O
	
	
We	O
describe	O
a	O
retrospective	O
series	O
of	O
patients	O
with	O
advanced	B-CANCER
head-and-neck	I-CANCER
cancer	I-CANCER
who	O
were	O
treated	O
with	O
induction	O
chemotherapy	O
followed	O
by	O
radical	O
chemo-radiation	O
.	O
	
Patients	O
treated	O
with	O
two	O
cycles	O
of	O
induction	O
chemotherapy	O
followed	O
by	O
definitive	O
chemo-radiation	O
for	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head-and-neck	I-CANCER
region	O
","	O
from	O
2001	O
=-	O
2006	O
at	O
the	O
Royal	O
Marsden	O
Hospital	O
","	O
formed	O
the	O
basis	O
of	O
this	O
study	O
.	O
	
Cisplatin	B-DRUG
(	O
75	O
mg	O
m	O
(	O
-2	O
)	O
)	O
on	O
day	O
1	O
and	O
5-FU	B-DRUG
(	O
1000	O
mg	O
m	O
(	O
-2	O
)	O
)	O
day	O
1	O
=-	O
4	O
was	O
the	O
standard	O
regimen	O
used	O
for	O
induction	O
treatment	O
.	O
	
Cisplatin	B-DRUG
(	O
100	O
mg	O
m	O
(	O
-2	O
)	O
)	O
on	O
day	O
1	O
and	O
day	O
29	O
was	O
used	O
for	O
concomitant	O
treatment	O
.	O
	
The	O
radiation	O
was	O
delivered	O
using	O
conformal	O
technique	O
.	O
	
Tissues	O
containing	O
macroscopic	O
and	O
microscopic	O
disease	O
were	O
treated	O
to	O
doses	O
of	O
65	O
Gray	O
(	O
Gy	O
)	O
in	O
30	O
fractions	O
and	O
50	O
Gy	O
in	O
25	O
fractions	O
","	O
respectively	O
.	O
	
Data	O
on	O
patterns	O
of	O
relapse	O
and	O
acute	B-TOXI
toxicity	I-TOXI
(	O
NCICTCv.3.0	O
)	O
were	O
collected	O
.	O
	
A	O
total	O
of	O
129	O
patients	O
were	O
included	O
","	O
median	O
age	O
was	O
58	O
(	O
range	O
:	O
27	O
=-	O
78	O
)	O
.	O
	
The	O
site	O
of	O
tumour	O
was	O
:	O
oropharynx	O
70	O
(	O
54	O
%	O
)	O
","	O
larynx	O
30	O
(	O
23	O
%	O
)	O
","	O
hypopharynx	O
24	O
(	O
19	O
%	O
)	O
and	O
other	O
5	O
(	O
4	O
%	O
)	O
.	O
	
The	O
median	O
follow-up	O
was	O
19	O
months	O
(	O
range	O
:	O
4	O
=-	O
58	O
)	O
.	O
	
Local	O
control	O
","	O
disease-specific	O
survival	O
and	O
overall	O
survival	O
at	O
2	O
years	O
were	O
71	O
%	O
","	O
68	O
%	O
and	O
63	O
%	O
","	O
respectively	O
.	O
	
The	O
distant	O
recurrence	O
rate	O
at	O
2	O
years	O
was	O
9	O
%	O
.	O
	
Ten	O
patients	O
required	O
dose	O
reduction	O
during	O
induction	O
chemotherapy	O
due	O
to	O
toxicity	O
.	O
	
The	O
dose	O
of	O
5-FU	B-DRUG
was	O
reduced	O
in	O
six	O
patients	O
and	O
that	O
of	O
cisplatin	B-DRUG
in	O
four	O
patients	O
.	O
	
The	O
incidence	O
of	O
grade	O
3	O
/	O
4	O
toxicity	O
was	O
:	O
neutropenia	B-TOXI
5	O
%	O
","	O
thrombocytopenia	B-TOXI
1	O
%	O
","	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
3	O
%	O
.	O
	
One	O
cycle	O
of	O
concurrent	O
cisplatin	B-DRUG
was	O
omitted	O
in	O
23	O
patients	O
due	O
to	O
toxicity	O
.	O
	
Full-dose	O
radiotherapy	O
was	O
administered	O
to	O
98	O
%	O
of	O
patients	O
.	O
	
The	O
incidence	O
of	O
grade	O
3	O
/	O
4	O
toxicity	O
was	O
:	O
skin	O
20	O
%	O
","	O
dysphagia	B-TOXI
65	O
%	O
","	O
mucositis	B-TOXI
60	O
%	O
","	O
neutropenia	B-TOXI
3	O
%	O
","	O
anaemia	B-TOXI
1	O
%	O
","	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
4	O
%	O
","	O
nephrotoxicity	B-TOXI
1	O
%	O
.	O
	
Induction	O
chemotherapy	O
followed	O
by	O
radical	O
chemo-radiation	O
is	O
a	O
safe	O
and	O
tolerable	O
regimen	O
in	O
the	O
treatment	O
of	O
advanced	B-CANCER
head-and-neck	I-CANCER
cancer	I-CANCER
.	O
	
Distant	O
recurrence	O
rates	O
are	O
lower	O
with	O
equivalent	O
local	O
control	O
and	O
survival	O
compared	O
to	O
chemo-radiation	O
alone	O
(	O
historical	O
controls	O
)	O
.	O
	
Salvage	O
chemotherapy	O
with	O
rituximab	B-DRUG
DHAP	O
for	O
relapsed	O
non-Hodgkin	B-CANCER
lymphoma	I-CANCER
:	O
a	O
phase	O
II	O
trial	O
in	O
the	O
North	O
Central	O
Cancer	O
Treatment	O
Group	O
.	O
	
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
learn	O
the	O
toxicity	O
and	O
efficacy	O
of	O
adding	O
4	O
doses	O
of	O
rituximab	B-DRUG
to	O
a	O
standard	O
platinum-based	B-DRUG
salvage	O
regimen	O
for	O
relapsed	O
CD20+	O
B-cell	O
non-Hodgkin	B-CANCER
lymphoma	I-CANCER
.	O
	
Patients	O
were	O
treated	O
with	O
rituximab	B-DRUG
375	O
mg	O
/	O
m	O
(	O
2	O
)	O
days	O
"1,8,15"	O
","	O
22	O
(	O
cycle	O
1	O
only	O
)	O
;	O
cisplatin	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
over	O
24	O
h	O
on	O
day	O
3	O
","	O
cytosine	B-DRUG
arabinoside	I-DRUG
2	O
g	O
/	O
m	O
(	O
2	O
)	O
IV	O
every	O
12	O
h	O
x	O
two	O
doses	O
on	O
day	O
4	O
","	O
dexamethasone	B-DRUG
40	O
mg	O
PO	O
/	O
IV	O
days	O
3月6日	O
","	O
and	O
G-CSF	B-DRUG
days	O
5月14日	O
.	O
	
The	O
ORR	O
was	O
82	O
%	O
(	O
47	O
/	O
57	O
)	O
with	O
33	O
%	O
(	O
19	O
/	O
57	O
)	O
complete	O
remissions	O
and	O
49	O
%	O
(	O
28	O
/	O
57	O
)	O
partial	O
remissions	O
.	O
	
The	O
duration	O
of	O
response	O
(	O
DR	O
)	O
for	O
the	O
47	O
responders	O
was	O
10.5	O
months	O
(	O
95	O
%	O
CI	O
:	O
5.3-16.8	O
)	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
(	O
TTP	O
)	O
was	O
10.3	O
months	O
(	O
95	O
%	O
CI	O
:	O
5.3-14.0	O
)	O
","	O
the	O
median	O
event-free	O
survival	O
(	O
EFS	O
)	O
was	O
5.3	O
months	O
(	O
95	O
%	O
CI	O
:	O
3.9-11.0	O
)	O
","	O
and	O
the	O
median	O
overall	O
survival	O
was	O
30.5	O
months	O
(	O
95	O
%	O
CI	O
:	O
17.8-60.6	O
)	O
.	O
	
We	O
conclude	O
that	O
rituximab	B-DRUG
can	O
be	O
safely	O
added	O
to	O
standard	O
DHAP	O
.	O
	
Phase	O
I	O
study	O
of	O
cladribine	B-DRUG
","	O
cytarabine	B-DRUG
(	O
Ara-C	B-DRUG
)	O
","	O
granulocyte	B-DRUG
colony	I-DRUG
stimulating	I-DRUG
factor	I-DRUG
(	O
G-CSF	B-DRUG
)	O
(	O
CLAG	O
Regimen	O
)	O
and	O
simultaneous	O
escalating	O
doses	O
of	O
imatinib	B-DRUG
mesylate	I-DRUG
(	O
Gleevec	B-DRUG
)	O
in	O
relapsed	O
/	O
refractory	O
AML	O
.	O
	
	
Receptor	O
activated	O
tyrosine	O
kinases	O
such	O
as	O
c-kit	O
","	O
c-fms	O
and	O
PDGFR	O
are	O
known	O
targets	O
of	O
inhibition	O
by	O
imatinib	B-DRUG
mesylate	I-DRUG
(	O
Gleevec	B-DRUG
)	O
and	O
are	O
expressed	O
on	O
AML	O
blasts	O
.	O
	
Marrow	O
stromal	O
cells	O
and	O
monocytes	O
express	O
KIT	O
ligand	O
","	O
M-CSF	O
and	O
PDGF	O
and	O
are	O
therefore	O
capable	O
of	O
activating	O
survival	O
pathways	O
in	O
these	O
leukemic	O
cells	O
.	O
	
Given	O
the	O
synergy	O
in	O
vitro	O
between	O
Ara-C	B-DRUG
and	O
imatinib	B-DRUG
mesylate	I-DRUG
on	O
AML	O
cell	O
growth	O
inhibition	O
","	O
we	O
initiated	O
a	O
Phase	O
I	O
study	O
combining	O
CLAG+imatinib	B-DRUG
mesylate	I-DRUG
in	O
AML	O
patients	O
.	O
	
Patients	O
with	O
relapsed	O
","	O
refractory	O
AML	O
or	O
CML	O
myeloid	O
blast	O
crisis	O
were	O
eligible	O
to	O
receive	O
Cladribine	B-DRUG
5mg	O
/	O
m	O
(	O
2	O
)	O
days	O
3月7日	O
","	O
Cytarabine	B-DRUG
2gm	O
/	O
m	O
(	O
2	O
)	O
days	O
3月7日	O
","	O
G-CSF	B-DRUG
300mcg	O
days	O
2月7日	O
","	O
and	O
escalating	O
doses	O
of	O
imatinib	B-DRUG
mesylate	I-DRUG
given	O
on	O
days	O
1月15日	O
.	O
	
The	O
level	O
1	O
Gleevec	B-DRUG
dose	O
was	O
400mg	O
","	O
while	O
level	O
2	O
was	O
600mg	O
and	O
the	O
level	O
3	O
dose	O
800mg	O
.	O
	
A	O
total	O
of	O
16	O
patients	O
were	O
enrolled	O
","	O
15	O
AML	O
and	O
1	O
CML	O
myeloid	O
blast	O
crisis	O
.	O
	
The	O
dose	O
escalation	O
occurred	O
as	O
planned	O
and	O
there	O
was	O
no	O
clear	O
evidence	O
of	O
added	O
toxicity	O
due	O
to	O
imatinib	B-DRUG
mesylate	I-DRUG
.	O
	
One	O
patient	O
with	O
an	O
extensive	O
cardiac	O
history	O
died	B-TOXI
of	O
cardiac	B-TOXI
causes	I-TOXI
on	O
day	O
1	O
of	O
therapy	O
however	O
no	O
other	O
deaths	B-TOXI
occurred	O
within	O
30	O
days	O
of	O
starting	O
therapy	O
.	O
	
One	O
patient	O
had	O
a	O
Grade	O
3	O
skin	B-TOXI
rash	I-TOXI
at	O
dose	O
level	O
2	O
The	O
most	O
common	O
toxicities	O
encountered	O
during	O
induction	O
therapy	O
were	O
nausea	B-TOXI
","	O
vomiting	B-TOXI
","	O
rash	B-TOXI
and	O
diarrhea	B-TOXI
that	O
were	O
transient	O
and	O
/	O
or	O
reversible	O
.	O
	
At	O
the	O
800mg	O
dose	O
1	O
patient	O
developed	O
a	O
decline	O
in	O
cardiac	O
ejection	O
fraction	O
on	O
day	O
20	O
who	O
later	O
died	B-TOXI
of	O
sepsis	B-TOXI
","	O
so	O
this	O
was	O
considered	O
a	O
dose	O
limiting	O
toxicity	O
.	O
	
Of	O
16	O
evaluable	O
patients	O
11	O
achieved	O
a	O
hypocellular	B-TOXI
marrow	I-TOXI
after	O
initial	O
induction	O
with	O
1	O
additional	O
patient	O
achieving	O
a	O
hypocellular	B-TOXI
marrow	I-TOXI
following	O
a	O
second	O
course	O
of	O
the	O
same	O
regimen	O
.	O
	
Four	O
patients	O
(	O
25	O
%	O
)	O
achieved	O
a	O
complete	O
morphologic	O
response	O
with	O
normal	O
cytogenetics	O
","	O
2	O
patients	O
(	O
12.5	O
%	O
)	O
achieved	O
a	O
complete	O
morphologic	O
response	O
only	O
and	O
1	O
patient	O
had	O
a	O
complete	O
response	O
in	O
the	O
bone	O
marrow	O
but	O
incomplete	O
blood	O
count	O
recovery	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
43.8	O
%	O
.	O
	
The	O
median	O
overall	O
survival	O
was	O
175	O
days	O
(	O
95	O
%	O
CI	O
16.24-333.76	O
)	O
and	O
the	O
median	O
relapse	O
free	O
survival	O
was	O
76	O
days	O
.	O
	
The	O
addition	O
of	O
imatinib	B-DRUG
mesylate	I-DRUG
to	O
CLAG	O
was	O
well	O
tolerated	O
with	O
acceptable	O
toxicities	O
and	O
response	O
rates	O
comparable	O
to	O
other	O
salvage	O
regimens	O
.	O
	
To	O
assess	O
the	O
efficacy	O
of	O
imatinib	B-DRUG
mesylate	I-DRUG
in	O
combination	O
with	O
CLAG	O
","	O
a	O
larger	O
phase	O
II	O
trial	O
is	O
now	O
planned	O
.	O
	
Phase	O
II	O
multicenter	O
study	O
of	O
bendamustine	B-DRUG
plus	O
rituximab	B-DRUG
in	O
patients	O
with	O
relapsed	O
indolent	O
B-cell	O
and	O
mantle	O
cell	O
non-Hodgkin	B-CANCER
's	I-CANCER
lymphoma	I-CANCER
.	O
	
	
Bendamustine	B-DRUG
HCl	O
is	O
a	O
bifunctional	O
mechlorethamine	O
derivative	O
with	O
clinical	O
activity	O
in	O
the	O
treatment	O
of	O
non-Hodgkin	B-CANCER
's	I-CANCER
lymphoma	I-CANCER
.	O
	
This	O
study	O
evaluated	O
bendamustine	B-DRUG
plus	O
rituximab	B-DRUG
in	O
67	O
adults	O
with	O
relapsed	O
","	O
indolent	O
B-cell	O
or	O
mantle	O
cell	O
lymphoma	B-CANCER
without	O
documented	O
resistance	O
to	O
prior	O
rituximab	B-DRUG
.	O
	
Patients	O
received	O
rituximab	B-DRUG
375	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
on	O
day	O
1	O
and	O
bendamustine	B-DRUG
90	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
on	O
days	O
2	O
and	O
3	O
of	O
each	O
28-day	O
cycle	O
for	O
four	O
to	O
six	O
cycles	O
.	O
	
An	O
additional	O
dose	O
of	O
rituximab	B-DRUG
was	O
administered	O
1	O
week	O
before	O
the	O
first	O
cycle	O
and	O
4	O
weeks	O
after	O
the	O
last	O
cycle	O
.	O
	
Sixty-six	O
patients	O
(	O
median	O
age	O
","	O
60	O
years	O
)	O
received	O
at	O
least	O
one	O
dose	O
of	O
both	O
drugs	O
.	O
	
Overall	O
response	O
rate	O
was	O
92	O
%	O
(	O
41	O
%	O
complete	O
response	O
","	O
14	O
%	O
unconfirmed	O
complete	O
response	O
","	O
and	O
38	O
%	O
partial	O
response	O
)	O
.	O
	
Median	O
duration	O
of	O
response	O
was	O
21	O
months	O
(	O
95	O
%	O
CI	O
","	O
18	O
to	O
24	O
months	O
)	O
.	O
	
Median	O
progression-free	O
survival	O
time	O
was	O
23	O
months	O
(	O
95	O
%	O
CI	O
","	O
20	O
to	O
26	O
months	O
)	O
.	O
	
Outcomes	O
were	O
similar	O
for	O
patients	O
with	O
indolent	O
or	O
mantle	O
cell	O
histologies	O
.	O
	
The	O
combination	O
was	O
generally	O
well	O
tolerated	O
;	O
the	O
primary	O
toxicity	O
was	O
myelosuppression	B-TOXI
(	O
grade	O
3	O
or	O
4	O
neutropenia	B-TOXI
","	O
36	O
%	O
;	O
grade	O
3	O
or	O
4	O
thrombocytopenia	B-TOXI
","	O
9	O
%	O
)	O
.	O
	
Bendamustine	B-DRUG
plus	O
rituximab	B-DRUG
is	O
an	O
active	O
combination	O
in	O
patients	O
with	O
relapsed	O
indolent	O
and	O
mantle	O
cell	O
lymphoma	B-CANCER
.	O
	
Preoperative	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
followed	O
by	O
gemcitabine-based	B-DRUG
chemoradiation	O
for	O
resectable	O
adenocarcinoma	B-CANCER
of	I-CANCER
the	I-CANCER
pancreatic	I-CANCER
head	I-CANCER
.	O
	
	
We	O
conducted	O
a	O
phase	O
II	O
trial	O
of	O
preoperative	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
chemotherapy	O
in	O
addition	O
to	O
chemoradiation	O
(	O
Gem-Cis-XRT	O
)	O
and	O
pancreaticoduodenectomy	O
(	O
PD	O
)	O
for	O
patients	O
with	O
stage	O
I	O
/	O
II	O
pancreatic	B-CANCER
adenocarcinoma	I-CANCER
.	O
	
Chemotherapy	O
consisted	O
of	O
gemcitabine	B-DRUG
(	O
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
cisplatin	B-DRUG
(	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
given	O
every	O
2	O
weeks	O
for	O
four	O
doses	O
.	O
	
Chemoradiation	O
consisted	O
of	O
four	O
weekly	O
infusions	O
of	O
gemcitabine	B-DRUG
(	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
combined	O
with	O
radiation	O
therapy	O
(	O
30	O
Gy	O
in	O
10	O
fractions	O
administered	O
over	O
2	O
weeks	O
)	O
delivered	O
5	O
days	O
per	O
week	O
.	O
	
Patients	O
underwent	O
restaging	O
4	O
to	O
6	O
weeks	O
after	O
completion	O
of	O
chemoradiation	O
and	O
","	O
in	O
the	O
absence	O
of	O
disease	O
progression	O
","	O
were	O
taken	O
to	O
surgery	O
.	O
	
The	O
study	O
enrolled	O
90	O
patients	O
;	O
79	O
patients	O
(	O
88	O
%	O
)	O
completed	O
chemo-chemoradiation	O
.	O
	
Sixty-two	O
(	O
78	O
%	O
)	O
of	O
79	O
patients	O
were	O
taken	O
to	O
surgery	O
and	O
52	O
(	O
66	O
%	O
)	O
of	O
79	O
underwent	O
PD.	O
The	O
median	O
overall	O
survival	O
of	O
all	O
90	O
patients	O
was	O
17.4	O
months	O
.	O
	
Median	O
survival	O
for	O
the	O
79	O
patients	O
who	O
completed	O
chemo-chemoradiation	O
was	O
18.7	O
months	O
","	O
with	O
a	O
median	O
survival	O
of	O
31	O
months	O
for	O
the	O
52	O
patients	O
who	O
underwent	O
PD	O
and	O
10.5	O
months	O
for	O
the	O
27	O
patients	O
who	O
did	O
not	O
undergo	O
surgical	O
resection	O
of	O
their	O
primary	O
tumor	O
(	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
.	O
	
Preoperative	O
Gem-Cis-XRT	O
did	O
not	O
improve	O
survival	O
beyond	O
that	O
achieved	O
with	O
preoperative	O
gemcitabine-based	B-DRUG
chemoradiation	O
(	O
Gem-XRT	O
)	O
alone	O
.	O
	
The	O
longer	O
preoperative	O
interval	O
required	O
more	O
durable	O
biliary	O
decompression	O
(	O
metal	O
stents	O
)	O
but	O
was	O
not	O
associated	O
with	O
local	O
tumor	O
progression	O
.	O
	
The	O
gemcitabine-based	B-DRUG
chemoradiation	O
platform	O
is	O
a	O
reasonable	O
foundation	O
on	O
which	O
to	O
build	O
future	O
phase	O
II	O
multimodality	O
trials	O
for	O
stage	O
I	O
/	O
II	O
pancreatic	B-CANCER
cancer	I-CANCER
incorporating	O
emerging	O
systemic	O
therapies	O
.	O
	
Phase	O
III	O
study	O
of	O
R-CVP	O
compared	O
with	O
cyclophosphamide	B-DRUG
","	O
vincristine	B-DRUG
","	O
and	O
prednisone	B-DRUG
alone	O
in	O
patients	O
with	O
previously	O
untreated	O
advanced	B-CANCER
follicular	I-CANCER
lymphoma	I-CANCER
.	O
	
	
To	O
compare	O
the	O
long-term	O
outcome	O
of	O
patients	O
with	O
previously	O
untreated	O
follicular	B-CANCER
lymphoma	I-CANCER
(	O
FL	O
)	O
needing	O
therapy	O
","	O
after	O
treatment	O
with	O
cyclophosphamide	B-DRUG
","	O
vincristine	B-DRUG
and	O
prednisone	B-DRUG
(	O
CVP	O
)	O
versus	O
CVP	O
plus	O
rituximab	B-DRUG
(	O
R-CVP	O
)	O
and	O
to	O
evaluate	O
the	O
predictive	O
value	O
of	O
known	O
prognostic	O
factors	O
after	O
treatment	O
with	O
R-CVP	O
.	O
	
Patients	O
with	O
previously	O
untreated	O
CD20-positive	O
stage	O
III	O
/	O
IV	O
FL	O
were	O
randomly	O
assigned	O
to	O
eight	O
cycles	O
of	O
R-CVP	O
(	O
n	O
=	O
159	O
)	O
or	O
CVP	O
alone	O
(	O
n	O
=	O
162	O
)	O
.	O
	
The	O
median	O
follow-up	O
period	O
was	O
53	O
months	O
.	O
	
The	O
primary	O
end	O
point-time	O
to	O
treatment	O
failure	O
(	O
TTF	O
)	O
","	O
which	O
included	O
patients	O
without	O
a	O
response	O
after	O
four	O
cycles	O
as	O
an	O
event-was	O
significantly	O
prolonged	O
in	O
patients	O
receiving	O
R-CVP	O
versus	O
CVP	O
(	O
P	O
&	O
lt	O
;	O
0.0001	O
)	O
.	O
	
Improvements	O
in	O
all	O
other	O
end	O
points	O
","	O
including	O
overall	O
and	O
complete	O
response	O
rates	O
(	O
P	O
&	O
lt	O
;	O
0.0001	O
)	O
","	O
time	O
to	O
progression	O
(	O
TTP	O
;	O
P	O
&	O
lt	O
;	O
0.0001	O
)	O
","	O
response	O
duration	O
(	O
P	O
&	O
lt	O
;	O
0.0001	O
)	O
","	O
time	O
to	O
next	O
antilymphoma	O
treatment	O
(	O
P	O
&	O
lt	O
;	O
0.0001	O
)	O
","	O
and	O
overall	O
survival	O
(	O
OS	O
;	O
P	O
=	O
0.029	O
;	O
4-year	O
OS	O
:	O
83	O
%	O
v	O
77	O
%	O
;	O
)	O
were	O
achieved	O
with	O
R-CVP	O
versus	O
CVP	O
alone	O
.	O
	
Univariate	O
analyses	O
demonstrated	O
an	O
improvement	O
in	O
TTP	O
with	O
R-CVP	O
versus	O
CVP	O
irrespective	O
of	O
the	O
Follicular	B-CANCER
Lymphoma	I-CANCER
International	O
Prognostic	O
Index	O
(	O
FLIPI	O
)	O
subgroup	O
","	O
the	O
International	O
Prognostic	O
Index	O
(	O
IPI	O
)	O
subgroup	O
","	O
baseline	O
histology	O
","	O
and	O
the	O
presence	O
or	O
absence	O
of	O
B	O
symptoms	O
or	O
bulky	O
disease	O
.	O
	
By	O
multivariate	O
analysis	O
","	O
FLIPI	O
retains	O
a	O
strong	O
predictive	O
power	O
for	O
TTP	O
in	O
the	O
presence	O
of	O
the	O
trial	O
treatment	O
effect	O
.	O
	
Analysis	O
of	O
all	O
outcome	O
measures	O
","	O
including	O
OS	O
","	O
confirm	O
the	O
benefit	O
of	O
adding	O
R	O
to	O
CVP	O
in	O
the	O
front-line	O
treatment	O
of	O
FL	O
.	O
	
Phase	O
I	O
study	O
of	O
preoperative	O
radiation	O
therapy	O
with	O
concurrent	O
infusional	B-DRUG
5-fluorouracil	I-DRUG
and	O
oxaliplatin	B-DRUG
followed	O
by	O
surgery	O
and	O
postoperative	O
5-fluorouracil	B-DRUG
plus	O
leucovorin	B-DRUG
for	O
T3	O
/	O
T4	O
rectal	B-CANCER
adenocarcinoma	I-CANCER
:	O
ECOG	O
E1297	O
.	O
	
	
Oxaliplatin	B-DRUG
is	O
a	O
platinum	O
analog	O
and	O
radiosensitizer	O
active	O
in	O
colorectal	B-CANCER
cancer	I-CANCER
.	O
	
We	O
performed	O
a	O
Phase	O
I	O
trial	O
to	O
test	O
the	O
safety	O
and	O
preliminary	O
efficacy	O
of	O
adding	O
oxaliplatin	B-DRUG
to	O
standard	O
preoperative	O
chemoradiation	O
therapy	O
for	O
rectal	B-CANCER
cancer	I-CANCER
.	O
	
Eligible	O
patients	O
had	O
T3	O
to	O
T4	O
rectal	B-CANCER
adenocarcinoma	I-CANCER
.	O
	
Patients	O
received	O
standard-dose	O
radiation	O
(	O
50.4	O
Gy	O
for	O
5.5	O
weeks	O
)	O
with	O
concurrent	O
infused	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
at	O
200	O
mg	O
/	O
m2	O
per	O
day	O
","	O
7	O
days	O
per	O
week	O
.	O
	
Oxaliplatin	B-DRUG
was	O
given	O
three	O
times	O
at	O
14-day	O
intervals	O
at	O
55	O
","	O
70	O
","	O
or	O
85	O
mg	O
/	O
m2	O
during	O
the	O
5.5-week	O
radiation	O
period	O
","	O
before	O
resection	O
.	O
	
Adjuvant	O
therapy	O
consisted	O
of	O
four	O
cycles	O
of	O
5-FU	B-DRUG
(	O
500	O
mg	O
/	O
m2	O
per	O
week	O
)	O
with	O
leucovorin	B-DRUG
(	O
500	O
mg	O
/	O
m2	O
per	O
week	O
)	O
given	O
every	O
6	O
weeks	O
.	O
	
The	O
main	O
goals	O
were	O
to	O
identify	O
the	O
maximum	O
tolerated	O
dose	O
of	O
oxaliplatin	B-DRUG
and	O
the	O
dose-limiting	O
toxicities	O
when	O
given	O
with	O
5-FU	B-DRUG
and	O
RT.	O
Secondary	O
goals	O
were	O
to	O
determine	O
resectability	O
","	O
pathologic	O
response	O
","	O
sphincter	O
preservation	O
","	O
and	O
overall	O
survival	O
rates	O
.	O
	
Twenty-one	O
patients	O
were	O
enrolled	O
","	O
5	O
at	O
the	O
55	O
mg	O
/	O
m2	O
oxaliplatin	B-DRUG
dose	O
level	O
","	O
5	O
at	O
70	O
mg	O
/	O
m2	O
","	O
and	O
11	O
at	O
85	O
mg	O
/	O
m2	O
.	O
	
All	O
patients	O
were	O
able	O
to	O
complete	O
the	O
preoperative	O
chemoradiation	O
regimen	O
with	O
no	O
dose	O
adjustments	O
.	O
	
No	O
dose-limiting	O
toxicities	O
or	O
differences	O
in	O
the	O
type	O
or	O
extent	O
of	O
toxicity	O
were	O
noted	O
among	O
the	O
groups	O
.	O
	
Nineteen	O
patients	O
underwent	O
surgery	O
(	O
three	O
abdominopelvic	O
resections	O
and	O
16	O
low	O
anterior	O
resections	O
)	O
","	O
for	O
an	O
84	O
%	O
sphincter	O
preservation	O
rate	O
.	O
	
The	O
pathologic	O
complete	O
response	O
rate	O
was	O
26	O
%	O
(	O
5	O
patients	O
)	O
","	O
and	O
minimal	O
microscopic	O
residual	O
tumor	O
was	O
found	O
in	O
21	O
%	O
(	O
4	O
additional	O
patients	O
)	O
.	O
	
Oxaliplatin	B-DRUG
was	O
well	O
tolerated	O
at	O
85	O
mg	O
/	O
m2	O
given	O
every	O
2	O
weeks	O
in	O
combination	O
with	O
standard	O
preoperative	O
chemoradiation	O
for	O
rectal	B-CANCER
cancer	I-CANCER
.	O
	
The	O
rates	O
of	O
major	O
pathologic	O
response	O
and	O
sphincter	O
preservation	O
are	O
promising	O
.	O
	
A	O
phase	O
II	O
study	O
of	O
UFT	B-DRUG
with	O
leucovorin	B-DRUG
administered	O
as	O
a	O
twice	O
daily	O
schedule	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
Prolonged	O
infusions	O
have	O
been	O
shown	O
to	O
be	O
safer	O
and	O
potentially	O
more	O
effective	O
than	O
bolus	O
regimens	O
of	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
as	O
treatment	O
for	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
mCRC	B-CANCER
)	O
.	O
	
However	O
","	O
infusional	B-DRUG
5-FU	I-DRUG
requires	O
central	O
venous	O
access	O
and	O
costly	O
infusion	O
pumps	O
.	O
	
Oral	O
fluoropyrimidines	B-DRUG
enable	O
longer	O
exposures	O
to	O
5-FU	B-DRUG
with	O
increased	O
convenience	O
.	O
	
Tegafur-uracil	B-DRUG
(	O
UFT	B-DRUG
)	O
with	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
given	O
thrice	O
daily	O
has	O
improved	O
safety	O
plus	O
comparable	O
survival	O
and	O
response	O
rates	O
to	O
bolus	O
5-FU	B-DRUG
/	O
LV	B-DRUG
.	O
	
We	O
conducted	O
a	O
phase	O
II	O
clinical	O
study	O
in	O
98	O
patients	O
with	O
mCRC	B-CANCER
to	O
evaluate	O
if	O
UFT	B-DRUG
with	O
LV	B-DRUG
given	O
twice	O
daily	O
provided	O
comparable	O
time	O
to	O
progression	O
(	O
TTP	O
)	O
","	O
efficacy	O
and	O
tolerability	O
to	O
that	O
reported	O
for	O
thrice	O
daily	O
in	O
two	O
phase	O
III	O
clinical	O
studies	O
.	O
	
Secondary	O
objectives	O
included	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O
	
Median	O
TTP	O
was	O
3.8	O
months	O
","	O
when	O
compared	O
with	O
3.5	O
months	O
for	O
thrice	O
daily	O
.	O
	
The	O
ORR	O
(	O
11	O
%	O
)	O
and	O
median	O
OS	O
(	O
12.8	O
months	O
)	O
with	O
twice	O
daily	O
administration	O
were	O
similar	O
to	O
that	O
of	O
thrice	O
daily	O
administration	O
(	O
12	O
%	O
and	O
12.4	O
months	O
)	O
.	O
	
The	O
incidence	O
of	O
grade	O
3	O
/	O
4	O
treatment-related	O
diarrhoea	B-TOXI
was	O
30	O
%	O
on	O
the	O
twice	O
daily	O
and	O
21	O
%	O
on	O
the	O
thrice	O
daily	O
schedule	O
.	O
	
These	O
results	O
suggest	O
that	O
twice	O
daily	O
administration	O
has	O
similar	O
efficacy	O
and	O
tolerability	O
to	O
thrice	O
daily	O
administration	O
and	O
is	O
an	O
acceptable	O
alternative	O
for	O
patients	O
who	O
would	O
benefit	O
from	O
UFT	B-DRUG
with	O
LV	B-DRUG
therapy	O
.	O
	
Lack	O
of	O
efficacy	O
of	O
high-dose	O
leucovorin	B-DRUG
and	O
fluorouracil	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
pancreatic	I-CANCER
adenocarcinoma	I-CANCER
.	O
	
	
Leucovorin	B-DRUG
potentiates	O
the	O
cytotoxicity	O
of	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
in	O
experimental	O
tumor	O
systems	O
and	O
appears	O
to	O
enhance	O
the	O
effectiveness	O
of	O
5-FU	B-DRUG
in	O
patients	O
with	O
colon	B-CANCER
cancer	I-CANCER
.	O
	
Twenty-two	O
eligible	O
patients	O
(	O
18	O
previously	O
untreated	O
)	O
with	O
advanced	B-CANCER
pancreatic	I-CANCER
adenocarcinoma	I-CANCER
were	O
treated	O
in	O
a	O
phase	O
II	O
trial	O
of	O
leucovorin	B-DRUG
500	O
mg	O
/	O
m2	O
/	O
d	O
for	O
6	O
days	O
by	O
continuous	O
intravenous	O
infusion	O
with	O
5-FU	B-DRUG
370	O
mg	O
/	O
m2	O
/	O
d	O
by	O
rapid	O
intravenous	O
injection	O
on	O
5	O
consecutive	O
days	O
","	O
beginning	O
24	O
hours	O
after	O
initiation	O
of	O
leucovorin	B-DRUG
infusion	O
.	O
	
Among	O
the	O
20	O
assessable	O
patients	O
","	O
there	O
were	O
no	O
complete	O
or	O
partial	O
regressions	O
","	O
although	O
there	O
was	O
one	O
minor	O
response	O
lasting	O
4	O
months	O
.	O
	
Three	O
patients	O
had	O
stable	O
disease	O
for	O
5	O
","	O
20	O
","	O
and	O
21	O
months	O
","	O
respectively	O
.	O
	
Median	O
survival	O
was	O
10	O
weeks	O
.	O
	
Toxicity	O
was	O
predominantly	O
mucosal	O
;	O
stomatitis	B-TOXI
grade	O
2	O
or	O
worse	O
was	O
seen	O
in	O
five	O
patients	O
","	O
and	O
diarrhea	B-TOXI
grade	O
2	O
or	O
worse	O
was	O
seen	O
in	O
four	O
.	O
	
Hospitalization	O
for	O
toxicity	O
was	O
necessary	O
in	O
four	O
previously	O
untreated	O
patients	O
and	O
three	O
previously	O
treated	O
patients	O
.	O
	
The	O
median	O
WBC	O
nadir	O
was	O
4.6	O
(	O
range	O
","	O
1.4	O
to	O
9.6	O
)	O
x	O
10	O
(	O
3	O
)	O
/	O
microL	O
","	O
and	O
the	O
median	O
platelet	O
nadir	O
was	O
147	O
(	O
range	O
","	O
69	O
to	O
240	O
)	O
x	O
10	O
(	O
3	O
)	O
/	O
microL	O
.	O
	
This	O
combination	O
of	O
leucovorin	B-DRUG
and	O
5-FU	B-DRUG
did	O
not	O
demonstrate	O
meaningful	O
therapeutic	O
activity	O
in	O
patients	O
with	O
adenocarcinoma	B-CANCER
of	I-CANCER
the	I-CANCER
pancreas	I-CANCER
and	O
was	O
associated	O
with	O
moderate	O
to	O
severe	B-TOXI
toxicity	I-TOXI
.	O
	
It	O
should	O
not	O
be	O
considered	O
a	O
standard	O
treatment	O
for	O
patients	O
with	O
this	O
disease	O
.	O
	
Phase	O
I	O
trial	O
of	O
erlotinib-based	B-DRUG
multimodality	O
therapy	O
for	O
inoperable	O
stage	O
III	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
This	O
Phase	O
I	O
trial	O
aimed	O
to	O
determine	O
the	O
maximum-tolerated-dose	O
of	O
erlotinib	B-DRUG
administered	O
with	O
two	O
standard	O
chemoradiotherapy	O
regimens	O
for	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
Unresectable	O
stage	O
III	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
patients	O
were	O
enrolled	O
in	O
this	O
2-arm	O
dose-escalation	O
study	O
.	O
	
Erlotinib	B-DRUG
","	O
given	O
only	O
during	O
chemoradiotherapy	O
","	O
was	O
escalated	O
from	O
50	O
to	O
150	O
mg	O
/	O
d	O
in	O
3	O
to	O
6	O
patient	O
cohorts	O
.	O
	
Arm	O
A	O
:	O
erlotinib	B-DRUG
with	O
cisplatin	B-DRUG
(	O
50	O
mg	O
/	O
m	O
IV	O
days	O
1	O
","	O
8	O
","	O
29	O
","	O
36	O
)	O
","	O
etoposide	B-DRUG
(	O
50	O
mg	O
/	O
m	O
IV	O
days	O
1月5日	O
","	O
29-33	O
)	O
and	O
chest	O
radiotherapy	O
(	O
66	O
Gy	O
","	O
2	O
Gy	O
/	O
d	O
)	O
followed	O
by	O
docetaxel	B-DRUG
(	O
75	O
mg	O
/	O
m	O
IV	O
Q21	O
d	O
)	O
for	O
3	O
cycles	O
.	O
	
Arm	O
B	O
:	O
induction	O
carboplatin	B-DRUG
(	O
AUC	O
6	O
)	O
and	O
paclitaxel	B-DRUG
(	O
200	O
mg	O
/	O
m	O
)	O
for	O
two	O
21-d	O
cycles	O
then	O
radiotherapy	O
with	O
erlotinib	B-DRUG
","	O
carboplatin	B-DRUG
(	O
AUC	O
=	O
2	O
/	O
wk	O
)	O
and	O
paclitaxel	B-DRUG
(	O
50	O
mg	O
/	O
m	O
/	O
wk	O
)	O
.	O
	
Seventeen	O
patients	O
were	O
treated	O
in	O
each	O
arm	O
.	O
	
performance	O
status	O
0	O
to	O
24	O
patients	O
","	O
1	O
to	O
10	O
patients	O
","	O
median	O
age	O
63	O
years	O
","	O
adenocarcinoma	B-CANCER
21	O
%	O
and	O
female	O
14	O
patients	O
.	O
	
Dose-escalation	O
of	O
erlotinib	B-DRUG
to	O
150	O
mg	O
/	O
d	O
was	O
possible	O
on	O
both	O
chemoradiotherapy	O
regimens	O
.	O
	
Grade	O
3	O
/	O
4	O
leukopenia	B-TOXI
and	O
neutropenia	B-TOXI
were	O
predominant	O
toxicities	O
in	O
both	O
arms	O
.	O
	
Grade	O
3	O
chemoradiotherapy	O
toxicities	O
in	O
arm	O
A	O
were	O
esophagitis	B-TOXI
(	O
3	O
patients	O
)	O
","	O
vomiting	B-TOXI
(	O
1	O
)	O
","	O
ototoxicity	B-TOXI
(	O
1	O
)	O
","	O
diarrhea	B-TOXI
(	O
2	O
)	O
","	O
dehydration	B-TOXI
(	O
3	O
)	O
","	O
pneumonitis	B-TOXI
(	O
1	O
)	O
;	O
and	O
arm	O
B	O
was	O
esophagitis	B-TOXI
(	O
6	O
)	O
.	O
	
Seven	O
patients	O
(	O
21	O
%	O
)	O
developed	O
rash	B-TOXI
(	O
all	O
grade	O
1	O
/	O
2	O
)	O
.	O
	
Median	O
survival	O
times	O
for	O
patients	O
on	O
Arm	O
A	O
and	O
B	O
were	O
10.2	O
and	O
13.7	O
months	O
","	O
respectively	O
.	O
	
Three-year	O
overall	O
survival	O
in	O
patients	O
with	O
and	O
without	O
rash	B-TOXI
were	O
53	O
%	O
and	O
10	O
%	O
","	O
respectively	O
(	O
log-rank	O
P	O
=	O
0.0807	O
)	O
.	O
	
Epidermal	B-DRUG
growth	I-DRUG
factor	I-DRUG
receptor	I-DRUG
IHC	O
or	O
FISH	O
positive	O
patients	O
showed	O
no	O
significant	O
overall	O
survival	O
difference	O
.	O
	
Addition	O
of	O
standard-dose	O
erlotinib	B-DRUG
to	O
chemoradiotherapy	O
is	O
feasible	O
without	O
evident	O
increase	O
in	O
toxicities	O
.	O
	
However	O
","	O
the	O
survival	O
data	O
are	O
disappointing	O
in	O
this	O
unselected	O
patient	O
population	O
and	O
does	O
not	O
support	O
further	O
investigation	O
of	O
this	O
approach	O
.	O
	
Phase	O
I	O
study	O
of	O
capecitabine	B-DRUG
in	O
combination	O
with	O
cisplatin	B-DRUG
and	O
irinotecan	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
malignancies	I-CANCER
.	O
	
	
This	O
phase	O
I	O
trial	O
assessed	O
the	O
safety	O
and	O
the	O
maximum	O
tolerated	O
dose	O
of	O
capecitabine	B-DRUG
given	O
for	O
10	O
days	O
prior	O
to	O
a	O
combination	O
of	O
cisplatin	B-DRUG
and	O
irinotecan	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
malignancies	I-CANCER
.	O
	
It	O
also	O
evaluated	O
the	O
changes	O
in	O
cisplatin	B-DRUG
DNA	O
adducts	O
induced	O
by	O
capecitabine	B-DRUG
.	O
	
Patients	O
with	O
refractory	O
solid	O
tumors	O
who	O
had	O
not	O
failed	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
analogs	O
or	O
topoisomerase	B-DRUG
I	I-DRUG
inhibitors	I-DRUG
were	O
eligible	O
.	O
	
All	O
cohorts	O
of	O
patients	O
first	O
received	O
a	O
28-day	O
cycle	O
of	O
cisplatin	B-DRUG
and	O
irinotecan	B-DRUG
.	O
	
Both	O
drugs	O
were	O
given	O
at	O
a	O
dose	O
of	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
on	O
day	O
1	O
","	O
followed	O
by	O
irinotecan	B-DRUG
on	O
days	O
8	O
and	O
15	O
at	O
the	O
same	O
dose	O
.	O
	
The	O
first	O
cycle	O
served	O
as	O
an	O
internal	O
control	O
.	O
	
Starting	O
from	O
the	O
second	O
cycle	O
","	O
patients	O
received	O
increasing	O
doses	O
per	O
cohort	O
of	O
capecitabine	B-DRUG
from	O
day	O
1	O
to	O
10	O
of	O
each	O
cycle	O
","	O
followed	O
by	O
cisplatin	B-DRUG
on	O
day	O
11	O
and	O
irinotecan	O
on	O
days	O
11	O
","	O
18	O
and	O
25	O
","	O
both	O
at	O
same	O
doses	O
as	O
the	O
first	O
cycle	O
.	O
	
Cycles	O
were	O
repeated	O
every	O
38	O
days	O
.	O
	
The	O
starting	O
dose	O
of	O
capecitabine	B-DRUG
was	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
which	O
was	O
escalated	O
by	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
in	O
the	O
subsequent	O
cohort	O
of	O
patients	O
to	O
reach	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
.	O
	
Later	O
","	O
additional	O
patients	O
were	O
treated	O
at	O
the	O
MTD	O
of	O
capecitabine	B-DRUG
to	O
further	O
evaluate	O
the	O
safety	O
","	O
pharmacodynamics	O
","	O
and	O
tumor	O
response	O
.	O
	
Patients	O
blood	O
was	O
tested	O
for	O
cisplatin-DNA	B-DRUG
adducts	O
to	O
determine	O
the	O
impact	O
of	O
capecitabine	B-DRUG
on	O
cisplatin-based	B-DRUG
therapy	O
.	O
	
Fifteen	O
patients	O
received	O
at	O
least	O
2	O
cycles	O
of	O
treatment	O
.	O
	
At	O
"1,250"	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
two	O
DLT	O
of	O
prolonged	O
neutropenia	B-TOXI
of	O
grade	O
&	O
gt	O
;	O
or	O
3	O
were	O
observed	O
.	O
	
The	O
MTD	O
for	O
capecitabine	B-DRUG
was	O
thus	O
determined	O
to	O
be	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
.	O
	
Fatigue	B-TOXI
and	O
diarrhea	B-TOXI
of	O
grade	O
1	O
or	O
2	O
were	O
the	O
most	O
frequent	O
toxicities	O
at	O
this	O
dose	O
level	O
.	O
	
No	O
significant	O
hematologic	B-TOXI
toxicity	I-TOXI
was	O
observed	O
at	O
the	O
MTD	O
.	O
	
Two	O
complete	O
and	O
three	O
partial	O
remissions	O
were	O
observed	O
.	O
	
Four	O
of	O
the	O
responders	O
had	O
received	O
a	O
platinum	B-DRUG
agent	O
and	O
/	O
or	O
5-FU	B-DRUG
in	O
the	O
past	O
.	O
	
A	O
sequential	O
treatment	O
with	O
capecitabine	B-DRUG
followed	O
by	O
cisplatin	B-DRUG
and	O
irinotecan	B-DRUG
is	O
well	O
tolerated	O
and	O
demonstrates	O
clinical	O
activity	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
malignancies	I-CANCER
.	O
	
The	O
influence	O
of	O
capecitabine	B-DRUG
","	O
if	O
any	O
","	O
on	O
the	O
efficacy	O
of	O
the	O
cisplatin-irinotecan	B-DRUG
combination	O
is	O
not	O
related	O
to	O
a	O
variation	O
in	O
cisplatin-DNA	B-DRUG
adducts	O
.	O
	
Adjuvant	O
paclitaxel	B-DRUG
plus	O
carboplatin	B-DRUG
compared	O
with	O
observation	O
in	O
stage	O
IB	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
CALGB	O
9633	O
with	O
the	O
Cancer	O
and	O
Leukemia	B-CANCER
Group	O
B	O
","	O
Radiation	O
Therapy	O
Oncology	O
Group	O
","	O
and	O
North	O
Central	O
Cancer	O
Treatment	O
Group	O
Study	O
Groups	O
.	O
	
	
Adjuvant	O
chemotherapy	O
for	O
resected	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
is	O
now	O
accepted	O
on	O
the	O
basis	O
of	O
several	O
randomized	O
clinical	O
trials	O
(	O
RCTs	O
)	O
that	O
demonstrated	O
improved	O
survival	O
.	O
	
Although	O
there	O
is	O
strong	O
evidence	O
that	O
adjuvant	O
chemotherapy	O
is	O
effective	O
in	O
stages	O
II	O
and	O
IIIA	O
NSCLC	B-CANCER
","	O
its	O
utility	O
in	O
stage	O
IB	O
disease	O
is	O
unclear	O
.	O
	
This	O
report	O
provides	O
a	O
mature	O
analysis	O
of	O
Cancer	O
and	O
Leukemia	B-CANCER
Group	O
B	O
(	O
CALGB	O
)	O
9633	O
","	O
the	O
only	O
RCT	O
designed	O
specifically	O
for	O
stage	O
IB	O
NSCLC	B-CANCER
.	O
	
Within	O
4	O
to	O
8	O
weeks	O
of	O
resection	O
","	O
patients	O
were	O
randomly	O
assigned	O
to	O
adjuvant	O
chemotherapy	O
or	O
observation	O
.	O
	
Eligible	O
patients	O
had	O
pathologically	O
confirmed	O
T2N0	O
NSCLC	B-CANCER
and	O
had	O
undergone	O
lobectomy	O
or	O
pneumonectomy	O
.	O
	
Chemotherapy	O
consisted	O
of	O
paclitaxel	B-DRUG
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
over	O
3	O
hours	O
and	O
carboplatin	B-DRUG
at	O
an	O
area	O
under	O
the	O
curve	O
dose	O
of	O
6	O
mg	O
/	O
mL	O
per	O
minute	O
intravenously	O
over	O
45	O
to	O
60	O
minutes	O
every	O
3	O
weeks	O
for	O
four	O
cycles	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
overall	O
survival	O
.	O
	
Three	O
hundred-forty-four	O
patients	O
were	O
randomly	O
assigned	O
.	O
	
Median	O
follow-up	O
was	O
74	O
months	O
.	O
	
Groups	O
were	O
well-balanced	O
with	O
regard	O
to	O
demographics	O
","	O
histology	O
","	O
and	O
extent	O
of	O
surgery	O
.	O
	
Grades	O
3	O
to	O
4	O
neutropenia	B-TOXI
were	O
the	O
predominant	O
toxicity	O
;	O
there	O
were	O
no	O
treatment-related	O
deaths	B-TOXI
.	O
	
Survival	O
was	O
not	O
significantly	O
different	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
","	O
0.83	O
;	O
CI	O
","	O
0.64	O
to	O
1.08	O
;	O
P	O
=	O
0.12	O
)	O
.	O
	
However	O
","	O
exploratory	O
analysis	O
demonstrated	O
a	O
significant	O
survival	O
difference	O
in	O
favor	O
of	O
adjuvant	O
chemotherapy	O
for	O
patients	O
who	O
had	O
tumors	O
&	O
gt	O
;	O
or	O
=	O
4	O
cm	O
in	O
diameter	O
(	O
HR	O
","	O
0.69	O
;	O
CI	O
","	O
0.48	O
to	O
0.99	O
;	O
P	O
=	O
0.043	O
)	O
.	O
	
Because	O
a	O
significant	O
survival	O
advantage	O
was	O
not	O
observed	O
across	O
the	O
entire	O
cohort	O
","	O
adjuvant	O
chemotherapy	O
should	O
not	O
be	O
considered	O
standard	O
care	O
in	O
stage	O
IB	O
NSCLC	B-CANCER
.	O
	
Given	O
the	O
magnitude	O
of	O
observed	O
survival	O
differences	O
","	O
CALGB	O
9633	O
was	O
underpowered	O
to	O
detect	O
small	O
but	O
clinically	O
meaningful	O
improvements	O
.	O
	
A	O
statistically	O
significant	O
survival	O
advantage	O
for	O
patients	O
who	O
had	O
tumors	O
&	O
gt	O
;	O
or	O
=	O
4	O
cm	O
supports	O
consideration	O
of	O
adjuvant	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
for	O
stage	O
IB	O
patients	O
who	O
have	O
large	O
tumors	O
.	O
	
Multi-center	O
phase	O
II	O
trial	O
of	O
chemo-radiotherapy	O
with	O
5-fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
and	O
oxaliplatin	B-DRUG
in	O
locally	O
advanced	B-CANCER
esophageal	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
activity	O
and	O
safety	O
of	O
oxaliplatin	B-DRUG
/	O
5-fluorouracil-based	B-DRUG
chemo-radiotherapy	O
in	O
patients	O
with	O
not	O
radically	O
resectable	O
locally	O
advanced	B-CANCER
esophageal	I-CANCER
cancer	I-CANCER
.	O
	
Fifty-nine	O
patients	O
with	O
adeno	O
or	O
squamous-cell	B-CANCER
carcinoma	I-CANCER
received	O
oxaliplatin	B-DRUG
(	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
and	O
leucovorin	B-DRUG
(	O
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
"1,8,15,29,36,43,50,57"	O
)	O
followed	O
by	O
continuous	O
infusion	O
fluorouracil	B-DRUG
(	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
day	O
on	O
days	O
1月22日	O
and	O
29-64	O
)	O
with	O
radiotherapy	O
(	O
1.8	O
Gy	O
daily	O
fractions	O
to	O
a	O
total	O
dose	O
of	O
45	O
Gy	O
","	O
from	O
days	O
29	O
to	O
64	O
)	O
.	O
	
When	O
feasible	O
","	O
surgery	O
was	O
scheduled	O
6月8日	O
weeks	O
after	O
chemo-radiotherapy	O
completion	O
.	O
	
The	O
primary	O
endpoint	O
was	O
1-year	O
progression-free	O
survival	O
.	O
	
Forty	O
(	O
68	O
%	O
)	O
patients	O
completed	O
treatment	O
without	O
modifications	O
.	O
	
An	O
objective	O
clinical	O
response	O
was	O
seen	O
in	O
35	O
patients	O
(	O
59	O
%	O
)	O
.	O
	
Esophagectomy	O
was	O
possible	O
in	O
33	O
patients	O
and	O
a	O
complete	O
resection	O
(	O
R0	O
)	O
was	O
achieved	O
in	O
26	O
(	O
79	O
%	O
)	O
with	O
6	O
pathologic	O
complete	O
responses	O
(	O
pCR	O
)	O
and	O
3	O
near	O
pCR	O
.	O
	
At	O
a	O
median	O
follow-up	O
of	O
39.7	O
months	O
for	O
the	O
surviving	O
patients	O
","	O
the	O
median	O
progression-free	O
and	O
overall	O
survivals	O
were	O
11	O
months	O
(	O
95	O
%	O
CI	O
6.5-14	O
)	O
and	O
18.5	O
months	O
(	O
95	O
%	O
CI	O
13-29	O
)	O
.	O
	
The	O
1-year	O
progression-free	O
and	O
overall	O
survivals	O
were	O
47.5	O
%	O
(	O
95	O
%	O
CI	O
34-59.5	O
%	O
)	O
and	O
63	O
%	O
(	O
95	O
%	O
CI	O
49-74	O
%	O
)	O
.	O
	
Major	O
toxicities	O
were	O
esophagitis	B-TOXI
(	O
20	O
%	O
G3	O
and	O
5	O
%	O
G4	O
)	O
and	O
diarrhea	B-TOXI
(	O
8.5	O
%	O
G3	O
and	O
8.5	O
%	O
G4	O
)	O
.	O
	
Hematological	B-TOXI
toxicity	I-TOXI
(	O
7	O
%	O
G3	O
and	O
3	O
%	O
G4	O
)	O
was	O
less	O
common	O
;	O
severe	B-TOXI
neurotoxicity	I-TOXI
(	O
3	O
%	O
G3	O
)	O
was	O
infrequent	O
.	O
	
Concurrent	O
oxaliplatin	B-DRUG
","	O
leucovorin	B-DRUG
","	O
fluorouracil	B-DRUG
and	O
radiotherapy	O
followed	O
or	O
not	O
by	O
esophagectomy	O
has	O
a	O
tolerable	O
toxicity	O
and	O
promising	O
activity	O
in	O
locally	O
advanced	B-CANCER
esophageal	I-CANCER
cancer	I-CANCER
.	O
	
A	O
phase	O
I	O
trial	O
of	O
pemetrexed	B-DRUG
plus	O
gemcitabine	B-DRUG
given	O
biweekly	O
with	O
B-vitamin	B-DRUG
support	O
in	O
solid	B-CANCER
tumor	I-CANCER
malignancies	I-CANCER
or	O
advanced	B-CANCER
epithelial	I-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
determine	O
the	O
maximally	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
biweekly	O
pemetrexed	B-DRUG
with	O
gemcitabine	B-DRUG
plus	O
B	B-DRUG
(	I-DRUG
12	I-DRUG
)	I-DRUG
and	O
folate	B-DRUG
supplementation	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
and	O
ovarian	B-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
no	O
prior	O
pemetrexed	B-DRUG
or	O
gemcitabine	B-DRUG
therapy	O
enrolled	O
in	O
cohorts	O
of	O
three	O
","	O
expanding	O
to	O
six	O
if	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
was	O
observed	O
.	O
	
Pemetrexed	B-DRUG
","	O
escalated	O
from	O
to	O
700	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
was	O
given	O
before	O
gemcitabine	B-DRUG
"1,500"	O
mg	O
/	O
m	O
(	O
2	O
)	O
every	O
14	O
days	O
.	O
	
DLTs	O
were	O
grade	O
4	O
neutropenia	B-TOXI
lasting	O
&	O
gt	O
;	O
7	O
days	O
or	O
febrile	B-TOXI
neutropenia	I-TOXI
","	O
grade	O
4	O
or	O
3	O
thrombocytopenia	B-TOXI
(	O
with	O
bleeding	B-TOXI
)	O
","	O
grade	O
&	O
gt	O
;	O
or	O
3	O
nonhematologic	B-TOXI
toxicity	I-TOXI
","	O
or	O
treatment	O
delay	O
of	O
&	O
gt	O
;	O
or	O
1	O
week	O
due	O
to	O
unresolved	O
toxicity	O
.	O
	
The	O
ovarian	B-CANCER
cancer	I-CANCER
cohort	O
enrolled	O
24	O
patients	O
with	O
unlimited	O
prior	O
cytotoxic	O
chemotherapies	O
.	O
	
MTD	O
was	O
observed	O
at	O
pemetrexed	B-DRUG
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
with	O
2	O
of	O
9	O
patients	O
experiencing	O
DLT	O
.	O
	
Most	O
common	O
grade	O
3	O
to	O
4	O
toxicities	O
per	O
patient	O
were	O
neutropenia	B-TOXI
(	O
83	O
%	O
)	O
","	O
leukopenia	B-TOXI
(	O
67	O
%	O
)	O
","	O
lymphopenia	B-TOXI
(	O
73	O
%	O
)	O
","	O
and	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
12	O
%	O
)	O
.	O
	
Median	O
cycle	O
per	O
patient	O
was	O
8	O
(	O
range	O
","	O
1月16日	O
)	O
.	O
	
Six	O
of	O
21	O
(	O
28	O
%	O
)	O
patients	O
had	O
confirmed	O
partial	O
responses	O
.	O
	
Study	O
protocol	O
was	O
modified	O
for	O
the	O
solid	B-CANCER
tumor	I-CANCER
cohort	O
(	O
n	O
=	O
30	O
)	O
to	O
enroll	O
patients	O
with	O
two	O
or	O
more	O
prior	O
cytotoxic	O
regimens	O
.	O
	
MTD	O
was	O
observed	O
at	O
pemetrexed	B-DRUG
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
with	O
1	O
of	O
9	O
patients	O
experiencing	O
DLT	O
.	O
	
Most	O
common	O
grade	O
3	O
to	O
4	O
toxicities	O
per	O
patient	O
were	O
neutropenia	B-TOXI
(	O
63	O
%	O
)	O
","	O
lymphopenia	B-TOXI
(	O
43	O
%	O
)	O
","	O
leukopenia	B-TOXI
(	O
70	O
%	O
)	O
and	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
6.6	O
%	O
)	O
.	O
	
Median	O
cycle	O
per	O
patient	O
was	O
4	O
(	O
range	O
","	O
1月20日	O
)	O
.	O
	
Three	O
of	O
29	O
(	O
10.3	O
%	O
)	O
response-evaluable	O
patients	O
had	O
confirmed	O
partial	O
responses	O
:	O
2	O
squamous	B-CANCER
cell	I-CANCER
carcinomas	I-CANCER
of	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
and	O
1	O
nasopharyngeal	B-CANCER
cancer	I-CANCER
.	O
	
MTDs	O
for	O
the	O
solid	B-CANCER
tumor	I-CANCER
and	O
ovarian	B-CANCER
cancer	I-CANCER
cohorts	O
were	O
reached	O
at	O
pemetrexed	B-DRUG
500	O
and	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
respectively	O
","	O
given	O
biweekly	O
with	O
gemcitabine	B-DRUG
"1,500"	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Phase	O
I	O
/	O
II	O
trial	O
of	O
induction	O
chemotherapy	O
followed	O
by	O
concurrent	O
chemoradiotherapy	O
and	O
surgery	O
for	O
locoregionally	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
	
We	O
used	O
a	O
novel	O
combination	O
of	O
induction	O
chemotherapy	O
with	O
gemcitabine	B-DRUG
(	O
GEM	B-DRUG
)	O
and	O
cisplatin	B-DRUG
(	O
CDDP	B-DRUG
)	O
","	O
followed	O
by	O
concurrent	O
chemoradiotherapy	O
(	O
CCRT	O
)	O
with	O
the	O
same	O
agents	O
in	O
patients	O
with	O
locoregionally	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
Surgery	O
or	O
additional	O
chemotherapy	O
followed	O
on	O
the	O
basis	O
of	O
response	O
.	O
	
Patients	O
with	O
borderline	O
resectable	O
or	O
locally	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
received	O
induction	O
weekly	O
with	O
GEM	B-DRUG
(	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
or	O
CDDP	B-DRUG
(	O
30	O
g	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O
	
Patients	O
without	O
progression	B-TOXI
of	I-TOXI
disease	I-TOXI
then	O
underwent	O
surgery	O
or	O
CCRT	O
","	O
including	O
four	O
cohorts	O
of	O
escalating	O
GEM	B-DRUG
/	O
CDDP	B-DRUG
doses	O
combined	O
with	O
full-dose	O
radiotherapy	O
.	O
	
After	O
CCRT	O
","	O
patients	O
deemed	O
resectable	O
underwent	O
surgery	O
;	O
patients	O
with	O
disease	O
that	O
remained	O
unresectable	O
and	O
that	O
did	O
not	O
progress	O
received	O
additional	O
GEM	B-DRUG
/	O
CDDP	B-DRUG
for	O
2	O
months	O
.	O
	
A	O
mean	O
76	O
%	O
of	O
intended	O
GEM	B-DRUG
dose	O
and	O
75	O
%	O
of	O
CDDP	B-DRUG
dose	O
was	O
delivered	O
during	O
induction	O
(	O
n	O
=	O
26	O
)	O
.	O
	
There	O
were	O
three	O
incidences	O
of	O
grade	O
4	O
toxicity	O
(	O
fever	B-TOXI
or	O
neutropenia	B-TOXI
)	O
.	O
	
After	O
induction	O
","	O
five	O
patients	O
progressed	O
and	O
one	O
patient	O
underwent	O
resection	O
.	O
	
Eighteen	O
patients	O
received	O
CCRT	O
","	O
and	O
three	O
patients	O
underwent	O
resection	O
.	O
	
After	O
CCRT	O
","	O
disease	O
of	O
10	O
patients	O
progressed	O
","	O
and	O
in	O
5	O
patients	O
","	O
it	O
remained	O
unresectable	O
without	O
progression	O
","	O
and	O
the	O
patient	O
received	O
additional	O
GEM	B-DRUG
/	O
CDDP	B-DRUG
.	O
	
Dose-limiting	O
toxicity	O
was	O
at	O
dose	O
level	O
IV	O
(	O
thrombocytopenia	B-TOXI
)	O
.	O
	
Median	O
overall	O
and	O
disease-specific	O
survival	O
was	O
13	O
months	O
.	O
	
GEM	B-DRUG
/	O
CDDP	B-DRUG
induction	O
chemotherapy	O
followed	O
by	O
CCRT	O
is	O
well	O
tolerated	O
and	O
rendered	O
the	O
disease	O
of	O
4	O
of	O
26	O
patients	O
resectable	O
in	O
this	O
study	O
.	O
	
The	O
recommended	O
phase	O
II	O
dose	O
for	O
GEM	B-DRUG
and	O
CDDP	B-DRUG
in	O
combination	O
with	O
full-dose	O
radiotherapy	O
(	O
5040	O
cGy	O
)	O
is	O
300	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
for	O
5	O
weeks	O
.	O
	
Median	O
survival	O
in	O
this	O
group	O
was	O
13	O
months	O
.	O
	
This	O
neoadjuvant	O
combined	O
modality	O
approach	O
is	O
both	O
feasible	O
and	O
active	O
;	O
further	O
studies	O
are	O
warranted	O
.	O
	
Phase	O
I	O
trial	O
of	O
oxaliplatin	B-DRUG
with	O
fluorouracil	B-DRUG
","	O
folinic	B-DRUG
acid	I-DRUG
and	O
concurrent	O
radiotherapy	O
for	O
oesophageal	B-CANCER
cancer	I-CANCER
.	O
	
	
This	O
dose	O
escalation	O
study	O
was	O
designed	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
recommended	O
doses	O
(	O
RDs	O
)	O
of	O
5-fluorouracil	B-DRUG
(	O
5FU	B-DRUG
)	O
","	O
folinic	B-DRUG
acid	I-DRUG
and	O
oxaliplatin	B-DRUG
(	O
FOLFOX	B-DRUG
)	O
with	O
concomitant	O
radiotherapy	O
in	O
inoperable	B-CANCER
/	I-CANCER
metastatic	I-CANCER
oesophageal	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
or	O
adenocarcinoma	B-CANCER
.	O
	
Patients	O
received	O
three	O
courses	O
of	O
LV5FU2	B-DRUG
regimen	O
(	O
folinic	B-DRUG
acid	I-DRUG
200	O
mg	O
m	O
(	O
-2	O
)	O
","	O
bolus	O
5FU	B-DRUG
300-400	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
continuous	O
infusion	O
5FU	B-DRUG
400-600	O
mg	O
m	O
(	O
-2	O
)	O
on	O
days	O
1	O
and	O
2	O
)	O
and	O
escalating	O
doses	O
of	O
oxaliplatin	B-DRUG
50	O
to	O
100	O
mg	O
m	O
(	O
-2	O
)	O
on	O
day	O
1	O
(	O
FOLFOX	B-DRUG
)	O
.	O
	
This	O
regimen	O
was	O
repeated	O
every	O
2	O
weeks	O
","	O
concomitant	O
to	O
a	O
50-gray	O
radiotherapy	O
per	O
5	O
weeks	O
.	O
	
Three	O
more	O
cycles	O
were	O
delivered	O
after	O
completion	O
of	O
radiation	O
therapy	O
.	O
	
Three	O
to	O
six	O
patients	O
were	O
allocated	O
to	O
each	O
of	O
the	O
five	O
dose	O
levels	O
until	O
MTD	O
was	O
reached	O
.	O
	
Thirty-three	O
patients	O
were	O
enroled	O
and	O
21	O
had	O
metastatic	O
disease	O
.	O
	
Maximum	O
tolerated	O
dose	O
was	O
oxaliplatin	B-DRUG
100	O
mg	O
m	O
(	O
-2	O
)	O
","	O
and	O
continuous	O
infusion	O
5FU	B-DRUG
was	O
600	O
mg	O
m	O
(	O
-2	O
)	O
day	O
(	O
=-	O
)	O
(	O
level	O
5	O
)	O
.	O
	
The	O
most	O
common	O
toxicities	O
were	O
neutropenia	B-TOXI
","	O
dysphagia	B-TOXI
and	O
oesophagitis	B-TOXI
.	O
	
The	O
RDs	O
were	O
those	O
of	O
FOLFOX-4	B-DRUG
regimen	O
(	O
oxaliplatin	B-DRUG
85	O
mg	O
m	O
(	O
-2	O
)	O
and	O
full	O
doses	O
of	O
LV5FU2	B-DRUG
)	O
.	O
	
The	O
overall	O
response	O
was	O
48.5	O
%	O
","	O
including	O
12	O
%	O
complete	O
response	O
.	O
	
Response	O
rate	O
on	O
primary	O
tumour	O
was	O
62.9	O
%	O
.	O
	
This	O
FOLFOX-4	B-DRUG
regimen	O
was	O
reasonably	O
well	O
tolerated	O
and	O
effective	O
in	O
inoperable	B-CANCER
/	I-CANCER
metastatic	I-CANCER
oesophageal	I-CANCER
carcinoma	I-CANCER
and	O
warrants	O
additional	O
investigation	O
.	O
	
Dose-escalation	O
study	O
of	O
fixed-dose	O
rate	O
gemcitabine	B-DRUG
combined	O
with	O
capecitabine	B-DRUG
in	O
advanced	B-CANCER
solid	I-CANCER
malignancies	I-CANCER
.	O
	
	
To	O
define	O
dose	O
limiting	O
toxicities	O
(	O
DLTs	O
)	O
and	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
capecitabine	B-DRUG
with	O
fixed-dose	O
rate	O
(	O
FDR	O
)	O
gemcitabine	B-DRUG
.	O
	
Eligible	O
adults	O
(	O
advanced	B-CANCER
solid	I-CANCER
tumor	I-CANCER
;	O
performance	O
status	O
&	O
lt	O
;	O
or=2	O
)	O
received	O
capecitabine	B-DRUG
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
PO	O
BID	O
days	O
1月14日	O
and	O
FDR	O
gemcitabine	B-DRUG
(	O
"400-1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
escalated	O
by	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
increments	O
)	O
at	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
min	O
days	O
1	O
and	O
8	O
on	O
a	O
21-day	O
cycle	O
.	O
	
A	O
traditional	O
3	O
=+	O
3	O
cohort	O
design	O
was	O
used	O
to	O
determine	O
the	O
MTD	O
.	O
	
Thirty	O
patients	O
(	O
median	O
age	O
59	O
years	O
)	O
were	O
enrolled	O
.	O
	
The	O
predominant	O
grade	O
&	O
gt	O
;	O
or=3	O
toxicity	O
was	O
myelosuppression	B-TOXI
","	O
particularly	O
neutropenia	B-TOXI
.	O
	
At	O
dose	O
level	O
4	O
(	O
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
gemcitabine	B-DRUG
)	O
","	O
two	O
out	O
of	O
five	O
evaluable	O
patients	O
had	O
a	O
DLT	O
(	O
grade	O
4	O
neutropenia	B-TOXI
&	O
gt	O
;	O
or=7	O
days	O
)	O
.	O
	
At	O
dose	O
level	O
3	O
(	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
gemcitabine	B-DRUG
)	O
","	O
one	O
patient	O
had	O
a	O
DLT	O
(	O
grade	O
3	O
neutropenia	B-TOXI
&	O
gt	O
;	O
or=7	O
days	O
)	O
among	O
six	O
evaluable	O
patients	O
.	O
	
Therefore	O
","	O
the	O
MTD	O
and	O
recommended	O
phase	O
II	O
dose	O
was	O
designated	O
as	O
capecitabine	B-DRUG
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
PO	O
BID	O
days	O
1月14日	O
with	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
FDR	O
gemcitabine	B-DRUG
days	O
1	O
and	O
8	O
infused	O
at	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
min	O
on	O
a	O
21-day	O
cycle	O
.	O
	
Partial	O
responses	O
occurred	O
in	O
pretreated	O
patients	O
with	O
esophageal	O
","	O
renal	O
cell	O
and	O
bladder	B-CANCER
carcinomas	I-CANCER
.	O
	
This	O
regimen	O
was	O
well	O
tolerated	O
and	O
may	O
deserve	O
evaluation	O
in	O
advanced	B-CANCER
gastrointestinal	I-CANCER
and	O
genitourinary	B-CANCER
carcinomas	I-CANCER
.	O
	
Phase	O
I	O
trial	O
of	O
weekly	O
cisplatin	B-DRUG
","	O
irinotecan	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
gastrointestinal	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
toxicities	O
","	O
and	O
suitable	O
dose	O
for	O
weekly	O
1-h	O
paclitaxel	B-DRUG
combined	O
with	O
weekly	O
cisplatin	B-DRUG
and	O
irinotecan	B-DRUG
to	O
treat	O
advanced	B-CANCER
gastrointestinal	I-CANCER
malignancies	I-CANCER
.	O
	
Thirty	O
patients	O
with	O
metastatic	O
or	O
locally	O
advanced	O
(	O
unresectable	O
or	O
recurrent	O
)	O
gastrointestinal	B-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
enrolled	O
on	O
this	O
single-center	O
","	O
phase	O
I	O
study	O
.	O
	
Patients	O
were	O
treated	O
with	O
paclitaxel	B-DRUG
given	O
over	O
1h	O
at	O
1	O
of	O
4	O
dose	O
levels	O
(	O
40	O
","	O
50	O
","	O
65	O
","	O
or	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O
	
Paclitaxel	B-DRUG
was	O
followed	O
by	O
fixed	O
doses	O
of	O
cisplatin	B-DRUG
(	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
irinotecan	B-DRUG
(	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O
	
All	O
treatment	O
was	O
administered	O
sequentially	O
","	O
once	O
a	O
week	O
","	O
in	O
6-week	O
cycles	O
(	O
4	O
weeks	O
on	O
","	O
2	O
weeks	O
off	O
)	O
.	O
	
Dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
was	O
defined	O
as	O
a	O
2-week	O
delay	O
in	O
treatment	O
for	O
grade	O
3	O
or	O
4	O
non-hematologic	B-TOXI
toxicity	I-TOXI
","	O
neutropenic	B-TOXI
fever	I-TOXI
","	O
a	O
1-week	O
delay	O
for	O
grade	O
4	O
hematologic	B-TOXI
toxicity	I-TOXI
","	O
or	O
a	O
2-week	O
delay	O
for	O
grade	O
3	O
hematologic	B-TOXI
toxicity	I-TOXI
.	O
	
Thirty	O
patients	O
were	O
recruited	O
;	O
28	O
patients	O
were	O
assessable	O
for	O
safety	O
.	O
	
Most	O
of	O
the	O
patients	O
(	O
70	O
%	O
)	O
had	O
no	O
prior	O
chemotherapy	O
.	O
	
The	O
primary	O
first-cycle	O
DLTs	O
were	O
neutropenia	B-TOXI
","	O
diarrhea	B-TOXI
","	O
and	O
nausea	B-TOXI
.	O
	
Paclitaxel	B-DRUG
at	O
65	O
mg	O
/	O
m	O
(	O
2	O
)	O
was	O
defined	O
as	O
the	O
MTD	O
.	O
	
The	O
most	O
common	O
grade	O
3月4日	O
toxicities	O
observed	O
during	O
all	O
cycles	O
were	O
neutropenia	B-TOXI
(	O
57	O
%	O
)	O
","	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
11	O
%	O
)	O
","	O
diarrhea	B-TOXI
(	O
29	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
29	O
%	O
)	O
","	O
and	O
nausea	B-TOXI
(	O
18	O
%	O
)	O
.	O
	
No	O
patients	O
had	O
G-CSF	B-DRUG
(	O
Neupogen	O
","	O
Amgen	O
Inc.	O
","	O
Thousand	O
Oaks	O
","	O
CA	O
)	O
support	O
.	O
	
Responses	O
were	O
observed	O
in	O
gastric	O
","	O
esophageal	O
","	O
and	O
pancreatic	B-CANCER
cancers	I-CANCER
.	O
	
Paclitaxel	B-DRUG
at	O
65	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
cisplatin	B-DRUG
(	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
and	O
irinotecan	B-DRUG
(	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
given	O
weekly	O
can	O
be	O
safely	O
administered	O
to	O
patients	O
with	O
solid	B-CANCER
tumor	I-CANCER
malignancies	I-CANCER
.	O
	
To	O
improve	O
cumulative	O
toxicities	O
","	O
a	O
schedule	O
modification	O
was	O
required	O
(	O
3-week	O
cycle	O
;	O
2-on	O
","	O
1-off	O
)	O
Neutropenia	B-TOXI
was	O
the	O
most	O
common	O
DLT	O
.	O
	
This	O
combination	O
showed	O
substantial	O
activity	O
","	O
particularly	O
in	O
patients	O
with	O
gastric	O
and	O
esophageal	B-CANCER
adenocarcinoma	I-CANCER
","	O
and	O
phase	O
II	O
evaluation	O
could	O
be	O
considered	O
.	O
	
Phase	O
II	O
trial	O
of	O
paclitaxel	B-DRUG
and	O
cisplatin	B-DRUG
in	O
patients	O
with	O
extensive	O
stage	O
small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
Cancer	O
and	O
Leukemia	B-CANCER
Group	O
B	O
Trial	O
9430	O
.	O
	
	
Cancer	O
and	O
Leukemia	B-CANCER
Group	O
B	O
trial	O
9430	O
was	O
a	O
randomized	O
phase	O
II	O
trial	O
which	O
investigated	O
the	O
safety	O
and	O
activity	O
of	O
four	O
novel	O
doublets	O
in	O
untreated	O
extensive	O
stage	O
small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
The	O
results	O
of	O
the	O
paclitaxel	B-DRUG
and	O
cisplatin	B-DRUG
arm	O
have	O
not	O
been	O
reported	O
.	O
	
Patients	O
received	O
paclitaxel	B-DRUG
230	O
mg	O
/	O
m	O
followed	O
by	O
cisplatin	B-DRUG
75	O
mg	O
/	O
m	O
on	O
day	O
1	O
every	O
21	O
days	O
.	O
	
All	O
patients	O
received	O
granulocyte	B-DRUG
colony	I-DRUG
stimulating	I-DRUG
factor	I-DRUG
5	O
microg	O
/	O
kg	O
/	O
d	O
beginning	O
on	O
day	O
3	O
of	O
each	O
cycle	O
.	O
	
The	O
patient	O
characteristics	O
of	O
the	O
34	O
patients	O
assigned	O
to	O
this	O
treatment	O
arm	O
were	O
:	O
median	O
age	O
61.5	O
years	O
(	O
range	O
41-82	O
)	O
","	O
male	O
(	O
76	O
%	O
)	O
","	O
performance	O
status	O
0	O
(	O
41	O
%	O
)	O
","	O
1	O
(	O
32	O
%	O
)	O
","	O
and	O
2	O
(	O
26	O
%	O
)	O
.	O
	
An	O
objective	O
response	O
was	O
observed	O
in	O
23	O
patients	O
(	O
68	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
49-83	O
%	O
)	O
;	O
2	O
complete	O
responses	O
(	O
6	O
%	O
)	O
and	O
21	O
partial	O
responses	O
(	O
62	O
%	O
)	O
.	O
	
Median	O
progression-free	O
survival	O
time	O
was	O
5.6	O
months	O
(	O
95	O
%	O
CI	O
:	O
4.8-7.1	O
month	O
)	O
","	O
and	O
median	O
overall	O
survival	O
time	O
was	O
7.7	O
months	O
(	O
95	O
%	O
CI	O
:	O
7.2-12.6	O
months	O
)	O
.	O
	
The	O
1-year	O
survival	O
rate	O
observed	O
was	O
29	O
%	O
(	O
95	O
%	O
CI	O
:	O
15-45	O
%	O
)	O
.	O
	
Grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
was	O
observed	O
in	O
5	O
(	O
15	O
%	O
)	O
and	O
4	O
(	O
12	O
%	O
)	O
patients	O
","	O
respectively	O
.	O
	
Two	O
patients	O
developed	O
febrile	O
neutropenia	B-TOXI
including	O
one	O
patient	O
who	O
died	B-TOXI
of	O
neutropenic	B-TOXI
sepsis	I-TOXI
.	O
	
Grade	O
3	O
/	O
4	O
nonhematologic	O
observed	O
were	O
:	O
sensory	B-TOXI
neuropathy	I-TOXI
in	O
eight	O
patients	O
(	O
24	O
%	O
)	O
;	O
and	O
hyperglycemia	B-TOXI
","	O
malaise	B-TOXI
and	O
nausea	B-TOXI
were	O
all	O
observed	O
in	O
four	O
patients	O
(	O
12	O
%	O
)	O
.	O
	
Cancer	O
and	O
Leukemia	B-CANCER
Group	O
B	O
will	O
not	O
pursue	O
further	O
investigation	O
of	O
paclitaxel	B-DRUG
and	O
cisplatin	B-DRUG
due	O
to	O
the	O
modest	O
activity	O
and	O
the	O
toxicity	O
observed	O
on	O
this	O
trial	O
.	O
	
Phase	O
I	O
study	O
of	O
paclitaxel	B-DRUG
with	O
standard	O
dose	O
ifosfamide	B-DRUG
in	O
children	O
with	O
refractory	O
solid	B-CANCER
tumors	I-CANCER
:	O
a	O
Pediatric	O
Oncology	O
Group	O
study	O
(	O
POG	O
9376	O
)	O
.	O
	
	
A	O
dose-escalation	O
Phase	O
I	O
study	O
of	O
taxol	B-DRUG
(	O
paclitaxel	B-DRUG
)	O
administered	O
in	O
combination	O
with	O
standard	O
dose	O
ifosfamide	B-DRUG
was	O
conducted	O
in	O
children	O
with	O
relapsed	O
or	O
refractory	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
Primary	O
objectives	O
were	O
to	O
estimate	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
to	O
describe	O
the	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
.	O
	
Paclitaxel	B-DRUG
was	O
administered	O
as	O
a	O
6-hr	O
continuous	O
infusion	O
(	O
hr	O
0-6	O
)	O
","	O
followed	O
by	O
intravenous	O
ifosfamide	B-DRUG
(	O
2	O
g	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
x	O
3	O
days	O
)	O
over	O
1	O
hr	O
at	O
hours	O
6月7日	O
","	O
24-25	O
","	O
and	O
48-49	O
.	O
	
Patients	O
at	O
dose	O
level	O
1	O
received	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
paclitaxel	B-DRUG
.	O
	
Subsequent	O
dose	O
escalation	O
proceeded	O
using	O
a	O
standard	O
3	O
x	O
3	O
Phase	O
I	O
design	O
.	O
	
Fifteen	O
patients	O
received	O
a	O
combined	O
46	O
courses	O
of	O
therapy	O
.	O
	
The	O
median	O
age	O
was	O
14.5	O
years	O
(	O
range	O
","	O
2月19日	O
years	O
)	O
","	O
and	O
diagnoses	O
included	O
sarcoma	B-TOXI
(	O
7	O
)	O
","	O
neuroblastoma	B-TOXI
(	O
3	O
)	O
","	O
and	O
other	O
(	O
5	O
)	O
.	O
	
Three	O
patients	O
received	O
paclitaxel	B-DRUG
at	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
10	O
courses	O
)	O
","	O
six	O
at	O
325	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
19	O
courses	O
)	O
","	O
three	O
at	O
425	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
8	O
courses	O
)	O
","	O
and	O
three	O
at	O
550	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
9	O
courses	O
)	O
.	O
	
DLTs	O
occurred	O
in	O
2	O
/	O
3	O
patients	O
at	O
550	O
mg	O
/	O
m	O
(	O
2	O
)	O
paclitaxel	B-DRUG
during	O
cycle	O
1	O
","	O
including	O
grade	O
3	O
hypotension	B-TOXI
and	O
grade	O
4	O
anaphylaxis	B-TOXI
in	O
1	O
patient	O
each	O
.	O
	
Common	O
non-dose-limiting	O
toxicities	O
included	O
bone	B-TOXI
marrow	I-TOXI
suppression	I-TOXI
and	O
peripheral	B-TOXI
neuropathy	I-TOXI
.	O
	
Response	O
was	O
evaluable	O
in	O
14	O
patients	O
and	O
included	O
mixed	O
response	O
(	O
3	O
)	O
","	O
stable	O
disease	O
(	O
5	O
)	O
","	O
and	O
progressive	O
disease	O
(	O
6	O
)	O
.	O
	
Paclitaxel	B-DRUG
hypersensitivity	B-TOXI
reactions	I-TOXI
were	O
dose	O
limiting	O
when	O
the	O
drug	O
was	O
administered	O
as	O
a	O
6-hr	O
infusion	O
.	O
	
The	O
MTD	O
and	O
recommended	O
Phase	O
II	O
dose	O
of	O
paclitaxel	B-DRUG
administered	O
as	O
a	O
6-hr	O
continuous	O
intravenous	O
infusion	O
followed	O
by	O
standard	O
dose	O
intravenous	O
ifosfamide	B-DRUG
is	O
425	O
mg	O
/	O
m	O
(	O
2	O
)	O
paclitaxel	B-DRUG
.	O
	
Randomized	O
phase	O
II	O
study	O
of	O
pulse	O
erlotinib	B-DRUG
before	O
or	O
after	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
current	O
or	O
former	O
smokers	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
A	O
prior	O
study	O
demonstrated	O
that	O
addition	O
of	O
continuous	O
daily	O
erlotinib	B-DRUG
fails	O
to	O
improve	O
response	O
rate	O
or	O
survival	O
in	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
patients	O
treated	O
with	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
.	O
	
However	O
","	O
preclinical	O
data	O
support	O
the	O
hypothesis	O
that	O
intermittent	O
administration	O
of	O
erlotinib	B-DRUG
before	O
or	O
after	O
chemotherapy	O
may	O
improve	O
efficacy	O
.	O
	
We	O
tested	O
this	O
hypothesis	O
in	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
Eligible	O
patients	O
were	O
former	O
or	O
current	O
smokers	O
with	O
chemotherapy-naive	O
stage	O
IIIB	O
or	O
IV	O
NSCLC	B-CANCER
.	O
	
All	O
patients	O
received	O
up	O
to	O
six	O
cycles	O
of	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
=	O
6	O
)	O
and	O
paclitaxel	B-DRUG
(	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
with	O
random	O
assignment	O
to	O
one	O
of	O
the	O
following	O
three	O
erlotinib	B-DRUG
treatments	O
:	O
erlotinib	B-DRUG
150	O
mg	O
on	O
days	O
1	O
and	O
2	O
with	O
chemotherapy	O
on	O
day	O
3	O
(	O
150	O
PRE	O
)	O
;	O
erlotinib	B-DRUG
"1,500"	O
mg	O
on	O
days	O
1	O
and	O
2	O
with	O
chemotherapy	O
on	O
day	O
3	O
(	O
"1,500"	O
PRE	O
)	O
;	O
or	O
chemotherapy	O
on	O
day	O
1	O
with	O
erlotinib	O
"1,500"	O
mg	O
on	O
days	O
2	O
and	O
3	O
(	O
"1,500"	O
POST	O
)	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
response	O
rate	O
.	O
	
Eighty-six	O
patients	O
received	O
treatment	O
.	O
	
The	O
response	O
rates	O
for	O
the	O
150	O
PRE	O
","	O
"1,500"	O
PRE	O
","	O
and	O
"1,500"	O
POST	O
arms	O
were	O
18	O
%	O
(	O
five	O
of	O
28	O
patients	O
)	O
","	O
34	O
%	O
(	O
10	O
of	O
29	O
patients	O
)	O
","	O
and	O
28	O
%	O
(	O
eight	O
of	O
29	O
patients	O
)	O
","	O
respectively	O
.	O
	
The	O
median	O
overall	O
survival	O
times	O
were	O
10	O
","	O
15	O
","	O
and	O
10	O
months	O
for	O
the	O
150	O
PRE	O
","	O
"1,500"	O
PRE	O
","	O
and	O
"1,500"	O
POST	O
arms	O
","	O
respectively	O
.	O
	
The	O
most	O
common	O
grade	O
3	O
and	O
4	O
toxicities	O
were	O
neutropenia	B-TOXI
(	O
39	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
15	O
%	O
)	O
","	O
and	O
anemia	B-TOXI
(	O
12	O
%	O
)	O
.	O
	
Grade	O
3	O
and	O
4	O
rash	B-TOXI
and	O
diarrhea	B-TOXI
were	O
uncommon	O
.	O
	
Patients	O
treated	O
on	O
the	O
"1,500"	O
PRE	O
arm	O
had	O
the	O
highest	O
response	O
rate	O
and	O
longest	O
survival	O
","	O
with	O
ranges	O
similar	O
to	O
those	O
reported	O
for	O
carboplatin	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
and	O
bevacizumab	B-DRUG
in	O
a	O
more	O
restricted	O
population	O
.	O
	
Further	O
evaluation	O
of	O
this	O
strategy	O
in	O
a	O
phase	O
III	O
trial	O
is	O
proposed	O
.	O
	
A	O
phase	O
II	O
study	O
of	O
imatinib	B-DRUG
mesylate	I-DRUG
and	O
capecitabine	B-DRUG
in	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
:	O
Southwest	O
Oncology	O
Group	O
Study	O
338	O
.	O
	
	
Imatinib	B-DRUG
mesylate	I-DRUG
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
Bcr-Abl	O
","	O
c-Kit	O
","	O
and	O
platelet-derived	O
growth	O
factor	O
receptor	O
(	O
PDGFR	O
)	O
tyrosine	O
kinases	O
.	O
	
On	O
the	O
basis	O
of	O
variable	O
expression	O
of	O
c-Kit	O
and	O
PDGFR	O
in	O
breast	B-CANCER
cancer	I-CANCER
and	O
of	O
in	O
vitro	O
data	O
supporting	O
synergy	O
between	O
imatinib	B-DRUG
and	O
capecitabine	B-DRUG
","	O
the	O
Southwest	O
Oncology	O
Group	O
conducted	O
a	O
phase	O
II	O
trial	O
of	O
the	O
combination	O
in	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Eligible	O
patients	O
had	O
progressive	O
","	O
measurable	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
and	O
received	O
&	O
lt	O
;	O
or=2	O
previous	O
chemotherapy	O
regimens	O
for	O
metastatic	O
disease	O
.	O
	
Previous	O
5-fluorouracil	B-DRUG
or	O
capecitabine	B-DRUG
for	O
metastatic	O
disease	O
was	O
not	O
allowed	O
.	O
	
Patients	O
were	O
accrued	O
on	O
a	O
2-stage	O
design	O
and	O
received	O
imatinib	B-DRUG
mesylate	I-DRUG
400	O
mg	O
by	O
mouth	O
daily	O
and	O
capecitabine	B-DRUG
at	O
1000	O
mg	O
/	O
m2	O
by	O
mouth	O
twice	O
daily	O
for	O
14	O
days	O
of	O
a	O
21-day	O
cycle	O
.	O
	
The	O
primary	O
endpoint	O
was	O
the	O
confirmed	O
response	O
rate	O
(	O
RR	O
)	O
.	O
	
Tumors	O
were	O
evaluated	O
for	O
c-Kit	O
","	O
PDGFR-beta	O
","	O
and	O
hormone	O
receptor	O
expression	O
.	O
	
Nineteen	O
fully	O
evaluable	O
patients	O
were	O
enrolled	O
","	O
with	O
a	O
confirmed	O
RR	O
of	O
11	O
%	O
(	O
95	O
%	O
CI	O
","	O
1	O
%	O
-33	O
%	O
)	O
.	O
	
Eleven	O
percent	O
had	O
unconfirmed	O
partial	O
responses	O
","	O
and	O
42	O
%	O
had	O
stable	O
disease	O
.	O
	
The	O
trial	O
did	O
not	O
accrue	O
to	O
the	O
second	O
stage	O
.	O
	
The	O
estimated	O
6-month	O
progression-free	O
survival	O
was	O
16	O
%	O
(	O
95	O
%	O
CI	O
","	O
0	O
%	O
-32	O
%	O
)	O
","	O
and	O
the	O
median	O
overall	O
survival	O
was	O
14	O
months	O
(	O
95	O
%	O
CI	O
","	O
7月15日	O
months	O
)	O
.	O
	
The	O
combination	O
was	O
well	O
tolerated	O
.	O
	
Of	O
8	O
available	O
tumor	O
samples	O
","	O
2	O
stained	O
for	O
c-Kit	O
","	O
and	O
all	O
had	O
stromal	O
staining	O
for	O
PDGFR-beta	O
.	O
	
In	O
unselected	O
patients	O
","	O
the	O
combination	O
of	O
imatinib	B-DRUG
mesylate	I-DRUG
and	O
capecitabine	B-DRUG
was	O
well	O
tolerated	O
but	O
did	O
not	O
result	O
in	O
improved	O
RRs	O
compared	O
to	O
those	O
reported	O
with	O
capecitabine	B-DRUG
alone	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
Triapine	B-DRUG
in	O
combination	O
with	O
doxorubicin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
To	O
assess	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
","	O
pharmacokinetics	O
and	O
antitumor	O
activity	O
of	O
Triapine	B-DRUG
administered	O
in	O
combination	O
with	O
doxorubicin	B-DRUG
.	O
	
Patients	O
were	O
treated	O
with	O
doxorubicin	B-DRUG
intravenously	O
(	O
IV	O
)	O
on	O
day	O
1	O
and	O
Triapine	B-DRUG
IV	O
on	O
days	O
1月4日	O
of	O
a	O
21-day	O
cycle	O
.	O
	
The	O
starting	O
dose	O
(	O
level	O
1	O
)	O
was	O
doxorubicin	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
Triapine	B-DRUG
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
PK	O
analysis	O
was	O
performed	O
at	O
various	O
time-points	O
before	O
and	O
after	O
treatment	O
.	O
	
Twenty	O
patients	O
received	O
a	O
total	O
of	O
49	O
courses	O
of	O
treatment	O
on	O
study	O
.	O
	
At	O
dose	O
level	O
2	O
(	O
doxorubicin	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
Triapine	B-DRUG
45	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
two	O
patients	O
experienced	O
DLTs	O
(	O
febrile	B-TOXI
neutropenia	I-TOXI
","	O
grade	O
4	O
thrombocytopenia	B-TOXI
)	O
.	O
	
An	O
additional	O
three	O
patients	O
were	O
enrolled	O
at	O
dose	O
level	O
1	O
without	O
initial	O
toxicity	O
.	O
	
Enrollment	O
then	O
resumed	O
at	O
dose	O
level	O
2a	O
with	O
a	O
decreased	O
dose	O
of	O
doxorubicin	B-DRUG
(	O
45	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
with	O
Triapine	B-DRUG
45	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
The	O
two	O
patients	O
enrolled	O
on	O
this	O
level	O
had	O
two	O
DLTs	O
(	O
diarrhea	O
","	O
CVA	O
)	O
.	O
	
Enrollment	O
was	O
planned	O
to	O
resume	O
at	O
dose	O
level	O
1	O
;	O
however	O
","	O
the	O
sixth	O
patient	O
enrolled	O
to	O
this	O
cohort	O
developed	O
grade	O
5	O
heart	B-TOXI
failure	I-TOXI
(	O
ejection	O
fraction	O
20	O
%	O
","	O
pretreatment	O
EF	O
62	O
%	O
)	O
after	O
the	O
second	O
course	O
.	O
	
Thus	O
","	O
doxorubicin	B-DRUG
and	O
Triapine	B-DRUG
were	O
reduced	O
to	O
45	O
and	O
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
respectively	O
(	O
level	O
1a	O
)	O
","	O
prior	O
to	O
resuming	O
enrollment	O
at	O
dose	O
level	O
1	O
","	O
the	O
MTD	O
.	O
	
The	O
main	O
drug-related	O
toxicity	O
was	O
myelosuppression	B-TOXI
.	O
	
Non-hematologic	B-TOXI
toxicities	I-TOXI
included	O
mild-to-moderate	O
fatigue	B-TOXI
","	O
grade	O
3	O
diarrhea	B-TOXI
and	O
grade	O
4	O
CVA	O
.	O
	
There	O
was	O
one	O
treatment-related	O
death	B-TOXI
due	O
to	O
heart	B-TOXI
failure	I-TOXI
.	O
	
While	O
no	O
objective	O
responses	O
were	O
observed	O
","	O
subjective	O
evidence	O
of	O
clinical	O
activity	O
was	O
observed	O
in	O
patients	O
with	O
refractory	O
melanoma	B-CANCER
and	O
prostate	B-CANCER
cancer	I-CANCER
.	O
	
Pretreated	O
patients	O
with	O
advanced	B-CANCER
malignancies	I-CANCER
can	O
tolerate	O
the	O
combination	O
of	O
Triapine	B-DRUG
and	O
doxorubicin	B-DRUG
at	O
doses	O
that	O
achieve	O
subjective	O
clinical	O
benefit	O
with	O
the	O
main	O
treatment-related	O
toxicities	O
being	O
myelosuppression	B-TOXI
and	O
fatigue	B-TOXI
.	O
	
The	O
MTD	O
was	O
determined	O
to	O
be	O
doxorubicin	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
and	O
Triapine	B-DRUG
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1月4日	O
of	O
a	O
21-day	O
cycle	O
.	O
	
Phase	O
II	O
trial	O
of	O
weekly	O
nab	B-DRUG
(	O
nanoparticle	B-DRUG
albumin-bound	I-DRUG
)	O
#NAME?	B-DRUG
(	O
nab-paclitaxel	B-DRUG
)	O
(	O
Abraxane	O
)	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
N0531	O
)	O
.	O
	
	
Nanoparticle	B-DRUG
albumin-bound	I-DRUG
(	O
nab	B-DRUG
)	O
#NAME?	B-DRUG
has	O
better	O
efficacy	O
and	O
practically	O
eliminates	O
the	O
risk	O
of	O
hypersensitivity	B-TOXI
reactions	I-TOXI
associated	O
with	O
solvent-based	O
paclitaxel	B-DRUG
.	O
	
We	O
studied	O
weekly	O
nab-paclitaxel	B-DRUG
and	O
gemcitabine	B-DRUG
combination	O
in	O
an	O
open-label	O
one-stage	O
","	O
phase	O
II	O
trial	O
in	O
patients	O
with	O
previously	O
untreated	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
MBC	B-CANCER
)	O
.	O
	
Nab-paclitaxel	B-DRUG
(	O
125	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
gemcitabine	B-DRUG
(	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
were	O
administered	O
on	O
days	O
1	O
and	O
8	O
of	O
a	O
21-day	O
cycle	O
until	O
disease	O
progression	O
.	O
	
Fifty	O
patients	O
were	O
enrolled	O
.	O
	
Forty	O
(	O
80	O
%	O
)	O
had	O
visceral	O
organ	O
involvement	O
and	O
30	O
(	O
60	O
%	O
)	O
had	O
&	O
gt	O
;	O
or=	O
3	O
sites	O
of	O
metastases	O
.	O
	
Four	O
(	O
8	O
%	O
)	O
and	O
21	O
(	O
42	O
%	O
)	O
patients	O
had	O
complete	O
and	O
partial	O
responses	O
by	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	B-CANCER
Tumors	I-CANCER
(	O
RECIST	O
)	O
criteria	O
.	O
	
Median	O
duration	O
of	O
response	O
was	O
6.9	O
months	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
5.7	O
","	O
not	O
reached	O
]	O
","	O
median	O
progression-free	O
survival	O
(	O
PFS	O
)	O
7.9	O
months	O
(	O
95	O
%	O
CI	O
5.4-10	O
months	O
)	O
","	O
and	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
not	O
reached	O
.	O
	
PFS	O
and	O
OS	O
at	O
6	O
months	O
were	O
60	O
%	O
(	O
95	O
%	O
CI	O
48	O
%	O
to	O
76	O
%	O
)	O
and	O
92	O
%	O
(	O
95	O
%	O
CI	O
85	O
%	O
to	O
100	O
%	O
)	O
","	O
respectively	O
.	O
	
Therapy	O
was	O
well	O
tolerated	O
.	O
	
Neutropenia	B-TOXI
was	O
commonest	O
toxicity	O
(	O
42	O
%	O
and	O
12	O
%	O
grades	O
3	O
and	O
4	O
neutropenia	B-TOXI
)	O
.	O
	
Only	O
one	O
patient	O
developed	O
febrile	B-TOXI
neutropenia	I-TOXI
.	O
	
Significant	O
activity	O
and	O
favorable	O
toxicity	O
profile	O
provides	O
a	O
basis	O
for	O
considering	O
this	O
regimen	O
for	O
further	O
evaluation	O
in	O
phase	O
III	O
trials	O
or	O
in	O
combination	O
with	O
biologic	O
agents	O
.	O
	
Phase	O
2	O
trial	O
of	O
carboplatin	B-DRUG
","	O
weekly	O
paclitaxel	B-DRUG
","	O
and	O
biweekly	O
bevacizumab	B-DRUG
in	O
patients	O
with	O
unresectable	O
stage	O
IV	O
melanoma	B-CANCER
:	O
a	O
North	O
Central	O
Cancer	O
Treatment	O
Group	O
study	O
","	O
N047A	O
.	O
	
	
Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
growth	O
and	O
metastatic	O
progression	O
of	O
melanoma	B-CANCER
.	O
	
Exposure	O
of	O
melanoma	B-CANCER
cells	O
to	O
chemotherapy	O
induces	O
VEGF	O
overproduction	O
","	O
which	O
in	O
turn	O
may	O
allow	O
melanoma	B-CANCER
cells	O
to	O
evade	O
cell	O
death	O
and	O
become	O
chemotherapy	O
resistant	O
.	O
	
Therefore	O
","	O
in	O
patients	O
with	O
metastatic	B-CANCER
melanoma	I-CANCER
","	O
the	O
combination	O
of	O
chemotherapy	O
with	O
an	O
agent	O
that	O
specifically	O
targets	O
VEGF	O
might	O
be	O
able	O
to	O
control	O
tumor	O
growth	O
and	O
progression	O
more	O
effectively	O
than	O
chemotherapy	O
alone	O
.	O
	
A	O
2-stage	O
phase	O
2	O
clinical	O
trial	O
was	O
conducted	O
in	O
patients	O
with	O
unresectable	O
stage	O
IV	O
(	O
metastatic	O
)	O
melanoma	B-CANCER
to	O
assess	O
antitumor	O
activity	O
and	O
the	O
toxicity	O
profile	O
of	O
the	O
combination	O
of	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
6	O
iv	O
on	O
Day	O
1	O
of	O
a	O
28-day	O
cycle	O
)	O
","	O
paclitaxel	B-DRUG
(	O
80	O
mg	O
/	O
m2	O
iv	O
on	O
Days	O
1	O
","	O
8	O
","	O
and	O
15	O
)	O
","	O
and	O
bevacizumab	B-DRUG
(	O
10	O
mg	O
/	O
kg	O
iv	O
on	O
Days	O
1	O
and	O
15	O
)	O
.	O
	
Treatment	O
was	O
continued	O
until	O
progression	O
or	O
intolerable	O
toxicity	O
.	O
	
Fifty-three	O
patients	O
(	O
62.3	O
%	O
male	O
)	O
were	O
enrolled	O
.	O
	
Nine	O
(	O
17	O
%	O
)	O
patients	O
achieved	O
partial	O
remission	O
","	O
and	O
another	O
30	O
(	O
57	O
%	O
)	O
achieved	O
stable	O
disease	O
for	O
at	O
least	O
8	O
weeks	O
.	O
	
Median	O
progression-free	O
survival	O
and	O
median	O
overall	O
survival	O
were	O
6	O
months	O
and	O
12	O
months	O
","	O
respectively	O
.	O
	
One	O
patient	O
died	B-TOXI
after	O
8	O
treatment	O
cycles	O
from	O
intracranial	B-TOXI
hemorrhage	I-TOXI
into	O
undiagnosed	O
brain	O
metastases	O
.	O
	
The	O
most	O
common	O
severe	O
(	O
grade	O
&	O
gt	O
;	O
or=3	O
)	O
toxicities	O
were	O
neutropenia	B-TOXI
(	O
53	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
11	O
%	O
)	O
","	O
hypertension	B-TOXI
(	O
9	O
%	O
)	O
","	O
and	O
anemia	B-TOXI
(	O
8	O
%	O
)	O
.	O
	
This	O
combination	O
of	O
carboplatin	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
and	O
bevacizumab	B-DRUG
appears	O
to	O
be	O
moderately	O
well	O
tolerated	O
and	O
clinically	O
beneficial	O
in	O
patients	O
with	O
metastatic	B-CANCER
melanoma	I-CANCER
.	O
	
Further	O
study	O
of	O
this	O
combination	O
is	O
warranted	O
.	O
	
Safety	O
and	O
pharmacokinetics	O
of	O
paclitaxel	B-DRUG
and	O
the	O
oral	O
mTOR	O
inhibitor	O
everolimus	B-DRUG
in	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
	
Everolimus	B-DRUG
displays	O
antiproliferative	O
effects	O
on	O
cancer	O
cells	O
","	O
yields	O
antiangiogenic	O
activity	O
in	O
established	O
tumours	O
","	O
and	O
shows	O
synergistic	O
activity	O
with	O
paclitaxel	B-DRUG
in	O
preclinical	O
models	O
.	O
	
This	O
study	O
assessed	O
the	O
safety	O
and	O
the	O
pharmacokinetic	O
interactions	O
of	O
everolimus	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
malignancies	I-CANCER
.	O
	
Everolimus	B-DRUG
was	O
dose	O
escalated	O
from	O
15	O
to	O
30	O
mg	O
and	O
administered	O
with	O
paclitaxel	B-DRUG
80	O
mg	O
m	O
(	O
-2	O
)	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
every	O
28	O
days	O
.	O
	
Safety	O
was	O
assessed	O
weekly	O
","	O
and	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
was	O
evaluated	O
in	O
cycle	O
1	O
A	O
total	O
of	O
16	O
patients	O
(	O
median	O
age	O
54.5	O
years	O
","	O
range	O
33-69	O
)	O
were	O
entered	O
;	O
11	O
had	O
prior	O
taxane	B-DRUG
therapy	O
for	O
breast	O
(	O
n=5	O
)	O
","	O
ovarian	O
(	O
n=3	O
)	O
","	O
and	O
vaginal	B-CANCER
cancer	I-CANCER
(	O
n=1	O
)	O
or	O
angiosarcoma	B-CANCER
(	O
n=2	O
)	O
.	O
	
Grade	O
3	O
neutropenia	B-TOXI
in	O
six	O
patients	O
met	O
the	O
criteria	O
for	O
DLT	O
in	O
two	O
patients	O
receiving	O
everolimus	B-DRUG
30	O
mg	O
weekly	O
.	O
	
Other	O
drug-related	O
grade	O
3	O
toxicities	O
were	O
leucopenia	B-TOXI
","	O
anaemia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
stomatitis	B-TOXI
","	O
asthenia	B-TOXI
","	O
and	O
increased	B-TOXI
liver	I-TOXI
enzymes	I-TOXI
.	O
	
Tumour	O
stabilisation	O
reported	O
in	O
11	O
patients	O
exceeded	O
6	O
months	O
in	O
2	O
patients	O
with	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
Everolimus	B-DRUG
showed	O
an	O
acceptable	O
safety	O
profile	O
at	O
the	O
dose	O
of	O
30	O
mg	O
when	O
combined	O
with	O
weekly	O
paclitaxel	B-DRUG
80	O
mg	O
m	O
(	O
-2	O
)	O
","	O
warranting	O
further	O
clinical	O
investigation	O
.	O
	
Phase	O
II	O
study	O
and	O
biomarker	O
analysis	O
of	O
cetuximab	B-DRUG
combined	O
with	O
modified	O
FOLFOX6	B-DRUG
in	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
	
This	O
prospective	O
study	O
was	O
conducted	O
with	O
the	O
Korean	O
Cancer	O
Study	O
Group	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
cetuximab	B-DRUG
combined	O
with	O
modified	O
FOLFOX6	B-DRUG
(	O
mFOLFOX6	B-DRUG
)	O
as	O
first-line	O
treatment	O
in	O
recurrent	B-CANCER
or	I-CANCER
metastatic	I-CANCER
gastric	I-CANCER
cancer	I-CANCER
and	O
to	O
identify	O
potential	O
predictive	O
biomarkers	O
.	O
	
Patients	O
received	O
cetuximab	B-DRUG
400	O
mg	O
m	O
(	O
-2	O
)	O
at	O
week	O
1	O
and	O
250	O
mg	O
m	O
(	O
-2	O
)	O
weekly	O
thereafter	O
until	O
disease	O
progression	O
.	O
	
Oxaliplatin	B-DRUG
(	O
100	O
mg	O
m	O
(	O
-2	O
)	O
)	O
and	O
leucovorin	B-DRUG
(	O
100	O
mg	O
m	O
(	O
-2	O
)	O
)	O
were	O
administered	O
as	O
a	O
2-h	O
infusion	O
followed	O
by	O
a	O
46-h	O
continuous	O
infusion	O
of	O
5-fluorouracil	B-DRUG
(	O
2400	O
mg	O
m	O
(	O
-2	O
)	O
)	O
every	O
2	O
weeks	O
for	O
a	O
maximum	O
of	O
12	O
cycles	O
.	O
	
Biomarkers	O
potentially	O
associated	O
with	O
efficacy	O
were	O
analysed	O
.	O
	
Among	O
38	O
evaluable	O
patients	O
","	O
confirmed	O
response	O
rate	O
(	O
RR	O
)	O
was	O
50	O
%	O
(	O
95	O
%	O
CI	O
34.1-65.9	O
)	O
.	O
	
Median	O
time-to-progression	O
(	O
TTP	O
)	O
was	O
5.5	O
months	O
(	O
95	O
%	O
CI	O
4.5-6.5	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
9.9	O
months	O
.	O
	
Eleven	O
patients	O
having	O
tumour	O
EGFR	O
expression	O
by	O
immunohistochemistry	O
with	O
low	O
serum	O
EGF	O
and	O
TGF-alpha	O
levels	O
showed	O
a	O
100	O
%	O
RR	O
compared	O
to	O
37	O
%	O
in	O
the	O
remaining	O
27	O
patients	O
(	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
.	O
	
Moreover	O
","	O
ligand	O
level	O
increased	O
when	O
disease	B-TOXI
progressed	I-TOXI
in	O
seven	O
out	O
of	O
eight	O
patients	O
with	O
EGFR	O
expression	O
and	O
low	O
baseline	O
ligand	O
level	O
.	O
	
No	O
patient	O
exhibited	O
EGFR	O
amplification	O
or	O
K-ras	O
mutations	O
.	O
	
Gastric	B-CANCER
cancer	I-CANCER
patients	O
with	O
EGFR	O
expression	O
and	O
low	O
ligand	O
levels	O
had	O
better	O
outcomes	O
with	O
cetuximab	B-DRUG
/	O
mFOLFOX6	B-DRUG
treatment	O
.	O
	
Phase	O
III	O
trial	O
of	O
cisplatin	B-DRUG
plus	O
gemcitabine	B-DRUG
with	O
either	O
placebo	B-DRUG
or	O
bevacizumab	B-DRUG
as	O
first-line	O
therapy	O
for	O
nonsquamous	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
AVAil	O
.	O
	
	
Bevacizumab	B-DRUG
","	O
a	O
monoclonal	O
antibody	O
targeting	O
vascular	B-DRUG
endothelial	I-DRUG
growth	I-DRUG
factor	I-DRUG
","	O
improves	O
survival	O
when	O
combined	O
with	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
for	O
advanced	B-CANCER
nonsquamous	I-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
This	O
randomized	O
phase	O
III	O
trial	O
investigated	O
the	O
efficacy	O
and	O
safety	O
of	O
cisplatin	B-DRUG
/	O
gemcitabine	B-DRUG
(	O
CG	O
)	O
plus	O
bevacizumab	B-DRUG
in	O
this	O
setting	O
.	O
	
Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
cisplatin	B-DRUG
80	O
mg	O
/	O
m2	O
and	O
gemcitabine	B-DRUG
"1,250"	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
up	O
to	O
six	O
cycles	O
plus	O
low-dose	O
bevacizumab	B-DRUG
(	O
7.5	O
mg	O
/	O
kg	O
)	O
","	O
high-dose	O
bevacizumab	B-DRUG
(	O
15	O
mg	O
/	O
kg	O
)	O
","	O
or	O
placebo	B-DRUG
every	O
3	O
weeks	O
until	O
disease	O
progression	O
.	O
	
The	O
trial	O
was	O
not	O
powered	O
to	O
compare	O
the	O
two	O
doses	O
directly	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
amended	O
from	O
overall	O
survival	O
(	O
OS	O
)	O
to	O
progression-free	O
survival	O
(	O
PFS	O
)	O
.	O
	
Between	O
February	O
2005	O
and	O
August	O
2006	O
","	O
"1,043"	O
patients	O
were	O
randomly	O
assigned	O
(	O
placebo	O
","	O
n	O
=	O
347	O
;	O
low	O
dose	O
","	O
n	O
=	O
345	O
;	O
high	O
dose	O
","	O
n	O
=	O
351	O
)	O
.	O
	
PFS	O
was	O
significantly	O
prolonged	O
;	O
the	O
hazard	O
ratios	O
for	O
PFS	O
were	O
0.75	O
(	O
median	O
PFS	O
","	O
6.7	O
v	O
6.1	O
months	O
for	O
placebo	O
;	O
P	O
=	O
0.003	O
)	O
in	O
the	O
low-dose	O
group	O
and	O
0.82	O
(	O
median	O
PFS	O
","	O
6.5	O
v	O
6.1	O
months	O
for	O
placebo	O
;	O
P	O
=	O
0.03	O
)	O
in	O
the	O
high-dose	O
group	O
compared	O
with	O
placebo	O
.	O
	
Objective	O
response	O
rates	O
were	O
20.1	O
%	O
","	O
34.1	O
%	O
","	O
and	O
30.4	O
%	O
for	O
placebo	O
","	O
low-dose	O
bevacizumab	B-DRUG
","	O
and	O
high-dose	O
bevacizumab	B-DRUG
plus	O
CG	O
","	O
respectively	O
.	O
	
Duration	O
of	O
follow-up	O
was	O
not	O
sufficient	O
for	O
OS	O
analysis	O
.	O
	
Incidence	O
of	O
grade	O
3	O
or	O
greater	O
adverse	O
events	O
was	O
similar	O
across	O
arms	O
.	O
	
Grade	O
&	O
gt	O
;	O
or	O
=	O
3	O
pulmonary	B-TOXI
hemorrhage	I-TOXI
rates	O
were	O
&	O
lt	O
;	O
or	O
=	O
1.5	O
%	O
for	O
all	O
arms	O
despite	O
9	O
%	O
of	O
patients	O
receiving	O
therapeutic	O
anticoagulation	O
.	O
	
Combining	O
bevacizumab	B-DRUG
(	O
7.5	O
or	O
15	O
mg	O
/	O
kg	O
)	O
with	O
CG	O
significantly	O
improved	O
PFS	O
and	O
objective	O
response	O
rate	O
.	O
	
Bevacizumab	B-DRUG
plus	O
platinum-based	O
chemotherapy	O
offers	O
clinical	O
benefit	O
for	O
bevacizumab-eligible	B-DRUG
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
Mitoxantrone	B-DRUG
","	O
fluorouracil	B-DRUG
","	O
and	O
high-dose	O
leucovorin	B-DRUG
:	O
an	O
effective	O
","	O
well-tolerated	O
regimen	O
for	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
Between	O
September	O
1988	O
and	O
August	O
1990	O
","	O
we	O
treated	O
35	O
women	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
with	O
a	O
novel	O
regimen	O
containing	O
mitoxantrone	B-DRUG
","	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
and	O
high-dose	O
leucovorin	B-DRUG
.	O
	
This	O
regimen	O
was	O
designed	O
to	O
take	O
full	O
advantage	O
of	O
the	O
favorable	O
toxicity	O
profiles	O
of	O
these	O
agents	O
while	O
maintaining	O
a	O
high	O
level	O
of	O
activity	O
.	O
	
All	O
patients	O
had	O
received	O
previous	O
chemotherapy	O
(	O
adjuvant	O
only	O
","	O
15	O
patients	O
;	O
at	O
least	O
one	O
metastatic	O
regimen	O
","	O
20	O
patients	O
)	O
.	O
	
Seven	O
patients	O
had	O
received	O
previous	O
doxorubicin	B-DRUG
","	O
but	O
none	O
within	O
6	O
months	O
of	O
study	O
entry	O
.	O
	
Of	O
31	O
assessable	O
patients	O
","	O
20	O
(	O
65	O
%	O
)	O
had	O
objective	O
responses	O
(	O
two	O
complete	O
","	O
18	O
partial	O
)	O
","	O
with	O
a	O
median	O
response	O
duration	O
of	O
6	O
months	O
(	O
range	O
","	O
3	O
to	O
16+	O
months	O
)	O
.	O
	
Four	O
patients	O
with	O
bone	O
metastases	O
(	O
abnormal	O
bone	O
scan	O
only	O
)	O
and	O
pain	O
were	O
not	O
considered	O
assessable	O
by	O
strict	O
response	O
criteria	O
;	O
two	O
of	O
these	O
patients	O
had	O
sustained	O
symptomatic	O
relief	O
for	O
6	O
and	O
8	O
months	O
","	O
respectively	O
.	O
	
Myelosuppression	B-TOXI
was	O
the	O
most	O
frequent	O
toxicity	O
but	O
was	O
mild	O
in	O
most	O
patients	O
;	O
only	O
four	O
hospitalizations	O
for	O
fever	B-TOXI
and	O
neutropenia	B-TOXI
were	O
required	O
(	O
2	O
%	O
of	O
courses	O
)	O
.	O
	
No	O
severe	O
thrombocytopenia	B-TOXI
occurred	O
and	O
no	O
RBC	O
transfusions	O
were	O
required	O
.	O
	
Alopecia	B-TOXI
","	O
mucositis	B-TOXI
","	O
and	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
were	O
uncommon	O
and	O
were	O
not	O
severe	O
in	O
any	O
patient	O
.	O
	
The	O
combination	O
of	O
mitoxantrone	B-DRUG
","	O
5-FU	B-DRUG
","	O
and	O
high-dose	O
leucovorin	B-DRUG
is	O
well	O
tolerated	O
and	O
active	O
as	O
a	O
first-	O
or	O
second-line	O
treatment	O
for	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Comparison	O
with	O
other	O
standard	O
regimens	O
for	O
breast	B-CANCER
cancer	I-CANCER
is	O
indicated	O
.	O
	
Phase	O
II	O
study	O
of	O
mitoxantrone	B-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
infusional	B-DRUG
fluorouracil	I-DRUG
for	O
treatment	O
of	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
A	O
new	O
combination	O
of	O
mitoxantrone	B-DRUG
","	O
folinic	B-DRUG
acid	I-DRUG
(	O
leucovorin	B-DRUG
)	O
","	O
and	O
infusional	B-DRUG
fluorouracil	I-DRUG
(	O
5-FU	B-DRUG
)	O
was	O
administered	O
to	O
57	O
previously	O
treated	O
patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
to	O
evaluate	O
the	O
response	O
rate	O
","	O
response	O
duration	O
","	O
and	O
toxicity	O
of	O
this	O
regimen	O
.	O
	
Fifty-three	O
patients	O
who	O
received	O
313	O
courses	O
of	O
therapy	O
were	O
assessable	O
for	O
response	O
and	O
toxicity	O
.	O
	
Median	O
age	O
was	O
48	O
years	O
(	O
range	O
","	O
33	O
to	O
80	O
years	O
)	O
","	O
and	O
the	O
patients	O
had	O
received	O
an	O
average	O
of	O
1.5	O
chemotherapy	O
regimens	O
before	O
this	O
study	O
.	O
	
Of	O
53	O
assessable	O
patients	O
","	O
24	O
(	O
45	O
%	O
","	O
or	O
42	O
%	O
of	O
all	O
entered	O
patients	O
)	O
experienced	O
partial	O
responses	O
(	O
PRs	O
)	O
with	O
a	O
median	O
duration	O
of	O
6	O
months	O
(	O
range	O
","	O
2	O
to	O
13	O
months	O
)	O
.	O
	
Nine	O
(	O
69	O
%	O
)	O
of	O
13	O
assessable	O
patients	O
without	O
prior	O
doxorubicin	B-DRUG
treatment	O
responded	O
","	O
compared	O
with	O
15	O
(	O
38	O
%	O
)	O
of	O
40	O
with	O
prior	O
doxorubicin	B-DRUG
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O
	
Toxicity	O
was	O
generally	O
mild	O
with	O
dose	O
reductions	O
necessitated	O
more	O
often	O
by	O
mucositis	B-TOXI
and	O
/	O
or	O
diarrhea	B-TOXI
than	O
by	O
myelosuppression	B-TOXI
.	O
	
One	O
patient	O
with	O
prior	O
high-dose	O
doxorubicin	B-DRUG
treatment	O
developed	O
congestive	B-TOXI
heart	I-TOXI
failure	I-TOXI
.	O
	
The	O
combination	O
of	O
mitoxantrone	B-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
infusional	B-DRUG
5-FU	I-DRUG
is	O
an	O
active	O
and	O
well-tolerated	O
regimen	O
for	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
and	O
deserves	O
further	O
evaluation	O
in	O
patients	O
without	O
prior	O
doxorubicin	B-DRUG
therapy	O
.	O
	
A	O
pilot	O
study	O
of	O
interferon	B-DRUG
alfa-2a	I-DRUG
in	O
combination	O
with	O
fluorouracil	B-DRUG
plus	O
high-dose	O
leucovorin	B-DRUG
in	O
metastatic	B-CANCER
gastrointestinal	I-CANCER
carcinoma	I-CANCER
.	O
	
	
Thirty-one	O
assessable	O
patients	O
with	O
metastatic	B-CANCER
adenocarcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
gastrointestinal	I-CANCER
tract	I-CANCER
were	O
entered	O
onto	O
a	O
pilot	O
study	O
designed	O
to	O
assess	O
the	O
impact	O
of	O
recombinant	O
interferon	B-DRUG
alpha-2a	I-DRUG
(	O
rIFN	B-DRUG
alpha-2a	I-DRUG
)	O
on	O
the	O
toxicity	O
and	O
pharmacokinetics	O
of	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
and	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
.	O
	
Patients	O
received	O
an	O
initial	O
cycle	O
of	O
5-FU	B-DRUG
(	O
370	O
or	O
425	O
mg	O
/	O
m2	O
/	O
d	O
)	O
with	O
LV	B-DRUG
(	O
500	O
mg	O
/	O
m2	O
/	O
d	O
)	O
for	O
5	O
days	O
.	O
	
If	O
tolerated	O
","	O
the	O
patient	O
received	O
the	O
same	O
dose	O
of	O
5-FU	B-DRUG
/	O
LV	B-DRUG
for	O
the	O
second	O
cycle	O
on	O
days	O
2	O
to	O
6	O
","	O
with	O
rIFN	B-DRUG
alpha-2a	I-DRUG
at	O
5	O
x	O
10	O
(	O
6	O
)	O
or	O
10	O
x	O
10	O
(	O
6	O
)	O
U	O
/	O
m2	O
/	O
d	O
on	O
days	O
1	O
to	O
7	O
","	O
or	O
with	O
3	O
x	O
10	O
(	O
6	O
)	O
U	O
/	O
m2	O
/	O
d	O
on	O
days	O
1	O
to	O
14	O
.	O
	
In	O
26	O
matched	O
cycles	O
","	O
rIFN	B-DRUG
alpha-2a	I-DRUG
administration	O
was	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
dose-limiting	O
mucositis	B-TOXI
and	O
diarrhea	B-TOXI
and	O
a	O
significantly	O
lower	O
median	O
platelet	O
nadir	O
;	O
rIFN	B-DRUG
alpha-2a	I-DRUG
did	O
not	O
significantly	O
affect	O
the	O
median	O
WBC	O
or	O
granulocyte	O
nadir	O
.	O
	
Dose-limiting	O
toxicity	O
occurred	O
in	O
all	O
six	O
patients	O
entered	O
at	O
425	O
mg	O
/	O
m2	O
/	O
d	O
of	O
5-FU	B-DRUG
/	O
LV	B-DRUG
within	O
two	O
cycles	O
.	O
	
The	O
majority	O
of	O
patients	O
treated	O
with	O
370	O
mg	O
/	O
m2	O
/	O
d	O
of	O
5-FU	B-DRUG
/	O
LV	B-DRUG
and	O
10	O
x	O
10	O
(	O
6	O
)	O
U	O
/	O
m2	O
/	O
d	O
rIFN	B-DRUG
alpha-2a	I-DRUG
experienced	O
grade	O
3	O
to	O
4	O
mucositis	B-TOXI
and	O
diarrhea	B-TOXI
","	O
whereas	O
patients	O
receiving	O
3	O
x	O
10	O
(	O
6	O
)	O
and	O
5	O
x	O
10	O
(	O
6	O
)	O
U	O
/	O
m2	O
/	O
d	O
rIFN	B-DRUG
alpha-2a	I-DRUG
had	O
acceptable	O
toxicity	O
.	O
	
Administration	O
of	O
rIFN	B-DRUG
alpha-2a	I-DRUG
was	O
associated	O
with	O
a	O
dose-dependent	O
decrease	O
in	O
5-FU	B-DRUG
clearance	O
.	O
	
The	O
increase	O
in	O
the	O
area	O
under	O
the	O
5-FU	B-DRUG
concentration-time	O
curve	O
(	O
AUC	O
)	O
was	O
1.3-fold	O
and	O
1.5-fold	O
in	O
patients	O
receiving	O
5	O
x	O
10	O
(	O
6	O
)	O
and	O
10	O
x	O
10	O
(	O
6	O
)	O
U	O
/	O
m2	O
/	O
d	O
rIFN	B-DRUG
alpha-2a	I-DRUG
","	O
respectively	O
.	O
	
Thus	O
","	O
the	O
increase	O
in	O
5-FU	B-DRUG
toxicity	O
with	O
rIFN	B-DRUG
alpha-2a	I-DRUG
may	O
be	O
explained	O
by	O
alterations	O
in	O
5-FU	B-DRUG
pharmacokinetics	O
.	O
	
In	O
22	O
patients	O
without	O
prior	O
5-FU	B-DRUG
therapy	O
","	O
three	O
complete	O
(	O
13.6	O
%	O
)	O
and	O
seven	O
partial	O
(	O
31.8	O
%	O
)	O
responses	O
were	O
seen	O
","	O
for	O
an	O
overall	O
response	O
rate	O
of	O
45.4	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
24.4	O
%	O
to	O
67.8	O
%	O
)	O
.	O
	
Since	O
the	O
5	O
x	O
10	O
(	O
6	O
)	O
U	O
/	O
m2	O
/	O
d	O
dose	O
of	O
rIFN	B-DRUG
alpha-2a	I-DRUG
increased	O
the	O
5-FU	B-DRUG
drug	O
exposure	O
and	O
was	O
associated	O
with	O
acceptable	O
toxicity	O
","	O
we	O
recommend	O
its	O
further	O
evaluation	O
as	O
given	O
on	O
days	O
1	O
to	O
7	O
in	O
combination	O
with	O
5-FU	B-DRUG
370	O
mg	O
/	O
m2	O
/	O
d	O
","	O
with	O
high-dose	O
LV	B-DRUG
given	O
on	O
days	O
2	O
to	O
6	O
.	O
	
Phase	O
I-II	O
study	O
of	O
two	O
consecutive	O
courses	O
of	O
high-dose	O
epipodophyllotoxin	B-DRUG
","	O
ifosfamide	B-DRUG
","	O
and	O
carboplatin	B-DRUG
with	O
autologous	O
bone	O
marrow	O
transplantation	O
for	O
treatment	O
of	O
adult	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
We	O
describe	O
a	O
phase	O
I-II	O
study	O
of	O
two	O
consecutive	O
5-day	O
courses	O
of	O
a	O
three-drug	O
regimen	O
of	O
ifosfamide	B-DRUG
(	O
IFM	B-DRUG
)	O
","	O
carboplatin	B-DRUG
(	O
CBDCA	B-DRUG
)	O
","	O
and	O
either	O
etoposide	B-DRUG
(	O
VP-16	B-DRUG
)	O
(	O
regimen	O
1	O
)	O
or	O
teniposide	B-DRUG
(	O
VM-26	B-DRUG
)	O
(	O
regimen	O
2	O
)	O
in	O
high	O
doses	O
together	O
with	O
autologous	O
bone	O
marrow	O
transplantation	O
(	O
ABMT	O
)	O
","	O
for	O
previously	O
treated	O
patients	O
with	O
ovarian	B-CANCER
carcinoma	I-CANCER
(	O
OC	B-CANCER
)	O
","	O
germ	B-CANCER
cell	I-CANCER
tumors	I-CANCER
(	O
GCT	B-CANCER
)	O
","	O
gestational	B-CANCER
trophoblastic	I-CANCER
disease	I-CANCER
(	O
GTD	B-CANCER
)	O
","	O
or	O
oat	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
OCC	B-CANCER
)	O
.	O
	
Forty-four	O
patients	O
entered	O
the	O
study	O
.	O
	
Two	O
patients	O
with	O
OC	B-CANCER
received	O
regimen	O
1	O
","	O
and	O
22	O
were	O
given	O
regimen	O
2	O
Sixteen	O
patients	O
with	O
GCT	B-CANCER
","	O
two	O
with	O
GTD	B-CANCER
","	O
and	O
two	O
with	O
OCC	B-CANCER
were	O
treated	O
with	O
regimen	O
1	O
Six	O
patients	O
(	O
13	O
%	O
)	O
died	B-TOXI
of	O
toxicity	O
.	O
	
Nephropathy	B-TOXI
and	O
esophagitis	B-TOXI
were	O
the	O
dose-limiting	O
toxic	O
effects	O
.	O
	
The	O
maximum-tolerated	O
doses	O
(	O
MTDs	O
)	O
were	O
"1,500"	O
and	O
200	O
mg	O
/	O
m2	O
/	O
d	O
for	O
5	O
days	O
for	O
IFM	B-DRUG
and	O
CBDCA	B-DRUG
","	O
respectively	O
","	O
in	O
combination	O
with	O
VP-16	B-DRUG
250	O
mg	O
/	O
m2	O
/	O
d	O
for	O
5	O
days	O
(	O
regimen	O
1	O
)	O
","	O
and	O
150	O
","	O
"1,500"	O
","	O
and	O
200	O
mg	O
/	O
m2	O
/	O
d	O
for	O
5	O
days	O
for	O
VM-26	B-DRUG
","	O
IFM	B-DRUG
","	O
and	O
CBDCA	B-DRUG
","	O
respectively	O
(	O
regimen	O
2	O
)	O
.	O
	
The	O
response	O
rate	O
of	O
patients	O
with	O
OC	O
was	O
78	O
%	O
(	O
complete	O
response	O
[	O
CR	O
]	O
","	O
14	O
%	O
)	O
.	O
	
For	O
patients	O
previously	O
resistant	O
to	O
chemotherapy	O
","	O
the	O
response	O
rate	O
was	O
70	O
%	O
.	O
	
There	O
were	O
no	O
long-term	O
disease-free	O
survivors	O
among	O
patients	O
with	O
OC	O
.	O
	
The	O
response	O
rate	O
of	O
patients	O
with	O
GCT	B-CANCER
was	O
60	O
%	O
(	O
CR	O
","	O
33	O
%	O
)	O
.	O
	
All	O
responders	O
with	O
GCT	B-CANCER
were	O
resistant	O
to	O
previous	O
chemotherapy	O
.	O
	
Unmaintained	O
CRs	O
lasted	O
2	O
","	O
6	O
","	O
8+	O
","	O
27+	O
","	O
and	O
37+	O
months	O
.	O
	
Of	O
the	O
two	O
patients	O
with	O
GTD	O
","	O
one	O
with	O
previous	O
resistance	O
to	O
chemotherapy	O
attained	O
a	O
CR	O
of	O
18+	O
months	O
.	O
	
One	O
patient	O
with	O
OCC	O
attained	O
a	O
CR	O
lasting	O
6	O
months	O
.	O
	
The	O
regimen	O
possesses	O
great	O
antitumor	O
activity	O
.	O
	
It	O
produced	O
CRs	O
of	O
long	O
duration	O
in	O
a	O
number	O
of	O
patients	O
with	O
GCT	B-CANCER
and	O
GTD	B-CANCER
who	O
were	O
previously	O
resistant	O
to	O
chemotherapy	O
.	O
	
Erlotinib	B-DRUG
and	O
bevacizumab	B-DRUG
in	O
patients	O
with	O
recurrent	B-CANCER
or	I-CANCER
metastatic	I-CANCER
squamous-cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
:	O
a	O
phase	O
I	O
/	O
II	O
study	O
.	O
	
	
Epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
is	O
a	O
validated	O
target	O
in	O
squamous-cell	B-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
","	O
but	O
in	O
patients	O
with	O
recurrent	O
or	O
metastatic	O
disease	O
","	O
EGFR	O
targeting	O
agents	O
have	O
displayed	O
modest	O
efficacy	O
.	O
	
Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
#NAME?	O
angiogenesis	O
has	O
been	O
implicated	O
as	O
a	O
mechanism	O
of	O
resistance	O
to	O
anti-EGFR	O
therapy	O
.	O
	
In	O
this	O
multi-institutional	O
phase	O
I	O
/	O
II	O
study	O
we	O
combined	O
an	O
EGFR	O
inhibitor	O
","	O
erlotinib	B-DRUG
","	O
with	O
an	O
anti-VEGF	O
antibody	O
","	O
bevacizumab	B-DRUG
.	O
	
Between	O
April	O
15	O
","	O
2003	O
","	O
and	O
Jan	O
27	O
","	O
2005	O
","	O
patients	O
with	O
recurrent	B-CANCER
or	I-CANCER
metastatic	I-CANCER
squamous-cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
were	O
enrolled	O
from	O
seven	O
centres	O
in	O
the	O
USA	O
and	O
were	O
given	O
erlotinib	B-DRUG
(	O
150	O
mg	O
daily	O
)	O
and	O
bevacizumab	B-DRUG
in	O
escalating	O
dose	O
cohorts	O
.	O
	
The	O
primary	O
objectives	O
in	O
the	O
phase	O
I	O
and	O
II	O
sections	O
","	O
respectively	O
","	O
were	O
to	O
establish	O
the	O
maximum	O
tolerated	O
dose	O
and	O
dose-limiting	O
toxicity	O
of	O
bevacizumab	B-DRUG
when	O
administered	O
with	O
erlotinib	B-DRUG
and	O
to	O
establish	O
the	O
proportion	O
of	O
objective	O
responses	O
and	O
time	O
to	O
disease	O
progression	O
.	O
	
Pretreatment	O
serum	O
and	O
tissues	O
were	O
collected	O
and	O
analysed	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
and	O
immunofluorescence	O
quantitative	O
laser	O
analysis	O
","	O
respectively	O
.	O
	
This	O
study	O
was	O
registered	O
with	O
ClinicalTrials.gov	O
","	O
number	O
NCT00055913	O
.	O
	
In	O
the	O
phase	O
I	O
section	O
of	O
the	O
trial	O
","	O
ten	O
patients	O
were	O
enrolled	O
in	O
three	O
successive	O
cohorts	O
with	O
no	O
dose-limiting	O
toxic	O
effects	O
noted	O
.	O
	
46	O
patients	O
were	O
enrolled	O
in	O
the	O
phase	O
II	O
section	O
of	O
the	O
trial	O
(	O
including	O
three	O
patients	O
from	O
the	O
phase	O
I	O
section	O
)	O
on	O
the	O
highest	O
dose	O
of	O
bevacizumab	B-DRUG
(	O
15	O
mg	O
/	O
kg	O
every	O
3	O
weeks	O
)	O
.	O
	
Two	O
additional	O
patients	O
were	O
accrued	O
beyond	O
the	O
protocol-stipulated	O
46	O
","	O
leaving	O
a	O
total	O
of	O
48	O
patients	O
for	O
the	O
phase	O
II	O
assessment	O
.	O
	
The	O
most	O
common	O
toxic	O
effects	O
of	O
any	O
grade	O
were	O
rash	B-TOXI
and	O
diarrhoea	B-TOXI
(	O
41	O
and	O
16	O
of	O
48	O
patients	O
","	O
respectively	O
)	O
.	O
	
Three	O
patients	O
had	O
serious	O
bleeding	B-TOXI
events	O
of	O
grade	O
3	O
or	O
higher	O
.	O
	
Seven	O
patients	O
had	O
a	O
response	O
","	O
with	O
four	O
showing	O
a	O
complete	O
response	O
allowing	O
rejection	O
of	O
the	O
null	O
hypothesis	O
.	O
	
Median	O
time	O
of	O
overall	O
survival	O
and	O
progression-free	O
survival	O
(	O
PFS	O
)	O
were	O
7.1	O
months	O
(	O
95	O
%	O
CI	O
5.7-9.0	O
)	O
and	O
4.1	O
months	O
(	O
2.8-4.4	O
)	O
","	O
respectively	O
.	O
	
Higher	O
ratios	O
of	O
tumour-cell	O
phosphorylated	O
VEGF	O
receptor-2	O
(	O
pVEGFR2	O
)	O
over	O
total	O
VEGFR2	O
and	O
endothelial-cell	O
pEGFR	O
over	O
total	O
EGFR	O
in	O
pretreatment	O
biopsies	O
were	O
associated	O
with	O
complete	O
response	O
(	O
0.704	O
vs	O
0.386	O
","	O
p=0.036	O
and	O
0.949	O
vs	O
0.332	O
","	O
p=0.036	O
","	O
respectively	O
)	O
and	O
tumour	O
shrinkage	O
(	O
p=0.007	O
and	O
p=0.008	O
","	O
respectively	O
)	O
in	O
a	O
subset	O
of	O
11	O
patients	O
with	O
available	O
tissue	O
.	O
	
The	O
combination	O
of	O
erlotinib	B-DRUG
and	O
bevacizumab	B-DRUG
is	O
well	O
tolerated	O
in	O
recurrent	B-CANCER
or	I-CANCER
metastatic	I-CANCER
squamous-cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
A	O
few	O
patients	O
seem	O
to	O
derive	O
a	O
sustained	O
benefit	O
and	O
complete	O
responses	O
were	O
associated	O
with	O
expression	O
of	O
putative	O
targets	O
in	O
pretreatment	O
tumour	O
tissue	O
.	O
	
A	O
phase	O
I	O
/	O
II	O
study	O
of	O
rituximab	B-DRUG
and	O
etanercept	B-DRUG
in	O
patients	O
with	O
chronic	B-CANCER
lymphocytic	I-CANCER
leukemia	I-CANCER
and	O
small	B-CANCER
lymphocytic	I-CANCER
lymphoma	I-CANCER
.	O
	
	
Rituximab	B-DRUG
has	O
modest	O
activity	O
in	O
relapsed	O
chronic	B-CANCER
lymphocytic	I-CANCER
leukemia	I-CANCER
(	O
CLL	B-CANCER
)	O
/	O
small	B-CANCER
lymphocytic	I-CANCER
lymphoma	I-CANCER
but	O
is	O
associated	O
with	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
release	O
that	O
can	O
cause	O
CLL	B-CANCER
proliferation	O
and	O
inhibit	O
apoptosis	O
.	O
	
We	O
examined	O
whether	O
disruption	O
of	O
TNF-alpha	O
by	O
etanercept	B-DRUG
improves	O
response	O
to	O
rituximab	B-DRUG
in	O
CLL	B-CANCER
.	O
	
Eligible	O
patients	O
had	O
previously	O
treated	O
CLL	B-CANCER
with	O
performance	O
status	O
0-3	O
.	O
	
Patients	O
received	O
etanercept	B-DRUG
25	O
mg	O
subcutaneously	O
twice	O
weekly	O
(	O
weeks	O
1月5日	O
)	O
and	O
rituximab	B-DRUG
375	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
thrice	O
weekly	O
(	O
weeks	O
2月5日	O
)	O
using	O
a	O
phase	O
I	O
/	O
II	O
design	O
.	O
	
Primary	O
end	O
points	O
were	O
response	O
and	O
toxicity	O
.	O
	
The	O
36	O
enrolled	O
patients	O
had	O
a	O
median	O
of	O
two	O
prior	O
treatments	O
;	O
50	O
%	O
were	O
fludarabine	B-DRUG
refractory	O
and	O
22	O
%	O
had	O
del	O
(	O
17p13.1	O
)	O
.	O
	
Of	O
the	O
34	O
response-evaluable	O
patients	O
","	O
10	O
(	O
29	O
%	O
)	O
responded	O
","	O
including	O
9	O
partial	O
responses	O
and	O
1	O
complete	O
remission	O
.	O
	
Response	O
was	O
not	O
affected	O
by	O
prior	O
rituximab	B-DRUG
or	O
fludarabine-refractory	B-DRUG
status	O
","	O
but	O
no	O
patients	O
with	O
del	O
(	O
17p13.1	O
)	O
responded	O
.	O
	
Median	O
progression-free	O
survival	O
for	O
responders	O
was	O
9	O
months	O
(	O
range	O
1-43	O
)	O
.	O
	
Ten	O
patients	O
have	O
had	O
treatment-free	O
intervals	O
exceeding	O
12	O
months	O
","	O
including	O
four	O
who	O
have	O
remained	O
untreated	O
for	O
32	O
","	O
43	O
","	O
46	O
and	O
56	O
months	O
.	O
	
Adverse	O
events	O
were	O
mild	O
","	O
including	O
mild	O
infusion	B-TOXI
reactions	I-TOXI
","	O
transient	B-TOXI
cytopenias	I-TOXI
and	O
grade	O
3	O
infections	B-TOXI
in	O
14	O
%	O
of	O
the	O
patients	O
.	O
	
The	O
combination	O
of	O
etanercept	B-DRUG
and	O
thrice	O
weekly	O
rituximab	B-DRUG
produces	O
durable	O
remissions	O
in	O
non-del	O
(	O
17p13.1	O
)	O
CLL	B-CANCER
patients	O
and	O
is	O
well	O
tolerated	O
.	O
	
Phase	O
I	O
study	O
of	O
epirubicin	B-DRUG
","	O
cisplatin	B-DRUG
and	O
capecitabine	B-DRUG
plus	O
matuzumab	B-DRUG
in	O
previously	O
untreated	O
patients	O
with	O
advanced	B-CANCER
oesophagogastric	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
evaluate	O
the	O
safety	O
","	O
tolerability	O
","	O
efficacy	O
","	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
the	O
humanised	O
antiepidermal	O
growth	O
factor	O
receptor	O
monoclonal	O
antibody	O
matuzumab	B-DRUG
combined	O
with	O
epirubicin	B-DRUG
","	O
cisplatin	B-DRUG
and	O
capecitabine	B-DRUG
(	O
ECX	B-DRUG
)	O
in	O
patients	O
as	O
first-line	O
treatment	O
for	O
advanced	B-CANCER
oesophagogastric	I-CANCER
cancer	I-CANCER
that	O
express	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
.	O
	
This	O
was	O
a	O
phase	O
I	O
dose	O
escalation	O
study	O
of	O
matuzumab	B-DRUG
at	O
400	O
and	O
800	O
mg	O
weekly	O
and	O
1200	O
mg	O
every	O
3	O
weeks	O
combined	O
with	O
ECX	B-DRUG
(	O
epirubicin	B-DRUG
50	O
mg	O
m	O
(	O
-2	O
)	O
","	O
cisplatin	O
60	O
mg	O
m	O
(	O
-2	O
)	O
on	O
day	O
1	O
and	O
capecitabine	B-DRUG
1000	O
mg	O
m	O
(	O
-2	O
)	O
daily	O
)	O
.	O
	
Patients	O
were	O
treated	O
until	O
disease	O
progression	O
","	O
unacceptable	O
toxicity	O
or	O
for	O
a	O
maximum	O
of	O
eight	O
cycles	O
.	O
	
Twenty-one	O
patients	O
were	O
treated	O
with	O
matuzumab	B-DRUG
at	O
three	O
different	O
dose	O
levels	O
(	O
DLs	O
)	O
combined	O
with	O
ECX	B-DRUG
.	O
	
The	O
main	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
was	O
grade	O
3	O
lethargy	B-TOXI
at	O
1200	O
mg	O
matuzumab	B-DRUG
every	O
3	O
weeks	O
and	O
thus	O
800	O
mg	O
matuzumab	B-DRUG
weekly	O
was	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
.	O
	
Other	O
common	O
toxicities	O
included	O
rash	B-TOXI
","	O
nausea	B-TOXI
","	O
stomatitis	B-TOXI
and	O
diarrhoea	B-TOXI
.	O
	
Pharmacokinetic	O
evaluation	O
demonstrated	O
that	O
the	O
coadministration	O
of	O
ECX	B-DRUG
did	O
not	O
alter	O
the	O
exposure	O
of	O
matuzumab	B-DRUG
.	O
	
Pharmacodynamic	O
studies	O
on	O
skin	O
biopsies	O
demonstrated	O
inhibition	O
of	O
the	O
EGFR	O
pathway	O
.	O
	
Objective	O
response	O
rates	O
of	O
65	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
43-82	O
)	O
","	O
disease	O
stabilisation	O
of	O
25	O
%	O
(	O
95	O
%	O
CI	O
:	O
11-47	O
)	O
and	O
a	O
disease	O
control	O
rate	O
(	O
CR	O
=+	O
PR	O
=+	O
SD	O
)	O
of	O
90	O
%	O
were	O
achieved	O
overall	O
.	O
	
The	O
MTD	O
of	O
matuzumab	B-DRUG
in	O
combination	O
with	O
ECX	B-DRUG
was	O
800	O
mg	O
weekly	O
","	O
and	O
at	O
this	O
DL	O
it	O
was	O
well-tolerated	O
and	O
showed	O
encouraging	O
antitumour	O
activity	O
.	O
	
At	O
the	O
doses	O
evaluated	O
in	O
serial	O
skin	O
biopsies	O
","	O
matuzumab	B-DRUG
decreased	O
phosphorylation	O
of	O
EGFR	O
and	O
MAPK	O
","	O
and	O
increased	O
phosphorylation	O
of	O
STAT-3	O
.	O
	
A	O
phase	O
II	O
study	O
of	O
paclitaxel	B-DRUG
=+	O
etoposide	B-DRUG
=+	O
cisplatin	B-DRUG
=+	O
concurrent	O
radiation	O
therapy	O
for	O
previously	O
untreated	O
limited	O
stage	O
small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
E2596	O
)	O
:	O
a	O
trial	O
of	O
the	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
.	O
	
	
To	O
determine	O
the	O
1-year	O
survival	O
","	O
response	O
rate	O
","	O
and	O
toxicity	O
for	O
patients	O
with	O
limited	O
stage	O
small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
treated	O
with	O
the	O
combination	O
of	O
cisplatin	B-DRUG
plus	O
etoposide	B-DRUG
plus	O
paclitaxel	B-DRUG
with	O
delayed	O
concurrent	O
(	O
starting	O
with	O
cycle	O
3	O
)	O
high	O
dose	O
thoracic	O
radiotherapy	O
.	O
	
Patients	O
with	O
previously	O
untreated	O
limited	O
stage	O
small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
","	O
Easter	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0-2	O
and	O
adequate	O
organ	O
function	O
were	O
eligible	O
.	O
	
Cycles	O
1	O
and	O
2	O
of	O
chemotherapy	O
consisted	O
of	O
paclitaxel	B-DRUG
170	O
mg	O
/	O
m	O
intravenous	O
day	O
1	O
","	O
etoposide	B-DRUG
80	O
mg	O
/	O
m	O
intravenous	O
days	O
1	O
to	O
3	O
","	O
and	O
cisplatin	B-DRUG
60	O
mg	O
/	O
m	O
intravenous	O
day	O
1	O
followed	O
by	O
filgrastim	B-DRUG
5	O
microg	O
/	O
kg	O
subcutaneously	O
days	O
4	O
to	O
13	O
.	O
	
Cycles	O
3	O
and	O
4	O
of	O
chemotherapy	O
consisted	O
of	O
a	O
reduced	O
dose	O
of	O
paclitaxel	B-DRUG
135	O
mg	O
/	O
m	O
intravenous	O
day	O
1	O
","	O
and	O
the	O
same	O
dose	O
of	O
etoposide	B-DRUG
and	O
cisplatin	B-DRUG
with	O
concurrent	O
thoracic	O
radiation	O
therapy	O
1.8	O
Gy	O
in	O
35	O
fractions	O
(	O
total	O
63	O
Gy	O
)	O
administered	O
over	O
7	O
weeks	O
.	O
	
Sixty-three	O
patients	O
were	O
entered	O
","	O
61	O
patients	O
were	O
eligible	O
.	O
	
The	O
most	O
common	O
grade	O
4	O
toxicity	O
seen	O
was	O
granulocytopenia	B-TOXI
(	O
62	O
%	O
)	O
.	O
	
Nonhematologic	B-TOXI
toxicities	I-TOXI
included	O
febrile	B-TOXI
neutropenia	I-TOXI
in	O
19	O
%	O
of	O
patients	O
","	O
grade	O
3	O
and	O
4	O
esophagitis	B-TOXI
in	O
32	O
%	O
of	O
patients	O
","	O
and	O
grade	O
3	O
peripheral	B-TOXI
neuropathy	I-TOXI
in	O
14	O
%	O
of	O
patients	O
.	O
	
Two	O
patients	O
suffered	O
lethal	B-TOXI
toxicities	I-TOXI
.	O
	
The	O
overall	O
response	O
rate	O
was	O
79	O
%	O
.	O
	
The	O
1-year	O
survival	O
rate	O
was	O
64	O
%	O
.	O
	
The	O
median	O
overall	O
survival	O
was	O
15.7	O
months	O
","	O
and	O
the	O
median	O
progression-free	O
survival	O
was	O
8.6	O
months	O
.	O
	
The	O
combination	O
of	O
cisplatin	B-DRUG
plus	O
etoposide	B-DRUG
plus	O
paclitaxel	B-DRUG
chemotherapy	O
and	O
concurrent	O
delayed	O
thoracic	O
radiotherapy	O
as	O
administered	O
in	O
this	O
trial	O
provide	O
no	O
apparent	O
advantage	O
with	O
respect	O
to	O
response	O
","	O
local	O
control	O
","	O
or	O
survival	O
compared	O
with	O
historical	O
controls	O
.	O
	
Phase	O
I	O
pharmacokinetic	O
study	O
of	O
the	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
tyrosine	O
kinase	O
inhibitor	O
vatalanib	B-DRUG
(	O
PTK787	O
)	O
plus	O
imatinib	B-DRUG
and	O
hydroxyurea	B-DRUG
for	O
malignant	B-CANCER
glioma	I-CANCER
.	O
	
	
This	O
study	O
determined	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
dose-limiting	O
toxicities	O
(	O
DLT	O
)	O
of	O
the	O
oral	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
(	O
VEGFR	O
)	O
inhibitor	O
","	O
vatalanib	B-DRUG
","	O
when	O
administered	O
with	O
imatinib	B-DRUG
and	O
hydroxyurea	B-DRUG
on	O
a	O
continuous	O
daily	O
schedule	O
among	O
recurrent	B-CANCER
malignant	I-CANCER
glioma	I-CANCER
patients	O
.	O
	
All	O
patients	O
received	O
500	O
mg	O
of	O
hydroxyurea	B-DRUG
twice	O
daily	O
.	O
	
Imatinib	B-DRUG
was	O
dosed	O
at	O
400	O
mg	O
per	O
day	O
for	O
patients	O
not	O
taking	O
enzyme-inducing	B-DRUG
antiepileptic	I-DRUG
drugs	I-DRUG
(	O
EIAEDs	B-DRUG
;	O
stratum	O
A	O
)	O
and	O
at	O
500	O
mg	O
twice-a-day	O
for	O
patients	O
taking	O
EIAEDs	B-DRUG
(	O
stratum	O
B	O
)	O
.	O
	
Vatalanib	B-DRUG
was	O
escalated	O
from	O
500	O
mg	O
to	O
1250	O
mg	O
twice	O
daily	O
in	O
successive	O
cohorts	O
","	O
independently	O
for	O
each	O
stratum	O
.	O
	
Pharmacokinetics	O
of	O
each	O
drug	O
were	O
assessed	O
.	O
	
A	O
total	O
of	O
37	O
recurrent	O
patients	O
","	O
34	O
(	O
92	O
%	O
)	O
with	O
glioblastoma	B-CANCER
and	O
3	O
(	O
8	O
%	O
)	O
with	O
grade	O
3	O
malignant	B-CANCER
glioma	I-CANCER
","	O
were	O
enrolled	O
.	O
	
Nineteen	O
patients	O
(	O
51	O
%	O
)	O
were	O
taking	O
EIAEDs	B-DRUG
.	O
	
The	O
MTD	O
of	O
vatalanib	B-DRUG
for	O
all	O
patients	O
was	O
1000	O
mg	O
twice-a-day	O
.	O
	
DLTs	O
were	O
hematologic	O
","	O
gastrointestinal	O
","	O
renal	O
","	O
and	O
hepatic	O
.	O
	
No	O
patients	O
developed	O
intracranial	B-TOXI
hemorrhage	I-TOXI
.	O
	
Concurrent	O
administration	O
of	O
imatinib	B-DRUG
and	O
hydroxyurea	B-DRUG
did	O
not	O
affect	O
vatalanib	B-DRUG
exposure	O
","	O
but	O
EIAEDs	B-DRUG
decreased	O
vatalanib	B-DRUG
and	O
imatinib	B-DRUG
plasma	O
exposures	O
.	O
	
Vatalanib	B-DRUG
doses	O
up	O
to	O
1000	O
mg	O
twice-a-day	O
combined	O
with	O
imatinib	B-DRUG
and	O
hydroxyurea	B-DRUG
were	O
well	O
tolerated	O
.	O
	
Strategies	O
to	O
target	O
tumor	O
blood	O
vessel	O
endothelial	O
cells	O
and	O
pericytes	O
by	O
inhibiting	O
VEGFR	O
and	O
platelet-derived	O
growth	O
factor	O
","	O
respectively	O
","	O
were	O
safe	O
among	O
recurrent	B-CANCER
malignant	I-CANCER
glioma	I-CANCER
patients	O
and	O
may	O
enhance	O
antiangiogenesis	O
activity	O
.	O
	
Results	O
of	O
a	O
phase	O
III	O
","	O
randomized	O
","	O
placebo-controlled	O
study	O
of	O
sorafenib	B-DRUG
in	O
combination	O
with	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
as	O
second-line	O
treatment	O
in	O
patients	O
with	O
unresectable	O
stage	O
III	O
or	O
stage	O
IV	O
melanoma	B-CANCER
.	O
	
	
This	O
phase	O
III	O
","	O
randomized	O
","	O
double-blind	O
","	O
placebo-controlled	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
sorafenib	B-DRUG
with	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
(	O
CP	B-DRUG
)	O
in	O
patients	O
with	O
advanced	B-CANCER
melanoma	I-CANCER
who	O
had	O
progressed	O
on	O
a	O
dacarbazine-	B-DRUG
or	O
temozolomide-containing	B-DRUG
regimen	O
.	O
	
A	O
total	O
of	O
270	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
intravenous	O
paclitaxel	B-DRUG
225	O
mg	O
/	O
m2	O
plus	O
intravenous	O
carboplatin	B-DRUG
at	O
area	O
under	O
curve	O
6	O
(	O
AUC	O
6	O
)	O
on	O
day	O
1	O
of	O
a	O
21-day	O
cycle	O
followed	O
by	O
either	O
placebo	B-DRUG
(	O
n	O
=	O
135	O
)	O
or	O
oral	O
sorafenib	B-DRUG
400	O
mg	O
(	O
n	O
=	O
135	O
)	O
twice	O
daily	O
on	O
days	O
2	O
to	O
19	O
.	O
	
The	O
primary	O
efficacy	O
end	O
point	O
was	O
progression-free	O
survival	O
(	O
PFS	O
)	O
;	O
secondary	O
and	O
tertiary	O
end	O
points	O
included	O
overall	O
survival	O
and	O
incidence	O
of	O
best	O
response	O
","	O
respectively	O
.	O
	
The	O
median	O
PFS	O
was	O
17.9	O
weeks	O
for	O
the	O
placebo	B-DRUG
plus	O
CP	B-DRUG
arm	O
and	O
17.4	O
weeks	O
for	O
the	O
sorafenib	B-DRUG
plus	O
CP	B-DRUG
arm	O
(	O
hazard	O
ratio	O
","	O
0.91	O
;	O
99	O
%	O
CI	O
","	O
0.63	O
to	O
1.31	O
;	O
two-sided	O
log-rank	O
test	O
P	O
=	O
0.49	O
)	O
.	O
	
Response	O
rate	O
was	O
11	O
%	O
with	O
placebo	B-DRUG
versus	O
12	O
%	O
with	O
sorafenib	B-DRUG
.	O
	
Dermatologic	O
events	O
","	O
grade	O
3	O
thrombocytopenia	B-TOXI
","	O
diarrhea	B-TOXI
","	O
and	O
fatigue	B-TOXI
were	O
more	O
common	O
in	O
patients	O
treated	O
with	O
sorafenib	B-DRUG
plus	O
CP	B-DRUG
versus	O
placebo	B-DRUG
plus	O
CP	B-DRUG
.	O
	
In	O
this	O
study	O
","	O
the	O
addition	O
of	O
sorafenib	B-DRUG
to	O
CP	B-DRUG
did	O
not	O
improve	O
any	O
of	O
the	O
end	O
points	O
over	O
placebo	B-DRUG
plus	O
CP	B-DRUG
and	O
can	O
not	O
be	O
recommended	O
in	O
the	O
second-line	O
setting	O
for	O
patients	O
with	O
advanced	B-CANCER
melanoma	I-CANCER
.	O
	
Both	O
regimens	O
had	O
clinically	O
acceptable	O
toxicity	O
profiles	O
with	O
no	O
unexpected	O
adverse	O
events	O
.	O
	
A	O
trial	O
of	O
similar	O
design	O
for	O
the	O
first-line	O
treatment	O
of	O
patients	O
with	O
advanced	B-CANCER
melanoma	I-CANCER
(	O
intergroup	O
trial	O
E2603	O
)	O
is	O
currently	O
ongoing	O
.	O
	
Phase	O
II	O
study	O
of	O
tirapazamine	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
etoposide	B-DRUG
and	O
concurrent	O
thoracic	O
radiotherapy	O
for	O
limited-stage	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
SWOG	O
222	O
.	O
	
	
A	O
SWOG	O
pilot	O
study	O
(	O
S0004	O
)	O
showed	O
that	O
tirapazamine	B-DRUG
(	O
TPZ	B-DRUG
)	O
when	O
combined	O
with	O
concurrent	O
chemoradiotherapy	O
yielded	O
a	O
promising	O
median	O
survival	O
of	O
22	O
months	O
in	O
limited-stage	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
LSCLC	B-CANCER
)	O
.	O
	
We	O
report	O
results	O
of	O
the	O
phase	O
II	O
study	O
designed	O
to	O
confirm	O
this	O
result	O
.	O
	
The	O
concurrent	O
phase	O
consisted	O
of	O
two	O
cycles	O
of	O
cisplatin	B-DRUG
","	O
etoposide	B-DRUG
","	O
and	O
once-daily	O
radiation	O
to	O
61	O
Gy	O
.	O
	
TPZ	B-DRUG
was	O
given	O
at	O
260	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
","	O
29	O
","	O
and	O
at	O
160	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
8	O
","	O
10	O
","	O
12	O
","	O
36	O
","	O
38	O
","	O
and	O
40	O
.	O
	
Consolidation	O
consisted	O
of	O
two	O
cycles	O
of	O
cisplatin	B-DRUG
and	O
etoposide	B-DRUG
.	O
	
Complete	O
responders	O
received	O
prophylactic	O
cranial	O
irradiation	O
.	O
	
Results	O
were	O
considered	O
promising	O
if	O
the	O
median	O
survival	O
time	O
was	O
at	O
least	O
21	O
months	O
and	O
of	O
no	O
further	O
interest	O
if	O
&	O
lt	O
;	O
or	O
=	O
14	O
months	O
.	O
	
S0222	O
was	O
closed	O
early	O
due	O
to	O
a	O
report	O
of	O
excess	O
toxicity	O
for	O
TPZ	B-DRUG
in	O
a	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
trial	O
elsewhere	O
.	O
	
Of	O
planned	O
85	O
patients	O
","	O
69	O
were	O
accrued	O
.	O
	
In	O
68	O
assessable	O
patients	O
","	O
17	O
(	O
25	O
%	O
)	O
had	O
grade	O
3	O
to	O
4	O
esophagitis	B-TOXI
and	O
eight	O
(	O
12	O
%	O
)	O
had	O
grade	O
3	O
febrile	B-TOXI
neutropenia	I-TOXI
during	O
the	O
concurrent	O
phase	O
.	O
	
There	O
were	O
three	O
possible	O
treatment-related	O
deaths	B-TOXI
","	O
two	O
in	O
concurrent	O
phase	O
(	O
one	O
progressive	O
disease	O
not	O
otherwise	O
specified	O
within	O
30	O
days	O
","	O
one	O
pericardial	B-TOXI
effusion	I-TOXI
)	O
and	O
one	O
in	O
consolidation	O
phase	O
(	O
esophageal	B-TOXI
hemorrhage	I-TOXI
)	O
.	O
	
At	O
a	O
median	O
follow-up	O
of	O
35	O
months	O
","	O
median	O
progression-free	O
survival	O
was	O
11	O
months	O
(	O
95	O
%	O
CI	O
","	O
10	O
to	O
13	O
months	O
)	O
and	O
median	O
overall	O
survival	O
was	O
21	O
months	O
(	O
95	O
%	O
CI	O
","	O
17	O
to	O
33	O
months	O
)	O
.	O
	
S0222	O
showed	O
acceptable	O
levels	O
of	O
toxicity	O
and	O
similar	O
promising	O
median	O
survival	O
as	O
S0004	O
.	O
	
Further	O
study	O
of	O
hypoxia-targeted	O
therapy	O
is	O
warranted	O
in	O
LSCLC	B-CANCER
.	O
	
Cetuximab	B-DRUG
in	O
combination	O
with	O
irinotecan	B-DRUG
/	O
5-fluorouracil	B-DRUG
/	O
folinic	B-DRUG
acid	I-DRUG
(	O
FOLFIRI	B-DRUG
)	O
in	O
the	O
initial	O
treatment	O
of	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
:	O
a	O
multicentre	O
two-part	O
phase	O
I	O
/	O
II	O
study	O
.	O
	
	
This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
efficacy	O
and	O
safety	O
of	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
inhibitor	O
cetuximab	B-DRUG
combined	O
with	O
irinotecan	B-DRUG
","	O
folinic	B-DRUG
acid	I-DRUG
(	O
FA	B-DRUG
)	O
and	O
two	O
different	O
doses	O
of	O
infusional	B-DRUG
5-fluorouracil	I-DRUG
(	O
5-FU	B-DRUG
)	O
in	O
the	O
first-line	O
treatment	O
of	O
EGFR-detectable	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
The	O
5-FU	B-DRUG
dose	O
was	O
selected	O
on	O
the	O
basis	O
of	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
during	O
part	O
I	O
of	O
the	O
study	O
.	O
	
Patients	O
received	O
cetuximab	B-DRUG
(	O
400	O
mg	O
/	O
m2	O
initial	O
dose	O
and	O
250	O
mg	O
/	O
m2	O
/	O
week	O
thereafter	O
)	O
and	O
every	O
2	O
weeks	O
irinotecan	B-DRUG
(	O
180	O
mg	O
/	O
m2	O
)	O
","	O
FA	O
(	O
400	O
mg	O
/	O
m2	O
)	O
and	O
5-FU	B-DRUG
(	O
either	O
low	O
dose	O
[	O
LD	O
]	O
","	O
300	O
mg	O
/	O
m2	O
bolus	O
plus	O
"2,000"	O
mg	O
/	O
m2	O
46-hour	O
infusion	O
","	O
n	O
=	O
7	O
;	O
or	O
","	O
high-dose	O
[	O
HD	O
]	O
","	O
400	O
mg	O
/	O
m2	O
bolus	O
plus	O
"2,400"	O
mg	O
/	O
m2	O
;	O
n	O
=	O
45	O
)	O
.	O
	
Only	O
two	O
DLTs	O
occurred	O
in	O
the	O
HD	O
group	O
","	O
and	O
HD	O
5-FU	B-DRUG
was	O
selected	O
for	O
use	O
in	O
part	O
II	O
.	O
	
Apart	O
from	O
rash	B-TOXI
","	O
commonly	O
observed	O
grade	O
3	O
/	O
4	O
adverse	O
events	O
such	O
as	O
leucopenia	B-TOXI
","	O
diarrhoea	B-TOXI
","	O
vomiting	B-TOXI
and	O
asthenia	B-TOXI
occurred	O
within	O
the	O
expected	O
range	O
for	O
FOLFIRI	B-DRUG
.	O
	
Among	O
52	O
patients	O
","	O
the	O
overall	O
response	O
rate	O
was	O
48	O
%	O
.	O
	
Median	O
progression-free	O
survival	O
(	O
PFS	O
)	O
was	O
8.6	O
months	O
(	O
counting	O
all	O
reported	O
progressions	O
)	O
and	O
the	O
median	O
overall	O
survival	O
was	O
22.4	O
months	O
.	O
	
Treatment	O
facilitated	O
the	O
resection	O
of	O
initially	O
unresectable	O
metastases	O
in	O
fourteen	O
patients	O
(	O
27	O
%	O
)	O
:	O
of	O
these	O
","	O
10	O
patients	O
(	O
71	O
%	O
)	O
had	O
no	O
residual	O
tumour	O
after	O
surgery	O
","	O
and	O
these	O
resections	O
hindered	O
the	O
estimation	O
of	O
PFS	O
.	O
	
The	O
combination	O
of	O
cetuximab	B-DRUG
and	O
FOLFIRI	B-DRUG
was	O
active	O
and	O
well	O
tolerated	O
in	O
this	O
setting	O
.	O
	
Initially	O
unresectable	O
metastases	O
became	O
resectable	O
in	O
one-quarter	O
of	O
patients	O
","	O
with	O
a	O
high	O
number	O
of	O
complete	O
resections	O
","	O
and	O
these	O
promising	O
results	O
formed	O
the	O
basis	O
for	O
the	O
investigation	O
of	O
FOLFIRI	B-DRUG
with	O
and	O
without	O
cetuximab	B-DRUG
in	O
the	O
phase	O
III	O
CRYSTAL	O
trial	O
.	O
	
A	O
sequential	O
treatment	O
approach	O
to	O
myoinvasive	B-CANCER
urothelial	I-CANCER
cancer	I-CANCER
:	O
a	O
phase	O
II	O
Southwest	O
Oncology	O
Group	O
trial	O
(	O
S0219	O
)	O
.	O
	
	
We	O
conducted	O
a	O
phase	O
II	O
trial	O
of	O
neoadjuvant	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
and	O
gemcitabine	B-DRUG
as	O
well	O
as	O
transurethral	O
resection	O
of	O
bladder	B-CANCER
tumor	I-CANCER
to	O
evaluate	O
the	O
clinical	O
T0	O
(	O
cT0	O
)	O
rate	O
with	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
and	O
gemcitabine	B-DRUG
","	O
and	O
to	O
study	O
cystoscopic	O
surveillance	O
or	O
immediate	O
cystectomy	O
for	O
patients	O
with	O
cT0	O
status	O
following	O
chemotherapy	O
.	O
	
Patients	O
with	O
T2-T4a	O
chemotherapy	O
and	O
radiation	O
naive	O
urothelial	B-CANCER
cancer	I-CANCER
were	O
eligible	O
.	O
	
T2+	O
tumor	O
had	O
to	O
be	O
diagnosed	O
by	O
transurethral	B-CANCER
bladder	I-CANCER
tumor	I-CANCER
resection	O
followed	O
by	O
a	O
second	O
transurethral	B-CANCER
bladder	I-CANCER
tumor	I-CANCER
resection	O
to	O
confirm	O
persistent	O
disease	O
within	O
16	O
weeks	O
of	O
the	O
first	O
resection	O
.	O
	
Three	O
cycles	O
of	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
and	O
gemcitabine	B-DRUG
were	O
administered	O
within	O
8	O
weeks	O
of	O
the	O
second	O
transurethral	B-CANCER
bladder	I-CANCER
tumor	I-CANCER
resection	O
.	O
	
Patients	O
with	O
cT0	O
status	O
after	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
and	O
gemcitabine	B-DRUG
therapy	O
could	O
elect	O
immediate	O
cystectomy	O
or	O
cystoscopic	O
surveillance	O
","	O
and	O
those	O
with	O
greater	O
than	O
cT0	O
status	O
were	O
to	O
undergo	O
immediate	O
cystectomy	O
.	O
	
Of	O
77	O
patients	O
74	O
were	O
assessable	O
","	O
and	O
cT0	O
status	O
after	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
and	O
gemcitabine	B-DRUG
was	O
achieved	O
in	O
34	O
of	O
74	O
patients	O
(	O
46	O
%	O
)	O
.	O
	
Of	O
the	O
34	O
patients	O
with	O
cT0	O
status	O
10	O
underwent	O
immediate	O
cystectomy	O
","	O
6	O
of	O
whom	O
had	O
persistent	O
cancer	O
.	O
	
Persistent	O
tumor	O
at	O
transurethral	B-CANCER
bladder	I-CANCER
tumor	I-CANCER
resection	O
was	O
seen	O
in	O
28	O
patients	O
(	O
38	O
%	O
)	O
and	O
21	O
underwent	O
cystectomy	O
.	O
	
Thus	O
","	O
35	O
of	O
74	O
patients	O
underwent	O
cystectomy	O
.	O
	
With	O
a	O
median	O
followup	O
of	O
22	O
months	O
2-year	O
overall	O
survival	O
was	O
59	O
%	O
(	O
95	O
%	O
CI	O
45	O
","	O
72	O
)	O
and	O
among	O
cT0	O
cases	O
it	O
was	O
75	O
%	O
(	O
95	O
%	O
CI	O
57	O
","	O
93	O
)	O
.	O
	
Although	O
neoadjuvant	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
and	O
gemcitabine	B-DRUG
had	O
a	O
promising	O
46	O
%	O
cT0	O
rate	O
","	O
the	O
study	O
failed	O
to	O
meet	O
the	O
primary	O
objective	O
as	O
there	O
was	O
an	O
unacceptably	O
high	O
rate	O
(	O
60	O
%	O
)	O
of	O
persistent	O
cancer	O
at	O
cystectomy	O
in	O
patients	O
presumed	O
to	O
have	O
pT0	O
status	O
.	O
	
Patients	O
completing	O
neoadjuvant	O
chemotherapy	O
should	O
strongly	O
consider	O
definitive	O
local	O
therapy	O
rather	O
than	O
cystoscopic	O
surveillance	O
regardless	O
of	O
post-chemotherapy	O
cT0	O
status	O
.	O
	
A	O
phase	O
I	O
","	O
pharmacokinetic	O
and	O
pharmacodynamic	O
study	O
on	O
vorinostat	B-DRUG
in	O
combination	O
with	O
5-fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
oxaliplatin	B-DRUG
in	O
patients	O
with	O
refractory	O
colorectal	B-CANCER
cancer	I-CANCER
.	O
	
	
We	O
conducted	O
a	O
phase	O
I	O
study	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
of	O
vorinostat	B-DRUG
in	O
combination	O
with	O
fixed	O
doses	O
of	O
5-fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
","	O
leucovorin	B-DRUG
","	O
and	O
oxaliplatin	B-DRUG
(	O
FOLFOX	B-DRUG
)	O
.	O
	
Vorinostat	B-DRUG
was	O
given	O
orally	O
twice	O
daily	O
for	O
1	O
week	O
every	O
2	O
weeks	O
.	O
	
FOLFOX	B-DRUG
was	O
given	O
on	O
days	O
4	O
and	O
5	O
of	O
vorinostat	B-DRUG
.	O
	
The	O
vorinostat	B-DRUG
starting	O
dose	O
was	O
100	O
mg	O
twice	O
daily	O
.	O
	
Escalation	O
occurred	O
in	O
cohorts	O
of	O
three	O
to	O
six	O
patients	O
.	O
	
Pharmacokinetics	O
of	O
vorinostat	B-DRUG
","	O
FU	B-DRUG
","	O
and	O
oxaliplatin	B-DRUG
were	O
studied	O
.	O
	
Twenty-one	O
patients	O
were	O
enrolled	O
.	O
	
Thrombocytopenia	B-TOXI
","	O
neutropenia	B-TOXI
","	O
gastrointestinal	B-TOXI
toxicities	I-TOXI
","	O
and	O
fatigue	B-TOXI
increased	O
in	O
frequency	O
and	O
severity	O
at	O
higher	O
dose	O
levels	O
of	O
vorinostat	B-DRUG
.	O
	
Two	O
of	O
4	O
evaluable	O
patients	O
at	O
dose	O
level	O
4	O
(	O
vorinostat	B-DRUG
400	O
mg	O
orally	O
twice	O
daily	O
)	O
developed	O
dose-limiting	O
fatigue	B-TOXI
.	O
	
One	O
of	O
10	O
evaluable	O
patients	O
at	O
dose	O
level	O
3	O
(	O
vorinostat	B-DRUG
300	O
mg	O
orally	O
twice	O
daily	O
)	O
had	O
dose-limiting	O
fatigue	B-TOXI
","	O
anorexia	B-TOXI
","	O
and	O
dehydration	B-TOXI
.	O
	
There	O
were	O
significant	O
relationships	O
between	O
vorinostat	B-DRUG
dose	O
and	O
the	O
area	O
under	O
the	O
curve	O
on	O
days	O
1	O
and	O
5	O
(	O
Pearson	O
","	O
&	O
lt	O
;	O
0.001	O
)	O
.	O
	
The	O
vorinostat	B-DRUG
area	O
under	O
the	O
curve	O
increased	O
(	O
P	O
=	O
0.005	O
)	O
and	O
clearance	O
decreased	O
(	O
P	O
=	O
0.003	O
)	O
on	O
day	O
5	O
compared	O
with	O
day	O
1	O
The	O
median	O
C	O
(	O
max	O
)	O
of	O
FU	O
at	O
each	O
dose	O
level	O
increased	O
significantly	O
with	O
increasing	O
doses	O
of	O
vorinostat	B-DRUG
","	O
suggesting	O
a	O
pharmacokinetic	O
interaction	O
between	O
FU	B-DRUG
and	O
vorinostat	B-DRUG
.	O
	
Vorinostat-induced	B-DRUG
thymidylate	O
synthase	O
(	O
TS	O
)	O
modulation	O
was	O
not	O
consistent	O
;	O
only	O
two	O
of	O
six	O
patients	O
had	O
a	O
decrease	O
in	O
intratumoral	O
TS	O
expression	O
by	O
reverse	O
transcription-PCR	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
of	O
vorinostat	B-DRUG
in	O
combination	O
with	O
FOLFOX	B-DRUG
is	O
300	O
mg	O
orally	O
twice	O
daily	O
x	O
1	O
week	O
every	O
2	O
weeks	O
.	O
	
Alternative	O
vorinostat	B-DRUG
dosing	O
schedules	O
may	O
be	O
needed	O
for	O
optimal	O
down-regulation	O
of	O
TS	O
expression	O
.	O
	
Phase	O
I	O
study	O
of	O
bortezomib	B-DRUG
and	O
cetuximab	B-DRUG
in	O
patients	O
with	O
solid	B-CANCER
tumours	I-CANCER
expressing	O
epidermal	O
growth	O
factor	O
receptor	O
.	O
	
	
Bortezomib	B-DRUG
inhibits	O
nuclear	O
factor-kappaB	O
(	O
NF-kappaB	O
)	O
.	O
	
Cetuximab	B-DRUG
is	O
a	O
chimeric	O
mouse-human	O
antibody	O
targeted	O
against	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
.	O
	
We	O
hypothesised	O
that	O
concomitant	O
blockade	O
of	O
NF-kappaB	O
and	O
EGFR	O
signalling	O
would	O
overcome	O
EGFR-mediated	O
resistance	O
to	O
single-agent	O
bortezomib	B-DRUG
and	O
induce	O
apoptosis	O
through	O
two	O
molecular	O
pathways	O
.	O
	
The	O
aim	O
of	O
this	O
phase	O
I	O
trial	O
was	O
to	O
establish	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
for	O
bortezomib	B-DRUG
plus	O
cetuximab	B-DRUG
in	O
patients	O
with	O
EGFR-expressing	O
epithelial	B-CANCER
tumours	I-CANCER
.	O
	
The	O
21-day	O
treatment	O
cycle	O
consisted	O
of	O
bortezomib	B-DRUG
administered	O
on	O
days	O
1	O
and	O
8	O
through	O
dose	O
escalation	O
(	O
1.3-2	O
mg	O
m	O
(	O
-2	O
)	O
)	O
.	O
	
Cetuximab	B-DRUG
was	O
delivered	O
at	O
a	O
dose	O
of	O
250	O
mg	O
m	O
(	O
-2	O
)	O
on	O
days	O
1	O
","	O
8	O
and	O
15	O
(	O
400	O
mg	O
m	O
(	O
-2	O
)	O
day	O
1	O
cycle	O
1	O
)	O
.	O
	
A	O
total	O
of	O
37	O
patients	O
were	O
enroled	O
and	O
given	O
a	O
total	O
91	O
cycles	O
.	O
	
No	O
grade	O
&	O
gt	O
;	O
or	O
3	O
haematological	B-TOXI
toxicity	I-TOXI
was	O
noted	O
.	O
	
Non-hematological	B-TOXI
grade	O
&	O
gt	O
;	O
or	O
3	O
toxicities	O
included	O
fatigue	B-TOXI
(	O
22	O
%	O
of	O
patients	O
)	O
","	O
dyspnoea	B-TOXI
(	O
16	O
%	O
)	O
and	O
infection	B-TOXI
(	O
11	O
%	O
)	O
.	O
	
The	O
MTD	O
was	O
not	O
reached	O
at	O
the	O
highest	O
tested	O
bortezomib	B-DRUG
dose	O
(	O
2	O
mg	O
m	O
(	O
-2	O
)	O
)	O
.	O
	
Efficacy	O
outcomes	O
included	O
disease	O
progression	O
in	O
21	O
patients	O
(	O
56.7	O
%	O
)	O
and	O
stable	O
disease	O
(	O
SD	O
)	O
at	O
6	O
weeks	O
in	O
16	O
patients	O
(	O
43.3	O
%	O
)	O
.	O
	
Five	O
of	O
the	O
six	O
patients	O
with	O
SD	O
at	O
12	O
weeks	O
were	O
diagnosed	O
with	O
cancers	B-CANCER
of	I-CANCER
the	I-CANCER
lungs	I-CANCER
or	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
This	O
combination	O
therapy	O
was	O
moderately	O
effective	O
in	O
extensively	O
pretreated	O
patients	O
with	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
or	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancers	I-CANCER
and	O
warrants	O
further	O
investigation	O
.	O
	
Phase	O
II	O
trial	O
of	O
carboplatin	B-DRUG
plus	O
cisplatin	B-DRUG
in	O
recurrent	B-CANCER
and	I-CANCER
advanced	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
	
Cisplatin	B-DRUG
is	O
one	O
of	O
the	O
most	O
active	O
chemotherapeutic	O
agents	O
for	O
the	O
treatment	O
of	O
squamous	B-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
;	O
however	O
","	O
neurotoxicity	B-TOXI
and	O
nephrotoxicity	B-TOXI
are	O
dose-limiting	O
.	O
	
The	O
analog	O
","	O
carboplatin	B-DRUG
","	O
is	O
a	O
promising	O
new	O
agent	O
with	O
similar	O
activity	O
but	O
a	O
different	O
spectrum	O
of	O
toxicity	O
.	O
	
To	O
evaluate	O
if	O
a	O
therapeutic	O
advantage	O
could	O
be	O
achieved	O
with	O
acceptable	O
toxicity	O
","	O
a	O
combination	O
of	O
carboplatin	B-DRUG
350	O
mg	O
/	O
m2	O
and	O
cisplatin	B-DRUG
50	O
mg	O
/	O
m2	O
were	O
administered	O
every	O
28	O
days	O
to	O
patients	O
with	O
recurrent	O
or	O
metastatic	O
disease	O
who	O
had	O
received	O
no	O
prior	O
chemotherapy	O
.	O
	
Of	O
24	O
patients	O
enrolled	O
in	O
this	O
study	O
","	O
21	O
were	O
assessable	O
for	O
response	O
and	O
toxicity	O
.	O
	
Five	O
partial	O
responses	O
were	O
observed	O
(	O
24	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
Cl	O
]	O
","	O
4.9	O
%	O
to	O
38.6	O
%	O
)	O
.	O
	
No	O
complete	O
response	O
occurred	O
.	O
	
Two	O
of	O
these	O
patients	O
received	O
definitive	O
radiotherapy	O
and	O
achieved	O
complete	O
responses	O
.	O
	
The	O
median	O
survival	O
of	O
all	O
patients	O
was	O
24	O
weeks	O
.	O
	
Hematologic	B-TOXI
toxicity	I-TOXI
was	O
dose-limiting	O
necessitating	O
a	O
decrease	O
in	O
the	O
starting	O
dose	O
of	O
carboplatin	B-DRUG
to	O
300	O
mg	O
/	O
m2	O
.	O
	
Nonhematologic	B-TOXI
toxicity	I-TOXI
was	O
infrequent	O
and	O
mild	O
.	O
	
Significant	O
renal	B-TOXI
impairment	I-TOXI
occurred	O
in	O
only	O
two	O
patients	O
.	O
	
Although	O
treatment	O
with	O
the	O
combination	O
of	O
carboplatin	B-DRUG
and	O
cisplatin	B-DRUG
is	O
feasible	O
","	O
we	O
found	O
no	O
therapeutic	O
advantage	O
in	O
terms	O
of	O
an	O
increased	O
response	O
or	O
survival	O
.	O
	
Initial	O
safety	O
report	O
of	O
NSABP	O
C-08	O
:	O
A	O
randomized	O
phase	O
III	O
study	O
of	O
modified	O
FOLFOX6	B-DRUG
with	O
or	O
without	O
bevacizumab	B-DRUG
for	O
the	O
adjuvant	O
treatment	O
of	O
patients	O
with	O
stage	O
II	O
or	O
III	O
colon	B-CANCER
cancer	I-CANCER
.	O
	
	
The	O
National	O
Surgical	O
Adjuvant	O
Breast	O
and	O
Bowel	O
Project	O
C-08	O
trial	O
was	O
designed	O
to	O
investigate	O
the	O
safety	O
and	O
effectiveness	O
of	O
adding	O
bevacizumab	B-DRUG
to	O
modified	O
infusional	B-DRUG
fluorouracil	I-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
oxaliplatin	B-DRUG
(	O
FOLFOX	B-DRUG
)	O
6	O
regimen	O
for	O
the	O
adjuvant	O
treatment	O
of	O
patients	O
with	O
stage	O
II	O
or	O
III	O
colon	B-CANCER
cancer	I-CANCER
.	O
	
We	O
present	O
safety	O
information	O
in	O
advance	O
of	O
the	O
planned	O
analysis	O
of	O
efficacy	O
.	O
	
Among	O
"2,710"	O
randomly	O
assigned	O
patients	O
","	O
demographic	O
factors	O
were	O
balanced	O
.	O
	
Patients	O
received	O
modified	O
FOLFOX6	B-DRUG
every	O
2	O
weeks	O
x	O
12	O
or	O
modified	O
FOLFOX6	B-DRUG
plus	O
bevacizumab	B-DRUG
(	O
5	O
mg	O
/	O
kg	O
every	O
2	O
weeks	O
x	O
26	O
","	O
experimental	O
group	O
)	O
.	O
	
Overall	O
rates	O
of	O
grade	O
4	O
or	O
5	O
toxicities	O
were	O
nearly	O
identical	O
in	O
the	O
FOLFOX6	B-DRUG
and	O
FOLFOX6	B-DRUG
plus	O
bevacizumab	B-DRUG
arms	O
(	O
15.2	O
%	O
and	O
15	O
%	O
","	O
respectively	O
)	O
.	O
	
Six-month	O
mortality	O
rates	O
were	O
0.96	O
%	O
and	O
0.9	O
%	O
for	O
the	O
control	O
and	O
experimental	O
groups	O
","	O
respectively	O
.	O
	
Grade	O
3+	O
toxicities	O
that	O
occurred	O
more	O
often	O
in	O
the	O
experimental	O
arm	O
versus	O
control	O
arm	O
included	O
hypertension	B-TOXI
(	O
12	O
%	O
v	O
1.8	O
%	O
","	O
respectively	O
)	O
","	O
wound	B-TOXI
complications	I-TOXI
(	O
abdominal	B-TOXI
incisional	I-TOXI
hernia	I-TOXI
or	O
infusion	B-TOXI
port	I-TOXI
dehiscence	I-TOXI
/	O
inflammation	B-TOXI
;	O
1.7	O
%	O
v	O
0.3	O
%	O
","	O
respectively	O
)	O
","	O
pain	B-TOXI
(	O
11.1	O
%	O
v	O
6.3	O
%	O
","	O
respectively	O
)	O
","	O
and	O
proteinuria	B-TOXI
(	O
2.7	O
%	O
v	O
0.8	O
%	O
","	O
respectively	O
)	O
.	O
	
Grade	O
2+	O
neuropathy	B-TOXI
was	O
increased	O
in	O
the	O
experimental	O
arm	O
versus	O
the	O
control	O
arm	O
(	O
grade	O
2	O
","	O
33	O
%	O
v	O
29	O
%	O
","	O
respectively	O
;	O
grade	O
3	O
","	O
16	O
%	O
v	O
14	O
%	O
","	O
respectively	O
;	O
and	O
grade	O
4	O
","	O
&	O
lt	O
;	O
1	O
%	O
each	O
)	O
.	O
	
In	O
the	O
experimental	O
arm	O
versus	O
control	O
arm	O
","	O
significantly	O
less	O
thrombocytopenia	B-TOXI
(	O
1.4	O
%	O
v	O
3.4	O
%	O
","	O
respectively	O
)	O
and	O
fewer	B-TOXI
allergic	I-TOXI
reactions	O
(	O
3.1	O
%	O
v	O
4.7	O
%	O
","	O
respectively	O
)	O
were	O
observed	O
.	O
	
Advanced	O
age	O
was	O
associated	O
with	O
a	O
significantly	O
greater	O
rate	O
of	O
grade	O
4	O
and	O
5	O
toxicities	O
regardless	O
of	O
treatment	O
.	O
	
Bevacizumab	B-DRUG
with	O
modified	O
FOLFOX6	B-DRUG
is	O
well	O
tolerated	O
in	O
the	O
surgical	O
adjuvant	O
setting	O
in	O
these	O
patients	O
.	O
	
No	O
significant	O
increase	O
in	O
GI	B-TOXI
perforation	I-TOXI
","	O
hemorrhage	B-TOXI
","	O
arterial	B-TOXI
or	O
venous	B-TOXI
thrombotic	I-TOXI
events	O
","	O
or	O
death	B-TOXI
with	O
the	O
addition	O
of	O
bevacizumab	B-DRUG
to	O
modified	O
FOLFOX6	B-DRUG
has	O
been	O
observed	O
.	O
	
Follow-up	O
for	O
potential	O
delayed	O
adverse	O
effects	O
and	O
efficacy	O
is	O
ongoing	O
.	O
	
Phase	O
II	O
clinical	O
trial	O
of	O
neoadjuvant	O
alternating	O
doublet	O
chemotherapy	O
with	O
ifosfamide	B-DRUG
/	O
doxorubicin	B-DRUG
and	O
etoposide	B-DRUG
/	O
cisplatin	B-DRUG
in	O
small-cell	B-CANCER
urothelial	I-CANCER
cancer	I-CANCER
.	O
	
	
Currently	O
","	O
treatment	O
recommendations	O
for	O
small-cell	B-CANCER
urothelial	I-CANCER
cancer	I-CANCER
(	O
SCUC	B-CANCER
)	O
are	O
based	O
on	O
anecdotal	O
case	O
reports	O
and	O
small	O
retrospective	O
series	O
.	O
	
We	O
now	O
report	O
results	O
from	O
the	O
first	O
phase	O
II	O
clinical	O
trial	O
developed	O
exclusively	O
for	O
SCUC	B-CANCER
","	O
to	O
our	O
knowledge	O
.	O
	
From	O
2001	O
to	O
2006	O
","	O
30	O
patients	O
with	O
SCUC	B-CANCER
provided	O
consent	O
and	O
were	O
treated	O
with	O
alternating	O
doublet	O
chemotherapy	O
.	O
	
Patients	O
with	O
surgically	O
resectable	O
disease	O
(	O
&	O
lt	O
;	O
or	O
=	O
cT4aN0M0	O
)	O
received	O
a	O
total	O
of	O
four	O
cycles	O
of	O
neoadjuvant	O
chemotherapy	O
","	O
whereas	O
those	O
with	O
unresectable	O
disease	O
(	O
&	O
gt	O
;	O
or	O
=	O
cT4b	O
","	O
N+	O
","	O
or	O
M+	O
)	O
received	O
two	O
cycles	O
beyond	O
maximal	O
response	O
.	O
	
Eighteen	O
patients	O
with	O
surgically	O
resectable	O
SCUC	B-CANCER
received	O
neoadjuvant	O
treatment	O
with	O
a	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
of	O
58	O
months	O
;	O
13	O
of	O
these	O
patients	O
remain	O
alive	O
and	O
cancer	O
free	O
.	O
	
For	O
patients	O
with	O
cT2N0M0	O
SCUC	B-CANCER
","	O
the	O
5-year	O
OS	O
rate	O
is	O
80	O
%	O
;	O
only	O
one	O
of	O
four	O
patients	O
with	O
cT3b-4aN0M0	O
remains	O
alive	O
(	O
median	O
OS	O
","	O
37.8	O
months	O
)	O
.	O
	
For	O
12	O
patients	O
with	O
unresectable	O
or	O
metastatic	B-CANCER
SCUC	I-CANCER
","	O
the	O
median	O
OS	O
was	O
13.3	O
months	O
.	O
	
Chemotherapy	O
was	O
well	O
tolerated	O
","	O
with	O
transfusion	B-TOXI
","	O
neutropenic	B-TOXI
fever	I-TOXI
","	O
and	O
infection	B-TOXI
remaining	O
the	O
most	O
frequent	O
grade	O
3	O
and	O
4	O
toxicities	O
.	O
	
There	O
was	O
only	O
one	O
postsurgical	B-TOXI
death	I-TOXI
.	O
	
Brain	O
metastases	O
were	O
strongly	O
associated	O
with	O
more	O
advanced-stage	O
disease	O
","	O
developing	O
in	O
eight	O
of	O
16	O
patients	O
with	O
either	O
bulky	O
tumors	O
(	O
&	O
gt	O
;	O
or	O
=	O
cT3b	O
)	O
or	O
metastatic	O
disease	O
(	O
P	O
=	O
0.004	O
)	O
.	O
	
These	O
clinical	O
trial	O
results	O
are	O
consistent	O
with	O
previously	O
reported	O
retrospective	O
data	O
demonstrating	O
long-term	O
survival	O
with	O
four	O
cycles	O
of	O
neoadjuvant	O
chemotherapy	O
for	O
surgically	O
resectable	O
SCUC	B-CANCER
.	O
	
Once	O
metastases	O
develop	O
","	O
the	O
prognosis	O
remains	O
poor	O
.	O
	
The	O
strong	O
positive	O
association	O
between	O
disease	O
stage	O
and	O
brain	O
metastases	O
highlights	O
a	O
patient	O
subset	O
that	O
may	O
potentially	O
benefit	O
from	O
prophylactic	O
cranial	O
irradiation	O
.	O
	
A	O
dose	O
escalation	O
and	O
pharmacokinetic	O
study	O
of	O
the	O
biweekly	O
administration	O
of	O
paclitaxel	B-DRUG
","	O
gemcitabine	B-DRUG
and	O
oxaliplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
To	O
determine	O
the	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
and	O
the	O
maximum	O
tolerated	O
doses	O
(	O
MTDs	O
)	O
of	O
the	O
paclitaxel	B-DRUG
","	O
gemcitabine	B-DRUG
","	O
oxaliplatin	B-DRUG
combination	O
administered	O
biweekly	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Patients	O
received	O
escalated	O
doses	O
of	O
paclitaxel	B-DRUG
(	O
starting	O
dose	O
:	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
gemcitabine	B-DRUG
(	O
starting	O
dose	O
:	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
oxaliplatin	B-DRUG
(	O
starting	O
dose	O
:	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
on	O
days	O
1	O
and	O
15	O
in	O
cycles	O
of	O
every	O
4	O
weeks	O
.	O
	
DLTs	O
were	O
evaluated	O
during	O
the	O
first	O
cycle	O
.	O
	
Twenty-seven	O
patients	O
(	O
median	O
age	O
65	O
years	O
)	O
with	O
performance	O
status	O
0-1	O
were	O
treated	O
on	O
six	O
dose	O
escalation	O
levels	O
.	O
	
Eleven	O
patients	O
(	O
40.7	O
%	O
)	O
were	O
chemotherapy	O
na茂ve	O
","	O
six	O
(	O
22.2	O
%	O
)	O
had	O
received	O
1	O
prior	O
chemotherapy	O
regimen	O
and	O
ten	O
(	O
37.1	O
%	O
)	O
2	O
or	O
more	O
.	O
	
The	O
DLT	O
level	O
was	O
reached	O
at	O
the	O
doses	O
of	O
paclitaxel	B-DRUG
110	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
gemcitabine	B-DRUG
"1,150"	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
LOHP	B-DRUG
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
The	O
dose-limiting	O
events	O
were	O
grade	O
4	O
neutropenia	B-TOXI
and	O
grade	O
3	O
febrile	B-TOXI
neutropenia	I-TOXI
.	O
	
Neutropenia	B-TOXI
was	O
the	O
most	O
common	O
adverse	O
event	O
.	O
	
A	O
median	O
of	O
3	O
cycles	O
per	O
patient	O
was	O
administered	O
.	O
	
One	O
complete	O
and	O
five	O
partial	O
responses	O
were	O
observed	O
in	O
patients	O
with	O
ovarian	B-CANCER
carcinoma	I-CANCER
","	O
NSCLC	B-CANCER
","	O
urothelial	B-CANCER
cancer	I-CANCER
","	O
mesothelioma	B-CANCER
and	O
cancer	O
of	O
unknown	O
primary	O
.	O
	
No	O
pharmacokinetic	O
drug	O
interactions	O
were	O
detected	O
.	O
	
The	O
recommended	O
doses	O
for	O
future	O
phase	O
II	O
studies	O
of	O
this	O
combination	O
are	O
paclitaxel	B-DRUG
110	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
oxaliplatin	B-DRUG
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
every	O
2	O
weeks	O
.	O
	
The	O
regimen	O
is	O
generally	O
well	O
tolerated	O
and	O
merits	O
further	O
evaluation	O
.	O
	
Phase	O
I	O
trial	O
of	O
weekly	O
docetaxel	B-DRUG
","	O
weekly	O
doxorubicin	B-DRUG
","	O
daily	O
oral	O
cyclophosphamide	B-DRUG
","	O
and	O
G-CSF	B-DRUG
(	O
ConTAC	O
regimen	O
)	O
in	O
advanced	B-CANCER
malignancies	I-CANCER
.	O
	
	
This	O
was	O
a	O
phase	O
I	O
study	O
evaluating	O
the	O
dose	O
limiting	O
toxicity	O
(	O
DLT	O
)	O
and	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
weekly	O
docetaxel	B-DRUG
","	O
doxorubicin	B-DRUG
and	O
daily	O
oral	O
cyclophosphamide	B-DRUG
with	O
G-CSF	B-DRUG
support	O
(	O
ConTAC	O
regimen	O
)	O
.	O
	
Cohorts	O
of	O
3月6日	O
patients	O
with	O
advanced	O
breast	O
or	O
other	O
solid	B-CANCER
malignancies	I-CANCER
were	O
entered	O
at	O
subsequently	O
higher	O
dose	O
levels	O
until	O
dose-limiting	O
toxicities	O
(	O
DLT	O
)	O
were	O
noted	O
in	O
2	O
or	O
more	O
patients	O
per	O
dose	O
level	O
during	O
the	O
first	O
6	O
weeks	O
of	O
therapy	O
.	O
	
This	O
study	O
escalated	O
dosages	O
of	O
docetaxel	B-DRUG
and	O
doxorubicin	B-DRUG
simultaneously	O
","	O
while	O
the	O
dose	O
of	O
oral	O
cyclophosphamide	B-DRUG
was	O
fixed	O
at	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
daily	O
.	O
	
Sixteen	O
patients	O
were	O
enrolled	O
.	O
	
Grade	O
3月4日	O
adverse	O
events	O
during	O
the	O
first	O
6	O
weeks	O
of	O
treatment	O
were	O
neutropenia	B-TOXI
(	O
n	O
=	O
1	O
at	O
dose	O
level	O
#	O
1	O
and	O
n	O
=	O
3	O
at	O
dose	O
level	O
#	O
4	O
)	O
","	O
anemia	B-TOXI
(	O
n	O
=	O
2	O
at	O
dose	O
levels	O
1	O
and	O
4	O
)	O
","	O
and	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
(	O
n	O
=	O
1	O
at	O
dose	O
level	O
#	O
4	O
)	O
.	O
	
After	O
6	O
weeks	O
of	O
therapy	O
","	O
grade	O
3月4日	O
toxicities	O
included	O
anemia	B-TOXI
(	O
n	O
=	O
3	O
)	O
","	O
neutropenia	B-TOXI
(	O
n	O
=	O
7	O
)	O
","	O
Hand-Foot	B-TOXI
syndrome	I-TOXI
(	O
n	O
=	O
2	O
)	O
and	O
grade	O
3	O
cystitis	B-TOXI
and	O
pneumonia	B-TOXI
(	O
n	O
=	O
1	O
at	O
dose	O
level	O
#	O
4	O
)	O
.	O
	
Five	O
patients	O
with	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
and	O
1	O
patient	O
with	O
metastatic	B-CANCER
lung	I-CANCER
cancer	I-CANCER
responded	O
to	O
the	O
chemotherapy	O
.	O
	
Grade	O
4	O
neutropenia	B-TOXI
was	O
the	O
DLT	O
.	O
	
The	O
MTD	O
","	O
was	O
established	O
at	O
dose	O
level	O
#	O
3	O
(	O
doxorubicin	B-DRUG
at	O
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
docetaxel	B-DRUG
at	O
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
with	O
oral	O
cyclophosphamide	B-DRUG
dose	O
of	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
daily	O
)	O
.	O
	
Myelosuppression	B-TOXI
at	O
that	O
dose	O
level	O
was	O
moderate	O
with	O
G-CSF	B-DRUG
given	O
concurrently	O
.	O
	
Efficacy	O
of	O
melphalan	B-DRUG
and	O
prednisone	B-DRUG
plus	O
thalidomide	B-DRUG
in	O
patients	O
older	O
than	O
75	O
years	O
with	O
newly	O
diagnosed	O
multiple	O
myeloma	B-CANCER
:	O
IFM	O
1	O
/	O
1	O
trial	O
.	O
	
	
Until	O
recently	O
","	O
melphalan	B-DRUG
and	O
prednisone	B-DRUG
were	O
the	O
standards	O
of	O
care	O
in	O
elderly	O
patients	O
with	O
multiple	O
myeloma	B-CANCER
.	O
	
The	O
addition	O
of	O
thalidomide	B-DRUG
to	O
this	O
combination	O
demonstrated	O
a	O
survival	O
benefit	O
for	O
patients	O
age	O
65	O
to	O
75	O
years	O
.	O
	
This	O
randomized	O
","	O
placebo-controlled	O
","	O
phase	O
III	O
trial	O
investigated	O
the	O
efficacy	O
of	O
melphalan	B-DRUG
and	O
prednisone	B-DRUG
plus	O
thalidomide	B-DRUG
in	O
patients	O
older	O
than	O
75	O
years	O
with	O
newly	O
diagnosed	O
myeloma	B-CANCER
.	O
	
Between	O
April	O
2002	O
and	O
December	O
2006	O
","	O
232	O
previously	O
untreated	O
patients	O
with	O
myeloma	B-CANCER
","	O
age	O
75	O
years	O
or	O
older	O
","	O
were	O
enrolled	O
and	O
229	O
were	O
randomly	O
assigned	O
to	O
treatment	O
.	O
	
All	O
patients	O
received	O
melphalan	B-DRUG
(	O
0.2	O
mg	O
/	O
kg	O
/	O
d	O
)	O
plus	O
prednisone	B-DRUG
(	O
2	O
mg	O
/	O
kg	O
/	O
d	O
)	O
for	O
12	O
courses	O
(	O
day	O
1	O
to	O
4	O
)	O
every	O
6	O
weeks	O
.	O
	
Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
100	O
mg	O
/	O
d	O
of	O
oral	O
thalidomide	B-DRUG
(	O
n	O
=	O
113	O
)	O
or	O
placebo	O
(	O
n	O
=	O
116	O
)	O
","	O
continuously	O
for	O
72	O
weeks	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
overall	O
survival	O
.	O
	
After	O
a	O
median	O
follow-up	O
of	O
47.5	O
months	O
","	O
overall	O
survival	O
was	O
significantly	O
longer	O
in	O
patients	O
who	O
received	O
melphalan	B-DRUG
and	O
prednisone	B-DRUG
plus	O
thalidomide	B-DRUG
compared	O
with	O
those	O
who	O
received	O
melphalan	B-DRUG
and	O
prednisone	B-DRUG
plus	O
placebo	O
(	O
median	O
","	O
44	O
v	O
29.1	O
months	O
;	O
P	O
=	O
0.028	O
)	O
.	O
	
Progression-free	O
survival	O
was	O
significantly	O
prolonged	O
in	O
the	O
melphalan	B-DRUG
and	O
prednisone	B-DRUG
plus	O
thalidomide	B-DRUG
group	O
(	O
median	O
","	O
24.1	O
v	O
18.5	O
months	O
;	O
P	O
=	O
0.001	O
)	O
.	O
	
Two	O
adverse	O
events	O
were	O
significantly	O
increased	O
in	O
the	O
melphalan	B-DRUG
and	O
prednisone	B-DRUG
plus	O
thalidomide	B-DRUG
group	O
:	O
grade	O
2	O
to	O
4	O
peripheral	B-TOXI
neuropathy	I-TOXI
(	O
20	O
%	O
v	O
5	O
%	O
in	O
the	O
melphalan	B-DRUG
and	O
prednisone	B-DRUG
plus	O
placebo	O
group	O
;	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
and	O
grade	O
3	O
to	O
4	O
neutropenia	B-TOXI
(	O
23	O
%	O
v	O
9	O
%	O
;	O
P	O
=	O
0.003	O
)	O
.	O
	
This	O
trial	O
confirms	O
the	O
superiority	O
of	O
the	O
combination	O
melphalan	B-DRUG
and	O
prednisone	B-DRUG
plus	O
thalidomide	B-DRUG
over	O
melphalan	B-DRUG
and	O
prednisone	B-DRUG
alone	O
for	O
prolonging	O
survival	O
in	O
very	O
elderly	O
patients	O
with	O
newly	O
diagnosed	O
myeloma	B-CANCER
.	O
	
Toxicity	O
was	O
acceptable	O
.	O
	
Phase	O
I	O
trial	O
of	O
fludarabine	B-DRUG
","	O
bortezomib	B-DRUG
and	O
rituximab	B-DRUG
for	O
relapsed	O
and	O
refractory	O
indolent	O
and	O
mantle	O
cell	O
non-Hodgkin	B-CANCER
lymphoma	I-CANCER
.	O
	
	
Based	O
on	O
the	O
hypothesis	O
that	O
bortezomib	B-DRUG
may	O
potentiate	O
fludarabine	B-DRUG
activity	O
by	O
inhibiting	O
DNA	O
repair	O
","	O
we	O
designed	O
a	O
phase	O
I	O
trial	O
using	O
this	O
combination	O
with	O
rituximab	B-DRUG
in	O
patients	O
with	O
relapsed	O
and	O
refractory	O
indolent	O
and	O
mantle	O
cell	O
non-Hodgkin	B-CANCER
lymphoma	I-CANCER
.	O
	
Twenty-four	O
patients	O
were	O
enrolled	O
.	O
	
Non-Hodgkin	B-CANCER
lymphoma	I-CANCER
subtypes	O
included	O
12	O
patients	O
with	O
follicular	B-CANCER
lymphoma	I-CANCER
","	O
four	O
with	O
marginal	B-CANCER
zone	I-CANCER
lymphoma	I-CANCER
","	O
three	O
with	O
lymphoplasmacytic	B-CANCER
lymphoma	I-CANCER
","	O
three	O
with	O
mantle	B-CANCER
cell	I-CANCER
lymphoma	I-CANCER
and	O
two	O
with	O
small	B-CANCER
lymphocytic	I-CANCER
/	O
chronic	B-CANCER
lymphocytic	I-CANCER
leukaemia	I-CANCER
.	O
	
Fludarabine	B-DRUG
and	O
bortezomib	B-DRUG
were	O
escalated	O
in	O
cohorts	O
of	O
three	O
patients	O
.	O
	
Rituximab	B-DRUG
was	O
added	O
to	O
the	O
maximum	O
tolerated	O
dose	O
of	O
fludarabine	B-DRUG
and	O
bortezomib	B-DRUG
and	O
added	O
significant	O
dose-limiting	O
myelosuppression	B-TOXI
.	O
	
The	O
maximum	O
tolerated	O
dose	O
was	O
fludarabine	B-DRUG
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1月3日	O
","	O
bortezomib	B-DRUG
1.3	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
","	O
4	O
","	O
8	O
","	O
11	O
","	O
with	O
rituximab	B-DRUG
375	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
administered	O
every	O
21	O
d.	O
Clinical	O
responses	O
were	O
observed	O
in	O
11	O
patients	O
","	O
five	O
of	O
whom	O
were	O
refractory	O
to	O
their	O
most	O
recent	O
treatment	O
regimen	O
.	O
	
Six	O
additional	O
patients	O
had	O
stable	O
disease	O
for	O
a	O
median	O
of	O
10	O
months	O
(	O
range	O
4-30+	O
)	O
.	O
	
Cumulative	O
myelosuppression	B-TOXI
and	O
neuropathy	B-TOXI
was	O
observed	O
.	O
	
The	O
combination	O
of	O
fludarabine	B-DRUG
","	O
bortezomib	B-DRUG
","	O
and	O
rituximab	B-DRUG
appears	O
to	O
be	O
an	O
active	O
regimen	O
with	O
manageable	O
toxicity	O
for	O
relapsed	O
NHL	B-CANCER
.	O
	
A	O
phase	O
II	O
study	O
of	O
leucovorin	B-DRUG
","	O
5-FU	B-DRUG
and	O
docetaxel	B-DRUG
combination	O
chemotherapy	O
in	O
patients	O
with	O
inoperable	O
or	O
postoperative	O
relapsed	O
gastric	B-CANCER
cancer	I-CANCER
.	O
	
	
To	O
estimate	O
the	O
effect	O
and	O
toxicity	O
of	O
bimonthly	O
low-dose	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
and	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
bolus	O
plus	O
continuous	O
infusion	O
(	O
LV5FU2	B-DRUG
)	O
with	O
docetaxel	B-DRUG
combination	O
chemotherapy	O
in	O
patients	O
with	O
inoperable	O
or	O
postoperative	O
relapsed	O
gastric	B-CANCER
cancer	I-CANCER
.	O
	
Total	O
27	O
patients	O
are	O
enrolled	O
in	O
this	O
study	O
.	O
	
LV	B-DRUG
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
bolus	O
)	O
","	O
5FU	B-DRUG
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
bolus	O
)	O
","	O
5-FU	B-DRUG
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
24-hour	O
continuous	O
infusion	O
)	O
on	O
day	O
1	O
","	O
2	O
","	O
15	O
","	O
and	O
16	O
","	O
docetaxel	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
1-hour	O
infusion	O
)	O
on	O
day	O
15	O
every	O
4	O
weeks	O
.	O
	
Total	O
of	O
141	O
cycles	O
were	O
administered	O
and	O
response	O
rate	O
were	O
36.8	O
%	O
with	O
2	O
complete	O
response	O
(	O
10.5	O
%	O
)	O
and	O
5	O
partial	O
response	O
(	O
26.3	O
%	O
)	O
in	O
19	O
evaluable	O
patients	O
.	O
	
The	O
median	O
response	O
duration	O
is	O
8.1	O
months	O
(	O
95	O
%	O
CI	O
","	O
4	O
approximately	O
12.1	O
)	O
.	O
	
The	O
median	O
progression-free	O
survival	O
time	O
is	O
6.7	O
months	O
(	O
95	O
%	O
CI	O
","	O
5	O
approximately	O
8.5	O
)	O
and	O
the	O
median	O
overall	O
survival	O
time	O
is	O
11.9	O
months	O
(	O
95	O
%	O
CI	O
","	O
4.8	O
approximately	O
19.1	O
)	O
.	O
	
The	O
grade	O
3月4日	O
toxicity	O
of	O
neutropenia	B-TOXI
(	O
24.8	O
%	O
)	O
and	O
anemia	B-TOXI
(	O
11.3	O
%	O
)	O
","	O
neutropenic	B-TOXI
fever	I-TOXI
(	O
2.8	O
%	O
)	O
is	O
observed	O
.	O
	
The	O
grade	O
1	O
toxicity	O
of	O
injection	O
site	O
reaction	O
is	O
observed	O
all	O
patients	O
and	O
the	O
grade	O
1月2日	O
toxicity	O
of	O
alopecia	B-TOXI
is	O
observed	O
60	O
%	O
.	O
	
LV5FU2	B-DRUG
with	O
docetaxel	B-DRUG
combination	O
chemotherapy	O
is	O
effective	O
and	O
tolerable	O
in	O
patients	O
with	O
inoperable	O
or	O
postoperative	O
relapsed	O
gastric	B-CANCER
cancer	I-CANCER
.	O
	
Phase	O
II	O
study	O
of	O
gemcitabine	B-DRUG
plus	O
cisplatin	B-DRUG
in	O
patients	O
with	O
anthracycline-	B-DRUG
and	O
taxane-	B-DRUG
pretreated	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
Metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
patients	O
are	O
usually	O
exposed	O
to	O
taxane	B-DRUG
and	O
anthracycline	B-DRUG
as	O
neoadjuvant	O
","	O
adjuvant	O
and	O
palliative	O
chemotherapeutic	O
agents	O
.	O
	
This	O
study	O
was	O
designed	O
to	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
the	O
use	O
of	O
a	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
(	O
GP	B-DRUG
)	O
combination	O
treatment	O
in	O
patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
that	O
were	O
pretreated	O
with	O
anthracycline	B-DRUG
and	O
taxane	B-DRUG
.	O
	
We	O
evaluated	O
the	O
use	O
of	O
a	O
GP	B-DRUG
regimen	O
(	O
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
gemcitabine	B-DRUG
administered	O
on	O
days	O
1	O
and	O
8	O
plus	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
cisplatin	B-DRUG
administered	O
on	O
day	O
1	O
every	O
3	O
weeks	O
)	O
in	O
38	O
breast	B-CANCER
cancer	I-CANCER
patients	O
who	O
had	O
received	O
prior	O
chemotherapy	O
with	O
anthracycline	B-DRUG
and	O
taxane	B-DRUG
as	O
an	O
adjuvant	O
or	O
neoadjuvant	O
therapy	O
","	O
or	O
as	O
a	O
palliative	O
therapy	O
.	O
	
The	O
median	O
patient	O
age	O
was	O
49	O
years	O
(	O
age	O
range	O
","	O
35	O
approximately	O
69	O
years	O
)	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
28.9	O
%	O
in	O
11	O
patients	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
14	O
approximately	O
44	O
%	O
)	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
was	O
5.2	O
months	O
(	O
95	O
%	O
CI	O
","	O
3.6	O
approximately	O
6.8	O
months	O
)	O
.	O
	
Median	O
survival	O
was	O
19.5	O
months	O
(	O
95	O
%	O
CI	O
","	O
11.2	O
approximately	O
27.8	O
months	O
)	O
.	O
	
Major	O
grade	O
3	O
/	O
4	O
hematological	B-TOXI
toxicity	I-TOXI
was	O
due	O
to	O
leukopenia	B-TOXI
(	O
36	O
of	O
157	O
cycles	O
","	O
23.1	O
%	O
)	O
.	O
	
Non-hematological	B-TOXI
toxicity	I-TOXI
was	O
rarely	O
severe	O
;	O
grade	O
1	O
/	O
2	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
were	O
observed	O
in	O
37.8	O
%	O
of	O
the	O
patients	O
.	O
	
There	O
were	O
no	O
treatment	B-TOXI
related	I-TOXI
deaths	I-TOXI
.	O
	
Our	O
results	O
suggest	O
that	O
the	O
use	O
of	O
gemcitabine	B-DRUG
plus	O
cisplatin	O
appears	O
to	O
be	O
effective	O
and	O
has	O
an	O
acceptable	O
toxicity	O
profile	O
in	O
patients	O
with	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
that	O
have	O
been	O
pretreated	O
with	O
anthracycline	B-DRUG
and	O
taxane	B-DRUG
.	O
	
A	O
phase	O
II	O
trial	O
of	O
paclitaxel	B-DRUG
","	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
and	O
cisplatin	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
or	I-CANCER
recurrent	I-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
	
We	O
wanted	O
to	O
assess	O
the	O
effectiveness	O
and	O
safety	O
of	O
combination	O
chemotherapy	O
with	O
paclitaxel	B-DRUG
","	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
and	O
cisplatin	B-DRUG
for	O
treating	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
metastatic	B-CANCER
or	I-CANCER
recurrent	I-CANCER
gastric	I-CANCER
cancer	I-CANCER
were	O
entered	O
into	O
this	O
study	O
.	O
	
Paclitaxel	B-DRUG
at	O
a	O
dose	O
of	O
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
","	O
5-FU	B-DRUG
1	O
g	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
in	O
a	O
24	O
hour	O
continuous	O
infusion	O
from	O
day	O
1	O
to	O
day	O
4	O
and	O
cisplatin	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
were	O
administered	O
.	O
	
This	O
regimen	O
was	O
repeated	O
every	O
3	O
weeks	O
.	O
	
A	O
total	O
of	O
34	O
patients	O
were	O
enrolled	O
in	O
this	O
study	O
.	O
	
Among	O
them	O
","	O
33	O
patients	O
were	O
finally	O
evaluable	O
for	O
their	O
response	O
.	O
	
17	O
(	O
51.5	O
%	O
)	O
patients	O
had	O
a	O
partial	O
response	O
(	O
95	O
%	O
CI	O
:	O
26	O
approximately	O
77	O
%	O
)	O
.	O
	
The	O
median	O
duration	O
of	O
overall	O
survival	O
was	O
13.2	O
months	O
.	O
	
Grade	O
3	O
or	O
4	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
were	O
observed	O
in	O
15.2	O
%	O
and	O
1.1	O
%	O
of	O
all	O
the	O
cycles	O
","	O
respectively	O
.	O
	
Grade	O
3	O
stomatitis	B-TOXI
and	O
neurotoxicity	B-TOXI
were	O
observed	O
in	O
20.6	O
%	O
and	O
1.1	O
%	O
of	O
all	O
patients	O
","	O
respectively	O
.	O
	
Grade	O
4	O
non-hematologic	B-TOXI
toxicity	I-TOXI
was	O
not	O
observed	O
.	O
	
The	O
regimen	O
of	O
paclitaxel	B-DRUG
","	O
5-FU	B-DRUG
and	O
cisplatin	B-DRUG
demonstrated	O
activity	O
and	O
acceptable	O
toxicity	O
for	O
treating	O
metastatic	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Gemcitabine	B-DRUG
and	O
carboplatin	B-DRUG
combination	O
chemotherapy	O
for	O
elderly	O
patients	O
with	O
advanced	B-CANCER
Non-Small	I-CANCER
Cell	I-CANCER
Lung	I-CANCER
Cancer	I-CANCER
:	O
a	O
feasibility	O
study	O
.	O
	
	
Although	O
platinum	B-DRUG
based	O
chemotherapy	O
is	O
known	O
to	O
improve	O
the	O
survival	O
duration	O
for	O
the	O
patients	O
with	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
","	O
the	O
role	O
of	O
platinum	B-DRUG
for	O
elderly	O
patient	O
is	O
not	O
yet	O
clear	O
.	O
	
We	O
administered	O
gemcitabine	B-DRUG
and	O
carboplatin	B-DRUG
combination	O
therapy	O
to	O
elderly	O
patients	O
with	O
NSCLC	B-CANCER
.	O
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
toxicities	O
of	O
this	O
regimen	O
for	O
elderly	O
patients	O
.	O
	
THE	O
ELIGIBILITY	O
CRITERIA	O
WERE	O
AS	O
FOLLOWS	O
:	O
pathologically	O
confirmed	O
NSCLC	B-CANCER
","	O
an	O
age	O
&	O
gt	O
;	O
or=65	O
years	O
","	O
advanced	O
disease	O
with	O
stage	O
IIIB	O
or	O
IV	O
and	O
the	O
patients	O
were	O
chemotherapy-naive	O
.	O
	
The	O
treatment	O
regimen	O
was	O
as	O
follows	O
;	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
was	O
administered	O
on	O
days	O
1	O
and	O
8	O
and	O
carboplatin	B-DRUG
AUC=5	O
was	O
administered	O
on	O
day	O
1	O
This	O
regimen	O
was	O
repeated	O
every	O
3	O
weeks	O
.	O
	
The	O
efficacy	O
was	O
evaluated	O
in	O
terms	O
of	O
the	O
response	O
rate	O
","	O
the	O
time	O
to	O
progression	O
and	O
the	O
overall	O
survival	O
duration	O
.	O
	
From	O
Dec	O
2001	O
to	O
Feb	O
2005	O
","	O
a	O
total	O
of	O
20	O
patients	O
were	O
entered	O
into	O
this	O
study	O
.	O
	
The	O
median	O
patient	O
age	O
was	O
68	O
years	O
(	O
range	O
:	O
65	O
approximately	O
75	O
)	O
.	O
	
19	O
patients	O
were	O
evaluable	O
for	O
their	O
treatment	O
response	O
.	O
	
A	O
partial	O
response	O
was	O
obtained	O
in	O
8	O
patients	O
(	O
response	O
rate	O
:	O
42.1	O
%	O
","	O
95	O
%	O
CI	O
:	O
19.4	O
approximately	O
64.8	O
%	O
)	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
and	O
the	O
survival	O
duration	O
were	O
136	O
days	O
and	O
453	O
days	O
","	O
respectively	O
.	O
	
Among	O
a	O
total	O
of	O
65	O
cycles	O
of	O
treatment	O
","	O
grade	O
3	O
or	O
4	O
leukopenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
were	O
observed	O
in	O
7.7	O
%	O
and	O
13.9	O
%	O
of	O
the	O
cycles	O
","	O
respectively	O
.	O
	
Grade	O
3	O
or	O
4	O
vomiting	B-TOXI
was	O
observed	O
in	O
7.7	O
%	O
of	O
the	O
cycles	O
.	O
	
Grade	O
3	O
skin	B-TOXI
rash	I-TOXI
developed	O
in	O
1.5	O
%	O
of	O
the	O
cycles	O
.	O
	
1	O
patient	O
died	B-TOXI
of	O
septic	B-TOXI
shock	I-TOXI
after	O
chemotherapy	O
.	O
	
Gemcitabine	B-DRUG
and	O
carboplatin	B-DRUG
combination	O
chemotherapy	O
was	O
relatively	O
safe	O
and	O
effective	O
for	O
treating	O
elderly	O
patients	O
with	O
NSCLC	B-CANCER
.	O
	
Phase	O
I	O
study	O
of	O
C-TPF	B-DRUG
in	O
patients	O
with	O
locally	O
advanced	B-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
	
Phase	O
I	O
study	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
in	O
the	O
docetaxel	B-DRUG
/	O
cisplatin	B-DRUG
/	O
FU	B-DRUG
(	O
TPF	B-DRUG
)	O
regimen	O
when	O
combined	O
with	O
cetuximab	B-DRUG
(	O
C	O
)	O
for	O
induction	O
treatment	O
of	O
locally	O
advanced	B-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	O
SCCHN	B-CANCER
)	O
.	O
	
Patients	O
with	O
previously	O
untreated	O
SCCHN	B-CANCER
were	O
enrolled	O
.	O
	
FU	B-DRUG
cohorts	O
were	O
700	O
","	O
850	O
","	O
and	O
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d	O
for	O
4	O
days	O
via	O
continuous	O
infusion	O
.	O
	
TPF	B-DRUG
given	O
every	O
3	O
weeks	O
for	O
three	O
cycles	O
and	O
C	O
was	O
given	O
weekly	O
for	O
a	O
total	O
of	O
9	O
weeks	O
","	O
starting	O
on	O
day	O
1	O
of	O
TPF	B-DRUG
.	O
	
All	O
patients	O
received	O
chemoradiotherapy	O
after	O
C-TPF	B-DRUG
.	O
	
A	O
total	O
of	O
30	O
patients	O
were	O
enrolled	O
and	O
28	O
were	O
assessable	O
.	O
	
The	O
median	O
age	O
was	O
57	O
years	O
","	O
92	O
%	O
had	O
stage	O
4	O
disease	O
","	O
71	O
%	O
were	O
oropharynx	O
","	O
and	O
100	O
%	O
had	O
a	O
performance	O
status	O
of	O
0	O
No	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
was	O
encountered	O
on	O
dose	O
levels	O
1	O
and	O
2	O
At	O
dose	O
level	O
3	O
of	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
one	O
DLT	O
was	O
encountered	O
and	O
three	O
more	O
patients	O
were	O
enrolled	O
with	O
no	O
DLTs	O
.	O
	
In	O
the	O
expansion	O
cohort	O
at	O
the	O
MTD	O
","	O
three	O
DLT	O
's	O
were	O
encountered	O
.	O
	
The	O
decision	O
was	O
made	O
to	O
decrease	O
the	O
FU	B-DRUG
from	O
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
to	O
dose	O
level	O
2	O
of	O
850	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
A	O
total	O
of	O
13	O
patients	O
were	O
enrolled	O
at	O
the	O
MTD	O
of	O
850	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
The	O
number	O
of	O
average	O
weeks	O
that	O
C	O
was	O
delivered	O
was	O
seven	O
of	O
nine	O
planned	O
.	O
	
C-TPF	B-DRUG
appears	O
to	O
be	O
safe	O
and	O
feasible	O
as	O
given	O
in	O
this	O
study	O
.	O
	
GI	O
toxicity	O
(	O
mucositis	B-TOXI
","	O
enteritis	B-TOXI
","	O
and	O
diarrhea	B-TOXI
)	O
appears	O
to	O
be	O
the	O
major	O
combined	O
DLT	O
.	O
	
Reducing	O
the	O
FU	B-DRUG
in	O
TPF	B-DRUG
to	O
850	O
mg	O
/	O
m	O
(	O
2	O
)	O
reduces	O
GI	O
toxicity	O
and	O
is	O
the	O
recommended	O
phase	O
II	O
dose	O
.	O
	
Pomalidomide	B-DRUG
(	O
CC4047	O
)	O
plus	O
low-dose	O
dexamethasone	B-DRUG
as	O
therapy	O
for	O
relapsed	O
multiple	B-CANCER
myeloma	I-CANCER
.	O
	
	
Thalidomide	B-DRUG
and	O
lenalidomide	B-DRUG
are	O
immunomodulatory	O
drugs	O
(	O
IMiDs	O
)	O
that	O
produce	O
high	O
remission	O
rates	O
in	O
the	O
treatment	O
of	O
multiple	B-CANCER
myeloma	I-CANCER
.	O
	
Pomalidomide	B-DRUG
is	O
a	O
new	O
IMiD	O
with	O
high	O
in	O
vitro	O
potency	O
.	O
	
We	O
report	O
","	O
to	O
our	O
knowledge	O
","	O
the	O
first	O
phase	O
II	O
trial	O
of	O
pomalidomide	B-DRUG
administered	O
in	O
combination	O
with	O
low-dose	O
dexamethasone	B-DRUG
for	O
the	O
treatment	O
of	O
relapsed	O
or	O
refractory	O
multiple	B-CANCER
myeloma	I-CANCER
.	O
	
Pomalidomide	B-DRUG
was	O
administered	O
orally	O
at	O
a	O
dose	O
of	O
2	O
mg	O
daily	O
on	O
days	O
1	O
through	O
28	O
of	O
a	O
28-day	O
cycle	O
.	O
	
Dexamethasone	B-DRUG
40	O
mg	O
daily	O
was	O
administered	O
orally	O
on	O
days	O
1	O
","	O
8	O
","	O
15	O
","	O
and	O
22	O
of	O
each	O
cycle	O
.	O
	
Responses	O
were	O
recorded	O
using	O
the	O
criteria	O
of	O
the	O
International	O
Myeloma	B-CANCER
Working	O
Group	O
.	O
	
Sixty	O
patients	O
were	O
enrolled	O
.	O
	
Thirty-eight	O
patients	O
(	O
63	O
%	O
)	O
achieved	O
confirmed	O
response	O
including	O
complete	O
response	O
in	O
three	O
patients	O
(	O
5	O
%	O
)	O
","	O
very	O
good	O
partial	O
response	O
in	O
17	O
patients	O
(	O
28	O
%	O
)	O
","	O
and	O
partial	O
response	O
in	O
18	O
patients	O
(	O
30	O
%	O
)	O
.	O
	
Responses	O
were	O
seen	O
in	O
40	O
%	O
of	O
lenalidomide-refractory	B-DRUG
patients	O
","	O
37	O
%	O
of	O
thalidomide-refractory	B-DRUG
patients	O
","	O
and	O
60	O
%	O
of	O
bortezomib-refractory	B-DRUG
patients	O
.	O
	
Responses	O
were	O
seen	O
in	O
74	O
%	O
of	O
patients	O
with	O
high-risk	O
cytogenetic	O
or	O
molecular	O
markers	O
.	O
	
Toxicity	O
consisted	O
primarily	O
of	O
myelosuppression	B-TOXI
.	O
	
Grade	O
3	O
or	O
4	O
hematologic	B-TOXI
toxicity	I-TOXI
consisted	O
of	O
anemia	B-TOXI
(	O
5	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
3	O
%	O
)	O
","	O
and	O
neutropenia	B-TOXI
(	O
32	O
%	O
)	O
.	O
	
One	O
patient	O
(	O
1.6	O
%	O
)	O
had	O
a	O
thromboembolic	B-TOXI
event	I-TOXI
.	O
	
The	O
median	O
progression-free	O
survival	O
time	O
was	O
11.6	O
months	O
and	O
was	O
not	O
significantly	O
different	O
in	O
patients	O
with	O
high-risk	O
disease	O
compared	O
with	O
patients	O
with	O
standard-risk	O
disease	O
.	O
	
The	O
combination	O
of	O
pomalidomide	B-DRUG
and	O
low-dose	O
dexamethasone	B-DRUG
is	O
extremely	O
active	O
in	O
the	O
treatment	O
of	O
relapsed	O
multiple	B-CANCER
myeloma	I-CANCER
","	O
including	O
high	O
response	O
rates	O
in	O
patients	O
refractory	O
to	O
other	O
novel	O
agents	O
.	O
	
Early	O
postoperative	O
paclitaxel	B-DRUG
followed	O
by	O
concurrent	O
paclitaxel	B-DRUG
and	O
cisplatin	B-DRUG
with	O
radiation	O
therapy	O
for	O
patients	O
with	O
resected	O
high-risk	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
:	O
report	O
of	O
the	O
phase	O
II	O
trial	O
RTOG	O
24	O
.	O
	
	
We	O
sought	O
to	O
improve	O
outcomes	O
for	O
patients	O
with	O
high-risk	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
squamous	I-CANCER
cell	I-CANCER
cancer	I-CANCER
(	O
HNSCC	B-CANCER
)	O
after	O
surgical	O
resection	O
by	O
testing	O
the	O
feasibility	O
and	O
safety	O
of	O
early	O
postoperative	O
chemotherapy	O
followed	O
by	O
concurrent	O
chemoradiotherapy	O
.	O
	
Eligible	O
patients	O
had	O
resected	O
","	O
stages	O
III	O
to	O
IV	O
HNSCC	B-CANCER
with	O
positive	O
margins	O
","	O
extracapsular	O
nodal	O
extension	O
","	O
or	O
multiple	O
positive	O
nodes	O
.	O
	
Paclitaxel	B-DRUG
(	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
was	O
given	O
once	O
weekly	O
during	O
postoperative	O
weeks	O
2	O
","	O
3	O
","	O
and	O
4	O
and	O
was	O
given	O
before	O
radiation	O
therapy	O
(	O
RT	O
)	O
.	O
	
Paclitaxel	B-DRUG
(	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
cisplatin	B-DRUG
(	O
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
were	O
given	O
once	O
weekly	O
during	O
the	O
last	O
3	O
weeks	O
of	O
RT	O
(	O
60	O
Gy	O
over	O
6	O
weeks	O
","	O
beginning	O
4	O
to	O
5	O
weeks	O
after	O
surgery	O
)	O
.	O
	
The	O
primary	O
end	O
points	O
were	O
treatment	O
safety	O
and	O
tolerability	O
compared	O
with	O
concurrent	O
cisplatin	B-DRUG
(	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
every	O
3	O
weeks	O
)	O
and	O
RT	O
","	O
as	O
tested	O
in	O
Radiation	O
Therapy	O
Oncology	O
Group	O
trial	O
RTOG	O
9501	O
.	O
	
The	O
median	O
follow-up	O
time	O
for	O
the	O
70	O
patients	O
enrolled	O
was	O
3.3	O
years	O
(	O
range	O
","	O
0.6	O
to	O
4.4	O
years	O
)	O
for	O
surviving	O
patients	O
.	O
	
Tolerability	O
of	O
all	O
treatment	O
components	O
was	O
comparable	O
to	O
that	O
of	O
RTOG	O
9501	O
treatment	O
","	O
which	O
is	O
the	O
current	O
standard	O
of	O
care	O
(	O
compliance	O
rate	O
","	O
75	O
%	O
;	O
95	O
%	O
CI	O
","	O
63	O
%	O
to	O
85	O
%	O
)	O
.	O
	
One	O
patient	O
died	B-TOXI
","	O
and	O
seven	O
patients	O
experienced	O
grade	O
4	O
nonhematologic	B-TOXI
toxicities	I-TOXI
.	O
	
Rates	O
of	O
locoregional	O
control	O
","	O
disease-free	O
survival	O
","	O
and	O
overall	O
survival	O
exceeded	O
those	O
of	O
RTOG	O
9501	O
after	O
adjustment	O
for	O
important	O
prognostic	O
variables	O
(	O
ie	O
","	O
positive	O
margins	O
","	O
extracapsular	O
extension	O
","	O
primary	O
site	O
","	O
and	O
performance	O
status	O
)	O
.	O
	
Chemotherapy	O
soon	O
after	O
surgery	O
followed	O
by	O
concurrent	O
chemoradiotherapy	O
therapy	O
was	O
feasible	O
;	O
tolerance	O
was	O
in	O
line	O
with	O
standard	O
postoperative	O
chemoradiotherapy	O
;	O
and	O
this	O
regimen	O
led	O
to	O
excellent	O
rates	O
of	O
locoregional	O
control	O
and	O
disease-free	O
survival	O
.	O
	
Frequent	O
pathologic	O
complete	O
responses	O
in	O
aggressive	O
stages	O
II	O
to	O
III	O
breast	B-CANCER
cancers	I-CANCER
with	O
every-4-week	O
carboplatin	B-DRUG
and	O
weekly	O
paclitaxel	B-DRUG
with	O
or	O
without	O
trastuzumab	B-DRUG
:	O
a	O
Brown	O
University	O
Oncology	O
Group	O
Study	O
.	O
	
	
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
neoadjuvant	O
carboplatin	B-DRUG
and	O
weekly	O
paclitaxel	B-DRUG
=+	O
/	O
=-	O
weekly	O
trastuzumab	B-DRUG
in	O
resectable	O
and	O
locally	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Women	O
with	O
stages	O
IIA	O
to	O
IIIB	O
disease	O
received	O
carboplatin	B-DRUG
dosed	O
by	O
six	O
times	O
the	O
area	O
under	O
the	O
curve	O
every	O
4	O
weeks	O
and	O
paclitaxel	B-DRUG
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
for	O
16	O
weeks	O
","	O
and	O
weekly	O
trastuzumab	B-DRUG
was	O
added	O
for	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
(	O
HER2	O
)	O
#NAME?	O
status	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
the	O
pathologic	O
complete	O
response	O
(	O
pCR	O
)	O
rate	O
","	O
defined	O
as	O
the	O
absence	O
of	O
invasive	O
disease	O
in	O
the	O
breast	O
and	O
axillary	O
nodes	O
.	O
	
Postoperative	O
therapies	O
were	O
at	O
the	O
discretion	O
of	O
the	O
treating	O
physicians	O
.	O
	
Fifty-five	O
patients	O
were	O
enrolled	O
","	O
and	O
of	O
these	O
43	O
had	O
resectable	O
disease	O
.	O
	
The	O
median	O
age	O
was	O
54	O
years	O
(	O
range	O
","	O
31	O
to	O
74	O
years	O
)	O
.	O
	
Treatment	O
was	O
well	O
tolerated	O
;	O
there	O
were	O
no	O
episodes	O
of	O
febrile	B-TOXI
neutropenia	I-TOXI
or	O
grade	O
4	O
thrombocytopenia	B-TOXI
","	O
and	O
there	O
were	O
only	O
two	O
instances	O
of	O
grade	O
3	O
peripheral	B-TOXI
neuropathy	I-TOXI
.	O
	
Overall	O
","	O
the	O
pCR	O
rate	O
was	O
45	O
%	O
.	O
	
The	O
pCR	O
rate	O
was	O
43	O
%	O
(	O
95	O
%	O
CI	O
","	O
28	O
%	O
to	O
58	O
%	O
)	O
in	O
patients	O
with	O
resectable	O
disease	O
.	O
	
Higher	O
pCR	O
rates	O
occurred	O
in	O
patients	O
with	O
HER2-positive	O
tumors	O
(	O
76	O
%	O
v	O
31	O
%	O
for	O
HER2-negative	O
tumors	O
;	O
P	O
=	O
0.003	O
)	O
","	O
with	O
estrogen	O
receptor	O
(	O
ER	O
)	O
#NAME?	O
tumors	O
(	O
75	O
%	O
v	O
27	O
%	O
for	O
ER-positive	O
tumors	O
;	O
P	O
=	O
0.001	O
)	O
","	O
or	O
with	O
triple-negative	O
tumors	O
(	O
67	O
%	O
v	O
12	O
%	O
ER-positive	O
and	O
HER2-negative	O
tumors	O
;	O
P	O
=	O
0.002	O
)	O
.	O
	
At	O
a	O
median	O
of	O
28	O
months	O
postoperation	O
","	O
recurrence-free	O
survival	O
(	O
RFS	O
)	O
was	O
88.7	O
%	O
.	O
	
If	O
patients	O
with	O
ER-positive	O
and	O
HER2-negative	O
tumors	O
are	O
excluded	O
from	O
analysis	O
","	O
patients	O
who	O
achieved	O
a	O
pCR	O
were	O
less	O
likely	O
to	O
experience	O
disease	O
recurrence	O
(	O
RFS	O
","	O
86	O
%	O
)	O
than	O
those	O
who	O
did	O
not	O
achieve	O
a	O
pCR	O
(	O
RFS	O
","	O
75	O
%	O
)	O
.	O
	
Neoadjuvant	O
carboplatin	B-DRUG
and	O
weekly	O
paclitaxel	B-DRUG
=+	O
/	O
=-	O
trastuzumab	B-DRUG
achieve	O
high	O
pCR	O
rates	O
in	O
patients	O
with	O
HER2-positive	O
and	O
triple-negative	O
disease	O
without	O
exposure	O
to	O
an	O
anthracycline	B-DRUG
.	O
	
Preliminary	O
RFS	O
results	O
are	O
encouraging	O
but	O
are	O
likely	O
influenced	O
by	O
adjuvant	O
therapy	O
received	O
.	O
	
Additional	O
study	O
of	O
this	O
regimen	O
in	O
high-risk	O
patients	O
is	O
warranted	O
.	O
	
Oxaliplatin	B-DRUG
","	O
5-FU	B-DRUG
","	O
folinic	B-DRUG
acid	I-DRUG
as	O
first-line	O
palliative	O
chemotherapy	O
in	O
elderly	O
patients	O
with	O
metastatic	B-CANCER
or	I-CANCER
recurrent	I-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
	
We	O
investigated	O
the	O
efficacy	O
and	O
safety	O
of	O
a	O
combination	O
of	O
oxaliplatin	B-DRUG
","	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
and	O
folinic	B-DRUG
acid	I-DRUG
(	O
FA	B-DRUG
)	O
as	O
first-line	O
palliative	O
chemotherapy	O
for	O
elderly	O
patients	O
with	O
metastatic	B-CANCER
or	I-CANCER
recurrent	I-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
The	O
study	O
patients	O
were	O
chemotherapy-na茂ve	O
patients	O
(	O
&	O
gt	O
;	O
65	O
years	O
old	O
)	O
with	O
histologically	O
confirmed	O
","	O
metastatic	B-CANCER
or	I-CANCER
recurrent	I-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Chemotherapy	O
consisted	O
of	O
oxaliplatin	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
FA	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
2-hour	O
infusion	O
)	O
","	O
and	O
then	O
5-FU	B-DRUG
2400	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
46-hour	O
continuous	O
infusion	O
)	O
every	O
2	O
weeks	O
.	O
	
A	O
total	O
of	O
37	O
patients	O
were	O
studied	O
between	O
April	O
2004	O
and	O
October	O
2006	O
.	O
	
Of	O
the	O
34	O
evaluable	O
patients	O
","	O
none	O
achieved	O
a	O
complete	O
response	O
(	O
CR	O
)	O
and	O
14	O
achieved	O
a	O
partial	O
response	O
(	O
PR	O
)	O
","	O
resulting	O
in	O
an	O
overall	O
response	O
rate	O
of	O
41.2	O
%	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
(	O
TTP	O
)	O
was	O
5.7	O
months	O
(	O
95	O
%	O
CI	O
:	O
4.2~6.3	O
months	O
)	O
and	O
the	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
9.8	O
months	O
(	O
95	O
%	O
CI	O
:	O
4.4~12.0	O
months	O
)	O
.	O
	
The	O
main	O
hematologic	B-TOXI
toxicities	I-TOXI
were	O
anemia	B-TOXI
and	O
neutropenia	B-TOXI
","	O
which	O
were	O
observed	O
in	O
56.7	O
%	O
and	O
32.4	O
%	O
of	O
the	O
patients	O
","	O
respectively	O
.	O
	
Grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
was	O
observed	O
in	O
8.1	O
%	O
of	O
the	O
patients	O
.	O
	
None	O
of	O
the	O
patients	O
experienced	O
febrile	B-TOXI
neutropenia	I-TOXI
.	O
	
Peripheral	B-TOXI
neuropathy	I-TOXI
occurred	O
in	O
35.1	O
%	O
of	O
the	O
patients	O
and	O
all	O
were	O
grade	O
1	O
/	O
2	O
This	O
oxaliplatin	B-DRUG
/	O
5-FU	B-DRUG
/	O
FA	B-DRUG
regimen	O
showed	O
good	O
efficacy	O
and	O
an	O
acceptable	O
toxicity	O
profile	O
in	O
elderly	O
patients	O
with	O
metastatic	B-CANCER
or	I-CANCER
recurrent	I-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Phase	O
II	O
study	O
of	O
the	O
histone	O
deacetylase	O
inhibitor	O
MGCD0103	B-DRUG
in	O
patients	O
with	O
previously	O
treated	O
chronic	B-CANCER
lymphocytic	I-CANCER
leukaemia	I-CANCER
.	O
	
	
MGCD0103	B-DRUG
","	O
an	O
orally	O
available	O
class	O
I	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
inhibitor	O
","	O
was	O
examined	O
for	O
pre-clinical	O
activity	O
in	O
chronic	B-CANCER
lymphocytic	I-CANCER
leukaemia	I-CANCER
(	O
CLL	B-CANCER
)	O
.	O
	
A	O
phase	O
II	O
clinical	O
trial	O
was	O
performed	O
","	O
starting	O
at	O
a	O
dose	O
of	O
85	O
mg	O
/	O
d	O
","	O
three	O
times	O
per	O
week	O
.	O
	
Dose	O
escalation	O
to	O
110	O
mg	O
or	O
the	O
addition	O
of	O
rituximab	B-DRUG
was	O
permitted	O
in	O
patients	O
without	O
a	O
response	O
after	O
two	O
or	O
more	O
cycles	O
.	O
	
MGCD0103	B-DRUG
demonstrated	O
pre-clinical	O
activity	O
against	O
CLL	B-CANCER
cells	O
with	O
a	O
LC	O
(	O
50	O
)	O
(	O
concentration	O
lethal	O
to	O
50	O
%	O
)	O
of	O
0.23	O
micromol	O
/	O
l	O
and	O
increased	O
acetylation	O
of	O
the	O
HDAC	O
class	O
I	O
specific	O
target	O
histone	O
H3	O
.	O
	
Twenty-one	O
patients	O
received	O
a	O
median	O
of	O
two	O
cycles	O
of	O
MGCD0103	B-DRUG
(	O
range	O
","	O
0-12	O
)	O
.	O
	
All	O
patients	O
had	O
previously	O
received	O
fludarabine	B-DRUG
","	O
33	O
%	O
were	O
fludarabine	B-DRUG
refractory	O
","	O
and	O
71	O
%	O
had	O
del	O
(	O
11q22.3	O
)	O
or	O
del	O
(	O
17p13.1	O
)	O
.	O
	
No	O
responses	O
according	O
to	O
the	O
National	O
Cancer	O
Institutes	O
1996	O
criteria	O
were	O
observed	O
.	O
	
Three	O
patients	O
received	O
110	O
mg	O
and	O
four	O
patients	O
received	O
concomitant	O
rituximab	B-DRUG
","	O
with	O
no	O
improvement	O
in	O
response	O
.	O
	
Grade	O
3月4日	O
toxicity	O
consisted	O
of	O
infections	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
anaemia	B-TOXI
","	O
diarrhoea	B-TOXI
","	O
and	O
fatigue	B-TOXI
.	O
	
HDAC	O
inhibition	O
was	O
observed	O
in	O
six	O
out	O
of	O
nine	O
patients	O
on	O
day	O
8	O
Limited	O
activity	O
was	O
observed	O
with	O
single	O
agent	O
MGCD0103	B-DRUG
in	O
high	O
risk	O
patients	O
with	O
CLL	B-CANCER
.	O
	
Future	O
investigations	O
in	O
CLL	B-CANCER
should	O
focus	O
on	O
broad	O
HDAC	O
inhibition	O
","	O
combination	O
strategies	O
","	O
and	O
approaches	O
to	O
diminish	O
constitutional	O
symptoms	O
associated	O
with	O
this	O
class	O
of	O
drugs	O
.	O
	
A	O
phase	O
II	O
study	O
of	O
irinotecan	B-DRUG
","	O
5-fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
for	O
treatment	O
in	O
patients	O
with	O
previously	O
untreated	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
We	O
prospectively	O
conducted	O
a	O
non-randomized	O
phase	O
II	O
trial	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
combination	O
irinotecan	B-DRUG
","	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
and	O
5-fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
as	O
a	O
first-line	O
regimen	O
for	O
treating	O
patients	O
with	O
previously	O
untreated	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
CRC	B-CANCER
)	O
.	O
	
Twenty-six	O
previously	O
untreated	O
patients	O
with	O
advanced	O
","	O
recurrent	B-CANCER
or	I-CANCER
metastatic	I-CANCER
CRC	I-CANCER
were	O
enrolled	O
in	O
this	O
study	O
.	O
	
The	O
patients	O
received	O
either	O
irinotecan	B-DRUG
180	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
with	O
LV	B-DRUG
bolus	O
of	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
FU	B-DRUG
bolus	O
of	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
and	O
this	O
was	O
followed	O
by	O
FU	B-DRUG
continuous	O
infusion	O
of	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
and	O
day	O
2	O
(	O
the	O
FOLFIRI	B-DRUG
regimen	O
)	O
","	O
or	O
they	O
were	O
treated	O
with	O
LV	B-DRUG
bolus	O
of	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
FU	B-DRUG
bolus	O
of	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
followed	O
by	O
FU	B-DRUG
continuous	O
infusion	O
of	O
"2,400"	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
46	O
hours	O
(	O
the	O
simplified	O
FOLFIRI	B-DRUG
regimen	O
)	O
","	O
and	O
these	O
treatments	O
were	O
repeated	O
every	O
2	O
weeks	O
until	O
disease	O
progression	O
.	O
	
The	O
objective	O
response	O
rate	O
was	O
23.1	O
%	O
(	O
6	O
/	O
26	O
)	O
respectively	O
","	O
for	O
both	O
treatments	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
was	O
5.3	O
months	O
(	O
range	O
:	O
0.4	O
approximately	O
19.9	O
)	O
","	O
and	O
the	O
overall	O
survival	O
was	O
11.2	O
months	O
(	O
range	O
:	O
0.5	O
approximately	O
52.3	O
)	O
.	O
	
The	O
prognostic	O
factor	O
for	O
longer	O
survival	O
was	O
the	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
(	O
ECOG	O
)	O
performance	O
status	O
(	O
PS	O
)	O
.	O
	
The	O
non-hematological	B-TOXI
toxicities	I-TOXI
were	O
similar	O
for	O
both	O
treatment	O
groups	O
","	O
with	O
more	O
frequent	O
grade	O
&	O
gt	O
;	O
or=3	O
neutropenia	B-TOXI
being	O
noted	O
for	O
the	O
simplified	O
FOLFIRI	B-DRUG
regimen	O
.	O
	
The	O
biweekly	O
irinotecan	B-DRUG
based	O
regimen	O
was	O
demonstrated	O
to	O
have	O
a	O
moderate	O
antitumor	O
activity	O
with	O
acceptable	O
toxicity	O
profiles	O
","	O
and	O
the	O
ECOG	O
PS	O
was	O
the	O
independent	O
prognostic	O
factor	O
.	O
	
Phase	O
II	O
study	O
of	O
cetuximab	B-DRUG
in	O
combination	O
with	O
cisplatin	B-DRUG
and	O
docetaxel	B-DRUG
in	O
patients	O
with	O
untreated	O
advanced	B-CANCER
gastric	I-CANCER
or	I-CANCER
gastro-oesophageal	I-CANCER
junction	I-CANCER
adenocarcinoma	I-CANCER
(	O
DOCETUX	O
study	O
)	O
.	O
	
	
The	O
conventional	O
treatment	O
options	O
for	O
advanced	B-CANCER
gastric	I-CANCER
patients	O
remain	O
unsatisfactory	O
in	O
terms	O
of	O
response	O
rate	O
","	O
response	O
duration	O
","	O
toxicity	O
","	O
and	O
overall	O
survival	O
benefit	O
.	O
	
The	O
purpose	O
of	O
this	O
phase	O
II	O
study	O
was	O
to	O
evaluate	O
the	O
activity	O
and	O
safety	O
of	O
cetuximab	B-DRUG
combined	O
with	O
cisplatin	B-DRUG
and	O
docetaxel	B-DRUG
as	O
a	O
first-line	O
treatment	O
for	O
advanced	B-CANCER
gastric	I-CANCER
or	I-CANCER
gastro-oesophageal	I-CANCER
junction	I-CANCER
adenocarcinoma	I-CANCER
.	O
	
Untreated	O
patients	O
with	O
histologically	O
confirmed	O
advanced	B-CANCER
gastric	I-CANCER
or	I-CANCER
gastro-oesophageal	I-CANCER
adenocarcinoma	I-CANCER
received	O
cetuximab	B-DRUG
at	O
an	O
initial	O
dose	O
of	O
400	O
mg	O
m	O
(	O
-2	O
)	O
i.v.	O
followed	O
by	O
weekly	O
doses	O
of	O
250	O
mg	O
m	O
(	O
-2	O
)	O
","	O
cisplatin	B-DRUG
75	O
mg	O
m	O
(	O
-2	O
)	O
i.v.	O
on	O
day	O
1	O
","	O
docetaxel	B-DRUG
75	O
mg	O
m	O
(	O
-2	O
)	O
i.v.	O
on	O
day	O
1	O
","	O
every	O
3	O
weeks	O
","	O
for	O
a	O
maximum	O
of	O
6	O
cycles	O
","	O
and	O
then	O
cetuximab	B-DRUG
maintenance	O
treatment	O
was	O
allowed	O
in	O
patients	O
with	O
a	O
complete	O
response	O
","	O
partial	O
response	O
","	O
or	O
stable	O
disease	O
.	O
	
Seventy-two	O
patients	O
(	O
stomach	O
81.9	O
%	O
and	O
gastro-oesophageal	O
junction	O
18.1	O
%	O
;	O
locally	O
advanced	O
disease	O
4.2	O
%	O
;	O
and	O
metastatic	O
disease	O
95.8	O
%	O
)	O
were	O
enrolled	O
.	O
	
The	O
ORR	O
was	O
41.2	O
%	O
(	O
95	O
%	O
CI	O
","	O
29.5-52.9	O
)	O
.	O
	
Median	O
time	O
to	O
progression	O
was	O
5	O
months	O
(	O
95	O
%	O
CI	O
","	O
3.7-5.4	O
)	O
.	O
	
Median	O
survival	O
time	O
was	O
9	O
months	O
(	O
95	O
%	O
CI	O
","	O
7月11日	O
)	O
.	O
	
The	O
most	O
frequent	O
grades	O
3月4日	O
toxicity	O
was	O
neutropenia	B-TOXI
(	O
44.4	O
%	O
)	O
.	O
	
No	O
toxic	B-TOXI
death	I-TOXI
was	O
observed	O
.	O
	
The	O
addition	O
of	O
cetuximab	B-DRUG
to	O
the	O
cisplatin	B-DRUG
/	O
docetaxel	B-DRUG
regimen	O
improved	O
the	O
ORR	O
of	O
the	O
cisplatin	B-DRUG
/	O
docetaxel	B-DRUG
doublet	O
in	O
the	O
first-line	O
treatment	O
of	O
advanced	B-CANCER
gastric	I-CANCER
and	I-CANCER
gastro-oesophageal	I-CANCER
junction	I-CANCER
adenocarcinoma	I-CANCER
","	O
but	O
this	O
combination	O
did	O
not	O
improve	O
the	O
TTP	O
and	O
OS	O
.	O
	
The	O
toxicity	O
of	O
cisplatin	B-DRUG
/	O
docetaxel	B-DRUG
chemotherapy	O
was	O
not	O
affected	O
by	O
the	O
addition	O
of	O
cetuximab	B-DRUG
.	O
	
Phase	O
I	O
/	O
II	O
study	O
of	O
concurrent	O
chemoradiotherapy	O
for	O
localized	O
nasal	O
natural	O
killer	O
/	O
T-cell	B-CANCER
lymphoma	I-CANCER
:	O
Japan	O
Clinical	O
Oncology	O
Group	O
Study	O
JCOG0211	O
.	O
	
	
To	O
explore	O
a	O
more	O
effective	O
treatment	O
for	O
localized	O
nasal	O
natural	O
killer	O
(	O
NK	O
)	O
/	O
T-cell	B-CANCER
lymphoma	I-CANCER
","	O
we	O
conducted	O
a	O
phase	O
I	O
/	O
II	O
study	O
of	O
concurrent	O
chemoradiotherapy	O
.	O
	
Treatments	O
comprised	O
concurrent	O
radiotherapy	O
(	O
50	O
Gy	O
)	O
and	O
3	O
courses	O
of	O
dexamethasone	B-DRUG
","	O
etoposide	B-DRUG
","	O
ifosfamide	B-DRUG
","	O
and	O
carboplatin	B-DRUG
(	O
DeVIC	B-DRUG
)	O
.	O
	
Patients	O
with	O
a	O
newly	O
diagnosed	O
stage	O
IE	O
or	O
contiguous	O
IIE	O
disease	O
with	O
cervical	O
node	O
involvement	O
and	O
a	O
performance	O
status	O
(	O
PS	O
)	O
of	O
0	O
to	O
2	O
were	O
eligible	O
for	O
enrollment	O
.	O
	
The	O
primary	O
end	O
point	O
of	O
the	O
phase	O
II	O
portion	O
was	O
a	O
2-year	O
overall	O
survival	O
in	O
patients	O
treated	O
with	O
the	O
recommended	O
dose	O
.	O
	
Of	O
the	O
33	O
patients	O
enrolled	O
","	O
10	O
patients	O
were	O
enrolled	O
in	O
the	O
phase	O
I	O
portion	O
and	O
a	O
two	O
thirds	O
dose	O
of	O
DeVIC	B-DRUG
was	O
established	O
as	O
the	O
recommended	O
dose	O
.	O
	
Twenty-seven	O
patients	O
(	O
range	O
","	O
21	O
to	O
68	O
;	O
median	O
","	O
56	O
years	O
)	O
treated	O
with	O
the	O
recommended	O
dose	O
showed	O
the	O
following	O
clinical	O
features	O
:	O
male	O
:	O
female	O
","	O
17:10	O
;	O
stage	O
IE	O
","	O
18	O
;	O
stage	O
IIE	O
","	O
9	O
;	O
B	O
symptoms	O
present	O
","	O
10	O
;	O
elevated	B-TOXI
serum	I-TOXI
lactate	I-TOXI
dehydrogenase	I-TOXI
","	O
5	O
;	O
and	O
PS	O
2	O
","	O
2	O
With	O
a	O
median	O
follow-up	O
of	O
32	O
months	O
","	O
the	O
2-year	O
overall	O
survival	O
was	O
78	O
%	O
(	O
95	O
%	O
CI	O
","	O
57	O
%	O
to	O
89	O
%	O
)	O
.	O
	
This	O
compared	O
favorably	O
with	O
the	O
historical	O
control	O
of	O
radiotherapy	O
alone	O
(	O
45	O
%	O
)	O
.	O
	
Of	O
the	O
26	O
patients	O
assessable	O
for	O
a	O
response	O
","	O
20	O
(	O
77	O
%	O
)	O
achieved	O
a	O
complete	O
response	O
","	O
with	O
one	O
partial	O
response	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
81	O
%	O
.	O
	
The	O
most	O
common	O
grade	O
3	O
nonhematologic	B-TOXI
toxicity	I-TOXI
was	O
mucositis	B-TOXI
related	O
to	O
radiation	O
(	O
30	O
%	O
)	O
.	O
	
No	O
treatment-related	O
deaths	B-TOXI
were	O
observed	O
.	O
	
Concurrent	O
chemoradiotherapy	O
using	O
multidrug	O
resistance-nonrelated	O
agents	O
and	O
etoposide	B-DRUG
is	O
a	O
safe	O
and	O
effective	O
treatment	O
for	O
localized	O
nasal	O
NK	O
/	O
T-cell	B-CANCER
lymphoma	I-CANCER
and	O
warrants	O
further	O
investigation	O
.	O
	
Phase	O
II	O
study	O
of	O
cisplatin	B-DRUG
plus	O
etoposide	B-DRUG
and	O
bevacizumab	B-DRUG
for	O
previously	O
untreated	O
","	O
extensive-stage	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
Study	O
E3501	O
.	O
	
	
To	O
investigate	O
the	O
efficacy	O
and	O
safety	O
of	O
bevacizumab	B-DRUG
plus	O
cisplatin	B-DRUG
and	O
etoposide	B-DRUG
in	O
patients	O
with	O
extensive-stage	O
disease	O
","	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
ED-SCLC	O
)	O
.	O
	
In	O
this	O
phase	O
II	O
trial	O
","	O
63	O
patients	O
were	O
treated	O
with	O
bevacizumab	B-DRUG
15	O
mg	O
/	O
kg	O
plus	O
cisplatin	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
etoposide	B-DRUG
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
which	O
was	O
followed	O
by	O
bevacizumab	B-DRUG
alone	O
until	O
death	B-TOXI
or	O
disease	O
progression	O
occurred	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
the	O
proportion	O
of	O
patients	O
alive	O
at	O
6	O
months	O
without	O
disease	O
progression	O
(	O
ie	O
","	O
progression-free	O
survival	O
[	O
PFS	O
]	O
)	O
.	O
	
Secondary	O
end	O
points	O
included	O
overall	O
survival	O
(	O
OS	O
)	O
","	O
objective	O
response	O
rate	O
","	O
and	O
toxicity	O
.	O
	
Correlative	O
studies	O
were	O
performed	O
to	O
explore	O
the	O
relationship	O
between	O
baseline	O
and	O
changes	O
in	O
plasma	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
","	O
soluble	O
cell	O
adhesion	O
molecules	O
(	O
ie	O
","	O
vascular	O
cell	O
adhesion	O
molecule	O
[	O
VCAM	O
]	O
","	O
intercellular	O
cell	O
adhesion	O
molecule	O
[	O
ICAM	O
]	O
","	O
and	O
E-selectin	O
)	O
and	O
basic	O
fibroblast	O
growth	O
factor	O
and	O
outcome	O
.	O
	
The	O
6-month	O
PFS	O
was	O
30.2	O
%	O
","	O
the	O
median	O
PFS	O
was	O
4.7	O
months	O
","	O
and	O
OS	O
was	O
10.9	O
months	O
.	O
	
The	O
response	O
rate	O
was	O
63.5	O
%	O
.	O
	
The	O
most	O
common	O
adverse	O
event	O
was	O
neutropenia	B-TOXI
(	O
57.8	O
%	O
)	O
.	O
	
Only	O
one	O
patient	O
had	O
grade	O
3	O
pulmonary	B-TOXI
hemorrhage	I-TOXI
.	O
	
Patients	O
who	O
had	O
high	O
baseline	O
VCAM	O
had	O
a	O
higher	O
risk	O
of	O
progression	O
or	O
death	B-TOXI
compared	O
with	O
those	O
who	O
had	O
low	O
baseline	O
VCAM	O
levels	O
.	O
	
No	O
relationships	O
between	O
outcome	O
and	O
any	O
other	O
biomarkers	O
were	O
seen	O
.	O
	
The	O
addition	O
of	O
bevacizumab	B-DRUG
to	O
cisplatin	B-DRUG
and	O
etoposide	B-DRUG
in	O
patients	O
with	O
ED-SCLC	O
results	O
in	O
improved	O
PFS	O
and	O
OS	O
relative	O
to	O
historical	O
controls	O
who	O
received	O
this	O
chemotherapy	O
regimen	O
without	O
bevacizumab	B-DRUG
.	O
	
This	O
regimen	O
appears	O
to	O
be	O
well	O
tolerated	O
and	O
has	O
minimal	O
increase	O
in	O
toxicities	O
compared	O
with	O
chemotherapy	O
alone	O
.	O
	
Baseline	O
VCAM	O
levels	O
predicted	O
survival	O
","	O
but	O
no	O
other	O
relationships	O
among	O
treatment	O
","	O
biomarkers	O
","	O
and	O
outcome	O
were	O
identified	O
.	O
	
A	O
dose	O
escalation	O
study	O
of	O
docetaxel	B-DRUG
plus	O
capecitabine	B-DRUG
in	O
combination	O
with	O
oxaliplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Capecitabine	B-DRUG
(	O
CAP	B-DRUG
)	O
","	O
Oxaliplatin	B-DRUG
(	O
OX	B-DRUG
)	O
and	O
Docetaxel	B-DRUG
(	O
DOC	B-DRUG
)	O
have	O
shown	O
considerable	O
activity	O
in	O
a	O
wide	O
range	O
of	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
A	O
phase	O
I	O
study	O
was	O
conducted	O
in	O
order	O
to	O
determine	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
of	O
their	O
combination	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Twenty-one	O
patients	O
were	O
enrolled	O
.	O
	
The	O
patient	O
's	O
median	O
age	O
was	O
68	O
years	O
","	O
15	O
were	O
male	O
","	O
and	O
12	O
were	O
chemo-na茂ve	O
.	O
	
DOC	B-DRUG
was	O
administered	O
on	O
day	O
1	O
as	O
an	O
1-hour	O
(	O
iv	O
)	O
infusion	O
at	O
a	O
standard	O
dose	O
of	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
OX	B-DRUG
was	O
administered	O
on	O
day	O
1	O
as	O
a	O
2-hour	O
(	O
iv	O
)	O
infusion	O
at	O
escalating	O
doses	O
ranging	O
from	O
70-80	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
CAP	B-DRUG
was	O
administered	O
orally	O
on	O
days	O
1	O
to	O
7	O
at	O
escalating	O
doses	O
ranging	O
from	O
"2,000-2,750"	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
as	O
two	O
daily	O
divided	O
doses	O
.	O
	
Treatment	O
was	O
repeated	O
every	O
two	O
weeks	O
.	O
	
Six	O
different	O
dose-levels	O
were	O
examined	O
.	O
	
At	O
dose-level	O
VI	O
","	O
two	O
of	O
three	O
enrolled	O
patients	O
presented	O
DLTs	O
(	O
one	O
patient	O
diarrhea	B-TOXI
and	O
asthenia	B-TOXI
grade	O
3	O
and	O
another	O
grade	O
3	O
diarrhea	B-TOXI
)	O
","	O
and	O
thus	O
","	O
the	O
recommended	O
MTD	O
for	O
future	O
phase	O
II	O
studies	O
is	O
CAP	B-DRUG
"2,750"	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
DOC	B-DRUG
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
OX	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
A	O
total	O
of	O
121	O
treatment	O
cycles	O
were	O
administered	O
.	O
	
Grade	O
3	O
neutropenia	B-TOXI
was	O
observed	O
in	O
six	O
(	O
5	O
%	O
)	O
treatment	O
cycles	O
and	O
grade	O
3	O
thrombocytopenia	B-TOXI
in	O
one	O
(	O
1	O
%	O
)	O
.	O
	
There	O
was	O
no	O
febrile	B-TOXI
episode	I-TOXI
.	O
	
Grade	O
3	O
asthenia	B-TOXI
was	O
observed	O
in	O
three	O
(	O
14	O
%	O
)	O
patients	O
","	O
grade	O
3	O
diarrhea	B-TOXI
in	O
four	O
(	O
19	O
%	O
)	O
","	O
grade	O
3	O
neuropathy	B-TOXI
in	O
one	O
(	O
5	O
%	O
)	O
","	O
and	O
grade	O
1	O
/	O
2	O
hand-foot	B-TOXI
syndrome	I-TOXI
in	O
three	O
(	O
14	O
%	O
)	O
.	O
	
Other	O
toxicities	O
were	O
uncommon	O
.	O
	
There	O
was	O
no	O
treatment	B-TOXI
related	I-TOXI
death	I-TOXI
.	O
	
Four	O
(	O
29	O
%	O
)	O
PRs	O
and	O
seven	O
(	O
50	O
%	O
)	O
SD	O
were	O
observed	O
among	O
14	O
evaluable	O
patients	O
.	O
	
Responses	O
were	O
seen	O
in	O
patients	O
with	O
renal	O
(	O
n	O
=	O
1	O
)	O
","	O
gastric	O
(	O
n	O
=	O
2	O
)	O
and	O
pancreatic	O
(	O
n	O
=	O
1	O
)	O
cancer	O
.	O
	
These	O
results	O
demonstrate	O
that	O
CAP	B-DRUG
","	O
DOC	B-DRUG
and	O
OX	B-DRUG
can	O
be	O
safely	O
combined	O
at	O
clinically	O
relevant	O
doses	O
and	O
this	O
regimen	O
merits	O
further	O
evaluation	O
.	O
	
Dose	O
finding	O
and	O
early	O
efficacy	O
study	O
of	O
gemcitabine	B-DRUG
plus	O
capecitabine	B-DRUG
in	O
combination	O
with	O
bevacizumab	B-DRUG
plus	O
erlotinib	B-DRUG
in	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
	
This	O
study	O
evaluated	O
safety	O
and	O
efficacy	O
of	O
chemotherapy	O
(	O
gemcitabine	B-DRUG
plus	O
capecitabine	B-DRUG
)	O
plus	O
bevacizumab	B-DRUG
/	O
erlotinib	B-DRUG
in	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
because	O
dual	O
epidermal	O
growth	O
factor	O
receptor	O
/	O
vascular	O
endothelial	O
growth	O
factor	O
blockade	O
has	O
a	O
rational	O
biologic	O
basis	O
in	O
this	O
malignancy	O
.	O
	
Patients	O
with	O
untreated	O
","	O
unresectable	O
","	O
locally	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
pancreatic	I-CANCER
carcinoma	I-CANCER
were	O
enrolled	O
onto	O
one	O
of	O
the	O
following	O
four	O
sequential	O
dose	O
levels	O
(	O
DLs	O
)	O
of	O
escalating	O
capecitabine	O
doses	O
(	O
days	O
1	O
to	O
21	O
)	O
:	O
DL1	O
","	O
910	O
mg	O
/	O
m	O
(	O
2	O
)	O
;	O
DL2	O
","	O
"1,160"	O
mg	O
/	O
m	O
(	O
2	O
)	O
;	O
DL3	O
","	O
"1,400"	O
mg	O
/	O
m	O
(	O
2	O
)	O
;	O
or	O
DL4	O
","	O
"1,660"	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Doses	O
of	O
coadministered	O
gemcitabine	B-DRUG
(	O
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
)	O
","	O
bevacizumab	B-DRUG
(	O
5	O
mg	O
/	O
kg	O
on	O
days	O
1	O
and	O
15	O
)	O
","	O
and	O
erlotinib	B-DRUG
(	O
100	O
mg	O
/	O
d	O
)	O
every	O
28	O
days	O
(	O
up	O
to	O
six	O
cycles	O
)	O
were	O
fixed	O
.	O
	
Using	O
a	O
3+3	O
study	O
design	O
","	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
was	O
assessed	O
in	O
cycle	O
1	O
Results	O
Twenty	O
assessable	O
patients	O
were	O
enrolled	O
(	O
DL1	O
","	O
n	O
=	O
8	O
;	O
DL2	O
","	O
n	O
=	O
3	O
;	O
DL3	O
","	O
n	O
=	O
6	O
;	O
and	O
DL4	O
","	O
n	O
=	O
3	O
)	O
;	O
97	O
cycles	O
were	O
administered	O
.	O
	
Median	O
age	O
was	O
63	O
years	O
(	O
range	O
","	O
33	O
to	O
77	O
years	O
)	O
","	O
and	O
male-to-female	O
ratio	O
was	O
10:10	O
.	O
	
Performance	O
status	O
was	O
0	O
and	O
1	O
in	O
two	O
and	O
17	O
patients	O
","	O
respectively	O
;	O
and	O
nine	O
and	O
11	O
patients	O
had	O
locally	O
advanced	O
and	O
metastatic	O
disease	O
","	O
respectively	O
.	O
	
DLT	O
occurred	O
in	O
one	O
patient	O
at	O
DL1	O
(	O
grade	O
3	O
epistaxis	B-TOXI
)	O
and	O
two	O
patients	O
at	O
DL4	O
(	O
grade	O
3	O
diarrhea	B-TOXI
and	O
grade	O
3	O
skin	B-TOXI
rash	I-TOXI
&	O
gt	O
;	O
7	O
days	O
)	O
.	O
	
Common	O
grade	O
3	O
and	O
4	O
toxicities	O
(	O
10	O
%	O
to	O
20	O
%	O
)	O
were	O
diarrhea	B-TOXI
","	O
hand-foot	B-TOXI
syndrome	I-TOXI
","	O
stomatitis	B-TOXI
","	O
and	O
skin	B-TOXI
rash	I-TOXI
.	O
	
Grade	O
3	O
lethargy	B-TOXI
and	O
grade	O
3	O
or	O
4	O
neutropenia	B-TOXI
occurred	O
in	O
40	O
%	O
and	O
45	O
%	O
of	O
patients	O
","	O
respectively	O
.	O
	
No	O
GI	B-TOXI
perforation	I-TOXI
","	O
grade	O
3	O
GI	B-TOXI
hemorrhage	I-TOXI
/	O
hypertension	B-TOXI
","	O
or	O
pneumonitis	B-TOXI
occurred	O
.	O
	
Ten	O
partial	O
responses	O
were	O
observed	O
.	O
	
Median	O
overall	O
and	O
progression-survival	O
times	O
(	O
all	O
patients	O
)	O
were	O
12.5	O
and	O
9	O
months	O
","	O
respectively	O
.	O
	
The	O
maximum-tolerated	O
dose	O
of	O
capecitabine	B-DRUG
was	O
"1,660"	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
The	O
recommended	O
capecitabine	B-DRUG
dose	O
in	O
this	O
cytotoxic	O
doublet	O
/	O
biologic	O
doublet	O
regimen	O
is	O
"1,440"	O
mg	O
/	O
m	O
(	O
2	O
)	O
;	O
this	O
regimen	O
is	O
under	O
evaluation	O
in	O
an	O
ongoing	O
phase	O
II	O
study	O
.	O
	
Molecular	O
and	O
clinical	O
responses	O
in	O
a	O
pilot	O
study	O
of	O
gefitinib	B-DRUG
with	O
paclitaxel	B-DRUG
and	O
radiation	O
in	O
locally	O
advanced	B-CANCER
head-and-neck	I-CANCER
cancer	I-CANCER
.	O
	
	
Epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
overexpression	O
in	O
head-and-neck	B-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
HNSCC	B-CANCER
)	O
stimulates	O
tumor	O
cell	O
proliferation	O
","	O
inhibits	O
apoptosis	O
","	O
and	O
increases	O
chemotherapy	O
and	O
radiation	O
resistance	O
.	O
	
We	O
examined	O
the	O
toxicity	O
","	O
safety	O
and	O
the	O
effects	O
on	O
EGFR	O
signaling	O
in	O
tumor	O
biopsy	O
samples	O
from	O
patients	O
with	O
locally	O
advanced	B-CANCER
HNSCC	I-CANCER
treated	O
with	O
the	O
EGFR	O
signaling	O
inhibitor	O
gefitinib	B-DRUG
(	O
GEF	B-DRUG
)	O
combined	O
with	O
weekly	O
intravenous	O
paclitaxel	B-DRUG
(	O
PAC	B-DRUG
)	O
and	O
radiation	O
therapy	O
(	O
RT	O
)	O
.	O
	
This	O
was	O
a	O
pilot	O
Phase	O
I	O
dose-escalation	O
study	O
.	O
	
Eligibility	O
included	O
Stage	O
III	O
to	O
IVB	O
HNSCC	B-CANCER
","	O
age	O
&	O
gt	O
;	O
or=18	O
years	O
","	O
no	O
prior	O
RT	O
or	O
chemotherapy	O
","	O
adequate	O
organ	O
function	O
","	O
and	O
informed	O
consent	O
.	O
	
Endpoints	O
included	O
determination	O
of	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
analysis	O
of	O
treatment	O
effect	O
on	O
EGFR	O
signaling	O
","	O
tumor	O
cell	O
proliferation	O
","	O
and	O
apoptosis	O
in	O
biopsy	O
samples	O
.	O
	
Ten	O
patients	O
were	O
treated	O
.	O
	
The	O
MTD	O
of	O
this	O
combination	O
was	O
GEF	B-DRUG
250	O
mg	O
/	O
d	O
with	O
PAC	B-DRUG
36	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
weekly	O
x	O
6	O
with	O
concurrent	O
RT.	O
Grade	O
3	O
/	O
4	O
toxicities	O
included	O
prolonged	O
(	O
&	O
gt	O
;	O
8	O
weeks	O
)	O
stomatitis	B-TOXI
(	O
7	O
patients	O
)	O
","	O
infection	B-TOXI
(	O
2	O
patients	O
)	O
","	O
and	O
interstitial	B-TOXI
pneumonitis	I-TOXI
(	O
1	O
patient	O
)	O
.	O
	
There	O
were	O
five	O
complete	O
responses	O
(	O
CR	O
)	O
and	O
two	O
partial	O
responses	O
(	O
PR	O
)	O
.	O
	
Of	O
7	O
patients	O
undergoing	O
serial	O
biopsies	O
","	O
only	O
1	O
patient	O
demonstrated	O
a	O
reduction	O
in	O
phosphorylated	O
EGFR	O
","	O
decreased	O
downstream	O
signaling	O
","	O
and	O
reduced	O
cellular	O
proliferation	O
after	O
initiating	O
GEF	B-DRUG
.	O
	
Inhibition	O
of	O
EGFR	O
by	O
GEF	B-DRUG
was	O
observed	O
in	O
only	O
one	O
of	O
seven	O
tumors	O
studied	O
.	O
	
The	O
addition	O
of	O
GEF	B-DRUG
to	O
PAC	B-DRUG
and	O
RT	O
did	O
not	O
appear	O
to	O
improve	O
the	O
response	O
of	O
locally	O
advanced	B-CANCER
HNSCC	I-CANCER
compared	O
with	O
our	O
prior	O
experience	O
with	O
PAC	B-DRUG
and	O
RT	O
alone	O
.	O
	
This	O
treatment	O
appeared	O
to	O
delay	O
recovery	O
from	O
stomatitis	B-TOXI
.	O
	
Phase	O
II	O
trial	O
of	O
concurrent	O
radiation	O
and	O
weekly	O
cisplatin	B-DRUG
followed	O
by	O
VIPD	O
chemotherapy	O
in	O
newly	O
diagnosed	O
","	O
stage	O
IE	O
to	O
IIE	O
","	O
nasal	B-CANCER
","	I-CANCER
extranodal	I-CANCER
NK	I-CANCER
/	I-CANCER
T-Cell	I-CANCER
Lymphoma	I-CANCER
:	O
Consortium	O
for	O
Improving	O
Survival	O
of	O
Lymphoma	B-CANCER
study	O
.	O
	
	
On	O
the	O
basis	O
of	O
the	O
benefits	O
of	O
frontline	O
radiation	O
in	O
early-stage	O
","	O
extranodal	O
","	O
natural	O
killer	O
(	O
NK	O
)	O
/	O
T-cell	B-CANCER
lymphoma	I-CANCER
(	O
ENKTL	O
)	O
","	O
we	O
conducted	O
a	O
phase	O
II	O
trial	O
of	O
concurrent	O
chemoradiotherapy	O
(	O
CCRT	O
)	O
followed	O
by	O
three	O
cycles	O
of	O
etoposide	B-DRUG
","	O
ifosfamide	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
dexamethasone	B-DRUG
(	O
VIPD	B-DRUG
)	O
.	O
	
Thirty	O
patients	O
with	O
newly	O
diagnosed	O
","	O
stages	O
IE	O
to	O
IIE	O
","	O
nasal	O
ENKTL	B-CANCER
received	O
CCRT	O
(	O
ie	O
radiation	O
40	O
to	O
52.8	O
Gy	O
and	O
cisplatin	B-DRUG
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
)	O
.	O
	
Three	O
cycles	O
of	O
VIPD	B-DRUG
(	O
etoposide	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
days	O
1	O
through	O
3	O
","	O
ifosfamide	B-DRUG
"1,200"	O
mg	O
/	O
m	O
(	O
2	O
)	O
days	O
1	O
through	O
3	O
","	O
cisplatin	B-DRUG
33	O
mg	O
/	O
m	O
(	O
2	O
)	O
days	O
1	O
through	O
3	O
","	O
and	O
dexamethasone	B-DRUG
40	O
mg	O
days	O
1	O
through	O
4	O
)	O
were	O
scheduled	O
after	O
CCRT	O
.	O
	
All	O
patients	O
completed	O
CCRT	O
","	O
which	O
resulted	O
in	O
100	O
%	O
response	O
that	O
included	O
22	O
complete	O
responses	O
(	O
CRs	O
)	O
and	O
eight	O
partial	O
responses	O
(	O
PRs	O
)	O
.	O
	
The	O
CR	O
rate	O
after	O
CCRT	O
was	O
73.3	O
%	O
(	O
ie	O
","	O
22	O
of	O
30	O
responses	O
;	O
95	O
%	O
CI	O
","	O
57.46	O
to	O
89.13	O
)	O
.	O
	
Twenty-six	O
of	O
30	O
patients	O
completed	O
the	O
planned	O
three	O
cycles	O
of	O
VIPD	B-DRUG
","	O
whereas	O
four	O
patients	O
did	O
not	O
because	O
they	O
withdrew	O
(	O
n	O
=	O
2	O
)	O
or	O
because	O
they	O
had	O
an	O
infection	B-TOXI
(	O
n	O
=	O
2	O
)	O
.	O
	
The	O
overall	O
response	O
rate	O
and	O
the	O
CR	O
rate	O
were	O
83.3	O
%	O
(	O
ie	O
;	O
25	O
of	O
30	O
responses	O
;	O
95	O
%	O
CI	O
","	O
65.28	O
to	O
94.36	O
)	O
and	O
80	O
%	O
(	O
ie	O
","	O
24	O
of	O
30	O
responses	O
;	O
95	O
%	O
CI	O
","	O
65.69	O
to	O
94.31	O
)	O
","	O
respectively	O
.	O
	
Only	O
one	O
patient	O
experienced	O
grade	O
3	O
toxicity	O
during	O
CCRT	O
(	O
nausea	B-TOXI
)	O
","	O
whereas	O
12	O
of	O
29	O
patients	O
experienced	O
grade	O
4	O
neutropenia	B-TOXI
.	O
	
The	O
estimated	O
3-year	O
","	O
progression-free	O
and	O
overall	O
survival	O
rates	O
were	O
85.19	O
%	O
(	O
95	O
%	O
CI	O
","	O
72.48	O
to	O
97.9	O
)	O
and	O
86.28	O
%	O
(	O
95	O
%	O
CI	O
","	O
73.97	O
to	O
98.59	O
)	O
","	O
respectively	O
.	O
	
Patients	O
with	O
newly	O
diagnosed	O
","	O
stages	O
IE	O
to	O
IIE	O
","	O
nasal	O
ENKTL	B-CANCER
are	O
best	O
treated	O
with	O
frontline	O
CCRT	O
.	O
	
Efficacy	O
of	O
sequential	O
methotrexate	B-DRUG
and	O
5-fluorouracil	B-DRUG
(	O
MTX	B-DRUG
/	O
5FU	B-DRUG
)	O
in	O
improving	O
oral	O
intake	O
in	O
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
with	O
severe	O
peritoneal	O
dissemination	O
.	O
	
	
Although	O
peritoneal	O
dissemination	O
of	O
gastric	B-CANCER
cancer	I-CANCER
is	O
common	O
and	O
often	O
causes	O
deterioration	O
of	O
the	O
patient	O
's	O
condition	O
and	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
","	O
these	O
patients	O
are	O
usually	O
excluded	O
from	O
clinical	O
trials	O
.	O
	
We	O
retrospectively	O
investigated	O
the	O
clinical	O
benefit	O
and	O
toxicity	O
of	O
sequential	O
methotrexate	B-DRUG
and	O
5-fluorouracil	B-DRUG
(	O
MTX	B-DRUG
/	O
5FU	B-DRUG
)	O
therapy	O
for	O
patients	O
with	O
peritoneal	O
dissemination	O
.	O
	
The	O
subjects	O
were	O
31	O
patients	O
with	O
severe	O
peritoneal	O
dissemination	O
of	O
gastric	B-CANCER
cancer	I-CANCER
who	O
were	O
treated	O
with	O
MTX	B-DRUG
/	O
5FU	B-DRUG
.	O
	
The	O
treatment	O
schedule	O
comprised	O
weekly	O
administration	O
of	O
MTX	B-DRUG
(	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
followed	O
by	O
5FU	B-DRUG
(	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O
	
Leucovorin	B-DRUG
(	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
was	O
administered	O
six	O
times	O
","	O
every	O
6	O
h	O
","	O
starting	O
24	O
h	O
after	O
MTX	B-DRUG
administration	O
.	O
	
The	O
median	O
survival	O
time	O
was	O
255	O
days	O
","	O
and	O
the	O
median	O
progression-free	O
survival	O
was	O
127	O
days	O
.	O
	
Of	O
the	O
21	O
patients	O
with	O
measurable	O
lesions	O
","	O
4	O
(	O
19	O
%	O
)	O
patients	O
achieved	O
a	O
partial	O
response	O
.	O
	
Ascites	B-TOXI
volume	O
decreased	O
markedly	O
in	O
14	O
(	O
54	O
%	O
)	O
of	O
the	O
26	O
patients	O
with	O
ascites	B-TOXI
.	O
	
Seventeen	O
patients	O
had	O
adequate	O
oral	O
intake	O
","	O
but	O
the	O
other	O
14	O
patients	O
had	O
required	O
nutritional	O
support	O
before	O
treatment	O
.	O
	
The	O
median	O
dripinfusion	O
free	O
survival	O
was	O
100	O
days	O
in	O
the	O
former	O
17	O
patients	O
","	O
and	O
oral	O
intake	O
improved	O
in	O
3	O
(	O
21	O
%	O
)	O
of	O
the	O
latter	O
14	O
patients	O
.	O
	
Grade	O
3	O
or	O
4	O
neutropenia	B-TOXI
was	O
observed	O
in	O
26	O
%	O
of	O
the	O
patients	O
and	O
anemia	B-TOXI
was	O
observed	O
in	O
45	O
%	O
.	O
	
The	O
grade	O
3	O
nonhematological	B-TOXI
toxicities	I-TOXI
were	O
vomiting	B-TOXI
(	O
6	O
%	O
)	O
and	O
fatigue	B-TOXI
(	O
10	O
%	O
)	O
.	O
	
Early	O
death	B-TOXI
","	O
within	O
30	O
days	O
of	O
the	O
last	O
administration	O
of	O
MTX	B-DRUG
/	O
5FU	B-DRUG
","	O
occurred	O
due	O
to	O
disease	O
progression	O
in	O
2	O
patients	O
","	O
but	O
there	O
were	O
no	O
treatment-related	O
deaths	B-TOXI
.	O
	
MTX	B-DRUG
/	O
5FU	B-DRUG
chemotherapy	O
may	O
be	O
effective	O
in	O
treating	O
peritoneal	O
dissemination	O
of	O
gastric	B-CANCER
cancer	I-CANCER
and	O
might	O
improve	O
the	O
patient	O
's	O
condition	O
in	O
terms	O
of	O
reducing	O
ascites	B-TOXI
and	O
improving	O
oral	O
intake	O
.	O
	
Phase	O
Ib	O
study	O
of	O
weekly	O
mammalian	O
target	O
of	O
rapamycin	B-DRUG
inhibitor	I-DRUG
ridaforolimus	B-DRUG
(	O
AP23573	O
;	O
MK-8669	O
)	O
with	O
weekly	O
paclitaxel	B-DRUG
.	O
	
	
The	O
additive	O
cytotoxicity	O
in	O
vitro	O
prompted	O
a	O
clinical	O
study	O
evaluating	O
the	O
non-prodrug	O
rapamycin	B-DRUG
analogue	O
ridaforolimus	B-DRUG
(	O
AP23573	O
;	O
MK-8669	O
;	O
formerly	O
deforolimus	B-DRUG
)	O
administered	O
i.v.	O
combined	O
with	O
paclitaxel	B-DRUG
(	O
PTX	B-DRUG
;	O
Taxol	O
)	O
.	O
	
Patients	O
with	O
taxane-sensitive	B-DRUG
solid	B-CANCER
tumors	I-CANCER
were	O
eligible	O
.	O
	
The	O
main	O
dose	O
escalation	O
foresaw	O
50	O
%	O
ridaforolimus	B-DRUG
increments	O
from	O
25	O
mg	O
with	O
a	O
fixed	O
PTX	B-DRUG
dose	O
of	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
both	O
given	O
weekly	O
3	O
weeks	O
in	O
a	O
4-week	O
cycle	O
.	O
	
Collateral	O
levels	O
with	O
a	O
lower	O
dose	O
of	O
either	O
drug	O
were	O
planned	O
upon	O
achievement	O
of	O
the	O
maximum	O
tolerated	O
dose	O
in	O
the	O
main	O
escalation	O
.	O
	
Pharmacodynamic	O
studies	O
in	O
plasma	O
","	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
and	O
skin	O
biopsies	O
and	O
pharmacokinetic	O
(	O
PK	O
)	O
interaction	O
studies	O
at	O
cycles	O
1	O
and	O
2	O
were	O
carried	O
out	O
.	O
	
Two	O
recommended	O
doses	O
were	O
determined	O
:	O
37.5	O
mg	O
ridaforolimus	B-DRUG
/	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
PTX	B-DRUG
and	O
12.5	O
mg	O
/	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Most	O
frequent	O
toxic	O
effects	O
were	O
mouth	B-TOXI
sores	I-TOXI
(	O
79	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
79	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
59	O
%	O
)	O
","	O
neutropenia	B-TOXI
(	O
55	O
%	O
)	O
and	O
dermatitis	B-TOXI
(	O
48	O
%	O
)	O
.	O
	
Two	O
partial	O
responses	O
were	O
observed	O
in	O
pharyngeal	B-CANCER
squamous	I-CANCER
cell	I-CANCER
and	O
pancreatic	B-CANCER
carcinoma	I-CANCER
.	O
	
Eight	O
patients	O
achieved	O
stable	O
disease	O
&	O
gt	O
;	O
or	O
4	O
months	O
.	O
	
No	O
drug	O
interaction	O
emerged	O
from	O
PK	O
studies	O
.	O
	
Decrease	O
of	O
eukaryotic	O
initiation	O
factor	O
4E-binding	O
protein1	O
(	O
4E-BP1	O
)	O
phosphorylation	O
was	O
shown	O
in	O
PBMCs	O
.	O
	
Similar	O
inhibition	O
of	O
phosphorylation	O
of	O
4E-BP1	O
and	O
mitogen-activated	O
protein	O
kinase	O
was	O
present	O
in	O
reparative	O
epidermis	O
and	O
vascular	O
tissues	O
","	O
respectively	O
.	O
	
Potential	O
antiangiogenic	O
effects	O
and	O
encouraging	O
antitumor	O
activity	O
justify	O
further	O
development	O
of	O
the	O
combination	O
.	O
	
Clinical	O
activity	O
of	O
gemcitabine	B-DRUG
plus	O
pertuzumab	B-DRUG
in	O
platinum-resistant	B-DRUG
ovarian	B-CANCER
cancer	I-CANCER
","	O
fallopian	B-CANCER
tube	I-CANCER
cancer	I-CANCER
","	O
or	O
primary	O
peritoneal	B-CANCER
cancer	I-CANCER
.	O
	
	
Pertuzumab	B-DRUG
is	O
a	O
humanized	O
monoclonal	O
antibody	O
that	O
inhibits	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
(	O
HER2	O
)	O
heterodimerization	O
and	O
has	O
single-agent	O
activity	O
in	O
recurrent	O
epithelial	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
The	O
primary	O
objective	O
of	O
this	O
phase	O
II	O
study	O
was	O
to	O
characterize	O
the	O
safety	O
and	O
estimate	O
progression-free	O
survival	O
(	O
PFS	O
)	O
of	O
pertuzumab	B-DRUG
with	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
platinum-resistant	O
ovarian	B-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
advanced	O
","	O
platinum-resistant	B-DRUG
epithelial	B-CANCER
ovarian	I-CANCER
","	O
fallopian	B-CANCER
tube	I-CANCER
","	O
or	O
primary	B-CANCER
peritoneal	I-CANCER
cancer	I-CANCER
who	O
had	O
received	O
a	O
maximum	O
of	O
one	O
prior	O
treatment	O
for	O
recurrent	B-CANCER
cancer	I-CANCER
were	O
randomly	O
assigned	O
to	O
gemcitabine	B-DRUG
plus	O
either	O
pertuzumab	B-DRUG
or	O
placebo	B-DRUG
.	O
	
Collection	O
of	O
archival	O
tissue	O
was	O
mandatory	O
to	O
permit	O
exploration	O
of	O
biomarkers	O
that	O
would	O
predict	O
benefit	O
from	O
pertuzumab	B-DRUG
in	O
this	O
setting	O
.	O
	
One	O
hundred	O
thirty	O
patients	O
(	O
65	O
per	O
arm	O
)	O
were	O
treated	O
.	O
	
Baseline	O
characteristics	O
were	O
similar	O
between	O
arms	O
.	O
	
The	O
adjusted	O
hazard	O
ratio	O
(	O
HR	O
)	O
for	O
PFS	O
was	O
0.66	O
(	O
95	O
%	O
CI	O
","	O
0.43	O
to	O
1.03	O
;	O
P	O
=	O
0.07	O
)	O
in	O
favor	O
of	O
gemcitabine	B-DRUG
=+	O
pertuzumab	B-DRUG
.	O
	
The	O
objective	O
response	O
rate	O
was	O
13.8	O
%	O
in	O
patients	O
who	O
received	O
gemcitabine	B-DRUG
=+	O
pertuzumab	B-DRUG
compared	O
with	O
4.6	O
%	O
in	O
patients	O
who	O
received	O
gemcitabine	B-DRUG
=+	O
placebo	B-DRUG
.	O
	
In	O
patients	O
whose	O
tumors	O
had	O
low	O
HER3	O
mRNA	O
expression	O
(	O
&	O
lt	O
;	O
median	O
","	O
n	O
=	O
61	O
)	O
","	O
an	O
increased	O
treatment	O
benefit	O
was	O
observed	O
in	O
the	O
gemcitabine	B-DRUG
=+	O
pertuzumab	B-DRUG
arm	O
compared	O
with	O
the	O
gemcitabine	B-DRUG
alone	O
arm	O
(	O
PFS	O
HR	O
=	O
0.32	O
;	O
95	O
%	O
CI	O
","	O
0.17	O
to	O
0.59	O
;	O
P	O
=	O
0.0002	O
)	O
.	O
	
Grade	O
3	O
to	O
4	O
neutropenia	B-TOXI
","	O
diarrhea	B-TOXI
","	O
and	O
back	B-TOXI
pain	I-TOXI
were	O
increased	O
in	O
patients	O
treated	O
with	O
gemcitabine	B-DRUG
=+	O
pertuzumab	B-DRUG
.	O
	
Symptomatic	B-TOXI
congestive	I-TOXI
heart	I-TOXI
failure	I-TOXI
was	O
reported	O
in	O
one	O
patient	O
in	O
the	O
gemcitabine	B-DRUG
=+	O
pertuzumab	B-DRUG
arm	O
.	O
	
Pertuzumab	B-DRUG
may	O
add	O
activity	O
to	O
gemcitabine	B-DRUG
for	O
the	O
treatment	O
of	O
platinum-resistant	B-DRUG
ovarian	B-CANCER
cancer	I-CANCER
.	O
	
Low	O
HER3	O
mRNA	O
expression	O
may	O
predict	O
pertuzumab	B-DRUG
clinical	O
benefit	O
and	O
be	O
a	O
valuable	O
prognostic	O
marker	O
.	O
	
Treatment	O
of	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
with	O
cisplatin	B-DRUG
","	O
5-fluorouracil	B-DRUG
","	O
and	O
leucovorin	B-DRUG
.	O
	
	
Based	O
on	O
in	O
vitro	O
studies	O
that	O
have	O
demonstrated	O
synergy	O
between	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
","	O
and	O
cisplatin	B-DRUG
(	O
CDDP	B-DRUG
)	O
against	O
human	O
colon	B-CANCER
cancer	I-CANCER
cell	O
lines	O
","	O
a	O
clinical	O
trial	O
was	O
initiated	O
to	O
determine	O
the	O
effects	O
of	O
this	O
combination	O
in	O
patients	O
with	O
advanced	B-CANCER
unresectable	I-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
.	O
	
Fifty-nine	O
patients	O
were	O
enrolled	O
in	O
the	O
study	O
and	O
12	O
of	O
them	O
had	O
received	O
prior	O
conventional	O
5-FU	B-DRUG
chemotherapy	O
.	O
	
Treatment	O
consisted	O
of	O
4	O
weekly	O
courses	O
of	O
high-dose	O
LV	B-DRUG
(	O
200	O
mg	O
/	O
m2	O
)	O
administered	O
by	O
intravenous	O
(	O
IV	O
)	O
bolus	O
","	O
followed	O
by	O
5-FU	B-DRUG
(	O
550	O
mg	O
/	O
m2	O
)	O
and	O
CDDP	B-DRUG
(	O
20	O
mg	O
/	O
m2	O
)	O
each	O
administered	O
as	O
a	O
2-hour	O
infusion	O
on	O
4	O
consecutive	O
days	O
.	O
	
After	O
a	O
median	O
of	O
5.5	O
treatment	O
cycles	O
","	O
objective	O
tumor	O
response	O
was	O
seen	O
in	O
20	O
of	O
59	O
patients	O
(	O
34	O
%	O
)	O
(	O
this	O
included	O
3	O
complete	O
remissions	O
)	O
.	O
	
The	O
response	O
rate	O
in	O
the	O
47	O
previously	O
untreated	O
patients	O
was	O
38	O
%	O
(	O
95	O
%	O
confidence	O
limits	O
","	O
26	O
%	O
to	O
53	O
%	O
)	O
.	O
	
Stable	O
disease	O
occurred	O
in	O
16	O
(	O
27	O
%	O
)	O
patients	O
","	O
whereas	O
the	O
tumor	O
progressed	O
in	O
23	O
(	O
39	O
%	O
)	O
patients	O
.	O
	
The	O
median	O
survival	O
time	O
was	O
11.5	O
months	O
","	O
with	O
15	O
%	O
of	O
the	O
patients	O
alive	O
at	O
2	O
years	O
.	O
	
The	O
regimen	O
was	O
well	O
tolerated	O
and	O
the	O
primary	O
side	O
effects	O
were	O
mild	O
and	O
reversible	B-TOXI
gastrointestinal	I-TOXI
symptoms	I-TOXI
and	O
myelosuppression	B-TOXI
.	O
	
There	O
was	O
no	O
episode	O
of	O
life-threatening	O
toxicity	O
.	O
	
Eastern	O
Cooperative	O
Oncology	O
Group	O
(	O
ECOG	O
)	O
Grade	O
III	O
adverse	O
reactions	O
that	O
required	O
25	O
%	O
dose	O
reductions	O
occurred	O
in	O
only	O
14	O
%	O
of	O
the	O
patients	O
.	O
	
The	O
results	O
of	O
this	O
trial	O
suggest	O
that	O
5-FU	B-DRUG
","	O
LV	B-DRUG
","	O
and	O
CDDP	B-DRUG
is	O
an	O
active	O
","	O
safe	O
","	O
and	O
well-tolerated	O
combination	O
regimen	O
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Induction	O
chemotherapy	O
and	O
cetuximab	B-DRUG
for	O
locally	B-CANCER
advanced	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
:	O
results	O
from	O
a	O
phase	O
II	O
prospective	O
trial	O
.	O
	
	
PURPOSE	O
To	O
determine	O
the	O
potential	O
efficacy	O
of	O
combining	O
cetuximab	B-DRUG
with	O
chemotherapy	O
in	O
patients	O
with	O
advanced	O
nodal	O
disease	O
","	O
we	O
conducted	O
a	O
phase	O
II	O
trial	O
with	O
induction	O
chemotherapy	O
(	O
ICT	O
)	O
consisting	O
of	O
six	O
weekly	O
cycles	O
of	O
paclitaxel	B-DRUG
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
=	O
2	O
)	O
with	O
cetuximab	B-DRUG
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
week	O
1	O
and	O
then	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
PCC	B-DRUG
)	O
.	O
	
PATIENTS	O
AND	O
METHODS	O
Forty-seven	O
previously	O
untreated	O
patients	O
(	O
41	O
with	O
oropharynx	O
primaries	O
;	O
33	O
men	O
","	O
14	O
women	O
;	O
median	O
age	O
","	O
53	O
years	O
;	O
performance	O
status	O
of	O
0	O
or	O
1	O
)	O
with	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	O
SCCHN	B-CANCER
;	O
T1-4	O
","	O
N2b	O
/	O
c	O
/	O
3	O
)	O
were	O
treated	O
and	O
evaluated	O
for	O
clinical	O
and	O
radiographic	O
response	O
.	O
	
After	O
ICT	O
","	O
patients	O
underwent	O
risk-based	O
local	O
therapy	O
","	O
which	O
consisted	O
of	O
either	O
radiation	O
","	O
concomitant	O
chemoradiotherapy	O
","	O
or	O
surgery	O
","	O
based	O
on	O
tumor	O
stage	O
and	O
site	O
at	O
diagnosis	O
.	O
	
Results	O
After	O
induction	O
PCC	B-DRUG
","	O
nine	O
patients	O
(	O
19	O
%	O
)	O
achieved	O
a	O
complete	O
response	O
","	O
and	O
36	O
patients	O
(	O
77	O
%	O
)	O
achieved	O
a	O
partial	O
response	O
.	O
	
The	O
most	O
common	O
grade	O
3	O
or	O
4	O
toxicity	O
was	O
skin	B-TOXI
rash	I-TOXI
(	O
45	O
%	O
)	O
","	O
followed	O
by	O
neutropenia	B-TOXI
(	O
21	O
%	O
)	O
without	B-TOXI
fever	I-TOXI
.	O
	
At	O
a	O
median	O
follow-up	O
time	O
of	O
33	O
months	O
","	O
locoregional	O
or	O
systemic	O
disease	O
progression	O
was	O
observed	O
in	O
six	O
patients	O
.	O
	
The	O
3-year	O
progression-free	O
survival	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
rates	O
were	O
87	O
%	O
(	O
95	O
%	O
CI	O
","	O
78	O
%	O
to	O
97	O
%	O
)	O
and	O
91	O
%	O
(	O
95	O
%	O
CI	O
","	O
84	O
%	O
to	O
99	O
%	O
)	O
","	O
respectively	O
.	O
	
Human	B-TOXI
papillomavirus	I-TOXI
(	O
HPV	O
)	O
16	O
","	O
found	O
in	O
12	O
(	O
46	O
%	O
)	O
of	O
26	O
biopsies	O
","	O
was	O
associated	O
with	O
improved	O
PFS	O
(	O
P	O
=	O
0.012	O
)	O
and	O
OS	O
(	O
P	O
=	O
0.046	O
)	O
.	O
	
CONCLUSION	O
ICT	O
with	O
weekly	O
PCC	B-DRUG
followed	O
by	O
risk-based	O
local	O
therapy	O
seems	O
to	O
be	O
feasible	O
","	O
effective	O
","	O
and	O
well	O
tolerated	O
.	O
	
PFS	O
is	O
promising	O
","	O
and	O
this	O
sequential	O
treatment	O
strategy	O
should	O
be	O
further	O
investigated	O
.	O
	
Patients	O
with	O
HPV-positive	B-TOXI
tumors	B-CANCER
have	O
an	O
excellent	O
prognosis	O
.	O
	
Randomized	O
","	O
double-blind	O
trial	O
of	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
with	O
either	O
daily	O
oral	B-DRUG
cediranib	I-DRUG
or	O
placebo	B-DRUG
in	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
NCIC	B-CANCER
clinical	O
trials	O
group	O
BR24	O
study	O
.	O
	
	
PURPOSE	O
This	O
phase	O
II	O
/	O
III	O
double-blind	O
study	O
assessed	O
efficacy	O
and	O
safety	O
of	O
cediranib	B-DRUG
with	O
standard	O
chemotherapy	O
as	O
initial	O
therapy	O
for	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
PATIENTS	O
AND	O
METHODS	O
Paclitaxel	B-DRUG
(	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
serum	O
concentration-time	O
curve	O
6	O
)	O
were	O
given	O
every	O
3	O
weeks	O
","	O
with	O
daily	O
oral	O
cediranib	B-DRUG
or	O
placebo	B-DRUG
at	O
30	O
mg	O
(	O
first	O
45	O
patients	O
received	O
45	O
mg	O
)	O
.	O
	
Progression-free	O
survival	O
(	O
PFS	O
)	O
was	O
the	O
primary	O
outcome	O
of	O
the	O
phase	O
II	O
interim	O
analysis	O
;	O
phase	O
III	O
would	O
proceed	O
if	O
the	O
hazard	O
ratio	O
(	O
HR	O
)	O
for	O
PFS	O
&	O
lt	O
;	O
or	O
=	O
0.77	O
and	O
toxicity	O
were	O
acceptable	O
.	O
	
Results	O
A	O
total	O
of	O
296	O
patients	O
were	O
enrolled	O
","	O
251	O
to	O
the	O
30-mg	O
cohort	O
.	O
	
The	O
phase	O
II	O
interim	O
analysis	O
demonstrated	O
a	O
significantly	O
higher	O
response	O
rate	O
(	O
RR	O
)	O
for	O
cediranib	B-DRUG
than	O
for	O
placebo	B-DRUG
","	O
HR	O
of	O
0.77	O
for	O
PFS	O
","	O
no	B-TOXI
excess	I-TOXI
hemoptysis	I-TOXI
","	O
and	O
a	O
similar	O
number	O
of	O
deaths	B-TOXI
in	O
each	O
arm	O
.	O
	
The	O
study	O
was	O
halted	O
to	O
review	O
imbalances	O
in	O
assigned	O
causes	O
of	O
death	B-TOXI
.	O
	
In	O
the	O
primary	O
phase	O
II	O
analysis	O
(	O
30-mg	O
cohort	O
)	O
","	O
the	O
adjusted	O
HR	O
for	O
PFS	O
was	O
0.77	O
(	O
95	O
%	O
CI	O
","	O
0.56	O
to	O
1.08	O
)	O
with	O
a	O
higher	O
RR	O
for	O
cediranib	B-DRUG
than	O
for	O
placebo	B-DRUG
(	O
38	O
%	O
v	O
16	O
%	O
;	O
P	O
&	O
lt	O
;	O
0.0001	O
)	O
.	O
	
Cediranib	B-DRUG
patients	O
had	O
more	O
hypertension	B-TOXI
","	O
hypothyroidism	B-TOXI
","	O
hand-foot	B-TOXI
syndrome	I-TOXI
","	O
and	O
GI	B-TOXI
toxicity	I-TOXI
.	O
	
Hypoalbuminemia	B-TOXI
","	O
age	O
&	O
gt	O
;	O
or	O
=	O
65	O
years	O
","	O
and	O
female	O
sex	O
predicted	O
increased	O
toxicity	O
.	O
	
Survival	O
update	O
(	O
N	O
=	O
296	O
)	O
10	O
months	O
after	O
study	O
unblinding	O
favored	O
cediranib	B-DRUG
over	O
placebo	B-DRUG
(	O
median	O
of	O
10.5	O
months	O
v	O
10.1	O
months	O
;	O
HR	O
","	O
0.78	O
;	O
95	O
%	O
CI	O
","	O
0.57	O
to	O
1.06	O
;	O
P	O
=	O
0.11	O
)	O
.	O
	
Causes	O
of	O
death	B-TOXI
in	O
the	O
cediranib	B-DRUG
30-mg	O
cohort	O
were	O
NSCLC	B-CANCER
(	O
81	O
%	O
)	O
","	O
protocol	O
toxicity	O
=+	O
/	O
=-	O
NSCLC	B-CANCER
(	O
13	O
%	O
)	O
","	O
and	O
other	O
(	O
6	O
%	O
)	O
;	O
for	O
the	O
placebo	B-DRUG
group	O
","	O
they	O
were	O
98	O
%	O
","	O
0	O
%	O
","	O
and	O
2	O
%	O
","	O
respectively	O
.	O
	
CONCLUSION	O
The	O
addition	O
of	O
cediranib	B-DRUG
to	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
results	O
in	O
improved	O
response	O
and	O
PFS	O
","	O
but	O
does	O
not	O
appear	O
tolerable	O
at	O
a	O
30-mg	O
dose	O
.	O
	
Consequently	O
","	O
the	O
National	O
Cancer	O
Institute	O
of	O
Canada	O
Clinical	O
Trials	O
Group	O
and	O
the	O
Australasian	O
Lung	B-CANCER
Cancer	I-CANCER
Trials	O
Group	O
initiated	O
a	O
randomized	O
","	O
double-blind	O
","	O
placebo-controlled	B-DRUG
trial	O
of	O
cediranib	B-DRUG
20	O
mg	O
with	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
Phase	O
II	O
study	O
of	O
carboplatin	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
and	O
bevacizumab	B-DRUG
with	O
maintenance	B-DRUG
bevacizumab	I-DRUG
as	O
first-line	O
chemotherapy	O
for	O
advanced	B-CANCER
mullerian	I-CANCER
tumors	I-CANCER
.	O
	
	
PURPOSE	O
New	O
strategies	O
are	O
needed	O
to	O
improve	O
outcomes	O
for	O
patients	O
with	O
advanced	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
Bevacizumab	B-DRUG
is	O
a	O
recombinant	O
humanized	O
monoclonal	O
antibody	O
that	O
neutralizes	O
vascular	O
endothelial	O
growth	O
factor	O
but	O
is	O
associated	O
with	O
GI	B-TOXI
perforations	I-TOXI
(	O
GIPs	B-TOXI
)	O
in	O
patients	O
with	O
recurrent	O
disease	O
.	O
	
PATIENTS	O
AND	O
METHODS	O
An	O
open-label	O
","	O
phase	O
II	O
clinical	O
trial	O
was	O
conducted	O
in	O
newly	O
diagnosed	O
patients	O
with	O
stage	O
&	O
gt	O
;	O
or	O
=	O
IC	O
epithelial	B-CANCER
m眉llerian	I-CANCER
tumors	I-CANCER
.	O
	
Patients	O
received	O
intravenous	O
(	O
IV	O
)	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
=	O
5	O
)	O
","	O
paclitaxel	B-DRUG
(	O
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
)	O
","	O
and	O
bevacizumab	B-DRUG
(	O
15	O
mg	O
/	O
kg	O
IV	O
)	O
for	O
six	O
to	O
eight	O
cycles	O
on	O
day	O
1	O
every	O
21	O
days	O
.	O
	
Bevacizumab	B-DRUG
was	O
omitted	O
in	O
the	O
first	O
cycle	O
and	O
continued	O
as	O
a	O
single	O
agent	O
for	O
1	O
year	O
.	O
	
Results	O
Sixty-two	O
women	O
participated	O
in	O
this	O
study	O
.	O
	
Fifty-one	O
patients	O
(	O
82	O
%	O
)	O
were	O
optimally	O
surgically	O
cytoreduced	O
before	O
treatment	O
.	O
	
The	O
median	O
age	O
was	O
58	O
years	O
(	O
range	O
","	O
18	O
to	O
77	O
years	O
)	O
.	O
	
Forty-five	O
women	O
(	O
73	O
%	O
)	O
had	O
ovarian	B-CANCER
cancer	I-CANCER
","	O
10	O
(	O
16	O
%	O
)	O
had	O
peritoneal	B-CANCER
cancer	I-CANCER
","	O
four	O
(	O
6	O
%	O
)	O
had	O
fallopian	B-CANCER
tube	I-CANCER
cancers	I-CANCER
","	O
and	O
three	O
(	O
5	O
%	O
)	O
had	O
uterine	B-CANCER
papillary	I-CANCER
serous	I-CANCER
tumors	I-CANCER
.	O
	
The	O
majority	O
of	O
patients	O
(	O
90	O
%	O
)	O
had	O
stage	O
III	O
or	O
IV	O
disease	O
.	O
	
A	O
median	O
of	O
17	O
maintenance	O
cycles	O
(	O
range	O
","	O
0	O
to	O
25+	O
cycles	O
)	O
of	O
bevacizumab	B-DRUG
(	O
556	O
cycles	O
)	O
were	O
administered	O
with	O
mild	O
toxicity	O
.	O
	
Treatment	O
was	O
associated	O
with	O
two	O
pulmonary	B-TOXI
embolisms	I-TOXI
and	O
two	O
GIPs	B-TOXI
","	O
all	O
occurring	O
during	O
the	O
chemotherapy	O
phase	O
of	O
treatment	O
(	O
364	O
total	O
cycles	O
)	O
.	O
	
No	O
grade	O
4	O
toxicities	O
were	O
seen	O
during	O
maintenance	O
bevacizumab	B-DRUG
treatment	O
.	O
	
Radiographic	B-TOXI
responses	I-TOXI
were	O
documented	O
in	O
21	O
(	O
75	O
%	O
)	O
of	O
28	O
women	O
with	O
measurable	O
disease	O
(	O
11	O
complete	O
responses	O
and	O
10	O
partial	O
responses	O
)	O
","	O
with	O
CA-125	B-TOXI
responses	I-TOXI
in	O
76	O
%	O
of	O
patients	O
(	O
11	O
complete	O
responses	O
","	O
21	O
%	O
;	O
and	O
35	O
partial	O
responses	O
","	O
55	O
%	O
)	O
.	O
	
The	O
progression-free	O
survival	O
rate	O
at	O
36	O
months	O
was	O
58	O
%	O
.	O
	
CONCLUSION	O
The	O
regimen	O
of	O
carboplatin	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
and	O
bevacizumab	B-DRUG
with	O
maintenance	B-DRUG
bevacizumab	I-DRUG
is	O
feasible	O
","	O
safe	O
","	O
and	O
worthy	O
of	O
future	O
study	O
in	O
advanced	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
Carboplatin	B-DRUG
and	O
Paclitaxel	B-DRUG
in	O
combination	O
with	O
either	O
vorinostat	B-DRUG
or	O
placebo	B-DRUG
for	O
first-line	O
therapy	O
of	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
PURPOSE	O
Vorinostat	B-DRUG
","	O
a	O
histone	O
deacetylase	O
inhibitor	O
","	O
exerts	O
anticancer	O
effects	O
by	O
both	O
histone	O
and	O
nonhistone-mediated	O
mechanisms	O
.	O
	
It	O
also	O
enhances	O
the	O
anticancer	O
effects	O
of	O
platinum	B-DRUG
compounds	I-DRUG
and	O
taxanes	B-DRUG
in	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
cell	O
lines	O
.	O
	
This	O
phase	O
II	O
randomized	O
","	O
double-blinded	O
","	O
placebo-controlled	B-DRUG
study	O
evaluated	O
the	O
efficacy	O
of	O
vorinostat	B-DRUG
in	O
combination	O
with	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
advanced-stage	B-CANCER
NSCLC	I-CANCER
.	O
	
PATIENTS	O
AND	O
METHODS	O
Patients	O
with	O
previously	O
untreated	O
stage	O
IIIB	O
(	O
ie	O
","	O
wet	O
)	O
or	O
IV	O
NSCLC	B-CANCER
were	O
randomly	O
assigned	O
(	O
02:01	O
)	O
to	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
","	O
6	O
mg	O
/	O
mL	O
x	O
min	O
)	O
and	O
paclitaxel	B-DRUG
(	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
day	O
3	O
)	O
with	O
either	O
vorinostat	B-DRUG
(	O
400	O
mg	O
by	O
mouth	O
daily	O
)	O
or	O
placebo	B-DRUG
.	O
	
Vorinostat	B-DRUG
or	O
placebo	B-DRUG
was	O
given	O
on	O
days	O
1	O
through	O
14	O
of	O
each	O
3-week	O
cycle	O
to	O
a	O
maximum	O
of	O
six	O
cycles	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
comparison	O
of	O
the	O
response	O
rate	O
.	O
	
Results	O
Ninety-four	O
patients	O
initiated	O
protocol	O
therapy	O
.	O
	
Baseline	O
patient	O
characteristics	O
were	O
similar	O
between	O
the	O
two	O
arms	O
.	O
	
The	O
median	O
number	O
of	O
cycles	O
was	O
four	O
for	O
both	O
treatment	O
arms	O
.	O
	
The	O
confirmed	O
response	O
rate	O
was	O
34	O
%	O
with	O
vorinostat	B-DRUG
versus	O
12.5	O
%	O
with	O
placebo	B-DRUG
(	O
P	O
=	O
0.02	O
)	O
.	O
	
There	O
was	O
a	O
trend	O
toward	O
improvement	O
in	O
median	O
progression-free	O
survival	O
(	O
6	O
months	O
v	O
4.1	O
months	O
;	O
P	O
=	O
0.48	O
)	O
and	O
overall	O
survival	O
(	O
13	O
months	O
v	O
9.7	O
months	O
;	O
P	O
=	O
0.17	O
)	O
in	O
the	O
vorinostat	B-DRUG
arm	O
.	O
	
Grade	O
4	O
platelet	B-TOXI
toxicity	I-TOXI
was	O
more	O
common	O
with	O
vorinostat	B-DRUG
(	O
18	O
%	O
v	O
3	O
%	O
;	O
P	O
&	O
lt	O
;	O
0.05	O
)	O
.	O
	
Nausea	B-TOXI
","	O
emesis	B-TOXI
","	O
fatigue	B-TOXI
","	O
dehydration	B-TOXI
","	O
and	O
hyponatremia	B-TOXI
also	O
were	O
more	O
frequent	O
with	O
vorinostat	B-DRUG
.	O
	
CONCLUSION	O
Vorinostat	B-DRUG
enhances	O
the	O
efficacy	O
of	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
HDAC	O
inhibition	O
is	O
a	O
promising	O
therapeutic	O
strategy	O
for	O
treatment	O
of	O
NSCLC	B-CANCER
.	O
	
A	O
phase	O
II	O
trial	O
of	O
haptaplatin	B-DRUG
/	O
5-FU	B-DRUG
and	O
leucovorin	B-DRUG
for	O
advanced	B-CANCER
stomach	I-CANCER
cancer	I-CANCER
.	O
	
	
Heptaplatin	B-DRUG
(	O
SKI-2053	O
R	O
)	O
is	O
a	O
new	O
platinum	B-DRUG
analogue	O
","	O
with	O
a	O
better	O
toxicity	O
profile	O
than	O
cisplatin	B-DRUG
","	O
and	O
has	O
antitumor	O
activity	O
even	O
in	O
cisplatin	B-DRUG
resistant	O
cell	O
lines	O
.	O
	
5-fluoruracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
has	O
shown	O
synergy	O
with	O
platinum	B-DRUG
compounds	I-DRUG
.	O
	
This	O
phase	O
II	O
trial	O
was	O
designed	O
to	O
determine	O
the	O
efficacy	O
and	O
toxicities	O
of	O
heptaplatin	B-DRUG
/	O
5-FU	B-DRUG
(	O
5-fluorouracil	B-DRUG
)	O
for	O
treating	O
stomach	B-CANCER
cancer	I-CANCER
.	O
	
Thirty-two	O
patients	O
with	O
advanced	O
","	O
measurable	B-CANCER
gastric	I-CANCER
adenocarcinomas	I-CANCER
were	O
enrolled	O
in	O
this	O
trial	O
.	O
	
The	O
treatment	O
consisted	O
of	O
heptaplatin	B-DRUG
","	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
(	O
1	O
hour	O
IV	O
infusion	O
)	O
","	O
on	O
day	O
1	O
and	O
5-FU	B-DRUG
","	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
(	O
12	O
hours	O
IV	O
infusion	O
)	O
","	O
on	O
days	O
1	O
to	O
5	O
The	O
cycles	O
were	O
repeated	O
every	O
3	O
weeks	O
.	O
	
Of	O
the	O
26	O
evaluable	O
patients	O
","	O
9	O
had	O
partial	O
responses	O
and	O
1a	O
complete	O
response	O
(	O
overall	O
response	O
rate	O
","	O
38	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
","	O
19	O
approximately	O
57	O
%	O
)	O
.	O
	
The	O
median	O
response	O
duration	O
was	O
23	O
weeks	O
(	O
range	O
:	O
4	O
approximately	O
60	O
weeks	O
)	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
was	O
26	O
weeks	O
(	O
range	O
:	O
3	O
approximately	O
68	O
weeks	O
)	O
.	O
	
The	O
grades	O
III-IV	O
toxicities	O
were	O
mostly	O
hematological	B-TOXI
toxicities	I-TOXI
:	O
leucopenia	B-TOXI
was	O
observed	O
in	O
11	O
patients	O
(	O
35	O
%	O
)	O
and	O
thrombocytopenia	B-TOXI
4	O
(	O
13	O
%	O
)	O
.	O
	
No	B-TOXI
definite	I-TOXI
neuropathy	I-TOXI
was	O
observed	O
.	O
	
Grade	O
I-II	O
nephropathy	B-TOXI
was	O
also	O
noted	O
:	O
grade	O
I	O
high	B-TOXI
BUN	I-TOXI
/	I-TOXI
creatinine	I-TOXI
levels	O
occurred	O
in	O
5	O
patients	O
(	O
16	O
%	O
)	O
","	O
grade	O
II	O
proteinuria	B-TOXI
2	O
(	O
6	O
%	O
)	O
","	O
grade	O
I	O
proteinuria	B-TOXI
5	O
(	O
16	O
%	O
)	O
.	O
	
Neutropenic	B-TOXI
fever	I-TOXI
developed	O
in	O
5	O
patients	O
(	O
16	O
%	O
)	O
and	O
1	O
died	B-TOXI
of	I-TOXI
pneumonia	I-TOXI
in	I-TOXI
a	I-TOXI
neutropenic	I-TOXI
state	I-TOXI
.	O
	
This	O
study	O
suggests	O
that	O
the	O
regimen	O
of	O
Heptaplatin	B-DRUG
/	O
5-FU	B-DRUG
should	O
be	O
effective	O
and	O
have	O
a	O
favorable	O
toxicity	O
profile	O
for	O
the	O
patients	O
suffering	O
with	O
advanced	B-CANCER
stomach	I-CANCER
cancer	I-CANCER
.	O
	
Oxaliplatin	B-DRUG
/	O
5-FU	B-DRUG
without	B-DRUG
leucovorin	I-DRUG
chemotherapy	O
in	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
Fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
and	O
leucovorin	B-DRUG
combination	O
therapy	O
have	O
shown	O
synergistic	O
or	O
additive	O
effect	O
against	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
","	O
but	O
the	O
frequency	O
of	O
mucositis	B-TOXI
and	O
diarrhea	B-TOXI
is	O
increased	O
.	O
	
Most	O
previous	O
studies	O
have	O
used	O
high	O
dose	O
leucovorin	B-DRUG
(	O
300	O
approximately	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O
	
However	O
","	O
some	O
studies	O
of	O
oxaliplatin	B-DRUG
and	O
5-FU	B-DRUG
with	O
low-dose	O
or	O
high-dose	O
leucovorin	B-DRUG
in	O
Korea	O
have	O
shown	O
similar	O
response	O
rates	O
.	O
	
Therefore	O
","	O
we	O
studied	O
the	O
necessity	O
of	O
leucovorin	B-DRUG
and	O
evaluated	O
the	O
objective	O
tumor	O
response	O
rates	O
and	O
toxicities	O
of	O
a	O
regimen	O
of	O
oxaliplatin	B-DRUG
and	O
5-FU	B-DRUG
without	B-DRUG
leucovorin	I-DRUG
every	O
2	O
weeks	O
in	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
patients	O
.	O
	
Twenty-four	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
were	O
enrolled	O
between	O
January	O
2002	O
and	O
March	O
2003	O
.	O
	
Patients	O
received	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
oxaliplatin	B-DRUG
on	O
day	O
1	O
","	O
a	O
bolus	B-DRUG
5-FU	I-DRUG
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
and	O
a	O
continuous	O
5-FU	B-DRUG
infusion	O
at	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
22	O
hours	O
days	O
1	O
and	O
2	O
","	O
every	O
2	O
weeks	O
.	O
	
Of	O
the	O
24	O
patients	O
treated	O
","	O
17	O
patients	O
received	O
previous	O
5FU	B-DRUG
with	O
leucovorin	B-DRUG
and	O
/	O
or	O
other	O
chemotherapy	O
.	O
	
Three	O
patients	O
could	O
not	O
be	O
evaluated	O
.	O
	
Five	O
partial	O
responses	O
were	O
observed	O
with	O
overall	O
response	O
rate	O
of	O
21	O
%	O
(	O
n=24	O
)	O
.	O
	
Of	O
the	O
previous	O
chemotherapy	O
group	O
(	O
n=17	O
)	O
","	O
4	O
partial	O
responses	O
were	O
observed	O
with	O
response	O
rate	O
of	O
24	O
%	O
.	O
	
Median	O
overall	O
survival	O
was	O
18	O
months	O
(	O
range	O
4	O
approximately	O
32	O
months	O
)	O
and	O
median	O
progression	O
free	O
survival	O
was	O
4	O
months	O
(	O
range	O
2	O
approximately	O
6	O
months	O
)	O
.	O
	
This	O
regimen	O
was	O
well	O
tolerated	O
and	O
only	O
1	O
grade	O
3	O
anemia	B-TOXI
was	O
observed	O
.	O
	
Oxaliplatin	B-DRUG
/	O
5-FU	B-DRUG
combination	O
therapy	O
without	B-DRUG
leucovorin	I-DRUG
achieved	O
a	O
relatively	O
high	O
response	O
rate	O
even	O
in	O
patients	O
resistant	O
to	O
the	O
previous	O
5-FU	B-DRUG
chemotherapy	O
","	O
and	O
toxicity	O
was	O
minimal	O
.	O
	
Oxaliplatin	B-DRUG
with	O
biweekly	O
low	O
dose	O
leucovorin	B-DRUG
and	O
bolus	O
and	O
continuous	O
infusion	O
of	O
5-fluorouracil	B-DRUG
(	O
modified	O
FOLFOX	B-DRUG
4	I-DRUG
)	O
as	O
a	O
salvage	O
therapy	O
for	O
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
determine	O
the	O
activity	O
and	O
the	O
toxicity	O
associated	O
with	O
a	O
low	O
dose	O
regimen	O
of	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
plus	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
combined	O
with	O
oxaliplatin	B-DRUG
every	O
two	O
weeks	O
(	O
modified	O
FOLFOX	B-DRUG
4	I-DRUG
)	O
as	O
a	O
salvage	O
therapy	O
for	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
patients	O
.	O
	
Between	O
December	O
2003	O
and	O
December	O
2004	O
","	O
33	O
patients	O
were	O
enrolled	O
in	O
this	O
study	O
.	O
	
The	O
patients	O
were	O
treated	O
with	O
oxaliplatin	B-DRUG
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
2-hour	O
infusion	O
on	O
the	O
first	O
day	O
plus	O
LV	B-DRUG
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
over	O
10	O
minutes	O
.	O
	
Subsequently	O
","	O
the	O
patients	O
were	O
given	O
a	O
5-FU	B-DRUG
bolus	I-DRUG
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
followed	O
by	O
a	O
22-hour	O
continuous	O
infusion	O
of	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
approximately	O
2	O
The	O
treatment	O
was	O
repeated	O
at	O
2	O
week	O
intervals	O
.	O
	
The	O
median	O
age	O
of	O
the	O
patients	O
was	O
50	O
years	O
(	O
range	O
:	O
31	O
approximately	O
74	O
)	O
","	O
82	O
%	O
(	O
27	O
/	O
33	O
)	O
had	O
the	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
was	O
0	O
and	O
1	O
Of	O
the	O
30	O
patients	O
who	O
could	O
be	O
evaluated	O
for	O
their	O
tumor	O
response	O
","	O
8	O
achieved	O
a	O
partial	O
response	O
","	O
with	O
an	O
overall	O
response	O
rate	O
of	O
26.7	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
20.5	O
approximately	O
32.7	O
%	O
)	O
.	O
	
Fifteen	O
patients	O
(	O
50	O
%	O
)	O
showed	O
stable	O
disease	O
and	O
7	O
patients	O
(	O
23.3	O
%	O
)	O
progressed	O
during	O
the	O
course	O
of	O
treatment	O
.	O
	
The	O
median	O
time	O
from	O
the	O
start	O
of	O
chemotherapy	O
to	O
progression	O
was	O
3.5	O
months	O
(	O
95	O
%	O
CI	O
:	O
2.6	O
approximately	O
4.4	O
months	O
)	O
and	O
the	O
median	O
overall	O
survival	O
time	O
was	O
7.9	O
months	O
(	O
95	O
%	O
CI	O
:	O
5.9	O
approximately	O
9.9	O
months	O
)	O
.	O
	
The	O
major	O
grade	O
3	O
/	O
4	O
hematological	B-TOXI
toxicity	I-TOXI
encountered	O
included	O
neutropenia	B-TOXI
(	O
45.4	O
%	O
)	O
and	O
thrombocytopenia	B-TOXI
(	O
3	O
%	O
)	O
.	O
	
Neutropenic	B-TOXI
fever	I-TOXI
occurred	O
during	O
only	O
2	O
of	O
the	O
178	O
cycles	O
.	O
	
The	O
most	O
common	O
non-hematological	B-TOXI
toxicity	I-TOXI
encountered	O
was	O
grade	O
1	O
/	O
2	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
","	O
which	O
occurred	O
in	O
18.2	O
%	O
of	O
patients	O
","	O
diarrhea	B-TOXI
in	O
12.1	O
%	O
and	O
neuropathy	B-TOXI
in	O
15.2	O
%	O
.	O
	
There	O
were	O
no	B-TOXI
treatment	I-TOXI
related	I-TOXI
deaths	I-TOXI
.	O
	
The	O
modified	O
FOLFOX	B-DRUG
4	I-DRUG
regimen	O
appears	O
to	O
be	O
a	O
safe	O
and	O
effective	O
salvage	O
therapy	O
for	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
patients	O
.	O
	
The	O
influence	O
of	O
drug	O
interval	O
on	O
the	O
effect	O
of	O
methotrexate	B-DRUG
and	O
fluorouracil	B-DRUG
in	O
the	O
treatment	O
of	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
importance	O
of	O
the	O
interval	O
between	O
methotrexate	B-DRUG
(	O
MTX	B-DRUG
)	O
and	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
was	O
studied	O
in	O
168	O
patients	O
with	O
previously	O
untreated	O
","	O
measurable	O
","	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
They	O
were	O
randomized	O
to	O
receive	O
MTX	B-DRUG
200	O
mg	O
/	O
m2	O
","	O
followed	O
by	O
5-FU	B-DRUG
600	O
mg	O
/	O
m2	O
either	O
24	O
hours	O
(	O
arm	O
A	O
)	O
or	O
1	O
hour	O
(	O
arm	O
B	O
)	O
after	O
MTX	B-DRUG
.	O
	
All	O
patients	O
received	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
24	O
hours	O
after	O
MTX	B-DRUG
","	O
10	O
mg	O
/	O
m2	O
orally	O
every	O
6	O
hours	O
for	O
six	O
doses	O
.	O
	
The	O
regimen	O
was	O
repeated	O
every	O
2	O
weeks	O
","	O
with	O
5-FU	B-DRUG
escalation	O
as	O
tolerated	O
.	O
	
Arm	O
A	O
was	O
significantly	O
better	O
than	O
arm	O
B	O
with	O
respect	O
to	O
overall	O
response	O
rate	O
(	O
29	O
%	O
v	O
14.5	O
%	O
","	O
P	O
=	O
0.026	O
)	O
","	O
time	O
to	O
progression	O
(	O
TTP	O
;	O
median	O
","	O
9.9	O
months	O
v	O
5.9	O
months	O
","	O
P	O
=	O
0.009	O
)	O
","	O
and	O
survival	O
(	O
median	O
","	O
15.3	O
months	O
v	O
11.4	O
months	O
","	O
P	O
=	O
0.003	O
)	O
.	O
	
Significant	O
differences	O
between	O
arms	O
were	O
not	O
found	O
in	O
response	O
rate	O
","	O
median	O
TTP	O
","	O
or	O
median	O
survival	O
for	O
the	O
subgroup	O
of	O
patients	O
with	O
rectal	O
primaries	O
who	O
comprised	O
20	O
%	O
of	O
the	O
patients	O
in	O
each	O
arm	O
.	O
	
Significant	O
factors	O
prognostic	O
for	O
survival	O
were	O
performance	O
status	O
and	O
number	O
of	O
metastases	O
","	O
as	O
well	O
as	O
treatment	O
.	O
	
Age	O
did	O
not	O
influence	O
survival	O
.	O
	
Toxicity	O
was	O
similar	O
in	O
both	O
arms	O
and	O
was	O
primarily	O
gastrointestinal	B-TOXI
.	O
	
More	O
mucositis	B-TOXI
was	O
seen	O
in	O
arm	O
A.	O
There	O
were	O
four	O
toxic	B-TOXI
deaths	I-TOXI
secondary	O
to	O
neutropenia	B-TOXI
and	O
infection	B-TOXI
(	O
one	O
from	O
arm	O
A	O
and	O
three	O
from	O
arm	O
B	O
)	O
and	O
three	O
other	O
deaths	B-TOXI
(	O
two	O
from	O
arm	O
A	O
and	O
one	O
from	O
arm	O
B	O
)	O
that	O
were	O
possibly	O
drug-related	O
.	O
	
The	O
combination	O
of	O
MTX	B-DRUG
with	O
LV	B-DRUG
rescue	O
and	O
5-FU	B-DRUG
is	O
an	O
active	O
regimen	O
in	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
;	O
its	O
efficacy	O
is	O
increased	O
in	O
colon	O
","	O
but	O
not	B-CANCER
rectal	I-CANCER
cancer	I-CANCER
","	O
when	O
the	O
interval	O
between	O
MTX	B-DRUG
and	O
5-FU	B-DRUG
is	O
long	O
(	O
24	O
hours	O
)	O
rather	O
than	O
short	O
(	O
1	O
hour	O
)	O
.	O
	
Concurrent	O
cisplatin	B-DRUG
","	O
infusional	B-DRUG
fluorouracil	I-DRUG
","	O
and	O
conventionally	O
fractionated	O
radiation	O
therapy	O
in	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
:	O
dose-limiting	B-TOXI
mucosal	I-TOXI
toxicity	I-TOXI
.	O
	
	
After	O
a	O
preliminary	O
dose-finding	O
study	O
involving	O
12	O
patients	O
with	O
advanced	B-CANCER
or	I-CANCER
locally	I-CANCER
recurrent	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
","	O
27	O
patients	O
were	O
treated	O
on	O
a	O
phase	O
II	O
protocol	O
","	O
using	O
fluorouracil	B-DRUG
350	O
mg	O
/	O
m2	O
/	O
d	O
by	O
continuous	O
intravenous	O
(	O
IV	O
)	O
infusion	O
over	O
5	O
days	O
","	O
followed	O
on	O
the	O
sixth	O
day	O
by	O
a	O
2-hour	O
IV	O
infusion	O
of	O
cisplatin	B-DRUG
50	O
mg	O
/	O
m2	O
","	O
administered	O
during	O
the	O
first	O
and	O
fourth	O
weeks	O
of	O
radiation	O
therapy	O
to	O
total	O
doses	O
between	O
60	O
and	O
64	O
Gy	O
","	O
using	O
2	O
Gy	O
daily	O
fractions	O
.	O
	
Eight	O
of	O
these	O
27	O
patients	O
had	O
American	O
Joint	O
Committee	O
on	O
Cancer	O
Staging	O
(	O
AJCC	O
)	O
stage	O
III	O
disease	O
","	O
and	O
12	O
had	O
stage	O
IV	O
disease	O
.	O
	
Four	O
had	O
recurrent	O
disease	O
after	O
surgery	O
.	O
	
Three-year	O
follow-up	O
is	O
now	O
available	O
.	O
	
Twenty-one	O
(	O
77.8	O
%	O
)	O
remitted	O
completely	O
following	O
treatment	O
","	O
and	O
11	O
remain	O
free	O
of	O
local	O
and	O
regional	O
relapse	O
at	O
3	O
years	O
.	O
	
Four	O
have	O
developed	O
systemic	O
metastases	O
.	O
	
Following	O
successful	O
salvage	O
treatment	O
in	O
two	O
cases	O
","	O
estimated	O
determinate	O
survival	O
at	O
3	O
years	O
is	O
64	O
%	O
.	O
	
Acute	B-TOXI
toxicity	I-TOXI
was	O
manageable	O
with	O
this	O
regime	O
.	O
	
Eleven	O
instances	O
of	O
grade	O
3	O
Radiation	O
Therapy	O
Oncology	O
Group	O
/	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(	O
RTOG	O
/	O
EORTC	O
)	O
mucositis	O
were	O
observed	O
","	O
which	O
caused	O
interruptions	O
to	O
radiotherapy	O
in	O
only	O
four	O
cases	O
.	O
	
No	O
late	O
sequelae	O
have	O
so	O
far	O
been	O
recorded	O
.	O
	
It	O
is	O
concluded	O
that	O
the	O
protocol	O
described	O
is	O
tolerable	O
but	O
probably	O
did	O
not	O
cause	O
a	O
greater	O
number	O
of	O
locoregional	O
	O
than	O
would	O
have	O
been	O
expected	O
following	O
conventional	O
radiotherapy	O
alone	O
in	O
this	O
group	O
of	O
patients	O
.	O
	
The	O
use	O
of	O
infusional	B-DRUG
fluorouracil	I-DRUG
with	O
concurrent	O
conventionally	O
fractionated	O
radiation	O
therapy	O
and	O
cisplatin	B-DRUG
infusion	O
results	O
in	O
mucositis	B-TOXI
that	O
limits	O
the	O
dose	O
of	O
fluorouracil	B-DRUG
to	O
levels	O
that	O
are	O
probably	O
subtherapeutic	O
.	O
	
Adjuvant	O
chemotherapy	O
and	O
timing	O
of	O
tamoxifen	B-DRUG
in	O
postmenopausal	O
patients	O
with	O
endocrine-responsive	O
","	O
node-positive	B-CANCER
breast	I-CANCER
cancer	I-CANCER
:	O
a	O
phase	O
3	O
","	O
open-label	O
","	O
randomised	O
controlled	O
trial	O
.	O
	
	
Tamoxifen	B-DRUG
is	O
standard	O
adjuvant	O
treatment	O
for	O
postmenopausal	O
women	O
with	O
hormone-receptor-positive	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
We	O
assessed	O
the	O
benefit	O
of	O
adding	O
chemotherapy	O
to	O
adjuvant	B-DRUG
tamoxifen	I-DRUG
and	O
whether	O
tamoxifen	B-DRUG
should	O
be	O
given	O
concurrently	O
or	O
after	O
chemotherapy	O
.	O
	
We	O
undertook	O
a	O
phase	O
3	O
","	O
parallel	O
","	O
randomised	O
trial	O
(	O
SWOG-8814	O
","	O
INT-0100	O
)	O
in	O
postmenopausal	O
women	O
with	O
hormone-receptor-positive	O
","	O
node-positive	B-CANCER
breast	I-CANCER
cancer	I-CANCER
to	O
test	O
two	O
major	O
objectives	O
:	O
whether	O
the	O
primary	O
outcome	O
","	O
disease-free	O
survival	O
","	O
was	O
longer	O
with	O
cyclophosphamide	B-DRUG
","	O
doxorubicin	B-DRUG
","	O
and	O
fluorouracil	B-DRUG
(	O
CAF	B-DRUG
)	O
given	O
every	O
4	O
weeks	O
for	O
six	O
cycles	O
plus	O
5	O
years	O
of	O
daily	O
tamoxifen	B-DRUG
than	O
with	O
tamoxifen	B-DRUG
alone	O
;	O
and	O
whether	O
disease-free	O
survival	O
was	O
longer	O
with	O
CAF	B-DRUG
followed	O
by	O
tamoxifen	B-DRUG
(	O
CAF-T	B-DRUG
)	O
than	O
with	O
CAF	B-DRUG
plus	O
concurrent	O
tamoxifen	B-DRUG
(	O
CAFT	B-DRUG
)	O
.	O
	
Overall	O
survival	O
and	O
toxicity	O
were	O
predefined	O
","	O
important	O
secondary	O
outcomes	O
for	O
each	O
objective	O
.	O
	
Patients	O
in	O
this	O
open-label	O
trial	O
were	O
randomly	O
assigned	O
by	O
a	O
computer	O
algorithm	O
in	O
a	O
02:03:03	O
ratio	O
(	O
tamoxifen	B-DRUG
:	O
CAF-T	B-DRUG
:	O
CAFT	B-DRUG
)	O
and	O
analysis	O
was	O
by	O
intention	O
to	O
treat	O
of	O
eligible	O
patients	O
.	O
	
Groups	O
were	O
compared	O
by	O
stratified	O
log-rank	O
tests	O
","	O
followed	O
by	O
Cox	O
regression	O
analyses	O
adjusted	O
for	O
significant	O
prognostic	O
factors	O
.	O
	
This	O
trial	O
is	O
registered	O
with	O
ClinicalTrials.gov	O
","	O
number	O
NCT00929591	O
.	O
	
Of	O
1558	O
randomised	O
women	O
","	O
1477	O
(	O
95	O
%	O
)	O
were	O
eligible	O
for	O
inclusion	O
in	O
the	O
analysis	O
.	O
	
After	O
a	O
maximum	O
of	O
13	O
years	O
of	O
follow-up	O
(	O
median	O
8.94	O
years	O
)	O
","	O
637	O
women	O
had	O
a	O
disease-free	O
survival	O
event	O
(	O
tamoxifen	B-DRUG
","	O
179	O
events	O
in	O
361	O
patients	O
;	O
CAF-T	B-DRUG
","	O
216	O
events	O
in	O
566	O
patients	O
;	O
CAFT	B-DRUG
","	O
242	O
events	O
in	O
550	O
patients	O
)	O
.	O
	
For	O
the	O
first	O
objective	O
","	O
therapy	O
with	O
the	O
CAF	B-DRUG
plus	O
tamoxifen	B-DRUG
groups	O
combined	O
(	O
CAFT	B-DRUG
or	O
CAF-T	B-DRUG
)	O
was	O
superior	O
to	O
tamoxifen	B-DRUG
alone	O
for	O
the	O
primary	O
endpoint	O
of	O
disease-free	O
survival	O
(	O
adjusted	O
Cox	O
regression	O
hazard	O
ratio	O
[	O
HR	O
]	O
0.76	O
","	O
95	O
%	O
CI	O
0.64-0.91	O
;	O
p=0.002	O
)	O
but	O
only	O
marginally	O
for	O
the	O
secondary	O
endpoint	O
of	O
overall	O
survival	O
(	O
HR	O
0.83	O
","	O
0.68-1.01	O
;	O
p=0.057	O
)	O
.	O
	
For	O
the	O
second	O
objective	O
","	O
the	O
adjusted	O
HRs	O
favoured	O
CAF-T	B-DRUG
over	O
CAFT	B-DRUG
but	O
did	O
not	O
reach	O
significance	O
for	O
disease-free	O
survival	O
(	O
HR	O
0.84	O
","	O
0.70-1.01	O
;	O
p=0.061	O
)	O
or	O
overall	O
survival	O
(	O
HR	O
0.9	O
","	O
0.73-1.10	O
;	O
p=0.30	O
)	O
.	O
	
Neutropenia	B-TOXI
","	O
stomatitis	B-TOXI
","	O
thromboembolism	B-TOXI
","	O
congestive	B-TOXI
heart	I-TOXI
failure	I-TOXI
","	O
and	O
leukaemia	B-TOXI
were	O
more	O
frequent	O
in	O
the	O
combined	O
CAF	B-DRUG
plus	O
tamoxifen	B-DRUG
groups	O
than	O
in	O
the	O
tamoxifen-alone	B-DRUG
group	O
.	O
	
Chemotherapy	O
with	O
CAF	B-DRUG
plus	O
tamoxifen	B-DRUG
given	O
sequentially	O
is	O
more	O
effective	O
adjuvant	O
therapy	O
for	O
postmenopausal	O
patients	O
with	O
endocrine-responsive	O
","	O
node-positive	B-CANCER
breast	I-CANCER
cancer	I-CANCER
than	O
is	O
tamoxifen	B-DRUG
alone	O
.	O
	
However	O
","	O
it	O
might	O
be	O
possible	O
to	O
identify	O
some	O
subgroups	O
that	O
do	O
not	O
benefit	O
from	O
anthracycline-based	B-DRUG
chemotherapy	O
despite	O
positive	O
nodes	O
.	O
	
National	O
Cancer	O
Institute	O
(	O
US	O
National	O
Institutes	O
of	O
Health	O
)	O
.	O
	
Flavopiridol	B-DRUG
","	O
fludarabine	B-DRUG
","	O
and	O
rituximab	B-DRUG
in	O
mantle	B-CANCER
cell	I-CANCER
lymphoma	I-CANCER
and	O
indolent	O
B-cell	O
lymphoproliferative	O
disorders	O
.	O
	
	
Flavopiridol	B-DRUG
downmodulates	O
antiapoptotic	O
proteins	O
associated	O
with	O
resistance	O
to	O
fludarabine	B-DRUG
and	O
rituximab	B-DRUG
and	O
is	O
effective	O
against	O
p53-mutated	O
chronic	B-CANCER
lymphocytic	I-CANCER
leukemia	I-CANCER
(	O
CLL	B-CANCER
)	O
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
study	O
of	O
flavopiridol	B-DRUG
","	O
fludarabine	B-DRUG
","	O
and	O
rituximab	B-DRUG
(	O
FFR	B-DRUG
)	O
in	O
patients	O
with	O
mantle-cell	B-CANCER
lymphoma	I-CANCER
(	O
MCL	B-CANCER
)	O
","	O
indolent	B-CANCER
B-cell	I-CANCER
non-Hodgkin	I-CANCER
's	I-CANCER
lymphomas	I-CANCER
(	O
B-NHL	B-CANCER
)	O
","	O
and	O
CLL	B-CANCER
to	O
determine	O
the	O
activity	O
of	O
FFR	B-DRUG
.	O
	
Therapy	O
included	O
fludarabine	B-DRUG
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
(	O
IV	O
)	O
days	O
1	O
to	O
5	O
and	O
rituximab	B-DRUG
375	O
mg	O
/	O
m	O
(	O
2	O
)	O
day	O
1	O
every	O
28	O
days	O
for	O
6	O
cycles	O
.	O
	
We	O
administered	O
flavopiridol	B-DRUG
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
by	O
1-hour	O
IV	O
bolus	O
(	O
IVB	O
)	O
day	O
1	O
(	O
n	O
=	O
15	O
)	O
;	O
day	O
1	O
to	O
2	O
(	O
n	O
=	O
6	O
)	O
;	O
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
30-minute	O
IVB	O
=+	O
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
4-hour	O
IV	O
infusion	O
(	O
n	O
=	O
3	O
)	O
;	O
or	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
=+	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
n	O
=	O
14	O
)	O
.	O
	
Thirty-eight	O
patients	O
(	O
median	O
age	O
","	O
62	O
years	O
)	O
with	O
MCL	B-CANCER
(	O
n	O
=	O
10	O
)	O
;	O
indolent	B-CANCER
B-NHL	I-CANCER
including	O
follicular	O
(	O
n	O
=	O
9	O
)	O
","	O
marginal	O
zone	O
(	O
n	O
=	O
4	O
)	O
","	O
lymphoplasmacytic	B-CANCER
(	O
n	O
=	O
1	O
)	O
","	O
or	O
small	B-CANCER
lymphocytic	I-CANCER
lymphoma	I-CANCER
(	O
n	O
=	O
3	O
)	O
;	O
and	O
CLL	B-CANCER
(	O
n	O
=	O
11	O
)	O
","	O
were	O
enrolled	O
.	O
	
Twenty-two	O
patients	O
were	O
previously	O
untreated	O
;	O
16	O
had	O
received	O
one	O
to	O
two	O
prior	O
therapies	O
.	O
	
Two	O
patients	O
in	O
cohort	O
2	O
developed	O
grade	O
3	O
dose-limiting	O
toxicity	O
(	O
seizures	B-TOXI
","	O
renal	B-TOXI
insufficiency	I-TOXI
)	O
.	O
	
The	O
median	O
number	O
of	O
treatment	O
cycles	O
was	O
4	O
","	O
with	O
cytopenias	B-TOXI
(	O
n	O
=	O
10	O
)	O
and	O
fatigue	B-TOXI
(	O
n	O
=	O
3	O
)	O
the	O
most	O
common	O
reasons	O
for	O
early	O
discontinuation	O
.	O
	
Overall	O
response	O
rate	O
was	O
82	O
%	O
(	O
complete	O
response	O
","	O
50	O
%	O
;	O
unconfirmed	O
complete	O
response	O
","	O
5	O
%	O
;	O
partial	O
response	O
","	O
26	O
%	O
)	O
","	O
including	O
80	O
%	O
of	O
patients	O
with	O
MCL	B-CANCER
(	O
median	O
age	O
","	O
68	O
;	O
seven	O
complete	O
responses	O
","	O
one	O
partial	O
response	O
)	O
.	O
	
Median	O
progression-free	O
survival	O
(	O
PFS	O
)	O
was	O
25.6	O
months	O
.	O
	
Median	O
PFS	O
of	O
patients	O
with	O
nonblastoid	O
variant	O
MCL	B-CANCER
(	O
n	O
=	O
8	O
)	O
was	O
35.9	O
months	O
.	O
	
FFR	B-DRUG
was	O
active	O
in	O
MCL	B-CANCER
","	O
indolent	B-CANCER
B-NHL	I-CANCER
","	O
and	O
CLL	B-CANCER
and	O
should	O
be	O
studied	O
for	O
older	O
patients	O
with	O
MCL	B-CANCER
who	O
are	O
not	O
candidates	O
for	O
aggressive	O
chemotherapy	O
.	O
	
A	O
phase	O
II	O
trial	O
of	O
trastuzumab	B-DRUG
plus	O
weekly	O
ixabepilone	B-DRUG
and	O
carboplatin	B-DRUG
in	O
patients	O
with	O
HER2-positive	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
:	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
Trial	O
.	O
	
	
The	O
epothilone	B-DRUG
B	I-DRUG
analogue	I-DRUG
","	O
ixabepilone	B-DRUG
","	O
binds	O
to	O
b-tubulin	B-DRUG
","	O
is	O
effective	O
for	O
taxane-refractory	B-DRUG
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
MBC	B-CANCER
)	O
","	O
and	O
may	O
be	O
given	O
every	O
3	O
weeks	O
or	O
weekly	O
.	O
	
We	O
evaluated	O
the	O
efficacy	O
of	O
weekly	O
ixabepilone	B-DRUG
(	O
I	O
)	O
plus	O
trastuzumab	B-DRUG
(	O
T	O
)	O
and	O
carboplatin	B-DRUG
(	O
C	O
)	O
as	O
first	O
line	O
therapy	O
in	O
HER2	O
=+	O
MBC	B-CANCER
.	O
	
Patients	O
with	O
HER2+	O
(	O
3+	O
by	O
IHC	O
or	O
FISH	O
amplified	O
)	O
MBC	B-CANCER
received	O
I	O
(	O
15	O
mg	O
/	O
m2	O
IV	O
)	O
and	O
C	O
(	O
area	O
under	O
the	O
curve	O
","	O
AUC	O
=	O
2	O
IV	O
)	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
of	O
a	O
28-day	O
cycle	O
for	O
a	O
maximum	O
of	O
6	O
cycles	O
","	O
plus	O
weekly	O
T	O
(	O
4	O
mg	O
/	O
kg	O
loading	O
dose	O
then	O
2	O
mg	O
/	O
kg	O
IV	O
)	O
during	O
chemotherapy	O
then	O
every	O
3	O
weeks	O
(	O
6	O
mg	O
/	O
kg	O
IV	O
)	O
until	O
disease	O
progression	O
.	O
	
The	O
primary	O
objective	O
was	O
to	O
determine	O
whether	O
the	O
combination	O
was	O
associated	O
with	O
a	O
response	O
rate	O
(	O
RR	O
)	O
of	O
at	O
least	O
75	O
%	O
.	O
	
Fifty-nine	O
patients	O
were	O
treated	O
","	O
and	O
39	O
had	O
HER2	O
overexpression	O
confirmed	O
in	O
a	O
central	O
lab	O
(	O
cHER2+	O
)	O
.	O
	
For	O
all	O
treated	O
patients	O
","	O
objective	O
response	O
occurred	O
in	O
26	O
patients	O
(	O
44	O
%	O
;	O
95	O
%	O
CI	O
31-58	O
%	O
)	O
","	O
median	O
time	O
to	O
progression	O
was	O
8.2	O
months	O
(	O
95	O
%	O
CI	O
6.3-9.9	O
)	O
","	O
and	O
median	O
overall	O
survival	O
was	O
34.7	O
months	O
(	O
95	O
%	O
CI	O
25.7	O
to	O
[	O
not	O
reached	O
]	O
)	O
.	O
	
Results	O
were	O
comparable	O
for	O
cHer2	O
?	O
	
cancers	O
.	O
	
Grade	O
3月4日	O
adverse	O
events	O
included	O
neutropenia	B-TOXI
(	O
49	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
14	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
12	O
%	O
)	O
","	O
nausea	B-TOXI
(	O
7	O
%	O
)	O
","	O
diarrhea	B-TOXI
(	O
7	O
%	O
)	O
","	O
and	O
neuropathy	B-TOXI
(	O
7	O
%	O
)	O
.	O
	
One	O
patient	O
died	B-TOXI
from	O
treatment	O
complications	O
during	O
cycle	O
1	O
Weekly	O
ixabepilone	B-DRUG
and	O
carboplatin	B-DRUG
plus	O
trastuzumab	B-DRUG
have	O
an	O
acceptable	O
toxicity	O
profile	O
","	O
but	O
are	O
not	O
likely	O
to	O
be	O
associated	O
with	O
an	O
RR	O
of	O
75	O
%	O
in	O
HER2+	O
MBC	B-CANCER
.	O
	
Efficacy	O
appears	O
comparable	O
to	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
trastuzumab	B-DRUG
.	O
	
Phase	O
I	O
/	O
II	O
trial	O
of	O
metronomic	O
chemotherapy	O
with	O
daily	O
dalteparin	B-DRUG
and	O
cyclophosphamide	B-DRUG
","	O
twice-weekly	O
methotrexate	B-DRUG
","	O
and	O
daily	O
prednisone	B-DRUG
as	O
therapy	O
for	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
using	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
soluble	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
levels	O
as	O
markers	O
of	O
response	O
.	O
	
	
PURPOSE	O
Preclinical	O
studies	O
indicate	O
that	O
metronomic	O
chemotherapy	O
is	O
antiangiogenic	O
and	O
synergistic	O
with	O
other	O
antiangiogenic	O
agents	O
.	O
	
We	O
designed	O
a	O
phase	O
I	O
/	O
II	O
study	O
to	O
evaluate	O
the	O
safety	O
and	O
activity	O
of	O
adding	O
dalteparin	B-DRUG
and	O
prednisone	B-DRUG
to	O
metronomic	B-DRUG
cyclophosphamide	I-DRUG
and	O
methotrexate	B-DRUG
in	O
women	O
with	O
measurable	B-CANCER
metastatic	I-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
MBC	B-CANCER
)	O
.	O
	
PATIENTS	O
AND	O
METHODS	O
Patients	O
received	O
daily	O
dalteparin	B-DRUG
and	O
oral	B-DRUG
cyclophosphamide	I-DRUG
","	O
twice-weekly	O
methotrexate	B-DRUG
","	O
and	O
daily	O
prednisone	B-DRUG
(	O
dalCMP	B-DRUG
)	O
.	O
	
The	O
primary	O
study	O
end	O
point	O
was	O
clinical	O
benefit	O
rate	O
(	O
CBR	O
)	O
","	O
a	O
combination	O
of	O
complete	O
response	O
(	O
CR	O
)	O
","	O
partial	O
response	O
(	O
PR	O
)	O
","	O
and	O
prolonged	O
stable	O
disease	O
for	O
&	O
gt	O
;	O
or	O
=	O
24	O
weeks	O
(	O
pSD	O
)	O
.	O
	
Secondary	O
end	O
points	O
included	O
time	O
to	O
progression	O
(	O
TTP	O
)	O
","	O
duration	O
of	O
response	O
","	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O
	
Biomarker	O
response	O
to	O
treatment	O
was	O
assessed	O
by	O
using	O
plasma	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
soluble	O
VEGF	O
receptors	O
(	O
sVEGFRs	O
)	O
-1	O
and	O
-2	O
.	O
	
Results	O
Forty-one	O
eligible	O
patients	O
were	O
accrued	O
.	O
	
Sixteen	O
(	O
39	O
%	O
)	O
had	O
no	O
prior	O
chemotherapy	O
for	O
MBC	B-CANCER
;	O
15	O
(	O
37	O
%	O
)	O
had	O
two	O
or	O
more	O
chemotherapy	O
regimens	O
for	O
MBC	B-CANCER
.	O
	
Toxicities	O
were	O
minimal	O
except	O
for	O
transient	O
grade	O
3	O
elevation	B-TOXI
of	I-TOXI
liver	I-TOXI
transaminases	I-TOXI
in	O
11	O
patients	O
(	O
27	O
%	O
)	O
and	O
grade	O
3	O
vomiting	B-TOXI
in	O
one	O
patient	O
(	O
2	O
%	O
)	O
.	O
	
One	O
patient	O
(	O
2	O
%	O
)	O
had	O
CR	O
","	O
six	O
(	O
15	O
%	O
)	O
had	O
PR	O
","	O
and	O
three	O
(	O
7	O
%	O
)	O
had	O
pSD	O
","	O
for	O
a	O
CBR	O
of	O
10	O
(	O
24	O
%	O
)	O
of	O
41	O
patients	O
.	O
	
Median	O
TTP	O
was	O
10	O
weeks	O
(	O
95	O
%	O
CI	O
","	O
8	O
to	O
17	O
weeks	O
)	O
","	O
and	O
median	O
OS	O
was	O
48	O
weeks	O
(	O
95	O
%	O
CI	O
","	O
32	O
to	O
79	O
weeks	O
)	O
.	O
	
VEGF	O
levels	O
decreased	O
but	O
not	O
significantly	O
","	O
whereas	O
sVEGFR-1	O
and	O
-2	O
levels	O
increased	O
significantly	O
after	O
2	O
weeks	O
of	O
therapy	O
.	O
	
There	O
was	O
no	O
correlation	O
between	O
response	O
and	O
VEGF	O
","	O
sVEGFR-1	O
","	O
or	O
sVEGFR-2	O
levels	O
.	O
	
CONCLUSION	O
Metronomic	O
dalCMP	B-DRUG
is	O
safe	O
","	O
well	O
tolerated	O
","	O
and	O
clinically	O
active	O
in	O
MBC	B-CANCER
.	O
	
Genotype-driven	O
phase	O
I	O
study	O
of	O
irinotecan	B-DRUG
administered	O
in	O
combination	O
with	O
fluorouracil	B-DRUG
/	O
leucovorin	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
PURPOSE	O
We	O
aimed	O
to	O
identify	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
irinotecan	B-DRUG
in	O
patients	O
with	O
cancer	O
with	O
UGT1A1*1	O
/	O
*1	O
and	O
*1	O
/	O
*28	O
genotypes	O
.	O
	
We	O
hypothesize	O
that	O
the	O
patients	O
without	O
the	O
*28	O
/	O
*28	O
genotype	O
tolerate	O
higher	O
doses	O
of	O
irinotecan	B-DRUG
.	O
	
PATIENTS	O
AND	O
METHODS	O
Patients	O
undergoing	O
first-line	O
treatment	O
for	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
CRC	B-CANCER
)	O
eligible	O
for	O
treatment	O
with	O
irinotecan	B-DRUG
plus	O
infusional	B-DRUG
fluorouracil	I-DRUG
/	O
leucovorin	B-DRUG
(	O
FOLFIRI	B-DRUG
)	O
were	O
screened	O
for	O
the	O
UGT1A1*28	O
/	O
*28	O
genotype	O
and	O
excluded	O
from	O
the	O
study	O
.	O
	
Fifty-nine	O
white	O
patients	O
with	O
either	O
the	O
*1	O
/	O
*1	O
or	O
the	O
*1	O
/	O
*28	O
genotype	O
were	O
eligible	O
for	O
dose	O
escalation	O
of	O
irinotecan	B-DRUG
.	O
	
The	O
starting	O
dose	O
of	O
biweekly	O
irinotecan	B-DRUG
was	O
215	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
both	O
genotype	O
groups	O
","	O
whereas	O
the	O
dose	O
of	O
infusional	B-DRUG
fluorouracil	I-DRUG
was	O
fixed	O
.	O
	
Pharmacokinetic	O
data	O
of	O
irinotecan	B-DRUG
and	O
metabolites	O
were	O
also	O
obtained	O
.	O
	
Results	O
The	O
dose	O
of	O
irinotecan	B-DRUG
was	O
escalated	O
to	O
370	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
patients	O
with	O
the	O
*1	O
/	O
*28	O
genotype	O
and	O
to	O
420	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
those	O
with	O
the	O
*1	O
/	O
*1	O
genotype	O
.	O
	
Dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
were	O
observed	O
in	O
two	O
of	O
four	O
of	O
*1	O
/	O
*28	O
patients	O
at	O
370	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
in	O
two	O
of	O
three	O
of	O
*1	O
/	O
*1	O
patients	O
at	O
420	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
No	O
DLTs	O
were	O
observed	O
in	O
10	O
*1	O
/	O
*28	O
patients	O
at	O
310	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
in	O
10	O
*1	O
/	O
*1	O
patients	O
at	O
370	O
mg	O
/	O
m	O
(	O
2	O
)	O
;	O
hence	O
these	O
dose	O
levels	O
were	O
the	O
MTD	O
for	O
each	O
genotype	O
group	O
.	O
	
The	O
most	O
common	O
grade	O
3	O
to	O
4	O
toxicities	O
were	O
neutropenia	B-TOXI
and	O
diarrhea	B-TOXI
.	O
	
The	O
pharmacokinetics	O
of	O
irinotecan	B-DRUG
and	O
SN-38	O
exhibit	O
linear	O
kinetics	O
.	O
	
CONCLUSION	O
The	O
recommended	O
dose	O
of	O
180	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
irinotecan	B-DRUG
in	O
FOLFIRI	B-DRUG
is	O
considerably	O
lower	O
than	O
the	O
dose	O
that	O
can	O
be	O
tolerated	O
when	O
patients	O
with	O
the	O
UGT1A1*28	O
/	O
*28	O
genotype	O
are	O
excluded	O
.	O
	
Prospective	O
genotype-driven	O
studies	O
should	O
test	O
the	O
efficacy	O
of	O
higher	O
irinotecan	O
doses	O
in	O
the	O
FOLFIRI	B-DRUG
schedule	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
S-1	B-DRUG
treatment	O
with	O
a	O
3	O
week	O
schedule	O
in	O
advanced	B-CANCER
biliary	I-CANCER
cancer	I-CANCER
patients	O
with	O
or	O
without	O
hepatic	B-TOXI
dysfunction	I-TOXI
.	O
	
	
A	O
3	O
week	O
treatment	O
schedule	O
consisting	O
of	O
2	O
weeks	O
of	O
S-1	B-DRUG
therapy	O
and	O
1	O
week	O
of	O
no	O
therapy	O
was	O
introduced	O
to	O
reduce	O
the	O
toxicity	O
and	O
increase	O
the	O
convenience	O
of	O
combination	O
chemotherapy	O
.	O
	
Hepatic	B-TOXI
dysfunction	I-TOXI
(	O
HD	B-TOXI
)	O
is	O
common	O
in	O
patients	O
with	O
biliary	B-CANCER
tract	I-CANCER
cancer	I-CANCER
.	O
	
A	O
phase	O
I	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
effects	O
of	O
a	O
3	O
week	O
treatment	O
schedule	O
in	O
Asian	O
patients	O
with	O
or	O
without	O
HD	B-TOXI
.	O
	
Forty-six	O
patients	O
were	O
stratified	O
into	O
four	O
groups	O
","	O
according	O
to	O
the	O
HD	B-TOXI
criteria	O
of	O
the	O
National	O
Cancer	O
Institute	O
Organ	O
Dysfunction	O
Working	O
Group	O
.	O
	
A	O
three	O
dose	O
escalation	O
schema	O
was	O
used	O
.	O
	
In	O
the	O
normal	O
hepatic	O
function	O
group	O
","	O
two	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
events	O
occurred	O
among	O
12	O
patients	O
at	O
the	O
prespecified	O
maximal	O
dose	O
of	O
100	O
mg	O
/	O
m虏	O
/	O
day	O
.	O
	
This	O
dose	O
was	O
thereby	O
established	O
as	O
the	O
maximal	O
tolerable	O
dose	O
(	O
MTD	O
)	O
.	O
	
No	O
DLT	O
events	O
were	O
observed	O
at	O
the	O
predefined	O
maximal	O
dose	O
of	O
80	O
mg	O
/	O
m虏	O
/	O
day	O
in	O
the	O
mild	O
HD	B-TOXI
group	O
.	O
	
In	O
the	O
moderate	B-TOXI
HD	I-TOXI
group	O
","	O
two	O
DLT	O
events	O
occurred	O
among	O
five	O
patients	O
treated	O
with	O
80	O
mg	O
/	O
m虏	O
/	O
day	O
","	O
and	O
the	O
MTD	O
was	O
defined	O
as	O
70	O
mg	O
/	O
m虏	O
/	O
day	O
.	O
	
Two	O
of	O
six	O
subjects	O
in	O
the	O
severe	B-TOXI
HD	I-TOXI
group	O
experienced	O
DLT	O
events	O
at	O
doses	O
of	O
60	O
mg	O
/	O
m虏	O
/	O
day	O
and	O
none	O
developed	O
DLT	O
events	O
at	O
50	O
mg	O
/	O
m虏	O
/	O
day	O
.	O
	
The	O
MTDs	O
for	O
a	O
3	O
week	O
schedule	O
of	O
S-1	B-DRUG
treatment	O
were	O
defined	O
in	O
patients	O
with	O
or	O
without	O
hepatic	B-TOXI
dysfunction	I-TOXI
.	O
	
A	O
3	O
week	O
treatment	O
regimen	O
of	O
S-1	B-DRUG
might	O
be	O
a	O
platform	O
for	O
combination	O
with	O
newer	O
cytotoxic	O
agents	O
or	O
biologics	O
.	O
	
Phase	O
I	O
dose	O
escalation	O
study	O
of	O
gemcitabine	B-DRUG
plus	O
irinotecan	B-DRUG
in	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
To	O
determine	O
the	O
maximally	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
recommended	O
phase	O
II	O
dose	O
(	O
RPTD	O
)	O
and	O
toxicity	O
profile	O
of	O
gemcitabine	B-DRUG
plus	O
irinotecan	B-DRUG
combination	O
.	O
	
Thirty-nine	O
evaluable	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
treated	O
with	O
gemcitabine	B-DRUG
(	O
Gem	B-DRUG
)	O
and	O
irinotecan	B-DRUG
(	O
Iri	B-DRUG
)	O
on	O
days	O
1	O
","	O
8	O
and	O
15	O
of	O
a	O
28-day	O
cycle	O
.	O
	
Dose	O
levels	O
included	O
Gem	B-DRUG
/	O
Iri	B-DRUG
700	O
/	O
50	O
","	O
900	O
/	O
50	O
","	O
900	O
/	O
75	O
","	O
500	O
/	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
respectively	O
.	O
	
Dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
was	O
assessed	O
during	O
cycle	O
one	O
;	O
toxicity	O
evaluation	O
was	O
closely	O
monitored	O
throughout	O
the	O
course	O
of	O
treatment	O
.	O
	
Treatment	O
continued	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
.	O
	
DLTs	O
primarily	O
consisted	O
of	O
grade	O
&	O
gt	O
;	O
or	O
=	O
3	O
thrombocytopenia	B-TOXI
lasting	O
&	O
gt	O
;	O
or	O
=	O
4	O
days	O
often	O
accompanied	O
by	O
grade	O
&	O
gt	O
;	O
or	O
=	O
3	O
neutropenia	B-TOXI
.	O
	
Other	O
grade	O
&	O
gt	O
;	O
or	O
=	O
3	O
toxicities	O
included	O
vomiting	B-TOXI
","	O
diarrhea	B-TOXI
","	O
fatigue	B-TOXI
and	O
elevated	B-TOXI
alkaline	I-TOXI
phosphatase	I-TOXI
.	O
	
Three	O
patients	O
had	O
a	O
partial	O
response	O
.	O
	
Stable	O
disease	O
as	O
best	O
response	O
was	O
seen	O
in	O
16	O
patients	O
","	O
ranging	O
from	O
2月18日	O
months	O
.	O
	
The	O
MTD	O
/	O
RPTD	O
is	O
gemcitabine	B-DRUG
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
plus	O
irinotecan	B-DRUG
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
","	O
8	O
and	O
15	O
of	O
a	O
28-day	O
cycle	O
.	O
	
Given	O
the	O
toxicity	O
profile	O
and	O
negative	O
results	O
of	O
phase	O
III	O
studies	O
","	O
no	O
further	O
testing	O
of	O
this	O
treatment	O
combination	O
is	O
recommended	O
.	O
	
Bortezomib	B-DRUG
as	O
induction	O
before	O
autologous	O
transplantation	O
","	O
followed	O
by	O
lenalidomide	B-DRUG
as	O
consolidation-maintenance	O
in	O
untreated	O
multiple	B-CANCER
myeloma	I-CANCER
patients	O
.	O
	
	
PURPOSE	O
To	O
evaluate	O
the	O
effect	O
of	O
bortezomib	B-DRUG
as	O
induction	O
therapy	O
before	O
autologous	O
transplantation	O
","	O
followed	O
by	O
lenalidomide	B-DRUG
as	O
consolidation-maintenance	O
in	O
myeloma	B-CANCER
patients	O
.	O
	
PATIENTS	O
AND	O
METHODS	O
Newly	O
diagnosed	O
patients	O
age	O
65	O
to	O
75	O
years	O
were	O
eligible	O
.	O
	
Induction	O
(	O
bortezomib	B-DRUG
","	O
doxorubicin	B-DRUG
","	O
and	O
dexamethasone	B-DRUG
[	O
PAD	O
]	O
)	O
included	O
four	O
21-day	O
cycles	O
of	O
bortezomib	B-DRUG
(	O
1.3	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
","	O
4	O
","	O
8	O
","	O
and	O
11	O
)	O
","	O
pegylated	B-DRUG
liposomal	I-DRUG
doxorubicin	I-DRUG
(	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
4	O
)	O
","	O
and	O
dexamethasone	B-DRUG
(	O
40	O
mg	O
/	O
d	O
;	O
cycle	O
1	O
:	O
days	O
1	O
to	O
4	O
","	O
8	O
to	O
11	O
","	O
and	O
15	O
to	O
18	O
;	O
cycles	O
2	O
to	O
4	O
:	O
days	O
1	O
to	O
4	O
)	O
.	O
	
Autologous	O
transplantation	O
was	O
tandem	B-DRUG
melphalan	I-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
MEL100	O
)	O
and	O
stem-cell	O
support	O
.	O
	
Consolidation	O
included	O
four	O
28-day	O
cycles	O
of	O
lenalidomide	B-DRUG
(	O
25	O
mg	O
/	O
d	O
on	O
days	O
1	O
to	O
21	O
every	O
28	O
days	O
)	O
plus	O
prednisone	B-DRUG
(	O
50	O
mg	O
every	O
other	O
day	O
)	O
","	O
followed	O
by	O
maintenance	O
with	O
lenalidomide	B-DRUG
(	O
LP-L	O
;	O
10	O
mg	O
/	O
d	O
on	O
days	O
1	O
to	O
21	O
)	O
until	O
relapse	O
.	O
	
Primary	O
end	O
points	O
were	O
safety	O
(	O
incidence	O
of	O
grade	O
3	O
to	O
4	O
adverse	O
events	O
[	O
AEs	O
]	O
)	O
and	O
efficacy	O
(	O
response	O
rate	O
)	O
.	O
	
Results	O
A	O
total	O
of	O
102	O
patients	O
were	O
enrolled	O
.	O
	
In	O
a	O
per-protocol	O
analysis	O
","	O
after	O
PAD	O
","	O
58	O
%	O
of	O
patients	O
had	O
very	O
good	O
partial	O
response	O
(	O
VGPR	O
)	O
or	O
better	O
","	O
including	O
13	O
%	O
with	O
complete	O
response	O
(	O
CR	O
)	O
;	O
after	O
MEL100	O
","	O
82	O
%	O
of	O
patients	O
had	O
at	O
least	O
VGPR	O
and	O
38	O
%	O
had	O
CR	O
;	O
and	O
after	O
LP-L	O
","	O
86	O
%	O
of	O
patients	O
had	O
at	O
least	O
VGPR	O
and	O
66	O
%	O
had	O
CR	O
.	O
	
After	O
median	O
follow-up	O
time	O
of	O
21	O
months	O
","	O
the	O
2-year	O
progression-free	O
survival	O
rate	O
was	O
69	O
%	O
","	O
and	O
the	O
2-year	O
overall	O
survival	O
rate	O
was	O
86	O
%	O
.	O
	
During	O
induction	O
","	O
treatment-related	O
mortality	O
was	O
3	O
%	O
;	O
grade	O
3	O
to	O
4	O
AEs	O
included	O
thrombocytopenia	B-TOXI
(	O
17	O
%	O
)	O
","	O
neutropenia	B-TOXI
(	O
10	O
%	O
)	O
","	O
peripheral	B-TOXI
neuropathy	I-TOXI
(	O
16	O
%	O
)	O
","	O
and	O
pneumonia	B-TOXI
(	O
10	O
%	O
)	O
.	O
	
During	O
consolidation-maintenance	O
","	O
grade	O
3	O
to	O
4	O
AEs	O
were	O
neutropenia	B-TOXI
(	O
16	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
6	O
%	O
)	O
","	O
pneumonia	B-TOXI
(	O
5	O
%	O
)	O
","	O
and	O
cutaneous	B-TOXI
rash	I-TOXI
(	O
4	O
%	O
)	O
.	O
	
CONCLUSION	O
Bortezomib	B-DRUG
as	O
induction	O
before	O
autologous	O
transplantation	O
","	O
followed	O
by	O
lenalidomide	B-DRUG
as	O
consolidation-maintenance	O
","	O
is	O
an	O
effective	O
regimen	O
.	O
	
A	O
modular	O
Phase	O
I	O
study	O
of	O
lenalidomide	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
metastatic	B-CANCER
castration-resistant	I-CANCER
prostate	I-CANCER
cancer	I-CANCER
following	O
prior	O
taxane	B-DRUG
therapy	O
.	O
	
	
Lenalidomide	B-DRUG
","	O
a	O
highly	O
potent	O
immunomodulatory	O
derivative	O
of	O
thalidomide	B-DRUG
","	O
potentiates	O
the	O
action	O
of	O
paclitaxel	B-DRUG
in	O
vitro	O
against	O
prostate	B-CANCER
cancer	I-CANCER
cell	O
lines	O
in	O
co-culture	O
with	O
mononuclear	O
cells	O
.	O
	
A	O
modular	O
Phase	O
I	O
study	O
of	O
lenalidomide	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
men	O
with	O
metastatic	B-CANCER
castration-resistant	I-CANCER
prostate	I-CANCER
cancer	I-CANCER
(	O
CRPC	B-CANCER
)	O
was	O
conducted	O
to	O
assess	O
PSA	O
kinetics	O
with	O
lead-in	O
lenalidomide	B-DRUG
and	O
the	O
feasibility	O
of	O
the	O
combination	O
.	O
	
Men	O
with	O
metastatic	B-CANCER
CRPC	I-CANCER
with	O
prior	O
taxane	B-DRUG
chemotherapy	O
were	O
planned	O
for	O
single-agent	O
	O
lenalidomide	B-DRUG
for	O
21	O
/	O
28	O
days	O
at	O
dose-levels	O
:	O
-1	O
(	O
5	O
mg	O
)	O
","	O
0	O
(	O
10	O
mg	O
)	O
","	O
1	O
(	O
15	O
mg	O
)	O
","	O
2	O
(	O
20	O
mg	O
)	O
","	O
3	O
(	O
25	O
mg	O
)	O
;	O
followed	O
by	O
lenalidomide	B-DRUG
at	O
the	O
same	O
dose	O
and	O
schedule	O
in	O
combination	O
with	O
weekly	O
intravenous	B-DRUG
paclitaxel	I-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
over	O
3	O
h	O
on	O
days	O
1	O
","	O
8	O
","	O
15	O
every	O
28	O
days	O
utilizing	O
a	O
3	O
=+	O
3	O
dose-escalation	O
design	O
.	O
	
Dose-limiting	O
toxicity	O
was	O
observed	O
in	O
4	O
/	O
6	O
patients	O
with	O
first-cycle	O
combination	O
therapy	O
at	O
the	O
10	O
mg	O
dose-level	O
and	O
3	O
/	O
6	O
patients	O
at	O
the	O
5	O
mg	O
dose-level	O
of	O
lenalidomide	B-DRUG
","	O
respectively	O
.	O
	
These	O
included	O
Grade	O
3	O
neutropenia	B-TOXI
precluding	O
planned	O
paclitaxel	B-DRUG
therapy	O
(	O
n	O
=	O
3	O
)	O
","	O
grade	O
3	O
gastrointestinal	B-DRUG
toxicity	I-DRUG
(	O
n	O
=	O
2	O
)	O
","	O
chest	O
pain	O
(	O
n	O
=	O
1	O
)	O
and	O
pulmonary	B-TOXI
embolism	I-TOXI
(	O
n	O
=	O
1	O
)	O
.	O
	
With	O
lead-in	O
lenalidomide	B-DRUG
","	O
two	O
patients	O
with	O
lymph-node	B-DRUG
dominant	I-DRUG
CRPC	I-DRUG
had	O
a	O
PSA-decline	O
and	O
regression	O
in	O
lymph	O
node	O
disease	O
","	O
respectively	O
.	O
	
Two	O
of	O
seven	O
evaluable	O
patients	O
had	O
PSA	O
declines	O
by	O
50	O
%	O
with	O
combination	O
therapy	O
.	O
	
Progression-free	O
survival	O
was	O
13	O
weeks	O
(	O
range	O
4-35	O
weeks	O
)	O
.	O
	
The	O
high	O
dose-limiting	O
toxicity	O
rates	O
observed	O
with	O
lenalidomide	B-DRUG
and	O
weekly	O
paclitaxel	B-DRUG
require	O
exploration	O
of	O
alternate	O
dose-schedules	O
of	O
the	O
combination	O
in	O
the	O
second-line	O
setting	O
of	O
CRPC	B-CANCER
.	O
	
These	O
early	O
observations	O
suggest	O
distinctive	O
toxicity	O
and	O
efficacy	O
outcomes	O
from	O
thalidomide	B-DRUG
in	O
combination	O
with	O
paclitaxel	B-DRUG
.	O
	
Melphalan	B-DRUG
","	O
prednisone	B-DRUG
","	O
thalidomide	B-DRUG
and	O
defibrotide	B-DRUG
in	O
relapsed	O
/	O
refractory	B-CANCER
multiple	I-CANCER
myeloma	I-CANCER
:	O
results	O
of	O
a	O
multicenter	O
phase	O
I	O
/	O
II	O
trial	O
.	O
	
	
Defibrotide	B-DRUG
is	O
a	O
novel	O
orally	O
bioavailable	O
polydisperse	O
oligonucleotide	O
with	O
anti-thrombotic	O
and	O
anti-adhesive	O
effects	O
.	O
	
In	O
SCID	O
/	O
NOD	O
mice	O
","	O
defibrotide	B-DRUG
showed	O
activity	O
in	O
human	O
myeloma	O
xenografts	O
.	O
	
This	O
phase	O
I	O
/	O
II	O
study	O
was	O
conducted	O
to	O
identify	O
the	O
most	O
appropriate	O
dose	O
of	O
defibrotide	B-DRUG
in	O
combination	O
with	O
melphalan	B-DRUG
","	O
prednisone	B-DRUG
and	O
thalidomide	B-DRUG
in	O
patients	O
with	O
relapsed	O
and	O
relapsed	O
/	O
refractory	B-CANCER
multiple	I-CANCER
myeloma	I-CANCER
","	O
and	O
to	O
determine	O
its	O
safety	O
and	O
tolerability	O
as	O
part	O
of	O
this	O
regimen	O
.	O
	
This	O
was	O
a	O
phase	O
I	O
/	O
II	O
","	O
multicenter	O
","	O
dose-escalating	O
","	O
non-comparative	O
","	O
open	O
label	O
study	O
.	O
	
Oral	B-DRUG
melphalan	I-DRUG
was	O
administered	O
at	O
a	O
dose	O
of	O
0.25	O
mg	O
/	O
kg	O
on	O
days	O
1月4日	O
","	O
prednisone	B-DRUG
at	O
a	O
dose	O
of	O
1.5	O
mg	O
/	O
kg	O
also	O
on	O
days	O
1月4日	O
and	O
thalidomide	B-DRUG
at	O
a	O
dose	O
of	O
50-100	O
mg	O
/	O
day	O
continuously	O
.	O
	
Defibrotide	B-DRUG
was	O
administered	O
orally	O
at	O
three	O
dose-levels	O
:	O
2.4	O
","	O
4.8	O
or	O
7.2	O
g	O
on	O
days	O
1月4日	O
and	O
1.6	O
","	O
3.2	O
","	O
or	O
4.8	O
g	O
on	O
days	O
5-35	O
.	O
	
Twenty-four	O
patients	O
with	O
relapsed	O
/	O
refractory	B-CANCER
multiple	I-CANCER
myeloma	I-CANCER
were	O
enrolled	O
.	O
	
No	O
dose-limiting	O
toxicity	O
was	O
observed	O
.	O
	
In	O
all	O
patients	O
","	O
the	O
complete	O
response	O
plus	O
very	O
good	O
partial	O
response	O
rate	O
was	O
9	O
%	O
","	O
and	O
the	O
partial	O
response	O
rate	O
was	O
43	O
%	O
.	O
	
The	O
1-year	O
progression-free	O
survival	O
and	O
1-year	O
overall	O
survival	O
rates	O
were	O
34	O
%	O
and	O
90	O
%	O
","	O
respectively	O
.	O
	
The	O
most	O
frequent	O
grade	O
3月4日	O
adverse	O
events	O
included	O
neutropenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
anemia	B-TOXI
and	O
fatigue	B-TOXI
.	O
	
Deep	B-TOXI
vein	I-TOXI
thrombosis	I-TOXI
was	O
reported	O
in	O
only	O
one	O
patient	O
.	O
	
This	O
combination	O
of	O
melphalan	B-DRUG
","	O
prednisone	B-DRUG
and	O
thalidomide	B-DRUG
together	O
with	O
defibrotide	B-DRUG
showed	O
anti-tumor	O
activity	O
with	O
a	O
favorable	O
tolerability	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
of	O
defibrotide	B-DRUG
was	O
identified	O
as	O
7.2	O
g	O
p.o.	O
on	O
days	O
1月4日	O
followed	O
by	O
4.8	O
g	O
p.o.	O
on	O
days	O
5-35	O
.	O
	
Further	O
trials	O
are	O
needed	O
to	O
confirm	O
the	O
role	O
of	O
this	O
regimen	O
and	O
to	O
evaluate	O
the	O
combination	O
of	O
defibrotide	B-DRUG
with	O
new	O
drugs	O
.	O
	
Docetaxel	B-DRUG
versus	O
paclitaxel	B-DRUG
combined	O
with	O
5-FU	B-DRUG
and	O
leucovorin	B-DRUG
in	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
:	O
combined	O
analysis	O
of	O
two	O
phase	O
II	O
trials	O
.	O
	
	
This	O
is	O
an	O
ad	O
hoc	O
analysis	O
of	O
two	O
phase	O
II	O
studies	O
which	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
two	O
taxanes	B-DRUG
(	O
paclitaxel	B-DRUG
and	O
docetaxel	B-DRUG
)	O
combined	O
with	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
and	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
in	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
adenocarcinoma	I-CANCER
who	O
were	O
untreated	O
or	O
had	O
only	O
received	O
first-line	O
chemotherapy	O
","	O
were	O
treated	O
with	O
either	O
paclitaxel	B-DRUG
(	O
PFL	O
;	O
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
or	O
docetaxel	B-DRUG
(	O
DFL	O
;	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
on	O
day	O
1	O
","	O
followed	O
by	O
a	O
bolus	B-DRUG
of	I-DRUG
LV	I-DRUG
(	O
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
days	O
1~3	O
)	O
and	O
a	O
24-hour	O
infusion	O
of	O
5-FU	B-DRUG
(	O
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
days	O
1~3	O
)	O
every	O
3	O
weeks	O
.	O
	
The	O
primary	O
endpoint	O
was	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
and	O
the	O
secondary	O
endpoint	O
included	O
survival	O
and	O
toxicity	O
.	O
	
Sixty-six	O
patients	O
received	O
DFL	O
(	O
first-line	O
[	O
n=38	O
]	O
;	O
and	O
second-line	O
[	O
n=28	O
]	O
)	O
and	O
60	O
patients	O
received	O
PFL	O
(	O
first-line	O
[	O
n=37	O
]	O
;	O
and	O
second-line	O
[	O
n=23	O
]	O
)	O
.	O
	
The	O
ORRs	O
were	O
not	O
significantly	O
different	O
between	O
the	O
2	O
groups	O
(	O
DFL	O
","	O
26	O
%	O
;	O
PFL	O
","	O
38	O
%	O
)	O
.	O
	
With	O
a	O
median	O
follow-up	O
of	O
9.5	O
months	O
","	O
the	O
progression	O
free	O
survival	O
was	O
5.2	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
4.2~6.5	O
months	O
)	O
for	O
DFL	O
and	O
3.3	O
months	O
(	O
95	O
%	O
CI	O
","	O
1.3~5.5	O
months	O
)	O
for	O
PFL	O
(	O
p=0.17	O
)	O
.	O
	
The	O
overall	O
survival	O
was	O
also	O
comparable	O
between	O
the	O
patients	O
who	O
received	O
DFL	O
and	O
PFL	O
(	O
10	O
months	O
[	O
95	O
%	O
CI	O
","	O
7.2~12.5	O
months	O
]	O
and	O
13.9	O
months	O
[	O
95	O
%	O
CI	O
","	O
10.9~19.2	O
months	O
]	O
","	O
respectively	O
;	O
p=0.37	O
)	O
.	O
	
The	O
most	O
frequent	O
grade	O
3~4	O
adverse	O
event	O
was	O
neutropenia	B-TOXI
(	O
DFL	O
","	O
71	O
%	O
;	O
PFL	O
","	O
62	O
%	O
)	O
.	O
	
DFL	O
and	O
PFL	O
had	O
different	O
non-hematologic	B-TOXI
toxicities	I-TOXI
;	O
specifically	O
","	O
grade	O
&	O
gt	O
;	O
or=3	O
mucositis	B-TOXI
(	O
5	O
%	O
)	O
and	O
diarrhea	B-TOXI
(	O
3	O
%	O
)	O
were	O
common	O
in	O
DFL	O
","	O
while	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
(	O
15	O
%	O
)	O
and	O
peripheral	B-TOXI
neuropathy	I-TOXI
(	O
5	O
%	O
)	O
were	O
common	O
in	O
PFL	O
.	O
	
Thus	O
","	O
the	O
two	O
taxanes	B-DRUG
had	O
similar	O
efficacy	O
in	O
the	O
treatment	O
of	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
","	O
but	O
different	O
toxicity	O
profiles	O
.	O
	
Prospective	O
comparative	O
studies	O
are	O
required	O
to	O
further	O
clarify	O
the	O
role	O
of	O
taxanes	B-DRUG
in	O
the	O
treatment	O
of	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Cetuximab	B-DRUG
plus	O
oxaliplatin	B-DRUG
/	O
leucovorin	B-DRUG
/	O
5-fluorouracil	B-DRUG
in	O
first-line	O
metastatic	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
:	O
a	O
phase	O
II	O
study	O
of	O
the	O
Arbeitsgemeinschaft	O
Internistische	O
Onkologie	O
(	O
AIO	O
)	O
.	O
	
	
Cetuximab	B-DRUG
enhances	O
the	O
efficacy	O
of	O
chemotherapy	O
in	O
several	O
cancer	O
types	O
.	O
	
This	O
trial	O
assessed	O
the	O
activity	O
of	O
cetuximab	B-DRUG
and	O
chemotherapy	O
in	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
previously	O
untreated	O
","	O
metastatic	O
","	O
gastric	B-CANCER
cancer	I-CANCER
received	O
cetuximab	B-DRUG
400	O
mg	O
m	O
(	O
-2	O
)	O
at	O
first	O
infusion	O
followed	O
by	O
weekly	O
infusions	O
of	O
250	O
mg	O
m	O
(	O
-2	O
)	O
combined	O
with	O
FUFOX	B-DRUG
(	O
oxaliplatin	B-DRUG
50	O
mg	O
m	O
(	O
-2	O
)	O
","	O
5-FU	O
2000	O
mg	O
m	O
(	O
-2	O
)	O
","	O
and	O
DL-folinic	B-DRUG
acid	I-DRUG
200	O
mg	O
m	O
(	O
-2	O
)	O
d1	O
","	O
8	O
","	O
15	O
and	O
22	O
qd36	O
)	O
.	O
	
The	O
primary	O
endpoint	O
was	O
tumour	O
response	O
.	O
	
Overall	O
","	O
52	O
patients	O
were	O
enrolled	O
.	O
	
The	O
most	O
common	O
grade	O
3	O
/	O
4	O
toxicities	O
were	O
diarrhoea	B-TOXI
(	O
33	O
%	O
)	O
","	O
and	O
skin	B-TOXI
toxicity	I-TOXI
(	O
24	O
%	O
)	O
.	O
	
Efficacy	O
was	O
evaluable	O
in	O
46	O
patients	O
who	O
showed	O
a	O
response	O
rate	O
of	O
65	O
%	O
(	O
CI	O
95	O
%	O
:	O
50-79	O
%	O
)	O
including	O
four	O
complete	O
responses	O
.	O
	
Time	O
to	O
progression	O
(	O
TTP	O
)	O
was	O
7.6	O
months	O
(	O
CI	O
95	O
%	O
:	O
5.0-10.1	O
months	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
9.5	O
months	O
(	O
CI	O
95	O
%	O
:	O
7.9-11.1	O
months	O
)	O
.	O
	
Epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
was	O
detectable	O
in	O
60	O
%	O
of	O
tumours	O
but	O
showed	O
no	O
correlation	O
with	O
treatment	O
outcome	O
.	O
	
A	O
KRAS	O
mutation	O
was	O
found	O
in	O
only	O
1	O
of	O
32	O
(	O
3	O
%	O
)	O
tumour	O
samples	O
analysed	O
.	O
	
Cetuximab	B-DRUG
plus	O
FUFOX	B-DRUG
showed	O
an	O
interesting	O
high	O
response	O
rate	O
in	O
metastatic	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Cetuximab	B-DRUG
plus	O
platinum-fluoropyrimidine	B-DRUG
chemotherapy	O
is	O
at	O
present	O
being	O
investigated	O
in	O
a	O
phase	O
III	O
randomised	O
controlled	O
trial	O
.	O
	
Phase	O
I	O
study	O
of	O
17-allylamino-17	B-DRUG
demethoxygeldanamycin	I-DRUG
","	O
gemcitabine	B-DRUG
and	O
/	O
or	O
cisplatin	B-DRUG
in	O
patients	O
with	O
refractory	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
To	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
characterize	O
the	O
dose-limiting	O
toxicities	O
(	O
DLT	O
)	O
of	O
17-AAG	B-DRUG
","	O
gemcitabine	B-DRUG
and	O
/	O
or	O
cisplatin	B-DRUG
.	O
	
Levels	O
of	O
the	O
proteins	O
Hsp90	O
","	O
Hsp70	O
and	O
ILK	O
were	O
measured	O
in	O
peripheral	O
blood	O
mononuclear	O
cell	O
(	O
PMBC	O
)	O
lysates	O
to	O
assess	O
the	O
effects	O
of	O
17-AAG	B-DRUG
.	O
	
Phase	O
I	O
dose-escalating	O
trial	O
using	O
a	O
	O
design	O
performed	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Once	O
the	O
MTD	O
of	O
gemcitabine	B-DRUG
=+	O
17-AAG	B-DRUG
=+	O
cisplatin	B-DRUG
was	O
determined	O
","	O
dose	O
escalation	O
of	O
17-AAG	B-DRUG
with	O
constant	O
doses	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
was	O
attempted	O
.	O
	
After	O
significant	O
hematologic	B-TOXI
toxicity	I-TOXI
occurred	O
","	O
the	O
protocol	O
was	O
amended	O
to	O
evaluate	O
three	O
cohorts	O
:	O
gemcitabine	B-DRUG
and	O
17-AAG	B-DRUG
;	O
17-AAG	B-DRUG
and	O
cisplatin	B-DRUG
;	O
and	O
gemcitabine	B-DRUG
","	O
17-AAG	B-DRUG
and	O
cisplatin	B-DRUG
with	O
modified	O
dosing	O
.	O
	
The	O
39	O
patients	O
enrolled	O
were	O
evaluable	O
for	O
toxicity	O
and	O
response	O
.	O
	
The	O
MTD	O
for	O
cohort	O
A	O
was	O
154	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
17-AAG	O
","	O
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
gemcitabine	B-DRUG
","	O
and	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
cisplatin	B-DRUG
.	O
	
In	O
cohort	O
A	O
","	O
DLTs	O
were	O
observed	O
at	O
the	O
higher	O
dose	O
level	O
and	O
included	O
neutropenia	B-TOXI
","	O
hyperbilirubinemia	B-TOXI
","	O
dehydration	B-TOXI
","	O
GGT	B-TOXI
elevation	I-TOXI
","	O
hyponatremia	B-TOXI
","	O
nausea	B-TOXI
","	O
vomiting	B-TOXI
","	O
and	O
thrombocytopenia	B-TOXI
.	O
	
The	O
MTD	O
for	O
cohort	O
C	O
was	O
154	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
17-AAG	B-DRUG
and	O
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
gemcitabine	B-TOXI
","	O
with	O
one	O
DLT	O
observed	O
(	O
alkaline	B-TOXI
phosphatase	I-TOXI
elevation	I-TOXI
)	O
observed	O
.	O
	
In	O
cohort	O
C	O
","	O
DLTs	O
of	O
thrombocytopenia	B-TOXI
","	O
fever	B-TOXI
and	O
dyspnea	B-TOXI
were	O
seen	O
at	O
the	O
higher	O
dose	O
level	O
.	O
	
The	O
remaining	O
cohorts	O
were	O
closed	O
to	O
accrual	O
due	O
to	O
toxicity	O
.	O
	
Six	O
patients	O
experienced	O
partial	O
responses	O
.	O
	
Mean	O
Hsp90	O
levels	O
were	O
decreased	O
and	O
levels	O
of	O
Hsp70	O
were	O
increased	O
compared	O
to	O
baseline	O
.	O
	
17-AAG	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
demonstrated	O
antitumor	O
activity	O
","	O
but	O
significant	O
hematologic	B-TOXI
toxicities	I-TOXI
were	O
encountered	O
.	O
	
17-AAG	B-DRUG
combined	O
with	O
gemcitabine	B-DRUG
is	O
tolerable	O
and	O
has	O
demonstrated	O
evidence	O
of	O
activity	O
at	O
the	O
MTD	O
.	O
	
The	O
recommended	O
phase	O
II	O
dose	O
is	O
defined	O
as	O
154	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
17-AAG	B-DRUG
and	O
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
gemcitabine	B-DRUG
","	O
and	O
is	O
currently	O
being	O
investigated	O
in	O
phase	O
II	O
studies	O
in	O
ovarian	B-CANCER
and	I-CANCER
pancreatic	I-CANCER
cancers	I-CANCER
.	O
	
There	O
is	O
no	O
recommended	O
phase	O
II	O
dose	O
for	O
the	O
cisplatin-containing	B-DRUG
combinations	O
.	O
	
Docetaxel	B-DRUG
","	O
ifosfamide	B-DRUG
and	O
cisplatin	B-DRUG
in	O
solid	B-CANCER
tumour	I-CANCER
treatment	O
:	O
a	O
phase	O
I	O
study	O
.	O
	
	
Docetaxel	B-DRUG
","	O
ifosfamide	B-DRUG
and	O
cisplatin	B-DRUG
have	O
proven	O
activity	O
in	O
a	O
broad	O
range	O
of	O
solid	B-CANCER
tumours	I-CANCER
and	O
interfere	O
with	O
different	O
phases	O
of	O
the	O
cell	O
cycle	O
.	O
	
We	O
performed	O
a	O
phase	O
I	O
study	O
with	O
the	O
aim	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
docetaxel	B-DRUG
","	O
ifosfamide	B-DRUG
and	O
cisplatin	B-DRUG
in	O
patients	O
with	O
solid	B-CANCER
tumours	I-CANCER
and	O
to	O
define	O
the	O
safety	O
","	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
and	O
the	O
recommended	O
dose	O
and	O
administration	O
schedule	O
of	O
docetaxel	B-DRUG
","	O
ifosfamide	B-DRUG
and	O
cisplatin	B-DRUG
for	O
further	O
phase	O
II	O
testing	O
.	O
	
Docetaxel	B-DRUG
was	O
given	O
by	O
1-h	O
infusion	O
on	O
day	O
1	O
","	O
followed	O
by	O
ifosfamide	B-DRUG
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
as	O
a	O
continuous	O
infusion	O
for	O
5	O
days	O
.	O
	
Mesna	B-DRUG
was	O
added	O
at	O
the	O
same	O
doses	O
to	O
the	O
same	O
infusion	O
bag	O
and	O
was	O
continued	O
for	O
12	O
h	O
after	O
the	O
end	O
of	O
ifosfamide	B-DRUG
.	O
	
Cisplatin	B-DRUG
was	O
administered	O
as	O
a	O
24-h	O
infusion	O
concomitantly	O
with	O
ifosfamide	B-DRUG
","	O
but	O
in	O
separate	O
infusion	O
bags	O
","	O
either	O
on	O
day	O
5	O
(	O
schedule	O
A	O
)	O
or	O
on	O
day	O
1	O
(	O
schedule	O
B	O
)	O
.	O
	
Escalation	O
steps	O
were	O
planned	O
only	O
for	O
docetaxel	B-DRUG
(	O
60	O
","	O
75	O
","	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
cisplatin	B-DRUG
(	O
50	O
","	O
75	O
","	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O
	
No	O
intrapatient	O
dose	O
escalation	O
was	O
permitted	O
.	O
	
Prophylactic	O
ciprofloxacin	B-DRUG
was	O
used	O
after	O
a	O
protocol	O
amendment	O
was	O
implemented	O
.	O
	
No	O
prophylactic	O
haematopoietic	O
growth	O
factors	O
were	O
used	O
.	O
	
Cycles	O
of	O
docetaxel	B-DRUG
","	O
ifosfamide	B-DRUG
and	O
cisplatin	B-DRUG
were	O
given	O
at	O
3-week	O
intervals	O
.	O
	
Toxicity	O
was	O
scored	O
according	O
to	O
National	O
Cancer	O
Institute	O
Canada-Common	O
Toxicity	O
Criteria	O
2	O
The	O
MTD	O
was	O
defined	O
as	O
the	O
dose	O
at	O
which	O
a	O
DLT	O
was	O
observed	O
in	O
fewer	O
than	O
two	O
of	O
six	O
patients	O
during	O
the	O
first	O
treatment	O
cycle	O
.	O
	
In	O
total	O
","	O
85	O
patients	O
received	O
309	O
cycles	O
.	O
	
Only	O
three	O
escalation	O
steps	O
could	O
be	O
explored	O
and	O
DLTs	O
were	O
observed	O
at	O
each	O
dose	O
level	O
.	O
	
In	O
total	O
","	O
32	O
patients	O
and	O
49	O
cycles	O
showed	O
DLTs	O
.	O
	
Febrile	B-TOXI
neutropenia	I-TOXI
occurred	O
in	O
20	O
patients	O
(	O
24	O
%	O
)	O
.	O
	
Only	O
two	O
DLTs	O
were	O
nonhaematological	B-TOXI
(	O
one	O
cerebral	B-TOXI
infarction	I-TOXI
and	O
one	O
encephalopathy	B-TOXI
grade	O
4	O
)	O
.	O
	
Neutropenia	B-TOXI
grade	O
4	O
lasted	O
for	O
greater	O
than	O
7	O
days	O
and	O
/	O
or	O
thrombocytopenia	B-TOXI
grade	O
4	O
was	O
dose	O
limiting	O
in	O
10	O
patients	O
.	O
	
Febrile	B-TOXI
neutropenia	I-TOXI
occurred	O
in	O
five	O
of	O
41	O
patients	O
(	O
12	O
%	O
)	O
who	O
received	O
prophylactic	O
ciprofloxacin	B-DRUG
and	O
in	O
15	O
of	O
44	O
patients	O
(	O
34	O
%	O
)	O
who	O
did	O
not	O
.	O
	
MTD	O
was	O
reached	O
at	O
level	O
3	O
(	O
docetaxel	B-DRUG
","	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
cisplatin	B-DRUG
","	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O
	
With	O
a	O
lower	O
dose	O
of	O
docetaxel	B-DRUG
(	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
both	O
schedules	O
A	O
and	O
B	O
were	O
feasible	O
","	O
although	O
","	O
overall	O
","	O
schedule	O
A	O
seemed	O
to	O
be	O
better	O
tolerated	O
.	O
	
On	O
the	O
basis	O
of	O
this	O
phase	O
I	O
study	O
","	O
the	O
recommended	O
docetaxel	B-DRUG
","	O
ifosfamide	B-DRUG
and	O
cisplatin	B-DRUG
regimen	O
is	O
docetaxel	B-DRUG
(	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
on	O
day	O
1	O
","	O
ifosfamide	B-DRUG
(	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
)	O
on	O
days	O
1月5日	O
and	O
cisplatin	B-DRUG
(	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
given	O
on	O
day	O
5	O
It	O
is	O
associated	O
with	O
substantial	O
haematological	B-TOXI
toxicity	I-TOXI
","	O
but	O
this	O
is	O
feasible	O
provided	O
prophylactic	O
antibiotics	O
are	O
used	O
.	O
	
Cetuximab	B-DRUG
and	O
first-line	O
taxane	B-DRUG
/	O
carboplatin	B-DRUG
chemotherapy	O
in	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
results	O
of	O
the	O
randomized	O
multicenter	O
phase	O
III	O
trial	O
BMS099	O
.	O
	
	
PURPOSE	O
To	O
evaluate	O
the	O
efficacy	O
of	O
cetuximab	B-DRUG
plus	O
taxane	B-DRUG
/	O
carboplatin	B-DRUG
(	O
TC	B-DRUG
)	O
as	O
first-line	O
treatment	O
of	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
PATIENTS	O
AND	O
METHODS	O
This	O
multicenter	O
","	O
open-label	O
","	O
phase	O
III	O
study	O
enrolled	O
676	O
chemotherapy-na茂ve	O
patients	O
with	O
stage	O
IIIB	O
(	O
pleural	O
effusion	O
)	O
or	O
IV	O
NSCLC	B-CANCER
","	O
without	O
restrictions	O
by	O
histology	O
or	O
epidermal	O
growth	O
factor	O
receptor	O
expression	O
.	O
	
Patients	O
were	O
randomly	O
assigned	O
to	O
cetuximab	B-DRUG
/	O
TC	B-DRUG
or	O
TC	B-DRUG
.	O
	
TC	B-DRUG
consisted	O
of	O
paclitaxel	B-DRUG
(	O
225	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
or	O
docetaxel	B-DRUG
(	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
at	O
the	O
investigator	O
's	O
discretion	O
","	O
and	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
=	O
6	O
)	O
on	O
day	O
1	O
every	O
3	O
weeks	O
for	O
&	O
lt	O
;	O
or	O
=	O
six	O
cycles	O
;	O
cetuximab	B-DRUG
(	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
","	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
)	O
was	O
administered	O
until	O
progression	O
or	O
unacceptable	O
toxicity	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
progression-free	O
survival	O
assessed	O
by	O
independent	O
radiologic	O
review	O
committee	O
(	O
PFS-IRRC	O
)	O
;	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
","	O
overall	O
survival	O
(	O
OS	O
)	O
","	O
quality	O
of	O
life	O
(	O
QoL	O
)	O
","	O
and	O
safety	O
were	O
key	O
secondary	O
end	O
points	O
.	O
	
PFS	O
and	O
ORR	O
assessed	O
by	O
investigators	O
were	O
also	O
evaluated	O
.	O
	
Results	O
Median	O
PFS-IRRC	O
was	O
4.4	O
months	O
with	O
cetuximab	B-DRUG
/	O
TC	B-DRUG
versus	O
4.24	O
months	O
with	O
TC	B-DRUG
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
=	O
0.902	O
;	O
95	O
%	O
CI	O
","	O
0.761	O
to	O
1.069	O
;	O
P	O
=	O
0.236	O
)	O
.	O
	
Median	O
OS	O
was	O
9.69	O
months	O
with	O
cetuximab	B-DRUG
/	O
TC	B-DRUG
versus	O
8.38	O
months	O
with	O
TC	B-DRUG
(	O
HR	O
=	O
0.89	O
;	O
95	O
%	O
CI	O
","	O
0.754	O
to	O
1.051	O
;	O
P	O
=	O
0.169	O
)	O
.	O
	
ORR-IRRC	O
was	O
25.7	O
%	O
with	O
cetuximab	B-DRUG
/	O
TC	B-DRUG
versus	O
17.2	O
%	O
with	O
TC	B-DRUG
(	O
P	O
=	O
0.007	O
)	O
.	O
	
The	O
safety	O
profile	O
of	O
this	O
combination	O
was	O
manageable	O
and	O
consistent	O
with	O
its	O
individual	O
components	O
.	O
	
CONCLUSION	O
The	O
addition	O
of	O
cetuximab	B-DRUG
to	O
TC	B-DRUG
did	O
not	O
significantly	O
improve	O
the	O
primary	O
end	O
point	O
","	O
PFS-IRRC	O
.	O
	
There	O
was	O
significant	O
improvement	O
in	O
ORR	O
by	O
IRRC	O
.	O
	
The	O
difference	O
in	O
OS	O
favored	O
cetuximab	B-DRUG
but	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O
	
Phase	O
I	O
trial	O
of	O
non-cytotoxic	B-DRUG
suramin	I-DRUG
as	O
a	O
modulator	O
of	O
docetaxel	B-DRUG
and	O
gemcitabine	B-DRUG
therapy	O
in	O
previously	O
treated	O
patients	O
with	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
In	O
preclinical	O
models	O
","	O
non-cytotoxic	B-DRUG
suramin	I-DRUG
(	O
concentrations	O
&	O
lt	O
;	O
50	O
渭M	O
)	O
potentiates	O
the	O
activity	O
of	O
multiple	O
chemotherapeutic	O
agents	O
.	O
	
The	O
present	O
study	O
evaluated	O
the	O
safety	O
and	O
tolerability	O
of	O
suramin	B-DRUG
in	O
combination	O
with	O
docetaxel	B-DRUG
or	O
gemcitabine	B-DRUG
in	O
previously	O
chemotherapy-treated	O
patients	O
with	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
received	O
suramin	O
intravenously	O
in	O
combination	O
with	O
either	O
docetaxel	B-DRUG
on	O
day	O
1	O
or	O
gemcitabine	B-DRUG
on	O
days	O
1	O
and	O
8	O
","	O
of	O
each	O
21-day	O
treatment	O
cycle	O
.	O
	
After	O
3	O
cycles	O
","	O
patients	O
with	O
partial	O
response	O
(	O
PR	O
)	O
or	O
better	O
continued	O
on	O
the	O
same	O
combination	O
","	O
whereas	O
patients	O
with	O
stable	O
disease	O
(	O
SD	O
)	O
or	O
worse	O
crossed-over	O
to	O
the	O
other	O
combination	O
.	O
	
Pharmacokinetic	O
analyses	O
were	O
performed	O
before	O
and	O
after	O
each	O
treatment	O
.	O
	
Eighteen	O
patients	O
received	O
a	O
total	O
of	O
79	O
courses	O
(	O
37	O
suramin	B-DRUG
plus	O
docetaxel	B-DRUG
","	O
42	O
suramin	B-DRUG
plus	O
gemcitabine	B-DRUG
)	O
.	O
	
The	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
was	O
febrile	B-TOXI
neutropenia	I-TOXI
","	O
observed	O
in	O
three	O
of	O
six	O
patients	O
treated	O
with	O
suramin	B-DRUG
and	O
docetaxel	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
No	O
DLTs	O
were	O
observed	O
with	O
suramin	B-DRUG
plus	O
docetaxel	B-DRUG
56	O
mg	O
/	O
m	O
(	O
2	O
)	O
or	O
suramin	B-DRUG
plus	O
gemcitabine	B-DRUG
"1,250"	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Common	O
adverse	O
events	O
included	O
neutropenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
anemia	B-TOXI
","	O
fatigue	B-TOXI
","	O
nausea	B-TOXI
","	O
vomiting	B-TOXI
","	O
skin	B-TOXI
rash	I-TOXI
","	O
hyperglycemia	B-TOXI
","	O
and	O
electrolyte	B-TOXI
abnormalities	I-TOXI
.	O
	
The	O
target	O
plasma	O
suramin	B-DRUG
concentration	O
range	O
of	O
10-50	O
渭M	O
was	O
achieved	O
in	O
90	O
%	O
of	O
treatments	O
.	O
	
Discernable	O
antitumor	O
activity	O
was	O
noted	O
in	O
11	O
patients	O
(	O
2	O
PR	O
","	O
9	O
SD	O
)	O
.	O
	
Non-cytotoxic	B-DRUG
suramin	I-DRUG
","	O
in	O
combination	O
with	O
docetaxel	B-DRUG
56	O
mg	O
/	O
m	O
(	O
2	O
)	O
or	O
gemcitabine	B-DRUG
"1,250"	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
was	O
reasonably	O
well-tolerated	O
with	O
a	O
manageable	O
toxicity	O
profile	O
.	O
	
Target	O
plasma	O
concentrations	O
were	O
correctly	O
predicted	O
by	O
our	O
previously	O
described	O
dosing	O
nomogram	O
.	O
	
The	O
observed	O
preliminary	O
evidence	O
of	O
antitumor	O
activity	O
encourages	O
evaluation	O
of	O
this	O
strategy	O
in	O
efficacy	O
trials	O
.	O
	
Plasma	O
and	O
cerebrospinal	O
fluid	O
pharmacokinetics	O
of	O
topotecan	B-DRUG
in	O
a	O
phase	O
I	O
trial	O
of	O
topotecan	B-DRUG
","	O
tamoxifen	B-DRUG
","	O
and	O
carboplatin	B-DRUG
","	O
in	O
the	O
treatment	O
of	O
recurrent	B-CANCER
or	I-CANCER
refractory	I-CANCER
brain	I-CANCER
or	O
spinal	B-CANCER
cord	I-CANCER
tumors	I-CANCER
.	O
	
	
This	O
study	O
was	O
designed	O
to	O
ascertain	O
the	O
dose-limiting	O
toxicities	O
(	O
DLT	O
)	O
and	O
maximally	O
tolerated	O
doses	O
of	O
the	O
combination	O
of	O
fixed-dose	O
tamoxifen	B-DRUG
and	O
carboplatin	B-DRUG
","	O
with	O
escalating	O
doses	O
of	O
topotecan	B-DRUG
","	O
and	O
to	O
determine	O
the	O
pharmacokinetics	O
of	O
topotecan	B-DRUG
in	O
the	O
plasma	O
and	O
cerebrospinal	O
fluid	O
.	O
	
Tamoxifen	B-DRUG
100	O
mg	O
po	O
bid	O
","	O
topotecan	B-DRUG
0.25	O
","	O
0.5	O
","	O
0.75	O
","	O
or	O
1	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d	O
IV	O
","	O
administered	O
as	O
a	O
72	O
h	O
continuous	O
infusion	O
on	O
days	O
1月3日	O
","	O
followed	O
by	O
carboplatin	B-DRUG
AUC	O
=	O
3	O
","	O
IV	O
on	O
day	O
3	O
Cycles	O
were	O
repeated	O
every	O
4	O
weeks	O
.	O
	
Seventeen	O
patients	O
received	O
39	O
cycles	O
of	O
treatment	O
:	O
median	O
2	O
","	O
(	O
range	O
1月5日	O
)	O
.	O
	
The	O
tumors	O
included	O
glioblastoma	B-CANCER
(	O
6	O
)	O
","	O
anaplastic	B-CANCER
astrocytoma	I-CANCER
(	O
2	O
)	O
","	O
metastatic	B-CANCER
non-small	I-CANCER
cell	I-CANCER
(	O
3	O
)	O
","	O
small	B-CANCER
cell	I-CANCER
lung	I-CANCER
(	O
2	O
)	O
","	O
and	O
one	O
each	O
with	O
medulloblastoma	B-CANCER
","	O
ependymoma	B-CANCER
","	O
and	O
metastatic	B-CANCER
breast	I-CANCER
or	I-CANCER
colon	I-CANCER
carcinoma	I-CANCER
.	O
	
The	O
median	O
Karnofsky	O
performance	O
status	O
was	O
70	O
%	O
(	O
range	O
60-90	O
%	O
)	O
and	O
age	O
:	O
52	O
(	O
range	O
24-75	O
)	O
.	O
	
Eleven	O
patients	O
were	O
female	O
and	O
six	O
male	O
.	O
	
Toxicities	O
included	O
thrombocytopenia	B-TOXI
(	O
2	O
)	O
","	O
neutropenia	B-TOXI
without	I-TOXI
fever	I-TOXI
lasting	O
6	O
days	O
(	O
1	O
)	O
","	O
DVT	B-TOXI
(	O
2	O
)	O
","	O
and	O
emesis	B-TOXI
(	O
1	O
)	O
.	O
	
Topotecan	B-DRUG
levels	O
","	O
total	O
and	O
lactone	O
","	O
were	O
measured	O
prior	O
to	O
the	O
end	O
of	O
infusion	O
in	O
plasma	O
and	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
.	O
	
At	O
1	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d	O
","	O
the	O
median	O
CSF	O
/	O
plasma	O
ratio	O
was	O
19.4	O
%	O
(	O
range	O
15.1-59.1	O
%	O
)	O
.	O
	
The	O
total	O
plasma	O
topotecan	B-DRUG
in	O
two	O
pts	O
with	O
DLTs	O
was	O
4.63	O
and	O
5.87	O
ng	O
/	O
ml	O
","	O
in	O
three	O
without	O
DLTs	O
at	O
the	O
same	O
dose	O
level	O
the	O
mean	O
total	O
plasma	O
topotecan	B-DRUG
was	O
3.4	O
ng	O
/	O
ml	O
(	O
range	O
3.02-3.83	O
)	O
.	O
	
Plasma	O
lactone	O
levels	O
were	O
33	O
%	O
of	O
the	O
total	O
;	O
CSF	O
penetration	O
was	O
20	O
%	O
of	O
the	O
total	O
plasma	O
levels	O
.	O
	
4	O
/	O
8	O
pts	O
with	O
high-grade	O
gliomas	B-TOXI
had	O
stable	O
disease	O
(	O
median	O
:	O
3	O
cycles	O
(	O
range	O
2月5日	O
)	O
)	O
.	O
	
Two	O
had	O
minor	O
responses	O
.	O
	
One	O
patient	O
with	O
metastatic	B-TOXI
non-small	I-TOXI
cell	I-TOXI
and	O
one	O
with	O
small	B-TOXI
cell	I-TOXI
lung	I-TOXI
cancer	I-TOXI
had	O
objective	O
PRs	O
.	O
	
The	O
recommended	O
phase	O
II	O
doses	O
are	O
:	O
tamoxifen	B-DRUG
100	O
mg	O
po	O
bid	O
","	O
topotecan	B-DRUG
0.75	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d	O
IV	O
continuous	O
infusion	O
for	O
72	O
h	O
","	O
followed	O
by	O
carboplatin	B-DRUG
AUC	O
=	O
3	O
IV	O
on	O
day	O
3	O
Measurable	O
topotecan	B-DRUG
levels	O
","	O
both	O
total	O
and	O
lactone	O
","	O
are	O
observed	O
in	O
the	O
CSF	O
.	O
	
Phase	O
I	O
/	O
II	O
trial	O
of	O
sunitinib	B-DRUG
plus	O
gefitinib	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
renal	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
	
Sunitinib	B-DRUG
is	O
an	O
oral	O
","	O
multitargeted	O
tyrosine	O
kinase	O
inhibitor	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
platelet-derived	O
growth	O
factor	O
receptors	O
with	O
proven	O
clinical	O
benefit	O
in	O
patients	O
with	O
metastatic	B-CANCER
renal	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
RCC	B-CANCER
)	O
.	O
	
This	O
phase	O
I	O
/	O
II	O
study	O
investigated	O
sunitinib	B-DRUG
in	O
combination	O
with	O
an	O
epidermal	O
growth	O
factor	O
receptor	O
inhibitor	O
","	O
gefitinib	B-DRUG
","	O
in	O
patients	O
with	O
metastatic	B-CANCER
RCC	I-CANCER
.	O
	
In	O
phase	O
I	O
","	O
patients	O
received	O
sunitinib	B-DRUG
37.5	O
or	O
50	O
mg	O
in	O
6-week	O
cycles	O
(	O
4	O
weeks	O
on	O
treatment	O
","	O
2	O
off	O
)	O
plus	O
gefitinib	B-DRUG
250	O
mg	O
","	O
both	O
once	O
daily	O
","	O
to	O
determine	O
the	O
sunitinib	B-DRUG
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
.	O
	
Pharmacokinetics	O
was	O
assessed	O
for	O
both	O
drugs	O
.	O
	
In	O
phase	O
II	O
","	O
patients	O
received	O
sunitinib	B-DRUG
MTD	O
plus	O
gefitinib	B-DRUG
to	O
evaluate	O
the	O
safety	O
and	O
antitumor	O
activity	O
of	O
this	O
combination	O
.	O
	
Forty-two	O
patients	O
were	O
enrolled	O
:	O
11	O
in	O
phase	O
I	O
","	O
and	O
31	O
in	O
phase	O
II	O
.	O
	
In	O
phase	O
I	O
","	O
2	O
dose-limiting	O
toxicities	O
were	O
observed	O
with	O
sunitinib	B-DRUG
50	O
mg	O
(	O
grade	O
2	O
left	B-TOXI
ventricular	I-TOXI
ejection	I-TOXI
fraction	I-TOXI
decline	I-TOXI
and	O
grade	O
3	O
fatigue	B-TOXI
)	O
","	O
and	O
37.5	O
mg	O
was	O
declared	O
the	O
MTD	O
.	O
	
Thirteen	O
patients	O
treated	O
at	O
the	O
MTD	O
achieved	O
a	O
partial	O
response	O
(	O
objective	O
response	O
rate	O
:	O
37	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
","	O
22-55	O
)	O
and	O
12	O
(	O
34	O
%	O
)	O
had	O
stable	O
disease	O
.	O
	
Median	O
progression-free	O
survival	O
was	O
11	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
6月17日	O
)	O
.	O
	
The	O
most	O
commonly	O
reported	O
grade	O
3	O
/	O
4	O
treatment-related	O
adverse	O
event	O
was	O
diarrhea	B-TOXI
(	O
14	O
%	O
)	O
","	O
the	O
only	O
grade	O
3	O
/	O
4	O
adverse	O
event	O
to	O
occur	O
in	O
&	O
gt	O
;	O
2	O
patients	O
.	O
	
Pharmacokinetic	O
analyses	O
did	O
not	O
indicate	O
any	O
drug-drug	O
interactions	O
.	O
	
In	O
metastatic	B-CANCER
RCC	I-CANCER
","	O
sunitinib	B-DRUG
plus	O
gefitinib	B-DRUG
demonstrated	O
comparable	O
efficacy	O
to	O
sunitinib	B-DRUG
monotherapy	O
with	O
an	O
acceptable	O
safety	O
profile	O
.	O
	
Dosing	O
","	O
pharmacokinetic	O
profile	O
","	O
and	O
safety	O
support	O
study	O
of	O
sunitinib	B-DRUG
plus	O
an	O
epidermal	O
growth	O
factor	O
receptor	O
inhibitor	O
in	O
other	O
tumor	O
types	O
.	O
	
Durable	O
responses	O
with	O
the	O
metronomic	O
rituximab	B-DRUG
and	O
thalidomide	B-DRUG
plus	O
prednisone	B-DRUG
","	O
etoposide	B-DRUG
","	O
procarbazine	B-DRUG
","	O
and	O
cyclophosphamide	B-DRUG
regimen	O
in	O
elderly	O
patients	O
with	O
recurrent	B-CANCER
mantle	I-CANCER
cell	I-CANCER
lymphoma	I-CANCER
.	O
	
	
Targeting	O
the	O
tumor	O
microenvironment	O
and	O
angiogenesis	O
is	O
a	O
novel	O
lymphoma	B-CANCER
therapeutic	O
strategy	O
.	O
	
The	O
authors	O
report	O
safety	O
","	O
activity	O
","	O
and	O
angiogenic	O
profiling	O
results	O
with	O
the	O
rituximab	B-DRUG
and	O
thalidomide	B-DRUG
plus	O
prednisone	B-DRUG
","	O
etoposide	B-DRUG
","	O
procarbazine	B-DRUG
","	O
and	O
cyclophosphamide	B-DRUG
(	O
RT-PEPC	B-DRUG
)	O
regimen	O
in	O
patients	O
with	O
recurrent	B-CANCER
mantle	I-CANCER
cell	I-CANCER
lymphoma	I-CANCER
(	O
MCL	B-CANCER
)	O
.	O
	
RT-PEPC	B-DRUG
included	O
induction	O
(	O
Months	O
1月3日	O
)	O
of	O
rituximab	B-DRUG
4	O
times	O
weekly	O
","	O
daily	O
thalidomide	B-DRUG
(	O
50	O
mg	O
)	O
","	O
and	O
PEPC	B-DRUG
followed	O
by	O
maintenance	O
thalidomide	B-DRUG
(	O
100	O
mg	O
)	O
","	O
oral	B-DRUG
PEPC	I-DRUG
titrated	O
to	O
the	O
neutrophil	O
count	O
","	O
and	O
rituximab	B-DRUG
every	O
4	O
months	O
.	O
	
Endpoints	O
included	O
safety	O
","	O
efficacy	O
","	O
quality	O
of	O
life	O
(	O
QoL	O
)	O
","	O
and	O
translational	O
studies	O
","	O
including	O
tumor	O
angiogenic	O
phenotyping	O
","	O
plasma	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
","	O
and	O
circulating	O
endothelial	O
cells	O
.	O
	
Twenty-five	O
patients	O
were	O
enrolled	O
","	O
and	O
22	O
were	O
evaluable	O
.	O
	
The	O
median	O
age	O
was	O
68	O
years	O
(	O
range	O
","	O
52-81	O
years	O
)	O
","	O
24	O
patients	O
(	O
96	O
%	O
)	O
had	O
stage	O
III	O
or	O
IV	O
disease	O
","	O
18	O
patients	O
(	O
72	O
%	O
)	O
had	O
an	O
International	O
Prognostic	O
Index	O
(	O
IPI	O
)	O
score	O
of	O
3	O
to	O
5	O
","	O
and	O
20	O
patients	O
(	O
80	O
%	O
)	O
had	O
high-risk	O
Mantle	O
Cell	O
International	O
Prognostic	O
Index	O
(	O
MIPI	O
)	O
scores	O
.	O
	
Patients	O
had	O
received	O
a	O
median	O
of	O
2	O
previous	O
therapies	O
(	O
range	O
","	O
1月7日	O
previous	O
therapies	O
)	O
","	O
and	O
15	O
patients	O
(	O
60	O
%	O
)	O
had	O
progressed	O
on	O
bortezomib	B-DRUG
.	O
	
At	O
a	O
median	O
follow-up	O
of	O
38	O
months	O
","	O
the	O
overall	O
response	O
rate	O
was	O
73	O
%	O
(	O
complete	O
response	O
[	O
CR	O
]	O
/	O
unconfirmed	O
CR	O
rate	O
","	O
32	O
%	O
;	O
partial	O
response	O
[	O
PR	O
]	O
rate	O
","	O
41	O
%	O
;	O
n	O
=	O
22	O
patients	O
)	O
","	O
and	O
the	O
median	O
progression-free	O
survival	O
was	O
10	O
months	O
.	O
	
Four	O
CRs	O
were	O
ongoing	O
(	O
&	O
gt	O
;	O
or	O
6	O
months	O
","	O
&	O
gt	O
;	O
or	O
31	O
months	O
","	O
&	O
gt	O
;	O
or	O
48	O
months	O
","	O
and	O
&	O
gt	O
;	O
or	O
50	O
months	O
)	O
.	O
	
Toxicities	O
included	O
grade	O
1	O
and	O
2	O
fatigue	B-TOXI
","	O
rash	B-TOXI
","	O
neuropathy	B-TOXI
","	O
and	O
cytopenias	B-TOXI
","	O
including	O
grade	O
1	O
and	O
2	O
thrombocytopenia	B-TOXI
(	O
64	O
%	O
)	O
and	O
grade	O
3	O
and	O
4	O
neutropenia	B-TOXI
(	O
64	O
%	O
)	O
.	O
	
Two	O
thromboses	B-TOXI
and	O
5	O
episodes	O
of	O
grade	O
3	O
or	O
4	O
infections	B-TOXI
occurred	O
.	O
	
QoL	O
was	O
maintained	O
or	O
improved	O
.	O
	
Correlative	O
studies	O
demonstrated	O
tumor	O
autocrine	O
angiogenic	O
loop	O
(	O
expression	O
of	O
VEGF	O
A	O
and	O
VEGF	O
receptor	O
1	O
)	O
and	O
heightened	O
angiogenesis	O
and	O
lymphangiogenesis	O
in	O
stroma	O
.	O
	
Plasma	O
VEGF	O
levels	O
and	O
circulating	O
endothelial	O
cells	O
trended	O
down	O
with	O
treatment	O
.	O
	
RT-PEPC	B-DRUG
had	O
significant	O
and	O
durable	O
activity	O
in	O
MCL	B-CANCER
with	O
manageable	O
toxicity	O
and	O
maintained	O
QoL	O
.	O
	
Novel	O
","	O
low-intensity	O
approaches	O
warrant	O
further	O
evaluation	O
","	O
potentially	O
as	O
initial	O
therapy	O
in	O
elderly	O
patients	O
.	O
	
Phase	O
I	O
trial	O
of	O
oblimersen	B-DRUG
(	O
Genasense庐	O
)	O
and	O
gemcitabine	B-DRUG
in	O
refractory	B-CANCER
and	I-CANCER
advanced	I-CANCER
malignancies	I-CANCER
.	O
	
	
Overexpression	O
of	O
Bcl-2	O
is	O
associated	O
with	O
worse	O
prognosis	O
for	O
a	O
number	O
of	O
cancer	O
types	O
.	O
	
The	O
present	O
study	O
was	O
designed	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
oblimersen	B-DRUG
(	O
antisense	O
Bcl-2	O
)	O
and	O
gemcitabine	B-DRUG
when	O
administered	O
to	O
patients	O
with	O
refractory	B-CANCER
malignancies	I-CANCER
.	O
	
Sixteen	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
refractory	O
to	O
standard	O
therapies	O
were	O
treated	O
with	O
escalating	O
doses	O
of	O
oblimersen	B-DRUG
continuous	O
","	O
120-h	O
intravenous	O
infusion	O
given	O
every	O
14	O
days	O
","	O
with	O
a	O
fixed-dose-rate	O
intravenous	O
infusion	O
of	O
gemcitabine	B-DRUG
administered	O
on	O
day	O
5	O
of	O
each	O
cycle	O
.	O
	
Serial	O
plasma	O
samples	O
were	O
collected	O
to	O
calculate	O
the	O
pharmacokinetics	O
of	O
oblimersen	B-DRUG
and	O
gemcitabine	B-DRUG
","	O
and	O
also	O
to	O
measure	O
the	O
effect	O
of	O
oblimersen	B-DRUG
on	O
Bcl-2	O
expression	O
.	O
	
7	O
women	O
and	O
9	O
men	O
","	O
median	O
age	O
55	O
years	O
(	O
range	O
35-74	O
years	O
)	O
","	O
received	O
a	O
5-day	O
infusion	O
of	O
oblimersen	B-DRUG
at	O
dose	O
levels	O
of	O
5	O
mg	O
/	O
kg	O
/	O
day	O
(	O
n	O
=	O
4	O
)	O
or	O
7	O
mg	O
/	O
kg	O
/	O
day	O
(	O
n	O
=	O
12	O
)	O
.	O
	
On	O
the	O
5th	O
day	O
of	O
the	O
infusion	O
","	O
gemcitabine	B-DRUG
was	O
given	O
at	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
h	O
for	O
a	O
total	O
dose	O
of	O
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
n	O
=	O
7	O
;	O
cohorts	O
I	O
and	O
II	O
)	O
","	O
"1,200"	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
n	O
=	O
3	O
;	O
cohort	O
III	O
)	O
","	O
or	O
"1,500"	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
n	O
=	O
6	O
;	O
cohort	O
IV	O
)	O
.	O
	
Edema	B-TOXI
was	O
the	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
","	O
necessitating	O
expansion	O
of	O
cohort	O
IV	O
.	O
	
No	O
subsequent	O
DLTs	O
were	O
noted	O
.	O
	
Thus	O
","	O
the	O
maximum	O
planned	O
doses	O
were	O
well	O
tolerated	O
","	O
and	O
a	O
formal	O
MTD	O
was	O
not	O
determined	O
.	O
	
Most	O
hematologic	B-TOXI
toxicities	I-TOXI
were	O
grade	O
1	O
or	O
2	O
There	O
was	O
low-grade	O
fatigue	B-TOXI
","	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
","	O
and	O
myalgias	B-TOXI
/	O
arthralgias	B-TOXI
.	O
	
Oblimersen	B-DRUG
C	O
(	O
ss	O
)	O
and	O
AUC	O
increased	O
in	O
relation	O
to	O
the	O
dose	O
escalation	O
","	O
but	O
gemcitabine	B-DRUG
triphosphate	I-DRUG
levels	O
did	O
not	O
correlate	O
well	O
with	O
dose	O
.	O
	
There	O
were	O
no	O
objective	O
responses	O
","	O
though	O
5	O
patients	O
had	O
stable	O
disease	O
.	O
	
A	O
&	O
gt	O
;	O
75	O
%	O
reduction	O
in	O
Bcl-2	O
expression	O
in	O
peripheral	O
blood	O
mononuclear	O
leucocytes	O
was	O
seen	O
more	O
frequently	O
in	O
patients	O
who	O
achieved	O
stable	O
disease	O
than	O
in	O
progressing	O
patients	O
.	O
	
The	O
maximal	O
planned	O
dose	O
levels	O
of	O
oblimersen	B-DRUG
and	O
gemcitabine	B-DRUG
in	O
combination	O
were	O
well	O
tolerated	O
.	O
	
Only	O
one	O
DLT	O
(	O
edema	O
)	O
occurred	O
.	O
	
There	O
was	O
a	O
correlation	O
between	O
Bcl-2	O
reduction	O
and	O
stable	O
disease	O
.	O
	
The	O
recommended	O
doses	O
of	O
the	O
drugs	O
for	O
future	O
studies	O
are	O
7	O
mg	O
/	O
kg	O
/	O
day	O
of	O
oblimersen	B-DRUG
on	O
days	O
1月5日	O
","	O
and	O
gemcitabine	B-DRUG
"1,500"	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
5	O
","	O
every	O
two	O
weeks	O
.	O
	
A	O
phase	O
II	O
study	O
of	O
weekly	O
paclitaxel	B-DRUG
","	O
cisplatin	B-DRUG
and	O
concurrent	O
radiation	O
therapy	O
for	O
locally-advanced	B-CANCER
unresectable	I-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
early	O
closure	O
due	O
to	O
lack	O
of	O
efficacy	O
.	O
	
	
In	O
this	O
phase	O
II	O
study	O
","	O
the	O
efficacy	O
and	O
safety	O
of	O
weekly	O
paclitaxel	B-DRUG
concomitant	O
with	O
cisplatin	B-DRUG
and	O
thoracic	O
radiotherapy	O
(	O
TRT	O
)	O
was	O
evaluated	O
in	O
patients	O
with	O
locally-advanced	O
unresectable	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Patients	O
with	O
stage	O
III	O
NSCLC	B-CANCER
(	O
without	O
pleural	B-TOXI
effusion	I-TOXI
or	O
cervical	B-TOXI
lymphadenopathy	I-TOXI
)	O
received	O
TRT	O
(	O
63	O
Gy	O
in	O
35	O
fractions	O
over	O
7	O
weeks	O
)	O
with	O
concurrent	O
weekly	O
cisplatin	B-CANCER
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
paclitaxel	B-CANCER
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
week	O
infused	O
over	O
3	O
hours	O
.	O
	
In	O
patients	O
without	O
evidence	O
of	O
disease	O
progression	O
","	O
the	O
administration	O
of	O
a	O
further	O
2	O
cycles	O
of	O
consolidation	O
chemotherapy	O
","	O
consisting	O
of	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
cisplatin	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
were	O
planned	O
after	O
completion	O
of	O
the	O
TRT	O
.	O
	
Between	O
Feb	O
2000	O
and	O
Dec	O
2002	O
","	O
20	O
patients	O
were	O
entered	O
into	O
the	O
study	O
;	O
13	O
completed	O
all	O
7	O
weeks	O
of	O
treatment	O
(	O
median	O
7.6	O
weeks	O
;	O
range	O
3.3	O
to	O
9.4	O
)	O
.	O
	
Seven	O
out	O
of	O
16	O
(	O
43.8	O
%	O
)	O
objective	O
responses	O
were	O
observed	O
","	O
with	O
15	O
(	O
75	O
%	O
)	O
patients	O
experiencing	O
at	O
least	O
one	O
episode	O
of	O
grade	O
3	O
/	O
4	O
toxicity	O
.	O
	
The	O
main	O
toxicities	O
were	O
moderate	O
to	O
severe	B-TOXI
neutropenia	I-TOXI
and	O
gastrointestinal	B-TOXI
toxicity	I-TOXI
.	O
	
The	O
unsatisfactory	O
response	O
rate	O
and	O
the	O
high	O
incidence	O
of	O
grade	O
3	O
/	O
4	O
hematologic	B-TOXI
and	I-TOXI
non-hematologic	I-TOXI
toxicities	I-TOXI
","	O
including	O
7	O
early	O
discontinuations	O
of	O
treatment	O
and	O
exceeding	O
the	O
study	O
stopping	O
rules	O
","	O
prompted	O
the	O
early	O
closure	O
of	O
the	O
study	O
.	O
	
In	O
view	O
of	O
the	O
activity	O
observed	O
","	O
the	O
protocol	O
was	O
amended	O
to	O
protracted	O
continuous	O
infusion	B-DRUG
paclitaxel	I-DRUG
","	O
cisplatin	B-DRUG
and	O
concurrent	O
TRT	O
.	O
	
Phase	O
II	O
study	O
of	O
irinotecan	B-DRUG
","	O
5-fluorouracil	B-DRUG
","	O
and	O
leucovorin	B-DRUG
in	O
relapsed	B-CANCER
or	I-CANCER
metastatic	I-CANCER
colorectal	I-CANCER
cancer	I-CANCER
as	O
first-line	O
therapy	O
.	O
	
	
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
efficacy	O
and	O
toxicity	O
of	O
biweekly	O
irinotecan	B-DRUG
plus	O
5-fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
and	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
in	O
patients	O
with	O
relapsed	B-CANCER
or	I-CANCER
metastatic	I-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Between	O
March	O
2002	O
and	O
May	O
2004	O
","	O
24	O
patients	O
with	O
histologically	O
confirmed	O
relapsed	B-CANCER
or	I-CANCER
metastatic	I-CANCER
colorectal	I-CANCER
cancer	I-CANCER
were	O
enrolled	O
in	O
this	O
study	O
.	O
	
One	O
chemotherapy	O
cycle	O
consisted	O
of	O
irinotecan	B-DRUG
180	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
and	O
15	O
;	O
5-FU	B-DRUG
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
bolus	O
IV	O
with	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
by	O
a	O
22	O
hour	O
intravenous	O
infusion	O
on	O
days	O
1	O
","	O
2	O
","	O
15	O
and	O
16	O
;	O
and	O
leucovorin	B-DRUG
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
","	O
2	O
","	O
15	O
and	O
16	O
","	O
every	O
4	O
weeks	O
.	O
	
The	O
median	O
age	O
of	O
the	O
24	O
was	O
57.5	O
years	O
(	O
range	O
","	O
38	O
approximately	O
69	O
)	O
.	O
	
Their	O
metastatic	O
sites	O
included	O
:	O
the	O
liver	O
(	O
62.5	O
%	O
)	O
","	O
lung	O
(	O
20.8	O
%	O
)	O
","	O
peritoneum	O
(	O
16.7	O
%	O
)	O
","	O
lymph	O
node	O
(	O
12.5	O
%	O
)	O
","	O
ovary	O
(	O
8.3	O
%	O
)	O
and	O
pelvis	O
/	O
vagina	O
(	O
8.3	O
%	O
)	O
.	O
	
Twenty-two	O
patients	O
were	O
evaluable	O
for	O
a	O
response	O
.	O
	
Six	O
and	O
7	O
patients	O
achieved	O
partial	O
responses	O
and	O
stable	O
diseases	O
","	O
respectively	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
27.3	O
%	O
(	O
95	O
%	O
Confidence	O
interval	O
;	O
10.3	O
approximately	O
44.5	O
%	O
)	O
.	O
	
The	O
median	O
follow-up	O
duration	O
for	O
surviving	O
patients	O
was	O
14.7	O
months	O
(	O
range	O
","	O
1.7	O
approximately	O
26.5	O
)	O
.	O
	
Median	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
1-year	O
OS	O
rates	O
were	O
19	O
months	O
and	O
86.3	O
%	O
","	O
respectively	O
.	O
	
Median	O
response	O
duration	O
and	O
median	O
progression	O
free	O
survival	O
were	O
7.47	O
and	O
5.57	O
months	O
","	O
respectively	O
.	O
	
A	O
total	O
of	O
83	O
cycles	O
(	O
median	O
4	O
cycles	O
)	O
were	O
administered	O
.	O
	
The	O
main	O
non-hematologic	B-TOXI
toxicities	I-TOXI
were	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
(	O
44.5	O
%	O
/	O
18.1	O
%	O
)	O
and	O
diarrhea	B-TOXI
(	O
8.4	O
%	O
)	O
.	O
	
The	O
most	O
common	O
hematologic	B-TOXI
toxicity	I-TOXI
was	O
NCI	O
grade	O
I	O
/	O
II	O
anemia	B-TOXI
(	O
31.3	O
%	O
)	O
and	O
grade	O
I	O
/	O
II	O
neutropenia	B-TOXI
was	O
10.8	O
%	O
.	O
	
There	O
was	O
no	O
life-threatening	O
toxicity	O
.	O
	
The	O
results	O
suggested	O
that	O
irinotecan	B-DRUG
","	O
5-FU	B-DRUG
and	O
leucovorin	B-DRUG
combination	O
chemotherapy	O
in	O
a	O
biweekly	O
schedule	O
is	O
a	O
practical	B-DRUG
and	O
tolerable	O
treatment	O
option	O
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Oxaliplatin	B-DRUG
","	O
5-fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
(	O
FOLFOX-4	B-DRUG
)	O
combination	O
chemotherapy	O
as	O
a	O
salvage	O
treatment	O
in	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
	
This	O
study	O
was	O
designed	O
to	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
FOLFOX-4	B-DRUG
chemotherapy	O
as	O
a	O
salvage	O
treatment	O
for	O
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
(	O
AGC	B-CANCER
)	O
.	O
	
The	O
AGC	B-CANCER
patients	O
with	O
an	O
ECOG	O
performance	O
status	O
of	O
0~1	O
and	O
progressive	O
disease	O
after	O
prior	O
treatments	O
were	O
registered	O
onto	O
this	O
phase	O
II	O
trial	O
.	O
	
The	O
patients	O
received	O
oxaliplatin	B-DRUG
(	O
85	O
mg	O
/	O
m虏	O
on	O
day	O
1	O
)	O
","	O
leucovorin	B-DRUG
(	O
200	O
mg	O
/	O
m虏	O
on	O
days	O
1	O
and	O
2	O
)	O
and	O
5-fluorouracil	B-DRUG
(	O
400	O
mg	O
/	O
m虏	O
as	O
a	O
bolus	O
and	O
600	O
mg	O
/	O
m虏	O
as	O
a	O
22-hour	O
infusion	O
on	O
days	O
1	O
and	O
2	O
)	O
every	O
2	O
weeks	O
.	O
	
For	O
the	O
42	O
treated	O
patients	O
","	O
a	O
total	O
of	O
228	O
chemotherapy	O
cycles	O
(	O
median	O
:	O
5	O
","	O
range	O
:	O
1~12	O
)	O
were	O
administered	O
.	O
	
Twenty-nine	O
patients	O
(	O
69	O
%	O
)	O
received	O
FOLFOX-4	B-DRUG
chemotherapy	O
as	O
a	O
third-	O
(	O
50	O
%	O
)	O
or	O
fourth-line	O
(	O
19	O
%	O
)	O
treatment	O
.	O
	
On	O
the	O
intent-to-treat	O
analysis	O
","	O
9	O
patients	O
(	O
21	O
%	O
)	O
achieved	O
a	O
partial	O
response	O
","	O
which	O
was	O
maintained	O
for	O
4.6	O
months	O
.	O
	
The	O
median	O
progression-free	O
survival	O
and	O
overall	O
survival	O
were	O
3	O
months	O
and	O
6.2	O
months	O
","	O
respectively	O
.	O
	
The	O
frequently	O
encountered	O
toxicities	O
were	O
neutropenia	B-TOXI
and	O
gastrointestinal	B-TOXI
side	I-TOXI
effects	I-TOXI
","	O
including	O
anorexia	B-TOXI
.	O
	
Although	O
there	O
was	O
one	O
possible	O
treatment-related	B-TOXI
death	I-TOXI
","	O
the	O
toxicity	O
profiles	O
were	O
generally	O
predictable	O
and	O
manageable	O
.	O
	
Salvage	O
chemotherapy	O
with	O
FOLFOX-4	B-DRUG
is	O
an	O
effective	O
and	O
tolerable	O
regimen	O
for	O
those	O
heavily	O
pretreated	O
AGC	B-CANCER
patients	O
who	O
have	O
a	O
good	O
performance	O
status	O
.	O
	
A	O
21-day	O
schedule	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
administration	O
in	O
the	O
treatment	O
of	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
carcinoma	I-CANCER
:	O
a	O
phase	O
II	O
study	O
.	O
	
	
To	O
evaluate	O
the	O
efficacy	O
and	O
toxicity	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
combination	O
chemotherapy	O
","	O
we	O
conducted	O
a	O
phase	O
II	O
study	O
of	O
this	O
regimen	O
in	O
patients	O
with	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
carcinoma	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
From	O
June	O
2001	O
to	O
August	O
2003	O
","	O
36	O
chemotherapy-naive	O
patients	O
with	O
stage	O
IIIB	O
or	O
IV	O
NSCLC	B-CANCER
were	O
enrolled	O
.	O
	
The	O
median	O
age	O
was	O
59	O
years	O
(	O
range	O
","	O
42	O
to	O
75	O
years	O
)	O
","	O
and	O
performance	O
status	O
was	O
0	O
or	O
1	O
Eleven	O
patients	O
had	O
stage	O
IIIB	O
disease	O
","	O
and	O
25	O
patients	O
had	O
stage	O
IV	O
disease	O
.	O
	
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
gemcitabine	B-DRUG
was	O
administered	O
on	O
day	O
1	O
&	O
amp	O
;	O
8	O
","	O
and	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
cisplatin	B-DRUG
was	O
administered	O
on	O
day	O
1	O
Each	O
cycle	O
was	O
repeated	O
every	O
21	O
days	O
.	O
	
Everyone	O
subject	O
who	O
participated	O
were	O
assessable	O
.	O
	
A	O
total	O
of	O
160	O
cycles	O
of	O
chemotherapy	O
were	O
delivered	O
","	O
and	O
the	O
median	O
number	O
of	O
chemotherapy	O
courses	O
was	O
3.5	O
(	O
range	O
","	O
2	O
to	O
9	O
)	O
.	O
	
Two	O
patients	O
(	O
5.6	O
%	O
)	O
achieved	O
a	O
complete	O
response	O
","	O
and	O
14	O
patients	O
(	O
38.9	O
%	O
)	O
achieved	O
a	O
partial	O
response	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
44.5	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
32.5	O
to	O
56.5	O
%	O
)	O
.	O
	
The	O
median	O
follow-up	O
duration	O
was	O
9.3	O
months	O
.	O
	
The	O
median	O
time	O
to	O
disease	O
progression	O
was	O
8.6	O
months	O
(	O
95	O
%	O
CI	O
7.4	O
to	O
9.9	O
months	O
)	O
","	O
and	O
median	O
survival	O
time	O
was	O
12.2	O
months	O
(	O
95	O
%	O
CI	O
","	O
10.5	O
to	O
12.9	O
months	O
)	O
.	O
	
Grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
occurred	O
in	O
9	O
patients	O
(	O
25	O
%	O
)	O
","	O
neutropenic	B-TOXI
fever	I-TOXI
occurred	O
in	O
3	O
patients	O
(	O
8.3	O
%	O
)	O
","	O
and	O
grade	O
3	O
/	O
4	O
thrombocytopenia	B-TOXI
occurred	O
in	O
7	O
patients	O
(	O
19.5	O
%	O
)	O
.	O
	
Mild	O
forms	O
of	O
non-hematologic	B-TOXI
toxicities	I-TOXI
","	O
such	O
as	O
nausea	B-TOXI
","	O
vomiting	B-TOXI
or	O
skin	B-TOXI
reactions	I-TOXI
","	O
were	O
observed	O
.	O
	
The	O
combination	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
in	O
a	O
21-day	O
schedule	O
is	O
an	O
effective	O
regimen	O
for	O
patients	O
with	O
NSCLC	B-CANCER
in	O
its	O
advanced	O
stages	O
.	O
	
A	O
dose	O
escalation	O
trial	O
of	O
biweekly	O
docetaxel	B-DRUG
and	O
gemcitabine	B-DRUG
with	O
filgrastim	B-DRUG
or	O
pegfilgrastim	B-DRUG
for	O
the	O
treatment	O
of	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
A	O
single-institution	O
phase	O
I	O
trial	O
to	O
determine	O
the	O
feasibility	O
of	O
using	O
filgrastim	B-DRUG
or	O
pegfilgrastim	B-DRUG
to	O
increase	O
the	O
dose	O
intensity	O
of	O
biweekly	O
docetaxel	B-DRUG
and	O
gemcitabine	B-DRUG
.	O
	
Patients	O
with	O
metastatic	B-CANCER
solid	I-CANCER
tumors	I-CANCER
received	O
gemcitabine	B-DRUG
"3,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
increasing	O
doses	O
of	O
docetaxel	B-DRUG
(	O
55	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
increments	O
)	O
every	O
14	O
days	O
with	O
filgrastim	B-DRUG
or	O
pegfilgrastim	B-DRUG
.	O
	
35	O
patients	O
enrolled	O
","	O
median	O
2	O
prior	O
therapies	O
","	O
158	O
cycles	O
of	O
therapy	O
.	O
	
There	O
was	O
1	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
(	O
sepsis	B-TOXI
)	O
at	O
docetaxel	B-DRUG
55	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
1	O
DLT	O
(	O
sepsis	B-TOXI
/	O
diarrhea	B-TOXI
)	O
at	O
docetaxel	B-DRUG
65	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
and	O
no	O
DLT	O
at	O
docetaxel	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
At	O
docetaxel	B-DRUG
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
2	O
/	O
4	O
patients	O
had	O
DLT	O
(	O
fatigue	B-TOXI
/	O
dyspnea	B-TOXI
","	O
diarrhea	B-TOXI
)	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
docetaxel	B-DRUG
was	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
1	O
/	O
12	O
patients	O
treated	O
at	O
MTD	O
experienced	O
DLT	O
(	O
sepsis	B-TOXI
/	O
dyspnea	B-TOXI
)	O
.	O
	
The	O
initial	O
25	O
patients	O
received	O
filgrastim	B-DRUG
(	O
average	O
7	O
doses	O
/	O
cycle	O
)	O
","	O
the	O
last	O
10	O
received	O
pegfilgrastim	B-DRUG
.	O
	
The	O
MTD	O
for	O
docetaxel	B-DRUG
was	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
with	O
gemcitabine	B-DRUG
"3,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
every	O
14	O
days	O
with	O
filgrastim	B-DRUG
or	O
pegfilgrastim	B-DRUG
.	O
	
This	O
regimen	O
was	O
well	O
tolerated	O
with	O
signs	O
of	O
clinical	O
activity	O
.	O
	
We	O
found	O
no	O
significant	O
differences	O
in	O
toxicities	O
or	O
effectiveness	O
between	O
daily	O
filgrastim	B-DRUG
and	O
pegfilgrastim	B-DRUG
given	O
13	O
days	O
before	O
the	O
next	O
chemotherapy	O
.	O
	
The	O
use	O
of	O
granulocyte	O
growth	O
factors	O
allowed	O
increased	O
dose	O
intensity	O
of	O
docetaxel	B-DRUG
and	O
gemcitabine	B-DRUG
.	O
	
This	O
regimen	O
warrants	O
further	O
study	O
in	O
chemotherapy-na茂ve	O
patients	O
and	O
patients	O
with	O
earlier	O
stages	O
.	O
	
Phase	O
I	O
/	O
II	O
study	O
of	O
erlotinib	B-DRUG
combined	O
with	O
cisplatin	B-DRUG
and	O
radiotherapy	O
in	O
patients	O
with	O
locally	B-CANCER
advanced	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
	
Erlotinib	B-DRUG
","	O
an	O
oral	B-DRUG
tyrosine	I-DRUG
kinase	I-DRUG
inhibitor	I-DRUG
","	O
is	O
active	O
against	O
head-and-neck	B-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
HNSCC	B-CANCER
)	O
and	O
possibly	O
has	O
a	O
synergistic	O
interaction	O
with	O
chemotherapy	O
and	O
radiotherapy	O
.	O
	
We	O
investigated	O
the	O
safety	O
and	O
efficacy	O
of	O
erlotinib	B-DRUG
added	O
to	O
cisplatin	B-DRUG
and	O
radiotherapy	O
in	O
locally	B-CANCER
advanced	I-CANCER
HNSCC	I-CANCER
.	O
	
In	O
this	O
Phase	O
I	O
/	O
II	O
trial	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
cisplatin	B-DRUG
was	O
administered	O
on	O
Days	O
8	O
","	O
29	O
","	O
and	O
50	O
","	O
and	O
radiotherapy	O
at	O
70	O
Gy	O
was	O
started	O
on	O
Day	O
8	O
During	O
Phase	O
I	O
","	O
the	O
erlotinib	B-DRUG
dose	O
was	O
escalated	O
(	O
50	O
mg	O
","	O
100	O
mg	O
","	O
and	O
150	O
mg	O
)	O
in	O
consecutive	O
cohorts	O
of	O
3	O
patients	O
","	O
starting	O
on	O
Day	O
1	O
and	O
continuing	O
during	O
radiotherapy	O
.	O
	
Dose-limiting	O
toxicity	O
was	O
defined	O
as	O
any	O
Grade	O
4	O
event	O
requiring	O
radiotherapy	O
interruptions	O
.	O
	
Phase	O
II	O
was	O
initiated	O
8	O
weeks	O
after	O
the	O
last	O
Phase	O
I	O
enrollment	O
.	O
	
The	O
study	O
accrued	O
9	O
patients	O
in	O
Phase	O
I	O
and	O
28	O
in	O
Phase	O
II	O
;	O
all	O
were	O
evaluable	O
for	O
efficacy	O
and	O
safety	O
.	O
	
No	O
dose-limiting	O
toxicity	O
occurred	O
in	O
Phase	O
I	O
","	O
and	O
the	O
recommended	O
Phase	O
II	O
dose	O
was	O
150	O
mg	O
.	O
	
The	O
most	O
frequent	O
nonhematologic	B-CANCER
toxicities	I-CANCER
were	O
nausea	B-CANCER
/	O
vomiting	B-CANCER
","	O
dysphagia	B-CANCER
","	O
stomatitis	B-CANCER
","	O
xerostomia	B-CANCER
and	O
in-field	B-CANCER
dermatitis	I-CANCER
","	O
acneiform	B-CANCER
rash	I-CANCER
","	O
and	O
diarrhea	B-CANCER
.	O
	
Of	O
the	O
31	O
patients	O
receiving	O
a	O
150-mg	O
daily	O
dose	O
of	O
erlotinib	B-DRUG
","	O
23	O
(	O
74	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
","	O
56.8	O
%	O
-86.3	O
%	O
)	O
had	O
a	O
complete	O
response	O
","	O
3	O
were	O
disease	O
free	O
after	O
salvage	O
surgery	O
","	O
4	O
had	O
inoperable	O
residual	O
disease	O
","	O
and	O
1	O
died	B-TOXI
of	I-TOXI
sepsis	I-TOXI
during	O
treatment	O
.	O
	
With	O
a	O
median	O
37	O
months	O
'	O
follow-up	O
","	O
the	O
3-year	O
progression-free	O
and	O
overall	O
survival	O
rates	O
were	O
61	O
%	O
and	O
72	O
%	O
","	O
respectively	O
.	O
	
This	O
combination	O
appears	O
safe	O
","	O
has	O
encouraging	O
activity	O
","	O
and	O
deserves	O
further	O
studies	O
in	O
locally	B-CANCER
advanced	I-CANCER
HNSCC	I-CANCER
.	O
	
Phase	O
II	O
evaluation	O
of	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
in	O
the	O
treatment	O
of	O
carcinosarcoma	B-CANCER
of	I-CANCER
the	I-CANCER
uterus	I-CANCER
:	O
a	O
Gynecologic	O
Oncology	O
Group	O
study	O
.	O
	
	
Platinum	B-DRUG
and	O
taxane	B-DRUG
compounds	I-DRUG
have	O
demonstrated	O
activity	O
in	O
uterine	B-CANCER
carcinosarcoma	I-CANCER
(	O
malignant	O
mixed	O
Mullerian	O
tumor	O
)	O
.	O
	
Ifosfamide	B-DRUG
plus	O
paclitaxel	B-DRUG
is	O
the	O
regimen	O
with	O
established	O
superiority	O
based	O
on	O
a	O
randomized	O
phase	O
III	O
trial	O
conducted	O
through	O
the	O
Gynecologic	O
Oncology	O
Group	O
.	O
	
However	O
","	O
the	O
toxicity	O
","	O
multiday	O
schedule	O
","	O
and	O
limited	O
activity	O
of	O
this	O
regimen	O
support	O
further	O
development	O
of	O
novel	O
regimens	O
.	O
	
Our	O
primary	O
objective	O
was	O
to	O
estimate	O
the	O
antitumor	O
activity	O
and	O
toxicity	O
of	O
paclitaxel	B-DRUG
plus	O
carboplatin	B-DRUG
in	O
patients	O
with	O
uterine	B-CANCER
carcinosarcomas	I-CANCER
.	O
	
Eligible	O
patients	O
had	O
advanced	O
stage	O
(	O
III	O
or	O
IV	O
)	O
","	O
persistent	O
or	O
recurrent	O
measurable	O
disease	O
","	O
and	O
no	O
prior	O
chemotherapy	O
.	O
	
Patients	O
received	O
paclitaxel	B-DRUG
at	O
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
(	O
IV	O
)	O
over	O
3	O
hours	O
plus	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
serum	O
concentration-time	O
curve	O
=	O
6	O
)	O
IV	O
over	O
30	O
minutes	O
every	O
3	O
weeks	O
until	O
disease	O
progression	O
or	O
until	O
adverse	O
effects	O
occurred	O
.	O
	
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
v3.0	O
was	O
used	O
to	O
grade	O
adverse	O
events	O
.	O
	
Fifty-five	O
patients	O
were	O
entered	O
onto	O
the	O
study	O
with	O
nine	O
being	O
excluded	O
from	O
analysis	O
","	O
leaving	O
46	O
evaluable	O
for	O
analysis	O
.	O
	
Treatment	O
was	O
well	O
tolerated	O
with	O
expected	O
hematologic	B-TOXI
toxicity	I-TOXI
and	O
minimal	O
nonhematologic	O
grade	O
4	O
toxicity	O
(	O
one	O
cardiovascular	B-TOXI
and	O
two	O
pain	B-TOXI
)	O
with	O
59	O
%	O
of	O
patients	O
completing	O
six	O
or	O
more	O
cycles	O
of	O
chemotherapy	O
.	O
	
The	O
proportions	O
of	O
patients	O
with	O
confirmed	O
complete	O
and	O
partial	O
responses	O
were	O
13	O
%	O
and	O
41	O
%	O
","	O
respectively	O
","	O
resulting	O
in	O
a	O
total	O
overall	O
response	O
rate	O
of	O
54	O
%	O
(	O
95	O
%	O
CI	O
","	O
37	O
%	O
to	O
67	O
%	O
)	O
.	O
	
Paclitaxel	B-DRUG
plus	O
carboplatin	B-DRUG
demonstrates	O
antitumor	O
activity	O
against	O
uterine	B-CANCER
carcinosarcoma	I-CANCER
with	O
acceptable	O
toxicity	O
and	O
warrants	O
further	O
evaluation	O
in	O
phase	O
III	O
randomized	O
trials	O
.	O
	
Pemetrexed	B-DRUG
plus	O
cisplatin	B-DRUG
/	O
carboplatin	B-DRUG
in	O
previously	O
treated	O
locally	B-CANCER
advanced	I-CANCER
or	I-CANCER
metastatic	I-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
patients	O
.	O
	
	
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
pemetrexed	B-DRUG
plus	O
cisplatin	B-DRUG
/	O
carboplatin	B-DRUG
in	O
locally	B-CANCER
advanced	I-CANCER
or	I-CANCER
metastatic	I-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
patients	O
previously	O
treated	O
with	O
platinum-based	B-DRUG
chemotherapy	O
.	O
	
Fifty-three	O
locally	B-CANCER
advanced	I-CANCER
or	I-CANCER
metastatic	I-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
patients	O
previously	O
treated	O
with	O
platinum-based	B-DRUG
chemotherapy	O
received	O
pemetrexed	B-DRUG
500	O
mg	O
/	O
m2	O
plus	O
cisplatin	B-DRUG
75	O
mg	O
/	O
m2	O
or	O
carboplatin	B-DRUG
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
5	O
every	O
21	O
days	O
","	O
with	O
dexamethasone	B-DRUG
","	O
folic	B-DRUG
acid	I-DRUG
and	O
vitamin	B-DRUG
B12	I-DRUG
being	O
administered	O
.	O
	
Median	O
age	O
was	O
52	O
years	O
.	O
	
Eastern	O
Cooperative	O
Oncology	O
Group	O
(	O
ECOG	O
)	O
performance	O
status	O
was	O
0-2	O
.	O
	
Thirty-eight	O
patients	O
had	O
stage	O
IV	O
tumors	O
.	O
	
Thirty-seven	O
patients	O
had	O
adenocarcinoma	B-CANCER
(	O
including	O
6	O
alveolar	B-CANCER
carcinoma	I-CANCER
patients	O
)	O
","	O
and	O
fourteen	O
patients	O
had	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
Thirty-four	O
patients	O
were	O
treated	O
in	O
second	O
line	O
","	O
15	O
in	O
third	O
line	O
","	O
and	O
4	O
in	O
fourth	O
line	O
.	O
	
Seven	O
patients	O
(	O
13.2	O
%	O
)	O
showed	O
partial	O
response	O
;	O
Thirty-six	O
(	O
67.9	O
%	O
)	O
had	O
stable	O
disease	O
.	O
	
The	O
median	O
progression	O
free	O
survival	O
time	O
was	O
6	O
months	O
and	O
the	O
median	O
overall	O
survival	O
time	O
was	O
10	O
months	O
.	O
	
The	O
1-year	O
survival	O
rate	O
was	O
40.9	O
%	O
.	O
	
Five	O
(	O
9.4	O
%	O
)	O
and	O
four	O
(	O
7.5	O
%	O
)	O
patients	O
experienced	O
grade	O
3	O
or	O
4	O
leukopenia	B-CANCER
and	O
thrombocytopenia	B-CANCER
","	O
respectively	O
.	O
	
Nonhematological	B-TOXI
toxicities	I-TOXI
included	O
grade	O
3	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
in	O
1	O
patient	O
(	O
1.9	O
%	O
)	O
","	O
grade	O
3	O
rash	B-TOXI
in	O
1	O
patient	O
","	O
grade	O
4	O
diarrhea	B-TOXI
in	O
1	O
patient	O
(	O
1.9	O
%	O
)	O
and	O
grade	O
4	O
creatinine	B-TOXI
increase	I-TOXI
in	O
1	O
patient	O
(	O
1.9	O
%	O
)	O
.	O
	
Locally	B-CANCER
advanced	I-CANCER
or	I-CANCER
metastatic	I-CANCER
NSCLC	I-CANCER
patients	O
previously	O
treated	O
with	O
platinum-based	B-DRUG
chemotherapy	O
could	O
benefit	O
from	O
pemetrexed	B-DRUG
plus	O
cisplatin	B-DRUG
/	O
carboplatin	B-DRUG
chemotherapy	O
with	O
tolerable	O
adverse	O
events	O
.	O
	
A	O
Phase	O
1	O
study	O
of	O
imatinib	B-DRUG
mesylate	I-DRUG
in	O
combination	O
with	O
cytarabine	B-DRUG
and	O
daunorubicin	B-DRUG
for	O
c-kit	B-CANCER
positive	I-CANCER
relapsed	I-CANCER
acute	I-CANCER
myeloid	I-CANCER
leukemia	I-CANCER
.	O
	
	
The	O
c-kit	O
receptor	O
is	O
expressed	O
in	O
95	O
%	O
of	O
relapsed	B-CANCER
acute	I-CANCER
myeloid	I-CANCER
leukemias	I-CANCER
(	O
AMLs	B-CANCER
)	O
and	O
mediates	O
leukemic	B-CANCER
proliferation	O
.	O
	
We	O
conducted	O
a	O
Phase	O
1	O
study	O
of	O
the	O
c-kit	B-DRUG
inhibitor	I-DRUG
","	O
imatinib	B-DRUG
mesylate	I-DRUG
(	O
IM	B-DRUG
)	O
","	O
in	O
combination	O
with	O
cytarabine	B-DRUG
and	O
daunorubicin	B-DRUG
(	O
7+3	O
)	O
in	O
c-kit+	B-CANCER
relapsed	I-CANCER
AML	I-CANCER
.	O
	
IM	B-DRUG
was	O
dose	O
escalated	O
using	O
a	O
3	O
by	O
3	O
design	O
.	O
	
Phosphorylated	O
STAT5	O
was	O
absent	O
to	O
minimally	O
present	O
in	O
residual	O
blasts	O
on	O
day	O
14	O
bone	O
marrows	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
of	O
IM	B-DRUG
was	O
300	O
mg	O
.	O
	
The	O
dose-limiting	O
toxicity	O
was	O
Grade	O
3月4日	O
hepatic	B-TOXI
toxicity	I-TOXI
.	O
	
The	O
CR	O
/	O
CRp	O
rate	O
was	O
57	O
%	O
.	O
	
Cytotoxic	O
therapy	O
that	O
includes	O
IM	B-DRUG
for	O
relapsed	B-CANCER
AML	I-CANCER
is	O
well-tolerated	O
and	O
effective	O
.	O
	
Phase	O
I	O
trial	O
of	O
dose-escalated	O
cisplatin	B-DRUG
with	O
concomitant	O
cetuximab	B-DRUG
and	O
hyperfractionated-accelerated	O
radiotherapy	O
in	O
locally	B-CANCER
advanced	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
	
Cetuximab	B-DRUG
is	O
active	O
in	O
the	O
treatment	O
of	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	O
SCCHN	B-CANCER
)	O
","	O
enhancing	O
both	O
radiotherapy	O
and	O
chemotherapy	O
effects	O
.	O
	
This	O
phase	O
I	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
safety	O
and	O
tolerability	O
of	O
combining	O
weekly	O
cisplatin	B-DRUG
treatment	O
with	O
cetuximab	B-DRUG
and	O
hyperfractionated-accelerated	O
radiotherapy	O
(	O
HART	O
)	O
for	O
locally	B-CANCER
advanced	I-CANCER
SCCHN	I-CANCER
.	O
	
Patients	O
with	O
unresectable	O
stage	O
III	O
or	O
IVA	O
/	O
B	O
SCCHN	B-CANCER
were	O
treated	O
with	O
cetuximab	B-CANCER
","	O
400	O
mg	O
/	O
m虏	O
initial	O
dose	O
on	O
day	O
-7	O
of	O
HART	O
","	O
followed	O
by	O
250	O
mg	O
/	O
m虏	O
weekly	O
during	O
the	O
administration	O
of	O
HART	O
","	O
which	O
started	O
with	O
2	O
Gy	O
/	O
day	O
(	O
5	O
days	O
/	O
week	O
)	O
for	O
3	O
weeks	O
followed	O
by	O
1.4	O
Gy	O
/	O
twice-daily	O
(	O
Monday	O
to	O
Friday	O
)	O
for	O
another	O
3	O
weeks	O
","	O
resulting	O
in	O
a	O
total	O
dose	O
of	O
70.6	O
Gy	O
.	O
	
Cisplatin	B-DRUG
was	O
administered	O
weekly	O
starting	O
on	O
the	O
first	O
day	O
of	O
radiotherapy	O
until	O
week	O
6	O
Cisplatin	B-DRUG
was	O
dose	O
escalated	O
of	O
four	O
dose	O
levels	O
from	O
20	O
to	O
40	O
mg	O
/	O
m虏	O
using	O
a	O
classical	O
3	O
=+	O
3	O
dose	O
escalation	O
algorithm	O
.	O
	
Eighteen	O
patients	O
were	O
enrolled	O
.	O
	
Sixteen	O
patients	O
were	O
eligible	O
for	O
toxicity	O
","	O
and	O
15	O
for	O
response	O
.	O
	
No	O
maximum	O
tolerated	O
dose	O
was	O
reached	O
for	O
cisplatin	B-DRUG
.	O
	
One	O
of	O
six	O
patients	O
of	O
dose	O
level	O
4	O
had	O
grade	O
4	O
neutropenia	B-TOXI
.	O
	
This	O
patient	O
died	B-TOXI
1	O
week	O
after	O
the	O
end	O
of	O
the	O
study	O
treatment	O
.	O
	
The	O
most	O
common	O
types	O
of	O
grade	O
3+	O
adverse	O
events	O
were	O
mucositis	B-TOXI
(	O
9	O
of	O
16	O
patients	O
)	O
","	O
in-field	B-TOXI
dermatitis	I-TOXI
(	O
6	O
of	O
16	O
patients	O
)	O
and	O
neutropenia	B-TOXI
(	O
4	O
of	O
16	O
patients	O
)	O
.	O
	
Cetuximab-related	B-DRUG
hypersensitivity	B-TOXI
was	O
observed	O
in	O
1	O
out	O
of	O
18	O
patients	O
.	O
	
Six	O
weeks	O
after	O
the	O
end	O
of	O
the	O
study	O
treatment	O
","	O
5	O
complete	O
responses	O
","	O
8	O
partial	O
responses	O
and	O
1	O
progressive	O
disease	O
(	O
at	O
distant	O
sites	O
)	O
were	O
documented	O
in	O
a	O
total	O
of	O
15	O
patients	O
(	O
objective	O
response	O
rate	O
87	O
%	O
)	O
.	O
	
The	O
combination	O
of	O
cisplatin	B-DRUG
with	O
cetuximab	B-DRUG
and	O
HART	O
is	O
active	O
","	O
well	O
tolerated	O
and	O
merits	O
additional	O
investigation	O
.	O
	
The	O
recommended	O
weekly	O
dose	O
of	O
cisplatin	B-DRUG
for	O
phase	O
II	O
studies	O
is	O
40	O
mg	O
/	O
m虏	O
.	O
	
A	O
phase	O
I	O
","	O
pharmacokinetic	O
","	O
and	O
pharmacodynamic	O
study	O
of	O
two	O
schedules	O
of	O
vorinostat	B-DRUG
in	O
combination	O
with	O
5-fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
in	O
patients	O
with	O
refractory	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
We	O
conducted	O
a	O
phase	O
I	O
clinical	O
trial	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
daily	O
or	O
twice	O
daily	O
vorinostat	B-DRUG
x	O
3	O
days	O
when	O
combined	O
with	O
fixed	O
doses	O
of	O
5-fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
and	O
leucovorin	B-DRUG
every	O
2	O
weeks	O
.	O
	
Vorinostat	B-DRUG
doses	O
were	O
escalated	O
in	O
a	O
standard	O
3	O
x	O
3	O
phase	O
I	O
design	O
.	O
	
FU	B-DRUG
/	O
leucovorin	B-DRUG
was	O
started	O
on	O
day	O
2	O
of	O
vorinostat	B-DRUG
and	O
consisted	O
of	O
leucovorin	B-DRUG
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
i.v.	O
over	O
2	O
hours	O
followed	O
by	O
FU	B-DRUG
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
i.v.	O
bolus	O
and	O
"2,400"	O
mg	O
/	O
m	O
(	O
2	O
)	O
over	O
46	O
hours	O
(	O
sLV5FU2	B-DRUG
)	O
.	O
	
Forty-three	O
patients	O
were	O
enrolled	O
.	O
	
Grade	O
3	O
fatigue	B-TOXI
","	O
and	O
hand	B-TOXI
and	I-TOXI
foot	I-TOXI
syndrome	I-TOXI
were	O
the	O
dose-limiting	O
toxicities	O
(	O
DLT	O
)	O
at	O
the	O
"2,000"	O
mg	O
vorinostat	B-DRUG
once-daily	O
dose	O
level	O
.	O
	
Grade	O
3	O
fatigue	B-TOXI
and	O
mucositis	B-TOXI
were	O
DLTs	O
at	O
the	O
800	O
mg	O
vorinostat	B-DRUG
twice-daily	O
dose	O
level	O
.	O
	
None	O
of	O
six	O
patients	O
at	O
the	O
"1,700"	O
mg	O
once	O
daily	O
or	O
six	O
patients	O
at	O
the	O
600	O
mg	O
twice	O
daily	O
dose	O
levels	O
had	O
a	O
DLT	O
;	O
those	O
dose	O
levels	O
represent	O
the	O
MTD	O
.	O
	
Twenty-one	O
of	O
38	O
patients	O
with	O
FU-refractory	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
had	O
stable	O
disease	O
","	O
and	O
one	O
had	O
a	O
partial	O
response	O
.	O
	
Vorinostat	B-DRUG
maximum	O
serum	O
concentrations	O
at	O
the	O
MTD	O
exceeded	O
concentrations	O
associated	O
with	O
thymidylate	O
synthase	O
downregulation	O
in	O
vitro	O
.	O
	
No	O
pharmacokinetic	O
interactions	O
were	O
noted	O
between	O
vorinostat	B-DRUG
and	O
FU	B-DRUG
.	O
	
The	O
MTD	O
of	O
vorinostat	B-DRUG
in	O
combination	O
with	O
sLV5FU2	B-DRUG
is	O
"1,700"	O
mg	O
orally	O
once	O
daily	O
x	O
3	O
or	O
600	O
mg	O
orally	O
twice	O
daily	O
x	O
3	O
days	O
every	O
2	O
weeks	O
.	O
	
Clinical	O
activity	O
in	O
refractory	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
supports	O
further	O
clinical	O
development	O
of	O
this	O
combination	O
.	O
	
Dose-dense	O
doxorubicin	B-DRUG
and	O
cyclophosphamide	B-DRUG
followed	O
by	O
weekly	O
paclitaxel	B-DRUG
with	O
trastuzumab	B-DRUG
and	O
lapatinib	B-DRUG
in	O
HER2	O
/	O
neu-overexpressed	O
/	O
amplified	O
breast	B-CANCER
cancer	I-CANCER
is	O
not	O
feasible	O
because	O
of	O
excessive	O
diarrhea	B-TOXI
.	O
	
	
Dose-dense	O
doxorubicin	B-DRUG
and	O
cyclophosphamide	B-DRUG
(	O
AC	B-DRUG
)	O
followed	O
by	O
paclitaxel	B-DRUG
and	O
trastuzumab	B-DRUG
(	O
PT	B-DRUG
)	O
is	O
feasible	O
.	O
	
Lapatinib	B-DRUG
is	O
effective	O
in	O
the	O
treatment	O
of	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
(	O
HER2	O
)	O
#NAME?	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
We	O
conducted	O
a	O
pilot	O
study	O
of	O
dose-dense	O
AC	B-DRUG
followed	O
by	O
PT	B-DRUG
plus	O
lapatinib	B-DRUG
(	O
PTL	B-DRUG
)	O
followed	O
by	O
trastuzumab	B-DRUG
plus	O
lapatinib	B-DRUG
(	O
TL	B-DRUG
)	O
.	O
	
Patients	O
with	O
stages	O
I	O
to	O
III	O
","	O
HER2-positive	O
breast	B-CANCER
cancer	I-CANCER
and	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
of	O
&	O
gt	O
;	O
or	O
=	O
50	O
%	O
were	O
enrolled	O
.	O
	
Treatment	O
consisted	O
of	O
AC	B-DRUG
(	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
for	O
4	O
cycles	O
every	O
2	O
weeks	O
(	O
with	O
pegfilgrastim	B-DRUG
6	O
mg	O
on	O
day	O
2	O
)	O
followed	O
by	O
paclitaxel	B-DRUG
(	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
for	O
12	O
doses	O
weekly	O
plus	O
trastuzumab	B-DRUG
and	O
lapatinib	B-DRUG
.	O
	
Trastuzumab	B-DRUG
(	O
4	O
mg	O
/	O
kg	O
loading	O
dose	O
","	O
then	O
2	O
mg	O
/	O
kg	O
weekly	O
during	O
paclitaxel	B-DRUG
then	O
6	O
mg	O
/	O
kg	O
every	O
3	O
weeks	O
after	O
paclitaxel	B-DRUG
)	O
and	O
lapatinib	B-DRUG
(	O
"1,000"	O
mg	O
daily	O
)	O
were	O
given	O
for	O
1	O
year	O
.	O
	
The	O
primary	O
end	O
points	O
were	O
feasibility	O
defined	O
as	O
&	O
gt	O
;	O
or	O
=	O
80	O
%	O
patients	O
completing	O
the	O
PTL	B-DRUG
phase	O
without	O
a	O
dose	O
delay	O
/	O
reduction	O
and	O
a	O
cardiac	B-TOXI
event	I-TOXI
rate	O
of	O
&	O
lt	O
;	O
or	O
=	O
4	O
%	O
.	O
	
From	O
March	O
2007	O
to	O
April	O
2008	O
","	O
we	O
enrolled	O
95	O
patients	O
.	O
	
Median	O
age	O
was	O
46	O
years	O
(	O
range	O
","	O
28	O
to	O
73	O
years	O
)	O
.	O
	
At	O
a	O
median	O
follow-up	O
of	O
22	O
months	O
","	O
92	O
were	O
evaluable	O
.	O
	
Of	O
the	O
92	O
patients	O
","	O
41	O
patients	O
(	O
45	O
%	O
)	O
withdrew	O
for	O
PTL-specific	B-TOXI
toxicities	I-TOXI
.	O
	
Overall	O
","	O
40	O
(	O
43	O
%	O
)	O
of	O
92	O
patients	O
had	O
lapatinib	B-DRUG
dose	O
reductions	O
","	O
and	O
27	O
(	O
29	O
%	O
)	O
of	O
92	O
patients	O
had	O
grade	O
3	O
diarrhea	B-TOXI
.	O
	
Three	O
patients	O
(	O
3	O
%	O
)	O
had	O
congestive	B-TOXI
heart	I-TOXI
failure	I-TOXI
;	O
three	O
patients	O
dropped	O
out	O
because	O
of	O
significant	O
asymptomatic	B-TOXI
LVEF	I-TOXI
decline	O
during	O
PTL	B-DRUG
followed	O
by	O
TL	B-DRUG
.	O
	
Dose-dense	O
AC	B-DRUG
followed	O
by	O
PTL	B-DRUG
and	O
then	O
followed	O
by	O
TL	B-DRUG
was	O
not	O
feasible	O
because	O
of	O
a	O
high	O
rate	O
of	O
lapatinib	B-DRUG
dose	O
reduction	O
","	O
mostly	O
caused	O
by	O
unacceptable	O
grade	O
3	O
diarrhea	B-TOXI
.	O
	
Lapatinib	B-DRUG
(	O
"1,000"	O
mg	O
/	O
d	O
)	O
was	O
not	O
feasible	O
combined	O
with	O
weekly	O
PT	B-DRUG
.	O
	
Phase	O
1	O
study	O
of	O
AMG	B-DRUG
386	I-DRUG
","	O
a	O
selective	O
angiopoietin	B-DRUG
1	O
/	O
2-neutralizing	O
peptibody	O
","	O
in	O
combination	O
with	O
chemotherapy	O
in	O
adults	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
To	O
evaluate	O
the	O
safety	O
","	O
pharmacokinetics	O
","	O
and	O
antitumor	O
activity	O
of	O
AMG	B-DRUG
386	I-DRUG
","	O
an	O
investigational	O
selective	O
angiopoietin	O
1	O
/	O
2-neutralizing	O
peptibody	O
","	O
in	O
combination	O
with	O
FOLFOX-4	B-DRUG
(	O
F	O
)	O
","	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
(	O
C	O
/	O
P	O
)	O
","	O
or	O
docetaxel	B-DRUG
(	O
D	O
)	O
","	O
in	O
adult	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Three	O
cohorts	O
of	O
patients	O
(	O
F	O
","	O
n	O
=	O
6	O
;	O
C	O
/	O
P	O
","	O
n	O
=	O
8	O
;	O
D	O
","	O
n	O
=	O
12	O
)	O
received	O
one	O
full	O
cycle	O
of	O
chemotherapy	O
alone	O
during	O
the	O
pretreatment	O
phase	O
","	O
followed	O
by	O
administration	O
of	O
AMG	B-DRUG
386	I-DRUG
10	O
mg	O
/	O
kg	O
i.v.	O
weekly	O
in	O
combination	O
with	O
chemotherapy	O
until	O
disease	O
progression	O
or	O
intolerance	O
.	O
	
Safety	O
and	O
tolerability	O
","	O
tumor	O
response	O
","	O
pharmacokinetic	O
profiles	O
","	O
and	O
biomarkers	O
were	O
assessed	O
.	O
	
Twenty-six	O
patients	O
were	O
enrolled	O
;	O
22	O
received	O
treatment	O
with	O
AMG	O
386	O
.	O
	
No	O
dose-limiting	O
toxicities	O
or	O
grade	O
3	O
or	O
4	O
adverse	O
events	O
related	O
to	O
AMG	B-DRUG
386	I-DRUG
were	O
reported	O
.	O
	
The	O
most	O
common	O
adverse	O
events	O
were	O
diarrhea	B-TOXI
and	O
hypomagnesemia	B-TOXI
(	O
n	O
=	O
3	O
each	O
)	O
.	O
	
One	O
patient	O
developed	O
grade	O
2	O
hypertension	B-TOXI
and	O
one	O
had	O
grade	O
1	O
subconjunctival	B-TOXI
eye	I-TOXI
hemorrhage	I-TOXI
.	O
	
No	O
neutralizing	O
antibodies	O
to	O
AMG	B-DRUG
386	I-DRUG
were	O
detected	O
.	O
	
There	O
were	O
no	O
pharmacokinetic	O
interactions	O
between	O
AMG	B-DRUG
386	I-DRUG
and	O
F	O
","	O
C	O
/	O
P	O
","	O
or	O
D.	O
One	O
patient	O
receiving	O
AMG	B-DRUG
386	I-DRUG
plus	O
C	O
/	O
P	O
for	O
bladder	B-CANCER
cancer	I-CANCER
refractory	O
to	O
gemcitabine	B-DRUG
/	O
cisplatin	B-DRUG
had	O
a	O
complete	O
response	O
at	O
week	O
8	O
The	O
remaining	O
best	O
tumor	O
responses	O
were	O
partial	O
response	O
(	O
n	O
=	O
3	O
","	O
one	O
from	O
each	O
cohort	O
)	O
","	O
stable	O
disease	O
&	O
gt	O
;	O
or	O
8	O
weeks	O
(	O
n	O
=	O
13	O
)	O
","	O
and	O
progressive	O
disease	O
(	O
n	O
=	O
1	O
)	O
.	O
	
Weekly	O
administration	O
of	O
AMG	B-DRUG
386	I-DRUG
in	O
combination	O
with	O
three	O
common	O
chemotherapy	O
regimens	O
was	O
well	O
tolerated	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
No	O
pharmacokinetic	O
interactions	O
between	O
AMG	B-DRUG
386	I-DRUG
and	O
any	O
of	O
the	O
tested	O
chemotherapy	O
regimens	O
were	O
noted	O
.	O
	
Promising	O
antitumor	O
activity	O
was	O
observed	O
with	O
all	O
three	O
treatment	O
combinations	O
.	O
	
Phase	O
II	O
trial	O
of	O
gemcitabine	B-DRUG
plus	O
cisplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
investigate	O
the	O
pharmacodynamics	O
and	O
pharmacokinetics	O
of	O
gemcitabine	B-DRUG
(	O
dFdC	O
)	O
administered	O
on	O
d	O
1	O
and	O
5	O
plus	O
cisplatin	B-DRUG
administered	O
on	O
d	O
1	O
in	O
chemonaive	O
patients	O
with	O
stage	O
IIIB	O
or	O
IV	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
In	O
each	O
combination	O
cycle	O
","	O
gemcitabine	B-DRUG
was	O
administered	O
at	O
a	O
dose	O
of	O
1250	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
30	O
min	O
intravenous	O
(	O
iv	O
)	O
infusion	O
on	O
d	O
1	O
and	O
5	O
followed	O
by	O
cisplatin	B-DRUG
at	O
a	O
dose	O
of	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
3	O
h	O
iv	O
infusion	O
on	O
d	O
1	O
every	O
3	O
weeks	O
.	O
	
There	O
was	O
an	O
interval	O
of	O
1	O
h	O
between	O
the	O
two	O
infusions	O
.	O
	
Clinical	O
response	O
and	O
toxicity	O
of	O
the	O
regimen	O
were	O
observed	O
.	O
	
Furthermore	O
","	O
the	O
plasma	O
concentrations	O
of	O
gemcitabine	B-DRUG
(	O
dFdC	O
)	O
and	O
its	O
metabolite	O
(	O
dFdU	O
)	O
at	O
different	O
time	O
points	O
were	O
detected	O
during	O
the	O
first	O
cycle	O
of	O
infusion	O
.	O
	
Pharmacokinetic	O
software	O
(	O
PKS	O
)	O
was	O
used	O
to	O
estimate	O
the	O
pharmacokinetic	O
parameters	O
of	O
gemcitabine	B-DRUG
and	O
its	O
metabolite	O
dFdU	O
.	O
	
A	O
total	O
of	O
28	O
patients	O
was	O
enrolled	O
in	O
the	O
study	O
.	O
	
The	O
median	O
age	O
was	O
54	O
years	O
(	O
range	O
27-75	O
years	O
)	O
","	O
and	O
most	O
patients	O
were	O
in	O
good	O
clinical	O
condition	O
.	O
	
Twenty-seven	O
patients	O
received	O
two	O
or	O
more	O
treatment	O
cycles	O
.	O
	
The	O
overall	O
clinical	O
response	O
rate	O
was	O
33.3	O
%	O
.	O
	
The	O
median	O
overall	O
survival	O
time	O
was	O
13	O
months	O
.	O
	
The	O
estimated	O
median	O
time	O
to	O
tumor	O
progression	O
(	O
TTP	O
)	O
was	O
6.2	O
months	O
","	O
and	O
the	O
1-year	O
survival	O
rate	O
was	O
55.6	O
%	O
.	O
	
Toxicities	O
were	O
tolerated	O
.	O
	
The	O
main	O
toxicity	O
was	O
myelosuppression	B-TOXI
;	O
35.7	O
%	O
of	O
patients	O
had	O
grade	O
3	O
/	O
4	O
hematologic	B-TOXI
toxicities	I-TOXI
and	O
28.6	O
%	O
had	O
grade	O
3	O
/	O
4	O
non-hematologic	B-TOXI
toxicities	I-TOXI
","	O
which	O
were	O
commonly	O
gastrointestinal	B-TOXI
responses	I-TOXI
.	O
	
The	O
pharmacokinetic	O
parameters	O
of	O
dFdC	O
and	O
dFdU	O
were	O
not	O
different	O
between	O
pre-	O
and	O
post-administration	O
of	O
gemcitabine	B-DRUG
on	O
d	O
1	O
and	O
5	O
dFdU	O
was	O
minimal	O
(	O
0.729+	O
/	O
-0.637	O
microg	O
/	O
mL	O
)	O
before	O
gemcitabine	B-DRUG
was	O
infused	O
on	O
d	O
5	O
","	O
and	O
gemcitabine	B-DRUG
was	O
not	O
present	O
.	O
	
The	O
regimen	O
is	O
active	O
and	O
well	O
tolerated	O
in	O
chemonaive	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
After	O
gemcitabine	B-DRUG
was	O
administered	O
on	O
d	O
1	O
and	O
5	O
","	O
the	O
pharmacokinetic	O
parameters	O
of	O
dFdC	O
and	O
dFdU	O
showed	O
no	O
difference	O
from	O
those	O
before	O
the	O
infusion	O
","	O
and	O
dFdU	O
was	O
minimal	O
before	O
gemcitabine	B-DRUG
was	O
administered	O
on	O
d	O
5	O
.	O
	
A	O
phase	O
I	O
dose-escalation	O
study	O
of	O
imatinib	B-DRUG
mesylate	I-DRUG
(	O
Gleevec	O
/	O
STI571	O
)	O
plus	O
capecitabine	B-DRUG
(	O
Xeloda	O
)	O
in	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
maximally	O
tolerated	O
dose	O
","	O
recommended	O
phase	O
II	O
dose	O
and	O
toxicity	O
profile	O
of	O
capecitabine	B-DRUG
plus	O
imatinib	B-DRUG
mesylate	I-DRUG
combination	O
.	O
	
Twenty-four	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
treated	O
with	O
capecitabine	O
twice	O
daily	O
on	O
days	O
1月14日	O
and	O
imatinib	B-DRUG
mesylate	I-DRUG
once	O
daily	O
on	O
a	O
21-day	O
cycle	O
.	O
	
Dose-limiting	O
toxicity	O
was	O
assessed	O
during	O
the	O
first	O
cycle	O
.	O
	
Treatment	O
continued	O
until	O
disease	O
progression	O
or	O
undesirable	O
toxicity	O
.	O
	
Six	O
patients	O
were	O
treated	O
with	O
capecitabine	B-DRUG
at	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
imatinib	B-DRUG
mesylate	I-DRUG
300	O
mg	O
;	O
unacceptable	O
toxicity	O
due	O
to	O
grade	O
2	O
intolerable	O
hand-foot	B-TOXI
syndrome	I-TOXI
and	O
/	O
or	O
grade	O
&	O
gt	O
;	O
or	O
=	O
2	O
diarrhea	B-TOXI
was	O
observed	O
.	O
	
Doses	O
were	O
subsequently	O
reduced	O
to	O
capecitabine	B-DRUG
at	O
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
imatinib	B-DRUG
mesylate	I-DRUG
at	O
300	O
mg	O
;	O
toxicities	O
were	O
better	O
tolerated	O
at	O
the	O
lower	O
dose	O
.	O
	
Dose-limiting	O
toxicities	O
consisted	O
of	O
grade	O
3	O
diarrhea	B-TOXI
","	O
anorexia	B-TOXI
and	O
fatigue	B-TOXI
lasting	O
&	O
gt	O
;	O
or	O
=	O
4	O
days	O
.	O
	
Treatment-related	O
adverse	O
events	O
greater	O
than	O
or	O
equal	O
to	O
grade	O
3	O
included	O
anemia	B-TOXI
","	O
diarrhea	B-TOXI
","	O
dysuria	B-TOXI
","	O
hypophosphatemia	B-TOXI
and	O
vertigo	B-TOXI
.	O
	
Minor	O
responses	O
were	O
observed	O
in	O
two	O
patients	O
:	O
stable	O
disease	O
&	O
gt	O
;	O
or	O
=	O
6	O
months	O
was	O
observed	O
in	O
two	O
out	O
of	O
twenty-one	O
evaluable	O
patients	O
.	O
	
Full	O
doses	O
of	O
capecitabine	B-DRUG
and	O
imatinib	B-DRUG
mesylate	I-DRUG
were	O
not	O
tolerable	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
and	O
the	O
recommended	O
phase	O
II	O
dose	O
for	O
this	O
drug	O
combination	O
is	O
capecitabine	B-DRUG
at	O
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
daily	O
for	O
1月14日	O
days	O
and	O
imatinib	B-DRUG
at	O
300	O
mg	O
once	O
daily	O
on	O
a	O
21-day	O
cycle	O
.	O
	
Imatinib	B-DRUG
plus	O
low-dose	O
doxorubicin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
gastrointestinal	I-CANCER
stromal	I-CANCER
tumors	I-CANCER
refractory	O
to	O
high-dose	O
imatinib	B-DRUG
:	O
a	O
phase	O
I-II	O
study	O
by	O
the	O
Spanish	O
Group	O
for	O
Research	O
on	O
Sarcomas	O
.	O
	
	
In	O
KIT-expressing	O
Ewing	O
sarcoma	O
cell	O
lines	O
","	O
the	O
addition	O
of	O
doxorubicin	B-DRUG
to	O
imatinib	B-DRUG
increases	O
apoptosis	O
","	O
compared	O
with	O
imatinib	B-DRUG
or	O
doxorubicin	B-DRUG
alone	O
.	O
	
On	O
the	O
basis	O
of	O
these	O
in	O
vitro	O
data	O
","	O
the	O
authors	O
conducted	O
a	O
phase	O
1月2日	O
trial	O
of	O
doxorubicin	B-DRUG
with	O
imatinib	B-DRUG
in	O
patients	O
with	O
gastrointestinal	B-CANCER
sarcoma	I-CANCER
tumors	I-CANCER
refractory	O
to	O
high-dose	O
imatinib	B-DRUG
therapy	O
.	O
	
Patients	O
with	O
metastatic	B-CANCER
gastrointestinal	I-CANCER
sarcoma	I-CANCER
tumor	I-CANCER
resistant	O
to	O
imatinib	B-DRUG
at	O
400	O
mg	O
by	O
mouth	O
(	O
p.o.	O
)	O
twice	O
a	O
day	O
were	O
eligible	O
for	O
this	O
multicenter	O
study	O
","	O
and	O
received	O
imatinib	B-DRUG
(	O
400	O
mg	O
p.o.	O
every	O
day	O
[	O
q.d.	O
]	O
)	O
concomitantly	O
with	O
doxorubicin	B-DRUG
15-20	O
mg	O
/	O
m2	O
/	O
weekly	O
for	O
4	O
cycles	O
(	O
monthly	O
cycles	O
)	O
","	O
followed	O
by	O
imatinib	B-DRUG
(	O
400	O
mg	O
p.o.	O
q.d.	O
)	O
maintenance	O
in	O
nonprogressive	O
patients	O
.	O
	
Spiral	O
computed	O
tomography	O
and	O
positron	O
emission	O
tomography	O
with	O
F18-fluorodeoxyglucose	B-DRUG
were	O
done	O
basally	O
and	O
after	O
2	O
months	O
of	O
therapy	O
to	O
evaluate	O
response	O
.	O
	
An	O
in	O
vitro	O
study	O
assessed	O
the	O
effect	O
of	O
combining	O
imatinib	B-DRUG
and	O
doxorubicin	B-DRUG
.	O
	
Twenty-six	O
patients	O
with	O
progressive	O
gastrointestinal	B-CANCER
sarcoma	I-CANCER
tumor	I-CANCER
were	O
entered	O
in	O
the	O
study	O
.	O
	
Treatment	O
was	O
well	O
tolerated	O
.	O
	
Three	O
(	O
14	O
%	O
)	O
of	O
22	O
evaluable	O
patients	O
had	O
partial	O
responses	O
per	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	B-CANCER
Tumors	I-CANCER
","	O
and	O
8	O
(	O
36	O
%	O
)	O
had	O
clinical	O
benefit	O
(	O
partial	O
response	O
or	O
stable	O
disease	O
for	O
&	O
gt	O
;	O
or=6	O
months	O
)	O
.	O
	
Median	O
progression-free	O
survival	O
(	O
PFS	O
)	O
was	O
100	O
days	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
62-138	O
)	O
","	O
and	O
median	O
survival	O
was	O
390	O
days	O
(	O
95	O
%	O
CI	O
","	O
264-516	O
)	O
.	O
	
Interestingly	O
","	O
PFS	O
was	O
211	O
days	O
(	O
95	O
%	O
CI	O
","	O
52-370	O
)	O
in	O
patients	O
with	O
wild	O
type	O
(	O
WT	O
)	O
KIT	O
and	O
82	O
days	O
(	O
95	O
%	O
CI	O
","	O
53-111	O
)	O
in	O
non-WT	O
patients	O
(	O
10	O
mutant	O
","	O
6	O
not	O
assessed	O
)	O
.	O
	
A	O
synergistic	O
effect	O
on	O
cell	O
line	O
proliferation	O
and	O
apoptosis	O
was	O
found	O
with	O
imatinib	B-DRUG
and	O
doxorubicin	B-DRUG
combination	O
.	O
	
Low-dose	O
chemobiotherapy	O
combination	O
showed	O
promising	O
activity	O
in	O
heavily	O
pretreated	O
gastrointestinal	B-CANCER
sarcoma	I-CANCER
tumor	I-CANCER
patients	O
","	O
especially	O
in	O
those	O
with	O
WT-KIT	O
genotype	O
.	O
	
A	O
study	O
of	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
bortezomib	B-DRUG
in	O
the	O
treatment	O
of	O
metastatic	B-CANCER
malignant	I-CANCER
melanoma	I-CANCER
:	O
a	O
phase	O
2	O
consortium	O
study	O
.	O
	
	
Chemotherapy	O
has	O
not	O
been	O
reported	O
to	O
have	O
a	O
significant	O
impact	O
on	O
survival	O
for	O
patients	O
with	O
metastatic	B-CANCER
melanoma	I-CANCER
.	O
	
Bortezomib	B-DRUG
was	O
shown	O
to	O
have	O
additive	O
/	O
synergistic	O
effects	O
with	O
several	O
chemotherapeutic	O
agents	O
","	O
including	O
paclitaxel	B-DRUG
and	O
platinum	B-DRUG
.	O
	
A	O
phase	O
1	O
trial	O
of	O
this	O
3-drug	O
combination	O
reported	O
that	O
6	O
of	O
28	O
patients	O
treated	O
with	O
bortezomib	B-DRUG
followed	O
by	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
achieved	O
a	O
partial	O
response	O
(	O
including	O
2	O
of	O
5	O
patients	O
with	O
metastatic	B-CANCER
melanoma	I-CANCER
)	O
.	O
	
A	O
2-stage	O
phase	O
2	O
clinical	O
trial	O
was	O
conducted	O
to	O
assess	O
the	O
antitumor	O
activity	O
of	O
this	O
3-agent	O
combination	O
in	O
patients	O
with	O
metastatic	B-CANCER
melanoma	I-CANCER
who	O
had	O
received	O
at	O
most	O
1	O
prior	O
chemotherapy	O
for	O
metastatic	O
disease	O
.	O
	
Treatment	O
included	O
bortezomib	B-DRUG
at	O
a	O
dose	O
of	O
1.3	O
mg	O
/	O
m2	O
intravenously	O
on	O
Days	O
1	O
","	O
4	O
","	O
and	O
8	O
;	O
paclitaxel	B-DRUG
at	O
a	O
dose	O
of	O
175	O
mg	O
/	O
m2	O
;	O
and	O
carboplatin	B-DRUG
at	O
an	O
area	O
under	O
the	O
concentration	O
(	O
AUC	O
)	O
of	O
6	O
on	O
Day	O
2	O
of	O
a	O
21-day	O
cycle	O
.	O
	
The	O
primary	O
endpoint	O
of	O
this	O
trial	O
was	O
tumor	O
response	O
rate	O
(	O
TRR	O
)	O
.	O
	
Seventeen	O
eligible	O
patients	O
were	O
enrolled	O
.	O
	
A	O
median	O
of	O
4	O
cycles	O
were	O
administered	O
(	O
range	O
","	O
1月7日	O
cycles	O
)	O
.	O
	
Three	O
patients	O
discontinued	O
treatment	O
due	O
to	O
persistent	O
grade	O
4	O
(	O
based	O
on	O
National	O
Cancer	O
Institute	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
[	O
version	O
3	O
]	O
)	O
neutropenia	O
with	O
grade	O
3	O
leukopenia	B-TOXI
(	O
2	O
patients	O
)	O
or	O
grade	O
4	O
pulmonary	B-TOXI
embolism	I-TOXI
(	O
1	O
patient	O
)	O
.	O
	
Grade	O
&	O
gt	O
;	O
or=3	O
toxicities	O
included	O
neutropenia	B-TOXI
(	O
71	O
%	O
)	O
","	O
leukopenia	B-TOXI
(	O
41	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
29	O
%	O
)	O
","	O
and	O
arthralgia	B-TOXI
(	O
12	O
%	O
)	O
.	O
	
Two	O
partial	O
responses	O
were	O
observed	O
(	O
TRR	O
","	O
11.8	O
%	O
)	O
.	O
	
Four	O
patients	O
had	O
stable	O
disease	O
at	O
&	O
gt	O
;	O
12	O
weeks	O
.	O
	
The	O
median	O
progression-free	O
survival	O
was	O
3.2	O
months	O
","	O
and	O
the	O
median	O
overall	O
survival	O
was	O
7	O
months	O
.	O
	
Due	O
to	O
insufficient	O
clinical	O
efficacy	O
","	O
this	O
trial	O
did	O
not	O
proceed	O
to	O
second-stage	O
accrual	O
.	O
	
The	O
combination	O
of	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
bortezomib	B-DRUG
demonstrated	O
limited	O
clinical	O
benefit	O
and	O
was	O
associated	O
with	O
significant	O
toxicity	O
.	O
	
A	O
phase	O
1	O
study	O
of	O
hepatic	O
arterial	O
infusion	O
of	O
oxaliplatin	B-DRUG
in	O
combination	O
with	O
systemic	O
5-fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
bevacizumab	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
metastatic	O
to	O
the	O
liver	O
.	O
	
	
Liver	O
metastases	O
in	O
patients	O
with	O
cancer	O
are	O
associated	O
with	O
poor	O
survival	O
.	O
	
The	O
authors	O
of	O
this	O
report	O
conducted	O
a	O
phase	O
1	O
study	O
of	O
hepatic	O
arterial	O
infusion	O
(	O
HAI	O
)	O
oxaliplatin	B-DRUG
combination	O
therapy	O
in	O
patients	O
with	O
advanced	B-CANCER
cancer	I-CANCER
and	O
liver	O
metastases	O
.	O
	
Treatment	O
consisted	O
of	O
escalating	O
doses	O
of	O
HAI	O
oxaliplatin	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
to	O
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
intra-arterial	B-DRUG
heparin	I-DRUG
3000	O
IU	O
(	O
Day	O
1	O
)	O
;	O
leucovorin	B-DRUG
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
(	O
iv	O
)	O
and	O
5-fluorouracil	B-DRUG
300	O
mg	O
/	O
m	O
(	O
2	O
)	O
bolus	O
plus	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
iv	O
(	O
Days	O
1	O
and	O
2	O
)	O
;	O
and	O
bevacizumab	B-DRUG
10	O
mg	O
/	O
kg	O
iv	O
(	O
Day	O
3	O
)	O
.	O
	
A	O
conventional	O
	O
design	O
was	O
used	O
.	O
	
Fifty-seven	O
patients	O
were	O
treated	O
","	O
including	O
30	O
women	O
and	O
27	O
men	O
.	O
	
The	O
median	O
age	O
was	O
57	O
years	O
","	O
and	O
the	O
patients	O
had	O
received	O
a	O
median	O
of	O
3	O
prior	O
therapies	O
(	O
range	O
","	O
1月7日	O
prior	O
therapies	O
)	O
.	O
	
The	O
most	O
common	O
cancer	O
was	O
colorectal	O
(	O
n	O
=	O
29	O
)	O
.	O
	
Overall	O
","	O
204	O
cycles	O
were	O
administered	O
(	O
median	O
per	O
patient	O
","	O
2	O
cycles	O
;	O
range	O
","	O
1月17日	O
cycles	O
)	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
HAI	O
oxaliplatin	B-DRUG
was	O
140	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Dose-limiting	O
toxicities	O
were	O
grade	O
4	O
thrombocytopenia	B-TOXI
(	O
n	O
=	O
1	O
)	O
and	O
grade	O
4	O
hypokalemia	B-TOXI
(	O
n	O
=	O
1	O
)	O
at	O
150	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
n	O
=	O
5	O
)	O
.	O
	
Thirty-three	O
patients	O
(	O
58	O
%	O
)	O
had	O
no	O
toxicity	O
greater	O
than	O
grade	O
1	O
The	O
most	O
common	O
toxicities	O
were	O
thrombocytopenia	B-TOXI
(	O
n	O
=	O
19	O
)	O
","	O
fatigue	B-TOXI
(	O
n	O
=	O
15	O
)	O
","	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
(	O
n	O
=	O
6	O
)	O
","	O
constipation	B-TOXI
(	O
n	O
=	O
6	O
)	O
","	O
and	O
diarrhea	B-TOXI
(	O
n	O
=	O
4	O
)	O
.	O
	
Of	O
55	O
patients	O
who	O
were	O
evaluable	O
for	O
response	O
(	O
according	O
to	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	B-CANCER
Tumors	I-CANCER
)	O
","	O
4	O
patients	O
(	O
7	O
%	O
)	O
had	O
a	O
partial	O
response	O
(	O
PR	O
)	O
","	O
and	O
32	O
patients	O
(	O
58	O
%	O
)	O
had	O
stable	O
disease	O
(	O
SD	O
)	O
","	O
including	O
15	O
patients	O
(	O
48	O
%	O
)	O
who	O
had	O
SD	O
for	O
&	O
gt	O
;	O
/	O
4	O
months	O
.	O
	
Of	O
28	O
patients	O
with	O
colorectal	B-CANCER
cancer	I-CANCER
","	O
3	O
patients	O
(	O
11	O
%	O
)	O
had	O
a	O
PR	O
","	O
and	O
9	O
patients	O
(	O
32	O
%	O
)	O
had	O
SD	O
for	O
&	O
gt	O
;	O
/	O
4	O
months	O
.	O
	
HAI	O
oxaliplatin	B-DRUG
combined	O
with	O
systemic	O
5-fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
bevacizumab	B-DRUG
had	O
antitumor	O
activity	O
in	O
patients	O
with	O
advanced	B-CANCER
cancer	I-CANCER
and	O
liver	O
metastases	O
","	O
and	O
the	O
current	O
results	O
indicated	O
that	O
this	O
combination	O
warrants	O
further	O
study	O
.	O
	
Cancer	O
2010	O
.	O
	
(	O
c	O
)	O
2010	O
American	O
Cancer	O
Society	O
.	O
	
A	O
Phase	O
II	O
Study	O
of	O
S-1	B-DRUG
Monotherapy	O
as	O
a	O
First-line	O
Combination	O
Therapy	O
of	O
S-1	B-DRUG
Plus	O
Cisplatin	B-DRUG
as	O
a	O
Second-line	O
Therapy	O
","	O
and	O
Weekly	O
Paclitaxel	O
Monotherapy	O
as	O
a	O
Third-line	O
Therapy	O
in	O
Patients	O
with	O
Advanced	B-CANCER
Gastric	I-CANCER
Carcinoma	I-CANCER
:	O
A	O
Second	O
Report	O
.	O
	
	
We	O
have	O
previousy	O
reported	O
on	O
a	O
Phase	O
II	O
study	O
of	O
S-1	B-DRUG
monotherapy	O
as	O
a	O
first	O
line	O
","	O
combination	O
therapy	O
of	O
S-1	B-DRUG
plus	O
cisplatin	B-DRUG
as	O
a	O
second	O
line	O
","	O
and	O
weekly	O
paclitaxel	B-DRUG
monotherapy	O
as	O
a	O
third	O
line	O
therapy	O
in	O
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
carcinomas	I-CANCER
.	O
	
The	O
median	O
survival	O
time	O
(	O
MST	O
)	O
of	O
patients	O
over	O
the	O
whole	O
course	O
of	O
treatment	O
was	O
not	O
previously	O
calculated	O
because	O
12	O
out	O
of	O
19	O
patients	O
had	O
not	O
yet	O
succumbed	O
.	O
	
Since	O
then	O
","	O
we	O
have	O
calculated	O
the	O
MST	O
for	O
this	O
study	O
and	O
herein	O
report	O
our	O
findings	O
.	O
	
Between	O
2002	O
and	O
2005	O
","	O
19	O
patients	O
were	O
enrolled	O
in	O
this	O
study	O
.	O
	
Chemotherapy	O
consisted	O
of	O
either	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
S-1	O
for	O
4	O
weeks	O
at	O
6-week	O
intervals	O
","	O
a	O
combination	O
of	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
S-1	B-DRUG
for	O
3	O
weeks	O
and	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
cisplatin	B-DRUG
on	O
day	O
8	O
at	O
5-week	O
intervals	O
","	O
or	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
paclitaxel	B-DRUG
at	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
","	O
at	O
4-week	O
intervals	O
.	O
	
The	O
regimens	O
were	O
repeated	O
until	O
the	O
occurrence	O
of	O
unacceptable	O
toxicities	O
","	O
disease	O
progression	O
","	O
or	O
patient	O
noncompliance	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
the	O
overall	O
survival	O
.	O
	
The	O
median	O
survival	O
time	O
was	O
774	O
days	O
.	O
	
The	O
response	O
rates	O
were	O
33.3	O
%	O
(	O
3	O
/	O
9	O
)	O
","	O
12.5	O
%	O
(	O
1	O
/	O
8	O
)	O
","	O
and	O
0	O
%	O
(	O
0	O
/	O
4	O
)	O
after	O
the	O
first	O
","	O
second	O
","	O
and	O
third	O
line	O
chemotherapies	O
","	O
respectively	O
.	O
	
The	O
major	O
adverse	B-TOXI
hematological	I-TOXI
toxicity	I-TOXI
was	O
leukopenia	B-TOXI
","	O
which	O
reached	O
grades	O
3月4日	O
in	O
all	O
lines	O
of	O
chemotherapy	O
investigated	O
.	O
	
In	O
addition	O
","	O
the	O
major	O
adverse	B-TOXI
non-hematological	I-TOXI
toxicity	I-TOXI
was	O
anorexia	B-TOXI
","	O
which	O
reached	O
grade	O
3月4日	O
in	O
second	O
line	O
chemotherapy	O
","	O
and	O
no	O
deaths	O
were	O
attributable	O
to	O
the	O
adverse	O
effects	O
of	O
the	O
drugs	O
.	O
	
This	O
sequential	O
therapy	O
was	O
an	O
effective	O
treatment	O
for	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
with	O
acceptable	O
toxic	O
side-effects	O
.	O
	
We	O
considered	O
this	O
therapy	O
to	O
be	O
effective	O
because	O
of	O
the	O
smooth	O
transition	O
to	O
the	O
next	O
regimen	O
.	O
	
Efficacy	O
and	O
safety	O
of	O
gemcitabine	B-DRUG
","	O
carboplatin	B-DRUG
","	O
dexamethasone	B-DRUG
","	O
and	O
rituximab	B-DRUG
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
lymphoma	B-CANCER
:	O
a	O
prospective	O
multi-center	O
phase	O
II	O
study	O
by	O
the	O
Puget	O
Sound	O
Oncology	O
Consortium	O
.	O
	
	
We	O
conducted	O
a	O
multi-center	O
phase	O
II	O
trial	O
of	O
gemcitabine	B-DRUG
(	O
G	O
)	O
","	O
carboplatin	B-DRUG
(	O
C	O
)	O
","	O
dexamethasone	B-DRUG
(	O
D	O
)	O
","	O
and	O
rituximab	B-DRUG
(	O
R	O
)	O
in	O
order	O
to	O
examine	O
its	O
safety	O
and	O
efficacy	O
as	O
an	O
outpatient	O
salvage	O
regimen	O
for	O
lymphoma	B-CANCER
.	O
	
Fifty-one	O
patients	O
received	O
2月4日	O
21-day	O
cycles	O
of	O
G	O
(	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
days	O
1	O
and	O
8	O
)	O
","	O
C	O
(	O
AUC	O
=	O
5	O
","	O
day	O
1	O
)	O
","	O
D	O
(	O
40	O
mg	O
","	O
daily	O
days	O
1月4日	O
)	O
","	O
and	O
R	O
(	O
375	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
day	O
8	O
for	O
CD20-positive	O
disease	O
)	O
and	O
were	O
evaluable	O
for	O
response	O
.	O
	
Characteristics	O
included	O
:	O
median	O
age	O
58	O
years	O
(	O
19-79	O
years	O
)	O
","	O
stage	O
III	O
/	O
IV	O
88	O
%	O
","	O
elevated	O
LDH	O
33	O
%	O
","	O
median	O
prior	O
therapies	O
2	O
","	O
prior	O
stem	O
cell	O
transplant	O
12	O
%	O
","	O
chemoresistant	O
62	O
%	O
","	O
median	O
prior	O
remission	O
duration	O
2.5	O
months	O
.	O
	
The	O
overall	O
and	O
complete	O
response	O
rates	O
were	O
67	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
54-80	O
%	O
)	O
and	O
31	O
%	O
(	O
95	O
%	O
CI	O
19-44	O
%	O
)	O
","	O
respectively	O
","	O
with	O
activity	O
seen	O
in	O
a	O
broad	O
variety	O
of	O
histologies	O
.	O
	
Responses	O
occurred	O
in	O
16	O
of	O
17	O
(	O
94	O
%	O
","	O
95	O
%	O
CI	O
83-100	O
%	O
)	O
transplant-eligible	O
patients	O
and	O
15	O
of	O
28	O
(	O
54	O
%	O
","	O
95	O
%	O
CI	O
34-71	O
%	O
)	O
with	O
chemoresistant	O
disease	O
.	O
	
The	O
median	O
CD34	O
yield	O
in	O
patients	O
attempting	O
peripheral	O
blood	O
stem	O
cell	O
(	O
PBSC	O
)	O
collection	O
following	O
this	O
regimen	O
was	O
10.9	O
x	O
10	O
(	O
6	O
)	O
CD34+	O
cells	O
/	O
kg	O
(	O
range	O
5.0-24.1	O
x	O
10	O
(	O
6	O
)	O
)	O
.	O
	
Hematologic	B-TOXI
toxicity	I-TOXI
was	O
common	O
","	O
but	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
2.5	O
%	O
)	O
and	O
grade	O
4	O
non-hematologic	B-TOXI
adverse	I-TOXI
events	I-TOXI
(	O
n	O
=	O
2	O
)	O
were	O
rare	O
","	O
with	O
no	O
treatment-related	O
deaths	O
.	O
	
GCD	O
(	O
R	O
)	O
is	O
a	O
safe	O
and	O
effective	O
outpatient	O
regimen	O
for	O
relapsed	O
lymphoma	B-CANCER
","	O
and	O
successfully	O
mobilizes	O
PBSCs	O
.	O
	
A	O
phase	O
I	O
study	O
evaluating	O
the	O
role	O
of	O
the	O
anti-epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
antibody	O
cetuximab	B-DRUG
as	O
a	O
radiosensitizer	O
with	O
chemoradiation	O
for	O
locally	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
	
(	O
1	O
)	O
To	O
determine	O
the	O
safety	O
of	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
antibody	O
cetuximab	B-DRUG
with	O
concurrent	O
gemcitabine	B-DRUG
and	O
abdominal	O
radiation	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
locally	O
advanced	B-CANCER
adenocarcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
pancreas	I-CANCER
.	O
	
(	O
2	O
)	O
To	O
evaluate	O
the	O
feasibility	O
of	O
pancreatic	B-CANCER
cancer	I-CANCER
cell	O
epithelial-mesenchymal	O
transition	O
(	O
EMT	O
)	O
molecular	O
profiling	O
as	O
a	O
potential	O
predictor	O
of	O
response	O
to	O
anti-EGFR	O
treatment	O
.	O
	
Patients	O
with	O
non-metastatic	O
","	O
locally	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
were	O
treated	O
in	O
this	O
dose	O
escalation	O
study	O
with	O
gemcitabine	B-DRUG
(	O
0-300	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
week	O
)	O
given	O
concurrently	O
with	O
cetuximab	B-DRUG
(	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
loading	O
dose	O
","	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
maintenance	O
dose	O
)	O
and	O
abdominal	O
irradiation	O
(	O
50.4	O
Gy	O
)	O
.	O
	
Expression	O
of	O
E-cadherin	O
and	O
vimentin	O
was	O
assessed	O
by	O
immunohistochemistry	O
in	O
diagnostic	O
endoscopic	O
ultrasound	O
fine-needle	O
aspiration	O
(	O
EUS-FNA	O
)	O
specimens	O
.	O
	
Sixteen	O
patients	O
were	O
enrolled	O
in	O
4	O
treatment	O
cohorts	O
with	O
escalating	O
doses	O
of	O
gemcitabine	B-DRUG
.	O
	
Incidence	O
of	O
grade	O
1月2日	O
adverse	O
events	O
was	O
96	O
%	O
","	O
and	O
incidence	O
of	O
3月4日	O
adverse	O
events	O
was	O
9	O
%	O
.	O
	
There	O
were	O
no	O
treatment-related	O
mortalities	O
.	O
	
Two	O
patients	O
who	O
exhibited	O
favorable	O
treatment	O
response	O
underwent	O
surgical	O
exploration	O
and	O
were	O
intraoperatively	O
confirmed	O
to	O
have	O
unresectable	O
tumors	O
.	O
	
Median	O
overall	O
survival	O
was	O
10.5	O
months	O
.	O
	
Pancreatic	B-CANCER
cancer	I-CANCER
cell	O
expression	O
of	O
E-cadherin	O
and	O
vimentin	O
was	O
successfully	O
determined	O
in	O
EUS-FNA	O
specimens	O
from	O
4	O
patients	O
.	O
	
Cetuximab	B-DRUG
can	O
be	O
safely	O
administered	O
with	O
abdominal	O
radiation	O
and	O
concurrent	O
gemcitabine	B-DRUG
(	O
up	O
to	O
300	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
week	O
)	O
in	O
patients	O
with	O
locally	O
advanced	B-CANCER
adenocarcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
pancreas	I-CANCER
.	O
	
This	O
combined	O
therapy	O
modality	O
exhibited	O
limited	O
activity	O
.	O
	
Diagnostic	O
EUS-FNA	O
specimens	O
could	O
be	O
analyzed	O
for	O
molecular	O
markers	O
of	O
EMT	O
in	O
a	O
minority	O
of	O
patients	O
with	O
pancreatic	B-CANCER
cancer	I-CANCER
.	O
	
A	O
phase	O
II	O
study	O
of	O
weekly	O
24-hour	O
infusion	O
with	O
high-dose	O
fluorouracil	B-DRUG
with	O
leucovorin	B-DRUG
in	O
colorectal	B-CANCER
carcinoma	I-CANCER
.	O
	
	
Twenty-two	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
were	O
enrolled	O
in	O
this	O
study	O
.	O
	
Ten	O
patients	O
had	O
received	O
prior	O
chemotherapy	O
that	O
included	O
the	O
combination	O
of	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
and	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
.	O
	
All	O
patients	O
required	O
subcutaneous	O
port	O
insertion	O
and	O
portable	O
external	O
infusion	O
pumps	O
to	O
allow	O
outpatient	O
treatment	O
.	O
	
5-FU	B-DRUG
(	O
"2,600"	O
mg	O
/	O
m2	O
)	O
was	O
administered	O
concurrently	O
with	O
LV	B-DRUG
(	O
500	O
mg	O
/	O
m2	O
)	O
over	O
24	O
hours	O
of	O
continuous	O
infusion	O
.	O
	
The	O
mean	O
steady-state	O
plasma	O
concentration	O
of	O
5-FU	B-DRUG
was	O
10	O
mumol	O
/	O
L	O
(	O
range	O
","	O
7	O
to	O
14	O
mumol	O
/	O
L	O
)	O
.	O
	
The	O
5-FU	B-DRUG
dose	O
was	O
based	O
on	O
our	O
previous	O
phase	O
I	O
study	O
","	O
in	O
which	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
5-FU	B-DRUG
was	O
determined	O
to	O
be	O
"2,600"	O
mg	O
/	O
m2	O
in	O
combination	O
with	O
a	O
fixed	O
dose	O
of	O
LV	B-DRUG
at	O
500	O
mg	O
/	O
m2	O
.	O
	
The	O
treatment	O
was	O
repeated	O
weekly	O
.	O
	
Twenty-two	O
patients	O
received	O
a	O
total	O
of	O
560	O
courses	O
of	O
treatment	O
.	O
	
Eleven	O
instances	O
of	O
grade	O
2月3日	O
toxicity	O
were	O
observed	O
:	O
diarrhea	B-TOXI
(	O
five	O
)	O
","	O
stomatitis	B-TOXI
(	O
three	O
)	O
","	O
hand	B-TOXI
/	I-TOXI
foot	I-TOXI
syndrome	I-TOXI
(	O
three	O
)	O
.	O
	
The	O
overall	O
objective	O
response	O
was	O
45	O
%	O
(	O
10	O
of	O
22	O
)	O
and	O
among	O
previously	O
untreated	O
patients	O
was	O
58	O
%	O
.	O
	
Three	O
of	O
the	O
responders	O
achieved	O
complete	O
response	O
(	O
CR	O
)	O
","	O
with	O
lung	O
and	O
liver	O
as	O
the	O
metastatic	O
sites	O
.	O
	
The	O
median	O
duration	O
of	O
survival	O
for	O
the	O
previously	O
untreated	O
patients	O
was	O
not	O
reached	O
at	O
22	O
months	O
","	O
and	O
was	O
10	O
months	O
for	O
the	O
previously	O
treated	O
patients	O
.	O
	
These	O
results	O
suggest	O
that	O
short-term	O
infusional	O
therapy	O
of	O
5-FU	B-DRUG
and	O
LV	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
metastatic	I-CANCER
colorectal	I-CANCER
cancer	I-CANCER
generates	O
acceptable	O
toxicity	O
","	O
with	O
equivalent	O
or	O
superior	O
survivability	O
in	O
previously	O
treated	O
and	O
untreated	O
patients	O
versus	O
alternative	O
methods	O
of	O
administration	O
of	O
the	O
two	O
agents	O
.	O
	
Phase	O
I	O
study	O
of	O
gemcitabine	B-DRUG
","	O
docetaxel	B-DRUG
and	O
imatinib	B-DRUG
in	O
refractory	B-CANCER
and	I-CANCER
relapsed	I-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
In	O
a	O
phase	O
I	O
study	O
","	O
the	O
combination	O
of	O
gemcitabine	B-DRUG
and	O
imatinib	B-DRUG
was	O
well	O
tolerated	O
with	O
broad	O
anticancer	O
activity	O
.	O
	
This	O
phase	O
I	O
trial	O
evaluated	O
the	O
triplet	O
of	O
docetaxel	B-DRUG
","	O
gemcitabine	B-DRUG
and	O
imatinib	B-DRUG
.	O
	
Imatinib	B-DRUG
was	O
administered	O
at	O
400	O
mg	O
daily	O
on	O
days	O
1月5日	O
","	O
8月12日	O
and	O
15-19	O
.	O
	
Gemcitabine	B-DRUG
was	O
started	O
at	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
at	O
a	O
rate	O
of	O
10	O
mg	O
/	O
min	O
on	O
days	O
3	O
and	O
10	O
and	O
docetaxel	B-DRUG
at	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
10	O
","	O
on	O
a	O
21-day	O
cycle	O
.	O
	
Diffusion	O
and	O
dynamic	O
contrast-enhanced	O
perfusion	O
MRI	O
was	O
performed	O
in	O
selected	O
patients	O
.	O
	
Twenty	O
patients	O
with	O
relapsed	B-CANCER
/	I-CANCER
refractory	I-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
enrolled	O
in	O
this	O
IRB-approved	O
study	O
.	O
	
The	O
mean	O
age	O
was	O
64	O
","	O
and	O
mean	O
ECOG	O
PS	O
was	O
1	O
Two	O
patients	O
were	O
evaluated	O
by	O
diffusion	O
/	O
perfusion	O
MRI	O
.	O
	
After	O
two	O
grade	O
3	O
hematological	B-TOXI
toxicities	I-TOXI
at	O
dose	O
level	O
1	O
","	O
the	O
protocol	O
was	O
amended	O
to	O
reduce	O
the	O
dose	O
of	O
imatinib	B-DRUG
.	O
	
MTDs	O
were	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
3	O
and	O
10	O
for	O
gemcitabine	B-DRUG
","	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
10	O
for	O
docetaxel	B-DRUG
","	O
and	O
400	O
mg	O
daily	O
on	O
days	O
1月5日	O
and	O
8月12日	O
for	O
imatinib	B-DRUG
.	O
	
Dose	O
limiting	O
toxicities	O
after	O
one	O
cycle	O
were	O
neutropenic	B-TOXI
fever	I-TOXI
","	O
and	O
pleural	B-TOXI
and	O
pericardial	B-TOXI
effusions	I-TOXI
.	O
	
The	O
best	O
response	O
achieved	O
was	O
stable	O
disease	O
","	O
for	O
six	O
cycles	O
","	O
in	O
one	O
patient	O
each	O
with	O
mesothelioma	B-CANCER
and	O
non	B-CANCER
small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
at	O
the	O
MTD	O
.	O
	
Two	O
patients	O
with	O
NSCLC	B-CANCER
had	O
stable	O
disease	O
for	O
four	O
cycles	O
.	O
	
An	O
unexpectedly	O
low	O
MTD	O
for	O
this	O
triplet	O
was	O
identified	O
.	O
	
Our	O
results	O
suggest	O
drug-drug	O
interactions	O
that	O
amplify	O
toxicities	O
with	O
little	O
evidence	O
of	O
improved	O
tumor	O
control	O
.	O
	
Final	O
results	O
of	O
a	O
phase	O
I	O
/	O
II	O
pilot	O
study	O
of	O
capecitabine	B-DRUG
with	O
or	O
without	O
vinorelbine	B-DRUG
after	O
sequential	O
dose-dense	O
epirubicin	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
high-risk	B-CANCER
early	I-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
integration	O
of	O
the	O
non-cross-resistant	O
chemotherapeutic	O
agents	O
capecitabine	B-DRUG
and	O
vinorelbine	B-DRUG
into	O
an	O
intensified	O
dose-dense	O
sequential	O
anthracycline-	B-DRUG
and	O
taxane-containing	B-DRUG
regimen	O
in	O
high-risk	B-CANCER
early	I-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
EBC	B-CANCER
)	O
could	O
improve	O
efficacy	O
","	O
but	O
this	O
combination	O
was	O
not	O
examined	O
in	O
this	O
context	O
so	O
far	O
.	O
	
Patients	O
with	O
stage	O
II	O
/	O
IIIA	O
EBC	B-CANCER
(	O
four	O
or	O
more	O
positive	O
lymph	O
nodes	O
)	O
received	O
post-operative	O
intensified	O
dose-dense	O
sequential	O
epirubicin	B-DRUG
(	O
150	O
mg	O
/	O
m	O
(	O
2	O
)	O
every	O
2	O
weeks	O
)	O
and	O
paclitaxel	B-DRUG
(	O
225	O
mg	O
/	O
m	O
(	O
2	O
)	O
every	O
2	O
weeks	O
)	O
with	O
filgrastim	B-DRUG
and	O
darbepoetin	B-DRUG
alpha	I-DRUG
","	O
followed	O
by	O
capecitabine	B-DRUG
alone	O
(	O
dose	O
levels	O
1	O
and	O
3	O
)	O
or	O
with	O
vinorelbine	B-DRUG
(	O
dose	O
levels	O
2	O
and	O
4	O
)	O
.	O
	
Capecitabine	B-DRUG
was	O
given	O
on	O
days	O
1月14日	O
every	O
21	O
days	O
at	O
1000	O
or	O
1250	O
mg	O
/	O
m2	O
twice	O
daily	O
(	O
dose	O
levels	O
1	O
/	O
2	O
and	O
3	O
/	O
4	O
","	O
respectively	O
)	O
.	O
	
Vinorelbine	B-DRUG
25	O
mg	O
/	O
m2	O
was	O
given	O
on	O
days	O
1	O
and	O
8	O
of	O
each	O
21-day	O
course	O
(	O
dose	O
levels	O
2	O
and	O
4	O
)	O
.	O
	
Fifty-one	O
patients	O
were	O
treated	O
.	O
	
There	O
was	O
one	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
at	O
dose	O
level	O
1	O
At	O
dose	O
level	O
2	O
(	O
capecitabine	B-DRUG
and	O
vinorelbine	B-DRUG
)	O
","	O
five	O
of	O
10	O
patients	O
experienced	O
DLTs	O
.	O
	
Therefore	O
evaluation	O
of	O
vinorelbine	B-DRUG
was	O
abandoned	O
and	O
dose	O
level	O
3	O
(	O
capecitabine	B-DRUG
monotherapy	O
)	O
was	O
expanded	O
.	O
	
Hand-foot	B-TOXI
syndrome	I-TOXI
and	O
diarrhoea	B-TOXI
were	O
dose	O
limiting	O
with	O
capecitabine	B-DRUG
1250	O
mg	O
/	O
m2	O
twice	O
daily	O
.	O
	
At	O
35.2	O
months	O
'	O
median	O
follow-up	O
","	O
the	O
estimated	O
3-year	O
relapse-free	O
and	O
overall	O
survival	O
rates	O
were	O
82	O
%	O
and	O
91	O
%	O
","	O
respectively	O
.	O
	
Administration	O
of	O
capecitabine	B-DRUG
monotherapy	O
after	O
sequential	O
dose-dense	O
epirubicin	B-DRUG
and	O
paclitaxel	B-DRUG
is	O
feasible	O
in	O
node-positive	O
EBC	B-CANCER
","	O
while	O
the	O
combination	O
of	O
capecitabine	B-DRUG
and	O
vinorelbine	B-DRUG
as	O
used	O
here	O
caused	O
more	O
DLTs	O
.	O
	
A	O
phase	O
I-II	O
trial	O
of	O
induction	O
chemotherapy	O
with	O
carboplatin	B-DRUG
and	O
fluorouracil	B-DRUG
in	O
locally	B-CANCER
advanced	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
:	O
a	O
report	O
from	O
the	O
UCL-Oncology	O
Group	O
","	O
Belgium	O
.	O
	
	
Eighty-three	O
patients	O
(	O
median	O
age	O
","	O
56	O
years	O
and	O
Karnofsky	O
performance	O
status	O
greater	O
than	O
or	O
equal	O
to	O
70	O
)	O
were	O
treated	O
with	O
carboplatin	B-DRUG
(	O
Carbo	B-DRUG
)	O
and	O
fluorouracil	B-DRUG
(	O
5Fu	B-DRUG
)	O
for	O
stage	O
III	O
and	O
IV	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
HNSCC	B-CANCER
)	O
.	O
	
5Fu	B-DRUG
(	O
1	O
g	O
/	O
m2	O
/	O
d	O
)	O
was	O
administered	O
from	O
day	O
1	O
to	O
4	O
by	O
continuous	O
infusion	O
.	O
	
Carbo	B-DRUG
was	O
given	O
on	O
day	O
1	O
and	O
","	O
in	O
order	O
to	O
evaluate	O
its	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
the	O
dose	O
level	O
was	O
progressively	O
increased	O
from	O
250	O
mg	O
/	O
m2	O
to	O
450	O
mg	O
/	O
m2	O
.	O
	
The	O
effectiveness	O
of	O
this	O
association	O
and	O
its	O
potential	O
role	O
in	O
local	O
control	O
were	O
also	O
evaluated	O
.	O
	
Three	O
patients	O
received	O
Carbo	B-DRUG
at	O
a	O
dose	O
of	O
250	O
mg	O
/	O
m2	O
","	O
13	O
received	O
300	O
mg	O
/	O
m2	O
","	O
one	O
received	O
330	O
mg	O
/	O
m2	O
","	O
12	O
received	O
350	O
mg	O
/	O
m2	O
","	O
six	O
received	O
375	O
mg	O
/	O
m2	O
","	O
26	O
received	O
400	O
mg	O
/	O
m2	O
","	O
18	O
received	O
420	O
mg	O
/	O
m2	O
","	O
and	O
four	O
received	O
450	O
mg	O
/	O
m2	O
.	O
	
Two	O
(	O
13	O
of	O
83	O
)	O
or	O
three	O
courses	O
(	O
64	O
of	O
83	O
)	O
","	O
repeated	O
every	O
4	O
weeks	O
","	O
were	O
administered	O
.	O
	
The	O
overall	O
(	O
primary	O
tumor	O
and	O
node	O
)	O
response	O
and	O
complete	O
response	O
(	O
CR	O
)	O
rates	O
were	O
33	O
%	O
and	O
14	O
%	O
","	O
respectively	O
.	O
	
For	O
primary	O
tumor	O
","	O
the	O
response	O
rate	O
(	O
RR	O
)	O
was	O
57	O
%	O
with	O
32	O
%	O
CR	O
and	O
18	O
%	O
pathologic	O
complete	O
response	O
(	O
PCR	O
)	O
;	O
the	O
RR	O
was	O
higher	O
for	O
patients	O
with	O
oropharyngeal	B-CANCER
tumor	I-CANCER
(	O
76	O
%	O
","	O
P	O
=	O
0.037	O
)	O
and	O
for	O
patients	O
treated	O
with	O
Carbo	B-DRUG
greater	O
than	O
or	O
equal	O
to	O
350	O
mg	O
/	O
m2	O
(	O
65	O
%	O
","	O
P	O
=	O
0.02	O
)	O
;	O
the	O
tumor	O
size	O
(	O
T1	O
=+	O
T2	O
v	O
T3	O
=+	O
T4	O
)	O
was	O
a	O
good	O
prognostic	O
factor	O
for	O
RR	O
(	O
90	O
%	O
v	O
46	O
%	O
","	O
P	O
=	O
0.001	O
)	O
","	O
CR	O
(	O
65	O
%	O
v	O
20	O
%	O
","	O
P	O
less	O
than	O
0.001	O
)	O
","	O
and	O
PCR	O
(	O
45	O
%	O
v	O
8	O
%	O
","	O
P	O
less	O
than	O
0.001	O
)	O
.	O
	
For	O
nodes	O
","	O
the	O
RR	O
was	O
33	O
%	O
with	O
11	O
%	O
CR	O
.	O
	
Grade	O
3月4日	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
were	O
experienced	O
by	O
17	O
%	O
and	O
28	O
%	O
of	O
the	O
patients	O
treated	O
with	O
420	O
mg	O
/	O
m2	O
of	O
Carbo	O
and	O
by	O
50	O
%	O
of	O
the	O
patients	O
treated	O
with	O
450	O
mg	O
/	O
m2	O
.	O
	
The	O
MTD	O
can	O
be	O
fixed	O
at	O
420	O
mg	O
/	O
m2	O
and	O
the	O
proposed	O
dose	O
at	O
400	O
mg	O
/	O
m2	O
.	O
	
Thirty-eight	O
patients	O
were	O
treated	O
with	O
surgery	O
plus	O
radiotherapy	O
","	O
33	O
with	O
radiotherapy	O
alone	O
","	O
and	O
seven	O
with	O
surgery	O
alone	O
.	O
	
The	O
median	O
follow-up	O
is	O
12	O
months	O
.	O
	
The	O
18-month	O
disease-free	O
survival	O
(	O
DFS	O
)	O
is	O
78	O
%	O
for	O
overall	O
complete	O
responders	O
and	O
39	O
%	O
for	O
the	O
others	O
(	O
P	O
=	O
0.04	O
)	O
.	O
	
There	O
is	O
no	O
primary	O
tumor	O
recurrence	O
among	O
the	O
12	O
patients	O
with	O
a	O
primary	O
tumor	O
PCR	O
treated	O
by	O
radiotherapy	O
alone	O
for	O
tumor	O
control	O
(	O
median	O
follow-up	O
","	O
17.3	O
months	O
)	O
.	O
	
The	O
association	O
of	O
Carbo-5Fu	B-DRUG
is	O
a	O
safe	O
induction	O
chemotherapy	O
regimen	O
for	O
HNSCC	B-CANCER
.	O
	
The	O
proposed	O
dose	O
of	O
Carbo	B-DRUG
for	O
future	O
treatment	O
is	O
400	O
mg	O
/	O
m2.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
	
Safety	O
and	O
Feasibility	O
of	O
Carboplatin	B-DRUG
and	O
Paclitaxel	B-DRUG
followed	O
by	O
Fluoropyrimidine	B-DRUG
Analogs	O
and	O
Radiation	O
as	O
Adjuvant	O
Therapy	O
for	O
Gastric	B-CANCER
Cancer	I-CANCER
.	O
	
	
BACKGROUND	O
:	O
Adjuvant	O
5-fluorouracil	B-DRUG
(	O
5FU	B-DRUG
)	O
#NAME?	O
chemo-radiotherapy	O
is	O
currently	O
considered	O
a	O
standard	O
of	O
care	O
for	O
the	O
treatment	O
of	O
gastric	B-CANCER
cancer	I-CANCER
.	O
	
The	O
impact	O
of	O
5FU-based	B-DRUG
adjuvant	O
therapy	O
on	O
the	O
rate	O
of	O
distant	O
recurrence	O
has	O
been	O
modest	O
.	O
	
In	O
order	O
to	O
improve	O
the	O
systemic	O
effects	O
of	O
adjuvant	O
therapy	O
","	O
we	O
have	O
been	O
treating	O
patients	O
with	O
resected	O
gastric	B-CANCER
cancer	I-CANCER
with	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
followed	O
by	O
fluoropyrimidine	B-DRUG
analogue	I-DRUG
and	O
radiation	O
.	O
	
METHODS	O
:	O
We	O
report	O
on	O
the	O
outcomes	O
of	O
21	O
consecutive	O
gastric	B-CANCER
cancer	I-CANCER
patients	O
treated	O
off	O
protocol	O
with	O
adjuvant	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
5	O
mg	O
/	O
ml	O
x	O
min	O
)	O
and	O
paclitaxel	B-DRUG
(	O
175-200	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
every	O
3	O
weeks	O
","	O
followed	O
by	O
concurrent	O
pyrimidine	B-DRUG
analogs	I-DRUG
(	O
either	O
capecitabine	B-DRUG
"1,600-2,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
in	O
17	O
patients	O
","	O
or	O
5FU	B-DRUG
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
in	O
4	O
patients	O
)	O
and	O
radiation	O
(	O
45-50.4	O
Gy	O
)	O
.	O
	
Patients	O
received	O
a	O
total	O
of	O
4月6日	O
cycles	O
of	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
.	O
	
RESULTS	O
:	O
The	O
median	O
age	O
at	O
diagnosis	O
was	O
60	O
years	O
.	O
	
Sixteen	O
patients	O
had	O
stage	O
3	O
disease	O
and	O
7	O
of	O
them	O
had	O
positive	O
surgical	O
margins	O
(	O
6	O
with	O
R1	O
and	O
1	O
with	O
R2	O
resection	O
)	O
","	O
3	O
patients	O
were	O
stage	O
2	O
","	O
and	O
2	O
patients	O
were	O
stage	O
1	O
(	O
all	O
had	O
R0	O
resection	O
)	O
.	O
	
All	O
patients	O
had	O
D1	O
/	O
D2	O
(	O
4	O
had	O
D2	O
and	O
17	O
had	O
D1	O
)	O
lymph	O
node	O
dissection	O
.	O
	
The	O
incidence	O
of	O
grade	O
3	O
or	O
higher	O
overall	O
","	O
hematologic	B-TOXI
","	O
or	O
gastrointestinal	B-TOXI
toxicity	I-TOXI
in	O
the	O
patients	O
receiving	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
was	O
57	O
","	O
48	O
and	O
10	O
%	O
","	O
respectively	O
.	O
	
No	B-TOXI
treatment-related	I-TOXI
deaths	I-TOXI
were	O
observed	O
.	O
	
After	O
adjuvant	O
treatment	O
15	O
patients	O
developed	O
recurrent	O
disease	O
","	O
10	O
of	O
whom	O
had	O
distant	O
metastases	O
.	O
	
The	O
median	O
recurrence-free	O
survival	O
(	O
RFS	O
)	O
was	O
12.3	O
months	O
.	O
	
The	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
16	O
months	O
.	O
	
Patients	O
with	O
R0	O
resection	O
had	O
significantly	O
longer	O
OS	O
than	O
did	O
those	O
with	O
positive	O
surgical	O
margins	O
(	O
log-rank	O
p	O
=	O
0.006	O
)	O
.	O
	
Median	O
OS	O
for	O
the	O
R0	O
resection	O
group	O
was	O
28.8	O
months	O
.	O
	
CONCLUSIONS	O
:	O
Carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
added	O
to	O
radiation	O
plus	O
fluoropyrimidine	B-DRUG
analogs	I-DRUG
is	O
a	O
well-tolerated	O
regimen	O
in	O
the	O
adjuvant	O
setting	O
.	O
	
The	O
activity	O
of	O
this	O
regimen	O
in	O
this	O
relatively	O
high-risk	O
group	O
of	O
gastric	B-CANCER
cancer	I-CANCER
patients	O
is	O
of	O
interest	O
for	O
future	O
development	O
.	O
	
Randomized	O
phase	O
II	O
study	O
of	O
sequential	O
docetaxel	B-DRUG
and	O
irinotecan	B-DRUG
with	O
5-fluorouracil	B-DRUG
/	O
folinic	B-DRUG
acid	I-DRUG
(	O
leucovorin	B-DRUG
)	O
in	O
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
:	O
the	O
GATAC	O
trial	O
.	O
	
	
The	O
optimal	O
chemotherapy	O
in	O
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
carcinoma	I-CANCER
(	O
GC	B-CANCER
)	O
is	O
yet	O
to	O
be	O
determined	O
.	O
	
We	O
compared	O
sequential	O
administration	O
of	O
docetaxel	B-DRUG
and	O
irinotecan	B-DRUG
","	O
both	O
in	O
combination	O
with	O
infused	O
5-fluorouracil	B-DRUG
/	O
leucovorin	B-DRUG
(	O
5-Fu	B-DRUG
/	O
Lv	B-DRUG
)	O
","	O
and	O
randomly	O
assigned	O
patients	O
to	O
start	O
with	O
either	O
of	O
the	O
two	O
.	O
	
Patients	O
with	O
previously	O
untreated	O
locally	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
GC	I-CANCER
and	O
with	O
measurable	O
lesions	O
(	O
response	O
evaluation	O
criteria	O
in	O
solid	B-CANCER
tumors	I-CANCER
;	O
RECIST	O
)	O
were	O
randomly	O
assigned	O
to	O
start	O
with	O
docetaxel	B-DRUG
45	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
arm	O
T	O
)	O
or	O
irinotecan	B-DRUG
180	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
arm	O
C	O
)	O
with	O
bolus	O
/	O
44-h	O
infusion	O
of	O
5-Fu	B-DRUG
/	O
Lv	B-DRUG
(	O
day	O
1	O
every	O
2	O
weeks	O
)	O
.	O
	
After	O
four	O
courses	O
","	O
there	O
was	O
a	O
prescheduled	O
crossover	O
to	O
the	O
alternative	O
regimen	O
for	O
four	O
additional	O
courses	O
.	O
	
Eighty-one	O
patients	O
were	O
randomized	O
and	O
78	O
started	O
treatment	O
.	O
	
Complete	O
and	O
partial	O
responses	O
were	O
seen	O
in	O
31	O
(	O
40	O
%	O
)	O
patients	O
after	O
8	O
weeks	O
and	O
in	O
32	O
(	O
41	O
%	O
)	O
after	O
16	O
weeks	O
","	O
with	O
similar	O
results	O
in	O
both	O
study	O
arms	O
.	O
	
The	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
11.5	O
and	O
10.6	O
months	O
in	O
arms	O
T	O
and	O
C	O
","	O
respectively	O
(	O
P	O
=	O
0.3	O
)	O
.	O
	
The	O
two	O
schedules	O
were	O
feasible	O
and	O
did	O
not	O
differ	O
in	O
the	O
overall	O
rate	O
of	O
severe	O
adverse	O
events	O
(	O
SAEs	O
)	O
.	O
	
This	O
is	O
the	O
first	O
randomized	O
comparison	O
of	O
two	O
of	O
the	O
newer	O
cytostatic	O
drugs	O
in	O
GC	B-CANCER
therapy	O
.	O
	
No	O
differences	O
favoring	O
either	O
arm	O
T	O
or	O
arm	O
C	O
were	O
found	O
with	O
respect	O
to	O
response	O
rate	O
","	O
OS	O
","	O
or	O
toxicity	O
.	O
	
The	O
median	O
OS	O
of	O
11	O
months	O
indicates	O
that	O
sequential	O
administration	O
of	O
the	O
two	O
combinations	O
is	O
effective	O
and	O
is	O
similar	O
to	O
triple	O
combinations	O
.	O
	
Thus	O
","	O
comparable	O
efficacy	O
to	O
platinum	B-DRUG
combinations	O
appears	O
to	O
be	O
obtained	O
with	O
newer	O
","	O
less	O
toxic	O
regimens	O
when	O
given	O
sequentially	O
.	O
	
A	O
phase	O
I	O
/	O
II	O
trial	O
of	O
sorafenib	B-DRUG
and	O
infliximab	B-DRUG
in	O
advanced	B-CANCER
renal	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
	
There	O
is	O
clinical	O
evidence	O
to	O
suggest	O
that	O
tumour	O
necrosis	O
factor-伪	O
(	O
TNF-伪	O
)	O
may	O
be	O
a	O
therapeutic	O
target	O
in	O
renal	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
RCC	B-CANCER
)	O
.	O
	
Multi-targeted	O
kinase	O
inhibitors	O
","	O
such	O
as	O
sorafenib	B-DRUG
and	O
sunitinib	B-DRUG
","	O
have	O
become	O
standard	O
of	O
care	O
in	O
advanced	B-CANCER
RCC	I-CANCER
.	O
	
The	O
anti-TNF-伪	O
monoclonal	O
antibody	O
infliximab	B-DRUG
and	O
sorafenib	B-DRUG
have	O
differing	O
cellular	O
mechanisms	O
of	O
action	O
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
/	O
II	O
trial	O
to	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
infliximab	B-DRUG
in	O
combination	O
with	O
sorafenib	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
RCC	I-CANCER
.	O
	
Eligible	O
patients	O
were	O
systemic	O
treatment-naive	O
or	O
had	O
received	O
previous	O
cytokine	O
therapy	O
only	O
.	O
	
Sorafenib	B-DRUG
and	O
infliximab	B-DRUG
were	O
administered	O
according	O
to	O
standard	O
schedules	O
.	O
	
The	O
study	O
had	O
two	O
phases	O
:	O
in	O
phase	O
I	O
","	O
the	O
safety	O
and	O
toxicity	O
of	O
the	O
combination	O
of	O
full-dose	O
sorafenib	B-DRUG
and	O
two	O
dose	O
levels	O
of	O
infliximab	B-DRUG
were	O
evaluated	O
in	O
three	O
and	O
three	O
patients	O
","	O
respectively	O
","	O
and	O
in	O
phase	O
II	O
","	O
further	O
safety	O
","	O
toxicity	O
and	O
efficacy	O
data	O
were	O
collected	O
in	O
an	O
expanded	O
patient	O
population	O
.	O
	
Acceptable	O
safety	O
was	O
reported	O
for	O
the	O
first	O
three	O
patients	O
(	O
infliximab	B-DRUG
5	O
mg	O
kg_宦	O
)	O
in	O
phase	O
1	O
Sorafenib	B-DRUG
400	O
mg	O
twice	O
daily	O
and	O
infliximab	B-DRUG
10	O
mg	O
kg_宦	O
were	O
administered	O
to	O
a	O
total	O
of	O
13	O
patients	O
(	O
three	O
in	O
phase	O
1	O
and	O
10	O
in	O
phase	O
2	O
)	O
.	O
	
Adverse	O
events	O
included	O
grade	O
3	O
hand-foot	B-TOXI
syndrome	I-TOXI
(	O
31	O
%	O
)	O
","	O
rash	B-TOXI
(	O
25	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
19	O
%	O
)	O
and	O
infection	B-TOXI
(	O
19	O
%	O
)	O
.	O
	
Although	O
manageable	O
","	O
toxicity	O
resulted	O
in	O
75	O
%	O
of	O
the	O
patients	O
requiring	O
at	O
least	O
one	O
dose	O
reduction	O
and	O
81	O
%	O
requiring	O
at	O
least	O
one	O
dose	O
delay	O
of	O
sorafenib	B-DRUG
.	O
	
Four	O
patients	O
were	O
progression-free	O
at	O
6	O
months	O
(	O
PFS_	O
31	O
%	O
)	O
;	O
median	O
PFS	O
and	O
overall	O
survival	O
were	O
6	O
and	O
14	O
months	O
","	O
respectively	O
.	O
	
Sorafenib	B-DRUG
and	O
infliximab	B-DRUG
can	O
be	O
administered	O
in	O
combination	O
","	O
but	O
a	O
significant	O
increase	O
in	O
the	O
numbers	O
of	O
adverse	O
events	O
requiring	O
dose	O
adjustments	O
of	O
sorafenib	B-DRUG
was	O
observed	O
.	O
	
There	O
was	O
no	O
evidence	O
of	O
increased	O
efficacy	O
compared	O
with	O
sorafenib	B-DRUG
alone	O
in	O
advanced	B-CANCER
RCC	I-CANCER
.	O
	
The	O
combination	O
of	O
sorafenib	B-DRUG
and	O
infliximab	B-DRUG
does	O
not	O
warrant	O
further	O
evaluation	O
in	O
patients	O
with	O
advanced	B-CANCER
RCC	I-CANCER
.	O
	
Phase	O
IB	O
study	O
of	O
the	O
mTOR	O
inhibitor	O
ridaforolimus	B-DRUG
with	O
capecitabine	B-DRUG
.	O
	
	
Synergistic	O
/	O
additive	O
cytotoxicity	O
in	O
tumor	O
models	O
and	O
widespread	O
applicability	O
of	O
fluoropyrimidines	B-DRUG
in	O
solid	B-CANCER
tumors	I-CANCER
prompted	O
the	O
study	O
of	O
the	O
combination	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	B-DRUG
(	O
mTOR	O
)	O
inhibitor	O
","	O
non-prodrug	O
rapamycin	B-DRUG
analog	I-DRUG
ridaforolimus	I-DRUG
","	O
with	O
capecitabine	B-DRUG
.	O
	
Thirty-two	O
adult	O
patients	O
were	O
treated	O
.	O
	
Intravenous	B-DRUG
ridaforolimus	I-DRUG
was	O
given	O
once	O
weekly	O
for	O
3	O
weeks	O
and	O
capecitabine	B-DRUG
was	O
given	O
from	O
days	O
1	O
to	O
14	O
every	O
4	O
weeks	O
.	O
	
Ridaforolimus	B-DRUG
was	O
given	O
at	O
25	O
","	O
37.5	O
","	O
50	O
","	O
or	O
75	O
mg	O
with	O
capecitabine	B-DRUG
at	O
"1,650"	O
mg	O
/	O
m	O
(	O
2	O
)	O
or	O
"1,800"	O
mg	O
/	O
m	O
(	O
2	O
)	O
divided	O
into	O
two	O
daily	O
doses	O
.	O
	
Pharmacokinetics	O
of	O
both	O
drugs	O
were	O
determined	O
during	O
cycles	O
1	O
and	O
2	O
Pharmacodynamic	O
studies	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
and	O
wound	O
tissue	O
of	O
the	O
skin	O
characterized	O
pathways	O
associated	O
with	O
the	O
metabolism	O
or	O
disposition	O
of	O
fluoropyrimidines	B-DRUG
and	O
mTOR	O
and	O
ERK	O
signaling	O
.	O
	
Two	O
recommended	O
doses	O
(	O
RDs	O
)	O
were	O
defined	O
:	O
75	O
mg	O
ridaforolimus	B-DRUG
/	O
"1,650"	O
mg	O
/	O
m	O
(	O
2	O
)	O
capecitabine	B-DRUG
and	O
50	O
mg	O
ridaforolimus	B-DRUG
/	O
"1,800"	O
mg	O
/	O
m	O
(	O
2	O
)	O
capecitabine	B-DRUG
.	O
	
Dose-limiting	O
toxicities	O
were	O
stomatitis	B-TOXI
and	O
skin	B-TOXI
rash	I-TOXI
.	O
	
One	O
patient	O
achieved	O
a	O
partial	O
response	O
lasting	O
10	O
months	O
and	O
10	O
of	O
29	O
evaluable	O
patients	O
had	O
stable	O
disease	O
for	O
_	O
6	O
months	O
.	O
	
The	O
only	O
pharmacokinetic	O
interaction	O
was	O
a	O
ridaforolimus-induced	B-DRUG
increase	O
in	O
plasma	O
exposure	O
to	O
fluorouracil	B-DRUG
.	O
	
PBMC	O
data	O
suggested	O
that	O
prolonged	O
exposure	O
to	O
capecitabine	B-DRUG
reduced	O
the	O
ridaforolimus	B-DRUG
inhibition	O
of	O
mTOR	O
.	O
	
Ridaforolimus	B-DRUG
influenced	O
the	O
metabolism	O
of	O
fluoropyrimidines	B-DRUG
and	O
inhibited	O
dihydropyrimidine	B-DRUG
dehydrogenase	I-DRUG
","	O
behavior	O
similar	O
to	O
that	O
of	O
rapamycin	B-DRUG
.	O
	
Inhibition	O
of	O
the	O
target	O
thymidylate	O
synthase	O
by	O
capecitabine	B-DRUG
was	O
unaffected	O
.	O
	
mTOR	O
and	O
ERK	O
signaling	O
was	O
inhibited	O
in	O
proliferating	O
endothelial	O
cells	O
and	O
was	O
more	O
pronounced	O
at	O
the	O
RD	O
with	O
the	O
larger	O
amount	O
of	O
ridaforolimus	B-DRUG
.	O
	
Good	O
tolerability	O
","	O
feasibility	O
of	O
prolonged	O
treatment	O
","	O
antitumor	O
activity	O
","	O
and	O
favorable	O
pharmacologic	O
profile	O
support	O
further	O
investigation	O
of	O
this	O
combination	O
.	O
	
North	O
Central	O
Cancer	O
Treatment	O
Group	O
Phase	O
I	O
trial	O
N057K	O
of	O
everolimus	B-DRUG
(	O
RAD001	O
)	O
and	O
temozolomide	B-DRUG
in	O
combination	O
with	O
radiation	O
therapy	O
in	O
patients	O
with	O
newly	O
diagnosed	O
glioblastoma	B-CANCER
multiforme	I-CANCER
.	O
	
	
The	O
mammalian	O
target	O
of	O
rapamycin	B-DRUG
(	O
mTOR	O
)	O
functions	O
within	O
the	O
PI3K	O
/	O
Akt	O
signaling	O
pathway	O
as	O
a	O
critical	O
modulator	O
of	O
cell	O
survival	O
.	O
	
On	O
the	O
basis	O
of	O
promising	O
preclinical	O
data	O
","	O
the	O
safety	O
and	O
tolerability	O
of	O
therapy	O
with	O
the	O
mTOR	O
inhibitor	O
RAD001	O
in	O
combination	O
with	O
radiation	O
(	O
RT	O
)	O
and	O
temozolomide	B-DRUG
(	O
TMZ	O
)	O
was	O
evaluated	O
in	O
this	O
Phase	O
I	O
study	O
.	O
	
All	O
patients	O
received	O
weekly	O
oral	O
RAD001	O
in	O
combination	O
with	O
standard	O
chemoradiotherapy	O
","	O
followed	O
by	O
RAD001	O
in	O
combination	O
with	O
standard	O
adjuvant	O
temozolomide	B-DRUG
.	O
	
RAD001	O
was	O
dose	O
escalated	O
in	O
cohorts	O
of	O
6	O
patients	O
.	O
	
Dose-limiting	O
toxicities	O
were	O
defined	O
during	O
RAD001	O
combination	O
therapy	O
with	O
TMZ	O
/	O
RT.	O
Eighteen	O
patients	O
were	O
enrolled	O
","	O
with	O
a	O
median	O
follow-up	O
of	O
8.4	O
months	O
.	O
	
Combined	O
therapy	O
was	O
well	O
tolerated	O
at	O
all	O
dose	O
levels	O
","	O
with	O
1	O
patient	O
on	O
each	O
dose	O
level	O
experiencing	O
a	O
dose-limiting	O
toxicity	O
:	O
Grade	O
3	O
fatigue	B-TOXI
","	O
Grade	O
4	O
hematologic	B-TOXI
toxicity	I-TOXI
","	O
and	O
Grade	O
4	O
liver	B-TOXI
dysfunction	I-TOXI
.	O
	
Throughout	O
therapy	O
","	O
there	O
were	O
no	O
Grade	O
5	O
events	O
","	O
3	O
patients	O
experienced	O
Grade	O
4	O
toxicities	O
","	O
and	O
6	O
patients	O
had	O
Grade	O
3	O
toxicities	O
attributable	O
to	O
treatment	O
.	O
	
On	O
the	O
basis	O
of	O
these	O
results	O
","	O
the	O
recommended	O
Phase	O
II	O
dosage	O
currently	O
being	O
tested	O
is	O
RAD001	O
70	O
mg	O
/	O
week	O
in	O
combination	O
with	O
standard	O
chemoradiotherapy	O
.	O
	
Fluorodeoxyglucose	B-DRUG
(	O
FDG	B-DRUG
)	O
positron	O
emission	O
tomography	O
scans	O
also	O
were	O
obtained	O
at	O
baseline	O
and	O
after	O
the	O
second	O
RAD001	O
dose	O
before	O
the	O
initiation	O
of	O
TMZ	O
/	O
RT	O
;	O
the	O
change	O
in	O
FDG	B-DRUG
uptake	O
between	O
scans	O
was	O
calculated	O
for	O
each	O
patient	O
.	O
	
Fourteen	O
patients	O
had	O
stable	O
metabolic	B-TOXI
disease	I-TOXI
","	O
and	O
4	O
patients	O
had	O
a	O
partial	B-TOXI
metabolic	I-TOXI
response	I-TOXI
.	O
	
RAD001	O
in	O
combination	O
with	O
RT	O
/	O
TMZ	O
and	O
adjuvant	O
TMZ	O
was	O
reasonably	O
well	O
tolerated	O
.	O
	
Changes	O
in	O
tumor	O
metabolism	O
can	O
be	O
detected	O
by	O
FDG	B-DRUG
positron	O
emission	O
tomography	O
in	O
a	O
subset	O
of	O
patients	O
within	O
days	O
of	O
initiating	O
RAD001	O
therapy	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
concurrent	O
chemotherapy	O
(	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
)	O
and	O
thoracic	O
radiotherapy	O
with	O
swallowed	O
manganese	B-DRUG
superoxide	I-DRUG
dismutase	I-DRUG
plasmid	I-DRUG
liposome	I-DRUG
protection	O
in	O
patients	O
with	O
locally	O
advanced	O
stage	O
III	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
Manganese	O
superoxide	O
dismutase	O
(	O
MnSOD	O
)	O
is	O
a	O
genetically	O
engineered	O
therapeutic	O
DNA	O
/	O
liposome	O
containing	O
the	O
human	O
MnSOD	O
transgene	O
.	O
	
Preclinical	O
studies	O
in	O
mouse	O
models	O
have	O
demonstrated	O
that	O
the	O
expression	O
of	O
the	O
human	O
MnSOD	O
transgene	O
confers	O
protection	O
of	O
normal	O
tissues	O
from	O
ionizing	O
irradiation	O
damage	O
.	O
	
This	O
is	O
a	O
phase	O
I	O
study	O
of	O
MnSOD	B-DRUG
plasmid	I-DRUG
liposome	I-DRUG
(	O
PL	O
)	O
in	O
combination	O
with	O
standard	O
chemoradiation	O
in	O
surgically	O
unresectable	O
stage	O
III	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
Chemotherapy	O
(	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
)	O
was	O
given	O
weekly	O
(	O
for	O
7	O
weeks	O
)	O
","	O
concurrently	O
with	O
radiation	O
.	O
	
MnSOD	B-DRUG
PL	I-DRUG
was	O
swallowed	O
twice	O
a	O
week	O
(	O
total	O
14	O
doses	O
)	O
","	O
at	O
three	O
dose	O
levels	O
:	O
0.3	O
","	O
3	O
","	O
and	O
30	O
mg	O
.	O
	
Dose	O
escalation	O
followed	O
a	O
standard	O
phase	O
I	O
design	O
.	O
	
Esophagoscopy	O
was	O
done	O
at	O
baseline	O
","	O
day	O
4	O
","	O
and	O
6	O
weeks	O
after	O
radiation	O
with	O
biopsies	O
of	O
the	O
squamous	O
lining	O
cells	O
.	O
	
DNA	O
was	O
extracted	O
and	O
analyzed	O
by	O
PCR	O
for	O
the	O
detection	O
of	O
the	O
MnSOD	O
transgene	O
DNA	O
.	O
	
Ten	O
patients	O
with	O
AJCC	O
stage	O
IIIA	O
(	O
three	O
)	O
and	O
IIIB	O
(	O
seven	O
)	O
completed	O
the	O
course	O
of	O
therapy	O
.	O
	
Five	O
had	O
squamous	O
histology	O
","	O
two	O
adenocarcinoma	B-CANCER
","	O
one	O
large	O
cell	O
","	O
and	O
two	O
not	O
specified	O
.	O
	
Patients	O
were	O
treated	O
in	O
three	O
cohorts	O
at	O
three	O
dose	O
levels	O
of	O
MnSOD	B-DRUG
PL	I-DRUG
:	O
0.3	O
(	O
three	O
patients	O
)	O
","	O
3	O
(	O
three	O
patients	O
)	O
","	O
and	O
30	O
mg	O
(	O
four	O
patients	O
)	O
.	O
	
The	O
median	O
dose	O
of	O
radiation	O
was	O
77.7	O
Gy	O
(	O
range	O
63-79.10	O
Gy	O
)	O
.	O
	
Overall	O
response	O
rate	O
for	O
the	O
standard	O
chemoradiation	O
regimen	O
was	O
70	O
%	O
(	O
n	O
=	O
10	O
)	O
.	O
	
There	O
were	O
no	O
dose-limiting	O
toxicities	O
reported	O
in	O
all	O
three	O
dosing	O
tiers	O
.	O
	
It	O
is	O
concluded	O
that	O
the	O
oral	O
administration	O
of	O
MnSOD	B-DRUG
PL	I-DRUG
is	O
feasible	O
and	O
safe	O
.	O
	
The	O
phase	O
II	O
recommended	O
dose	O
is	O
30	O
mg	O
.	O
	
A	O
phase	O
II	O
first-line	O
study	O
of	O
gemcitabine	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
bevacizumab	B-DRUG
in	O
advanced	O
stage	O
nonsquamous	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
Bevacizumab	B-DRUG
improves	O
responses	O
and	O
progression-free	O
survival	O
when	O
added	O
to	O
first-line	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
or	O
cisplatin	B-DRUG
/	O
gemcitabine	B-DRUG
for	O
patients	O
with	O
advanced	B-CANCER
nonsquamous	I-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
This	O
study	O
was	O
designed	O
to	O
evaluate	O
toxicities	O
and	O
efficacy	O
of	O
gemcitabine	B-DRUG
/	O
carboplatin	B-DRUG
/	O
bevacizumab	B-DRUG
.	O
	
Patients	O
with	O
untreated	O
advanced	B-CANCER
nonsquamous	I-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
","	O
with	O
no	O
evidence	O
of	O
brain	O
metastases	O
and	O
not	O
on	O
anticoagulation	O
were	O
eligible	O
.	O
	
Patients	O
received	O
gemcitabine	B-DRUG
1000	O
mg	O
/	O
m	O
on	O
days	O
1	O
and	O
8	O
;	O
carboplatin	B-DRUG
area	O
under	O
the	O
curve	O
5	O
day	O
1	O
;	O
and	O
bevacizumab	B-DRUG
15	O
mg	O
/	O
kg	O
day	O
1	O
every	O
3	O
weeks	O
for	O
up	O
to	O
six	O
cycles	O
.	O
	
Bevacizumab	B-DRUG
was	O
then	O
continued	O
every	O
3	O
weeks	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
.	O
	
From	O
July	O
2006	O
to	O
December	O
2008	O
","	O
48	O
patients	O
were	O
enrolled	O
:	O
23	O
(	O
48	O
%	O
)	O
men	O
","	O
25	O
(	O
52	O
%	O
)	O
women	O
","	O
and	O
19	O
(	O
40	O
%	O
)	O
never	O
smokers	O
.	O
	
One	O
patient	O
never	O
received	O
therapy	O
and	O
is	O
not	O
included	O
in	O
the	O
analysis	O
.	O
	
Median	O
cycle	O
number	O
was	O
8	O
(	O
1-42	O
)	O
with	O
37	O
patients	O
(	O
78.7	O
%	O
)	O
completing	O
_4	O
cycles	O
of	O
three	O
drugs	O
.	O
	
Dose	O
reductions	O
occurred	O
in	O
34	O
(	O
72.3	O
%	O
)	O
patients	O
.	O
	
Grade	O
3	O
/	O
4	O
toxicities	O
included	O
neutropenia	B-TOXI
(	O
47	O
%	O
/	O
15	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
11	O
%	O
/	O
15	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
6	O
%	O
/	O
0	O
%	O
)	O
","	O
dyspnea	B-TOXI
(	O
6	O
%	O
/	O
2	O
%	O
)	O
","	O
bacterial	B-TOXI
pneumonia	I-TOXI
(	O
4	O
%	O
/	O
0	O
%	O
)	O
","	O
and	O
hypertension	B-TOXI
(	O
4	O
%	O
/	O
2	O
%	O
)	O
.	O
	
No	B-TOXI
neutropenic	I-TOXI
fevers	I-TOXI
occurred	O
.	O
	
One	O
patient	O
died	B-TOXI
of	I-TOXI
hemoptysis	I-TOXI
.	O
	
Grade	O
3	O
bleeding	B-TOXI
occurred	O
in	O
three	O
other	O
patients	O
.	O
	
There	O
were	O
seven	O
(	O
14.9	O
%	O
)	O
partial	O
responses	O
.	O
	
Median	O
time	O
to	O
first	O
event	O
(	O
progression	O
/	O
death	B-TOXI
/	O
toxicity	O
requiring	O
discontinuation	O
)	O
was	O
6.4	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
4.8-7.9	O
months	O
)	O
.	O
	
The	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
12.8	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
10.0-16.5	O
)	O
.	O
	
The	O
OS	O
is	O
57	O
%	O
at	O
1	O
year	O
and	O
10	O
%	O
at	O
2	O
years	O
.	O
	
Although	O
perhaps	O
skewed	O
by	O
a	O
high	O
proportion	O
of	O
nonsmokers	O
and	O
women	O
","	O
treatment	O
with	O
gemcitabine	B-DRUG
/	O
carboplatin	B-DRUG
/	O
bevacizumab	B-DRUG
has	O
an	O
acceptable	O
toxicity	O
profile	O
with	O
promising	O
median	O
OS	O
despite	O
a	O
low	O
response	O
rate	O
.	O
	
Phase	O
I	O
study	O
of	O
everolimus	B-DRUG
plus	O
weekly	O
paclitaxel	B-DRUG
and	O
trastuzumab	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
pretreated	O
with	O
trastuzumab	B-DRUG
.	O
	
	
To	O
determine	O
the	O
recommended	O
dose	O
of	O
everolimus	B-DRUG
","	O
a	O
mammalian	O
target	O
of	O
rapamycin	B-DRUG
inhibitor	I-DRUG
","	O
combined	O
with	O
paclitaxel	B-DRUG
and	O
trastuzumab	B-DRUG
in	O
patients	O
with	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
(	O
HER2	O
)	O
#NAME?	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
pretreated	O
with	O
trastuzumab	B-DRUG
.	O
	
In	O
this	O
phase	O
Ib	O
","	O
multicenter	O
","	O
dose-escalation	O
study	O
","	O
patients	O
were	O
treated	O
with	O
everolimus	B-DRUG
5	O
mg	O
/	O
d	O
","	O
10	O
mg	O
/	O
d	O
","	O
or	O
30	O
mg	O
/	O
wk	O
in	O
combination	O
with	O
paclitaxel	B-DRUG
(	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
every	O
4	O
weeks	O
)	O
and	O
trastuzumab	B-DRUG
(	O
2	O
mg	O
/	O
kg	O
weekly	O
)	O
.	O
	
End	O
points	O
included	O
end-of-cycle	O
1	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
rate	O
(	O
primary	O
end	O
point	O
)	O
","	O
safety	O
","	O
relative	O
dose	O
intensity	O
of	O
study	O
drugs	O
","	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
","	O
and	O
pharmacokinetics	O
.	O
	
Of	O
33	O
patients	O
enrolled	O
","	O
31	O
were	O
pretreated	O
with	O
taxanes	B-DRUG
","	O
and	O
32	O
were	O
resistant	O
to	O
trastuzumab	B-DRUG
.	O
	
Patients	O
received	O
a	O
median	O
of	O
two	O
lines	O
of	O
chemotherapy	O
in	O
the	O
metastatic	O
setting	O
(	O
range	O
","	O
0	O
to	O
17	O
lines	O
)	O
.	O
	
Three	O
patients	O
experienced	O
cycle	O
1	O
DLTs	O
:	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
5	O
mg	O
/	O
d	O
)	O
","	O
stomatitis	B-TOXI
(	O
10	O
mg	O
/	O
d	O
)	O
","	O
and	O
confusion	B-TOXI
(	O
30	O
mg	O
/	O
wk	O
)	O
.	O
	
Grade	O
3	O
to	O
4	O
neutropenia	B-TOXI
was	O
the	O
most	O
common	O
toxicity	O
observed	O
(	O
n	O
=	O
17	O
patients	O
[	O
52	O
%	O
]	O
)	O
.	O
	
On	O
the	O
basis	O
of	O
observed	O
DLTs	O
and	O
overall	O
safety	O
","	O
10	O
mg	O
/	O
d	O
was	O
recommended	O
for	O
additional	O
development	O
.	O
	
Twenty-seven	O
patients	O
had	O
measurable	B-TOXI
disease	I-TOXI
and	O
were	O
evaluable	O
for	O
efficacy	O
.	O
	
Among	O
these	O
patients	O
","	O
ORR	O
was	O
44	O
%	O
.	O
	
Overall	O
disease	O
was	O
controlled	O
for	O
6	O
months	O
or	O
more	O
in	O
74	O
%	O
.	O
	
Median	O
progression-free	O
survival	O
was	O
34	O
weeks	O
(	O
95	O
%	O
CI	O
","	O
29.1	O
to	O
40.7	O
weeks	O
)	O
.	O
	
Among	O
11	O
patients	O
who	O
were	O
resistant	O
to	O
both	O
trastuzumab	B-DRUG
and	O
taxane	B-DRUG
","	O
a	O
similar	O
level	O
of	O
antitumor	O
activity	O
was	O
observed	O
(	O
ORR	O
","	O
55	O
%	O
)	O
.	O
	
Everolimus	B-DRUG
combined	O
with	O
weekly	O
paclitaxel	B-DRUG
and	O
trastuzumab	B-DRUG
was	O
generally	O
well	O
tolerated	O
and	O
had	O
encouraging	O
antitumor	O
activity	O
in	O
patients	O
with	O
trastuzumab-pretreated	B-DRUG
and	O
#NAME?	O
metastatic	O
HER2-overexpressing	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
Phase	O
I	O
dose-escalating	O
study	O
of	O
biweekly	O
fixed-dose	O
rate	O
gemcitabine	B-DRUG
plus	O
pemetrexed	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
To	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
the	O
recommended	O
phase	O
II	O
dose	O
and	O
to	O
identify	O
the	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
of	O
gemcitabine	B-DRUG
","	O
administered	O
by	O
fixed-dose	O
rate	O
(	O
FDR	O
)	O
infusion	O
","	O
combined	O
with	O
the	O
antifolate	O
agent	O
pemetrexed	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Eligible	O
patients	O
were	O
entered	O
into	O
this	O
open	O
label	O
","	O
phase	O
I	O
trial	O
.	O
	
Using	O
a	O
3	O
=+	O
3	O
dose	O
escalation	O
design	O
","	O
patients	O
received	O
intravenous	B-DRUG
pemetrexed	I-DRUG
300-800	O
mg	O
/	O
m	O
(	O
2	O
)	O
followed	O
by	O
FDR	O
gemcitabine	B-DRUG
"900-1,500"	O
mg	O
/	O
m	O
(	O
2	O
)	O
at	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
min	O
on	O
Day	O
1	O
every	O
2	O
weeks	O
.	O
	
All	O
patients	O
received	O
folic	B-DRUG
acid	I-DRUG
and	O
vitamin	B-DRUG
B	I-DRUG
(	O
12	O
)	O
supplementation	O
.	O
	
Patients	O
continued	O
until	O
DLT	O
or	O
disease	O
progression	O
.	O
	
A	O
total	O
of	O
33	O
patients	O
were	O
treated	O
at	O
7	O
dose	O
levels	O
with	O
a	O
total	O
of	O
230	O
cycles	O
(	O
median	O
:	O
4	O
cycles	O
;	O
mean	O
:	O
7	O
cycles	O
;	O
range	O
:	O
1-35	O
cycles	O
)	O
.	O
	
The	O
MTD	O
of	O
the	O
combination	O
was	O
pemetrexed	B-DRUG
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
gemcitabine	B-DRUG
"1,500"	O
mg	O
/	O
m	O
(	O
2	O
)	O
over	O
150	O
min	O
.	O
	
DLTs	O
were	O
febrile	B-TOXI
neutropenia	I-TOXI
and	O
grade	O
3	O
renal	B-TOXI
failure	I-TOXI
.	O
	
Of	O
the	O
28	O
patients	O
evaluable	O
for	O
response	O
","	O
3	O
patients	O
experienced	O
a	O
partial	O
response	O
(	O
10.7	O
%	O
)	O
and	O
13	O
patients	O
had	O
stable	O
disease	O
(	O
46.4	O
%	O
)	O
;	O
the	O
disease	O
control	O
rate	O
was	O
57.1	O
%	O
.	O
	
The	O
recommended	O
phase	O
II	O
dose	O
for	O
biweekly	O
pemetrexed	B-DRUG
with	O
FDR	O
gemcitabine	B-DRUG
is	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
"1,200"	O
mg	O
/	O
m	O
(	O
2	O
)	O
_	O
120	O
min	O
","	O
respectively	O
.	O
	
This	O
regimen	O
allows	O
good	O
dose	O
intensity	O
of	O
both	O
drugs	O
to	O
be	O
administered	O
on	O
a	O
simple	O
schedule	O
with	O
an	O
excellent	O
tolerability	O
profile	O
.	O
	
This	O
regimen	O
showed	O
moderate	O
activity	O
in	O
a	O
diverse	O
phase	O
I	O
population	O
","	O
possibly	O
greater	O
than	O
either	O
single	O
agent	O
.	O
	
Further	O
assessment	O
of	O
the	O
combination	O
in	O
a	O
phase	O
II	O
setting	O
is	O
suggested	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
temsirolimus	B-DRUG
and	O
metformin	B-DRUG
in	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
	
The	O
purpose	O
of	O
this	O
phase	O
I	O
trial	O
was	O
to	O
establish	O
the	O
maximum	O
tolerated	O
dose	O
and	O
define	O
the	O
dose-limiting	O
toxicities	O
of	O
a	O
combination	O
of	O
temsirolimus	B-DRUG
and	O
metformin	B-DRUG
.	O
	
Patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
who	O
had	O
exhausted	O
standard	O
treatment	O
options	O
were	O
eligible	O
.	O
	
Treatment	O
included	O
weekly	O
intravenous	B-DRUG
temsirolimus	I-DRUG
and	O
daily	O
oral	B-DRUG
metformin	I-DRUG
.	O
	
Eleven	O
patients	O
were	O
enrolled	O
.	O
	
Dose-limiting	O
toxicities	O
were	O
observed	O
in	O
all	O
patients	O
at	O
the	O
initial	O
dose	O
level	O
of	O
25	O
mg	O
weekly	O
of	O
temsirolimus	B-DRUG
and	O
metformin	B-DRUG
500	O
mg	O
po	O
BID	O
.	O
	
At	O
dose	O
level	O
-1	O
","	O
2	O
of	O
8	O
patients	O
experienced	O
dose-limiting	O
toxicities	O
.	O
	
Toxicities	O
included	O
grade	O
4	O
pneumonitis	B-TOXI
","	O
persistent	O
grade	O
3	O
fatigue	B-TOXI
","	O
and	O
thrombocytopenia	B-TOXI
requiring	O
dose	O
delays	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
(	O
level	O
-1	O
)	O
was	O
20	O
mg	O
temsirolimus	B-DRUG
weekly	O
and	O
500	O
mg	O
po	O
daily	O
of	O
metformin	B-DRUG
.	O
	
One	O
patient	O
with	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
experienced	O
a	O
partial	O
response	O
.	O
	
Five	O
patients	O
had	O
stable	O
disease	O
including	O
a	O
patient	O
with	O
melanoma	B-CANCER
who	O
had	O
stable	O
disease	O
for	O
22	O
months	O
.	O
	
Rituximab	B-DRUG
and	O
CHOP	B-DRUG
chemotherapy	O
plus	O
GM-CSF	B-DRUG
for	O
previously	O
untreated	O
diffuse	O
large	B-CANCER
B-cell	I-CANCER
lymphoma	I-CANCER
in	O
the	O
elderly	O
:	O
a	O
Wisconsin	O
oncology	O
network	O
study	O
.	O
	
	
Human	O
recombinant	O
granulocyte-macrophage	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
(	O
GM-CSF	B-DRUG
)	O
may	O
potentiate	O
rituximab	B-DRUG
activity	O
by	O
upregulating	O
CD20	O
expression	O
and	O
activating	O
effector	O
cells	O
necessary	O
for	O
antibody-dependent	O
cellular	O
cytotoxicity	O
.	O
	
GM-CSF	B-DRUG
was	O
combined	O
with	O
standard	O
rituximab	B-DRUG
=+	O
CHOP	B-DRUG
(	O
cyclophosphamide	B-DRUG
/	O
doxorubicin	B-DRUG
/	O
vincristine	B-DRUG
/	O
prednisone	B-DRUG
)	O
chemotherapy	O
(	O
R-CHOP	B-DRUG
)	O
in	O
the	O
treatment	O
of	O
elderly	O
patients	O
with	O
de	O
novo	O
diffuse	B-CANCER
large	I-CANCER
B-cell	I-CANCER
lymphoma	I-CANCER
(	O
DLBCL	B-CANCER
)	O
.	O
	
Thirty-eight	O
patients	O
over	O
the	O
age	O
of	O
60	O
years	O
with	O
newly	O
diagnosed	O
DLBCL	B-CANCER
were	O
treated	O
with	O
R-CHOP	B-DRUG
every	O
21	O
days	O
for	O
6月8日	O
cycles	O
and	O
GM-CSF	B-DRUG
250	O
碌g	O
/	O
m2	O
per	O
day	O
on	O
days	O
3月10日	O
.	O
	
Patients	O
were	O
evaluated	O
for	O
response	O
after	O
cycles	O
4	O
","	O
6	O
","	O
and	O
8	O
The	O
primary	O
endpoint	O
was	O
the	O
rate	O
of	O
complete	O
response	O
","	O
and	O
secondary	O
endpoints	O
were	O
progression-free	O
survival	O
(	O
PFS	O
)	O
","	O
event-free	O
survival	O
","	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O
	
Thirty-eight	O
patients	O
were	O
enrolled	O
","	O
with	O
a	O
median	O
age	O
of	O
72	O
years	O
","	O
and	O
29	O
%	O
of	O
patients	O
having	O
high-risk	O
disease	O
(	O
International	O
Prognostic	O
Index	O
[	O
IPI	O
]	O
score	O
_	O
4	O
)	O
.	O
	
A	O
complete	O
or	O
unconfirmed	O
complete	O
response	O
(	O
CR	O
)	O
was	O
achieved	O
in	O
53	O
%	O
of	O
patients	O
.	O
	
After	O
a	O
median	O
follow-up	O
of	O
51.1	O
months	O
","	O
the	O
3-year	O
PFS	O
and	O
OS	O
were	O
78	O
%	O
and	O
84	O
%	O
.	O
	
Twenty-one	O
percent	O
of	O
patients	O
discontinued	O
protocol	O
treatment	O
because	O
of	O
chemotherapy-related	B-TOXI
toxicity	I-TOXI
and	O
16	O
%	O
because	O
of	O
GM-CSF	B-DRUG
toxicity	B-TOXI
.	O
	
Dose	O
intensity	O
for	O
planned	O
chemotherapy	O
cycles	O
was	O
81.1	O
%	O
.	O
	
These	O
data	O
suggest	O
that	O
survival	O
outcomes	O
may	O
be	O
modestly	O
improved	O
when	O
GM-CSF	B-DRUG
is	O
combined	O
with	O
R-CHOP	B-DRUG
in	O
the	O
treatment	O
of	O
elderly	O
DLBCL	B-CANCER
.	O
	
GM-CSF	B-DRUG
had	O
toxicity	O
precluding	O
planned	O
administration	O
in	O
16	O
%	O
of	O
patients	O
","	O
which	O
may	O
limit	O
usefulness	O
of	O
this	O
agent	O
.	O
	
Further	O
investigation	O
of	O
GM-CSF	B-DRUG
in	O
combination	O
with	O
rituximab-containing	B-DRUG
chemotherapy	O
is	O
warranted	O
.	O
	
Autologous	O
versus	O
reduced-intensity	O
allogeneic	O
hematopoietic	O
cell	O
transplantation	O
for	O
patients	O
with	O
chemosensitive	O
follicular	B-CANCER
non-Hodgkin	I-CANCER
lymphoma	I-CANCER
beyond	O
first	O
complete	O
response	O
or	O
first	O
partial	O
response	O
.	O
	
	
Patients	O
with	O
follicular	B-CANCER
lymphoma	I-CANCER
(	O
FL	B-CANCER
)	O
typically	O
experience	O
an	O
indolent	O
course	O
;	O
however	O
","	O
the	O
disease	O
is	O
rarely	O
curable	O
with	O
conventional	O
chemotherapy	O
.	O
	
Autologous	O
hematopoietic	O
cell	O
transplantation	O
(	O
HCT	O
)	O
can	O
extend	O
progression-free	O
survival	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
","	O
but	O
relapse	O
is	O
the	O
primary	O
cause	O
of	O
failure	O
.	O
	
Allogeneic	O
HCT	O
confers	O
lower	O
relapse	O
rates	O
due	O
to	O
a	O
graft-versus-lymphoma	B-CANCER
effect	O
.	O
	
Reduced-intensity	O
conditioning	O
(	O
RIC	O
)	O
allows	O
the	O
performance	O
of	O
allogeneic	O
HCT	O
with	O
lower	O
toxicity	O
.	O
	
The	O
Blood	O
and	O
Marrow	O
Transplant	O
Clinical	O
Trials	O
Network	O
conducted	O
a	O
prospective	O
multicenter	O
trial	O
comparing	O
these	O
two	O
strategies	O
in	O
patients	O
with	O
relapsed	O
","	O
chemotherapy-sensitive	O
FL	B-CANCER
.	O
	
Patients	O
were	O
assigned	O
to	O
a	O
treatment	O
arm	O
based	O
on	O
the	O
availability	O
of	O
an	O
HLA-matched	O
sibling	O
donor	O
(	O
MSD	O
)	O
.	O
	
Those	O
with	O
an	O
MSD	O
underwent	O
allogeneic	O
HCT	O
(	O
n	O
=	O
8	O
)	O
with	O
the	O
FCR	O
preparative	O
regimen	O
(	O
fludarabine	O
","	O
cyclophosphamide	B-DRUG
[	O
Cy	O
]	O
","	O
rituximab	B-DRUG
[	O
RTX	O
]	O
)	O
and	O
received	O
tacrolimus	B-DRUG
and	O
methotrexate	B-DRUG
for	O
graft-versus-host	O
disease	O
(	O
GVHD	O
)	O
prophylaxis	O
.	O
	
Those	O
without	O
an	O
MSD	O
(	O
n	O
=	O
22	O
)	O
underwent	O
mobilization	O
with	O
Cy	O
","	O
RTX	O
","	O
and	O
filgrastim	B-DRUG
and	O
received	O
a	O
conditioning	O
regimen	O
of	O
either	O
CBV	O
(	O
Cy	O
","	O
carmustine	B-DRUG
","	O
Etoposide	B-DRUG
[	O
VP16	O
]	O
)	O
or	O
total	O
body	O
irradiation	O
with	O
Cy	O
and	O
VP16	O
.	O
	
Patients	O
undergoing	O
autologous	O
HCT	O
received	O
4	O
doses	O
of	O
weekly	O
maintenance	O
RTX	O
(	O
375	O
mg	O
/	O
m虏	O
)	O
starting	O
on	O
day	O
42	O
post-HCT	O
.	O
	
Sixteen	O
patients	O
were	O
in	O
complete	O
remission	O
","	O
10	O
patients	O
were	O
in	O
partial	O
remission	O
","	O
and	O
1	O
patient	O
had	O
stable	O
disease	O
after	O
salvage	O
therapy	O
and	O
before	O
HCT	O
.	O
	
Median	O
follow-up	O
was	O
36	O
months	O
(	O
range	O
","	O
1-51	O
months	O
)	O
.	O
	
OS	O
was	O
73	O
%	O
in	O
autologous	O
HCT	O
versus	O
100	O
%	O
in	O
allogeneic	O
HCT	O
","	O
and	O
PFS	O
was	O
63	O
%	O
in	O
autologous	O
HCT	O
versus	O
86	O
%	O
in	O
allogeneic	O
HCT	O
.	O
	
No	O
patient	O
had	O
grade	O
II-IV	O
acute	B-TOXI
GVHD	I-TOXI
;	O
two	O
patients	O
developed	O
extensive	O
chronic	B-TOXI
GVHD	I-TOXI
.	O
	
Three	O
autologous	O
recipients	O
died	B-TOXI
from	I-TOXI
nonrelapse	I-TOXI
causes	I-TOXI
.	O
	
This	O
trial	O
closed	O
early	O
because	O
of	O
slow	O
accrual	O
.	O
	
We	O
show	O
that	O
the	O
FCR	O
regimen	O
is	O
well	O
tolerated	O
","	O
and	O
that	O
both	O
allogeneic	O
and	O
autologous	O
HCT	O
result	O
in	O
promising	O
3-year	O
OS	O
and	O
PFS	O
in	O
patients	O
with	O
relapsed	O
FL	B-CANCER
.	O
	
Combined	O
Chemotherapy	O
with	O
Mitomycin	B-DRUG
C	I-DRUG
","	O
Folinic	B-DRUG
Acid	I-DRUG
","	O
and	O
5-Fluorouracil	B-DRUG
(	O
MiFoFU	B-DRUG
)	O
as	O
Salvage	O
Treatment	O
for	O
Patients	O
with	O
Liver	O
Metastases	O
from	O
Breast	B-CANCER
Cancer	I-CANCER
=-	O
a	O
Retrospective	O
Analysis	O
.	O
	
	
BACKGROUND	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
activity	O
and	O
tolerability	O
of	O
a	O
combined	O
chemotherapy	O
with	O
mitomycin	B-DRUG
C	I-DRUG
","	O
folinic	B-DRUG
acid	I-DRUG
","	O
and	O
5-fluorouracil	B-DRUG
(	O
MiFoFU	B-DRUG
)	O
in	O
patients	O
with	O
hepatic	O
metastases	O
from	O
breast	B-CANCER
cancer	I-CANCER
","	O
and	O
in	O
particular	O
in	O
patients	O
with	O
impaired	B-TOXI
liver	I-TOXI
function	I-TOXI
.	O
	
PATIENTS	O
AND	O
METHODS	O
:	O
We	O
retrospectively	O
studied	O
the	O
charts	O
of	O
44	O
patients	O
who	O
were	O
treated	O
with	O
a	O
MiFoFU	B-DRUG
combination	O
therapy	O
because	O
of	O
progressive	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Predominant	O
site	O
of	O
metastases	O
was	O
the	O
liver	O
.	O
	
Primary	O
endpoints	O
were	O
response	O
and	O
time	O
to	O
progression	O
(	O
TTP	O
)	O
;	O
secondary	O
endpoints	O
were	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
tolerability	O
.	O
	
RESULTS	O
:	O
Median	O
age	O
prior	O
to	O
treatment	O
was	O
59	O
years	O
.	O
	
A	O
median	O
of	O
6	O
treatment	O
cycles	O
were	O
administered	O
per	O
patient	O
.	O
	
Clinical	O
benefit	O
rate	O
amounted	O
to	O
64	O
%	O
.	O
	
A	O
mean	O
TTP	O
of	O
9	O
months	O
and	O
a	O
mean	O
OS	O
of	O
14	O
months	O
were	O
found	O
.	O
	
Main	O
clinical	O
signs	O
of	O
nonhematological	B-TOXI
toxicity	I-TOXI
were	O
stomatitis	B-TOXI
","	O
nausea	B-TOXI
","	O
and	O
diarrhea	B-TOXI
.	O
	
Grade	O
III	O
/	O
IV	O
hematotoxicity	B-TOXI
was	O
seen	O
in	O
only	O
9	O
patients	O
.	O
	
16	O
patients	O
showed	O
clinical	O
signs	O
of	O
liver	B-TOXI
dysfunction	I-TOXI
.	O
	
A	O
clinical	O
benefit	O
could	O
be	O
achieved	O
in	O
8	O
of	O
these	O
patients	O
.	O
	
CONCLUSION	O
:	O
MiFoFU	B-DRUG
combination	O
chemotherapy	O
is	O
a	O
well-tolerated	O
treatment	O
alternative	O
in	O
the	O
palliative	O
therapy	O
of	O
patients	O
with	O
liver	O
metastases	O
from	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
Particularly	O
in	O
patients	O
with	O
hepatic	B-TOXI
dysfunction	I-TOXI
","	O
this	O
regimen	O
seems	O
to	O
represent	O
a	O
helpful	O
treatment	O
option	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
bevacizumab	B-DRUG
(	O
B	O
)	O
in	O
combination	O
with	O
everolimus	B-DRUG
(	O
E	O
)	O
and	O
erlotinib	B-DRUG
(	O
E	O
)	O
in	O
advanced	B-CANCER
cancer	I-CANCER
(	O
BEE	O
)	O
.	O
	
	
VEGF	O
","	O
mTOR	O
","	O
and	O
EGFR	O
inhibitors	O
have	O
demonstrated	O
anti-tumor	O
and	O
anti-angiogenic	O
effects	O
alone	O
and	O
in	O
combination	O
with	O
each	O
other	O
.	O
	
This	O
study	O
evaluated	O
the	O
safety	O
","	O
tolerability	O
","	O
and	O
pharmacokinetics	O
of	O
bevacizumab	B-DRUG
","	O
everolimus	B-DRUG
","	O
and	O
erlotinib	B-DRUG
combination	O
.	O
	
Doublet	O
therapy	O
consisted	O
of	O
bevacizumab	B-DRUG
at	O
10	O
mg	O
/	O
kg	O
every	O
14	O
days	O
and	O
everolimus	B-DRUG
5	O
mg	O
daily	O
which	O
escalated	O
to	O
10	O
mg	O
daily	O
.	O
	
Erlotinib	B-DRUG
75	O
mg	O
daily	O
was	O
added	O
to	O
the	O
phase	O
II	O
dose	O
recommended	O
phase	O
II	O
dose	O
(	O
RPTD	O
)	O
of	O
bevacizumab	B-DRUG
and	O
everolimus	B-DRUG
.	O
	
Dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
was	O
assessed	O
in	O
cycle	O
1	O
Forty-eight	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
malignancies	I-CANCER
were	O
evaluable	O
for	O
DLT	O
and	O
efficacy	O
.	O
	
No	O
DLTs	O
were	O
observed	O
in	O
the	O
doublet	O
dose	O
escalation	O
.	O
	
Two	O
DLTs	O
(	O
grade	O
3	O
mucositis	B-TOXI
and	O
grade	O
3	O
rash	B-TOXI
)	O
were	O
observed	O
with	O
the	O
addition	O
of	O
erlotinib	B-DRUG
75	O
mg	O
daily	O
.	O
	
Consequently	O
","	O
triplet	O
doses	O
were	O
adjusted	O
and	O
were	O
better	O
tolerated	O
.	O
	
Four	O
patients	O
had	O
a	O
partial	O
response	O
.	O
	
Median	O
progression-free	O
survival	O
(	O
PFS	O
)	O
for	O
the	O
doublet	O
therapy	O
was	O
6	O
months	O
(	O
0.5	O
to	O
32+	O
months	O
)	O
and	O
5.5	O
months	O
(	O
0.8	O
to	O
27+	O
months	O
)	O
for	O
the	O
triplet	O
therapy	O
.	O
	
Systemic	O
exposure	O
of	O
everolimus	B-DRUG
was	O
significantly	O
higher	O
in	O
combination	O
with	O
erlotinib	B-DRUG
(	O
476	O
卤	O
161	O
ng	O
h	O
/	O
mL	O
)	O
compared	O
to	O
when	O
given	O
alone	O
(	O
393	O
卤	O
156	O
ng	O
h	O
/	O
mL	O
;	O
P	O
=	O
0.02	O
)	O
.	O
	
The	O
RPTD	O
for	O
the	O
doublet	O
therapy	O
is	O
bevacizumab	B-DRUG
10	O
mg	O
/	O
kg	O
every	O
14	O
days	O
and	O
everolimus	B-DRUG
10	O
mg	O
daily	O
","	O
and	O
the	O
RPTD	O
for	O
the	O
triplet	O
therapy	O
is	O
bevacizumab	B-DRUG
5	O
mg	O
/	O
kg	O
every	O
14	O
days	O
","	O
everolimus	B-DRUG
5	O
mg	O
and	O
erlotinib	B-DRUG
75	O
mg	O
daily	O
.	O
	
Prolonged	O
disease	O
stability	O
was	O
demonstrated	O
in	O
tumors	O
known	O
to	O
respond	O
to	O
mTOR	O
inhibition	O
and	O
potentially	O
resistant	O
to	O
VEGF	O
blockade	O
.	O
	
Fluorouracil	B-DRUG
","	O
doxorubicin	B-DRUG
","	O
cyclophosphamide	B-DRUG
","	O
and	O
cisplatin	B-DRUG
combination	O
chemotherapy	O
in	O
advanced	O
or	O
recurrent	O
salivary	B-CANCER
gland	I-CANCER
carcinoma	I-CANCER
.	O
	
	
Seventeen	O
patients	O
with	O
recurrent	O
or	O
unresectable	O
salivary	B-CANCER
gland	I-CANCER
carcinomas	I-CANCER
were	O
treated	O
with	O
combination	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
doxorubicin	B-DRUG
","	O
cyclophosphamide	B-DRUG
","	O
and	O
cisplatin	B-DRUG
(	O
FACP	B-DRUG
)	O
.	O
	
Sixteen	O
patients	O
were	O
assessable	O
for	O
response	O
and	O
toxicity	O
.	O
	
A	O
total	O
of	O
111	O
courses	O
of	O
chemotherapy	O
were	O
given	O
","	O
yielding	O
one	O
complete	O
and	O
seven	O
partial	O
responses	O
","	O
for	O
an	O
objective	O
response	O
rate	O
of	O
50	O
%	O
.	O
	
Two	O
other	O
patients	O
had	O
stable	O
disease	O
and	O
two	O
had	O
a	O
minor	O
response	O
.	O
	
The	O
median	O
duration	O
of	O
objective	O
response	O
was	O
32	O
weeks	O
(	O
range	O
","	O
4	O
to	O
72	O
)	O
;	O
median	O
survival	O
for	O
the	O
16	O
patients	O
was	O
72	O
weeks	O
.	O
	
Hematologic	B-TOXI
toxicity	I-TOXI
was	O
significant	O
","	O
with	O
88	O
%	O
developing	O
a	O
nadir	B-TOXI
granulocyte	I-TOXI
count	O
of	O
less	O
than	O
"1,000"	O
cells	O
per	O
microliter	O
(	O
median	O
","	O
300	O
cells	O
per	O
microliter	O
)	O
","	O
and	O
53	O
%	O
a	O
nadir	B-TOXI
platelet	I-TOXI
count	O
of	O
less	O
than	O
"100,000"	O
cells	O
per	O
microliter	O
(	O
median	O
","	O
"68,000"	O
cells	O
per	O
microliter	O
)	O
.	O
	
Seven	O
patients	O
(	O
44	O
%	O
)	O
developed	O
neutropenic	B-TOXI
fever	I-TOXI
","	O
and	O
three	O
(	O
18	O
%	O
)	O
developed	O
an	O
increase	O
in	O
serum	B-TOXI
creatinine	I-TOXI
greater	O
than	O
1.5	O
mg	O
/	O
dL	O
during	O
the	O
course	O
of	O
treatment	O
.	O
	
This	O
combination	O
of	O
chemotherapy	O
was	O
active	O
;	O
however	O
","	O
an	O
increased	O
response	O
rate	O
was	O
not	O
observed	O
above	O
that	O
reported	O
for	O
other	O
combinations	O
.	O
	
Response	O
duration	O
","	O
or	O
overall	O
patient	O
survival	O
","	O
on	O
this	O
intensive	O
regimen	O
was	O
similar	O
as	O
compared	O
with	O
other	O
published	O
therapeutic	O
trials	O
of	O
this	O
disease	O
entity	O
.	O
	
Sunitinib	B-DRUG
in	O
combination	O
with	O
paclitaxel	B-DRUG
plus	O
carboplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
:	O
phase	O
I	O
study	O
results	O
.	O
	
	
To	O
evaluate	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
safety	O
","	O
and	O
antitumor	O
activity	O
of	O
sunitinib	B-DRUG
combined	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
.	O
	
Successive	O
cohorts	O
of	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
received	O
oral	B-DRUG
sunitinib	I-DRUG
(	O
25	O
","	O
37.5	O
","	O
or	O
50	O
mg	O
)	O
for	O
2	O
consecutive	O
weeks	O
of	O
a	O
3-week	O
cycle	O
(	O
Schedule	O
2	O
/	O
1	O
)	O
or	O
as	O
a	O
continuous	O
daily	O
dose	O
for	O
3-week	O
cycles	O
(	O
CDD	O
schedule	O
)	O
in	O
combination	O
with	O
paclitaxel	B-DRUG
(	O
175-200	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
plus	O
carboplatin	B-DRUG
(	O
AUC	O
6	O
mg	O
min	O
/	O
ml	O
)	O
on	O
day	O
one	O
of	O
each	O
of	O
4	O
cycles	O
.	O
	
Dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
and	O
adverse	O
events	O
(	O
AEs	O
)	O
were	O
evaluated	O
to	O
determine	O
the	O
MTD	O
.	O
	
Efficacy	O
parameters	O
were	O
analyzed	O
in	O
patients	O
with	O
measurable	O
disease	O
.	O
	
Forty-three	O
patients	O
were	O
enrolled	O
(	O
n	O
=	O
25	O
Schedule	O
2	O
/	O
1	O
;	O
n	O
=	O
18	O
CDD	O
schedule	O
)	O
.	O
	
Across	O
all	O
doses	O
","	O
6	O
DLTs	O
were	O
observed	O
[	O
grade	O
4	O
papilledema	B-TOXI
","	O
grade	O
5	O
GI	B-TOXI
hemorrhage	I-TOXI
","	O
grade	O
3	O
neutropenic	B-TOXI
infection	I-TOXI
","	O
and	O
grade	O
4	O
thrombocytopenia	B-TOXI
(	O
n	O
=	O
3	O
)	O
]	O
.	O
	
The	O
MTD	O
for	O
Schedule	O
2	O
/	O
1	O
was	O
sunitinib	B-DRUG
25	O
mg	O
plus	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
carboplatin	B-DRUG
AUC	O
6	O
mg	O
min	O
/	O
ml	O
.	O
	
The	O
MTD	O
was	O
not	O
determined	O
for	O
the	O
CDD	O
schedule	O
.	O
	
Treatment-related	O
AEs	O
included	O
neutropenia	B-TOXI
(	O
77	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
56	O
%	O
)	O
","	O
and	O
fatigue	B-TOXI
(	O
47	O
%	O
)	O
.	O
	
Of	O
38	O
evaluable	O
patients	O
","	O
4	O
(	O
11	O
%	O
)	O
had	O
partial	O
responses	O
and	O
12	O
(	O
32	O
%	O
)	O
had	O
stable	O
disease	O
.	O
	
PK	O
data	O
indicated	O
an	O
increase	O
in	O
maximum	O
and	O
total	O
plasma	O
exposures	O
to	O
sunitinib	B-DRUG
and	O
its	O
active	O
metabolite	O
when	O
given	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
compared	O
with	O
sunitinib	B-DRUG
monotherapy	O
.	O
	
Myelosuppression	B-TOXI
resulting	O
in	O
prolonged	O
dose	O
delays	O
and	O
frequent	O
interruptions	O
was	O
observed	O
","	O
suggesting	O
that	O
this	O
treatment	O
combination	O
is	O
not	O
feasible	O
in	O
the	O
general	O
cancer	O
population	O
.	O
	
Phase	O
I	O
study	O
of	O
pazopanib	B-DRUG
in	O
combination	O
with	O
weekly	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
To	O
evaluate	O
the	O
maximum	O
tolerated	O
regimen	O
(	O
MTR	O
)	O
","	O
dose-limiting	O
toxicities	O
","	O
and	O
pharmacokinetics	O
of	O
pazopanib	B-DRUG
","	O
an	O
oral	B-DRUG
small-molecule	I-DRUG
tyrosine	I-DRUG
kinase	I-DRUG
inhibitor	I-DRUG
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
","	O
platelet-derived	O
growth	O
factor	O
receptor	O
","	O
and	O
c-Kit	O
","	O
in	O
combination	O
with	O
paclitaxel	B-DRUG
.	O
	
Pazopanib	B-DRUG
was	O
given	O
daily	O
with	O
weekly	O
paclitaxel	B-DRUG
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
every	O
28	O
days	O
.	O
	
Dose	O
levels	O
of	O
pazopanib	B-DRUG
(	O
mg	O
/	O
day	O
)	O
/	O
paclitaxel	B-DRUG
(	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
were	O
400	O
/	O
15	O
","	O
800	O
/	O
15	O
","	O
800	O
/	O
50	O
","	O
and	O
800	O
/	O
80	O
.	O
	
An	O
expanded	O
cohort	O
was	O
enrolled	O
at	O
the	O
MTR	O
.	O
	
Plasma	O
samples	O
were	O
collected	O
to	O
evaluate	O
the	O
effect	O
of	O
pazopanib	B-DRUG
","	O
an	O
inhibitor	O
of	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
3A4	O
","	O
on	O
the	O
pharmacokinetics	O
of	O
paclitaxel	B-DRUG
","	O
a	O
CYP3A4	O
and	O
CYP2C8	O
substrate	O
.	O
	
Of	O
26	O
enrolled	O
patients	O
","	O
17	O
were	O
treated	O
at	O
the	O
MTR	O
of	O
800	O
mg	O
pazopanib	B-DRUG
and	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
paclitaxel	B-DRUG
.	O
	
Dose-limiting	O
toxicities	O
included	O
a	O
grade	O
3	O
abscess	B-TOXI
and	O
grade	O
2	O
hyperbilirubinemia	B-TOXI
.	O
	
Other	O
toxicities	O
included	O
elevated	B-TOXI
liver	I-TOXI
transaminases	I-TOXI
and	O
diarrhea	B-TOXI
.	O
	
Six	O
patients	O
(	O
23	O
%	O
)	O
had	O
partial	O
responses	O
and	O
15	O
patients	O
(	O
58	O
%	O
)	O
had	O
stable	O
disease	O
.	O
	
Administration	O
of	O
800	O
mg	O
pazopanib	B-DRUG
resulted	O
in	O
a	O
14	O
%	O
lower	O
paclitaxel	B-DRUG
clearance	O
and	O
a	O
31	O
%	O
higher	O
paclitaxel	B-DRUG
maximal	O
concentration	O
than	O
with	O
administration	O
of	O
paclitaxel	B-DRUG
alone	O
at	O
15	O
","	O
50	O
","	O
and	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
At	O
the	O
MTR	O
","	O
coadministration	O
of	O
800	O
mg	O
pazopanib	B-DRUG
and	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
paclitaxel	B-DRUG
resulted	O
in	O
a	O
26	O
%	O
higher	O
geometric	O
mean	O
paclitaxel	B-DRUG
area	O
under	O
the	O
curve	O
.	O
	
Pazopanib	B-DRUG
","	O
at	O
a	O
dose	O
of	O
800	O
mg	O
daily	O
","	O
can	O
be	O
safely	O
combined	O
with	O
a	O
therapeutic	O
dose	O
of	O
paclitaxel	B-DRUG
at	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
when	O
administered	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
","	O
every	O
28	O
days	O
.	O
	
The	O
observed	O
greater	O
plasma	O
concentrations	O
of	O
paclitaxel	B-DRUG
given	O
concurrently	O
with	O
pazopanib	B-DRUG
suggest	O
that	O
pazopanib	B-DRUG
is	O
a	O
weak	O
inhibitor	O
of	O
CYP3A4	O
and	O
CYP2C8	O
.	O
	
Combination	O
mTOR	O
and	O
IGF-1R	O
inhibition	O
:	O
phase	O
I	O
trial	O
of	O
everolimus	B-DRUG
and	O
figitumumab	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
sarcomas	I-CANCER
and	O
other	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
Preclinical	O
models	O
demonstrate	O
synergistic	O
antitumor	O
activity	O
with	O
combination	O
blockade	O
of	O
mTOR	O
and	O
IGF-1R	O
signaling	O
.	O
	
We	O
aimed	O
to	O
determine	O
the	O
safety	O
","	O
tolerability	O
","	O
and	O
recommended	O
phase	O
II	O
dose	O
(	O
RP2D	O
)	O
of	O
the	O
combination	O
of	O
figitumumab	B-DRUG
","	O
a	O
fully	O
human	O
IgG	O
(	O
2	O
)	O
anti-insulin-like	O
growth	O
factor-1	O
receptor	O
(	O
IGF-1R	O
)	O
monoclonal	O
antibody	O
(	O
Pfizer	O
)	O
and	O
the	O
mTOR	O
inhibitor	O
","	O
everolimus	B-DRUG
(	O
Novartis	O
)	O
.	O
	
Pharmacokinetics	O
and	O
preliminary	O
antitumor	O
effects	O
of	O
the	O
combination	O
were	O
evaluated	O
.	O
	
Phase	O
I	O
trial	O
in	O
patients	O
with	O
advanced	B-CANCER
sarcomas	I-CANCER
and	O
other	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
Initial	O
cohort	O
combined	O
full	O
phase	O
2	O
dose	O
figitumumab	B-DRUG
(	O
20	O
mg	O
/	O
kg	O
IV	O
every	O
21	O
days	O
)	O
with	O
full	O
dose	O
everolimus	B-DRUG
(	O
10	O
mg	O
orally	O
once	O
daily	O
)	O
.	O
	
Intercohort	O
dose	O
de-escalation	O
was	O
planned	O
for	O
unacceptable	O
toxicities	O
.	O
	
Dose	O
modifications	O
were	O
allowed	O
beyond	O
cycle	O
1	O
No	O
DLTs	O
were	O
observed	O
in	O
the	O
initial	O
cohort	O
during	O
cycle	O
one	O
","	O
therefore	O
full	O
dose	O
figitumumab	B-DRUG
and	O
everolimus	B-DRUG
was	O
declared	O
the	O
RP2D	O
.	O
	
In	O
total	O
","	O
21	O
patients	O
were	O
enrolled	O
on	O
study	O
.	O
	
Most	O
toxicities	O
were	O
grade	O
1	O
or	O
2	O
","	O
and	O
were	O
similar	O
to	O
reported	O
toxicities	O
of	O
the	O
single	O
agents	O
.	O
	
Mucositis	B-TOXI
was	O
the	O
most	O
frequently	O
observed	O
grade	O
3	O
toxicity	O
.	O
	
Median	O
time	O
on	O
study	O
was	O
104	O
days	O
(	O
range	O
17-300	O
)	O
.	O
	
Of	O
18	O
patients	O
evaluable	O
for	O
response	O
","	O
best	O
response	O
was	O
partial	O
response	O
in	O
1	O
patient	O
with	O
malignant	B-CANCER
solitary	I-CANCER
fibrous	I-CANCER
tumor	I-CANCER
and	O
","	O
stable	O
disease	O
in	O
15	O
patients	O
.	O
	
There	O
were	O
no	O
apparent	O
pharmacokinetic	O
interactions	O
between	O
everolimus	B-DRUG
and	O
figitumumab	B-DRUG
.	O
	
Combination	O
figitumumab	B-DRUG
plus	O
everolimus	B-DRUG
at	O
full	O
doses	O
appears	O
safe	O
and	O
well	O
tolerated	O
with	O
no	O
unexpected	O
toxicities	O
.	O
	
Dose	O
reductions	O
in	O
everolimus	B-DRUG
may	O
be	O
required	O
after	O
prolonged	O
drug	O
administration	O
.	O
	
This	O
regimen	O
exhibits	O
interesting	O
antitumor	O
activity	O
warranting	O
further	O
investigation	O
.	O
	
Phase	O
II	O
study	O
of	O
modified	O
docetaxel	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
fluorouracil	B-DRUG
with	O
bevacizumab	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
gastroesophageal	I-CANCER
adenocarcinoma	I-CANCER
.	O
	
	
To	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
a	O
modified	O
administration	O
schedule	O
of	O
docetaxel	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
fluorouracil	B-DRUG
(	O
mDCF	O
)	O
with	O
bevacizumab	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
gastroesophageal	I-CANCER
malignancies	I-CANCER
.	O
	
Previously	O
untreated	O
patients	O
with	O
metastatic	B-CANCER
gastroesophageal	I-CANCER
adenocarcinoma	I-CANCER
received	O
bevacizumab	B-DRUG
10	O
mg	O
/	O
kg	O
","	O
docetaxel	B-DRUG
40	O
mg	O
/	O
m虏	O
","	O
fluorouracil	B-DRUG
400	O
mg	O
/	O
m虏	O
","	O
leucovorin	B-DRUG
400	O
mg	O
/	O
m虏	O
on	O
day	O
1	O
","	O
fluorouracil	B-DRUG
"1,000"	O
mg	O
/	O
m虏	O
/	O
d	O
_	O
2	O
days	O
intravenous	O
continuous	O
infusion	O
beginning	O
on	O
day	O
1	O
","	O
and	O
cisplatin	B-DRUG
40	O
mg	O
/	O
m虏	O
on	O
day	O
3	O
The	O
primary	O
objective	O
was	O
to	O
improve	O
6-month	O
progression-free	O
survival	O
(	O
PFS	O
)	O
from	O
43	O
%	O
(	O
historical	O
DCF	O
control	O
)	O
to	O
63	O
%	O
with	O
the	O
addition	O
of	O
bevacizumab	B-DRUG
.	O
	
The	O
target	O
accrual	O
was	O
44	O
patients	O
to	O
have	O
10	O
%	O
type	O
I	O
and	O
II	O
error	O
rates	O
.	O
	
In	O
total	O
","	O
44	O
eligible	O
patients	O
with	O
cancer	O
were	O
enrolled	O
from	O
October	O
2006	O
to	O
October	O
2008	O
:	O
22	O
gastric	O
","	O
20	O
gastroesophageal	O
junction	O
(	O
GEJ	O
)	O
","	O
and	O
two	O
esophagus	O
.	O
	
In	O
39	O
patients	O
with	O
measurable	O
disease	O
","	O
the	O
confirmed	O
response	O
rate	O
was	O
67	O
%	O
(	O
95	O
%	O
CI	O
","	O
50	O
%	O
to	O
81	O
%	O
)	O
.	O
	
Six-month	O
PFS	O
was	O
79	O
%	O
(	O
95	O
%	O
CI	O
","	O
63	O
%	O
to	O
88	O
%	O
)	O
","	O
and	O
median	O
PFS	O
was	O
12	O
months	O
(	O
95	O
%	O
CI	O
","	O
8.8	O
to	O
18.2	O
months	O
)	O
.	O
	
With	O
26-month	O
follow-up	O
","	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
16.8	O
months	O
(	O
95	O
%	O
CI	O
","	O
12.1	O
to	O
26.1	O
months	O
)	O
","	O
and	O
2-year	O
survival	O
was	O
37	O
%	O
.	O
	
Treatment-related	O
grade	O
3	O
to	O
4	O
toxicity	O
was	O
as	O
follows	O
:	O
neutropenia	B-TOXI
without	I-TOXI
fever	I-TOXI
(	O
50	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
25	O
%	O
)	O
","	O
venous	B-TOXI
thromboembolism	I-TOXI
(	O
39	O
%	O
)	O
","	O
and	O
nausea	B-TOXI
","	O
vomiting	B-TOXI
","	O
mucositis	B-TOXI
","	O
neuropathy	B-TOXI
","	O
and	O
febrile	B-TOXI
neutropenia	I-TOXI
less	O
than	O
10	O
%	O
each	O
.	O
	
In	O
subset	O
analysis	O
","	O
diffuse	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
had	O
significantly	O
worse	O
PFS	O
and	O
OS	O
","	O
and	O
the	O
response	O
rate	O
in	O
proximal	O
/	O
GEJ	O
tumors	O
was	O
85	O
%	O
(	O
95	O
%	O
CI	O
","	O
62	O
%	O
to	O
97	O
%	O
)	O
.	O
	
mDCF	O
with	O
bevacizumab	B-DRUG
appears	O
tolerable	O
and	O
has	O
notable	O
patient	O
outcomes	O
in	O
patients	O
with	O
advanced	B-CANCER
gastroesophageal	I-CANCER
adenocarcinoma	I-CANCER
.	O
	
Six-month	O
PFS	O
was	O
79	O
%	O
","	O
surpassing	O
our	O
predefined	O
efficacy	O
end	O
point	O
","	O
and	O
median	O
and	O
2-year	O
OS	O
were	O
16.8	O
months	O
and	O
37	O
%	O
","	O
respectively	O
.	O
	
Bortezomib	B-DRUG
plus	O
CHOP-rituximab	B-DRUG
for	O
previously	O
untreated	O
diffuse	B-CANCER
large	I-CANCER
B-cell	I-CANCER
lymphoma	I-CANCER
and	O
mantle	B-CANCER
cell	I-CANCER
lymphoma	I-CANCER
.	O
	
	
The	O
proteasome	O
inhibitor	O
bortezomib	B-DRUG
may	O
enhance	O
activity	O
of	O
chemoimmunotherapy	O
in	O
lymphoma	B-CANCER
.	O
	
We	O
evaluated	O
dose-escalated	O
bortezomib	B-DRUG
plus	O
standard	O
cyclophosphamide	B-DRUG
","	O
doxorubicin	B-DRUG
","	O
vincristine	B-DRUG
","	O
and	O
prednisone	B-DRUG
(	O
CHOP	B-DRUG
)	O
plus	O
rituximab	B-DRUG
(	O
R	O
)	O
in	O
patients	O
with	O
diffuse	B-CANCER
large	I-CANCER
B-cell	I-CANCER
lymphoma	I-CANCER
(	O
DLBCL	B-CANCER
)	O
and	O
mantle	B-CANCER
cell	I-CANCER
lymphoma	I-CANCER
(	O
MCL	B-CANCER
)	O
.	O
	
Seventy-six	O
subjects	O
with	O
untreated	O
DLBCL	B-CANCER
(	O
n	O
=	O
40	O
)	O
and	O
MCL	B-CANCER
(	O
n	O
=	O
36	O
)	O
received	O
standard	O
CHOP	B-DRUG
every	O
21	O
days	O
(	O
CHOP-21	O
)	O
with	O
R	O
plus	O
bortezomib	B-DRUG
at	O
0.7	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
n	O
=	O
4	O
)	O
","	O
1	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
n	O
=	O
9	O
)	O
","	O
or	O
1.3	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
n	O
=	O
63	O
)	O
on	O
days	O
1	O
and	O
4	O
for	O
six	O
cycles	O
.	O
	
Median	O
age	O
was	O
63	O
years	O
(	O
range	O
","	O
20	O
to	O
87	O
)	O
","	O
and	O
International	O
Prognostic	O
Index	O
(	O
IPI	O
)	O
scores	O
were	O
generally	O
unfavorable	O
(	O
39	O
%	O
with	O
IPI	O
of	O
2	O
","	O
and	O
49	O
%	O
with	O
IPI	O
of	O
3	O
to	O
5	O
)	O
","	O
as	O
were	O
Mantle	B-CANCER
Cell	I-CANCER
Lymphoma	I-CANCER
International	O
Prognostic	O
Index	O
scores	O
in	O
patients	O
with	O
MCL	B-CANCER
(	O
28	O
%	O
intermediate	O
risk	O
and	O
39	O
%	O
high	O
risk	O
)	O
.	O
	
Toxicity	O
was	O
manageable	O
","	O
including	O
neuropathy	B-TOXI
in	O
49	O
subjects	O
(	O
8	O
%	O
grade	O
2	O
and	O
4	O
%	O
grade	O
3	O
)	O
and	O
grade	O
3	O
/	O
4	O
anemia	B-TOXI
(	O
13	O
%	O
)	O
","	O
neutropenia	B-TOXI
(	O
41	O
%	O
)	O
","	O
and	O
thrombocytopenia	B-TOXI
(	O
25	O
%	O
)	O
.	O
	
For	O
DLBCL	B-CANCER
","	O
the	O
evaluable	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
was	O
100	O
%	O
with	O
86	O
%	O
complete	O
response	O
(	O
CR	O
)	O
/	O
CR	O
unconfirmed	O
(	O
CRu	O
;	O
n	O
=	O
35	O
)	O
.	O
	
Intent-to-treat	O
(	O
ITT	O
","	O
n	O
=	O
40	O
)	O
ORR	O
was	O
88	O
%	O
with	O
75	O
%	O
CR	O
/	O
CRu	O
","	O
2-year	O
progression-free	O
survival	O
(	O
PFS	O
)	O
of	O
64	O
%	O
(	O
95	O
%	O
CI	O
","	O
47	O
%	O
to	O
77	O
%	O
)	O
and	O
2-year	O
overall	O
survival	O
(	O
OS	O
)	O
of	O
70	O
%	O
(	O
95	O
%	O
CI	O
","	O
53	O
%	O
to	O
82	O
%	O
)	O
.	O
	
For	O
MCL	B-CANCER
","	O
the	O
evaluable	O
ORR	O
was	O
91	O
%	O
with	O
72	O
%	O
CR	O
/	O
CRu	O
(	O
n	O
=	O
32	O
)	O
.	O
	
The	O
ITT	O
(	O
n	O
=	O
36	O
)	O
ORR	O
was	O
81	O
%	O
with	O
64	O
%	O
CR	O
/	O
CRu	O
","	O
2-year	O
PFS	O
44	O
%	O
(	O
95	O
%	O
CI	O
","	O
27	O
%	O
to	O
60	O
%	O
)	O
and	O
2-year	O
OS	O
86	O
%	O
(	O
95	O
%	O
CI	O
","	O
70	O
%	O
to	O
94	O
%	O
)	O
.	O
	
IPI	O
and	O
MIPI	O
correlated	O
with	O
survival	O
in	O
DLBCL	B-CANCER
and	O
MCL	B-CANCER
","	O
respectively	O
.	O
	
Unlike	O
in	O
DLBCL	B-CANCER
treated	O
with	O
R-CHOP	B-DRUG
alone	O
","	O
nongerminal	O
center	O
B	O
cell	O
(	O
non-GCB	O
)	O
and	O
GCB	O
subtypes	O
had	O
similar	O
outcomes	O
.	O
	
Bortezomib	B-DRUG
with	O
R-CHOP-21	B-DRUG
can	O
be	O
safely	O
administered	O
and	O
may	O
enhance	O
outcomes	O
","	O
particularly	O
in	O
non-GCB	O
DLBCL	B-DRUG
","	O
justifying	O
randomized	O
studies	O
.	O
	
Cetuximab	B-DRUG
in	O
combination	O
with	O
chemoradiotherapy	O
before	O
surgery	O
in	O
patients	O
with	O
resectable	O
","	O
locally	B-CANCER
advanced	I-CANCER
esophageal	I-CANCER
carcinoma	I-CANCER
:	O
a	O
prospective	O
","	O
multicenter	O
phase	O
IB	O
/	O
II	O
Trial	O
(	O
SAKK	O
75	O
/	O
6	O
)	O
.	O
	
	
This	O
multicenter	O
phase	O
IB	O
/	O
II	O
trial	O
investigated	O
cetuximab	B-DRUG
added	O
to	O
preoperative	O
chemoradiotherapy	O
for	O
esophageal	B-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
resectable	O
","	O
locally	O
advanced	B-CANCER
esophageal	I-CANCER
cancer	I-CANCER
received	O
two	O
3-week	O
cycles	O
of	O
induction	O
chemoimmunotherapy	O
(	O
cisplatin	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
day	O
1	O
","	O
docetaxel	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
day	O
1	O
","	O
cetuximab	B-DRUG
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
days	O
1	O
","	O
"8,15"	O
[	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
loading	O
dose	O
]	O
)	O
followed	O
by	O
chemoimmunoradiation	O
therapy	O
(	O
CIRT	O
)	O
and	O
surgery	O
.	O
	
CIRT	O
consisted	O
of	O
45	O
Gy	O
radiotherapy	O
(	O
RT	O
)	O
plus	O
concurrent	O
cisplatin	B-DRUG
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
cetuximab	B-DRUG
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
for	O
5	O
weeks	O
in	O
cohort	O
1	O
If	O
fewer	O
than	O
three	O
of	O
seven	O
patients	O
experienced	O
limiting	O
toxicity	O
(	O
LT	O
)	O
","	O
the	O
next	O
seven	O
patients	O
also	O
received	O
docetaxel	B-DRUG
(	O
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
_	O
5	O
)	O
.	O
	
If	O
fewer	O
than	O
three	O
patients	O
experienced	O
LTs	O
","	O
13	O
additional	O
patients	O
were	O
treated	O
at	O
this	O
dose	O
.	O
	
In	O
total	O
","	O
28	O
patients	O
(	O
median	O
age	O
","	O
64	O
years	O
)	O
with	O
predominantly	O
node-positive	O
(	O
82	O
%	O
)	O
esophageal	B-CANCER
adenocarcinoma	I-CANCER
(	O
15	O
patients	O
)	O
or	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
13	O
patients	O
)	O
were	O
enrolled	O
and	O
24	O
(	O
86	O
%	O
)	O
completed	O
the	O
entire	O
trimodal	O
therapy	O
.	O
	
During	O
CIRT	O
","	O
no	O
LT	O
occurred	O
","	O
rash	O
was	O
not	O
exacerbated	O
within	O
the	O
RT	O
field	O
","	O
and	O
the	O
main	O
grade	O
3	O
toxicities	O
were	O
esophagitis	B-TOXI
(	O
seven	O
patients	O
)	O
","	O
anorexia	B-TOXI
(	O
three	O
)	O
","	O
fatigue	B-TOXI
(	O
three	O
)	O
","	O
and	O
thrombosis	B-TOXI
(	O
two	O
)	O
.	O
	
Surgery	O
(	O
R0	O
resection	O
)	O
was	O
performed	O
in	O
25	O
patients	O
.	O
	
Anastomotic	B-TOXI
leakage	I-TOXI
occurred	O
in	O
three	O
patients	O
:	O
two	O
recovered	O
spontaneously	O
and	O
one	O
successfully	O
underwent	O
re-operation	O
.	O
	
There	O
were	O
no	O
deaths	O
at	O
30	O
days	O
and	O
no	O
treatment-related	O
mortality	O
after	O
12	O
months	O
.	O
	
Nineteen	O
patients	O
(	O
68	O
%	O
)	O
showed	O
complete	O
or	O
near	O
complete	O
pathologic	O
regression	O
.	O
	
Adding	O
cetuximab	B-DRUG
to	O
preoperative	O
chemoradiotherapy	O
is	O
feasible	O
without	O
increasing	O
postoperative	O
mortality	O
.	O
	
Phase	O
III	O
investigation	O
has	O
begun	O
based	O
on	O
the	O
high	O
histopathologic	O
response	O
and	O
R0	O
resection	O
rate	O
.	O
	
Cetuximab	B-DRUG
is	O
associated	O
with	O
excessive	O
toxicity	O
when	O
combined	O
with	O
bevacizumab	B-DRUG
Plus	O
mFOLFOX6	B-DRUG
in	O
metastatic	B-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
.	O
	
	
The	O
bevacizumab-cetuximab	B-DRUG
combination	O
has	O
shown	O
promising	O
activity	O
in	O
chemotherapy-refractory	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
mCRC	B-CANCER
)	O
.	O
	
We	O
sought	O
to	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
cetuximab	O
added	O
to	O
bevacizumab	B-DRUG
plus	O
standard	O
mFOLFOX6	B-DRUG
(	O
modified	O
5-fluorouracil	B-DRUG
[	O
5-FU	B-DRUG
]	O
/	O
leucovorin	B-DRUG
/	O
oxaliplatin	B-DRUG
)	O
as	O
first-line	O
therapy	O
for	O
mCRC	B-CANCER
.	O
	
Sixty-six	O
patients	O
received	O
cetuximab	B-DRUG
(	O
400	O
mg	O
/	O
m2	O
loading	O
dose	O
","	O
then	O
250	O
mg	O
/	O
m2	O
weekly	O
intravenously	O
[	O
I.V.	O
]	O
)	O
plus	O
bevacizumab	B-DRUG
5	O
mg	O
/	O
kg	O
and	O
mFOLFOX6	B-DRUG
chemotherapy	O
every	O
2	O
weeks	O
.	O
	
The	O
primary	O
endpoint	O
was	O
toxicity	O
.	O
	
The	O
most	O
common	O
grade	O
3月4日	O
events	O
included	O
diarrhea	B-TOXI
(	O
14	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
14	O
%	O
)	O
","	O
neuropathy	B-TOXI
(	O
12	O
%	O
)	O
","	O
venous	B-TOXI
thrombosis	I-TOXI
(	O
9	O
%	O
)	O
","	O
acneiform	B-TOXI
rash	I-TOXI
(	O
8	O
%	O
)	O
","	O
and	O
desquamation	B-TOXI
(	O
8	O
%	O
)	O
.	O
	
A	O
protocol-defined	O
prohibitive	O
adverse	O
event	O
occurred	O
in	O
4	O
patients	O
(	O
6	O
%	O
)	O
","	O
including	O
2	O
treatment-associated	B-TOXI
deaths	I-TOXI
.	O
	
Thirty-seven	O
patients	O
(	O
56	O
%	O
)	O
discontinued	O
therapy	O
before	O
disease	O
progression	O
because	O
of	O
either	O
toxicity	O
(	O
n	O
=	O
19	O
;	O
29	O
%	O
)	O
or	O
patient	O
withdrawal	O
(	O
n	O
=	O
18	O
;	O
27	O
%	O
)	O
.	O
	
Twenty-eight	O
of	O
37	O
patients	O
(	O
76	O
%	O
)	O
who	O
discontinued	O
therapy	O
before	O
disease	O
progression	O
did	O
so	O
because	O
of	O
cetuximab-associated	B-DRUG
toxicity	B-TOXI
.	O
	
Although	O
the	O
addition	O
of	O
cetuximab	B-DRUG
to	O
bevacizumab	B-DRUG
plus	O
mFOLFOX6	B-DRUG
was	O
not	O
associated	O
with	O
excessive	O
life-threatening	O
toxicity	O
","	O
many	O
patients	O
discontinued	O
therapy	O
because	O
of	O
cetuximab-associated	B-DRUG
toxicity	B-TOXI
.	O
	
Taken	O
together	O
with	O
the	O
results	O
of	O
recently	O
reported	O
phase	O
III	O
trials	O
","	O
cetuximab	B-DRUG
should	O
not	O
be	O
used	O
concurrently	O
with	O
bevacizumab	B-DRUG
and	O
infusional	O
5-FU	B-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
oxaliplatin	B-DRUG
chemotherapy	O
for	O
the	O
treatment	O
of	O
mCRC	B-CANCER
.	O
	
Phase	O
I	O
trial	O
of	O
oxaliplatin	B-DRUG
","	O
infusional	O
5-fluorouracil	B-DRUG
","	O
and	O
leucovorin	B-DRUG
(	O
FOLFOX4	B-DRUG
)	O
with	O
erlotinib	B-DRUG
and	O
bevacizumab	B-DRUG
in	O
colorectal	B-CANCER
cancer	I-CANCER
.	O
	
	
This	O
phase	O
I	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
erlotinib	B-DRUG
","	O
an	O
oral	O
epidermal	O
growth	O
factor	O
receptor	O
tyrosine	O
kinase	O
inhibitor	O
","	O
with	O
5-fluorouracil	B-DRUG
/	O
leucovorin	B-DRUG
/	O
oxaliplatin	B-DRUG
(	O
FOLFOX4	B-DRUG
)	O
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
CRC	B-CANCER
)	O
.	O
	
Bevacizumab	B-DRUG
was	O
later	O
included	O
as	O
standard	O
of	O
care	O
at	O
the	O
MTD	O
.	O
	
Patients	O
received	O
FOLFOX4	B-DRUG
with	O
escalating	O
doses	O
of	O
erlotinib	B-DRUG
:	O
dose	O
level	O
(	O
DL	O
)	O
1	O
","	O
50	O
mg	O
;	O
DL	O
2	O
","	O
100	O
mg	O
;	O
and	O
DL	O
3	O
","	O
150	O
mg	O
once	O
daily	O
continuously	O
.	O
	
Bevacizumab	B-DRUG
5	O
mg	O
/	O
kg	O
days	O
1	O
and	O
15	O
was	O
added	O
at	O
the	O
MTD	O
upon	O
Food	O
and	O
Drug	O
Administration	O
approval	O
.	O
	
Correlative	O
studies	O
included	O
pharmacokinetics	O
","	O
pharmacodynamics	O
was	O
assessed	O
in	O
paired	O
skin	O
biopsies	O
","	O
and	O
fluorodeoxyglucose	O
positron	O
emission	O
tomography	O
scans	O
.	O
	
Fifteen	O
patients	O
received	O
60	O
cycles	O
(	O
120	O
FOLFOX	B-DRUG
treatments	O
)	O
.	O
	
Two	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
were	O
seen	O
at	O
DL	O
3	O
:	O
intolerable	O
grade	O
2	O
rash	B-TOXI
(	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
version	O
2	O
)	O
lasting	O
&	O
gt	O
;	O
1	O
week	O
","	O
and	O
grade	O
4	O
neutropenia	B-TOXI
.	O
	
Dose	O
level	O
2	O
was	O
expanded	O
to	O
6	O
more	O
patients	O
","	O
this	O
time	O
adding	O
bevacizumab	B-DRUG
","	O
and	O
1	O
DLT	O
of	O
grade	O
3	O
mucositis	B-TOXI
occurred	O
.	O
	
As	O
expected	O
","	O
the	O
primary	O
toxicities	O
were	O
cytopenias	B-TOXI
","	O
diarrhea	B-TOXI
","	O
rash	B-TOXI
","	O
and	O
fatigue	B-TOXI
.	O
	
There	O
were	O
2	O
occurrences	O
of	O
pneumatosis	B-TOXI
.	O
	
One	O
patient	O
experienced	O
an	O
unrelated	O
grade	O
4	O
myocardial	B-TOXI
infarction	I-TOXI
before	O
starting	O
chemotherapy	O
.	O
	
No	O
pharmacokinetic	O
drug	O
interactions	O
were	O
observed	O
.	O
	
The	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	O
Tumors	O
response	O
rate	O
was	O
11	O
of	O
14	O
(	O
78	O
%	O
)	O
","	O
median	O
progression-free	O
survival	O
was	O
9.5	O
months	O
","	O
and	O
median	O
overall	O
survival	O
was	O
30	O
months	O
.	O
	
Three	O
patients	O
are	O
currently	O
alive	O
&	O
gt	O
;	O
3	O
years	O
","	O
with	O
1	O
having	O
no	O
evidence	O
of	O
disease	O
.	O
	
The	O
MTD	O
of	O
erlotinib	B-DRUG
with	O
FOLFOX4	B-DRUG
with	O
or	O
without	O
bevacizumab	B-DRUG
is	O
100	O
mg	O
daily	O
.	O
	
The	O
regimen	O
appeared	O
to	O
increase	O
toxicity	O
but	O
showed	O
activity	O
in	O
patients	O
with	O
CRC	B-CANCER
.	O
	
Exploratory	O
study	O
of	O
hepatic	O
arterial	O
infusion	O
oxaliplatin	B-DRUG
with	O
systemic	O
5-fluorouracil	B-DRUG
/	O
bevacizumab	B-DRUG
in	O
patients	O
with	O
refractory	O
solid	B-CANCER
tumor	I-CANCER
and	O
extensive	O
liver	O
metastases	O
.	O
	
	
This	O
pilot	O
clinical	O
trial	O
explored	O
the	O
feasibility	O
","	O
safety	O
","	O
and	O
efficacy	O
of	O
regional	O
hepatic	O
therapy	O
combined	O
with	O
systemic	O
anticancer	O
agents	O
in	O
patients	O
with	O
refractory	O
solid	B-CANCER
tumors	I-CANCER
and	O
extensive	O
unresectable	O
liver	O
involvement	O
","	O
including	O
those	O
with	O
compromised	B-TOXI
hepatic	I-TOXI
function	I-TOXI
.	O
	
Six	O
patients	O
with	O
colorectal	O
(	O
N	O
=	O
3	O
)	O
","	O
ovarian	O
(	O
N	O
=	O
2	O
)	O
","	O
and	O
hepatocellular	B-CANCER
carcinoma	I-CANCER
(	O
N	O
=	O
1	O
)	O
received	O
intra-arterial	B-DRUG
hepatic	I-DRUG
oxaliplatin	I-DRUG
followed	O
by	O
intravenous	B-DRUG
5-fluorouracil	I-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
bevacizumab	B-DRUG
every	O
2	O
weeks	O
until	O
disease	O
progression	O
.	O
	
All	O
had	O
extensive	O
liver	B-TOXI
metastases	I-TOXI
;	O
four	O
had	O
elevated	B-TOXI
baseline	I-TOXI
serum	I-TOXI
total	I-TOXI
bilirubin	I-TOXI
.	O
	
Median	O
total	O
bilirubin	O
was	O
2.8	O
mg	O
/	O
dL	O
(	O
range	O
","	O
0.2-5.2	O
mg	O
/	O
dL	O
)	O
.	O
	
Median	O
Child-Pugh	O
score	O
was	O
7	O
(	O
range	O
","	O
5月10日	O
)	O
.	O
	
Thirty	O
treatments	O
were	O
delivered	O
(	O
2月7日	O
per	O
patient	O
)	O
.	O
	
Median	O
age	O
of	O
patients	O
was	O
57	O
years	O
(	O
range	O
","	O
25-69	O
years	O
)	O
.	O
	
Three	O
patients	O
(	O
1	O
with	O
colorectal	O
","	O
1	O
with	O
hepatocellular	O
","	O
and	O
1	O
with	O
ovarian	B-CANCER
cancer	I-CANCER
)	O
attained	O
partial	O
responses	O
.	O
	
Two	O
had	O
failed	O
previous	O
oxaliplatin	B-DRUG
and	O
cisplatin	B-DRUG
treatment	O
.	O
	
Some	O
with	O
elevated	B-TOXI
bilirubin	I-TOXI
at	O
baseline	O
had	O
a	O
significant	O
drop	B-TOXI
in	I-TOXI
bilirubin	I-TOXI
with	O
treatment	O
(	O
bilirubin	O
5.2	O
_	O
1	O
mg	O
/	O
dL	O
","	O
4.8	O
_	O
1.1	O
mg	O
/	O
dL	O
","	O
and	O
5.2	O
_	O
1.8	O
mg	O
/	O
dL	O
)	O
.	O
	
The	O
regimen	O
was	O
generally	O
well	O
tolerated	O
;	O
the	O
most	O
common	O
side	O
effects	O
were	O
grade	O
1	O
fatigue	B-TOXI
","	O
anorexia	B-TOXI
","	O
and	O
/	O
or	O
hypertension	B-TOXI
.	O
	
One	O
patient	O
died	B-TOXI
of	I-TOXI
enzyme-linked	I-TOXI
","	O
immunoassay-confirmed	O
","	O
heparin-induced	B-TOXI
thrombocytopenia	I-TOXI
during	O
the	O
sixth	O
cycle	O
of	O
therapy	O
.	O
	
At	O
doses	O
tested	O
","	O
this	O
regimen	O
was	O
safe	O
and	O
demonstrated	O
antitumor	O
activity	O
in	O
patients	O
with	O
advanced	B-CANCER
refractory	I-CANCER
malignancies	I-CANCER
involving	O
the	O
liver	O
","	O
including	O
those	O
with	O
hepatic	B-TOXI
insufficiency	I-TOXI
.	O
	
Further	O
study	O
is	O
warranted	O
.	O
	
A	O
phase	O
I	O
study	O
with	O
an	O
expanded	O
cohort	O
to	O
assess	O
the	O
feasibility	O
of	O
intraperitoneal	O
carboplatin	B-DRUG
and	O
intravenous	B-DRUG
paclitaxel	I-DRUG
in	O
untreated	O
ovarian	O
","	O
fallopian	O
tube	O
","	O
and	O
primary	O
peritoneal	B-CANCER
carcinoma	I-CANCER
:	O
A	O
Gynecologic	O
Oncology	O
Group	O
study	O
.	O
	
	
This	O
study	O
aimed	O
to	O
determine	O
the	O
first-cycle	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
intraperitoneal	O
carboplatin	B-DRUG
in	O
combination	O
with	O
intravenous	B-DRUG
paclitaxel	I-DRUG
and	O
then	O
assess	O
the	O
feasibility	O
of	O
this	O
dose	O
over	O
multiple	O
cycles	O
.	O
	
Beginning	O
at	O
an	O
intraperitoneal	O
(	O
IP	O
)	O
carboplatin	B-DRUG
dose	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
of	O
5	O
and	O
a	O
fixed	O
intravenous	O
dose	O
of	O
175mg	O
/	O
m	O
(	O
2	O
)	O
paclitaxel	B-DRUG
","	O
patients	O
were	O
entered	O
on	O
a	O
dose-escalating	O
phase	O
evaluating	O
first-cycle	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
.	O
	
After	O
estimating	O
the	O
MTD	O
","	O
cohorts	O
of	O
20	O
patients	O
were	O
then	O
entered	O
in	O
an	O
expanded	O
phase	O
to	O
evaluate	O
DLT	O
over	O
four	O
cycles	O
.	O
	
Twenty-one	O
patients	O
were	O
entered	O
on	O
the	O
dose-escalating	O
phase	O
.	O
	
A	O
first-cycle	O
MTD	O
of	O
carboplatin	B-DRUG
at	O
AUC	O
8	O
was	O
tolerated	O
although	O
thrombocytopenia	B-TOXI
was	O
dose-limiting	O
over	O
multiple	O
cycles	O
.	O
	
An	O
additional	O
69	O
patients	O
were	O
treated	O
in	O
expanded	O
cohorts	O
.	O
	
Only	O
5	O
/	O
90	O
(	O
5.6	O
%	O
)	O
patients	O
discontinued	O
treatment	O
because	O
of	O
a	O
port	O
problem	O
.	O
	
Four-cycle	O
DLT	O
required	O
de-escalation	O
to	O
a	O
carboplatin	B-DRUG
AUC	O
of	O
6	O
","	O
and	O
even	O
at	O
that	O
dose	O
","	O
there	O
were	O
14	O
dose-limiting	O
toxic	O
effects	O
in	O
40	O
patients	O
(	O
35	O
%	O
)	O
.	O
	
Seven	O
dose-limiting	O
toxicities	O
were	O
due	O
to	O
neutropenia	B-TOXI
","	O
and	O
6	O
were	O
due	O
to	O
grade	O
3	O
/	O
4	O
thrombocytopenia	B-TOXI
.	O
	
Six	O
cycles	O
of	O
therapy	O
were	O
completed	O
in	O
75	O
%	O
of	O
eligible	O
patients	O
","	O
but	O
dose	O
adjustments	O
were	O
required	O
.	O
	
The	O
first-cycle	O
MTD	O
did	O
not	O
predict	O
the	O
tolerability	O
of	O
this	O
regimen	O
over	O
multiple	O
cycles	O
.	O
	
Using	O
an	O
IP	O
carboplatin	B-DRUG
dose	O
of	O
AUC	O
6	O
in	O
combination	O
with	O
paclitaxel	B-DRUG
","	O
the	O
regimen	O
can	O
be	O
administered	O
with	O
a	O
high	O
completion	O
rate	O
over	O
multiple	O
cycles	O
.	O
	
Because	O
neutropenia	B-TOXI
is	O
a	O
frequent	O
DLT	O
","	O
the	O
addition	O
of	O
hematopoietic	O
growth	O
factors	O
may	O
permit	O
a	O
high	O
completion	O
rate	O
while	O
maintaining	O
this	O
dose	O
.	O
	
FCR	B-DRUG
(	O
Fludarabine	B-DRUG
","	O
Cyclophosphamide	B-DRUG
","	O
Rituximab	B-DRUG
)	O
regimen	O
followed	O
by	O
90Yttrium	O
ibritumomab	B-DRUG
tiuxetan	I-DRUG
consolidation	O
for	O
the	O
treatment	O
of	O
relapsed	O
grades	O
1	O
and	O
2	O
follicular	B-CANCER
lymphoma	I-CANCER
:	O
a	O
report	O
of	O
9	O
cases	O
.	O
	
	
This	O
retrospective	O
analysis	O
is	O
focused	O
on	O
the	O
efficacy	O
and	O
safety	O
of	O
radioimmunotherapy	O
(	O
RIT	O
)	O
with	O
Zevalin庐	O
in	O
nine	O
patients	O
with	O
recurrent	B-CANCER
follicular	I-CANCER
lymphoma	I-CANCER
(	O
FL	B-CANCER
)	O
who	O
were	O
treated	O
in	O
a	O
consolidation	O
setting	O
after	O
having	O
achieved	O
complete	O
remission	O
or	O
partial	O
remission	O
with	O
FCR	B-DRUG
.	O
	
The	O
median	O
age	O
was	O
63	O
yrs	O
(	O
range	O
46-77	O
)	O
","	O
all	O
patients	O
were	O
relapsed	O
with	O
histologically	O
confirmed	O
CD20-positive	O
(	O
grade	O
1	O
or	O
2	O
)	O
FL	O
","	O
at	O
relapse	O
they	O
received	O
FCR	B-DRUG
every	O
28	O
days	O
:	O
F	O
(	O
25	O
mg	O
/	O
m2x	O
3	O
days	O
)	O
","	O
C	O
(	O
1	O
gr	O
/	O
m2	O
day	O
1	O
)	O
and	O
R	O
(	O
375	O
mg	O
/	O
m2	O
day	O
4	O
)	O
for	O
4	O
cycles	O
.	O
	
Who	O
achieved	O
at	O
least	O
a	O
partial	O
remission	O
","	O
with	O
&	O
lt	O
;	O
25	O
%	O
bone	O
marrow	O
involvement	O
","	O
was	O
treated	O
with	O
90Yttrium	O
Ibritumomab	B-DRUG
Tiuxetan	I-DRUG
11.1	O
or	O
14.8	O
MBq	O
/	O
Kg	O
up	O
to	O
a	O
maximum	O
dose	O
1184	O
MBq	O
","	O
at	O
3	O
months	O
after	O
the	O
completion	O
of	O
FCR	B-DRUG
.	O
	
The	O
patients	O
underwent	O
a	O
further	O
restaging	O
at	O
12	O
weeks	O
after	O
90Y-RIT	O
with	O
total	O
body	O
CT	O
scan	O
","	O
FDG-PET	O
/	O
CT	O
and	O
bilateral	O
bone	O
marrow	O
biopsy	O
.	O
	
Nine	O
patients	O
have	O
completed	O
the	O
treatment	O
:	O
FCR	B-DRUG
followed	O
by	O
90Y-RIT	O
(	O
6	O
patients	O
at	O
14.8	O
MBq	O
/	O
Kg	O
","	O
3	O
patients	O
at	O
11.1	O
MBq	O
/	O
Kg	O
)	O
.	O
	
After	O
FCR	B-DRUG
7	O
patients	O
obtained	O
CR	O
and	O
2	O
PR	O
;	O
after	O
90Y-RIT	O
two	O
patients	O
in	O
PR	O
converted	O
to	O
CR	O
12	O
weeks	O
later	O
.	O
	
With	O
median	O
follow	O
up	O
of	O
34	O
months	O
(	O
range	O
13-50	O
)	O
the	O
current	O
analysis	O
has	O
shown	O
that	O
overall	O
survival	O
(	O
OS	O
)	O
is	O
89	O
%	O
at	O
2	O
years	O
","	O
76	O
%	O
at	O
3	O
years	O
and	O
61	O
%	O
at	O
4	O
years	O
.	O
	
The	O
most	O
common	O
grade	O
3	O
or	O
4	O
adverse	O
events	O
were	O
hematologic	B-TOXI
","	O
one	O
patient	O
developed	O
herpes	B-TOXI
zoster	I-TOXI
infection	I-TOXI
after	O
8	O
months	O
following	O
valacyclovir	B-DRUG
discontinuation	O
;	O
another	O
patient	O
developed	O
fungal	B-TOXI
infection	I-TOXI
.	O
	
Our	O
experience	O
indicate	O
feasibility	O
","	O
tolerability	O
and	O
efficacy	O
of	O
FCR	B-DRUG
regimen	O
followed	O
by	O
90Y-RIT	O
in	O
patients	O
relapsed	O
with	O
grades	O
1	O
and	O
2	O
FL	O
with	O
no	O
unexpected	O
toxicities	O
.	O
	
A	O
longer	O
follow	O
up	O
and	O
a	O
larger	O
number	O
of	O
patients	O
with	O
relapsed	O
grades	O
1	O
and	O
2	O
FL	B-CANCER
are	O
required	O
to	O
determine	O
the	O
impact	O
of	O
this	O
regimen	O
on	O
long-term	O
duration	O
of	O
response	O
and	O
PFS	O
.	O
	
Phase	O
II	O
study	O
of	O
cisplatin	B-DRUG
plus	O
cetuximab	B-DRUG
in	O
advanced	O
","	O
recurrent	O
","	O
and	O
previously	O
treated	O
cancers	B-CANCER
of	I-CANCER
the	I-CANCER
cervix	I-CANCER
and	O
evaluation	O
of	O
epidermal	O
growth	O
factor	O
receptor	O
immunohistochemical	O
expression	O
:	O
a	O
Gynecologic	O
Oncology	O
Group	O
study	O
.	O
	
	
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
cetuximab	B-DRUG
(	O
C225	O
)	O
","	O
an	O
antibody	O
that	O
inhibits	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
activity	O
","	O
with	O
cisplatin	B-DRUG
and	O
to	O
explore	O
associations	O
between	O
EGFR	O
protein	O
expression	O
with	O
patient	O
demographics	O
or	O
clinical	O
outcome	O
.	O
	
Women	O
with	O
advanced	O
","	O
persistent	O
","	O
or	O
recurrent	O
carcinoma	B-CANCER
of	I-CANCER
the	I-CANCER
cervix	I-CANCER
were	O
eligible	O
.	O
	
The	O
women	O
received	O
cisplatin	B-DRUG
at	O
30mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
and	O
8	O
with	O
a	O
loading	O
dose	O
of	O
cetuximab	B-DRUG
at	O
400mg	O
/	O
m	O
(	O
2	O
)	O
followed	O
by	O
250mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
in	O
a	O
21day	O
cycle	O
.	O
	
Adverse	O
events	O
were	O
assessed	O
with	O
CTCAE	O
v	O
3.0.	O
Primary	O
measure	O
of	O
efficacy	O
was	O
tumor	O
response	O
by	O
RECIST	O
.	O
	
The	O
study	O
was	O
stratified	O
by	O
prior	O
chemotherapy	O
(	O
CT	O
)	O
.	O
	
EGFR	O
protein	O
expression	O
in	O
pre-treatment	O
tumor	O
was	O
analyzed	O
by	O
immunohistochemistry	O
.	O
	
Between	O
September	O
2004	O
and	O
March	O
2008	O
","	O
76	O
patients	O
were	O
enrolled	O
.	O
	
Of	O
these	O
","	O
69	O
were	O
eligible	O
and	O
evaluable	O
;	O
44	O
(	O
64	O
%	O
)	O
received	O
prior	O
chemotherapy	O
.	O
	
There	O
were	O
4	O
responses	O
in	O
each	O
group	O
","	O
prior	O
chemotherapy	O
and	O
no	O
chemotherapy	O
","	O
9	O
%	O
and	O
16	O
%	O
","	O
respectively	O
.	O
	
Grade	O
4	O
toxicities	O
included	O
anemia	B-TOXI
(	O
1	O
)	O
","	O
allergy	B-TOXI
(	O
1	O
)	O
","	O
metabolic	B-TOXI
(	O
1	O
)	O
","	O
and	O
vascular	B-TOXI
(	O
1	O
)	O
.	O
	
The	O
most	O
common	O
grade	O
3	O
toxicities	O
were	O
metabolic	B-TOXI
(	O
15	O
)	O
","	O
dermatologic	B-TOXI
(	O
8	O
)	O
","	O
fatigue	B-TOXI
(	O
6	O
)	O
","	O
and	O
gastrointestinal	B-TOXI
(	O
6	O
)	O
.	O
	
EGFR	O
protein	O
was	O
expressed	O
in	O
47	O
/	O
48	O
(	O
98	O
%	O
)	O
of	O
tumors	O
analyzed	O
with	O
a	O
median	O
cellular	O
expression	O
of	O
81	O
%	O
.	O
	
Exploratory	O
analyses	O
revealed	O
a	O
trend	O
between	O
the	O
percentage	O
of	O
cells	O
expressing	O
EGFR	O
protein	O
and	O
PFS	O
(	O
hazard	O
ratio=1.76	O
","	O
95	O
%	O
confidence	O
interval=0.96-3.21	O
)	O
.	O
	
The	O
combination	O
of	O
cetuximab	B-DRUG
with	O
cisplatin	B-DRUG
was	O
adequately	O
tolerated	O
but	O
did	O
not	O
indicate	O
additional	O
benefit	O
beyond	O
cisplatin	B-DRUG
therapy	O
.	O
	
Phase	O
II	O
evaluation	O
of	O
early	O
oral	B-DRUG
estramustine	I-DRUG
","	O
oral	B-DRUG
etoposide	I-DRUG
","	O
and	O
intravenous	B-DRUG
paclitaxel	I-DRUG
combined	O
with	O
hormonal	O
therapy	O
in	O
patients	O
with	O
high-risk	O
metastatic	B-CANCER
prostate	I-CANCER
adenocarcinoma	I-CANCER
:	O
Southwest	O
Oncology	O
Group	O
S0032	O
.	O
	
	
To	O
assess	O
the	O
efficacy	O
of	O
a	O
multiagent	O
taxane-based	B-DRUG
chemotherapy	O
combined	O
with	O
hormonal	O
therapy	O
in	O
men	O
with	O
metastatic	O
androgen-dependent	O
prostate	B-CANCER
cancer	I-CANCER
in	O
a	O
multicenter	O
","	O
cooperative	O
group	O
","	O
single-arm	O
trial	O
.	O
	
A	O
total	O
of	O
41	O
patients	O
with	O
newly	O
diagnosed	O
metastatic	B-CANCER
prostate	I-CANCER
cancer	I-CANCER
involving	O
both	O
the	O
axial	O
and	O
the	O
appendicular	O
skeletons	O
or	O
viscera	O
were	O
enrolled	O
.	O
	
Of	O
the	O
41	O
patients	O
","	O
35	O
were	O
treated	O
with	O
combined	O
androgen	O
blockade	O
and	O
_4	O
cycles	O
of	O
oral	B-DRUG
estramustine	I-DRUG
(	O
280	O
mg	O
orally	O
3	O
times	O
daily	O
)	O
and	O
etoposide	B-DRUG
(	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
daily	O
)	O
for	O
14	O
days	O
of	O
each	O
21-day	O
cycle	O
","	O
with	O
paclitaxel	B-DRUG
(	O
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
within	O
1	O
hour	O
)	O
on	O
day	O
2	O
of	O
each	O
cycle	O
.	O
	
Chemotherapy	O
was	O
started	O
within	O
30	O
days	O
of	O
the	O
initiation	O
of	O
hormonal	O
therapy	O
.	O
	
The	O
patients	O
were	O
followed	O
up	O
to	O
determine	O
the	O
progression-free	O
survival	O
.	O
	
The	O
35	O
patients	O
received	O
a	O
total	O
of	O
126	O
cycles	O
of	O
chemotherapy	O
","	O
with	O
30	O
receiving	O
all	O
4	O
cycles	O
.	O
	
The	O
median	O
progression-free	O
survival	O
for	O
the	O
evaluable	O
population	O
was	O
13	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
10月16日	O
)	O
","	O
with	O
a	O
median	O
overall	O
survival	O
of	O
38	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
28-49	O
)	O
.	O
	
The	O
main	O
toxicities	O
were	O
myelosuppression	B-TOXI
","	O
with	O
9	O
patients	O
experiencing	O
grade	O
3	O
or	O
greater	O
neutropenia	B-TOXI
and	O
1	O
developing	O
grade	O
4	O
thrombocytopenia	B-TOXI
.	O
	
One	O
patient	O
died	B-TOXI
of	I-TOXI
neutropenic	I-TOXI
infection	I-TOXI
.	O
	
Thrombosis	B-TOXI
embolism	I-TOXI
occurred	O
4	O
times	O
(	O
3	O
of	O
grade	O
4	O
and	O
1	O
of	O
grade	O
3	O
)	O
","	O
with	O
1	O
episode	O
of	O
grade	O
4	O
cardiac	B-TOXI
ischemia	I-TOXI
.	O
	
The	O
results	O
of	O
our	O
study	O
have	O
shown	O
that	O
the	O
administration	O
of	O
chemotherapy	O
to	O
this	O
population	O
is	O
feasible	O
","	O
with	O
moderate	B-TOXI
toxicity	I-TOXI
.	O
	
Taxane-based	B-DRUG
chemotherapy	O
did	O
not	O
demonstrate	O
significant	O
efficacy	O
in	O
this	O
high-risk	O
population	O
of	O
patients	O
with	O
a	O
poor	B-TOXI
prognosis	I-TOXI
.	O
	
A	O
multicentre	O
dose-escalating	O
study	O
of	O
cabazitaxel	B-DRUG
(	O
XRP6258	O
)	O
in	O
combination	O
with	O
capecitabine	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
progressing	O
after	O
anthracycline	B-DRUG
and	O
taxane	B-DRUG
treatment	O
:	O
a	O
phase	O
I	O
/	O
II	O
study	O
.	O
	
	
Most	O
patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
MBC	B-CANCER
)	O
progress	O
after	O
chemotherapy	O
.	O
	
Cabazitaxel	B-DRUG
(	O
XRP6258	O
)	O
is	O
a	O
new	O
taxoid	B-DRUG
that	O
is	O
active	O
in	O
chemotherapy-resistant	O
tumour	O
cell	O
lines	O
.	O
	
The	O
objectives	O
of	O
this	O
phase	O
I	O
/	O
II	O
study	O
were	O
to	O
assess	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
safety	O
profile	O
","	O
pharmacokinetics	O
","	O
and	O
activity	O
of	O
cabazitaxel	B-DRUG
plus	O
capecitabine	B-DRUG
in	O
patients	O
with	O
MBC	B-CANCER
who	O
had	O
been	O
previously	O
treated	O
with	O
taxanes	B-DRUG
and	O
anthracyclines	B-DRUG
.	O
	
In	O
part	O
I	O
","	O
we	O
used	O
a	O
3+3	O
dose-escalation	O
scheme	O
to	O
assess	O
the	O
MTD	O
of	O
intravenous	B-DRUG
cabazitaxel	I-DRUG
(	O
day	O
1	O
)	O
with	O
oral	B-DRUG
capecitabine	I-DRUG
twice	O
daily	O
(	O
days	O
1月14日	O
)	O
every	O
3	O
weeks	O
.	O
	
In	O
part	O
II	O
","	O
we	O
evaluated	O
the	O
objective	O
response	O
rate	O
(	O
ORR	O
)	O
at	O
the	O
MTD	O
.	O
	
Thirty-three	O
patients	O
were	O
enrolled	O
and	O
treated	O
(	O
15	O
in	O
part	O
I	O
;	O
18	O
in	O
part	O
II	O
)	O
.	O
	
Cabazitaxel	B-DRUG
20mg	O
/	O
m	O
(	O
2	O
)	O
plus	O
capecitabine	B-DRUG
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
was	O
the	O
MTD	O
.	O
	
Pharmacokinetic	O
analysis	O
showed	O
no	O
apparent	O
drug-drug	O
interaction	O
.	O
	
In	O
all	O
patients	O
","	O
the	O
main	O
grade	O
3月4日	O
toxicities	O
were	O
asthenia	B-TOXI
(	O
n=5	O
)	O
","	O
hand-foot	B-TOXI
syndrome	I-TOXI
(	O
n=5	O
)	O
","	O
neutropenia	B-TOXI
(	O
n=21	O
)	O
","	O
neutropenic	B-TOXI
infection	I-TOXI
(	O
n=1	O
)	O
","	O
and	O
neutropenic	B-TOXI
colitis	I-TOXI
(	O
n=1	O
)	O
.	O
	
One	O
patient	O
had	O
febrile	B-TOXI
neutropenia	I-TOXI
.	O
	
Antitumour	O
activity	O
was	O
observed	O
at	O
all	O
dose-levels	O
with	O
two	O
complete	O
responses	O
","	O
five	O
partial	O
responses	O
(	O
PRs	O
)	O
","	O
and	O
20	O
disease	O
stabilisations	O
(	O
seven	O
unconfirmed	O
PR	O
)	O
.	O
	
At	O
the	O
MTD	O
","	O
21	O
patients	O
were	O
evaluable	O
for	O
efficacy	O
.	O
	
The	O
ORR	O
was	O
23.8	O
%	O
(	O
95	O
%	O
CI	O
:	O
8.2-47.2	O
%	O
)	O
.	O
	
The	O
median	O
response	O
duration	O
was	O
3.1	O
months	O
(	O
95	O
%	O
CI	O
:	O
2.1-8.4	O
months	O
)	O
","	O
with	O
four	O
of	O
five	O
lasting	O
for	O
more	O
than	O
3	O
months	O
.	O
	
Median	O
time	O
to	O
progression	O
was	O
4.9	O
months	O
.	O
	
Cabazitaxel	B-DRUG
combined	O
with	O
capecitabine	B-DRUG
is	O
active	O
","	O
has	O
a	O
safety	O
profile	O
consistent	O
with	O
a	O
taxane	B-DRUG
plus	O
capecitabine	B-DRUG
combination	O
and	O
warrants	O
further	O
investigation	O
in	O
patients	O
with	O
MBC	B-CANCER
.	O
	
Chemotherapy	O
versus	O
tamoxifen	B-DRUG
versus	O
chemotherapy	O
plus	O
tamoxifen	B-DRUG
in	O
node-positive	O
","	O
oestrogen	B-DRUG
receptor-positive	O
breast	B-CANCER
cancer	I-CANCER
patients.	O
Very	O
late	O
results	O
of	O
the	O
'gruppo	O
di	O
ricerca	O
per	O
la	O
chemio-ormonoterapia	O
adiuvante	O
(	O
GROCTA	O
)	O
'	O
01-Trial	O
in	O
early	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
	
First	O
","	O
to	O
evaluate	O
whether	O
the	O
benefits	O
of	O
combined	O
chemotherapy	O
(	O
CT	O
)	O
and	O
Tamoxifen	B-DRUG
(	O
T	O
)	O
","	O
previously	O
documented	O
in	O
the	O
GROCTA-01	O
Trial	O
","	O
were	O
long-lasting	O
and	O
","	O
second	O
","	O
to	O
show	O
whether	O
ER	O
or	O
PgR	O
levels	O
could	O
allow	O
the	O
identification	O
of	O
the	O
patients	O
who	O
could	O
benefit	O
from	O
T	O
alone	O
.	O
	
504	O
node-positive	O
","	O
ER-positive	O
","	O
women	O
were	O
randomly	O
assigned	O
to	O
ten	O
CT	O
courses	O
or	O
to	O
5	O
years	O
of	O
T	O
or	O
to	O
the	O
combination	O
of	O
the	O
two	O
(	O
CTT	O
)	O
.	O
	
Disease-free	O
(	O
DFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
were	O
the	O
primary	O
trial-endpoints	O
.	O
	
DFS	O
data	O
were	O
updated	O
in	O
75	O
%	O
of	O
the	O
patients	O
and	O
S	O
data	O
in	O
95	O
%	O
of	O
them	O
.	O
	
Cox	O
regression	O
models	O
were	O
used	O
to	O
check	O
for	O
prognostic	O
features	O
to	O
estimate	O
hazard	O
ratios	O
for	O
treatment	O
comparisons	O
and	O
to	O
test	O
for	O
possible	O
interaction	O
between	O
variables	O
and	O
treatment	O
effects	O
.	O
	
Interactions	O
between	O
treatments	O
and	O
ER	O
or	O
PgR	O
median	O
levels	O
were	O
studied	O
with	O
the	O
sub-population	O
treatment	O
effect	O
pattern	O
plot	O
(	O
STEPP	O
)	O
methodology	O
.	O
	
After	O
a	O
median	O
follow-up	O
time	O
of	O
21	O
years	O
","	O
the	O
DFS	O
and	O
OS	O
benefits	O
","	O
previously	O
favouring	O
T	O
over	O
CT	O
","	O
continued	O
to	O
be	O
observed	O
","	O
even	O
though	O
they	O
were	O
more	O
evident	O
in	O
the	O
first	O
6月7日	O
years	O
.	O
	
The	O
CTT	O
advantages	O
of	O
DFS	O
and	O
OS	O
over	O
T	O
alone	O
were	O
also	O
confirmed	O
.	O
	
However	O
","	O
the	O
additional	O
benefit	O
was	O
limited	O
to	O
the	O
first	O
10月12日	O
years	O
as	O
S	O
curves	O
crossed	O
over	O
afterwards	O
.	O
	
After	O
STEPP	O
analysis	O
","	O
neither	O
ER	O
nor	O
PgR	O
concentrations	O
fully	O
discriminated	O
the	O
patients	O
who	O
could	O
benefit	O
from	O
T	O
alone	O
.	O
	
Even	O
after	O
such	O
a	O
long	O
follow-up	O
time	O
","	O
we	O
have	O
demonstrated	O
that	O
T	O
is	O
an	O
effective	O
alternative	O
to	O
CT	O
for	O
node-positive	O
","	O
ER-positive	O
","	O
breast	B-CANCER
cancer	I-CANCER
patients	O
","	O
regardless	O
of	O
their	O
actual	O
menopausal	O
status	O
","	O
and	O
that	O
the	O
additional	O
benefit	O
","	O
especially	O
on	O
late	O
survival	O
","	O
provided	O
by	O
the	O
addition	O
of	O
CT	O
to	O
this	O
anti-oestrogen	B-DRUG
","	O
was	O
minimal	O
.	O
	
A	O
phase	O
1	O
study	O
of	O
everolimus	B-DRUG
and	O
sorafenib	B-DRUG
for	O
metastatic	B-CANCER
clear	I-CANCER
cell	I-CANCER
renal	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
	
The	O
current	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
safety	O
","	O
pharmacokinetics	O
","	O
and	O
preliminary	O
antitumor	O
effect	O
of	O
everolimus	B-DRUG
","	O
a	O
mammalian	O
target	O
of	O
rapamycin	O
inhibitor	O
","	O
in	O
combination	O
with	O
sorafenib	B-DRUG
","	O
a	O
tyrosine	O
kinase	O
inhibitor	O
","	O
in	O
patients	O
with	O
metastatic	B-CANCER
clear	I-CANCER
cell	I-CANCER
renal	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
Sequential	O
cohorts	O
of	O
patients	O
received	O
escalating	O
doses	O
of	O
everolimus	B-DRUG
and	O
sorafenib	B-DRUG
in	O
28-day	O
cycles	O
in	O
the	O
absence	O
of	O
a	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
or	O
disease	O
progression	O
were	O
examined	O
.	O
	
Twenty	O
patients	O
with	O
a	O
median	O
age	O
of	O
65	O
years	O
received	O
therapy	O
in	O
3	O
cohorts	O
.	O
	
Dose	O
level	O
1	O
was	O
comprised	O
of	O
everolimus	B-DRUG
at	O
a	O
dose	O
of	O
2.5	O
mg	O
daily	O
and	O
sorafenib	B-DRUG
at	O
a	O
dose	O
of	O
400	O
mg	O
twice	O
daily	O
(	O
6	O
patients	O
)	O
","	O
dose	O
level	O
2	O
was	O
comprised	O
of	O
everolimus	B-DRUG
at	O
a	O
dose	O
of	O
5	O
mg	O
daily	O
and	O
sorafenib	B-DRUG
at	O
a	O
dose	O
of	O
400	O
mg	O
twice	O
daily	O
(	O
8	O
patients	O
)	O
","	O
and	O
dose	O
level	O
3	O
was	O
comprised	O
of	O
everolimus	B-DRUG
at	O
a	O
dose	O
of	O
10	O
mg	O
daily	O
and	O
sorafenib	B-DRUG
at	O
a	O
dose	O
of	O
200	O
mg	O
twice	O
daily	O
(	O
6	O
patients	O
)	O
.	O
	
DLTs	O
included	O
grade	O
4	O
(	O
according	O
to	O
National	O
Cancer	O
Institute	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
[	O
version	O
3	O
]	O
)	O
hyperuricemia	B-TOXI
with	O
grade	O
2	O
gout	B-TOXI
and	O
grade	O
3	O
lipase	O
associated	O
with	O
grade	O
2	O
pancreatitis	B-TOXI
at	O
dose	O
level	O
2	O
","	O
and	O
grade	O
3	O
rash	B-TOXI
in	O
2	O
patients	O
at	O
dose	O
level	O
3	O
Dose	O
level	O
2	O
(	O
everolimus	B-DRUG
at	O
a	O
dose	O
of	O
5	O
mg	O
daily	O
and	O
sorafenib	B-DRUG
at	O
a	O
dose	O
of	O
400	O
mg	O
twice	O
daily	O
)	O
was	O
established	O
as	O
the	O
maximum	O
tolerated	O
dose	O
.	O
	
Treatment-related	O
adverse	O
events	O
occurring	O
in	O
&	O
gt	O
;	O
20	O
%	O
of	O
patients	O
included	O
diarrhea	B-TOXI
","	O
hand-foot	B-TOXI
syndrome	I-TOXI
","	O
hypertension	B-TOXI
","	O
hypophosphatemia	B-TOXI
","	O
hypothyroidism	B-TOXI
","	O
and	O
rash	B-TOXI
.	O
	
Five	O
of	O
20	O
patients	O
achieved	O
Response	O
Evaluation	O
Criteria	O
In	O
Solid	O
Tumors	O
(	O
RECIST	O
)	O
#NAME?	O
partial	O
responses	O
","	O
all	O
of	O
which	O
occurred	O
in	O
patients	O
without	O
a	O
history	O
of	O
prior	O
systemic	O
therapy	O
.	O
	
Seven	O
of	O
8	O
patients	O
treated	O
at	O
dose	O
level	O
2	O
experienced	O
a	O
partial	O
response	O
or	O
stable	O
disease	O
.	O
	
Pharmacokinetic	O
analysis	O
revealed	O
no	O
interaction	O
between	O
everolimus	B-DRUG
and	O
sorafenib	B-DRUG
.	O
	
The	O
combination	O
of	O
everolimus	B-DRUG
and	O
sorafenib	B-DRUG
was	O
associated	O
with	O
acceptable	O
toxicity	O
and	O
evidence	O
of	O
antitumor	O
activity	O
in	O
previously	O
untreated	O
patients	O
with	O
metastatic	B-CANCER
renal	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
Randomised	O
phase	O
II	O
trial	O
of	O
gemcitabine	B-DRUG
plus	O
vinorelbine	B-DRUG
vs	O
gemcitabine	B-DRUG
plus	O
cisplatin	B-DRUG
vs	O
gemcitabine	B-DRUG
plus	O
capecitabine	B-DRUG
in	O
patients	O
with	O
pretreated	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
An	O
increasing	O
proportion	O
of	O
patients	O
are	O
exposed	O
to	O
anthracyclines	B-DRUG
and	O
/	O
or	O
taxanes	B-DRUG
in	O
the	O
adjuvant	O
or	O
neoadjuvant	O
setting	O
.	O
	
Re-exposure	O
in	O
the	O
metastatic	O
stage	O
is	O
limited	O
by	O
drug	O
resistance	O
","	O
thus	O
evaluation	O
of	O
non-cross-resistant	O
regimens	O
is	O
mandatory	O
.	O
	
Anthracycline-pretreated	B-DRUG
patients	O
were	O
randomly	O
assigned	O
to	O
three	O
gemcitabine-based	B-DRUG
regimens	O
.	O
	
Chemotherapy	O
consisted	O
of	O
gemcitabine	B-DRUG
1	O
mg	O
m	O
(	O
-2	O
)	O
plus	O
vinorelbin	B-DRUG
25	O
mg	O
m	O
(	O
-2	O
)	O
on	O
days	O
1+8	O
(	O
GemVin	B-DRUG
)	O
","	O
or	O
plus	O
cisplatin	B-DRUG
30	O
mg	O
m	O
(	O
-2	O
)	O
on	O
days	O
1+8	O
(	O
GemCis	B-DRUG
)	O
","	O
or	O
plus	O
capecitabine	B-DRUG
650	O
mg	O
m	O
(	O
-2	O
)	O
b.i.d.	O
orally	O
days	O
1月14日	O
(	O
GemCap	B-DRUG
)	O
","	O
q3w	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
response	O
rate	O
.	O
	
A	O
total	O
of	O
141	O
patients	O
were	O
recruited	O
on	O
the	O
trial	O
.	O
	
The	O
overall	O
response	O
rates	O
were	O
39	O
%	O
(	O
GemVin	B-DRUG
)	O
","	O
47.7	O
%	O
(	O
GemCis	B-DRUG
)	O
and	O
34.7	O
%	O
(	O
GemCap	B-DRUG
)	O
.	O
	
Median	O
progression-free	O
survival	O
was	O
estimated	O
with	O
5.7	O
","	O
6.9	O
and	O
8.3	O
months	O
","	O
respectively	O
.	O
	
Corresponding	O
median	O
survival	O
times	O
were	O
17.5	O
(	O
GemVin	B-DRUG
)	O
","	O
13	O
(	O
GemCis	B-DRUG
)	O
and	O
19.4	O
months	O
(	O
GemCap	B-DRUG
)	O
.	O
	
Neutropenia	B-TOXI
_grade	O
3	O
occurred	O
in	O
16.7	O
%	O
(	O
Gem	B-DRUG
/	O
Vin	B-DRUG
)	O
","	O
4.4	O
%	O
(	O
GemCis	B-DRUG
)	O
and	O
0	O
%	O
(	O
Gem	B-DRUG
/	O
Cap	B-DRUG
)	O
","	O
whereas	O
non-haematological	B-TOXI
toxicities	I-TOXI
were	O
rarely	O
severe	O
except	O
grade	O
3	O
hand-foot	B-TOXI
syndrome	I-TOXI
in	O
2	O
%	O
of	O
the	O
GemCap	O
patients	O
(	O
per	O
patient	O
analysis	O
)	O
.	O
	
This	O
randomised	O
phase	O
II	O
trial	O
has	O
revealed	O
comparable	O
results	O
for	O
three	O
gemcitabine-based	B-DRUG
regimens	O
regarding	O
treatment	O
efficacy	O
and	O
toxicity	O
.	O
	
Gemcitabine-based	B-DRUG
chemotherapy	O
appears	O
to	O
be	O
a	O
worthwhile	O
treatment	O
option	O
for	O
pretreated	O
patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Temsirolimus	B-DRUG
and	O
rituximab	B-DRUG
in	O
patients	O
with	O
relapsed	O
or	O
refractory	O
mantle	B-CANCER
cell	I-CANCER
lymphoma	I-CANCER
:	O
a	O
phase	O
2	O
study	O
.	O
	
	
Temsirolimus	B-DRUG
is	O
a	O
mammalian	O
target	O
of	O
rapamycin	B-DRUG
(	O
mTOR	O
)	O
inhibitor	O
with	O
single-agent	O
antitumour	O
activity	O
in	O
patients	O
with	O
mantle	B-CANCER
cell	I-CANCER
lymphoma	I-CANCER
.	O
	
We	O
therefore	O
tested	O
its	O
efficacy	O
and	O
toxicity	O
in	O
combination	O
with	O
rituximab	B-DRUG
(	O
an	O
antiCD20	O
antibody	O
)	O
in	O
patients	O
with	O
relapsed	O
or	O
refractory	O
mantle	B-CANCER
cell	I-CANCER
lymphoma	I-CANCER
.	O
	
In	O
a	O
phase	O
2	O
study	O
","	O
patients	O
(	O
aged	O
_18	O
years	O
)	O
at	O
35	O
centres	O
in	O
the	O
USA	O
were	O
given	O
temsirolimus	B-DRUG
25	O
mg	O
/	O
week	O
","	O
and	O
rituximab	B-DRUG
375	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
week	O
for	O
4	O
weeks	O
during	O
the	O
first	O
cycle	O
and	O
thereafter	O
a	O
single	O
dose	O
of	O
rituximab	B-DRUG
every	O
other	O
28-day	O
cycle	O
.	O
	
Both	O
drugs	O
were	O
administered	O
intravenously	O
.	O
	
Responding	O
patients	O
after	O
six	O
cycles	O
could	O
continue	O
treatment	O
for	O
a	O
total	O
of	O
12	O
cycles	O
","	O
and	O
were	O
then	O
observed	O
without	O
additional	O
maintenance	O
treatment	O
.	O
	
The	O
primary	O
endpoint	O
was	O
the	O
proportion	O
of	O
patients	O
with	O
either	O
rituximab-sensitive	B-DRUG
or	O
rituximab-refractory	B-DRUG
disease	O
who	O
had	O
at	O
least	O
a	O
partial	O
response	O
.	O
	
The	O
analyses	O
were	O
done	O
on	O
all	O
patients	O
who	O
were	O
treated	O
.	O
	
The	O
study	O
was	O
registered	O
with	O
ClinicalTrials.gov	O
","	O
number	O
NCT00109967	O
.	O
	
71	O
patients	O
with	O
mantle	B-CANCER
cell	I-CANCER
lymphoma	I-CANCER
were	O
enrolled	O
and	O
69	O
were	O
assessable	O
and	O
were	O
included	O
in	O
the	O
final	O
analysis	O
.	O
	
The	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
was	O
59	O
%	O
(	O
41	O
of	O
69	O
patients	O
)	O
-13	O
(	O
19	O
%	O
)	O
patients	O
had	O
complete	O
responses	O
and	O
28	O
(	O
41	O
%	O
)	O
had	O
partial	O
responses	O
.	O
	
The	O
ORR	O
was	O
63	O
%	O
(	O
30	O
of	O
48	O
;	O
95	O
%	O
CI	O
47-76	O
)	O
for	O
rituximab-sensitive	B-DRUG
patients	O
","	O
and	O
52	O
%	O
(	O
11	O
of	O
21	O
;	O
30-74	O
)	O
for	O
rituximab-refractory	B-DRUG
patients	O
.	O
	
The	O
most	O
common	O
treatment-related	O
grade	O
3	O
or	O
4	O
adverse	O
events	O
in	O
rituximab-sensitive	B-TOXI
and	O
rituximab-refractory	B-TOXI
patients	O
were	O
thrombocytopenia	B-TOXI
(	O
eight	O
[	O
17	O
%	O
]	O
and	O
eight	O
[	O
38	O
%	O
]	O
","	O
respectively	O
)	O
","	O
neutropenia	B-TOXI
(	O
ten	O
[	O
21	O
%	O
]	O
and	O
five	O
[	O
24	O
%	O
]	O
","	O
respectively	O
)	O
","	O
fatigue	B-TOXI
(	O
eight	O
[	O
17	O
%	O
]	O
and	O
two	O
[	O
10	O
%	O
]	O
","	O
respectively	O
)	O
","	O
leucopenia	B-TOXI
(	O
six	O
[	O
13	O
%	O
]	O
and	O
three	O
[	O
14	O
%	O
]	O
","	O
respectively	O
)	O
","	O
pneumonia	B-TOXI
(	O
five	O
[	O
10	O
%	O
]	O
and	O
two	O
[	O
10	O
%	O
]	O
","	O
respectively	O
)	O
","	O
lymphopenia	B-TOXI
(	O
five	O
[	O
10	O
%	O
]	O
and	O
two	O
[	O
10	O
%	O
]	O
","	O
respectively	O
)	O
","	O
pneumonitis	B-TOXI
(	O
four	O
[	O
8	O
%	O
]	O
and	O
none	O
","	O
respectively	O
)	O
","	O
oedema	B-TOXI
(	O
four	O
[	O
8	O
%	O
]	O
and	O
none	O
","	O
respectively	O
)	O
","	O
dyspnoea	B-TOXI
(	O
three	O
[	O
6	O
%	O
]	O
and	O
two	O
[	O
10	O
%	O
]	O
","	O
respectively	O
)	O
","	O
and	O
hypertriglyceridaemia	B-TOXI
(	O
three	O
[	O
6	O
%	O
]	O
and	O
two	O
[	O
10	O
%	O
]	O
","	O
respectively	O
)	O
.	O
	
mTOR	O
inhibitors	O
in	O
combination	O
with	O
rituximab	B-DRUG
could	O
have	O
a	O
role	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
relapsed	O
and	O
refractory	O
mantle	B-CANCER
cell	I-CANCER
lymphoma	I-CANCER
.	O
	
National	O
Institutes	O
of	O
Health	O
and	O
the	O
Predolin	O
Foundation	O
.	O
	
Randomized	O
","	O
placebo-controlled	B-DRUG
","	O
phase	O
III	O
study	O
of	O
first-line	O
oxaliplatin-based	B-DRUG
chemotherapy	O
plus	O
PTK787	B-DRUG
/	O
ZK	B-DRUG
222584	I-DRUG
","	O
an	O
oral	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
inhibitor	O
","	O
in	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
adenocarcinoma	I-CANCER
.	O
	
	
PTK787	B-DRUG
/	O
ZK	B-DRUG
222584	I-DRUG
(	O
PTK	B-DRUG
/	O
ZK	B-DRUG
;	O
vatalanib	B-DRUG
)	O
","	O
an	O
orally	O
active	O
","	O
multitargeted	O
angiogenesis	O
inhibitor	O
","	O
has	O
shown	O
tolerability	O
and	O
promising	O
activity	O
in	O
early-phase	O
studies	O
","	O
which	O
led	O
to	O
a	O
phase	O
III	O
trial	O
in	O
combination	O
with	O
oxaliplatin	B-DRUG
","	O
fluorouracil	B-DRUG
","	O
and	O
leucovorin	B-DRUG
(	O
FOLFOX4	B-DRUG
)	O
.	O
	
Patients	O
(	O
N	O
=	O
"1,168"	O
)	O
with	O
previously	O
untreated	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
were	O
randomly	O
assigned	O
01:01	O
to	O
receive	O
FOLFOX4	B-DRUG
plus	O
PTK	O
/	O
ZK	O
or	O
placebo	B-DRUG
(	O
ClinicalTrials.gov	O
identifier	O
:	O
NCT00056459	O
)	O
.	O
	
Stratification	O
factors	O
included	O
WHO	O
performance	O
status	O
(	O
0	O
v	O
1	O
or	O
2	O
)	O
and	O
serum	O
lactate	O
dehydrogenase	O
(	O
LDH	O
;	O
_	O
v	O
&	O
gt	O
;	O
1.5_	O
the	O
upper	O
limit	O
of	O
normal	O
)	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
progression-free	O
survival	O
(	O
PFS	O
)	O
.	O
	
Secondary	O
end	O
points	O
included	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
.	O
	
PFS	O
","	O
OS	O
","	O
and	O
ORR	O
were	O
not	O
statistically	O
improved	O
with	O
PTK	B-DRUG
/	O
ZK	B-DRUG
(	O
P	O
&	O
gt	O
;	O
0.05	O
)	O
.	O
	
Median	O
PFS	O
by	O
central	O
review	O
was	O
7.7	O
months	O
with	O
PTK	B-DRUG
/	O
ZK	B-DRUG
versus	O
7.6	O
months	O
with	O
placebo	B-DRUG
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
","	O
0.88	O
;	O
95	O
%	O
CI	O
","	O
0.74	O
to	O
1.03	O
;	O
P	O
=	O
0.118	O
)	O
;	O
median	O
OS	O
was	O
21.4	O
months	O
with	O
PTK	B-DRUG
/	O
ZK	B-DRUG
versus	O
20.5	O
months	O
with	O
placebo	B-DRUG
(	O
HR	O
","	O
1.08	O
;	O
95	O
%	O
CI	O
","	O
0.94	O
to	O
1.24	O
;	O
P	O
=	O
0.26	O
)	O
.	O
	
In	O
an	O
exploratory	O
post	O
hoc	O
analysis	O
of	O
PFS	O
in	O
patients	O
(	O
n	O
=	O
158	O
per	O
arm	O
)	O
with	O
high	O
serum	O
LDH	O
","	O
a	O
potential	O
marker	O
of	O
hypoxia	B-TOXI
","	O
PFS	O
was	O
longer	O
with	O
PTK	B-DRUG
/	O
ZK	B-DRUG
versus	O
placebo	B-DRUG
(	O
7.7	O
v	O
5.8	O
months	O
","	O
respectively	O
;	O
HR	O
","	O
0.67	O
;	O
95	O
%	O
CI	O
","	O
0.49	O
to	O
0.91	O
;	O
P	O
=	O
0.009	O
)	O
.	O
	
Although	O
the	O
efficacy	O
objectives	O
of	O
this	O
study	O
were	O
not	O
met	O
","	O
a	O
subgroup	O
of	O
patients	O
who	O
may	O
potentially	O
benefit	O
from	O
small-molecule	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
inhibitor	O
therapy	O
has	O
been	O
identified	O
and	O
further	O
research	O
is	O
warranted	O
.	O
	
A	O
phase	O
I	O
trial	O
to	O
determine	O
the	O
safety	O
of	O
imatinib	B-DRUG
in	O
combination	O
with	O
vatalanib	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
malignancies	I-CANCER
.	O
	
	
The	O
role	O
of	O
tyrosine	B-DRUG
kinase	I-DRUG
inhibitors	I-DRUG
(	O
TKIs	B-DRUG
)	O
in	O
the	O
treatment	O
of	O
advanced	B-CANCER
malignancies	I-CANCER
is	O
well	O
established	O
.	O
	
Imatinib	B-DRUG
and	O
vatalanib	B-DRUG
are	O
oral	B-DRUG
TKIs	I-DRUG
with	O
different	O
mechanisms	O
of	O
action	O
.	O
	
This	O
trial	O
sought	O
to	O
establish	O
the	O
safety	O
","	O
tolerability	O
","	O
and	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
the	O
two	O
agents	O
in	O
combination	O
.	O
	
Secondary	O
objectives	O
included	O
determination	O
of	O
potential	O
pharmacologic	O
interactions	O
among	O
vatalanib	B-DRUG
and	O
imatinib	B-DRUG
and	O
observation	O
of	O
antitumor	O
activity	O
.	O
	
Patients	O
with	O
biopsy-proven	O
advanced	B-CANCER
refractory	I-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
enrolled	O
in	O
this	O
single-center	O
dose-escalation	O
trial	O
.	O
	
Patients	O
initially	O
received	O
imatinib	B-DRUG
and	O
vatalanib	B-DRUG
once	O
daily	O
following	O
a	O
14-day	O
run-in	O
period	O
of	O
daily	O
oral	B-DRUG
vatalanib	I-DRUG
only	O
","	O
and	O
were	O
observed	O
for	O
a	O
full	O
28-day	O
treatment	O
cycle	O
prior	O
to	O
dose	O
escalation	O
.	O
	
An	O
amendment	O
divided	O
the	O
vatalanib	B-DRUG
dose	O
into	O
two	O
daily	O
doses	O
and	O
gradually	O
escalated	O
the	O
dose	O
over	O
a	O
2月3日	O
week	O
period	O
.	O
	
Patients	O
continued	O
combination	O
therapy	O
until	O
disease	O
progression	O
or	O
intolerable	O
toxicity	O
.	O
	
Forty-five	O
patients	O
were	O
enrolled	O
between	O
September	O
2004	O
and	O
November	O
2007	O
.	O
	
As	O
of	O
September	O
2009	O
","	O
a	O
total	O
of	O
247	O
cycles	O
of	O
treatment	O
had	O
been	O
administered	O
(	O
range	O
:	O
1	O
=-44+	O
","	O
median	O
=	O
2	O
)	O
.	O
	
The	O
MTD	O
was	O
determined	O
to	O
be	O
vatalanib	B-DRUG
1250	O
mg	O
daily	O
and	O
imatinib	B-DRUG
400	O
mg	O
daily	O
.	O
	
Thirty-five	O
patients	O
(	O
78	O
%	O
)	O
were	O
evaluable	O
for	O
response	O
;	O
2	O
patients	O
achieved	O
PR	O
","	O
while	O
14	O
patients	O
had	O
SD	O
(	O
10	O
had	O
stable	O
disease	O
_	O
6	O
cycles	O
)	O
.	O
	
The	O
combination	O
of	O
vatalanib	B-DRUG
and	O
imatinib	B-DRUG
was	O
well	O
tolerated	O
.	O
	
Twice-daily	O
vatalanib	B-DRUG
dosing	O
improved	O
tolerability	O
and	O
ease	O
of	O
full-dose	O
administration	O
.	O
	
These	O
results	O
suggest	O
that	O
vatalanib-containing	B-DRUG
combinations	O
may	O
be	O
active	O
and	O
tolerable	O
","	O
warranting	O
further	O
study	O
.	O
	
A	O
phase	O
II	O
trial	O
of	O
nab-paclitaxel	B-DRUG
(	O
ABI-007	B-DRUG
)	O
and	O
carboplatin	B-DRUG
in	O
patients	O
with	O
unresectable	O
stage	O
IV	O
melanoma	B-CANCER
:	O
a	O
North	O
Central	O
Cancer	O
Treatment	O
Group	O
Study	O
","	O
N057E	O
(	O
1	O
)	O
.	O
	
	
There	O
is	O
increasing	O
evidence	O
that	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
are	O
clinically	O
active	O
in	O
the	O
treatment	O
of	O
metastatic	B-CANCER
melanoma	I-CANCER
(	O
MM	O
)	O
.	O
	
ABI-007	B-DRUG
is	O
an	O
albumin-bound	O
formulation	O
of	O
paclitaxel	B-DRUG
that	O
has	O
demonstrated	O
single-agent	O
activity	O
against	O
metastatic	B-CANCER
melanoma	I-CANCER
.	O
	
A	O
parallel	O
phase	O
II	O
trial	O
was	O
conducted	O
in	O
patients	O
with	O
unresectable	O
stage	O
IV	O
melanoma	B-CANCER
who	O
were	O
either	O
chemotherapy	O
naive	O
(	O
CN	O
)	O
or	O
previously	O
treated	O
(	O
PT	O
)	O
.	O
	
The	O
treatment	O
regimen	O
consisted	O
of	O
ABI-007	B-DRUG
(	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
carboplatin	B-DRUG
area	O
under	O
the	O
curve	O
(	O
AUC2	O
)	O
administered	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
every	O
28	O
days	O
.	O
	
The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
objective	O
response	O
rate	O
(	O
RECIST	O
)	O
.	O
	
Seventy-six	O
patients	O
(	O
41	O
CN	O
and	O
35	O
PT	O
)	O
were	O
enrolled	O
between	O
November	O
2006	O
and	O
July	O
2007	O
.	O
	
Three	O
patients	O
withdrew	O
consent	O
prior	O
to	O
starting	O
treatment	O
.	O
	
The	O
median	O
number	O
of	O
treatment	O
cycles	O
was	O
4	O
There	O
were	O
10	O
(	O
25.6	O
%	O
)	O
responses	O
(	O
1	O
complete	O
response	O
[	O
CR	O
]	O
and	O
9	O
partial	O
responses	O
[	O
PRs	O
]	O
)	O
in	O
the	O
CN	O
cohort	O
(	O
90	O
%	O
CI	O
","	O
16.7	O
%	O
-42.3	O
%	O
)	O
and	O
3	O
(	O
8.8	O
%	O
)	O
responses	O
(	O
3	O
PRs	O
)	O
in	O
the	O
PT	O
cohort	O
(	O
90	O
%	O
CI	O
","	O
2.5	O
%	O
-21.3	O
%	O
)	O
.	O
	
Median	O
progression-free	O
survival	O
was	O
4.5	O
months	O
in	O
the	O
CN	O
cohort	O
and	O
4.1	O
months	O
in	O
the	O
PT	O
cohort	O
.	O
	
Median	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
11.1	O
months	O
in	O
the	O
CN	O
group	O
and	O
10.9	O
months	O
in	O
the	O
PT	O
group	O
.	O
	
Severe	O
toxicities	O
in	O
both	O
groups	O
(	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Effects	O
v.3.0	O
_grade	O
3	O
)	O
included	O
neutropenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
neurosensory	B-TOXI
problems	I-TOXI
","	O
fatigue	B-TOXI
","	O
nausea	B-TOXI
","	O
and	O
vomiting	B-TOXI
.	O
	
The	O
weekly	O
combination	O
of	O
ABI-007	B-DRUG
and	O
carboplatin	B-DRUG
appears	O
to	O
be	O
moderately	O
well	O
tolerated	O
","	O
with	O
promising	O
clinical	O
activity	O
as	O
therapy	O
in	O
patients	O
who	O
are	O
chemotherapy	O
naive	O
and	O
with	O
modest	O
antitumor	O
activity	O
in	O
those	O
previously	O
treated	O
.	O
	
Randomized	O
phase	O
II	O
study	O
of	O
bevacizumab	B-DRUG
in	O
combination	O
with	O
chemotherapy	O
in	O
previously	O
untreated	O
extensive-stage	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
results	O
from	O
the	O
SALUTE	O
trial	O
.	O
	
	
Because	O
of	O
promising	O
efficacy	O
signals	O
in	O
single-arm	O
studies	O
","	O
a	O
placebo-controlled	B-DRUG
","	O
double-blind	O
","	O
randomized	O
phase	O
II	O
trial	O
was	O
designed	O
to	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
adding	O
bevacizumab	B-DRUG
to	O
first-line	O
standard	O
chemotherapy	O
for	O
treatment	O
of	O
extensive-stage	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
SCLC	B-CANCER
)	O
.	O
	
Patients	O
with	O
SCLC	B-CANCER
were	O
randomly	O
assigned	O
to	O
receive	O
bevacizumab	B-DRUG
or	O
placebo	B-DRUG
","	O
with	O
cisplatin	B-DRUG
or	O
carboplatin	B-DRUG
plus	O
etoposide	B-DRUG
","	O
for	O
four	O
cycles	O
followed	O
by	O
single-agent	O
bevacizumab	B-DRUG
or	O
placebo	B-DRUG
until	O
progression	O
or	O
unacceptable	O
toxicity	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
progression-free	O
survival	O
(	O
PFS	O
)	O
.	O
	
Fifty-two	O
patients	O
were	O
randomly	O
assigned	O
to	O
the	O
bevacizumab	B-DRUG
group	O
and	O
50	O
to	O
the	O
placebo	B-DRUG
group	O
;	O
69	O
%	O
versus	O
66	O
%	O
","	O
respectively	O
","	O
completed	O
four	O
cycles	O
of	O
therapy	O
.	O
	
Median	O
PFS	O
was	O
higher	O
in	O
the	O
bevacizumab	B-DRUG
group	O
(	O
5.5	O
months	O
)	O
than	O
in	O
the	O
placebo	B-DRUG
group	O
(	O
4.4	O
months	O
;	O
hazard	O
ratio	O
[	O
HR	O
]	O
","	O
0.53	O
;	O
95	O
%	O
CI	O
","	O
0.32	O
to	O
0.86	O
)	O
.	O
	
Median	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
similar	O
for	O
both	O
groups	O
(	O
9.4	O
v	O
10.9	O
months	O
for	O
bevacizumab	B-DRUG
and	O
placebo	B-DRUG
groups	O
","	O
respectively	O
)	O
","	O
with	O
an	O
HR	O
of	O
1.16	O
(	O
95	O
%	O
CI	O
","	O
0.66	O
to	O
2.04	O
)	O
.	O
	
Overall	O
response	O
rates	O
were	O
58	O
%	O
(	O
95	O
%	O
CI	O
","	O
43	O
%	O
to	O
71	O
%	O
)	O
for	O
the	O
bevacizumab	B-DRUG
group	O
and	O
48	O
%	O
(	O
95	O
%	O
CI	O
","	O
34	O
%	O
to	O
62	O
%	O
)	O
for	O
the	O
placebo	B-DRUG
group	O
.	O
	
Median	O
duration	O
of	O
response	O
was	O
4.7	O
months	O
for	O
the	O
bevacizumab	B-DRUG
group	O
and	O
3.2	O
months	O
for	O
the	O
placebo	B-DRUG
group	O
.	O
	
In	O
the	O
bevacizumab	B-DRUG
and	O
placebo	B-DRUG
groups	O
","	O
75	O
%	O
versus	O
60	O
%	O
of	O
patients	O
","	O
respectively	O
","	O
experienced	O
one	O
or	O
more	O
grade	O
3	O
or	O
higher	O
adverse	O
events	O
.	O
	
No	O
new	O
or	O
unexpected	O
safety	O
signals	O
for	O
bevacizumab	B-DRUG
were	O
observed	O
.	O
	
The	O
addition	O
of	O
bevacizumab	B-DRUG
to	O
cisplatin	B-DRUG
or	O
carboplatin	B-DRUG
plus	O
etoposide	B-DRUG
for	O
treatment	O
of	O
extensive-stage	O
SCLC	B-CANCER
improved	O
PFS	O
","	O
with	O
an	O
acceptable	O
toxicity	O
profile	O
.	O
	
However	O
","	O
no	O
improvement	O
in	O
OS	O
was	O
observed	O
.	O
	
Palliative	O
first-line	O
therapy	O
with	O
weekly	O
high-dose	O
5-fluorouracil	B-DRUG
and	O
sodium	B-DRUG
folinic	I-DRUG
acid	I-DRUG
as	O
a	O
24-hour	O
infusion	O
(	O
AIO	O
regimen	O
)	O
combined	O
with	O
weekly	O
irinotecan	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
adenocarcinoma	I-CANCER
of	O
the	O
stomach	O
or	O
esophagogastric	O
junction	O
followed	O
by	O
secondary	O
metastatic	O
resection	O
after	O
downsizing	O
.	O
	
	
The	O
aim	O
of	O
this	O
retrospective	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
weekly	O
high-dose	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
/	O
folinic	B-DRUG
acid	I-DRUG
(	O
FA	B-DRUG
)	O
as	O
24-h	O
infusion	O
(	O
AIO	O
regimen	O
)	O
plus	O
irinotecan	B-DRUG
in	O
patients	O
with	O
histologically	O
proven	O
metastatic	B-CANCER
gastroesophageal	I-CANCER
adenocarcinoma	I-CANCER
(	O
UICC	O
stage	O
IV	O
)	O
.	O
	
From	O
8	O
/	O
1999	O
to	O
12	O
/	O
2008	O
","	O
76	O
registered	O
","	O
previously	O
untreated	O
patients	O
were	O
evaluable	O
.	O
	
Treatment	O
regimen	O
:	O
irinotecan	B-DRUG
(	O
80	O
mg	O
/	O
m虏	O
)	O
as	O
1-h	O
infusion	O
followed	O
by	O
5-FU	B-DRUG
(	O
2000	O
mg	O
/	O
m虏	O
)	O
combined	O
with	O
FA	B-DRUG
(	O
500	O
mg	O
/	O
m虏	O
)	O
as	O
24-h	O
infusion	O
(	O
d1	O
","	O
8	O
","	O
15	O
","	O
22	O
","	O
29	O
","	O
36	O
","	O
qd	O
57	O
)	O
.	O
	
Median	O
age	O
:	O
59	O
years	O
;	O
male	O
/	O
female	O
:	O
74	O
%	O
/	O
26	O
%	O
;	O
ECOG	O
_1	O
:	O
83	O
%	O
;	O
response	O
:	O
CR	O
:	O
1	O
%	O
","	O
PR	O
:	O
16	O
%	O
","	O
SD	O
:	O
61	O
%	O
","	O
PD	O
:	O
17	O
%	O
","	O
not	O
evaluable	O
in	O
terms	O
of	O
response	O
:	O
5	O
%	O
;	O
tumor	O
control	O
:	O
78	O
%	O
;	O
median	O
OS	O
:	O
11.2	O
months	O
;	O
median	O
time-to-progression	O
:	O
5.3	O
months	O
;	O
1-year	O
survival	O
rate	O
:	O
49	O
%	O
;	O
2-year	O
survival	O
rate	O
:	O
17	O
%	O
;	O
no	O
evidence	O
of	O
disease	O
:	O
6.6	O
%	O
;	O
higher	O
grade	O
toxicities	O
(	O
grade	O
3	O
/	O
4	O
)	O
:	O
anemia	B-TOXI
:	O
7	O
%	O
","	O
leucopenia	B-TOXI
:	O
1	O
%	O
","	O
ascites	B-TOXI
:	O
3	O
%	O
","	O
nausea	B-TOXI
:	O
3	O
%	O
","	O
infections	B-TOXI
:	O
12	O
%	O
","	O
vomiting	B-TOXI
:	O
9	O
%	O
","	O
GI	B-TOXI
bleeding	I-TOXI
of	O
the	O
primary	O
tumor	O
:	O
4	O
%	O
","	O
diarrhea	B-TOXI
:	O
17	O
%	O
","	O
thromboembolic	B-TOXI
events	I-TOXI
:	O
4	O
%	O
;	O
secondary	O
metastatic	O
resection	O
after	O
downsizing	O
:	O
16	O
patients	O
(	O
21	O
%	O
)	O
","	O
R-classification	O
of	O
secondary	O
resections	O
:	O
R0	O
/	O
R1	O
/	O
R2	O
:	O
81	O
%	O
/	O
6	O
%	O
/	O
13	O
%	O
","	O
median	O
survival	O
of	O
the	O
16	O
patients	O
with	O
secondary	O
resection	O
:	O
23.7	O
months	O
.	O
	
Combined	O
5-FU	B-DRUG
/	O
FA	B-DRUG
as	O
24-h	O
infusion	O
plus	O
irinotecan	B-DRUG
may	O
be	O
considered	O
as	O
an	O
active	O
palliative	O
first-line	O
treatment	O
accompanied	O
by	O
tolerable	O
toxicity	O
;	O
thus	O
offering	O
an	O
alternative	O
to	O
cisplatin-based	B-DRUG
treatment	O
regimens	O
.	O
	
Thanks	O
to	O
efficient	O
interdisciplinary	O
teamwork	O
","	O
secondary	O
metastatic	O
resections	O
could	O
be	O
performed	O
in	O
16	O
patients	O
.	O
	
In	O
total	O
","	O
the	O
patients	O
who	O
had	O
undergone	O
secondary	O
resection	O
had	O
a	O
median	O
survival	O
of	O
23.7	O
months	O
","	O
whereas	O
the	O
median	O
survival	O
of	O
patients	O
without	O
secondary	O
resection	O
was	O
10.1	O
months	O
(	O
p_0.001	O
)	O
.	O
	
A	O
randomized	O
phase	O
III	O
trial	O
of	O
IV	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
_	O
3	O
courses	O
followed	O
by	O
observation	O
versus	O
weekly	O
maintenance	O
low-dose	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
early-stage	O
ovarian	B-CANCER
carcinoma	I-CANCER
:	O
a	O
Gynecologic	O
Oncology	O
Group	O
Study	O
.	O
	
	
To	O
compare	O
the	O
recurrence-free	O
interval	O
(	O
RFI	O
)	O
and	O
safety	O
profile	O
in	O
patients	O
with	O
completely	O
resected	O
high-risk	O
early-stage	O
ovarian	B-CANCER
cancer	I-CANCER
treated	O
with	O
intravenous	O
(	O
IV	O
)	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
with	O
or	O
without	O
maintenance	O
low-dose	O
paclitaxel	B-DRUG
for	O
24	O
weeks	O
.	O
	
Eligibility	O
was	O
limited	O
to	O
patients	O
with	O
stage	O
IA	O
/	O
B	O
(	O
grade	O
3	O
or	O
clear	O
cell	O
)	O
","	O
all	O
IC	O
or	O
II	O
epithelial	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
All	O
patients	O
were	O
to	O
receive	O
carboplatin	B-DRUG
AUC	O
6	O
and	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m虏	O
q3	O
weeks	O
_	O
3	O
courses	O
with	O
random	O
assignment	O
to	O
either	O
observation	O
or	O
maintenance	O
paclitaxel	B-DRUG
40	O
mg	O
/	O
m虏	O
/	O
week	O
_	O
24	O
weeks	O
.	O
	
Recurrence	O
required	O
clinical	O
or	O
radiological	O
evidence	O
of	O
new	O
tumor	O
.	O
	
There	O
were	O
571	O
patients	O
enrolled	O
onto	O
this	O
study	O
","	O
of	O
whom	O
29	O
were	O
deemed	O
ineligible	O
due	O
to	O
inappropriate	O
stage	O
or	O
pathology	O
","	O
leaving	O
542	O
patients	O
.	O
	
At	O
least	O
3	O
cycles	O
of	O
treatment	O
were	O
administered	O
to	O
524	O
/	O
542	O
(	O
97	O
%	O
)	O
of	O
patients	O
","	O
and	O
among	O
those	O
assigned	O
to	O
maintenance	O
paclitaxel	B-DRUG
","	O
80	O
%	O
completed	O
the	O
regimen	O
.	O
	
The	O
incidence	O
of	O
grade	O
2	O
or	O
worse	B-TOXI
peripheral	I-TOXI
neuropathy	I-TOXI
(	O
15.5	O
%	O
vs.	O
6	O
%	O
)	O
","	O
infection	B-TOXI
/	O
fever	B-TOXI
(	O
19.9	O
%	O
vs.	O
8.7	O
%	O
)	O
","	O
and	O
dermatologic	B-TOXI
events	I-TOXI
(	O
70.8	O
%	O
vs.	O
52.1	O
%	O
)	O
was	O
higher	O
on	O
the	O
maintenance	O
regimen	O
(	O
p	O
&	O
lt	O
;	O
0.001	O
)	O
.	O
	
The	O
cumulative	O
probability	O
of	O
recurring	O
within	O
5	O
years	O
for	O
the	O
maintenance	O
paclitaxel	B-DRUG
regimen	O
is	O
20	O
%	O
vs.	O
23	O
%	O
for	O
surveillance	O
(	O
hazard	O
ratio	O
0.807	O
;	O
95	O
%	O
CI	O
:	O
0.565-1.15	O
)	O
.	O
	
The	O
probability	O
of	O
surviving	O
5	O
years	O
was	O
85.4	O
%	O
and	O
86.2	O
%	O
","	O
respectively	O
.	O
	
Maintenance	O
paclitaxel	B-DRUG
at	O
40	O
mg	O
/	O
m虏	O
/	O
week	O
_	O
24	O
weeks	O
added	O
to	O
standard	O
dose	O
AUC6	O
and	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m虏	O
_	O
3	O
doses	O
provides	O
no	O
significant	O
increase	O
in	O
RFI	O
.	O
	
Phase	O
II	O
study	O
of	O
cetuximab	B-DRUG
in	O
combination	O
with	O
chemoradiation	O
in	O
patients	O
with	O
stage	O
IIIA	O
/	O
B	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
RTOG	O
324	O
.	O
	
	
Non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
commonly	O
expresses	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
","	O
which	O
is	O
associated	O
with	O
poor	O
clinical	O
outcome	O
.	O
	
Cetuximab	B-DRUG
is	O
a	O
chimerized	O
monoclonal	O
antibody	O
that	O
targets	O
the	O
EGFR	O
and	O
","	O
in	O
preclinical	O
models	O
","	O
it	O
demonstrates	O
radiosensitization	O
properties	O
.	O
	
We	O
report	O
a	O
phase	O
II	O
trial	O
testing	O
the	O
combination	O
of	O
cetuximab	B-DRUG
with	O
chemoradiotherapy	O
(	O
CRT	O
)	O
in	O
unresectable	O
stage	O
III	O
NSCLC	B-CANCER
.	O
	
Eligibility	O
criteria	O
included	O
unresectable	O
stage	O
III	O
NSCLC	B-CANCER
","	O
Zubrod	O
performance	O
status	O
_	O
1	O
","	O
weight	O
loss	O
_	O
5	O
%	O
","	O
forced	O
expiratory	O
volume	O
in	O
1	O
second	O
_	O
1.2	O
L	O
","	O
and	O
adequate	O
organ	O
function	O
.	O
	
Patients	O
received	O
an	O
initial	O
dose	O
of	O
cetuximab	B-DRUG
(	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
on	O
day	O
1	O
of	O
week	O
1	O
and	O
then	O
weekly	O
doses	O
of	O
cetuximab	B-DRUG
(	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
until	O
completion	O
of	O
therapy	O
(	O
weeks	O
2	O
through	O
17	O
)	O
.	O
	
During	O
week	O
2	O
","	O
patients	O
started	O
CRT	O
(	O
63	O
Gy	O
in	O
35	O
fractions	O
)	O
with	O
weekly	O
carboplatin	B-DRUG
at	O
area	O
under	O
the	O
[	O
concentration-time	O
]	O
curve	O
(	O
AUC	O
)	O
2	O
and	O
six	O
doses	O
of	O
paclitaxel	B-DRUG
at	O
45	O
mg	O
/	O
m	O
(	O
2	O
)	O
followed	O
by	O
carboplatin	B-DRUG
(	O
AUC	O
6	O
)	O
and	O
two	O
cycles	O
of	O
paclitaxel	B-DRUG
(	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
during	O
weeks	O
12	O
through	O
17	O
.	O
	
Primary	O
end	O
points	O
included	O
safety	O
and	O
compliance	O
of	O
concurrent	O
cetuximab	B-DRUG
and	O
CRT	O
.	O
	
In	O
all	O
","	O
93	O
patients	O
were	O
enrolled	O
and	O
87	O
were	O
evaluable	O
.	O
	
Median	O
follow-up	O
was	O
21.6	O
months	O
.	O
	
Response	O
rate	O
was	O
62	O
%	O
(	O
n	O
=	O
54	O
)	O
","	O
median	O
survival	O
was	O
22.7	O
months	O
","	O
and	O
24-month	O
overall	O
survival	O
was	O
49.3	O
%	O
.	O
	
Adverse	O
events	O
related	O
to	O
treatment	O
included	O
20	O
%	O
grade	O
4	O
hematologic	B-TOXI
toxicities	I-TOXI
","	O
8	O
%	O
grade	O
3	O
esophagitis	B-TOXI
","	O
and	O
7	O
%	O
grade	O
3	O
to	O
4	O
pneumonitis	B-TOXI
.	O
	
There	O
were	O
five	O
grade	O
5	O
events	O
.	O
	
The	O
combination	O
of	O
cetuximab	B-DRUG
with	O
CRT	O
is	O
feasible	O
and	O
shows	O
promising	O
activity	O
.	O
	
The	O
median	O
and	O
overall	O
survival	O
achieved	O
with	O
this	O
regimen	O
were	O
longer	O
than	O
any	O
previously	O
reported	O
by	O
the	O
Radiation	O
Therapy	O
Oncology	O
Group	O
.	O
	
A	O
prospective	O
clinical	O
trial	O
of	O
lenalidomide	B-DRUG
with	O
topotecan	B-DRUG
in	O
women	O
with	O
advanced	B-CANCER
epithelial	I-CANCER
ovarian	I-CANCER
carcinoma	I-CANCER
.	O
	
	
Lenalidomide	B-DRUG
is	O
an	O
anti-angiogenic	O
IMiD	O
(	O
庐	O
)	O
immunomodulatory	O
drug	O
.	O
	
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
overall	O
safety	O
profile	O
","	O
and	O
activity	O
of	O
oral	B-DRUG
lenalidomide	I-DRUG
in	O
combination	O
with	O
topotecan	B-DRUG
in	O
women	O
with	O
advanced	B-CANCER
epithelial	I-CANCER
ovarian	I-CANCER
or	O
primary	B-CANCER
peritoneal	I-CANCER
carcinoma	I-CANCER
.	O
	
In	O
this	O
Phase	O
I	O
/	O
II	O
open-label	O
","	O
dose-escalation	O
study	O
","	O
patients	O
with	O
histologically	O
or	O
cytologically	O
confirmed	O
advanced	B-CANCER
ovarian	I-CANCER
or	O
primary	B-CANCER
peritoneal	I-CANCER
carcinoma	I-CANCER
with	O
disease	O
progression	O
or	O
recurrence	O
following	O
first-line	O
therapy	O
with	O
a	O
platinum	B-DRUG
agent	O
and	O
paclitaxel	B-DRUG
were	O
eligible	O
.	O
	
The	O
Phase	O
I	O
trial	O
utilized	O
a	O
standard	O
dose-escalation	O
design	O
to	O
define	O
the	O
MTD	O
and	O
evaluate	O
the	O
safety	O
profile	O
of	O
lenalidomide	B-DRUG
and	O
topotecan	B-DRUG
.	O
	
The	O
starting	O
doses	O
were	O
lenalidomide	B-DRUG
5	O
mg	O
","	O
days	O
1月14日	O
","	O
and	O
intravenous	B-DRUG
topotecan	I-DRUG
1.25	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
days	O
1月5日	O
of	O
a	O
21-day	O
cycle	O
.	O
	
Only	O
the	O
lenalidomide	B-DRUG
dose	O
was	O
escalated	O
","	O
in	O
5-mg	O
increments	O
up	O
to	O
25	O
mg	O
.	O
	
Toxicity	O
was	O
graded	O
according	O
to	O
the	O
National	O
Cancer	O
Institute	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
.	O
	
The	O
Phase	O
II	O
portion	O
was	O
designed	O
to	O
evaluate	O
the	O
antitumor	O
activity	O
based	O
on	O
objective	O
response	O
rate	O
of	O
lenalidomide	B-DRUG
and	O
topotecan	B-DRUG
.	O
	
Five	O
women	O
with	O
advanced	B-CANCER
epithelial	I-CANCER
ovarian	I-CANCER
carcinoma	I-CANCER
were	O
enrolled	O
","	O
each	O
receiving	O
5	O
mg	O
oral	B-DRUG
lenalidomide	I-DRUG
and	O
1.25	O
mg	O
/	O
m	O
(	O
2	O
)	O
topotecan	B-DRUG
.	O
	
Four	O
patients	O
discontinued	O
because	O
of	O
dose-limiting	O
toxicity	O
","	O
most	O
commonly	O
grade	O
4	O
neutropenia	B-TOXI
(	O
n	O
=	O
3	O
)	O
.	O
	
One	O
patient	O
discontinued	O
because	O
of	O
lack	O
of	O
therapeutic	B-TOXI
effect	I-TOXI
.	O
	
The	O
study	O
was	O
terminated	O
early	O
for	O
reasons	O
of	O
toxicity	O
.	O
	
The	O
addition	O
of	O
lenalidomide	B-DRUG
to	O
topotecan	B-DRUG
is	O
not	O
a	O
feasible	O
drug	O
combination	O
in	O
women	O
with	O
advanced	B-CANCER
epithelial	I-CANCER
ovarian	I-CANCER
carcinoma	I-CANCER
because	O
of	O
dose-limiting	O
toxicity	O
.	O
	
Safety	O
and	O
pharmacokinetics	O
of	O
motesanib	B-DRUG
in	O
combination	O
with	O
panitumumab	B-DRUG
and	O
gemcitabine-Cisplatin	B-DRUG
in	O
patients	O
with	O
advanced	O
cancer	O
.	O
	
	
Purpose	O
.	O
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
safety	O
and	O
tolerability	O
of	O
motesanib	B-DRUG
(	O
an	O
orally	O
administered	O
small-molecule	O
antagonist	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptors	O
1	O
","	O
2	O
","	O
and	O
3	O
","	O
platelet-derived	O
growth	O
factor	O
receptor	O
","	O
and	O
Kit	O
)	O
when	O
administered	O
in	O
combination	O
with	O
panitumumab	B-DRUG
","	O
gemcitabine	B-DRUG
","	O
and	O
cisplatin	B-DRUG
.	O
	
Methods	O
.	O
	
This	O
was	O
an	O
open-label	O
","	O
multicenter	O
phase	O
1b	O
study	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
with	O
an	O
ECOG	O
performance	O
status	O
_1	O
and	O
for	O
whom	O
a	O
gemcitabine	B-DRUG
/	O
cisplatin	B-DRUG
regimen	O
was	O
indicated	O
.	O
	
Patients	O
received	O
motesanib	B-DRUG
(	O
0	O
mg	O
[	O
control	O
]	O
","	O
50	O
mg	O
once	O
daily	O
[	O
QD	O
]	O
","	O
75	O
mg	O
QD	O
","	O
100	O
mg	O
QD	O
","	O
125	O
mg	O
QD	O
","	O
or	O
75	O
mg	O
twice	O
daily	O
[	O
BID	O
]	O
)	O
with	O
panitumumab	B-DRUG
(	O
9	O
mg	O
/	O
kg	O
)	O
","	O
gemcitabine	B-DRUG
(	O
1250	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
cisplatin	B-DRUG
(	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
in	O
21-day	O
cycles	O
.	O
	
The	O
primary	O
endpoint	O
was	O
the	O
incidence	O
of	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
.	O
	
Results	O
.	O
	
Forty-one	O
patients	O
were	O
enrolled	O
and	O
received	O
treatment	O
(	O
including	O
8	O
control	O
patients	O
)	O
.	O
	
One	O
of	O
eight	O
patients	O
in	O
the	O
50	O
mg	O
QD	O
cohort	O
and	O
5	O
/	O
11	O
patients	O
in	O
the	O
125	O
mg	O
QD	O
cohort	O
experienced	O
DLTs	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
was	O
established	O
as	O
100	O
mg	O
QD	O
.	O
	
Among	O
patients	O
who	O
received	O
motesanib	B-DRUG
(	O
n	O
=	O
33	O
)	O
","	O
29	O
had	O
motesanib-related	B-DRUG
adverse	O
events	O
.	O
	
Fourteen	O
patients	O
had	O
serious	O
motesanib-related	B-DRUG
events	O
.	O
	
Ten	O
patients	O
had	O
motesanib-related	B-DRUG
venous	B-TOXI
thromboembolic	I-TOXI
events	I-TOXI
and	O
three	O
had	O
motesanib-related	B-DRUG
arterial	B-TOXI
thromboembolic	I-TOXI
events	I-TOXI
","	O
two	O
of	O
which	O
were	O
considered	O
serious	O
.	O
	
One	O
patient	O
had	O
a	O
complete	O
response	O
and	O
nine	O
had	O
partial	O
responses	O
as	O
their	O
best	O
objective	O
response	O
.	O
	
Conclusions	O
.	O
	
The	O
combination	O
of	O
motesanib	B-DRUG
","	O
panitumumab	B-DRUG
","	O
and	O
gemcitabine	B-DRUG
/	O
cisplatin	B-DRUG
could	O
not	O
be	O
administered	O
consistently	O
and	O
","	O
at	O
the	O
described	O
doses	O
and	O
schedule	O
","	O
may	O
be	O
intolerable	O
.	O
	
However	O
","	O
encouraging	O
antitumor	O
activity	O
was	O
noted	O
in	O
some	O
cases	O
.	O
	
Concurrent	O
chemotherapy	O
/	O
radiotherapy	O
for	O
limited	O
small-cell	B-CANCER
lung	I-CANCER
carcinoma	I-CANCER
:	O
a	O
Southwest	O
Oncology	O
Group	O
Study	O
.	O
	
	
The	O
Southwest	O
Oncology	O
Group	O
(	O
SWOG	O
)	O
has	O
conducted	O
a	O
phase	O
II	O
study	O
to	O
explore	O
the	O
efficacy	O
and	O
toxicity	O
of	O
initial	O
","	O
concurrent	O
use	O
of	O
radiation	O
therapy	O
with	O
cisplatin	B-DRUG
","	O
etoposide	B-DRUG
(	O
VP-16	B-DRUG
)	O
","	O
and	O
vincristine	B-DRUG
in	O
limited-stage	O
small-cell	B-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
lung	I-CANCER
.	O
	
Two	O
courses	O
of	O
cisplatin	B-DRUG
","	O
VP-16	B-DRUG
","	O
and	O
vincristine	B-DRUG
chemotherapy	O
were	O
given	O
with	O
concurrent	O
radiotherapy	O
(	O
XRT	O
)	O
to	O
the	O
primary	O
tumor	O
to	O
a	O
total	O
dose	O
of	O
"4,500"	O
cGy	O
.	O
	
Elective	O
brain	O
XRT	O
was	O
given	O
to	O
all	O
patients	O
concurrent	O
with	O
a	O
third	O
course	O
of	O
cisplatin	B-DRUG
/	O
VP-16	B-DRUG
therapy	O
.	O
	
Consolidation	O
chemotherapy	O
consisting	O
of	O
vincristine	B-DRUG
","	O
methotrexate	B-DRUG
","	O
and	O
VP-16	B-DRUG
alternating	O
with	O
Adriamycin	B-DRUG
(	O
doxorubicin	B-DRUG
;	O
Adria	O
Laboratories	O
","	O
Columbus	O
","	O
OH	O
)	O
and	O
cyclophosphamide	B-DRUG
","	O
was	O
given	O
for	O
12	O
weeks	O
following	O
the	O
initial	O
induction	O
chemotherapy	O
/	O
XRT	O
program	O
.	O
	
Patients	O
with	O
a	O
complete	O
response	O
had	O
all	O
therapy	O
discontinued	O
.	O
	
Among	O
154	O
eligible	O
patients	O
treated	O
","	O
the	O
complete	O
response	O
rate	O
was	O
56	O
%	O
","	O
with	O
a	O
partial	O
response	O
rate	O
of	O
27	O
%	O
.	O
	
The	O
median	O
survival	O
is	O
17.5	O
months	O
with	O
an	O
estimated	O
30	O
%	O
survival	O
rate	O
at	O
4	O
years	O
from	O
initiation	O
of	O
treatment	O
.	O
	
Combined	O
modality	O
toxicities	O
were	O
acceptable	O
with	O
the	O
predominant	O
toxicity	O
being	O
moderate	O
to	O
severe	B-TOXI
leukopenia	I-TOXI
and	O
mild	B-TOXI
radiation	I-TOXI
esophagitis	I-TOXI
.	O
	
The	O
results	O
of	O
this	O
treatment	O
program	O
appear	O
superior	O
to	O
any	O
previously	O
reported	O
by	O
our	O
group	O
and	O
compare	O
favorably	O
to	O
those	O
in	O
the	O
literature	O
at	O
large	O
.	O
	
Phase	O
I	O
dose-escalation	O
study	O
to	O
determine	O
the	O
safety	O
","	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
brivanib	B-DRUG
alaninate	I-DRUG
in	O
combination	O
with	O
full-dose	O
cetuximab	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
gastrointestinal	I-CANCER
malignancies	I-CANCER
who	O
have	O
failed	O
prior	O
therapy	O
.	O
	
	
The	O
objectives	O
of	O
this	O
phase	O
I	O
study	O
were	O
to	O
determine	O
the	O
safety	O
","	O
pharmacokinetics	O
(	O
PK	O
)	O
","	O
pharmacodynamics	O
and	O
efficacy	O
of	O
brivanib	B-DRUG
combined	O
with	O
full-dose	O
cetuximab	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
gastrointestinal	I-CANCER
malignancies	I-CANCER
.	O
	
Patients	O
with	O
advanced	B-CANCER
gastrointestinal	I-CANCER
malignancies	I-CANCER
who	O
had	O
failed	O
prior	O
therapies	O
received	O
brivanib	B-DRUG
(	O
320	O
","	O
600	O
or	O
800	O
mg	O
daily	O
)	O
plus	O
cetuximab	B-DRUG
(	O
400	O
mg	O
m	O
(	O
-2	O
)	O
loading	O
dose	O
then	O
250	O
mg	O
m	O
(	O
-2	O
)	O
weekly	O
)	O
.	O
	
Assessments	O
included	O
adverse	O
events	O
","	O
PK	O
","	O
tumour	O
response	O
","	O
2	B-DRUG
[	I-DRUG
18F	I-DRUG
]	I-DRUG
fluoro-2-deoxyglucose	I-DRUG
positron-emitting	O
tomography	O
and	O
K-Ras	O
mutation	O
analyses	O
.	O
	
Toxicities	O
observed	O
were	O
manageable	O
;	O
the	O
most	O
common	O
treatment-related	O
toxicities	O
(	O
&	O
gt	O
;	O
10	O
%	O
of	O
patients	O
)	O
were	O
fatigue	B-TOXI
","	O
diarrhoea	B-TOXI
","	O
anorexia	B-TOXI
","	O
increase	B-TOXI
in	I-TOXI
aspartate	I-TOXI
aminotransferase	I-TOXI
and	I-TOXI
alanine	I-TOXI
aminotransferase	I-TOXI
","	O
acneiform	B-TOXI
dermatitis	I-TOXI
","	O
headache	B-TOXI
","	O
mucosal	B-TOXI
inflammation	I-TOXI
","	O
nausea	B-TOXI
","	O
dry	B-TOXI
skin	I-TOXI
","	O
vomiting	B-TOXI
","	O
hypertension	B-TOXI
","	O
pruritus	B-TOXI
","	O
proteinuria	B-TOXI
and	O
weight	B-TOXI
loss	I-TOXI
.	O
	
Of	O
62	O
patients	O
","	O
6	O
(	O
9.7	O
%	O
)	O
had	O
objective	O
radiographic	O
partial	O
responses	O
","	O
with	O
an	O
overall	O
response	O
rate	O
of	O
10	O
%	O
.	O
	
Median	O
duration	O
of	O
response	O
was	O
9.2	O
months	O
;	O
median	O
progression-free	O
survival	O
was	O
3.9	O
months	O
.	O
	
The	O
acceptable	O
toxicity	O
profile	O
and	O
efficacy	O
of	O
brivanib	O
observed	O
in	O
this	O
study	O
were	O
promising	O
.	O
	
These	O
findings	O
are	O
being	O
further	O
evaluated	O
in	O
a	O
phase	O
III	O
study	O
of	O
brivanib	O
plus	O
cetuximab	B-DRUG
vs	O
cetuximab	B-DRUG
alone	O
in	O
patients	O
previously	O
treated	O
with	O
combination	O
chemotherapy	O
for	O
K-Ras	O
wild-type	O
advanced	B-CANCER
metastatic	I-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Randomized	O
phase	O
III	O
placebo-controlled	B-DRUG
trial	O
of	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
with	O
or	O
without	O
the	O
vascular	O
disrupting	O
agent	O
vadimezan	B-DRUG
(	O
ASA404	B-DRUG
)	O
in	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
This	O
phase	O
III	O
trial	O
was	O
conducted	O
to	O
test	O
whether	O
the	O
novel	O
vascular	O
disrupting	O
agent	O
ASA404	B-DRUG
(	O
vadimezan	B-DRUG
)	O
","	O
when	O
combined	O
with	O
first-line	O
platinum-based	B-DRUG
chemotherapy	O
","	O
improves	O
survival	O
in	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
versus	O
chemotherapy	O
alone	O
.	O
	
Patients	O
with	O
advanced	O
stage	O
IIIB	O
or	O
IV	O
NSCLC	B-CANCER
","	O
stratified	O
by	O
sex	O
and	O
tumor	O
histology	O
","	O
were	O
randomly	O
assigned	O
01:01	O
to	O
paclitaxel	B-DRUG
(	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
","	O
6	O
)	O
with	O
or	O
without	O
ASA404	B-DRUG
(	O
"1,800"	O
mg	O
m	O
(	O
2	O
)	O
)	O
","	O
given	O
intravenously	O
once	O
every	O
3	O
weeks	O
for	O
six	O
cycles	O
followed	O
by	O
maintenance	O
ASA404	B-DRUG
or	O
placebo	B-DRUG
.	O
	
Primary	O
end	O
point	O
was	O
overall	O
survival	O
(	O
OS	O
)	O
;	O
secondary	O
end	O
points	O
included	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
and	O
progression-free	O
survival	O
(	O
PFS	O
)	O
.	O
	
One	O
thousand	O
two	O
hundred	O
ninety-nine	O
patients	O
were	O
randomly	O
assigned	O
.	O
	
The	O
trial	O
was	O
stopped	O
for	O
futility	O
at	O
interim	O
analysis	O
.	O
	
At	O
final	O
analysis	O
","	O
there	O
was	O
no	O
difference	O
in	O
OS	O
seen	O
between	O
ASA404	B-DRUG
(	O
n	O
=	O
649	O
)	O
and	O
placebo	B-DRUG
(	O
n	O
=	O
650	O
)	O
arms	O
:	O
median	O
OS	O
was	O
13.4	O
and	O
12.7	O
months	O
respectively	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
","	O
1.01	O
;	O
95	O
%	O
CI	O
","	O
0.85	O
to	O
1.19	O
;	O
P	O
=	O
0.535	O
)	O
.	O
	
Similarly	O
","	O
no	O
OS	O
difference	O
was	O
seen	O
in	O
the	O
histologic	O
(	O
squamous	O
or	O
nonsquamous	O
)	O
and	O
sex	O
(	O
male	O
or	O
female	O
)	O
strata	O
.	O
	
Median	O
PFS	O
was	O
5.5	O
months	O
in	O
both	O
arms	O
(	O
HR	O
","	O
1.04	O
;	O
P	O
=	O
0.727	O
)	O
","	O
while	O
ORR	O
was	O
25	O
%	O
in	O
both	O
arms	O
(	O
P	O
=	O
1	O
)	O
.	O
	
Overall	O
rate	O
of	O
adverse	O
events	O
(	O
AEs	O
)	O
was	O
comparable	O
between	O
the	O
ASA404	B-DRUG
and	O
placebo	B-DRUG
arms	O
.	O
	
Grade	O
4	O
neutropenia	B-TOXI
(	O
27	O
%	O
v	O
19	O
%	O
)	O
and	O
infusion	B-TOXI
site	I-TOXI
pain	I-TOXI
(	O
10	O
%	O
v	O
0.5	O
%	O
)	O
were	O
reported	O
more	O
frequently	O
in	O
the	O
ASA404	B-DRUG
arm	O
.	O
	
The	O
addition	O
of	O
ASA404	B-DRUG
to	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
","	O
although	O
generally	O
well	O
tolerated	O
","	O
failed	O
to	O
improve	O
frontline	O
efficacy	O
in	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
Lenalidomide	B-DRUG
can	O
be	O
safely	O
combined	O
with	O
R-CHOP	B-DRUG
(	O
R2CHOP	B-DRUG
)	O
in	O
the	O
initial	O
chemotherapy	O
for	O
aggressive	O
B-cell	B-CANCER
lymphomas	I-CANCER
:	O
phase	O
I	O
study	O
.	O
	
	
Lenalidomide	B-DRUG
was	O
shown	O
to	O
have	O
significant	O
single-agent	O
activity	O
in	O
relapsed	O
aggressive	O
non-Hodgkin	B-CANCER
's	I-CANCER
lymphoma	I-CANCER
(	O
NHL	B-CANCER
)	O
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
trial	O
to	O
establish	O
the	O
maximum	O
tolerated	O
dose	O
of	O
lenalidomide	B-DRUG
that	O
could	O
be	O
combined	O
with	O
R-CHOP	B-DRUG
(	O
rituximab-cyclophosphamide	B-DRUG
","	O
doxorubicin	B-DRUG
","	O
vincristine	B-DRUG
","	O
and	O
prednisone	B-DRUG
)	O
.	O
	
Eligible	O
patients	O
were	O
adults	O
with	O
newly	O
diagnosed	O
","	O
untreated	O
CD20	O
positive	O
diffuse	O
large	O
cell	O
or	O
follicular	O
grade	O
III	O
NHL	B-CANCER
.	O
	
Patients	O
received	O
oral	B-DRUG
lenalidomide	I-DRUG
on	O
days	O
1月10日	O
with	O
standard	O
dose	O
R-CHOP	B-DRUG
every	O
21	O
days	O
.	O
	
All	O
patients	O
received	O
pegfilgrastim	B-DRUG
on	O
day	O
2	O
of	O
the	O
cycle	O
and	O
aspirin	B-DRUG
prophylaxis	I-DRUG
.	O
	
The	O
lenalidomide	B-DRUG
dose	O
levels	O
tested	O
were	O
15	O
","	O
20	O
and	O
25	O
mg	O
.	O
	
A	O
total	O
of	O
24	O
patients	O
were	O
enrolled	O
.	O
	
The	O
median	O
age	O
was	O
65	O
(	O
35-82	O
)	O
years	O
and	O
54	O
%	O
were	O
over	O
60	O
years	O
.	O
	
Three	O
patients	O
received	O
15	O
mg	O
","	O
3	O
received	O
20	O
mg	O
and	O
18	O
received	O
25	O
mg	O
of	O
lenalidomide	B-DRUG
.	O
	
No	O
dose	O
limiting	O
toxicity	O
was	O
found	O
","	O
and	O
25	O
mg	O
on	O
days	O
1月10日	O
is	O
the	O
recommended	O
dose	O
for	O
phase	O
II	O
.	O
	
The	O
incidence	O
of	O
grade	O
IV	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
was	O
67	O
%	O
and	O
21	O
%	O
","	O
respectively	O
.	O
	
Febrile	B-TOXI
neutropenia	I-TOXI
was	O
rare	O
(	O
4	O
%	O
)	O
and	O
there	O
were	O
no	O
toxic	O
deaths	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
100	O
%	O
with	O
a	O
complete	O
response	O
rate	O
of	O
77	O
%	O
.	O
	
Lenalidomide	B-DRUG
at	O
the	O
dose	O
of	O
25	O
mg	O
/	O
day	O
administered	O
on	O
days	O
1	O
to	O
10	O
of	O
21-day	O
cycle	O
can	O
be	O
safely	O
combined	O
with	O
R-CHOP	B-DRUG
in	O
the	O
initial	O
chemotherapy	O
of	O
aggressive	O
B-cell	B-CANCER
lymphoma	I-CANCER
.	O
	
Figitumumab	B-DRUG
combined	O
with	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
treatment-na茂ve	O
Japanese	O
patients	O
with	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
insulin-like	B-DRUG
growth	O
factor	O
(	O
IGF	O
)	O
signaling	O
pathway	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
numerous	O
tumor	O
types	O
","	O
including	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Figitumumab	B-DRUG
is	O
a	O
fully	O
human	O
IgG2	O
monoclonal	O
antibody	O
against	O
IGF-1	O
receptor	O
(	O
IGF-1R	O
)	O
.	O
	
This	O
phase	O
I	O
","	O
open-label	O
","	O
dose-escalation	O
study	O
(	O
ClinicalTrials.gov	O
:	O
NCT00603538	O
)	O
assessed	O
the	O
safety	O
and	O
tolerability	O
of	O
figitumumab	B-DRUG
(	O
6	O
","	O
10	O
and	O
20	O
mg	O
/	O
kg	O
)	O
in	O
combination	O
with	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
:	O
6	O
mg路min	O
/	O
mL	O
)	O
and	O
paclitaxel	B-DRUG
(	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
in	O
Japanese	O
patients	O
(	O
N	O
=	O
19	O
)	O
with	O
chemotherapy-na茂ve	O
","	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
Treatments	O
were	O
administered	O
intravenously	O
on	O
day	O
1	O
of	O
a	O
21-day	O
cycle	O
for	O
four	O
to	O
six	O
cycles	O
.	O
	
Pharmacokinetics	O
","	O
biomarkers	O
","	O
and	O
antitumor	O
activity	O
were	O
also	O
evaluated	O
.	O
	
Figitumumab	B-DRUG
in	O
combination	O
with	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
was	O
well	O
tolerated	O
at	O
doses	O
up	O
to	O
20	O
mg	O
/	O
kg	O
;	O
no	O
dose-limiting	O
toxicities	O
were	O
observed	O
at	O
this	O
dose	O
level	O
.	O
	
When	O
given	O
in	O
combination	O
","	O
figitumumab	B-DRUG
plasma	O
exposure	O
increased	O
in	O
an	O
approximately	O
dose-proportional	O
manner	O
.	O
	
The	O
approximate	O
2-fold	O
accumulation	O
following	O
repeated	O
administration	O
supported	O
the	O
21-day	O
regimen	O
as	O
appropriate	O
for	O
figitumumab	B-DRUG
administration	O
.	O
	
Serum	O
total	O
IGF-1	O
and	O
IGF	O
binding	O
protein-3	O
concentrations	O
increased	O
following	O
figitumumab	B-DRUG
dosing	O
","	O
but	O
a	O
clear	O
dose-dependent	O
relationship	O
was	O
not	O
demonstrated	O
.	O
	
Seven	O
of	O
18	O
evaluable	O
patients	O
experienced	O
a	O
partial	O
response	O
.	O
	
Figitumumab	B-DRUG
20	O
mg	O
/	O
kg	O
in	O
combination	O
with	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
was	O
well	O
tolerated	O
in	O
chemotherapy-na茂ve	O
Japanese	O
patients	O
with	O
NSCLC	B-CANCER
.	O
	
Further	O
analysis	O
of	O
biomarker	O
data	O
is	O
necessary	O
for	O
the	O
development	O
of	O
figitumumab	B-DRUG
therapy	O
.	O
	
Phase	O
I	O
trial	O
of	O
cixutumumab	B-DRUG
combined	O
with	O
temsirolimus	B-DRUG
in	O
patients	O
with	O
advanced	O
cancer	O
.	O
	
	
Mammalian	O
target	O
of	O
rapamycin	B-DRUG
(	O
mTOR	O
)	O
inhibitors	O
mediate	O
AKT	O
activation	O
through	O
a	O
type	O
1	O
insulin-like	B-DRUG
growth	O
factor	O
receptor	O
(	O
IGF-1R	O
)	O
#NAME?	O
mechanism	O
.	O
	
Combining	O
the	O
mTOR	O
inhibitor	O
temsirolimus	B-DRUG
with	O
cixutumumab	B-DRUG
","	O
a	O
fully	O
human	O
immunoglobulin	B-DRUG
G1	O
monoclonal	O
antibody	O
directed	O
against	O
IGF-1R	O
","	O
was	O
expected	O
to	O
enhance	O
mTOR-targeted	O
anticancer	O
activity	O
by	O
modulating	O
resistance	O
to	O
mTOR	O
inhibition	O
.	O
	
The	O
objectives	O
of	O
this	O
phase	O
I	O
study	O
were	O
to	O
evaluate	O
the	O
tolerability	O
and	O
activity	O
of	O
temsirolimus	B-DRUG
and	O
cixutumumab	B-DRUG
.	O
	
Patients	O
in	O
sequential	O
cohorts	O
(	O
	O
design	O
)	O
received	O
escalating	O
doses	O
of	O
temsirolimus	B-DRUG
with	O
cixutumumab	B-DRUG
weekly	O
for	O
28	O
days	O
.	O
	
At	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
21	O
patients	O
were	O
randomized	O
into	O
three	O
separate	O
drug	O
sequence	O
treatment	O
groups	O
for	O
serial	O
blood	O
draws	O
and	O
2	B-DRUG
[	I-DRUG
18F	I-DRUG
]	I-DRUG
fluoro-2-deoxy-d-glucose	I-DRUG
positron	O
emission	O
tomography	O
combined	O
with	O
X-ray	O
computed	O
tomography	O
(	O
FDG-PET	O
/	O
CT	O
)	O
scans	O
for	O
pharmacodynamic	O
analyses	O
(	O
PD	O
)	O
.	O
	
Forty-two	O
patients	O
with	O
advanced	B-CANCER
cancer	I-CANCER
(	O
19	O
male	O
/	O
23	O
female	O
","	O
median	O
age	O
=	O
53	O
","	O
median	O
number	O
of	O
prior	O
therapies	O
=	O
4	O
)	O
were	O
enrolled	O
.	O
	
MTD	O
was	O
reached	O
at	O
cixutumumab	B-DRUG
","	O
6	O
mg	O
/	O
kg	O
IV	O
and	O
temsirolimus	B-DRUG
","	O
25	O
mg	O
IV	O
.	O
	
Dose-limiting	O
toxicities	O
included	O
grade	O
3	O
mucositis	B-TOXI
","	O
febrile	B-TOXI
neutropenia	I-TOXI
","	O
and	O
grade	O
4	O
thrombocytopenia	B-TOXI
.	O
	
The	O
most	O
frequent	O
toxicities	O
were	O
hypercholesterolemia	B-TOXI
","	O
hypertriglyceridemia	B-TOXI
","	O
hyperglycemia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
and	O
mucositis	B-TOXI
.	O
	
Tumor	O
reduction	O
was	O
observed	O
in	O
2	O
of	O
3	O
patients	O
with	O
Ewing	B-CANCER
's	I-CANCER
sarcoma	I-CANCER
and	O
in	O
4	O
of	O
10	O
patients	O
with	O
adrenocortical	B-CANCER
carcinoma	I-CANCER
.	O
	
PD	O
data	O
suggest	O
that	O
cixutumumab	B-DRUG
alone	O
or	O
combined	O
with	O
temsirolimus	B-DRUG
increased	O
plasma	O
IGF-1	O
and	O
IGF	O
binding	O
protein	O
3	O
FDG-PET	O
/	O
CT	O
showed	O
the	O
odds	O
of	O
achieving	O
stable	O
disease	O
decreased	O
by	O
58	O
%	O
(	O
P	O
=	O
0.1213	O
)	O
with	O
a	O
one-unit	O
increase	O
in	O
absolute	O
change	O
of	O
standard	O
uptake	O
value	O
from	O
baseline	O
to	O
day	O
3	O
Temsirolimus	B-DRUG
combined	O
with	O
cixutumumab	B-DRUG
was	O
well	O
tolerated	O
.	O
	
We	O
are	O
currently	O
enrolling	O
expansion	O
cohorts	O
at	O
the	O
MTD	O
for	O
Ewing	B-CANCER
's	I-CANCER
sarcoma	I-CANCER
and	O
adrenocortical	B-CANCER
carcinoma	I-CANCER
.	O
	
Postoperative	O
intraperitoneal	O
5-fluoro-2'-deoxyuridine	B-DRUG
added	O
to	O
chemoradiation	O
in	O
patients	O
curatively	O
resected	O
(	O
R0	O
)	O
for	O
locally	O
advanced	B-CANCER
gastric	I-CANCER
and	I-CANCER
gastroesophageal	I-CANCER
junction	I-CANCER
adenocarcinoma	I-CANCER
.	O
	
	
Chemoradiation	O
after	O
surgery	O
for	O
locally	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
improves	O
overall	O
and	O
relapse-free	O
survival	O
compared	O
with	O
observation	O
.	O
	
However	O
","	O
locoregional	O
recurrences	O
remain	O
high	O
.	O
	
Accordingly	O
","	O
we	O
instituted	O
this	O
pilot	O
/	O
feasibility	O
study	O
","	O
including	O
intraperitoneal	B-DRUG
5-fluoro-2'-deoxyuridine	I-DRUG
(	O
IP	B-DRUG
FUDR	I-DRUG
)	O
as	O
part	O
of	O
the	O
treatment	O
.	O
	
Gastric	B-CANCER
/	I-CANCER
gastroesophageal	I-CANCER
junction	I-CANCER
adenocarcinoma	I-CANCER
stage	O
Ib-IV	O
(	O
M0	O
)	O
patients	O
who	O
underwent	O
R	O
(	O
0	O
)	O
resection	O
were	O
eligible	O
and	O
had	O
IP	O
catheters	O
inserted	O
at	O
time	O
of	O
surgery	O
.	O
	
IP	B-DRUG
FUDR	I-DRUG
(	O
3	O
g	O
/	O
dose	O
/	O
day	O
)	O
was	O
given	O
during	O
study	O
days	O
1月3日	O
and	O
15-17	O
before	O
combined	O
5-fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
external	O
beam	O
radiation	O
(	O
45	O
Gy	O
)	O
.	O
	
Endpoints	O
included	O
toxicity	O
","	O
completion	O
rate	O
","	O
locoregional	O
recurrence	O
","	O
and	O
survival	O
.	O
	
Twenty-eight	O
patients	O
(	O
22	O
men	O
)	O
were	O
enrolled	O
from	O
2002-2006	O
at	O
two	O
institutions	O
;	O
their	O
median	O
age	O
was	O
59.5	O
years	O
.	O
	
After	O
R	O
(	O
0	O
)	O
resection	O
","	O
a	O
median	O
22	O
(	O
range	O
","	O
8-102	O
)	O
lymph	O
nodes	O
were	O
examined	O
","	O
and	O
22	O
patients	O
had	O
positive	O
nodes	O
.	O
	
AJCC	O
stages	O
were	O
IB	O
(	O
n	O
=	O
8	O
)	O
","	O
II	O
(	O
n	O
=	O
10	O
)	O
","	O
IIIA	O
(	O
n	O
=	O
5	O
)	O
","	O
IIIB	O
(	O
n	O
=	O
1	O
)	O
","	O
and	O
IV	O
(	O
n	O
=	O
4	O
)	O
.	O
	
Full-dose	O
IP	B-DRUG
FUDR	I-DRUG
and	O
chemoradiation	O
treatment	O
was	O
completed	O
in	O
20	O
and	O
25	O
patients	O
","	O
respectively	O
.	O
	
At	O
nearly	O
4-year	O
median	O
follow-up	O
","	O
11	O
patients	O
were	O
disease-free	O
","	O
5	O
were	O
alive	O
with	O
disease	O
","	O
7	O
were	O
dead	B-TOXI
of	O
disease	O
","	O
and	O
1	O
was	O
dead	B-TOXI
from	O
other	O
cause	O
;	O
4	O
have	O
been	O
lost	O
to	O
follow-up	O
.	O
	
Recurrences	O
were	O
local	O
in	O
one	O
","	O
intra-abdominal	O
in	O
six	O
","	O
distant	O
in	O
two	O
","	O
multiple	O
sites	O
in	O
two	O
","	O
and	O
unknown	O
in	O
one	O
.	O
	
The	O
median	O
relapse-free	O
survival	O
is	O
65.3	O
months	O
","	O
and	O
the	O
median	O
overall	O
survival	O
has	O
not	O
yet	O
been	O
reached	O
.	O
	
IP	B-DRUG
FUDR	I-DRUG
before	O
chemoradiation	O
after	O
R	O
(	O
0	O
)	O
gastric	B-CANCER
cancer	I-CANCER
resection	O
is	O
well	O
tolerated	O
without	O
compromising	O
completion	O
of	O
postoperative	O
adjuvant	O
treatment	O
.	O
	
Larger	O
randomized	O
trials	O
studying	O
IP	B-DRUG
FUDR	I-DRUG
as	O
part	O
of	O
gastric	B-CANCER
cancer	I-CANCER
multidisciplinary	O
treatment	O
are	O
needed	O
to	O
prove	O
efficacy	O
in	O
reducing	O
regional	O
recurrence	O
and	O
improving	O
survival	O
.	O
	
Phase	O
I	O
study	O
of	O
continuous	O
and	O
intermittent	O
schedules	O
of	O
lapatinib	B-DRUG
in	O
combination	O
with	O
vinorelbine	B-DRUG
in	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
Chemotherapy	O
in	O
combination	O
with	O
small-molecule	O
epidermal	O
growth	O
factor	O
receptor	O
inhibitors	O
has	O
yielded	O
inconsistent	O
results	O
.	O
	
Based	O
on	O
preclinical	O
models	O
","	O
we	O
conducted	O
a	O
phase	O
I	O
trial	O
of	O
two	O
schedules	O
of	O
lapatinib	B-DRUG
and	O
vinorelbine	B-DRUG
.	O
	
Patients	O
had	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
and	O
up	O
to	O
two	O
prior	O
chemotherapeutic	O
regimens	O
.	O
	
Patients	O
were	O
enrolled	O
on	O
two	O
dose-escalating	O
schedules	O
of	O
lapatinib	B-DRUG
","	O
continuous	O
(	O
arm	O
A	O
)	O
or	O
intermittent	O
(	O
arm	O
B	O
)	O
","	O
with	O
vinorelbine	B-DRUG
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
of	O
a	O
28-day	O
cycle	O
.	O
	
Tumors	O
from	O
a	O
subset	O
of	O
patients	O
were	O
evaluated	O
for	O
gene	O
mutations	O
and	O
expression	O
of	O
targets	O
of	O
interest	O
.	O
	
Fifty-one	O
patients	O
were	O
treated	O
.	O
	
The	O
most	O
common	O
grade	O
3	O
/	O
4	O
toxic	O
effects	O
included	O
leukopenia	B-TOXI
","	O
neutropenia	B-TOXI
","	O
and	O
fatigue	B-TOXI
.	O
	
Dose-limiting	O
toxic	O
effects	O
were	O
grade	O
3	O
infection	B-TOXI
","	O
febrile	B-TOXI
neutropenia	I-TOXI
","	O
and	O
diarrhea	B-TOXI
(	O
arm	O
A	O
)	O
and	O
bone	B-TOXI
pain	I-TOXI
and	O
fatigue	B-TOXI
(	O
arm	O
B	O
)	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
was	O
vinorelbine	B-DRUG
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
and	O
lapatinib	B-DRUG
1500	O
mg	O
daily	O
(	O
arm	O
A	O
)	O
and	O
vinorelbine	B-DRUG
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
and	O
lapatinib	B-DRUG
1500	O
mg	O
intermittently	O
(	O
arm	O
B	O
)	O
.	O
	
One	O
patient	O
on	O
each	O
arm	O
had	O
a	O
complete	O
response	O
;	O
both	O
had	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2-positive	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
In	O
a	O
subset	O
of	O
patients	O
","	O
lack	O
of	O
tumor	O
PTEN	O
expression	O
correlated	O
with	O
a	O
shorter	O
time	O
to	O
progression	O
.	O
	
In	O
an	O
unselected	O
population	O
","	O
two	O
schedules	O
of	O
lapatinib	B-DRUG
and	O
vinorelbine	B-DRUG
were	O
feasible	O
and	O
well	O
tolerated	O
.	O
	
Safety	O
and	O
pharmacokinetics	O
of	O
motesanib	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
and	O
erlotinib	B-DRUG
for	O
the	O
treatment	O
of	O
solid	B-CANCER
tumors	I-CANCER
:	O
a	O
phase	O
1b	O
study	O
.	O
	
	
This	O
phase	O
1b	O
study	O
assessed	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
safety	O
","	O
and	O
pharmacokinetics	O
of	O
motesanib	B-DRUG
(	O
a	O
small-molecule	O
antagonist	O
of	O
VEGF	O
receptors	O
1	O
","	O
2	O
","	O
and	O
3	O
;	O
platelet-derived	O
growth	O
factor	O
receptor	O
;	O
and	O
Kit	O
)	O
administered	O
once	O
daily	O
(	O
QD	O
)	O
or	O
twice	O
daily	O
(	O
BID	O
)	O
in	O
combination	O
with	O
erlotinib	B-DRUG
and	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
Patients	O
received	O
weekly	O
intravenous	B-DRUG
gemcitabine	I-DRUG
(	O
1000	O
mg	O
/	O
m2	O
)	O
and	O
erlotinib	B-DRUG
(	O
100	O
mg	O
QD	O
)	O
alone	O
(	O
control	O
cohort	O
)	O
or	O
in	O
combination	O
with	O
motesanib	B-DRUG
(	O
50	O
mg	O
QD	O
","	O
75	O
mg	O
BID	O
","	O
125	O
mg	O
QD	O
","	O
or	O
100	O
mg	O
QD	O
;	O
cohorts	O
1月4日	O
)	O
;	O
or	O
erlotinib	B-DRUG
(	O
150	O
mg	O
QD	O
)	O
in	O
combination	O
with	O
motesanib	B-DRUG
(	O
100	O
or	O
125	O
mg	O
QD	O
;	O
cohorts	O
5	O
and	O
6	O
)	O
.	O
	
Fifty-six	O
patients	O
were	O
enrolled	O
and	O
received	O
protocol-specified	O
treatment	O
.	O
	
Dose-limiting	O
toxicities	O
occurred	O
in	O
11	O
patients	O
in	O
cohorts	O
1	O
(	O
n	O
=	O
2	O
)	O
","	O
2	O
(	O
n	O
=	O
4	O
)	O
","	O
3	O
(	O
n	O
=	O
3	O
)	O
","	O
and	O
6	O
(	O
n	O
=	O
2	O
)	O
.	O
	
The	O
MTD	O
of	O
motesanib	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
and	O
erlotinib	B-DRUG
was	O
100	O
mg	O
QD	O
.	O
	
Motesanib	B-DRUG
125	O
mg	O
QD	O
was	O
tolerable	O
only	O
in	O
combination	O
with	O
erlotinib	B-DRUG
alone	O
.	O
	
Frequently	O
occurring	O
motesanib-related	B-DRUG
adverse	O
events	O
included	O
diarrhea	B-TOXI
(	O
n	O
=	O
19	O
)	O
","	O
nausea	B-TOXI
(	O
n	O
=	O
18	O
)	O
","	O
vomiting	B-TOXI
(	O
n	O
=	O
13	O
)	O
","	O
and	O
fatigue	B-TOXI
(	O
n	O
=	O
12	O
)	O
","	O
which	O
were	O
mostly	O
of	O
worst	O
grade	O
&	O
lt	O
;	O
3	O
The	O
pharmacokinetics	O
of	O
motesanib	B-DRUG
was	O
not	O
markedly	O
affected	O
by	O
coadministration	O
of	O
gemcitabine	B-DRUG
and	O
erlotinib	B-DRUG
","	O
or	O
erlotinib	B-DRUG
alone	O
.	O
	
Erlotinib	B-DRUG
exposure	O
","	O
however	O
","	O
appeared	O
lower	O
after	O
coadministration	O
with	O
gemcitabine	B-DRUG
and	O
/	O
or	O
motesanib	B-DRUG
.	O
	
Of	O
49	O
evaluable	O
patients	O
","	O
1	O
had	O
a	O
confirmed	O
partial	O
response	O
and	O
26	O
had	O
stable	O
disease	O
.	O
	
Treatment	O
with	O
motesanib	B-DRUG
100	O
mg	O
QD	O
plus	O
erlotinib	B-DRUG
and	O
gemcitabine	B-DRUG
was	O
tolerable	O
.	O
	
Motesanib	B-DRUG
125	O
mg	O
QD	O
was	O
tolerable	O
only	O
in	O
combination	O
with	O
erlotinib	B-DRUG
alone	O
.	O
	
ClinicalTrials.gov	O
NCT01235416	O
.	O
	
Phase	O
I	O
and	O
pharmacokinetic	O
study	O
of	O
capecitabine	B-DRUG
and	O
the	O
oral	O
mTOR	O
inhibitor	O
everolimus	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
malignancies	I-CANCER
.	O
	
	
Everolimus	B-DRUG
is	O
an	O
oral	O
mTOR-inhibitor	O
.	O
	
Preclinical	O
data	O
show	O
synergistic	O
effects	O
of	O
mTOR	O
inhibition	O
in	O
combination	O
with	O
5-fluorouracil-based	B-DRUG
anticancer	O
therapy	O
.	O
	
The	O
combination	O
of	O
everolimus	B-DRUG
with	O
capecitabine	B-DRUG
seems	O
therefore	O
an	O
attractive	O
new	O
","	O
orally	O
available	O
","	O
treatment	O
regimen	O
.	O
	
Safety	O
","	O
preliminary	O
efficacy	O
and	O
pharmacokinetics	O
of	O
everolimus	B-DRUG
in	O
combination	O
with	O
capecitabine	B-DRUG
were	O
investigated	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
malignancies	I-CANCER
.	O
	
Patients	O
were	O
treated	O
with	O
fixed	O
dose	O
everolimus	B-DRUG
10	O
mg	O
/	O
day	O
continuously	O
","	O
plus	O
capecitabine	B-DRUG
bid	O
for	O
14	O
days	O
in	O
three-weekly	O
cycles	O
.	O
	
Dose	O
escalation	O
of	O
capecitabine	B-DRUG
proceeded	O
according	O
to	O
the	O
standard	O
3	O
_	O
3	O
phase	O
I	O
design	O
in	O
four	O
predefined	O
dose	O
levels	O
(	O
"500-1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
bid	O
)	O
.	O
	
In	O
total	O
","	O
18	O
patients	O
were	O
enrolled	O
.	O
	
Median	O
(	O
range	O
)	O
treatment	O
duration	O
with	O
everolimus	B-DRUG
was	O
70	O
days	O
(	O
21-414	O
)	O
.	O
	
Capecitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
bid	O
combined	O
with	O
10	O
mg	O
/	O
day	O
everolimus	B-DRUG
was	O
declared	O
the	O
maximum	O
tolerated	O
dose	O
","	O
at	O
which	O
level	O
one	O
patient	O
developed	O
dose-limiting	O
toxicity	O
(	O
stomatitis	B-TOXI
grade	O
3	O
)	O
.	O
	
Drug-related	O
adverse	O
events	O
were	O
mostly	O
grade	O
_	O
2	O
and	O
included	O
mainly	O
fatigue	B-TOXI
(	O
56	O
%	O
)	O
","	O
stomatitis	B-TOXI
(	O
50	O
%	O
)	O
","	O
and	O
hand-foot	B-TOXI
syndrome	I-TOXI
(	O
33	O
%	O
)	O
.	O
	
Partial	O
response	O
was	O
documented	O
in	O
three	O
patients	O
","	O
and	O
four	O
had	O
stable	O
disease	O
.	O
	
There	O
was	O
no	O
pharmacokinetic	O
interaction	O
between	O
everolimus	B-DRUG
and	O
capecitabine	B-DRUG
.	O
	
Everolimus	B-DRUG
10	O
mg	O
/	O
day	O
continuously	O
combined	O
with	O
capecitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
bid	O
for	O
14	O
days	O
every	O
3	O
weeks	O
is	O
a	O
patient-convenient	O
","	O
safe	O
and	O
tolerable	O
oral	O
treatment	O
regimen	O
.	O
	
This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
feasibility	O
of	O
this	O
combination	O
at	O
doses	O
with	O
proven	O
single	O
agent	O
efficacy	O
in	O
a	O
number	O
of	O
tumors	O
.	O
	
Prolonged	O
clinical	O
benefit	O
was	O
observed	O
in	O
an	O
encouraging	O
39	O
%	O
of	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
malignancies	I-CANCER
.	O
	
Phase	O
I	O
feasibility	O
study	O
of	O
intraperitoneal	B-DRUG
cisplatin	I-DRUG
and	O
intravenous	B-DRUG
paclitaxel	I-DRUG
followed	O
by	O
intraperitoneal	B-DRUG
paclitaxel	I-DRUG
in	O
untreated	O
ovarian	B-CANCER
","	I-CANCER
fallopian	I-CANCER
tube	I-CANCER
","	I-CANCER
and	I-CANCER
primary	I-CANCER
peritoneal	I-CANCER
carcinoma	I-CANCER
:	O
a	O
gynecologic	O
oncology	O
group	O
study	O
.	O
	
	
Intraperitoneal	O
chemotherapy	O
has	O
shown	O
a	O
survival	O
advantage	O
over	O
intravenous	O
chemotherapy	O
for	O
women	O
with	O
newly	O
diagnosed	O
optimally	O
debulked	O
epithelial	B-CANCER
ovarian	I-CANCER
","	I-CANCER
fallopian	I-CANCER
tube	I-CANCER
","	I-CANCER
or	I-CANCER
primary	I-CANCER
peritoneal	I-CANCER
carcinoma	I-CANCER
.	O
	
However	O
","	O
significant	O
toxicity	O
has	O
limited	O
its	O
acceptance	O
.	O
	
In	O
an	O
effort	O
to	O
reduce	O
toxicity	O
","	O
the	O
Gynecologic	O
Oncology	O
Group	O
conducted	O
a	O
Phase	O
I	O
study	O
to	O
evaluate	O
the	O
feasibility	O
of	O
day	O
1	O
intravenous	O
(	O
IV	O
)	O
paclitaxel	B-DRUG
and	O
intraperitoneal	O
(	O
IP	O
)	O
cisplatin	B-DRUG
followed	O
by	O
day	O
8	O
IP	O
paclitaxel	B-DRUG
on	O
an	O
every	O
21-day	O
cycle	O
.	O
	
Patients	O
with	O
Stage	O
IIB-IV	O
epithelial	B-CANCER
ovarian	I-CANCER
","	I-CANCER
fallopian	I-CANCER
tube	I-CANCER
","	I-CANCER
primary	I-CANCER
peritoneal	I-CANCER
carcinomas	I-CANCER
or	I-CANCER
carcinosarcoma	I-CANCER
received	O
paclitaxel	B-DRUG
135mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
over	O
3h	O
followed	O
by	O
cisplatin	B-DRUG
75mg	O
/	O
m	O
(	O
2	O
)	O
IP	O
on	O
day	O
1	O
and	O
paclitaxel	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
IP	O
on	O
day	O
8	O
of	O
a	O
21	O
day	O
cycle	O
with	O
6	O
cycles	O
planned	O
.	O
	
Dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
was	O
defined	O
as	O
febrile	B-TOXI
neutropenia	I-TOXI
or	O
dose-delay	O
of	O
greater	O
than	O
2	O
weeks	O
due	O
to	O
failure	O
to	O
recover	O
counts	O
","	O
or	O
Grade	O
3月5日	O
non-hematologic	B-TOXI
toxicity	I-TOXI
occurring	O
within	O
the	O
first	O
4	O
cycles	O
of	O
treatment	O
.	O
	
Twenty	O
of	O
23	O
patients	O
enrolled	O
were	O
evaluable	O
and	O
nineteen	O
(	O
95	O
%	O
)	O
completed	O
all	O
six	O
cycles	O
of	O
therapy	O
.	O
	
Three	O
patients	O
experienced	O
a	O
DLT	O
consisting	O
of	O
infection	B-TOXI
with	I-TOXI
normal	I-TOXI
absolute	I-TOXI
neutrophil	I-TOXI
count	I-TOXI
","	O
grade	O
3	O
hyperglycemia	B-TOXI
","	O
and	O
grade	O
4	O
abdominal	B-TOXI
pain	I-TOXI
.	O
	
This	O
modified	O
IP	O
regimen	O
which	O
administers	O
both	O
IV	B-DRUG
paclitaxel	I-DRUG
and	O
IP	B-DRUG
cisplatin	I-DRUG
on	O
day	O
one	O
","	O
followed	O
by	O
IP	B-DRUG
paclitaxel	I-DRUG
on	O
day	O
eight	O
","	O
of	O
a	O
twenty-one	O
day	O
cycle	O
appears	O
feasible	O
and	O
is	O
an	O
attractive	O
alternative	O
to	O
the	O
intraperitoneal	O
treatment	O
regimen	O
administered	O
in	O
GOG-0172	O
.	O
	
Bevacizumab	B-DRUG
in	O
combination	O
with	O
chemotherapy	O
as	O
first-line	O
therapy	O
in	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
:	O
a	O
randomized	O
","	O
double-blind	O
","	O
placebo-controlled	B-DRUG
phase	O
III	O
study	O
.	O
	
	
The	O
Avastin	O
in	O
Gastric	B-CANCER
Cancer	I-CANCER
(	O
AVAGAST	O
)	O
trial	O
was	O
a	O
multinational	O
","	O
randomized	O
","	O
placebo-controlled	B-DRUG
trial	O
designed	O
to	O
evaluate	O
the	O
efficacy	O
of	O
adding	O
bevacizumab	B-DRUG
to	O
capecitabine-cisplatin	B-DRUG
in	O
the	O
first-line	O
treatment	O
of	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
received	O
bevacizumab	B-DRUG
7.5	O
mg	O
/	O
kg	O
or	O
placebo	B-DRUG
followed	O
by	O
cisplatin	B-DRUG
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
plus	O
capecitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
daily	O
for	O
14	O
days	O
every	O
3	O
weeks	O
.	O
	
Fluorouracil	B-DRUG
was	O
permitted	O
in	O
patients	O
unable	O
to	O
take	O
oral	O
medications	O
.	O
	
Cisplatin	B-DRUG
was	O
given	O
for	O
six	O
cycles	O
;	O
capecitabine	B-DRUG
and	O
bevacizumab	B-DRUG
were	O
administered	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
overall	O
survival	O
(	O
OS	O
)	O
.	O
	
Log-rank	O
test	O
was	O
used	O
to	O
test	O
the	O
OS	O
difference	O
.	O
	
In	O
all	O
","	O
774	O
patients	O
were	O
enrolled	O
;	O
387	O
were	O
assigned	O
to	O
each	O
treatment	O
group	O
(	O
intention-to-treat	O
population	O
)	O
","	O
and	O
517	O
deaths	B-TOXI
were	O
observed	O
.	O
	
Median	O
OS	O
was	O
12.1	O
months	O
with	O
bevacizumab	B-DRUG
plus	O
fluoropyrimidine-cisplatin	B-DRUG
and	O
10.1	O
months	O
with	O
placebo	B-DRUG
plus	O
fluoropyrimidine-cisplatin	B-DRUG
(	O
hazard	O
ratio	O
0.87	O
;	O
95	O
%	O
CI	O
","	O
0.73	O
to	O
1.03	O
;	O
P	O
=	O
0.1002	O
)	O
.	O
	
Both	O
median	O
progression-free	O
survival	O
(	O
6.7	O
v	O
5.3	O
months	O
;	O
hazard	O
ratio	O
","	O
0.8	O
;	O
95	O
%	O
CI	O
","	O
0.68	O
to	O
0.93	O
;	O
P	O
=	O
0.0037	O
)	O
and	O
overall	O
response	O
rate	O
(	O
46	O
%	O
v	O
37.4	O
%	O
;	O
P	O
=	O
0.0315	O
)	O
were	O
significantly	O
improved	O
with	O
bevacizumab	B-DRUG
versus	O
placebo	B-DRUG
.	O
	
Preplanned	O
subgroup	O
analyses	O
revealed	O
regional	O
differences	O
in	O
efficacy	O
outcomes	O
.	O
	
The	O
most	O
common	O
grade	O
3	O
to	O
5	O
adverse	O
events	O
were	O
neutropenia	B-TOXI
(	O
35	O
%	O
","	O
bevacizumab	B-DRUG
plus	O
fluoropyrimidine-cisplatin	B-DRUG
;	O
37	O
%	O
","	O
placebo	B-DRUG
plus	O
fluoropyrimidine-cisplatin	B-DRUG
)	O
","	O
anemia	B-TOXI
(	O
10	O
%	O
v	O
14	O
%	O
)	O
","	O
and	O
decreased	B-TOXI
appetite	I-TOXI
(	O
8	O
%	O
v	O
11	O
%	O
)	O
.	O
	
No	O
new	O
bevacizumab-related	B-DRUG
safety	O
signals	O
were	O
identified	O
.	O
	
Although	O
AVAGAST	O
did	O
not	O
reach	O
its	O
primary	O
objective	O
","	O
adding	O
bevacizumab	B-DRUG
to	O
chemotherapy	O
was	O
associated	O
with	O
significant	O
increases	O
in	O
progression-free	O
survival	O
and	O
overall	O
response	O
rate	O
in	O
the	O
first-line	O
treatment	O
of	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Initial	O
toxicity	O
assessment	O
of	O
ICON6	O
:	O
a	O
randomised	O
trial	O
of	O
cediranib	B-DRUG
plus	O
chemotherapy	O
in	O
platinum-sensitive	B-DRUG
relapsed	O
ovarian	B-CANCER
cancer	I-CANCER
.	O
	
	
Cediranib	B-DRUG
is	O
a	O
potent	O
oral	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
signalling	O
inhibitor	O
with	O
activity	O
against	O
all	O
three	O
VEGF	O
receptors	O
.	O
	
The	O
International	O
Collaboration	O
for	O
Ovarian	O
Neoplasia	O
6	O
(	O
ICON6	O
)	O
trial	O
was	O
initiated	O
based	O
on	O
evidence	O
of	O
single-agent	O
activity	O
in	O
ovarian	B-CANCER
cancer	I-CANCER
with	O
acceptable	O
toxicity	O
.	O
	
The	O
ICON6	O
trial	O
is	O
a	O
3-arm	O
","	O
3-stage	O
","	O
double-blind	O
","	O
placebo-controlled	B-DRUG
randomised	O
trial	O
in	O
first	O
relapse	O
of	O
platinum-sensitive	B-DRUG
ovarian	B-CANCER
cancer	I-CANCER
.	O
	
Patients	O
are	O
randomised	O
(	O
2	O
:	O
3	O
:	O
3	O
)	O
to	O
receive	O
six	O
cycles	O
of	O
carboplatin	B-DRUG
(	O
AUC5	O
/	O
6	O
)	O
plus	O
paclitaxel	B-DRUG
(	O
175	O
mg	O
m	O
(	O
-2	O
)	O
)	O
with	O
either	O
placebo	B-DRUG
(	O
reference	O
)	O
","	O
cediranib	B-DRUG
20	O
mg	O
per	O
day	O
","	O
followed	O
by	O
placebo	B-DRUG
(	O
concurrent	O
)	O
","	O
or	O
cediranib	B-DRUG
20	O
mg	O
per	O
day	O
","	O
followed	O
by	O
cediranib	B-DRUG
(	O
concurrent	O
plus	O
maintenance	O
)	O
.	O
	
Cediranib	B-DRUG
or	O
placebo	B-DRUG
was	O
continued	O
for	O
18	O
months	O
or	O
until	O
disease	O
progression	O
.	O
	
The	O
primary	O
outcome	O
measure	O
for	O
stage	O
I	O
was	O
safety	O
","	O
and	O
the	O
blinded	O
results	O
are	O
presented	O
here	O
.	O
	
Sixty	O
patients	O
were	O
included	O
in	O
the	O
stage	O
I	O
analysis	O
.	O
	
A	O
total	O
of	O
53	O
patients	O
had	O
received	O
three	O
cycles	O
of	O
chemotherapy	O
and	O
42	O
patients	O
had	O
completed	O
six	O
cycles	O
.	O
	
In	O
all	O
","	O
19	O
out	O
of	O
60	O
patients	O
discontinued	O
cediranib	B-DRUG
or	O
placebo	B-DRUG
during	O
chemotherapy	O
because	O
of	O
adverse	O
events	O
/	O
intercurrent	O
illness	O
(	O
n=9	O
)	O
;	O
disease	O
progression	O
(	O
n=1	O
)	O
;	O
death	B-TOXI
(	O
n=3	O
)	O
;	O
patient	O
decision	O
(	O
n=1	O
)	O
;	O
administrative	O
reasons	O
(	O
n=1	O
)	O
;	O
and	O
multiple	O
reasons	O
(	O
n=4	O
)	O
.	O
	
Grade	O
3	O
and	O
4	O
toxicity	O
was	O
experienced	O
by	O
30	O
(	O
50	O
%	O
)	O
and	O
3	O
(	O
5	O
%	O
)	O
patients	O
","	O
respectively	O
.	O
	
No	O
gastrointestinal	O
perforations	O
were	O
observed	O
.	O
	
The	O
addition	O
of	O
cediranib	B-DRUG
to	O
platinum-based	B-DRUG
chemotherapy	O
is	O
sufficiently	O
well	O
tolerated	O
to	O
expand	O
the	O
ICON6	O
trial	O
and	O
progress	O
to	O
stage	O
II	O
.	O
	
Phase	O
I	O
study	O
of	O
temsirolimus	B-DRUG
in	O
combination	O
with	O
EKB-569	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Purpose	O
Activation	O
of	O
EGFR	O
can	O
stimulate	O
proliferative	O
and	O
survival	O
signaling	O
through	O
mTOR	O
.	O
	
Preclinical	O
data	O
demonstrates	O
synergistic	O
activity	O
of	O
combined	O
EGFR	O
and	O
mTOR	O
inhibition	O
.	O
	
We	O
undertook	O
a	O
phase	O
I	O
trial	O
of	O
temsirolimus	B-DRUG
(	O
T	O
","	O
an	O
mTOR	O
inhibitor	O
)	O
and	O
EKB-569	B-DRUG
(	O
E	O
","	O
an	O
EGFR	O
inhibitor	O
)	O
to	O
determine	O
the	O
safety	O
and	O
tolerability	O
.	O
	
Methods	O
The	O
primary	O
aim	O
was	O
to	O
determine	O
the	O
maximally	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
this	O
combination	O
in	O
adults	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
Following	O
the	O
dose-escalation	O
phase	O
","	O
(	O
Cohort	O
A	O
)	O
","	O
two	O
subsequent	O
cohorts	O
were	O
used	O
to	O
assess	O
any	O
pharmacokinetic	O
(	O
PK	O
)	O
interaction	O
between	O
the	O
agents	O
.	O
	
Results	O
Forty	O
eight	O
patients	O
were	O
enrolled	O
.	O
	
The	O
MTD	O
of	O
this	O
combination	O
was	O
E	O
","	O
35	O
mg	O
daily	O
and	O
T	O
","	O
30	O
mg	O
on	O
days	O
1月3日	O
and	O
15-17	O
using	O
a	O
28-day	O
cycle	O
.	O
	
The	O
most	O
common	O
toxicities	O
were	O
nausea	B-TOXI
","	O
diarrhea	B-TOXI
","	O
fatigue	B-TOXI
","	O
anorexia	B-TOXI
","	O
stomatitis	B-TOXI
","	O
rash	B-TOXI
","	O
anemia	B-TOXI
","	O
neutropenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
and	O
hypertriglyceridemia	B-TOXI
.	O
	
Sixteen	O
patients	O
(	O
36	O
%	O
)	O
had	O
at	O
least	O
one	O
grade	O
3	O
toxicity	O
.	O
	
The	O
most	O
frequent	O
grade	O
3	O
/	O
4	O
toxicities	O
were	O
diarrhea	B-TOXI
","	O
dehydration	B-TOXI
","	O
and	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
(	O
19	O
%	O
each	O
)	O
.	O
	
No	O
grade	O
5	O
events	O
were	O
seen	O
.	O
	
Four	O
patients	O
had	O
a	O
partial	O
response	O
and	O
15	O
had	O
stable	O
disease	O
.	O
	
Clinical	O
benefit	O
was	O
seen	O
across	O
a	O
range	O
of	O
tumor	O
types	O
and	O
in	O
all	O
cohorts	O
.	O
	
PK	O
analysis	O
revealed	O
no	O
significant	O
interaction	O
between	O
E	O
and	O
T.	O
Conclusions	O
This	O
combination	O
of	O
agents	O
is	O
associated	O
with	O
tolerable	O
toxicities	O
at	O
doses	O
that	O
induced	O
responses	O
.	O
	
PK	O
studies	O
revealed	O
no	O
interaction	O
between	O
the	O
drugs	O
.	O
	
Further	O
investigations	O
of	O
this	O
targeting	O
strategy	O
may	O
be	O
attractive	O
in	O
renal	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
","	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
","	O
alveolar	B-CANCER
sarcoma	I-CANCER
","	O
and	O
carcinoid	B-CANCER
tumor	I-CANCER
.	O
	
Phase	O
1	O
trial	O
of	O
everolimus	B-DRUG
plus	O
sunitinib	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
renal	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
	
Simultaneous	O
inhibition	O
of	O
the	O
vascular	O
epithelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
the	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
pathway	O
may	O
improve	O
treatment	O
response	O
in	O
advanced	B-CANCER
renal	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
RCC	B-CANCER
)	O
.	O
	
Everolimus	B-DRUG
","	O
an	O
oral	O
mTOR	O
inhibitor	O
","	O
and	O
sunitinib	B-DRUG
","	O
an	O
oral	O
tyrosine	O
kinase	O
inhibitor	O
targeting	O
VEGF	O
","	O
are	O
standard	O
agents	O
in	O
the	O
management	O
of	O
metastatic	B-CANCER
RCC	I-CANCER
.	O
	
Sequential	O
cohorts	O
of	O
3	O
to	O
6	O
patients	O
with	O
advanced	B-CANCER
RCC	I-CANCER
received	O
dose-escalated	O
combinations	O
of	O
sunitinib	B-DRUG
(	O
37.5	O
or	O
50	O
mg	O
daily	O
","	O
4	O
weeks	O
on	O
/	O
2	O
weeks	O
off	O
)	O
with	O
everolimus	B-DRUG
(	O
2.5-5	O
mg	O
daily	O
or	O
20-30	O
mg	O
weekly	O
)	O
.	O
	
Dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
were	O
assessed	O
in	O
the	O
first	O
6-week	O
cycle	O
to	O
determine	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
.	O
	
Pharmacokinetic	O
profiles	O
were	O
obtained	O
.	O
	
Twenty	O
patients	O
(	O
13	O
clear	O
cell	O
and	O
7	O
nonclear	O
cell	O
RCC	O
)	O
were	O
enrolled	O
in	O
5	O
cohorts	O
.	O
	
Daily	O
everolimus	B-DRUG
was	O
not	O
tolerated	O
when	O
combined	O
with	O
sunitinib	B-DRUG
;	O
the	O
first	O
2	O
patients	O
on	O
the	O
second	O
cohort	O
suffered	O
DLTs	O
.	O
	
With	O
weekly	O
everolimus	B-DRUG
","	O
the	O
MTD	O
was	O
30	O
mg	O
everolimus	B-DRUG
on	O
days	O
7	O
","	O
14	O
","	O
21	O
","	O
and	O
28	O
","	O
plus	O
37.5	O
mg	O
sunitinib	B-DRUG
on	O
days	O
1	O
to	O
28	O
of	O
a	O
42-day	O
cycle	O
;	O
however	O
","	O
chronic	O
treatment	O
was	O
associated	O
with	O
grade	O
3	O
and	O
4	O
toxicities	O
.	O
	
A	O
schedule	O
of	O
20	O
mg	O
everolimus	B-DRUG
weekly	O
/	O
37.5	O
mg	O
sunitinib	B-DRUG
was	O
tolerated	O
as	O
chronic	O
therapy	O
.	O
	
Five	O
patients	O
(	O
25	O
%	O
)	O
had	O
confirmed	O
partial	O
responses	O
","	O
and	O
3	O
had	O
nonclear	B-CANCER
cell	I-CANCER
RCC	I-CANCER
.	O
	
No	O
unexpected	O
accumulation	O
of	O
everolimus	B-DRUG
","	O
sunitinib	B-DRUG
","	O
or	O
N-desethyl	B-DRUG
sunitinib	I-DRUG
was	O
observed	O
.	O
	
The	O
combination	O
of	O
everolimus	B-DRUG
and	O
sunitinib	B-DRUG
is	O
associated	O
with	O
significant	O
acute	O
and	O
chronic	O
toxicities	O
and	O
is	O
only	O
tolerated	O
at	O
attenuated	O
doses	O
.	O
	
Responses	O
were	O
observed	O
in	O
nonclear	O
cell	O
and	O
clear	B-CANCER
cell	I-CANCER
RCC	I-CANCER
.	O
	
A	O
phase	O
I	O
study	O
of	O
5-azacytidine	B-DRUG
and	O
erlotinib	B-DRUG
in	O
advanced	B-CANCER
solid	I-CANCER
tumor	I-CANCER
malignancies	I-CANCER
.	O
	
	
The	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
is	O
a	O
validated	O
target	O
in	O
malignancy	B-CANCER
;	O
however	O
","	O
patients	O
with	O
wild	O
type	O
EGFR	O
obtain	O
little	O
sustained	O
benefit	O
from	O
anti-EGFR	O
monotherapy	O
.	O
	
Epigenetic	O
therapy	O
to	O
reactivate	O
tumor	O
suppressor	O
genes	O
may	O
enhance	O
the	O
anti-proliferative	O
effect	O
of	O
erlotinib	B-DRUG
.	O
	
This	O
phase	O
I	O
study	O
evaluated	O
the	O
combination	O
of	O
erlotinib	B-DRUG
and	O
5-azacytidine	B-DRUG
for	O
safety	O
and	O
maximal	O
tolerated	O
dose	O
(	O
MTD	O
)	O
.	O
	
Thirty	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
treated	O
in	O
a	O
standard	O
3	O
=+	O
3	O
cohort	O
design	O
.	O
	
Erlotinib	B-DRUG
was	O
dosed	O
at	O
150	O
mg	O
daily	O
","	O
and	O
5-azacytidine	B-DRUG
was	O
escalated	O
by	O
increasing	O
the	O
number	O
of	O
daily	O
doses	O
of	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
cycle	O
.	O
	
Patients	O
were	O
followed	O
for	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
.	O
	
Efficacy	O
was	O
assessed	O
by	O
RECIST	O
criteria	O
.	O
	
Common	O
non-hematologic	B-TOXI
toxicities	I-TOXI
included	O
rash	B-TOXI
","	O
diarrhea	B-TOXI
","	O
nausea	B-TOXI
","	O
and	O
fatigue	B-TOXI
;	O
the	O
majority	O
was	O
_	O
Grade	O
2	O
DLTs	O
included	O
conjunctivitis	O
in	O
cohort	O
1	O
and	O
infusion	O
reaction	O
in	O
cohort	O
2	O
No	O
DLTs	O
occurred	O
in	O
cohorts	O
3	O
","	O
4	O
","	O
or	O
5	O
;	O
however	O
","	O
2	O
serious	B-TOXI
neutropenic	I-TOXI
infections	I-TOXI
arose	O
in	O
cohort	O
5	O
after	O
cycle	O
1	O
Cohort	O
4	O
was	O
expanded	O
to	O
6	O
patients	O
and	O
was	O
the	O
MTD	O
.	O
	
Partial	O
response	O
(	O
lung	O
","	O
ovarian	O
)	O
and	O
stable	O
disease	O
occurred	O
in	O
2	O
and	O
11	O
patients	O
","	O
respectively	O
.	O
	
Median	O
progression-free	O
survival	O
was	O
2	O
months	O
.	O
	
Two	O
patients	O
with	O
lung	B-CANCER
and	I-CANCER
larynx	I-CANCER
cancer	I-CANCER
had	O
prolonged	O
stable	O
disease	O
.	O
	
The	O
combination	O
of	O
erlotinib	B-DRUG
and	O
5-azacytidine	B-DRUG
was	O
well	O
tolerated	O
with	O
interesting	O
clinical	O
activity	O
in	O
lung	B-CANCER
","	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
","	I-CANCER
and	I-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
The	O
recommended	O
dose	O
for	O
phase	O
II	O
study	O
is	O
erlotinib	B-DRUG
150	O
mg	O
daily	O
and	O
5-azacytidine	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
daily	O
on	O
days	O
1月4日	O
and	O
15-18	O
of	O
a	O
28-day	O
cycle	O
.	O
	
Sequential	O
vs.	O
concurrent	O
chemoradiation	O
for	O
stage	O
III	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
randomized	O
phase	O
III	O
trial	O
RTOG	O
9410	O
.	O
	
	
The	O
combination	O
of	O
chemotherapy	O
with	O
thoracic	O
radiotherapy	O
(	O
TRT	O
)	O
compared	O
with	O
TRT	O
alone	O
has	O
been	O
shown	O
to	O
confer	O
a	O
survival	O
advantage	O
for	O
good	O
performance	O
status	O
patients	O
with	O
stage	O
III	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
However	O
","	O
it	O
is	O
not	O
known	O
whether	O
sequential	O
or	O
concurrent	O
delivery	O
of	O
these	O
therapies	O
is	O
the	O
optimal	O
combination	O
strategy	O
.	O
	
A	O
total	O
of	O
610	O
patients	O
were	O
randomly	O
assigned	O
to	O
two	O
concurrent	O
regimens	O
and	O
one	O
sequential	O
chemotherapy	O
and	O
TRT	O
regimen	O
in	O
a	O
three-arm	O
phase	O
III	O
trial	O
.	O
	
The	O
sequential	O
arm	O
included	O
cisplatin	B-DRUG
at	O
100	O
mg	O
/	O
m2	O
on	O
days	O
1	O
and	O
29	O
and	O
vinblastine	B-DRUG
at	O
5	O
mg	O
/	O
m2	O
per	O
week	O
for	O
5	O
weeks	O
with	O
63	O
Gy	O
TRT	O
delivered	O
as	O
once-daily	O
fractions	O
beginning	O
on	O
day	O
50	O
.	O
	
Arm	O
2	O
used	O
the	O
same	O
chemotherapy	O
regimen	O
as	O
arm	O
1	O
with	O
63	O
Gy	O
TRT	O
delivered	O
as	O
once-daily	O
fractions	O
beginning	O
on	O
day	O
1	O
[	O
corrected	O
]	O
.	O
	
Arm	O
3	O
used	O
cisplatin	B-DRUG
at	O
50	O
mg	O
/	O
m2	O
on	O
days	O
1	O
","	O
8	O
","	O
29	O
","	O
and	O
36	O
with	O
oral	O
etoposide	B-DRUG
at	O
50	O
mg	O
twice	O
daily	O
for	O
10	O
weeks	O
on	O
days	O
1	O
","	O
2	O
","	O
5	O
","	O
and	O
6	O
with	O
69.6	O
Gy	O
delivered	O
as	O
1.2	O
Gy	O
twice-daily	O
fractions	O
beginning	O
on	O
day	O
1	O
The	O
primary	O
endpoint	O
was	O
overall	O
survival	O
","	O
and	O
secondary	O
endpoints	O
included	O
tumor	O
response	O
and	O
time	O
to	O
tumor	O
progression	O
.	O
	
Kaplan-Meier	O
analyses	O
were	O
used	O
to	O
assess	O
survival	O
","	O
and	O
toxic	O
effects	O
were	O
examined	O
using	O
the	O
Wilcoxon	O
rank	O
sum	O
test	O
.	O
	
All	O
statistical	O
tests	O
were	O
two-sided	O
.	O
	
Median	O
survival	O
times	O
were	O
14.6	O
","	O
17	O
","	O
and	O
15.6	O
months	O
for	O
arms	O
1月3日	O
","	O
respectively	O
.	O
	
Five-year	O
survival	O
was	O
statistically	O
significantly	O
higher	O
for	O
patients	O
treated	O
with	O
the	O
concurrent	O
regimen	O
with	O
once-daily	O
TRT	O
compared	O
with	O
the	O
sequential	O
treatment	O
(	O
5-year	O
survival	O
:	O
sequential	O
","	O
arm	O
1	O
","	O
10	O
%	O
[	O
20	O
patients	O
]	O
","	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
7	O
%	O
to	O
15	O
%	O
;	O
concurrent	O
","	O
arm	O
2	O
","	O
16	O
%	O
[	O
31	O
patients	O
]	O
","	O
95	O
%	O
CI	O
=	O
11	O
%	O
to	O
22	O
%	O
","	O
P	O
=	O
0.046	O
;	O
concurrent	O
","	O
arm	O
3	O
","	O
13	O
%	O
[	O
22	O
patients	O
]	O
","	O
95	O
%	O
CI	O
=	O
9	O
%	O
to	O
18	O
%	O
)	O
.	O
	
With	O
a	O
median	O
follow-up	O
time	O
of	O
11	O
years	O
","	O
the	O
rates	O
of	O
acute	O
grade	O
3月5日	O
nonhematologic	B-TOXI
toxic	I-TOXI
effects	I-TOXI
were	O
higher	O
with	O
concurrent	O
than	O
sequential	O
therapy	O
","	O
but	O
late	O
toxic	O
effects	O
were	O
similar	O
.	O
	
Concurrent	O
delivery	O
of	O
cisplatin-based	B-DRUG
chemotherapy	O
with	O
TRT	O
confers	O
a	O
long-term	O
survival	O
benefit	O
compared	O
with	O
the	O
sequential	O
delivery	O
of	O
these	O
therapies	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
daily	O
everolimus	B-DRUG
plus	O
low-dose	O
weekly	O
cisplatin	B-DRUG
for	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Preclinical	O
studies	O
demonstrate	O
synergistic	O
anti-tumor	O
activity	O
with	O
the	O
combination	O
of	O
everolimus	B-DRUG
and	O
cisplatin	B-DRUG
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
study	O
to	O
establish	O
the	O
recommended	O
phase	O
II	O
of	O
oral	B-DRUG
everolimus	I-DRUG
to	O
be	O
given	O
with	O
low-dose	O
weekly	O
intravenous	B-DRUG
cisplatin	I-DRUG
.	O
	
Part	O
A	O
used	O
a	O
standard	O
3	O
=+	O
3	O
dose	O
escalation	O
scheme	O
.	O
	
There	O
were	O
4	O
planned	O
dose	O
levels	O
of	O
everolimus	B-DRUG
:	O
2.5	O
","	O
5	O
","	O
7.5	O
","	O
and	O
10	O
mg	O
/	O
day	O
.	O
	
Subjects	O
received	O
oral	B-DRUG
everolimus	I-DRUG
during	O
days	O
1月21日	O
and	O
cisplatin	B-DRUG
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
(	O
fixed	O
dose	O
)	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
of	O
a	O
28-day	O
cycle	O
.	O
	
Pharmacokinetic	O
(	O
PK	O
)	O
blood	O
samples	O
were	O
collected	O
on	O
day	O
1	O
and	O
day	O
8	O
of	O
cycle	O
1	O
in	O
Part	O
A.	O
After	O
the	O
phase	O
II	O
recommended	O
dose	O
was	O
established	O
(	O
Part	O
A	O
)	O
","	O
6	O
additional	O
subjects	O
were	O
enrolled	O
in	O
an	O
expansion	O
cohort	O
(	O
Part	O
B	O
)	O
.	O
	
Response	O
was	O
assessed	O
by	O
RECIST	O
q	O
2	O
cycles	O
for	O
all	O
subjects	O
.	O
	
Thirty	O
patients	O
were	O
enrolled	O
(	O
18	O
male	O
","	O
12	O
female	O
)	O
and	O
29	O
were	O
treated	O
.	O
	
Median	O
age	O
was	O
61	O
years	O
(	O
31-79	O
)	O
and	O
the	O
median	O
number	O
of	O
prior	O
cytotoxic	O
chemotherapy	O
regimens	O
was	O
2	O
(	O
0-3	O
)	O
.	O
	
Eighty-three	O
percent	O
of	O
subjects	O
had	O
received	O
prior	O
RT.	O
DLTs	O
occurred	O
at	O
dose	O
level	O
1	O
(	O
sudden	O
death	B-CANCER
of	O
unclear	O
cause	O
in	O
a	O
patient	O
with	O
melanoma	B-CANCER
metastatic	O
to	O
liver	O
)	O
and	O
dose	O
level	O
2	O
(	O
bowel	O
obstruction	O
)	O
.	O
	
No	O
DLTs	O
occurred	O
at	O
dose	O
levels	O
3	O
and	O
4	O
The	O
most	O
common	O
adverse	O
events	O
(	O
_grade	O
3	O
)	O
among	O
28	O
patients	O
evaluable	O
for	O
toxicity	O
were	O
lymphopenia	B-TOXI
(	O
36	O
%	O
)	O
","	O
hyperglycemia	B-TOXI
(	O
11	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
11	O
%	O
)	O
","	O
and	O
venous	B-TOXI
thrombosis	I-TOXI
(	O
11	O
%	O
)	O
.	O
	
PK	O
analysis	O
of	O
everolimus	B-DRUG
demonstrated	O
dose-proportional	O
increases	O
in	O
C	O
(	O
max	O
)	O
(	O
mean	O
91.9	O
ng	O
/	O
ml	O
)	O
and	O
AUC	O
(	O
0-INF	O
)	O
(	O
mean	O
680.5	O
h*ng	O
/	O
ml	O
)	O
at	O
dose	O
level	O
4	O
Three	O
partial	O
responses	O
were	O
seen	O
(	O
metastatic	B-CANCER
pulmonary	I-CANCER
carcinoid	I-CANCER
","	O
n	O
=	O
2	O
;	O
metastatic	B-CANCER
sinus	I-CANCER
carcinoma	I-CANCER
","	O
n	O
=	O
1	O
)	O
.	O
	
Prolonged	O
stable	O
disease	O
_6	O
cycles	O
occurred	O
in	O
subjects	O
with	O
pulmonary	B-CANCER
carcinoid	I-CANCER
","	O
oropharyngeal	B-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
","	O
basal	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
","	O
papillary	B-CANCER
thyroid	I-CANCER
carcinoma	I-CANCER
","	O
and	O
esthesioneuroblastoma	B-CANCER
(	O
n	O
=	O
1	O
each	O
)	O
.	O
	
The	O
phase	O
II	O
recommended	O
dose	O
is	O
everolimus	B-DRUG
10	O
mg	O
/	O
day	O
(	O
days	O
1月21日	O
)	O
=+	O
cisplatin	B-DRUG
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
)	O
of	O
a	O
28-day	O
cycle	O
.	O
	
PK	O
data	O
demonstrate	O
dose-proportional	O
increases	O
in	O
exposure	O
","	O
as	O
previously	O
described	O
for	O
everolimus	B-DRUG
monotherapy	O
.	O
	
Anti-tumor	O
activity	O
was	O
observed	O
in	O
several	O
tumor	O
types	O
.	O
	
Phase	O
II	O
study	O
of	O
Gleevec庐	B-DRUG
plus	O
hydroxyurea	B-DRUG
(	O
HU	O
)	O
in	O
adults	O
with	O
progressive	O
or	O
recurrent	B-CANCER
meningioma	I-CANCER
.	O
	
	
We	O
prospectively	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
imatinib	B-DRUG
plus	O
hydroxyurea	B-DRUG
in	O
patients	O
with	O
progressive	O
/	O
recurrent	B-CANCER
meningioma	I-CANCER
.	O
	
A	O
total	O
of	O
21	O
patients	O
with	O
progressive	O
/	O
recurrent	B-CANCER
meningioma	I-CANCER
were	O
enrolled	O
in	O
this	O
dual	O
center	O
","	O
single-arm	O
","	O
phase	O
II	O
trial	O
.	O
	
All	O
patients	O
received	O
500	O
mg	O
of	O
hydroxyurea	B-DRUG
twice	O
a	O
day	O
.	O
	
Imatinib	B-DRUG
was	O
administered	O
at	O
400	O
mg	O
/	O
day	O
for	O
patients	O
not	O
on	O
CYP3A	O
enzyme	O
inducing	O
anti-epileptic	O
drugs	O
(	O
EIAEDs	O
)	O
and	O
at	O
500	O
mg	O
twice	O
a	O
day	O
for	O
patients	O
on	O
EIAEDs	O
.	O
	
The	O
primary	O
endpoint	O
was	O
progression-free	O
survival	O
at	O
6	O
months	O
(	O
PFS-6	O
)	O
and	O
secondary	O
endpoints	O
were	O
safety	O
","	O
radiographic	O
response	O
rate	O
","	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O
	
Best	O
radiographic	O
response	O
was	O
stable	O
disease	O
and	O
was	O
observed	O
in	O
14	O
patients	O
(	O
67	O
%	O
)	O
.	O
	
PFS-6	O
for	O
all	O
patients	O
","	O
those	O
with	O
grade	O
I	O
tumors	O
(	O
n	O
=	O
8	O
)	O
and	O
those	O
with	O
grade	O
II	O
or	O
III	O
tumors	O
(	O
n	O
=	O
13	O
)	O
was	O
61.9	O
","	O
87.5	O
and	O
46.2	O
%	O
","	O
respectively	O
.	O
	
Patients	O
with	O
grade	O
II	O
or	O
III	O
tumors	O
had	O
poorer	O
PFS	O
and	O
OS	O
than	O
those	O
with	O
grade	O
I	O
tumors	O
","	O
(	O
P	O
=	O
0.025	O
and	O
P	O
=	O
0.018	O
)	O
respectively	O
.	O
	
The	O
only	O
grade	O
3	O
or	O
greater	O
adverse	O
event	O
occurring	O
in	O
_	O
10	O
%	O
of	O
patients	O
was	O
anemia	B-TOXI
(	O
10	O
%	O
)	O
.	O
	
Imatinib	B-DRUG
plus	O
hydroxyurea	B-DRUG
is	O
well	O
tolerated	O
among	O
patients	O
with	O
meningioma	B-CANCER
but	O
has	O
modest	O
anti-tumor	O
activity	O
for	O
this	O
indication	O
.	O
	
Efficacy	O
and	O
safety	O
of	O
bevacizumab	B-DRUG
plus	O
chemotherapy	O
in	O
Chinese	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
:	O
a	O
randomized	O
phase	O
III	O
ARTIST	O
trial	O
.	O
	
	
The	O
efficacy	O
and	O
safety	O
of	O
bevacizumab	B-DRUG
with	O
modified	O
irinotecan	B-DRUG
","	O
leucovorin	B-DRUG
bolus	O
","	O
and	O
5-fluorouracil	B-DRUG
intravenous	O
infusion	O
(	O
mIFL	O
)	O
in	O
the	O
first-line	O
treatment	O
of	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
mCRC	B-CANCER
)	O
has	O
not	O
been	O
well	O
evaluated	O
in	O
randomized	O
clinical	O
trials	O
in	O
Chinese	O
patients	O
.	O
	
We	O
conducted	O
a	O
phrase	O
III	O
trial	O
in	O
which	O
patients	O
with	O
previously	O
untreated	O
mCRC	B-CANCER
were	O
randomized	O
02:01	O
to	O
the	O
mIFL	B-DRUG
[	O
irinotecan	B-DRUG
(	O
125	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
leucovorin	B-DRUG
(	O
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
bolus	O
","	O
and	O
5-fluorouracil	B-DRUG
intravenous	O
infusion	O
(	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
weekly	O
for	O
four	O
weeks	O
every	O
six	O
weeks	O
]	O
plus	O
bevacizumab	B-DRUG
(	O
5	O
mg	O
/	O
kg	O
every	O
two	O
weeks	O
)	O
group	O
and	O
the	O
mIFL	B-DRUG
group	O
","	O
respectively	O
.	O
	
Co-primary	O
objectives	O
were	O
progression-free	O
survival	O
(	O
PFS	O
)	O
and	O
6-month	O
PFS	O
rate	O
.	O
	
In	O
total	O
","	O
214	O
patients	O
were	O
enrolled	O
.	O
	
Our	O
results	O
showed	O
that	O
addition	O
of	O
bevacizumab	B-DRUG
to	O
mIFL	B-DRUG
significantly	O
improved	O
median	O
PFS	O
(	O
4.2	O
months	O
in	O
the	O
mIFL	B-DRUG
group	O
vs.	O
8.3	O
months	O
in	O
the	O
bevacizumab	B-DRUG
plus	O
mIFL	B-DRUG
group	O
","	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
","	O
6-month	O
PFS	O
rate	O
(	O
25	O
%	O
vs.	O
62.6	O
%	O
","	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
","	O
median	O
overall	O
survival	O
(	O
13.4	O
months	O
vs.	O
18.7	O
months	O
","	O
P	O
=	O
0.014	O
)	O
","	O
and	O
response	O
rate	O
(	O
17	O
%	O
vs.	O
35	O
%	O
","	O
P	O
=	O
0.013	O
)	O
.	O
	
Grades	O
3	O
and	O
4	O
adverse	O
events	O
included	O
diarrhea	B-TOXI
(	O
21	O
%	O
in	O
the	O
mIFL	B-DRUG
group	O
and	O
26	O
%	O
in	O
the	O
bevacizumab	B-DRUG
plus	O
mIFL	B-DRUG
group	O
)	O
and	O
neutropenia	B-TOXI
(	O
19	O
%	O
in	O
the	O
mIFL	B-DRUG
group	O
and	O
33	O
%	O
in	O
the	O
bevacizumab	B-DRUG
plus	O
mIFL	B-DRUG
group	O
)	O
.	O
	
No	B-TOXI
wound-healing	I-TOXI
complications	I-TOXI
or	O
congestive	B-TOXI
heart	I-TOXI
failure	I-TOXI
occurred	O
.	O
	
Our	O
results	O
suggested	O
that	O
bevacizumab	B-DRUG
plus	O
mIFL	B-DRUG
is	O
effective	O
and	O
well	O
tolerated	O
as	O
first-line	O
treatment	O
for	O
Chinese	O
patients	O
with	O
mCRC	B-CANCER
.	O
	
Clinical	O
benefit	O
and	O
safety	O
profiles	O
were	O
consistent	O
with	O
those	O
observed	O
in	O
pivotal	O
phase	O
III	O
trials	O
with	O
mainly	O
Caucasian	O
patients	O
.	O
	
The	O
European	O
Medicines	O
Agency	O
review	O
of	O
Tegafur	O
/	O
Gimeracil	O
/	O
Oteracil	O
(	O
Teysuno_	O
)	O
for	O
the	O
treatment	O
of	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
when	O
given	O
in	O
combination	O
with	O
cisplatin	B-DRUG
:	O
summary	O
of	O
the	O
Scientific	O
Assessment	O
of	O
the	O
Committee	O
for	O
medicinal	O
products	O
for	O
human	O
use	O
(	O
CHMP	O
)	O
.	O
	
	
The	O
product	O
Teysuno_	B-DRUG
(	O
S-1	B-DRUG
)	O
contains	O
tegafur	B-DRUG
","	O
a	O
prodrug	O
of	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
and	O
two	O
modulators	O
of	O
5-FU	B-DRUG
metabolism	I-DRUG
","	O
gimeracil	B-DRUG
and	O
oteracil	B-DRUG
.	O
	
The	O
main	O
clinical	O
study	O
in	O
this	O
application	O
was	O
a	O
randomized	O
controlled	O
study	O
comparing	O
S-1	B-DRUG
plus	O
cisplatin	B-DRUG
with	O
5-FU	B-DRUG
plus	O
cisplatin	B-DRUG
.	O
	
In	O
this	O
study	O
","	O
median	O
overall	O
survival	O
times	O
of	O
8.6	O
months	O
and	O
7.9	O
months	O
for	O
S-1	B-DRUG
plus	O
cisplatin	B-DRUG
and	O
5-FU	B-DRUG
plus	O
cisplatin	B-DRUG
","	O
respectively	O
","	O
were	O
observed	O
(	O
hazard	O
ratio	O
","	O
0.92	O
;	O
95	O
%	O
confidence	O
interval	O
","	O
0.80-1.05	O
)	O
.	O
	
The	O
Committee	O
for	O
Medicinal	O
Products	O
for	O
Human	O
Use	O
of	O
the	O
European	O
Medicines	O
Agency	O
concluded	O
that	O
S-1	B-DRUG
in	O
combination	O
with	O
cisplatin	B-DRUG
(	O
75	O
mg	O
/	O
m虏	O
)	O
was	O
noninferior	O
to	O
5-FU	B-DRUG
plus	O
cisplatin	B-DRUG
(	O
100	O
mg	O
/	O
m虏	O
)	O
in	O
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
and	O
adopted	O
a	O
positive	O
opinion	O
recommending	O
the	O
marketing	O
authorization	O
for	O
this	O
product	O
for	O
the	O
treatment	O
of	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
when	O
given	O
in	O
combination	O
with	O
cisplatin	B-DRUG
.	O
	
The	O
recommended	O
dose	O
of	O
S-1	B-DRUG
is	O
25	O
mg	O
/	O
m虏	O
(	O
expressed	O
as	O
tegafur	O
content	O
)	O
twice	O
a	O
day	O
","	O
for	O
21	O
consecutive	O
days	O
followed	O
by	O
7	O
days	O
rest	O
(	O
one	O
treatment	O
cycle	O
)	O
","	O
in	O
combination	O
with	O
75	O
mg	O
/	O
m虏	O
cisplatin	B-DRUG
i.v.	O
administered	O
on	O
day	O
1	O
This	O
treatment	O
cycle	O
is	O
repeated	O
every	O
4	O
weeks	O
.	O
	
The	O
most	O
common	O
side	O
effects	O
reported	O
in	O
the	O
pivotal	O
study	O
were	O
anemia	B-TOXI
","	O
neutropenia	B-TOXI
","	O
vomiting	B-TOXI
","	O
diarrhea	B-TOXI
","	O
abdominal	B-TOXI
pain	I-TOXI
","	O
weight	B-TOXI
decrease	I-TOXI
","	O
anorexia	B-TOXI
","	O
and	O
fatigue	B-TOXI
.	O
	
The	O
objective	O
of	O
this	O
paper	O
is	O
to	O
summarize	O
the	O
scientific	O
review	O
of	O
the	O
application	O
leading	O
to	O
approval	O
in	O
the	O
EU	O
.	O
	
The	O
full	O
scientific	O
assessment	O
report	O
and	O
the	O
summary	O
of	O
product	O
characteristics	O
are	O
available	O
on	O
the	O
European	O
Medicines	O
Agency	O
website	O
(	O
http	O
:	O
/	O
/	O
www.ema.europa.eu	O
)	O
.	O
	
Dose-dense	O
doxorubicin	B-DRUG
and	O
cyclophosphamide	B-DRUG
followed	O
by	O
dose-dense	O
albumin-bound	B-DRUG
paclitaxel	B-DRUG
plus	O
bevacizumab	B-DRUG
is	O
safe	O
as	O
adjuvant	O
therapy	O
in	O
patients	O
with	O
early	O
stage	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
	
Every-2-week	O
(	O
dose-dense	O
)	O
adjuvant	O
doxorubicin	B-DRUG
(	O
A	O
)	O
plus	O
cyclophosphamide	B-DRUG
(	O
C	O
)	O
followed	O
by	O
cremophor-formulated	B-DRUG
paclitaxel	I-DRUG
(	O
cf-P	B-DRUG
)	O
was	O
efficacious	O
in	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
BC	B-CANCER
)	O
.	O
	
Albumin-bound	B-DRUG
paclitaxel	I-DRUG
(	O
ab-P	B-DRUG
)	O
was	O
safe	O
and	O
more	O
effective	O
than	O
cf-P	B-DRUG
","	O
and	O
the	O
addition	O
of	O
bevacizumab	B-DRUG
to	O
cf-P	B-DRUG
improved	O
efficacy	O
.	O
	
This	O
study	O
compared	O
the	O
safety	O
of	O
dose-dense	O
ab-P	B-DRUG
vs	O
cf-P	B-DRUG
plus	O
bevacizumab	B-DRUG
following	O
dose-dense	O
adjuvant	O
AC	O
for	O
early-stage	O
BC	B-CANCER
.	O
	
Women	O
with	O
operable	O
","	O
histologically	O
confirmed	O
BC	B-CANCER
were	O
randomized	O
to	O
4	O
cycles	O
of	O
dose-dense	O
A	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
plus	O
C	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
with	O
SC	O
pegfilgrastim	O
","	O
followed	O
by	O
4	O
cycles	O
of	O
either	O
dose-dense	O
IV	O
ab-P	B-DRUG
260	O
mg	O
/	O
m	O
(	O
2	O
)	O
or	O
cf-P	B-DRUG
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Bevacizumab	B-DRUG
was	O
given	O
during	O
and	O
following	O
chemotherapy	O
.	O
	
97	O
and	O
96	O
%	O
of	O
patients	O
completed	O
4	O
cycles	O
of	O
AC	O
therapy	O
","	O
while	O
84	O
and	O
85	O
%	O
of	O
patients	O
completed	O
4	O
cycles	O
of	O
taxane	B-DRUG
therapy	O
in	O
the	O
ab-P	B-DRUG
and	O
cf-P	B-DRUG
arms	O
","	O
respectively	O
(	O
N	O
=	O
197	O
)	O
.	O
	
Baseline	O
patient	O
characteristics	O
were	O
similar	O
.	O
	
The	O
most	O
common	O
grade	O
_3	O
taxane-related	O
adverse	O
events	O
(	O
AEs	O
)	O
were	O
fatigue	B-TOXI
and	O
neutropenia	B-TOXI
.	O
	
Dose	O
reductions	O
were	O
similar	O
between	O
the	O
treatment	O
arms	O
.	O
	
During	O
AC	O
therapy	O
","	O
the	O
majority	O
of	O
dose	O
reductions	O
were	O
due	O
to	O
febrile	B-TOXI
neutropenia	I-TOXI
;	O
during	O
taxane	B-DRUG
therapy	O
","	O
the	O
majority	O
of	O
cases	O
were	O
due	O
to	O
neuropathy	B-TOXI
.	O
	
No	O
taxane-related	O
dose	O
interruption	O
occurred	O
in	O
the	O
ab-P	B-DRUG
arm	O
","	O
while	O
3	O
occurred	O
in	O
the	O
cf-P	B-DRUG
arm	O
due	O
to	O
hypersensitivity	B-TOXI
reactions	I-TOXI
.	O
	
The	O
mean	O
cumulative	O
paclitaxel	B-DRUG
dose	O
was	O
950.5	O
and	O
660.8	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
the	O
ab-P	B-DRUG
and	O
cf-P	B-DRUG
arms	O
","	O
respectively	O
.	O
	
A	O
44	O
%	O
higher	O
paclitaxel	B-DRUG
dose	O
was	O
delivered	O
in	O
the	O
ab-P	B-DRUG
compared	O
with	O
the	O
cf-P	B-DRUG
arm	O
(	O
P	O
&	O
lt	O
;	O
0.0001	O
)	O
","	O
while	O
achieving	O
a	O
similar	O
safety	O
profile	O
.	O
	
ab-P	B-DRUG
plus	O
bevacizumab	B-DRUG
following	O
AC	O
therapy	O
without	O
prophylactic	O
premedications	O
was	O
tolerable	O
in	O
early-stage	O
BC	B-CANCER
patients	O
.	O
	
A	O
phase	O
I	O
dose-escalation	O
and	O
pharmacokinetic	O
study	O
of	O
sunitinib	B-DRUG
in	O
combination	O
with	O
pemetrexed	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
malignancies	I-CANCER
","	O
with	O
an	O
expanded	O
cohort	O
in	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
primary	O
objective	O
of	O
this	O
phase	O
I	O
dose-escalation	O
study	O
was	O
to	O
identify	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
sunitinib	B-DRUG
plus	O
pemetrexed	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
cancer	I-CANCER
.	O
	
Using	O
a	O
3	O
=+	O
3	O
dose-escalation	O
design	O
","	O
patients	O
received	O
oral	B-DRUG
sunitinib	I-DRUG
qd	O
by	O
continuous	O
daily	O
dosing	O
(	O
CDD	O
schedule	O
;	O
37.5	O
or	O
50	O
mg	O
)	O
or	O
2	O
weeks	O
on	O
/	O
1	O
week	O
off	O
treatment	O
schedule	O
(	O
Schedule	O
2	O
/	O
1	O
;	O
50	O
mg	O
)	O
.	O
	
Pemetrexed	B-DRUG
(	O
300-500	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
)	O
was	O
administered	O
q3w	O
.	O
	
At	O
the	O
proposed	O
recommended	O
phase	O
2	O
dose	O
(	O
RP2D	O
)	O
","	O
additional	O
patients	O
with	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
were	O
enrolled	O
.	O
	
Thirty-five	O
patients	O
were	O
enrolled	O
on	O
the	O
CDD	O
schedule	O
and	O
seven	O
on	O
Schedule	O
2	O
/	O
1	O
MTDs	O
were	O
sunitinib	B-DRUG
37.5	O
mg	O
/	O
day	O
(	O
CDD	O
/	O
RP2D	O
)	O
or	O
50	O
mg	O
/	O
day	O
(	O
Schedule	O
2	O
/	O
1	O
)	O
with	O
pemetrexed	B-DRUG
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Dose-limiting	O
toxicities	O
included	O
grade	O
(	O
G	O
)	O
5	O
cerebral	B-TOXI
hemorrhage	I-TOXI
","	O
G3	O
febrile	B-TOXI
neutropenia	I-TOXI
","	O
and	O
G3	O
anorexia	B-TOXI
.	O
	
Common	O
G3	O
/	O
4	O
drug-related	O
non-hematologic	B-TOXI
adverse	I-TOXI
events	I-TOXI
(	O
AEs	O
)	O
at	O
the	O
CDD	O
MTD	O
included	O
fatigue	B-TOXI
","	O
anorexia	B-TOXI
","	O
and	O
hand-foot	B-TOXI
syndrome	I-TOXI
.	O
	
G3	O
/	O
4	O
hematologic	B-TOXI
AEs	I-TOXI
included	O
lymphopenia	B-TOXI
","	O
neutropenia	B-TOXI
","	O
and	O
thrombocytopenia	B-TOXI
.	O
	
No	O
significant	O
drug-drug	O
interactions	O
were	O
identified	O
.	O
	
Five	O
(	O
24	O
%	O
)	O
NSCLC	B-CANCER
patients	O
had	O
partial	O
responses	O
.	O
	
In	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
malignancies	I-CANCER
","	O
the	O
MTD	O
of	O
sunitinib	B-DRUG
plus	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
pemetrexed	B-DRUG
was	O
37.5	O
mg	O
/	O
day	O
(	O
CDD	O
schedule	O
)	O
or	O
50	O
mg	O
/	O
day	O
(	O
Schedule	O
2	O
/	O
1	O
)	O
.	O
	
The	O
CDD	O
schedule	O
MTD	O
was	O
tolerable	O
and	O
demonstrated	O
promising	O
clinical	O
benefit	O
in	O
NSCLC	B-CANCER
.	O
	
Cetuximab	B-DRUG
plus	O
FOLFIRINOX	B-DRUG
(	O
ERBIRINOX	B-DRUG
)	O
as	O
first-line	O
treatment	O
for	O
unresectable	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
:	O
a	O
phase	O
II	O
trial	O
.	O
	
	
Triplet	O
chemotherapy	O
has	O
demonstrated	O
manageable	O
toxicities	O
and	O
a	O
favorable	O
response	O
rate	O
.	O
	
The	O
addition	O
of	O
cetuximab	B-DRUG
to	O
chemotherapy	O
can	O
increase	O
treatment	O
efficacy	O
.	O
	
We	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
cetuximab	B-DRUG
plus	O
5-fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
","	O
irinotecan	B-DRUG
","	O
and	O
oxaliplatin	B-DRUG
(	O
FOLFIRINOX	B-DRUG
)	O
","	O
the	O
ERBIRINOX	B-DRUG
regimen	O
","	O
as	O
first-line	O
treatment	O
in	O
patients	O
with	O
unresectable	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
mCRC	B-CANCER
)	O
.	O
	
In	O
a	O
phase	O
II	O
study	O
","	O
treatment	O
consisted	O
of	O
weekly	O
cetuximab	B-DRUG
plus	O
biweekly	O
.	O
	
Treatment	O
was	O
continued	O
for	O
a	O
maximum	O
of	O
12	O
cycles	O
and	O
tumor	O
response	O
was	O
evaluated	O
every	O
four	O
cycles	O
.	O
	
The	O
primary	O
efficacy	O
criterion	O
was	O
the	O
complete	O
response	O
(	O
CR	O
)	O
rate	O
.	O
	
From	O
April	O
2006	O
to	O
April	O
2008	O
","	O
42	O
patients	O
were	O
enrolled	O
.	O
	
The	O
median	O
age	O
was	O
60	O
years	O
(	O
range	O
","	O
32-76	O
years	O
)	O
.	O
	
The	O
median	O
duration	O
of	O
treatment	O
was	O
5.2	O
months	O
(	O
range	O
","	O
0.7-8.5	O
months	O
)	O
","	O
and	O
a	O
median	O
of	O
nine	O
cycles	O
was	O
given	O
per	O
patient	O
(	O
range	O
","	O
1月12日	O
cycles	O
)	O
.	O
	
Five	O
patients	O
(	O
11.9	O
%	O
)	O
showed	O
a	O
CR	O
","	O
with	O
a	O
median	O
duration	O
of	O
23.1	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
10.8-39.7	O
months	O
)	O
.	O
	
The	O
objective	O
response	O
rate	O
was	O
80.9	O
%	O
(	O
95	O
%	O
CI	O
","	O
65.9	O
%	O
-91.4	O
%	O
)	O
.	O
	
The	O
median	O
overall	O
and	O
progression-free	O
survival	O
times	O
were	O
24.7	O
months	O
(	O
95	O
%	O
CI	O
","	O
22.6	O
months	O
to	O
not	O
reached	O
)	O
and	O
9.5	O
months	O
(	O
95	O
%	O
CI	O
","	O
7.6-10.4	O
months	O
)	O
","	O
respectively	O
.	O
	
The	O
most	O
frequent	O
grade	O
3月4日	O
adverse	O
events	O
were	O
diarrhea	B-TOXI
(	O
52	O
%	O
)	O
","	O
neutropenia	B-TOXI
(	O
38	O
%	O
)	O
","	O
and	O
asthenia	B-TOXI
(	O
32	O
%	O
)	O
.	O
	
The	O
ERBIRINOX	B-DRUG
regimen	O
appears	O
to	O
be	O
effective	O
and	O
feasible	O
in	O
first-line	O
treatment	O
of	O
mCRC	B-CANCER
patients	O
.	O
	
These	O
promising	O
results	O
led	O
us	O
to	O
initiate	O
a	O
multicenter	O
","	O
randomized	O
","	O
phase	O
II	O
trial	O
(	O
[	O
Research	O
Partnership	O
for	O
Digestive	O
Oncology	O
]	O
PRODIGE	O
14	O
)	O
in	O
patients	O
with	O
potentially	O
resectable	O
mCRC	B-CANCER
.	O
	
Modified	O
FOLFIRI	B-DRUG
as	O
Second-Line	O
Chemotherapy	O
after	O
Failure	O
of	O
Modified	O
FOLFOX-4	B-DRUG
in	O
Advanced	B-CANCER
Gastric	I-CANCER
Cancer	I-CANCER
.	O
	
	
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
efficacy	O
and	O
toxicity	O
of	O
irinotecan	B-DRUG
","	O
leucovorin	B-DRUG
and	O
5-fluorouracil	B-DRUG
(	O
FOLFIRI	B-DRUG
)	O
as	O
second-line	O
treatment	O
after	O
failure	O
of	O
oxaliplatin	B-DRUG
","	O
leucovorin	B-DRUG
and	O
5-fluorouracil	B-DRUG
(	O
FOLFOX	B-DRUG
)	O
for	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
who	O
received	O
modified	O
FOLFOX-4	B-DRUG
as	O
first-line	O
treatment	O
and	O
then	O
received	O
sequential	O
modified	O
FOLFIRI	B-DRUG
for	O
disease	O
progression	O
were	O
included	O
in	O
this	O
study	O
.	O
	
The	O
modified	O
FOLFIRI	B-DRUG
regimen	O
consisted	O
of	O
irinotecan	B-DRUG
150	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
a	O
90-minute	O
intravenous	O
infusion	O
on	O
day	O
1	O
","	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
bolus	O
followed	O
by	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
22-hour	O
infusion	O
on	O
days	O
1	O
and	O
2	O
with	O
the	O
same	O
dose	O
of	O
5-FU	B-DRUG
/	O
LV	B-DRUG
of	O
modified	O
FOLFOX-4	B-DRUG
every	O
2	O
weeks	O
.	O
	
A	O
total	O
of	O
32	O
patients	O
received	O
126	O
courses	O
of	O
FOLFIRI	B-DRUG
chemotherapy	O
.	O
	
No	O
complete	O
response	O
was	O
achieved	O
.	O
	
Three	O
patients	O
(	O
9.4	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
0	O
to	O
20.1	O
%	O
)	O
achieved	O
partial	O
response	O
","	O
whereas	O
11	O
(	O
34.4	O
%	O
;	O
95	O
%	O
CI	O
","	O
17	O
to	O
51.8	O
%	O
)	O
patients	O
showed	O
stable	O
disease	O
.	O
	
Disease	O
control	O
rate	O
(	O
complete	O
response	O
","	O
partial	O
responses	O
and	O
stable	O
diseases	O
)	O
was	O
43.8	O
%	O
(	O
95	O
%	O
CI	O
","	O
25.6	O
to	O
61.9	O
%	O
)	O
and	O
median	O
follow	O
up	O
duration	O
was	O
11.3	O
months	O
(	O
range	O
","	O
2.23	O
to	O
37.9	O
months	O
)	O
.	O
	
Median	O
time	O
to	O
progression	O
was	O
2	O
months	O
(	O
95	O
%	O
CI	O
","	O
1.49	O
to	O
2.51	O
months	O
)	O
","	O
and	O
median	O
overall	O
survival	O
from	O
the	O
start	O
of	O
FOLFIRI	B-DRUG
was	O
5.84	O
months	O
(	O
95	O
%	O
CI	O
","	O
4.34	O
to	O
7.34	O
months	O
)	O
.	O
	
Toxicities	O
were	O
tolerable	O
.	O
	
Modified	O
FOLFIRI	B-DRUG
as	O
second-line	O
chemotherapy	O
after	O
failure	O
of	O
the	O
modified	O
FOLFOX-4	B-DRUG
in	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
was	O
tolerable	O
but	O
showed	O
a	O
lower	O
response	O
rate	O
.	O
	
Further	O
study	O
about	O
retrying	O
5-FU	B-DRUG
/	O
LV	B-DRUG
with	O
irinotecan	B-DRUG
after	O
failure	O
of	O
the	O
5-FU	B-DRUG
/	O
LV	B-DRUG
combined	O
regimen	O
is	O
necessary	O
in	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Feasibility	O
of	O
biweekly	O
combination	O
chemotherapy	O
with	O
capecitabine	B-DRUG
","	O
irinotecan	B-DRUG
","	O
and	O
oxaliplatin	B-DRUG
in	O
patients	O
with	O
metastatic	O
solid	O
tumors	O
:	O
results	O
of	O
a	O
two-step	O
phase	O
I	O
trial	O
:	O
XELIRI	B-DRUG
and	O
XELIRINOX	B-DRUG
.	O
	
	
Biweekly	O
schedule	O
of	O
capecitabine	B-DRUG
combined	O
with	O
irinotecan	B-DRUG
(	O
XELIRI	B-DRUG
)	O
","	O
consecutively	O
with	O
irinotecan	B-DRUG
and	O
oxaliplatin	B-DRUG
(	O
XELIRINOX	B-DRUG
)	O
","	O
was	O
evaluated	O
in	O
patients	O
with	O
metastatic	B-CANCER
cancer	I-CANCER
from	O
any	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
In	O
this	O
two-step	O
phase	O
I	O
trial	O
","	O
seventeen	O
and	O
eleven	O
patients	O
were	O
enrolled	O
in	O
the	O
XELIRI	B-DRUG
and	O
XELIRINOX	B-DRUG
stages	O
","	O
respectively	O
.	O
	
In	O
XELIRI	B-DRUG
","	O
a	O
total	O
of	O
136	O
chemotherapy	O
cycles	O
were	O
administered	O
with	O
a	O
median	O
number	O
of	O
8	O
cycles	O
per	O
patient	O
(	O
2月16日	O
)	O
.	O
	
Main	O
dose-limiting	O
toxicities	O
(	O
DLT	O
)	O
were	O
grade	O
3月4日	O
neutropenia	B-TOXI
","	O
with	O
one	O
toxicity-related	B-TOXI
death	I-TOXI
.	O
	
Maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
for	O
capecitabine	B-DRUG
combined	O
with	O
180	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
irinotecan	B-DRUG
was	O
"3,500"	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
.	O
	
In	O
XELIRINOX	B-DRUG
","	O
capecitabine	B-DRUG
starting	O
dose	O
was	O
"2,500"	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
.	O
	
Fifty-eight	O
chemotherapy	O
cycles	O
were	O
administered	O
with	O
a	O
median	O
of	O
4	O
cycles	O
per	O
patient	O
(	O
1月16日	O
)	O
.	O
	
DLT	O
included	O
3	O
grade	O
4	O
neutropenia	B-TOXI
","	O
associated	O
with	O
1	O
grade	O
3	O
diarrhea	B-TOXI
","	O
and	O
1	O
grade	O
4	O
pneumopathy	B-TOXI
leading	O
to	O
patient	O
death	B-TOXI
.	O
	
MTD	O
for	O
capecitabine	B-DRUG
with	O
180	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
irinotecan	B-DRUG
and	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
oxaliplatin	B-DRUG
was	O
"3,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
.	O
	
The	O
recommended	O
doses	O
for	O
capecitabine	B-DRUG
were	O
"3,000"	O
and	O
"2,500"	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
D1-D7	O
in	O
combination	O
with	O
180	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
irinotecan	B-DRUG
in	O
XELIRI	O
","	O
plus	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
oxaliplatin	B-DRUG
in	O
XELIRINOX	B-DRUG
(	O
D1	O
=	O
D14	O
)	O
","	O
respectively	O
.	O
	
XELIRI	B-DRUG
and	O
XELIRINOX	B-DRUG
regimens	O
are	O
feasible	O
and	O
warrant	O
further	O
investigation	O
in	O
combination	O
with	O
targeted	O
therapy	O
in	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
patients	O
.	O
	
Phase	O
I	O
study	O
of	O
continuous	B-DRUG
afatinib	I-DRUG
(	O
BIBW	B-DRUG
2992	I-DRUG
)	O
in	O
patients	O
with	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
after	O
prior	O
chemotherapy	O
/	O
erlotinib	B-DRUG
/	O
gefitinib	B-DRUG
(	O
LUX-Lung	O
4	O
)	O
.	O
	
	
This	O
Phase	O
I	O
study	O
determined	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
afatinib	B-DRUG
(	O
Afatinib	B-DRUG
is	O
an	O
investigational	O
compound	O
and	O
its	O
safety	O
and	O
efficacy	O
have	O
not	O
yet	O
been	O
established	O
)	O
(	O
BIBW	B-DRUG
2992	I-DRUG
;	O
trade	O
name	O
not	O
yet	O
approved	O
by	O
FDA	O
)	O
","	O
an	O
irreversible	O
inhibitor	O
of	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
/	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
HER	O
)	O
1	O
and	O
2	O
","	O
up	O
to	O
a	O
dose	O
of	O
50	O
mg	O
/	O
day	O
in	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
","	O
to	O
establish	O
the	O
recommended	O
dose	O
for	O
Phase	O
II	O
.	O
	
Patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
who	O
had	O
received	O
prior	O
platinum-doublet	B-DRUG
chemotherapy	O
and	O
/	O
or	O
erlotinib	B-DRUG
/	O
gefitinib	B-DRUG
therapy	O
","	O
or	O
who	O
were	O
ineligible	O
for	O
","	O
or	O
not	O
amenable	O
to	O
","	O
treatment	O
with	O
established	O
therapies	O
","	O
received	O
oral	B-DRUG
afatinib	I-DRUG
once	O
daily	O
.	O
	
The	O
MTD	O
was	O
determined	O
based	O
on	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
;	O
other	O
assessments	O
included	O
safety	O
","	O
pharmacokinetic	O
profile	O
","	O
antitumour	O
activity	O
according	O
to	O
response	O
evaluation	O
criteria	O
in	O
solid	B-CANCER
tumours	I-CANCER
and	O
EGFR	O
/	O
HER1	O
mutation	O
analysis	O
where	O
possible	O
.	O
	
Twelve	O
evaluable	O
patients	O
were	O
treated	O
at	O
doses	O
of	O
20-50	O
mg	O
/	O
day	O
.	O
	
One	O
DLT	O
was	O
observed	O
at	O
50	O
mg	O
/	O
day	O
in	O
Course	O
1	O
(	O
Grade	O
3	O
mucositis	B-TOXI
)	O
.	O
	
The	O
most	O
frequent	O
drug-related	O
adverse	O
events	O
were	O
diarrhoea	B-TOXI
","	O
dry	B-TOXI
skin	I-TOXI
","	O
stomatitis	B-TOXI
","	O
rash	B-TOXI
","	O
paronychia	B-TOXI
and	O
anorexia	B-TOXI
;	O
most	O
were	O
Grade	O
1	O
or	O
2	O
Six	O
out	O
of	O
12	O
patients	O
had	O
tumour	O
size	O
reductions	O
;	O
durable	O
stable	O
disease	O
was	O
achieved	O
in	O
three	O
patients	O
including	O
one	O
with	O
EGFR	O
/	O
HER1	O
exon	O
19	O
and	O
T790	O
M	O
mutations	O
.	O
	
Peak	O
plasma	O
concentrations	O
of	O
afatinib	B-DRUG
were	O
reached	O
3月4日	O
h	O
after	O
administration	O
and	O
declined	O
with	O
a	O
half-life	O
of	O
30-40	O
h.	O
Afatinib	B-DRUG
50	O
mg	O
/	O
day	O
was	O
well	O
tolerated	O
with	O
an	O
acceptable	O
safety	O
profile	O
during	O
Phase	O
I.	O
Recommended	O
dose	O
for	O
Phase	O
II	O
was	O
defined	O
as	O
50	O
mg	O
/	O
day	O
for	O
Japanese	O
patients	O
;	O
the	O
same	O
as	O
for	O
non-Japanese	O
patients	O
.	O
	
Randomized	O
phase	O
III	O
study	O
of	O
surgery	O
alone	O
or	O
surgery	O
plus	O
preoperative	O
cisplatin	B-DRUG
and	O
gemcitabine	B-DRUG
in	O
stages	O
IB	O
to	O
IIIA	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
This	O
study	O
aimed	O
to	O
determine	O
whether	O
three	O
preoperative	O
cycles	O
of	O
gemcitabine	B-DRUG
plus	O
cisplatin	B-DRUG
followed	O
by	O
radical	O
surgery	O
provides	O
a	O
reduction	O
in	O
the	O
risk	O
of	O
progression	O
compared	O
with	O
surgery	O
alone	O
in	O
patients	O
with	O
stages	O
IB	O
to	O
IIIA	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Patients	O
with	O
chemotherapy-naive	O
NSCLC	B-CANCER
(	O
stages	O
IB	O
","	O
II	O
","	O
or	O
IIIA	O
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
three	O
cycles	O
of	O
gemcitabine	B-DRUG
"1,250"	O
mg	O
/	O
m	O
(	O
2	O
)	O
days	O
1	O
and	O
8	O
every	O
3	O
weeks	O
plus	O
cisplatin	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
day	O
1	O
every	O
3	O
weeks	O
followed	O
by	O
surgery	O
","	O
or	O
surgery	O
alone	O
.	O
	
Randomization	O
was	O
stratified	O
by	O
center	O
and	O
disease	O
stage	O
(	O
IB	O
/	O
IIA	O
v	O
IIB	O
/	O
IIIA	O
)	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
progression-free	O
survival	O
(	O
PFS	O
)	O
.	O
	
Results	O
The	O
study	O
was	O
prematurely	O
closed	O
after	O
the	O
random	O
assignment	O
of	O
270	O
patients	O
:	O
129	O
to	O
chemotherapy	O
plus	O
surgery	O
and	O
141	O
to	O
surgery	O
alone	O
.	O
	
Median	O
age	O
was	O
61.8	O
years	O
and	O
83.3	O
%	O
were	O
male	O
.	O
	
Slightly	O
more	O
patients	O
in	O
the	O
surgery	O
alone	O
arm	O
had	O
disease	O
stage	O
IB	O
/	O
IIA	O
(	O
55.3	O
%	O
v	O
48.8	O
%	O
)	O
.	O
	
The	O
chemotherapy	O
response	O
rate	O
was	O
35.4	O
%	O
.	O
	
The	O
hazard	O
ratios	O
for	O
PFS	O
and	O
overall	O
survival	O
were	O
0.7	O
(	O
95	O
%	O
CI	O
","	O
0.5	O
to	O
0.97	O
;	O
P	O
=	O
0.003	O
)	O
and	O
0.63	O
(	O
95	O
%	O
CI	O
","	O
0.43	O
to	O
0.92	O
;	O
P	O
=	O
0.02	O
)	O
","	O
respectively	O
","	O
both	O
in	O
favor	O
of	O
chemotherapy	O
plus	O
surgery	O
.	O
	
A	O
statistically	O
significant	O
impact	O
of	O
preoperative	O
chemotherapy	O
on	O
outcomes	O
was	O
observed	O
in	O
the	O
stage	O
IIB	O
/	O
IIIA	O
subgroup	O
(	O
3-year	O
PFS	O
rate	O
:	O
36.1	O
%	O
v	O
55.4	O
%	O
;	O
P	O
=	O
0.002	O
)	O
.	O
	
The	O
most	O
common	O
grade	O
3	O
or	O
4	O
chemotherapy-related	O
adverse	O
events	O
were	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
.	O
	
No	O
treatment-by-histology	O
interaction	O
effect	O
was	O
apparent	O
.	O
	
Although	O
the	O
study	O
was	O
terminated	O
early	O
","	O
preoperative	O
gemcitabine	B-DRUG
plus	O
cisplatin	B-DRUG
followed	O
by	O
radical	O
surgery	O
improved	O
survival	O
in	O
patients	O
with	O
clinical	O
stage	O
IIB	O
/	O
IIIA	O
NSCLC	B-CANCER
.	O
	
Phase	O
I-II	O
study	O
of	O
everolimus	B-DRUG
and	O
low-dose	O
oral	B-DRUG
cyclophosphamide	I-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
renal	I-CANCER
cell	I-CANCER
cancer	I-CANCER
.	O
	
	
For	O
patients	O
with	O
metastatic	B-CANCER
renal	I-CANCER
cell	I-CANCER
cancer	I-CANCER
(	O
mRCC	B-CANCER
)	O
who	O
progressed	O
on	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
receptor	O
tyrosine	O
kinase	O
inhibitor	O
therapy	O
","	O
the	O
orally	O
administered	O
mammalian	O
target	O
of	O
rapamycin	B-DRUG
(	O
mTOR	O
)	O
inhibitor	O
everolimus	B-DRUG
has	O
been	O
shown	O
to	O
prolong	O
progression	O
free	O
survival	O
.	O
	
Intriguingly	O
","	O
inhibition	O
of	O
mTOR	O
also	O
promotes	O
expansion	O
of	O
immunosuppressive	O
regulatory	O
T	O
cells	O
(	O
Tregs	O
)	O
that	O
can	O
inhibit	O
anti-tumor	O
immune	O
responses	O
in	O
a	O
clinically	O
relevant	O
way	O
in	O
various	O
tumor	O
types	O
including	O
RCC	B-CANCER
.	O
	
This	O
study	O
intends	O
to	O
investigate	O
whether	O
the	O
antitumor	O
efficacy	O
of	O
everolimus	B-DRUG
can	O
be	O
increased	O
by	O
preventing	O
the	O
detrimental	O
everolimus	B-DRUG
induced	O
expansion	O
of	O
Tregs	O
using	O
a	O
metronomic	O
schedule	O
of	O
cyclophosphamide	B-DRUG
.	O
	
This	O
phase	O
I-II	O
trial	O
is	O
a	O
national	O
multi-center	O
study	O
of	O
different	O
doses	O
and	O
schedules	O
of	O
low-dose	O
oral	O
cyclophosphamide	B-DRUG
in	O
combination	O
with	O
a	O
fixed	O
dose	O
of	O
everolimus	B-DRUG
in	O
patients	O
with	O
mRCC	B-CANCER
not	O
amenable	O
to	O
or	O
progressive	O
after	O
a	O
VEGF-receptor	O
tyrosine	O
kinase	O
inhibitor	O
containing	O
treatment	O
regimen	O
.	O
	
In	O
the	O
phase	O
I	O
part	O
of	O
the	O
study	O
the	O
optimal	O
Treg-depleting	O
dose	O
and	O
schedule	O
of	O
metronomic	O
oral	O
cyclophosphamide	B-DRUG
when	O
given	O
in	O
combination	O
with	O
everolimus	B-DRUG
will	O
be	O
determined	O
.	O
	
In	O
the	O
phase	O
II	O
part	O
of	O
the	O
study	O
we	O
will	O
evaluate	O
whether	O
the	O
percentage	O
of	O
patients	O
progression	O
free	O
at	O
4	O
months	O
of	O
everolimus	B-DRUG
treatment	O
can	O
be	O
increased	O
from	O
50	O
%	O
to	O
70	O
%	O
by	O
adding	O
metronomic	O
cyclophosphamide	B-DRUG
(	O
in	O
the	O
dose	O
and	O
schedule	O
determined	O
in	O
the	O
phase	O
I	O
part	O
)	O
.	O
	
In	O
addition	O
to	O
efficacy	O
","	O
we	O
will	O
perform	O
extensive	O
immune	O
monitoring	O
with	O
a	O
focus	O
on	O
the	O
number	O
","	O
phenotype	O
and	O
function	O
of	O
Tregs	O
","	O
evaluate	O
the	O
safety	O
and	O
feasibility	O
of	O
the	O
combination	O
of	O
everolimus	B-DRUG
and	O
cyclophosphamide	B-DRUG
","	O
perform	O
monitoring	O
of	O
selected	O
angiogenesis	O
parameters	O
and	O
analyze	O
everolimus	B-DRUG
and	O
cyclophosphamide	B-DRUG
drug	O
levels	O
.	O
	
This	O
phase	O
I-II	O
study	O
is	O
designed	O
to	O
determine	O
whether	O
metronomic	O
cyclophosphamide	B-DRUG
can	O
be	O
used	O
to	O
counter	O
the	O
mTOR	O
inhibitor	O
everolimus	B-DRUG
induced	O
Treg	O
expansion	O
in	O
patients	O
with	O
metastatic	B-CANCER
renal	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
and	O
increase	O
the	O
antitumor	O
efficacy	O
of	O
everolimus	B-DRUG
.	O
	
ClinicalTrials.gov	O
Identifier	O
NCT01462214	O
","	O
EudraCT	O
number	O
2010-024515-13	O
","	O
Netherlands	O
Trial	O
Register	O
number	O
NTR3085	O
.	O
	
A	O
phase	O
I	O
study	O
with	O
an	O
expanded	O
cohort	O
to	O
assess	O
the	O
feasibility	O
of	O
intravenous	B-DRUG
paclitaxel	I-DRUG
","	O
intraperitoneal	B-DRUG
carboplatin	I-DRUG
and	O
intraperitoneal	B-DRUG
paclitaxel	I-DRUG
in	O
patients	O
with	O
untreated	O
ovarian	B-CANCER
","	I-CANCER
fallopian	I-CANCER
tube	I-CANCER
or	I-CANCER
primary	I-CANCER
peritoneal	I-CANCER
carcinoma	I-CANCER
:	O
a	O
Gynecologic	O
Oncology	O
Group	O
study	O
.	O
	
	
To	O
define	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
assess	O
the	O
feasibility	O
of	O
intravenous	O
(	O
IV	O
)	O
paclitaxel	B-DRUG
","	O
intraperitoneal	O
(	O
IP	O
)	O
carboplatin	B-DRUG
","	O
and	O
IP	O
paclitaxel	B-DRUG
in	O
women	O
with	O
newly	O
diagnosed	O
Stages	O
II-IV	O
ovarian	B-CANCER
","	I-CANCER
fallopian	I-CANCER
tube	I-CANCER
","	I-CANCER
or	I-CANCER
primary	I-CANCER
peritoneal	I-CANCER
carcinoma	I-CANCER
.	O
	
Patients	O
received	O
escalating	O
doses	O
of	O
paclitaxel	B-DRUG
IV	O
and	O
carboplatin	B-DRUG
IP	O
on	O
day	O
1	O
and	O
paclitaxel	B-DRUG
IP	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
8	O
A	O
standard	O
3+3	O
design	O
was	O
used	O
in	O
the	O
escalation	O
phase	O
.	O
	
A	O
two-stage	O
group	O
sequential	O
design	O
with	O
20	O
patients	O
at	O
the	O
MTD	O
was	O
used	O
in	O
the	O
feasibility	O
phase	O
.	O
	
Patient-reported	O
neurotoxicity	B-TOXI
was	O
assessed	O
pre	O
and	O
post	O
treatment	O
.	O
	
Patients	O
were	O
treated	O
with	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
and	O
carboplatin	B-DRUG
IP	O
from	O
AUC	O
5月7日	O
on	O
day	O
1	O
and	O
paclitaxel	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
IP	O
on	O
day	O
8	O
The	O
MTD	O
was	O
estimated	O
at	O
carboplatin	B-DRUG
AUC	O
6	O
IP	O
and	O
25	O
patients	O
enrolled	O
at	O
this	O
dose	O
level	O
.	O
	
Within	O
the	O
first	O
4	O
cycles	O
","	O
seven	O
(	O
35	O
%	O
)	O
of	O
twenty	O
evaluable	O
patients	O
had	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
including	O
grade	O
4	O
thrombocytopenia	B-TOXI
(	O
1	O
)	O
","	O
grade	O
3	O
neutropenic	B-TOXI
fever	I-TOXI
(	O
3	O
)	O
","	O
&	O
gt	O
;	O
2	O
week	O
delay	O
due	O
to	O
ANC	B-TOXI
recovery	I-TOXI
(	O
1	O
)	O
","	O
grade	O
3	O
LFT	B-TOXI
(	O
1	O
)	O
","	O
and	O
grade	O
3	O
infection	B-TOXI
(	O
1	O
)	O
.	O
	
De-escalation	O
to	O
paclitaxel	B-DRUG
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
was	O
given	O
to	O
improve	O
the	O
safety	O
.	O
	
After	O
six	O
evaluable	O
patients	O
completed	O
4	O
cycles	O
without	O
a	O
DLT	O
","	O
bevacizumab	B-DRUG
was	O
added	O
and	O
six	O
evaluable	O
patients	O
completed	O
4	O
cycles	O
with	O
one	O
DLT	O
(	O
grade	O
3	O
hyponatremia	B-TOXI
)	O
.	O
	
Paclitaxel	B-DRUG
at	O
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
","	O
carboplatin	B-DRUG
AUC	O
6	O
IP	O
day	O
1	O
and	O
paclitaxel	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
IP	O
day	O
8	O
yield	O
18-56	O
%	O
patients	O
with	O
DLTs	O
.	O
	
The	O
tolerability	O
of	O
the	O
regimen	O
in	O
combination	O
with	O
bevacizumab	B-DRUG
was	O
indicated	O
in	O
a	O
small	O
cohort	O
.	O
	
Phase	O
I	O
trial	O
of	O
everolimus	B-DRUG
plus	O
sorafenib	B-DRUG
for	O
patients	O
with	O
advanced	B-DRUG
renal	I-DRUG
cell	I-DRUG
cancer	I-DRUG
.	O
	
	
Everolimus	B-DRUG
","	O
a	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
inhibitor	O
","	O
and	O
sorafenib	B-DRUG
","	O
a	O
RAF	O
kinase	O
inhibitor	O
","	O
has	O
shown	O
efficacy	O
in	O
renal	B-CANCER
cell	I-CANCER
cancer	I-CANCER
(	O
RCC	B-CANCER
)	O
as	O
single	O
agents	O
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
study	O
to	O
evaluate	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
combining	O
these	O
agents	O
for	O
potential	O
additive	O
or	O
synergistic	O
effects	O
when	O
treating	O
progressive	O
metastatic	B-CANCER
RCC	I-CANCER
(	O
mRCC	B-CANCER
)	O
.	O
	
The	O
15	O
patients	O
enrolled	O
in	O
the	O
study	O
had	O
predominantly	O
clear	O
cell	O
RCC	B-CANCER
(	O
cRCC	B-CANCER
)	O
and	O
progressive	O
measurable	O
disease	O
with	O
previous	O
treatment	O
that	O
included	O
immunotherapy	O
","	O
tyrosine	O
kinase	O
inhibitors	O
","	O
and	O
/	O
or	O
everolimus	B-DRUG
.	O
	
Patients	O
received	O
daily	O
everolimus	B-DRUG
and	O
twice-daily	O
sorafenib	B-DRUG
at	O
escalating	O
dose	O
levels	O
of	O
2.5	O
mg	O
/	O
400	O
mg	O
(	O
cohort	O
1	O
)	O
","	O
5	O
mg	O
/	O
400	O
mg	O
(	O
cohort	O
2	O
)	O
","	O
and	O
10	O
mg	O
/	O
400	O
mg	O
(	O
cohort	O
3	O
)	O
","	O
and	O
they	O
were	O
evaluated	O
weekly	O
for	O
toxicity	O
and	O
every	O
8	O
weeks	O
for	O
response	O
","	O
using	O
computed	O
tomography	O
/	O
positron	O
emission	O
tomography	O
(	O
CT	O
/	O
PET	O
)	O
and	O
CT	O
at	O
baseline	O
and	O
at	O
first	O
staging	O
.	O
	
In	O
cohort	O
1	O
","	O
2	O
of	O
6	O
patients	O
experienced	O
dose-limited	O
toxicity	O
(	O
DLT	O
)	O
of	O
thrombocytopenia	B-TOXI
/	O
leukopenia	B-TOXI
and	O
pneumonitis	B-TOXI
.	O
	
In	O
cohort	O
2	O
","	O
1	O
of	O
6	O
patients	O
experienced	O
a	O
DLT	O
of	O
pulmonary	B-TOXI
embolism	I-TOXI
","	O
and	O
the	O
3	O
patients	O
in	O
cohort	O
3	O
experienced	O
no	O
DLTs	O
.	O
	
The	O
MTD	O
was	O
10	O
mg	O
/	O
400	O
mg	O
.	O
	
Common	O
adverse	O
events	O
included	O
grade	O
1	O
/	O
2	O
hand-foot	B-TOXI
syndrome	I-TOXI
.	O
	
Using	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	B-CANCER
Tumors	I-CANCER
(	O
RECIST	O
)	O
","	O
1	O
patient	O
achieved	O
a	O
pathologic	O
complete	O
response	O
(	O
CR	O
)	O
","	O
1	O
patient	O
achieved	O
a	O
radiographic	O
CR	O
","	O
and	O
1	O
patient	O
achieved	O
a	O
surgical	O
CR	O
.	O
	
Seven	O
patients	O
achieved	O
stable	O
disease	O
;	O
10	O
patients	O
had	O
decreased	B-TOXI
fluorine-18	I-TOXI
fluorodeoxyglucose	I-TOXI
uptake	I-TOXI
.	O
	
Median	O
progressive-free	O
survival	O
was	O
5.6	O
months	O
;	O
overall	O
survival	O
was	O
7.9	O
months	O
.	O
	
The	O
MTD	O
of	O
daily	O
everolimus	B-DRUG
10	O
mg	O
and	O
twice-daily	O
sorafenib	B-DRUG
400	O
mg	O
is	O
safe	O
and	O
effective	O
for	O
progressive	O
mRCC	B-CANCER
.	O
	
Addition	O
of	O
bevacizumab	B-DRUG
to	O
standard	O
chemoradiation	O
for	O
locoregionally	O
advanced	B-CANCER
nasopharyngeal	I-CANCER
carcinoma	I-CANCER
(	O
RTOG	O
615	O
)	O
:	O
a	O
phase	O
2	O
multi-institutional	O
trial	O
.	O
	
	
We	O
aimed	O
to	O
improve	O
the	O
outcomes	O
for	O
locoregionally	O
advanced	B-CANCER
nasopharyngeal	I-CANCER
carcinoma	I-CANCER
by	O
testing	O
the	O
feasibility	O
and	O
safety	O
of	O
the	O
addition	O
of	O
bevacizumab	B-DRUG
to	O
chemoradiotherapy	O
.	O
	
We	O
enrolled	O
patients	O
older	O
than	O
18	O
years	O
with	O
stage	O
IIB-IVB	O
nasopharyngeal	B-CANCER
carcinoma	I-CANCER
from	O
19	O
centres	O
in	O
North	O
America	O
and	O
Hong	O
Kong	O
.	O
	
Treatment	O
consisted	O
of	O
three	O
cycles	O
of	O
bevacizumab	B-DRUG
(	O
15	O
mg	O
/	O
kg	O
)	O
and	O
cisplatin	B-DRUG
(	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
both	O
given	O
on	O
days	O
1	O
","	O
22	O
","	O
and	O
43	O
of	O
radiation	O
(	O
70	O
Gy	O
)	O
with	O
intensity-modulated	O
radiation	O
therapy	O
delivered	O
over	O
33	O
days	O
on	O
a	O
daily	O
basis	O
","	O
Monday	O
through	O
Friday	O
.	O
	
Patients	O
then	O
received	O
three	O
cycles	O
of	O
bevacizumab	B-DRUG
(	O
15	O
mg	O
/	O
kg	O
)	O
and	O
cisplatin	B-DRUG
(	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
both	O
given	O
on	O
days	O
64	O
","	O
85	O
","	O
and	O
106	O
after	O
radiation	O
","	O
and	O
three	O
cycles	O
of	O
fluorouracil	B-DRUG
(	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
day	O
)	O
","	O
given	O
on	O
days	O
64-67	O
","	O
85-88	O
","	O
and	O
106-109	O
after	O
radiation	O
.	O
	
The	O
primary	O
endpoint	O
was	O
the	O
occurrence	O
of	O
treatment-related	O
grade	O
4	O
haemorrhage	B-TOXI
or	O
any	O
grade	O
5	O
adverse	O
event	O
in	O
the	O
first	O
year	O
.	O
	
Analyses	O
were	O
done	O
with	O
all	O
eligible	O
patients	O
who	O
started	O
protocol	O
treatment	O
.	O
	
The	O
trial	O
is	O
registered	O
at	O
ClinicalTrials.gov	O
","	O
number	O
NCT00408694	O
.	O
	
From	O
Dec	O
13	O
","	O
2006	O
","	O
to	O
Feb	O
5	O
","	O
2009	O
","	O
we	O
enrolled	O
46	O
patients	O
","	O
of	O
whom	O
44	O
were	O
eligible	O
for	O
analysis	O
.	O
	
We	O
recorded	O
no	O
grade	O
3月4日	O
haemorrhages	B-TOXI
or	O
grade	O
5	O
adverse	O
events	O
;	O
nine	O
patients	O
(	O
20	O
%	O
)	O
had	O
a	O
treatment-related	O
grade	O
1月2日	O
haemorrhage	B-TOXI
.	O
	
Nine	O
patients	O
had	O
one	O
or	O
more	O
grade	O
4	O
blood	B-TOXI
or	O
bone	B-TOXI
marrow-related	I-TOXI
complication	I-TOXI
(	O
grade	O
4	O
leucopenia	B-TOXI
was	O
noted	O
in	O
six	O
patients	O
","	O
grade	O
4	O
lymphopenia	B-TOXI
in	O
five	O
","	O
grade	O
4	O
neutrophils	B-TOXI
in	O
five	O
","	O
and	O
grade	O
4	O
anaemia	B-TOXI
in	O
one	O
)	O
.	O
	
One	O
patient	O
had	O
two	O
grade	O
4	O
infections	B-TOXI
with	O
grade	O
3月4日	O
neutrophils	B-TOXI
.	O
	
One	O
patient	O
reported	O
grade	O
4	O
tinnitus	B-TOXI
","	O
one	O
patient	O
reported	O
grade	O
4	O
thrombosis	B-TOXI
","	O
one	O
reported	O
grade	O
4	O
radiation	B-TOXI
mucositis	I-TOXI
","	O
and	O
two	O
reported	O
grade	O
4	O
pharyngolaryngeal	B-TOXI
pain	I-TOXI
.	O
	
With	O
a	O
median	O
follow-up	O
of	O
2路5	O
years	O
(	O
IQR	O
2路1-2路9	O
)	O
","	O
the	O
estimated	O
2	O
year	O
locoregional	O
progression-free	O
interval	O
was	O
83路7	O
%	O
(	O
95	O
%	O
CI	O
72路6-94路9	O
)	O
","	O
the	O
2	O
year	O
distant	O
metastasis-free	O
interval	O
was	O
90路8	O
%	O
(	O
82路2-99路5	O
)	O
","	O
the	O
2	O
year	O
progression-free	O
survival	O
was	O
74路7	O
%	O
(	O
61路8-87路6	O
)	O
","	O
and	O
2	O
year	O
overall	O
survival	O
was	O
90路9	O
%	O
(	O
82路3-99路4	O
)	O
.	O
	
The	O
addition	O
of	O
bevacizumab	B-DRUG
to	O
standard	O
chemoradiation	O
treatment	O
for	O
patients	O
with	O
nasopharyngeal	B-CANCER
carcinoma	I-CANCER
is	O
feasible	O
","	O
and	O
might	O
delay	O
the	O
progression	O
of	O
subclinical	O
distant	O
disease	O
.	O
	
National	O
Cancer	O
Institute	O
","	O
USA	O
.	O
	
Phase	O
II	O
trial	O
of	O
erlotinib	B-DRUG
and	O
docetaxel	B-DRUG
in	O
advanced	B-CANCER
and	I-CANCER
refractory	I-CANCER
hepatocellular	I-CANCER
and	I-CANCER
biliary	I-CANCER
cancers	I-CANCER
:	O
Hoosier	O
Oncology	O
Group	O
GI06-101	O
.	O
	
	
Patients	O
with	O
advanced	B-CANCER
hepatocellular	I-CANCER
(	O
HCC	B-CANCER
)	O
and	O
biliary	B-CANCER
tract	I-CANCER
carcinomas	I-CANCER
(	O
BTC	O
)	O
have	O
poor	O
prognosis	O
.	O
	
While	O
the	O
EGFR	O
pathway	O
is	O
overactive	O
in	O
HCC	B-CANCER
and	O
BTC	B-CANCER
","	O
single	O
agent	O
anti-EGFR	O
therapies	O
confer	O
modest	O
activity	O
.	O
	
Preclinical	O
data	O
showed	O
synergistic	O
antiproliferative	O
and	O
proapoptotic	O
effects	O
between	O
anti-EGFR	O
therapies	O
and	O
taxanes	B-DRUG
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
study	O
of	O
erlotinib	B-DRUG
and	O
docetaxel	B-DRUG
in	O
solid	B-CANCER
tumors	I-CANCER
","	O
and	O
noted	O
good	O
tolerability	O
and	O
sustained	O
complete	O
(	O
5	O
years	O
=+	O
)	O
and	O
partial	O
responses	O
in	O
patients	O
with	O
HCC	B-CANCER
and	O
BTC	B-CANCER
.	O
	
This	O
trial	O
evaluated	O
the	O
efficacy	O
of	O
erlotinib	B-DRUG
with	O
docetaxel	B-DRUG
in	O
refractory	B-CANCER
hepatobiliary	I-CANCER
cancers	I-CANCER
.	O
	
Eligible	O
patients	O
were	O
allowed	O
to	O
have	O
two	O
prior	O
systemic	O
therapies	O
.	O
	
Docetaxel	B-DRUG
30	O
mg	O
/	O
m2	O
i.v.	O
was	O
administered	O
on	O
days	O
1	O
","	O
8	O
","	O
15	O
","	O
and	O
erlotinib	B-DRUG
150	O
mg	O
was	O
dosed	O
orally	O
on	O
days	O
2月7日	O
","	O
9月14日	O
","	O
16-28	O
of	O
each	O
28-day	O
cycle	O
.	O
	
The	O
primary	O
endpoint	O
was	O
16	O
weeks	O
progression-free	O
survival	O
(	O
PFS	O
)	O
","	O
and	O
secondary	O
endpoints	O
included	O
response	O
","	O
stable	O
disease	O
","	O
and	O
overall	O
survival	O
.	O
	
Tumor	O
samples	O
were	O
analyzed	O
for	O
KRAS	O
gene	O
mutations	O
and	O
E-cadherin	O
expression	O
by	O
immunohistochemistry	O
(	O
IHC	O
)	O
.	O
	
Patients	O
with	O
BTC	B-CANCER
and	O
HCC	B-CANCER
were	O
accrued	O
and	O
assessed	O
in	O
separate	O
strata	O
for	O
the	O
efficacy	O
endpoints	O
","	O
but	O
for	O
the	O
two-stage	O
initial	O
design	O
of	O
the	O
study	O
","	O
combined	O
PFS	O
was	O
considered	O
.	O
	
A	O
Simon	O
optimal	O
two-stage	O
design	O
tested	O
the	O
hypothesis	O
that	O
the	O
16-week	O
PFS	O
is	O
_	O
15	O
%	O
(	O
clinically	O
inactive	O
)	O
versus	O
the	O
alternative	O
of	O
_	O
30	O
%	O
(	O
warranting	O
further	O
study	O
)	O
.	O
	
Twenty-five	O
patients	O
","	O
14	O
with	O
HCC	B-CANCER
and	O
11	O
with	O
BTC	B-CANCER
","	O
were	O
enrolled	O
.	O
	
Common	O
toxicities	O
were	O
rash	B-TOXI
(	O
76	O
%	O
)	O
","	O
diarrhea	B-TOXI
(	O
56	O
%	O
)	O
","	O
and	O
fatigue	B-TOXI
(	O
52	O
%	O
)	O
","	O
mostly	O
grade	O
1	O
or	O
2	O
No	O
objective	O
responses	O
were	O
seen	O
.	O
	
Seven	O
BTC	B-CANCER
(	O
64	O
%	O
)	O
and	O
6	O
HCC	B-CANCER
patients	O
(	O
46	O
%	O
)	O
had	O
stable	O
disease	O
as	O
best	O
response	O
","	O
with	O
a	O
median	O
duration	O
of	O
16.1	O
weeks	O
(	O
95	O
%	O
CI	O
3.7-56.3	O
)	O
for	O
BTC	B-CANCER
","	O
and	O
17.6	O
weeks	O
(	O
95	O
%	O
CI	O
8.1-49.8	O
)	O
for	O
HCC	B-CANCER
.	O
	
The	O
16-week	O
PFS	O
was	O
64	O
%	O
for	O
BTC	B-CANCER
(	O
95	O
%	O
CI	O
29.7-84.5	O
)	O
","	O
and	O
38	O
%	O
for	O
HCC	B-CANCER
(	O
95	O
%	O
CI	O
14.1-62.8	O
)	O
.	O
	
Median	O
overall	O
survival	O
was	O
5.7	O
and	O
6.7	O
months	O
for	O
BTC	B-CANCER
and	O
HCC	B-CANCER
patients	O
","	O
respectively	O
.	O
	
BTC	B-CANCER
patients	O
with	O
grade	O
_	O
2	O
rash	B-TOXI
had	O
higher	O
median	O
PFS	O
(	O
6.2	O
vs	O
2.2	O
months	O
)	O
and	O
OS	O
(	O
14.2	O
vs.	O
4.2	O
months	O
)	O
.	O
	
HCC	B-CANCER
patients	O
with	O
negative	O
/	O
low	O
E-cadherin	O
expression	O
had	O
higher	O
median	O
PFS	O
(	O
6.7	O
vs.	O
2.1	O
months	O
)	O
and	O
OS	O
(	O
14.5	O
vs.	O
4	O
months	O
)	O
.	O
	
Erlotinib	B-DRUG
with	O
docetaxel	B-DRUG
met	O
the	O
16-week	O
PFS	O
_	O
30	O
%	O
endpoint	O
","	O
but	O
overall	O
survival	O
was	O
comparable	O
to	O
that	O
seen	O
with	O
single-agent	O
erlotinib	B-DRUG
.	O
	
With	O
the	O
limitation	O
of	O
small	O
numbers	O
of	O
patients	O
","	O
grade	O
_	O
2	O
rash	B-TOXI
(	O
in	O
BTC	B-CANCER
)	O
","	O
and	O
negative	O
/	O
low	O
E-cadherin	O
expression	O
(	O
HCC	O
)	O
were	O
associated	O
with	O
higher	O
PFS	O
and	O
OS	O
.	O
	
Discussion	O
Refractory	B-CANCER
biliary	I-CANCER
tract	I-CANCER
and	I-CANCER
hepatocellular	I-CANCER
cancers	I-CANCER
are	O
difficult	O
to	O
treat	O
","	O
and	O
no	O
chemotherapy	O
or	O
biologically	O
targeted	O
therapies	O
have	O
impacted	O
survival	O
.	O
	
Based	O
on	O
preclinical	O
synergism	O
and	O
prior	O
phase	O
I	O
data	O
","	O
we	O
conducted	O
a	O
multi-institutional	O
study	O
sequentially	O
combining	O
the	O
EGFR-targeted	O
agent	O
erlotinib	B-DRUG
with	O
docetaxel	B-DRUG
.	O
	
Results	O
from	O
this	O
study	O
show	O
that	O
the	O
primary	O
endpoint	O
","	O
16-week	O
PFS	O
of	O
_	O
30	O
%	O
","	O
was	O
met	O
for	O
the	O
combined	O
group	O
of	O
BTC	B-CANCER
and	O
HCC	B-CANCER
patients	O
(	O
as	O
originally	O
planned	O
in	O
the	O
study	O
design	O
)	O
","	O
as	O
well	O
as	O
in	O
each	O
disease	O
category	O
:	O
63.6	O
%	O
for	O
BTC	B-CANCER
and	O
38.5	O
%	O
for	O
HCC	B-CANCER
patients	O
.	O
	
Nevertheless	O
","	O
no	O
patients	O
attained	O
an	O
objective	O
response	O
and	O
the	O
median	O
survival	O
of	O
5.7	O
months	O
for	O
BTC	B-CANCER
","	O
and	O
6.7	O
months	O
for	O
HCC	B-CANCER
patients	O
(	O
while	O
heavily	O
pretreated	O
)	O
","	O
is	O
comparable	O
to	O
that	O
seen	O
with	O
single-agent	O
EGFR-targeted	O
therapies	O
.	O
	
Safety	O
analysis	O
shows	O
that	O
this	O
regimen	O
was	O
generally	O
well	O
tolerated	O
","	O
and	O
most	O
adverse	O
events	O
were	O
grade	O
1	O
or	O
2	O
Few	O
patients	O
had	O
reversible	O
grade	O
3	O
transaminase	B-TOXI
elevation	I-TOXI
(	O
8	O
%	O
)	O
","	O
and	O
severe	B-TOXI
anorexia	I-TOXI
","	O
fatigue	B-TOXI
","	O
and	O
rash	B-TOXI
were	O
uncommon	O
.	O
	
As	O
expected	O
","	O
patients	O
with	O
grade	O
_	O
2	O
rash	B-TOXI
experienced	O
higher	O
PFS	O
and	O
OS	O
","	O
but	O
this	O
was	O
noted	O
only	O
among	O
the	O
BTC	B-CANCER
group	O
","	O
likely	O
because	O
too	O
few	O
HCC	B-CANCER
patients	O
had	O
grade	O
_	O
2	O
rash	B-TOXI
.	O
	
KRAS	O
is	O
an	O
important	O
predictive	O
marker	O
for	O
anti-EGFR	O
therapies	O
for	O
lung	B-CANCER
and	I-CANCER
colorectal	I-CANCER
cancers	I-CANCER
","	O
but	O
for	O
HCC	B-CANCER
or	O
the	O
heterogeneous	O
group	O
of	O
BTC	B-CANCER
(	O
with	O
10-50	O
%	O
KRAS	O
mutations	O
)	O
no	O
significant	O
correlations	O
have	O
been	O
established	O
.	O
	
We	O
were	O
not	O
able	O
to	O
identify	O
a	O
correlation	O
between	O
KRAS	O
and	O
benefit	O
from	O
erlotinib-based	B-DRUG
therapy	O
","	O
as	O
all	O
but	O
one	O
HCC	B-CANCER
patient	O
had	O
KRAS	O
wild	O
type	O
gene	O
status	O
.	O
	
Preclinical	O
data	O
in	O
multiple	O
tumor	O
types	O
showed	O
that	O
E-cadherin	O
","	O
a	O
signature	O
marker	O
for	O
an	O
	O
tumor	O
phenotype	O
when	O
overexpressed	O
","	O
predicts	O
EGFR	O
pathway	O
activation	O
and	O
determines	O
sensitivity	O
to	O
EGFR-targeted	O
agents	O
.	O
	
E-cadherin	O
is	O
often	O
seen	O
as	O
a	O
poor	O
prognostic	O
marker	O
when	O
downregulated	O
","	O
as	O
noted	O
during	O
cancer	O
progression	O
.	O
	
Not	O
all	O
studies	O
demonstrate	O
beneficial	O
effects	O
from	O
E-cadherin	O
overexpression	O
","	O
possibly	O
due	O
to	O
histological	O
expression	O
variability	O
or	O
tumor	O
type	O
specificity	O
for	O
this	O
biomarker	O
.	O
	
Six	O
BTC	B-CANCER
and	O
8	O
HCC	B-CANCER
patients	O
had	O
evaluable	O
tumor	O
samples	O
for	O
E-cadherin	O
analysis	O
.	O
	
While	O
the	O
numbers	O
were	O
small	O
and	O
conclusions	O
should	O
be	O
viewed	O
with	O
caution	O
","	O
negative	O
/	O
low	O
E-cadherin	O
expression	O
was	O
associated	O
with	O
improved	O
PFS	O
and	O
OS	O
for	O
hepatobiliary	B-CANCER
cancers	I-CANCER
(	O
most	O
significant	O
in	O
HCC	B-CANCER
)	O
in	O
this	O
refractory	O
patient	O
population	O
where	O
we	O
expected	O
lower	O
expression	O
levels	O
.	O
	
In	O
conclusion	O
","	O
the	O
combination	O
of	O
erlotinib	B-DRUG
with	O
docetaxel	B-DRUG
provided	O
a	O
16-week	O
PFS	O
of	O
_	O
30	O
%	O
but	O
showed	O
no	O
appreciable	O
differences	O
in	O
overall	O
survival	O
from	O
historical	O
data	O
with	O
single-agent	O
erlotinib	B-DRUG
.	O
	
While	O
EGFR	O
represents	O
an	O
important	O
target	O
in	O
this	O
group	O
of	O
malignancies	B-CANCER
","	O
it	O
is	O
clear	O
that	O
hepatobiliary	B-CANCER
cancers	I-CANCER
are	O
heterogeneous	O
","	O
thus	O
a	O
meaningful	O
improvement	O
in	O
survival	O
most	O
likely	O
will	O
require	O
careful	O
treatment	O
selection	O
based	O
on	O
patient	O
tumor	O
's	O
molecular	O
and	O
genetic	O
profiling	O
.	O
	
A	O
double-blind	O
","	O
randomized	O
","	O
placebo-controlled	B-DRUG
","	O
phase	O
2	O
study	O
of	O
maintenance	O
enzastaurin	O
with	O
5-fluorouracil	B-DRUG
/	O
leucovorin	B-DRUG
plus	O
bevacizumab	B-DRUG
after	O
first-line	O
therapy	O
for	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
Enzastaurin	B-DRUG
and	O
bevacizumab	B-DRUG
have	O
demonstrated	O
synergistic	O
antitumor	O
effects	O
and	O
","	O
in	O
phase	O
1	O
studies	O
","	O
the	O
combination	O
was	O
well	O
tolerated	O
.	O
	
This	O
phase	O
2	O
study	O
assessed	O
enzastaurin	B-DRUG
with	O
5-fluorouracil	B-DRUG
/	O
leucovorin	B-DRUG
plus	O
bevacizumab	B-DRUG
as	O
maintenance	O
therapy	O
for	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
MCRC	B-CANCER
)	O
.	O
	
Patients	O
with	O
locally	O
advanced	O
or	O
MCRC	B-CANCER
and	O
stable	O
or	O
responding	O
disease	O
after	O
completing	O
6	O
cycles	O
of	O
first-line	O
chemotherapy	O
randomly	O
received	O
a	O
loading	O
dose	O
of	O
enzastaurin	B-CANCER
1125	O
mg	O
","	O
followed	O
by	O
500	O
mg	O
/	O
d	O
subsequent	O
doses	O
or	O
placebo	B-CANCER
.	O
	
Both	O
arms	O
received	O
5-fluorouracil	B-DRUG
/	O
leucovorin	B-DRUG
(	O
leucovorin	B-DRUG
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
[	O
IV	O
]	O
","	O
5-fluorouracil	B-DRUG
400-mg	O
/	O
m	O
(	O
2	O
)	O
bolus	O
","	O
5-fluorouracil	B-DRUG
2400	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
)	O
plus	O
bevacizumab	B-DRUG
5	O
mg	O
/	O
kg	O
IV	O
","	O
every	O
2	O
weeks	O
.	O
	
The	O
primary	O
endpoint	O
was	O
progression-free	O
survival	O
(	O
PFS	O
)	O
","	O
from	O
randomization	O
.	O
	
Overall	O
survival	O
(	O
OS	O
)	O
and	O
PFS	O
were	O
also	O
assessed	O
from	O
start	O
of	O
first-line	O
therapy	O
.	O
	
Enrollment	O
was	O
stopped	O
","	O
and	O
the	O
final	O
analysis	O
was	O
conducted	O
after	O
73	O
PFS	O
events	O
.	O
	
Fifty-eight	O
patients	O
were	O
randomized	O
to	O
enzastaurin	B-DRUG
and	O
59	O
to	O
placebo	B-DRUG
.	O
	
For	O
the	O
enzastaurin	B-DRUG
and	O
placebo	B-DRUG
arms	O
","	O
respectively	O
","	O
the	O
median	O
cycles	O
received	O
were	O
9	O
and	O
10	O
","	O
and	O
the	O
median	O
PFS	O
was	O
5.8	O
and	O
8.1	O
months	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
","	O
1.35	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
0.84-2.16	O
;	O
P	O
=	O
0.896	O
)	O
.	O
	
Median	O
OS	O
was	O
not	O
calculable	O
because	O
of	O
high	O
censoring	O
(	O
77.6	O
%	O
enzastaurin	B-DRUG
;	O
91.5	O
%	O
placebo	B-DRUG
)	O
.	O
	
The	O
median	O
PFS	O
from	O
start	O
of	O
first-line	O
therapy	O
was	O
8.9	O
months	O
for	O
enzastaurin	B-DRUG
and	O
11.3	O
months	O
for	O
placebo	B-DRUG
(	O
HR	O
","	O
1.39	O
;	O
95	O
%	O
CI	O
","	O
0.86-2.23	O
;	O
P	O
=	O
0.913	O
)	O
.	O
	
More	O
enzastaurin	B-DRUG
patients	O
developed	O
thrombosis	B-TOXI
or	O
embolism	B-TOXI
compared	O
with	O
placebo	B-DRUG
(	O
15.8	O
%	O
and	O
1.7	O
%	O
;	O
P	O
=	O
0.008	O
)	O
.	O
	
One	O
possibly	O
enzastaurin-related	B-TOXI
death	I-TOXI
occurred	O
because	O
of	O
arrhythmia	B-TOXI
.	O
	
Enzastaurin	B-DRUG
combined	O
with	O
bevacizumab-based	B-DRUG
therapy	O
is	O
tolerable	O
","	O
but	O
does	O
not	O
improve	O
PFS	O
during	O
maintenance	O
therapy	O
in	O
patients	O
with	O
MCRC	B-CANCER
compared	O
with	O
bevacizumab-based	B-DRUG
therapy	O
alone	O
.	O
	
Phase	O
I	O
trial	O
of	O
sorafenib	B-DRUG
in	O
combination	O
with	O
5-fluorouracil	B-DRUG
/	O
leucovorin	B-DRUG
in	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
This	O
dose	O
escalation	O
","	O
uncontrolled	O
phase	O
I	O
study	O
evaluated	O
the	O
tolerability	O
","	O
pharmacokinetics	O
(	O
PK	O
)	O
","	O
and	O
antitumor	O
activity	O
of	O
oral	O
sorafenib	B-DRUG
100	O
","	O
200	O
","	O
or	O
400	O
mg	O
twice	O
daily	O
(	O
bid	O
","	O
continuous	O
regimen	O
)	O
in	O
combination	O
with	O
5-fluorouracil	B-DRUG
/	O
leucovorin	B-DRUG
(	O
5-FU	B-DRUG
/	O
LCV	B-DRUG
","	O
intravenous	O
infusion	O
or	O
bolus	O
)	O
in	O
patients	O
with	O
advanced	O
","	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
A	O
total	O
of	O
47	O
patients	O
(	O
median	O
age	O
57	O
years	O
;	O
colon	B-CANCER
cancer	I-CANCER
","	O
55	O
%	O
;	O
pancreatic	B-CANCER
cancer	I-CANCER
","	O
21	O
%	O
;	O
prior	O
systemic	O
therapy	O
","	O
96	O
%	O
)	O
received	O
treatment	O
;	O
24	O
were	O
included	O
in	O
the	O
PK	O
analyses	O
","	O
and	O
38	O
were	O
evaluable	O
for	O
tumor	O
response	O
.	O
	
Treatment-emergent	O
adverse	O
events	O
were	O
observed	O
in	O
98	O
%	O
of	O
patients	O
(	O
_grade	O
3	O
","	O
55	O
%	O
)	O
;	O
the	O
most	O
frequently	O
reported	O
were	O
fatigue	B-TOXI
(	O
51	O
%	O
)	O
","	O
stomatitis	B-TOXI
/	O
pharyngitis	B-TOXI
(	O
47	O
%	O
)	O
","	O
and	O
hand-foot	B-TOXI
skin	I-TOXI
reaction	I-TOXI
(	O
45	O
%	O
)	O
.	O
	
Concomitant	O
5-FU	B-DRUG
/	O
LCV	B-DRUG
resulted	O
in	O
no	O
clinically	O
relevant	O
changes	O
in	O
the	O
area	O
under	O
the	O
plasma	O
concentration-time	O
curve	O
in	O
the	O
dosing	O
interval	O
(	O
AUC	O
(	O
0-12	O
)	O
)	O
and	O
maximum	O
plasma	O
concentration	O
(	O
C	O
(	O
max	O
)	O
)	O
of	O
sorafenib	B-DRUG
(	O
100-400	O
mg	O
bid	O
)	O
at	O
steady	O
state	O
.	O
	
Although	O
the	O
start	O
of	O
infusion	O
until	O
the	O
last	O
quantifiable	O
plasma	O
concentration	O
(	O
AUC	O
(	O
0-tn	O
)	O
)	O
and	O
C	O
(	O
max	O
)	O
of	O
5-FU	B-DRUG
were	O
increased	O
by	O
concomitant	O
sorafenib	B-DRUG
100	O
to	O
200	O
mg	O
","	O
no	O
consistent	O
effect	O
was	O
observed	O
with	O
400	O
mg	O
sorafenib	B-DRUG
.	O
	
Two	O
(	O
5	O
%	O
)	O
patients	O
with	O
colon	B-CANCER
cancer	I-CANCER
achieved	O
partial	O
response	O
;	O
16	O
(	O
42	O
%	O
)	O
patients	O
(	O
the	O
majority	O
with	O
colon	B-CANCER
and	I-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
)	O
had	O
stable	O
disease	O
.	O
	
Sorafenib	O
plus	O
5-FU	B-DRUG
/	O
LCV	B-DRUG
was	O
generally	O
well	O
tolerated	O
with	O
encouraging	O
antitumor	O
activity	O
and	O
no	O
clinically	O
relevant	O
drug-drug	O
interactions	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Adjuvant	O
PEFG	O
(	O
cisplatin	B-DRUG
","	O
epirubicin	B-DRUG
","	O
5-fluorouracil	B-DRUG
","	O
gemcitabine	B-DRUG
)	O
or	O
gemcitabine	B-DRUG
followed	O
by	O
chemoradiation	O
in	O
pancreatic	B-CANCER
cancer	I-CANCER
:	O
a	O
randomized	O
phase	O
II	O
trial	O
.	O
	
	
Information	O
from	O
randomized	O
trials	O
on	O
the	O
role	O
of	O
combination	O
chemotherapy	O
in	O
the	O
adjuvant	O
treatment	O
of	O
pancreatic	B-CANCER
adenocarcinoma	I-CANCER
is	O
limited	O
.	O
	
This	O
randomized	O
phase	O
II	O
trial	O
aimed	O
to	O
identify	O
the	O
most	O
promising	O
regimen	O
warranting	O
phase	O
III	O
evaluation	O
.	O
	
Therapy-naive	O
patients	O
","	O
age	O
18-75	O
years	O
","	O
Karnofsky	O
Performance	O
Status	O
(	O
KPS	O
)	O
&	O
gt	O
;	O
60	O
","	O
gross	O
total	O
resection	O
of	O
stage	O
IB-III	O
pancreatic	B-CANCER
adenocarcinoma	I-CANCER
","	O
stratified	O
for	O
center	O
and	O
surgical	O
margins	O
","	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
gemcitabine	B-DRUG
1	O
g	O
/	O
m2	O
weekly	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
(	O
arm	O
A	O
)	O
or	O
the	O
PEFG	O
regimen	O
(	O
cisplatin	B-DRUG
and	O
epirubicin	B-DRUG
40	O
mg	O
/	O
m2	O
","	O
day	O
1	O
;	O
gemcitabine	B-DRUG
600	O
mg	O
/	O
m2	O
","	O
days	O
1	O
","	O
8	O
;	O
5-fluorouracil	O
200	O
mg	O
/	O
m2	O
daily	O
","	O
days	O
1月28日	O
)	O
(	O
arm	O
B	O
)	O
.	O
	
Chemotherapy	O
was	O
administered	O
every	O
4	O
weeks	O
for	O
3	O
months	O
and	O
followed	O
by	O
irradiation	O
concurrent	O
to	O
continuous	O
infusion	O
of	O
5-fluorouracil	B-DRUG
250	O
mg	O
/	O
m2	O
daily	O
.	O
	
Primary	O
endpoint	O
was	O
the	O
probability	O
of	O
being	O
disease-free	O
at	O
1	O
year	O
from	O
surgery	O
.	O
	
Assuming	O
P0=35	O
%	O
and	O
P1=55	O
%	O
","	O
伪=.05	O
and	O
尾=.10	O
","	O
the	O
study	O
was	O
to	O
enroll	O
51	O
patients	O
per	O
arm	O
.	O
	
A	O
total	O
of	O
102	O
patients	O
were	O
randomized	O
;	O
100	O
were	O
eligible	O
(	O
arm	O
A	O
:	O
51	O
;	O
arm	O
B	O
:	O
49	O
)	O
.	O
	
Baseline	O
characteristic	O
(	O
A	O
/	O
B	O
)	O
were	O
:	O
Median	O
age	O
was	O
61	O
/	O
60	O
years	O
;	O
75	O
%	O
had	O
KPS	O
&	O
gt	O
;	O
80	O
75	O
/	O
76	O
%	O
;	O
36	O
%	O
grade	O
3	O
tumor	O
29	O
/	O
43	O
%	O
","	O
79	O
%	O
stage	O
IIB	O
/	O
III	O
75	O
/	O
84	O
%	O
","	O
31	O
%	O
R1	O
resection	O
35	O
/	O
29	O
%	O
.	O
	
Survival	O
figures	O
(	O
A	O
/	O
B	O
)	O
were	O
:	O
Median	O
disease-free	O
survival	O
was	O
11.7	O
and	O
15.2	O
months	O
;	O
1-year	O
disease-free	O
survival	O
49	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
95	O
%	O
CI	O
]	O
35-63	O
%	O
)	O
and	O
69.4	O
%	O
(	O
95	O
%	O
CI	O
56-83	O
%	O
)	O
;	O
median	O
survival	O
24.8	O
and	O
28.9	O
months	O
.	O
	
Combination	O
chemotherapy	O
produced	O
more	O
hematological	B-TOXI
toxicity	I-TOXI
without	O
relevant	O
differences	O
in	O
nonhematological	B-TOXI
toxicities	I-TOXI
.	O
	
The	O
4-drug	O
regimen	O
deserves	O
further	O
assessment	O
in	O
resectable	O
pancreatic	B-CANCER
cancer	I-CANCER
.	O
	
Phase	O
I	O
trial	O
of	O
oral	O
S-1	B-DRUG
combined	O
with	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
for	O
advanced	B-CANCER
biliary	I-CANCER
tract	I-CANCER
cancer	I-CANCER
(	O
KHBO1002	O
)	O
.	O
	
	
We	O
aimed	O
to	O
determine	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
of	O
the	O
addition	O
of	O
S-1	B-DRUG
","	O
an	O
oral	O
fluorouracil	B-DRUG
derivative	O
","	O
to	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
combination	O
therapy	O
","	O
which	O
is	O
the	O
current	O
standard	O
treatment	O
for	O
advanced	B-CANCER
biliary	I-CANCER
tract	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
histologically	O
or	O
cytologically	O
confirmed	O
unresectable	O
or	O
recurrent	B-CANCER
biliary	I-CANCER
tract	I-CANCER
cancer	I-CANCER
were	O
eligible	O
for	O
inclusion	O
.	O
	
The	O
planned	O
dosages	O
of	O
gemcitabine	B-DRUG
(	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
/	O
cisplatin	B-DRUG
(	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
/	O
S-1	O
(	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
)	O
were	O
as	O
follows	O
:	O
level	O
0	O
","	O
800	O
/	O
25	O
/	O
60	O
;	O
level	O
1	O
","	O
"1,000"	O
/	O
25	O
/	O
60	O
;	O
and	O
levels	O
2	O
and	O
3	O
","	O
"1,000"	O
/	O
25	O
/	O
80	O
.	O
	
In	O
each	O
cycle	O
","	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
were	O
intravenously	O
administered	O
on	O
day	O
1	O
(	O
or	O
days	O
1	O
and	O
8	O
at	O
level	O
3	O
)	O
","	O
and	O
S-1	B-DRUG
was	O
orally	O
administered	O
twice	O
daily	O
on	O
days	O
1月7日	O
(	O
or	O
days	O
1月14日	O
at	O
level	O
3	O
)	O
;	O
this	O
was	O
repeated	O
every	O
14	O
days	O
(	O
or	O
21	O
days	O
at	O
level	O
3	O
)	O
.	O
	
Seventeen	O
patients	O
were	O
enrolled	O
","	O
and	O
level	O
1	O
was	O
chosen	O
as	O
the	O
starting	O
dose	O
.	O
	
Two	O
of	O
six	O
patients	O
developed	O
DLTs	O
(	O
grade	O
4	O
neutropenia	B-TOXI
and	O
grade	O
3	O
febrile	B-TOXI
neutropenia	I-TOXI
)	O
at	O
level	O
1	O
","	O
and	O
the	O
dose	O
was	O
escalated	O
to	O
level	O
2	O
DLTs	O
(	O
grade	O
3	O
rashes	B-TOXI
and	O
grade	O
3	O
vasovagal	B-TOXI
reactions	I-TOXI
)	O
occurred	O
in	O
two	O
of	O
six	O
assessable	O
patients	O
at	O
level	O
2	O
;	O
we	O
then	O
proceeded	O
to	O
level	O
3	O
The	O
first	O
three	O
assessable	O
patients	O
enrolled	O
at	O
level	O
3	O
developed	O
DLTs	O
(	O
two	O
cases	O
of	O
grade	O
4	O
neutropenia	B-TOXI
","	O
one	O
of	O
grade	O
4	O
leucopenia	B-TOXI
","	O
two	O
of	O
grade	O
3	O
fatigue	B-TOXI
","	O
one	O
of	O
grade	O
3	O
anorexia	B-TOXI
","	O
and	O
one	O
of	O
grade	O
3	O
febrile	B-TOXI
neutropenia	I-TOXI
)	O
during	O
their	O
first	O
cycle	O
","	O
and	O
this	O
dose	O
was	O
determined	O
to	O
be	O
the	O
MTD	O
.	O
	
Therefore	O
","	O
we	O
selected	O
level	O
2	O
as	O
the	O
recommended	O
dose	O
(	O
RD	O
)	O
for	O
a	O
subsequent	O
phase	O
II	O
study	O
.	O
	
We	O
determined	O
the	O
RD	O
of	O
gemcitabine	B-DRUG
/	O
cisplatin	B-DRUG
/	O
S-1	B-DRUG
combination	O
therapy	O
for	O
advanced	B-CANCER
biliary	I-CANCER
tract	I-CANCER
cancer	I-CANCER
;	O
we	O
are	O
proceeding	O
to	O
a	O
phase	O
II	O
study	O
to	O
investigate	O
the	O
efficacy	O
of	O
this	O
combination	O
therapy	O
for	O
advanced	B-CANCER
biliary	I-CANCER
tract	I-CANCER
cancer	I-CANCER
.	O
	
A	O
phase	O
I	O
trial	O
of	O
vatalanib	B-DRUG
(	O
PTK	O
/	O
ZK	O
)	O
in	O
combination	O
with	O
bevacizumab	B-DRUG
in	O
patients	O
with	O
refractory	O
and	O
/	O
or	O
advanced	B-CANCER
malignancies	I-CANCER
.	O
	
	
Vatalanib	B-DRUG
is	O
an	O
orally	O
active	O
","	O
small	O
molecule	O
tyrosine	O
kinase	O
inhibitor	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
(	O
VEGFR	O
)	O
.	O
	
Bevacizumab	B-DRUG
is	O
also	O
an	O
angiogenesis	O
inhibitor	O
","	O
but	O
it	O
possesses	O
a	O
different	O
mechanism	O
of	O
action	O
.	O
	
This	O
phase	O
I	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
dose-limiting	O
toxicity	O
","	O
maximum-tolerated	O
doses	O
","	O
and	O
recommended	O
phase	O
II	O
doses	O
of	O
the	O
combination	O
of	O
vatalanib	B-DRUG
and	O
bevacizumab	B-DRUG
.	O
	
Treatment	O
cycles	O
were	O
4	O
weeks	O
in	O
length	O
.	O
	
Patients	O
received	O
oral	O
vatalanib	B-DRUG
once	O
or	O
twice	O
daily	O
continuously	O
.	O
	
Bevacizumab	B-DRUG
was	O
administered	O
intravenously	O
starting	O
on	O
day	O
15	O
of	O
cycle	O
1	O
","	O
and	O
dosing	O
was	O
repeated	O
at	O
2-week	O
intervals	O
in	O
patients	O
with	O
at	O
least	O
stable	O
disease	O
for	O
4	O
cycles	O
.	O
	
After	O
4	O
cycles	O
","	O
only	O
patients	O
with	O
a	O
partial	O
or	O
complete	O
response	O
continued	O
treatment	O
with	O
the	O
combination	O
of	O
vatalanib	B-DRUG
and	O
bevacizumab	B-DRUG
.	O
	
Patients	O
with	O
stable	O
disease	O
were	O
allowed	O
to	O
continue	O
single-agent	O
vatalanib	B-DRUG
from	O
cycle	O
5	O
until	O
disease	O
progression	O
or	O
intolerable	O
toxicity	O
.	O
	
A	O
total	O
of	O
27	O
patients	O
received	O
93	O
cycles	O
of	O
treatment	O
.	O
	
Dose	O
escalation	O
was	O
difficult	O
due	O
to	O
enhanced	O
toxicities	O
(	O
primarily	B-TOXI
proteinuria	I-TOXI
and	O
hypertension	B-TOXI
)	O
with	O
the	O
regimen	O
that	O
required	O
numerous	O
dose	O
modifications	O
.	O
	
Interruption	O
of	O
vatalanib	B-DRUG
and	O
bevacizumab	B-DRUG
dosing	O
due	O
to	O
proteinuria	B-TOXI
occurred	O
in	O
4	O
patients	O
enrolled	O
at	O
dose	O
level	O
3	O
","	O
with	O
1	O
of	O
these	O
patients	O
developing	O
grade	O
3	O
nephrotic	B-TOXI
range	I-TOXI
proteinuria	I-TOXI
.	O
	
As	O
a	O
result	O
","	O
further	O
dose	O
escalation	O
with	O
the	O
combination	O
regimen	O
was	O
abandoned	O
.	O
	
Further	O
development	O
of	O
bevacizumab	B-DRUG
and	O
oral	O
VEGF	O
tyrosine	O
kinase	O
inhibitor	O
combination	O
regimens	O
is	O
questionable	O
due	O
to	O
the	O
additive	B-TOXI
toxicities	I-TOXI
that	O
occur	O
;	O
future	O
investigations	O
should	O
proceed	O
with	O
caution	O
.	O
	
Randomized	O
phase	O
III	O
study	O
of	O
thoracic	O
radiation	O
in	O
combination	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
with	O
or	O
without	O
thalidomide	B-DRUG
in	O
patients	O
with	O
stage	O
III	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
the	O
ECOG	O
3598	O
study	O
.	O
	
	
The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
survival	O
of	O
patients	O
with	O
unresectable	O
stage	O
III	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
treated	O
with	O
combined	O
chemoradiotherapy	O
with	O
or	O
without	O
thalidomide	B-DRUG
.	O
	
Patients	O
were	O
randomly	O
assigned	O
to	O
the	O
control	O
arm	O
(	O
PC	O
)	O
involving	O
two	O
cycles	O
of	O
induction	O
paclitaxel	B-DRUG
225	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
carboplatin	B-DRUG
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
6	O
followed	O
by	O
60	O
Gy	O
thoracic	O
radiation	O
administered	O
concurrently	O
with	O
weekly	O
paclitaxel	B-DRUG
45	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
carboplatin	B-DRUG
AUC	O
2	O
","	O
or	O
to	O
the	O
experimental	O
arm	O
(	O
TPC	O
)	O
","	O
receiving	O
the	O
same	O
treatment	O
in	O
combination	O
with	O
thalidomide	B-DRUG
at	O
a	O
starting	O
dose	O
of	O
200	O
mg	O
daily	O
.	O
	
The	O
protocol	O
allowed	O
an	O
increase	O
in	O
thalidomide	B-DRUG
dose	O
up	O
to	O
"1,000"	O
mg	O
daily	O
based	O
on	O
patient	O
tolerability	O
.	O
	
A	O
total	O
of	O
546	O
patients	O
were	O
eligible	O
","	O
including	O
275	O
in	O
the	O
PC	O
arm	O
and	O
271	O
in	O
the	O
TPC	O
arm	O
.	O
	
Median	O
overall	O
survival	O
","	O
progression-free	O
survival	O
","	O
and	O
overall	O
response	O
rate	O
were	O
15.3	O
months	O
","	O
7.4	O
months	O
","	O
and	O
35	O
%	O
","	O
respectively	O
","	O
for	O
patients	O
in	O
the	O
PC	O
arm	O
","	O
in	O
comparison	O
with	O
16	O
months	O
(	O
P	O
=	O
0.99	O
)	O
","	O
7.8	O
months	O
(	O
P	O
=	O
0.96	O
)	O
","	O
and	O
38.2	O
%	O
(	O
P	O
=	O
0.47	O
)	O
","	O
respectively	O
","	O
for	O
patients	O
in	O
the	O
TPC	O
arm	O
.	O
	
Overall	O
","	O
there	O
was	O
higher	O
incidence	O
of	O
grade	O
3	O
toxicities	O
in	O
patients	O
treated	O
with	O
thalidomide	B-DRUG
.	O
	
Several	O
grade	O
3	O
or	O
higher	O
events	O
were	O
observed	O
more	O
often	O
in	O
the	O
TPC	O
arm	O
","	O
including	O
thromboembolism	B-TOXI
","	O
fatigue	B-TOXI
","	O
depressed	B-TOXI
consciousness	I-TOXI
","	O
dizziness	B-TOXI
","	O
sensory	B-TOXI
neuropathy	I-TOXI
","	O
tremor	B-TOXI
","	O
constipation	B-TOXI
","	O
dyspnea	B-TOXI
","	O
hypoxia	B-TOXI
","	O
hypokalemia	B-TOXI
","	O
rash	B-TOXI
","	O
and	O
edema	B-TOXI
.	O
	
Low-dose	O
aspirin	B-DRUG
did	O
not	O
reduce	O
the	O
thromboembolic	B-TOXI
rate	I-TOXI
.	O
	
The	O
addition	O
of	O
thalidomide	B-DRUG
to	O
chemoradiotherapy	O
increased	O
toxicities	O
but	O
did	O
not	O
improve	O
survival	O
in	O
patients	O
with	O
locally	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
A	O
phase	O
II	O
study	O
of	O
oxaliplatin	O
with	O
5-FU	B-DRUG
/	O
folinic	B-DRUG
acid	I-DRUG
and	O
concomitant	O
radiotherapy	O
as	O
a	O
preoperative	O
treatment	O
in	O
patients	O
with	O
locally	B-DRUG
advanced	I-DRUG
rectal	I-DRUG
cancer	I-DRUG
.	O
	
	
To	O
evaluate	O
the	O
activity	O
and	O
safety	O
of	O
adding	O
oxaliplatin	B-DRUG
to	O
a	O
standard	O
chemoradiotherapy	O
schema	O
","	O
including	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
/	O
folinic	B-DRUG
acid	I-DRUG
(	O
FA	B-DRUG
)	O
","	O
in	O
locally-advanced	B-CANCER
rectal	I-CANCER
cancer	I-CANCER
(	O
LARC	B-CANCER
)	O
.	O
	
Two	O
cycles	O
of	O
oxaliplatin	B-DRUG
130	O
mg	O
/	O
m	O
(	O
2	O
)	O
plus	O
FA	B-DRUG
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
bolus	O
for	O
5	O
days	O
and	O
5-FU	B-DRUG
350	O
mg	O
/	O
m	O
(	O
2	O
)	O
continuous	O
infusion	O
for	O
5	O
days	O
were	O
given	O
during	O
week	O
1	O
and	O
4	O
of	O
pelvic	O
radiotherapy	O
46	O
Gy	O
.	O
	
Patients	O
with	O
a	O
T3	O
/	O
4	O
and	O
/	O
or	O
node-positive	B-CANCER
rectal	I-CANCER
tumour	I-CANCER
were	O
eligible	O
.	O
	
Surgery	O
was	O
performed	O
4月6日	O
weeks	O
after	O
radiotherapy	O
.	O
	
The	O
primary	O
endpoint	O
was	O
to	O
determine	O
the	O
rate	O
of	O
pathological	O
response	O
.	O
	
Secondary	O
endpoints	O
were	O
to	O
assess	O
the	O
rate	O
of	O
clinical	O
response	O
and	O
the	O
safety	O
profile	O
.	O
	
Between	O
March	O
2005	O
and	O
January	O
2009	O
","	O
a	O
total	O
of	O
35	O
patients	O
were	O
enrolled	O
.	O
	
The	O
pathological	O
down-staging	O
rate	O
was	O
79	O
%	O
with	O
a	O
pathological	O
complete	O
response	O
rate	O
of	O
17	O
%	O
.	O
	
The	O
overall	O
clinical	O
response	O
rate	O
(	O
assessed	O
by	O
computed	O
tomography	O
or	O
transrectal	O
ultrasound	O
)	O
was	O
77	O
%	O
.	O
	
Grade	O
3	O
diarrhoea	B-TOXI
and	O
Grade	O
3	O
neutropaenia	B-TOXI
were	O
reported	O
in	O
14	O
%	O
and	O
11	O
%	O
of	O
the	O
patients	O
","	O
respectively	O
.	O
	
Eleven	O
patients	O
did	O
not	O
undergo	O
surgery	O
:	O
four	O
of	O
them	O
refused	O
the	O
operation	O
","	O
and	O
seven	O
patients	O
were	O
inoperable	O
due	O
to	O
disease	O
progression	O
.	O
	
In	O
24	O
patients	O
who	O
had	O
surgery	O
","	O
a	O
sphincter-preserving	O
procedure	O
could	O
be	O
performed	O
in	O
29	O
%	O
.	O
	
At	O
the	O
median	O
follow-up	O
time	O
of	O
28.1	O
months	O
","	O
25	O
patients	O
(	O
71	O
%	O
)	O
survived	O
with	O
no	O
evidence	O
of	O
disease	O
.	O
	
The	O
promising	O
results	O
in	O
terms	O
of	O
pathological	O
response	O
","	O
and	O
the	O
associated	O
good	O
safety	O
profile	O
of	O
a	O
regimen	O
of	O
oxaliplatin	B-DRUG
plus	O
5-FU	B-DRUG
/	O
FA	B-DRUG
with	O
concomitant	O
radiotherapy	O
","	O
suggest	O
that	O
the	O
regimen	O
could	O
be	O
used	O
in	O
LARC	B-CANCER
.	O
	
A	O
phase	O
I	O
study	O
of	O
veliparib	B-DRUG
in	O
combination	O
with	O
metronomic	B-DRUG
cyclophosphamide	I-DRUG
in	O
adults	O
with	O
refractory	B-CANCER
solid	I-CANCER
tumors	I-CANCER
and	O
lymphomas	B-CANCER
.	O
	
	
Oral	O
administration	O
of	O
the	O
alkylating	B-DRUG
agent	I-DRUG
cyclophosphamide	I-DRUG
at	O
low	O
doses	O
","	O
metronomic	O
dosing	O
","	O
is	O
well	O
tolerated	O
","	O
with	O
efficacy	O
in	O
multiple	O
tumor	O
types	O
.	O
	
PARP	O
inhibition	O
potentiates	O
effects	O
of	O
cyclophosphamide	B-DRUG
in	O
preclinical	O
models	O
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
trial	O
of	O
the	O
PARP	O
inhibitor	O
veliparib	B-DRUG
and	O
metronomic	B-DRUG
cyclophosphamide	I-DRUG
in	O
patients	O
with	O
refractory	B-CANCER
solid	I-CANCER
tumors	I-CANCER
and	O
lymphoid	B-CANCER
malignancies	I-CANCER
.	O
	
Objectives	O
were	O
to	O
establish	O
the	O
safety	O
and	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
the	O
combination	O
;	O
characterize	O
veliparib	B-DRUG
pharmacokinetics	O
(	O
PK	O
)	O
;	O
measure	O
poly	O
(	O
ADP-ribose	O
)	O
(	O
PAR	O
)	O
","	O
a	O
product	O
of	O
PARP	O
","	O
in	O
tumor	O
biopsies	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
;	O
and	O
measure	O
the	O
DNA-damage	O
marker	O
纬H2AX	O
in	O
PBMCs	O
and	O
circulating	O
tumor	O
cells	O
(	O
CTC	O
)	O
.	O
	
Cyclophosphamide	B-DRUG
was	O
administered	O
once	O
daily	O
in	O
21-day	O
cycles	O
in	O
combination	O
with	O
veliparib	B-DRUG
administered	O
once	O
daily	O
for	O
7	O
","	O
14	O
","	O
or	O
21	O
days	O
.	O
	
Thirty-five	O
patients	O
were	O
enrolled	O
.	O
	
The	O
study	O
treatment	O
was	O
well	O
tolerated	O
","	O
and	O
the	O
MTD	O
was	O
established	O
as	O
veliparib	B-DRUG
60	O
mg	O
with	O
cyclophosphamide	B-DRUG
50	O
mg	O
given	O
once	O
daily	O
.	O
	
Seven	O
patients	O
had	O
partial	O
responses	O
;	O
an	O
additional	O
six	O
patients	O
had	O
disease	O
stabilization	O
for	O
at	O
least	O
six	O
cycles	O
.	O
	
PAR	O
was	O
significantly	O
decreased	O
in	O
PBMCs	O
(	O
by	O
at	O
least	O
50	O
%	O
)	O
and	O
tumor	O
biopsies	O
(	O
by	O
at	O
least	O
80	O
%	O
)	O
across	O
dose	O
levels	O
(	O
DL	O
)	O
;	O
纬H2AX	O
levels	O
were	O
increased	O
in	O
CTCs	O
from	O
seven	O
of	O
nine	O
patients	O
evaluated	O
after	O
drug	O
administration	O
.	O
	
The	O
combination	O
of	O
veliparib	B-DRUG
with	O
metronomic	B-DRUG
cyclophosphamide	I-DRUG
is	O
well	O
tolerated	O
and	O
shows	O
promising	O
activity	O
in	O
a	O
subset	O
of	O
patients	O
with	O
BRCA	O
mutations	O
.	O
	
A	O
phase	O
II	O
trial	O
of	O
the	O
combination	O
compared	O
with	O
single-agent	O
cyclophosphamide	B-DRUG
is	O
ongoing	O
in	O
BRCA-positive	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
","	O
triple-negative	B-CANCER
breast	I-CANCER
cancer	I-CANCER
","	O
and	O
low-grade	B-CANCER
lymphoma	I-CANCER
.	O
	
Phase	O
I	O
/	O
II	O
trial	O
of	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
chemotherapy	O
in	O
combination	O
with	O
intravenous	O
oncolytic	O
reovirus	O
in	O
patients	O
with	O
advanced	B-CANCER
malignancies	I-CANCER
.	O
	
	
Reovirus	O
type	O
3	O
Dearing	O
(	O
RT3D	O
)	O
replicates	O
preferentially	O
in	O
Ras-activated	B-CANCER
cancers	I-CANCER
.	O
	
RT3D	O
shows	O
synergistic	O
in	O
vitro	O
cytotoxicity	O
in	O
combination	O
with	O
platins	B-DRUG
and	O
taxanes	B-DRUG
.	O
	
The	O
purpose	O
of	O
this	O
phase	O
I	O
/	O
II	O
study	O
was	O
to	O
assess	O
RT3D	O
combined	O
with	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
advanced	O
cancers	O
.	O
	
Patients	O
were	O
initially	O
treated	O
in	O
a	O
dose-escalating	O
","	O
phase	O
I	O
trial	O
with	O
intravenous	O
RT3D	O
days	O
1	O
to	O
5	O
","	O
carboplatin	B-DRUG
[	O
area	O
under	O
curve	O
(	O
AUC	O
)	O
5	O
","	O
day	O
1	O
]	O
and	O
paclitaxel	B-DRUG
(	O
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
day	O
1	O
)	O
3-weekly	O
.	O
	
RT3D	O
was	O
escalated	O
through	O
three	O
dose	O
levels	O
:	O
3	O
_	O
10	O
(	O
9	O
)	O
","	O
1	O
_	O
10	O
(	O
10	O
)	O
","	O
and	O
3	O
_	O
10	O
(	O
10	O
)	O
TCID	O
(	O
50	O
)	O
in	O
cohorts	O
of	O
three	O
.	O
	
Primary	O
endpoints	O
were	O
to	O
define	O
the	O
maximum	O
tolerated	O
dose	O
and	O
dose-limiting	O
toxicity	O
and	O
to	O
recommend	O
a	O
dose	O
for	O
phase	O
II	O
studies	O
.	O
	
Secondary	O
endpoints	O
included	O
pharmacokinetics	O
","	O
immune	O
response	O
","	O
and	O
antitumor	O
activity	O
.	O
	
A	O
subsequent	O
phase	O
II	O
study	O
using	O
the	O
3	O
_	O
10	O
(	O
10	O
)	O
TCID	O
(	O
50	O
)	O
dose	O
characterized	O
the	O
response	O
rate	O
in	O
patients	O
with	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
.	O
	
Thirty-one	O
heavily	O
pretreated	O
patients	O
received	O
study	O
therapy	O
.	O
	
There	O
were	O
no	O
dose-limiting	O
toxicities	O
during	O
dose-escalation	O
and	O
most	O
toxicities	O
were	O
grade	O
I	O
/	O
II	O
.	O
	
Overall	O
effectiveness	O
rates	O
were	O
as	O
follows	O
:	O
one	O
patient	O
had	O
a	O
complete	O
response	O
(	O
3.8	O
%	O
)	O
","	O
six	O
patients	O
(	O
23.1	O
%	O
)	O
had	O
partial	O
response	O
","	O
two	O
patients	O
(	O
7.6	O
%	O
)	O
had	O
major	O
clinical	O
responses	O
clinically	O
evaluated	O
in	O
radiation	O
pretreated	O
lesions	O
which	O
are	O
not	O
evaluable	O
by	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	B-CANCER
Tumors	I-CANCER
(	O
RECIST	O
)	O
","	O
nine	O
patients	O
(	O
34.6	O
%	O
)	O
had	O
stable	O
disease	O
","	O
and	O
eight	O
patients	O
(	O
30.8	O
%	O
)	O
had	O
disease	O
progression	O
.	O
	
Viral	B-TOXI
shedding	I-TOXI
was	O
minimal	O
and	O
antiviral	O
immune	O
responses	O
were	O
attenuated	O
compared	O
with	O
previous	O
single-agent	O
data	O
for	O
RT3D	O
.	O
	
The	O
combination	O
of	O
RT3D	O
plus	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
is	O
well	O
tolerated	O
with	O
evidence	O
of	O
activity	O
in	O
cancer	B-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
A	O
randomized	O
phase	O
III	O
study	O
is	O
currently	O
open	O
for	O
recruitment	O
.	O
	
Phase	O
I	O
study	O
of	O
Rigosertib	B-DRUG
","	O
an	O
inhibitor	O
of	O
the	O
phosphatidylinositol	O
3-kinase	O
and	O
Polo-like	O
kinase	O
1	O
pathways	O
","	O
combined	O
with	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
and	O
pancreatic	B-CANCER
cancer	I-CANCER
.	O
	
	
Rigosertib	B-DRUG
","	O
a	O
dual	O
non-ATP	O
inhibitor	O
of	O
polo-like	O
kinase	O
1	O
(	O
Plk1	O
)	O
and	O
phosphoinositide	O
3-kinase	O
pathways	O
(	O
PI3K	O
)	O
","	O
and	O
gemcitabine	B-DRUG
have	O
synergistic	O
antitumor	O
activity	O
when	O
combined	O
in	O
preclinical	O
studies	O
.	O
	
This	O
phase	O
I	O
study	O
aimed	O
to	O
determine	O
the	O
recommended	O
phase	O
II	O
dose	O
(	O
RPTD	O
)	O
of	O
the	O
combination	O
of	O
rigosertib	B-DRUG
and	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
cancer	O
.	O
	
Patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
who	O
failed	O
standard	O
therapy	O
or	O
were	O
candidates	O
for	O
gemcitabine-based	B-DRUG
therapy	O
were	O
eligible	O
.	O
	
Gemcitabine	B-DRUG
was	O
administered	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
on	O
a	O
28-day	O
cycle	O
and	O
rigosertib	B-DRUG
on	O
days	O
1	O
","	O
4	O
","	O
8	O
","	O
11	O
","	O
15	O
","	O
and	O
18	O
.	O
	
Pharmacokinetic	O
studies	O
were	O
conducted	O
during	O
an	O
expansion	O
cohort	O
of	O
patients	O
with	O
advanced	B-CANCER
pancreatic	I-CANCER
ductal	I-CANCER
adenocarcinoma	I-CANCER
(	O
PDA	B-CANCER
)	O
.	O
	
Forty	O
patients	O
were	O
treated	O
","	O
19	O
in	O
the	O
dose-escalation	O
phase	O
and	O
21	O
in	O
the	O
expansion	O
cohort	O
.	O
	
Dose	O
levels	O
evaluated	O
were	O
(	O
gemcitabine	B-DRUG
/	O
rigosertib	B-DRUG
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
:	O
750	O
/	O
600	O
(	O
n	O
=	O
4	O
)	O
","	O
750	O
/	O
"1,200"	O
(	O
n	O
=	O
3	O
)	O
","	O
"1,000"	O
/	O
600	O
(	O
n	O
=	O
3	O
)	O
","	O
"1,000"	O
/	O
"1,200"	O
(	O
n	O
=	O
3	O
)	O
","	O
and	O
"1,000"	O
/	O
"1,800"	O
(	O
n	O
=	O
6	O
=+	O
21	O
)	O
.	O
	
One	O
dose-limiting	O
toxicity	O
(	O
death	B-TOXI
)	O
occurred	O
at	O
the	O
highest	O
dose	O
level	O
(	O
"1,000"	O
/	O
"1,800"	O
)	O
tested	O
.	O
	
Non-dose-limiting	O
_grade	O
II	O
/	O
III	O
toxicities	O
included	O
neutropenia	B-TOXI
","	O
lymphopenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
fatigue	B-TOXI
","	O
and	O
nausea	B-TOXI
.	O
	
Grade	O
III	O
/	O
IV	O
neutropenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
and	O
fatigue	B-TOXI
were	O
seen	O
in	O
two	O
","	O
one	O
","	O
and	O
two	O
patients	O
in	O
the	O
expansion	O
cohort	O
.	O
	
Partial	O
responses	O
were	O
observed	O
in	O
PDA	B-CANCER
","	O
thymic	B-CANCER
cancer	I-CANCER
","	O
and	O
Hodgkin	B-CANCER
lymphoma	I-CANCER
","	O
including	O
gemcitabine-pretreated	B-DRUG
PDA	B-CANCER
.	O
	
The	O
pharmacokinetic	O
profile	O
of	O
rigosertib	B-DRUG
was	O
not	O
affected	O
by	O
gemcitabine	B-DRUG
.	O
	
The	O
RPTD	O
established	O
in	O
this	O
study	O
is	O
rigosertib	B-DRUG
"1,800"	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
This	O
regimen	O
is	O
well	O
tolerated	O
with	O
a	O
toxicity	O
profile	O
of	O
the	O
combination	O
similar	O
to	O
the	O
profile	O
of	O
gemcitabine	B-DRUG
alone	O
.	O
	
Antitumor	O
efficacy	O
was	O
observed	O
in	O
patients	O
who	O
previously	O
progressed	O
on	O
gemcitabine-based	B-DRUG
therapy	O
.	O
	
A	O
phase	O
I	O
","	O
open-label	O
dose-escalation	O
study	O
of	O
continuous	O
treatment	O
with	O
BIBF	B-DRUG
1120	I-DRUG
in	O
combination	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
as	O
first-line	O
treatment	O
in	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
BIBF	B-DRUG
1120	I-DRUG
is	O
an	O
oral	O
potent	O
inhibitor	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
","	O
fibroblast	O
growth	O
factor	O
receptor	O
and	O
platelet-derived	O
growth	O
factor	O
receptor	O
","	O
the	O
three	O
key	O
receptor	O
families	O
involved	O
in	O
angiogenesis	O
.	O
	
This	O
phase	O
I	O
","	O
open-label	O
dose-escalation	O
study	O
investigated	O
BIBF	B-DRUG
1120	I-DRUG
combined	O
with	O
paclitaxel	B-DRUG
(	O
Taxol	B-DRUG
)	O
and	O
carboplatin	B-DRUG
in	O
first-line	O
patients	O
with	O
advanced	O
(	O
IIIB	O
/	O
IV	O
)	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
received	O
BIBF	B-DRUG
1120	I-DRUG
(	O
starting	O
dose	O
50	O
mg	O
b.i.d.	O
)	O
on	O
days	O
2月21日	O
and	O
paclitaxel	B-DRUG
(	O
200	O
mg	O
/	O
m2	O
)	O
and	O
carboplatin	B-DRUG
[	O
area	O
under	O
curve	O
(	O
AUC	O
)	O
6	O
mg	O
/	O
ml	O
/	O
min	O
]	O
on	O
day	O
1	O
of	O
each	O
21-day	O
cycle	O
.	O
	
Primary	O
end	O
points	O
were	O
safety	O
and	O
BIBF	B-DRUG
1120	I-DRUG
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
in	O
this	O
combination	O
.	O
	
Pharmacokinetics	O
(	O
PK	O
)	O
profiles	O
were	O
evaluated	O
.	O
	
Twenty-six	O
patients	O
were	O
treated	O
(	O
BIBF	B-DRUG
1120	I-DRUG
50-250	O
mg	O
b.i.d.	O
)	O
.	O
	
BIBF	B-DRUG
1120	I-DRUG
MTD	O
was	O
200	O
mg	O
b.i.d.	O
in	O
combination	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
.	O
	
Six	O
dose-limiting	O
toxicity	O
events	O
occurred	O
during	O
treatment	O
cycle	O
1	O
(	O
liver	B-TOXI
enzyme	I-TOXI
elevations	I-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
abdominal	B-TOXI
pain	I-TOXI
","	O
and	O
rash	B-TOXI
)	O
.	O
	
Best	O
responses	O
included	O
7	O
confirmed	O
partial	O
responses	O
(	O
26.9	O
%	O
)	O
;	O
10	O
patients	O
had	O
stable	O
disease	O
.	O
	
BIBF	B-DRUG
1120	I-DRUG
200	O
mg	O
b.i.d.	O
had	O
no	O
clinically	O
relevant	O
influence	O
on	O
the	O
PK	O
of	O
paclitaxel	B-DRUG
200	O
mg	O
/	O
m2	O
and	O
carboplatin	B-DRUG
AUC	O
6	O
mg	O
/	O
ml	O
/	O
min	O
and	O
vice	O
versa	O
.	O
	
BIBF	B-DRUG
1120	I-DRUG
MTD	O
was	O
200	O
mg	O
b.i.d	O
when	O
given	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
;	O
this	O
combination	O
demonstrated	O
an	O
acceptable	O
safety	O
profile	O
.	O
	
No	O
relevant	O
changes	O
in	O
PK	O
parameters	O
of	O
the	O
backbone	B-DRUG
chemotherapeutic	I-DRUG
agents	I-DRUG
or	O
BIBF	B-DRUG
1120	I-DRUG
were	O
observed	O
.	O
	
A	O
phase	O
I	O
/	O
II	O
","	O
non-randomized	O
","	O
feasibility	O
/	O
safety	O
and	O
efficacy	O
study	O
of	O
the	O
combination	O
of	O
everolimus	B-DRUG
","	O
cetuximab	B-DRUG
and	O
capecitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
	
Improvements	O
in	O
knowledge	O
of	O
molecular	O
mechanisms	O
in	O
cancer	O
are	O
the	O
basis	O
for	O
new	O
studies	O
combining	O
chemotherapy	O
with	O
targeted	O
drugs	O
.	O
	
Inhibition	O
of	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
by	O
erlotinib	B-DRUG
or	O
cetuximab	B-DRUG
has	O
limited	O
or	O
no	O
activity	O
","	O
respectively	O
","	O
in	O
pancreatic	B-CANCER
cancer	I-CANCER
.	O
	
The	O
crosstalk	O
between	O
EGFR	O
and	O
mammalian	O
target	O
of	O
rapamycin	B-DRUG
(	O
mTOR	O
)	O
pathways	O
is	O
a	O
potential	O
mechanism	O
of	O
resistance	O
;	O
therefore	O
we	O
conducted	O
a	O
study	O
to	O
explore	O
safety	O
and	O
efficacy	O
of	O
multiple	O
pathway	O
inhibition	O
by	O
cetuximab	B-DRUG
and	O
everolimus	B-DRUG
in	O
combination	O
with	O
capecitabine	B-DRUG
.	O
	
Safety	O
and	O
efficacy	O
of	O
fixed	O
standard	O
dose	O
cetuximab	B-DRUG
in	O
combination	O
with	O
various	O
dose	O
levels	O
of	O
everolimus	B-DRUG
(	O
5月10日	O
mg	O
/	O
day	O
)	O
and	O
capecitabine	B-DRUG
(	O
600-800	O
mg	O
/	O
m	O
(	O
2	O
)	O
bid	O
","	O
2	O
weeks	O
every	O
3	O
weeks	O
)	O
were	O
investigated	O
in	O
a	O
phase	O
I	O
/	O
II	O
study	O
in	O
patients	O
with	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
The	O
primary	O
endpoint	O
was	O
objective	O
response	O
.	O
	
Sixteen	O
patients	O
were	O
treated	O
in	O
the	O
phase	O
I	O
part	O
at	O
two	O
dose	O
levels	O
.	O
	
Mucositis	B-TOXI
","	O
rash	B-TOXI
and	O
hand-foot	B-TOXI
syndrome	I-TOXI
were	O
dose-limiting	O
toxicities	O
.	O
	
Dose	O
level	O
1	O
(	O
everolimus	B-DRUG
5	O
mg	O
/	O
day	O
","	O
capecitabine	B-DRUG
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
bid	O
for	O
2	O
weeks	O
every	O
3	O
weeks	O
and	O
cetuximab	B-DRUG
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
)	O
was	O
considered	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
.	O
	
Of	O
31	O
patients	O
in	O
the	O
phase	O
II	O
part	O
","	O
partial	O
response	O
was	O
documented	O
in	O
two	O
patients	O
(	O
6.5	O
%	O
)	O
and	O
five	O
(	O
16.1	O
%	O
)	O
had	O
stable	O
disease	O
.	O
	
Median	O
overall	O
survival	O
was	O
5	O
months	O
(	O
CI	O
3.1-6.8	O
)	O
.	O
	
The	O
schedule	O
of	O
capecitabine	B-DRUG
","	O
everolimus	B-DRUG
and	O
cetuximab	B-DRUG
resulted	O
in	O
considerable	B-TOXI
epidermal	I-TOXI
and	I-TOXI
mucosal	I-TOXI
toxicities	I-TOXI
and	O
prevented	O
escalation	O
to	O
optimal	O
dose	O
levels	O
.	O
	
Because	O
of	O
toxicity	O
and	O
low	O
efficacy	O
this	O
treatment	O
combination	O
can	O
not	O
be	O
recommended	O
for	O
treatment	O
in	O
pancreatic	B-CANCER
cancer	I-CANCER
patients	O
.	O
	
A	O
phase	O
I	O
combination	O
study	O
of	O
olaparib	B-DRUG
with	O
cisplatin	B-DRUG
and	O
gemcitabine	B-DRUG
in	O
adults	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
To	O
determine	O
the	O
safety	O
and	O
tolerability	O
of	O
olaparib	B-DRUG
with	O
cisplatin	B-DRUG
and	O
gemcitabine	B-DRUG
","	O
establish	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
and	O
evaluate	O
the	O
pharmacodynamic	O
and	O
pharmacokinetic	O
profile	O
of	O
the	O
combination	O
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
study	O
of	O
olaparib	B-DRUG
with	O
cisplatin	B-DRUG
and	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Treatment	O
at	O
dose	O
level	O
1	O
(	O
DL1	O
)	O
consisted	O
of	O
olaparib	B-DRUG
100	O
mg	O
orally	O
every	O
12	O
hours	O
on	O
days	O
1	O
to	O
4	O
","	O
gemcitabine	B-DRUG
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
3	O
and	O
10	O
","	O
and	O
cisplatin	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
3	O
PAR	O
levels	O
were	O
measured	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O
	
Dose-limiting	O
toxicities	O
(	O
DLT	O
)	O
in	O
two	O
of	O
three	O
patients	O
at	O
DL1	O
included	O
thrombocytopenia	B-TOXI
and	O
febrile	B-TOXI
neutropenia	I-TOXI
.	O
	
The	O
protocol	O
was	O
amended	O
to	O
enroll	O
patients	O
treated	O
with	O
_	O
2	O
prior	O
severely	O
myelosuppressive	O
chemotherapy	O
regimens	O
and	O
treated	O
with	O
olaparib	B-DRUG
100	O
mg	O
once	O
daily	O
on	O
days	O
1	O
to	O
4	O
(	O
DL-1	O
)	O
.	O
	
No	O
DLTs	O
were	O
seen	O
in	O
six	O
patients	O
at	O
DL-1	O
.	O
	
Because	O
of	O
persistent	O
thrombocytopenia	B-TOXI
and	O
neutropenia	B-TOXI
following	O
a	O
return	O
to	O
DL1	O
","	O
patients	O
received	O
100	O
mg	O
olaparib	B-DRUG
every	O
12	O
hours	O
on	O
day	O
1	O
only	O
.	O
	
No	O
hematologic	O
DLTs	O
were	O
observed	O
;	O
nonhematologic	O
DLTs	O
included	O
gastrointestinal	B-TOXI
bleed	I-TOXI
","	O
syncope	B-TOXI
","	O
and	O
hypoxia	B-TOXI
.	O
	
Of	O
21	O
patients	O
evaluable	O
for	O
response	O
","	O
two	O
had	O
partial	O
response	O
.	O
	
Olaparib	B-DRUG
inhibited	O
PARP	O
in	O
PBMCs	O
and	O
tumor	O
tissue	O
","	O
although	O
PAR	O
levels	O
were	O
less	O
effectively	O
inhibited	O
when	O
olaparib	B-DRUG
was	O
used	O
for	O
a	O
short	O
duration	O
.	O
	
Olaparib	B-DRUG
in	O
combination	O
with	O
cisplatin	B-DRUG
and	O
gemcitabine	B-DRUG
is	O
associated	O
with	O
myelosuppression	B-TOXI
even	I-TOXI
at	O
relatively	O
low	O
doses	O
.	O
	
Modified	O
schedules	O
of	O
olaparib	B-DRUG
in	O
chemotherapy	O
naive	O
patients	O
will	O
have	O
to	O
be	O
explored	O
with	O
standard	O
doses	O
of	O
chemotherapy	O
.	O
	
Phase	O
I	O
trial	O
of	O
intraperitoneal	O
pemetrexed	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
paclitaxel	B-DRUG
in	O
optimally	O
debulked	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
	
This	O
phase	O
I	O
trial	O
evaluated	O
intraperitoneal	O
(	O
i.p.	O
)	O
pemetrexed	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
paclitaxel	B-DRUG
in	O
optimally	O
debulked	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
Dose	O
escalation	O
of	O
day	O
1	O
i.p.	O
pemetrexed	O
accrued	O
three	O
patients	O
to	O
each	O
of	O
five	O
dose	O
levels	O
(	O
"60-1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
along	O
with	O
day	O
2	O
i.p.	O
cisplatin	B-DRUG
(	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
day	O
8	O
i.p.	O
paclitaxel	B-DRUG
(	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O
	
The	O
goals	O
were	O
to	O
determine	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
18-month	O
progression-free	O
survival	O
(	O
PFS	O
)	O
","	O
and	O
pharmacokinetics	O
of	O
i.p.	O
pemetrexed	B-DRUG
.	O
	
Cycles	O
","	O
given	O
every	O
21	O
days	O
","	O
had	O
an	O
80	O
%	O
6-cycle	O
completion	O
rate	O
.	O
	
There	O
was	O
minimal	O
grade	O
III	O
toxicity	O
in	O
the	O
first	O
4	O
dose	O
levels	O
and	O
remarkably	O
an	O
almost	O
complete	O
absence	O
of	O
peripheral	B-TOXI
neuropathy	I-TOXI
and	O
alopecia	B-TOXI
.	O
	
At	O
the	O
highest	O
dose	O
level	O
","	O
two	O
of	O
three	O
patients	O
experienced	O
_	O
grade	O
III	O
and	O
dose-limiting	O
toxicity	O
(	O
DLT	O
;	O
hematologic	B-TOXI
","	O
infection	B-TOXI
","	O
gastrointestinal	B-TOXI
)	O
.	O
	
There	O
was	O
a	O
pharmacokinetic	O
advantage	O
for	O
i.p.	O
pemetrexed	B-DRUG
with	O
an	O
intraperitoneal	O
:	O
plasma	O
area	O
under	O
the	O
concentration-time	O
curve	O
ratio	O
of	O
13-fold	O
.	O
	
Neither	O
analysis	O
of	O
pharmacokinetic	O
nor	O
homocysteine	O
levels	O
explains	O
the	O
unexpected	O
severity	O
of	O
toxicity	O
in	O
those	O
two	O
patients	O
.	O
	
On	O
the	O
basis	O
of	O
plasma	O
C	O
(	O
24h	O
)	O
levels	O
","	O
the	O
42	O
cycles	O
at	O
_	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
i.p.	O
pemetrexed	B-DRUG
without	O
DLT	O
","	O
the	O
MTD	O
appears	O
to	O
be	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Median	O
PFS	O
is	O
30.1	O
months	O
;	O
18-month	O
PFS	O
is	O
78.6	O
%	O
(	O
median	O
follow-up	O
22.4	O
months	O
)	O
.	O
	
This	O
i.p.-only	O
regimen	O
in	O
front-line	O
ovarian	B-CANCER
cancer	I-CANCER
is	O
feasible	O
with	O
PFS	O
in	O
line	O
with	O
recent	O
literature	O
.	O
	
We	O
suggest	O
phase	O
II	O
trials	O
of	O
this	O
regimen	O
in	O
this	O
population	O
with	O
i.p.	O
pemetrexed	B-DRUG
at	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
The	O
favorable	O
toxicity	O
profile	O
at	O
doses	O
&	O
lt	O
;	O
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
which	O
needs	O
to	O
be	O
confirmed	O
","	O
appears	O
to	O
compare	O
well	O
with	O
standard	O
combination	O
i.v.	O
/	O
i.p.	O
platinum	B-DRUG
/	O
taxane	B-DRUG
chemotherapy	O
in	O
this	O
disease	O
.	O
	
Melphalan	B-DRUG
180	O
mg	O
/	O
m2	O
can	O
be	O
safely	O
administered	O
as	O
conditioning	O
regimen	O
before	O
an	O
autologous	O
stem	O
cell	O
transplantation	O
(	O
ASCT	O
)	O
in	O
multiple	B-CANCER
myeloma	I-CANCER
patients	O
with	O
creatinine	O
clearance	O
60	O
mL	O
/	O
min	O
/	O
1.73	O
m2	O
or	O
lower	O
with	O
use	O
of	O
palifermin	B-DRUG
for	O
cytoprotection	O
:	O
results	O
of	O
a	O
phase	O
I	O
trial	O
.	O
	
	
High-dose	O
melphalan	B-DRUG
140	O
mg	O
/	O
m2	O
is	O
the	O
standard	O
of	O
care	O
for	O
patients	O
with	O
multiple	B-CANCER
myeloma	I-CANCER
(	O
MM	B-CANCER
)	O
with	O
renal	B-TOXI
insufficiency	I-TOXI
(	O
RI	O
)	O
.	O
	
Palifermin	B-DRUG
as	O
a	O
cytoprotective	O
agent	O
has	O
demonstrated	O
efficacy	O
in	O
reducing	O
the	O
intensity	O
and	O
duration	O
of	O
oral	B-TOXI
mucositis	I-TOXI
(	O
OM	B-TOXI
)	O
in	O
patients	O
who	O
receive	O
intensive	O
chemotherapy	O
/	O
radiotherapy	O
.	O
	
There	O
is	O
no	O
prospective	O
data	O
on	O
the	O
use	O
of	O
palifermin	B-DRUG
in	O
patients	O
with	O
MM	B-CANCER
with	O
RI	O
.	O
	
creatinine	O
clearance	O
_60	O
mL	O
/	O
minute	O
/	O
1.73	O
m2	O
","	O
age	O
&	O
gt	O
;	O
18	O
years	O
","	O
no	O
dialysis	O
","	O
no	O
active	O
OM	B-TOXI
","	O
and	O
a	O
suitable	O
candidate	O
for	O
autologous	O
stem	O
cell	O
transplant	O
(	O
ASCT	O
)	O
.	O
	
Melphalan	B-DRUG
dose	O
ranged	O
from	O
140	O
to	O
200	O
mg	O
/	O
m2	O
and	O
escalated	O
at	O
the	O
increment	O
of	O
20	O
mg	O
/	O
m2	O
.	O
	
Six	O
dosages	O
of	O
palifermin	B-DRUG
60	O
mcg	O
/	O
kg	O
/	O
day	O
were	O
given	O
intravenously	O
between	O
day	O
-5	O
to	O
day	O
3	O
Dose	O
escalations	O
were	O
to	O
stop	O
if	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
occurred	O
at	O
melphalan	B-DRUG
dose	O
in	O
_2	O
of	O
3	O
patients	O
","	O
with	O
that	O
dose	O
declared	O
as	O
the	O
maximal	O
administered	O
dose	O
and	O
the	O
level	O
below	O
where	O
_1	O
of	O
6	O
patients	O
had	O
DLTs	O
was	O
considered	O
the	O
maximally	O
tolerated	O
dose	O
(	O
MTD	O
)	O
.	O
	
Nineteen	O
patients	O
were	O
enrolled	O
from	O
June	O
2007	O
to	O
June	O
2011	O
.	O
	
Data	O
on	O
15	O
evaluable	O
patients	O
is	O
reported	O
as	O
4	O
patients	O
were	O
removed	O
.	O
	
Median	O
age	O
was	O
59	O
years	O
(	O
range	O
","	O
36-67	O
years	O
)	O
.	O
	
The	O
overall	O
incidence	O
of	O
OM	B-TOXI
_	O
grade	O
3	O
was	O
53	O
%	O
(	O
8	O
of	O
15	O
)	O
and	O
a	O
median	O
duration	O
of	O
_grade	O
3	O
OM	B-TOXI
was	O
6.5	O
days	O
(	O
range	O
","	O
3-42	O
days	O
)	O
.	O
	
One	O
patient	O
in	O
L2	O
(	O
melphalan	B-DRUG
160	O
mg	O
/	O
m2	O
)	O
developed	O
atrial	B-TOXI
fibrillation	I-TOXI
on	O
day	O
9	O
Two	O
patients	O
in	O
L4	O
(	O
melphalan	B-DRUG
200	O
mg	O
/	O
m2	O
)	O
developed	O
grade	O
4	O
OM	B-TOXI
","	O
hence	O
reaching	O
DLT	O
.	O
	
No	O
DLT	O
was	O
observed	O
in	O
6	O
patients	O
enrolled	O
in	O
L3	O
(	O
melphalan	B-DRUG
180	O
mg	O
/	O
m2	O
)	O
.	O
	
Palifermin	B-DRUG
has	O
permitted	O
safe	O
dose	O
escalation	O
of	O
melphalan	B-DRUG
up	O
to	O
180	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
patients	O
with	O
RI	O
.	O
	
Safety	O
","	O
pharmacokinetic	O
","	O
and	O
pharmacodynamic	O
phase	O
I	O
dose-escalation	O
trial	O
of	O
PF-00562271	O
","	O
an	O
inhibitor	O
of	O
focal	O
adhesion	O
kinase	O
","	O
in	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
PF-00562271	O
is	O
a	O
novel	O
inhibitor	O
of	O
focal	O
adhesion	O
kinase	O
(	O
FAK	O
)	O
.	O
	
The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
identify	O
the	O
recommended	O
phase	O
II	O
dose	O
(	O
RP2D	O
)	O
and	O
assess	O
safety	O
and	O
tolerability	O
","	O
pharmacokinetics	O
(	O
PK	O
)	O
","	O
pharmacodynamics	O
(	O
PD	O
)	O
","	O
and	O
antitumor	O
activity	O
of	O
PF-00562271	O
.	O
	
Part	O
1	O
was	O
a	O
dose	O
escalation	O
without	O
and	O
with	O
food	O
.	O
	
Part	O
2	O
enrolled	O
specific	O
tumor	O
types	O
in	O
an	O
expansion	O
at	O
the	O
RP2D	O
and	O
also	O
assessed	O
the	O
effect	O
of	O
PF-00562271	O
on	O
single-dose	O
midazolam	O
PK	O
in	O
a	O
subgroup	O
of	O
patients	O
.	O
	
Ninety-nine	O
patients	O
(	O
median	O
age	O
","	O
60	O
years	O
;	O
98	O
%	O
with	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
or	O
1	O
)	O
were	O
treated	O
in	O
12	O
fasting	O
and	O
three	O
fed	O
cohorts	O
.	O
	
The	O
125-mg	O
twice-per-day	O
fed	O
dose	O
was	O
deemed	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
RP2D	O
.	O
	
Grade	O
3	O
dose-limiting	O
toxicities	O
included	O
headache	B-TOXI
","	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
","	O
dehydration	B-TOXI
","	O
and	O
edema	B-TOXI
.	O
	
Nausea	B-TOXI
was	O
the	O
most	O
frequently	O
observed	O
toxicity	O
(	O
60	O
%	O
of	O
patients	O
","	O
all	O
grades	O
1	O
or	O
2	O
at	O
RP2D	O
)	O
.	O
	
PF-00562271	O
exposure	O
increased	O
with	O
increasing	O
dose	O
;	O
serum	O
concentration-time	O
profiles	O
showed	O
characteristic	O
nonlinear	O
disposition	O
.	O
	
Steady-state	O
exposures	O
were	O
reached	O
within	O
1	O
week	O
.	O
	
On	O
coadministration	O
","	O
geometric	O
mean	O
values	O
of	O
midazolam	O
maximal	O
observed	O
serum	O
concentration	O
and	O
area	O
under	O
the	O
serum	O
concentration-time	O
curve	O
increased	O
by	O
60	O
%	O
and	O
more	O
than	O
two-fold	O
","	O
respectively	O
.	O
	
Of	O
14	O
patients	O
evaluable	O
by	O
[	O
(	O
18	O
)	O
F	O
]	O
fluorodeoxyglucose	O
positron	O
emission	O
tomography	O
in	O
the	O
expansion	O
cohorts	O
","	O
seven	O
metabolic	O
responses	O
were	O
observed	O
.	O
	
With	O
conventional	O
imaging	O
","	O
31	O
patients	O
had	O
stable	O
disease	O
at	O
first	O
restaging	O
scans	O
","	O
and	O
15	O
of	O
these	O
remained	O
stable	O
for	O
six	O
or	O
more	O
cycles	O
.	O
	
The	O
MTD	O
and	O
RP2D	O
of	O
PF-00562271	O
is	O
125	O
mg	O
twice	O
per	O
day	O
with	O
food	O
.	O
	
PF-00562271	O
displayed	O
time-	O
and	O
dose-dependent	O
nonlinear	O
PK	O
and	O
is	O
likely	O
a	O
potent	O
CYP	O
3A	O
inhibitor	O
.	O
	
This	O
first-in-class	O
study	O
supports	O
further	O
investigation	O
of	O
FAK	O
as	O
a	O
promising	O
therapeutic	O
target	O
.	O
	
Radiochemoimmunotherapy	O
with	O
intensity-modulated	O
concomitant	O
boost	O
:	O
interim	O
analysis	O
of	O
the	O
REACH	O
trial	O
.	O
	
	
To	O
evaluate	O
efficacy	O
and	O
toxicity	O
clinical	O
in	O
the	O
intensified	O
treatment	O
of	O
locally	O
advanced	B-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	O
SCCHN	B-CANCER
)	O
with	O
the	O
combination	O
of	O
chemotherapy	O
","	O
the	O
EGFR	O
antibody	O
cetuximab	B-DRUG
","	O
and	O
intensity-modulated	O
radiation	O
therapy	O
(	O
IMRT	O
)	O
in	O
a	O
concomitant	O
boost	O
concept	O
.	O
	
REACH	O
is	O
a	O
prospective	O
","	O
bi-centric	O
phase	O
II	O
trial	O
of	O
carboplatin	B-DRUG
/	O
5-FU	B-DRUG
and	O
cetuximab	B-DRUG
weekly	O
combined	O
with	O
IMRT	O
.	O
	
Primary	O
endpoint	O
is	O
locoregional	O
control	O
","	O
secondary	O
endpoints	O
include	O
acute	O
radiation	O
effects	O
and	O
adverse	O
events	O
.	O
	
Evaluation	O
of	O
disease	O
response	O
is	O
carried	O
out	O
according	O
to	O
the	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	B-DRUG
Tumors	I-DRUG
(	O
RECIST	O
)	O
;	O
toxicity	O
is	O
assessed	O
using	O
NCI	O
CTC	O
v	O
3.0.	O
Treatment	O
was	O
tolerated	O
moderately	O
well	O
","	O
acneiforme	B-DRUG
erythema	I-DRUG
occurred	O
in	O
74.1	O
%	O
(	O
grade	O
II	O
/	O
III	O
)	O
","	O
mucositis	B-DRUG
grade	O
III	O
in	O
28.6	O
%	O
","	O
and	O
radiation	B-DRUG
dermatitis	I-DRUG
grade	O
III	O
in	O
14.3	O
%	O
.	O
	
Higher-grade	O
side-effects	O
resolved	O
quickly	O
until	O
the	O
first	O
follow-up	O
post	O
treatment	O
.	O
	
Objective	O
response	O
rates	O
were	O
promising	O
with	O
28.6	O
%	O
CR	O
at	O
first	O
follow-up	O
and	O
92.9	O
%	O
thereafter	O
.	O
	
The	O
combination	O
of	O
standard	O
carboplatin	B-DRUG
/	O
5-FU	B-DRUG
and	O
cetuximab	B-DRUG
is	O
feasible	O
and	O
results	O
in	O
promising	O
objective	O
response	O
rates	O
.	O
	
The	O
use	O
of	O
an	O
IMRT	O
concomitant	O
boost	O
is	O
practicable	O
in	O
a	O
routine	O
clinical	O
setting	O
resulting	O
in	O
only	O
moderate	O
overall	O
toxicity	O
of	O
the	O
regimen	O
.	O
	
ISRCTN87356938	O
.	O
	
Multifactorial	O
pharmacogenetic	O
analysis	O
in	O
colorectal	B-CANCER
cancer	I-CANCER
patients	O
receiving	O
5-fluorouracil-based	B-DRUG
therapy	O
together	O
with	O
cetuximab-irinotecan	B-DRUG
.	O
	
	
To	O
examine	O
the	O
predictive	O
value	O
of	O
gene	O
polymorphisms	O
potentially	O
linked	O
to	O
toxicity	O
","	O
clinical	O
response	O
","	O
time	O
to	O
progression	O
and	O
overall	O
survival	O
","	O
following	O
cetuximab-tegafur-uracil	B-DRUG
(	O
UFT	B-DRUG
)	O
#NAME?	B-DRUG
therapy	O
.	O
	
Fifty-two	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
were	O
enrolled	O
in	O
an	O
ancillary	O
pharmacogenetic	O
study	O
of	O
the	O
phase	O
II	O
CETUFTIRI	O
trial	O
.	O
	
Treatment	O
consisted	O
of	O
21	O
day	O
cycles	O
of	O
cetuximab	B-DRUG
(	O
day	O
1-day	O
8-day	O
15	O
","	O
250	O
mg	O
m	O
(	O
-2	O
)	O
week	O
(	O
-1	O
)	O
following	O
a	O
400	O
mg	O
m	O
(	O
-2	O
)	O
initial	O
dose	O
)	O
together	O
with	O
irinotecan	B-DRUG
(	O
day	O
1	O
","	O
250	O
mg	O
m	O
(	O
-2	O
)	O
)	O
and	O
UFT-folinic	B-DRUG
acid	B-DRUG
(	O
days	O
1月14日	O
","	O
250	O
mg	O
m	O
(	O
-2	O
)	O
day	O
(	O
-1	O
)	O
UFT	O
","	O
90	O
mg	O
day	O
(	O
-1	O
)	O
folinic	B-DRUG
acid	I-DRUG
)	O
.	O
	
Analysed	O
gene	O
polymorphisms	O
(	O
blood	O
DNA	O
)	O
were	O
as	O
follows	O
:	O
EGFR	O
(	O
CA	O
repeats	O
in	O
intron	O
1	O
","	O
-216G	O
&	O
gt	O
;	O
T	O
","	O
-191C	O
&	O
gt	O
;	O
A	O
)	O
","	O
EGF	O
(	O
61A	O
&	O
gt	O
;	O
G	O
)	O
","	O
FCGR2A	O
(	O
131Arg	O
&	O
gt	O
;	O
His	O
)	O
","	O
FCGR3A	O
(	O
158Phe	O
&	O
gt	O
;	O
Val	O
)	O
","	O
UDP-glycosyltransferase1-polypeptide	O
A1	O
(	O
TA	O
repeats	O
)	O
","	O
TYMS	O
(	O
28	O
bp	O
repeats	O
","	O
including	O
the	O
G	O
&	O
gt	O
;	O
C	O
mutation	O
on	O
the	O
3R	O
allele	O
","	O
6	O
bp	O
deletion	O
in	O
3	O
'	O
UTR	O
)	O
and	O
MTHFR	O
(	O
677C	O
&	O
gt	O
;	O
T	O
","	O
1298A	O
&	O
gt	O
;	O
C	O
)	O
.	O
	
Maximum	O
toxicity	O
grade	O
was	O
linked	O
to	O
EGFR-191C	O
&	O
gt	O
;	O
A	O
polymorphism	O
","	O
with	O
71.1	O
%	O
grade	O
3月4日	O
toxicity	O
in	O
CC	O
patients	O
vs.	O
28.6	O
%	O
in	O
other	O
patients	O
(	O
P=	O
0.01	O
)	O
.	O
	
A	O
tendency	O
to	O
a	O
better	O
response	O
was	O
observed	O
in	O
patients	O
bearing	O
the	O
TYMS	O
3RG	O
allele	O
(	O
P=	O
0.029	O
)	O
and	O
those	O
bearing	O
the	O
FCGR3A	O
158Val	O
genotype	O
(	O
P=	O
0.02	O
)	O
.	O
	
The	O
greater	O
the	O
score	O
of	O
favourable	O
TYMS	O
and	O
FCGR3A	O
genotypes	O
","	O
the	O
better	O
the	O
response	O
rate	O
(	O
P=	O
0.009	O
)	O
and	O
the	O
longer	O
the	O
overall	O
survival	O
(	O
P=	O
0.007	O
)	O
.	O
	
In	O
multivariate	O
analysis	O
","	O
the	O
score	O
of	O
favourable	O
genotypes	O
was	O
a	O
stronger	O
survival	O
predictor	O
than	O
the	O
performance	O
status	O
.	O
	
Present	O
data	O
suggest	O
the	O
importance	O
of	O
FCGR3A	O
158Phe	O
&	O
gt	O
;	O
Val	O
and	O
TYMS	O
5	O
'	O
UTR	O
polymorphisms	O
in	O
responsiveness	O
and	O
survival	O
of	O
patients	O
receiving	O
cetuximab-fluoropyrimidine-based	B-DRUG
therapy	O
.	O
	
Preoperative	O
chemotherapy	O
plus	O
trastuzumab	B-DRUG
","	O
lapatinib	B-DRUG
","	O
or	O
both	O
in	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2-positive	O
operable	O
breast	B-CANCER
cancer	I-CANCER
:	O
results	O
of	O
the	O
randomized	O
phase	O
II	O
CHER-LOB	O
study	O
.	O
	
	
This	O
is	O
a	O
noncomparative	O
","	O
randomized	O
","	O
phase	O
II	O
trial	O
of	O
preoperative	O
taxane-anthracycline	B-DRUG
in	O
combination	O
with	O
trastuzumab	B-DRUG
","	O
lapatinib	B-DRUG
","	O
or	O
combined	O
trastuzumab	B-DRUG
plus	O
lapatinib	B-DRUG
in	O
patients	O
with	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
(	O
HER2	O
)	O
#NAME?	O
","	O
stage	O
II	O
to	O
IIIA	O
operable	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
The	O
primary	O
aim	O
was	O
to	O
estimate	O
the	O
percentage	O
of	O
pathologic	O
complete	O
response	O
(	O
pCR	O
;	O
no	O
invasive	O
tumor	O
in	O
breast	O
and	O
axillary	O
nodes	O
)	O
.	O
	
In	O
the	O
three	O
arms	O
","	O
chemotherapy	O
consisted	O
of	O
weekly	O
paclitaxel	B-DRUG
(	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
for	O
12	O
weeks	O
followed	O
by	O
fluorouracil	B-DRUG
","	O
epirubicin	B-DRUG
","	O
and	O
cyclophosphamide	B-DRUG
for	O
four	O
courses	O
every	O
3	O
weeks	O
.	O
	
The	O
patients	O
randomly	O
assigned	O
to	O
arm	O
A	O
received	O
a	O
4-mg	O
loading	O
dose	O
of	O
trastuzumab	B-DRUG
followed	O
by	O
2	O
mg	O
weekly	O
;	O
in	O
arm	O
B	O
patients	O
received	O
lapatinib	B-DRUG
"1,500"	O
mg	O
orally	O
(	O
PO	O
)	O
daily	O
;	O
and	O
in	O
arm	O
C	O
","	O
patients	O
received	O
trastuzumab	B-DRUG
and	O
lapatinib	B-DRUG
"1,000"	O
mg	O
PO	O
daily	O
.	O
	
A	O
total	O
of	O
121	O
patients	O
were	O
randomly	O
assigned	O
.	O
	
Diarrhea	B-TOXI
and	O
dermatologic	B-TOXI
and	O
hepatic	B-TOXI
toxicities	I-TOXI
were	O
observed	O
more	O
frequently	O
in	O
patients	O
receiving	O
lapatinib	B-DRUG
.	O
	
No	O
episodes	O
of	O
congestive	B-DRUG
heart	I-DRUG
failure	I-DRUG
were	O
observed	O
.	O
	
The	O
rates	O
of	O
breast-conserving	O
surgery	O
were	O
66.7	O
%	O
","	O
57.9	O
%	O
","	O
and	O
68.9	O
%	O
in	O
arms	O
A	O
","	O
B	O
and	O
C	O
","	O
respectively	O
.	O
	
The	O
pCR	O
rates	O
were	O
25	O
%	O
(	O
90	O
%	O
CI	O
","	O
13.1	O
%	O
to	O
36.9	O
%	O
)	O
in	O
arm	O
A	O
","	O
26.3	O
%	O
(	O
90	O
%	O
CI	O
","	O
14.5	O
%	O
to	O
38.1	O
%	O
)	O
in	O
arm	O
B	O
","	O
and	O
46.7	O
%	O
(	O
90	O
%	O
CI	O
","	O
34.4	O
%	O
to	O
58.9	O
%	O
)	O
in	O
arm	O
C	O
(	O
exploratory	O
P	O
=	O
0.019	O
)	O
.	O
	
The	O
primary	O
end	O
point	O
of	O
the	O
study	O
was	O
met	O
","	O
with	O
a	O
relative	O
increase	O
of	O
80	O
%	O
in	O
the	O
pCR	O
rate	O
achieved	O
with	O
chemotherapy	O
plus	O
trastuzumab	B-DRUG
and	O
lapatinib	B-DRUG
compared	O
with	O
chemotherapy	O
plus	O
either	O
trastuzumab	B-DRUG
or	O
lapatinib	B-DRUG
.	O
	
These	O
data	O
add	O
further	O
evidence	O
supporting	O
the	O
superiority	O
of	O
a	O
dual-HER2	O
inhibition	O
for	O
the	O
treatment	O
of	O
HER2-positive	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Efficacy	O
and	O
safety	O
of	O
metronomic	O
chemotherapy	O
for	O
patients	O
with	O
advanced	B-CANCER
primary	I-CANCER
hepatocellular	I-CANCER
carcinoma	I-CANCER
with	O
major	O
portal	O
vein	O
tumor	O
thrombosis	O
.	O
	
	
Low-dose	O
metronomic	O
chemotherapy	O
involves	O
the	O
frequent	O
administration	O
of	O
comparatively	O
low	O
doses	O
of	O
cytotoxic	O
agents	O
with	O
no	O
extended	O
breaks	O
","	O
and	O
it	O
may	O
be	O
as	O
efficient	O
as	O
and	O
less	O
toxic	O
than	O
the	O
conventional	O
maximum	O
tolerated	O
dose	O
therapy	O
.	O
	
This	O
study	O
evaluated	O
the	O
feasibility	O
and	O
therapeutic	O
efficacy	O
of	O
metronomic	O
chemotherapy	O
in	O
patients	O
with	O
advanced	B-CANCER
hepatocellular	I-CANCER
carcinoma	I-CANCER
(	O
HCC	B-CANCER
)	O
with	O
major	O
portal	O
vein	O
thrombosis	O
(	O
PVT	O
)	O
.	O
	
Thirty	O
consecutive	O
HCC	B-CANCER
patients	O
with	O
major	O
PVT	O
with	O
or	O
without	O
extrahepatic	O
metastasis	O
were	O
prospectively	O
allocated	O
to	O
metronomic	O
chemotherapy	O
consisting	O
of	O
epirubicin	B-DRUG
being	O
infused	O
through	O
the	O
correct	O
hepatic	O
artery	O
at	O
a	O
dose	O
of	O
30	O
mg	O
/	O
body	O
surface	O
area	O
(	O
BSA	O
)	O
every	O
4	O
weeks	O
","	O
and	O
cisplatin	B-DRUG
(	O
15	O
mg	O
/	O
BSA	O
)	O
and	O
5-fluorouracil	B-DRUG
(	O
50	O
mg	O
/	O
BSA	O
)	O
every	O
week	O
for	O
3	O
weeks	O
","	O
with	O
intervening	O
1	O
week	O
breaks	O
.	O
	
The	O
treatment	O
response	O
was	O
assessed	O
using	O
response	O
evaluation	O
criteria	O
in	O
solid	B-CANCER
tumors	I-CANCER
(	O
RECIST	O
)	O
.	O
	
In	O
total	O
","	O
116	O
cycles	O
of	O
metronomic	O
chemotherapy	O
were	O
administered	O
to	O
the	O
30	O
patients	O
","	O
with	O
a	O
median	O
of	O
3	O
cycles	O
given	O
to	O
individual	O
patients	O
(	O
range	O
","	O
1月15日	O
cycles	O
)	O
.	O
	
Six	O
patients	O
(	O
20	O
%	O
)	O
achieved	O
a	O
partial	O
response	O
and	O
six	O
patients	O
(	O
20	O
%	O
)	O
had	O
stable	O
disease	O
.	O
	
The	O
median	O
time	O
to	O
disease	O
progression	O
and	O
overall	O
survival	O
were	O
63	O
days	O
(	O
range	O
","	O
26-631	O
days	O
)	O
and	O
162	O
days	O
(	O
95	O
%	O
confidence	O
interval	O
;	O
range	O
","	O
62-262	O
days	O
)	O
","	O
respectively	O
.	O
	
Overall	O
survival	O
was	O
significantly	O
associated	O
with	O
baseline	O
alpha-fetoprotein	O
level	O
(	O
P=0.001	O
)	O
and	O
tumor	O
response	O
(	O
P=0.005	O
)	O
.	O
	
The	O
baseline	O
alpha-fetoprotein	O
level	O
was	O
significantly	O
associated	O
with	O
the	O
disease	O
control	O
rate	O
(	O
P=0.007	O
)	O
.	O
	
Adverse	O
events	O
were	O
tolerable	O
and	O
managed	O
successfully	O
with	O
conservative	O
treatment	O
.	O
	
Metronomic	O
chemotherapy	O
may	O
be	O
a	O
safe	O
and	O
useful	O
palliative	O
treatment	O
in	O
HCC	B-CANCER
patients	O
with	O
major	O
PVT	O
.	O
	
Phase	O
I	O
evaluation	O
of	O
TNFerade	O
biologic	O
plus	O
chemoradiotherapy	O
before	O
esophagectomy	O
for	O
locally	O
advanced	B-CANCER
resectable	I-CANCER
esophageal	I-CANCER
cancer	I-CANCER
.	O
	
	
Neoadjuvant	O
chemoradiotherapy	O
followed	O
by	O
surgery	O
is	O
the	O
primary	O
treatment	O
option	O
for	O
patients	O
with	O
locally	B-CANCER
advanced	I-CANCER
esophageal	I-CANCER
cancer	I-CANCER
.	O
	
This	O
multicenter	O
phase	O
I	O
trial	O
examined	O
intratumoral	O
injection	O
of	O
TNFerade	O
biologic	O
","	O
an	O
adenoviral	O
vector	O
that	O
expresses	O
the	O
human	O
tumor	O
necrosis	O
factor-伪	O
gene	O
","	O
with	O
chemoradiotherapy	O
in	O
locally	B-CANCER
advanced	I-CANCER
esophageal	I-CANCER
cancer	I-CANCER
.	O
	
To	O
assess	O
pathologic	O
complete	O
response	O
(	O
pCR	O
)	O
","	O
time	O
to	O
disease	O
progression	O
","	O
progression-free	O
survival	O
","	O
survival	O
","	O
and	O
safety	O
and	O
tolerance	O
in	O
patients	O
treated	O
with	O
preoperative	O
chemoradiation	O
combined	O
with	O
endoscopy	O
or	O
EUS-guided	O
intratumoral	O
injection	O
of	O
TNFerade	O
biologic	O
.	O
	
Five	O
weekly	O
injections	O
of	O
TNFerade	O
biologic	O
","	O
dose-escalated	O
logarithmically	O
from	O
4	O
_	O
10	O
(	O
8	O
)	O
to	O
4	O
_	O
10	O
(	O
11	O
)	O
particle	O
units	O
(	O
PU	O
)	O
","	O
were	O
given	O
in	O
combination	O
with	O
cisplatin	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
intravenous	O
5-fluorouracil	B-DRUG
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
d	O
for	O
96	O
hours	O
on	O
days	O
1	O
and	O
29	O
","	O
and	O
concurrent	O
radiation	O
therapy	O
to	O
45	O
Gy	O
.	O
	
Surgery	O
was	O
performed	O
9	O
to	O
15	O
weeks	O
after	O
treatment	O
.	O
	
U.S.	O
multicenter	O
study	O
.	O
	
Patients	O
with	O
stage	O
II	O
and	O
III	O
esophageal	B-CANCER
cancer	I-CANCER
were	O
enrolled	O
.	O
	
Primary	O
outcome	O
measures	O
were	O
safety	O
","	O
feasibility	O
","	O
tolerability	O
","	O
and	O
rate	O
of	O
pCR	O
.	O
	
Secondary	O
outcome	O
measures	O
were	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
disease-free	O
survival	O
.	O
	
Twenty-four	O
patients	O
with	O
a	O
median	O
age	O
of	O
61	O
years	O
were	O
enrolled	O
;	O
88	O
%	O
of	O
the	O
patients	O
were	O
men	O
","	O
21	O
%	O
were	O
stage	O
II	O
","	O
and	O
79	O
%	O
were	O
stage	O
III	O
.	O
	
Six	O
(	O
29	O
%	O
)	O
had	O
a	O
pCR	O
","	O
observed	O
among	O
21	O
patients	O
(	O
20	O
who	O
underwent	O
esophagectomy	O
and	O
1	O
at	O
autopsy	O
)	O
.	O
	
Dose-limiting	O
toxicities	O
were	O
not	O
observed	O
.	O
	
The	O
most	O
frequent	O
potentially	O
related	O
adverse	O
events	O
were	O
fatigue	B-TOXI
(	O
54	O
%	O
)	O
","	O
fever	B-TOXI
(	O
38	O
%	O
)	O
","	O
nausea	B-TOXI
(	O
29	O
%	O
)	O
","	O
vomiting	B-TOXI
(	O
21	O
%	O
)	O
","	O
esophagitis	B-TOXI
(	O
21	O
%	O
)	O
","	O
and	O
chills	B-TOXI
(	O
21	O
%	O
)	O
.	O
	
At	O
the	O
top	O
dose	O
of	O
4	O
_	O
10	O
(	O
11	O
)	O
PU	O
","	O
thromboembolic	B-TOXI
events	I-TOXI
developed	O
in	O
5	O
of	O
8	O
patients	O
.	O
	
The	O
median	O
OS	O
was	O
47.8	O
months	O
.	O
	
The	O
-3	O
and	O
5-year	O
OS	O
rates	O
and	O
disease-free	O
survival	O
rates	O
were	O
54	O
%	O
and	O
41	O
%	O
and	O
38	O
%	O
and	O
38	O
%	O
","	O
respectively	O
.	O
	
We	O
included	O
primarily	O
adenocarcinoma	B-TOXI
.	O
	
Preoperative	O
TNFerade	O
","	O
in	O
combination	O
with	O
chemoradiotherapy	O
","	O
is	O
active	O
and	O
safe	O
at	O
doses	O
up	O
to	O
4	O
_	O
10	O
(	O
10	O
)	O
PU	O
and	O
is	O
associated	O
with	O
long	O
survival	O
.	O
	
This	O
regimen	O
warrants	O
additional	O
studies	O
.	O
	
Ipilimumab	B-DRUG
in	O
combination	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
as	O
first-line	O
treatment	O
in	O
stage	O
IIIB	O
/	O
IV	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
results	O
from	O
a	O
randomized	O
","	O
double-blind	O
","	O
multicenter	O
phase	O
II	O
study	O
.	O
	
	
Ipilimumab	B-DRUG
","	O
which	O
is	O
an	O
anti-cytotoxic	O
T-cell	O
lymphocyte-4	O
monoclonal	O
antibody	O
","	O
showed	O
a	O
survival	O
benefit	O
in	O
melanoma	B-CANCER
with	O
adverse	O
events	O
(	O
AEs	O
)	O
managed	O
by	O
protocol-defined	O
guidelines	O
.	O
	
A	O
phase	O
II	O
study	O
in	O
lung	B-CANCER
cancer	I-CANCER
assessed	O
the	O
activity	O
of	O
ipilimumab	B-DRUG
plus	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
.	O
	
Patients	O
(	O
N	O
=	O
204	O
)	O
with	O
chemotherapy-naive	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
were	O
randomly	O
assigned	O
01:01:01	O
to	O
receive	O
paclitaxel	B-DRUG
(	O
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
","	O
6	O
)	O
with	O
either	O
placebo	B-DRUG
(	O
control	O
)	O
or	O
ipilimumab	B-DRUG
in	O
one	O
of	O
the	O
following	O
two	O
regimens	O
:	O
concurrent	O
ipilimumab	B-DRUG
(	O
four	O
doses	O
of	O
ipilimumab	B-DRUG
plus	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
followed	O
by	O
two	O
doses	O
of	O
placebo	B-DRUG
plus	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
)	O
or	O
phased	O
ipilimumab	B-DRUG
(	O
two	O
doses	O
of	O
placebo	B-DRUG
plus	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
followed	O
by	O
four	O
doses	O
of	O
ipilimumab	B-DRUG
plus	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
)	O
.Treatment	O
was	O
administered	O
intravenously	O
every	O
3	O
weeks	O
for	O
_	O
18	O
weeks	O
(	O
induction	O
)	O
.	O
	
Eligible	O
patients	O
continued	O
ipilimumab	B-DRUG
or	O
placebo	B-DRUG
every	O
12	O
weeks	O
as	O
maintenance	O
therapy	O
.	O
	
Response	O
was	O
assessed	O
by	O
using	O
immune-related	O
response	O
criteria	O
and	O
modified	O
WHO	O
criteria	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
immune-related	O
progression-free	O
survival	O
(	O
irPFS	O
)	O
.	O
	
Other	O
end	O
points	O
were	O
progression-free	O
survival	O
(	O
PFS	O
)	O
","	O
best	O
overall	O
response	O
rate	O
(	O
BORR	O
)	O
","	O
immune-related	O
BORR	O
(	O
irBORR	O
)	O
","	O
overall	O
survival	O
(	O
OS	O
)	O
","	O
and	O
safety	O
.	O
	
The	O
study	O
met	O
its	O
primary	O
end	O
point	O
of	O
improved	O
irPFS	O
for	O
phased	O
ipilimumab	B-DRUG
versus	O
the	O
control	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
","	O
0.72	O
;	O
P	O
=	O
0.05	O
)	O
","	O
but	O
not	O
for	O
concurrent	O
ipilimumab	B-DRUG
(	O
HR	O
","	O
0.81	O
;	O
P	O
=	O
0.13	O
)	O
.	O
	
Phased	O
ipilimumab	B-DRUG
also	O
improved	O
PFS	O
according	O
to	O
modified	O
WHO	O
criteria	O
(	O
HR	O
","	O
0.69	O
;	O
P	O
=	O
0.02	O
)	O
.	O
	
Phased	O
ipilimumab	B-DRUG
","	O
concurrent	O
ipilimumab	B-DRUG
","	O
and	O
control	O
treatments	O
were	O
associated	O
with	O
a	O
median	O
irPFS	O
of	O
5.7	O
","	O
5.5	O
","	O
and	O
4.6	O
months	O
","	O
respectively	O
","	O
a	O
median	O
PFS	O
of	O
5.1	O
","	O
4.1	O
","	O
and	O
4.2	O
months	O
","	O
respectively	O
","	O
an	O
irBORR	O
of	O
32	O
%	O
","	O
21	O
%	O
and	O
18	O
%	O
","	O
respectively	O
","	O
a	O
BORR	O
of	O
32	O
%	O
","	O
21	O
%	O
and	O
14	O
%	O
","	O
respectively	O
","	O
and	O
a	O
median	O
OS	O
of	O
12.2	O
","	O
9.7	O
","	O
and	O
8.3	O
months	O
.	O
	
Overall	O
rates	O
of	O
grade	O
3	O
and	O
4	O
immune-related	O
AEs	O
were	O
15	O
%	O
","	O
20	O
%	O
","	O
and	O
6	O
%	O
for	O
phased	O
ipilimumab	B-DRUG
","	O
concurrent	O
ipilimumab	B-DRUG
","	O
and	O
the	O
control	O
","	O
respectively	O
.	O
	
Two	O
patients	O
(	O
concurrent	O
","	O
one	O
patient	O
;	O
control	O
","	O
one	O
patient	O
)	O
died	B-TOXI
from	O
treatment-related	O
toxicity	O
.	O
	
Phased	O
ipilimumab	B-DRUG
plus	O
paclitaxel	B-DRUG
and	O
carboplatin	O
improved	O
irPFS	O
and	O
PFS	O
","	O
which	O
supports	O
additional	O
investigation	O
of	O
ipilimumab	B-DRUG
in	O
NSCLC	B-CANCER
.	O
	
A	O
phase	O
Ib	O
","	O
dose-finding	O
study	O
of	O
erlotinib	B-DRUG
in	O
combination	O
with	O
a	O
fixed	O
dose	O
of	O
pertuzumab	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
Pertuzumab	B-DRUG
","	O
a	O
dimerization	O
inhibitor	O
of	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
(	O
HER2	O
)	O
","	O
has	O
demonstrated	O
pharmacodynamic	O
activity	O
","	O
with	O
stable	O
disease	O
in	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
Combining	O
erlotinib	B-DRUG
and	O
pertuzumab	B-DRUG
may	O
enhance	O
antitumor	O
activity	O
.	O
	
This	O
study	O
aimed	O
to	O
establish	O
the	O
recommended	O
dosing	O
of	O
the	O
erlotinib	B-DRUG
and	O
pertuzumab	B-DRUG
combination	O
;	O
assess	O
safety	O
","	O
preliminary	O
efficacy	O
","	O
and	O
pharmacokinetics	O
;	O
and	O
analyze	O
biomarkers	O
.	O
	
Fifteen	O
patients	O
with	O
stage	O
IIIb	O
/	O
IV	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
who	O
failed	O
chemotherapy	O
were	O
recruited	O
.	O
	
The	O
patients	O
received	O
erlotinib	B-DRUG
(	O
days	O
-8	O
to	O
-1	O
)	O
","	O
then	O
combination	O
therapy	O
(	O
21-day	O
cycles	O
for	O
6	O
cycles	O
)	O
.	O
	
Pertuzumab	B-DRUG
was	O
given	O
intravenous	O
at	O
840	O
mg	O
","	O
then	O
420	O
mg	O
once	O
every	O
three	O
weeks	O
","	O
with	O
erlotinib	B-DRUG
given	O
daily	O
(	O
100	O
or	O
150	O
mg	O
)	O
.	O
	
No	O
dose-limiting	O
toxicities	O
were	O
observed	O
.	O
	
Adverse	O
events	O
were	O
generally	O
grade	O
1	O
/	O
2	O
and	O
manageable	O
.	O
	
The	O
objective	O
response	O
rate	O
was	O
20	O
%	O
(	O
3	O
/	O
15	O
patients	O
;	O
2	O
responders	O
had	O
mutant	O
HER1	O
","	O
1	O
responder	O
had	O
wild-type	O
HER1	O
)	O
","	O
median	O
overall	O
progression-free	O
survival	O
was	O
9.3	O
weeks	O
.	O
	
High	O
HER1	O
","	O
HER2	O
","	O
and	O
HER3	O
messenger	O
RNA	O
expression	O
correlated	O
with	O
increased	O
progression-free	O
survival	O
.	O
	
Combination	O
therapy	O
did	O
not	O
affect	O
erlotinib	B-DRUG
's	I-DRUG
pharmacokinetics	O
;	O
however	O
","	O
pertuzumab	B-DRUG
mean	O
exposures	O
(	O
maximum	O
concentration	O
","	O
231	O
mg	O
/	O
L	O
;	O
area	O
under	O
the	O
concentration-time	O
curve	O
from	O
0	O
to	O
21	O
days	O
","	O
1780	O
mg*d	O
/	O
L	O
)	O
were	O
slightly	O
higher	O
than	O
in	O
previous	O
studies	O
.	O
	
Combination	O
therapy	O
was	O
well	O
tolerated	O
in	O
patients	O
with	O
good	O
performance	O
status	O
","	O
with	O
encouraging	O
efficacy	O
.	O
	
A	O
loading	O
dose	O
of	O
pertuzumab	B-DRUG
840	O
mg	O
followed	O
by	O
420	O
mg	O
once	O
every	O
three	O
weeks	O
plus	O
daily	O
erlotinib	B-DRUG
150	O
mg	O
appears	O
to	O
be	O
the	O
most	O
appropriate	O
regimen	O
for	O
this	O
combination	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
sunitinib	B-DRUG
combined	O
with	O
modified	B-DRUG
FOLFOX6	I-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
This	O
phase	O
I	O
study	O
assessed	O
the	O
safety	O
","	O
tolerability	O
","	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
pharmacokinetics	O
","	O
and	O
preliminary	O
antitumor	O
effects	O
of	O
sunitinib	B-DRUG
combined	O
with	O
modified	B-DRUG
FOLFOX6	I-DRUG
(	O
mFOLFOX6	B-DRUG
)	O
.	O
	
Patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
malignancies	I-CANCER
received	O
mFOLFOX6	B-DRUG
in	O
2-week	O
cycles	O
with	O
escalating	O
sunitinib	B-DRUG
doses	O
(	O
25	O
","	O
37.5	O
","	O
and	O
50	O
mg	O
/	O
day	O
)	O
on	O
three	O
schedules	O
:	O
2	O
weeks	O
on	O
","	O
2	O
weeks	O
off	O
(	O
2	O
/	O
2	O
)	O
;	O
4	O
weeks	O
on	O
","	O
2	O
weeks	O
off	O
(	O
4	O
/	O
2	O
)	O
;	O
or	O
continuous	O
daily	O
dosing	O
(	O
CDD	O
)	O
.	O
	
Patients	O
received	O
up	O
to	O
8	O
treatment	O
cycles	O
(	O
Schedule	O
2	O
/	O
2	O
and	O
CDD	O
schedule	O
)	O
or	O
6	O
cycles	O
(	O
Schedule	O
4	O
/	O
2	O
)	O
.	O
	
An	O
expansion	O
cohort	O
enrolled	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
at	O
the	O
Schedule	O
2	O
/	O
2	O
MTD	O
.	O
	
Overall	O
","	O
53	O
patients	O
were	O
enrolled	O
","	O
with	O
43	O
evaluable	O
for	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
.	O
	
On	O
Schedule	O
2	O
/	O
2	O
(	O
n	O
=	O
18	O
)	O
","	O
DLTs	O
occurred	O
in	O
three	O
patients	O
at	O
50	O
mg	O
/	O
day	O
(	O
grade	O
4	O
neutropenia	B-TOXI
[	O
n	O
=	O
1	O
]	O
;	O
grades	O
3	O
and	O
4	O
thrombocytopenia	B-TOXI
[	O
n	O
=	O
2	O
]	O
)	O
and	O
two	O
patients	O
achieved	O
partial	O
responses	O
(	O
PRs	O
)	O
.	O
	
On	O
Schedule	O
4	O
/	O
2	O
(	O
n	O
=	O
13	O
)	O
","	O
37.5	O
mg	O
/	O
day	O
exceeded	O
the	O
MTD	O
with	O
two	O
DLTs	O
(	O
febrile	B-TOXI
neutropenia	I-TOXI
and	O
grade	O
4	O
hypokalemia	B-TOXI
","	O
respectively	O
)	O
.	O
	
On	O
the	O
CDD	O
schedule	O
(	O
n	O
=	O
12	O
)	O
","	O
the	O
MTD	O
was	O
25	O
mg	O
/	O
day	O
;	O
one	O
DLT	O
(	O
grade	O
3	O
stomatitis	B-TOXI
)	O
was	O
reported	O
and	O
two	O
patients	O
achieved	O
PRs	O
.	O
	
The	O
most	O
common	O
adverse	O
events	O
were	O
neutropenia	B-TOXI
","	O
fatigue	B-TOXI
","	O
and	O
thrombocytopenia	B-TOXI
.	O
	
No	O
clinically	O
significant	O
drug-drug	O
interactions	O
were	O
apparent	O
between	O
sunitinib	B-DRUG
","	O
its	O
metabolite	O
SU12662	B-DRUG
","	O
and	O
mFOLFOX6	B-DRUG
.	O
	
Sunitinib	B-DRUG
combined	O
with	O
mFOLFOX6	B-DRUG
had	O
acceptable	O
tolerability	O
.	O
	
The	O
MTDs	O
were	O
sunitinib	B-DRUG
50	O
mg	O
/	O
day	O
on	O
Schedule	O
2	O
/	O
2	O
and	O
25	O
mg	O
/	O
day	O
on	O
the	O
CDD	O
schedule	O
.	O
	
A	O
MTD	O
for	O
Schedule	O
4	O
/	O
2	O
was	O
not	O
established	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
bevacizumab	B-DRUG
","	O
everolimus	B-DRUG
and	O
panitumumab	B-DRUG
in	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Preclinical	O
data	O
suggest	O
concurrent	O
inhibition	O
of	O
VEGF	O
","	O
mTOR	O
and	O
EGFR	O
pathways	O
may	O
augment	O
antitumor	O
and	O
antiangiogenic	O
effects	O
compared	O
to	O
inhibition	O
of	O
each	O
pathway	O
alone	O
.	O
	
This	O
study	O
evaluated	O
the	O
maximum	O
tolerated	O
dose	O
/	O
recommended	O
phase	O
II	O
dose	O
and	O
safety	O
and	O
tolerability	O
of	O
bevacizumab	B-DRUG
","	O
everolimus	B-DRUG
and	O
panitumumab	B-DRUG
drug	O
combination	O
.	O
	
Subjects	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
received	O
escalating	O
doses	O
of	O
everolimus	B-DRUG
and	O
flat	O
dosing	O
of	O
panitumumab	B-DRUG
at	O
4.8	O
mg	O
/	O
kg	O
and	O
bevacizumab	B-DRUG
at	O
10	O
mg	O
/	O
kg	O
every	O
2	O
weeks	O
.	O
	
Dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
were	O
assessed	O
in	O
cycle	O
1	O
;	O
toxicity	O
evaluation	O
was	O
closely	O
monitored	O
throughout	O
treatment	O
.	O
	
Treatment	O
continued	O
until	O
disease	O
progression	O
or	O
undesirable	O
toxicity	O
.	O
	
Thirty-two	O
subjects	O
were	O
evaluable	O
for	O
toxicity	O
;	O
31	O
subjects	O
were	O
evaluable	O
for	O
tumor	O
response	O
.	O
	
DLTs	O
were	O
observed	O
in	O
cohorts	O
with	O
everolimus	B-DRUG
at	O
10	O
and	O
5	O
mg	O
daily	O
and	O
included	O
grade	O
3	O
mucositis	B-DRUG
","	O
skin	B-DRUG
rash	I-DRUG
and	O
thrombocytopenia	B-DRUG
.	O
	
Therefore	O
","	O
everolimus	B-DRUG
was	O
dose-reduced	O
to	O
5	O
mg	O
three	O
times	O
weekly	O
","	O
which	O
improved	O
the	O
tolerability	O
of	O
the	O
treatment	O
regimen	O
.	O
	
Common	O
adverse	O
events	O
were	O
skin	B-TOXI
rash	I-TOXI
/	O
pruritus	B-TOXI
(	O
91	O
%	O
)	O
","	O
mucositis	B-TOXI
/	O
stomatitis	B-TOXI
(	O
75	O
%	O
)	O
","	O
hypomagnesemia	B-TOXI
(	O
72	O
%	O
)	O
","	O
hypocalcemia	B-TOXI
(	O
56	O
%	O
)	O
and	O
hypokalemia	B-TOXI
(	O
50	O
%	O
)	O
.	O
	
There	O
were	O
3	O
partial	O
responses	O
;	O
an	O
additional	O
10	O
subjects	O
had	O
stable	O
disease	O
_6	O
months	O
.	O
	
Three	O
subjects	O
with	O
ovarian	B-CANCER
cancer	I-CANCER
and	O
one	O
with	O
endometrial	B-CANCER
cancer	I-CANCER
achieved	O
prolonged	O
disease	O
control	O
ranging	O
from	O
11	O
to	O
&	O
gt	O
;	O
40	O
months	O
.	O
	
The	O
recommended	O
phase	O
II	O
dose	O
is	O
everolimus	B-DRUG
at	O
5	O
mg	O
three	O
times	O
weekly	O
plus	O
panitumumab	B-DRUG
at	O
4.8	O
mg	O
/	O
kg	O
and	O
bevacizumab	B-DRUG
at	O
10	O
mg	O
/	O
kg	O
every	O
2	O
weeks	O
.	O
	
This	O
dosing	O
regimen	O
has	O
an	O
acceptable	O
safety	O
and	O
tolerability	O
profile	O
and	O
appears	O
to	O
have	O
moderate	O
the	O
clinical	O
activity	O
in	O
refractory	B-CANCER
tumors	I-CANCER
.	O
	
A	O
phase	O
I	O
study	O
of	O
temsirolimus	B-DRUG
plus	O
carboplatin	B-DRUG
plus	O
paclitaxel	B-DRUG
for	O
patients	O
with	O
recurrent	O
or	O
metastatic	O
(	O
R	O
/	O
M	O
)	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
squamous	I-CANCER
cell	I-CANCER
cancer	I-CANCER
(	O
HNSCC	B-CANCER
)	O
.	O
	
	
The	O
mammalian	O
target	O
of	O
rapamycin	B-DRUG
complex	O
1	O
(	O
mTORC1	O
)	O
is	O
aberrantly	O
activated	O
in	O
many	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinomas	I-CANCER
(	O
HNSCCs	B-CANCER
)	O
.	O
	
This	O
phase	O
I	O
study	O
combines	O
the	O
mTORC1	O
inhibitor	O
temsirolimus	B-DRUG
with	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
.	O
	
This	O
was	O
a	O
single	O
institution	O
phase	O
I	O
study	O
for	O
patients	O
with	O
R	O
/	O
M	O
HNSCC	B-CANCER
with	O
a	O
standard	O
3	O
=+	O
3	O
design	O
.	O
	
Three	O
doses	O
of	O
temsirolimus	B-DRUG
were	O
planned	O
:	O
15	O
","	O
20	O
","	O
and	O
25	O
mg	O
.	O
	
Due	O
to	O
excessive	O
toxicity	O
with	O
the	O
original	O
study	O
regimen	O
","	O
the	O
protocol	O
was	O
amended	O
to	O
carboplatin	B-DRUG
AUC	O
1.5	O
","	O
paclitaxel	B-DRUG
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
and	O
temsirolimus	B-DRUG
(	O
according	O
to	O
dose	O
escalation	O
plan	O
)	O
","	O
all	O
on	O
days	O
1	O
and	O
8	O
of	O
a	O
21-day	O
cycle	O
.	O
	
18	O
patients	O
(	O
14	O
male	O
","	O
4	O
female	O
)	O
enrolled	O
","	O
with	O
median	O
age	O
56	O
years	O
(	O
range	O
33-78	O
)	O
.	O
	
The	O
most	O
common	O
toxicities	O
were	O
anemia	B-TOXI
","	O
leukopenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
and	O
hyperglycemia	B-TOXI
.	O
	
Among	O
all	O
patients	O
treated	O
","	O
the	O
confirmed	O
objective	O
partial	O
response	O
(	O
cPR	O
)	O
rate	O
was	O
22	O
%	O
.	O
	
DLT	O
was	O
not	O
exceeded	O
among	O
6	O
patients	O
treated	O
at	O
dose	O
level	O
3	O
of	O
the	O
revised	O
protocol	O
","	O
and	O
4	O
of	O
6	O
subjects	O
treated	O
at	O
this	O
dose	O
level	O
had	O
cPRs	O
.	O
	
The	O
phase	O
II	O
recommended	O
regimen	O
is	O
temsirolimus	B-DRUG
25	O
mg	O
","	O
carboplatin	B-DRUG
AUC	O
1.5	O
","	O
and	O
paclitaxel	B-DRUG
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
all	O
on	O
days	O
1	O
and	O
8	O
of	O
a	O
21-day	O
cycle	O
.	O
	
A	O
phase	O
II	O
study	O
of	O
this	O
regimen	O
in	O
R	O
/	O
M	O
HNSCC	B-CANCER
is	O
ongoing	O
.	O
	
Safety	O
and	O
preliminary	O
efficacy	O
analysis	O
of	O
the	O
mTOR	O
inhibitor	O
ridaforolimus	B-DRUG
in	O
patients	O
with	O
taxane-treated	B-DRUG
","	O
castration-resistant	O
prostate	B-CANCER
cancer	I-CANCER
.	O
	
	
Few	O
options	O
are	O
available	O
after	O
taxane-based	B-DRUG
therapy	O
in	O
men	O
with	O
CRPC	B-CANCER
.	O
	
Genetic	O
alterations	O
involving	O
the	O
mTOR	O
pathway	O
have	O
been	O
associated	O
with	O
CRPC	B-CANCER
development	O
","	O
raising	O
the	O
hypothesis	O
that	O
blocking	O
mTOR	O
signaling	O
may	O
be	O
an	O
effective	O
targeted	O
approach	O
to	O
treatment	O
.	O
	
In	O
this	O
open-label	O
phase	O
II	O
study	O
","	O
the	O
mTOR	O
inhibitor	O
Ridaforolimus	B-DRUG
was	O
administered	O
at	O
a	O
dose	O
of	O
50	O
mg	O
intravenous	O
once	O
weekly	O
to	O
38	O
patients	O
with	O
taxane-treated	B-DRUG
CRPC	B-CANCER
.	O
	
The	O
primary	O
end	O
point	O
was	O
best	O
overall	O
response	O
according	O
to	O
modified	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	B-CANCER
Tumors	I-CANCER
guidelines	O
.	O
	
Serum	O
prostate-specific	O
antigen	O
levels	O
were	O
prospectively	O
monitored	O
as	O
a	O
biomarker	O
for	O
cancer	O
activity	O
.	O
	
No	O
objective	O
responses	O
were	O
observed	O
","	O
but	O
18	O
patients	O
(	O
47.4	O
%	O
)	O
had	O
stable	O
disease	O
as	O
their	O
best	O
response	O
.	O
	
Based	O
on	O
progression-free	O
survival	O
analysis	O
","	O
median	O
time	O
to	O
progression	O
with	O
Ridaforolimus	B-DRUG
was	O
28	O
days	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
27-29	O
)	O
.	O
	
Eight	O
patients	O
(	O
21.1	O
%	O
)	O
had	O
stable	O
disease	O
as	O
their	O
best	O
overall	O
prostate-specific	O
antigen	O
response	O
.	O
	
The	O
median	O
number	O
of	O
days	O
from	O
first	O
to	O
last	O
dose	O
was	O
109.5	O
days	O
(	O
range	O
","	O
1-442	O
days	O
)	O
.	O
	
Ridaforolimus	B-DRUG
was	O
generally	O
well	O
tolerated	O
","	O
with	O
a	O
safety	O
profile	O
similar	O
to	O
that	O
observed	O
in	O
patients	O
with	O
advanced	B-CANCER
malignancies	I-CANCER
.	O
	
The	O
most	O
common	O
side	O
effects	O
were	O
typically	O
mild	O
or	O
moderate	O
in	O
severity	O
.	O
	
Ridaforolimus	B-DRUG
was	O
generally	O
well	O
tolerated	O
.	O
	
Treatment	O
did	O
not	O
produce	O
objective	O
responses	O
","	O
but	O
stable	O
disease	O
was	O
observed	O
in	O
some	O
patients	O
with	O
taxane-treated	B-DRUG
CRPC	B-CANCER
.	O
	
Alternative	O
treatment	O
regimens	O
","	O
such	O
as	O
combination	O
therapy	O
with	O
a	O
taxane	B-DRUG
or	O
in	O
a	O
maintenance	O
treatment	O
paradigm	O
","	O
should	O
be	O
considered	O
for	O
further	O
evaluation	O
in	O
this	O
patient	O
population	O
.	O
	
Phase	O
I	O
study	O
of	O
cetuximab	B-DRUG
","	O
irinotecan	B-DRUG
","	O
and	O
vandetanib	B-DRUG
(	O
ZD6474	O
)	O
as	O
therapy	O
for	O
patients	O
with	O
previously	O
treated	O
metastastic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
safety	O
","	O
and	O
explore	O
efficacy	O
and	O
biomarkers	O
of	O
vandetanib	B-DRUG
with	O
cetuximab	B-DRUG
and	O
irinotecan	B-DRUG
in	O
second-line	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Vandetanib	B-DRUG
(	O
an	O
orally	O
bioavailable	O
VEGFR-2	O
and	O
EGFR	O
tyrosine	O
kinases	O
inhibitor	O
)	O
was	O
combined	O
at	O
100	O
mg	O
","	O
200	O
mg	O
","	O
or	O
300	O
mg	O
daily	O
with	O
standard	O
dosed	O
cetuximab	B-DRUG
and	O
irinotecan	B-DRUG
(	O
3+3	O
dose-escalation	O
design	O
)	O
.	O
	
Ten	O
patients	O
were	O
treated	O
at	O
the	O
MTD	O
and	O
plasma	O
angiogenesis	O
biomarkers	O
(	O
VEGF	O
","	O
PlGF	O
","	O
bFGF	O
","	O
sVEGFR1	O
","	O
sVEGFR2	O
","	O
IL-1尾	O
","	O
IL-6	O
","	O
IL-8	O
","	O
TNF-伪	O
","	O
SDF1伪	O
)	O
were	O
measured	O
before	O
and	O
after	O
treatment	O
.	O
	
Twenty-seven	O
patients	O
were	O
enrolled	O
at	O
4	O
dose	O
levels	O
and	O
the	O
MTD	O
.	O
	
Two	O
dose-limiting	O
toxicities	O
(	O
grade	O
3	O
QTc	O
prolongation	B-TOXI
and	O
diarrhea	B-TOXI
)	O
were	O
detected	O
at	O
300	O
mg	O
of	O
vandetanib	B-DRUG
with	O
cetuximab	B-DRUG
and	O
irinotecan	B-DRUG
resulting	O
in	O
200	O
mg	O
being	O
the	O
MTD	O
.	O
	
Seven	O
percent	O
of	O
patients	O
had	O
a	O
partial	O
response	O
","	O
59	O
%	O
stable	O
disease	O
and	O
34	O
%	O
progressed	O
.	O
	
Median	O
progression-free	O
survival	O
was	O
3.6	O
months	O
(	O
95	O
%	O
CI	O
","	O
3.2-5.6	O
)	O
and	O
median	O
overall	O
survival	O
was	O
10.5	O
months	O
(	O
95	O
%	O
CI	O
","	O
5.1-20.7	O
)	O
.	O
	
Toxicities	O
were	O
fairly	O
manageable	O
with	O
grade	O
3	O
or	O
4	O
diarrhea	B-TOXI
being	O
most	O
prominent	O
(	O
30	O
%	O
)	O
.	O
	
Vandetanib	B-DRUG
and	O
cetuximab	B-DRUG
treatment	O
induced	O
a	O
sustained	O
increase	O
in	O
plasma	O
PlGF	O
and	O
a	O
transient	O
decrease	O
in	O
plasma	O
sVEGFR1	O
","	O
but	O
no	O
changes	O
in	O
plasma	O
VEGF	O
and	O
sVEGFR2	O
.	O
	
Vandetanib	B-DRUG
can	O
be	O
safely	O
combined	O
with	O
cetuximab	B-DRUG
and	O
irinotecan	B-DRUG
for	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Exploratory	O
biomarker	O
analyses	O
suggest	O
differential	O
effects	O
on	O
certain	O
plasma	O
biomarkers	O
for	O
VEGFR	O
inhibition	O
when	O
combined	O
with	O
EGFR	O
blockade	O
and	O
a	O
potential	O
correlation	O
between	O
baseline	O
sVEGFR1	O
and	O
response	O
.	O
	
However	O
","	O
while	O
the	O
primary	O
endpoint	O
was	O
safety	O
","	O
the	O
observed	O
efficacy	O
raises	O
concern	O
for	O
moving	O
forward	O
with	O
this	O
combination	O
.	O
	
Clinicaltrials.gov	O
NCT00436072	O
.	O
	
A	O
Phase	O
II	O
Study	O
of	O
Docetaxel	B-DRUG
","	O
Cisplatin	B-DRUG
and	O
-5	B-DRUG
Fluorouracil	I-DRUG
(	O
TPF	B-DRUG
)	O
In	O
Patients	O
with	O
Locally	B-CANCER
Advanced	I-CANCER
Head	I-CANCER
and	I-CANCER
Neck	I-CANCER
Carcinomas	I-CANCER
.	O
	
	
The	O
combination	O
of	O
cisplatin	B-DRUG
and	O
5-fluorouracil	B-DRUG
(	O
PF	B-DRUG
)	O
is	O
currently	O
considered	O
a	O
standard	O
and	O
effective	O
regimen	O
for	O
the	O
treatment	O
of	O
advanced	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
carcinomas	I-CANCER
.	O
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
docetaxel	B-DRUG
","	O
cisplatin	B-DRUG
and	O
5-fluorouracil	B-DRUG
(	O
TPF	B-DRUG
)	O
in	O
patients	O
with	O
unresectable	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
carcinomas	I-CANCER
.	O
	
Forty-six	O
patients	O
with	O
previously	O
untreated	O
non-metastatic	O
stage	O
IV	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
carcinomas	I-CANCER
were	O
enrolled	O
.	O
	
All	O
patients	O
received	O
three	O
cycles	O
of	O
induction	O
chemotherapy	O
with	O
docetaxel	B-DRUG
(	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
cisplatin	B-DRUG
(	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
(	O
days	O
1月2日	O
)	O
","	O
and	O
5-FU	B-DRUG
(	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
days	O
1月3日	O
)	O
","	O
repeated	O
every	O
21	O
days	O
.	O
	
Following	O
induction	O
chemotherapy	O
","	O
all	O
patients	O
underwent	O
concurrent	O
chemoradiotherapy	O
using	O
weekly	O
cisplatin	B-DRUG
(	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
a	O
median	O
total	O
dose	O
of	O
70	O
Gy	O
was	O
delivered	O
.	O
	
Clinical	O
response	O
rate	O
and	O
toxicity	O
were	O
the	O
primary	O
and	O
secondary	O
end-points	O
of	O
the	O
study	O
.	O
	
There	O
were	O
31	O
men	O
and	O
15	O
women	O
.	O
	
All	O
patients	O
had	O
non-metastatic	O
stage	O
IV	O
(	O
T2-3N2-3	O
or	O
T4N0-3	O
)	O
of	O
disease	O
.	O
	
Overall	O
and	O
complete	O
response	O
rates	O
were	O
74	O
%	O
and	O
24	O
%	O
respectively	O
.	O
	
Advanced	O
T4	O
classification	O
was	O
associated	O
with	O
poorer	O
response	O
rate	O
(	O
p	O
value=0.042	O
)	O
.	O
	
The	O
major	O
(	O
grade	O
3月4日	O
)	O
treatment-related	O
toxicities	O
were	O
myelosuppression	B-TOXI
(	O
78	O
%	O
)	O
","	O
anorexia	B-TOXI
(	O
13	O
%	O
)	O
","	O
diarrhea	B-TOXI
(	O
7	O
%	O
)	O
","	O
emesis	B-TOXI
(	O
11	O
%	O
)	O
and	O
stomatitis	B-TOXI
/	O
pharyngitis	B-TOXI
(	O
24	O
%	O
)	O
.	O
	
In	O
comparison	O
with	O
the	O
data	O
of	O
historical	O
published	O
trials	O
of	O
the	O
PF	B-DRUG
regimen	O
","	O
the	O
TPF	B-DRUG
regimen	O
was	O
more	O
effective	O
.	O
	
However	O
","	O
the	O
TPF	B-DRUG
regimen	O
appears	O
to	O
be	O
associated	O
with	O
a	O
higher	O
incidence	O
of	O
major	O
toxicities	O
.	O
	
Therefore	O
","	O
our	O
limited	O
findings	O
support	O
the	O
TPF	B-DRUG
regimen	O
as	O
an	O
alternative	O
chemotherapeutic	O
regimen	O
for	O
advanced	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
carcinomas	I-CANCER
.	O
	
Phase	O
I	O
study	O
of	O
bevacizumab	B-DRUG
","	O
everolimus	B-DRUG
","	O
and	O
panobinostat	B-DRUG
(	O
LBH-589	O
)	O
in	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
To	O
define	O
the	O
maximum	O
tolerated	O
dose	O
","	O
clinical	O
toxicities	O
","	O
and	O
pharmacodynamics	O
of	O
bevacizumab	B-DRUG
","	O
everolimus	B-DRUG
","	O
and	O
panobinostat	B-DRUG
(	O
LBH-589	O
)	O
when	O
administered	O
in	O
combination	O
to	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumor	I-CANCER
malignancies	I-CANCER
.	O
	
Subjects	O
received	O
10	O
mg	O
of	O
panobinostat	B-DRUG
three	O
times	O
weekly	O
","	O
5	O
or	O
10	O
mg	O
everolimus	B-DRUG
daily	O
","	O
and	O
bevacizumab	B-DRUG
at	O
10	O
mg	O
/	O
kg	O
every	O
2	O
weeks	O
.	O
	
Dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
were	O
assessed	O
in	O
cycle	O
1	O
;	O
toxicity	O
evaluation	O
was	O
closely	O
monitored	O
throughout	O
treatment	O
.	O
	
Treatment	O
continued	O
until	O
disease	O
progression	O
or	O
undesirable	O
toxicity	O
.	O
	
Protein	O
acetylation	O
was	O
assessed	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
both	O
at	O
baseline	O
and	O
on	O
treatment	O
.	O
	
Twelve	O
subjects	O
were	O
evaluable	O
for	O
toxicity	O
and	O
nine	O
subjects	O
for	O
response	O
.	O
	
DLTs	O
in	O
cohort	O
1	O
included	O
grade	O
2	O
esophagitis	B-TOXI
and	O
grade	O
3	O
oral	B-TOXI
mucositis	I-TOXI
;	O
DLTs	O
in	O
cohort	O
-1	O
were	O
grade	O
2	O
ventricular	B-TOXI
arrhythmia	I-TOXI
and	O
grade	O
2	O
intolerable	B-TOXI
skin	I-TOXI
rash	I-TOXI
.	O
	
Common	O
adverse	O
events	O
were	O
diarrhea	B-TOXI
(	O
50	O
%	O
)	O
","	O
headache	B-TOXI
(	O
33	O
%	O
)	O
","	O
mucositis	B-TOXI
/	O
stomatitis	B-TOXI
(	O
25	O
%	O
)	O
","	O
hyperlipidemia	B-TOXI
(	O
25	O
%	O
)	O
","	O
and	O
thrombocytopenia	B-TOXI
(	O
25	O
%	O
)	O
.	O
	
There	O
was	O
1	O
partial	O
response	O
;	O
an	O
additional	O
2	O
subjects	O
had	O
stable	O
disease	O
as	O
best	O
response	O
.	O
	
No	O
consistent	O
changes	O
in	O
protein	O
acetylation	O
in	O
PBMC	B-CANCER
were	O
observed	O
in	O
samples	O
available	O
from	O
eight	O
patients	O
on	O
treatment	O
compared	O
with	O
baseline	O
.	O
	
Bevacizumab	B-DRUG
","	O
everolimus	B-DRUG
","	O
and	O
panobinostat	B-DRUG
in	O
combination	O
at	O
the	O
lowest	O
proposed	O
doses	O
did	O
not	O
have	O
an	O
acceptable	O
safety	O
and	O
tolerability	O
profile	O
and	O
did	O
not	O
consistently	O
inhibit	O
HDAC	O
activity	O
;	O
therefore	O
","	O
we	O
do	O
not	O
recommend	O
further	O
evaluation	O
.	O
	
International	O
","	O
randomized	O
","	O
placebo-controlled	B-DRUG
","	O
double-blind	O
phase	O
III	O
study	O
of	O
motesanib	B-DRUG
plus	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
nonsquamous	I-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
MONET1	O
.	O
	
	
We	O
evaluated	O
whether	O
motesanib	B-DRUG
(	O
a	O
selective	O
oral	O
inhibitor	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptors	O
1	O
","	O
2	O
","	O
and	O
3	O
;	O
platelet-derived	O
growth	O
factor	O
receptor	O
;	O
and	O
Kit	O
)	O
combined	O
with	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
improved	O
overall	O
survival	O
(	O
OS	O
)	O
versus	O
chemotherapy	O
alone	O
in	O
patients	O
with	O
nonsquamous	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
and	O
in	O
the	O
subset	O
of	O
patients	O
with	O
adenocarcinoma	B-CANCER
.	O
	
Patients	O
with	O
stage	O
IIIB	O
/	O
IV	O
or	O
recurrent	O
nonsquamous	B-CANCER
NSCLC	I-CANCER
(	O
no	O
prior	O
systemic	O
therapy	O
for	O
advanced	O
disease	O
)	O
were	O
randomly	O
assigned	O
01:01	O
to	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
","	O
6	O
mg	O
/	O
ml	O
路	O
min	O
)	O
and	O
paclitaxel	B-DRUG
(	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
intravenously	O
for	O
up	O
to	O
six	O
3-week	O
cycles	O
plus	O
either	O
motesanib	B-DRUG
125	O
mg	O
(	O
arm	O
A	O
)	O
or	O
placebo	B-DRUG
(	O
arm	O
B	O
)	O
once	O
daily	O
orally	O
.	O
	
OS	O
was	O
the	O
primary	O
end	O
point	O
.	O
	
Secondary	O
end	O
points	O
included	O
progression-free	O
survival	O
(	O
PFS	O
)	O
","	O
objective	O
response	O
rate	O
(	O
ORR	O
)	O
","	O
adverse	O
events	O
(	O
AEs	O
)	O
","	O
and	O
association	O
between	O
placental	O
growth	O
factor	O
(	O
PLGF	O
)	O
change	O
and	O
OS	O
.	O
	
A	O
total	O
of	O
"1,090"	O
patients	O
with	O
nonsquamous	B-CANCER
NSCLC	I-CANCER
were	O
randomly	O
assigned	O
(	O
arms	O
A	O
/	O
B	O
","	O
n	O
=	O
541	O
of	O
549	O
)	O
;	O
of	O
those	O
","	O
890	O
had	O
adenocarcinoma	B-CANCER
(	O
n	O
=	O
448	O
of	O
442	O
)	O
.	O
	
Median	O
OS	O
in	O
arms	O
A	O
and	O
B	O
was	O
13	O
and	O
11	O
months	O
","	O
respectively	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
","	O
0.9	O
;	O
95	O
%	O
CI	O
","	O
0.78	O
to	O
1.04	O
;	O
P	O
=	O
0.14	O
)	O
;	O
median	O
OS	O
for	O
the	O
adenocarcinoma	B-CANCER
subset	O
was	O
13.5	O
and	O
11	O
months	O
","	O
respectively	O
(	O
HR	O
","	O
0.88	O
;	O
95	O
%	O
CI	O
","	O
0.75	O
to	O
1.03	O
;	O
P	O
=	O
0.11	O
)	O
.	O
	
In	O
descriptive	O
analyses	O
(	O
arms	O
A	O
v	O
B	O
)	O
","	O
median	O
PFS	O
was	O
5.6	O
months	O
versus	O
5.4	O
months	O
(	O
P	O
=	O
&	O
lt	O
;	O
0.001	O
)	O
;	O
ORR	O
was	O
40	O
%	O
versus	O
26	O
%	O
(	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
.	O
	
There	O
was	O
no	O
association	O
between	O
PLGF	O
change	O
and	O
OS	O
in	O
arm	O
A.	O
The	O
incidence	O
of	O
grade	O
_	O
3	O
AEs	O
(	O
arms	O
A	O
and	O
B	O
","	O
73	O
%	O
and	O
59	O
%	O
","	O
respectively	O
)	O
and	O
grade	O
5	O
AEs	O
(	O
14	O
%	O
and	O
9	O
%	O
","	O
respectively	O
)	O
was	O
higher	O
with	O
motesanib	B-DRUG
treatment	O
.	O
	
Motesanib	B-DRUG
plus	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
did	O
not	O
significantly	O
improve	O
OS	O
over	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
alone	O
in	O
patients	O
with	O
advanced	B-CANCER
nonsquamous	I-CANCER
NSCLC	I-CANCER
or	O
in	O
the	O
adenocarcinoma	B-CANCER
subset	O
.	O
	
Vinorelbine	B-DRUG
and	O
gemcitabine	B-DRUG
vs	O
vinorelbine	B-DRUG
and	O
carboplatin	B-DRUG
as	O
first-line	O
treatment	O
of	O
advanced	B-CANCER
NSCLC.	I-CANCER
A	O
phase	O
III	O
randomised	O
controlled	O
trial	O
by	O
the	O
Norwegian	O
Lung	B-CANCER
Cancer	I-CANCER
Study	O
Group	O
.	O
	
	
Platinum-based	B-DRUG
doublet	O
chemotherapy	O
is	O
the	O
standard	O
first-line	O
treatment	O
for	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
","	O
but	O
earlier	O
studies	O
have	O
suggested	O
that	O
non-platinum	B-DRUG
combinations	O
are	O
equally	O
effective	O
and	O
better	O
tolerated	O
.	O
	
We	O
conducted	O
a	O
national	O
","	O
randomised	O
study	O
to	O
compare	O
a	O
non-platinum	O
with	O
a	O
platinum	B-DRUG
combination	O
.	O
	
Eligible	O
patients	O
had	O
stage	O
IIIB	O
/	O
IV	O
NSCLC	B-CANCER
and	O
performance	O
status	O
(	O
PS	O
)	O
0-2	O
.	O
	
Patients	O
received	O
up	O
to	O
three	O
cycles	O
of	O
vinorelbine	B-DRUG
60	O
mg	O
m	O
(	O
-2	O
)	O
p.o.+gemcitabine	B-DRUG
1000	O
mg	O
m	O
(	O
-2	O
)	O
i.v.	O
day	O
1	O
and	O
8	O
(	O
VG	O
)	O
or	O
vinorelbine	B-DRUG
60	O
mg	O
m	O
(	O
-2	O
)	O
p.o.	O
day	O
1	O
and	O
8+carboplatin	B-DRUG
area	O
under	O
the	O
curve=5	O
(	O
Calvert	O
's	O
formula	O
)	O
i.v.	O
day	O
1	O
(	O
VC	O
)	O
.	O
	
Patients	O
_75	O
years	O
received	O
75	O
%	O
of	O
the	O
dose	O
.	O
	
Endpoints	O
were	O
overall	O
survival	O
","	O
health-related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
","	O
toxicity	O
","	O
and	O
the	O
use	O
of	O
radiotherapy	O
.	O
	
We	O
randomised	O
444	O
patients	O
from	O
September	O
2007	O
to	O
April	O
2009	O
.	O
	
The	O
median	O
age	O
was	O
65	O
years	O
","	O
58	O
%	O
were	O
men	O
and	O
25	O
%	O
had	O
PS	O
2	O
Median	O
survival	O
was	O
VG	O
:	O
6.3	O
months	O
;	O
VC	O
:	O
7	O
months	O
","	O
P=0.802	O
.	O
	
Vinorelbine	B-DRUG
plus	O
carboplatin	B-DRUG
patients	O
had	O
more	O
grade	O
III	O
/	O
IV	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
(	O
VG	O
:	O
4	O
%	O
","	O
VC	O
:	O
12	O
%	O
","	O
P=0.008	O
)	O
and	O
grade	O
IV	O
neutropenia	B-TOXI
(	O
VG	O
:	O
7	O
%	O
","	O
VC	O
:	O
19	O
%	O
","	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
.	O
	
Infections	B-TOXI
","	O
HRQoL	O
and	O
the	O
use	O
of	O
radiotherapy	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
treatment	O
groups	O
.	O
	
The	O
two	O
regimens	O
yielded	O
similar	O
overall	O
survival	O
.	O
	
The	O
VG	O
combination	O
had	O
only	O
a	O
slightly	O
better	O
toxicity	O
profile	O
.	O
	
VEGF	O
remains	O
an	O
interesting	O
target	O
in	O
advanced	B-CANCER
pancreas	I-CANCER
cancer	I-CANCER
(	O
APCA	B-CANCER
)	O
:	O
results	O
of	O
a	O
multi-institutional	O
phase	O
II	O
study	O
of	O
bevacizumab	B-DRUG
","	O
gemcitabine	B-DRUG
","	O
and	O
infusional	B-DRUG
5-fluorouracil	I-DRUG
in	O
patients	O
with	O
APCA	B-CANCER
.	O
	
	
We	O
investigated	O
the	O
safety	O
and	O
efficacy	O
of	O
bevacizumab	B-DRUG
combined	O
with	O
gemcitabine	B-DRUG
followed	O
by	O
infusional	B-DRUG
5-fluorouracil	I-DRUG
(	O
5-FU	B-DRUG
)	O
in	O
patients	O
with	O
advanced	B-CANCER
pancreas	I-CANCER
cancer	I-CANCER
(	O
APCA	B-CANCER
)	O
.	O
	
Patients	O
with	O
untreated	O
APCA	B-CANCER
received	O
bevacizumab	B-DRUG
10	O
mg	O
/	O
kg	O
","	O
gemcitabine	B-DRUG
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
over	O
100	O
min	O
","	O
and	O
5-FU	B-DRUG
2400	O
mg	O
/	O
m	O
(	O
2	O
)	O
over	O
48	O
h	O
on	O
days	O
1	O
and	O
15	O
of	O
each	O
28-day	O
cycle	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
the	O
proportion	O
of	O
patients	O
with	O
progression-free	O
survival	O
(	O
PFS	O
)	O
at	O
6	O
months	O
from	O
initiation	B-DRUG
of	O
therapy	O
.	O
	
If	O
PFS	O
at	O
6	O
months	O
was	O
_41	O
%	O
","	O
the	O
regimen	O
would	O
be	O
considered	O
promising	O
.	O
	
Forty-two	O
patients	O
were	O
enrolled	O
in	O
the	O
study	O
;	O
of	O
which	O
","	O
39	O
were	O
evaluable	O
for	O
primary	O
end	O
point	O
.	O
	
PFS	O
at	O
6	O
months	O
was	O
49	O
%	O
(	O
95	O
%	O
CI	O
34	O
%	O
to	O
64	O
%	O
)	O
.	O
	
Median	O
PFS	O
was	O
5.9	O
months	O
(	O
95	O
%	O
CI	O
3.5	O
to	O
8.1	O
)	O
and	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
7.4	O
months	O
(	O
95	O
%	O
CI	O
4.7	O
to	O
11.2	O
)	O
.	O
	
Partial	O
response	O
and	O
stable	O
disease	O
occurred	O
in	O
30	O
%	O
and	O
45	O
%	O
of	O
patients	O
","	O
respectively	O
.	O
	
Treatment-related	O
hypertension	B-TOXI
and	O
normal	O
baseline	O
albumin	O
correlated	O
with	O
an	O
improved	O
response	O
rate	O
","	O
PFS	O
and	O
OS	O
.	O
	
Grade	O
3	O
to	O
4	O
toxicities	O
included	O
fatigue	B-TOXI
(	O
14	O
%	O
)	O
","	O
hypertension	B-TOXI
(	O
5	O
%	O
)	O
","	O
and	O
venous	B-TOXI
thrombosis	I-TOXI
(	O
5	O
%	O
)	O
.	O
	
The	O
study	O
met	O
its	O
primary	O
end	O
point	O
.	O
	
Further	O
investigation	O
of	O
anti-VEGF	O
therapy	O
in	O
combination	O
with	O
fluoropyrimidine-based	B-DRUG
therapy	O
is	O
warranted	O
in	O
APCA	B-CANCER
.	O
	
Treatment-related	O
hypertension	B-TOXI
and	O
normal	O
baseline	O
albumin	O
may	O
predict	O
for	O
the	O
efficacy	O
of	O
bevacizumab	B-TOXI
and	O
should	O
be	O
investigated	O
in	O
prospective	O
studies	O
.	O
	
Phase	O
II	O
study	O
of	O
palliative	O
S-1	B-DRUG
in	O
combination	O
with	O
cisplatin	B-DRUG
as	O
second-line	O
chemotherapy	O
for	O
gemcitabine-refractory	B-DRUG
pancreatic	B-CANCER
cancer	I-CANCER
patients	O
.	O
	
	
In	O
this	O
study	O
","	O
we	O
examined	O
the	O
efficacy	O
and	O
toxicity	O
of	O
S-1	B-DRUG
with	O
cisplatin	B-DRUG
as	O
a	O
second-line	O
palliative	O
chemotherapy	O
for	O
gemcitabine-refractory	B-DRUG
pancreatic	B-CANCER
cancer	I-CANCER
patients	O
.	O
	
Patients	O
who	O
had	O
been	O
previously	O
treated	O
with	O
gemcitabine-based	B-DRUG
chemotherapy	O
as	O
palliative	O
first-line	O
chemotherapy	O
received	O
S-1	B-DRUG
/	O
cisplatin	B-DRUG
[	O
body	O
surface	O
area	O
(	O
BSA	O
)	O
&	O
lt	O
;	O
1.25	O
m	O
(	O
2	O
)	O
","	O
S-1	O
40	O
mg	O
/	O
day	O
;	O
BSA	O
_1.25	O
to	O
&	O
lt	O
;	O
1.5	O
m	O
(	O
2	O
)	O
","	O
50	O
mg	O
/	O
day	O
;	O
BSA	O
_1.5	O
m	O
(	O
2	O
)	O
60	O
mg	O
/	O
day	O
","	O
orally	O
","	O
bid	O
","	O
daily	O
on	O
days	O
1月14日	O
followed	O
by	O
a	O
7-day	O
washout	O
and	O
cisplatin	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
intravenously	O
on	O
day	O
1	O
]	O
every	O
three	O
weeks	O
.	O
	
The	O
enrollment	O
of	O
32	O
patients	O
was	O
planned	O
","	O
but	O
the	O
study	O
was	O
terminated	O
early	O
","	O
prior	O
to	O
the	O
first	O
stage	O
","	O
following	O
the	O
enrollment	O
of	O
11	O
patients	O
.	O
	
The	O
median	O
age	O
of	O
the	O
patients	O
was	O
56	O
(	O
range	O
","	O
42-74	O
)	O
years	O
.	O
	
Nine	O
patients	O
had	O
a	O
performance	O
status	O
(	O
PS	O
)	O
of	O
one	O
.	O
	
In	O
total	O
","	O
there	O
were	O
21	O
chemotherapy	O
cycles	O
and	O
the	O
median	O
treatment	O
duration	O
was	O
21	O
(	O
range	O
","	O
7-96	O
)	O
days	O
.	O
	
Of	O
the	O
11	O
patients	O
","	O
five	O
could	O
not	O
be	O
evaluated	O
due	O
to	O
discontinuation	O
prior	O
to	O
the	O
response	O
evaluation	O
.	O
	
One	O
of	O
the	O
six	O
evaluable	O
patients	O
achieved	O
stable	O
disease	O
(	O
9.1	O
%	O
in	O
intention	O
to	O
treat	O
analysis	O
and	O
16.7	O
%	O
in	O
per-protocol	O
analysis	O
)	O
","	O
while	O
five	O
had	O
progressive	O
disease	O
.	O
	
Grade	O
3月4日	O
hematological	B-TOXI
toxicities	I-TOXI
were	O
anemia	B-TOXI
in	O
one	O
","	O
neutropenia	B-TOXI
in	O
one	O
and	O
thrombocytopenia	B-TOXI
in	O
one	O
cycle	O
.	O
	
Grade	O
3月4日	O
nonhematological	B-TOXI
toxicities	I-TOXI
were	O
fatigue	B-TOXI
in	O
three	O
","	O
nausea	B-TOXI
in	O
four	O
","	O
anorexia	B-TOXI
in	O
two	O
","	O
diarrhea	B-TOXI
in	O
one	O
and	O
peripheral	B-TOXI
neuropathy	I-TOXI
in	O
two	O
cycles	O
.	O
	
With	O
a	O
median	O
follow-up	O
period	O
of	O
8.9	O
(	O
range	O
","	O
3.2-11.3	O
)	O
months	O
","	O
the	O
median	O
time	O
to	O
progression	O
was	O
44	O
days	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
25.4-62.6	O
]	O
and	O
the	O
median	O
overall	O
survival	O
was	O
81	O
days	O
(	O
95	O
%	O
CI	O
9.3-152.7	O
)	O
.	O
	
Combination	O
chemotherapy	O
with	O
S-1	B-DRUG
and	O
cisplatin	B-DRUG
as	O
applied	O
in	O
this	O
study	O
did	O
not	O
result	O
in	O
promising	O
antitumor	O
activity	O
","	O
a	O
high	O
degree	O
of	O
toxicity	O
and	O
poor	O
compliance	O
.	O
	
Phase	O
I	O
study	O
investigating	O
the	O
safety	O
and	O
feasibility	O
of	O
combining	O
imatinib	B-DRUG
mesylate	I-DRUG
(	O
Gleevec	B-DRUG
)	O
with	O
sorafenib	B-DRUG
in	O
patients	O
with	O
refractory	O
castration-resistant	O
prostate	B-CANCER
cancer	I-CANCER
.	O
	
	
Determining	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
the	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
of	O
sorafenib	B-DRUG
(	O
S	O
)	O
plus	O
imatinib	B-DRUG
(	O
IM	O
)	O
in	O
castration-resistant	B-CANCER
prostate	I-CANCER
cancer	I-CANCER
(	O
CRPC	B-CANCER
)	O
patients	O
.	O
	
Refractory	O
CRPC	B-CANCER
patients	O
were	O
enrolled	O
onto	O
this	O
3+3	O
dose	O
escalation	O
designed	O
study	O
.	O
	
Imatinib	B-DRUG
pharmacokinetics	O
(	O
PK	O
)	O
were	O
determined	O
on	O
day	O
15	O
","	O
4	O
h	O
post	O
dose	O
with	O
a	O
validated	O
LC-MS	O
assay	O
.	O
	
Seventeen	O
patients	O
were	O
enrolled	O
;	O
10	O
evaluable	O
(	O
6	O
at	O
400	O
mg	O
S	O
qd	O
with	O
300	O
mg	O
IM	O
qd	O
(	O
DL0	O
)	O
and	O
4	O
at	O
400	O
mg	O
S	O
bid	O
with	O
300	O
mg	O
IM	O
qd	O
(	O
DL1	O
)	O
)	O
;	O
inevaluable	O
patients	O
received	O
&	O
lt	O
;	O
1	O
cycle	O
.	O
	
The	O
median	O
age	O
was	O
73	O
(	O
57-89	O
)	O
;	O
median	O
prostatic	O
serum	O
antigen	O
was	O
284	O
ng	O
ml	O
(	O
-1	O
)	O
(	O
11.7-9027	O
)	O
.	O
	
Median	O
number	O
of	O
prior	O
non-hormonal	O
therapies	O
was	O
3	O
(	O
1月12日	O
)	O
.	O
	
Dose-limiting	O
toxicities	O
were	O
diarrhoea	B-TOXI
and	O
hand-foot	B-TOXI
syndrome	I-TOXI
.	O
	
Maximum	O
tolerated	O
dose	O
was	O
400	O
mg	O
S	O
and	O
300	O
mg	O
IM	O
both	O
daily	O
.	O
	
No	O
biochemical	O
responses	O
were	O
observed	O
.	O
	
Two	O
patients	O
had	O
stable	O
disease	O
by	O
RECIST	O
.	O
	
Median	O
time	O
to	O
progression	O
was	O
2	O
months	O
(	O
1月5日	O
)	O
.	O
	
Median	O
OS	O
was	O
6	O
months	O
(	O
1-30+	O
)	O
with	O
3	O
/	O
17	O
patients	O
(	O
17	O
%	O
)	O
alive	O
at	O
21	O
months	O
median	O
follow-up	O
.	O
	
Ten	O
patients	O
had	O
PK	O
data	O
suggesting	O
that	O
S	O
reduced	O
IM	O
clearance	O
by	O
55	O
%	O
","	O
resulting	O
in	O
77	O
%	O
increased	O
exposure	O
(	O
P=0.005	O
;	O
compared	O
with	O
historical	O
data	O
)	O
.	O
	
This	O
is	O
the	O
first	O
report	O
showing	O
that	O
S+IM	O
can	O
be	O
administered	O
in	O
CRPC	B-CANCER
at	O
a	O
dose	O
of	O
400	O
mg	O
S	O
and	O
300	O
mg	O
IM	O
","	O
daily	O
.	O
	
First-line	O
combination	O
of	O
gemcitabine	B-DRUG
","	O
oxaliplatin	B-DRUG
","	O
and	O
L-asparaginase	B-DRUG
(	O
GELOX	B-DRUG
)	O
followed	O
by	O
involved-field	O
radiation	O
therapy	O
for	O
patients	O
with	O
stage	O
IE	O
/	O
IIE	O
extranodal	O
natural	O
killer	O
/	O
T-cell	B-CANCER
lymphoma	I-CANCER
.	O
	
	
Extranodal	O
natural	O
killer	O
/	O
T-cell	B-CANCER
lymphoma	I-CANCER
","	O
nasal	O
type	O
(	O
ENKTL	B-CANCER
)	O
is	O
a	O
distinct	O
subtype	O
of	O
non-Hodgkin	B-CANCER
lymphoma	I-CANCER
in	O
which	O
the	O
upper	O
aerodigestive	O
tract	O
is	O
the	O
most	O
commonly	O
involved	O
site	O
.	O
	
To	O
date	O
","	O
optimal	O
treatment	O
strategies	O
and	O
prognosis	O
for	O
patients	O
with	O
ENKTL	B-CANCER
have	O
not	O
been	O
fully	O
defined	O
.	O
	
This	O
prospective	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
profiles	O
of	O
first-line	O
combined	O
gemcitabine	B-DRUG
","	O
oxaliplatin	B-DRUG
","	O
and	O
L-asparaginase	B-DRUG
(	O
GELOX	B-DRUG
)	O
followed	O
by	O
involved-field	O
radiation	O
therapy	O
for	O
patients	O
with	O
stage	O
IE	O
/	O
IIE	O
ENKTL	B-CANCER
.	O
	
The	O
primary	O
endpoints	O
were	O
the	O
complete	O
response	O
rate	O
","	O
the	O
objective	O
response	O
rate	O
","	O
and	O
toxicities	O
.	O
	
Secondary	O
endpoints	O
were	O
overall	O
survival	O
and	O
progression-free	O
survival	O
.	O
	
Twenty-seven	O
patients	O
with	O
newly	O
diagnosed	O
ENKTL	B-CANCER
were	O
enrolled	O
and	O
completed	O
the	O
entire	O
course	O
of	O
treatment	O
.	O
	
At	O
the	O
end	O
of	O
treatment	O
","	O
the	O
overall	O
response	O
rate	O
was	O
96.3	O
%	O
","	O
including	O
20	O
patients	O
(	O
74.1	O
%	O
)	O
who	O
attained	O
a	O
complete	O
response	O
and	O
6	O
patients	O
(	O
22.2	O
%	O
)	O
who	O
attained	O
a	O
partial	O
response	O
.	O
	
No	O
patients	O
developed	O
disease	O
progression	O
during	O
therapy	O
.	O
	
Grade	O
1	O
and	O
2	O
toxicities	O
were	O
frequent	O
during	O
GELOX	B-DRUG
","	O
but	O
grade	O
3	O
and	O
4	O
toxicities	O
were	O
few	O
","	O
and	O
no	B-TOXI
treatment-related	I-TOXI
deaths	I-TOXI
occurred	O
.	O
	
At	O
a	O
median	O
follow-up	O
of	O
27.37	O
months	O
","	O
7	O
patients	O
(	O
25.9	O
%	O
)	O
experienced	O
disease	O
progression	O
","	O
and	O
4	O
of	O
those	O
patients	O
died	B-TOXI
of	O
disease	O
.	O
	
The	O
rates	O
of	O
2-year	O
overall	O
and	O
progression-free	O
survival	O
were	O
both	O
86	O
%	O
","	O
and	O
patients	O
who	O
attained	O
a	O
complete	O
response	O
at	O
the	O
end	O
of	O
treatment	O
had	O
significantly	O
longer	O
progression-free	O
survival	O
(	O
P	O
=	O
0.012	O
)	O
and	O
overall	O
survival	O
(	O
P	O
=	O
0.021	O
)	O
than	O
patients	O
who	O
did	O
not	O
attain	O
a	O
complete	O
response	O
.	O
	
The	O
current	O
results	O
indicated	O
that	O
GELOX	B-DRUG
followed	O
by	O
involved-field	O
radiation	O
therapy	O
can	O
be	O
an	O
effective	O
and	O
feasible	O
treatment	O
strategy	O
for	O
patients	O
with	O
stage	O
IE	O
/	O
IIE	O
ENKTL	B-CANCER
of	O
the	O
upper	O
aerodigestive	O
tract	O
.	O
	
These	O
results	O
will	O
require	O
further	O
investigation	O
in	O
larger	O
prospective	O
trials	O
.	O
	
A	O
pilot	O
study	O
evaluating	O
the	O
safety	O
and	O
toxicity	O
of	O
epirubicin	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
UFT	B-DRUG
(	O
ECU	B-DRUG
regimen	I-DRUG
)	O
in	O
advanced	B-CANCER
gastric	I-CANCER
carcinoma	I-CANCER
.	O
	
	
Best	O
response	O
rates	O
have	O
been	O
achieved	O
with	O
three-drug	O
regimens	O
containing	O
5-FU	B-DRUG
in	O
the	O
treatment	O
of	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
(	O
AGC	B-CANCER
)	O
and	O
oral	B-DRUG
fluoropyrimidines	I-DRUG
are	O
the	O
best	O
alternatives	O
as	O
substitutes	O
for	O
infusional	B-DRUG
5-FU	I-DRUG
.	O
	
This	O
study	O
aimed	O
to	O
evaluate	O
the	O
safety	O
and	O
toxicity	O
of	O
epirubicin	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
UFT	B-DRUG
(	O
ECU	B-DRUG
regimen	I-DRUG
)	O
regimens	O
in	O
AGC	B-CANCER
outpatients	O
.	O
	
Forty-one	O
patients	O
with	O
AGC	B-CANCER
received	O
epirubicin	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
oral	B-DRUG
UFT	I-DRUG
plus	O
leucovorin	B-DRUG
.	O
	
Epirubicin	B-DRUG
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
cisplatin	B-DRUG
60mg	O
/	O
m	O
(	O
2	O
)	O
were	O
administered	O
on	O
Day	O
1	O
Three	O
hundreds	O
(	O
300	O
)	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
UFT	B-DRUG
was	O
administered	O
with	O
leucovorin	B-DRUG
at	O
a	O
fixed	O
oral	O
dose	O
of	O
90	O
mg	O
/	O
day	O
for	O
21	O
days	O
","	O
followed	O
by	O
a	O
7-day	O
rest	O
period	O
.	O
	
Cycles	O
were	O
repeated	O
every	O
4	O
weeks	O
.	O
	
Performance	O
status	O
was	O
either	O
as	O
0	O
and	O
1	O
Among	O
the	O
41	O
patients	O
enrolled	O
","	O
complete	O
and	O
partial	O
response	O
was	O
achieved	O
in	O
7.3	O
%	O
and	O
36.6	O
%	O
of	O
patients	O
","	O
respectively	O
","	O
with	O
an	O
overall	O
response	O
rate	O
of	O
43.9	O
%	O
.	O
	
Stable	O
disease	O
was	O
observed	O
in	O
34.1	O
%	O
of	O
patients	O
and	O
22	O
%	O
showed	O
disease	O
progression	O
.	O
	
Median	O
time	O
to	O
progression	O
was	O
5.2	O
months	O
and	O
median	O
survival	O
was	O
12.3	O
months	O
.	O
	
A	O
median	O
of	O
4	O
cycles	O
(	O
range	O
:	O
1月6日	O
)	O
of	O
chemotherapy	O
were	O
administered	O
.	O
	
The	O
main	O
grade	O
III-IV	O
toxicities	O
were	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
(	O
19.4	O
%	O
)	O
and	O
neutropenia	B-TOXI
(	O
12.1	O
%	O
)	O
.	O
	
Grade	O
IV	O
toxicities	O
were	O
gastric	B-TOXI
perforation	I-TOXI
and	O
renal	B-TOXI
failure	I-TOXI
.	O
	
ECU	O
appears	O
to	O
be	O
an	O
effective	O
regimen	O
in	O
the	O
treatment	O
of	O
AGC	B-CANCER
","	O
with	O
acceptable	O
tolerability	O
and	O
manageable	O
toxicity	O
.	O
	
In	O
three-drug	O
regimens	O
","	O
substitution	O
of	O
infusional	B-DRUG
5-FU	I-DRUG
by	O
UFT	B-DRUG
offers	O
the	O
possibility	O
of	O
increased	O
AGC	B-CANCER
outpatient	O
compliance	O
.	O
	
A	O
phase	O
I	O
trial	O
of	O
dasatinib	B-DRUG
","	O
an	O
SRC-family	O
kinase	O
inhibitor	O
","	O
in	O
combination	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
in	O
patients	O
with	O
advanced	O
or	O
recurrent	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
	
We	O
conducted	O
a	O
phase	O
I	O
study	O
of	O
dasatinib	B-DRUG
","	O
an	O
oral	O
SRC-family	O
tyrosine	O
kinase	O
inhibitor	O
","	O
in	O
combination	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
in	O
the	O
treatment	O
of	O
advanced	O
and	O
recurrent	O
epithelial	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
The	O
primary	O
objective	O
was	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
.	O
	
Secondary	O
objectives	O
included	O
defining	O
toxicity	O
","	O
response	O
rate	O
(	O
RR	O
)	O
","	O
pharmacokinetics	O
","	O
and	O
pharmacodynamics	O
.	O
	
Using	O
a	O
	O
design	O
","	O
cohorts	O
of	O
three	O
to	O
six	O
patients	O
received	O
paclitaxel	B-DRUG
(	O
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
carboplatin	B-DRUG
(	O
AUC	O
6	O
)	O
every	O
3	O
weeks	O
with	O
escalating	O
doses	O
of	O
dasatinib	B-DRUG
(	O
100	O
","	O
120	O
","	O
and	O
150	O
mg	O
daily	O
)	O
","	O
followed	O
by	O
an	O
eight-patient	O
expansion	O
cohort	O
.	O
	
Twenty	O
patients	O
were	O
enrolled	O
between	O
June	O
2007	O
and	O
December	O
2009	O
.	O
	
The	O
median	O
age	O
was	O
61	O
years	O
(	O
range	O
:	O
42-82	O
)	O
with	O
a	O
median	O
of	O
2	O
prior	O
regimens	O
(	O
range	O
:	O
0-6	O
)	O
","	O
and	O
71	O
%	O
had	O
platinum-sensitive	B-DRUG
disease	O
.	O
	
There	O
were	O
three	O
to	O
six	O
patients	O
in	O
each	O
cohort	O
","	O
and	O
eight	O
in	O
the	O
expansion	O
cohort	O
.	O
	
Pharmacokinetics	O
were	O
observed	O
over	O
the	O
first	O
two	O
cycles	O
of	O
therapy	O
.	O
	
One	O
DLT	O
was	O
observed	O
in	O
the	O
100	O
mg	O
dasatinib	B-DRUG
cohort	O
(	O
grade	O
3	O
myalgia	B-TOXI
)	O
.	O
	
Other	O
toxicities	O
in	O
all	O
cycles	O
included	O
neutropenia	B-TOXI
(	O
95	O
%	O
grade	O
3月4日	O
;	O
91	O
%	O
in	O
the	O
150	O
mg	O
dosing	O
cohort	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
35	O
%	O
grade	O
3月4日	O
)	O
","	O
and	O
fatigue	B-TOXI
(	O
10	O
%	O
grade	O
3	O
)	O
.	O
	
The	O
RR	O
was	O
40	O
%	O
[	O
three	O
complete	O
responses	O
","	O
(	O
15	O
%	O
)	O
;	O
five	O
partial	O
responses	O
","	O
(	O
25	O
%	O
)	O
]	O
",10"	O
patients	O
(	O
50	O
%	O
)	O
had	O
stable	O
disease	O
","	O
and	O
two	O
were	O
not	O
evaluable	O
.	O
	
The	O
PFS	O
(	O
6-month	O
)	O
actuarial	O
estimate	O
was	O
86	O
%	O
.	O
	
The	O
median	O
PFS	O
and	O
OS	O
were	O
7.8	O
and	O
16.2	O
months	O
","	O
respectively	O
.	O
	
Due	O
to	O
the	O
high	O
incidence	O
of	O
myelosuppression	B-TOXI
with	O
subsequent	O
cycles	O
","	O
the	O
recommended	O
phase	O
II	O
dose	O
of	O
dasatinib	B-DRUG
is	O
150	O
mg	O
daily	O
in	O
combination	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
.	O
	
The	O
combination	O
was	O
safe	O
with	O
evidence	O
of	O
clinical	O
activity	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
prolonged	O
infusion	O
of	O
triapine	B-DRUG
in	O
combination	O
with	O
fixed	O
dose	O
rate	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Prolonged	O
exposure	O
of	O
cancer	O
cells	O
to	O
triapine	B-DRUG
","	O
an	O
inhibitor	O
of	O
ribonucleotide	O
reductase	O
","	O
followed	O
by	O
gemcitabine	B-DRUG
enhances	O
gemcitabine	B-DRUG
activity	O
in	O
vitro	O
.	O
	
Fixed-dose-rate	O
gemcitabine	B-DRUG
(	O
FDR-G	O
)	O
has	O
improved	O
efficacy	O
compared	O
to	O
standard-dose	O
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
trial	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
safety	O
","	O
pharmacokinetics	O
(	O
PK	O
)	O
","	O
pharmacodynamics	O
(	O
PD	O
)	O
","	O
and	O
preliminary	O
efficacy	O
of	O
prolonged	O
triapine	O
infusion	O
followed	O
by	O
FDR-G	O
.	O
	
Triapine	B-DRUG
was	O
given	O
as	O
a	O
24-hour	O
infusion	O
","	O
immediately	O
followed	O
by	O
FDR-G	O
(	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
over	O
100-minute	O
)	O
.	O
	
Initially	O
","	O
this	O
combination	O
was	O
administered	O
days	O
1	O
and	O
8	O
of	O
a	O
21-day	O
cycle	O
(	O
Arm	O
A	O
","	O
triapine	B-DRUG
starting	O
dose	O
120	O
mg	O
)	O
;	O
but	O
because	O
of	O
myelosuppression	B-TOXI
","	O
it	O
was	O
changed	O
to	O
days	O
1	O
and	O
15	O
of	O
a	O
28-day	O
cycle	O
(	O
Arm	O
B	O
","	O
starting	O
dose	O
of	O
triapine	B-DRUG
75	O
mg	O
)	O
.	O
	
Triapine	B-DRUG
steady-state	O
concentrations	O
(	O
Css	O
)	O
and	O
circulating	O
ribonucleotide	O
reductase	O
M2-subunit	O
(	O
RRM2	O
)	O
were	O
measured	O
.	O
	
Thirty-six	O
patients	O
were	O
enrolled	O
.	O
	
The	O
MTD	O
was	O
determined	O
to	O
be	O
triapine	B-DRUG
90	O
mg	O
(	O
24-hour	O
infusion	O
)	O
immediately	O
followed	O
by	O
gemcitabine	B-DRUG
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
100-minute	O
infusion	O
)	O
","	O
every	O
2	O
weeks	O
of	O
a	O
4-week	O
cycle	O
.	O
	
DLTs	O
included	O
grade	O
4	O
thrombocytopenia	B-TOXI
","	O
leukopenia	B-TOXI
and	O
neutropenia	B-TOXI
.	O
	
The	O
treatment	O
was	O
well	O
tolerated	O
with	O
fatigue	B-TOXI
","	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
","	O
fever	B-TOXI
","	O
transaminitis	B-TOXI
","	O
and	O
cytopenias	B-TOXI
being	O
the	O
most	O
common	O
toxicities	O
.	O
	
Among	O
30	O
evaluable	O
patients	O
","	O
1	O
had	O
a	O
partial	O
response	O
and	O
15	O
had	O
stable	O
disease	O
.	O
	
Triapine	B-DRUG
PK	O
was	O
similar	O
","	O
although	O
more	O
variable	O
","	O
compared	O
to	O
previous	O
studies	O
using	O
doses	O
normalized	O
to	O
body-surface-area	O
.	O
	
Steady	O
decline	O
in	O
circulating	O
levels	O
of	O
RRM2	O
may	O
correlate	O
with	O
outcome	O
.	O
	
This	O
combination	O
was	O
well	O
tolerated	O
and	O
showed	O
evidence	O
of	O
preliminary	O
activity	O
in	O
this	O
heavily	O
pretreated	O
patient	O
population	O
","	O
including	O
prior	O
gemcitabine	B-DRUG
failure	O
.	O
	
Phase	O
I	O
pharmacokinetic	O
and	O
pharmacodynamic	O
study	O
of	O
the	O
pan-PI3K	O
/	O
mTORC	O
vascular	O
targeted	O
pro-drug	O
SF1126	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
and	O
B-cell	B-CANCER
malignancies	I-CANCER
.	O
	
	
SF1126	B-DRUG
is	O
a	O
peptidic	O
pro-drug	O
inhibitor	O
of	O
pan-PI3K	O
/	O
mTORC	O
.	O
	
A	O
first-in-human	O
study	O
evaluated	O
safety	O
","	O
dose	O
limiting	O
toxicities	O
(	O
DLT	O
)	O
","	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
pharmacokinetics	O
(	O
PK	O
)	O
","	O
pharmacodynamics	O
(	O
PD	O
)	O
and	O
efficacy	O
of	O
SF1126	B-DRUG
","	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
and	I-CANCER
B-cell	I-CANCER
malignancies	I-CANCER
.	O
	
SF1126	B-DRUG
was	O
administered	O
IV	O
days	O
1	O
and	O
4	O
","	O
weekly	O
in	O
28day-cycles	O
.	O
	
Dose	O
escalation	O
utilised	O
modified	O
Fibonacci	O
3+3.	O
Samples	O
to	O
monitor	O
PK	O
and	O
PD	O
were	O
obtained	O
.	O
	
Forty	O
four	O
patients	O
were	O
treated	O
at	O
9	O
dose	O
levels	O
(	O
90-1110	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
)	O
.	O
	
Most	O
toxicity	O
was	O
grade	O
1	O
and	O
2	O
with	O
a	O
single	O
DLT	O
at180	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
diarrhoea	B-TOXI
)	O
.	O
	
Exposure	O
measured	O
by	O
peak	O
concentration	O
(	O
C	O
(	O
max	O
)	O
)	O
and	O
area	O
under	O
the	O
time-concentration	O
curve	O
(	O
AUC	O
(	O
0	O
)	O
(	O
t	O
)	O
)	O
was	O
dose	O
proportional	O
.	O
	
Stable	O
disease	O
(	O
SD	O
)	O
was	O
the	O
best	O
response	O
in	O
19	O
of	O
33	O
(	O
58	O
%	O
)	O
evaluable	O
patients	O
.	O
	
MTD	O
was	O
not	O
reached	O
but	O
the	O
maximum	O
administered	O
dose	O
(	O
MAD	O
)	O
was	O
1110	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
The	O
protocol	O
was	O
amended	O
to	O
enrol	O
patients	O
with	O
CD20+	O
B-cell	B-CANCER
malignancies	I-CANCER
at	O
1110	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
A	O
CLL	O
patient	O
who	O
progressed	O
on	O
rituximab	B-DRUG
[	O
R	O
]	O
achieved	O
SD	O
after	O
2	O
months	O
on	O
SF1126	B-DRUG
alone	O
but	O
in	O
combination	O
with	O
R	O
achieved	O
a	O
55	O
%	O
decrease	O
in	O
absolute	O
lymphocyte	O
count	O
and	O
a	O
lymph	O
node	O
response	O
.	O
	
PD	O
studies	O
of	O
CLL	O
cells	O
demonstrated	O
SF1126	B-DRUG
reduced	O
p-AKT	O
and	O
increased	O
apoptosis	O
indicating	O
inhibition	O
of	O
activated	O
PI3K	O
signalling	O
.	O
	
SF1126	B-DRUG
is	O
well	O
tolerated	O
with	O
SD	O
as	O
the	O
best	O
response	O
in	O
patients	O
with	O
advanced	B-CANCER
malignancies	I-CANCER
.	O
	
Addition	O
of	O
aflibercept	B-DRUG
to	O
fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
irinotecan	B-DRUG
improves	O
survival	O
in	O
a	O
phase	O
III	O
randomized	O
trial	O
in	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
previously	O
treated	O
with	O
an	O
oxaliplatin-based	B-DRUG
regimen	O
.	O
	
	
Treatment	O
for	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
mCRC	B-CANCER
)	O
commonly	O
involves	O
a	O
fluoropyrimidine-based	B-DRUG
chemotherapy	O
regimen	O
such	O
as	O
infusional	B-DRUG
fluorouracil	I-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
irinotecan	B-DRUG
(	O
FOLFIRI	B-DRUG
)	O
or	O
fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
oxaliplatin	B-DRUG
","	O
often	O
combined	O
with	O
bevacizumab	B-DRUG
or	O
an	O
epidermal	O
growth	O
factor	O
receptor	O
monoclonal	O
antibody	O
.	O
	
We	O
studied	O
the	O
effect	O
of	O
adding	O
the	O
novel	O
antiangiogenic	O
agent	O
aflibercept	B-DRUG
(	O
also	O
known	O
as	O
ziv-aflibercept	B-DRUG
in	O
the	O
United	O
States	O
)	O
to	O
FOLFIRI	B-DRUG
in	O
patients	O
with	O
mCRC	B-CANCER
previously	O
treated	O
with	O
oxaliplatin	B-DRUG
","	O
including	O
patients	O
who	O
received	O
prior	O
bevacizumab	B-DRUG
.	O
	
Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
aflibercept	B-DRUG
(	O
4	O
mg	O
/	O
kg	O
intravenously	O
;	O
612	O
patients	O
)	O
or	O
placebo	O
(	O
614	O
patients	O
)	O
every	O
2	O
weeks	O
in	O
combination	O
with	O
FOLFIRI	O
.	O
	
Treatment	O
was	O
administered	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
overall	O
survival	O
.	O
	
Adding	O
aflibercept	B-DRUG
to	O
FOLFIRI	B-DRUG
significantly	O
improved	O
overall	O
survival	O
relative	O
to	O
placebo	B-DRUG
plus	O
FOLFIRI	B-DRUG
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
","	O
0.817	O
;	O
95.34	O
%	O
CI	O
","	O
0.713	O
to	O
0.937	O
;	O
P	O
=	O
0.0032	O
)	O
with	O
median	O
survival	O
times	O
of	O
13.5	O
versus	O
12.06	O
months	O
","	O
respectively	O
.	O
	
Aflibercept	B-DRUG
also	O
significantly	O
improved	O
progression-free	O
survival	O
(	O
PFS	O
;	O
HR	O
","	O
0.758	O
;	O
95	O
%	O
CI	O
","	O
0.661	O
to	O
0.869	O
;	O
P	O
&	O
lt	O
;	O
0.0001	O
)	O
","	O
with	O
median	O
PFS	O
times	O
of	O
6.9	O
versus	O
4.67	O
months	O
","	O
respectively	O
.	O
	
The	O
effects	O
on	O
overall	O
survival	O
and	O
PFS	O
exhibited	O
a	O
consistent	O
trend	O
across	O
prespecified	O
subgroup	O
analyses	O
","	O
including	O
bevacizumab	B-DRUG
pretreated	O
patients	O
.	O
	
Response	O
rate	O
was	O
19.8	O
%	O
(	O
95	O
%	O
CI	O
","	O
16.4	O
%	O
to	O
23.2	O
%	O
)	O
with	O
aflibercept	B-DRUG
plus	O
FOLFIRI	B-DRUG
compared	O
with	O
11.1	O
%	O
(	O
95	O
%	O
CI	O
","	O
8.5	O
%	O
to	O
13.8	O
%	O
)	O
with	O
placebo	B-DRUG
plus	O
FOLFIRI	B-DRUG
(	O
P	O
=	O
0.0001	O
)	O
.	O
	
Adverse	O
effects	O
reported	O
with	O
aflibercept	B-DRUG
combined	O
with	O
FOLFIRI	B-DRUG
included	O
the	O
characteristic	O
anti-vascular	O
endothelial	O
growth	O
factor	O
effects	O
and	O
also	O
reflected	O
an	O
increased	O
incidence	O
of	O
some	O
chemotherapy-related	O
toxicities	O
.	O
	
Aflibercept	B-DRUG
in	O
combination	O
with	O
FOLFIRI	B-DRUG
conferred	O
a	O
statistically	O
significant	O
survival	O
benefit	O
over	O
FOLFIRI	B-DRUG
combined	O
with	O
placebo	B-DRUG
in	O
patients	O
with	O
mCRC	B-CANCER
previously	O
treated	O
with	O
oxaliplatin	B-DRUG
.	O
	
A	O
phase	O
II	O
trial	O
of	O
intraperitoneal	O
cisplatin	B-DRUG
and	O
etoposide	B-DRUG
for	O
primary	O
treatment	O
of	O
ovarian	B-CANCER
epithelial	I-CANCER
cancer	I-CANCER
.	O
	
	
We	O
conducted	O
a	O
phase	O
II	O
trial	O
of	O
intraperitoneal	O
(	O
IP	O
)	O
cisplatin	B-DRUG
(	O
DDP	O
)	O
and	O
etoposide	B-DRUG
(	O
VP-16	O
)	O
in	O
stage	O
III	O
and	O
IV	O
newly	O
diagnosed	O
ovarian	B-CANCER
carcinoma	I-CANCER
patients	O
with	O
residual	O
disease	O
of	O
any	O
size	O
.	O
	
Twenty-three	O
patients	O
were	O
entered	O
","	O
19	O
had	O
stage	O
III	O
and	O
four	O
stage	O
IV	O
disease	O
.	O
	
DDP	O
200	O
mg	O
/	O
m2	O
and	O
VP-16	O
350	O
mg	O
/	O
m2	O
were	O
given	O
in	O
2	O
L	O
saline	O
IP	O
via	O
a	O
Port-A-Cath	O
(	O
Pharmacia-Deltec	O
","	O
St	O
Paul	O
","	O
MN	O
)	O
.	O
	
Sodium	B-DRUG
thiosulfate	I-DRUG
4	O
g	O
/	O
m2	O
was	O
given	O
intravenously	O
(	O
IV	O
)	O
just	O
before	O
the	O
start	O
of	O
IP	O
instillation	O
","	O
and	O
continued	O
as	O
a	O
constant	O
IV	O
infusion	O
of	O
2	O
g	O
/	O
m2	O
/	O
hr	O
IV	O
for	O
a	O
total	O
of	O
6	O
hours	O
.	O
	
Treatment	O
was	O
given	O
once	O
every	O
4	O
weeks	O
;	O
six	O
cycles	O
of	O
therapy	O
were	O
planned	O
.	O
	
Thirteen	O
patients	O
(	O
56	O
%	O
)	O
were	O
in	O
complete	O
clinical	O
remission	O
at	O
the	O
end	O
of	O
treatment	O
(	O
normal	O
physical	O
exam	O
","	O
computed	O
tomographic	O
[	O
CT	O
]	O
scan	O
","	O
CA-125	O
","	O
and	O
peritoneal	O
cytology	O
)	O
.	O
	
Seven	O
of	O
these	O
13	O
underwent	O
a	O
second-look	O
laparotomy	O
:	O
three	O
(	O
13	O
%	O
)	O
were	O
in	O
pathologic	O
complete	O
remission	O
and	O
four	O
(	O
17	O
%	O
)	O
had	O
microscopic	O
disease	O
only	O
.	O
	
Projected	O
survival	O
is	O
68	O
%	O
at	O
27	O
months	O
","	O
with	O
10	O
patients	O
being	O
alive	O
and	O
continuously	O
free	O
of	O
disease	O
.	O
	
There	O
was	O
a	O
very	O
rapid	O
fall	O
in	O
mean	O
CA-125	O
to	O
within	O
normal	O
limits	O
at	O
the	O
end	O
of	O
the	O
second	O
course	O
of	O
treatment	O
.	O
	
The	O
major	O
toxicity	O
was	O
myelosuppression	B-TOXI
with	O
median	B-TOXI
nadir	I-TOXI
WBC	I-TOXI
","	O
granulocyte	O
","	O
and	O
platelet	O
counts	O
of	O
"2,600"	O
","	O
896	O
","	O
and	O
"205,000"	O
/	O
microL	O
","	O
respectively	O
.	O
	
There	O
was	O
no	B-TOXI
cumulative	I-TOXI
renal	I-TOXI
damage	I-TOXI
","	O
anemia	B-TOXI
","	O
hypomagnesemia	B-TOXI
","	O
or	O
chemical	B-TOXI
peritonitis	I-TOXI
.	O
	
Neurotoxicity	O
was	O
similar	O
to	O
that	O
observed	O
with	O
IV	O
dosing	O
.	O
	
We	O
conclude	O
that	O
therapy	O
with	O
the	O
IP	O
DDP	O
/	O
VP-16	O
/	O
IV	O
thiosulfate	B-DRUG
regimen	O
","	O
in	O
which	O
all	O
cytotoxic	O
drugs	O
are	O
given	O
only	O
by	O
the	O
IP	O
route	O
","	O
produces	O
less	O
anemia	B-TOXI
and	O
renal	B-TOXI
damage	I-TOXI
than	O
standard	O
IV	O
DDP-containing	O
regimens	O
","	O
and	O
that	O
survival	O
with	O
this	O
regimen	O
appears	O
to	O
be	O
at	O
least	O
as	O
good	O
as	O
that	O
produced	O
by	O
IV	O
programs	O
.	O
	
Phase	O
I	O
trial	O
of	O
oxaliplatin	B-DRUG
plus	O
S-1	B-DRUG
chemotherapy	O
in	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
Advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
can	O
be	O
effectively	O
treated	O
with	O
S-1	B-DRUG
","	O
as	O
well	O
as	O
with	O
a	O
combination	O
of	O
oxaliplatin	B-DRUG
","	O
5-fluorouracil	B-DRUG
(	O
5FU	B-DRUG
)	O
and	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
.	O
	
However	O
","	O
S-1	B-DRUG
together	O
with	O
oxaliplatin	B-DRUG
may	O
provide	O
a	O
more	O
convenient	O
alternative	O
to	O
5FU	B-DRUG
/	O
LV	B-DRUG
.	O
	
To	O
evaluate	O
the	O
performance	O
of	O
S-1	B-DRUG
combined	O
with	O
oxaliplatin	B-DRUG
for	O
patients	O
with	O
colorectal	B-CANCER
cancer	I-CANCER
","	O
we	O
conducted	O
a	O
Phase	O
I	O
clinical	O
trial	O
in	O
an	O
outpatient	O
setting	O
.	O
	
We	O
administered	O
S-1	B-DRUG
to	O
15	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
adenocarcinoma	I-CANCER
for	O
two	O
weeks	O
followed	O
by	O
one	O
week	O
of	O
rest	O
.	O
	
Oxaliplatin	B-DRUG
was	O
also	O
administered	O
on	O
day	O
1	O
of	O
the	O
S-1	B-DRUG
cycle	O
.	O
	
The	O
dose	O
of	O
oxaliplatin	B-DRUG
was	O
increased	O
from	O
40	O
to	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
to	O
define	O
the	O
maximum	O
tolerated	O
dose	O
and	O
recommended	O
dose	O
in	O
preparation	O
for	O
a	O
Phase	O
II	O
trial	O
.	O
	
We	O
administered	O
102	O
courses	O
of	O
treatment	O
to	O
15	O
patients	O
.	O
	
Grade	O
3	O
thrombocytopenia	B-TOXI
developed	O
in	O
only	O
1	O
patient	O
at	O
a	O
dose	O
of	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
oxaliplatin	B-DRUG
plus	O
oral	B-DRUG
S-1	I-DRUG
.	O
	
No	O
other	O
grade	O
3月4日	O
toxicities	O
developed	O
.	O
	
No	O
dose-limiting	O
toxicity	O
developed	O
at	O
level	O
4	O
of	O
our	O
regimen	O
(	O
oxaliplatin	B-DRUG
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
and	O
the	O
recommended	O
dose	O
for	O
a	O
Phase	O
II	O
trial	O
was	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
oxaliplatin	B-DRUG
in	O
an	O
outpatient	O
setting	O
.	O
	
Everolimus	B-DRUG
and	O
erlotinib	B-DRUG
as	O
second-	O
or	O
third-line	O
therapy	O
in	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
epidermal	O
growth	O
factor	O
receptor	O
inhibitor	O
erlotinib	B-DRUG
is	O
an	O
approved	O
treatment	O
for	O
chemotherapy-refractory	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Because	O
activated	O
epidermal	O
growth	O
factor	O
receptor	O
signals	O
through	O
the	O
phosphatidylinositol	O
3-kinase	O
/	O
Akt	O
/	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
pathway	O
","	O
adding	O
the	O
oral	O
mTOR	O
inhibitor	O
everolimus	B-DRUG
to	O
erlotinib	B-DRUG
may	O
improve	O
efficacy	O
by	O
blocking	O
multiple	O
components	O
of	O
the	O
same	O
pathway	O
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
study	O
to	O
determine	O
feasible	O
dosages	O
of	O
combination	O
therapy	O
with	O
erlotinib	B-DRUG
and	O
everolimus	B-DRUG
for	O
previously	O
treated	O
metastatic	O
or	O
unresectable	O
NSCLC	B-CANCER
.	O
	
Participants	O
had	O
advanced	B-CANCER
NSCLC	I-CANCER
progressing	O
after	O
two	O
or	O
less	O
previous	O
chemotherapy	O
regimens	O
.	O
	
Feasibility	O
of	O
daily	O
/	O
weekly	O
everolimus	B-DRUG
plus	O
daily	O
erlotinib	B-DRUG
was	O
determined	O
using	O
a	O
6	O
=+	O
6	O
dose-escalation	O
design	O
based	O
on	O
the	O
rate	O
of	O
dose-limiting	O
toxicities	O
.	O
	
Antitumor	O
activity	O
was	O
assessed	O
by	O
the	O
Response	O
Evaluation	O
Criteria	O
In	O
Solid	O
Tumors	O
study	O
.	O
	
Of	O
the	O
94	O
patients	O
enrolled	O
","	O
90	O
%	O
had	O
stage	O
IV	O
NSCLC	B-CANCER
","	O
19	O
%	O
never	O
smoked	O
","	O
and	O
15	O
%	O
were	O
current	O
smokers	O
.	O
	
Eighty-nine	O
patients	O
experienced	O
one	O
or	O
more	O
adverse	O
events	O
possibly	O
related	O
to	O
any	O
study	O
medication	O
.	O
	
The	O
most	O
common	O
dose-limiting	O
toxicities	O
were	O
stomatitis	B-TOXI
(	O
n	O
=	O
5	O
)	O
","	O
rash	B-TOXI
(	O
n	O
=	O
4	O
)	O
","	O
and	O
diarrhea	B-TOXI
(	O
n	O
=	O
3	O
)	O
.	O
	
Maximum	O
tolerated	O
doses	O
were	O
everolimus	B-DRUG
5	O
mg	O
per	O
day	O
or	O
50	O
mg	O
per	O
week	O
plus	O
erlotinib	B-DRUG
150	O
mg	O
per	O
day	O
.	O
	
In	O
daily	O
everolimus	B-DRUG
cohorts	O
(	O
n	O
=	O
74	O
)	O
","	O
nine	O
patients	O
achieved	O
a	O
complete	O
/	O
partial	O
response	O
and	O
28	O
had	O
stable	O
disease	O
(	O
median	O
duration	O
disease	O
control	O
","	O
9.3	O
months	O
)	O
.	O
	
In	O
weekly	O
everolimus	B-DRUG
cohorts	O
(	O
n	O
=	O
20	O
)	O
","	O
no	O
tumor	O
response	O
was	O
observed	O
;	O
seven	O
patients	O
had	O
stable	O
disease	O
(	O
median	O
duration	O
","	O
9.6	O
months	O
)	O
.	O
	
Combination	O
therapy	O
with	O
everolimus	B-DRUG
5	O
mg	O
per	O
day	O
or	O
50	O
mg	O
per	O
week	O
and	O
erlotinib	B-DRUG
150	O
mg	O
per	O
day	O
provided	O
acceptable	O
tolerability	O
and	O
disease	O
control	O
.	O
	
A	O
randomized	O
phase	O
II	O
study	O
evaluating	O
this	O
combination	O
in	O
comparison	O
with	O
erlotinib	B-DRUG
alone	O
is	O
complete	O
and	O
is	O
being	O
analyzed	O
.	O
	
Phase	O
I	O
trial	O
of	O
axitinib	B-DRUG
combined	O
with	O
platinum	B-DRUG
doublets	O
in	O
patients	O
with	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
and	O
other	O
solid	B-CANCER
tumours	I-CANCER
.	O
	
	
This	O
phase	O
I	O
dose-finding	O
trial	O
evaluated	O
safety	O
","	O
efficacy	O
and	O
pharmacokinetics	O
of	O
axitinib	B-DRUG
","	O
a	O
potent	O
and	O
selective	O
second-generation	O
inhibitor	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptors	O
","	O
combined	O
with	O
platinum	B-DRUG
doublets	O
in	O
patients	O
with	O
advanced	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
and	O
other	O
solid	B-CANCER
tumours	I-CANCER
.	O
	
In	O
all	O
","	O
49	O
patients	O
received	O
axitinib	B-DRUG
5	O
mg	O
twice	O
daily	O
(	O
b.i.d.	O
)	O
with	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
or	O
gemcitabine	B-DRUG
/	O
cisplatin	B-DRUG
in	O
3-week	O
cycles	O
.	O
	
Following	O
determination	O
of	O
the	O
maximum	O
tolerated	O
dose	O
","	O
a	O
squamous	B-CANCER
cell	I-CANCER
NSCLC	I-CANCER
expansion	O
cohort	O
was	O
enroled	O
and	O
received	O
axitinib	B-DRUG
5	O
mg	O
b.i.d.	O
with	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
.	O
	
Two	O
patients	O
experienced	O
dose-limiting	O
toxicities	O
:	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
n=1	O
)	O
in	O
the	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
cohort	O
and	O
fatigue	B-TOXI
(	O
n=1	O
)	O
in	O
the	O
gemcitabine	B-DRUG
/	O
cisplatin	B-DRUG
cohort	O
.	O
	
Common	O
nonhaematologic	O
treatment-related	O
adverse	O
events	O
were	O
hypertension	B-TOXI
(	O
36.7	O
%	O
)	O
","	O
diarrhoea	B-TOXI
(	O
34.7	O
%	O
)	O
and	O
fatigue	B-TOXI
(	O
28.6	O
%	O
)	O
.	O
	
No	O
grade	O
_3	O
haemoptysis	B-TOXI
occurred	O
among	O
12	O
patients	O
with	O
squamous	B-CANCER
cell	I-CANCER
NSCLC	I-CANCER
.	O
	
The	O
objective	O
response	O
rate	O
was	O
37	O
%	O
for	O
patients	O
receiving	O
axitinib	B-DRUG
/	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
(	O
n=27	O
)	O
and	O
23.8	O
%	O
for	O
patients	O
receiving	O
axitinib	B-DRUG
/	O
gemcitabine	B-DRUG
/	O
cisplatin	B-DRUG
(	O
n=21	O
)	O
.	O
	
Pharmacokinetics	O
of	O
axitinib	B-DRUG
and	O
chemotherapeutic	O
agents	O
were	O
similar	O
when	O
administered	O
alone	O
or	O
in	O
combination	O
.	O
	
Axitinib	B-DRUG
5	O
mg	O
b.i.d.	O
may	O
be	O
combined	O
with	O
standard	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
or	O
gemcitabine	B-DRUG
/	O
cisplatin	B-DRUG
regimens	O
without	O
evidence	O
of	O
overt	O
drug-drug	O
interactions	O
.	O
	
Both	O
combinations	O
demonstrated	O
clinical	O
efficacy	O
and	O
were	O
well	O
tolerated	O
.	O
	
A	O
phase	O
2	O
trial	O
of	O
induction	O
nab-paclitaxel	B-DRUG
and	O
cetuximab	B-DRUG
given	O
with	O
cisplatin	B-DRUG
and	O
5-fluorouracil	B-DRUG
followed	O
by	O
concurrent	O
cisplatin	B-DRUG
and	O
radiation	O
for	O
locally	O
advanced	B-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
	
Complete	O
response	O
(	O
CR	O
)	O
at	O
the	O
primary	O
tumor	O
site	O
as	O
assessed	O
by	O
clinical	O
examination	O
following	O
induction	O
chemotherapy	O
with	O
PF	B-DRUG
(	O
cisplatin	B-DRUG
and	O
5-fluorouracil	B-DRUG
[	O
5-FU	B-DRUG
]	O
)	O
is	O
a	O
favorable	O
predictive	O
factor	O
for	O
overall	O
survival	O
and	O
disease	O
control	O
in	O
patients	O
with	O
locally	O
advanced	B-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
In	O
most	O
series	O
","	O
the	O
rate	O
of	O
CR	O
at	O
the	O
primary	O
site	O
after	O
induction	O
PF	B-DRUG
was	O
20	O
%	O
to	O
30	O
%	O
.	O
	
This	O
study	O
evaluated	O
the	O
efficacy	O
and	O
feasibility	O
of	O
induction	O
nab-paclitaxel	B-DRUG
and	O
cetuximab	B-DRUG
given	O
with	O
PF	B-DRUG
(	O
ACPF	B-DRUG
)	O
followed	O
by	O
definitive	O
chemoradiation	O
(	O
CRT	O
)	O
in	O
a	O
phase	O
2	O
trial	O
.	O
	
Patients	O
with	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
were	O
treated	O
with	O
ACPF	B-DRUG
(	O
nab-paclitaxel	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
week	O
;	O
cetuximab	B-DRUG
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
week	O
;	O
cisplatin	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
;	O
5-FU	B-DRUG
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
on	O
days	O
1	O
through	O
3	O
)	O
every	O
21	O
days	O
for	O
3	O
cycles	O
followed	O
by	O
CRT	O
(	O
cisplatin	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
","	O
22	O
","	O
and	O
43	O
of	O
radiation	O
therapy	O
[	O
RT	O
]	O
)	O
.	O
	
CR	O
at	O
the	O
primary	O
tumor	O
site	O
after	O
2	O
cycles	O
of	O
ACPF	B-DRUG
was	O
the	O
primary	O
endpoint	O
.	O
	
Thirty	O
patients	O
were	O
enrolled	O
","	O
of	O
which	O
22	O
(	O
73	O
%	O
)	O
had	O
large	O
(	O
T3	O
/	O
T4	O
)	O
primary	O
tumors	O
.	O
	
The	O
CR	O
rate	O
at	O
the	O
primary	O
tumor	O
site	O
after	O
2	O
cycles	O
of	O
ACPF	B-DRUG
was	O
53	O
%	O
and	O
the	O
overall	O
response	O
rate	O
was	O
100	O
%	O
.	O
	
Twenty-nine	O
(	O
96	O
%	O
)	O
patients	O
completed	O
3	O
cycles	O
of	O
ACPF	B-DRUG
","	O
26	O
(	O
90	O
%	O
)	O
completed	O
definitive	O
RT	O
per	O
protocol	O
","	O
and	O
22	O
of	O
the	O
27	O
evaluable	O
patients	O
(	O
81	O
%	O
)	O
received	O
&	O
gt	O
;	O
2	O
of	O
the	O
3	O
planned	O
doses	O
of	O
cisplatin	B-DRUG
with	O
RT.	O
The	O
estimated	O
2-year	O
overall	O
and	O
progression-free	O
survival	O
rates	O
were	O
84	O
%	O
and	O
65	O
%	O
","	O
respectively	O
.	O
	
Induction	O
ACPF	B-DRUG
resulted	O
in	O
a	O
high	O
CR	O
rate	O
(	O
53	O
%	O
)	O
at	O
the	O
primary	O
tumor	O
site	O
even	O
in	O
large	O
tumors	O
and	O
did	O
not	O
adversely	O
affect	O
delivery	O
of	O
definitive	O
CRT	O
.	O
	
Further	O
investigation	O
of	O
ACPF	B-DRUG
is	O
warranted	O
.	O
	
Combination	O
antiangiogenic	O
therapy	O
in	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
:	O
a	O
phase	O
1	O
trial	O
of	O
vandetanib	B-DRUG
","	O
a	O
VEGFR	O
inhibitor	O
","	O
and	O
metronomic	O
chemotherapy	O
","	O
with	O
correlative	O
platelet	O
proteomics	O
.	O
	
	
This	O
phase	O
1	O
study	O
evaluated	O
the	O
safety	O
and	O
tolerability	O
of	O
antiangiogenic	O
therapy	O
using	O
vandetanib	B-DRUG
and	O
metronomic	B-DRUG
cyclophosphamide	I-DRUG
and	O
methotrexate	B-DRUG
in	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Eligible	O
patients	O
had	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
with	O
0-4	O
prior	O
chemotherapy	O
regimens	O
.	O
	
All	O
received	O
cyclophosphamide	B-DRUG
50	O
mg	O
daily	O
","	O
methotrexate	B-DRUG
2.5	O
mg	O
days	O
1月2日	O
weekly	O
","	O
and	O
vandetanib	B-DRUG
daily	O
in	O
3	O
dose-escalation	O
cohorts	O
:	O
100	O
mg	O
(	O
C1	O
)	O
","	O
200	O
mg	O
(	O
C2	O
)	O
","	O
and	O
300	O
mg	O
(	O
C3	O
)	O
.	O
	
The	O
primary	O
endpoint	O
was	O
safety	O
and	O
tolerability	O
;	O
secondary	O
endpoints	O
included	O
response	O
rate	O
and	O
evaluation	O
of	O
platelet-associated	O
proteins	O
.	O
	
Twenty	O
three	O
patients	O
were	O
treated	O
and	O
evaluable	O
for	O
toxicity	O
.	O
	
Common	O
mild	O
toxicities	O
included	O
nausea	B-TOXI
","	O
vomiting	B-TOXI
","	O
LFTs	B-TOXI
abnormalities	I-TOXI
","	O
fatigue	B-TOXI
","	O
and	O
rash	B-TOXI
.	O
	
Three	O
episodes	O
of	O
dose-limiting	O
toxicity	O
occurred	O
in	O
C3	O
.	O
	
In	O
all	O
cohorts	O
","	O
1	O
/	O
3	O
of	O
patients	O
required	O
vandetanib	B-DRUG
dose	O
reduction	O
","	O
and	O
22	O
%	O
ended	O
therapy	O
for	O
toxicity	O
.	O
	
Of	O
the	O
20	O
response-evaluable	O
patients	O
","	O
10	O
%	O
demonstrated	O
partial	O
response	O
and	O
15	O
%	O
stable	O
disease	O
_24	O
weeks	O
.	O
	
Proteomic	O
analyses	O
demonstrated	O
changes	O
in	O
platelet	O
content	O
of	O
angiogenesis	O
regulators	O
","	O
including	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
platelet	O
factor	O
4	O
","	O
with	O
exposure	O
to	O
therapy	O
.	O
	
This	O
regimen	O
was	O
tolerable	O
at	O
a	O
maximum	O
vandetanib	B-DRUG
dose	O
of	O
200	O
mg	O
;	O
modest	O
clinical	O
activity	O
was	O
observed	O
in	O
this	O
heavily	O
pretreated	O
population	O
.	O
	
Changes	O
in	O
the	O
platelet	O
proteome	O
may	O
serve	O
as	O
pharmacodynamic	O
markers	O
of	O
angiogenesis	O
inhibition	O
.	O
	
Metronomic	O
chemotherapy	O
is	O
an	O
attractive	O
partner	O
with	O
biologics	O
and	O
deserves	O
further	O
study	O
in	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
A	O
Phase	O
I	O
clinical	O
trial	O
of	O
the	O
combination	O
of	O
imatinib	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
solid	I-CANCER
tumors	I-CANCER
refractory	O
to	O
standard	O
therapy	O
.	O
	
	
Pre-clinical	O
data	O
suggest	O
that	O
combining	O
imatinib	B-DRUG
with	O
traditional	O
cytotoxic	O
chemotherapy	O
may	O
improve	O
imatinib	B-DRUG
efficacy	O
.	O
	
We	O
conducted	O
a	O
Phase	O
I	O
study	O
of	O
imatinib	B-DRUG
in	O
combination	O
with	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Patients	O
were	O
accrued	O
to	O
the	O
study	O
in	O
a	O
standard	O
3	O
=+	O
3	O
design	O
.	O
	
Patients	O
were	O
restaged	O
every	O
two	O
cycles	O
","	O
and	O
those	O
with	O
stable	O
disease	O
(	O
SD	O
)	O
","	O
or	O
better	O
","	O
continued	O
study	O
treatment	O
without	O
interruption	O
.	O
	
Maximally	O
tolerated	O
doses	O
(	O
MTDs	O
)	O
and	O
pharmacokinetic	O
profiles	O
of	O
combination	O
imatinib	B-DRUG
and	O
paclitaxel	B-DRUG
were	O
assessed	O
.	O
	
Fifty-eight	O
patients	O
were	O
enrolled	O
","	O
including	O
40	O
in	O
the	O
Phase	O
I	O
dose	O
escalation	O
portion	O
.	O
	
Alternating	O
dose	O
escalation	O
of	O
imatinib	B-DRUG
and	O
paclitaxel	B-DRUG
on	O
a	O
28-day	O
cycle	O
resulted	O
in	O
MTDs	O
of	O
800	O
mg	O
imatinib	B-DRUG
daily	O
","	O
on	O
days	O
1月4日	O
","	O
8月11日	O
","	O
15-18	O
","	O
and	O
22-25	O
","	O
and	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
paclitaxel	B-DRUG
weekly	O
","	O
on	O
days	O
3	O
","	O
10	O
","	O
and	O
17	O
.	O
	
Two	O
expansion	O
cohorts	O
","	O
comprising	O
10	O
breast	B-CANCER
cancer	I-CANCER
patients	O
and	O
8	O
patients	O
with	O
soft-tissue	O
sarcomas	O
","	O
were	O
enrolled	O
at	O
the	O
MTDs	O
.	O
	
The	O
most	O
common	O
adverse	O
events	O
were	O
flu-like	B-TOXI
symptoms	I-TOXI
(	O
64	O
%	O
)	O
and	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
(	O
71	O
%	O
)	O
.	O
	
The	O
most	O
common	O
Grade	O
3	O
/	O
4	O
toxicities	O
were	O
neutropenia	B-TOXI
(	O
26	O
%	O
)	O
","	O
flu-like	B-TOXI
symptoms	I-TOXI
(	O
12	O
%	O
)	O
","	O
and	O
pain	B-TOXI
(	O
12	O
%	O
)	O
.	O
	
There	O
were	O
no	O
relevant	O
differences	O
in	O
the	O
pharmacokinetic	O
profiles	O
of	O
either	O
drug	O
when	O
given	O
in	O
combination	O
compared	O
with	O
alone	O
.	O
	
Thirty-eight	O
subjects	O
were	O
evaluable	O
for	O
response	O
","	O
18	O
(	O
47.4	O
%	O
)	O
of	O
whom	O
experienced	O
clinical	O
benefit	O
.	O
	
Five	O
patients	O
(	O
13.2	O
%	O
)	O
had	O
a	O
partial	O
response	O
(	O
PR	O
)	O
and	O
13	O
patients	O
(	O
34.2	O
%	O
)	O
had	O
SD	O
;	O
the	O
average	O
time	O
to	O
progression	O
in	O
those	O
with	O
clinical	O
benefit	O
was	O
17	O
weeks	O
(	O
range	O
:	O
7月28日	O
weeks	O
)	O
.	O
	
This	O
combination	O
of	O
imatinib	B-DRUG
and	O
paclitaxel	B-DRUG
was	O
reasonably	O
safe	O
and	O
tolerable	O
","	O
and	O
demonstrated	O
evidence	O
of	O
anti-tumor	O
activity	O
.	O
	
Further	O
exploration	O
in	O
disease-specific	O
Phase	O
II	O
trials	O
is	O
warranted	O
.	O
	
A	O
multi-center	O
phase	O
Ib	O
study	O
of	O
oxaliplatin	B-DRUG
(	O
NSC	O
#	O
266046	O
)	O
in	O
combination	O
with	O
fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
in	O
pediatric	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Platinum	B-DRUG
agents	O
have	O
been	O
used	O
for	O
a	O
variety	O
of	O
cancers	O
","	O
including	O
pivotal	O
use	O
in	O
pediatric	B-CANCER
tumors	I-CANCER
for	O
many	O
years	O
.	O
	
Oxaliplatin	B-DRUG
","	O
a	O
third	O
generation	O
platinum	B-DRUG
","	O
has	O
a	O
different	O
side	O
effect	O
profile	O
and	O
may	O
provide	O
improved	O
activity	O
in	O
pediatric	B-CANCER
cancers	I-CANCER
.	O
	
Patients	O
21	O
years	O
or	O
younger	O
with	O
progressive	O
or	O
refractory	O
malignant	B-CANCER
solid	I-CANCER
tumors	I-CANCER
","	O
including	O
tumors	O
of	O
the	O
central	O
nervous	O
system	O
were	O
enrolled	O
on	O
this	O
multi-center	O
open	O
label	O
","	O
non-randomized	O
Phase	O
1	O
dose	O
escalation	O
study	O
.	O
	
The	O
study	O
used	O
a	O
standard	O
3	O
=+	O
3	O
dose	O
escalation	O
design	O
with	O
2	O
dose	O
levels	O
(	O
85	O
and	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
with	O
an	O
expansion	O
cohort	O
of	O
15	O
additional	O
patients	O
at	O
the	O
recommended	O
dose	O
.	O
	
Patients	O
received	O
oxaliplatin	B-DRUG
at	O
the	O
assigned	O
dose	O
level	O
and	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
bolus	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
followed	O
by	O
a	O
46-hour	O
5-FU	B-DRUG
infusion	O
of	O
"2,400"	O
mg	O
/	O
m	O
(	O
2	O
)	O
every	O
14	O
days	O
.	O
	
The	O
leucovorin	B-DRUG
dose	O
was	O
fixed	O
at	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
all	O
cohorts	O
.	O
	
Thirty-one	O
evaluable	O
patients	O
were	O
enrolled	O
","	O
8	O
at	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
23	O
at	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
a	O
total	O
of	O
121	O
courses	O
.	O
	
The	O
median	O
age	O
was	O
12	O
years	O
(	O
range	O
2月19日	O
years	O
)	O
.	O
	
The	O
main	O
toxicities	O
were	O
hematologic	B-TOXI
","	O
primarily	O
neutrophils	B-TOXI
and	O
platelets	B-TOXI
.	O
	
The	O
most	O
common	O
non-hematologic	B-TOXI
toxicities	I-TOXI
were	O
gastrointestinal	B-TOXI
.	O
	
Stable	O
disease	O
was	O
noted	O
in	O
11	O
patients	O
(	O
54	O
%	O
of	O
evaluable	O
patients	O
)	O
and	O
1	O
confirmed	O
partial	O
response	O
in	O
a	O
patient	O
with	O
osteosarcoma	B-TOXI
.	O
	
The	O
maximum	O
planned	O
dose	O
of	O
oxaliplatin	B-DRUG
at	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
dose	O
in	O
combination	O
with	O
5-FU	B-DRUG
and	O
leucovorin	B-DRUG
was	O
safe	O
and	O
well	O
tolerated	O
and	O
in	O
this	O
patient	O
population	O
.	O
	
This	O
combination	O
demonstrated	O
modest	O
activity	O
in	O
patients	O
with	O
refractory	O
or	O
relapsed	B-CANCER
solid	I-CANCER
tumor	I-CANCER
and	O
warrants	O
further	O
study	O
.	O
	
Pediatr	O
Blood	O
Cancer	O
2013	O
;	O
60:230-236	O
.	O
	
漏	O
2012	O
Wiley	O
Periodicals	O
","	O
Inc	O
.	O
	
A	O
Phase	O
II	O
study	O
of	O
pulse	O
dose	O
imatinib	B-DRUG
mesylate	I-DRUG
and	O
weekly	O
paclitaxel	B-DRUG
in	O
patients	O
aged	O
70	O
and	O
over	O
with	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
In	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
","	O
interstitial	B-TOXI
hypertension	I-TOXI
is	O
a	O
barrier	O
to	O
chemotherapy	O
delivery	O
","	O
and	O
is	O
mediated	O
by	O
platelet	O
derived	O
growth	O
factor	O
receptor	O
(	O
PDGFR	O
)	O
.	O
	
Antagonizing	O
PDGFR	O
with	O
imatinib	B-DRUG
may	O
improve	O
intra-tumoral	O
delivery	O
of	O
paclitaxel	B-DRUG
","	O
increasing	O
response	O
rate	O
(	O
RR	O
)	O
.	O
	
This	O
single-stage	O
","	O
open-label	O
phase	O
II	O
study	O
evaluated	O
pulse	O
dose	O
imatinib	B-DRUG
and	O
weekly	O
paclitaxel	B-DRUG
in	O
elderly	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
Eligible	O
patients	O
were	O
aged	O
_	O
70	O
with	O
untreated	O
","	O
stage	O
IIIB-IV	O
NSCLC	B-CANCER
and	O
ECOG	O
performance	O
status	O
0-2	O
.	O
	
Primary	O
endpoint	O
was	O
RR	O
.	O
	
Secondary	O
endpoints	O
included	O
median	O
progression	O
free	O
and	O
overall	O
survival	O
(	O
PFS	O
","	O
OS	O
)	O
and	O
correlatives	O
of	O
PDGFR	O
pathway	O
activation	O
.	O
	
Baseline	O
Charlson	O
Comorbidity	O
Index	O
(	O
CCI	O
)	O
and	O
Vulnerable	O
Elder	O
Survey-13	O
(	O
VES-13	O
)	O
were	O
correlated	O
with	O
outcomes	O
.	O
	
Thirty-four	O
patients	O
with	O
median	O
age	O
75	O
enrolled	O
.	O
	
Eleven	O
of	O
29	O
(	O
38	O
%	O
)	O
were	O
frail	O
by	O
VES-13	O
score	O
.	O
	
Overall	O
RR	O
was	O
11	O
/	O
34	O
(	O
32	O
%	O
;	O
95	O
%	O
CI	O
17	O
%	O
-51	O
%	O
)	O
","	O
meeting	O
the	O
primary	O
endpoint	O
.	O
	
Median	O
PFS	O
and	O
OS	O
were	O
3.6	O
and	O
7.3	O
months	O
","	O
respectively	O
.	O
	
High	O
tumoral	O
PDGF-B	O
expression	O
predicted	O
inferior	O
PFS	O
.	O
	
Frail	O
patients	O
by	O
VES-13	O
had	O
significantly	O
worse	O
median	O
PFS	O
(	O
3.2	O
vs.	O
4.5	O
months	O
;	O
p=0.02	O
)	O
and	O
OS	O
(	O
4.8	O
vs.	O
12	O
months	O
;	O
p=0.02	O
)	O
than	O
non-frail	O
.	O
	
The	O
combination	O
of	O
imatinib	B-DRUG
and	O
paclitaxel	B-DRUG
had	O
encouraging	O
activity	O
as	O
measured	O
by	O
the	O
primary	O
endpoint	O
of	O
RR	O
.	O
	
However	O
","	O
PFS	O
and	O
OS	O
were	O
typical	O
for	O
elderly	O
patients	O
treated	O
with	O
single	O
agent	O
chemotherapy	O
and	O
the	O
regimen	O
is	O
not	O
recommended	O
for	O
further	O
study	O
.	O
	
Adjunct	B-DRUG
imatinib	I-DRUG
did	O
not	O
overcome	O
the	O
established	O
association	O
of	O
tumoral	O
PDGF-B	O
expression	O
with	O
inferior	O
PFS	O
.	O
	
VES-13	O
was	O
a	O
powerful	O
predictor	O
of	O
poor	O
survival	O
outcomes	O
.	O
	
Frailty	O
should	O
be	O
further	O
studied	O
as	O
a	O
predictor	O
of	O
non-benefit	O
from	O
chemotherapy	O
.	O
	
ClinicalTrials.gov	O
NCT01011075	O
.	O
	
A	O
phase	O
I	O
trial	O
of	O
nab-paclitaxel	B-DRUG
","	O
gemcitabine	B-DRUG
","	O
and	O
capecitabine	B-DRUG
for	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
	
Substantial	O
antitumor	O
activity	O
has	O
previously	O
been	O
demonstrated	O
with	O
the	O
addition	O
of	O
nab-paclitaxel	B-DRUG
(	O
Abraxane	B-DRUG
[	O
Celgene	O
","	O
Summit	O
","	O
NJ	O
]	O
)	O
","	O
an	O
albumin-bound	O
formulation	O
of	O
paclitaxel	B-DRUG
","	O
to	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
Given	O
preclinical	O
evidence	O
of	O
synergy	O
when	O
a	O
fluoropyrimidine	B-DRUG
is	O
added	O
to	O
gemcitabine	B-DRUG
plus	O
a	O
taxane	B-DRUG
in	O
a	O
sequence-specific	O
schedule	O
","	O
we	O
conducted	O
a	O
phase	O
I	O
study	O
to	O
evaluate	O
the	O
combination	O
of	O
nab-paclitaxel	B-DRUG
","	O
gemcitabine	B-DRUG
","	O
and	O
capecitabine	B-DRUG
administered	O
biweekly	O
in	O
patients	O
with	O
metastatic	B-CANCER
pancreatic	I-CANCER
adenocarcinoma	I-CANCER
.	O
	
Patients	O
with	O
previously	O
untreated	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
and	O
an	O
ECOG	O
performance	O
status	O
of	O
0-1	O
were	O
eligible	O
to	O
participate	O
.	O
	
Study	O
design	O
utilized	O
a	O
3	O
=+	O
3	O
dose-escalation	O
schema	O
","	O
with	O
expanded	O
cohort	O
at	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
.	O
	
Treatment	O
was	O
administered	O
in	O
14-day	O
cycles	O
","	O
with	O
capecitabine	B-DRUG
given	O
on	O
days	O
1月7日	O
and	O
both	O
gemcitabine	B-DRUG
(	O
at	O
fixed-dose	O
rate	O
infusion	O
)	O
and	O
nab-paclitaxel	B-DRUG
on	O
day	O
4	O
of	O
each	O
cycle	O
.	O
	
Dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
definitions	O
included	O
grade	O
3月4日	O
hematologic	B-TOXI
toxicities	I-TOXI
and	O
grade	O
2月4日	O
hand-foot	B-TOXI
syndrome	I-TOXI
","	O
neuropathy	B-TOXI
","	O
or	O
diarrhea	B-TOXI
.	O
	
Fifteen	O
patients	O
were	O
enrolled	O
across	O
two	O
dose	O
levels	O
.	O
	
Final	O
MTD	O
was	O
established	O
at	O
nab-paclitaxel	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
gemcitabine	B-DRUG
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
and	O
capecitabine	B-DRUG
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
daily	O
.	O
	
Patients	O
received	O
a	O
median	O
of	O
four	O
treatment	O
cycles	O
(	O
range	O
1月16日	O
)	O
.	O
	
The	O
most	O
frequent	O
adverse	O
events	O
(	O
any	O
grade	O
)	O
for	O
the	O
entire	O
study	O
cohort	O
included	O
fatigue	B-TOXI
","	O
rash	B-TOXI
/	O
hand-foot	B-TOXI
syndrome	I-TOXI
","	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
","	O
diarrhea	B-TOXI
","	O
neuropathy	B-TOXI
","	O
and	O
elevated	B-TOXI
liver	I-TOXI
function	I-TOXI
tests	I-TOXI
.	O
	
Ten	O
patients	O
(	O
66.7	O
%	O
)	O
experienced	O
at	O
least	O
one	O
grade	O
3月4日	O
adverse	O
event	O
.	O
	
Grade	O
3月4日	O
hematologic	B-TOXI
toxicities	I-TOXI
were	O
uncommon	O
.	O
	
Two	O
of	O
14	O
evaluable	O
patients	O
(	O
14.3	O
%	O
)	O
exhibited	O
a	O
partial	O
response	O
","	O
and	O
6	O
of	O
12	O
patients	O
(	O
50	O
%	O
)	O
with	O
elevated	O
CA19-9	O
at	O
baseline	O
had	O
a	O
_50	O
%	O
biomarker	O
decline	O
.	O
	
While	O
well	O
tolerated	O
overall	O
","	O
this	O
regimen	O
demonstrated	O
only	O
modest	O
antitumor	O
activity	O
in	O
patients	O
with	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
Recognizing	O
the	O
limits	O
of	O
cross-study	O
comparisons	O
and	O
small	O
sample	O
size	O
","	O
these	O
results	O
do	O
not	O
match	O
those	O
reported	O
at	O
MTD	O
in	O
the	O
phase	O
I	O
/	O
II	O
trial	O
of	O
gemcitabine	B-DRUG
/	O
nab-paclitaxel	B-DRUG
.	O
	
The	O
lower	O
doses	O
used	O
in	O
the	O
current	O
study	O
suggest	O
that	O
dose	O
intensity	O
may	O
be	O
a	O
critical	O
aspect	O
to	O
optimize	O
multidrug	O
regimens	O
.	O
	
A	O
Phase	O
I	O
study	O
of	O
pazopanib	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Pazopanib	B-DRUG
plus	O
gemcitabine	B-DRUG
combination	O
therapy	O
was	O
explored	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
In	O
a	O
modified	O
3	O
=+	O
3	O
enrollment	O
scheme	O
","	O
oral	O
once-daily	O
pazopanib	B-DRUG
was	O
administered	O
with	O
intravenous	O
gemcitabine	B-DRUG
(	O
Days	O
1	O
and	O
8	O
","	O
21-day	O
cycles	O
)	O
.	O
	
Three	O
protocol-specified	O
dose	O
levels	O
were	O
tested	O
:	O
pazopanib	B-DRUG
400	O
mg	O
plus	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
pazopanib	B-DRUG
800	O
mg	O
plus	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
and	O
pazopanib	B-DRUG
800	O
mg	O
plus	O
gemcitabine	B-DRUG
"1,250"	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Maximum-tolerated	O
dose	O
was	O
based	O
on	O
dose-limiting	O
toxicities	O
during	O
treatment	O
Cycle	O
1	O
In	O
the	O
expansion	O
phase	O
","	O
six	O
additional	O
patients	O
were	O
enrolled	O
at	O
the	O
highest	O
tolerable	O
dose	O
level	O
.	O
	
Twenty-two	O
patients	O
were	O
enrolled	O
.	O
	
At	O
the	O
highest	O
dose	O
level	O
tested	O
(	O
pazopanib	B-DRUG
800	O
plus	O
gemcitabine	B-DRUG
"1,250"	O
)	O
","	O
patients	O
received	O
&	O
gt	O
;	O
80	O
%	O
of	O
their	O
planned	O
dose	O
and	O
the	O
regimen	O
was	O
deemed	O
safe	O
and	O
tolerable	O
.	O
	
The	O
most	O
common	O
treatment-related	O
adverse	O
events	O
included	O
fatigue	B-TOXI
","	O
neutropenia	B-TOXI
","	O
nausea	B-TOXI
","	O
and	O
decreased	B-TOXI
appetite	I-TOXI
.	O
	
Neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
were	O
the	O
most	O
common	O
events	O
leading	O
to	O
dose	O
modifications	O
.	O
	
Pharmacokinetic	O
interaction	O
between	O
pazopanib	B-DRUG
and	O
gemcitabine	B-DRUG
was	O
not	O
observed	O
.	O
	
One	O
objective	O
partial	O
response	O
at	O
the	O
highest	O
dose	O
was	O
observed	O
in	O
a	O
patient	O
with	O
metastatic	B-CANCER
melanoma	I-CANCER
.	O
	
Prolonged	O
disease	O
stabilization	O
(	O
&	O
gt	O
;	O
12	O
cycles	O
)	O
was	O
reported	O
in	O
three	O
patients	O
(	O
metastatic	B-CANCER
melanoma	I-CANCER
","	O
cholangiocarcinoma	B-CANCER
","	O
and	O
colorectal	B-CANCER
carcinoma	I-CANCER
)	O
.	O
	
Combination	O
pazopanib	B-DRUG
plus	O
gemcitabine	B-DRUG
therapy	O
is	O
tolerable	O
","	O
with	O
an	O
adverse	O
event	O
profile	O
reflective	O
of	O
that	O
associated	O
with	O
the	O
individual	O
agents	O
.	O
	
There	O
was	O
no	O
apparent	O
pharmacokinetic	O
interaction	O
with	O
pazopanib	B-DRUG
plus	O
gemcitabine	B-DRUG
co-administration	O
","	O
although	O
patient	O
numbers	O
were	O
limited	O
.	O
	
Further	O
investigation	O
of	O
combined	O
pazopanib	B-DRUG
plus	O
gemcitabine	B-DRUG
is	O
warranted	O
.	O
	
Bimonthly	O
regimen	O
of	O
high-dose	O
leucovorin	B-DRUG
","	O
infusional	O
5-fluorouracil	B-DRUG
","	O
docetaxel	B-DRUG
","	O
and	O
cisplatin	B-DRUG
(	O
modified	B-DRUG
DCF	I-DRUG
)	O
in	O
advanced	B-CANCER
gastric	I-CANCER
adenocarcinoma	I-CANCER
.	O
	
	
The	O
combination	O
of	O
docetaxel	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
5-fluorouracil	B-DRUG
(	O
DCF	B-DRUG
)	O
is	O
an	O
effective	O
but	O
highly	O
toxic	O
regimen	O
for	O
the	O
treatment	O
of	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
To	O
improve	O
tolerability	O
while	O
maintaining	O
the	O
efficacy	O
of	O
the	O
DCF	B-DRUG
regimen	O
","	O
we	O
developed	O
a	O
modified	B-DRUG
DCF	I-DRUG
regimen	O
including	O
an	O
infusional	O
5-fluorouracil	B-DRUG
administration	O
according	O
to	O
the	O
de	O
Gramont	O
regimen	O
.	O
	
In	O
this	O
study	O
","	O
70	O
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
were	O
treated	O
.	O
	
Each	O
2-week	O
cycle	O
consisted	O
of	O
docetaxel	B-DRUG
(	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
cisplatin	B-DRUG
(	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
a	O
5-fluorouracil	B-DRUG
(	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
i.v.	O
bolus	O
","	O
and	O
5-fluorouracil	B-DRUG
(	O
"2,400"	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
i.v.	O
over	O
46	O
h	O
plus	O
leucovorin	B-DRUG
(	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
i.v.	O
over	O
2	O
h.	O
The	O
median	O
progression-free	O
survival	O
and	O
overall	O
survival	O
were	O
9	O
months	O
(	O
95	O
%	O
CI	O
","	O
7.1-10.9	O
)	O
and	O
10.8	O
months	O
(	O
95	O
%	O
CI	O
","	O
7.4-14.2	O
)	O
","	O
respectively	O
;	O
the	O
1-year	O
and	O
2-year	O
overall	O
survival	O
rates	O
were	O
46.3	O
and	O
18.4	O
%	O
","	O
respectively	O
.	O
	
Twenty-nine	O
(	O
41.4	O
%	O
)	O
partial	O
responses	O
","	O
19	O
(	O
27.1	O
%	O
)	O
stable	O
disease	O
","	O
and	O
22	O
(	O
31.4	O
%	O
)	O
progression	O
of	O
disease	O
were	O
observed	O
.	O
	
Grade	O
3月4日	O
toxicities	O
included	O
neutropenia	B-TOXI
(	O
37.1	O
%	O
)	O
","	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
15.7	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
10	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
8.6	O
%	O
)	O
","	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
(	O
10	O
%	O
)	O
","	O
stomatitis	B-TOXI
(	O
5.7	O
%	O
)	O
","	O
infection	B-TOXI
(	O
8.6	O
%	O
)	O
","	O
and	O
diarrhea	B-TOXI
(	O
2.9	O
%	O
)	O
.	O
	
Our	O
results	O
show	O
that	O
a	O
de	O
Gramont-based	O
DCF	B-DRUG
regimen	O
may	O
have	O
tolerable	O
toxicities	O
and	O
be	O
an	O
effective	O
and	O
convenient	O
palliative	O
treatment	O
for	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
PR-104	B-DRUG
a	O
bioreductive	O
pre-prodrug	O
combined	O
with	O
gemcitabine	B-DRUG
or	O
docetaxel	B-DRUG
in	O
a	O
phase	O
Ib	O
study	O
of	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
	
The	O
purpose	O
of	O
this	O
phase	O
Ib	O
clinical	O
trial	O
was	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
PR-104	B-DRUG
a	O
bioreductive	O
pre-prodrug	O
given	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
or	O
docetaxel	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
PR-104	B-DRUG
was	O
administered	O
as	O
a	O
one-hour	O
intravenous	O
infusion	O
combined	O
with	O
docetaxel	B-DRUG
60	O
to	O
75	O
mg	O
/	O
m2	O
on	O
day	O
one	O
given	O
with	O
or	O
without	O
granulocyte	O
colony	O
stimulating	O
factor	O
(	O
G-CSF	O
)	O
on	O
day	O
two	O
or	O
administrated	O
with	O
gemcitabine	B-DRUG
800	O
mg	O
/	O
m2	O
on	O
days	O
one	O
and	O
eight	O
","	O
of	O
a	O
21-day	O
treatment	O
cycle	O
.	O
	
Patients	O
were	O
assigned	O
to	O
one	O
of	O
ten	O
PR-104	B-DRUG
dose-levels	O
ranging	O
from	O
140	O
to	O
1100	O
mg	O
/	O
m2	O
and	O
to	O
one	O
of	O
four	O
combination	O
groups	O
.	O
	
Pharmacokinetic	O
studies	O
were	O
scheduled	O
for	O
cycle	O
one	O
day	O
one	O
and	O
18F	B-DRUG
fluoromisonidazole	I-DRUG
(	O
FMISO	B-DRUG
)	O
positron	O
emission	O
tomography	O
hypoxia	O
imaging	O
at	O
baseline	O
and	O
after	O
two	O
treatment	O
cycles	O
.	O
	
Forty	O
two	O
patients	O
(	O
23	O
females	O
and	O
19	O
males	O
)	O
were	O
enrolled	O
with	O
ages	O
ranging	O
from	O
27	O
to	O
85	O
years	O
and	O
a	O
wide	O
range	O
of	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
The	O
MTD	O
of	O
PR-104	B-DRUG
was	O
140	O
mg	O
/	O
m2	O
when	O
combined	O
with	O
gemcitabine	B-DRUG
","	O
200	O
mg	O
/	O
m2	O
when	O
combined	O
with	O
docetaxel	B-DRUG
60	O
mg	O
/	O
m2	O
","	O
770	O
mg	O
/	O
m2	O
when	O
combined	O
with	O
docetaxel	B-DRUG
60	O
mg	O
/	O
m2	O
plus	O
G-CSF	B-DRUG
and	O
_770	O
mg	O
/	O
m2	O
when	O
combined	O
with	O
docetaxel	B-DRUG
75	O
mg	O
/	O
m2	O
plus	O
G-CSF	B-DRUG
.	O
	
Dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
across	O
all	O
four	O
combination	O
settings	O
included	O
thrombocytopenia	B-TOXI
","	O
neutropenic	B-TOXI
fever	I-TOXI
and	O
fatigue	B-TOXI
.	O
	
Other	O
common	O
grade	O
three	O
or	O
four	O
toxicities	O
included	O
neutropenia	B-TOXI
","	O
anaemia	B-TOXI
and	O
leukopenia	B-TOXI
.	O
	
Four	O
patients	O
had	O
partial	O
tumour	O
response	O
.	O
	
Eleven	O
of	O
17	O
patients	O
undergoing	O
FMISO	B-DRUG
scans	O
showed	O
tumour	O
hypoxia	O
at	O
baseline	O
.	O
	
Plasma	O
pharmacokinetics	O
of	O
PR-104	B-DRUG
","	O
its	O
metabolites	O
(	O
alcohol	O
PR-104A	O
","	O
glucuronide	O
PR-104G	O
","	O
hydroxylamine	O
PR-104H	O
","	O
amine	O
PR-104M	O
and	O
semi-mustard	O
PR-104S1	O
)	O
","	O
docetaxel	B-DRUG
and	O
gemcitabine	B-DRUG
were	O
similar	O
to	O
that	O
of	O
their	O
single	O
agents	O
.	O
	
Combination	O
of	O
PR-104	B-DRUG
with	O
docetaxel	B-DRUG
or	O
gemcitabine	B-DRUG
caused	O
dose-limiting	O
and	O
severe	O
myelotoxicity	O
","	O
but	O
prophylactic	O
G-CSF	B-DRUG
allowed	O
PR-104	B-DRUG
dose	O
escalation	O
with	O
docetaxel	B-DRUG
.	O
	
Dose-limiting	O
thrombocytopenia	B-TOXI
prohibited	O
further	O
evaluation	O
of	O
the	O
PR104-gemcitabine	B-DRUG
combination	O
.	O
	
A	O
recommended	O
dose	O
was	O
identified	O
for	O
phase	O
II	O
trials	O
of	O
PR-104	B-DRUG
of	O
770	O
mg	O
/	O
m2	O
combined	O
with	O
docetaxel	B-DRUG
60	O
to	O
75	O
mg	O
/	O
m2	O
both	O
given	O
on	O
day	O
one	O
of	O
a	O
21-day	O
treatment	O
cycle	O
supported	O
by	O
prophylactic	O
G-CSF	B-DRUG
(	O
NCT00459836	O
)	O
.	O
	
A	O
phase	O
2	O
trial	O
of	O
ixabepilone	B-DRUG
plus	O
cetuximab	B-DRUG
in	O
first-line	O
treatment	O
of	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
aim	O
of	O
this	O
phase	O
2	O
study	O
was	O
to	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
ixabepilone	B-DRUG
plus	O
cetuximab	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
Eligible	O
patients	O
had	O
advanced	B-CANCER
pancreatic	I-CANCER
adenocarcinoma	I-CANCER
that	O
was	O
metastatic	O
or	O
not	O
amenable	O
to	O
resection	O
","	O
a	O
Karnofsky	O
performance	O
status	O
_70	O
%	O
","	O
and	O
no	O
prior	O
therapy	O
for	O
advanced	O
disease	O
.	O
	
Patients	O
received	O
ixabepilone	B-DRUG
32	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
3-hour	O
IV	O
infusion	O
)	O
every	O
3	O
weeks	O
and	O
cetuximab	B-DRUG
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
1-hour	O
IV	O
infusion	O
)	O
weekly	O
.	O
	
The	O
primary	O
efficacy	O
end	O
point	O
was	O
the	O
6-month	O
survival	O
rate	O
.	O
	
Secondary	O
end	O
points	O
included	O
tumor	O
response	O
rate	O
","	O
overall	O
survival	O
","	O
progression-free	O
survival	O
","	O
and	O
tolerability	O
.	O
	
A	O
total	O
of	O
54	O
patients	O
were	O
enrolled	O
on	O
this	O
study	O
.	O
	
The	O
6-month	O
survival	O
rate	O
was	O
57	O
%	O
(	O
31	O
/	O
54	O
:	O
95	O
%	O
CI	O
:	O
43-71	O
%	O
)	O
with	O
a	O
median	O
overall	O
survival	O
of	O
7.6	O
months	O
(	O
95	O
%	O
CI	O
:	O
5.5-12.2	O
months	O
)	O
.	O
	
Patients	O
who	O
developed	O
acneiform	B-TOXI
rash	I-TOXI
(	O
n	O
=	O
36	O
)	O
had	O
a	O
median	O
survival	O
of	O
8.8	O
months	O
","	O
compared	O
with	O
2.6	O
months	O
for	O
those	O
without	O
rash	B-TOXI
(	O
n	O
=	O
18	O
)	O
.	O
	
Of	O
31	O
patients	O
with	O
measurable	O
disease	O
(	O
defined	O
as	O
response-evaluable	O
)	O
","	O
4	O
had	O
confirmed	O
partial	O
responses	O
and	O
an	O
additional	O
24	O
had	O
stable	O
disease	O
.	O
	
The	O
combination	O
was	O
generally	O
well-tolerated	O
with	O
the	O
most	O
common	O
grade	O
3	O
/	O
4	O
hematological	B-TOXI
toxicities	O
being	O
leucopenia	B-TOXI
(	O
39	O
%	O
)	O
and	O
neutropenia	B-TOXI
(	O
33	O
%	O
)	O
.	O
	
The	O
most	O
common	O
grade	O
3	O
/	O
4	O
nonhematologic	B-TOXI
toxicity	I-TOXI
was	O
fatigue	B-TOXI
(	O
17	O
%	O
)	O
.	O
	
The	O
combination	O
of	O
ixabepilone	B-DRUG
and	O
cetuximab	B-DRUG
was	O
active	O
and	O
had	O
acceptable	O
toxicity	O
.	O
	
The	O
efficacy	O
results	O
are	O
similar	O
to	O
single-agent	O
ixabepilone	B-DRUG
and	O
gemcitabine-based	B-DRUG
combination	O
therapies	O
in	O
patients	O
with	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
Exploratory	O
analyses	O
suggest	O
a	O
trend	O
toward	O
improved	O
survival	O
for	O
patients	O
who	O
experienced	O
rash	B-TOXI
.	O
	
Treatment	O
of	O
hairy	B-CANCER
cell	I-CANCER
leukemia	I-CANCER
with	O
alternating	O
cycles	O
of	O
pentostatin	B-DRUG
and	O
recombinant	O
leukocyte	B-DRUG
A	I-DRUG
interferon	I-DRUG
:	O
results	O
of	O
a	O
phase	O
II	O
study	O
.	O
	
	
Fifteen	O
patients	O
with	O
hairy	B-CANCER
cell	I-CANCER
leukemia	I-CANCER
(	O
HCL	B-CANCER
)	O
were	O
treated	O
with	O
deoxycoformycin	B-DRUG
(	O
pentostatin	B-DRUG
;	O
dCF	O
)	O
(	O
4	O
mg	O
/	O
m2	O
intravenous	O
[	O
IV	O
]	O
every	O
week	O
x	O
3	O
)	O
and	O
recombinant	B-DRUG
interferon-alpha	I-DRUG
2a	I-DRUG
(	O
rIFN-alpha	B-DRUG
2a	I-DRUG
)	O
(	O
3	O
x	O
10	O
(	O
6	O
)	O
units	O
subcutaneously	O
[	O
SC	O
]	O
daily	O
x	O
4	O
weeks	O
)	O
in	O
alternating	O
months	O
for	O
a	O
total	O
of	O
14	O
months	O
.	O
	
Eleven	O
patients	O
had	O
undergone	O
splenectomy	O
;	O
four	O
had	O
received	O
prior	O
systemic	O
therapy	O
with	O
chlorambucil	B-DRUG
and	O
/	O
or	O
steroids	B-DRUG
.	O
	
All	O
15	O
are	O
evaluable	O
for	O
toxicity	O
and	O
peripheral	B-TOXI
blood	I-TOXI
response	I-TOXI
","	O
while	O
14	O
are	O
assessable	O
for	O
bone	B-TOXI
marrow	I-TOXI
response	I-TOXI
.	O
	
Toxicity	O
was	O
tolerable	O
with	O
grade	O
3	O
or	O
4	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
in	O
three	O
patients	O
","	O
neutropenic	B-TOXI
fevers	I-TOXI
in	O
five	O
","	O
transient	O
but	O
significant	O
depression	B-TOXI
in	O
eight	O
","	O
and	O
localized	O
cutaneous	B-TOXI
herpes	I-TOXI
zoster	I-TOXI
in	O
four	O
.	O
	
Circulating	O
hairy	O
cells	O
were	O
undetectable	O
by	O
the	O
end	O
of	O
the	O
first	O
month	O
in	O
10	O
of	O
13	O
patients	O
","	O
and	O
by	O
the	O
end	O
of	O
the	O
second	O
month	O
in	O
the	O
other	O
three	O
.	O
	
Fourteen	O
patients	O
had	O
bilateral	O
bone	O
marrow	O
biopsies	O
performed	O
at	O
baseline	O
after	O
6	O
months	O
of	O
treatment	O
","	O
at	O
the	O
end	O
of	O
treatment	O
(	O
14	O
months	O
)	O
","	O
and	O
at	O
6-month	O
intervals	O
during	O
follow-up	O
.	O
	
Before	O
treatment	O
","	O
all	O
patients	O
had	O
hypercellular	O
marrows	O
with	O
hairy	O
cels	O
replacing	O
normal	O
marrow	O
elements	O
;	O
all	O
showed	O
at	O
least	O
a	O
95	O
%	O
clearing	O
of	O
their	O
hairy	O
cell	O
infiltrate	O
by	O
6	O
months	O
of	O
therapy	O
.	O
	
However	O
","	O
small	O
collections	O
of	O
residual	O
hairy	O
cells	O
could	O
be	O
detected	O
intermittently	O
on	O
at	O
least	O
one	O
side	O
of	O
bilateral	O
samples	O
in	O
all	O
patients	O
.	O
	
All	O
patients	O
have	O
completed	O
treatment	O
with	O
a	O
median	O
duration	O
of	O
follow-up	O
off	O
therapy	O
of	O
27	O
months	O
(	O
range	O
","	O
15	O
to	O
31	O
months	O
)	O
.	O
	
To	O
date	O
","	O
all	O
peripheral	O
counts	O
and	O
serum	O
soluble	O
interleukin-2	O
receptor	O
(	O
sIL2R	O
)	O
levels	O
remain	O
stable	O
","	O
and	O
no	O
patient	O
has	O
had	O
progression	O
of	O
the	O
hairy	O
cell	O
infiltrate	O
in	O
the	O
bone	O
marrow	O
.	O
	
Although	O
no	O
patient	O
achieved	O
a	O
pathologic	O
complete	O
response	O
","	O
alternating	O
monthly	O
cycles	O
of	O
dCF	O
and	O
rIFN-alpha	O
2a	O
produced	O
durable	O
partial	O
remissions	O
(	O
PRs	O
)	O
in	O
all	O
patients	O
.	O
	
Continued	O
follow-up	O
is	O
required	O
to	O
determine	O
the	O
length	O
of	O
such	O
remissions	O
.	O
	
Phase	O
I	O
pharmacokinetic	O
and	O
pharmacodynamic	O
study	O
of	O
lapatinib	B-DRUG
in	O
combination	O
with	O
sorafenib	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
refractory	I-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
The	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
and	O
ERBB2	O
(	O
HER2	O
)	O
pathways	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
#NAME?	O
angiogenesis	O
have	O
a	O
pivotal	O
role	O
in	O
cancer	O
pathogenesis	O
and	O
progression	O
.	O
	
Robust	O
experimental	O
evidence	O
has	O
shown	O
that	O
these	O
pathways	O
are	O
functionally	O
linked	O
and	O
implicated	O
in	O
acquired	O
resistance	O
to	O
targeted	O
therapies	O
making	O
them	O
attractive	O
candidates	O
for	O
joined	O
targeting	O
.	O
	
We	O
undertook	O
this	O
phase	O
I	O
trial	O
to	O
assess	O
the	O
safety	O
","	O
the	O
recommended	O
dose	O
for	O
phase	O
II	O
trials	O
(	O
RPTD	O
)	O
","	O
pharmacokinetics	O
(	O
PK	O
)	O
","	O
pharmacodynamics	O
(	O
PD	O
)	O
","	O
and	O
the	O
preliminary	O
antitumour	O
activity	O
of	O
the	O
combination	O
of	O
lapatinib	B-DRUG
and	O
sorafenib	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
refractory	I-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
Four	O
cohorts	O
of	O
at	O
least	O
three	O
patients	O
each	O
received	O
lapatinib	B-DRUG
once	O
daily	O
and	O
sorafenib	B-DRUG
twice	O
daily	O
together	O
on	O
a	O
continuous	O
schedule	O
.	O
	
Doses	O
of	O
lapatinib	B-DRUG
and	O
sorafenib	B-DRUG
were	O
escalated	O
based	O
on	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
in	O
the	O
first	O
treatment	O
cycle	O
following	O
a	O
traditional	O
3+3	O
design	O
until	O
the	O
RPTD	O
was	O
reached	O
.	O
	
Additional	O
patients	O
were	O
treated	O
at	O
the	O
RPTD	O
to	O
characterise	O
PK	O
profiles	O
of	O
this	O
combination	O
and	O
to	O
investigate	O
the	O
potential	O
interaction	O
between	O
lapatinib	B-DRUG
and	O
sorafenib	B-DRUG
.	O
	
Serum	O
samples	O
were	O
collected	O
at	O
baseline	O
and	O
then	O
prospectively	O
every	O
two	O
cycles	O
to	O
assess	O
changes	O
in	O
PD	O
parameters	O
.	O
	
This	O
trial	O
is	O
registered	O
with	O
ClinicalTrials.gov	O
","	O
number	O
NCT00984425	O
.	O
	
Thirty	O
patients	O
with	O
advanced	B-CANCER
refractory	I-CANCER
solid	I-CANCER
tumours	I-CANCER
were	O
enroled	O
.	O
	
DLTs	O
were	O
grade	O
three	O
fatigue	B-TOXI
and	O
grade	O
3	O
atypical	B-TOXI
skin	I-TOXI
rash	I-TOXI
observed	O
at	O
dose	O
levels	O
3	O
and	O
4	O
","	O
respectively	O
.	O
	
The	O
higher	O
dose	O
level	O
explored	O
(	O
lapatinib	B-DRUG
1250mg	O
/	O
day	O
and	O
sorafenib	B-DRUG
400mg	O
twice	O
daily	O
)	O
represented	O
the	O
RPTD	O
of	O
the	O
combination	O
.	O
	
The	O
most	O
common	O
drug-related	O
adverse	O
events	O
were	O
fatigue	B-TOXI
(	O
68	O
%	O
)	O
","	O
hypocalcemia	B-TOXI
(	O
61	O
%	O
)	O
","	O
diarrhoea	B-TOXI
(	O
57	O
%	O
)	O
","	O
lymphopaenia	B-TOXI
(	O
54	O
%	O
)	O
","	O
anorexia	B-TOXI
(	O
50	O
%	O
)	O
","	O
rash	B-TOXI
(	O
50	O
%	O
)	O
","	O
and	O
hypophosphatemia	B-TOXI
(	O
46	O
%	O
)	O
.	O
	
PK	O
analysis	O
revealed	O
no	O
significant	O
effect	O
of	O
sorafenib	B-DRUG
on	O
the	O
PK	O
profile	O
of	O
lapatinib	B-DRUG
.	O
	
Of	O
the	O
27	O
assessable	O
patients	O
for	O
clinical	O
activity	O
","	O
one	O
achieved	O
a	O
confirmed	O
complete	O
response	O
","	O
four	O
(	O
15	O
%	O
)	O
had	O
a	O
partial	O
response	O
","	O
and	O
12	O
(	O
44	O
%	O
)	O
achieved	O
disease	O
stabilisation	O
.	O
	
The	O
disease	O
control	O
rate	O
overall	O
was	O
63	O
%	O
.	O
	
Combination	O
treatment	O
with	O
lapatinib	B-DRUG
and	O
sorafenib	B-DRUG
was	O
feasible	O
with	O
promising	O
clinical	O
activity	O
and	O
without	O
significant	O
PK	O
interactions	O
.	O
	
Long	O
term	O
tolerability	O
seems	O
to	O
be	O
challenging	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
intravenous	O
aflibercept	B-DRUG
with	O
FOLFIRI	B-DRUG
in	O
Japanese	O
patients	O
with	O
previously	O
treated	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
Aflibercept	B-DRUG
","	O
a	O
recombinant	O
fusion	O
protein	O
","	O
is	O
a	O
potent	O
inhibitor	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
#NAME?	O
","	O
VEGF-B	O
","	O
and	O
the	O
placental	O
growth	O
factor	O
(	O
PlGF	O
)	O
.	O
	
The	O
present	O
study	O
was	O
an	O
open-label	O
","	O
sequential-cohort	O
","	O
dose-escalation	O
trial	O
of	O
intravenous	O
aflibercept	B-DRUG
administered	O
every	O
2	O
weeks	O
in	O
combination	O
with	O
5-fluorouracil	B-DRUG
","	O
levofolinate	B-DRUG
","	O
and	O
irinotecan	B-DRUG
(	O
FOLFIRI	B-DRUG
)	O
in	O
patients	O
with	O
previously	O
treated	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
mCRC	B-CANCER
)	O
.	O
	
We	O
aimed	O
to	O
assess	O
the	O
safety	O
","	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
","	O
pharmacokinetics	O
","	O
and	O
preliminary	O
efficacy	O
of	O
the	O
combination	O
therapy	O
to	O
determine	O
the	O
recommended	O
phase	O
II	O
dose	O
(	O
RPTD	O
)	O
for	O
Japanese	O
patients	O
.	O
	
Two	O
doses	O
of	O
aflibercept	B-DRUG
(	O
2	O
and	O
4	O
mg	O
/	O
kg	O
)	O
were	O
set	O
","	O
and	O
DLTs	O
were	O
evaluated	O
in	O
the	O
first	O
2	O
cycles	O
.	O
	
The	O
subjects	O
comprised	O
16	O
patients	O
(	O
n	O
=	O
3	O
and	O
13	O
for	O
2	O
and	O
4	O
mg	O
/	O
kg	O
aflibercept	B-DRUG
","	O
respectively	O
)	O
who	O
received	O
a	O
total	O
of	O
149	O
cycles	O
of	O
aflibercept	B-DRUG
with	O
FOLFIRI	B-DRUG
.	O
	
No	O
DLTs	O
were	O
observed	O
at	O
both	O
doses	O
.	O
	
The	O
frequent	O
adverse	O
events	O
encountered	O
were	O
leukopenia	B-TOXI
","	O
neutropenia	B-TOXI
","	O
anemia	B-TOXI
","	O
diarrhea	B-TOXI
","	O
fatigue	B-TOXI
","	O
decreased	B-TOXI
appetite	I-TOXI
","	O
stomatitis	B-TOXI
","	O
dysphonia	B-TOXI
","	O
nausea	B-TOXI
","	O
and	O
epistaxis	B-TOXI
.	O
	
The	O
most	O
common	O
grade	O
3	O
/	O
4	O
adverse	O
events	O
were	O
neutropenia	B-TOXI
for	O
both	O
doses	O
and	O
hypertension	B-TOXI
for	O
the	O
4	O
mg	O
/	O
kg	O
dose	O
.	O
	
Free	O
aflibercept	B-DRUG
exposure	O
increased	O
with	O
the	O
dose	O
","	O
whereas	O
exposure	O
to	O
VEGF-bound	O
aflibercept	B-DRUG
remained	O
similar	O
at	O
both	O
doses	O
.	O
	
The	O
response	O
rate	O
and	O
progression-free	O
survival	O
at	O
4	O
mg	O
/	O
kg	O
was	O
8.3	O
%	O
and	O
7.59	O
months	O
","	O
respectively	O
.	O
	
In	O
conclusion	O
","	O
the	O
combination	O
of	O
aflibercept	B-DRUG
and	O
FOLFIRI	B-DRUG
was	O
well	O
tolerated	O
at	O
both	O
doses	O
.	O
	
The	O
RPTD	O
of	O
aflibercept	B-DRUG
in	O
combination	O
with	O
FOLFIRI	B-DRUG
for	O
Japanese	O
patients	O
with	O
mCRC	B-CANCER
was	O
determined	O
to	O
be	O
4	O
mg	O
/	O
kg	O
every	O
2	O
weeks	O
.	O
	
ClinicalTrials.gov	O
identifier	O
:	O
NCT00921661	O
.	O
	
Phase	O
I	O
study	O
of	O
imatinib	B-DRUG
","	O
cisplatin	B-DRUG
and	O
5-fluoruracil	B-DRUG
or	O
capecitabine	B-DRUG
in	O
advanced	B-CANCER
esophageal	I-CANCER
and	I-CANCER
gastric	I-CANCER
adenocarcinoma	I-CANCER
.	O
	
	
Despite	O
all	O
benefit	O
provided	O
by	O
established	O
therapies	O
prognosis	O
of	O
gastric	B-CANCER
cancer	I-CANCER
remains	O
poor	O
.	O
	
Targeted	O
inhibition	O
of	O
platelet	O
derived	O
growth	O
factor	O
receptor	O
(	O
PDGFR	O
)	O
by	O
imatinib	B-DRUG
may	O
influence	O
tumor	O
growth	O
and	O
amplify	O
chemotherapeutic	O
effects	O
.	O
	
This	O
phase	O
I	O
study	O
evaluated	O
dose	O
limiting	O
toxicity	O
(	O
DLT	O
)	O
of	O
imatinib	B-DRUG
combinated	O
with	O
chemotherapy	O
according	O
to	O
a	O
3-patient	O
cohort	O
dose-escalating	O
design	O
.	O
	
Thirty-five	O
patients	O
received	O
cisplatin	B-DRUG
(	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
d1	O
q	O
3w	O
)	O
/	O
capecitabine	B-DRUG
(	O
1250	O
mg	O
/	O
m	O
(	O
2	O
)	O
bid	O
d1-14	O
q	O
21	O
)	O
or	O
cisplatin	B-DRUG
(	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
d1	O
q	O
2w	O
)	O
/	O
5-fluoruracil	B-DRUG
(	O
2	O
g	O
/	O
m	O
(	O
2	O
)	O
d1	O
","	O
q	O
1w	O
)	O
.	O
	
Imatinib	B-DRUG
was	O
started	O
d	O
=-	O
4	O
with	O
dose	O
escalation	O
from	O
300	O
to	O
700	O
mg	O
QD	O
in	O
100	O
mg	O
steps	O
.	O
	
At	O
imatinib	B-DRUG
dose	O
level	O
1	O
(	O
300mg	O
)	O
one	O
DLT	O
was	O
observed	O
","	O
three	O
more	O
patients	O
were	O
enrolled	O
without	O
further	O
DLT	O
.	O
	
At	O
dose	O
level	O
5	O
(	O
700	O
mg	O
)	O
two	O
gastric	B-TOXI
perforations	I-TOXI
occurred	O
","	O
so	O
600	O
mg	O
imatinib	B-DRUG
emerged	O
as	O
the	O
maximum	O
tolerated	O
dose	O
.	O
	
Major	O
grade	O
3	O
/	O
4	O
toxicities	O
were	O
nausea	B-TOXI
(	O
6	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
6	O
%	O
)	O
and	O
fatigue	B-TOXI
(	O
3	O
%	O
)	O
.	O
	
Response	O
evaluation	O
revealed	O
partial	O
response	O
in	O
27	O
%	O
and	O
stable	O
disease	O
in	O
43	O
%	O
of	O
the	O
assessable	O
patients	O
.	O
	
Combination	O
of	O
imatinib	B-DRUG
and	O
chemotherapy	O
is	O
well	O
tolerated	O
.	O
	
Response	O
rates	O
were	O
not	O
superior	O
to	O
those	O
of	O
standard	O
therapy	O
.	O
	
Further	O
investigations	O
of	O
a	O
larger	O
group	O
of	O
patients	O
are	O
required	O
to	O
confirm	O
the	O
amplification	O
of	O
chemotherapy	O
effects	O
by	O
imatinib	B-DRUG
.	O
	
European	O
Clinical	O
Trials	O
Database	O
:	O
Eudra-CT2006-005792-17	O
and	O
Clinical	O
Trials	O
Database	O
:	O
NCT00601510	O
.	O
	
Randomized	O
phase	O
III	O
placebo-controlled	B-DRUG
trial	O
of	O
letrozole	B-DRUG
plus	O
oral	B-DRUG
temsirolimus	I-DRUG
as	O
first-line	O
endocrine	O
therapy	O
in	O
postmenopausal	O
women	O
with	O
locally	B-CANCER
advanced	I-CANCER
or	I-CANCER
metastatic	I-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
Recent	O
data	O
showed	O
improvement	O
in	O
progression-free	O
survival	O
(	O
PFS	O
)	O
when	O
adding	O
everolimus	B-DRUG
to	O
exemestane	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
experiencing	O
recurrence	O
/	O
progression	O
after	O
nonsteroidal	O
aromatase	O
inhibitor	O
(	O
AI	O
)	O
therapy	O
.	O
	
Here	O
","	O
we	O
report	O
clinical	O
outcomes	O
of	O
combining	O
the	O
mammalian	O
target	O
of	O
rapamycin	B-DRUG
(	O
mTOR	B-DRUG
)	O
inhibitor	O
temsirolimus	B-DRUG
with	O
letrozole	B-DRUG
in	O
AI-naive	O
patients	O
.	O
	
This	O
phase	O
III	O
randomized	O
placebo-controlled	B-DRUG
study	O
tested	O
efficacy	O
/	O
safety	O
of	O
first-line	O
oral	B-DRUG
letrozole	I-DRUG
2.5	O
mg	O
daily	O
/	O
temsirolimus	B-DRUG
30	O
mg	O
daily	O
(	O
5	O
days	O
every	O
2	O
weeks	O
)	O
versus	O
letrozole	B-DRUG
/	O
placebo	B-DRUG
in	O
"1,112"	O
patients	O
with	O
AI-naive	O
","	O
hormone	O
receptor-positive	O
advanced	O
disease	O
.	O
	
An	O
independent	O
data	O
monitoring	O
committee	O
recommended	O
study	O
termination	O
for	O
futility	O
at	O
the	O
second	O
preplanned	O
interim	O
analysis	O
(	O
382	O
PFS	O
events	O
)	O
.	O
	
Patients	O
were	O
balanced	O
(	O
median	O
age	O
","	O
63	O
years	O
;	O
10	O
%	O
stage	O
III	O
","	O
40	O
%	O
had	O
received	O
adjuvant	O
endocrine	O
therapy	O
)	O
.	O
	
Those	O
on	O
letrozole	B-DRUG
/	O
temsirolimus	B-DRUG
experienced	O
more	O
grade	O
3	O
to	O
4	O
events	O
(	O
37	O
%	O
v	O
24	O
%	O
)	O
.	O
	
There	O
was	O
no	O
overall	O
improvement	O
in	O
primary	O
end	O
point	O
PFS	O
(	O
median	O
","	O
9	O
months	O
;	O
hazard	O
ratio	O
[	O
HR	O
]	O
","	O
0.9	O
;	O
95	O
%	O
CI	O
","	O
0.76	O
to	O
1.07	O
;	O
P	O
=	O
0.25	O
)	O
nor	O
in	O
the	O
40	O
%	O
patient	O
subset	O
with	O
prior	O
adjuvant	O
endocrine	O
therapy	O
.	O
	
An	O
exploratory	O
analysis	O
showed	O
improved	O
PFS	O
favoring	O
letrozole	B-DRUG
/	O
temsirolimus	B-DRUG
in	O
patients	O
_	O
age	O
65	O
years	O
(	O
9	O
v	O
5.6	O
months	O
;	O
HR	O
","	O
0.75	O
;	O
95	O
%	O
CI	O
","	O
0.6	O
to	O
0.93	O
;	O
P	O
=	O
0.009	O
)	O
","	O
which	O
was	O
separately	O
examined	O
by	O
an	O
exploratory	O
analysis	O
of	O
5-month	O
PFS	O
using	O
subpopulation	O
treatment	O
effect	O
pattern	O
plot	O
methodology	O
(	O
P	O
=	O
0.003	O
)	O
.	O
	
Adding	O
temsirolimus	B-DRUG
to	O
letrozole	B-DRUG
did	O
not	O
improve	O
PFS	O
as	O
first-line	O
therapy	O
in	O
patients	O
with	O
AI-naive	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Exploratory	O
analyses	O
of	O
benefit	O
in	O
younger	O
postmenopausal	O
patients	O
require	O
external	O
confirmation	O
.	O
	
Phase	O
III	O
trial	O
of	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
with	O
or	O
without	O
sorafenib	B-DRUG
in	O
metastatic	B-CANCER
melanoma	I-CANCER
.	O
	
	
The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
carboplatin	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
and	O
sorafenib	B-DRUG
(	O
CPS	O
)	O
improve	O
overall	O
survival	O
(	O
OS	O
)	O
compared	O
with	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
(	O
CP	O
)	O
in	O
chemotherapy-naive	O
patients	O
with	O
metastatic	B-CANCER
melanoma	I-CANCER
.	O
	
In	O
this	O
double-blind	O
","	O
randomized	O
","	O
placebo-controlled	B-DRUG
phase	O
III	O
study	O
","	O
all	O
patients	O
received	O
carboplatin	B-DRUG
at	O
area	O
under	O
the	O
[	O
concentration-time	O
]	O
curve	O
6	O
and	O
paclitaxel	B-DRUG
225	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
once	O
every	O
21	O
days	O
with	O
random	O
assignment	O
to	O
sorafenib	B-DRUG
400	O
mg	O
orally	O
twice	O
per	O
day	O
on	O
days	O
2	O
through	O
19	O
every	O
21	O
days	O
or	O
placebo	B-DRUG
.	O
	
The	O
primary	O
end	O
point	O
was	O
OS	O
","	O
and	O
secondary	O
end	O
points	O
included	O
progression-free	O
survival	O
","	O
objective	O
tumor	O
response	O
","	O
and	O
toxicity	O
.	O
	
In	O
all	O
","	O
823	O
patients	O
were	O
enrolled	O
over	O
34	O
months	O
.	O
	
At	O
final	O
analysis	O
","	O
the	O
median	O
OS	O
was	O
11.3	O
months	O
(	O
95	O
%	O
CI	O
","	O
9.8	O
to	O
12.2	O
months	O
)	O
for	O
CP	O
and	O
11.1	O
months	O
(	O
95	O
%	O
CI	O
","	O
10.3	O
to	O
12.3	O
months	O
)	O
for	O
CPS	O
;	O
the	O
difference	O
in	O
the	O
OS	O
distribution	O
was	O
not	O
statistically	O
significant	O
by	O
the	O
stratified	O
log-rank	O
test	O
","	O
stratified	O
on	O
American	O
Joint	O
Committee	O
on	O
Cancer	O
(	O
AJCC	O
)	O
stage	O
","	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
(	O
ECOG	O
)	O
performance	O
status	O
","	O
and	O
prior	O
therapy	O
(	O
P	O
=	O
0.878	O
)	O
.	O
	
Median	O
progression-free	O
survival	O
was	O
4.9	O
months	O
for	O
CPS	O
and	O
4.2	O
months	O
for	O
CP	O
(	O
P	O
=	O
0.092	O
","	O
stratified	O
log-rank	O
test	O
)	O
.	O
	
Response	O
rate	O
was	O
20	O
%	O
for	O
CPS	O
and	O
18	O
%	O
for	O
CP	O
(	O
P	O
=	O
0.427	O
)	O
.	O
	
More	O
patients	O
on	O
the	O
CPS	O
arm	O
had	O
grade	O
3	O
or	O
higher	O
toxicities	O
(	O
84	O
%	O
v	O
78	O
%	O
;	O
P	O
=	O
0.027	O
)	O
","	O
with	O
increased	O
rash	B-TOXI
","	O
hand-foot	B-TOXI
syndrome	I-TOXI
","	O
and	O
thrombocytopenia	B-TOXI
accounting	O
for	O
most	O
of	O
the	O
difference	O
.	O
	
Sorafenib	B-DRUG
does	O
not	O
improve	O
OS	O
when	O
given	O
in	O
combination	O
with	O
CP	O
for	O
chemotherapy-naive	O
patients	O
with	O
metastatic	B-CANCER
melanoma	I-CANCER
.	O
	
This	O
study	O
establishes	O
benchmark	O
end	O
points	O
for	O
the	O
CP	O
regimen	O
in	O
first-line	O
therapy	O
of	O
metastatic	B-CANCER
melanoma	I-CANCER
.	O
	
A	O
phase	O
I	O
trial	O
of	O
gefitinib	B-DRUG
and	O
nimotuzumab	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
	
Nimotuzumab	B-DRUG
(	O
TheraCIM庐	O
)	O
is	O
a	O
humanized	O
anti-epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
with	O
minimal	B-DRUG
skin	I-DRUG
toxicity	I-DRUG
.	O
	
Combining	O
a	O
different	O
class	O
of	O
anti-EGFR	O
drug	O
with	O
gefitinib	B-DRUG
is	O
a	O
new	O
strategy	O
to	O
overcome	O
intrinsic	O
and	O
acquired	O
resistance	O
to	O
gefitinib	B-DRUG
.	O
	
The	O
aim	O
of	O
this	O
phase	O
I	O
trial	O
was	O
to	O
determine	O
recommended	O
phase	O
II	O
dose	O
(	O
RPIID	O
)	O
and	O
the	O
safety	O
of	O
gefitinib	B-DRUG
and	O
nimotuzumab	B-DRUG
combination	O
treatment	O
.	O
	
Patients	O
with	O
advanced	B-CANCER
/	I-CANCER
metastatic	I-CANCER
NSCLC	I-CANCER
were	O
treated	O
with	O
escalating	O
doses	O
of	O
weekly	O
nimotuzumab	B-DRUG
(	O
100mg	O
or	O
200mg	O
","	O
IV	O
)	O
and	O
fixed	O
doses	O
of	O
daily	O
gefitinib	B-DRUG
(	O
250	O
mg	O
/	O
day	O
","	O
PO	O
)	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
.	O
	
We	O
planned	O
to	O
enroll	O
10	O
additional	O
patients	O
at	O
RPIID	O
to	O
ascertain	O
the	O
safety	O
of	O
treatment	O
.	O
	
EGFR	O
mutations	O
and	O
KRAS	O
mutations	O
were	O
analyzed	O
from	O
available	O
tumor	O
samples	O
.	O
	
A	O
total	O
of	O
16	O
patients	O
were	O
enrolled	O
(	O
3	O
in	O
100mg	O
cohort	O
","	O
13	O
in	O
200mg	O
cohort	O
)	O
.	O
	
Six	O
patients	O
(	O
37.5	O
%	O
)	O
were	O
female	O
","	O
and	O
5	O
(	O
31.3	O
%	O
)	O
were	O
never	O
smokers	O
.	O
	
Adenocarcinoma	B-CANCER
was	O
the	O
major	O
histologic	O
type	O
(	O
13	O
patients	O
","	O
81.3	O
%	O
)	O
.	O
	
Treatment	O
was	O
well-tolerated	O
without	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
.	O
	
Four	O
patients	O
(	O
25	O
%	O
)	O
experienced	O
grade	O
2	O
skin	B-TOXI
toxicity	I-TOXI
(	O
1	O
in	O
100mg	O
cohorts	O
","	O
3	O
in	O
200mg	O
cohort	O
)	O
.	O
	
Other	O
common	O
grade	O
1	O
/	O
2	O
toxicities	O
were	O
fatigue	B-TOXI
(	O
37.5	O
%	O
)	O
and	O
diarrhea	B-TOXI
(	O
25	O
%	O
)	O
.	O
	
Among	O
16	O
evaluable	O
patients	O
","	O
four	O
patients	O
(	O
25	O
%	O
)	O
achieved	O
partial	O
response	O
and	O
7	O
patients	O
(	O
43.8	O
%	O
)	O
had	O
stable	O
disease	O
.	O
	
Two	O
of	O
4	O
responders	O
had	O
EGFR	O
mutation	O
(	O
exon	O
19	O
deletion	O
)	O
.	O
	
Dual	O
agent	O
molecular	O
targeting	O
of	O
EGFR	O
with	O
nimotuzumab	B-DRUG
and	O
gefitinib	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
is	O
well-tolerated	O
.	O
	
The	O
RPIID	O
for	O
nimotuzumab	B-DRUG
is	O
200mg	O
weekly	O
IV	O
and	O
for	O
gefitinib	B-DRUG
250	O
mg	O
/	O
day	O
PO	O
.	O
	
Based	O
upon	O
this	O
phase	O
I	O
trial	O
","	O
we	O
are	O
planning	O
to	O
conduct	O
a	O
randomized	O
phase	O
II	O
trial	O
comparing	O
gefitinib	B-DRUG
and	O
nimotuzumab	B-DRUG
with	O
gefitinib	B-DRUG
alone	O
in	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
Randomized	O
Phase	O
II	O
trial	O
of	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
followed	O
by	O
gemcitabine	B-DRUG
switch-maintenance	O
therapy	O
versus	O
gemcitabine	B-DRUG
and	O
carboplatin	B-DRUG
followed	O
by	O
gemcitabine	B-DRUG
continuation-maintenance	O
therapy	O
in	O
previously	O
untreated	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
In	O
recent	O
years	O
","	O
maintenance	O
chemotherapy	O
is	O
increasingly	O
being	O
recognized	O
as	O
a	O
new	O
treatment	O
strategy	O
to	O
improve	O
the	O
outcome	O
of	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
However	O
","	O
the	O
optimal	O
maintenance	O
strategy	O
is	O
still	O
controversial	O
.	O
	
Gemcitabine	B-DRUG
is	O
a	O
promising	O
candidate	O
for	O
single-agent	O
maintenance	O
therapy	O
because	O
of	O
little	O
toxicity	O
and	O
good	O
tolerability	O
.	O
	
We	O
have	O
conducted	O
a	O
randomized	O
phase	O
II	O
study	O
to	O
evaluate	O
the	O
validity	O
of	O
single-agent	O
maintenance	O
chemotherapy	O
of	O
gemcitabine	B-DRUG
and	O
to	O
compare	O
continuation-	O
and	O
switch-maintenance	O
.	O
	
Chemona茂ve	O
patients	O
with	O
stage	O
IIIB	O
/	O
IV	O
NSCLC	B-CANCER
were	O
randomly	O
assigned	O
01:01	O
to	O
either	O
arm	O
A	O
or	O
B.	O
Patients	O
received	O
paclitaxel	B-CANCER
(	O
200	O
mg	O
/	O
m2	O
","	O
day	O
1	O
)	O
plus	O
carboplatin	B-CANCER
(	O
AUC	O
6	O
mg	O
/	O
mL	O
/	O
min	O
","	O
day	O
1	O
)	O
every	O
3	O
weeks	O
in	O
arm	O
A	O
","	O
or	O
gemcitabine	B-CANCER
(	O
1000	O
mg	O
/	O
m2	O
","	O
days	O
1	O
and	O
8	O
)	O
plus	O
carboplatin	B-CANCER
(	O
AUC	O
5	O
mg	O
/	O
mL	O
/	O
min	O
","	O
day1	O
)	O
every	O
3	O
weeks	O
in	O
arm	O
B.	O
Non-progressive	O
patients	O
following	O
3	O
cycles	O
of	O
induction	O
chemotherapy	O
received	O
maintenance	O
gemcitabine	B-CANCER
(	O
1000	O
mg	O
/	O
m2	O
","	O
days	O
1	O
and	O
8	O
)	O
every	O
3	O
weeks	O
.	O
	
(	O
UMIN000008252	O
)	O
RESULTS	O
:	O
The	O
study	O
was	O
stopped	O
because	O
of	O
delayed	O
accrual	O
at	O
interim	O
analysis	O
.	O
	
Of	O
the	O
randomly	O
assigned	O
50	O
patients	O
","	O
49	O
except	O
for	O
one	O
in	O
arm	O
B	O
were	O
evaluable	O
.	O
	
Median	O
progression-free	O
survival	O
(	O
PFS	O
)	O
was	O
4.6	O
months	O
for	O
arm	O
A	O
vs.	O
3.5	O
months	O
for	O
arm	O
B	O
(	O
HR	O
=	O
1.03	O
;	O
95	O
%	O
CI	O
","	O
0.45-2.27	O
;	O
p	O
=	O
0.95	O
)	O
and	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
15	O
months	O
for	O
arm	O
A	O
vs.	O
14.8	O
months	O
for	O
arm	O
B	O
(	O
HR	O
=	O
0.79	O
;	O
95	O
%	O
CI	O
","	O
0.40-1.51	O
;	O
p	O
=	O
0.6	O
)	O
","	O
showing	O
no	O
difference	O
between	O
the	O
two	O
arms	O
.	O
	
The	O
response	O
rate	O
","	O
disease	O
control	O
rate	O
","	O
and	O
the	O
transit	O
rate	O
to	O
maintenance	O
phase	O
were	O
36	O
%	O
(	O
9	O
/	O
25	O
)	O
","	O
64	O
%	O
(	O
16	O
/	O
25	O
)	O
","	O
and	O
48	O
%	O
(	O
12	O
/	O
25	O
)	O
for	O
arm	O
A	O
vs.	O
16.7	O
%	O
(	O
4	O
/	O
24	O
)	O
","	O
50	O
%	O
(	O
12	O
/	O
24	O
)	O
","	O
and	O
33	O
%	O
(	O
8	O
/	O
24	O
)	O
for	O
arm	O
B	O
","	O
which	O
were	O
also	O
statistically	O
similar	O
between	O
the	O
two	O
arms	O
(	O
p	O
=	O
0.13	O
","	O
p	O
=	O
0.32	O
","	O
and	O
p	O
=	O
0.3	O
","	O
respectively	O
)	O
.	O
	
Both	O
induction	O
regimens	O
were	O
tolerable	O
","	O
except	O
that	O
more	O
patients	O
experienced	O
peripheral	B-TOXI
neuropathy	I-TOXI
in	O
arm	O
A.	O
Toxicities	O
during	O
the	O
maintenance	O
phase	O
were	O
also	O
minimal	O
.	O
	
Survival	O
and	O
overall	O
response	O
were	O
not	O
significantly	O
different	O
between	O
the	O
two	O
arms	O
.	O
	
Gemcitabine	B-DRUG
may	O
be	O
well-tolerable	O
and	O
feasible	O
for	O
maintenance	O
therapy	O
.	O
	
Phase	O
2	O
study	O
of	O
preoperative	O
radiation	O
with	O
concurrent	O
capecitabine	B-DRUG
","	O
oxaliplatin	B-DRUG
","	O
and	O
bevacizumab	B-DRUG
followed	O
by	O
surgery	O
and	O
postoperative	O
5-fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
","	O
oxaliplatin	B-DRUG
(	O
FOLFOX	B-DRUG
)	O
","	O
and	O
bevacizumab	B-DRUG
in	O
patients	O
with	O
locally	B-CANCER
advanced	I-CANCER
rectal	I-CANCER
cancer	I-CANCER
:	O
ECOG	O
3204	O
.	O
	
	
Recent	O
studies	O
have	O
demonstrated	O
the	O
feasibility	O
of	O
combining	O
oxaliplatin	B-DRUG
with	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
or	O
capecitibine	B-DRUG
and	O
radiation	O
therapy	O
.	O
	
The	O
addition	O
of	O
bevacizumab	B-DRUG
to	O
chemotherapy	O
improves	O
overall	O
survival	O
for	O
metastatic	O
disease	O
.	O
	
We	O
initiated	O
a	O
phase	O
2	O
trial	O
to	O
evaluate	O
preoperative	O
capecitabine	B-DRUG
","	O
oxaliplatin	B-DRUG
","	O
and	O
bevacizumab	B-DRUG
with	O
radiation	O
therapy	O
followed	O
by	O
surgery	O
and	O
postoperative	O
5-FU	B-DRUG
","	O
leucovorin	B-DRUG
","	O
oxaliplatin	B-DRUG
(	O
FOLFOX	B-DRUG
)	O
and	O
bevacizumab	B-DRUG
for	O
locally	B-CANCER
advanced	I-CANCER
rectal	I-CANCER
cancer	I-CANCER
.	O
	
Fifty-seven	O
patients	O
with	O
resectable	O
T3	O
/	O
T4	O
rectal	O
adenocarcinoma	B-CANCER
were	O
enrolled	O
.	O
	
Preoperative	O
treatment	O
was	O
capecitabine	B-DRUG
(	O
825	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
daily	O
from	O
Monday	O
to	O
Friday	O
)	O
","	O
oxaliplatin	B-DRUG
(	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
)	O
","	O
bevacizumab	B-DRUG
(	O
5	O
mg	O
/	O
kg	O
on	O
days	O
1	O
","	O
15	O
","	O
29	O
)	O
","	O
and	O
radiation	O
therapy	O
(	O
50.4	O
Gy	O
)	O
.	O
	
Surgery	O
was	O
performed	O
by	O
6	O
weeks	O
after	O
neoadjuvant	O
therapy	O
.	O
	
Beginning	O
8	O
to	O
12	O
weeks	O
after	O
surgery	O
","	O
patients	O
received	O
FOLFOX	B-DRUG
plus	O
bevacizumab	B-DRUG
(	O
5	O
mg	O
/	O
kg	O
)	O
every	O
2	O
weeks	O
for	O
12	O
cycles	O
.	O
	
Fifty-four	O
of	O
57	O
enrolled	O
patients	O
were	O
eligible	O
.	O
	
Forty-nine	O
(	O
91	O
%	O
)	O
patients	O
completed	O
preoperative	O
therapy	O
and	O
underwent	O
surgery	O
.	O
	
Nine	O
patients	O
(	O
17	O
%	O
;	O
90	O
%	O
confidence	O
interval	O
","	O
9	O
%	O
-27	O
%	O
)	O
achieved	O
pathologic	O
complete	O
response	O
.	O
	
Thirty-two	O
patients	O
(	O
59	O
%	O
)	O
experienced	O
pathologic	B-TOXI
tumor	I-TOXI
downstaging	I-TOXI
","	O
and	O
53	O
%	O
and	O
15	O
%	O
of	O
patients	O
experienced	O
worst	O
grade	O
3	O
and	O
grade	O
4	O
acute	B-TOXI
toxicity	I-TOXI
","	O
respectively	O
.	O
	
Forty-seven	O
percent	O
of	O
patients	O
who	O
underwent	O
surgery	O
experienced	O
a	O
surgical	B-TOXI
complication	I-TOXI
.	O
	
The	O
primary	O
endpoint	O
of	O
a	O
30	O
%	O
pathologic	O
complete	O
response	O
rate	O
was	O
not	O
reached	O
;	O
however	O
","	O
the	O
majority	O
of	O
patients	O
experienced	O
pathologic	B-TOXI
downstaging	I-TOXI
with	O
this	O
regimen	O
.	O
	
Increased	O
wound-healing	B-TOXI
delays	I-TOXI
and	O
complications	O
may	O
have	O
been	O
related	O
to	O
the	O
addition	O
of	O
bevacizumab	B-DRUG
","	O
oxaliplatin	B-DRUG
","	O
or	O
both	O
.	O
	
Continued	O
observation	O
of	O
these	O
patients	O
will	O
establish	O
the	O
long-term	O
morbidity	O
and	O
efficacy	O
of	O
this	O
combined	O
modality	O
approach	O
.	O
	
A	O
phase	O
Ib	O
","	O
open-label	O
study	O
to	O
assess	O
the	O
safety	O
of	O
continuous	O
oral	O
treatment	O
with	O
afatinib	B-DRUG
in	O
combination	O
with	O
two	O
chemotherapy	O
regimens	O
:	O
cisplatin	B-DRUG
plus	O
paclitaxel	B-DRUG
and	O
cisplatin	B-DRUG
plus	O
5-fluorouracil	B-DRUG
","	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
In	O
this	O
phase	O
Ib	O
","	O
dose-escalation	O
study	O
","	O
the	O
oral	O
irreversible	O
ErbB	O
family	O
blocker	O
afatinib	B-DRUG
(	O
BIBW	O
2992	O
)	O
was	O
combined	O
with	O
cisplatin	B-DRUG
(	O
Cadila	O
Healthcare	O
Ltd	O
","	O
Ahmedabad	O
","	O
India	O
)	O
50	O
or	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
paclitaxel	B-DRUG
(	O
Bristol-Myers	O
Squibb	O
Pharmaceuticals	O
Ltd	O
","	O
New	O
York	O
","	O
USA	O
)	O
(	O
Taxol	O
)	O
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
regimen	O
A	O
)	O
or	O
cisplatin	B-DRUG
75-100	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
5-fluorouracil	B-DRUG
750-1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
regimen	O
B	O
)	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
The	O
primary	O
objective	O
was	O
to	O
assess	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
during	O
cycle	O
1	O
for	O
each	O
regimen	O
","	O
from	O
which	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
was	O
determined	O
.	O
	
Patients	O
received	O
once	O
daily	O
oral	O
afatinib	B-DRUG
20	O
","	O
30	O
","	O
40	O
or	O
50	O
mg	O
in	O
21-day	O
cycles	O
(	O
3	O
=+	O
3	O
design	O
)	O
.	O
	
The	O
MTD	O
for	O
afatinib	B-DRUG
in	O
regimens	O
A	O
(	O
n	O
=	O
26	O
)	O
and	O
B	O
(	O
n	O
=	O
21	O
)	O
was	O
determined	O
as	O
20	O
mg	O
and	O
30	O
mg	O
following	O
DLTs	O
in	O
five	O
and	O
four	O
patients	O
in	O
cycle	O
1	O
","	O
respectively	O
.	O
	
Most	O
frequent	O
adverse	O
events	O
(	O
AEs	O
","	O
any	O
grade	O
)	O
were	O
diarrhea	B-TOXI
and	O
nausea	B-TOXI
.	O
	
Disease	O
control	O
was	O
observed	O
in	O
54	O
%	O
and	O
29	O
%	O
of	O
patients	O
in	O
regimens	O
A	O
and	O
B	O
","	O
respectively	O
.	O
	
Plasma	O
sampling	O
suggested	O
no	O
relevant	O
pharmacokinetic	O
interaction	O
between	O
afatinib	B-DRUG
and	O
the	O
chemotherapeutic	O
agents	O
.	O
	
The	O
MTD	O
of	O
afatinib	B-DRUG
was	O
20	O
mg	O
with	O
cisplatin-paclitaxel	B-DRUG
and	O
30	O
mg	O
with	O
cisplatin-5-fluorouracil	B-DRUG
.	O
	
Pre-emptive	O
management	O
of	O
side-effects	O
is	O
important	O
to	O
maintain	O
adequate	O
safety	O
and	O
tolerability	O
.	O
	
Both	O
combinations	O
showed	O
antitumor	O
activity	O
across	O
tumor	O
types	O
and	O
lines	O
of	O
prior	O
treatment	O
.	O
	
Phase	O
II	O
Trial	O
of	O
Paclitaxel	B-DRUG
/	O
Cisplatin	B-DRUG
Followed	O
by	O
Surgery	O
and	O
Adjuvant	O
Radiation	O
Therapy	O
and	O
5-Fluorouracil	B-DRUG
/	O
Leucovorin	B-DRUG
for	O
Gastric	B-CANCER
Cancer	I-CANCER
(	O
ECOG	O
E7296	O
)	O
.	O
	
	
Randomized	O
trials	O
have	O
shown	O
an	O
increase	O
in	O
survival	O
with	O
perioperative	O
chemotherapy	O
as	O
well	O
as	O
with	O
postoperative	O
chemoradiation	O
.	O
	
It	O
was	O
hypothesized	O
that	O
combining	O
induction	O
chemotherapy	O
with	O
postoperative	O
chemoradiation	O
would	O
be	O
well	O
tolerated	O
and	O
improve	O
pathologic	O
complete	O
response	O
.	O
	
Patients	O
with	O
resectable	O
cancers	O
of	O
the	O
stomach	O
/	O
gastroesophageal	O
junction	O
were	O
eligible	O
.	O
	
Neoadjuvant	O
chemotherapy	O
consisted	O
of	O
3	O
cycles	O
of	O
paclitaxel	B-DRUG
and	O
cisplatin	B-DRUG
.	O
	
Adjuvant	O
therapy	O
consisted	O
of	O
1	O
cycle	O
of	O
5-fluorouracil	B-DRUG
(	O
FU	B-DRUG
)	O
and	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
followed	O
by	O
chemoradiation	O
(	O
45	O
Gy	O
with	O
concurrent	O
5-FU	B-DRUG
/	O
LV	B-DRUG
)	O
.	O
	
Chemoradiation	O
was	O
followed	O
by	O
2	O
additional	O
cycles	O
of	O
5-FU	B-DRUG
/	O
LV	B-DRUG
.	O
	
Response	O
to	O
neoadjuvant	O
therapy	O
was	O
based	O
on	O
pathology	O
.	O
	
From	O
1999	O
to	O
2002	O
","	O
38	O
eligible	O
patients	O
were	O
enrolled	O
;	O
35	O
completed	O
induction	O
chemotherapy	O
","	O
and	O
29	O
went	O
on	O
to	O
surgery	O
.	O
	
Sixteen	O
patients	O
did	O
not	O
develop	O
metastatic	O
progression	O
","	O
10	O
developed	O
metastatic	O
disease	O
","	O
and	O
12	O
were	O
unevaluable	O
.	O
	
There	O
were	O
no	O
pathologic	O
complete	O
responses	O
after	O
induction	O
therapy	O
.	O
	
Twenty-five	O
of	O
38	O
patients	O
suffered	O
grade	O
3月4日	O
toxicities	O
during	O
induction	O
paclitaxel	B-DRUG
/	O
cisplatin	B-DRUG
.	O
	
Six	O
of	O
the	O
7	O
patients	O
who	O
received	O
postoperative	O
therapy	O
suffered	O
grade	O
3月4日	O
toxicities	O
.	O
	
Only	O
3	O
of	O
38	O
(	O
7.9	O
%	O
)	O
eligible	O
patients	O
completed	O
all	O
assigned	O
treatment	O
.	O
	
The	O
median	O
overall	O
survival	O
was	O
1.6	O
years	O
","	O
and	O
the	O
2-year	O
survival	O
was	O
40	O
%	O
.	O
	
This	O
regimen	O
of	O
neoadjuvant	O
paclitaxel	B-DRUG
/	O
cisplatin	B-DRUG
followed	O
by	O
postoperative	O
5-FU	B-DRUG
/	O
LV-based	B-DRUG
chemoradiation	O
did	O
not	O
have	O
a	O
high	O
enough	O
response	O
rate	O
and	O
proved	O
to	O
be	O
too	O
toxic	O
for	O
further	O
development	O
.	O
	
Safety	O
and	O
clinical	O
activity	O
of	O
a	O
combination	O
therapy	O
comprising	O
two	O
antibody-based	O
targeting	O
agents	O
for	O
the	O
treatment	O
of	O
non-Hodgkin	B-CANCER
lymphoma	I-CANCER
:	O
results	O
of	O
a	O
phase	O
I	O
/	O
II	O
study	O
evaluating	O
the	O
immunoconjugate	O
inotuzumab	B-DRUG
ozogamicin	I-DRUG
with	O
rituximab	B-DRUG
.	O
	
	
Inotuzumab	B-DRUG
ozogamicin	I-DRUG
(	O
INO	B-DRUG
)	O
is	O
an	O
antibody-targeted	O
chemotherapy	O
agent	O
composed	O
of	O
a	O
humanized	O
anti-CD22	O
antibody	O
conjugated	O
to	O
calicheamicin	B-DRUG
","	O
a	O
potent	O
cytotoxic	O
agent	O
.	O
	
We	O
performed	O
a	O
phase	O
I	O
/	O
II	O
study	O
to	O
determine	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
safety	O
","	O
efficacy	O
","	O
and	O
pharmacokinetics	O
of	O
INO	B-DRUG
plus	O
rituximab	B-DRUG
(	O
R-INO	B-DRUG
)	O
for	O
treatment	O
of	O
relapsed	O
/	O
refractory	O
CD20	O
(	O
=+	O
)	O
/	O
CD22	O
(	O
=+	O
)	O
B-cell	B-CANCER
non-Hodgkin	I-CANCER
lymphoma	I-CANCER
(	O
NHL	B-CANCER
)	O
.	O
	
A	O
dose-escalation	O
phase	O
to	O
determine	O
the	O
MTD	O
of	O
R-INO	O
was	O
followed	O
by	O
an	O
expanded	O
cohort	O
to	O
further	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
at	O
the	O
MTD	O
.	O
	
Patients	O
with	O
relapsed	O
follicular	B-CANCER
lymphoma	I-CANCER
(	O
FL	B-CANCER
)	O
","	O
relapsed	O
diffuse	B-CANCER
large	I-CANCER
B-cell	I-CANCER
lymphoma	I-CANCER
(	O
DLBCL	B-CANCER
)	O
","	O
or	O
refractory	O
aggressive	O
NHL	B-CANCER
received	O
R-INO	B-DRUG
every	O
4	O
weeks	O
for	O
up	O
to	O
eight	O
cycles	O
.	O
	
In	O
all	O
","	O
118	O
patients	O
received	O
one	O
or	O
more	O
cycles	O
of	O
R-INO	B-DRUG
(	O
median	O
","	O
four	O
cycles	O
)	O
.	O
	
Most	O
common	O
grade	O
3	O
to	O
4	O
adverse	O
events	O
were	O
thrombocytopenia	B-TOXI
(	O
31	O
%	O
)	O
and	O
neutropenia	B-TOXI
(	O
22	O
%	O
)	O
.	O
	
Common	O
low-grade	O
toxicities	O
included	O
hyperbilirubinemia	B-TOXI
(	O
25	O
%	O
)	O
and	O
increased	B-TOXI
AST	I-TOXI
(	O
36	O
%	O
)	O
.	O
	
The	O
MTD	O
of	O
INO	B-DRUG
in	O
combination	O
with	O
rituximab	B-DRUG
(	O
375	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
was	O
confirmed	O
to	O
be	O
the	O
same	O
as	O
that	O
for	O
single-agent	O
INO	B-DRUG
(	O
1.8	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O
	
Treatment	O
at	O
the	O
MTD	O
yielded	O
objective	O
response	O
rates	O
of	O
87	O
%	O
","	O
74	O
%	O
","	O
and	O
20	O
%	O
for	O
relapsed	O
FL	B-CANCER
(	O
n	O
=	O
39	O
)	O
","	O
relapsed	O
DLBCL	B-CANCER
(	O
n	O
=	O
42	O
)	O
","	O
and	O
refractory	O
aggressive	O
NHL	B-CANCER
(	O
n	O
=	O
30	O
)	O
","	O
respectively	O
.	O
	
The	O
2-year	O
progression-free	O
survival	O
(	O
PFS	O
)	O
rate	O
was	O
68	O
%	O
(	O
median	O
","	O
not	O
reached	O
)	O
for	O
FL	B-CANCER
and	O
42	O
%	O
(	O
median	O
","	O
17.1	O
months	O
)	O
for	O
relapsed	O
DLBCL	B-CANCER
.	O
	
R-INO	B-DRUG
demonstrated	O
high	O
response	O
rates	O
and	O
long	O
PFS	O
in	O
patients	O
with	O
relapsed	O
FL	B-CANCER
or	O
DLBCL	B-CANCER
.	O
	
This	O
and	O
the	O
manageable	O
toxicity	O
profile	O
suggest	O
that	O
R-INO	B-DRUG
may	O
be	O
a	O
promising	O
option	O
for	O
CD20	O
(	O
=+	O
)	O
/	O
CD22	O
(	O
=+	O
)	O
B-cell	B-CANCER
NHL	I-CANCER
.	O
	
Phase	O
I	O
and	O
pharmacokinetic	O
study	O
of	O
gefitinib	B-DRUG
and	O
S-1	B-DRUG
combination	O
therapy	O
for	O
advanced	B-CANCER
adenocarcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
lung	I-CANCER
.	O
	
	
A	O
phase	O
I	O
dose-escalation	O
study	O
was	O
performed	O
to	O
investigate	O
the	O
safety	O
and	O
pharmacokinetics	O
of	O
the	O
combination	O
of	O
S-1	B-DRUG
and	O
gefitinib	B-DRUG
in	O
patients	O
with	O
pulmonary	B-CANCER
adenocarcinoma	I-CANCER
who	O
had	O
failed	O
previous	O
chemotherapy	O
.	O
	
Patients	O
received	O
gefitinib	B-DRUG
at	O
a	O
fixed	O
daily	O
oral	O
dose	O
of	O
250	O
mg	O
","	O
and	O
S-1	B-DRUG
was	O
administered	O
on	O
days	O
1月14日	O
every	O
21	O
days	O
at	O
doses	O
starting	O
at	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
level	O
1	O
)	O
and	O
escalating	O
to	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
level	O
2	O
)	O
.	O
	
The	O
primary	O
end	O
point	O
of	O
the	O
study	O
was	O
determination	O
of	O
the	O
recommended	O
dose	O
for	O
S-1	B-DRUG
given	O
in	O
combination	O
with	O
a	O
fixed	O
dose	O
of	O
gefitinib	B-DRUG
.	O
	
Twenty	O
patients	O
were	O
enrolled	O
in	O
the	O
study	O
.	O
	
Two	O
of	O
the	O
first	O
six	O
patients	O
at	O
dose	O
level	O
2	O
experienced	O
a	O
dose-limiting	O
toxicity	O
(	O
elevation	B-TOXI
of	I-TOXI
alkaline	I-TOXI
phosphatase	I-TOXI
of	O
grade	O
3	O
in	O
one	O
patient	O
;	O
elevations	O
of	B-TOXI
aspartate	I-TOXI
and	I-TOXI
alanine	I-TOXI
aminotransferases	I-TOXI
of	O
grade	O
3	O
in	O
the	O
other	O
)	O
.	O
	
The	O
recommended	O
dose	O
was	O
thus	O
determined	O
as	O
level	O
2	O
","	O
and	O
an	O
additional	O
11	O
patients	O
were	O
assigned	O
to	O
this	O
level	O
.	O
	
All	O
observed	O
adverse	O
events	O
were	O
well	O
managed	O
.	O
	
The	O
response	O
rate	O
was	O
50	O
%	O
(	O
10	O
of	O
20	O
patients	O
)	O
","	O
and	O
the	O
median	O
progression-free	O
survival	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
times	O
were	O
10.5	O
and	O
21.2	O
months	O
","	O
respectively	O
.	O
	
In	O
EGFR	O
mutation-positive	O
patients	O
(	O
n	O
=	O
9	O
)	O
","	O
seven	O
patients	O
achieved	O
an	O
objective	O
response	O
and	O
the	O
median	O
PFS	O
was	O
12.4	O
months	O
","	O
whereas	O
none	O
with	O
wild-type	O
EGFR	O
(	O
n	O
=	O
6	O
)	O
responded	O
.	O
	
No	O
pharmacokinetic	O
interaction	O
between	O
S-1	B-DRUG
and	O
gefitinib	B-DRUG
was	O
detected	O
.	O
	
The	O
combination	O
of	O
S-1	B-DRUG
and	O
gefitinib	B-DRUG
is	O
well	O
tolerated	O
and	O
appears	O
to	O
possess	O
activity	O
against	O
EGFR	O
mutation-positive	O
NSCLC	B-CANCER
.	O
	
Phase	O
II	O
study	O
of	O
gemcitabine	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
bevacizumab	B-DRUG
in	O
patients	O
with	O
advanced	O
unresectable	O
or	O
metastatic	B-CANCER
urothelial	I-CANCER
cancer	I-CANCER
.	O
	
	
Although	O
gemcitabine	B-DRUG
and	O
carboplatin	B-DRUG
(	O
GCa	B-DRUG
)	O
is	O
a	O
standard	O
option	O
for	O
patients	O
with	O
advanced	B-CANCER
urothelial	I-CANCER
cancer	I-CANCER
(	O
UC	B-CANCER
)	O
who	O
are	O
ineligible	O
for	O
cisplatin	B-DRUG
","	O
outcomes	O
remain	O
poor	O
.	O
	
This	O
trial	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
bevacizumab	B-DRUG
with	O
GCa	B-DRUG
in	O
advanced	B-CANCER
UC	I-CANCER
.	O
	
Patients	O
with	O
Karnofsky	O
performance	O
status	O
of	O
60	O
%	O
to	O
70	O
%	O
","	O
creatinine	O
clearance	O
less	O
than	O
60	O
mL	O
/	O
min	O
","	O
visceral	O
metastasis	O
","	O
or	O
solitary	O
kidney	O
were	O
eligible	O
and	O
received	O
a	O
lead-in	O
dose	O
of	O
bevacizumab	B-DRUG
10	O
mg	O
/	O
kg	O
followed	O
2	O
weeks	O
later	O
by	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
and	O
8	O
and	O
carboplatin	B-DRUG
at	O
area	O
under	O
the	O
[	O
concentration-time	O
]	O
curve	O
(	O
AUC	O
)	O
5	O
or	O
4.5	O
and	O
bevacizumab	B-DRUG
15	O
mg	O
/	O
kg	O
on	O
day	O
1	O
every	O
21	O
days	O
for	O
six	O
cycles	O
.	O
	
Patients	O
achieving	O
at	O
least	O
stable	O
disease	O
(	O
SD	O
)	O
continued	O
bevacizumab	B-DRUG
15	O
mg	O
/	O
kg	O
every	O
21	O
days	O
for	O
18	O
additional	O
cycles	O
.	O
	
The	O
study	O
was	O
powered	O
to	O
detect	O
a	O
50	O
%	O
improvement	O
in	O
median	O
progression-free	O
survival	O
(	O
PFS	O
)	O
over	O
a	O
historical	O
control	O
.	O
	
Fifty-one	O
patients	O
","	O
median	O
age	O
67	O
years	O
(	O
range	O
","	O
42	O
to	O
83	O
years	O
)	O
","	O
were	O
enrolled	O
onto	O
the	O
study	O
and	O
were	O
evaluable	O
for	O
toxicity	O
.	O
	
Twenty	O
(	O
39	O
%	O
)	O
experienced	O
grade	O
3	O
to	O
4	O
toxicity	O
","	O
and	O
10	O
(	O
20	O
%	O
)	O
had	O
thromboembolic	B-TOXI
events	I-TOXI
(	O
deep	B-TOXI
venous	I-TOXI
thrombosis	I-TOXI
or	O
pulmonary	B-TOXI
embolism	I-TOXI
)	O
.	O
	
Four	O
received	O
one	O
or	O
fewer	O
cycles	O
leaving	O
47	O
evaluable	O
for	O
outcomes	O
.	O
	
Twenty-three	O
(	O
49	O
%	O
)	O
achieved	O
response	O
(	O
three	O
complete	O
;	O
20	O
partial	O
)	O
","	O
and	O
11	O
had	O
SD	O
.	O
	
Median	O
PFS	O
was	O
6.5	O
months	O
(	O
95	O
%	O
CI	O
","	O
4.7	O
to	O
7.8	O
months	O
)	O
;	O
PFS	O
was	O
greater	O
in	O
the	O
carboplatin	B-DRUG
AUC	O
5	O
group	O
(	O
P	O
=	O
0.04	O
)	O
.	O
	
Median	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
13.9	O
months	O
.	O
	
The	O
95	O
%	O
one-sided	O
lower	O
confidence	O
bound	O
of	O
4.77	O
months	O
for	O
median	O
PFS	O
did	O
not	O
meet	O
the	O
predesignated	O
PFS	O
of	O
more	O
than	O
4.8	O
months	O
considered	O
sufficient	O
for	O
further	O
study	O
.	O
	
Median	O
OS	O
was	O
greater	O
than	O
expected	O
.	O
	
An	O
ongoing	O
phase	O
III	O
trial	O
in	O
patients	O
who	O
are	O
eligible	O
for	O
therapy	O
with	O
cisplatin	B-DRUG
will	O
define	O
the	O
role	O
of	O
bevacizumab	B-DRUG
in	O
UC	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
pulse	O
high-dose	O
vorinostat	B-DRUG
(	O
V	O
)	O
plus	O
rituximab	B-DRUG
(	O
R	O
)	O
","	O
ifosphamide	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
etoposide	B-DRUG
(	O
ICE	O
)	O
in	O
patients	O
with	O
relapsed	B-CANCER
lymphoma	I-CANCER
.	O
	
	
Given	O
the	O
poor	O
outcomes	O
of	O
relapsed	O
aggressive	O
lymphomas	B-CANCER
and	O
preclinical	O
data	O
suggesting	O
that	O
_2路5	O
渭mol	O
/	O
l	O
concentrations	O
of	O
vorinostat	B-DRUG
synergize	O
with	O
both	O
etoposide	B-DRUG
and	O
platinums	B-DRUG
","	O
we	O
hypothesized	O
that	O
pulse	O
high-dose	O
vorinostat	B-DRUG
could	O
safely	O
augment	O
the	O
anti-tumour	O
activity	O
of	O
(	O
R	O
)	O
ICE	O
[	O
(	O
rituximab	B-DRUG
)	O
","	O
ifosphamide	B-DRUG
","	O
carboplatin	B-DRUG
","	O
etoposide	B-DRUG
]	O
chemotherapy	O
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
dose	O
escalation	O
study	O
using	O
a	O
schedule	O
with	O
oral	O
vorinostat	B-DRUG
ranging	O
from	O
400	O
mg	O
/	O
d	O
to	O
700	O
mg	O
bid	O
for	O
5	O
d	O
in	O
combination	O
with	O
the	O
standard	O
(	O
R	O
)	O
ICE	O
regimen	O
(	O
days	O
3	O
","	O
4	O
and	O
5	O
)	O
.	O
	
Twenty-nine	O
patients	O
[	O
median	O
age	O
56	O
years	O
","	O
median	O
2	O
prior	O
therapies	O
","	O
14	O
chemoresistant	O
(	O
of	O
27	O
evaluable	O
)	O
","	O
2	O
prior	O
transplants	O
]	O
were	O
enrolled	O
and	O
treated	O
.	O
	
The	O
maximally	O
tolerated	O
vorinostat	B-DRUG
dose	O
was	O
defined	O
as	O
500	O
mg	O
twice	O
daily	O
_	O
5	O
d.	O
Common	O
dose	O
limiting	O
toxicities	O
included	O
infection	B-TOXI
(	O
n	O
=	O
2	O
)	O
","	O
hypokalaemia	B-TOXI
(	O
n	O
=	O
2	O
)	O
","	O
and	O
transaminitis	B-TOXI
(	O
n	O
=	O
2	O
)	O
.	O
	
Grade	O
3	O
related	O
gastrointestinal	B-TOXI
toxicity	I-TOXI
was	O
seen	O
in	O
9	O
patients	O
.	O
	
The	O
median	O
vorinostat	B-DRUG
concentration	O
on	O
day	O
3	O
was	O
4路5	O
渭mol	O
/	O
l	O
(	O
range	O
4路2-6路0	O
渭mol	O
/	O
l	O
)	O
and	O
in	O
vitro	O
data	O
confirmed	O
the	O
augmented	O
antitumour	O
and	O
histone	O
acetylation	O
activity	O
at	O
these	O
levels	O
.	O
	
Responses	O
were	O
observed	O
in	O
19	O
of	O
27	O
evaluable	O
patients	O
(	O
70	O
%	O
)	O
including	O
8	O
complete	O
response	O
/	O
unconfirmed	O
complete	O
response	O
.	O
	
High-dose	O
vorinostat	B-DRUG
can	O
be	O
delivered	O
safely	O
with	O
(	O
R	O
)	O
ICE	O
","	O
achieves	O
potentially	O
synergistic	O
drug	O
levels	O
","	O
and	O
warrants	O
further	O
study	O
","	O
although	O
adequate	O
gastrointestinal	O
prophylaxis	O
is	O
warranted	O
.	O
	
Lenalidomide	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
as	O
first-line	O
treatment	O
for	O
patients	O
with	O
metastatic	B-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
pancreas	I-CANCER
:	O
a	O
Sarah	O
Cannon	O
Research	O
Institute	O
phase	O
II	O
trial	O
.	O
	
	
To	O
evaluate	O
the	O
6-mo	O
overall	O
survival	O
","	O
safety	O
and	O
tolerability	O
of	O
lenalidomide	B-DRUG
in	O
combination	O
with	O
standard	O
gemcitabine	B-DRUG
as	O
first-line	O
treatment	O
for	O
patients	O
with	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
Eligibility	O
included	O
:	O
previously	O
untreated	O
metastatic	B-CANCER
adenocarcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
pancreas	I-CANCER
with	O
metastases	O
incurable	O
by	O
surgery	O
/	O
radiation	O
therapy	O
;	O
ECOG	O
PS	O
0-2	O
;	O
adequate	O
organ	O
function	O
;	O
prophylactic	O
anticoagulation	O
for	O
venous	B-TOXI
thromboembolic	I-TOXI
events	I-TOXI
(	O
VTEs	B-TOXI
)	O
.	O
	
Patients	O
received	O
lenalidomide	B-DRUG
25	O
mg	O
PO	O
(	O
days	O
1月21日	O
)	O
and	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
(	O
days	O
1	O
","	O
8	O
and	O
15	O
)	O
each	O
28-day	O
cycle	O
","	O
with	O
response	O
evaluations	O
every	O
eight	O
weeks	O
.	O
	
Between	O
5	O
/	O
Apr-09	O
/	O
2010	O
","	O
72	O
patients	O
(	O
median	O
age	O
64	O
years	O
;	O
68	O
%	O
male	O
;	O
42	O
%	O
ECOG	O
PS	O
0	O
)	O
were	O
enrolled	O
in	O
this	O
multicenter	O
","	O
community-based	O
study	O
.	O
	
Six-month	O
OS	O
was	O
37	O
%	O
(	O
95	O
%	O
CI	O
26-48	O
%	O
)	O
.	O
	
Median	O
PFS	O
and	O
OS	O
were	O
2.3	O
(	O
95	O
%	O
CI	O
1.9-3.5	O
)	O
and	O
4.7	O
(	O
95	O
%	O
CI	O
3.4-5.7	O
)	O
months	O
","	O
respectively	O
.	O
	
Eight	O
partial	O
responses	O
(	O
11	O
%	O
)	O
were	O
documented	O
.	O
	
Thirty-nine	O
patients	O
(	O
54	O
%	O
)	O
experienced	O
thrombocytopenia	B-TOXI
(	O
2	O
patients	O
","	O
3	O
%	O
grade	O
4	O
)	O
.	O
	
Hematologic	B-TOXI
toxicities	I-TOXI
resulted	O
in	O
dose	O
modifications	O
for	O
the	O
majority	O
of	O
patients	O
.	O
	
Twenty	O
patients	O
(	O
28	O
%	O
)	O
developed	O
VTEs	B-TOXI
during	O
treatment	O
.	O
	
The	O
observed	O
6-month	O
OS	O
(	O
37	O
%	O
)	O
of	O
lenalidomide	B-DRUG
with	O
gemcitabine	B-DRUG
does	O
not	O
suggest	O
improvement	O
compared	O
with	O
historical	O
results	O
with	O
gemcitabine	B-DRUG
alone	O
.	O
	
Toxicities	O
and	O
dose	O
modifications	O
likely	O
limited	O
dose	O
intensity	O
.	O
	
Further	O
development	O
of	O
this	O
regimen	O
in	O
pancreas	B-CANCER
cancer	I-CANCER
is	O
not	O
recommended	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
hepatic	O
arterial	O
infusion	O
of	O
nab-paclitaxel	B-DRUG
in	O
combination	O
with	O
intravenous	O
gemcitabine	B-DRUG
and	O
bevacizumab	B-DRUG
for	O
patients	O
with	O
advanced	B-CANCER
cancers	I-CANCER
and	I-CANCER
predominant	I-CANCER
liver	I-CANCER
metastases	I-CANCER
.	O
	
	
We	O
conducted	O
a	O
phase	O
I	O
clinical	O
trial	O
for	O
patients	O
with	O
advanced	B-CANCER
cancer	I-CANCER
and	I-CANCER
predominant	I-CANCER
liver	I-CANCER
disease	I-CANCER
.	O
	
Patients	O
were	O
treated	O
with	O
HAI	O
nab-paclitaxel	B-DRUG
(	O
120-210	O
mg	O
/	O
m	O
(	O
2	O
)	O
;	O
day	O
1	O
)	O
;	O
intravenous	O
bevacizumab	B-DRUG
(	O
10	O
mg	O
/	O
kg	O
;	O
day	O
1	O
)	O
;	O
and	O
intravenous	O
gemcitabine	B-DRUG
(	O
600-800	O
mg	O
/	O
m	O
(	O
2	O
)	O
;	O
days	O
1	O
and	O
8	O
)	O
.	O
	
A	O
conventional	O
	O
study	O
design	O
was	O
used	O
.	O
	
Fifty	O
patients	O
with	O
advanced	B-CANCER
cancer	I-CANCER
and	I-CANCER
predominant	I-CANCER
liver	I-CANCER
metastases	I-CANCER
were	O
treated	O
(	O
median	O
age	O
","	O
58	O
years	O
;	O
27	O
women	O
","	O
23	O
men	O
;	O
median	O
number	O
of	O
prior	O
therapies	O
","	O
3	O
[	O
range	O
0-12	O
]	O
)	O
.	O
	
The	O
most	O
common	O
cancers	O
were	O
breast	O
(	O
n	O
=	O
9	O
)	O
and	O
pancreatic	O
(	O
n	O
=	O
9	O
)	O
.	O
	
Overall	O
","	O
264	O
cycles	O
were	O
administered	O
(	O
median	O
/	O
patient	O
","	O
4	O
;	O
range	O
1月17日	O
)	O
.	O
	
No	O
dose-limiting	O
toxicities	O
were	O
noted	O
during	O
the	O
escalation	O
phase	O
.	O
	
On	O
dose	O
level	O
4	O
","	O
3	O
patients	O
were	O
unable	O
to	O
receive	O
gemcitabine	B-DRUG
on	O
day	O
8	O
because	O
of	O
severe	O
thrombocytopenia	B-TOXI
.	O
	
Dose	O
level	O
3	O
was	O
selected	O
as	O
the	O
maximum-tolerated	O
dose	O
(	O
HAI	O
nab-paclitaxel	B-DRUG
180	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
intravenous	O
gemcitabine	B-DRUG
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
bevacizumab	B-DRUG
10	O
mg	O
/	O
kg	O
)	O
;	O
32	O
patients	O
were	O
treated	O
in	O
the	O
expansion	O
phase	O
.	O
	
The	O
most	O
common	O
treatment-related	O
toxicities	O
were	O
thrombocytopenia	B-TOXI
(	O
n	O
=	O
17	O
)	O
","	O
neutropenia	B-TOXI
(	O
n	O
=	O
10	O
)	O
","	O
and	O
fatigue	B-TOXI
(	O
n	O
=	O
12	O
)	O
.	O
	
Of	O
46	O
patients	O
evaluable	O
for	O
response	O
","	O
9	O
(	O
20	O
%	O
)	O
had	O
a	O
partial	O
response	O
(	O
PR	O
)	O
and	O
9	O
(	O
20	O
%	O
)	O
had	O
stable	O
disease	O
for	O
_6	O
months	O
.	O
	
The	O
median	O
overall	O
survival	O
duration	O
was	O
7	O
months	O
(	O
95	O
%	O
CI	O
:	O
4	O
","	O
22	O
months	O
)	O
","	O
and	O
the	O
median	O
progression-free	O
survival	O
duration	O
was	O
4.2	O
months	O
(	O
95	O
%	O
CI	O
:	O
2.7	O
","	O
8.6	O
months	O
)	O
.	O
	
HAI	O
nab-paclitaxel	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
and	O
bevacizumab	B-DRUG
was	O
well	O
tolerated	O
and	O
had	O
antitumor	O
activity	O
in	O
selected	O
patients	O
with	O
advanced	B-CANCER
cancer	I-CANCER
and	I-CANCER
liver	I-CANCER
metastases	I-CANCER
.	O
	
Phase	O
Ib	O
trial	O
of	O
the	O
Toll-like	O
receptor	O
9	O
agonist	O
IMO-2055	B-DRUG
in	O
combination	O
with	O
5-fluorouracil	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
cetuximab	B-DRUG
as	O
first-line	O
palliative	O
treatment	O
in	O
patients	O
with	O
recurrent	B-CANCER
/	I-CANCER
metastatic	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
	
This	O
Phase	O
Ib	O
trial	O
assessed	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
safety	O
of	O
the	O
Toll-like	O
receptor	O
9	O
agonist	O
IMO-2055	B-DRUG
combined	O
with	O
5-fluorouracil	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
cetuximab	B-DRUG
(	O
PFE	B-DRUG
)	O
as	O
first-line	O
palliative	O
treatment	O
in	O
patients	O
with	O
relapsed	O
and	O
/	O
or	O
metastatic	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	O
R	O
/	O
M	O
SCCHN	B-CANCER
)	O
.	O
	
A	O
standard	O
3+3	O
study	O
design	O
was	O
used	O
.	O
	
Patients	O
were	O
sequentially	O
enrolled	O
to	O
be	O
treated	O
with	O
IMO-2055	B-DRUG
(	O
0.16	O
","	O
0.32	O
","	O
or	O
0.48	O
mg	O
/	O
kg	O
/	O
day	O
;	O
days	O
1	O
","	O
8	O
","	O
15	O
)	O
","	O
5-fluorouracil	B-DRUG
(	O
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
;	O
days	O
1月4日	O
)	O
","	O
cisplatin	B-DRUG
(	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
;	O
day	O
1	O
)	O
and	O
cetuximab	B-DRUG
(	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
first	O
dose	O
;	O
then	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
;	O
days	O
1	O
","	O
8	O
","	O
15	O
)	O
every	O
3	O
weeks	O
.	O
	
Thirteen	O
patients	O
received	O
IMO-2055	B-DRUG
.	O
	
Dose-limiting	O
toxicities	O
(	O
DLTs	O
;	O
ie	O
","	O
any	O
Grade	O
[	O
G	O
]	O
3	O
/	O
4	O
treatment-related	O
adverse	O
events	O
[	O
TEAEs	O
]	O
in	O
cycle	O
1	O
)	O
occurred	O
in	O
2	O
/	O
4	O
patients	O
treated	O
with	O
IMO-2055	B-DRUG
0.32	O
mg	O
/	O
kg	O
(	O
G4	O
hypokalemia	B-TOXI
and	O
hypomagnesemia	B-TOXI
[	O
n=1	O
]	O
;	O
G4	O
septicemia	B-TOXI
","	O
hyperthermia	B-TOXI
","	O
febrile	B-TOXI
neutropenia	I-TOXI
","	O
and	O
G3	O
hypotension	B-TOXI
[	O
n=1	O
]	O
)	O
.	O
	
In	O
the	O
IMO-2055	B-DRUG
0.16-mg	O
/	O
kg	O
expansion	O
cohort	O
","	O
1	O
patient	O
experienced	O
DLTs	O
of	O
G3	O
sepsis	B-TOXI
","	O
bacteremia	B-TOXI
","	O
and	O
hyperthermia	B-TOXI
.	O
	
The	O
most	O
common	O
G	O
_	O
3	O
TEAEs	O
were	O
neutropenia	B-TOXI
(	O
n=9	O
;	O
not	O
including	O
febrile	B-TOXI
neutropenia	I-TOXI
[	O
n=1	O
]	O
)	O
","	O
hypokalemia	B-TOXI
(	O
n=5	O
)	O
","	O
and	O
hypomagnesemia	B-TOXI
(	O
n=4	O
)	O
.	O
	
Serious	O
adverse	O
events	O
(	O
SAEs	O
)	O
occurred	O
in	O
8	O
patients	O
","	O
including	O
4	O
with	O
SAEs	O
considered	O
IMO-2055	B-DRUG
related	O
;	O
1	O
of	O
these	O
patients	O
died	B-TOXI
.	O
	
Best	O
response	O
achieved	O
overall	O
was	O
partial	O
response	O
in	O
3	O
patients	O
and	O
stable	O
disease	O
in	O
9	O
patients	O
.	O
	
The	O
overall	O
safety	O
profile	O
led	O
to	O
early	O
trial	O
termination	O
;	O
the	O
safety	O
monitoring	O
committee	O
did	O
not	O
confirm	O
the	O
MTD	O
(	O
formally	O
IMO-2055	B-DRUG
0.16	O
mg	O
/	O
kg	O
)	O
.	O
	
Regimens	O
combining	O
IMO-2055	B-DRUG
and	O
PFE	B-DRUG
can	O
not	O
be	O
recommended	O
for	O
further	O
development	O
in	O
R	O
/	O
M	O
SCCHN	B-CANCER
patients	O
.	O
	
A	O
phase	O
1	O
study	O
of	O
everolimus	B-DRUG
plus	O
docetaxel	B-DRUG
plus	O
cisplatin	B-DRUG
as	O
induction	O
chemotherapy	O
for	O
patients	O
with	O
locally	O
and	O
/	O
or	O
regionally	O
advanced	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
.	O
	
	
Activation	O
of	O
the	O
phosphatidylinositol-3-kinase	O
(	O
PI3K	O
)	O
/	O
Akt	O
/	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
pathway	O
is	O
common	O
in	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
cancers	I-CANCER
","	O
and	O
it	O
has	O
been	O
demonstrated	O
that	O
inhibition	O
of	O
mTOR	O
complex	O
1	O
sensitizes	O
cell	O
lines	O
to	O
platinum	B-CANCER
and	O
taxane	B-CANCER
chemotherapy	O
.	O
	
The	O
authors	O
conducted	O
a	O
phase	O
1	O
study	O
to	O
evaluate	O
the	O
addition	O
of	O
oral	O
everolimus	B-DRUG
to	O
cisplatin	B-DRUG
and	O
docetaxel	B-DRUG
as	O
induction	O
chemotherapy	O
for	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
.	O
	
In	O
this	O
single-institution	O
phase	O
1	O
study	O
","	O
3	O
doses	O
of	O
daily	O
everolimus	B-DRUG
were	O
explored	O
:	O
5	O
mg	O
daily	O
","	O
7.5	O
mg	O
daily	O
(	O
administered	O
as	O
5	O
mg	O
daily	O
alternating	O
with	O
10	O
mg	O
daily	O
)	O
","	O
and	O
10	O
mg	O
daily	O
of	O
each	O
21-day	O
cycle	O
.	O
	
Cisplatin	B-DRUG
and	O
docetaxel	B-DRUG
doses	O
were	O
fixed	O
(	O
both	O
were	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
of	O
21-day	O
cycle	O
)	O
at	O
each	O
dose	O
level	O
with	O
pegfilgrastim	B-DRUG
support	O
.	O
	
A	O
standard	O
3	O
=+	O
3	O
dose-escalation	O
plan	O
was	O
used	O
.	O
	
After	O
induction	O
","	O
patients	O
were	O
removed	O
from	O
protocol	O
.	O
	
Eighteen	O
patients	O
were	O
enrolled	O
(	O
15	O
men	O
","	O
3	O
women	O
)	O
","	O
and	O
their	O
median	O
Karnofsky	O
performance	O
status	O
was	O
90	O
.	O
	
The	O
most	O
common	O
toxicities	O
were	O
hyperglycemia	B-TOXI
","	O
low	B-TOXI
hemoglobin	I-TOXI
","	O
fatigue	B-TOXI
","	O
and	O
thrombocytopenia	B-TOXI
.	O
	
Dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
were	O
neutropenic	B-TOXI
fever	I-TOXI
(	O
1	O
event	O
at	O
dose	O
level	O
2	O
","	O
2	O
events	O
at	O
dose	O
level	O
3	O
)	O
","	O
and	O
all	O
patients	O
recovered	O
fully	O
from	O
these	O
DLTs	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
was	O
exceeded	O
at	O
dose	O
level	O
3	O
The	O
progression-free	O
survival	O
rate	O
at	O
1	O
year	O
was	O
87.5	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
56.8	O
%	O
-96.7	O
%	O
)	O
;	O
and	O
","	O
at	O
2	O
years	O
","	O
it	O
was	O
76.6	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
41.2	O
%	O
-92.3	O
%	O
)	O
.	O
	
Activating	O
PI3K	O
catalytic	O
subunit	O
伪	O
(	O
PIK3CA	O
)	O
gene	O
mutations	O
were	O
identified	O
in	O
2	O
human	O
papillomavirus-associated	O
oropharyngeal	B-CANCER
cancers	I-CANCER
.	O
	
The	O
phase	O
2	O
recommended	O
dose	O
was	O
7.5	O
mg	O
daily	O
for	O
everolimus	B-DRUG
plus	O
cisplatin	B-DRUG
and	O
docetaxel	B-DRUG
(	O
both	O
at	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
of	O
a	O
21-day	O
cycle	O
)	O
given	O
with	O
pegfilgrastim	B-DRUG
support	O
.	O
	
Induction	O
chemotherapy	O
with	O
docetaxel	B-DRUG
","	O
cisplatin	B-DRUG
and	O
capecitabine	B-DRUG
","	O
followed	O
by	O
combined	O
cetuximab	B-DRUG
and	O
radiotherapy	O
in	O
patients	O
with	O
locally	O
advanced	B-CANCER
inoperable	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
:	O
a	O
phase	O
I-II	O
study	O
.	O
	
	
To	O
replace	O
5-fluorouracil	B-DRUG
with	O
capecitabine	B-DRUG
within	O
a	O
trial	O
of	O
induction	O
chemotherapy	O
followed	O
by	O
cetuximab	B-DRUG
plus	O
radiotherapy	O
(	O
RT	O
)	O
in	O
patients	O
with	O
locally	O
advanced	O
(	O
LA	O
)	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	O
SCCHN	B-CANCER
)	O
.	O
	
Also	O
","	O
to	O
replace	O
cisplatin	B-DRUG
with	O
cetuximab	B-DRUG
after	O
induction	O
chemotherapy	O
.	O
	
Docetaxel	B-DRUG
and	O
cisplatin	B-DRUG
were	O
given	O
at	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
while	O
capecitabine	B-DRUG
was	O
initially	O
given	O
at	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
a	O
day	O
and	O
subsequently	O
escalated	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
was	O
used	O
for	O
the	O
phase	O
II	O
study	O
.	O
	
Seven	O
patients	O
were	O
enrolled	O
.	O
	
At	O
dose	O
level	O
1	O
","	O
two	O
dose-limiting	O
toxicities	O
were	O
observed	O
in	O
the	O
first	O
4	O
patients	O
(	O
grade	O
4	O
neutropenia	B-TOXI
and	O
grade	O
3	O
diarrhea	B-TOXI
)	O
.	O
	
In	O
both	O
patients	O
","	O
capecitabine	B-DRUG
was	O
withdrawn	O
and	O
toxicities	O
resolved	O
.	O
	
Dose	O
escalation	O
was	O
halted	O
and	O
a	O
lower	O
capecitabine	B-DRUG
dose	O
(	O
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
daily	O
)	O
was	O
selected	O
.	O
	
Two	O
complete	O
responses	O
and	O
five	O
partial	O
responses	O
were	O
observed	O
after	O
induction	O
chemotherapy	O
.	O
	
Four	O
patients	O
were	O
evaluable	O
for	O
response	O
after	O
cetuximab-RT	B-DRUG
(	O
3	O
complete	O
response	O
and	O
1	O
partial	O
response	O
)	O
.	O
	
Combined	O
chemoradiotherapy	O
is	O
still	O
the	O
gold	O
standard	O
in	O
LA	O
SCCHN	B-CANCER
and	O
no	O
studies	O
currently	O
support	O
the	O
use	O
of	O
early	O
induction	O
chemotherapy	O
.	O
	
Our	O
study	O
did	O
not	O
contribute	O
toward	O
addressing	O
this	O
issue	O
since	O
it	O
was	O
discontinued	O
early	O
because	O
of	O
toxicity	O
.	O
	
Preoperative	O
cetuximab	B-DRUG
","	O
irinotecan	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
radiation	O
therapy	O
for	O
patients	O
with	O
locally	O
advanced	B-CANCER
esophageal	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
determine	O
the	O
efficacy	O
and	O
toxicity	O
of	O
weekly	O
neoadjuvant	B-DRUG
cetuximab	I-DRUG
combined	O
with	O
irinotecan	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
radiation	O
therapy	O
in	O
patients	O
with	O
locally	O
advanced	B-CANCER
esophageal	I-CANCER
or	I-CANCER
gastroesophageal	I-CANCER
junction	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
stage	O
IIA-IVA	O
esophageal	B-CANCER
or	I-CANCER
gastroesophageal	I-CANCER
junction	I-CANCER
cancer	I-CANCER
were	O
enrolled	O
in	O
a	O
Simon	O
's	O
two-stage	O
phase	O
II	O
study	O
.	O
	
Patients	O
received	O
weekly	O
cetuximab	B-DRUG
on	O
weeks	O
0-8	O
and	O
irinotecan	B-DRUG
and	O
cisplatin	B-DRUG
on	O
weeks	O
1	O
","	O
2	O
","	O
4	O
","	O
and	O
5	O
","	O
with	O
concurrent	O
radiotherapy	O
(	O
50.4	O
Gy	O
on	O
weeks	O
1月6日	O
)	O
","	O
followed	O
by	O
surgical	O
resection	O
.	O
	
In	O
the	O
first	O
stage	O
","	O
17	O
patients	O
were	O
enrolled	O
","	O
16	O
of	O
whom	O
had	O
adenocarcinoma	B-CANCER
.	O
	
Because	O
of	O
a	O
low	O
pathologic	O
complete	O
response	O
(	O
pCR	O
)	O
rate	O
in	O
this	O
cohort	O
","	O
the	O
trial	O
was	O
discontinued	O
for	O
patients	O
with	O
adenocarcinoma	B-CANCER
but	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
patients	O
continued	O
to	O
be	O
enrolled	O
;	O
two	O
additional	O
patients	O
were	O
enrolled	O
before	O
the	O
study	O
was	O
closed	O
as	O
a	O
result	O
of	O
poor	O
accrual	O
.	O
	
Of	O
the	O
19	O
patients	O
enrolled	O
","	O
18	O
patients	O
proceeded	O
to	O
surgery	O
","	O
and	O
16	O
patients	O
underwent	O
an	O
R0	O
resection	O
.	O
	
Three	O
patients	O
(	O
16	O
%	O
)	O
had	O
a	O
pCR	O
.	O
	
The	O
median	O
progression-free	O
survival	O
interval	O
was	O
10	O
months	O
","	O
and	O
the	O
median	O
overall	O
survival	O
duration	O
was	O
31	O
months	O
.	O
	
Severe	O
neutropenia	B-TOXI
occurred	O
in	O
47	O
%	O
of	O
patients	O
","	O
and	O
severe	B-TOXI
diarrhea	I-TOXI
occurred	O
in	O
47	O
%	O
of	O
patients	O
.	O
	
One	O
patient	O
died	B-TOXI
preoperatively	O
from	O
sepsis	B-TOXI
","	O
and	O
one	O
patient	O
died	B-TOXI
prior	O
to	O
hospital	O
discharge	O
following	O
surgical	O
resection	O
.	O
	
This	O
schedule	O
of	O
cetuximab	B-DRUG
in	O
combination	O
with	O
irinotecan	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
radiation	O
therapy	O
was	O
toxic	B-DRUG
and	O
did	O
not	O
achieve	O
a	O
sufficient	O
pCR	O
rate	O
in	O
patients	O
with	O
localized	O
esophageal	B-CANCER
adenocarcinoma	I-CANCER
to	O
undergo	O
further	O
evaluation	O
.	O
	
Efficacy	O
of	O
goserelin	B-DRUG
plus	O
anastrozole	B-DRUG
in	O
premenopausal	O
women	O
with	O
advanced	O
or	O
recurrent	B-CANCER
breast	I-CANCER
cancer	I-CANCER
refractory	O
to	O
an	O
LH-RH	O
analogue	O
with	O
tamoxifen	B-DRUG
:	O
results	O
of	O
the	O
JMTO	O
BC08-01	O
phase	O
II	O
trial	O
.	O
	
	
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
assess	O
the	O
efficacy	O
and	O
tolerability	O
of	O
a	O
luteinizing	O
hormone-releasing	O
hormone	O
(	O
LH-RH	B-DRUG
)	O
analogue	O
plus	O
an	O
aromatase	O
inhibitor	O
following	O
failure	O
to	O
respond	O
to	O
standard	O
LH-RH	B-DRUG
analogue	I-DRUG
plus	O
tamoxifen	B-DRUG
(	O
TAM	B-DRUG
)	O
in	O
premenopausal	O
patients	O
.	O
	
Premenopausal	O
women	O
with	O
estrogen	O
receptor	O
(	O
ER	O
)	O
#NAME?	O
and	O
/	O
or	O
progesterone-receptor	O
positive	O
","	O
advanced	B-CANCER
or	I-CANCER
recurrent	I-CANCER
breast	I-CANCER
cancer	I-CANCER
refractory	O
to	O
an	O
LH-RH	B-DRUG
analogue	I-DRUG
plus	O
TAM	B-DRUG
received	O
goserelin	B-DRUG
(	O
GOS	B-DRUG
)	O
in	O
conjunction	O
with	O
anastrozole	B-DRUG
(	O
ANA	B-DRUG
)	O
.	O
	
The	O
primary	O
endpoint	O
was	O
the	O
objective	O
response	O
rate	O
(	O
ORR	O
)	O
.	O
	
Secondary	O
endpoints	O
included	O
progression-free	O
survival	O
(	O
PFS	O
)	O
","	O
overall	O
survival	O
(	O
OS	O
)	O
","	O
clinical	O
benefit	O
rate	O
(	O
CBR	O
)	O
and	O
safety	O
.	O
	
Between	O
September	O
2008	O
and	O
November	O
2010	O
","	O
37	O
patients	O
were	O
enrolled	O
.	O
	
Thirty-five	O
patients	O
(	O
94.6	O
%	O
)	O
had	O
ER-positive	O
tumors	O
","	O
and	O
36	O
(	O
97.3	O
%	O
)	O
had	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
HER	O
)	O
2-negative	O
tumors	O
.	O
	
Thirty-six	O
(	O
97.3	O
%	O
)	O
had	O
measurable	B-TOXI
lesions	I-TOXI
and	O
1	O
(	O
2.7	O
%	O
)	O
had	O
only	O
bone	B-TOXI
metastasis	I-TOXI
.	O
	
The	O
ORR	O
was	O
18.9	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
","	O
8.0-35.2	O
%	O
]	O
","	O
the	O
CBR	O
was	O
62.2	O
%	O
(	O
95	O
%	O
CI	O
","	O
44.8-77.5	O
%	O
)	O
and	O
the	O
median	O
PFS	O
was	O
7.3	O
months	O
.	O
	
Eight	O
patients	O
had	O
adverse	O
drug	O
reactions	O
but	O
none	O
resulted	O
in	O
discontinuation	O
of	O
treatment	O
.	O
	
GOS	B-DRUG
plus	O
ANA	B-DRUG
is	O
a	O
safe	O
effective	O
treatment	O
for	O
premenopausal	O
women	O
with	O
hormone	O
receptor-positive	O
","	O
recurrent	B-CANCER
or	I-CANCER
advanced	I-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
The	O
treatment	O
may	O
become	O
viable	O
treatment	O
in	O
the	O
future	O
","	O
particularly	O
when	O
TAM	B-DRUG
is	O
ineffective	O
or	O
contraindicated	O
.	O
	
Further	O
studies	O
and	O
discussion	O
are	O
warranted	O
.	O
	
Cisplatin	B-DRUG
and	O
radiotherapy	O
with	O
or	O
without	O
erlotinib	B-DRUG
in	O
locally	O
advanced	B-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
:	O
a	O
randomized	O
phase	O
II	O
trial	O
.	O
	
	
The	O
combination	O
of	O
cisplatin	B-DRUG
and	O
radiotherapy	O
is	O
a	O
standard	O
treatment	O
for	O
patients	O
with	O
locally	O
advanced	B-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	O
SCCHN	B-CANCER
)	O
.	O
	
Cetuximab-radiotherapy	B-DRUG
is	O
superior	O
to	O
radiotherapy	O
alone	O
in	O
this	O
population	O
","	O
validating	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
as	O
a	O
target	O
.	O
	
Erlotinib	B-DRUG
is	O
a	O
small-molecule	O
inhibitor	O
of	O
EGFR	O
.	O
	
Adding	O
EGFR	O
inhibition	O
to	O
standard	O
cisplatin-radiotherapy	B-DRUG
may	O
improve	O
efficacy	O
.	O
	
Patients	O
with	O
locally	O
advanced	B-CANCER
SCCHN	I-CANCER
were	O
randomly	O
assigned	O
to	O
receive	O
cisplatin	B-CANCER
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
","	O
22	O
","	O
and	O
43	O
combined	O
with	O
70	O
Gy	O
of	O
radiotherapy	O
(	O
arm	O
A	O
)	O
or	O
the	O
same	O
chemoradiotherapy	O
with	O
erlotinib	B-CANCER
150	O
mg	O
per	O
day	O
","	O
starting	O
1	O
week	O
before	O
radiotherapy	O
and	O
continued	O
to	O
its	O
completion	O
(	O
arm	O
B	O
)	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
complete	O
response	O
rate	O
(	O
CRR	O
)	O
","	O
evaluated	O
by	O
central	O
review	O
.	O
	
The	O
secondary	O
end	O
point	O
was	O
progression-free	O
survival	O
(	O
PFS	O
)	O
.	O
	
Available	O
tumors	O
were	O
tested	O
for	O
p16	O
and	O
EGFR	O
by	O
fluorescent	O
in	O
situ	O
hybridization	O
.	O
	
Between	O
December	O
2006	O
and	O
October	O
2011	O
","	O
204	O
patients	O
were	O
randomly	O
assigned	O
.	O
	
Arms	O
were	O
well	O
balanced	O
for	O
all	O
patient	O
characteristics	O
including	O
p16	O
","	O
with	O
the	O
exception	O
of	O
more	O
women	O
on	O
arm	O
A.	O
Patients	O
on	O
arm	O
B	O
had	O
more	O
rash	B-TOXI
","	O
but	O
treatment	O
arms	O
did	O
not	O
differ	O
regarding	O
rates	O
of	O
other	O
grade	O
3	O
or	O
4	O
toxicities	O
.	O
	
Arm	O
A	O
had	O
a	O
CRR	O
of	O
40	O
%	O
and	O
arm	O
B	O
had	O
a	O
CRR	O
of	O
52	O
%	O
(	O
P	O
=	O
0.08	O
)	O
when	O
evaluated	O
by	O
central	O
review	O
.	O
	
With	O
a	O
median	O
follow-up	O
time	O
of	O
26	O
months	O
and	O
54	O
progression	O
events	O
","	O
there	O
was	O
no	O
difference	O
in	O
PFS	O
(	O
hazard	O
ratio	O
","	O
0.9	O
;	O
P	O
=	O
0.71	O
)	O
.	O
	
Erlotinib	B-DRUG
did	O
not	O
increase	O
the	O
toxicity	O
of	O
cisplatin	B-DRUG
and	O
radiotherapy	O
in	O
patients	O
with	O
locally	O
advanced	B-CANCER
HNSCC	I-CANCER
but	O
failed	O
to	O
significantly	O
increase	O
CRR	O
or	O
PFS	O
.	O
	
A	O
phase	O
I	O
trial	O
to	O
determine	O
the	O
safety	O
","	O
pharmacokinetics	O
","	O
and	O
pharmacodynamics	O
of	O
intercalated	O
BMS-690514	O
with	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
(	O
PC	B-DRUG
)	O
in	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
solid	I-CANCER
malignancies	I-CANCER
.	O
	
	
A	O
phase	O
I	O
dose	O
escalation	O
study	O
was	O
performed	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
intercalated	O
dosing	O
of	O
BMS-690514	B-DRUG
","	O
a	O
reversible	O
oral	O
panHER	O
/	O
VEGF	O
receptor	O
inhibitor	O
","	O
combined	O
with	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
(	O
PC	B-DRUG
)	O
in	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Secondary	O
endpoints	O
included	O
safety	O
","	O
pharmacokinetics	O
(	O
PK	O
)	O
","	O
exploratory	O
pharmacodynamics	O
(	O
PD	O
)	O
","	O
and	O
preliminary	O
efficacy	O
.	O
	
Patients	O
received	O
fixed	O
doses	O
of	O
P	O
(	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
C	O
(	O
AUC	O
6	O
mg	O
/	O
mL	O
min	O
)	O
q21	O
days	O
with	O
intercalated	O
BMS-690514	B-DRUG
(	O
Days	O
4月19日	O
)	O
starting	O
at	O
100	O
mg	O
/	O
day	O
and	O
increasing	O
by	O
50	O
mg	O
/	O
day	O
using	O
a	O
3	O
=+	O
3	O
dose	O
escalation	O
design	O
until	O
the	O
MTD	O
was	O
reached	O
.	O
	
Twenty	O
additional	O
patients	O
were	O
enrolled	O
in	O
the	O
expansion	O
cohort	O
at	O
the	O
recommended	O
phase	O
II	O
dose	O
(	O
RP2D	O
)	O
.	O
	
The	O
MTD	O
was	O
reached	O
at	O
150	O
mg	O
/	O
day	O
.	O
	
DLTs	O
included	O
grade	O
3	O
thrombosis	B-TOXI
at	O
100	O
mg	O
(	O
1	O
patient	O
)	O
and	O
grade	O
3	O
diarrhea	B-TOXI
at	O
150	O
mg	O
(	O
1	O
patient	O
)	O
and	O
200	O
mg	O
(	O
2	O
patients	O
)	O
.	O
	
Serious	O
adverse	O
events	O
(	O
AEs	O
)	O
occurring	O
in	O
20	O
/	O
37	O
patients	O
included	O
neutropenia	B-TOXI
(	O
n	O
=	O
5	O
)	O
","	O
diarrhea	B-TOXI
(	O
n	O
=	O
4	O
)	O
","	O
pulmonary	B-TOXI
embolism	I-TOXI
(	O
n	O
=	O
3	O
)	O
","	O
and	O
simultaneous	B-TOXI
dehydration	I-TOXI
","	O
acute	B-TOXI
renal	I-TOXI
failure	I-TOXI
","	O
and	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
n	O
=	O
2	O
)	O
.	O
	
BMS-690514-related	B-DRUG
AEs	O
included	O
diarrhea	B-TOXI
(	O
97	O
%	O
)	O
","	O
acneiform	B-TOXI
rash	I-TOXI
(	O
60	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
43	O
%	O
)	O
","	O
nausea	B-TOXI
(	O
30	O
%	O
)	O
","	O
and	O
anorexia	B-TOXI
(	O
30	O
%	O
)	O
.	O
	
There	O
were	O
no	O
treatment-related	O
deaths	O
.	O
	
Sequential	O
intermittent	O
administration	O
of	O
PC	O
did	O
not	O
affect	O
the	O
PK	O
of	O
BMS-690514	B-DRUG
.	O
	
Of	O
the	O
32	O
patients	O
evaluable	O
for	O
efficacy	O
","	O
there	O
were	O
12	O
partial	O
responses	O
including	O
five	O
patients	O
with	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
and	O
12	O
patients	O
with	O
stable	O
disease	O
.	O
	
The	O
MTD	O
of	O
intercalated	O
BMS-609514	B-DRUG
combined	O
with	O
PC	O
was	O
150	O
mg	O
/	O
day	O
.	O
	
This	O
approach	O
was	O
tolerable	O
with	O
manageable	O
toxicities	O
and	O
antitumor	O
activity	O
in	O
a	O
variety	O
of	O
solid	B-CANCER
tumor	I-CANCER
types	O
.	O
	
Results	O
of	O
a	O
phase	O
I	O
dose	O
escalation	O
study	O
of	O
eltrombopag	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
soft	I-CANCER
tissue	I-CANCER
sarcoma	I-CANCER
receiving	O
doxorubicin	B-DRUG
and	O
ifosfamide	B-DRUG
.	O
	
	
The	O
objective	O
of	O
this	O
Phase	O
I	O
dose	O
escalation	O
study	O
was	O
to	O
explore	O
the	O
safety	O
and	O
tolerability	O
of	O
eltrombopag	B-DRUG
","	O
an	O
oral	O
","	O
nonpeptide	B-DRUG
","	O
thrombopoietin	B-DRUG
receptor	I-DRUG
agonist	I-DRUG
","	O
in	O
patients	O
with	O
advanced	B-CANCER
soft	I-CANCER
tissue	I-CANCER
sarcoma	I-CANCER
(	O
STS	B-CANCER
)	O
and	O
thrombocytopenia	B-CANCER
due	O
to	O
treatment	O
with	O
doxorubicin	B-DRUG
and	O
ifosfamide	B-DRUG
(	O
AI	O
)	O
combination	O
chemotherapy	O
.	O
	
Patients	O
aged	O
18	O
or	O
older	O
with	O
histologically	O
confirmed	O
","	O
locally	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
STS	I-CANCER
were	O
treated	O
with	O
1	O
cycle	O
of	O
AI	O
followed	O
by	O
AI	O
with	O
eltrombopag	B-DRUG
starting	O
at	O
Cycle	O
2	O
","	O
using	O
2	O
different	O
dosing	O
schedules	O
.	O
	
The	O
study	O
design	O
included	O
an	O
eltrombopag	B-DRUG
dose	O
escalation	O
phase	O
starting	O
at	O
75	O
mg	O
daily	O
to	O
determine	O
the	O
optimal	O
biological	O
dose	O
(	O
OBD	O
)	O
.	O
	
Eighteen	O
patients	O
were	O
enrolled	O
and	O
15	O
received	O
at	O
least	O
1	O
dose	O
of	O
chemotherapy	O
;	O
3	O
patients	O
withdrew	O
prior	O
to	O
receiving	O
eltrombopag	B-DRUG
.	O
	
Seven	O
","	O
4	O
","	O
and	O
1	O
patients	O
received	O
75	O
mg	O
","	O
100	O
mg	O
","	O
and	O
150	O
mg	O
eltrombopag	B-DRUG
daily	O
","	O
respectively	O
.	O
	
No	O
dose-limiting	O
toxicities	O
were	O
reported	O
.	O
	
Due	O
to	O
slow	O
recruitment	O
","	O
the	O
study	O
was	O
closed	O
prior	O
to	O
identifying	O
an	O
OBD	O
.	O
	
The	O
most	O
common	O
hematologic	B-TOXI
adverse	I-TOXI
events	I-TOXI
(	O
AEs	O
)	O
were	O
thrombocytopenia	B-TOXI
(	O
80	O
%	O
)	O
","	O
neutropenia	B-TOXI
(	O
73	O
%	O
)	O
","	O
and	O
anemia	B-TOXI
(	O
67	O
%	O
)	O
.	O
	
The	O
most	O
common	O
nonhematologic	B-TOXI
AEs	I-TOXI
were	O
fatigue	B-TOXI
(	O
53	O
%	O
)	O
","	O
alanine	B-TOXI
aminotransferase	I-TOXI
increased	I-TOXI
","	O
constipation	B-TOXI
","	O
and	O
nausea	B-TOXI
(	O
47	O
%	O
each	O
)	O
.	O
	
Eleven	O
of	O
12	O
patients	O
who	O
received	O
eltrombopag	B-DRUG
completed	O
at	O
least	O
2	O
chemotherapy	O
cycles	O
;	O
all	O
had	O
increased	O
platelet	O
counts	O
on	O
Day	O
1	O
of	O
Cycle	O
2	O
(	O
cycle	O
with	O
eltrombopag	B-DRUG
)	O
compared	O
to	O
Day	O
1	O
of	O
Cycle	O
1	O
(	O
cycle	O
without	O
eltrombopag	B-DRUG
)	O
.	O
	
Although	O
data	O
are	O
limited	O
","	O
safety	O
data	O
were	O
consistent	O
with	O
the	O
known	O
toxicities	O
of	O
AI	O
combination	O
chemotherapy	O
or	O
the	O
side	O
effect	O
profile	O
of	O
eltrombopag	B-DRUG
seen	O
in	O
other	O
studies	O
.	O
	
Available	O
data	O
suggest	O
a	O
potential	O
pre-	O
and	O
post-chemotherapy	O
dosing	O
scheme	O
for	O
eltrombopag	B-DRUG
when	O
administered	O
with	O
AI	O
chemotherapy	O
","	O
and	O
support	O
further	O
investigation	O
of	O
eltrombopag	B-DRUG
treatment	O
in	O
patients	O
with	O
chemotherapy-induced	O
thrombocytopenia	B-TOXI
.	O
	
Sunitinib	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
for	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
:	O
a	O
phase	O
I	O
dose-finding	O
study	O
.	O
	
	
This	O
phase	O
I	O
","	O
dose-finding	O
study	O
determined	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
safety	O
","	O
and	O
pharmacokinetics	O
of	O
sunitinib	B-DRUG
plus	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
Two	O
schedules	O
with	O
sunitinib	B-DRUG
(	O
25-50	O
mg	O
per	O
day	O
)	O
and	O
IV	O
gemcitabine	B-DRUG
(	O
750-1250	O
mg	O
m	O
(	O
-2	O
)	O
)	O
in	O
escalating	O
doses	O
were	O
studied	O
.	O
	
First	O
","	O
patients	O
received	O
sunitinib	B-DRUG
on	O
a	O
4-weeks-on-2-weeks-off	O
schedule	O
(	O
Schedule	O
4	O
/	O
2	O
)	O
plus	O
gemcitabine	B-DRUG
on	O
days	O
1	O
","	O
8	O
","	O
22	O
","	O
and	O
29	O
.	O
	
Second	O
","	O
patients	O
received	O
sunitinib	B-DRUG
on	O
a	O
2-weeks-on-1-week-off	O
schedule	O
(	O
Schedule	O
2	O
/	O
1	O
)	O
plus	O
gemcitabine	B-DRUG
on	O
days	O
1	O
and	O
8	O
The	O
primary	O
endpoint	O
was	O
determination	O
of	O
MTD	O
and	O
tolerability	O
.	O
	
Forty-four	O
patients	O
received	O
the	O
combination	O
(	O
Schedule	O
4	O
/	O
2	O
","	O
n=8	O
;	O
Schedule	O
2	O
/	O
1	O
","	O
n=36	O
)	O
.	O
	
With	O
no	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
at	O
maximum	O
dose	O
levels	O
on	O
Schedule	O
2	O
/	O
1	O
","	O
MTD	O
was	O
not	O
reached	O
.	O
	
Grade	O
4	O
treatment-related	O
AEs	O
and	O
laboratory	O
abnormalities	O
included	O
cerebrovascular	B-TOXI
accident	I-TOXI
","	O
hypertension	B-TOXI
","	O
and	O
pulmonary	B-TOXI
embolism	I-TOXI
(	O
n=1	O
each	O
)	O
","	O
and	O
neutropenia	B-TOXI
(	O
n=3	O
)	O
","	O
thrombocytopenia	B-TOXI
and	O
increased	B-TOXI
uric	I-TOXI
acid	I-TOXI
(	O
both	O
n=2	O
)	O
","	O
and	O
lymphopenia	B-TOXI
(	O
n=1	O
)	O
.	O
	
There	O
were	O
no	O
clinically	O
significant	O
drug-drug	O
interactions	O
.	O
	
Antitumor	O
activity	O
occurred	O
across	O
dose	O
levels	O
and	O
tumour	O
types	O
.	O
	
In	O
poor-risk	O
and	O
/	O
or	O
high-grade	O
renal	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
patients	O
(	O
n=12	O
)	O
","	O
5	O
had	O
partial	O
responses	O
and	O
7	O
stable	O
disease	O
_	O
6	O
weeks	O
.	O
	
Sunitinib	B-DRUG
plus	O
gemcitabine	B-DRUG
on	O
Schedule	O
2	O
/	O
1	O
with	O
growth	O
factor	O
support	O
was	O
well	O
tolerated	O
and	O
safely	O
administered	O
at	O
maximum	O
doses	O
of	O
each	O
drug	O
","	O
without	O
significant	O
drug-drug	O
interactions	O
.	O
	
Temsirolimus	B-DRUG
combined	O
with	O
sorafenib	B-DRUG
in	O
hepatocellular	B-CANCER
carcinoma	I-CANCER
:	O
a	O
phase	O
I	O
dose-finding	O
trial	O
with	O
pharmacokinetic	O
and	O
biomarker	O
correlates	O
.	O
	
	
Based	O
upon	O
preclinical	O
evidence	O
for	O
improved	O
antitumor	O
activity	O
in	O
combination	O
","	O
this	O
phase	O
I	O
study	O
investigated	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
safety	O
","	O
activity	O
","	O
pharmacokinetics	O
(	O
PK	O
)	O
","	O
and	O
biomarkers	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	O
inhibitor	O
","	O
temsirolimus	B-DRUG
","	O
combined	O
with	O
sorafenib	B-DRUG
in	O
hepatocellular	B-CANCER
carcinoma	I-CANCER
(	O
HCC	B-CANCER
)	O
.	O
	
Patients	O
with	O
incurable	O
HCC	B-CANCER
and	O
Child	O
Pugh	O
score	O
_B7	O
were	O
treated	O
with	O
sorafenib	B-DRUG
plus	O
temsirolimus	B-DRUG
by	O
3	O
=+	O
3	O
design	O
.	O
	
The	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
interval	O
was	O
28	O
days	O
.	O
	
The	O
response	O
was	O
assessed	O
every	O
two	O
cycles	O
.	O
	
PK	O
of	O
temsirolimus	B-DRUG
was	O
measured	O
in	O
a	O
cohort	O
at	O
MTD	O
.	O
	
Twenty-five	O
patients	O
were	O
enrolled	O
.	O
	
The	O
MTD	O
was	O
temsirolimus	B-DRUG
10	O
mg	O
weekly	O
plus	O
sorafenib	B-DRUG
200	O
mg	O
twice	O
daily	O
.	O
	
Among	O
18	O
patients	O
at	O
MTD	O
","	O
DLT	O
included	O
grade	O
3	O
hand-foot	B-TOXI
skin	I-TOXI
reaction	I-TOXI
(	O
HFSR	B-TOXI
)	O
and	O
grade	O
3	O
thrombocytopenia	B-TOXI
.	O
	
Grade	O
3	O
or	O
4	O
related	O
adverse	O
events	O
at	O
MTD	O
included	B-TOXI
hypophosphatemia	I-TOXI
(	O
33	O
%	O
)	O
","	O
infection	B-TOXI
(	O
22	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
17	O
%	O
)	O
","	O
HFSR	B-TOXI
(	O
11	O
%	O
)	O
","	O
and	O
fatigue	B-TOXI
(	O
11	O
%	O
)	O
.	O
	
With	O
sorafenib	B-DRUG
","	O
temsirolimus	B-DRUG
clearance	O
was	O
more	O
rapid	O
(	O
P	O
&	O
lt	O
;	O
0.05	O
)	O
.	O
	
Two	O
patients	O
(	O
8	O
%	O
)	O
had	O
a	O
confirmed	O
partial	O
response	O
(	O
PR	O
)	O
;	O
15	O
(	O
60	O
%	O
)	O
had	O
stable	O
disease	O
(	O
SD	O
)	O
.	O
	
Alpha-fetoprotein	B-TOXI
(	I-TOXI
AFP	I-TOXI
)	I-TOXI
declined	I-TOXI
_50	O
%	O
in	O
60	O
%	O
assessable	O
patients	O
.	O
	
The	O
MTD	O
of	O
sorafenib	B-DRUG
plus	O
temsirolimus	B-DRUG
in	O
HCC	B-CANCER
was	O
lower	O
than	O
in	O
other	O
tumor	O
types	O
.	O
	
HCC-specific	B-CANCER
phase	O
I	O
studies	O
are	O
necessary	O
.	O
	
The	O
observed	O
efficacy	O
warrants	O
further	O
study	O
.	O
	
A	O
phase	O
I	O
schedule	O
dependency	O
study	O
of	O
the	O
aurora	O
kinase	O
inhibitor	O
MSC1992371A	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
MSC1992371A	B-DRUG
is	O
an	O
aurora	O
kinase	O
inhibitor	O
with	O
potential	O
antitumor	O
activity	O
.	O
	
This	O
trial	O
established	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
of	O
oral	O
MSC1992371A	B-DRUG
given	O
before	O
or	O
after	O
gemcitabine	B-DRUG
(	O
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
in	O
a	O
21-day	O
cycle	O
in	O
patients	O
with	O
advanced	B-CANCER
malignancies	I-CANCER
.	O
	
In	O
schedule	O
1	O
(	O
n	O
=	O
31	O
)	O
","	O
gemcitabine	B-DRUG
was	O
administered	O
on	O
days	O
1	O
and	O
8	O
followed	O
by	O
escalating	O
doses	O
of	O
MSC1992371A	B-DRUG
on	O
days	O
2	O
and	O
9	O
In	O
schedule	O
2	O
(	O
n	O
=	O
35	O
)	O
","	O
MSC1992371A	B-DRUG
was	O
given	O
on	O
days	O
1	O
and	O
8	O
followed	O
by	O
gemcitabine	B-DRUG
on	O
days	O
2	O
and	O
9	O
Patients	O
had	O
a	O
range	O
of	O
solid	B-CANCER
tumors	I-CANCER
","	O
the	O
most	O
frequent	O
of	O
which	O
was	O
colorectal	B-CANCER
(	O
n	O
=	O
19	O
)	O
.	O
	
In	O
both	O
schedules	O
","	O
the	O
37	O
mg	O
/	O
m	O
(	O
2	O
)	O
dose	O
level	O
was	O
defined	O
as	O
the	O
MTD	O
.	O
	
The	O
main	O
DLT	O
was	O
grade	O
4	O
neutropenia	B-TOXI
.	O
	
Adverse	O
events	O
consisted	O
of	O
neutropenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
asthenia	B-TOXI
","	O
fatigue	B-TOXI
","	O
nausea	B-TOXI
","	O
vomiting	B-TOXI
","	O
anorexia	B-TOXI
","	O
and	O
diarrhea	B-TOXI
.	O
	
Administration	O
of	O
MSC1992371A	B-DRUG
prior	O
to	O
gemcitabine	B-DRUG
had	O
no	O
effect	O
on	O
the	O
metabolism	O
or	O
elimination	O
of	O
gemcitabine	B-DRUG
.	O
	
Time	O
to	O
reach	O
maximum	O
plasma	O
concentration	O
and	O
area	O
under	O
the	O
plasma	O
concentration-time	O
curve	O
for	O
MSC1992371A	B-DRUG
increased	O
proportionally	O
with	O
dose	O
.	O
	
Exploration	O
of	O
drug-target-related	O
and	O
tumor	O
biomarkers	O
did	O
not	O
identify	O
predictors	O
of	O
biologic	O
activity	O
or	O
response	O
.	O
	
Two	O
patients	O
(	O
1	O
with	O
lung	B-CANCER
carcinoma	I-CANCER
and	O
1	O
with	O
hepatocellular	B-CANCER
carcinoma	I-CANCER
)	O
had	O
durable	O
partial	O
responses	O
in	O
schedule	O
2	O
","	O
and	O
5	O
patients	O
had	O
stable	O
disease	O
(	O
SD	O
)	O
lasting	O
6	O
=-	O
14	O
months	O
.	O
	
Oral	O
MSC1992371A	B-DRUG
can	O
be	O
administered	O
at	O
a	O
MTD	O
of	O
37	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
combination	O
with	O
the	O
standard	O
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
dose	O
of	O
gemcitabine	B-DRUG
","	O
but	O
hematologic	B-TOXI
toxicity	I-TOXI
requires	O
careful	O
monitoring	O
.	O
	
Preliminary	O
signs	O
of	O
efficacy	O
were	O
indicated	O
by	O
durable	O
responses	O
and	O
SD	O
.	O
	
Oral	O
lenalidomide	B-DRUG
with	O
rituximab	B-DRUG
in	O
relapsed	O
or	O
refractory	O
diffuse	O
large	O
cell	O
","	O
follicular	B-CANCER
and	I-CANCER
transformed	I-CANCER
lymphoma	I-CANCER
:	O
a	O
phase	O
II	O
clinical	O
trial	O
.	O
	
	
Lenalidomide-rituximab	B-DRUG
therapy	O
is	O
effective	O
in	O
grade	O
1月2日	O
follicular	B-CANCER
and	I-CANCER
mantle	I-CANCER
cell	I-CANCER
lymphoma	I-CANCER
","	O
but	O
its	O
efficacy	O
in	O
diffuse	B-CANCER
large	I-CANCER
B-cell	I-CANCER
lymphoma	I-CANCER
(	O
DLBCL	B-CANCER
)	O
","	O
transformed	B-CANCER
large	I-CANCER
cell	I-CANCER
lymphoma	I-CANCER
(	O
TL	B-CANCER
)	O
and	O
grade	O
3	O
follicular	B-CANCER
lymphoma	I-CANCER
(	O
FLG3	B-CANCER
)	O
is	O
unknown	O
.	O
	
In	O
this	O
phase	O
II	O
trial	O
","	O
45	O
patients	O
with	O
relapsed	O
or	O
refractory	O
DLBCL	B-CANCER
(	O
n=32	O
)	O
","	O
TL	B-CANCER
(	O
n=9	O
)	O
or	O
FLG3	B-CANCER
(	O
n=4	O
)	O
who	O
had	O
received	O
1月4日	O
prior	O
lines	O
of	O
treatment	O
were	O
given	O
20	O
mg	O
oral	B-DRUG
lenalidomide	I-DRUG
on	O
days	O
1月21日	O
of	O
each	O
28-day	O
cycle	O
","	O
and	O
intravenous	B-DRUG
rituximab	I-DRUG
(	O
375	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
weekly	O
during	O
cycle	O
1	O
Grade	O
3	O
/	O
4	O
hematological	B-TOXI
toxicities	I-TOXI
included	O
neutropenia	B-TOXI
(	O
53	O
%	O
)	O
","	O
lymphopenia	B-TOXI
(	O
40	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
33	O
%	O
)	O
","	O
leukopenia	B-TOXI
(	O
27	O
%	O
)	O
and	O
anemia	B-TOXI
(	O
18	O
%	O
)	O
","	O
with	O
a	O
median	O
follow-up	O
time	O
of	O
29.1	O
months	O
(	O
range	O
14.7-52.0	O
months	O
)	O
.	O
	
Overall	O
response	O
(	O
OR	O
)	O
rate	O
was	O
33	O
%	O
;	O
median	O
response	O
duration	O
was	O
10.2	O
months	O
.	O
	
Median	O
progression-free	O
survival	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
were	O
3.7	O
and	O
10.7	O
months	O
","	O
respectively	O
.	O
	
Nine	O
of	O
the	O
15	O
responding	O
patients	O
(	O
three	O
partial	O
response	O
(	O
PR	O
)	O
","	O
six	O
complete	O
response	O
(	O
CR	O
)	O
)	O
proceeded	O
with	O
stem	O
cell	O
transplantation	O
(	O
SCT	O
)	O
and	O
were	O
censored	O
at	O
the	O
time	O
of	O
transplantation	O
.	O
	
When	O
data	O
were	O
analyzed	O
without	O
censoring	O
","	O
median	O
PFS	O
remained	O
3.7	O
months	O
and	O
response	O
duration	O
increased	O
to	O
30.9	O
months	O
.	O
	
Rituximab	B-DRUG
plus	O
oral	B-DRUG
lenalidomide	I-DRUG
is	O
well	O
tolerated	O
and	O
effective	O
for	O
patients	O
with	O
relapsed	O
/	O
refractory	O
DLBCL	B-CANCER
and	O
TL	B-CANCER
.	O
	
SCT	O
after	O
lenalidomide-rituximab	B-DRUG
is	O
associated	O
with	O
prolonged	O
response	O
duration	O
.	O
	
Molecular	O
characterization	O
of	O
anastrozole	B-DRUG
resistance	O
in	O
breast	B-CANCER
cancer	I-CANCER
:	O
pivotal	O
role	O
of	O
the	O
Akt	O
/	O
mTOR	O
pathway	O
in	O
the	O
emergence	O
of	O
de	O
novo	O
or	O
acquired	O
resistance	O
and	O
importance	O
of	O
combining	O
the	O
allosteric	O
Akt	O
inhibitor	O
MK-2206	B-DRUG
with	O
an	O
aromatase	B-DRUG
inhibitor	I-DRUG
.	O
	
	
Acquisition	O
of	O
resistance	O
to	O
aromatase	B-DRUG
inhibitors	I-DRUG
(	O
AIs	O
)	O
remains	O
a	O
major	O
drawback	O
in	O
the	O
treatment	O
of	O
estrogen	O
receptor	O
alpha	O
(	O
ER伪	O
)	O
#NAME?	O
breast	B-CANCER
cancers	I-CANCER
.	O
	
The	O
Res-Ana	O
cells	O
","	O
a	O
new	O
model	O
of	O
acquired	O
resistance	O
to	O
anastrozole	B-DRUG
","	O
were	O
established	O
by	O
long-term	O
exposure	O
of	O
aromatase-overexpressing	O
MCF-7	O
cells	O
to	O
this	O
drug	O
.	O
	
These	O
resistant	O
cells	O
developed	O
ER-independent	O
mechanisms	O
of	O
resistance	O
and	O
decreased	O
sensitivity	O
to	O
the	O
AI	O
letrozole	B-DRUG
or	O
to	O
ER伪	B-DRUG
antagonists	I-DRUG
.	O
	
They	O
also	O
displayed	O
a	O
constitutive	O
activation	O
of	O
the	O
PI3K	O
/	O
Akt	O
/	O
mTOR	O
pathway	O
and	O
a	O
deregulated	O
expression	O
of	O
several	O
ErbB	O
receptors	O
.	O
	
An	O
observed	O
increase	O
in	O
the	O
phospho-Akt	O
/	O
Akt	O
ratio	O
between	O
primary	O
and	O
matched	O
recurrent	B-CANCER
breast	I-CANCER
tumors	I-CANCER
of	O
patients	O
who	O
relapsed	O
under	O
anastrozole	B-DRUG
adjuvant	O
therapy	O
also	O
argued	O
for	O
a	O
pivotal	O
role	O
of	O
the	O
Akt	O
pathway	O
in	O
acquired	O
resistance	O
to	O
anastrozole	B-DRUG
.	O
	
Ectopic	O
overexpression	O
of	O
constitutively	O
active	O
Akt1	O
in	O
control	O
cells	O
was	O
sufficient	O
to	O
induce	O
de	O
novo	O
resistance	O
to	O
anastrozole	B-DRUG
.	O
	
Strikingly	O
","	O
combining	O
anastrozole	B-DRUG
with	O
the	O
highly	O
selective	O
and	O
allosteric	O
Akt	O
inhibitor	O
MK-2206	O
or	O
with	O
the	O
mTOR	O
inhibitor	O
rapamycin	B-DRUG
increased	O
sensitivity	O
to	O
this	O
AI	O
in	O
the	O
control	O
cells	O
and	O
was	O
sufficient	O
to	O
overcome	O
resistance	O
and	O
restore	O
sensitivity	O
to	O
endocrine	B-DRUG
therapy	O
in	O
the	O
resistant	O
cells	O
.	O
	
Our	O
findings	O
lead	O
to	O
us	O
proposing	O
a	O
model	O
of	O
anastrozole-acquired	B-DRUG
resistance	O
based	O
on	O
the	O
selection	O
of	O
cancer-initiating-like	O
cells	O
possessing	O
self-renewing	O
properties	O
","	O
intrinsic	O
resistance	O
to	O
anastrozole	B-DRUG
and	O
sensitivity	O
to	O
MK-2206	B-DRUG
.	O
	
Altogether	O
","	O
our	O
work	O
demonstrated	O
that	O
the	O
Akt	O
/	O
mTOR	O
pathway	O
plays	O
a	O
key	O
role	O
in	O
resistance	O
to	O
anastrozole	B-DRUG
and	O
that	O
combining	O
anastrozole	O
with	O
Akt	O
/	O
mTOR	O
pathway	O
inhibitors	O
represents	O
a	O
promising	O
strategy	O
in	O
the	O
clinical	O
management	O
of	O
hormone-dependent	O
breast	B-CANCER
cancer	I-CANCER
patients	O
.	O
	
Phase	O
III	O
","	O
multicenter	O
","	O
randomized	O
trial	O
of	O
maintenance	O
chemotherapy	O
versus	O
observation	O
in	O
patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
after	O
achieving	O
disease	O
control	O
with	O
six	O
cycles	O
of	O
gemcitabine	B-DRUG
plus	O
paclitaxel	B-DRUG
as	O
first-line	O
chemotherapy	O
:	O
KCSG-BR07-02	O
.	O
	
	
The	O
primary	O
purpose	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
whether	O
maintenance	O
chemotherapy	O
with	O
paclitaxel	B-DRUG
/	O
gemcitabine	B-DRUG
(	O
PG	B-DRUG
)	O
was	O
superior	O
to	O
observation	O
in	O
improving	O
progression-free	O
survival	O
(	O
PFS	O
)	O
in	O
patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
MBC	B-CANCER
)	O
who	O
achieved	O
disease	O
control	O
with	O
an	O
initial	O
six	O
cycles	O
of	O
PG	B-DRUG
as	O
their	O
first-line	O
treatment	O
.	O
	
The	O
study	O
was	O
a	O
prospective	O
","	O
randomized	O
","	O
multicenter	O
","	O
phase	O
III	O
trial	O
.	O
	
Patients	O
MBC	B-CANCER
with	O
who	O
achieved	O
disease	O
control	O
after	O
six	O
cycles	O
of	O
PG	B-DRUG
chemotherapy	O
were	O
randomly	O
assigned	O
to	O
maintenance	O
chemotherapy	O
or	O
observation	O
until	O
progression	O
.	O
	
Of	O
324	O
patients	O
from	O
10	O
centers	O
enrolled	O
","	O
231	O
patients	O
with	O
MBC	B-CANCER
exhibited	O
disease	O
control	O
(	O
complete	O
response	O
=+	O
partial	O
response	O
=+	O
stable	O
disease	O
)	O
with	O
first-line	O
PG	B-DRUG
and	O
were	O
randomly	O
assigned	O
to	O
maintenance	O
chemotherapy	O
(	O
n	O
=	O
116	O
)	O
or	O
observation	O
(	O
n	O
=	O
115	O
)	O
.	O
	
The	O
median	O
age	O
was	O
48	O
years	O
(	O
range	O
","	O
28	O
to	O
76	O
years	O
)	O
","	O
median	O
follow-up	O
was	O
33	O
months	O
","	O
and	O
median	O
number	O
of	O
chemotherapy	O
cycles	O
in	O
the	O
maintenance	O
group	O
after	O
random	O
assignment	O
was	O
six	O
.	O
	
The	O
median	O
PFS	O
time	O
after	O
random	O
assignment	O
was	O
longer	O
in	O
the	O
maintenance	O
group	O
than	O
in	O
the	O
observation	O
group	O
(	O
7.5	O
v	O
3.8	O
months	O
","	O
respectively	O
;	O
P	O
=	O
0.026	O
)	O
.	O
	
The	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
time	O
was	O
longer	O
in	O
the	O
maintenance	O
group	O
than	O
in	O
the	O
observation	O
group	O
(	O
32.3	O
v	O
23.5	O
months	O
","	O
respectively	O
;	O
P	O
=	O
0.047	O
)	O
.	O
	
The	O
rate	O
of	O
grade	O
3	O
or	O
higher	B-TOXI
neutropenia	I-TOXI
after	O
random	O
assignment	O
was	O
higher	O
in	O
the	O
maintenance	O
group	O
than	O
in	O
the	O
observation	O
group	O
(	O
61	O
%	O
v	O
0.9	O
%	O
","	O
respectively	O
;	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
.	O
	
In	O
patients	O
with	O
MBC	B-CANCER
who	O
achieved	O
disease	O
control	O
with	O
an	O
initial	O
six	O
cycles	O
of	O
PG	B-DRUG
chemotherapy	O
","	O
maintenance	O
PG	B-DRUG
chemotherapy	O
resulted	O
in	O
better	O
PFS	O
and	O
OS	O
compared	O
with	O
observation	O
.	O
	
A	O
phase	O
1b	O
study	O
of	O
trametinib	B-DRUG
","	O
an	O
oral	O
Mitogen-activated	O
protein	O
kinase	O
kinase	O
(	O
MEK	O
)	O
inhibitor	O
","	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
	
This	O
phase	O
1b	O
study	O
determined	O
the	O
safety	O
","	O
tolerability	O
","	O
and	O
recommended	O
phase	O
2	O
dose	O
(	O
RP2D	O
)	O
and	O
schedule	O
of	O
trametinib	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
.	O
	
Secondary	O
objectives	O
included	O
assessment	O
of	O
clinical	O
activity	O
and	O
steady-state	O
pharmacokinetics	O
.	O
	
Adults	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
","	O
adequate	O
organ	O
function	O
and	O
Eastern	O
Co-operative	O
Oncology	O
Group	O
performance	O
status	O
(	O
ECOG	O
PS	O
)	O
猢	O
1	O
were	O
eligible	O
.	O
	
Once-daily	O
oral	O
trametinib	B-DRUG
(	O
1mg	O
","	O
2mg	O
","	O
2.5mg	O
)	O
was	O
escalated	O
in	O
a	O
3+3	O
design	O
with	O
standard	O
gemcitabine	B-DRUG
dosing	O
(	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
Days	O
1	O
","	O
8	O
","	O
and	O
15	O
of	O
28-day	O
cycles	O
)	O
.	O
	
During	O
expansion	O
","	O
trametinib	B-DRUG
2mg	O
was	O
combined	O
with	O
gemcitabine	B-DRUG
.	O
	
Pharmacokinetics	O
samples	O
were	O
collected	O
on	O
Day	O
15	O
pre-dose	O
and	O
1	O
","	O
2	O
","	O
4	O
and	O
6h	O
post-dose	O
;	O
tumour	O
assessments	O
were	O
repeated	O
every	O
two	O
cycles	O
.	O
	
Between	O
8	O
/	O
2009	O
and	O
11	O
/	O
2010	O
","	O
31	O
patients	O
(	O
pancreas	O
=	O
11	O
","	O
breast	O
=	O
6	O
","	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
=	O
4	O
","	O
other	O
=	O
10	O
)	O
were	O
treated	O
.	O
	
Dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
occurred	O
in	O
each	O
cohort	O
","	O
and	O
included	O
febrile	B-TOXI
neutropenia	I-TOXI
","	O
transaminase	B-TOXI
elevation	I-TOXI
and	O
uveitis	B-TOXI
.	O
	
The	O
RP2D	O
was	O
declared	O
as	O
trametinib	B-DRUG
2mg	O
daily	O
with	O
standard	O
gemcitabine	B-DRUG
dosing	O
.	O
	
Common	O
grade	O
3	O
/	O
4	O
toxicities	O
at	O
the	O
RP2D	O
included	O
:	O
neutropenia	B-TOXI
(	O
38	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
19	O
%	O
)	O
and	O
transaminase	B-TOXI
elevation	I-TOXI
(	O
14	O
%	O
)	O
.	O
	
Of	O
10	O
patients	O
with	O
measurable	O
pancreatic	B-CANCER
cancer	I-CANCER
","	O
three	O
partial	O
responses	O
(	O
30	O
%	O
)	O
were	O
documented	O
;	O
two	O
additional	O
patients	O
achieved	O
objective	O
responses	O
(	O
breast	O
","	O
complete	O
response	O
(	O
CR	O
)	O
;	O
salivary	O
glands	O
","	O
partial	O
response	O
(	O
PR	O
)	O
)	O
.	O
	
Pharmacokinetics	O
suggested	O
no	O
change	O
in	O
exposures	O
of	O
either	O
drug	O
in	O
combination	O
.	O
	
Administration	O
of	O
trametinib	B-DRUG
at	O
its	O
full	O
monotherapy	O
dose	O
of	O
2mg	O
daily	O
in	O
combination	O
with	O
standard	O
gemcitabine	B-DRUG
dosing	O
(	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
Days	O
1	O
","	O
8	O
","	O
and	O
15	O
every	O
28	O
days	O
)	O
was	O
feasible	O
.	O
	
Though	O
most	O
toxicities	O
were	O
manageable	O
","	O
the	O
addition	O
of	O
trametinib	B-DRUG
may	O
increase	O
gemcitabine-associated	B-DRUG
myelosuppression	B-TOXI
.	O
	
Future	O
studies	O
of	O
this	O
combination	O
will	O
require	O
monitoring	O
to	O
maintain	O
dose	O
and	O
schedule	O
.	O
	
Induction	O
chemotherapy	O
with	O
cetuximab	B-DRUG
","	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
for	O
the	O
treatment	O
of	O
locally	O
advanced	B-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
	
Although	O
controversy	O
exists	O
in	O
the	O
management	O
of	O
locally	O
advanced	B-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	O
LA-SCCHN	B-CANCER
)	O
","	O
clinicians	O
often	O
use	O
induction	O
chemotherapy	O
for	O
treatment	O
of	O
the	O
most	O
advanced	O
cases	O
.	O
	
One	O
promising	O
regimen	O
combines	O
weekly	O
cetuximab	B-DRUG
(	O
400	O
mg	O
/	O
m	O
	
Feasibility	O
of	O
Oxaliplatin	B-DRUG
","	O
Leucovorin	B-DRUG
","	O
and	O
5-Fluorouracil	B-DRUG
(	O
FOLFOX-4	B-DRUG
)	O
Chemotherapy	O
in	O
Heavily	O
Pretreated	O
Patients	O
with	O
Recurrent	O
Epithelial	B-CANCER
Ovarian	I-CANCER
Cancer	I-CANCER
.	O
	
	
The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
the	O
efficacy	O
and	O
toxicity	O
of	O
oxaliplatin	B-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
5-fluorouracil	B-DRUG
(	O
FOLFOX-4	B-DRUG
)	O
chemotherapy	O
in	O
heavily	O
pretreated	O
patients	O
with	O
recurrent	O
epithelial	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
(	O
EOC	B-CANCER
)	O
.	O
	
Clinical	O
data	O
were	O
reviewed	O
in	O
28	O
patients	O
who	O
received	O
FOLFOX-4	B-DRUG
as	O
more	O
than	O
the	O
second-line	O
chemotherapy	O
","	O
consisting	O
of	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
oxaliplatin	B-DRUG
as	O
a	O
2-hour	O
infusion	O
","	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
leucovorin	B-DRUG
as	O
a	O
2-hour	O
infusion	O
","	O
and	O
bolus	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
","	O
followed	O
by	O
a	O
22-hour	O
infusion	O
of	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
5-fluorouracil	B-DRUG
for	O
two	O
consecutive	O
days	O
every	O
three	O
weeks	O
.	O
	
In	O
addition	O
","	O
its	O
efficacy	O
and	O
toxicity	O
were	O
compared	O
with	O
those	O
reported	O
in	O
in	O
three	O
previous	O
relevant	O
studies	O
.	O
	
A	O
total	O
of	O
128	O
cycles	O
of	O
FOLFOX-4	B-DRUG
were	O
administered	O
with	O
the	O
median	O
number	O
of	O
five	O
cycles	O
(	O
range	O
","	O
1	O
to	O
10	O
cycles	O
)	O
.	O
	
In	O
nine	O
patients	O
with	O
measurable	O
disease	O
","	O
complete	O
response	O
(	O
CR	O
)	O
and	O
partial	O
response	O
(	O
PR	O
)	O
were	O
observed	O
in	O
0	O
(	O
0	O
%	O
)	O
and	O
two	O
(	O
22.2	O
%	O
)	O
patients	O
","	O
whereas	O
in	O
19	O
patients	O
with	O
non-measurable	O
disease	O
","	O
CR	O
and	O
PR	O
were	O
observed	O
in	O
0	O
(	O
0	O
%	O
)	O
and	O
five	O
(	O
26.3	O
%	O
)	O
patients	O
.	O
	
Among	O
all	O
patients	O
","	O
grade	O
3	O
anemia	B-TOXI
","	O
neutropenia	B-TOXI
","	O
and	O
thrombocytopenia	B-TOXI
were	O
observed	O
in	O
two	O
(	O
7.1	O
%	O
)	O
","	O
three	O
(	O
10.7	O
%	O
)	O
","	O
and	O
one	O
(	O
3.6	O
%	O
)	O
patient	O
","	O
and	O
grade	O
3	O
fatigue	B-TOXI
","	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
","	O
and	O
peripheral	B-TOXI
neuropathy	I-TOXI
were	O
observed	O
in	O
one	O
(	O
3.6	O
%	O
)	O
","	O
two	O
(	O
7.1	O
%	O
)	O
","	O
and	O
three	O
(	O
10.7	O
%	O
)	O
patients	O
.	O
	
In	O
addition	O
","	O
median	O
values	O
of	O
time	O
to	O
progressive	O
disease	O
and	O
chemotherapy-specific	O
survival	O
were	O
three	O
months	O
(	O
range	O
","	O
0	O
to	O
10	O
months	O
)	O
and	O
nine	O
months	O
(	O
range	O
","	O
4	O
to	O
24	O
months	O
)	O
.	O
	
FOLFOX-4	B-DRUG
is	O
feasible	O
as	O
salvage	O
chemotherapy	O
with	O
acceptable	O
toxicity	O
for	O
heavily	O
pretreated	O
patients	O
with	O
recurrent	O
EOC	B-CANCER
.	O
	
Sorafenib	B-DRUG
and	O
everolimus	B-DRUG
in	O
advanced	B-CANCER
clear	I-CANCER
cell	I-CANCER
renal	I-CANCER
carcinoma	I-CANCER
:	O
a	O
phase	O
I	O
/	O
II	O
trial	O
of	O
the	O
SCRI	O
Oncology	O
Research	O
Consortium	O
.	O
	
	
To	O
evaluate	O
the	O
feasibility	O
and	O
efficacy	O
of	O
sorafenib	B-DRUG
and	O
everolimus	B-DRUG
in	O
renal	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
RCC	B-CANCER
)	O
.	O
	
Patients	O
with	O
advanced	B-CANCER
RCC	I-CANCER
and	O
_	O
1	O
previous	O
targeted	O
therapy	O
were	O
treated	O
.	O
	
Maximum	O
tolerated	O
doses	O
were	O
sorafenib	B-DRUG
200	O
mg	O
PO	O
BID	O
","	O
everolimus	B-DRUG
35	O
mg	O
PO	O
once	O
weekly	O
.	O
	
Dose-limiting	O
toxicity	O
was	O
hand-foot	B-TOXI
syndrome	I-TOXI
.	O
	
The	O
response	O
rate	O
was	O
13	O
%	O
;	O
median	O
PFS	O
was	O
5.45	O
months	O
(	O
95	O
%	O
CI	O
:	O
3.8-7.6	O
)	O
.	O
	
Skin	B-TOXI
toxicity	I-TOXI
","	O
fatigue	B-TOXI
","	O
hypertension	B-TOXI
","	O
proteinuria	B-TOXI
","	O
and	O
mucositis	B-TOXI
(	O
usually	O
Grade	O
2	O
)	O
were	O
common	O
.	O
	
Fifty	O
percent	O
doses	O
of	O
sorafenib	B-DRUG
and	O
everolimus	B-DRUG
were	O
required	O
when	O
these	O
drugs	O
were	O
combined	O
.	O
	
No	O
increase	O
in	O
efficacy	O
was	O
suggested	O
;	O
toxicity	O
was	O
modestly	O
increased	O
.	O
	
A	O
phase	O
I	O
trial	O
of	O
oral	O
ridaforolimus	B-DRUG
(	O
AP23573	O
;	O
MK-8669	O
)	O
in	O
combination	O
with	O
bevacizumab	B-DRUG
for	O
patients	O
with	O
advanced	O
cancers	O
.	O
	
	
This	O
phase	O
I	O
dose-escalation	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
combination	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	O
inhibitor	O
ridaforolimus	B-DRUG
with	O
the	O
vascular	O
endothelial	O
growth	O
factor	O
inhibitor	O
bevacizumab	B-DRUG
.	O
	
Seventeen	O
adult	O
patients	O
with	O
refractory	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
received	O
oral	O
ridaforolimus	B-DRUG
(	O
30	O
or	O
40	O
mg	O
)	O
once	O
daily	O
for	O
5	O
days	O
per	O
week	O
(	O
QDx5	O
/	O
wk	O
)	O
combined	O
with	O
intravenous	O
bevacizumab	B-DRUG
(	O
10	O
mg	O
/	O
kg	O
every	O
2	O
weeks	O
[	O
Q2wk	O
]	O
or	O
15	O
mg	O
/	O
kg	O
every	O
3	O
weeks	O
[	O
Q3wk	O
]	O
)	O
.	O
	
Patients	O
were	O
evaluated	O
for	O
dose-limiting	O
toxicities	O
","	O
safety	O
and	O
anti-tumour	O
activity	O
.	O
	
A	O
40	O
mg	O
dose	O
of	O
ridaforolimus	B-DRUG
with	O
either	O
bevacizumab	B-DRUG
dosing	O
schedule	O
was	O
the	O
recommended	O
phase	O
II	O
dose	O
.	O
	
No	O
dose-limiting	O
toxicities	O
were	O
reported	O
;	O
the	O
most	O
common	O
drug-related	O
adverse	O
events	O
were	O
mucosal	B-TOXI
inflammation	I-TOXI
and	O
anorexia	B-TOXI
.	O
	
Seven	O
patients	O
","	O
with	O
clinical	O
features	O
that	O
included	O
primary	O
tumour	O
of	O
the	O
abdominal	O
origin	O
(	O
colorectal	O
","	O
pancreatic	O
or	O
gynaecological	O
cancers	O
)	O
and	O
previous	O
abdominal	O
radiotherapy	O
","	O
reported	O
serious	O
adverse	O
events	O
related	O
to	O
bowel	O
perforations	O
.	O
	
There	O
were	O
no	O
objective	O
responses	O
","	O
but	O
65	O
%	O
of	O
patients	O
had	O
a	O
best	O
response	O
of	O
stable	O
disease	O
.	O
	
Oral	B-DRUG
ridaforolimus	I-DRUG
(	O
40	O
mg	O
QDx5	O
/	O
wk	O
)	O
is	O
feasible	O
to	O
combine	O
with	O
standard	O
doses	O
of	O
bevacizumab	B-DRUG
","	O
although	O
careful	O
patient	O
selection	O
would	O
be	O
needed	O
to	O
mitigate	O
the	O
risk	O
of	O
bowel	B-TOXI
perforation-related	I-TOXI
adverse	I-TOXI
events	I-TOXI
.	O
	
Combination	O
therapy	O
produced	O
prolonged	O
stable	O
disease	O
in	O
several	O
heavily	O
pretreated	O
patients	O
.	O
	
Combination	O
neratinib	B-DRUG
(	O
HKI-272	O
)	O
and	O
paclitaxel	B-DRUG
therapy	O
in	O
patients	O
with	O
HER2-positive	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
Neratinib	B-DRUG
is	O
a	O
potent	O
irreversible	O
pan-ErbB	O
tyrosine	O
kinase	O
inhibitor	O
that	O
has	O
demonstrated	O
antitumour	O
activity	O
and	O
an	O
acceptable	O
safety	O
profile	O
in	O
patients	O
with	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
HER	O
)	O
#NAME?	O
breast	B-CANCER
cancer	I-CANCER
and	O
other	O
solid	B-CANCER
tumours	I-CANCER
.	O
	
This	O
was	O
a	O
phase	O
I	O
/	O
II	O
","	O
open-label	O
","	O
two-part	O
study	O
.	O
	
Part	O
1	O
was	O
a	O
dose-escalation	O
study	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
neratinib	B-DRUG
plus	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
solid	B-CANCER
tumours	I-CANCER
.	O
	
Part	O
2	O
evaluated	O
the	O
safety	O
","	O
efficacy	O
","	O
and	O
pharmacokinetics	O
of	O
the	O
combination	O
at	O
the	O
MTD	O
in	O
patients	O
with	O
HER2-positive	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
Eight	O
patients	O
were	O
included	O
in	O
the	O
dose-escalation	O
study	O
;	O
no	O
dose-limiting	O
toxicities	O
were	O
observed	O
","	O
and	O
an	O
MTD	O
of	O
oral	O
neratinib	B-DRUG
240	O
mg	O
once	O
daily	O
plus	O
intravenous	O
paclitaxel	B-DRUG
80	O
mg	O
m	O
(	O
-2	O
)	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
of	O
each	O
28-day	O
cycle	O
was	O
determined	O
.	O
	
A	O
total	O
of	O
102	O
patients	O
with	O
HER2-positive	O
breast	B-CANCER
cancer	I-CANCER
were	O
enrolled	O
in	O
part	O
2	O
The	O
overall	O
median	O
treatment	O
duration	O
was	O
47.9	O
weeks	O
(	O
range	O
:	O
0.1-147.3	O
weeks	O
)	O
.	O
	
Common	O
treatment-emergent	O
adverse	O
events	O
(	O
all	O
grades	O
/	O
grade	O
_3	O
)	O
included	O
diarrhoea	B-TOXI
(	O
92	O
%	O
/	O
29	O
%	O
;	O
none	O
grade	O
4	O
)	O
","	O
peripheral	B-TOXI
sensory	I-TOXI
neuropathy	I-TOXI
(	O
51	O
%	O
/	O
3	O
%	O
)	O
","	O
neutropenia	B-TOXI
(	O
50	O
%	O
/	O
20	O
%	O
)	O
","	O
alopecia	B-TOXI
(	O
46	O
%	O
/	O
0	O
%	O
)	O
","	O
leukopenia	B-TOXI
(	O
41	O
%	O
/	O
18	O
%	O
)	O
","	O
anaemia	B-TOXI
(	O
37	O
%	O
/	O
8	O
%	O
)	O
","	O
and	O
nausea	B-TOXI
(	O
34	O
%	O
/	O
1	O
%	O
)	O
.	O
	
Three	O
(	O
3	O
%	O
)	O
patients	O
discontinued	O
treatment	O
due	O
to	O
an	O
adverse	O
event	O
(	O
mouth	B-TOXI
ulceration	I-TOXI
","	O
left	B-TOXI
ventricular	I-TOXI
ejection	I-TOXI
fraction	I-TOXI
reduction	I-TOXI
","	O
and	O
acute	B-TOXI
renal	I-TOXI
failure	I-TOXI
)	O
.	O
	
Among	O
the	O
99	O
evaluable	O
patients	O
in	O
part	O
2	O
of	O
the	O
study	O
","	O
the	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
was	O
73	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
62.9-81.2	O
%	O
)	O
","	O
including	O
7	O
(	O
7	O
%	O
)	O
patients	O
who	O
achieved	O
a	O
complete	O
response	O
;	O
an	O
additional	O
9	O
(	O
9	O
%	O
)	O
patients	O
achieved	O
stable	O
disease	O
for	O
at	O
least	O
24	O
weeks	O
.	O
	
ORR	O
was	O
71	O
%	O
among	O
patients	O
with	O
0	O
/	O
1	O
prior	O
chemotherapy	O
regimen	O
for	O
metastatic	O
disease	O
and	O
no	O
prior	O
lapatinib	B-CANCER
","	O
and	O
77	O
%	O
among	O
those	O
with	O
2	O
/	O
3	O
prior	O
chemotherapy	O
regimens	O
for	O
metastatic	O
disease	O
with	O
prior	O
lapatinib	B-CANCER
permitted	O
.	O
	
Kaplan-Meier	O
median	O
progression-free	O
survival	O
was	O
57	O
weeks	O
(	O
95	O
%	O
CI	O
:	O
47.7-81.6	O
weeks	O
)	O
.	O
	
Pharmacokinetic	O
analyses	O
indicated	O
no	O
interaction	O
between	O
neratinib	B-DRUG
and	O
paclitaxel	B-DRUG
.	O
	
The	O
combination	O
of	O
neratinib	B-DRUG
and	O
paclitaxel	B-DRUG
was	O
associated	O
with	O
higher	O
toxicity	O
than	O
that	O
of	O
neratinib	B-DRUG
as	O
a	O
single	O
agent	O
","	O
but	O
was	O
manageable	O
with	O
antidiarrhoeal	O
agents	O
and	O
dose	O
reductions	O
in	O
general	O
.	O
	
The	O
combination	O
therapy	O
also	O
demonstrated	O
a	O
high	O
rate	O
of	O
response	O
in	O
patients	O
with	O
HER2-positive	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
A	O
phase	O
III	O
trial	O
is	O
ongoing	O
to	O
assess	O
the	O
benefit	O
and	O
risk	O
of	O
this	O
combination	O
in	O
the	O
first-line	O
setting	O
.	O
	
Weekly	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
/	O
trastuzumab	B-DRUG
therapy	O
improves	O
pathologic	O
complete	O
remission	O
in	O
aggressive	O
HER2-positive	O
breast	B-CANCER
cancers	I-CANCER
","	O
especially	O
in	O
luminal-B	O
subtype	O
","	O
compared	O
with	O
a	O
once-every-3-weeks	O
schedule	O
.	O
	
	
The	O
efficacy	O
and	O
tolerability	O
of	O
two	O
different	O
schedules	O
of	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
trastuzumab	B-DRUG
(	O
PCarH	B-DRUG
)	O
for	O
HER2-positive	O
","	O
locally	O
aggressive	O
(	O
stage	O
IIB-IIIC	O
)	O
breast	B-CANCER
cancers	I-CANCER
were	O
evaluated	O
in	O
this	O
phase	O
II	O
trial	O
.	O
	
Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
weekly	O
(	O
12	O
doses	O
over	O
16	O
weeks	O
)	O
or	O
once-every-3-weeks	O
(	O
4	O
doses	O
over	O
12	O
weeks	O
)	O
treatment	O
.	O
	
The	O
primary	O
endpoint	O
was	O
pathologic	O
complete	O
remission	O
(	O
pCR	O
)	O
in	O
the	O
breast	O
and	O
axilla	O
.	O
	
To	O
detect	O
an	O
assumed	O
35	O
%	O
pCR	O
absolute	O
difference	O
between	O
the	O
two	O
schedules	O
","	O
a	O
minimum	O
of	O
26	O
assessable	O
patients	O
in	O
each	O
group	O
was	O
required	O
(	O
two-sided	O
伪	O
=	O
0.05	O
","	O
尾	O
=	O
0.2	O
)	O
.	O
	
A	O
total	O
of	O
56	O
patients	O
were	O
enrolled	O
(	O
weekly	O
group	O
","	O
n	O
=	O
29	O
;	O
every-3-weeks	O
group	O
","	O
n	O
=	O
27	O
)	O
.	O
	
In	O
the	O
intent-to-treat	O
analysis	O
","	O
pCR	O
in	O
the	O
breast	O
/	O
axilla	O
were	O
found	O
in	O
31	O
patients	O
(	O
55	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
41	O
%	O
-69	O
%	O
)	O
.	O
	
Compared	O
with	O
the	O
every-3-weeks	O
schedule	O
","	O
the	O
weekly	O
administration	O
achieved	O
higher	O
pCR	O
(	O
41	O
%	O
vs.	O
69	O
%	O
;	O
p	O
=	O
0.03	O
)	O
.	O
	
After	O
adjustment	O
for	O
clinical	O
and	O
pathological	O
factors	O
","	O
the	O
weekly	O
administration	O
was	O
more	O
effective	O
than	O
the	O
every-3-weeks	O
schedule	O
","	O
with	O
hazard	O
ratio	O
of	O
0.3	O
(	O
95	O
%	O
CI	O
:	O
0.1-0.9	O
;	O
p	O
=	O
0.03	O
)	O
.	O
	
Interestingly	O
","	O
weekly	O
administration	O
resulted	O
in	O
high	O
pCR	O
rates	O
in	O
both	O
luminal-B	O
(	O
HER2-positive	O
)	O
and	O
ERBB2+	O
tumors	O
(	O
67	O
%	O
vs.	O
71	O
%	O
;	O
p	O
=	O
0.78	O
)	O
","	O
whereas	O
luminal-B	O
(	O
HER2-positive	O
)	O
tumors	O
benefited	O
less	O
from	O
the	O
every-3-weeks	O
schedule	O
compared	O
with	O
the	O
ERBB2+	O
tumors	O
(	O
21	O
%	O
vs.	O
62	O
%	O
","	O
p	O
=	O
0.03	O
)	O
.	O
	
These	O
results	O
remain	O
after	O
multivariate	O
adjustment	O
","	O
showing	O
weekly	O
administration	O
was	O
more	O
effective	O
in	O
the	O
luminal-B	O
(	O
HER2-positive	O
)	O
subgroup	O
(	O
p	O
=	O
0.02	O
)	O
but	O
not	O
in	O
the	O
ERBB2+	O
subgroup	O
(	O
p	O
=	O
0.5	O
)	O
.	O
	
A	O
more	O
frequent	O
administration	O
might	O
improve	O
the	O
possibility	O
of	O
eradicating	O
invasive	O
cancer	B-CANCER
in	I-CANCER
the	I-CANCER
breast	I-CANCER
and	I-CANCER
axilla	I-CANCER
","	O
especially	O
in	O
the	O
luminal-B	O
(	O
HER2-positive	O
)	O
subtype	O
.	O
	
Further	O
studies	O
to	O
validate	O
our	O
findings	O
are	O
warranted	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
the	O
oral	O
gamma	O
secretase	O
inhibitor	O
R04929097	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
(	O
PHL-078	O
/	O
CTEP	O
8575	O
)	O
.	O
	
	
To	O
establish	O
the	O
recommended	O
phase	O
II	O
dose	O
of	O
the	O
oral	O
纬-secretase	O
inhibitor	O
RO4929097	B-DRUG
(	O
RO	O
)	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
;	O
secondary	O
objectives	O
include	O
the	O
evaluation	O
of	O
safety	O
","	O
tolerability	O
","	O
pharmacokinetics	O
","	O
biomarkers	O
of	O
Notch	O
signaling	O
and	O
preliminary	O
anti-tumor	O
activity	O
.	O
	
Patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
enrolled	O
in	O
cohorts	O
of	O
escalating	O
RO	O
dose	O
levels	O
(	O
DLs	O
)	O
.	O
	
Tested	O
RO	O
DLs	O
were	O
20	O
mg	O
","	O
30	O
mg	O
","	O
45	O
mg	O
and	O
90	O
mg	O
.	O
	
RO	O
was	O
administered	O
orally	O
","	O
once	O
daily	O
on	O
days	O
1月3日	O
","	O
8月10日	O
","	O
15-17	O
","	O
22-24	O
.	O
	
Gemcitabine	B-DRUG
was	O
administered	O
at	O
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
d1	O
","	O
8	O
","	O
and	O
15	O
in	O
28	O
d	O
cycles	O
.	O
	
Dose	O
limiting	O
toxicities	O
(	O
DLTs	O
)	O
were	O
assessed	O
by	O
CTCAE	O
v4	O
.	O
	
Serial	O
plasma	O
was	O
collected	O
for	O
RO	O
(	O
total	O
and	O
unbound	O
)	O
and	O
gemcitabine	B-DRUG
pharmacokinetic	O
analysis	O
.	O
	
Biomarkers	O
of	O
Notch	O
signaling	O
were	O
assessed	O
by	O
immunohistochemistry	O
in	O
archival	O
tissue	O
.	O
	
Antitumor	O
activity	O
was	O
evaluated	O
(	O
RECIST	O
1.1	O
)	O
.	O
	
A	O
total	O
of	O
18	O
patients	O
were	O
enrolled	O
to	O
establish	O
the	O
recommended	O
phase	O
II	O
dose	O
.	O
	
Of	O
these	O
","	O
3	O
patients	O
received	O
20	O
mg	O
RO	O
","	O
7	O
patients	O
received	O
30	O
mg	O
RO	O
","	O
6	O
patients	O
received	O
45	O
mg	O
RO	O
and	O
2	O
patients	O
received	O
90	O
mg	O
RO	O
.	O
	
DLTs	O
were	O
grade	O
3	O
transaminitis	B-TOXI
(	O
30	O
mg	O
RO	O
)	O
","	O
grade	O
3	O
transaminitis	B-TOXI
and	O
maculopapular	B-TOXI
rash	I-TOXI
(	O
45	O
mg	O
RO	O
)	O
","	O
and	O
grade	O
3	O
transaminitis	B-TOXI
and	O
failure	O
to	O
receive	O
75	O
%	O
of	O
planned	O
RO	O
doses	O
secondary	O
to	O
prolonged	O
neutropenia	B-TOXI
(	O
90	O
mg	O
)	O
;	O
all	O
were	O
reversible	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
was	O
exceeded	O
at	O
90	O
mg	O
RO	O
.	O
	
Pharmacokinetic	O
analysis	O
of	O
both	O
total	O
and	O
free	O
RO	O
confirmed	O
the	O
presence	O
of	O
autoinduction	O
at	O
45	O
and	O
90	O
mg	O
.	O
	
Median	O
levels	O
of	O
Notch3	O
staining	O
were	O
higher	O
in	O
individuals	O
who	O
received	O
fewer	O
than	O
4	O
cycles	O
(	O
p	O
=	O
0.029	O
)	O
.	O
	
Circulating	O
angiogenic	O
factor	O
levels	O
did	O
not	O
correlate	O
with	O
time	O
to	O
progression	O
or	O
_	O
grade	O
3	O
adverse	O
events	O
.	O
	
Best	O
response	O
(	O
RECIST	O
1.1	O
)	O
was	O
partial	O
response	O
(	O
nasopharyngeal	B-CANCER
cancer	I-CANCER
)	O
and	O
stable	O
disease	O
&	O
gt	O
;	O
4	O
months	O
was	O
observed	O
in	O
3	O
patients	O
(	O
pancreas	O
","	O
tracheal	O
","	O
and	O
breast	B-CANCER
primary	I-CANCER
cancers	I-CANCER
)	O
.	O
	
RO	O
and	O
gemcitabine	B-DRUG
can	O
be	O
safely	O
combined	O
.	O
	
The	O
recommended	O
phase	O
II	O
dose	O
of	O
RO	O
was	O
30	O
mg	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Although	O
RO	O
exposure	O
was	O
limited	O
by	O
the	O
presence	O
of	O
autoinduction	O
","	O
RO	O
levels	O
achieved	O
exceeded	O
the	O
area	O
under	O
the	O
concentration-time	O
curve	O
for	O
0-24	O
h	O
(	O
AUC	O
(	O
0-24	O
)	O
)	O
predicted	O
for	O
efficacy	O
in	O
preclinical	O
models	O
using	O
daily	O
dosing	O
.	O
	
Evidence	O
of	O
clinical	O
antitumor	O
activity	O
and	O
prolonged	O
stable	O
disease	O
were	O
identified	O
.	O
	
Phase	O
I	O
study	O
of	O
the	O
combination	O
of	O
temsirolimus	B-DRUG
and	O
pazopanib	B-DRUG
in	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Inhibition	O
of	O
either	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
or	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
signaling	O
improves	O
outcomes	O
in	O
patients	O
with	O
several	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
trial	O
of	O
temsirolimus	B-DRUG
with	O
pazopanib	B-DRUG
to	O
investigate	O
the	O
feasibility	O
of	O
simultaneous	O
'vertical	O
inhibition	O
'	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
and	O
mTOR	O
pathways	O
.	O
	
Patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
","	O
no	O
previous	O
pazopanib	B-DRUG
or	O
mTOR	O
inhibitor	O
","	O
good	O
performance	O
status	O
","	O
and	O
acceptable	O
end-organ	O
function	O
were	O
eligible	O
.	O
	
In	O
a	O
typical	O
3+3	O
escalation	O
design	O
starting	O
at	O
temsirolimus	B-DRUG
15	O
mg	O
by	O
an	O
intravenous	O
infusion	O
weekly	O
and	O
pazopanib	B-DRUG
400	O
mg	O
orally	O
daily	O
","	O
we	O
defined	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
as	O
attributable	O
grade	O
3	O
or	O
higher	O
nonhematologic	O
adverse	O
events	O
in	O
the	O
first	O
28-day	O
cycle	O
and	O
the	O
maximum	O
tolerable	O
dose	O
as	O
the	O
maximum	O
dose	O
level	O
at	O
which	O
less	O
than	O
two	O
patients	O
experienced	O
DLT	O
.	O
	
At	O
the	O
initial	O
dose	O
level	O
","	O
two	O
patients	O
had	O
four	O
DLTs	O
(	O
anorexia	B-TOXI
","	O
fatigue	B-TOXI
","	O
hyponatremia	B-TOXI
","	O
and	O
hypophosphatemia	B-TOXI
)	O
.	O
	
After	O
reduction	O
to	O
temsirolimus	B-DRUG
10	O
mg	O
intravenous	O
infusion	O
weekly	O
and	O
pazopanib	B-DRUG
200	O
mg	O
orally	O
daily	O
","	O
one	O
of	O
three	O
patients	O
had	O
DLT	O
(	O
fatigue	B-TOXI
)	O
and	O
the	O
first	O
patient	O
in	O
the	O
subsequent	O
expansion	O
had	O
dose-limiting	O
hypophosphatemia	B-TOXI
.	O
	
Attributable	O
grade	O
3	O
or	O
higher	O
adverse	O
events	O
in	O
more	O
than	O
one	O
patient	O
included	O
leukopenia	B-TOXI
","	O
neutropenia	B-TOXI
","	O
fatigue	B-TOXI
","	O
and	O
hypophosphatemia	B-TOXI
.	O
	
Tumor	O
reduction	O
not	O
fulfilling	O
the	O
RECIST	O
criteria	O
for	O
partial	O
response	O
was	O
the	O
best	O
response	O
in	O
four	O
of	O
seven	O
evaluable	O
patients	O
.	O
	
The	O
combination	O
of	O
temsirolimus	B-DRUG
and	O
pazopanib	B-DRUG
was	O
not	O
feasible	O
at	O
clinically	O
meaningful	O
doses	O
in	O
this	O
population	O
because	O
of	O
constitutional	O
and	O
electrolyte	B-TOXI
disturbances	I-TOXI
.	O
	
Phase	O
Ib	O
study	O
of	O
tivozanib	B-DRUG
(	O
AV-951	O
)	O
in	O
combination	O
with	O
temsirolimus	B-DRUG
in	O
patients	O
with	O
renal	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
	
Tivozanib	B-DRUG
is	O
a	O
potent	O
and	O
selective	O
tyrosine	O
kinase	O
inhibitor	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptors	O
(	O
VEGFR	O
)	O
-1	O
","	O
-2	O
and	O
-3	O
","	O
with	O
a	O
long	O
half-life	O
.	O
	
Tivozanib	B-DRUG
has	O
demonstrated	O
clinical	O
activity	O
and	O
acceptable	O
tolerability	O
in	O
renal	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
RCC	B-CANCER
)	O
.	O
	
This	O
phase	O
Ib	O
study	O
determined	O
the	O
recommended	O
phase	O
II	O
dose	O
(	O
RP2D	O
)	O
and	O
evaluated	O
the	O
safety	O
and	O
clinical	O
activity	O
of	O
tivozanib	B-DRUG
plus	O
temsirolimus	B-DRUG
","	O
a	O
mammalian	O
target	O
of	O
rapamycin	O
inhibitor	O
.	O
	
Patients	O
with	O
advanced	B-CANCER
RCC	I-CANCER
were	O
administered	O
open-label	O
tivozanib	B-CANCER
0.5	O
","	O
1	O
or	O
1.5mg	O
/	O
d	O
orally	O
(	O
3	O
weeks	O
on	O
/	O
1	O
week	O
off	O
)	O
and	O
temsirolimus	B-CANCER
15	O
or	O
25	O
mg	O
/	O
week	O
intravenously	O
in	O
a	O
3+3	O
dose-escalation	O
design	O
and	O
subsequent	O
expansion	O
cohort	O
.	O
	
Of	O
27	O
patients	O
treated	O
","	O
20	O
patients	O
had	O
received	O
_	O
1	O
prior	O
VEGF-targeted	O
therapy	O
.	O
	
No	O
dose-limiting	O
toxicities	O
occurred	O
;	O
the	O
RP2D	O
was	O
determined	O
to	O
be	O
tivozanib	B-DRUG
1.5mg	O
/	O
d	O
plus	O
temsirolimus	B-DRUG
25mg	O
/	O
week	O
.	O
	
Combination	O
of	O
tivozanib	B-DRUG
plus	O
temsirolimus	B-DRUG
demonstrated	O
acceptable	O
tolerability	O
and	O
suggested	O
no	O
synergistic	O
toxicity	O
.	O
	
The	O
most	O
common	O
grade	O
_	O
3	O
adverse	O
events	O
were	O
fatigue	B-TOXI
and	O
thrombocytopenia	B-TOXI
(	O
15	O
%	O
each	O
)	O
.	O
	
One	O
patient	O
each	O
required	O
dose	O
reduction	O
of	O
tivozanib	B-DRUG
or	O
temsirolimus	B-DRUG
due	O
to	O
an	O
adverse	O
event	O
.	O
	
Confirmed	O
partial	O
responses	O
and	O
stable	O
disease	O
were	O
achieved	O
at	O
23	O
%	O
and	O
68	O
%	O
","	O
respectively	O
.	O
	
Pharmacokinetic	O
analyses	O
may	O
suggest	O
lack	O
of	O
an	O
interaction	O
between	O
tivozanib	B-DRUG
and	O
temsirolimus	B-DRUG
.	O
	
In	O
this	O
small	O
phase	O
Ib	O
study	O
","	O
tivozanib	B-DRUG
and	O
temsirolimus	B-DRUG
were	O
safely	O
combined	O
at	O
the	O
fully	O
recommended	O
dose	O
and	O
schedule	O
of	O
both	O
agents	O
.	O
	
The	O
observed	O
clinical	O
activity	O
and	O
manageable	O
toxicity	O
profile	O
of	O
this	O
combination	O
warrant	O
further	O
exploration	O
in	O
patients	O
with	O
RCC	B-CANCER
.	O
	
Biweekly	O
docetaxel	B-DRUG
","	O
fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
","	O
oxaliplatin	B-DRUG
(	O
TEF	B-DRUG
)	O
as	O
first-line	O
treatment	O
for	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
and	O
adenocarcinoma	B-CANCER
of	I-CANCER
the	I-CANCER
gastroesophageal	I-CANCER
junction	I-CANCER
:	O
safety	O
and	O
efficacy	O
in	O
a	O
multicenter	O
cohort	O
.	O
	
	
Docetaxel-cisplatin-5-FU	B-DRUG
chemotherapy	O
is	O
superior	O
to	O
5-FU-cisplatin	B-DRUG
in	O
terms	O
of	O
response	O
rate	O
and	O
survival	O
in	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
(	O
AGC	B-CANCER
)	O
","	O
but	O
is	O
more	O
toxic	O
.	O
	
Oxaliplatin	B-DRUG
is	O
better	O
tolerated	O
than	O
cisplatin	B-DRUG
","	O
which	O
it	O
can	O
effectively	O
replace	O
in	O
this	O
setting	O
.	O
	
We	O
hypothesize	O
that	O
incorporating	O
docetaxel	B-DRUG
into	O
a	O
simplified	O
FOLFOX	B-DRUG
regimen	O
should	O
be	O
a	O
tolerable	O
and	O
effective	O
option	O
in	O
first-line	O
treatment	O
of	O
AGC	B-CANCER
.	O
	
Data	O
were	O
collected	O
at	O
six	O
French	O
centers	O
from	O
patients	O
with	O
metastatic	O
or	O
local	O
AGC	B-CANCER
who	O
received	O
docetaxel	B-DRUG
","	O
fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
","	O
or	O
oxaliplatin	B-DRUG
(	O
TEF	B-DRUG
)	O
as	O
first-line	O
treatment	O
.	O
	
TEF	B-DRUG
was	O
administered	O
as	O
follows	O
:	O
docetaxel	B-DRUG
(	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
oxaliplatin	B-DRUG
(	O
85	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
and	O
leucovorin	B-DRUG
(	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
on	O
day	O
1	O
","	O
and	O
5-FU	B-DRUG
continuous	O
infusion	O
for	O
48	O
h	O
(	O
2400	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
every	O
2	O
weeks	O
.	O
	
Forty-one	O
patients	O
were	O
enrolled	O
.	O
	
Performance	O
status	O
was	O
grade	O
0	O
and	O
1	O
in	O
respectively	O
27	O
and	O
58	O
%	O
of	O
patients	O
;	O
17	O
patients	O
had	O
adenocarcinoma	B-CANCER
of	I-CANCER
the	I-CANCER
gastroesophageal	I-CANCER
junction	I-CANCER
;	O
37	O
patients	O
had	O
metastatic	O
disease	O
","	O
22	O
had	O
a	O
poorly	O
differentiated	O
or	O
diffuse	O
type	O
.	O
	
Objective	O
response	O
rate	O
was	O
66	O
%	O
","	O
with	O
a	O
complete	O
response	O
in	O
two	O
patients	O
(	O
5	O
%	O
)	O
.	O
	
Median	O
progression-free	O
survival	O
and	O
overall	O
survival	O
were	O
respectively	O
6.3	O
and	O
12.1	O
months	O
.	O
	
Tolerability	O
was	O
acceptable	O
with	O
no	O
treatment-related	O
deaths	O
.	O
	
The	O
most	O
frequent	O
grade	O
3月4日	O
toxicities	O
were	O
neutropenia	B-TOXI
(	O
30	O
%	O
)	O
and	O
neuropathy	B-TOXI
(	O
12.5	O
%	O
)	O
.	O
	
Curative	O
intent	O
surgery	O
after	O
response	O
to	O
TEF	B-DRUG
was	O
performed	O
in	O
seven	O
patients	O
(	O
17	O
%	O
)	O
.	O
	
TEF	B-DRUG
is	O
an	O
effective	O
first-line	O
treatment	O
with	O
an	O
acceptable	O
toxicity	O
profile	O
for	O
patients	O
with	O
AGC	B-CANCER
.	O
	
It	O
may	O
allow	O
curative	O
resection	O
in	O
initially	O
unresectable	O
patients	O
.	O
	
TEF	B-DRUG
should	O
now	O
be	O
evaluated	O
in	O
prospective	O
randomized	O
trials	O
.	O
	
A	O
Phase	O
1	O
trial	O
of	O
the	O
poly	O
(	O
ADP-ribose	O
)	O
polymerase	O
inhibitor	O
olaparib	B-DRUG
(	O
AZD2281	O
)	O
in	O
combination	O
with	O
the	O
anti-angiogenic	O
cediranib	B-DRUG
(	O
AZD2171	O
)	O
in	O
recurrent	O
epithelial	O
ovarian	O
or	O
triple-negative	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
	
Poly	O
(	O
ADP-ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
#NAME?	O
and	O
anti-angiogenics	O
have	O
activity	O
in	O
recurrent	O
ovarian	B-CANCER
and	I-CANCER
breast	I-CANCER
cancer	I-CANCER
;	O
however	O
","	O
the	O
effect	O
of	O
combined	O
therapy	O
against	O
PARP	O
and	O
angiogenesis	O
in	O
this	O
population	O
has	O
not	O
been	O
reported	O
.	O
	
We	O
investigated	O
the	O
toxicities	O
and	O
recommended	O
phase	O
2	O
dosing	O
(	O
RP2D	O
)	O
of	O
the	O
combination	O
of	O
cediranib	B-DRUG
","	O
a	O
multitargeted	O
inhibitor	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
(	O
VEGFR	O
)	O
-1	O
/	O
2	O
/	O
3	O
and	O
olaparib	B-DRUG
","	O
a	O
PARP-inhibitor	O
(	O
NCT01116648	O
)	O
.	O
	
Cediranib	B-DRUG
tablets	O
once	O
daily	O
and	O
olaparib	B-DRUG
capsules	I-DRUG
twice	O
daily	O
were	O
administered	O
orally	O
in	O
a	O
standard	O
3+3	O
dose	O
escalation	O
design	O
.	O
	
Patients	O
with	O
recurrent	O
ovarian	O
or	O
metastatic	O
triple-negative	O
breast	B-CANCER
cancer	I-CANCER
were	O
eligible	O
.	O
	
Patients	O
had	O
measurable	O
disease	O
by	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	B-CANCER
Tumors	I-CANCER
(	O
RECIST	O
)	O
1.1	O
or	O
met	O
Gynecologic	B-CANCER
Cancer	I-CANCER
InterGroup	O
(	O
GCIG	O
)	O
CA125	O
criteria	O
.	O
	
No	O
prior	O
PARP-inhibitors	O
or	O
anti-angiogenics	O
in	O
the	O
recurrent	O
setting	O
were	O
allowed	O
.	O
	
28	O
patients	O
(	O
20	O
ovarian	O
","	O
8	O
breast	O
)	O
enrolled	O
to	O
4	O
dose	O
levels	O
.	O
	
2	O
dose	O
limiting	O
toxicities	O
(	O
DLTs	O
)	O
(	O
1	O
grade	O
4	O
neutropenia	B-TOXI
_	O
4	O
days	O
;	O
1	O
grade	O
4	O
thrombocytopenia	B-TOXI
)	O
occurred	O
at	O
the	O
highest	O
dose	O
level	O
(	O
cediranib	B-DRUG
30	O
mg	O
daily	O
;	O
olaparib	B-DRUG
400	O
mg	O
twice	O
daily	O
[	O
BID	O
]	O
)	O
.	O
	
The	O
RP2D	O
was	O
cediranib	B-DRUG
30	O
mg	O
daily	O
and	O
olaparib	B-DRUG
200	O
mg	O
BID	O
.	O
	
Grade	O
3	O
or	O
higher	O
toxicities	O
occurred	O
in	O
75	O
%	O
of	O
patients	O
","	O
and	O
included	O
grade	O
3	O
hypertension	B-TOXI
(	O
25	O
%	O
)	O
and	O
grade	O
3	O
fatigue	B-TOXI
(	O
18	O
%	O
)	O
.	O
	
One	O
grade	O
3	O
bowel	B-TOXI
obstruction	I-TOXI
occurred	O
.	O
	
The	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
in	O
the	O
18	O
RECIST-evaluable	O
ovarian	B-CANCER
cancer	I-CANCER
patients	O
was	O
44	O
%	O
","	O
with	O
a	O
clinical	O
benefit	O
rate	O
(	O
ORR	O
plus	O
stable	O
disease	O
(	O
SD	O
)	O
&	O
gt	O
;	O
24	O
weeks	O
)	O
of	O
61	O
%	O
.	O
	
None	O
of	O
the	O
seven	O
evaluable	O
breast	B-CANCER
cancer	I-CANCER
patients	O
achieved	O
clinical	O
response	O
;	O
two	O
patients	O
had	O
stable	O
disease	O
for	O
&	O
gt	O
;	O
24	O
weeks	O
.	O
	
The	O
combination	O
of	O
cediranib	B-DRUG
and	O
olaparib	B-DRUG
has	O
haematologic	O
DLTs	O
and	O
anticipated	O
class	O
toxicities	O
","	O
with	O
promising	O
evidence	O
of	O
activity	O
in	O
ovarian	B-CANCER
cancer	I-CANCER
patients	O
.	O
	
Randomized	O
phase	O
I	O
pharmacokinetic	O
study	O
of	O
ipilimumab	B-DRUG
with	O
or	O
without	O
one	O
of	O
two	O
different	O
chemotherapy	O
regimens	O
in	O
patients	O
with	O
untreated	O
advanced	B-CANCER
melanoma	I-CANCER
.	O
	
	
We	O
describe	O
a	O
randomized	O
three-arm	O
phase	O
I	O
study	O
of	O
ipilimumab	B-DRUG
administered	O
alone	O
(	O
I	O
group	O
)	O
or	O
in	O
combination	O
with	O
dacarbazine	B-DRUG
(	O
D	O
group	O
)	O
or	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
(	O
CP	O
group	O
)	O
in	O
patients	O
with	O
previously	O
untreated	O
advanced	B-CANCER
melanoma	I-CANCER
.	O
	
The	O
primary	O
objective	O
was	O
to	O
estimate	O
the	O
effect	O
of	O
ipilimumab	B-DRUG
on	O
the	O
pharmacokinetics	O
(	O
PK	O
)	O
of	O
dacarbazine	B-DRUG
and	O
paclitaxel	B-DRUG
and	O
","	O
conversely	O
","	O
to	O
estimate	O
the	O
effects	O
of	O
dacarbazine	B-DRUG
and	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
on	O
the	O
PK	O
of	O
ipilimumab	B-DRUG
.	O
	
Secondary	O
objectives	O
included	O
evaluation	O
of	O
the	O
safety	O
and	O
anti-tumor	O
activity	O
of	O
ipilimumab	B-DRUG
when	O
administered	O
alone	O
or	O
with	O
either	O
dacarbazine	B-DRUG
or	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
","	O
and	O
assessment	O
of	O
pharmacodynamic	O
(	O
PD	O
)	O
effects	O
of	O
ipilimumab	B-DRUG
on	O
the	O
immune	O
system	O
when	O
administered	O
alone	O
or	O
with	O
either	O
of	O
the	O
two	O
chemotherapies	O
.	O
	
Ipilimumab	B-DRUG
was	O
administered	O
at	O
a	O
dose	O
of	O
10	O
mg	O
/	O
kg	O
intravenously	O
(	O
IV	O
)	O
every	O
3	O
weeks	O
for	O
up	O
to	O
4	O
doses	O
.	O
	
Patients	O
in	O
the	O
D	O
group	O
received	O
dacarbazine	B-DRUG
850	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
every	O
3	O
weeks	O
.	O
	
Patients	O
in	O
the	O
CP	O
group	O
received	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
and	O
carboplatin	B-DRUG
[	O
AUC=6	O
]	O
IV	O
every	O
3	O
weeks	O
.	O
	
Starting	O
at	O
week	O
24	O
","	O
patients	O
without	O
dose-limiting	O
toxicities	O
were	O
eligible	O
to	O
receive	O
maintenance	O
ipilimumab	B-DRUG
at	O
10	O
mg	O
/	O
kg	O
every	O
12	O
weeks	O
until	O
disease	O
progressed	O
or	O
toxicity	O
required	O
discontinuation	O
.	O
	
Of	O
59	O
randomized	O
patients	O
","	O
18	O
(	O
30.5	O
%	O
)	O
discontinued	O
treatment	O
due	O
to	O
adverse	O
events	O
.	O
	
Response	O
rates	O
by	O
modified	O
WHO	O
criteria	O
were	O
29.4	O
%	O
(	O
I	O
group	O
)	O
","	O
27.8	O
%	O
(	O
D	O
group	O
)	O
","	O
and	O
11.1	O
%	O
(	O
CP	O
group	O
)	O
.	O
	
No	O
major	O
PK	O
or	O
PD	O
interactions	O
were	O
observed	O
when	O
ipilimumab	B-DRUG
was	O
administered	O
with	O
dacarbazine	B-DRUG
or	O
with	O
the	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
combination	O
.	O
	
This	O
study	O
demonstrated	O
that	O
ipilimumab	B-DRUG
can	O
be	O
combined	O
safely	O
with	O
two	O
chemotherapy	O
regimens	O
commonly	O
used	O
in	O
advanced	B-CANCER
melanoma	I-CANCER
.	O
	
Combined	O
effects	O
of	O
goserelin	B-DRUG
and	O
tamoxifen	B-DRUG
on	O
estradiol	O
level	O
","	O
breast	O
density	O
","	O
and	O
endometrial	O
thickness	O
in	O
premenopausal	O
and	O
perimenopausal	O
women	O
with	O
early-stage	O
hormone	O
receptor-positive	O
breast	B-CANCER
cancer	I-CANCER
:	O
a	O
randomised	O
controlled	O
clinical	O
trial	O
.	O
	
	
This	O
study	O
is	O
to	O
investigate	O
the	O
effects	O
of	O
geserelin+tamoxifen	B-DRUG
(	O
TAM	O
)	O
on	O
estradiol	O
level	O
","	O
breast	O
density	O
(	O
BD	O
)	O
","	O
endometrial	O
thickness	O
(	O
ET	O
)	O
","	O
and	O
blood	O
lipids	O
in	O
premenopausal	O
and	O
perimenopausal	O
women	O
with	O
hormone	O
receptor-positive	O
early-stage	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
This	O
study	O
recruited	O
110	O
premenopausal	O
and	O
perimenopausal	O
patients	O
with	O
hormone	O
receptor-positive	O
early-stage	O
breast	B-CANCER
cancer	I-CANCER
between	O
22	O
June	O
2008	O
and	O
31	O
December	O
2009	O
and	O
randomly	O
assigned	O
them	O
to	O
receive	O
either	O
goserelin	B-DRUG
plus	O
TAM	B-DRUG
or	O
TAM	B-DRUG
alone	O
for	O
1.5	O
years	O
.	O
	
Blood	O
levels	O
of	O
sex	O
hormones	O
and	O
lipids	O
and	O
ET	O
were	O
determined	O
at	O
0	O
","	O
3	O
","	O
6	O
","	O
12	O
","	O
and	O
18	O
months	O
.	O
	
Contralateral	O
BD	O
was	O
also	O
measured	O
at	O
0	O
","	O
12	O
","	O
and	O
18	O
months	O
.	O
	
Five	O
participants	O
dropped	O
out	O
of	O
the	O
goserelin	B-DRUG
plus	O
TAM	B-DRUG
group	O
","	O
and	O
two	O
participants	O
dropped	O
out	O
of	O
the	O
TAM-alone	B-DRUG
group	O
before	O
initiation	O
of	O
endocrine	B-DRUG
therapy	O
.	O
	
The	O
rest	O
of	O
patients	O
received	O
scheduled	O
treatment	O
and	O
3	O
years	O
of	O
median	O
follow-up	O
.	O
	
No	O
serious	O
adverse	O
effects	O
were	O
observed	O
","	O
and	O
only	O
two	O
local	O
recurrences	O
have	O
been	O
observed	O
in	O
these	O
patients	O
.	O
	
Estradiol	O
level	O
and	O
BD	O
were	O
lower	O
in	O
the	O
goserelin	B-DRUG
plus	O
TAM	B-DRUG
group	O
than	O
in	O
the	O
TAM-alone	B-DRUG
group	O
(	O
P	O
&	O
lt	O
;	O
0.05	O
)	O
.	O
	
The	O
endometrium	O
in	O
the	O
goserelin	B-DRUG
plus	O
TAM	B-DRUG
group	O
was	O
significantly	O
thinner	O
than	O
that	O
in	O
the	O
TAM-alone	B-DRUG
group	O
(	O
P	O
&	O
lt	O
;	O
0.05	O
)	O
","	O
and	O
women	O
in	O
the	O
TAM-alone	B-DRUG
group	O
exhibited	O
endometrial	O
thickening	O
over	O
the	O
course	O
of	O
the	O
study	O
.	O
	
Furthermore	O
","	O
no	O
significant	O
differences	O
in	O
blood	O
lipid	O
levels	O
were	O
reported	O
between	O
the	O
two	O
groups	O
.	O
	
The	O
data	O
from	O
the	O
current	O
study	O
demonstrated	O
that	O
the	O
addition	O
of	O
goserelin	B-DRUG
to	O
TAM	B-DRUG
results	O
in	O
downregulation	O
of	O
estradiol	O
level	O
","	O
followed	O
by	O
significant	O
reduction	O
in	O
BD	O
and	O
ET	O
in	O
premenopausal	O
and	O
perimenopausal	O
women	O
with	O
hormone	O
receptor-positive	O
breast	B-CANCER
cancer	I-CANCER
","	O
which	O
may	O
eventually	O
lead	O
to	O
better	O
outcome	O
in	O
these	O
patients	O
.	O
	
Phase	O
1	O
study	O
of	O
lenvatinib	B-DRUG
combined	O
with	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
This	O
dose-finding	O
study	O
evaluated	O
lenvatinib	B-DRUG
","	O
an	O
oral	O
multitargeted	O
receptor	O
tyrosine	O
kinase	O
inhibitor	O
","	O
in	O
combination	O
with	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
in	O
chemotherapy-na茂ve	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
patients	O
.	O
	
Patients	O
received	O
lenvatinib	B-DRUG
twice	O
daily	O
(	O
BID	O
)	O
with	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
6	O
mg	O
ml	O
(	O
-1	O
)	O
min	O
(	O
-1	O
)	O
","	O
day	O
1	O
)	O
/	O
paclitaxel	B-DRUG
(	O
200	O
mg	O
m	O
(	O
-2	O
)	O
","	O
day	O
1	O
)	O
every	O
3	O
weeks	O
.	O
	
The	O
initial	O
dose	O
of	O
lenvatinib	B-DRUG
was	O
6	O
mg	O
BID	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
lenvatinib	B-DRUG
.	O
	
At	O
the	O
MTD	O
","	O
the	O
cohort	O
was	O
expanded	O
by	O
16	O
patients	O
.	O
	
Safety	O
","	O
pharmacokinetics	O
","	O
pharmacodynamics	O
","	O
and	O
antitumor	O
effects	O
were	O
evaluated	O
.	O
	
Twenty-eight	O
patients	O
were	O
treated	O
.	O
	
At	O
6	O
mg	O
BID	O
","	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
included	O
febrile	B-TOXI
neutropenia	I-TOXI
/	O
gingival	B-TOXI
infection	I-TOXI
(	O
n=2	O
)	O
.	O
	
No	O
DLTs	O
occurred	O
with	O
4	O
mg	O
BID	O
","	O
the	O
recommended	O
MTD	O
for	O
the	O
expansion	O
.	O
	
Common	O
grade	O
3	O
/	O
4	O
toxicities	O
included	O
neutropenia	B-TOXI
","	O
leukopenia	B-TOXI
","	O
hypertension	B-TOXI
","	O
and	O
thrombocytopenia	B-TOXI
.	O
	
The	O
combination	O
had	O
no	O
significant	O
impact	O
on	O
individual	O
drug	O
pharmacokinetics	O
.	O
	
Response	O
rate	O
and	O
median	O
progression-free	O
survival	O
were	O
68	O
%	O
and	O
9	O
months	O
","	O
respectively	O
","	O
with	O
4	O
mg	O
BID	O
.	O
	
In	O
the	O
plasma	O
biomarker	O
analysis	O
","	O
stromal	O
cell-derived	O
factor	O
1伪	O
","	O
stem	O
cell	O
factor	O
","	O
and	O
granulocyte	O
colony-stimulating	O
factor	O
correlated	O
with	O
antitumor	O
activity	O
.	O
	
The	O
MTD	O
for	O
lenvatinib	B-DRUG
with	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
is	O
4	O
mg	O
BID	O
in	O
advanced	B-CANCER
NSCLC	I-CANCER
patients	O
.	O
	
This	O
regimen	O
demonstrated	O
manageable	O
tolerability	O
and	O
encouraging	O
antitumor	O
activity	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
AT-101	O
with	O
cisplatin	B-DRUG
and	O
etoposide	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
with	O
an	O
expanded	O
cohort	O
in	O
extensive-stage	O
small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
A	O
phase	O
I	O
","	O
dose-escalation	O
study	O
of	O
AT-101	O
with	O
cisplatin	B-DRUG
and	O
etoposide	B-DRUG
was	O
conducted	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
/	O
recommended	O
phase	O
2	O
dose	O
(	O
RP2D	O
)	O
","	O
safety	O
and	O
pharmacokinetics	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
","	O
with	O
an	O
expanded	O
cohort	O
in	O
patients	O
with	O
extensive-stage	B-CANCER
small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
ES-SCLC	B-CANCER
)	O
to	O
assess	O
preliminary	O
activity	O
.	O
	
In	O
the	O
dose	O
escalation	O
portion	O
","	O
increasing	O
doses	O
of	O
AT-101	O
were	O
administered	O
orally	O
BID	O
on	O
days	O
1月3日	O
along	O
with	O
cisplatin	B-DRUG
on	O
day	O
1	O
and	O
etoposide	B-DRUG
on	O
days	O
1月3日	O
of	O
a	O
21	O
day	O
cycle	O
.	O
	
At	O
the	O
RP2D	O
","	O
an	O
additional	O
7	O
patients	O
with	O
untreated	O
ES-SCLC	B-CANCER
were	O
enrolled	O
.	O
	
Twenty	O
patients	O
were	O
enrolled	O
in	O
the	O
dose-escalation	O
cohort	O
","	O
and	O
7	O
patients	O
with	O
ES-SCLC	B-CANCER
were	O
enrolled	O
in	O
the	O
expanded	O
cohort	O
.	O
	
The	O
MTD	O
/	O
RP2D	O
was	O
established	O
at	O
AT-101	O
40	O
mg	O
BID	O
days	O
1月3日	O
with	O
cisplatin	B-DRUG
60	O
mg	O
/	O
m2	O
and	O
etoposide	B-DRUG
120	O
mg	O
/	O
m2	O
on	O
day	O
1	O
of	O
a	O
21	O
day	O
cycle	O
with	O
pegfilgrastim	B-DRUG
support	O
.	O
	
Two	O
DLTs	O
of	O
neutropenic	B-TOXI
fever	I-TOXI
were	O
seen	O
at	O
dose	O
level	O
1	O
After	O
the	O
addition	O
of	O
pegfilgrastim	B-DRUG
","	O
no	O
additional	O
DLTs	O
were	O
observed	O
.	O
	
Grade	O
3	O
/	O
4	O
treatment-related	O
toxicities	O
included	O
:	O
diarrhea	B-TOXI
","	O
increased	B-TOXI
AST	I-TOXI
","	O
neutropenia	B-TOXI
","	O
hypophosphatemia	B-TOXI
","	O
hyponatremia	B-TOXI
","	O
myocardial	B-TOXI
infarction	I-TOXI
and	O
pulmonary	B-TOXI
embolism	I-TOXI
.	O
	
No	O
apparent	O
PK	O
interactions	O
were	O
observed	O
between	O
the	O
agents	O
.	O
	
Preliminary	O
activity	O
was	O
observed	O
with	O
PRs	O
in	O
patients	O
with	O
ES-SCLC	B-CANCER
","	O
high-grade	B-CANCER
neuroendocrine	I-CANCER
tumor	I-CANCER
","	O
esophageal	B-CANCER
cancer	I-CANCER
and	O
NSCLC	B-CANCER
.	O
	
AT-101	O
with	O
cisplatin	B-DRUG
and	O
etoposide	B-DRUG
is	O
well	O
tolerated	O
with	O
growth	O
factor	O
support	O
.	O
	
Anti-tumor	O
activity	O
was	O
observed	O
in	O
a	O
variety	O
of	O
cancers	O
including	O
ES-SCLC	B-CANCER
","	O
supporting	O
further	O
investigation	O
with	O
BH-3	O
mimetics	O
in	O
combination	O
with	O
standard	O
chemotherapy	O
for	O
ES-SCLC	B-CANCER
.	O
	
Phase	O
I	O
","	O
dose-escalation	O
study	O
of	O
AZD7762	B-DRUG
alone	O
and	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
Japanese	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
	
AZD7762	B-DRUG
","	O
a	O
potent	O
Chk1	O
/	O
Chk2	O
inhibitor	O
","	O
has	O
shown	O
chemosensitizing	O
activity	O
with	O
gemcitabine	B-DRUG
in	O
xenograft	O
models	O
.	O
	
This	O
open-label	O
","	O
Phase	O
I	O
","	O
dose-escalation	O
study	O
evaluated	O
the	O
safety	O
","	O
pharmacokinetics	O
(	O
PK	O
)	O
and	O
preliminary	O
efficacy	O
(	O
RECIST	O
)	O
of	O
AZD7762	B-DRUG
alone	O
and	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
Japanese	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
(	O
NCT00937664	O
)	O
.	O
	
Patients	O
received	O
intravenous	O
AZD7762	B-DRUG
alone	O
on	O
days	O
1	O
and	O
8	O
of	O
a	O
14-day	O
cycle	O
(	O
cycle	O
0	O
)	O
","	O
followed	O
by	O
AZD7762	B-DRUG
plus	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
and	O
8	O
of	O
22-day	O
cycles	O
","	O
in	O
ascending	O
AZD7762	B-DRUG
dose	O
cohorts	O
.	O
	
Twenty	O
patients	O
received	O
AZD7762	B-DRUG
at	O
doses	O
of	O
6	O
mg	O
(	O
n	O
=	O
3	O
)	O
","	O
9	O
mg	O
(	O
n	O
=	O
3	O
)	O
","	O
21	O
mg	O
(	O
n	O
=	O
6	O
)	O
and	O
30	O
mg	O
(	O
n	O
=	O
8	O
)	O
.	O
	
Dose-limiting	O
toxicities	O
occurred	O
in	O
2	O
/	O
6	O
evaluable	O
patients	O
in	O
the	O
30-mg	O
cohort	O
:	O
one	O
","	O
CTCAE	O
grade	O
3	O
elevated	B-TOXI
troponin	I-TOXI
T	I-TOXI
(	O
cycle	O
0	O
:	O
AZD7762	O
monotherapy	O
)	O
;	O
one	O
","	O
neutropenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
and	O
elevated	B-TOXI
aspartate	I-TOXI
aminotransferase	I-TOXI
and	O
alanine	B-TOXI
aminotransferase	I-TOXI
(	O
cycle	O
1	O
:	O
combination	O
therapy	O
)	O
.	O
	
The	O
30	O
mg	O
dose	O
was	O
therefore	O
regarded	O
as	O
non-tolerable	O
.	O
	
The	O
most	O
common	O
adverse	O
events	O
(	O
AEs	O
)	O
in	O
cycle	O
0	O
(	O
AZD7762	B-DRUG
monotherapy	O
)	O
were	O
bradycardia	B-TOXI
(	O
50	O
%	O
)	O
","	O
hypertension	B-TOXI
(	O
25	O
%	O
)	O
and	O
fatigue	B-TOXI
(	O
15	O
%	O
)	O
.	O
	
Overall	O
","	O
the	O
most	O
common	O
AEs	O
were	O
bradycardia	B-TOXI
(	O
55	O
%	O
)	O
","	O
neutropenia	B-TOXI
(	O
45	O
%	O
)	O
and	O
hypertension	B-TOXI
","	O
fatigue	B-TOXI
and	O
rash	B-TOXI
(	O
30	O
%	O
each	O
)	O
.	O
	
Grade	O
_3	O
AEs	O
were	O
reported	O
in	O
11	O
patients	O
","	O
the	O
most	O
common	O
being	O
neutropenia	B-TOXI
(	O
45	O
%	O
)	O
and	O
leukopenia	B-TOXI
(	O
25	O
%	O
)	O
.	O
	
AZD7762	B-DRUG
exposure	O
increased	O
approximately	O
linearly	O
.	O
	
Gemcitabine	B-DRUG
did	O
not	O
appear	O
to	O
affect	O
AZD7762	B-DRUG
PK	O
.	O
	
There	O
were	O
no	O
objective	O
responses	O
;	O
five	O
patients	O
(	O
all	O
lung	O
cancer	O
)	O
had	O
stable	O
disease	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
of	O
AZD7762	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
","	O
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
was	O
determined	O
as	O
21	O
mg	O
in	O
Japanese	O
patients	O
.	O
	
Randomized	O
","	O
phase	O
II	O
","	O
placebo-controlled	B-DRUG
","	O
double-blind	O
study	O
with	O
and	O
without	O
enzastaurin	B-DRUG
in	O
combination	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
as	O
first-line	O
treatment	O
followed	O
by	O
maintenance	O
treatment	O
in	O
advanced	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
	
Enzastaurin	B-DRUG
is	O
an	O
oral	O
serine	O
/	O
threonine	O
kinase	O
inhibitor	O
antitumor	O
agent	O
.	O
	
Our	O
phase	O
II	O
trial	O
tested	O
the	O
efficacy	O
and	O
safety	O
of	O
enzastaurin	B-DRUG
added	O
to	O
a	O
standard	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
chemotherapy	O
regimen	O
in	O
patients	O
with	O
newly	O
diagnosed	O
advanced	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
This	O
was	O
a	O
randomized	O
","	O
placebo-controlled	B-DRUG
study	O
in	O
patients	O
with	O
International	O
Federation	O
of	O
Gynecology	O
and	O
Obstetrics	O
stage	O
IIB	O
to	O
IV	O
ovarian	O
","	O
fallopian	O
tube	O
","	O
or	O
peritoneal	B-CANCER
epithelial	I-CANCER
carcinoma	I-CANCER
.	O
	
Patients	O
were	O
randomly	O
assigned	O
to	O
six	O
cycles	O
of	O
chemotherapy	O
(	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
卤	O
enzastaurin	B-DRUG
[	O
PCE	B-DRUG
/	O
PC	B-DRUG
]	O
)	O
followed	O
by	O
maintenance	O
therapy	O
(	O
enzastaurin	B-DRUG
/	O
placebo	B-DRUG
)	O
.	O
	
Primary	O
end	O
point	O
was	O
progression-free	O
survival	O
(	O
PFS	O
)	O
.	O
	
Secondary	O
measures	O
included	O
response	O
rate	O
","	O
safety	O
assessment	O
","	O
and	O
translational	O
research	O
.	O
	
A	O
total	O
of	O
142	O
patients	O
were	O
randomly	O
assigned	O
to	O
PCE	B-DRUG
(	O
n	O
=	O
69	O
)	O
or	O
PC	B-DRUG
(	O
n	O
=	O
73	O
)	O
.	O
	
Patients	O
in	O
the	O
PCE	B-DRUG
group	O
had	O
a	O
3.7-month	O
longer	O
median	O
PFS	O
compared	O
with	O
patients	O
in	O
the	O
PC	B-DRUG
group	O
;	O
this	O
was	O
not	O
statistically	O
significant	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
","	O
0.8	O
;	O
95	O
%	O
CI	O
","	O
0.5	O
to	O
1.29	O
;	O
P	O
=	O
0.37	O
)	O
.	O
	
Safety	O
profiles	O
of	O
the	O
treatment	O
arms	O
were	O
comparable	O
.	O
	
Frequency	O
of	O
discontinuation	O
because	O
of	O
adverse	O
events	O
was	O
similar	O
(	O
PCE	B-DRUG
","	O
11.9	O
%	O
;	O
PC	B-DRUG
","	O
9.7	O
%	O
)	O
.	O
	
Multivariate	O
analyses	O
confirmed	O
the	O
importance	O
of	O
optimal	O
debulking	O
with	O
regard	O
to	O
PFS	O
(	O
debulking	O
optimal	O
v	O
suboptimal	O
:	O
HR	O
","	O
0.51	O
;	O
95	O
%	O
CI	O
","	O
0.3	O
to	O
0.85	O
;	O
P	O
=	O
0.009	O
)	O
.	O
	
HR	O
for	O
covariate	O
stage	O
(	O
stage	O
IIB	O
to	O
IIIB	O
v	O
IIIC	O
to	O
IV	O
)	O
was	O
not	O
statistically	O
significant	O
(	O
0.75	O
;	O
95	O
%	O
CI	O
","	O
0.38	O
to	O
1.47	O
;	O
P	O
=	O
0.4	O
)	O
.	O
	
Translational	O
research	O
of	O
immunohistochemistry	O
protein	O
assays	O
did	O
not	O
identify	O
any	O
markers	O
significantly	O
associated	O
with	O
treatment	O
difference	O
regarding	O
PFS	O
.	O
	
The	O
PCE	B-DRUG
combination	O
increased	O
PFS	O
","	O
but	O
it	O
was	O
not	O
significantly	O
superior	O
to	O
PC	B-DRUG
in	O
this	O
phase	O
II	O
study	O
.	O
	
Toxicity	O
Analysis	O
in	O
the	O
ADEBAR	O
Trial	O
:	O
Sequential	O
Anthracycline-Taxane	B-DRUG
Therapy	O
Compared	O
with	O
FEC120	O
for	O
the	O
Adjuvant	O
Treatment	O
of	O
High-Risk	O
Breast	B-CANCER
Cancer	I-CANCER
.	O
	
	
Data	O
from	O
meta-analyses	O
have	O
shown	O
taxane-containing	B-DRUG
therapies	O
to	O
be	O
superior	O
to	O
anthracycline-based	B-DRUG
treatments	O
for	O
high-risk	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
The	O
ADEBAR	O
trial	O
was	O
a	O
multicenter	O
phase	O
III	O
trial	O
in	O
which	O
patients	O
with	O
lymph	O
node-positive	O
breast	B-CANCER
cancer	I-CANCER
were	O
prospectively	O
randomized	O
for	O
either	O
sequential	O
anthracycline-taxane	B-DRUG
or	O
FEC120	B-DRUG
therapy	O
.	O
	
Patients	O
received	O
4_	O
epirubicin	B-DRUG
(	O
90	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
cyclophosphamide	B-DRUG
(	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
every	O
3	O
weeks	O
(	O
q3w	O
)	O
","	O
followed	O
by	O
4_	O
docetaxel	B-DRUG
(	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
q3w	O
(	O
EC-Doc	O
arm	O
)	O
","	O
or	O
6_	O
epirubicin	B-DRUG
(	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
5-fluorouracil	B-DRUG
(	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
on	O
days	O
1	O
and	O
8	O
and	O
cyclophosphamide	B-DRUG
(	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
on	O
days	O
1月14日	O
","	O
q4w	O
(	O
FEC	O
arm	O
)	O
.	O
	
We	O
compared	O
both	O
arms	O
with	O
respect	O
to	O
toxicity	O
and	O
feasibility	O
.	O
	
Hematological	B-TOXI
toxicity	I-TOXI
was	O
found	O
significantly	O
more	O
often	O
in	O
the	O
FEC	O
arm	O
.	O
	
Febrile	B-TOXI
neutropenia	I-TOXI
was	O
seen	O
in	O
11.3	O
%	O
of	O
patients	O
in	O
the	O
FEC	O
arm	O
and	O
in	O
8.4	O
%	O
of	O
patients	O
in	O
the	O
EC-Doc	O
arm	O
(	O
p	O
=	O
0.027	O
)	O
.	O
	
Non-hematological	B-TOXI
side	I-TOXI
effects	I-TOXI
of	O
grade	O
3	O
/	O
4	O
were	O
rarely	O
seen	O
in	O
either	O
arm	O
.	O
	
Therapy	O
was	O
terminated	O
due	O
to	O
toxicity	O
in	O
3.7	O
%	O
of	O
the	O
patients	O
in	O
the	O
EC-Doc	O
arm	O
and	O
in	O
8	O
%	O
of	O
the	O
patients	O
in	O
the	O
FEC	O
arm	O
(	O
p	O
=	O
0.0009	O
)	O
.	O
	
The	O
sequential	O
anthracycline-taxane	B-DRUG
regimen	O
is	O
a	O
well-tolerated	O
and	O
feasible	O
alternative	O
to	O
FEC120	B-DRUG
therapy	O
.	O
	
Phase	O
1	O
pharmacokinetic	O
study	O
of	O
MK-0646	B-DRUG
(	O
dalotuzumab	B-DRUG
)	O
","	O
an	O
anti-insulin-like	O
growth	O
factor-1	O
receptor	O
monoclonal	O
antibody	O
","	O
in	O
combination	O
with	O
cetuximab	B-DRUG
and	O
irinotecan	B-DRUG
in	O
Japanese	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
safety	O
","	O
tolerability	O
","	O
and	O
pharmacokinetic	O
(	O
PK	O
)	O
interactions	O
of	O
MK-0646	B-DRUG
in	O
combination	O
with	O
cetuximab	B-DRUG
and	O
irinotecan	B-DRUG
were	O
investigated	O
in	O
Japanese	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Twenty	O
patients	O
were	O
treated	O
in	O
the	O
following	O
study	O
arms	O
in	O
combination	O
with	O
cetuximab	B-DRUG
and	O
irinotecan	B-DRUG
:	O
A	O
[	O
MK-0646	B-DRUG
(	O
10	O
mg	O
/	O
kg	O
)	O
weekly	O
starting	O
on	O
Day	O
22	O
]	O
","	O
B	O
[	O
MK-0646	B-DRUG
(	O
15	O
mg	O
/	O
kg	O
)	O
on	O
Day	O
8	O
","	O
followed	O
by	O
7.5	O
mg	O
/	O
kg	O
every	O
2	O
weeks	O
]	O
","	O
or	O
C	O
[	O
MK-0646	B-DRUG
(	O
10	O
mg	O
/	O
kg	O
)	O
on	O
Day	O
1	O
and	O
weekly	O
starting	O
on	O
Day	O
22	O
]	O
.	O
	
Dose	O
limiting	O
toxicities	O
(	O
DLTs	O
)	O
were	O
evaluated	O
during	O
a	O
prespecified	O
4-week	O
period	O
in	O
arms	O
A	O
and	O
B.	O
Full	O
PK	O
sampling	O
was	O
performed	O
to	O
evaluate	O
the	O
PK	O
interactions	O
.	O
	
One	O
of	O
the	O
6	O
evaluable	O
patients	O
in	O
arm	O
A	O
developed	O
a	O
DLT	O
(	O
grade	O
3	O
hyperglycemia	B-TOXI
)	O
;	O
no	O
DLTs	O
occurred	O
in	O
the	O
6	O
patients	O
in	O
arm	O
B.	O
Common	O
treatment-related	O
adverse	O
events	O
included	O
leukopenia	B-TOXI
","	O
neutropenia	B-TOXI
","	O
dermatitis	B-TOXI
acneiform	I-TOXI
","	O
paronychia	B-TOXI
","	O
nausea	B-TOXI
","	O
stomatitis	B-TOXI
","	O
diarrhea	B-TOXI
","	O
and	O
decreased	B-TOXI
appetite	I-TOXI
.	O
	
The	O
co-administration	O
of	O
cetuximab	B-DRUG
and	O
irinotecan	B-DRUG
with	O
MK-0646	B-DRUG
increased	O
the	O
MK-0646	B-DRUG
AUC0-168h	O
by	O
25	O
%	O
","	O
with	O
MK-0646	B-DRUG
accumulation	O
from	O
the	O
previous	O
dose	O
contributing	O
to	O
the	O
observed	O
increase	O
.	O
	
The	O
co-administration	O
of	O
MK-0646	B-DRUG
with	O
cetuximab	B-DRUG
and	O
irinotecan	B-DRUG
did	O
not	O
affect	O
the	O
PK	O
of	O
cetuximab	B-DRUG
and	O
irinotecan	B-DRUG
","	O
but	O
reduced	O
the	O
C	O
max	O
(	O
from	O
16.8	O
to	O
13	O
ng	O
/	O
mL	O
)	O
and	O
the	O
AUC0-24h	O
(	O
by	O
13	O
%	O
)	O
of	O
SN-38	B-DRUG
","	O
the	O
active	O
metabolite	O
of	O
irinotecan	B-DRUG
.	O
	
The	O
triple	O
combination	O
of	O
MK-0646	B-DRUG
","	O
cetuximab	B-DRUG
","	O
and	O
irinotecan	B-DRUG
was	O
well	O
tolerated	O
in	O
Japanese	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
These	O
results	O
indicate	O
a	O
minimal	O
potential	O
for	O
PK	O
interactions	O
between	O
MK-0646	B-DRUG
and	O
cetuximab	B-DRUG
and	O
between	O
MK-0646	B-DRUG
and	O
irinotecan	B-DRUG
/	O
SN-38	B-DRUG
.	O
	
Tolerability	O
","	O
safety	O
and	O
pharmacokinetics	O
of	O
ridaforolimus	B-DRUG
in	O
combination	O
with	O
bicalutamide	B-DRUG
in	O
patients	O
with	O
asymptomatic	O
","	O
metastatic	O
castration-resistant	B-CANCER
prostate	I-CANCER
cancer	I-CANCER
(	O
CRPC	B-CANCER
)	O
.	O
	
	
Recent	O
data	O
indicate	O
that	O
there	O
is	O
a	O
significant	O
cross-talk	O
between	O
the	O
PI3K	O
/	O
Akt	O
/	O
mTOR	O
and	O
androgen	O
receptor	O
signaling	O
pathways	O
.	O
	
We	O
evaluated	O
safety	O
and	O
tolerability	O
as	O
well	O
as	O
potential	O
drug-drug	O
interaction	O
of	O
ridaforolimus	B-DRUG
","	O
a	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
inhibitor	O
","	O
when	O
combined	O
with	O
the	O
androgen	O
receptor	O
inhibitor	O
bicalutamide	B-DRUG
in	O
patients	O
with	O
asymptomatic	O
","	O
metastatic	O
castration-resistant	B-CANCER
prostate	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
were	O
treated	O
with	O
the	O
combination	O
of	O
ridaforolimus	B-DRUG
30	O
mg	O
/	O
day	O
for	O
5	O
consecutive	O
days	O
each	O
week	O
and	O
bicalutamide	B-DRUG
50	O
mg	O
/	O
day	O
.	O
	
Ridaforolimus	B-DRUG
pharmacokinetics	O
was	O
assessed	O
with	O
and	O
without	O
bicalutamide	B-DRUG
.	O
	
Twelve	O
patients	O
were	O
enrolled	O
including	O
1	O
screen	O
failure	O
.	O
	
Dose	O
reductions	O
were	O
required	O
in	O
7	O
patients	O
.	O
	
Three	O
of	O
the	O
11	O
patients	O
experienced	O
a	O
dose-limited	O
toxicity	O
","	O
1	O
with	O
Grade	O
3	O
hyperglycemia	B-TOXI
and	O
2	O
with	O
Grade	O
2	O
stomatitis	B-TOXI
leading	O
to	O
&	O
lt	O
;	O
75	O
%	O
of	O
planned	O
ridaforolimus	B-DRUG
dose	O
during	O
the	O
first	O
35	O
days	O
of	O
study	O
treatment	O
.	O
	
The	O
pharmacokinetic	O
results	O
showed	O
no	O
differences	O
in	O
exposures	O
to	O
ridaforolimus	B-DRUG
with	O
and	O
without	O
concomitant	O
bicalutamide	B-DRUG
administration	O
.	O
	
Although	O
there	O
was	O
no	O
evidence	O
of	O
a	O
clinically	O
relevant	O
pharmacological	O
drug-drug	O
interaction	O
","	O
the	O
occurrence	O
of	O
dose-limiting	O
toxicities	O
in	O
3	O
of	O
11	O
evaluable	O
patients	O
at	O
a	O
reduced	O
dose	O
of	O
ridaforolimus	B-DRUG
of	O
30	O
mg	O
/	O
day	O
suggests	O
that	O
this	O
combination	O
may	O
not	O
be	O
well	O
suited	O
for	O
asymptomatic	O
or	O
minimally	O
symptomatic	O
prostate	B-CANCER
cancer	I-CANCER
patients	O
.	O
	
Phase	O
I	O
study	O
investigating	O
everolimus	B-DRUG
combined	O
with	O
sorafenib	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
hepatocellular	I-CANCER
carcinoma	I-CANCER
.	O
	
	
Sorafenib	B-DRUG
is	O
the	O
only	O
therapy	O
shown	O
to	O
improve	O
overall	O
survival	O
in	O
advanced	B-CANCER
hepatocellular	I-CANCER
carcinoma	I-CANCER
(	O
HCC	B-CANCER
)	O
.	O
	
Combination	O
therapy	O
targeting	O
multiple	O
signaling	O
pathways	O
may	O
improve	O
outcomes	O
.	O
	
This	O
phase	O
I	O
study	O
was	O
designed	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
everolimus	B-DRUG
given	O
with	O
sorafenib	B-DRUG
400mg	O
twice	O
daily	O
in	O
patients	O
with	O
advanced	B-CANCER
HCC	I-CANCER
of	O
Child-Pugh	O
class	O
A	O
liver	O
function	O
who	O
were	O
naive	O
to	O
systemic	O
therapy	O
.	O
	
Everolimus	B-DRUG
was	O
initiated	O
at	O
2.5mg	O
once	O
daily	O
and	O
increased	O
per	O
a	O
Bayesian	O
sequential	O
dose-escalation	O
scheme	O
based	O
on	O
the	O
dose-limiting	O
toxicities	O
experienced	O
within	O
the	O
first	O
28	O
days	O
of	O
treatment	O
.	O
	
Adverse	O
events	O
were	O
assessed	O
continuously	O
.	O
	
Efficacy	O
was	O
evaluated	O
using	O
the	O
best	O
overall	O
response	O
rate	O
per	O
RECIST	O
.	O
	
Thirty	O
patients	O
were	O
enrolled	O
;	O
25	O
were	O
evaluable	O
for	O
MTD	O
determination	O
.	O
	
One	O
out	O
of	O
12	O
patients	O
treated	O
with	O
everolimus	B-DRUG
2.5mg	O
once	O
daily	O
and	O
6	O
out	O
of	O
13	O
patients	O
treated	O
with	O
everolimus	B-DRUG
5.0mg	O
once	O
daily	O
experienced	O
a	O
dose-limiting	O
toxicity	O
","	O
most	O
commonly	O
thrombocytopenia	B-TOXI
(	O
n=5	O
)	O
.	O
	
All	O
patients	O
experienced	O
1	O
adverse	O
event	O
","	O
most	O
commonly	O
diarrhea	B-TOXI
(	O
66.7	O
%	O
)	O
","	O
hand-foot	B-TOXI
skin	I-TOXI
reaction	I-TOXI
(	O
66.7	O
%	O
)	O
","	O
and	O
thrombocytopenia	B-TOXI
(	O
50	O
%	O
)	O
.	O
	
Best	O
overall	O
response	O
was	O
stable	O
disease	O
(	O
62.5	O
%	O
and	O
42.9	O
%	O
in	O
the	O
2.5-mg	O
and	O
5.0-mg	O
cohorts	O
","	O
respectively	O
)	O
.	O
	
Median	O
time	O
to	O
progression	O
and	O
overall	O
survival	O
in	O
the	O
2.5-mg	O
cohort	O
were	O
4.5	O
months	O
and	O
7.4	O
months	O
","	O
respectively	O
","	O
and	O
1.8	O
months	O
and	O
11.7	O
months	O
","	O
respectively	O
","	O
in	O
the	O
5.0-mg	O
cohort	O
.	O
	
In	O
patients	O
with	O
advanced	B-CANCER
HCC	I-CANCER
","	O
the	O
everolimus	B-DRUG
MTD	O
in	O
combination	O
with	O
standard-dose	O
sorafenib	B-DRUG
was	O
2.5mg	O
once	O
daily	O
.	O
	
The	O
inability	O
to	O
achieve	O
a	O
biologically	O
effective	O
everolimus	B-DRUG
concentration	O
at	O
the	O
MTD	O
precluded	O
phase	O
II	O
study	O
of	O
this	O
combination	O
.	O
	
Phase	O
I	O
/	O
II	O
trial	O
of	O
capecitabine	B-DRUG
and	O
oxaliplatin	B-DRUG
in	O
combination	O
with	O
bevacizumab	B-DRUG
and	O
imatinib	B-DRUG
in	O
patients	O
with	O
metastatic	O
colorectal	B-CANCER
cancer	I-CANCER
:	O
AIO	O
KRK	O
205	O
.	O
	
	
Combined	O
inhibition	O
of	O
platelet-derived	O
growth	O
factor	O
receptor	O
beta	O
signalling	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
promotes	O
vascular	O
normalisation	O
in	O
preclinical	O
models	O
and	O
may	O
lead	O
to	O
increased	O
delivery	O
of	O
chemotherapy	O
to	O
tumour	O
tissue	O
.	O
	
This	O
phase	O
I	O
/	O
II	O
trial	O
assessed	O
the	O
safety	O
and	O
efficacy	O
of	O
capecitabine	B-DRUG
plus	O
oxaliplatin	B-DRUG
(	O
XELOX	B-DRUG
)	O
plus	O
bevacizumab	B-DRUG
and	O
imatinib	B-DRUG
in	O
the	O
first-line	O
treatment	O
of	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Two	O
dose	O
levels	O
(	O
I	O
/	O
II	O
)	O
were	O
defined	O
:	O
capecitabine	B-DRUG
850	O
/	O
1000	O
mg	O
m	O
(	O
-2	O
)	O
twice	O
daily	O
on	O
days	O
1月14日	O
;	O
oxaliplatin	B-DRUG
100	O
/	O
130	O
mg	O
m	O
(	O
-2	O
)	O
on	O
day	O
1	O
;	O
bevacizumab	B-DRUG
7.5	O
mg	O
kg	O
(	O
-1	O
)	O
on	O
day	O
1	O
;	O
imatinib	B-DRUG
300	O
mg	O
day	O
(	O
-1	O
)	O
on	O
days	O
1月21日	O
every	O
21	O
days	O
.	O
	
The	O
primary	O
study	O
endpoint	O
was	O
safety	O
.	O
	
The	O
phase	O
II	O
secondary	O
endpoint	O
was	O
6-month	O
progression-free	O
survival	O
(	O
PFS	O
)	O
.	O
	
Dose	O
level	O
I	O
was	O
chosen	O
for	O
phase	O
II	O
testing	O
because	O
","	O
even	O
though	O
further	O
dose	O
escalation	O
was	O
permitted	O
by	O
the	O
protocol	O
","	O
gastrointestinal	B-TOXI
toxicities	I-TOXI
were	O
considered	O
to	O
be	O
clinically	O
significant	O
.	O
	
A	O
total	O
of	O
49	O
patients	O
were	O
evaluated	O
.	O
	
The	O
6-month	O
PFS	O
rate	O
was	O
76	O
%	O
","	O
median	O
PFS	O
was	O
10.6	O
months	O
and	O
median	O
overall	O
survival	O
was	O
23.2	O
months	O
.	O
	
Haematological	B-TOXI
toxicities	I-TOXI
were	O
generally	O
mild	O
.	O
	
Sensory	B-TOXI
neuropathy	I-TOXI
and	O
diarrhoea	B-TOXI
were	O
the	O
most	O
common	O
grade	O
3	O
toxicities	O
.	O
	
The	O
combination	O
of	O
XELOX	B-DRUG
with	O
bevacizumab	B-DRUG
and	O
imatinib	B-DRUG
is	O
tolerable	O
and	O
has	O
promising	O
efficacy	O
.	O
	
A	O
phase-1b	O
study	O
of	O
everolimus	B-DRUG
plus	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
pathway	O
is	O
dysregulated	O
in	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
SCLC	B-CANCER
)	O
and	O
everolimus	B-DRUG
is	O
an	O
oral	O
mTOR	O
inhibitor	O
.	O
	
This	O
phase-1b	O
study	O
assessed	O
everolimus	B-DRUG
safety	O
at	O
the	O
levels	O
of	O
2.5	O
","	O
5	O
","	O
or	O
10	O
mg	O
once	O
daily	O
in	O
combination	O
with	O
paclitaxel	B-DRUG
(	O
175	O
mg	O
m	O
(	O
-2	O
)	O
)	O
once	O
every	O
3	O
weeks	O
in	O
previously	O
treated	O
SCLC	B-CANCER
patients	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
of	O
everolimus	B-DRUG
.	O
	
Among	O
21	O
enrolled	O
patients	O
","	O
common	O
drug-related	O
adverse	O
events	O
were	O
anaemia	B-TOXI
","	O
neutropenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
pain	B-TOXI
","	O
hyperglycemia	B-TOXI
","	O
and	O
stomatitis	B-TOXI
.	O
	
Out	O
of	O
11	O
evaluable	O
patients	O
treated	O
with	O
everolimus	B-DRUG
at	O
the	O
level	O
of	O
5	O
mg	O
","	O
1	O
patient	O
experienced	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
of	O
grade	O
4	O
febrile	B-TOXI
neutropenia	I-TOXI
and	O
grade	O
3	O
thrombocytopenia	B-TOXI
.	O
	
The	O
other	O
two	O
DLTs	O
(	O
grade	O
4	O
thrombocytopenia	B-TOXI
and	O
grade	O
3	O
hyperglycemia	B-TOXI
)	O
occurred	O
in	O
two	O
out	O
of	O
three	O
patients	O
receiving	O
everolimus	B-DRUG
10	O
mg	O
.	O
	
The	O
overall	O
objective	O
response	O
rate	O
was	O
28	O
%	O
.	O
	
Everolimus	B-DRUG
showed	O
an	O
acceptable	O
safety	O
profile	O
and	O
preliminary	O
antitumour	O
activity	O
at	O
the	O
dose	O
of	O
5	O
mg	O
once	O
daily	O
when	O
combined	O
with	O
3-weekly	O
paclitaxel	B-DRUG
175	O
mg	O
m	O
(	O
-2	O
)	O
in	O
patients	O
with	O
SCLC	B-CANCER
.	O
	
Sunitinib	B-DRUG
combined	O
with	O
pemetrexed	B-DRUG
and	O
carboplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
malignancies	I-CANCER
=--	O
results	O
of	O
a	O
phase	O
I	O
dose-escalation	O
study	O
.	O
	
	
The	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
overall	O
safety	O
of	O
sunitinib	B-DRUG
plus	O
pemetrexed	B-DRUG
and	O
carboplatin	B-DRUG
was	O
determined	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
malignancies	I-CANCER
.	O
	
In	O
this	O
phase	O
I	O
dose-escalation	O
study	O
","	O
patients	O
received	O
oral	O
sunitinib	B-DRUG
on	O
a	O
continuous	O
daily	O
dosing	O
(	O
CDD	O
)	O
schedule	O
(	O
37.5	O
mg	O
/	O
day	O
)	O
or	O
Schedule	O
2	O
/	O
1	O
(	O
2	O
weeks	O
on	O
treatment	O
","	O
1	O
week	O
off	O
treatment	O
;	O
37.5	O
or	O
50	O
mg	O
/	O
day	O
)	O
.	O
	
Pemetrexed	B-DRUG
(	O
400-500	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
)	O
and	O
carboplatin	B-DRUG
(	O
AUC	O
=	O
5	O
mg路min	O
/	O
ml	O
IV	O
)	O
were	O
administered	O
q3w	O
.	O
	
At	O
the	O
MTD	O
for	O
the	O
chosen	O
schedule	O
","	O
a	O
cohort	O
of	O
patients	O
with	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
or	O
mesothelioma	B-CANCER
was	O
further	O
evaluated	O
.	O
	
Twenty-one	O
patients	O
were	O
enrolled	O
on	O
Schedule	O
2	O
/	O
1	O
(	O
expansion	O
cohort	O
included	O
)	O
and	O
3	O
patients	O
on	O
the	O
CDD	O
schedule	O
.	O
	
The	O
MTD	O
on	O
Schedule	O
2	O
/	O
1	O
was	O
sunitinib	B-DRUG
37.5	O
mg	O
/	O
day	O
with	O
pemetrexed	B-DRUG
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
carboplatin	B-DRUG
AUC	O
=	O
5	O
mg路min	O
/	O
ml	O
;	O
MTD	O
on	O
the	O
CDD	O
schedule	O
was	O
not	O
established	O
.	O
	
Dose-limiting	O
toxicities	O
included	O
grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
","	O
grade	O
3	O
thrombocytopenia	B-TOXI
","	O
and	O
grade	O
3	O
hand-foot	B-TOXI
syndrome	I-TOXI
.	O
	
The	O
most	O
common	O
grade	O
3	O
/	O
4	O
drug-related	O
non-hematologic	B-TOXI
adverse	I-TOXI
events	I-TOXI
at	O
Schedule	O
2	O
/	O
1	O
MTD	O
were	O
fatigue	B-TOXI
/	O
asthenia	B-TOXI
and	O
diarrhea	B-TOXI
(	O
both	O
n	O
=	O
4	O
)	O
.	O
	
Grade	O
3	O
/	O
4	O
hematologic	B-TOXI
abnormalities	I-TOXI
included	O
neutropenia	B-TOXI
(	O
83	O
%	O
)	O
and	O
leukopenia	B-TOXI
(	O
83	O
%	O
)	O
.	O
	
Pharmacokinetic	O
data	O
revealed	O
no	O
clinically	O
significant	O
drug-drug	O
interactions	O
.	O
	
Best	O
response	O
at	O
the	O
Schedule	O
2	O
/	O
1	O
MTD	O
was	O
stable	O
disease	O
_8	O
weeks	O
in	O
3	O
/	O
5	O
evaluable	O
patients	O
(	O
60	O
%	O
)	O
.	O
	
With	O
this	O
combination	O
","	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
malignancies	I-CANCER
","	O
sunitinib	B-DRUG
MTD	O
on	O
Schedule	O
2	O
/	O
1	O
was	O
37.5	O
mg	O
/	O
day	O
.	O
	
Sunitinib	B-DRUG
plus	O
pemetrexed	B-DRUG
and	O
carboplatin	B-DRUG
were	O
tolerable	O
at	O
the	O
MTD	O
","	O
although	O
sunitinib	B-DRUG
dose	O
delays	O
and	O
reductions	O
were	O
often	O
required	O
due	O
to	O
myelosuppression	B-TOXI
.	O
	
Phase	O
2	O
study	O
of	O
pemetrexed	B-DRUG
plus	O
carboplatin	B-DRUG
","	O
or	O
pemetrexed	B-DRUG
plus	O
cisplatin	B-DRUG
with	O
concurrent	O
radiation	O
therapy	O
followed	O
by	O
pemetrexed	B-DRUG
consolidation	O
in	O
patients	O
with	O
favorable-prognosis	O
inoperable	O
stage	O
IIIA	O
/	O
B	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
There	O
is	O
no	O
consensus	O
chemotherapy	O
regimen	O
with	O
concurrent	O
radiotherapy	O
(	O
RT	O
)	O
for	O
inoperable	O
stage	O
IIIA	O
/	O
B	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
This	O
trial	O
evaluated	O
pemetrexed	B-DRUG
with	O
carboplatin	B-DRUG
(	O
PCb	B-DRUG
)	O
or	O
cisplatin	B-DRUG
(	O
PC	B-DRUG
)	O
with	O
concurrent	O
RT	O
followed	O
by	O
consolidation	O
pemetrexed	B-DRUG
.	O
	
In	O
this	O
open-label	O
","	O
noncomparative	O
phase	O
II	O
trial	O
","	O
patients	O
with	O
inoperable	O
stage	O
IIIA	O
/	O
B	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
initially	O
all	O
histologies	O
","	O
later	O
restricted	O
to	O
nonsquamous	O
)	O
were	O
randomized	O
(	O
01:01	O
)	O
to	O
PCb	O
or	O
PC	B-DRUG
with	O
concurrent	O
RT	O
(	O
64-68	O
Gy	O
over	O
days	O
1-45	O
)	O
.	O
	
Consolidation	O
pemetrexed	B-DRUG
monotherapy	O
was	O
administered	O
every	O
21	O
days	O
for	O
three	O
cycles	O
.	O
	
Primary	O
endpoint	O
was	O
2-year	O
overall	O
survival	O
(	O
OS	O
)	O
rate	O
.	O
	
From	O
June	O
2007	O
to	O
November	O
2009	O
","	O
98	O
patients	O
were	O
enrolled	O
(	O
PCb	O
:	O
46	O
;	O
PC	O
:	O
52	O
)	O
.	O
	
The	O
2-year	O
OS	O
rate	O
was	O
PCb	B-DRUG
:	O
45.4	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
29.5-60.0	O
%	O
)	O
;	O
PC	B-DRUG
:	O
58.4	O
%	O
(	O
95	O
%	O
CI	O
","	O
42.6-71.3	O
%	O
)	O
","	O
and	O
in	O
nonsquamous	O
patients	O
was	O
PCb	B-DRUG
:	O
48	O
%	O
(	O
95	O
%	O
CI	O
","	O
29.0-64.8	O
%	O
)	O
;	O
PC	B-DRUG
:	O
55.8	O
%	O
(	O
95	O
%	O
CI	O
","	O
38.0-70.3	O
%	O
)	O
.	O
	
Median	O
time	O
to	O
disease	O
progression	O
was	O
PCb	B-DRUG
:	O
8.8	O
months	O
(	O
95	O
%	O
CI	O
","	O
6.0-12.6	O
months	O
)	O
;	O
PC	B-DRUG
:	O
13.1	O
months	O
(	O
95	O
%	O
CI	O
","	O
8.3-not	O
evaluable	O
[	O
NE	O
]	O
)	O
.	O
	
Median	O
OS	O
(	O
months	O
)	O
was	O
PCb	B-DRUG
:	O
18.7	O
(	O
95	O
%	O
CI	O
","	O
12.9-NE	O
)	O
;	O
PC	B-DRUG
:	O
27	O
(	O
95	O
%	O
CI	O
","	O
23.2-NE	O
)	O
.	O
	
The	O
objective	O
response	O
rates	O
(	O
ORRs	O
)	O
were	O
PCb	B-DRUG
:	O
52.2	O
%	O
;	O
PC	O
:	O
46.2	O
%	O
.	O
	
Grade	O
4	O
treatment-related	O
toxicities	O
(	O
%	O
PCb	B-DRUG
/	O
%	O
PC	B-DRUG
)	O
were	O
:	O
anemia	B-TOXI
","	O
0	O
/	O
1.9	O
;	O
neutropenia	B-TOXI
","	O
6.5	O
/	O
3.8	O
;	O
thrombocytopenia	B-TOXI
","	O
4.3	O
/	O
1.9	O
;	O
and	O
esophagitis	B-TOXI
","	O
0	O
/	O
1.9.	O
Most	O
patients	O
completed	O
scheduled	O
chemotherapy	O
and	O
RT	O
during	O
induction	O
and	O
consolidation	O
phases	O
.	O
	
No	B-TOXI
drug-related	I-TOXI
deaths	I-TOXI
were	O
reported	O
during	O
chemoradiotherapy	O
.	O
	
Because	O
of	O
study	O
design	O
","	O
efficacy	O
comparisons	O
can	O
not	O
be	O
made	O
.	O
	
However	O
","	O
both	O
combinations	O
with	O
concurrent	O
RT	O
were	O
active	O
and	O
well	O
tolerated	O
.	O
	
Phase	O
I	O
clinical	O
and	O
pharmacokinetic	O
/	O
pharmacogenetic	O
study	O
of	O
a	O
triplet	O
regimen	O
of	O
S-1	B-DRUG
/	O
irinotecan	B-DRUG
/	O
oxaliplatin	B-DRUG
in	O
patients	O
with	O
metastatic	O
colorectal	B-CANCER
or	I-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
	
We	O
conducted	O
a	O
phase	O
I	O
study	O
of	O
S-1	B-DRUG
combined	O
with	O
irinotecan	B-DRUG
and	O
oxaliplatin	B-DRUG
(	O
TIROX	B-DRUG
)	O
to	O
determine	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
recommended	O
dose	O
(	O
RD	O
)	O
and	O
to	O
assess	O
its	O
safety	O
","	O
pharmacokinetics	O
","	O
pharmacogenetics	O
","	O
and	O
preliminary	O
efficacy	O
in	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
MCRC	B-CANCER
)	O
or	O
metastatic	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
(	O
MGC	B-CANCER
)	O
.	O
	
Patients	O
received	O
escalating	O
doses	O
of	O
S-1	B-DRUG
(	O
30-40	O
mg	O
/	O
m虏	O
b.i.d.	O
)	O
orally	O
on	O
days	O
1月14日	O
","	O
an	O
escalating	O
dose	O
of	O
intravenous	B-DRUG
irinotecan	I-DRUG
(	O
120-150	O
mg	O
/	O
m虏	O
)	O
on	O
day	O
1	O
","	O
and	O
a	O
fixed	O
dose	O
of	O
intravenous	B-DRUG
oxaliplatin	I-DRUG
(	O
85	O
mg	O
/	O
m虏	O
)	O
on	O
day	O
1	O
every	O
3	O
weeks	O
.	O
	
Twenty-three	O
patients	O
(	O
10	O
MCRC	B-CANCER
","	O
13	O
MGC	B-CANCER
;	O
13	O
chemonaive	O
","	O
10	O
previously	O
treated	O
for	O
metastatic	O
disease	O
)	O
were	O
treated	O
across	O
six	O
dose	O
levels	O
.	O
	
Because	O
only	O
one	O
patient	O
experienced	O
a	O
dose-limiting	O
toxicity	O
of	O
grade	O
3	O
anorexia	B-TOXI
at	O
the	O
highest	O
dose	O
level	O
(	O
S-1	B-DRUG
40	O
mg	O
/	O
m虏	O
b.i.d.	O
","	O
irinotecan	B-DRUG
150	O
mg	O
/	O
m虏	O
","	O
and	O
oxaliplatin	B-DRUG
85	O
mg	O
/	O
m虏	O
)	O
(	O
n	O
=	O
8	O
)	O
","	O
the	O
MTD	O
was	O
not	O
obtained	O
","	O
and	O
this	O
level	O
was	O
established	O
as	O
the	O
RD.	O
With	O
a	O
median	O
of	O
10	O
cycles	O
per	O
patient	O
","	O
the	O
most	O
common	O
grade	O
3	O
or	O
4	O
adverse	O
events	O
included	O
neutropenia	B-TOXI
(	O
43	O
%	O
)	O
","	O
diarrhea	B-TOXI
(	O
13	O
%	O
)	O
","	O
and	O
nausea	B-TOXI
(	O
13	O
%	O
)	O
.	O
	
In	O
22	O
efficacy-evaluable	O
patients	O
","	O
the	O
objective	O
tumor	O
response	O
rate	O
was	O
59.1	O
%	O
(	O
75	O
%	O
for	O
both	O
MCRC	B-CANCER
and	O
MGC	B-CANCER
in	O
the	O
first-line	O
setting	O
)	O
and	O
the	O
disease	O
control	O
rate	O
was	O
100	O
%	O
.	O
	
The	O
exploratory	O
pharmacokinetic	O
/	O
pharmacogenetic	O
study	O
showed	O
that	O
CYP2A6	O
variants	O
(	O
*4	O
","	O
*7	O
","	O
*9	O
)	O
are	O
associated	O
with	O
a	O
lower	O
metabolic	O
ratio	O
of	O
S-1	B-DRUG
(	O
exposure	O
ratio	O
of	O
5-fluorouracil	B-DRUG
to	O
tegafur	B-DRUG
)	O
.	O
	
The	O
new	O
triplet	O
TIROX	B-DRUG
regimen	O
has	O
shown	O
promising	O
antitumor	O
activity	O
and	O
a	O
favorable	O
toxicity	O
profile	O
in	O
patients	O
with	O
MCRC	B-CANCER
and	O
MGC	B-CANCER
.	O
	
Phase	O
I	O
clinical	O
trial	O
of	O
lenalidomide	B-DRUG
in	O
combination	O
with	O
temsirolimus	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
cancer	I-CANCER
.	O
	
	
Lenalidomide	B-DRUG
","	O
an	O
immunomodulatory	O
and	O
anti-angiogenic	O
drug	O
","	O
and	O
temsirolimus	B-DRUG
","	O
an	O
mTOR	O
inhibitor	O
","	O
have	O
synergistic	O
anti-cancer	O
effects	O
in	O
preclinical	O
models	O
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
study	O
of	O
the	O
combination	O
in	O
patients	O
with	O
advanced	B-CANCER
cancers	I-CANCER
.	O
	
A	O
	O
study	O
design	O
was	O
used	O
.	O
	
During	O
the	O
escalation	O
phase	O
","	O
lenalidomide	B-DRUG
(	O
orally	O
","	O
days	O
1月21日	O
)	O
and	O
temsirolimus	B-DRUG
(	O
intravenously	O
","	O
once	O
a	O
week	O
)	O
were	O
given	O
at	O
the	O
following	O
respective	O
doses	O
:	O
level	O
1	O
(	O
10	O
mg	O
","	O
15	O
mg	O
)	O
;	O
level	O
2	O
(	O
10	O
mg	O
","	O
20	O
mg	O
)	O
;	O
level	O
3	O
(	O
20	O
mg	O
","	O
20	O
mg	O
)	O
;	O
and	O
level	O
4	O
(	O
20	O
mg	O
","	O
25	O
mg	O
)	O
(	O
1	O
cycle	O
=	O
28	O
days	O
)	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
","	O
dose-limiting	O
toxicity	O
","	O
and	O
response	O
were	O
assessed	O
.	O
	
Forty-three	O
patients	O
were	O
treated	O
(	O
median	O
age	O
:	O
58	O
years	O
(	O
range	O
","	O
21-80	O
)	O
;	O
male	O
/	O
female	O
:	O
26	O
/	O
17	O
)	O
.	O
	
The	O
most	O
common	O
diagnoses	O
were	O
colorectal	B-CANCER
cancer	I-CANCER
(	O
N	O
=	O
5	O
)	O
","	O
sarcoma	B-CANCER
(	O
N	O
=	O
5	O
)	O
","	O
neuroendocrine	B-CANCER
carcinoma	I-CANCER
(	O
N	O
=	O
4	O
)	O
and	O
adenoid	B-CANCER
cystic	I-CANCER
carcinoma	I-CANCER
(	O
N	O
=	O
4	O
)	O
.	O
	
Overall	O
","	O
121	O
cycles	O
(	O
median	O
:	O
2	O
)	O
were	O
administered	O
.	O
	
No	O
dose-limiting	O
toxicities	O
were	O
observed	O
.	O
	
The	O
maximum	O
tested	O
dose	O
(	O
dose	O
level	O
4	O
)	O
was	O
used	O
in	O
the	O
expansion	O
phase	O
.	O
	
Grade	O
3月4日	O
treatment-related	O
hematologic	B-TOXI
toxicities	I-TOXI
(	O
all	O
reversible	O
)	O
were	O
seen	O
in	O
19	O
(	O
72	O
%	O
)	O
patients	O
and	O
included	O
neutropenia	B-TOXI
(	O
N	O
=	O
12	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
N	O
=	O
6	O
)	O
","	O
and	O
infection	B-TOXI
(	O
N	O
=	O
1	O
)	O
.	O
	
Grade	O
3	O
hyperglycemia	B-TOXI
and	O
Grade	O
3	O
hypertriglyceridemia	B-TOXI
were	O
noted	O
in	O
21	O
%	O
and	O
20	O
%	O
of	O
patients	O
","	O
respectively	O
.	O
	
Of	O
43	O
patients	O
","	O
30	O
(	O
70	O
%	O
)	O
received	O
prophylactic	B-TOXI
anticoagulation	I-TOXI
.	O
	
There	O
were	O
no	B-TOXI
thrombotic	I-TOXI
events	I-TOXI
.	O
	
Response	O
was	O
evaluable	O
in	O
40	O
patients	O
:	O
one	O
(	O
2.5	O
%	O
)	O
patient	O
had	O
a	O
partial	O
response	O
and	O
19	O
(	O
48	O
%	O
)	O
had	O
stable	O
disease	O
(	O
SD	O
)	O
","	O
with	O
SD	O
_	O
6	O
months	O
in	O
6	O
(	O
15	O
%	O
)	O
patients	O
.	O
	
Tumor	O
types	O
with	O
SD	O
_	O
6	O
months	O
were	O
soft	B-CANCER
tissue	I-CANCER
sarcoma	I-CANCER
(	O
2	O
/	O
5	O
;	O
40	O
%	O
)	O
","	O
adenoid	B-CANCER
cystic	I-CANCER
carcinoma	I-CANCER
(	O
1	O
/	O
4	O
;	O
25	O
%	O
)	O
","	O
parotid	B-CANCER
adenocarcinoma	I-CANCER
(	O
1	O
/	O
2	O
;	O
50	O
%	O
)	O
","	O
adrenocortical	B-CANCER
carcinoma	I-CANCER
(	O
1	O
/	O
3	O
;	O
33	O
%	O
)	O
","	O
and	O
neuroendocrine	B-CANCER
carcinoma	I-CANCER
(	O
1	O
/	O
4	O
;	O
25	O
%	O
)	O
.	O
	
The	O
median	O
progression-free	O
survival	O
duration	O
was	O
2.2	O
months	O
(	O
95	O
%	O
CI	O
","	O
1.5-2.9	O
)	O
","	O
and	O
the	O
median	O
overall	O
survival	O
duration	O
was	O
7.8	O
months	O
(	O
95	O
%	O
CI	O
","	O
5.1-10.6	O
)	O
.	O
	
Lenalidomide	B-DRUG
and	O
temsirolimus	B-DRUG
combination	O
therapy	O
was	O
well	O
tolerated	O
and	O
associated	O
with	O
clinical	O
benefit	O
in	O
patients	O
with	O
soft	B-CANCER
tissue	I-CANCER
sarcoma	I-CANCER
","	O
adenoid	B-CANCER
cystic	I-CANCER
carcinoma	I-CANCER
","	O
neuroendocrine	B-CANCER
carcinoma	I-CANCER
","	O
parotid	B-CANCER
carcinoma	I-CANCER
","	O
and	O
adrenocortical	B-CANCER
carcinoma	I-CANCER
.	O
	
A	O
phase	O
1	O
trial	O
of	O
imatinib	B-DRUG
","	O
bevacizumab	B-DRUG
","	O
and	O
metronomic	B-DRUG
cyclophosphamide	I-DRUG
in	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
This	O
phase	O
1	O
clinical	O
trial	O
was	O
conducted	O
to	O
determine	O
the	O
safety	O
","	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
and	O
pharmacokinetics	O
of	O
imatinib	B-DRUG
","	O
bevacizumab	B-DRUG
","	O
and	O
metronomic	B-DRUG
cyclophosphamide	I-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
CRC	B-CANCER
)	O
.	O
	
Patients	O
with	O
refractory	O
stage	O
IV	O
CRC	B-CANCER
were	O
treated	O
with	O
bevacizumab	B-DRUG
5	O
mg	O
kg	O
(	O
-1	O
)	O
i.v.	O
every	O
2	O
weeks	O
(	O
fixed	O
dose	O
)	O
plus	O
oral	O
cyclophosphamide	B-DRUG
q.d.	O
and	O
imatinib	B-DRUG
q.d.	O
or	O
b.i.d.	O
in	O
28-day	O
cycles	O
with	O
3+3	O
dose	O
escalation	O
.	O
	
Response	O
was	O
assessed	O
every	O
two	O
cycles	O
.	O
	
Pharmacokinetics	O
of	O
imatinib	B-DRUG
and	O
cyclophosphamide	B-DRUG
and	O
circulating	O
tumour	O
","	O
endothelial	O
","	O
and	O
immune	O
cell	O
subsets	O
were	O
measured	O
.	O
	
Thirty-five	O
patients	O
were	O
enrolled	O
.	O
	
Maximum-tolerated	O
doses	O
were	O
cyclophosphamide	B-DRUG
50	O
mg	O
q.d.	O
","	O
imatinib	B-DRUG
400	O
mg	O
q.d.	O
","	O
and	O
bevacizumab	B-DRUG
5	O
mg	O
kg	O
(	O
-1	O
)	O
i.v.	O
every	O
2	O
weeks	O
.	O
	
Dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
included	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
","	O
neutropaenia	B-TOXI
","	O
hyponatraemia	B-TOXI
","	O
fistula	B-TOXI
","	O
and	O
haematuria	B-TOXI
.	O
	
The	O
DLT	O
window	O
required	O
expansion	O
to	O
42	O
days	O
(	O
1.5	O
cycles	O
)	O
to	O
capture	O
delayed	O
toxicities	O
.	O
	
Imatinib	B-DRUG
exposure	O
increased	O
insignificantly	O
after	O
adding	O
cyclophosphamide	B-DRUG
.	O
	
Seven	O
patients	O
(	O
20	O
%	O
)	O
experienced	O
stable	O
disease	O
for	O
&	O
gt	O
;	O
6	O
months	O
.	O
	
Circulating	O
tumour	O
","	O
endothelial	O
","	O
or	O
immune	O
cells	O
were	O
not	O
associated	O
with	O
progression-free	O
survival	O
.	O
	
The	O
combination	O
of	O
metronomic	B-DRUG
cyclophosphamide	I-DRUG
","	O
imatinib	B-DRUG
","	O
and	O
bevacizumab	B-DRUG
is	O
safe	O
and	O
tolerable	O
without	O
significant	O
drug	O
interactions	O
.	O
	
A	O
subset	O
of	O
patients	O
experienced	O
prolonged	O
stable	O
disease	O
independent	O
of	O
dose	O
level	O
.	O
	
Phase	O
II	O
study	O
of	O
pegylated	B-DRUG
liposomal	I-DRUG
doxorubicin	I-DRUG
","	O
low-dose	O
dexamethasone	B-DRUG
","	O
and	O
lenalidomide	B-DRUG
in	O
patients	O
with	O
newly	O
diagnosed	O
multiple	O
myeloma	B-CANCER
.	O
	
	
Our	O
previous	O
phase	O
I	O
/	O
II	O
trial	O
of	O
pegylated	B-DRUG
liposomal	I-DRUG
doxorubicin	I-DRUG
(	O
PLD	O
)	O
","	O
low-dose	O
dexamethasone	B-DRUG
","	O
and	O
lenalidomide	B-DRUG
in	O
patients	O
with	O
relapsed	O
and	O
refractory	O
myeloma	B-CANCER
showed	O
an	O
overall	O
response	O
rate	O
of	O
75	O
%	O
","	O
with	O
29	O
%	O
achieving	O
_	O
VGPR	O
.	O
	
Here	O
","	O
we	O
investigated	O
this	O
combination	O
(	O
PLD	O
30	O
or	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
","	O
day	O
1	O
;	O
dexamethasone	B-DRUG
40	O
mg	O
orally	O
","	O
days	O
1月4日	O
;	O
lenalidomide	B-DRUG
25	O
mg	O
orally	O
","	O
days	O
1月21日	O
;	O
administered	O
every	O
28	O
days	O
)	O
in	O
a	O
phase	O
II	O
study	O
in	O
patients	O
with	O
newly	O
diagnosed	O
symptomatic	O
multiple	O
myeloma	B-CANCER
to	O
determine	O
its	O
efficacy	O
and	O
tolerability	O
(	O
ClinicalTrials.gov	O
NCT00617591	O
)	O
.	O
	
At	O
best	O
response	O
","	O
patients	O
could	O
proceed	O
with	O
high-dose	O
melphalan	B-DRUG
or	O
with	O
maintenance	O
lenalidomide	B-DRUG
and	O
dexamethasone	B-DRUG
.	O
	
In	O
57	O
patients	O
","	O
we	O
found	O
that	O
the	O
overall	O
response	O
rate	O
and	O
rate	O
of	O
very	O
good	O
partial	O
response	O
and	O
better	O
on	O
intent-to-treat	O
","	O
our	O
primary	O
endpoints	O
","	O
were	O
77.2	O
%	O
and	O
42.1	O
%	O
","	O
respectively	O
","	O
with	O
responses	O
per	O
the	O
International	O
Myeloma	B-CANCER
Working	O
Group	O
.	O
	
Median	O
progression-free	O
survival	O
was	O
28	O
months	O
(	O
95	O
%	O
CI	O
18.1-34.8	O
)	O
","	O
with	O
-1	O
and	O
2-year	O
overall	O
survival	O
rates	O
of	O
98.1	O
and	O
79.6	O
%	O
.	O
	
During	O
induction	O
","	O
grade	O
3	O
/	O
4	O
toxicities	O
were	O
neutropenia	B-TOXI
(	O
49.1	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
15.8	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
7	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
14	O
%	O
)	O
","	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
8.8	O
%	O
)	O
","	O
and	O
venous	B-TOXI
thromboembolic	I-TOXI
events	I-TOXI
(	O
8.8	O
%	O
)	O
.	O
	
During	O
maintenance	O
","	O
grade	O
3	O
/	O
4	O
toxicities	O
were	O
mainly	O
hematologic	O
.	O
	
We	O
found	O
this	O
combination	O
to	O
be	O
active	O
in	O
patients	O
with	O
newly	O
diagnosed	O
myeloma	B-CANCER
","	O
with	O
results	O
comparable	O
to	O
other	O
lenalidomide-based	B-DRUG
induction	O
strategies	O
without	O
proteasome	O
inhibition	O
.	O
	
In	O
addition	O
","	O
maintenance	O
therapy	O
with	O
lenalidomide	B-DRUG
was	O
well	O
tolerated	O
.	O
	
Phase	O
I	O
study	O
evaluating	O
the	O
combination	O
of	O
lapatinib	B-DRUG
(	O
a	O
Her2	O
/	O
Neu	O
and	O
EGFR	O
inhibitor	O
)	O
and	O
everolimus	B-DRUG
(	O
an	O
mTOR	O
inhibitor	O
)	O
in	O
patients	O
with	O
advanced	B-CANCER
cancers	I-CANCER
:	O
South	O
West	O
Oncology	O
Group	O
(	O
SWOG	O
)	O
Study	O
S0528	O
.	O
	
	
Everolimus	B-DRUG
","	O
an	O
oral	O
inhibitor	O
of	O
mammalian	O
target	O
of	O
rapamycin	O
","	O
can	O
augment	O
the	O
efficacy	O
of	O
HER	O
inhibitors	O
in	O
preclinical	O
studies	O
.	O
	
This	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
safety	O
and	O
pharmacokinetics	O
(	O
PK	O
)	O
of	O
the	O
combination	O
of	O
lapatinib	B-DRUG
","	O
a	O
Her1	O
and	O
2	O
inhibitor	O
","	O
and	O
everolimus	B-DRUG
and	O
to	O
describe	O
its	O
anti-tumor	O
activity	O
in	O
the	O
Phase	O
I	O
setting	O
.	O
	
In	O
Part	O
I	O
","	O
dose	O
escalation	O
to	O
define	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
was	O
performed	O
.	O
	
In	O
Part	O
II	O
","	O
PK	O
of	O
both	O
drugs	O
were	O
analyzed	O
to	O
assess	O
drug-drug	O
interaction	O
.	O
	
Twenty-three	O
evaluable	O
patients	O
with	O
advanced	B-CANCER
cancers	I-CANCER
were	O
treated	O
on	O
six	O
different	O
dose	O
levels	O
in	O
Part	O
I	O
of	O
the	O
study	O
.	O
	
The	O
dose-limiting	O
toxicities	O
were	O
diarrhea	B-TOXI
","	O
rash	B-TOXI
","	O
mucositis	B-TOXI
","	O
and	O
fatigue	B-TOXI
.	O
	
The	O
MTD	O
of	O
the	O
combination	O
was	O
"1,250"	O
mg	O
of	O
lapatinib	B-DRUG
and	O
5	O
mg	O
of	O
everolimus	B-DRUG
once	O
daily	O
.	O
	
In	O
Part	O
II	O
of	O
the	O
study	O
","	O
54	O
patients	O
were	O
treated	O
with	O
the	O
combination	O
at	O
the	O
MTD	O
.	O
	
The	O
mean	O
everolimus	B-DRUG
time	O
to	O
maximum	O
concentration	O
was	O
increased	O
by	O
44	O
%	O
","	O
and	O
mean	O
clearance	O
was	O
decreased	O
by	O
25	O
%	O
when	O
co-administered	O
with	O
lapatinib	B-DRUG
","	O
though	O
these	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O
	
There	O
was	O
no	O
significant	O
influence	O
on	O
the	O
PK	O
of	O
lapatinib	B-DRUG
by	O
everolimus	B-DRUG
.	O
	
Two	O
patients	O
achieved	O
a	O
partial	O
response	O
[	O
thymic	B-CANCER
cancer	I-CANCER
(	O
45+	O
months	O
)	O
and	O
breast	B-CANCER
cancer	I-CANCER
(	O
unconfirmed	O
PR	O
;	O
7	O
months	O
)	O
]	O
;	O
11	O
patients	O
attained	O
stable	O
disease	O
of	O
at	O
least	O
4	O
months	O
.	O
	
Lapatinib	B-DRUG
and	O
everolimus	B-DRUG
are	O
well	O
tolerated	O
at	O
doses	O
of	O
"1,250"	O
and	O
5	O
mg	O
po	O
daily	O
","	O
respectively	O
.	O
	
Stable	O
disease	O
_4	O
months	O
/	O
PR	O
was	O
achieved	O
in	O
13	O
of	O
78	O
patients	O
(	O
17	O
%	O
)	O
.	O
	
Phase	O
I	O
trial	O
of	O
the	O
oral	O
PARP	O
inhibitor	O
olaparib	B-DRUG
in	O
combination	O
with	O
paclitaxel	B-DRUG
for	O
first-	O
or	O
second-line	O
treatment	O
of	O
patients	O
with	O
metastatic	O
triple-negative	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
	
This	O
Phase	O
I	O
study	O
evaluated	O
the	O
safety	O
","	O
tolerability	O
and	O
efficacy	O
of	O
olaparib	B-DRUG
","	O
a	O
potent	O
oral	O
poly	O
(	O
ADPribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
inhibitor	O
","	O
in	O
combination	O
with	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
triple-negative	I-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
mTNBC	B-CANCER
)	O
.	O
	
Eligible	O
patients	O
who	O
had	O
received	O
_1	O
prior	O
cytotoxic	O
regimen	O
for	O
mTNBC	B-CANCER
were	O
treated	O
with	O
olaparib	B-DRUG
200	O
mg	O
bid	O
continuously	O
plus	O
weekly	O
paclitaxel	B-DRUG
90	O
mg	O
/	O
m2	O
for	O
three	O
weeks	O
per	O
four-week	O
cycle	O
.	O
	
Dose	O
modifications	O
in	O
a	O
large	O
proportion	O
of	O
patients	O
due	O
to	O
neutropenia	B-TOXI
resulted	O
in	O
enrollment	O
of	O
a	O
second	O
cohort	O
of	O
patients	O
who	O
","	O
if	O
they	O
experienced	O
grade	O
_2	O
neutropenia	B-TOXI
in	O
cycle	O
1	O
","	O
received	O
granulocyte-colony	O
stimulating	O
factor	O
","	O
which	O
was	O
continued	O
prophylactically	O
in	O
subsequent	O
cycles	O
.	O
	
All	O
patients	O
had	O
measurable	O
disease	O
;	O
tumor	O
responses	O
were	O
evaluated	O
according	O
to	O
RECIST	O
(	O
version	O
1	O
)	O
.	O
	
Nineteen	O
patients	O
(	O
cohort	O
1	O
","	O
n	O
=	O
9	O
;	O
cohort	O
2	O
","	O
n	O
=	O
10	O
)	O
received	O
treatment	O
;	O
15	O
had	O
received	O
prior	O
taxane	B-DRUG
chemotherapy	O
.	O
	
The	O
most	O
frequent	O
adverse	O
events	O
were	O
diarrhea	B-TOXI
(	O
n	O
=	O
12	O
","	O
63	O
%	O
)	O
","	O
nausea	B-TOXI
(	O
n	O
=	O
11	O
","	O
58	O
%	O
)	O
and	O
neutropenia	B-TOXI
(	O
n	O
=	O
11	O
","	O
58	O
%	O
)	O
.	O
	
Seven	O
neutropenia	B-TOXI
events	O
were	O
reported	O
in	O
cohort	O
1	O
(	O
four	O
grade	O
_3	O
)	O
and	O
four	O
in	O
cohort	O
2	O
(	O
two	O
grade	O
_3	O
","	O
including	O
one	O
event	O
of	O
febrile	B-TOXI
neutropenia	I-TOXI
)	O
.	O
	
The	O
median	O
(	O
range	O
)	O
dose	O
intensity	O
of	O
paclitaxel	B-DRUG
was	O
57	O
%	O
(	O
26	O
to	O
100	O
%	O
)	O
in	O
cohort	O
1	O
and	O
73	O
%	O
(	O
29	O
to	O
100	O
%	O
)	O
in	O
cohort	O
2	O
Seven	O
patients	O
(	O
37	O
%	O
)	O
had	O
a	O
confirmed	O
partial	O
response	O
;	O
one	O
patient	O
remains	O
on	O
olaparib	B-DRUG
monotherapy	O
without	O
progression	O
.	O
	
The	O
combination	O
of	O
olaparib	B-DRUG
and	O
weekly	O
paclitaxel	B-DRUG
was	O
complicated	O
by	O
a	O
significant	O
clinical	O
interaction	O
","	O
with	O
higher-than-expected	O
rates	O
of	O
neutropenia	B-TOXI
despite	O
secondary	O
prophylaxis	O
.	O
	
Given	O
the	O
encouraging	O
response	O
rate	O
","	O
alternative	O
scheduling	O
and	O
dosing	O
strategies	O
should	O
be	O
considered	O
(	O
funded	O
by	O
AstraZeneca	O
;	O
ClinicalTrials.gov	O
","	O
NCT00707707	O
)	O
.	O
	
A	O
phase	O
1	O
study	O
of	O
everolimus	B-DRUG
=+	O
weekly	O
cisplatin	B-DRUG
=+	O
intensity	O
modulated	O
radiation	O
therapy	O
in	O
head-and-neck	B-CANCER
cancer	I-CANCER
.	O
	
	
Elevated	O
expression	O
of	O
eukaryotic	O
protein	O
synthesis	O
initiation	O
factor	O
4E	O
(	O
eIF4E	O
)	O
in	O
histologically	O
cancer-free	O
margins	O
of	O
resected	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinomas	I-CANCER
(	O
HNSCCs	B-CANCER
)	O
is	O
mediated	O
by	O
mammalian	O
target	O
of	O
rapamycin	O
complex	O
1	O
(	O
mTORC1	O
)	O
and	O
has	O
been	O
associated	O
with	O
increased	O
risk	O
of	O
disease	O
recurrence	O
.	O
	
Preclinically	O
","	O
inhibition	O
of	O
mTORC1	O
with	O
everolimus	B-DRUG
sensitizes	O
cancer	O
cells	O
to	O
cisplatin	B-DRUG
and	O
radiation	O
.	O
	
This	O
was	O
single-institution	O
phase	O
1	O
study	O
to	O
establish	O
the	O
maximum	O
tolerated	O
dose	O
of	O
daily	O
everolimus	B-DRUG
given	O
with	O
fixed	O
dose	O
cisplatin	B-DRUG
(	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
_	O
6	O
)	O
and	O
concurrent	O
intensity	O
modulated	O
radiation	O
therapy	O
for	O
patients	O
with	O
locally	O
and	O
/	O
or	O
regionally	O
advanced	B-CANCER
head-and-neck	I-CANCER
cancer	I-CANCER
.	O
	
The	O
study	O
had	O
a	O
standard	O
3	O
=+	O
3	O
dose-escalation	O
design	O
.	O
	
Tumor	O
primary	O
sites	O
were	O
oral	O
cavity	O
(	O
4	O
)	O
","	O
salivary	O
gland	O
(	O
4	O
)	O
","	O
oropharynx	O
(	O
2	O
)	O
","	O
nasopharynx	O
(	O
1	O
)	O
","	O
scalp	O
(	O
1	O
)	O
","	O
and	O
neck	O
node	O
with	O
occult	O
primary	O
(	O
1	O
)	O
.	O
	
In	O
4	O
of	O
4	O
cases	O
in	O
which	O
resected	O
HNSCC	B-CANCER
surgical	O
pathology	O
specimens	O
were	O
available	O
for	O
immunohistochemistry	O
","	O
elevated	O
expression	O
of	O
eIF4E	O
was	O
observed	O
in	O
the	O
cancer-free	O
margins	O
.	O
	
The	O
most	O
common	O
grade	O
_3	O
treatment-related	O
adverse	O
event	O
was	O
lymphopenia	B-TOXI
(	O
92	O
%	O
)	O
","	O
and	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
were	O
mucositis	B-TOXI
(	O
n=2	O
)	O
and	O
failure	B-TOXI
to	I-TOXI
thrive	I-TOXI
(	O
n=1	O
)	O
.	O
	
With	O
a	O
median	O
follow	O
up	O
of	O
19.4	O
months	O
","	O
2	O
patients	O
have	O
experienced	O
recurrent	O
disease	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
was	O
everolimus	B-DRUG
5	O
mg	O
/	O
day	O
.	O
	
Head-and-neck	B-CANCER
cancer	I-CANCER
patients	O
tolerated	O
everolimus	B-DRUG
at	O
therapeutic	O
doses	O
(	O
5	O
mg	O
/	O
day	O
)	O
given	O
with	O
weekly	O
cisplatin	B-DRUG
and	O
intensity	O
modulated	O
radiation	O
therapy	O
.	O
	
The	O
regimen	O
merits	O
further	O
evaluation	O
","	O
especially	O
among	O
patients	O
who	O
are	O
status	O
post	O
resection	O
of	O
HNSCCs	B-CANCER
that	O
harbor	O
mTORC1-mediated	O
activation	O
of	O
eIF4E	O
in	O
histologically	O
negative	O
surgical	O
margins	O
.	O
	
Phase	O
I	O
dose-finding	O
study	O
of	O
cabazitaxel	B-DRUG
administered	O
weekly	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
	
Cabazitaxel	B-DRUG
is	O
approved	O
in	O
patients	O
with	O
metastatic	O
hormone-refractory	O
prostate	B-CANCER
cancer	I-CANCER
previously	O
treated	O
with	O
a	O
docetaxel-containing	B-DRUG
regimen	O
.	O
	
This	O
study	O
evaluated	O
a	O
weekly	O
cabazitaxel	B-DRUG
dosing	O
regimen	O
.	O
	
Primary	O
objectives	O
were	O
to	O
report	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
and	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
.	O
	
Efficacy	O
","	O
safety	O
and	O
pharmacokinetics	O
were	O
secondary	O
objectives	O
.	O
	
Cabazitaxel	B-DRUG
was	O
administered	O
weekly	O
(	O
1-hour	O
intravenous	O
infusion	O
at	O
1.5-12	O
mg	O
/	O
m虏	O
doses	O
)	O
for	O
the	O
first	O
4	O
weeks	O
of	O
a	O
5-week	O
cycle	O
in	O
patients	O
with	O
solid	B-CANCER
tumours	I-CANCER
.	O
	
Monitoring	O
of	O
DLTs	O
was	O
used	O
to	O
determine	O
the	O
MTD	O
and	O
the	O
recommended	O
weekly	O
dose	O
.	O
	
Thirty-one	O
patients	O
were	O
enrolled	O
.	O
	
Two	O
of	O
six	O
patients	O
experienced	O
DLTs	O
at	O
12	O
mg	O
/	O
m虏	O
","	O
which	O
was	O
declared	O
the	O
MTD	O
.	O
	
Gastrointestinal	B-TOXI
disorders	I-TOXI
were	O
the	O
most	O
common	O
adverse	O
event	O
.	O
	
Eight	O
patients	O
developed	O
neutropenia	B-TOXI
(	O
three	O
_	O
Grade	O
3	O
)	O
;	O
one	O
occurrence	O
of	O
febrile	B-TOXI
neutropenia	I-TOXI
was	O
reported	O
.	O
	
There	O
were	O
two	O
partial	O
responses	O
(	O
in	O
breast	B-CANCER
cancer	I-CANCER
)	O
and	O
13	O
patients	O
had	O
stable	O
disease	O
(	O
median	O
duration	O
of	O
3.3	O
months	O
)	O
.	O
	
Increases	O
in	O
C	O
(	O
max	O
)	O
and	O
AUC	O
(	O
0-t	O
)	O
were	O
dose	O
proportional	O
for	O
the	O
6月12日	O
mg	O
/	O
m虏	O
doses	O
.	O
	
The	O
MTD	O
of	O
weekly	O
cabazitaxel	B-DRUG
was	O
12	O
mg	O
/	O
m虏	O
and	O
the	O
recommended	O
weekly	O
dose	O
was	O
10	O
mg	O
/	O
m虏	O
.	O
	
The	O
observed	O
safety	O
profile	O
and	O
antitumour	O
activity	O
of	O
cabazitaxel	B-DRUG
were	O
consistent	O
with	O
those	O
observed	O
with	O
other	O
taxanes	B-DRUG
in	O
similar	O
dosing	O
regimens	O
.	O
	
The	O
study	O
was	O
registered	O
with	O
ClinicalTrials.gov	O
as	O
NCT01755390	O
.	O
	
A	O
phase	O
2	O
study	O
of	O
everolimus	B-DRUG
combined	O
with	O
trastuzumab	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
HER2-overexpressing	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
that	O
progressed	O
during	O
prior	O
trastuzumab	B-DRUG
and	O
taxane	B-DRUG
therapy	O
.	O
	
	
Increased	O
activation	O
of	O
the	O
PI3K	O
/	O
Akt	O
/	O
mTOR	O
pathway	O
is	O
a	O
common	O
factor	O
in	O
putative	O
mechanisms	O
of	O
trastuzumab	B-DRUG
resistance	O
","	O
resulting	O
in	O
dysregulation	O
of	O
cell	O
migration	O
","	O
growth	O
","	O
proliferation	O
","	O
and	O
survival	O
.	O
	
Data	O
from	O
preclinical	O
and	O
phase	O
1	O
/	O
2	O
clinical	O
studies	O
suggest	O
that	O
adding	O
everolimus	B-DRUG
(	O
an	O
oral	O
mTOR	O
inhibitor	O
)	O
to	O
trastuzumab	B-DRUG
plus	O
chemotherapy	O
may	O
enhance	O
the	O
efficacy	O
of	O
","	O
and	O
restore	O
sensitivity	O
to	O
","	O
trastuzumab-based	B-DRUG
therapy	O
.	O
	
In	O
this	O
phase	O
2	O
multicenter	O
study	O
","	O
adult	O
patients	O
with	O
HER2-positive	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
resistant	O
to	O
trastuzumab	B-DRUG
and	O
pretreated	O
with	O
a	O
taxane	B-DRUG
received	O
everolimus	B-DRUG
10	O
mg	O
/	O
day	O
in	O
combination	O
with	O
paclitaxel	B-DRUG
(	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
every	O
4	O
weeks	O
)	O
and	O
trastuzumab	B-DRUG
(	O
4	O
mg	O
/	O
kg	O
loading	O
dose	O
followed	O
by	O
2	O
mg	O
/	O
kg	O
weekly	O
)	O
","	O
administered	O
in	O
28-day	O
cycles	O
.	O
	
Endpoints	O
included	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
","	O
progression-free	O
survival	O
(	O
PFS	O
)	O
","	O
overall	O
survival	O
(	O
OS	O
)	O
","	O
and	O
safety	O
.	O
	
Fifty-five	O
patients	O
were	O
enrolled	O
;	O
one	O
remained	O
on	O
study	O
treatment	O
at	O
the	O
time	O
of	O
data	O
cutoff	O
.	O
	
The	O
median	O
number	O
of	O
prior	O
chemotherapy	O
lines	O
for	O
advanced	O
disease	O
was	O
3.5	O
(	O
range	O
1月11日	O
)	O
.	O
	
The	O
ORR	O
was	O
21.8	O
%	O
","	O
the	O
clinical	O
benefit	O
rate	O
was	O
36.4	O
%	O
","	O
the	O
median	O
PFS	O
estimate	O
was	O
5.5	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
4.99-7.69	O
months	O
)	O
","	O
and	O
the	O
median	O
OS	O
estimate	O
was	O
18.1	O
months	O
(	O
95	O
%	O
CI	O
:	O
12.85-24.11	O
months	O
)	O
.	O
	
Hematologic	O
grade	O
3	O
/	O
4	O
adverse	O
events	O
(	O
AEs	O
)	O
included	O
neutropenia	B-TOXI
(	O
25.5	O
%	O
grade	O
3	O
","	O
3.6	O
%	O
grade	O
4	O
)	O
","	O
anemia	O
(	O
7.3	O
%	O
grade	O
3	O
)	O
","	O
and	O
thrombocytopenia	B-TOXI
(	O
5.5	O
%	O
grade	O
3	O
","	O
1.8	O
%	O
grade	O
4	O
)	O
.	O
	
Nonhematologic	O
grade	O
3	O
/	O
4	O
AEs	O
included	O
stomatitis	B-TOXI
(	O
20	O
%	O
)	O
","	O
diarrhea	B-TOXI
(	O
5.5	O
%	O
)	O
","	O
vomiting	B-TOXI
(	O
5.5	O
%	O
)	O
","	O
fatigue	O
(	O
5.5	O
%	O
)	O
","	O
and	O
pneumonia	B-TOXI
(	O
5.5	O
%	O
)	O
","	O
all	O
grade	O
3	O
These	O
findings	O
suggest	O
that	O
the	O
combination	O
of	O
everolimus	B-DRUG
plus	O
trastuzumab	B-DRUG
and	O
paclitaxel	B-DRUG
is	O
feasible	O
","	O
with	O
promising	O
activity	O
in	O
patients	O
with	O
highly	O
resistant	O
HER2-positive	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
This	O
combination	O
is	O
currently	O
under	O
investigation	O
in	O
the	O
BOLERO-1	O
phase	O
3	O
trial	O
.	O
	
Phase	O
1	O
and	O
pharmacodynamic	O
trial	O
of	O
everolimus	B-DRUG
in	O
combination	O
with	O
cetuximab	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
cancer	I-CANCER
.	O
	
	
Preclinical	O
and	O
clinical	O
studies	O
suggest	O
mTOR	O
(	O
mammalian	O
target	O
of	O
rapamycin	O
)	O
inhibitors	O
may	O
have	O
metabolic	O
and	O
antiangiogenic	O
effects	O
","	O
and	O
synergize	O
with	O
epidermal	O
growth	O
factor	O
pathway	O
inhibitors	O
.	O
	
Therefore	O
","	O
a	O
phase	O
1	O
/	O
pharmacodynamic	O
trial	O
of	O
everolimus	B-DRUG
with	O
cetuximab	B-DRUG
was	O
performed	O
.	O
	
A	O
total	O
of	O
29	O
patients	O
were	O
randomized	O
to	O
a	O
run-in	O
of	O
oral	O
everolimus	B-DRUG
(	O
30	O
","	O
50	O
","	O
or	O
70	O
mg	O
)	O
or	O
cetuximab	B-DRUG
(	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
loading	O
","	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
maintenance	O
)	O
weekly	O
","	O
followed	O
by	O
the	O
combination	O
in	O
this	O
dose-escalation	O
study	O
.	O
	
Primary	O
endpoints	O
were	O
phase	O
2	O
dose	O
and	O
toxicity	O
characterization	O
.	O
	
[	B-DRUG
(	I-DRUG
18	I-DRUG
)	I-DRUG
F	I-DRUG
]	I-DRUG
Fluorodeoxyglucose	I-DRUG
positron	O
emission	O
tomography	O
(	O
FDG-PET	O
)	O
was	O
performed	O
as	O
a	O
pharmacodynamic	O
marker	O
of	O
mTOR	O
inhibition	O
","	O
and	O
dynamic	O
contrast-enhanced	O
magnetic	O
resonance	O
imaging	O
(	O
DCE-MRI	O
)	O
was	O
performed	O
as	O
an	O
indicator	O
of	O
tumor	O
perfusion	O
changes	O
","	O
at	O
3	O
time	O
points	O
.	O
	
Everolimus	B-DRUG
and	O
cetuximab	B-DRUG
were	O
tolerable	O
at	O
full	O
doses	O
","	O
with	O
an	O
expected	O
toxicity	O
profile	O
.	O
	
Dose-limiting	O
toxicities	O
in	O
the	O
everolimus	B-DRUG
70	O
mg	O
group	O
included	O
grade	O
3	O
skin	B-TOXI
toxicity	I-TOXI
in	O
2	O
patients	O
","	O
and	O
mucositis	B-TOXI
in	O
1	O
patient	O
.	O
	
Of	O
16	O
patients	O
evaluable	O
for	O
response	O
","	O
5	O
had	O
stable	O
disease	O
lasting	O
4	O
to	O
19	O
months	O
.	O
	
Mean	O
change	O
in	O
maximum	O
standardized	O
uptake	O
value	O
(	O
SUV	O
(	O
max	O
)	O
)	O
for	O
those	O
treated	O
initially	O
with	O
everolimus	B-DRUG
was	O
-24	O
%	O
(	O
2	O
%	O
to	O
-54	O
%	O
)	O
","	O
and	O
with	O
cetuximab	B-DRUG
was	O
-5	O
%	O
(	O
-23	O
to	O
36	O
%	O
)	O
.	O
	
The	O
K	O
(	O
trans	O
)	O
measured	O
by	O
DCE-MRI	O
did	O
not	O
decrease	O
","	O
regardless	O
of	O
run-in	O
drug	O
.	O
	
Everolimus	B-DRUG
and	O
cetuximab	B-DRUG
can	O
be	O
safely	O
administered	O
at	O
standard	O
doses	O
","	O
and	O
are	O
associated	O
with	O
prolonged	O
disease	O
control	O
.	O
	
The	O
recommended	O
phase	O
2	O
dose	O
of	O
oral	O
weekly	O
everolimus	B-DRUG
is	O
70	O
mg	O
in	O
combination	O
with	O
standard	O
cetuximab	B-DRUG
.	O
	
Imaging	O
studies	O
reveal	O
that	O
metabolic	O
inhibition	O
by	O
everolimus	B-DRUG
alone	O
and	O
in	O
combination	O
with	O
cetuximab	B-DRUG
predominates	O
over	O
changes	O
in	O
tumor	O
perfusion	O
in	O
this	O
patient	O
population	O
.	O
	
Cisplatin	B-DRUG
","	O
vinblastine	B-DRUG
","	O
and	O
bleomycin	B-DRUG
in	O
inoperable	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
Forty	O
two	O
patients	O
with	O
inoperable	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
were	O
entered	O
into	O
a	O
phase	O
II	O
study	O
of	O
the	O
combination	O
chemotherapy	O
regimen	O
PVB	O
(	O
cisplatin	B-DRUG
60	O
mg	O
/	O
m2	O
by	O
intravenous	O
infusion	O
over	O
two	O
hours	O
on	O
day	O
1	O
","	O
vinblastine	B-DRUG
4	O
mg	O
/	O
m2	O
by	O
intravenous	O
bolus	O
on	O
days	O
1	O
and	O
2	O
","	O
and	O
bleomycin	B-DRUG
15	O
mg	O
intramuscularly	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
)	O
","	O
repeated	O
at	O
three	O
weekly	O
intervals	O
.	O
	
Twelve	O
of	O
40	O
evaluable	O
patients	O
(	O
30	O
%	O
)	O
achieved	O
partial	O
responses	O
;	O
there	O
were	O
no	O
complete	O
responses	O
.	O
	
The	O
median	O
duration	O
of	O
response	O
was	O
16	O
weeks	O
(	O
range	O
greater	O
than	O
8-73	O
weeks	O
)	O
.	O
	
The	O
median	O
survival	O
of	O
responding	O
patients	O
calculated	O
from	O
entry	O
to	O
the	O
study	O
until	O
death	B-TOXI
(	O
40	O
weeks	O
)	O
was	O
superior	O
to	O
that	O
of	O
patients	O
failing	O
to	O
respond	O
(	O
15	O
weeks	O
)	O
.	O
	
Treatment	O
was	O
accompanied	O
by	O
signs	O
of	O
moderate	O
toxicity	O
","	O
particularly	B-TOXI
myelosuppression	I-TOXI
","	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
","	O
alopecia	B-TOXI
","	O
and	O
neuropathy	B-TOXI
.	O
	
One	O
patient	O
died	B-TOXI
from	O
a	O
neutropenic	B-TOXI
infection	I-TOXI
.	O
	
PVB	O
is	O
a	O
moderately	O
toxic	O
regimen	O
for	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
and	O
appears	O
similar	O
in	O
efficacy	O
and	O
toxicity	O
to	O
high	O
dose	O
cisplatin	B-DRUG
and	O
vindesine	B-DRUG
.	O
	
Phase	O
I	O
trial	O
of	O
carboplatin	B-DRUG
and	O
etoposide	B-DRUG
in	O
combination	O
with	O
panobinostat	B-DRUG
in	O
patients	O
with	O
lung	B-CANCER
cancer	I-CANCER
.	O
	
	
A	O
phase	O
I	O
trial	O
consisting	O
of	O
panobinostat	B-DRUG
(	O
a	O
HDAC	O
inhibitor	O
)	O
","	O
carboplatin	B-DRUG
and	O
etoposide	B-DRUG
was	O
conducted	O
in	O
patients	O
with	O
lung	B-CANCER
cancer	I-CANCER
.	O
	
Patients	O
received	O
carboplatin	B-DRUG
AUC5	O
on	O
day	O
1	O
and	O
etoposide	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
","	O
2	O
and	O
3	O
","	O
every	O
21	O
days	O
.	O
	
Concurrent	O
oral	B-DRUG
panobinostat	I-DRUG
was	O
given	O
3	O
times	O
weekly	O
on	O
a	O
2-weeks-on	O
and	O
1-week-off	O
schedule	O
during	O
the	O
4月6日	O
cycles	O
of	O
chemotherapy	O
and	O
then	O
continued	O
as	O
maintenance	O
therapy	O
.	O
	
Six	O
evaluable	O
patients	O
were	O
treated	O
at	O
the	O
first	O
dose	O
level	O
of	O
panobinostat	B-DRUG
(	O
10	O
mg	O
)	O
.	O
	
Dose-limiting	O
toxicity	O
occurred	O
in	O
two	O
patients	O
(	O
33	O
%	O
)	O
during	O
the	O
first	O
cycle	O
.	O
	
One	O
patient	O
developed	O
grade	O
4	O
thrombocytopenia	B-TOXI
and	O
another	O
grade	O
4	O
febrile	B-TOXI
neutropenia	I-TOXI
.	O
	
Therefore	O
","	O
the	O
study	O
was	O
suspended	O
based	O
on	O
the	O
pre-specified	O
study	O
design	O
.	O
	
No	O
recommended	O
phase	O
II	O
starting	O
dose	O
was	O
established	O
.	O
	
The	O
addition	O
of	O
panobinostat	B-DRUG
to	O
carboplatin	B-DRUG
and	O
etoposide	B-DRUG
was	O
not	O
tolerable	O
at	O
the	O
lowest	O
dose	O
level	O
tested	O
in	O
this	O
trial	O
.	O
	
Further	O
research	O
and	O
development	O
into	O
this	O
combination	O
is	O
not	O
recommended	O
.	O
	
Increased	O
survival	O
in	O
pancreatic	B-CANCER
cancer	I-CANCER
with	O
nab-paclitaxel	B-DRUG
plus	O
gemcitabine	B-DRUG
.	O
	
	
In	O
a	O
phase	O
1月2日	O
trial	O
of	O
albumin-bound	B-DRUG
paclitaxel	B-DRUG
(	O
nab-paclitaxel	B-DRUG
)	O
plus	O
gemcitabine	B-DRUG
","	O
substantial	O
clinical	O
activity	O
was	O
noted	O
in	O
patients	O
with	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
We	O
conducted	O
a	O
phase	O
3	O
study	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
the	O
combination	O
versus	O
gemcitabine	B-DRUG
monotherapy	O
in	O
patients	O
with	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
We	O
randomly	O
assigned	O
patients	O
with	O
a	O
Karnofsky	O
performance-status	O
score	O
of	O
70	O
or	O
more	O
(	O
on	O
a	O
scale	O
from	O
0	O
to	O
100	O
","	O
with	O
higher	O
scores	O
indicating	O
better	O
performance	O
status	O
)	O
to	O
nab-paclitaxel	B-DRUG
(	O
125	O
mg	O
per	O
square	O
meter	O
of	O
body-surface	O
area	O
)	O
followed	O
by	O
gemcitabine	B-DRUG
(	O
1000	O
mg	O
per	O
square	O
meter	O
)	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
every	O
4	O
weeks	O
or	O
gemcitabine	B-DRUG
monotherapy	O
(	O
1000	O
mg	O
per	O
square	O
meter	O
)	O
weekly	O
for	O
7	O
of	O
8	O
weeks	O
(	O
cycle	O
1	O
)	O
and	O
then	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
every	O
4	O
weeks	O
(	O
cycle	O
2	O
and	O
subsequent	O
cycles	O
)	O
.	O
	
Patients	O
received	O
the	O
study	O
treatment	O
until	O
disease	O
progression	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
overall	O
survival	O
;	O
secondary	O
end	O
points	O
were	O
progression-free	O
survival	O
and	O
overall	O
response	O
rate	O
.	O
	
A	O
total	O
of	O
861	O
patients	O
were	O
randomly	O
assigned	O
to	O
nab-paclitaxel	B-DRUG
plus	O
gemcitabine	B-DRUG
(	O
431	O
patients	O
)	O
or	O
gemcitabine	B-DRUG
(	O
430	O
)	O
.	O
	
The	O
median	O
overall	O
survival	O
was	O
8.5	O
months	O
in	O
the	O
nab-paclitaxel-gemcitabine	B-DRUG
group	O
as	O
compared	O
with	O
6.7	O
months	O
in	O
the	O
gemcitabine	B-DRUG
group	O
(	O
hazard	O
ratio	O
for	O
death	O
","	O
0.72	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
0.62	O
to	O
0.83	O
;	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
.	O
	
The	O
survival	O
rate	O
was	O
35	O
%	O
in	O
the	O
nab-paclitaxel-gemcitabine	B-DRUG
group	O
versus	O
22	O
%	O
in	O
the	O
gemcitabine	B-DRUG
group	O
at	O
1	O
year	O
","	O
and	O
9	O
%	O
versus	O
4	O
%	O
at	O
2	O
years	O
.	O
	
The	O
median	O
progression-free	O
survival	O
was	O
5.5	O
months	O
in	O
the	O
nab-paclitaxel-gemcitabine	B-DRUG
group	O
","	O
as	O
compared	O
with	O
3.7	O
months	O
in	O
the	O
gemcitabine	B-DRUG
group	O
(	O
hazard	O
ratio	O
for	O
disease	O
progression	O
or	O
death	B-TOXI
","	O
0.69	O
;	O
95	O
%	O
CI	O
","	O
0.58	O
to	O
0.82	O
;	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
;	O
the	O
response	O
rate	O
according	O
to	O
independent	O
review	O
was	O
23	O
%	O
versus	O
7	O
%	O
in	O
the	O
two	O
groups	O
(	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
.	O
	
The	O
most	O
common	O
adverse	O
events	O
of	O
grade	O
3	O
or	O
higher	O
were	O
neutropenia	B-TOXI
(	O
38	O
%	O
in	O
the	O
nab-paclitaxel-gemcitabine	B-DRUG
group	O
vs.	O
27	O
%	O
in	O
the	O
gemcitabine	B-DRUG
group	O
)	O
","	O
fatigue	B-TOXI
(	O
17	O
%	O
vs.	O
7	O
%	O
)	O
","	O
and	O
neuropathy	B-TOXI
(	O
17	O
%	O
vs.	O
1	O
%	O
)	O
.	O
	
Febrile	B-TOXI
neutropenia	I-TOXI
occurred	O
in	O
3	O
%	O
versus	O
1	O
%	O
of	O
the	O
patients	O
in	O
the	O
two	O
groups	O
.	O
	
In	O
the	O
nab-paclitaxel-gemcitabine	B-DRUG
group	O
","	O
neuropathy	B-TOXI
of	O
grade	O
3	O
or	O
higher	O
improved	O
to	O
grade	O
1	O
or	O
lower	O
in	O
a	O
median	O
of	O
29	O
days	O
.	O
	
In	O
patients	O
with	O
metastatic	B-CANCER
pancreatic	I-CANCER
adenocarcinoma	I-CANCER
","	O
nab-paclitaxel	B-DRUG
plus	O
gemcitabine	B-DRUG
significantly	O
improved	O
overall	O
survival	O
","	O
progression-free	O
survival	O
","	O
and	O
response	O
rate	O
","	O
but	O
rates	O
of	O
peripheral	B-TOXI
neuropathy	I-TOXI
and	O
myelosuppression	B-TOXI
were	O
increased	O
.	O
	
(	O
Funded	O
by	O
Celgene	O
;	O
ClinicalTrials.gov	O
number	O
","	O
NCT00844649.	O
)	O
.	O
	
Phase	O
I	O
trial	O
of	O
preoperative	O
chemoradiation	O
plus	O
sorafenib	B-DRUG
for	O
high-risk	O
extremity	O
soft	B-CANCER
tissue	I-CANCER
sarcomas	I-CANCER
with	O
dynamic	O
contrast-enhanced	O
MRI	O
correlates	O
.	O
	
	
We	O
conducted	O
a	O
phase	O
I	O
trial	O
of	O
the	O
addition	O
of	O
sorafenib	B-DRUG
to	O
a	O
chemoradiotherapy	O
regimen	O
in	O
patients	O
with	O
high-risk	O
(	O
intermediate	O
/	O
high	O
grade	O
","	O
&	O
gt	O
;	O
5	O
cm	O
)	O
extremity	O
soft	B-CANCER
tissue	I-CANCER
sarcoma	I-CANCER
undergoing	O
limb	O
salvage	O
surgery	O
.	O
	
We	O
conducted	O
a	O
correlative	O
study	O
of	O
quantitative	O
dynamic	O
contrast-enhanced	O
MRI	O
(	O
DCE-MRI	O
)	O
to	O
assess	O
response	O
to	O
treatment	O
.	O
	
Patients	O
were	O
treated	O
at	O
increasing	O
dose	O
levels	O
of	O
sorafenib	B-DRUG
(	O
200	O
mg	O
daily	O
","	O
400	O
mg	O
daily	O
","	O
400	O
mg	O
twice	O
daily	O
)	O
initiated	O
14	O
days	O
before	O
three	O
preoperative	O
and	O
three	O
postoperative	O
cycles	O
of	O
epirubicin	B-DRUG
/	O
ifosfamide	B-DRUG
.	O
	
Radiation	O
(	O
28	O
Gy	O
)	O
was	O
administered	O
during	O
cycle	O
2	O
with	O
epirubicin	B-DRUG
omitted	O
.	O
	
The	O
primary	O
objective	O
was	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
sorafenib	B-DRUG
.	O
	
DCE-MRI	O
was	O
conducted	O
at	O
baseline	O
","	O
after	O
2	O
weeks	O
of	O
sorafenib	B-DRUG
","	O
and	O
before	O
surgery	O
.	O
	
The	O
imaging	O
data	O
were	O
subjected	O
to	O
quantitative	O
pharmacokinetic	O
analyses	O
.	O
	
Eighteen	O
subjects	O
were	O
enrolled	O
","	O
of	O
which	O
16	O
were	O
evaluable	O
.	O
	
The	O
MTD	O
of	O
sorafenib	B-DRUG
was	O
400	O
mg	O
daily	O
.	O
	
Common	O
grade	O
3月4日	O
adverse	O
events	O
included	O
neutropenia	B-TOXI
(	O
94	O
%	O
)	O
","	O
hypophosphatemia	B-TOXI
(	O
75	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
69	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
50	O
%	O
)	O
","	O
and	O
neutropenic	B-TOXI
fever	I-TOXI
/	O
infection	B-TOXI
(	O
50	O
%	O
)	O
.	O
	
Of	O
note	O
","	O
38	O
%	O
developed	O
wound	O
complications	O
requiring	O
surgical	O
intervention	O
.	O
	
The	O
rate	O
of	O
_95	O
%	O
histopathologic	B-TOXI
tumor	I-TOXI
necrosis	I-TOXI
was	O
44	O
%	O
.	O
	
Changes	O
in	O
DCE-MRI	O
biomarker	O
_K	O
(	O
trans	O
)	O
after	O
2	O
weeks	O
of	O
sorafenib	B-DRUG
correlated	O
with	O
histologic	O
response	O
(	O
R	O
(	O
2	O
)	O
=	O
0.67	O
","	O
P	O
=	O
0.012	O
)	O
at	O
surgery	O
.	O
	
The	O
addition	O
of	O
sorafenib	B-DRUG
to	O
preoperative	O
chemoradiotherapy	O
is	O
feasible	O
and	O
warrants	O
further	O
investigation	O
in	O
a	O
larger	O
trial	O
.	O
	
DCE-MRI	O
detected	O
changes	O
in	O
tumor	O
perfusion	O
after	O
2	O
weeks	O
of	O
sorafenib	O
and	O
may	O
be	O
a	O
minimally	O
invasive	O
tool	O
for	O
rapid	O
assessment	O
of	O
drug	O
effect	O
in	O
soft	B-CANCER
tissue	I-CANCER
sarcoma	I-CANCER
.	O
	
PointBreak	O
:	O
a	O
randomized	O
phase	O
III	O
study	O
of	O
pemetrexed	B-DRUG
plus	O
carboplatin	B-DRUG
and	O
bevacizumab	B-DRUG
followed	O
by	O
maintenance	O
pemetrexed	B-DRUG
and	O
bevacizumab	B-DRUG
versus	O
paclitaxel	B-DRUG
plus	O
carboplatin	B-DRUG
and	O
bevacizumab	B-DRUG
followed	O
by	O
maintenance	O
bevacizumab	B-DRUG
in	O
patients	O
with	O
stage	O
IIIB	O
or	O
IV	O
nonsquamous	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
PointBreak	O
(	O
A	O
Study	O
of	O
Pemetrexed	B-DRUG
","	O
Carboplatin	B-DRUG
and	O
Bevacizumab	B-DRUG
in	O
Patients	O
With	O
Nonsquamous	B-CANCER
Non-Small	I-CANCER
Cell	I-CANCER
Lung	I-CANCER
Cancer	I-CANCER
)	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
pemetrexed	B-DRUG
(	O
Pem	O
)	O
plus	O
carboplatin	B-DRUG
(	O
C	O
)	O
plus	O
bevacizumab	B-DRUG
(	O
Bev	O
)	O
followed	O
by	O
pemetrexed	B-DRUG
plus	O
bevacizumab	B-DRUG
(	O
PemCBev	O
)	O
with	O
paclitaxel	B-DRUG
(	O
Pac	O
)	O
plus	O
carboplatin	B-DRUG
(	O
C	O
)	O
plus	O
bevacizumab	B-DRUG
(	O
Bev	O
)	O
followed	O
by	O
bevacizumab	B-DRUG
(	O
PacCBev	O
)	O
in	O
patients	O
with	O
advanced	O
nonsquamous	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Patients	O
with	O
previously	O
untreated	O
stage	O
IIIB	O
or	O
IV	O
nonsquamous	B-CANCER
NSCLC	I-CANCER
and	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
to	O
1	O
were	O
randomly	O
assigned	O
to	O
receive	O
pemetrexed	B-DRUG
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
or	O
paclitaxel	B-DRUG
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
combined	O
with	O
carboplatin	B-DRUG
area	O
under	O
the	O
curve	O
6	O
and	O
bevacizumab	B-DRUG
15	O
mg	O
/	O
kg	O
every	O
3	O
weeks	O
for	O
up	O
to	O
four	O
cycles	O
.	O
	
Eligible	O
patients	O
received	O
maintenance	O
until	O
disease	O
progression	O
:	O
pemetrexed	B-DRUG
plus	O
bevacizumab	B-DRUG
(	O
for	O
the	O
PemCBev	O
group	O
)	O
or	O
bevacizumab	B-DRUG
(	O
for	O
the	O
PacCBev	O
group	O
)	O
.	O
	
The	O
primary	O
end	O
point	O
of	O
this	O
superiority	O
study	O
was	O
overall	O
survival	O
(	O
OS	O
)	O
.	O
	
Patients	O
were	O
randomly	O
assigned	O
to	O
PemCBev	O
(	O
n	O
=	O
472	O
)	O
or	O
PacCBev	O
(	O
n	O
=	O
467	O
)	O
.	O
	
For	O
PemCBev	O
versus	O
PacCBev	O
","	O
OS	O
hazard	O
ratio	O
(	O
HR	O
)	O
was	O
1	O
(	O
median	O
OS	O
","	O
12.6	O
v	O
13.4	O
months	O
;	O
P	O
=	O
0.949	O
)	O
;	O
progression-free	O
survival	O
(	O
PFS	O
)	O
HR	O
was	O
0.83	O
(	O
median	O
PFS	O
","	O
6	O
v	O
5.6	O
months	O
;	O
P	O
=	O
0.012	O
)	O
;	O
overall	O
response	O
rate	O
was	O
34.1	O
%	O
versus	O
33	O
%	O
;	O
and	O
disease	O
control	O
rate	O
was	O
65.9	O
%	O
versus	O
69.8	O
%	O
.	O
	
Significantly	O
more	O
study	O
drug-related	O
grade	O
3	O
or	O
4	O
anemia	B-TOXI
(	O
14.5	O
%	O
v	O
2.7	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
23.3	O
%	O
v	O
5.6	O
%	O
)	O
","	O
and	O
fatigue	B-TOXI
(	O
10.9	O
%	O
v	O
5	O
%	O
)	O
occurred	O
with	O
PemCBev	O
;	O
significantly	O
more	O
grade	O
3	O
or	O
4	O
neutropenia	B-TOXI
(	O
40.6	O
%	O
v	O
25.8	O
%	O
)	O
","	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
4.1	O
%	O
v	O
1.4	O
%	O
)	O
","	O
sensory	B-TOXI
neuropathy	I-TOXI
(	O
4.1	O
%	O
v	O
0	O
%	O
)	O
","	O
and	O
alopecia	B-TOXI
(	O
grade	O
1	O
or	O
2	O
;	O
36.8	O
%	O
v	O
6.6	O
%	O
)	O
occurred	O
with	O
PacCBev	O
.	O
	
OS	O
did	O
not	O
improve	O
with	O
the	O
PemCBev	O
regimen	O
compared	O
with	O
the	O
PacCBev	O
regimen	O
","	O
although	O
PFS	O
was	O
significantly	O
improved	O
with	O
PemCBev	O
.	O
	
Toxicity	O
profiles	O
differed	O
;	O
both	O
regimens	O
demonstrated	O
tolerability	O
.	O
	
A	O
dose-escalating	O
phase	O
I	O
of	O
imatinib	B-DRUG
mesylate	I-DRUG
with	O
fixed	O
dose	O
of	O
metronomic	O
cyclophosphamide	B-DRUG
in	O
targeted	O
solid	B-CANCER
tumours	I-CANCER
.	O
	
	
Preclinical	O
findings	O
suggest	O
that	O
imatinib	B-DRUG
mesylate	I-DRUG
(	O
IM	O
)	O
and	O
metronomic	B-DRUG
cyclophosphamide	I-DRUG
(	O
MC	O
)	O
combination	O
provides	O
synergistic	O
antiangiogenic	O
activity	O
on	O
both	O
pericytes	O
and	O
endothelial	O
cells	O
.	O
	
We	O
have	O
designed	O
a	O
3+3	O
dose-escalating	O
phase	O
I	O
trial	O
with	O
a	O
fixed	O
dose	O
of	O
MC	O
(	O
50	O
mg	O
two	O
times	O
daily	O
)	O
plus	O
IM	O
(	O
400	O
mg	O
per	O
day	O
;	O
300	O
and	O
400	O
mg	O
two	O
times	O
daily	O
)	O
.	O
	
Enrolled	O
patients	O
had	O
IM-	O
and	O
sutininib-refractory	B-DRUG
advanced	B-CANCER
gastrointestinal	I-CANCER
stromal	I-CANCER
tumours	I-CANCER
(	O
GIST	B-CANCER
)	O
(	O
n=17	O
)	O
","	O
chordoma	B-CANCER
(	O
n=7	O
)	O
and	O
mucosal	B-CANCER
melanoma	I-CANCER
(	O
n=2	O
)	O
.	O
	
Dose-limiting	O
toxicities	O
were	O
monitored	O
for	O
the	O
first	O
6	O
weeks	O
.	O
	
Progression-free	O
survival	O
(	O
PFS	O
)	O
and	O
response	O
assessment	O
are	O
based	O
on	O
RECIST	O
1	O
guidelines	O
.	O
	
Pharmacokinetics	O
of	O
IM	O
were	O
measured	O
before	O
and	O
after	O
exposure	O
to	O
MC	O
.	O
	
No	O
dose-limiting	O
toxicity	O
was	O
observed	O
.	O
	
Fourteen	O
patients	O
of	O
the	O
expanded	O
cohort	O
received	O
400	O
mg	O
two	O
times	O
daily	O
of	O
IM	O
with	O
MC	O
.	O
	
Apart	O
from	O
a	O
case	O
of	O
possibly	O
related	O
acute	O
leukaemia	B-CANCER
occurring	O
after	O
4	O
years	O
of	O
treatment	O
","	O
we	O
did	O
not	O
see	O
unexpected	O
toxicity	O
.	O
	
No	O
drug-drug	O
pharmacokinetic	O
interaction	O
was	O
observed	O
.	O
	
There	O
was	O
no	O
objective	O
response	O
.	O
	
We	O
have	O
observed	O
long-lasting	O
stable	O
disease	O
in	O
chordoma	B-CANCER
patients	O
(	O
median	O
PFS=10.2	O
months	O
;	O
range	O
","	O
4.2-18+	O
)	O
and	O
short-term	O
stable	O
disease	O
in	O
heavily	O
GIST	O
pretreated	O
patients	O
(	O
median	O
PFS=2.3	O
months	O
;	O
range	O
","	O
2.1-6.6	O
)	O
.	O
	
This	O
combination	O
is	O
feasible	O
and	O
may	O
warrant	O
further	O
exploration	O
in	O
refractory	O
GIST	B-DRUG
or	O
chordoma	B-DRUG
patients	O
.	O
	
Phase	O
II	O
trial	O
of	O
carboplatin	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
cetuximab	B-DRUG
","	O
and	O
bevacizumab	B-DRUG
followed	O
by	O
cetuximab	B-DRUG
and	O
bevacizumab	B-DRUG
in	O
advanced	B-CANCER
nonsquamous	I-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
SWOG	O
S0536	O
.	O
	
	
Cetuximab	B-DRUG
and	O
bevacizumab	B-DRUG
have	O
each	O
been	O
demonstrated	O
to	O
prolong	O
survival	O
when	O
added	O
to	O
chemotherapy	O
in	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
However	O
","	O
the	O
potential	O
benefit	O
of	O
combining	O
cetuximab	B-DRUG
and	O
bevacizumab	B-DRUG
together	O
with	O
a	O
platinum-based	B-DRUG
doublet	O
had	O
not	O
been	O
explored	O
.	O
	
We	O
designed	O
this	O
phase	O
II	O
trial	O
to	O
evaluate	O
the	O
safety	O
","	O
tolerability	O
","	O
and	O
efficacy	O
of	O
the	O
combination	O
of	O
carboplatin	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
cetuximab	B-DRUG
","	O
and	O
bevacizumab	B-DRUG
in	O
chemotherapy-naive	O
patients	O
with	O
advanced	O
","	O
nonsquamous	B-CANCER
NSCLC	I-CANCER
.	O
	
Patients	O
received	O
with	O
up	O
to	O
six	O
cycles	O
of	O
carboplatin	B-DRUG
(	O
area	O
under	O
curve	O
6	O
)	O
","	O
paclitaxel	B-DRUG
(	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
cetuximab	B-DRUG
(	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
day	O
1	O
then	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
)	O
","	O
and	O
bevacizumab	B-DRUG
(	O
15	O
mg	O
/	O
kg	O
)	O
every	O
21	O
days	O
.	O
	
Patients	O
with	O
an	O
objective	O
response	O
or	O
stable	O
disease	O
received	O
maintenance	O
cetuximab	B-DRUG
(	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
)	O
and	O
bevacizumab	B-DRUG
(	O
15	O
mg	O
/	O
kg	O
every	O
21	O
days	O
)	O
until	O
disease	O
progression	O
.	O
	
The	O
primary	O
endpoint	O
was	O
safety	O
as	O
defined	O
by	O
the	O
frequency	O
and	O
severity	O
of	O
hemorrhagic	B-TOXI
toxicities	I-TOXI
.	O
	
Secondary	O
endpoints	O
included	O
response	O
rate	O
","	O
progression-free	O
survival	O
","	O
overall	O
survival	O
","	O
and	O
toxicity	O
.	O
	
Molecular	O
biomarkers	O
were	O
assessed	O
in	O
an	O
exploratory	O
manner	O
.	O
	
The	O
primary	O
endpoint	O
of	O
grade	O
4	O
or	O
higher	B-TOXI
hemorrhage	I-TOXI
of	O
2	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
0	O
%	O
-7	O
%	O
)	O
met	O
prespecified	O
criteria	O
for	O
safety	O
.	O
	
One	O
hundred	O
ten	O
patients	O
were	O
enrolled	O
.	O
	
There	O
were	O
four	O
treatment-related	O
deaths	B-TOXI
including	O
lung	B-TOXI
hemorrhage	I-TOXI
(	O
2	O
)	O
","	O
infection	B-TOXI
(	O
1	O
)	O
","	O
and	O
unknown	O
(	O
1	O
)	O
.	O
	
Median	O
progression-free	O
survival	O
was	O
7	O
months	O
and	O
median	O
overall	O
survival	O
was	O
15	O
months	O
.	O
	
The	O
response	O
rate	O
was	O
56	O
%	O
with	O
an	O
overall	O
disease	O
control	O
rate	O
of	O
77	O
%	O
.	O
	
This	O
regimen	O
was	O
safe	O
","	O
feasible	O
","	O
and	O
effective	O
as	O
a	O
frontline	O
treatment	O
of	O
advanced	B-CANCER
NSCLC	I-CANCER
","	O
providing	O
the	O
basis	O
for	O
the	O
ongoing	O
phase	O
III	O
trial	O
S0819	O
.	O
	
A	O
phase	O
1b	O
clinical	O
trial	O
of	O
the	O
multi-targeted	O
tyrosine	O
kinase	O
inhibitor	O
lenvatinib	B-DRUG
(	O
E7080	O
)	O
in	O
combination	O
with	O
everolimus	B-DRUG
for	O
treatment	O
of	O
metastatic	B-CANCER
renal	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
RCC	B-CANCER
)	O
.	O
	
	
Lenvatinib	B-DRUG
is	O
an	O
oral	O
multi-targeted	O
tyrosine	O
kinase	O
inhibitor	O
of	O
VEGFR1-3	O
","	O
FGFR1-4	O
","	O
PDGFR尾	O
","	O
RET	O
","	O
and	O
KIT	O
.	O
	
Everolimus	B-DRUG
is	O
an	O
oral	O
mammalian	O
target	O
of	O
rapamycin	O
inhibitor	O
approved	O
for	O
advanced	B-CANCER
renal	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
RCC	B-CANCER
)	O
.	O
	
This	O
phase	O
1b	O
study	O
assessed	O
safety	O
","	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
and	O
preliminary	O
antitumor	O
activity	O
of	O
lenvatinib	B-DRUG
plus	O
everolimus	B-DRUG
in	O
metastatic	B-CANCER
RCC	I-CANCER
(	O
mRCC	B-CANCER
)	O
patients	O
.	O
	
Patients	O
with	O
advanced	O
unresectable	O
or	O
mRCC	B-CANCER
and	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
0-1	O
were	O
eligible	O
(	O
number	O
of	O
prior	O
treatments	O
not	O
restricted	O
)	O
.	O
	
Starting	O
dose	O
was	O
lenvatinib	B-DRUG
12	O
mg	O
once	O
daily	O
with	O
everolimus	B-DRUG
5	O
mg	O
once	O
daily	O
administered	O
continuously	O
in	O
28-day	O
cycles	O
using	O
a	O
conventional	O
3	O
=+	O
3	O
dose-escalation	O
design	O
.	O
	
At	O
the	O
MTD	O
","	O
additional	O
patients	O
were	O
enrolled	O
in	O
an	O
expansion	O
cohort	O
.	O
	
Twenty	O
patients	O
(	O
mean	O
58.4	O
years	O
)	O
received	O
lenvatinib	B-DRUG
[	O
12	O
mg	O
(	O
n	O
=	O
7	O
)	O
;	O
18	O
mg	O
(	O
n	O
=	O
11	O
)	O
;	O
24	O
mg	O
(	O
n	O
=	O
2	O
)	O
]	O
plus	O
everolimus	B-DRUG
5	O
mg	O
.	O
	
MTD	O
was	O
established	O
as	O
once	O
daily	O
lenvatinib	B-DRUG
18	O
mg	O
plus	O
everolimus	B-DRUG
5	O
mg	O
.	O
	
The	O
most	O
common	O
treatment-related	O
treatment-emergent	O
adverse	O
events	O
(	O
all	O
dosing	O
cohorts	O
)	O
were	O
fatigue	B-TOXI
60	O
%	O
(	O
Grade	O
_3	O
:	O
10	O
%	O
)	O
","	O
mucosal	B-TOXI
inflammation	I-TOXI
50	O
%	O
","	O
proteinuria	B-TOXI
(	O
Grade	O
_3	O
:	O
15	O
%	O
)	O
","	O
diarrhea	B-TOXI
(	O
Grade	O
_3	O
:	O
10	O
%	O
)	O
","	O
vomiting	B-TOXI
(	O
Grade	O
_3	O
:	O
5	O
%	O
)	O
","	O
hypertension	B-TOXI
","	O
and	O
nausea	B-TOXI
","	O
each	O
40	O
%	O
.	O
	
In	O
MTD	O
and	O
lowest-dose	O
cohorts	O
(	O
n	O
=	O
18	O
)	O
","	O
best	O
responses	O
of	O
partial	O
response	O
and	O
stable	O
disease	O
were	O
achieved	O
in	O
6	O
(	O
33	O
%	O
)	O
and	O
9	O
(	O
50	O
%	O
)	O
patients	O
","	O
respectively	O
.	O
	
Lenvatinib	B-DRUG
18	O
mg	O
combined	O
with	O
everolimus	B-DRUG
5	O
mg	O
was	O
associated	O
with	O
manageable	O
toxicity	O
consistent	O
with	O
individual	O
agents	O
and	O
no	O
new	O
safety	O
signals	O
.	O
	
Observed	O
activity	O
warrants	O
further	O
evaluation	O
of	O
the	O
combination	O
in	O
advanced	B-CANCER
RCC	I-CANCER
patients	O
.	O
	
A	O
phase	O
1	O
study	O
evaluating	O
the	O
combination	O
of	O
an	O
allosteric	O
AKT	O
inhibitor	O
(	O
MK-2206	O
)	O
and	O
trastuzumab	B-DRUG
in	O
patients	O
with	O
HER2-positive	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
Trastuzumab	B-DRUG
is	O
effective	O
in	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
(	O
HER2	O
)	O
#NAME?	O
breast	B-CANCER
and	I-CANCER
gastric	I-CANCER
cancers	I-CANCER
.	O
	
However	O
","	O
patients	O
may	O
develop	O
resistance	O
through	O
downstream	O
signaling	O
via	O
the	O
phosphatidylinositol	O
3-kinase	O
(	O
PI3K	O
)	O
/	O
AKT	O
pathway	O
.	O
	
This	O
phase	O
1	O
trial	O
was	O
conducted	O
to	O
determine	O
the	O
safety	O
and	O
tolerability	O
of	O
the	O
investigational	O
AKT	O
inhibitor	O
MK-2206	B-DRUG
","	O
to	O
prepare	O
for	O
future	O
studies	O
to	O
determine	O
whether	O
the	O
combination	O
with	O
trastuzumab	B-DRUG
could	O
inhibit	O
compensatory	O
signaling	O
.	O
	
Patients	O
with	O
HER2+	O
treatment-refractory	O
breast	B-CANCER
and	I-CANCER
gastroesophageal	I-CANCER
cancer	I-CANCER
were	O
enrolled	O
.	O
	
Treatment	O
consisted	O
of	O
standard	O
doses	O
of	O
intravenous	O
trastuzumab	B-DRUG
and	O
escalating	O
dose	O
levels	O
of	O
oral	O
MK-2206	B-DRUG
using	O
either	O
an	O
every-other-day	O
(	O
45	O
mg	O
and	O
60	O
mg	O
QOD	O
)	O
or	O
once-weekly	O
(	O
135	O
mg	O
and	O
200	O
mg	O
QW	O
)	O
schedule	O
.	O
	
A	O
total	O
of	O
34	O
patients	O
with	O
HER2+	O
disease	O
were	O
enrolled	O
;	O
31	O
received	O
study-drug	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
for	O
MK-2206	B-DRUG
in	O
combination	O
with	O
trastuzumab	B-DRUG
was	O
60	O
mg	O
for	O
the	O
QOD	O
schedule	O
and	O
135	O
mg	O
for	O
the	O
QW	O
schedule	O
","	O
although	O
a	O
TRUE	O
MTD	O
was	O
not	O
established	O
due	O
to	O
early	O
termination	O
of	O
the	O
trial	O
.	O
	
The	O
most	O
common	O
treatment-emergent	O
toxicities	O
included	O
fatigue	B-TOXI
","	O
hyperglycemia	B-TOXI
","	O
and	O
dermatologic	B-TOXI
rash	I-TOXI
","	O
consistent	O
with	O
prior	O
experience	O
;	O
one	O
death	B-TOXI
unrelated	O
to	O
treatment	O
was	O
reported	O
.	O
	
There	O
was	O
one	O
complete	O
response	O
in	O
a	O
patient	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
","	O
one	O
patient	O
achieved	O
a	O
partial	O
response	O
","	O
and	O
5	O
patients	O
had	O
stable	O
disease	O
for	O
at	O
least	O
4	O
months	O
","	O
despite	O
progression	O
on	O
multiple	O
prior	O
trastuzumab-	B-DRUG
and	O
lapatinib-based	B-DRUG
therapies	O
.	O
	
Results	O
also	O
indicate	O
that	O
trastuzumab	B-DRUG
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
MK-2206	B-DRUG
.	O
	
Results	O
suggest	O
the	O
AKT	O
inhibitor	O
MK-2206	B-DRUG
can	O
be	O
safely	O
combined	O
with	O
trastuzumab	B-DRUG
","	O
and	O
is	O
associated	O
with	O
clinical	O
activity	O
","	O
supporting	O
further	O
investigation	O
.	O
	
ClinicalTrials.gov	O
;	O
identifier	O
:	O
NCT00963547	O
.	O
	
Neoadjuvant	O
hyperfractionated-accelerated	O
radiotherapy	O
with	O
concomitant	O
chemotherapy	O
in	O
esophageal	B-CANCER
cancer	I-CANCER
:	O
phase	O
II	O
study	O
.	O
	
	
Concomitant	O
use	O
of	O
chemotherapy	O
and	O
a	O
radiation	O
dose	O
schedule	O
that	O
is	O
more	O
efficient	O
compared	O
to	O
conventional	O
radiotherapy	O
may	O
provide	O
better	O
outcomes	O
in	O
patients	O
with	O
esophageal	B-CANCER
cancer	I-CANCER
.	O
	
This	O
study	O
aimed	O
to	O
assess	O
the	O
efficacy	O
and	O
tolerability	O
of	O
neoadjuvant	O
cisplatin-based	B-DRUG
chemotherapy	O
and	O
hyperfractionated	O
accelerated	O
radiotherapy	O
regimen	O
in	O
this	O
group	O
of	O
patients	O
.	O
	
A	O
total	O
of	O
20	O
newly	O
diagnosed	O
treatment-na茂ve	O
esophageal	B-CANCER
cancer	I-CANCER
patients	O
were	O
included	O
in	O
the	O
study	O
.	O
	
Neoadjuvant	O
cisplatin	B-DRUG
and	O
5-FU	B-DRUG
were	O
given	O
with	O
28-day	O
intervals	O
in	O
a	O
total	O
of	O
three	O
courses	O
.	O
	
Along	O
with	O
the	O
third	O
course	O
of	O
chemotherapy	O
","	O
hyperfractionated	O
accelerated	O
radiotherapy	O
(	O
HART	O
)	O
was	O
given	O
with	O
the	O
following	O
dose	O
schedule	O
:	O
5760	O
cGy	O
/	O
36	O
fr	O
/	O
16	O
day	O
.	O
	
All	O
patients	O
could	O
receive	O
the	O
planned	O
RT	O
dose	O
of	O
5760	O
cGy	O
.	O
	
Odynophagia	B-TOXI
was	O
the	O
most	O
frequent	O
grade	O
III	O
acute	O
toxicity	O
(	O
50	O
%	O
)	O
.	O
	
None	O
of	O
the	O
acute	O
toxicity	O
reactions	O
required	O
treatment	O
discontinuation	O
.	O
	
Grade	O
III	O
or	O
higher	B-TOXI
subacute	I-TOXI
/	O
late	B-TOXI
toxicity	I-TOXI
occurred	O
in	O
10	O
patients	O
(	O
75	O
%	O
)	O
including	O
5	O
deaths	B-TOXI
","	O
mostly	B-TOXI
esophageal	I-TOXI
.	O
	
Radiologically	O
","	O
8	O
patients	O
(	O
40	O
%	O
)	O
had	O
complete	O
response	O
","	O
8	O
(	O
40	O
%	O
)	O
had	O
partial	O
response	O
","	O
and	O
3	O
(	O
15	O
%	O
)	O
had	O
stable	O
disease	O
","	O
with	O
only	O
1	O
patient	O
(	O
5	O
%	O
)	O
having	O
progressive	O
disease	O
.	O
	
Seven	O
patients	O
underwent	O
surgery	O
.	O
	
Overall	O
","	O
8	O
patients	O
(	O
40	O
%	O
)	O
had	O
local	O
control	O
.	O
	
The	O
5	O
years	O
overall	O
survival	O
rate	O
was	O
38.1	O
%	O
.	O
	
Neoadjuvant	O
hyperfractionated	O
accelerated	O
radiotherapy	O
plus	O
chemotherapy	O
may	O
help	O
to	O
target	O
local	O
disease	O
control	O
and	O
increase	O
survival	O
in	O
patients	O
with	O
esophageal	B-CANCER
cancer	I-CANCER
.	O
	
Further	O
studies	O
to	O
improve	O
neoadjuvant	O
and	O
radical	O
chemoradiotherapy	O
dose	O
schedules	O
are	O
warranted	O
for	O
maximum	O
tumor	O
control	O
rates	O
with	O
minimal	O
toxicity	O
.	O
	
A	O
Phase	O
II	O
Trial	O
of	O
Cetuximab	B-DRUG
","	O
Gemcitabine	B-DRUG
","	O
5-Fluorouracil	B-DRUG
","	O
and	O
Radiation	O
Therapy	O
in	O
Locally	O
Advanced	B-CANCER
Nonmetastatic	I-CANCER
Pancreatic	I-CANCER
Adenocarcinoma	I-CANCER
.	O
	
	
Pancreatic	B-CANCER
cancer	I-CANCER
is	O
the	O
fourth	O
leading	O
cause	O
of	O
cancer	O
deaths	B-TOXI
in	O
the	O
United	O
States	O
.	O
	
A	O
minority	O
of	O
patients	O
present	O
with	O
localized	O
disease	O
and	O
surgical	O
resection	O
still	O
offers	O
patients	O
the	O
only	O
hope	O
for	O
long-term	O
survival	O
.	O
	
Locally	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
is	O
defined	O
as	O
surgically	O
unresectable	O
","	O
but	O
has	O
no	O
evidence	O
of	O
distant	O
metastases	O
.	O
	
The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
cetuximab	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
and	O
5-FU	B-DRUG
along	O
with	O
radiation	O
therapy	O
in	O
locally	O
advanced	B-CANCER
non-resectable	I-CANCER
","	I-CANCER
pancreatic	I-CANCER
adenocarcinoma	I-CANCER
","	O
using	O
progression	O
free	O
survival	O
as	O
the	O
primary	O
end	O
point	O
.	O
	
This	O
was	O
a	O
prospective	O
","	O
single	O
arm	O
","	O
open	O
label	O
pilot	O
phase	O
II	O
study	O
to	O
evaluate	O
the	O
anti-tumor	O
activity	O
of	O
gemcitabine	B-DRUG
(	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
week	O
)	O
and	O
cetuximab	B-DRUG
(	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
week	O
after	O
an	O
initial	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
loading	O
dose	O
)	O
with	O
continuous	O
infusion	O
5-FU	B-DRUG
(	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
over	O
96	O
hours	O
)	O
and	O
daily	O
concurrent	O
external	O
beam	O
radiation	O
therapy	O
(	O
50.4	O
Gy	O
total	O
dose	O
)	O
for	O
six	O
weeks	O
(	O
cycle	O
1	O
)	O
in	O
patients	O
with	O
non-metastatic	O
","	O
locally	O
advanced	B-CANCER
pancreatic	I-CANCER
adenocarcinoma	I-CANCER
.	O
	
Following	O
neoadjuvant	O
treatment	O
","	O
subjects	O
were	O
re-evaluated	O
for	O
response	O
and	O
surgical	O
candidacy	O
with	O
restaging	O
scans	O
.	O
	
After	O
resection	O
","	O
or	O
also	O
if	O
not	O
resected	O
;	O
subjects	O
received	O
further	O
therapy	O
with	O
four	O
28-day	O
cycles	O
(	O
cycles	O
2月5日	O
)	O
of	O
weekly	O
gemcitabine	B-DRUG
(	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
cetuximab	B-DRUG
(	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
.	O
	
Between	O
2006	O
and	O
2011	O
","	O
twenty-six	O
patients	O
were	O
screened	O
and	O
eleven	O
of	O
them	O
were	O
enrolled	O
in	O
the	O
study	O
.	O
	
Most	O
common	O
reasons	O
for	O
screen	O
failures	O
were	O
having	O
resectable	O
disease	O
","	O
metastatic	O
disease	O
or	O
co-morbidity	O
.	O
	
Ten	O
patients	O
were	O
able	O
to	O
tolerate	O
and	O
complete	O
cycle	O
1	O
of	O
chemoradiotherapy	O
.	O
	
One	O
patient	O
stopped	O
the	O
study	O
prematurely	O
due	O
to	O
grade	O
III	O
diarrhea	B-TOXI
.	O
	
All	O
except	O
this	O
one	O
patient	O
received	O
planned	O
radiation	O
therapy	O
.	O
	
The	O
response	O
evaluation	O
after	O
cycle	O
1	O
showed	O
one	O
Partial	O
Response	O
","	O
eight	O
Stable	O
Disease	O
and	O
two	O
Progressive	O
Disease	O
.	O
	
Four	O
patients	O
subsequently	O
underwent	O
surgical	O
resection	O
of	O
the	O
tumor	O
.	O
	
All	O
patients	O
had	O
R0	O
resections	O
.	O
	
There	O
was	O
one	O
preoperative	O
mortality	O
due	O
to	O
multiple	B-TOXI
organ	I-TOXI
failure	I-TOXI
.	O
	
Median	O
progression	O
free	O
survival	O
(	O
PFS	O
)	O
for	O
four	O
resected	O
patients	O
was	O
9	O
months	O
while	O
for	O
unresected	O
patients	O
median	O
PFS	O
was	O
7.1	O
months	O
.	O
	
Median	O
overall	O
survival	O
(	O
OS	O
)	O
for	O
four	O
resected	O
patients	O
was	O
47.4	O
months	O
and	O
for	O
unresected	O
patients	O
median	O
OS	O
was	O
17	O
months	O
.	O
	
Most	O
common	O
adverse	O
events	O
were	O
hematologic	B-TOXI
(	O
27	O
%	O
)	O
.	O
	
Only	O
two	O
patients	O
developed	O
grade	O
3	O
neutropenia	B-TOXI
.	O
	
Most	O
common	O
treatment	O
related	O
non-hematologic	B-TOXI
adverse	I-TOXI
events	I-TOXI
were	O
diarrhea	B-TOXI
(	O
10	O
of	O
11	O
)	O
","	O
nausea	B-TOXI
(	O
8	O
of	O
11	O
)	O
and	O
skin	B-TOXI
rash	I-TOXI
(	O
10	O
of	O
11	O
patients	O
)	O
.	O
	
Only	O
9.5	O
%	O
of	O
all	O
reported	O
non-hematologic	B-TOXI
adverse	I-TOXI
events	I-TOXI
were	O
grade	O
3	O
or	O
higher	O
.	O
	
The	O
combination	O
of	O
cetuximab	B-DRUG
","	O
weekly	O
gemcitabine	B-DRUG
and	O
continuous	O
infusion	O
of	O
5-FU	B-DRUG
with	O
radiotherapy	O
was	O
quite	O
well	O
tolerated	O
with	O
intriguing	O
clinical	O
benefit	O
and	O
survival	O
results	O
in	O
carefully	O
selected	O
patients	O
with	O
locally	O
advanced	B-CANCER
pancreatic	I-CANCER
adenocarcinoma	I-CANCER
.	O
	
A	O
trial	O
with	O
larger	O
sample	O
size	O
will	O
be	O
necessary	O
to	O
confirm	O
these	O
results	O
.	O
	
Phase	O
I	O
study	O
of	O
neratinib	B-DRUG
in	O
combination	O
with	O
temsirolimus	B-DRUG
in	O
patients	O
with	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2-dependent	O
and	O
other	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
Human	O
epidermal	O
growth	O
factor	O
(	O
HER	O
)	O
#NAME?	O
signaling	O
is	O
critical	O
in	O
many	O
cancers	O
","	O
including	O
subsets	O
of	O
breast	B-CANCER
and	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
HER	O
family	O
members	O
signal	O
via	O
the	O
phosphatidylinositide	O
3-kinase	O
(	O
PI3K	O
)	O
#NAME?	O
/	O
protein	O
kinase	O
B-mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
cascade	O
;	O
mTOR	O
activation	O
is	O
critical	O
for	O
the	O
expression	O
of	O
multiple	O
contributors	O
to	O
tumor	O
growth	O
and	O
invasion	O
.	O
	
On	O
the	O
basis	O
of	O
preclinical	O
data	O
suggesting	O
synergy	O
of	O
HER2	O
inhibition	O
and	O
mTOR	O
inhibition	O
in	O
breast	B-CANCER
and	I-CANCER
lung	I-CANCER
cancer	I-CANCER
models	O
","	O
we	O
conducted	O
a	O
phase	O
I	O
combination	O
study	O
of	O
neratinib	B-DRUG
","	O
a	O
small-molecule	O
irreversible	O
pan-HER	O
tyrosine	O
kinase	O
inhibitor	O
","	O
and	O
temsirolimus	B-DRUG
","	O
an	O
mTOR	O
inhibitor	O
","	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
This	O
study	O
enrolled	O
patients	O
to	O
dosing	O
combinations	O
of	O
neratinib	B-DRUG
and	O
temsirolimus	B-DRUG
.	O
	
The	O
primary	O
objective	O
was	O
to	O
estimate	O
the	O
toxicity	O
contour	O
of	O
the	O
combination	O
and	O
establish	O
recommended	O
phase	O
II	O
doses	O
.	O
	
Sixty	O
patients	O
were	O
treated	O
on	O
12	O
of	O
16	O
possible	O
dosing	O
combinations	O
.	O
	
Diarrhea	B-TOXI
was	O
the	O
most	O
common	O
drug-related	O
(	O
93	O
%	O
)	O
and	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
","	O
constituting	O
four	O
of	O
10	O
DLTs	O
.	O
	
Dose-limiting	O
grade	O
3	O
metabolic	B-TOXI
abnormalities	I-TOXI
were	O
also	O
observed	O
.	O
	
Other	O
frequent	O
drug-related	O
toxicities	O
included	O
nausea	B-TOXI
","	O
stomatitis	B-TOXI
(	O
both	O
53	O
%	O
)	O
","	O
and	O
anemia	B-TOXI
(	O
48	O
%	O
)	O
.	O
	
Two	O
maximum-tolerated	O
dose	O
combinations	O
were	O
identified	O
:	O
200	O
mg	O
of	O
neratinib	B-DRUG
/	O
25	O
mg	O
of	O
temsirolimus	B-DRUG
and	O
160	O
mg	O
of	O
neratinib	B-DRUG
/	O
50	O
mg	O
of	O
temsirolimus	B-DRUG
.	O
	
Responses	O
were	O
noted	O
in	O
patients	O
with	O
HER2-amplified	O
breast	B-CANCER
cancer	I-CANCER
resistant	O
to	O
trastuzumab	B-DRUG
","	O
HER2-mutant	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
","	O
and	O
tumor	O
types	O
without	O
identified	O
mutations	O
in	O
the	O
HER-PI3K-mTOR	O
pathway	O
.	O
	
The	O
combination	O
of	O
neratinib	B-DRUG
and	O
temsirolimus	B-DRUG
was	O
tolerable	O
and	O
demonstrated	O
antitumor	O
activity	O
in	O
multiple	O
tumor	O
types	O
","	O
warranting	O
further	O
evaluation	O
.	O
	
A	O
phase	O
II	O
study	O
of	O
combined	O
fulvestrant	B-DRUG
and	O
everolimus	B-DRUG
in	O
patients	O
with	O
metastatic	O
estrogen	O
receptor	O
(	O
ER	O
)	O
#NAME?	O
breast	B-CANCER
cancer	I-CANCER
after	O
aromatase	O
inhibitor	O
(	O
AI	O
)	O
failure	O
.	O
	
	
Fulvestrant	B-DRUG
","	O
which	O
degrades	O
ER	O
","	O
is	O
used	O
after	O
AI	O
failure	O
in	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
but	O
resistance	O
develops	O
quickly	O
.	O
	
We	O
hypothesized	O
that	O
using	O
everolimus	B-DRUG
to	O
inhibit	O
mTOR	O
","	O
a	O
key	O
signaling	O
pathway	O
in	O
endocrine	B-DRUG
resistance	O
","	O
may	O
delay	O
fulvestrant	O
resistance	O
in	O
patients	O
and	O
thus	O
improve	O
its	O
efficacy	O
.	O
	
We	O
conducted	O
a	O
phase	O
II	O
trial	O
of	O
combined	O
fulvestrant	B-DRUG
and	O
everolimus	B-DRUG
in	O
postmenopausal	O
women	O
with	O
disease	O
progression	O
or	O
relapse	O
after	O
an	O
AI	O
.	O
	
Primary	O
endpoint	O
was	O
time	O
to	O
progression	O
(	O
TTP	O
)	O
and	O
secondary	O
endpoints	O
included	O
objective	O
response	O
rate	O
","	O
clinical	O
benefit	O
rate	O
(	O
CBR	O
)	O
","	O
safety	O
","	O
and	O
biomarker	O
correlates	O
.	O
	
Tumor	O
blocks	O
were	O
collected	O
and	O
biopsy	O
of	O
accessible	O
tumor	O
was	O
done	O
for	O
future	O
biomarker	O
analysis	O
.	O
	
Of	O
33	O
patients	O
enrolled	O
two	O
were	O
ruled	O
ineligible	O
after	O
enrollment	O
and	O
were	O
excluded	O
from	O
study	O
analysis	O
","	O
for	O
a	O
total	O
of	O
31	O
evaluable	O
patients	O
.	O
	
Median	O
age	O
was	O
54	O
years	O
(	O
range	O
45-85	O
)	O
.	O
	
Prior	O
therapy	O
included	O
tamoxifen	B-DRUG
(	O
81	O
%	O
)	O
","	O
chemotherapy	O
(	O
71	O
%	O
)	O
","	O
with	O
26	O
%	O
of	O
patients	O
having	O
received	O
3	O
or	O
more	O
endocrine	B-DRUG
agents	O
.	O
	
Median	O
TTP	O
was	O
7.4	O
months	O
(	O
95	O
%	O
CI	O
1.9-12.1	O
)	O
with	O
an	O
objective	O
response	O
rate	O
of	O
13	O
%	O
and	O
CBR	O
of	O
49	O
%	O
.	O
	
Of	O
particular	O
note	O
","	O
32	O
%	O
of	O
patients	O
exhibited	O
de	O
novo	O
resistance	O
to	O
study	O
treatment	O
with	O
disease	O
progression	O
as	O
their	O
best	O
response	O
.	O
	
Most	O
common	O
adverse	O
events	O
(	O
AEs	O
)	O
were	O
elevated	B-TOXI
AST	I-TOXI
(	O
87	O
%	O
)	O
and	O
ALT	B-TOXI
(	O
77	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
74	O
%	O
)	O
","	O
hyperglycemia	B-TOXI
(	O
71	O
%	O
)	O
","	O
and	O
hypercholesterolemia	B-TOXI
(	O
68	O
%	O
)	O
.	O
	
Prominent	O
clinical	O
toxicities	O
were	O
mucositis	B-TOXI
(	O
58	O
%	O
)	O
","	O
weight	B-TOXI
loss	I-TOXI
(	O
48	O
%	O
)	O
","	O
and	O
rash	B-TOXI
(	O
42	O
%	O
)	O
.	O
	
Most	O
AEs	O
were	O
grade	O
1	O
or	O
2	O
and	O
largely	O
reversible	O
with	O
infrequent	O
need	O
for	O
everolimus	B-DRUG
dose	O
reduction	O
.	O
	
To	O
conclude	O
","	O
everolimus	B-DRUG
plus	O
fulvestrant	B-DRUG
is	O
effective	O
after	O
AI	O
failure	O
in	O
heavily	O
pretreated	O
metastatic	O
ER-positive	O
breast	B-CANCER
cancer	I-CANCER
and	O
has	O
manageable	O
toxicity	O
.	O
	
Further	O
study	O
of	O
this	O
combination	O
is	O
warranted	O
in	O
randomized	O
studies	O
.	O
	
Since	O
not	O
all	O
patients	O
experience	O
benefit	O
","	O
and	O
in	O
view	O
of	O
potential	O
toxicities	O
","	O
biomarker	O
examination	O
is	O
critical	O
to	O
help	O
select	O
patients	O
most	O
likely	O
to	O
benefit	O
from	O
this	O
strategy	O
in	O
future	O
studies	O
.	O
	
A	O
phase	O
I	O
","	O
open-label	O
study	O
of	O
trebananib	B-DRUG
combined	O
with	O
sorafenib	B-DRUG
or	O
sunitinib	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
renal	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
	
Trebananib	B-DRUG
","	O
an	O
investigational	O
peptibody	O
","	O
binds	O
to	O
angiopoietin	O
1	O
and	O
2	O
","	O
thereby	O
blocking	O
their	O
interaction	O
with	O
Tie2	O
.	O
	
This	O
open-label	O
phase	O
I	O
study	O
examined	O
trebananib	B-DRUG
3	O
mg	O
/	O
kg	O
or	O
10	O
mg	O
/	O
kg	O
intravenous	O
(	O
I.V.	O
)	O
once	O
weekly	O
plus	O
sorafenib	B-DRUG
400	O
mg	O
twice	O
per	O
day	O
or	O
sunitinib	B-DRUG
50	O
mg	O
once	O
per	O
day	O
in	O
advanced	B-CANCER
RCC	I-CANCER
.	O
	
Primary	O
end	O
points	O
were	O
adverse	O
event	O
incidence	O
and	O
pharmacokinetics	O
.	O
	
Thirty-seven	O
patients	O
were	O
enrolled	O
.	O
	
During	O
trebananib	B-DRUG
plus	O
sorafenib	B-DRUG
administration	O
(	O
n	O
=	O
17	O
)	O
","	O
the	O
most	O
common	O
treatment-related	O
adverse	O
events	O
(	O
TRAEs	O
)	O
included	O
rash	B-TOXI
(	O
n	O
=	O
12	O
;	O
71	O
%	O
)	O
","	O
diarrhea	B-TOXI
(	O
n	O
=	O
12	O
;	O
71	O
%	O
)	O
","	O
hypertension	B-TOXI
(	O
n	O
=	O
11	O
;	O
65	O
%	O
)	O
","	O
and	O
fatigue	B-TOXI
(	O
n	O
=	O
11	O
;	O
65	O
%	O
)	O
;	O
grade	O
_	O
3	O
TRAEs	B-TOXI
(	O
n	O
=	O
7	O
;	O
41	O
%	O
)	O
;	O
and	O
2	O
patients	O
(	O
12	O
%	O
)	O
had	O
peripheral	B-TOXI
edema	I-TOXI
.	O
	
During	O
trebananib	B-DRUG
plus	O
sunitinib	B-DRUG
administration	O
(	O
n	O
=	O
19	O
)	O
","	O
the	O
most	O
common	O
TRAEs	B-TOXI
included	O
diarrhea	B-TOXI
(	O
n	O
=	O
14	O
;	O
74	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
n	O
=	O
13	O
;	O
68	O
%	O
)	O
","	O
hypertension	B-TOXI
(	O
n	O
=	O
11	O
;	O
58	O
%	O
)	O
","	O
and	O
decreased	B-TOXI
appetite	I-TOXI
(	O
n	O
=	O
11	O
;	O
58	O
%	O
)	O
;	O
grade	O
_	O
3	O
TRAEs	B-TOXI
(	O
n	O
=	O
13	O
;	O
68	O
%	O
)	O
;	O
and	O
8	O
(	O
42	O
%	O
)	O
patients	O
had	O
peripheral	B-TOXI
edema	I-TOXI
.	O
	
Trebananib	B-DRUG
did	O
not	O
appear	O
to	O
alter	O
the	O
pharmacokinetics	O
of	O
sorafenib	B-DRUG
or	O
sunitinib	B-DRUG
.	O
	
No	O
patient	O
developed	O
anti-trebananib	B-DRUG
antibodies	O
.	O
	
Objective	O
response	O
rates	O
were	O
29	O
%	O
(	O
trebananib	B-DRUG
plus	O
sorafenib	B-DRUG
)	O
and	O
53	O
%	O
(	O
trebananib	B-DRUG
plus	O
sunitinib	B-DRUG
)	O
.	O
	
The	O
toxicities	O
of	O
trebananib	B-DRUG
3	O
mg	O
/	O
kg	O
or	O
10	O
mg	O
/	O
kg	O
I.V.	O
plus	O
sorafenib	B-DRUG
or	O
sunitinib	B-DRUG
in	O
RCC	B-CANCER
were	O
similar	O
to	O
those	O
of	O
sorafenib	B-DRUG
or	O
sunitinib	B-DRUG
monotherapy	O
","	O
with	O
peripheral	B-TOXI
edema	I-TOXI
being	O
likely	O
specific	O
to	O
the	O
combinations	O
.	O
	
Antitumor	O
activity	O
was	O
observed	O
.	O
	
Phase	O
1	O
trial	O
of	O
the	O
oral	O
AKT	O
inhibitor	O
MK-2206	B-DRUG
plus	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
","	O
docetaxel	B-DRUG
","	O
or	O
erlotinib	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Inhibition	O
of	O
AKT	O
with	O
MK-2206	B-DRUG
has	O
demonstrated	O
synergism	O
with	O
anticancer	O
agents	O
.	O
	
This	O
phase	O
1	O
study	O
assessed	O
the	O
MTD	O
","	O
DLTs	O
","	O
PK	O
","	O
and	O
efficacy	O
of	O
MK-2206	B-DRUG
in	O
combination	O
with	O
cytotoxic	B-DRUG
and	O
targeted	O
therapies	O
.	O
	
Advanced	B-CANCER
solid	I-CANCER
tumor	I-CANCER
patients	O
received	O
oral	O
MK-2206	B-DRUG
45	O
or	O
60	O
mg	O
(	O
QOD	O
)	O
with	O
either	O
carboplatin	B-DRUG
(	O
AUC	O
6	O
)	O
and	O
paclitaxel	B-DRUG
200	O
mg	O
/	O
m2	O
(	O
arm	O
1	O
)	O
","	O
docetaxel	B-DRUG
75	O
mg	O
/	O
m2	O
(	O
arm	O
2	O
)	O
","	O
or	O
erlotinib	B-DRUG
100	O
or	O
150	O
mg	O
daily	O
(	O
arm	O
3	O
)	O
;	O
alternative	O
schedules	O
of	O
MK-2206	B-DRUG
135-200	O
mg	O
QW	O
or	O
90-250	O
mg	O
Q3W	O
were	O
also	O
tested	O
.	O
	
MTD	O
of	O
MK-2206	B-DRUG
(	O
N	O
=	O
72	O
)	O
was	O
45	O
mg	O
QOD	O
or	O
200	O
mg	O
Q3W	O
(	O
arm	O
1	O
)	O
;	O
MAD	O
was	O
200	O
mg	O
Q3W	O
(	O
arm	O
2	O
)	O
and	O
135	O
mg	O
QW	O
(	O
arm	O
3	O
)	O
.	O
	
DLTs	O
included	O
skin	B-TOXI
rash	I-TOXI
(	O
arms	O
1	O
","	O
3	O
)	O
","	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
QOD	O
","	O
arms	O
1	O
","	O
2	O
)	O
","	O
tinnitus	B-TOXI
(	O
Q3W	O
","	O
arm	O
2	O
)	O
","	O
and	O
stomatitis	B-TOXI
(	O
QOD	O
","	O
arm	O
3	O
)	O
.	O
	
Common	O
drug-related	O
toxicities	O
included	O
fatigue	B-TOXI
(	O
68	O
%	O
)	O
","	O
nausea	B-TOXI
(	O
49	O
%	O
)	O
","	O
and	O
rash	B-TOXI
(	O
47	O
%	O
)	O
.	O
	
Two	O
patients	O
with	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	O
arm	O
1	O
;	O
Q3W	O
)	O
demonstrated	O
a	O
complete	O
and	O
partial	O
response	O
(	O
PR	O
)	O
;	O
additional	O
PRs	O
were	O
observed	O
in	O
patients	O
(	O
1	O
each	O
)	O
with	O
melanoma	B-CANCER
","	O
endometrial	B-CANCER
","	O
neuroendocrine	B-CANCER
prostate	I-CANCER
","	O
NSCLC	B-CANCER
","	O
and	O
cervical	B-CANCER
cancers	I-CANCER
.	O
	
Six	O
patients	O
had	O
stable	O
disease	O
_6	O
months	O
.	O
	
MK-2206	B-DRUG
plus	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
","	O
docetaxel	B-DRUG
","	O
or	O
erlotinib	B-DRUG
was	O
well-tolerated	O
","	O
with	O
early	O
evidence	O
of	O
antitumor	O
activity	O
.	O
	
Phase	O
I	O
study	O
of	O
elisidepsin	B-DRUG
(	O
Irvalec庐	O
)	O
in	O
combination	O
with	O
carboplatin	B-DRUG
or	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
malignancies	I-CANCER
.	O
	
	
To	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
and	O
the	O
recommended	O
dose	O
(	O
RD	O
)	O
for	O
phase	O
II	O
trials	O
of	O
elisidepsin	B-DRUG
(	O
Irvalec庐	O
)	O
in	O
combination	O
with	O
carboplatin	B-DRUG
or	O
gemcitabine	B-DRUG
.	O
	
Open-label	O
","	O
dose-escalating	O
","	O
two-arm	O
","	O
uncontrolled	O
","	O
phase	O
I	O
study	O
.	O
	
Patients	O
received	O
carboplatin	B-DRUG
on	O
Day	O
(	O
D	O
)	O
1	O
","	O
followed	O
by	O
elisidepsin	B-DRUG
on	O
D1	O
and	O
D8	O
","	O
every	O
3	O
weeks	O
","	O
or	O
gemcitabine	B-DRUG
on	O
D1	O
and	O
D15	O
","	O
followed	O
by	O
elisidepsin	B-DRUG
on	O
D1	O
and	O
D15	O
","	O
every	O
4	O
weeks	O
.	O
	
A	O
pharmacokinetic	O
analysis	O
was	O
done	O
from	O
blood	O
samples	O
collected	O
during	O
the	O
first	O
treatment	O
infusion	O
.	O
	
Fifteen	O
patients	O
were	O
treated	O
with	O
carboplatin	B-DRUG
/	O
elisidepsin	B-DRUG
at	O
doses	O
from	O
4	O
AUC	O
/	O
1	O
mg	O
flat	O
dose	O
(	O
FD	O
)	O
to	O
5	O
AUC	O
/	O
2.5	O
mg	O
FD	O
.	O
	
Two	O
patients	O
had	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
at	O
5	O
AUC	O
/	O
2	O
mg	O
","	O
a	O
dose	O
delay	O
&	O
gt	O
;	O
2	O
weeks	O
due	O
to	O
grade-2	O
ALT	B-TOXI
increase	I-TOXI
and	O
grade-3	O
thrombocytopenia	B-TOXI
","	O
and	O
a	O
D8	O
infusion	O
omission	O
due	O
to	O
grade-3	O
ALT	B-TOXI
increase	I-TOXI
.	O
	
The	O
RD	O
was	O
established	O
at	O
4	O
AUC	O
/	O
1	O
mg	O
.	O
	
Toxicity	O
consisted	O
mainly	O
of	O
mild-moderate	O
anorexia	B-TOXI
","	O
fatigue	B-TOXI
","	O
and	O
nausea	B-TOXI
.	O
	
Twenty-two	O
patients	O
were	O
treated	O
with	O
gemcitabine	B-DRUG
/	O
elisidepsin	B-DRUG
at	O
doses	O
from	O
"1,000"	O
mg*m	O
(	O
2	O
)	O
/	O
1	O
mg	O
FD	O
to	O
"1,250"	O
mg*m	O
(	O
2	O
)	O
/	O
7.5	O
mg	O
FD	O
.	O
	
Two	O
patients	O
had	O
DLTs	O
at	O
"1,250"	O
mg*m	O
(	O
2	O
)	O
/	O
7.5	O
mg	O
","	O
both	O
a	O
D15	O
dose	O
omission	O
due	O
to	O
grade-2	O
ALT	B-TOXI
increase	I-TOXI
.	O
	
The	O
RD	O
was	O
defined	O
at	O
"1,250"	O
mg*m	O
(	O
2	O
)	O
/	O
5	O
mg	O
.	O
	
Toxicity	O
consisted	O
mainly	O
of	O
mild-moderate	O
fatigue	B-TOXI
","	O
pruritus	B-TOXI
","	O
erythema	B-TOXI
","	O
and	O
myalgia	B-TOXI
.	O
	
No	O
objective	O
response	O
was	O
observed	O
.	O
	
No	O
relevant	O
pharmacokinetic	O
interaction	O
was	O
detected	O
.	O
	
Infra-optimal	O
doses	O
of	O
elisidepsin	B-DRUG
and	O
carboplatin	B-DRUG
and	O
a	O
lack	O
of	O
antitumor	O
activity	O
despite	O
using	O
active	O
drug	O
concentrations	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
do	O
not	O
warrant	O
further	O
clinical	O
development	O
for	O
these	O
two	O
combinations	O
.	O
	
Phase	O
I	O
study	O
of	O
panobinostat	B-DRUG
and	O
imatinib	B-DRUG
in	O
patients	O
with	O
treatment-refractory	O
metastatic	O
gastrointestinal	B-CANCER
stromal	I-CANCER
tumors	I-CANCER
.	O
	
	
Panobinostat	B-DRUG
","	O
a	O
pan-deacetylase	O
inhibitor	O
","	O
overcomes	O
imatinib	B-DRUG
resistance	O
in	O
preclinical	O
models	O
of	O
gastrointestinal	B-CANCER
stromal	I-CANCER
tumours	I-CANCER
(	O
GIST	B-CANCER
)	O
.	O
	
Here	O
we	O
determined	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
dose-limiting	O
toxicities	O
(	O
DLT	O
)	O
of	O
panobinostat	B-DRUG
in	O
combination	O
with	O
imatinib	B-DRUG
(	O
IM	O
)	O
for	O
treatment	O
of	O
patients	O
with	O
refractory	O
GIST	B-CANCER
.	O
	
Following	O
a	O
7-day	O
run-in	O
phase	O
of	O
IM	O
(	O
400	O
mg	O
per	O
day	O
)	O
","	O
escalating	O
doses	O
of	O
panobinostat	B-DRUG
were	O
added	O
following	O
a	O
'3	O
plus	O
3	O
'	O
design	O
.	O
	
Twelve	O
heavily	O
pretreated	O
GIST	B-CANCER
patients	O
were	O
enrolled	O
in	O
two	O
dose	O
levels	O
.	O
	
Most	O
common	O
adverse	O
events	O
were	O
thrombocytopenia	B-TOXI
","	O
anaemia	B-TOXI
","	O
fatigue	B-TOXI
","	O
creatinine	B-TOXI
elevation	I-TOXI
","	O
nausea	B-TOXI
","	O
emesis	B-TOXI
and	O
diarrhoea	B-TOXI
.	O
	
Twenty	O
micrograms	O
of	O
panobinostat	B-DRUG
and	O
400	O
mg	O
IM	O
were	O
declared	O
the	O
MTD	O
.	O
	
Pharmacologically	O
active	O
concentrations	O
of	O
panobinostat	B-DRUG
and	O
IM	O
were	O
achieved	O
as	O
evidenced	O
by	O
histone	O
H3	O
acetylation	O
in	O
blood	O
mononuclear	O
cells	O
in	O
vivo	O
and	O
inhibition	O
of	O
the	O
IM-resistant	O
KIT	O
(	O
D816	O
)	O
mutation	O
in	O
vitro	O
.	O
	
In	O
FDG-PET-CT	O
scans	O
after	O
IM	O
run-in	O
and	O
following	O
3	O
weeks	O
panobinostat	B-DRUG
treatment	O
","	O
1	O
out	O
of	O
11	O
evaluable	O
patients	O
showed	O
a	O
metabolic	O
partial	O
response	O
","	O
7	O
patients	O
were	O
metabolically	O
stable	O
and	O
3	O
patients	O
progressed	O
.	O
	
Longest	O
treatment	O
duration	O
was	O
17	O
weeks	O
(	O
median	O
6	O
)	O
.	O
	
Panobinostat	B-DRUG
and	O
IM	O
can	O
be	O
administered	O
at	O
doses	O
achieving	O
target	O
inhibition	O
in	O
vivo	O
.	O
	
Further	O
clinical	O
exploration	O
of	O
patients	O
with	O
treatment-refractory	O
GIST	B-CANCER
is	O
warranted	O
.	O
	
Correlative	O
studies	O
in	O
this	O
trial	O
may	O
help	O
to	O
optimise	O
dosing	O
schedules	O
in	O
GIST	B-CANCER
.	O
	
Phase	O
I	O
dose-escalation	O
study	O
of	O
AZD7762	B-DRUG
","	O
a	O
checkpoint	O
kinase	O
inhibitor	O
","	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
US	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
AZD7762	B-DRUG
is	O
a	O
Chk1	O
kinase	O
inhibitor	O
which	O
increases	O
sensitivity	O
to	O
DNA-damaging	O
agents	O
","	O
including	O
gemcitabine	B-DRUG
.	O
	
We	O
evaluated	O
the	O
safety	O
of	O
AZD7762	B-DRUG
monotherapy	O
and	O
with	O
gemcitabine	B-DRUG
in	O
advanced	B-CANCER
solid	I-CANCER
tumor	I-CANCER
patients	O
.	O
	
In	O
this	O
Phase	O
I	O
study	O
","	O
patients	O
received	O
intravenous	O
AZD7762	B-DRUG
on	O
days	O
1	O
and	O
8	O
of	O
a	O
14-day	O
run-in	O
cycle	O
(	O
cycle	O
0	O
;	O
AZD7762	B-DRUG
monotherapy	O
)	O
","	O
followed	O
by	O
AZD7762	B-DRUG
plus	O
gemcitabine	B-DRUG
"750-1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
and	O
8	O
","	O
every	O
21	O
days	O
","	O
in	O
ascending	O
AZD7762	B-DRUG
doses	O
(	O
cycle	O
1	O
;	O
combination	O
therapy	O
)	O
.	O
	
Forty-two	O
patients	O
received	O
AZD7762	B-DRUG
6	O
mg	O
(	O
n	O
=	O
9	O
)	O
","	O
9	O
mg	O
(	O
n	O
=	O
3	O
)	O
","	O
14	O
mg	O
(	O
n	O
=	O
6	O
)	O
","	O
21	O
mg	O
(	O
n	O
=	O
3	O
)	O
","	O
30	O
mg	O
(	O
n	O
=	O
7	O
)	O
","	O
32	O
mg	O
(	O
n	O
=	O
6	O
)	O
","	O
and	O
40	O
mg	O
(	O
n	O
=	O
8	O
)	O
","	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
.	O
	
Common	O
adverse	O
events	O
(	O
AEs	O
)	O
were	O
fatigue	B-TOXI
[	O
41	O
%	O
(	O
17	O
/	O
42	O
)	O
patients	O
]	O
","	O
neutropenia	B-TOXI
/	O
leukopenia	B-TOXI
[	O
36	O
%	O
(	O
15	O
/	O
42	O
)	O
patients	O
]	O
","	O
anemia	B-TOXI
/	I-TOXI
Hb	I-TOXI
decrease	I-TOXI
[	O
29	O
%	O
(	O
12	O
/	O
42	O
)	O
patients	O
]	O
and	O
nausea	B-TOXI
","	O
pyrexia	B-TOXI
and	O
alanine	B-TOXI
aminotransferase	I-TOXI
/	I-TOXI
aspartate	I-TOXI
aminotransferase	I-TOXI
increase	I-TOXI
[	O
26	O
%	O
(	O
11	O
/	O
42	O
)	O
patients	O
each	O
]	O
.	O
	
Grade	O
_3	O
AEs	O
occurred	O
in	O
19	O
and	O
52	O
%	O
of	O
patients	O
in	O
cycles	O
0	O
and	O
1	O
","	O
respectively	O
.	O
	
Cardiac	O
dose-limiting	O
toxicities	O
occurred	O
in	O
two	O
patients	O
(	O
both	O
AZD7762	B-DRUG
monotherapy	O
)	O
:	O
grade	O
3	O
troponin	B-TOXI
I	I-TOXI
increase	I-TOXI
(	O
32	O
mg	O
)	O
and	O
grade	O
3	O
myocardial	B-TOXI
ischemia	I-TOXI
with	I-TOXI
chest	I-TOXI
pain	I-TOXI
","	O
electrocardiogram	B-TOXI
changes	I-TOXI
","	O
decreased	B-TOXI
left	I-TOXI
ventricular	I-TOXI
ejection	I-TOXI
fraction	I-TOXI
","	O
and	O
increased	B-TOXI
troponin	I-TOXI
I	O
(	O
40	O
mg	O
)	O
.	O
	
AZD7762	B-DRUG
exposure	O
increased	O
linearly	O
.	O
	
Gemcitabine	B-DRUG
did	O
not	O
affect	O
AZD7762	B-DRUG
pharmacokinetics	O
.	O
	
Two	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
patients	O
achieved	O
partial	O
tumor	O
responses	O
(	O
AZD7762	B-CANCER
6	O
mg	O
/	O
gemcitabine	B-CANCER
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
AZD7762	B-CANCER
9	O
mg	O
cohort	O
)	O
.	O
	
The	O
maximum-tolerated	O
dose	O
of	O
AZD7762	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
was	O
30	O
mg	O
.	O
	
Although	O
development	O
of	O
AZD7762	B-DRUG
is	O
not	O
going	O
forward	O
owing	O
to	O
unpredictable	B-TOXI
cardiac	I-TOXI
toxicity	I-TOXI
","	O
Chk1	O
remains	O
an	O
important	O
therapeutic	O
target	O
.	O
	
A	O
phase	O
Ib	O
trial	O
of	O
LY2584702	B-DRUG
tosylate	I-DRUG
","	O
a	O
p70	O
S6	O
inhibitor	O
","	O
in	O
combination	O
with	O
erlotinib	B-DRUG
or	O
everolimus	B-DRUG
in	O
patients	O
with	O
solid	B-CANCER
tumours	I-CANCER
.	O
	
	
LY2584702	B-DRUG
tosylate	I-DRUG
(	O
hereafter	O
referred	O
to	O
as	O
LY2584702	B-DRUG
)	O
is	O
an	O
oral	O
","	O
selective	O
ATP	O
competitive	O
inhibitor	O
of	O
p70	O
S6	O
kinase	O
.	O
	
Preclinical	O
studies	O
with	O
LY2584702	B-DRUG
demonstrated	O
significant	O
synergistic	O
activity	O
with	O
erlotinib	B-DRUG
and	O
everolimus	B-DRUG
.	O
	
The	O
primary	O
objective	O
was	O
to	O
determine	O
a	O
phase	O
II	O
dose	O
and	O
schedule	O
.	O
	
Secondary	O
objectives	O
included	O
evaluation	O
of	O
safety	O
","	O
toxicity	O
and	O
pharmacokinetics	O
of	O
LY2584702	B-DRUG
in	O
combination	O
with	O
erlotinib	B-DRUG
or	O
everolimus	B-DRUG
.	O
	
Patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
were	O
treated	O
with	O
a	O
total	O
daily	O
dose	O
of	O
50-200mg	O
of	O
LY2584702	B-DRUG
in	O
combination	O
with	O
erlotinib	B-DRUG
150	O
mg	O
once	O
daily	O
(	O
Arm	O
A	O
)	O
or	O
everolimus	B-DRUG
10mg	O
once	O
daily	O
(	O
Arm	O
B	O
)	O
.	O
	
Dose	O
escalation	O
was	O
based	O
on	O
3+3	O
design	O
and	O
used	O
the	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
Version	O
4.0.	O
Twenty-nine	O
patients	O
were	O
enrolled	O
","	O
17	O
in	O
Arm	O
A	O
and	O
12	O
in	O
Arm	O
B.	O
Dose	O
limiting	O
toxicities	O
(	O
DLTs	O
)	O
in	O
cycle	O
1	O
were	O
observed	O
in	O
Arm	O
A	O
in	O
four	O
patients	O
and	O
consisted	O
of	O
Grade	O
3	O
vomiting	B-TOXI
","	O
hypophosphataemia	B-TOXI
","	O
pulmonary	B-TOXI
embolism	I-TOXI
and	O
decreased	B-TOXI
clotting	I-TOXI
factor	I-TOXI
V.	I-TOXI
No	I-TOXI
DLTs	I-TOXI
were	O
observed	O
in	O
Arm	O
B	O
at	O
cycle	O
1	O
","	O
and	O
the	O
most	O
frequent	O
treatment-emergent	O
adverse	O
events	O
related	O
to	O
study	O
drug	O
were	O
:	O
fatigue	B-TOXI
","	O
anorexia	B-TOXI
","	O
diarrhoea	B-TOXI
","	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
.	O
	
Seven	O
patients	O
received	O
_4	O
cycles	O
(	O
3	O
in	O
A	O
","	O
4	O
in	O
B	O
)	O
.	O
	
Best	O
overall	O
response	O
was	O
stable	O
disease	O
.	O
	
Exposure	O
accumulation	O
of	O
LY2584702	B-DRUG
occurred	O
with	O
BID	O
(	O
twice	O
daily	O
)	O
dosing	O
.	O
	
Exposure	O
of	O
erlotinib	B-DRUG
increased	O
when	O
administered	O
in	O
combination	O
with	O
LY2584702	B-DRUG
.	O
	
LY2584702	B-DRUG
was	O
not	O
well	O
tolerated	O
when	O
administered	O
with	O
erlotinib	B-DRUG
","	O
therefore	O
this	O
combination	O
is	O
not	O
feasible	O
.	O
	
The	O
combination	O
with	O
everolimus	B-DRUG
was	O
better	O
tolerated	O
but	O
yielded	O
very	O
limited	O
clinical	O
benefit	O
.	O
	
Phase	O
Ib	O
study	O
of	O
Buparlisib	B-DRUG
plus	O
Trastuzumab	B-DRUG
in	O
patients	O
with	O
HER2-positive	O
advanced	B-CANCER
or	I-CANCER
metastatic	I-CANCER
breast	I-CANCER
cancer	I-CANCER
that	O
has	O
progressed	O
on	O
Trastuzumab-based	B-DRUG
therapy	O
.	O
	
	
Phosphoinositide	B-DRUG
3-kinase	O
(	O
PI3K	O
)	O
/	O
AKT	O
/	O
mTOR	O
pathway	O
activation	O
in	O
patients	O
with	O
HER2-positive	O
(	O
HER2	O
(	O
=+	O
)	O
)	O
breast	B-CANCER
cancer	I-CANCER
has	O
been	O
implicated	O
in	O
de	O
novo	O
and	O
acquired	O
trastuzumab	B-DRUG
resistance	O
.	O
	
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
clinical	O
activity	O
of	O
the	O
PI3K	O
inhibitor	O
buparlisib	B-DRUG
(	O
BKM120	O
)	O
in	O
patients	O
with	O
HER2	O
(	O
=+	O
)	O
advanced	O
/	O
metastatic	O
breast	B-CANCER
cancer	I-CANCER
resistant	O
to	O
trastuzumab-based	B-DRUG
therapy	O
.	O
	
In	O
the	O
dose-escalation	O
portion	O
of	O
this	O
phase	O
I	O
/	O
II	O
study	O
","	O
patients	O
with	O
trastuzumab-resistant	B-DRUG
locally	O
advanced	O
or	O
metastatic	O
HER2	O
(	O
=+	O
)	O
breast	B-CANCER
cancer	I-CANCER
were	O
treated	O
with	O
daily	O
oral	O
doses	O
of	O
buparlisib	B-DRUG
and	O
weekly	O
intravenous	O
trastuzumab	B-DRUG
(	O
2	O
mg	O
/	O
kg	O
)	O
.	O
	
Dose	O
escalation	O
was	O
guided	O
by	O
a	O
Bayesian	O
logistic	O
regression	O
model	O
with	O
overdose	O
control	O
.	O
	
Of	O
18	O
enrolled	O
patients	O
","	O
17	O
received	O
buparlisib	B-DRUG
.	O
	
One	O
dose-limiting	O
toxicity	O
of	O
grade	O
3	O
general	B-TOXI
weakness	I-TOXI
was	O
reported	O
at	O
the	O
100-mg	O
/	O
day	O
dose	O
level	O
(	O
the	O
single-agent	O
maximum	O
tolerated	O
dose	O
)	O
and	O
this	O
dose	O
level	O
was	O
declared	O
the	O
recommended	O
phase	O
II	O
dose	O
(	O
RP2D	O
)	O
of	O
buparlisib	B-DRUG
in	O
combination	O
with	O
trastuzumab	B-DRUG
.	O
	
Common	O
(	O
&	O
gt	O
;	O
25	O
%	O
)	O
adverse	O
events	O
included	O
rash	B-TOXI
(	O
39	O
%	O
)	O
","	O
hyperglycemia	B-TOXI
(	O
33	O
%	O
)	O
","	O
and	O
diarrhea	B-TOXI
(	O
28	O
%	O
)	O
.	O
	
The	O
pharmacokinetic	O
profile	O
of	O
buparlisib	B-DRUG
was	O
not	O
affected	O
by	O
its	O
combination	O
with	O
trastuzumab	B-DRUG
.	O
	
At	O
the	O
RP2D	O
","	O
there	O
were	O
two	O
(	O
17	O
%	O
)	O
partial	O
responses	O
","	O
7	O
(	O
58	O
%	O
)	O
patients	O
had	O
stable	O
disease	O
(	O
_6	O
weeks	O
)	O
","	O
and	O
the	O
disease	O
control	O
rate	O
was	O
75	O
%	O
.	O
	
Pharmacodynamic	O
studies	O
showed	O
inhibition	O
of	O
the	O
PI3K	O
/	O
AKT	O
/	O
mTOR	O
and	O
RAS	O
/	O
MEK	O
/	O
ERK	O
pathways	O
.	O
	
In	O
this	O
patient	O
population	O
","	O
the	O
combination	O
of	O
buparlisib	B-DRUG
and	O
trastuzumab	B-DRUG
was	O
well	O
tolerated	O
","	O
and	O
preliminary	O
signs	O
of	O
clinical	O
activity	O
were	O
observed	O
.	O
	
The	O
phase	O
II	O
portion	O
of	O
this	O
study	O
will	O
further	O
explore	O
the	O
safety	O
and	O
efficacy	O
of	O
this	O
combination	O
at	O
the	O
RP2D	O
.	O
	
Clin	O
Cancer	O
Res	O
;	O
20	O
(	O
7	O
)	O
;	O
1935-45	O
.	O
	
漏2014	O
AACR	O
.	O
	
Phase	O
I	O
safety	O
and	O
pharmacokinetic	O
study	O
of	O
the	O
PI3K	O
/	O
mTOR	O
inhibitor	O
SAR245409	B-DRUG
(	O
XL765	O
)	O
in	O
combination	O
with	O
erlotinib	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
The	O
primary	O
objectives	O
of	O
this	O
phase	O
I	O
study	O
were	O
to	O
evaluate	O
the	O
safety	O
and	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
SAR245409	B-DRUG
","	O
a	O
pan-class	O
I	O
phosphatidylinositol	O
3-kinase	O
(	O
PI3K	O
)	O
/	O
mammalian	O
target	O
of	O
rapamycin	O
inhibitor	O
","	O
combined	O
with	O
erlotinib	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Forty-six	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
enrolled	O
.	O
	
Patients	O
with	O
lung	B-CANCER
cancer	I-CANCER
(	O
n	O
=	O
37	O
)	O
had	O
received	O
an	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
inhibitor	O
before	O
study	O
entry	O
.	O
	
SAR245409	B-DRUG
30	O
","	O
50	O
","	O
70	O
","	O
or	O
90	O
mg	O
once	O
daily	O
(	O
QD	O
)	O
or	O
20	O
or	O
30	O
mg	O
twice	O
daily	O
(	O
BID	O
)	O
was	O
administered	O
","	O
in	O
combination	O
with	O
erlotinib	B-DRUG
100	O
mg	O
QD	O
","	O
in	O
28-day	O
cycles	O
.	O
	
Dose	O
escalation	O
of	O
SAR245409	B-DRUG
followed	O
a	O
standard	O
3	O
=+	O
3	O
design	O
.	O
	
Patients	O
were	O
evaluated	O
for	O
adverse	O
events	O
(	O
AEs	O
)	O
.	O
	
Additional	O
evaluations	O
included	O
pharmacokinetics	O
","	O
pharmacodynamic	O
effects	O
on	O
PI3K	O
and	O
EGFR	O
/	O
mitogen-activated	O
protein	O
kinase	O
signaling	O
pathways	O
in	O
tumor	O
and	O
skin	O
samples	O
","	O
and	O
tumor	O
response	O
.	O
	
The	O
MTDs	O
of	O
SAR245409	B-DRUG
","	O
in	O
combination	O
with	O
erlotinib	B-DRUG
100	O
mg	O
QD	O
","	O
were	O
70	O
mg	O
QD	O
and	O
20	O
mg	O
BID	O
.	O
	
The	O
most	O
frequently	O
reported	O
treatment-related	O
AEs	O
(	O
any	O
grade	O
)	O
were	O
diarrhea	B-TOXI
(	O
35	O
%	O
)	O
","	O
rash	B-TOXI
(	O
35	O
%	O
)	O
","	O
and	O
nausea	B-TOXI
(	O
28	O
%	O
)	O
.	O
	
No	O
treatment-related	O
AE	O
occurred	O
at	O
grade	O
3	O
/	O
4	O
in	O
more	O
than	O
one	O
patient	O
(	O
2.2	O
%	O
)	O
.	O
	
No	O
major	O
pharmacokinetic	O
interaction	O
between	O
SAR245409	B-DRUG
and	O
erlotinib	B-DRUG
was	O
noted	O
.	O
	
Suppression	O
of	O
PI3K	O
and	O
EGFR	O
/	O
mitogen-activated	O
protein	O
kinase	O
signaling	O
pathway	O
biomarkers	O
was	O
observed	O
in	O
skin	O
and	O
tumor	O
samples	O
.	O
	
Stable	O
disease	O
was	O
the	O
best	O
overall	O
response	O
reported	O
","	O
occurring	O
in	O
12	O
of	O
32	O
(	O
37.5	O
%	O
)	O
evaluable	O
patients	O
.	O
	
MTDs	O
of	O
SAR245409	B-DRUG
and	O
erlotinib	B-DRUG
were	O
below	O
the	O
single-agent	O
doses	O
of	O
either	O
agent	O
","	O
despite	O
the	O
lack	O
of	O
major	O
pharmacokinetic	O
interaction	O
.	O
	
Phase	O
I	O
study	O
of	O
weekly	O
nab-paclitaxel	B-DRUG
=+	O
weekly	O
cetuximab	B-DRUG
=+	O
intensity-modulated	O
radiation	O
therapy	O
(	O
IMRT	O
)	O
in	O
patients	O
with	O
stage	O
III-IVB	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
HNSCC	B-CANCER
)	O
.	O
	
	
There	O
is	O
a	O
clinical	O
need	O
to	O
improve	O
the	O
efficacy	O
of	O
standard	O
cetuximab	B-DRUG
=+	O
concurrent	O
intensity-modulated	O
radiation	O
therapy	O
(	O
IMRT	O
)	O
for	O
patients	O
with	O
locally	O
and	O
/	O
or	O
regionally	O
advanced	B-CANCER
HNSCC	I-CANCER
.	O
	
Taxanes	B-DRUG
have	O
radiosensitizing	O
activity	O
against	O
HNSCC	B-CANCER
","	O
and	O
nab-paclitaxel	B-DRUG
may	O
offer	O
therapeutic	O
advantage	O
in	O
comparison	O
with	O
other	O
taxanes	B-DRUG
.	O
	
This	O
was	O
a	O
single-institution	O
phase	O
I	O
study	O
with	O
a	O
modified	O
3	O
=+	O
3	O
design	O
.	O
	
Four	O
dose	O
levels	O
(	O
DLs	O
)	O
of	O
weekly	O
nab-paclitaxel	B-DRUG
were	O
explored	O
(	O
30	O
","	O
45	O
","	O
60	O
","	O
and	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
given	O
with	O
standard	O
weekly	O
cetuximab	B-DRUG
(	O
450	O
mg	O
/	O
m	O
(	O
2	O
)	O
loading	O
dose	O
followed	O
by	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
)	O
and	O
concurrent	O
IMRT	O
(	O
total	O
dose	O
","	O
70	O
Gy	O
)	O
.	O
	
Twenty-five	O
eligible	O
patients	O
(	O
20	O
M	O
","	O
5	O
F	O
)	O
enrolled	O
","	O
with	O
median	O
age	O
58	O
years	O
(	O
range	O
","	O
46-84	O
years	O
)	O
.	O
	
Primary	O
tumor	O
sites	O
were	O
oropharynx	O
","	O
19	O
(	O
10	O
human	O
papillomavirus	O
[	O
HPV	O
]	O
pos	O
","	O
8	O
HPV	O
neg	O
","	O
1	O
not	O
done	O
)	O
;	O
neck	O
node	O
with	O
unknown	O
primary	O
","	O
2	O
;	O
larynx	O
2	O
;	O
and	O
oral	O
cavity	O
and	O
maxillary	O
sinus	O
","	O
1	O
each	O
.	O
	
Seven	O
patients	O
had	O
received	O
prior	O
induction	O
chemotherapy	O
.	O
	
Maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
was	O
exceeded	O
at	O
DL4	O
(	O
nab-paclitaxel	B-DRUG
","	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
with	O
three	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
(	O
grade	O
3	O
neuropathy	B-TOXI
","	O
grade	O
3	O
dehydration	B-TOXI
","	O
with	O
grade	O
3	O
mucositis	B-TOXI
grade	O
3	O
anemia	B-TOXI
)	O
among	O
five	O
assessable	O
patients	O
.	O
	
There	O
was	O
only	O
one	O
DLT	O
(	O
grade	O
3	O
supraventricular	B-TOXI
tachycardia	I-TOXI
)	O
among	O
six	O
patients	O
at	O
DL3	O
(	O
nab-paclitaxel	B-DRUG
","	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
and	O
this	O
was	O
deemed	O
the	O
MTD	O
.	O
	
Among	O
23	O
assessable	O
patients	O
","	O
the	O
most	O
common	O
_	O
g3	O
AEs	O
were	O
lymphopenia	B-TOXI
100	O
%	O
","	O
functional	B-TOXI
mucositis	I-TOXI
65	O
%	O
","	O
and	O
pain	B-TOXI
in	I-TOXI
throat	I-TOXI
/	I-TOXI
oral	I-TOXI
cavity	I-TOXI
52	O
%	O
.	O
	
At	O
a	O
median	O
follow-up	O
of	O
33	O
months	O
","	O
2-year	O
failure-free	O
survival	O
(	O
FFS	O
)	O
is	O
65	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
42	O
%	O
to	O
81	O
%	O
]	O
and	O
2-year	O
overall	O
survival	O
(	O
OS	O
)	O
is	O
91	O
%	O
(	O
95	O
%	O
CI	O
69-97	O
)	O
.	O
	
The	O
recommended	O
phase	O
II	O
dose	O
for	O
nab-paclitaxel	B-DRUG
is	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
when	O
given	O
standard	O
weekly	O
cetuximab	B-DRUG
and	O
concurrent	O
IMRT	O
.	O
	
This	O
regimen	O
merits	O
further	O
study	O
as	O
a	O
nonplatinum	O
alternative	O
to	O
IMRT	B-DRUG
=+	O
cetuximab	B-DRUG
alone	O
.	O
	
NCT00736619	O
.	O
	
Myeloablative	O
I-131-tositumomab	B-DRUG
with	O
escalating	O
doses	O
of	O
fludarabine	B-DRUG
and	O
autologous	O
hematopoietic	O
transplantation	O
for	O
adults	O
age	O
_	O
60	O
years	O
with	O
B	B-CANCER
cell	I-CANCER
lymphoma	I-CANCER
.	O
	
	
Myeloablative	O
therapy	O
and	O
autologous	O
stem	O
cell	O
transplantation	O
(	O
ASCT	O
)	O
are	O
underutilized	O
in	O
older	O
patients	O
with	O
B	B-CANCER
cell	I-CANCER
non-Hodgkin	I-CANCER
(	O
B-NHL	B-CANCER
)	O
lymphoma	B-CANCER
.	O
	
We	O
hypothesized	O
that	O
myeloablative	O
doses	O
of	O
(	B-DRUG
131	I-DRUG
)	I-DRUG
I-tositumomab	I-DRUG
could	O
be	O
augmented	O
by	O
concurrent	O
fludarabine	B-DRUG
","	O
based	O
on	O
preclinical	O
data	O
indicating	O
synergy	O
.	O
	
Patients	O
were	O
_	O
60	O
years	O
of	O
age	O
and	O
had	O
high-risk	O
","	O
relapsed	O
","	O
or	O
refractory	O
B-NHL	B-CANCER
.	O
	
Therapeutic	O
infusions	O
of	O
(	B-DRUG
131	I-DRUG
)	I-DRUG
I-tositumomab	I-DRUG
were	O
derived	O
from	O
individualized	O
organ-specific	O
absorbed	O
dose	O
estimates	O
delivering	O
_	O
27	O
Gy	O
to	O
critical	O
organs	O
.	O
	
Fludarabine	B-DRUG
was	O
initiated	O
72	O
hours	O
later	O
followed	O
by	O
ASCT	O
to	O
define	O
the	O
maximally	O
tolerated	O
dose	O
.	O
	
Thirty-six	O
patients	O
with	O
a	O
median	O
age	O
of	O
65	O
years	O
(	O
range	O
","	O
60	O
to	O
76	O
)	O
","	O
2	O
(	O
range	O
","	O
1	O
to	O
9	O
)	O
prior	O
regimens	O
","	O
and	O
33	O
%	O
with	O
chemoresistant	O
disease	O
were	O
treated	O
on	O
this	O
trial	O
.	O
	
Dose-limiting	O
organs	O
included	O
lung	O
(	O
30	O
)	O
","	O
kidney	O
(	O
4	O
)	O
","	O
and	O
liver	O
(	O
2	O
)	O
with	O
a	O
median	O
administered	O
(	O
131	O
)	O
I	O
activity	O
of	O
471	O
mCi	O
(	O
range	O
","	O
260	O
to	O
1620	O
)	O
.	O
	
Fludarabine	B-DRUG
was	O
safely	O
escalated	O
to	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
_	O
7	O
days	O
.	O
	
Engraftment	O
was	O
prompt	O
","	O
there	O
were	O
no	O
early	O
treatment-related	O
deaths	B-TOXI
","	O
and	O
2	O
patients	O
had	O
_	O
grade	O
4	O
nonhematologic	B-TOXI
toxicities	I-TOXI
.	O
	
The	O
estimated	O
3-year	O
overall	O
survival	O
","	O
progression-free	O
survival	O
","	O
and	O
nonrelapse	O
mortality	O
were	O
54	O
%	O
","	O
53	O
%	O
","	O
and	O
7	O
%	O
","	O
respectively	O
(	O
median	O
follow	O
up	O
of	O
3.9	O
years	O
)	O
.	O
	
Fludarabine	B-DRUG
up	O
to	O
210	O
mg	O
/	O
m	O
(	O
2	O
)	O
can	O
be	O
safely	O
delivered	O
with	O
myeloablative	O
(	B-DRUG
131	I-DRUG
)	I-DRUG
I-tositumomab	I-DRUG
and	O
ASCT	O
in	O
older	O
adults	O
with	O
B-NHL	B-CANCER
.	O
	
Cisplatin	B-DRUG
","	O
5-fluorouracil	B-DRUG
","	O
and	O
cetuximab	B-DRUG
(	O
PFE	B-DRUG
)	O
with	O
or	O
without	O
cilengitide	B-DRUG
in	O
recurrent	O
/	O
metastatic	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
:	O
results	O
of	O
the	O
randomized	O
phase	O
I	O
/	O
II	O
ADVANTAGE	O
trial	O
(	O
phase	O
II	O
part	O
)	O
.	O
	
	
Recurrent	O
and	O
/	O
or	O
metastatic	B-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	O
R	O
/	O
M-SCCHN	B-CANCER
)	O
overexpresses	O
伪v尾5	O
integrin	O
.	O
	
Cilengitide	O
selectively	O
inhibits	O
伪v尾3	O
and	O
伪v尾5	O
integrins	O
and	O
is	O
investigated	O
as	O
a	O
treatment	O
strategy	O
.	O
	
The	O
phase	O
I	O
/	O
II	O
study	O
ADVANTAGE	O
evaluated	O
cilengitide	B-DRUG
combined	O
with	O
cisplatin	B-DRUG
","	O
5-fluorouracil	B-DRUG
","	O
and	O
cetuximab	B-DRUG
(	O
PFE	B-DRUG
)	O
in	O
R	O
/	O
M-SCCHN	B-CANCER
.	O
	
The	O
phase	O
II	O
part	O
reported	O
here	O
was	O
an	O
open-label	O
","	O
randomized	O
","	O
controlled	O
trial	O
investigating	O
progression-free	O
survival	O
(	O
PFS	O
)	O
.	O
	
Patients	O
received	O
up	O
to	O
six	O
cycles	O
of	O
PFE	B-DRUG
alone	O
or	O
combined	O
with	O
cilengitide	B-DRUG
2000	O
mg	O
once	O
(	O
CIL1W	O
)	O
or	O
twice	O
(	O
CIL2W	O
)	O
weekly	O
.	O
	
Thereafter	O
","	O
patients	O
received	O
maintenance	O
therapy	O
(	O
cilengitide	O
arms	O
:	O
cilengitide	B-DRUG
plus	O
cetuximab	B-DRUG
;	O
PFE-alone	B-DRUG
arm	O
:	O
cetuximab	B-DRUG
only	O
)	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
.	O
	
One	O
hundred	O
and	O
eighty-two	O
patients	O
were	O
treated	O
.	O
	
Median	O
PFS	O
per	O
investigator	O
read	O
was	O
similar	O
for	O
CIL1W	O
=+	O
PFE	B-DRUG
","	O
CIL2W	O
=+	O
PFE	B-DRUG
","	O
and	O
PFE	B-DRUG
alone	O
(	O
6.4	O
","	O
5.6	O
","	O
and	O
5.7	O
months	O
","	O
respectively	O
)	O
.	O
	
Accordingly	O
","	O
median	O
overall	O
survival	O
and	O
objective	O
response	O
rates	O
were	O
not	O
improved	O
with	O
cilengitide	B-DRUG
(	O
12.4	O
months	O
/	O
47	O
%	O
","	O
10.6	O
months	O
/	O
27	O
%	O
","	O
and	O
11.6	O
months	O
/	O
36	O
%	O
","	O
respectively	O
)	O
.	O
	
No	O
clinically	O
meaningful	O
safety	O
differences	O
were	O
observed	O
between	O
groups	O
.	O
	
None	O
of	O
the	O
tested	O
biomarkers	O
(	O
expression	O
of	O
integrins	O
","	O
CD31	O
","	O
Ki-67	O
","	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
","	O
vascular	O
endothelial-cadherin	O
","	O
type	O
IV	O
collagen	O
","	O
epidermal	O
growth	O
factor	O
receptor	O
","	O
or	O
p16	O
for	O
human	O
papillomavirus	O
)	O
were	O
predictive	O
of	O
outcome	O
.	O
	
Neither	O
of	O
the	O
cilengitide-containing	B-DRUG
regimens	O
demonstrated	O
a	O
PFS	O
benefit	O
over	O
PFE	B-DRUG
alone	O
in	O
R	O
/	O
M-SCCHN	B-CANCER
patients	O
.	O
	
Phase	O
I	O
study	O
of	O
5-fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
and	O
bevacizumab	B-DRUG
in	O
combination	O
with	O
radiation	O
therapy	O
in	O
patients	O
with	O
locally	O
advanced	B-CANCER
rectal	I-CANCER
cancer	I-CANCER
.	O
	
	
A	O
phase	O
I	O
clinical	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
recommended	O
dose	O
(	O
RD	O
)	O
of	O
the	O
standard	O
treatment	O
of	O
5-fluorouracil	B-DRUG
/	O
l-leucovorin	B-DRUG
(	O
5-FU	B-DRUG
/	O
LV	B-DRUG
)	O
with	O
bevacizumab	B-DRUG
","	O
in	O
combination	O
with	O
radiation	O
therapy	O
in	O
patients	O
with	O
locally	O
advanced	B-CANCER
rectal	I-CANCER
cancer	I-CANCER
.	O
	
Eligible	O
patients	O
had	O
previously	O
untreated	O
stage	O
T3	O
or	O
T4	O
locally	O
advanced	B-CANCER
rectal	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
received	O
radiotherapy	O
to	O
the	O
pelvis	O
","	O
at	O
a	O
total	O
dose	O
of	O
45	O
Gy	O
in	O
25	O
fractions	O
.	O
	
During	O
radiotherapy	O
","	O
patients	O
received	O
three	O
courses	O
of	O
a	O
simplified	O
LV	B-DRUG
and	O
5-FU	B-DRUG
regimen	O
(	O
sLV5FU2	O
)	O
","	O
in	O
combination	O
with	O
bevacizumab	B-DRUG
.	O
	
Bevacizumab	B-DRUG
was	O
infused	O
at	O
a	O
fixed	O
dose	O
of	O
5	O
mg	O
/	O
kg	O
on	O
Days	O
1	O
","	O
15	O
and	O
29	O
.	O
	
The	O
sLV5FU2	O
regimen	O
consisted	O
of	O
200	O
mg	O
/	O
m	O
	
Methotrexate	B-DRUG
and	O
gemcitabine	B-DRUG
combination	O
chemotherapy	O
for	O
the	O
treatment	O
of	O
malignant	B-CANCER
pleural	I-CANCER
mesothelioma	I-CANCER
.	O
	
	
Malignant	B-CANCER
pleural	I-CANCER
mesothelioma	I-CANCER
(	O
MPM	B-CANCER
)	O
is	O
an	O
aggressive	O
tumor	O
of	O
serosal	O
surfaces	O
with	O
a	O
poor	O
prognosis	O
.	O
	
Methotrexate	B-DRUG
and	O
gemcitabine	B-DRUG
have	O
exhibited	O
single-agent	O
activity	O
in	O
MPM	B-CANCER
.	O
	
We	O
evaluated	O
the	O
feasibility	O
of	O
sequential	O
administration	O
of	O
these	O
agents	O
in	O
the	O
treatment	O
of	O
MPM	B-CANCER
.	O
	
A	O
total	O
of	O
21	O
patients	O
with	O
MPM	B-CANCER
received	O
a	O
30-min	O
infusion	O
of	O
100	O
mg	O
/	O
m	O
	
Clinical	O
experience	O
with	O
radio-	O
","	O
chemo-	O
and	O
hyperthermotherapy	O
combined	O
trimodality	O
on	O
locally	O
advanced	B-CANCER
esophageal	I-CANCER
cancer	I-CANCER
.	O
	
	
Esophageal	B-CANCER
cancer	I-CANCER
is	O
a	O
highly	O
malignant	O
and	O
lethal	O
disease	O
with	O
a	O
low	O
5-year	O
survival	O
rate	O
.	O
	
Therefore	O
","	O
an	O
effective	O
treatment	O
modality	O
is	O
required	O
.	O
	
To	O
investigate	O
the	O
treatment	O
efficacy	O
and	O
toxicity	O
of	O
radio-	O
","	O
chemo-	O
and	O
hyper-thermotherapy	O
combined	O
trimodality	O
on	O
locally	O
advanced	B-CANCER
esophageal	I-CANCER
cancer	I-CANCER
","	O
the	O
medical	O
records	O
of	O
78	O
patients	O
with	O
pathologically	O
confirmed	O
esophageal	B-CANCER
cancer	I-CANCER
treated	O
with	O
chemoradiotherapy	O
plus	O
hyperthemia	B-TOXI
at	O
our	O
institution	O
were	O
retrospectively	O
investigated	O
and	O
the	O
3-year	O
outcome	O
was	O
carefully	O
assessed	O
.	O
	
All	O
78	O
patients	O
received	O
intensity-modulated	O
radiation	O
therapy	O
at	O
a	O
total	O
dose	O
of	O
60-66	O
Gy	O
","	O
in	O
a	O
conventional	O
schedule	O
of	O
1.8-2.1	O
Gy	O
/	O
fraction	O
","	O
5	O
fractions	O
/	O
week	O
.	O
	
They	O
also	O
received	O
4月6日	O
courses	O
of	O
chemotherapy	O
","	O
consisting	O
of	O
450	O
mg	O
/	O
m	O
	
Phase	O
I-II	O
study	O
of	O
carboplatin	B-DRUG
vincristine	I-DRUG
methotrexate	I-DRUG
and	O
bleomycin	B-DRUG
(	O
COMB	O
)	O
in	O
carcinoma	B-CANCER
of	I-CANCER
the	I-CANCER
cervix	I-CANCER
.	O
	
	
Platinum	B-DRUG
based	O
combination	O
chemotherapy	O
has	O
been	O
associated	O
with	O
a	O
high	O
response	O
rate	O
in	O
patients	O
with	O
cervical	B-CANCER
carcinoma	I-CANCER
.	O
	
To	O
determine	O
whether	O
the	O
toxicity	O
could	O
be	O
reduced	O
but	O
the	O
efficacy	O
maintained	O
carboplatin	B-DRUG
200	O
mg	O
m-2	O
was	O
substituted	O
for	O
cisplatin	B-DRUG
in	O
a	O
regimen	O
that	O
was	O
repeated	O
two	O
weekly	O
and	O
also	O
contained	O
vincristine	B-DRUG
","	O
methotrexate	B-DRUG
and	O
bleomycin	B-DRUG
.	O
	
Twenty-four	O
patients	O
with	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
cervix	I-CANCER
of	O
whom	O
17	O
had	O
relapsed	O
following	O
radiotherapy	O
were	O
studied	O
.	O
	
Only	O
5	O
of	O
the	O
19	O
evaluable	O
patients	O
had	O
a	O
partial	O
response	O
(	O
26	O
%	O
","	O
95	O
confidence	O
limits	O
45.7-6.3	O
%	O
)	O
compared	O
to	O
30	O
of	O
43	O
(	O
70	O
%	O
","	O
84-56	O
%	O
)	O
who	O
received	O
a	O
cisplatin	B-DRUG
combination	O
in	O
a	O
previous	O
study	O
(	O
P	O
less	O
than	O
0.01	O
)	O
(	O
Rustin	O
et	O
al.	O
","	O
1987	O
)	O
.	O
	
Carboplatin	B-DRUG
as	O
given	O
in	O
the	O
COMB	O
regimen	O
appears	O
less	O
effective	O
than	O
cisplatin	B-DRUG
containing	O
combinations	O
for	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
cervix	I-CANCER
.	O
	
Addition	O
of	O
lenalidomide	B-DRUG
to	O
rituximab	B-DRUG
","	O
ifosfamide	B-DRUG
","	O
carboplatin	B-DRUG
","	O
etoposide	B-DRUG
(	O
RICER	B-DRUG
)	O
in	O
first-relapse	O
/	O
primary	O
refractory	O
diffuse	B-CANCER
large	I-CANCER
B-cell	I-CANCER
lymphoma	I-CANCER
.	O
	
	
Relapsed	O
/	O
refractory	O
diffuse	B-CANCER
large	I-CANCER
B-cell	I-CANCER
lymphoma	I-CANCER
(	O
DLBCL	B-CANCER
)	O
is	O
associated	O
with	O
a	O
poor	O
prognosis	O
.	O
	
Outcomes	O
are	O
particularly	O
poor	O
following	O
immunochemotherapy	O
failure	O
or	O
relapse	O
within	O
12	O
months	O
of	O
induction	O
.	O
	
We	O
conducted	O
a	O
Phase	O
I	O
/	O
II	O
trial	O
of	O
lenalidomide	B-DRUG
plus	O
RICE	B-DRUG
(	O
rituximab	B-DRUG
","	O
ifosfamide	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
etoposide	B-DRUG
)	O
(	O
RICER	B-DRUG
)	O
as	O
a	O
salvage	O
regimen	O
for	O
first-relapse	O
or	O
primary	O
refractory	O
DLBCL	B-CANCER
.	O
	
Dose-escalated	O
lenalidomide	B-DRUG
was	O
combined	O
with	O
RICE	B-DRUG
every	O
14	O
d.	O
After	O
three	O
cycles	O
of	O
RICER	B-DRUG
","	O
patients	O
with	O
chemosensitive	O
disease	O
underwent	O
stem	O
cell	O
collection	O
and	O
consolidation	O
with	O
BEAM	B-DRUG
[	O
BCNU	B-DRUG
(	O
carmustine	B-DRUG
)	O
","	O
etoposide	B-DRUG
","	O
cytarabine	B-DRUG
","	O
melphalan	B-DRUG
]	O
followed	O
by	O
autologous	O
stem	O
cell	O
transplantation	O
(	O
autoSCT	O
)	O
.	O
	
Patients	O
who	O
recovered	O
from	O
autoSCT	O
toxicities	O
within	O
90	O
d	O
initiated	O
maintenance	O
treatment	O
with	O
lenalidomide	B-DRUG
25	O
mg	O
daily	O
for	O
21	O
d	O
every	O
28	O
d	O
for	O
12	O
months	O
.	O
	
No	O
dose-limiting	O
or	O
unexpected	O
toxicities	O
occurred	O
with	O
lenalidomide	B-DRUG
25	O
mg	O
plus	O
RICE	B-DRUG
.	O
	
Grade	O
3	O
/	O
4	O
haematological	B-TOXI
toxicities	I-TOXI
resolved	O
appropriately	O
","	O
and	O
planned	O
dose	O
density	O
and	O
dose	O
intensity	O
of	O
RICER	B-DRUG
were	O
preserved	O
.	O
	
No	O
lenalidomide	B-DRUG
or	O
RICE	B-DRUG
dose	O
reductions	O
were	O
required	O
in	O
any	O
of	O
the	O
three	O
cycles	O
.	O
	
After	O
two	O
cycles	O
of	O
RICER	B-DRUG
","	O
nine	O
of	O
15	O
patients	O
(	O
60	O
%	O
)	O
achieved	O
a	O
complete	O
response	O
","	O
and	O
two	O
achieved	O
a	O
partial	O
response	O
(	O
13	O
%	O
)	O
.	O
	
Combining	O
lenalidomide	B-DRUG
with	O
RICE	B-DRUG
is	O
feasible	O
","	O
and	O
results	O
in	O
promising	O
response	O
rates	O
(	O
particularly	O
complete	O
response	O
rates	O
)	O
in	O
high-risk	O
DLBCL	B-CANCER
patients	O
.	O
	
Stand	O
up	O
to	O
cancer	O
phase	O
Ib	O
study	O
of	O
pan-phosphoinositide-3-kinase	O
inhibitor	O
buparlisib	B-DRUG
with	O
letrozole	B-DRUG
in	O
estrogen	O
receptor-positive	O
/	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2-negative	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
Buparlisib	B-DRUG
","	O
an	O
oral	O
reversible	O
inhibitor	O
of	O
all	O
class	O
I	O
phosphoinositide-3-kinases	O
","	O
has	O
shown	O
antitumoral	O
activity	O
against	O
estrogen	O
receptor	O
(	O
ER	O
)	O
#NAME?	O
breast	B-CANCER
cancer	I-CANCER
cell	O
lines	O
and	O
xenografts	O
","	O
alone	O
and	O
with	O
endocrine	O
therapy	O
.	O
	
This	O
phase	O
Ib	O
study	O
evaluated	O
buparlisib	B-DRUG
plus	O
letrozole	B-DRUG
's	I-DRUG
safety	O
","	O
tolerability	O
","	O
and	O
preliminary	O
activity	O
in	O
patients	O
with	O
metastatic	O
ER-positive	O
breast	B-CANCER
cancer	I-CANCER
refractory	O
to	O
endocrine	O
therapy	O
.	O
	
Patients	O
received	O
letrozole	B-DRUG
and	O
buparlisib	B-DRUG
in	O
two	O
different	O
administration	O
schedules	O
.	O
	
Outcomes	O
were	O
assessed	O
by	O
standard	O
solid-tumor	O
phase	O
I	O
methods	O
.	O
	
[	B-DRUG
(	I-DRUG
18	I-DRUG
)	I-DRUG
F	I-DRUG
]	I-DRUG
fluorodeoxyglucose-positron	I-DRUG
emission	O
tomography	O
/	O
computed	O
tomography	O
(	B-DRUG
[	I-DRUG
(	I-DRUG
18	I-DRUG
)	I-DRUG
F	I-DRUG
]	I-DRUG
FDG-PET	I-DRUG
/	I-DRUG
CT	I-DRUG
)	I-DRUG
scans	O
were	O
done	O
at	O
baseline	O
and	O
2	O
weeks	O
after	O
treatment	O
initiation	O
.	O
	
Tumor	O
blocks	O
were	O
collected	O
for	O
phosphoinositide-3-kinase	O
pathway	O
mutation	O
analysis	O
.	O
	
Fifty-one	O
patients	O
were	O
allocated	O
sequentially	O
to	O
continuous	O
or	O
intermittent	O
(	O
five	O
on	O
/	O
two	O
off	O
days	O
)	O
buparlisib	B-DRUG
administration	O
on	O
an	O
every-4-week	O
schedule	O
.	O
	
Buparlisib	B-DRUG
's	I-DRUG
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
was	O
100	O
mg	O
/	O
d.	O
Common	O
drug-related	O
adverse	O
events	O
included	O
_	O
grade	O
2	O
hyperglycemia	B-TOXI
","	O
nausea	B-TOXI
","	O
fatigue	B-TOXI
","	O
transaminitis	B-TOXI
","	O
and	O
mood	B-TOXI
disorders	I-TOXI
.	O
	
The	O
clinical	O
benefit	O
rate	O
(	O
lack	O
of	O
progression	O
_	O
6	O
months	O
)	O
among	O
all	O
patients	O
treated	O
at	O
the	O
MTD	O
was	O
31	O
%	O
","	O
including	O
two	O
objective	O
responses	O
in	O
the	O
continuous	O
dose	O
arm	O
.	O
	
Of	O
seven	O
patients	O
remaining	O
on	O
treatment	O
_	O
12	O
months	O
","	O
three	O
had	O
tumors	O
with	O
PIK3CA	O
hot-spot	O
mutation	O
.	O
	
Patients	O
exhibiting	O
metabolic	O
disease	O
progression	O
by	O
[	B-DRUG
(	I-DRUG
18	I-DRUG
)	I-DRUG
F	I-DRUG
]	I-DRUG
FDG-PET	I-DRUG
/	I-DRUG
CT	I-DRUG
scan	O
at	O
2	O
weeks	O
progressed	O
rapidly	O
on	O
therapy	O
.	O
	
The	O
letrozole	B-DRUG
and	O
buparlisib	B-DRUG
combination	O
was	O
safe	O
","	O
with	O
reversible	O
toxicities	O
regardless	O
of	O
schedule	O
administration	O
.	O
	
Clinical	O
activity	O
was	O
observed	O
independent	O
of	O
PIK3CA	O
mutation	O
status	O
.	O
	
No	O
metabolic	O
response	O
by	O
[	B-DRUG
(	I-DRUG
18	I-DRUG
)	I-DRUG
F	I-DRUG
]	I-DRUG
FDG-PET	I-DRUG
/	O
CT	O
scan	O
at	O
2	O
weeks	O
was	O
associated	O
with	O
rapid	O
disease	O
progression	O
.	O
	
Phase	O
III	O
trials	O
of	O
buparlisib	B-DRUG
and	O
endocrine	B-DRUG
therapy	O
in	O
patients	O
with	O
ER-positive	O
breast	B-CANCER
cancer	I-CANCER
are	O
ongoing	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
temsirolimus	B-DRUG
and	O
bryostatin-1	B-DRUG
in	O
patients	O
with	O
metastatic	O
renal	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
and	O
soft	B-CANCER
tissue	I-CANCER
sarcoma	I-CANCER
.	O
	
	
Temsirolimus	B-DRUG
","	O
an	O
inhibitor	O
of	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
complex	O
1	O
","	O
is	O
approved	O
for	O
the	O
treatment	O
of	O
metastatic	O
renal	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
RCC	B-CANCER
)	O
.	O
	
Bryostatin-1	B-DRUG
inhibits	O
protein	O
kinase	O
C	O
","	O
a	O
downstream	O
effector	O
of	O
mTOR	O
complex	O
2	O
We	O
observed	O
antitumor	O
effects	O
with	O
the	O
combination	O
of	O
temsirolimus	B-DRUG
and	O
bryostatin-1	B-DRUG
in	O
RCC	B-CANCER
cell	O
lines	O
.	O
	
METHODS	O
.	O
	
Four	O
cohorts	O
of	O
patients	O
received	O
weekly	O
bryostatin-1	B-DRUG
(	O
20	O
渭g	O
/	O
m虏	O
)	O
with	O
temsirolimus	B-DRUG
(	O
10	O
","	O
15	O
","	O
25	O
","	O
or	O
37.5	O
mg	O
)	O
in	O
28-day	O
cycles	O
.	O
	
Thirty	O
patients	O
received	O
a	O
total	O
of	O
138	O
cycles	O
across	O
four	O
dose	O
levels	O
.	O
	
Twenty-five	O
patients	O
had	O
RCC	B-CANCER
(	O
17	O
clear	O
cell	O
","	O
7	O
papillary	O
","	O
and	O
1	O
unclassified	O
)	O
.	O
	
Two	O
sarcoma	B-CANCER
patients	O
with	O
prior	O
cytotoxic	O
therapy	O
experienced	O
dose-limiting	O
toxicity	O
at	O
15	O
mg	O
of	O
temsirolimus	B-DRUG
(	O
grade	O
3	O
neutropenia	B-TOXI
and	O
grade	O
3	O
hypophosphatemia	B-TOXI
)	O
.	O
	
Subsequently	O
","	O
patients	O
with	O
prior	O
cytotoxic	O
therapy	O
were	O
excluded	O
.	O
	
Two	O
additional	O
dose-limiting	O
toxicities	O
were	O
noted	O
with	O
37.5	O
mg	O
of	O
temsirolimus	B-DRUG
(	O
grade	O
3	O
neutropenia	B-TOXI
and	O
grade	O
3	O
creatinine	B-TOXI
elevation	I-TOXI
)	O
.	O
	
Consequently	O
","	O
the	O
maximum	O
tolerated	O
dose	O
was	O
defined	O
as	O
temsirolimus	B-DRUG
at	O
25	O
mg	O
and	O
bryostatin-1	B-DRUG
at	O
20	O
渭g	O
/	O
m虏	O
every	O
28	O
days	O
.	O
	
Of	O
the	O
25	O
RCC	B-CANCER
patients	O
","	O
3	O
patients	O
had	O
partial	O
responses	O
that	O
lasted	O
for	O
14	O
months	O
","	O
28	O
months	O
","	O
and	O
_	O
80	O
months	O
","	O
respectively	O
.	O
	
Partial	O
responses	O
were	O
seen	O
in	O
both	O
clear	O
cell	O
and	O
papillary	O
histology	O
.	O
	
This	O
combination	O
of	O
37.5	O
mg	O
of	O
temsirolimus	B-DRUG
with	O
20	O
渭g	O
/	O
m虏	O
of	O
bryostatin-1	B-DRUG
was	O
reasonably	O
safe	O
and	O
well	O
tolerated	O
.	O
	
Durable	O
responses	O
were	O
observed	O
in	O
3	O
of	O
25	O
patients	O
with	O
RCC	B-CANCER
.	O
	
Bosutinib	B-DRUG
in	O
combination	O
with	O
the	O
aromatase	O
inhibitor	O
letrozole	B-DRUG
:	O
a	O
phase	O
II	O
trial	O
in	O
postmenopausal	O
women	O
evaluating	O
first-line	O
endocrine	O
therapy	O
in	O
locally	O
advanced	O
or	O
metastatic	O
hormone	O
receptor-positive	O
/	O
HER2-negative	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
	
Endocrine	O
therapy	O
resistance	O
in	O
hormone	O
receptor-positive	O
(	O
HR+	O
)	O
breast	B-CANCER
cancer	I-CANCER
(	O
BC	O
)	O
may	O
involve	O
crosstalk	O
between	O
HRs	O
and	O
growth	O
factor	O
signaling	O
pathways	O
.	O
	
We	O
evaluated	O
bosutinib	B-DRUG
","	O
a	O
dual	O
Src	O
/	O
Abl	O
tyrosine	O
kinase	O
inhibitor	O
that	O
has	O
previously	O
demonstrated	O
some	O
antitumor	O
activity	O
in	O
BC	B-CANCER
","	O
plus	O
letrozole	B-DRUG
as	O
first-line	O
endocrine	O
therapy	O
in	O
locally	O
advanced	O
or	O
metastatic	O
HR+	O
/	O
HER2-	O
BC	B-CANCER
.	O
	
METHODS	O
;	O
Sixteen	O
postmenopausal	O
women	O
were	O
enrolled	O
in	O
a	O
phase	O
II	O
study	O
evaluating	O
the	O
safety	O
/	O
efficacy	O
of	O
bosutinib	B-DRUG
plus	O
letrozole	B-DRUG
.	O
	
In	O
the	O
single-arm	O
safety	O
/	O
dose-confirming	O
lead-in	O
(	O
part	O
1	O
)	O
","	O
patients	O
received	O
oral	O
bosutinib	B-DRUG
at	O
400	O
mg	O
/	O
day	O
plus	O
letrozole	B-DRUG
at	O
2.5	O
mg	O
/	O
day	O
;	O
adverse	O
events	O
(	O
AEs	O
)	O
and	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
were	O
monitored	O
","	O
and	O
initial	O
efficacy	O
was	O
assessed	O
.	O
	
A	O
randomized	O
efficacy	O
/	O
safety	O
phase	O
(	O
part	O
2	O
)	O
was	O
planned	O
to	O
evaluate	O
the	O
combination	O
versus	O
letrozole	B-DRUG
monotherapy	O
.	O
	
Fifteen	O
of	O
16	O
subjects	O
experienced	O
treatment-related	O
AEs	O
","	O
most	O
commonly	O
diarrhea	B-TOXI
(	O
69	O
%	O
)	O
.	O
	
Treatment-related	O
hepatotoxicity	B-TOXI
AEs	I-TOXI
(	O
primarily	O
alanine	O
aminotransferase	O
[	O
ALT	O
]	O
or	O
aspartate	O
aminotransferase	O
[	O
AST	O
]	O
elevations	O
)	O
occurred	O
in	O
6	O
of	O
16	O
patients	O
(	O
38	O
%	O
)	O
.	O
	
Four	O
of	O
15	O
evaluable	O
patients	O
(	O
27	O
%	O
)	O
experienced	O
a	O
DLT	O
(	O
grade	O
3	O
/	O
4	O
ALT	B-TOXI
/	I-TOXI
AST	I-TOXI
elevations	I-TOXI
","	O
n	O
=	O
2	O
;	O
grade	O
3	O
rash	B-TOXI
","	O
n	O
=	O
1	O
;	O
grade	O
3	O
diarrhea	B-TOXI
or	O
vomiting	B-TOXI
","	O
n	O
=	O
1	O
)	O
","	O
including	O
1	O
Hy	O
's	O
law	O
hepatotoxicity	O
case	O
.	O
	
All	O
DLTs	O
resolved	O
following	O
treatment	O
discontinuation	O
.	O
	
One	O
patient	O
achieved	O
confirmed	O
partial	O
response	O
;	O
one	O
had	O
stable	O
disease	O
for	O
&	O
gt	O
;	O
24	O
weeks	O
.	O
	
Study	O
termination	O
occurred	O
before	O
part	O
2	O
The	O
unfavorable	O
risk-benefit	O
ratio	O
did	O
not	O
warrant	O
further	O
investigation	O
of	O
bosutinib	B-DRUG
plus	O
letrozole	B-DRUG
.	O
	
A	O
phase	O
Ib	O
study	O
of	O
combined	O
VEGFR	O
and	O
mTOR	O
inhibition	O
with	O
vatalanib	B-DRUG
and	O
everolimus	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
renal	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
	
Vatalanib	B-DRUG
is	O
an	O
oral	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
(	O
VEGFR	O
)	O
tyrosine	O
kinase	O
inhibitor	O
(	O
TKI	O
)	O
","	O
whereas	O
everolimus	B-DRUG
inhibits	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
.	O
	
Combination	O
therapy	O
with	O
VEGFR	O
and	O
mTOR	O
inhibitors	O
has	O
not	O
been	O
well	O
tolerated	O
to	O
date	O
but	O
may	O
have	O
efficacy	O
in	O
renal	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
RCC	B-CANCER
)	O
.	O
	
A	O
phase	O
Ib	O
study	O
of	O
vatalanib	B-DRUG
and	O
everolimus	B-DRUG
was	O
performed	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
safety	O
","	O
and	O
tolerability	O
of	O
the	O
combination	O
.	O
	
A	O
dose-expansion	O
cohort	O
of	O
20	O
patients	O
with	O
metastatic	B-CANCER
RCC	I-CANCER
was	O
studied	O
to	O
further	O
define	O
toxicity	O
and	O
preliminary	O
efficacy	O
in	O
patients	O
with	O
RCC	B-CANCER
.	O
	
We	O
evaluated	O
32	O
patients	O
over	O
3	O
dose	O
levels	O
and	O
a	O
dose-expansion	O
cohort	O
.	O
	
The	O
most	O
common	O
toxicities	O
of	O
any	O
grade	O
were	O
proteinuria	B-TOXI
","	O
fatigue	B-TOXI
","	O
hypertriglyceridemia	B-TOXI
","	O
nausea	B-TOXI
","	O
and	O
vomiting	B-TOXI
.	O
	
Dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
included	O
severe	O
hypertension	B-TOXI
","	O
diarrhea	B-TOXI
","	O
neutropenia	B-TOXI
","	O
mucositis	B-TOXI
","	O
and	O
fatigue	B-TOXI
.	O
	
The	O
MTD	O
for	O
the	O
combination	O
was	O
vatalanib	B-DRUG
1000	O
mg	O
daily	O
and	O
everolimus	B-DRUG
5	O
mg	O
daily	O
.	O
	
In	O
all	O
patients	O
","	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
16.3	O
months	O
.	O
	
In	O
patients	O
with	O
RCC	B-CANCER
","	O
median	O
progression-free	O
survival	O
(	O
PFS	O
)	O
was	O
5.8	O
months	O
","	O
and	O
OS	O
was	O
16.5	O
months	O
.	O
	
OS	O
was	O
significantly	O
better	O
in	O
treatment-naive	O
patients	O
(	O
25.1	O
months	O
)	O
compared	O
with	O
patients	O
who	O
had	O
received	O
previous	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
#NAME?	O
therapy	O
(	O
6.3	O
months	O
)	O
.	O
	
Seven	O
of	O
24	O
(	O
29.2	O
%	O
)	O
evaluable	O
patients	O
demonstrated	O
a	O
partial	O
response	O
","	O
and	O
an	O
additional	O
15	O
patients	O
exhibited	O
stable	O
disease	O
.	O
	
Long-term	O
tolerability	O
(	O
&	O
gt	O
;	O
1	O
year	O
)	O
was	O
demonstrated	O
in	O
19	O
%	O
of	O
patients	O
.	O
	
Relevant	O
doses	O
of	O
vatalanib	B-DRUG
and	O
everolimus	B-DRUG
were	O
achieved	O
in	O
combination	O
","	O
with	O
expected	O
toxicities	O
.	O
	
A	O
substantial	O
number	O
of	O
patients	O
with	O
RCC	B-CANCER
achieved	O
an	O
objective	O
response	O
in	O
the	O
treatment-naive	O
setting	O
","	O
with	O
prolonged	O
tolerability	O
and	O
survival	O
.	O
	
Further	O
comparative	O
phase	O
II	O
/	O
III	O
studies	O
of	O
specifically	O
targeted	O
VEGF	O
and	O
mTOR	O
inhibitor	O
combinations	O
may	O
be	O
warranted	O
in	O
patients	O
with	O
RCC	B-CANCER
.	O
	
Randomized	O
Phase	O
II	O
Trial	O
of	O
Irinotecan	B-DRUG
/	O
Docetaxel	B-DRUG
or	O
Irinotecan	B-DRUG
/	O
Docetaxel	B-DRUG
Plus	O
Cetuximab	B-DRUG
for	O
Metastatic	B-CANCER
Pancreatic	I-CANCER
Cancer	I-CANCER
:	O
An	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
Study	O
.	O
	
	
The	O
primary	O
objective	O
was	O
to	O
determine	O
the	O
response	O
rate	O
in	O
patients	O
with	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
treated	O
in	O
first	O
line	O
with	O
irinotecan	B-DRUG
/	O
docetaxel	B-DRUG
combination	O
(	O
Arm	O
A	O
)	O
or	O
with	O
irinotecan	B-DRUG
/	O
docetaxel	B-DRUG
/	O
cetuximab	B-DRUG
combination	O
(	O
Arm	O
B	O
)	O
.	O
	
Secondary	O
endpoints	O
were	O
progression-free	O
survival	O
(	O
PFS	O
)	O
","	O
overall	O
survival	O
(	O
OS	O
)	O
","	O
toxicity	O
","	O
and	O
the	O
rate	O
of	O
thromboembolic	B-TOXI
events	I-TOXI
with	O
prophylactic	O
enoxaparin	B-DRUG
sodium	I-DRUG
.	O
	
Patients	O
were	O
eligible	O
who	O
had	O
measurable	O
","	O
metastatic	O
adenocarcinoma	B-CANCER
of	I-CANCER
the	I-CANCER
pancreas	I-CANCER
","	O
and	O
normal	O
bilirubin	O
.	O
	
All	O
patients	O
received	O
anticoagulation	O
.	O
	
Docetaxel	B-DRUG
(	O
35	O
mg	O
/	O
m	O
)	O
and	O
irinotecan	B-DRUG
(	O
50	O
mg	O
/	O
m	O
)	O
were	O
administered	O
once	O
a	O
week	O
for	O
4	O
weeks	O
followed	O
by	O
2	O
weeks	O
rest	O
(	O
Arm	O
A	O
)	O
alone	O
or	O
with	O
the	O
addition	O
of	O
cetuximab	B-DRUG
(	O
Arm	O
B	O
)	O
.	O
	
The	O
primary	O
endpoint	O
was	O
response	O
rate	O
.	O
	
A	O
total	O
of	O
87	O
eligible	O
patients	O
were	O
enrolled	O
and	O
treated	O
.	O
	
Grade	O
3	O
/	O
4	O
toxicity	O
was	O
observed	O
in	O
74	O
%	O
of	O
patients	O
in	O
Arm	O
A	O
and	O
76	O
%	O
in	O
Arm	O
B.	O
The	O
principal	O
grade	O
3	O
/	O
4	O
toxicity	O
was	O
diarrhea	B-TOXI
.	O
	
Response	O
rates	O
were	O
4.5	O
%	O
in	O
Arm	O
A	O
and	O
7	O
%	O
in	O
Arm	O
B.	O
Median	O
PFS	O
and	O
OS	O
were	O
3.9	O
and	O
6.5	O
months	O
in	O
Arm	O
A	O
and	O
4.5	O
and	O
5.4	O
months	O
in	O
Arm	O
B.	O
Docetaxel	B-DRUG
/	O
irinotecan	B-DRUG
combination	O
is	O
associated	O
with	O
considerable	O
toxicity	O
.	O
	
Objective	O
responses	O
were	O
infrequent	O
and	O
addition	O
of	O
cetuximab	B-DRUG
in	O
an	O
unselected	O
population	O
was	O
not	O
beneficial	O
","	O
but	O
PFS	O
and	O
OS	O
were	O
comparable	O
with	O
those	O
achieved	O
with	O
other	O
regimens	O
.	O
	
Docetaxel	B-DRUG
/	O
irinotecan	B-DRUG
therapy	O
is	O
active	O
in	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
PEAK	O
:	O
a	O
randomized	O
","	O
multicenter	O
phase	O
II	O
study	O
of	O
panitumumab	B-DRUG
plus	O
modified	O
fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
oxaliplatin	B-DRUG
(	O
mFOLFOX6	B-DRUG
)	O
or	O
bevacizumab	B-DRUG
plus	O
mFOLFOX6	B-DRUG
in	O
patients	O
with	O
previously	O
untreated	O
","	O
unresectable	O
","	O
wild-type	O
KRAS	O
exon	O
2	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
evaluate	O
panitumumab	B-DRUG
plus	O
modified	O
fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
oxaliplatin	B-DRUG
(	O
mFOLFOX6	B-DRUG
)	O
or	O
bevacizumab	B-DRUG
plus	O
mFOLFOX6	B-DRUG
in	O
patients	O
with	O
previously	O
untreated	O
wild-type	O
(	O
WT	O
)	O
KRAS	O
exon	O
2	O
(	O
codons	O
12	O
and	O
13	O
)	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
mCRC	B-CANCER
)	O
.	O
	
A	O
prespecified	O
secondary	O
objective	O
was	O
to	O
assess	O
treatment	O
effects	O
in	O
an	O
extended	O
RAS	O
analysis	O
that	O
included	O
exons	O
2	O
","	O
3	O
","	O
and	O
4	O
of	O
KRAS	O
and	O
NRAS	O
.	O
	
Patients	O
with	O
WT	O
KRAS	O
exon	O
2	O
tumors	O
were	O
randomly	O
assigned	O
at	O
a	O
one-to-one	O
ratio	O
to	O
panitumumab	B-DRUG
plus	O
mFOLFOX6	B-DRUG
or	O
bevacizumab	B-DRUG
plus	O
mFOLFOX6	B-DRUG
.	O
	
The	O
primary	O
end	O
point	O
was	O
progression-free	O
survival	O
(	O
PFS	O
)	O
;	O
secondary	O
end	O
points	O
included	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
safety	O
.	O
	
Of	O
285	O
randomly	O
assigned	O
patients	O
","	O
278	O
received	O
treatment	O
.	O
	
In	O
the	O
WT	O
KRAS	O
exon	O
2	O
intent-to-treat	O
group	O
","	O
PFS	O
was	O
similar	O
between	O
arms	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
","	O
0.87	O
;	O
95	O
%	O
CI	O
","	O
0.65	O
to	O
1.17	O
;	O
P	O
=	O
0.353	O
)	O
.	O
	
Median	O
OS	O
was	O
34.2	O
and	O
24.3	O
months	O
in	O
the	O
panitumumab	B-DRUG
and	O
bevacizumab	B-DRUG
arms	O
","	O
respectively	O
(	O
HR	O
","	O
0.62	O
;	O
95	O
%	O
CI	O
","	O
0.44	O
to	O
0.89	O
;	O
P	O
=	O
0.009	O
)	O
.	O
	
In	O
the	O
WT	O
RAS	O
subgroup	O
(	O
WT	O
exons	O
2	O
","	O
3	O
","	O
and	O
4	O
of	O
KRAS	O
and	O
NRAS	O
)	O
","	O
PFS	O
favored	O
the	O
panitumumab	B-DRUG
arm	O
(	O
HR	O
","	O
0.65	O
;	O
95	O
%	O
CI	O
","	O
0.44	O
to	O
0.96	O
;	O
P	O
=	O
0.029	O
)	O
.	O
	
Median	O
OS	O
was	O
41.3	O
and	O
28.9	O
months	O
(	O
HR	O
","	O
0.63	O
;	O
95	O
%	O
CI	O
","	O
0.39	O
to	O
1.02	O
;	O
P	O
=	O
0.058	O
)	O
in	O
the	O
panitumumab	B-DRUG
and	O
bevacizumab	B-DRUG
arms	O
","	O
respectively	O
.	O
	
Treatment	O
discontinuation	O
rates	O
because	O
of	O
adverse	O
events	O
were	O
similar	O
between	O
arms	O
.	O
	
PFS	O
was	O
similar	O
and	O
OS	O
was	O
improved	O
with	O
panitumumab	B-DRUG
relative	O
to	O
bevacizumab	B-DRUG
when	O
combined	O
with	O
mFOLFOX6	B-DRUG
in	O
patients	O
with	O
WT	O
KRAS	O
exon	O
2	O
tumors	O
.	O
	
Patients	O
with	O
WT	O
RAS	O
tumors	O
seemed	O
to	O
experience	O
more	O
clinical	O
benefit	O
with	O
anti-epidermal	O
growth	O
factor	O
receptor	O
therapy	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
concurrent	O
individualized	O
","	O
isotoxic	O
accelerated	O
radiotherapy	O
and	O
cisplatin-vinorelbine-cetuximab	B-DRUG
in	O
patients	O
with	O
stage	O
III	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
In	O
this	O
open-label	O
phase	O
I	O
study	O
","	O
the	O
maximum-tolerated	O
dose	O
of	O
cetuximab	B-DRUG
with	O
concurrent	O
chemoradiotherapy	O
(	O
C-CRT	O
)	O
in	O
stage	O
III	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
together	O
with	O
individualized	O
","	O
isotoxic	O
accelerated	O
radiotherapy	O
(	O
RT	O
)	O
was	O
investigated	O
.	O
	
Patients	O
with	O
stage	O
III	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
","	O
World	O
Health	O
Organization	O
performance	O
status	O
0-1	O
","	O
forced	O
expiratory	O
volume	O
in	O
1	O
second	O
more	O
than	O
50	O
%	O
","	O
carbon	O
monoxide	O
diffusing	O
capacity	O
more	O
than	O
50	O
%	O
","	O
weight	O
loss	O
less	O
than	O
10	O
%	O
","	O
and	O
no	O
severe	O
comorbidity	O
were	O
enrolled	O
.	O
	
Patients	O
without	O
progression	O
after	O
one	O
to	O
two	O
cycles	O
of	O
gemcitabine-carboplatin	B-DRUG
were	O
included	O
and	O
treated	O
with	O
cetuximab	B-DRUG
400	O
mg	O
/	O
kg	O
d7	O
and	O
250	O
mg	O
/	O
kg	O
weekly	O
together	O
with	O
RT	O
and	O
cisplatin	B-DRUG
(	O
50	O
mg	O
/	O
m	O
d1	O
","	O
8	O
;	O
40	O
mg	O
/	O
m	O
d22	O
)	O
#NAME?	B-DRUG
for	O
5	O
weeks	O
.	O
	
Vinorelbine	B-DRUG
was	O
escalated	O
in	O
three	O
steps	O
;	O
(	O
1	O
)	O
10	O
mg	O
/	O
m	O
d1	O
","	O
8	O
and	O
8	O
mg	O
/	O
m	O
d22	O
","	O
29	O
;	O
(	O
2	O
)	O
20	O
mg	O
/	O
m	O
d1	O
","	O
8	O
and	O
8	O
mg	O
/	O
m	O
d22	O
","	O
29	O
;	O
(	O
3	O
)	O
20	O
mg	O
/	O
m	O
d1	O
","	O
8	O
;	O
15	O
mg	O
/	O
m	O
d22	O
","	O
29	O
.	O
	
An	O
individualized	O
prescribed	O
RT	O
dose	O
based	O
on	O
normal	O
tissue	O
dose	O
constraints	O
was	O
applied	O
(	O
e.g.	O
","	O
mean	O
lung	O
dose	O
19	O
Gy	O
)	O
.	O
	
The	O
primary	O
endpoint	O
was	O
the	O
maximum-tolerated	O
dose	O
3	O
months	O
after	O
the	O
end	O
of	O
C-CRT	O
;	O
secondary	O
endpoints	O
were	O
toxicity	O
and	O
metabolic	O
response	O
as	O
assessed	O
by	O
positron	O
emission	O
tomography	O
.	O
	
Between	O
September	O
2007	O
and	O
October	O
2010	O
","	O
25	O
patients	O
(	O
12	O
men	O
","	O
13	O
women	O
","	O
mean	O
age	O
59	O
years	O
)	O
were	O
included	O
.	O
	
The	O
mean	O
RT	O
dose	O
was	O
62	O
卤	O
6.6	O
Gy	O
.	O
	
The	O
vinorelbine	B-DRUG
dose	O
could	O
be	O
escalated	O
to	O
dose	O
level	O
3	O
Twelve	O
of	O
25	O
patients	O
experienced	O
greater	O
than	O
or	O
equal	O
to	O
grade	O
3	O
toxicity	O
(	O
esophagitis	B-TOXI
3	O
","	O
rash	B-TOXI
1	O
","	O
diarrhea	B-TOXI
1	O
","	O
cough	B-TOXI
1	O
","	O
dyspnea	B-TOXI
1	O
","	O
vomiting	B-TOXI
1	O
","	O
and	O
pulmonary	B-TOXI
embolism	I-TOXI
1	O
)	O
.	O
	
No	O
dose-limiting	O
toxicities	O
were	O
observed	O
.	O
	
One	O
patient	O
with	O
a	O
complete	O
pathological	O
response	O
in	O
dose	O
level	O
3	O
developed	O
a	O
fatal	B-TOXI
hemoptysis	I-TOXI
4	O
months	O
after	O
RT.	O
Metabolic	O
remissions	O
were	O
observed	O
in	O
19	O
of	O
22	O
patients	O
.	O
	
C-CRT	B-DRUG
with	O
cetuximab	B-DRUG
and	O
cisplatin-vinorelbine	B-DRUG
is	O
safe	O
to	O
deliver	O
at	O
full	O
dose	O
.	O
	
The	O
recommended	O
phase	O
II	O
dose	O
is	O
therefore	O
cetuximab	B-DRUG
400	O
mg	O
/	O
m	O
d7	O
and	O
250	O
mg	O
/	O
m	O
weekly	O
","	O
cisplatin	B-DRUG
50	O
mg	O
/	O
m	O
d1	O
","	O
8	O
;	O
40	O
mg	O
/	O
m	O
d22	O
and	O
vinorelbine	B-DRUG
20	O
mg	O
/	O
m	O
d1	O
","	O
8	O
;	O
15	O
mg	O
/	O
m	O
d22	O
","	O
29	O
for	O
5	O
weeks	O
together	O
with	O
RT	O
.	O
	
Phase	O
I	O
trial	O
of	O
N-	B-DRUG
(	I-DRUG
phosphonacetyl	I-DRUG
)	I-DRUG
#NAME?	I-DRUG
","	O
methotrexate	B-DRUG
","	O
and	O
5-fluorouracil	B-DRUG
with	O
leucovorin	B-DRUG
rescue	O
in	O
patients	O
with	O
advanced	B-CANCER
cancer	I-CANCER
.	O
	
	
Based	O
on	O
an	O
animal	O
model	O
to	O
improve	O
the	O
antitumor	O
activity	O
of	O
5-fluorouracil	B-DRUG
(	O
FUra	B-DRUG
)	O
","	O
a	O
Phase	O
I	O
study	O
of	O
N-	B-DRUG
(	I-DRUG
phosphonacetyl	I-DRUG
)	I-DRUG
#NAME?	I-DRUG
","	O
methotrexate	B-DRUG
","	O
FUra	B-DRUG
","	O
and	O
leucovorin	B-DRUG
was	O
conducted	O
on	O
44	O
patients	O
.	O
	
Methotrexate	B-DRUG
was	O
given	O
in	O
an	O
intermediate	O
dose	O
(	O
250	O
mg	O
/	O
m2	O
)	O
to	O
overcome	O
potential	O
drug	O
resistance	O
","	O
and	O
N-	B-DRUG
(	I-DRUG
phosphonacetyl	I-DRUG
)	I-DRUG
#NAME?	I-DRUG
was	O
given	O
at	O
a	O
low	O
dose	O
(	O
250	O
mg	O
/	O
m2	O
)	O
in	O
order	O
to	O
allow	O
escalation	O
of	O
FUra	B-DRUG
to	O
toxicity	O
.	O
	
These	O
two	O
drugs	O
were	O
given	O
24	O
h	O
before	O
FUra	B-DRUG
to	O
enhance	O
maximal	O
incorporation	O
of	O
FUra	B-DRUG
into	O
RNA	O
.	O
	
Two	O
schedules	O
of	O
administration	O
were	O
used	O
;	O
one	O
every	O
other	O
week	O
and	O
one	O
weekly	O
for	O
2	O
weeks	O
.	O
	
The	O
every	O
other	O
week	O
schedule	O
was	O
well	O
tolerated	O
","	O
with	O
minimal	O
gastrointestinal	B-TOXI
and	I-TOXI
hematological	I-TOXI
toxicity	I-TOXI
.	O
	
However	O
","	O
the	O
weekly	O
for	O
2	O
weeks	O
schedule	O
was	O
more	O
toxic	O
with	O
increased	B-TOXI
mucositis	I-TOXI
","	O
diarrhea	B-TOXI
requiring	B-TOXI
therapy	I-TOXI
","	O
and	O
decreased	B-TOXI
performance	I-TOXI
status	I-TOXI
of	O
20	O
%	O
in	O
4	O
of	O
6	O
patients	O
.	O
	
There	O
were	O
no	O
responders	O
in	O
the	O
every	O
other	O
week	O
schedule	O
.	O
	
There	O
was	O
one	O
partial	O
response	O
and	O
three	O
patients	O
with	O
stable	O
disease	O
in	O
four	O
evaluable	O
patients	O
on	O
the	O
weekly	O
for	O
2	O
weeks	O
schedule	O
.	O
	
At	O
24	O
h	O
post-N-	B-DRUG
(	I-DRUG
phosphonacetyl	I-DRUG
)	I-DRUG
#NAME?	I-DRUG
treatment	O
","	O
PRPP	O
levels	O
were	O
doubled	O
in	O
bone	O
marrow	O
biopsies	O
","	O
and	O
increased	O
-2.5	O
to	O
25-fold	O
in	O
tumor	O
biopsies	O
.	O
	
We	O
have	O
currently	O
added	O
uridine	B-DRUG
rescue	O
to	O
this	O
combination	O
with	O
the	O
hope	O
of	O
further	O
escalating	O
the	O
dose	O
of	O
FUra	B-DRUG
.	O
	
A	O
phase	O
I	O
dose	O
escalation	O
study	O
of	O
oral	O
c-MET	O
inhibitor	O
tivantinib	B-DRUG
(	O
ARQ	B-DRUG
197	I-DRUG
)	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
Tivantinib	B-DRUG
(	O
ARQ	B-DRUG
197	I-DRUG
)	O
is	O
an	O
orally	O
available	O
","	O
non-adenosine	O
triphosphate	O
competitive	O
","	O
selective	O
c-MET	O
inhibitor	O
.	O
	
The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
safety	O
","	O
tolerability	O
and	O
to	O
establish	O
the	O
recommended	O
phase	O
II	O
dose	O
(	O
RP2D	O
)	O
of	O
tivantinib	B-DRUG
and	O
gemcitabine	B-DRUG
combination	O
.	O
	
Patients	O
with	O
advanced	O
or	O
metastatic	B-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
treated	O
with	O
escalating	O
doses	O
of	O
tivantinib	B-DRUG
(	O
120-360	O
mg	O
capsules	O
)	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
(	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
for	O
3	O
of	O
4	O
weeks	O
)	O
.	O
	
Different	O
schedules	O
of	O
administration	O
were	O
tested	O
and	O
modified	O
based	O
on	O
emerging	O
preclinical	O
data	O
.	O
	
Tivantinib	O
was	O
given	O
continuously	O
","	O
twice	O
a	O
day	O
(	O
b.i.d.	O
)	O
for	O
2	O
","	O
3	O
or	O
4	O
weeks	O
of	O
a	O
28-day	O
cycle	O
or	O
on	O
a	O
5-day	O
on	O
","	O
2-day	O
off	O
schedule	O
(	O
the	O
day	O
before	O
and	O
day	O
of	O
gemcitabine	B-DRUG
administration	O
)	O
.	O
	
Twenty-nine	O
patients	O
were	O
treated	O
with	O
gemcitabine	B-DRUG
and	O
escalating	O
doses	O
of	O
tivantinib	B-DRUG
:	O
120	O
mg	O
b.i.d	O
.	O
	
(	O
n	O
=	O
4	O
)	O
","	O
240	O
mg	O
b.i.d	O
.	O
	
(	O
n	O
=	O
6	O
)	O
and	O
360	O
mg	O
b.i.d	O
.	O
	
(	O
n	O
=	O
19	O
)	O
.	O
	
No	O
dose-limiting	O
toxicities	O
were	O
observed	O
in	O
escalation	O
.	O
	
The	O
RP2D	O
was	O
360	O
mg	O
b.i.d.	O
daily	O
","	O
and	O
45	O
additional	O
patients	O
were	O
enrolled	O
in	O
the	O
expansion	O
cohort	O
.	O
	
Grade	O
_3	O
treatment-related	O
toxicities	O
were	O
observed	O
in	O
54	O
of	O
74	O
(	O
73	O
%	O
)	O
patients	O
with	O
the	O
most	O
common	O
being	O
neutropenia	B-TOXI
(	O
43	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
30	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
28	O
%	O
)	O
and	O
fatigue	B-TOXI
(	O
15	O
%	O
)	O
.	O
	
There	O
was	O
one	O
treatment-related	O
death	B-TOXI
due	O
to	O
neutropenia	B-TOXI
.	O
	
Administration	O
of	O
gemcitabine	B-DRUG
did	O
not	O
affect	O
tivantinib	B-DRUG
concentration	O
.	O
	
Fifty-six	O
patients	O
were	O
assessable	O
for	O
response	O
.	O
	
Eleven	O
(	O
20	O
%	O
)	O
patients	O
achieved	O
a	O
partial	O
response	O
and	O
26	O
(	O
46	O
%	O
)	O
had	O
stable	O
disease	O
(	O
SD	O
)	O
","	O
including	O
15	O
(	O
27	O
%	O
)	O
who	O
achieved	O
SD	O
for	O
over	O
4	O
months	O
.	O
	
Ten	O
of	O
37	O
patients	O
with	O
clinical	O
benefit	O
had	O
prior	O
exposure	O
to	O
gemcitabine	B-DRUG
.	O
	
The	O
combination	O
of	O
tivantinib	B-DRUG
at	O
its	O
monotherapy	O
dose	O
and	O
standard	O
dose	O
gemcitabine	B-DRUG
was	O
safe	O
and	O
tolerable	O
.	O
	
Early	O
signs	O
of	O
antitumor	O
activity	O
may	O
warrant	O
further	O
development	O
of	O
this	O
combination	O
in	O
nonsmall-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
","	O
ovarian	B-CANCER
","	O
pancreatic	B-CANCER
and	O
cholangiocarcinoma	B-CANCER
.	O
	
NCT00874042	O
.	O
	
Phase	O
1	O
dose	O
escalation	O
and	O
pharmacokinetic	O
evaluation	O
of	O
oral	O
gemcitabine	B-DRUG
prodrug	O
(	O
LY2334737	O
)	O
in	O
combination	O
with	O
docetaxel	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
This	O
Phase	O
1	O
study	O
aimed	O
to	O
determine	O
the	O
recommended	O
Phase	O
2	O
dose	O
of	O
LY2334737	B-DRUG
","	O
an	O
oral	O
gemcitabine	B-DRUG
prodrug	O
","	O
when	O
combined	O
with	O
standard	O
dose	O
docetaxel	B-DRUG
treatment	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Pharmacokinetics	O
(	O
PK	O
)	O
and	O
antitumor	O
activity	O
were	O
additionally	O
evaluated	O
.	O
	
Patients	O
with	O
advanced	O
/	O
metastatic	O
solid	B-CANCER
tumors	I-CANCER
received	O
escalating	O
doses	O
of	O
LY2334737	B-DRUG
once	O
daily	O
(	O
QD	O
)	O
for	O
14	O
days	O
","	O
followed	O
by	O
a	O
7-day	O
drug-free	O
period	O
.	O
	
Docetaxel	B-DRUG
was	O
given	O
at	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
every	O
3	O
weeks	O
(	O
q3w	O
)	O
.	O
	
Cycles	O
were	O
repeated	O
until	O
progressive	O
disease	O
(	O
PD	O
)	O
or	O
unacceptable	O
toxicity	O
.	O
	
Of	O
22	O
patients	O
recruited	O
","	O
all	O
Caucasian	O
","	O
7	O
received	O
an	O
LY2334737	B-DRUG
dose	O
of	O
10	O
mg	O
/	O
day	O
","	O
10	O
received	O
20	O
mg	O
/	O
day	O
","	O
5	O
received	O
30	O
mg	O
/	O
day	O
.	O
	
Nineteen	O
patients	O
discontinued	O
due	O
to	O
PD	O
","	O
2	O
due	O
to	O
adverse	O
events	O
","	O
1	O
due	O
to	O
investigator	O
decision	O
.	O
	
Dose-limiting	O
toxicities	O
:	O
2_	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
G3	O
)	O
","	O
2_	O
fatigue	B-TOXI
(	O
1_	O
G2	O
","	O
1_	O
G3	O
)	O
","	O
1_	O
neutropenia	B-TOXI
(	O
G4	O
)	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
was	O
identified	O
to	O
be	O
10	O
mg	O
/	O
day	O
.	O
	
Two	O
patients	O
achieved	O
partial	O
response	O
","	O
10	O
patients	O
stable	O
disease	O
.	O
	
Enrollment	O
was	O
stopped	O
after	O
unexpected	O
hepatic	B-TOXI
toxicities	I-TOXI
were	O
observed	O
with	O
LY2334737	B-DRUG
QD	O
for	O
14	O
days	O
per	O
cycle	O
in	O
another	O
study	O
of	O
Japanese	O
patients	O
.	O
	
PK	O
data	O
were	O
consistent	O
with	O
the	O
first-in-man	O
study	O
of	O
LY2334737	B-DRUG
and	O
did	O
not	O
reveal	O
any	O
drug-drug	O
interaction	O
between	O
LY2334737	B-DRUG
and	O
docetaxel	B-DRUG
.	O
	
Combination	O
of	O
LY2334737	B-DRUG
at	O
doses	O
up	O
to	O
30	O
mg	O
/	O
day	O
QD	O
for	O
14	O
days	O
per	O
cycle	O
with	O
docetaxel	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
q3w	O
resulted	O
in	O
an	O
undesirable	O
toxicity	O
profile	O
and	O
a	O
low	O
MTD	O
of	O
10	O
mg	O
/	O
day	O
.	O
	
Alternative	O
treatment	O
schedules	O
of	O
LY2334737	B-DRUG
should	O
be	O
explored	O
.	O
	
Outcomes	O
in	O
patients	O
with	O
relapsed	O
or	O
refractory	O
multiple	B-CANCER
myeloma	I-CANCER
in	O
a	O
phase	O
I	O
study	O
of	O
everolimus	B-DRUG
in	O
combination	O
with	O
lenalidomide	B-DRUG
.	O
	
	
Everolimus	B-DRUG
","	O
an	O
oral	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
inhibitor	O
","	O
has	O
been	O
studied	O
in	O
multiple	B-CANCER
myeloma	I-CANCER
(	O
MM	B-CANCER
)	O
but	O
lacks	O
significant	O
single	O
agent	O
activity	O
.	O
	
Based	O
on	O
preclinical	O
studies	O
showing	O
synergistic	O
activity	O
of	O
mTOR	O
inhibitors	O
with	O
lenalidomide	B-DRUG
","	O
we	O
studied	O
the	O
combination	O
of	O
lenalidomide	B-DRUG
and	O
everolimus	B-DRUG
in	O
relapsed	O
or	O
refractory	O
MM	B-CANCER
in	O
a	O
phase	O
I	O
clinical	O
trial	O
.	O
	
We	O
assessed	O
patient	O
samples	O
using	O
gene	O
expression	O
","	O
Western	O
blotting	O
and	O
immunohistochemistry	O
to	O
probe	O
the	O
mTOR	O
pathway	O
.	O
	
Twenty-six	O
patients	O
were	O
evaluable	O
for	O
toxicity	O
.	O
	
Dose-limiting	O
toxicities	O
included	O
grade	O
4	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
.	O
	
The	O
maximum	O
tolerated	O
dose	O
was	O
lenalidomide	B-DRUG
15	O
mg	O
and	O
everolimus	B-DRUG
5	O
mg	O
for	O
21	O
d	O
with	O
a	O
7	O
d	O
rest	O
period	O
.	O
	
Grade	O
3	O
/	O
4	O
adverse	O
events	O
included	O
thrombocytopenia	B-TOXI
(	O
35	O
%	O
)	O
and	O
neutropenia	B-TOXI
(	O
42	O
%	O
)	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
65	O
%	O
(	O
1	O
complete	O
response	O
=+	O
4	O
partial	O
response	O
=+	O
10	O
minimal	O
response	O
)	O
.	O
	
The	O
median	O
progression-free	O
survival	O
was	O
5路5	O
months	O
and	O
median	O
overall	O
survival	O
was	O
29路5	O
months	O
.	O
	
Biomarker	O
data	O
demonstrated	O
downregulation	O
of	O
phosphorylated	O
p70S6K	O
.	O
	
Gene	O
expression	O
profiling	O
suggested	O
activation	O
of	O
mTOR	O
in	O
responders	O
versus	O
non-responders	O
.	O
	
The	O
combination	O
of	O
lenalidomide	B-DRUG
and	O
everolimus	B-DRUG
was	O
well	O
tolerated	O
with	O
predictable	O
toxicities	O
and	O
showed	O
responses	O
in	O
a	O
heavily	O
pretreated	O
population	O
.	O
	
When	O
confirmed	O
with	O
larger	O
patient	O
numbers	O
","	O
this	O
analysis	O
may	O
guide	O
patient	O
selection	O
for	O
future	O
clinical	O
trials	O
of	O
mTOR	O
inhibition	O
in	O
MM	B-CANCER
.	O
	
Weekly	O
administration	O
of	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
with	O
concurrent	O
thoracic	O
radiation	O
in	O
previously	O
untreated	O
elderly	O
patients	O
with	O
locally	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
A	O
case	O
series	O
of	O
20	O
patients	O
.	O
	
	
Elderly	O
patients	O
with	O
stage	O
III	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
are	O
frequently	O
underrepresented	O
in	O
clinical	O
trials	O
that	O
evaluate	O
chemoradiotherapy	O
","	O
due	O
to	O
their	O
poor	O
functional	O
status	O
","	O
coexisting	O
illnesses	O
and	O
limited	O
life	O
expectancy	O
.	O
	
The	O
Japan	O
Clinical	O
Oncology	O
Group	O
301	O
trial	O
(	O
JCOG0301	O
)	O
was	O
the	O
first	O
study	O
to	O
demonstrate	O
that	O
thoracic	O
radiation	O
therapy	O
(	O
TRT	O
)	O
with	O
daily	O
low-dose	O
carboplatin	B-DRUG
may	O
improve	O
the	O
outcome	O
of	O
elderly	O
patients	O
with	O
stage	O
III	O
NSCLC	B-CANCER
.	O
	
However	O
","	O
the	O
efficacy	O
and	O
safety	O
profiles	O
of	O
chemoradiotherapy	O
","	O
including	O
platinum	B-DRUG
doublets	O
","	O
have	O
not	O
been	O
clearly	O
determined	O
in	O
this	O
patient	O
population	O
.	O
	
We	O
retrospectively	O
assessed	O
the	O
efficacy	O
and	O
toxicity	O
of	O
weekly	O
paclitaxel	B-DRUG
in	O
combination	O
with	O
carboplatin	B-DRUG
and	O
concurrent	O
TRT	O
in	O
patients	O
aged	O
_75	O
years	O
with	O
previously	O
untreated	O
locally	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
Between	O
February	O
","	O
2004	O
and	O
July	O
","	O
2013	O
","	O
we	O
collected	O
the	O
data	O
of	O
20	O
patients	O
treated	O
with	O
weekly	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
for	O
6	O
weeks	O
and	O
concurrent	O
TRT	O
.	O
	
The	O
objective	O
response	O
rate	O
was	O
90	O
%	O
","	O
the	O
disease	O
control	O
rate	O
was	O
95	O
%	O
","	O
the	O
median	O
progression-free	O
survival	O
was	O
8.63	O
months	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
5.7-16.7	O
]	O
and	O
the	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
16.1	O
months	O
(	O
95	O
%	O
CI	O
:	O
10.7-41.6	O
)	O
.	O
	
There	O
were	O
no	O
grade	O
4	O
hematological	B-TOXI
or	I-TOXI
non-hematological	I-TOXI
toxicities	I-TOXI
and	O
no	O
reported	O
treatment-related	O
deaths	O
.	O
	
Therefore	O
","	O
platinum	B-DRUG
doublet	O
therapy	O
in	O
combination	O
with	O
TRT	O
did	O
not	O
provide	O
a	O
clinically	O
significant	O
survival	O
benefit	O
in	O
our	O
population	O
of	O
elderly	O
patients	O
with	O
locally	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
However	O
","	O
the	O
present	O
study	O
demonstrated	O
the	O
good	O
feasibility	O
and	O
safety	O
of	O
this	O
regimen	O
.	O
	
Further	O
prospective	O
clinical	O
trials	O
are	O
required	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
platinum	B-DRUG
doublet	O
with	O
TRT	O
in	O
elderly	O
patients	O
.	O
	
Phase	O
I	O
study	O
of	O
weekly	O
paclitaxel	B-DRUG
in	O
combination	O
with	O
pazopanib	B-DRUG
and	O
lapatinib	B-DRUG
in	O
advanced	B-CANCER
solid	I-CANCER
malignancies	I-CANCER
.	O
	
	
We	O
assessed	O
the	O
maximum	O
tolerated	O
regimen	O
(	O
MTR	O
)	O
and	O
dose-limiting	O
toxicities	O
of	O
pazopanib	B-DRUG
and	O
lapatinib	B-DRUG
in	O
combination	O
with	O
weekly	O
paclitaxel	B-DRUG
","	O
and	O
the	O
effect	O
of	O
pazopanib	B-DRUG
and	O
lapatinib	B-DRUG
on	O
paclitaxel	B-DRUG
pharmacokinetics	O
.	O
	
Patients	O
received	O
intravenous	O
paclitaxel	B-DRUG
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
of	O
a	O
28-day	O
cycle	O
concurrently	O
with	O
daily	O
pazopanib	B-DRUG
and	O
lapatinib	B-DRUG
.	O
	
Dose	O
levels	O
of	O
paclitaxel	B-DRUG
(	O
mg	O
m	O
(	O
-2	O
)	O
)	O
/	O
pazopanib	B-DRUG
(	O
mg	O
)	O
/	O
lapatinib	B-DRUG
(	O
mg	O
)	O
were	O
50	O
/	O
400	O
/	O
1000	O
","	O
50	O
/	O
800	O
/	O
1000	O
","	O
80	O
/	O
800	O
/	O
1000	O
","	O
and	O
80	O
/	O
400	O
/	O
1000	O
.	O
	
At	O
the	O
MTR	O
","	O
additional	O
patients	O
were	O
enrolled	O
to	O
further	O
evaluate	O
tolerability	O
","	O
and	O
the	O
potential	O
effects	O
of	O
pazopanib	B-DRUG
and	O
lapatinib	B-DRUG
","	O
inhibitors	O
of	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
3A4	O
","	O
on	O
the	O
pharmacokinetics	O
of	O
paclitaxel	B-DRUG
","	O
a	O
CYP2C8	O
and	O
CYP3A4	O
substrate	O
.	O
	
Twenty-six	O
patients	O
were	O
enrolled	O
.	O
	
Dose-limiting	O
toxicities	O
at	O
the	O
MTR	O
(	O
80	O
/	O
400	O
/	O
1000	O
)	O
included	O
grade	O
4	O
thrombosis	B-TOXI
and	O
grade	O
3	O
aspartate	B-TOXI
aminotransferase	I-TOXI
elevation	I-TOXI
.	O
	
Other	O
toxicities	O
included	O
diarrhoea	B-TOXI
","	O
neutropenia	B-TOXI
","	O
fatigue	B-TOXI
","	O
and	O
liver	B-TOXI
enzyme	I-TOXI
elevations	I-TOXI
.	O
	
Coadministration	O
of	O
pazopanib	B-DRUG
400	O
mg	O
and	O
lapatinib	B-DRUG
1000	O
mg	O
increased	O
paclitaxel	O
maximum	O
plasma	O
concentration	O
(	O
38	O
%	O
)	O
and	O
area	O
under	O
the	O
curve	O
(	O
37	O
%	O
)	O
relative	O
to	O
paclitaxel	B-DRUG
alone	O
.	O
	
One	O
patient	O
with	O
a	O
salivary	B-CANCER
gland	I-CANCER
tumour	I-CANCER
had	O
a	O
partial	O
response	O
;	O
three	O
patients	O
had	O
stable	O
disease	O
(	O
猢6	O
months	O
)	O
.	O
	
Pazopanib	B-DRUG
400	O
mg	O
per	O
day	O
and	O
lapatinib	B-DRUG
1000	O
mg	O
per	O
day	O
can	O
be	O
combined	O
with	O
paclitaxel	B-DRUG
80	O
mg	O
m	O
(	O
-2	O
)	O
in	O
28-day	O
cycles	O
.	O
	
Coadministration	O
of	O
pazopanib	B-DRUG
and	O
lapatinib	B-DRUG
","	O
weak	O
inhibitors	O
of	O
CYP2C8	O
and	O
CYP3A4	O
","	O
had	O
an	O
inhibitory	O
effect	O
on	O
paclitaxel	B-DRUG
clearance	O
.	O
	
A	O
phase	O
I	O
trial	O
of	O
everolimus	B-DRUG
in	O
combination	O
with	O
5-FU	B-DRUG
/	O
LV	B-DRUG
","	O
mFOLFOX6	B-DRUG
and	O
mFOLFOX6	B-DRUG
plus	O
panitumumab	B-DRUG
in	O
patients	O
with	O
refractory	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
This	O
phase	O
I	O
study	O
investigated	O
the	O
safety	O
","	O
dose-limiting	O
toxicity	O
","	O
and	O
efficacy	O
in	O
three	O
cohorts	O
all	O
treated	O
with	O
the	O
mTOR	O
inhibitor	O
everolimus	B-DRUG
that	O
was	O
delivered	O
(	O
1	O
)	O
in	O
combination	O
with	O
5-fluorouracil	B-DRUG
with	O
leucovorin	B-DRUG
(	O
5-FU	B-DRUG
/	O
LV	B-DRUG
)	O
","	O
(	O
2	O
)	O
with	O
mFOLFOX6	B-DRUG
(	O
5-FU	B-DRUG
/	O
LV	B-DRUG
=+	O
oxaliplatin	B-DRUG
)	O
","	O
and	O
(	O
3	O
)	O
with	O
mFOLFOX6	B-DRUG
=+	O
panitumumab	B-DRUG
in	O
patients	O
with	O
refractory	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Patients	O
were	O
accrued	O
using	O
a	O
3-patient	O
cohort	O
design	O
consisting	O
of	O
two	O
sub-trials	O
in	O
which	O
the	O
maximum	O
tolerated	O
combination	O
(	O
MTC	O
)	O
and	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
of	O
everolimus	B-DRUG
and	O
5-FU	B-DRUG
/	O
LV	B-DRUG
was	O
established	O
in	O
Sub-trial	O
A	O
and	O
of	O
everolimus	B-DRUG
in	O
combination	O
with	O
mFOLFOX6	B-DRUG
and	O
mFOLFOX6	B-DRUG
plus	O
panitumumab	B-DRUG
in	O
Sub-trial	O
B.	O
Thirty-six	O
patients	O
were	O
evaluable	O
for	O
toxicity	O
","	O
21	O
on	O
Sub-trial	O
A	O
and	O
15	O
on	O
Sub-trial	O
B.	O
In	O
Sub-trial	O
A	O
","	O
DLT	O
was	O
observed	O
in	O
1	O
/	O
6	O
patients	O
enrolled	O
on	O
dose	O
level	O
1A	O
and	O
2	O
/	O
3	O
patients	O
in	O
level	O
6A	O
.	O
	
In	O
Sub-trial	O
B	O
","	O
2	O
/	O
3	O
patients	O
experienced	O
DLT	O
on	O
level	O
1B	O
and	O
subsequent	O
patients	O
were	O
enrolled	O
on	O
level	O
1B-1	O
without	O
DLT	O
.	O
	
Three	O
of	O
six	O
patients	O
in	O
cohort	O
2B-1	O
experienced	O
grade	O
3	O
mucositis	B-TOXI
","	O
and	O
further	O
study	O
of	O
the	O
combination	O
of	O
everolimus	B-DRUG
","	O
mFOLFOX6	B-DRUG
and	O
panitumumab	B-DRUG
was	O
aborted	O
.	O
	
Among	O
the	O
24	O
patients	O
enrolled	O
with	O
refractory	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
","	O
the	O
median	O
time	O
on	O
treatment	O
was	O
2.7	O
months	O
with	O
45	O
%	O
of	O
patients	O
remaining	O
on	O
treatment	O
with	O
stable	O
disease	O
for	O
at	O
least	O
3	O
months	O
.	O
	
While	O
a	O
regimen	O
of	O
everolimus	B-DRUG
in	O
addition	O
to	O
5-FU	B-DRUG
/	O
LV	B-DRUG
and	O
mFOLFOX6	B-DRUG
appears	O
safe	O
and	O
tolerable	O
","	O
the	O
further	O
addition	O
of	O
panitumumab	B-DRUG
resulted	O
in	O
an	O
unacceptable	O
level	O
of	O
toxicity	O
that	O
can	O
not	O
be	O
recommended	O
for	O
further	O
study	O
.	O
	
Further	O
investigation	O
is	O
warranted	O
to	O
better	O
elucidate	O
the	O
role	O
which	O
mTOR	O
inhibitors	O
play	O
in	O
patients	O
with	O
refractory	B-CANCER
solid	I-CANCER
tumors	I-CANCER
","	O
with	O
a	O
specific	O
focus	O
on	O
mCRC	B-CANCER
as	O
a	O
potential	O
for	O
the	O
combination	O
of	O
this	O
targeted	O
and	O
cytotoxic	O
therapy	O
in	O
future	O
studies	O
.	O
	
Accelerated	B-DRUG
methotrexate	I-DRUG
","	O
vinblastine	B-DRUG
","	O
doxorubicin	B-DRUG
","	O
and	O
cisplatin	B-DRUG
is	O
safe	O
","	O
effective	O
","	O
and	O
efficient	O
neoadjuvant	O
treatment	O
for	O
muscle-invasive	B-CANCER
bladder	I-CANCER
cancer	I-CANCER
:	O
results	O
of	O
a	O
multicenter	O
phase	O
II	O
study	O
with	O
molecular	O
correlates	O
of	O
response	O
and	O
toxicity	O
.	O
	
	
Neoadjuvant	O
cisplatin-based	B-DRUG
chemotherapy	O
is	O
standard	O
of	O
care	O
for	O
muscle-invasive	B-CANCER
bladder	I-CANCER
cancer	I-CANCER
(	O
MIBC	B-CANCER
)	O
;	O
however	O
","	O
it	O
is	O
infrequently	O
adopted	O
in	O
practice	O
because	O
of	O
concerns	O
regarding	O
toxicity	O
and	O
delay	O
to	O
cystectomy	O
.	O
	
We	O
hypothesized	O
that	O
three	O
cycles	O
of	O
neoadjuvant	O
accelerated	B-DRUG
methotrexate	I-DRUG
","	O
vinblastine	B-DRUG
","	O
doxorubicin	B-DRUG
","	O
and	O
cisplatin	B-DRUG
(	O
AMVAC	B-DRUG
)	O
would	O
be	O
safe	O
","	O
shorten	O
the	O
time	O
to	O
surgery	O
","	O
and	O
yield	O
similar	O
pathologic	O
complete	O
response	O
(	O
pT0	O
)	O
rates	O
compared	O
with	O
historical	O
controls	O
.	O
	
Patients	O
with	O
cT2-T4a	O
and	O
N0-N1	O
MIBC	O
were	O
eligible	O
and	O
received	O
three	O
cycles	O
of	O
AMVAC	B-DRUG
with	O
pegfilgrastim	B-DRUG
followed	O
by	O
radical	O
cystectomy	O
with	O
lymph	O
node	O
dissection	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
pT0	O
rate	O
.	O
	
Telomere	O
length	O
(	O
TL	O
)	O
and	O
p53	O
mutation	O
status	O
were	O
correlated	O
with	O
response	O
and	O
toxicity	O
.	O
	
Forty-four	O
patients	O
were	O
accrued	O
;	O
60	O
%	O
had	O
stage	O
III	O
to	O
IV	O
disease	O
;	O
median	O
age	O
was	O
64	O
years	O
.	O
	
Forty	O
patients	O
were	O
evaluable	O
for	O
response	O
","	O
with	O
15	O
(	O
38	O
%	O
;	O
95	O
%	O
CI	O
","	O
23	O
%	O
to	O
53	O
%	O
)	O
showing	O
pT0	O
at	O
cystectomy	O
","	O
meeting	O
the	O
primary	O
end	O
point	O
of	O
the	O
study	O
.	O
	
Another	O
six	O
patients	O
(	O
14	O
%	O
)	O
were	O
downstaged	O
to	O
non-muscle	O
invasive	O
disease	O
.	O
	
Most	O
(	O
82	O
%	O
)	O
experienced	O
only	O
grade	O
1	O
to	O
2	O
treatment-related	O
toxicities	O
.	O
	
There	O
were	O
no	O
grade	O
3	O
or	O
4	O
renal	O
toxicities	O
and	O
no	O
treatment-related	O
deaths	O
.	O
	
One	O
patient	O
developed	O
metastases	O
and	O
thus	O
did	O
not	O
undergo	O
cystectomy	O
;	O
all	O
others	O
(	O
n	O
=	O
43	O
)	O
proceeded	O
to	O
cystectomy	O
within	O
8	O
weeks	O
after	O
last	O
chemotherapy	O
administration	O
.	O
	
Median	O
time	O
from	O
start	O
of	O
chemotherapy	O
to	O
cystectomy	O
was	O
9.7	O
weeks	O
.	O
	
TL	O
and	O
p53	O
mutation	O
did	O
not	O
predict	O
response	O
or	O
toxicity	O
.	O
	
AMVAC	B-DRUG
is	O
well	O
tolerated	O
and	O
results	O
in	O
similar	O
pT0	O
rates	O
with	O
6	O
weeks	O
of	O
treatment	O
compared	O
with	O
standard	O
12-week	O
regimens	O
.	O
	
Further	O
analysis	O
is	O
ongoing	O
to	O
ascertain	O
whether	O
molecular	O
alterations	O
in	O
tumor	O
samples	O
can	O
predict	O
response	O
to	O
chemotherapy	O
.	O
	
Interferon	B-DRUG
alpha	I-DRUG
plus	O
13-cis-retinoic	B-DRUG
acid	I-DRUG
modulation	I-DRUG
of	O
BCL-2	O
plus	O
paclitaxel	B-DRUG
for	O
recurrent	B-CANCER
small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
SCLC	B-CANCER
)	O
:	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
study	O
(	O
E6501	O
)	O
.	O
	
	
Patients	O
with	O
recurrent	B-CANCER
small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
SCLC	B-CANCER
)	O
have	O
dismal	O
outcomes	O
.	O
	
The	O
failure	O
of	O
salvage	O
therapy	O
is	O
due	O
to	O
the	O
possible	O
development	O
of	O
resistance	O
mechanisms	O
","	O
such	O
as	O
the	O
upregulation	O
of	O
the	O
anti-apoptosis	O
protein	O
","	O
Bcl-2	O
.	O
	
We	O
conducted	O
a	O
phase	O
II	O
study	O
to	O
evaluate	O
if	O
modulation	O
of	O
Bcl-2	B-DRUG
with	O
13-cis-retinoic	B-DRUG
acid	I-DRUG
(	O
13-CRA	B-DRUG
)	O
and	O
interferon	B-DRUG
alpha	I-DRUG
could	O
improve	O
response	O
rates	O
when	O
combined	O
with	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
recurrent	B-CANCER
SCLC	I-CANCER
.	O
	
Patients	O
with	O
recurrent	B-CANCER
SCLC	I-CANCER
and	O
measurable	O
disease	O
were	O
treated	O
with	O
interferon	B-DRUG
alpha	I-DRUG
at	O
6	O
million	O
units	O
/	O
m虏	O
subcutaneously	O
and	O
13-CRA	B-DRUG
1	O
mg	O
/	O
kg	O
orally	O
on	O
days	O
1	O
and	O
2	O
and	O
paclitaxel	B-DRUG
75	O
mg	O
/	O
m虏	O
intravenously	O
on	O
day	O
2	O
of	O
each	O
week	O
for	O
6	O
weeks	O
of	O
an	O
8-week	O
treatment	O
cycle	O
.	O
	
Treatment	O
was	O
continued	O
until	O
disease	O
progression	O
","	O
development	O
of	O
unacceptable	O
toxicity	O
","	O
or	O
withdrawal	O
of	O
consent	O
.	O
	
The	O
primary	O
endpoint	O
was	O
response	O
rate	O
with	O
secondary	O
endpoints	O
of	O
progression-free	O
survival	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O
	
Bcl-2	B-DRUG
levels	O
were	O
assessed	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
.	O
	
Thirty-seven	O
patients	O
were	O
enrolled	O
;	O
34	O
were	O
included	O
in	O
the	O
intention-to-treat	O
analysis	O
as	O
3	O
patients	O
were	O
ineligible	O
for	O
the	O
study	O
.	O
	
There	O
were	O
3	O
partial	O
responses	O
(	O
9	O
%	O
)	O
","	O
and	O
5	O
patients	O
had	O
stable	O
disease	O
(	O
15	O
%	O
)	O
as	O
best	O
response	O
.	O
	
The	O
median	O
PFS	O
was	O
2	O
months	O
","	O
and	O
median	O
OS	O
was	O
6.2	O
months	O
.	O
	
Although	O
mean	O
Bcl-2	B-DRUG
protein	O
levels	O
decreased	O
with	O
therapy	O
in	O
PBMCs	B-CANCER
","	O
there	O
was	O
no	O
association	O
between	O
Bcl-2	B-DRUG
levels	O
and	O
response	O
rate	O
or	O
survival	O
.	O
	
Despite	O
sound	O
pre-clinical	O
evidence	O
","	O
the	O
addition	O
of	O
13-CRA	B-DRUG
and	O
interferon	B-DRUG
alpha	I-DRUG
to	O
paclitaxel	B-DRUG
did	O
not	O
improve	O
outcomes	O
for	O
recurrent	B-CANCER
SCLC	I-CANCER
.	O
	
Lenalidomide	B-DRUG
and	O
rituximab	B-DRUG
for	O
the	O
initial	O
treatment	O
of	O
patients	O
with	O
chronic	B-CANCER
lymphocytic	I-CANCER
leukemia	I-CANCER
:	O
a	O
multicenter	O
clinical-translational	O
study	O
from	O
the	O
chronic	B-CANCER
lymphocytic	I-CANCER
leukemia	I-CANCER
research	O
consortium	O
.	O
	
	
Lenalidomide	B-DRUG
is	O
an	O
immunomodulatory	O
agent	O
with	O
therapeutic	O
activity	O
in	O
chronic	B-CANCER
lymphocytic	I-CANCER
leukemia	I-CANCER
(	O
CLL	B-CANCER
)	O
.	O
	
In	O
preclinical	O
models	O
","	O
lenalidomide	B-DRUG
acted	O
synergistically	O
with	O
rituximab	B-DRUG
.	O
	
The	O
CLL	B-CANCER
Research	O
Consortium	O
initiated	O
a	O
phase	O
II	O
study	O
to	O
evaluate	O
this	O
combination	O
in	O
treatment-naive	O
patients	O
.	O
	
Lenalidomide	B-DRUG
was	O
initiated	O
at	O
2.5	O
mg	O
/	O
day	O
and	O
was	O
escalated	O
based	O
on	O
treatment	O
tolerability	O
to	O
a	O
maximum	O
of	O
10	O
mg	O
/	O
day	O
","	O
for	O
21	O
days	O
/	O
cycle	O
","	O
for	O
a	O
maximum	O
of	O
seven	O
cycles	O
.	O
	
Rituximab	B-DRUG
was	O
administered	O
at	O
the	O
end	O
of	O
cycle	O
1	O
and	O
was	O
continued	O
for	O
seven	O
cycles	O
.	O
	
Patients	O
received	O
allopurinol	B-DRUG
and	O
aspirin	B-DRUG
for	O
prophylaxis	O
.	O
	
Sixty-nine	O
patients	O
enrolled	O
onto	O
one	O
of	O
two	O
age-specific	O
strata	O
;	O
patients	O
'	O
median	O
age	O
was	O
56	O
and	O
70	O
years	O
for	O
arms	O
A	O
and	O
B	O
","	O
respectively	O
.	O
	
Patients	O
in	O
the	O
older-patient	O
stratum	O
more	O
frequently	O
had	O
elevated	B-TOXI
serum	I-TOXI
beta-2	I-TOXI
microglobulin	I-TOXI
levels	O
","	O
high-risk	B-TOXI
Rai	I-TOXI
stage	I-TOXI
","	O
and	O
were	O
less	O
likely	O
to	O
complete	O
the	O
maximum	O
planned	O
therapy	O
.	O
	
Adverse	O
events	O
were	O
similar	O
in	O
the	O
two	O
arms	O
.	O
	
Nonhematologic	B-TOXI
toxicity	I-TOXI
was	O
predominantly	O
at	O
grade	O
1	O
/	O
2	O
","	O
and	O
neutropenia	B-TOXI
was	O
the	O
most	O
common	O
hematologic	B-TOXI
adverse	I-TOXI
event	I-TOXI
.	O
	
The	O
response	O
rate	O
for	O
arm	O
A	O
was	O
95	O
%	O
","	O
with	O
20	O
%	O
complete	O
responses	O
(	O
CRs	O
)	O
and	O
20	O
%	O
nodular	O
partial	O
responses	O
.	O
	
Of	O
arm	O
B	O
patients	O
","	O
78	O
%	O
achieved	O
a	O
response	O
","	O
of	O
which	O
11	O
%	O
were	O
CRs	O
.	O
	
Median	O
progression-free	O
survival	O
(	O
PFS	O
)	O
was	O
19	O
months	O
for	O
the	O
younger	O
cohort	O
and	O
20	O
months	O
for	O
the	O
older	O
cohort	O
.	O
	
Intrapatient	O
dose-escalation	O
was	O
safe	O
.	O
	
The	O
majority	O
of	O
patients	O
reached	O
the	O
maximum	O
lenalidomide	B-DRUG
dose	O
and	O
experienced	O
a	O
response	O
to	O
a	O
defined	O
seven-cycle	O
course	O
of	O
lenalidomide	B-DRUG
and	O
rituximab	B-DRUG
therapy	O
.	O
	
Despite	O
differences	O
in	O
baseline	O
characteristics	O
and	O
the	O
response	O
rate	O
between	O
the	O
two	O
strata	O
","	O
the	O
PFS	O
did	O
not	O
differ	O
.	O
	
Randomized	O
","	O
phase	O
III	O
trial	O
of	O
first-line	O
figitumumab	B-DRUG
in	O
combination	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
versus	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
alone	O
in	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
Figitumumab	B-DRUG
(	O
"CP-751,871"	O
)	O
","	O
a	O
fully	O
human	O
immunoglobulin	O
G2	O
monoclonal	O
antibody	O
","	O
inhibits	O
the	O
insulin-like	O
growth	O
factor	O
1	O
receptor	O
(	O
IGF-1R	O
)	O
.	O
	
Our	O
multicenter	O
","	O
randomized	O
","	O
phase	O
III	O
study	O
compared	O
figitumumab	B-DRUG
plus	O
chemotherapy	O
with	O
chemotherapy	O
alone	O
as	O
first-line	O
treatment	O
in	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Patients	O
with	O
stage	O
IIIB	O
/	O
IV	O
or	O
recurrent	O
NSCLC	B-CANCER
disease	O
with	O
nonadenocarcinoma	B-CANCER
histology	O
received	O
open-label	O
figitumumab	B-CANCER
(	O
20	O
mg	O
/	O
kg	O
)	O
plus	O
paclitaxel	B-CANCER
(	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
carboplatin	B-CANCER
(	O
area	O
under	O
the	O
concentration-time	O
curve	O
","	O
6	O
mg	O
路	O
min	O
/	O
mL	O
)	O
or	O
paclitaxel	B-CANCER
and	O
carboplatin	B-CANCER
alone	O
once	O
every	O
3	O
weeks	O
for	O
up	O
to	O
six	O
cycles	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
overall	O
survival	O
(	O
OS	O
)	O
.	O
	
Of	O
681	O
randomly	O
assigned	O
patients	O
","	O
671	O
received	O
treatment	O
.	O
	
The	O
study	O
was	O
closed	O
early	O
by	O
an	O
independent	O
Data	O
Safety	O
Monitoring	O
Committee	O
because	O
of	O
futility	O
and	O
an	O
increased	O
incidence	O
of	O
serious	O
adverse	O
events	O
(	O
SAEs	O
)	O
and	O
treatment-related	O
deaths	B-TOXI
with	O
figitumumab	B-DRUG
.	O
	
Median	O
OS	O
was	O
8.6	O
months	O
for	O
figitumumab	B-DRUG
plus	O
chemotherapy	O
and	O
9.8	O
months	O
for	O
chemotherapy	O
alone	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
","	O
1.18	O
;	O
95	O
%	O
CI	O
","	O
0.99	O
to	O
1.4	O
;	O
P	O
=	O
0.06	O
)	O
;	O
median	O
progression-free	O
survival	O
was	O
4.7	O
months	O
(	O
95	O
%	O
CI	O
","	O
4.2	O
to	O
5.4	O
)	O
and	O
4.6	O
months	O
(	O
95	O
%	O
CI	O
","	O
4.2	O
to	O
5.4	O
)	O
","	O
respectively	O
(	O
HR	O
","	O
1.1	O
;	O
P	O
=	O
0.27	O
)	O
;	O
the	O
objective	O
response	O
rates	O
were	O
33	O
%	O
and	O
35	O
%	O
","	O
respectively	O
.	O
	
The	O
respective	O
rates	O
of	O
all-causality	O
SAEs	O
were	O
66	O
%	O
and	O
51	O
%	O
;	O
P	O
&	O
lt	O
;	O
0.01	O
)	O
.	O
	
Treatment-related	O
grade	O
5	O
adverse	O
events	O
were	O
also	O
more	O
common	O
with	O
figitumumab	B-DRUG
(	O
5	O
%	O
v	O
1	O
%	O
;	O
P	O
&	O
lt	O
;	O
0.01	O
)	O
.	O
	
Adding	O
figitumumab	B-DRUG
to	O
standard	O
chemotherapy	O
failed	O
to	O
increase	O
OS	O
in	O
patients	O
with	O
advanced	B-CANCER
nonadenocarcinoma	I-CANCER
NSCLC	I-CANCER
.	O
	
Further	O
clinical	O
development	O
of	O
figitumumab	B-DRUG
is	O
not	O
being	O
pursued	O
.	O
	
A	O
therapeutic	O
trial	O
of	O
decitabine	B-DRUG
and	O
vorinostat	B-DRUG
in	O
combination	O
with	O
chemotherapy	O
for	O
relapsed	O
/	O
refractory	O
acute	B-CANCER
lymphoblastic	I-CANCER
leukemia	I-CANCER
.	O
	
	
DNA	O
hypermethylation	O
and	O
histone	O
deacetylation	O
are	O
pathways	O
of	O
leukemia	B-CANCER
resistance	O
.	O
	
We	O
investigated	O
the	O
tolerability	O
and	O
efficacy	O
of	O
decitabine	B-DRUG
and	O
vorinostat	B-DRUG
plus	O
chemotherapy	O
in	O
relapse	O
/	O
refractory	O
acute	B-CANCER
lymphoblastic	I-CANCER
leukemia	I-CANCER
(	O
ALL	B-CANCER
)	O
.	O
	
Decitabine	B-DRUG
(	O
15	O
mg	O
/	O
m	O
(	O
2	O
)	O
iv	O
)	O
and	O
vorinostat	B-DRUG
(	O
230	O
mg	O
/	O
m	O
(	O
2	O
)	O
PO	O
div	O
BID	O
)	O
were	O
given	O
days	O
1月4日	O
followed	O
by	O
vincristine	B-DRUG
","	O
prednisone	B-DRUG
","	O
PEG-asparaginase	B-DRUG
","	O
and	O
doxorubicin	B-DRUG
.	O
	
Genome	O
wide	O
methylation	O
profiles	O
were	O
performed	O
in	O
8	O
matched	O
patient	O
bone	O
marrow	O
(	O
BM	O
)	O
samples	O
taken	O
at	O
day	O
0	O
and	O
day	O
5	O
(	O
postdecitabine	B-DRUG
)	O
.	O
	
The	O
median	O
age	O
was	O
16	O
(	O
range	O
","	O
3-54	O
)	O
years	O
.	O
	
All	O
patients	O
had	O
a	O
prior	O
BM	O
relapse	O
","	O
with	O
five	O
relapsing	O
after	O
allogeneic	O
transplant	O
.	O
	
The	O
most	O
common	O
nonhematological	B-TOXI
toxicities	I-TOXI
possibly	O
related	O
to	O
decitabine	B-DRUG
or	O
vorinostat	B-DRUG
were	O
infection	O
with	O
neutropenia	B-TOXI
(	O
grade	O
3	O
;	O
n	O
=	O
4	O
)	O
and	O
fever	B-TOXI
/	O
neutropenia	B-TOXI
(	O
grade	O
3	O
","	O
n	O
=	O
4	O
;	O
grade	O
4	O
","	O
n	O
=	O
1	O
)	O
.	O
	
Of	O
the	O
13	O
eligible	O
patients	O
","	O
four	O
achieved	O
complete	O
remission	O
without	O
platelet	O
recovery	O
(	O
CRp	O
)	O
","	O
two	O
partial	O
response	O
(	O
PR	O
)	O
","	O
one	O
stable	O
disease	O
(	O
SD	O
)	O
","	O
one	O
progressive	O
disease	O
(	O
PD	O
)	O
","	O
two	O
deaths	B-TOXI
on	O
study	O
and	O
three	O
patients	O
who	O
did	O
not	O
have	O
end	O
of	O
therapy	O
disease	O
evaluations	O
for	O
an	O
overall	O
response	O
rate	O
of	O
46.2	O
%	O
(	O
CRp	O
=+	O
PR	O
)	O
.	O
	
Following	O
decitabine	B-DRUG
","	O
significant	O
genome-wide	O
hypo-methylation	O
was	O
observed	O
.	O
	
Comparison	O
of	O
clinical	O
responders	O
with	O
nonresponders	O
identified	O
methylation	O
profiles	O
of	O
clinical	O
and	O
biological	O
relevance	O
.	O
	
Decitabine	B-DRUG
and	O
vorinostat	B-DRUG
followed	O
by	O
re-Induction	O
chemotherapy	O
was	O
tolerable	O
and	O
demonstrated	O
clinical	O
benefit	O
in	O
relapsed	O
patients	O
with	O
ALL	B-CANCER
.	O
	
Methylation	O
differences	O
were	O
identified	O
between	O
responders	O
and	O
nonresponders	O
indicating	O
interpatient	O
variation	O
","	O
which	O
could	O
impact	O
clinical	O
outcome	O
.	O
	
This	O
study	O
was	O
registered	O
at	O
www.clinicaltrials.gov	O
as	O
NCT00882206	O
.	O
	
A	O
phase	O
I	O
dose	O
escalation	O
trial	O
of	O
tremelimumab	B-DRUG
(	O
"CP-675,206"	O
)	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
chemotherapy-naive	O
patients	O
with	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
	
Tremelimumab	B-DRUG
(	O
"CP-675,206"	O
)	O
is	O
a	O
fully	O
human	O
monoclonal	O
antibody	O
binding	O
to	O
cytotoxic	O
T-lymphocyte-associated	O
antigen	O
4	O
(	O
CTLA4	O
)	O
on	O
T	O
cells	O
that	O
stimulates	O
the	O
immune	O
system	O
by	O
blocking	O
the	O
CTLA4-negative	O
regulatory	O
signal	O
.	O
	
Combination	O
with	O
standard	O
chemotherapy	O
may	O
strengthen	O
antitumor	O
therapy	O
.	O
	
This	O
is	O
a	O
phase	O
Ib	O
","	O
multisite	O
","	O
open-label	O
","	O
nonrandomized	O
dose	O
escalation	O
trial	O
evaluating	O
the	O
safety	O
","	O
tolerability	O
","	O
and	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
tremelimumab	B-DRUG
combined	O
with	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
Gemcitabine	B-DRUG
(	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
of	O
each	O
28-day	O
cycles	O
)	O
was	O
administrated	O
with	O
escalating	O
doses	O
of	O
i.v.	O
tremelimumab	B-DRUG
(	O
6	O
","	O
10	O
","	O
or	O
15	O
mg	O
/	O
kg	O
)	O
on	O
day	O
1	O
of	O
each	O
84-day	O
cycle	O
for	O
a	O
maximum	O
of	O
4	O
cycles	O
.	O
	
The	O
first	O
18	O
patients	O
had	O
an	O
initial	O
4-week	O
gemcitabine-only	B-DRUG
lead-in	O
period	O
.	O
	
Dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
related	O
to	O
tremelimumab	B-DRUG
were	O
evaluated	O
during	O
the	O
first	O
6	O
weeks	O
after	O
the	O
first	O
dose	O
of	O
tremelimumab	B-DRUG
.	O
	
From	O
June	O
2008	O
to	O
August	O
2011	O
","	O
34	O
patients	O
were	O
enrolled	O
and	O
received	O
at	O
least	O
one	O
dose	O
of	O
tremelimumab	B-DRUG
.	O
	
No	O
DLTs	O
related	O
to	O
tremelimumab	B-DRUG
were	O
observed	O
at	O
any	O
dose	O
","	O
even	O
when	O
the	O
maximum	O
dose	O
established	O
for	O
tremelimumab	B-DRUG
(	O
15	O
mg	O
/	O
kg	O
)	O
was	O
used	O
.	O
	
Most	O
frequent	O
grade	O
3	O
/	O
4	O
toxicities	O
were	O
asthenia	B-TOXI
(	O
11.8	O
%	O
)	O
and	O
nausea	B-TOXI
(	O
8.8	O
%	O
)	O
.	O
	
Only	O
one	O
patient	O
had	O
a	O
serious	O
drug-related	O
event	O
(	O
diarrhea	B-TOXI
with	O
dehydration	B-TOXI
)	O
.	O
	
The	O
median	O
overall	O
survival	O
was	O
7.4	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
5.8-9.4	O
months	O
)	O
.	O
	
At	O
the	O
end	O
of	O
treatment	O
","	O
two	O
patients	O
achieved	O
partial	O
response	O
.	O
	
Both	O
patients	O
received	O
tremelimumab	B-DRUG
15-mg	O
/	O
kg	O
group	O
(	O
n	O
=	O
2	O
/	O
19	O
","	O
10.5	O
%	O
)	O
.	O
	
Tremelimumab	B-DRUG
plus	O
gemcitabine	B-DRUG
demonstrated	O
a	O
safety	O
and	O
tolerability	O
profile	O
","	O
warranting	O
further	O
study	O
in	O
patients	O
with	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
NCT00556023	O
.	O
	
Anastrozole	B-DRUG
and	O
everolimus	B-DRUG
in	O
advanced	B-CANCER
gynecologic	I-CANCER
and	I-CANCER
breast	I-CANCER
malignancies	I-CANCER
:	O
activity	O
and	O
molecular	O
alterations	O
in	O
the	O
PI3K	O
/	O
AKT	O
/	O
mTOR	O
pathway	O
.	O
	
	
Since	O
PI3K	O
/	O
AKT	O
/	O
mTOR	O
pathway	O
activation	O
diminishes	O
the	O
effects	O
of	O
hormone	O
therapy	O
","	O
combining	O
aromatase	O
inhibitors	O
(	O
anatrozole	B-DRUG
)	O
with	O
mTOR	O
inhibitors	O
(	O
everolimus	B-DRUG
)	O
was	O
investigated	O
.	O
	
We	O
evaluated	O
anastrozole	B-DRUG
and	O
everolimus	B-DRUG
in	O
55	O
patients	O
with	O
metastatic	O
estrogen	O
(	O
ER	O
)	O
and	O
/	O
or	O
progesterone	O
receptor	O
(	O
PR	O
)	O
#NAME?	O
breast	B-CANCER
and	I-CANCER
gynecologic	I-CANCER
tumors	I-CANCER
.	O
	
Endpoints	O
were	O
safety	O
","	O
antitumor	O
activity	O
and	O
molecular	O
correlates	O
.	O
	
Full	O
doses	O
of	O
anastrozole	B-DRUG
(	O
1	O
mg	O
PO	O
daily	O
)	O
and	O
everolimus	B-DRUG
(	O
10	O
mg	O
PO	O
daily	O
)	O
were	O
well	O
tolerated	O
.	O
	
Twelve	O
of	O
50	O
evaluable	O
patients	O
(	O
24	O
%	O
)	O
(	O
median	O
=	O
3	O
prior	O
therapies	O
)	O
achieved	O
stable	O
disease	O
(	O
SD	O
)	O
_	O
6	O
months	O
/	O
partial	O
response	O
(	O
PR	O
)	O
/	O
complete	O
response	O
(	O
CR	O
)	O
(	O
n	O
=	O
5	O
(	O
10	O
%	O
)	O
with	O
PR	O
/	O
CR	O
)	O
:	O
9	O
of	O
32	O
(	O
28	O
%	O
)	O
with	O
breast	B-CANCER
cancer	I-CANCER
(	O
n=5	O
(	O
16	O
%	O
)	O
with	O
PR	O
/	O
CR	O
)	O
;	O
2	O
of	O
10	O
(	O
20	O
%	O
)	O
","	O
ovarian	B-CANCER
cancer	I-CANCER
;	O
and	O
1	O
of	O
6	O
(	O
17	O
%	O
)	O
","	O
endometrial	B-CANCER
cancer	I-CANCER
.	O
	
Six	O
of	O
22	O
patients	O
(	O
27	O
%	O
)	O
with	O
molecular	O
alterations	O
in	O
the	O
PI3K	O
/	O
AKT	O
/	O
mTOR	O
pathway	O
achieved	O
SD	O
_	O
6	O
months	O
/	O
PR	O
/	O
CR	O
.	O
	
Six	O
of	O
8	O
patients	O
(	O
75	O
%	O
)	O
with	O
SD	O
_	O
6	O
months	O
/	O
PR	O
/	O
CR	O
with	O
molecular	O
testing	O
demonstrated	O
at	O
least	O
one	O
alteration	O
in	O
the	O
PI3K	O
/	O
AKT	O
/	O
mTOR	O
pathway	O
:	O
mutations	O
in	O
PIK3CA	O
(	O
n=3	O
)	O
and	O
AKT1	O
(	O
n=1	O
)	O
or	O
PTEN	O
loss	O
(	O
n=3	O
)	O
.	O
	
All	O
three	O
responders	O
(	O
CR	O
(	O
n	O
=	O
1	O
)	O
;	O
PR	O
(	O
n=2	O
)	O
)	O
who	O
had	O
next	O
generation	O
sequencing	O
demonstrated	O
additional	O
alterations	O
:	O
amplifications	O
in	O
CCNE1	O
","	O
IRS2	O
","	O
MCL1	O
","	O
CCND1	O
","	O
FGFR1	O
and	O
MYC	O
and	O
a	O
rearrangement	O
in	O
PRKDC	O
.	O
	
Combination	O
anastrozole	B-DRUG
and	O
everolimus	B-DRUG
is	O
well	O
tolerated	O
at	O
full	O
approved	O
doses	O
","	O
and	O
is	O
active	O
in	O
heavily-pretreated	O
patients	O
with	O
ER	O
and	O
/	O
or	O
PR-positive	O
breast	O
","	O
ovarian	B-CANCER
and	I-CANCER
endometrial	I-CANCER
cancers	I-CANCER
.	O
	
Responses	O
were	O
observed	O
in	O
patients	O
with	O
multiple	O
molecular	O
aberrations	O
.	O
	
CLINICAL	O
TRAILS	O
INCLUDED	O
:	O
NCT01197170	O
.	O
	
A	O
phase	O
I	O
clinical	O
trial	O
of	O
navitoclax	B-DRUG
","	O
a	O
targeted	O
high-affinity	O
Bcl-2	O
family	O
inhibitor	O
","	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
To	O
investigate	O
the	O
safety	O
","	O
optimal	O
dosing	O
","	O
pharmacokinetics	O
and	O
clinical	O
activity	O
of	O
a	O
regimen	O
of	O
navitoclax	B-DRUG
(	O
ABT-263	O
)	O
combined	O
with	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
Patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
for	O
which	O
gemcitabine	B-DRUG
was	O
deemed	O
an	O
appropriate	O
therapy	O
were	O
enrolled	O
into	O
one	O
of	O
two	O
different	O
dosing	O
schedules	O
(	O
21-day	O
dosing	O
schedule	O
:	O
navitoclax	B-DRUG
administered	O
orally	O
on	O
days	O
1月3日	O
and	O
8月10日	O
","	O
;	O
and	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
and	O
8	O
;	O
28-day	O
dosing	O
schedule	O
:	O
navitoclax	B-DRUG
administrated	O
orally	O
on	O
days	O
1月3日	O
","	O
8月10日	O
","	O
and	O
15-17	O
;	O
and	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
","	O
8	O
and	O
15	O
)	O
.	O
	
Navitoclax	B-DRUG
doses	O
were	O
escalated	O
from	O
150	O
to	O
425	O
mg	O
.	O
	
An	O
expanded	O
safety	O
cohort	O
was	O
conducted	O
for	O
the	O
21-day	O
dosing	O
schedule	O
at	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
navitoclax	B-DRUG
.	O
	
Forty-six	O
patients	O
were	O
enrolled	O
at	O
three	O
U.S.	O
centers	O
.	O
	
The	O
most	O
common	O
adverse	O
events	O
included	O
:	O
hematologic	B-TOXI
abnormalities	I-TOXI
(	O
thrombocytopenia	B-TOXI
","	O
neutropenia	B-TOXI
","	O
and	O
anemia	B-TOXI
)	O
","	O
liver	B-TOXI
enzyme	I-TOXI
elevations	I-TOXI
(	O
ALT	O
and	O
AST	O
)	O
","	O
and	O
gastrointestinal	B-TOXI
disturbances	I-TOXI
(	O
diarrhea	B-TOXI
","	O
nausea	B-TOXI
","	O
and	O
vomiting	B-TOXI
)	O
.	O
	
Dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
observed	O
in	O
cycle	O
1	O
were	O
grade	O
4	O
thrombocytopenia	B-TOXI
(	O
2	O
patients	O
)	O
","	O
grade	O
4	O
neutropenia	B-TOXI
(	O
1	O
patient	O
)	O
","	O
and	O
grade	O
3	O
AST	B-TOXI
elevation	I-TOXI
(	O
2	O
patients	O
)	O
.	O
	
The	O
MTD	O
of	O
navitoclax	B-DRUG
was	O
325	O
mg	O
co-administered	O
with	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
the	O
21-day	O
schedule	O
.	O
	
No	O
clinically	O
significant	O
pharmacokinetic	O
drug-drug	O
interactions	O
were	O
observed	O
.	O
	
There	O
were	O
no	O
objective	O
responses	O
.	O
	
Stable	O
disease	O
","	O
reported	O
at	O
the	O
end	O
of	O
cycle	O
2	O
","	O
was	O
the	O
best	O
response	O
in	O
54	O
%	O
of	O
evaluable	O
patients	O
(	O
n	O
=	O
39	O
)	O
.	O
	
The	O
combination	O
of	O
navitoclax	B-DRUG
325	O
mg	O
with	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
was	O
generally	O
well	O
tolerated	O
and	O
exhibited	O
a	O
favorable	O
safety	O
profile	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
A	O
multicenter	O
phase	O
1	O
study	O
of	O
PX-866	B-DRUG
and	O
cetuximab	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
or	O
recurrent	O
/	O
metastatic	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
	
This	O
phase	O
I	O
","	O
dose-finding	O
study	O
determined	O
the	O
safety	O
","	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
/	O
recommended	O
phase	O
2	O
dose	O
(	O
RP2D	O
)	O
","	O
and	O
antitumor	O
activity	O
of	O
PX-866	B-DRUG
","	O
a	O
phosphatidylinositol	O
3-kinase	O
inhibitor	O
","	O
combined	O
with	O
cetuximab	B-DRUG
in	O
patients	O
with	O
incurable	O
colorectal	B-CANCER
cancer	I-CANCER
or	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
PX-866	B-DRUG
was	O
administered	O
at	O
escalating	O
doses	O
(	O
6月8日	O
mg	O
daily	O
)	O
combined	O
with	O
cetuximab	B-DRUG
given	O
at	O
a	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
loading	O
dose	O
followed	O
by	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
.	O
	
A	O
	O
study	O
design	O
was	O
used	O
.	O
	
Prior	O
therapy	O
with	O
anti-EGFR	O
therapies	O
","	O
including	O
cetuximab	B-DRUG
","	O
was	O
allowed	O
.	O
	
Eleven	O
patients	O
were	O
enrolled	O
.	O
	
The	O
most	O
frequent	O
treatment-emergent	O
adverse	O
event	O
was	O
diarrhea	B-TOXI
(	O
90.1	O
%	O
)	O
","	O
followed	O
by	O
hypomagnesemia	B-TOXI
(	O
72.2	O
%	O
)	O
","	O
vomiting	B-TOXI
(	O
72.2	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
54.5	O
%	O
)	O
","	O
nausea	B-TOXI
(	O
54.5	O
%	O
)	O
","	O
rash	B-TOXI
(	O
45.5	O
%	O
)	O
and	O
peripheral	B-TOXI
edema	I-TOXI
(	O
40	O
%	O
)	O
.	O
	
No	O
dose	O
limiting	O
toxicities	O
were	O
observed	O
.	O
	
The	O
RP2D	O
was	O
8	O
mg	O
","	O
the	O
same	O
as	O
the	O
single-agent	O
PX-866	B-DRUG
MTD	O
.	O
	
Best	O
responses	O
in	O
9	O
evaluable	O
patients	O
were	O
:	O
4	O
partial	O
responses	O
(	O
44.4	O
%	O
)	O
","	O
4	O
stable	O
disease	O
(	O
44.4	O
%	O
)	O
","	O
and	O
1	O
disease	O
progression	O
(	O
11.1	O
%	O
)	O
.	O
	
The	O
median	O
progression	O
free	O
survival	O
was	O
106	O
days	O
(	O
range	O
:	O
1-271	O
)	O
.	O
	
Treatment	O
with	O
PX-866	B-DRUG
and	O
cetuximab	B-DRUG
was	O
tolerated	O
with	O
signs	O
of	O
anti-tumor	O
activity	O
.	O
	
Further	O
development	O
of	O
this	O
combination	O
is	O
warranted	O
.	O
	
Phase	O
1b	O
study	O
of	O
otlertuzumab	B-DRUG
(	O
TRU-016	O
)	O
","	O
an	O
anti-CD37	O
monospecific	O
ADAPTIR_	O
therapeutic	O
protein	O
","	O
in	O
combination	O
with	O
rituximab	B-DRUG
and	O
bendamustine	B-DRUG
in	O
relapsed	O
indolent	B-CANCER
lymphoma	I-CANCER
patients	O
.	O
	
	
CD37	O
is	O
cell	O
surface	O
tetraspanin	O
present	O
on	O
normal	O
and	O
malignant	O
B	O
cells	O
.	O
	
Otlertuzumab	B-DRUG
(	O
TRU-016	B-DRUG
)	O
is	O
a	O
novel	O
humanized	O
anti-CD37	O
protein	O
therapeutic	O
that	O
triggers	O
direct	O
caspase	O
independent	O
apoptosis	O
of	O
malignant	O
B	O
cells	O
and	O
induces	O
antibody-dependent	O
cell-mediated	O
cytotoxicity	O
.	O
	
This	O
study	O
evaluated	O
the	O
safety	O
","	O
pharmacokinetics	O
","	O
and	O
efficacy	O
of	O
otlertuzumab	B-DRUG
administered	O
in	O
combination	O
with	O
rituximab	B-DRUG
and	O
bendamustine	B-DRUG
to	O
patients	O
with	O
relapsed	O
","	O
indolent	O
B-cell	O
non-Hodgkin	B-CANCER
Lymphoma	I-CANCER
(	O
NHL	B-CANCER
)	O
.	O
	
Patients	O
with	O
relapsed	O
or	O
refractory	O
NHL	B-CANCER
received	O
otlertuzumab	B-DRUG
(	O
10	O
or	O
20	O
mg	O
/	O
kg	O
)	O
intravenously	O
(	O
IV	O
)	O
on	O
days	O
1	O
and	O
15	O
","	O
bendamustine	B-DRUG
(	O
90	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
on	O
days	O
1	O
and	O
2	O
","	O
and	O
rituximab	B-DRUG
(	O
375	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
on	O
day	O
1	O
for	O
up	O
to	O
six	O
28	O
day	O
cycles	O
.	O
	
Responses	O
were	O
determined	O
using	O
standard	O
criteria	O
.	O
	
Twelve	O
patients	O
were	O
treated	O
with	O
6	O
patients	O
at	O
each	O
dose	O
level	O
;	O
median	O
age	O
was	O
57	O
years	O
(	O
range	O
","	O
51-79	O
)	O
","	O
and	O
median	O
number	O
of	O
prior	O
regimens	O
was	O
3	O
(	O
range	O
","	O
1月4日	O
)	O
.	O
	
All	O
patients	O
had	O
relapsed	O
after	O
prior	O
rituximab	B-DRUG
including	O
7	O
refractory	O
to	O
their	O
most	O
recent	O
previous	O
treatment	O
.	O
	
In	O
the	O
10	O
and	O
20	O
mg	O
/	O
kg	O
dose	O
cohorts	O
","	O
the	O
mean	O
half-life	O
was	O
8	O
and	O
10	O
days	O
following	O
the	O
first	O
dose	O
","	O
and	O
12	O
or	O
14	O
days	O
following	O
12	O
doses	O
of	O
otlertuzumab	B-DRUG
","	O
respectively	O
.	O
	
Overall	O
response	O
rate	O
was	O
83	O
%	O
(	O
10	O
/	O
12	O
)	O
with	O
4	O
CRs	O
(	O
32	O
%	O
)	O
.	O
	
The	O
most	O
frequent	O
adverse	O
events	O
were	O
neutropenia	B-TOXI
","	O
nausea	B-TOXI
","	O
fatigue	B-TOXI
","	O
leukopenia	B-TOXI
","	O
and	O
insomnia	B-TOXI
;	O
most	O
were	O
grade	O
1	O
or	O
2	O
Otlertuzumab	B-DRUG
in	O
combination	O
with	O
rituximab	B-DRUG
and	O
bendamustine	B-DRUG
was	O
well	O
tolerated	O
and	O
induced	O
responses	O
in	O
the	O
majority	O
of	O
patients	O
with	O
relapsed	O
indolent	O
B-NHL	B-CANCER
.	O
	
NCI	O
Clinical	O
Trials	O
Network	O
registration	O
:	O
NCT01317901	O
.	O
	
Phase	O
I	O
clinical	O
trial	O
of	O
ifosfamide	B-DRUG
","	O
oxaliplatin	B-DRUG
","	O
and	O
etoposide	B-DRUG
(	O
IOE	B-DRUG
)	O
in	O
pediatric	O
patients	O
with	O
refractory	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Oxaliplatin	B-DRUG
","	O
although	O
related	O
to	O
cisplatin	B-DRUG
and	O
carboplatin	B-DRUG
","	O
has	O
a	O
more	O
favorable	O
toxicity	O
profile	O
and	O
may	O
offer	O
advantages	O
in	O
combination	O
regimens	O
.	O
	
We	O
combined	O
oxaliplatin	B-DRUG
","	O
ifosfamide	B-DRUG
","	O
and	O
etoposide	B-DRUG
(	O
IOE	B-DRUG
)	O
and	O
estimated	O
the	O
regimen	O
's	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
in	O
children	O
with	O
refractory	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
and	O
MTD	O
were	O
assessed	O
at	O
3	O
dose	O
levels	O
in	O
a	O
21-day	O
regimen	O
:	O
day	O
1	O
","	O
oxaliplatin	B-DRUG
130	O
mg	O
/	O
m	O
(	O
consistent	O
dose	O
)	O
;	O
days	O
1	O
to	O
3	O
","	O
ifosfamide	B-DRUG
1200	O
mg	O
/	O
m	O
/	O
d	O
(	O
level	O
0	O
)	O
or	O
1500	O
mg	O
/	O
m	O
/	O
d	O
(	O
levels	O
1	O
and	O
2	O
)	O
and	O
etoposide	B-DRUG
75	O
mg	O
/	O
m	O
/	O
d	O
(	O
levels	O
0	O
and	O
1	O
)	O
or	O
100	O
mg	O
/	O
m	O
/	O
d	O
(	O
level	O
2	O
)	O
.	O
	
Course	O
1	O
filgrastim	B-DRUG
/	O
pegfilgrastim	B-DRUG
was	O
permitted	O
after	O
initial	O
DLT	O
determination	O
","	O
if	O
neutropenia	B-TOXI
was	O
dose	O
limiting	O
.	O
	
Seventeen	O
patients	O
received	O
59	O
courses	O
.	O
	
Without	O
filgrastim	B-DRUG
(	O
n=9	O
)	O
","	O
DLT	O
was	O
neutropenia	B-TOXI
in	O
2	O
patients	O
at	O
dose	O
level	O
1	O
No	O
DLT	O
was	O
observed	O
after	O
adding	O
filgrastim	B-DRUG
(	O
n=8	O
)	O
.	O
	
There	O
was	O
no	B-TOXI
ototoxicity	I-TOXI
","	O
nephrotoxicity	B-TOXI
&	O
gt	O
;	O
grade	O
1	O
","	O
or	O
neurotoxicity	B-TOXI
&	O
gt	O
;	O
grade	O
2	O
One	O
patient	O
experienced	O
a	O
partial	O
response	O
and	O
9	O
had	O
stable	O
disease	O
after	O
2	O
courses	O
.	O
	
In	O
conclusion	O
","	O
the	O
IOE	B-DRUG
regimen	O
was	O
well	O
tolerated	O
.	O
	
Without	O
filgrastim	B-DRUG
","	O
neutropenia	B-TOXI
was	O
dose	O
limiting	O
with	O
MTD	O
at	O
ifosfamide	B-DRUG
1200	O
mg	O
/	O
m	O
/	O
d	O
and	O
etoposide	B-DRUG
75	O
mg	O
/	O
m	O
/	O
d.	O
The	O
MTD	O
with	O
filgrastim	B-DRUG
was	O
not	O
defined	O
due	O
to	O
early	O
study	O
closure	O
.	O
	
Filgrastim	B-DRUG
allowed	O
ifosfamide	B-DRUG
and	O
etoposide	B-DRUG
dose	O
escalation	O
and	O
should	O
be	O
included	O
in	O
future	O
studies	O
.	O
	
A	O
phase	O
IIa	O
dose-finding	O
and	O
safety	O
study	O
of	O
first-line	O
pertuzumab	B-DRUG
in	O
combination	O
with	O
trastuzumab	B-DRUG
","	O
capecitabine	B-DRUG
and	O
cisplatin	B-DRUG
in	O
patients	O
with	O
HER2-positive	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
	
Pertuzumab	B-DRUG
plus	O
trastuzumab	B-DRUG
provides	O
a	O
more	O
comprehensive	O
blockade	O
of	O
HER2	O
signalling	O
than	O
trastuzumab	B-DRUG
alone	O
.	O
	
Therefore	O
","	O
we	O
conducted	O
a	O
phase	O
IIa	O
study	O
of	O
the	O
pharmacokinetics	O
and	O
safety	O
of	O
pertuzumab	B-DRUG
plus	O
trastuzumab	B-DRUG
and	O
chemotherapy	O
in	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
(	O
aGC	B-CANCER
)	O
.	O
	
Patients	O
received	O
pertuzumab	B-DRUG
840	O
mg	O
for	O
cycle	O
1	O
and	O
420	O
mg	O
q3w	O
for	O
cycles	O
2月6日	O
(	O
Arm	O
A	O
)	O
or	O
pertuzumab	B-DRUG
840	O
mg	O
q3w	O
for	O
six	O
cycles	O
(	O
Arm	O
B	O
)	O
.	O
	
Trastuzumab	B-DRUG
","	O
cisplatin	B-DRUG
and	O
capecitabine	B-DRUG
were	O
also	O
given	O
for	O
six	O
cycles	O
","	O
then	O
trastuzumab	B-DRUG
q3w	O
until	O
disease	O
progression	O
or	O
unmanageable	O
toxicity	O
.	O
	
The	O
co-primary	O
endpoints	O
were	O
day	O
43	O
pertuzumab	B-DRUG
serum	O
trough	O
concentration	O
(	O
Cmin	O
)	O
and	O
safety	O
.	O
	
Thirty	O
patients	O
were	O
randomised	O
.	O
	
Mean	O
pertuzumab	B-DRUG
Cmin	O
at	O
day	O
43	O
was	O
40	O
渭g	O
ml	O
(	O
-1	O
)	O
(	O
s.d.	O
:	O
17.3	O
)	O
in	O
Arm	O
A	O
and	O
62.7	O
渭g	O
ml	O
(	O
-1	O
)	O
(	O
29.1	O
)	O
in	O
Arm	O
B.	O
Mean	O
day	O
43	O
Cmin	O
in	O
Arm	O
A	O
was	O
~37	O
%	O
lower	O
than	O
that	O
seen	O
in	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
The	O
safety	O
profiles	O
were	O
similar	O
between	O
arms	O
and	O
treatment	O
was	O
well	O
tolerated	O
.	O
	
Partial	O
responses	O
were	O
achieved	O
by	O
86	O
%	O
and	O
55	O
%	O
of	O
patients	O
in	O
Arms	O
A	O
and	O
B	O
","	O
respectively	O
.	O
	
On	O
the	O
basis	O
of	O
the	O
pharmacokinetic	O
and	O
safety	O
data	O
","	O
the	O
840	O
mg	O
q3w	O
pertuzumab	B-DRUG
dose	O
has	O
been	O
selected	O
for	O
a	O
phase	O
III	O
study	O
of	O
pertuzumab	B-DRUG
","	O
trastuzumab	B-DRUG
and	O
chemotherapy	O
in	O
HER2-positive	O
aGC	B-CANCER
.	O
	
Combined	O
MTOR	O
and	O
autophagy	O
inhibition	O
:	O
phase	O
I	O
trial	O
of	O
hydroxychloroquine	B-DRUG
and	O
temsirolimus	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
and	O
melanoma	B-CANCER
.	O
	
	
The	O
combination	O
of	O
temsirolimus	B-DRUG
(	O
TEM	B-DRUG
)	O
","	O
an	O
MTOR	O
inhibitor	O
","	O
and	O
hydroxychloroquine	B-DRUG
(	O
HCQ	B-DRUG
)	O
","	O
an	O
autophagy	O
inhibitor	O
","	O
augments	O
cell	O
death	O
in	O
preclinical	O
models	O
.	O
	
This	O
phase	O
1	O
dose-escalation	O
study	O
evaluated	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
safety	O
","	O
preliminary	O
activity	O
","	O
pharmacokinetics	O
","	O
and	O
pharmacodynamics	O
of	O
HCQ	B-DRUG
in	O
combination	O
with	O
TEM	B-DRUG
in	O
cancer	O
patients	O
.	O
	
In	O
the	O
dose	O
escalation	O
portion	O
","	O
27	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
malignancies	I-CANCER
were	O
enrolled	O
","	O
followed	O
by	O
a	O
cohort	O
expansion	O
at	O
the	O
top	O
dose	O
level	O
in	O
12	O
patients	O
with	O
metastatic	B-CANCER
melanoma	I-CANCER
.	O
	
The	O
combination	O
of	O
HCQ	B-DRUG
and	O
TEM	B-DRUG
was	O
well	O
tolerated	O
","	O
and	O
grade	O
3	O
or	O
4	O
toxicity	O
was	O
limited	O
to	O
anorexia	B-TOXI
(	O
7	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
7	O
%	O
)	O
","	O
and	O
nausea	B-TOXI
(	O
7	O
%	O
)	O
.	O
	
An	O
MTD	O
was	O
not	O
reached	O
for	O
HCQ	B-DRUG
","	O
and	O
the	O
recommended	O
phase	O
II	O
dose	O
was	O
HCQ	B-DRUG
600	O
mg	O
twice	O
daily	O
in	O
combination	O
with	O
TEM	B-DRUG
25	O
mg	O
weekly	O
.	O
	
Other	O
common	O
grade	O
1	O
or	O
2	O
toxicities	O
included	O
fatigue	B-TOXI
","	O
anorexia	B-TOXI
","	O
nausea	B-TOXI
","	O
stomatitis	B-TOXI
","	O
rash	B-TOXI
","	O
and	O
weight	B-TOXI
loss	I-TOXI
.	O
	
No	O
responses	O
were	O
observed	O
;	O
however	O
","	O
14	O
/	O
21	O
(	O
67	O
%	O
)	O
patients	O
in	O
the	O
dose	O
escalation	O
and	O
14	O
/	O
19	O
(	O
74	O
%	O
)	O
patients	O
with	O
melanoma	B-CANCER
achieved	O
stable	O
disease	O
.	O
	
The	O
median	O
progression-free	O
survival	O
in	O
13	O
melanoma	B-CANCER
patients	O
treated	O
with	O
HCQ	B-DRUG
1200mg	O
/	O
d	O
in	O
combination	O
with	O
TEM	B-DRUG
was	O
3.5	O
mo.	O
Novel	O
18-fluorodeoxyglucose	B-DRUG
positron	O
emission	O
tomography	O
(	O
FDG-PET	O
)	O
measurements	O
predicted	O
clinical	O
outcome	O
and	O
provided	O
further	O
evidence	O
that	O
the	O
addition	O
of	O
HCQ	B-DRUG
to	O
TEM	B-DRUG
produced	O
metabolic	O
stress	O
on	O
tumors	O
in	O
patients	O
that	O
experienced	O
clinical	O
benefit	O
.	O
	
Pharmacodynamic	O
evidence	O
of	O
autophagy	O
inhibition	O
was	O
evident	O
in	O
serial	O
PBMC	O
and	O
tumor	O
biopsies	O
only	O
in	O
patients	O
treated	O
with	O
1200	O
mg	O
daily	O
HCQ	B-DRUG
.	O
	
This	O
study	O
indicates	O
that	O
TEM	B-DRUG
and	O
HCQ	B-DRUG
is	O
safe	O
and	O
tolerable	O
","	O
modulates	O
autophagy	O
in	O
patients	O
","	O
and	O
has	O
significant	O
antitumor	O
activity	O
.	O
	
Further	O
studies	O
combining	O
MTOR	O
and	O
autophagy	O
inhibitors	O
in	O
cancer	O
patients	O
are	O
warranted	O
.	O
	
A	O
phase	O
II	O
study	O
of	O
GW786034	B-DRUG
(	O
pazopanib	B-DRUG
)	O
with	O
or	O
without	O
bicalutamide	B-DRUG
in	O
patients	O
with	O
castration-resistant	O
prostate	B-CANCER
cancer	I-CANCER
.	O
	
	
Pazopanib	B-DRUG
is	O
an	O
oral	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
(	O
VEGFR	O
)	O
tyrosine	O
kinase	O
inhibitor	O
.	O
	
In	O
this	O
randomized	O
","	O
open	O
label	O
phase	O
II	O
study	O
","	O
pazopanib	B-DRUG
alone	O
or	O
in	O
combination	O
with	O
bicalutamide	B-DRUG
was	O
evaluated	O
in	O
patients	O
with	O
chemotherapy-naive	O
castration-resistant	B-CANCER
prostate	I-CANCER
cancer	I-CANCER
(	O
CRPC	B-CANCER
)	O
.	O
	
Patients	O
received	O
either	O
pazopanib	B-DRUG
800	O
mg	O
daily	O
(	O
arm	O
A	O
)	O
or	O
pazopanib	B-DRUG
800	O
mg	O
plus	O
bicalutamide	B-DRUG
50	O
mg	O
daily	O
(	O
arm	O
B	O
)	O
.	O
	
A	O
2-stage	O
study	O
design	O
was	O
used	O
","	O
and	O
the	O
primary	O
endpoint	O
was	O
prostate-specific	O
antigen	O
(	O
PSA	O
)	O
response	O
rate	O
(	O
defined	O
as	O
a	O
confirmed	O
_	O
50	O
%	O
decline	O
from	O
baseline	O
)	O
.	O
	
A	O
total	O
of	O
23	O
patients	O
(	O
arm	O
A	O
","	O
10	O
;	O
arm	O
B	O
","	O
13	O
)	O
were	O
accrued	O
.	O
	
The	O
main	O
grade	O
3+	O
toxicities	O
were	O
hypertension	B-TOXI
","	O
fatigue	B-TOXI
","	O
decreased	B-TOXI
lymphocytes	I-TOXI
","	O
and	O
increased	B-TOXI
alanine	I-TOXI
transaminase	I-TOXI
.	O
	
Owing	O
to	O
significant	O
toxicity	O
","	O
the	O
protocol	O
was	O
amended	O
after	O
the	O
first	O
11	O
patients	O
and	O
the	O
pazopanib	B-DRUG
starting	O
dose	O
was	O
reduced	O
to	O
600	O
mg	O
daily	O
.	O
	
In	O
arm	O
A	O
","	O
of	O
9	O
evaluable	O
patients	O
","	O
there	O
was	O
1	O
patient	O
(	O
11	O
%	O
)	O
with	O
a	O
PSA	O
response	O
","	O
3	O
(	O
33	O
%	O
)	O
with	O
stable	O
PSA	O
","	O
and	O
5	O
(	O
56	O
%	O
)	O
with	O
PSA	O
progression	O
;	O
in	O
arm	O
B	O
","	O
of	O
12	O
evaluable	O
patients	O
","	O
there	O
were	O
2	O
patients	O
(	O
17	O
%	O
)	O
with	O
PSA	O
responses	O
","	O
6	O
(	O
50	O
%	O
)	O
with	O
stable	O
PSA	O
","	O
and	O
4	O
(	O
33	O
%	O
)	O
with	O
PSA	O
progression	O
.	O
	
Median	O
progression-free	O
survival	O
was	O
similar	O
in	O
both	O
arms	O
at	O
7.3	O
months	O
(	O
95	O
%	O
CI	O
","	O
2.5	O
months	O
to	O
not	O
reached	O
)	O
.	O
	
Long-term	O
stable	O
disease	O
was	O
seen	O
in	O
4	O
patients	O
who	O
remained	O
on	O
treatment	O
for	O
18	O
months	O
(	O
arm	O
A	O
)	O
","	O
26	O
months	O
(	O
arm	O
A	O
)	O
","	O
35	O
months	O
(	O
arm	O
B	O
)	O
","	O
and	O
52	O
months	O
(	O
arm	O
B	O
)	O
.	O
	
In	O
this	O
unselected	O
patient	O
population	O
","	O
pazopanib	B-DRUG
either	O
alone	O
or	O
in	O
combination	O
with	O
bicalutamide	B-DRUG
failed	O
to	O
show	O
sufficient	O
activity	O
to	O
warrant	O
further	O
evaluation	O
.	O
	
However	O
","	O
4	O
patients	O
had	O
long-term	O
benefit	O
","	O
suggesting	O
that	O
targeting	O
the	O
VEGFR	O
pathway	O
may	O
still	O
be	O
relevant	O
in	O
selected	O
patients	O
and	O
emphasizing	O
the	O
need	O
for	O
improved	O
predictive	O
markers	O
for	O
patients	O
with	O
CRPC	B-CANCER
.	O
	
Phase	O
Ib	O
study	O
of	O
dovitinib	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
plus	O
cisplatin	B-DRUG
or	O
gemcitabine	B-DRUG
plus	O
carboplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Dovitinib	B-DRUG
is	O
a	O
small	O
molecule	O
kinase	O
inhibitor	O
with	O
activity	O
against	O
the	O
fibroblast	O
growth	O
factor	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
families	O
.	O
	
The	O
purpose	O
of	O
this	O
phase	O
Ib	O
study	O
was	O
to	O
define	O
the	O
recommended	O
phase	O
2	O
dose	O
of	O
the	O
combinations	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
or	O
gemcitabine	B-DRUG
and	O
carboplatin	B-DRUG
plus	O
dovitinib	B-DRUG
.	O
	
Patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
enrolled	O
in	O
two	O
parallel	O
dose	O
escalation	O
arms	O
(	O
cisplatin-	B-DRUG
or	O
carboplatin-based	B-DRUG
regimens	O
)	O
.	O
	
Treatment	O
was	O
administered	O
with	O
gemcitabine	B-DRUG
(	O
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
and	O
8	O
)	O
","	O
cisplatin	B-DRUG
(	O
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
or	O
carboplatin	B-DRUG
(	O
AUC	O
5	O
)	O
on	O
day	O
1	O
","	O
and	O
dovitinib	B-DRUG
(	O
orally	O
on	O
days	O
1月5日	O
","	O
8月12日	O
","	O
and	O
15-19	O
)	O
","	O
every	O
21	O
days	O
.	O
	
The	O
starting	O
dose	O
of	O
dovitinib	B-DRUG
was	O
300	O
mg	O
and	O
was	O
dose	O
escalated	O
in	O
successive	O
cohorts	O
using	O
3	O
=+	O
3	O
dose	O
escalation	O
rules	O
.	O
	
Fourteen	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
enrolled	O
","	O
five	O
to	O
the	O
cisplatin	B-DRUG
arm	O
and	O
nine	O
to	O
the	O
carboplatin	B-DRUG
arm	O
.	O
	
Patients	O
enrolled	O
in	O
the	O
cisplatin	B-DRUG
arm	O
received	O
a	O
median	O
of	O
two	O
cycles	O
of	O
treatment	O
(	O
range	O
1月5日	O
)	O
","	O
and	O
patients	O
enrolled	O
in	O
the	O
carboplatin	B-DRUG
arm	O
received	O
a	O
median	O
of	O
one	O
cycle	O
of	O
treatment	O
(	O
range	O
1月4日	O
)	O
.	O
	
There	O
were	O
no	O
protocol-defined	O
dose-limiting	O
toxicities	O
in	O
the	O
cisplatin	B-DRUG
arm	O
.	O
	
However	O
","	O
the	O
cohort	O
was	O
closed	O
due	O
to	O
the	O
need	O
for	O
frequent	O
dose	O
delays	O
and	O
/	O
or	O
reductions	O
and	O
two	O
patients	O
experiencing	O
severe	O
thromboembolic	B-TOXI
events	I-TOXI
.	O
	
There	O
were	O
two	O
dose-limiting	O
toxicities	O
in	O
the	O
carboplatin	B-DRUG
arm	O
at	O
the	O
starting	O
dose	O
level	O
of	O
dovitinib	B-DRUG
(	O
both	O
prolonged	B-TOXI
neutropenia	I-TOXI
)	O
","	O
and	O
the	O
dose	O
of	O
dovitinib	B-DRUG
was	O
de-escalated	O
to	O
200	O
mg	O
.	O
	
Two	O
additional	O
dose-limiting	O
toxicities	O
(	O
prolonged	B-TOXI
neutropenia	I-TOXI
and	O
febrile	B-TOXI
neutropenia	I-TOXI
)	O
occurred	O
in	O
the	O
lower	O
dose	O
cohort	O
","	O
and	O
the	O
study	O
was	O
closed	O
.	O
	
No	O
patients	O
achieved	O
an	O
objective	O
response	O
to	O
treatment	O
.	O
	
Dovitinib	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
plus	O
cisplatin	B-DRUG
or	O
gemcitabine	B-DRUG
plus	O
carboplatin	B-DRUG
was	O
poorly	O
tolerated	O
due	O
to	O
myelosuppression	B-TOXI
.	O
	
Dose-dense	O
sequential	O
adjuvant	O
chemotherapy	O
followed	O
","	O
as	O
indicated	O
","	O
by	O
trastuzumab	B-DRUG
for	O
one	O
year	O
in	O
patients	O
with	O
early	O
breast	B-CANCER
cancer	I-CANCER
:	O
first	O
report	O
at	O
5-year	O
median	O
follow-up	O
of	O
a	O
Hellenic	O
Cooperative	O
Oncology	O
Group	O
randomized	O
phase	O
III	O
trial	O
.	O
	
	
Dose-dense	O
sequential	O
chemotherapy	O
including	O
anthracyclines	B-DRUG
and	O
taxanes	B-DRUG
has	O
been	O
established	O
in	O
the	O
adjuvant	O
setting	O
of	O
high-risk	O
operable	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
However	O
","	O
the	O
preferable	O
taxane	B-DRUG
and	O
optimal	O
schedule	O
of	O
administration	O
in	O
a	O
dose-dense	O
regimen	O
have	O
not	O
been	O
defined	O
yet	O
.	O
	
From	O
July	O
2005	O
to	O
November	O
2008	O
","	O
1001	O
patients	O
(	O
990	O
eligible	O
)	O
were	O
randomized	O
to	O
receive	O
","	O
every	O
2	O
weeks	O
","	O
3	O
cycles	O
of	O
epirubicin	B-DRUG
110	O
mg	O
/	O
m2	O
followed	O
by	O
3	O
cycles	O
of	O
paclitaxel	B-DRUG
200	O
mg	O
/	O
m2	O
followed	O
by	O
3	O
cycles	O
of	O
intensified	O
CMF	O
(	O
Arm	O
A	O
;	O
333	O
patients	O
)	O
","	O
or	O
3	O
cycles	O
of	O
epirubicin	B-DRUG
followed	O
by	O
3	O
cycles	O
of	O
CMF	O
","	O
as	O
in	O
Arm	O
A	O
","	O
followed	O
3	O
weeks	O
later	O
by	O
9	O
weekly	O
cycles	O
of	O
docetaxel	B-DRUG
35	O
mg	O
/	O
m2	O
(	O
Arm	O
B	O
;	O
331	O
)	O
","	O
or	O
9	O
weekly	O
cycles	O
of	O
paclitaxel	B-DRUG
80	O
mg	O
/	O
m2	O
(	O
Arm	O
C	O
;	O
326	O
)	O
.	O
	
Trastuzumab	B-DRUG
was	O
administered	O
for	O
one	O
year	O
to	O
HER2-positive	O
patients	O
post-radiation	O
.	O
	
At	O
a	O
median	O
follow-up	O
of	O
60.5	O
months	O
","	O
the	O
3-year	O
disease-free	O
survival	O
(	O
DFS	O
)	O
rate	O
was	O
86	O
%	O
","	O
90	O
%	O
and	O
88	O
%	O
","	O
for	O
Arms	O
A	O
","	O
B	O
and	O
C	O
","	O
respectively	O
","	O
while	O
the	O
3-year	O
overall	O
survival	O
(	O
OS	O
)	O
rate	O
was	O
96	O
%	O
in	O
all	O
arms	O
.	O
	
No	O
differences	O
were	O
found	O
in	O
DFS	O
or	O
OS	O
between	O
the	O
combined	O
B	O
and	O
C	O
Arms	O
versus	O
Arm	O
A	O
(	O
DFS	O
:	O
HR	O
=	O
0.81	O
","	O
95	O
%	O
CI	O
:	O
0.59-1.11	O
","	O
P	O
=	O
0.2	O
;	O
OS	O
:	O
HR	O
=	O
0.84	O
","	O
95	O
%	O
CI	O
:	O
0.55-1.30	O
","	O
P	O
=	O
0.43	O
)	O
.	O
	
Among	O
the	O
255	O
patients	O
who	O
received	O
trastuzumab	B-DRUG
","	O
189	O
patients	O
(	O
74	O
%	O
)	O
completed	O
1	O
year	O
of	O
treatment	O
uneventfully	O
.	O
	
In	O
all	O
arms	O
","	O
the	O
most	O
frequently	O
reported	O
severe	O
adverse	O
events	O
were	O
neutropenia	B-TOXI
(	O
30	O
%	O
vs.	O
27	O
%	O
vs.	O
26	O
%	O
)	O
and	O
leucopenia	B-TOXI
(	O
12	O
%	O
vs.	O
13	O
%	O
vs.	O
12	O
%	O
)	O
","	O
while	O
febrile	B-TOXI
neutropenia	I-TOXI
occurred	O
in	O
fifty-one	O
patients	O
(	O
6	O
%	O
vs.	O
4	O
%	O
vs.	O
5	O
%	O
)	O
.	O
	
Patients	O
in	O
Arm	O
A	O
experienced	O
more	O
often	O
severe	B-TOXI
pain	I-TOXI
(	O
P	O
=	O
0.002	O
)	O
","	O
neurological	B-TOXI
complications	I-TOXI
(	O
P	O
=	O
0.004	O
)	O
and	O
allergic	B-TOXI
reactions	I-TOXI
(	O
P	O
=	O
0.004	O
)	O
","	O
while	O
patients	O
in	O
Arm	O
B	O
suffered	O
more	O
often	O
from	O
severe	B-TOXI
skin	I-TOXI
reactions	I-TOXI
(	O
P	O
=	O
0.02	O
)	O
.	O
	
No	O
significant	O
differences	O
in	O
survival	O
between	O
the	O
regimens	O
were	O
found	O
in	O
the	O
present	O
phase	O
III	O
trial	O
.	O
	
Taxane	B-DRUG
scheduling	O
influenced	O
the	O
type	O
of	O
severe	O
toxicities	O
.	O
	
HER2-positive	O
patients	O
demonstrated	O
comparable	O
3-year	O
DFS	O
and	O
OS	O
rates	O
with	O
those	O
reported	O
in	O
other	O
similar	O
studies	O
.	O
	
Australian	O
New	O
Zealand	O
Clinical	O
Trials	O
Registry	O
ACTRN12610000151033	O
.	O
	
Combination	O
of	O
antiangiogenic	O
therapy	O
using	O
the	O
mTOR-inhibitor	O
everolimus	B-DRUG
and	O
low-dose	O
chemotherapy	O
for	O
locally	O
advanced	O
and	O
/	O
or	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
:	O
a	O
dose-finding	O
study	O
.	O
	
	
Pancreatic	B-CANCER
adenocarcinomas	I-CANCER
are	O
associated	O
with	O
a	O
poor	O
survival	O
prognosis	O
.	O
	
Besides	O
curative	O
surgical	O
resection	O
","	O
only	O
limited	O
therapies	O
with	O
modest	O
impact	O
are	O
available	O
.	O
	
New	O
evidence	O
suggests	O
that	O
the	O
mammalian	O
target	O
of	O
rapamycin	O
pathway	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
neuroendocrine	B-CANCER
tumors	I-CANCER
","	O
and	O
breast	B-CANCER
and	I-CANCER
renal	I-CANCER
cell	I-CANCER
cancer	I-CANCER
.	O
	
The	O
phase	O
I	O
study	O
described	O
here	O
was	O
therefore	O
designed	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
of	O
escalating	O
doses	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	O
inhibitor	O
everolimus	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
Eligible	O
patients	O
had	O
histologically	O
confirmed	O
locally	O
advanced	O
and	O
/	O
or	O
metastatic	B-CANCER
pancreatic	I-CANCER
carcinoma	I-CANCER
and	O
were	O
administered	O
5	O
mg	O
everolimus	B-DRUG
every	O
second	O
day	O
(	O
cohort	O
1	O
","	O
2	O
","	O
3	O
)	O
or	O
5	O
mg	O
daily	O
(	O
cohort	O
4	O
","	O
5	O
)	O
in	O
combination	O
with	O
escalating	O
low-dose	O
gemcitabine	B-DRUG
.	O
	
It	O
was	O
found	O
that	O
if	O
two	O
patients	O
showed	O
DLTs	O
","	O
MTD	O
was	O
reached	O
and	O
gemcitabine	B-DRUG
dose	O
escalation	O
was	O
stopped	O
at	O
this	O
level	O
.	O
	
Twenty-seven	O
patients	O
were	O
enrolled	O
in	O
the	O
study	O
(	O
cohort	O
1	O
:	O
n=3	O
;	O
cohort	O
2	O
:	O
n=4	O
;	O
cohort	O
3	O
:	O
n=6	O
;	O
cohort	O
4	O
:	O
n=7	O
;	O
cohort	O
5	O
:	O
n=7	O
)	O
and	O
received	O
a	O
maximum	O
600	O
mg	O
gemcitabine	B-DRUG
/	O
week	O
.	O
	
In	O
cohort	O
5	O
","	O
two	O
of	O
the	O
six	O
patients	O
experienced	O
DLTs	O
(	O
grade	O
3	O
liver	B-TOXI
toxicity	I-TOXI
lasting	O
for	O
&	O
gt	O
;	O
7	O
days	O
)	O
.	O
	
MTD	O
was	O
measured	O
as	O
400	O
mg	O
/	O
m	O
/	O
week	O
gemcitabine	B-DRUG
plus	O
5	O
mg	O
/	O
day	O
everolimus	B-DRUG
.	O
	
The	O
MTD	O
of	O
a	O
low-dose	O
gemcitabine	B-DRUG
treatment	O
in	O
combination	O
with	O
everolimus	B-DRUG
was	O
determined	O
and	O
no	O
new	O
safety	O
concerns	O
were	O
identified	O
in	O
patients	O
with	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
Combination	O
of	O
vemurafenib	B-DRUG
and	O
cobimetinib	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
BRAF	I-CANCER
(	I-CANCER
V600	I-CANCER
)	I-CANCER
#NAME?	I-CANCER
melanoma	I-CANCER
:	O
a	O
phase	O
1b	O
study	O
.	O
	
	
Addition	O
of	O
a	O
MEK	O
inhibitor	O
to	O
a	O
BRAF	O
inhibitor	O
enhances	O
tumour	O
growth	O
inhibition	O
","	O
delays	O
acquired	O
resistance	O
","	O
and	O
abrogates	O
paradoxical	O
activation	O
of	O
the	O
MAPK	O
pathway	O
in	O
preclinical	O
models	O
of	O
BRAF-mutated	B-CANCER
melanoma	I-CANCER
.	O
	
We	O
assessed	O
the	O
safety	O
and	O
efficacy	O
of	O
combined	O
BRAF	O
inhibition	O
with	O
vemurafenib	B-DRUG
and	O
MEK	O
inhibition	O
with	O
cobimetinib	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
BRAF-mutated	I-CANCER
melanoma	I-CANCER
.	O
	
We	O
undertook	O
a	O
phase	O
1b	O
study	O
in	O
patients	O
with	O
advanced	B-CANCER
BRAF	I-CANCER
(	I-CANCER
V600	I-CANCER
)	I-CANCER
#NAME?	I-CANCER
melanoma	I-CANCER
.	O
	
We	O
included	O
individuals	O
who	O
had	O
either	O
recently	O
progressed	O
on	O
vemurafenib	B-DRUG
or	O
never	O
received	O
a	O
BRAF	O
inhibitor	O
.	O
	
In	O
the	O
dose-escalation	O
phase	O
of	O
our	O
study	O
","	O
patients	O
received	O
vemurafenib	B-DRUG
720	O
mg	O
or	O
960	O
mg	O
twice	O
a	O
day	O
continuously	O
and	O
cobimetinib	B-DRUG
60	O
mg	O
","	O
80	O
mg	O
","	O
or	O
100	O
mg	O
once	O
a	O
day	O
for	O
either	O
14	O
days	O
on	O
and	O
14	O
days	O
off	O
(	O
14	O
/	O
14	O
)	O
","	O
21	O
days	O
on	O
and	O
7	O
days	O
off	O
(	O
21	O
/	O
7	O
)	O
","	O
or	O
continuously	O
(	O
28	O
/	O
0	O
)	O
.	O
	
The	O
primary	O
endpoint	O
was	O
safety	O
of	O
the	O
drug	O
combination	O
and	O
to	O
identify	O
dose-limiting	O
toxic	O
effects	O
and	O
the	O
maximum	O
tolerated	O
dose	O
.	O
	
Efficacy	O
was	O
a	O
key	O
secondary	O
endpoint	O
.	O
	
All	O
patients	O
treated	O
with	O
vemurafenib	B-DRUG
and	O
cobimetinib	B-DRUG
were	O
included	O
in	O
safety	O
and	O
efficacy	O
analyses	O
(	O
intention-to-treat	O
)	O
.	O
	
The	O
study	O
completed	O
accrual	O
and	O
all	O
analyses	O
are	O
final	O
.	O
	
This	O
study	O
is	O
registered	O
with	O
ClinicalTrials.gov	O
","	O
number	O
NCT01271803	O
.	O
	
129	O
patients	O
were	O
treated	O
at	O
ten	O
dosing	O
regimens	O
combining	O
vemurafenib	B-DRUG
and	O
cobimetinib	B-DRUG
:	O
66	O
had	O
recently	O
progressed	O
on	O
vemurafenib	B-DRUG
and	O
63	O
had	O
never	O
received	O
a	O
BRAF	O
inhibitor	O
.	O
	
Dose-limiting	O
toxic	O
effects	O
arose	O
in	O
four	O
patients	O
.	O
	
One	O
patient	O
on	O
a	O
schedule	O
of	O
vemurafenib	B-DRUG
960	O
mg	O
twice	O
a	O
day	O
and	O
cobimetinib	B-DRUG
80	O
mg	O
once	O
a	O
day	O
14	O
/	O
14	O
had	O
grade	O
3	O
fatigue	B-TOXI
for	O
more	O
than	O
7	O
days	O
;	O
one	O
patient	O
on	O
a	O
schedule	O
of	O
vemurafenib	B-DRUG
960	O
mg	O
twice	O
a	O
day	O
and	O
cobimetinib	B-DRUG
60	O
mg	O
once	O
a	O
day	O
21	O
/	O
7	O
had	O
a	O
grade	O
3	O
prolongation	B-TOXI
of	I-TOXI
QTc	I-TOXI
;	O
and	O
two	O
patients	O
on	O
a	O
schedule	O
of	O
vemurafenib	B-DRUG
960	O
mg	O
twice	O
a	O
day	O
and	O
cobimetinib	B-DRUG
60	O
mg	O
28	O
/	O
0	O
had	O
dose-limiting	O
toxic	O
effects-one	O
developed	O
grade	O
3	O
stomatitis	B-TOXI
and	O
fatigue	B-TOXI
and	O
one	O
developed	O
arthralgia	B-TOXI
and	O
myalgia	B-TOXI
.	O
	
The	O
maximum	O
tolerated	O
dose	O
was	O
established	O
as	O
vemurafenib	B-DRUG
960	O
mg	O
twice	O
a	O
day	O
in	O
combination	O
with	O
cobimetinib	B-DRUG
60	O
mg	O
21	O
/	O
7	O
Across	O
all	O
dosing	O
regimens	O
","	O
the	O
most	O
common	O
adverse	O
events	O
were	O
diarrhoea	B-TOXI
(	O
83	O
patients	O
","	O
64	O
%	O
)	O
","	O
non-acneiform	B-TOXI
rash	I-TOXI
(	O
77	O
patients	O
","	O
60	O
%	O
)	O
","	O
liver	B-TOXI
enzyme	I-TOXI
abnormalities	I-TOXI
(	O
64	O
patients	O
","	O
50	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
62	O
patients	O
","	O
48	O
%	O
)	O
","	O
nausea	B-TOXI
(	O
58	O
patients	O
","	O
45	O
%	O
)	O
","	O
and	O
photosensitivity	B-TOXI
(	O
52	O
patients	O
","	O
40	O
%	O
)	O
.	O
	
Most	O
adverse	O
events	O
were	O
mild-to-moderate	O
in	O
severity	O
.	O
	
The	O
most	O
common	O
grade	O
3	O
or	O
4	O
adverse	O
events	O
were	O
cutaneous	B-CANCER
squamous-cell	I-CANCER
carcinoma	I-CANCER
(	O
12	O
patients	O
","	O
9	O
%	O
;	O
all	O
grade	O
3	O
)	O
","	O
raised	B-TOXI
amounts	I-TOXI
of	I-TOXI
alkaline	I-TOXI
phosphatase	I-TOXI
(	O
11	O
patients	O
","	O
9	O
%	O
]	O
)	O
","	O
and	O
anaemia	B-TOXI
(	O
nine	O
patients	O
","	O
7	O
%	O
)	O
.	O
	
Confirmed	O
objective	O
responses	O
were	O
recorded	O
in	O
ten	O
(	O
15	O
%	O
)	O
of	O
66	O
patients	O
who	O
had	O
recently	O
progressed	O
on	O
vemurafenib	B-DRUG
","	O
with	O
a	O
median	O
progression-free	O
survival	O
of	O
2路8	O
months	O
(	O
95	O
%	O
CI	O
2路6-3路4	O
)	O
.	O
	
Confirmed	O
objective	O
responses	O
were	O
noted	O
in	O
55	O
(	O
87	O
%	O
)	O
of	O
63	O
patients	O
who	O
had	O
never	O
received	O
a	O
BRAF	O
inhibitor	O
","	O
including	O
six	O
(	O
10	O
%	O
)	O
who	O
had	O
a	O
complete	O
response	O
;	O
median	O
progression-free	O
survival	O
was	O
13路7	O
months	O
(	O
95	O
%	O
CI	O
10路1-17路5	O
)	O
.	O
	
The	O
combination	O
of	O
vemurafenib	B-DRUG
and	O
cobimetinib	B-DRUG
was	O
safe	O
and	O
tolerable	O
when	O
administered	O
at	O
the	O
respective	O
maximum	O
tolerated	O
doses	O
.	O
	
The	O
combination	O
has	O
promising	O
antitumour	O
activity	O
and	O
further	O
clinical	O
development	O
is	O
warranted	O
in	O
patients	O
with	O
advanced	B-CANCER
BRAF	I-CANCER
(	I-CANCER
V600	I-CANCER
)	I-CANCER
#NAME?	I-CANCER
melanoma	I-CANCER
","	O
particularly	O
in	O
those	O
who	O
have	O
never	O
received	O
a	O
BRAF	O
inhibitor	O
;	O
confirmatory	O
clinical	O
testing	O
is	O
ongoing	O
.	O
	
F	O
Hoffmann-La	O
Roche	O
/	O
Genentech	O
.	O
	
A	O
phase	O
I	O
","	O
dose-escalation	O
trial	O
of	O
continuous-	O
and	O
pulsed-dose	O
afatinib	B-DRUG
combined	O
with	O
pemetrexed	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Afatinib	B-DRUG
","	O
an	O
irreversible	O
ErbB	O
family	O
blocker	O
","	O
demonstrated	O
synergistic	O
inhibition	O
of	O
epidermal	O
growth	O
factor	O
receptor-mutant	O
cell	O
growth	O
with	O
pemetrexed	B-DRUG
.	O
	
This	O
phase	O
I	O
study	O
investigated	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
safety	O
","	O
pharmacokinetics	O
","	O
and	O
antitumor	O
activity	O
of	O
afatinib	B-DRUG
plus	O
pemetrexed	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
In	O
a	O
3	O
=+	O
3	O
dose-escalation	O
design	O
","	O
patients	O
were	O
given	O
intravenous	O
pemetrexed	B-DRUG
(	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
on	O
day	O
1	O
of	O
a	O
21-day	O
cycle	O
(	O
maximum	O
6	O
cycles	O
)	O
","	O
combined	O
with	O
continuous	O
daily	O
oral	O
afatinib	B-DRUG
(	O
schedule	O
A	O
[	O
SA	O
]	O
;	O
starting	O
dose	O
30	O
mg	O
","	O
escalation	O
to	O
50	O
mg	O
)	O
or	O
pulsed-dose	O
daily	O
oral	O
afatinib	B-DRUG
(	O
schedule	O
B	O
[	O
SB	O
]	O
;	O
starting	O
dose	O
50	O
mg	O
","	O
escalation	O
to	O
70	O
mg	O
)	O
on	O
days	O
1月6日	O
of	O
each	O
21-day	O
cycle	O
.	O
	
Primary	O
endpoint	O
was	O
determination	O
of	O
MTD	O
based	O
on	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
in	O
cycle	O
1	O
Fifty-three	O
patients	O
were	O
treated	O
(	O
SA	O
:	O
n	O
=	O
23	O
;	O
SB	O
:	O
n	O
=	O
30	O
)	O
.	O
	
Eight	O
patients	O
had	O
DLTs	O
in	O
SA	O
","	O
11	O
patients	O
in	O
SB	O
;	O
diarrhea	B-TOXI
and	O
fatigue	B-TOXI
were	O
the	O
most	O
common	O
.	O
	
MTD	O
of	O
afatinib	B-DRUG
was	O
30	O
mg	O
in	O
SA	O
and	O
50	O
mg	O
in	O
SB	O
.	O
	
Six	O
patients	O
in	O
SA	O
and	O
eight	O
in	O
SB	O
completed	O
6	O
treatment	O
cycles	O
.	O
	
One	O
patient	O
in	O
each	O
schedule	O
had	O
confirmed	O
objective	O
response	O
;	O
18	O
/	O
53	O
patients	O
had	O
disease	O
control	O
(	O
SA	O
:	O
n	O
=	O
7	O
;	O
SB	O
:	O
n	O
=	O
11	O
)	O
.	O
	
Most	O
frequent	O
drug-related	O
adverse	O
events	O
were	O
diarrhea	B-TOXI
","	O
rash	B-TOXI
","	O
fatigue	B-TOXI
","	O
and	O
stomatitis	B-TOXI
.	O
	
No	O
relevant	O
pharmacokinetic	O
interactions	O
were	O
observed	O
.	O
	
Continuous-	O
or	O
pulsed-dose	O
afatinib	B-DRUG
combined	O
with	O
pemetrexed	B-DRUG
exhibited	O
a	O
manageable	O
safety	O
profile	O
.	O
	
Pulsed	O
dosing	O
conferred	O
no	O
apparent	O
safety	O
or	O
dose	O
advantage	O
.	O
	
Continuous-dose	O
afatinib	B-DRUG
30	O
mg	O
/	O
day	O
with	O
pemetrexed	B-DRUG
is	O
recommended	O
for	O
phase	O
II	O
studies	O
.	O
	
Dose	O
escalating	O
study	O
of	O
cetuximab	B-DRUG
and	O
5-FU	B-DRUG
/	O
folinic	B-DRUG
acid	I-DRUG
(	O
FA	B-DRUG
)	O
/	O
oxaliplatin	B-DRUG
/	O
irinotecan	B-DRUG
(	O
FOLFOXIRI	B-DRUG
)	O
in	O
first	O
line	O
therapy	O
of	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
FOLFOXIRI	B-DRUG
regimen	O
(	O
irinotecan	B-DRUG
","	O
oxaliplatin	B-DRUG
","	O
fluorouracil	B-DRUG
[	O
5-FU	B-DRUG
]	O
and	O
folinic	B-DRUG
acid	I-DRUG
[	O
FA	B-DRUG
]	O
)	O
increased	O
the	O
response	O
rate	O
and	O
overall	O
survival	O
compared	O
to	O
FOLFIRI	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
mCRC	B-CANCER
)	O
.	O
	
Adding	O
cetuximab	B-DRUG
to	O
FOLFOX	B-DRUG
or	O
FOLFIRI	B-DRUG
increased	O
efficacy	O
in	O
patients	O
with	O
k-ras	O
wild	O
type	O
mCRC	B-CANCER
.	O
	
We	O
explored	O
the	O
dose	O
limiting	O
toxicity	O
and	O
feasibility	O
of	O
the	O
combination	O
cetuximab	B-DRUG
","	O
irinotecan	B-DRUG
","	O
oxaliplatin	B-DRUG
","	O
5-FU	B-DRUG
and	O
FA	B-DRUG
in	O
mCRC	B-CANCER
patients	O
.	O
	
In	O
a	O
dose-escalation	O
study	O
patients	O
with	O
previously	O
untreated	O
mCRC	B-CANCER
and	O
a	O
WHO	O
performance	O
status	O
0-1	O
received	O
cetuximab	B-DRUG
(	O
500	O
mg	O
/	O
m2	O
","	O
2	O
h	O
)	O
","	O
followed	O
by	O
irinotecan	B-DRUG
(	O
95	O
","	O
125	O
","	O
and	O
165	O
mg	O
/	O
m2	O
in	O
the	O
dose	O
levels	O
[	O
DL	O
]	O
1	O
","	O
2	O
","	O
and	O
3	O
respectively	O
)	O
","	O
followed	O
by	O
oxaliplatin	B-DRUG
(	O
85	O
mg	O
/	O
m2	O
","	O
2	O
h	O
)	O
which	O
was	O
given	O
parallel	O
to	O
FA	B-DRUG
(	O
400	O
mg	O
/	O
m2	O
","	O
2	O
h	O
)	O
and	O
followed	O
by	O
5-FU	B-DRUG
(	O
3200	O
mg	O
/	O
m2	O
","	O
46	O
h	O
)	O
in	O
an	O
outpatient	O
setting	O
every	O
two	O
weeks	O
.	O
	
The	O
primary	O
endpoints	O
were	O
the	O
maximum	O
tolerable	O
dose	O
and	O
the	O
safety	O
.	O
	
The	O
trial	O
was	O
approved	O
by	O
the	O
local	O
ethics	O
committee	O
.	O
	
From	O
2007	O
to	O
2008	O
","	O
twenty	O
patients	O
were	O
treated	O
in	O
this	O
trial	O
.	O
	
In	O
the	O
first	O
dose	O
level	O
(	O
irinotecan	B-DRUG
95	O
mg	O
/	O
m2	O
)	O
one	O
patient	O
developed	O
neutropenia	B-TOXI
grade	O
4	O
One	O
patient	O
experienced	O
diarrhoea	B-TOXI
grade	O
3	O
as	O
DLT	O
in	O
dose	O
level	O
2	O
(	O
irinotecan	B-DRUG
125	O
mg	O
/	O
m2	O
)	O
.	O
	
In	O
dose	O
level	O
3	O
(	O
irinotecan	B-DRUG
165	O
mg	O
/	O
m2	O
)	O
","	O
three	O
patients	O
experienced	O
a	O
DLT	O
(	O
diarrhoea	B-TOXI
grade	O
3	O
and	O
two	O
patients	O
with	O
neutropenia	B-TOXI
grade	O
4	O
)	O
.	O
	
Thus	O
","	O
the	O
recommended	O
dose	O
for	O
a	O
phase	O
II	O
trial	O
is	O
125	O
mg	O
/	O
m2	O
irinotecan	B-DRUG
in	O
combination	O
with	O
oxaliplatin	B-DRUG
","	O
5-FU	B-DRUG
/	O
FA	B-DRUG
and	O
cetuximab	B-DRUG
.	O
	
Most	O
common	O
grade	O
_3	O
toxicities	O
were	O
neutropenia	B-TOXI
(	O
40	O
%	O
)	O
","	O
diarrhoea	B-TOXI
(	O
25	O
%	O
)	O
and	O
acne-like	B-TOXI
rash	I-TOXI
(	O
15	O
%	O
)	O
.	O
	
No	O
therapy	O
associated	O
death	B-TOXI
occurred.The	O
confirmed	O
overall	O
response	O
rate	O
in	O
all	O
cohorts	O
was	O
75	O
%	O
(	O
95	O
%	O
#NAME?	O
51-91	O
%	O
)	O
.	O
	
The	O
best	O
response	O
was	O
reached	O
after	O
a	O
median	O
of	O
3	O
(	O
95	O
%	O
#NAME?	O
2.2	O
to	O
3.7	O
)	O
months	O
.	O
	
Median	O
progression	O
free	O
survival	O
(	O
PFS	O
)	O
is	O
16	O
(	O
95	O
%	O
#NAME?	O
12.6-19.4	O
)	O
months	O
","	O
overall	O
survival	O
(	O
OS	O
)	O
33	O
(	O
95	O
%	O
#NAME?	O
26.2-39.8	O
)	O
months	O
.	O
	
The	O
combination	O
of	O
cetuximab	B-DRUG
and	O
FOLFOXIRIis	B-DRUG
feasible	O
and	O
has	O
an	O
acceptable	O
toxicity	O
profile	O
in	O
patients	O
with	O
a	O
good	O
performance	O
status	O
.	O
	
The	O
observed	O
clinical	O
activity	O
with	O
a	O
confirmed	O
response	O
rate	O
of	O
75	O
%	O
is	O
promising	O
and	O
further	O
evaluated	O
in	O
the	O
ongoing	O
CELIM2	O
.	O
	
http	O
:	O
/	O
/	O
www.clinicaltrials.gov	O
:	O
NCT00422773	O
.	O
	
Phase	O
Ib	O
/	O
II	O
trial	O
of	O
gemcitabine	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
lenalidomide	B-DRUG
as	O
first-line	O
therapy	O
in	O
patients	O
with	O
metastatic	B-CANCER
urothelial	I-CANCER
carcinoma	I-CANCER
.	O
	
	
Outcomes	O
with	O
current	O
chemotherapy	O
in	O
metastatic	B-CANCER
urothelial	I-CANCER
carcinoma	I-CANCER
(	O
MUC	B-CANCER
)	O
remain	O
poor	O
.	O
	
Lenalidomide	B-DRUG
","	O
an	O
antiangiogenic	O
and	O
immunomodulatory	O
agent	O
","	O
enhances	O
the	O
effects	O
of	O
chemotherapy	O
in	O
preclinical	O
studies	O
.	O
	
In	O
this	O
phase	O
Ib	O
/	O
II	O
study	O
","	O
we	O
sought	O
to	O
determine	O
a	O
tolerable	O
dose	O
of	O
lenalidomide	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
(	O
GCL	B-DRUG
)	O
in	O
patients	O
with	O
MUC	B-CANCER
and	O
to	O
explore	O
the	O
safety	O
and	O
activity	O
of	O
this	O
regimen	O
.	O
	
Patients	O
with	O
chemotherapy-na茂ve	O
MUC	B-CANCER
received	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
and	O
8	O
and	O
cisplatin	B-DRUG
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
every	O
21	O
days	O
.	O
	
In	O
phase	O
Ib	O
","	O
there	O
were	O
four	O
planned	O
escalating	O
dose	O
levels	O
of	O
lenalidomide	B-DRUG
(	O
10	O
","	O
15	O
","	O
20	O
","	O
and	O
25	O
mg	O
)	O
daily	O
on	O
days	O
1月14日	O
.	O
	
Seven	O
patients	O
received	O
GCL	B-DRUG
in	O
phase	O
Ib	O
.	O
	
The	O
dose	O
of	O
lenalidomide	B-DRUG
was	O
not	O
escalated	O
beyond	O
10	O
mg	O
because	O
of	O
cytopenias	B-DRUG
requiring	O
repeated	O
dose	O
delays	O
and	O
reductions	O
.	O
	
Two	O
additional	O
patients	O
were	O
enrolled	O
in	O
phase	O
II	O
","	O
but	O
the	O
study	O
was	O
ultimately	O
terminated	O
due	O
to	O
poor	O
tolerability	O
and	O
slow	O
accrual	O
.	O
	
The	O
most	O
frequent	O
grade	O
_	O
3	O
adverse	O
events	O
were	O
cytopenias	B-TOXI
and	O
diarrhea	B-TOXI
.	O
	
Three	O
of	O
the	O
nine	O
patients	O
experienced	O
an	O
objective	O
response	O
(	O
one	O
complete	O
response	O
","	O
two	O
partial	O
responses	O
)	O
.	O
	
Chronic	O
administration	O
of	O
the	O
GCL	B-DRUG
regimen	O
was	O
poorly	O
tolerated	O
because	O
of	O
additive	B-TOXI
and	I-TOXI
cumulative	I-TOXI
myelosuppression	I-TOXI
.	O
	
Phase	O
I	O
trial	O
of	O
rituximab	B-DRUG
","	O
cladribine	B-DRUG
","	O
and	O
temsirolimus	B-DRUG
(	O
RCT	B-DRUG
)	O
for	O
initial	O
therapy	O
of	O
mantle	B-CANCER
cell	I-CANCER
lymphoma	I-CANCER
.	O
	
	
We	O
conducted	O
this	O
trial	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
temsirolimus	B-DRUG
added	O
to	O
an	O
established	O
regimen	O
comprised	O
of	O
rituximab	B-DRUG
and	O
cladribine	B-DRUG
for	O
the	O
initial	O
treatment	O
of	O
mantle	B-CANCER
cell	I-CANCER
lymphoma	I-CANCER
.	O
	
A	O
standard	O
phase	O
I	O
cohort	O
of	O
three	O
study	O
design	O
was	O
utilized	O
.	O
	
The	O
fixed	O
doses	O
of	O
rituximab	B-DRUG
and	O
cladribine	B-DRUG
were	O
375	O
mg	O
/	O
m	O
(	O
2	O
)	O
i.v.	O
day	O
1	O
and	O
5	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
i.v.	O
days	O
1月5日	O
of	O
a	O
28-day	O
cycle	O
","	O
respectively	O
.	O
	
There	O
were	O
five	O
planned	O
temsirolimus	B-DRUG
i.v.	O
dose	O
levels	O
:	O
15	O
mg	O
day	O
1	O
;	O
25	O
mg	O
day	O
1	O
;	O
25	O
mg	O
days	O
1	O
and	O
15	O
;	O
25	O
mg	O
days	O
1	O
","	O
8	O
and	O
15	O
;	O
and	O
25	O
mg	O
days	O
1	O
","	O
8	O
","	O
15	O
","	O
and	O
22	O
.	O
	
Seventeen	O
patients	O
were	O
treated	O
:	O
three	O
each	O
at	O
levels	O
1月4日	O
and	O
five	O
at	O
dose	O
level	O
5	O
The	O
median	O
age	O
was	O
75	O
years	O
(	O
52-86	O
years	O
)	O
.	O
	
Mantle	O
Cell	O
International	O
Prognostic	O
Index	O
(	O
MIPI	O
)	O
scores	O
were	O
low	O
in	O
6	O
%	O
(	O
1	O
)	O
","	O
intermediate	O
in	O
59	O
%	O
(	O
10	O
)	O
","	O
and	O
high	O
in	O
35	O
%	O
(	O
6	O
)	O
of	O
patients	O
.	O
	
Five	O
patients	O
were	O
treated	O
at	O
level	O
5	O
without	O
dose	O
limiting	O
toxicity	O
.	O
	
Hematologic	B-TOXI
toxicity	I-TOXI
was	O
frequent	O
:	O
grade	O
3	O
anemia	B-TOXI
in	O
12	O
%	O
","	O
grade	O
3	O
thrombocytopenia	B-TOXI
in	O
41	O
%	O
","	O
grade	O
4	O
thrombocytopenia	B-TOXI
in	O
24	O
%	O
","	O
grade	O
3	O
neutropenia	B-TOXI
in	O
6	O
%	O
","	O
and	O
grade	O
4	O
neutropenia	B-TOXI
in	O
18	O
%	O
of	O
patients	O
.	O
	
The	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
was	O
94	O
%	O
with	O
53	O
%	O
complete	O
response	O
and	O
41	O
%	O
partial	O
response	O
.	O
	
The	O
median	O
progression-free	O
survival	O
was	O
18.7	O
months	O
.	O
	
Temsirolimus	B-DRUG
25	O
mg	O
i.v.	O
weekly	O
may	O
be	O
safely	O
added	O
to	O
rituximab	B-DRUG
and	O
cladribine	B-DRUG
at	O
375	O
mg	O
/	O
m	O
(	O
2	O
)	O
i.v.	O
day	O
1	O
and	O
5	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
i.v.	O
days	O
1月5日	O
of	O
a	O
28-day	O
cycle	O
","	O
respectively	O
.	O
	
This	O
regimen	O
had	O
promising	O
preliminary	O
activity	O
in	O
an	O
elderly	O
cohort	O
of	O
patients	O
with	O
mantle	B-CANCER
cell	I-CANCER
lymphoma	I-CANCER
.	O
	
NCT00787969	O
.	O
	
Phase	O
1	O
and	O
pharmacokinetic	O
study	O
of	O
everolimus	B-DRUG
in	O
combination	O
with	O
cetuximab	B-DRUG
and	O
carboplatin	B-DRUG
for	O
recurrent	B-CANCER
/	I-CANCER
metastatic	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
	
Platinum-based	O
therapy	O
combined	O
with	O
cetuximab	B-DRUG
is	O
standard	O
first-line	O
therapy	O
for	O
recurrent	B-CANCER
or	I-CANCER
metastatic	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	O
RMSCCHN	B-CANCER
)	O
.	O
	
Preclinical	O
studies	O
have	O
suggested	O
that	O
mammalian	O
target	O
of	O
rapamycin	O
inhibitors	O
may	O
overcome	O
resistance	O
to	O
epidermal	O
growth	O
factor	O
receptor	O
blockers	O
and	O
may	O
augment	O
cetuximab	B-DRUG
antitumor	O
activity	O
.	O
	
We	O
conducted	O
a	O
phase	O
1b	O
trial	O
of	O
carboplatin	B-DRUG
","	O
cetuximab	B-DRUG
","	O
and	O
everolimus	B-DRUG
for	O
untreated	O
RMSCCHN	B-CANCER
.	O
	
Patients	O
received	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
=	O
2	O
mg	O
/	O
ml	O
/	O
min	O
;	O
3	O
weeks	O
on	O
","	O
1	O
week	O
off	O
)	O
","	O
cetuximab	B-DRUG
(	O
with	O
a	O
loading	O
dose	O
of	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
then	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
)	O
","	O
and	O
dose-escalating	O
everolimus	B-DRUG
(	O
2.5	O
","	O
5	O
","	O
7.5	O
","	O
and	O
10	O
mg	O
/	O
day	O
)	O
with	O
a	O
3+3	O
design	O
.	O
	
After	O
4	O
cycles	O
","	O
patients	O
without	O
progression	O
continued	O
cetuximab	B-DRUG
/	O
everolimus	B-DRUG
until	O
progression	O
or	O
intolerable	O
toxicity	O
.	O
	
Patients	O
(	O
age	O
_	O
18	O
years	O
)	O
had	O
previously	O
untreated	O
","	O
unresectable	O
RMSCCHN	B-CANCER
not	O
amenable	O
to	O
radiotherapy	O
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
to	O
2	O
The	O
study	O
enrolled	O
20	O
patients	O
(	O
male	O
/	O
female	O
=	O
18	O
/	O
2	O
)	O
with	O
RMSCCHN	B-CANCER
;	O
the	O
median	O
age	O
was	O
65	O
years	O
(	O
44-75	O
years	O
)	O
.	O
	
Thirteen	O
patients	O
received	O
everolimus	B-DRUG
(	O
male	O
/	O
female	O
=	O
92	O
%	O
)	O
.	O
	
Two	O
of	O
6	O
patients	O
receiving	O
2.5	O
mg	O
/	O
day	O
experienced	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
with	O
grade	O
3	O
hyponatremia	B-TOXI
and	O
nausea	B-TOXI
.	O
	
In	O
7	O
patients	O
receiving	O
de-escalated	O
everolimus	B-DRUG
(	O
2.5	O
mg	O
every	O
other	O
day	O
)	O
","	O
grade	O
3	O
hyperglycemia	B-TOXI
produced	O
DLT	O
in	O
1	O
of	O
6	O
patients	O
.	O
	
The	O
objective	O
response	O
rate	O
(	O
RR	O
)	O
was	O
61.5	O
%	O
(	O
all	O
partial	O
responses	O
)	O
.	O
	
Progression-free	O
survival	O
(	O
PFS	O
)	O
was	O
8.15	O
months	O
.	O
	
The	O
pharmacokinetics	O
of	O
everolimus	B-DRUG
was	O
described	O
with	O
a	O
2-compartment	O
mixed-effects	O
model	O
.	O
	
There	O
was	O
a	O
significant	O
correlation	O
between	O
tumor	O
p-p44	O
/	O
42	O
staining	O
and	O
response	O
(	O
P	O
=	O
0.044	O
)	O
and	O
a	O
marginally	O
significant	O
correlation	O
between	O
phosphorylated	O
mammalian	O
target	O
of	O
rapamycin	O
and	O
overall	O
survival	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
of	O
everolimus	B-DRUG
with	O
cetuximab	B-DRUG
and	O
carboplatin	B-DRUG
was	O
2.5	O
mg	O
every	O
other	O
day	O
.	O
	
The	O
regimen	O
was	O
associated	O
with	O
an	O
encouraging	O
RR	O
and	O
PFS	O
","	O
and	O
this	O
suggested	O
possible	O
clinical	O
efficacy	O
in	O
a	O
select	O
group	O
of	O
patients	O
with	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
Phase	O
I	O
dose-escalation	O
study	O
of	O
cabazitaxel	B-DRUG
administered	O
in	O
combination	O
with	O
cisplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Cabazitaxel	B-DRUG
is	O
a	O
second-generation	O
taxane	O
with	O
in	O
vivo	O
activity	O
against	O
taxane-sensitive	B-DRUG
and	O
#NAME?	O
tumor	O
cell	O
lines	O
and	O
tumor	O
xenografts	O
.	O
	
Cabazitaxel	B-DRUG
/	O
cisplatin	B-DRUG
have	O
therapeutic	O
synergism	O
in	O
tumor-bearing	O
mice	O
","	O
providing	O
a	O
rationale	O
for	O
assessing	O
this	O
combination	O
in	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
The	O
primary	O
objectives	O
of	O
this	O
study	O
were	O
to	O
determine	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
and	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
a	O
cabazitaxel	B-DRUG
/	O
cisplatin	B-DRUG
combined	O
regimen	O
(	O
Part	O
1	O
)	O
and	O
to	O
assess	O
antitumor	O
activity	O
at	O
the	O
MTD	O
(	O
Part	O
2	O
)	O
.	O
	
Safety	O
and	O
pharmacokinetics	O
(	O
PK	O
)	O
were	O
also	O
examined	O
.	O
	
Twenty-five	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
enrolled	O
(	O
10	O
in	O
Part	O
1	O
;	O
15	O
in	O
Part	O
2	O
)	O
.	O
	
In	O
Part	O
1	O
","	O
two	O
dose	O
levels	O
were	O
evaluated	O
;	O
the	O
MTD	O
for	O
cabazitaxel	B-DRUG
/	O
cisplatin	B-DRUG
(	O
given	O
Q3W	O
)	O
was	O
15	O
/	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
DLTs	O
occurring	O
during	O
Cycle	O
1	O
at	O
the	O
maximum	O
administered	O
dose	O
(	O
20	O
/	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
;	O
acute	B-TOXI
renal	I-TOXI
failure	I-TOXI
and	O
febrile	B-TOXI
neutropenia	I-TOXI
)	O
and	O
the	O
MTD	O
(	O
febrile	B-TOXI
neutropenia	I-TOXI
and	O
hypersensitivity	B-TOXI
despite	I-TOXI
pre-medication	I-TOXI
)	O
were	O
as	O
expected	O
for	O
taxane	B-DRUG
/	O
platinum	B-DRUG
combinations	O
.	O
	
For	O
the	O
18	O
patients	O
treated	O
at	O
the	O
MTD	O
","	O
the	O
most	O
frequent	O
possibly	O
related	O
non-hematologic	O
treatment-emergent	O
adverse	O
events	O
(	O
Grade	O
_	O
3	O
)	O
were	O
nausea	B-TOXI
(	O
16.7	O
%	O
)	O
","	O
fatigue	B-TOXI
","	O
acute	B-TOXI
renal	I-TOXI
failure	I-TOXI
and	O
decreased	B-TOXI
appetite	I-TOXI
(	O
each	O
11.1	O
%	O
)	O
.	O
	
Neutropenia	B-TOXI
was	O
the	O
most	O
frequent	O
treatment-emergent	O
Grade	O
_	O
3	O
hematologic	B-TOXI
laboratory	I-TOXI
abnormality	I-TOXI
at	O
the	O
MTD	O
(	O
77.8	O
%	O
)	O
.	O
	
The	O
best	O
overall	O
response	O
at	O
the	O
MTD	O
was	O
stable	O
disease	O
","	O
observed	O
in	O
66.7	O
%	O
of	O
patients	O
.	O
	
PK	O
results	O
of	O
the	O
combination	O
did	O
not	O
appear	O
to	O
differ	O
from	O
single-agent	O
administration	O
for	O
each	O
agent	O
.	O
	
Combination	O
treatment	O
with	O
cabazitaxel	B-DRUG
/	O
cisplatin	B-DRUG
had	O
a	O
manageable	O
safety	O
profile	O
;	O
no	O
PK	O
interactions	O
were	O
evident	O
.	O
	
The	O
recommended	O
Phase	O
II	O
dose	O
for	O
this	O
combination	O
is	O
cabazitaxel	B-DRUG
/	O
cisplatin	B-DRUG
15	O
/	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
administered	O
every	O
3	O
weeks	O
.	O
	
Antitumor	O
activity	O
findings	O
suggest	O
that	O
further	O
evaluation	O
of	O
this	O
combination	O
in	O
disease-specific	O
trials	O
is	O
warranted	O
.	O
	
Advanced	B-CANCER
biliary	I-CANCER
tract	I-CANCER
carcinomas	I-CANCER
:	O
a	O
retrospective	O
multicenter	O
analysis	O
of	O
first	O
and	O
second-line	O
chemotherapy	O
.	O
	
	
Gemcitabine	B-DRUG
/	O
Cisplatin	B-DRUG
(	O
Gem	B-DRUG
/	O
CDDP	B-DRUG
)	O
combination	O
has	O
demonstrated	O
a	O
clear	O
survival	O
advantage	O
over	O
gemcitabine	B-DRUG
alone	O
and	O
has	O
become	O
a	O
new	O
standard	O
in	O
advanced	B-CANCER
Biliary	I-CANCER
Tract	I-CANCER
Carcinoma	I-CANCER
(	O
aBTC	B-CANCER
)	O
.	O
	
However	O
","	O
Gemcitabine	B-DRUG
/	O
Oxaliplatin	B-DRUG
(	O
GEMOX	B-DRUG
)	O
combination	O
and	O
Gemcitabine	B-DRUG
/	O
Carboplatin	B-DRUG
(	O
Gem	B-DRUG
/	O
Carb	B-DRUG
)	O
combination	O
regimens	O
have	O
shown	O
efficacy	O
in	O
phase	O
II	O
trials	O
and	O
there	O
is	O
no	O
comparative	O
study	O
between	O
different	O
platinum	O
salts.We	O
assessed	O
the	O
efficacy	O
and	O
safety	O
of	O
different	O
platinum-based	O
chemotherapies	O
at	O
first	O
line	O
in	O
aBTC	B-CANCER
patients	O
.	O
	
We	O
also	O
analysed	O
the	O
second-line	O
chemotherapy	O
.	O
	
Sixty-four	O
consecutive	O
patients	O
with	O
aBTC	B-CANCER
diagnosed	O
between	O
1998	O
and	O
2010	O
were	O
included	O
for	O
analysis	O
.	O
	
At	O
first	O
line	O
chemotherapy	O
","	O
44	O
patients	O
received	O
one	O
day	O
GEMOX	B-DRUG
regimen	O
(	O
gemcitabine	B-DRUG
1000	O
mg	O
/	O
m2	O
and	O
oxaliplatin	B-DRUG
100	O
mg	O
/	O
m2	O
Day	O
1	O
","	O
every	O
2	O
weeks	O
)	O
","	O
and	O
20	O
patients	O
received	O
Gem	B-DRUG
/	O
Carb	B-DRUG
regimen	O
(	O
gemcitabine	B-DRUG
at	O
1000	O
mg	O
/	O
m2	O
Days	O
1	O
and	O
8	O
with	O
carboplatin	B-DRUG
delivered	O
according	O
to	O
an	O
area-under-the-curve	O
(	O
AUC	O
)	O
5	O
at	O
day	O
1	O
","	O
every	O
3	O
weeks	O
)	O
.	O
	
At	O
second	O
line	O
","	O
a	O
total	O
of	O
16	O
patients	O
received	O
a	O
fluoropyrimidine-based	B-DRUG
chemotherapy	O
.	O
	
With	O
GEMOX	B-DRUG
regimen	O
","	O
median	O
progression-free	O
survival	O
(	O
PFS	O
)	O
was	O
3.7	O
months	O
(	O
95	O
%	O
CI	O
","	O
2.4	O
to	O
5	O
)	O
and	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
10.5	O
months	O
(	O
95	O
%	O
CI	O
","	O
6.4	O
to14.7	O
)	O
.	O
	
The	O
main	O
toxicity	O
was	O
peripheral	B-TOXI
neuropathy	I-TOXI
(	O
20	O
%	O
grade	O
2	O
and	O
7	O
%	O
grade	O
3	O
)	O
.	O
	
Grade	O
3	O
/	O
4	O
haematological	B-TOXI
toxicities	I-TOXI
were	O
rare.With	O
Gem	B-DRUG
/	O
Carb	B-DRUG
regimen	O
","	O
PFS	O
was	O
2.5	O
months	O
(	O
95	O
%	O
CI	O
","	O
2.1	O
to	O
3.7	O
)	O
and	O
OS	O
was	O
4.8	O
months	O
(	O
95	O
%	O
CI	O
","	O
3.7	O
to	O
5.8	O
)	O
.	O
	
The	O
main	O
grade	O
3	O
/	O
4	O
toxicities	O
were	O
haematological	O
:	O
anaemia	B-TOXI
(	O
45	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
45	O
%	O
)	O
","	O
and	O
neutropenia	B-TOXI
(	O
40	O
%	O
)	O
.At	O
second-line	O
","	O
fluoropyrimidine-based	B-DRUG
chemotherapy	O
was	O
feasible	O
in	O
only	O
a	O
fourth	O
of	O
the	O
patients	O
.	O
	
The	O
median	O
OS	O
was	O
5.3	O
months	O
(	O
95	O
%	O
CI	O
","	O
4.1	O
to	O
6.6	O
)	O
","	O
and	O
median	O
PFS	O
was	O
4	O
months	O
(	O
95	O
%	O
CI	O
","	O
2.6	O
to	O
5.5	O
)	O
.	O
	
One	O
day	O
GEMOX	B-DRUG
regimen	O
has	O
a	O
favourable	O
toxicity	O
profile	O
and	O
could	O
be	O
an	O
alternative	O
to	O
standard	O
Gem	B-DRUG
/	O
CDDP	B-DRUG
regimen	O
","	O
in	O
particular	O
in	O
unfit	O
patients	O
for	O
CDDP.At	B-DRUG
second-line	O
","	O
selective	O
patients	O
may	O
benefit	O
from	O
fluoropyrimidine-based	B-DRUG
chemotherapy	O
.	O
	
Brentuximab	B-DRUG
vedotin	I-DRUG
in	O
the	O
front-line	O
treatment	O
of	O
patients	O
with	O
CD30+	O
peripheral	O
T-cell	B-CANCER
lymphomas	I-CANCER
:	O
results	O
of	O
a	O
phase	O
I	O
study	O
.	O
	
	
Front-line	O
treatment	O
of	O
peripheral	B-CANCER
T-cell	I-CANCER
lymphomas	I-CANCER
(	O
PTCL	B-CANCER
)	O
involves	O
regimens	O
such	O
as	O
cyclophosphamide	B-DRUG
","	O
doxorubicin	B-DRUG
","	O
vincristine	B-DRUG
","	O
prednisone	B-DRUG
(	O
CHOP	B-DRUG
)	O
and	O
results	O
in	O
a	O
5-year	O
overall	O
survival	O
(	O
OS	O
)	O
rate	O
of	O
less	O
than	O
50	O
%	O
.	O
	
This	O
phase	O
I	O
open-label	O
study	O
evaluated	O
the	O
safety	O
and	O
activity	O
of	O
brentuximab	B-DRUG
vedotin	I-DRUG
administered	O
sequentially	O
with	O
CHOP	B-DRUG
or	O
in	O
combination	O
with	O
CHP	B-DRUG
(	O
CHOP	B-DRUG
without	O
vincristine	B-DRUG
)	O
as	O
front-line	O
treatment	O
in	O
patients	O
with	O
CD30	O
(	O
=+	O
)	O
PTCL	B-CANCER
.	O
	
Patients	O
received	O
sequential	O
treatment	O
(	O
once	O
every	O
3	O
weeks	O
)	O
with	O
brentuximab	B-DRUG
vedotin	I-DRUG
1.8	O
mg	O
/	O
kg	O
(	O
two	O
cycles	O
)	O
followed	O
by	O
CHOP	B-DRUG
(	O
six	O
cycles	O
)	O
or	O
brentuximab	B-DRUG
vedotin	I-DRUG
1.8	O
mg	O
/	O
kg	O
plus	O
CHP	B-DRUG
(	O
BV+CHP	B-DRUG
)	O
for	O
six	O
cycles	O
(	O
once	O
every	O
3	O
weeks	O
)	O
.	O
	
Responders	O
received	O
single-agent	O
brentuximab	B-DRUG
vedotin	I-DRUG
for	O
eight	O
to	O
10	O
additional	O
cycles	O
(	O
for	O
a	O
total	O
of	O
16	O
cycles	O
)	O
.	O
	
The	O
primary	O
objective	O
was	O
assessment	O
of	O
safety	O
;	O
secondary	O
end	O
points	O
included	O
objective	O
response	O
rate	O
","	O
complete	O
remission	O
(	O
CR	O
)	O
rate	O
","	O
progression-free	O
survival	O
rate	O
(	O
PFS	O
)	O
","	O
and	O
OS	O
.	O
	
There	O
were	O
no	O
prespecified	O
comparisons	O
of	O
the	O
two	O
treatment	O
approaches	O
.	O
	
After	O
sequential	O
treatment	O
","	O
11	O
(	O
85	O
%	O
)	O
of	O
13	O
patients	O
achieved	O
an	O
objective	O
response	O
(	O
CR	O
rate	O
","	O
62	O
%	O
;	O
estimated	O
1-year	O
PFS	O
rate	O
","	O
77	O
%	O
)	O
.	O
	
Grade	O
3	O
/	O
4	O
adverse	O
events	O
occurred	O
in	O
eight	O
(	O
62	O
%	O
)	O
of	O
13	O
patients	O
.	O
	
At	O
the	O
end	O
of	O
combination	O
treatment	O
","	O
all	O
patients	O
(	O
n	O
=	O
26	O
)	O
achieved	O
an	O
objective	O
response	O
(	O
CR	O
rate	O
","	O
88	O
%	O
;	O
estimated	O
1-year	O
PFS	O
rate	O
","	O
71	O
%	O
)	O
.	O
	
All	O
seven	O
patients	O
without	O
anaplastic	B-CANCER
large-cell	I-CANCER
lymphoma	I-CANCER
achieved	O
CR	O
.	O
	
Grade	O
3	O
/	O
4	O
adverse	O
events	O
(	O
_	O
10	O
%	O
)	O
in	O
the	O
combination-treatment	O
group	O
were	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
31	O
%	O
)	O
","	O
neutropenia	B-TOXI
(	O
23	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
15	O
%	O
)	O
","	O
and	O
pulmonary	B-TOXI
embolism	I-TOXI
(	O
12	O
%	O
)	O
.	O
	
Brentuximab	B-DRUG
vedotin	I-DRUG
","	O
administered	O
sequentially	O
with	O
CHOP	B-DRUG
or	O
in	O
combination	O
with	O
CHP	B-DRUG
","	O
had	O
a	O
manageable	O
safety	O
profile	O
and	O
exhibited	O
substantial	O
antitumor	O
activity	O
in	O
newly	O
diagnosed	O
patients	O
with	O
CD30	O
(	O
=+	O
)	O
PTCL	B-CANCER
.	O
	
A	O
randomized	O
phase	O
III	O
trial	O
is	O
under	O
way	O
","	O
comparing	O
BV+CHP	B-DRUG
with	O
CHOP	B-DRUG
(	O
clinical	O
trial	O
No	O
.	O
	
NCT01777152	O
)	O
.	O
	
A	O
Phase	O
IB	O
multicentre	O
dose-determination	O
study	O
of	O
BHQ880	B-DRUG
in	O
combination	O
with	O
anti-myeloma	O
therapy	O
and	O
zoledronic	B-DRUG
acid	I-DRUG
in	O
patients	O
with	O
relapsed	O
or	O
refractory	B-CANCER
multiple	I-CANCER
myeloma	I-CANCER
and	O
prior	O
skeletal-related	O
events	O
.	O
	
	
Dickkopf-1	O
(	O
DKK1	O
)	O
","	O
expressed	O
by	O
myeloma	B-CANCER
cells	O
","	O
suppresses	O
osteoblast	O
function	O
and	O
plays	O
a	O
key	O
role	O
in	O
bone	O
disease	O
in	O
multiple	B-CANCER
myeloma	I-CANCER
.	O
	
BHQ880	B-DRUG
","	O
a	O
human	O
neutralizing	O
IgG1	O
anti-DKK1	O
monoclonal	O
antibody	O
","	O
is	O
being	O
investigated	O
for	O
its	O
impact	O
on	O
multiple	O
myeloma-related	O
bone	O
disease	O
and	O
as	O
an	O
agent	O
with	O
potential	O
anti-myeloma	O
activity	O
.	O
	
The	O
primary	O
objectives	O
of	O
this	O
Phase	O
IB	O
study	O
were	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
BHQ880	B-DRUG
and	O
to	O
characterize	O
the	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
of	O
escalating	O
doses	O
in	O
combination	O
with	O
anti-myeloma	O
therapy	O
and	O
zoledronic	B-DRUG
acid	I-DRUG
.	O
	
Twenty-eight	O
patients	O
were	O
enrolled	O
and	O
received	O
BHQ880	B-DRUG
at	O
doses	O
of	O
3-40	O
mg	O
/	O
kg	O
.	O
	
No	O
DLTs	O
were	O
reported	O
","	O
therefore	O
","	O
the	O
MTD	O
was	O
not	O
determined	O
.	O
	
The	O
recommended	O
Phase	O
II	O
dose	O
was	O
declared	O
as	O
10	O
mg	O
/	O
kg	O
","	O
based	O
mainly	O
on	O
saturation	O
data	O
.	O
	
There	O
was	O
a	O
general	O
trend	O
towards	O
increased	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
observed	O
over	O
time	O
;	O
specific	O
increases	O
in	O
spine	O
BMD	O
from	O
Cycle	O
12	O
onwards	O
irrespective	O
of	O
new	O
skeletal-related	O
events	O
on	O
study	O
were	O
observed	O
","	O
and	O
increases	O
in	O
bone	O
strength	O
at	O
the	O
spine	O
and	O
hip	O
were	O
also	O
demonstrated	O
in	O
some	O
patients	O
.	O
	
BHQ880	B-DRUG
in	O
combination	O
with	O
zoledronic	B-DRUG
acid	I-DRUG
and	O
anti-myeloma	O
therapy	O
was	O
well	O
tolerated	O
and	O
demonstrated	O
potential	O
clinical	O
activity	O
in	O
patients	O
with	O
relapsed	B-CANCER
or	I-CANCER
refractory	I-CANCER
multiple	I-CANCER
myeloma	I-CANCER
.	O
	
Phase	O
I	O
study	O
of	O
sunitinib	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
and	O
capecitabine	B-DRUG
for	O
first-line	O
treatment	O
of	O
metastatic	B-CANCER
or	I-CANCER
unresectable	I-CANCER
renal	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
	
The	O
combination	O
of	O
gemcitabine	B-DRUG
plus	O
capecitabine	B-DRUG
and	O
sunitinib	B-DRUG
(	O
GCS	B-DRUG
)	O
shows	O
activity	O
in	O
metastatic	B-CANCER
renal	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
mRCC	B-CANCER
)	O
.	O
	
We	O
tested	O
the	O
multitargeted	O
	O
regimen	O
as	O
first-line	O
treatment	O
in	O
patients	O
with	O
mRCC	B-CANCER
.	O
	
We	O
assessed	O
the	O
maximum	O
tolerated	O
dose	O
and	O
antitumor	O
activity	O
of	O
GCS	B-DRUG
in	O
treatment-na茂ve	O
","	O
advanced	B-CANCER
mRCC	I-CANCER
patients	O
.	O
	
Treatment	O
consisted	O
of	O
intravenous	O
gemcitabine	B-DRUG
on	O
days	O
1	O
and	O
8	O
","	O
oral	O
capecitabine	B-DRUG
twice	O
daily	O
on	O
days	O
1月14日	O
","	O
and	O
oral	O
sunitinib	B-DRUG
daily	O
for	O
six	O
21-day	O
cycles	O
","	O
followed	O
by	O
sunitinib	B-DRUG
monotherapy	O
at	O
the	O
investigator	O
's	O
discretion	O
.	O
	
Dose	O
level	O
0	O
(	O
DL0	O
)	O
was	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
day	O
plus	O
capecitabine	B-DRUG
650	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
12	O
hours	O
plus	O
sunitinib	B-DRUG
37.5	O
mg	O
/	O
day	O
;	O
DL1	O
was	O
gemcitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
day	O
plus	O
capecitabine	B-DRUG
850	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
12	O
hours	O
plus	O
sunitinib	B-DRUG
37.5	O
mg	O
/	O
day	O
.	O
	
Sixteen	O
patients	O
were	O
enrolled	O
.	O
	
At	O
DL1	O
","	O
two	O
of	O
four	O
patients	O
had	O
dose-limiting	O
toxicity	O
(	O
DLT	O
;	O
grade	O
3	O
diarrhea	B-TOXI
and	O
grade	O
4	O
thrombocytopenia	B-TOXI
)	O
.	O
	
The	O
dose	O
was	O
reduced	O
to	O
DL0	O
when	O
only	O
1	O
of	O
12	O
patients	O
experienced	O
DLT	O
(	O
grade	O
3	O
diarrhea	B-TOXI
","	O
grade	O
3	O
mucositis	B-TOXI
","	O
and	O
grade	O
3	O
thrombocytopenia	B-TOXI
)	O
.	O
	
Dose	O
reductions	O
were	O
frequent	O
(	O
58	O
%	O
of	O
patients	O
)	O
","	O
and	O
only	O
seven	O
patients	O
were	O
able	O
to	O
receive	O
the	O
three	O
drugs	O
for	O
more	O
than	O
three	O
cycles	O
.	O
	
One	O
patient	O
achieved	O
a	O
complete	O
response	O
","	O
three	O
had	O
partial	O
responses	O
","	O
and	O
the	O
best	O
response	O
for	O
four	O
was	O
stable	O
disease	O
.	O
	
The	O
safety	O
profile	O
of	O
the	O
combination	O
does	O
not	O
seem	O
manageable	O
in	O
this	O
patient	O
population	O
.	O
	
No	O
further	O
development	O
of	O
the	O
combination	O
is	O
recommended	O
.	O
	
Safety	O
and	O
activity	O
of	O
alectinib	B-DRUG
against	O
systemic	O
disease	O
and	O
brain	O
metastases	O
in	O
patients	O
with	O
crizotinib-resistant	B-DRUG
ALK-rearranged	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
AF-002JG	O
)	O
:	O
results	O
from	O
the	O
dose-finding	O
portion	O
of	O
a	O
phase	O
1	O
/	O
2	O
study	O
.	O
	
	
Patients	O
with	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
and	O
ALK	O
rearrangements	O
generally	O
have	O
a	O
progression-free	O
survival	O
of	O
8月11日	O
months	O
while	O
on	O
treatment	O
with	O
the	O
ALK	O
inhibitor	O
crizotinib	B-DRUG
.	O
	
However	O
","	O
resistance	O
inevitably	O
develops	O
","	O
with	O
the	O
brain	O
a	O
common	O
site	O
of	O
progression	O
.	O
	
More	O
potent	O
ALK	O
inhibitors	O
with	O
consistently	O
demonstrable	O
CNS	O
activity	O
and	O
good	O
tolerability	O
are	O
needed	O
urgently	O
.	O
	
Alectinib	B-DRUG
is	O
a	O
novel	O
","	O
highly	O
selective	O
","	O
and	O
potent	O
ALK	O
inhibitor	O
that	O
has	O
shown	O
clinical	O
activity	O
in	O
patients	O
with	O
crizotinib-naive	B-DRUG
ALK-rearranged	O
NSCLC	B-CANCER
.	O
	
We	O
did	O
a	O
phase	O
1	O
/	O
2	O
study	O
of	O
alectinib	B-DRUG
to	O
establish	O
the	O
recommended	O
phase	O
2	O
dose	O
of	O
the	O
drug	O
and	O
examine	O
its	O
activity	O
in	O
patients	O
resistant	O
or	O
intolerant	O
to	O
crizotinib	B-DRUG
.	O
	
We	O
enrolled	O
patients	O
with	O
ALK-rearranged	O
NSCLC	B-CANCER
who	O
progressed	O
on	O
or	O
were	O
intolerant	O
to	O
crizotinib	B-DRUG
.	O
	
We	O
administered	O
various	O
oral	O
doses	O
of	O
alectinib	B-DRUG
(	O
300-900	O
mg	O
twice	O
a	O
day	O
)	O
during	O
the	O
dose-escalation	O
portion	O
of	O
the	O
study	O
(	O
phase	O
1	O
)	O
","	O
to	O
ascertain	O
the	O
recommended	O
dose	O
for	O
phase	O
2	O
We	O
used	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	O
Tumors	O
criteria	O
(	O
version	O
1.1	O
)	O
to	O
investigate	O
the	O
activity	O
of	O
alectinib	B-DRUG
in	O
all	O
patients	O
with	O
a	O
baseline	O
scan	O
and	O
at	O
least	O
one	O
post-treatment	O
scan	O
(	O
CT	O
or	O
MRI	O
)	O
","	O
with	O
central	O
radiological	O
review	O
of	O
individuals	O
with	O
brain	O
metastases	O
.	O
	
We	O
assessed	O
safety	O
in	O
all	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
alectinib	B-DRUG
.	O
	
Here	O
","	O
we	O
present	O
data	O
for	O
the	O
phase	O
1	O
portion	O
of	O
the	O
study	O
","	O
the	O
primary	O
objective	O
of	O
which	O
was	O
to	O
establish	O
the	O
recommended	O
phase	O
2	O
dose	O
;	O
phase	O
2	O
is	O
ongoing	O
.	O
	
This	O
trial	O
is	O
registered	O
at	O
ClinicalTrials.gov	O
","	O
number	O
NCT01588028	O
.	O
	
47	O
patients	O
were	O
enrolled	O
.	O
	
Alectinib	B-DRUG
was	O
well	O
tolerated	O
","	O
with	O
the	O
most	O
common	O
adverse	O
events	O
being	O
fatigue	B-DRUG
(	O
14	O
[	O
30	O
%	O
]	O
;	O
all	O
grade	O
1月2日	O
)	O
","	O
myalgia	B-DRUG
(	O
eight	O
[	O
17	O
%	O
]	O
;	O
all	O
grade	O
1月2日	O
)	O
","	O
and	O
peripheral	B-DRUG
oedema	I-DRUG
(	O
seven	O
[	O
15	O
%	O
]	O
grade	O
1月2日	O
","	O
one	O
[	O
2	O
%	O
]	O
grade	O
3	O
)	O
.	O
	
Dose-limiting	O
toxic	O
effects	O
were	O
recorded	O
in	O
two	O
patients	O
in	O
the	O
cohort	O
receiving	O
alectinib	B-DRUG
900	O
mg	O
twice	O
a	O
day	O
;	O
one	O
individual	O
had	O
grade	O
3	O
headache	B-DRUG
and	O
the	O
other	O
had	O
grade	O
3	O
neutropenia	B-DRUG
.	O
	
The	O
most	O
common	O
grade	O
3月4日	O
adverse	O
events	O
were	O
increased	B-TOXI
levels	I-TOXI
of	I-TOXI
纬-glutamyl	I-TOXI
transpeptidase	I-TOXI
(	O
two	O
[	O
4	O
%	O
]	O
)	O
","	O
a	O
reduction	B-TOXI
in	I-TOXI
the	I-TOXI
number	I-TOXI
of	I-TOXI
neutrophils	I-TOXI
(	O
two	O
[	O
4	O
%	O
]	O
)	O
","	O
and	O
hypophosphataemia	B-TOXI
(	O
two	O
[	O
4	O
%	O
]	O
)	O
.	O
	
Three	O
patients	O
reported	O
four	O
grade	O
4	O
serious	O
adverse	O
events	O
that	O
were	O
deemed	O
unrelated	O
to	O
alectinib	B-DRUG
:	O
acute	B-TOXI
renal	I-TOXI
failure	I-TOXI
;	O
pleural	B-TOXI
effusion	I-TOXI
and	O
pericardial	B-TOXI
effusion	I-TOXI
;	O
and	O
brain	B-TOXI
metastasis	I-TOXI
.	O
	
At	O
data	O
cut-off	O
(	O
median	O
follow-up	O
126	O
days	O
[	O
IQR	O
84-217	O
]	O
)	O
","	O
44	O
patients	O
could	O
be	O
assessed	O
for	O
activity	O
.	O
	
Investigator-assessed	O
objective	O
responses	O
were	O
noted	O
in	O
24	O
(	O
55	O
%	O
)	O
patients	O
","	O
with	O
a	O
confirmed	O
complete	O
response	O
in	O
one	O
(	O
2	O
%	O
)	O
","	O
a	O
confirmed	O
partial	O
response	O
in	O
14	O
(	O
32	O
%	O
)	O
","	O
and	O
an	O
unconfirmed	O
partial	O
response	O
in	O
nine	O
(	O
20	O
%	O
)	O
.	O
	
16	O
(	O
36	O
%	O
)	O
patients	O
had	O
stable	O
disease	O
;	O
the	O
remaining	O
four	O
(	O
9	O
%	O
)	O
had	O
progressive	O
disease	O
.	O
	
Of	O
21	O
patients	O
with	O
CNS	O
metastases	O
at	O
baseline	O
","	O
11	O
(	O
52	O
%	O
)	O
had	O
an	O
objective	O
response	O
;	O
six	O
(	O
29	O
%	O
)	O
had	O
a	O
complete	O
response	O
(	O
three	O
unconfirmed	O
)	O
and	O
five	O
(	O
24	O
%	O
)	O
had	O
a	O
partial	O
response	O
(	O
one	O
unconfirmed	O
)	O
;	O
eight	O
(	O
38	O
%	O
)	O
patients	O
had	O
stable	O
disease	O
and	O
the	O
remaining	O
two	O
(	O
10	O
%	O
)	O
had	O
progressive	O
disease	O
.	O
	
Pharmacokinetic	O
data	O
indicated	O
that	O
mean	O
exposure	O
(	O
AUC0-10	O
)	O
after	O
multiple	O
doses	O
of	O
alectinib	B-DRUG
(	O
300-600	O
mg	O
twice	O
a	O
day	O
)	O
was	O
dose-dependent	O
.	O
	
Alectinib	O
was	O
well	O
tolerated	O
","	O
with	O
promising	O
antitumour	O
activity	O
in	O
patients	O
with	O
ALK-rearranged	O
NSCLC	B-CANCER
resistant	O
to	O
crizotinib	B-DRUG
","	O
including	O
those	O
with	O
CNS	O
metastases	O
.	O
	
On	O
the	O
basis	O
of	O
activity	O
","	O
tolerability	O
","	O
and	O
pharmacokinetic	O
data	O
","	O
we	O
chose	O
alectinib	B-DRUG
600	O
mg	O
twice	O
a	O
day	O
as	O
the	O
recommended	O
dose	O
for	O
phase	O
2	O
Chugai	O
Pharmaceuticals	O
","	O
F	O
Hoffmann	O
La-Roche	O
.	O
	
Eltrombopag	O
with	O
gemcitabine-based	B-DRUG
chemotherapy	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
:	O
a	O
randomized	O
phase	O
I	O
study	O
.	O
	
	
Preventing	O
chemotherapy-induced	O
thrombocytopenia	B-TOXI
could	O
avoid	O
chemotherapy	O
dose	O
reductions	O
and	O
delays	O
.	O
	
The	O
safety	O
and	O
maximum	O
tolerated	O
dose	O
of	O
eltrombopag	B-DRUG
","	O
an	O
oral	O
thrombopoietin	B-DRUG
receptor	I-DRUG
agonist	I-DRUG
","	O
with	O
gemcitabine-based	B-DRUG
therapy	O
was	O
evaluated	O
.	O
	
Patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
and	O
platelets	O
_300	O
_	O
10	O
(	O
9	O
)	O
/	O
L	O
receiving	O
gemcitabine	B-DRUG
plus	O
cisplatin	B-DRUG
or	O
carboplatin	B-DRUG
(	O
Group	O
A	O
)	O
or	O
gemcitabine	B-DRUG
monotherapy	O
(	O
Group	O
B	O
)	O
were	O
randomized	O
03:01	O
to	O
receive	O
eltrombopag	B-DRUG
or	O
placebo	B-DRUG
at	O
a	O
starting	O
dose	O
of	O
100	O
mg	O
daily	O
administered	O
on	O
days	O
-5	O
to	O
-1	O
and	O
days	O
2月6日	O
starting	O
from	O
cycle	O
2	O
of	O
treatment	O
.	O
	
Nineteen	O
patients	O
(	O
Group	O
A	O
","	O
n	O
=	O
9	O
;	O
Group	O
B	O
","	O
n	O
=	O
10	O
)	O
received	O
eltrombopag	B-DRUG
100	O
mg	O
and	O
seven	O
(	O
Group	O
A	O
","	O
n	O
=	O
3	O
;	O
Group	O
B	O
","	O
n	O
=	O
4	O
)	O
received	O
matching	O
placebo	B-DRUG
.	O
	
Nine	O
eltrombopag	B-DRUG
patients	O
in	O
Group	O
A	O
and	O
eight	O
in	O
Group	O
B	O
had	O
38	O
and	O
54	O
occurrences	O
of	O
platelet	O
counts	O
_400	O
_	O
10	O
(	O
9	O
)	O
/	O
L	O
","	O
respectively	O
.	O
	
Mean	O
platelet	O
nadirs	O
across	O
cycles	O
2月6日	O
were	O
115	O
_	O
10	O
(	O
9	O
)	O
/	O
L	O
and	O
143	O
_	O
10	O
(	O
9	O
)	O
/	O
L	O
for	O
eltrombopag-treated	B-DRUG
patients	O
versus	O
53	O
_	O
10	O
(	O
9	O
)	O
/	O
L	O
and	O
103	O
_	O
10	O
(	O
9	O
)	O
/	O
L	O
for	O
placebo-treated	B-DRUG
patients	O
in	O
Groups	O
A	O
and	O
B	O
","	O
respectively	O
.	O
	
No	O
dose-limiting	O
toxicities	O
were	O
reported	O
for	O
eltrombopag	B-DRUG
;	O
however	O
","	O
due	O
to	O
several	O
occurrences	O
of	O
thrombocytosis	B-TOXI
","	O
a	O
decision	O
was	O
made	O
not	O
to	O
dose-escalate	O
eltrombopag	B-DRUG
to	O
&	O
gt	O
;	O
100	O
mg	O
daily	O
.	O
	
In	O
Groups	O
A	O
and	O
B	O
","	O
14	O
%	O
of	O
eltrombopag	B-DRUG
versus	O
50	O
%	O
of	O
placebo	B-DRUG
patients	O
required	O
chemotherapy	O
dose	O
reductions	O
and	O
/	O
or	O
delays	O
for	O
any	O
reason	O
across	O
cycles	O
3月6日	O
.	O
	
Eltrombopag	B-DRUG
100	O
mg	O
once	O
daily	O
administered	O
5	O
days	O
before	O
and	O
after	O
day	O
1	O
of	O
chemotherapy	O
was	O
well	O
tolerated	O
with	O
an	O
acceptable	O
safety	O
profile	O
","	O
and	O
will	O
be	O
further	O
tested	O
in	O
a	O
phase	O
II	O
trial	O
.	O
	
Fewer	O
patients	O
receiving	O
eltrombopag	B-DRUG
required	O
chemotherapy	O
dose	O
delays	O
and	O
/	O
or	O
reductions	O
compared	O
with	O
those	O
receiving	O
placebo	B-DRUG
.	O
	
Phase	O
1	O
combination	O
study	O
of	O
eribulin	B-DRUG
mesylate	I-DRUG
with	O
trastuzumab	B-DRUG
for	O
advanced	O
or	O
recurrent	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
positive	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
	
Eribulin	B-DRUG
mesylate	I-DRUG
(	O
Halaven庐	O
)	O
is	O
a	O
novel	O
inhibitor	O
of	O
microtubule	O
dynamics	O
that	O
has	O
demonstrated	O
a	O
survival	O
benefit	O
in	O
patients	O
with	O
locally	O
recurrent	O
or	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
who	O
previously	O
received	O
at	O
least	O
two	O
chemotherapeutic	O
regimens	O
including	O
an	O
anthracycline	B-DRUG
and	O
a	O
taxane	B-DRUG
.	O
	
Although	O
trastuzumab	B-DRUG
is	O
indicated	O
for	O
patients	O
with	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
positive	O
(	O
HER2+	O
)	O
breast	B-CANCER
cancer	I-CANCER
","	O
a	O
phase	O
1	O
study	O
to	O
evaluate	O
tolerability	O
/	O
safety	O
of	O
eribulin	B-DRUG
mesylate	I-DRUG
with	O
trastuzumab	B-DRUG
has	O
not	O
been	O
conducted	O
.	O
	
Therefore	O
","	O
a	O
study	O
of	O
eribulin	B-DRUG
mesylate	I-DRUG
in	O
combination	O
with	O
trastuzumab	B-DRUG
was	O
conducted	O
to	O
evaluate	O
dose	O
limiting	O
toxicity	O
(	O
DLT	O
)	O
","	O
tolerability	O
/	O
safety	O
","	O
pharmacokinetics	O
(	O
PK	O
)	O
","	O
and	O
efficacy	O
and	O
to	O
estimate	O
the	O
recommended	O
dose	O
in	O
Japanese	O
patients	O
with	O
advanced	O
or	O
recurrent	O
HER2+	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
Eribulin	B-DRUG
mesylate	I-DRUG
(	O
1.4	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
was	O
administered	O
on	O
days	O
1	O
and	O
8	O
of	O
every	O
3	O
week	O
cycle	O
.	O
	
Trastuzumab	B-DRUG
was	O
administered	O
with	O
a	O
4	O
mg	O
/	O
kg	O
loading	O
dose	O
followed	O
by	O
2	O
mg	O
/	O
kg	O
weekly	O
doses	O
or	O
with	O
an	O
8	O
mg	O
/	O
kg	O
loading	O
dose	O
followed	O
by	O
6	O
mg	O
/	O
kg	O
tri-weekly	O
doses	O
.	O
	
A	O
total	O
of	O
12	O
patients	O
(	O
six	O
for	O
each	O
regimen	O
)	O
received	O
eribulin	B-DRUG
mesylate	I-DRUG
and	O
trastuzumab	B-DRUG
.	O
	
No	O
DLT	O
was	O
observed	O
and	O
the	O
recommended	O
dose	O
of	O
eribulin	B-DRUG
mesylate	I-DRUG
in	O
combination	O
with	O
trastuzumab	B-DRUG
was	O
estimated	O
as	O
1.4	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Common	O
adverse	O
events	O
were	O
neutropenia	B-TOXI
","	O
leukopenia	B-TOXI
","	O
anaemia	B-TOXI
and	O
alopecia	B-TOXI
.	O
	
This	O
combination	O
therapy	O
was	O
well	O
tolerated	O
and	O
the	O
neutropenia	B-TOXI
observed	O
was	O
manageable	O
.	O
	
No	O
PK	O
drug-drug	O
interaction	O
between	O
eribulin	B-DRUG
and	O
trastuzumab	B-DRUG
was	O
observed	O
.	O
	
Since	O
a	O
transient	O
ejection	O
fraction	O
decreased	O
was	O
observed	O
in	O
two	O
patients	O
","	O
cardiac	O
function	O
should	O
be	O
routinely	O
assessed	O
in	O
patients	O
receiving	O
the	O
combination	O
therapy	O
of	O
eribulin	B-DRUG
mesylate	I-DRUG
with	O
trastuzumab	B-DRUG
(	O
ClinicalTrials.gov	O
Identifier	O
:	O
NCT01432886	O
)	O
.	O
	
A	O
phase	O
I	O
/	O
II	O
study	O
of	O
bortezomib	B-DRUG
in	O
combination	O
with	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
concurrent	O
thoracic	O
radiation	O
therapy	O
for	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
North	O
Central	O
Cancer	O
Treatment	O
Group	O
(	O
NCCTG	O
)	O
0	O
.	O
	
	
Despite	O
the	O
advances	O
in	O
radiation	O
techniques	O
and	O
chemotherapy	O
","	O
survival	O
with	O
current	O
platinum-based	B-DRUG
chemotherapy	O
and	O
concomitant	O
thoracic	O
radiation	O
remains	O
dismal	O
.	O
	
Bortezomib	B-DRUG
","	O
a	O
proteasome	O
inhibitor	O
","	O
modulates	O
apoptosis	O
and	O
cell	O
cycle	O
through	O
disruption	O
of	O
protein	O
degradation	O
.	O
	
The	O
combination	O
of	O
bortezomib	B-DRUG
and	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
and	O
concurrent	O
radiation	O
in	O
unresectable	O
stage	O
III	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
was	O
evaluated	O
in	O
this	O
phase	O
I	O
/	O
II	O
study	O
.	O
	
Patients	O
with	O
histologic	O
or	O
cytologic	O
confirmed	O
stage	O
III	O
nonmetastatic	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
who	O
were	O
candidates	O
for	O
radiation	O
therapy	O
were	O
eligible	O
.	O
	
In	O
the	O
phase	O
I	O
portion	O
","	O
patients	O
received	O
escalating	O
doses	O
of	O
bortezomib	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
and	O
carboplatin	B-DRUG
concomitantly	O
with	O
thoracic	O
radiation	O
(	O
60	O
Gy	O
/	O
30	O
daily	O
fractions	O
)	O
using	O
a	O
modified	O
3	O
=+	O
3	O
design	O
.	O
	
The	O
primary	O
endpoint	O
for	O
the	O
phase	O
II	O
portion	O
was	O
the	O
12-month	O
survival	O
rate	O
(	O
12MS	O
)	O
.	O
	
A	O
one-stage	O
design	O
with	O
an	O
interim	O
analysis	O
yielded	O
81	O
%	O
power	O
to	O
detect	O
a	O
TRUE	O
12MS	O
of	O
75	O
%	O
","	O
with	O
a	O
0.09	O
level	O
of	O
significance	O
if	O
the	O
TRUE	O
12MS	O
was	O
60	O
%	O
using	O
a	O
sample	O
size	O
of	O
60	O
patients	O
.	O
	
Secondary	O
endpoints	O
consisted	O
of	O
adverse	O
events	O
(	O
AEs	O
)	O
","	O
overall	O
survival	O
","	O
progression-free	O
survival	O
","	O
and	O
the	O
confirmed	O
response	O
rate	O
.	O
	
Thirty-one	O
patients	O
enrolled	O
during	O
the	O
phase	O
I	O
portion	O
of	O
the	O
trial	O
","	O
of	O
which	O
four	O
cancelled	O
before	O
receiving	O
treatment	O
","	O
leaving	O
27	O
evaluable	O
patients	O
.	O
	
Of	O
these	O
27	O
patients	O
","	O
two	O
dose-limiting	O
toxicities	O
were	O
observed	O
","	O
one	O
(	O
grade	O
3	O
pneumonitis	B-TOXI
)	O
at	O
dose	O
level	O
1	O
(	O
bortezomib	B-DRUG
at	O
0.5	O
mg	O
/	O
m	O
","	O
paclitaxel	B-DRUG
at	O
150	O
mg	O
/	O
m	O
","	O
and	O
carboplatin	B-DRUG
at	O
area	O
under	O
the	O
curve	O
of	O
5	O
)	O
and	O
one	O
(	O
grade	O
4	O
neutropenia	B-TOXI
lasting	O
_8	O
days	O
)	O
at	O
dose	O
level	O
6	O
(	O
bortezomib	B-DRUG
1.2	O
mg	O
/	O
m	O
","	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m	O
","	O
and	O
carboplatin	B-DRUG
at	O
area	O
under	O
the	O
curve	O
of	O
6	O
)	O
.	O
	
During	O
the	O
phase	O
I	O
portion	O
","	O
the	O
most	O
common	O
grade	O
3	O
of	O
4	O
AEs	O
were	O
leukopenia	B-TOXI
(	O
44	O
%	O
)	O
","	O
neutropenia	B-TOXI
(	O
37	O
%	O
)	O
","	O
dyspnea	B-TOXI
(	O
22	O
%	O
)	O
","	O
and	O
dysphagia	B-TOXI
(	O
11	O
%	O
)	O
.	O
	
Dose	O
level	O
6	O
was	O
declared	O
to	O
be	O
the	O
recommended	O
phase	O
II	O
dose	O
(	O
RP2D	O
)	O
and	O
the	O
phase	O
II	O
portion	O
of	O
the	O
study	O
opened	O
.	O
	
After	O
the	O
first	O
26	O
evaluable	O
patients	O
were	O
enrolled	O
to	O
the	O
RP2D	O
","	O
a	O
per	O
protocol	O
interim	O
analysis	O
occurred	O
.	O
	
Of	O
these	O
26	O
patients	O
","	O
23	O
(	O
88	O
%	O
)	O
survived	O
at	O
least	O
6	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
70-98	O
%	O
)	O
","	O
which	O
was	O
enough	O
to	O
continue	O
to	O
full	O
accrual	O
per	O
study	O
design	O
.	O
	
However	O
","	O
due	O
to	O
slow	O
accrual	O
","	O
the	O
study	O
was	O
stopped	O
after	O
27	O
evaluable	O
patients	O
were	O
enrolled	O
(	O
6-phase	O
I	O
RP2D	O
;	O
21-phase	O
II	O
)	O
.	O
	
Of	O
these	O
27	O
patients	O
","	O
the	O
12MS	O
was	O
73	O
%	O
(	O
95	O
%	O
CI	O
","	O
58-92	O
%	O
)	O
","	O
the	O
median	O
overall	O
survival	O
was	O
25	O
months	O
(	O
95	O
%	O
CI	O
","	O
15.6-35.8	O
)	O
","	O
and	O
the	O
median	O
progression-free	O
survival	O
was	O
8.4	O
months	O
(	O
95	O
%	O
CI	O
","	O
4.1-10.5	O
)	O
.	O
	
The	O
confirmed	O
response	O
rate	O
was	O
26	O
%	O
(	O
seven	O
of	O
27	O
;	O
95	O
%	O
CI	O
","	O
11-46	O
%	O
)	O
","	O
consisting	O
of	O
four	O
partial	O
responses	O
and	O
three	O
complete	O
responses	O
.	O
	
Grade	O
3+	O
and	O
grade	O
4+	O
AEs	O
occurred	O
in	O
82	O
%	O
and	O
56	O
%	O
of	O
patients	O
","	O
respectively	O
.	O
	
One	O
patient	O
experienced	O
grade	O
5	O
pneumonitis	B-TOXI
that	O
was	O
possibly	O
related	O
to	O
the	O
treatment	O
.	O
	
Grade	O
3	O
and	O
4	O
hematological	B-TOXI
toxicities	I-TOXI
were	O
observed	O
in	O
82	O
%	O
and	O
56	O
%	O
patients	O
","	O
respectively	O
.	O
	
The	O
addition	O
of	O
bortezomib	B-DRUG
to	O
concurrent	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
and	O
radiation	O
seemed	O
to	O
be	O
feasible	O
","	O
although	O
associated	O
with	O
increased	O
hematological	B-TOXI
toxicities	I-TOXI
.	O
	
A	O
favorable	O
median	O
overall	O
survival	O
of	O
25	O
months	O
suggests	O
a	O
potential	O
benefit	O
for	O
this	O
regimen	O
.	O
	
A	O
phase	O
I	O
open-label	O
study	O
of	O
the	O
safety	O
","	O
tolerability	O
","	O
and	O
pharmacokinetics	O
of	O
pazopanib	B-DRUG
in	O
combination	O
with	O
irinotecan	B-DRUG
and	O
cetuximab	B-DRUG
for	O
relapsed	O
or	O
refractory	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
Pazopanib	B-DRUG
is	O
a	O
multi-targeted	O
tyrosine	O
kinase	O
inhibitor	O
shown	O
to	O
be	O
clinically	O
active	O
in	O
the	O
treatment	O
of	O
various	O
cancer	O
types	O
.	O
	
This	O
study	O
aimed	O
to	O
evaluate	O
the	O
maximum	O
tolerated	O
regimen	O
(	O
MTR	O
)	O
","	O
safety	O
","	O
and	O
pharmacokinetics	O
of	O
pazopanib	B-DRUG
in	O
combination	O
with	O
irinotecan	B-DRUG
and	O
cetuximab	B-DRUG
in	O
adult	O
patients	O
with	O
relapsed	O
or	O
refractory	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
mCRC	B-CANCER
)	O
.	O
	
This	O
was	O
a	O
Phase	O
I	O
","	O
3	O
=+	O
3	O
design	O
","	O
open-label	O
","	O
dose-escalation	O
study	O
(	O
NCT0050943	O
;	O
VEG108925	O
)	O
conducted	O
in	O
sequential	O
cohorts	O
to	O
determine	O
the	O
MTR	O
of	O
pazopanib	B-DRUG
and	O
irinotecan	B-DRUG
administered	O
with	O
cetuximab	B-DRUG
.	O
	
Twenty-five	O
patients	O
received	O
treatment	O
in	O
three	O
dosing	O
cohorts	O
and	O
were	O
evaluated	O
for	O
safety	O
and	O
tolerability	O
of	O
the	O
combination	O
and	O
pharmacokinetics	O
of	O
individual	O
drugs	O
.	O
	
The	O
MTR	O
was	O
determined	O
to	O
be	O
400	O
mg	O
pazopanib	B-DRUG
per	O
day	O
orally	O
in	O
combination	O
with	O
150	O
mg	O
/	O
m	O
(	O
2	O
)	O
irinotecan	B-DRUG
biweekly	O
and	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
cetuximab	B-DRUG
weekly	O
by	O
infusion	O
.	O
	
Neutropenia	B-TOXI
was	O
the	O
main	O
dose-limiting	O
toxicity	O
.	O
	
Pharmacokinetic	O
results	O
suggested	O
that	O
the	O
overall	O
systemic	O
exposure	O
to	O
SN-38	O
","	O
the	O
active	O
metabolite	O
of	O
irinotecan	B-DRUG
","	O
was	O
affected	O
by	O
pazopanib	B-DRUG
to	O
a	O
greater	O
extent	O
than	O
was	O
the	O
systemic	O
exposure	O
to	O
irinotecan	B-DRUG
itself	O
.	O
	
This	O
study	O
provided	O
evidence	O
for	O
the	O
manageable	O
safety	O
profile	O
and	O
feasibility	O
of	O
using	O
the	O
novel	O
triplet	O
combination	O
of	O
pazopanib	B-DRUG
","	O
irinotecan	B-DRUG
","	O
and	O
cetuximab	B-DRUG
in	O
patients	O
with	O
refractory	O
mCRC	B-CANCER
.	O
	
Further	O
large-scale	O
Phase	O
II	O
studies	O
are	O
warranted	O
.	O
	
An	O
open-label	O
phase	O
Ib	O
dose-escalation	O
study	O
of	O
TRC105	B-DRUG
(	O
anti-endoglin	O
antibody	O
)	O
with	O
bevacizumab	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
cancer	I-CANCER
.	O
	
	
Endoglin	B-DRUG
","	O
an	O
endothelial	O
cell	O
membrane	O
receptor	O
expressed	O
on	O
angiogenic	O
tumor	O
vessels	O
","	O
is	O
essential	O
for	O
angiogenesis	O
and	O
upregulated	O
in	O
the	O
setting	O
of	O
VEGF	O
inhibition	O
.	O
	
TRC105	B-DRUG
is	O
an	O
anti-endoglin	O
IgG1	O
monoclonal	O
antibody	O
that	O
potentiates	O
VEGF	O
inhibitors	O
in	O
preclinical	O
models	O
.	O
	
This	O
study	O
assessed	O
safety	O
","	O
pharmacokinetics	O
","	O
and	O
antitumor	O
activity	O
of	O
TRC105	B-DRUG
in	O
combination	O
with	O
bevacizumab	B-DRUG
.	O
	
Patients	O
(	O
n	O
=	O
38	O
)	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
","	O
Eastern	O
Cooperative	O
Group	O
performance	O
status	O
0-1	O
","	O
and	O
normal	O
organ	O
function	O
were	O
treated	O
with	O
escalating	O
doses	O
of	O
TRC105	B-DRUG
plus	O
bevacizumab	B-DRUG
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
using	O
a	O
standard	O
3	O
=+	O
3	O
phase	O
I	O
design	O
.	O
	
TRC105	B-DRUG
and	O
bevacizumab	B-DRUG
were	O
well	O
tolerated	O
at	O
their	O
recommended	O
single-agent	O
doses	O
(	O
10	O
mg	O
/	O
kg	O
)	O
when	O
the	O
initial	O
dose	O
of	O
TRC105	B-DRUG
was	O
delayed	O
by	O
one	O
week	O
and	O
divided	O
over	O
2	O
days	O
to	O
limit	O
the	O
frequency	O
of	O
headache	B-TOXI
.	O
	
The	O
concurrent	O
administration	O
of	O
bevacizumab	B-DRUG
and	O
TRC105	B-DRUG
did	O
not	O
otherwise	O
potentiate	O
known	O
toxicities	O
of	O
TRC105	B-DRUG
or	O
bevacizumab	B-DRUG
.	O
	
Hypertension	B-TOXI
and	O
proteinuria	B-TOXI
were	O
observed	O
","	O
though	O
not	O
at	O
rates	O
expected	O
for	O
single-agent	O
bevacizumab	B-DRUG
.	O
	
Several	O
patients	O
who	O
had	O
previously	O
progressed	O
on	O
bevacizumab	B-DRUG
or	O
VEGF	O
receptor	O
tyrosine	O
kinase	O
inhibitor	O
(	O
VEGFR	O
TKI	O
)	O
treatment	O
experienced	O
reductions	O
in	O
tumor	O
volume	O
","	O
including	O
two	O
partial	O
responses	O
by	O
RECIST	O
","	O
and	O
6	O
remained	O
without	O
progression	O
for	O
longer	O
periods	O
than	O
during	O
their	O
prior	O
VEGF	O
inhibitor	O
therapy	O
.	O
	
TRC105	B-DRUG
was	O
well	O
tolerated	O
with	O
bevacizumab	B-DRUG
and	O
clinical	O
activity	O
was	O
observed	O
in	O
a	O
VEGF	O
inhibitor-refractory	O
population	O
.	O
	
Ongoing	O
clinical	O
trials	O
are	O
testing	O
TRC105	B-DRUG
in	O
combination	O
with	O
bevacizumab	B-DRUG
in	O
glioblastoma	B-CANCER
and	O
with	O
VEGFR	O
TKIs	O
in	O
renal	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
","	O
hepatocellular	B-CANCER
carcinoma	I-CANCER
","	O
and	O
soft	B-CANCER
tissue	I-CANCER
sarcoma	I-CANCER
.	O
	
A	O
phase	O
I	O
trial	O
of	O
vertical	O
inhibition	O
of	O
IGF	O
signalling	O
using	O
cixutumumab	B-DRUG
","	O
an	O
anti-IGF-1R	O
antibody	O
","	O
and	O
selumetinib	B-DRUG
","	O
an	O
MEK	O
1	O
/	O
2	O
inhibitor	O
","	O
in	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
	
We	O
completed	O
a	O
phase	O
I	O
clinical	O
trial	O
to	O
test	O
the	O
safety	O
and	O
toxicity	O
of	O
combined	O
treatment	O
with	O
cixutumumab	B-DRUG
(	O
anti-IGF-1R	O
antibody	O
)	O
and	O
selumetinib	B-DRUG
(	O
MEK	O
1	O
/	O
2	O
inhibitor	O
)	O
.	O
	
Patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
","	O
refractory	O
to	O
standard	O
therapy	O
received	O
selumetinib	B-DRUG
hydrogen	I-DRUG
sulphate	I-DRUG
capsules	I-DRUG
orally	O
twice	O
daily	O
","	O
and	O
cixutumumab	B-DRUG
intravenously	O
on	O
days	O
1	O
and	O
15	O
of	O
each	O
28-day	O
cycle	O
.	O
	
The	O
study	O
used	O
a	O
3+3	O
design	O
","	O
with	O
a	O
dose-finding	O
cohort	O
followed	O
by	O
an	O
expansion	O
cohort	O
at	O
the	O
maximally	O
tolerated	O
dose	O
that	O
included	O
pharmacokinetic	O
and	O
pharmacodynamic	O
correlative	O
studies	O
.	O
	
Thirty	O
patients	O
were	O
enrolled	O
","	O
with	O
16	O
in	O
the	O
dose-finding	O
cohort	O
and	O
14	O
in	O
the	O
expansion	O
cohort	O
.	O
	
Grade	O
3	O
or	O
greater	O
toxicities	O
included	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
","	O
anaemia	B-TOXI
","	O
CVA	B-TOXI
","	O
hypertension	B-TOXI
","	O
hyperglycaemia	B-TOXI
","	O
and	O
ophthalmic	B-TOXI
symptoms	I-TOXI
.	O
	
The	O
maximally	O
tolerated	O
combination	O
dose	O
was	O
50	O
mg	O
twice	O
daily	O
of	O
selumetinib	B-DRUG
and	O
12	O
mg	O
kg	O
(	O
-1	O
)	O
every	O
2	O
weeks	O
of	O
cixutumumab	B-DRUG
.	O
	
Two	O
patients	O
achieved	O
a	O
partial	O
response	O
(	O
one	O
unconfirmed	O
)	O
","	O
including	O
a	O
patient	O
with	O
BRAF	B-CANCER
wild-type	I-CANCER
thyroid	I-CANCER
carcinoma	I-CANCER
","	O
and	O
a	O
patient	O
with	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
tongue	I-CANCER
","	O
and	O
six	O
patients	O
achieved	O
time	O
to	O
progression	O
of	O
&	O
gt	O
;	O
6	O
months	O
","	O
including	O
patients	O
with	O
thyroid	B-CANCER
carcinoma	I-CANCER
","	O
colorectal	B-CANCER
carcinoma	I-CANCER
","	O
and	O
basal	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
Comparison	O
of	O
pre-	O
and	O
on-treatment	O
biopsies	O
showed	O
significant	O
suppression	O
of	O
pERK	O
and	O
pS6	O
activity	O
with	O
treatment	O
.	O
	
Our	O
study	O
of	O
anti-IGF-1R	O
antibody	O
cixutumumab	B-DRUG
and	O
MEK	O
1	O
/	O
2	O
inhibitor	O
selumetinib	B-DRUG
showed	O
that	O
the	O
combination	O
is	O
safe	O
and	O
well-tolerated	O
at	O
these	O
doses	O
","	O
with	O
preliminary	O
evidence	O
of	O
clinical	O
benefit	O
and	O
pharmacodynamic	O
evidence	O
of	O
target	O
inhibition	O
.	O
	
Pilot	O
clinical	O
trial	O
of	O
hedgehog	O
pathway	O
inhibitor	O
GDC-0449	B-DRUG
(	O
vismodegib	B-DRUG
)	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
pancreatic	I-CANCER
adenocarcinoma	I-CANCER
.	O
	
	
The	O
hedgehog	O
(	O
HH	O
)	O
signaling	O
pathway	O
is	O
a	O
key	O
regulator	O
in	O
tumorigenesis	O
of	O
pancreatic	B-CANCER
adenocarcinoma	I-CANCER
and	O
is	O
upregulated	O
in	O
pancreatic	B-CANCER
adenocarcinoma	I-CANCER
cancer	O
stem	O
cells	O
(	O
CSCs	O
)	O
.	O
	
GDC-0449	O
is	O
an	O
oral	O
small-molecule	O
inhibitor	O
of	O
the	O
HH	O
pathway	O
.	O
	
This	O
study	O
assessed	O
the	O
effect	O
of	O
GDC-0449-mediated	B-DRUG
HH	O
inhibition	O
in	O
paired	O
biopsies	O
","	O
followed	O
by	O
combined	O
treatment	O
with	O
gemcitabine	B-DRUG
","	O
in	O
patients	O
with	O
metastatic	B-CANCER
pancreatic	I-CANCER
adenocarcinoma	I-CANCER
.	O
	
Twenty-five	O
patients	O
were	O
enrolled	O
of	O
which	O
23	O
underwent	O
core	O
biopsies	O
at	O
baseline	O
and	O
following	O
3	O
weeks	O
of	O
GDC-0449	B-DRUG
.	O
	
On	O
day	O
29	O
","	O
23	O
patients	O
started	O
weekly	O
gemcitabine	B-DRUG
while	O
continuing	O
GDC-0449	B-DRUG
.	O
	
We	O
evaluated	O
GLI1	O
and	O
PTCH1	O
inhibition	O
","	O
change	O
in	O
CSCs	O
","	O
Ki-67	O
","	O
fibrosis	O
","	O
and	O
assessed	O
tumor	O
response	O
","	O
survival	O
and	O
toxicity	O
.	O
	
On	O
pretreatment	O
biopsy	O
","	O
75	O
%	O
of	O
patients	O
had	O
elevated	O
sonic	O
hedgehog	O
(	O
SHH	O
)	O
expression	O
.	O
	
On	O
posttreatment	O
biopsy	O
","	O
GLI1	O
and	O
PTCH1	O
decreased	O
in	O
95.6	O
%	O
and	O
82.6	O
%	O
of	O
23	O
patients	O
","	O
fibrosis	O
decreased	O
in	O
45.4	O
%	O
of	O
22	O
","	O
and	O
Ki-67	O
in	O
52.9	O
%	O
of	O
17	O
evaluable	O
patients	O
.	O
	
No	O
significant	O
changes	O
were	O
detected	O
in	O
CSCs	O
pre-	O
and	O
postbiopsy	O
.	O
	
The	O
median	O
progression-free	O
and	O
overall	O
survival	O
for	O
all	O
treated	O
patients	O
were	O
2.8	O
and	O
5.3	O
months	O
.	O
	
The	O
response	O
and	O
disease	O
control	O
rate	O
was	O
21.7	O
%	O
and	O
65.2	O
%	O
.	O
	
No	O
significant	O
correlation	O
was	O
noted	O
between	O
CSCs	O
","	O
fibrosis	O
","	O
SHH	O
","	O
Ki-67	O
","	O
GLI1	O
","	O
PTCH1	O
(	O
baseline	O
values	O
or	O
relative	O
change	O
on	O
posttreatment	O
biopsy	O
)	O
","	O
and	O
survival	O
.	O
	
Grade	O
_	O
3	O
adverse	O
events	O
were	O
noted	O
in	O
56	O
%	O
of	O
patients	O
.	O
	
We	O
show	O
that	O
GDC-0449	B-DRUG
for	O
3	O
weeks	O
leads	O
to	O
downmodulation	O
of	O
GLI1	O
and	O
PTCH1	O
","	O
without	O
significant	O
changes	O
in	O
CSCs	O
compared	O
with	O
baseline	O
.	O
	
GDC-0449	B-DRUG
and	O
gemcitabine	B-DRUG
were	O
not	O
superior	O
to	O
gemcitabine	B-DRUG
alone	O
in	O
the	O
treatment	O
of	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
Safety	O
and	O
efficacy	O
of	O
neratinib	B-DRUG
in	O
combination	O
with	O
capecitabine	B-DRUG
in	O
patients	O
with	O
metastatic	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2-positive	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
	
Neratinib	B-DRUG
is	O
a	O
potent	O
irreversible	O
pan-tyrosine	O
kinase	O
inhibitor	O
with	O
antitumor	O
activity	O
and	O
acceptable	O
tolerability	O
in	O
patients	O
with	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
(	O
HER2	O
)	O
#NAME?	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
A	O
multinational	O
","	O
open-label	O
","	O
phase	O
I	O
/	O
II	O
trial	O
was	O
conducted	O
to	O
determine	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
neratinib	B-DRUG
plus	O
capecitabine	B-DRUG
in	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
(	O
part	O
one	O
)	O
and	O
to	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
neratinib	B-DRUG
plus	O
capecitabine	B-DRUG
in	O
patients	O
with	O
HER2-positive	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
part	O
two	O
)	O
.	O
	
Part	O
one	O
was	O
a	O
3	O
=+	O
3	O
dose-escalation	O
study	O
in	O
which	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
received	O
oral	O
neratinib	B-DRUG
once	O
per	O
day	O
continuously	O
plus	O
capecitabine	B-DRUG
twice	O
per	O
day	O
on	O
days	O
1	O
to	O
14	O
of	O
a	O
21-day	O
cycle	O
at	O
predefined	O
dose	O
levels	O
.	O
	
In	O
part	O
two	O
","	O
patients	O
with	O
trastuzumab-pretreated	B-DRUG
HER2-positive	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
received	O
neratinib	B-DRUG
plus	O
capecitabine	B-DRUG
at	O
the	O
MTD	O
.	O
	
The	O
primary	O
end	O
point	O
in	O
part	O
two	O
was	O
objective	O
response	O
rate	O
(	O
ORR	O
)	O
.	O
	
In	O
part	O
one	O
(	O
n	O
=	O
33	O
)	O
","	O
the	O
combination	O
of	O
neratinib	B-DRUG
240	O
mg	O
per	O
day	O
plus	O
capecitabine	B-DRUG
"1,500"	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
day	O
was	O
defined	O
as	O
the	O
MTD	O
","	O
which	O
was	O
further	O
evaluated	O
in	O
part	O
2	O
(	O
n	O
=	O
72	O
)	O
.	O
	
The	O
most	O
common	O
drug-related	O
adverse	O
events	O
were	O
diarrhea	B-TOXI
(	O
88	O
%	O
)	O
and	O
palmar-plantar	B-TOXI
erythrodysesthesia	I-TOXI
syndrome	I-TOXI
(	O
48	O
%	O
)	O
.	O
	
In	O
part	O
two	O
","	O
the	O
ORR	O
was	O
64	O
%	O
(	O
n	O
=	O
39	O
of	O
61	O
)	O
in	O
patients	O
with	O
no	O
prior	O
lapatinib	B-DRUG
exposure	O
and	O
57	O
%	O
(	O
n	O
=	O
4	O
of	O
7	O
)	O
in	O
patients	O
previously	O
treated	O
with	O
lapatinib	B-DRUG
.	O
	
Median	O
progression-free	O
survival	O
was	O
40.3	O
and	O
35.9	O
weeks	O
","	O
respectively	O
.	O
	
Neratinib	B-DRUG
in	O
combination	O
with	O
capecitabine	B-DRUG
had	O
a	O
manageable	O
toxicity	O
profile	O
and	O
showed	O
promising	O
antitumor	O
activity	O
in	O
patients	O
with	O
HER2-positive	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
pretreated	O
with	O
trastuzumab	B-DRUG
and	O
lapatinib	B-DRUG
.	O
	
Comparison	O
of	O
pemetrexed	B-DRUG
plus	O
cisplatin	B-DRUG
with	O
gemcitabine	B-DRUG
plus	O
docetaxel	B-DRUG
in	O
refractory	O
/	O
metastatic	O
osteosarcoma	B-CANCER
:	O
Clinical	O
outcomes	O
from	O
a	O
retrospective	O
database	O
monitored	O
in	O
a	O
single	O
institute	O
.	O
	
	
The	O
prognosis	O
for	O
patients	O
with	O
relapsed	O
/	O
metastatic	O
osteosarcoma	B-CANCER
is	O
poor	O
and	O
the	O
optimal	O
treatment	O
strategy	O
remains	O
to	O
be	O
refined	O
.	O
	
Whilst	O
gemcitabine	B-DRUG
plus	O
docetaxel	B-DRUG
combination	O
treatment	O
has	O
already	O
been	O
demonstrated	O
to	O
have	O
certain	O
promising	O
results	O
in	O
the	O
treatment	O
of	O
osteosarcoma	B-CANCER
","	O
the	O
use	O
of	O
pemetrexed	B-DRUG
","	O
a	O
multi-targeted	B-DRUG
antifolate	I-DRUG
","	O
remains	O
controversial	O
.	O
	
In	O
the	O
present	O
study	O
","	O
a	O
retrospective	O
investigation	O
was	O
conducted	O
to	O
evaluate	O
the	O
toxicity	O
and	O
efficacy	O
of	O
the	O
pemetrexed	B-DRUG
plus	O
cisplatin	B-DRUG
combination	O
in	O
relapsed	O
/	O
metastatic	O
osteosarcoma	B-CANCER
.	O
	
Comparison	O
of	O
this	O
treatment	O
with	O
that	O
of	O
the	O
gemcitabine	B-DRUG
plus	O
docetaxel	B-DRUG
combination	O
was	O
also	O
conducted	O
.	O
	
Clinical	O
data	O
from	O
39	O
patients	O
suffering	O
from	O
refractory	O
/	O
metastatic	O
osteosarcoma	B-CANCER
between	O
January	O
2005	O
and	O
May	O
2011	O
were	O
reviewed	O
retrospectively	O
.	O
	
Of	O
these	O
patients	O
","	O
21	O
were	O
administered	O
the	O
gemcitabine	B-DRUG
plus	O
docetaxel	B-DRUG
combination	O
","	O
and	O
18	O
were	O
provided	O
the	O
pemetrexed	B-DRUG
plus	O
cisplatin	B-DRUG
combination	O
.	O
	
Treatment	O
was	O
continued	O
until	O
the	O
occurrence	O
of	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
.	O
	
In	O
the	O
gemcitabine	B-DRUG
plus	O
docetaxel	B-DRUG
group	O
","	O
the	O
overall	O
response	O
rate	O
and	O
disease	O
control	O
rate	O
were	O
found	O
to	O
be	O
9.5	O
and	O
28.5	O
%	O
respectively	O
","	O
compared	O
with	O
5.5	O
and	O
33.3	O
%	O
respectively	O
in	O
the	O
pemetrexed	B-DRUG
plus	O
cisplatin	B-DRUG
group	O
.	O
	
The	O
median	O
progression-free	O
survival	O
(	O
PFS	O
)	O
time	O
was	O
found	O
to	O
be	O
1.8	O
months	O
for	O
both	O
the	O
gemcitabine	B-DRUG
plus	O
docetaxel	B-DRUG
and	O
pemetrexed	B-DRUG
plus	O
cisplatin	B-DRUG
groups	O
.	O
	
The	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
time	O
was	O
6	O
months	O
in	O
the	O
gemcitabine	B-DRUG
plus	O
docetaxel	B-DRUG
group	O
and	O
7	O
months	O
in	O
the	O
pemetrexed	B-DRUG
plus	O
cisplatin	B-DRUG
group	O
.	O
	
No	O
statistically	O
significant	O
differences	O
were	O
recognized	O
between	O
the	O
overall	O
response	O
rates	O
","	O
disease	O
control	O
rates	O
","	O
PFS	O
times	O
and	O
OS	O
times	O
in	O
the	O
two	O
groups	O
.	O
	
The	O
two	O
combinations	O
appeared	O
to	O
be	O
well	O
tolerated	O
.	O
	
However	O
","	O
the	O
incidence	O
of	O
grade	O
3	O
/	O
4	O
thrombocytopenia	B-TOXI
and	O
leucopenia	B-TOXI
was	O
higher	O
in	O
the	O
gemcitabine	B-DRUG
plus	O
docetaxel	B-DRUG
group	O
than	O
in	O
the	O
pemetrexed	B-DRUG
plus	O
cisplatin	B-DRUG
group	O
.	O
	
The	O
present	O
study	O
clearly	O
demonstrated	O
that	O
both	O
chemo-combinations	O
were	O
well-tolerated	O
and	O
exerted	O
antitumor	O
activity	O
in	O
patients	O
with	O
refractory	O
/	O
metastatic	O
osteosarcoma	B-CANCER
.	O
	
However	O
","	O
with	O
regard	O
to	O
grade	O
3	O
/	O
4	O
toxicity	O
","	O
the	O
pemetrexed	B-DRUG
plus	O
cisplatin	B-DRUG
chemotherapy	O
appears	O
to	O
be	O
better	O
tolerated	O
.	O
	
Bosutinib	B-DRUG
plus	O
capecitabine	B-DRUG
for	O
selected	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
:	O
results	O
of	O
a	O
phase	O
1	O
dose-escalation	O
study	O
.	O
	
	
This	O
phase	O
1	O
study	O
evaluated	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
safety	O
","	O
and	O
efficacy	O
of	O
bosutinib	B-DRUG
(	O
competitive	O
Src	O
/	O
Abl	O
tyrosine	O
kinase	O
inhibitor	O
)	O
plus	O
capecitabine	B-DRUG
.	O
	
Patients	O
with	O
locally	O
advanced	O
/	O
metastatic	O
breast	O
","	O
pancreatic	O
","	O
or	O
colorectal	B-CANCER
cancers	I-CANCER
;	O
cholangiocarcinoma	B-CANCER
;	O
or	O
glioblastoma	B-CANCER
received	O
bosutinib	B-DRUG
plus	O
capecitabine	B-DRUG
at	O
eight	O
of	O
nine	O
possible	O
dose	O
combinations	O
using	O
an	O
'up-down	O
'	O
design	O
to	O
determine	O
the	O
toxicity	O
contour	O
of	O
the	O
combination	O
.	O
	
Among	O
32	O
enrolled	O
patients	O
","	O
none	O
of	O
the	O
9	O
patients	O
receiving	O
MTD	O
(	O
bosutinib	B-DRUG
300	O
mg	O
once	O
daily	O
plus	O
capecitabine	B-DRUG
1000	O
mg	O
m	O
(	O
-2	O
)	O
twice	O
daily	O
)	O
experienced	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
.	O
	
Overall	O
","	O
2	O
out	O
of	O
31	O
(	O
6	O
%	O
)	O
evaluable	O
patients	O
experienced	O
DLTs	O
(	O
grade	O
3	O
neurologic	B-TOXI
pain	I-TOXI
(	O
n=1	O
)	O
;	O
grade	O
3	O
pruritus	B-TOXI
/	O
rash	B-TOXI
and	O
increased	B-TOXI
alanine	I-TOXI
aminotransferase	I-TOXI
(	O
n=1	O
)	O
)	O
.	O
	
Most	O
common	O
treatment-related	O
adverse	O
events	O
(	O
AEs	O
)	O
were	O
diarrhoea	B-TOXI
","	O
nausea	B-TOXI
","	O
vomiting	B-TOXI
","	O
palmar-plantar	B-TOXI
erythrodysesthesia	I-TOXI
(	O
PPE	B-TOXI
)	O
","	O
fatigue	B-TOXI
;	O
most	O
frequent	O
grade	O
3	O
/	O
4	O
AEs	O
:	O
PPE	B-TOXI
","	O
fatigue	B-TOXI
","	O
and	O
increased	B-TOXI
alanine	I-TOXI
/	I-TOXI
aspartate	I-TOXI
aminotransferase	I-TOXI
.	O
	
Although	O
diarrhoea	B-TOXI
was	O
common	O
","	O
91	O
%	O
of	O
affected	O
patients	O
experienced	O
maximum	O
grade	O
1	O
/	O
2	O
events	O
that	O
resolved	O
.	O
	
Best	O
overall	O
confirmed	O
partial	O
response	O
or	O
stable	O
disease	O
&	O
gt	O
;	O
24	O
weeks	O
(	O
all	O
tumour	O
types	O
)	O
was	O
observed	O
in	O
6	O
and	O
13	O
%	O
of	O
patients	O
.	O
	
In	O
this	O
population	O
of	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
","	O
bosutinib	B-DRUG
plus	O
capecitabine	B-DRUG
demonstrated	O
a	O
safety	O
profile	O
similar	O
to	O
that	O
previously	O
reported	O
for	O
bosutinib	B-DRUG
or	O
capecitabine	B-DRUG
monotherapy	O
;	O
limited	O
efficacy	O
was	O
observed	O
.	O
	
A	O
parallel-arm	O
phase	O
I	O
trial	O
of	O
the	O
humanised	O
anti-IGF-1R	O
antibody	O
dalotuzumab	B-DRUG
in	O
combination	O
with	O
the	O
AKT	O
inhibitor	O
MK-2206	B-DRUG
","	O
the	O
mTOR	O
inhibitor	O
ridaforolimus	B-DRUG
","	O
or	O
the	O
NOTCH	O
inhibitor	O
MK-0752	B-DRUG
","	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
	
Two	O
strategies	O
to	O
interrogate	O
the	O
insulin	O
growth	O
factor	O
1	O
receptor	O
(	O
IGF-1R	O
)	O
pathway	O
were	O
investigated	O
:	O
vertical	O
inhibition	O
with	O
dalotuzumab	B-DRUG
and	O
MK-2206	B-DRUG
or	O
ridaforolimus	B-DRUG
to	O
potentiate	O
PI3K	O
pathway	O
targeting	O
and	O
horizontal	O
cross-talk	O
inhibition	O
with	O
dalotuzumab	B-DRUG
and	O
MK-0752	B-DRUG
to	O
exert	O
effects	O
against	O
cellular	O
proliferation	O
","	O
angiogenesis	O
","	O
and	O
stem	O
cell	O
propagation	O
.	O
	
A	O
phase	O
I	O
","	O
multi-cohort	O
dose	O
escalation	O
study	O
was	O
conducted	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
Patients	O
received	O
dalotuzumab	B-DRUG
(	O
10	O
mg	O
kg	O
(	O
-1	O
)	O
)	O
and	O
escalating	O
doses	O
of	O
MK-2206	B-DRUG
(	O
90-200	O
mg	O
)	O
or	O
escalating	O
doses	O
of	O
dalotuzumab	B-DRUG
(	O
7.5-10	O
mg	O
kg	O
(	O
-1	O
)	O
)	O
and	O
MK-0752	B-DRUG
(	O
1800	O
mg	O
)	O
weekly	O
.	O
	
Upon	O
maximum	O
tolerated	O
dose	O
determination	O
","	O
patients	O
with	O
low-RAS	O
signature	O
","	O
high-IGF1	O
expression	O
ovarian	B-CANCER
cancer	I-CANCER
were	O
randomised	O
to	O
dalotuzumab	B-DRUG
/	O
MK-2206	B-DRUG
versus	O
dalotuzumab	B-DRUG
/	O
ridaforolimus	B-DRUG
","	O
whereas	O
patients	O
with	O
high	O
IGF1	O
/	O
low	O
IGF2	O
expression	O
colorectal	B-CANCER
cancer	I-CANCER
received	O
dalotuzumab	B-DRUG
/	O
MK-0752	B-DRUG
.	O
	
A	O
total	O
of	O
47	O
patients	O
were	O
enrolled	O
:	O
29	O
in	O
part	O
A	O
(	O
18	O
in	O
the	O
dalotuzumab	B-DRUG
/	O
MK-2206	B-DRUG
arm	O
and	O
11	O
in	O
the	O
dalotuzumab	B-DRUG
/	O
MK-0752	B-DRUG
arm	O
)	O
and	O
18	O
in	O
part	O
B	O
(	O
6	O
in	O
each	O
arm	O
)	O
.	O
	
Dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
for	O
dalotuzumab	B-DRUG
/	O
MK-2206	B-DRUG
included	O
grade	O
4	O
neutropenia	B-TOXI
and	O
grade	O
3	O
serum	B-TOXI
sickness-like	I-TOXI
reaction	I-TOXI
","	O
maculopapular	B-TOXI
rash	I-TOXI
","	O
and	O
gastrointestinal	B-TOXI
inflammation	I-TOXI
.	O
	
For	O
dalotuzumab	B-DRUG
/	O
MK-0752	B-DRUG
","	O
DLTs	O
included	O
grade	O
3	O
dehydration	B-TOXI
","	O
rash	B-TOXI
","	O
and	O
diarrhoea	B-TOXI
.	O
	
Seven	O
patients	O
remained	O
on	O
study	O
for	O
&	O
gt	O
;	O
4	O
cycles	O
.	O
	
Dalotuzumab	B-DRUG
/	O
MK-2206	B-DRUG
and	O
dalotuzumab	B-DRUG
/	O
MK-0752	B-DRUG
combinations	O
were	O
tolerable	O
.	O
	
Further	O
developments	O
of	O
prospectively	O
validated	O
predictive	O
biomarkers	O
to	O
aid	O
in	O
patient	O
selection	O
for	O
anti-IGF-1R	O
therapies	O
are	O
needed	O
.	O
	
Tolerability	O
of	O
nintedanib	B-DRUG
(	O
BIBF	O
1120	O
)	O
in	O
combination	O
with	O
docetaxel	B-DRUG
:	O
a	O
phase	O
1	O
study	O
in	O
Japanese	O
patients	O
with	O
previously	O
treated	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
This	O
phase	O
I	O
","	O
open-label	O
study	O
evaluated	O
the	O
safety	O
/	O
tolerability	O
and	O
maximum	O
tolerated	O
dose	O
of	O
second-line	O
nintedanib	B-DRUG
combined	O
with	O
docetaxel	B-DRUG
in	O
Japanese	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
Eligible	O
patients	O
received	O
docetaxel	B-DRUG
60	O
or	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
day	O
1	O
)	O
plus	O
nintedanib	B-DRUG
100	O
","	O
150	O
","	O
or	O
200	O
mg	O
twice	O
daily	O
(	O
bid	O
;	O
days	O
2月21日	O
)	O
in	O
21-day	O
cycles	O
.	O
	
Standard	O
3	O
=+	O
3	O
dose	O
escalations	O
were	O
performed	O
separately	O
in	O
patient	O
cohorts	O
with	O
a	O
body	O
surface	O
area	O
(	O
BSA	O
)	O
of	O
less	O
than	O
1.5	O
m	O
(	O
2	O
)	O
(	O
BSA	O
&	O
lt	O
;	O
1.5	O
)	O
and	O
BSA	O
greater	O
than	O
or	O
equal	O
to	O
1.5	O
","	O
respectively	O
.	O
	
Forty-two	O
patients	O
(	O
17	O
BSA	O
&	O
lt	O
;	O
1.5	O
","	O
25	O
BSA	O
_	O
1.5	O
)	O
were	O
treated	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
of	O
nintedanib	B-DRUG
was	O
150	O
and	O
200	O
mg	O
bid	O
in	O
patients	O
with	O
BSA	O
less	O
than	O
1.5	O
and	O
BSA	O
greater	O
than	O
or	O
equal	O
to	O
1.5	O
(	O
BSA	O
_	O
1.5	O
)	O
","	O
respectively	O
","	O
in	O
combination	O
with	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
docetaxel	B-DRUG
.	O
	
Dose-limiting	O
toxicities	O
(	O
all	O
grade	O
3	O
hepatic	B-DRUG
enzyme	I-DRUG
elevations	I-DRUG
)	O
occurred	O
in	O
12	O
patients	O
(	O
six	O
per	O
cohort	O
)	O
.	O
	
Drug-related	O
adverse	O
events	O
included	O
neutropenia	B-TOXI
(	O
95	O
%	O
)	O
","	O
leukopenia	B-TOXI
(	O
83	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
76	O
%	O
)	O
","	O
alopecia	B-TOXI
(	O
71	O
%	O
)	O
","	O
decreased	B-TOXI
appetite	I-TOXI
(	O
67	O
%	O
)	O
","	O
and	O
elevations	B-TOXI
in	I-TOXI
alanine	I-TOXI
aminotransferase	I-TOXI
(	O
64	O
%	O
)	O
and	O
aspartate	B-TOXI
aminotransferase	I-TOXI
(	O
64	O
%	O
)	O
.	O
	
All	O
hepatic	O
enzyme	O
elevations	O
were	O
reversible	O
and	O
manageable	O
with	O
dose	O
reduction	O
or	O
discontinuation	O
.	O
	
Among	O
38	O
evaluable	O
patients	O
","	O
10	O
(	O
26	O
%	O
)	O
had	O
a	O
partial	O
response	O
and	O
18	O
(	O
47	O
%	O
)	O
had	O
stable	O
disease	O
.	O
	
Continuous	O
treatment	O
with	O
second-line	O
nintedanib	B-DRUG
combined	O
with	O
docetaxel	B-DRUG
was	O
manageable	O
and	O
showed	O
promising	O
signs	O
of	O
efficacy	O
in	O
Japanese	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
Clinical	O
analysis	O
of	O
osteosarcoma	B-CANCER
patients	O
treated	O
with	O
high-dose	B-DRUG
methotrexate-free	I-DRUG
neoadjuvant	O
chemotherapy	O
.	O
	
	
High-dose	B-DRUG
methotrexate	I-DRUG
(	O
hdmtx	B-DRUG
)	O
is	O
a	O
common	O
therapeutic	O
agent	O
in	O
the	O
treatment	O
of	O
osteosarcoma	B-CANCER
.	O
	
However	O
","	O
hdmtx	B-DRUG
is	O
highly	O
toxic	O
and	O
requires	O
complex	O
pharmacokinetic	O
monitoring	O
and	O
leucovorin	B-DRUG
rescue	O
.	O
	
Thus	O
","	O
alternative	O
therapeutic	O
strategies	O
are	O
necessary	O
.	O
	
Here	O
","	O
we	O
analyzed	O
the	O
clinical	O
efficacy	O
of	O
a	O
dia	O
regimen	O
(	O
cisplatin-ifosfamide-doxorubicin	B-DRUG
)	O
to	O
evaluate	O
its	O
potential	O
as	O
an	O
alternative	O
to	O
hdmtx-based	B-DRUG
therapy	O
.	O
	
Patients	O
received	O
12	O
cycles	O
of	O
chemotherapy	O
administered	O
over	O
2	O
years	O
(	O
2	O
preoperative	O
cycles	O
and	O
10	O
postoperative	O
cycles	O
)	O
.	O
	
Cumulative	O
dose	O
was	O
the	O
same	O
in	O
all	O
cycles	O
:	O
cisplatin	B-DRUG
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
of	O
week	O
1	O
","	O
followed	O
by	O
ifosfamide	B-DRUG
2	O
g	O
/	O
m	O
(	O
2	O
)	O
days	O
1月5日	O
of	O
week	O
2	O
","	O
and	O
doxorubicin	B-DRUG
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
days	O
1月3日	O
of	O
week	O
2	O
Between	O
January	O
2004	O
and	O
October	O
2008	O
","	O
39	O
eligible	O
patients	O
(	O
median	O
age	O
:	O
16	O
years	O
)	O
were	O
enrolled	O
","	O
with	O
36	O
being	O
evaluable	O
for	O
the	O
study	O
.	O
	
Of	O
those	O
36	O
patients	O
","	O
20	O
(	O
55.6	O
%	O
)	O
had	O
a	O
good	O
histologic	O
response	O
to	O
preoperative	O
chemotherapy	O
(	O
&	O
gt	O
;	O
90	O
%	O
tumour	O
necrosis	O
)	O
.	O
	
The	O
estimated	O
5-year	O
rates	O
of	O
event-free	O
survival	O
(	O
efs	O
)	O
and	O
overall	O
survival	O
were	O
54.8	O
%	O
and	O
61.5	O
%	O
respectively	O
.	O
	
The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
","	O
in	O
osteosarcoma	B-CANCER
patients	O
","	O
the	O
dia	O
regimen	O
produces	O
an	O
efs	O
rate	O
and	O
survival	O
outcomes	O
comparable	O
to	O
those	O
attained	O
with	O
hdmtx-containing	B-DRUG
regimens	O
","	O
with	O
fewer	O
adverse	O
reactions	O
.	O
	
The	O
dia	O
regimen	O
is	O
well	O
tolerated	O
","	O
and	O
we	O
observed	O
a	O
high	O
level	O
of	O
patient	O
compliance	O
.	O
	
Our	O
results	O
demonstrate	O
that	O
hdmtx-free	B-DRUG
osteosarcoma	B-CANCER
treatment	O
regimens	O
can	O
be	O
effective	O
","	O
warranting	O
further	O
investigation	O
.	O
	
Ifosfamide	B-DRUG
and	O
vinorelbine	B-DRUG
is	O
an	O
effective	O
reinduction	O
regimen	O
in	O
children	O
with	O
refractory	O
/	O
relapsed	O
Hodgkin	B-CANCER
lymphoma	I-CANCER
","	O
AHOD00P1	O
:	O
a	O
children	O
's	O
oncology	O
group	O
report	O
.	O
	
	
We	O
assessed	O
the	O
safety	O
and	O
efficacy	O
of	O
ifosfamide	B-DRUG
and	O
vinorelbine	B-DRUG
(	O
IV	O
)	O
as	O
a	O
less	O
toxic	O
and	O
effective	O
reinduction	O
regimen	O
for	O
pediatric	O
patients	O
with	O
relapsed	O
or	O
refractory	O
Hodgkin	B-DRUG
Lymphoma	I-DRUG
.	O
	
This	O
multi-center	O
Children	O
's	O
Oncology	O
Group	O
phase	O
II	O
pilot	O
study	O
enrolled	O
patients	O
&	O
lt	O
;	O
30	O
years	O
of	O
age	O
with	O
biopsy-proven	O
Hodgkin	B-CANCER
Lymphoma	I-CANCER
in	O
relapse	O
or	O
refractory	O
disease	O
after	O
front-line	O
therapy	O
.	O
	
Treatment	O
consisted	O
of	O
ifosfamide	B-DRUG
"3,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenous	O
infusion	O
over	O
24	O
hr	O
on	O
Days	O
1月4日	O
and	O
vinorelbine	B-DRUG
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
dose	O
intravenous	O
push	O
on	O
Days	O
1	O
and	O
5	O
of	O
each	O
21	O
day	O
cycle	O
with	O
cytokine	O
support	O
.	O
	
The	O
study	O
endpoints	O
included	O
estimation	O
of	O
key	O
toxicities	O
(	O
cardiac	B-TOXI
","	O
hepatic	B-TOXI
","	O
or	O
renal	B-TOXI
toxicity	I-TOXI
or	O
toxic	B-TOXI
death	I-TOXI
)	O
","	O
the	O
rate	O
of	O
successful	O
peripheral	O
stem	O
cell	O
harvesting	O
","	O
and	O
response	O
after	O
two	O
cycles	O
of	O
therapy	O
.	O
	
Sixty-six	O
patients	O
received	O
a	O
median	O
of	O
two	O
cycles	O
of	O
IV	O
.	O
	
Sixty-four	O
of	O
66	O
were	O
heavily	O
pretreated	O
","	O
4	O
had	O
refractory	O
disease	O
","	O
55	O
%	O
were	O
male	O
and	O
79	O
%	O
had	O
nodular	O
sclerosis	O
HL	B-CANCER
.	O
	
The	O
primary	O
toxicities	O
were	O
hematologic	O
.	O
	
Harvested	O
peripheral	O
stem	O
cells	O
were	O
sufficient	O
for	O
autologous	O
transplantation	O
in	O
46	O
of	O
54	O
patients	O
for	O
whom	O
stem	O
cell	O
collection	O
was	O
attempted	O
.	O
	
The	O
overall	O
response	O
rate	O
(	O
72	O
%	O
;	O
95	O
%	O
CI	O
59-83	O
%	O
)	O
permitted	O
the	O
majority	O
of	O
patients	O
to	O
undergo	O
subsequent	O
stem	O
cell	O
transplantation	O
.	O
	
IV	O
is	O
a	O
safe	O
and	O
effective	O
re-induction	O
regimen	O
for	O
salvage	O
of	O
pediatric	O
patients	O
with	O
relapsed	O
or	O
refractory	O
Hodgkin	B-CANCER
Lymphoma	I-CANCER
with	O
an	O
excellent	O
response	O
rate	O
and	O
success	O
of	O
post	O
chemotherapy	O
stem	O
cell	O
harvest	O
.	O
	
It	O
avoids	O
the	O
use	O
of	O
etoposide	B-DRUG
","	O
an	O
agent	O
associated	O
with	O
secondary	O
malignancy	O
after	O
stem	O
cell	O
transplantation	O
.	O
	
Phase	O
I	O
/	O
II	O
trial	O
of	O
vorinostat	B-DRUG
with	O
rituximab	B-DRUG
","	O
cyclophosphamide	B-DRUG
","	O
etoposide	B-DRUG
and	O
prednisone	B-DRUG
as	O
palliative	O
treatment	O
for	O
elderly	O
patients	O
with	O
relapsed	O
or	O
refractory	O
diffuse	B-CANCER
large	I-CANCER
B-cell	I-CANCER
lymphoma	I-CANCER
not	O
eligible	O
for	O
autologous	O
stem	O
cell	O
transplantation	O
.	O
	
	
The	O
standard	O
treatment	O
of	O
relapsed	O
/	O
refractory	O
diffuse	B-CANCER
large	I-CANCER
B-cell	I-CANCER
lymphoma	I-CANCER
(	O
DLBCL	B-CANCER
)	O
in	O
frail	O
elderly	O
patients	O
has	O
not	O
been	O
established	O
.	O
	
A	O
variation	O
was	O
made	O
on	O
rituximab	B-DRUG
(	O
R	O
)	O
","	O
cyclophosphamide	B-DRUG
(	O
C	O
)	O
","	O
etoposide	B-DRUG
(	O
E	O
)	O
","	O
procarbazine	B-DRUG
and	O
prednisone	B-DRUG
(	O
P	O
)	O
","	O
substituting	B-DRUG
vorinostat	I-DRUG
(	O
V	O
)	O
for	O
procarbazine	B-DRUG
.	O
	
Patients	O
_aged	O
60	O
years	O
with	O
relapsed	O
/	O
refractory	O
DLBCL	B-CANCER
","	O
not	O
candidates	O
for	O
autologous	O
stem	O
cell	O
transplantation	O
","	O
were	O
treated	O
R-CVEP	O
[	O
R	O
375	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
(	O
IV	O
)	O
","	O
day	O
1	O
;	O
C	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
days	O
1	O
","	O
8	O
:	O
E	O
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
day	O
1	O
","	O
140	O
mg	O
/	O
m	O
(	O
2	O
)	O
days	O
2	O
","	O
3	O
orally	O
(	O
PO	O
)	O
;	O
V	O
(	O
300	O
vs.	O
400	O
mg	O
)	O
PO	O
and	O
P	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
PO	O
days	O
1月10日	O
]	O
every	O
28	O
d	O
for	O
six	O
cycles	O
.	O
	
Quality	O
of	O
life	O
(	O
QoL	O
)	O
was	O
assessed	O
in	O
addition	O
to	O
response	O
.	O
	
Thirty	O
patients	O
(	O
median	O
age	O
76	O
years	O
","	O
69-88	O
)	O
were	O
enrolled	O
(	O
one	O
died	B-TOXI
before	O
treatment	O
)	O
.	O
	
Maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
for	O
V	O
was	O
300	O
mg	O
.	O
	
For	O
23	O
patients	O
at	O
MTD	O
(	O
six	O
phase	O
I	O
=+	O
17	O
phase	O
II	O
)	O
","	O
two	O
were	O
discontinued	O
for	O
toxicity	O
","	O
one	O
withdrew	O
consent	O
","	O
eight	O
achieved	O
complete	O
response	O
(	O
35	O
%	O
)	O
","	O
five	O
achieved	O
partial	O
response	O
(	O
22	O
%	O
)	O
and	O
seven	O
progressed	O
(	O
25	O
%	O
)	O
.	O
	
Median	O
overall	O
survival	O
was	O
17路5	O
months	O
.	O
	
Median	O
progression-free	O
survival	O
was	O
9路2	O
months	O
.	O
	
Nine	O
patients	O
are	O
alive	O
.	O
	
QoL	O
declined	O
during	O
treatment	O
but	O
improved	O
above	O
baseline	O
for	O
patients	O
who	O
completed	O
treatment	O
.	O
	
In	O
conclusion	O
","	O
R-CVEP	O
was	O
tolerated	O
at	O
MTD	O
and	O
produced	O
durable	O
responses	O
with	O
improved	O
QoL	O
.	O
	
Abituzumab	B-DRUG
combined	O
with	O
cetuximab	B-DRUG
plus	O
irinotecan	B-DRUG
versus	O
cetuximab	B-DRUG
plus	O
irinotecan	B-DRUG
alone	O
for	O
patients	O
with	O
KRAS	O
wild-type	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
:	O
the	O
randomised	O
phase	O
I	O
/	O
II	O
POSEIDON	O
trial	O
.	O
	
	
Integrins	B-DRUG
are	O
involved	O
in	O
tumour	O
progression	O
and	O
metastasis	O
","	O
and	O
differentially	O
expressed	O
on	O
colorectal	B-CANCER
cancer	I-CANCER
(	O
CRC	B-CANCER
)	O
cells	O
.	O
	
Abituzumab	B-DRUG
(	O
EMD	O
525797	O
)	O
","	O
a	O
humanised	O
monoclonal	O
antibody	O
targeting	O
integrin	O
伪谓	O
heterodimers	O
","	O
has	O
demonstrated	O
preclinical	O
activity	O
.	O
	
This	O
trial	O
was	O
designed	O
to	O
assess	O
the	O
tolerability	O
of	O
different	O
doses	O
of	O
abituzumab	B-DRUG
in	O
combination	O
with	O
cetuximab	B-DRUG
and	O
irinotecan	B-DRUG
(	O
phase	O
I	O
)	O
and	O
explore	O
the	O
efficacy	O
and	O
tolerability	O
of	O
the	O
combination	O
versus	O
that	O
of	O
cetuximab	B-DRUG
and	O
irinotecan	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
CRC	I-CANCER
(	O
mCRC	B-CANCER
)	O
(	O
phase	O
II	O
part	O
)	O
.	O
	
Eligible	O
patients	O
had	O
KRAS	O
(	O
exon	O
2	O
)	O
wild-type	O
mCRC	B-CANCER
and	O
had	O
received	O
prior	O
oxaliplatin-containing	B-CANCER
therapy	O
.	O
	
The	O
trial	O
comprised	O
an	O
initial	O
safety	O
run-in	O
using	O
abituzumab	B-DRUG
doses	O
up	O
to	O
1000	O
mg	O
combined	O
with	O
a	O
standard	O
of	O
care	O
(	O
SoC	B-DRUG
:	O
cetuximab	B-DRUG
plus	O
irinotecan	B-DRUG
)	O
and	O
a	O
phase	O
II	O
part	O
in	O
which	O
patients	O
were	O
randomised	O
1	O
:	O
1	O
:	O
1	O
to	O
receive	O
abituzumab	B-DRUG
500	O
mg	O
(	O
arm	O
A	O
)	O
or	O
1000	O
mg	O
(	O
arm	O
B	O
)	O
every	O
2	O
weeks	O
combined	O
with	O
SoC	B-DRUG
","	O
or	O
SoC	B-DRUG
alone	O
(	O
arm	O
C	O
)	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
investigator-assessed	O
progression-free	O
survival	O
(	O
PFS	O
)	O
.	O
	
Secondary	O
end	O
points	O
included	O
overall	O
survival	O
(	O
OS	O
)	O
","	O
response	O
rate	O
(	O
RR	O
)	O
and	O
tolerability	O
.	O
	
Associations	O
between	O
tumour	O
integrin	O
expression	O
and	O
outcomes	O
were	O
also	O
assessed	O
.	O
	
Phase	O
I	O
showed	O
that	O
abituzumab	B-DRUG
doses	O
up	O
to	O
1000	O
mg	O
were	O
well	O
tolerated	O
in	O
combination	O
with	O
SoC	B-DRUG
.	O
	
Seventy-three	O
(	O
arm	O
A	O
)	O
","	O
71	O
(	O
arm	O
B	O
)	O
and	O
72	O
(	O
arm	O
C	O
)	O
patients	O
were	O
randomised	O
to	O
the	O
phase	O
II	O
part	O
.	O
	
Baseline	O
characteristics	O
were	O
balanced	O
.	O
	
PFS	O
was	O
similar	O
in	O
the	O
three	O
arms	O
:	O
arm	O
A	O
versus	O
SoC	B-DRUG
","	O
hazard	O
ratio	O
(	O
HR	O
)	O
1.13	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0.78-1.64	O
]	O
;	O
arm	O
B	O
versus	O
SoC	B-DRUG
","	O
HR	O
1.11	O
(	O
95	O
%	O
CI	O
0.77-1.61	O
)	O
.	O
	
RRs	O
were	O
also	O
similar	O
.	O
	
A	O
trend	O
toward	O
improved	O
OS	O
was	O
observed	O
:	O
arm	O
A	O
versus	O
SoC	B-DRUG
","	O
HR	O
0.83	O
(	O
95	O
%	O
CI	O
0.54-1.28	O
)	O
;	O
arm	O
B	O
versus	O
SoC	B-DRUG
","	O
HR	O
0.8	O
(	O
95	O
%	O
CI	O
0.52-1.25	O
)	O
.	O
	
Grade	O
_3	O
treatment-emergent	O
adverse	O
events	O
were	O
observed	O
in	O
72	O
%	O
","	O
78	O
%	O
and	O
67	O
%	O
of	O
patients	O
.	O
	
High	O
tumour	O
integrin	O
伪v尾6	O
expression	O
was	O
associated	O
with	O
longer	O
OS	O
in	O
arms	O
A	O
[	O
HR	O
0.55	O
(	O
0.30-1.00	O
)	O
]	O
and	O
B	O
[	O
HR	O
0.41	O
(	O
0.21-0.81	O
)	O
]	O
than	O
in	O
arm	O
C.	O
The	O
primary	O
PFS	O
end	O
point	O
was	O
not	O
met	O
","	O
although	O
predefined	O
exploratory	O
biomarker	O
analyses	O
identified	O
subgroups	O
of	O
patients	O
in	O
whom	O
abituzumab	B-DRUG
may	O
have	O
benefit	O
.	O
	
The	O
tolerability	O
of	O
abituzumab	B-DRUG
combined	O
with	O
cetuximab	B-DRUG
and	O
irinotecan	B-DRUG
was	O
acceptable	O
.	O
	
Further	O
study	O
is	O
warranted	O
.	O
	
CLINICALTRIALS.GOV	O
IDENTIFIER	O
:	O
NCT01008475	O
.	O
	
Combination	O
of	O
the	O
mTOR	O
inhibitor	O
ridaforolimus	B-DRUG
and	O
the	O
anti-IGF1R	O
monoclonal	O
antibody	O
dalotuzumab	B-DRUG
:	O
preclinical	O
characterization	O
and	O
phase	O
I	O
clinical	O
trial	O
.	O
	
	
Mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
inhibition	O
activates	O
compensatory	O
insulin-like	O
growth	O
factor	O
receptor	O
(	O
IGFR	O
)	O
signaling	O
.	O
	
We	O
evaluated	O
the	O
ridaforolimus	B-DRUG
(	O
mTOR	O
inhibitor	O
)	O
and	O
dalotuzumab	B-DRUG
(	O
anti-IGF1R	O
antibody	O
)	O
combination	O
.	O
	
In	O
vitro	O
and	O
in	O
vivo	O
models	O
","	O
and	O
a	O
phase	O
I	O
study	O
in	O
which	O
patients	O
with	O
advanced	O
cancer	O
received	O
ridaforolimus	B-DRUG
(	O
10-40	O
mg	O
/	O
day	O
every	O
day	O
_	O
5	O
/	O
week	O
)	O
and	O
dalotuzumab	B-DRUG
(	O
10	O
mg	O
/	O
kg	O
/	O
week	O
or	O
7.5	O
mg	O
/	O
kg	O
/	O
every	O
other	O
week	O
)	O
were	O
explored	O
.	O
	
Preclinical	O
studies	O
demonstrated	O
enhanced	O
pathway	O
inhibition	O
with	O
ridaforolimus	B-DRUG
and	O
dalotuzumab	B-DRUG
.	O
	
With	O
87	O
patients	O
treated	O
in	O
the	O
phase	O
I	O
study	O
","	O
main	O
dose-limiting	O
toxicities	O
(	O
DLT	O
)	O
of	O
the	O
combination	O
were	O
primarily	O
mTOR-related	O
stomatitis	B-TOXI
and	O
asthenia	B-TOXI
at	O
doses	O
of	O
ridaforolimus	B-DRUG
lower	O
than	O
expected	O
","	O
suggesting	O
blockade	O
of	O
compensatory	O
pathways	O
in	O
normal	O
tissues	O
.	O
	
Six	O
confirmed	O
partial	O
responses	O
were	O
reported	O
(	O
3	O
patients	O
with	O
breast	B-CANCER
cancer	I-CANCER
)	O
;	O
10	O
of	O
23	O
patients	O
with	O
breast	B-CANCER
cancer	I-CANCER
and	O
6	O
of	O
11	O
patients	O
with	O
ER	O
(	O
=+	O
)	O
/	O
high-proliferative	O
breast	B-CANCER
cancer	I-CANCER
showed	O
antitumor	O
activity	O
.	O
	
Our	O
study	O
provides	O
proof-of-concept	O
that	O
inhibiting	O
the	O
IGF1R	O
compensatory	O
response	O
to	O
mTOR	O
inhibition	O
is	O
feasible	O
with	O
promising	O
clinical	O
activity	O
in	O
heavily	O
pretreated	O
advanced	B-CANCER
cancer	I-CANCER
","	O
particularly	O
in	O
ER	O
(	O
=+	O
)	O
/	O
high-proliferative	O
breast	B-CANCER
cancer	I-CANCER
(	O
ClinicalTrials.gov	O
identifier	O
:	O
NCT00730379	O
)	O
.	O
	
A	O
phase	O
I	O
trial	O
of	O
combination	O
trastuzumab	B-DRUG
","	O
lapatinib	B-DRUG
","	O
and	O
bevacizumab	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
cancer	I-CANCER
.	O
	
	
Preclinical	O
data	O
indicate	O
that	O
combination	O
HER2-directed	O
and	O
anti-VEGF	O
therapy	O
may	O
bypass	O
resistance	O
to	O
trastuzumab	B-DRUG
.	O
	
A	O
phase	O
I	O
trial	O
was	O
performed	O
to	O
assess	O
safety	O
","	O
activity	O
","	O
and	O
correlates	O
.	O
	
Patients	O
with	O
advanced	O
","	O
refractory	B-CANCER
malignancy	I-CANCER
were	O
enrolled	O
(	O
modified	O
3	O
=+	O
3	O
design	O
with	O
expansions	O
for	O
responding	O
tumor	O
types	O
)	O
.	O
	
Patients	O
received	O
lapatinib	B-DRUG
daily	O
for	O
21	O
days	O
","	O
and	O
bevacizumab	B-DRUG
and	O
trastuzumab	B-DRUG
every	O
3	O
weeks	O
.	O
	
Correlates	O
included	O
HER2	O
extracellular	O
domain	O
levels	O
(	O
ECD	O
)	O
and	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
.	O
	
Ninety-four	O
patients	O
were	O
treated	O
(	O
median	O
=	O
four	O
prior	O
systemic	O
therapies	O
)	O
.	O
	
The	O
most	O
common	O
related	O
adverse	O
events	O
_	O
grade	O
2	O
were	O
diarrhea	B-TOXI
(	O
n	O
=	O
33	O
","	O
35	O
%	O
)	O
and	O
hypertension	B-TOXI
(	O
n	O
=	O
10	O
","	O
11	O
%	O
)	O
.	O
	
The	O
recommended	O
phase	O
2	O
dose	O
was	O
trastuzumab	B-DRUG
6	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
loading	O
=	O
8	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
bevacizumab	B-DRUG
15	O
mg	O
/	O
kg	O
every	O
3	O
weeks	O
","	O
with	O
lapatinib	B-DRUG
"1,250"	O
mg	O
daily	O
(	O
full	O
FDA-approved	O
dose	O
of	O
each	O
drug	O
)	O
.	O
	
One	O
patient	O
(	O
1	O
%	O
)	O
achieved	O
a	O
complete	O
response	O
(	O
CR	O
)	O
;	O
eight	O
(	O
9	O
%	O
)	O
","	O
a	O
partial	O
response	O
(	O
PR	O
)	O
(	O
includes	O
breast	O
(	O
n	O
=	O
7	O
","	O
one	O
of	O
which	O
was	O
HER2	O
2+	O
by	O
IHC	O
)	O
and	O
salivary	B-CANCER
ductal	I-CANCER
carcinoma	I-CANCER
(	O
n	O
=	O
1	O
)	O
;	O
and	O
14	O
(	O
15	O
%	O
)	O
","	O
stable	O
disease	O
(	O
SD	O
)	O
_6	O
months	O
(	O
total	O
SD	O
_	O
6	O
months	O
/	O
PR	O
/	O
CR	O
23	O
(	O
25	O
%	O
)	O
.	O
	
All	O
patients	O
with	O
PR	O
/	O
CR	O
received	O
prior	O
trastuzumab	B-DRUG
=+	O
/	O
=-	O
lapatinib	B-DRUG
.	O
	
SD	O
_	O
6	O
months	O
/	O
PR	O
/	O
CR	O
rate	O
and	O
time	O
to	O
treatment	O
failure	O
(	O
TTF	O
)	O
correlated	O
with	O
elevated	O
baseline	O
HER2	O
ECD	O
(	O
N	O
=	O
75	O
patients	O
tested	O
)	O
but	O
not	O
with	O
HER2	O
SNPs	O
.	O
	
Combination	O
trastuzumab	B-DRUG
","	O
lapatinib	B-DRUG
","	O
and	O
bevacizumab	B-DRUG
was	O
well-tolerated	O
and	O
demonstrated	O
antitumor	O
activity	O
in	O
heavily	O
pretreated	O
patients	O
with	O
advanced	B-CANCER
malignancy	I-CANCER
.	O
	
A	O
phase	O
Ib	O
study	O
of	O
linsitinib	B-DRUG
(	O
OSI-906	B-DRUG
)	O
","	O
a	O
dual	O
inhibitor	O
of	O
IGF-1R	O
and	O
IR	O
tyrosine	O
kinase	O
","	O
in	O
combination	O
with	O
everolimus	B-DRUG
as	O
treatment	O
for	O
patients	O
with	O
refractory	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
the	O
combination	O
of	O
linsitinib	B-DRUG
(	O
OSI-906	B-DRUG
)	O
","	O
a	O
dual	O
inhibitor	O
of	O
IGFR	O
and	O
IR	O
tyrosine	O
kinase	O
activity	O
","	O
and	O
everolimus	B-DRUG
as	O
treatment	O
for	O
patients	O
with	O
refractory	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
mCRC	B-CANCER
)	O
.	O
	
Eligible	O
adult	O
patients	O
with	O
refractory	O
mCRC	B-CANCER
","	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
(	O
ECOG	O
)	O
performance	O
status	O
of	O
0	O
or	O
1	O
","	O
and	O
adequate	O
end-organ	O
function	O
received	O
escalating	O
doses	O
of	O
OSI-906	B-DRUG
and	O
everolimus	B-DRUG
in	O
a	O
3	O
=+	O
3	O
design	O
.	O
	
Treatment	O
continued	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
","	O
with	O
response	O
evaluations	O
every	O
8	O
weeks	O
.	O
	
Eighteen	O
patients	O
with	O
metastatic	B-CANCER
CRC	I-CANCER
were	O
treated	O
.	O
	
There	O
were	O
no	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
in	O
the	O
first	O
dose	O
level	O
(	O
DL	O
","	O
OSI-906	B-DRUG
50	O
mg	O
BID	O
;	O
everolimus	B-DRUG
5	O
mg	O
QD	O
)	O
.	O
	
At	O
DL2	O
(	O
OSI-906	B-DRUG
100	O
mg	O
BID	O
;	O
everolimus	B-DRUG
10	O
mg	O
QD	O
","	O
n	O
6	O
)	O
","	O
three	O
patients	O
had	O
DLTs	O
considered	O
related	O
to	O
everolimus	B-DRUG
(	O
grade	O
3	O
mucositis	B-TOXI
","	O
2	O
;	O
grade	O
3	O
thrombocytopenia	B-TOXI
","	O
1	O
)	O
.	O
	
An	O
amendment	O
introduced	O
DL2a	O
(	O
OSI-906	B-DRUG
100	O
mg	O
BID	O
;	O
everolimus	B-DRUG
5	O
mg	O
QD	O
","	O
n	O
5	O
)	O
;	O
DLTs	O
were	O
seen	O
in	O
two	O
patients	O
(	O
one	O
patient	O
each	O
:	O
grade	O
3	O
thrombocytopenia	B-TOXI
with	I-TOXI
bleeding	I-TOXI
;	O
inability	O
to	O
receive	O
75	O
%	O
of	O
doses	O
due	O
to	O
neutropenia	B-TOXI
/	O
thrombocytopenia	B-TOXI
)	O
.	O
	
DL1	O
was	O
the	O
MTD	O
;	O
a	O
total	O
of	O
7	O
patients	O
were	O
treated	O
at	O
this	O
dose	O
.	O
	
Common	O
adverse	O
events	O
across	O
all	O
DLs	O
included	O
grade	O
1	O
/	O
2	O
fatigue	B-TOXI
(	O
50	O
%	O
)	O
and	O
anorexia	B-TOXI
(	O
50	O
%	O
)	O
.	O
	
There	O
were	O
no	O
objective	O
responses	O
to	O
treatment	O
;	O
median	O
time	O
of	O
study	O
treatment	O
was	O
7.6	O
weeks	O
(	O
range	O
:	O
3.9-53	O
weeks	O
)	O
.	O
	
The	O
MTD	O
of	O
OSI-906	B-DRUG
and	O
everolimus	B-DRUG
was	O
50	O
mg	O
BID	O
and	O
5	O
mg	O
QD	O
","	O
respectively	O
.	O
	
No	O
indications	O
of	O
clinical	O
activity	O
were	O
observed	O
in	O
refractory	O
mCRC	B-CANCER
patients	O
.	O
	
A	O
phase	O
IB	O
trial	O
of	O
the	O
oral	O
MEK	O
inhibitor	O
trametinib	B-DRUG
(	O
GSK1120212	B-DRUG
)	O
in	O
combination	O
with	O
everolimus	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
This	O
phase	O
Ib	O
trial	O
investigated	O
the	O
safety	O
","	O
tolerability	O
","	O
and	O
recommended	O
phase	O
II	O
dose	O
and	O
schedule	O
of	O
the	O
MEK	O
inhibitor	O
trametinib	B-DRUG
in	O
combination	O
with	O
the	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
inhibitor	O
everolimus	B-DRUG
.	O
	
Secondary	O
objectives	O
included	O
pharmacokinetic	O
(	O
PK	O
)	O
characterization	O
and	O
evaluation	O
of	O
clinical	O
activity	O
.	O
	
A	O
total	O
of	O
67	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
enrolled	O
in	O
this	O
open-label	O
","	O
single-arm	O
","	O
dose-escalation	O
study	O
.	O
	
Dose	O
escalation	O
followed	O
a	O
3	O
=+	O
3	O
design	O
.	O
	
Patients	O
were	O
assigned	O
to	O
one	O
of	O
10	O
different	O
cohorts	O
","	O
involving	O
either	O
daily	O
dosing	O
with	O
both	O
agents	O
or	O
daily	O
dosing	O
with	O
trametinib	B-DRUG
and	O
intermittent	O
everolimus	B-DRUG
dosing	O
.	O
	
This	O
included	O
an	O
expansion	O
cohort	O
comprising	O
patients	O
with	O
pancreatic	B-CANCER
tumors	I-CANCER
.	O
	
PKs	O
samples	O
were	O
collected	O
predose	O
","	O
as	O
well	O
as	O
1	O
","	O
2	O
","	O
4	O
","	O
and	O
6	O
h	O
post-dose	O
on	O
day	O
15	O
of	O
the	O
first	O
treatment	O
cycle	O
.	O
	
Concurrent	O
treatment	O
with	O
trametinib	B-DRUG
and	O
everolimus	B-DRUG
resulted	O
in	O
frequent	O
treatment-related	O
adverse	O
events	O
","	O
including	O
mucosal	B-TOXI
inflammation	I-TOXI
(	O
40	O
%	O
)	O
","	O
stomatitis	B-TOXI
(	O
25	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
54	O
%	O
)	O
","	O
and	O
diarrhea	B-TOXI
(	O
42	O
%	O
)	O
.	O
	
PK	O
assessment	O
did	O
not	O
suggest	O
drug-drug	O
interactions	O
between	O
these	O
two	O
agents	O
.	O
	
Of	O
the	O
67	O
enrolled	O
patients	O
","	O
5	O
(	O
7	O
%	O
)	O
achieved	O
partial	O
response	O
(	O
PR	O
)	O
to	O
treatment	O
and	O
21	O
(	O
31	O
%	O
)	O
displayed	O
stable	O
disease	O
(	O
SD	O
)	O
.	O
	
Among	O
the	O
21	O
patients	O
with	O
pancreatic	B-CANCER
cancer	I-CANCER
","	O
PR	O
was	O
observed	O
in	O
1	O
patient	O
(	O
5	O
%	O
)	O
and	O
SD	O
in	O
6	O
patients	O
(	O
29	O
%	O
)	O
.	O
	
This	O
study	O
was	O
unable	O
to	O
identify	O
a	O
recommended	O
phase	O
II	O
dose	O
and	O
schedule	O
of	O
trametinib	B-DRUG
in	O
combination	O
with	O
everolimus	B-DRUG
that	O
provided	O
an	O
acceptable	O
tolerability	O
and	O
adequate	O
drug	O
exposure	O
.	O
	
Phase	O
I	O
study	O
of	O
the	O
halichondrin	O
B	O
analogue	O
eribulin	B-DRUG
mesylate	I-DRUG
in	O
combination	O
with	O
cisplatin	B-DRUG
in	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Eribulin	B-DRUG
mesylate	I-DRUG
is	O
a	O
synthetic	O
macrocyclic	O
ketone	O
analogue	O
of	O
Halichondrin	O
B	O
that	O
has	O
demonstrated	O
high	O
antitumor	O
activity	O
in	O
preclinical	O
and	O
clinical	O
settings	O
.	O
	
This	O
phase	O
I	O
study	O
aimed	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
","	O
and	O
pharmacokinetics	O
in	O
combination	O
with	O
cisplatin	B-DRUG
(	O
CP	O
)	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
Thirty-six	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
received	O
eribulin	B-DRUG
mesylate	I-DRUG
0.7-1.4	O
mg	O
m	O
(	O
-2	O
)	O
and	O
CP	O
60-75	O
mg	O
m	O
(	O
-2	O
)	O
.	O
	
Eribulin	B-DRUG
mesylate	I-DRUG
was	O
administered	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
in	O
combination	O
with	O
CP	O
day	O
1	O
every	O
28-day	O
cycle	O
.	O
	
The	O
protocol	O
was	O
amended	O
after	O
dose	O
level	O
4	O
(	O
eribulin	B-DRUG
mesylate	I-DRUG
1.4	O
mg	O
m	O
(	O
-2	O
)	O
","	O
CP	O
60	O
mg	O
m	O
(	O
-2	O
)	O
)	O
when	O
it	O
was	O
not	O
feasible	O
to	O
administer	O
eribulin	B-DRUG
mesylate	I-DRUG
on	O
day	O
15	O
because	O
of	O
neutropenia	B-TOXI
;	O
the	O
treatment	O
schedule	O
was	O
changed	O
to	O
eribulin	B-DRUG
mesylate	I-DRUG
on	O
days	O
1	O
and	O
8	O
and	O
CP	O
on	O
day	O
1	O
every	O
21	O
days	O
.	O
	
On	O
the	O
28-day	O
schedule	O
","	O
three	O
patients	O
had	O
DLT	O
during	O
the	O
first	O
cycle	O
:	O
grade	O
(	O
G	O
)	O
4	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
1	O
mg	O
m	O
(	O
-2	O
)	O
","	O
60	O
mg	O
m	O
(	O
-2	O
)	O
)	O
;	O
G	O
3	O
anorexia	B-TOXI
/	O
fatigue	B-TOXI
/	O
hypokalemia	B-TOXI
(	O
1.2	O
mg	O
m	O
(	O
-2	O
)	O
","	O
60	O
mg	O
m	O
(	O
-2	O
)	O
)	O
;	O
and	O
G	O
3	O
stomatitis	B-TOXI
/	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
/	O
fatigue	B-TOXI
(	O
1.4	O
mg	O
m	O
(	O
-2	O
)	O
","	O
60	O
mg	O
m	O
(	O
-2	O
)	O
)	O
.	O
	
On	O
the	O
21-day	O
schedule	O
","	O
three	O
patients	O
had	O
DLT	O
during	O
the	O
first	O
cycle	O
:	O
G	O
3	O
hypokalemia	B-TOXI
/	O
hyponatremia	B-TOXI
(	O
1.4	O
mg	O
m	O
(	O
-2	O
)	O
","	O
60	O
mg	O
m	O
(	O
-2	O
)	O
)	O
;	O
G	O
4	O
mucositis	B-TOXI
(	O
1.4	O
mg	O
m	O
(	O
-2	O
)	O
","	O
60	O
mg	O
m	O
(	O
-2	O
)	O
)	O
;	O
and	O
G	O
3	O
hypokalemia	B-TOXI
(	O
1.2	O
mg	O
m	O
(	O
-2	O
)	O
","	O
75	O
mg	O
m	O
(	O
-2	O
)	O
)	O
.	O
	
The	O
MTD	O
and	O
recommended	O
phase	O
II	O
dose	O
was	O
determined	O
as	O
eribulin	B-DRUG
mesylate	I-DRUG
1.2	O
mg	O
m	O
(	O
-2	O
)	O
(	O
days	O
1	O
","	O
8	O
)	O
and	O
CP	O
75	O
mg	O
m	O
(	O
-2	O
)	O
(	O
day	O
1	O
)	O
","	O
on	O
a	O
21-day	O
cycle	O
.	O
	
Two	O
patients	O
had	O
unconfirmed	O
partial	O
responses	O
(	O
PR	O
)	O
(	O
pancreatic	B-CANCER
and	I-CANCER
breast	I-CANCER
cancers	I-CANCER
)	O
and	O
two	O
had	O
PR	O
(	O
oesophageal	B-CANCER
and	I-CANCER
bladder	I-CANCER
cancers	I-CANCER
)	O
.	O
	
On	O
the	O
21-day	O
cycle	O
","	O
eribulin	B-DRUG
mesylate	I-DRUG
1.2	O
mg	O
m	O
(	O
-2	O
)	O
","	O
administered	O
on	O
days	O
1	O
and	O
8	O
","	O
in	O
combination	O
with	O
CP	O
75	O
mg	O
m	O
(	O
-2	O
)	O
","	O
administered	O
on	O
day	O
1	O
is	O
well	O
tolerated	O
and	O
showed	O
preliminary	O
anticancer	O
activity	O
.	O
	
Phase	O
I	O
study	O
of	O
vandetanib	B-DRUG
with	O
radiation	O
therapy	O
with	O
or	O
without	O
cisplatin	B-DRUG
in	O
locally	O
advanced	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
	
Vandetanib	B-DRUG
","	O
added	O
to	O
cisplatin	B-DRUG
and	O
radiation	O
therapy	O
(	O
RT	O
)	O
overcomes	O
chemoradiation	O
therapy	O
(	O
CRT	O
)	O
and	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
inhibitor	O
resistance	O
in	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
HNSCC	B-CANCER
)	O
lines	O
and	O
models	O
.	O
	
Patients	O
with	O
previously	O
untreated	O
HNSCC	B-CANCER
received	O
vandetanib	B-CANCER
daily	O
for	O
14	O
days	O
(	O
starting	O
dose	O
100	O
mg	O
)	O
and	O
then	O
vandetanib	B-CANCER
=+	O
RT	O
(	O
2.2	O
Gy	O
/	O
day	O
","	O
5	O
days	O
/	O
week	O
)	O
for	O
6	O
weeks	O
(	O
regimen	O
1	O
)	O
or	O
vandetanib	B-CANCER
=+	O
RT	O
(	O
2	O
Gy	O
/	O
day	O
","	O
5	O
days	O
/	O
week	O
)	O
=+	O
cisplatin	B-CANCER
(	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
)	O
for	O
7	O
weeks	O
(	O
regimen	O
2	O
)	O
.	O
	
The	O
primary	O
objective	O
was	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
vandetanib	B-DRUG
with	O
RT	O
=+	O
/	O
=-	O
cisplatin	B-DRUG
.	O
	
Of	O
33	O
treated	O
patients	O
","	O
30	O
completed	O
therapy	O
(	O
regimen	O
1	O
","	O
n	O
=	O
12	O
;	O
regimen	O
2	O
","	O
n	O
=	O
18	O
)	O
.	O
	
MTD	O
in	O
regimen	O
2	O
was	O
100	O
mg	O
(	O
3	O
dose	O
limiting	O
toxicities	O
[	O
DLTs	O
]	O
at	O
200	O
mg	O
)	O
","	O
whereas	O
regimen	O
1	O
was	O
stopped	O
because	O
of	O
poor	O
recruitment	O
(	O
1	O
DLT	O
at	O
200	O
mg	O
)	O
.	O
	
Most	O
common	O
grade	O
_3	O
adverse	O
events	O
(	O
AEs	O
)	O
were	O
dysphagia	B-TOXI
(	O
30	O
%	O
)	O
","	O
stomatitis	B-TOXI
(	O
33	O
%	O
)	O
","	O
and	O
mucosal	B-TOXI
inflammation	I-TOXI
(	O
27	O
%	O
)	O
.	O
	
Five	O
patients	O
discontinued	O
vandetanib	B-DRUG
because	O
of	O
AEs	O
.	O
	
Vandetanib	B-DRUG
with	O
CRT	O
was	O
feasible	O
.	O
	
A	O
phase	O
1	O
/	O
1b	O
study	O
of	O
rituximab	B-DRUG
","	O
bendamustine	B-DRUG
","	O
and	O
ibrutinib	B-DRUG
in	O
patients	O
with	O
untreated	O
and	O
relapsed	O
/	O
refractory	O
non-Hodgkin	B-CANCER
lymphoma	I-CANCER
.	O
	
	
Ibrutinib	B-DRUG
has	O
single	O
agent	O
activity	O
of	O
22	O
%	O
to	O
68	O
%	O
in	O
relapsed	O
B-cell	B-CANCER
non-Hodgkin	I-CANCER
lymphoma	I-CANCER
(	O
NHL	B-CANCER
)	O
.	O
	
This	O
study	O
evaluated	O
the	O
safety	O
and	O
efficacy	O
of	O
ibrutinib	B-DRUG
combined	O
with	O
rituximab	B-DRUG
(	O
R	O
)	O
and	O
bendamustine	B-DRUG
.	O
	
Patients	O
received	O
R	O
(	O
375	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
on	O
day	O
1	O
","	O
bendamustine	B-DRUG
(	O
90	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
on	O
days	O
1	O
and	O
2	O
","	O
and	O
ibrutinib	B-DRUG
(	O
280	O
or	O
560	O
mg	O
)	O
on	O
days	O
1	O
to	O
28	O
every	O
28	O
days	O
for	O
6	O
cycles	O
followed	O
by	O
ibrutinib	B-DRUG
alone	O
until	O
progression	O
.	O
	
Forty-eight	O
patients	O
enrolled	O
","	O
including	O
12	O
patients	O
with	O
follicular	B-CANCER
lymphoma	I-CANCER
(	O
FL	B-CANCER
)	O
","	O
16	O
with	O
diffuse	B-CANCER
large	I-CANCER
B-cell	I-CANCER
lymphoma	I-CANCER
(	O
DLCL	B-CANCER
)	O
","	O
and	O
17	O
with	O
mantle	B-CANCER
cell	I-CANCER
lymphoma	I-CANCER
(	O
MCL	B-CANCER
)	O
.	O
	
No	O
dose-limiting	O
toxicities	O
were	O
observed	O
.	O
	
Patients	O
received	O
a	O
median	O
of	O
8	O
cycles	O
","	O
with	O
26	O
completing	O
6	O
cycles	O
and	O
continuing	O
ibrutinib	B-DRUG
alone	O
in	O
cycles	O
7	O
to	O
34	O
.	O
	
The	O
overall	O
response	O
(	O
OR	O
)	O
rate	O
was	O
72	O
%	O
","	O
with	O
52	O
%	O
complete	O
responses	O
(	O
CRs	O
)	O
.	O
	
By	O
histology	O
","	O
the	O
OR	O
rate	O
was	O
94	O
%	O
(	O
76	O
%	O
CR	O
)	O
in	O
MCL	B-CANCER
","	O
37	O
%	O
(	O
31	O
%	O
CR	O
)	O
in	O
DLCL	B-CANCER
","	O
and	O
90	O
%	O
(	O
50	O
%	O
CR	O
)	O
in	O
FL	B-CANCER
.	O
	
Grade	O
3	O
to	O
4	O
toxicities	O
included	O
lymphopenia	B-TOXI
(	O
77	O
%	O
)	O
","	O
neutropenia	B-TOXI
(	O
33	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
19	O
%	O
)	O
","	O
and	O
rash	B-TOXI
(	O
25	O
%	O
)	O
.	O
	
Median	O
progression-free	O
survival	O
has	O
not	O
been	O
reached	O
(	O
95	O
%	O
CI	O
","	O
8.7	O
months	O
to	O
not	O
reached	O
)	O
.	O
	
The	O
recommended	O
phase	O
2	O
dose	O
of	O
ibrutinib	B-DRUG
in	O
combination	O
with	O
R-bendamustine	B-DRUG
in	O
patients	O
with	O
NHL	B-CANCER
is	O
560	O
mg	O
.	O
	
The	O
combination	O
has	O
promising	O
efficacy	O
","	O
particularly	O
in	O
MCL	B-CANCER
and	O
FL	B-CANCER
.	O
	
This	O
trial	O
was	O
registered	O
at	O
www.clinicaltrials.gov	O
as	O
#	O
NCT01479842	O
.	O
	
Dual	O
antiangiogenic	O
inhibition	O
:	O
a	O
phase	O
I	O
dose	O
escalation	O
and	O
expansion	O
trial	O
targeting	O
VEGF-A	O
and	O
VEGFR	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Angiogenesis	O
plays	O
a	O
pivotal	O
role	O
in	O
tumor	O
growth	O
and	O
metastasis	O
.	O
	
Sorafenib	B-DRUG
","	O
a	O
tyrosine	O
kinase	O
inhibitor	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
(	O
VEGFR	O
)	O
","	O
combined	O
with	O
bevacizumab	B-DRUG
","	O
a	O
monoclonal	O
antibody	O
to	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF-A	O
)	O
","	O
would	O
vertically	O
inhibit	O
VEGF	O
/	O
VEGFR	O
signaling	O
.	O
	
A	O
phase	O
I	O
trial	O
was	O
performed	O
to	O
assess	O
safety	O
","	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
and	O
clinical	O
correlates	O
.	O
	
Patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
refractory	O
to	O
standard	O
therapy	O
were	O
eligible	O
.	O
	
In	O
cohorts	O
of	O
escalating	O
doses	O
","	O
patients	O
received	O
sorafenib	B-DRUG
daily	O
for	O
28	O
days	O
and	O
bevacizumab	B-DRUG
every	O
two	O
weeks	O
.	O
	
Clinical	O
correlates	O
included	O
VEGF	O
polymorphisms	O
.	O
	
Expansion	O
cohorts	O
of	O
responding	O
tumor	O
types	O
were	O
enrolled	O
.	O
	
One	O
hundred	O
fifteen	O
patients	O
were	O
treated	O
","	O
and	O
the	O
MTD	O
was	O
identified	O
as	O
200	O
mg	O
twice	O
daily	O
sorafenib	B-DRUG
and	O
5	O
mg	O
/	O
kg	O
bevacizumab	B-DRUG
every	O
two	O
weeks	O
.	O
	
Median	O
number	O
of	O
prior	O
therapies	O
was	O
four	O
.	O
	
Twenty-nine	O
patients	O
(	O
25	O
%	O
)	O
achieved	O
stable	O
disease	O
_6	O
months	O
;	O
six	O
patients	O
(	O
5	O
%	O
)	O
achieved	O
a	O
partial	O
response	O
(	O
total	O
SD	O
_	O
6	O
months	O
/	O
PR=35	O
(	O
30	O
%	O
)	O
)	O
.	O
	
76	O
patients	O
(	O
66	O
%	O
)	O
experienced	O
adverse	O
events	O
of	O
grade	O
2	O
or	O
higher	O
","	O
most	O
commonly	O
hand	B-TOXI
and	I-TOXI
foot	I-TOXI
syndrome	I-TOXI
(	O
n	O
=	O
27	O
","	O
24	O
%	O
)	O
and	O
hypertension	B-TOXI
(	O
n	O
=	O
24	O
","	O
21	O
%	O
)	O
.	O
	
Dose-limiting	O
toxicity	O
occurred	O
in	O
eight	O
patients	O
(	O
7	O
%	O
)	O
","	O
and	O
45	O
patients	O
(	O
39	O
%	O
)	O
required	O
dose	O
reduction	O
for	O
toxicity	O
.	O
	
Grade	O
3	O
and	O
4	O
hypertension	B-TOXI
was	O
associated	O
with	O
longer	O
time	O
to	O
treatment	O
failure	O
","	O
overall	O
survival	O
","	O
and	O
higher	O
response	O
rate	O
.	O
	
Combination	O
sorafenib	B-DRUG
and	O
bevacizumab	B-DRUG
was	O
well-tolerated	O
and	O
demonstrated	O
antitumor	O
activity	O
in	O
heavily	O
pretreated	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Phase	O
I	O
Study	O
to	O
Assess	O
the	O
Combination	O
of	O
Afatinib	B-DRUG
with	O
Trastuzumab	B-DRUG
in	O
Patients	O
with	O
Advanced	O
or	O
Metastatic	O
HER2-Positive	O
Breast	B-CANCER
Cancer	I-CANCER
.	O
	
	
The	O
HER2	O
mAb	O
","	O
trastuzumab	B-DRUG
","	O
is	O
a	O
standard	O
therapy	O
for	O
patients	O
with	O
HER2-positive	O
breast	B-CANCER
cancer	I-CANCER
before	O
acquired	O
resistance	O
.	O
	
Afatinib	B-DRUG
","	O
an	O
irreversible	O
","	O
oral	O
","	O
small-molecule	O
ErbB	O
family	O
blocker	O
","	O
shows	O
clinical	O
activity	O
in	O
trastuzumab-refractory	B-DRUG
HER2-positive	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
This	O
phase	O
I	O
study	O
used	O
a	O
3+3	O
dose	O
escalation	O
to	O
determine	O
the	O
MTD	O
of	O
oral	O
once-daily	O
afatinib	B-DRUG
in	O
combination	O
with	O
the	O
recommended	O
dose	O
of	O
intravenous	O
trastuzumab	B-DRUG
(	O
4	O
mg	O
/	O
kg	O
week	O
1	O
;	O
2	O
mg	O
/	O
kg	O
/	O
wk	O
thereafter	O
)	O
.	O
	
Adult	O
women	O
with	O
confirmed	O
advanced	O
/	O
metastatic	O
HER2-positive	O
breast	B-CANCER
cancer	I-CANCER
were	O
eligible	O
.	O
	
Of	O
18	O
patients	O
treated	O
","	O
16	O
received	O
daily	O
afatinib	B-DRUG
20	O
mg	O
and	O
two	O
30	O
mg	O
.	O
	
Overall	O
","	O
4	O
of	O
13	O
and	O
2	O
of	O
2	O
patients	O
receiving	O
afatinib	B-DRUG
20	O
mg	O
and	O
30	O
mg	O
","	O
respectively	O
","	O
experienced	O
dose-limiting	O
toxicity	O
(	O
DLT	O
;	O
all	O
CTCAE	O
grade	O
3	O
diarrhea	B-TOXI
)	O
.	O
	
Most	O
frequent	O
treatment-related	O
adverse	O
events	O
were	O
diarrhea	B-TOXI
(	O
94	O
%	O
)	O
","	O
rash	B-TOXI
(	O
56	O
%	O
)	O
","	O
and	O
fatigue	B-TOXI
(	O
56	O
%	O
)	O
.	O
	
Overall	O
","	O
pharmacokinetic	O
profiles	O
of	O
afatinib	B-DRUG
and	O
trastuzumab	B-DRUG
in	O
combination	O
were	O
consistent	O
with	O
the	O
known	O
characteristics	O
of	O
each	O
alone	O
.	O
	
Overall	O
","	O
objective	O
response	O
and	O
disease	O
control	O
rates	O
were	O
11	O
%	O
and	O
39	O
%	O
","	O
respectively	O
","	O
with	O
median	O
progression-free	O
survival	O
111	O
days	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
56.0-274.0	O
)	O
.	O
	
The	O
MTD	O
of	O
afatinib	B-DRUG
was	O
20	O
mg	O
daily	O
combined	O
with	O
the	O
recommended	O
weekly	O
dose	O
of	O
trastuzumab	B-DRUG
","	O
with	O
1	O
of	O
6	O
patients	O
showing	O
DLTs	O
in	O
the	O
dose	O
escalation	O
.	O
	
However	O
","	O
additional	O
DLTs	O
occurred	O
in	O
the	O
dose-expansion	O
phase	O
meaning	O
that	O
this	O
MTD	O
can	O
not	O
be	O
recommended	O
for	O
phase	O
II	O
development	O
without	O
strict	O
diarrhea	B-TOXI
management	O
.	O
	
There	O
was	O
no	O
evidence	O
suggesting	O
relevant	O
pharmacokinetic	O
drug-drug	O
interactions	O
.	O
	
Signs	O
of	O
clinical	O
activity	O
were	O
seen	O
in	O
trastuzumab-resistant	B-DRUG
HER2-positive	O
breast	B-CANCER
cancer	I-CANCER
","	O
suggesting	O
further	O
investigation	O
with	O
optimal	O
diarrhea	B-TOXI
management	O
is	O
warranted	O
.	O
	
PRONOUNCE	O
:	O
randomized	O
","	O
open-label	O
","	O
phase	O
III	O
study	O
of	O
first-line	O
pemetrexed	B-DRUG
=+	O
carboplatin	B-DRUG
followed	O
by	O
maintenance	O
pemetrexed	B-DRUG
versus	O
paclitaxel	B-DRUG
=+	O
carboplatin	B-DRUG
=+	O
bevacizumab	B-DRUG
followed	O
by	O
maintenance	O
bevacizumab	B-DRUG
in	O
patients	O
ith	O
advanced	B-CANCER
nonsquamous	I-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
PRONOUNCE	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
pemetrexed+carboplatin	B-DRUG
followed	O
by	O
pemetrexed	B-DRUG
(	O
Pem+Cb	B-DRUG
)	O
with	O
paclitaxel+carboplatin+bevacizumab	B-DRUG
followed	O
by	O
bevacizumab	B-DRUG
(	O
Pac+Cb+Bev	B-DRUG
)	O
in	O
patients	O
with	O
advanced	B-CANCER
nonsquamous	I-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Patients	O
_18	O
years	O
of	O
age	O
with	O
stage	O
IV	O
nonsquamous	B-CANCER
NSCLC	I-CANCER
(	O
American	O
Joint	O
Committee	O
on	O
Cancer	O
v7.0	O
)	O
","	O
and	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
0	O
/	O
1	O
were	O
randomized	O
(	O
01:01	O
)	O
to	O
four	O
cycles	O
of	O
induction	O
Pem+Cb	B-DRUG
(	O
pemetrexed	B-DRUG
","	O
500	O
mg	O
/	O
m	O
","	O
carboplatin	B-DRUG
","	O
area	O
under	O
the	O
curve	O
=	O
6	O
)	O
followed	O
by	O
Pem	B-DRUG
maintenance	O
or	O
Pac+Cb+Bev	B-DRUG
(	O
paclitaxel	B-DRUG
","	O
200	O
mg	O
/	O
m	O
","	O
carboplatin	B-DRUG
","	O
area	O
under	O
the	O
curve	O
=	O
6	O
","	O
and	O
bevacizumab	B-DRUG
","	O
15	O
mg	O
/	O
kg	O
)	O
followed	O
by	O
Bev	B-DRUG
maintenance	O
in	O
the	O
absence	O
of	O
progressive	O
disease	O
or	O
discontinuation	O
.	O
	
The	O
primary	O
objective	O
was	O
progression-free	O
survival	O
(	O
PFS	O
)	O
without	O
grade	O
4	O
toxicity	O
(	O
G4PFS	O
)	O
.	O
	
Secondary	O
end	O
points	O
were	O
PFS	O
","	O
overall	O
survival	O
(	O
OS	O
)	O
","	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
","	O
disease	O
control	O
rate	O
(	O
DCR	O
)	O
","	O
and	O
safety	O
.	O
	
Resource	O
utilization	O
was	O
also	O
assessed	O
.	O
	
Baseline	O
characteristics	O
of	O
the	O
patients	O
randomized	O
to	O
Pem+Cb	B-DRUG
(	O
N	O
=	O
182	O
)	O
and	O
Pac+Cb+Bev	B-DRUG
(	O
N	O
=	O
179	O
)	O
were	O
well	O
balanced	O
between	O
the	O
arms	O
.	O
	
Median	O
(	O
months	O
)	O
G4PFS	O
was	O
3.91	O
for	O
Pem+Cb	B-DRUG
and	O
2.86	O
for	O
Pac+Cb+Bev	B-DRUG
(	O
hazard	O
ratio	O
=	O
0.85	O
","	O
90	O
%	O
confidence	O
interval	O
","	O
0.7-1.04	O
;	O
p	O
=	O
0.176	O
)	O
;	O
PFS	O
","	O
OS	O
","	O
ORR	O
","	O
or	O
DCR	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
arms	O
.	O
	
Significantly	O
more	O
drug-related	O
grade	O
3	O
/	O
4	O
anemia	B-TOXI
(	O
18.7	O
%	O
versus	O
5.4	O
%	O
)	O
and	O
thrombocytopenia	B-TOXI
(	O
24	O
%	O
versus	O
9.6	O
%	O
)	O
were	O
reported	O
for	O
Pem+Cb	B-DRUG
.	O
	
Significantly	O
more	O
grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
(	O
48.8	O
%	O
versus	O
24.6	O
%	O
)	O
","	O
grade	O
1	O
/	O
2	O
alopecia	B-TOXI
(	O
28.3	O
%	O
versus	O
8.2	O
%	O
)	O
","	O
and	O
grade	O
1	O
/	O
2	O
sensory	B-TOXI
neuropathy	I-TOXI
were	O
reported	O
for	O
Pac+Cb+Bev	B-DRUG
.	O
	
Number	O
of	O
hospitalizations	O
and	O
overall	O
length	O
of	O
stay	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
arms	O
.	O
	
Pem+Cb	B-DRUG
did	O
not	O
produce	O
significantly	O
better	O
G4PFS	O
compared	O
with	O
Pac+Cb+Bev	B-DRUG
.	O
	
Pem+Cb	B-DRUG
was	O
not	O
superior	O
in	O
PFS	O
","	O
OS	O
","	O
ORR	O
","	O
or	O
DCR	O
compared	O
with	O
Pac+Cb+Bev	B-DRUG
.	O
	
Both	O
regimens	O
were	O
well	O
tolerated	O
","	O
although	O
","	O
toxicity	O
profiles	O
differed	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
the	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
inhibitor	O
entinostat	B-DRUG
","	O
in	O
combination	O
with	O
sorafenib	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Based	O
on	O
preclinical	O
data	O
demonstrating	O
cytotoxic	O
synergy	O
between	O
sorafenib	B-DRUG
and	O
entinostat	B-DRUG
","	O
a	O
phase	O
I	O
study	O
of	O
this	O
combination	O
was	O
conducted	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Enrollment	O
followed	O
the	O
traditional	O
	O
dose	O
escalation	O
scheme	O
.	O
	
Entinostat	B-DRUG
was	O
given	O
orally	O
once	O
every	O
2	O
weeks	O
","	O
starting	O
at	O
a	O
dose	O
of	O
4	O
mg	O
and	O
escalating	O
to	O
6	O
and	O
10	O
mg	O
every	O
2	O
weeks	O
.	O
	
Sorafenib	B-DRUG
was	O
administered	O
as	O
a	O
continuous	O
oral	O
dose	O
","	O
escalating	O
from	O
200	O
to	O
400	O
mg	O
twice	O
daily	O
.	O
	
A	O
treatment	O
cycle	O
was	O
28	O
days	O
.	O
	
A	O
total	O
of	O
31	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
enrolled	O
on	O
the	O
study	O
.	O
	
The	O
three	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
observed	O
were	O
grade	O
3	O
hand-foot	B-TOXI
syndrome	I-TOXI
","	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
","	O
and	O
fatigue	B-TOXI
.	O
	
MTD	O
was	O
not	O
reached	O
.	O
	
The	O
recommended	O
phase	O
II	O
dose	O
was	O
defined	O
as	O
the	O
full	O
dose	O
of	O
the	O
respective	O
drugs	O
administered	O
individually	O
.	O
	
The	O
most	O
common	O
grade	O
3月4日	O
toxicities	O
were	O
muscle	B-TOXI
weakness	I-TOXI
(	O
13	O
%	O
)	O
","	O
skin	B-TOXI
rash	I-TOXI
(	O
10	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
6	O
%	O
)	O
","	O
diarrhea	B-TOXI
(	O
6	O
%	O
)	O
","	O
and	O
hand-foot	B-TOXI
syndrome	I-TOXI
(	O
3	O
%	O
)	O
.	O
	
One	O
NSCLC	B-CANCER
patient	O
achieved	O
a	O
partial	O
response	O
.	O
	
Two	O
patients	O
(	O
adenocarcinoma	B-CANCER
of	O
GE	O
junction	O
and	O
Hurthle	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	O
the	O
thyroid	O
)	O
were	O
on	O
the	O
study	O
for	O
more	O
than	O
9	O
months	O
with	O
stable	O
disease	O
.	O
	
The	O
combination	O
of	O
entinostat	B-DRUG
and	O
sorafenib	B-DRUG
was	O
well	O
tolerated	O
.	O
	
Entinostat	B-DRUG
10	O
mg	O
orally	O
once	O
every	O
2	O
weeks	O
in	O
combination	O
with	O
sorafenib	B-DRUG
400	O
mg	O
orally	O
twice	O
daily	O
","	O
representing	O
full	O
single	O
agent	O
doses	O
of	O
each	O
drug	O
was	O
identified	O
as	O
the	O
recommended	O
phase	O
2	O
dose	O
(	O
RP2D	O
)	O
.	O
	
These	O
data	O
support	O
future	O
clinical	O
development	O
of	O
the	O
combination	O
of	O
entinostat	B-DRUG
and	O
sorafenib	B-DRUG
.	O
	
Phase	O
I	O
clinical	O
trial	O
of	O
temsirolimus	B-DRUG
and	O
vinorelbine	B-DRUG
in	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
To	O
determine	O
the	O
maximal	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
the	O
combination	O
of	O
weekly	O
temsirolimus	B-DRUG
and	O
every	O
other	O
week	O
vinorelbine	B-DRUG
in	O
patients	O
with	O
advanced	O
or	O
refractory	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Patients	O
were	O
treated	O
with	O
intravenous	O
temsirolimus	B-DRUG
on	O
days	O
1	O
","	O
8	O
","	O
15	O
","	O
and	O
22	O
and	O
intravenous	O
vinorelbine	B-DRUG
on	O
days	O
1	O
and	O
15	O
.	O
	
Cycles	O
were	O
repeated	O
every	O
28	O
days	O
.	O
	
Nineteen	O
patients	O
were	O
enrolled	O
in	O
the	O
study	O
.	O
	
Tumor	O
types	O
included	O
lung	O
(	O
5	O
)	O
","	O
prostate	O
(	O
2	O
)	O
","	O
neuroendocrine	O
of	O
pancreas	O
(	O
1	O
)	O
","	O
bladder	O
(	O
2	O
)	O
","	O
uterus	O
(	O
3	O
)	O
","	O
cervix	O
(	O
4	O
)	O
","	O
and	O
vagina	O
(	O
2	O
)	O
.	O
	
All	O
patients	O
had	O
received	O
prior	O
chemotherapy	O
.	O
	
Four	O
patients	O
were	O
enrolled	O
to	O
dose	O
level	O
I	O
","	O
nine	O
to	O
dose	O
level	O
II	O
","	O
and	O
six	O
to	O
dose	O
level	O
III	O
.	O
	
Six	O
patients	O
were	O
inevaluable	O
and	O
replaced	O
.	O
	
Fifty-seven	O
total	O
cycles	O
were	O
administered	O
.	O
	
There	O
was	O
1	O
dose-limiting	O
toxicity	O
at	O
level	O
II	O
(	O
grade	O
3	O
anorexia	B-TOXI
/	O
dehydration	B-TOXI
)	O
and	O
2	O
at	O
level	O
III	O
(	O
grade	O
3	O
hypokalemia	B-TOXI
;	O
grade	O
4	O
neutropenia	B-TOXI
)	O
.	O
	
Two	O
patients	O
died	O
at	O
dose	O
level	O
III	O
;	O
one	O
was	O
study-related	O
with	O
grade	O
4	O
neutropenia	B-TOXI
.	O
	
Grade	O
3	O
/	O
4	O
toxicities	O
observed	O
during	O
the	O
first	O
cycle	O
included	O
neutropenia	B-TOXI
(	O
2	O
)	O
","	O
anemia	B-TOXI
(	O
1	O
)	O
","	O
anorexia	B-TOXI
(	O
1	O
)	O
","	O
dehydration	B-TOXI
(	O
1	O
)	O
","	O
hyperglycemia	B-TOXI
(	O
1	O
)	O
","	O
hypertriglyceridemia	B-TOXI
(	O
1	O
)	O
","	O
and	O
hypokalemia	B-TOXI
(	O
1	O
)	O
.	O
	
Best	O
response	O
included	O
two	O
patients	O
(	O
prostate	O
and	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
)	O
with	O
partial	O
response	O
and	O
eight	O
patients	O
with	O
stable	O
disease	O
with	O
median	O
duration	O
of	O
best	O
response	O
of	O
3.2	O
months	O
.	O
	
Temsirolimus	B-DRUG
25	O
mg	O
given	O
days	O
1	O
","	O
8	O
","	O
15	O
","	O
and	O
22	O
in	O
combination	O
with	O
vinorelbine	B-DRUG
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
days	O
1	O
and	O
15	O
every	O
4	O
weeks	O
was	O
found	O
to	O
be	O
the	O
MTD	O
.	O
	
This	O
dose	O
combination	O
is	O
considered	O
feasible	O
in	O
phase	O
II	O
trials	O
.	O
	
A	O
phase	O
1b	O
/	O
2	O
study	O
of	O
vosaroxin	B-DRUG
in	O
combination	O
with	O
cytarabine	B-DRUG
in	O
patients	O
with	O
relapsed	O
or	O
refractory	O
acute	B-CANCER
myeloid	I-CANCER
leukemia	I-CANCER
.	O
	
	
Vosaroxin	B-DRUG
is	O
a	O
first-in-class	O
anticancer	O
quinolone	B-DRUG
derivative	O
that	O
intercalates	O
DNA	O
and	O
inhibits	O
topoisomerase	O
II	O
.	O
	
This	O
study	O
assessed	O
the	O
safety	O
and	O
tolerability	O
of	O
vosaroxin	B-DRUG
plus	O
cytarabine	B-DRUG
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
acute	B-CANCER
myeloid	I-CANCER
leukemia	I-CANCER
.	O
	
Escalating	O
vosaroxin	O
doses	O
(	O
10-minute	O
infusion	O
;	O
10-90	O
mg	O
/	O
m	O
(	O
2	O
)	O
;	O
days	O
1	O
","	O
4	O
)	O
were	O
given	O
in	O
combination	O
with	O
cytarabine	O
on	O
one	O
of	O
two	O
schedules	O
:	O
schedule	O
A	O
(	O
24-hour	O
continuous	O
intravenous	O
infusion	O
","	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
","	O
days	O
1月5日	O
)	O
or	O
schedule	O
B	O
(	O
2-hour	O
intravenous	O
infusion	O
","	O
1	O
g	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
","	O
days	O
1月5日	O
)	O
.	O
	
Following	O
dose	O
escalation	O
","	O
enrollment	O
was	O
expanded	O
at	O
the	O
maximum	O
tolerated	O
dose	O
.	O
	
Of	O
110	O
patients	O
enrolled	O
","	O
108	O
received	O
treatment	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
of	O
vosaroxin	B-DRUG
was	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
schedule	O
A	O
(	O
dose-limiting	O
toxicities	O
:	O
grade	O
3	O
bowel	B-TOXI
obstruction	I-TOXI
and	O
stomatitis	B-TOXI
)	O
and	O
was	O
not	O
reached	O
for	O
schedule	O
B	O
(	O
recommended	O
phase	O
2	O
dose	O
:	O
90	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O
	
In	O
the	O
efficacy	O
population	O
(	O
all	O
patients	O
in	O
first	O
relapse	O
or	O
with	O
primary	O
refractory	O
disease	O
treated	O
with	O
vosaroxin	B-DRUG
80-90	O
mg	O
/	O
m	O
(	O
2	O
)	O
;	O
n=69	O
)	O
","	O
the	O
complete	O
remission	O
rate	O
was	O
25	O
%	O
and	O
the	O
complete	O
remission	O
/	O
complete	O
remission	O
with	O
incomplete	O
blood	O
count	O
recovery	O
rate	O
was	O
28	O
%	O
.	O
	
The	O
30-day	O
all-cause	O
mortality	O
rate	O
was	O
2.5	O
%	O
among	O
all	O
patients	O
treated	O
at	O
a	O
dose	O
of	O
80-90	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Based	O
upon	O
these	O
results	O
","	O
a	O
phase	O
3	O
trial	O
of	O
vosaroxin	B-DRUG
plus	O
cytarabine	B-DRUG
was	O
initiated	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
acute	B-CANCER
myeloid	I-CANCER
leukemia	I-CANCER
.	O
	
(	O
Clinicaltrials.gov	O
identifier	O
:	O
NCT00541866	O
)	O
.	O
	
A	O
phase	O
II	O
study	O
of	O
induction	O
chemotherapy	O
followed	O
by	O
thoracic	O
radiotherapy	O
and	O
erlotinib	B-DRUG
in	O
poor-risk	O
stage	O
III	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
results	O
of	O
CALGB	O
30605	O
(	O
Alliance	O
)	O
/	O
RTOG	O
972	O
(	O
NRG	O
)	O
.	O
	
	
Patients	O
with	O
stage	O
III	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
and	O
poor	O
performance	O
status	O
and	O
/	O
or	O
weight	B-TOXI
loss	I-TOXI
do	O
not	O
seem	O
to	O
benefit	O
from	O
standard	O
therapy	O
.	O
	
Based	O
on	O
the	O
preclinical	O
interaction	O
between	O
epidermal	O
growth	O
factor	O
receptor	O
inhibitors	O
and	O
radiation	O
","	O
we	O
designed	O
a	O
trial	O
of	O
induction	O
chemotherapy	O
followed	O
by	O
thoracic	O
radiotherapy	O
and	O
concurrent	O
erlotinib	B-DRUG
.	O
	
Patients	O
with	O
poor-risk	O
unresectable	O
stage	O
III	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
received	O
two	O
cycles	O
of	O
carboplatin	B-DRUG
at	O
an	O
AUC	O
of	O
5	O
and	O
nab-paclitaxel	B-DRUG
at	O
100	O
mg	O
/	O
m	O
on	O
days	O
1	O
and	O
8	O
every	O
21	O
days	O
","	O
followed	O
by	O
erlotinib	B-DRUG
administered	O
concurrently	O
with	O
thoracic	O
radiotherapy	O
.	O
	
Maintenance	O
was	O
not	O
permitted	O
.	O
	
Molecular	O
analysis	O
was	O
performed	O
in	O
available	O
specimens	O
.	O
	
Seventy-two	O
eligible	O
patients	O
were	O
required	O
to	O
test	O
whether	O
the	O
1-year	O
survival	O
rate	O
was	O
less	O
than	O
50	O
%	O
or	O
greater	O
than	O
or	O
equal	O
to	O
65	O
%	O
with	O
approximately	O
90	O
%	O
power	O
at	O
a	O
significance	O
level	O
of	O
0.1	O
.	O
	
From	O
March	O
2008	O
to	O
October	O
2011	O
","	O
78	O
patients	O
were	O
enrolled	O
","	O
three	O
of	O
whom	O
were	O
ineligible	O
.	O
	
The	O
median	O
age	O
was	O
68	O
(	O
range	O
","	O
39-88	O
)	O
and	O
32	O
%	O
were	O
aged	O
greater	O
than	O
or	O
equal	O
to	O
75	O
years	O
.	O
	
Patients	O
were	O
evenly	O
distributed	O
between	O
stages	O
IIIA	O
and	O
IIIB	O
and	O
the	O
majority	O
had	O
performance	O
status	O
2	O
The	O
overall	O
response	O
rate	O
was	O
67	O
%	O
and	O
the	O
disease	O
control	O
rate	O
was	O
93	O
%	O
.	O
	
Treatment	O
was	O
well	O
tolerated	O
.	O
	
The	O
median	O
PFS	O
and	O
OS	O
were	O
11	O
and	O
17	O
months	O
","	O
respectively	O
.	O
	
The	O
overall	O
12-month	O
OS	O
was	O
57	O
%	O
","	O
which	O
narrowly	O
missed	O
the	O
prespecified	O
target	O
for	O
significance	O
.	O
	
Patients	O
with	O
poor-risk	O
stage	O
III	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
had	O
better	O
than	O
expected	O
outcomes	O
with	O
a	O
regimen	O
of	O
induction	O
carboplatin	B-DRUG
/	O
nab-paclitaxel	B-DRUG
followed	O
by	O
thoracic	O
radiotherapy	O
and	O
erlotinib	B-DRUG
.	O
	
However	O
","	O
as	O
per	O
the	O
statistical	O
design	O
","	O
the	O
12-month	O
OS	O
was	O
not	O
sufficiently	O
high	O
to	O
warrant	O
further	O
studies	O
.	O
	
Biweekly	O
cetuximab	B-DRUG
in	O
combination	O
with	O
FOLFOX-4	B-DRUG
in	O
the	O
first-line	O
treatment	O
of	O
wild-type	O
KRAS	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
:	O
final	O
results	O
of	O
a	O
phase	O
II	O
","	O
open-label	O
","	O
clinical	O
trial	O
(	O
OPTIMIX-ACROSS	O
Study	O
)	O
.	O
	
	
This	O
phase	O
II	O
study	O
aims	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
biweekly	O
cetuximab	B-DRUG
in	O
combination	O
with	O
oxaliplatin	B-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
fluorouracil	B-DRUG
(	O
FOLFOX-4	B-DRUG
)	O
as	O
first-line	O
treatment	O
of	O
metastatic	B-CANCER
wild-type	I-CANCER
KRAS	I-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Previously	O
untreated	O
patients	O
with	O
wild-type	B-CANCER
KRAS	I-CANCER
tumours	I-CANCER
received	O
biweekly	O
cetuximab	B-DRUG
(	O
500	O
mg	O
/	O
m2	O
on	O
day	O
1	O
)	O
plus	O
FOLFOX-4	B-DRUG
(	O
oxaliplatin	B-DRUG
85	O
mg	O
/	O
m2	O
on	O
day	O
1	O
","	O
leucovorin	B-DRUG
200	O
mg	O
/	O
m2	O
on	O
days	O
1	O
and	O
2	O
","	O
and	O
fluorouracil	B-DRUG
as	O
a	O
400	O
mg	O
/	O
m2	O
bolus	O
followed	O
by	O
a	O
22-hour	O
600	O
mg	O
/	O
m2	O
infusion	O
on	O
day	O
1	O
and	O
2	O
)	O
.	O
	
Treatment	O
was	O
continued	O
until	O
disease	O
progression	O
","	O
onset	O
of	O
unacceptable	O
toxicities	O
","	O
metastases	O
surgery	O
","	O
or	O
discontinuation	O
request	O
.	O
	
The	O
primary	O
endpoint	O
was	O
ORR	O
.	O
	
The	O
intention-to-treat	O
population	O
included	O
99	O
patients	O
with	O
a	O
median	O
age	O
of	O
64.1	O
years	O
(	O
range	O
","	O
34-82	O
)	O
.	O
	
The	O
ORR	O
was	O
60.6	O
%	O
(	O
95	O
%	O
CI	O
","	O
50.3	O
%	O
to	O
70.3	O
%	O
)	O
.	O
	
The	O
median	O
follow-up	O
was	O
17.8	O
months	O
;	O
the	O
median	O
OS	O
and	O
PFS	O
were	O
20.8	O
and	O
10.1	O
months	O
","	O
respectively	O
.	O
	
Metastases	O
from	O
colorectal	B-CANCER
cancer	I-CANCER
were	O
surgically	O
resected	O
in	O
26	O
(	O
26.3	O
%	O
)	O
patients	O
","	O
with	O
complete	O
resection	O
achieved	O
in	O
18	O
(	O
69.2	O
%	O
)	O
patients	O
.	O
	
Median	O
PFS	O
and	O
OS	O
in	O
patients	O
undergoing	O
metastatic	O
resection	O
were	O
12.6	O
and	O
29.5	O
months	O
","	O
respectively	O
.	O
	
The	O
most	O
common	O
grade	O
3月4日	O
toxicities	O
were	O
neutropenia	B-TOXI
(	O
32.3	O
%	O
)	O
","	O
acne-like	B-TOXI
rash	I-TOXI
(	O
15.2	O
%	O
)	O
and	O
diarrhoea	B-TOXI
(	O
11.1	O
%	O
)	O
.	O
	
The	O
efficacy	O
of	O
the	O
biweekly	O
combination	O
of	O
cetuximab	B-DRUG
with	O
FOLFOX-4	B-DRUG
in	O
patients	O
with	O
wild-type	B-CANCER
KRAS	I-CANCER
tumours	I-CANCER
supports	O
the	O
administration	O
of	O
cetuximab	B-DRUG
in	O
a	O
dosing	O
regimen	O
more	O
convenient	O
for	O
patients	O
and	O
healthcare	O
providers	O
.	O
	
The	O
activity	O
of	O
the	O
biweekly	O
administration	O
is	O
similar	O
to	O
what	O
has	O
been	O
reported	O
for	O
the	O
weekly	O
regimen	O
.	O
	
Reported	O
toxicity	O
was	O
also	O
consistent	O
with	O
the	O
known	O
toxicity	O
profile	O
of	O
weekly	O
cetuximab	B-DRUG
.	O
	
EudraCT	O
Number	O
2.00801E+11	O
.	O
	
Phase	O
I	O
study	O
of	O
the	O
MEK	O
inhibitor	O
trametinib	B-DRUG
in	O
combination	O
with	O
the	O
AKT	O
inhibitor	O
afuresertib	B-DRUG
in	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
and	O
multiple	B-CANCER
myeloma	I-CANCER
.	O
	
	
To	O
identify	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
recommended	O
Phase	O
II	O
dose	O
of	O
MEK	O
/	O
AKT	O
inhibitor	O
combination	O
of	O
trametinib	B-DRUG
and	O
afuresertib	B-DRUG
.	O
	
Eligibility	O
criteria	O
were	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
","	O
18	O
years	O
or	O
older	O
","	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
0	O
or	O
1	O
","	O
and	O
adequate	O
organ	O
function	O
.	O
	
Exclusion	O
criteria	O
included	O
Type	B-TOXI
1	I-TOXI
diabetes	I-TOXI
","	O
active	B-TOXI
GI	I-TOXI
disease	I-TOXI
","	O
leptomeningeal	B-TOXI
disease	I-TOXI
","	O
or	O
current	O
evidence	O
/	O
risk	O
of	O
retinal	B-TOXI
venous	I-TOXI
occlusion	I-TOXI
/	O
central	B-TOXI
serous	I-TOXI
retinopathy	I-TOXI
.	O
	
Clinical	O
safety	O
parameters	O
and	O
response	O
were	O
evaluated	O
and	O
analyzed	O
.	O
	
Twenty	O
patients	O
were	O
enrolled	O
.	O
	
Dose-limiting	O
toxicities	O
(	O
Grade	O
2	O
esophagitis	B-TOXI
;	O
Grade	O
3	O
aspartate	B-TOXI
aminotransferase	I-TOXI
increased	I-TOXI
","	O
mucosal	B-TOXI
inflammation	I-TOXI
and	O
hypokalemia	B-TOXI
)	O
were	O
reported	O
at	O
starting	O
dose	O
(	O
1.5	O
mg	O
trametinib	B-DRUG
/	O
50	O
mg	O
afuresertib	B-DRUG
once	O
daily	O
continuously	O
)	O
","	O
exceeding	O
the	O
MTD	O
.	O
	
Subsequent	O
de-escalation	O
cohorts	O
(	O
1.5	O
mg	O
/	O
25	O
mg	O
or	O
1	O
mg	O
/	O
50	O
mg	O
trametinib	B-DRUG
/	O
afuresertib	B-DRUG
)	O
were	O
defined	O
as	O
MTDs	O
for	O
continuous	O
dosing	O
.	O
	
Intermittent	O
dosing	O
schedule	O
[	O
1.5	O
mg	O
trametinib	B-DRUG
(	O
continuous	O
)	O
/	O
50	O
mg	O
afuresertib	B-DRUG
(	O
Days	O
1月10日	O
every	O
28	O
days	O
)	O
]	O
was	O
evaluated	O
and	O
considered	O
tolerable	O
.	O
	
No	O
patients	O
were	O
enrolled	O
in	O
Phase	O
II	O
.	O
	
The	O
most	O
common	O
adverse	O
events	O
reported	O
(	O
_10	O
%	O
of	O
all	O
patients	O
)	O
included	O
:	O
diarrhea	B-TOXI
(	O
60	O
%	O
)	O
","	O
dermatitis	B-TOXI
acneiform	I-TOXI
(	O
55	O
%	O
)	O
","	O
maculo-papular	B-TOXI
rash	I-TOXI
(	O
45	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
30	O
%	O
)	O
","	O
dry	B-TOXI
skin	I-TOXI
(	O
25	O
%	O
)	O
","	O
nausea	B-TOXI
(	O
25	O
%	O
)	O
","	O
dyspnea	B-TOXI
(	O
20	O
%	O
)	O
","	O
and	O
vomiting	B-TOXI
(	O
20	O
%	O
)	O
.	O
	
One	O
partial	O
response	O
(	O
BRAF	B-CANCER
wild-type	I-CANCER
melanoma	I-CANCER
)	O
was	O
reported	O
;	O
four	O
patients	O
had	O
stable	O
disease	O
as	O
best	O
response	O
.	O
	
Continuous	O
daily	O
dosing	O
of	O
trametinib	B-DRUG
/	O
afuresertib	B-DRUG
combination	O
was	O
poorly	O
tolerated	O
.	O
	
Evaluation	O
of	O
intermittent	O
dose	O
schedule	O
showed	O
greater	O
tolerability	O
.	O
	
Given	O
the	O
interest	O
in	O
combination	O
treatment	O
regimens	O
of	O
MAPK	O
and	O
PI3K	O
/	O
AKT	O
pathway	O
inhibitors	O
","	O
further	O
study	O
of	O
intermittent	O
dose	O
schedule	O
or	O
combination	O
of	O
trametinib	B-DRUG
with	O
more	O
selective	O
inhibitors	O
may	O
be	O
warranted	O
.	O
	
Phase	O
I	O
trial	O
of	O
S-1	B-DRUG
every	O
other	O
day	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
/	O
cisplatin	B-DRUG
for	O
inoperable	O
biliary	B-CANCER
tract	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
date	O
","	O
gemcitabine-based	B-DRUG
or	O
fluoropyrimidine-based	B-DRUG
regimens	O
are	O
recommended	O
for	O
unresectable	O
advanced	B-CANCER
biliary	I-CANCER
tract	I-CANCER
cancer	I-CANCER
.	O
	
Then	O
","	O
we	O
conducted	O
a	O
phase	O
I	O
study	O
of	O
gemcitabine	B-DRUG
/	O
cisplatin	B-DRUG
and	O
S-1	B-DRUG
that	O
is	O
an	O
oral	O
fluoropyrimidine	B-DRUG
.	O
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
","	O
maximum-tolerated	O
dose	O
","	O
and	O
a	O
recommended	O
phase	O
II	O
dose	O
of	O
S-1	B-DRUG
.	O
	
Response	O
was	O
assessed	O
as	O
a	O
secondary	O
endpoint	O
.	O
	
Patients	O
who	O
have	O
been	O
diagnosed	O
with	O
unresectable	O
or	O
postoperative	O
recurrent	O
biliary	B-CANCER
tract	I-CANCER
cancer	I-CANCER
received	O
cisplatin	B-DRUG
(	O
25	O
mg	O
/	O
m虏	O
i.v.	O
for	O
120	O
min	O
)	O
followed	O
by	O
gemcitabine	B-DRUG
(	O
"1,000"	O
mg	O
/	O
m虏	O
i.v.	O
for	O
30	O
min	O
)	O
on	O
days	O
1	O
and	O
8	O
","	O
and	O
oral	O
S-1	O
on	O
alternate	O
days	O
;	O
this	O
regimen	O
was	O
repeated	O
at	O
21-day	O
intervals	O
.	O
	
A	O
standard	O
'3	O
=+	O
3	O
'	O
phase	O
I	O
dose-escalation	O
design	O
was	O
adopted	O
.	O
	
This	O
study	O
was	O
registered	O
with	O
University	O
hospital	O
Medical	O
Information	O
Network	O
(	O
UMIN	O
)	O
Center	O
in	O
Japan	O
","	O
number	O
UMIN000008415	O
.	O
	
Twelve	O
patients	O
were	O
evaluable	O
in	O
this	O
study	O
.	O
	
No	O
patients	O
developed	O
DLTs	O
.	O
	
Recommended	O
dose	O
of	O
S-1	B-DRUG
was	O
80	O
(	O
&	O
lt	O
;	O
1.25	O
m虏	O
)	O
","	O
100	O
(	O
1.25	O
_	O
1.5	O
m虏	O
)	O
","	O
and	O
120	O
mg	O
(	O
1.5	O
m虏_	O
)	O
per	O
day	O
.	O
	
One	O
patient	O
could	O
achieve	O
conversion	O
to	O
curative	O
surgery	O
.	O
	
This	O
phase	O
I	O
study	O
was	O
performed	O
safely	O
and	O
demonstrated	O
encouraging	O
response	O
.	O
	
Intercalated	O
chemotherapy	O
and	O
erlotinib	B-DRUG
for	O
advanced	B-CANCER
NSCLC	I-CANCER
:	O
high	O
proportion	O
of	O
complete	O
remissions	O
and	O
prolonged	O
progression-free	O
survival	O
among	O
patients	O
with	O
EGFR	O
activating	O
mutations	O
.	O
	
	
Pharmaco-dynamic	O
separation	O
of	O
cytotoxic	O
and	O
targeted	O
drugs	O
might	O
avoid	O
their	O
mutual	O
antagonistic	O
effect	O
in	O
the	O
treatment	O
of	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Eligible	O
patients	O
were	O
treatment-naive	O
with	O
stage	O
IIIB	O
or	O
IV	O
NSCLC	B-CANCER
.	O
	
In	O
addition	O
","	O
inclusion	O
was	O
limited	O
to	O
never-smokers	O
or	O
light	O
smokers	O
or	O
","	O
after	O
2010	O
","	O
to	O
patients	O
with	O
activating	O
epidermal	O
growth-factor	O
receptor	O
(	O
EGFR	O
)	O
mutations	O
.	O
	
Treatment	O
started	O
with	O
3-weekly	O
cycles	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
on	O
days	O
1	O
","	O
2	O
and	O
4	O
and	O
erlotinib	B-DRUG
on	O
days	O
5	O
to	O
15	O
.	O
	
After	O
4	O
to	O
6	O
cycles	O
","	O
patients	O
continued	O
with	O
erlotinib	B-DRUG
maintenance	O
.	O
	
Fifty-three	O
patients	O
were	O
recruited	O
into	O
the	O
trial	O
:	O
24	O
prior	O
to	O
2010	O
(	O
of	O
whom	O
9	O
were	O
later	O
found	O
to	O
be	O
positive	O
for	O
EGFR	O
mutations	O
)	O
","	O
and	O
29	O
EGFR	O
mutation-positive	O
patients	O
recruited	O
later	O
.	O
	
Unfavourable	O
prognostic	O
factors	O
included	O
stage	O
IV	O
disease	O
(	O
51	O
patients	O
=-	O
96	O
%	O
)	O
","	O
performance	O
status	O
2月3日	O
(	O
11	O
patients	O
=-	O
21	O
%	O
)	O
and	O
brain	O
metastases	O
(	O
15	O
patients	O
-28	O
%	O
)	O
.	O
	
Grade	O
4	O
toxicity	O
included	O
2	O
cases	O
of	O
neutropenia	B-TOXI
and	O
4	O
thrombo-embolic	B-TOXI
events	I-TOXI
.	O
	
The	O
15	O
EGFR	O
negative	O
patients	O
had	O
33	O
%	O
objective	O
response	O
rate	O
","	O
median	O
progression-free	O
survival	O
(	O
PFS	O
)	O
6	O
months	O
and	O
median	O
survival	O
7.6	O
months	O
.	O
	
Among	O
38	O
EGFR	O
positive	O
patients	O
","	O
complete	O
response	O
(	O
CR	O
)	O
or	O
partial	O
response	O
(	O
PR	O
)	O
were	O
seen	O
in	O
16	O
(	O
42.1	O
%	O
)	O
and	O
17	O
(	O
44.7	O
%	O
)	O
cases	O
","	O
respectively	O
.	O
	
PET-CT	O
scanning	O
was	O
performed	O
in	O
30	O
patients	O
and	O
confirmed	O
CR	O
and	O
PR	O
in	O
16	O
(	O
53.3	O
%	O
)	O
and	O
9	O
(	O
30	O
%	O
)	O
cases	O
","	O
respectively	O
.	O
	
Median	O
PFS	O
for	O
EGFR	O
mutated	O
patients	O
was	O
21.2	O
months	O
and	O
median	O
survival	O
was	O
32.5	O
months	O
.	O
	
While	O
patients	O
with	O
EGFR	O
negative	O
tumors	O
do	O
not	O
benefit	O
from	O
addition	O
of	O
erlotinib	B-DRUG
","	O
the	O
intercalated	O
schedule	O
appears	O
most	O
promising	O
for	O
those	O
with	O
EGFR	O
activating	O
mutations	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
everolimus	B-DRUG
and	O
docetaxel	B-DRUG
in	O
patients	O
with	O
castration-resistant	B-CANCER
prostate	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
PTEN	O
tumor	O
suppressor	O
is	O
frequently	O
lost	O
in	O
CRPC	B-CANCER
","	O
with	O
activation	O
of	O
Akt-mTOR	O
signaling	O
","	O
driving	O
growth	O
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
trial	O
of	O
the	O
mTOR	O
inhibitor	O
","	O
everolimus	B-DRUG
","	O
and	O
docetaxel	B-DRUG
in	O
CRPC	B-CANCER
.	O
	
Eligible	O
patients	O
had	O
progressive	O
","	O
metastatic	O
","	O
chemotherapy-naive	O
CRPC	B-CANCER
.	O
	
Patients	O
received	O
everolimus	B-DRUG
10	O
mg	O
daily	O
for	O
2	O
weeks	O
and	O
underwent	O
a	O
restaging	O
FDG-PET	O
/	O
computed	O
tomography	O
scan	O
.	O
	
Patient	O
cohorts	O
were	O
subsequently	O
treated	O
at	O
3	O
dose	O
levels	O
of	O
everolimus	B-DRUG
with	O
docetaxel	B-DRUG
:	O
5	O
mg	O
to	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
10	O
mg	O
to	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
and	O
10	O
mg	O
to	O
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
the	O
safety	O
and	O
tolerability	O
of	O
combination	O
therapy	O
.	O
	
Accrual	O
was	O
4	O
patients	O
at	O
level	O
1	O
","	O
3	O
patients	O
at	O
level	O
2	O
","	O
and	O
8	O
patients	O
at	O
level	O
3	O
Common	O
toxicities	O
were	O
hematologic	B-TOXI
and	O
fatigue	B-TOXI
.	O
	
Serum	O
concentrations	O
of	O
everolimus	B-DRUG
when	O
administered	O
with	O
docetaxel	B-DRUG
were	O
1.5	O
to	O
14.8	O
ng	O
/	O
mL	O
in	O
patients	O
receiving	O
5	O
mg	O
everolimus	B-DRUG
and	O
4.5	O
to	O
55.4	O
ng	O
/	O
mL	O
in	O
patients	O
receiving	O
10	O
mg	O
everolimus	B-DRUG
.	O
	
Four	O
patients	O
had	O
partial	O
metabolic	O
response	O
(	O
PMR	O
)	O
using	O
FDG-PET	O
","	O
12	O
had	O
stable	O
metabolic	O
disease	O
","	O
and	O
2	O
had	O
progressive	O
metabolic	O
disease	O
after	O
a	O
2-week	O
treatment	O
with	O
everolimus	B-DRUG
alone	O
.	O
	
Five	O
of	O
12	O
evaluable	O
patients	O
experienced	O
a	O
prostate-specific	O
antigen	O
(	O
PSA	O
)	O
reduction	O
_	O
50	O
%	O
during	O
treatment	O
with	O
everolimus	B-DRUG
together	O
with	O
docetaxel	B-DRUG
.	O
	
All	O
4	O
patients	O
with	O
a	O
PMR	O
according	O
to	O
PET	O
imaging	O
experienced	O
a	O
PSA	O
reduction	O
in	O
response	O
to	O
everolimus	B-DRUG
with	O
docetaxel	B-DRUG
","	O
and	O
3	O
of	O
4	O
had	O
PSA	O
declines	O
_	O
50	O
%	O
.	O
	
Everolimus	B-DRUG
10	O
mg	O
daily	O
and	O
docetaxel	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
was	O
safe	O
in	O
CRPC	B-CANCER
patients	O
and	O
these	O
were	O
the	O
recommended	O
doses	O
in	O
combination	O
.	O
	
FDG-PET	O
response	O
might	O
serve	O
as	O
a	O
biomarker	O
for	O
target	O
inhibition	O
by	O
mTOR	O
inhibitors	O
.	O
	
Safety	O
and	O
tolerability	O
of	O
ixazomib	B-DRUG
","	O
an	O
oral	O
proteasome	O
inhibitor	O
","	O
in	O
combination	O
with	O
lenalidomide	B-DRUG
and	O
dexamethasone	B-DRUG
in	O
patients	O
with	O
previously	O
untreated	O
multiple	B-CANCER
myeloma	I-CANCER
:	O
an	O
open-label	O
phase	O
1	O
/	O
2	O
study	O
.	O
	
	
The	O
combination	O
of	O
bortezomib	B-DRUG
","	O
lenalidomide	B-DRUG
","	O
and	O
dexamethasone	B-DRUG
is	O
a	O
highly	O
effective	O
therapy	O
for	O
newly	O
diagnosed	O
multiple	B-CANCER
myeloma	I-CANCER
.	O
	
Ixazomib	B-DRUG
is	O
an	O
investigational	O
","	O
oral	O
","	O
proteasome	O
inhibitor	O
with	O
promising	O
anti-myeloma	O
effects	O
and	O
low	B-TOXI
rates	I-TOXI
of	I-TOXI
peripheral	I-TOXI
neuropathy	I-TOXI
.	O
	
In	O
a	O
phase	O
1	O
/	O
2	O
trial	O
we	O
aimed	O
to	O
assess	O
the	O
safety	O
","	O
tolerability	O
","	O
and	O
activity	O
of	O
ixazomib	B-DRUG
in	O
combination	O
with	O
lenalidomide	B-DRUG
and	O
dexamethasone	B-DRUG
in	O
newly	O
diagnosed	O
multiple	B-CANCER
myeloma	I-CANCER
.	O
	
We	O
enrolled	O
patients	O
newly	O
diagnosed	O
with	O
multiple	B-CANCER
myeloma	I-CANCER
aged	O
18	O
years	O
or	O
older	O
with	O
measurable	O
disease	O
","	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
0-2	O
","	O
and	O
no	O
grade	O
2	O
or	O
higher	B-TOXI
peripheral	I-TOXI
neuropathy	I-TOXI
","	O
and	O
treated	O
them	O
with	O
oral	O
ixazomib	B-DRUG
(	O
days	O
1	O
","	O
8	O
","	O
15	O
)	O
plus	O
lenalidomide	B-DRUG
25	O
mg	O
(	O
days	O
1月21日	O
)	O
and	O
dexamethasone	B-DRUG
40	O
mg	O
(	O
days	O
1	O
","	O
8	O
","	O
15	O
","	O
22	O
)	O
for	O
up	O
to	O
12	O
28-day	O
cycles	O
","	O
followed	O
by	O
maintenance	O
therapy	O
with	O
ixazomib	B-DRUG
alone	O
.	O
	
In	O
phase	O
1	O
","	O
we	O
gave	O
patients	O
escalating	O
doses	O
of	O
ixazomib	B-DRUG
(	O
1路68-3路95	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
to	O
establish	O
the	O
recommended	O
dose	O
for	O
phase	O
2	O
The	O
primary	O
endpoints	O
were	O
maximum	O
tolerated	O
dose	O
for	O
phase	O
1	O
","	O
and	O
the	O
rate	O
of	O
very	O
good	O
partial	O
response	O
or	O
better	O
for	O
phase	O
2	O
Safety	O
analyses	O
were	O
done	O
in	O
all	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
drug	O
;	O
efficacy	O
analyses	O
were	O
done	O
in	O
all	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
drug	O
at	O
the	O
phase	O
2	O
dose	O
","	O
had	O
measurable	O
disease	O
at	O
baseline	O
","	O
and	O
had	O
at	O
least	O
one	O
post-baseline	O
response	O
assessment	O
.	O
	
This	O
study	O
is	O
registered	O
at	O
ClinicalTrials.gov	O
","	O
number	O
NCT01217957	O
.	O
	
Between	O
Nov	O
22	O
","	O
2010	O
","	O
and	O
Feb	O
28	O
","	O
2012	O
","	O
we	O
enrolled	O
65	O
patients	O
(	O
15	O
to	O
phase	O
1	O
and	O
50	O
to	O
phase	O
2	O
)	O
.	O
	
Four	O
dose-limiting	O
toxic	O
events	O
were	O
noted	O
in	O
phase	O
1	O
:	O
one	O
at	O
a	O
dose	O
of	O
ixazomib	B-DRUG
of	O
2路97	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
three	O
at	O
3路95	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
of	O
ixazomib	B-DRUG
was	O
established	O
as	O
2路97	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
the	O
recommended	O
phase	O
2	O
dose	O
was	O
2路23	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
which	O
was	O
converted	O
to	O
a	O
4路0	O
mg	O
fixed	O
dose	O
based	O
on	O
population	O
pharmacokinetic	O
results	O
.	O
	
Grade	O
3	O
or	O
higher	O
adverse	O
events	O
related	O
to	O
any	O
drug	O
were	O
reported	O
in	O
41	O
(	O
63	O
%	O
)	O
patients	O
","	O
including	O
skin	B-TOXI
and	I-TOXI
subcutaneous	I-TOXI
tissue	I-TOXI
disorders	I-TOXI
(	O
11	O
patients	O
","	O
17	O
%	O
)	O
","	O
neutropenia	B-TOXI
(	O
eight	O
patients	O
","	O
12	O
%	O
)	O
","	O
and	O
thrombocytopenia	B-TOXI
(	O
five	O
patients	O
","	O
8	O
%	O
)	O
;	O
drug-related	O
peripheral	B-TOXI
neuropathy	I-TOXI
of	O
grade	O
3	O
or	O
higher	O
occurred	O
in	O
four	O
(	O
6	O
%	O
)	O
patients	O
.	O
	
Five	O
patients	O
discontinued	O
because	O
of	O
adverse	O
events	O
.	O
	
In	O
64	O
response-evaluable	O
patients	O
","	O
37	O
(	O
58	O
%	O
","	O
95	O
%	O
CI	O
45-70	O
)	O
had	O
a	O
very	O
good	O
partial	O
response	O
or	O
better	O
.	O
	
The	O
all-oral	O
combination	O
of	O
weekly	O
ixazomib	B-DRUG
plus	O
lenalidomide	B-DRUG
and	O
dexamethasone	B-DRUG
was	O
generally	O
well	O
tolerated	O
and	O
appeared	O
active	O
in	O
newly	O
diagnosed	O
multiple	B-CANCER
myeloma	I-CANCER
.	O
	
These	O
results	O
support	O
the	O
phase	O
3	O
trial	O
development	O
of	O
this	O
combination	O
for	O
multiple	B-CANCER
myeloma	I-CANCER
.	O
	
Millennium	O
Pharmaceuticals	O
","	O
a	O
wholly	O
owned	O
subsidiary	O
of	O
Takeda	O
Pharmaceutical	O
International	O
Company	O
.	O
	
Phase	O
I	O
trial	O
of	O
sunitinib	B-DRUG
and	O
temsirolimus	B-DRUG
in	O
metastatic	B-CANCER
renal	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
	
Preclinical	O
data	O
suggest	O
that	O
anti-vascular	O
endothelial	O
growth	O
factor	O
agents	O
combined	O
with	O
mammalian	O
target	O
of	O
rapamycin	O
inhibitors	O
yield	O
synergistic	O
antitumor	O
effects	O
.	O
	
A	O
phase	O
I	O
trial	O
with	O
a	O
3+3	O
dose	O
escalation	O
design	O
of	O
S	O
with	O
T	O
was	O
stopped	O
after	O
the	O
first	O
dose	O
pair	O
led	O
to	O
2	O
of	O
3	O
patients	O
experiencing	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
.	O
	
To	O
explore	O
multiple	O
potential	O
dosing	O
pairs	O
of	O
S	O
and	O
T	O
","	O
a	O
2-stage	O
outcome-adaptive	O
Bayesian	O
dose-finding	O
method	O
was	O
designed	O
.	O
	
The	O
primary	O
objective	O
was	O
to	O
find	O
the	O
MTD	O
of	O
S	O
and	O
T	O
in	O
patients	O
with	O
advanced	B-CANCER
renal	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
A	O
3-week	O
treatment	O
cycle	O
consisted	O
of	O
daily	O
S	O
","	O
2	O
weeks	O
of	O
treatment	O
","	O
1	O
week	O
without	O
treatment	O
","	O
and	O
weekly	O
T.	O
Twenty	O
patients	O
received	O
study	O
drugs	O
;	O
the	O
median	O
number	O
of	O
previous	O
therapies	O
was	O
1	O
The	O
number	O
of	O
patients	O
(	O
S	O
and	O
T	O
doses	O
in	O
mg	O
)	O
was	O
:	O
2	O
(	O
S	O
","	O
12.5	O
;	O
T	O
","	O
6	O
)	O
","	O
1	O
(	O
S	O
","	O
25	O
;	O
T	O
","	O
12.5	O
)	O
","	O
1	O
(	O
S	O
","	O
12.5	O
;	O
T	O
","	O
8	O
)	O
","	O
8	O
(	O
S	O
","	O
12.5	O
alternate	O
25	O
;	O
T	O
","	O
9	O
)	O
","	O
2	O
(	O
S	O
","	O
25	O
;	O
T	O
","	O
6	O
)	O
","	O
2	O
(	O
S	O
","	O
25	O
alternate	O
37.5	O
;	O
T	O
","	O
6	O
)	O
","	O
2	O
(	O
S	O
","	O
37.5	O
;	O
T	O
","	O
6	O
)	O
","	O
and	O
2	O
(	O
S	O
","	O
37.5	O
;	O
T	O
","	O
8	O
)	O
.	O
	
Six	O
patients	O
required	O
dose	O
reduction	O
","	O
3	O
because	O
of	O
Grade	O
3	O
stomatitis	B-TOXI
","	O
2	O
because	O
of	O
Grade	O
3	O
thrombocytopenia	B-TOXI
;	O
the	O
mean	O
number	O
of	O
cycles	O
was	O
6.6	O
卤	O
5.3	O
","	O
the	O
mean	O
time	O
during	O
study	O
was	O
159	O
卤	O
120	O
days	O
.	O
	
One	O
patient	O
experienced	O
a	O
DLT	O
in	O
cycle	O
1	O
and	O
was	O
nonevaluable	O
","	O
1	O
had	O
a	O
partial	O
response	O
","	O
16	O
had	O
stable	O
disease	O
","	O
and	O
2	O
had	O
progressive	O
disease	O
as	O
best	O
response	O
.	O
	
There	O
were	O
21	O
Grade	O
3	O
/	O
4	O
adverse	O
events	O
but	O
no	O
treatment-related	O
deaths	B-TOXI
.	O
	
The	O
MTD	O
of	O
S	O
and	O
T	O
were	O
not	O
determined	O
because	O
of	O
premature	O
trial	O
closure	O
.	O
	
S	O
37.5	O
mg	O
/	O
d	O
","	O
2	O
weeks	O
of	O
treatment	O
","	O
1	O
week	O
with	O
no	O
treatment	O
","	O
and	O
T	O
8	O
mg	O
to	O
10	O
mg	O
weekly	O
are	O
close	O
to	O
the	O
MTD	O
.	O
	
Neoadjuvant	O
treatment	O
with	O
docetaxel	B-DRUG
plus	O
lapatinib	B-DRUG
","	O
trastuzumab	B-DRUG
","	O
or	O
both	O
followed	O
by	O
an	O
anthracycline-based	B-DRUG
chemotherapy	O
in	O
HER2-positive	O
breast	B-CANCER
cancer	I-CANCER
:	O
results	O
of	O
the	O
randomised	O
phase	O
II	O
EORTC	O
10054	O
study	O
.	O
	
	
Neoadjuvant	O
trials	O
conducted	O
using	O
a	O
double	O
HER2	O
blockade	O
with	O
lapatinib	B-DRUG
and	O
trastuzumab	B-DRUG
","	O
combined	O
with	O
different	O
paclitaxel-containing	B-DRUG
chemotherapy	O
regimens	O
","	O
have	O
shown	O
high	O
pathological	O
complete	O
response	O
(	O
pCR	O
)	O
rates	O
","	O
but	O
at	O
the	O
cost	O
of	O
important	O
toxicity	O
.	O
	
We	O
hypothesised	O
that	O
this	O
toxicity	O
might	O
be	O
due	O
to	O
a	O
specific	O
interaction	O
between	O
paclitaxel	B-DRUG
and	O
lapatinib	B-DRUG
.	O
	
This	O
trial	O
assesses	O
the	O
toxicity	O
and	O
activity	O
of	O
the	O
combination	O
of	O
docetaxel	B-DRUG
with	O
lapatinib	B-DRUG
and	O
trastuzumab	B-DRUG
.	O
	
Patients	O
with	O
stage	O
IIA	O
to	O
IIIC	O
HER2-positive	O
breast	B-CANCER
cancer	I-CANCER
received	O
six	O
cycles	O
of	O
chemotherapy	O
(	O
three	O
cycles	O
of	O
docetaxel	B-DRUG
followed	O
by	O
three	O
cycles	O
of	O
fluorouracil	B-DRUG
","	O
epirubicin	B-DRUG
","	O
cyclophosphamide	B-DRUG
)	O
.	O
	
They	O
were	O
randomised	O
1	O
:	O
1	O
:	O
1	O
to	O
receive	O
during	O
the	O
first	O
three	O
cycles	O
either	O
lapatinib	B-DRUG
(	O
1000	O
mg	O
orally	O
daily	O
)	O
","	O
trastuzumab	B-DRUG
(	O
4	O
mg	O
/	O
kg	O
loading	O
dose	O
followed	O
by	O
2	O
mg	O
/	O
kg	O
weekly	O
)	O
","	O
or	O
trastuzumab	B-DRUG
=+	O
lapatinib	B-DRUG
at	O
the	O
same	O
dose	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
pCR	O
rate	O
defined	O
as	O
ypT0	O
/	O
is.	O
Secondary	O
end	O
points	O
included	O
safety	O
and	O
toxicity	O
.	O
	
pCR	O
rate	O
defined	O
as	O
ypT0	O
/	O
is	O
ypN0	O
was	O
assessed	O
as	O
an	O
exploratory	O
analysis	O
.	O
	
In	O
June	O
2012	O
","	O
arm	O
A	O
was	O
closed	O
for	O
futility	O
based	O
on	O
the	O
results	O
from	O
other	O
studies	O
.	O
	
From	O
October	O
2010	O
to	O
January	O
2013	O
","	O
128	O
patients	O
were	O
included	O
in	O
14	O
centres	O
.	O
	
The	O
percentage	O
of	O
the	O
122	O
assessable	O
patients	O
with	O
pCR	O
in	O
the	O
breast	O
","	O
and	O
pCR	O
in	O
the	O
breast	O
and	O
nodes	O
","	O
was	O
numerically	O
highest	O
in	O
the	O
lapatinib	B-DRUG
=+	O
trastuzumab	B-DRUG
group	O
(	O
60	O
%	O
and	O
56	O
%	O
","	O
respectively	O
)	O
","	O
intermediate	O
in	O
the	O
trastuzumab	B-DRUG
group	O
(	O
52	O
%	O
and	O
52	O
%	O
)	O
","	O
and	O
lowest	O
in	O
the	O
lapatinib	B-DRUG
group	O
(	O
46	O
%	O
and	O
36	O
%	O
)	O
.	O
	
Frequency	O
(	O
%	O
)	O
of	O
the	O
most	O
common	O
grade	O
3月4日	O
toxicities	O
in	O
the	O
lapatinib	B-DRUG
/	O
trastuzumab	B-DRUG
/	O
lapatinib	B-DRUG
=+	O
trastuzumab	B-DRUG
arms	O
were	O
:	O
febrile	B-TOXI
neutropenia	I-TOXI
23	O
/	O
15	O
/	O
10	O
","	O
diarrhoea	B-TOXI
9	O
/	O
2	O
/	O
18	O
","	O
infection	B-TOXI
(	O
other	O
)	O
9	O
/	O
4	O
/	O
8	O
","	O
and	O
hepatic	B-TOXI
toxicity	I-TOXI
0	O
/	O
2	O
/	O
8	O
This	O
study	O
demonstrates	O
a	O
numerically	O
modest	O
pCR	O
rate	O
increase	O
with	O
double	O
anti-HER2	O
blockade	O
plus	O
chemotherapy	O
","	O
but	O
suggests	O
that	O
the	O
use	O
of	O
docetaxel	B-DRUG
rather	O
than	O
paclitaxel	B-DRUG
may	O
not	O
reduce	O
toxicity	O
.	O
	
NCT00450892	O
.	O
	
A	O
phase	O
I	O
and	O
pharmacodynamic	O
study	O
of	O
the	O
histone	O
deacetylase	O
inhibitor	O
belinostat	B-DRUG
plus	O
azacitidine	B-DRUG
in	O
advanced	B-CANCER
myeloid	I-CANCER
neoplasia	I-CANCER
.	O
	
	
Background	O
We	O
hypothesized	O
that	O
targeting	O
two	O
mechanisms	O
of	O
epigenetic	O
silencing	O
would	O
be	O
additive	O
or	O
synergistic	O
with	O
regard	O
to	O
expression	O
of	O
specific	O
target	O
genes	O
.	O
	
The	O
primary	O
objective	O
of	O
the	O
study	O
was	O
to	O
establish	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
belinostat	B-DRUG
in	O
combination	O
with	O
a	O
fixed	O
dose	O
of	O
azacitidine	B-DRUG
(	O
AZA	B-DRUG
)	O
.	O
	
Methods	O
In	O
Part	O
A	O
of	O
the	O
study	O
","	O
patients	O
received	O
a	O
fixed	O
dose	O
of	O
AZA	B-DRUG
","	O
with	O
escalating	O
doses	O
of	O
belinostat	B-DRUG
given	O
on	O
the	O
same	O
days	O
1月5日	O
","	O
in	O
a	O
28	O
day	O
cycle	O
.	O
	
Part	O
B	O
was	O
designed	O
to	O
evaluate	O
the	O
relative	O
contribution	O
of	O
belinostat	B-DRUG
to	O
the	O
combination	O
based	O
on	O
analysis	O
of	O
pharmacodynamic	O
markers	O
","	O
and	O
incorporated	O
a	O
design	O
in	O
which	O
patients	O
were	O
randomized	O
during	O
cycle	O
1	O
to	O
AZA	B-DRUG
alone	O
","	O
or	O
the	O
combination	O
","	O
at	O
the	O
maximally	O
tolerated	O
dose	O
of	O
belinostat	B-DRUG
.	O
	
Results	O
56	O
patients	O
with	O
myeloid	B-CANCER
neoplasia	I-CANCER
were	O
enrolled	O
.	O
	
Dose	O
escalation	O
was	O
feasible	O
in	O
part	O
A	O
","	O
up	O
to	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
dose	O
level	O
of	O
belinostat	B-DRUG
.	O
	
In	O
Part	O
B	O
","	O
18	O
patients	O
were	O
assessable	O
for	O
quantitative	O
analysis	O
of	O
specific	O
target	O
genes	O
.	O
	
At	O
day	O
5	O
of	O
therapy	O
","	O
MDR1	O
was	O
significantly	O
up-regulated	O
in	O
the	O
belinostat	B-DRUG
/	O
AZA	B-DRUG
arm	O
compared	O
with	O
AZA	B-DRUG
alone	O
arm	O
(	O
p	O
=	O
0.0023	O
)	O
.	O
	
There	O
were	O
18	O
responses	O
among	O
the	O
56	O
patients	O
.	O
	
Conclusions	O
The	O
combination	O
of	O
belinostat	B-DRUG
and	O
AZA	B-DRUG
is	O
feasible	O
and	O
associated	O
with	O
clinical	O
activity	O
.	O
	
The	O
recommended	O
phase	O
II	O
dose	O
is	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
belinostat	B-DRUG
plus	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
AZA	B-DRUG
on	O
days	O
1月5日	O
","	O
every	O
28	O
days	O
.	O
	
Upregulation	O
in	O
MDR1	O
was	O
observed	O
in	O
the	O
combination	O
arm	O
at	O
day	O
5	O
compared	O
with	O
the	O
AZA	B-DRUG
alone	O
arm	O
","	O
suggesting	O
a	O
relative	O
biologic	O
contribution	O
of	O
belinostat	B-DRUG
to	O
the	O
combination	O
.	O
	
Multicenter	O
Phase	O
II	O
Trial	O
of	O
Temsirolimus	B-DRUG
and	O
Bevacizumab	B-DRUG
in	O
Pancreatic	B-CANCER
Neuroendocrine	I-CANCER
Tumors	I-CANCER
.	O
	
	
There	O
are	O
few	O
effective	O
therapies	O
for	O
pancreatic	B-CANCER
neuroendocrine	I-CANCER
tumors	I-CANCER
(	O
PNETs	B-CANCER
)	O
.	O
	
Recent	O
placebo-controlled	B-DRUG
phase	O
III	O
trials	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
inhibitor	O
everolimus	B-DRUG
and	O
the	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
/	O
platelet-derived	O
growth	O
factor	O
receptor	O
inhibitor	O
sunitinib	B-DRUG
have	O
noted	O
improved	O
progression-free	O
survival	O
(	O
PFS	O
)	O
.	O
	
Preclinical	O
studies	O
have	O
suggested	O
enhanced	O
antitumor	O
effects	O
with	O
combined	O
mTOR	O
and	O
VEGF	O
pathway-targeted	O
therapy	O
.	O
	
We	O
conducted	O
a	O
clinical	O
trial	O
to	O
evaluate	O
combination	O
therapy	O
against	O
these	O
targets	O
in	O
PNETs	B-CANCER
.	O
	
We	O
conducted	O
a	O
two-stage	O
single-arm	O
phase	O
II	O
trial	O
of	O
the	O
mTOR	O
inhibitor	O
temsirolimus	B-DRUG
25	O
mg	O
intravenously	O
(	O
IV	O
)	O
once	O
per	O
week	O
and	O
the	O
VEGF-A	O
monoclonal	O
antibody	O
bevacizumab	B-DRUG
10	O
mg	O
/	O
kg	O
IV	O
once	O
every	O
2	O
weeks	O
in	O
patients	O
with	O
well	O
or	O
moderately	O
differentiated	O
PNETs	O
and	O
progressive	O
disease	O
by	O
RECIST	O
within	O
7	O
months	O
of	O
study	O
entry	O
.	O
	
Coprimary	O
end	O
points	O
were	O
tumor	O
response	O
rate	O
and	O
6-month	O
PFS	O
.	O
	
A	O
total	O
of	O
58	O
patients	O
were	O
enrolled	O
","	O
and	O
56	O
patients	O
were	O
eligible	O
for	O
response	O
assessment	O
.	O
	
Confirmed	O
response	O
rate	O
(	O
RR	O
)	O
was	O
41	O
%	O
(	O
23	O
of	O
56	O
patients	O
)	O
.	O
	
PFS	O
at	O
6	O
months	O
was	O
79	O
%	O
(	O
44	O
of	O
56	O
)	O
.	O
	
Median	O
PFS	O
was	O
13.2	O
months	O
(	O
95	O
%	O
CI	O
","	O
11.2	O
to	O
16.6	O
)	O
.	O
	
Median	O
overall	O
survival	O
was	O
34	O
months	O
(	O
95	O
%	O
CI	O
","	O
27.1	O
to	O
not	O
reached	O
)	O
.	O
	
For	O
evaluable	O
patients	O
","	O
the	O
most	O
common	O
grade	O
3	O
to	O
4	O
adverse	O
events	O
attributed	O
to	O
therapy	O
were	O
hypertension	B-TOXI
(	O
21	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
16	O
%	O
)	O
","	O
lymphopenia	B-TOXI
(	O
14	O
%	O
)	O
","	O
and	O
hyperglycemia	B-TOXI
(	O
14	O
%	O
)	O
.	O
	
The	O
combination	O
of	O
temsirolimus	B-DRUG
and	O
bevacizumab	B-DRUG
had	O
substantial	O
activity	O
and	O
reasonable	O
tolerability	O
in	O
a	O
multicenter	O
phase	O
II	O
trial	O
","	O
with	O
RR	O
of	O
41	O
%	O
","	O
well	O
in	O
excess	O
of	O
single	O
targeted	O
agents	O
in	O
patients	O
with	O
progressive	O
PNETs	B-CANCER
.	O
	
Six-month	O
PFS	O
was	O
a	O
notable	O
79	O
%	O
in	O
a	O
population	O
of	O
patients	O
with	O
disease	O
progression	O
by	O
RECIST	O
criteria	O
within	O
7	O
months	O
of	O
study	O
entry	O
.	O
	
On	O
the	O
basis	O
of	O
this	O
trial	O
","	O
continued	O
evaluation	O
of	O
combination	O
mTOR	O
and	O
VEGF	O
pathway	O
inhibitors	O
is	O
warranted	O
.	O
	
A	O
phase	O
Ib	O
dose-escalation	O
study	O
of	O
the	O
oral	O
pan-PI3K	O
inhibitor	O
buparlisib	B-DRUG
(	O
BKM120	B-DRUG
)	O
in	O
combination	O
with	O
the	O
oral	O
MEK1	O
/	O
2	O
inhibitor	O
trametinib	B-DRUG
(	O
GSK1120212	B-DRUG
)	O
in	O
patients	O
with	O
selected	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
MAPK	O
and	O
PI3K	O
/	O
AKT	O
/	O
mTOR	O
pathways	O
play	O
important	O
roles	O
in	O
many	O
tumors	O
.	O
	
In	O
this	O
study	O
","	O
safety	O
","	O
antitumor	O
activity	O
","	O
and	O
pharmacokinetics	O
of	O
buparlisib	B-DRUG
(	O
pan	O
class	O
PI3K	O
inhibitor	O
)	O
and	O
trametinib	B-DRUG
(	O
MEK	O
inhibitor	O
)	O
were	O
evaluated	O
.	O
	
This	O
open-label	O
","	O
dose-finding	O
","	O
phase	O
Ib	O
study	O
comprised	O
dose	O
escalation	O
","	O
followed	O
by	O
expansion	O
part	O
in	O
patients	O
with	O
RAS-	O
or	O
BRAF-mutant	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
","	O
ovarian	O
","	O
or	O
pancreatic	B-CANCER
cancer	I-CANCER
.	O
	
Of	O
note	O
","	O
113	O
patients	O
were	O
enrolled	O
","	O
66	O
and	O
47	O
in	O
dose-escalation	O
and	O
#NAME?	O
parts	O
","	O
respectively	O
.	O
	
MTD	O
was	O
established	O
as	O
buparlisib	B-DRUG
70	O
mg	O
=+	O
trametinib	B-DRUG
1.5	O
mg	O
daily	O
[	O
5	O
/	O
15	O
","	O
33	O
%	O
patients	O
with	O
dose-limiting	O
toxicities	O
(	O
DLT	O
)	O
]	O
and	O
recommended	O
phase	O
II	O
dose	O
(	O
RP2D	O
)	O
buparlisib	B-DRUG
60	O
mg	O
=+	O
trametinib	B-DRUG
1.5	O
mg	O
daily	O
(	O
1	O
/	O
10	O
","	O
10	O
%	O
patients	O
with	O
DLTs	O
)	O
.	O
	
DLTs	O
included	O
stomatitis	B-TOXI
(	O
8	O
/	O
103	O
","	O
8	O
%	O
)	O
","	O
diarrhea	B-TOXI
","	O
dysphagia	B-TOXI
","	O
and	O
creatine	B-TOXI
kinase	I-TOXI
(	I-TOXI
CK	I-TOXI
)	I-TOXI
increase	I-TOXI
(	O
2	O
/	O
103	O
","	O
2	O
%	O
each	O
)	O
.	O
	
Treatment-related	O
grade	O
3	O
/	O
4	O
adverse	O
events	O
(	O
AEs	O
)	O
occurred	O
in	O
73	O
patients	O
(	O
65	O
%	O
)	O
;	O
mainly	O
CK	B-TOXI
increase	I-TOXI
","	O
stomatitis	B-TOXI
","	O
AST	B-TOXI
/	I-TOXI
ALT	I-TOXI
(	I-TOXI
aspartate	I-TOXI
aminotransferase	I-TOXI
/	I-TOXI
alanine	I-TOXI
aminotransferase	I-TOXI
)	I-TOXI
increase	I-TOXI
","	O
and	O
rash	B-TOXI
.	O
	
For	O
all	O
(	O
21	O
)	O
patients	O
with	O
ovarian	B-CANCER
cancer	I-CANCER
","	O
overall	O
response	O
rate	O
was	O
29	O
%	O
[	O
1	O
complete	O
response	O
","	O
5	O
partial	O
responses	O
(	O
PR	O
)	O
]	O
","	O
disease	O
control	O
rate	O
76	O
%	O
","	O
and	O
median	O
progression-free	O
survival	O
was	O
7	O
months	O
.	O
	
Minimal	O
activity	O
was	O
observed	O
in	O
patients	O
with	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
1	O
/	O
17	O
PR	O
)	O
and	O
pancreatic	B-CANCER
cancer	I-CANCER
(	O
best	O
overall	O
response	O
was	O
SD	O
)	O
.	O
	
Relative	O
to	O
historical	O
data	O
","	O
buparlisib	B-DRUG
exposure	O
increased	O
and	O
trametinib	B-DRUG
exposure	O
slightly	O
increased	O
with	O
the	O
combination	O
.	O
	
At	O
RP2D	O
","	O
buparlisib	B-DRUG
60	O
mg	O
=+	O
trametinib	B-DRUG
1.5	O
mg	O
daily	O
shows	O
promising	O
antitumor	O
activity	O
for	O
patients	O
with	O
KRAS-mutant	O
ovarian	B-CANCER
cancer	I-CANCER
.	O
	
Long-term	O
tolerability	O
of	O
the	O
combination	O
at	O
RP2D	O
is	O
challenging	O
","	O
due	O
to	O
frequent	O
dose	O
interruptions	O
and	O
reductions	O
for	O
toxicity	O
.	O
	
Concurrent	O
IMRT	O
and	O
weekly	O
cisplatin	B-DRUG
followed	O
by	O
GDP	O
chemotherapy	O
in	O
newly	O
diagnosed	O
","	O
stage	O
IE	O
to	O
IIE	O
","	O
nasal	O
","	O
extranodal	B-CANCER
NK	I-CANCER
/	I-CANCER
T-Cell	I-CANCER
lymphoma	I-CANCER
.	O
	
	
On	O
the	O
basis	O
of	O
the	O
benefits	O
of	O
frontline	O
radiation	O
in	O
early-stage	O
","	O
extranodal	B-CANCER
natural	I-CANCER
killer	I-CANCER
(	I-CANCER
NK	I-CANCER
)	I-CANCER
/	I-CANCER
T-cell	I-CANCER
lymphoma	I-CANCER
(	O
ENKTL	B-CANCER
)	O
","	O
we	O
conducted	O
the	O
trial	O
of	O
concurrent	O
chemoradiotherapy	O
(	O
CCRT	O
)	O
followed	O
by	O
three	O
cycles	O
of	O
gemcitabine	B-DRUG
","	O
dexamethasone	B-DRUG
and	O
cisplatin	B-DRUG
(	O
GDP	B-DRUG
)	O
.	O
	
Thirty-two	O
patients	O
with	O
newly	O
diagnosed	O
","	O
stage	O
IE	O
to	O
IIE	O
","	O
nasal	O
ENKTL	B-CANCER
received	O
CCRT	O
(	O
that	O
is	O
","	O
all	O
patients	O
received	O
intensity-modulated	O
radiotherapy	O
56	O
Gy	O
and	O
cisplatin	B-DRUG
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
","	O
3月5日	O
weeks	O
)	O
.	O
	
Three	O
cycles	O
of	O
GDP	B-DRUG
(	O
gemcitabine	B-DRUG
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
intravenously	O
(	O
i.v.	O
)	O
on	O
days	O
1	O
and	O
8	O
","	O
dexamethasone	B-DRUG
40	O
mg	O
orally	O
on	O
days	O
1月4日	O
and	O
cisplatin	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
i.v.	O
on	O
day	O
1	O
(	O
GDP	O
)	O
","	O
every	O
21	O
days	O
as	O
an	O
outpatient	O
were	O
scheduled	O
after	O
CCRT	O
.	O
	
All	O
patients	O
completed	O
CCRT	O
","	O
which	O
resulted	O
in	O
100	O
%	O
response	O
that	O
included	O
24	O
complete	O
responses	O
(	O
CRs	O
)	O
and	O
eight	O
partial	O
responses	O
.	O
	
The	O
CR	O
rate	O
after	O
CCRT	O
was	O
75	O
%	O
(	O
that	O
is	O
","	O
24	O
of	O
32	O
responses	O
)	O
.	O
	
Twenty-eight	O
of	O
the	O
32	O
patients	O
completed	O
the	O
planned	O
three	O
cycles	O
of	O
GDP	B-DRUG
","	O
whereas	O
four	O
patients	O
did	O
not	O
because	O
they	O
withdrew	O
(	O
n	O
=	O
1	O
)	O
or	O
because	O
they	O
had	O
an	O
infection	O
(	O
n	O
=	O
3	O
)	O
.	O
	
The	O
overall	O
response	O
rate	O
and	O
the	O
CR	O
rate	O
were	O
90.6	O
%	O
(	O
that	O
is	O
","	O
29	O
of	O
32	O
responses	O
)	O
and	O
84.4	O
%	O
(	O
that	O
is	O
","	O
27	O
of	O
32	O
responses	O
)	O
","	O
respectively	O
.	O
	
Only	O
two	O
patient	O
experienced	O
grade	O
3	O
toxicity	O
during	O
CCRT	O
(	O
nausea	B-TOXI
)	O
","	O
whereas	O
13	O
of	O
the	O
30	O
patients	O
experienced	O
grade	O
4	O
neutropenia	B-TOXI
.	O
	
The	O
estimated	O
3-year	O
overall	O
survival	O
and	O
progression-free	O
rates	O
were	O
87.5	O
%	O
and	O
84.38	O
%	O
","	O
respectively	O
.	O
	
In	O
conclusion	O
","	O
CCRT	O
followed	O
by	O
GDP	B-DRUG
chemotherapy	O
can	O
be	O
a	O
feasible	O
and	O
effective	O
treatment	O
strategy	O
for	O
stage	O
IE	O
to	O
IIE	O
nasal	O
ENKTL	B-CANCER
.	O
	
Radicals	O
involved	O
in	O
photoallergen	O
/	O
protein	O
interactions	O
.	O
	
	
Aqueous	O
solutions	O
(	O
pH	O
=	O
8	O
)	O
of	O
both	O
"3,3'-dimethyl"	O
and	O
"4,4'-dimethyl"	O
substituted	O
analogues	O
of	O
the	O
photoallergen	O
fentichlor	B-DRUG
(	O
bis	O
(	O
2-hydroxy-5-chlorophenyl	O
)	O
sulphide	O
)	O
produced	O
stable	O
semiquinone	O
radicals	O
when	O
irradiated	O
with	O
u.v.	O
light	O
(	O
greater	O
than	O
310	O
nm	O
)	O
.	O
	
These	O
radicals	O
have	O
been	O
characterised	O
using	O
electron	O
spin	O
resonance	O
techniques	O
:	O
the	O
results	O
confirm	O
the	O
assignment	O
of	O
hyperfine	O
coupling	O
constants	O
for	O
the	O
parent	O
fentichlor	B-DRUG
radical	O
.	O
	
The	O
binding	O
of	O
fentichlor	B-DRUG
to	O
HSA	O
was	O
found	O
to	O
be	O
partly	O
oxygen	O
dependent	O
demonstrating	O
a	O
role	O
for	O
semiquinone	O
type	O
radicals	O
in	O
the	O
binding	O
mechanism	O
.	O
	
The	O
stoichiometry	O
and	O
specificity	O
of	O
the	O
binding	O
of	O
the	O
dimethyl	O
analogues	O
to	O
soluble	O
proteins	O
were	O
found	O
to	O
be	O
similar	O
to	O
that	O
of	O
fentichlor	B-DRUG
itself	O
.	O
	
The	O
cyclin-dependent	O
kinase	O
4	O
/	O
6	O
inhibitor	O
palbociclib	B-DRUG
in	O
combination	O
with	O
letrozole	B-DRUG
versus	O
letrozole	B-DRUG
alone	O
as	O
first-line	O
treatment	O
of	O
oestrogen	O
receptor-positive	O
","	O
HER2-negative	O
","	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
PALOMA-1	O
/	O
TRIO-18	O
)	O
:	O
a	O
randomised	O
phase	O
2	O
study	O
.	O
	
	
Palbociclib	B-DRUG
(	O
PD-0332991	B-DRUG
)	O
is	O
an	O
oral	O
","	O
small-molecule	O
inhibitor	O
of	O
cyclin-dependent	O
kinases	O
(	O
CDKs	O
)	O
4	O
and	O
6	O
with	O
preclinical	O
evidence	O
of	O
growth-inhibitory	O
activity	O
in	O
oestrogen	O
receptor-positive	O
breast	B-CANCER
cancer	I-CANCER
cells	O
and	O
synergy	O
with	O
anti-oestrogens	O
.	O
	
We	O
aimed	O
to	O
assess	O
the	O
safety	O
and	O
efficacy	O
of	O
palbociclib	B-DRUG
in	O
combination	O
with	O
letrozole	B-DRUG
as	O
first-line	O
treatment	O
of	O
patients	O
with	O
advanced	O
","	O
oestrogen	O
receptor-positive	O
","	O
HER2-negative	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
In	O
this	O
open-label	O
","	O
randomised	O
phase	O
2	O
study	O
","	O
postmenopausal	O
women	O
with	O
advanced	O
oestrogen	O
receptor-positive	O
and	O
HER2-negative	O
breast	B-CANCER
cancer	I-CANCER
who	O
had	O
not	O
received	O
any	O
systemic	O
treatment	O
for	O
their	O
advanced	O
disease	O
were	O
eligible	O
to	O
participate	O
.	O
	
Patients	O
were	O
enrolled	O
in	O
two	O
separate	O
cohorts	O
that	O
accrued	O
sequentially	O
:	O
in	O
cohort	O
1	O
","	O
patients	O
were	O
enrolled	O
on	O
the	O
basis	O
of	O
their	O
oestrogen	O
receptor-positive	O
and	O
HER2-negative	O
biomarker	O
status	O
alone	O
","	O
whereas	O
in	O
cohort	O
2	O
they	O
were	O
also	O
required	O
to	O
have	O
cancers	O
with	O
amplification	O
of	O
cyclin	O
D1	O
(	O
CCND1	O
)	O
","	O
loss	O
of	O
p16	O
(	O
INK4A	O
or	O
CDKN2A	O
)	O
","	O
or	O
both	O
.	O
	
In	O
both	O
cohorts	O
","	O
patients	O
were	O
randomly	O
assigned	O
01:01	O
via	O
an	O
interactive	O
web-based	O
randomisation	O
system	O
","	O
stratified	O
by	O
disease	O
site	O
and	O
disease-free	O
interval	O
","	O
to	O
receive	O
continuous	O
oral	O
letrozole	B-DRUG
2.5	O
mg	O
daily	O
or	O
continuous	O
oral	O
letrozole	B-DRUG
2.5	O
mg	O
daily	O
plus	O
oral	O
palbociclib	B-DRUG
125	O
mg	O
","	O
given	O
once	O
daily	O
for	O
3	O
weeks	O
followed	O
by	O
1	O
week	O
off	O
over	O
28-day	O
cycles	O
.	O
	
The	O
primary	O
endpoint	O
was	O
investigator-assessed	O
progression-free	O
survival	O
in	O
the	O
intention-to-treat	O
population	O
.	O
	
Accrual	O
to	O
cohort	O
2	O
was	O
stopped	O
after	O
an	O
unplanned	O
interim	O
analysis	O
of	O
cohort	O
1	O
and	O
the	O
statistical	O
analysis	O
plan	O
for	O
the	O
primary	O
endpoint	O
was	O
amended	O
to	O
a	O
combined	O
analysis	O
of	O
cohorts	O
1	O
and	O
2	O
(	O
instead	O
of	O
cohort	O
2	O
alone	O
)	O
.	O
	
The	O
study	O
is	O
ongoing	O
but	O
closed	O
to	O
accrual	O
;	O
these	O
are	O
the	O
results	O
of	O
the	O
final	O
analysis	O
of	O
progression-free	O
survival	O
.	O
	
The	O
study	O
is	O
registered	O
with	O
the	O
ClinicalTrials.gov	O
","	O
number	O
NCT00721409	O
.	O
	
Between	O
Dec	O
22	O
","	O
2009	O
","	O
and	O
May	O
12	O
","	O
2012	O
","	O
we	O
randomly	O
assigned	O
165	O
patients	O
","	O
84	O
to	O
palbociclib	B-DRUG
plus	O
letrozole	B-DRUG
and	O
81	O
to	O
letrozole	B-DRUG
alone	O
.	O
	
At	O
the	O
time	O
of	O
the	O
final	O
analysis	O
for	O
progression-free	O
survival	O
(	O
median	O
follow-up	O
29.6	O
months	O
[	O
95	O
%	O
CI	O
27.9-36.0	O
]	O
for	O
the	O
palbociclib	B-DRUG
plus	O
letrozole	B-DRUG
group	O
and	O
27.9	O
months	O
[	O
25.5-31.1	O
]	O
for	O
the	O
letrozole	B-DRUG
group	O
)	O
","	O
41	O
progression-free	O
survival	O
events	O
had	O
occurred	O
in	O
the	O
palbociclib	B-DRUG
plus	O
letrozole	B-DRUG
group	O
and	O
59	O
in	O
the	O
letrozole	B-DRUG
group	O
.	O
	
Median	O
progression-free	O
survival	O
was	O
10.2	O
months	O
(	O
95	O
%	O
CI	O
5.7-12.6	O
)	O
for	O
the	O
letrozole	B-DRUG
group	O
and	O
20.2	O
months	O
(	O
13.8-27.5	O
)	O
for	O
the	O
palbociclib	B-DRUG
plus	O
letrozole	B-DRUG
group	O
(	O
HR	O
0.488	O
","	O
95	O
%	O
CI	O
0.319-0.748	O
;	O
one-sided	O
p=0.0004	O
)	O
.	O
	
In	O
cohort	O
1	O
(	O
n=66	O
)	O
","	O
median	O
progression-free	O
survival	O
was	O
5.7	O
months	O
(	O
2.6-10.5	O
)	O
for	O
the	O
letrozole	O
group	O
and	O
26.1	O
months	O
(	O
11.2-not	O
estimable	O
)	O
for	O
the	O
palbociclib	B-DRUG
plus	O
letrozole	B-DRUG
group	O
(	O
HR	O
0.299	O
","	O
0.156-0.572	O
;	O
one-sided	O
p	O
&	O
lt	O
;	O
0.0001	O
)	O
;	O
in	O
cohort	O
2	O
(	O
n=99	O
)	O
","	O
median	O
progression-free	O
survival	O
was	O
11.1	O
months	O
(	O
7.1-16.4	O
)	O
for	O
the	O
letrozole	B-DRUG
group	O
and	O
18.1	O
months	O
(	O
13.1-27.5	O
)	O
for	O
the	O
palbociclib	B-DRUG
plus	O
letrozole	B-DRUG
group	O
(	O
HR	O
0.508	O
","	O
0.303-0.853	O
;	O
one-sided	O
p=0.0046	O
)	O
.	O
	
Grade	O
3月4日	O
neutropenia	B-TOXI
was	O
reported	O
in	O
45	O
(	O
54	O
%	O
)	O
of	O
83	O
patients	O
in	O
the	O
palbociclib	B-DRUG
plus	O
letrozole	B-DRUG
group	O
versus	O
one	O
(	O
1	O
%	O
)	O
of	O
77	O
patients	O
in	O
the	O
letrozole	B-DRUG
group	O
","	O
leucopenia	B-TOXI
in	O
16	O
(	O
19	O
%	O
)	O
versus	O
none	O
","	O
and	O
fatigue	B-TOXI
in	O
four	O
(	O
4	O
%	O
)	O
versus	O
one	O
(	O
1	O
%	O
)	O
.	O
	
Serious	O
adverse	O
events	O
that	O
occurred	O
in	O
more	O
than	O
one	O
patient	O
in	O
the	O
palbociclib	B-DRUG
plus	O
letrozole	B-DRUG
group	O
were	O
pulmonary	B-TOXI
embolism	I-TOXI
(	O
three	O
[	O
4	O
%	O
]	O
patients	O
)	O
","	O
back	B-TOXI
pain	I-TOXI
(	O
two	O
[	O
2	O
%	O
]	O
)	O
","	O
and	O
diarrhoea	B-TOXI
(	O
two	O
[	O
2	O
%	O
]	O
)	O
.	O
	
No	O
cases	O
of	O
febrile	B-TOXI
neutropenia	I-TOXI
or	O
neutropenia-related	B-TOXI
infections	I-TOXI
were	O
reported	O
during	O
the	O
study	O
.	O
	
11	O
(	O
13	O
%	O
)	O
patients	O
in	O
the	O
palbociclib	B-DRUG
plus	O
letrozole	B-DRUG
group	O
and	O
two	O
(	O
2	O
%	O
)	O
in	O
the	O
letrozole	B-DRUG
group	O
discontinued	O
the	O
study	O
because	O
of	O
adverse	O
events	O
.	O
	
The	O
addition	O
of	O
palbociclib	B-DRUG
to	O
letrozole	B-DRUG
in	O
this	O
phase	O
2	O
study	O
significantly	O
improved	O
progression-free	O
survival	O
in	O
women	O
with	O
advanced	O
oestrogen	O
receptor-positive	O
and	O
HER2-negative	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
A	O
phase	O
3	O
trial	O
is	O
currently	O
underway	O
.	O
	
Pfizer	O
.	O
	
A	O
Phase	O
I	O
/	O
biomarker	O
study	O
of	O
bevacizumab	B-DRUG
in	O
combination	O
with	O
CNTO	B-DRUG
95	I-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Inhibition	O
of	O
tumor	O
angiogenesis	O
is	O
an	O
effective	O
mechanism	O
to	O
limit	O
tumor	O
growth	O
;	O
dual	O
inhibition	O
may	O
result	O
in	O
additional	O
benefit	O
.	O
	
Bevacizumab	B-DRUG
is	O
a	O
monoclonal	O
antibody	O
directed	O
against	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
","	O
and	O
intetumumab	B-DRUG
is	O
a	O
fully	O
humanized	O
monoclonal	O
antibody	O
that	O
blocks	O
伪v	O
integrins	O
when	O
complexed	O
with	O
尾	O
integrins	O
.	O
	
We	O
evaluated	O
the	O
safety	O
","	O
tolerability	O
","	O
and	O
efficacy	O
of	O
the	O
combination	O
of	O
bevacizumab	B-DRUG
plus	O
intetumumab	B-DRUG
in	O
patients	O
with	O
refractory	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
We	O
also	O
explored	O
the	O
effects	O
of	O
these	O
agents	O
on	O
plasma-based	O
biomarkers	O
and	O
wound	O
angiogenesis	O
.	O
	
Patients	O
with	O
refractory	B-CANCER
solid	I-CANCER
tumors	I-CANCER
","	O
Karnofsky	O
performance	O
status	O
_70	O
%	O
","	O
and	O
adequate	O
organ	O
function	O
were	O
eligible	O
.	O
	
Plasma	O
samples	O
and	O
wound	O
biopsies	O
were	O
obtained	O
at	O
baseline	O
and	O
on-treatment	O
.	O
	
Twelve	O
patients	O
were	O
enrolled	O
and	O
received	O
study	O
drug	O
.	O
	
No	O
tumor	O
responses	O
were	O
noted	O
.	O
	
Observed	O
toxicities	O
included	O
three	O
cases	O
of	O
transient	O
uveitis	O
likely	O
related	O
to	O
intetumumab	B-DRUG
and	O
one	O
case	O
of	O
reversible	B-TOXI
posterior	I-TOXI
leukoencephalopathy	I-TOXI
syndrome	I-TOXI
likely	O
related	O
to	O
bevacizumab	B-DRUG
.	O
	
Biomarker	O
analysis	O
revealed	O
changes	O
in	O
soluble	O
endoglin	O
","	O
soluble	O
E-cadherin	O
","	O
and	O
soluble	O
E-selectin	O
as	O
well	O
as	O
PlGF	O
and	O
VEGF-D	O
while	O
on	O
treatment	O
.	O
	
There	O
was	O
no	O
observed	O
impact	O
of	O
bevacizumab	B-DRUG
plus	O
intetumumab	B-DRUG
on	O
the	O
phosphorylated	O
or	O
total	O
levels	O
of	O
paxillin	B-DRUG
in	O
wound	O
tissue	O
;	O
however	O
","	O
an	O
increase	O
in	O
the	O
ratio	O
of	O
phospho	B-DRUG
/	O
total	O
paxillin	B-DRUG
levels	O
was	O
noted	O
.	O
	
Bevacizumab	B-DRUG
and	O
intetumumab	B-DRUG
can	O
be	O
administered	O
safely	O
in	O
combination	O
.	O
	
Bevacizumab	B-DRUG
plus	O
intetumumab	B-DRUG
treatment	O
resulted	O
in	O
changes	O
in	O
the	O
plasma	O
levels	O
of	O
several	O
extracellular	O
matrix	O
interacting	O
proteins	O
and	O
angiogenic	O
factors	O
.	O
	
Phase	O
I	O
/	O
II	O
trial	O
of	O
the	O
combination	O
of	O
midostaurin	B-DRUG
(	O
PKC412	B-DRUG
)	O
and	O
5-azacytidine	B-DRUG
for	O
patients	O
with	O
acute	B-CANCER
myeloid	I-CANCER
leukemia	I-CANCER
and	O
myelodysplastic	B-CANCER
syndrome	I-CANCER
.	O
	
	
We	O
investigated	O
the	O
combination	O
of	O
midostaurin	B-DRUG
and	O
azacitidine	B-DRUG
(	O
AZA	B-DRUG
)	O
in	O
patients	O
with	O
acute	B-CANCER
myeloid	I-CANCER
leukemia	I-CANCER
(	O
AML	B-CANCER
)	O
and	O
high	O
risk	O
myelodysplastic	B-CANCER
syndrome	I-CANCER
(	O
MDS	O
)	O
.	O
	
Patients	O
received	O
AZA	B-DRUG
75	O
mg	O
m	O
(	O
-2	O
)	O
on	O
days	O
1月7日	O
and	O
midostaurin	B-DRUG
25	O
mg	O
bid	O
(	O
in	O
cohort	O
1	O
of	O
phase	O
I	O
)	O
or	O
50	O
mg	O
bid	O
(	O
in	O
cohort	O
2	O
of	O
Phase	O
I	O
and	O
in	O
Phase	O
II	O
)	O
orally	O
on	O
day	O
8月21日	O
during	O
the	O
first	O
cycle	O
and	O
continuously	O
thereafter	O
.	O
	
Fourteen	O
patients	O
were	O
enrolled	O
in	O
the	O
phase	O
I	O
and	O
40	O
in	O
the	O
phase	O
II	O
.	O
	
Overall	O
response	O
rate	O
was	O
26	O
%	O
.	O
	
The	O
median	O
remission	O
duration	O
(	O
RD	O
)	O
was	O
20	O
weeks	O
and	O
was	O
significantly	O
longer	O
in	O
patients	O
with	O
FLT3	O
mutations	O
not	O
previously	O
exposed	O
to	O
other	O
FLT3	O
inhibitors	O
(	O
P	O
=	O
0.05	O
)	O
and	O
in	O
patients	O
not	O
previously	O
transplanted	O
(	O
P	O
=	O
0.01	O
)	O
.	O
	
Thirty-two	O
(	O
59	O
%	O
)	O
patients	O
have	O
died	B-TOXI
","	O
all	O
of	O
complications	O
related	O
to	O
disease	O
progression	O
.	O
	
G3-4	O
nonhematological	B-TOXI
toxicity	I-TOXI
was	O
reported	O
in	O
38	O
(	O
70	O
%	O
)	O
patients	O
","	O
most	O
frequently	O
infections	B-TOXI
(	O
56	O
%	O
)	O
","	O
ejection	B-TOXI
fraction	I-TOXI
reduction	I-TOXI
(	O
11	O
%	O
)	O
","	O
and	O
diarrhea	B-TOXI
or	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
(	O
9	O
%	O
each	O
)	O
.	O
	
The	O
combination	O
of	O
midostaurin	B-DRUG
and	O
AZA	B-DRUG
is	O
an	O
effective	O
and	O
safe	O
regimen	O
in	O
patients	O
with	O
AML	B-CANCER
and	O
high-risk	O
MDS	B-CANCER
.	O
	
Patients	O
with	O
FLT3	O
mutations	O
but	O
not	O
previously	O
exposed	O
to	O
other	O
FLT3	O
inhibitors	O
and	O
patients	O
not	O
previously	O
transplanted	O
derived	O
the	O
greatest	O
benefit	O
.	O
	
Further	O
studies	O
with	O
this	O
combination	O
are	O
warranted	O
.	O
	
Phase	O
I	O
dose-escalation	O
study	O
of	O
aflibercept	B-DRUG
plus	O
docetaxel	B-DRUG
in	O
nasopharyngeal	B-CANCER
carcinoma	I-CANCER
and	O
other	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
To	O
confirm	O
whether	O
the	O
aflibercept	B-DRUG
dose	O
","	O
plus	O
docetaxel	B-DRUG
","	O
in	O
western	O
study	O
TCD6120	O
is	O
appropriate	O
for	O
Chinese	O
patients	O
with	O
nasopharyngeal	B-CANCER
carcinoma	I-CANCER
(	O
NPC	B-CANCER
)	O
and	O
other	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
To	O
assess	O
dose-limiting	O
toxicity	O
of	O
every	O
3-week	O
4	O
mg	O
/	O
kg	O
or	O
6	O
mg	O
/	O
kg	O
aflibercept	B-DRUG
plus	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
docetaxel	B-DRUG
.	O
	
Previously	O
treated	O
patients	O
(	O
16	O
with	O
NPC	B-CANCER
and	O
4	O
with	O
lung	B-CANCER
cancer	I-CANCER
)	O
were	O
enrolled	O
.	O
	
At	O
6	O
mg	O
/	O
kg	O
aflibercept	B-DRUG
:	O
one	O
dose-limiting	O
toxicity	O
was	O
seen	O
(	O
neutropenic	B-TOXI
infection	I-TOXI
)	O
;	O
the	O
most	O
frequently	O
reported	O
all-grade	O
adverse	O
events	O
were	O
oropharyngeal	B-TOXI
pain	O
","	O
stomatitis	B-TOXI
and	O
alopecia	B-TOXI
;	O
the	O
most	O
frequently	O
reported	O
grade	O
3	O
/	O
4	O
adverse	O
events	O
were	O
oropharyngeal	B-TOXI
pain	I-TOXI
","	O
stomatitis	B-TOXI
and	O
neutropenic	B-TOXI
infection	I-TOXI
.	O
	
Eleven	O
patients	O
had	O
partial	O
response	O
and	O
3	O
had	O
stable	O
disease	O
.	O
	
Preliminary	O
efficacy	O
data	O
for	O
docetaxel	B-DRUG
/	O
aflibercept	B-DRUG
are	O
encouraging	O
in	O
Chinese	O
patients	O
with	O
NPC	B-CANCER
.	O
	
This	O
study	O
was	O
registered	O
with	O
the	O
University	O
Hospital	O
Medical	O
Information	O
Network	O
Clinical	O
Trials	O
Registry	O
(	O
ClinicalTrials.gov	O
","	O
NCT01148615	O
)	O
.	O
	
Phase	O
1	O
study	O
of	O
oral	O
abexinostat	B-DRUG
","	O
a	O
histone	O
deacetylase	O
inhibitor	O
","	O
in	O
combination	O
with	O
doxorubicin	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
sarcoma	I-CANCER
.	O
	
	
It	O
has	O
been	O
demonstrated	O
that	O
several	O
inhibitors	O
of	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
can	O
enhance	O
chemotherapy-induced	O
apoptosis	O
and	O
reduce	O
sarcoma	B-TOXI
tumor	I-TOXI
volume	O
in	O
preclinical	O
models	O
.	O
	
The	O
authors	O
sought	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
","	O
pharmacokinetics	O
/	O
pharmacodynamics	O
","	O
safety	O
","	O
and	O
toxicity	O
of	O
the	O
HDAC	O
inhibitor	O
abexinostat	B-DRUG
(	O
PCI-24781	B-DRUG
)	O
when	O
administered	O
with	O
doxorubicin	B-DRUG
to	O
patients	O
with	O
metastatic	B-CANCER
sarcomas	I-CANCER
.	O
	
Participants	O
were	O
enrolled	O
in	O
a	O
standard	O
","	O
phase	O
1	O
","	O
3	O
=+	O
3	O
","	O
dose-escalation	O
study	O
design	O
.	O
	
Abexinostat	B-DRUG
was	O
administered	O
on	O
days	O
1	O
through	O
5	O
with	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
doxorubicin	B-DRUG
administered	O
on	O
day	O
4	O
of	O
every	O
21-day	O
cycle	O
until	O
patients	O
developed	O
disease	O
progression	O
or	O
drug	O
intolerance	O
or	O
reached	O
a	O
cumulative	O
lifetime	O
doxorubicin	B-DRUG
dose	O
of	O
450	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Granulocyte-colony-stimulating	O
factor	O
(	O
G-CSF	O
)	O
support	O
was	O
provided	O
at	O
physician	O
discretion	O
on	O
arm	O
A	O
and	O
was	O
provided	O
to	O
all	O
participants	O
in	O
arm	O
B.	O
From	O
3	O
to	O
6	O
participants	O
initially	O
received	O
abexinostat	B-DRUG
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
daily	O
","	O
and	O
subsequent	O
cohorts	O
were	O
administered	O
doses	O
of	O
15	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
45	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
or	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
daily	O
.	O
	
All	O
patients	O
without	O
progressive	O
disease	O
after	O
receiving	O
a	O
cumulative	O
lifetime	O
doxorubicin	B-DRUG
dose	O
of	O
450	O
mg	O
/	O
m	O
(	O
2	O
)	O
were	O
given	O
the	O
option	O
to	O
continue	O
with	O
abexinostat	B-DRUG
as	O
a	O
single	O
agent	O
until	O
they	O
developed	O
disease	O
progression	O
.	O
	
In	O
total	O
","	O
22	O
participants	O
(	O
10	O
who	O
had	O
previously	O
experienced	O
tumor	O
growth	O
after	O
doxorubicin	B-DRUG
therapy	O
)	O
were	O
enrolled	O
(	O
6	O
in	O
arm	O
A	O
","	O
14	O
in	O
arm	O
B	O
)	O
","	O
20	O
were	O
evaluable	O
for	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
","	O
and	O
17	O
were	O
evaluable	O
for	O
radiologic	O
response	O
.	O
	
In	O
arm	O
A	O
","	O
participants	O
received	O
abexinostat	B-DRUG
15	O
mg	O
/	O
m	O
(	O
2	O
)	O
or	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
daily	O
.	O
	
DLTs	O
of	O
grade	O
3	O
and	O
4	O
neutropenia	B-TOXI
were	O
observed	O
in	O
2	O
of	O
3	O
participants	O
who	O
received	O
abexinostat	B-DRUG
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
daily	O
.	O
	
Neither	O
of	O
those	O
patients	O
received	O
G-CSF	O
prophylaxis	O
.	O
	
In	O
arm	O
B	O
","	O
participants	O
received	O
abexinostat	B-DRUG
at	O
doses	O
of	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
45	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
or	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
daily	O
","	O
all	O
with	O
mandated	O
G-CSF	O
support	O
.	O
	
Two	O
DLTs	O
were	O
observed	O
at	O
the	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice-daily	O
dose	O
(	O
grade	O
3	O
infection	B-TOXI
","	O
grade	O
4	O
thrombocytopenia	B-TOXI
)	O
.	O
	
The	O
pharmacokinetics	O
of	O
abexinostat	B-DRUG
were	O
not	O
affected	O
by	O
doxorubicin	B-DRUG
.	O
	
HDAC	O
activity	O
","	O
as	O
measured	O
by	O
histone	O
acetylation	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
","	O
was	O
maximally	O
inhibited	O
at	O
the	O
abexinostat	B-DRUG
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice-daily	O
dose	O
.	O
	
Of	O
the	O
17	O
participants	O
who	O
were	O
evaluable	O
for	O
radiologic	O
response	O
","	O
1	O
patient	O
had	O
a	O
partial	O
response	O
","	O
9	O
patients	O
had	O
stable	O
disease	O
","	O
and	O
7	O
patients	O
had	O
progressive	O
disease	O
as	O
their	O
best	O
response	O
;	O
and	O
8	O
patients	O
completed	O
_	O
5	O
cycles	O
.	O
	
Three	O
of	O
those	O
participants	O
had	O
stable	O
disease	O
as	O
their	O
most	O
recent	O
disease	O
status	O
when	O
the	O
current	O
report	O
was	O
written	O
.	O
	
Four	O
participants	O
who	O
continued	O
on	O
monotherapy	O
remained	O
in	O
stable	O
disease	O
for	O
a	O
median	O
of	O
9.8	O
weeks	O
after	O
completing	O
doxorubicin	B-DRUG
.	O
	
The	O
most	O
common	O
toxicities	O
were	O
fatigue	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
and	O
anemia	B-TOXI
.	O
	
No	O
study-related	O
deaths	B-TOXI
were	O
observed	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
for	O
abexinostat	B-DRUG
was	O
45	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
daily	O
administered	O
on	O
days	O
1	O
through	O
5	O
when	O
patients	O
received	O
doxorubicin	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
4	O
of	O
a	O
3-week	O
cycle	O
and	O
G-CSF	O
support	O
was	O
mandated	O
.	O
	
Toxicities	O
were	O
manageable	O
","	O
and	O
tumor	O
responses	O
were	O
observed	O
.	O
	
Additional	O
studies	O
are	O
needed	O
to	O
further	O
define	O
the	O
specific	O
contributions	O
of	O
HDAC	O
inhibition	O
in	O
patients	O
who	O
receive	O
doxorubicin	B-DRUG
for	O
the	O
treatment	O
of	O
metastatic	B-CANCER
sarcoma	I-CANCER
.	O
	
Phase	O
I	O
/	O
II	O
study	O
of	O
pilaralisib	B-DRUG
(	O
SAR245408	O
)	O
in	O
combination	O
with	O
trastuzumab	B-DRUG
or	O
trastuzumab	B-DRUG
plus	O
paclitaxel	B-DRUG
in	O
trastuzumab-refractory	B-DRUG
HER2-positive	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
This	O
phase	O
I	O
/	O
II	O
dose-escalation	O
study	O
investigated	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
safety	O
","	O
pharmacokinetics	O
","	O
and	O
efficacy	O
of	O
the	O
pan-class	O
I	O
phosphoinositide	O
3-kinase	O
inhibitor	O
pilaralisib	B-DRUG
in	O
combination	O
with	O
trastuzumab	B-DRUG
(	O
Arm	O
1	O
)	O
or	O
trastuzumab	B-DRUG
plus	O
paclitaxel	B-DRUG
(	O
Arm	O
2	O
)	O
in	O
patients	O
with	O
HER2-positive	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
had	O
progressed	O
on	O
prior	O
trastuzumab	B-DRUG
(	O
Arms	O
1	O
and	O
2	O
)	O
and	O
received	O
prior	O
taxane	B-DRUG
(	O
Arm	O
2	O
)	O
.	O
	
The	O
MTD	O
of	O
pilaralisib	B-DRUG
was	O
determined	O
using	O
a	O
3	O
=+	O
3	O
dose-escalation	O
design	O
(	O
starting	O
dose	O
200	O
mg	O
once	O
daily	O
)	O
.	O
	
Forty-two	O
patients	O
were	O
enrolled	O
(	O
21	O
in	O
each	O
arm	O
)	O
.	O
	
Five	O
patients	O
had	O
a	O
dose-limiting	O
toxicity	O
(	O
DLT	O
;	O
three	O
in	O
Arm	O
1	O
and	O
two	O
in	O
Arm	O
2	O
)	O
.	O
	
Dose-limiting	O
toxicities	O
were	O
rash	B-TOXI
(	O
three	O
patients	O
)	O
and	O
neutropenia	B-TOXI
(	O
two	O
patients	O
)	O
.	O
	
The	O
MTD	O
of	O
pilaralisib	B-DRUG
was	O
determined	O
at	O
400	O
mg	O
once	O
daily	O
in	O
both	O
arms	O
.	O
	
The	O
most	O
frequently	O
reported	O
treatment-related	O
adverse	O
events	O
(	O
AEs	O
)	O
were	O
diarrhea	B-TOXI
(	O
23.8	O
%	O
in	O
Arm	O
1	O
vs.	O
66.7	O
%	O
in	O
Arm	O
2	O
)	O
","	O
fatigue	B-TOXI
(	O
14.3	O
vs.	O
42.9	O
%	O
)	O
","	O
and	O
rash	B-TOXI
(	O
33.3	O
vs.	O
38.1	O
%	O
)	O
.	O
	
The	O
most	O
frequently	O
reported	O
treatment-related	O
grade	O
_3	O
AEs	O
were	O
erythematous	B-TOXI
rash	I-TOXI
(	O
9.5	O
%	O
)	O
in	O
Arm	O
1	O
and	O
diarrhea	B-TOXI
","	O
peripheral	B-TOXI
neuropathy	I-TOXI
","	O
and	O
neutropenia	B-TOXI
(	O
14.3	O
%	O
each	O
)	O
in	O
Arm	O
2	O
Steady-state	O
pilaralisib	B-DRUG
exposure	O
was	O
similar	O
to	O
previous	O
studies	O
with	O
pilaralisib	B-DRUG
monotherapy	O
.	O
	
No	O
responses	O
occurred	O
in	O
Arm	O
1	O
;	O
four	O
of	O
20	O
evaluable	O
patients	O
(	O
20	O
%	O
)	O
in	O
Arm	O
2	O
had	O
a	O
partial	O
response	O
.	O
	
Observed	O
PIK3CA	O
mutations	O
in	O
cell-free	O
circulating	O
DNA	O
did	O
not	O
correlate	O
with	O
response	O
.	O
	
Pilaralisib	O
in	O
combination	O
with	O
trastuzumab	B-DRUG
with	O
or	O
without	O
paclitaxel	B-DRUG
had	O
an	O
acceptable	O
safety	O
profile	O
in	O
metastatic	O
HER2-positive	O
breast	B-CANCER
cancer	I-CANCER
","	O
with	O
clinical	O
activity	O
in	O
the	O
paclitaxel	B-DRUG
arm	O
.	O
	
PACMEL	O
:	O
a	O
phase	O
1	O
dose	O
escalation	O
trial	O
of	O
trametinib	B-DRUG
(	O
GSK1120212	B-DRUG
)	O
in	O
combination	O
with	O
paclitaxel	B-DRUG
.	O
	
	
We	O
sought	O
to	O
determine	O
the	O
maximal	O
tolerated	O
dose	O
of	O
the	O
MEK	O
inhibitor	O
trametinib	B-DRUG
with	O
weekly	O
paclitaxel	B-DRUG
","	O
with	O
a	O
view	O
to	O
exploring	O
the	O
combination	O
's	O
activity	O
in	O
melanoma	B-CANCER
lacking	O
a	O
BRAF	O
V600	O
mutation	O
.	O
	
In	O
this	O
phase	O
1	O
study	O
we	O
used	O
a	O
fixed	O
dose	O
of	O
paclitaxel	B-DRUG
(	O
80	O
mg	O
/	O
m2	O
intravenous	O
(	O
IV	O
)	O
on	O
days	O
1	O
","	O
8	O
and	O
15	O
of	O
each	O
4	O
week	O
cycle	O
)	O
and	O
escalated	O
the	O
dose	O
of	O
trametinib	B-DRUG
(	O
to	O
a	O
maximum	O
2mg	O
orally	O
(	O
PO	O
)	O
daily	O
)	O
","	O
following	O
a	O
3+3	O
design	O
.	O
	
Eligible	O
patients	O
had	O
advanced	B-CANCER
melanoma	I-CANCER
and	O
could	O
have	O
received	O
up	O
to	O
two	O
previous	O
lines	O
of	O
treatment	O
for	O
metastatic	O
disease	O
.	O
	
15	O
patients	O
were	O
enrolled	O
","	O
all	O
but	O
one	O
of	O
whose	O
melanoma	B-CANCER
was	O
wild	O
type	O
for	O
BRAF	O
at	O
codon	O
600	O
.	O
	
The	O
maximal	O
monotherapy	O
dose	O
of	O
trametinib	B-DRUG
proved	O
tolerable	O
with	O
weekly	O
paclitaxel	B-DRUG
.	O
	
The	O
most	O
frequent	O
adverse	O
events	O
observed	O
were	O
rash	B-TOXI
and	O
fatigue	B-TOXI
.	O
	
Six	O
(	O
40	O
%	O
)	O
partial	O
responses	O
were	O
reported	O
","	O
including	O
four	O
of	O
eight	O
patients	O
with	O
NRAS	O
mutations	O
.	O
	
Median	O
progression	O
free	O
survival	O
was	O
5.5	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.8-7.8	O
months	O
)	O
and	O
overall	O
survival	O
","	O
14.1	O
months	O
(	O
95	O
%	O
CI	O
4.6-not	O
reached	O
)	O
.	O
	
Trametinib	B-DRUG
can	O
safely	O
be	O
given	O
with	O
weekly	O
paclitaxel	B-DRUG
at	O
the	O
full	O
monotherapy	O
dose	O
.	O
	
In	O
this	O
small	O
group	O
promising	O
progression	O
free	O
and	O
overall	O
survival	O
were	O
observed	O
in	O
patients	O
with	O
melanoma	B-CANCER
lacking	O
a	O
V600	O
BRAF	O
mutation	O
.	O
	
Weekly	O
paclitaxel	B-DRUG
and	O
concurrent	O
pazopanib	B-DRUG
following	O
doxorubicin	B-DRUG
and	O
cyclophosphamide	B-DRUG
as	O
neoadjuvant	O
therapy	O
for	O
HER-negative	O
locally	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
:	O
NSABP	O
Foundation	O
FB-6	O
","	O
a	O
phase	O
II	O
study	O
.	O
	
	
This	O
multicenter	O
single-arm	O
phase	O
II	O
study	O
evaluated	O
the	O
addition	O
of	O
pazopanib	B-DRUG
to	O
concurrent	O
weekly	O
paclitaxel	B-DRUG
following	O
doxorubicin	B-DRUG
and	O
cyclophosphamide	B-DRUG
as	O
neoadjuvant	O
therapy	O
in	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
HER2	O
)	O
#NAME?	O
locally	B-CANCER
advanced	I-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
LABC	B-CANCER
)	O
.	O
	
Patients	O
with	O
HER2-negative	O
stage	O
III	O
breast	B-CANCER
cancer	I-CANCER
were	O
treated	O
with	O
doxorubicin	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
cyclophosphamide	B-DRUG
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
four	O
cycles	O
every	O
3	O
weeks	O
followed	O
by	O
weekly	O
paclitaxel	B-DRUG
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
every	O
28	O
days	O
for	O
four	O
cycles	O
concurrently	O
with	O
pazopanib	B-DRUG
800	O
mg	O
orally	O
daily	O
prior	O
to	O
surgery	O
.	O
	
Post-operatively	O
","	O
pazopanib	B-DRUG
was	O
given	O
daily	O
for	O
6	O
months	O
.	O
	
The	O
primary	O
endpoint	O
was	O
pathologic	O
complete	O
response	O
(	O
pCR	O
)	O
in	O
the	O
breast	O
and	O
lymph	O
nodes	O
.	O
	
Between	O
July	O
2009	O
and	O
March	O
2011	O
","	O
101	O
patients	O
with	O
stage	O
IIIA-C	O
HER2-negative	O
breast	B-CANCER
cancer	I-CANCER
were	O
enrolled	O
.	O
	
The	O
pCR	O
rate	O
in	O
evaluable	O
patients	O
who	O
initiated	O
paclitaxel	B-DRUG
and	O
pazopanib	B-DRUG
was	O
17	O
%	O
(	O
16	O
/	O
93	O
)	O
.	O
	
The	O
pCR	O
rate	O
was	O
9	O
%	O
(	O
6	O
/	O
67	O
)	O
in	O
hormone	O
receptor-positive	O
tumors	O
and	O
38	O
%	O
(	O
10	O
/	O
26	O
)	O
in	O
triple-negative	O
tumors	O
.	O
	
Pre-operative	O
pazopanib	B-DRUG
was	O
completed	O
in	O
only	O
39	O
%	O
of	O
patients	O
.	O
	
The	O
most	O
frequent	O
grade	O
3	O
and	O
4	O
adverse	O
events	O
during	O
paclitaxel	B-DRUG
and	O
pazopanib	B-DRUG
were	O
neutropenia	B-TOXI
(	O
27	O
%	O
)	O
","	O
diarrhea	B-TOXI
(	O
5	O
%	O
)	O
","	O
ALT	B-TOXI
and	I-TOXI
AST	I-TOXI
elevations	I-TOXI
(	O
each	O
5	O
%	O
)	O
","	O
and	O
hypertension	B-TOXI
(	O
5	O
%	O
)	O
.	O
	
Although	O
the	O
pCR	O
rate	O
of	O
paclitaxel	B-DRUG
and	O
pazopanib	B-DRUG
following	O
AC	O
chemotherapy	O
given	O
as	O
neoadjuvant	O
therapy	O
in	O
women	O
with	O
LABC	B-CANCER
met	O
the	O
pre-specified	O
criteria	O
for	O
activity	O
","	O
there	O
was	O
substantial	O
toxicity	O
","	O
which	O
led	O
to	O
a	O
high	O
discontinuation	O
rate	O
of	O
pazopanib	B-DRUG
.	O
	
The	O
combination	O
does	O
not	O
appear	O
to	O
warrant	O
further	O
evaluation	O
in	O
the	O
neoadjuvant	O
setting	O
for	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
Paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
with	O
or	O
without	O
sorafenib	B-DRUG
in	O
the	O
first-line	O
treatment	O
of	O
patients	O
with	O
stage	O
III	O
/	O
IV	O
epithelial	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
:	O
a	O
randomized	O
phase	O
II	O
study	O
of	O
the	O
Sarah	O
Cannon	O
Research	O
Institute	O
.	O
	
	
This	O
trial	O
compared	O
the	O
efficacy	O
and	O
toxicity	O
of	O
standard	O
first-line	O
treatment	O
with	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
versus	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
plus	O
sorafenib	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
ovarian	I-CANCER
carcinoma	I-CANCER
.	O
	
Patients	O
with	O
stage	O
3	O
or	O
4	O
epithelial	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
with	O
residual	O
measurable	O
disease	O
or	O
elevated	O
CA-125	O
levels	O
after	O
maximal	O
surgical	O
cytoreduction	O
were	O
randomized	O
(	O
01:01	O
)	O
to	O
receive	O
treatment	O
with	O
paclitaxel	B-DRUG
(	O
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
3	O
h	O
infusion	O
","	O
day	O
1	O
)	O
and	O
carboplatin	B-DRUG
(	O
AUC	O
6	O
","	O
IV	O
","	O
day	O
1	O
)	O
with	O
or	O
without	O
sorafenib	B-DRUG
400	O
mg	O
orally	O
twice	O
daily	O
(	O
PO	O
BID	O
)	O
.	O
	
Patients	O
were	O
reevaluated	O
for	O
response	O
after	O
completing	O
6	O
weeks	O
of	O
treatment	O
(	O
two	O
cycles	O
)	O
;	O
responding	O
or	O
stable	O
patients	O
received	O
six	O
cycles	O
of	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
.	O
	
Patients	O
receiving	O
the	O
sorafenib-containing	B-DRUG
regimen	O
continued	O
sorafenib	B-DRUG
(	O
400	O
PO	O
BID	O
)	O
for	O
a	O
total	O
of	O
52	O
weeks	O
.	O
	
Eighty-five	O
patients	O
were	O
randomized	O
and	O
received	O
treatment.Efficacy	O
was	O
similar	O
for	O
patients	O
receiving	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
/	O
sorafenib	B-DRUG
versus	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
:	O
overall	O
response	O
rates	O
69	O
%	O
versus	O
74	O
%	O
;	O
median	O
progression-free	O
survival	O
15.4	O
versus	O
16.3	O
months	O
;	O
2	O
year	O
survival	O
76	O
%	O
versus	O
81	O
%	O
.	O
	
The	O
addition	O
of	O
sorafenib	B-DRUG
added	O
substantially	O
to	O
the	O
toxicity	O
of	O
the	O
regimen	O
;	O
rash	B-TOXI
","	O
hand-foot	B-TOXI
syndrome	I-TOXI
","	O
mucositis	B-TOXI
","	O
and	O
hypertension	B-TOXI
were	O
significantly	O
more	O
common	O
in	O
patients	O
treated	O
with	O
sorafenib	B-DRUG
.	O
	
The	O
addition	O
of	O
sorafenib	B-DRUG
to	O
standard	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
did	O
not	O
improve	O
efficacy	O
and	O
substantially	O
increased	O
toxicity	O
in	O
the	O
first-line	O
treatment	O
of	O
advanced	B-CANCER
epithelial	I-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
Based	O
on	O
evidence	O
from	O
this	O
study	O
and	O
other	O
completed	O
trials	O
","	O
sorafenib	B-DRUG
is	O
unlikely	O
to	O
have	O
a	O
role	O
in	O
the	O
treatment	O
of	O
ovarian	B-CANCER
cancer	I-CANCER
.	O
	
Stimulation	O
of	O
FA	O
and	O
phosphatase-1	O
activities	O
by	O
insulin	B-DRUG
in	O
3T3-L1	O
cells	O
.	O
	
	
The	O
phosphatase-1	O
activator	O
FA	O
and	O
phosphatase-1	O
were	O
assayed	O
in	O
3T3-L1	O
cells	O
exposed	O
to	O
insulin	B-DRUG
.	O
	
The	O
cytosolic	O
FA	O
activity	O
was	O
transiently	O
stimulated	O
(	O
7-8-fold	O
)	O
1	O
and	O
2	O
min	O
after	O
exposure	O
to	O
10	O
(	O
-8	O
)	O
M	O
insulin	B-DRUG
and	O
returned	O
to	O
control	O
values	O
within	O
5月10日	O
min	O
.	O
	
Cytosolic	O
phosphatase-1	O
(	O
assayed	O
after	O
trypsin	O
treatment	O
)	O
was	O
activated	O
(	O
120-140	O
%	O
of	O
controls	O
)	O
between	O
2	O
and	O
5	O
min	O
and	O
returned	O
to	O
control	O
values	O
within	O
10	O
min	O
.	O
	
Insulin	B-DRUG
effects	O
were	O
dose-dependent	O
","	O
with	O
maximum	O
stimulation	O
of	O
both	O
activities	O
at	O
10	O
(	O
-8	O
)	O
M	O
insulin	B-DRUG
.	O
	
The	O
possibility	O
that	O
FA	O
and	O
other	O
kinases	O
mediate	O
phosphatase	O
activation	O
by	O
insulin	B-DRUG
is	O
discussed	O
.	O
	
Combination	O
of	O
trabectedin	B-DRUG
and	O
gemcitabine	B-DRUG
for	O
advanced	B-CANCER
soft	I-CANCER
tissue	I-CANCER
sarcomas	I-CANCER
:	O
results	O
of	O
a	O
phase	O
I	O
dose	O
escalating	O
trial	O
of	O
the	O
German	O
Interdisciplinary	O
Sarcoma	O
Group	O
(	O
GISG	O
)	O
.	O
	
	
Evaluation	O
of	O
the	O
potential	O
efficacy	O
and	O
safety	O
of	O
combination	O
therapies	O
for	O
advanced	B-CANCER
soft	I-CANCER
tissue	I-CANCER
sarcomas	I-CANCER
(	O
STS	B-CANCER
)	O
has	O
increased	O
substantially	O
after	O
approval	O
of	O
trabectedin	B-DRUG
and	O
pazopanib	B-DRUG
.	O
	
Trabectedin	B-DRUG
's	I-DRUG
introduction	O
in	O
Europe	O
in	O
2007	O
depended	O
mainly	O
on	O
its	O
activity	O
in	O
so-called	O
L-sarcomas	B-CANCER
(	O
liposarcoma	B-CANCER
and	O
leiomyosarcoma	B-CANCER
)	O
;	O
combination	O
of	O
trabectedin	B-DRUG
with	O
other	O
chemotherapies	O
used	O
in	O
STS	B-CANCER
seems	O
of	O
particular	O
interest	O
.	O
	
We	O
initiated	O
within	O
the	O
German	O
Interdisciplinary	O
Sarcoma	O
Group	O
(	O
GISG	O
)	O
a	O
phase	O
I	O
dose	O
escalating	O
trial	O
evaluating	O
the	O
combination	O
of	O
trabectedin	B-DRUG
and	B-DRUG
gemcitabine	I-DRUG
in	O
patients	O
with	O
advanced	O
and	O
/	O
or	O
metastatic	B-CANCER
L-sarcomas	I-CANCER
(	O
GISG-02	O
;	O
ClinicalTrials.gov	O
NCT01426633	O
)	O
.	O
	
Patients	O
were	O
treated	O
with	O
increasing	O
doses	O
of	O
trabectedin	B-DRUG
and	O
gemcitabine	B-DRUG
.	O
	
The	O
primary	O
endpoint	O
was	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
.	O
	
Five	O
patients	O
were	O
included	O
in	O
the	O
study	O
.	O
	
Two	O
patients	O
were	O
treated	O
on	O
dose	O
level	O
1	O
comprising	O
trabectedin	B-DRUG
0.9	O
mg	O
/	O
m2	O
on	O
day	O
1	O
and	O
gemcitabine	B-DRUG
700	O
mg	O
/	O
m2	O
on	O
days	O
1	O
=+	O
8	O
","	O
every	O
3	O
weeks	O
.	O
	
Due	O
to	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
in	O
both	O
patients	O
(	O
elevated	B-TOXI
transaminases	I-TOXI
and	O
thrombocytopenia	B-TOXI
)	O
","	O
an	O
additional	O
three	O
patients	O
were	O
treated	O
on	O
dose	O
level	O
-1	O
with	O
trabectedin	B-DRUG
0.7	O
mg	O
/	O
m2	O
plus	O
gemcitabine	B-DRUG
700	O
mg	O
/	O
m2	O
.	O
	
Of	O
these	O
three	O
patients	O
","	O
two	O
demonstrated	O
another	O
DLT	O
;	O
therefore	O
","	O
the	O
trial	O
was	O
stopped	O
and	O
none	O
of	O
the	O
dose	O
levels	O
could	O
be	O
recommended	O
for	O
phase	O
II	O
testing	O
.	O
	
The	O
GISG-02	O
phase	O
I	O
study	O
was	O
stopped	O
with	O
the	O
conclusion	O
that	O
the	O
combination	O
of	O
gemcitabine	B-DRUG
and	O
trabectedin	B-DRUG
is	O
generally	O
not	O
recommended	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
advanced	O
and	O
/	O
or	O
metastatic	B-CANCER
leiomyosarcoma	I-CANCER
or	O
liposarcoma	B-CANCER
.	O
	
Also	O
","	O
this	O
phase	O
I	O
study	O
strongly	O
supports	O
the	O
necessity	O
for	O
careful	O
evaluation	O
of	O
combination	O
therapies	O
.	O
	
A	O
phase	O
Ib	O
study	O
of	O
the	O
VEGF	O
receptor	O
tyrosine	O
kinase	O
inhibitor	O
tivozanib	B-DRUG
and	O
modified	O
FOLFOX-6	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
gastrointestinal	I-CANCER
malignancies	I-CANCER
.	O
	
	
Tivozanib	B-DRUG
hydrochloride	I-DRUG
(	O
tivozanib	B-DRUG
)	O
is	O
a	O
potent	O
and	O
selective	O
tyrosine	O
kinase	O
inhibitor	O
of	O
all	O
3	O
vascular	O
endothelial	O
growth	O
factor	O
receptors	O
with	O
antitumor	O
activity	O
additive	O
to	O
5-fluorouracil	B-DRUG
in	O
preclinical	O
models	O
.	O
	
This	O
study	O
was	O
conducted	O
to	O
determine	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
","	O
pharmacokinetics	O
(	O
PKs	O
)	O
","	O
and	O
antitumor	O
activity	O
of	O
escalating	O
doses	O
of	O
tivozanib	B-DRUG
with	O
a	O
modified	O
(	O
m	O
)	O
FOLFOX-6	B-DRUG
(	O
leucovorin	B-DRUG
","	O
5-fluorouracil	B-DRUG
[	O
5-FU	B-DRUG
]	O
","	O
and	O
85	O
mg	O
/	O
kg	O
(	O
2	O
)	O
oxaliplatin	B-DRUG
)	O
regimen	O
in	O
patients	O
with	O
advanced	B-CANCER
gastrointestinal	I-CANCER
tumors	I-CANCER
.	O
	
Tivozanib	B-DRUG
was	O
administered	O
orally	O
once	O
daily	O
for	O
21	O
days	O
in	O
28-day	O
cycles	O
","	O
with	O
mFOLFOX-6	B-DRUG
administered	O
every	O
14	O
days	O
.	O
	
Patients	O
were	O
allowed	O
to	O
continue	O
tivozanib	B-DRUG
after	O
discontinuation	O
of	O
mFOLFOX-6	B-DRUG
.	O
	
Thirty	O
patients	O
were	O
assigned	O
to	O
tivozanib	B-DRUG
0.5	O
mg	O
(	O
n	O
=	O
9	O
)	O
","	O
1	O
mg	O
(	O
n	O
=	O
3	O
)	O
","	O
or	O
1.5	O
mg	O
(	O
n	O
=	O
18	O
)	O
with	O
mFOLFOX-6	B-DRUG
.	O
	
Patients	O
received	O
a	O
median	O
of	O
5.2	O
(	O
range	O
","	O
0.03-26.9	O
)	O
months	O
of	O
tivozanib	B-DRUG
.	O
	
DLTs	O
were	O
observed	O
in	O
2	O
patients	O
:	O
Grade	O
3	O
/	O
4	O
transaminase	B-TOXI
level	I-TOXI
increases	I-TOXI
with	O
tivozanib	B-DRUG
0.5	O
mg	O
","	O
and	O
Grade	O
3	O
dizziness	B-TOXI
with	O
tivozanib	B-DRUG
1.5	O
mg	O
.	O
	
Other	O
Grade	O
3	O
/	O
4	O
adverse	O
events	O
included	O
hypertension	B-TOXI
(	O
n	O
=	O
8	O
)	O
","	O
fatigue	B-TOXI
(	O
n	O
=	O
8	O
)	O
","	O
and	O
neutropenia	B-TOXI
(	O
n	O
=	O
6	O
)	O
.	O
	
MTD	O
for	O
tivozanib	B-DRUG
with	O
mFOLFOX-6	B-DRUG
was	O
confirmed	O
as	O
1.5	O
mg	O
.	O
	
No	O
PK	O
interactions	O
between	O
tivozanib	B-DRUG
and	O
mFOLFOX-6	B-DRUG
were	O
observed	O
.	O
	
One	O
patient	O
had	O
an	O
ongoing	O
clinical	O
complete	O
response	O
","	O
10	O
had	O
a	O
partial	O
response	O
","	O
and	O
11	O
obtained	O
prolonged	O
stable	O
disease	O
.	O
	
Tivozanib	B-DRUG
and	O
mFOLFOX-6	B-DRUG
is	O
feasible	O
and	O
appears	O
to	O
be	O
safe	O
.	O
	
The	O
recommended	O
dose	O
for	O
tivozanib	B-DRUG
with	O
mFOLFOX-6	B-DRUG
is	O
1.5	O
mg	O
/	O
d.	O
Observed	O
clinical	O
activity	O
merits	O
further	O
exploration	O
in	O
gastrointestinal	B-CANCER
tumors	I-CANCER
.	O
	
Phase	O
I	O
/	O
II	O
study	O
of	O
(	B-DRUG
131	I-DRUG
)	I-DRUG
I-MIBG	I-DRUG
with	O
vincristine	B-DRUG
and	O
5	O
days	O
of	O
irinotecan	B-DRUG
for	O
advanced	B-CANCER
neuroblastoma	I-CANCER
.	O
	
	
(	B-DRUG
131	I-DRUG
)	I-DRUG
I-metaiodobenzylguanidine	I-DRUG
(	O
MIBG	B-DRUG
)	O
is	O
an	O
active	O
radiopharmaceutical	O
in	O
neuroblastoma	B-CANCER
.	O
	
A	O
previous	O
study	O
demonstrated	O
that	O
MIBG	B-DRUG
could	O
be	O
combined	O
with	O
vincristine	B-DRUG
and	O
prolonged	O
irinotecan	B-DRUG
","	O
although	O
25	O
%	O
of	O
first	O
courses	O
had	O
grade	O
3	O
diarrhoea	B-TOXI
.	O
	
The	O
current	O
phase	O
I	O
/	O
II	O
study	O
evaluated	O
MIBG	B-DRUG
with	O
vincristine	B-DRUG
and	O
5	O
days	O
of	O
higher-dose	O
irinotecan	B-DRUG
.	O
	
Patients	O
1月30日	O
years	O
old	O
with	O
advanced	B-CANCER
neuroblastoma	I-CANCER
were	O
eligible	O
.	O
	
Patients	O
received	O
cefixime	B-DRUG
on	O
days	O
-1	O
to	O
6	O
","	O
irinotecan	B-DRUG
(	O
50	O
mg	O
m	O
(	O
-2	O
)	O
per	O
dose	O
IV	O
)	O
on	O
days	O
0-4	O
","	O
vincristine	B-DRUG
(	O
2	O
mg	O
m	O
(	O
-2	O
)	O
)	O
on	O
day	O
0	O
","	O
MIBG	B-DRUG
(	O
555	O
or	O
666	O
MBq	O
kg	O
(	O
-1	O
)	O
)	O
on	O
day	O
1	O
","	O
and	O
peripheral	O
blood	O
stem	O
cells	O
on	O
day	O
13	O
.	O
	
UGT1A1	O
genotyping	O
was	O
performed	O
in	O
consenting	O
patients	O
.	O
	
Thirty-two	O
patients	O
(	O
12	O
phase	O
I	O
;	O
20	O
phase	O
II	O
)	O
received	O
42	O
courses	O
.	O
	
No	O
dose-limiting	O
toxicities	O
were	O
seen	O
during	O
dose	O
escalation	O
and	O
the	O
recommended	O
administered	O
activity	O
was	O
666	O
MBq	O
kg	O
(	O
-1	O
)	O
.	O
	
Myelosuppression	B-TOXI
and	O
diarrhoea	B-TOXI
were	O
the	O
most	O
common	O
toxicities	O
","	O
with	O
grade	O
3	O
diarrhoea	B-TOXI
in	O
6	O
%	O
of	O
first	O
courses	O
.	O
	
Patients	O
homozygous	O
for	O
UGT1A1*28	O
had	O
more	O
grade	O
4	O
thrombocytopenia	B-TOXI
(	O
80	O
%	O
vs	O
37	O
%	O
;	O
P=0.14	O
)	O
.	O
	
Responses	O
(	O
five	O
complete	O
and	O
four	O
partial	O
)	O
occurred	O
in	O
9	O
out	O
of	O
32	O
(	O
28	O
%	O
)	O
patients	O
.	O
	
MIBG	B-DRUG
(	O
666	O
MBq	O
kg	O
(	O
-1	O
)	O
)	O
with	O
vincristine	B-DRUG
and	O
this	O
irinotecan	B-DRUG
schedule	O
is	O
tolerable	O
and	O
active	O
","	O
with	O
less	O
severe	O
diarrhoea	B-TOXI
compared	O
with	O
a	O
regimen	O
using	O
more	O
protracted	O
irinotecan	B-DRUG
.	O
	
A	O
phase	O
I	O
dose	O
escalation	O
study	O
of	O
oxaliplatin	B-DRUG
plus	O
oral	O
S-1	B-DRUG
and	O
pelvic	O
radiation	O
in	O
patients	O
with	O
locally	O
advanced	B-CANCER
rectal	I-CANCER
cancer	I-CANCER
(	O
SHOGUN	O
trial	O
)	O
.	O
	
	
The	O
objective	O
of	O
this	O
phase	O
I	O
study	O
was	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
recommended	O
dose	O
(	O
RD	O
)	O
of	O
preoperative	O
chemoradiotherapy	O
(	O
CRT	O
)	O
with	O
S-1	B-DRUG
plus	O
oxaliplatin	B-DRUG
in	O
patients	O
with	O
locally	O
advanced	B-CANCER
rectal	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
received	O
radiotherapy	O
in	O
a	O
total	O
dose	O
of	O
50.4	O
Gy	O
in	O
28	O
fractions	O
.	O
	
Concurrent	O
chemotherapy	O
consisted	O
of	O
a	O
fixed	O
oral	O
dose	O
of	O
S-1	B-DRUG
(	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
)	O
on	O
days	O
1月5日	O
","	O
8月12日	O
","	O
22-27	O
","	O
and	O
29-33	O
","	O
plus	O
escalated	O
doses	O
of	O
oxaliplatin	B-DRUG
as	O
an	O
intravenous	O
infusion	O
on	O
days	O
1	O
","	O
8	O
","	O
22	O
","	O
and	O
29	O
.	O
	
Oxaliplatin	B-DRUG
was	O
initially	O
given	O
in	O
a	O
dose	O
of	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
week	O
to	O
three	O
patients	O
.	O
	
The	O
dose	O
was	O
then	O
increased	O
in	O
a	O
stepwise	O
fashion	O
to	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
week	O
and	O
the	O
highest	O
dose	O
level	O
of	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
week	O
until	O
the	O
MTD	O
was	O
attained	O
.	O
	
Thirteen	O
patients	O
were	O
enrolled	O
","	O
and	O
12	O
received	O
CRT	O
.	O
	
Dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
occurred	O
in	O
two	O
of	O
six	O
patients	O
(	O
persistent	O
grade	O
2	O
neutropenia	B-TOXI
","	O
delaying	O
oxaliplatin	B-DRUG
treatment	O
by	O
more	O
than	O
3	O
days	O
)	O
at	O
dose	O
level	O
3	O
;	O
there	O
were	O
no	O
grade	O
3	O
or	O
4	O
adverse	O
events	O
defined	O
as	O
DLT	O
.	O
	
The	O
RD	O
was	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
week	O
of	O
oxaliplatin	B-DRUG
on	O
days	O
1	O
","	O
8	O
","	O
22	O
","	O
and	O
29	O
.	O
	
Twelve	O
patients	O
underwent	O
histologically	O
confirmed	O
R0	O
resections	O
","	O
and	O
two	O
out	O
of	O
six	O
patients	O
(	O
33	O
%	O
)	O
given	O
dose	O
level	O
3	O
had	O
pathological	O
complete	O
responses	O
.	O
	
The	O
RD	O
for	O
further	O
studies	O
is	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
S-1	B-DRUG
5	O
days	O
per	O
week	O
plus	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
oxaliplatin	B-DRUG
on	O
days	O
1	O
","	O
8	O
","	O
22	O
","	O
and	O
29	O
and	O
concurrent	O
radiotherapy	O
.	O
	
Although	O
our	O
results	O
are	O
preliminary	O
","	O
this	O
new	O
regimen	O
for	O
neoadjuvant	O
chemoradiotherapy	O
is	O
considered	O
safe	O
and	O
active	O
.	O
	
This	O
trial	O
was	O
registered	O
with	O
Clinicaltrials.gov	O
(	O
identifier	O
:	O
NCT01227239	O
)	O
.	O
	
Phase	O
1b	O
study	O
of	O
the	O
oral	O
gemcitabine	B-DRUG
'Pro-drug	O
'	O
LY2334737	B-DRUG
in	O
combination	O
with	O
capecitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Background	O
This	O
Phase	O
1b	O
study	O
aimed	O
to	O
determine	O
the	O
recommended	O
Phase	O
2	O
dose	O
of	O
LY2334737	O
","	O
an	O
oral	O
pro-drug	O
of	O
gemcitabine	B-DRUG
","	O
in	O
combination	O
with	O
capecitabine	B-DRUG
","	O
an	O
oral	O
pro-drug	O
of	O
5-fluorouracil	B-DRUG
","	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
In	O
addition	O
","	O
pharmacokinetics	O
(	O
PK	O
)	O
and	O
tumor	O
response	O
were	O
evaluated	O
.	O
	
Patients	O
and	O
methods	O
Patients	O
with	O
advanced	O
/	O
metastatic	B-CANCER
solid	I-CANCER
tumors	I-CANCER
received	O
650	O
mg	O
/	O
m	O
(	O
2	O
)	O
capecitabine	B-DRUG
twice	O
daily	O
(	O
BID	O
)	O
and	O
escalating	O
doses	O
of	O
LY2334737	B-DRUG
once	O
daily	O
(	O
QD	O
;	O
initial	O
dose	O
10	O
mg	O
/	O
day	O
)	O
","	O
both	O
for	O
14	O
days	O
followed	O
by	O
7-day	O
drug	O
holiday	O
.	O
	
Cycles	O
were	O
repeated	O
until	O
progressive	O
disease	O
(	O
PD	O
)	O
or	O
unacceptable	O
toxicity	O
.	O
	
Results	O
Fifteen	O
patients	O
received	O
a	O
median	O
of	O
2	O
(	O
range	O
1月7日	O
)	O
treatment	O
cycles	O
;	O
14	O
patients	O
discontinued	O
due	O
to	O
PD	O
","	O
1	O
due	O
to	O
toxicity	O
(	O
pyrexia	B-TOXI
)	O
.	O
	
LY2334737	B-DRUG
doses	O
up	O
to	O
40	O
mg	O
/	O
day	O
were	O
explored	O
.	O
	
Three	O
dose-limiting	O
toxicities	O
were	O
reported	O
by	O
2	O
patients	O
(	O
fatigue	B-TOXI
","	O
diarrhea	B-TOXI
","	O
hyponatremia	B-TOXI
;	O
all	O
Grade	O
3	O
)	O
.	O
	
Seven	O
patients	O
achieved	O
stable	O
disease	O
.	O
	
Enrollment	O
was	O
stopped	O
after	O
unexpected	O
hepatic	B-TOXI
toxicities	I-TOXI
were	O
observed	O
with	O
LY2334737	B-DRUG
QD	O
in	O
a	O
study	O
of	O
Japanese	O
patients	O
.	O
	
PK	O
parameters	O
for	O
LY2334737	B-DRUG
were	O
consistent	O
with	O
the	O
first-in-human	O
study	O
of	O
LY2334737	B-DRUG
;	O
PK	O
data	O
after	O
14	O
day	O
combination	O
treatment	O
revealed	O
no	O
drug-drug	O
interactions	O
between	O
LY2334737	B-DRUG
and	O
capecitabine	B-DRUG
.	O
	
Conclusions	O
No	O
drug	O
interactions	O
or	O
unexpected	O
toxicities	O
were	O
observed	O
in	O
US	O
patients	O
when	O
LY2334737	B-DRUG
at	O
doses	O
up	O
to	O
40	O
mg	O
/	O
day	O
was	O
administered	O
QD	O
in	O
combination	O
with	O
capecitabine	B-DRUG
BID	O
;	O
the	O
maximum	O
tolerated	O
dose	O
was	O
not	O
reached	O
.	O
	
A	O
phase	O
1	O
study	O
of	O
cetuximab	B-DRUG
and	O
lapatinib	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumor	I-CANCER
malignancies	I-CANCER
.	O
	
	
Acquired	O
resistance	O
to	O
antiepidermal	O
growth	O
factor	O
receptor	O
(	O
anti-EGFR	O
)	O
therapy	O
may	O
be	O
caused	O
by	O
EGFR-v-erb-b2	O
avian	O
erythroblastic	O
leukemia	O
viral	O
oncogene	O
homolog	O
2	O
(	O
ErbB2	O
)	O
heterodimerization	O
and	O
pathway	O
reactivation	O
.	O
	
In	O
preclinical	O
studies	O
","	O
inhibiting	O
ErbB2	O
blocked	O
this	O
resistance	O
mechanism	O
and	O
resensitized	O
cells	O
to	O
anti-EGFR	O
therapy	O
.	O
	
Cetuximab	B-DRUG
targets	O
EGFR	O
","	O
whereas	O
lapatinib	B-DRUG
inhibits	O
both	O
EGFR	O
and	O
ErbB2	O
.	O
	
The	O
objective	O
of	O
this	O
phase	O
1	O
trial	O
was	O
to	O
assess	O
the	O
safety	O
","	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
","	O
and	O
maximum	O
tolerated	O
doses	O
(	O
MTDs	O
)	O
of	O
cetuximab	B-DRUG
and	O
lapatinib	B-DRUG
in	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
Patients	O
received	O
standard	O
weekly	O
cetuximab	B-DRUG
with	O
escalating	O
lapatinib	B-DRUG
doses	O
of	O
750	O
mg	O
","	O
1000	O
mg	O
","	O
or	O
1250	O
mg	O
daily	O
in	O
3-week	O
cycles	O
.	O
	
DLTs	O
were	O
monitored	O
through	O
the	O
end	O
of	O
cycle	O
2	O
Pretreatment	O
and	O
post-treatment	O
tumor	O
biopsies	O
and	O
germline	B-DRUG
DNA	O
samples	O
were	O
obtained	O
for	O
correlative	O
studies	O
.	O
	
Twenty-two	O
patients	O
were	O
enrolled	O
","	O
and	O
18	O
patients	O
each	O
were	O
evaluable	O
for	O
toxicity	O
and	O
response	O
.	O
	
Fifty-nine	O
percent	O
of	O
patients	O
had	O
received	O
prior	O
anti-EGFR	O
therapy	O
.	O
	
Common	O
toxicities	O
included	O
rash	B-TOXI
and	O
diarrhea	B-TOXI
.	O
	
No	O
patient	O
experienced	O
a	O
DLT	O
at	O
the	O
highest	O
dose	O
level	O
","	O
and	O
no	O
grade	O
4	O
toxicity	O
was	O
observed	O
.	O
	
Response	O
included	O
no	O
complete	O
responses	O
","	O
3	O
partial	O
responses	O
","	O
9	O
patients	O
with	O
stable	O
disease	O
","	O
and	O
6	O
patients	O
with	O
disease	O
progression	O
","	O
for	O
an	O
overall	O
response	O
rate	O
of	O
17	O
%	O
and	O
a	O
clinical	O
benefit	O
rate	O
of	O
67	O
%	O
.	O
	
The	O
clinical	O
benefit	O
rate	O
in	O
patients	O
who	O
had	O
previously	O
received	O
anti-EGFR	O
therapy	O
was	O
70	O
%	O
.	O
	
The	O
mean	O
treatment	O
duration	O
was	O
4.7	O
cycles	O
(	O
range	O
","	O
1月14日	O
cycles	O
)	O
.	O
	
Decreased	O
expression	O
of	O
EGFR	O
/	O
ErbB2	O
pathway	O
components	O
after	O
treatment	O
was	O
correlated	O
with	O
response	O
","	O
whereas	O
increased	O
expression	O
in	O
the	O
PI3K	O
","	O
Jak	O
/	O
Stat	O
","	O
and	O
MAPK	O
pathways	O
occurred	O
in	O
nonresponders	O
.	O
	
The	O
combination	O
of	O
cetuximab	B-DRUG
and	O
lapatinib	B-DRUG
was	O
well	O
tolerated	O
","	O
had	O
the	O
expected	O
toxicities	O
","	O
and	O
exhibited	O
notable	O
clinical	O
activity	O
","	O
including	O
in	O
patients	O
who	O
had	O
received	O
previous	O
anti-EGFR	O
therapy	O
.	O
	
Further	O
clinical	O
study	O
of	O
this	O
combination	O
is	O
warranted	O
.	O
	
Phase	O
1b	O
study	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	O
inhibitor	O
sirolimus	B-DRUG
in	O
combination	O
with	O
nanoparticle	O
albumin-bound	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
The	O
optimal	O
weekly	O
oral	O
dose	O
of	O
sirolimus	B-DRUG
and	O
intravenous	O
nanoparticle	B-DRUG
albumin-bound	O
paclitaxel	B-DRUG
(	O
nab-paclitaxel	B-DRUG
)	O
were	O
evaluated	O
.	O
	
A	O
phase	O
1b	O
study	O
was	O
performed	O
to	O
evaluate	O
escalating	O
doses	O
of	O
oral	O
sirolimus	B-DRUG
(	O
5-60	O
mg	O
)	O
on	O
days	O
2	O
","	O
9	O
","	O
and	O
16	O
with	O
intravenous	O
nab-paclitaxel	B-DRUG
(	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
in	O
a	O
28-day	O
cycle	O
.	O
	
A	O
run-in	O
treatment	O
of	O
nab-paclitaxel	B-DRUG
(	O
day	O
-14	O
)	O
and	O
sirolimus	B-DRUG
(	O
day	O
-7	O
)	O
was	O
administered	O
for	O
pharmacokinetic	O
and	O
pharmacodynamic	O
assessments	O
.	O
	
Clinical	O
trial	O
endpoints	O
included	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
","	O
maximum	O
tolerated	O
doses	O
","	O
and	O
response	O
rates	O
.	O
	
Pharmacodynamics	O
included	O
immunohistochemistry	O
for	O
phosphatase	O
and	O
tensin	O
homolog	O
","	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
","	O
AKT	O
","	O
phosphorylated	O
AKT	O
","	O
S6K1	O
","	O
and	O
phosphorylated	O
S6K1	O
;	O
exploratory	O
gene	O
expression	O
analysis	O
;	O
and	O
[	B-DRUG
(	I-DRUG
18	I-DRUG
)	I-DRUG
F	I-DRUG
]	I-DRUG
fludeoxyglucose	I-DRUG
(	O
FDG	B-DRUG
)	O
positron	O
emission	O
tomography	O
.	O
	
Twenty-three	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
treated	O
.	O
	
Fifteen	O
patients	O
had	O
prior	O
taxane	B-DRUG
therapy	O
.	O
	
Twenty-two	O
patients	O
were	O
evaluable	O
for	O
responses	O
.	O
	
One	O
patient	O
had	O
a	O
complete	O
response	O
","	O
and	O
5	O
patients	O
had	O
a	O
partial	O
response	O
(	O
3	O
confirmed	O
)	O
.	O
	
DLTs	O
were	O
seen	O
in	O
1	O
patient	O
each	O
at	O
10	O
(	O
grade	O
3	O
dyspnea	B-TOXI
/	O
hypoxia	B-TOXI
)	O
and	O
40	O
mg	O
(	O
grade	O
4	O
leukopenia	B-TOXI
/	O
neutropenia	B-TOXI
)	O
and	O
in	O
2	O
patients	O
at	O
60	O
mg	O
(	O
grade	O
3	O
fatigue	B-TOXI
and	O
grade	O
4	O
pericardial	B-TOXI
effusion	I-TOXI
)	O
.	O
	
Patients	O
with	O
higher	O
expression	O
of	O
posttreatment	O
AKT	O
and	O
a	O
greater	O
decline	O
in	O
FDG	B-DRUG
activity	O
were	O
more	O
likely	O
to	O
have	O
a	O
treatment	O
response	O
or	O
stable	O
disease	O
.	O
	
Sirolimus	B-DRUG
showed	O
an	O
acceptable	O
safety	O
profile	O
at	O
a	O
weekly	O
dose	O
of	O
40	O
mg	O
with	O
weekly	O
intravenous	O
nab-paclitaxel	B-DRUG
at	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
every	O
28	O
days	O
.	O
	
The	O
posttreatment	O
AKT	O
score	O
and	O
changes	O
in	O
FDG	B-DRUG
activity	O
may	O
have	O
roles	O
as	O
early	O
predictors	O
of	O
responses	O
to	O
mTOR	O
inhibitors	O
.	O
	
Phase	O
1	O
trial	O
of	O
bevacizumab	B-DRUG
with	O
concurrent	O
chemoradiation	O
therapy	O
for	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
with	O
exploratory	O
functional	O
imaging	O
of	O
tumor	O
hypoxia	B-TOXI
","	O
proliferation	B-TOXI
","	O
and	O
perfusion	B-TOXI
.	O
	
	
A	O
phase	O
1	O
trial	O
was	O
completed	O
to	O
examine	O
the	O
safety	O
and	O
feasibility	O
of	O
combining	O
bevacizumab	B-DRUG
with	O
radiation	O
and	O
cisplatin	B-DRUG
in	O
patients	O
with	O
locoregionally	O
advanced	B-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	O
HNSCC	B-CANCER
)	O
treated	O
with	O
curative	O
intent	O
.	O
	
Additionally	O
","	O
we	O
assessed	O
the	O
capacity	O
of	O
bevacizumab	B-DRUG
to	O
induce	O
an	O
early	O
tumor	O
response	O
as	O
measured	O
by	O
a	O
series	O
of	O
biological	O
imaging	O
studies	O
.	O
	
All	O
patients	O
received	O
a	O
single	O
induction	O
dose	O
of	O
bevacizumab	B-DRUG
(	O
15	O
mg	O
/	O
kg	O
)	O
delivered	O
3	O
weeks	O
(	O
卤3	O
days	O
)	O
before	O
the	O
initiation	O
of	O
chemoradiation	O
therapy.	O
After	O
the	O
initial	O
dose	O
of	O
bevacizumab	B-DRUG
","	O
comprehensive	O
head	O
and	O
neck	O
chemoradiation	O
therapy	O
was	O
delivered	O
with	O
curative	O
intent	O
to	O
70	O
Gy	O
in	O
33	O
fractions	O
with	O
concurrent	O
weekly	O
cisplatin	B-DRUG
at	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
bevacizumab	B-DRUG
every	O
3	O
weeks	O
(	O
weeks	O
1	O
","	O
4	O
","	O
7	O
)	O
with	O
dose	O
escalation	O
from	O
5	O
to	O
10	O
to	O
15	O
mg	O
/	O
kg	O
.	O
	
All	O
patients	O
underwent	O
experimental	O
imaging	O
with	O
[	B-DRUG
(	I-DRUG
18	I-DRUG
)	I-DRUG
F	I-DRUG
]	I-DRUG
fluorothymidine	I-DRUG
positron	O
emission	O
tomography	O
(	O
FLT-PET	O
)	O
(	O
proliferation	O
)	O
","	O
[	O
(	O
61	O
)	O
Cu	O
]	O
Cu-diacetyl-bis	O
(	O
N4-methylthiosemicarbazone	O
)	O
PET	O
(	O
Cu-ATSM-PET	O
)	O
(	O
hypoxia	O
)	O
","	O
and	O
dynamic	O
contrast-enhanced	O
computed	O
tomography	O
(	O
DCE-CT	O
)	O
(	O
perfusion	O
)	O
at	O
3	O
time	O
points	O
:	O
before	O
bevacizumab	B-DRUG
monotherapy	O
","	O
after	O
bevacizumab	B-DRUG
monotherapy	O
","	O
and	O
during	O
the	O
combined	O
therapy	O
course	O
.	O
	
Ten	O
patients	O
were	O
enrolled	O
.	O
	
All	O
had	O
stage	O
IV	O
HNSCC	B-CANCER
","	O
all	O
achieved	O
a	O
complete	O
response	O
to	O
treatment	O
","	O
and	O
9	O
of	O
10	O
remain	O
alive	O
","	O
with	O
a	O
mean	O
survival	O
time	O
of	O
61.3	O
months	O
.	O
	
All	O
patients	O
experienced	O
grade	O
3	O
toxicity	O
","	O
but	O
no	O
dose-limiting	O
toxicities	O
or	O
significant	O
bleeding	B-TOXI
episodes	O
were	O
observed	O
.	O
	
Significant	O
reductions	O
were	O
noted	O
in	O
tumor	O
proliferation	O
(	O
FLT-PET	O
)	O
","	O
tumor	O
hypoxia	O
(	O
Cu-ATSM-PET	O
)	O
","	O
and	O
DCE-CT	O
contrast	O
enhancement	O
after	O
bevacizumab	B-DRUG
monotherapy	O
","	O
with	O
further	O
decreases	O
in	O
FLT-PET	O
and	O
Cu-ATSM-PET	O
during	O
the	O
combined	O
therapy	O
course	O
.	O
	
The	O
incorporation	O
of	O
bevacizumab	B-DRUG
into	O
comprehensive	O
chemoradiation	O
therapy	O
regimens	O
for	O
patients	O
with	O
HNSCC	B-CANCER
appears	O
safe	O
and	O
feasible	O
.	O
	
Experimental	O
imaging	O
demonstrates	O
measureable	O
changes	O
in	O
tumor	O
proliferation	O
","	O
hypoxia	O
","	O
and	O
perfusion	O
after	O
bevacizumab	B-DRUG
monotherapy	O
and	O
during	O
chemoradiation	O
therapy	O
.	O
	
These	O
findings	O
suggest	O
opportunities	O
to	O
preview	O
the	O
clinical	O
outcomes	O
for	O
individual	O
patients	O
and	O
thereby	O
design	O
personalized	O
therapy	O
approaches	O
in	O
future	O
trials	O
.	O
	
Phase	O
I	O
dose-escalation	O
study	O
of	O
pilaralisib	B-DRUG
(	O
SAR245408	O
","	O
XL147	O
)	O
","	O
a	O
pan-class	O
I	O
PI3K	O
inhibitor	O
","	O
in	O
combination	O
with	O
erlotinib	B-DRUG
in	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
This	O
phase	O
I	O
study	O
evaluated	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
safety	O
","	O
pharmacokinetics	O
(	O
PK	O
)	O
","	O
and	O
pharmacodynamics	O
of	O
pilaralisib	B-DRUG
(	O
SAR245408	O
)	O
","	O
an	O
oral	O
pan-class	O
I	O
phosphoinositide	O
3-kinase	O
(	O
PI3K	O
)	O
inhibitor	O
","	O
in	O
combination	O
with	O
erlotinib	B-DRUG
","	O
an	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
inhibitor	O
.	O
	
In	O
a	O
3	O
=+	O
3	O
dose-escalation	O
study	O
","	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
received	O
pilaralisib	B-DRUG
capsules	O
once	O
daily	O
(	O
21	O
days	O
per	O
28-day	O
cycle	O
;	O
50-600	O
mg	O
)	O
plus	O
erlotinib	B-DRUG
tablets	O
once	O
daily	O
(	O
28	O
days	O
per	O
28-day	O
cycle	O
;	O
100	O
or	O
150	O
mg	O
)	O
.	O
	
An	O
MTD	O
expansion	O
cohort	O
of	O
patients	O
with	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
who	O
had	O
previously	O
received	O
treatment	O
with	O
an	O
EGFR	O
inhibitor	O
was	O
included	O
.	O
	
Thirty-five	O
patients	O
were	O
enrolled	O
.	O
	
Only	O
one	O
patient	O
had	O
an	O
EGFR	O
activating	O
mutation	O
.	O
	
One	O
dose-limiting	O
toxicity	O
was	O
reported	O
(	O
grade	O
4	O
drug	O
reaction	O
or	O
rash	B-TOXI
with	O
eosinophilia	B-TOXI
and	O
systemic	B-TOXI
symptoms	I-TOXI
)	O
.	O
	
MTD	O
was	O
pilaralisib	B-DRUG
400	O
mg	O
plus	O
erlotinib	B-DRUG
150	O
mg	O
.	O
	
The	O
most	O
commonly	O
reported	O
treatment-related	O
adverse	O
events	O
were	O
rash	B-TOXI
(	O
62.9	O
%	O
)	O
","	O
diarrhea	B-TOXI
(	O
42.9	O
%	O
)	O
","	O
and	O
fatigue	B-TOXI
(	O
40	O
%	O
)	O
.	O
	
Pilaralisib	B-DRUG
PK	O
findings	O
were	O
consistent	O
with	O
previous	O
studies	O
","	O
suggesting	O
erlotinib	B-DRUG
had	O
no	O
effect	O
on	O
pilaralisib	B-DRUG
pharmacokinetics	O
.	O
	
Pharmacodynamic	O
analyses	O
indicated	O
moderate	O
inhibition	O
of	O
PI3K	O
","	O
mitogen-activated	O
protein	O
kinase	O
","	O
and	O
EGFR	O
pathways	O
.	O
	
Of	O
27	O
evaluable	O
patients	O
","	O
one	O
had	O
a	O
partial	O
response	O
(	O
3.7	O
%	O
)	O
and	O
14	O
(	O
51.9	O
%	O
)	O
had	O
stable	O
disease	O
.	O
	
There	O
was	O
no	O
association	O
between	O
molecular	O
alterations	O
of	O
PI3K	O
pathway	O
components	O
and	O
clinical	O
activity	O
.	O
	
Pilaralisib	B-DRUG
plus	O
erlotinib	B-DRUG
had	O
limited	O
antitumor	O
activity	O
.	O
	
Safety	O
findings	O
were	O
similar	O
to	O
recent	O
studies	O
of	O
single-agent	O
pilaralisib	B-DRUG
or	O
other	O
PI3K	O
inhibitors	O
.	O
	
Phase	O
I	O
dose	O
escalation	O
trial	O
of	O
the	O
novel	O
proteasome	O
inhibitor	O
carfilzomib	B-DRUG
in	O
patients	O
with	O
relapsed	O
chronic	B-CANCER
lymphocytic	I-CANCER
leukemia	I-CANCER
and	O
small	B-CANCER
lymphocytic	I-CANCER
lymphoma	I-CANCER
.	O
	
	
The	O
proteasome	O
complex	O
degrades	O
proteins	O
involved	O
in	O
a	O
variety	O
of	O
cellular	O
processes	O
and	O
is	O
a	O
powerful	O
therapeutic	O
target	O
in	O
several	O
malignancies	B-CANCER
.	O
	
Carfilzomib	B-DRUG
is	O
a	O
potent	O
proteasome	O
inhibitor	O
which	O
induces	O
rapid	O
chronic	B-CANCER
lymphocytic	I-CANCER
leukemia	I-CANCER
(	O
CLL	B-CANCER
)	O
cell	O
apoptosis	O
in	O
vitro	O
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
dose-escalation	O
trial	O
to	O
determine	O
the	O
safety	O
and	O
tolerability	O
of	O
carfilzomib	B-DRUG
in	O
relapsed	O
/	O
refractory	B-CANCER
CLL	I-CANCER
or	O
small	B-CANCER
lymphocytic	I-CANCER
lymphoma	I-CANCER
(	O
SLL	B-CANCER
)	O
.	O
	
Nineteen	O
patients	O
were	O
treated	O
with	O
carfilzomib	B-DRUG
initially	O
at	O
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
then	O
escalated	O
in	O
four	O
cohorts	O
(	O
27	O
","	O
36	O
","	O
45	O
and	O
56	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
on	O
days	O
1	O
","	O
2	O
","	O
8	O
","	O
9	O
","	O
15	O
and	O
16	O
of	O
28-day	O
cycles	O
.	O
	
Therapy	O
was	O
generally	O
well	O
tolerated	O
","	O
and	O
no	O
dose	O
limiting	O
toxicities	O
were	O
observed	O
.	O
	
The	O
most	O
common	O
hematologic	B-TOXI
toxicities	I-TOXI
were	O
thrombocytopenia	B-TOXI
and	O
neutropenia	B-TOXI
.	O
	
All	O
patients	O
evaluable	O
for	O
response	O
had	O
stable	O
disease	O
","	O
including	O
patients	O
with	O
del17p13	O
and	O
fludarabine-resistant	B-DRUG
disease	O
.	O
	
This	O
trial	O
shows	O
acceptable	O
tolerability	O
and	O
limited	O
preliminary	O
efficacy	O
of	O
carfilzomib	B-DRUG
in	O
CLL	B-CANCER
and	O
SLL	B-CANCER
.	O
	
Phase	O
I	O
trial	O
of	O
oral	O
S-1	B-DRUG
combined	O
with	O
hepatic	O
arterial	O
infusion	O
of	O
gemcitabine	B-DRUG
in	O
unresectable	O
biliary	B-CANCER
tract	I-CANCER
cancer	I-CANCER
.	O
	
	
S-1	B-DRUG
and	O
gemcitabine	B-DRUG
(	O
GS	B-DRUG
)	O
combination	O
therapy	O
is	O
a	O
promising	O
treatment	O
for	O
advanced	B-CANCER
biliary	I-CANCER
tract	I-CANCER
cancer	I-CANCER
(	O
BTC	B-CANCER
)	O
.	O
	
However	O
","	O
systemic	O
administration	O
of	O
GS	B-DRUG
is	O
associated	O
with	O
a	O
high	O
rate	O
of	O
grade	O
3	O
and	O
4	O
neutropenia	B-TOXI
.	O
	
Hepatic	O
arterial	O
infusion	O
(	O
HAI	O
)	O
of	O
gemcitabine	B-DRUG
may	O
overcome	O
this	O
problem	O
.	O
	
We	O
conducted	O
a	O
prospective	O
phase	O
1	O
trial	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
S-1	O
and	O
rates	O
of	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
associated	O
with	O
HAI	O
of	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
unresectable	O
BTC	B-CANCER
.	O
	
BTC	B-CANCER
patients	O
were	O
treated	O
with	O
21-day	O
cycles	O
of	O
HAI	O
of	O
gemcitabine	B-DRUG
(	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
and	O
8	O
)	O
and	O
oral	O
S-1	B-DRUG
(	O
60	O
","	O
70	O
","	O
or	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1月14日	O
)	O
until	O
disease	O
progression	O
occurred	O
.	O
	
Fifteen	O
patients	O
were	O
enrolled	O
in	O
the	O
study	O
.	O
	
Grade	O
3	O
and	O
4	O
neutropenia	B-TOXI
occurred	O
in	O
five	O
of	O
15	O
(	O
33	O
%	O
)	O
patients	O
.	O
	
Among	O
six	O
patients	O
who	O
were	O
treated	O
with	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
S-1	O
","	O
one	O
developed	O
grade	O
4	O
neutropenia	B-TOXI
.	O
	
DLTs	O
(	O
grade	O
4	O
neutropenia	B-TOXI
and	O
bladder	B-TOXI
infection	I-TOXI
)	O
occurred	O
in	O
two	O
of	O
six	O
patients	O
who	O
were	O
treated	O
with	O
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
S-1	B-DRUG
.	O
	
Two	O
of	O
the	O
three	O
patients	O
who	O
were	O
treated	O
with	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
S-1	O
experienced	O
DLTs	O
(	O
grade	O
4	O
leukopenia	B-TOXI
and	O
neutropenia	B-TOXI
and	O
grade	O
3	O
febrile	B-TOXI
neutropenia	I-TOXI
)	O
.	O
	
Thus	O
","	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
was	O
defined	O
as	O
the	O
MTD	O
of	O
S-1	B-DRUG
.	O
	
The	O
MTD	O
of	O
oral	O
S-1	B-DRUG
in	O
GS	B-DRUG
therapy	O
is	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Furthermore	O
","	O
HAI	O
of	O
gemcitabine	B-DRUG
may	O
reduce	O
the	O
rate	O
of	O
grade	O
3	O
and	O
4	O
neutropenia	B-TOXI
in	O
BTC	B-CANCER
patients	O
receiving	O
GS	B-DRUG
therapy	O
.	O
	
SU2C	O
phase	O
Ib	O
study	O
of	O
paclitaxel	B-DRUG
and	O
MK-2206	B-DRUG
in	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
and	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
There	O
is	O
preclinical	O
synergism	O
between	O
taxanes	B-DRUG
and	O
MK-2206	B-DRUG
.	O
	
We	O
aim	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
","	O
safety	O
","	O
and	O
activity	O
of	O
combining	O
MK-2206	B-DRUG
and	O
paclitaxel	B-DRUG
in	O
metastatic	B-CANCER
cancer	I-CANCER
.	O
	
Patients	O
received	O
weekly	O
doses	O
of	O
paclitaxel	B-DRUG
at	O
80mg	O
/	O
m2	O
on	O
day	O
1	O
","	O
followed	O
by	O
MK-2206	B-DRUG
orally	O
on	O
day	O
2	O
escalated	O
at	O
90mg	O
","	O
135mg	O
","	O
and	O
200mg	O
.	O
	
Treatment	O
continued	O
until	O
progression	O
","	O
excessive	O
toxicity	O
","	O
or	O
patient	O
request	O
.	O
	
Blood	O
and	O
tissue	O
were	O
collected	O
for	O
pharmacokinetic	O
and	O
pharmacodynamics	O
markers	O
.	O
	
A	O
cycle	O
consisted	O
of	O
three	O
weeks	O
of	O
therapy	O
.	O
	
Dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
was	O
defined	O
as	O
unacceptable	O
toxicity	O
during	O
the	O
first	O
cycle	O
.	O
	
All	O
statistical	O
tests	O
were	O
two-sided	O
.	O
	
Twenty-two	O
patients	O
were	O
treated	O
","	O
nine	O
in	O
dose	O
escalation	O
and	O
13	O
in	O
dose	O
expansion	O
.	O
	
Median	O
age	O
was	O
55	O
years	O
.	O
	
Median	O
number	O
of	O
cycles	O
was	O
four	O
.	O
	
Dose	O
escalation	O
was	O
completed	O
with	O
no	O
DLT	O
.	O
	
CTCAE	O
Grade	O
3	O
or	O
higher	O
adverse	O
events	O
were	O
fatigue	B-TOXI
(	O
n	O
=	O
2	O
)	O
","	O
rash	B-TOXI
(	O
n	O
=	O
2	O
)	O
","	O
hyperglycemia	B-TOXI
(	O
n	O
=	O
1	O
)	O
","	O
and	O
neutropenia	B-TOXI
(	O
n	O
=	O
7	O
)	O
.	O
	
Four	O
patients	O
in	O
the	O
expansion	O
phase	O
required	O
MK-2206	B-DRUG
dose	O
reduction	O
.	O
	
Phase	O
II	O
recommended	O
dose	O
was	O
established	O
as	O
paclitaxel	B-DRUG
80mg	O
/	O
m2	O
weekly	O
on	O
day	O
1	O
","	O
and	O
MK-2206	B-DRUG
135mg	O
weekly	O
on	O
day	O
2	O
Paclitaxel	B-DRUG
systemic	O
exposure	O
was	O
similar	O
in	O
the	O
presence	O
or	O
absence	O
of	O
MK-2206	B-DRUG
.	O
	
Plasma	O
MK-2206	B-DRUG
concentrations	O
were	O
similar	O
to	O
data	O
from	O
previous	O
phase	O
I	O
monotherapy	O
.	O
	
There	O
was	O
a	O
statistically	O
significant	O
decrease	O
in	O
expression	O
of	O
pAKT	O
S473	O
(	O
P	O
=	O
0.01	O
)	O
and	O
pAKT	O
T308	O
(	O
P	O
=	O
0.002	O
)	O
after	O
therapy	O
.	O
	
PI3K	O
/	O
AKT	O
/	O
mTOR	O
downregulation	O
in	O
tumor	O
tissues	O
and	O
circulating	O
markers	O
did	O
not	O
correlate	O
with	O
tumor	O
response	O
or	O
clinical	O
benefit	O
.	O
	
There	O
were	O
five	O
objective	O
responses	O
","	O
and	O
nine	O
patients	O
had	O
stable	O
disease	O
.	O
	
MK-2206	B-DRUG
was	O
well	O
tolerated	O
with	O
paclitaxel	B-DRUG
.	O
	
Preliminary	O
antitumor	O
activity	O
was	O
documented	O
.	O
	
Pharmacokinetics	O
and	O
dose	O
recommendations	O
for	O
cyclosporine	B-DRUG
and	O
tacrolimus	B-DRUG
when	O
coadministered	O
with	O
ABT-450	B-DRUG
","	O
ombitasvir	B-DRUG
","	O
and	O
dasabuvir	B-DRUG
.	O
	
	
ABT-450	B-DRUG
","	O
ombitasvir	B-DRUG
","	O
and	O
dasabuvir	B-DRUG
are	O
direct-acting	O
antiviral	O
agents	O
(	O
DAAs	O
)	O
that	O
have	O
been	O
developed	O
for	O
combination	O
treatment	O
of	O
chronic	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
.	O
	
Because	O
these	O
DAAs	O
have	O
metabolic	O
and	O
transporter	O
profiles	O
that	O
overlap	O
with	O
cyclosporine	B-DRUG
and	O
tacrolimus	B-DRUG
disposition	O
","	O
there	O
is	O
potential	O
for	O
drug	O
interactions	O
.	O
	
Two	O
Phase	O
1	O
studies	O
assessed	O
effects	O
of	O
ABT-450	B-DRUG
(	O
150	O
mg	O
coadministered	O
with	O
ritonavir	B-DRUG
100	O
mg	O
once	O
daily	O
)	O
","	O
ombitasvir	B-DRUG
(	O
25	O
mg	O
once	O
daily	O
)	O
","	O
and	O
dasabuvir	B-DRUG
(	O
400	O
mg	O
twice	O
daily	O
)	O
on	O
the	O
pharmacokinetics	O
","	O
safety	O
","	O
and	O
tolerability	O
of	O
a	O
single	O
dose	O
of	O
cyclosporine	B-DRUG
(	O
30	O
mg	O
)	O
or	O
tacrolimus	B-DRUG
(	O
2	O
mg	O
)	O
in	O
healthy	O
volunteers	O
(	O
N	O
=	O
12	O
per	O
study	O
)	O
.	O
	
In	O
the	O
presence	O
of	O
steady-state	O
concentrations	O
of	O
all	O
3	O
DAAs	O
","	O
dose-normalized	O
cyclosporine	B-DRUG
concentration	O
at	O
24	O
hours	O
(	O
C___	O
)	O
","	O
and	O
area	O
under	O
the	O
concentration-time	O
curve	O
from	O
time	O
0	O
to	O
infinity	O
(	O
AUC	O
(	O
_	O
)	O
)	O
were	O
15.8-fold	O
and	O
5.8-fold	O
","	O
respectively	O
","	O
and	O
dose-normalized	O
tacrolimus	B-DRUG
C___	O
and	O
AUC	O
(	O
_	O
)	O
were	O
17-fold	O
and	O
57-fold	O
","	O
respectively	O
","	O
of	O
either	O
agent	O
alone	O
.	O
	
Cyclosporine	O
and	O
tacrolimus	B-DRUG
half-lives	O
increased	O
from	O
7	O
to	O
25	O
h	O
and	O
32	O
to	O
232	O
h	O
","	O
respectively	O
.	O
	
There	O
were	O
no	O
major	O
safety	O
or	O
tolerability	O
issues	O
in	O
these	O
studies	O
.	O
	
The	O
results	O
suggest	O
that	O
cyclosporine	B-DRUG
and	O
tacrolimus	B-DRUG
doses	O
and	O
dosing	O
frequency	O
should	O
be	O
reduced	O
in	O
HCV-infected	O
posttransplant	O
patients	O
being	O
treated	O
with	O
this	O
3-DAA	O
regimen	O
.	O
	
Phase	O
I	O
/	O
II	O
study	O
of	O
the	O
combination	O
of	O
panobinostat	B-DRUG
and	O
carfilzomib	B-DRUG
in	O
patients	O
with	O
relapsed	O
/	O
refractory	B-CANCER
multiple	I-CANCER
myeloma	I-CANCER
.	O
	
	
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
safety	O
and	O
efficacy	O
of	O
the	O
combination	O
of	O
panobinostat	B-DRUG
and	O
carfilzomib	B-DRUG
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	B-CANCER
myeloma	I-CANCER
.	O
	
Patients	O
with	O
multiple	B-CANCER
myeloma	I-CANCER
who	O
had	O
relapsed	O
after	O
at	O
least	O
one	O
prior	O
treatment	O
were	O
eligible	O
to	O
participate	O
.	O
	
In	O
the	O
dose	O
escalation	O
part	O
of	O
the	O
study	O
a	O
standard	O
3+3	O
design	O
was	O
used	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
of	O
four	O
planned	O
dose	O
levels	O
of	O
the	O
combination	O
of	O
carfilzomib	B-DRUG
and	O
panobinostat	B-DRUG
.	O
	
Panobinostat	B-DRUG
was	O
administered	O
on	O
days	O
1	O
","	O
3	O
","	O
5	O
","	O
15	O
","	O
17	O
","	O
and	O
19	O
.	O
	
Carfilzomib	B-DRUG
was	O
administered	O
on	O
days	O
1	O
","	O
2	O
","	O
8	O
","	O
9	O
","	O
15	O
","	O
and	O
16	O
of	O
each	O
28-day	O
cycle	O
.	O
	
Treatment	O
was	O
continued	O
until	O
progression	O
or	O
intolerable	O
toxicity	O
.	O
	
Forty-four	O
patients	O
were	O
accrued	O
into	O
the	O
trial	O
","	O
13	O
in	O
the	O
phase	O
I	O
part	O
and	O
31	O
in	O
the	O
phase	O
II	O
part	O
of	O
the	O
study	O
.	O
	
The	O
median	O
age	O
of	O
the	O
patients	O
was	O
66	O
years	O
and	O
the	O
median	O
number	O
of	O
prior	O
therapies	O
was	O
five	O
.	O
	
The	O
expansion	O
dose	O
was	O
established	O
as	O
30	O
mg	O
panobinostat	B-DRUG
","	O
20	O
/	O
45	O
mg	O
/	O
m	O
(	O
2	O
)	O
carfilzomib	B-DRUG
.	O
	
The	O
overall	O
response	O
rate	O
was	O
67	O
%	O
for	O
all	O
patients	O
","	O
67	O
%	O
for	O
patients	O
refractory	O
to	O
prior	O
proteasome	O
inhibitor	O
treatment	O
and	O
75	O
%	O
for	O
patients	O
refractory	O
to	O
prior	O
immune	O
modulating	O
drug	O
treatment	O
.	O
	
At	O
a	O
median	O
follow	O
up	O
of	O
17	O
months	O
","	O
median	O
progression-free	O
survival	O
was	O
7.7	O
months	O
","	O
median	O
time	O
to	O
progression	O
was	O
7.7	O
months	O
","	O
and	O
median	O
overall	O
survival	O
had	O
not	O
been	O
reached	O
.	O
	
The	O
regimen	O
was	O
well	O
tolerated	O
","	O
although	O
there	O
were	O
several	O
panobinostat	B-DRUG
dose	O
reductions	O
.	O
	
In	O
conclusion	O
","	O
the	O
combination	O
of	O
panobinostat	B-DRUG
and	O
carfilzomib	B-DRUG
is	O
feasible	O
and	O
effective	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	B-CANCER
myeloma	I-CANCER
.	O
	
(	O
Trial	O
registered	O
at	O
ClinicalTrials.gov	O
:	O
NCT01496118	O
)	O
.	O
	
Feasibility	O
and	O
cardiac	O
safety	O
of	O
trastuzumab	B-DRUG
emtansine	I-DRUG
after	O
anthracycline-based	B-DRUG
chemotherapy	O
as	O
(	O
neo	O
)	O
adjuvant	O
therapy	O
for	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2-positive	O
early-stage	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
Trastuzumab	B-DRUG
emtansine	I-DRUG
(	O
T-DM1	B-DRUG
)	O
","	O
an	O
antibody-drug	O
conjugate	O
comprising	O
the	O
cytotoxic	O
agent	O
DM1	O
","	O
a	O
stable	O
linker	O
","	O
and	O
trastuzumab	B-DRUG
","	O
has	O
demonstrated	O
substantial	O
activity	O
in	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
(	O
HER2	O
)	O
#NAME?	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
","	O
raising	O
interest	O
in	O
evaluating	O
the	O
feasibility	O
and	O
cardiac	O
safety	O
of	O
T-DM1	B-DRUG
in	O
early-stage	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
EBC	B-CANCER
)	O
.	O
	
Patients	O
(	O
N	O
=	O
153	O
)	O
with	O
HER2-positive	O
EBC	B-CANCER
and	O
prechemotherapy	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
_	O
55	O
%	O
received	O
(	O
neo	O
)	O
adjuvant	O
doxorubicin	B-DRUG
plus	O
cyclophosphamide	B-DRUG
or	O
fluorouracil	B-DRUG
plus	O
epirubicin	B-DRUG
plus	O
cyclophosphamide	B-DRUG
followed	O
by	O
T-DM1	B-DRUG
for	O
four	O
cycles	O
.	O
	
Patients	O
could	O
then	O
receive	O
three	O
to	O
four	O
cycles	O
of	O
optional	O
docetaxel	B-DRUG
with	O
or	O
without	O
trastuzumab	B-DRUG
.	O
	
T-DM1	B-DRUG
was	O
then	O
resumed	O
with	O
optional	O
radiotherapy	O
(	O
sequential	O
or	O
concurrent	O
)	O
for	O
1	O
year	O
(	O
planned	O
)	O
of	O
HER2-directed	O
therapy	O
.	O
	
The	O
coprimary	O
end	O
points	O
were	O
rate	O
of	O
prespecified	O
cardiac	B-TOXI
events	I-TOXI
and	O
safety	O
.	O
	
Median	O
follow-up	O
was	O
24.6	O
months	O
.	O
	
No	O
prespecified	O
cardiac	B-TOXI
events	I-TOXI
or	O
symptomatic	B-TOXI
congestive	I-TOXI
heart	I-TOXI
failures	I-TOXI
were	O
reported	O
.	O
	
Four	O
patients	O
(	O
2.7	O
%	O
)	O
had	O
asymptomatic	B-TOXI
LVEF	I-TOXI
declines	I-TOXI
(	O
_	O
10	O
percentage	O
points	O
from	O
baseline	O
to	O
LVEF	O
&	O
lt	O
;	O
50	O
%	O
)	O
","	O
leading	O
to	O
T-DM1	B-TOXI
discontinuation	I-TOXI
in	O
one	O
patient	O
.	O
	
Of	O
148	O
patients	O
who	O
received	O
_	O
one	O
cycle	O
of	O
T-DM1	B-DRUG
","	O
82.4	O
%	O
completed	O
the	O
planned	O
1-year	O
duration	O
of	O
HER2-directed	O
therapy	O
.	O
	
During	O
T-DM1	B-DRUG
treatment	O
","	O
38.5	O
%	O
and	O
2.7	O
%	O
of	O
patients	O
experienced	O
grade	O
3	O
and	O
4	O
adverse	O
events	O
","	O
respectively	O
.	O
	
Approximately	O
95	O
%	O
of	O
patients	O
receiving	O
T-DM1	B-DRUG
plus	O
radiotherapy	O
completed	O
_	O
95	O
%	O
of	O
the	O
planned	O
radiation	O
dose	O
with	O
delay	O
_	O
5	O
days	O
.	O
	
Use	O
of	O
T-DM1	B-DRUG
for	O
approximately	O
1	O
year	O
after	O
anthracycline-based	B-DRUG
chemotherapy	O
was	O
feasible	O
and	O
generally	O
well	O
tolerated	O
by	O
patients	O
with	O
HER2-positive	O
EBC	B-CANCER
","	O
providing	O
support	O
for	O
phase	O
III	O
trials	O
of	O
T-DM1	B-DRUG
in	O
this	O
setting	O
.	O
	
FOLFIRI	B-DRUG
plus	O
bevacizumab	B-DRUG
as	O
a	O
second-line	O
therapy	O
for	O
metastatic	B-CANCER
intrahepatic	I-CANCER
cholangiocarcinoma	I-CANCER
.	O
	
	
To	O
evaluate	O
the	O
efficacy	O
and	O
tolerance	O
of	O
FOLFIRI	B-DRUG
plus	O
bevacizumab	B-DRUG
treatment	O
outcome	O
as	O
second-line	O
treatment	O
for	O
metastatic	B-CANCER
intrahepatic	I-CANCER
cholangiocarcinoma	I-CANCER
.	O
	
Thirteen	O
consecutive	O
patients	O
with	O
metastatic	B-CANCER
intrahepatic	I-CANCER
cholangiocarcinoma	I-CANCER
who	O
were	O
refractory	O
to	O
first-line	O
therapy	O
consisting	O
of	O
gemcitabine	B-DRUG
plus	O
oxaliplatin-based	B-DRUG
first-line	O
chemotherapy	O
given	O
intravenously	O
via	O
intra-arterial	O
infusion	O
were	O
treated	O
with	O
FOLFIRI	B-DRUG
[	O
irinotecan	B-DRUG
(	O
180	O
mg	O
/	O
m虏	O
i.v.	O
over	O
90	O
min	O
)	O
concurrently	O
with	O
folinic	B-DRUG
acid	O
(	O
400	O
mg	O
/	O
m虏	O
i.v.	O
over	O
120	O
min	O
)	O
followed	O
by	O
fluorouracil	B-DRUG
(	O
400	O
mg	O
/	O
m虏	O
i.v.	O
bolus	O
)	O
then	O
fluorouracil	B-DRUG
2400	O
mg	O
/	O
m虏	O
intravenous	O
infusion	O
over	O
46	O
h	O
]	O
and	O
bevacizumab	B-DRUG
(	O
5	O
mg	O
/	O
kg	O
)	O
every	O
2	O
wk	O
.	O
	
Tumor	O
response	O
was	O
evaluated	O
by	O
computed	O
tomography	O
scan	O
every	O
4	O
cycles	O
.	O
	
The	O
best	O
tumor	O
responses	O
using	O
response	O
evaluation	O
criteria	O
in	O
solid	O
tumor	O
criteria	O
were	O
:	O
complete	O
response	O
for	O
1	O
patient	O
","	O
partial	O
response	O
for	O
4	O
patients	O
","	O
and	O
stable	O
disease	O
for	O
6	O
patients	O
after	O
6	O
mo	O
of	O
follow-up	O
.	O
	
The	O
response	O
rate	O
was	O
38.4	O
%	O
(	O
95	O
%	O
CI	O
:	O
12.5-89	O
)	O
and	O
the	O
disease	O
control	O
rate	O
was	O
84.5	O
%	O
(	O
95	O
%	O
CI	O
:	O
42-100	O
)	O
.	O
	
Seven	O
deaths	B-TOXI
occurred	O
at	O
the	O
time	O
of	O
analysis	O
","	O
progression	O
free	O
survival	O
was	O
8	O
mo	O
(	O
95	O
%	O
CI	O
:	O
7月16日	O
)	O
","	O
and	O
median	O
overall	O
survival	O
was	O
20	O
mo	O
(	O
95	O
%	O
CI	O
:	O
8-48	O
)	O
.	O
	
No	O
grade	O
4	O
toxic	O
events	O
were	O
observed	O
.	O
	
Four	O
grade	O
3	O
hematological	B-TOXI
toxicities	I-TOXI
and	O
one	O
grade	O
3	O
digestive	B-TOXI
toxicity	I-TOXI
occurred	O
.	O
	
An	O
adaptive	O
reduction	O
in	O
chemotherapy	O
dosage	O
was	O
required	O
in	O
2	O
patients	O
due	O
to	O
hematological	B-TOXI
toxicity	I-TOXI
","	O
and	O
a	O
delay	O
in	O
chemotherapy	O
cycles	O
was	O
required	O
for	O
3	O
patients	O
.	O
	
FOLFIRI	B-DRUG
plus	O
bevacizumab	B-DRUG
combination	O
treatment	O
showed	O
promising	O
efficacy	O
and	O
safety	O
as	O
second-line	O
treatment	O
for	O
metastatic	B-CANCER
intrahepatic	I-CANCER
cholangiocarcinoma	I-CANCER
after	O
failure	O
of	O
the	O
first-line	O
treatment	O
of	O
gemcitabine	B-CANCER
plus	O
oxaliplatin	B-CANCER
chemotherapy	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
bendamustine	B-DRUG
","	O
lenalidomide	B-DRUG
and	O
rituximab	B-DRUG
in	O
relapsed	B-CANCER
and	I-CANCER
refractory	I-CANCER
lymphomas	I-CANCER
.	O
	
	
Many	O
patients	O
with	O
non-Hodgkin	B-CANCER
(	O
NHL	B-CANCER
)	O
or	O
Hodgkin	B-CANCER
lymphoma	I-CANCER
(	O
HL	B-CANCER
)	O
relapse	O
or	O
are	O
refractory	O
to	O
initial	O
therapy	O
and	O
require	O
additional	O
options	O
.	O
	
Bendamustine	B-DRUG
(	O
B	O
)	O
","	O
lenalidomide	B-DRUG
(	O
L	O
)	O
and	O
rituximab	B-DRUG
(	O
R	O
)	O
each	O
have	O
activity	O
in	O
this	O
setting	O
.	O
	
This	O
study	O
was	O
performed	O
to	O
determine	O
the	O
safety	O
of	O
BLR	O
and	O
its	O
optimal	O
phase	O
II	O
dose	O
.	O
	
Patients	O
with	O
NHL	B-CANCER
or	O
HL	B-CANCER
failing	O
standard	O
therapies	O
received	O
B	O
(	O
90	O
mg	O
/	O
m	O
(	O
2	O
)	O
days	O
1	O
","	O
2	O
every	O
28	O
days	O
)	O
","	O
and	O
L	O
(	O
escalating	O
from	O
5	O
mg	O
21	O
/	O
28	O
days	O
)	O
for	O
six	O
cycles	O
","	O
followed	O
by	O
6	O
months	O
of	O
L.	O
At	O
the	O
highest	O
dose	O
R	O
375	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
one	O
of	O
each	O
cycle	O
was	O
added	O
for	O
patients	O
with	O
B-NHL	B-CANCER
.	O
	
Histologies	O
included	O
diffuse	B-CANCER
large	I-CANCER
B-cell	I-CANCER
lymphoma	I-CANCER
(	O
DLBCL	B-CANCER
","	O
11	O
)	O
","	O
marginal	B-CANCER
zone	I-CANCER
lymphoma	I-CANCER
(	O
3	O
)	O
","	O
HL	B-CANCER
(	O
2	O
)	O
","	O
and	O
one	O
each	O
of	O
transformed	B-CANCER
follicular	I-CANCER
lymphoma	I-CANCER
","	O
S茅zary	O
syndrome	O
","	O
Waldenstr枚m	O
macroglobulinaemia	O
and	O
mantle	B-CANCER
cell	I-CANCER
lymphoma	I-CANCER
.	O
	
Neutropenia	B-TOXI
was	O
the	O
most	O
common	O
grade	O
3	O
and	O
4	O
toxicity	O
","	O
but	O
no	O
maximum	O
tolerated	O
dose	O
was	O
identified	O
.	O
	
Of	O
20	O
patients	O
","	O
seven	O
responded	O
(	O
35	O
%	O
)	O
","	O
including	O
four	O
complete	O
remissions	O
","	O
with	O
five	O
unmaintained	O
responses	O
from	O
28+	O
to	O
37+	O
months	O
","	O
including	O
2	O
DLBCL	B-CANCER
.	O
	
BR	O
with	O
20	O
mg	O
l	O
at	O
","	O
21	O
/	O
28	O
days	O
achieved	O
durable	O
responses	O
;	O
however	O
","	O
in	O
light	O
of	O
its	O
modest	O
activity	O
","	O
and	O
the	O
availability	O
of	O
newer	O
targeted	O
therapies	O
","	O
the	O
future	O
of	O
BLR	O
is	O
uncertain	O
.	O
	
Safety	O
and	O
efficacy	O
of	O
Temsirolimus	B-DRUG
in	O
combination	O
with	O
Bendamustine	B-DRUG
and	O
Rituximab	B-DRUG
in	O
relapsed	B-CANCER
mantle	I-CANCER
cell	I-CANCER
and	I-CANCER
follicular	I-CANCER
lymphoma	I-CANCER
.	O
	
	
In	O
this	O
phase	O
I	O
/	O
II	O
study	O
","	O
we	O
explored	O
the	O
combination	O
of	O
Temsirolimus	B-DRUG
with	O
Bendamustine	B-DRUG
and	O
Rituximab	B-DRUG
(	O
BeRT	O
)	O
in	O
patients	O
with	O
r	O
/	O
r	O
follicular	B-CANCER
lymphoma	I-CANCER
(	O
FL	B-CANCER
)	O
or	O
mantle	B-CANCER
cell	I-CANCER
lymphoma	I-CANCER
(	O
MCL	B-CANCER
)	O
.	O
	
Patients	O
with	O
1月3日	O
prior	O
therapies	O
received	O
Bendamustine	B-DRUG
(	O
90	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
day	O
1+2	O
)	O
and	O
Rituximab	B-DRUG
(	O
375	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
day	O
1	O
)	O
with	O
Temsirolimus	B-DRUG
in	O
doses	O
from	O
25	O
to	O
75	O
mg	O
added	O
on	O
day	O
1	O
","	O
8	O
","	O
15	O
of	O
a	O
28-day	O
cycle	O
.	O
	
Fifteen	O
(	O
11	O
MCL	B-CANCER
","	O
4	O
FL	B-CANCER
)	O
patients	O
were	O
included	O
in	O
the	O
phase	O
I.	O
Median	O
age	O
was	O
73	O
years	O
and	O
median	O
pretreatment	O
number	O
was	O
2	O
No	O
formal	O
dose-limiting	O
toxicity	O
was	O
observed	O
.	O
	
Dominant	O
non-hematological	B-TOXI
side	I-TOXI
effects	I-TOXI
were	O
fatigue	B-TOXI
in	O
11	O
(	O
73	O
%	O
)	O
","	O
nausea	B-TOXI
in	O
9	O
(	O
60	O
%	O
)	O
","	O
mucositis	B-TOXI
in	O
7	O
(	O
47	O
%	O
)	O
and	O
vomiting	B-TOXI
in	O
6	O
patients	O
(	O
40	O
%	O
)	O
.	O
	
Cough	B-TOXI
","	O
diarrhea	B-TOXI
","	O
pyrexia	B-TOXI
and	O
rash	B-TOXI
were	O
observed	O
in	O
five	O
patients	O
(	O
33	O
%	O
)	O
each	O
.	O
	
Grade	O
3	O
/	O
4	O
events	O
included	O
leukopenia	B-TOXI
in	O
6	O
(	O
40	O
%	O
)	O
","	O
neutropenia	B-TOXI
in	O
4	O
(	O
27	O
%	O
)	O
and	O
thrombocytopenia	B-TOXI
in	O
2	O
patients	O
(	O
13	O
%	O
)	O
.	O
	
An	O
objective	O
response	O
was	O
observed	O
in	O
14	O
/	O
15	O
patients	O
(	O
93	O
%	O
)	O
","	O
including	O
5	O
complete	O
response	O
(	O
33	O
%	O
;	O
all	O
MCL	B-CANCER
)	O
.	O
	
After	O
a	O
median	O
follow-up	O
of	O
19	O
months	O
","	O
67	O
%	O
of	O
patients	O
are	O
without	O
signs	O
of	O
progression	O
.	O
	
Temsirolimus	B-DRUG
can	O
be	O
safely	O
added	O
to	O
BR	O
with	O
promising	O
preliminary	O
activity	O
.	O
	
Recruitment	O
in	O
phase	O
II	O
is	O
ongoing	O
.	O
	
Ex	O
vivo	O
antibody-dependent	O
cellular	O
cytotoxicity	O
inducibility	O
predicts	O
efficacy	O
of	O
cetuximab	B-DRUG
.	O
	
	
We	O
conducted	O
in	O
vitro	O
studies	O
and	O
a	O
clinical	O
trial	O
for	O
patients	O
with	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	O
SCCHN	B-CANCER
)	O
to	O
study	O
the	O
relationship	O
between	O
Fc纬RIIIa	O
polymorphisms	O
and	O
antibody-dependent	O
cellular	O
cytotoxicity	O
(	O
ADCC	O
)	O
.	O
	
In	O
vitro	O
","	O
Fc纬RIIIa	O
genotype	O
was	O
correlated	O
with	O
ADCC	O
and	O
innate	O
cytotoxicity	O
using	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
harvested	O
from	O
healthy	O
donors	O
.	O
	
In	O
the	O
phase	O
II	O
study	O
","	O
patients	O
with	O
recurrent	O
or	O
metastatic	B-CANCER
SCCHN	I-CANCER
were	O
treated	O
with	O
cetuximab	B-DRUG
(	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
i.v.	O
every	O
2	O
weeks	O
)	O
and	O
lenalidomide	B-DRUG
(	O
25	O
mg	O
daily	O
)	O
.	O
	
Fc纬RIIIa	O
genotype	O
and	O
ex	O
vivo	O
ADCC	O
were	O
correlated	O
with	O
clinical	O
response	O
","	O
progression-free	O
survival	O
(	O
PFS	O
)	O
","	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O
	
In	O
vitro	O
","	O
healthy	O
donors	O
with	O
a	O
Fc纬RIIIa	O
158-V	O
allele	O
demonstrated	O
more	O
effective	O
ADCC	O
against	O
two	O
colon	B-CANCER
cancer	I-CANCER
cell	O
lines	O
HT29	O
and	O
SW480	O
","	O
mean	O
cytotoxicity	O
:	O
FF	O
16.1	O
%	O
","	O
VF	O
/	O
VV	O
24.3	O
%	O
(	O
P	O
=	O
0.015	O
)	O
and	O
FF	O
11.7	O
%	O
","	O
VF	O
/	O
VV	O
21	O
%	O
(	O
P	O
=	O
0.008	O
)	O
","	O
respectively	O
.	O
	
We	O
observed	O
a	O
linear	O
relationship	O
between	O
ADCC	O
response	O
and	O
innate	O
cytotoxicity	O
.	O
	
In	O
the	O
phase	O
II	O
trial	O
","	O
40	O
patients	O
received	O
cetuximab	B-DRUG
and	O
lenalidomide	B-DRUG
with	O
median	O
PFS	O
of	O
7.2	O
weeks	O
and	O
OS	O
of	O
16.4	O
weeks	O
.	O
	
Thirty-six	O
patients	O
had	O
Fc纬RIIIa	O
genotype	O
:	O
VV	O
(	O
2	O
)	O
","	O
VF	O
(	O
20	O
)	O
","	O
and	O
FF	O
(	O
14	O
)	O
","	O
and	O
25	O
patients	O
had	O
sufficient	O
NK-cell	O
yield	O
to	O
perform	O
ex	O
vivo	O
ADCC	O
.	O
	
Fc纬RIIIa	O
genotype	O
was	O
not	O
associated	O
with	O
any	O
clinical	O
outcomes	O
.	O
	
Patients	O
mounting	O
ex	O
vivo	O
ADCC	O
response	O
had	O
a	O
higher	O
likelihood	O
of	O
stable	O
disease	O
(	O
P	O
=	O
0.01	O
)	O
and	O
showed	O
a	O
trend	O
toward	O
increased	O
PFS	O
:	O
14	O
weeks	O
versus	O
6.8	O
weeks	O
","	O
respectively	O
(	O
P	O
=	O
0.13	O
)	O
.	O
	
Enhanced	O
ex	O
vivo	O
ADCC	O
and	O
innate	O
immunity	O
responses	O
were	O
more	O
predictive	O
of	O
clinical	O
response	O
than	O
Fc纬RIIIa	O
and	O
may	O
offer	O
a	O
functional	O
assay	O
to	O
select	O
patients	O
suitable	O
for	O
cetuximab	B-DRUG
therapy	O
.	O
	
Phase	O
II	O
trial	O
of	O
bevacizumab	B-DRUG
=+	O
cetuximab	B-DRUG
=+	O
cisplatin	B-DRUG
with	O
concurrent	O
intensity-modulated	O
radiation	O
therapy	O
for	O
patients	O
with	O
stage	O
III	O
/	O
IVB	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
	
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
tolerability	O
of	O
the	O
addition	O
of	O
2	O
monoclonal	O
antibodies	O
","	O
bevacizumab	B-DRUG
and	O
cetuximab	B-DRUG
","	O
to	O
2	O
cycles	O
of	O
high-dose	O
cisplatin	B-DRUG
administered	O
concurrently	O
with	O
intensity-modulated	O
radiation	O
therapy	O
(	O
IMRT	O
)	O
for	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
HNSCC	B-CANCER
)	O
.	O
	
Patients	O
with	O
newly	O
diagnosed	O
stage	O
III	O
/	O
IVB	O
(	O
M0	O
)	O
HNSCC	B-CANCER
received	O
cetuximab	B-DRUG
(	O
400	O
mg	O
/	O
m	O
(	O
2	O
)	O
loading	O
dose	O
","	O
followed	O
by	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
)	O
","	O
bevacizumab	B-DRUG
(	O
15	O
mg	O
/	O
kg	O
","	O
days	O
1	O
and	O
22	O
)	O
","	O
and	O
cisplatin	B-DRUG
(	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
days	O
1	O
","	O
2	O
","	O
22	O
","	O
and	O
23	O
)	O
concurrently	O
with	O
IMRT	O
(	O
70	O
Gy	O
)	O
.	O
	
The	O
primary	O
endpoint	O
was	O
progression-free	O
survival	O
(	O
PFS	O
)	O
.	O
	
Secondary	O
endpoints	O
were	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
safety	O
and	O
tolerability	O
.	O
	
Among	O
30	O
patients	O
enrolled	O
in	O
this	O
study	O
","	O
the	O
primary	O
tumor	O
site	O
was	O
the	O
oropharynx	O
in	O
24	O
patients	O
(	O
p16	O
immunohistochemistry	O
was	O
positive	O
in	O
17	O
","	O
negative	O
in	O
1	O
","	O
and	O
not	O
done	O
in	O
6	O
of	O
the	O
oropharyngeal	B-CANCER
tumors	I-CANCER
)	O
.	O
	
Median	O
age	O
was	O
57	O
years	O
(	O
range	O
","	O
38-77	O
years	O
)	O
and	O
27	O
patients	O
had	O
clinical	O
stage	O
IVA	O
disease	O
.	O
	
All	O
patients	O
completed	O
the	O
full	O
planned	O
dose	O
of	O
radiation	O
therapy	O
.	O
	
The	O
most	O
common	O
_	O
grade	O
3	O
adverse	O
events	O
were	O
lymphopenia	B-TOXI
","	O
mucositis	B-TOXI
(	O
functional	O
)	O
","	O
and	O
dysphagia	B-TOXI
.	O
	
With	O
a	O
median	O
follow-up	O
of	O
33.8	O
months	O
","	O
2-year	O
PFS	O
was	O
88.5	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
68.1-96.1	O
)	O
and	O
2-year	O
OS	O
was	O
92.8	O
%	O
(	O
95	O
%	O
CI	O
=	O
74.2-98.1	O
)	O
.	O
	
The	O
addition	O
of	O
bevacizumab	B-DRUG
and	O
cetuximab	B-DRUG
to	O
2	O
cycles	O
of	O
cisplatin	B-DRUG
","	O
given	O
concurrently	O
with	O
IMRT	O
","	O
was	O
well-tolerated	O
and	O
was	O
associated	O
with	O
favorable	O
efficacy	O
outcomes	O
in	O
this	O
patient	O
population	O
.	O
	
漏	O
2015	O
Wiley	O
Periodicals	O
","	O
Inc.	O
Head	O
Neck	O
38	O
:	O
E566-E570	O
","	O
2016	O
.	O
	
Phase	O
1	O
/	O
2	O
study	O
of	O
carfilzomib	B-DRUG
plus	O
melphalan	B-DRUG
and	O
prednisone	B-DRUG
in	O
patients	O
aged	O
over	O
65	O
years	O
with	O
newly	O
diagnosed	O
multiple	B-CANCER
myeloma	I-CANCER
.	O
	
	
This	O
phase	O
1	O
/	O
2	O
dose-escalation	O
study	O
investigated	O
the	O
combination	O
of	O
carfilzomib	B-DRUG
with	O
melphalan	B-DRUG
and	O
prednisone	B-DRUG
(	O
CMP	O
)	O
in	O
patients	O
aged	O
&	O
gt	O
;	O
65	O
years	O
with	O
newly	O
diagnosed	O
multiple	B-CANCER
myeloma	I-CANCER
(	O
MM	B-CANCER
)	O
.	O
	
Melphalan	B-DRUG
and	O
prednisone	B-DRUG
were	O
administered	O
orally	O
on	O
days	O
1	O
to	O
4	O
;	O
carfilzomib	O
was	O
IV	O
administered	O
on	O
days	O
1	O
","	O
2	O
","	O
8	O
","	O
9	O
","	O
22	O
","	O
23	O
","	O
29	O
","	O
and	O
30	O
of	O
a	O
42-day	O
cycle	O
.	O
	
Patients	O
received	O
up	O
to	O
9	O
cycles	O
of	O
CMP	O
.	O
	
In	O
the	O
phase	O
1	O
dose-escalation	O
portion	O
","	O
the	O
primary	O
objectives	O
were	O
to	O
determine	O
the	O
incidence	O
of	O
dose-limiting	O
toxicities	O
during	O
the	O
first	O
cycle	O
of	O
CMP	O
treatment	O
to	O
define	O
the	O
maximal	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
carfilzomib	B-DRUG
.	O
	
In	O
the	O
phase	O
2	O
portion	O
","	O
the	O
primary	O
objective	O
was	O
to	O
evaluate	O
the	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
of	O
CMP	O
.	O
	
In	O
the	O
phase	O
1	O
portion	O
of	O
the	O
study	O
","	O
24	O
patients	O
received	O
CMP	O
at	O
carfilzomib	B-DRUG
dosing	O
levels	O
of	O
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
27	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
36	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
and	O
45	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
The	O
MTD	O
was	O
established	O
as	O
36	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
In	O
the	O
phase	O
2	O
portion	O
of	O
the	O
study	O
","	O
44	O
patients	O
were	O
enrolled	O
at	O
the	O
MTD	O
.	O
	
Among	O
50	O
efficacy-evaluable	O
patients	O
treated	O
at	O
the	O
MTD	O
","	O
the	O
ORR	O
was	O
90	O
%	O
.	O
	
The	O
projected	O
3-year	O
overall	O
survival	O
rate	O
was	O
80	O
%	O
.	O
	
The	O
combination	O
of	O
CMP	O
was	O
observed	O
to	O
be	O
effective	O
in	O
elderly	O
patients	O
with	O
newly	O
diagnosed	O
MM	B-CANCER
.	O
	
This	O
trial	O
was	O
registered	O
at	O
www.clinicaltrials.gov	O
as	O
#	O
NCT01279694	O
(	O
Eudract	O
identifier	O
2010-019462-92	O
)	O
.	O
	
Phase	O
I	O
study	O
of	O
the	O
safety	O
and	O
pharmacokinetics	O
of	O
trabectedin	B-DRUG
with	O
docetaxel	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
malignancies	I-CANCER
.	O
	
	
Combination	O
therapy	O
with	O
trabectedin	B-DRUG
and	O
docetaxel	B-DRUG
was	O
evaluated	O
in	O
patients	O
with	O
advanced	B-CANCER
malignancies	I-CANCER
.	O
	
In	O
this	O
open-label	O
phase	O
1	O
study	O
","	O
docetaxel	B-DRUG
(	O
60	O
or	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
;	O
1-h	O
intravenous	O
infusion	O
)	O
was	O
given	O
on	O
day	O
1	O
of	O
a	O
21-day	O
cycle	O
in	O
combination	O
with	O
escalating	O
doses	O
of	O
trabectedin	B-DRUG
(	O
0.4-1.3	O
mg	O
/	O
m	O
(	O
2	O
)	O
by	O
3-h	O
intravenous	O
infusion	O
","	O
1	O
h	O
after	O
docetaxel	B-DRUG
)	O
and	O
prophylactic	O
granulocyte	O
colony-stimulating	O
factor	O
(	O
G-CSF	O
)	O
.	O
	
Maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
as	O
primary	O
objective	O
and	O
safety	O
","	O
plasma	O
pharmacokinetics	O
","	O
and	O
antitumor	O
activity	O
as	O
secondary	O
objectives	O
were	O
assessed	O
.	O
	
Patients	O
(	O
N	O
=	O
49	O
)	O
received	O
a	O
median	O
of	O
four	O
cycles	O
of	O
treatment	O
.	O
	
MTD	O
was	O
1.3	O
mg	O
/	O
m	O
(	O
2	O
)	O
trabectedin	B-DRUG
and	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
docetaxel	B-DRUG
for	O
patients	O
with	O
limited	O
and	O
1.1	O
mg	O
/	O
m	O
(	O
2	O
)	O
trabectedin	B-DRUG
and	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
docetaxel	B-DRUG
for	O
patients	O
with	O
unlimited	O
prior	O
chemotherapy	O
.	O
	
Dose-limiting	O
toxicities	O
(	O
during	O
cycle	O
1	O
)	O
included	O
elevated	B-TOXI
alanine	I-TOXI
aminotransferase	I-TOXI
(	O
ALT	O
)	O
and	O
fatigue	B-TOXI
in	O
patients	O
with	O
limited	O
prior	O
chemotherapy	O
and	O
elevated	B-TOXI
ALT	I-TOXI
and	O
febrile	B-TOXI
neutropenia	I-TOXI
in	O
those	O
with	O
unlimited	O
prior	O
chemotherapy	O
.	O
	
The	O
most	O
common	O
drug-related	O
adverse	O
events	O
were	O
nausea	B-TOXI
(	O
65	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
63	O
%	O
)	O
","	O
and	O
neutropenia	B-TOXI
(	O
53	O
%	O
)	O
.	O
	
One	O
patient	O
achieved	O
a	O
complete	O
response	O
.	O
	
Thirty	O
patients	O
had	O
stable	O
disease	O
","	O
and	O
11	O
had	O
stable	O
disease	O
for	O
_6	O
months	O
.	O
	
Pharmacokinetic	O
results	O
for	O
trabectedin	B-DRUG
plus	O
docetaxel	B-DRUG
were	O
similar	O
to	O
those	O
previously	O
reported	O
for	O
the	O
single	O
agents	O
.	O
	
In	O
patients	O
with	O
previously	O
treated	O
","	O
advanced	B-CANCER
malignancies	I-CANCER
","	O
the	O
combination	O
of	O
therapeutic	O
doses	O
of	O
trabectedin	B-DRUG
and	O
docetaxel	B-DRUG
showed	O
clinical	O
activity	O
and	O
was	O
tolerable	O
with	O
prophylactic	O
G-CSF	O
","	O
with	O
no	O
evidence	O
of	O
clinically	O
important	O
drug	O
interactions	O
.	O
	
A	O
phase	O
II	O
study	O
of	O
adjuvant	O
gemcitabine	B-DRUG
plus	O
docetaxel	B-DRUG
followed	O
by	O
concurrent	O
chemoradation	O
in	O
resected	O
pancreaticobiliary	B-CANCER
carcinoma	I-CANCER
.	O
	
	
Adjuvant	O
gemcitabine	B-DRUG
with	O
or	O
without	O
chemoradiation	O
is	O
a	O
standard	O
therapeutic	O
option	O
for	O
patients	O
with	O
resected	O
pancreatic	B-CANCER
cancer	I-CANCER
.	O
	
The	O
feasibility	O
and	O
toxicity	O
of	O
gemcitabine	B-DRUG
with	O
docetaxel	B-DRUG
before	O
and	O
after	O
5-fluorouracil	B-DRUG
(	O
5FU	B-DRUG
)	O
#NAME?	O
chemoradiation	O
in	O
the	O
adjuvant	O
pancreatic	B-CANCER
and	I-CANCER
biliary	I-CANCER
cancer	I-CANCER
setting	O
were	O
investigated	O
.	O
	
After	O
a	O
curative-intent	O
resection	O
","	O
eligible	O
patients	O
with	O
pancreaticobiliary	B-CANCER
cancers	I-CANCER
were	O
treated	O
with	O
two	O
cycles	O
of	O
gemcitabine	B-DRUG
and	O
docetaxel	B-DRUG
followed	O
by	O
5FU-based	B-DRUG
chemoradiation	O
.	O
	
Four	O
weeks	O
after	O
completing	O
chemoradiation	O
","	O
two	O
cycles	O
of	O
gemcitabine	B-DRUG
and	O
docetaxel	B-DRUG
were	O
administered	O
.	O
	
The	O
primary	O
endpoint	O
was	O
the	O
incidence	O
of	O
severe	O
toxicities	O
.	O
	
Secondary	O
endpoints	O
included	O
disease-free	O
survival	O
(	O
DFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O
	
Fifty	O
patients	O
with	O
pancreaticobiliary	B-CANCER
cancers	I-CANCER
were	O
enrolled	O
.	O
	
Twenty-nine	O
patients	O
had	O
pancreatic	B-CANCER
cancer	I-CANCER
whereas	O
21	O
patients	O
had	O
biliary	B-CANCER
tract	I-CANCER
or	I-CANCER
ampullary	I-CANCER
cancers	I-CANCER
.	O
	
There	O
was	O
one	O
death	B-TOXI
as	O
a	O
result	O
of	O
pneumonia	B-TOXI
","	O
and	O
15	O
%	O
of	O
patients	O
experienced	O
grade	O
3	O
or	O
greater	O
non-haematological	B-TOXI
toxicities	I-TOXI
.	O
	
The	O
median	O
DFS	O
and	O
OS	O
for	O
patients	O
with	O
pancreatic	B-CANCER
cancer	I-CANCER
were	O
9.6	O
and	O
17	O
months	O
","	O
respectively	O
","	O
and	O
for	O
those	O
with	O
resected	O
biliary	B-CANCER
tract	I-CANCER
cancer	I-CANCER
were	O
12	O
and	O
23	O
months	O
","	O
respectively	O
.	O
	
This	O
combination	O
of	O
gemcitabine	B-DRUG
and	O
docetaxel	B-DRUG
with	O
chemoradiation	O
is	O
feasible	O
and	O
tolerable	O
in	O
the	O
adjuvant	O
setting	O
.	O
	
Future	O
studies	O
utilizing	O
a	O
different	O
gemcitabine	B-DRUG
/	O
taxane	B-DRUG
combination	O
and	O
schedule	O
may	O
be	O
appropriate	O
in	O
the	O
adjuvant	O
treatment	O
of	O
both	O
pancreatic	B-CANCER
cancer	I-CANCER
and	O
biliary	B-CANCER
tumours	I-CANCER
.	O
	
Ofatumumab	B-DRUG
in	O
combination	O
with	O
glucocorticoids	B-DRUG
for	O
primary	O
therapy	O
of	O
chronic	O
graft-versus-host	O
disease	O
:	O
phase	O
I	O
trial	O
results	O
.	O
	
	
Standard	O
primary	O
therapy	O
for	O
chronic	O
graft-versus-host	O
disease	O
(	O
GVHD	O
)	O
is	O
incompletely	O
effective	O
.	O
	
Based	O
on	O
biologic	O
insights	O
implicating	O
pathogenic	O
B	O
cells	O
","	O
we	O
conducted	O
a	O
phase	O
I	O
trial	O
examining	O
the	O
combination	O
of	O
standard	O
(	O
1	O
mg	O
/	O
kg	O
/	O
day	O
prednisone	B-DRUG
)	O
glucocorticoid	O
therapy	O
with	O
ofatumumab	B-DRUG
","	O
a	O
humanized	O
anti-CD20	O
monoclonal	O
antibody	O
","	O
for	O
primary	O
chronic	O
GVHD	O
therapy	O
.	O
	
Patients	O
ages	O
_	O
18	O
with	O
National	O
Institutes	O
of	O
Health	O
Consensus	O
moderate-to-severe	O
chronic	O
GVHD	O
newly	O
requiring	O
1	O
mg	O
/	O
kg	O
/	O
day	O
prednisone	B-DRUG
were	O
treated	O
at	O
3	O
escalating	O
dose	O
levels	O
(	O
300	O
mg	O
","	O
700	O
mg	O
","	O
and	O
1000	O
mg	O
)	O
of	O
i.v.	O
ofatumumab	B-DRUG
on	O
days	O
1	O
and	O
14	O
of	O
initial	O
glucocorticoid	B-DRUG
therapy	O
.	O
	
Dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
was	O
defined	O
by	O
grade	O
4	O
infusion	B-TOXI
reactions	I-TOXI
","	O
related	O
grade	O
4	O
constitutional	B-TOXI
symptoms	I-TOXI
","	O
related	O
grade	O
_	O
3	O
organ	B-TOXI
toxicities	I-TOXI
","	O
or	O
grade	O
4	O
neutropenia	B-TOXI
lasting	O
&	O
gt	O
;	O
14	O
days	O
.	O
	
A	O
total	O
of	O
12	O
patients	O
(	O
median	O
age	O
54	O
;	O
range	O
","	O
25	O
to	O
72	O
)	O
were	O
treated	O
(	O
dose	O
level	O
1	O
:	O
n	O
=	O
3	O
;	O
level	O
2	O
:	O
n	O
=	O
3	O
;	O
level	O
3	O
:	O
n	O
=	O
6	O
)	O
.	O
	
At	O
enrollment	O
","	O
overall	O
chronic	O
GVHD	O
was	O
moderate	O
(	O
n	O
=	O
7	O
)	O
or	O
severe	O
(	O
n	O
=	O
5	O
)	O
","	O
with	O
diverse	O
organ	O
involvement	O
(	O
skin	O
:	O
n	O
=	O
8	O
;	O
mouth	O
:	O
n	O
=	O
8	O
;	O
eye	O
:	O
n	O
=	O
8	O
;	O
lung	O
:	O
n	O
=	O
4	O
;	O
gastrointestinal	O
:	O
n	O
=	O
3	O
;	O
liver	O
:	O
n	O
=	O
5	O
;	O
genital	O
:	O
n	O
=	O
2	O
;	O
joint	O
/	O
fascia	O
:	O
n	O
=	O
5	O
)	O
.	O
	
Infusion	O
of	O
ofatumumab	B-DRUG
was	O
well	O
tolerated	O
","	O
and	O
no	O
DLT	O
was	O
observed	O
.	O
	
From	O
the	O
total	O
number	O
of	O
adverse	O
events	O
(	O
n	O
=	O
29	O
)	O
","	O
possibly	O
related	O
adverse	O
events	O
(	O
n	O
=	O
4	O
)	O
included	O
grade	O
1	O
fatigue	B-TOXI
","	O
grade	O
1	O
transaminitis	B-TOXI
","	O
and	O
2	O
infusion	B-TOXI
reactions	I-TOXI
(	O
grades	O
2	O
and	O
3	O
)	O
.	O
	
Infectious	B-TOXI
complications	I-TOXI
were	O
expected	O
","	O
and	O
there	O
were	O
no	O
cases	O
of	O
hepatitis	O
B	O
reactivation	O
or	O
progressive	O
multifocal	O
leukoencephalopathy	O
.	O
	
Ofatumumab	B-DRUG
in	O
combination	O
with	O
prednisone	B-DRUG
is	O
safe	O
and	O
a	O
phase	O
II	O
examination	O
of	O
efficacy	O
is	O
ongoing	O
.	O
	
Phase	O
II	O
study	O
of	O
capecitabine	B-DRUG
and	O
the	O
oral	O
mTOR	O
inhibitor	O
everolimus	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
combination	O
of	O
an	O
mTOR	O
inhibitor	O
with	O
5-fluorouracil-based	B-DRUG
anticancer	O
therapy	O
is	O
attractive	O
because	O
of	O
preclinical	O
evidence	O
of	O
synergy	O
between	O
these	O
drugs	O
.	O
	
According	O
to	O
our	O
phase	O
I	O
study	O
","	O
the	O
combination	O
of	O
capecitabine	B-DRUG
and	O
everolimus	B-DRUG
is	O
safe	O
and	O
feasible	O
","	O
with	O
potential	O
activity	O
in	O
pancreatic	B-CANCER
cancer	I-CANCER
patients	O
.	O
	
Patients	O
with	O
advanced	B-CANCER
adenocarcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
pancreas	I-CANCER
were	O
enrolled	O
.	O
	
Eligible	O
patients	O
had	O
a	O
WHO	O
performance	O
status	O
0-2	O
and	O
adequate	O
hepatic	O
and	O
renal	O
functions	O
.	O
	
The	O
treatment	O
regimen	O
consisted	O
of	O
capecitabine	B-DRUG
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
BID	O
day	O
1月14日	O
and	O
everolimus	B-DRUG
10	O
mg	O
daily	O
(	O
5	O
mg	O
BID	O
)	O
in	O
a	O
continuous	O
21-day	O
schedule	O
.	O
	
Tumor	O
assessment	O
was	O
performed	O
with	O
CT-scan	O
every	O
three	O
cycles	O
.	O
	
Primary	O
endpoint	O
was	O
response	O
rate	O
(	O
RR	O
)	O
according	O
to	O
RECIST	O
1.0.	O
Secondary	O
endpoints	O
were	O
progression-free	O
survival	O
","	O
overall	O
survival	O
and	O
1-year	O
survival	O
rate	O
.	O
	
In	O
total	O
","	O
31	O
patients	O
were	O
enrolled	O
.	O
	
Median	O
(	O
range	O
)	O
treatment	O
duration	O
with	O
everolimus	B-DRUG
was	O
76	O
days	O
(	O
1-431	O
)	O
.	O
	
Principal	O
grade	O
3	O
/	O
4	O
toxicities	O
were	O
hyperglycemia	B-TOXI
(	O
45	O
%	O
)	O
","	O
hand-foot	B-TOXI
syndrome	I-TOXI
(	O
16	O
%	O
)	O
","	O
diarrhea	B-TOXI
(	O
6	O
%	O
)	O
and	O
mucositis	B-TOXI
(	O
3	O
%	O
)	O
.	O
	
Prominent	O
grade	O
1	O
/	O
2	O
toxicities	O
were	O
anemia	B-TOXI
(	O
81	O
%	O
)	O
","	O
rash	B-TOXI
(	O
65	O
%	O
)	O
","	O
mucositis	B-TOXI
(	O
58	O
%	O
)	O
and	O
fatigue	B-TOXI
(	O
55	O
%	O
)	O
.	O
	
RR	O
was	O
6	O
%	O
.	O
	
Ten	O
patients	O
(	O
32	O
%	O
)	O
had	O
stable	O
disease	O
resulting	O
in	O
a	O
disease	O
control	O
rate	O
of	O
38	O
%	O
.	O
	
Median	O
overall	O
survival	O
was	O
8.9	O
months	O
(	O
95	O
%	O
CI	O
4.6-13.1	O
)	O
.	O
	
Progression-free	O
survival	O
was	O
3.6	O
months	O
(	O
95	O
%	O
CI	O
1.9-5.3	O
)	O
.	O
	
The	O
oral	O
regimen	O
with	O
the	O
combination	O
of	O
capecitabine	B-DRUG
and	O
everolimus	B-DRUG
is	O
a	O
moderately	O
active	O
treatment	O
for	O
patients	O
with	O
advanced	B-DRUG
pancreatic	I-DRUG
cancer	I-DRUG
","	O
with	O
an	O
acceptable	O
toxicity	O
profile	O
at	O
the	O
applied	O
dose	O
level	O
.	O
	
A	O
phase	O
I	O
/	O
II	O
study	O
of	O
biweekly	O
capecitabine	B-DRUG
and	O
irinotecan	B-DRUG
plus	O
bevacizumab	B-DRUG
as	O
second-line	O
chemotherapy	O
in	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
Triweekly	O
capecitabine	B-DRUG
plus	O
irinotecan	B-DRUG
(	O
XELIRI	B-DRUG
)	O
is	O
not	O
completely	O
regarded	O
as	O
a	O
valid	O
substitute	O
for	O
fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
irinotecan	B-DRUG
(	O
FOLFIRI	B-DRUG
)	O
in	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
mCRC	B-CANCER
)	O
because	O
of	O
the	O
potential	O
for	O
greater	O
toxicity	O
.	O
	
We	O
conducted	O
a	O
phase	O
I	O
/	O
II	O
study	O
to	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
biweekly	O
XELIRI	B-DRUG
plus	O
bevacizumab	B-DRUG
(	O
BV	O
)	O
as	O
second-line	O
chemotherapy	O
for	O
mCRC	B-CANCER
.	O
	
Patients	O
with	O
mCRC	B-CANCER
who	O
had	O
received	O
prior	O
chemotherapy	O
including	O
oxaliplatin	B-DRUG
and	O
BV	O
and	O
had	O
a	O
UGT1A1	O
genotype	O
of	O
wild-type	O
or	O
heterozygous	O
for	O
UGT1A1*6	O
or	O
*28	O
were	O
eligible	O
for	O
this	O
study	O
.	O
	
Treatment	O
comprised	O
capecitabine	B-DRUG
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
daily	O
from	O
the	O
evening	O
of	O
day	O
1	O
to	O
the	O
morning	O
of	O
day	O
8	O
","	O
intravenous	O
irinotecan	B-DRUG
on	O
day	O
1	O
","	O
and	O
BV	O
5	O
mg	O
/	O
kg	O
on	O
day	O
1	O
every	O
2	O
weeks	O
.	O
	
The	O
phase	O
I	O
study	O
consisted	O
of	O
two	O
steps	O
(	O
irinotecan	B-DRUG
150	O
and	O
180	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
and	O
dose-limiting	O
toxicity	O
was	O
assessed	O
during	O
the	O
first	O
treatment	O
cycle	O
.	O
	
The	O
primary	O
endpoint	O
of	O
the	O
phase	O
II	O
study	O
was	O
progression-free	O
survival	O
(	O
PFS	O
)	O
.	O
	
The	O
recommended	O
dose	O
of	O
irinotecan	B-DRUG
was	O
determined	O
to	O
be	O
180	O
mg	O
/	O
m	O
(	O
2	O
)	O
in	O
the	O
phase	O
I	O
study	O
.	O
	
Between	O
November	O
2010	O
and	O
August	O
2013	O
","	O
44	O
patients	O
were	O
enrolled	O
in	O
phase	O
II	O
.	O
	
The	O
patients	O
'	O
characteristics	O
were	O
as	O
follows	O
(	O
N=44	O
)	O
:	O
median	O
age	O
","	O
60	O
years	O
(	O
range	O
32-80	O
)	O
;	O
male	O
/	O
female	O
","	O
21	O
/	O
23	O
;	O
and	O
UGT1A1	O
wild-type	O
/	O
heterozygous	O
","	O
29	O
/	O
15	O
.	O
	
The	O
median	O
PFS	O
was	O
6.8	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
5.3-8.2	O
months	O
)	O
","	O
and	O
the	O
primary	O
endpoint	O
was	O
met	O
.	O
	
Median	O
overall	O
survival	O
was	O
18.3	O
months	O
.	O
	
The	O
response	O
rate	O
was	O
22.7	O
%	O
.	O
	
There	O
was	O
no	O
significant	O
difference	O
in	O
PFS	O
or	O
overall	O
survival	O
according	O
to	O
UGT1A1	O
status	O
.	O
	
Grade	O
3	O
or	O
higher	O
adverse	O
events	O
were	O
mainly	O
neutropenia	B-TOXI
in	O
six	O
patients	O
and	O
diarrhea	B-TOXI
in	O
five	O
patients	O
.	O
	
There	O
were	O
no	O
other	O
severe	O
adverse	O
events	O
or	O
treatment-related	O
deaths	B-TOXI
.	O
	
In	O
mCRC	B-CANCER
patients	O
with	O
wild-type	O
or	O
heterozygous	O
UGT1A1*6	O
or	O
*28	O
genotype	O
","	O
biweekly	O
XELIRI	B-DRUG
=+	O
BV	O
is	O
effective	O
and	O
feasible	O
as	O
second-line	O
chemotherapy	O
.	O
	
Biweekly	O
XELIRI	B-DRUG
=+	O
BV	O
is	O
considered	O
a	O
valid	O
substitute	O
for	O
FOLFIRI	B-DRUG
=+	O
BV	O
in	O
mCRC	B-CANCER
.	O
	
A	O
phase	O
I	O
dose-escalation	O
study	O
of	O
lenalidomide	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
	
Lenalidomide	B-DRUG
have	O
both	O
immunomodulatory	O
and	O
anti-angiogenic	O
properties	O
which	O
could	O
confer	O
anti-cancer	O
effects	O
.	O
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
feasibility	O
of	O
combining	O
lenalidomide	B-DRUG
with	O
the	O
standard	O
treatment	O
gemcitabine	B-DRUG
in	O
pancreatic	B-CANCER
cancer	I-CANCER
patients	O
with	O
advanced	O
disease	O
.	O
	
Eligible	O
patients	O
had	O
locally	O
advanced	O
or	O
metastatic	B-CANCER
adenocarcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
pancreas	I-CANCER
.	O
	
Patients	O
received	O
lenalidomide	B-DRUG
days	O
1月21日	O
orally	O
and	O
gemcitabine	B-DRUG
1000	O
mg	O
/	O
m2	O
intravenously	O
(	O
days	O
1	O
","	O
8	O
and	O
15	O
)	O
","	O
each	O
28	O
day	O
cycle	O
.	O
	
Three	O
cohorts	O
of	O
lenalidomide	B-DRUG
were	O
examined	O
(	O
Cohort	O
I	O
=	O
15	O
mg	O
","	O
Cohort	O
II	O
=	O
20	O
mg	O
and	O
Cohort	O
III	O
=	O
25	O
mg	O
daily	O
)	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
lenalidomide	B-DRUG
given	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
was	O
defined	O
as	O
the	O
highest	O
dose	O
level	O
at	O
which	O
no	O
more	O
than	O
one	O
out	O
of	O
four	O
(	O
25	O
%	O
)	O
subjects	O
experiences	O
a	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
.	O
	
Patients	O
should	O
also	O
be	O
able	O
to	O
receive	O
daily	O
low	O
molecular	O
weight	O
heparin	O
(	O
LMWH	O
)	O
(	O
e.g.	O
dalteparin	B-DRUG
5000	O
IU	O
s.c.	O
daily	O
)	O
as	O
a	O
prophylactic	O
anticoagulant	O
for	O
venous	B-TOXI
thromboembolic	I-TOXI
events	I-TOXI
(	O
VTEs	B-TOXI
)	O
.	O
	
Twelve	O
patients	O
(	O
n	O
=	O
4	O
","	O
n	O
=	O
3	O
and	O
n	O
=	O
5	O
in	O
cohort	O
I	O
","	O
II	O
and	O
III	O
","	O
respectively	O
)	O
were	O
enrolled	O
in	O
this	O
study	O
.	O
	
Median	O
duration	O
of	O
treatment	O
was	O
11	O
weeks	O
(	O
range	O
1-66	O
)	O
","	O
and	O
median	O
number	O
of	O
treatment	O
cycles	O
were	O
three	O
(	O
range	O
1月14日	O
)	O
.	O
	
The	O
only	O
DLT	O
was	O
a	O
cardiac	B-TOXI
failure	I-TOXI
grade	O
3	O
in	O
cohort	O
III	O
.	O
	
Frequent	O
treatment-related	O
adverse	O
events	O
(	O
AEs	O
)	O
(	O
all	O
grades	O
)	O
included	O
neutropenia	B-TOXI
","	O
leucopenia	B-TOXI
and	O
fatigue	B-TOXI
(	O
83	O
%	O
each	O
","	O
but	O
there	O
was	O
no	O
febrile	B-TOXI
neutropenia	I-TOXI
)	O
;	O
thrombocytopenia	B-TOXI
(	O
75	O
%	O
)	O
;	O
dermatological	B-TOXI
toxicity	I-TOXI
(	O
75	O
%	O
)	O
;	O
diarrhea	B-TOXI
and	O
nausea	B-TOXI
(	O
42	O
%	O
each	O
)	O
;	O
and	O
neuropathy	B-TOXI
(	O
42	O
%	O
)	O
.	O
	
This	O
phase	O
I	O
study	O
demonstrates	O
the	O
feasibility	O
of	O
the	O
combination	O
of	O
lenalidomide	B-DRUG
and	O
gemcitabine	B-DRUG
as	O
first-line	O
treatment	O
in	O
patients	O
with	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
The	O
tolerability	O
profile	O
demonstrated	O
in	O
the	O
dose	O
escalation	O
schedule	O
of	O
lenalidomide	B-DRUG
suggests	O
the	O
dosing	O
of	O
lenalidomide	B-DRUG
to	O
be	O
25	O
mg	O
daily	O
on	O
days	O
1月21日	O
with	O
standard	O
dosing	O
of	O
gemcitabine	B-DRUG
and	O
merits	O
further	O
evaluation	O
in	O
a	O
phase	O
II	O
trial	O
.	O
	
ClinicalTrials.gov	O
NCT01547260	O
.	O
	
A	O
multicenter	O
","	O
open-label	O
","	O
Phase	O
1	O
study	O
evaluating	O
the	O
safety	O
and	O
tolerability	O
of	O
pegaspargase	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
advanced	B-CANCER
metastatic	I-CANCER
solid	I-CANCER
tumors	I-CANCER
and	O
lymphoma	B-CANCER
.	O
	
	
To	O
evaluate	O
the	O
maximum	O
tolerated	O
dose	O
","	O
safety	O
profile	O
","	O
pharmacokinetics	O
","	O
and	O
pharmacodynamics	O
of	O
pegaspargase	B-DRUG
(	O
PEG-ASP	B-DRUG
)	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
metastatic	I-CANCER
solid	I-CANCER
tumors	I-CANCER
and	O
lymphoma	B-CANCER
.	O
	
We	O
conducted	O
a	O
multicenter	O
","	O
open	O
label	O
","	O
nonrandomized	O
","	O
Phase	O
1	O
dose	O
escalation	O
study	O
designed	O
to	O
evaluate	O
up	O
to	O
10	O
cohorts	O
of	O
patients	O
with	O
advanced	O
or	O
metastatic	B-CANCER
solid	I-CANCER
tumors	I-CANCER
and	O
lymphoma	B-CANCER
.	O
	
Seventeen	O
patients	O
were	O
treated	O
with	O
of	O
PEG-ASP	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
.	O
	
The	O
study	O
was	O
terminated	O
early	O
because	O
the	O
doses	O
for	O
PEG-ASP	B-DRUG
suggested	O
for	O
de-escalation	O
were	O
predicted	O
not	O
to	O
provide	O
desired	O
sustained	O
asparaginase	O
concentrations	O
based	O
on	O
the	O
analysis	O
of	O
treated	O
patients	O
.	O
	
The	O
combination	O
of	O
milatuzumab	B-DRUG
","	O
a	O
humanized	O
anti-CD74	O
antibody	O
","	O
and	O
veltuzumab	B-DRUG
","	O
a	O
humanized	O
anti-CD20	O
antibody	O
","	O
demonstrates	O
activity	O
in	O
patients	O
with	O
relapsed	O
and	O
refractory	O
B-cell	B-CANCER
non-Hodgkin	I-CANCER
lymphoma	I-CANCER
.	O
	
	
As	O
a	O
result	O
of	O
the	O
anti-tumour	O
activity	O
observed	O
in	O
vitro	O
and	O
in	O
vivo	O
with	O
combined	O
anti-CD20	O
and	O
anti-CD74	O
antibodies	O
","	O
we	O
initiated	O
a	O
phase	O
I	O
/	O
II	O
trial	O
of	O
veltuzumab	B-DRUG
and	O
milatuzumab	B-DRUG
in	O
patients	O
with	O
relapsed	O
or	O
refractory	O
B-cell	B-CANCER
non-Hodgkin	I-CANCER
lymphoma	I-CANCER
(	O
NHL	B-CANCER
)	O
.	O
	
Patients	O
received	O
an	O
induction	O
of	O
veltuzumab	B-DRUG
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
combined	O
with	O
escalating	O
doses	O
of	O
milatuzumab	B-DRUG
at	O
8	O
","	O
16	O
and	O
20	O
mg	O
/	O
kg	O
weekly	O
for	O
4	O
weeks	O
.	O
	
Patients	O
without	O
disease	O
progression	O
could	O
receive	O
an	O
extended	O
induction	O
with	O
treatment	O
on	O
weeks	O
12	O
","	O
20	O
","	O
28	O
and	O
36	O
.	O
	
A	O
total	O
of	O
35	O
patients	O
enrolled	O
on	O
the	O
study	O
.	O
	
Median	O
age	O
was	O
63	O
years	O
","	O
median	O
number	O
of	O
prior	O
therapies	O
was	O
3	O
","	O
and	O
63	O
%	O
of	O
patients	O
were	O
rituximab	B-DRUG
refractory	O
.	O
	
No	O
dose-limiting	O
toxicities	O
were	O
observed	O
in	O
the	O
phase	O
I	O
study	O
.	O
	
Related	O
grade	O
3月4日	O
toxicities	O
included	O
lymphopenia	B-TOXI
","	O
leucopenia	B-TOXI
","	O
neutropenia	B-TOXI
","	O
anaemia	B-TOXI
","	O
infusion	B-TOXI
reactions	I-TOXI
","	O
hyperglycaemia	B-TOXI
","	O
fatigue	B-TOXI
and	O
atrial	B-TOXI
tachycardia	I-TOXI
.	O
	
Median	O
weeks	O
of	O
therapy	O
was	O
12	O
and	O
29	O
%	O
of	O
patients	O
completed	O
all	O
36	O
weeks	O
of	O
therapy	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
24	O
%	O
","	O
median	O
duration	O
of	O
response	O
was	O
12	O
months	O
","	O
and	O
responses	O
were	O
observed	O
at	O
all	O
dose	O
levels	O
and	O
in	O
50	O
%	O
of	O
patients	O
refractory	O
to	O
rituximab	B-DRUG
.	O
	
Combination	O
therapy	O
with	O
veltuzumab	B-DRUG
and	O
milatuzumab	B-DRUG
demonstrated	O
activity	O
in	O
a	O
population	O
of	O
heavily	O
pre-treated	O
patients	O
with	O
relapsed	O
or	O
refractory	B-CANCER
indolent	I-CANCER
NHL	I-CANCER
.	O
	
NRG	O
Oncology	O
/	O
RTOG	O
921	O
:	O
A	O
phase	O
2	O
study	O
of	O
postoperative	O
intensity-modulated	O
radiotherapy	O
with	O
concurrent	O
cisplatin	B-DRUG
and	O
bevacizumab	B-DRUG
followed	O
by	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
for	O
patients	O
with	O
endometrial	B-CANCER
cancer	I-CANCER
.	O
	
	
The	O
current	O
study	O
was	O
conducted	O
to	O
assess	O
acute	O
and	O
late	O
adverse	O
events	O
(	O
AEs	O
)	O
","	O
overall	O
survival	O
(	O
OS	O
)	O
","	O
pelvic	O
failure	O
","	O
regional	O
failure	O
","	O
distant	O
failure	O
","	O
and	O
disease-free	O
survival	O
in	O
a	O
prospective	O
phase	O
2	O
clinical	O
trial	O
of	O
bevacizumab	B-DRUG
and	O
pelvic	O
intensity-modulated	O
radiotherapy	O
(	O
IMRT	O
)	O
with	O
chemotherapy	O
in	O
patients	O
with	O
high-risk	O
endometrial	B-CANCER
cancer	I-CANCER
.	O
	
Patients	O
underwent	O
a	O
hysterectomy	O
and	O
lymph	O
node	O
removal	O
","	O
and	O
had	O
_1	O
of	O
the	O
following	O
high-risk	O
factors	O
:	O
grade	O
3	O
carcinoma	B-TOXI
with	O
&	O
gt	O
;	O
50	O
%	O
myometrial	O
invasion	O
","	O
grade	O
2	O
or	O
3	O
disease	B-TOXI
with	I-TOXI
any	I-TOXI
cervical	I-TOXI
stromal	I-TOXI
invasion	I-TOXI
","	O
or	O
known	O
extrauterine	B-TOXI
extension	I-TOXI
confined	O
to	O
the	O
pelvis	O
.	O
	
Treatment	O
included	O
pelvic	O
IMRT	O
and	O
concurrent	O
cisplatin	B-DRUG
on	O
days	O
1	O
and	O
29	O
of	O
radiation	O
and	O
bevacizumab	B-DRUG
(	O
at	O
a	O
dose	O
of	O
5	O
mg	O
/	O
kg	O
on	O
days	O
1	O
","	O
15	O
","	O
and	O
29	O
of	O
radiation	O
)	O
followed	O
by	O
adjuvant	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
for	O
4	O
cycles	O
.	O
	
The	O
primary	O
endpoint	O
was	O
grade	O
_3	O
AEs	O
occurring	O
within	O
the	O
first	O
90	O
days	O
(	O
toxicity	O
was	O
graded	O
according	O
to	O
the	O
National	O
Cancer	O
Institute	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
[	O
version	O
4	O
]	O
)	O
.	O
	
A	O
total	O
of	O
34	O
patients	O
were	O
accrued	O
from	O
November	O
2009	O
through	O
December	O
2011	O
","	O
30	O
of	O
whom	O
were	O
eligible	O
and	O
received	O
study	O
treatment	O
.	O
	
Seven	O
of	O
30	O
patients	O
(	O
23.3	O
%	O
;	O
1-sided	O
95	O
%	O
confidence	O
interval	O
","	O
10.6	O
%	O
-36	O
%	O
)	O
developed	O
grade	O
_3	O
treatment-related	O
nonhematologic	B-TOXI
toxicities	I-TOXI
within	O
90	O
days	O
;	O
an	O
additional	O
6	O
patients	O
experienced	O
grade	O
_3	O
toxicities	O
between	O
90	O
and	O
365	O
days	O
after	O
treatment	O
.	O
	
The	O
2-year	O
OS	O
rate	O
was	O
96.7	O
%	O
and	O
the	O
disease-free	O
survival	O
rate	O
was	O
79.1	O
%	O
.	O
	
No	O
patient	O
developed	O
a	O
within-field	O
pelvic	B-TOXI
failure	I-TOXI
and	O
no	O
patients	O
with	O
International	O
Federation	O
of	O
Gynecology	O
and	O
Obstetrics	O
stage	O
I	O
to	O
IIIA	O
disease	O
developed	O
disease	O
recurrence	O
after	O
a	O
median	O
follow-up	O
of	O
26	O
months	O
.	O
	
Postoperative	O
bevacizumab	B-DRUG
added	O
to	O
chemotherapy	O
and	O
pelvic	O
IMRT	O
appears	O
to	O
be	O
well	O
tolerated	O
and	O
results	O
in	O
high	O
OS	O
rates	O
at	O
2	O
years	O
for	O
patients	O
with	O
high-risk	O
endometrial	B-CANCER
carcinoma	I-CANCER
.	O
	
A	O
phase	O
I	O
/	O
II	O
study	O
of	O
oral	O
clofarabine	B-DRUG
plus	O
low-dose	O
cytarabine	B-DRUG
in	O
previously	O
treated	O
acute	O
myeloid	B-CANCER
leukaemia	I-CANCER
and	O
high-risk	O
myelodysplastic	O
syndrome	O
patients	O
at	O
least	O
60	O
years	O
of	O
age	O
.	O
	
	
Outcomes	O
for	O
older	O
adults	O
with	O
acute	B-CANCER
myeloid	I-CANCER
leukaemia	I-CANCER
(	O
AML	B-CANCER
)	O
and	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
are	O
generally	O
poor	O
","	O
and	O
new	O
effective	O
therapies	O
are	O
needed	O
.	O
	
We	O
investigated	O
oral	O
clofarabine	B-DRUG
combined	O
with	O
low-dose	O
cytarabine	B-DRUG
(	O
LDAC	O
)	O
in	O
patients	O
aged	O
60	O
years	O
and	O
above	O
with	O
relapsed	O
or	O
refractory	O
AML	B-CANCER
or	O
high-risk	O
MDS	O
in	O
a	O
phase	O
I	O
/	O
II	O
trial	O
.	O
	
A	O
3	O
=+	O
3	O
dose	O
escalation	O
of	O
oral	O
clofarabine	B-DRUG
was	O
followed	O
by	O
a	O
phase	O
II	O
expansion	O
with	O
the	O
aim	O
of	O
obtaining	O
a	O
complete	O
response	O
(	O
CR	O
)	O
rate	O
_30	O
%	O
.	O
	
We	O
identified	O
20	O
mg	O
/	O
d	O
for	O
5	O
d	O
as	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
oral	O
clofarabine	B-DRUG
.	O
	
A	O
total	O
of	O
35	O
patients	O
","	O
with	O
a	O
median	O
age	O
of	O
72	O
years	O
","	O
were	O
treated	O
.	O
	
Of	O
26	O
patients	O
enrolled	O
at	O
the	O
MTD	O
","	O
4	O
had	O
treatment-related	O
grade	O
3月4日	O
non-haematological	B-TOXI
toxicities	I-TOXI
","	O
but	O
none	O
died	B-TOXI
within	O
28	O
d.	O
The	O
observed	O
CR	O
rate	O
and	O
median	O
survival	O
were	O
34	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
","	O
18-50	O
%	O
]	O
and	O
6.8	O
months	O
overall	O
and	O
38	O
%	O
[	O
95	O
%	O
CI	O
","	O
19-57	O
%	O
]	O
and	O
7.2	O
months	O
at	O
the	O
MTD	O
.	O
	
The	O
median	O
disease-free	O
survival	O
was	O
7.4	O
months	O
.	O
	
Fifty-two	O
percent	O
(	O
23	O
/	O
44	O
)	O
of	O
cycles	O
administered	O
at	O
the	O
MTD	O
were	O
done	O
without	O
hospital	O
admission	O
.	O
	
This	O
combination	O
of	O
oral	O
clofarabine	B-DRUG
and	O
LDAC	O
demonstrated	O
efficacy	O
with	O
a	O
CR	O
rate	O
of	O
&	O
gt	O
;	O
30	O
%	O
and	O
acceptable	O
toxicity	O
in	O
older	O
patients	O
.	O
	
A	O
phase	O
I	O
/	O
II	O
trial	O
of	O
second-line	O
chemotherapy	O
with	O
paclitaxel	B-DRUG
and	O
irinotecan	B-DRUG
in	O
fluoropyrimidine-	B-DRUG
and	O
platinum-pretreated	B-DRUG
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
	
This	O
is	O
a	O
phase	O
I	O
/	O
II	O
study	O
of	O
second-line	O
chemotherapy	O
with	O
paclitaxel	B-DRUG
and	O
irinotecan	B-DRUG
in	O
fluoropyrimidine-	B-DRUG
and	O
platinum-pretreated	B-DRUG
patients	O
with	O
metastatic	O
or	O
recurrent	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Phase	O
I	O
part	O
with	O
a	O
standard	O
3	O
=+	O
3	O
dose-escalation	O
design	O
was	O
conducted	O
to	O
define	O
the	O
recommended	O
phase	O
II	O
dose	O
(	O
RP2D	O
)	O
using	O
four	O
predefined	O
dose	O
levels	O
of	O
paclitaxel	B-DRUG
and	O
irinotecan	B-DRUG
.	O
	
The	O
efficacy	O
of	O
RP2D	O
was	O
evaluated	O
in	O
a	O
phase	O
II	O
part	O
.	O
	
In	O
phase	O
I	O
part	O
","	O
12	O
patients	O
were	O
enrolled	O
.	O
	
Dose-limiting	O
toxicity	O
was	O
not	O
observed	O
.	O
	
The	O
RP2D	O
was	O
established	O
as	O
level	O
4	O
(	O
paclitaxel-135	B-DRUG
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
irinotecan-160	B-DRUG
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
every	O
3	O
weeks	O
)	O
.	O
	
In	O
phase	O
II	O
part	O
","	O
27	O
patients	O
were	O
enrolled	O
.	O
	
Thirty	O
patients	O
","	O
including	O
three	O
patients	O
at	O
dose	O
level	O
4	O
in	O
the	O
phase	O
I	O
part	O
","	O
were	O
analyzed	O
for	O
efficacy	O
.	O
	
There	O
was	O
no	O
complete	O
response	O
.	O
	
Partial	O
response	O
and	O
stable	O
disease	O
were	O
reported	O
in	O
four	O
and	O
16	O
patients	O
","	O
respectively	O
(	O
response	O
rate	O
13.3	O
%	O
","	O
95	O
%	O
CI	O
0.0-25.5	O
%	O
;	O
disease	O
control	O
rate	O
66.6	O
%	O
","	O
95	O
%	O
CI	O
49.0-83.0	O
%	O
)	O
.	O
	
The	O
median	O
time	O
to	O
progression	O
and	O
overall	O
survival	O
was	O
3	O
months	O
(	O
95	O
%	O
CI	O
1.8-4.2	O
)	O
and	O
10.1	O
months	O
(	O
95	O
%	O
CI	O
6.6-13.6	O
)	O
","	O
respectively	O
.	O
	
Grade	O
3	O
/	O
4	O
toxicities	O
included	O
neutropenia	B-TOXI
(	O
2	O
patients	O
","	O
7.4	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
1	O
","	O
3.7	O
%	O
)	O
","	O
neutropenic	B-TOXI
fever	I-TOXI
(	O
1	O
","	O
3.7	O
%	O
)	O
","	O
and	O
diarrhea	B-TOXI
(	O
1	O
","	O
3.7	O
%	O
)	O
.	O
	
There	O
were	O
no	O
treatment-related	O
deaths	B-TOXI
.	O
	
The	O
RP2D	O
of	O
the	O
paclitaxel	B-DRUG
and	O
irinotecan	B-DRUG
combination	O
is	O
paclitaxel	B-DRUG
(	O
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
irinotecan	B-DRUG
(	O
160	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
","	O
every	O
3	O
weeks	O
.	O
	
This	O
combination	O
as	O
a	O
second-line	O
treatment	O
for	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
shows	O
tolerable	O
toxicity	O
and	O
modest	O
efficacy	O
.	O
	
The	O
combination	O
of	O
axitinib	B-DRUG
followed	O
by	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
yields	O
extended	O
survival	O
in	O
advanced	O
BRAF	O
wild-type	O
melanoma	B-CANCER
:	O
results	O
of	O
a	O
clinical	O
/	O
correlative	O
prospective	O
phase	O
II	O
clinical	O
trial	O
.	O
	
	
Simultaneous	O
chemotherapy	O
with	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
inhibition	O
has	O
not	O
shown	O
additional	O
benefit	O
over	O
chemotherapy	O
alone	O
in	O
advanced	B-CANCER
melanoma	I-CANCER
.	O
	
We	O
tested	O
administration	O
of	O
the	O
potent	O
VEGF	O
inhibitor	O
axitinib	B-DRUG
followed	O
by	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
to	O
determine	O
whether	O
enhanced	O
tumour	O
proliferation	O
during	O
axitinib	B-DRUG
withdrawal	O
leads	O
to	O
sustained	O
chemosensitivity	O
.	O
	
We	O
conducted	O
a	O
prospective	O
phase	O
II	O
trial	O
in	O
metastatic	B-CANCER
melanoma	I-CANCER
patients	O
with	O
ECOG	O
performance	O
status	O
0-1	O
and	O
normal	O
organ	O
function	O
.	O
	
Axitinib	O
5	O
mg	O
PO	O
b.i.d.	O
was	O
taken	O
on	O
days	O
1月14日	O
of	O
each	O
21-day	O
treatment	O
cycle	O
","	O
and	O
carboplatin	B-DRUG
(	O
AUC=5	O
)	O
with	O
paclitaxel	B-DRUG
(	O
175	O
mg	O
m	O
(	O
-2	O
)	O
)	O
was	O
administered	O
on	O
day	O
1	O
starting	O
with	O
cycle	O
2	O
3'-Deoxy-3'-	B-DRUG
(	I-DRUG
18	I-DRUG
)	I-DRUG
F-fluorothymidine	I-DRUG
(	I-DRUG
(	I-DRUG
18	I-DRUG
)	I-DRUG
F-FLT	I-DRUG
)	I-DRUG
#NAME?	I-DRUG
scans	O
were	O
performed	O
in	O
five	O
patients	O
to	O
assess	O
tumour	O
proliferation	O
on	O
days	O
1	O
","	O
14	O
","	O
17	O
","	O
and	O
20	O
of	O
cycle	O
1	O
Molecular	O
profiling	O
for	O
BRAF	O
was	O
performed	O
for	O
all	O
patients	O
with	O
cutaneous	O
","	O
acral	O
","	O
or	O
mucosal	B-CANCER
melanoma	I-CANCER
.	O
	
The	O
treatment	O
was	O
well	O
tolerated	O
.	O
	
The	O
most	O
common	O
grade	O
3	O
AEs	O
were	O
hypertension	B-TOXI
","	O
neutropenia	B-TOXI
","	O
and	O
anaemia	B-TOXI
.	O
	
Grade	O
4	O
non-haematologic	B-TOXI
AEs	I-TOXI
were	O
not	O
observed	O
.	O
	
Four	O
of	O
five	O
patients	O
completing	O
(	B-DRUG
18	I-DRUG
)	I-DRUG
F-FLT-PET	I-DRUG
scans	O
showed	O
increases	O
(	O
23-92	O
%	O
)	O
in	O
SUV	O
values	O
during	O
the	O
axitinib	B-DRUG
holiday	O
.	O
	
Of	O
36	O
evaluable	O
patients	O
","	O
there	O
were	O
8	O
confirmed	O
PRs	O
by	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	B-CANCER
Tumors	I-CANCER
.	O
	
Overall	O
","	O
20	O
patients	O
had	O
SD	O
and	O
8	O
had	O
PD	O
as	O
the	O
best	O
response	O
.	O
	
The	O
median	O
PFS	O
was	O
8.7	O
months	O
and	O
the	O
median	O
overall	O
survival	O
was	O
14	O
months	O
.	O
	
Five	O
BRAF	O
(	O
V600E	O
/	O
K	O
)	O
patients	O
had	O
significantly	O
worse	O
PFS	O
than	O
patients	O
without	O
these	O
mutations	O
.	O
	
Axitinib	B-DRUG
followed	O
by	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
was	O
well	O
tolerated	O
and	O
effective	O
in	O
BRAF	O
wild-type	O
metastatic	B-CANCER
melanoma	I-CANCER
.	O
	
3'-Deoxy-3'-	B-DRUG
(	I-DRUG
18	I-DRUG
)	I-DRUG
F-fluorothymidine-PET	I-DRUG
scans	O
showed	O
increased	O
proliferation	O
during	O
axitinib	B-DRUG
withdrawal	O
.	O
	
Phase	O
I	O
study	O
of	O
the	O
anti-IGF1R	O
antibody	O
cixutumumab	B-DRUG
with	O
everolimus	B-DRUG
and	O
octreotide	B-DRUG
in	O
advanced	O
well-differentiated	O
neuroendocrine	B-CANCER
tumors	I-CANCER
.	O
	
	
Preclinical	O
data	O
suggest	O
multiple	O
roles	O
for	O
the	O
IGF1	O
receptor	O
(	O
IGF1R	O
)	O
in	O
neuroendocrine	B-CANCER
tumors	I-CANCER
(	O
NETs	B-CANCER
)	O
","	O
including	O
mediating	O
resistance	O
to	O
mammalian	O
target	O
of	O
rapamycin	B-DRUG
(	O
mTOR	O
)	O
inhibitors	O
.	O
	
Everolimus	B-DRUG
","	O
an	O
oral	O
mTOR	O
inhibitor	O
","	O
and	O
octreotide	O
long-acting	O
repeatable	O
(	O
LAR	O
)	O
are	O
approved	O
for	O
subgroups	O
of	O
well-differentiated	O
NET	B-CANCER
.	O
	
The	O
primary	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
establish	O
the	O
safety	O
and	O
recommended	O
phase	O
II	O
dose	O
(	O
RP2D	O
)	O
of	O
cixutumumab	B-DRUG
","	O
a	O
monoclonal	O
antibody	O
(	O
MAB	O
)	O
against	O
IGF1R	O
","	O
with	O
everolimus	B-DRUG
and	O
octreotide	B-DRUG
LAR	I-DRUG
.	O
	
Patients	O
with	O
well-differentiated	O
NET	B-CANCER
were	O
treated	O
with	O
10	O
mg	O
everolimus	B-DRUG
p.o.	O
daily	O
","	O
20	O
mg	O
octreotide	B-DRUG
LAR	I-DRUG
i.m.	O
every	O
21	O
days	O
","	O
and	O
escalating	O
doses	O
of	O
cixutumumab	B-DRUG
.	O
	
An	O
expansion	O
cohort	O
was	O
enrolled	O
at	O
RP2D	O
.	O
	
Correlative	O
studies	O
included	O
the	O
evaluation	O
of	O
mTOR	O
pathway	O
inhibition	O
in	O
paired	O
tumor	O
biopsies	O
and	O
the	O
effects	O
of	O
this	O
combination	O
on	O
metabolism	O
via	O
indirect	O
calorimetry	O
.	O
	
Nineteen	O
patients	O
with	O
progressive	O
disease	O
were	O
enrolled	O
","	O
including	O
nine	O
to	O
the	O
expansion	O
portion	O
.	O
	
Two	O
patients	O
had	O
dose-limiting	O
toxicities	O
of	O
grade	O
3	O
mucositis	B-TOXI
at	O
15	O
mg	O
/	O
kg	O
cixutumumab	B-DRUG
.	O
	
Long-term	O
tolerance	O
at	O
RP2D	O
was	O
problematic	B-TOXI
","	O
and	O
the	O
most	O
common	O
_grade	O
3	O
adverse	O
event	O
was	O
fatigue	B-TOXI
.	O
	
One	O
patient	O
with	O
metastatic	B-CANCER
insulinoma	I-CANCER
had	O
a	O
confirmed	O
partial	O
response	O
","	O
whereas	O
17	O
had	O
stable	O
disease	O
.	O
	
The	O
median	O
progression-free	O
survival	O
was	O
43.6	O
weeks	O
","	O
and	O
the	O
median	O
overall	O
survival	O
was	O
25.5	O
months	O
.	O
	
The	O
RP2D	O
of	O
this	O
combination	O
per	O
the	O
predefined	O
study	O
protocol	O
of	O
10	O
mg	O
/	O
kg	O
cixutumumab	B-DRUG
i.v.	O
","	O
20	O
mg	O
octreotide	B-DRUG
LAR	I-DRUG
i.m.	O
every	O
21	O
days	O
plus	O
10	O
mg	O
everolimus	B-DRUG
p.o.	O
daily	O
is	O
associated	O
with	O
non-dose-limiting	O
toxicities	O
that	O
limit	O
long-term	O
tolerance	O
.	O
	
Although	O
a	O
signal	O
of	O
activity	O
was	O
noted	O
in	O
the	O
present	O
study	O
","	O
this	O
will	O
need	O
to	O
be	O
reconciled	O
with	O
limited	O
tolerance	O
of	O
the	O
combination	O
and	O
data	O
from	O
larger	O
studies	O
of	O
anti-IGF1R	O
MABs	O
in	O
NET	B-CANCER
that	O
have	O
been	O
disappointing	O
.	O
	
Phase	O
I	O
combination	O
of	O
pazopanib	B-DRUG
and	O
everolimus	B-DRUG
in	O
PIK3CA	O
mutation	O
positive	O
/	O
PTEN	O
loss	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
refractory	O
to	O
standard	O
therapy	O
.	O
	
	
Combining	O
agents	O
that	O
block	O
both	O
the	O
VEGF	O
and	O
PI3K	O
/	O
AKT	O
/	O
mTOR	O
pathways	O
may	O
be	O
synergistic	O
.	O
	
We	O
explored	O
a	O
novel	O
dosing	O
schedule	O
to	O
assess	O
safety	O
","	O
toxicity	O
and	O
activity	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Patients	O
with	O
refractory	B-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
enrolled	O
in	O
a	O
modified	O
3	O
=+	O
3	O
Phase	O
I	O
dose	O
escalation	O
study	O
to	O
determine	O
dose	O
limiting	O
toxicities	O
(	O
DLTs	O
)	O
and	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
a	O
combination	O
of	O
everolimus	B-DRUG
(	O
mTOR	O
inhibitor	O
)	O
and	O
pazopanib	B-DRUG
(	O
tyrosine	O
kinase	O
inhibitor	O
with	O
anti-VEGF	O
activity	O
)	O
.	O
	
An	O
expansion	O
cohort	O
selected	O
for	O
patients	O
with	O
molecular	O
alterations	O
in	O
the	O
PI3K	O
/	O
AKT	O
/	O
mTOR	O
pathway	O
.	O
	
Sixty-two	O
patients	O
were	O
enrolled	O
;	O
median	O
age	O
was	O
60	O
years	O
;	O
29	O
were	O
women	O
.	O
	
The	O
MTD	O
was	O
pazopanib	B-DRUG
600	O
mg	O
every	O
other	O
day	O
(	O
QOD	O
)	O
alternating	O
with	O
everolimus	B-DRUG
10	O
mg	O
PO	O
QOD	O
.	O
	
DLTs	O
were	O
grade	O
3	O
thrombocytopenia	B-TOXI
and	O
creatinine	B-TOXI
elevation	I-TOXI
.	O
	
Most	O
common	O
toxicities	O
of	O
any	O
grade	O
were	O
thrombocytopenia	B-TOXI
","	O
transaminitis	B-TOXI
","	O
leukopenia	B-TOXI
/	O
neutropenia	B-TOXI
and	O
lipid	B-TOXI
abnormalities	I-TOXI
.	O
	
Among	O
52	O
patients	O
evaluable	O
for	O
response	O
","	O
the	O
clinical	O
benefit	O
rate	O
(	O
CBR	O
)	O
was	O
27	O
%	O
(	O
14	O
/	O
52	O
)	O
including	O
four	O
partial	O
responses	O
(	O
PR	O
)	O
","	O
and	O
10	O
stable	O
disease	O
(	O
SD	O
)	O
_6	O
months	O
.	O
	
26	O
of	O
45	O
patients	O
evaluated	O
for	O
molecular	O
alterations	O
had	O
at	O
least	O
one	O
alteration	O
in	O
the	O
PI3K	O
/	O
AKT	O
/	O
mTOR	O
pathway	O
.	O
	
CBR	O
in	O
patients	O
with	O
a	O
matched	O
alteration	O
was	O
27	O
%	O
(	O
7	O
/	O
26	O
)	O
versus	O
26	O
%	O
(	O
5	O
/	O
19	O
)	O
for	O
patients	O
without	O
an	O
alteration	O
(	O
p	O
=	O
0.764	O
)	O
.	O
	
However	O
","	O
64	O
%	O
of	O
those	O
with	O
CBR	O
and	O
molecular	O
testing	O
done	O
for	O
alteration	O
in	O
the	O
PI3K	O
/	O
AKT	O
/	O
mTOR	O
pathway	O
were	O
positive	O
.	O
	
Combination	O
treatment	O
with	O
pazopanib	B-DRUG
and	O
everolimus	B-DRUG
was	O
well	O
tolerated	O
and	O
demonstrated	O
activity	O
in	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
Further	O
exploration	O
of	O
this	O
combination	O
and	O
molecular	O
correlation	O
with	O
treatment	O
outcomes	O
is	O
warranted	O
.	O
	
Dual	O
targeting	O
of	O
HER1	O
/	O
EGFR	O
and	O
HER2	O
with	O
cetuximab	B-DRUG
and	O
trastuzumab	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
after	O
gemcitabine	B-DRUG
failure	O
:	O
results	O
of	O
the	O
	O
phase	O
1月2日	O
trial	O
.	O
	
	
To	O
improve	O
treatment	O
efficacy	O
","	O
we	O
decided	O
to	O
simultaneously	O
target	O
HER1	O
and	O
HER2	O
with	O
trastuzumab	B-DRUG
and	O
cetuximab	B-DRUG
.	O
	
Following	O
promising	O
preclinical	O
results	O
","	O
we	O
conducted	O
a	O
phase	O
1月2日	O
trial	O
in	O
advanced	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
patients	O
after	O
first-line	O
gemcitabine-based	B-DRUG
chemotherapy	O
failure	O
.	O
	
In	O
this	O
single-arm	O
","	O
non-randomized	O
","	O
multicenter	O
trial	O
","	O
patients	O
received	O
weekly	O
cetuximab	B-DRUG
(	O
400mg	O
/	O
m虏	O
","	O
then	O
250mg	O
/	O
m虏	O
)	O
.	O
	
They	O
were	O
sequentially	O
included	O
in	O
two	O
trastuzumab	B-DRUG
dose	O
levels	O
:	O
3	O
or	O
4.0mg	O
/	O
kg	O
","	O
then	O
1.5	O
or	O
2.0mg	O
/	O
kg	O
/	O
weekly	O
.	O
	
Endpoints	O
were	O
the	O
objective	O
response	O
rate	O
","	O
safety	O
","	O
progression-free	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O
	
During	O
phase	O
1	O
(	O
n=10	O
patients	O
)	O
","	O
toxicities	O
were	O
evenly	O
distributed	O
except	O
for	O
skin	B-TOXI
toxicities	I-TOXI
that	O
frequently	O
caused	O
compliance	O
issues	O
.	O
	
The	O
higher	O
dose	O
level	O
was	O
defined	O
as	O
the	O
trastuzumab	B-DRUG
recommended	O
dose	O
.	O
	
During	O
phase	O
2	O
(	O
n=39	O
patients	O
)	O
","	O
toxicities	O
were	O
mainly	O
cutaneous	B-TOXI
reactions	I-TOXI
and	O
asthenia	B-TOXI
.	O
	
No	O
objective	O
response	O
was	O
observed	O
.	O
	
Nine	O
patients	O
were	O
stabilized	O
but	O
arrested	O
treatment	O
due	O
to	O
toxicity	O
.	O
	
Median	O
PFS	O
was	O
1.8	O
months	O
(	O
95	O
%	O
CI	O
:	O
1.7-2.0	O
months	O
)	O
and	O
median	O
OS	O
was	O
4.6	O
months	O
(	O
95	O
%	O
CI	O
:	O
2.7-6.6	O
months	O
)	O
.	O
	
Both	O
were	O
positively	O
correlated	O
with	O
skin	B-TOXI
toxicity	I-TOXI
severity	O
(	O
P=0.027	O
and	O
P=0.001	O
","	O
respectively	O
)	O
.	O
	
Conventional	O
phase	O
1	O
dose-escalation	O
schedules	O
are	O
unsuitable	O
for	O
targeted	O
therapies	O
because	O
most	O
cutaneous	B-TOXI
toxicities	I-TOXI
are	O
not	O
considered	O
dose-limiting	O
toxicities	O
.	O
	
The	O
compliance	O
issues	O
caused	O
by	O
skin	B-TOXI
toxicities	I-TOXI
were	O
particularly	O
detrimental	O
because	O
of	O
the	O
toxicity-response	O
correlation	O
.	O
	
Phase	O
I	O
study	O
of	O
ipilimumab	B-DRUG
in	O
phased	O
combination	O
with	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
in	O
Japanese	O
patients	O
with	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
Ipilimumab	B-DRUG
is	O
an	O
antibody	O
that	O
targets	O
the	O
cytotoxic	O
T-lymphocyte	O
antigen-4	O
to	O
potentiate	O
an	O
antitumor	O
response	O
.	O
	
Adding	O
ipilimumab	B-DRUG
10	O
mg	O
/	O
kg	O
to	O
paclitaxel	B-DRUG
(	O
PTX	B-DRUG
)	O
and	O
carboplatin	B-DRUG
(	O
CBDCA	B-DRUG
)	O
in	O
a	O
phased	O
schedule	O
improved	O
progression-free	O
survival	O
in	O
a	O
phase	O
II	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
study	O
.	O
	
This	O
dose-escalating	O
","	O
phase	O
I	O
study	O
was	O
designed	O
to	O
identify	O
the	O
recommended	O
dose	O
of	O
ipilimumab	B-DRUG
(	O
3	O
or	O
10	O
mg	O
/	O
kg	O
)	O
by	O
evaluating	O
dose-limiting	O
toxicity	O
(	O
DLT	O
;	O
Cycles	O
3	O
and	O
4	O
)	O
in	O
phased	O
combination	O
with	O
PTX	B-DRUG
(	O
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
CBDCA	B-DRUG
(	O
area	O
under	O
the	O
curve	O
=	O
6	O
)	O
in	O
Japanese	O
patients	O
with	O
advanced	O
NSCLC	B-CANCER
.	O
	
Treatment	O
was	O
administered	O
intravenously	O
every	O
3	O
weeks	O
initially	O
","	O
followed	O
by	O
some	O
eligible	O
patients	O
receiving	O
maintenance	O
ipilimumab	B-DRUG
once	O
every	O
12	O
weeks	O
.	O
	
Additional	O
endpoints	O
included	O
safety	O
","	O
tumor	O
response	O
","	O
pharmacokinetics	O
","	O
and	O
immunogenicity	O
.	O
	
Fifteen	O
patients	O
were	O
enrolled	O
and	O
12	O
received	O
ipilimumab	B-DRUG
(	O
n	O
=	O
6	O
","	O
3	O
mg	O
/	O
kg	O
;	O
n	O
=	O
6	O
","	O
10	O
mg	O
/	O
kg	O
)	O
in	O
combination	O
with	O
PTX	B-DRUG
and	O
CBDCA	B-DRUG
.	O
	
DLTs	O
occurred	O
in	O
2	O
patients	O
(	O
ipilimumab	B-DRUG
3	O
mg	O
/	O
kg	O
)	O
and	O
1	O
patient	O
(	O
ipilimumab	B-DRUG
10	O
mg	O
/	O
kg	O
)	O
.	O
	
The	O
most	O
common	O
grade	O
3	O
/	O
4	O
adverse	O
events	O
(	O
AEs	O
)	O
were	O
decreased	B-TOXI
hemoglobin	I-TOXI
","	O
leukopenia	B-TOXI
","	O
and	O
neutropenia	B-TOXI
.	O
	
The	O
most	O
common	O
immune-related	B-TOXI
AEs	I-TOXI
affected	O
the	O
skin	O
","	O
gastrointestinal	O
","	O
and	O
nervous	O
system	O
.	O
	
The	O
safety	O
profile	O
was	O
similar	O
in	O
both	O
cohorts	O
.	O
	
Three	O
patients	O
in	O
each	O
cohort	O
achieved	O
a	O
partial	O
response	O
.	O
	
The	O
pharmacokinetic	O
(	O
PK	O
)	O
profile	O
of	O
ipilimumab	B-DRUG
in	O
Japanese	O
patients	O
was	O
similar	O
to	O
that	O
observed	O
in	O
previous	O
studies	O
in	O
non-Japanese	O
patients	O
.	O
	
Conclusions	O
The	O
recommended	O
dose	O
of	O
ipilimumab	B-DRUG
in	O
phased	O
combination	O
with	O
PTX	B-DRUG
and	O
CBDCA	B-DRUG
in	O
Japanese	O
patients	O
with	O
NSCLC	B-CANCER
was	O
identified	O
as	O
10	O
mg	O
/	O
kg	O
.	O
	
The	O
safety	O
profile	O
was	O
consistent	O
with	O
the	O
previously	O
defined	O
AE	O
profile	O
.	O
	
A	O
phase	O
II	O
clinical	O
trial	O
of	O
weekly	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
in	O
combination	O
with	O
panitumumab	B-DRUG
in	O
metastatic	B-CANCER
triple	I-CANCER
negative	I-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
Women	O
with	O
metastatic	B-CANCER
triple	I-CANCER
negative	I-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
TNBC	B-CANCER
)	O
can	O
have	O
a	O
poor	O
prognosis	O
with	O
treatment	O
limited	O
to	O
cytotoxic	O
chemotherapy	O
.	O
	
The	O
identification	O
of	O
effective	O
therapies	O
that	O
may	O
limit	O
exposure	O
to	O
cytotoxic	O
chemotherapy	O
and	O
lead	O
to	O
prolonged	O
survival	O
is	O
an	O
unmet	O
medical	O
need	O
.	O
	
We	O
tested	O
an	O
inhibitor	O
of	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
","	O
panitumumab	B-DRUG
in	O
combination	O
with	O
chemotherapy	O
.	O
	
We	O
conducted	O
a	O
single	O
arm	O
clinical	O
trial	O
in	O
women	O
with	O
metastatic	O
or	O
locally	O
advanced	O
TNBC	B-CANCER
to	O
paclitaxel	B-DRUG
80	O
mg	O
/	O
m2	O
and	O
carboplatin	B-DRUG
AUC	O
of	O
2	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
and	O
panitumumab	B-DRUG
6	O
mg	O
/	O
kg	O
on	O
days	O
1	O
and	O
15	O
for	O
a	O
cycle	O
length	O
of	O
28	O
days	O
.	O
	
The	O
objectives	O
were	O
to	O
evaluate	O
the	O
response	O
rate	O
and	O
safety	O
of	O
the	O
combination	O
in	O
comparison	O
to	O
historical	O
controls	O
.	O
	
Fourteen	O
patients	O
with	O
TNBC	B-CANCER
were	O
enrolled	O
with	O
a	O
median	O
age	O
of	O
53	O
years	O
.	O
	
The	O
majority	O
of	O
women	O
were	O
African	O
American	O
(	O
64.3	O
%	O
)	O
with	O
visceral	O
metastasis	O
(	O
64.2	O
%	O
)	O
.	O
	
Hematologic	B-TOXI
toxicities	I-TOXI
","	O
particularly	B-TOXI
neutropenia	I-TOXI
and	O
thrombocytopenia	B-TOXI
","	O
were	O
a	O
major	O
cause	O
of	O
missed	O
chemotherapy	O
and	O
delayed	O
treatment	O
in	O
this	O
study	O
.	O
	
The	O
overall	O
response	O
rate	O
(	O
complete	O
and	O
partial	O
response	O
)	O
of	O
the	O
13	O
evaluable	O
patients	O
was	O
46	O
%	O
.	O
	
The	O
median	O
time	O
to	O
best	O
response	O
was	O
2.4	O
months	O
and	O
the	O
median	O
time	O
to	O
disease	O
progression	O
was	O
3.6	O
months	O
.	O
	
We	O
were	O
able	O
to	O
perform	O
the	O
PAM50	O
analysis	O
on	O
tumors	O
from	O
7	O
of	O
our	O
subjects	O
.	O
	
All	O
the	O
samples	O
tested	O
clustered	O
within	O
the	O
basal-like	O
subtype	O
.	O
	
In	O
our	O
experience	O
the	O
response	O
rate	O
of	O
carboplatin	B-DRUG
","	O
paclitaxel	B-DRUG
and	O
panitumumab	B-DRUG
was	O
consistent	O
with	O
other	O
reports	O
of	O
response	O
for	O
cytotoxic	O
chemotherapy	O
in	O
metastatic	O
TNBC	B-CANCER
.	O
	
Pharmacokinetic	O
Drug-Drug	O
Interaction	O
Study	O
Between	O
Raltegravir	O
and	O
Atorvastatin	O
20	O
mg	O
in	O
Healthy	O
Volunteers	O
.	O
	
	
Dyslipidemia	B-TOXI
is	O
highly	O
prevalent	O
among	O
patients	O
with	O
HIV	B-CANCER
infection	I-CANCER
and	O
contributes	O
to	O
an	O
increased	O
risk	O
of	O
cardiovascular	B-TOXI
disease	I-TOXI
.	O
	
We	O
investigated	O
the	O
influence	O
of	O
a	O
frequently	O
used	O
statin	B-DRUG
","	O
atorvastatin	B-DRUG
","	O
on	O
the	O
pharmacokinetics	O
of	O
the	O
HIV-integrase	O
inhibitor	O
raltegravir	B-DRUG
and	O
vice	O
versa	O
.	O
	
Open-label	O
","	O
crossover	O
3-period	O
phase	O
I	O
trial	O
in	O
24	O
healthy	O
volunteers	O
.	O
	
Subjects	O
took	O
raltegravir	B-DRUG
400	O
mg	O
two	O
times	O
a	O
day	O
for	O
7	O
days	O
","	O
atorvastatin	B-DRUG
20	O
mg	O
once	O
a	O
day	O
for	O
7	O
days	O
","	O
and	O
the	O
combination	O
of	O
atorvastatin	B-DRUG
20	O
mg	O
once	O
a	O
day	O
=+	O
raltegravir	B-DRUG
400	O
mg	O
two	O
times	O
a	O
day	O
for	O
7	O
days	O
with	O
2-week	O
washout	O
periods	O
in	O
between	O
.	O
	
Intensive	O
steady-state	O
-12	O
and	O
24-hour	O
pharmacokinetic	O
blood	O
sampling	O
was	O
performed	O
.	O
	
Geometric	O
mean	O
ratios	O
of	O
the	O
test	O
treatment	O
(	O
combination	O
raltegravir	B-DRUG
=+	O
atorvastatin	B-DRUG
)	O
versus	O
the	O
reference	O
treatment	O
(	O
raltegravir	B-DRUG
or	O
atorvastatin	B-DRUG
alone	O
)	O
and	O
90	O
%	O
confidence	O
intervals	O
were	O
calculated	O
for	O
the	O
area	O
under	O
the	O
plasma	O
concentration-time	O
curve	O
(	O
AUC	O
)	O
.	O
	
Fasting	O
lipid	O
profiles	O
were	O
obtained	O
to	O
assess	O
short-term	O
lipid-lowering	O
effect	O
of	O
atorvastatin	B-DRUG
with	O
or	O
without	O
concomitant	O
raltegravir	B-DRUG
use	O
.	O
	
Twenty-four	O
healthy	O
volunteers	O
(	O
11	O
males	O
)	O
were	O
enrolled	O
.	O
	
All	O
but	O
1	O
subject	O
completed	O
the	O
trial	O
","	O
and	O
no	O
serious	O
adverse	O
events	O
were	O
reported	O
.	O
	
Geometric	O
mean	O
ratios	O
(	O
90	O
%	O
confidence	O
interval	O
)	O
were	O
1.01	O
(	O
0.68-1.51	O
)	O
for	O
raltegravir	B-DRUG
AUC	O
(	O
0-12h	O
)	O
and	O
1	O
(	O
0.90-1.11	O
)	O
for	O
atorvastatin	B-DRUG
AUC	O
(	O
0-24h	O
)	O
.	O
	
The	O
AUC	O
(	O
0-24h	O
)	O
metabolite-to-parent	O
ratio	O
for	O
atorvastatin	B-DRUG
lactone	I-DRUG
","	O
ortho-hydroxy	B-DRUG
","	O
and	O
para-hydroxy	B-DRUG
atorvastatin	I-DRUG
did	O
not	O
change	O
during	O
concomitant	O
raltegravir	B-DRUG
use	O
.	O
	
The	O
effect	O
of	O
atorvastatin	B-DRUG
on	O
low-density	O
lipoprotein	B-DRUG
cholesterol	I-DRUG
was	O
not	O
significantly	O
different	O
when	O
combined	O
with	O
raltegravir	B-DRUG
versus	O
atorvastatin	B-DRUG
alone	O
(	O
P	O
=	O
0.638	O
)	O
.	O
	
Atorvastatin	B-DRUG
20	O
mg	O
has	O
no	O
clinically	O
relevant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
raltegravir	B-DRUG
and	O
vice	O
versa	O
.	O
	
The	O
combination	O
was	O
well	O
tolerated	O
and	O
can	O
be	O
administered	O
without	O
dose	O
adjustments	O
.	O
	
Phase	O
1	O
study	O
of	O
the	O
safety	O
","	O
pharmacokinetics	O
","	O
and	O
antitumour	O
activity	O
of	O
the	O
BCL2	O
inhibitor	O
navitoclax	B-DRUG
in	O
combination	O
with	O
rituximab	B-DRUG
in	O
patients	O
with	O
relapsed	O
or	O
refractory	O
CD20+	O
lymphoid	B-CANCER
malignancies	I-CANCER
.	O
	
	
The	O
oral	O
BCL2	O
inhibitor	O
navitoclax	B-DRUG
has	O
moderate	O
single-agent	O
efficacy	O
in	O
chronic	B-CANCER
lymphocytic	I-CANCER
leukaemia	I-CANCER
(	O
CLL	B-CANCER
)	O
and	O
minor	O
activity	O
in	O
lymphoma	B-CANCER
in	O
Phase	O
1	O
trials	O
.	O
	
Navitoclax	B-DRUG
synergizes	O
with	O
rituximab	B-DRUG
in	O
preclinical	B-DRUG
models	O
of	O
B-cell	B-CANCER
lymphoid	I-CANCER
cancers	I-CANCER
.	O
	
We	O
report	O
the	O
safety	O
","	O
pharmacokinetics	O
and	O
clinical	O
activity	O
of	O
this	O
combination	O
.	O
	
Patients	O
received	O
navitoclax	B-DRUG
(	O
200-325	O
mg	O
)	O
daily	O
and	O
four	O
standard	O
weekly	O
doses	O
of	O
rituximab	B-DRUG
.	O
	
Twenty-nine	O
patients	O
were	O
enrolled	O
across	O
three	O
dose-escalation	O
cohorts	O
and	O
a	O
safety	O
expansion	O
cohort	O
(	O
250	O
mg	O
/	O
d	O
navitoclax	B-DRUG
)	O
.	O
	
The	O
combination	O
was	O
well	O
tolerated	O
.	O
	
Common	O
toxicities	O
were	O
mild	O
diarrhoea	B-TOXI
(	O
79	O
%	O
)	O
and	O
nausea	B-TOXI
(	O
72	O
%	O
)	O
.	O
	
Grade	O
4	O
thrombocytopenia	B-TOXI
occurred	O
in	O
17	O
%	O
of	O
patients	O
(	O
dose	O
limiting	O
at	O
325	O
mg	O
/	O
d	O
)	O
.	O
	
CD19	O
(	O
=+	O
)	O
counts	O
were	O
severely	O
reduced	O
","	O
while	O
CD3	O
(	O
=+	O
)	O
cells	O
(	O
~	O
20	O
%	O
)	O
and	O
serum	O
immunoglobulin	O
M	O
levels	O
(	O
~	O
33	O
%	O
)	O
were	O
also	O
reduced	O
during	O
the	O
first	O
year	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
for	O
navitoclax	B-DRUG
in	O
combination	O
was	O
250	O
mg	O
/	O
d.	O
Pharmacokinetic	O
analyses	O
revealed	O
no	O
apparent	O
interactions	O
between	O
the	O
drugs	O
.	O
	
The	O
response	O
rate	O
in	O
patients	O
with	O
follicular	B-CANCER
lymphoma	I-CANCER
was	O
9	O
/	O
12	O
","	O
including	O
five	O
complete	O
responses	O
.	O
	
All	O
five	O
patients	O
with	O
CLL	B-CANCER
/	O
small	B-CANCER
lymphocytic	I-CANCER
leukaemia	I-CANCER
achieved	O
partial	O
responses	O
.	O
	
One	O
of	O
nine	O
patients	O
with	O
aggressive	O
lymphoma	B-CANCER
responded	O
.	O
	
The	O
addition	O
of	O
rituximab	B-DRUG
to	O
navitoclax	B-DRUG
250	O
mg	O
/	O
d	O
is	O
safe	O
;	O
the	O
combination	O
demonstrates	O
higher	O
response	O
rates	O
for	O
low-grade	O
lymphoid	B-CANCER
cancers	I-CANCER
than	O
observed	O
for	O
either	O
agent	O
alone	O
in	O
previous	O
Phase	O
1	O
trials	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
IV	O
doxorubicin	B-DRUG
plus	O
intraperitoneal	B-DRUG
(	O
IP	O
)	O
paclitaxel	B-DRUG
and	O
IV	O
or	O
IP	O
cisplatin	B-DRUG
in	O
endometrial	B-CANCER
cancer	I-CANCER
patients	O
at	O
high	O
risk	O
for	O
peritoneal	B-TOXI
failure	I-TOXI
(	O
GOG	O
9920	O
)	O
:	O
an	O
NRG	O
Oncology	O
/	O
Gynecologic	O
Oncology	O
Group	O
study	O
.	O
	
	
To	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
a	O
modified	O
paclitaxel	B-DRUG
/	O
doxorubicin	B-DRUG
/	O
cisplatin	B-DRUG
(	O
TAP	O
)	O
regimen	O
which	O
incorporated	O
intraperitoneal	O
(	O
IP	O
)	O
paclitaxel	B-DRUG
or	O
IP	O
paclitaxel	B-DRUG
/	O
cisplatin	B-DRUG
in	O
advanced	B-CANCER
endometrial	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
(	O
pts	O
)	O
with	O
FIGO	O
(	O
1998	O
)	O
Stage	O
IIIA	O
/	O
IIIC	O
with	O
positive	O
cytologic	O
washings	O
/	O
ascites	O
","	O
adnexa	O
","	O
or	O
serosa	O
or	O
Stage	O
IV	O
(	O
intraperitoneal	O
disease	O
spread	O
)	O
","	O
histologically	O
confirmed	O
endometrial	B-CANCER
cancer	I-CANCER
were	O
eligible	O
.	O
	
The	O
study	O
was	O
designed	O
as	O
a	O
phase	O
I	O
","	O
3+3	O
dose	O
escalation	O
study	O
evaluating	O
5	O
dose	O
levels	O
(	O
DL	O
)	O
.	O
	
All	O
pts	O
received	O
cycles	O
1月2日	O
with	O
IV	O
TAP	O
","	O
and	O
cycles	O
3月6日	O
with	O
IV	O
/	O
IP	O
therapy	O
","	O
on	O
a	O
21day	O
schedule	O
.	O
	
Adverse	O
events	O
were	O
evaluated	O
on	O
cycles	O
3月4日	O
for	O
dose	O
limiting	O
toxicity	O
(	O
DLT	O
)	O
and	O
dose	O
escalation	O
decisions	O
.	O
	
Twenty-one	O
pts	O
were	O
enrolled	O
","	O
of	O
which	O
17	O
were	O
evaluable	O
for	O
DLT	O
.	O
	
Most	O
pts	O
had	O
Stage	O
IV	O
disease	O
(	O
76	O
%	O
)	O
and	O
serous	O
/	O
clear	O
cell	O
histology	O
(	O
59	O
%	O
)	O
.	O
	
The	O
MTD	O
was	O
determined	O
to	O
be	O
DL	O
3	O
(	O
cycles	O
3月6日	O
including	O
paclitaxel	B-DRUG
90mg	O
/	O
m	O
(	O
2	O
)	O
IP	O
","	O
doxorubicin	B-DRUG
45mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
","	O
cisplatin	B-DRUG
50mg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O
	
Three	O
DLT	O
events	O
occurred	O
and	O
were	O
related	O
to	O
grades	O
3月4日	O
metabolic	B-TOXI
toxicities	I-TOXI
.	O
	
There	O
was	O
one	O
grade	O
2	O
sensory	B-TOXI
neuropathy	I-TOXI
event	I-TOXI
and	O
myelosupression	B-TOXI
was	O
tolerable	O
without	O
the	O
use	O
of	O
G-CSF	O
.	O
	
88	O
%	O
of	O
evaluable	O
pts	O
completed	O
6cycles	O
of	O
therapy	O
.	O
	
With	O
a	O
median	O
follow-up	O
of	O
22months	O
","	O
46	O
%	O
of	O
patients	O
remain	O
progression-free	O
at	O
2years	O
.	O
	
We	O
described	O
an	O
IV	O
/	O
IP	O
based	O
modification	O
of	O
a	O
standard	O
TAP	O
regimen	O
in	O
endometrial	B-CANCER
cancer	I-CANCER
.	O
	
Based	O
on	O
the	O
high	O
rate	O
of	O
completing	O
6cycles	O
of	O
therapy	O
","	O
low	O
rates	O
of	O
neuropathy	O
","	O
and	O
promising	O
PFS	O
","	O
further	O
study	O
of	O
IP	O
therapy	O
in	O
endometrial	B-CANCER
cancer	I-CANCER
is	O
warranted	O
.	O
	
Phase	O
I	O
study	O
of	O
FOLFIRI	B-DRUG
plus	O
pimasertib	B-DRUG
as	O
second-line	O
treatment	O
for	O
KRAS-mutated	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
mitogen-activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
pathway	O
has	O
been	O
implicated	O
in	O
the	O
molecular	O
pathogenesis	O
of	O
human	O
cancers	O
","	O
including	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
mCRC	B-CANCER
)	O
.	O
	
This	O
provides	O
a	O
rationale	O
for	O
the	O
development	O
of	O
MAPK-targeted	O
agents	O
such	O
as	O
pimasertib	B-DRUG
.	O
	
Patients	O
with	O
KRAS	O
mutant	O
mCRC	B-CANCER
were	O
treated	O
in	O
the	O
second-line	O
setting	O
with	O
FOLFIRI	B-DRUG
(	O
5-fluorouracil	B-DRUG
/	O
folinic	B-DRUG
acid	I-DRUG
/	O
irinotecan	B-DRUG
)	O
plus	O
pimasertib	B-DRUG
.	O
	
The	O
primary	O
objective	O
of	O
the	O
safety	O
run-in	O
phase	O
was	O
to	O
determine	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
the	O
recommended	O
phase	O
II	O
dose	O
of	O
pimasertib	B-DRUG
combined	O
with	O
FOLFIRI	B-DRUG
.	O
	
Sixteen	O
patients	O
were	O
enrolled	O
in	O
the	O
trial	O
.	O
	
Ten	O
and	O
six	O
patients	O
were	O
treated	O
daily	O
with	O
45	O
and	O
60	O
mg	O
of	O
pimasertib	B-DRUG
plus	O
FOLFIRI	B-DRUG
","	O
respectively	O
.	O
	
The	O
MTD	O
was	O
considered	O
to	O
be	O
45	O
mg	O
per	O
day	O
.	O
	
The	O
most	O
common	O
treatment-emergent	O
adverse	O
events	O
were	O
diarrhoea	B-TOXI
","	O
nausea	B-TOXI
","	O
vomiting	B-TOXI
","	O
asthenia	B-TOXI
and	O
skin	B-TOXI
/	I-TOXI
rash	I-TOXI
event	I-TOXI
.	O
	
Of	O
the	O
15	O
patients	O
in	O
the	O
efficacy	O
analysis	O
group	O
","	O
two	O
patients	O
had	O
partial	O
response	O
","	O
nine	O
patients	O
had	O
stable	O
disease	O
","	O
three	O
patients	O
had	O
progressive	O
disease	O
as	O
their	O
best	O
overall	O
response	O
and	O
one	O
patient	O
could	O
not	O
be	O
evaluated	O
.	O
	
Dose	O
escalation	O
of	O
pimasertib	B-DRUG
in	O
combination	O
with	O
FOLFIRI	B-DRUG
was	O
limited	O
by	O
toxicity	O
.	O
	
At	O
the	O
MTD	O
of	O
45	O
mg	O
per	O
day	O
","	O
pimasertib	B-DRUG
was	O
adequately	O
tolerated	O
in	O
patients	O
with	O
mCRC	B-CANCER
and	O
no	O
unexpected	O
or	O
new	O
safety	O
signals	O
or	O
concerns	O
were	O
identified	O
.	O
	
Phase	O
II	O
study	O
of	O
docetaxel	B-DRUG
","	O
oxaliplatin	B-DRUG
","	O
and	O
S-1	B-DRUG
therapy	O
in	O
patients	O
with	O
metastatic	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
	
Although	O
the	O
docetaxel	B-DRUG
","	O
5-fluorouracil	B-DRUG
","	O
and	O
cisplatin	B-DRUG
triplet	I-DRUG
has	O
yielded	O
significant	O
improvements	O
in	O
time	O
to	O
progression	O
","	O
overall	O
survival	O
","	O
and	O
overall	O
response	O
rate	O
","	O
the	O
high	O
incidence	O
of	O
severe	O
adverse	O
events	O
limits	O
the	O
use	O
of	O
the	O
docetaxel	B-DRUG
","	O
5-fluorouracil	B-DRUG
","	O
and	O
cisplatin	B-DRUG
triplet	I-DRUG
.	O
	
To	O
overcome	O
this	O
limitation	O
","	O
we	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
the	O
combination	O
of	O
docetaxel	B-DRUG
","	O
oxaliplatin	B-DRUG
","	O
and	O
S-1	B-DRUG
for	O
the	O
treatment	O
of	O
metastatic	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Chemotherapy-naive	O
patients	O
with	O
pathologically	O
proven	O
unresectable	O
recurrent	O
or	O
metastatic	B-CANCER
gastric	I-CANCER
adenocarcinoma	I-CANCER
were	O
assessed	O
for	O
eligibility	O
.	O
	
Docetaxel	B-DRUG
at	O
52.5	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
oxaliplatin	B-DRUG
at	O
105	O
mg	O
/	O
m	O
(	O
2	O
)	O
were	O
administered	O
intravenously	O
on	O
day	O
1	O
","	O
and	O
S-1	O
was	O
administered	O
orally	O
at	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1月14日	O
of	O
every	O
21-day	O
cycle	O
.	O
	
Forty-four	O
patients	O
(	O
median	O
age	O
54.5	O
years	O
)	O
were	O
enrolled	O
.	O
	
All	O
patients	O
had	O
metastatic	O
disease	O
.	O
	
A	O
total	O
of	O
340	O
cycles	O
of	O
chemotherapy	O
were	O
administered	O
(	O
median	O
of	O
eight	O
cycles	O
per	O
patient	O
;	O
range	O
1-36	O
cycles	O
)	O
.	O
	
Toxicities	O
were	O
evaluated	O
in	O
43	O
patients	O
","	O
and	O
the	O
responses	O
were	O
evaluated	O
in	O
40	O
patients	O
.	O
	
Major	O
toxicities	O
included	O
grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
(	O
37.2	O
%	O
)	O
and	O
leukopenia	B-TOXI
(	O
27.9	O
%	O
)	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
54.5	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
40.1-68.3	O
%	O
]	O
in	O
the	O
intention-to-treat	O
population	O
.	O
	
The	O
median	O
progression-free	O
survival	O
and	O
overall	O
survival	O
were	O
7.6	O
months	O
(	O
95	O
%	O
CI	O
6.2-9.0	O
months	O
)	O
and	O
12	O
months	O
(	O
95	O
%	O
CI	O
6.9-17.2	O
months	O
)	O
","	O
respectively	O
.	O
	
These	O
data	O
suggest	O
that	O
the	O
docetaxel	B-DRUG
","	O
oxaliplatin	B-DRUG
","	O
and	O
S-1	B-DRUG
combination	O
regimen	O
is	O
effective	O
and	O
relatively	O
well	O
tolerable	O
","	O
and	O
it	O
seems	O
to	O
have	O
potential	O
to	O
be	O
a	O
reasonable	O
therapeutic	O
strategy	O
in	O
patients	O
with	O
metastatic	O
or	O
recurrent	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
A	O
randomized	O
Phase	O
II	O
clinical	O
study	O
of	O
combining	O
panitumumab	B-DRUG
and	O
bevacizumab	B-DRUG
","	O
plus	O
irinotecan	B-DRUG
","	O
5-fluorouracil	B-DRUG
","	O
and	O
leucovorin	B-DRUG
(	O
FOLFIRI	B-DRUG
)	O
compared	O
with	O
FOLFIRI	B-DRUG
alone	O
as	O
second-line	O
treatment	O
for	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
and	O
KRAS	O
mutation	O
.	O
	
	
This	O
study	O
investigated	O
the	O
efficacy	O
and	O
safety	O
of	O
a	O
new	O
treatment	O
strategy	O
of	O
combining	O
panitumumab	B-DRUG
and	O
bevacizumab	B-DRUG
","	O
plus	O
irinotecan	B-DRUG
","	O
5-fluorouracil	B-DRUG
","	O
and	O
leucovorin	B-DRUG
(	O
FOLFIRI	B-DRUG
)	O
versus	O
FOLFIRI	B-DRUG
alone	O
as	O
second-line	O
chemotherapy	O
for	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
(	O
mCRC	B-CANCER
)	O
patients	O
with	O
known	O
V-Ki-ras2	O
Kirsten	O
rat	O
sarcoma	O
viral	O
oncogene	O
(	O
KRAS	O
)	O
mutation	O
status	O
.	O
	
Patients	O
with	O
mCRC	B-CANCER
who	O
had	O
known	O
KRAS	O
tumor	O
status	O
and	O
unsuccessful	O
previous	O
oxaliplatin-based	B-DRUG
chemotherapy	O
were	O
included	O
in	O
the	O
study	O
.	O
	
They	O
were	O
randomly	O
assigned	O
to	O
two	O
groups	O
to	O
receive	O
panitumumab	B-DRUG
and	O
bevacizumab	B-DRUG
plus	O
FOLFIRI	B-DRUG
","	O
or	O
FOLFIRI	B-DRUG
alone	O
.	O
	
In	O
panitumumab	B-DRUG
and	O
bevacizumab	B-DRUG
plus	O
FOLFIRI	B-DRUG
group	O
","	O
patients	O
were	O
given	O
4	O
mg	O
/	O
kg	O
panitumumab	B-DRUG
and	O
bevacizumab	B-DRUG
plus	O
FOLFIRI	B-DRUG
every	O
2	O
weeks	O
.	O
	
In	O
all	O
","	O
65	O
patients	O
were	O
assigned	O
to	O
panitumumab	B-DRUG
and	O
bevacizumab	B-DRUG
plus	O
FOLFIRI	B-DRUG
group	O
","	O
and	O
77	O
to	O
FOLFIRI	B-DRUG
alone	O
group	O
.	O
	
For	O
WT	O
KRAS	O
patients	O
","	O
the	O
median	O
progression-free	O
survival	O
(	O
PFS	O
)	O
was	O
5.7	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
2.4-7.5	O
months	O
)	O
for	O
panitumumab	B-DRUG
and	O
bevacizumab	B-DRUG
plus	O
FOLFIRI	B-DRUG
and	O
3.8	O
months	O
(	O
95	O
%	O
CI	O
","	O
3.0-6.7	O
months	O
)	O
for	O
FOLFIRI	B-DRUG
alone	O
;	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
15.2	O
months	O
(	O
95	O
%	O
CI	O
","	O
8.9-19.7	O
months	O
)	O
for	O
panitumumab	B-DRUG
and	O
bevacizumab	B-DRUG
plus	O
FOLFIRI	B-DRUG
and	O
11	O
months	O
(	O
95	O
%	O
CI	O
","	O
8.2-15.4	O
months	O
)	O
for	O
FOLFIRI	B-DRUG
alone	O
.	O
	
For	O
MU	O
KRAS	O
patients	O
","	O
median	O
PFS	O
was	O
5.1	O
months	O
(	O
95	O
%	O
CI	O
","	O
2.7-10.2	O
months	O
)	O
for	O
panitumumab	B-DRUG
and	O
bevacizumab	B-DRUG
plus	O
FOLFIRI	B-DRUG
and	O
4.1	O
months	O
(	O
95	O
%	O
CI	O
","	O
2.5-8.4	O
months	O
)	O
for	O
FOLFIRI	B-DRUG
alone	O
;	O
median	O
OS	O
was	O
12.8	O
months	O
(	O
95	O
%	O
CI	O
","	O
7.8-15.8	O
months	O
)	O
for	O
panitumumab	B-DRUG
and	O
bevacizumab	B-DRUG
plus	O
FOLFIRI	B-DRUG
and	O
10.5	O
months	O
(	O
95	O
%	O
CI	O
","	O
6.1-15.3	O
months	O
)	O
for	O
FOLFIRI	B-DRUG
alone	O
.	O
	
Grade	O
3	O
and	O
4	O
adverse	O
events	O
were	O
associated	O
with	O
panitumumab	B-DRUG
and	O
bevacizumab	B-DRUG
plus	O
FOLFIRI	B-DRUG
but	O
tolerable	O
among	O
patients	O
.	O
	
Patients	O
with	O
mCRC	B-CANCER
can	O
be	O
safely	O
and	O
efficiently	O
treated	O
with	O
second-line	O
chemotherapy	O
of	O
combining	O
panitumumab	B-DRUG
and	O
bevacizumab	B-DRUG
plus	O
FOLFIRI	B-DRUG
","	O
despite	O
their	O
KRAS	O
mutation	O
status	O
.	O
	
Preliminary	O
Safety	O
","	O
Pharmacokinetics	O
","	O
and	O
Efficacy	O
of	O
Regorafenib	B-DRUG
","	O
Cisplatin	B-DRUG
","	O
and	O
Pemetrexed	B-DRUG
in	O
Patients	O
With	O
Advanced	B-CANCER
Nonsquamous	I-CANCER
Non-Small-Cell	I-CANCER
Lung	I-CANCER
Cancers	I-CANCER
.	O
	
	
Regorafenib	B-DRUG
is	O
an	O
oral	O
multitargeted	O
kinase	O
inhibitor	O
with	O
potent	O
antiangiogenic	O
activity	O
.	O
	
In	O
this	O
phase	O
I	O
trial	O
we	O
evaluated	O
the	O
safety	O
","	O
pharmacokinetics	O
","	O
and	O
efficacy	O
of	O
regorafenib	B-DRUG
with	O
cisplatin	B-DRUG
and	O
pemetrexed	B-DRUG
for	O
patients	O
with	O
advanced	B-CANCER
nonsquamous	I-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancers	I-CANCER
(	O
nsNSCLCs	B-CANCER
)	O
.	O
	
Nine	O
patients	O
enrolled	O
before	O
premature	O
termination	O
of	O
the	O
study	O
.	O
	
Five	O
of	O
9	O
(	O
56	O
%	O
)	O
patients	O
had	O
a	O
partial	O
response	O
and	O
the	O
median	O
progression-free	O
survival	O
was	O
7	O
months	O
(	O
range	O
","	O
1.5-15.1	O
months	O
)	O
.	O
	
Regorafenib	B-DRUG
had	O
acceptable	O
tolerability	O
and	O
minor	O
pharmacokinetic	O
interactions	O
in	O
combination	O
with	O
standard	O
doses	O
of	O
cisplatin	B-DRUG
and	O
pemetrexed	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
nsNSCLCs	I-CANCER
.	O
	
The	O
combination	O
of	O
bevacizumab	B-DRUG
","	O
an	O
antiangiogenesis	O
agent	O
","	O
with	O
cytotoxic	O
chemotherapy	O
improves	O
survival	O
in	O
patients	O
with	O
advanced	B-CANCER
nonsquamous	I-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancers	I-CANCER
(	O
nsNSCLCs	B-CANCER
)	O
.	O
	
Regorafenib	B-DRUG
is	O
an	O
oral	O
multitargeted	O
kinase	O
inhibitor	O
with	O
potent	O
antiangiogenic	O
activity	O
that	O
is	O
approved	O
for	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
and	O
gastrointestinal	B-CANCER
stromal	I-CANCER
tumors	I-CANCER
.	O
	
In	O
this	O
phase	O
I	O
trial	O
we	O
evaluated	O
the	O
safety	O
","	O
pharmacokinetics	O
(	O
PK	O
)	O
","	O
and	O
efficacy	O
of	O
regorafenib	B-DRUG
with	O
cisplatin	B-DRUG
and	O
pemetrexed	B-DRUG
for	O
patients	O
with	O
advanced	B-CANCER
nsNSCLCs	I-CANCER
.	O
	
Chemotherapy-naive	O
patients	O
with	O
advanced	B-CANCER
nsNSCLCs	I-CANCER
were	O
treated	O
with	O
regorafenib	B-DRUG
60	O
mg	O
/	O
d	O
continuously	O
and	O
cisplatin	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
with	O
pemetrexed	B-DRUG
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
once	O
every	O
21	O
days	O
for	O
up	O
to	O
6	O
cycles	O
.	O
	
Thereafter	O
","	O
regorafenib	B-DRUG
with	O
or	O
without	O
pemetrexed	B-DRUG
could	O
be	O
continued	O
as	O
maintenance	O
.	O
	
Nine	O
patients	O
enrolled	O
before	O
premature	O
termination	O
of	O
the	O
study	O
because	O
of	O
slow	O
recruitment	O
and	O
a	O
change	O
in	O
the	O
development	O
strategy	O
of	O
regorafenib	B-DRUG
by	O
the	O
study	O
sponsor	O
.	O
	
Five	O
patients	O
experienced	O
at	O
least	O
1	O
treatment-related	O
Grade	O
3	O
adverse	O
event	O
.	O
	
No	O
Grade	O
4	O
or	O
5	O
toxicity	O
occurred	O
.	O
	
Five	O
of	O
9	O
(	O
56	O
%	O
)	O
patients	O
had	O
a	O
partial	O
response	O
and	O
the	O
median	O
progression-free	O
survival	O
was	O
7	O
months	O
(	O
range	O
","	O
1.5-15.1	O
months	O
)	O
.	O
	
Minor	O
PK	O
interactions	O
between	O
regorafenib	B-DRUG
and	O
chemotherapy	O
were	O
observed	O
.	O
	
Regorafenib	B-DRUG
had	O
acceptable	O
tolerability	O
and	O
minor	O
PK	O
interactions	O
in	O
combination	O
with	O
standard	O
doses	O
of	O
cisplatin	B-DRUG
and	O
pemetrexed	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
nsNSCLCs	I-CANCER
.	O
	
Encouraging	O
activity	O
was	O
appreciated	O
in	O
chemotherapy-naive	O
patients	O
with	O
advanced	B-CANCER
nsNSCLCs	I-CANCER
.	O
	
However	O
","	O
the	O
small	O
number	O
of	O
patients	O
treated	O
limits	O
conclusions	O
that	O
can	O
be	O
drawn	O
from	O
these	O
results	O
.	O
	
BEYOND	O
:	O
A	O
Randomized	O
","	O
Double-Blind	O
","	O
Placebo-Controlled	B-DRUG
","	O
Multicenter	O
","	O
Phase	O
III	O
Study	O
of	O
First-Line	O
Carboplatin	B-DRUG
/	O
Paclitaxel	B-DRUG
Plus	O
Bevacizumab	B-DRUG
or	O
Placebo	B-DRUG
in	O
Chinese	O
Patients	O
With	O
Advanced	O
or	O
Recurrent	B-CANCER
Nonsquamous	I-CANCER
Non-Small-Cell	I-CANCER
Lung	I-CANCER
Cancer	I-CANCER
.	O
	
	
The	O
phase	O
III	O
BEYOND	O
trial	O
was	O
undertaken	O
to	O
confirm	O
in	O
a	O
Chinese	O
patient	O
population	O
the	O
efficacy	O
seen	O
with	O
first-line	O
bevacizumab	B-DRUG
plus	O
platinum	B-DRUG
doublet	O
chemotherapy	O
in	O
globally	O
conducted	O
studies	O
.	O
	
Patients	O
age	O
_	O
18	O
years	O
with	O
locally	O
advanced	O
","	O
metastatic	O
","	O
or	O
recurrent	O
advanced	O
nonsquamous	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
","	O
6	O
)	O
intravenously	O
and	O
paclitaxel	B-DRUG
(	O
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
intravenously	O
(	O
CP	O
)	O
on	O
day	O
1	O
of	O
each	O
3-week	O
cycle	O
","	O
for	O
_	O
six	O
cycles	O
","	O
plus	O
placebo	B-DRUG
(	O
Pl+CP	O
)	O
or	O
bevacizumab	B-DRUG
(	O
B+CP	O
)	O
15	O
mg	O
/	O
kg	O
intravenously	O
","	O
on	O
day	O
1	O
of	O
each	O
cycle	O
","	O
until	O
progression	O
","	O
unacceptable	O
toxicity	O
","	O
or	O
death	B-TOXI
.	O
	
The	O
primary	O
end	O
point	O
was	O
progression-free	O
survival	O
(	O
PFS	O
)	O
;	O
secondary	O
end	O
points	O
were	O
objective	O
response	O
rate	O
","	O
overall	O
survival	O
","	O
exploratory	O
biomarkers	O
","	O
safety	O
.	O
	
A	O
total	O
of	O
276	O
patients	O
were	O
randomly	O
assigned	O
","	O
138	O
to	O
each	O
arm	O
.	O
	
PFS	O
was	O
prolonged	O
with	O
B+CP	O
versus	O
Pl+CP	O
(	O
median	O
","	O
9.2	O
v	O
6.5	O
months	O
","	O
respectively	O
;	O
hazard	O
ratio	O
[	O
HR	O
]	O
","	O
0.4	O
;	O
95	O
%	O
CI	O
","	O
0.29	O
to	O
0.54	O
;	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
.	O
	
Objective	O
response	O
rate	O
was	O
improved	O
with	O
B+CP	O
compared	O
with	O
Pl+CP	O
(	O
54	O
%	O
v	O
26	O
%	O
","	O
respectively	O
)	O
.	O
	
Overall	O
survival	O
was	O
also	O
prolonged	O
with	O
B+CP	O
compared	O
with	O
Pl+CP	O
(	O
median	O
","	O
24.3	O
v	O
17.7	O
months	O
","	O
respectively	O
;	O
HR	O
","	O
0.68	O
;	O
95	O
%	O
CI	O
","	O
0.5	O
to	O
0.93	O
;	O
P	O
=	O
0.0154	O
)	O
.	O
	
Median	O
PFS	O
was	O
12.4	O
months	O
with	O
B+CP	O
and	O
7.9	O
months	O
with	O
Pl+CP	O
(	O
HR	O
","	O
0.27	O
;	O
95	O
%	O
CI	O
","	O
0.12	O
to	O
0.63	O
)	O
in	O
EGFR	O
mutation-positive	O
tumors	O
and	O
8.3	O
and	O
5.6	O
months	O
","	O
respectively	O
(	O
HR	O
","	O
0.33	O
;	O
95	O
%	O
CI	O
","	O
0.21	O
to	O
0.53	O
)	O
","	O
in	O
wild-type	O
tumors	O
.	O
	
Safety	O
was	O
similar	O
to	O
previous	O
studies	O
of	O
B+CP	O
in	O
NSCLC	B-CANCER
;	O
no	O
new	O
safety	O
signals	O
were	O
observed	O
.	O
	
The	O
addition	O
to	O
bevacizumab	B-DRUG
to	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
was	O
well	O
tolerated	O
and	O
resulted	O
in	O
a	O
clinically	O
meaningful	O
treatment	O
benefit	O
in	O
Chinese	O
patients	O
with	O
advanced	B-CANCER
nonsquamous	I-CANCER
NSCLC	I-CANCER
.	O
	
Phase	O
I	O
dose-escalation	O
study	O
of	O
the	O
PI3K	O
/	O
mTOR	O
inhibitor	O
voxtalisib	B-DRUG
(	O
SAR245409	O
","	O
XL765	O
)	O
plus	O
temozolomide	B-DRUG
with	O
or	O
without	O
radiotherapy	O
in	O
patients	O
with	O
high-grade	O
glioma	B-CANCER
.	O
	
	
This	O
phase	O
I	O
study	O
aimed	O
to	O
evaluate	O
safety	O
","	O
maximum	O
tolerated	O
dose	O
","	O
pharmacokinetics	O
","	O
pharmacodynamics	O
","	O
and	O
preliminary	O
efficacy	O
of	O
voxtalisib	B-DRUG
(	O
SAR245409	O
","	O
XL765	O
)	O
","	O
a	O
pan-class	O
I	O
phosphoinositide	B-DRUG
3-kinase	O
(	O
PI3K	O
)	O
and	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
inhibitor	O
","	O
in	O
combination	O
with	O
temozolomide	B-DRUG
(	O
TMZ	O
)	O
","	O
with	O
or	O
without	O
radiation	O
therapy	O
(	O
RT	O
)	O
","	O
in	O
patients	O
with	O
high-grade	O
glioma	B-CANCER
.	O
	
Patients	O
received	O
voxtalisib	B-DRUG
30-90	O
mg	O
once	O
daily	O
(	O
q.d.	O
)	O
or	O
20-50	O
mg	O
twice	O
daily	O
(	O
b.i.d.	O
)	O
","	O
in	O
combination	O
with	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
TMZ	O
(	O
n	O
=	O
49	O
)	O
","	O
or	O
voxtalisib	B-DRUG
20	O
mg	O
q.d.	O
with	O
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
TMZ	O
and	O
RT	O
(	O
n	O
=	O
5	O
)	O
.	O
	
A	O
standard	O
3	O
=+	O
3	O
dose-escalation	O
design	O
was	O
used	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
.	O
	
Patients	O
were	O
evaluated	O
for	O
adverse	O
events	O
(	O
AEs	O
)	O
","	O
plasma	O
pharmacokinetics	O
","	O
pharmacodynamic	O
effects	O
in	O
skin	O
biopsies	O
","	O
and	O
tumor	O
response	O
.	O
	
The	O
maximum	O
tolerated	O
doses	O
were	O
90	O
mg	O
q.d.	O
and	O
40	O
mg	O
b.i.d.	O
for	O
voxtalisib	B-DRUG
in	O
combination	O
with	O
TMZ	O
.	O
	
The	O
most	O
frequently	O
reported	O
treatment-related	O
AEs	O
were	O
nausea	B-TOXI
(	O
48	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
43	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
26	O
%	O
)	O
","	O
and	O
diarrhea	B-TOXI
(	O
24	O
%	O
)	O
.	O
	
The	O
most	O
frequently	O
reported	O
treatment-related	O
grade	O
_3	O
AEs	O
were	O
lymphopenia	B-TOXI
(	O
13	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
","	O
and	O
decreased	B-TOXI
platelet	I-TOXI
count	I-TOXI
(	O
9	O
%	O
each	O
)	O
.	O
	
Pharmacokinetic	O
parameters	O
were	O
similar	O
to	O
previous	O
studies	O
with	O
voxtalisib	B-DRUG
monotherapy	O
.	O
	
Moderate	O
inhibition	O
of	O
PI3K	O
signaling	O
was	O
observed	O
in	O
skin	O
biopsies	O
.	O
	
Best	O
response	O
was	O
partial	O
response	O
in	O
4	O
%	O
of	O
evaluable	O
patients	O
","	O
with	O
stable	O
disease	O
observed	O
in	O
68	O
%	O
.	O
	
Voxtalisib	B-DRUG
in	O
combination	O
with	O
TMZ	O
with	O
or	O
without	O
RT	O
in	O
patients	O
with	O
high-grade	O
gliomas	B-CANCER
demonstrated	O
a	O
favorable	O
safety	O
profile	O
and	O
a	O
moderate	O
level	O
of	O
PI3K	O
/	O
mTOR	O
pathway	O
inhibition	O
.	O
	
Phase	O
I	O
dose-escalation	O
study	O
of	O
cabazitaxel	B-DRUG
administered	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
metastatic	O
or	O
unresectable	O
advanced	B-CANCER
solid	I-CANCER
malignancies	I-CANCER
.	O
	
	
Taxane-gemcitabine	B-DRUG
combinations	O
have	O
demonstrated	O
antitumor	O
activity	O
.	O
	
This	O
phase	O
I	O
study	O
(	O
NCT01001221	O
)	O
aimed	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
of	O
cabazitaxel	B-DRUG
plus	O
gemcitabine	B-DRUG
and	O
to	O
assess	O
the	O
preliminary	O
efficacy	O
of	O
this	O
combination	O
.	O
	
The	O
patients	O
included	O
had	O
metastatic	O
or	O
unresectable	O
solid	B-CANCER
tumors	I-CANCER
and	O
had	O
exhausted	O
standard	O
treatment	O
.	O
	
Cohorts	O
of	O
three	O
to	O
six	O
patients	O
received	O
cabazitaxel	B-DRUG
(	O
15-20	O
mg	O
/	O
m	O
)	O
before	O
(	O
part	O
1a	O
)	O
or	O
after	O
(	O
part	O
1b	O
)	O
gemcitabine	B-DRUG
(	O
700-1000	O
mg	O
/	O
m	O
)	O
on	O
Day	O
1	O
and	O
gemcitabine	B-DRUG
alone	O
on	O
Day	O
8	O
Prophylactic	O
growth	O
factors	O
were	O
not	O
allowed	O
in	O
cycle	O
1	O
In	O
part	O
1a	O
(	O
n=12	O
)	O
","	O
five	O
patients	O
received	O
20	O
mg	O
/	O
m	O
cabazitaxel	B-DRUG
plus	O
1000	O
mg	O
/	O
m	O
gemcitabine	B-DRUG
(	O
20	O
/	O
1000	O
)	O
","	O
five	O
received	O
15	O
/	O
900	O
","	O
two	O
received	O
15	O
/	O
700	O
.	O
	
In	O
part	O
1b	O
","	O
all	O
six	O
patients	O
received	O
the	O
lowest	O
dose	O
(	O
700	O
/	O
15	O
)	O
.	O
	
At	O
all	O
doses	O
","	O
two	O
or	O
more	O
patients	O
experienced	O
a	O
DLT	O
","	O
regardless	O
of	O
administration	O
sequence	O
","	O
including	O
febrile	B-TOXI
neutropenia	I-TOXI
(	O
n=4	O
)	O
","	O
grade	O
4	O
neutropenia	B-TOXI
(	O
n=2	O
)	O
","	O
grade	O
4	O
thrombocytopenia	B-TOXI
(	O
n=2	O
)	O
","	O
and	O
grade	O
3	O
aspartate	B-TOXI
transaminase	I-TOXI
increase	I-TOXI
(	O
n=1	O
)	O
.	O
	
The	O
MTD	O
was	O
not	O
established	O
as	O
all	O
cohorts	O
exceeded	O
the	O
MTD	O
by	O
definition	O
.	O
	
All	O
patients	O
experienced	O
an	O
adverse	O
event	O
;	O
the	O
most	O
frequent	O
all-grade	O
nonhematologic	B-CANCER
events	I-CANCER
were	O
fatigue	B-CANCER
(	O
66.7	O
%	O
)	O
","	O
decreased	B-CANCER
appetite	I-CANCER
(	O
50	O
%	O
)	O
","	O
and	O
diarrhea	B-CANCER
(	O
44.4	O
%	O
)	O
.	O
	
The	O
most	O
frequent	O
grade	O
3月4日	O
hematologic	B-TOXI
abnormalities	I-TOXI
were	O
neutropenia	B-TOXI
(	O
83.3	O
%	O
)	O
","	O
leukopenia	B-TOXI
(	O
77.8	O
%	O
)	O
","	O
and	O
lymphopenia	B-TOXI
(	O
72.2	O
%	O
)	O
.	O
	
Toxicity	O
was	O
sequence-independent	O
but	O
appeared	O
worse	O
with	O
gemcitabine	B-DRUG
followed	O
by	O
cabazitaxel	B-DRUG
.	O
	
Durable	O
partial	O
responses	O
were	O
observed	O
in	O
three	O
patients	O
(	O
prostate	B-CANCER
cancer	I-CANCER
","	O
appendiceal	B-CANCER
cancer	I-CANCER
","	O
and	O
melanoma	B-CANCER
)	O
.	O
	
The	O
unacceptable	O
DLTs	O
with	O
cabazitaxel	B-DRUG
plus	O
gemcitabine	B-DRUG
","	O
at	O
doses	O
reduced	O
more	O
than	O
25	O
%	O
from	O
single-agent	O
doses	O
","	O
preclude	O
further	O
investigation	O
.	O
	
Phase	O
I	O
trial	O
of	O
5-FU	B-DRUG
","	O
docetaxel	B-DRUG
","	O
and	O
nedaplatin	B-DRUG
(	O
UDON	O
)	O
combination	O
therapy	O
for	O
recurrent	O
or	O
metastatic	B-CANCER
esophageal	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
aims	O
of	O
this	O
dose-escalating	O
phase	O
I	O
study	O
were	O
to	O
determine	O
the	O
maximum	O
tolerable	O
dose	O
(	O
MTD	O
)	O
and	O
recommended	O
dose	O
(	O
RD	O
)	O
of	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
docetaxel	B-DRUG
","	O
and	O
nedaplatin	B-DRUG
(	O
UDON	O
)	O
combination	O
therapy	O
for	O
future	O
phase	O
II	O
studies	O
","	O
and	O
to	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
this	O
regimen	O
in	O
patients	O
with	O
untreated	O
recurrent	O
or	O
metastatic	B-CANCER
esophageal	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
were	O
administered	O
5-FU	B-DRUG
on	O
days	O
1月5日	O
","	O
docetaxel	B-DRUG
on	O
days	O
1	O
and	O
15	O
","	O
and	O
nedaplatin	B-DRUG
on	O
day	O
1	O
at	O
4-week	O
intervals	O
.	O
	
The	O
dose	O
levels	O
of	O
5-FU	B-DRUG
/	O
docetaxel	B-DRUG
/	O
nedaplatin	B-DRUG
were	O
escalated	O
as	O
follows	O
(	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
:	O
level	O
1	O
","	O
800	O
/	O
30	O
/	O
80	O
;	O
level	O
2	O
","	O
800	O
/	O
30	O
/	O
90	O
;	O
and	O
level	O
3	O
","	O
800	O
/	O
35	O
/	O
90	O
.	O
	
Toxicity	O
was	O
evaluated	O
using	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
version	O
4.0.	O
Overall	O
","	O
nine	O
patients	O
were	O
enrolled	O
in	O
this	O
study	O
.	O
	
All	O
patients	O
had	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
or	O
1	O
and	O
were	O
diagnosed	O
with	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
No	O
dose-limiting	O
toxicity	O
was	O
observed	O
at	O
any	O
level	O
","	O
and	O
planned	O
dose	O
escalation	O
was	O
completed	O
without	O
reaching	O
the	O
MTD	O
.	O
	
No	O
grade	O
4	O
or	O
higher	O
toxicity	O
was	O
observed	O
in	O
this	O
study	O
.	O
	
The	O
observed	O
grade	O
3	O
hematological	B-TOXI
toxicities	I-TOXI
included	O
neutropenia	B-TOXI
in	O
five	O
patients	O
(	O
55.6	O
%	O
)	O
and	O
leukopenia	B-TOXI
in	O
three	O
patients	O
(	O
33.3	O
%	O
)	O
.	O
	
None	O
of	O
the	O
patients	O
developed	O
febrile	B-TOXI
neutropenia	I-TOXI
","	O
and	O
no	O
grade	O
3	O
or	O
4	O
non-hematological	B-TOXI
toxicities	I-TOXI
were	O
observed	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
77.8	O
%	O
","	O
including	O
two	O
complete	O
responses	O
","	O
and	O
the	O
disease	O
control	O
rate	O
was	O
100	O
%	O
.	O
	
The	O
RD	O
of	O
UDON	O
was	O
identified	O
as	O
level	O
3	O
The	O
good	O
tolerability	O
and	O
high	O
antitumor	O
efficacy	O
of	O
this	O
regimen	O
warrant	O
further	O
evaluation	O
in	O
this	O
setting	O
.	O
	
Phase	O
I	O
study	O
of	O
the	O
mTOR	O
inhibitor	O
ridaforolimus	B-DRUG
and	O
the	O
HDAC	O
inhibitor	O
vorinostat	B-DRUG
in	O
advanced	B-CANCER
renal	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
and	O
other	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
Drugs	O
inhibiting	O
the	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
are	O
approved	O
in	O
the	O
treatment	O
of	O
renal	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
RCC	B-CANCER
)	O
","	O
but	O
resistance	O
inevitably	O
emerges	O
.	O
	
Proposed	O
escape	O
pathways	O
include	O
increased	O
phosphorylation	O
of	O
Akt	O
","	O
which	O
can	O
be	O
down	O
regulated	O
by	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
inhibitors	O
.	O
	
We	O
hypothesized	O
that	O
co-treatment	O
with	O
the	O
mTOR	O
inhibitor	O
ridaforolimus	B-DRUG
and	O
the	O
HDAC	O
inhibitor	O
vorinostat	B-DRUG
may	O
abrogate	O
resistance	O
in	O
RCC	B-CANCER
.	O
	
This	O
phase	O
1	O
study	O
evaluated	O
the	O
co-administration	O
of	O
ridaforolimus	B-DRUG
and	O
vorinostat	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
The	O
primary	O
objective	O
was	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
in	O
RCC	B-CANCER
patients	O
.	O
	
Although	O
all	O
solid	B-CANCER
tumors	I-CANCER
were	O
allowed	O
","	O
prior	O
cytotoxic	O
chemotherapy	O
was	O
limited	O
to	O
1	O
regimen	O
.	O
	
Using	O
a	O
modified	O
3	O
=+	O
3	O
dose	O
escalation	O
design	O
","	O
various	O
dose	O
combinations	O
were	O
tested	O
concurrently	O
in	O
separate	O
cohorts	O
.	O
	
Efficacy	O
was	O
a	O
secondary	O
endpoint	O
.	O
	
Fifteen	O
patients	O
were	O
treated	O
at	O
one	O
of	O
three	O
dose	O
levels	O
","	O
thirteen	O
with	O
RCC	B-CANCER
(	O
10	O
clear	O
cell	O
","	O
3	O
papillary	O
)	O
.	O
	
Dosing	O
was	O
limited	O
by	O
thrombocytopenia	B-TOXI
.	O
	
The	O
MTD	O
was	O
determined	O
to	O
be	O
ridaforolimus	B-DRUG
20	O
mg	O
daily	O
days	O
1月5日	O
with	O
vorinostat	B-DRUG
100	O
mg	O
BID	O
days	O
1月3日	O
weekly	O
","	O
however	O
late	O
onset	O
thrombocytopenia	B-TOXI
led	O
to	O
a	O
lower	O
recommended	O
phase	O
II	O
dose	O
:	O
ridaforolimus	B-DRUG
20	O
mg	O
daily	O
days	O
1月5日	O
with	O
vorinostat	B-DRUG
100	O
mg	O
daily	O
days	O
1月3日	O
weekly	O
.	O
	
Two	O
patients	O
","	O
both	O
with	O
papillary	O
RCC	B-CANCER
","	O
maintained	O
disease	O
control	O
for	O
54	O
and	O
80	O
weeks	O
","	O
respectively	O
.	O
	
The	O
combination	O
of	O
ridaforolimus	B-DRUG
and	O
vorinostat	B-DRUG
was	O
tolerable	O
at	O
the	O
recommended	O
phase	O
II	O
dose	O
.	O
	
Two	O
patients	O
with	O
papillary	O
RCC	B-CANCER
experienced	O
prolonged	O
disease	O
stabilization	O
","	O
thus	O
further	O
study	O
of	O
combined	O
HDAC	O
and	O
mTOR	O
inhibition	O
in	O
this	O
population	O
is	O
warranted	O
.	O
	
Combination	O
of	O
everolimus	B-DRUG
with	O
trastuzumab	B-DRUG
plus	O
paclitaxel	B-DRUG
as	O
first-line	O
treatment	O
for	O
patients	O
with	O
HER2-positive	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
BOLERO-1	O
)	O
:	O
a	O
phase	O
3	O
","	O
randomised	O
","	O
double-blind	O
","	O
multicentre	O
trial	O
.	O
	
	
mTOR	O
inhibition	O
reverses	O
trastuzumab	B-DRUG
resistance	O
via	O
the	O
hyperactivated	O
PIK	O
/	O
AKT	O
/	O
mTOR	O
pathway	O
due	O
to	O
PTEN	O
loss	O
","	O
by	O
sensitising	O
PTEN-deficient	O
tumours	O
to	O
trastuzumab	B-DRUG
.	O
	
The	O
BOLERO-1	O
study	O
assessed	O
the	O
efficacy	O
and	O
safety	O
of	O
adding	O
everolimus	B-DRUG
to	O
trastuzumab	B-DRUG
and	O
paclitaxel	B-DRUG
as	O
first-line	O
treatment	O
for	O
patients	O
with	O
HER2-positive	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
In	O
this	O
phase	O
3	O
","	O
randomised	O
","	O
double-blind	O
trial	O
","	O
patients	O
were	O
enrolled	O
across	O
141	O
sites	O
in	O
28	O
countries	O
.	O
	
Eligible	O
patients	O
were	O
aged	O
18	O
years	O
or	O
older	O
","	O
with	O
locally	O
assessed	O
HER2-positive	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
","	O
with	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
(	O
ECOG	O
)	O
performance	O
status	O
of	O
0-1	O
","	O
who	O
had	O
not	O
received	O
previous	O
trastuzumab	B-DRUG
or	O
chemotherapy	O
for	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
within	O
12	O
months	O
of	O
randomisation	O
","	O
had	O
measurable	O
disease	O
as	O
per	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	B-CANCER
Tumors	I-CANCER
(	O
RECIST	O
)	O
or	O
bone	O
lesions	O
in	O
the	O
absence	O
of	O
measurable	O
disease	O
","	O
without	O
previous	O
systemic	O
treatment	O
for	O
advanced	O
disease	O
except	O
endocrine	O
therapy	O
.	O
	
Patients	O
were	O
randomly	O
assigned	O
(	O
02:01	O
)	O
with	O
an	O
interactive	O
voice	O
and	O
web	O
response	O
system	O
to	O
receive	O
either	O
10	O
mg	O
everolimus	B-DRUG
once	O
a	O
day	O
orally	O
or	O
placebo	B-DRUG
plus	O
weekly	O
trastuzumab	B-DRUG
intravenously	O
at	O
4	O
mg	O
/	O
kg	O
loading	O
dose	O
on	O
day	O
1	O
with	O
subsequent	O
weekly	O
doses	O
of	O
2	O
mg	O
/	O
kg	O
of	O
each	O
4	O
week	O
cycle	O
plus	O
paclitaxel	B-DRUG
intravenously	O
at	O
a	O
dose	O
of	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
of	O
each	O
4	O
week	O
cycle	O
.	O
	
Randomisation	O
was	O
stratified	O
according	O
to	O
previous	O
use	O
of	O
trastuzumab	B-DRUG
and	O
visceral	O
metastasis	O
.	O
	
Patients	O
and	O
investigators	O
were	O
masked	O
to	O
the	O
assigned	O
treatments	O
.	O
	
Identity	O
of	O
experimental	O
treatments	O
was	O
concealed	O
by	O
use	O
of	O
everolimus	B-DRUG
and	O
placebo	B-DRUG
that	O
were	O
identical	O
in	O
packaging	O
","	O
labelling	O
","	O
appearance	O
","	O
and	O
administration	O
schedule	O
.	O
	
The	O
two	O
primary	O
objectives	O
were	O
investigator-assessed	O
progression-free	O
survival	O
in	O
the	O
full	O
study	O
population	O
and	O
in	O
the	O
subset	O
of	O
patients	O
with	O
hormone	O
receptor-negative	O
breast	B-CANCER
cancer	I-CANCER
at	O
baseline	O
;	O
the	O
latter	O
was	O
added	O
during	O
the	O
course	O
of	O
the	O
study	O
","	O
before	O
unmasking	O
based	O
on	O
new	O
clinical	O
and	O
biological	O
findings	O
from	O
other	O
studies	O
.	O
	
All	O
efficacy	O
analyses	O
were	O
based	O
on	O
the	O
intention-to-treat	O
population	O
.	O
	
Enrolment	O
for	O
this	O
trial	O
is	O
closed	O
and	O
results	O
of	O
the	O
final	O
progression-free	O
survival	O
analyses	O
are	O
presented	O
here	O
.	O
	
This	O
trial	O
is	O
registered	O
with	O
ClinicalTrials.gov	O
","	O
number	O
NCT00876395	O
.	O
	
Between	O
Sept	O
10	O
","	O
2009	O
","	O
and	O
Dec	O
16	O
","	O
2012	O
","	O
719	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
everolimus	B-DRUG
(	O
n=480	O
)	O
or	O
placebo	B-DRUG
(	O
n=239	O
)	O
.	O
	
Median	O
follow-up	O
was	O
41路3	O
months	O
(	O
IQR	O
35路4-46路6	O
)	O
.	O
	
In	O
the	O
full	O
population	O
","	O
median	O
progression-free	O
survival	O
was	O
14路95	O
months	O
(	O
95	O
%	O
CI	O
14路55-17路91	O
)	O
with	O
everolimus	B-DRUG
versus	O
14路49	O
months	O
(	O
12路29-17路08	O
)	O
with	O
placebo	B-DRUG
(	O
hazard	O
ratio	O
0路89	O
","	O
95	O
%	O
CI	O
0路73-1路08	O
;	O
p=0路1166	O
)	O
.	O
	
In	O
the	O
HR-negative	O
subpopulation	O
(	O
n=311	O
)	O
","	O
median	O
progression-free	O
survival	O
with	O
everolimus	B-DRUG
was	O
20路27	O
months	O
(	O
95	O
%	O
CI	O
14路95-24路08	O
)	O
versus	O
13路08	O
months	O
(	O
10路05-16路56	O
)	O
with	O
placebo	B-DRUG
(	O
hazard	O
ratio	O
0路66	O
","	O
95	O
%	O
CI	O
0路48-0路91	O
;	O
p=0路0049	O
)	O
;	O
however	O
","	O
the	O
protocol-specified	O
significance	O
threshold	O
(	O
p=0路0044	O
)	O
was	O
not	O
crossed	O
.	O
	
The	O
most	O
common	O
adverse	O
events	O
with	O
everolimus	B-DRUG
were	O
stomatitis	B-TOXI
(	O
314	O
[	O
67	O
%	O
]	O
of	O
472	O
patients	O
in	O
the	O
everolimus	B-DRUG
group	O
vs	O
77	O
[	O
32	O
%	O
]	O
of	O
238	O
patients	O
in	O
the	O
placebo	B-DRUG
group	O
)	O
","	O
diarrhoea	B-TOXI
(	O
267	O
[	O
57	O
%	O
]	O
vs	O
111	O
[	O
47	O
%	O
]	O
patients	O
)	O
","	O
and	O
alopecia	B-TOXI
(	O
221	O
[	O
47	O
%	O
]	O
vs	O
125	O
[	O
53	O
%	O
]	O
)	O
.	O
	
The	O
most	O
frequently	O
reported	O
grade	O
3	O
or	O
4	O
adverse	O
events	O
in	O
the	O
everolimus	B-DRUG
group	O
versus	O
the	O
placebo	B-DRUG
group	O
were	O
neutropenia	B-TOXI
(	O
117	O
[	O
25	O
%	O
]	O
vs	O
35	O
[	O
15	O
%	O
]	O
)	O
","	O
stomatitis	B-TOXI
(	O
59	O
[	O
13	O
%	O
]	O
vs	O
three	O
[	O
1	O
%	O
]	O
)	O
","	O
anaemia	B-TOXI
(	O
46	O
[	O
10	O
%	O
]	O
vs	O
six	O
[	O
3	O
%	O
]	O
)	O
and	O
diarrhoea	B-TOXI
(	O
43	O
[	O
9	O
%	O
]	O
vs	O
10	O
[	O
4	O
%	O
]	O
)	O
On-treatment	O
adverse	O
event-related	O
deaths	B-TOXI
were	O
reported	O
in	O
17	O
(	O
4	O
%	O
)	O
patients	O
in	O
the	O
everolimus	B-DRUG
group	O
and	O
none	O
in	O
the	O
placebo	B-DRUG
group	O
.	O
	
Although	O
progression-free	O
survival	O
was	O
not	O
significantly	O
different	O
between	O
groups	O
in	O
the	O
full	O
analysis	O
population	O
","	O
the	O
7路2	O
months	O
prolongation	O
we	O
noted	O
with	O
the	O
addition	O
of	O
everolimus	B-DRUG
in	O
the	O
HR-negative	O
","	O
HER2-positive	O
population	O
warrants	O
further	O
investigation	O
","	O
even	O
if	O
it	O
did	O
not	O
meet	O
prespecified	O
criteria	O
for	O
significance	O
.	O
	
The	O
safety	O
profile	O
was	O
generally	O
consistent	O
with	O
what	O
was	O
previously	O
reported	O
in	O
BOLERO-3	O
.	O
	
Proactive	O
monitoring	O
and	O
early	O
management	O
of	O
adverse	O
events	O
in	O
patients	O
given	O
everolimus	B-DRUG
and	O
chemotherapy	O
is	O
crucial	O
.	O
	
Novartis	O
Pharmaceuticals	O
.	O
	
Phase	O
I	O
Trial	O
of	O
Carboplatin	B-DRUG
and	O
Gemcitabine	B-DRUG
Chemotherapy	O
and	O
Stereotactic	O
Ablative	O
Radiosurgery	O
for	O
the	O
Palliative	O
Treatment	O
of	O
Persistent	O
or	O
Recurrent	B-CANCER
Gynecologic	I-CANCER
Cancer	I-CANCER
.	O
	
	
We	O
conducted	O
a	O
phase	O
I	O
trial	O
to	O
determine	O
the	O
safety	O
of	O
systemic	O
chemotherapy	O
prior	O
to	O
abdominopelvic	O
robotic	O
stereotactic	O
ablative	O
radiotherapy	O
(	O
SABR	O
)	O
in	O
women	O
with	O
persistent	O
or	O
recurrent	B-CANCER
gynecologic	I-CANCER
cancers	I-CANCER
.	O
	
Patients	O
were	O
assigned	O
to	O
dose-finding	O
cohorts	O
of	O
day	O
1	O
carboplatin	B-DRUG
(	O
AUC	O
2	O
or	O
4	O
)	O
and	O
gemcitabine	B-DRUG
(	O
600	O
or	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
followed	O
by	O
day	O
2	O
to	O
day	O
4	O
Cyberknife	O
SABR	O
(	O
8	O
Gy	O
_	O
three	O
consecutive	O
daily	O
doses	O
)	O
.	O
	
Toxicities	O
were	O
graded	O
prospectively	O
by	O
common	O
terminology	O
criteria	O
for	O
adverse	O
events	O
","	O
version	O
4.0.	O
SABR	O
target	O
and	O
best	O
overall	O
treatment	O
responses	O
were	O
recorded	O
according	O
to	O
response	O
evaluation	O
criteria	O
in	O
solid	B-CANCER
tumors	I-CANCER
","	O
version	O
1.1.	O
The	O
maximum	O
tolerated	O
dose	O
of	O
chemotherapy	O
preceding	O
SABR	O
was	O
carboplatin	B-DRUG
AUC	O
4	O
and	O
gemcitabine	B-DRUG
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
One	O
patient	O
experienced	O
manageable	O
","	O
dose-limiting	O
grade	O
4	O
neutropenia	B-TOXI
","	O
grade	O
4	O
hypokalemia	B-TOXI
","	O
and	O
grade	O
3	O
nausea	B-TOXI
attributed	O
to	O
study	O
treatment	O
.	O
	
One	O
patient	O
had	O
a	O
late	O
grade	O
3	O
rectovaginal	B-TOXI
fistula	I-TOXI
16	O
months	O
after	O
trial	O
therapy	O
.	O
	
Among	O
28	O
SABR	O
targets	O
","	O
22	O
(	O
79	O
%	O
)	O
showed	O
a	O
partial	O
response	O
and	O
6	O
(	O
21	O
%	O
)	O
remained	O
stable	O
.	O
	
Systemic	O
chemotherapy	O
may	O
be	O
given	O
safely	O
prior	O
to	O
abdominopelvic	O
robotic	O
SABR	O
with	O
further	O
investigation	O
warranted	O
.	O
	
5-Fluorouracil	B-DRUG
","	O
leucovorin	B-DRUG
","	O
and	O
oxaliplatin	B-DRUG
(	O
mFOLFOX6	B-DRUG
)	O
plus	O
sunitinib	B-DRUG
or	O
bevacizumab	B-DRUG
as	O
first-line	O
treatment	O
for	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
:	O
a	O
randomized	O
Phase	O
IIb	O
study	O
.	O
	
	
Sunitinib	B-DRUG
is	O
an	O
oral	O
inhibitor	O
of	O
tyrosine	O
kinase	O
receptors	O
implicated	O
in	O
tumor	O
proliferation	O
","	O
angiogenesis	O
","	O
and	O
metastasis	O
.	O
	
In	O
this	O
randomized	O
","	O
multicenter	O
","	O
open-label	O
Phase	O
IIb	O
study	O
","	O
sunitinib	B-DRUG
plus	O
mFOLFOX6	B-DRUG
(	O
oxaliplatin	B-DRUG
plus	O
leucovorin	B-DRUG
plus	O
5-fluorouracil	B-DRUG
)	O
was	O
compared	O
with	O
bevacizumab	B-DRUG
plus	O
mFOLFOX6	B-DRUG
as	O
first-line	O
therapy	O
in	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
were	O
stratified	O
by	O
performance	O
status	O
","	O
baseline	O
lactate	O
dehydrogenase	O
level	O
","	O
and	O
prior	O
adjuvant	O
treatment	O
","	O
and	O
randomized	O
01:01	O
to	O
receive	O
sunitinib	B-DRUG
37.5	O
mg	O
/	O
day	O
for	O
4	O
weeks	O
on	O
and	O
2	O
weeks	O
off	O
plus	O
mFOLFOX6	B-DRUG
every	O
2	O
weeks	O
or	O
bevacizumab	B-DRUG
5	O
mg	O
/	O
kg	O
every	O
2	O
weeks	O
plus	O
mFOLFOX6	B-DRUG
every	O
2	O
weeks	O
.	O
	
The	O
primary	O
endpoint	O
was	O
progression-free	O
survival	O
.	O
	
Secondary	O
endpoints	O
included	O
objective	O
response	O
rate	O
","	O
overall	O
survival	O
","	O
safety	O
","	O
and	O
quality	O
of	O
life	O
.	O
	
Enrollment	O
was	O
closed	O
early	O
following	O
accrual	O
of	O
191	O
patients	O
","	O
based	O
on	O
an	O
interim	O
analysis	O
showing	O
an	O
inferior	O
trend	O
in	O
the	O
primary	O
progression-free	O
survival	O
efficacy	O
endpoint	O
for	O
sunitinib	B-DRUG
.	O
	
Ninety-six	O
patients	O
were	O
randomized	O
to	O
sunitinib	B-DRUG
plus	O
mFOLFOX6	B-DRUG
and	O
95	O
to	O
bevacizumab	B-DRUG
plus	O
mFOLFOX6	B-DRUG
.	O
	
Median	O
progression-free	O
survival	O
was	O
9.3	O
months	O
and	O
15.4	O
months	O
","	O
respectively	O
","	O
but	O
the	O
objective	O
response	O
rate	O
was	O
similar	O
between	O
the	O
study	O
arms	O
.	O
	
Median	O
overall	O
survival	O
was	O
23.7	O
months	O
and	O
34.1	O
months	O
","	O
respectively	O
.	O
	
Dose	O
reductions	O
and	O
interruptions	O
were	O
more	O
common	O
with	O
sunitinib	B-DRUG
.	O
	
Hematologic	B-TOXI
toxicity	I-TOXI
was	O
more	O
common	O
in	O
the	O
sunitinib	B-DRUG
arm	O
.	O
	
While	O
the	O
results	O
of	O
the	O
sunitinib	B-DRUG
arm	O
are	O
comparable	O
with	O
those	O
of	O
previously	O
reported	O
FOLFOX	B-DRUG
combinations	O
","	O
the	O
sunitinib-based	B-DRUG
combination	O
was	O
associated	O
with	O
more	O
toxicity	O
than	O
that	O
observed	O
with	O
bevacizumab	B-DRUG
and	O
mFOLFOX6	B-DRUG
.	O
	
The	O
bevacizumab	B-DRUG
arm	O
had	O
an	O
unexpectedly	O
good	O
outcome	O
","	O
and	O
was	O
much	O
better	O
than	O
that	O
seen	O
in	O
the	O
Phase	O
III	O
trials	O
.	O
	
Combination	O
therapy	O
with	O
sunitinib	B-DRUG
plus	O
mFOLFOX6	B-DRUG
is	O
not	O
recommended	O
for	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Phase	O
I	O
study	O
of	O
intravenous	O
(	O
IV	O
)	O
docetaxel	B-DRUG
and	O
intraperitoneal	O
(	O
IP	O
)	O
oxaliplatin	B-DRUG
in	O
recurrent	O
ovarian	B-CANCER
and	I-CANCER
fallopian	I-CANCER
tube	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
primary	O
objective	O
was	O
to	O
define	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
of	O
IV	O
docetaxel	B-DRUG
and	O
IP	O
oxaliplatin	B-DRUG
in	O
women	O
with	O
recurrent	O
ovarian	O
(	O
OV	O
)	O
","	O
fallopian	O
tube	O
(	O
FT	O
)	O
or	O
peritoneal	O
(	O
PP	O
)	O
cancer	O
.	O
	
Secondary	O
objectives	O
included	O
response	O
rate	O
","	O
time	O
to	O
progression	O
","	O
pharmacokinetics	O
(	O
PK	O
)	O
and	O
quality	O
of	O
life	O
(	O
QoL	O
)	O
.	O
	
Patients	O
received	O
docetaxel	B-DRUG
75mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
day	O
(	O
d	O
)	O
1	O
and	O
oxaliplatin	B-DRUG
escalating	O
from	O
50mg	O
/	O
m	O
(	O
2	O
)	O
IP	O
d2	O
every	O
3weeks	O
using	O
a	O
3+3	O
design	O
.	O
	
Treatment	O
continued	O
until	O
disease	O
progression	O
","	O
remission	O
","	O
or	O
intolerable	O
toxicity	O
.	O
	
Plasma	O
and	O
IP	O
samples	O
were	O
taken	O
to	O
determine	O
drug	O
concentrations	O
.	O
	
MD	O
Anderson	O
Symptom	O
Inventory	O
and	O
symptom	O
interference	O
scale	O
were	O
completed	O
weekly	O
.	O
	
Thirteen	O
patients	O
were	O
included	O
.	O
	
Median	O
number	O
of	O
cycles	O
was	O
6	O
(	O
range	O
1月10日	O
)	O
.	O
	
Ten	O
patients	O
had	O
measureable	O
disease	O
.	O
	
Best	O
response	O
was	O
partial	O
response	O
(	O
PR-2	O
)	O
","	O
stable	O
disease	O
(	O
SD-7	O
)	O
","	O
and	O
progressive	O
disease	O
(	O
PD-1	O
)	O
.	O
	
Twenty-one	O
Grades	O
3月4日	O
toxicities	O
were	O
noted	O
","	O
commonly	O
hematologic	O
.	O
	
Two	O
patients	O
had	O
DLTs	O
:	O
prolonged	B-TOXI
neutropenia	I-TOXI
(	O
1	O
)	O
and	O
abdominal	B-TOXI
pain	I-TOXI
(	O
1	O
)	O
.	O
	
MTD	O
was	O
d1	O
docetaxel	B-DRUG
75mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
and	O
d2	O
oxaliplatin	B-DRUG
50mg	O
/	O
m	O
(	O
2	O
)	O
IP	O
.	O
	
Symptom	O
burden	O
peaked	O
week	O
one	O
and	O
returned	O
to	O
baseline	O
by	O
week	O
two	O
of	O
each	O
cycle	O
on	O
dose	O
level	O
1	O
Dose	O
level	O
2	O
had	O
persistently	O
high	O
symptom	O
burden	O
and	O
interference	O
.	O
	
At	O
IP	O
oxaliplatin	B-DRUG
doses	O
of	O
50mg	O
/	O
m	O
(	O
2	O
)	O
","	O
total	O
unbound	O
drug	O
exposure	O
(	O
AUC	O
)	O
averaged	O
8	O
times	O
larger	O
and	O
Cmax	O
reached	O
concentrations	O
50-fold	O
greater	O
in	O
IP	O
fluid	B-DRUG
compared	O
to	O
plasma	O
.	O
	
Docetaxel	B-DRUG
75mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
d1	O
and	O
oxaliplatin	B-DRUG
50mg	O
/	O
m	O
(	O
2	O
)	O
IP	O
d2	O
is	O
the	O
MTD	O
.	O
	
Most	O
patients	O
had	O
PR	O
or	O
SD	O
.	O
	
Patient-reported	O
outcomes	O
demonstrate	O
temporary	O
but	O
tolerable	O
decrements	O
in	O
QoL	O
.	O
	
IP	O
oxaliplatin	B-DRUG
provides	O
PK	O
advantages	O
over	O
IV	O
administration	O
.	O
	
Safety	O
and	O
activity	O
of	O
BTK	O
inhibitor	O
ibrutinib	B-DRUG
combined	O
with	O
ofatumumab	B-DRUG
in	O
chronic	B-CANCER
lymphocytic	I-CANCER
leukemia	I-CANCER
:	O
a	O
phase	O
1b	O
/	O
2	O
study	O
.	O
	
	
Ibrutinib	B-DRUG
represents	O
a	O
therapeutic	O
advance	O
in	O
chronic	B-CANCER
lymphocytic	I-CANCER
leukemia	I-CANCER
(	O
CLL	B-CANCER
)	O
but	O
as	O
monotherapy	O
produces	O
few	O
complete	O
remissions	O
in	O
previously	O
treated	O
patients	O
.	O
	
Anti-CD20	O
antibodies	O
have	O
improved	O
response	O
and	O
progression-free	O
survival	O
(	O
PFS	O
)	O
when	O
combined	O
with	O
chemotherapy	O
.	O
	
We	O
evaluated	O
the	O
safety	O
and	O
activity	O
of	O
adding	O
ofatumumab	B-DRUG
to	O
ibrutinib	B-DRUG
in	O
3	O
different	O
administration	O
sequences	O
.	O
	
Patients	O
with	O
CLL	B-CANCER
/	O
small	B-CANCER
lymphocytic	I-CANCER
lymphoma	I-CANCER
(	O
SLL	B-CANCER
)	O
","	O
prolymphocytic	B-CANCER
leukemia	I-CANCER
","	O
or	O
Richter	O
's	O
transformation	O
who	O
failed	O
_2	O
prior	O
therapies	O
were	O
enrolled	O
.	O
	
Patients	O
received	O
ibrutinib	B-DRUG
420	O
mg	O
daily	O
and	O
12	O
doses	O
of	O
ofatumumab	B-DRUG
300	O
/	O
2000	O
mg	O
in	O
3	O
schedules	O
:	O
ibrutinib	B-DRUG
lead-in	O
(	O
group	O
1	O
;	O
n	O
=	O
27	O
)	O
","	O
concurrent	O
start	O
(	O
group	O
2	O
;	O
n	O
=	O
20	O
)	O
","	O
or	O
ofatumumab	B-DRUG
lead-in	O
(	O
group	O
3	O
;	O
n	O
=	O
24	O
)	O
.	O
	
Seventy-one	O
patients	O
were	O
treated	O
;	O
most	O
had	O
high-risk	O
disease	O
including	O
del	O
(	O
17	O
)	O
(	O
p13.1	O
)	O
(	O
44	O
%	O
)	O
or	O
del	O
(	O
11	O
)	O
(	O
q22.3	O
)	O
(	O
31	O
%	O
)	O
.	O
	
The	O
most	O
frequent	O
adverse	O
events	O
(	O
any	O
grade	O
)	O
were	O
diarrhea	B-TOXI
(	O
70	O
%	O
)	O
","	O
infusion-related	B-TOXI
reaction	I-TOXI
(	O
45	O
%	O
)	O
","	O
and	O
peripheral	B-TOXI
sensory	I-TOXI
neuropathy	I-TOXI
(	O
44	O
%	O
)	O
.	O
	
Overall	O
response	O
rates	O
in	O
CLL	B-CANCER
/	O
SLL	B-CANCER
patients	O
(	O
n	O
=	O
66	O
)	O
were	O
100	O
%	O
","	O
79	O
%	O
","	O
and	O
71	O
%	O
in	O
groups	O
1	O
","	O
2	O
","	O
and	O
3	O
","	O
respectively	O
.	O
	
Estimated	O
12-month	O
PFSs	O
for	O
all	O
patients	O
were	O
89	O
%	O
","	O
85	O
%	O
","	O
and	O
75	O
%	O
","	O
respectively	O
.	O
	
Four	O
patients	O
in	O
group	O
3	O
progressed	O
prior	O
to	O
receiving	O
ibrutinib	B-DRUG
.	O
	
This	O
study	O
demonstrates	O
the	O
tolerability	O
and	O
clinical	O
activity	O
of	O
this	O
combination	O
with	O
quicker	O
time	O
to	O
best	O
response	O
than	O
single-agent	O
ibrutinib	B-DRUG
and	O
with	O
durable	O
responses	O
.	O
	
This	O
trial	O
was	O
registered	O
at	O
www.clinicaltrials.gov	O
as	O
#	O
NCT01217749	O
.	O
	
Stromal	O
Caveolin-1	O
Is	O
Associated	O
With	O
Response	O
and	O
Survival	O
in	O
a	O
Phase	O
II	O
Trial	O
of	O
nab-Paclitaxel	B-DRUG
With	O
Carboplatin	B-DRUG
for	O
Advanced	B-CANCER
NSCLC	I-CANCER
Patients	O
.	O
	
	
In	O
this	O
phase	O
II	O
trial	O
","	O
carboplatin	B-DRUG
with	O
nanoparticle	O
albumin-bound	O
(	O
nab	O
)	O
#NAME?	B-DRUG
as	O
first-line	O
therapy	O
for	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
was	O
evaluated	O
.	O
	
Most	O
patients	O
had	O
squamous	O
cell	O
histology	O
.	O
	
Tumor-associated	O
stromal	O
caveolin-1	O
(	O
Cav-1	O
)	O
expression	O
was	O
correlated	O
with	O
improved	O
response	O
rate	O
and	O
survival	O
in	O
NSCLC	B-CANCER
patients	O
who	O
received	O
nab-paclitaxel	B-DRUG
in	O
this	O
phase	O
II	O
trial	O
.	O
	
These	O
results	O
suggest	O
Cav-1	O
might	O
serve	O
as	O
a	O
potential	O
biomarker	O
in	O
this	O
patient	O
population	O
.	O
	
The	O
combination	O
of	O
bevacizumab	B-DRUG
with	O
platinum-based	B-DRUG
chemotherapy	O
results	O
in	O
greater	O
response	O
rate	O
(	O
RR	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Bevacizumab	B-DRUG
is	O
contraindicated	O
in	O
patients	O
with	O
squamous	O
histology	O
or	O
hemoptysis	O
.	O
	
Nanoparticle	O
albumin-bound	O
(	O
nab	O
)	O
#NAME?	B-DRUG
is	O
a	O
novel	O
formulation	O
of	O
paclitaxel	B-DRUG
with	O
greater	O
dose	O
tolerance	O
and	O
improved	O
efficacy	O
.	O
	
We	O
hypothesized	O
that	O
nab-paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
would	O
be	O
superior	O
to	O
alternative	O
doublets	O
in	O
advanced	B-CANCER
NSCLC	I-CANCER
patients	O
ineligible	O
for	O
bevacizumab	B-DRUG
.	O
	
We	O
conducted	O
a	O
single-arm	O
phase	O
II	O
trial	O
(	O
NCT00729612	O
)	O
with	O
carboplatin	B-DRUG
and	O
nab-paclitaxel	B-DRUG
on	O
day	O
1	O
of	O
a	O
21-day	O
cycle	O
to	O
evaluate	O
RR	O
(	O
primary	O
end	O
point	O
)	O
","	O
safety	O
","	O
toxicity	O
","	O
and	O
OS	O
.	O
	
Eligibility	O
included	O
:	O
squamous	O
histology	O
","	O
hemoptysis	O
","	O
or	O
ongoing	O
anticoagulation	O
.	O
	
Correlative	O
studies	O
included	O
immunohistochemistry	O
for	O
secreted	O
protein	O
acid	O
rich	O
in	O
cysteine	O
(	O
SPARC	O
)	O
and	O
caveolin-1	O
(	O
Cav-1	O
)	O
.	O
	
Sixty-three	O
patients	O
were	O
enrolled	O
.	O
	
Most	O
patients	O
had	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
n	O
=	O
48	O
)	O
;	O
other	O
reasons	O
for	O
eligibility	O
included	O
hemoptysis	B-TOXI
(	O
n	O
=	O
11	O
)	O
and	O
anticoagulation	B-TOXI
(	O
n	O
=	O
2	O
)	O
.	O
	
Toxicity	O
Grade	O
_	O
3	O
/	O
4	O
included	O
neuropathy	B-TOXI
","	O
cytopenias	B-TOXI
","	O
and	O
fatigue	B-TOXI
.	O
	
RR	O
was	O
38	O
%	O
(	O
24	O
partial	O
response	O
/	O
0	O
complete	O
response	O
)	O
;	O
20	O
patients	O
had	O
stable	O
disease	O
(	O
32	O
%	O
)	O
.	O
	
Median	O
progression-free	O
survival	O
was	O
5	O
months	O
and	O
median	O
OS	O
was	O
9.7	O
months	O
.	O
	
Immunohistochemistry	O
for	O
SPARC	O
and	O
Cav-1	O
was	O
performed	O
in	O
38	O
and	O
37	O
patients	O
respectively	O
.	O
	
Although	O
no	O
association	O
was	O
found	O
for	O
SPARC	O
expression	O
in	O
tumor	O
or	O
stroma	O
with	O
RR	O
or	O
OS	O
","	O
we	O
found	O
that	O
higher	O
Cav-1	O
levels	O
in	O
tumor-associated	O
stroma	O
was	O
associated	O
with	O
improved	O
RR	O
and	O
OS	O
.	O
	
Carboplatin	B-DRUG
and	O
nab-paclitaxel	B-DRUG
every	O
21	O
days	O
demonstrated	O
promising	O
efficacy	O
with	O
tolerable	O
toxicity	O
in	O
NSCLC	B-CANCER
patients	O
ineligible	O
for	O
bevacizumab	B-DRUG
therapy	O
.	O
	
Further	O
analysis	O
and	O
validation	O
of	O
Cav-1	O
and	O
SPARC	O
expression	O
in	O
tumor	O
and	O
stromal	O
compartments	O
as	O
prognostic	O
and	O
/	O
or	O
predictive	O
biomarkers	O
of	O
NSCLC	B-CANCER
or	O
nab-paclitaxel	B-DRUG
treatment	O
is	O
warranted	O
.	O
	
Safety	O
and	O
Pharmacokinetics	O
of	O
Second-line	O
Ramucirumab	B-DRUG
plus	O
FOLFIRI	B-DRUG
in	O
Japanese	O
Patients	O
with	O
Metastatic	B-CANCER
Colorectal	I-CANCER
Carcinoma	I-CANCER
.	O
	
	
This	O
phase	O
Ib	O
study	O
evaluated	O
the	O
pharmacokinetic	O
profile	O
and	O
safety	O
of	O
ramucirumab	B-DRUG
","	O
a	O
recombinant	O
human	O
IgG1	O
neutralizing	O
monoclonal	O
antibody	O
specific	O
for	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
","	O
in	O
combination	O
with	O
irinotecan	B-DRUG
","	O
levofolinate	B-DRUG
and	O
5-fluorouracil	B-DRUG
(	O
FOLFIRI	B-DRUG
)	O
in	O
Japanese	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
(	O
mCRC	B-CANCER
)	O
.	O
	
Eligible	O
patients	O
had	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
0-1	O
","	O
and	O
disease	O
progression	O
during	O
or	O
within	O
6	O
months	O
following	O
first-line	O
therapy	O
with	O
bevacizumab	B-DRUG
","	O
oxaliplatin	B-DRUG
and	O
a	O
fluoropyrimidine	B-DRUG
.	O
	
Six	O
enrolled	O
patients	O
received	O
8	O
mg	O
/	O
kg	O
ramucirumab	B-DRUG
plus	O
FOLFIRI	B-DRUG
every	O
2	O
weeks	O
.	O
	
One	O
out	O
of	O
six	O
patients	O
experienced	O
a	O
dose-limiting	O
toxicity	O
(	O
grade	O
2	O
proteinuria	B-TOXI
and	O
grade	O
4	O
neutropenia	B-TOXI
","	O
resulting	O
in	O
a	O
dose	O
delay	O
&	O
gt	O
;	O
2	O
weeks	O
)	O
.	O
	
All	O
patients	O
experienced	O
at	O
least	O
one	O
grade	O
3	O
or	O
higher	O
adverse	O
event	O
:	O
neutropenia	B-TOXI
(	O
five	O
patients	O
","	O
83	O
%	O
)	O
","	O
proteinuria	B-TOXI
(	O
two	O
patients	O
;	O
33	O
%	O
)	O
and	O
anemia	B-TOXI
","	O
thrombocytopenia	B-TOXI
and	O
hypertension	B-TOXI
(	O
one	O
patient	O
each	O
","	O
17	O
%	O
)	O
.	O
	
There	O
were	O
no	O
serious	O
adverse	O
events	O
or	O
deaths	B-TOXI
.	O
	
Ramucirumab	B-DRUG
plus	O
FOLFIRI	B-DRUG
was	O
well-tolerated	O
in	O
Japanese	O
patients	O
with	O
mCRC	B-CANCER
","	O
warranting	O
further	O
investigation	O
of	O
this	O
combination	O
therapy	O
.	O
	
Phase	O
I	O
study	O
of	O
combination	O
of	O
pasireotide	B-DRUG
LAR	I-DRUG
=+	O
gemcitabine	B-DRUG
in	O
locally	O
advanced	O
or	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
	
Pasireotide	B-DRUG
LAR	I-DRUG
(	O
SOM230	O
LAR	O
)	O
is	O
a	O
cyclohexapeptide	O
engineered	O
to	O
bind	O
to	O
multiple	O
somatostatin	O
receptor	O
subtypes	O
to	O
mimic	O
the	O
action	O
of	O
naturally	O
occurring	O
somatostatin	O
with	O
higher	O
affinity	O
to	O
these	O
receptors	O
than	O
octreotide	O
and	O
is	O
a	O
potent	O
inhibitor	O
of	O
insulin-like	O
growth	O
factor-1	O
(	O
IGF-1	O
)	O
.	O
	
Somatostatin	O
receptors	O
and	O
IGF	O
receptors	O
are	O
highly	O
expressed	O
in	O
pancreatic	B-CANCER
cancer	I-CANCER
","	O
thereby	O
potentially	O
making	O
it	O
a	O
valuable	O
target	O
.	O
	
This	O
phase	O
I	O
study	O
evaluated	O
safety	O
","	O
tolerability	O
and	O
preliminary	O
tumor	O
response	O
of	O
pasireotide	B-DRUG
LAR	I-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
locally	O
advanced	O
or	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
previously	O
untreated	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
were	O
included	O
.	O
	
A	O
3	O
=+	O
3	O
dose-escalation	O
design	O
was	O
used	O
.	O
	
Patients	O
received	O
gemcitabine	B-DRUG
on	O
days	O
1	O
","	O
8	O
and	O
15	O
and	O
pasireotide	B-DRUG
LAR	I-DRUG
IM	O
monthly	O
in	O
a	O
28-day	O
cycle	O
.	O
	
Two	O
dose	O
levels	O
of	O
pasireotide	B-DRUG
LAR	I-DRUG
were	O
planned	O
:	O
40	O
mg	O
IM	O
and	O
60	O
mg	O
.	O
	
Cohort	O
was	O
expanded	O
by	O
ten	O
more	O
patients	O
at	O
the	O
highest	O
tested	O
dose	O
to	O
further	O
assess	O
the	O
safety	O
and	O
efficacy	O
.	O
	
Twenty	O
patients	O
were	O
consented	O
on	O
this	O
trial	O
","	O
and	O
16	O
patients	O
were	O
evaluable	O
for	O
safety	O
and	O
efficacy	O
.	O
	
No	O
dose-limiting	O
toxicities	O
were	O
observed	O
.	O
	
Two	O
out	O
sixteen	O
patients	O
(	O
12	O
%	O
)	O
had	O
partial	O
response	O
","	O
and	O
nine	O
of	O
sixteen	O
(	O
56	O
%	O
)	O
had	O
stable	O
disease	O
as	O
best	O
response	O
.	O
	
Median	O
progression-free	O
survival	O
was	O
4.1	O
months	O
(	O
range	O
1月16日	O
months	O
)	O
","	O
and	O
median	O
overall	O
survival	O
was	O
6.9	O
months	O
(	O
range	O
1月25日	O
months	O
)	O
.	O
	
Most	O
common	O
grade	O
3	O
or	O
4	O
toxicities	O
were	O
hyperglycemia	B-TOXI
(	O
n	O
=	O
5	O
)	O
","	O
hyperbilirubinemia	B-TOXI
(	O
n	O
=	O
1	O
)	O
and	O
thrombocytopenia	B-TOXI
(	O
n	O
=	O
2	O
)	O
.	O
	
Median	O
baseline	O
IGF-1	O
level	O
was	O
lower	O
in	O
patients	O
with	O
stable	O
disease	O
than	O
in	O
those	O
with	O
progressive	O
disease	O
(	O
63	O
vs	O
71	O
ng	O
/	O
ml	O
)	O
.	O
	
Pasireotide	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
was	O
well	O
tolerated	O
with	O
disease	O
control	O
rate	O
of	O
68	O
%	O
.	O
	
Larger	O
trials	O
are	O
needed	O
in	O
the	O
future	O
to	O
establish	O
its	O
efficacy	O
in	O
the	O
treatment	O
of	O
pancreatic	B-CANCER
cancer	I-CANCER
.	O
	
NCT01385956	O
.	O
	
Phase	O
I	O
/	O
II	O
trial	O
of	O
neoadjuvant	O
sunitinib	B-DRUG
administered	O
with	O
weekly	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
in	O
patients	O
with	O
locally	O
advanced	B-CANCER
triple-negative	I-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
purpose	O
of	O
the	O
study	O
is	O
to	O
evaluate	O
the	O
feasibility	O
and	O
efficacy	O
of	O
adding	O
sunitinib	B-DRUG
to	O
paclitaxel	B-DRUG
/	O
carboplatin	B-DRUG
in	O
the	O
neoadjuvant	O
therapy	O
of	O
patients	O
with	O
triple-negative	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
TNBC	B-CANCER
)	O
.	O
	
Patients	O
had	O
histologically	O
proven	O
","	O
previously	O
untreated	O
","	O
triple-negative	B-CANCER
adenocarcinoma	I-CANCER
","	O
with	O
disease	O
limited	O
to	O
the	O
breast	O
and	O
axilla	O
(	O
clinical	O
T1-T3	O
","	O
N0-N2	O
","	O
M0	O
;	O
T1N1M0	O
excluded	O
)	O
.	O
	
Following	O
determination	O
of	O
the	O
maximum	O
tolerated	O
doses	O
in	O
the	O
phase	O
I	O
portion	O
","	O
patients	O
in	O
the	O
phase	O
II	O
study	O
received	O
paclitaxel	B-DRUG
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
;	O
carboplatin	B-DRUG
AUC	O
5	O
IV	O
day	O
1	O
;	O
sunitinib	O
25	O
mg	O
orally	O
daily	O
;	O
treatment	O
was	O
administered	O
for	O
six	O
28-day	O
cycles	O
followed	O
by	O
definitive	O
surgery	O
.	O
	
Sunitinib	B-DRUG
was	O
resumed	O
postoperatively	O
to	O
complete	O
a	O
52-week	O
course	O
.	O
	
Pathologic	O
complete	O
response	O
(	O
pCR	O
)	O
rate	O
was	O
the	O
primary	O
endpoint	O
.	O
	
Fifty-four	O
patients	O
enrolled	O
;	O
41	O
received	O
treatment	O
in	O
the	O
phase	O
II	O
study	O
.	O
	
Sixteen	O
patients	O
(	O
39	O
%	O
)	O
were	O
able	O
to	O
complete	O
six	O
cycles	O
of	O
neoadjuvant	O
therapy	O
;	O
18	O
additional	O
patients	O
had	O
surgery	O
after	O
completing	O
2月5日	O
cycles	O
of	O
treatment	O
.	O
	
The	O
pCR	O
rate	O
in	O
these	O
34	O
evaluable	O
patients	O
was	O
35	O
%	O
.	O
	
The	O
toxicity	O
of	O
the	O
regimen	O
was	O
considerable	O
","	O
with	O
myelosuppression	B-TOXI
resulting	O
in	O
numerous	O
dose	O
reductions	O
and	O
/	O
or	O
omissions	O
of	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
.	O
	
Eleven	O
patients	O
(	O
27	O
%	O
)	O
discontinued	O
sunitinib	B-DRUG
during	O
neoadjuvant	O
therapy	O
","	O
and	O
six	O
patients	O
(	O
14	O
%	O
)	O
completed	O
52	O
weeks	O
of	O
single-agent	O
sunitinib	B-DRUG
.	O
	
In	O
the	O
neoadjuvant	O
treatment	O
of	O
patients	O
with	O
TNBC	B-CANCER
","	O
the	O
combination	O
of	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
sunitinib	B-DRUG
was	O
difficult	O
to	O
administer	O
","	O
and	O
produced	O
a	O
pCR	O
rate	O
comparable	O
to	O
other	O
less	O
toxic	O
regimens	O
.	O
	
This	O
combination	O
is	O
not	O
recommended	O
for	O
further	O
evaluation	O
.	O
	
At	O
present	O
","	O
sunitinib	B-DRUG
has	O
no	O
defined	O
role	O
in	O
the	O
treatment	O
of	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
A	O
phase	O
III	O
randomized	O
multicenter	O
trial	O
evaluating	O
cognition	O
in	O
post-menopausal	O
breast	B-CANCER
cancer	I-CANCER
patients	O
receiving	O
adjuvant	O
hormonotherapy	O
.	O
	
	
Cognitive	O
impairment	O
","	O
especially	O
verbal	O
episodic	O
memory	O
and	O
executive	O
function	O
impairments	O
","	O
has	O
been	O
considered	O
to	O
be	O
a	O
possible	O
adverse	O
effect	O
of	O
aromatase	O
inhibitors	O
(	O
AI	O
)	O
.	O
	
This	O
phase	O
III	O
open-label	O
study	O
compared	O
the	O
impact	O
of	O
tamoxifen	B-DRUG
and	O
AI	O
on	O
verbal	O
episodic	O
memory	O
(	O
Rey	O
auditory	O
verbal	O
learning	O
test-RAVLT	O
)	O
and	O
other	O
cognitive	O
functions	O
(	O
visual	O
memory	O
","	O
psychomotor	O
speed	O
","	O
and	O
executive	O
functions	O
)	O
after	O
6	O
and	O
12	O
months	O
of	O
treatment	O
in	O
breast	B-CANCER
cancer	I-CANCER
patients	O
undergoing	O
adjuvant	O
hormonotherapy	O
.	O
	
Menopausal	O
chemo-na茂ve	O
patients	O
with	O
resectable	O
breast	B-CANCER
cancer	I-CANCER
were	O
randomly	O
assigned	O
(	O
01:01	O
)	O
at	O
the	O
end	O
of	O
the	O
radiotherapy	O
to	O
receive	O
tamoxifen	B-DRUG
or	O
AI	O
.	O
	
Neuropsychological	O
assessments	O
","	O
self-reported	O
quality	O
of	O
life	O
","	O
and	O
depression	O
assessments	O
were	O
performed	O
at	O
baseline	O
","	O
before	O
any	O
hormonal	O
treatment	O
","	O
and	O
at	O
6	O
and	O
12	O
months	O
.	O
	
Mixed	O
design	O
analysis	O
models	O
of	O
variance	O
was	O
used	O
to	O
compare	O
the	O
evolution	O
of	O
the	O
scores	O
between	O
the	O
groups	O
during	O
follow-up	O
.	O
	
A	O
total	O
of	O
74	O
evaluable	O
patients	O
were	O
enrolled	O
(	O
Tamoxifen	B-DRUG
arm	O
","	O
n	O
=	O
37	O
;	O
AI	O
arm	O
","	O
n	O
=	O
37	O
;	O
letrozole	B-DRUG
n	O
=	O
18	O
;	O
anastrozole	B-DRUG
n	O
=	O
16	O
;	O
exemestane	B-DRUG
n	O
=	O
3	O
)	O
.	O
	
The	O
median	O
age	O
at	O
inclusion	O
was	O
61	O
years	O
(	O
range	O
","	O
minimum	O
49-maximum	O
69	O
)	O
.	O
	
The	O
patient	O
and	O
breast	B-CANCER
cancer	I-CANCER
characteristics	O
were	O
well	O
balanced	O
between	O
arms	O
.	O
	
After	O
6	O
months	O
","	O
no	O
significant	O
differential	O
effect	O
of	O
AI	O
or	O
tamoxifen	B-DRUG
was	O
observed	O
on	O
the	O
RAVLT	O
.	O
	
Moreover	O
","	O
considering	O
the	O
other	O
cognitive	O
measures	O
and	O
the	O
quality	O
of	O
life	O
questionnaires	O
","	O
there	O
were	O
also	O
no	O
differences	O
between	O
the	O
groups	O
during	O
the	O
1-year	O
follow-up	O
.	O
	
In	O
this	O
study	O
","	O
AI	O
has	O
not	O
demonstrated	O
worse	O
adverse	O
effects	O
on	O
cognitive	O
functions	O
than	O
tamoxifen	B-DRUG
during	O
a	O
1-year	O
follow-up	O
.	O
	
The	O
Safety	O
of	O
Pegylated	B-DRUG
Liposomal	I-DRUG
Doxorubicin	I-DRUG
Plus	O
Irinotecan	B-DRUG
in	O
Recurrent	B-CANCER
Ovarian	I-CANCER
Cancer	I-CANCER
Patients	O
:	O
A	O
Phase	O
I	O
Trial	O
.	O
	
	
The	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
safety	O
of	O
combined	O
chemotherapy	O
with	O
pegylated	B-DRUG
liposomal	I-DRUG
doxorubicin	I-DRUG
(	O
PLD	B-DRUG
)	O
and	O
irinotecan	B-DRUG
(	O
CPT-11	B-DRUG
)	O
in	O
patients	O
with	O
recurrent	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
Six	O
patients	O
with	O
platinum-resistant	B-DRUG
and	O
taxane-pretreated	B-DRUG
ovarian	B-CANCER
cancer	I-CANCER
were	O
enrolled	O
in	O
the	O
study	O
based	O
on	O
the	O
traditional	O
3-plus-3	O
design	O
.	O
	
PLD	B-DRUG
was	O
administered	O
intravenously	O
on	O
day	O
1	O
and	O
CPT-11	B-DRUG
on	O
days	O
1	O
and	O
8	O
of	O
each	O
28-day	O
course	O
.	O
	
Initial	O
doses	O
were	O
30	O
mg	O
/	O
m	O
(	O
2	O
)	O
PLD	B-DRUG
and	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
CPT-11	B-DRUG
.	O
	
Hematotoxicity	O
was	O
the	O
principal	O
toxicity	O
(	O
1	O
patient	O
developed	O
grade	O
3	O
neutropenia	B-TOXI
and	O
2	O
developed	O
grade	O
3	O
leukocytopenia	B-TOXI
)	O
;	O
hand-foot	B-TOXI
syndrome	I-TOXI
was	O
not	O
observed	O
.	O
	
Furthermore	O
","	O
1	O
patient	O
achieved	O
complete	O
response	O
","	O
whereas	O
2	O
patients	O
achieved	O
partial	O
response	O
.	O
	
The	O
combined	O
PLD	B-DRUG
and	O
CPT-11	B-DRUG
regimen	O
was	O
well-tolerated	O
indicating	O
its	O
potential	O
clinical	O
benefit	O
for	O
ovarian	B-CANCER
cancer	I-CANCER
patients	O
.	O
	
(	B-DRUG
90	I-DRUG
)	I-DRUG
Y-clivatuzumab	I-DRUG
tetraxetan	I-DRUG
with	O
or	O
without	O
low-dose	O
gemcitabine	B-DRUG
:	O
A	O
phase	O
Ib	O
study	O
in	O
patients	O
with	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
after	O
two	O
or	O
more	O
prior	O
therapies	O
.	O
	
	
For	O
patients	O
with	O
metastatic	B-CANCER
pancreatic	I-CANCER
adenocarcinoma	I-CANCER
","	O
there	O
are	O
no	O
approved	O
or	O
established	O
treatments	O
beyond	O
the	O
2nd	O
line	O
.	O
	
A	O
Phase	O
Ib	O
study	O
of	O
fractionated	O
radioimmunotherapy	O
was	O
undertaken	O
in	O
this	O
setting	O
","	O
administering	O
(	B-DRUG
90	I-DRUG
)	I-DRUG
Y-clivatuzumab	I-DRUG
tetraxetan	I-DRUG
(	O
yttrium-90-radiolabelled	O
humanised	O
antibody	O
targeting	O
pancreatic	B-CANCER
adenocarcinoma	I-CANCER
mucin	O
)	O
with	O
or	O
without	O
low	O
radiosensitising	O
doses	O
of	O
gemcitabine	B-DRUG
.	O
	
Fifty-eight	O
patients	O
with	O
three	O
(	O
2月7日	O
)	O
median	O
prior	O
treatments	O
were	O
treated	O
on	O
Arm	O
A	O
(	O
N=29	O
","	O
(	B-DRUG
90	I-DRUG
)	I-DRUG
Y-clivatuzumab	I-DRUG
tetraxetan	I-DRUG
","	O
weekly	O
6.5	O
mCi	O
/	O
m	O
(	O
2	O
)	O
doses_3	O
","	O
plus	O
gemcitabine	B-DRUG
","	O
weekly	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
doses_4	O
starting	O
1	O
week	O
earlier	O
)	O
or	O
Arm	O
B	O
(	O
N=29	O
","	O
(	B-DRUG
90	I-DRUG
)	I-DRUG
Y-clivatuzumab	I-DRUG
tetraxetan	I-DRUG
alone	O
","	O
weekly	O
6.5	O
mCi	O
/	O
m	O
(	O
2	O
)	O
doses_3	O
)	O
","	O
repeating	O
cycles	O
after	O
4-week	O
delays	O
.	O
	
Safety	O
was	O
the	O
primary	O
endpoint	O
;	O
efficacy	O
was	O
also	O
evaluated	O
.	O
	
Cytopaenias	B-TOXI
(	O
predominantly	O
transient	B-TOXI
thrombocytopenia	I-TOXI
)	O
were	O
the	O
only	O
significant	O
toxicities	O
.	O
	
Fifty-three	O
patients	O
(	O
27	O
Arm	O
A	O
","	O
26	O
Arm	O
B	O
","	O
91	O
%	O
overall	O
)	O
completed	O
猢1	O
full	O
treatment	O
cycles	O
","	O
with	O
23	O
(	O
12	O
Arm	O
A	O
","	O
11	O
Arm	O
B	O
;	O
40	O
%	O
)	O
receiving	O
multiple	O
cycles	O
","	O
including	O
seven	O
(	O
6	O
Arm	O
A	O
","	O
1	O
Arm	O
B	O
;	O
12	O
%	O
)	O
given	O
3月9日	O
cycles	O
.	O
	
Two	O
patients	O
in	O
Arm	O
A	O
had	O
partial	O
responses	O
by	O
RECIST	O
criteria	O
.	O
	
Kaplan-Meier	O
overall	O
survival	O
(	O
OS	O
)	O
appeared	O
improved	O
in	O
Arm	O
A	O
versus	O
B	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
0.55	O
","	O
95	O
%	O
CI	O
:	O
0.29-0.86	O
;	O
P=0.017	O
","	O
log-rank	O
)	O
and	O
the	O
median	O
OS	O
for	O
Arm	O
A	O
versus	O
Arm	O
B	O
increased	O
to	O
7.9	O
versus	O
3.4	O
months	O
with	O
multiple	O
cycles	O
(	O
HR	O
0.32	O
","	O
P=0.004	O
)	O
","	O
including	O
three	O
patients	O
in	O
Arm	O
A	O
surviving	O
&	O
gt	O
;	O
1	O
year	O
.	O
	
Clinical	O
studies	O
of	O
(	B-DRUG
90	I-DRUG
)	I-DRUG
Y-clivatuzumab	I-DRUG
tetraxetan	I-DRUG
combined	O
with	O
low-dose	O
gemcitabine	B-DRUG
appear	O
feasible	O
in	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
patients	O
beyond	O
2nd	O
line	O
and	O
a	O
Phase	O
III	O
trial	O
of	O
this	O
combination	O
is	O
now	O
underway	O
in	O
this	O
setting	O
.	O
	
A	O
Phase	O
I	O
Trial	O
of	O
Combined	O
Ridaforolimus	B-DRUG
and	O
MK-2206	B-DRUG
in	O
Patients	O
with	O
Advanced	B-CANCER
Malignancies	I-CANCER
.	O
	
	
The	O
PI3K	O
/	O
Akt	O
/	O
mTOR	O
signaling	O
pathway	O
is	O
aberrantly	O
activated	O
in	O
many	O
cancers	O
.	O
	
Combining	O
ridaforolimus	B-DRUG
","	O
an	O
mTOR	O
inhibitor	O
","	O
with	O
MK-2206	B-DRUG
","	O
an	O
Akt	O
inhibitor	O
","	O
may	O
more	O
completely	O
block	O
the	O
PI3K	O
pathway	O
and	O
inhibit	O
tumor	O
growth	O
.	O
	
This	O
phase	O
I	O
study	O
assessed	O
dose-limiting	O
toxicities	O
(	O
DLT	O
)	O
and	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
for	O
the	O
combination	O
of	O
oral	O
ridaforolimus	B-DRUG
plus	O
oral	O
MK-2206	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Efficacy	O
was	O
evaluated	O
in	O
patients	O
with	O
biomarker-identified	O
estrogen	O
receptor-positive	O
breast	B-CANCER
cancer	I-CANCER
(	O
low	O
RAS	O
gene	O
signature	O
and	O
high	O
Ki67	O
index	O
)	O
or	O
castration-resistant	O
prostate	B-CANCER
cancer	I-CANCER
(	O
PTEN	O
deficiency	O
)	O
with	O
PI3K	O
pathway	O
addiction	O
.	O
	
Thirty-five	O
patients	O
were	O
enrolled	O
:	O
11	O
patients	O
in	O
part	O
A	O
(	O
three	O
breast	B-CANCER
cancer	I-CANCER
)	O
and	O
24	O
biomarker-eligible	O
patients	O
in	O
part	O
B	O
(	O
16	O
breast	B-CANCER
cancer	I-CANCER
","	O
eight	O
prostate	B-CANCER
cancer	I-CANCER
)	O
.	O
	
One	O
patient	O
with	O
breast	B-CANCER
cancer	I-CANCER
from	O
part	O
A	O
was	O
also	O
found	O
to	O
be	O
biomarker-eligible	O
when	O
tested	O
after	O
she	O
had	O
clinical	O
response	O
.	O
	
The	O
MTD	O
was	O
10	O
mg	O
/	O
d	O
ridaforolimus	B-DRUG
5	O
d	O
/	O
wk	O
=+	O
90	O
mg	O
/	O
wk	O
MK-2206	B-DRUG
;	O
1	O
of	O
17	O
patients	O
experienced	O
DLT	O
(	O
grade	O
3	O
rash	B-TOXI
)	O
at	O
this	O
dose	O
.	O
	
The	O
most	O
common	O
adverse	O
events	O
at	O
MTD	O
were	O
rash	B-TOXI
(	O
44.4	O
%	O
)	O
","	O
stomatitis	B-TOXI
(	O
38.9	O
%	O
)	O
","	O
diarrhea	B-TOXI
(	O
27.8	O
%	O
)	O
","	O
and	O
decreased	B-TOXI
appetite	I-TOXI
(	O
27.8	O
%	O
)	O
.	O
	
By	O
investigator	O
assessment	O
","	O
2	O
of	O
16	O
(	O
12.5	O
%	O
)	O
evaluable	O
patients	O
with	O
breast	B-CANCER
cancer	I-CANCER
had	O
partial	O
response	O
;	O
by	O
central	O
assessment	O
","	O
2	O
of	O
14	O
(	O
14.3	O
%	O
)	O
evaluable	O
patients	O
had	O
complete	O
response	O
.	O
	
Two	O
patients	O
had	O
durable	O
stable	O
disease	O
(	O
SD	O
)	O
for	O
416	O
and	O
285	O
days	O
","	O
respectively	O
.	O
	
No	O
patients	O
with	O
prostate	B-CANCER
cancer	I-CANCER
responded	O
;	O
one	O
patient	O
had	O
SD	O
for	O
_	O
6	O
months	O
.	O
	
Combination	O
ridaforolimus	B-DRUG
and	O
MK-2206	B-DRUG
showed	O
promising	O
activity	O
and	O
good	O
tolerability	O
in	O
heavily	O
pretreated	O
patients	O
with	O
hormone-positive	O
and	O
#NAME?	O
breast	B-CANCER
cancer	I-CANCER
exhibiting	O
PI3K	O
pathway	O
dependence	O
.	O
	
Results	O
of	O
a	O
phase	O
1	O
trial	O
combining	O
ridaforolimus	B-DRUG
and	O
MK-0752	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
	
The	O
phosphatidylinositol	O
3-kinase	O
/	O
protein	O
kinase-B	O
/	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
PI3K-AKT-mTOR	O
)	O
signalling	O
pathway	O
is	O
aberrantly	O
activated	O
in	O
several	O
cancers	O
.	O
	
Notch	O
signalling	O
maintains	O
cell	O
proliferation	O
","	O
growth	O
and	O
metabolism	O
in	O
part	O
by	O
driving	O
the	O
PI3K	O
pathway	O
.	O
	
Combining	O
the	O
mTOR	O
inhibitor	O
ridaforolimus	B-DRUG
with	O
the	O
Notch	O
inhibitor	O
MK-0752	B-DRUG
may	O
increase	O
blockade	O
of	O
the	O
PI3K	O
pathway	O
.	O
	
This	O
phase	O
I	O
dose-escalation	O
study	O
(	O
NCT01295632	O
)	O
aimed	O
to	O
define	O
the	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
and	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
combination	O
oral	O
ridaforolimus	B-DRUG
(	O
rising	O
doses	O
starting	O
at	O
20	O
mg	O
","	O
5	O
days	O
/	O
week	O
)	O
and	O
oral	O
MK-0752	B-DRUG
(	O
1800	O
mg	O
once	O
weekly	O
)	O
in	O
patients	O
with	O
solid	B-CANCER
tumours	I-CANCER
.	O
	
No	O
intrapatient	O
dose	O
escalation	O
was	O
permitted	O
.	O
	
Twenty	O
eight	O
patients	O
were	O
treated	O
on	O
study	O
.	O
	
Ridaforolimus	B-DRUG
doses	O
were	O
escalated	O
from	O
20	O
to	O
30	O
mg	O
/	O
day	O
.	O
	
Among	O
14	O
evaluable	O
patients	O
receiving	O
ridaforolimus	B-DRUG
20	O
mg	O
","	O
one	O
DLT	O
(	O
grade	O
2	O
stomatitis	B-TOXI
","	O
second	O
episode	O
)	O
was	O
reported	O
.	O
	
Among	O
eight	O
evaluable	O
patients	O
receiving	O
ridaforolimus	B-DRUG
30	O
mg	O
","	O
three	O
DLTs	O
were	O
reported	O
(	O
one	O
each	O
grade	O
3	O
stomatitis	B-TOXI
","	O
grade	O
3	O
diarrhoea	B-TOXI
","	O
and	O
grade	O
3	O
asthenia	B-TOXI
)	O
.	O
	
The	O
MTD	O
was	O
20	O
mg	O
daily	O
ridaforolimus	B-DRUG
5	O
days	O
/	O
week+1800	O
mg	O
weekly	O
MK-0752	B-DRUG
.	O
	
The	O
most	O
common	O
drug-related	O
adverse	O
events	O
included	O
stomatitis	B-TOXI
","	O
diarrhoea	B-TOXI
","	O
decreased	B-TOXI
appetite	I-TOXI
","	O
hyperglycaemia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
asthenia	B-TOXI
and	O
rash	B-TOXI
.	O
	
Two	O
of	O
15	O
(	O
13	O
%	O
)	O
patients	O
with	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
(	O
HNSCC	B-CANCER
)	O
had	O
responses	O
:	O
one	O
with	O
complete	O
response	O
and	O
one	O
with	O
partial	O
response	O
.	O
	
In	O
addition	O
","	O
one	O
patient	O
experienced	O
stable	O
disease	O
猢6	O
months	O
.	O
	
Combined	O
ridaforolimus	B-DRUG
and	O
MK-0752	B-DRUG
showed	O
activity	O
in	O
HNSCC	B-CANCER
.	O
	
However	O
","	O
a	O
high	O
number	O
of	O
adverse	O
events	O
were	O
reported	O
at	O
the	O
MTD	O
","	O
which	O
would	O
require	O
careful	O
management	O
during	O
future	O
clinical	O
development	O
.	O
	
A	O
phase	O
1	O
study	O
of	O
intermittently	O
administered	O
pazopanib	B-DRUG
in	O
combination	O
with	O
continuous	O
daily	O
dosing	O
of	O
lapatinib	B-DRUG
in	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
Preclinically	O
","	O
pazopanib	B-DRUG
/	O
lapatinib	B-DRUG
combination	O
acted	O
synergistically	O
to	O
suppress	O
the	O
activity	O
of	O
multiple	O
tyrosine	O
kinases	O
","	O
including	O
VEGFR-1	O
","	O
2	O
","	O
3	O
","	O
PDGFR	O
and	O
c-kit	O
(	O
pazopanib	B-DRUG
)	O
","	O
HER1	O
/	O
EGFR	O
and	O
HER2	O
(	O
lapatinib	B-DRUG
)	O
","	O
and	O
several	O
other	O
tyrosine	O
kinases	O
including	O
c-Met	O
through	O
","	O
plausibly	O
","	O
network	O
inhibition	O
effects	O
.	O
	
Clinically	O
","	O
continuous	O
dosing	O
of	O
pazopanib	B-DRUG
/	O
lapatinib	B-DRUG
combination	O
was	O
associated	O
with	O
a	O
higher	O
response	O
rate	O
than	O
with	O
lapatinib	B-DRUG
monotherapy	O
","	O
with	O
poor	O
tolerance	O
.	O
	
We	O
explored	O
multiple	O
intermittent	O
dose	O
levels	O
of	O
pazopanib	B-DRUG
combined	O
with	O
continuous	O
daily	O
dosing	O
of	O
lapatinib	B-DRUG
in	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
The	O
present	O
study	O
used	O
a	O
phase	O
1	O
","	O
modified	O
3	O
=+	O
3	O
","	O
dose-escalation	O
design	O
to	O
evaluate	O
the	O
safety	O
and	O
tolerability	O
of	O
the	O
combination	O
of	O
orally	O
received	O
pazopanib	B-DRUG
once	O
every	O
other	O
day	O
with	O
continuous	O
daily	O
dosing	O
of	O
lapatinib	B-DRUG
for	O
28	O
days	O
.	O
	
In	O
the	O
expansion	O
phase	O
","	O
tumor	O
response	O
was	O
evaluated	O
in	O
patients	O
with	O
specific	O
genetic	O
alterations	O
(	O
HER2	O
amplification	O
","	O
HER2	O
mutation	O
","	O
c-Met	O
amplification	O
","	O
c-Met	O
mutation	O
","	O
and	O
EGFR	O
mutation	O
)	O
.	O
	
Twenty-four	O
patients	O
were	O
treated	O
.	O
	
The	O
most	O
common	O
drug-related	O
adverse	O
events	O
were	O
fatigue	B-TOXI
7	O
/	O
24	O
(	O
29	O
%	O
)	O
","	O
skin	B-TOXI
rash	I-TOXI
5	O
/	O
21	O
(	O
21	O
%	O
)	O
","	O
and	O
diarrhea	B-TOXI
3	O
/	O
24	O
(	O
17	O
%	O
)	O
","	O
with	O
4	O
/	O
24	O
(	O
16	O
%	O
)	O
patients	O
experiencing	O
grade	O
_3	O
drug-related	O
adverse	O
events	O
.	O
	
Escalation	O
to	O
the	O
FDA-approved	O
dose	O
(	O
800	O
mg	O
daily	O
for	O
pazopanib	B-DRUG
and	O
1500	O
mg	O
every	O
day	O
for	O
lapatinib	B-DRUG
)	O
was	O
not	O
feasible	O
due	O
to	O
toxicities	O
.	O
	
Pazopanib	B-DRUG
200	O
mg	O
every	O
other	O
day	O
=+	O
lapatinib	B-DRUG
500	O
mg	O
daily	O
was	O
considered	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
.	O
	
No	O
tumor	O
response	O
was	O
observed	O
","	O
including	O
in	O
patients	O
with	O
the	O
specific	O
molecular	O
genetic	O
alterations	O
tested	O
.	O
	
Every	O
other	O
day	O
dosing	O
of	O
pazopanib	B-DRUG
combined	O
with	O
daily	O
lapatinib	B-DRUG
was	O
tolerated	O
at	O
the	O
established	O
MTD	O
","	O
but	O
no	O
complete	O
or	O
partial	O
tumor	O
responses	O
were	O
observed	O
at	O
these	O
dose	O
levels	O
.	O
	
Phase	O
I	O
and	O
pharmacokinetic	O
study	O
of	O
erlotinib	B-DRUG
administered	O
in	O
combination	O
with	O
amrubicin	B-DRUG
in	O
patients	O
with	O
previously	O
treated	O
","	O
advanced	B-CANCER
non-small	I-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
We	O
conducted	O
a	O
phase	O
I	O
trial	O
of	O
erlotinib	B-DRUG
","	O
an	O
epidermal	O
growth	O
factor	O
receptor	O
tyrosine	O
kinase	O
inhibitor	O
","	O
combined	O
with	O
amrubicin	B-DRUG
","	O
a	O
topoisomerase	O
II	O
inhibitor	O
.	O
	
The	O
aim	O
was	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
","	O
the	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
","	O
and	O
the	O
pharmacokinetics	O
of	O
this	O
combination	O
in	O
patients	O
with	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
who	O
had	O
received	O
previous	O
chemotherapy	O
.	O
	
A	O
total	O
of	O
9	O
patients	O
with	O
stage	O
IV	O
disease	O
were	O
treated	O
at	O
3-week	O
intervals	O
with	O
erlotinib	B-DRUG
once	O
daily	O
on	O
days	O
1	O
through	O
21	O
plus	O
a	O
5-minute	O
intravenous	O
injection	O
of	O
amrubicin	B-DRUG
on	O
days	O
1	O
through	O
3	O
The	O
dose	O
levels	O
evaluated	O
were	O
erlotinib	B-DRUG
(	O
mg	O
/	O
body	O
)	O
/	O
amrubicin	B-DRUG
(	O
mg	O
/	O
m	O
)	O
:	O
100	O
/	O
30	O
(	O
n=3	O
)	O
","	O
100	O
/	O
35	O
(	O
n=3	O
)	O
","	O
and	O
150	O
/	O
30	O
(	O
n=3	O
)	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
of	O
erlotinib	B-DRUG
and	O
amrubicin	B-DRUG
was	O
100	O
mg	O
/	O
body	O
and	O
35	O
mg	O
/	O
m	O
because	O
2	O
of	O
the	O
3	O
patients	O
experienced	O
DLTs	O
during	O
the	O
first	O
cycle	O
of	O
treatment	O
at	O
the	O
third	O
dose	O
level	O
of	O
150	O
mg	O
/	O
body	O
and	O
30	O
mg	O
/	O
m.	O
Cessation	O
of	O
erlotinib	B-DRUG
administration	O
for	O
8	O
days	O
because	O
of	O
grade	O
3	O
leukopenia	B-TOXI
and	O
grade	O
3	O
skin	B-TOXI
infection	I-TOXI
(	O
erysipelas	B-TOXI
)	O
were	O
the	O
DLTs	O
.	O
	
No	O
drug-drug	O
interactions	O
between	O
erlotinib	B-DRUG
and	O
amrubicin	B-DRUG
were	O
observed	O
in	O
this	O
study	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
33	O
%	O
","	O
including	O
3	O
partial	O
responses	O
","	O
in	O
the	O
9	O
patients	O
.	O
	
The	O
median	O
progression-free	O
survival	O
for	O
all	O
patients	O
was	O
quite	O
long	O
","	O
11.3	O
months	O
","	O
and	O
the	O
median	O
overall	O
survival	O
has	O
not	O
yet	O
been	O
reached	O
.	O
	
Combined	O
erlotinib	B-DRUG
plus	O
amrubicin	B-DRUG
therapy	O
seems	O
to	O
be	O
highly	O
effective	O
","	O
with	O
acceptable	O
toxicity	O
","	O
against	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
The	O
recommended	O
dose	O
for	O
phase	O
II	O
studies	O
was	O
erlotinib	B-DRUG
100	O
mg	O
once	O
daily	O
on	O
days	O
1	O
through	O
21	O
","	O
and	O
amrubicin	B-DRUG
35	O
mg	O
/	O
m	O
on	O
days	O
1	O
through	O
3	O
administered	O
every	O
21	O
days	O
.	O
	
A	O
Phase	O
1c	O
Trial	O
Comparing	O
the	O
Efficacy	O
and	O
Safety	O
of	O
a	O
New	O
Aqueous	O
Formulation	O
of	O
Alphaxalone	B-DRUG
with	O
Propofol	B-DRUG
.	O
	
	
Phaxan_	B-DRUG
(	O
PHAX	O
","	O
Chemic	O
Labs	O
","	O
Canton	O
","	O
MA	O
)	O
is	O
an	O
aqueous	O
solution	O
of	O
10	O
mg	O
/	O
mL	O
alphaxalone	B-DRUG
and	O
13	O
%	O
7-sulfobutylether	B-DRUG
尾-cyclodextrin	I-DRUG
(	O
betadex	B-DRUG
)	O
.	O
	
In	O
preclinical	O
studies	O
","	O
PHAX	B-DRUG
is	O
a	O
fast	O
onset-offset	O
IV	O
anesthetic	O
like	O
propofol	B-DRUG
","	O
but	O
causes	O
less	O
cardiovascular	B-TOXI
depression	I-TOXI
.	O
	
This	O
first-in-man	O
study	O
was	O
designed	O
to	O
find	O
the	O
anesthetic	O
dose	O
of	O
PHAX	B-DRUG
and	O
to	O
compare	O
it	O
with	O
an	O
equivalent	O
dose	O
of	O
propofol	B-DRUG
for	O
safety	O
","	O
efficacy	O
","	O
and	O
quality	O
of	O
recovery	O
from	O
anesthesia	O
and	O
sedation	O
.	O
	
The	O
study	O
adhered	O
to	O
compliance	O
with	O
Good	O
Clinical	O
Practices	O
regulations	O
(	O
clinical	O
trials	O
registry	O
number	O
","	O
ACTRN12611000343909	O
)	O
.	O
	
This	O
randomized	O
","	O
double-blind	O
study	O
compared	O
PHAX	B-DRUG
and	O
propofol	B-DRUG
using	O
a	O
Bayesian	O
algorithm	O
to	O
determine	O
dose	O
equivalence	O
for	O
effects	O
on	O
the	O
bispectral	O
index	O
(	O
BIS	O
)	O
.	O
	
Male	O
volunteers	O
","	O
ASA	O
physical	O
status	O
I	O
","	O
gave	O
written	O
informed	O
consent	O
(	O
n	O
=	O
12	O
per	O
group	O
;	O
PHAX	B-DRUG
or	O
propofol	B-DRUG
)	O
.	O
	
Parameters	O
assessed	O
for	O
80	O
minutes	O
after	O
drug	O
injection	O
(	O
single	O
bolus	O
dose	O
)	O
were	O
pain	O
on	O
injection	O
","	O
involuntary	O
movement	O
","	O
BIS	O
","	O
blood	O
pressure	O
","	O
need	O
for	O
airway	O
support	O
","	O
and	O
","	O
as	O
measures	O
of	O
recovery	O
from	O
sedation	O
","	O
the	O
Richmond	O
Agitation	O
and	O
Sedation	O
Scale	O
and	O
the	O
Digit	O
Symbol	O
Substitution	O
Test	O
.	O
	
Arterial	O
blood	O
was	O
withdrawn	O
for	O
biochemistry	O
","	O
hematology	O
","	O
and	O
complement	O
levels	O
.	O
	
No	O
subject	O
complained	O
of	O
pain	B-TOXI
on	O
injection	O
with	O
PHAX	B-DRUG
","	O
whereas	O
8	O
of	O
the	O
12	O
subjects	O
given	O
propofol	B-DRUG
did	O
.	O
	
Nine	O
PHAX	B-DRUG
and	O
8	O
propofol	B-DRUG
subjects	O
reached	O
BIS	O
values	O
of	O
_50	O
:	O
median	O
(	O
interquartile	O
range	O
[	O
IQR	O
]	O
)	O
mg	O
/	O
kg	O
dose	O
=	O
0.5	O
(	O
0.5-0.6	O
)	O
for	O
PHAX	B-DRUG
and	O
2.9	O
(	O
2.4-3.0	O
)	O
for	O
propofol	B-DRUG
.	O
	
The	O
lowest	O
median	O
BIS	O
reached	O
was	O
27	O
to	O
28	O
for	O
both	O
agents	O
with	O
no	O
significant	O
differences	O
between	O
them	O
for	O
timing	O
of	O
onset	O
and	O
recovery	O
of	O
BIS	O
.	O
	
The	O
concomitant	O
median	O
changes	O
in	O
systolic	O
and	O
diastolic	O
blood	O
pressures	O
were	O
-11	O
%	O
vs	O
-19	O
%	O
for	O
systolic	O
and	O
-25	O
%	O
vs	O
-37	O
%	O
for	O
diastolic	O
in	O
PHAX-	B-DRUG
and	O
propofol-treated	B-DRUG
subjects	O
","	O
respectively	O
.	O
	
Nine	O
of	O
the	O
12	O
propofol-treated	B-DRUG
subjects	O
and	O
none	O
of	O
12	O
PHAX-treated	B-DRUG
subjects	O
required	O
airway	O
support	O
.	O
	
For	O
subjects	O
reaching	O
an	O
equivalent	O
BIS	O
of	O
_50	O
:	O
a	O
Richmond	O
Agitation	O
and	O
Sedation	O
Scale	O
score	O
of	O
0	O
was	O
reached	O
at	O
a	O
median	O
of	O
5	O
(	O
IQR	O
","	O
5月10日	O
)	O
and	O
15	O
(	O
IQR	O
","	O
10月20日	O
)	O
minutes	O
after	O
PHAX	B-DRUG
and	O
propofol	B-DRUG
","	O
respectively	O
;	O
BIS	O
returned	O
to	O
90	O
at	O
a	O
mean	O
of	O
21	O
(	O
SD	O
","	O
10.1	O
)	O
and	O
21	O
(	O
SD	O
","	O
9.2	O
)	O
minutes	O
after	O
PHAX	B-DRUG
and	O
propofol	B-DRUG
","	O
respectively	O
;	O
and	O
Digit	O
Symbol	O
Substitution	O
Test	O
scores	O
returned	O
to	O
predrug	O
injection	O
values	O
at	O
median	O
of	O
50	O
(	O
IQR	O
","	O
35-72.5	O
)	O
and	O
42.5	O
(	O
IQR	O
","	O
35-76.3	O
)	O
minutes	O
after	O
PHAX	B-DRUG
and	O
propofol	B-DRUG
","	O
respectively	O
.	O
	
There	O
was	O
no	O
increase	O
in	O
C3	O
and	O
C4	O
complement	O
fractions	O
after	O
either	O
drug	O
.	O
	
PHAX	B-DRUG
causes	O
fast-onset	O
","	O
short-duration	O
anesthesia	O
with	O
fast	O
cognitive	O
recovery	O
similar	O
to	O
propofol	B-DRUG
","	O
but	O
with	O
less	O
cardiovascular	B-TOXI
depression	I-TOXI
","	O
or	O
airway	B-TOXI
obstruction	I-TOXI
and	O
no	O
pain	O
on	O
injection	O
.	O
	
Phase	O
I	O
dose-finding	O
and	O
pharmacokinetic	O
study	O
of	O
docetaxel	B-DRUG
and	O
gefitinib	B-DRUG
in	O
patients	O
with	O
advanced	O
or	O
metastatic	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
evaluation	O
of	O
drug-drug	O
interaction	O
.	O
	
	
Docetaxel	B-DRUG
and	O
gefitinib	B-DRUG
play	O
key	O
roles	O
in	O
the	O
treatment	O
of	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
","	O
and	O
their	O
combination	O
could	O
be	O
of	O
interest	O
.	O
	
Both	O
drugs	O
are	O
mainly	O
metabolized	O
by	O
CYP3A4	O
","	O
and	O
drug-drug	O
interactions	O
are	O
a	O
major	O
concern	O
.	O
	
This	O
phase	O
I	O
dose-finding	O
study	O
was	O
designed	O
to	O
assess	O
the	O
tolerability	O
and	O
drug-drug	O
interactions	O
in	O
this	O
combination	O
using	O
full	O
pharmacokinetic	O
(	O
PK	O
)	O
samplings	O
.	O
	
Docetaxel	B-DRUG
was	O
intravenously	O
administered	O
on	O
days	O
1	O
and	O
22	O
at	O
a	O
dose	O
of	O
45	O
or	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Gefitinib	B-DRUG
(	O
250	O
mg	O
/	O
day	O
)	O
was	O
orally	O
administrated	O
starting	O
on	O
day	O
2	O
Ten	O
PK	O
samplings	O
of	O
docetaxel	B-DRUG
were	O
performed	O
on	O
days	O
1	O
and	O
22	O
.	O
	
Seven	O
PK	O
samplings	O
of	O
gefitinib	B-DRUG
were	O
performed	O
on	O
day	O
18	O
卤	O
3	O
and	O
on	O
day	O
22	O
.	O
	
Twelve	O
patients	O
with	O
advanced	O
or	O
metastatic	B-CANCER
NSCLC	I-CANCER
were	O
enrolled	O
without	O
considering	O
EGFR	O
mutation	O
status	O
.	O
	
The	O
major	O
toxicity	O
was	O
neutropenia	B-TOXI
.	O
	
Two	O
patients	O
withdrew	O
from	O
this	O
study	O
due	O
to	O
dose-limiting	O
toxicities	O
;	O
however	O
","	O
the	O
toxicity	O
profiles	O
in	O
this	O
combination	O
were	O
generally	O
acceptable	O
.	O
	
The	O
docetaxel	B-DRUG
AUC0-24	O
and	O
C	O
max	O
did	O
not	O
differ	O
whether	O
administered	O
alone	O
or	O
with	O
gefitinib	B-DRUG
","	O
and	O
the	O
geometric	O
mean	O
ratios	O
(	O
GMRs	O
)	O
of	O
AUC0-24	O
and	O
C	O
max	O
(	O
co-administrated	O
/	O
administrated	O
alone	O
)	O
were	O
0.95	O
(	O
90	O
%	O
CI	O
0.85-1.06	O
)	O
and	O
0.95	O
(	O
90	O
%	O
CI	O
0.85-1.05	O
)	O
","	O
respectively	O
.	O
	
Furthermore	O
","	O
the	O
GMRs	O
of	O
the	O
steady	O
state	O
gefitinib	B-DRUG
AUC0-24	O
and	O
C	O
max	O
were	O
0.93	O
(	O
90	O
%	O
CI	O
0.84-1.03	O
)	O
and	O
0.98	O
(	O
90	O
%	O
CI	O
0.88-1.09	O
)	O
","	O
respectively	O
.	O
	
The	O
tolerability	O
of	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
docetaxel	B-DRUG
with	O
250	O
mg	O
/	O
day	O
gefitinib	B-DRUG
was	O
confirmed	O
","	O
and	O
we	O
observed	O
no	O
drug-drug	O
interaction	O
in	O
this	O
combination	O
.	O
	
Phase	O
I	O
trial	O
of	O
afatinib	B-DRUG
plus	O
vinorelbine	B-DRUG
in	O
Japanese	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
","	O
including	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
	
This	O
phase	O
I	O
trial	O
assessed	O
afatinib	B-DRUG
","	O
an	O
irreversible	O
ErbB	O
family	O
blocker	O
","	O
plus	O
vinorelbine	B-DRUG
in	O
Japanese	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
not	O
amenable	O
to	O
standard	O
treatment	O
.	O
	
Primary	O
objectives	O
were	O
evaluation	O
of	O
safety	O
and	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
once-daily	O
(	O
QD	O
)	O
afatinib	B-DRUG
plus	O
weekly	O
intravenous	O
vinorelbine	B-DRUG
.	O
	
Secondary	O
objectives	O
included	O
pharmacokinetic	O
assessments	O
and	O
preliminary	O
efficacy	O
.	O
	
Dose	O
finding	O
utilized	O
a	O
3	O
=+	O
3	O
design	O
","	O
with	O
a	O
starting	O
dose	O
of	O
afatinib	B-DRUG
20	O
mg	O
QD	O
plus	O
vinorelbine	B-DRUG
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
.	O
	
Seventeen	O
patients	O
were	O
enrolled	O
.	O
	
Dose	O
level	O
2	O
(	O
afatinib	B-DRUG
40	O
mg	O
and	O
vinorelbine	B-DRUG
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
exceeded	O
the	O
MTD	O
;	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
were	O
considered	O
vinorelbine-related	B-DRUG
.	O
	
Dose	O
finding	O
continued	O
with	O
modified	O
dose	O
levels	O
;	O
dose	O
level	O
2a	O
:	O
afatinib	B-DRUG
40	O
mg	O
and	O
a	O
reduced	O
dose	O
of	O
vinorelbine	B-DRUG
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
dose	O
level	O
3	O
:	O
afatinib	B-DRUG
40	O
mg	O
and	O
vinorelbine	B-DRUG
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
allowing	O
omission	O
of	O
vinorelbine	B-DRUG
for	O
grade	O
_2	O
neutropenia	B-TOXI
/	O
thrombocytopenia	B-TOXI
and	O
afatinib	B-DRUG
dose	O
modification	O
for	O
adverse	O
events	O
(	O
AEs	O
)	O
.	O
	
At	O
dose	O
level	O
3	O
","	O
1	O
/	O
6	O
patients	O
had	O
a	O
DLT	O
(	O
upper	B-TOXI
abdominal	I-TOXI
pain	I-TOXI
requiring	O
afatinib	B-DRUG
dose	O
reduction	O
)	O
.	O
	
Overall	O
","	O
the	O
most	O
frequent	O
treatment-related	O
AEs	O
(	O
any	O
/	O
grade	O
3	O
and	O
4	O
)	O
were	O
:	O
neutropenia	B-TOXI
(	O
100	O
/	O
71	O
%	O
)	O
","	O
leukopenia	B-TOXI
(	O
100	O
/	O
59	O
%	O
)	O
","	O
diarrhea	B-TOXI
(	O
94	O
/	O
0	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
71	O
/	O
12	O
%	O
)	O
and	O
stomatitis	B-TOXI
(	O
65	O
/	O
0	O
%	O
)	O
.	O
	
Two	O
patients	O
with	O
breast	B-CANCER
cancer	I-CANCER
achieved	O
a	O
partial	O
response	O
;	O
eight	O
patients	O
(	O
various	O
cancer	O
indications	O
)	O
had	O
stable	O
disease	O
.	O
	
Pharmacokinetic	O
analyses	O
suggested	O
no	O
relevant	O
drug-drug	O
interactions	O
.	O
	
Afatinib	B-DRUG
40	O
mg	O
QD	O
plus	O
vinorelbine	B-DRUG
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
weekly	O
was	O
tolerated	O
in	O
Japanese	O
patients	O
when	O
dose	O
modifications	O
for	O
known	O
AEs	O
for	O
either	O
compound	O
were	O
allowed	O
.	O
	
Tumor	O
shrinkage	O
was	O
also	O
observed	O
.	O
	
This	O
dose	O
schedule	O
was	O
recommended	O
for	O
phase	O
II	O
/	O
III	O
trials	O
in	O
Japanese	O
patients	O
.	O
	
A	O
phase	O
I	O
/	O
Ib	O
study	O
of	O
trametinib	B-DRUG
(	O
GSK1120212	O
)	O
alone	O
and	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
Japanese	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Trametinib	B-DRUG
is	O
an	O
inhibitor	O
of	O
MEK1	O
/	O
MEK2	O
activation	O
and	O
kinase	O
activity	O
.	O
	
In	O
order	O
to	O
evaluate	O
the	O
safety	O
","	O
tolerability	O
","	O
pharmacokinetics	O
","	O
and	O
preliminary	O
efficacy	O
of	O
single-agent	O
trametinib	B-DRUG
(	O
part	O
1	O
)	O
and	O
trametinib	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
(	O
part	O
2	O
)	O
","	O
we	O
undertook	O
the	O
first	O
clinical	O
study	O
of	O
this	O
combination	O
in	O
Japanese	O
patients	O
with	O
cancer	O
and	O
herein	O
report	O
our	O
results	O
.	O
	
In	O
part	O
1	O
","	O
13	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
enrolled	O
into	O
3	O
dose	O
cohorts	O
","	O
receiving	O
trametinib	B-DRUG
once	O
daily	O
at	O
a	O
dose	O
of	O
1	O
","	O
2	O
","	O
or	O
3	O
mg	O
.	O
	
In	O
part	O
2	O
","	O
5	O
patients	O
with	O
pancreatic	B-CANCER
cancer	I-CANCER
received	O
trametinib	B-DRUG
(	O
2	O
mg	O
once	O
daily	O
)	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
(	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O
	
In	O
part	O
1	O
","	O
a	O
dose-limiting	O
toxicity	O
was	O
observed	O
in	O
a	O
patient	O
in	O
the	O
2.0-mg	O
dose	O
cohort	O
","	O
but	O
the	O
maximum	O
tolerated	O
dose	O
was	O
not	O
reached	O
at	O
doses	O
up	O
to	O
3	O
mg	O
daily	O
.	O
	
The	O
best	O
overall	O
response	O
was	O
a	O
PR	O
in	O
1	O
patient	O
","	O
and	O
6	O
patients	O
had	O
SD	O
.	O
	
In	O
part	O
2	O
","	O
the	O
combination	O
of	O
trametinib	B-DRUG
and	O
gemcitabine	B-DRUG
was	O
tolerated	O
for	O
a	O
short	O
period	O
of	O
time	O
.	O
	
However	O
","	O
serious	O
interstitial	O
lung	O
disease	O
(	O
ILD	O
)	O
was	O
observed	O
in	O
3	O
of	O
5	O
patients	O
4	O
weeks	O
or	O
more	O
after	O
the	O
start	O
of	O
the	O
treatment	O
","	O
including	O
1	O
fatal	O
case	O
.	O
	
Three	O
patients	O
achieved	O
a	O
PR	O
","	O
and	O
2	O
patients	O
had	O
SD	O
.	O
	
The	O
most	O
common	O
adverse	O
event	O
was	O
rash	B-TOXI
(	O
85	O
%	O
in	O
part	O
1	O
and	O
100	O
%	O
in	O
part	O
2	O
)	O
.	O
	
Trametinib	B-DRUG
monotherapy	O
was	O
tolerable	O
in	O
Japanese	O
patients	O
with	O
cancer	O
.	O
	
However	O
","	O
the	O
combination	O
of	O
trametinib	B-DRUG
plus	O
gemcitabine	B-DRUG
carried	O
a	O
higher	O
risk	O
as	O
compared	O
with	O
monotherapy	O
","	O
during	O
which	O
no	O
ILD	O
was	O
observed	O
.	O
	
(	O
ClinicalTrials.gov	O
number	O
","	O
NCT01324258.	O
)	O
.	O
	
A	O
Phase	O
1	O
","	O
Dose-escalation	O
","	O
Double-blind	O
","	O
Block-randomized	O
","	O
Controlled	O
Trial	O
of	O
Safety	O
and	O
Efficacy	O
of	O
Neosaxitoxin	B-DRUG
Alone	O
and	O
in	O
Combination	O
with	O
0.2	O
%	O
Bupivacaine	B-DRUG
","	O
with	O
and	O
without	O
Epinephrine	B-DRUG
","	O
for	O
Cutaneous	O
Anesthesia	O
.	O
	
	
Neosaxitoxin	B-DRUG
(	O
NeoSTX	B-DRUG
)	O
is	O
a	O
site-1	O
sodium	O
channel	O
blocker	O
that	O
produces	O
prolonged	O
local	O
anesthesia	O
in	O
animals	O
and	O
humans	O
.	O
	
Under	O
a	O
Food	O
and	O
Drug	O
Administration-approved	O
phase	O
1	O
Investigational	O
New	O
Drug	O
trial	O
","	O
the	O
authors	O
evaluated	O
safety	O
and	O
efficacy	O
of	O
NeoSTX	B-DRUG
alone	O
and	O
combined	O
with	O
0.2	O
%	O
bupivacaine	B-DRUG
(	O
Bup	B-DRUG
)	O
with	O
and	O
without	O
epinephrine	B-DRUG
.	O
	
The	O
authors	O
conducted	O
a	O
double-blind	O
","	O
randomized	O
","	O
controlled	O
trial	O
involving	O
healthy	O
male	O
volunteers	O
aged	O
18	O
to	O
35	O
yr	O
receiving	O
two	O
10-ml	O
subcutaneous	O
injections	O
.	O
	
Control	O
sites	O
received	O
Bup	O
.	O
	
In	O
part	O
1	O
","	O
active	O
sites	O
received	O
(	O
1	O
)	O
5	O
to	O
40	O
渭g	O
NeoSTX+Saline	B-DRUG
(	O
NeoSTX-Saline	B-DRUG
)	O
","	O
(	O
2	O
)	O
5	O
to	O
40	O
渭g	O
NeoSTX+Bup	B-DRUG
(	O
NeoSTX-Bup	B-DRUG
)	O
","	O
or	O
(	O
3	O
)	O
placebo	B-DRUG
(	O
Saline	B-DRUG
)	O
.	O
	
In	O
part	O
2	O
","	O
active	O
sites	O
received	O
10	O
or	O
30	O
渭g	O
NeoSTX+Bup+Epinephrine	B-DRUG
(	O
NeoSTX-Bup-Epi	B-DRUG
)	O
or	O
placebo	B-DRUG
.	O
	
Primary	O
outcome	O
measures	O
were	O
safety	O
and	O
adverse	O
events	O
associated	O
with	O
NeoSTX	B-DRUG
.	O
	
Secondary	O
outcomes	O
included	O
clinical	O
biochemistry	O
","	O
NeoSTX	B-DRUG
pharmacokinetics	O
","	O
and	O
cutaneous	O
hypoesthesia	O
.	O
	
A	O
total	O
of	O
84	O
subjects	O
were	O
randomized	O
and	O
completed	O
the	O
two-part	O
trial	O
with	O
no	O
serious	O
adverse	O
events	O
or	O
clinically	O
significant	O
physiologic	O
impairments	O
.	O
	
Perioral	O
numbness	O
and	O
tingling	O
increased	O
with	O
NeoSTX	B-DRUG
dose	O
for	O
NeoSTX-Saline	B-DRUG
and	O
NeoSTX-Bup	B-DRUG
.	O
	
All	O
symptoms	O
resolved	O
without	O
intervention	O
.	O
	
NeoSTX-Bup-Epi	B-DRUG
dramatically	O
reduced	O
symptoms	O
compared	O
with	O
other	O
NeoSTX	B-DRUG
combinations	O
(	O
tingling	O
:	O
0	O
vs.	O
70	O
%	O
","	O
P	O
=	O
0.004	O
;	O
numbness	O
:	O
0	O
vs.	O
60	O
%	O
","	O
P	O
=	O
0.013	O
)	O
at	O
the	O
same	O
dose	O
.	O
	
Mean	O
peak	O
plasma	O
NeoSTX	B-DRUG
concentration	O
for	O
NeoSTX-Bup-Epi	B-DRUG
was	O
reduced	O
at	O
least	O
two-fold	O
compared	O
with	O
NeoSTX-Saline	B-DRUG
and	O
NeoSTX-Bup	B-DRUG
(	O
67	O
卤	O
14	O
","	O
134	O
卤	O
63	O
","	O
and	O
164	O
卤	O
81	O
pg	O
/	O
ml	O
","	O
respectively	O
;	O
P	O
=	O
0.016	O
)	O
.	O
	
NeoSTX-Bup	B-DRUG
showed	O
prolonged	O
cutaneous	O
block	O
duration	O
compared	O
with	O
Bup	B-DRUG
","	O
NeoSTX-Saline	B-DRUG
","	O
or	O
placebo	B-DRUG
","	O
at	O
all	O
doses	O
.	O
	
Median	O
time	O
to	O
near-complete	O
recovery	O
for	O
10	O
渭g	O
NeoSTX-Bup-Epi	B-DRUG
was	O
almost	O
five-fold	O
longer	O
compared	O
with	O
Bup	B-DRUG
(	O
50	O
vs.	O
10	O
h	O
","	O
P	O
=	O
0.007	O
)	O
.	O
	
NeoSTX	B-DRUG
combinations	O
have	O
a	O
tolerable	O
side	O
effect	O
profile	O
and	O
appear	O
promising	O
for	O
prolonged	O
local	O
anesthesia	O
.	O
	
Randomized	O
","	O
Double-Blind	O
Phase	O
II	O
Trial	O
With	O
Prospective	O
Classification	O
by	O
ATM	O
Protein	O
Level	O
to	O
Evaluate	O
the	O
Efficacy	O
and	O
Tolerability	O
of	O
Olaparib	B-DRUG
Plus	O
Paclitaxel	B-DRUG
in	O
Patients	O
With	O
Recurrent	O
or	O
Metastatic	B-CANCER
Gastric	I-CANCER
Cancer	I-CANCER
.	O
	
	
Gastric	B-CANCER
cancer	I-CANCER
cell	O
lines	O
","	O
particularly	O
those	O
with	O
low	O
levels	O
of	O
ataxia	O
telangiectasia	O
mutated	O
(	O
ATM	O
)	O
","	O
a	O
key	O
activator	O
of	O
DNA	O
damage	O
response	O
","	O
are	O
sensitive	O
to	O
the	O
poly	O
(	O
ADP-ribose	O
)	O
polymerase	O
inhibitor	O
olaparib	B-DRUG
.	O
	
We	O
compared	O
the	O
efficacy	O
of	O
olaparib	B-DRUG
plus	O
paclitaxel	B-DRUG
(	O
olaparib	B-DRUG
/	O
paclitaxel	B-DRUG
)	O
with	O
paclitaxel	B-DRUG
alone	O
in	O
patients	O
with	O
recurrent	O
or	O
metastatic	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
and	O
assessed	O
whether	O
low	O
ATM	O
expression	O
is	O
predictive	O
of	O
improved	O
clinical	O
outcome	O
for	O
olaparib	B-DRUG
/	O
paclitaxel	B-DRUG
.	O
	
In	O
this	O
phase	O
II	O
","	O
double-blind	O
study	O
(	O
Study	O
39	O
;	O
NCT01063517	O
)	O
","	O
patients	O
were	O
randomly	O
assigned	O
to	O
oral	O
olaparib	B-DRUG
100	O
mg	O
twice	O
per	O
day	O
(	O
tablets	O
)	O
plus	O
paclitaxel	B-DRUG
(	O
80	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
day	O
intravenously	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
of	O
every	O
28-day	O
cycle	O
)	O
or	O
placebo	B-DRUG
plus	O
paclitaxel	B-DRUG
(	O
placebo	B-DRUG
/	O
paclitaxel	B-DRUG
)	O
","	O
followed	O
by	O
maintenance	O
monotherapy	O
with	O
olaparib	B-DRUG
(	O
200	O
mg	O
twice	O
per	O
day	O
)	O
or	O
placebo	B-DRUG
.	O
	
The	O
study	O
population	O
was	O
enriched	O
to	O
50	O
%	O
for	O
patients	O
with	O
low	O
or	O
undetectable	O
ATM	O
levels	O
(	O
ATMlow	O
)	O
.	O
	
Primary	O
end	O
point	O
was	O
progression-free	O
survival	O
(	O
PFS	O
)	O
.	O
	
One	O
hundred	O
twenty-three	O
of	O
124	O
randomly	O
assigned	O
patients	O
received	O
treatment	O
(	O
olaparib	B-DRUG
/	O
paclitaxel	B-DRUG
","	O
n	O
=	O
61	O
;	O
placebo	B-DRUG
/	O
paclitaxel	B-DRUG
","	O
n	O
=	O
62	O
)	O
.	O
	
The	O
screening	O
prevalence	O
of	O
ATMlow	O
patients	O
was	O
14	O
%	O
.	O
	
Olaparib	B-DRUG
/	O
paclitaxel	B-DRUG
did	O
not	O
lead	O
to	O
a	O
significant	O
improvement	O
in	O
PFS	O
versus	O
placebo	B-DRUG
/	O
paclitaxel	B-DRUG
(	O
overall	O
population	O
:	O
hazard	O
ratio	O
[	O
HR	O
]	O
","	O
0.8	O
;	O
median	O
PFS	O
","	O
3.91	O
v	O
3.55	O
months	O
","	O
respectively	O
;	O
ATMlow	O
population	O
:	O
HR	O
","	O
0.74	O
;	O
median	O
PFS	O
","	O
5.29	O
v	O
3.68	O
months	O
","	O
respectively	O
)	O
.	O
	
However	O
","	O
olaparib	B-DRUG
/	O
paclitaxel	B-DRUG
significantly	O
improved	O
overall	O
survival	O
(	O
OS	O
)	O
versus	O
placebo	B-DRUG
/	O
paclitaxel	B-DRUG
in	O
both	O
the	O
overall	O
population	O
(	O
HR	O
","	O
0.56	O
;	O
80	O
%	O
CI	O
","	O
0.41	O
to	O
0.75	O
;	O
P	O
=	O
0.005	O
;	O
median	O
OS	O
","	O
13.1	O
v	O
8.3	O
months	O
","	O
respectively	O
)	O
and	O
the	O
ATMlow	O
population	O
(	O
HR	O
","	O
0.35	O
;	O
80	O
%	O
CI	O
","	O
0.22	O
to	O
0.56	O
;	O
P	O
=	O
0.002	O
;	O
median	O
OS	O
","	O
not	O
reached	O
v	O
8.2	O
months	O
","	O
respectively	O
)	O
.	O
	
Olaparib	B-DRUG
/	O
paclitaxel	B-DRUG
was	O
generally	O
well	O
tolerated	O
","	O
with	O
no	O
unexpected	O
safety	O
findings	O
.	O
	
Olaparib	B-DRUG
/	O
paclitaxel	B-DRUG
is	O
active	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
metastatic	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
","	O
with	O
a	O
greater	O
OS	O
benefit	O
in	O
ATMlow	O
patients	O
.	O
	
A	O
phase	O
III	O
trial	O
in	O
this	O
setting	O
is	O
under	O
way	O
.	O
	
Phase	O
I	O
study	O
of	O
LY2603618	B-DRUG
","	O
a	O
CHK1	O
inhibitor	O
","	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
Japanese	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
This	O
phase	O
I	O
trial	O
evaluated	O
LY2603618	B-DRUG
","	O
a	O
selective	O
inhibitor	O
of	O
the	O
DNA	O
damage	O
checkpoint	O
kinase	O
1	O
","	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
.	O
	
Japanese	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
enrolled	O
.	O
	
All	O
patients	O
received	O
gemcitabine	B-DRUG
(	O
1000	O
mg	O
/	O
m	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
every	O
28	O
days	O
)	O
and	O
either	O
170	O
mg	O
(	O
cohort	O
1	O
)	O
or	O
230	O
mg	O
(	O
cohort	O
2	O
)	O
of	O
LY2603618	B-DRUG
.	O
	
The	O
primary	O
objective	O
was	O
assessment	O
of	O
safety	O
/	O
tolerability	O
.	O
	
Pharmacokinetic	O
/	O
pharmacodynamic	O
marker	O
profiles	O
were	O
secondary	O
objectives	O
.	O
	
Of	O
the	O
17	O
patients	O
enrolled	O
","	O
dose-limiting	O
toxicities	O
were	O
observed	O
in	O
one	O
patient	O
in	O
cohort	O
1	O
(	O
n=7	O
)	O
and	O
in	O
two	O
patients	O
in	O
cohort	O
2	O
(	O
n=10	O
)	O
.	O
	
The	O
most	O
common	O
grade	O
3	O
or	O
more	O
drug-related	O
treatment-emergent	O
adverse	O
events	O
were	O
hematological	O
.	O
	
Three	O
patients	O
discontinued	O
because	O
of	O
adverse	O
events	O
.	O
	
Dose-dependent	O
decreases	O
in	O
LY2603618	B-DRUG
exposure	O
were	O
observed	O
","	O
but	O
the	O
LY2603618	B-DRUG
pharmacokinetics	O
at	O
each	O
dose	O
were	O
consistent	O
within	O
and	O
between	O
cycles	O
and	O
did	O
not	O
influence	O
gemcitabine	B-DRUG
pharmacokinetics	O
.	O
	
Circulating	O
plasma	O
DNA	O
decreased	O
from	O
baseline	O
in	O
all	O
four	O
patients	O
who	O
achieved	O
a	O
partial	O
response	O
.	O
	
Administration	O
of	O
170	O
or	O
230	O
mg	O
of	O
LY2603618	B-DRUG
following	O
a	O
standard	O
dose	O
of	O
gemcitabine	B-DRUG
showed	O
acceptable	O
safety	O
and	O
tolerability	O
in	O
Japanese	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
Phase	O
I	O
and	O
pharmacological	O
study	O
of	O
pazopanib	B-DRUG
in	O
combination	O
with	O
oral	O
topotecan	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
	
This	O
phase	O
I	O
study	O
evaluated	O
the	O
safety	O
","	O
tolerability	O
","	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
pharmacokinetics	O
of	O
two	O
dosing	O
schedules	O
of	O
oral	O
topotecan	B-DRUG
in	O
combination	O
with	O
pazopanib	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
Stage	O
I	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
there	O
was	O
an	O
impact	O
of	O
pazopanib	B-DRUG
on	O
topotecan	B-DRUG
exposure	O
.	O
	
In	O
stage	O
II	O
","	O
the	O
MTD	O
and	O
safety	O
profile	O
of	O
oral	O
topotecan	B-DRUG
given	O
weekly	O
on	O
days	O
1	O
","	O
8	O
and	O
15	O
in	O
a	O
28-day	O
cycle	O
;	O
or	O
daily-times-five	O
on	O
days	O
1月5日	O
in	O
a	O
21-day	O
cycle	O
","	O
both	O
in	O
combination	O
with	O
daily	O
pazopanib	B-DRUG
","	O
were	O
explored	O
.	O
	
In	O
total	O
","	O
67	O
patients	O
were	O
enroled	O
.	O
	
Pazopanib	O
co-administration	O
caused	O
a	O
substantial	O
increase	O
in	O
exposure	O
to	O
total	O
topotecan	B-DRUG
(	O
1.7-fold	O
)	O
compared	O
with	O
topotecan	B-DRUG
alone	O
","	O
which	O
is	O
considered	O
clinically	O
relevant	O
.	O
	
Topotecan	B-DRUG
had	O
no	O
effect	O
on	O
pazopanib	B-DRUG
concentrations	O
.	O
	
Safety	O
findings	O
were	O
consistent	O
with	O
the	O
known	O
profile	O
of	O
both	O
agents	O
.	O
	
There	O
were	O
three	O
drug-related	O
deaths	B-TOXI
","	O
liver	B-TOXI
failure	I-TOXI
","	O
tumour	B-TOXI
haemorrhage	I-TOXI
and	O
myelosuppression	B-TOXI
.	O
	
Two	O
patients	O
experienced	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
;	O
hand-foot	B-TOXI
syndrome	I-TOXI
","	O
myelosuppression	B-TOXI
and	O
diarrhoea	B-TOXI
)	O
on	O
the	O
weekly	O
topotecan	B-DRUG
schedule	O
and	O
four	O
patients	O
experienced	O
DLTs	O
(	O
myelosuppression	B-TOXI
)	O
on	O
the	O
daily-times-five	O
topotecan	B-DRUG
schedule	O
.	O
	
When	O
combined	O
with	O
pazopanib	B-DRUG
","	O
800	O
mg	O
daily	O
","	O
the	O
recommended	O
doses	O
for	O
oral	O
topotecan	B-DRUG
are	O
:	O
8	O
mg	O
weekly	O
and	O
2.5	O
mg	O
daily-times-five	O
.	O
	
Seven	O
of	O
eight	O
patients	O
with	O
partial	O
response	O
had	O
platinum-resistant	O
ovarian	B-CANCER
cancer	I-CANCER
.	O
	
In	O
addition	O
","	O
54	O
%	O
of	O
patients	O
had	O
stable	O
disease	O
with	O
22	O
%	O
stable	O
for	O
6	O
months	O
.	O
	
Total	O
topotecan	B-DRUG
exposure	O
is	O
1.7-fold	O
higher	O
when	O
co-administered	O
with	O
pazopanib	B-DRUG
.	O
	
Both	O
schedules	O
of	O
administration	O
were	O
tolerated	O
and	O
would	O
permit	O
further	O
evaluation	O
","	O
especially	O
the	O
weekly	O
schedule	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
daily	O
afatinib	B-DRUG
","	O
an	O
irreversible	O
ErbB	O
family	O
blocker	O
","	O
in	O
combination	O
with	O
weekly	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
	
This	O
phase	O
I	O
study	O
evaluated	O
afatinib	B-DRUG
","	O
an	O
irreversible	O
ErbB	O
family	O
blocker	O
","	O
plus	O
paclitaxel	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
likely	O
to	O
express	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
HER1	O
/	O
EGFR	O
)	O
or	O
HER2	O
.	O
	
Oral	O
afatinib	B-DRUG
was	O
combined	O
with	O
intravenous	O
paclitaxel	B-DRUG
(	O
80mg	O
/	O
m	O
(	O
2	O
)	O
;	O
days	O
1	O
","	O
8	O
and	O
15	O
every	O
four	O
weeks	O
)	O
starting	O
at	O
20mg	O
once	O
daily	O
and	O
escalated	O
to	O
40	O
and	O
50mg	O
in	O
successive	O
cohorts	O
of	O
猢3	O
patients	O
.	O
	
The	O
primary	O
objective	O
was	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
afatinib	O
combined	O
with	O
paclitaxel	B-DRUG
.	O
	
Secondary	O
objectives	O
included	O
safety	O
","	O
pharmacokinetics	O
and	O
antitumour	O
activity	O
.	O
	
Sixteen	O
patients	O
were	O
treated	O
.	O
	
Dose-limiting	O
toxicities	O
with	O
afatinib	B-DRUG
50mg	O
were	O
fatigue	B-TOXI
and	O
mucositis	B-TOXI
.	O
	
The	O
MTD	O
was	O
determined	O
as	O
afatinib	B-DRUG
40mg	O
with	O
paclitaxel	B-DRUG
80mg	O
/	O
m	O
(	O
2	O
)	O
","	O
which	O
proved	O
tolerable	O
with	O
repeated	O
dosing	O
.	O
	
Frequent	O
adverse	O
events	O
(	O
AEs	O
)	O
included	O
diarrhoea	B-TOXI
(	O
94	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
81	O
%	O
)	O
","	O
rash	B-TOXI
/	O
acne	B-TOXI
(	O
81	O
%	O
)	O
","	O
decreased	B-TOXI
appetite	I-TOXI
(	O
69	O
%	O
)	O
and	O
inflammation	B-TOXI
of	I-TOXI
mucosal	I-TOXI
membranes	I-TOXI
(	O
69	O
%	O
)	O
;	O
no	O
grade	O
4	O
treatment-related	O
AEs	O
were	O
observed	O
.	O
	
Five	O
(	O
31	O
%	O
)	O
confirmed	O
partial	O
responses	O
were	O
observed	O
in	O
patients	O
with	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
n=3	O
)	O
","	O
oesophageal	B-CANCER
cancer	I-CANCER
and	O
cholangiocarcinoma	B-CANCER
;	O
eight	O
(	O
50	O
%	O
)	O
patients	O
remained	O
on	O
study	O
for	O
猢6months	O
.	O
	
Pharmacokinetic	O
parameters	O
of	O
afatinib	B-DRUG
and	O
paclitaxel	B-DRUG
were	O
similar	O
for	O
single	O
administration	O
or	O
in	O
combination	O
.	O
	
The	O
MTD	O
and	O
recommended	O
phase	O
II	O
dose	O
of	O
once-daily	O
afatinib	B-DRUG
combined	O
with	O
paclitaxel	B-DRUG
80mg	O
/	O
m	O
(	O
2	O
)	O
(	O
days	O
1	O
","	O
8	O
and	O
15	O
every	O
four	O
weeks	O
)	O
was	O
40mg	O
.	O
	
AEs	O
at	O
or	O
below	O
this	O
dose	O
were	O
generally	O
manageable	O
with	O
repeated	O
dosing	O
.	O
	
No	O
pharmacokinetic	O
interactions	O
were	O
observed	O
.	O
	
This	O
combination	O
demonstrated	O
promising	O
antitumour	O
activity	O
.	O
	
ClinicalTrials.gov	O
","	O
NCT00809133	O
.	O
	
An	O
open-label	O
expanded-access	O
trial	O
of	O
bendamustine	B-DRUG
in	O
patients	O
with	O
rituximab-refractory	B-DRUG
indolent	O
non-Hodgkin	B-CANCER
lymphoma	I-CANCER
or	O
previously	O
untreated	O
chronic	B-CANCER
lymphocytic	I-CANCER
leukemia	I-CANCER
:	O
BEND-ACT	O
.	O
	
	
Bendamustine	B-DRUG
is	O
a	O
bifunctional	O
alkylating	O
agent	O
with	O
unique	O
properties	O
that	O
distinguish	O
it	O
from	O
other	O
agents	O
in	O
its	O
class	O
.	O
	
Bendamustine	B-DRUG
is	O
used	O
as	O
monotherapy	O
or	O
in	O
combination	O
with	O
other	O
agents	O
to	O
treat	O
patients	O
with	O
non-Hodgkin	B-CANCER
lymphoma	I-CANCER
(	O
nhl	B-CANCER
)	O
and	O
chronic	B-CANCER
lymphocytic	I-CANCER
leukemia	I-CANCER
(	O
cll	B-CANCER
)	O
.	O
	
The	O
prospective	O
interventional	O
open-label	O
bend-act	O
trial	O
evaluated	O
bendamustine	B-DRUG
in	O
patients	O
with	O
rituximab-refractory	B-DRUG
indolent	O
nhl	B-CANCER
(	O
inhl	O
)	O
and	O
previously	O
untreated	O
cll	B-CANCER
.	O
	
Study	O
objectives	O
were	O
to	O
assess	O
the	O
safety	O
and	O
tolerability	O
of	O
bendamustine	B-DRUG
monotherapy	O
and	O
to	O
provide	O
patients	O
with	O
access	O
to	O
bendamustine	B-DRUG
before	O
Health	O
Canada	O
approval	O
.	O
	
The	O
study	O
aimed	O
to	O
enrol	O
up	O
to	O
100	O
patients	O
.	O
	
All	O
patients	O
with	O
inhl	B-CANCER
received	O
an	O
intravenous	O
dose	O
of	O
bendamustine	B-DRUG
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
over	O
60	O
minutes	O
on	O
days	O
1	O
and	O
2	O
for	O
up	O
to	O
eight	O
-21	O
or	O
28-day	O
treatment	O
cycles	O
.	O
	
All	O
patients	O
with	O
cll	B-CANCER
received	O
an	O
intravenous	O
dose	O
of	O
bendamustine	B-DRUG
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
over	O
30	O
minutes	O
on	O
days	O
1	O
and	O
2	O
for	O
up	O
to	O
six	O
28-day	O
treatment	O
cycles	O
.	O
	
Of	O
90	O
patients	O
treated	O
on	O
study	O
(	O
16	O
with	O
cll	B-CANCER
and	O
74	O
with	O
inhl	B-CANCER
)	O
","	O
35	O
completed	O
the	O
study	O
(	O
4	O
with	O
cll	B-CANCER
and	O
31	O
with	O
inhl	B-CANCER
)	O
.	O
	
The	O
most	O
common	O
treatment-emergent	O
adverse	O
events	O
(	O
teaes	O
)	O
were	O
nausea	B-TOXI
(	O
70	O
%	O
)	O
","	O
fatigue	B-TOXI
(	O
57	O
%	O
)	O
","	O
vomiting	B-TOXI
(	O
40	O
%	O
)	O
","	O
and	O
diarrhea	B-TOXI
(	O
33	O
%	O
)	O
#NAME?	O
grades	O
1	O
and	O
2	O
Ondansetron	B-DRUG
was	O
the	O
most	O
common	O
supportive	O
medication	O
used	O
in	O
the	O
patients	O
(	O
63.5	O
%	O
of	O
those	O
with	O
inhl	B-CANCER
and	O
68.8	O
%	O
of	O
those	O
with	O
cll	B-CANCER
)	O
.	O
	
Neutropenia	B-TOXI
(	O
32	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
23	O
%	O
)	O
","	O
and	O
thrombocytopenia	B-TOXI
(	O
21	O
%	O
)	O
were	O
the	O
most	O
frequent	O
hematologic	B-TOXI
teaes	I-TOXI
","	O
with	O
neutropenia	B-TOXI
being	O
the	O
most	O
common	O
grade	O
3	O
or	O
4	O
teae	O
leading	O
to	O
dose	O
modification	O
.	O
	
Dose	O
delays	O
occurred	O
in	O
28	O
patients	O
(	O
31.3	O
%	O
)	O
because	O
of	O
grade	O
3	O
or	O
4	O
teaes	O
","	O
with	O
a	O
higher	O
incidence	O
of	O
dose	O
delays	O
being	O
observed	O
in	O
inhl	O
patients	O
on	O
the	O
21-day	O
treatment	O
cycle	O
than	O
in	O
those	O
on	O
the	O
28-day	O
treatment	O
cycle	O
(	O
50	O
%	O
vs.	O
24.1	O
%	O
)	O
.	O
	
During	O
the	O
study	O
","	O
33	O
patients	O
(	O
36.7	O
%	O
)	O
experienced	O
at	O
least	O
1	O
serious	O
adverse	O
event	O
","	O
and	O
4	O
deaths	B-TOXI
were	O
reported	O
(	O
all	O
in	O
patients	O
with	O
inhl	B-CANCER
)	O
.	O
	
The	O
type	O
and	O
frequency	O
of	O
the	O
teaes	O
reported	O
accorded	O
with	O
observations	O
in	O
earlier	O
clinical	O
trials	O
and	O
post-marketing	O
experiences	O
","	O
thus	O
confirming	O
the	O
acceptable	O
and	O
manageable	O
safety	O
profile	O
of	O
bendamustine	B-DRUG
.	O
	
Safety	O
and	O
efficacy	O
of	O
combination	O
therapy	O
with	O
low-dose	O
gemcitabine	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
and	O
sorafenib	B-DRUG
in	O
patients	O
with	O
cisplatin-resistant	B-DRUG
urothelial	B-CANCER
cancer	I-CANCER
.	O
	
	
Various	O
regimens	O
including	O
molecular	O
targeted	O
agents	O
have	O
been	O
examined	O
in	O
patients	O
with	O
cisplatin	B-DRUG
(	O
CDDP	B-DRUG
)	O
#NAME?	O
urothelial	B-CANCER
cancer	I-CANCER
(	O
UC	B-CANCER
)	O
.	O
	
However	O
","	O
some	O
studies	O
have	O
been	O
stopped	O
owing	O
to	O
the	O
development	O
of	O
severe	O
adverse	O
events	O
.	O
	
The	O
main	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
anticancer	O
effects	O
","	O
changes	O
in	O
the	O
quality	O
of	O
life	O
(	O
QoL	O
)	O
","	O
and	O
safety	O
of	O
combined	O
therapy	O
of	O
low-dose	O
gemcitabine	B-DRUG
","	O
paclitaxel	B-DRUG
","	O
and	O
sorafenib	B-DRUG
(	O
LD-GPS	O
)	O
in	O
patients	O
with	O
CDDP-resistant	B-DRUG
UC	B-CANCER
.	O
	
Twenty	O
patients	O
were	O
treated	O
with	O
gemcitabine	B-DRUG
(	O
700	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
)	O
","	O
paclitaxel	B-DRUG
(	O
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
)	O
","	O
and	O
sorafenib	B-DRUG
(	O
400	O
mg	O
/	O
day	O
on	O
days	O
8月22日	O
)	O
.	O
	
QoL	O
and	O
pain	O
relief	O
were	O
evaluated	O
using	O
the	O
short-form	O
survey	O
(	O
SF	O
)	O
-36	O
for	O
bodily	B-TOXI
pain	I-TOXI
and	O
the	O
visual	O
analog	O
scale	O
(	O
VAS	O
)	O
.	O
	
VAS	O
scores	O
were	O
significantly	O
decreased	O
by	O
both	O
the	O
second-	O
and	O
third-line	O
therapies	O
(	O
P	O
=	O
0.012	O
and	O
0.028	O
","	O
respectively	O
)	O
.	O
	
The	O
bodily	B-TOXI
pain	I-TOXI
score	O
from	O
the	O
SF-36	O
survey	O
was	O
also	O
significantly	O
(	O
P	O
=	O
0.012	O
)	O
decreased	O
.	O
	
Complete	O
responses	O
","	O
partial	O
responses	O
","	O
and	O
stable	O
disease	O
were	O
found	O
in	O
0	O
(	O
0	O
%	O
)	O
","	O
1	O
(	O
5	O
%	O
)	O
","	O
and	O
13	O
patients	O
(	O
65	O
%	O
)	O
","	O
respectively	O
.	O
	
The	O
median	O
(	O
interquartile	O
range	O
)	O
period	O
of	O
overall	O
survival	O
after	O
starting	O
of	O
this	O
therapy	O
was	O
7	O
(	O
5月11日	O
)	O
months	O
.	O
	
Three	O
patients	O
(	O
15	O
%	O
)	O
stopped	O
therapy	O
because	O
of	O
grade	O
3	O
fatigue	B-TOXI
and	O
hand-foot	B-TOXI
reactions	I-TOXI
.	O
	
LD-GPS	O
therapy	O
was	O
well	O
tolerated	O
by	O
patients	O
with	O
CDDP-resistant	B-DRUG
UC	B-CANCER
.	O
	
QoL	O
was	O
maintained	O
","	O
and	O
improvements	O
in	O
their	O
pain	O
levels	O
were	O
found	O
after	O
treatment	O
;	O
pain	O
relief	O
was	O
detected	O
after	O
third-line	O
therapy	O
.	O
	
We	O
suggest	O
that	O
this	O
treatment	O
regimen	O
is	O
worthy	O
of	O
consideration	O
as	O
second-	O
and	O
third-line	O
therapy	O
for	O
patients	O
with	O
CDDP-resistant	B-DRUG
UC	B-CANCER
.	O
	
A	O
phase	O
I	O
study	O
of	O
volasertib	B-DRUG
combined	O
with	O
afatinib	B-DRUG
","	O
in	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
To	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
volasertib	B-DRUG
","	O
a	O
Polo-like	O
kinase	O
inhibitor	O
","	O
combined	O
with	O
afatinib	B-DRUG
","	O
an	O
oral	O
irreversible	O
ErbB	O
family	O
blocker	O
","	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
(	O
NCT01206816	O
;	O
Study	O
1230.2	O
)	O
.	O
	
Patients	O
with	O
advanced	O
non-resectable	O
and	O
/	O
or	O
metastatic	O
disease	O
following	O
failure	O
of	O
conventional	O
treatment	O
received	O
intravenous	O
volasertib	B-DRUG
150-300	O
mg	O
on	O
day	O
1	O
every	O
21	O
days	O
","	O
combined	O
with	O
oral	O
afatinib	B-DRUG
30-40	O
mg	O
on	O
days	O
2月21日	O
of	O
a	O
3-week	O
cycle	O
(	O
Schedule	O
A	O
)	O
","	O
or	O
50-90	O
mg	O
on	O
days	O
2月6日	O
of	O
a	O
3-week	O
cycle	O
(	O
Schedule	O
B	O
)	O
.	O
	
The	O
primary	O
objective	O
was	O
to	O
determine	O
the	O
MTD	O
of	O
volasertib	B-DRUG
in	O
combination	O
with	O
afatinib	B-DRUG
.	O
	
Fifty-seven	O
patients	O
(	O
Schedule	O
A	O
","	O
N	O
=	O
29	O
;	O
Schedule	O
B	O
","	O
N	O
=	O
28	O
)	O
were	O
treated	O
.	O
	
The	O
MTDs	O
were	O
volasertib	B-DRUG
300	O
mg	O
plus	O
afatinib	B-DRUG
30	O
mg	O
days	O
2月21日	O
and	O
70	O
mg	O
days	O
2月6日	O
of	O
a	O
3-week	O
cycle	O
for	O
Schedules	O
A	O
and	O
B	O
","	O
respectively	O
.	O
	
The	O
most	O
common	O
Grade	O
3	O
/	O
4	O
adverse	O
events	O
were	O
neutropenia	B-TOXI
(	O
31	O
%	O
)	O
","	O
diarrhea	B-TOXI
(	O
13.8	O
%	O
)	O
","	O
and	O
thrombocytopenia	B-TOXI
(	O
10.3	O
%	O
)	O
in	O
Schedule	O
A	O
;	O
neutropenia	B-TOXI
(	O
39.3	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
35.7	O
%	O
)	O
","	O
hypokalemia	B-TOXI
(	O
14.3	O
%	O
)	O
","	O
febrile	B-TOXI
neutropenia	I-TOXI
","	O
and	O
nausea	B-TOXI
(	O
each	O
10.7	O
%	O
)	O
in	O
Schedule	O
B.	O
The	O
best	O
overall	O
response	O
was	O
two	O
partial	O
responses	O
(	O
6.9	O
%	O
;	O
both	O
in	O
Schedule	O
A	O
)	O
;	O
eight	O
patients	O
in	O
each	O
schedule	O
achieved	O
stable	O
disease	O
.	O
	
Volasertib	B-DRUG
showed	O
multi-exponential	O
pharmacokinetic	O
(	O
PK	O
)	O
behavior	O
;	O
co-administration	O
of	O
volasertib	B-DRUG
and	O
afatinib	B-DRUG
had	O
no	O
significant	O
effects	O
on	O
the	O
PK	O
profile	O
of	O
either	O
drug	O
.	O
	
Volasertib	B-DRUG
combined	O
with	O
afatinib	B-DRUG
had	O
manageable	O
adverse	O
effects	O
and	O
limited	O
antitumor	O
activity	O
in	O
this	O
heavily	O
pretreated	O
population	O
.	O
	
Phase	O
3	O
","	O
open-label	O
","	O
randomized	O
study	O
comparing	O
3-monthly	O
with	O
monthly	O
goserelin	B-DRUG
in	O
pre-menopausal	O
women	O
with	O
estrogen	B-DRUG
receptor-positive	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
Monthly	O
goserelin	B-DRUG
3.6	O
mg	O
dosing	O
suppresses	O
estradiol	B-DRUG
(	O
E2	O
)	O
production	O
and	O
has	O
proven	O
efficacy	O
in	O
pre-menopausal	O
women	O
with	O
estrogen	O
receptor	O
(	O
ER	O
)	O
#NAME?	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
This	O
non-inferiority	O
study	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
3-monthly	O
goserelin	B-DRUG
10.8	O
mg	O
compared	O
with	O
monthly	O
goserelin	B-DRUG
3.6	O
mg	O
.	O
	
This	O
was	O
a	O
Phase	O
3	O
","	O
open-label	O
","	O
multicenter	O
trial	O
.	O
	
Pre-menopausal	O
women	O
with	O
ER-positive	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
were	O
randomized	O
to	O
3-monthly	O
goserelin	B-DRUG
10.8	O
mg	O
or	O
monthly	O
goserelin	B-DRUG
3.6	O
mg	O
;	O
all	O
patients	O
received	O
concomitant	O
tamoxifen	B-DRUG
(	O
20	O
mg	O
daily	O
)	O
.	O
	
The	O
primary	O
endpoint	O
was	O
progression-free	O
survival	O
(	O
PFS	O
)	O
rate	O
at	O
24	O
weeks	O
;	O
non-inferiority	O
was	O
to	O
be	O
confirmed	O
if	O
the	O
entire	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
for	O
the	O
treatment	O
difference	O
was	O
above	O
-17.5	O
%	O
.	O
	
Secondary	O
endpoints	O
included	O
objective	O
response	O
rate	O
(	O
ORR	O
)	O
","	O
serum	O
E2	O
levels	O
","	O
safety	O
","	O
and	O
tolerability	O
.	O
	
In	O
total	O
","	O
222	O
patients	O
were	O
randomized	O
(	O
goserelin	B-DRUG
10.8	O
mg	O
","	O
n	O
=	O
109	O
;	O
goserelin	B-DRUG
3.6	O
mg	O
","	O
n	O
=	O
113	O
)	O
.	O
	
PFS	O
rate	O
at	O
week	O
24	O
was	O
61.5	O
%	O
(	O
goserelin	B-DRUG
10.8	O
mg	O
)	O
and	O
60.2	O
%	O
(	O
goserelin	B-DRUG
3.6	O
mg	O
)	O
;	O
treatment	O
difference	O
(	O
95	O
%	O
CI	O
)	O
was	O
1.3	O
%	O
(	O
-11.4	O
","	O
13.9	O
)	O
","	O
confirming	O
non-inferiority	O
of	O
goserelin	B-DRUG
10.8	O
mg	O
compared	O
with	O
goserelin	B-DRUG
3.6	O
mg	O
.	O
	
ORR	O
was	O
23.9	O
%	O
(	O
goserelin	B-DRUG
10.8	O
mg	O
)	O
and	O
26.9	O
%	O
(	O
goserelin	B-DRUG
3.6	O
mg	O
)	O
;	O
treatment	O
difference	O
(	O
95	O
%	O
CI	O
)	O
was	O
-3	O
%	O
(	O
-15.5	O
","	O
9.7	O
)	O
.	O
	
At	O
week	O
24	O
","	O
mean	O
serum	O
E2	O
concentrations	O
were	O
similar	O
in	O
the	O
goserelin	B-DRUG
10.8	O
mg	O
and	O
goserelin	B-DRUG
3.6	O
mg	O
groups	O
(	O
20.3	O
pg	O
/	O
mL	O
and	O
24.8	O
pg	O
/	O
mL	O
","	O
respectively	O
)	O
.	O
	
A	O
regimen	O
of	O
3-monthly	O
goserelin	B-DRUG
10.8	O
mg	O
demonstrated	O
non-inferiority	O
compared	O
with	O
monthly	O
goserelin	B-DRUG
3.6	O
mg	O
for	O
PFS	O
rate	O
at	O
24	O
weeks	O
","	O
with	O
similar	O
pharmacodynamic	O
and	O
safety	O
profiles	O
","	O
in	O
pre-menopausal	O
women	O
with	O
ER-positive	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
Randomized	O
","	O
Double-Blind	O
","	O
Phase	O
II	O
Study	O
of	O
Ruxolitinib	B-DRUG
or	O
Placebo	B-DRUG
in	O
Combination	O
With	O
Capecitabine	B-DRUG
in	O
Patients	O
With	O
Metastatic	B-CANCER
Pancreatic	I-CANCER
Cancer	I-CANCER
for	O
Whom	O
Therapy	O
With	O
Gemcitabine	B-DRUG
Has	O
Failed	O
.	O
	
	
Patients	O
with	O
advanced	B-CANCER
pancreatic	I-CANCER
adenocarcinoma	I-CANCER
have	O
a	O
poor	O
prognosis	O
and	O
limited	O
second-line	O
treatment	O
options	O
.	O
	
Evidence	O
suggests	O
a	O
role	O
for	O
the	O
Janus	O
kinase	O
(	O
JAK	O
)	O
/	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
pathway	O
in	O
the	O
pathogenesis	O
and	O
clinical	O
course	O
of	O
pancreatic	B-CANCER
cancer	I-CANCER
.	O
	
In	O
this	O
double-blind	O
","	O
phase	O
II	O
study	O
","	O
patients	O
with	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
who	O
had	O
experienced	O
treatment	O
failure	O
with	O
gemcitabine	B-DRUG
were	O
randomly	O
assigned	O
01:01	O
to	O
the	O
JAK1	O
/	O
JAK2	O
inhibitor	O
ruxolitinib	B-DRUG
(	O
15	O
mg	O
twice	O
daily	O
)	O
plus	O
capecitabine	B-DRUG
(	O
"1,000"	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
daily	O
)	O
or	O
placebo	B-DRUG
plus	O
capecitabine	B-DRUG
.	O
	
The	O
primary	O
end	O
point	O
was	O
overall	O
survival	O
(	O
OS	O
)	O
;	O
secondary	O
end	O
points	O
included	O
progression-free	O
survival	O
","	O
clinical	O
benefit	O
response	O
","	O
objective	O
response	O
rate	O
","	O
and	O
safety	O
.	O
	
Prespecified	O
subgroup	O
analyses	O
evaluated	O
treatment	O
heterogeneity	O
and	O
efficacy	O
in	O
patients	O
with	O
evidence	O
of	O
inflammation	B-TOXI
.	O
	
In	O
the	O
intent-to-treat	O
population	O
(	O
ruxolitinib	B-DRUG
","	O
n	O
=	O
64	O
;	O
placebo	O
","	O
n	O
=	O
63	O
)	O
","	O
the	O
hazard	O
ratio	O
was	O
0.79	O
(	O
95	O
%	O
CI	O
","	O
0.53	O
to	O
1.18	O
;	O
P	O
=	O
0.25	O
)	O
for	O
OS	O
and	O
was	O
0.75	O
(	O
95	O
%	O
CI	O
","	O
0.52	O
to	O
1.1	O
;	O
P	O
=	O
0.14	O
)	O
for	O
progression-free	O
survival	O
.	O
	
In	O
a	O
prespecified	O
subgroup	O
analysis	O
of	O
patients	O
with	O
inflammation	O
","	O
defined	O
by	O
serum	O
C-reactive	O
protein	O
levels	O
greater	O
than	O
the	O
study	O
population	O
median	O
(	O
ie	O
","	O
13	O
mg	O
/	O
L	O
)	O
","	O
OS	O
was	O
significantly	O
greater	O
with	O
ruxolitinib	B-DRUG
than	O
with	O
placebo	B-DRUG
(	O
hazard	O
ratio	O
","	O
0.47	O
;	O
95	O
%	O
CI	O
","	O
0.26	O
to	O
0.85	O
;	O
P	O
=	O
0.011	O
)	O
.	O
	
Prolonged	O
survival	O
in	O
this	O
subgroup	O
was	O
supported	O
by	O
post	O
hoc	O
analyses	O
of	O
OS	O
that	O
categorized	O
patients	O
by	O
the	O
modified	O
Glasgow	O
Prognostic	O
Score	O
","	O
a	O
systemic	O
inflammation-based	O
prognostic	O
system	O
.	O
	
Grade	O
3	O
or	O
greater	O
adverse	O
events	O
were	O
observed	O
with	O
similar	O
frequency	O
in	O
the	O
ruxolitinib	B-DRUG
(	O
74.6	O
%	O
)	O
and	O
placebo	B-DRUG
(	O
81.7	O
%	O
)	O
groups	O
.	O
	
Grade	O
3	O
or	O
greater	O
anemia	B-TOXI
was	O
more	O
frequent	O
with	O
ruxolitinib	B-DRUG
(	O
15.3	O
%	O
;	O
placebo	B-DRUG
","	O
1.7	O
%	O
)	O
.	O
	
Ruxolitinib	B-DRUG
plus	O
capecitabine	B-DRUG
was	O
generally	O
well	O
tolerated	O
and	O
may	O
improve	O
survival	O
in	O
patients	O
with	O
metastatic	B-CANCER
pancreatic	I-CANCER
cancer	I-CANCER
and	O
evidence	O
of	O
systemic	B-TOXI
inflammation	I-TOXI
.	O
	
Phase	O
I	O
and	O
pharmacological	O
trial	O
of	O
lapatinib	B-DRUG
in	O
combination	O
with	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
Lapatinib	B-DRUG
has	O
proven	O
efficacy	O
as	O
monotherapy	O
and	O
in	O
combination	O
with	O
capecitabine	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
MBC	B-CANCER
)	O
overexpressing	O
HER2	O
and	O
/	O
or	O
EGFR	O
.	O
	
Gemcitabine	B-DRUG
also	O
has	O
anti-tumor	O
activity	O
in	O
MBC	B-CANCER
and	O
a	O
favourable	O
toxicity	O
profile	O
.	O
	
In	O
this	O
phase	O
I	O
study	O
lapatinib	B-DRUG
and	O
gemcitabine	B-DRUG
were	O
combined	O
.	O
	
Female	O
patients	O
with	O
advanced	B-CANCER
BC	I-CANCER
were	O
given	O
lapatinib	B-DRUG
once	O
daily	O
(	O
QD	O
)	O
in	O
28-day	O
cycles	O
with	O
gemcitabine	B-DRUG
administered	O
on	O
day	O
1	O
","	O
8	O
and	O
15	O
.	O
	
Physical	O
examinations	O
","	O
vital	O
signs	O
and	O
blood	O
sampling	O
for	O
hematology	O
","	O
clinical	O
chemistry	O
and	O
pharmacokinetics	O
(	O
PK	O
)	O
and	O
radiological	O
assessments	O
of	O
disease	O
were	O
performed	O
at	O
regular	O
intervals	O
.	O
	
In	O
total	O
","	O
33	O
patients	O
were	O
included	O
.	O
	
Six	O
dose-limiting	O
toxicities	O
were	O
observed	O
","	O
mostly	O
grade	O
3	O
increases	O
in	O
liver	O
function	O
tests	O
.	O
	
Most	O
common	O
toxicities	O
were	O
fatigue	B-TOXI
(	O
73	O
%	O
)	O
","	O
nausea	B-TOXI
(	O
70	O
%	O
)	O
","	O
diarrhea	B-TOXI
(	O
58	O
%	O
)	O
","	O
increases	B-TOXI
in	I-TOXI
ALAT	I-TOXI
and	I-TOXI
ASAT	I-TOXI
(	O
55	O
and	O
52	O
%	O
","	O
respectively	O
)	O
and	O
rash	B-TOXI
(	O
46	O
%	O
)	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
was	O
lapatinib	B-DRUG
1250	O
mg	O
QD	O
with	O
gemcitabine	B-DRUG
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
Lapatinib	B-DRUG
and	O
gemcitabine	B-DRUG
PK	O
did	O
not	O
appear	O
to	O
be	O
influenced	O
by	O
each	O
other	O
.	O
	
Anti-tumor	O
activity	O
was	O
observed	O
with	O
one	O
patient	O
(	O
4	O
%	O
)	O
showing	O
complete	O
response	O
and	O
six	O
(	O
23	O
%	O
)	O
partial	O
response	O
.	O
	
Despite	O
a	O
slightly	O
increased	O
toxicity	O
profile	O
compared	O
to	O
their	O
respective	O
monotherapies	O
","	O
lapatinib	B-DRUG
and	O
gemcitabine	B-DRUG
can	O
be	O
safely	O
combined	O
while	O
showing	O
signs	O
of	O
anti-tumor	O
activity	O
.	O
	
Phase	O
I	O
dose	O
escalation	O
and	O
pharmacokinetic	O
evaluation	O
of	O
two	O
different	O
schedules	O
of	O
LY2334737	B-DRUG
","	O
an	O
oral	O
gemcitabine	B-DRUG
prodrug	O
","	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
This	O
Phase-I-study	O
aimed	O
to	O
determine	O
the	O
recommended	O
Phase-II-dosing-schedule	O
of	O
LY2334737	B-DRUG
","	O
an	O
oral	O
gemcitabine	B-DRUG
prodrug	O
","	O
in	O
patients	O
with	O
advanced	O
/	O
metastatic	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
Pharmacokinetics	O
","	O
cytokeratin-18	O
(	O
CK18	O
)	O
levels	O
","	O
genetic	O
polymorphisms	O
","	O
and	O
antitumor	O
activity	O
were	O
additionally	O
evaluated	O
.	O
	
Patients	O
received	O
escalating	O
doses	O
of	O
LY2334737	B-DRUG
either	O
every	O
other	O
day	O
for	O
21	O
days	O
(	O
d	O
)	O
followed	O
by	O
7	O
days-drug-free	O
period	O
(	O
QoD-arm	O
)	O
or	O
once	O
daily	O
for	O
7	O
days	O
every	O
other	O
week	O
(	O
QD-arm	O
)	O
.	O
	
The	O
28	O
days-cycles	O
were	O
repeated	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
.	O
	
Standard	O
3	O
=+	O
3	O
dose-escalation	O
was	O
succeeded	O
by	O
a	O
dose-confirmation	O
phase	O
(	O
12	O
additional	O
patients	O
to	O
be	O
enrolled	O
on	O
the	O
maximum	O
tolerated	O
dose	O
[	O
MTD	O
]	O
)	O
.	O
	
Forty-one	O
patients	O
received	O
QoD-	O
(	O
40-100	O
mg	O
)	O
and	O
32	O
QD-dosing	O
(	O
40-90	O
mg	O
)	O
.	O
	
On	O
QoD	O
","	O
3	O
/	O
9	O
patients	O
experienced	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
on	O
the	O
100	O
mg	O
dose	O
(	O
2	O
_	O
G3	O
diarrhea	B-TOXI
","	O
1	O
_	O
G3	O
transaminase	B-TOXI
increase	I-TOXI
)	O
;	O
1	O
additional	O
DLT	O
(	O
G3	O
diarrhea	B-TOXI
)	O
occurred	O
during	O
dose	O
confirmation	O
at	O
90	O
mg	O
(	O
12	O
patients	O
)	O
.	O
	
On	O
QD	O
","	O
1	O
patient	O
each	O
experienced	O
DLTs	O
on	O
60	O
mg	O
(	O
G3	O
transaminase	B-TOXI
increase	I-TOXI
)	O
and	O
80	O
mg	O
(	O
G3	O
prolonged	O
QTcF-interval	O
)	O
;	O
2	O
/	O
7	O
patients	O
had	O
3	O
DLTs	O
on	O
the	O
90	O
mg	O
dose	O
(	O
diarrhea	B-TOXI
","	O
edema	B-TOXI
","	O
liver-failure	B-TOXI
;	O
all	O
G3	O
)	O
.	O
	
The	O
MTD	O
was	O
established	O
at	O
90	O
mg	O
for	O
the	O
QoD-arm	O
.	O
	
Seven	O
patients	O
on	O
QoD	O
and	O
4	O
on	O
QD	O
achieved	O
SD	O
(	O
no	O
CR	O
=+	O
PR	O
)	O
.	O
	
Pharmacokinetics	O
showed	O
a	O
dose-proportional	O
increase	O
in	O
exposure	O
of	O
LY2334737	B-DRUG
and	O
dFdC	O
without	O
accumulation	O
after	O
repeated	O
dosing	O
.	O
	
Significant	O
increases	O
in	O
CK18	O
levels	O
were	O
observed	O
.	O
	
Genetic	O
polymorphism	O
of	O
the	O
cytidine	O
deaminase	O
gene	O
(	O
rs818202	O
)	O
could	O
be	O
associated	O
with	O
_	O
G3	O
hepatotoxicity	B-TOXI
.	O
	
Both	O
schedules	O
displayed	O
linear	O
pharmacokinetics	O
and	O
acceptable	O
safety	O
profiles	O
.	O
	
The	O
recommended	O
dose	O
and	O
schedule	O
of	O
LY2334737	B-DRUG
for	O
subsequent	O
Phase-II-studies	O
is	O
90	O
mg	O
given	O
QoD	O
for	O
21	O
day	O
.	O
	
Intensity-modulated	O
extended-field	O
chemoradiation	O
plus	O
simultaneous	O
integrated	O
boost	O
in	O
the	O
pre-operative	O
treatment	O
of	O
locally	O
advanced	B-CANCER
cervical	I-CANCER
cancer	I-CANCER
:	O
a	O
dose-escalation	O
study	O
.	O
	
	
To	O
investigate	O
the	O
feasibility	O
and	O
determine	O
the	O
recommended	O
pre-operative	O
intensity-modulated	O
radiotherapy	O
(	O
IMRT	O
)	O
dose	O
of	O
extended-field	O
chemoradiation	O
along	O
with	O
simultaneous	O
integrated	O
boost	O
(	O
SIB	O
)	O
dose	O
escalation	O
.	O
	
A	O
radiation	O
dose	O
of	O
40	O
Gy	O
over	O
4	O
weeks	O
","	O
2	O
Gy	O
/	O
fraction	O
","	O
was	O
delivered	O
to	O
the	O
tumour	O
and	O
the	O
lymphatic	O
drainage	O
(	O
planning	O
target	O
volume	O
","	O
PTV3	O
)	O
","	O
which	O
encompassed	O
a	O
volume	O
larger	O
than	O
standard	O
(	O
common	O
iliac	O
lymphatic	O
area	O
up	O
to	O
its	O
apex	O
","	O
in	O
front	O
of	O
the	O
L3	O
vertebra	O
)	O
","	O
concurrently	O
with	O
chemotherapy	O
(	O
cisplatin	B-DRUG
and	O
5-fluorouracil	B-DRUG
)	O
.	O
	
Radiation	O
dose	O
was	O
escalated	O
to	O
the	O
pelvis	O
(	O
PTV2	O
)	O
and	O
to	O
the	O
macroscopic	O
disease	O
(	O
PTV1	O
)	O
with	O
the	O
SIB-IMRT	O
strategy	O
.	O
	
Three	O
dose	O
levels	O
were	O
planned	O
:	O
Level	O
1	O
(	O
PTV3	O
:	O
40	O
/	O
2	O
Gy	O
;	O
PTV2	O
:	O
40	O
/	O
2	O
Gy	O
;	O
PTV1	O
:	O
45	O
/	O
2.25	O
Gy	O
)	O
","	O
Level	O
2	O
(	O
PTV3	O
:	O
40	O
/	O
2	O
Gy	O
;	O
PTV2	O
:	O
45	O
/	O
2.25	O
Gy	O
;	O
PTV1	O
:	O
45	O
/	O
2.25	O
Gy	O
)	O
and	O
Level	O
3	O
(	O
PTV3	O
:	O
40	O
/	O
2	O
Gy	O
;	O
PTV2	O
:	O
45	O
/	O
2.25	O
Gy	O
;	O
PTV1	O
:	O
50	O
/	O
2.5	O
Gy	O
)	O
.	O
	
All	O
treatments	O
were	O
delivered	O
in	O
20	O
fractions	O
.	O
	
Patients	O
were	O
treated	O
in	O
cohorts	O
of	O
between	O
three	O
and	O
six	O
per	O
group	O
using	O
a	O
Phase	O
I	O
study	O
design	O
.	O
	
The	O
recommended	O
dose	O
was	O
exceeded	O
if	O
two	O
of	O
the	O
six	O
patients	O
in	O
a	O
cohort	O
experienced	O
dose-limiting	O
toxicity	O
within	O
3	O
months	O
from	O
treatment	O
.	O
	
19	O
patients	O
[	O
median	O
age	O
:	O
46	O
years	O
;	O
The	O
International	O
Federation	O
of	O
Gynecology	O
and	O
Obstetrics	O
(	O
FIGO	O
)	O
stage	O
IB2	O
:	O
3	O
","	O
IIB	O
:	O
10	O
","	O
IIIA-IIIB	O
:	O
6	O
]	O
were	O
enrolled	O
.	O
	
Median	O
follow-up	O
was	O
24	O
months	O
(	O
9-60	O
months	O
)	O
.	O
	
The	O
most	O
common	O
grade	O
3	O
/	O
4	O
toxicity	O
was	O
gastrointestinal	B-TOXI
(	O
GI	O
)	O
(	O
diarrhoea	B-TOXI
","	O
mucous	B-TOXI
discharge	I-TOXI
","	O
rectal	B-TOXI
/	I-TOXI
abdominal	I-TOXI
pain	I-TOXI
)	O
.	O
	
At	O
Levels	O
1	O
and	O
2	O
","	O
only	O
one	O
grade	O
3	O
GI	O
toxicity	O
per	O
level	O
was	O
recorded	O
","	O
whereas	O
at	O
Level	O
3	O
","	O
two	O
grade	O
3	O
GI	O
toxicities	O
(	O
diarrhoea	B-TOXI
","	O
emesis	B-TOXI
and	O
nausea	B-TOXI
)	O
were	O
recorded	O
.	O
	
The	O
SIB-IMRT	O
technique	O
was	O
found	O
to	O
be	O
feasible	O
and	O
safe	O
at	O
the	O
recommended	O
doses	O
of	O
45	O
Gy	O
to	O
PTV1	O
and	O
PTV2	O
and	O
40	O
Gy	O
to	O
PTV3	O
in	O
the	O
pre-operative	O
treatment	O
of	O
patients	O
with	O
locally	O
advanced	B-CANCER
cervical	I-CANCER
cancer	I-CANCER
.	O
	
Unfortunately	O
","	O
this	O
complex	O
technique	O
was	O
unable	O
to	O
safely	O
escalate	O
dose	O
beyond	O
levels	O
already	O
achieved	O
with	O
three-dimensional	O
conformal	O
radiotherapy	O
technique	O
given	O
acute	O
GI	O
toxicity	O
.	O
	
A	O
Phase	O
I	O
radiotherapy	O
dose-escalation	O
trial	O
with	O
SIB-IMRT	O
technique	O
is	O
proposed	O
in	O
cervical	B-CANCER
cancer	I-CANCER
.	O
	
This	O
complex	O
technique	O
is	O
feasible	O
and	O
safe	O
at	O
the	O
recommended	O
doses	O
.	O
	
Nivolumab	B-DRUG
versus	O
Everolimus	B-DRUG
in	O
Advanced	B-CANCER
Renal-Cell	I-CANCER
Carcinoma	I-CANCER
.	O
	
	
Nivolumab	B-DRUG
","	O
a	O
programmed	O
death	O
1	O
(	O
PD-1	O
)	O
checkpoint	O
inhibitor	O
","	O
was	O
associated	O
with	O
encouraging	O
overall	O
survival	O
in	O
uncontrolled	O
studies	O
involving	O
previously	O
treated	O
patients	O
with	O
advanced	B-CANCER
renal-cell	I-CANCER
carcinoma	I-CANCER
.	O
	
This	O
randomized	O
","	O
open-label	O
","	O
phase	O
3	O
study	O
compared	O
nivolumab	B-DRUG
with	O
everolimus	B-DRUG
in	O
patients	O
with	O
renal-cell	B-CANCER
carcinoma	I-CANCER
who	O
had	O
received	O
previous	O
treatment	O
.	O
	
A	O
total	O
of	O
821	O
patients	O
with	O
advanced	O
clear-cell	O
renal-cell	B-CANCER
carcinoma	I-CANCER
for	O
which	O
they	O
had	O
received	O
previous	O
treatment	O
with	O
one	O
or	O
two	O
regimens	O
of	O
antiangiogenic	O
therapy	O
were	O
randomly	O
assigned	O
(	O
in	O
a	O
01:01	O
ratio	O
)	O
to	O
receive	O
3	O
mg	O
of	O
nivolumab	B-DRUG
per	O
kilogram	O
of	O
body	O
weight	O
intravenously	O
every	O
2	O
weeks	O
or	O
a	O
10-mg	O
everolimus	B-DRUG
tablet	O
orally	O
once	O
daily	O
.	O
	
The	O
primary	O
end	O
point	O
was	O
overall	O
survival	O
.	O
	
The	O
secondary	O
end	O
points	O
included	O
the	O
objective	O
response	O
rate	O
and	O
safety	O
.	O
	
The	O
median	O
overall	O
survival	O
was	O
25	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
21.8	O
to	O
not	O
estimable	O
)	O
with	O
nivolumab	B-DRUG
and	O
19.6	O
months	O
(	O
95	O
%	O
CI	O
","	O
17.6	O
to	O
23.1	O
)	O
with	O
everolimus	B-DRUG
.	O
	
The	O
hazard	O
ratio	O
for	O
death	O
with	O
nivolumab	B-DRUG
versus	O
everolimus	B-DRUG
was	O
0.73	O
(	O
98.5	O
%	O
CI	O
","	O
0.57	O
to	O
0.93	O
;	O
P=0.002	O
)	O
","	O
which	O
met	O
the	O
prespecified	O
criterion	O
for	O
superiority	O
(	O
P_0.0148	O
)	O
.	O
	
The	O
objective	O
response	O
rate	O
was	O
greater	O
with	O
nivolumab	B-DRUG
than	O
with	O
everolimus	B-DRUG
(	O
25	O
%	O
vs.	O
5	O
%	O
;	O
odds	O
ratio	O
","	O
5.98	O
[	O
95	O
%	O
CI	O
","	O
3.68	O
to	O
9.72	O
]	O
;	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
.	O
	
The	O
median	O
progression-free	O
survival	O
was	O
4.6	O
months	O
(	O
95	O
%	O
CI	O
","	O
3.7	O
to	O
5.4	O
)	O
with	O
nivolumab	B-DRUG
and	O
4.4	O
months	O
(	O
95	O
%	O
CI	O
","	O
3.7	O
to	O
5.5	O
)	O
with	O
everolimus	B-DRUG
(	O
hazard	O
ratio	O
","	O
0.88	O
;	O
95	O
%	O
CI	O
","	O
0.75	O
to	O
1.03	O
;	O
P=0.11	O
)	O
.	O
	
Grade	O
3	O
or	O
4	O
treatment-related	O
adverse	O
events	O
occurred	O
in	O
19	O
%	O
of	O
the	O
patients	O
receiving	O
nivolumab	B-DRUG
and	O
in	O
37	O
%	O
of	O
the	O
patients	O
receiving	O
everolimus	B-DRUG
;	O
the	O
most	O
common	O
event	O
with	O
nivolumab	B-DRUG
was	O
fatigue	B-TOXI
(	O
in	O
2	O
%	O
of	O
the	O
patients	O
)	O
","	O
and	O
the	O
most	O
common	O
event	O
with	O
everolimus	B-DRUG
was	O
anemia	B-TOXI
(	O
in	O
8	O
%	O
)	O
.	O
	
Among	O
patients	O
with	O
previously	O
treated	O
advanced	B-CANCER
renal-cell	I-CANCER
carcinoma	I-CANCER
","	O
overall	O
survival	O
was	O
longer	O
and	O
fewer	O
grade	O
3	O
or	O
4	O
adverse	O
events	O
occurred	O
with	O
nivolumab	B-DRUG
than	O
with	O
everolimus	B-DRUG
.	O
	
(	O
Funded	O
by	O
Bristol-Myers	O
Squibb	O
;	O
CheckMate	O
25	O
ClinicalTrials.gov	O
number	O
","	O
NCT01668784.	O
)	O
.	O
	
Safety	O
","	O
efficacy	O
","	O
and	O
pharmacokinetics	O
of	O
navitoclax	B-DRUG
(	O
ABT-263	B-DRUG
)	O
in	O
combination	O
with	O
erlotinib	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
Navitoclax	B-DRUG
(	O
ABT-263	B-DRUG
)	O
","	O
a	O
novel	O
","	O
oral	O
Bcl-2	O
inhibitor	O
","	O
enhances	O
the	O
antitumor	O
effects	O
of	O
chemotherapy	O
in	O
vitro	O
by	O
lowering	O
the	O
apoptotic	O
threshold	O
.	O
	
This	O
phase	O
I	O
study	O
(	O
NCT01009073	O
)	O
evaluated	O
the	O
safety	O
","	O
pharmacokinetics	O
","	O
and	O
preliminary	O
antitumor	O
activity	O
of	O
navitoclax	B-DRUG
combined	O
with	O
erlotinib	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
An	O
open-label	O
dose	O
escalation	O
study	O
included	O
an	O
arm	O
evaluating	O
navitoclax	B-DRUG
combined	O
with	O
erlotinib	B-DRUG
","	O
which	O
included	O
a	O
dose	O
escalation	O
cohort	O
and	O
a	O
planned	O
safety	O
expansion	O
cohort	O
.	O
	
Patients	O
with	O
documented	O
cancers	O
for	O
whom	O
erlotinib	B-DRUG
therapy	O
was	O
appropriate	O
received	O
erlotinib	B-DRUG
150	O
mg	O
orally	O
once	O
daily	O
plus	O
navitoclax	B-DRUG
150	O
mg	O
orally	O
once	O
daily	O
","	O
with	O
navitoclax	B-DRUG
dose	O
escalation	O
via	O
a	O
continuous	O
reassessment	O
method	O
model	O
.	O
	
Eleven	O
patients	O
were	O
enrolled	O
","	O
including	O
six	O
patients	O
with	O
nonsmall	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
Dose-limiting	O
toxicities	O
","	O
most	O
commonly	O
diarrhea	B-TOXI
","	O
were	O
observed	O
in	O
4	O
patients	O
.	O
	
Navitoclax	B-DRUG
dosing	O
remained	O
at	O
150	O
mg	O
/	O
day	O
because	O
the	O
maximum	O
tolerated	O
dose	O
was	O
exceeded	O
at	O
this	O
starting	O
dose	O
.	O
	
The	O
planned	O
dose	O
escalation	O
did	O
not	O
occur	O
;	O
no	O
recommended	O
phase	O
II	O
dose	O
(	O
RPTD	O
)	O
was	O
identified	O
","	O
and	O
there	O
was	O
no	O
safety	O
expansion	O
cohort	O
.	O
	
The	O
most	O
common	O
treatment-related	O
adverse	O
events	O
were	O
diarrhea	B-TOXI
","	O
nausea	B-TOXI
","	O
vomiting	B-TOXI
","	O
and	O
decreased	B-TOXI
appetite	I-TOXI
.	O
	
Pharmacokinetic	O
analysis	O
showed	O
no	O
apparent	O
interactions	O
between	O
co-administered	O
navitoclax	B-DRUG
and	O
erlotinib	B-DRUG
.	O
	
No	O
objective	O
responses	O
were	O
observed	O
;	O
the	O
disease	O
control	O
rate	O
was	O
27	O
%	O
(	O
95	O
%	O
CI	O
","	O
6-61	O
%	O
)	O
.	O
	
At	O
the	O
erlotinib	B-DRUG
and	O
navitoclax	B-DRUG
doses	O
administered	O
","	O
RPTD	O
was	O
not	O
reached	O
","	O
but	O
the	O
safety	O
profile	O
of	O
the	O
combination	O
was	O
consistent	O
with	O
data	O
from	O
monotherapy	O
studies	O
.	O
	
There	O
were	O
no	O
apparent	O
pharmacokinetic	O
interactions	O
between	O
erlotinib	B-DRUG
and	O
navitoclax	B-DRUG
.	O
	
Three	O
patients	O
had	O
stable	O
disease	O
.	O
	
Safety	O
","	O
efficacy	O
","	O
and	O
pharmacokinetics	O
of	O
navitoclax	B-DRUG
(	O
ABT-263	B-DRUG
)	O
in	O
combination	O
with	O
irinotecan	B-DRUG
:	O
results	O
of	O
an	O
open-label	O
","	O
phase	O
1	O
study	O
.	O
	
	
The	O
oral	O
Bcl-2	O
inhibitor	O
navitoclax	B-DRUG
demonstrated	O
activity	O
in	O
solid	O
and	O
hematologic	B-CANCER
malignancies	I-CANCER
as	O
monotherapy	O
and	O
in	O
combination	O
with	O
other	O
cytotoxic	O
agents	O
in	O
preclinical	O
and	O
early	O
clinical	O
studies	O
.	O
	
We	O
evaluated	O
the	O
safety	O
","	O
pharmacokinetics	O
(	O
PK	O
)	O
","	O
and	O
antitumor	O
activity	O
of	O
navitoclax	B-DRUG
plus	O
irinotecan	B-DRUG
.	O
	
In	O
this	O
multicenter	O
","	O
open-label	O
","	O
phase	O
1	O
dose	O
escalation	O
study	O
","	O
adults	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
received	O
navitoclax	B-DRUG
(	O
starting	O
dose	O
150	O
mg	O
/	O
day	O
)	O
in	O
combination	O
with	O
1	O
of	O
2	O
irinotecan	B-DRUG
schedules	O
during	O
a	O
21-day	O
cycle	O
:	O
a	O
once-every-3-week	O
regimen	O
(	O
Q3W	O
180	O
","	O
250	O
","	O
or	O
350	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
or	O
a	O
once-weekly	O
regimen	O
(	O
QW	O
75	O
or	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O
	
Enrollment	O
occurred	O
until	O
a	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
/	O
or	O
recommended	O
phase	O
2	O
dose	O
(	O
RPTD	O
)	O
was	O
reached	O
.	O
	
All	O
patients	O
(	O
Q3W	O
","	O
n	O
=	O
14	O
;	O
QW	O
","	O
n	O
=	O
17	O
)	O
were	O
evaluable	O
for	O
safety	O
","	O
PK	O
","	O
and	O
efficacy	O
.	O
	
The	O
most	O
common	O
adverse	O
event	O
in	O
both	O
groups	O
was	O
diarrhea	B-TOXI
(	O
Q3W	O
92.9	O
%	O
;	O
QW	O
76.5	O
%	O
)	O
","	O
which	O
was	O
the	O
most	O
frequent	O
grade	O
3	O
/	O
grade	O
4	O
adverse	O
event	O
(	O
Q3W	O
42.9	O
%	O
;	O
QW	O
29.4	O
%	O
)	O
.	O
	
The	O
study	O
was	O
amended	O
to	O
exclude	O
4	O
UGT1A1*28	O
7	O
/	O
7	O
homozygous	O
patients	O
due	O
to	O
frequent	O
irinotecan-related	B-DRUG
grade	O
3	O
/	O
grade	O
4	O
diarrhea	B-TOXI
and	O
/	O
or	O
febrile	B-TOXI
neutropenia	I-TOXI
.	O
	
No	O
apparent	O
PK	O
interactions	O
between	O
navitoclax	B-DRUG
and	O
irinotecan	B-DRUG
were	O
observed	O
.	O
	
The	O
MTD	O
of	O
the	O
combination	O
was	O
exceeded	O
in	O
the	O
Q3W	O
group	O
at	O
the	O
lowest	O
dose	O
administered	O
.	O
	
In	O
the	O
QW	O
group	O
","	O
the	O
MTD	O
and	O
RPTD	O
for	O
navitoclax	B-DRUG
were	O
150	O
mg	O
when	O
combined	O
with	O
irinotecan	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O
	
One	O
patient	O
in	O
each	O
group	O
achieved	O
a	O
partial	O
response	O
.	O
	
The	O
RPTD	O
of	O
navitoclax	B-DRUG
in	O
combination	O
with	O
irinotecan	B-DRUG
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
QW	O
during	O
a	O
21-day	O
cycle	O
was	O
150	O
mg	O
in	O
these	O
heavily	O
pretreated	O
patients	O
.	O
	
A	O
phase	O
1	O
study	O
evaluating	O
the	O
pharmacokinetics	O
and	O
preliminary	O
efficacy	O
of	O
veliparib	B-DRUG
(	O
ABT-888	B-DRUG
)	O
in	O
combination	O
with	O
carboplatin	B-DRUG
/	O
paclitaxel	B-DRUG
in	O
Japanese	O
subjects	O
with	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
	
Veliparib	B-DRUG
is	O
a	O
potent	O
","	O
orally	O
bioavailable	O
PARP	O
inhibitor	O
that	O
enhances	O
efficacy	O
of	O
DNA-damaging	O
chemotherapeutic	O
agents	O
.	O
	
The	O
study	O
objectives	O
were	O
to	O
determine	O
the	O
recommended	O
phase	O
2	O
dose	O
(	O
RPTD	O
)	O
of	O
veliparib	B-DRUG
plus	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
","	O
and	O
assess	O
pharmacokinetics	O
(	O
PK	O
)	O
","	O
tolerability	O
","	O
and	O
preliminary	O
efficacy	O
in	O
Japanese	O
patients	O
with	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
Carboplatin	B-DRUG
(	O
AUC	O
6	O
mg	O
/	O
mL	O
min	O
)	O
and	O
paclitaxel	B-DRUG
(	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
were	O
administered	O
on	O
day	O
3	O
of	O
a	O
21-day	O
cycle	O
.	O
	
Oral	O
veliparib	B-DRUG
(	O
40	O
","	O
80	O
","	O
or	O
120	O
mg	O
BID	O
)	O
was	O
administered	O
on	O
days	O
1月7日	O
.	O
	
Patients	O
received	O
_6	O
cycles	O
.	O
	
Adverse	O
events	O
(	O
AEs	O
)	O
were	O
reported	O
using	O
NCI-CTCAE	O
version	O
4.03	O
","	O
PK	O
parameters	O
were	O
analyzed	O
using	O
noncompartmental	O
methods	O
","	O
and	O
responses	O
were	O
measured	O
by	O
RECIST	O
version	O
1.1.	O
Twelve	O
patients	O
with	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
were	O
treated	O
.	O
	
Common	O
treatment-emergent	O
AEs	O
","	O
consistent	O
with	O
toxicities	O
associated	O
with	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
","	O
included	O
leukopenia	B-TOXI
(	O
100	O
%	O
)	O
","	O
neutropenia	B-TOXI
(	O
100	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
83	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
75	O
%	O
)	O
","	O
increased	B-TOXI
alanine	I-TOXI
aminotransferase	I-TOXI
(	O
67	O
%	O
)	O
","	O
and	O
increased	B-TOXI
aspartate	I-TOXI
aminotransferase	I-TOXI
(	O
67	O
%	O
)	O
.	O
	
Grade	O
3	O
/	O
4	O
AEs	O
(	O
in	O
_2	O
patients	O
)	O
included	O
neutropenia	B-TOXI
(	O
100	O
%	O
)	O
","	O
leukopenia	B-TOXI
(	O
33	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
25	O
%	O
)	O
","	O
and	O
hyponatremia	B-TOXI
(	O
17	O
%	O
)	O
.	O
	
No	O
AEs	O
led	O
to	O
veliparib	B-DRUG
","	O
carboplatin	B-DRUG
","	O
or	O
paclitaxel	B-DRUG
interruption	O
;	O
no	O
DLTs	O
were	O
observed	O
.	O
	
The	O
RPTD	O
was	O
determined	O
to	O
be	O
120	O
mg	O
BID	O
.	O
	
Veliparib	B-DRUG
C	O
max	O
and	O
AUC	O
were	O
approximately	O
dose	O
proportional	O
.	O
	
Six	O
partial	O
responses	O
were	O
observed	O
.	O
	
Veliparib	B-DRUG
PK	O
was	O
not	O
impacted	O
by	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
.	O
	
The	O
safety	O
profile	O
was	O
manageable	O
.	O
	
The	O
120	O
mg	O
BID	O
RPTD	O
confirmed	O
in	O
Japanese	O
patients	O
is	O
the	O
dose	O
being	O
evaluated	O
in	O
global	O
studies	O
of	O
veliparib	B-DRUG
.	O
	
Preliminary	O
efficacy	O
suggests	O
veliparib	B-DRUG
may	O
enhance	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
activity	O
","	O
providing	O
benefit	O
to	O
patients	O
with	O
NSCLC	B-CANCER
.	O
	
Phase	O
I	O
study	O
of	O
afatinib	B-DRUG
combined	O
with	O
nintedanib	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
	
This	O
Phase	O
I	O
study	O
evaluated	O
continuous-	O
and	O
intermittent-dosing	O
(	O
every	O
other	O
week	O
)	O
of	O
afatinib	B-DRUG
plus	O
nintedanib	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
.	O
	
In	O
the	O
dose-escalation	O
phase	O
(	O
n=45	O
)	O
","	O
maximum	O
tolerated	O
doses	O
(	O
MTDs	O
)	O
were	O
determined	O
for	O
continuous	O
/	O
intermittent	O
afatinib	B-DRUG
10	O
","	O
20	O
","	O
30	O
or	O
40	O
mg	O
once	O
daily	O
plus	O
continuous	O
nintedanib	B-DRUG
150	O
or	O
200	O
mg	O
twice	O
daily	O
.	O
	
Secondary	O
objectives	O
included	O
safety	O
and	O
efficacy	O
.	O
	
Clinical	O
activity	O
of	O
continuous	O
afatinib	B-DRUG
plus	O
nintedanib	B-DRUG
at	O
the	O
MTD	O
was	O
further	O
evaluated	O
in	O
an	O
expansion	O
phase	O
(	O
n=25	O
)	O
.	O
	
The	O
most	O
frequent	O
dose-limiting	O
toxicities	O
were	O
diarrhoea	B-TOXI
(	O
11	O
%	O
)	O
and	O
transaminase	B-TOXI
elevations	I-TOXI
(	O
7	O
%	O
)	O
.	O
	
Maximum	O
tolerated	O
doses	O
were	O
afatinib	B-DRUG
30	O
mg	O
continuously	O
plus	O
nintedanib	B-DRUG
150	O
mg	O
","	O
and	O
afatinib	B-DRUG
40	O
mg	O
intermittently	O
plus	O
nintedanib	B-DRUG
150	O
mg	O
.	O
	
Treatment-related	O
adverse	O
events	O
(	O
mostly	O
Grade猢3	O
)	O
included	O
diarrhoea	B-TOXI
(	O
98	O
%	O
)	O
","	O
asthenia	B-TOXI
(	O
64	O
%	O
)	O
","	O
nausea	B-TOXI
(	O
62	O
%	O
)	O
and	O
vomiting	B-TOXI
(	O
60	O
%	O
)	O
.	O
	
In	O
the	O
dose-escalation	O
phase	O
","	O
two	O
patients	O
had	O
partial	O
responses	O
(	O
PRs	O
)	O
and	O
27	O
(	O
60	O
%	O
)	O
had	O
stable	O
disease	O
(	O
SD	O
)	O
.	O
	
In	O
the	O
expansion	O
phase	O
","	O
one	O
complete	O
response	O
and	O
three	O
PRs	O
were	O
observed	O
(	O
all	O
non-small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
)	O
","	O
with	O
SD	O
in	O
13	O
(	O
52	O
%	O
)	O
patients	O
.	O
	
No	O
pharmacokinetic	O
interactions	O
were	O
observed	O
.	O
	
MTDs	O
of	O
continuous	O
or	O
intermittent	O
afatinib	B-DRUG
plus	O
nintedanib	B-DRUG
demonstrated	O
a	O
manageable	O
safety	O
profile	O
with	O
proactive	O
management	O
of	O
diarrhoea	B-TOXI
.	O
	
Antitumour	O
activity	O
was	O
observed	O
in	O
patients	O
with	O
solid	B-CANCER
tumours	I-CANCER
.	O
	
A	O
phase	O
I	O
combination	O
dose-escalation	O
study	O
of	O
eribulin	B-DRUG
mesylate	I-DRUG
and	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
:	O
a	O
study	O
of	O
the	O
Princess	O
Margaret	O
Consortium	O
.	O
	
	
Eribulin	B-DRUG
mesylate	I-DRUG
is	O
a	O
synthetic	O
microtubule	O
inhibitor	O
that	O
showed	O
cytotoxic	O
synergy	O
in	O
combination	O
with	O
gemcitabine	B-DRUG
preclinically	O
.	O
	
This	O
combination	O
was	O
assessed	O
in	O
a	O
Phase	O
I	O
dose-finding	O
trial	O
in	O
patients	O
diagnosed	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
who	O
had	O
received	O
up	O
to	O
two	O
prior	O
chemotherapy	O
regimens	O
for	O
metastatic	O
disease	O
(	O
CP	O
cohort	O
)	O
.	O
	
Dose	O
escalation	O
was	O
performed	O
in	O
a	O
3+3	O
design	O
to	O
identify	O
the	O
recommended	O
phase	O
II	O
dose	O
(	O
RP2D	O
)	O
.	O
	
Two	O
additional	O
expansion	O
cohorts	O
in	O
women	O
with	O
gynaecologic	B-CANCER
cancers	I-CANCER
at	O
the	O
RP2D	O
(	O
G	O
)	O
","	O
and	O
further	O
dose	O
escalation	O
of	O
metastatic	O
chemotherapy-naive	O
patients	O
(	O
CN	O
)	O
","	O
were	O
evaluated	O
.	O
	
45	O
patients	O
were	O
treated	O
:	O
21	O
(	O
CP	O
)	O
","	O
10	O
(	O
G	O
)	O
and	O
14	O
(	O
CN	O
)	O
.	O
	
The	O
initial	O
combination	O
of	O
eribulin	B-DRUG
and	O
gemcitabine	B-DRUG
was	O
administered	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
of	O
a	O
28-day	O
cycle	O
;	O
however	O
","	O
due	O
to	O
2	O
out	O
of	O
6	O
dose-limiting	O
haematological	B-TOXI
toxicities	I-TOXI
at	O
the	O
first	O
dose	O
level	O
","	O
a	O
reduced	O
dose-intense	O
schedule	O
was	O
assessed	O
.	O
	
The	O
RP2D	O
was	O
defined	O
at	O
1	O
mg	O
m	O
(	O
-2	O
)	O
eribulin	B-DRUG
and	O
1000	O
mg	O
m	O
(	O
-2	O
)	O
gemcitabine	B-DRUG
day	O
1	O
and	O
8	O
q3	O
weeks	O
.	O
	
No	O
other	O
significant	O
toxicities	O
were	O
observed	O
in	O
the	O
G	O
expansion	O
cohort	O
.	O
	
Neutropenia	B-TOXI
prevented	O
further	O
dose	O
escalation	O
in	O
the	O
CN	O
cohort	O
.	O
	
Objective	O
responses	O
were	O
seen	O
in	O
all	O
three	O
cohorts	O
=-	O
2	O
/	O
21	O
(	O
CP	O
)	O
","	O
1	O
/	O
10	O
(	O
G	O
)	O
and	O
2	O
/	O
14	O
(	O
CN	O
)	O
.	O
	
The	O
combination	O
of	O
eribulin	B-DRUG
and	O
gemcitabine	B-DRUG
was	O
well	O
tolerated	O
at	O
the	O
RP2D	O
.	O
	
Complications	O
of	O
hyperglycaemia	B-TOXI
with	O
PI3K-AKT-mTOR	O
inhibitors	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumours	I-CANCER
on	O
Phase	O
I	O
clinical	O
trials	O
.	O
	
	
PI3K-AKT-mTOR	O
inhibitors	O
(	O
PAMi	O
)	O
are	O
promising	O
anticancer	O
treatments	O
.	O
	
Hyperglycaemia	B-TOXI
is	O
a	O
mechanism-based	O
toxicity	O
of	O
these	O
agents	O
and	O
is	O
becoming	O
increasingly	O
important	O
with	O
their	O
use	O
in	O
larger	O
numbers	O
of	O
patients	O
.	O
	
Retrospective	O
case-control	O
study	O
comparing	O
incidence	O
and	O
severity	O
of	O
hyperglycaemia	B-TOXI
(	O
all	O
grades	O
)	O
between	O
a	O
case	O
group	O
of	O
387	O
patients	O
treated	O
on	O
18	O
phase	O
I	O
clinical	O
trials	O
with	O
PAMi	O
(	O
78	O
patients	O
with	O
PI3Ki	O
","	O
138	O
with	O
mTORi	O
","	O
144	O
with	O
AKTi	O
and	O
27	O
with	O
PI3K	O
/	O
mTORi	O
)	O
and	O
a	O
control	O
group	O
of	O
109	O
patients	O
treated	O
on	O
10	O
phase	O
I	O
clinical	O
trials	O
with	O
agents	O
not	O
directly	O
targeting	O
the	O
PAM	O
pathway	O
.	O
	
Diabetic	O
patients	O
were	O
excluded	O
in	O
both	O
groups	O
.	O
	
The	O
incidence	O
of	O
hyperglycaemia	B-TOXI
was	O
not	O
significantly	O
different	O
between	O
cases	O
and	O
controls	O
(	O
86.6	O
%	O
vs	O
80.7	O
%	O
","	O
respectively	O
","	O
P=0.129	O
)	O
.	O
	
However	O
","	O
high	O
grade	O
(	O
grade	O
3月4日	O
)	O
hyperglycaemia	B-TOXI
was	O
more	O
frequent	O
in	O
the	O
PAMi	O
group	O
than	O
in	O
controls	O
(	O
6.7	O
%	O
vs	O
0	O
%	O
","	O
respectively	O
","	O
P=0.005	O
)	O
.	O
	
The	O
incidence	O
of	O
grade	O
3月4日	O
hyperglycaemia	B-TOXI
was	O
greater	O
with	O
AKT	O
and	O
multikinase	O
inhibitors	O
compared	O
with	O
other	O
PAMi	O
(	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
.	O
	
All	O
patients	O
with	O
high-grade	O
hyperglycaemia	B-TOXI
received	O
antihyperglycemic	O
treatment	O
and	O
none	O
developed	O
severe	O
metabolic	B-TOXI
complications	I-TOXI
(	O
diabetic	B-TOXI
ketoacidosis	I-TOXI
or	O
hyperosmolar	B-TOXI
hyperglycemic	I-TOXI
nonketotic	I-TOXI
state	I-TOXI
)	O
.	O
	
High-grade	O
hyperglycaemia	B-TOXI
was	O
the	O
cause	O
of	O
permanent	O
PAMi	O
discontinuation	O
in	O
nine	O
patients	O
.	O
	
PI3K-AKT-mTOR	O
inhibitors	O
are	O
associated	O
with	O
small	O
(	O
6.7	O
%	O
)	O
but	O
statistically	O
significant	O
increased	O
risk	O
of	O
high-grade	O
hyperglycaemia	B-TOXI
compared	O
with	O
non-PAM	O
targeting	O
agents	O
.	O
	
However	O
","	O
PAMi-induced	O
hyperglycaemia	B-TOXI
was	O
not	O
found	O
to	O
be	O
associated	O
with	O
severe	O
metabolic	O
complications	O
in	O
this	O
non-diabetic	O
population	O
of	O
patients	O
with	O
advanced	O
cancers	O
.	O
	
A	O
Phase	O
I	O
Trial	O
of	O
BKM120	B-DRUG
(	O
Buparlisib	B-DRUG
)	O
in	O
Combination	O
with	O
Fulvestrant	O
in	O
Postmenopausal	O
Women	O
with	O
Estrogen	O
Receptor-Positive	O
Metastatic	B-CANCER
Breast	I-CANCER
Cancer	I-CANCER
.	O
	
	
This	O
trial	O
was	O
conducted	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
preliminary	O
efficacy	O
of	O
buparlisib	B-DRUG
","	O
an	O
oral	O
pan-class	O
I	O
PI3K	O
inhibitor	O
","	O
plus	O
fulvestrant	B-DRUG
in	O
postmenopausal	O
women	O
with	O
metastatic	O
estrogen	O
receptor	O
positive	O
(	O
ER	O
(	O
=+	O
)	O
)	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
Phase	O
IA	O
employed	O
a	O
3+3	O
design	O
to	O
determine	O
the	O
MTD	O
of	O
buparlisib	B-DRUG
daily	O
plus	O
fulvestrant	B-DRUG
.	O
	
Subsequent	O
cohorts	O
(	O
phase	O
IB	O
and	O
cohort	O
C	O
)	O
evaluated	O
intermittent	O
(	O
5	O
/	O
7-day	O
)	O
and	O
continuous	O
dosing	O
of	O
buparlisib	B-DRUG
(	O
100	O
mg	O
daily	O
)	O
.	O
	
No	O
more	O
than	O
3	O
prior	O
systemic	O
treatments	O
in	O
the	O
metastatic	O
setting	O
were	O
allowed	O
in	O
these	O
subsequent	O
cohorts	O
.	O
	
Thirty-one	O
patients	O
were	O
enrolled	O
.	O
	
MTD	O
was	O
defined	O
as	O
buparlisib	B-DRUG
100	O
mg	O
daily	O
plus	O
fulvestrant	B-DRUG
.	O
	
Common	O
adverse	O
events	O
(	O
AE	O
)	O
included	O
fatigue	B-TOXI
(	O
38.7	O
%	O
)	O
","	O
transaminases	B-TOXI
elevation	I-TOXI
(	O
35.5	O
%	O
)	O
","	O
rash	B-TOXI
(	O
29	O
%	O
)	O
","	O
and	O
diarrhea	B-TOXI
(	O
19.4	O
%	O
)	O
.	O
	
C-peptide	O
was	O
significantly	O
increased	O
during	O
treatment	O
","	O
consistent	O
with	O
on-target	O
effect	O
of	O
buparlisib	B-DRUG
.	O
	
Compared	O
with	O
intermittent	O
dosing	O
","	O
daily	O
buparlisib	B-DRUG
was	O
associated	O
with	O
more	O
frequent	O
early	O
onset	O
AEs	O
and	O
higher	O
buparlisib	B-DRUG
plasma	O
concentrations	O
.	O
	
Among	O
the	O
29	O
evaluable	O
patients	O
","	O
the	O
clinical	O
benefit	O
rate	O
was	O
58.6	O
%	O
(	O
95	O
%	O
CI	O
","	O
40.7	O
%	O
-74.5	O
%	O
)	O
.	O
	
Response	O
was	O
not	O
associated	O
with	O
PIK3CA	O
mutation	O
or	O
treatment	O
cohort	O
;	O
however	O
","	O
loss	O
of	O
PTEN	O
","	O
progesterone	O
receptor	O
(	O
PgR	O
)	O
expression	O
","	O
or	O
mutation	O
in	O
TP53	O
was	O
most	O
common	O
in	O
resistant	O
cases	O
","	O
and	O
mutations	O
inAKT1	O
and	O
ESR1	O
did	O
not	O
exclude	O
treatment	O
response	O
.	O
	
Buparlisib	B-DRUG
plus	O
fulvestrant	B-DRUG
is	O
clinically	O
active	O
with	O
manageable	O
AEs	O
in	O
patients	O
with	O
metastatic	O
ER	O
(	O
=+	O
)	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
Weekend	O
breaks	O
in	O
buparlisib	B-DRUG
dosing	O
reduced	O
toxicity	O
.	O
	
Patients	O
with	O
PgR	O
negative	O
and	O
TP53	O
mutation	O
did	O
poorly	O
","	O
suggesting	O
buparlisib	B-DRUG
plus	O
fulvestrant	B-DRUG
may	O
not	O
be	O
adequately	O
effective	O
against	O
tumors	O
with	O
these	O
poor	O
prognostic	O
molecular	O
features	O
.	O
	
A	O
phase	O
I	O
study	O
of	O
MK-5108	B-DRUG
","	O
an	O
oral	O
aurora	O
a	O
kinase	O
inhibitor	O
","	O
administered	O
both	O
as	O
monotherapy	O
and	O
in	O
combination	O
with	O
docetaxel	B-DRUG
","	O
in	O
patients	O
with	O
advanced	O
or	O
refractory	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
	
MK-5108	B-DRUG
is	O
a	O
potent	O
/	O
highly	O
selective	O
Aurora	O
A	O
kinase	O
inhibitor	O
.	O
	
A	O
randomized	O
Phase	O
I	O
study	O
of	O
MK-5108	B-DRUG
","	O
administered	O
p.o.	O
BID	O
Q12h	O
on	O
days	O
1月2日	O
in	O
14-21	O
day	O
cycles	O
either	O
alone	O
(	O
MT	O
;	O
Panel1	O
/	O
n	O
=	O
18	O
;	O
200	O
to	O
1800	O
mg	O
)	O
or	O
in	O
combination	O
(	O
CT	O
;	O
Panel2	O
/	O
n	O
=	O
17	O
;	O
100	O
to	O
225	O
mg	O
)	O
with	O
IV	O
docetaxel	B-DRUG
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
","	O
determined	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
pharmacokinetics	O
(	O
PK	O
)	O
","	O
pharmacodynamics	O
(	O
Panel1	O
","	O
only	O
)	O
and	O
tumor	O
response	O
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
.	O
	
This	O
study	O
was	O
terminated	O
early	O
due	O
to	O
toxicities	O
in	O
Panel2	O
at	O
MK-5108	B-DRUG
doses	O
below	O
the	O
anticipated	O
PK	O
exposure	O
target	O
.	O
	
35	O
patients	O
enrolled	O
(	O
33	O
evaluable	O
for	O
tumor	O
response	O
)	O
.	O
	
No	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
were	O
observed	O
in	O
Panel1	O
;	O
three	O
patients	O
had	O
3	O
DLTs	O
in	O
Panel2	O
(	O
G3	O
and	O
G4	O
febrile	B-TOXI
neutropenia	I-TOXI
at	O
200	O
and	O
450	O
mg	O
/	O
day	O
","	O
respectively	O
;	O
G3	O
infection	O
at	O
450	O
mg	O
/	O
day	O
)	O
.	O
	
In	O
Panel1	O
","	O
AUC0-12hr	O
and	O
Cmax	O
increased	O
less	O
than	O
dose	O
proportionally	O
following	O
the	O
first	O
MT	O
dose	O
but	O
increased	O
roughly	O
dose	O
proportionally	O
across	O
200	O
to	O
3600	O
mg	O
/	O
day	O
after	O
4th	O
dose	O
.	O
	
The	O
t1	O
/	O
2	O
ranged	O
from	O
6.6	O
to	O
13.5	O
h	O
across	O
both	O
panels	O
.	O
	
No	O
clear	O
effects	O
on	O
immunohistochemistry	O
markers	O
were	O
observed	O
;	O
however	O
","	O
significant	O
dose-related	O
increases	O
in	O
gene	O
expression	O
were	O
seen	O
pre-	O
/	O
post-treatment	O
.	O
	
Best	O
responses	O
were	O
9	O
/	O
17	O
stable	O
disease	O
(	O
SD	O
)	O
(	O
Panel1	O
)	O
as	O
well	O
as	O
1	O
/	O
16	O
PR	O
and	O
7	O
/	O
16	O
SD	O
(	O
Panel2	O
)	O
(	O
450	O
mg	O
/	O
day	O
)	O
.	O
	
MK-5108	B-DRUG
MT	O
was	O
well	O
tolerated	O
at	O
doses	O
up	O
to	O
3600	O
mg	O
/	O
day	O
with	O
plasma	O
levels	O
exceeding	O
the	O
minimum	O
daily	O
exposure	O
target	O
(	O
83	O
渭M*hr	O
)	O
.	O
	
The	O
MTD	O
for	O
MK-5108	B-DRUG
=+	O
docetaxel	O
(	O
CT	O
)	O
was	O
established	O
at	O
300	O
mg	O
/	O
day	O
","	O
below	O
the	O
exposure	O
target	O
.	O
	
Use	O
of	O
pharmacodynamic	O
gene	O
expression	O
assays	O
to	O
determine	O
target	O
engagement	O
was	O
validated	O
.	O
	
Preoperative	O
chemotherapy	O
in	O
locally	O
advanced	O
and	O
nonresectable	O
gastric	B-CANCER
cancer	I-CANCER
:	O
a	O
phase	O
II	O
study	O
with	O
etoposide	B-DRUG
","	O
doxorubicin	B-DRUG
","	O
and	O
cisplatin	B-DRUG
.	O
	
	
Thirty-four	O
patients	O
with	O
locally	O
advanced	O
","	O
nonresectable	O
gastric	B-CANCER
cancer	I-CANCER
(	O
staged	O
by	O
laparotomy	O
)	O
received	O
etoposide	B-DRUG
","	O
Adriamycin	B-DRUG
(	O
doxorubicin	B-DRUG
;	O
Adria	O
Laboratories	O
","	O
Columbus	O
","	O
OH	O
)	O
","	O
and	O
cisplatin	B-DRUG
(	O
EAP	O
)	O
.	O
	
Thirty-three	O
patients	O
were	O
evaluable	O
for	O
response	O
and	O
toxicity	O
.	O
	
Second-look	O
surgery	O
with	O
removal	O
of	O
residual	O
tumor	O
by	O
gastrectomy	O
and	O
lymphadenectomy	O
was	O
performed	O
in	O
case	O
of	O
complete	O
/	O
partial	O
remission	O
(	O
CR	O
/	O
PR	O
)	O
after	O
EAP	O
.	O
	
After	O
successful	O
resection	O
(	O
R0-	O
and	O
R1-resection	O
)	O
","	O
two	O
cycles	O
of	O
EAP	O
were	O
administered	O
for	O
consolidation	O
therapy	O
.	O
	
Patients	O
refusing	O
reoperation	O
received	O
up	O
to	O
six	O
cycles	O
of	O
EAP	O
.	O
	
The	O
response	O
rate	O
(	O
CR	O
/	O
PR	O
)	O
after	O
EAP	O
was	O
70	O
%	O
(	O
23	O
/	O
33	O
)	O
","	O
including	O
a	O
21	O
%	O
(	O
7	O
/	O
33	O
)	O
rate	O
of	O
clinical	O
CRs	O
(	O
CCRs	O
)	O
.	O
	
Two	O
patients	O
had	O
minor	O
remission	O
(	O
MR	O
)	O
/	O
no	O
change	O
and	O
seven	O
had	O
progressive	O
disease	O
.	O
	
There	O
was	O
one	O
early	O
death	B-TOXI
.	O
	
Nineteen	O
of	O
23	O
responders	O
(	O
5	O
CCRs	O
","	O
14	O
clinical	O
PRs	O
[	O
CPRs	O
]	O
)	O
and	O
one	O
patient	O
with	O
MR	O
underwent	O
second-look	O
surgery	O
.	O
	
Five	O
CCRs	O
were	O
pathologically	O
confirmed	O
;	O
10	O
patients	O
with	O
CPR	O
were	O
without	O
evidence	O
of	O
disease	O
(	O
NED	O
)	O
after	O
resection	O
.	O
	
In	O
three	O
patients	O
(	O
CPR	O
)	O
","	O
R1-resections	O
(	O
microscopically	O
tumor-cell	O
positive	O
proximal	O
margin	O
)	O
were	O
performed	O
;	O
two	O
patients	O
are	O
disease-free	O
","	O
22+	O
and	O
33+	O
months	O
after	O
consolidation	O
chemotherapy	O
.	O
	
In	O
two	O
patients	O
","	O
the	O
tumor	O
was	O
again	O
considered	O
nonresectable	O
.	O
	
Twenty	O
patients	O
were	O
disease-free	O
after	O
EAP	O
=+	O
/	O
=-	O
surgery	O
=+	O
/	O
=-	O
consolidation	O
chemotherapy	O
.	O
	
Toxicity	O
was	O
primarily	O
hematologic	O
.	O
	
Leukopenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
of	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
grade	O
3	O
occurred	O
in	O
30	O
%	O
and	O
9	O
%	O
","	O
respectively	O
and	O
grade	O
4	O
in	O
18	O
%	O
and	O
9	O
%	O
of	O
the	O
patients	O
","	O
respectively	O
.	O
	
There	O
was	O
no	O
increased	O
peri-	O
or	O
postoperative	O
morbidity	O
.	O
	
After	O
a	O
median	O
follow-up	O
of	O
20	O
months	O
for	O
disease-free	O
patients	O
","	O
the	O
relapse	O
rate	O
is	O
60	O
%	O
(	O
12	O
/	O
20	O
)	O
.	O
	
The	O
median	O
survival	O
time	O
for	O
all	O
patients	O
is	O
18	O
months	O
and	O
for	O
disease-free	O
patients	O
24	O
months	O
.	O
	
EAP	O
is	O
highly	O
effective	O
in	O
locally	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
","	O
and	O
offers	O
a	O
chance	O
for	O
surgery	O
with	O
curative	O
intention	O
in	O
patients	O
with	O
an	O
otherwise	O
fatal	O
prognosis	O
.	O
	
c	O
.	O
	
	
Both	O
cisplatin	B-DRUG
and	O
leucovorin	B-DRUG
may	O
increase	O
the	O
activity	O
of	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
by	O
increasing	O
the	O
intracellular	O
concentration	O
of	O
reduced	O
folates	O
.	O
	
Therefore	O
","	O
a	O
Phase	O
I	O
study	O
was	O
conducted	O
in	O
patients	O
with	O
recurrent	O
or	O
metastatic	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
in	O
which	O
high	O
doses	O
of	O
oral	O
leucovorin	B-DRUG
were	O
added	O
to	O
the	O
combination	O
of	O
cisplatin	B-DRUG
and	O
5-FU	B-DRUG
.	O
	
Patients	O
received	O
intravenous	O
cisplatin	B-DRUG
100	O
mg	O
/	O
m2	O
on	O
day	O
1	O
","	O
followed	O
by	O
a	O
continuous	O
intravenous	O
infusion	O
of	O
5-FU	B-DRUG
at	O
600	O
mg	O
/	O
m2	O
/	O
day	O
for	O
5	O
days	O
.	O
	
Leucovorin	B-DRUG
50	O
mg	O
/	O
m2	O
orally	O
was	O
administered	O
from	O
the	O
start	O
of	O
the	O
cisplatin	B-DRUG
infusion	O
and	O
then	O
every	O
6	O
hours	O
throughout	O
the	O
5-FU	B-DRUG
infusion	O
.	O
	
The	O
dose	O
of	O
5-FU	B-DRUG
was	O
increased	O
to	O
800	O
mg	O
/	O
m2	O
/	O
day	O
and	O
1	O
g	O
/	O
m2	O
/	O
day	O
according	O
to	O
observed	O
toxicity	O
.	O
	
In	O
a	O
second	O
phase	O
of	O
the	O
study	O
","	O
the	O
dose	O
of	O
leucovorin	B-DRUG
was	O
increased	O
to	O
50	O
mg	O
/	O
m2	O
orally	O
every	O
4	O
hours	O
.	O
	
Twenty-five	O
patients	O
were	O
registered	O
:	O
23	O
had	O
recurrent	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
after	O
extensive	O
treatment	O
;	O
two	O
had	O
newly	O
diagnosed	O
metastatic	O
disease	O
.	O
	
The	O
maximum	O
tolerated	O
dose	O
of	O
5-FU	B-DRUG
was	O
800	O
mg	O
/	O
m2	O
/	O
day	O
with	O
leucovorin	B-DRUG
administered	O
every	O
6	O
hours	O
.	O
	
Toxicities	O
at	O
that	O
level	O
included	O
mild-to-moderate	O
myelosuppression	B-TOXI
.	O
	
Mucositis	B-TOXI
in	O
the	O
previously	O
irradiated	O
field	O
prevented	O
the	O
further	O
increase	O
of	O
the	O
5-FU	B-DRUG
dose	O
to	O
1	O
g	O
/	O
m2	O
/	O
day	O
.	O
	
Identical	O
toxicities	O
were	O
observed	O
when	O
administering	O
5-FU	B-DRUG
at	O
800	O
mg	O
/	O
m2	O
/	O
day	O
with	O
50	O
mg	O
/	O
m2	O
of	O
leucovorin	B-DRUG
every	O
4	O
hours	O
.	O
	
Eighteen	O
patients	O
were	O
evaluated	O
for	O
response	O
:	O
one	O
had	O
a	O
pathologic	O
complete	O
response	O
;	O
nine	O
had	O
a	O
partial	O
response	O
(	O
including	O
four	O
who	O
had	O
previously	O
received	O
cisplatin	B-DRUG
and	O
5-FU	B-DRUG
as	O
induction	O
chemotherapy	O
)	O
.	O
	
Eight	O
patients	O
did	O
not	O
respond	O
.	O
	
The	O
median	O
survival	O
for	O
all	O
25	O
patients	O
was	O
6.5	O
months	O
.	O
	
It	O
was	O
concluded	O
that	O
the	O
combination	O
of	O
cisplatin	B-DRUG
","	O
5-FU	B-DRUG
","	O
and	O
leucovorin	B-DRUG
is	O
active	O
in	O
the	O
treatment	O
of	O
recurrent	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
.	O
	
The	O
maximum	O
tolerated	O
dose	O
of	O
5-FU	B-DRUG
in	O
previously	O
treated	O
patients	O
is	O
800	O
mg	O
/	O
m2	O
/	O
day	O
","	O
with	O
mucositis	O
being	O
the	O
dose-limiting	O
toxicity	O
.	O
	
Further	O
investigation	O
of	O
this	O
regimen	O
as	O
neoadjuvant	O
chemotherapy	O
in	O
previously	O
untreated	O
patients	O
with	O
locally	O
advanced	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
is	O
in	O
progress	O
.	O
	
VP-16	B-DRUG
and	O
carboplatin	B-DRUG
in	O
previously	O
untreated	O
patients	O
with	O
extensive	O
small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
a	O
study	O
of	O
the	O
National	O
Cancer	O
Institute	O
of	O
Canada	O
Clinical	O
Trials	O
Group	O
.	O
	
	
Thirty-four	O
previously	O
untreated	O
patients	O
with	O
extensive	O
small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
were	O
treated	O
with	O
a	O
combination	O
of	O
carboplatin	B-CANCER
300	O
mg	O
m-2	O
i.v.	O
on	O
day	O
1	O
and	O
etoposide	B-CANCER
100	O
mg	O
m-2	O
i.v.	O
on	O
days	O
1	O
","	O
2	O
and	O
3	O
every	O
28	O
days	O
.	O
	
Thirty-two	O
patients	O
were	O
assessable	O
for	O
response	O
.	O
	
Eighteen	O
patients	O
(	O
56	O
%	O
)	O
achieved	O
an	O
objective	O
response	O
(	O
95	O
%	O
confidence	O
limits	O
38	O
%	O
-73	O
%	O
)	O
.	O
	
Five	O
(	O
16	O
%	O
)	O
had	O
a	O
complete	O
response	O
and	O
13	O
(	O
41	O
%	O
)	O
had	O
a	O
partial	O
response	O
.	O
	
The	O
median	O
time	O
to	O
response	O
was	O
7.8	O
weeks	O
and	O
the	O
median	O
duration	O
of	O
response	O
was	O
23.1	O
weeks	O
(	O
range	O
6.2	O
to	O
54	O
weeks	O
)	O
.	O
	
The	O
median	O
survival	O
of	O
all	O
34	O
extensive	O
disease	O
patients	O
was	O
34.7	O
weeks	O
(	O
range	O
1.3-59.3	O
weeks	O
)	O
.	O
	
Myelosuppression	B-TOXI
(	O
leukopenia	B-TOXI
)	O
was	O
the	O
main	O
toxicity	O
.	O
	
There	O
was	O
one	O
early	O
death	B-TOXI
that	O
may	O
have	O
been	O
treatment-related	O
.	O
	
Biochemical	B-TOXI
renal	I-TOXI
dysfunction	I-TOXI
was	O
noted	O
in	O
two	O
patients	O
.	O
	
Paresthesiae	B-TOXI
and	O
tinnitus	B-TOXI
/	O
hearing	B-TOXI
loss	I-TOXI
were	O
described	O
by	O
three	O
and	O
two	O
patients	O
respectively	O
.	O
	
Serious	O
gastrointestinal	B-TOXI
toxicity	I-TOXI
was	O
infrequent	O
.	O
	
This	O
and	O
other	O
studies	O
have	O
shown	O
this	O
combination	O
to	O
be	O
active	O
and	O
well	O
tolerated	O
in	O
small	B-CANCER
cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
;	O
however	O
","	O
it	O
is	O
not	O
yet	O
clear	O
if	O
it	O
is	O
as	O
efficacious	O
as	O
the	O
more	O
commonly	O
used	O
VP-16-cisplatin	B-DRUG
regimen	O
.	O
	
Carboplatin	B-DRUG
(	O
Paraplatin	B-DRUG
;	O
JM8	O
)	O
and	O
etoposide	B-DRUG
(	O
VP-16	B-DRUG
)	O
as	O
first-line	O
combination	O
therapy	O
for	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
Fifty-two	O
previously	O
untreated	O
patients	O
with	O
small-cell	B-CANCER
lung	I-CANCER
carcinoma	I-CANCER
(	O
SCLC	B-CANCER
)	O
were	O
treated	O
with	O
a	O
combination	O
of	O
carboplatin	B-DRUG
300	O
mg	O
/	O
m2	O
intravenously	O
(	O
IV	O
)	O
on	O
day	O
1	O
and	O
etoposide	B-DRUG
100	O
mg	O
/	O
m2	O
IV	O
on	O
days	O
1	O
through	O
3	O
every	O
28	O
days	O
for	O
four	O
courses	O
.	O
	
Patients	O
with	O
limited	O
disease	O
(	O
LD	O
)	O
subsequently	O
received	O
thoracic	O
radiotherapy	O
;	O
no	O
prophylactic	O
cranial	O
radiotherapy	O
was	O
used	O
.	O
	
Forty-four	O
patients	O
(	O
85	O
%	O
)	O
achieved	O
an	O
objective	O
response	O
","	O
including	O
82	O
%	O
(	O
29	O
%	O
complete	O
remissions	O
)	O
of	O
LD	O
patients	O
and	O
88	O
%	O
(	O
13	O
%	O
complete	O
remissions	O
)	O
of	O
extensive-disease	O
(	O
ED	O
)	O
patients	O
.	O
	
Median	O
response	O
duration	O
for	O
LD	O
patients	O
was	O
7	O
months	O
and	O
5.5	O
months	O
for	O
ED	O
patients	O
.	O
	
Median	O
survival	O
for	O
both	O
LD	O
and	O
ED	O
patients	O
was	O
9.5	O
months	O
.	O
	
Myelosuppression	B-TOXI
was	O
the	O
main	O
toxicity	O
","	O
with	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
grade	O
3	O
/	O
4	O
leucopenia	B-TOXI
occurring	O
in	O
44	O
%	O
of	O
patients	O
.	O
	
There	O
was	O
one	O
(	O
2	O
%	O
)	O
treatment-related	O
neutropenic	B-TOXI
death	I-TOXI
.	O
	
Treatment	O
was	O
otherwise	O
well	O
tolerated	O
","	O
and	O
in	O
particular	O
no	B-TOXI
renal	I-TOXI
toxicity	I-TOXI
","	O
neurotoxicity	B-TOXI
","	O
or	O
ototoxicity	B-TOXI
was	O
seen	O
.	O
	
This	O
new	O
combination	O
is	O
highly	O
active	O
in	O
terms	O
of	O
response	O
rate	O
","	O
but	O
response	O
duration	O
and	O
survival	O
is	O
disappointing	O
","	O
and	O
might	O
be	O
improved	O
by	O
prolonged	O
treatment	O
or	O
by	O
the	O
use	O
of	O
additional	O
drugs	O
in	O
combination	O
.	O
	
A	O
pilot	O
study	O
of	O
carboplatin	B-DRUG
(	O
JM8	O
","	O
CBDCA	O
)	O
and	O
chlorambucil	B-DRUG
in	O
combination	O
for	O
advanced	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
	
Forty-six	O
patients	O
with	O
previously	O
untreated	O
","	O
advanced	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
received	O
carboplatin	B-DRUG
(	O
JM8	O
","	O
CBDCA	O
)	O
and	O
chlorambucil	B-DRUG
(	O
CLB	O
)	O
to	O
assess	O
the	O
efficacy	O
and	O
toxicity	O
of	O
this	O
combination	O
.	O
	
Carboplatin	B-DRUG
300	O
mg	O
m-2	O
was	O
given	O
on	O
day	O
1	O
with	O
CLB	O
10	O
mg	O
daily	O
for	O
7	O
","	O
10	O
or	O
14	O
days	O
;	O
6	O
treatment	O
courses	O
were	O
given	O
at	O
4月6日	O
weekly	O
intervals	O
in	O
the	O
absence	O
of	O
disease	O
progression	O
.	O
	
Tumour	O
response	O
was	O
assessed	O
","	O
where	O
possible	O
","	O
by	O
restaging	O
laparotomy	O
after	O
6	O
treatment	O
cycles	O
.	O
	
Five	O
complete	O
and	O
16	O
partial	O
remission	O
were	O
seen	O
in	O
37	O
evaluable	O
patients	O
giving	O
an	O
overall	O
response	O
rate	O
of	O
57	O
%	O
.	O
	
The	O
median	O
survival	O
of	O
all	O
patients	O
was	O
15	O
months	O
.	O
	
The	O
major	O
toxicity	O
was	O
myelosuppression	B-TOXI
.	O
	
Nausea	B-TOXI
and	O
vomiting	B-TOXI
were	O
generally	O
minor	O
(	O
WHO	O
","	O
grades	O
I	O
or	O
II	O
)	O
and	O
most	O
courses	O
were	O
given	O
on	O
an	O
outpatient	O
basis	O
.	O
	
Leucopenia	B-TOXI
was	O
the	O
major	O
factor	O
causing	O
treatment	O
delays	O
","	O
particularly	O
with	O
the	O
10	O
and	O
14	O
day	O
CLB	O
regimens	O
.	O
	
Thrombocytopenia	B-TOXI
was	O
minimal	O
in	O
the	O
early	O
chemotherapy	O
cycles	O
but	O
the	O
data	O
suggest	O
that	O
cumulative	O
toxicity	O
may	O
occur	O
.	O
	
This	O
combination	O
may	O
provide	O
a	O
satisfactory	O
degree	O
of	O
efficacy	O
with	O
less	O
toxicity	O
than	O
cisplatin-based	B-DRUG
regimens	O
.	O
	
Randomized	O
clinical	O
trial	O
of	O
tamoxifen	B-DRUG
alone	O
or	O
combined	O
with	O
fluoxymesterone	B-DRUG
in	O
postmenopausal	O
women	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
A	O
randomized	O
clinical	O
trial	O
was	O
performed	O
to	O
determine	O
if	O
combination	O
hormonal	O
therapy	O
with	O
tamoxifen	B-DRUG
(	O
TAM	B-DRUG
)	O
and	O
fluoxymesterone	B-DRUG
(	O
FLU	B-DRUG
)	O
was	O
more	O
efficacious	O
than	O
TAM	B-DRUG
alone	O
for	O
the	O
treatment	O
of	O
postmenopausal	O
women	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
failing	O
TAM	B-DRUG
could	O
subsequently	O
receive	O
FLU	B-DRUG
.	O
	
The	O
dose	O
of	O
both	O
drugs	O
was	O
10	O
mg	O
orally	O
twice	O
daily	O
.	O
	
Objective	O
responses	O
were	O
seen	O
in	O
50	O
of	O
119	O
TAM	B-DRUG
patients	O
(	O
42	O
%	O
)	O
and	O
63	O
of	O
119	O
TAM	B-DRUG
plus	O
FLU	B-DRUG
patients	O
(	O
53	O
%	O
)	O
(	O
one-sided	O
P	O
=	O
0.05	O
)	O
.	O
	
Time	O
to	O
disease	O
progression	O
distributions	O
were	O
better	O
for	O
TAM	B-DRUG
plus	O
FLU	B-DRUG
(	O
median	O
","	O
350	O
days	O
v	O
199	O
days	O
)	O
","	O
but	O
the	O
log	O
rank	O
test	O
only	O
approached	O
statistical	O
significance	O
(	O
one-sided	O
P	O
=	O
0.07	O
)	O
.	O
	
Duration	O
of	O
response	O
and	O
survival	O
distributions	O
were	O
similar	O
between	O
the	O
two	O
treatment	O
arms	O
.	O
	
Toxicities	O
","	O
in	O
terms	O
of	O
androgenic	B-TOXI
side	I-TOXI
effects	I-TOXI
","	O
were	O
greater	O
on	O
the	O
TAM	B-TOXI
plus	O
FLU	B-TOXI
regimen	O
.	O
	
Fifty-two	O
patients	O
are	O
evaluable	O
for	O
response	O
with	O
FLU	B-DRUG
following	O
TAM	B-DRUG
and	O
21	O
(	O
40	O
%	O
)	O
have	O
achieved	O
a	O
response	O
.	O
	
We	O
conclude	O
that	O
the	O
advantages	O
in	O
terms	O
of	O
response	O
rate	O
and	O
time	O
to	O
progression	O
observed	O
with	O
TAM	B-DRUG
plus	O
FLU	B-DRUG
probably	O
represent	O
a	O
biological	O
effect	O
","	O
but	O
are	O
not	O
of	O
sufficient	O
magnitude	O
to	O
justify	O
the	O
routine	O
clinical	O
use	O
of	O
this	O
combination	O
given	O
the	O
lack	O
of	O
survival	O
advantage	O
and	O
side	O
effects	O
encountered	O
.	O
	
A	O
phase	O
I-II	O
trial	O
of	O
carboplatin	B-DRUG
and	O
5-fluorouracil	B-DRUG
combination	O
chemotherapy	O
in	O
advanced	B-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
	
Twenty-nine	O
patients	O
with	O
recurrent	O
or	O
advanced	O
","	O
incurable	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
were	O
entered	O
into	O
a	O
phase	O
I-II	O
trial	O
of	O
carboplatin	B-DRUG
in	O
combination	O
with	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
"1,000"	O
mg	O
/	O
m2	O
/	O
d	O
continuous	O
intravenous	O
(	O
IV	O
)	O
infusion	O
for	O
five	O
days	O
every	O
28	O
days	O
.	O
	
The	O
initial	O
dose	O
of	O
carboplatin	B-DRUG
was	O
300	O
mg	O
/	O
m2	O
for	O
patients	O
with	O
Karnofsky	O
performance	O
scores	O
greater	O
than	O
or	O
equal	O
to	O
70	O
%	O
","	O
and	O
240	O
mg	O
/	O
m2	O
for	O
patients	O
with	O
scores	O
of	O
50	O
%	O
to	O
60	O
%	O
.	O
	
Subsequent	O
doses	O
were	O
modified	O
to	O
achieve	O
grade	O
2	O
myelo-suppression	B-TOXI
:	O
WBC	O
","	O
"2,000"	O
to	O
"2,999"	O
cells	O
/	O
microL	O
;	O
granulocytes	O
","	O
"1,000"	O
to	O
"1,499"	O
cells	O
/	O
microL	O
;	O
and	O
platelets	O
","	O
"50,000"	O
to	O
"75,000"	O
cells	O
/	O
microL	O
.	O
	
Dose	O
levels	O
were	O
180	O
","	O
240	O
","	O
300	O
","	O
360	O
","	O
and	O
420	O
mg	O
/	O
m2	O
.	O
	
Twenty-eight	O
patients	O
had	O
squamous-cell	B-CANCER
cancers	I-CANCER
and	O
one	O
had	O
an	O
adenoid	B-CANCER
cystic	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
parotid	I-CANCER
.	O
	
There	O
were	O
26	O
patients	O
with	O
recurrent	O
disease	O
;	O
22	O
had	O
received	O
prior	O
RT	O
;	O
only	O
two	O
had	O
received	O
other	O
chemotherapy	O
immediately	O
before	O
study	O
entry	O
.	O
	
Three	O
patients	O
had	O
newly	O
diagnosed	O
incurable	O
stage	O
IV	O
disease	O
.	O
	
The	O
median	O
performance	O
status	O
was	O
80	O
%	O
(	O
range	O
","	O
60	O
%	O
to	O
90	O
%	O
)	O
.	O
	
All	O
patients	O
had	O
objectively	O
measurable	O
disease	O
","	O
and	O
28	O
were	O
evaluable	O
for	O
response	O
.	O
	
There	O
were	O
three	O
complete	O
responses	O
(	O
CRs	O
)	O
and	O
ten	O
partial	O
responses	O
(	O
PRs	O
)	O
(	O
48	O
%	O
CR	O
and	O
PR	O
)	O
;	O
the	O
median	O
duration	O
of	O
response	O
was	O
4.7	O
months	O
(	O
range	O
","	O
1.5	O
to	O
15+	O
months	O
)	O
.	O
	
Dose-limiting	O
toxicities	O
were	O
granulocytopenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
and	O
stomatitis	B-TOXI
.	O
	
Prolonged	O
myelosuppression	B-TOXI
delayed	O
retreatment	O
in	O
eight	O
patients	O
and	O
delayed	O
19	O
of	O
107	O
(	O
18	O
%	O
)	O
courses	O
.	O
	
Stomatitis	B-TOXI
occurred	O
in	O
61	O
%	O
and	O
diarrhea	B-TOXI
in	O
29	O
%	O
.	O
	
5-FU	B-DRUG
dosage	O
was	O
decreased	O
in	O
ten	O
patients	O
(	O
36	O
%	O
)	O
for	O
grade	O
2	O
or	O
greater	O
stomatitis	B-TOXI
or	O
diarrhea	B-TOXI
.	O
	
Mild	O
to	O
moderate	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
occurred	O
in	O
66	O
%	O
of	O
patient	O
trials	O
in	O
which	O
no	O
pretreatment	O
antiemetics	O
were	O
administered	O
.	O
	
Other	O
toxicities	O
included	O
phlebitis	B-TOXI
from	O
5-FU	B-DRUG
in	O
71	O
%	O
","	O
skin	B-TOXI
toxicity	I-TOXI
in	O
11	O
%	O
","	O
mild	B-TOXI
alopecia	I-TOXI
in	O
25	O
%	O
","	O
and	O
fatigue	B-TOXI
in	O
54	O
%	O
of	O
patients	O
.	O
	
Nephrotoxicity	B-TOXI
(	O
creatinine	B-DRUG
greater	O
than	O
2	O
mg	O
/	O
dL	O
)	O
occurred	O
in	O
one	O
patient	O
.	O
	
The	O
dose	O
of	O
carboplatin	B-DRUG
resulting	O
in	O
grade	O
2	O
toxicity	O
was	O
180	O
mg	O
/	O
m2	O
in	O
one	O
patient	O
","	O
240	O
mg	O
/	O
m2	O
in	O
one	O
","	O
300	O
mg	O
/	O
m2	O
in	O
seven	O
","	O
360	O
mg	O
/	O
m2	O
in	O
ten	O
","	O
and	O
420	O
mg	O
/	O
m2	O
in	O
one	O
.	O
	
Based	O
on	O
these	O
results	O
","	O
we	O
recommend	O
a	O
starting	O
dose	O
of	O
carboplatin	B-DRUG
","	O
300	O
mg	O
/	O
m2	O
","	O
in	O
combination	O
with	O
five	O
days	O
of	O
continuous	O
infusion	O
5-FU	B-DRUG
.	O
	
In	O
this	O
dose	O
and	O
schedule	O
","	O
this	O
combination	O
was	O
well	O
tolerated	O
and	O
demonstrated	O
antitumor	O
activity	O
in	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
.	O
	
To	O
confirm	O
these	O
promising	O
results	O
","	O
a	O
Southwest	O
Oncology	O
Group	O
prospective	O
randomized	O
trial	O
is	O
in	O
progress	O
comparing	O
carboplatin	B-DRUG
and	O
5-FU	B-DRUG
","	O
cisplatin	B-DRUG
and	O
5-FU	B-DRUG
","	O
and	O
standard-dose	O
weekly	O
methotrexate	B-DRUG
in	O
recurrent-disease	O
patients	O
.	O
	
Intensive	O
combination	O
chemotherapy	O
(	O
ROAP	O
10	O
)	O
and	O
splenectomy	O
in	O
the	O
management	O
of	O
chronic	B-CANCER
myelogenous	I-CANCER
leukemia	I-CANCER
.	O
	
	
To	O
investigate	O
the	O
role	O
of	O
intensive	O
chemotherapy	O
in	O
chronic	B-CANCER
myelogenous	I-CANCER
leukemia	I-CANCER
(	O
CML	B-CANCER
)	O
","	O
we	O
treated	O
37	O
patients	O
who	O
had	O
Philadelphia-positive	O
benign-phase	O
disease	O
with	O
rubidazone	B-DRUG
300	O
mg	O
/	O
m2	O
/	O
d	O
1	O
(	O
or	O
daunorubicin	B-DRUG
30	O
mg	O
/	O
m2	O
/	O
d	O
X	O
4	O
)	O
","	O
cytosine	B-DRUG
arabinoside	I-DRUG
80	O
mg	O
/	O
m2	O
/	O
d	O
X	O
10	O
","	O
vincristine	B-DRUG
2	O
mg	O
/	O
d	O
1	O
","	O
and	O
prednisone	B-DRUG
100	O
mg	O
/	O
d	O
X	O
5	O
(	O
ROAP	O
10	O
)	O
","	O
every	O
four	O
weeks	O
for	O
a	O
median	O
of	O
three	O
cycles	O
.	O
	
This	O
treatment	O
was	O
followed	O
by	O
splenectomy	O
and	O
by	O
subsequent	O
maintenance	O
therapy	O
with	O
1	O
to	O
5	O
g	O
hydroxyurea	B-DRUG
daily	O
in	O
intermittent	O
courses	O
.	O
	
After	O
a	O
median	O
follow-up	O
of	O
42	O
months	O
(	O
range	O
","	O
24	O
to	O
54	O
months	O
)	O
","	O
20	O
patients	O
(	O
54	O
%	O
)	O
remain	O
in	O
benign	O
phase	O
.	O
	
The	O
projected	O
median	O
survival	O
is	O
52	O
months	O
","	O
and	O
the	O
three-year	O
survival	O
rate	O
is	O
67	O
%	O
.	O
	
Six	O
patients	O
(	O
16	O
%	O
)	O
developed	O
blastic	O
crisis	O
","	O
and	O
eight	O
died	B-TOXI
in	O
the	O
benign	O
phase	O
.	O
	
A	O
significant	O
cytogenetic	O
response	O
","	O
defined	O
as	O
a	O
fall	O
in	O
the	O
percentage	O
of	O
Philadelphia-positive	O
cells	O
to	O
less	O
than	O
or	O
equal	O
to	O
30	O
%	O
","	O
occurred	O
in	O
18	O
(	O
53	O
%	O
)	O
of	O
34	O
patients	O
who	O
had	O
serial	O
cytogenetic	O
studies	O
.	O
	
Six	O
patients	O
(	O
18	O
%	O
)	O
had	O
reductions	O
to	O
35	O
%	O
to	O
90	O
%	O
","	O
whereas	O
ten	O
remained	O
100	O
%	O
positive	O
.	O
	
Cytogenetic	O
response	O
lasted	O
for	O
a	O
median	O
of	O
six	O
months	O
from	O
the	O
time	O
of	O
maximal	O
response	O
(	O
range	O
","	O
1	O
to	O
18	O
months	O
)	O
.	O
	
Blastic	O
crisis	O
or	O
accelerated	O
disease	O
developed	O
in	O
seven	O
(	O
44	O
%	O
)	O
of	O
the	O
16	O
patients	O
who	O
manifested	O
minimal	O
or	O
no	O
cytogenetic	O
response	O
","	O
compared	O
to	O
only	O
two	O
of	O
the	O
18	O
patients	O
(	O
11	O
%	O
)	O
who	O
achieved	O
a	O
significant	O
cytogenetic	O
response	O
.	O
	
Toxicity	O
","	O
which	O
resulted	O
in	O
one	O
death	B-TOXI
","	O
was	O
due	O
to	O
myelosuppression	B-TOXI
and	O
consisted	O
of	O
febrile	B-TOXI
episodes	O
during	O
neutropenia	B-TOXI
(	O
24	O
%	O
of	O
courses	O
)	O
","	O
documented	B-TOXI
infections	I-TOXI
(	O
8	O
%	O
of	O
courses	O
)	O
","	O
and	O
bleeding	B-TOXI
(	O
8	O
%	O
of	O
courses	O
)	O
.	O
	
ROAP	O
10	O
intensive	O
therapy	O
produces	O
moderate	O
survival	O
improvement	O
for	O
CML	B-CANCER
patients	O
compared	O
to	O
a	O
matched	O
historical	O
control	O
group	O
of	O
patients	O
treated	O
at	O
our	O
institution	O
","	O
but	O
it	O
has	O
considerable	O
myelosuppressive	B-TOXI
toxicity	O
.	O
	
The	O
Philadelphia	O
chromosome	O
response	O
is	O
an	O
important	O
treatment-related	O
prognostic	O
factor	O
.	O
	
Phase	O
I	O
study	O
of	O
topotecan	B-DRUG
and	O
cisplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
:	O
a	O
cancer	O
and	O
leukemia	B-CANCER
group	O
B	O
study	O
.	O
	
	
The	O
objectives	O
of	O
this	O
phase	O
I	O
trial	O
were	O
to	O
determine	O
the	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
of	O
the	O
novel	O
topoisomerase	O
I	O
inhibitor	O
topotecan	B-DRUG
combined	O
with	O
cisplatin	B-DRUG
","	O
to	O
define	O
the	O
maximum-tolerated	O
doses	O
(	O
MTDs	O
)	O
of	O
the	O
combination	O
without	O
and	O
with	O
the	O
use	O
of	O
filgrastim	B-DRUG
","	O
and	O
to	O
define	O
recommended	O
doses	O
for	O
phase	O
II	O
trials	O
.	O
	
Patients	O
with	O
advanced	B-CANCER
solid	I-CANCER
tumors	I-CANCER
were	O
eligible	O
if	O
they	O
had	O
normal	O
bone	O
marrow	O
","	O
renal	O
","	O
and	O
hepatic	O
function	O
and	O
had	O
not	O
previously	O
been	O
treated	O
with	O
platinum	B-DRUG
compounds	O
.	O
	
Topotecan	B-DRUG
was	O
administered	O
intravenously	O
on	O
days	O
1	O
through	O
5	O
and	O
cisplatin	B-DRUG
was	O
administered	O
intravenously	O
on	O
day	O
1	O
of	O
a	O
21-day	O
cycle	O
.	O
	
The	O
topotecan	B-DRUG
dose	O
was	O
fixed	O
at	O
1	O
mg	O
/	O
m2	O
/	O
d	O
on	O
the	O
first	O
four	O
dose	O
levels	O
","	O
and	O
cisplatin	B-DRUG
was	O
escalated	O
in	O
25-mg	O
/	O
m2	O
increments	O
from	O
25	O
to	O
100	O
mg	O
/	O
m2	O
without	O
filgrastim	B-DRUG
.	O
	
After	O
encountering	O
DLT	O
","	O
the	O
dose	O
of	O
cisplatin	B-DRUG
was	O
decreased	O
by	O
one	O
level	O
and	O
topotecan	B-DRUG
dose	O
escalation	O
was	O
attempted	O
.	O
	
After	O
defining	O
the	O
MTD	O
without	O
growth	O
factor	O
","	O
the	O
study	O
proceeded	O
with	O
escalating	O
cisplatin	B-DRUG
doses	O
to	O
define	O
the	O
MTD	O
with	O
filgrastim	B-DRUG
5	O
micrograms	O
/	O
kg	O
subcutaneously	O
(	O
SC	O
)	O
daily	O
starting	O
on	O
day	O
6	O
of	O
treatment	O
.	O
	
Priming	O
with	O
filgrastim	B-DRUG
5	O
micrograms	O
/	O
kg	O
SC	O
on	O
days	O
-6	O
to	O
-2	O
before	O
the	O
first	O
course	O
was	O
explored	O
last	O
.	O
	
Of	O
38	O
patients	O
entered	O
","	O
37	O
were	O
eligible	O
","	O
35	O
assessable	O
for	O
toxicity	O
in	O
the	O
first	O
course	O
","	O
and	O
28	O
assessable	O
for	O
response	O
.	O
	
The	O
principal	O
toxicity	O
was	O
grade	O
4	O
neutropenia	B-TOXI
","	O
which	O
had	O
to	O
last	O
more	O
than	O
7	O
days	O
to	O
be	O
considered	O
dose-limiting	O
.	O
	
No	O
DLT	O
was	O
observed	O
at	O
the	O
starting	O
cisplatin	B-DRUG
dose	O
of	O
25	O
mg	O
/	O
m2	O
(	O
dose	O
level	O
1	O
)	O
.	O
	
On	O
level	O
2	O
(	O
cisplatin	B-DRUG
50	O
mg	O
/	O
m2	O
","	O
one	O
patient	O
had	O
dose-limiting	O
neutropenia	B-TOXI
and	O
one	O
patient	O
had	O
grade	O
3	O
renal	B-TOXI
toxicity	I-TOXI
.	O
	
On	O
level	O
3	O
(	O
cisplatin	B-DRUG
75	O
mg	O
/	O
m2	O
)	O
","	O
two	O
patients	O
had	O
dose-limiting	O
neutropenia	B-TOXI
.	O
	
Therefore	O
","	O
cisplatin	B-DRUG
dose	O
escalation	O
was	O
stopped	O
.	O
	
On	O
dose	O
level	O
5	O
(	O
cisplatin	B-DRUG
50	O
mg	O
/	O
m2	O
and	O
topotecan	B-DRUG
1.25	O
mg	O
/	O
m2	O
/	O
d	O
)	O
","	O
one	O
patient	O
had	O
grade	O
4	O
neutropenia	B-TOXI
that	O
lasted	O
more	O
than	O
7	O
days	O
and	O
one	O
patient	O
died	B-TOXI
of	O
neutropenic	B-TOXI
sepsis	I-TOXI
.	O
	
The	O
remaining	O
dose	O
levels	O
used	O
topotecan	B-DRUG
1	O
mg	O
/	O
m2	O
/	O
d	O
plus	O
cisplatin	B-DRUG
75	O
mg	O
/	O
m2	O
(	O
level	O
6	O
)	O
and	O
100	O
mg	O
/	O
m2	O
(	O
levels	O
7	O
and	O
8	O
)	O
with	O
filgrastim	B-DRUG
.	O
	
No	O
DLT	O
was	O
observed	O
on	O
level	O
6	O
On	O
level	O
7	O
","	O
two	O
patients	O
had	O
dose-limiting	O
neutropenia	B-TOXI
and	O
one	O
patient	O
had	O
grade	O
3	O
hyperbilirubinemia	B-TOXI
.	O
	
Priming	O
with	O
filgrastim	B-DRUG
on	O
level	O
8	O
demonstrated	O
no	O
obvious	O
advantage	O
over	O
level	O
7	O
","	O
and	O
one	O
patient	O
had	O
grade	O
4	O
thrombocytopenia	B-TOXI
that	O
lasted	O
more	O
than	O
7	O
days	O
.	O
	
Three	O
patients	O
with	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
achieved	O
a	O
partial	O
response	O
and	O
one	O
patient	O
with	O
breast	B-CANCER
cancer	I-CANCER
had	O
a	O
complete	O
response	O
.	O
	
Topotecan	B-DRUG
and	O
cisplatin	B-DRUG
in	O
combination	O
cause	O
more	O
neutropenia	B-TOXI
than	O
expected	O
from	O
either	O
drug	O
given	O
alone	O
at	O
the	O
same	O
dosage	O
.	O
	
The	O
recommended	O
phase	O
II	O
doses	O
are	O
topotecan	B-DRUG
1	O
mg	O
/	O
m2	O
/	O
d	O
for	O
5	O
days	O
in	O
combination	O
with	O
cisplatin	B-DRUG
50	O
mg	O
/	O
m2	O
on	O
day	O
1	O
without	O
filgrastim	B-DRUG
or	O
cisplatin	B-DRUG
75	O
mg	O
/	O
m2	O
on	O
day	O
1	O
with	O
filgrastim	B-DRUG
support	O
.	O
	
Symptom	O
relief	O
with	O
MVP	O
(	O
mitomycin	B-DRUG
C	I-DRUG
","	O
vinblastine	B-DRUG
and	O
cisplatin	B-DRUG
)	O
chemotherapy	O
in	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
role	O
of	O
chemotherapy	O
in	O
the	O
palliation	O
of	O
patients	O
with	O
advanced	O
stage	O
(	O
IIIB	O
and	O
IV	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
remains	O
controversial	O
.	O
	
We	O
have	O
carried	O
out	O
a	O
chemotherapy	O
study	O
emphasising	O
symptom	O
relief	O
","	O
a	O
topic	O
not	O
normally	O
discussed	O
in	O
previous	O
similar	O
studies	O
.	O
	
A	O
total	O
of	O
120	O
patients	O
with	O
locally	O
advanced	O
or	O
metastatic	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
were	O
treated	O
with	O
a	O
moderate-dose	O
palliative	O
chemotherapy	O
regimen	O
consisting	O
of	O
mitomycin	B-DRUG
C	I-DRUG
8	O
mg	O
m-2	O
i.v.	O
on	O
day	O
1	O
(	O
alternate	O
courses	O
)	O
","	O
vinblastine	B-DRUG
6	O
mg	O
m-2	O
i.v.	O
on	O
day	O
1	O
and	O
cisplatin	B-DRUG
50	O
mg	O
m-2	O
i.v.	O
on	O
day	O
1	O
(	O
MVP	O
)	O
","	O
repeating	O
every	O
21	O
days	O
for	O
a	O
maximum	O
of	O
six	O
courses	O
.	O
	
Thirty-eight	O
of	O
118	O
assessable	O
patients	O
(	O
32	O
%	O
)	O
achieved	O
an	O
objective	O
response	O
.	O
	
Patients	O
with	O
locally	O
advanced	O
disease	O
(	O
stage	O
IIIB	O
)	O
had	O
a	O
significantly	O
better	O
response	O
rate	O
(	O
52	O
%	O
)	O
than	O
those	O
with	O
metastatic	O
disease	O
(	O
25	O
%	O
)	O
(	O
P	O
&	O
lt	O
;	O
0.01	O
)	O
.	O
	
In	O
76	O
out	O
of	O
110	O
(	O
69	O
%	O
)	O
patients	O
","	O
with	O
tumour-related	O
symptoms	O
including	O
24	O
out	O
of	O
31	O
patients	O
(	O
78	O
%	O
)	O
with	O
locally	O
advanced	O
disease	O
","	O
symptoms	O
completely	O
disappeared	O
or	O
substantially	O
improved	O
.	O
	
In	O
only	O
15	O
patients	O
(	O
14	O
%	O
)	O
did	O
symptoms	O
progress	O
during	O
treatment	O
.	O
	
Symptomatic	O
improvement	O
was	O
achieved	O
after	O
one	O
course	O
of	O
chemotherapy	O
in	O
61	O
%	O
and	O
after	O
two	O
courses	O
in	O
96	O
%	O
of	O
responding	O
patients	O
.	O
	
The	O
schedule	O
was	O
well	O
tolerated	O
.	O
	
Only	O
19	O
%	O
developed	O
WHO	O
grade	O
3	O
/	O
4	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
","	O
and	O
only	O
3	O
%	O
developed	O
significant	O
alopecia	B-TOXI
.	O
	
Other	O
toxicities	O
were	O
minimal	O
.	O
	
MVP	O
is	O
a	O
pragmatic	O
inexpensive	O
chemotherapy	O
regimen	O
that	O
offers	O
useful	O
symptom	O
palliation	O
in	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
and	O
merits	O
a	O
1月2日	O
course	O
therapeutic	O
trial	O
in	O
such	O
patients	O
.	O
	
The	O
schedule	O
should	O
also	O
be	O
assessed	O
as	O
primary	O
(	O
neoadjuvant	O
)	O
chemotherapy	O
before	O
radical	O
radiotherapy	O
for	O
locally	O
advanced	B-CANCER
NSCLC	I-CANCER
in	O
a	O
randomised	O
trial	O
.	O
	
Laevofolinic	B-DRUG
acid	I-DRUG
","	O
5-fluorouracil	B-DRUG
","	O
cyclophosphamide	B-DRUG
and	O
escalating	O
doses	O
of	O
epirubicin	B-DRUG
with	O
granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
support	O
in	O
locally	O
advanced	O
and	O
/	O
or	O
metastatic	B-CANCER
breast	I-CANCER
carcinoma	I-CANCER
:	O
a	O
phase	O
I-II	O
study	O
of	O
the	O
Southern	O
Italy	O
Oncology	O
Group	O
(	O
GOIM	O
)	O
.	O
	
	
Sixty-four	O
consecutive	O
patients	O
with	O
locally	O
advanced	O
(	O
n	O
=	O
7	O
)	O
or	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
(	O
n	O
=	O
57	O
)	O
","	O
were	O
treated	O
with	O
a	O
combination	O
of	O
laevofolinic	B-DRUG
acid	I-DRUG
100	O
mg	O
m-2	O
plus	O
5-fluorouracil	B-DRUG
340	O
mg	O
m-2	O
i.v.	O
on	O
days	O
1月3日	O
","	O
cyclophosphamide	B-DRUG
600	O
mg	O
m-2	O
i.v.	O
on	O
day	O
1	O
and	O
epirubicin	B-DRUG
90	O
mg	O
m-2	O
i.v.	O
on	O
day	O
1	O
Epirubicin	B-DRUG
dose	O
was	O
progressively	O
escalated	O
by	O
10	O
mg	O
m-2	O
per	O
cycle	O
up	O
to	O
120	O
mg	O
m-2	O
in	O
the	O
absence	O
of	O
dose-limiting	O
toxicities	O
.	O
	
Granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
(	O
G-CSF	B-DRUG
)	O
was	O
given	O
subcutaneously	O
in	O
order	O
to	O
prevent	O
neutropenia	B-TOXI
.	O
	
Epirubicin	B-DRUG
dosage	O
could	O
be	O
increased	O
to	O
100	O
mg	O
m-2	O
in	O
53	O
patients	O
(	O
87	O
%	O
)	O
","	O
to	O
110	O
mg	O
m-2	O
in	O
31	O
patients	O
(	O
51	O
%	O
)	O
and	O
to	O
120	O
mg	O
m-2	O
in	O
18	O
cases	O
(	O
30	O
%	O
)	O
.	O
	
In	O
most	O
patients	O
the	O
dose-limiting	O
toxicity	O
was	O
represented	O
by	O
myelosuppression	B-TOXI
.	O
	
A	O
statistically	O
significant	O
correlation	O
was	O
found	O
between	O
median	O
white	O
blood	O
count	O
(	O
WBC	O
)	O
or	O
absolute	O
neutrophil	O
count	O
(	O
ANC	O
)	O
nadir	O
and	O
epirubicin	B-DRUG
dose	O
level	O
(	O
P	O
=	O
0.009	O
;	O
P	O
=	O
0.008	O
)	O
.	O
	
Moreover	O
","	O
a	O
statistically	O
significant	O
correlation	O
was	O
observed	O
between	O
the	O
number	O
of	O
chemotherapeutic	O
cycles	O
","	O
nadir	O
ANC	O
and	O
WBC	O
and	O
the	O
occurrence	O
of	O
anaemia	B-TOXI
and	O
thrombocytopenia	B-TOXI
of	O
increasing	O
severity	O
.	O
	
These	O
data	O
suggest	O
the	O
occurrence	O
of	O
progressive	O
cumulative	O
bone	B-TOXI
marrow	I-TOXI
toxicity	I-TOXI
.	O
	
Although	O
patients	O
who	O
reached	O
different	O
epirubicin	B-DRUG
levels	O
showed	O
differences	O
in	O
mean	O
dose	O
intensity	O
","	O
such	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O
	
No	O
correlation	O
was	O
found	O
between	O
the	O
increase	O
in	O
dose	O
intensity	O
and	O
type	O
","	O
rate	O
or	O
duration	O
of	O
objective	O
responses	O
.	O
	
In	O
patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
the	O
overall	O
response	O
rate	O
was	O
72	O
%	O
(	O
95	O
%	O
CL	O
66-78	O
%	O
)	O
with	O
a	O
25	O
%	O
complete	O
response	O
rate	O
.	O
	
Median	O
duration	O
of	O
response	O
was	O
10	O
and	O
13	O
months	O
respectively	O
for	O
complete	O
and	O
partial	O
responses	O
.	O
	
All	O
patients	O
with	O
locally	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
had	O
an	O
objective	O
response	O
and	O
underwent	O
radical	O
mastectomy	O
.	O
	
Projected	O
median	O
survival	O
of	O
the	O
whole	O
series	O
of	O
patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
was	O
20	O
=+	O
months	O
.	O
	
These	O
data	O
demonstrate	O
that	O
the	O
combination	O
of	O
5-fluorouracil	B-DRUG
with	O
laevofolinic	B-DRUG
acid	I-DRUG
","	O
cyclophosphamide	B-DRUG
and	O
epirubicin	B-DRUG
is	O
very	O
active	O
against	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Use	O
of	O
G-CSF	B-DRUG
allows	O
epirubicin	B-DRUG
dosage	O
to	O
be	O
increased	O
up	O
to	O
120	O
mg	O
m-2	O
cycle-1	O
","	O
but	O
its	O
use	O
may	O
be	O
linked	O
to	O
the	O
occurrence	O
of	O
sometimes	O
severe	O
cumulative	O
haematological	B-TOXI
toxicity	I-TOXI
.	O
	
The	O
importance	O
of	O
bleomycin	B-DRUG
in	O
combination	O
chemotherapy	O
for	O
good-prognosis	O
germ	B-CANCER
cell	I-CANCER
carcinoma.	I-CANCER
Australasian	O
Germ	O
Cell	O
Trial	O
Group	O
.	O
	
	
In	O
an	O
effort	O
to	O
maintain	O
the	O
excellent	O
long-term	O
results	O
achieved	O
with	O
combination	O
chemotherapy	O
for	O
good-prognosis	O
germ	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
","	O
but	O
to	O
reduce	O
the	O
toxicities	O
encountered	O
","	O
a	O
randomized	O
trial	O
was	O
conducted	O
comparing	O
cisplatin	B-DRUG
and	O
vinblastine	B-DRUG
with	O
or	O
without	O
bleomycin	B-DRUG
.	O
	
Two	O
hundred	O
eighteen	O
assessable	O
patients	O
with	O
a	O
good	O
prognosis	O
were	O
randomized	O
to	O
receive	O
induction	O
chemotherapy	O
with	O
cisplatin	B-DRUG
100	O
mg	O
/	O
m2	O
intravenously	O
(	O
IV	O
)	O
day	O
1	O
and	O
vinblastine	B-DRUG
6	O
mg	O
/	O
m2	O
IV	O
days	O
1	O
and	O
2	O
every	O
3	O
weeks	O
(	O
PV	O
)	O
with	O
or	O
without	O
bleomycin	B-DRUG
30	O
mg	O
intramuscularly	O
(	O
IM	O
)	O
weekly	O
(	O
PVB	O
)	O
for	O
a	O
maximum	O
of	O
12	O
weeks	O
.	O
	
Once	O
maximum	O
response	O
was	O
achieved	O
","	O
patients	O
with	O
a	O
complete	O
remission	O
(	O
CR	O
)	O
received	O
two	O
courses	O
of	O
consolidation	O
chemotherapy	O
","	O
while	O
those	O
with	O
residual	O
abnormalities	O
and	O
normal	O
tumor	O
markers	O
underwent	O
surgical	O
resection	O
whenever	O
possible	O
.	O
	
Toxicities	O
encountered	O
in	O
this	O
study	O
were	O
clearly	O
greater	O
for	O
those	O
patients	O
who	O
received	O
bleomycin	B-DRUG
","	O
with	O
significantly	O
more	O
leukopenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
anemia	B-TOXI
","	O
alopecia	B-TOXI
","	O
and	O
renal	B-TOXI
and	I-TOXI
pulmonary	I-TOXI
toxicities	I-TOXI
.	O
	
The	O
proportion	O
of	O
patients	O
who	O
achieved	O
CR	O
and	O
had	O
no	O
evidence	O
of	O
disease	O
(	O
resection	O
of	O
all	O
viable	O
malignancy	O
)	O
was	O
89	O
%	O
for	O
PV	O
and	O
94	O
%	O
for	O
PVB	O
(	O
P	O
=	O
0.29	O
)	O
.	O
	
After	O
a	O
minimum	O
of	O
4	O
years	O
of	O
follow-up	O
","	O
relapses	O
have	O
occurred	O
in	O
7	O
%	O
of	O
patients	O
who	O
received	O
PV	O
and	O
5	O
%	O
who	O
received	O
PVB	O
.	O
	
A	O
total	O
of	O
five	O
patients	O
on	O
each	O
therapy	O
arm	O
were	O
successfully	O
treated	O
with	O
further	O
salvage	O
chemotherapy	O
and	O
surgery	O
.	O
	
Thus	O
","	O
deaths	B-TOXI
from	O
progressive	O
malignancy	O
have	O
occurred	O
in	O
15	O
%	O
of	O
patients	O
on	O
PV	O
and	O
5	O
%	O
on	O
PVB	O
(	O
P	O
=	O
0.02	O
)	O
","	O
a	O
rate	O
that	O
was	O
partly	O
offset	O
by	O
the	O
higher	O
proportion	O
of	O
toxic	O
deaths	B-TOXI
with	O
PVB	O
(	O
P	O
=	O
0.06	O
)	O
.	O
	
Despite	O
the	O
toxicities	O
encountered	O
with	O
bleomycin	B-DRUG
in	O
cisplatin-based	B-DRUG
combination	O
chemotherapy	O
for	O
these	O
patients	O
","	O
complete	O
deletion	O
of	O
this	O
drug	O
compromises	O
therapeutic	O
efficacy	O
.	O
	
Phase	O
II	O
study	O
of	O
concurrent	O
radiotherapy	O
and	O
chemotherapy	O
for	O
unresectable	O
stage	O
III	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer.	I-CANCER
Southern	O
Osaka	O
Lung	B-CANCER
Cancer	I-CANCER
Study	O
Group	O
.	O
	
	
To	O
evaluate	O
the	O
response	O
rate	O
","	O
toxicity	O
","	O
and	O
2-year	O
survival	O
rate	O
of	O
concurrent	O
radiotherapy	O
and	O
chemotherapy	O
for	O
unresectable	O
stage	O
III	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Between	O
July	O
1989	O
and	O
October	O
1990	O
","	O
65	O
patients	O
with	O
histologically	O
or	O
cytologically	O
proven	O
unresectable	O
stage	O
III	O
NSCLC	B-CANCER
without	O
T3N0-1M0	O
disease	O
were	O
entered	O
onto	O
this	O
study	O
.	O
	
Sixty-one	O
patients	O
were	O
eligible	O
for	O
response	O
","	O
survival	O
","	O
and	O
toxicity	O
analysis	O
.	O
	
Chemotherapy	O
consisted	O
of	O
vindesine	B-DRUG
(	O
3	O
mg	O
/	O
m2	O
on	O
days	O
1	O
","	O
8	O
","	O
29	O
","	O
and	O
36	O
)	O
","	O
cisplatin	B-DRUG
(	O
100	O
mg	O
/	O
m2	O
on	O
days	O
1	O
and	O
29	O
)	O
","	O
and	O
mitomycin	B-DRUG
(	O
8	O
mg	O
/	O
m2	O
on	O
days	O
1	O
and	O
29	O
)	O
.	O
	
Radiotherapy	O
was	O
administered	O
for	O
3	O
weeks	O
(	O
2	O
Gy	O
given	O
13	O
times	O
","	O
five	O
fractions	O
per	O
week	O
)	O
","	O
followed	O
by	O
10-day	O
rest	O
periods	O
and	O
then	O
the	O
previous	O
schedule	O
of	O
radiotherapy	O
repeated	O
for	O
3	O
weeks	O
.	O
	
Of	O
61	O
eligible	O
patients	O
","	O
53	O
(	O
86.9	O
%	O
)	O
had	O
a	O
partial	O
response	O
(	O
PR	O
)	O
.	O
	
The	O
median	O
response	O
duration	O
was	O
39.1	O
weeks	O
(	O
range	O
","	O
8.4	O
to	O
163+	O
)	O
.	O
	
The	O
median	O
survival	O
time	O
was	O
16	O
months	O
and	O
the	O
2-year	O
survival	O
rate	O
was	O
36.7	O
%	O
.	O
	
Of	O
53	O
responding	O
patients	O
","	O
10	O
(	O
16.4	O
%	O
)	O
are	O
alive	O
and	O
disease-free	O
after	O
2	O
years	O
.	O
	
The	O
major	O
toxicity	O
was	O
leukopenia	B-TOXI
(	O
&	O
gt	O
;	O
or	O
=	O
grade	O
3	O
","	O
95	O
%	O
)	O
.	O
	
Other	O
toxicities	O
of	O
&	O
gt	O
;	O
or	O
=	O
grade	O
3	O
included	O
thrombocytopenia	B-TOXI
(	O
45	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
28	O
%	O
)	O
","	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
(	O
16	O
%	O
)	O
","	O
fever	B-TOXI
(	O
11	O
%	O
)	O
","	O
and	O
esophagitis	B-TOXI
(	O
6	O
%	O
)	O
.	O
	
Treatment-related	O
death	B-TOXI
occurred	O
in	O
two	O
patients	O
.	O
	
One	O
patient	O
died	B-TOXI
of	I-TOXI
pulmonary	I-TOXI
toxicity	I-TOXI
(	O
interstitial	B-TOXI
pneumonitis	I-TOXI
)	O
and	O
the	O
other	O
of	O
esophagobronchial	B-TOXI
fistula	I-TOXI
with	I-TOXI
pulmonary	I-TOXI
infection	I-TOXI
.	O
	
Concurrent	O
radiotherapy	O
plus	O
chemotherapy	O
with	O
mitomycin	B-DRUG
","	O
vindesine	B-DRUG
","	O
and	O
cisplatin	B-DRUG
(	O
MVP	O
)	O
can	O
be	O
safely	O
administered	O
to	O
patients	O
with	O
stage	O
III	O
NSCLC	B-CANCER
","	O
with	O
excellent	O
response	O
rates	O
and	O
2-year	O
survival	O
rates	O
.	O
	
Phase	O
II	O
randomized	O
study	O
of	O
cisplatin	B-DRUG
plus	O
etoposide	B-DRUG
phosphate	I-DRUG
or	O
etoposide	B-DRUG
in	O
the	O
treatment	O
of	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
This	O
randomized	O
phase	O
II	O
study	O
evaluated	O
the	O
efficacy	O
and	O
toxicity	O
of	O
etoposide	B-DRUG
phosphate	I-DRUG
when	O
used	O
in	O
combination	O
with	O
cisplatin	B-DRUG
in	O
the	O
treatment	O
of	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
previously	O
untreated	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
were	O
randomized	O
to	O
receive	O
cisplatin	B-DRUG
in	O
combination	O
with	O
either	O
etoposide	B-DRUG
or	O
etoposide	B-DRUG
phosphate	I-DRUG
.	O
	
Molar-equivalent	O
doses	O
of	O
etoposide	B-DRUG
and	O
etoposide	B-DRUG
phosphate	I-DRUG
were	O
used	O
.	O
	
Response	O
rate	O
","	O
time	O
to	O
progression	O
","	O
survival	O
","	O
and	O
toxicity	O
were	O
compared	O
.	O
	
Major	O
response	O
rates	O
with	O
etoposide	B-DRUG
phosphate	I-DRUG
and	O
etoposide	B-DRUG
were	O
61	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
55	O
%	O
to	O
67	O
%	O
)	O
and	O
58	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
52	O
%	O
to	O
64	O
%	O
)	O
","	O
respectively	O
(	O
P	O
=	O
0.85	O
)	O
.	O
	
No	O
significant	O
differences	O
in	O
median	O
time	O
to	O
progression	O
or	O
survival	O
were	O
observed	O
in	O
patients	O
who	O
received	O
etoposide	B-DRUG
phosphate	I-DRUG
versus	O
etoposide	B-DRUG
.	O
	
Grade	O
3	O
and	O
4	O
leukopenia	B-TOXI
occurred	O
in	O
63	O
%	O
of	O
patients	O
who	O
received	O
etoposide	B-DRUG
phosphate	I-DRUG
compared	O
with	O
77	O
%	O
who	O
received	O
etoposide	B-DRUG
(	O
P	O
=	O
0.16	O
)	O
.	O
	
The	O
combination	O
of	O
etoposide	B-DRUG
phosphate	I-DRUG
and	O
cisplatin	B-DRUG
is	O
effective	O
in	O
the	O
treatment	O
of	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
","	O
and	O
can	O
be	O
administered	O
with	O
acceptable	O
toxicity	O
.	O
	
Although	O
this	O
study	O
was	O
not	O
designed	O
to	O
be	O
a	O
formal	O
comparative	O
trial	O
","	O
the	O
efficacy	O
and	O
toxicity	O
observed	O
with	O
this	O
regimen	O
were	O
found	O
to	O
be	O
similar	O
to	O
a	O
standard	O
etoposide	B-DRUG
/	O
cisplatin	B-DRUG
regimen	O
","	O
using	O
molar-equivalent	O
etoposide	B-DRUG
doses	O
.	O
	
Because	O
of	O
its	O
greater	O
ease	O
of	O
administration	O
","	O
etoposide	B-DRUG
phosphate	I-DRUG
is	O
preferable	O
to	O
etoposide	B-DRUG
for	O
routine	O
clinical	O
use	O
.	O
	
Treatment	O
of	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
with	O
the	O
combination	O
fluorouracil	B-CANCER
","	O
leucovorin	B-CANCER
","	O
etoposide	B-CANCER
","	O
and	O
cisplatin	B-CANCER
:	O
a	O
phase	O
II	O
study	O
of	O
the	O
ONCOPAZ	O
Cooperative	O
Group	O
.	O
	
	
A	O
phase	O
II	O
study	O
was	O
performed	O
to	O
assess	O
the	O
efficacy	O
and	O
toxicity	O
of	O
the	O
combination	O
of	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
","	O
etoposide	B-DRUG
","	O
and	O
cisplatin	B-DRUG
(	O
FLEP	B-DRUG
)	O
in	O
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
carcinoma	I-CANCER
.	O
	
A	O
total	O
of	O
46	O
consecutive	O
","	O
previously	O
untreated	O
patients	O
with	O
unresectable	O
","	O
measurable	B-CANCER
gastric	I-CANCER
carcinoma	I-CANCER
were	O
treated	O
with	O
300	O
mg	O
/	O
m2	O
LV	B-DRUG
","	O
100	O
mg	O
/	O
m2	O
etoposide	B-DRUG
","	O
500	O
mg	O
/	O
m2	O
5-FU	B-DRUG
","	O
and	O
30	O
mg	O
/	O
m2	O
cisplatin	B-DRUG
on	O
days	O
1月3日	O
every	O
28	O
days	O
.	O
	
All	O
courses	O
were	O
given	O
on	O
an	O
outpatient	O
basis	O
.	O
	
A	O
total	O
of	O
169	O
courses	O
of	O
treatment	O
were	O
given	O
.	O
	
In	O
all	O
","	O
18	O
of	O
the	O
46	O
patients	O
(	O
39	O
%	O
)	O
had	O
an	O
objective	O
response	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
","	O
25	O
%	O
-54	O
%	O
]	O
and	O
2	O
(	O
4	O
%	O
)	O
patients	O
experienced	O
a	O
clinical	O
complete	O
response	O
.	O
	
The	O
median	O
duration	O
of	O
response	O
was	O
5	O
months	O
.	O
	
The	O
main	O
side	O
effects	O
were	O
hematological	B-TOXI
and	O
gastrointestinal	B-TOXI
.	O
	
Grade	O
3月4日	O
toxicity	O
was	O
encountered	O
as	O
follows	O
:	O
leukopenia	B-TOXI
","	O
in	O
9.5	O
%	O
of	O
the	O
courses	O
;	O
anemia	B-TOXI
","	O
in	O
3	O
%	O
;	O
thrombocytopenia	B-TOXI
","	O
in	O
3	O
%	O
;	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
","	O
in	O
4	O
%	O
;	O
and	O
diarrhea	B-TOXI
","	O
in	O
5	O
%	O
.	O
	
Hospitalization	O
due	O
to	O
fever	B-TOXI
and	O
granulocytopenia	B-TOXI
was	O
required	O
in	O
5	O
patients	O
","	O
3	O
of	O
whom	O
died	B-TOXI
of	I-TOXI
sepsis	I-TOXI
.	O
	
In	O
conclusion	O
","	O
FLEP	O
shows	O
moderate	O
activity	O
in	O
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
carcinoma	I-CANCER
","	O
albeit	O
at	O
the	O
cost	O
of	O
a	O
high	O
degree	O
of	O
toxicity	O
.	O
	
For	O
this	O
reason	O
we	O
do	O
not	O
recommend	O
its	O
use	O
.	O
	
Continuous	O
infusion	O
fluorouracil	B-DRUG
/	O
leucovorin	B-DRUG
and	O
bolus	O
mitomycin-C	B-DRUG
as	O
a	O
salvage	O
regimen	O
for	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
No	O
effective	O
systemic	O
salvage	O
therapy	O
exists	O
for	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
who	O
progress	O
after	O
receiving	O
bolus	O
fluorouracil	B-CANCER
(	O
FU	B-CANCER
)	O
and	O
leucovorin	B-CANCER
(	O
LV	B-CANCER
)	O
chemotherapy	O
.	O
	
In	O
vitro	O
data	O
suggest	O
that	O
bolus	O
FU	B-DRUG
resistance	O
can	O
be	O
overcome	O
by	O
continuous	O
infusion	O
(	O
CI	O
)	O
FU	B-DRUG
","	O
and	O
that	O
the	O
cytotoxic	O
effects	O
of	O
Mitomycin-C	B-DRUG
(	O
MMC	B-DRUG
)	O
and	O
FU	B-DRUG
are	O
synergistic	O
.	O
	
Based	O
on	O
this	O
data	O
","	O
a	O
Phase	O
II	O
trial	O
of	O
CI	O
FU	B-DRUG
and	O
LV	B-DRUG
with	O
bolus	O
MMC	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
who	O
progressed	O
on	O
only	O
one	O
previous	O
chemotherapy	O
regimen	O
was	O
performed	O
.	O
	
Twenty-eight	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
who	O
had	O
progressed	O
after	O
one	O
previous	O
chemotherapy	O
regimen	O
of	O
bolus	O
FU	B-DRUG
/	O
LV	B-DRUG
were	O
treated	O
with	O
bolus	O
MMC	B-DRUG
10	O
mg	O
/	O
m2	O
every	O
6	O
weeks	O
and	O
CI	O
FU	B-DRUG
200	O
mg	O
/	O
m2	O
/	O
day	O
admixed	O
with	O
LV	B-DRUG
10	O
mg	O
/	O
m2	O
/	O
day	O
given	O
14	O
days	O
on	O
/	O
7	O
days	O
off	O
.	O
	
The	O
partial	O
response	O
rate	O
in	O
24	O
evaluable	O
patients	O
was	O
17	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
2-32	O
%	O
)	O
with	O
a	O
median	O
response	O
duration	O
of	O
9.5	O
months	O
(	O
range	O
","	O
4.2-12.0	O
months	O
)	O
.	O
	
Twelve	O
(	O
50	O
%	O
)	O
additional	O
patients	O
achieved	O
disease	O
stabilization	O
.	O
	
Median	O
survival	O
was	O
9.9	O
months	O
in	O
the	O
whole	O
group	O
(	O
28	O
patients	O
)	O
and	O
11.5	O
months	O
in	O
the	O
24	O
evaluable	O
patients	O
.	O
	
The	O
major	O
toxicities	O
were	O
grade	O
4	O
diarrhea	B-TOXI
occurring	O
in	O
two	O
patients	O
and	O
grade	O
3	O
mucositis	B-TOXI
occurring	O
in	O
five	O
patients	O
.	O
	
There	O
was	O
minimal	O
myelosuppression	B-TOXI
(	O
grade	O
3	O
thrombocytopenia	B-TOXI
in	O
one	O
patient	O
)	O
and	O
no	O
occurrences	O
of	O
hand-foot	B-TOXI
syndrome	I-TOXI
or	I-TOXI
cardiotoxicity	I-TOXI
.	O
	
This	O
regimen	O
demonstrates	O
modest	O
activity	O
with	O
acceptable	O
toxicity	O
in	O
colorectal	B-CANCER
cancer	I-CANCER
patients	O
who	O
have	O
failed	O
a	O
single-bolus	O
FU	B-DRUG
/	O
LV	B-DRUG
regimen	O
.	O
	
Modifications	O
of	O
this	O
and	O
other	O
infusional	O
FU-based	B-DRUG
chemotherapy	O
regimens	O
should	O
be	O
explored	O
as	O
potential	O
salvage	O
chemotherapy	O
regimens	O
in	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
Phase	O
II	O
trial	O
of	O
an	O
all-oral	O
regimen	O
of	O
tegafur	B-DRUG
and	O
folinic	B-DRUG
acid	I-DRUG
in	O
patients	O
with	O
previously	O
treated	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
Tegafur	B-DRUG
is	O
an	O
antimetabolite	O
slowly	O
metabolized	O
to	O
5-fluorouracil	B-DRUG
in	O
vivo	O
.	O
	
Protracted	O
administration	O
of	O
oral	O
tegafur	B-DRUG
is	O
active	O
in	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
","	O
with	O
reported	O
response	O
rates	O
ranging	O
from	O
29	O
to	O
44	O
%	O
.	O
	
The	O
addition	O
of	O
folinic	B-DRUG
acid	I-DRUG
could	O
improve	O
the	O
efficacy	O
of	O
tegafur	B-DRUG
by	O
means	O
of	O
biochemical	O
modulation	O
.	O
	
A	O
prospective	O
Phase	O
II	O
trial	O
in	O
patients	O
with	O
pretreated	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
was	O
performed	O
.	O
	
The	O
regimen	O
consisted	O
of	O
oral	O
tegafur	B-DRUG
(	O
750	O
mg	O
/	O
m2	O
/	O
day	O
)	O
and	O
oral	O
folinic	B-DRUG
acid	I-DRUG
(	O
45	O
mg	O
/	O
day	O
)	O
for	O
21	O
days	O
","	O
recycling	O
at	O
day	O
28	O
.	O
	
Twenty-five	O
patients	O
were	O
included	O
.	O
	
Eight	O
partial	O
responses	O
were	O
observed	O
for	O
an	O
objective	O
response	O
rate	O
of	O
32	O
%	O
(	O
95	O
%	O
confidence	O
intervals	O
for	O
response	O
","	O
23-41	O
%	O
)	O
.	O
	
The	O
median	O
duration	O
of	O
response	O
was	O
7	O
months	O
.	O
	
According	O
to	O
WHO	O
criteria	O
","	O
24	O
%	O
of	O
patients	O
experienced	O
grade	O
3	O
mucositis	B-TOXI
and	O
12	O
%	O
grade	O
3	O
diarrhea	B-TOXI
","	O
but	O
no	O
other	O
significant	O
toxicities	O
were	O
observed	O
.	O
	
Twenty-eight	O
percent	O
of	O
patients	O
required	O
dose	O
reductions	O
for	O
toxicity	O
.	O
	
A	O
significant	O
response	O
rate	O
with	O
oral	O
tegafur	B-DRUG
and	O
folinic	B-DRUG
acid	I-DRUG
in	O
patients	O
with	O
heavily	O
pretreated	O
breast	B-CANCER
cancer	I-CANCER
was	O
found	O
.	O
	
This	O
all-oral	O
regimen	O
","	O
which	O
could	O
be	O
safely	O
administered	O
on	O
an	O
outpatient	O
basis	O
","	O
deserves	O
further	O
evaluation	O
to	O
define	O
the	O
role	O
of	O
folinic	B-DRUG
acid	I-DRUG
on	O
the	O
activity	O
of	O
tegafur	B-DRUG
in	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Maximum-tolerated	O
doses	O
of	O
ifosfamide	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
etoposide	B-DRUG
given	O
over	O
6	O
days	O
followed	O
by	O
autologous	O
stem-cell	O
rescue	O
:	O
toxicity	O
profile	O
.	O
	
	
A	O
phase	O
I	O
dose-escalation	O
study	O
of	O
ifosfamide	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
etoposide	B-DRUG
(	O
ICE	B-DRUG
)	O
with	O
autologous	O
stem-cell	O
rescue	O
(	O
ASCR	O
)	O
was	O
conducted	O
to	O
determine	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
ICE	B-DRUG
given	O
over	O
6	O
days	O
.	O
	
One	O
hundred	O
fifty-four	O
patients	O
with	O
a	O
variety	O
of	O
poor-prognosis	O
malignancies	B-CANCER
received	O
escalating	O
doses	O
of	O
ifosfamide	B-DRUG
"6,000"	O
to	O
"24,000"	O
mg	O
/	O
m2	O
","	O
carboplatin	B-DRUG
"1,200"	O
to	O
"2,100"	O
mg	O
/	O
m2	O
","	O
and	O
etoposide	B-DRUG
"1,800"	O
to	O
"3,000"	O
mg	O
/	O
m2	O
divided	O
over	O
6	O
days	O
.	O
	
Mesna	O
was	O
administered	O
in	O
a	O
dose	O
equal	O
to	O
ifosfamide	B-DRUG
.	O
	
ASCR	O
was	O
performed	O
48	O
hours	O
after	O
the	O
completion	O
of	O
ICE	B-DRUG
.	O
	
The	O
source	O
of	O
stem	O
cells	O
was	O
bone	O
marrow	O
(	O
BM	O
)	O
in	O
patients	O
without	O
BM	O
micrometastases	O
and	O
peripheral-blood	O
stem	O
cells	O
(	O
PBSC	O
)	O
in	O
patients	O
with	O
BM	O
micrometastases	O
.	O
	
Patients	O
were	O
evaluated	O
for	O
hematologic	B-TOXI
and	I-TOXI
nonhematologic	I-TOXI
toxicities	I-TOXI
","	O
as	O
well	O
as	O
response	O
to	O
therapy	O
.	O
	
The	O
MTD	O
of	O
the	O
ICE	B-DRUG
regimen	O
is	O
"20,100"	O
mg	O
/	O
m2	O
of	O
ifosfamide	B-DRUG
","	O
"1,800"	O
mg	O
/	O
m2	O
of	O
carboplatin	B-DRUG
","	O
and	O
"3,000"	O
mg	O
/	O
m2	O
of	O
etoposide	B-DRUG
.	O
	
The	O
dose-limiting	O
toxicities	O
of	O
ICE	B-DRUG
were	O
CNS	B-TOXI
toxicity	I-TOXI
and	O
acute	B-TOXI
renal	I-TOXI
failure	I-TOXI
.	O
	
Additionally	O
","	O
reversible	B-TOXI
elevations	I-TOXI
of	I-TOXI
serum	I-TOXI
creatinine	I-TOXI
levels	I-TOXI
were	O
noted	O
in	O
29	O
%	O
of	O
patients	O
treated	O
at	O
the	O
upper	O
dose	O
levels	O
.	O
	
Forty-six	O
patients	O
were	O
treated	O
at	O
the	O
MTD	O
.	O
	
Severe	O
","	O
reversible	O
mucositis	B-TOXI
and	O
enteritis	B-TOXI
were	O
the	O
major	O
nonhematologic	B-TOXI
toxicities	I-TOXI
seen	O
at	O
the	O
MTD	O
(	O
78	O
%	O
and	O
33	O
%	O
","	O
respectively	O
)	O
.	O
	
The	O
overall	O
mortality	O
rate	O
was	O
8	O
%	O
for	O
all	O
dose	O
levels	O
(	O
4	O
%	O
at	O
the	O
MTD	O
)	O
.	O
	
At	O
the	O
MTD	O
","	O
the	O
median	O
times	O
to	O
an	O
absolute	O
neutrophil	O
count	O
&	O
gt	O
;	O
or	O
=	O
0.5	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
","	O
to	O
a	O
platelet	O
count	O
&	O
gt	O
;	O
or	O
=	O
20	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
","	O
and	O
to	O
discharge	O
were	O
18	O
","	O
22	O
","	O
and	O
24	O
days	O
","	O
respectively	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
40	O
%	O
for	O
77	O
patients	O
with	O
assessable	O
disease	O
at	O
the	O
time	O
of	O
treatment	O
.	O
	
ICE	B-DRUG
is	O
well	O
tolerated	O
","	O
with	O
acceptable	O
hematopoietic	B-TOXI
side	I-TOXI
effects	I-TOXI
and	O
predictable	O
organ	B-TOXI
toxicity	I-TOXI
.	O
	
Cisplatin	B-DRUG
","	O
vincristine	B-DRUG
and	O
ifosphamide	B-DRUG
combination	O
chemotherapy	O
of	O
metastatic	B-CANCER
seminoma	I-CANCER
:	O
results	O
of	O
EORTC	O
trial	O
30874	O
EORTC	O
GU	O
Group	O
.	O
	
	
The	O
aims	O
of	O
the	O
trial	O
were	O
to	O
establish	O
the	O
response	O
rate	O
and	O
determine	O
the	O
toxicity	O
of	O
combination	O
chemotherapy	O
with	O
ifosphamide	B-DRUG
","	O
vincristine	B-DRUG
and	O
cisplatin	B-DRUG
(	O
HOP	O
regimen	O
)	O
in	O
advanced	B-CANCER
metastatic	I-CANCER
seminoma	I-CANCER
and	O
to	O
study	O
the	O
role	O
of	O
post-chemotherapy	O
consolidation	O
treatment	O
.	O
	
Patients	O
with	O
bulky	O
metastatic	O
non-alpha-fetoprotein-producing	O
seminomas	B-CANCER
were	O
eligible	O
for	O
this	O
phase	O
II	O
study	O
[	O
serum	O
human	O
chorionic	O
gonadotropin	B-DRUG
&	O
lt	O
;	O
200	O
U	O
l-1	O
(	O
&	O
lt	O
;	O
40	O
ng	O
l-1	O
)	O
]	O
if	O
they	O
presented	O
with	O
abdominal	O
masses	O
&	O
gt	O
;	O
or	O
=	O
10	O
cm	O
or	O
had	O
extra-gonadal	O
seminoma	B-CANCER
or	O
had	O
relapsed	O
after	O
previous	O
radiotherapy	O
.	O
	
The	O
HOP	O
regimen	O
consisted	O
of	O
four	O
3-weekly	O
cycles	O
of	O
the	O
following	O
drug	O
combination	O
:	O
ifosphamide	B-DRUG
(	O
days	O
1月5日	O
","	O
1.2	O
mg	O
m-2	O
day-1	O
)	O
","	O
vincristine	B-DRUG
(	O
day	O
1	O
","	O
2	O
mg	O
)	O
and	O
cisplatin	B-DRUG
(	O
days	O
1月5日	O
","	O
20	O
mg	O
m-2	O
day-1	O
)	O
.	O
	
Residual	O
masses	O
persisting	O
6	O
months	O
after	O
chemotherapy	O
could	O
be	O
considered	O
for	O
consolidation	O
surgery	O
or	O
radiotherapy	O
.	O
	
Maximal	O
response	O
to	O
the	O
HOP	O
chemotherapy	O
(	O
evaluated	O
at	O
any	O
time	O
)	O
was	O
based	O
on	O
the	O
WHO	O
criteria	O
.	O
	
The	O
median	O
observation	O
time	O
was	O
2.5	O
years	O
(	O
range	O
1.8-5.5	O
years	O
)	O
.	O
	
Thirteen	O
institutions	O
treated	O
42	O
eligible	O
patients	O
within	O
the	O
study	O
(	O
testicular	B-CANCER
cancer	I-CANCER
stage	O
&	O
gt	O
;	O
or	O
=	O
IID	O
","	O
25	O
;	O
extragonadal	O
","	O
5	O
;	O
relapse	O
after	O
previous	O
radiotherapy	O
","	O
12	O
)	O
.	O
	
Two	O
patients	O
were	O
not	O
evaluable	O
for	O
response	O
owing	O
to	O
premature	O
treatment	O
discontinuation	O
.	O
	
Maximal	O
response	O
was	O
as	O
follows	O
:	O
complete	O
remission	O
(	O
CR	O
)	O
","	O
26	O
(	O
65	O
%	O
)	O
;	O
partial	O
remission	O
(	O
PR	O
)	O
11	O
(	O
28	O
%	O
)	O
;	O
no	O
change	O
(	O
NC	O
)	O
","	O
2	O
(	O
5	O
%	O
)	O
;	O
progressive	O
disease	O
(	O
PD	O
)	O
","	O
1	O
(	O
3	O
%	O
)	O
.	O
	
Four	O
patients	O
have	O
died	B-TOXI
","	O
three	O
from	O
their	O
malignancy	B-CANCER
(	O
two	O
without	O
previous	O
irradiation	O
and	O
one	O
with	O
prior	O
radiotherapy	O
)	O
.	O
	
The	O
fourth	O
patient	O
died	B-TOXI
of	O
treatment-related	O
toxicity	O
.	O
	
The	O
3	O
year	O
survival	O
for	O
all	O
42	O
eligible	O
patients	O
was	O
90	O
%	O
.	O
	
Dose	O
reduction	O
and	O
treatment	O
postponement	O
were	O
necessary	O
in	O
25	O
and	O
14	O
patients	O
respectively	O
.	O
	
Ten	O
patients	O
experienced	O
granulocytic	B-TOXI
fever	I-TOXI
.	O
	
Previously	O
irradiated	O
patients	O
tolerated	O
chemotherapy	O
as	O
well	O
as	O
non-irradiated	O
patients	O
.	O
	
Immediately	O
after	O
HOP	O
chemotherapy	O
a	O
mass	O
persisted	O
in	O
16	O
of	O
17	O
patients	O
with	O
retroperitoneal	O
masses	O
of	O
&	O
gt	O
;	O
or	O
=	O
100	O
mm	O
at	O
presentation	O
.	O
	
Three	O
of	O
these	O
residual	O
lesions	O
were	O
resected	O
within	O
the	O
following	O
6	O
months	O
showing	O
complete	O
necrosis	B-TOXI
.	O
	
Four	O
lesions	O
dissolved	O
spontaneously	O
during	O
the	O
first	O
year	O
of	O
follow-up	O
.	O
	
Nine	O
lesions	O
persisted	O
for	O
&	O
gt	O
;	O
or	O
=	O
1	O
year	O
(	O
one	O
after	O
consolidation	O
radiotherapy	O
)	O
without	O
leading	O
to	O
relapse	O
.	O
	
Four	O
of	O
seven	O
patients	O
with	O
mediastinal	O
lesions	O
achieved	O
CR	O
and	O
three	O
a	O
PR	O
after	O
HOP	O
chemotherapy	O
.	O
	
The	O
HOP	O
chemotherapy	O
regimen	O
is	O
highly	O
effective	O
in	O
patients	O
with	O
advanced	B-CANCER
metastatic	I-CANCER
seminoma	I-CANCER
or	O
those	O
relapsing	O
after	O
previous	O
radiotherapy	O
","	O
but	O
is	O
associated	O
with	O
a	O
high	O
risk	O
of	O
toxicity	O
","	O
in	O
particular	O
myelotoxicity	B-TOXI
.	O
	
Sequential	O
methotrexate	B-DRUG
","	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
and	O
high	O
dose	O
leucovorin	B-DRUG
versus	O
5-FU	B-DRUG
and	O
high	O
dose	O
leucovorin	B-DRUG
versus	O
5-FU	B-DRUG
alone	O
for	O
advanced	B-CANCER
colorectal	I-CANCER
cancer.	I-CANCER
A	O
multi-institutional	O
randomized	O
trial	O
.	O
	
	
The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
single-biochemical	O
modulation	O
of	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
and	O
leucovorin	B-DRUG
with	O
that	O
of	O
the	O
double-biochemical	O
modulation	O
of	O
methotrexate	B-DRUG
and	O
leucovorin	B-DRUG
.	O
	
Because	O
of	O
the	O
Martin	O
et	O
al.	O
study	O
in	O
which	O
an	O
experimental	O
model	O
showed	O
similar	O
effects	O
of	O
5-FU	B-DRUG
at	O
maximum	O
tolerated	O
doses	O
to	O
the	O
modulation	O
with	O
leucovorin	B-DRUG
at	O
standard	O
doses	O
","	O
a	O
third	O
treatment	O
arm	O
of	O
5-FU	B-DRUG
alone	O
was	O
also	O
studied	O
.	O
	
A	O
randomized	O
trial	O
was	O
performed	O
using	O
a	O
500-mg	O
/	O
m2	O
intravenous	O
(	O
i.v.	O
)	O
1-hour	O
infusion	O
of	O
methotrexate	B-DRUG
","	O
and	O
12	O
hours	O
later	O
","	O
a	O
600-mg	O
/	O
m2	O
i.v.	O
bolus	O
of	O
5-FU	B-DRUG
plus	O
a	O
200-mg	O
/	O
m2	O
i.v.	O
1-hour	O
infusion	O
of	O
leucovorin	B-DRUG
(	O
MFL	B-DRUG
)	O
every	O
2	O
weeks	O
versus	O
5-FU	B-DRUG
plus	O
leucovorin	B-DRUG
at	O
an	O
equal	O
dose	O
and	O
schedule	O
(	O
FL	B-DRUG
)	O
","	O
versus	O
a	O
1200-mg	O
/	O
m2	O
i.v.	O
dose	O
of	O
5-FU	B-DRUG
every	O
2	O
weeks	O
.	O
	
Of	O
186	O
patients	O
included	O
in	O
the	O
study	O
","	O
178	O
were	O
evaluable	O
.	O
	
In	O
a	O
preliminary	O
analysis	O
with	O
94	O
evaluable	O
patients	O
","	O
two	O
significant	O
statistical	O
differences	O
were	O
shown	O
.	O
	
First	O
","	O
the	O
toxicity	O
rate	O
of	O
the	O
5-FU	B-DRUG
=--	O
alone	O
(	O
F	O
)	O
treatment	O
arm	O
was	O
higher	O
than	O
that	O
of	O
the	O
other	O
arms	O
(	O
MFL	B-DRUG
vs.	O
F	O
","	O
P	O
=	O
0.0002	O
;	O
FL	B-DRUG
vs.	O
F	O
","	O
P	O
=	O
0.00001	O
)	O
.	O
	
Second	O
","	O
the	O
median	O
survival	O
was	O
worse	O
in	O
the	O
F	O
treatment	O
arm	O
with	O
a	O
rate	O
of	O
12.6	O
months	O
for	O
the	O
MFL	B-DRUG
and	O
FL	B-DRUG
arms	O
and	O
7.5	O
months	O
for	O
the	O
F	O
arm	O
(	O
P	O
&	O
lt	O
;	O
0.05	O
)	O
.	O
	
Considering	O
these	O
results	O
","	O
the	O
F	O
treatment	O
arm	O
was	O
discontinued	O
.	O
	
The	O
final	O
results	O
included	O
70	O
evaluable	O
patients	O
for	O
MFL	B-DRUG
and	O
74	O
patients	O
for	O
FL	B-DRUG
.	O
	
No	O
difference	O
was	O
found	O
in	O
the	O
distribution	O
of	O
prognostic	O
factors	O
.	O
	
The	O
response	O
rates	O
were	O
25.7	O
%	O
for	O
MFL	B-DRUG
(	O
95	O
%	O
CI	O
","	O
16-37.5	O
)	O
and	O
14.8	O
%	O
for	O
FL	B-DRUG
(	O
95	O
%	O
CI	O
","	O
7.6-25	O
)	O
","	O
(	O
P	O
=	O
0.1	O
)	O
.	O
	
The	O
median	O
survival	O
was	O
14.3	O
months	O
for	O
patients	O
treated	O
with	O
MFL	B-DRUG
and	O
12.3	O
months	O
for	O
those	O
treated	O
with	O
FL	B-DRUG
.	O
	
The	O
hematologic	B-TOXI
toxicity	I-TOXI
was	O
mild	O
","	O
with	O
no	O
grade	O
3	O
/	O
4	O
leukopenia	B-TOXI
in	O
either	O
treatment	O
arm	O
.	O
	
The	O
major	O
nonhematologic	B-TOXI
toxicity	I-TOXI
in	O
the	O
MFL	B-DRUG
and	O
FL	B-DRUG
treatment	O
arms	O
was	O
ocular	O
;	O
nongrade	O
3	O
/	O
4	O
diarrhea	B-DRUG
also	O
was	O
observed	O
.	O
	
The	O
results	O
of	O
MFL	B-DRUG
double-biochemical	O
modulation	O
failed	O
to	O
show	O
a	O
significant	O
statistical	O
difference	O
from	O
that	O
of	O
single-biochemical	O
modulation	O
for	O
this	O
dose	O
and	O
schedule	O
.	O
	
Treatment	O
of	O
advanced	B-CANCER
mycosis	I-CANCER
fungoides	I-CANCER
and	O
S茅zary	O
syndrome	O
with	O
continuous	O
infusions	O
of	O
methotrexate	B-DRUG
followed	O
by	O
fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
rescue	O
.	O
	
	
The	O
treatment	O
of	O
advanced	B-CANCER
mycosis	I-CANCER
fungoides	I-CANCER
is	O
a	O
therapeutic	O
challenge	O
.	O
	
A	O
variety	O
of	O
treatment	O
approaches	O
have	O
been	O
used	O
.	O
	
In	O
our	O
experience	O
","	O
chemotherapy	O
has	O
been	O
most	O
useful	O
.	O
	
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
the	O
synergy	O
previously	O
demonstrated	O
between	O
methotrexate	B-DRUG
and	O
fluorouracil	B-DRUG
in	O
the	O
treatment	O
of	O
advanced	B-CANCER
mycosis	I-CANCER
fungoides	I-CANCER
.	O
	
Ten	O
patients	O
with	O
mycosis	B-CANCER
fungoides	I-CANCER
and	O
S茅zary	O
syndrome	O
stages	O
IIa	O
(	O
n	O
=	O
1	O
)	O
","	O
II-b	O
(	O
n	O
=	O
4	O
)	O
","	O
III	O
(	O
n	O
=	O
1	O
)	O
","	O
IVa	O
(	O
n	O
=	O
2	O
)	O
","	O
and	O
IVb	O
(	O
n	O
=	O
2	O
)	O
were	O
treated	O
with	O
sequential	O
methotrexate	B-DRUG
followed	O
by	O
fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
rescue	O
.	O
	
Each	O
patient	O
received	O
several	O
courses	O
of	O
chemotherapy	O
at	O
varying	O
intervals	O
","	O
as	O
required	O
for	O
control	O
of	O
their	O
disease	O
.	O
	
The	O
duration	O
of	O
treatment	O
ranged	O
from	O
3	O
to	O
78	O
months	O
","	O
with	O
an	O
average	O
duration	O
of	O
33	O
months	O
.	O
	
The	O
number	O
of	O
cycles	O
of	O
chemotherapy	O
administered	O
to	O
each	O
patient	O
ranged	O
from	O
five	O
to	O
45	O
","	O
with	O
an	O
average	O
of	O
18	O
infusions	O
per	O
patient	O
.	O
	
The	O
average	O
survival	O
in	O
patients	O
with	O
tumors	O
was	O
5.25	O
years	O
","	O
with	O
a	O
median	O
survival	O
of	O
6	O
years	O
.	O
	
Eight	O
of	O
10	O
patients	O
achieved	O
at	O
least	O
80	O
%	O
clearing	O
and	O
the	O
remaining	O
two	O
achieved	O
at	O
least	O
60	O
%	O
clearing	O
.	O
	
Adverse	O
reactions	O
were	O
minimal	O
and	O
included	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
","	O
mucositis	B-TOXI
","	O
and	O
leukopenia	B-TOXI
in	O
only	O
one	O
patient	O
.	O
	
Sequential	O
methotrexate	B-DRUG
and	O
fluorouracil	B-DRUG
chemotherapy	O
is	O
an	O
effective	O
and	O
safe	O
treatment	O
for	O
advanced	B-CANCER
mycosis	I-CANCER
fungoides	I-CANCER
and	O
S茅zary	O
syndrome	O
.	O
	
This	O
regimen	O
is	O
extremely	O
well	O
tolerated	O
","	O
with	O
minimal	O
toxic	O
side	O
effects	O
.	O
	
Adjuvant	O
CMFVP	B-DRUG
versus	O
tamoxifen	B-DRUG
versus	O
concurrent	O
CMFVP	B-DRUG
and	O
tamoxifen	B-DRUG
for	O
postmenopausal	O
","	O
node-positive	O
","	O
and	O
estrogen	O
receptor-positive	O
breast	B-CANCER
cancer	I-CANCER
patients	O
:	O
a	O
Southwest	O
Oncology	O
Group	O
study	O
.	O
	
	
To	O
compare	O
chemohormonal	O
therapy	O
","	O
chemotherapy	O
alone	O
","	O
and	O
hormonal	O
therapy	O
alone	O
in	O
postmenopausal	O
patients	O
with	O
estrogen	O
receptor	O
(	O
ER	O
)	O
#NAME?	O
operable	O
breast	B-CANCER
cancer	I-CANCER
and	O
positive	O
axillary	O
nodes	O
with	O
respect	O
to	O
survival	O
and	O
disease-free	O
survival	O
(	O
DFS	O
)	O
.	O
	
Eight	O
hundred	O
ninety-two	O
postmenopausal	O
women	O
with	O
ER-positive	O
","	O
node-positive	O
breast	B-CANCER
cancer	I-CANCER
were	O
enrolled	O
by	O
the	O
Southwest	O
Oncology	O
Group	O
(	O
SWOG	O
)	O
from	O
July	O
1979	O
to	O
March	O
1989	O
and	O
74	O
by	O
the	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
(	O
ECOG	O
)	O
between	O
June	O
1987	O
and	O
March	O
1989	O
.	O
	
Patients	O
were	O
stratified	O
according	O
to	O
number	O
of	O
involved	O
nodes	O
and	O
type	O
of	O
primary	O
surgery	O
and	O
randomized	O
to	O
receive	O
the	O
following	O
:	O
(	O
1	O
)	O
tamoxifen	B-DRUG
10	O
mg	O
twice	O
daily	O
by	O
mouth	O
for	O
1	O
year	O
;	O
(	O
2	O
)	O
cyclophosphamide	B-DRUG
60	O
mg	O
/	O
m2	O
/	O
d	O
by	O
mouth	O
for	O
1	O
year	O
","	O
methotrexate	B-DRUG
15	O
mg	O
/	O
m2	O
intravenously	O
(	O
IV	O
)	O
weekly	O
for	O
1	O
year	O
","	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
400	O
mg	O
/	O
m2	O
IV	O
weekly	O
for	O
1	O
year	O
","	O
vincristine	B-DRUG
0.625	O
mg	O
/	O
m2	O
IV	O
weekly	O
for	O
the	O
first	O
10	O
weeks	O
","	O
and	O
prednisone	B-DRUG
during	O
weeks	O
1	O
to	O
10	O
with	O
doses	O
decreasing	O
from	O
30	O
mg	O
/	O
m2	O
to	O
2.5	O
mg	O
/	O
m2	O
(	O
CMFVP	O
)	O
;	O
or	O
(	O
3	O
)	O
the	O
combination	O
of	O
tamoxifen	B-DRUG
and	O
CMFVP	B-DRUG
.	O
	
The	O
median	O
follow-up	O
duration	O
is	O
6.5	O
years	O
","	O
with	O
a	O
maximum	O
of	O
12.8	O
years	O
.	O
	
Treatment	O
arms	O
are	O
not	O
significantly	O
different	O
with	O
respect	O
to	O
either	O
survival	O
or	O
DFS	O
(	O
log-rank	O
","	O
2	O
df	O
","	O
P	O
=	O
0.82	O
and	O
0.23	O
","	O
respectively	O
)	O
.	O
	
The	O
5-year	O
survival	O
rate	O
is	O
77	O
%	O
for	O
the	O
tamoxifen	B-DRUG
arm	O
","	O
78	O
%	O
for	O
CMFVP	B-DRUG
","	O
and	O
75	O
%	O
for	O
the	O
combination	O
.	O
	
No	O
significant	O
differences	O
were	O
observed	O
in	O
node	O
or	O
receptor	O
level	O
subsets	O
.	O
	
Severe	O
or	O
worse	O
toxicity	O
was	O
experienced	O
by	O
56	O
%	O
of	O
patients	O
on	O
CMFVP	B-DRUG
and	O
61	O
%	O
on	O
CMFVP	B-DRUG
plus	O
tamoxifen	B-DRUG
","	O
compared	O
with	O
5	O
%	O
on	O
tamoxifen	B-DRUG
alone	O
.	O
	
CMFVP	B-DRUG
chemotherapy	O
","	O
either	O
alone	O
or	O
in	O
combination	O
with	O
tamoxifen	B-DRUG
","	O
has	O
not	O
been	O
shown	O
to	O
be	O
superior	O
to	O
tamoxifen	B-DRUG
alone	O
in	O
the	O
treatment	O
of	O
postmenopausal	O
women	O
with	O
node-positive	O
","	O
ER-positive	O
","	O
operable	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
Multiinstitutional	O
phase	O
II	O
trial	O
of	O
intensive	O
combination	O
chemoimmunotherapy	O
for	O
metastatic	B-CANCER
melanoma	I-CANCER
.	O
	
	
To	O
evaluate	O
the	O
activity	O
and	O
toxicity	O
of	O
combined	O
high-dose	O
cisplatin	B-DRUG
","	O
dacarbazine	B-DRUG
(	O
DTIC	B-DRUG
)	O
","	O
and	O
tamoxifen	B-DRUG
chemotherapy	O
and	O
high-dose	O
bolus	O
interleukin-2	B-DRUG
(	O
IL-2	B-DRUG
)	O
in	O
patients	O
with	O
metastatic	B-CANCER
melanoma	I-CANCER
.	O
	
Patients	O
with	O
metastatic	B-CANCER
melanoma	I-CANCER
","	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
(	O
ECOG	O
)	O
performance	O
status	O
of	O
0	O
or	O
1	O
","	O
and	O
normal	O
organ	O
function	O
were	O
enrolled	O
onto	O
this	O
multiinstitutional	O
Cytokine	O
Working	O
Group	O
trial	O
.	O
	
Patients	O
received	O
intensive	O
chemoimmunotherapy	O
consisting	O
of	O
cisplatin	B-DRUG
(	O
50	O
mg	O
/	O
m2	O
)	O
and	O
DTIC	B-DRUG
(	O
350	O
mg	O
/	O
m2	O
)	O
intravenously	O
(	O
IV	O
)	O
on	O
days	O
1	O
to	O
3	O
and	O
43	O
to	O
45	O
","	O
IL-2	B-DRUG
"600,000"	O
IU	O
/	O
kg	O
IV	O
every	O
8	O
hours	O
on	O
days	O
12	O
to	O
16	O
and	O
26	O
to	O
30	O
(	O
maximum	O
","	O
28	O
doses	O
)	O
","	O
and	O
tamoxifen	B-DRUG
20	O
mg	O
orally	O
each	O
day	O
.	O
	
Patients	O
were	O
evaluated	O
for	O
response	O
at	O
day	O
63	O
of	O
each	O
cycle	O
","	O
and	O
responding	O
patients	O
were	O
given	O
a	O
second	O
cycle	O
of	O
therapy	O
beginning	O
on	O
day	O
71	O
to	O
85	O
.	O
	
Thirty-eight	O
patients	O
were	O
entered	O
onto	O
this	O
study	O
.	O
	
Toxicities	O
were	O
as	O
expected	O
for	O
the	O
chemotherapy	O
and	O
immunotherapy	O
components	O
of	O
this	O
regimen	O
.	O
	
Overlapping	O
toxicity	O
consisted	O
primarily	O
of	O
thrombocytopenia	B-TOXI
(	O
76	O
%	O
of	O
patients	O
required	O
platelet	O
transfusions	O
)	O
","	O
neutropenia	B-TOXI
","	O
anemia	B-TOXI
","	O
fatigue	B-TOXI
","	O
and	O
weight	B-TOXI
loss	I-TOXI
.	O
	
Despite	O
these	O
cytopenias	B-TOXI
","	O
bleeding	B-TOXI
and	O
infectious	B-TOXI
complications	I-TOXI
were	O
rare	O
.	O
	
There	O
were	O
no	B-TOXI
treatment-related	I-TOXI
deaths	I-TOXI
.	O
	
Three	O
patients	O
achieved	O
a	O
complete	O
response	O
(	O
CR	O
;	O
8	O
%	O
)	O
","	O
and	O
13	O
achieved	O
a	O
partial	O
response	O
(	O
PR	O
)	O
.	O
	
The	O
overall	O
objective	O
response	O
rate	O
was	O
42	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
26	O
%	O
to	O
58	O
%	O
)	O
.	O
	
Six	O
additional	O
patients	O
had	O
greater	O
than	O
50	O
%	O
tumor	O
reduction	O
at	O
day	O
63	O
","	O
which	O
did	O
not	O
persist	O
until	O
a	O
subsequent	O
evaluation	O
.	O
	
The	O
median	O
duration	O
of	O
response	O
was	O
5	O
months	O
(	O
range	O
","	O
2	O
to	O
20+	O
)	O
","	O
and	O
the	O
median	O
survival	O
duration	O
was	O
11	O
months	O
.	O
	
This	O
intensive	O
treatment	O
regimen	O
appears	O
to	O
possess	O
activity	O
in	O
metastatic	B-CANCER
melanoma	I-CANCER
comparable	O
","	O
but	O
not	O
superior	O
","	O
to	O
that	O
of	O
other	O
less	O
intensive	O
cisplatin-	B-DRUG
and	O
IL-2-based	B-DRUG
chemoimmunotherapy	O
regimens	O
.	O
	
Although	O
the	O
toxicity	O
and	O
complexity	O
of	O
this	O
regimen	O
make	O
it	O
unsuitable	O
for	O
phase	O
III	O
testing	O
and	O
impractical	O
for	O
more	O
widespread	O
use	O
","	O
the	O
results	O
of	O
this	O
study	O
support	O
a	O
potential	O
favorable	O
interaction	O
between	O
IL-2	B-DRUG
and	O
chemotherapy	O
in	O
this	O
disease	O
and	O
highlight	O
the	O
need	O
for	O
appropriately	O
designed	O
phase	O
III	O
trials	O
.	O
	
Dose-dependent	O
interleukin-3	B-DRUG
stimulation	O
of	O
thrombopoiesis	O
and	O
neutropoiesis	O
in	O
patients	O
with	O
small-cell	B-CANCER
lung	I-CANCER
carcinoma	I-CANCER
before	O
and	O
following	O
chemotherapy	O
:	O
a	O
placebo-controlled	B-DRUG
randomized	O
phase	O
Ib	O
study	O
.	O
	
	
To	O
evaluate	O
the	O
safety	O
","	O
tolerance	O
","	O
and	O
hematologic	B-TOXI
effects	I-TOXI
of	O
recombinant	O
human	O
interleukin-3	B-DRUG
(	O
IL-3	B-DRUG
)	O
in	O
patients	O
with	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
SCLC	B-CANCER
)	O
before	O
and	O
following	O
multiagent	O
antineoplastic	O
therapy	O
in	O
a	O
placebo-controlled	B-DRUG
","	O
randomized	O
","	O
double-blind	O
study	O
.	O
	
Twenty-eight	O
patients	O
(	O
22	O
men	O
and	O
six	O
women	O
;	O
median	O
age	O
","	O
60	O
years	O
)	O
with	O
previously	O
untreated	O
SCLC	B-CANCER
entered	O
the	O
study	O
.	O
	
Patients	O
were	O
assigned	O
to	O
six	O
groups	O
of	O
escalating-dose	O
IL-3	B-DRUG
ranging	O
from	O
0.25	O
to	O
10	O
micrograms	O
/	O
kg	O
/	O
d	O
administered	O
by	O
continuous	O
infusion	O
for	O
7	O
days	O
","	O
with	O
one	O
patient	O
in	O
each	O
group	O
receiving	O
placebo	B-DRUG
.	O
	
After	O
a	O
1-week	O
interval	O
","	O
the	O
first	O
of	O
three	O
cycles	O
of	O
carboplatin	B-DRUG
","	O
etoposide	B-DRUG
(	O
VP16	B-DRUG
)	O
","	O
and	O
epirubicin	B-DRUG
(	O
CVE	B-DRUG
)	O
given	O
every	O
3	O
weeks	O
was	O
administered	O
.	O
	
The	O
second	O
cycle	O
of	O
CVE	B-DRUG
was	O
followed	O
by	O
7	O
days	O
of	O
IL-3	B-DRUG
administered	O
at	O
the	O
same	O
daily	O
dose	O
as	O
administered	O
during	O
the	O
first	O
infusion	O
.	O
	
The	O
maximum-tolerated	O
dose	O
was	O
not	O
encountered	O
in	O
this	O
study	O
.	O
	
Fever	B-TOXI
was	O
the	O
most	O
frequently	O
observed	O
side	O
effect	O
.	O
	
Before	O
any	O
chemotherapy	O
","	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
grade	O
II	O
fever	O
only	O
appeared	O
at	O
doses	O
&	O
gt	O
;	O
or	O
=	O
2.5	O
micrograms	O
/	O
kg	O
/	O
d.	O
Other	O
side	O
effects	O
included	O
rash	B-TOXI
","	O
headache	B-TOXI
","	O
and	O
myalgia	B-TOXI
.	O
	
During	O
the	O
first	O
infusion	O
of	O
IL-3	B-DRUG
","	O
before	O
administration	O
of	O
chemotherapy	O
","	O
dose-dependent	O
increases	O
in	O
peripheral-platelet	O
counts	O
(	O
r	O
=	O
0.613	O
;	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
and	O
neutrophil	O
counts	O
(	O
r	O
=	O
0.505	O
;	O
P	O
=	O
0.007	O
)	O
were	O
observed	O
.	O
	
Following	O
the	O
second	O
cycle	O
of	O
CVE	B-DRUG
","	O
recovery	O
of	O
peripheral	O
platelet	O
counts	O
was	O
faster	O
as	O
compared	O
with	O
the	O
first	O
cycle	O
of	O
CVE	B-DRUG
for	O
patients	O
treated	O
with	O
7.5	O
and	O
10	O
micrograms	O
/	O
kg	O
of	O
IL-3	B-DRUG
(	O
P	O
=	O
0.021	O
)	O
.	O
	
Chemotherapy	O
postponements	O
due	O
to	O
myelotoxicity	B-TOXI
were	O
also	O
less	O
frequent	O
following	O
the	O
second	O
cycle	O
of	O
CVE	B-DRUG
as	O
compared	O
with	O
the	O
first	O
for	O
patients	O
treated	O
with	O
&	O
gt	O
;	O
or	O
=	O
2.5	O
micrograms	O
/	O
kg	O
of	O
IL-3	O
(	O
P	O
=	O
0.036	O
)	O
.	O
	
Compared	O
with	O
an	O
age-matched	O
historical	O
group	O
receiving	O
identical	O
chemotherapy	O
(	O
n	O
=	O
191	O
)	O
","	O
administration	O
of	O
IL-3	B-DRUG
did	O
not	O
modify	O
either	O
disease-free	O
survival	O
or	O
overall	O
patient	O
survival	O
rates	O
.	O
	
IL-3	B-DRUG
is	O
well	O
tolerated	O
at	O
doses	O
up	O
to	O
10	O
micrograms	O
/	O
kg	O
/	O
d.	O
In	O
the	O
absence	O
of	O
chemotherapy	O
","	O
biologic	O
effects	O
on	O
both	O
neutrophils	O
and	O
platelets	O
were	O
seen	O
at	O
doses	O
&	O
gt	O
;	O
or	O
=	O
2.5	O
micrograms	O
/	O
kg	O
/	O
d.	O
IL-3	B-DRUG
infusion	O
following	O
the	O
second	O
cycle	O
of	O
CVE	B-DRUG
appears	O
to	O
reduce	O
chemotherapy-induced	O
myelosuppression	B-TOXI
","	O
but	O
does	O
not	O
alter	O
tumor	O
response	O
or	O
patient	O
survival	O
rates	O
.	O
	
Early	O
evaluation	O
of	O
combined	O
fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
as	O
a	O
radiation	O
enhancer	O
for	O
locally	O
unresectable	O
","	O
residual	O
","	O
or	O
recurrent	B-CANCER
gastrointestinal	I-CANCER
carcinoma.	I-CANCER
The	O
North	O
Central	O
Cancer	O
Treatment	O
Group	O
.	O
	
	
To	O
develop	O
a	O
tolerable	O
regimen	O
of	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
low-dose	O
leucovorin	B-DRUG
","	O
and	O
radiation	O
","	O
and	O
to	O
obtain	O
an	O
early	O
estimate	O
of	O
therapeutic	O
effectiveness	O
.	O
	
Forty	O
patients	O
with	O
locally	O
unresectable	O
or	O
recurrent	B-CANCER
gastrointestinal	I-CANCER
carcinoma	I-CANCER
were	O
studied	O
(	O
pancreas	O
","	O
n	O
=	O
22	O
;	O
rectum	O
and	O
sigmoid	O
","	O
n	O
=	O
10	O
;	O
gastric	O
","	O
n	O
=	O
6	O
;	O
other	O
","	O
n	O
=	O
2	O
)	O
.	O
	
Irradiation	O
therapy	O
was	O
administered	O
in	O
1.8-Gy	O
fractions	O
5	O
days	O
per	O
week	O
","	O
with	O
total	O
doses	O
ranging	O
from	O
45	O
to	O
54	O
Gy	O
.	O
	
5-FU	B-DRUG
400	O
mg	O
/	O
m2	O
/	O
d	O
plus	O
leucovorin	B-DRUG
20	O
mg	O
/	O
m2	O
/	O
d	O
","	O
both	O
by	O
rapid	O
intravenous	O
injection	O
","	O
were	O
administered	O
for	O
3	O
or	O
4	O
days	O
during	O
the	O
first	O
and	O
fifth	O
weeks	O
of	O
radiation	O
.	O
	
5-FU	B-DRUG
425	O
mg	O
/	O
m2	O
/	O
d	O
plus	O
leucovorin	B-DRUG
20	O
mg	O
/	O
m2	O
/	O
d	O
were	O
administered	O
for	O
4	O
days	O
at	O
4	O
weeks	O
following	O
radiation	O
and	O
for	O
5	O
days	O
at	O
9	O
weeks	O
.	O
	
Major	O
toxicities	O
with	O
upper	O
abdominal	O
treatment	O
were	O
nausea	B-TOXI
","	O
vomiting	B-TOXI
","	O
weight	B-TOXI
loss	I-TOXI
","	O
and	O
leukopenia	B-TOXI
.	O
	
A	O
tolerable	O
dosage	O
regimen	O
was	O
radiation	O
at	O
45	O
Gy	O
with	O
4	O
days	O
of	O
5-FU	B-DRUG
plus	O
leucovorin	B-DRUG
during	O
the	O
first	O
week	O
and	O
3	O
days	O
during	O
the	O
last	O
week	O
with	O
postradiation	O
chemotherapy	O
.	O
	
Major	O
toxicities	O
with	O
pelvic	O
radiation	O
were	O
diarrhea	B-TOXI
and	O
leukopenia	B-TOXI
.	O
	
A	O
tolerable	O
regimen	O
was	O
54	O
Gy	O
with	O
4	O
days	O
of	O
5-FU	B-DRUG
plus	O
leucovorin	B-DRUG
during	O
the	O
first	O
and	O
fifth	O
week	O
followed	O
by	O
the	O
postradiation	O
chemotherapy	O
.	O
	
Median	O
survival	O
durations	O
for	O
pancreatic	O
and	O
rectal	O
/	O
sigmoid	B-CANCER
carcinomas	I-CANCER
are	O
13	O
months	O
and	O
31	O
months	O
","	O
respectively	O
.	O
	
Five	O
patients	O
have	O
no	O
evidence	O
of	O
disease	O
from	O
38	O
to	O
50	O
months	O
after	O
the	O
onset	O
of	O
therapy	O
(	O
rectal	O
","	O
n	O
=	O
2	O
;	O
stomach	O
","	O
n	O
=	O
2	O
;	O
pancreas	O
","	O
n	O
=	O
1	O
)	O
.	O
	
We	O
have	O
developed	O
patient-tolerable	O
regimens	O
for	O
combined	O
5-FU	B-DRUG
plus	O
leucovorin	B-DRUG
followed	O
by	O
radiation	O
to	O
the	O
abdomen	O
and	O
to	O
the	O
pelvis	O
.	O
	
The	O
favorable	O
results	O
observed	O
in	O
locally	O
unresectable	O
disease	O
allow	O
cautious	O
optimism	O
for	O
possible	O
effectiveness	O
in	O
the	O
surgical	O
adjuvant	O
setting	O
","	O
a	O
possibility	O
currently	O
being	O
tested	O
in	O
national	O
trials	O
of	O
rectal	O
and	O
gastric	B-CANCER
carcinoma	I-CANCER
.	O
	
Cisplatin	B-DRUG
","	O
fluorouracil	B-DRUG
","	O
and	O
leucovorin.	B-DRUG
Increased	O
toxicity	O
without	O
improved	O
response	O
in	O
squamous	B-CANCER
cell	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
evaluate	O
the	O
activity	O
and	O
toxicity	O
of	O
the	O
drug	O
combination	O
cisplatin	B-DRUG
","	O
fluorouracil	B-DRUG
by	O
continuous	O
infusion	O
","	O
and	O
high-dose	O
oral	O
leucovorin	B-DRUG
calcium	I-DRUG
(	O
PFL	B-DRUG
)	O
as	O
induction	O
chemotherapy	O
in	O
patients	O
with	O
advanced	O
and	O
untreated	O
squamous	B-CANCER
cell	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	I-CANCER
SCHN	I-CANCER
)	I-CANCER
cancer	I-CANCER
.	O
	
Nonrandomized	O
","	O
prospective	O
trial	O
.	O
	
Referral	O
center	O
(	O
comprehensive	O
cancer	O
center	O
)	O
.	O
	
Twenty-two	O
patients	O
with	O
stage	O
III	O
(	O
n	O
=	O
7	O
)	O
and	O
IV	O
(	O
n	O
=	O
15	O
)	O
M0	O
SCHN	B-CANCER
cancer	I-CANCER
of	O
the	O
larynx	O
(	O
n	O
=	O
13	O
)	O
","	O
hypopharynx	O
(	O
n	O
=	O
7	O
)	O
","	O
and	O
oropharynx	O
(	O
n	O
=	O
2	O
)	O
whose	O
standard	O
treatment	O
would	O
have	O
required	O
total	O
laryngectomy	O
.	O
	
Three	O
cycles	O
of	O
PFL	B-DRUG
were	O
administered	O
prior	O
to	O
local-regional	O
therapy	O
(	O
concomitant	O
cisplatin	B-DRUG
and	O
radiation	O
and	O
/	O
or	O
neck	O
dissection	O
","	O
with	O
total	O
laryngectomy	O
reserved	O
for	O
nonresponse	O
or	O
relapse	O
)	O
.	O
	
Chemotherapy	O
included	O
cisplatin	B-DRUG
(	O
100	O
mg	O
/	O
m2	O
)	O
on	O
day	O
1	O
by	O
short	O
intravenous	O
infusion	O
;	O
fluorouracil	B-DRUG
(	O
800	O
mg	O
/	O
m2	O
)	O
on	O
days	O
1	O
through	O
5	O
by	O
continuous	O
infusion	O
;	O
and	O
leucovorin	B-DRUG
(	O
100	O
mg	O
)	O
every	O
4	O
hours	O
by	O
mouth	O
for	O
30	O
doses	O
.	O
	
The	O
PFL	B-DRUG
combination	O
was	O
administered	O
every	O
21	O
days	O
.	O
	
Clinical	O
response	O
to	O
chemotherapy	O
and	O
observed	O
toxic	O
effects	O
during	O
chemotherapy	O
.	O
	
Five	O
patients	O
were	O
inevaluable	O
for	O
response	O
","	O
with	O
three	O
early	O
deaths	B-TOXI
(	O
infection	B-TOXI
in	O
two	O
and	O
sudden	B-TOXI
death	I-TOXI
in	O
one	O
)	O
","	O
one	O
cerebrovascular	B-TOXI
accident	I-TOXI
","	O
and	O
one	O
patient	O
declining	O
further	O
chemotherapy	O
.	O
	
Of	O
the	O
remaining	O
17	O
patients	O
","	O
10	O
had	O
a	O
major	O
response	O
to	O
chemotherapy	O
","	O
but	O
in	O
only	O
five	O
patients	O
(	O
29	O
%	O
)	O
was	O
this	O
complete	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
8	O
%	O
to	O
51	O
%	O
)	O
.	O
	
Other	O
significant	O
toxic	O
effects	O
included	O
grade	O
3	O
to	O
4	O
mucositis	B-TOXI
in	O
eight	O
patients	O
and	O
grade	O
3	O
to	O
4	O
neutropenia	B-TOXI
in	O
10	O
.	O
	
While	O
PFL	B-DRUG
is	O
active	O
in	O
patients	O
with	O
SCHN	B-CANCER
cancer	I-CANCER
","	O
we	O
were	O
unable	O
to	O
reproduce	O
the	O
high	O
complete	O
response	O
rates	O
reported	O
by	O
other	O
centers	O
.	O
	
Its	O
use	O
can	O
be	O
associated	O
with	O
significant	O
toxic	O
effects	O
.	O
	
We	O
do	O
not	O
recommend	O
the	O
use	O
of	O
PFL	B-DRUG
for	O
the	O
treatment	O
of	O
patients	O
with	O
SCHN	B-CANCER
cancer	I-CANCER
outside	O
the	O
context	O
of	O
a	O
clinical	O
trial	O
until	O
there	O
is	O
further	O
critical	O
assessment	O
of	O
its	O
activity	O
and	O
toxicity	O
.	O
	
Combination	O
chemotherapy	O
with	O
or	O
without	O
thoracic	O
radiotherapy	O
in	O
limited-stage	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
a	O
randomized	O
trial	O
of	O
the	O
Southeastern	O
Cancer	O
Study	O
Group	O
.	O
	
	
The	O
primary	O
objective	O
of	O
this	O
randomized	O
prospective	O
study	O
was	O
to	O
compare	O
the	O
survival	O
of	O
limited-stage	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
SCLC	B-CANCER
)	O
patients	O
treated	O
with	O
chemotherapy	O
alone	O
or	O
chemotherapy	O
plus	O
thoracic	O
radiotherapy	O
(	O
TRT	O
)	O
.	O
	
A	O
secondary	O
objective	O
was	O
to	O
determine	O
the	O
effect	O
of	O
consolidation	O
chemotherapy	O
on	O
survival	O
.	O
	
This	O
multiinstitutional	O
phase	O
III	O
study	O
included	O
386	O
patients	O
with	O
limited-stage	O
SCLC	B-CANCER
.	O
	
All	O
patients	O
received	O
cyclophosphamide	B-DRUG
"1,000"	O
mg	O
/	O
m2	O
","	O
doxorubicin	B-DRUG
40	O
mg	O
/	O
m2	O
","	O
and	O
vincristine	B-DRUG
1	O
mg	O
/	O
m2	O
(	O
CAV	B-DRUG
)	O
every	O
3	O
weeks	O
for	O
six	O
cycles	O
.	O
	
Irradiated	O
patients	O
received	O
30	O
Gy	O
in	O
10	O
fractions	O
during	O
weeks	O
1	O
and	O
2	O
of	O
chemotherapy	O
.	O
	
Fifteen	O
Gy	O
in	O
five	O
fractions	O
was	O
administered	O
during	O
week	O
7	O
(	O
total	O
dose	O
","	O
45	O
Gy	O
)	O
.	O
	
Following	O
CAV	B-DRUG
","	O
responding	O
patients	O
were	O
randomized	O
to	O
receive	O
two	O
cycles	O
of	O
consolidation	O
chemotherapy	O
(	O
cisplatin	B-DRUG
20	O
mg	O
/	O
m2	O
/	O
d	O
for	O
4	O
days	O
plus	O
etoposide	B-DRUG
100	O
mg	O
/	O
m2	O
/	O
d	O
for	O
4	O
days	O
)	O
or	O
observation	O
.	O
	
Complete	O
(	O
46	O
%	O
and	O
38	O
%	O
;	O
P	O
=	O
0.14	O
)	O
and	O
overall	O
response	O
rates	O
(	O
67	O
%	O
and	O
64	O
%	O
;	O
P	O
=	O
0.58	O
)	O
were	O
not	O
statistically	O
significantly	O
different	O
.	O
	
Although	O
not	O
significantly	O
different	O
","	O
median	O
(	O
14.4	O
v	O
12.8	O
months	O
)	O
and	O
2-year	O
survival	O
(	O
33	O
%	O
v	O
23.5	O
%	O
)	O
rates	O
favored	O
the	O
irradiated	O
patients	O
.	O
	
Grade	O
4	O
hematologic	B-TOXI
toxicity	I-TOXI
was	O
greater	O
in	O
irradiated	O
patients	O
(	O
60	O
%	O
and	O
39	O
%	O
;	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
.	O
	
Patients	O
given	O
consolidation	O
chemotherapy	O
experienced	O
superior	O
median	O
(	O
21.1	O
v	O
13.2	O
months	O
;	O
P	O
=	O
0.028	O
)	O
and	O
2-year	O
survival	O
(	O
44	O
%	O
v	O
26	O
%	O
;	O
P	O
=	O
0.028	O
)	O
rates	O
.	O
	
The	O
concurrent	O
use	O
of	O
TRT	B-DRUG
and	O
CAV	B-DRUG
chemotherapy	O
as	O
administered	O
in	O
this	O
study	O
failed	O
to	O
improve	O
the	O
survival	O
of	O
limited-stage	O
SCLC	B-CANCER
patients	O
compared	O
with	O
CAV	B-DRUG
alone	O
.	O
	
Life-threatening	O
hematologic	B-TOXI
toxicities	I-TOXI
were	O
more	O
frequent	O
with	O
combined-modality	O
therapy	O
.	O
	
The	O
survival	O
of	O
limited-stage	O
patients	O
treated	O
with	O
CAV	B-DRUG
(	O
with	O
or	O
without	O
TRT	O
)	O
was	O
improved	O
with	O
two	O
cycles	O
of	O
cisplatin	B-DRUG
and	O
etoposide	B-DRUG
consolidation	O
therapy	O
.	O
	
Whether	O
similar	O
survival	O
results	O
could	O
be	O
achieved	O
with	O
cisplatin	B-DRUG
and	O
etoposide	B-DRUG
alone	O
requires	O
additional	O
study	O
.	O
	
Carboplatin	B-DRUG
plus	O
ifosfamide	B-DRUG
as	O
salvage	O
treatment	O
of	O
epithelial	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
:	O
a	O
pilot	O
study	O
.	O
	
	
This	O
study	O
aimed	O
to	O
evaluate	O
the	O
activity	O
and	O
toxicity	O
of	O
carboplatin	B-DRUG
(	O
PPL	B-DRUG
)	O
and	O
ifosfamide	B-DRUG
(	O
IFO	B-DRUG
)	O
in	O
patients	O
with	O
epithelial	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
previously	O
treated	O
with	O
cisplatin	B-DRUG
(	O
CDDP	B-DRUG
)	O
#NAME?	O
regimens	O
.	O
	
From	O
July	O
1989	O
to	O
December	O
1991	O
","	O
35	O
patients	O
with	O
epithelial	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
relapsed	O
or	O
refractory	O
to	O
CDDP	B-DRUG
as	O
first-line	O
chemotherapy	O
were	O
treated	O
.	O
	
PPL	B-DRUG
was	O
administered	O
at	O
a	O
dose	O
of	O
300	O
mg	O
/	O
m2	O
intravenously	O
(	O
IV	O
)	O
on	O
day	O
1	O
and	O
IFO	B-DRUG
at	O
a	O
dose	O
of	O
"1,500"	O
mg	O
/	O
m2	O
IV	O
on	O
days	O
1	O
to	O
3	O
every	O
3	O
to	O
4	O
weeks	O
.	O
	
Criteria	O
for	O
evaluating	O
previous	O
response	O
to	O
CDDP	B-DRUG
were	O
strictly	O
defined	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
43	O
%	O
(	O
complete	O
response	O
[	O
CR	O
]	O
","	O
6	O
%	O
;	O
partial	O
response	O
[	O
PR	O
]	O
","	O
37	O
%	O
)	O
and	O
the	O
median	O
duration	O
of	O
response	O
was	O
7	O
months	O
(	O
range	O
","	O
3	O
to	O
16	O
)	O
.	O
	
In	O
potentially	O
platinum-sensitive	B-DRUG
(	O
PPS	B-DRUG
;	O
relapsed	O
)	O
patients	O
","	O
the	O
overall	O
response	O
rate	O
was	O
56	O
%	O
.	O
	
None	O
of	O
the	O
primary	O
platinum-resistant	B-DRUG
(	O
PPR	B-DRUG
)	O
patients	O
obtained	O
a	O
clinical	O
response	O
to	O
PPL	B-DRUG
plus	O
IFO	B-DRUG
","	O
whereas	O
one	O
of	O
five	O
secondary	O
platinum-resistant	B-DRUG
(	O
SPR	B-DRUG
)	O
patients	O
obtained	O
a	O
PR	O
.	O
	
The	O
regimen	O
was	O
easily	O
manageable	O
.	O
	
PPL	B-DRUG
plus	O
IFO	B-DRUG
is	O
useful	O
and	O
well-tolerated	O
combination	O
in	O
salvage	O
treatment	O
of	O
patients	O
with	O
advanced	B-CANCER
ovarian	I-CANCER
cancer	I-CANCER
.	O
	
However	O
","	O
clear	O
synergism	O
between	O
PPL	B-DRUG
and	O
IFO	B-DRUG
that	O
could	O
overcome	O
intrinsic	O
or	O
acquired	O
CDDP	B-DRUG
resistance	O
was	O
not	O
observed	O
.	O
	
The	O
advantage	O
of	O
PPL	B-DRUG
plus	O
IFO	B-DRUG
as	O
compared	O
with	O
CDDP-containing	B-DRUG
regimens	O
is	O
represented	O
by	O
the	O
increased	O
tolerability	O
and	O
the	O
reduced	O
neurotoxicity	B-TOXI
","	O
nephrotoxicity	B-TOXI
","	O
and	O
ototoxicity	B-TOXI
as	O
compared	O
with	O
CDDP-containing	B-DRUG
regimens	O
.	O
	
It	O
is	O
essential	O
that	O
the	O
patient	O
population	O
be	O
defined	O
according	O
to	O
their	O
previous	O
response	O
to	O
platinum	B-DRUG
therapy	O
in	O
trials	O
involving	O
second-line	O
therapy	O
of	O
ovarian	B-CANCER
cancer	I-CANCER
.	O
	
Cisplatin	B-DRUG
","	O
fluorouracil	B-DRUG
","	O
and	O
leucovorin	B-DRUG
augmented	O
by	O
interferon	B-DRUG
alfa-2b	I-DRUG
in	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
:	O
a	O
clinical	O
and	O
pharmacologic	O
analysis	O
.	O
	
	
To	O
increase	O
the	O
activity	O
of	O
cisplatin	B-DRUG
","	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
and	O
leucovorin	B-DRUG
(	O
PFL	B-DRUG
)	O
through	O
further	O
biochemical	O
modulation	O
and	O
study	O
the	O
pharmacologic	O
interaction	O
of	O
5-FU	B-DRUG
and	O
interferon	B-DRUG
alfa-2b	I-DRUG
(	O
IFN	B-DRUG
)	O
.	O
	
Escalating	O
doses	O
of	O
IFN	B-DRUG
(	O
0.5	O
to	O
4	O
x	O
10	O
(	O
6	O
)	O
U	O
/	O
m2	O
/	O
d	O
x	O
6	O
)	O
were	O
added	O
to	O
cisplatin	B-DRUG
100	O
mg	O
/	O
m2	O
","	O
continuous	O
infusion	O
5-FU	B-DRUG
800	O
or	O
640	O
mg	O
/	O
m2	O
/	O
d	O
x	O
5	O
","	O
and	O
leucovorin	B-DRUG
100	O
mg	O
orally	O
every	O
4	O
hours	O
.	O
	
Forty-eight	O
previously	O
untreated	O
patients	O
with	O
locoregionally	O
advanced	B-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
received	O
up	O
to	O
three	O
cycles	O
of	O
PFL-IFN	B-DRUG
.	O
	
Twenty-one	O
patients	O
were	O
treated	O
during	O
a	O
phase	O
I	O
cohort	O
study	O
.	O
	
Dose-limiting	O
mucositis	B-TOXI
was	O
seen	O
with	O
800	O
mg	O
/	O
m2	O
/	O
d	O
of	O
5-FU	B-DRUG
and	O
0.5	O
x	O
10	O
(	O
6	O
)	O
U	O
/	O
m2	O
/	O
d	O
of	O
IFN	B-DRUG
.	O
	
After	O
decreasing	O
the	O
5-FU	B-DRUG
dose	O
to	O
640	O
mg	O
/	O
m2	O
/	O
d	O
","	O
the	O
maximally	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
IFN	B-DRUG
was	O
2	O
x	O
10	O
(	O
6	O
)	O
U	O
/	O
m2	O
/	O
d.	O
Mucositis	B-TOXI
and	O
myelosuppression	B-TOXI
were	O
dose-limiting	O
.	O
	
Of	O
34	O
patients	O
treated	O
at	O
this	O
MTD	O
","	O
56	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
39	O
%	O
to	O
73	O
%	O
)	O
had	O
a	O
complete	O
remission	O
.	O
	
There	O
was	O
no	O
correlation	O
between	O
5-FU	B-DRUG
clearance	O
and	O
IFN	B-DRUG
dose	O
.	O
	
Pharmacodynamic	O
analyses	O
at	O
the	O
MTD	O
showed	O
that	O
older	O
age	O
","	O
female	O
sex	O
","	O
and	O
higher	O
5-FU	B-DRUG
area	O
under	O
the	O
time	O
versus	O
concentration	O
curve	O
(	O
AUC	O
)	O
were	O
associated	O
with	O
lower	B-TOXI
nadir	I-TOXI
counts	I-TOXI
and	O
/	O
or	O
increased	B-TOXI
mucositis	I-TOXI
.	O
	
Seven	O
patients	O
with	O
diabetes	O
mellitus	O
had	O
significantly	O
increased	B-TOXI
myelosuppression	I-TOXI
","	O
serum	B-TOXI
creatinine	I-TOXI
","	O
hypocalcemia	B-TOXI
","	O
higher	O
5-FU	B-DRUG
concentrations	O
","	O
and	O
lower	O
5-FU	B-DRUG
clearance	O
compared	O
with	O
nondiabetics	O
.	O
	
The	O
recommended	O
doses	O
for	O
PFL-IFN	B-DRUG
are	O
640	O
mg	O
/	O
m2	O
/	O
d	O
for	O
5-FU	B-DRUG
and	O
2	O
x	O
10	O
(	O
6	O
)	O
U	O
/	O
m2	O
/	O
d	O
for	O
IFN	B-DRUG
.	O
	
Sex	O
","	O
age	O
","	O
5-FU	B-DRUG
AUC	O
","	O
and	O
diabetes	O
mellitus	O
may	O
have	O
an	O
impact	O
on	O
the	O
pharmacodynamics	O
of	O
this	O
regimen	O
.	O
	
A	O
phase	O
I-II	O
study	O
of	O
epirubicin	B-DRUG
","	O
5-fluorouracil	B-DRUG
","	O
and	O
leucovorin	B-DRUG
in	O
advanced	B-CANCER
adenocarcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
stomach	I-CANCER
.	O
	
	
To	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
of	O
epirubicin	B-DRUG
for	O
use	O
in	O
combination	O
with	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
and	O
low-dose	O
leucovorin	B-DRUG
(	O
LV	B-DRUG
)	O
","	O
a	O
Phase	O
I-II	O
trial	O
was	O
conducted	O
in	O
37	O
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
carcinoma	I-CANCER
.	O
	
The	O
doses	O
of	O
5-FU	B-DRUG
(	O
425	O
mg	O
/	O
m2	O
)	O
and	O
LV	B-DRUG
(	O
20	O
mg	O
/	O
m2	O
)	O
","	O
both	O
given	O
intravenously	O
on	O
days	O
1月5日	O
","	O
were	O
held	O
constant	O
while	O
the	O
dose	O
of	O
epirubicin	B-DRUG
was	O
escalated	O
in	O
cohorts	O
of	O
patients	O
(	O
beginning	O
dose	O
","	O
50	O
mg	O
/	O
m2	O
on	O
day	O
1	O
)	O
.	O
	
Cycles	O
were	O
repeated	O
every	O
4	O
weeks	O
.	O
	
Significant	O
gastrointestinal	B-TOXI
symptoms	I-TOXI
and	O
myelosuppression	B-TOXI
were	O
observed	O
infrequently	O
at	O
the	O
initial	O
dose	O
level	O
.	O
	
At	O
a	O
dose	O
of	O
60	O
mg	O
/	O
m2	O
of	O
epirubicin	B-DRUG
on	O
day	O
1	O
","	O
however	O
","	O
five	O
of	O
eight	O
patients	O
had	O
significant	O
mucosal	B-DRUG
toxic	I-DRUG
effects	I-DRUG
during	O
the	O
first	O
cycle	O
of	O
therapy	O
.	O
	
In	O
addition	O
","	O
two	O
patients	O
treated	O
at	O
this	O
dose	O
level	O
had	O
Grade	O
4	O
granulocytopenia	B-TOXI
with	O
insufficient	O
recovery	O
to	O
permit	O
a	O
second	O
course	O
by	O
day	O
28	O
","	O
and	O
one	O
patient	O
each	O
had	O
severe	O
diarrhea	B-TOXI
and	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
.	O
	
Among	O
37	O
patients	O
with	O
assessable	O
disease	O
","	O
there	O
were	O
3	O
complete	O
and	O
11	O
partial	O
responses	O
(	O
response	O
rate	O
","	O
38	O
%	O
)	O
.	O
	
LV	B-DRUG
modulation	O
of	O
5-FU	B-DRUG
can	O
be	O
incorporated	O
safely	O
into	O
combination	O
chemotherapy	O
with	O
epirubicin	B-DRUG
and	O
provides	O
a	O
relatively	O
active	O
regimen	O
for	O
treatment	O
of	O
disseminated	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Carboplatin	B-DRUG
and	O
etoposide	B-DRUG
in	O
advanced	B-CANCER
colorectal	I-CANCER
carcinoma.	I-CANCER
A	O
phase	O
II	O
study	O
.	O
	
	
For	O
advanced	B-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
","	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
#NAME?	B-DRUG
is	O
the	O
best	O
therapy	O
available	O
.	O
	
To	O
improve	O
results	O
","	O
a	O
variety	O
of	O
drugs	O
were	O
added	O
","	O
including	O
cisplatin	B-DRUG
(	O
CDDP	B-DRUG
)	O
","	O
sometimes	O
with	O
controversial	O
results	O
.	O
	
The	O
combination	O
of	O
CDDP	B-DRUG
and	O
etoposide	B-DRUG
(	O
VP-16	B-DRUG
)	O
has	O
shown	O
synergistic	O
activity	O
in	O
other	O
settings	O
.	O
	
Although	O
VP-16	B-DRUG
alone	O
is	O
considered	O
rather	O
inactive	O
in	O
colorectal	B-CANCER
carcinoma	I-CANCER
","	O
the	O
authors	O
believed	O
it	O
was	O
appropriate	O
to	O
evaluate	O
the	O
combination	O
of	O
VP-16	B-DRUG
and	O
carboplatin	B-DRUG
(	O
CBDCA	B-DRUG
)	O
in	O
this	O
disease	O
because	O
the	O
newer	O
platinum	O
analogue	O
CBDCA	B-DRUG
has	O
more	O
limited	O
side	O
effects	O
than	O
the	O
parent	O
compound	O
.	O
	
Twenty-eight	O
patients	O
with	O
advanced	B-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
were	O
treated	O
with	O
CBDCA	B-DRUG
(	O
200	O
mg	O
/	O
m2	O
","	O
days	O
1月3日	O
)	O
and	O
VP-16	B-DRUG
(	O
100	O
mg	O
/	O
m2	O
","	O
days	O
1月5日	O
)	O
.	O
	
Cycles	O
were	O
repeated	O
every	O
4	O
weeks	O
.	O
	
All	O
patients	O
received	O
at	O
least	O
two	O
cycles	O
(	O
median	O
","	O
six	O
cycles	O
;	O
range	O
","	O
two	O
to	O
eight	O
cycles	O
)	O
.	O
	
There	O
were	O
three	O
complete	O
responses	O
and	O
four	O
partial	O
responses	O
.	O
	
The	O
median	O
duration	O
of	O
response	O
was	O
35	O
weeks	O
(	O
range	O
","	O
25-84	O
weeks	O
)	O
.	O
	
The	O
median	O
time	O
to	O
tumor	O
progression	O
was	O
23	O
weeks	O
(	O
range	O
","	O
9-84	O
weeks	O
)	O
.	O
	
The	O
median	O
survival	O
time	O
was	O
49	O
weeks	O
(	O
range	O
","	O
9-151+	O
weeks	O
)	O
.	O
	
Toxic	O
effects	O
generally	O
were	O
assessed	O
as	O
mild	O
","	O
with	O
no	O
Grade	O
4	O
(	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
classification	O
)	O
toxic	O
effects	O
observed	O
during	O
this	O
study	O
.	O
	
Response	O
rate	O
and	O
toxic	O
effects	O
observed	O
during	O
this	O
study	O
warrant	O
additional	O
studies	O
comparing	O
this	O
regimen	O
with	O
5-FU-based	B-DRUG
regimens	O
in	O
advanced	B-CANCER
colorectal	I-CANCER
carcinoma	I-CANCER
.	O
	
Paclitaxel	B-DRUG
with	O
mitoxantrone	B-DRUG
","	B-DRUG
fluorouracil	I-DRUG
","	O
and	O
high-dose	O
leucovorin	B-DRUG
in	O
the	O
treatment	O
of	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
:	O
a	O
phase	O
II	O
trial	O
.	O
	
	
Paclitaxel	B-DRUG
is	O
a	O
highly	O
active	O
single	O
agent	O
in	O
the	O
treatment	O
of	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
However	O
","	O
its	O
optimal	O
incorporation	O
into	O
combination	O
regimens	O
awaits	O
definition	O
.	O
	
In	O
this	O
phase	O
II	O
study	O
","	O
we	O
added	O
paclitaxel	B-DRUG
","	O
administered	O
by	O
1-hour	O
infusion	O
","	O
to	O
a	O
previously	O
described	O
combination	O
regimen	O
that	O
included	O
mitoxantrone	B-DRUG
","	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
and	O
high-dose	O
leucovorin	B-DRUG
(	O
NFL	B-DRUG
)	O
.	O
	
Forty-six	O
patients	O
with	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
received	O
the	O
following	O
regimen	O
as	O
first-	O
or	O
second-line	O
treatment	O
:	O
paclitaxel	B-DRUG
135	O
mg	O
/	O
m2	O
by	O
1-hour	O
intravenous	O
(	O
i.v.	O
)	O
infusion	O
on	O
day	O
1	O
","	O
mitoxantrone	B-DRUG
10	O
mg	O
/	O
m2	O
by	O
i.v.	O
bolus	O
on	O
day	O
1	O
","	O
5-FU	B-DRUG
350	O
mg2	O
/	O
m	O
by	O
i.v.	O
bolus	O
on	O
days	O
1	O
","	O
2	O
","	O
and	O
3	O
","	O
and	O
leucovorin	B-DRUG
300	O
mg	O
i.v.	O
over	O
30	O
to	O
60	O
minutes	O
immediately	O
preceding	O
5-FU	B-DRUG
on	O
days	O
1	O
","	O
2	O
","	O
and	O
3	O
Courses	O
were	O
administered	O
at	O
3-week	O
intervals	O
for	O
a	O
total	O
of	O
eight	O
courses	O
in	O
responding	O
patients	O
.	O
	
Twenty-three	O
of	O
45	O
assessable	O
patients	O
(	O
51	O
%	O
)	O
had	O
major	O
responses	O
.	O
	
Previous	O
chemotherapy	O
","	O
and	O
in	O
particular	O
previous	O
treatment	O
with	O
doxorubicin	B-DRUG
","	O
did	O
not	O
affect	O
response	O
rate	O
.	O
	
The	O
median	O
response	O
duration	O
was	O
7.5	O
months	O
.	O
	
Myelosuppression	B-TOXI
was	O
moderately	O
severe	O
","	O
with	O
76	O
%	O
of	O
courses	O
resulting	O
in	O
grade	O
3	O
or	O
4	O
leukopenia	B-TOXI
.	O
	
Hospitalization	O
for	O
treatment	O
of	O
fever	B-TOXI
during	O
neutropenia	B-TOXI
was	O
required	O
in	O
13	O
%	O
of	O
courses	O
","	O
and	O
two	O
patients	O
died	B-TOXI
as	O
a	O
result	O
of	O
sepsis	B-TOXI
.	O
	
Two	O
patients	O
developed	O
severe	O
congestive	O
heart	B-TOXI
failure	I-TOXI
after	O
a	O
large	O
cumulative	O
anthracycline	O
dose	O
.	O
	
This	O
combination	O
regimen	O
was	O
active	O
as	O
first-	O
or	O
second-line	O
therapy	O
for	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
","	O
although	O
its	O
activity	O
compared	O
with	O
other	O
combination	O
regimens	O
or	O
with	O
paclitaxel	B-DRUG
alone	O
is	O
unclear	O
.	O
	
Myelosuppression	B-TOXI
was	O
more	O
severe	O
than	O
anticipated	O
based	O
on	O
previous	O
results	O
with	O
the	O
NFL	B-DRUG
regimen	O
or	O
with	O
paclitaxel	B-DRUG
administered	O
at	O
this	O
dose	O
and	O
schedule	O
as	O
a	O
single	O
agent	O
.	O
	
The	O
infrequent	O
development	O
of	O
cardiotoxicity	B-TOXI
in	O
these	O
patients	O
suggests	O
that	O
the	O
paclitaxel	B-DRUG
/	O
mitoxantrone	B-DRUG
combination	O
may	O
not	O
share	O
the	O
problems	O
previously	O
reported	O
with	O
the	O
paclitaxel	B-DRUG
/	O
doxorubicin	B-DRUG
combination	O
.	O
	
Paclitaxel	B-DRUG
in	O
combination	O
chemotherapy	O
with	O
radiotherapy	O
in	O
patients	O
with	O
unresectable	O
stage	O
III	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
addition	O
of	O
combination	O
chemotherapy	O
to	O
standard	O
radiation	O
therapy	O
has	O
improved	O
treatment	O
for	O
locally	O
unresectable	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
In	O
this	O
phase	O
II	O
study	O
","	O
we	O
evaluated	O
the	O
toxicity	O
and	O
efficacy	O
of	O
a	O
novel	O
chemotherapy	O
regimen	O
that	O
included	O
paclitaxel	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
etoposide	B-DRUG
plus	O
concurrent	O
radiation	O
therapy	O
in	O
this	O
group	O
of	O
patients	O
.	O
	
Thirty-three	O
patients	O
with	O
previously	O
untreated	O
","	O
unresectable	O
stage	O
III	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
stage	O
IIIA	O
","	O
11	O
patients	O
;	O
stage	O
IIIB	O
","	O
22	O
patients	O
)	O
initially	O
received	O
two	O
courses	O
of	O
chemotherapy	O
","	O
which	O
included	O
paclitaxel	B-DRUG
135	O
mg	O
/	O
m2	O
by	O
1-hour	O
infusion	O
on	O
day	O
1	O
","	O
cisplatin	B-DRUG
60	O
mg	O
/	O
m	O
/	O
intravenously	O
(	O
i.v.	O
)	O
on	O
day	O
2	O
","	O
and	O
etoposide	B-DRUG
100	O
mg	O
/	O
m2	O
i.v.	O
on	O
days	O
1	O
","	O
2	O
and	O
3	O
On	O
week	O
6	O
","	O
radiation	O
therapy	O
(	O
60	O
Gy	O
in	O
30	O
fractions	O
)	O
was	O
initiated	O
in	O
conjunction	O
with	O
two	O
additional	O
courses	O
of	O
chemotherapy	O
:	O
paclitaxel	B-DRUG
135	O
mg	O
/	O
m2	O
i.v.	O
by	O
1-hour	O
infusion	O
on	O
day	O
1	O
","	O
cisplatin	B-DRUG
5	O
mg	O
/	O
m2	O
i.v.	O
on	O
days	O
-2	O
to	O
10	O
","	O
and	O
etoposide	B-DRUG
25	O
mg	O
/	O
m2	O
on	O
days	O
1	O
to	O
10	O
.	O
	
This	O
combined	O
modality	O
program	O
was	O
feasible	O
and	O
well	O
tolerated	O
by	O
most	O
patients	O
.	O
	
During	O
the	O
two	O
courses	O
of	O
induction	O
chemotherapy	O
","	O
grade	O
3	O
or	O
4	O
myelosuppression	B-TOXI
occurred	O
in	O
only	O
six	O
patients	O
(	O
18	O
%	O
)	O
.	O
	
Esophagitis	B-TOXI
was	O
common	O
during	O
combined	O
modality	O
therapy	O
(	O
grade	O
3	O
","	O
10	O
patients	O
;	O
grade	O
4	O
five	O
patients	O
)	O
.	O
	
Forty-two	O
percent	O
of	O
patients	O
had	O
partial	O
response	O
after	O
two	O
courses	O
of	O
induction	O
therapy	O
","	O
and	O
82	O
%	O
of	O
patients	O
had	O
an	O
objective	O
response	O
at	O
completion	O
of	O
therapy	O
.	O
	
Twelve	O
patients	O
(	O
36	O
%	O
)	O
had	O
a	O
complete	O
response	O
.	O
	
Nineteen	O
patients	O
remain	O
progression-free	O
at	O
a	O
median	O
of	O
8	O
months	O
;	O
the	O
median	O
survival	O
time	O
has	O
not	O
been	O
reached	O
.	O
	
This	O
paclitaxel-containing	B-DRUG
combined	O
modality	O
therapy	O
is	O
feasible	O
and	O
highly	O
active	O
in	O
patients	O
with	O
inoperable	O
stage	O
III	O
lung	B-CANCER
cancer	I-CANCER
.	O
	
Esophagitis	B-TOXI
is	O
the	O
most	O
common	O
severe	O
toxicity	O
with	O
this	O
program	O
.	O
	
Further	O
studies	O
with	O
paclitaxel-containing	B-DRUG
combination	O
regimens	O
in	O
patients	O
with	O
stage	O
III	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
are	O
indicated	O
.	O
	
Phase	O
I	O
dose-escalation	O
trial	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
for	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
usefulness	O
of	O
mathematic	O
modeling	O
to	O
determine	O
maximum-tolerable	O
dose	O
.	O
	
	
This	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
maximum-tolerated	O
doses	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
","	O
each	O
given	O
weekly	O
for	O
3	O
weeks	O
with	O
a	O
1-week	O
rest	O
.	O
	
Patients	O
less	O
than	O
75	O
years	O
of	O
age	O
were	O
eligible	O
if	O
they	O
had	O
stage	O
III	O
/	O
IV	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
","	O
life	O
expectancy	O
&	O
gt	O
;	O
or	O
=	O
12	O
weeks	O
","	O
hemoglobin	O
level	O
&	O
gt	O
;	O
or	O
=	O
10	O
g	O
/	O
dL	O
","	O
granulocyte	O
count	O
&	O
gt	O
;	O
or	O
=	O
2	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
","	O
platelet	O
count	O
&	O
gt	O
;	O
or	O
=	O
100	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
","	O
hepatic	O
enzymes	O
&	O
lt	O
;	O
or	O
=	O
three	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
","	O
and	O
creatinine	O
concentration	O
&	O
lt	O
;	O
or	O
=	O
130	O
mumoles	O
/	O
L.	O
The	O
starting	O
doses	O
for	O
gemcitabine	B-CANCER
and	O
cisplatin	B-CANCER
were	O
"1,000"	O
mg	O
/	O
m2	O
and	O
25	O
mg	O
/	O
m2	O
per	O
week	O
for	O
3	O
weeks	O
.	O
	
At	O
dose	O
level	O
2	O
","	O
cisplatin	B-DRUG
was	O
increased	O
to	O
30	O
mg	O
/	O
m2	O
/	O
wk	O
for	O
3	O
weeks	O
","	O
and	O
thereafter	O
only	O
gemcitabine	B-DRUG
was	O
increased	O
by	O
250	O
mg	O
/	O
m2	O
/	O
wk	O
at	O
each	O
dose	O
level	O
to	O
a	O
maximum	O
of	O
"2,250"	O
mg	O
/	O
m2	O
/	O
wk	O
.	O
	
There	O
were	O
33	O
men	O
and	O
17	O
women	O
","	O
with	O
a	O
median	O
age	O
of	O
62	O
years	O
.	O
	
Pathology	O
included	O
adenocarcinoma	B-CANCER
in	O
35	O
patients	O
","	O
squamous	B-CANCER
in	O
eight	O
","	O
large	O
cell	O
in	O
six	O
","	O
and	O
mixed	O
histology	O
in	O
one	O
.	O
	
Sixteen	O
patients	O
had	O
stage	O
III	O
and	O
34	O
had	O
stage	O
IV	O
tumors	O
.	O
	
The	O
median	O
nadir	B-TOXI
granulocyte	I-TOXI
and	I-TOXI
platelet	I-TOXI
counts	I-TOXI
decreased	I-TOXI
with	O
each	O
dose	O
level	O
","	O
but	O
cycle	O
1	O
dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
in	O
&	O
gt	O
;	O
or	O
=	O
two	O
patients	O
was	O
not	O
encountered	O
in	O
cycle	O
1	O
","	O
even	O
at	O
the	O
highest	O
dose	O
level	O
.	O
	
Cumulative	B-TOXI
marrow	I-TOXI
toxicity	I-TOXI
was	O
seen	O
at	O
all	O
levels	O
","	O
which	O
resulted	O
in	O
frequent	O
dose	O
reductions	O
or	O
omissions	O
.	O
	
A	O
mathematic	O
model	O
of	O
all	O
toxicities	O
over	O
time	O
suggested	O
that	O
dose	O
level	O
4	O
(	O
cisplatin	B-DRUG
30	O
mg	O
/	O
m2	O
/	O
wk	O
and	O
gemcitabine	B-DRUG
"1,500"	O
mg	O
/	O
m2	O
/	O
wk	O
)	O
would	O
be	O
the	O
maximum	O
dose	O
at	O
which	O
grade	O
4	O
toxicity	O
would	O
be	O
expected	O
in	O
&	O
lt	O
;	O
or	O
=	O
33	O
%	O
of	O
patients	O
over	O
four	O
cycles	O
.	O
	
Of	O
47	O
assessable	O
patients	O
","	O
14	O
achieved	O
a	O
partial	O
response	O
(	O
30	O
%	O
;	O
confidence	O
interval	O
","	O
17	O
%	O
to	O
43	O
%	O
)	O
.	O
	
The	O
median	O
duration	O
was	O
16	O
weeks	O
and	O
the	O
median	O
survival	O
time	O
was	O
24	O
weeks	O
(	O
range	O
","	O
3.5-64+	O
)	O
.	O
	
Weekly	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
are	O
active	O
against	O
NSCLC	B-CANCER
","	O
and	O
the	O
recommended	O
phase	O
II	O
doses	O
are	O
30	O
and	O
"1,500"	O
mg	O
/	O
m2	O
/	O
wk	O
for	O
3	O
weeks	O
","	O
respectively	O
.	O
	
Anastrozole	B-DRUG
","	O
a	O
potent	O
and	O
selective	O
aromatase	O
inhibitor	O
","	O
versus	O
megestrol	B-DRUG
acetate	I-DRUG
in	O
postmenopausal	O
women	O
with	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
:	O
results	O
of	O
overview	O
analysis	O
of	O
two	O
phase	O
III	O
trials.	O
Arimidex	O
Study	O
Group	O
.	O
	
	
To	O
compare	O
the	O
efficacy	O
and	O
tolerability	O
of	O
anastrozole	B-DRUG
(	O
1	O
and	O
10	O
mg	O
once	O
daily	O
)	O
","	O
a	O
selective	O
","	O
oral	O
","	O
nonsteroidal	O
aromatase	O
inhibitor	O
","	O
and	O
megestrol	B-DRUG
acetate	I-DRUG
(	O
40	O
mg	O
four	O
times	O
daily	O
)	O
","	O
in	O
postmenopausal	O
women	O
who	O
progressed	O
following	O
tamoxifen	B-DRUG
treatment	O
.	O
	
Two	O
randomized	O
","	O
double-blind	O
for	O
anastrozole	B-DRUG
","	O
open-label	O
for	O
megestrol	B-DRUG
acetate	I-DRUG
","	O
parallel-group	O
","	O
multicenter	O
trials	O
were	O
conducted	O
in	O
764	O
patients	O
.	O
	
Because	O
both	O
trials	O
were	O
identical	O
in	O
design	O
","	O
an	O
analysis	O
of	O
the	O
combined	O
results	O
was	O
performed	O
to	O
strengthen	O
interpretation	O
of	O
results	O
from	O
each	O
trial	O
.	O
	
The	O
median	O
follow-up	O
duration	O
was	O
approximately	O
6	O
months	O
.	O
	
The	O
estimated	O
progression	O
hazards	O
ratios	O
were	O
0.97	O
(	O
97.5	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
0.75	O
to	O
1.24	O
)	O
for	O
anastrozole	B-DRUG
1	O
mg	O
versus	O
megestrol	B-DRUG
acetate	I-DRUG
and	O
0.92	O
(	O
97.5	O
%	O
CI	O
","	O
0.71	O
to	O
1.19	O
)	O
for	O
anastrozole	B-DRUG
10	O
mg	O
versus	O
megestrol	B-DRUG
acetate	I-DRUG
.	O
	
The	O
overall	O
median	O
time	O
to	O
progression	O
was	O
approximately	O
21	O
weeks	O
.	O
	
Approximately	O
one	O
third	O
of	O
patients	O
in	O
each	O
group	O
benefited	O
from	O
treatment	O
.	O
	
Twenty-seven	O
patients	O
(	O
10.3	O
%	O
)	O
in	O
the	O
anastrozole	B-DRUG
1-mg	O
group	O
","	O
22	O
(	O
8.9	O
%	O
)	O
in	O
the	O
anastrozole	B-DRUG
10-mg	O
group	O
","	O
and	O
20	O
(	O
7.9	O
%	O
)	O
in	O
the	O
megestrol	B-DRUG
acetate	I-DRUG
group	O
had	O
a	O
complete	O
or	O
partial	O
response	O
","	O
and	O
66	O
(	O
25.1	O
%	O
)	O
","	O
56	O
(	O
22.6	O
%	O
)	O
","	O
and	O
66	O
(	O
26.1	O
%	O
)	O
patients	O
","	O
respectively	O
","	O
had	O
stable	O
disease	O
for	O
&	O
gt	O
;	O
or	O
=	O
24	O
weeks	O
.	O
	
For	O
all	O
end	O
points	O
","	O
individual	O
trial	O
results	O
were	O
similar	O
to	O
the	O
results	O
of	O
the	O
combined	O
analysis	O
.	O
	
Anastrozole	B-DRUG
and	O
megestrol	B-DRUG
acetate	I-DRUG
were	O
well	O
tolerated	O
.	O
	
Gastrointestinal	B-TOXI
disturbance	I-TOXI
was	O
more	O
common	O
among	O
patients	O
in	O
the	O
anastrozole	B-DRUG
groups	O
than	O
the	O
megestrol	B-DRUG
acetate	I-DRUG
group	O
;	O
the	O
difference	O
between	O
the	O
anastrozole	B-DRUG
10	O
mg	O
and	O
megestrol	B-DRUG
acetate	I-DRUG
groups	O
was	O
significant	O
(	O
P	O
=	O
0.005	O
)	O
.	O
	
Significantly	O
fewer	O
patients	O
in	O
the	O
anastrozole	B-DRUG
1-mg	O
(	O
P	O
&	O
lt	O
;	O
0.0001	O
)	O
and	O
10-mg	O
(	O
P	O
&	O
lt	O
;	O
0.002	O
)	O
groups	O
had	O
weight	O
gain	O
than	O
in	O
the	O
megestrol	B-DRUG
acetate	I-DRUG
group	O
.	O
	
More	O
than	O
30	O
%	O
of	O
megestrol	B-DRUG
acetate-treated	I-DRUG
patients	O
had	O
weight	O
gain	O
&	O
gt	O
;	O
or	O
=	O
5	O
%	O
","	O
and	O
10	O
%	O
of	O
patients	O
had	O
weight	O
gain	O
&	O
gt	O
;	O
or	O
=	O
10	O
%	O
.	O
	
Patients	O
who	O
received	O
megestrol	B-DRUG
acetate	I-DRUG
continued	O
to	O
gain	O
weight	O
over	O
time	O
.	O
	
Anastrozole	B-DRUG
","	O
1	O
and	O
10	O
mg	O
once	O
daily	O
","	O
is	O
well	O
tolerated	O
and	O
as	O
effective	O
as	O
megestrol	B-DRUG
acetate	I-DRUG
in	O
the	O
treatment	O
of	O
postmenopausal	O
women	O
with	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
who	O
progressed	O
following	O
tamoxifen	B-DRUG
treatment	O
.	O
	
Moreover	O
","	O
anastrozole	B-DRUG
therapy	O
avoids	O
the	O
weight	O
gain	O
associated	O
with	O
megestrol	B-DRUG
acetate	I-DRUG
treatment	O
.	O
	
Paclitaxel	B-DRUG
plus	O
carboplatin	B-DRUG
in	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
a	O
phase	O
II	O
trial	O
.	O
	
	
Studies	O
conducted	O
by	O
the	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
(	O
ECOG	O
)	O
indicate	O
both	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
are	O
associated	O
with	O
an	O
improvement	O
in	O
1-year	O
survival	O
in	O
patients	O
with	O
stage	O
IV	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Based	O
on	O
these	O
findings	O
","	O
a	O
phase	O
II	O
trial	O
of	O
these	O
agents	O
in	O
combination	O
was	O
conducted	O
in	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
Eligibility	O
included	O
previously	O
untreated	O
stage	O
IIIB	O
or	O
IV	O
NSCLC	B-CANCER
patients	O
with	O
a	O
good	O
performance	O
status	O
(	O
PS	O
)	O
.	O
	
Paclitaxel	B-DRUG
(	O
135	O
or	O
175	O
mg	O
/	O
m2	O
)	O
was	O
administered	O
by	O
24-hour	O
infusion	O
on	O
day	O
1	O
","	O
followed	O
by	O
a	O
1-hour	O
infusion	O
of	O
carboplatin	B-DRUG
on	O
day	O
2	O
(	O
300	O
mg	O
/	O
m2	O
or	O
dosed	O
to	O
an	O
area	O
under	O
the	O
concentration-time	O
curve	O
[	O
AUC	O
]	O
of	O
6	O
mg	O
/	O
mL.min	O
)	O
.	O
	
Treatment	O
was	O
repeated	O
every	O
28	O
days	O
for	O
a	O
total	O
of	O
six	O
cycles	O
.	O
	
Hematopoietic	O
growth	O
factors	O
were	O
not	O
routinely	O
used	O
.	O
	
Among	O
51	O
eligible	O
patients	O
","	O
there	O
were	O
no	O
complete	O
and	O
14	O
partial	O
responses	O
","	O
for	O
an	O
overall	O
response	O
rate	O
of	O
27	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
17	O
%	O
to	O
41	O
%	O
)	O
.	O
	
The	O
median	O
progression-free	O
survival	O
time	O
was	O
23.8	O
weeks	O
(	O
range	O
","	O
12.1	O
to	O
73.9	O
)	O
and	O
median	O
survival	O
time	O
","	O
38	O
weeks	O
.	O
	
The	O
survival	O
rate	O
at	O
1	O
year	O
was	O
32	O
%	O
.	O
	
Grade	O
3	O
or	O
4	O
granulocytopenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
were	O
observed	O
in	O
47	O
%	O
and	O
3	O
%	O
","	O
respectively	O
","	O
of	O
the	O
184	O
treatment	O
cycles	O
administered	O
.	O
	
The	O
most	O
common	O
nonhematologic	B-TOXI
toxicities	I-TOXI
included	O
nausea	B-TOXI
and	O
emesis	B-TOXI
","	O
neuropathy	B-TOXI
","	O
and	O
arthralgia	B-TOXI
/	O
myalgia	B-TOXI
.	O
	
Paclitaxel	B-DRUG
plus	O
carboplatin	B-DRUG
is	O
a	O
moderately	O
active	O
regimen	O
in	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
and	O
warrants	O
comparison	O
with	O
existing	O
cisplatin-based	B-DRUG
regimens	O
in	O
a	O
prospective	O
randomized	O
trial	O
.	O
	
The	O
toxicities	O
of	O
this	O
regimen	O
are	O
well	O
tolerated	O
in	O
patients	O
with	O
a	O
good	O
PS	O
.	O
	
Randomized	O
","	O
double-blind	O
","	O
placebo-controlled	B-DRUG
trial	O
comparing	O
the	O
response	O
rates	O
of	O
carmustine	B-DRUG
","	O
dacarbazine	B-DRUG
","	O
and	O
cisplatin	B-DRUG
with	O
and	O
without	O
tamoxifen	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
melanoma.	I-CANCER
National	O
Cancer	O
Institute	O
of	O
Canada	O
Clinical	O
Trials	O
Group	O
.	O
	
	
We	O
designed	O
and	O
conducted	O
a	O
randomized	O
","	O
double-blind	O
","	O
placebo-controlled	B-DRUG
trial	O
to	O
compare	O
the	O
response	O
rates	O
and	O
survival	O
of	O
patients	O
with	O
metastatic	B-CANCER
melanoma	I-CANCER
who	O
received	O
carmustine	B-DRUG
(	O
BCNU	B-DRUG
)	O
","	O
dacarbazine	B-DRUG
(	O
DTIC	B-DRUG
)	O
","	O
and	O
cisplatin	B-DRUG
with	O
tamoxifen	B-DRUG
","	O
or	O
the	O
same	O
chemotherapy	O
with	O
placebo	B-DRUG
.	O
	
Eligible	O
patients	O
with	O
metastatic	B-CANCER
melanoma	I-CANCER
received	O
either	O
BCNU	B-DRUG
150	O
mg	O
/	O
m2	O
intravenously	O
(	O
i.v.	O
)	O
on	O
day	O
1	O
","	O
DTIC	B-DRUG
220	O
mg	O
/	O
m2	O
i.v.	O
daily	O
on	O
days	O
1	O
to	O
3	O
and	O
on	O
days	O
22	O
to	O
24	O
","	O
and	O
cisplatin	B-DRUG
25	O
mg	O
/	O
m2	O
i.v.	O
daily	O
on	O
days	O
1	O
to	O
3	O
and	O
on	O
days	O
22	O
to	O
24	O
with	O
placebo	B-DRUG
every	O
6	O
weeks	O
","	O
or	O
the	O
same	O
chemotherapy	O
with	O
tamoxifen	B-DRUG
160	O
mg	O
orally	O
daily	O
for	O
7	O
days	O
before	O
chemotherapy	O
and	O
40	O
mg	O
orally	O
daily	O
throughout	O
the	O
remainder	O
of	O
the	O
treatment	O
cycle	O
.	O
	
Patients	O
were	O
treated	O
on	O
protocol	O
for	O
up	O
to	O
three	O
cycles	O
depending	O
on	O
the	O
type	O
of	O
response	O
.	O
	
Assuming	O
that	O
a	O
minimum	O
increase	O
in	O
response	O
rate	O
of	O
20	O
%	O
would	O
be	O
necessary	O
to	O
conclude	O
that	O
tamoxifen	B-DRUG
conferred	O
a	O
clinically	O
important	O
benefit	O
","	O
we	O
designed	O
the	O
study	O
with	O
an	O
80	O
%	O
chance	O
of	O
detecting	O
that	O
difference	O
at	O
the	O
5	O
%	O
level	O
(	O
two-sided	O
)	O
.	O
	
Between	O
February	O
1992	O
and	O
January	O
1995	O
","	O
211	O
patients	O
were	O
accrued	O
","	O
199	O
of	O
whom	O
were	O
considered	O
assessable	O
for	O
response	O
and	O
toxicity	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
21	O
%	O
in	O
the	O
placebo	B-DRUG
group	O
and	O
30	O
%	O
in	O
the	O
tamoxifen	B-DRUG
group	O
(	O
P	O
=	O
0.187	O
)	O
.	O
	
Complete	O
and	O
partial	O
responses	O
were	O
3	O
%	O
and	O
27	O
%	O
","	O
respectively	O
","	O
for	O
the	O
tamoxifen	B-DRUG
group	O
and	O
6	O
%	O
and	O
14	O
%	O
","	O
respectively	O
","	O
for	O
the	O
placebo	B-DRUG
group	O
.	O
	
Poor	O
performance	O
status	O
and	O
liver	O
involvement	O
were	O
associated	O
with	O
a	O
reduced	O
likelihood	O
to	O
respond	O
to	O
treatment	O
.	O
	
Major	O
toxicities	O
were	O
similar	O
in	O
both	O
groups	O
with	O
no	O
statistically	O
significant	O
difference	O
in	O
the	O
rates	O
of	O
deep	B-TOXI
vein	I-TOXI
thrombosis	I-TOXI
","	O
pulmonary	B-TOXI
thromboembolus	I-TOXI
","	O
grade	O
4	O
neutropenia	B-TOXI
","	O
or	O
grade	O
4	O
thrombocytopenia	B-TOXI
.	O
	
These	O
results	O
demonstrate	O
that	O
the	O
addition	O
of	O
high	O
doses	O
of	O
tamoxifen	B-DRUG
to	O
this	O
chemotherapy	O
regimen	O
does	O
not	O
increase	O
the	O
response	O
rate	O
compared	O
with	O
chemotherapy	O
alone	O
in	O
unselected	O
patients	O
with	O
metastatic	B-CANCER
melanoma	I-CANCER
.	O
	
Modulation	O
of	O
high-dose	O
infusional	O
fluorouracil	B-DRUG
by	O
low-dose	O
methotrexate	B-DRUG
in	O
patients	O
with	O
advanced	O
or	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
:	O
final	O
results	O
of	O
a	O
randomized	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Study	O
.	O
	
	
Methotrexate	B-DRUG
(	O
MTX	B-DRUG
)	O
has	O
been	O
described	O
to	O
modulate	O
the	O
activity	O
of	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
in	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
The	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(	O
EORTC	O
)	O
Gastrointestinal	B-CANCER
Tract	I-CANCER
Cancer	I-CANCER
Cooperative	O
Group	O
(	O
GITCCG	O
)	O
conducted	O
a	O
phase	O
III	O
trial	O
to	O
investigate	O
the	O
efficacy	O
and	O
tolarability	O
of	O
the	O
addition	O
of	O
low-dose	O
MTX	B-DRUG
(	O
40	O
mg	O
/	O
m2	O
)	O
to	O
high-dose	O
infusional	O
5-FU	B-DRUG
(	O
60	O
mg	O
/	O
kg	O
over	O
48	O
hours	O
)	O
given	O
weekly	O
for	O
4	O
weeks	O
and	O
thereafter	O
every	O
2	O
(	O
for	O
4	O
weeks	O
)	O
and	O
3	O
weeks	O
.	O
	
Three	O
hundred	O
ten	O
patients	O
were	O
randomized	O
between	O
1987	O
and	O
1992	O
.	O
	
Eligible	O
patients	O
had	O
measurable	O
advanced	O
or	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
and	O
had	O
not	O
been	O
pretreated	O
with	O
antifolates	B-DRUG
or	O
fluorodinated	B-DRUG
pyrimidines	I-DRUG
.	O
	
All	O
297	O
eligible	O
patients	O
were	O
evaluated	O
for	O
survival	O
;	O
toxicity	O
was	O
assessed	O
in	O
292	O
patients	O
who	O
received	O
at	O
least	O
one	O
course	O
of	O
treatment	O
.	O
	
Patients	O
with	O
bidimensionally	O
measurable	O
disease	O
(	O
n	O
=	O
230	O
)	O
were	O
also	O
evaluated	O
for	O
response	O
according	O
to	O
standard	O
criteria	O
.	O
	
The	O
addition	O
of	O
low-dose	O
MTX	B-DRUG
to	O
high-dose	O
infusional	O
5-FU	B-DRUG
led	O
to	O
a	O
doubling	O
of	O
the	O
response	O
rate	O
from	O
10	O
%	O
to	O
21	O
%	O
(	O
P	O
=	O
0.025	O
)	O
.	O
	
The	O
median	O
survival	O
time	O
also	O
increased	O
from	O
9.3	O
to	O
12.5	O
months	O
","	O
but	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
P	O
=	O
0.12	O
)	O
.	O
	
High-dose	O
infusional	O
5-FU	B-DRUG
with	O
or	O
without	O
low-dose	O
MTX	B-DRUG
was	O
well	O
tolerated	O
","	O
with	O
grade	O
3	O
to	O
4	O
toxicity	O
in	O
greater	O
than	O
10	O
%	O
of	O
patients	O
only	O
occurring	O
for	O
stomatitis	B-TOXI
with	O
the	O
combination	O
treatment	O
.	O
	
Performance	O
status	O
was	O
the	O
sole	O
prognostic	O
factor	O
for	O
survival	O
in	O
a	O
multivariate	O
analysis	O
.	O
	
Low-dose	O
MTX	B-DRUG
effectively	O
modulated	O
high-dose	O
infusional	O
5-FU	B-DRUG
in	O
a	O
large	O
","	O
randomized	O
trial	O
in	O
which	O
less	O
than	O
5	O
%	O
of	O
patients	O
received	O
leucovorin	B-DRUG
.	O
	
Phase	O
II	O
study	O
of	O
topotecan	B-DRUG
in	O
patients	O
with	O
extensive-stage	O
small-cell	B-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
lung	I-CANCER
:	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
Trial	O
.	O
	
	
To	O
determine	O
the	O
response	O
rate	O
and	O
survival	O
of	O
chemotherapy-naive	O
patients	O
with	O
extensive-stage	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
SCLC	B-CANCER
)	O
treated	O
with	O
topotecan	B-DRUG
","	O
and	O
to	O
determine	O
the	O
relationship	O
of	O
topotecan	B-DRUG
pharmacokinetics	O
with	O
response	O
and	O
toxicity	O
.	O
	
Forty-eight	O
patients	O
with	O
previously	O
untreated	O
","	O
extensive-stage	O
SCLC	B-CANCER
received	O
2	O
mg	O
/	O
m2	O
of	O
topotecan	B-DRUG
daily	O
for	O
5	O
days	O
.	O
	
The	O
first	O
13	O
patients	O
were	O
treated	O
without	O
colony-stimulating	B-DRUG
factor	I-DRUG
(	O
CSF	B-DRUG
)	O
support	O
;	O
the	O
next	O
35	O
patients	O
received	O
5	O
micrograms	O
/	O
kg	O
of	O
granulocyte-colony-stimulating	B-DRUG
factor	I-DRUG
(	O
G-CSF	B-DRUG
)	O
for	O
10	O
to	O
14	O
days	O
starting	O
on	O
day	O
6	O
Cycles	O
were	O
repeated	O
every	O
3	O
weeks	O
for	O
a	O
maximum	O
of	O
four	O
cycles	O
.	O
	
Patients	O
who	O
had	O
a	O
partial	O
response	O
to	O
topotecan	B-DRUG
after	O
four	O
cycles	O
","	O
stable	O
disease	O
after	O
two	O
cycles	O
","	O
or	O
progressive	O
disease	O
at	O
any	O
time	O
received	O
salvage	O
chemotherapy	O
with	O
cisplatin	B-DRUG
and	O
etoposide	B-DRUG
.	O
	
Topotecan	B-DRUG
pharmacokinetics	O
were	O
measured	O
using	O
a	O
four-point	O
sampling	O
scheme	O
.	O
	
Of	O
48	O
patients	O
","	O
none	O
had	O
a	O
complete	O
response	O
and	O
19	O
had	O
a	O
partial	O
response	O
","	O
for	O
an	O
objective	O
response	O
rate	O
of	O
39	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
25.2	O
%	O
to	O
53	O
%	O
)	O
.	O
	
The	O
median	O
response	O
duration	O
was	O
4.8	O
months	O
(	O
95	O
%	O
CI	O
","	O
3	O
to	O
7.3	O
)	O
.	O
	
After	O
a	O
median	O
follow-up	O
duration	O
of	O
18.2	O
months	O
","	O
the	O
overall	O
median	O
survival	O
time	O
was	O
10	O
months	O
(	O
95	O
%	O
CI	O
","	O
8.2	O
to	O
12.7	O
)	O
;	O
the	O
1-year	O
survival	O
rate	O
was	O
39	O
%	O
(	O
95	O
%	O
CI	O
","	O
25.2	O
%	O
to	O
53	O
%	O
)	O
.	O
	
Eight	O
of	O
34	O
patients	O
(	O
24	O
%	O
)	O
who	O
received	O
salvage	O
chemotherapy	O
responded	O
.	O
	
Four	O
of	O
17	O
patients	O
who	O
did	O
not	O
respond	O
to	O
first-line	O
therapy	O
with	O
topotecan	B-DRUG
responded	O
to	O
cisplatin	B-DRUG
and	O
etoposide	B-DRUG
.	O
	
The	O
most	O
common	O
toxicity	O
was	O
hematologic	O
.	O
	
Ninety-two	O
percent	O
of	O
patients	O
treated	O
without	O
G-CSF	B-DRUG
developed	O
grade	O
3	O
or	O
4	O
neutropenia	B-TOXI
","	O
compared	O
with	O
29	O
%	O
who	O
received	O
G-CSF	B-DRUG
.	O
	
However	O
","	O
the	O
incidence	O
of	O
neutropenic	B-TOXI
fevers	I-TOXI
was	O
similar	O
between	O
the	O
two	O
groups	O
(	O
8	O
%	O
and	O
11	O
%	O
","	O
respectively	O
)	O
","	O
and	O
one	O
patient	O
in	O
each	O
group	O
died	B-TOXI
of	I-TOXI
neutropenic	I-TOXI
fevers	I-TOXI
.	O
	
There	O
were	O
no	O
differences	O
in	O
objective	O
tumor	O
response	O
","	O
duration	O
of	O
response	O
","	O
time	O
to	O
treatment	O
failure	O
","	O
or	O
survival	O
between	O
the	O
13	O
patients	O
who	O
entered	O
the	O
study	O
before	O
G-CSF	B-DRUG
administration	O
was	O
mandated	O
and	O
the	O
35	O
patients	O
who	O
entered	O
after	O
and	O
received	O
G-CSF	B-DRUG
.	O
	
There	O
was	O
poor	O
correlation	O
between	O
the	O
WBC	O
count	O
and	O
absolute	O
neutrophil	O
counts	O
(	O
ANCs	O
)	O
and	O
both	O
the	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
and	O
maximum	O
concentration++	O
(	O
Cmx	O
)	O
of	O
total	O
topotecan	B-DRUG
in	O
plasma	O
.	O
	
There	O
was	O
no	O
correlation	O
between	O
the	O
tumor	O
response	O
and	O
either	O
AUC	O
or	O
Cmx	O
of	O
total	O
topotecan	B-DRUG
.	O
	
The	O
activity	O
of	O
topotecan	B-DRUG
in	O
extensive-stage	O
SCLC	B-CANCER
noted	O
in	O
this	O
study	O
warrants	O
further	O
investigation	O
of	O
this	O
agent	O
in	O
phase	O
III	O
clinical	O
trials	O
.	O
	
Randomized	O
trial	O
of	O
vinorelbine	B-DRUG
compared	O
with	O
fluorouracil	B-DRUG
plus	O
leucovorin	B-DRUG
in	O
patients	O
with	O
stage	O
IV	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
This	O
prospective	O
randomized	O
trial	O
was	O
performed	O
to	O
compare	O
the	O
effectiveness	O
of	O
intravenous	O
vinorelbine	B-DRUG
tartrate	I-DRUG
with	O
intravenous	O
fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
(	O
5-FU	B-DRUG
/	O
LV	B-DRUG
)	O
on	O
the	O
primary	O
end	O
points	O
of	O
survival	O
","	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
","	O
and	O
relief	O
of	O
cancer-related	O
symptoms	O
in	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Secondary	O
end	O
points	O
included	O
tumor	O
response	O
rates	O
and	O
time	O
to	O
treatment	O
failure	O
.	O
	
In	O
addition	O
","	O
the	O
safety	O
of	O
both	O
treatment	O
regimens	O
was	O
evaluated	O
in	O
this	O
multicenter	O
study	O
.	O
	
Two	O
hundred	O
sixteen	O
patients	O
with	O
stage	O
IV	O
NSCLC	B-CANCER
were	O
enrolled	O
onto	O
this	O
study	O
from	O
18	O
centers	O
.	O
	
Vinorelbine	B-DRUG
was	O
administered	O
at	O
a	O
dose	O
of	O
30	O
mg	O
/	O
m2	O
/	O
wk	O
.	O
	
5-FU	B-DRUG
/	O
LV	B-DRUG
was	O
administered	O
at	O
a	O
dose	O
of	O
425	O
mg	O
/	O
m2	O
and	O
20	O
mg	O
/	O
m2	O
","	O
respectively	O
","	O
for	O
5	O
consecutive	O
days	O
every	O
4	O
weeks	O
.	O
	
Patients	O
with	O
progressive	O
disease	O
or	O
toxicity	O
were	O
removed	O
from	O
study	O
while	O
responding	O
and	O
stable	O
patients	O
were	O
continued	O
on	O
therapy	O
.	O
	
The	O
median	O
survival	O
time	O
of	O
patients	O
who	O
received	O
vinorelbine	B-DRUG
was	O
30	O
weeks	O
","	O
with	O
25	O
%	O
of	O
patients	O
alive	O
at	O
1	O
year	O
","	O
compared	O
with	O
a	O
median	O
survival	O
time	O
of	O
22	O
weeks	O
and	O
16	O
%	O
of	O
patients	O
alive	O
at	O
1	O
year	O
for	O
those	O
treated	O
with	O
5-FU	B-DRUG
/	O
LV	B-DRUG
(	O
P	O
=	O
0.03	O
","	O
log-rank	O
test	O
)	O
.	O
	
This	O
improvement	O
in	O
survival	O
was	O
associated	O
with	O
a	O
higher	O
objective	O
response	O
rate	O
(	O
12	O
%	O
v	O
3	O
%	O
)	O
and	O
time	O
to	O
treatment	O
failure	O
(	O
10	O
weeks	O
v	O
8	O
weeks	O
)	O
for	O
vinorelbine	B-DRUG
versus	O
5-FU	B-DRUG
/	O
LV	B-DRUG
.	O
	
The	O
dose-limiting	O
toxicity	O
of	O
vinorelbine	B-DRUG
was	O
granulocytopenia	B-TOXI
","	O
with	O
54	O
%	O
of	O
patients	O
experiencing	O
grade	O
3	O
/	O
4	O
granulocytopenia	B-TOXI
.	O
	
Nonhematologic	B-TOXI
toxicity	I-TOXI
of	O
vinorelbine	B-DRUG
was	O
generally	O
grade	O
1	O
or	O
2	O
The	O
most	O
common	O
grade	O
3	O
toxicities	O
were	O
related	O
to	O
injection-site	O
reactions	O
.	O
	
This	O
trial	O
confirms	O
the	O
efficacy	O
of	O
vinorelbine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
The	O
clinical	O
activity	O
and	O
relatively	O
favorable	O
toxicity	O
profile	O
of	O
this	O
agent	O
make	O
it	O
a	O
reasonable	O
and	O
useful	O
treatment	O
option	O
in	O
the	O
management	O
of	O
patients	O
with	O
this	O
disease	O
.	O
	
Biweekly	O
intensified	O
ambulatory	O
chronomodulated	O
chemotherapy	O
with	O
oxaliplatin	B-DRUG
","	O
fluorouracil	B-DRUG
","	O
and	O
leucovorin	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
This	O
study	O
sought	O
to	O
determine	O
the	O
feasibility	O
and	O
antitumor	O
efficacy	O
of	O
an	O
intensified	O
three-drug	O
chronomodulated	O
regimen	O
with	O
maximum	O
delivery	O
at	O
04:00	O
AM	O
for	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
#NAME?	B-DRUG
(	O
folinic	B-DRUG
acid	I-DRUG
[	O
FA	B-DRUG
]	O
)	O
and	O
at	O
04:00	O
PM	O
for	O
oxaliplatin	B-DRUG
(	O
I-OHP	B-DRUG
)	O
.	O
	
Fifty	O
patients	O
with	O
metastatic	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
were	O
enrolled	O
in	O
the	O
trial	O
.	O
	
The	O
first	O
treatment	O
course	O
consisted	O
of	O
daily	O
administration	O
of	O
5-FU	B-DRUG
(	O
700	O
mg	O
/	O
m2	O
/	O
d	O
)	O
","	O
FA	B-DRUG
(	O
300	O
mg	O
/	O
m2	O
/	O
d	O
)	O
","	O
and	O
L-OHP	B-DRUG
(	O
25	O
mg	O
/	O
m2	O
/	O
d	O
)	O
for	O
4	O
days	O
with	O
a	O
multichannel	O
programmable	O
pump	O
.	O
	
Courses	O
were	O
repeated	O
every	O
14	O
days	O
","	O
with	O
5-FU	B-DRUG
escalation	O
by	O
100	O
mg	O
/	O
m2	O
/	O
d	O
if	O
toxicity	O
was	O
less	O
than	O
grade	O
2	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
#NAME?	O
grade	O
3	O
or	O
4	O
diarrhea	B-TOXI
(	O
40	O
%	O
of	O
patients	O
and	O
7	O
%	O
of	O
courses	O
)	O
or	O
stomatitis	B-TOXI
(	O
28	O
%	O
of	O
patients	O
and	O
4	O
%	O
of	O
courses	O
)	O
or	O
grade	O
2	O
cumulative	B-TOXI
peripheral	I-TOXI
sensitive	I-TOXI
neuropathy	I-TOXI
(	O
28	O
%	O
of	O
patients	O
)	O
were	O
dose-limiting	O
.	O
	
Median	O
5-FU	B-DRUG
and	O
L-OHP	B-DRUG
dose-intensities	O
(	O
DIs	O
)	O
","	O
were	O
increased	O
by	O
32	O
%	O
and	O
18	O
%	O
","	O
respectively	O
","	O
as	O
compared	O
with	O
our	O
previous	O
5	O
days	O
on-16	O
days	O
off	O
schedule	O
.	O
	
The	O
overall	O
objective	O
response	O
rate	O
was	O
48	O
%	O
(	O
95	O
%	O
confidence	O
limits	O
[	O
CL	O
]	O
","	O
34	O
%	O
to	O
62	O
%	O
)	O
","	O
being	O
40	O
%	O
(	O
24	O
%	O
to	O
57	O
%	O
)	O
in	O
37	O
previously	O
treated	O
patients	O
and	O
69	O
%	O
(	O
48	O
%	O
to	O
90	O
%	O
)	O
in	O
13	O
chemotherapy-naive	O
patients	O
.	O
	
A	O
5-FU	B-DRUG
DI	O
&	O
gt	O
;	O
"1,400"	O
mg	O
/	O
m2	O
/	O
wk	O
over	O
four	O
courses	O
was	O
associated	O
with	O
a	O
near	O
doubling	O
of	O
the	O
response	O
rate	O
.	O
	
Residual	O
metastases	O
were	O
surgically	O
removed	O
in	O
13	O
patients	O
(	O
26	O
%	O
)	O
.	O
	
Median	O
progression-free	O
survival	O
and	O
survival	O
durations	O
were	O
9.3	O
months	O
(	O
95	O
%	O
CL	O
","	O
6.6	O
to	O
11.2	O
)	O
and	O
17.8	O
months	O
(	O
95	O
%	O
CL	O
","	O
14.1	O
to	O
21.4	O
)	O
","	O
respectively	O
.	O
	
This	O
highly	O
effective	O
fully	O
ambulatory	O
outpatient	O
regimen	O
deserves	O
further	O
testing	O
in	O
randomized	O
trials	O
both	O
in	O
chemotherapy-naive	O
patients	O
and	O
before	O
surgery	O
to	O
remove	O
metastases	O
.	O
	
Cisplatin-gemcitabine	B-DRUG
combination	O
in	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
a	O
phase	O
II	O
study	O
.	O
	
	
The	O
nucleoside	B-DRUG
analog	I-DRUG
","	O
gemcitabine	B-DRUG
","	O
has	O
shown	O
activity	O
as	O
a	O
single	O
agent	O
in	O
the	O
treatment	O
of	O
metastatic	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Its	O
combination	O
with	O
cisplatin	B-DRUG
in	O
preclinical	O
models	O
suggested	O
synergy	O
between	O
the	O
two	O
drugs	O
.	O
	
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
clinical	O
efficacy	O
and	O
toxicity	O
of	O
the	O
cisplatin-gemcitabine	B-DRUG
combination	O
in	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
Forty-eight	O
consecutive	O
previously	O
untreated	O
NSCLC	B-CANCER
patients	O
entered	O
the	O
trial	O
from	O
January	O
to	O
June	O
1994	O
.	O
	
The	O
median	O
age	O
was	O
60	O
years	O
(	O
range	O
","	O
37	O
to	O
70	O
)	O
and	O
performance	O
status	O
(	O
PS	O
)	O
was	O
0	O
or	O
1	O
;	O
22	O
patients	O
had	O
unresectable	O
stage	O
III	O
disease	O
(	O
21	O
stage	O
IIIB	O
and	O
one	O
stage	O
IIIA	O
)	O
and	O
26	O
had	O
stage	O
IV	O
disease	O
.	O
	
Gemcitabine	B-DRUG
1	O
g	O
/	O
m2	O
was	O
administered	O
weekly	O
(	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
)	O
followed	O
by	O
a	O
1-week	O
rest	O
and	O
cisplatin	B-DRUG
100	O
mg	O
/	O
m2	O
on	O
day	O
2	O
of	O
each	O
28-day	O
cycle	O
.	O
	
Survival	O
and	O
response	O
were	O
determined	O
in	O
accordance	O
with	O
the	O
intention-to-treat	O
principle	O
in	O
all	O
enrolled	O
patients	O
.	O
	
Of	O
48	O
assessable	O
patients	O
","	O
one	O
(	O
stage	O
IV	O
)	O
had	O
a	O
complete	O
response	O
(	O
CR	O
)	O
and	O
25	O
achieved	O
a	O
partial	O
response	O
(	O
PR	O
)	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
54	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
40	O
%	O
to	O
68	O
%	O
)	O
.	O
	
Thrombocytopenia	B-TOXI
was	O
the	O
main	O
side	O
effect	O
","	O
with	O
52	O
%	O
of	O
patients	O
experiencing	O
grade	O
III	O
to	O
IV	O
toxicity	O
","	O
which	O
was	O
usually	O
short-lived	O
and	O
responsible	O
for	O
the	O
omission	O
of	O
gemcitabine	B-TOXI
administration	O
on	O
day	O
15	O
in	O
50	O
%	O
of	O
chemotherapy	O
courses	O
.	O
	
The	O
median	O
survival	O
time	O
was	O
61.5	O
weeks	O
(	O
95	O
%	O
CI	O
","	O
40	O
to	O
71	O
)	O
.	O
	
The	O
combination	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
induced	O
a	O
high	O
response	O
rate	O
in	O
both	O
stage	O
IIIB	O
and	O
IV	O
NSCLC	B-CANCER
","	O
with	O
modest	O
side	O
effects	O
.	O
	
The	O
regimen	O
deserves	O
further	O
careful	O
evaluation	O
in	O
a	O
phase	O
III	O
prospective	O
randomized	O
trial	O
.	O
	
Weekly	O
gemcitabine	B-DRUG
with	O
monthly	O
cisplatin	B-DRUG
:	O
effective	O
chemotherapy	O
for	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
efficacy	O
of	O
a	O
regimen	O
of	O
initial	O
gemcitabine	B-DRUG
followed	O
by	O
cisplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
Fifty-three	O
patients	O
(	O
36	O
men	O
and	O
17	O
women	O
;	O
age	O
range	O
","	O
35	O
to	O
74	O
years	O
)	O
were	O
enrolled	O
.	O
	
Patients	O
had	O
bidimensionally	O
measurable	O
disease	O
.	O
	
Gemcitabine	B-DRUG
(	O
phase-specific	O
agent	O
)	O
was	O
administered	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
at	O
a	O
dose	O
of	O
"1,000"	O
mg	O
/	O
m2	O
.	O
	
Cisplatin	B-DRUG
(	O
cycle-specific	O
agent	O
)	O
was	O
administered	O
on	O
day	O
15	O
(	O
100	O
mg	O
/	O
m2	O
)	O
.	O
	
Chemotherapy	O
was	O
administered	O
in	O
28-day	O
cycles	O
.	O
	
Of	O
53	O
patients	O
enrolled	O
","	O
50	O
were	O
assessable	O
for	O
response	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
52	O
%	O
.	O
	
There	O
were	O
two	O
complete	O
responses	O
(	O
4	O
%	O
)	O
and	O
24	O
partial	O
responses	O
(	O
48	O
%	O
)	O
.	O
	
The	O
median	O
survival	O
duration	O
was	O
13	O
months	O
and	O
the	O
1-year	O
survival	O
rate	O
was	O
61	O
%	O
.	O
	
The	O
regimen	O
was	O
generally	O
well	O
tolerated	O
.	O
	
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
grade	O
3	O
and	O
4	O
neutropenia	B-TOXI
occurred	O
in	O
38.8	O
%	O
and	O
19.2	O
%	O
of	O
patients	O
","	O
respectively	O
.	O
	
Grade	O
3	O
and	O
4	O
thrombocytopenia	B-TOXI
occurred	O
in	O
13.3	O
%	O
and	O
7.7	O
%	O
of	O
patients	O
","	O
respectively	O
.	O
	
Most	O
patients	O
experienced	O
mild	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
.	O
	
Few	O
patients	O
had	O
hair	B-TOXI
loss	I-TOXI
and	O
oral	B-TOXI
toxicity	I-TOXI
was	O
mild	O
.	O
	
Relatively	O
few	O
patients	O
required	O
dose	O
modifications	O
for	O
any	O
of	O
the	O
three	O
weekly	O
doses	O
of	O
chemotherapy	O
.	O
	
For	O
the	O
first	O
two	O
cycles	O
of	O
chemotherapy	O
","	O
the	O
dose-intensity	O
per	O
infusion	O
was	O
947	O
mg	O
/	O
m2	O
for	O
gemcitabine	B-DRUG
and	O
85	O
mg	O
/	O
m2	O
for	O
cisplatin	B-DRUG
.	O
	
This	O
regimen	O
of	O
gemcitabine	B-DRUG
and	O
cisplatin	B-DRUG
was	O
effective	O
","	O
with	O
high	O
response	O
and	O
survival	O
rates	O
and	O
few	O
dosage	O
modifications	O
during	O
its	O
administration	O
.	O
	
Prospective	O
randomized	O
studies	O
with	O
other	O
cisplatin-based	B-DRUG
combination	O
chemotherapy	O
regimens	O
are	O
indicated	O
.	O
	
Phase	O
I	O
and	O
pharmacologic	O
study	O
of	O
the	O
combination	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
as	O
first-line	O
chemotherapy	O
in	O
stage	O
III	O
and	O
IV	O
ovarian	B-CANCER
cancer	I-CANCER
.	O
	
	
To	O
determine	O
the	O
maximum-tolerated	O
dose	O
for	O
the	O
combination	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
administered	O
every	O
4	O
weeks	O
and	O
to	O
gain	O
more	O
insight	O
into	O
the	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
this	O
combination	O
in	O
previously	O
untreated	O
ovarian	B-CANCER
cancer	I-CANCER
patients	O
.	O
	
Thirty-five	O
chemotherapy-naive	O
patients	O
with	O
suboptimally	O
debulked	O
stage	O
III	O
(	O
tumor	O
masses	O
&	O
gt	O
;	O
3	O
cm	O
)	O
and	O
stage	O
IV	O
ovarian	B-CANCER
cancer	I-CANCER
were	O
entered	O
onto	O
this	O
phase	O
I	O
trial	O
in	O
which	O
paclitaxel	B-DRUG
was	O
administered	O
as	O
a	O
3-hour	O
intravenous	O
(	O
IV	O
)	O
infusion	O
at	O
dosages	O
of	O
125	O
to	O
225	O
mg	O
/	O
m2	O
immediately	O
followed	O
by	O
carboplatin	B-DRUG
over	O
30	O
minutes	O
at	O
dosages	O
of	O
300	O
to	O
600	O
mg	O
/	O
m2	O
.	O
	
A	O
total	O
of	O
six	O
courses	O
was	O
planned	O
","	O
followed	O
by	O
a	O
second-look	O
laparoscopy	O
/	O
laparotomy	O
.	O
	
Patients	O
with	O
a	O
response	O
and	O
/	O
or	O
minimal	O
residual	O
disease	O
at	O
second-look	O
laparoscopy	O
received	O
three	O
additional	O
courses	O
.	O
	
Twenty-six	O
patients	O
participated	O
in	O
the	O
pharmacokinetic	O
part	O
of	O
the	O
study	O
.	O
	
The	O
most	O
important	O
hematologic	B-TOXI
toxicity	I-TOXI
encountered	O
was	O
neutropenia	B-TOXI
.	O
	
Neutropenia	B-TOXI
was	O
more	O
pronounced	O
for	O
the	O
higher	O
dose	O
levels	O
(	O
DLs	O
)	O
and	O
was	O
cumulative	O
.	O
	
Thrombocytopenia	B-TOXI
was	O
mild	O
in	O
the	O
first	O
eight	O
DLs	O
","	O
but	O
increased	O
during	O
the	O
treatment	O
courses	O
.	O
	
Nonhematologic	B-TOXI
toxicities	I-TOXI
consisted	O
mainly	O
of	O
vomiting	B-TOXI
","	O
neuropathy	B-TOXI
","	O
fatigue	B-TOXI
","	O
rash	B-TOXI
","	O
pruritus	B-TOXI
","	O
myalgia	B-TOXI
","	O
and	O
arthralgia	B-TOXI
.	O
	
Dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
in	O
this	O
trial	O
were	O
neutropenic	B-TOXI
fever	I-TOXI
","	O
thrombocytopenia	B-TOXI
that	O
required	O
platelet	O
transfusions	O
","	O
and	O
cumulative	B-TOXI
neuropathy	I-TOXI
.	O
	
Of	O
33	O
patients	O
assessable	O
for	O
response	O
","	O
26	O
major	O
responders	O
(	O
78	O
%	O
","	O
20	O
complete	O
response	O
[	O
CR	O
]	O
and	O
six	O
partial	O
response	O
[	O
PR	O
]	O
)	O
were	O
documented	O
.	O
	
The	O
maximal	O
concentration	O
(	O
Cmax	O
)	O
of	O
paclitaxel	B-DRUG
and	O
the	O
area	O
under	O
the	O
concentration-time	O
curve	O
(	O
AUC	O
)	O
were	O
not	O
different	O
from	O
the	O
historical	O
data	O
for	O
paclitaxel	B-DRUG
as	O
a	O
single	O
agent	O
.	O
	
Retrospective	O
analysis	O
using	O
a	O
modified	O
Calvert	O
formula	O
showed	O
that	O
the	O
measured	O
carboplatin	B-DRUG
AUCs	O
in	O
plasma	O
ultrafiltrate	O
(	O
pUF	O
)	O
were	O
30	O
%	O
=+	O
/	O
=-	O
3.4	O
%	O
less	O
than	O
the	O
calculated	O
carboplatin	B-DRUG
AUC	O
.	O
	
Neutropenia	B-TOXI
was	O
more	O
pronounced	O
than	O
could	O
be	O
expected	O
on	O
the	O
basis	O
of	O
the	O
historical	O
times	O
above	O
a	O
threshold	O
concentration	O
greater	O
than	O
0.1	O
mumol	O
/	O
L	O
(	O
T	O
&	O
gt	O
;	O
or	O
=	O
0.1	O
mumol	O
/	O
L	O
)	O
or	O
0.05	O
mumol	O
/	O
L	O
(	O
T	O
&	O
gt	O
;	O
or	O
=	O
0.05	O
mumol	O
/	O
L	O
)	O
","	O
and	O
thrombocytopenia	B-TOXI
was	O
less	O
than	O
could	O
be	O
expected	O
from	O
historical	O
sigmoidal	O
Emax	O
models	O
.	O
	
The	O
combination	O
of	O
paclitaxel	B-DRUG
200	O
mg	O
/	O
m2	O
and	O
carboplatin	B-DRUG
550	O
mg	O
/	O
m2	O
every	O
4	O
weeks	O
is	O
a	O
well-tolerated	O
treatment	O
modality	O
.	O
	
The	O
paclitaxel-carboplatin	B-DRUG
combination	O
is	O
highly	O
active	O
in	O
stage	O
III	O
(	O
bulky	O
)	O
and	O
stage	O
IV	O
ovarian	B-CANCER
cancer	I-CANCER
.	O
	
No	O
indications	O
for	O
a	O
pharmacokinetic	O
drug-drug	O
interaction	O
between	O
carboplatin	B-DRUG
and	O
paclitaxel	B-DRUG
were	O
found	O
.	O
	
Gemcitabine	B-DRUG
versus	O
the	O
combination	O
of	O
cisplatin	B-DRUG
and	O
etoposide	B-DRUG
in	O
patients	O
with	O
inoperable	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
in	O
a	O
phase	O
II	O
randomized	O
study	O
.	O
	
	
A	O
phase	O
II	O
randomized	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
efficacy	O
and	O
toxicity	O
of	O
gemcitabine	B-DRUG
(	O
GEM	B-DRUG
)	O
versus	O
the	O
combination	O
of	O
cisplatin	B-DRUG
and	O
etoposide	B-DRUG
(	O
EP	B-DRUG
)	O
in	O
Chinese	O
patients	O
with	O
inoperable	O
(	O
stage	O
III	O
or	O
IV	O
)	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
From	O
March	O
1995	O
to	O
February	O
1996	O
","	O
53	O
patients	O
were	O
enrolled	O
onto	O
the	O
study	O
:	O
27	O
onto	O
the	O
GEM	B-DRUG
arm	O
and	O
26	O
onto	O
the	O
EP	B-DRUG
arm	O
.	O
	
In	O
the	O
GEM	B-DRUG
arm	O
","	O
gemcitabine	B-DRUG
"1,250"	O
mg	O
/	O
m2	O
was	O
given	O
as	O
a	O
30-minute	O
intravenous	O
(	O
i.v.	O
)	O
infusion	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
of	O
each	O
28-day	O
cycle	O
.	O
	
In	O
the	O
EP	B-DRUG
arm	O
","	O
cisplatin	B-DRUG
80	O
mg	O
/	O
m2	O
was	O
given	O
on	O
day	O
1	O
and	O
etoposide	B-DRUG
80	O
mg	O
/	O
m2	O
was	O
given	O
on	O
days	O
1	O
","	O
2	O
","	O
and	O
3	O
of	O
each	O
28-day	O
cycle	O
.	O
	
Twenty-six	O
patients	O
are	O
assessable	O
for	O
treatment	O
response	O
on	O
the	O
GEM	B-DRUG
arm	O
and	O
24	O
on	O
the	O
EP	B-DRUG
arm	O
.	O
	
Five	O
patients	O
(	O
19.2	O
%	O
)	O
on	O
the	O
GEM	B-DRUG
arm	O
and	O
five	O
patients	O
(	O
20.8	O
%	O
)	O
on	O
the	O
EP	B-DRUG
arm	O
achieved	O
a	O
partial	O
response	O
(	O
PR	O
)	O
.	O
	
No	O
complete	O
responses	O
were	O
attained	O
on	O
either	O
treatment	O
arm	O
.	O
	
All	O
patients	O
enrolled	O
onto	O
the	O
study	O
were	O
eligible	O
for	O
toxicity	O
assessment	O
.	O
	
The	O
main	O
toxicities	O
were	O
myelosuppression	B-TOXI
and	O
vomiting	B-TOXI
","	O
which	O
included	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
grade	O
3	O
or	O
4	O
leukopenia	B-TOXI
(	O
3.7	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
7.4	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
7.4	O
%	O
)	O
","	O
and	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
(	O
3.7	O
%	O
)	O
on	O
the	O
GEM	B-DRUG
arm	O
","	O
and	O
WHO	O
grade	O
3	O
or	O
4	O
leukopenia	B-TOXI
(	O
30.8	O
%	O
)	O
","	O
thrombocytopenia	B-TOXI
(	O
7.7	O
%	O
)	O
","	O
anemia	B-TOXI
(	O
15.4	O
%	O
)	O
","	O
and	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
(	O
34.6	O
%	O
)	O
on	O
the	O
EP	B-DRUG
arm	O
.	O
	
The	O
median	O
survival	O
time	O
was	O
37	O
weeks	O
on	O
the	O
GEM	B-DRUG
arm	O
and	O
48	O
weeks	O
on	O
the	O
EP	B-DRUG
arm	O
.	O
	
Gemcitabine	B-DRUG
is	O
a	O
well-tolerated	O
chemotherapeutic	O
agent	O
for	O
NSCLC	B-CANCER
.	O
	
The	O
antitumor	O
activity	O
was	O
promising	O
","	O
with	O
a	O
19.2	O
%	O
single-drug	O
response	O
rate	O
","	O
when	O
compared	O
with	O
EP	B-DRUG
combination	O
chemotherapy	O
","	O
which	O
had	O
a	O
response	O
rate	O
of	O
20.8	O
%	O
.	O
	
The	O
safety	O
profile	O
is	O
better	O
than	O
that	O
of	O
EP	B-DRUG
treatment	O
.	O
	
Phase	O
II	O
trial	O
of	O
hepatic	O
arterial	O
infusion	O
of	O
fluorouracil	B-DRUG
and	O
recombinant	O
human	O
interferon	O
alfa-2b	B-DRUG
for	O
liver	O
metastases	O
of	O
colorectal	B-CANCER
cancer	I-CANCER
refractory	O
to	O
systemic	O
fluorouracil	B-DRUG
and	O
leucovorin	B-DRUG
.	O
	
	
To	O
determine	O
the	O
toxicity	O
","	O
response	O
rate	O
","	O
and	O
survival	O
in	O
patients	O
treated	O
with	O
hepatic	O
arterial	O
infusion	O
(	O
HAI	O
)	O
of	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
plus	O
recombinant	O
human	O
interferon	O
alfa-2b	B-DRUG
(	O
rIFN-alpha	B-DRUG
2b	I-DRUG
)	O
(	O
Intron-A	B-DRUG
;	O
Schering-Plough	O
","	O
Inc	O
","	O
Kenilworth	O
","	O
NJ	O
)	O
for	O
colorectal	B-CANCER
carcinoma	I-CANCER
(	O
CRC	B-CANCER
)	O
liver	O
metastases	O
refractory	O
to	O
systemic	O
5-FU	B-DRUG
plus	O
leucovorin	B-DRUG
(	O
LCV	B-DRUG
)	O
.	O
	
Forty-eight	O
patients	O
were	O
given	O
a	O
6-hour	O
HAI	O
of	O
rIFN-alpha	B-DRUG
2b	I-DRUG
5	O
MU	O
/	O
m2	O
followed	O
by	O
an	O
18-hour	O
HAI	O
of	O
5-FU	B-DRUG
","	O
"1,500"	O
mg	O
/	O
m2	O
daily	O
for	O
5	O
days	O
.	O
	
Twenty-nine	O
patients	O
were	O
treated	O
through	O
percutaneously	O
placed	O
catheters	O
and	O
19	O
through	O
implantable	O
infusion	O
pumps	O
(	O
Shiley	O
Infusaid	O
Inc	O
","	O
Noorwood	O
","	O
MA	O
)	O
.	O
	
Treatment	O
cycles	O
were	O
repeated	O
every	O
28	O
to	O
35	O
days	O
.	O
	
There	O
were	O
three	O
(	O
6.6	O
%	O
)	O
complete	O
remissions	O
(	O
CRs	O
)	O
and	O
12	O
(	O
26.6	O
%	O
)	O
partial	O
remissions	O
(	O
PRs	O
)	O
","	O
for	O
a	O
CR	O
plus	O
PR	O
rate	O
of	O
33.3	O
%	O
among	O
45	O
assessable	O
patients	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
20	O
%	O
to	O
49	O
%	O
)	O
.	O
	
The	O
median	O
response	O
duration	O
was	O
7	O
months	O
","	O
while	O
median	O
survival	O
duration	O
was	O
15	O
months	O
.	O
	
Grade	O
3	O
to	O
4	O
treatment-related	O
toxic	O
effects	O
included	O
mucositis	B-TOXI
(	O
40	O
%	O
)	O
","	O
neutropenia	B-TOXI
(	O
42	O
%	O
)	O
","	O
and	O
thrombocytopenia	B-TOXI
(	O
12	O
%	O
)	O
.	O
	
No	B-TOXI
hepatobiliary	I-TOXI
toxicity	I-TOXI
was	O
encountered	O
in	O
any	O
of	O
the	O
patients	O
.	O
	
Treatment	O
was	O
discontinued	O
because	O
of	O
progressive	O
liver	B-TOXI
disease	I-TOXI
in	O
23	O
patients	O
and	O
extrahepatic	B-TOXI
progression	I-TOXI
in	O
16	O
","	O
while	O
six	O
patients	O
continue	O
treatment	O
through	O
an	O
infusaid	O
pump	O
.	O
	
HAI	O
of	O
5-FU	B-DRUG
plus	O
rIFN-alpha	B-DRUG
2b	I-DRUG
is	O
well	O
tolerated	O
","	O
devoid	O
of	O
hepatobiliary	B-TOXI
toxicity	I-TOXI
","	O
and	O
can	O
produce	O
a	O
response	O
rate	O
of	O
33.3	O
%	O
among	O
patients	O
refractory	O
to	O
bolus	O
intravenous	O
(	O
IV	O
)	O
5-FU	B-DRUG
plus	O
LCV	B-DRUG
.	O
	
The	O
lack	O
of	O
hepatobiliary	O
toxicity	O
may	O
permit	O
salvage	O
HAI	O
with	O
floxuridine	B-DRUG
(	O
FUDR	B-DRUG
)	O
in	O
patients	O
whose	O
liver	O
tumors	O
fail	O
to	O
respond	O
to	O
HAI	O
of	O
5-FU	B-DRUG
plus	O
rIFN-alpha	B-DRUG
2b	I-DRUG
.	O
	
Because	O
diarrhea	B-TOXI
was	O
not	O
a	O
common	O
side	O
effect	O
of	O
HAI	O
of	O
5-FU	B-DRUG
plus	O
rIFN-alpha	B-DRUG
2b	I-DRUG
","	O
it	O
would	O
be	O
of	O
interest	O
to	O
investigate	O
whether	O
alternating	O
HAI	O
of	O
5-FU	B-DRUG
and	O
rIFN-alpha	B-DRUG
2b	I-DRUG
with	O
systemic	O
irinotecan	B-DRUG
(	O
CPT-11	B-DRUG
)	O
will	O
decrease	O
the	O
incidence	O
of	O
both	O
hepatic	O
and	O
extrahepatic	O
disease	O
progression	O
.	O
	
Randomized	O
trial	O
of	O
cyclophosphamide	B-DRUG
","	O
methotrexate	B-DRUG
","	O
and	O
fluorouracil	B-DRUG
chemotherapy	O
added	O
to	O
tamoxifen	B-DRUG
as	O
adjuvant	O
therapy	O
in	O
postmenopausal	O
women	O
with	O
node-positive	O
estrogen	O
and	O
/	O
or	O
progesterone	O
receptor-positive	O
breast	B-CANCER
cancer	I-CANCER
:	O
a	O
report	O
of	O
the	O
National	O
Cancer	O
Institute	O
of	O
Canada	O
Clinical	O
Trials	O
Group.	O
Breast	B-CANCER
Cancer	I-CANCER
Site	O
Group	O
.	O
	
	
By	O
the	O
mid	O
1980s	O
","	O
tamoxifen	B-DRUG
alone	O
was	O
considered	O
standard	O
adjuvant	O
therapy	O
for	O
postmenopausal	O
women	O
with	O
node-positive	O
","	O
estrogen	O
receptor	O
(	O
ER	O
)	O
=-	O
or	O
progesterone	O
receptor	O
(	O
PgR	O
)	O
#NAME?	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
From	O
1984	O
through	O
1990	O
","	O
705	O
eligible	O
postmenopausal	O
women	O
with	O
node-positive	O
","	O
ER-	O
or	O
PgR-positive	O
breast	B-CANCER
cancer	I-CANCER
were	O
randomized	O
to	O
a	O
National	O
Cancer	O
Institute	O
of	O
Canada	O
Clinical	O
Trials	O
Group	O
(	O
NCIC	O
CTG	O
)	O
study	O
that	O
compared	O
tamoxifen	B-DRUG
30	O
mg	O
by	O
mouth	O
daily	O
for	O
2	O
years	O
(	O
TAM	B-DRUG
)	O
versus	O
TAM	B-DRUG
plus	O
chemotherapy	O
with	O
all-intravenous	O
cyclophosphamide	B-DRUG
600	O
mg	O
/	O
m2	O
","	O
methotrexate	B-DRUG
40	O
mg	O
/	O
m2	O
","	O
and	O
fluorouracil	B-DRUG
600	O
mg	O
/	O
m2	O
given	O
every	O
21	O
days	O
for	O
eight	O
cycles	O
(	O
CMF	B-DRUG
)	O
.	O
	
There	O
were	O
no	O
significant	O
differences	O
in	O
overall	O
survival	O
","	O
recurrence-free	O
survival	O
","	O
locoregional	O
recurrence-free	O
survival	O
","	O
or	O
distant	O
recurrence-free	O
survival	O
between	O
the	O
two	O
treatment	O
arms	O
.	O
	
However	O
","	O
there	O
was	O
significantly	O
greater	O
severe	O
toxicity	O
","	O
which	O
included	O
leukopenia	B-TOXI
(	O
P	O
&	O
lt	O
;	O
0.0001	O
)	O
","	O
nausea	B-TOXI
and	O
vomiting	B-TOXI
(	O
P	O
&	O
lt	O
;	O
0.0001	O
)	O
","	O
and	O
thromboembolic	B-TOXI
events	I-TOXI
(	O
P	O
&	O
lt	O
;	O
0.0001	O
)	O
","	O
as	O
well	O
as	O
significantly	O
more	O
mild	O
or	O
greater	O
toxicity	O
","	O
which	O
included	O
thrombocytopenia	B-TOXI
(	O
P	O
=	O
0.04	O
)	O
","	O
anemia	B-TOXI
(	O
P	O
=	O
0.02	O
)	O
","	O
infection	B-TOXI
(	O
P	O
=	O
0.0004	O
)	O
","	O
mucositis	B-TOXI
(	O
P	O
=	O
0.0001	O
)	O
","	O
diarrhea	B-TOXI
(	O
P	O
=	O
0.0001	O
)	O
","	O
and	O
neurologic	B-TOXI
toxicity	I-TOXI
(	O
P	O
=	O
0.006	O
)	O
","	O
in	O
women	O
who	O
received	O
TAM	B-DRUG
plus	O
CMF	B-DRUG
.	O
	
The	O
addition	O
of	O
CMF	B-DRUG
to	O
TAM	B-DRUG
adds	O
no	O
benefit	O
and	O
considerable	O
toxicity	O
in	O
this	O
group	O
of	O
women	O
.	O
	
Carcinoma	B-CANCER
of	I-CANCER
unknown	I-CANCER
primary	I-CANCER
site	I-CANCER
:	O
treatment	O
with	O
1-hour	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
extended-schedule	O
etoposide	B-DRUG
.	O
	
	
To	O
evaluate	O
the	O
efficacy	O
and	O
toxicity	O
of	O
a	O
novel	O
chemotherapy	O
combination	O
that	O
includes	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
extended-schedule	O
etoposide	B-DRUG
in	O
the	O
treatment	O
of	O
patients	O
with	O
carcinoma	B-CANCER
of	I-CANCER
unknown	I-CANCER
primary	I-CANCER
tumor	I-CANCER
site	I-CANCER
.	O
	
Fifty-five	O
patients	O
with	O
carcinoma	B-CANCER
of	I-CANCER
unknown	I-CANCER
primary	I-CANCER
tumor	I-CANCER
site	I-CANCER
were	O
treated	O
with	O
the	O
following	O
regimen	O
","	O
administered	O
every	O
21	O
days	O
:	O
paclitaxel	B-DRUG
200	O
mg	O
/	O
m2	O
by	O
1-hour	O
intravenous	O
(	O
I.V.	O
)	O
infusion	O
on	O
day	O
1	O
","	O
carboplatin	B-DRUG
at	O
an	O
estimated	O
area	O
under	O
the	O
concentration-time	O
curve	O
(	O
AUC	O
)	O
of	O
6	O
on	O
day	O
1	O
","	O
and	O
etoposide	B-DRUG
50	O
mg	O
alternated	O
with	O
100	O
mg	O
orally	O
on	O
days	O
1	O
through	O
10	O
.	O
	
Responding	O
patients	O
received	O
a	O
total	O
of	O
four	O
courses	O
of	O
treatment	O
.	O
	
The	O
following	O
histologies	O
were	O
included	O
:	O
adenocarcinoma	B-CANCER
","	O
30	O
patients	O
;	O
poorly	B-CANCER
differentiated	I-CANCER
carcinoma	I-CANCER
(	O
PDC	B-CANCER
)	O
or	O
poorly	B-CANCER
differentiated	I-CANCER
adenocarcinoma	I-CANCER
(	O
PDA	B-CANCER
)	O
","	O
21	O
;	O
poorly	B-CANCER
differentiated	I-CANCER
neuroendocrine	I-CANCER
carcinoma	I-CANCER
","	O
three	O
;	O
and	O
squamous	B-CANCER
carcinoma	I-CANCER
","	O
one	O
.	O
	
Twenty-five	O
of	O
53	O
assessable	O
patients	O
(	O
47	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
33	O
%	O
to	O
61	O
%	O
)	O
had	O
major	O
objective	O
responses	O
to	O
treatment	O
(	O
seven	O
complete	O
responses	O
)	O
.	O
	
Response	O
rates	O
were	O
similar	O
in	O
patients	O
with	O
adenocarcinoma	B-CANCER
versus	O
PDC	B-CANCER
(	O
45	O
%	O
and	O
48	O
%	O
","	O
respectively	O
)	O
.	O
	
The	O
actuarial	O
median	O
survival	O
time	O
for	O
the	O
entire	O
group	O
was	O
13.4	O
months	O
.	O
	
The	O
regimen	O
was	O
well	O
tolerated	O
","	O
with	O
only	O
seven	O
hospitalizations	O
for	O
treatment	O
of	O
neutropenia	B-TOXI
and	O
fever	B-TOXI
(	O
4	O
%	O
of	O
courses	O
)	O
and	O
no	B-TOXI
treatment-related	I-TOXI
deaths	I-TOXI
.	O
	
The	O
combination	O
of	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
extended-schedule	O
etoposide	B-DRUG
is	O
highly	O
active	O
and	O
well	O
tolerated	O
in	O
patients	O
with	O
carcinoma	B-CANCER
of	I-CANCER
unknown	I-CANCER
primary	I-CANCER
tumor	I-CANCER
site	I-CANCER
.	O
	
Response	O
rates	O
and	O
survival	O
in	O
this	O
multicenter	O
community-based	O
trial	O
compare	O
favorably	O
with	O
all	O
previously	O
studied	O
empiric	O
regimens	O
.	O
	
In	O
addition	O
","	O
this	O
regimen	O
is	O
substantially	O
less	O
toxic	O
and	O
easier	O
to	O
administer	O
than	O
the	O
cisplatin-based	B-DRUG
regimens	O
previously	O
used	O
in	O
this	O
setting	O
.	O
	
If	O
this	O
level	O
of	O
efficacy	O
is	O
confirmed	O
","	O
this	O
treatment	O
should	O
be	O
considered	O
standard	O
first-line	O
therapy	O
in	O
patients	O
with	O
carcinoma	B-CANCER
of	I-CANCER
unknown	I-CANCER
primary	I-CANCER
tumor	I-CANCER
site	I-CANCER
.	O
	
Adjuvant	O
chemotherapy	O
in	O
colorectal	B-CANCER
cancer	I-CANCER
with	O
high-dose	O
leucovorin	B-DRUG
and	O
fluorouracil	B-DRUG
:	O
impact	O
on	O
disease-free	O
survival	O
and	O
overall	O
survival	O
.	O
	
	
The	O
rationale	O
for	O
using	O
adjuvant	O
chemotherapy	O
in	O
colorectal	B-CANCER
cancer	I-CANCER
is	O
to	O
achieve	O
better	O
disease	O
control	O
and	O
thus	O
reduce	O
the	O
high	O
rates	O
of	O
tumor	O
recurrence	O
and	O
mortality	O
in	O
patients	O
who	O
undergo	O
curative	O
surgery	O
.	O
	
The	O
current	O
literature	O
","	O
including	O
relevant	O
abstracts	O
","	O
on	O
clinical	O
trials	O
of	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
in	O
combination	O
with	O
high-dose	O
leucovorin	B-DRUG
as	O
adjuvant	O
chemotherapy	O
for	O
colorectal	B-CANCER
cancer	I-CANCER
is	O
reviewed	O
.	O
	
The	O
intent	O
is	O
not	O
to	O
present	O
new	O
data	O
","	O
but	O
to	O
present	O
the	O
reader	O
with	O
a	O
broad	O
perspective	O
and	O
larger	O
patient	O
experience	O
on	O
which	O
to	O
base	O
well-reasoned	O
treatment	O
decisions	O
.	O
	
Published	O
clinical	O
trials	O
and	O
abstracts	O
presented	O
at	O
the	O
1996	O
American	O
Society	O
of	O
Clinical	O
Oncology	O
(	O
ASCO	O
)	O
meeting	O
that	O
assessed	O
5-FU	B-DRUG
in	O
combination	O
with	O
high-dose	O
leucovorin	B-DRUG
as	O
adjuvant	O
chemotherapy	O
for	O
colorectal	B-CANCER
cancer	I-CANCER
were	O
surveyed	O
.	O
	
End	O
points	O
of	O
interest	O
were	O
disease-free	O
survival	O
(	O
DFS	O
)	O
","	O
overall	O
survival	O
","	O
and	O
toxicity	O
.	O
	
In	O
randomized	O
trials	O
that	O
used	O
high-dose	O
leucovorin	B-DRUG
at	O
doses	O
that	O
ranged	O
from	O
daily-times-five	O
200	O
mg	O
/	O
m2	O
to	O
weekly	O
500	O
mg	O
/	O
m2	O
in	O
combination	O
with	O
5-FU	B-DRUG
","	O
significant	O
improvements	O
in	O
both	O
DFS	O
and	O
overall	O
survival	O
were	O
observed	O
over	O
surgery	O
alone	O
(	O
control	O
)	O
.	O
	
In	O
patients	O
treated	O
with	O
high-dose	O
leucovorin	B-DRUG
/	O
5-FU	B-DRUG
","	O
DFS	O
rates	O
ranged	O
from	O
71	O
%	O
to	O
77	O
%	O
compared	O
with	O
control	O
(	O
58	O
%	O
to	O
64	O
%	O
)	O
.	O
	
A	O
similar	O
trend	O
was	O
seen	O
in	O
overall	O
survival	O
","	O
with	O
a	O
range	O
of	O
75	O
%	O
to	O
84	O
%	O
compared	O
with	O
control	O
(	O
63	O
%	O
to	O
77	O
%	O
)	O
.	O
	
Toxicities	O
observed	O
for	O
high-dose	O
leucovorin	B-DRUG
administered	O
on	O
a	O
weekly	O
or	O
daily-times-five	O
schedule	O
were	O
diarrhea	B-TOXI
","	O
stomatitis	B-TOXI
","	O
myelosuppression	B-TOXI
","	O
and	O
nausea	B-TOXI
.	O
	
Overall	O
","	O
the	O
results	O
of	O
these	O
randomized	O
trials	O
support	O
the	O
use	O
of	O
high-dose	O
leucovorin	B-DRUG
/	O
5-FU	B-DRUG
as	O
adjuvant	O
therapy	O
for	O
colorectal	B-CANCER
cancer	I-CANCER
.	O
	
Longer	O
follow-up	O
studies	O
are	O
needed	O
to	O
compare	O
the	O
benefits	O
of	O
these	O
different	O
regimens	O
in	O
terms	O
of	O
survival	O
and	O
to	O
characterize	O
adverse	O
effects	O
","	O
especially	O
those	O
that	O
may	O
not	O
be	O
immediately	O
evident	O
.	O
	
Adjuvant	O
therapy	O
with	O
high-dose	O
leucovorin	B-DRUG
/	O
5-FU	B-DRUG
is	O
an	O
effective	O
regimen	O
that	O
is	O
well	O
tolerated	O
by	O
many	O
patients	O
with	O
colorectal	B-CANCER
cancer	I-CANCER
.	O
	
A	O
phase	O
II	O
study	O
of	O
weekly	O
high-dose	O
cisplatin	B-DRUG
combined	O
with	O
oral	O
etoposide	B-DRUG
in	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
As	O
a	O
dose-response	O
relationship	O
has	O
been	O
suggested	O
for	O
cisplatin	B-DRUG
","	O
it	O
appeared	O
attractive	O
to	O
explore	O
high-dose-intensity	O
regimens	O
in	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
In	O
a	O
phase	O
I	O
study	O
of	O
weekly	O
administration	O
of	O
cisplatin	B-DRUG
combined	O
with	O
oral	O
etoposide	B-DRUG
we	O
achieved	O
a	O
cisplatin	B-DRUG
dose	O
intensity	O
of	O
52.5-60	O
mg	O
/	O
m2	O
per	O
week	O
in	O
most	O
patients	O
.	O
	
We	O
subsequently	O
explored	O
this	O
regimen	O
in	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
were	O
treated	O
with	O
cisplatin	B-DRUG
infused	O
at	O
70	O
mg	O
/	O
m2	O
on	O
days	O
1	O
","	O
8	O
","	O
15	O
and	O
29	O
","	O
36	O
","	O
43	O
in	O
combination	O
with	O
oral	O
etoposide	B-DRUG
given	O
at	O
50	O
mg	O
on	O
days	O
1月15日	O
and	O
29-43	O
.	O
	
Patients	O
showing	O
stable	O
disease	O
or	O
a	O
better	O
response	O
were	O
continued	O
on	O
treatment	O
with	O
oral	O
etoposide	B-DRUG
given	O
at	O
50	O
mg	O
/	O
m2	O
per	O
day	O
on	O
days	O
1月21日	O
every	O
28	O
days	O
for	O
a	O
maximum	O
of	O
four	O
cycles	O
.	O
	
In	O
all	O
","	O
22	O
patients	O
with	O
stage	O
III	O
disease	O
and	O
31	O
patients	O
with	O
stage	O
IV	O
disease	O
entered	O
the	O
study	O
.	O
	
The	O
median	O
number	O
of	O
cisplatin	B-DRUG
administration	O
was	O
6	O
per	O
patient	O
;	O
17	O
patients	O
reached	O
the	O
planned	O
cisplatin	B-DRUG
dose	O
intensity	O
of	O
60	O
mg	O
/	O
m2	O
per	O
week	O
","	O
11	O
patients	O
achieved	O
52.5	O
mg	O
/	O
m2	O
per	O
week	O
","	O
and	O
7	O
patients	O
reached	O
47	O
mg	O
/	O
m2	O
per	O
week	O
.	O
	
Overall	O
","	O
11	O
of	O
21	O
stage	O
III	O
patients	O
had	O
a	O
partial	O
response	O
[	O
response	O
rate	O
51	O
%	O
","	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
36-81	O
%	O
]	O
","	O
as	O
did	O
9	O
of	O
28	O
patients	O
with	O
stage	O
IV	O
disease	O
(	O
32	O
%	O
;	O
95	O
%	O
CI	O
15-49	O
%	O
)	O
.	O
	
Toxicity	O
was	O
mainly	O
hematologic	B-TOXI
","	O
with	O
leukocytopenia	B-TOXI
being	O
the	O
most	O
frequent	O
cause	O
of	O
treatment	O
delay	O
.	O
	
Nephrotoxicity	B-TOXI
of	O
grade	O
1	O
was	O
observed	O
in	O
seven	O
patients	O
.	O
	
Two	O
patients	O
developed	O
clinical	O
hearing	O
loss	O
.	O
	
With	O
this	O
schedule	O
a	O
high	O
median	O
cisplatin	B-DRUG
dose	O
intensity	O
of	O
52.5-60	O
mg	O
/	O
m2	O
per	O
week	O
was	O
reached	O
.	O
	
The	O
51	O
%	O
response	O
rate	O
achieved	O
in	O
stage	O
III	O
disease	O
makes	O
this	O
schedule	O
attractive	O
for	O
further	O
exploration	O
;	O
however	O
","	O
it	O
is	O
not	O
recommended	O
for	O
routine	O
use	O
in	O
stage	O
IV	O
disease	O
.	O
	
Intensive	O
weekly	O
chemotherapy	O
for	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
using	O
fluorouracil	B-DRUG
","	O
cisplatin	B-DRUG
","	O
epi-doxorubicin	B-DRUG
","	O
6S-leucovorin	B-DRUG
","	O
glutathione	B-DRUG
","	O
and	O
filgrastim	B-DRUG
:	O
a	O
report	O
from	O
the	O
Italian	O
Group	O
for	O
the	O
Study	O
of	O
Digestive	O
Tract	B-CANCER
Cancer	I-CANCER
.	O
	
	
A	O
multiinstitutional	O
trial	O
was	O
performed	O
to	O
confirm	O
the	O
clinical	O
activity	O
","	O
in	O
terms	O
of	O
response	O
rate	O
and	O
toxicity	O
(	O
primary	O
objectives	O
)	O
and	O
duration	O
of	O
responses	O
and	O
survival	O
(	O
secondary	O
objectives	O
)	O
","	O
of	O
an	O
intensive	O
weekly	O
regimen	O
in	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
.	O
	
Patients	O
with	O
measurable	O
unresectable	O
and	O
/	O
or	O
metastatic	B-CANCER
gastric	I-CANCER
carcinoma	I-CANCER
received	O
1-day	O
per	O
week	O
administration	O
of	O
cisplatin	B-DRUG
(	O
CDDP	B-DRUG
)	O
40	O
mg	O
/	O
m2	O
","	O
fluorouracil	B-DRUG
(	O
5FU	B-DRUG
)	O
500	O
mg	O
/	O
m2	O
","	O
epi-doxorubicin	B-DRUG
(	O
epi-ADR	B-DRUG
)	O
35	O
mg	O
/	O
m2	O
","	O
6S-stereoisomer	O
of	O
leucovorin	B-DRUG
250	O
mg	O
/	O
m2	O
","	O
and	O
glutathione	B-DRUG
1.5	O
g	O
/	O
m2	O
.	O
	
On	O
the	O
other	O
days	O
","	O
filgrastim	B-DRUG
was	O
administered	O
by	O
subcutaneous	O
injection	O
at	O
a	O
dose	O
of	O
5	O
mg	O
/	O
kg	O
.	O
	
One	O
cycle	O
of	O
therapy	O
consisted	O
of	O
eight	O
1-week	O
treatments	O
.	O
	
Patients	O
who	O
showed	O
a	O
response	O
or	O
stable	O
disease	O
received	O
a	O
further	O
6	O
weeks	O
of	O
therapy	O
.	O
	
Of	O
105	O
enrolled	O
patients	O
","	O
11	O
had	O
locally	O
advanced	O
unresectable	O
disease	O
only	O
;	O
33	O
had	O
primary	O
nonresected	O
and	O
metastatic	O
disease	O
;	O
48	O
had	O
metastatic	O
disease	O
and	O
primary	O
tumor	O
resected	O
;	O
10	O
had	O
locoregional	O
recurrence	O
and	O
metastatic	O
disease	O
;	O
and	O
three	O
had	O
locoregional	O
recurrence	O
only	O
.	O
	
After	O
one	O
cycle	O
","	O
18	O
complete	O
responses	O
(	O
CRs	O
)	O
and	O
47	O
partial	O
responses	O
(	O
PRs	O
)	O
were	O
achieved	O
","	O
for	O
an	O
overall	O
response	O
rate	O
of	O
62	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
53	O
%	O
to	O
71	O
%	O
)	O
.	O
	
Twenty	O
patients	O
had	O
stable	O
disease	O
and	O
20	O
progressed	O
on	O
therapy	O
.	O
	
The	O
median	O
survival	O
duration	O
of	O
all	O
105	O
patients	O
was	O
11	O
months	O
","	O
with	O
-1	O
and	O
2-year	O
survival	O
rates	O
of	O
42	O
%	O
and	O
5	O
%	O
","	O
respectively	O
.	O
	
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
grade	O
III	O
to	O
IV	O
toxicity	O
","	O
in	O
terms	O
of	O
anemia	B-TOXI
","	O
neutropenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
and	O
mucositis	B-TOXI
","	O
was	O
experienced	O
by	O
40	O
patients	O
(	O
38	O
%	O
)	O
.	O
	
There	O
were	O
no	O
treatment-related	O
deaths	B-TOXI
.	O
	
These	O
data	O
support	O
the	O
results	O
of	O
the	O
pilot	O
study	O
and	O
confirmed	O
the	O
high	O
activity	O
of	O
the	O
regimen	O
","	O
with	O
acceptable	O
toxicity	O
.	O
	
This	O
schedule	O
deserves	O
evaluation	O
in	O
the	O
adjuvant	O
setting	O
.	O
	
Prospectively	O
randomized	O
North	O
Central	O
Cancer	O
Treatment	O
Group	O
trial	O
of	O
intensive-course	O
fluorouracil	B-DRUG
combined	O
with	O
the	O
l-isomer	O
of	O
intravenous	O
leucovorin	B-DRUG
","	O
oral	B-DRUG
leucovorin	I-DRUG
","	O
or	O
intravenous	B-DRUG
leucovorin	I-DRUG
for	O
the	O
treatment	O
of	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
.	O
	
	
A	O
three-arm	O
randomized	O
phase	O
III	O
trial	O
in	O
advanced	B-CANCER
colorectal	I-CANCER
cancer	I-CANCER
patients	O
was	O
designed	O
to	O
test	O
whether	O
substitution	O
of	O
an	O
equivalent	O
dose	O
of	O
(	O
1	O
)	O
l-leucovorin	B-DRUG
or	O
(	O
2	O
)	O
oral	B-DRUG
leucovorin	I-DRUG
would	O
more	O
effectively	O
potentiate	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
than	O
standard	O
intravenous	O
(	O
I.V	O
.	O
)	O
	
(	B-DRUG
d	I-DRUG
","	I-DRUG
l	I-DRUG
)	I-DRUG
#NAME?	I-DRUG
.	O
	
A	O
total	O
of	O
926	O
chemotherapy-naive	O
patients	O
participated	O
.	O
	
Patients	O
received	O
one	O
of	O
three	O
treatments	O
:	O
(	O
A	O
)	O
intensive-course	O
5-FU	B-DRUG
plus	O
l-leucovorin	B-DRUG
with	O
I.V.	O
leucovorin	B-DRUG
(	O
Immunex	O
Corp	O
","	O
Seattle	O
","	O
WA	O
)	O
at	O
100	O
mg	O
/	O
m2	O
and	O
I.V.	O
5-FU	B-DRUG
at	O
370	O
mg	O
/	O
m2	O
;	O
(	O
B	O
)	O
intensive-course	O
5-FU	B-DRUG
plus	O
oral	O
(	B-DRUG
d	I-DRUG
","	I-DRUG
l	I-DRUG
)	I-DRUG
#NAME?	I-DRUG
with	O
oral	B-DRUG
leucovarin	I-DRUG
at	O
125	O
mg	O
/	O
m2	O
on	O
hours	O
0	O
","	O
1	O
","	O
2	O
","	O
and	O
3	O
(	O
total	O
dose	O
","	O
500	O
mg	O
/	O
m2	O
)	O
followed	O
by	O
5-FU	B-DRUG
370	O
mg	O
/	O
m2	O
on	O
hour	O
4	O
;	O
or	O
(	O
C	O
)	O
intensive-course	O
5-FU	B-DRUG
plus	O
I.V	O
.	O
	
(	O
d	O
","	O
l	O
)	O
#NAME?	B-DRUG
with	O
I.V.	O
leucovorin	B-DRUG
200	O
mg	O
/	O
m2	O
and	O
5-FU	B-DRUG
370	O
mg	O
/	O
m2	O
.	O
	
Drugs	O
were	O
administered	O
daily	O
for	O
5	O
consecutive	O
days	O
.	O
	
Courses	O
were	O
repeated	O
at	O
4	O
and	O
8	O
weeks	O
","	O
and	O
every	O
5	O
weeks	O
thereafter	O
.	O
	
Dosage	O
was	O
reduced	O
for	O
neutropenia	B-TOXI
","	O
thrombocytopenia	B-TOXI
","	O
diarrhea	B-TOXI
","	O
stomatitis	B-TOXI
","	O
and	O
dermatitis	B-TOXI
.	O
	
Of	O
926	O
eligible	O
patients	O
","	O
756	O
have	O
died	B-TOXI
.	O
	
The	O
overall	O
response	O
rate	O
for	O
patients	O
with	O
measurable	O
disease	O
was	O
32	O
%	O
(	O
165	O
of	O
514	O
)	O
.	O
	
There	O
were	O
no	O
differences	O
between	O
regimens	O
in	O
response	O
rates	O
(	O
arm	O
A	O
","	O
28	O
%	O
[	O
47	O
of	O
140	O
]	O
;	O
arm	O
B	O
","	O
34	O
%	O
[	O
60	O
of	O
174	O
]	O
;	O
and	O
arm	O
C	O
","	O
34	O
%	O
[	O
58	O
of	O
170	O
]	O
)	O
or	O
in	O
survival	O
.	O
	
There	O
have	O
been	O
nine	O
possible	O
chemotherapy-related	O
fatalities	O
.	O
	
Grade	O
III	O
to	O
IV	O
toxic	O
effects	O
did	O
not	O
differ	O
appreciably	O
by	O
arm	O
and	O
included	O
stomatitis	B-TOXI
(	O
12	O
%	O
to	O
14	O
%	O
)	O
","	O
diarrhea	B-TOXI
(	O
15	O
%	O
to	O
19	O
%	O
)	O
","	O
nausea	B-TOXI
(	O
7	O
%	O
to	O
9	O
%	O
)	O
","	O
and	O
vomiting	B-TOXI
(	O
6	O
%	O
to	O
8	O
%	O
)	O
.	O
	
There	O
was	O
no	O
difference	O
in	O
response	O
","	O
survival	O
","	O
or	O
toxicity	O
between	O
these	O
three	O
different	O
leucovorin	B-DRUG
formulations	O
combined	O
with	O
5-FU	B-DRUG
.	O
	
Paclitaxel	B-DRUG
plus	O
carboplatin	B-DRUG
in	O
advanced	B-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
urothelium	I-CANCER
:	O
an	O
active	O
and	O
tolerable	O
outpatient	O
regimen	O
.	O
	
	
To	O
determine	O
the	O
toxicity	O
and	O
efficacy	O
of	O
an	O
outpatient	O
regimen	O
of	O
paclitaxel	O
plus	O
carboplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
urothelium	I-CANCER
.	O
	
Patients	O
received	O
paclitaxel	B-DRUG
150	O
to	O
225	O
mg	O
/	O
m2	O
over	O
3	O
hours	O
followed	O
by	O
carboplatin	B-DRUG
(	O
targeted	O
area	O
under	O
the	O
concentration-time	O
curve	O
[	O
AUC	O
]	O
","	O
6	O
mg	O
/	O
mL	O
x	O
min	O
)	O
every	O
3	O
weeks	O
.	O
	
During	O
phase	O
I	O
accrual	O
","	O
16	O
patients	O
were	O
treated	O
;	O
17	O
additional	O
patients	O
were	O
enrolled	O
at	O
the	O
phase	O
II	O
dose	O
.	O
	
The	O
median	O
age	O
was	O
70	O
years	O
(	O
range	O
","	O
47	O
to	O
82	O
)	O
.	O
	
The	O
median	O
serum	O
creatinine	O
concentration	O
was	O
1.1	O
mg	O
/	O
dL	O
(	O
range	O
","	O
0.7	O
to	O
2.7	O
)	O
and	O
the	O
median	O
estimated	O
creatinine	O
clearance	O
was	O
52	O
mL	O
/	O
min	O
(	O
range	O
","	O
24	O
to	O
110	O
)	O
.	O
	
During	O
phase	O
I	O
accrual	O
","	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
the	O
regimen	O
was	O
not	O
defined	O
.	O
	
Phase	O
II	O
accrual	O
occurred	O
at	O
the	O
paclitaxel	B-DRUG
225	O
mg	O
/	O
m2	O
dose	O
level	O
.	O
	
A	O
total	O
of	O
156	O
cycles	O
were	O
administered	O
.	O
	
The	O
median	O
number	O
of	O
cycles	O
received	O
was	O
five	O
(	O
range	O
","	O
one	O
to	O
eight	O
)	O
.	O
	
Sensorimotor	B-TOXI
neuropathy	I-TOXI
was	O
the	O
principal	O
nonhematologic	B-TOXI
toxicity	I-TOXI
.	O
	
Significant	O
granulocytopenia	B-TOXI
was	O
common	O
","	O
but	O
significant	O
thrombocytopenia	B-TOXI
was	O
not	O
.	O
	
Objective	O
responses	O
were	O
demonstrated	O
at	O
all	O
dose	O
levels	O
.	O
	
At	O
the	O
phase	O
II	O
dose	O
(	O
paclitaxel	B-DRUG
225	O
mg	O
/	O
m2	O
followed	O
by	O
carboplatin	B-DRUG
at	O
AUC	O
6	O
mg	O
/	O
mL	O
x	O
min	O
)	O
","	O
the	O
objective	O
response	O
rate	O
was	O
50	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
","	O
28	O
%	O
to	O
72	O
%	O
)	O
.	O
	
Paclitaxel	B-DRUG
plus	O
carboplatin	B-DRUG
is	O
an	O
active	O
and	O
tolerable	O
outpatient	O
treatment	O
for	O
patients	O
with	O
advanced	B-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
urothelium	I-CANCER
.	O
	
The	O
ability	O
to	O
administer	O
this	O
combination	O
over	O
multiple	O
cycles	O
even	O
to	O
patients	O
with	O
advanced	O
age	O
and	O
abnormal	O
renal	O
function	O
makes	O
it	O
well	O
suited	O
for	O
this	O
patient	O
population	O
.	O
	
Confirmatory	O
trials	O
of	O
this	O
regimen	O
are	O
ongoing	O
.	O
	
Phase	O
II	O
study	O
of	O
carmustine	B-DRUG
","	O
dacarbazine	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
tamoxifen	B-DRUG
in	O
advanced	B-CANCER
melanoma	I-CANCER
:	O
a	O
Southwest	O
Oncology	O
Group	O
study	O
.	O
	
	
The	O
combination	O
of	O
carmustine	B-DRUG
(	O
BCNU	B-DRUG
)	O
","	O
dacarbazine	B-DRUG
(	O
DTIC	B-DRUG
)	O
","	O
cisplatin	B-DRUG
(	O
DDP	B-DRUG
)	O
","	O
and	O
tamoxifen	B-DRUG
(	O
Tam	B-DRUG
)	O
has	O
been	O
reported	O
in	O
small	O
series	O
to	O
provide	O
a	O
response	O
rate	O
of	O
50	O
%	O
","	O
but	O
with	O
significant	O
myelosuppression	B-TOXI
and	O
risk	O
of	O
thromboembolic	B-TOXI
complications	I-TOXI
.	O
	
We	O
performed	O
this	O
phase	O
II	O
study	O
to	O
assess	O
the	O
antitumor	O
activity	O
and	O
important	O
toxicities	O
of	O
this	O
combination	O
in	O
the	O
cooperative	O
group	O
setting	O
.	O
	
Seventy-nine	O
eligible	O
patients	O
were	O
treated	O
with	O
BCNU	B-DRUG
150	O
mg	O
/	O
m2	O
/	O
d	O
","	O
every	O
6	O
weeks	O
","	O
DTIC	B-DRUG
220	O
mg	O
/	O
m2	O
/	O
d	O
on	O
days	O
1	O
to	O
3	O
every	O
3	O
weeks	O
","	O
DDP	B-DRUG
25	O
mg	O
/	O
m2	O
/	O
d	O
on	O
days	O
1	O
to	O
3	O
every	O
3	O
weeks	O
","	O
and	O
Tam	O
20	O
mg	O
orally	O
daily	O
throughout	O
treatment	O
.	O
	
Treatment	O
cycles	O
were	O
repeated	O
every	O
6	O
weeks	O
in	O
responding	O
or	O
stable	O
patients	O
for	O
a	O
maximum	O
duration	O
of	O
1	O
year	O
.	O
	
Twelve	O
objective	O
responses	O
were	O
achieved	O
(	O
response	O
rate	O
15	O
%	O
","	O
95	O
%	O
confidence	O
interval	O
8	O
%	O
-25	O
%	O
)	O
.	O
	
Five	O
responses	O
were	O
complete	O
(	O
CR	O
)	O
and	O
seven	O
were	O
partial	O
(	O
PR	O
)	O
.	O
	
The	O
median	O
response	O
duration	O
was	O
8+	O
(	O
range	O
","	O
4-19+	O
)	O
months	O
","	O
(	O
16+	O
[	O
4-19+	O
]	O
for	O
CR	O
and	O
8+	O
[	O
4月11日	O
]	O
for	O
PR	O
)	O
","	O
and	O
the	O
median	O
survival	O
of	O
the	O
entire	O
group	O
was	O
9	O
months	O
.	O
	
The	O
toxicities	O
were	O
predominantly	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
.	O
	
Four	O
patients	O
developed	O
thromboembolic	B-TOXI
events	I-TOXI
.	O
	
Two	O
patients	O
died	B-TOXI
while	O
on	O
protocol	O
therapy	O
","	O
one	O
with	O
complications	O
of	O
neutropenia	B-TOXI
","	O
and	O
the	O
other	O
with	O
disease	O
progression	O
.	O
	
The	O
activity	O
of	O
this	O
regimen	O
is	O
in	O
the	O
range	O
reported	O
for	O
single	O
agents	O
or	O
DTIC	B-DRUG
plus	O
DDP	B-DRUG
","	O
and	O
the	O
addition	O
of	O
BCNU	B-DRUG
and	O
Tam	B-DRUG
appears	O
to	O
increase	O
toxicity	O
.	O
	
We	O
do	O
not	O
recommend	O
this	O
combination	O
for	O
routine	O
treatment	O
of	O
advanced	B-CANCER
melanoma	I-CANCER
or	O
as	O
the	O
control	O
arm	O
in	O
randomized	O
studies	O
of	O
combination	O
therapy	O
.	O
	
Phase	O
I	O
study	O
of	O
concomitant	O
chemoradiotherapy	O
with	O
paclitaxel	B-DRUG
","	O
fluorouracil	B-DRUG
","	O
and	O
hydroxyurea	B-DRUG
with	O
granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
support	O
for	O
patients	O
with	O
poor-prognosis	O
cancer	B-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
.	O
	
	
We	O
have	O
previously	O
demonstrated	O
high	O
locoregional	O
control	O
rates	O
in	O
patients	O
with	O
poor-prognosis	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
cancer	I-CANCER
using	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
hydroxyurea	B-DRUG
(	O
HU	B-DRUG
)	O
","	O
and	O
concomitant	O
radiotherapy	O
(	O
RT	O
)	O
(	O
FHX	O
)	O
.	O
	
In	O
the	O
trial	O
reported	O
here	O
","	O
we	O
added	O
paclitaxel	B-DRUG
to	O
the	O
FHX	O
base	O
and	O
used	O
hyperfractionated	B-DRUG
RT	O
to	O
determine	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
","	O
toxicities	O
","	O
and	O
response	O
rate	O
in	O
a	O
poor-prognosis	O
group	O
of	O
patients	O
.	O
	
Fifty-five	O
patients	O
who	O
had	O
either	O
failed	O
to	O
respond	O
to	O
prior	O
RT	O
(	O
n	O
=	O
25	O
)	O
or	O
surgery	O
","	O
had	O
a	O
coexistent	O
or	O
prior	O
second	O
malignancy	O
","	O
or	O
who	O
had	O
unresectable	O
or	O
metastatic	O
disease	O
and	O
an	O
expected	O
2-year	O
survival	O
rate	O
less	O
than	O
10	O
%	O
","	O
were	O
treated	O
.	O
	
Chemoradiotherapy	O
consisted	O
of	O
2	O
Gy	O
on	O
days	O
2	O
to	O
6	O
(	O
once-daily	O
RT	O
cohorts	O
)	O
or	O
1.5	O
Gy	O
twice	O
a	O
day	O
(	O
hyperfractionated	O
cohorts	O
)	O
.	O
	
Simultaneous	O
HU	B-DRUG
(	O
500	O
or	O
"1,000"	O
mg	O
twice	O
per	O
day	O
for	O
11	O
doses	O
)	O
and	O
infusional	O
5-FU	B-DRUG
(	O
600-800	O
mg	O
/	O
m2	O
/	O
d	O
for	O
5	O
days	O
)	O
were	O
given	O
along	O
with	O
infusional	O
paclitaxel	B-DRUG
at	O
escalating	O
doses	O
of	O
5	O
to	O
25	O
mg	O
/	O
m2	O
/	O
d	O
for	O
5	O
days	O
.	O
	
Granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
(	O
G-CSF	B-DRUG
)	O
was	O
administered	O
on	O
days	O
7	O
through	O
13	O
at	O
5	O
microg	O
/	O
kg	O
/	O
d.	O
Cycles	O
were	O
repeated	O
every	O
14	O
days	O
until	O
completion	O
of	O
RT.	O
Plasma	O
paclitaxel	B-DRUG
levels	O
were	O
determined	O
on	O
day	O
4	O
of	O
cycle	O
1	O
Dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
consisted	O
of	O
myelosuppression	B-TOXI
","	O
mucositis	B-TOXI
","	O
dermatitis	B-TOXI
","	O
and	O
diarrhea	B-TOXI
.	O
	
Plasma	O
concentrations	O
of	O
paclitaxel	B-DRUG
greater	O
than	O
10	O
nmol	O
/	O
L	O
were	O
achieved	O
in	O
65	O
%	O
of	O
patients	O
at	O
the	O
recommended	O
phase	O
II	O
dose	O
(	O
RPTD	O
)	O
level	O
of	O
paclitaxel	B-DRUG
.	O
	
Seventy	O
percent	O
of	O
assessable	O
patients	O
achieved	O
a	O
complete	O
response	O
(	O
CR	O
)	O
to	O
therapy	O
.	O
	
Twenty	O
patients	O
were	O
treated	O
at	O
the	O
RPTD	O
of	O
HU	B-DRUG
500	O
mg	O
orally	O
twice	O
daily	O
for	O
11	O
doses	O
","	O
5-FU	B-DRUG
600	O
mg	O
/	O
m2	O
/	O
d	O
by	O
continuous	O
infusion	O
for	O
5	O
days	O
;	O
and	O
paclitaxel	B-DRUG
20	O
mg	O
/	O
m2	O
/	O
d	O
by	O
continuous	O
infusion	O
for	O
5	O
days	O
","	O
with	O
twice-daily	O
RT.	O
The	O
addition	O
of	O
infusional	O
paclitaxel	B-DRUG
and	O
hyperfractionated	B-DRUG
RT	O
to	O
FHX	O
is	O
feasible	O
.	O
	
Radiosensitizing	O
levels	O
of	O
paclitaxel	B-DRUG
are	O
achieved	O
in	O
most	O
patients	O
.	O
	
The	O
high	O
locoregional	O
control	O
rate	O
of	O
this	O
regimen	O
justifies	O
further	O
investigation	O
in	O
previously	O
untreated	O
patients	O
.	O
	
Phase	O
II	O
study	O
of	O
irinotecan	B-DRUG
combined	O
with	O
cisplatin	B-DRUG
in	O
patients	O
with	O
previously	O
untreated	O
small-cell	B-CANCER
lung	I-CANCER
cancer.	I-CANCER
West	O
Japan	O
Lung	O
Cancer	O
Group	O
.	O
	
	
Irinotecan	B-DRUG
(	O
CPT-11	B-DRUG
)	O
is	O
effective	O
against	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
SCLC	B-CANCER
)	O
as	O
monotherapy	O
.	O
	
Cisplatin	B-DRUG
is	O
also	O
a	O
key	O
drug	O
against	O
SCLC	B-CANCER
.	O
	
We	O
conducted	O
a	O
phase	O
II	O
study	O
of	O
CPT-11	B-DRUG
combined	O
with	O
cisplatin	B-DRUG
to	O
evaluate	O
the	O
efficacy	O
and	O
toxicity	O
of	O
this	O
regimen	O
in	O
patients	O
with	O
previously	O
untreated	O
SCLC	B-CANCER
.	O
	
Seventy-five	O
patients	O
with	O
previously	O
untreated	O
SCLC	B-CANCER
were	O
enrolled	O
onto	O
the	O
study	O
.	O
	
CPT-11	B-DRUG
60	O
mg	O
/	O
m2	O
was	O
administered	O
intravenously	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
in	O
combination	O
with	O
cisplatin	B-DRUG
60	O
mg	O
/	O
m2	O
on	O
day	O
1	O
every	O
28	O
days	O
.	O
	
Four	O
courses	O
of	O
chemotherapy	O
followed	O
by	O
thoracic	O
irradiation	O
were	O
given	O
to	O
patients	O
with	O
limited	O
disease	O
(	O
LD	O
)	O
and	O
six	O
courses	O
to	O
patients	O
with	O
extensive	O
disease	O
(	O
ED	O
)	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
84	O
%	O
","	O
with	O
a	O
complete	O
response	O
(	O
CR	O
)	O
rate	O
of	O
29	O
%	O
.	O
	
Forty	O
patients	O
with	O
LD	O
achieved	O
an	O
overall	O
response	O
rate	O
of	O
83	O
%	O
and	O
a	O
CR	O
rate	O
of	O
30	O
%	O
and	O
35	O
patients	O
with	O
ED	O
achieved	O
an	O
overall	O
response	O
rate	O
of	O
86	O
%	O
and	O
a	O
CR	O
rate	O
of	O
29	O
%	O
.	O
	
The	O
median	O
response	O
duration	O
was	O
8	O
months	O
for	O
LD	O
patients	O
and	O
6.6	O
months	O
for	O
ED	O
patients	O
.	O
	
The	O
median	O
survival	O
was	O
14.3	O
months	O
for	O
LD	O
patients	O
and	O
13	O
months	O
for	O
ED	O
patients	O
.	O
	
The	O
major	O
grade	O
3	O
or	O
4	O
toxicities	O
were	O
neutropenia	B-TOXI
(	O
77	O
%	O
)	O
","	O
leukopenia	B-TOXI
(	O
45	O
%	O
)	O
","	O
diarrhea	B-TOXI
(	O
19	O
%	O
)	O
","	O
and	O
anemia	B-TOXI
(	O
39	O
%	O
)	O
.	O
	
Two	O
patients	O
died	B-TOXI
with	O
concomitant	O
neutropenia	B-TOXI
and	O
diarrhea	B-TOXI
.	O
	
This	O
is	O
a	O
new	O
active	O
regimen	O
for	O
SCLC	B-CANCER
","	O
especially	O
ED-SCLC	B-CANCER
","	O
with	O
acceptable	O
toxicity	O
.	O
	
A	O
phase	O
III	O
study	O
that	O
compares	O
CPT-11	B-DRUG
/	O
cisplatin	B-DRUG
with	O
etoposide	B-DRUG
/	O
cisplatin	B-DRUG
for	O
ED-SCLC	B-CANCER
is	O
now	O
being	O
conducted	O
.	O
	
Induction	O
chemotherapy	O
with	O
docetaxel	B-DRUG
","	O
cisplatin	B-DRUG
","	O
fluorouracil	B-DRUG
","	O
and	O
leucovorin	B-DRUG
for	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
:	O
a	O
phase	O
I	O
/	O
II	O
trial	O
.	O
	
	
A	O
phase	O
I	O
/	O
II	O
trial	O
of	O
docetaxel	B-DRUG
","	O
cisplatin	B-DRUG
","	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
and	O
leucovorin	B-DRUG
(	O
TPFL5	B-DRUG
)	O
induction	O
chemotherapy	O
for	O
patients	O
with	O
locally	O
advanced	B-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
(	O
SCCHN	B-CANCER
)	O
.	O
	
Twenty-three	O
previously	O
untreated	O
patients	O
with	O
stage	O
III	O
or	O
IV	O
SCCHN	B-CANCER
and	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
functional	O
status	O
less	O
than	O
or	O
equal	O
to	O
2	O
were	O
treated	O
with	O
TPFL5	B-DRUG
.	O
	
Postchemotherapy	O
home	O
support	O
included	O
intravenous	O
fluids	B-DRUG
","	O
prophylactic	B-DRUG
antibiotics	I-DRUG
","	O
and	O
granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
(	O
G-CSF	B-DRUG
)	O
.	O
	
Docetaxel	B-DRUG
dose	O
was	O
escalated	O
to	O
determine	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
.	O
	
Fifteen	O
patients	O
were	O
treated	O
with	O
three	O
cycles	O
of	O
TPFL5	B-DRUG
at	O
MTD	O
.	O
	
Patients	O
who	O
achieved	O
either	O
a	O
partial	O
response	O
(	O
PR	O
)	O
or	O
complete	O
response	O
(	O
CR	O
)	O
to	O
three	O
cycles	O
of	O
TPFL5	B-DRUG
then	O
received	O
definitive	O
twice-daily	O
radiation	O
therapy	O
.	O
	
Toxicity	O
and	O
clinical	O
and	O
pathologic	O
response	O
to	O
TPFL5	B-DRUG
were	O
assessed	O
.	O
	
Twenty-three	O
patients	O
received	O
a	O
total	O
of	O
69	O
cycles	O
of	O
TPFL5	B-DRUG
.	O
	
The	O
MTD	O
was	O
determined	O
to	O
be	O
docetaxel	B-DRUG
60	O
mg	O
/	O
m2	O
.	O
	
Dose-limiting	O
toxicity	O
(	O
DLT	O
)	O
was	O
neutropenia	B-TOXI
.	O
	
Additional	O
significant	O
toxicities	O
at	O
MTD	O
were	O
nausea	B-TOXI
","	O
mucositis	B-TOXI
","	O
diarrhea	B-TOXI
","	O
peripheral	B-TOXI
neuropathy	I-TOXI
","	O
and	O
sodium-wasting	B-TOXI
nephropathy	I-TOXI
.	O
	
The	O
overall	O
response	O
rate	O
to	O
TPFL5	B-DRUG
was	O
100	O
%	O
","	O
which	O
included	O
14	O
of	O
23	O
(	O
61	O
%	O
)	O
clinical	O
CRs	O
and	O
nine	O
of	O
23	O
(	O
39	O
%	O
)	O
clinical	O
PRs	O
.	O
	
Primary-site	O
clinical	O
and	O
pathologic	O
CR	O
rates	O
were	O
19	O
of	O
22	O
(	O
86	O
%	O
)	O
CRs	O
and	O
20	O
of	O
22	O
(	O
91	O
%	O
)	O
CRs	O
","	O
respectively	O
.	O
	
Eight	O
patients	O
had	O
less	O
than	O
a	O
CR	O
in	O
the	O
neck	O
to	O
chemotherapy	O
and	O
","	O
therefore	O
","	O
had	O
postradiation	O
neck	O
dissections	O
","	O
four	O
of	O
which	O
were	O
positive	O
for	O
residual	O
tumor	O
.	O
	
TPFL5	B-DRUG
is	O
a	O
tolerable	O
induction	O
regimen	O
in	O
patients	O
with	O
good	O
performance	O
status	O
.	O
	
The	O
DLT	O
is	O
neutropenia	B-TOXI
with	O
significant	O
mucositis	B-TOXI
","	O
diarrhea	B-TOXI
","	O
peripheral	B-TOXI
neuropathy	I-TOXI
","	O
and	O
sodium-wasting	B-TOXI
nephropathy	I-TOXI
.	O
	
The	O
high	O
response	O
rates	O
to	O
TPFL5	O
justify	O
further	O
evaluation	O
of	O
this	O
combination	O
of	O
agents	O
in	O
the	O
context	O
of	O
formal	O
clinical	O
trials	O
.	O
	
Carboplatin	B-DRUG
plus	O
vinorelbine	B-DRUG
","	O
a	O
new	O
well-tolerated	O
and	O
active	O
regimen	O
for	O
the	O
treatment	O
of	O
extensive-stage	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
:	O
a	O
phase	O
II	O
study.	O
Gruppo	O
Oncologico	O
Centro-Sud-Isole	O
.	O
	
	
To	O
evaluate	O
the	O
activity	O
and	O
toxicity	O
of	O
the	O
combination	O
carboplatin	B-DRUG
plus	O
vinorelbine	B-DRUG
in	O
extensive	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
SCLC	B-CANCER
)	O
.	O
	
A	O
two-stage	O
optimal	O
Simon	O
design	O
was	O
applied	O
.	O
	
To	O
proceed	O
after	O
the	O
first	O
stage	O
","	O
responses	O
from	O
8	O
of	O
11	O
treated	O
patients	O
were	O
needed	O
.	O
	
Overall	O
","	O
31	O
responses	O
of	O
43	O
treated	O
patients	O
were	O
required	O
to	O
comply	O
with	O
the	O
design	O
parameters	O
.	O
	
Inclusion	O
criteria	O
were	O
cytohistologically	O
proven	O
SCLC	B-CANCER
;	O
extensive	O
disease	O
;	O
age	O
of	O
70	O
years	O
or	O
less	O
;	O
Eastern	O
Cooperative	O
Oncology	O
group	O
performance	O
status	O
(	O
ps	O
ECOG	O
)	O
of	O
2	O
or	O
less	O
;	O
normal	O
cardiac	O
","	O
hepatic	O
","	O
renal	O
","	O
and	O
bone	O
marrow	O
functions	O
;	O
and	O
no	O
previous	O
chemotherapy	O
.	O
	
Patients	O
were	O
staged	O
by	O
physical	O
examination	O
;	O
biochemistry	O
;	O
chest	O
radiograph	O
;	O
brain	O
","	O
thoracic	O
;	O
and	O
abdominal	O
computed	O
tomographic	O
(	O
CT	O
)	O
scans	O
","	O
and	O
bone	O
scan	O
.	O
	
All	O
patients	O
received	O
carboplatin	B-DRUG
300	O
mg	O
/	O
m2	O
intravenously	O
(	O
i.v.	O
)	O
day	O
1	O
and	O
vinorelbine	B-DRUG
25	O
mg	O
/	O
m2	O
i.v.	O
on	O
days	O
1	O
and	O
8	O
every	O
4	O
weeks	O
up	O
to	O
six	O
cycles	O
.	O
	
Of	O
43	O
enrolled	O
patients	O
","	O
36	O
were	O
men	O
and	O
7	O
women	O
","	O
with	O
a	O
median	O
age	O
of	O
63	O
years	O
(	O
range	O
","	O
46	O
to	O
70	O
years	O
)	O
.	O
	
All	O
patients	O
were	O
assessable	O
for	O
response	O
and	O
toxicity	O
.	O
	
We	O
observed	O
32	O
(	O
74	O
%	O
)	O
objective	O
responses	O
","	O
with	O
23	O
%	O
complete	O
responses	O
.	O
	
Median	O
time	O
to	O
progression	O
was	O
25	O
weeks	O
","	O
and	O
median	O
survival	O
was	O
37	O
weeks	O
.	O
	
The	O
treatment	O
was	O
well	O
tolerated	O
.	O
	
The	O
reported	O
main	O
toxicities	O
were	O
leukopenia	B-TOXI
grade	O
3	O
in	O
21	O
%	O
of	O
patients	O
and	O
grade	O
4	O
in	O
5	O
%	O
of	O
patients	O
","	O
anemia	B-TOXI
grade	O
2	O
in	O
11	O
%	O
of	O
patients	O
and	O
grade	O
3	O
in	O
2	O
%	O
of	O
patients	O
","	O
and	O
thrombocytopenia	B-TOXI
grade	O
3	O
in	O
7	O
%	O
of	O
patients	O
.	O
	
These	O
data	O
show	O
that	O
carboplatin	B-DRUG
plus	O
vinorelbine	B-DRUG
is	O
an	O
active	O
and	O
well-tolerated	O
regimen	O
in	O
extensive	O
SCLC	B-CANCER
.	O
	
In	O
view	O
of	O
the	O
activity	O
","	O
low	O
toxicity	O
","	O
and	O
ease	O
of	O
administration	O
","	O
it	O
may	O
be	O
a	O
reasonable	O
alternative	O
to	O
more	O
toxic	O
cisplatin-containing	B-DRUG
regimens	O
.	O
	
FEP	B-DRUG
regimen	O
(	O
epidoxorubicin	B-DRUG
","	O
etoposide	B-DRUG
and	O
cisplatin	B-DRUG
)	O
in	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
","	O
with	O
or	O
without	O
low-dose	O
GM-CSF	B-DRUG
:	O
an	O
Italian	O
Trial	O
in	O
Medical	O
Oncology	O
(	O
ITMO	O
)	O
study	O
.	O
	
	
The	O
new	O
regimens	O
developed	O
over	O
the	O
last	O
few	O
years	O
have	O
led	O
to	O
an	O
improvement	O
in	O
the	O
treatment	O
of	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
","	O
and	O
our	O
previous	O
experience	O
confirmed	O
the	O
fact	O
that	O
the	O
combination	O
of	O
etoposide	B-DRUG
","	O
doxorubicin	B-DRUG
and	O
cisplatin	B-DRUG
(	O
EAP	B-DRUG
regimen	O
)	O
is	O
an	O
active	O
treatment	O
that	O
leads	O
to	O
interesting	O
complete	O
remission	O
rates	O
.	O
	
The	O
primary	O
end	O
point	O
of	O
the	O
present	O
multicentre	O
","	O
randomized	O
","	O
parallel-group	O
phase	O
II	O
study	O
was	O
to	O
determine	O
the	O
activity	O
of	O
the	O
simplified	O
2-day	O
EAP	B-DRUG
schedule	O
in	O
patients	O
with	O
locally	O
advanced	O
or	O
metastatic	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
","	O
and	O
to	O
verify	O
whether	O
the	O
addition	O
of	O
low	O
doses	O
of	O
granulocyte-macrophage	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
(	O
GM-CSF	B-DRUG
)	O
made	O
it	O
possible	O
to	O
increase	O
dose	O
intensity	O
.	O
	
Of	O
the	O
62	O
enrolled	O
patients	O
","	O
30	O
were	O
randomized	O
to	O
receive	O
epirubicin	B-DRUG
35	O
mg	O
m	O
(	O
-2	O
)	O
","	O
etoposide	B-DRUG
120	O
mg	O
m	O
(	O
-2	O
)	O
and	O
cisplatin	B-DRUG
45	O
mg	O
m	O
(	O
-2	O
)	O
(	O
FEP	O
)	O
on	O
days	O
1	O
and	O
2	O
every	O
28	O
days	O
and	O
32	O
to	O
receive	O
the	O
same	O
schedule	O
plus	O
subcutaneous	O
GM-CSF	B-DRUG
(	O
molgramostin	B-DRUG
)	O
150	O
microg	O
day	O
(	O
-1	O
)	O
on	O
days	O
5月14日	O
every	O
21	O
days	O
.	O
	
The	O
patients	O
were	O
stratified	O
by	O
age	O
and	O
the	O
number	O
of	O
disease	O
sites	O
.	O
	
The	O
characteristics	O
of	O
the	O
patients	O
were	O
well	O
balanced	O
between	O
the	O
two	O
groups	O
.	O
	
The	O
objective	O
response	O
rate	O
of	O
the	O
patients	O
as	O
a	O
whole	O
was	O
34	O
%	O
(	O
21	O
out	O
of	O
62	O
;	O
95	O
%	O
confidence	O
interval	O
22-46	O
)	O
","	O
with	O
only	O
one	O
complete	O
remission	O
.	O
	
The	O
median	O
response	O
duration	O
was	O
4.5	O
months	O
(	O
range	O
1月24日	O
months	O
)	O
.	O
	
The	O
median	O
time	O
to	O
treatment	O
failure	O
was	O
5	O
months	O
(	O
range	O
1月14日	O
months	O
)	O
","	O
without	O
any	O
difference	O
between	O
the	O
two	O
groups	O
.	O
	
The	O
median	O
survival	O
of	O
the	O
patients	O
as	O
a	O
whole	O
was	O
9	O
months	O
.	O
	
Full	O
doses	O
were	O
administered	O
in	O
92	O
%	O
and	O
94	O
%	O
of	O
the	O
cycles	O
in	O
the	O
control	O
and	O
GM-CSF	B-DRUG
arms	O
respectively	O
.	O
	
The	O
average	O
dose	O
intensity	O
calculated	O
for	O
all	O
drugs	O
was	O
0.96	O
%	O
in	O
the	O
control	O
and	O
1.27	O
%	O
in	O
the	O
GM-CSF	B-DRUG
group	O
.	O
	
CTC-NCI	O
grade	O
3月4日	O
neutropenia	B-TOXI
was	O
reported	O
in	O
39	O
%	O
vs	O
45	O
%	O
of	O
patients	O
","	O
thrombocytopenia	B-TOXI
in	O
11	O
%	O
vs	O
35	O
%	O
(	O
P	O
=	O
0.02	O
)	O
and	O
anaemia	B-TOXI
in	O
7	O
%	O
vs	O
35	O
%	O
(	O
P	O
=	O
0.014	O
)	O
.	O
	
The	O
FEP	O
combination	O
is	O
as	O
active	O
(	O
OR	O
:	O
34	O
%	O
)	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
advanced	B-CANCER
gastric	I-CANCER
cancer	I-CANCER
as	O
the	O
EAP	O
regimen	O
","	O
although	O
it	O
leads	O
to	O
fewer	O
complete	O
remissions	O
.	O
	
The	O
patients	O
randomized	O
to	O
receive	O
low-dose	O
GM-CSF	B-DRUG
achieved	O
a	O
significantly	O
higher	O
dose	O
intensity	O
than	O
controls	O
(	O
P	O
=	O
0.0001	O
)	O
.	O
	
Randomized	O
phase	O
II	O
trial	O
of	O
BCDT	B-DRUG
[	O
carmustine	B-DRUG
(	O
BCNU	B-DRUG
)	O
","	O
cisplatin	B-DRUG
","	O
dacarbazine	B-DRUG
(	O
DTIC	B-DRUG
)	O
and	O
tamoxifen	B-DRUG
]	O
with	O
or	O
without	O
interferon	B-DRUG
alpha	I-DRUG
(	O
IFN-alpha	B-DRUG
)	O
and	O
interleukin	B-DRUG
(	O
IL-2	B-DRUG
)	O
in	O
patients	O
with	O
metastatic	B-CANCER
melanoma	I-CANCER
.	O
	
	
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
in	O
a	O
randomized	O
phase	O
II	O
trial	O
the	O
efficacy	O
and	O
toxicity	O
of	O
combination	O
biochemotherapy	O
compared	O
with	O
chemotherapy	O
alone	O
in	O
patients	O
with	O
metastatic	B-CANCER
melanoma	I-CANCER
.	O
	
Sixty-five	O
patients	O
with	O
metastatic	B-CANCER
melanoma	I-CANCER
(	O
ECOG	O
performance	O
status	O
0	O
or	O
1	O
)	O
were	O
randomized	O
to	O
receive	O
intravenous	O
BCNU	B-CANCER
100	O
mg	O
m	O
(	O
-2	O
)	O
(	O
day	O
1	O
","	O
alternate	O
courses	O
)	O
","	O
cisplatin	B-CANCER
25	O
mg	O
m	O
(	O
-2	O
)	O
(	O
days	O
1月3日	O
)	O
","	O
DTIC	B-CANCER
220	O
mg	O
m	O
(	O
-2	O
)	O
(	O
days	O
1月3日	O
)	O
and	O
oral	O
tamoxifen	B-CANCER
40	O
mg	O
(	O
BCDT	O
regimen	O
)	O
with	O
(	O
n	O
=	O
35	O
)	O
or	O
without	O
(	O
n	O
=	O
30	O
)	O
subcutaneous	O
interleukin	B-CANCER
2	O
(	O
IL-2	O
)	O
18	O
x	O
10	O
(	O
6	O
)	O
iu	O
t.d.s	O
.	O
	
(	O
day	O
=-	O
2	O
)	O
","	O
9	O
x	O
10	O
(	O
6	O
)	O
iu	O
b.d	O
.	O
	
(	O
day	O
=-	O
1	O
and	O
0	O
)	O
and	O
interferon	O
2	O
alpha	O
(	O
IFN-alpha	B-DRUG
)	O
9	O
MU	O
(	O
days	O
1月3日	O
)	O
.	O
	
Evidence	O
for	O
immune	O
activation	O
was	O
determined	O
by	O
flow	O
cytometric	O
analysis	O
of	O
peripheral	O
blood	O
lymphocytes	O
.	O
	
Treatment	O
was	O
repeated	O
every	O
4	O
weeks	O
up	O
to	O
six	O
courses	O
depending	O
on	O
response	O
.	O
	
The	O
overall	O
response	O
rate	O
of	O
BCDT	B-DRUG
with	O
IL-2	B-DRUG
/	O
IFN-alpha	B-DRUG
was	O
23	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
10-40	O
%	O
]	O
with	O
one	O
complete	O
response	O
(	O
CR	O
)	O
and	O
seven	O
partial	O
responses	O
(	O
PR	O
)	O
","	O
and	O
for	O
BCDT	O
alone	O
27	O
%	O
(	O
95	O
%	O
CI	O
12-46	O
%	O
)	O
with	O
eight	O
PRs	O
;	O
the	O
median	O
durations	O
of	O
response	O
were	O
2.8	O
months	O
and	O
2.5	O
months	O
respectively	O
.	O
	
Sites	O
of	O
response	O
were	O
similar	O
in	O
both	O
groups	O
.	O
	
There	O
was	O
no	O
difference	O
between	O
the	O
two	O
groups	O
in	O
progression-free	O
survival	O
or	O
overall	O
survival	O
(	O
median	O
survival	O
5	O
months	O
for	O
BCDT	B-DRUG
with	O
IL-2	B-DRUG
/	O
IFNalpha	B-DRUG
and	O
5.5	O
months	O
for	O
BCDT	B-DRUG
alone	O
)	O
.	O
	
Although	O
3	O
days	O
of	O
subcutaneous	O
IL-2	B-DRUG
resulted	O
in	O
significant	O
lymphopenia	B-TOXI
","	O
evidence	O
of	O
immune	O
activation	O
was	O
indicated	O
by	O
a	O
significant	O
rise	O
in	O
the	O
percentage	O
of	O
CD56-	O
(	O
NK	O
cells	O
)	O
and	O
CD3	O
/	O
HLA-DR-positive	O
(	O
activated	O
T	O
cells	O
)	O
subsets	O
","	O
without	O
any	O
change	O
in	O
the	O
percentage	O
of	O
CD4	O
or	O
CD4	O
T-cell	O
subsets	O
.	O
	
Toxicity	O
assessment	O
revealed	O
a	O
significantly	O
higher	O
incidence	O
of	O
severe	O
thrombocytopenia	B-TOXI
in	O
patients	O
treated	O
with	O
combination	O
chemotherapy	O
than	O
with	O
chemotherapy	O
alone	O
(	O
37	O
%	O
vs	O
13	O
%	O
","	O
P	O
=	O
0.03	O
)	O
and	O
a	O
higher	O
incidence	O
of	O
grade	O
3	O
/	O
4	O
flu-like	O
symptoms	B-TOXI
(	O
20	O
%	O
vs	O
10	O
%	O
)	O
and	O
fatigue	B-TOXI
(	O
26	O
%	O
vs	O
13	O
%	O
)	O
.	O
	
The	O
addition	O
of	O
subcutaneous	O
IL-2	B-DRUG
and	O
IFNalpha	B-DRUG
to	O
BCDT	B-DRUG
chemotherapy	O
in	O
a	O
randomized	O
phase	O
II	O
trial	O
resulted	O
in	O
immune	O
activation	O
but	O
did	O
not	O
improve	O
response	O
rates	O
in	O
patients	O
with	O
metastatic	B-CANCER
melanoma	I-CANCER
","	O
and	O
indeed	O
may	O
increase	O
some	O
treatment-related	O
toxicity	O
.	O
	
Phase	O
II	O
trial	O
of	O
paclitaxel	B-DRUG
","	O
fluorouracil	B-DRUG
","	O
and	O
cisplatin	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
esophagus	I-CANCER
.	O
	
	
We	O
have	O
previously	O
identified	O
paclitaxel	B-DRUG
as	O
an	O
active	O
single	O
agent	O
in	O
the	O
treatment	O
of	O
esophageal	B-CANCER
cancer	I-CANCER
.	O
	
We	O
performed	O
a	O
phase	O
II	O
trial	O
of	O
paclitaxel	B-DRUG
in	O
combination	O
with	O
cisplatin	B-DRUG
and	O
fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
conventionally	O
used	O
chemotherapy	O
for	O
esophageal	B-CANCER
cancer	I-CANCER
.	O
	
The	O
antitumor	O
response	O
","	O
toxicity	O
","	O
and	O
survival	O
of	O
patients	O
treated	O
with	O
the	O
three-drug	O
regimen	O
were	O
evaluated	O
.	O
	
Sixty-one	O
patients	O
with	O
advanced	O
","	O
surgically	O
unresectable	O
","	O
or	O
metastatic	B-CANCER
squamous	I-CANCER
cell	I-CANCER
or	I-CANCER
adenocarcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
esophagus	I-CANCER
were	O
treated	O
.	O
	
No	O
prior	O
chemotherapy	O
was	O
allowed	O
.	O
	
Thirty	O
patients	O
had	O
adenocarcinoma	B-CANCER
and	O
31	O
patients	O
had	O
squamous	B-CANCER
cell	I-CANCER
carcinoma	I-CANCER
.	O
	
The	O
majority	O
(	O
47	O
patients	O
;	O
77	O
%	O
)	O
had	O
metastatic	O
disease	O
and	O
14	O
patients	O
(	O
23	O
%	O
)	O
had	O
an	O
unresectable	O
primary	O
or	O
locally	O
recurrent	O
tumor	O
.	O
	
Patients	O
received	O
paclitaxel	B-DRUG
175	O
mg	O
/	O
m2	O
by	O
3-hour	O
infusion	O
day	O
1	O
;	O
cisplatin	O
20	O
mg	O
/	O
m2	O
daily	O
days	O
1	O
through	O
5	O
","	O
and	O
5-FU	B-DRUG
by	O
continuous	O
infusion	O
at	O
a	O
dose	O
of	O
"1,000"	O
mg	O
/	O
m2	O
daily	O
days	O
1	O
through	O
5	O
Because	O
of	O
toxicity	O
observed	O
in	O
the	O
first	O
10	O
patients	O
treated	O
","	O
the	O
starting	O
dose	O
of	O
5-FU	B-DRUG
was	O
subsequently	O
reduced	O
to	O
750	O
mg	O
/	O
m2	O
daily	O
in	O
the	O
remaining	O
patients	O
.	O
	
A	O
planned	O
attenuation	O
of	O
cisplatin	B-DRUG
to	O
15	O
mg	O
/	O
m2	O
daily	O
was	O
made	O
after	O
the	O
first	O
three	O
cycles	O
.	O
	
Granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
(	O
G-CSF	B-DRUG
)	O
was	O
not	O
routinely	O
administered	O
unless	O
the	O
patient	O
had	O
an	O
episode	O
of	O
febrile	B-TOXI
neutropenia	I-TOXI
or	O
prolonged	O
grade	O
4	O
neutropenia	B-TOXI
.	O
	
Treatment	O
was	O
recycled	O
every	O
28	O
days	O
.	O
	
Sixty-one	O
patients	O
completed	O
a	O
median	O
of	O
five	O
cycles	O
","	O
and	O
60	O
patients	O
were	O
assessable	O
for	O
response	O
.	O
	
Major	O
responses	O
were	O
seen	O
in	O
29	O
patients	O
(	O
48	O
%	O
;	O
95	O
%	O
confidence	O
intervals	O
","	O
35	O
to	O
61	O
)	O
","	O
which	O
included	O
seven	O
complete	O
responses	O
(	O
12	O
%	O
)	O
.	O
	
Comparable	O
response	O
rates	O
were	O
seen	O
for	O
patients	O
with	O
adenocarcinoma	B-TOXI
(	O
46	O
%	O
)	O
and	O
those	O
with	O
squamous	B-TOXI
carcinoma	I-TOXI
(	O
50	O
%	O
)	O
","	O
and	O
for	O
patients	O
with	O
metastatic	O
disease	O
(	O
22	O
of	O
46	O
patients	O
;	O
48	O
%	O
)	O
and	O
those	O
with	O
locally	O
advanced	O
disease	O
(	O
seven	O
of	O
14	O
patients	O
;	O
50	O
%	O
)	O
.	O
	
A	O
significantly	O
higher	O
complete	O
response	O
rate	O
was	O
observed	O
in	O
patients	O
with	O
squamous	B-CANCER
carcinoma	I-CANCER
(	O
20	O
%	O
)	O
compared	O
with	O
those	O
with	O
adenocarcinoma	B-CANCER
(	O
3	O
%	O
;	O
chi2	O
P=.04	O
)	O
.	O
	
The	O
median	O
duration	O
of	O
response	O
was	O
5.7	O
months	O
(	O
range	O
","	O
1	O
to	O
18.6	O
months	O
)	O
.	O
	
Median	O
survival	O
was	O
10.8	O
months	O
(	O
range	O
","	O
1.5	O
to	O
25	O
months	O
)	O
.	O
	
Toxicity	O
was	O
severe	O
but	O
manageable	O
with	O
dose	O
attenuation	O
","	O
and	O
included	O
18	O
%	O
of	O
patients	O
with	O
grade	O
3	O
neurologic	B-TOXI
toxicity	I-TOXI
.	O
	
Twenty-eight	O
patients	O
(	O
46	O
%	O
)	O
required	O
a	O
dose	O
attenuation	O
for	O
toxicity	O
","	O
and	O
42	O
of	O
275	O
treatment	O
cycles	O
(	O
15	O
%	O
)	O
required	O
a	O
dose	O
attenuation	O
.	O
	
Twenty-nine	O
patients	O
(	O
48	O
%	O
)	O
required	O
hospitalization	O
for	O
toxicity	O
","	O
which	O
included	O
11	O
patients	O
for	O
neutropenic	B-TOXI
fever	I-TOXI
(	O
18	O
%	O
)	O
.	O
	
There	O
were	O
no	O
treatment-related	O
deaths	B-TOXI
.	O
	
The	O
combination	O
of	O
paclitaxel	B-DRUG
","	O
cisplatin	B-DRUG
","	O
and	O
5-FU	B-DRUG
has	O
substantial	O
antitumor	O
activity	O
in	O
metastatic	B-CANCER
esophageal	I-CANCER
carcinoma	I-CANCER
","	O
with	O
a	O
remarkable	O
complete	O
response	O
rate	O
noted	O
in	O
patients	O
with	O
squamous	B-CANCER
carcinoma	I-CANCER
.	O
	
Paclitaxel	B-DRUG
is	O
an	O
important	O
new	O
agent	O
in	O
the	O
treatment	O
of	O
esophageal	B-CANCER
carcinoma	I-CANCER
","	O
and	O
further	O
evaluation	O
of	O
this	O
agent	O
in	O
combination	O
chemotherapy	O
is	O
warranted	O
.	O
	
Given	O
the	O
toxicity	O
associated	O
with	O
the	O
current	O
regimen	O
","	O
the	O
optimal	O
dose	O
and	O
schedule	O
of	O
paclitaxel	B-DRUG
in	O
combination	O
chemotherapy	O
remain	O
to	O
be	O
established	O
.	O
	
Phase	O
II	O
trial	O
of	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
in	O
the	O
treatment	O
of	O
advanced	B-CANCER
urothelial	I-CANCER
carcinoma	I-CANCER
.	O
	
	
Both	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
have	O
single-agent	O
activity	O
against	O
carcinoma	B-CANCER
of	I-CANCER
the	I-CANCER
urothelium	I-CANCER
.	O
	
We	O
evaluated	O
the	O
combination	O
of	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
in	O
the	O
treatment	O
of	O
advanced	B-CANCER
cancers	I-CANCER
of	I-CANCER
the	I-CANCER
urothelium	I-CANCER
.	O
	
Patients	O
with	O
cancers	B-CANCER
of	I-CANCER
the	I-CANCER
urothelium	I-CANCER
who	O
had	O
no	O
prior	O
chemotherapy	O
(	O
prior	O
adjuvant	O
chemotherapy	O
&	O
gt	O
;	O
6	O
months	O
allowed	O
)	O
were	O
eligible	O
for	O
treatment	O
.	O
	
Eligibility	O
requirements	O
were	O
performance	O
status	O
of	O
2	O
or	O
less	O
","	O
creatinine	O
level	O
less	O
than	O
2	O
mg	O
/	O
dL	O
","	O
granulocyte	O
count	O
(	O
AGC	O
)	O
"1,500"	O
/	O
microL	O
or	O
greater	O
","	O
platelet	O
count	O
"100,000"	O
/	O
microL	O
or	O
greater	O
","	O
and	O
total	O
bilirubin	O
level	O
less	O
than	O
1.5	O
mg	O
/	O
dL	O
.	O
	
Paclitaxel	B-DRUG
200	O
mg	O
/	O
m2	O
followed	O
by	O
carboplatin	B-DRUG
(	O
area	O
under	O
the	O
curve	O
[	O
AUC	O
]	O
5	O
","	O
Calvert	O
formula	O
)	O
were	O
administered	O
every	O
21	O
days	O
.	O
	
Patients	O
were	O
evaluated	O
for	O
toxicity	O
weekly	O
and	O
assessed	O
for	O
response	O
every	O
6	O
weeks	O
.	O
	
Thirty-six	O
patients	O
were	O
entered	O
onto	O
the	O
study	O
and	O
35	O
patients	O
were	O
assessable	O
for	O
response	O
.	O
	
A	O
total	O
of	O
184	O
cycles	O
were	O
administered	O
(	O
median	O
","	O
six	O
cycles	O
per	O
patient	O
)	O
.	O
	
Nine	O
patients	O
required	O
one	O
dose	O
reduction	O
","	O
and	O
seven	O
patients	O
required	O
two	O
dose	O
reductions	O
for	O
a	O
nadir	O
AGC	O
less	O
than	O
500	O
/	O
microL	O
","	O
with	O
only	O
one	O
episode	O
of	O
febrile	B-TOXI
neutropenia	I-TOXI
and	O
sepsis	B-TOXI
.	O
	
Myalgias	B-TOXI
and	O
arthralgias	B-TOXI
of	O
grades	O
1	O
to	O
2	O
occurred	O
in	O
16	O
patients	O
and	O
usually	O
lasted	O
2	O
to	O
3	O
days	O
after	O
treatment	O
.	O
	
There	O
were	O
no	O
treatment	O
delays	O
because	O
of	O
toxicity	O
.	O
	
There	O
were	O
18	O
responses	O
;	O
seven	O
complete	O
responses	O
(	O
CRs	O
)	O
and	O
11	O
partial	O
responses	O
(	O
PRs	O
)	O
(	O
response	O
rate	O
51.5	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
","	O
35	O
to	O
68	O
)	O
.	O
	
Median	O
response	O
durations	O
for	O
CR	O
and	O
PR	O
were	O
6	O
and	O
4	O
months	O
","	O
respectively	O
.	O
	
Overall	O
median	O
survival	O
was	O
9.5	O
months	O
.	O
	
The	O
combination	O
of	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
is	O
an	O
active	O
and	O
well-tolerated	O
regimen	O
for	O
the	O
treatment	O
of	O
advanced	B-CANCER
urothelial	I-CANCER
carcinoma	I-CANCER
.	O
	
Because	O
of	O
the	O
modest	O
toxicity	O
of	O
this	O
combination	O
","	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
should	O
be	O
considered	O
for	O
addition	O
to	O
other	O
agents	O
with	O
activity	O
in	O
urothelial	B-CANCER
carcinomas	I-CANCER
.	O
	
Phase	O
II	O
study	O
of	O
docetaxel	B-DRUG
and	O
cisplatin	B-DRUG
in	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
Docetaxel	B-DRUG
(	O
Taxotere	B-DRUG
","	O
Rhone-Poulenc	O
Rorer	O
","	O
Antony	O
","	O
France	O
)	O
and	O
cisplatin	B-DRUG
are	O
two	O
of	O
the	O
most	O
active	O
single	O
agents	O
used	O
in	O
the	O
treatment	O
of	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
.	O
	
A	O
recently	O
reported	O
phase	O
I	O
study	O
of	O
the	O
combination	O
of	O
docetaxel	B-DRUG
and	O
cisplatin	B-DRUG
recommended	O
a	O
dose	O
of	O
75	O
mg	O
/	O
m2	O
of	O
both	O
drugs	O
every	O
3	O
weeks	O
for	O
subsequent	O
phase	O
II	O
study	O
.	O
	
Eligible	O
patients	O
were	O
aged	O
18	O
to	O
75	O
years	O
with	O
a	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
performance	O
status	O
&	O
lt	O
;	O
or	O
=	O
2	O
and	O
life	O
expectancy	O
&	O
gt	O
;	O
or	O
=	O
12	O
weeks	O
","	O
with	O
metastatic	O
and	O
/	O
or	O
locally	O
advanced	B-CANCER
NSCLC	I-CANCER
proven	O
histologically	O
or	O
cytologically	O
.	O
	
Patients	O
were	O
not	O
permitted	O
to	O
have	O
received	O
prior	O
chemotherapy	O
","	O
extensive	O
radiotherapy	O
","	O
or	O
any	O
radiotherapy	O
to	O
the	O
target	B-TOXI
lesion	I-TOXI
and	O
must	O
have	O
had	O
measurable	O
disease	O
.	O
	
Concurrent	O
treatment	O
with	O
colony-stimulating	B-DRUG
factors	I-DRUG
(	O
CSFs	B-DRUG
)	O
or	O
prophylactic	B-DRUG
antibiotics	I-DRUG
was	O
not	O
permitted	O
.	O
	
Docetaxel	B-DRUG
(	O
75	O
mg	O
/	O
m2	O
)	O
in	O
250	O
mL	O
5	O
%	O
dextrose	B-DRUG
was	O
given	O
intravenously	O
(	O
i.v.	O
)	O
over	O
1	O
hour	O
immediately	O
before	O
cisplatin	B-DRUG
(	O
75	O
mg	O
/	O
m2	O
)	O
in	O
500	O
mL	O
normal	O
saline	O
given	O
i.v.	O
over	O
1	O
hour	O
in	O
3-week	O
cycles	O
.	O
	
Premedication	O
included	O
ondansetron	B-DRUG
","	O
dexamethasone	B-DRUG
","	O
promethazine	B-DRUG
","	O
and	O
standard	O
hyperhydration	O
with	O
magnesium	B-DRUG
supplementation	O
.	O
	
A	O
total	O
of	O
47	O
patients	O
","	O
two	O
thirds	O
of	O
whom	O
had	O
metastatic	O
disease	O
","	O
were	O
entered	O
onto	O
this	O
phase	O
II	O
study	O
.	O
	
The	O
majority	O
of	O
patients	O
were	O
male	O
(	O
72	O
%	O
)	O
and	O
of	O
good	O
(	O
WHO	O
0	O
to	O
1	O
)	O
performance	O
status	O
(	O
85	O
%	O
)	O
.	O
	
All	O
47	O
patients	O
were	O
assessable	O
for	O
toxicity	O
and	O
36	O
were	O
for	O
response	O
.	O
	
Three	O
patients	O
were	O
ineligible	O
and	O
eight	O
(	O
17	O
%	O
)	O
discontinued	O
treatment	O
because	O
of	O
significant	O
toxicity	O
.	O
	
In	O
assessable	O
patients	O
","	O
the	O
overall	O
objective	O
response	O
rate	O
was	O
38.9	O
%	O
(	O
95	O
%	O
confidence	O
limits	O
[	O
CL	O
]	O
","	O
23.1	O
%	O
to	O
56.5	O
%	O
)	O
","	O
36.1	O
%	O
had	O
stable	O
disease	O
","	O
and	O
25	O
%	O
progressive	O
disease	O
.	O
	
On	O
an	O
intention-to-treat	O
analysis	O
","	O
the	O
objective	O
response	O
rate	O
was	O
29.8	O
%	O
.	O
	
Median	O
survival	O
was	O
9.6	O
months	O
and	O
estimated	O
1-year	O
survival	O
was	O
33	O
%	O
.	O
	
Significant	O
(	O
grade	O
3	O
/	O
4	O
)	O
toxicities	O
included	O
nausea	B-TOXI
(	O
26	O
%	O
)	O
","	O
hypotension	B-TOXI
(	O
15	O
%	O
)	O
","	O
diarrhea	B-TOXI
(	O
13	O
%	O
)	O
","	O
and	O
dyspnea	B-TOXI
mainly	O
related	O
to	O
chest	B-TOXI
infection	I-TOXI
(	O
13	O
%	O
)	O
.	O
	
One	O
patient	O
experienced	O
National	O
Cancer	O
Institute	O
(	O
NCI	O
)	O
grade	O
3	O
neurosensory	B-TOXI
toxicity	I-TOXI
after	O
eight	O
cycles	O
.	O
	
Grade	O
3	O
/	O
4	O
neutropenia	B-TOXI
was	O
common	O
and	O
occurred	O
in	O
87	O
%	O
of	O
patients	O
","	O
but	O
thrombocytopenia	B-TOXI
&	O
gt	O
;	O
or	O
=	O
grade	O
3	O
was	O
rare	O
(	O
one	O
patient	O
)	O
.	O
	
Significant	O
(	O
grade	O
3	O
/	O
4	O
)	O
abnormalities	B-TOXI
of	I-TOXI
magnesium	I-TOXI
levels	I-TOXI
were	O
common	O
(	O
24	O
%	O
)	O
.	O
	
Febrile	B-TOXI
neutropenia	I-TOXI
occurred	O
in	O
13	O
%	O
of	O
patients	O
and	O
neutropenic	B-TOXI
infection	I-TOXI
in	O
11	O
%	O
","	O
contributing	O
to	O
two	O
treatment-related	O
deaths	B-TOXI
.	O
	
No	B-TOXI
neutropenic	I-TOXI
enterocolitis	I-TOXI
or	O
severe	B-TOXI
fluid	I-TOXI
retention	I-TOXI
was	O
reported	O
.	O
	
Compared	O
with	O
other	O
active	O
regimens	O
used	O
in	O
this	O
setting	O
","	O
the	O
combination	O
of	O
docetaxel	B-DRUG
and	O
cisplatin	B-DRUG
in	O
advanced	B-CANCER
NSCLC	I-CANCER
is	O
an	O
active	O
regimen	O
with	O
a	O
similar	O
toxicity	O
profile	O
to	O
other	O
combination	O
regimens	O
.	O
	
Phase	O
I	O
trial	O
of	O
retinoic	B-DRUG
acid	I-DRUG
and	O
cis-platinum	B-DRUG
for	O
advanced	B-CANCER
squamous	I-CANCER
cell	I-CANCER
cancer	I-CANCER
of	I-CANCER
the	I-CANCER
head	I-CANCER
and	I-CANCER
neck	I-CANCER
based	O
on	O
experimental	O
evidence	O
of	O
drug	O
synergism	O
.	O
	
	
Cis-platinum	B-DRUG
and	O
13-cis-retinoic	B-DRUG
acid	I-DRUG
have	O
received	O
much	O
attention	O
in	O
the	O
treatment	O
of	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
squamous	I-CANCER
cell	I-CANCER
cancer	I-CANCER
.	O
	
Even	O
though	O
they	O
have	O
different	O
mechanisms	O
of	O
action	O
","	O
little	O
information	O
is	O
available	O
on	O
their	O
interaction	O
.	O
	
This	O
paper	O
reviews	O
experimental	O
evidence	O
for	O
retinoic	O
acid-cis-platinum	B-DRUG
synergy	O
and	O
presents	O
toxicity	O
data	O
from	O
patients	O
with	O
stage	O
IV	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
squamous	I-CANCER
cell	I-CANCER
cancer	I-CANCER
participating	O
in	O
a	O
phase	O
I	O
trial	O
combining	O
13-cis-retinoic	B-DRUG
acid	I-DRUG
and	O
cis-platinum	B-DRUG
.	O
	
Patients	O
were	O
given	O
13-cis-retinoic	O
acid	O
orally	O
daily	O
for	O
7	O
days	O
before	O
and	O
daily	O
during	O
high-dose	O
(	O
150	O
mg	O
/	O
m2	O
per	O
week	O
for	O
4	O
weeks	O
)	O
intraarterial	O
cis-platinum	B-DRUG
treatment	O
with	O
concurrent	O
radiation	O
.	O
	
Toxicity	O
was	O
scored	O
with	O
use	O
of	O
the	O
cancer	O
and	O
leukemia	B-CANCER
group	O
B	O
scale	O
.	O
	
In	O
the	O
phase	O
I	O
clinical	O
trial	O
","	O
15	O
patients	O
were	O
treated	O
to	O
determine	O
a	O
maximum	O
tolerated	O
dosage	O
for	O
13-cis-retinoic	B-DRUG
acid	I-DRUG
of	O
20	O
mg	O
/	O
day	O
.	O
	
Grade	O
4	O
hematologic	B-TOXI
toxicity	I-TOXI
was	O
dose	O
limiting	O
in	O
3	O
of	O
8	O
patients	O
treated	O
with	O
40	O
mg	O
/	O
day	O
and	O
in	O
1	O
patient	O
treated	O
with	O
60	O
mg	O
/	O
day	O
.	O
	
There	O
were	O
no	O
deaths	O
caused	O
by	O
toxicity	O
;	O
12	O
of	O
the	O
15	O
patients	O
received	O
all	O
four	O
weekly	O
doses	O
and	O
the	O
remaining	O
3	O
received	O
three	O
doses	O
.	O
	
Of	O
10	O
patients	O
with	O
fully	O
evaluable	O
data	O
","	O
all	O
achieved	O
a	O
complete	O
response	O
at	O
the	O
primary	O
site	O
and	O
9	O
had	O
a	O
complete	O
response	O
in	O
the	O
neck	O
.	O
	
One	O
patient	O
had	O
persistent	O
neck	O
disease	O
after	O
chemoradiation	O
","	O
and	O
this	O
tumor	O
was	O
removed	O
with	O
neck	O
dissection	O
.	O
	
13-Cis-retinoic	B-DRUG
acid	I-DRUG
and	O
cis-platinum	B-DRUG
are	O
strongly	O
synergistic	O
against	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
squamous	I-CANCER
cell	I-CANCER
cancer	I-CANCER
in	O
vitro	O
.	O
	
Pretreatment	O
with	O
retinoic	B-DRUG
acid	I-DRUG
results	O
in	O
stronger	O
synergy	O
than	O
concurrent	O
drug	O
exposure	O
alone	O
.	O
	
Preliminary	O
clinical	O
experience	O
with	O
combined	O
retinoic	B-DRUG
acid	I-DRUG
and	O
cis-platinum	B-DRUG
in	O
a	O
design	O
that	O
parallels	O
the	O
in	O
vitro	O
study	O
indicates	O
that	O
toxicity	O
is	O
acceptable	O
with	O
13-cis-retinoic	B-DRUG
acid	I-DRUG
dosages	O
of	O
20	O
mg	O
/	O
day	O
in	O
a	O
high-dose-intensity	O
intraarterial	O
chemoradiation	O
regimen	O
.	O
	
Cyclophosphamide	B-DRUG
","	O
methotrexate	B-DRUG
and	O
infusional	O
5-fluorouracil	B-DRUG
(	O
infusional	O
CMF	B-DRUG
)	O
in	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
	
Bolus	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
is	O
a	O
phase-specific	O
drug	O
with	O
a	O
short	O
plasma	O
half-life	O
that	O
is	O
used	O
in	O
combination	O
with	O
bolus	O
cyclophosphamide	B-DRUG
and	O
methotrexate	B-DRUG
in	O
the	O
treatment	O
of	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
The	O
efficacy	O
of	O
5-FU	B-DRUG
can	O
be	O
improved	O
by	O
continuous	O
intravenous	O
infusion	O
using	O
portable	O
infusion	O
pumps	O
(	O
infusional	O
5-FU	B-DRUG
)	O
.	O
	
Infusional	O
5-FU	B-DRUG
","	O
200	O
mg	O
m	O
(	O
-2	O
)	O
day	O
(	O
-1	O
)	O
","	O
in	O
combination	O
with	O
standard	O
doses	O
of	O
bolus	O
cyclophosphamide	B-DRUG
and	O
methotrexate	B-DRUG
","	O
was	O
evaluated	O
in	O
a	O
phase	O
I	O
/	O
II	O
dose-finding	O
study	O
.	O
	
The	O
cyclophosphamide	B-DRUG
and	O
methotrexate	B-DRUG
were	O
administered	O
in	O
28-day	O
cycles	O
as	O
follows	O
:	O
cohort	O
1	O
","	O
cyclophosphamide	B-DRUG
600	O
mg	O
m	O
(	O
-2	O
)	O
","	O
days	O
1	O
and	O
8	O
","	O
and	O
methotrexate	B-DRUG
40	O
mg	O
m	O
(	O
-2	O
)	O
","	O
day	O
1	O
;	O
cohort	O
2	O
","	O
cyclophosphamide	B-DRUG
400	O
mg	O
m	O
(	O
-2	O
)	O
","	O
days	O
1	O
and	O
8	O
","	O
and	O
methotrexate	B-DRUG
40	O
mg	O
m	O
(	O
-2	O
)	O
","	O
day	O
1	O
;	O
cohort	O
3	O
","	O
cyclophosphamide	B-DRUG
480	O
mg	O
(	O
m-2	O
)	O
","	O
days	O
1	O
and	O
8	O
","	O
and	O
methotrexate	B-DRUG
40	O
mg	O
m	O
(	O
-2	O
)	O
","	O
day	O
1	O
;	O
cohort	O
4	O
","	O
cyclophosphamide	B-DRUG
480	O
mg	O
m	O
(	O
-2	O
)	O
","	O
days	O
1	O
and	O
8	O
","	O
and	O
methotrexate	B-DRUG
40	O
mg	O
m	O
(	O
-2	O
)	O
","	O
days	O
1	O
and	O
8	O
Median	O
overall	O
survival	O
was	O
10	O
months	O
(	O
range	O
3月21日	O
months	O
)	O
.	O
	
Objective	O
tumour	O
responses	O
were	O
seen	O
in	O
9	O
of	O
25	O
patients	O
(	O
36	O
%	O
","	O
95	O
%	O
CI	O
18-58	O
%	O
)	O
","	O
including	O
3	O
of	O
13	O
patients	O
(	O
23	O
%	O
)	O
previously	O
treated	O
for	O
metastatic	O
disease	O
.	O
	
Cohorts	O
1	O
and	O
4	O
proved	O
to	O
be	O
too	O
toxic	O
","	O
with	O
five	O
of	O
six	O
patients	O
in	O
cohort	O
1	O
and	O
three	O
of	O
four	O
in	O
cohort	O
4	O
developing	O
grade	O
III	O
/	O
IV	O
neutropenia	B-TOXI
.	O
	
The	O
dose	O
intensity	O
of	O
cyclophosphamide	B-DRUG
achieved	O
was	O
as	O
follows	O
:	O
cohort	O
1	O
","	O
82	O
%	O
;	O
cohort	O
2	O
","	O
86	O
%	O
;	O
cohort	O
3	O
","	O
97	O
%	O
;	O
cohort	O
4	O
","	O
90	O
%	O
.	O
	
Infusional	O
5-FU	B-DRUG
can	O
be	O
administered	O
safely	O
and	O
is	O
effective	O
in	O
combination	O
with	O
cyclophosphamide	B-DRUG
480	O
mg	O
m	O
(	O
-2	O
)	O
","	O
days	O
1	O
and	O
8	O
","	O
and	O
methotrexate	B-DRUG
40	O
mg	O
m	O
(	O
-2	O
)	O
","	O
day	O
1	O
","	O
in	O
the	O
treatment	O
of	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
in	O
patients	O
with	O
metastatic	B-CANCER
urothelial	I-CANCER
cancer	I-CANCER
:	O
results	O
of	O
a	O
phase	O
II	O
trial	O
.	O
	
	
The	O
present	O
phase	O
II	O
trial	O
was	O
undertaken	O
to	O
assess	O
the	O
efficacy	O
and	O
toxicity	O
of	O
a	O
combination	O
of	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
as	O
first-line	O
chemotherapy	O
in	O
patients	O
with	O
metastatic	B-CANCER
transitional	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
urothelium	I-CANCER
.	O
	
Twenty	O
patients	O
(	O
age	O
range	O
50-79	O
years	O
;	O
inclusion	O
criteria	O
:	O
WHO	O
performance	O
status	O
0-2	O
","	O
no	O
previous	O
cytotoxic	O
treatment	O
)	O
with	O
metastatic	B-CANCER
transitional	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
of	I-CANCER
the	I-CANCER
urothelium	I-CANCER
were	O
recruited	O
and	O
received	O
cytotoxic	O
treatment	O
with	O
paclitaxel	B-DRUG
at	O
a	O
dosage	O
of	O
175	O
mg	O
m	O
(	O
-2	O
)	O
administered	O
over	O
a	O
3-h	O
infusion	O
and	O
carboplatin	B-DRUG
given	O
at	O
an	O
AUC	O
of	O
5	O
mg	O
ml	O
(	O
-1	O
)	O
min	O
(	O
according	O
to	O
creatinine	O
clearance	O
)	O
administered	O
every	O
21	O
days	O
.	O
	
A	O
total	O
of	O
65	O
%	O
of	O
patients	O
achieved	O
remissions	O
(	O
CR+PR	O
)	O
","	O
with	O
CR	O
occurring	O
in	O
40	O
%	O
of	O
patients	O
.	O
	
A	O
further	O
15	O
%	O
of	O
patients	O
experienced	O
stable	O
disease	O
.	O
	
Remissions	O
occurred	O
after	O
2.4	O
=+	O
/	O
=-	O
0.8	O
(	O
mean	O
=+	O
/	O
=-	O
standard	O
deviation	O
;	O
range	O
two	O
to	O
four	O
)	O
treatment	O
cycles	O
.	O
	
The	O
mean	O
duration	O
of	O
responses	O
(	O
CR+PR	O
)	O
was	O
8.5	O
=+	O
/	O
=-	O
5.5	O
months	O
.	O
	
After	O
a	O
mean	O
observation	O
period	O
of	O
11.4	O
=+	O
/	O
=-	O
4.8	O
months	O
","	O
16	O
patients	O
(	O
80	O
%	O
)	O
are	O
alive	O
.	O
	
Toxicity	O
included	O
alopecia	B-TOXI
of	O
WHO	O
grade	O
3	O
in	O
all	O
patients	O
","	O
leucopenia	B-TOXI
of	O
WHO	O
grades	O
1	O
and	O
2	O
in	O
ten	O
patients	O
","	O
grade	O
3	O
in	O
eight	O
and	O
grade	O
4	O
in	O
two	O
patients	O
and	O
","	O
finally	O
","	O
severe	B-TOXI
thrombocytopenia	I-TOXI
grade	O
3	O
in	O
only	O
three	O
patients	O
.	O
	
Non-haematological	B-TOXI
toxicity	I-TOXI
consisted	O
of	O
polyneuropathy	B-TOXI
of	O
WHO	O
grade	O
1	O
in	O
13	O
patients	O
and	O
grade	O
2	O
in	O
five	O
patients	O
.	O
	
We	O
thus	O
conclude	O
that	O
a	O
combination	O
of	O
paclitaxel	B-DRUG
and	O
carboplatin	B-DRUG
at	O
the	O
given	O
dosage	O
and	O
schedule	O
constitutes	O
an	O
active	O
","	O
well-tolerated	O
first-line	O
cytotoxic	O
treatment	O
for	O
patients	O
with	O
metastatic	B-CANCER
urothelial	I-CANCER
cancer	I-CANCER
.	O
	
Effective	O
treatment	O
of	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
with	O
vinorelbine	B-DRUG
","	O
5-fluorouracil	B-DRUG
and	O
l-leucovorin	B-DRUG
plus	O
human	B-DRUG
granulocyte	I-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
.	O
	
	
A	O
phase	O
II	O
trial	O
was	O
performed	O
to	O
investigate	O
the	O
efficacy	O
and	O
tolerance	O
of	O
vinorelbine	B-DRUG
(	O
VNB	O
)	O
","	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
","	O
l-leucovorin	B-DRUG
(	O
LLV	B-DRUG
)	O
and	O
recombinant	O
human	O
granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
(	O
G-CSF	B-DRUG
)	O
in	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Between	O
August	O
1994	O
and	O
October	O
1996	O
","	O
53	O
patients	O
entered	O
this	O
trial	O
.	O
	
Thirty-seven	O
patients	O
were	O
previously	O
untreated	O
and	O
16	O
patients	O
had	O
failed	O
previous	O
palliative	O
chemotherapy	O
with	O
(	O
n	O
=	O
12	O
)	O
or	O
without	O
anthracyclines	B-DRUG
(	O
n	O
=	O
4	O
)	O
.	O
	
Therapy	O
consisted	O
of	O
VNB	O
40	O
mg	O
m	O
(	O
-2	O
)	O
diluted	O
in	O
250	O
ml	O
of	O
saline	O
infused	O
over	O
30	O
min	O
on	O
days	O
1	O
and	O
14	O
and	O
LLV	O
100	O
mg	O
m	O
(	O
-2	O
)	O
administered	O
by	O
intravenous	O
bolus	O
injection	O
and	O
5-FU	B-DRUG
400	O
mg	O
m	O
(	O
-2	O
)	O
diluted	O
in	O
500	O
ml	O
of	O
saline	O
infused	O
over	O
2	O
h	O
","	O
both	O
given	O
on	O
days	O
1月5日	O
every	O
4	O
weeks	O
.	O
	
G-CSF	B-DRUG
was	O
administered	O
at	O
5	O
microg	O
kg	O
(	O
-1	O
)	O
day	O
(	O
-1	O
)	O
subcutaneously	O
on	O
days	O
6月10日	O
during	O
each	O
cycle	O
.	O
	
Treatment	O
was	O
continued	O
in	O
cases	O
of	O
response	O
or	O
stable	O
disease	O
until	O
a	O
total	O
of	O
six	O
courses	O
were	O
completed	O
.	O
	
The	O
overall	O
response	O
rate	O
was	O
59	O
%	O
for	O
chemotherapeutically	O
naive	O
patients	O
(	O
95	O
%	O
confidence	O
interval	O
42-75	O
%	O
)	O
","	O
including	O
five	O
complete	O
responses	O
(	O
CR	O
;	O
13	O
%	O
)	O
and	O
17	O
partial	O
responses	O
(	O
PR	O
;	O
46	O
%	O
)	O
;	O
ten	O
patients	O
(	O
27	O
%	O
)	O
had	O
stable	O
disease	O
(	O
SD	O
)	O
and	O
only	O
five	O
(	O
14	O
%	O
)	O
progressed	O
(	O
PD	O
)	O
.	O
	
Second-line	O
chemotherapy	O
with	O
this	O
regimen	O
resulted	O
in	O
3	O
/	O
16	O
(	O
19	O
%	O
)	O
objective	O
remissions	O
","	O
but	O
nine	O
patients	O
had	O
SD	O
and	O
four	O
had	O
PD.	O
The	O
median	O
time	O
to	O
progression	O
was	O
10.5	O
months	O
(	O
range	O
2月23日	O
)	O
in	O
previously	O
untreated	O
patients	O
and	O
7	O
months	O
(	O
range	O
2月19日	O
)	O
in	O
those	O
who	O
had	O
failed	O
prior	O
chemotherapy	O
.	O
	
After	O
a	O
median	O
follow-up	O
time	O
of	O
14	O
months	O
","	O
29	O
patients	O
(	O
55	O
%	O
)	O
are	O
still	O
alive	O
with	O
metastatic	O
disease	O
;	O
median	O
survival	O
has	O
not	O
been	O
reached	O
yet	O
.	O
	
The	O
dose-limiting	O
toxicity	O
was	O
myelosuppression	B-TOXI
:	O
WHO	O
grade	O
III	O
and	O
IV	O
neutropenia	B-TOXI
occurred	O
in	O
15	O
(	O
28	O
%	O
)	O
and	O
four	O
patients	O
(	O
8	O
%	O
)	O
","	O
and	O
was	O
complicated	O
by	O
septicaemia	B-TOXI
in	O
two	O
;	O
grade	O
III	O
anaemia	B-TOXI
and	O
thrombocytopenia	B-TOXI
were	O
noted	O
in	O
four	O
(	O
8	O
%	O
)	O
and	O
three	O
(	O
6	O
%	O
)	O
patients	O
respectively	O
.	O
	
Severe	O
(	O
WHO	O
grade	O
3	O
)	O
non-haematological	B-TOXI
toxicities	I-TOXI
included	O
stomatitis	B-TOXI
in	O
6	O
%	O
and	O
nausea	B-TOXI
/	O
vomiting	B-TOXI
and	O
alopecia	B-TOXI
in	O
2	O
%	O
each	O
.	O
	
Our	O
data	O
suggest	O
that	O
the	O
combination	O
of	O
vinorelbine	B-DRUG
","	O
5-fluorouracil	B-DRUG
and	O
l-leucovorin	B-DRUG
plus	O
G-CSF	B-DRUG
is	O
an	O
effective	O
first	O
line	O
regimen	O
for	O
treatment	O
of	O
advanced	B-CANCER
breast	I-CANCER
cancer	I-CANCER
.	O
	
Overall	O
toxicity	O
was	O
modest	O
","	O
with	O
myelosuppression	B-TOXI
being	O
the	O
dose-limiting	O
side-effect	O
.	O
	
Other	O
severe	O
adverse	O
reactions	O
were	O
uncommon	O
.	O
	
Clinical	O
evaluation	O
of	O
two	O
dosages	O
and	O
schedules	O
of	O
ifosfamide	B-DRUG
in	O
combination	O
with	O
cisplatin	B-DRUG
in	O
neo-adjuvant	O
chemotherapy	O
of	O
patients	O
with	O
advanced	O
(	O
stage	O
III-IV	O
)	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
squamous	I-CANCER
cell	I-CANCER
carcinoma	I-CANCER
:	O
a	O
phase	O
II	O
randomized	O
study	O
.	O
	
	
The	O
aims	O
of	O
the	O
present	O
open	O
","	O
randomized	O
","	O
single-blind	O
(	O
patient	O
)	O
","	O
single	O
institution	O
","	O
phase	O
II	O
study	O
were	O
:	O
i	O
)	O
to	O
compare	O
the	O
therapeutic	O
effectiveness	O
and	O
toxicity	O
of	O
two	O
dosages	O
and	O
schedules	O
of	O
ifosfamide	B-DRUG
(	O
IFO	B-DRUG
)	O
in	O
combination	O
with	O
cisplatin	B-DRUG
(	O
CDDP	B-DRUG
)	O
mainly	O
in	O
the	O
neo-adjuvant	O
setting	O
of	O
patients	O
(	O
pts	O
)	O
with	O
locally	O
advanced	O
(	O
stage	O
III-IV	O
)	O
head	B-CANCER
and	I-CANCER
neck	I-CANCER
squamous	I-CANCER
cell	I-CANCER
cancer	I-CANCER
(	O
HNSCC	B-CANCER
)	O
(	O
primary	O
endpoint	O
)	O
;	O
ii	O
)	O
to	O
assess	O
the	O
quality	O
of	O
life	O
(	O
QL	O
)	O
of	O
pts	O
included	O
in	O
the	O
study	O
before	O
and	O
after	O
treatment	O
(	O
secondary	O
endpoint	O
)	O
.	O
	
From	O
July	O
1996	O
to	O
June	O
1997	O
","	O
28	O
pts	O
","	O
all	O
males	O
(	O
mean	O
age	O
56.79	O
years	O
","	O
range	O
37-72	O
)	O
","	O
hospitalized	O
in	O
the	O
Department	O
of	O
Medical	O
Oncology	O
","	O
University	O
of	O
Cagliari	O
","	O
were	O
enrolled	O
in	O
the	O
study	O
.	O
	
Twenty	O
pts	O
(	O
M	O
/	O
F	O
20	O
/	O
0	O
","	O
mean	O
age	O
53.6	O
","	O
range	O
37-71	O
years	O
;	O
stage	O
III	O
1	O
pt	O
","	O
stage	O
IV	O
19	O
pts	O
)	O
were	O
evaluable	O
for	O
response	O
and	O
all	O
28	O
pts	O
enrolled	O
were	O
evaluable	O
for	O
toxicity	O
.	O
	
Arm	O
A	O
:	O
IFO	O
2.2	O
g	O
/	O
m2	O
i.v.	O
as	O
a	O
4	O
h	O
infusion	O
on	O
days	O
1月5日	O
","	O
Mesna	O
600	O
mg	O
i.v.	O
as	O
push	O
injection	O
at	O
0	O
h	O
","	O
4	O
h	O
","	O
8	O
h	O
on	O
days	O
1月5日	O
","	O
CDDP	O
20	O
mg	O
i.v.	O
as	O
a	O
60	O
min	O
infusion	O
on	O
days	O
1月5日	O
.	O
	
The	O
regimen	O
was	O
repeated	O
every	O
28	O
days	O
for	O
2	O
cycles	O
.	O
	
Fifteen	O
pts	O
(	O
11	O
of	O
whom	O
were	O
evaluable	O
)	O
were	O
enrolled	O
in	O
this	O
Arm	O
.	O
	
Arm	O
B	O
:	O
IFO	O
1.5	O
g	O
/	O
m2	O
i.v.	O
as	O
a	O
4	O
h	O
infusion	O
on	O
days	O
1月5日	O
","	O
Mesna	O
600	O
mg	O
i.v.	O
as	O
push	O
injection	O
at	O
0	O
h	O
","	O
4	O
h	O
","	O
8	O
h	O
on	O
days	O
1月5日	O
","	O
CDDP	O
20	O
mg	O
i.v.	O
as	O
a	O
60	O
min	O
infusion	O
on	O
days	O
1月5日	O
.	O
	
The	O
regimen	O
was	O
repeated	O
every	O
28	O
days	O
for	O
3	O
cycles	O
.	O
	
Thirteen	O
pts	O
(	O
9	O
of	O
whom	O
were	O
evaluable	O
)	O
were	O
enrolled	O
in	O
this	O
Arm	O
.	O
	
The	O
two	O
Arms	O
were	O
well-balanced	O
for	O
sex	O
","	O
age	O
","	O
site	O
of	O
primary	O
","	O
ECOG	O
PS	O
and	O
clinical	O
stage	O
.	O
	
After	O
completion	O
of	O
2	O
(	O
Arm	O
A	O
)	O
or	O
3	O
(	O
Arm	O
B	O
)	O
cycles	O
of	O
chemotherapy	O
","	O
the	O
pts	O
were	O
assessed	O
for	O
response	O
.	O
	
All	O
evaluable	O
pts	O
received	O
treatment	O
as	O
planned	O
.	O
	
Six	O
pts	O
(	O
54.5	O
%	O
)	O
of	O
Arm	O
A	O
and	O
4	O
pts	O
(	O
44.5	O
%	O
)	O
of	O
Arm	O
B	O
had	O
partial	O
response	O
(	O
PR	O
)	O
with	O
an	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
of	O
54.5	O
%	O
and	O
44.5	O
%	O
","	O
respectively	O
:	O
it	O
is	O
worth	O
noting	O
that	O
all	O
(	O
100	O
%	O
)	O
pts	O
who	O
had	O
PR	O
in	O
Arm	O
B	O
achieved	O
a	O
high-grade	O
PR	O
","	O
i.e.	O
&	O
gt	O
;	O
/	O
70	O
%	O
","	O
whereas	O
only	O
one	O
pt	O
(	O
16.7	O
%	O
)	O
who	O
had	O
PR	O
in	O
Arm	O
A	O
achieved	O
a	O
high-grade	O
PR	O
.	O
	
Three	O
pts	O
(	O
27.3	O
%	O
)	O
in	O
Arm	O
A	O
and	O
2	O
pts	O
(	O
22.2	O
%	O
)	O
in	O
Arm	O
B	O
had	O
stable	O
disease	O
(	O
SD	O
)	O
;	O
2	O
pts	O
(	O
18.2	O
%	O
)	O
in	O
Arm	O
A	O
and	O
3	O
pts	O
(	O
33.3	O
%	O
)	O
in	O
Arm	O
B	O
had	O
progressive	O
disease	O
(	O
PD	O
)	O
.	O
	
The	O
actual	O
dose	O
intensity	O
was	O
over	O
80	O
%	O
of	O
the	O
projected	O
dose	O
intensity	O
for	O
both	O
drugs	O
and	O
for	O
both	O
Arms	O
.	O
	
Over	O
a	O
total	O
of	O
59	O
cycles	O
administered	O
","	O
the	O
total	O
number	O
of	O
episodes	B-DRUG
of	O
toxicity	O
was	O
24	O
for	O
Arm	O
A	O
and	O
17	O
for	O
Arm	O
B.	O
Three	O
pts	O
out	O
of	O
28	O
evaluable	O
for	O
toxicity	O
(	O
10.8	O
%	O
)	O
died	O
for	O
Grade	O
5	O
hematological	B-TOXI
toxicity	I-TOXI
:	O
all	O
pts	O
were	O
included	O
in	O
Arm	O
A.	O
In	O
Arm	O
A	O
","	O
2	O
pts	O
(	O
13.3	O
%	O
)	O
experienced	O
hematological	O
Grade	O
3	O
toxicity	O
and	O
2	O
pts	O
(	O
13.3	O
%	O
)	O
hematological	O
Grade	O
4	O
toxicity	O
.	O
	
In	O
Arm	O
B	O
no	O
pt	O
experienced	O
Grade	O
3月4日	O
hematological	B-TOXI
toxicity	I-TOXI
.	O
	
No	O
Grade	O
3月4日	O
toxicity	O
of	O
any	O
other	O
type	O
was	O
found	O
in	O
either	O
Arm	O
.	O
	
The	O
QL	O
evaluation	O
","	O
using	O
the	O
Cella	O
's	O
FACT-G	O
scale	O
supplemented	O
with	O
disease-specific	O
scale	O
(	O
FACT-H	O
&	O
amp	O
;	O
N	O
scale	O
)	O
","	O
did	O
not	O
show	O
significant	O
beneficial	O
effect	O
of	O
neo-adjuvant	O
chemotherapy	O
treatment	O
.	O
	
Multiinstitutional	O
phase	O
II	O
trial	O
of	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
concurrent	O
radiation	O
therapy	O
for	O
locally	O
advanced	B-CANCER
non-small-cell	I-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
Combined	O
modality	O
therapy	O
for	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
)	O
has	O
produced	O
promising	O
results	O
.	O
	
A	O
multiinstitutional	O
phase	O
II	O
clinical	O
trial	O
was	O
conducted	O
to	O
evaluate	O
the	O
activity	O
and	O
toxicity	O
of	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
concurrent	O
radiation	O
therapy	O
on	O
patients	O
with	O
locally	O
advanced	B-CANCER
NSCLC	I-CANCER
.	O
	
Forty	O
previously	O
untreated	O
patients	O
with	O
inoperable	O
locally	O
advanced	B-CANCER
NSCLC	I-CANCER
entered	O
onto	O
a	O
phase	O
II	O
study	O
from	O
March	O
1995	O
to	O
December	O
1996	O
.	O
	
On	O
an	O
outpatient	O
basis	O
for	O
7	O
weeks	O
","	O
patients	O
received	O
paclitaxel	B-DRUG
50	O
mg	O
/	O
m2	O
weekly	O
over	O
1	O
hour	O
;	O
carboplatin	B-DRUG
at	O
(	O
area	O
under	O
the	O
curve	O
)	O
AUC	O
2	O
weekly	O
;	O
and	O
radiation	O
therapy	O
of	O
66	O
Gy	O
in	O
33	O
fractions	O
.	O
	
After	O
chemoradiation	O
therapy	O
","	O
patients	O
received	O
an	O
additional	O
two	O
cycles	O
of	O
paclitaxel	B-DRUG
200	O
mg	O
/	O
m2	O
over	O
3	O
hours	O
and	O
carboplatin	B-DRUG
at	O
AUC	O
6	O
every	O
3	O
weeks	O
.	O
	
Thirty-nine	O
patients	O
were	O
eligible	O
for	O
the	O
study	O
.	O
	
The	O
survival	O
rates	O
at	O
12	O
months	O
were	O
56.3	O
%	O
","	O
and	O
at	O
24	O
months	O
","	O
38.3	O
%	O
","	O
with	O
a	O
median	O
overall	O
survival	O
of	O
20.5	O
months	O
.	O
	
The	O
progression-free	O
survival	O
rates	O
at	O
12	O
months	O
were	O
43.6	O
%	O
","	O
and	O
at	O
24	O
months	O
","	O
34.7	O
%	O
","	O
with	O
a	O
median	O
progression-free	O
survival	O
of	O
9	O
months	O
.	O
	
Two	O
patients	O
did	O
not	O
receive	O
more	O
than	O
2	O
weeks	O
of	O
concurrent	O
chemoradiotherapy	O
and	O
were	O
not	O
assessable	O
for	O
toxicity	O
and	O
response	O
.	O
	
The	O
overall	O
response	O
rate	O
(	O
partial	O
plus	O
complete	O
response	O
)	O
of	O
37	O
assessable	O
patients	O
was	O
75.7	O
%	O
.	O
	
The	O
major	O
toxicity	O
was	O
esophagitis	B-TOXI
.	O
	
Seventeen	O
patients	O
(	O
46	O
%	O
)	O
developed	O
grade	O
3	O
or	O
4	O
esophagitis	B-TOXI
.	O
	
However	O
","	O
only	O
two	O
patients	O
developed	O
late	O
esophageal	B-TOXI
toxicity	I-TOXI
with	O
stricture	O
at	O
3	O
and	O
6	O
months	O
posttreatment	O
.	O
	
Combined	O
modality	O
therapy	O
with	O
paclitaxel	B-DRUG
","	O
carboplatin	B-DRUG
","	O
and	O
radiation	O
is	O
a	O
promising	O
treatment	O
for	O
locally	O
advanced	B-CANCER
NSCLC	I-CANCER
that	O
has	O
a	O
high	O
response	O
rate	O
and	O
acceptable	O
toxicity	O
and	O
survival	O
rates	O
.	O
	
A	O
randomized	O
trial	O
will	O
be	O
necessary	O
to	O
fully	O
evaluate	O
the	O
usefulness	O
of	O
these	O
findings	O
.	O
	
Combination	O
of	O
irinotecan	B-DRUG
and	O
etoposide	B-DRUG
for	O
treatment	O
of	O
refractory	O
or	O
relapsed	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
To	O
determine	O
the	O
response	O
rate	O
","	O
survival	O
","	O
and	O
toxicity	O
of	O
irinotecan	B-DRUG
(	O
CPT-11	B-DRUG
)	O
","	O
a	O
topoisomerase	O
I	O
inhibitor	O
","	O
combined	O
with	O
etoposide	B-DRUG
","	O
a	O
topoisomerase	O
II	O
inhibitor	O
","	O
in	O
refractory	O
or	O
relapsed	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
SCLC	B-CANCER
)	O
.	O
	
Twenty-five	O
patients	O
with	O
refractory	O
or	O
relapsed	O
SCLC	B-CANCER
were	O
entered	O
onto	O
the	O
trial	O
.	O
	
All	O
25	O
patients	O
had	O
been	O
pretreated	O
with	O
some	O
form	O
of	O
cisplatin-based	B-DRUG
combination	O
chemotherapy	O
and	O
had	O
also	O
received	O
previous	O
etoposide-	B-DRUG
or	O
anthracyclinecontaining	O
chemotherapy	O
.	O
	
The	O
median	O
time	O
off	O
chemotherapy	O
was	O
6.7	O
months	O
(	O
range	O
","	O
0.9	O
to	O
23.5	O
)	O
.	O
	
Patients	O
were	O
treated	O
at	O
4-week	O
intervals	O
using	O
CPT-11	B-DRUG
(	O
a	O
starting	O
dose	O
of	O
70	O
mg	O
/	O
m2	O
intravenously	O
on	O
days	O
1	O
","	O
8	O
","	O
and	O
15	O
)	O
plus	O
etoposide	B-DRUG
(	O
80	O
mg	O
/	O
m2	O
intravenously	O
on	O
days	O
1	O
to	O
3	O
)	O
","	O
with	O
a	O
subsequent	O
dose	O
based	O
on	O
toxicity	O
.	O
	
In	O
addition	O
","	O
recombinant	O
human	O
granulocyte	B-DRUG
colony-stimulating	I-DRUG
factor	I-DRUG
(	O
rhG-CSF	B-DRUG
;	O
2	O
microg	O
/	O
kg	O
/	O
d	O
)	O
was	O
given	O
from	O
day	O
4	O
to	O
day	O
21	O
","	O
except	O
on	O
the	O
days	O
of	O
CPT-11	B-DRUG
administration	O
.	O
	
All	O
patients	O
were	O
assessable	O
for	O
toxicity	O
and	O
survival	O
.	O
	
Twenty-four	O
patients	O
were	O
assessable	O
for	O
response	O
.	O
	
There	O
were	O
14	O
partial	O
responses	O
(	O
PRs	O
)	O
and	O
three	O
complete	O
responses	O
(	O
CRs	O
)	O
","	O
for	O
an	O
overall	O
response	O
rate	O
of	O
71	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
53	O
%	O
to	O
89	O
%	O
)	O
.	O
	
The	O
median	O
response	O
duration	O
was	O
4.6	O
months	O
.	O
	
Median	O
survival	O
was	O
271	O
days	O
.	O
	
Major	O
toxicities	O
were	O
myelosuppression	B-TOXI
(	O
predominantly	B-TOXI
leukopenia	I-TOXI
)	O
and	O
diarrhea	B-TOXI
.	O
	
Grade	O
3	O
to	O
4	O
neutropenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
occurred	O
in	O
56	O
%	O
and	O
20	O
%	O
of	O
patients	O
","	O
respectively	O
.	O
	
Grade	O
3	O
to	O
4	O
diarrhea	B-TOXI
was	O
observed	O
in	O
4	O
%	O
.	O
	
There	O
was	O
one	O
treatment-related	O
death	B-TOXI
due	O
to	O
severe	O
myelosuppression	B-TOXI
.	O
	
A	O
combination	O
of	O
CPT-11	B-DRUG
and	O
etoposide	B-DRUG
with	O
rhG-CSF	B-DRUG
support	O
is	O
an	O
active	O
therapy	O
against	O
refractory	O
or	O
relapsed	B-CANCER
SCLC	I-CANCER
and	O
deserves	O
to	O
be	O
studied	O
more	O
extensively	O
in	O
a	O
phase	O
III	O
trial	O
.	O
	
Pharmacokinetic	O
interaction	O
between	O
ondansetron	B-DRUG
and	O
cyclophosphamide	B-DRUG
during	O
high-dose	O
chemotherapy	O
for	O
breast	B-CANCER
cancer	I-CANCER
.	O
	
	
Both	O
ondansetron	B-DRUG
and	O
cyclophosphamide	B-DRUG
are	O
thought	O
to	O
be	O
metabolized	O
by	O
hepatic	O
microsomal	O
processes	O
.	O
	
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
potential	O
pharmacokinetic	O
interactions	O
between	O
ondansetron	B-DRUG
and	O
high-dose	O
alkylating	O
agent	O
chemotherapy	O
.	O
	
A	O
total	O
of	O
54	O
breast	B-CANCER
cancer	I-CANCER
patients	O
receiving	O
high-dose	O
cyclophosphamide	B-DRUG
","	O
cisplatin	B-DRUG
and	O
carmustine	B-DRUG
were	O
treated	O
prospectively	O
in	O
four	O
sequential	O
cohorts	O
.	O
	
Cohorts	O
I	O
and	O
II	O
received	O
continuous	O
infusions	O
of	O
both	O
ondansetron	B-DRUG
and	O
prochlorperazine	B-DRUG
","	O
and	O
cohorts	O
III	O
and	O
IV	O
received	O
a	O
continuous	O
infusion	O
of	O
ondansetron	B-DRUG
alone	O
at	O
the	O
same	O
doses	O
.	O
	
All	O
patients	O
received	O
lorazepam	B-DRUG
every	O
4	O
h.	O
A	O
group	O
of	O
75	O
matched	O
historical	O
controls	O
had	O
received	O
a	O
continuous	O
infusion	O
of	O
prochlorperazine	B-DRUG
with	O
lorazepam	B-DRUG
.	O
	
Pharmacokinetic	O
monitoring	O
of	O
each	O
drug	O
used	O
in	O
the	O
high-dose	O
chemotherapy	O
regimen	O
was	O
conducted	O
.	O
	
Median	O
AUCs	O
of	O
cyclophosphamide	B-DRUG
in	O
patients	O
receiving	O
ondansetron	B-DRUG
(	O
73.6	O
mg	O
/	O
ml	O
x	O
min	O
)	O
were	O
lower	O
than	O
those	O
of	O
the	O
control	O
patients	O
(	O
88.3	O
mg	O
/	O
ml	O
x	O
min	O
","	O
n	O
=	O
75	O
","	O
P	O
=	O
0.0004	O
)	O
","	O
but	O
the	O
median	O
cisplatin	B-DRUG
AUC	O
was	O
approximately	O
10	O
%	O
higher	O
and	O
no	O
difference	O
in	O
the	O
disposition	O
of	O
carmustine	B-DRUG
was	O
demonstrated	O
.	O
	
Patients	O
treated	O
with	O
ondansetron	B-DRUG
displayed	O
a	O
higher	O
frequency	O
of	O
headaches	O
than	O
the	O
controls	O
.	O
	
The	O
frequency	O
of	O
achieving	O
complete	O
emetic	O
control	O
was	O
greater	O
in	O
the	O
ondansetron	B-DRUG
=+	O
prochlorperazine	B-DRUG
groups	O
compared	O
to	O
the	O
ondansetron	B-DRUG
alone	O
groups	O
and	O
was	O
greater	O
in	O
both	O
these	O
groups	O
than	O
in	O
the	O
prochlorperazine	B-DRUG
alone	O
group	O
on	O
the	O
first	O
day	O
of	O
therapy	O
only	O
.	O
	
Ondansetron	B-DRUG
altered	O
the	O
systemic	O
exposure	O
to	O
cyclophosphamide	B-DRUG
when	O
these	O
agents	O
were	O
administered	O
concomitantly	O
.	O
	
Ondansetron	B-DRUG
did	O
not	O
substantially	O
improve	O
overall	O
emetic	O
control	O
when	O
used	O
alone	O
but	O
may	O
improve	O
control	O
in	O
combination	O
with	O
prochlorperazine	B-DRUG
.	O
	
Future	O
randomized	O
studies	O
are	O
needed	O
to	O
delineate	O
the	O
effect	O
of	O
ondansetron	B-DRUG
on	O
the	O
disposition	O
of	O
the	O
active	O
cyclophosphamide	B-DRUG
metabolites	O
so	O
that	O
clinical	O
implications	O
can	O
be	O
addressed	O
.	O
	
Phase	O
I	O
study	O
to	O
determine	O
the	O
maximum-tolerated	O
dose	O
of	O
radiation	O
in	O
standard	O
daily	O
and	O
hyperfractionated-accelerated	O
twice-daily	O
radiation	O
schedules	O
with	O
concurrent	O
chemotherapy	O
for	O
limited-stage	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
	
An	O
improvement	O
in	O
radiation	O
dose	O
schedule	O
is	O
necessary	O
to	O
increase	O
local	O
tumor	O
control	O
and	O
survival	O
in	O
limited-stage	O
small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
.	O
	
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
maximum-tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
radiation	O
(	O
RT	O
)	O
in	O
both	O
standard	O
daily	O
and	O
hyperfractionated-accelerated	O
(	O
HA	O
)	O
twice-daily	O
RT	O
schedules	O
in	O
concurrent	O
chemoradiation	O
.	O
	
The	O
study	O
design	O
consisted	O
of	O
a	O
sequential	O
dose	O
escalation	O
in	O
both	O
daily	O
and	O
HA	O
twice-daily	O
RT	O
regimens	O
.	O
	
RT	O
dose	O
to	O
the	O
initial	O
volume	O
was	O
kept	O
at	O
40	O
to	O
40.5	O
Gy	O
","	O
while	O
it	O
was	O
gradually	O
increased	O
to	O
the	O
boost	O
volume	O
by	O
adding	O
a	O
7	O
%	O
to	O
11	O
%	O
increment	O
of	O
total	O
dose	O
to	O
subsequent	O
cohorts	O
.	O
	
The	O
MTD	O
was	O
defined	O
as	O
the	O
radiation	O
dose	O
level	O
at	O
one	O
cohort	O
below	O
that	O
which	O
resulted	O
in	O
more	O
than	O
33	O
%	O
of	O
patients	O
experiencing	O
grade	O
&	O
gt	O
;	O
or	O
=	O
4	O
acute	B-TOXI
esophagitis	I-TOXI
and	O
/	O
or	O
grade	O
&	O
gt	O
;	O
or	O
=	O
3	O
pulmonary	B-TOXI
toxicity	I-TOXI
.	O
	
The	O
study	O
plan	O
included	O
nine	O
cohorts	O
","	O
five	O
on	O
HA	O
twice-daily	O
and	O
four	O
on	O
daily	O
regimens	O
for	O
the	O
dose	O
escalation	O
.	O
	
Chemotherapy	O
consisted	O
of	O
three	O
cycles	O
of	O
cisplatin	B-DRUG
33	O
mg	O
/	O
m2	O
/	O
d	O
on	O
days	O
1	O
to	O
3	O
over	O
30	O
minutes	O
","	O
cyclophosphamide	B-DRUG
500	O
mg	O
/	O
m2	O
on	O
day	O
1	O
intravenously	O
(	O
IV	O
)	O
over	O
1	O
hour	O
","	O
and	O
etoposide	B-DRUG
80	O
mg	O
/	O
m2	O
/	O
d	O
on	O
days	O
1	O
to	O
3	O
over	O
1	O
hour	O
every	O
3	O
weeks	O
(	O
PCE	O
)	O
and	O
two	O
cycles	O
of	O
PE	O
.	O
	
RT	O
was	O
started	O
at	O
the	O
initiation	O
of	O
the	O
fourth	O
cycle	O
of	O
chemotherapy	O
.	O
	
Fifty	O
patients	O
were	O
enrolled	O
onto	O
the	O
study	O
.	O
	
The	O
median	O
age	O
was	O
60	O
years	O
(	O
range	O
","	O
38-79	O
)	O
","	O
sex	O
ratio	O
2.3:1	O
for	O
male	O
to	O
female	O
","	O
weight	O
loss	O
less	O
than	O
5	O
%	O
in	O
73	O
%	O
","	O
and	O
performance	O
score	O
0	O
to	O
1	O
in	O
94	O
%	O
and	O
2	O
in	O
6	O
%	O
of	O
patients	O
.	O
	
In	O
HA	O
twice-daily	O
RT	O
","	O
grade	O
&	O
gt	O
;	O
or	O
=	O
4	O
acute	B-TOXI
esophagitis	I-TOXI
was	O
noted	O
in	O
two	O
of	O
five	O
(	O
40	O
%	O
)	O
","	O
two	O
of	O
seven	O
(	O
29	O
%	O
)	O
","	O
four	O
of	O
six	O
(	O
67	O
%	O
)	O
","	O
and	O
five	O
of	O
six	O
patients	O
(	O
86	O
%	O
)	O
at	O
50	O
(	O
1.25	O
Gy	O
twice	O
daily	O
)	O
","	O
45	O
","	O
50	O
","	O
and	O
55.5	O
Gy	O
in	O
1.5	O
Gy	O
twice	O
daily	O
","	O
5	O
d	O
/	O
wk	O
","	O
respectively	O
.	O
	
Grade	O
&	O
gt	O
;	O
or	O
=	O
3	O
pulmonary	B-TOXI
toxicity	I-TOXI
was	O
not	O
seen	O
in	O
any	O
of	O
these	O
24	O
patients	O
.	O
	
Therefore	O
","	O
the	O
MTD	O
for	O
HA	O
twice-daily	O
RT	O
was	O
judged	O
to	O
be	O
45	O
Gy	O
in	O
30	O
fractions	O
over	O
3	O
weeks	O
.	O
	
In	O
daily	O
RT	O
","	O
grade	O
&	O
gt	O
;	O
or	O
=	O
4	O
acute	B-TOXI
esophagitis	I-TOXI
was	O
noted	O
in	O
zero	O
of	O
four	O
","	O
zero	O
of	O
four	O
","	O
one	O
of	O
five	O
(	O
20	O
%	O
)	O
","	O
and	O
two	O
of	O
six	O
patients	O
(	O
33	O
%	O
)	O
at	O
56	O
","	O
60	O
","	O
66	O
","	O
and	O
70	O
Gy	O
on	O
a	O
schedule	O
of	O
2	O
Gy	O
per	O
fraction	O
per	O
day	O
","	O
five	O
fractions	O
per	O
week	O
.	O
	
Grade	O
&	O
gt	O
;	O
or	O
=	O
3	O
pneumonitis	B-TOXI
was	O
not	O
observed	O
in	O
any	O
of	O
the	O
19	O
patients	O
.	O
	
Thus	O
","	O
the	O
MTD	O
for	O
daily	O
RT	O
was	O
judged	O
to	O
be	O
at	O
least	O
70	O
Gy	O
in	O
35	O
fractions	O
over	O
7	O
weeks	O
.	O
	
Grade	O
4	O
granulocytopenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
were	O
observed	O
in	O
53	O
%	O
and	O
6	O
%	O
of	O
patients	O
","	O
respectively	O
","	O
during	O
the	O
first	O
three	O
cycles	O
of	O
PCE	O
.	O
	
During	O
chemotherapy	O
cycles	O
4	O
to	O
5	O
","	O
grade	O
4	O
granulocytopenia	B-TOXI
and	O
thrombocytopenia	B-TOXI
were	O
noted	O
in	O
43	O
%	O
and	O
29	O
%	O
of	O
patients	O
at	O
45	O
Gy	O
in	O
30	O
fractions	O
over	O
3	O
weeks	O
(	O
MTD	O
)	O
by	O
HA	O
twice-daily	O
RT	O
and	O
50	O
%	O
and	O
17	O
%	O
at	O
70	O
Gy	O
in	O
35	O
fractions	O
over	O
7	O
weeks	O
(	O
MTD	O
)	O
by	O
daily	O
RT	O
","	O
respectively	O
.	O
	
The	O
overall	O
tumor	O
response	O
consisted	O
of	O
complete	O
remission	O
(	O
CR	O
)	O
in	O
51	O
%	O
(	O
24	O
of	O
47	O
)	O
","	O
partial	O
remission	O
(	O
PR	O
)	O
in	O
38	O
%	O
(	O
1	O
8	O
of	O
47	O
)	O
","	O
and	O
stable	O
disease	O
in	O
2	O
%	O
(	O
one	O
of	O
47	O
)	O
.	O
	
The	O
median	O
survival	O
time	O
of	O
all	O
patients	O
was	O
24.4	O
months	O
and	O
-2	O
and	O
3-year	O
survival	O
rates	O
were	O
53	O
%	O
and	O
28	O
%	O
","	O
respectively	O
.	O
	
With	O
regard	O
to	O
the	O
different	O
radiation	O
schedules	O
","	O
-2	O
and	O
3-year	O
survival	O
rates	O
were	O
52	O
%	O
and	O
25	O
%	O
for	O
the	O
HA	O
twice-daily	O
and	O
54	O
%	O
and	O
35	O
%	O
for	O
the	O
daily	O
RT	O
cohorts	O
.	O
	
The	O
MTD	O
of	O
HA	O
twice-daily	O
RT	O
was	O
determined	O
to	O
be	O
45	O
Gy	O
in	O
30	O
fractions	O
over	O
3	O
weeks	O
","	O
while	O
it	O
was	O
judged	O
to	O
be	O
at	O
least	O
70	O
Gy	O
in	O
35	O
fractions	O
over	O
7	O
weeks	O
for	O
daily	O
RT.	O
A	O
phase	O
III	O
randomized	O
trial	O
to	O
compare	O
standard	O
daily	O
RT	O
with	O
HA	O
twice-daily	O
RT	O
at	O
their	O
MTD	O
for	O
local	O
tumor	O
control	O
and	O
survival	O
would	O
be	O
a	O
sensible	O
research	O
in	O
searching	O
for	O
a	O
more	O
effective	O
RT	O
dose-schedule	O
than	O
those	O
that	O
are	O
being	O
used	O
currently	O
.	O
	
High-dose	O
thiotepa	B-DRUG
and	O
etoposide-based	B-DRUG
regimens	O
with	O
autologous	O
hematopoietic	O
support	O
for	O
high-risk	O
or	O
recurrent	O
CNS	B-CANCER
tumors	I-CANCER
in	O
children	O
and	O
adults	O
.	O
	
	
The	O
prognosis	O
in	O
patients	O
with	O
primary	O
brain	B-CANCER
tumors	I-CANCER
treated	O
with	O
surgery	O
","	O
radiotherapy	O
and	O
conventional	O
chemotherapy	O
remains	O
poor	O
.	O
	
To	O
improve	O
outcome	O
","	O
combination	O
high-dose	O
chemotherapy	O
(	O
HDC	O
)	O
has	O
been	O
explored	O
in	O
children	O
","	O
but	O
rarely	O
in	O
adults	O
.	O
	
This	O
study	O
was	O
performed	O
to	O
determine	O
the	O
tolerability	O
of	O
three-drug	O
combination	O
high-dose	O
thiotepa	B-DRUG
(	O
T	O
)	O
and	O
etoposide	B-DRUG
(	O
E	O
)	O
#NAME?	O
regimens	O
in	O
pediatric	O
and	O
adult	O
patients	O
with	O
high-risk	O
or	O
recurrent	O
primary	O
brain	B-CANCER
tumors	I-CANCER
.	O
	
Thirty-one	O
patients	O
(	O
13	O
children	O
and	O
18	O
adults	O
)	O
with	O
brain	O
tumors	O
were	O
treated	O
with	O
high-dose	O
chemotherapy	O
:	O
19	O
with	O
BCNU	B-DRUG
(	O
B	O
)	O
and	O
TE	O
(	O
BTE	B-DRUG
regimen	O
)	O
","	O
and	O
12	O
with	O
carboplatin	B-DRUG
(	O
C	O
)	O
and	O
TE	O
(	O
CTE	B-DRUG
regimen	O
)	O
.	O
	
Patients	O
received	O
growth	O
factors	O
and	O
hematopoietic	O
support	O
with	O
marrow	O
(	O
n	O
=	O
15	O
)	O
","	O
peripheral	O
blood	O
progenitor	O
cells	O
(	O
PBPC	O
)	O
(	O
n	O
=	O
11	O
)	O
or	O
both	O
(	O
n	O
=	O
5	O
)	O
.	O
	
The	O
100	O
day	O
toxic	O
mortality	O
rate	O
was	O
3	O
%	O
(	O
1	O
/	O
31	O
)	O
.	O
	
Grade	O
III	O
/	O
IV	O
toxicities	O
included	O
mucositis	B-TOXI
(	O
58	O
%	O
)	O
","	O
hepatitis	B-TOXI
(	O
39	O
%	O
)	O
and	O
diarrhea	B-TOXI
(	O
42	O
%	O
)	O
.	O
	
Five	O
patients	O
had	O
seizures	O
and	O
two	O
had	O
transient	B-TOXI
encephalopathy	I-TOXI
(	O
23	O
%	O
)	O
.	O
	
All	O
patients	O
had	O
neutropenic	B-TOXI
fever	I-TOXI
and	O
all	O
pediatric	O
patients	O
required	O
hyperalimentation	O
.	O
	
Median	O
time	O
to	O
engraftment	O
with	O
absolute	O
neutrophil	O
count	O
(	O
ANC	O
)	O
&	O
gt	O
;	O
0.5	O
x	O
10	O
(	O
9	O
)	O
/	O
l	O
was	O
11	O
days	O
(	O
range	O
8-37	O
days	O
)	O
.	O
	
Time	O
to	O
ANC	O
engraftment	O
was	O
significantly	O
longer	O
(	O
P	O
=	O
0.0001	O
)	O
in	O
patients	O
receiving	O
marrow	O
(	O
median	O
14	O
days	O
","	O
range	O
10-37	O
)	O
than	O
for	O
PBPC	O
(	O
median	O
9.5	O
days	O
","	O
range	O
8月10日	O
)	O
.	O
	
Platelet	O
engraftment	O
&	O
gt	O
;	O
50	O
x	O
10	O
(	O
9	O
)	O
/	O
l	O
was	O
24	O
days	O
(	O
range	O
14-53	O
days	O
)	O
in	O
children	O
.	O
	
In	O
adults	O
","	O
platelet	O
engraftment	O
&	O
gt	O
;	O
20	O
x	O
10	O
(	O
9	O
)	O
/	O
l	O
was	O
12	O
days	O
(	O
range	O
9-65	O
days	O
)	O
.	O
	
In	O
11	O
patients	O
supported	O
with	O
PBPC	O
","	O
there	O
was	O
a	O
significant	O
inverse	O
correlation	O
between	O
CD34+	O
dose	O
and	O
days	O
to	O
ANC	O
(	O
rho	O
=	O
-0.87	O
","	O
P	O
=	O
0.009	O
)	O
and	O
platelet	O
engraftment	O
(	O
rho	O
=	O
-0.85	O
","	O
P	O
=	O
0.005	O
)	O
","	O
with	O
CD34+	O
dose	O
predicting	O
time	O
to	O
engraftment	O
following	O
HDC	O
.	O
	
Overall	O
","	O
30	O
%	O
of	O
evaluable	O
patients	O
(	O
7	O
/	O
24	O
)	O
had	O
a	O
complete	O
response	O
(	O
CR	O
)	O
(	O
n	O
=	O
3	O
)	O
or	O
partial	O
response	O
(	O
PR	O
)	O
(	O
n	O
=	O
4	O
)	O
.	O
	
Median	O
time	O
to	O
tumor	O
progression	O
(	O
TTP	O
)	O
was	O
7	O
months	O
","	O
with	O
an	O
overall	O
median	O
survival	O
of	O
12	O
months	O
.	O
	
These	O
TE-based	O
BCNU	O
or	O
carboplatin	B-DRUG
three-drug	O
combination	O
HDC	O
regimens	O
are	O
safe	O
and	O
tolerable	O
with	O
promising	O
response	O
rates	O
in	O
both	O
children	O
and	O
older	O
adults	O
.	O
	
A	O
Phase	O
I	O
study	O
of	O
capecitabine	B-DRUG
in	O
combination	O
with	O
oral	O
leucovorin	B-DRUG
in	O
patients	O
with	O
intractable	O
solid	B-CANCER
tumors	I-CANCER
.	O
	
	
Capecitabine	B-DRUG
(	O
Xeloda	B-DRUG
)	O
is	O
a	O
novel	O
rationally	O
designed	O
fluoropyrimidine	B-DRUG
carbamate	I-DRUG
.	O
	
It	O
passes	O
through	O
the	O
intestinal	O
mucosal	O
membrane	O
intact	O
and	O
is	O
subsequently	O
activated	O
by	O
a	O
cascade	O
of	O
three	O
enzymes	O
resulting	O
in	O
preferential	O
release	O
of	O
5-fluorouracil	B-DRUG
(	O
5-FU	B-DRUG
)	O
at	O
the	O
tumor	O
site	O
.	O
	
Preclinical	O
studies	O
indicated	O
an	O
enhancement	O
of	O
the	O
therapeutic	O
index	O
when	O
capecitabine	B-DRUG
was	O
combined	O
with	O
leucovorin	B-DRUG
.	O
	
This	O
Phase	O
I	O
trial	O
was	O
designed	O
to	O
determine	O
the	O
safety	O
profile	O
","	O
maximal	O
tolerated	O
dose	O
","	O
and	O
pharmacokinetic	O
profile	O
of	O
the	O
combination	O
of	O
capecitabine	B-DRUG
plus	O
a	O
fixed	O
dose	O
of	O
p.o.	O
leucovorin	B-DRUG
(	O
60	O
mg	O
/	O
day	O
)	O
during	O
administration	O
to	O
patients	O
with	O
refractory	O
advanced	B-CANCER
cancers	I-CANCER
.	O
	
The	O
intention	O
was	O
to	O
administer	O
both	O
drugs	O
continuously	O
","	O
but	O
the	O
starting	O
dose	O
of	O
capecitabine	B-DRUG
was	O
also	O
the	O
maximum	O
tolerated	O
dose	O
(	O
1004	O
mg	O
/	O
m2	O
/	O
day	O
)	O
in	O
six	O
patients	O
treated	O
with	O
this	O
regimen	O
.	O
	
A	O
cycle	O
of	O
treatment	O
was	O
then	O
redefined	O
as	O
leucovorin	B-DRUG
and	O
capecitabine	B-DRUG
given	O
p.o.	O
","	O
twice	O
daily	O
for	O
2	O
consecutive	O
weeks	O
followed	O
by	O
a	O
1-week	O
rest	O
period	O
.	O
	
Capecitabine	B-DRUG
doses	O
from	O
1004	O
mg	O
/	O
m2	O
/	O
day	O
to	O
2510	O
mg	O
/	O
m2	O
/	O
day	O
were	O
evaluated	O
with	O
the	O
intermittent	O
schedule	O
over	O
approximately	O
80	O
courses	O
in	O
an	O
additional	O
25	O
patients	O
.	O
	
The	O
dose-limiting	O
toxicities	O
that	O
defined	O
the	O
maximum	O
tolerated	O
dose	O
at	O
2000	O
mg	O
/	O
m2	O
/	O
day	O
were	O
diarrhea	B-TOXI
","	O
nausea	B-TOXI
","	O
vomiting	B-TOXI
","	O
and	O
palmar	B-TOXI
plantar	I-TOXI
erythrodysesthesia	I-TOXI
.	O
	
The	O
recommended	O
Phase	O
II	O
dose	O
using	O
this	O
schedule	O
was	O
1650	O
mg	O
/	O
m2	O
/	O
day	O
of	O
capecitabine	O
plus	O
leucovorin	B-DRUG
60	O
mg	O
/	O
day	O
.	O
	
Plasma	O
concentrations	O
of	O
capecitabine	B-DRUG
","	O
intermediate	O
metabolites	O
","	O
and	O
5-FU	B-DRUG
were	O
measured	O
in	O
26	O
patients	O
on	O
days	O
1	O
and	O
14	O
of	O
therapy	O
.	O
	
The	O
pharmacokinetics	O
of	O
capecitabine	B-DRUG
were	O
characterized	O
by	O
rapid	O
GI	O
absorption	O
","	O
with	O
Cmax	O
at	O
1	O
h	O
","	O
followed	O
by	O
conversion	O
to	O
active	O
drug	O
.	O
	
The	O
coadministration	O
of	O
leucovorin	B-DRUG
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
capecitabine	B-DRUG
.	O
	
Two	O
patients	O
with	O
colorectal	B-CANCER
cancer	I-CANCER
","	O
both	O
previously	O
treated	O
with	O
5-FU	B-DRUG
","	O
had	O
partial	O
responses	O
.	O
	
Phase	O
II	O
studies	O
have	O
confirmed	O
the	O
promising	O
antitumor	O
activity	O
of	O
this	O
drug	O
","	O
and	O
capecitabine	B-DRUG
is	O
currently	O
in	O
Phase	O
III	O
evaluation	O
.	O
	
Phase	O
I	O
study	O
of	O
docetaxel	B-DRUG
dose	O
escalation	O
in	O
combination	O
with	O
fixed	O
weekly	O
gemcitabine	B-DRUG
in	O
patients	O
with	O
advanced	B-CANCER
malignancies	I-CANCER
.	O
	
	
To	O
determine	O
the	O
maximum-tolerated	O
dose	O
of	O
monthly	O
docetaxel	B-DRUG
combined	O
with	O
fixed-dose	O
weekly	O
gemcitabine	B-DRUG
and	O
describe	O
the	O
dose-limiting	O
toxicities	O
(	O
DLTs	O
)	O
of	O
the	O
combination	O
.	O
	
Patients	O
with	O
refractory	O
solid	O
tumors	O
were	O
treated	O
with	O
gemcitabine	B-DRUG
days	O
1	O
","	O
8	O
","	O
and	O
15	O
every	O
4	O
weeks	O
at	O
a	O
fixed	O
dose	O
of	O
800	O
mg	O
/	O
m2	O
.	O
	
Two	O
docetaxel	B-DRUG
administration	O
schedules	O
were	O
studied	O
","	O
with	O
the	O
drug	O
administered	O
either	O
day	O
1	O
or	O
day	O
15	O
at	O
doses	O
of	O
45	O
","	O
60	O
","	O
75	O
","	O
and	O
100	O
mg	O
/	O
m2	O
per	O
cycle	O
.	O
	
Forty	O
patients	O
received	O
132	O
cycles	O
of	O
chemotherapy	O
.	O
	
On	O
the	O
day-1	O
schedule	O
","	O
the	O
maximum-tolerated	O
docetaxel	B-DRUG
dose	O
was	O
the	O
highest	O
planned	O
dose	O
of	O
100	O
mg	O
/	O
m2	O
with	O
two	O
DLT	O
episodes	O
among	O
12	O
patients	O
treated	O
with	O
34	O
cycles	O
at	O
this	O
dose	O
level	O
.	O
	
On	O
the	O
day-15	O
schedule	O
","	O
delivery	O
of	O
the	O
planned	O
docetaxel	B-DRUG
doses	O
was	O
not	O
feasible	O
because	O
of	O
thrombocytopenia	B-TOXI
and	O
hepatic	B-TOXI
dysfunction	I-TOXI
.	O
	
Hematologic	B-TOXI
toxicities	I-TOXI
included	O
grade	O
4	O
neutropenia	B-TOXI
in	O
16	O
patients	O
","	O
with	O
three	O
episodes	O
of	O
febrile	B-TOXI
neutropenia	I-TOXI
;	O
grades	O
3	O
to	O
4	O
thrombocytopenia	B-TOXI
in	O
nine	O
patients	O
;	O
and	O
anemia	O
that	O
required	O
RBC	O
transfusions	O
in	O
10	O
patients	O
.	O
	
For	O
patients	O
treated	O
at	O
the	O
highest	O
docetaxel	B-DRUG
dose	O
level	O
","	O
myelosuppression	B-TOXI
was	O
not	O
dose	O
limiting	O
and	O
only	O
one	O
of	O
34	O
cycles	O
was	O
complicated	O
by	O
febrile	B-TOXI
neutropenia	I-TOXI
.	O
	
The	O
most	O
common	O
nonhematologic	B-TOXI
toxicities	I-TOXI
were	O
asthenia	B-TOXI
","	O
flu-like	B-TOXI
symptoms	I-TOXI
","	O
and	O
fluid	B-TOXI
retention	I-TOXI
.	O
	
Antineoplastic	O
activity	O
was	O
noteworthy	O
","	O
with	O
partial	O
responses	O
in	O
nine	O
of	O
21	O
patients	O
with	O
pretreated	O
non-small-cell	B-CANCER
lung	I-CANCER
cancer	I-CANCER
(	O
NSCLC	B-CANCER
;	O
43	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
","	O
22	O
to	O
66	O
)	O
","	O
in	O
four	O
of	O
seven	O
patients	O
with	O
breast	B-CANCER
cancer	I-CANCER
","	O
and	O
in	O
one	O
patient	O
with	O
esophageal	B-CANCER
adenocarcinoma	I-CANCER
.	O
	
Gemcitabine	B-DRUG
800	O
mg	O
/	O
m2	O
days	O
"1,8"	O
","	O
and	O
15	O
can	O
be	O
safely	O
combined	O
with	O
docetaxel	B-DRUG
100	O
mg	O
/	O
m2	O
day	O
1	O
of	O
a	O
28-day	O
cycle	O
.	O
	
The	O
observed	O
antitumor	O
activity	O
warrants	O
phase	O
II	O
evaluation	O
.	O
	
Epirubicin-containing	B-DRUG
high-dose	O
chemotherapy	O
followed	O
by	O
autologous	O
hematopoietic	O
progenitor	O
cell	O
transfusion	O
for	O
patients	O
with	O
chemotherapy-sensitive	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
:	O
results	O
of	O
5-year	O
follow-up	O
.	O
	
	
Conventional	O
chemotherapy	O
for	O
metastatic	B-CANCER
breast	I-CANCER
cancer	I-CANCER
results	O
in	O
very	O
few	O
long-term	O
survivors	O
.	O
	
With	O
a	O
view	O
to	O
overcoming	O
this	O
problem	O
","	O
we	O
hypothesized	O
that	O
a	O
higher	O
rate	O
of	O
complete	O
response	O
(	O
CR	O
)	O
would	O
lead	O
to	O
more	O
long-term	O
survivors	O
.	O
	
Therefore	O
","	O
we	O
conducted	O
a	O
phase	O
II	O
study	O
of	O
epirubicin-containing	B-DRUG
high-dose	O
chemotherapy	O
(	O
HDC	O
)	O
followed	O
by	O
autologous	O
hematopoietic	O
progenitor	O
cell	O
transfusion	O
in	O
patients	O
who	O
were	O
sensitive	O
to	O
induction	O
chemotherapy	O
.	O
	
The	O
induction	O
chemotherapy	O
consisted	O
of	O
doxorubicin	B-DRUG
60	O
mg	O
/	O
m2	O
","	O
cyclophosphamide	B-DRUG
750	O
mg	O
/	O
m2	O
and	O
fluorouracil	B-DRUG
750	O
mg	O
/	O
m2	O
on	O
day	O
1	O
Supported	O
by	O
G-CSF	B-DRUG
","	O
this	O
chemotherapy	O
was	O
repeated	O
for	O
at	O
least	O
three	O
cycles	O
at	O
intervals	O
of	O
2	O
weeks	O
until	O
the	O
achievement	O
of	O
&	O
gt	O
;	O
50	O
%	O
tumor	O
regression	O
.	O
	
The	O
HDC	O
comprised	O
epirubicin	B-DRUG
120	O
mg	O
/	O
m2	O
on	O
day	O
1	O
","	O
cyclophosphamide	B-DRUG
60	O
mg	O
/	O
kg	O
on	O
days	O
1	O
to	O
3	O
and	O
thiotepa	B-DRUG
6	O
mg	O
/	O
kg	O
on	O
days	O
1	O
to	O
3	O
","	O
followed	O
by	O
autologous	O
bone	O
marrow	O
transplantation	O
and	O
peripheral	O
blood	O
stem	O
cell	O
transfusion	O
.	O
	
Of	O
25	O
patients	O
who	O
achieved	O
a	O
partial	O
response	O
to	O
the	O
induction	O
chemotherapy	O
","	O
17	O
were	O
treated	O
with	O
the	O
HDC	O
.	O
	
Of	O
the	O
15	O
patients	O
evaluable	O
for	O
response	O
","	O
10	O
achieved	O
a	O
CR	O
(	O
67	O
%	O
)	O
","	O
giving	O
an	O
overall	O
CR	O
rate	O
of	O
43	O
%	O
(	O
10	O
/	O
25	O
)	O
.	O
	
The	O
disease-free	O
survival	O
rate	O
at	O
5	O
years	O
was	O
27	O
%	O
.	O
	
The	O
median	O
duration	O
of	O
overall	O
survival	O
was	O
21	O
months	O
and	O
the	O
overall	O
survival	O
rate	O
at	O
5	O
years	O
was	O
31	O
%	O
.	O
	
However	O
","	O
the	O
survival	O
curves	O
were	O
not	O
significantly	O
different	O
from	O
those	O
of	O
the	O
historical	O
controls	O
who	O
achieved	O
a	O
CR	O
or	O
PR	O
to	O
conventional	O
chemotherapy	O
.	O
	
There	O
were	O
three	O
early	O
deaths	B-TOXI
","	O
one	O
as	O
a	O
consequence	O
of	O
disease	O
progression	O
and	O
two	O
treatment-related	O
(	O
sepsis	B-TOXI
and	O
heart	B-TOXI
failure	I-TOXI
)	O
.	O
	
Diarrhea	B-TOXI
(	O
grade	O
3	O
","	O
76	O
%	O
)	O
and	O
stomatitis	B-TOXI
(	O
grade	O
3月4日	O
","	O
29	O
%	O
)	O
were	O
the	O
dose-limiting	O
toxicities	O
.	O
	
The	O
present	O
study	O
suggests	O
that	O
epirubicin-containing	B-DRUG
HDC	O
is	O
able	O
to	O
induce	O
a	O
high	O
rate	O
of	O
CR	O
","	O
but	O
its	O
benefit	O
in	O
terms	O
of	O
survival	O
is	O
still	O
unclear	O
.	O
	
To	O
determine	O
whether	O
HDC	O
can	O
achieve	O
a	O
cure	O
in	O
some	O
patients	O
","	O
further	O
studies	O
in	O
a	O
larger	O
number	O
of	O
patients	O
","	O
with	O
a	O
longer	O
follow-up	O
","	O
are	O
necessary	O
.	O